PT	AU	BA	BE	GP	AF	BF	CA	TI	SO	SE	BS	LA	DT	CT	CY	CL	SP	HO	DE	ID	AB	C1	RP	EM	RI	OI	FU	FX	CR	NR	TC	Z9	U1	U2	PU	PI	PA	SN	EI	BN	J9	JI	PD	PY	VL	IS	PN	SU	SI	MA	BP	EP	AR	DI	D2	EA	PG	WC	SC	GA	UT	PM	OA	HC	HP	DA
J	Simmons, AN; Flagan, TM; Wittmann, M; Strigo, IA; Matthews, SC; Donovan, H; Lohr, JB; Paulus, MP				Simmons, Alan N.; Flagan, Taru M.; Wittmann, Marc; Strigo, Irina A.; Matthews, Scott C.; Donovan, Heather; Lohr, James B.; Paulus, Martin P.			The effects of temporal unpredictability in anticipation of negative events in combat veterans with PTSD	JOURNAL OF AFFECTIVE DISORDERS			English	Article						Predictability; Anticipation; Insula; Posttraumatic stress disorder; Time; FMRI	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; AVERSIVE VISUAL-STIMULI; INSULA ACTIVATION; ANTERIOR INSULA; NEURAL MECHANISMS; TIME PERCEPTION; ANXIETY; UNCERTAINTY; AMYGDALA	Background: Exposure to psychological stress during combat can lead to posttraumatic stress disorder (PTSD). Anticipation of aversive events is often associated with an intense emotional state in individuals with PTSD. Both the valence (i.e., positive or negative) of the anticipated event and the degree of temporal predictability (i.e., one's ability to predict when an event will occur) have profound effects on an individual's emotional experience. This investigation tested the hypothesis that individuals with combat-related PTSD would show increased activation in the insula and related emotion-processing circuitry when anticipating emotionally significant events such as portrayed in combat-related images, and this heighted response within the insula would be particularly enhanced during temporal unpredictability. Methods: About 15 male veterans with PTSD and 15 male veterans with combat-exposure but no current or lifetime history of PTSD (combat exposed controls/CEC) performed a temporal unpredictability anticipation task of unpleasant (combat-related) and pleasant images during fMRI. Results: As expected, greater activation in the bilateral anterior insulae was observed in the PTSD versus the CEC subjects during anticipation of combat-related images when the anticipatory period was of uncertain duration (p<0.05). Furthermore, activation in the right anterior insula was related to greater perceived threat in the CEC group (rho=0.619). Limitations: The current study looks only at combat-related PTSD in a modest preliminary sized sample. Conclusions: These findings suggest that an excessive anticipatory reaction in individuals with PTSD to temporally unpredictable aversive stimulus may relate to greater perceived threat. These findings are concordant with psychological models of PTSD that focus on the association of PTSD with the experience of decreased predictability and control. Published by Elsevier B.V.	[Simmons, Alan N.; Strigo, Irina A.; Matthews, Scott C.] VA San Diego Healthcare Syst, Res Serv, San Diego, CA 92130 USA; [Simmons, Alan N.; Wittmann, Marc; Matthews, Scott C.; Donovan, Heather; Lohr, James B.; Paulus, Martin P.] VA San Diego Healthcare Syst, Psychiat Serv, San Diego, CA 92130 USA; [Simmons, Alan N.; Strigo, Irina A.; Donovan, Heather; Lohr, James B.; Paulus, Martin P.] VA Ctr Excellence Stress & Mental Hlth CESAMH, San Diego, CA USA; [Matthews, Scott C.] VA Mental Illness Res Educ & Clin Ctr MIRECC, San Diego, CA USA; [Simmons, Alan N.; Flagan, Taru M.; Wittmann, Marc; Strigo, Irina A.; Matthews, Scott C.; Donovan, Heather; Lohr, James B.; Paulus, Martin P.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Wittmann, Marc] Inst Frontier Areas Psychol & Mental Hlth, Dept Empir & Analyt Psychophys, Freiburg, Germany	Simmons, AN (corresponding author), 3350 La Jolla Village Dr, San Diego, CA 92130 USA.	ansimmons@ucsd.edu	strigo, irina A/L-9882-2016; Simmons, Alan N/A-9815-2008; Wittmann, Marc/ABC-6363-2020	strigo, irina A/0000-0002-8799-716X; Simmons, Alan N/0000-0003-3963-2112; Wittmann, Marc/0000-0002-4483-7334	veteran's association	This paper was funded through research grant administrated by the veteran's association which exerted to bias on the interpretation of the results.	Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; BOHN MJ, 1995, J STUD ALCOHOL, V56, P423, DOI 10.15288/jsa.1995.56.423; Bremner JD, 2003, PSYCHONEUROENDOCRINO, V28, P733, DOI 10.1016/S0306-4530(02)00067-7; Brunia CHM, 2000, EXP BRAIN RES, V130, P328, DOI 10.1007/s002219900293; Craig AD, 2009, PHILOS T R SOC B, V364, P1933, DOI 10.1098/rstb.2009.0008; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Etkin A, 2007, AM J PSYCHIAT, V164, P1476, DOI 10.1176/appi.ajp.2007.07030504; FALK JL, 1954, J EXP PSYCHOL, V47, P279, DOI 10.1037/h0061946; Fan J, 2007, J NEUROSCI, V27, P2272, DOI 10.1523/JNEUROSCI.3470-06.2007; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; First MB., 1997, STRUCTURED CLIN INTE; FOA EB, 1992, PSYCHOL BULL, V112, P218, DOI 10.1037/0033-2909.112.2.218; Gan T, 2009, NEUROREPORT, V20, P839, DOI 10.1097/WNR.0b013e32832be7dc; Grillon C, 2008, PSYCHOPHARMACOLOGY, V199, P421, DOI 10.1007/s00213-007-1019-1; Grillon C, 2008, AM J PSYCHIAT, V165, P898, DOI 10.1176/appi.ajp.2007.07101581; Grillon C, 2009, BIOL PSYCHIAT, V66, P47, DOI 10.1016/j.biopsych.2008.12.028; Grupe DW, 2011, EMOTION, V11, P413, DOI 10.1037/a0022583; Hancock PA, 2005, THEOR ISS ERGON SCI, V6, P193, DOI 10.1080/14639220512331325747; HARRINGTON DE, 1993, ARCH PHYS MED REHAB, V74, P579, DOI 10.1016/0003-9993(93)90155-4; King LA, 2006, MIL PSYCHOL, V18, P89, DOI 10.1207/s15327876mp1802_1; Lake JI, 2011, FRONT INTEGR NEUROSC, V5, DOI 10.3389/fnint.2011.00055; Lewis PA, 2003, NEUROPSYCHOLOGIA, V41, P1583, DOI 10.1016/S0028-3932(03)00118-0; Lovero KL, 2009, NEUROIMAGE, V45, P976, DOI 10.1016/j.neuroimage.2008.12.070; Meck WH, 2007, BEHAV NEUROSCI, V121, P707, DOI 10.1037/0735-7044.121.4.707; Meek PM, 1999, AM J RESP CRIT CARE, V159, P321; Mella N, 2011, BRAIN COGNITION, V75, P182, DOI 10.1016/j.bandc.2010.11.012; Morillon B, 2009, J NEUROSCI, V29, P14803, DOI 10.1523/JNEUROSCI.3222-09.2009; Nitschke JB, 2006, NEUROIMAGE, V29, P106, DOI 10.1016/j.neuroimage.2005.06.068; Paulus MP, 2006, BIOL PSYCHIAT, V60, P383, DOI 10.1016/j.biopsych.2006.03.042; Sarinopoulos I, 2010, CEREB CORTEX, V20, P929, DOI 10.1093/cercor/bhp155; Simmons A, 2004, NEUROREPORT, V15, P2261, DOI 10.1097/00001756-200410050-00024; Simmons A, 2008, NEUROREPORT, V19, P1033, DOI 10.1097/WNR.0b013e328305b722; Simmons A, 2008, NEUROSCI LETT, V430, P92, DOI 10.1016/j.neulet.2007.10.030; Simmons A, 2006, BIOL PSYCHIAT, V60, P402, DOI 10.1016/j.biopsych.2006.04.038; Simmons A, 2009, PSYCHOSOM MED, V71, P373, DOI 10.1097/PSY.0b013e3181a56ed8; Simmons AN, 2008, BIOL PSYCHIAT, V64, P681, DOI 10.1016/j.biopsych.2008.05.027; Simmons AN, 2012, NEUROREPORT, V23, P234, DOI 10.1097/WNR.0b013e3283503275; Simmons AN, 2012, NEUROPHARMACOLOGY, V62, P598, DOI 10.1016/j.neuropharm.2011.03.016; Simmons AN, 2011, HUM BRAIN MAPP, V32, P1836, DOI 10.1002/hbm.21154; Smith A, 2003, NEUROIMAGE, V20, P344, DOI 10.1016/S1053-8119(03)00337-9; Strigo IA, 2008, ARCH GEN PSYCHIAT, V65, P1275, DOI 10.1001/archpsyc.65.11.1275; Strigo IA, 2010, BIOL PSYCHIAT, V68, P442, DOI 10.1016/j.biopsych.2010.03.034; von Leupoldt A, 2008, AM J RESP CRIT CARE, V177, P1026, DOI 10.1164/rccm.200712-1821OC; Wiener M, 2010, NEUROIMAGE, V49, P1728, DOI 10.1016/j.neuroimage.2009.09.064; Wilson, 1991, NATL ADULT READING T; Wittmann Marc, 2010, J Neurosci Psychol Econ, V3, P15; Wittmann M, 2010, FRONT HUM NEUROSCI, V4, DOI 10.3389/neuro.09.002.2010; Wittmann M, 2009, PHILOS T R SOC B, V364, P1955, DOI 10.1098/rstb.2009.0003; Wittmann M, 2009, PHILOS T R SOC B, V364, P1809, DOI 10.1098/rstb.2009.0025; Zvolensky MJ, 2000, BEHAV RES THER, V38, P653, DOI 10.1016/S0005-7967(99)00090-X	50	23	24	0	42	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0327			J AFFECT DISORDERS	J. Affect. Disord.	APR 25	2013	146	3					426	432		10.1016/j.jad.2012.08.006			7	Clinical Neurology; Psychiatry	Neurosciences & Neurology; Psychiatry	098WV	WOS:000315580700018	22910447				2021-06-18	
J	Haneef, Z; Levin, HS; Frost, JD; Mizrahi, EM				Haneef, Zulfi; Levin, Harvey S.; Frost, James D., Jr.; Mizrahi, Eli M.			Electroencephalography and Quantitative Electroencephalography in Mild Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						EEG; mild traumatic brain injury; postconcussive syndrome; quantitative EEG; TBI	MINOR HEAD-INJURY; POSTCONCUSSIONAL-SYNDROME; AMERICAN ACADEMY; BIOPHYSICAL LINKAGE; SPECTRAL-ANALYSIS; EEG; NEUROLOGY; ABNORMALITIES; FOLLOW; STATE	Mild traumatic brain injury (mTBI) causes brain injury resulting in electrophysiologic abnormalities visible in electroencephalography (EEG) recordings. Quantitative EEG (qEEG) makes use of quantitative techniques to analyze EEG characteristics such as frequency, amplitude, coherence, power, phase, and symmetry over time independently or in combination. QEEG has been evaluated for its use in making a diagnosis of mTBI and assessing prognosis, including the likelihood of progressing to the postconcussive syndrome (PCS) phase. We review the EEG and qEEG changes of mTBI described in the literature. An attempt is made to separate the findings seen during the acute, subacute, and chronic phases after mTBI. Brief mention is also made of the neurobiological correlates of qEEG using neuroimaging techniques or in histopathology. Although the literature indicates the promise of qEEG in making a diagnosis and indicating prognosis of mTBI, further study is needed to corroborate and refine these methods.	[Haneef, Zulfi; Frost, James D., Jr.; Mizrahi, Eli M.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Haneef, Zulfi] Michael E Debakey VA Med Ctr, Dept Neurol, Houston, TX USA; [Levin, Harvey S.] Baylor Coll Med, Dept Phys Med & Rehabil, Houston, TX 77030 USA	Haneef, Z (corresponding author), Baylor Coll Med, Dept Neurol, 1 Baylor Plaza,MS NB302, Houston, TX 77030 USA.	haneef@bcm.edu			Department of DefenseUnited States Department of Defense [W81XWH-08-2-0149, PT74693P22]; Mission Connect Translational MTBI Translational Research Consortium: Neurophysiology Core; Mission Connect Translational MTBI Translational Research Consortium: Neuropsychology Core	This research is supported by the Department of Defense (Contract # W81XWH-08-2-0149; Grant # PT74693P22); The Mission Connect Translational MTBI Translational Research Consortium: Neurophysiology Core (Eli M. Mizrahi, PI) and Neuropsychology Core (Harvey S. Levin, PI).	American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Arciniegas DB, 2011, INT J PSYCHOPHYSIOL, V82, P41, DOI 10.1016/j.ijpsycho.2011.03.004; Chen Xi-Ping, 2006, Neurosci Bull, V22, P165; Dow RS, 1944, AM J PSYCHIAT, V101, P174, DOI 10.1176/ajp.101.2.174; FENTON G, 1993, BRIT J PSYCHIAT, V162, P493, DOI 10.1192/bjp.162.4.493; Fenton GW, 1996, CLIN ELECTROENCEPHAL, V27, P174; Gaetz M, 2001, J HEAD TRAUMA REHAB, V16, P386, DOI 10.1097/00001199-200108000-00008; Geets W, 1985, Rev Electroencephalogr Neurophysiol Clin, V14, P333; GEETS W, 1985, ACTA NEUROL BELG, V85, P277; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Hayes R L, 1988, Brain Inj, V2, P31, DOI 10.3109/02699058809150930; Hoffman DA, 1999, J NEUROPSYCH CLIN N, V11, P401, DOI 10.1176/jnp.11.3.401; Johnstone J, 1991, J Insur Med, V23, P228; Kane NM, 1998, ELECTROEN CLIN NEURO, V106, P244, DOI 10.1016/S0013-4694(97)00141-7; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; KOUFEN H, 1978, FORTSCHR NEUROL PSYC, V46, P165; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; MCCLELLAND RJ, 1994, J ROY SOC MED, V87, P508; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; Moeller JJ, 2011, ARCH NEUROL-CHICAGO, V68, P1595, DOI 10.1001/archneurol.2011.1080; Nuwer M, 1997, NEUROLOGY, V49, P277, DOI 10.1212/WNL.49.1.277; Nuwer MR, 2005, CLIN NEUROPHYSIOL, V116, P2001, DOI 10.1016/j.clinph.2005.05.008; Parsons LC, 1997, J NEUROTRAUM, V14, P549, DOI 10.1089/neu.1997.14.549; SCHERZER E, 1966, PSYCHIAT NEUROL, V152, P207; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; Thatcher RW, 1998, NEUROIMAGE, V7, P352, DOI 10.1006/nimg.1998.0330; Thatcher RW, 1998, NEUROIMAGE, V8, P307, DOI 10.1006/nimg.1998.0365; Thatcher RW, 2001, J NEUROPSYCH CLIN N, V13, P77, DOI 10.1176/appi.neuropsych.13.1.77; Thatcher RW, 1999, CLIN ELECTROENCEPHAL, V30, P94, DOI 10.1177/155005949903000304; THATCHER RW, 1989, ELECTROEN CLIN NEURO, V73, P94, DOI 10.1016/0013-4694(89)90188-0; Trudeau DL, 1998, J NEUROPSYCH CLIN N, V10, P308, DOI 10.1176/jnp.10.3.308; VONBIERBRAUER A, 1992, EEG-EMG-Z ELEK ELEKT, V23, P151; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; WATSON MR, 1995, BRIT J PSYCHIAT, V167, P514, DOI 10.1192/bjp.167.4.514	34	23	24	1	18	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2013	30	8			SI		653	656		10.1089/neu.2012.2585			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PO	WOS:000318151500007	23249295	Green Published			2021-06-18	
J	Lathan, C; Spira, JL; Bleiberg, J; Vice, J; Tsao, JW				Lathan, Corinna; Spira, James L.; Bleiberg, Joseph; Vice, Jack; Tsao, Jack W.			Defense Automated Neurobehavioral Assessment (DANA)-Psychometric Properties of a New Field-Deployable Neurocognitive Assessment Tool	MILITARY MEDICINE			English	Article							NEUROPSYCHOLOGICAL ASSESSMENT METRICS; TRAUMATIC BRAIN-INJURY; TEST-RETEST RELIABILITY; SCREEN; INDEX	The Defense Automated Neurobehavioral Assessment (DANA) is a new neurocognitive assessment tool that includes a library of standardized cognitive and psychological assessments, with three versions that range from a brief 5-minute screen to a 45-minute complete assessment. DANA is written using the Android open-source operating system and is suitable for multiple mobile platforms. This article presents testing of DANA by 224 active duty U.S. service members in five operationally relevant environments (desert, jungle, mountain, arctic, and shipboard). DANA was found to be a reliable instrument and compared favorably to other computer-based neurocognitive assessments. Implications for using DANA in far-forward military settings are discussed.	[Lathan, Corinna; Vice, Jack] AnthroTronix, Silver Spring, MD 20910 USA; [Spira, James L.] Pacific Isl Hlth Care Syst, Natl Ctr PTSD, Dept Vet Affairs, Honolulu, HI 96819 USA; [Bleiberg, Joseph] Walter Reed Natl Mil Med Ctr, Natl Intrepid Ctr Excellence, Bethesda, MD 20889 USA; [Tsao, Jack W.] US Navy Bur Med & Surg, Wounded Ill & Injured Directorate, Falls Church, VA 22032 USA	Lathan, C (corresponding author), AnthroTronix, 8737 Colesville Rd,Suite L-203, Silver Spring, MD 20910 USA.			Bleiberg, Joseph/0000-0003-0867-5494	U.S. Navy Bureau of Medicine and Surgery [N00189-10-P-Z967]	We thank the following people for their help in data collection and/or analysis: James Drane, Jon Farris, and Lindsay Long. This work was supported by the U.S. Navy Bureau of Medicine and Surgery, Wounded, Ill and Injured Directorate, Contract No. N00189-10-P-Z967 as well as with resources and the use of facilities at the Department of Veterans Affairs, National Center for PTSD, Pacific Islands Health Care System.	Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; Bliese PD, 2008, J CONSULT CLIN PSYCH, V76, P272, DOI 10.1037/0022-006X.76.2.272; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cernich A, 2007, ARCH CLIN NEUROPSYCH, V22, pS101, DOI 10.1016/j.acn.2006.10.008; Cernich AN, 2007, ARCH CLIN NEUROPSYCH, V22, pS39, DOI 10.1016/j.acn.2006.10.004; Keane T.M., 1989, PSYCHOL ASSESSMENT J, V1, P53, DOI DOI 10.1037/1040-3590.1.1.53; Kroenke K, 2009, J AFFECT DISORDERS, V114, P163, DOI 10.1016/j.jad.2008.06.026; Marx RG, 2003, J CLIN EPIDEMIOL, V56, P730, DOI 10.1016/S0895-4356(03)00084-2; Meterko M, 2012, J HEAD TRAUMA REHAB, V27, P55, DOI 10.1097/HTR.0b013e318230fb17; Prins A, 2004, PRIMARY CARE PSYCHIA, V9, P151, DOI 10.1185/135525703125002360; Prins A, 2003, PRIMARY CARE PSYCHIA, V9, P9; Raja Beharelle A, 2011, FRONT HUM NEUROSCI, V5, DOI 10.3389/fnhum.2011.00164; Reeves DL, 2006, MIL MED, V171, P982, DOI 10.7205/MILMED.171.10.982; Segalowitz SJ, 2007, NEUROREHABILITATION, V22, P243; Vincent AS, 2008, MIL MED, V173, P836, DOI 10.7205/MILMED.173.9.836; Vincent AS, 2012, MIL MED, V177, P256, DOI 10.7205/MILMED-D-11-00289; Weir JP, 2005, J STRENGTH COND RES, V19, P231, DOI 10.1519/15184.1; Wilson JA, 2010, IEEE T BIO-MED ENG, V57, P1785, DOI 10.1109/TBME.2010.2047259	18	23	23	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	APR	2013	178	4					365	371		10.7205/MILMED-D-12-00438			7	Medicine, General & Internal	General & Internal Medicine	AN7TY	WOS:000340805100004	23707818	Bronze			2021-06-18	
J	Shi, HY; Hwang, SL; Lee, KT; Lin, CL				Shi, Hon-Yi; Hwang, Shiuh-Lin; Lee, King-Teh; Lin, Chih-Lung			Temporal trends and volume-outcome associations after traumatic brain injury: a 12-year study in Taiwan	JOURNAL OF NEUROSURGERY			English	Article						traumatic brain injury; temporal trend; hospital volume; surgeon volume; outcome analysis	MANAGEMENT	Object. The purpose of this study was to evaluate temporal trends in traumatic brain injury (TBI); the impact of hospital volume and surgeon volume on length of stay (LOS), hospitalization cost, and in-hospital mortality rate; and to explore predictors of these outcomes in a nationwide population in Taiwan. Methods. This population-based patient cohort study retrospectively analyzed 16,956 patients who had received surgical treatment for TBI between 1998 and 2009. Bootstrap estimation was used to derive 95% confidence intervals for differences in effect sizes. Hierarchical linear regression models were used to predict outcomes. Results. Patients treated in very-high-volume hospitals were more responsive than those treated in low-volume hospitals in terms of LOS (-0.11; 95% CI -0.20 to -0.03) and hospitalization cost (-0.28; 95% CI -0.49 to -0.06). Patients treated by high-volume surgeons were also more responsive than those treated by low-volume surgeons in terms of LOS (-0.19; 95% CI -0.37 to -0.01) and hospitalization cost (-0.43; 95% CI -0.81 to -0.05). The mean LOS was 24.3 days and the average LOS for very-high-volume hospitals and surgeons was 61% and 64% shorter, respectively, than that for low-volume hospitals and surgeons. The mean hospitalization cost was US $7,292.10, and the average hospitalization cost for very-high-volume hospitals and surgeons was 19% and 22% lower, respectively, than that for low-volume hospitals and surgeons. Advanced age, male sex, high Charlson Comorbidity Index score, treatment in a low-volume hospital, and treatment by a low-volume surgeon were significantly associated with adverse outcomes (p < 0.001). Conclusions. The data suggest that annual surgical volume is the key factor in surgical outcomes in patients with TBI. The results improve the understanding of medical resource allocation for this surgical procedure, and can help to formulate public health policies for optimizing hospital resource utilization for related diseases. (http://thejns.org/doi/abs/10.3171/2012.12.JNS12693)	[Shi, Hon-Yi; Lee, King-Teh] Kaohsiung Med Univ, Dept Hlth Care Adm & Med Informat, Kaohsiung, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ Hosp, Dept Neurosurg, Kaohsiung 80708, Taiwan; [Hwang, Shiuh-Lin; Lin, Chih-Lung] Kaohsiung Med Univ, Fac Med, Coll Med, Kaohsiung, Taiwan; [Lee, King-Teh] Kaohsiung Med Univ Hosp, Dept Surg, Div Hepatobiliary Surg, Kaohsiung, Taiwan	Lin, CL (corresponding author), Kaohsiung Med Univ Hosp, Dept Neurosurg, 100 Shih Chun 1st Rd, Kaohsiung 80708, Taiwan.	hshi@kmu.edu.tw			National Science Council, TaiwanMinistry of Science and Technology, Taiwan [NSC99-2314-B-037-069-MY3]	This study was supported by funding from the National Science Council, Taiwan (Grant No. NSC99-2314-B-037-069-MY3). The authors report no conflict of interest concerning the materials and methods used in this study or the findings specified in this paper.	Bagshaw SM, 2007, CURR OPIN CRIT CARE, V13, P541, DOI 10.1097/MCC.0b013e3282e2a978; Cadotte DW, 2011, J NEUROSURG, V114, P1502, DOI 10.3171/2010.12.JNS10808; Chlu WT, 2007, J CLIN NEUROSCI, V14, P930, DOI 10.1016/j.jocn.2006.08.004; DEYO RA, 1992, J CLIN EPIDEMIOL, V45, P613, DOI 10.1016/0895-4356(92)90133-8; Funk LM, 2011, ANN SURG, V253, P912, DOI 10.1097/SLA.0b013e318213862f; Huang SJ, 2010, BRAIN INJURY, V24, P1606, DOI 10.3109/02699052.2010.523056; Livingston EH, 2010, JAMA-J AM MED ASSOC, V304, P95, DOI 10.1001/jama.2010.905; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Ogilvy CS, 2011, J NEUROSURG, V114, P120, DOI 10.3171/2010.3.JNS091384; Ogiso S, 2011, SURG ENDOSC, V25, P1907, DOI 10.1007/s00464-010-1485-0; Panageas KS, 2003, ANN INTERN MED, V139, P658, DOI 10.7326/0003-4819-139-8-200310210-00009; Pandor A, 2011, HEALTH TECHNOL ASSES, V15, P1, DOI 10.3310/hta15270; Peek-Asa C, 2011, ACCIDENT ANAL PREV, V43, P595, DOI 10.1016/j.aap.2010.07.019; Reaven Nancy L, 2009, J Intensive Care Med, V24, P131, DOI 10.1177/0885066608330211; Rosenthal G, 2011, J NEUROSURG, V114, P62, DOI 10.3171/2010.6.JNS091360; Saunders-Pullman R, 2011, GENDER MED, V8, P209, DOI 10.1016/j.genm.2011.05.002; Shamim MS, 2011, J NEUROSURG, V115, P1007, DOI 10.3171/2011.7.JNS101829; Singla A, 2010, SURG ENDOSC, V24, P662, DOI 10.1007/s00464-009-0665-2; Stein SC, 2010, J NEUROSURG, V112, P1105, DOI 10.3171/2009.8.JNS09738; Walkey AJ, 2011, CRIT CARE MED, V39, P1322, DOI 10.1097/CCM.0b013e3182120829; Warner MA, 2010, J NEUROSURG, V113, P539, DOI 10.3171/2009.12.JNS091337; Zheng C, 2011, SURG ENDOSC, V25, P249, DOI 10.1007/s00464-010-1167-y	22	23	23	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	APR	2013	118	4					732	738		10.3171/2012.12.JNS12693			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	114BT	WOS:000316715700008	23350773				2021-06-18	
J	Sullivan, S; Friess, SH; Ralston, J; Smith, C; Propert, KJ; Rapp, PE; Margulies, SS				Sullivan, Sarah; Friess, Stuart H.; Ralston, Jill; Smith, Colin; Propert, Kathleen J.; Rapp, Paul E.; Margulies, Susan S.			Behavioral Deficits and Axonal Injury Persistence after Rotational Head Injury Are Direction Dependent	JOURNAL OF NEUROTRAUMA			English	Article						behavioral assessments; cognitive function; pediatric brain injury; TBI	TRAUMATIC BRAIN-INJURY; QUANTITATIVE ASSESSMENT; ANIMAL-MODELS; RAT BEHAVIOR; NEONATAL PIG; SUS-SCROFA; RESPONSES; MICROSTRUCTURE; DISORDERS; PIGLETS	Pigs continue to grow in importance as a tool in neuroscience. However, behavioral tests that have been validated in the rodent model do not translate well to pigs because of their very different responses to behavioral stimuli. We refined metrics for assessing porcine open field behavior to detect a wide spectrum of clinically relevant behaviors in the piglet post-traumatic brain injury (TBI). Female neonatal piglets underwent a rapid non-impact head rotation in the sagittal plane (n = 8 evaluable) or were instrumented shams (n = 7 evaluable). Open field testing was conducted 1 day prior to injury (day -1) in order to establish an individual baseline for analysis, and at days +1 and +4 after injury. Animals were then killed on day +6 after injury for neuropathological assessment of axonal injury. Injured piglets were less interested in interacting with environmental stimuli and had a lower activity level than did shams. These data were compared with previously published data for axial rotational injuries in neonatal piglets. Acute behavioral outcomes post-TBI showed a dependence on the rotational plane of the brain injury, with animals with sagittal injuries demonstrating a greater level of inactivity and less random usage of the open field space than those with axial injuries. The persistence of axonal injury is also dependent on the rotational plane, with sagittal rotations causing more prolonged injuries than axial rotations. These results are consistent with animal studies, finite element models, and studies of concussions in football, which have all demonstrated differences in injury severity depending upon the direction of head impact rotation.	[Sullivan, Sarah; Ralston, Jill; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Propert, Kathleen J.] Univ Penn, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Friess, Stuart H.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Smith, Colin] Univ Edinburgh, Dept Pathol, Edinburgh, Midlothian, Scotland; [Rapp, Paul E.] Uniformed Serv Univ Hlth Sci, Dept Mil & Emergency Med, Bethesda, MD USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, 240 Skirkanich Hall,210 South 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu		Smith, Colin/0000-0002-4507-5132	National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, U01NS069545, K08NS064051]; Traumatic Injury Research Program of the Uniformed Services University of the Health Sciences; Defense Medical Research and Development Program; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, U01NS069545, K08NS064051] Funding Source: NIH RePORTER	The authors acknowledge Benjamin Bruins for his contribution in conducting the assessments. This study was made possible by the support of National Institutes of Health (NIH)/National Institute of Neurological Disorders and Stroke (NINDS) grants R01NS039679, U01NS069545, and K08NS064051. Dr. Rapp acknowledges support of the Traumatic Injury Research Program of the Uniformed Services University of the Health Sciences and the Defense Medical Research and Development Program. The opinions and assertions contained herein are the private opinions of the authors and are not to be construed as official or reflecting the views of their respective commands, the United States Navy, or the Department of Defense.	Cellucci CJ, 2005, PHYS REV E, V71, DOI 10.1103/PhysRevE.71.066208; Ciurli P, 2011, J HEAD TRAUMA REHAB, V26, P116, DOI 10.1097/HTR.0b013e3181dedd0e; DOBBING J, 1979, EARLY HUM DEV, V3, P79, DOI 10.1016/0378-3782(79)90022-7; Donald RD, 2011, PHYSIOL BEHAV, V104, P906, DOI 10.1016/j.physbeh.2011.05.031; Duhaime AC, 2006, DEV NEUROSCI-BASEL, V28, P380, DOI 10.1159/000094164; Emack J, 2011, HORM BEHAV, V60, P589, DOI 10.1016/j.yhbeh.2011.08.008; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Fang MR, 2005, NEUROSIGNALS, V14, P102, DOI 10.1159/000086292; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli TA., 1987, 872197 SAE; Gieling ET, 2011, CURR TOP BEHAV NEURO, V7, P359, DOI 10.1007/7854_2010_112; Gieling ET, 2011, ANIM COGN, V14, P151, DOI 10.1007/s10071-010-0364-3; Hagberg H, 2002, DEV NEUROSCI-BASEL, V24, P364, DOI 10.1159/000069040; Kanitz E, 2004, BRAIN BEHAV IMMUN, V18, P35, DOI 10.1016/S0889-1591(03)00085-0; Kant R, 1998, BRAIN INJURY, V12, P87, DOI 10.1080/026990598122908; Kim E, 2002, NEUROREHABILITATION, V17, P297; Kornum BR, 2011, NEUROSCI BIOBEHAV R, V35, P437, DOI 10.1016/j.neubiorev.2010.05.004; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; Lind NM, 2007, NEUROSCI BIOBEHAV R, V31, P728, DOI 10.1016/j.neubiorev.2007.02.003; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; Naim MY, 2010, DEV NEUROSCI-BASEL, V32, P466, DOI 10.1159/000322448; PAULUS MP, 1992, NEUROPSYCHOPHARMACOL, V7, P15; PAULUS MP, 1993, PSYCHOPHARMACOLOGY, V113, P177, DOI 10.1007/BF02245695; PAULUS MP, 1993, PSYCHOPHARMACOLOGY, V113, P187, DOI 10.1007/BF02245696; PAULUS MP, 1990, P NATL ACAD SCI USA, V87, P723, DOI 10.1073/pnas.87.2.723; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Rapp PE, 2011, BMC PSYCHIATRY, V11, DOI 10.1186/1471-244X-11-119; Rapp PE, 2007, COGN NEURODYNAMICS, V1, P287, DOI 10.1007/s11571-007-9027-8; Serebro-Sorek K, 2007, BRAIN INJURY, V21, P583, DOI 10.1080/02699050701426840; van der Staay FJ, 2009, PSYCHOPHARMACOLOGY, V206, P715, DOI 10.1007/s00213-009-1599-z; Watanabe TAA, 2003, PSYCHOPHYSIOLOGY, V40, P77, DOI 10.1111/1469-8986.00009; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Ylvisaker Mark, 2007, Phys Med Rehabil Clin N Am, V18, P133, DOI 10.1016/j.pmr.2006.11.007	38	23	23	0	7	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	APR	2013	30	7					538	545		10.1089/neu.2012.2594			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	133PD	WOS:000318150300005	23216054	Green Published			2021-06-18	
J	Tang, ZH; Sun, XC; Huo, G; Xie, YF; Shi, QH; Chen, S; Wang, XS; Liao, ZB				Tang, Zhaohua; Sun, Xiaochuan; Huo, Gang; Xie, Yanfeng; Shi, Quanhong; Chen, Song; Wang, Xiaoshu; Liao, Zhengbu			Protective effects of erythropoietin on astrocytic swelling after oxygen-glucose deprivation and reoxygenation: Mediation through AQP4 expression and MAPK pathway	NEUROPHARMACOLOGY			English	Article						Erythropoietin; Neuroprotection; Brain edema; Astrocyte; Aquaporin4; MAPK	RECOMBINANT-HUMAN-ERYTHROPOIETIN; FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; CULTURED ASTROCYTES; SUBARACHNOID HEMORRHAGE; GLIAL-CELLS; AQUAPORIN-4; PHOSPHORYLATION; KINASE; INHIBITION	Recent in vivo studies have shown that erythropoietin (EPO) offers strong protection against brain edema. However, the intracellular and molecular mechanisms behind this beneficial effect have not been specified. The aim of this study was to determine whether human erythropoietin (rhEPO) reduces the astrocytic swelling created by oxygen-glucose deprivation followed by reoxygenation (OGD/Reox) in vitro and whether this effect can be mediated through the modulation of aquaporin4 (AQP4) expression in the plasma membrane (PM) and phosphorylation of the mitogen-activated protein kinase pathway (MAPK) pathway. Our results showed that OGD/Reox produced increase in cell volume, morphological swelling, and mitochondrial swelling. These changes were associated with the up-regulation of AQP4 in PM and the over-activation of MAPK. Silencing AQP4 expression using small interfering ribonucleic acid for AQP4 was found to block astrocytic swelling. Inhibition of the over-activation of MAPK mitigated the PM AQP4 overabundance and cellular swelling. As expected, treatment with rhEPO significantly reduced the OGD/Reox-induced increase in cell volume, morphological swelling, and mitochondrial swelling as well as the up-regulation of AQP4 in PM. In addition, cultures treated with the neutralizing anti-EPO antibody worsened the PM AQP4 abundance and cellular swelling, abolishing the protective effects mediated by rhEPO treatment. Furthermore, the over-activation of these MAPK after OGD/Reox was attenuated by rhEPO treatment significantly. In conclusion, our data strongly suggest that rhEPO can protect astrocytes from swelling caused by ischemia and reperfusion-like injury. This neuroprotective capacity is partially mediated by diminishing the MAPK-activity-dependent overabundance of AQP4 in PM. (c) 2012 Elsevier Ltd. All rights reserved.	[Tang, Zhaohua; Sun, Xiaochuan; Huo, Gang; Xie, Yanfeng; Shi, Quanhong; Wang, Xiaoshu; Liao, Zhengbu] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing 400016, Peoples R China; [Chen, Song] Chongqing Med Univ, Lab Med Mol Biol, Chongqing 400016, Peoples R China	Liao, ZB (corresponding author), Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, 1 Youyi Rd, Chongqing 400016, Peoples R China.	liaozhengbu@hotmail.com		sun, xiao chuan/0000-0001-6992-332X	National Natural Science Funds of ChinaNational Natural Science Foundation of China (NSFC) [30801182]	This research was supported by the National Natural Science Funds of China (30801182). We would like to thank Xinggang Zhi for his technical assistance.	Badaut J, 2011, J CEREBR BLOOD F MET, V31, P819, DOI 10.1038/jcbfm.2010.163; Bender AS, 1998, J NEUROSCI RES, V54, P673, DOI 10.1002/(SICI)1097-4547(19981201)54:5<673::AID-JNR12>3.3.CO;2-G; Bouzat P, 2011, CRIT CARE MED, V39, P2099, DOI 10.1097/CCM.0b013e31821cb7b2; Brines M, 2004, P NATL ACAD SCI USA, V101, P14907, DOI 10.1073/pnas.0406491101; DUCIS I, 1990, BRAIN RES, V531, P318, DOI 10.1016/0006-8993(90)90793-B; Eid T, 2004, J NEUROPATH EXP NEUR, V63, P73, DOI 10.1093/jnen/63.1.73; Giovannini MG, 2001, J NEUROSCI, V21, P7053, DOI 10.1523/JNEUROSCI.21-18-07053.2001; Grasso G, 2002, P NATL ACAD SCI USA, V99, P5627, DOI 10.1073/pnas.082097299; He ZH, 2012, STROKE, V43, P484, DOI 10.1161/STROKEAHA.111.626432; Jayakumar AR, 2006, J NEUROSCI, V26, P4774, DOI 10.1523/JNEUROSCI.0120-06.2006; Kadohira I, 2008, BIOCHEM BIOPH RES CO, V377, P463, DOI 10.1016/j.bbrc.2008.09.155; Kilic E, 2005, FASEB J, V19, P2026, DOI 10.1096/fj.05-3941fje; KIMELBERG HK, 1995, J NEUROSURG, V83, P1051, DOI 10.3171/jns.1995.83.6.1051; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLETZIEN RF, 1975, ANAL BIOCHEM, V68, P537, DOI 10.1016/0003-2697(75)90649-1; Kreegipuu A, 1999, NUCLEIC ACIDS RES, V27, P237, DOI 10.1093/nar/27.1.237; Leist M, 2004, SCIENCE, V305, P239, DOI 10.1126/science.1098313; MARPLES D, 1995, AM J PHYSIOL-CELL PH, V269, pC655; Murray B, 1998, P NATL ACAD SCI USA, V95, P11975, DOI 10.1073/pnas.95.20.11975; Nielsen S, 1997, J NEUROSCI, V17, P171; Panickar KS, 2009, EXP NEUROL, V216, P420, DOI 10.1016/j.expneurol.2008.12.024; Qiao HM, 2012, BRAIN RES, V1448, P71, DOI 10.1016/j.brainres.2012.02.003; Rabie T, 2008, PHYSIOLOGY, V23, P263, DOI 10.1152/physiol.00016.2008; Rao KVR, 2011, J NEUROTRAUM, V28, P371, DOI 10.1089/neu.2010.1705; Rao KVR, 2010, GLIA, V58, P1490, DOI 10.1002/glia.21023; Su KH, 2011, J CELL PHYSIOL, V226, P3330, DOI 10.1002/jcp.22678; Talving P, 2010, ANN SURG, V251, P1, DOI 10.1097/SLA.0b013e3181b844fa; Valable S, 2010, J CEREBR BLOOD F MET, V30, P361, DOI 10.1038/jcbfm.2009.222; Wang XY, 2004, J NEUROCHEM, V91, P900, DOI 10.1111/j.1471-4159.2004.02769.x; Yang BX, 2008, J BIOL CHEM, V283, P15280, DOI 10.1074/jbc.M801425200; Yang D, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0033596; Yip HK, 2011, CRIT CARE, V15, DOI 10.1186/cc10002; Zechariah A, 2010, STROKE, V41, P1008, DOI 10.1161/STROKEAHA.109.574418; Zelenina M, 2010, NEUROCHEM INT, V57, P468, DOI 10.1016/j.neuint.2010.03.022; Zhang J, 2010, CYTOKINE, V52, P252, DOI 10.1016/j.cyto.2010.08.011; Zhuang SG, 2006, J PHARMACOL EXP THER, V319, P991, DOI 10.1124/jpet.106.107367	36	23	34	0	23	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908			NEUROPHARMACOLOGY	Neuropharmacology	APR	2013	67						8	15		10.1016/j.neuropharm.2012.10.017			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	097ME	WOS:000315477400002	23142737				2021-06-18	
J	Cockshell, SJ; Mathias, JL				Cockshell, Susan J.; Mathias, Jane L.			Cognitive Deficits in Chronic Fatigue Syndrome and Their Relationship to Psychological Status, Symptomatology, and Everyday Functioning	NEUROPSYCHOLOGY			English	Article						chronic fatigue syndrome; cognitive problems; depression; symptoms; everyday functioning	MONOZYGOTIC TWINS DISCORDANT; TRAUMATIC BRAIN-INJURY; SLEEP QUALITY INDEX; NEUROPSYCHOLOGICAL IMPAIRMENT; PROCESSING SPEED; DSM-IV; PERSONALITY; DEPRESSION; PERFORMANCE; COMPLAINTS	Objective: To examine cognitive deficits in people with chronic fatigue syndrome (CFS) and their relationship to psychological status, CFS symptoms, and everyday functioning. Method: The current study compared the cognitive performance (reaction time, attention, memory, motor functioning, verbal abilities, and visuospatial abilities) of a sample with CFS (n = 50) with that of a sample of healthy controls (n = 50), all of whom had demonstrated high levels of effort and an intention to perform well, and examined the extent to which psychological status, CFS symptoms, and everyday functioning were related to cognitive performance. Results: The CFS group showed impaired information processing speed (reaction time), relative to the controls, but comparable performance on tests of attention, memory, motor functioning, verbal ability, and visuospatial ability. Moreover, information processing speed was not related to psychiatric status, depression, anxiety, the number or severity of CFS symptoms, fatigue, sleep quality, or everyday functioning. Conclusion: A slowing in information processing speed appears to be the main cognitive deficit seen in persons with CFS whose performance on effort tests is not compromised. Importantly, this slowing does not appear to be the consequence of other CFS-related variables, such as depression and fatigue, or motor speed.	[Cockshell, Susan J.; Mathias, Jane L.] Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia	Mathias, JL (corresponding author), Univ Adelaide, Sch Psychol, Adelaide, SA 5005, Australia.	jane.mathias@adelaide.edu.au	Mathias, J L/L-6295-2013	Mathias, Jane/0000-0001-8957-8594			ABBEY SE, 1991, REV INFECT DIS, V13, pS73; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Ayotte BJ, 2009, INT J GERIATR PSYCH, V24, P1010, DOI 10.1002/gps.2213; Ball N, 2004, J PSYCHOSOM RES, V56, P207, DOI 10.1016/S0022-3999(03)00598-1; Beaver KM, 2012, PSYCHIAT QUART, V83, P145, DOI 10.1007/s11126-011-9190-2; Binder LM, 2004, J CLIN EXP NEUROPSYC, V26, P369, DOI 10.1080/13803390490510095; Busichio K, 2004, J INT NEUROPSYCH SOC, V10, P278, DOI 10.1017/S1355617704102178; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Cassimjee N, 2010, S AFR J PSYCHOL, V40, P125, DOI 10.1177/008124631004000202; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Christodoulou C, 1998, J NEUROL NEUROSUR PS, V64, P431, DOI 10.1136/jnnp.64.4.431; Clark K., 2006, MYALGIC ENCEPHALOPAT; Claypoole KH, 2007, NEUROPSYCHOLOGY, V21, P507, DOI 10.1037/0894-4105.21.4.507; Cockshell SJ, 2010, PSYCHOL MED, V40, P1253, DOI 10.1017/S0033291709992054; Cockshell SJ, 2012, J CLIN EXP NEUROPSYC, V34, P679, DOI 10.1080/13803395.2012.668176; COHEN J, 1992, PSYCHOL BULL, V112, P155, DOI 10.1037/0033-2909.112.1.155; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Courjaret J, 2009, J PSYCHOSOM RES, V66, P13, DOI 10.1016/j.jpsychores.2008.07.001; Deary V, 2010, PSYCHOL HEALTH, V25, P465, DOI 10.1080/08870440802403863; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Delis DC, 2000, CALIFORNIA VERBAL LE; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DeLuca J, 2004, REHABIL PSYCHOL, V49, P62, DOI 10.1037/0090-5550.49.1.62; DeLuca J, 2004, J INT NEUROPSYCH SOC, V10, P101; DeLuca J, 1997, J PSYCHIAT RES, V31, P83, DOI 10.1016/S0022-3956(96)00052-0; DeLuca J, 1997, J NEUROL NEUROSUR PS, V62, P151, DOI 10.1136/jnnp.62.2.151; Duits A, 2008, J NEUROL NEUROSUR PS, V79, P143, DOI 10.1136/jnnp.2007.114595; Fiedler N, 1996, PSYCHOSOM MED, V58, P38, DOI 10.1097/00006842-199601000-00007; Fossey M, 2004, J BEHAV MED, V27, P581, DOI 10.1007/s10865-004-0004-y; Fuentes K, 2001, CLIN NEUROPSYCHOL, V15, P210, DOI 10.1076/clin.15.2.210.1896; FUKUDA K, 1994, ANN INTERN MED, V121, P953, DOI 10.7326/0003-4819-121-12-199412150-00009; Fuller-Thomson E, 2008, FAM PRACT, V25, P414, DOI 10.1093/fampra/cmn064; GRAFMAN J, 1993, J NEUROL NEUROSUR PS, V56, P684, DOI 10.1136/jnnp.56.6.684; GRONWALL DMA, 1977, PERCEPT MOTOR SKILL, V44, P367, DOI 10.2466/pms.1977.44.2.367; Harvey SB, 2008, PSYCHOL MED, V38, P933, DOI 10.1017/S0033291707001900; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Henderson M, 2005, J PSYCHOSOM RES, V59, P181, DOI 10.1016/j.jpsychores.2004.04.374; Henderson M, 2004, J PSYCHOSOM RES, V56, P251, DOI 10.1016/S0022-3999(03)00571-3; Jason L. A., 2003, HDB CHRONIC FATIGUE, P417; Jason LA, 1999, ARCH INTERN MED, V159, P2129, DOI 10.1001/archinte.159.18.2129; Johnson S K, 1997, Appl Neuropsychol, V4, P145, DOI 10.1207/s15324826an0403_1; JOHNSON SK, 1994, CLIN INFECT DIS, V18, pS84, DOI 10.1093/clinids/18.Supplement_1.S84; Kane RL, 1997, NEUROPSY NEUROPSY BE, V10, P25; KRUPP LB, 1994, ARCH NEUROL-CHICAGO, V51, P705, DOI 10.1001/archneur.1994.00540190089021; Le Bon O, 2000, Sleep Res Online, V3, P43; Magee CA, 2008, SLEEP BIOL RHYTHMS, V6, P222, DOI 10.1111/j.1479-8425.2008.00371.x; Mahurin RK, 2004, NEUROPSYCHOLOGY, V18, P232, DOI 10.1037/0894-4105.18.2.232; Marshall PS, 1997, PSYCHOSOM MED, V59, P58, DOI 10.1097/00006842-199701000-00008; Metzger FA, 2002, ANN BEHAV MED, V24, P106, DOI 10.1207/S15324796ABM2402_07; Michiels V, 1998, J INT NEUROPSYCH SOC, V4, P456, DOI 10.1017/S135561779845505X; Michiels V, 2001, ACTA PSYCHIAT SCAND, V103, P84, DOI 10.1034/j.1600-0447.2001.00017.x; Morriss RK, 1998, J ROY SOC MED, V91, P365, DOI 10.1177/014107689809100706; MossMorris R, 1996, J NEUROL NEUROSUR PS, V60, P474, DOI 10.1136/jnnp.60.5.474; Nater UM, 2010, PSYCHOTHER PSYCHOSOM, V79, P312, DOI 10.1159/000319312; Porter RJ, 2007, AUST NZ J PSYCHIAT, V41, P115, DOI 10.1080/00048670601109881; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Short K, 2002, J PSYCHOSOM RES, V52, P475, DOI 10.1016/S0022-3999(02)00290-8; Smith A, 1996, HUM PSYCHOPHARM CLIN, V11, P161, DOI 10.1002/(SICI)1099-1077(199605)11:3<161::AID-HUP784>3.0.CO;2-5; Stulemeijer M, 2007, J PSYCHOSOM RES, V63, P637, DOI 10.1016/j.jpsychores.2007.06.023; Sullivan KA, 2012, BRAIN INJURY, V26, P1098, DOI 10.3109/02699052.2012.666367; Tabachnick BG, 2007, USING MULTIVARIATE S; Thomas Marie, 2009, Open Neurol J, V3, P13, DOI 10.2174/1874205X00903010013; Tiersky L A, 2001, Appl Neuropsychol, V8, P41, DOI 10.1207/S15324826AN0801_6; Tiersky LA, 2000, MIL PSYCHOL, V12, P233, DOI 10.1207/S15327876MP1204_01; Tiersky LA, 2003, J NERV MENT DIS, V191, P324, DOI 10.1097/00005053-200305000-00008; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; Tiersky LA, 1998, CLIN NEUROPSYCHOL, V12, P503, DOI 10.1076/clin.12.4.503.7237; Unger ER, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-6; van der Werf SP, 2000, NEUROPSY NEUROPSY BE, V13, P199; van der Werf SP, 2002, NEUROPSY NEUROPSY BE, V15, P2; van Geelen SM, 2007, CLIN PSYCHOL REV, V27, P885, DOI 10.1016/j.cpr.2007.01.010; Vercoulen JHMM, 1998, J CLIN EXP NEUROPSYC, V20, P144, DOI 10.1076/jcen.20.2.144.1160; VERCOULEN JHMM, 1994, J PSYCHOSOM RES, V38, P383, DOI 10.1016/0022-3999(94)90099-X; Wagner David L., 2005, P8; Ware JE., 2001, SF 36 PHYS MENTAL HL, V2; Wearden A, 1997, PSYCHOL MED, V27, P81, DOI 10.1017/S0033291796004035; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7; Wolfson D., 1993, HALSTEAD REITAN NEUR; Wood B, 1999, J PSYCHOSOM RES, V47, P385, DOI 10.1016/S0022-3999(99)00025-2; Zakzanis KK, 1998, NEUROPSY NEUROPSY BE, V11, P111; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	81	23	25	0	27	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	MAR	2013	27	2					230	242		10.1037/a0032084			13	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	111NT	WOS:000316528700010	23527651				2021-06-18	
J	Kurowski, BG; Wade, SL; Kirkwood, MW; Brown, TM; Stancin, T; Cassedy, A; Taylor, HG				Kurowski, Brad G.; Wade, Shari L.; Kirkwood, Michael W.; Brown, Tanya M.; Stancin, Terry; Cassedy, Amy; Taylor, H. Gerry			Association of Parent Ratings of Executive Function With Global- and Setting-Specific Behavioral Impairment After Adolescent Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article; Proceedings Paper	Meeting of the Association-of-Academic-Physiatrists	APR 14, 2011	Phoenix, AZ	Assoc Acad Physiatrists		Adolescent; Brain injuries; Executive function; Memory; Rehabilitation	PROBLEM-SOLVING SKILLS; SELF-REGULATION; CRITERION VALIDITY; SOCIAL COMPETENCE; YOUNG-CHILDREN; FOLLOW-UP; CHILDHOOD; TERM; OUTCOMES; TBI	Objective: To determine the association of primary caregiver-rated behavioral and metacognitive aspects of executive function (EF) with impaired functioning after adolescent traumatic brain injury (TBI). Design: Multicenter cross-sectional study. Setting: Outpatient. Participants: Primary caregivers and children (N=132) aged 12 to 17 years who sustained a moderate or severe TBI within the past 1 to 6 months. Interventions: Not applicable. Main Outcome Measures: Primary caregiver ratings of EF, tests of memory and processing speed (PS), and a structured parent interview to assess clinical impairments in behavioral functioning were used. Logistic regression was used to examine the relation of ratings of EF with clinical ratings of impairment in global adolescent functioning and in functioning in the home, school, and community settings after controlling for sex, race, socioeconomic status, injury severity, and performance on the tests of memory and PS. Results: Caregiver ratings of poor EF were associated with impairment in both global behavioral functioning (odds ratio [OR] = 4.73; 95% confidence interval [CI], 1.54-14.52; P<.01) and community functioning (OR = 13.28; 95% CI, 1.94-90.87; P<.01). Conclusions: Caregiver ratings of deficits in EF were associated with impaired behavioral functioning after adolescent TBI and were independent of performance on tests of memory and processing speed. Understanding the relation of EF with clinical impairments as manifested in different settings will help hone assessment batteries and focus treatments where they are needed most. Archives of Physical Medicine and Rehabilitation 2013;94:543-50 (C) 2013 by the American Congress of Rehabilitation Medicine	[Kurowski, Brad G.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Kurowski, Brad G.; Wade, Shari L.; Cassedy, Amy] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Kirkwood, Michael W.] Childrens Hosp Colorado, Dept Phys Med & Rehabil, Aurora, CO USA; [Kirkwood, Michael W.] Univ Colorado, Sch Med, Aurora, CO USA; [Brown, Tanya M.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Stancin, Terry] Metrohlth Med Ctr, Dept Pediat, Div Pediat Psychol, Cleveland, OH USA; [Stancin, Terry] Case Western Reserve Univ, Cleveland, OH 44106 USA; [Cassedy, Amy] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Div Biostat & Epidemiol, Cincinnati, OH 45229 USA; [Taylor, H. Gerry] Case Western Reserve Univ, Dept Pediat, Div Dev & Behav Pediat & Psychol, Cleveland, OH 44106 USA; [Taylor, H. Gerry] Univ Hosp Case Med Ctr, Rainbow Babies & Childrens Hosp, Cleveland, OH USA	Kurowski, BG (corresponding author), Cincinnati Childrens Hosp Med Ctr, 3333 Burnet Ave,MLC 4009, Cincinnati, OH 45229 USA.	brad.kurowski@cchmc.org	Stancin, Terry/L-7993-2019		NCATS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1 TR000077] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [2K12 HD001097-16, K12 HD001097] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01-MH073764, R01 MH073764] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH073764] Funding Source: NIH RePORTER		Allen DN, 2010, PSYCHOL ASSESSMENT, V22, P57, DOI 10.1037/a0016056; Anderson P, 2002, CHILD NEUROPSYCHOL, V8, P71, DOI 10.1076/chin.8.2.71.8724; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V A, 1999, Pediatr Rehabil, V3, P159; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Centers for Disease Control and Prevention, INJ PREV CONTR TRAM; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; DeJong J, 2009, ASSESSMENT, V16, P328, DOI 10.1177/1073191109336989; Delis D, 1994, CALIFORNIA VERBAL LE; Delis DC, 2000, CALIFORNIA VERBAL LE; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; Donders J, 2008, J INT NEUROPSYCH SOC, V14, P651, DOI 10.1017/S1355617708080752; Donders J, 2010, J NEUROPSYCHOL, V4, P197, DOI 10.1348/174866409X478970; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; Ganesalingam K, 2011, NEUROPSYCHOLOGY, V25, P466, DOI 10.1037/a0022768; Ganesalingam K, 2007, J NEUROPSYCHOL, V1, P149, DOI 10.1348/174866407X185300; Gioia G. A., 2000, BRIEF BEHAV RATING I; Gioia G. A., 2003, BRIEF P BEHAV RATING; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2000, CHILD NEUROPSYCHOL, V6, P235, DOI 10.1076/chin.6.3.235.3152; HODGES K, 1999, J CHILD FAM STUD, V8, P109; Hodges K., 1996, J CHILD FAM STUD, V5, P445, DOI [10.1007/BF02233865, DOI 10.1007/BF02233865]; Hodges K., 2005, CAFAS MANUAL TRAININ, V3; Hodges K., 2004, J CHILD FAM STUD, V13, P325, DOI [10.1023/B:, DOI 10.1023/B]; Horneman G, 2009, BRAIN INJURY, V23, P907, DOI 10.1080/02699050903283239; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; Janusz JA, 2002, CHILD NEUROPSYCHOL, V8, P179, DOI 10.1076/chin.8.3.179.13499; Jonsson CA, 2009, BRAIN INJURY, V23, P1008, DOI 10.3109/02699050903379354; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Mangeot S, 2002, CHILD NEUROPSYCHOL, V8, P271, DOI 10.1076/chin.8.4.271.13503; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P223, DOI 10.1016/S0003-9993(96)90102-1; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; MCDONALD CM, 1994, ARCH PHYS MED REHAB, V75, P328, DOI 10.1016/0003-9993(94)90038-8; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; Muscara F, 2008, J NEUROPSYCHOL, V2, P445, DOI 10.1348/174866407X250820; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Quist RM, 2000, ADOLESCENCE, V35, P181; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; Ryu WHA, 2010, INT J REHABIL RES, V33, P84, DOI 10.1097/MRR.0b013e32832e6b4b; Sesma HW, 2008, PEDIATRICS, V121, pE1686, DOI 10.1542/peds.2007-2461; Shanahan L, 2011, BRAIN INJURY, V25, P1080, DOI 10.3109/02699052.2011.607781; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Struchen MA, 2008, NEUROREHABILITATION, V23, P185; TEASDALE G, 1974, LANCET, V2, P81; Tonks James, 2011, Clin Child Psychol Psychiatry, V16, P185, DOI 10.1177/1359104511403583; Vriezen ER, 2002, CHILD NEUROPSYCHOL, V8, P296, DOI 10.1076/chin.8.4.296.13505; Ward H, 2007, CHILD NEUROPSYCHOL, V13, P219, DOI 10.1080/09297040600910003; Wechsler D, 2003, WISC 4 ADM MANUAL; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wood RLL, 2006, J INT NEUROPSYCH SOC, V12, P350, DOI 10.1017/S1355617706060498; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2004, J INT NEUROPSYCH SOC, V10, P412, DOI 10.1017/S1355617704103093	58	23	23	4	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2013	94	3					543	550		10.1016/j.apmr.2012.10.029			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	106PZ	WOS:000316158500020	23131527	Green Accepted			2021-06-18	
J	Pretz, CR; Kozlowski, AJ; Dams-O'Connor, K; Kreider, S; Cuthbert, JP; Corrigan, JD; Heinemann, AW; Whiteneck, G				Pretz, Christopher R.; Kozlowski, Allan J.; Dams-O'Connor, Kristen; Kreider, Scott; Cuthbert, Jeffery P.; Corrigan, John D.; Heinemann, Allen W.; Whiteneck, Gale			Descriptive Modeling of Longitudinal Outcome Measures in Traumatic Brain Injury: A National Institute on Disability and Rehabilitation Research Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Longitudinal studies; Regression analysis; Rehabilitation; Rehabilitation outcome; Traumatic brain injury	FUNCTIONAL INDEPENDENCE MEASURE; INPATIENT REHABILITATION; FIM INSTRUMENT; SCALE	Establishing accurate mathematical models of outcome measures is essential in understanding change throughout the rehabilitation process. The goal of this study is to identify the best-fitting descriptive models for a set of commonly adopted outcome measures found within the Traumatic Brain Injury Model Systems National Database where the modeling is based on data submission through 2011 and the complete range of recorded time points since injury for each individual, where time points range from admission to rehabilitation to 20 years postinjury. The statistical methodology and the application of the methodology contained herein may be used to assist researchers and clinicians in (1) modeling the outcome measures considered, (2) modeling various portions of these outcomes by stratification and/or truncating time periods, (3) modeling longitudinal outcome measures not considered, and (4) establishing models as a necessary precursor in conducting individual growth curve analysis. Archives of Physical Medicine and Rehabilitation 2013;94:579-88 (C) 2013 by the American Congress of Rehabilitation Medicine	[Pretz, Christopher R.; Kreider, Scott; Cuthbert, Jeffery P.; Whiteneck, Gale] Craig Hosp, Englewood, CO 80132 USA; [Pretz, Christopher R.; Kreider, Scott; Cuthbert, Jeffery P.; Whiteneck, Gale] Traumat Brain Injury Natl Stat & Data Ctr, Englewood, CO 80132 USA; [Kozlowski, Allan J.; Heinemann, Allen W.] Rehabil Inst Chicago, Ctr Rehabil Outcomes Res, Chicago, IL 60611 USA; [Kozlowski, Allan J.] Northwestern Univ, Feinberg Med Sch, Ctr Healthcare Studies, Chicago, IL 60611 USA; [Heinemann, Allen W.] Northwestern Univ, Feinberg Med Sch, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Dams-O'Connor, Kristen] Mt Sinai Sch Med, New York, NY USA; [Corrigan, John D.] Ohio State Univ, Wexner Med Ctr, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Pretz, CR (corresponding author), Craig Hosp, 3425 South Clarkson St, Englewood, CO 80132 USA.	cpretz@craighospital.org	Heinemann, Allen W/K-6283-2012; Heinemann, Allen W./AAI-2790-2021	Heinemann, Allen W/0000-0003-2782-7326; Heinemann, Allen W./0000-0003-2782-7326	Traumatic Brain Injury Model Systems National Data and Statistical Center; National Institute on Disability and Rehabilitation Research (NIDRR) [H133A110006]; NIDRR through the Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes [H133B090024]; Traumatic Brain Injury Model System Centers grants from the NIDRR [H133A070029]; Mount Sinai Medical Center [H133A070033]	Supported by the Traumatic Brain Injury Model Systems National Data and Statistical Center, the National Institute on Disability and Rehabilitation Research (NIDRR) (grant no. H133A110006); the NIDRR through the Rehabilitation Research and Training Center on Improving Measurement of Medical Rehabilitation Outcomes (grant no. H133B090024); and Traumatic Brain Injury Model System Centers grants from the NIDRR to Ohio State University (grant no. H133A070029) and Mount Sinai Medical Center (grant no. H133A070033).	Boake C, 2000, SUPERVISION RATING S; Burnham KP, 2004, SOCIOL METHOD RES, V33, P261, DOI 10.1177/0049124104268644; DeLucia C, 2006, J PEDIATR PSYCHOL, V31, P1002, DOI 10.1093/jpepsy/jsj074; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2010, J HEAD TRAUMA REHAB, V25, P81, DOI 10.1097/HTR.0b013e3181cd3528; Fitzmaurice GM., 2004, APPL LONGITUDINAL AN; Granger CV, 2007, AM J PHYS MED REHAB, V86, P883, DOI 10.1097/PHM.0b013e318152058a; Houlden H, 2006, CLIN REHABIL, V20, P153, DOI 10.1191/0269215506cr917oa; Jackson DL, 2010, REHABIL PSYCHOL, V55, P272, DOI 10.1037/a0020462; Kozlowski AJ, 2013, ARCH PHYS MED REHAB, V94, P589, DOI 10.1016/j.apmr.2012.08.199; Kwok OM, 2008, REHABIL PSYCHOL, V53, P370, DOI 10.1037/a0012765; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; Raudenbush S. W., 2001, HIERARCHICAL LINEAR; Scheuringer M, 2011, EUR J PHYS REHAB MED, V47, P25; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013; Singer J.D., 2003, APPL LONGITUDINAL DA; The SAS Institute, MIXED PROC; Traumatic Brain Injury Model Systems, TRAUM BRAIN INJ MOD; Warschausky S, 2001, ARCH PHYS MED REHAB, V82, P329, DOI 10.1053/apmr.2001.21510; Williams G, 2006, ARCH PHYS MED REHAB, V87, P437, DOI 10.1016/j.apmr.2005.10.028; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	21	23	23	0	9	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2013	94	3					579	588		10.1016/j.apmr.2012.08.197			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	106PZ	WOS:000316158500025	22902888				2021-06-18	
J	Yeo, RA; Thoma, RJ; Gasparovic, C; Monnig, M; Harlaar, N; Calhoun, VD; Kalyanam, R; Mayer, AR; Durazzo, TC; Hutchison, KE				Yeo, Ronald A.; Thoma, Robert J.; Gasparovic, Charles; Monnig, Mollie; Harlaar, Nicole; Calhoun, Vince D.; Kalyanam, Ravi; Mayer, Andrew R.; Durazzo, Timothy C.; Hutchison, Kent E.			Neurometabolite concentration and clinical features of chronic alcohol use: A proton magnetic resonance spectroscopy study	PSYCHIATRY RESEARCH-NEUROIMAGING			English	Article						Alcohol use disorders; Magnetic resonance spectroscopy; Choline; NAA	TRAUMATIC BRAIN-INJURY; GENE-EXPRESSION; RAT-BRAIN; CONSUMPTION; WITHDRAWAL; EXPOSURE; CHOLINE; CORTEX; DAMAGE; SCALE	Chronic, heavy alcohol consumption may affect the concentration of neurometabolites assessed with proton magnetic resonance spectroscopy (H-1-MRS). We investigated the largest sample reported to date (N=213) with the primary goal of determining how specific clinical features impact neurometabolite concentrations in an anterior cingulate gray matter voxel. This community-dwelling sample included both treatment-seeking and non-treatment-seeking individuals. A healthy control group (N=66) was matched for age and education. In multivariate analyses predicting neurometabolite concentrations, the heavy drinking group had greater concentrations overall. An age by group interaction was noted, as group difference across neurometabolites increased with age. More years drinking, but not more drinks per drinking day (DPDD), predicted greater concentrations of choline-containing compounds (Cho), creatine-phosphocreatine (Cre), glutamate-glutamine (Glx), and N-acetyl-aspartate (NAA). The effects of other clinical variables (depression, cigarette smoking, marijuana use) were negligible. After controlling for DPDD and years drinking, treatment-seeking status had no impact on neurometabolites. In the very oldest portion of the sample (mean age=50), however, a negative relationship was seen between NAA and years drinking. These results suggest that the nature of neurometabolite abnormalities in chronic heavy drinkers may vary as a function of duration of abuse. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Yeo, Ronald A.; Gasparovic, Charles; Monnig, Mollie; Mayer, Andrew R.] Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA; [Yeo, Ronald A.; Thoma, Robert J.; Gasparovic, Charles; Harlaar, Nicole; Calhoun, Vince D.; Kalyanam, Ravi; Mayer, Andrew R.; Hutchison, Kent E.] Mind Res Network, Albuquerque, NM USA; [Calhoun, Vince D.] Univ New Mexico, Dept Elect & Comp Engn, Albuquerque, NM 87131 USA; [Thoma, Robert J.] Univ New Mexico, Dept Psychiat, Albuquerque, NM 87131 USA; [Durazzo, Timothy C.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA; [Hutchison, Kent E.] Univ Colorado, Dept Psychol & Neurosci, Boulder, CO 80309 USA	Yeo, RA (corresponding author), Univ New Mexico, Dept Psychol, Albuquerque, NM 87131 USA.	ryeo@unm.edu			National Institute on Alcoholism and Alcohol AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA012238, AA013930]; National Institute of Biomedical Imaging and BioengineeringUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB005846]; Mind Research Network; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB005846] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA012238, R29AA012238, R01AA014886, F31AA021631] Funding Source: NIH RePORTER	This research was supported by grants from the National Institute on Alcoholism and Alcohol Abuse (AA012238 and AA013930; KH), the National Institute of Biomedical Imaging and Bioengineering (R01EB005846; VDC) and a grant from the Mind Research Network.	Beck AT., 1996, BECK DEPRESSION INVE, V2; Beckmann M, 2009, J NEUROSCI, V29, P1175, DOI 10.1523/JNEUROSCI.3328-08.2009; Cohen E, 2007, DRUG ALCOHOL DEPEN, V86, P214, DOI 10.1016/j.drugalcdep.2006.06.008; Crews FT, 2009, ALCOHOL ALCOHOLISM, V44, P115, DOI 10.1093/alcalc/agn079; Durazzo TC, 2004, ALCOHOL CLIN EXP RES, V28, P1849, DOI 10.1097/01.ALC.0000148112.92525.AC; Ende G, 2005, BIOL PSYCHIAT, V58, P974, DOI 10.1016/j.biopsych.2005.05.038; Ende G, 2006, NEUROIMAGE, V32, P740, DOI 10.1016/j.neuroimage.2006.03.049; Fein G, 2005, ALCOHOL, V35, P19, DOI 10.1016/j.alcohol.2004.10.007; Flatscher-Bader T, 2006, GENES BRAIN BEHAV, V5, P78, DOI 10.1111/j.1601-183X.2006.00197.x; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; Gallinat J, 2007, PHARMACOPSYCHIATRY, V40, P64, DOI 10.1055/s-2007-970144; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Garnett MR, 2000, BRAIN, V123, P2046, DOI 10.1093/brain/123.10.2046; Gasparovic C, 2001, J NEUROTRAUM, V18, P241, DOI 10.1089/08977150151070856; Gasparovic C, 2009, J NEUROTRAUM, V26, P1635, DOI [10.1089/neu.2009.0896, 10.1089/neu.2009-0896]; Gazdzinski S, 2008, ALCOHOL, V42, P67, DOI 10.1016/j.alcohol.2008.01.002; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; Kantarci K, 2007, BRIT J RADIOL, V80, pS146, DOI 10.1259/bjr/60346217; KLOSE U, 1990, MAGNET RESON MED, V14, P26, DOI 10.1002/mrm.1910140104; Lambe EK, 2003, NEUROPSYCHOPHARMACOL, V28, P216, DOI 10.1038/sj.npp.1300032; Lee H, 2003, J MAGN RESON IMAGING, V18, P147, DOI 10.1002/jmri.10335; Maddock R.J., 2012, CURRENT TOPICS BEHAV; Makris N, 2008, BIOL PSYCHIAT, V64, P192, DOI 10.1016/j.biopsych.2008.01.018; Meyerhoff D. J., 2011, CURRENT TOPICS BEHAV; Meyerhoff DJ, 2004, ALCOHOL CLIN EXP RES, V28, P650, DOI 10.1097/01.ALC.0000121805.12350.CA; Moffett JR, 2007, PROG NEUROBIOL, V81, P89, DOI 10.1016/j.pneurobio.2006.12.003; Mullins PG, 2008, MAGN RESON MED, V60, P964, DOI 10.1002/mrm.21696; Oscar-Berman M, 2007, NEUROPSYCHOL REV, V17, P239, DOI 10.1007/s11065-007-9038-6; Pan Y, 2011, BEHAV BRAIN RES, V216, P66, DOI 10.1016/j.bbr.2010.07.017; Pederzolli CD, 2009, METAB BRAIN DIS, V24, P283, DOI 10.1007/s11011-009-9137-6; Provencher SW, 2001, NMR BIOMED, V14, P260, DOI 10.1002/nbm.698; ROSS HE, 1990, J STUD ALCOHOL, V51, P506, DOI 10.15288/jsa.1990.51.506; Schweinsburg BC, 2003, AM J PSYCHIAT, V160, P1180, DOI 10.1176/appi.ajp.160.6.1180; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; SKINNER HA, 1982, J ABNORM PSYCHOL, V91, P199, DOI 10.1037/0021-843X.91.3.199; Smith S, 2010, ALCOHOL CLIN EXP RES, V34, P2097, DOI 10.1111/j.1530-0277.2010.01306.x; SULLIVAN JT, 1989, BRIT J ADDICT, V84, P1353; Surendran S, 2011, INT J NEUROSCI, V121, P305, DOI 10.3109/00207454.2011.558225; Yeo RA, 2006, J NEUROTRAUM, V23, P1427, DOI 10.1089/neu.2006.23.1427; Yeo RA, 2011, J NEUROTRAUM, V28, P1, DOI 10.1089/neu.2010.1578; Zahr NM, 2009, NEUROPSYCHOPHARMACOL, V34, P1427, DOI 10.1038/npp.2008.119	41	23	25	0	13	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0925-4927	1872-7506		PSYCHIAT RES-NEUROIM	Psychiatry Res. Neuroimaging	FEB 28	2013	211	2					141	147		10.1016/j.pscychresns.2012.05.005			7	Clinical Neurology; Neuroimaging; Psychiatry	Neurosciences & Neurology; Psychiatry	115RA	WOS:000316828400007	23154093	Green Accepted			2021-06-18	
J	Paintlia, MK; Paintlia, AS; Singh, AK; Singh, I				Paintlia, Manjeet K.; Paintlia, Ajaib S.; Singh, Avtar K.; Singh, Inderjit			S-Nitrosoglutathione Induces Ciliary Neurotrophic Factor Expression in Astrocytes, Which Has Implications to Protect the Central Nervous System under Pathological Conditions	JOURNAL OF BIOLOGICAL CHEMISTRY			English	Article							FIBRILLARY ACIDIC PROTEIN; ACTIVATED-RECEPTOR-GAMMA; TRAUMATIC BRAIN-INJURY; NITRIC-OXIDE ACTIVATION; IN-VITRO; SIGNALING PATHWAY; GLIAL-CELLS; CYCLOOXYGENASE-2 EXPRESSION; OLIGODENDROCYTE PROGENITORS; DEMYELINATING DISEASES	Accumulating evidence suggests that reactive astrogliosis has beneficial and detrimental outcomes in various CNS disorders, but the mechanism behind this dichotomy is unclear. Recent advances in this direction suggested that NO signaling is critical to regulate the outcomes of reactive astrogliosis in vivo. Using biochemical and genetic approaches, we here investigated the effect of S-nitrosoglutathione (GSNO; a physiological NO donor) in astrocytes in vitro settings. GSNO enhanced the expressions of glial fibrillary acidic protein and neurotrophic factors including ciliary neurotrophic factor (CNTF) in astrocytes in a dose-dependent manner. The enhanced CNTF expression in GSNO-treated astrocytes was ascribed to NO-mediated sGC/cGMP/PKG signaling. It was associated with p38 MAPK-dependent increased peroxisome proliferator-activated receptor-gamma transactivation. In addition, the chromatin accessibility of peroxisome proliferator-activated receptor-gamma accompanied with ATF2 and CREB (cAMP-response element-binding protein) was enhanced across the CNTF gene promoter in GSNO treated astrocytes. Interestingly, secreted CNTF was responsible for increased expression of glial fibrillary acidic protein in GSNO-treated astrocytes in an autocrine manner via a JAK2- and STAT3-dependent mechanism. In addition, CNTF secreted by GSNO-treated astrocytes enhanced the differentiation of immature oligodendrocytes in vitro. These effects of GSNO were consistent with an endogenously produced NO in astrocytes stimulated with proinflammatory cytokines in vitro. We conclude that NO signaling induces CNTF expression in astrocytes that favors the beneficial outcomes of reactive astrogliosis in vivo. Our data suggest that the endogenously produced NO or its exogenous source has potential to modulate the outcomes of reactive astrogliosis to protect CNS under pathological conditions.	[Paintlia, Manjeet K.; Paintlia, Ajaib S.; Singh, Inderjit] Med Univ S Carolina, Dept Pediat, Darby Childrens Res Inst, Charleston, SC 29425 USA; [Singh, Avtar K.] Ralph H Johnson Vet Affairs Med Ctr, Dept Pathol & Lab Med, Charleston, SC 29425 USA	Singh, I (corresponding author), Med Univ S Carolina, Dept Pediat, 173 Ashley Ave, Charleston, SC 29425 USA.	singhi@musc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-22576, NS-37766, VA-1BX001072, VA-BX001999, C06 RR018823, C06 RR015455]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [C06RR015455, C06RR018823] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS072511, R37NS022576, R01NS037766, R01NS022576] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX001072] Funding Source: NIH RePORTER	This work was supported, in whole or in part, by National Institutes of Health Grants NS-22576, NS-37766, VA-1BX001072, VA-BX001999, C06 RR018823, and C06 RR015455.	Abramov AY, 2005, PHILOS T R SOC B, V360, P2309, DOI 10.1098/rstb.2005.1766; Albrecht PJ, 2003, NEUROBIOL DIS, V13, P89, DOI 10.1016/S0969-9961(03)00019-6; ARNOLD WP, 1977, P NATL ACAD SCI USA, V74, P3203, DOI 10.1073/pnas.74.8.3203; Bayir H, 2007, J NEUROCHEM, V101, P168, DOI 10.1111/j.1471-4159.2006.04353.x; Bishop A, 2005, TOXICOLOGY, V208, P193, DOI 10.1016/j.tox.2004.11.034; Brahmachari S, 2006, J NEUROSCI, V26, P4930, DOI 10.1523/JNEUROSCI.5480-05.2006; Browning DD, 1999, J BIOL CHEM, V274, P537, DOI 10.1074/jbc.274.1.537; Browning DD, 2000, J BIOL CHEM, V275, P2811, DOI 10.1074/jbc.275.4.2811; BRUHWYLER J, 1993, NEUROSCI BIOBEHAV R, V17, P373, DOI 10.1016/S0149-7634(05)80114-9; Chien WL, 2008, EUR J PHARMACOL, V590, P233, DOI 10.1016/j.ejphar.2008.06.040; Chou PCT, 2011, J MAGN RESON IMAGING, V33, P1301, DOI 10.1002/jmri.22574; Ciani E, 2002, J NEUROCHEM, V82, P1282, DOI 10.1046/j.1471-4159.2002.01080.x; Crowe DL, 2000, ANTICANCER RES, V20, P2945; Dong YS, 2001, GLIA, V36, P180, DOI 10.1002/glia.1107; Doronzo G, 2011, ATHEROSCLEROSIS, V216, P44, DOI 10.1016/j.atherosclerosis.2011.01.019; ENG LF, 1994, BRAIN PATHOL, V4, P229, DOI 10.1111/j.1750-3639.1994.tb00838.x; Escartin C, 2007, J NEUROSCI, V27, P7094, DOI 10.1523/JNEUROSCI.0174-07.2007; GHIRNIKAR RS, 1994, J NEUROSCI RES, V38, P376, DOI 10.1002/jnr.490380403; GIULIAN D, 1986, J NEUROSCI, V6, P2163; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Han J, 1997, NATURE, V386, P296, DOI 10.1038/386296a0; Hebert MA, 2000, ANN NY ACAD SCI, V914, P238, DOI 10.1111/j.1749-6632.2000.tb05200.x; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Hess DT, 2012, J BIOL CHEM, V287, P4411, DOI 10.1074/jbc.R111.285742; Hess DT, 2005, NAT REV MOL CELL BIO, V6, P150, DOI 10.1038/nrm1569; HUGHES SM, 1988, NATURE, V335, P70, DOI 10.1038/335070a0; Janabi N, 2002, J IMMUNOL, V168, P4747, DOI 10.4049/jimmunol.168.9.4747; Kacem K, 1998, GLIA, V23, P1; Kahn MA, 1997, J NEUROCHEM, V68, P1413; Khan M, 2005, J CEREBR BLOOD F MET, V25, P177, DOI 10.1038/sj.jcbfm.9600012; Khan M, 2006, NITRIC OXIDE-BIOL CH, V15, P114, DOI 10.1016/j.niox.2006.01.008; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Li ZM, 2004, J NEUROSCI RES, V78, P824, DOI 10.1002/jnr.20346; LIPTON SA, 1993, NATURE, V364, P626, DOI 10.1038/364626a0; Liu B, 2001, ARCH OPHTHALMOL-CHIC, V119, P240; LOUIS JC, 1993, SCIENCE, V259, P689, DOI 10.1126/science.8430320; Luna-Medina R, 2005, J BIOL CHEM, V280, P21453, DOI 10.1074/jbc.M414390200; MAGRINAT G, 1992, BLOOD, V80, P1880; Makwana M, 2007, J NEUROSCI, V27, P11201, DOI 10.1523/JNEUROSCI.2255-07.2007; Mander PK, 2006, J IMMUNOL, V176, P1046, DOI 10.4049/jimmunol.176.2.1046; MAYER M, 1994, DEVELOPMENT, V120, P143; MCCARTHY KD, 1980, J CELL BIOL, V85, P890, DOI 10.1083/jcb.85.3.890; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Murphy S, 2000, GLIA, V29, P1, DOI 10.1002/(SICI)1098-1136(20000101)29:1<1::AID-GLIA1>3.0.CO;2-N; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Na YJ, 2007, J NEUROCHEM, V103, P637, DOI 10.1111/j.1471-4159.2007.04769.x; Nath N, 2010, J NEUROIMMUNE PHARM, V5, P240, DOI 10.1007/s11481-009-9187-x; NATHAN C, 1992, FASEB J, V6, P3051; Nedergaard M, 2003, TRENDS NEUROSCI, V26, P523, DOI 10.1016/j.tins.2003.08.008; Niedbala W, 2011, P NATL ACAD SCI USA, V108, P9220, DOI 10.1073/pnas.1100667108; Paintlia AS, 2006, J IMMUNOL, V176, P4385, DOI 10.4049/jimmunol.176.7.4385; Paintlia AS, 2010, GLIA, V58, P1669, DOI 10.1002/glia.21039; Paintlia AS, 2008, MOL PHARMACOL, V73, P1381, DOI 10.1124/mol.107.044230; Paintlia AS, 2005, FASEB J, V19, P1407, DOI 10.1096/fj.05-3861com; Prasad R, 2007, GLIA, V55, P65, DOI 10.1002/glia.20436; Ptasinska A, 2007, FASEB J, V21, P950, DOI 10.1096/fj.06-6822com; Puigserver P, 2001, MOL CELL, V8, P971, DOI 10.1016/S1097-2765(01)00390-2; Que LG, 2005, SCIENCE, V308, P1618, DOI 10.1126/science.1108228; Rostworowski M, 1997, J NEUROSCI, V17, P3664; Seifert G, 2006, NAT REV NEUROSCI, V7, P194, DOI 10.1038/nrn1870; Sharma HS, 2000, ACTA NEUROCHIR SUPPL, V76, P81; Singh I, 1998, J BIOL CHEM, V273, P20354, DOI 10.1074/jbc.273.32.20354; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Sriram K, 2004, J BIOL CHEM, V279, P19936, DOI 10.1074/jbc.M309304200; Vega-Avelaira D, 2007, BRAIN BEHAV IMMUN, V21, P617, DOI 10.1016/j.bbi.2006.10.007; Wilkins A, 2005, J NEUROCHEM, V92, P1487, DOI 10.1111/j.1471-4159.2004.02981.x; YU ACH, 1993, J NEUROSCI RES, V34, P295, DOI 10.1002/jnr.490340306	69	23	23	0	2	AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA		1083-351X		J BIOL CHEM	J. Biol. Chem.	FEB 8	2013	288	6					3831	3843		10.1074/jbc.M112.405654			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	088OP	WOS:000314845000015	23264628	Other Gold, Green Published			2021-06-18	
J	Kraemer, WJ; Looney, DP; Martin, GJ; Ratamess, NA; Vingren, JL; French, DN; Hatfield, DL; Fragala, MS; Spiering, BA; Howard, RL; Cortis, C; Szivak, TK; Comstock, BA; Dunn-Lewis, C; Hooper, DR; Flanagan, SD; Volek, JS; Anderson, JM; Maresh, CM; Fleck, SJ				Kraemer, William J.; Looney, David P.; Martin, Gerard J.; Ratamess, Nicholas A.; Vingren, Jakob L.; French, Duncan N.; Hatfield, Disa L.; Fragala, Maren S.; Spiering, Barry A.; Howard, Robert L.; Cortis, Cristina; Szivak, Tunde K.; Comstock, Brett A.; Dunn-Lewis, Courtenay; Hooper, David R.; Flanagan, Shawn D.; Volek, Jeff S.; Anderson, Jeffrey M.; Maresh, Carl M.; Fleck, Steven J.			CHANGES IN CREATINE KINASE AND CORTISOL IN NATIONAL COLLEGIATE ATHLETIC ASSOCIATION DIVISION I AMERICAN FOOTBALL PLAYERS DURING A SEASON	JOURNAL OF STRENGTH AND CONDITIONING RESEARCH			English	Article						clinical chemistries; muscle damage; strength training; sports medicine	PREVENTING SUDDEN-DEATH; TRAINING-PROGRAMS; MUSCLE DAMAGE; RESPONSES; EXERCISE; PERFORMANCE; GAME	Kraemer, WJ, Looney, DP, Martin, GJ, Ratamess, NA, Vingren, JL, French, DN, Hatfield, DL, Fragala, MS, Spiering, BA, Howard, RL, Cortis, C, Szivak, TK, Comstock, BA, Dunn-Lewis, C, Hooper, DR, Flanagan, SD, Volek, JS, Anderson, JM, Maresh, CM, and Fleck, SJ. Changes in creatine kinase and cortisol in national collegiate athletic association division I American football players during a season. J Strength Cond Res 27(2): 434-441, 2013-The purpose of this study was to track creatine kinase (CK) and serum cortisol over an American college football season starting with the preseason practice. A secondary purpose was to observe changes in basic clinical chemistries. Twenty-two National Collegiate Athletic Association Division I football players (age: 20.4 +/- 1.1 years, height: 188.27 +/- 8.3 cm, weight: 115.8 +/- 29.7 kg) volunteered to participate in this study. Each of the players had participated in the summer strength and conditioning supervised program. Resting blood samples were obtained just before the start of preseason practice (T-1), 2 weeks later (T-2), and the day after game 2 (T-3), game 4 (T-4), game 6 (T-5), and game 9 (T-6) of a 12-game season. Creatine kinase, a panel of clinical chemistries, cortisol, and testosterone were assayed at each time point. No significant changes in CK concentrations were observed over the season with peak values of each range <= 1,070.0 IU.L-1, but the largest range was observed at T-6 after game 9 (119-2,834 IU.L-1. The analysis of covariance analysis demonstrated that the number of plays in the ninth game (T-6) explained the magnitude of the changes in CK. No changes in serum cortisol concentrations were observed yet, again large variations existed with peak values of each range <= 465.0 nmol.L-1. Clinical chemistries showed various significant changes from T-1, but none were considered clinically relevant changes for any player over the time course of the study. In conclusion, the strength and conditioning program before preseason camp or the structure of summer camp practices and the in-season strength and conditioning appeared to mute muscle damage and the stress response of cortisol. Such data demonstrate that changes in muscle damage and adrenal cortical stress over the season are minimal, yet large individual variations can be observed. Management of these variables appears to be related to optimal strength and conditioning and sports medicine programs. Thus, the greater concerns for student-athlete safety in the sport of American football are related to preventing sudden death, traumatic injury, and managing concussion syndromes.	[Kraemer, William J.; Looney, David P.; Martin, Gerard J.; Ratamess, Nicholas A.; Vingren, Jakob L.; French, Duncan N.; Hatfield, Disa L.; Fragala, Maren S.; Spiering, Barry A.; Howard, Robert L.; Cortis, Cristina; Szivak, Tunde K.; Comstock, Brett A.; Dunn-Lewis, Courtenay; Hooper, David R.; Flanagan, Shawn D.; Volek, Jeff S.; Anderson, Jeffrey M.; Maresh, Carl M.] Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT USA; [Fleck, Steven J.] Univ Wisconsin Parkside, Kenosha, WI USA	Kraemer, WJ (corresponding author), Univ Connecticut, Dept Kinesiol, Human Performance Lab, Storrs, CT USA.	william.kraemer@uconn.edu	Dunn-Lewis, Courtenay/G-8524-2017; CORTIS, Cristina/AAB-9960-2020; Flanagan, Shawn/AAC-6018-2021	Dunn-Lewis, Courtenay/0000-0002-2406-4215; CORTIS, Cristina/0000-0001-9643-5532; Flanagan, Shawn/0000-0002-6531-4567	University of Connecticut's Human Performance Laboratory	The investigators want to thank a dedicated group of student-athletes who participated in this investigation. The findings in this study do not reflect any endorsement by the National Strength and Conditioning Association. No conflict of interest exists, and this study was funded by internal funds at the University of Connecticut's Human Performance Laboratory.	BERG K, 1990, RES Q EXERCISE SPORT, V61, P395, DOI 10.1080/02701367.1990.10607504; Casa DJ, 2012, J ATHL TRAINING, V47, P477, DOI 10.4085/1062-6050-47.4.08; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Fragala MS, 2011, SPORTS MED, V41, P621, DOI 10.2165/11590430-000000000-00000; Hoffman JR, 2005, MED SCI SPORT EXER, V37, P1237, DOI 10.1249/01.mss.0000170068.97498.26; Hoffman JR, 2004, J STRENGTH COND RES, V18, P129; Hoffman JR, 2003, J STRENGTH COND RES, V17, P561; Hoffman JR, 2002, MED SCI SPORT EXER, V34, P1845, DOI 10.1097/00005768-200211000-00023; Kraemer WJ, 2009, J STRENGTH COND RES, V23, P2, DOI 10.1519/JSC.0b013e31819306f2; KRAEMER WJ, 1993, J APPL PHYSIOL, V74, P450; Kraemer WJ, 2000, EXERCISE SPORT SCI, P795; KRAEMER WJ, 1992, STRENGTH POWER SPORT, P64; Mclellan CP, 2010, J STRENGTH COND RES, V24, P2908, DOI 10.1519/JSC.0b013e3181c1fcb1; Spiering BA, 2008, SPORTS MED, V38, P527, DOI 10.2165/00007256-200838070-00001; Spiering BA, 2008, MED SCI SPORT EXER, V40, P1039, DOI 10.1249/MSS.0b013e31816722bd; Young WB, 2012, J STRENGTH COND RES, V26, P492, DOI 10.1519/JSC.0b013e318225a1c4	16	23	23	0	23	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1064-8011			J STRENGTH COND RES	J. Strength Cond. Res.	FEB	2013	27	2					434	441		10.1519/JSC.0b013e318281d1b0			8	Sport Sciences	Sport Sciences	086WB	WOS:000314718600020	23358319				2021-06-18	
J	Morgan, AT; Masterton, R; Pigdon, L; Connelly, A; Liegeois, FJ				Morgan, Angela T.; Masterton, Richard; Pigdon, Lauren; Connelly, Alan; Liegeois, Frederique J.			Functional magnetic resonance imaging of chronic dysarthric speech after childhood brain injury: reliance on a left-hemisphere compensatory network	BRAIN			English	Article						brain injury; traumatic brain injury; plasticity; speech; dysarthria; functional MRI	DIFFERENTIAL-DIAGNOSIS; MOTOR-PERFORMANCE; LANGUAGE; FMRI; CHILDREN; REORGANIZATION; CLASSIFICATION; ARTICULATION; CEREBELLUM; PLASTICITY	Severe and persistent speech disorder, dysarthria, may be present for life after brain injury in childhood, yet the neural correlates of this chronic disorder remain elusive. Although abundant literature is available on language reorganization after lesions in childhood, little is known about the capacity of motor speech networks to reorganize after injury. Here, we examine the structural and functional neural correlates associated with chronic dysarthria after childhood-onset traumatic brain injury. Forty-nine participants aged 12 years 3 months to 24 years 11 months were recruited to the study: (i) a group with chronic dysarthria (n = 17); matched for age and sex with two control groups of (ii) healthy control subjects (n = 17); and (iii) individuals without dysarthria after traumatic brain injury (n = 15). A high-resolution 3D T-1-weighted whole-brain data set was acquired for voxel-based morphometry analyses of group differences in grey matter. Functional magnetic resonance imaging was used to localize activation associated with speaking single words (baseline: listening to words). Group differences on voxel-based morphometry revealed widespread grey matter reductions in the dysarthric group compared with healthy control subjects, including in numerous speech motor regions bilaterally, such as the cerebellum, the basal ganglia and primary motor cortex representation of the articulators. Relative to the non-dysarthric traumatic brain injury group, individuals with dysarthria showed reduced grey matter bilaterally in the ventral sensorimotor cortex, but this reduction was concomitant with increased functional activation only in the left-hemisphere cluster during speech. Finally, increased recruitment of Broca's area (Brodmann area 45, pars triangularis) but not its right homologue, correlated with better speech outcome, suggesting that this 'higher-level' area may be more critically involved with production when associated motor speech regions are damaged. We suggest that the bilateral morphological abnormalities within cortical speech networks in childhood prevented reorganization of speech function from the left-to right-hemisphere. Rather, functional reorganization involved over-recruitment of left-hemisphere motor regions, a reorganization method that was only partly relatively effective, given the presence of persisting yet mild speech deficits. The bilateral structural abnormalities found to limit functional reorganization here, may also be critical to poor speech prognosis for populations with congenital, degenerative or acquired neurological disorders throughout the lifespan.	[Morgan, Angela T.; Pigdon, Lauren] Murdoch Childrens Res Inst, Parkville, Vic 3052, Australia; [Morgan, Angela T.] Univ Melbourne, Dept Paediat, Melbourne, Vic 3010, Australia; [Morgan, Angela T.] Royal Childrens Hosp, Melbourne, Vic 3052, Australia; [Masterton, Richard; Connelly, Alan] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic 3084, Australia; [Liegeois, Frederique J.] UCL, Inst Child Hlth, London WC1N 1EH, England	Morgan, AT (corresponding author), Murdoch Childrens Res Inst, Flemington Rd, Parkville, Vic 3052, Australia.	angela.morgan@mcri.edu.au	Connelly, Alan/A-9065-2013; Liegeois, Frederique/A-6351-2009; Morgan, Angela/J-5235-2017	Connelly, Alan/0000-0001-7159-8079; Morgan, Angela/0000-0003-1147-7405; Liegeois, Frederique/0000-0002-8640-6217	Transport Accident Commission: Victorian Neurotrauma Initiative [D131]; National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [607315, 1023043]	This study was supported by grant D131 from the Transport Accident Commission: Victorian Neurotrauma Initiative, awarded to A.T.M., F.J.L, A.C., and J-D.T.; and grants 607315 and 1023043 from the National Health and Medical Research Council awarded to A.T.M.	Anderson V, 2011, BRAIN, V134, P2197, DOI 10.1093/brain/awr103; Anderson V, 2010, NEUROPSYCHOLOGIA, V48, P2041, DOI 10.1016/j.neuropsychologia.2010.03.025; Ashburner J, 2005, NEUROIMAGE, V26, P839, DOI 10.1016/j.neuroimage.2005.02.018; Bunton K, 2007, J SPEECH LANG HEAR R, V50, P1481, DOI 10.1044/1092-4388(2007/102); Cahill LM, 2005, BRAIN INJURY, V19, P41, DOI 10.1080/02699050410001719961; Cahill LM, 2002, BRAIN INJURY, V16, P415, DOI 10.1080/02699050110119871; Darley F., 1975, MOTOR SPEECH DISORDE; Duffy JR, 2001, APHASIOLOGY, V15, P275, DOI 10.1080/02687040042000269; Duffy JR, 2019, MOTOR SPEECH DISORDE; Eickhoff SB, 2009, PHILOS T R SOC A, V367, P2399, DOI 10.1098/rsta.2008.0287; Erickson-Levendoski E, 2011, J VOICE, V25, pE215, DOI 10.1016/j.jvoice.2011.02.009; Fair DA, 2010, BRAIN LANG, V114, P135, DOI 10.1016/j.bandl.2009.09.001; Gaillard WD, 2007, NEUROLOGY, V69, P1761, DOI 10.1212/01.wnl.0000289650.48830.1a; Gauthier LV, 2008, STROKE, V39, P1520, DOI 10.1161/STROKEAHA.107.502229; Golfinopoulos E, 2010, NEUROIMAGE, V52, P862, DOI 10.1016/j.neuroimage.2009.10.023; Guzzetta A, 2008, NEUROPEDIATRICS, V39, P157, DOI 10.1055/s-0028-1085465; Hayden D.A., 1999, VERBAL MOTOR PRODUCT; Heuninckx S, 2008, J NEUROSCI, V28, P91, DOI 10.1523/JNEUROSCI.3300-07.2008; Holland R, 2011, CURR BIOL, V21, P1403, DOI 10.1016/j.cub.2011.07.021; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Kent RD, 2001, J SPEECH LANG HEAR R, V44, P535, DOI 10.1044/1092-4388(2001/042); Lidzba K, 2011, BRAIN LANG, V119, P6, DOI 10.1016/j.bandl.2011.02.003; Lidzba K, 2009, BRAIN, V132, DOI 10.1093/brain/awp197; Liegeois F, 2003, NAT NEUROSCI, V6, P1230, DOI 10.1038/nn1138; Liegeois F, 2011, EUR J PAEDIATR NEURO, V15, P283, DOI 10.1016/j.ejpn.2011.04.006; Liegeois F, 2004, BRAIN, V127, P1229, DOI 10.1093/brain/awh159; Liegeois F, NEUROLOGY IN PRESS; Liegeois F, 2010, BRAIN LANG, V114, P126, DOI 10.1016/j.bandl.2009.12.004; Liegeois FJ, 2012, NEUROSCI BIOBEHAV R, V36, P439, DOI 10.1016/j.neubiorev.2011.07.011; Loibl M, 2011, BEHAV BRAIN RES, V223, P280, DOI 10.1016/j.bbr.2011.04.040; Malec JF, 2007, J NEUROTRAUM, V24, P1417, DOI 10.1089/neu.2006.0245; Morgan AT, 2007, BRAIN INJURY, V21, P1183, DOI 10.1080/02699050701649573; Morgan AT, 2011, BRAIN LANG, V117, P69, DOI 10.1016/j.bandl.2011.01.002; Morgan AT, 2010, FOLIA PHONIATR LOGO, V62, P120, DOI 10.1159/000287210; Morgan AT, 2010, CHILD CARE HLTH DEV, V36, P44, DOI 10.1111/j.1365-2214.2009.00961.x; Morgan AT, 2011, J EVAL CLIN PRACT, V17, P275, DOI 10.1111/j.1365-2753.2010.01436.x; Morgan AT, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006279.pub2; Murdoch B E, 1999, Pediatr Rehabil, V3, P5; Parslow RC, 2005, ARCH DIS CHILD, V90, P1182, DOI 10.1136/adc.2005.072405; Pennington L, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006937.pub2; Price CJ, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00237; Price CJ, 2010, ANN NY ACAD SCI, V1191, P62, DOI 10.1111/j.1749-6632.2010.05444.x; Riecker A, 2005, NEUROLOGY, V64, P700, DOI 10.1212/01.WNL.0000152156.90779.89; Riecker A, 2002, NEUROCASE, V8, P417, DOI 10.1076/neur.8.5.417.16181; Saur D, 2012, ARCH PHYS MED REHAB, V93, pS15, DOI 10.1016/j.apmr.2011.03.036; Sidtis JJ, 2010, BRAIN LANG, V114, P43, DOI 10.1016/j.bandl.2010.03.007; Simmons KC, 1997, J COMMUN DISORD, V30, P117, DOI 10.1016/S0021-9924(96)00058-5; Takai O, 2010, BRAIN LANG, V113, P39, DOI 10.1016/j.bandl.2010.01.008; Tillema JM, 2008, BRAIN LANG, V105, P99, DOI 10.1016/j.bandl.2007.07.127; Turkeltaub PE, 2011, NEUROLOGY, V76, P1726, DOI 10.1212/WNL.0b013e31821a44c1; Urban PP, 2006, BRAIN, V129, P767, DOI 10.1093/brain/awh708; Ventura MI, 2009, BMC NEUROSCI, V10, DOI 10.1186/1471-2202-10-58; Wechsler D., 2011, WECHLSER ABBREVIATED; Wenke RJ, 2008, BRAIN INJURY, V22, P339, DOI 10.1080/02699050801960987; Wilcox K. A., 1999, CHILDRENS SPEECH INT; Witt RE, 2011, OTOLARYNG HEAD NECK, V144, P108, DOI 10.1177/0194599810390893; WORKINGER M S, 1992, Brain Injury, V6, P183, DOI 10.3109/02699059209029657	57	23	25	0	27	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	FEB	2013	136		2				646	657		10.1093/brain/aws355			12	Clinical Neurology; Neurosciences	Neurosciences & Neurology	090QX	WOS:000314995200030	23378215	Bronze			2021-06-18	
J	Schroeder, RW; Buddin, WH; Hargrave, DD; VonDran, EJ; Campbell, EB; Brockman, CJ; Heinrichs, RJ; Baade, LE				Schroeder, R. W.; Buddin, W. H., Jr.; Hargrave, D. D.; VonDran, E. J.; Campbell, E. B.; Brockman, C. J.; Heinrichs, R. J.; Baade, L. E.			Efficacy of Test of Memory Malingering Trial 1, Trial 2, the Retention Trial, and the Albany Consistency Index in a Criterion Group Forensic Neuropsychological Sample	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Test of Memory Malingering; TOMM; Albany consistency index; Forensic neuropsychology; Validity	TRAUMATIC BRAIN-INJURY; SYMPTOM VALIDITY TESTS; CLASSIFICATION ACCURACY; CHRONIC PAIN; SCALE-III; TOMM; PERFORMANCE; EXAGGERATION; VALIDATION; DEPRESSION	The Test of Memory Malingering is one of the most popular and heavily researched validity tests available for use in neuropsychological evaluations. Recent research has suggested, however, that the original indices and cutoffs may require modifications to increase sensitivity rates. Some of these modifications lack cross-validation and no study has examined all indices in a single sample. This study compares Trial 1, Trial 2, the Retention Trial, and the newly created Albany Consistency Index in a criterion group forensic neuropsychological sample. Findings lend support for the newly created indices and cutoff scores. Implications and cautionary statements are provided and discussed.	[Schroeder, R. W.; Buddin, W. H., Jr.; Hargrave, D. D.; VonDran, E. J.; Campbell, E. B.; Brockman, C. J.; Heinrichs, R. J.; Baade, L. E.] Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67206 USA	Schroeder, RW (corresponding author), Univ Kansas, Sch Med, Dept Psychiat & Behav Sci, Wichita, KS 67206 USA.	ryan.w.schroeder.psyd@hotmail.com					Arnold G, 2005, CLIN NEUROPSYCHOL, V19, P105, DOI 10.1080/13854040490888567; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Boone, 2007, ASSESSMENT FEIGNED C; Boone KB, 2009, CLIN NEUROPSYCHOL, V23, P729, DOI 10.1080/13854040802427803; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Committee on Mild Traumatic Brain Injury American Congress of Rehabilitation Medicine (ACRM), 1993, J HEAD TRAUMA REHAB, V8, P86; Curtis KL, 2009, ASSESSMENT, V16, P401, DOI 10.1177/1073191109338161; Denning JH, 2012, ARCH CLIN NEUROPSYCH, V27, P417, DOI 10.1093/arclin/acs044; Frederick R.I., 1997, VALIDITY INDICATOR P; Green P., 2003, GREENS WORD MEMORY T; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2009, CLIN NEUROPSYCHOL, V23, P534, DOI 10.1080/13854040802232690; Gunner JH, 2012, ARCH CLIN NEUROPSYCH, V27, P1, DOI 10.1093/arclin/acr089; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Iverson GL, 2007, CLIN NEUROPSYCHOL, V21, P532, DOI 10.1080/13854040600611392; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Larrabee GJ, 2008, CLIN NEUROPSYCHOL, V22, P666, DOI 10.1080/13854040701494987; Marshall P, 2010, CLIN NEUROPSYCHOL, V24, P1204, DOI 10.1080/13854046.2010.514290; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; O'Bryant SE, 2007, CLIN NEUROPSYCHOL, V21, P511, DOI 10.1080/13854040600611368; Ord JS, 2008, CLIN NEUROPSYCHOL, V22, P689, DOI 10.1080/13854040701425437; Pearson, 2009, ADV CLIN SOL WAIS 4; Schroeder RW, 2012, ASSESSMENT, V19, P21, DOI 10.1177/1073191111428764; Schroeder RW, 2012, CLIN NEUROPSYCHOL, V26, P129, DOI 10.1080/13854046.2011.639314; Schroeder RW, 2011, CLIN NEUROPSYCHOL, V25, P437, DOI 10.1080/13854046.2011.556668; Sharland MJ, 2007, ARCH CLIN NEUROPSYCH, V22, P213, DOI 10.1016/j.acn.2006.12.004; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Tombaugh T.N., 2003, J FORENSIC NEUROPSYC, V2, P69, DOI [DOI 10.1300/J151V02N03_04, 10.1300/J151v02n03_04]; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Wechsler D., 2009, WECHSLER MEMORY SCAL; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed	37	23	23	0	17	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	FEB	2013	28	1					21	29		10.1093/arclin/acs094			9	Psychology, Clinical; Psychology	Psychology	073EP	WOS:000313726600003	23079153	Bronze			2021-06-18	
J	Atkins, CM; Cepero, ML; Kang, Y; Liebl, DJ; Dietrich, WD				Atkins, Coleen M.; Cepero, Maria L.; Kang, Yuan; Liebl, Daniel J.; Dietrich, W. Dalton			Effects of early rolipram treatment on histopathological outcome after controlled cortical impact injury in mice	NEUROSCIENCE LETTERS			English	Article						Cyclic AMP; Contusion; Controlled cortical impact; Mice; Phosphodiesterase; Rolipram	TRAUMATIC BRAIN-INJURY; CEREBRAL-BLOOD-FLOW; PHOSPHODIESTERASE INHIBITORS; POSTTRAUMATIC HYPOTHERMIA; FUNCTIONAL RECOVERY; PROTEIN-LEVELS; IV INHIBITOR; LONG-TERM; RATS; MEMORY	Traumatic brain injury (TBI) pathology includes contusions, cavitation, cell death, all of which can be exacerbated by inflammation. We hypothesized that an anti-inflammatory drug, rolipram, may reduce pathology after TBI, since in several CNS injury models rolipram reduces inflammation and improves cell survival and functional recovery. Adult male C57BL/6 mice received a craniotomy over the right parietotemporal cortex. Vertically directed controlled cortical impact (CCI) injury was delivered. Naive controls were used for comparison. At 30 min post-surgery, animals were treated with vehicle or rolipram (1 mg/kg), and then once per day for 3 days. On day 3, the brains were systematically sectioned and stained to visualize the resulting pathology using hematoxylin and eosin (H&E) staining and NeuN immunocytochemistry. Total parietotemporal cortical contusion and cavity volume were significantly increased in rolipram-treated as compared to vehicle-treated CCI animals. Contusion areas at specific bregma levels indicated a significant effect of drug across bregma levels. Neuronal cell loss in the dentate hilus and area CA3 of the hippocampus were similar between vehicle and rolipram-treated animals. Although rolipram is well known to reduce pathology and inflammation in several other CNS injury models, the pathology resulting from CCI was worsened with rolipram at this particular dose and administration schedule. These studies suggest that consideration of the unique characteristics of TBI pathology is important in the extrapolation of promising therapeutic interventions from other CNS injury models. (C) 2012 Elsevier Ireland Ltd. All rights reserved.	[Atkins, Coleen M.; Cepero, Maria L.; Kang, Yuan; Liebl, Daniel J.; Dietrich, W. Dalton] Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, Miami, FL 33136 USA	Atkins, CM (corresponding author), Univ Miami, Miller Sch Med, Dept Neurol Surg, Miami Project Cure Paralysis, 1095 NW 14th Terrace,3-17, Miami, FL 33136 USA.	catkins@med.miami.edu		Atkins, Coleen/0000-0003-4718-7493	NIH/NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS069721, NS056072, NS030291]; Miami Project; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069721, P50NS030291, R01NS056072] Funding Source: NIH RePORTER	This work was supported by NIH/NINDS NS069721 (C.M.A.), NS056072 (W.D.D.), and NS030291 (W.D.D., D.J.L.), and The Miami Project to Cure Paralysis. We thank David Sequiera for technical support.	Ariga M, 2004, J IMMUNOL, V173, P7531, DOI 10.4049/jimmunol.173.12.7531; Atkins CM, 2012, J NEUROSCI RES, V90, P1861, DOI 10.1002/jnr.23069; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Block F, 1997, NEUROREPORT, V8, P3829, DOI 10.1097/00001756-199712010-00033; Chang YC, 2008, PEDIATR RES, V64, P234, DOI 10.1203/PDR.0b013e31817cfc87; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Fann JR, 2009, J NEUROTRAUM, V26, P2383, DOI 10.1089/neu.2009.1091; Faul M.D., 2010, TRAUMATIC BRAIN INJU; GORMAN LK, 1993, BRAIN RES, V614, P29, DOI 10.1016/0006-8993(93)91014-J; Gurney ME, 2011, HANDB EXP PHARMACOL, V204, P167, DOI 10.1007/978-3-642-17969-3_7; Helmy A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039677; Imanishi T, 1997, EUR J PHARMACOL, V321, P273, DOI 10.1016/S0014-2999(96)00969-7; Jin S-L Catherine, 2012, Chang Gung Med J, V35, P197; Jin SLC, 2005, J IMMUNOL, V175, P1523, DOI 10.4049/jimmunol.175.3.1523; KATO H, 1995, EUR J PHARMACOL, V272, P107, DOI 10.1016/0014-2999(94)00694-3; Kinoshita K, 2002, NEUROSURGERY, V51, P195, DOI 10.1097/00006123-200207000-00027; Kochanek PM, 2011, J TRAUMA, V71, pS15, DOI 10.1097/TA.0b013e31822117fe; Kochanek PM, 2002, J NEUROTRAUM, V19, P1029, DOI 10.1089/089771502760341947; Li LX, 2011, METAB BRAIN DIS, V26, P37, DOI 10.1007/s11011-011-9235-0; Li YF, 2011, J NEUROSCI, V31, P172, DOI 10.1523/JNEUROSCI.5236-10.2011; Lotocki G, 2009, J NEUROTRAUM, V26, P1123, DOI 10.1089/neu.2008.0802; Maas AIR, 2012, LANCET NEUROL, V11, P12, DOI 10.1016/S1474-4422(11)70267-8; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Nikulina E, 2004, P NATL ACAD SCI USA, V101, P8786, DOI 10.1073/pnas.0402595101; Passineau MJ, 2001, EXP NEUROL, V168, P373, DOI 10.1006/exnr.2000.7623; Patel AD, 2010, J NEUROPATH EXP NEUR, V69, P1177, DOI 10.1097/NEN.0b013e3181fbf6d6; Pearse DD, 2004, NAT MED, V10, P610, DOI 10.1038/nm1056; Raghupathi R, 1998, P W PHARMACOL SOC, V41, P241; Reneerkens OAH, 2009, PSYCHOPHARMACOLOGY, V202, P419, DOI 10.1007/s00213-008-1273-x; Reyes-Irisarri E, 2007, J NEUROPATH EXP NEUR, V66, P923, DOI 10.1097/nen.0b013e3181567c31; Rutten K, 2009, NEUROPSYCHOPHARMACOL, V34, P1914, DOI 10.1038/npp.2009.24; Schaal SM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0043634; Shah MK, 2002, J CARDIOVASC PHARM, V39, P142, DOI 10.1097/00005344-200201000-00015; Simard JM, 2009, J NEUROTRAUM, V26, P2257, DOI 10.1089/neu.2009.1021; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stein DM, 2012, SHOCK, V37, P563, DOI 10.1097/SHK.0b013e3182534f93; Theus MH, 2010, STEM CELLS, V28, P1231, DOI 10.1002/stem.449; Utagawa A, 2008, BRAIN RES, V1207, P155, DOI 10.1016/j.brainres.2008.02.057; Vitarbo EA, 2004, NEUROSURGERY, V55, P416, DOI 10.1227/01.NEU.0000130036.52521.2C; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac; Zhang HT, 2009, CURR PHARM DESIGN, V15, P1688, DOI 10.2174/138161209788168092; Zhang J, 2008, TOXICOL PATHOL, V36, P827, DOI 10.1177/0192623308322308	45	23	23	0	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	JAN 4	2013	532						1	6		10.1016/j.neulet.2012.10.019			6	Neurosciences	Neurosciences & Neurology	076DM	WOS:000313936700001	23103712	Green Accepted			2021-06-18	
J	Axelson, HW; Winkler, T; Flygt, J; Djupsjo, A; Hanell, A; Marklund, N				Axelson, Hans W.; Winkler, Tomas; Flygt, Johanna; Djupsjo, Anders; Hanell, Anders; Marklund, Niklas			Plasticity of the contralateral motor cortex following focal traumatic brain injury in the rat	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Traumatic brain injury; motor cortex; mapping; microstimulation; motor evoked potential	FOREBRAIN CHOLINERGIC SYSTEM; PRIMARY SOMATOSENSORY CORTEX; CONTROLLED CORTICAL IMPACT; FUNCTIONAL RECOVERY; ADULT RATS; NOGO-A; BEHAVIORAL RECOVERY; SENSORIMOTOR CORTEX; NEUROTROPHIC FACTOR; CEREBRAL-ISCHEMIA	Purpose: Recovery is limited following traumatic brain injury (TBI) since injured axons regenerate poorly and replacement of lost cells is minimal. Behavioral improvements could instead be due to plasticity of uninjured brain regions. We hypothesized that plasticity of the uninjured hemisphere occurs contralateral to a focal TBI in the adult rat. Thus, we performed cortical mapping of the cortex contralateral to the TBI using intracortical microstimulation (ICMS). Methods: A focal TBI was induced using the weight-drop technique (n = 5) and sham-injured animals were used as controls (n = 4). At five weeks post-injury, ICMS was used to map the motor area contralateral to the injury. Motor responses were detected by visual inspection and electromyography (EMG). Results: In sham-and brain-injured animals, numerous fore- and hindlimb motor responses contralateral to the stimulation (ipsilateral to the injury) were obtained. Compared to sham-injured controls, there was a markedly increased (p < 0.05) number of fore- and hindlimb responses ipsilateral to the stimulation after TBI. Conclusion: Following focal TBI in the rat, our data suggest reorganization of cortical and/or subcortical regions in the uninjured hemisphere contralateral to a focal TBI leading to an altered responsiveness to ICMS. Although we cannot exclude that these changes are maladaptive, it is plausible that this plasticity process positively influences motor recovery after TBI.	[Axelson, Hans W.; Winkler, Tomas; Flygt, Johanna; Djupsjo, Anders; Hanell, Anders; Marklund, Niklas] Uppsala Univ, Dept Neurosci, S-75185 Uppsala, Sweden	Marklund, N (corresponding author), Uppsala Univ, Univ Uppsala Hosp, Neurosurg Sect, Dept Neurosci, Entrance 85,2nd Floor, S-75185 Uppsala, Sweden.	niklas.marklund@neuro.uu.se	Axelson, Hans/K-2246-2019; Hanell, Anders/E-4776-2011	Hanell, Anders/0000-0001-9369-3886; Marklund, Niklas/0000-0002-9797-5626	Swedish Research CouncilSwedish Research CouncilEuropean Commission; Uppsala University	This work was supported by grants from the Swedish Research Council and grants from Uppsala University. We thank Drs Gwendolyn L. Kartje and April J. Emerick for initial methodological advice. The authors thank P-O Fallmar for invaluable engineering assistance.	Abo M, 2001, NEUROREPORT, V12, P1543, DOI 10.1097/00001756-200105250-00048; Adkins DL, 2005, NEUROSCI LETT, V380, P214, DOI 10.1016/j.neulet.2005.01.036; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Benowitz LI, 2010, NEUROBIOL DIS, V37, P259, DOI 10.1016/j.nbd.2009.11.009; Biernaskie J, 2004, J NEUROSCI, V24, P1245, DOI 10.1523/JNEUROSCI.3834-03.2004; Biernaskie J, 2005, EUR J NEUROSCI, V21, P989, DOI 10.1111/j.1460-9568.2005.03899.x; Biernaskie J, 2001, J NEUROSCI, V21, P5272, DOI 10.1523/JNEUROSCI.21-14-05272.2001; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; CASTROALAMANCOS MA, 1992, EUR J NEUROSCI, V4, P853, DOI 10.1111/j.1460-9568.1992.tb00195.x; CASTROALAMANCOS MA, 1995, NEUROSCIENCE, V68, P793, DOI 10.1016/0306-4522(95)00178-L; Chen P, 2002, P NATL ACAD SCI USA, V99, P9031, DOI 10.1073/pnas.132076299; Christman CW, 1997, ACTA NEUROPATHOL, V94, P329, DOI 10.1007/s004010050715; Clausen F, 2005, NEUROSURGERY, V57, P154, DOI 10.1227/01.NEU.0000163412.07546.57; Conner JM, 2005, NEURON, V46, P173, DOI 10.1016/j.neuron.2005.03.003; Conner JM, 2003, NEURON, V38, P819, DOI 10.1016/S0896-6273(03)00288-5; Cramer SC, 2006, EXP BRAIN RES, V168, P25, DOI 10.1007/s00221-005-0082-2; Dancause N, 2006, J NEUROPHYSIOL, V96, P3506, DOI 10.1152/jn.00792.2006; Dijkhuizen RM, 2001, P NATL ACAD SCI USA, V98, P12766, DOI 10.1073/pnas.231235598; Dijkhuizen RM, 2003, J NEUROSCI, V23, P510; DUNNMEYNELL AA, 1995, BRAIN RES, V675, P143, DOI 10.1016/0006-8993(95)00050-Z; Eisner-Janowicz I, 2008, J NEUROPHYSIOL, V100, P1498, DOI 10.1152/jn.90447.2008; Emerick AJ, 2003, J NEUROSCI, V23, P4826; Emery DL, 2000, J COMP NEUROL, V424, P521; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Frost SB, 2003, J NEUROPHYSIOL, V89, P3205, DOI 10.1152/jn.01143.2002; Gaffan D, 2008, CORTEX, V44, P928, DOI 10.1016/j.cortex.2008.03.005; Griesbach GS, 2004, BRAIN RES, V1016, P154, DOI 10.1016/j.brainres.2004.04.079; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hall KD, 2010, BRAIN RES, V1323, P161, DOI 10.1016/j.brainres.2010.01.067; Hanell A, 2010, J NEUROTRAUM, V27, P1297, DOI 10.1089/neu.2009.1255; Harris NG, 2010, J NEUROPATH EXP NEUR, V69, P139, DOI 10.1097/NEN.0b013e3181cb5bee; Hulsebosch CE, 1998, NEUROSCI LETT, V255, P83, DOI 10.1016/S0304-3940(98)00712-5; Ip EY, 2003, J CEREBR BLOOD F MET, V23, P900, DOI 10.1097/01.WCB.0000076702.71231.F2; Israelsson C, 2008, J NEUROTRAUM, V25, P959, DOI 10.1089/neu.2008.0562; Jenkins WM, 1987, PROG BRAIN RES <D>, V71, P249; Jones TA, 1999, J NEUROSCI, V19, P10153; JONES TA, 1994, J NEUROSCI, V14, P2140; Jorgensen OS, 1997, EXP NEUROL, V144, P326, DOI 10.1006/exnr.1996.6372; Kaeser M, 2010, J NEUROPHYSIOL, V103, P1630, DOI 10.1152/jn.00459.2009; Kerr AL, 2011, J COMMUN DISORD, V44, P538, DOI 10.1016/j.jcomdis.2011.04.011; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; Kobori N, 2002, MOL BRAIN RES, V104, P148, DOI 10.1016/S0169-328X(02)00331-5; KOLB B, 1989, PROG NEUROBIOL, V32, P235, DOI 10.1016/0301-0082(89)90023-3; KOZLOWSKI DA, 1994, RESTOR NEUROL NEUROS, V7, P119, DOI 10.3233/RNN-1994-7207; LEE RG, 1995, CAN J NEUROL SCI, V22, P257, DOI 10.1017/S0317167100039445; Lenzlinger PM, 2005, NEUROSCIENCE, V134, P1047, DOI 10.1016/j.neuroscience.2005.04.048; Leocani L, 2006, NEUROL SCI, V27, pS27, DOI 10.1007/s10072-006-0542-x; Li HH, 2004, J NEUROTRAUM, V21, P1141, DOI 10.1089/0897715041953777; Liu Y, 1999, EXP BRAIN RES, V128, P149, DOI 10.1007/s002210050830; MacDonald E, 2007, NEUROREHAB NEURAL RE, V21, P486, DOI 10.1177/1545968307305521; Marklund N, 2006, EXP NEUROL, V197, P70, DOI 10.1016/j.expneurol.2005.08.029; Marklund N, 2007, J NEUROSURG, V107, P844, DOI 10.3171/JNS-07/10/0844; Marklund N, 2006, NEUROCHEM RES, V31, P1085, DOI 10.1007/s11064-006-9120-0; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; Murphy TH, 2009, NAT REV NEUROSCI, V10, P861, DOI 10.1038/nrn2735; Napieralski JA, 1996, J COMP NEUROL, V373, P484; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Nishibe M, 2010, J NEUROTRAUM, V27, P2221, DOI 10.1089/neu.2010.1456; Nishimura Y, 2007, SCIENCE, V318, P1150, DOI 10.1126/science.1147243; Nudo RJ, 2006, CURR OPIN NEUROBIOL, V16, P638, DOI 10.1016/j.conb.2006.10.004; Nudo RJ, 1996, J NEUROPHYSIOL, V75, P2144; Nudo RJ, 1996, SCIENCE, V272, P1791, DOI 10.1126/science.272.5269.1791; Papadopoulos CM, 2009, STROKE, V40, P294, DOI 10.1161/STROKEAHA.108.519769; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Papathanasiou ES, 2006, EXP NEUROL, V199, P122, DOI 10.1016/j.expneurol.2006.02.115; Plowman EK, 2010, J COMMUN DISORD, V43, P286, DOI 10.1016/j.jcomdis.2010.04.005; Ramanathan D, 2006, P NATL ACAD SCI USA, V103, P11370, DOI 10.1073/pnas.0601065103; Reinecke S, 2003, EUR J NEUROSCI, V17, P623, DOI 10.1046/j.1460-9568.2003.02459.x; Rema V, 2003, J NEUROSCI, V23, P10378; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shanina EV, 2006, NEUROSCIENCE, V139, P1495, DOI 10.1016/j.neuroscience.2006.01.016; Skoglosa Y, 1999, NEUROSCIENCE, V90, P235, DOI 10.1016/S0306-4522(98)00414-X; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Ueno M, 2012, BRAIN, V135, P1253, DOI 10.1093/brain/aws053; Uryu K, 2001, NEUROSCIENCE, V105, P307, DOI 10.1016/S0306-4522(01)00203-2; Witte OW, 1997, ADV NEUROL, V73, P207; Xerri C, 2003, NEUROSCIENCE, V118, P161, DOI 10.1016/S0306-4522(02)00911-9; Xerri C, 1998, J NEUROPHYSIOL, V79, P2119; Zai LL, 2009, J NEUROSCI, V29, P8187, DOI 10.1523/JNEUROSCI.0414-09.2009; Zhang YL, 2010, BRAIN RES, V1353, P249, DOI 10.1016/j.brainres.2010.07.046	81	23	24	0	10	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028	1878-3627		RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2013	31	1					73	85		10.3233/RNN-2012-120242			13	Neurosciences	Neurosciences & Neurology	073JY	WOS:000313740500007	23047494				2021-06-18	
J	Deknuydt, F; Roquilly, A; Cinotti, R; Altare, F; Asehnoune, K				Deknuydt, Florence; Roquilly, Antoine; Cinotti, Raphael; Altare, Frederic; Asehnoune, Karim			An In Vitro Model of Mycobacterial Granuloma to Investigate the Immune Response in Brain-Injured Patients	CRITICAL CARE MEDICINE			English	Article						brain injury; cellular immunity; granulomas; immunosuppression; natural killer cells; nosocomial pneumonia; gamma delta t cells	VENTILATOR-ASSOCIATED PNEUMONIA; MULTINUCLEATED GIANT-CELLS; SYSTEMIC INFLAMMATORY RESPONSE; T-CELLS; INTERFERON-GAMMA; DENDRITIC CELLS; ORGAN FAILURE; TRAUMA; INNATE; INFECTIONS	Objective: We investigated the overall immune response to pathogens in brain-injured patients, and assessed its relationship to nosocomial pneumonia. Design: Observational study. Setting: Two surgical ICUs of a single institution. Patients: Severe brain-injured patients (n = 32) requiring mechanical ventilation and sex- and age-matched healthy donors (n = 25). Interventions: None. Measurements and Main Results: We evaluated, ex vivo, the ability of peripheral blood mononuclear cells from brain injury patients to develop an effective granulomatous response to mycobacteria. Thirty-two consecutive patients (25 traumatic brain injured and seven subarachnoid hemorrhage) were included. Median Glasgow Coma Scale was 7 (5-8). Thirteen (41%) patients developed nosocomial pneumonia. Peripheral blood mononuclear cells from brain-injured patients with nosocomial pneumonia generated significantly fewer mature granulomas compared with brain-injured patients without nosocomial pneumonia and with healthy donors. The percentage of multinucleated giant cells was lower in brain-injured patients without nosocomial pneumonia (1% [range: 0%-7%]) and in brain-injured patients with nosocomial pneumonia (4% [range: 2%-5%]) compared with healthy donors (20% [range: 15%-28%]). The blood levels of gamma delta T cells were significantly increased in brain-injured patients without nosocomial pneumonia (66% [range: 34%-69%]) compared with healthy donors (23% [range: 8%-61%]) and was not altered in brain-injured patients with nosocomial pneumonia (31% [range: 12%-44%]). The percentage of gamma delta T cells in granulomas was significantly decreased in brain injury patients with nosocomial pneumonia (5% [range: 4%-43%]) compared with healthy donors (43% [range: 19%-54%]) and was not significantly altered in brain-injured patients without nosocomial pneumonia (26% [range: 10%-41%]). The blood levels of natural killer cells were not altered in brain-injured patients. The percentage of natural killer cells in granulomas was significantly decreased in brain-injured patients with nosocomial pneumonia (3% [range: 1%-9%]) compared with brain-injured patients without nosocomial pneumonia (16% [range: 6%-29%]) and with healthy donors (17% [range: 10%-29%]). Conclusions: Brain-injured patients experienced a maturation defect of the ex vivo granulomatous response involving monocytes as well as natural killer cells and gamma delta T cells. (Crit Care Med 2013; 41:245-254)	[Deknuydt, Florence; Altare, Frederic] Univ Nantes, Inst Rech Therapeut, INSERM, U892, Nantes, France; [Roquilly, Antoine; Asehnoune, Karim] CHU Nantes, Serv Anesthesie Reanimat Chirurg, Hotel Dieu, F-44035 Nantes 01, France; [Roquilly, Antoine; Asehnoune, Karim] Univ Nantes, Fac Med, Lab UPRES EA Therapeut Clin & Expt Infect 3826, Nantes, France; [Cinotti, Raphael] CHU Nantes, Serv Anesthesie Reanimat Chirurg, HGRL, F-44035 Nantes 01, France	Deknuydt, F (corresponding author), Univ Nantes, Inst Rech Therapeut, INSERM, U892, Nantes, France.	karim.asehnoune@chu-nantes.fr	altare, frederic/K-8664-2015; Roquilly, Antoine/P-9826-2017	altare, frederic/0000-0002-5077-4616; 			Agbaht K, 2007, INTENS CARE MED, V33, P1387, DOI 10.1007/s00134-007-0729-5; [Anonymous], 2005, AM J RESP CRIT CARE, V171, P388, DOI 10.1164/rccm.200405-644ST; Bederson JB, 2009, STROKE, V40, P994, DOI 10.1161/STROKEAHA.108.191395; Bonneville M, 2006, CURR OPIN IMMUNOL, V18, P539, DOI 10.1016/j.coi.2006.07.002; Bonneville M, 2010, NAT REV IMMUNOL, V10, P467, DOI 10.1038/nri2781; Borovikova LV, 2000, NATURE, V405, P458; Bronchard G, 2004, ANESTHESIOLOGY, V100, P234, DOI 10.1097/00000542-200402000-00009; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cheadle WG, 2005, AM J SURG, V190, P173, DOI 10.1016/j.amjsurg.2005.05.006; Cheron A, 2010, CRIT CARE, V14, DOI 10.1186/cc9331; Czaja AS, 2009, J TRAUMA, V67, P805, DOI 10.1097/TA.0b013e318185e1fb; Divangahi M, 2009, NAT IMMUNOL, V10, P899, DOI 10.1038/ni.1758; Hamada S, 2008, IMMUNOLOGY, V125, P170, DOI 10.1111/j.1365-2567.2008.02841.x; Heffernan DS, 2012, CRIT CARE, V16, DOI 10.1186/cc11157; Kalyan S, 2004, J INFECT DIS, V189, P1892, DOI 10.1086/383478; Kistowska M, 2008, EUR J IMMUNOL, V38, P2200, DOI 10.1002/eji.200838366; Lay G, 2007, J PATHOL, V211, P76, DOI 10.1002/path.2092; Lepelletier D, 2010, J NEUROSURG ANESTH, V22, P32, DOI 10.1097/ANA.0b013e3181bdf52f; Matsushima A, 2004, SHOCK, V22, P11, DOI 10.1097/01.shk.0000129203.84330.b3; McNally AK, 2011, ADV EXP MED BIOL, V713, P97, DOI 10.1007/978-94-007-0763-4_7; Medzhitov R, 2000, NEW ENGL J MED, V343, P338, DOI 10.1056/NEJM200008033430506; Meisel C, 2005, NAT REV NEUROSCI, V6, P775, DOI 10.1038/nrn1765; Meisel C, 2011, NEW ENGL J MED, V365, P2134, DOI 10.1056/NEJMcibr1112454; Moretta A, 2002, NAT REV IMMUNOL, V2, P957, DOI 10.1038/nri956; MOST J, 1990, EUR J IMMUNOL, V20, P1661, DOI 10.1002/eji.1830200807; Mrakovcic-Sutic I, 2010, SCAND J IMMUNOL, V72, P57, DOI 10.1111/j.1365-3083.2010.02407.x; Munz C, 2005, J EXP MED, V202, P203, DOI 10.1084/jem.20050810; NEWTON DW, 1992, NAT IMMUN, V11, P335; Osborn TM, 2004, CRIT CARE MED, V32, P2234, DOI 10.1097/01.CCM.0000145586.23276.0F; Pelosi P, 2011, CRIT CARE MED, V39, P1482, DOI 10.1097/CCM.0b013e31821209a8; Prass K, 2003, J EXP MED, V198, P725, DOI 10.1084/jem.20021098; Puissegur MP, 2004, CELL MICROBIOL, V6, P423, DOI 10.1111/j.1462-5822.2004.00371.x; Rincon-Ferrari MD, 2004, J TRAUMA, V57, P1234, DOI 10.1097/01.TA.0000119200.70853.23; Roquilly A, 2011, JAMA-J AM MED ASSOC, V305, P1201, DOI 10.1001/jama.2011.360; Roquilly A, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0013228; Russell DG, 2009, NAT IMMUNOL, V10, P943, DOI 10.1038/ni.1781; Safdar N, 2005, CRIT CARE MED, V33, P2184, DOI 10.1097/01.CCM.0000181731.53912.D9; Sallusto F, 2010, IMMUNITY, V33, P451, DOI 10.1016/j.immuni.2010.10.008; Sarrafzadeh A, 2011, STROKE, V42, P53, DOI 10.1161/STROKEAHA.110.594705; Seguin P, 2006, CRIT CARE MED, V34, P1514, DOI 10.1097/01.CCM.0000214516.73076.82; Souza-Fonseca-Guimaraes F, 2012, MOL MED, V18, P270, DOI 10.2119/molmed.2011.00201; Spruijt NE, 2010, CRIT CARE, V14, DOI 10.1186/cc9218; Sun JC, 2011, NAT REV IMMUNOL, V11, P645, DOI 10.1038/nri3044; TAKASHIMA T, 1993, J IMMUNOL, V150, P3002; Trouillet JL, 1998, AM J RESP CRIT CARE, V157, P531, DOI 10.1164/ajrccm.157.2.9705064; Tsuji S, 2000, INFECT IMMUN, V68, P6883, DOI 10.1128/IAI.68.12.6883-6890.2000; Venet F, 2008, J LEUKOCYTE BIOL, V83, P523, DOI 10.1189/jlb.0607371; Wesselkamper SC, 2008, J IMMUNOL, V181, P5481, DOI 10.4049/jimmunol.181.8.5481; Woiciechowsky C, 1999, J MOL MED-JMM, V77, P769, DOI 10.1007/s001099900051; Wong CHY, 2011, SCIENCE, V334, P101, DOI 10.1126/science.1210301; Xiao WZ, 2011, J EXP MED, V208, P2581, DOI 10.1084/jem.20111354	51	23	23	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JAN	2013	41	1					245	254		10.1097/CCM.0b013e3182676052			10	Critical Care Medicine	General & Internal Medicine	065LR	WOS:000313150300027	23128384				2021-06-18	
J	Farhad, K; Khan, HMR; Ji, AB; Yacoub, HA; Qureshi, AI; Souayah, N				Farhad, Khosro; Khan, Hafiz M. R.; Ji, Andrew B.; Yacoub, Hussam A.; Qureshi, Adnan I.; Souayah, Nizar			Trends in Outcomes and Hospitalization Costs for Traumatic Brain Injury in Adult Patients in the United States	JOURNAL OF NEUROTRAUMA			English	Article						death rates; hospitalization charges; ICDMAP-90; mechanical ventilation; TBI	NEUROLOGICAL INTENSIVE-CARE; CHILDREN; SYSTEM	Several new therapeutic strategies have been introduced for the management of adult traumatic brain injury (TBI) over the last decade, such as the development of management pathways and specialized TBI units and improved treatment of cerebral perfusion. The purpose of this study is to compare TBI-related hospitalization outcomes in the United States between two time periods, 1993-1994 and 2006-2007. We determined the rates of occurrence, in-hospital outcomes, and mean hospital charges for patients hospitalized with adult TBI in 1993-1994 using the nationally representative all-payer Nationwide Inpatient Survey (NIS) database, and compared these outcomes with homologous data from 2006-2007. The incidence of TBI admissions was reduced by 35% in 2006-2007 compared with 1993-1994; (22/100,000 versus 34/100,000 population; p<0.0001). The mean length of hospitalization (mean +/- SD, in days) was significantly lower in 2006-2007 than in 1993-1994 (2.5 +/- 2.4 days versus 2.7 +/- 2.6 days; p<0.0001). In-hospital mortality increased significantly in 2006-2007 compared with 1993-1994 (0.8% versus 0.4%, p<0.0001). Average hospitalization charges were significantly higher in 2006-2007 compared with 19993-1994 ($21,460 +/-$21,212 versus $5,142 +/-$4,625; p<0.0001), even after adjusting for inflation. In both time periods, most hospitalized adult TBI patients were graded as mild (98.2% in 1993-1994 versus 98.0% in 2006-2007; p=0.20). There was a significant increase in average hospitalization charges and death rates in all TBI severity subgroups in 2006-2007 compared with 1993-1994. The decline in rate of hospitalization between the two time periods was predominantly related to the decline in the number of admissions of patients with mild TBI. Although the number of TBI admissions was reduced, a significant increase in average hospitalization charges and in-hospital mortality rate was observed in 2006-2007 compared with 1993-1994.	[Farhad, Khosro; Ji, Andrew B.; Yacoub, Hussam A.; Souayah, Nizar] Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol, Newark, NJ 07101 USA; [Khan, Hafiz M. R.] Florida Int Univ, Robert Stempel Coll Publ Hlth & Social Work, Dept Biostat, Miami, FL 33199 USA; [Qureshi, Adnan I.] Univ Minnesota, Zeenat Qureshi Stroke Res Ctr, Minneapolis, MN USA	Souayah, N (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Dept Neurol, 90 Bergen St,DOC 8100, Newark, NJ 07101 USA.	souayani@umdnj.edu		Qureshi, Adnan/0000-0003-4962-540X			BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Baldo V, 2003, EUR J EPIDEMIOL, V18, P1059, DOI 10.1023/A:1026192020963; Bowman SM, 2008, PEDIATRICS, V122, P988, DOI 10.1542/peds.2007-3511; Brener I, 2004, J HEAD TRAUMA REHAB, V19, P405, DOI 10.1097/00001199-200409000-00005; Bulger EM, 2007, ANN EMERG MED, V49, P293, DOI 10.1016/j.annemergmed.2006.06.038; Chumney ECG, 2004, PHARMACOECONOMICS, V22, P1209, DOI 10.2165/00019053-200422180-00005; Colantonio A, 2009, J TRAUMA, V66, P179, DOI 10.1097/TA.0b013e3181715d66; Conner KA, 2010, J SAFETY RES, V41, P17, DOI 10.1016/j.jsr.2009.10.005; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Ferrando J, 2000, Inj Prev, V6, P184, DOI 10.1136/ip.6.3.184; HSIA DC, 1988, NEW ENGL J MED, V318, P352, DOI 10.1056/NEJM198802113180604; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P681, DOI 10.1016/0003-9993(93)90024-5; KRAUS JF, 1994, JAMA-J AM MED ASSOC, V272, P1506, DOI 10.1001/jama.272.19.1506; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; Mayer SA, 2006, NEUROCRIT CARE, V5, P159, DOI 10.1385/NCC:5:2:159; Mayer SA, 2006, NEUROCRIT CARE, V5, P82, DOI 10.1385/NCC:5:2:82; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Shore AD, 2005, BRAIN INJURY, V19, P613, DOI 10.1080/02699050400013568; Simpson L, 2005, AMBUL PEDIATR, V5, P6, DOI 10.1367/A04-119R.1; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Tiesman H, 2007, J NEUROTRAUM, V24, P1189, DOI 10.1089/neu.2006.0196; Tsang KK, 2011, BR J ORAL MAXILLOFAC, V50, P298	24	23	23	0	6	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2013	30	2					84	90		10.1089/neu.2011.2283			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	069NT	WOS:000313444000003	22978433				2021-06-18	
J	Foley, LM; O'Meara, AMI; Wisniewski, SR; Hitchens, TK; Melick, JA; Ho, C; Jenkins, LW; Kochanek, PM				Foley, Lesley M.; O'Meara, Alia M. Iqbal; Wisniewski, Stephen R.; Hitchens, T. Kevin; Melick, John A.; Ho, Chien; Jenkins, Larry W.; Kochanek, Patrick M.			MRI assessment of cerebral blood flow after experimental traumatic brain injury combined with hemorrhagic shock in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						ASL-MRI; hemorrhagic shock; traumatic brain injury	CONTROLLED CORTICAL IMPACT; SECONDARY INSULTS; RAT-BRAIN; RESUSCITATION; HYPOTENSION; PERFUSION; MODEL; ISCHEMIA; DAMAGE; TIME	Secondary insults such as hypotension or hemorrhagic shock (HS) can greatly worsen outcome after traumatic brain injury (TBI). We recently developed a mouse combined injury model of TBI and HS using a controlled cortical impact (CCI) model and showed that 90 minutes of HS can exacerbate neuronal death in hippocampus beneath the contusion. This combined injury model has three clinically relevant phases, a shock, pre hospital, and definitive care phases. Mice were randomly assigned to four groups, shams as well as a CCI only, an HS only, and a CCI HS groups. The CCI and HS reduced cerebral blood flow (CBF) in multiple regions of interest (ROIs) in the hemisphere ipsilateral and contralateral to injury. Hemorrhagic shock to a level of similar to 30 mm Hg exacerbated the CCI-induced CBF reductions in multiple ROIs ipsilateral to injury (hemisphere and thalamus) and in the hemisphere contralateral to injury (hemisphere, thalamus, hippocannpus, and cortex, all P<0.05 versus CCI only, HS only or both). An important effect of HS duration was also seen after CCI with maximal CBF reduction seen at 90 minutes (P<0.0001 group-time effect in ipsilateral hippocampus). Given that neuronal death in hippocampus is exacerbated by 90 minutes of HS in this model, our data suggest an important role for exacerbation of posttraumatic ischemia in mediating the secondary injury in CCI plus HS. In conclusion, the serial, non invasive assessment of CBF using ASL-MRI (magnetic resonance imaging with arterial spin labeling) is feasible in mice even in the complex setting of combined CCI HS. The impact of resuscitation therapies and various mutant mouse strains on CBF and other outcomes merits investigation in this model. Journal of Cerebral Blood Flow & Metabolism (2013) 33, 129-136; doi:10.1038/jcbfm.2012.145; published online 17 October 2012	[O'Meara, Alia M. Iqbal; Melick, John A.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.] Univ Pittsburgh, Dept Epidemiol, Grad Sch Publ Hlth, Pittsburgh, PA 15260 USA; [Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Mellon Inst, Pittsburgh NMR Ctr Biomed Res, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Jenkins, Larry W.] Univ Pittsburgh, Dept Neurol Surg, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Sch Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X; , Alia Marie/0000-0003-3158-7943; Wisniewski, Stephen/0000-0002-3877-9860	DARPAUnited States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-10-C2124]; NS [30318];  [W81XWH-09-2-0187];  [W81XWH-06-1-0247];  [P41EB-001977]	This study was supported by W81XWH-09-2-0187 (PMK), W81XWH-06-1-0247 (PMK), DARPA N66001-10-C2124 (PMK); NS 30318 (PMK), and P41EB-001977 (CH). The views, opinions, and/or findings contained in this article/presentation are those of the author/presenter and should not be interpreted as representing the official views or policies, either expressed or implied, of the Defense Advanced Research Projects Agency or the Department of Defense. Approved for Public Release, Distribution Unlimited.	Atkins JL, 2011, P ATACCC FORT LAUD F; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Carrillo P, 1998, J TRAUMA, V45, P239, DOI 10.1097/00005373-199808000-00007; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Crookes BA, 2004, J TRAUMA, V57, P547, DOI 10.1097/01.TA.0000135162.85859.4C; CRUMRINE RC, 1991, J CEREBR BLOOD F MET, V11, P272, DOI 10.1038/jcbfm.1991.59; Dennis AM, 2009, J NEUROTRAUM, V26, P889, DOI 10.1089/neu.2008.0512; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 2009, J NEUROTRAUM, V26, P877, DOI 10.1089/neu.2007.0439; DEWITT DS, 1992, AM J PHYSIOL, V263, pH1276; Exo JL, 2009, J NEUROTRAUM, V26, P2403, DOI 10.1089/neu.2009.0980; Feinstein AJ, 2005, J AM COLL SURGEONS, V201, P536, DOI 10.1016/j.jamcollsurg.2005.05.031; Foley LM, 2008, J NEUROTRAUM, V25, P299, DOI 10.1089/neu.2007.0471; Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621; Garner J, 2010, ANN SURG, V251, P1131, DOI 10.1097/SLA.0b013e3181e00fcb; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Hellmich HL, 2005, ANESTHESIOLOGY, V102, P806, DOI 10.1097/00000542-200504000-00017; Hemerka JN, 2012, J NEUROTRAUM, V29, P2192, DOI 10.1089/neu.2011.2303; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; JENKINS LW, 1989, BRAIN RES, V477, P211, DOI 10.1016/0006-8993(89)91409-1; Kochanek PM, 2006, J CEREBR BLOOD F MET, V26, P565, DOI 10.1038/sj.jcbfm.9600218; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Lacombe P, 2005, STROKE, V36, P1053, DOI 10.1161/01.STR.0000163080.82766.eb; Lammie GA, 1999, J NEUROTRAUM, V16, P603, DOI 10.1089/neu.1999.16.603; Lee EJ, 1999, J NEUROL SCI, V164, P117, DOI 10.1016/S0022-510X(99)00068-4; Ling G, 2009, J NEUROTRAUM, V26, P815, DOI 10.1089/neu.2007.0484; Manole MD, 2009, J CEREBR BLOOD F MET, V29, P197, DOI 10.1038/jcbfm.2008.112; Marion DW, 2011, J NEUROTRAUM, V28, P517, DOI 10.1089/neu.2010.1638; Matsushita Y, 2001, J CEREBR BLOOD F MET, V21, P847, DOI 10.1097/00004647-200107000-00010; Nelson TJ, 2006, J AM COLL SURGEONS, V202, P418, DOI 10.1016/j.jamcollsurg.2005.11.011; Robertson CS, 2012, J NEUROTRAUM, V29, P1156, DOI 10.1089/neu.2011.1827; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Sidman R. L., 1971, ATLAS MOUSE BRAIN SP; SINGH NC, 1992, J CEREBR BLOOD F MET, V12, P802, DOI 10.1038/jcbfm.1992.111; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Stern S, 2009, SHOCK, V31, P64, DOI 10.1097/SHK.0b013e3181778dc3; Strebel S, 1997, SURG NEUROL, V47, P128, DOI 10.1016/S0090-3019(96)00459-4; Trabold R, 2006, BRAIN RES, V1071, P237, DOI 10.1016/j.brainres.2005.11.095; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YUAN XQ, 1992, SURG GYNECOL OBSTET, V174, P305; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	51	23	26	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	2013	33	1					129	136		10.1038/jcbfm.2012.145			8	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	066MJ	WOS:000313224600017	23072750	Bronze, Green Published			2021-06-18	
J	Gu, L; Li, J; Feng, DF; Cheng, ET; Li, DC; Yang, XQ; Wang, BC				Gu, Lei; Li, Jia; Feng, Dong-Fu; Cheng, Er-Tao; Li, Dao-Chang; Yang, Xian-Qing; Wang, Bo-Cheng			Detection of white matter lesions in the acute stage of diffuse axonal injury predicts long-term cognitive impairments: A clinical diffusion tensor imaging study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Diffuse axonal injury; diffusion tensor imaging; cognitive impairment; working memory; attention	TRAUMATIC BRAIN-INJURY; CORPUS-CALLOSUM; HEAD-INJURY; ACUTE MILD; MODERATE; MEMORY; INTEGRITY; METRICS; ADULTS; MODEL	BACKGROUND: White matter disruption is known to contribute to neurocognitive deficits after diffuse axonal injury (DAI). This study evaluated the relationship between white matter integrity using diffusion tensor imaging in the early stage and cognitions in the chronic stage. METHODS: Diffusion tensor imaging was performed in 15 patients with DAI within 7 days of injury and in 15 patients in the control group. Fractional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD) were calculated within regions of interest, including the posterior limb of the internal capsule, uncinate fasciculus (UF), anterior corona radiate (ACR), superior longitudinal fasciculus (SLF), inferior longitudinal fasciculus (ILF), genu of the corpus callosum, body of the corpus callosum, and splenium of the corpus callosum and cingulum bundle (CB). The patients with DAI and the patients in the control group also underwent neuropsychological testing during the chronic stage after DAI. RESULTS: The region-of-interest analysis showed significantly reduced FA and AD values in all nine regions within 7 days of injury as well as increased MD values in the corpus callosum among patients in the DAI group. The patients demonstrated significantly poorer performance on the working memory tests and attention test. In patients, working memory function was positively correlated with the AD value in the UF and with the FA value in the CB, UF, SLF, and ILF. Working memory function was inversely correlated with the RD value in the CB, SLF, and ILF and with the MD value in the SLF and ILF. In addition, the attention function demonstrated a positive correlation with the RD value in the ACR, SLF, and ILF and with the MD value in the ACR, SLF, and ILF. In addition, attention was inversely correlated with the FA values for the posterior limb of the internal capsule, ACR, SLF, and ILF. CONCLUSION: The results indicated that the presence of white matter changes during the early stage of DAI may be helpful for predicting cognitive dysfunction over the long term. (J Trauma Acute Care Surg. 2013;74: 242-247. Copyright (C) 2013 by Lippincott Williams & Wilkins)	[Gu, Lei; Li, Jia; Feng, Dong-Fu; Cheng, Er-Tao] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Neurosurg, Shanghai 200030, Peoples R China; [Gu, Lei; Li, Dao-Chang; Yang, Xian-Qing] Luan Tradit Chinese Med Hosp, Dept Neurosurg, Luan, Anhui, Peoples R China; [Feng, Dong-Fu] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China; [Wang, Bo-Cheng] Shanghai Jiao Tong Univ, Sch Med, Peoples Hosp 3, Dept Radiol, Shanghai 200030, Peoples R China	Feng, DF (corresponding author), Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, 280 Mo He Rd, Shanghai 201900, Peoples R China.	feng_df@yahoo.com			Research Foundation of Shanghai Health Bureau [2010167]; Shanghai Committee of Science and TechnologyShanghai Science & Technology Committee [114119a8300]	This study was supported by the Research Foundation of Shanghai Health Bureau (grant no. 2010167) and the Shanghai Committee of Science and Technology (grant no. 114119a8300)	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Chang MC, 2010, NEUROREHABILITATION, V26, P347, DOI 10.3233/NRE-2010-0572; Delis D, 2000, CALIFORNIA VERBAL LE; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Hammes J., 1971, STROOP KLEUR WOORDTE; Hicks RR, 2010, J TRAUMA, V68, P1257, DOI 10.1097/TA.0b013e3181d8956d; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; Kumar R, 2009, J NEUROTRAUM, V26, P481, DOI 10.1089/neu.2008.0461; Li J, 2011, EUR J NEUROSCI, V33, P933, DOI 10.1111/j.1460-9568.2010.07573.x; Li XY, 2010, NEUROSCIENCE, V169, P357, DOI 10.1016/j.neuroscience.2010.04.075; Li XY, 2009, J CLIN NEUROSCI, V16, P614, DOI 10.1016/j.jocn.2008.08.005; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Lipton ML, 2008, J NEUROTRAUM, V25, P1335, DOI 10.1089/neu.2008.0547; Mac Donald CL, 2007, EXP NEUROL, V205, P116, DOI 10.1016/j.expneurol.2007.01.035; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Matsushita M, 2011, J NEUROSURG, V115, P130, DOI 10.3171/2011.2.JNS101547; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.077875; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; Niogi SN, 2008, BRAIN, V131, P3209, DOI 10.1093/brain/awn247; Perlbarg V, 2009, HUM BRAIN MAPP, V30, P3924, DOI 10.1002/hbm.20817; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; STRICH SJ, 1961, LANCET, V2, P443; Sugiyama K, 2009, J NEUROTRAUM, V26, P1879, DOI [10.1089/neu.2008.0839, 10.1089/neu.2008-0839]; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Warner MA, 2010, J NEUROTRAUM, V27, P2121, DOI 10.1089/neu.2010.1429; Wechsler D, 1985, WECHSLER ADULT INTEL; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wu TC, 2010, J NEUROTRAUM, V27, P303, DOI 10.1089/neu.2009.1110; Xu J, 2007, J NEUROTRAUM, V24, P753, DOI 10.1089/neu.2006.0208	36	23	24	0	19	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	JAN	2013	74	1					242	247		10.1097/TA.0b013e3182684fe8			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	071VI	WOS:000313623300056	23064612				2021-06-18	
J	McGrath, N; Dinn, WM; Collins, MW; Lovell, MR; Elbin, RJ; Kontos, AP				McGrath, Neal; Dinn, Wayne M.; Collins, Michael W.; Lovell, Mark R.; Elbin, R. J.; Kontos, Anthony P.			Post-exertion neurocognitive test failure among student-athletes following concussion	BRAIN INJURY			English	Article						Sports concussion; ImPACT; neuropsychological testing; post-concussive symptoms	TEST-RETEST RELIABILITY; INTERNATIONAL-CONFERENCE; FOOTBALL PLAYERS; SPORT; STATEMENT; IMPACT; PERFORMANCE; MANAGEMENT; SYMPTOMS; RISK	Objective: The purpose of the present study was to examine post-exertion (PE) neurocognitive performance among student-athletes following concussion who were asymptomatic and returned to baseline normal neurocognitive test levels at rest. This study examined the neurocognitive performance of a sub-set of student-athletes who 'failed' to perform at baseline levels of neurocognitive function, i.e. exhibited downward reliable change index (RCI) alterations following a moderate exertional protocol during recovery from concussion. Method: A retrospective records review was carried out of Immediate Post-concussion Assessment and Cognitive Testing (ImPACT) and neuropsychological consultation data among athletes with sports-related concussion from a network of 22 schools and one junior hockey programme. Results: Fifty-four student-athletes met inclusion criteria and participated in the study. A total of 27.7% of concussed student-athletes who were symptom-free and returned to baseline on ImPACT at rest (i.e. no longer demonstrated performance deficits on neurocognitive tests) exhibited cognitive decline following moderate physical exertion. The PE cognitive changes were not simply general performance effects, but significant changes in memory ability in the presence of intact processing speed functions. The PE-Pass and PE-Fail groups did not, however, differ on post-concussive symptoms or concussion history. Conclusions: Clinicians' return-to-play evaluation protocols should include post-exertional computerized neurocognitive testing.	[McGrath, Neal; Dinn, Wayne M.] Sports Concuss New England, Brookline, MA 02446 USA; [Dinn, Wayne M.] Fatih Univ, Dept Psychol, Istanbul, Turkey; [Collins, Michael W.; Lovell, Mark R.; Elbin, R. J.; Kontos, Anthony P.] Univ Pittsburgh, UPMC Sports Med Concuss Program, Dept Orthopaed Surg, Pittsburgh, PA USA	McGrath, N (corresponding author), Sports Concuss New England, 1368 Beacon St,Suite 116, Brookline, MA 02446 USA.	dr.neal@sportsconcussion.net		Kontos, Anthony/0000-0002-3749-4310			Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CANTU RC, 1995, PHYSICIAN SPORTSMED, V23, P27, DOI 10.1080/00913847.1995.11947799; Covassin T, 2007, BRIT J SPORT MED, V41, P370, DOI 10.1136/bjsm.2006.032334; Elbin RJ, 2011, AM J SPORT MED, V39, P2319, DOI 10.1177/0363546511417173; Fazio VC, 2007, NEUROREHABILITATION, V22, P207; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Lambourne K, 2010, BRAIN RES, V1341, P12, DOI 10.1016/j.brainres.2010.03.091; Lovell M.R., 2006, SPORTS NEUROPSYCHOLO, P193; Lovell MR, 2004, AM J SPORT MED, V32, P47, DOI 10.1177/0363546503260723; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory P, 2009, J CLIN NEUROSCI, V16, P755, DOI 10.1016/j.jocn.2009.02.002; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Schatz P, 2006, ARCH CLIN NEUROPSYCH, V21, P91, DOI 10.1016/j.acn.2005.08.001; Schatz P, 2010, AM J SPORT MED, V38, P47, DOI 10.1177/0363546509343805; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	21	23	23	0	65	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	2013	27	1					103	113		10.3109/02699052.2012.729282			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	059IY	WOS:000312699300011	23252441				2021-06-18	
J	Moraes, DP; Sassi, FC; Mangilli, LD; Zilberstein, B; de Andrade, CRF				Moraes, Danielle Pedroni; Sassi, Fernanda Chiarion; Mangilli, Laura Davison; Zilberstein, Bruno; Furquim de Andrade, Claudia Regina			Clinical prognostic indicators of dysphagia following prolonged orotracheal intubation in ICU patients	CRITICAL CARE			English	Article							TRAUMATIC BRAIN-INJURY; FIBEROPTIC ENDOSCOPIC EVALUATION; ENDOTRACHEAL INTUBATION; ACUTE STROKE; OROPHARYNGEAL DYSPHAGIA; REHABILITATIVE MANAGEMENT; SWALLOWING DYSFUNCTION; ASPIRATION PNEUMONIA; FUNCTIONAL OUTCOMES; PREDICTORS	Introduction: The development of postextubation swallowing dysfunction is well documented in the literature with high prevalence in most studies. However, there are relatively few studies with specific outcomes that focus on the follow-up of these patients until hospital discharge. The purpose of our study was to determine prognostic indicators of dysphagia in ICU patients submitted to prolonged orotracheal intubation (OTI). Methods: We conducted a retrospective, observational cohort study from 2010 to 2012 of all patients over 18 years of age admitted to a university hospital ICU who were submitted to prolonged OTI and subsequently received a bedside swallow evaluation (BSE) by a speech pathologist. The prognostic factors analyzed included dysphagia severity rate at the initial swallowing assessment and at hospital discharge, age, time to initiate oral feeding, amount of individual treatment, number of orotracheal intubations, intubation time and length of hospital stay. Results: After we excluded patients with neurologic diseases, tracheostomy, esophageal dysphagia and those who were submitted to surgical procedures involving the head and neck, our study sample size was 148 patients. The logistic regression model was used to examine the relationships between independent variables. In the univariate analyses, we found that statistically significant prognostic indicators of dysphagia included dysphagia severity rate at the initial swallowing assessment, time to initiate oral feeding and amount of individual treatment. In the multivariate analysis, we found that dysphagia severity rate at the initial swallowing assessment remained associated with good treatment outcomes. Conclusions: Studies of prognostic indicators in different populations with dysphagia can contribute to the design of more effective procedures when evaluating, treating, and monitoring individuals with this type of disorder. Additionally, this study stresses the importance of the initial assessment ratings.	[Moraes, Danielle Pedroni] Univ Sao Paulo, Sch Med, Hosp Clin, BR-05403001 Sao Paulo, Brazil; [Sassi, Fernanda Chiarion; Furquim de Andrade, Claudia Regina] Univ Sao Paulo, Sch Med, Dept Physiotherapy Speech Language & Hearing Sci, BR-05403001 Sao Paulo, Brazil; [Mangilli, Laura Davison] Univ Sao Paulo, Sch Med, Med Invest Lab LIM Rehabil Sci 34, BR-05403001 Sao Paulo, Brazil; [Zilberstein, Bruno] Univ Sao Paulo, Sch Med, Digest Surg Div, BR-05403001 Sao Paulo, Brazil	de Andrade, CRF (corresponding author), Univ Sao Paulo, Sch Med, Dept Physiotherapy Speech Language & Hearing Sci, Rua Ovideo Pires Campos,186,Cerqueira Cesar, BR-05403001 Sao Paulo, Brazil.	clauan@usp.br	Sassi, Fernanda C/I-5384-2013; Zilberstein, Bruno/K-2087-2016; Mangilli, Laura D/G-6122-2012; Andrade, Claudia F/D-2187-2012	Mangilli, Laura D/0000-0003-2739-126X; 			Ajemian MS, 2001, ARCH SURG-CHICAGO, V136, P434, DOI 10.1001/archsurg.136.4.434; Almirall J, 2007, MED CLIN-BARCELONA, V129, P424, DOI 10.1157/13110467; American Speech-Language-Hearing Association National Outcome Measurement System (NOMS), 2003, AD SPEECH LANG PATH; Barker J, 2009, CAN J SURG, V52, P119; Barquist E, 2001, CRIT CARE MED, V29, P1710, DOI 10.1097/00003246-200109000-00009; Becker R, 2011, DYSPHAGIA, V26, P108, DOI 10.1007/s00455-009-9270-8; Bordon A, 2011, AM J SURG, V202, P679, DOI 10.1016/j.amjsurg.2011.06.030; Broadley S, 2005, DYSPHAGIA, V20, P303, DOI 10.1007/s00455-005-0032-y; Broadley S, 2003, J CLIN NEUROSCI, V10, P300, DOI 10.1016/S0967-5868(03)00022-5; Brown CVR, 2011, J CRIT CARE, V26, DOI 10.1016/j.jcrc.2010.05.036; Cabre M, 2010, AGE AGEING, V39, P39, DOI 10.1093/ageing/afp100; Clave P, 2005, MED CLIN-BARCELONA, V124, P742, DOI 10.1157/13075447; Clave P, 2008, CLIN NUTR, V27, P806, DOI 10.1016/j.clnu.2008.06.011; Crary MA, 2005, ARCH PHYS MED REHAB, V86, P1516, DOI 10.1016/j.apmr.2004.11.049; DELARMINAT V, 1995, CRIT CARE MED, V23, P486, DOI 10.1097/00003246-199503000-00012; Frank U, 2007, DYSPHAGIA, V22, P20, DOI 10.1007/s00455-006-9036-5; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Heffner JE, 2010, CHEST, V137, P509, DOI 10.1378/chest.09-2477; Kozlow JH, 2003, CRIT CARE MED, V31, P1930, DOI 10.1097/01.CCM.0000069738.73602.5F; Leder SB, 1998, DYSPHAGIA, V13, P208, DOI 10.1007/PL00009573; Leder SB, 2009, GERONTOLOGY, V55, P714, DOI 10.1159/000235824; Luker JA, 2010, INT J STROKE, V5, P466, DOI 10.1111/j.1747-4949.2010.00488.x; Macht M, 2011, CRIT CARE, V15, DOI 10.1186/cc10472; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; Mangilli LD, 2012, ACTA TROP, V122, P241, DOI 10.1016/j.actatropica.2012.02.069; Martin-Harris B, 2003, J APPL PHYSIOL, V94, P1735, DOI 10.1152/japplphysiol.00806.2002; McMicken BL, 2009, DISABIL REHABIL, V31, P2196, DOI 10.3109/09638280902956894; Monteleoni C, 2004, BMJ-BRIT MED J, V329, P491, DOI 10.1136/bmj.329.7464.491; Moraes Danielle Pedroni, 2011, J. Soc. Bras. Fonoaudiol., V23, P89, DOI 10.1590/S2179-64912011000100018; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; Padovani AR, 2012, DISFAGIA PRATICA BAS, P62; Partik B, 2000, AM J ROENTGENOL, V174, P1409, DOI 10.2214/ajr.174.5.1741409; Postma GN, 2007, LARYNGOSCOPE, V117, P1720, DOI 10.1097/MLG.0b013e31811ff906; Romero CM, 2010, CHEST, V137, P1278, DOI 10.1378/chest.09-2792; Rumbach AF, 2012, J BURN CARE RES, V33, P336, DOI 10.1097/BCR.0b013e3182356143; Schindler A, 2008, DYSPHAGIA, V23, P230, DOI 10.1007/s00455-007-9121-4; Schindler JS, 2002, LARYNGOSCOPE, V112, P589, DOI 10.1097/00005537-200204000-00001; Schroeder MF, 2006, J REHABIL RES DEV, V43, P301, DOI 10.1682/JRRD.2004.12.0154; Skeat J, 2005, DYSPHAGIA, V20, P113, DOI 10.1007/s00455-004-0028-z; Skoretz SA, 2010, CHEST, V137, P665, DOI 10.1378/chest.09-1823; Smith HA, 2000, AGE AGEING, V29, P495, DOI 10.1093/ageing/29.6.495; Solh EA, 2003, INTENS CARE MED, V29, P1451; Starks B, 2011, CRIT CARE NURSE, V31, P38, DOI 10.4037/ccn2011462; STAUFFER JL, 1981, AM J MED, V70, P65, DOI 10.1016/0002-9343(81)90413-7; Terre R, 2006, NEUROGASTROENT MOTIL, V18, P200, DOI 10.1111/j.1365-2982.2005.00729.x; Thwaites CL, 2003, BMJ-BRIT MED J, V326, P117, DOI 10.1136/bmj.326.7381.117; Ward EC, 2007, J HEAD TRAUMA REHAB, V22, P184, DOI 10.1097/01.HTR.0000271119.96780.f5; Wesling M, 2003, DYSPHAGIA, V18, P203, DOI 10.1007/s00455-002-0098-8; Zaidi NH, 1995, AGE AGEING, V54, pS59	49	23	24	0	13	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2013	17	5							R243	10.1186/cc13069			10	Critical Care Medicine	General & Internal Medicine	AB1HA	WOS:000331540900059	24138781	DOAJ Gold, Green Published			2021-06-18	
J	Rienstra, A; Groot, PFC; Spaan, PEJ; Majoie, CBLM; Nederveen, AJ; Walstra, GJM; de Jonghe, JFM; van Gool, WA; Olabarriaga, SD; Korkhov, VV; Schmand, B				Rienstra, Anne; Groot, Paul F. C.; Spaan, Pauline E. J.; Majoie, Charles B. L. M.; Nederveen, Aart J.; Walstra, Gerard J. M.; de Jonghe, Jos F. M.; van Gool, Willem A.; Olabarriaga, Silvia D.; Korkhov, Vladimir V.; Schmand, Ben			Symptom validity testing in memory clinics: Hippocampal-memory associations and relevance for diagnosing mild cognitive impairment	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article						Mild cognitive impairment; Alzheimer's disease; Early symptoms; Hippocampal volumetry; Symptom validity testing	TRAUMATIC BRAIN-INJURY; SURFACE-BASED ANALYSIS; TOMM PERFORMANCE; DEMENTIA; DEPRESSION; SEGMENTATION; VALIDATION; VOLUMES; ANXIETY; SCALES	Patients with mild cognitive impairment (MCI) do not always convert to dementia. In such cases, abnormal neuropsychological test results may not validly reflect cognitive symptoms due to brain disease, and the usual brain-behavior relationships may be absent. This study examined symptom validity in a memory clinic sample and its effect on the associations between hippocampal volume and memory performance. Eleven of 170 consecutive patients (6.5%; 13% of patients younger than 65 years) referred to memory clinics showed noncredible performance on symptom validity tests (SVTs, viz. Word Memory Test and Test of Memory Malingering). They were compared to a demographically matched group (n=57) selected from the remaining patients. Hippocampal volume, measured by an automated volumetric method (Freesurfer), was correlated with scores on six verbal memory tests. The median correlation was r = .49 in the matched group. However, the relation was absent (median r =-.11) in patients who failed SVTs. Memory clinic samples may include patients who show noncredible performance, which invalidates their MCI diagnosis. This underscores the importance of applying SVTs in evaluating patients with cognitive complaints that may signify a predementia stage, especially when these patients are relatively young.	[Rienstra, Anne; Spaan, Pauline E. J.; Schmand, Ben] Univ Amsterdam, Dept Brain & Cognit, NL-1018 XA Amsterdam, Netherlands; [Groot, Paul F. C.; Majoie, Charles B. L. M.; Nederveen, Aart J.] Univ Amsterdam, Acad Med Ctr, Dept Radiol, NL-1105 AZ Amsterdam, Netherlands; [Rienstra, Anne; Walstra, Gerard J. M.; van Gool, Willem A.; Schmand, Ben] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [de Jonghe, Jos F. M.] Med Ctr Alkmaar, Dept Geriatr, Alkmaar, Netherlands; [Olabarriaga, Silvia D.; Korkhov, Vladimir V.] Univ Amsterdam, Dept Clin Epidemiol Biostat & Bioinformat, NL-1018 XA Amsterdam, Netherlands	Rienstra, A (corresponding author), Univ Amsterdam, Dept Brain & Cognit, Weesperpl 4, NL-1018 XA Amsterdam, Netherlands.	a.rienstra@uva.nl	Van Gool, Willem A/G-5985-2012; Korkhov, Vladimir/H-6685-2013	Korkhov, Vladimir/0000-0003-2458-3194; Spaan, Pauline/0000-0001-5858-2419	Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organization for Scientific Research, NWO)Netherlands Organization for Scientific Research (NWO)	We performed computations using the e-bioinfra platform at the Academic Medical Center (AMC), using resources of the Dutch e-Science Grid, BiGGrid project, which is financially supported by the Nederlandse Organisatie voor Wetenschappelijk Onderzoek (Netherlands Organization for Scientific Research, NWO). There are no conflicts of interest.	Albert MS, 2011, ALZHEIMERS DEMENT, V7, P270, DOI 10.1016/j.jalz.2011.03.008; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dandachi-FitzGerald B, 2011, CLIN NEUROPSYCHOL, V25, P812, DOI 10.1080/13854046.2011.583280; de Toledo-Morrell L, 2000, HIPPOCAMPUS, V10, P136, DOI 10.1002/(SICI)1098-1063(2000)10:2<136::AID-HIPO2>3.0.CO;2-J; Dean AC, 2009, CLIN NEUROPSYCHOL, V23, P133, DOI 10.1080/13854040701819050; Dickerson BC, 2010, NEUROPSYCHOPHARMACOL, V35, P86, DOI 10.1038/npp.2009.126; Echavarri C, 2011, BRAIN STRUCT FUNCT, V215, P265, DOI 10.1007/s00429-010-0283-8; Fischl B, 1999, NEUROIMAGE, V9, P195, DOI 10.1006/nimg.1998.0396; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gauthier S, 2005, ARCH NEUROL-CHICAGO, V62, P1164, DOI 10.1001/archneur.62.7.1164; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Goodrich-Hunsaker NJ, 2009, NEUROPSYCHOLOGY, V23, P529, DOI 10.1037/a0015444; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; Green P., 2003, GREENS WORD MEMORY T; Green P., 2003, J FORENSIC NEUROPSYC, V2, P97, DOI DOI 10.1300/J151V02N03_05; Green P., 1996, WORD MEMORY TEST USE; Green P, 2011, APPL NEUROPSYCHOL, V18, P86, DOI 10.1080/09084282.2010.523389; Greve KW, 2008, CLIN NEUROPSYCHOL, V22, P896, DOI 10.1080/13854040701565208; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P439, DOI 10.1016/j.acn.2006.06.004; GROBER E, 1988, NEUROLOGY, V38, P900, DOI 10.1212/WNL.38.6.900; Haggerty KA, 2007, CLIN NEUROPSYCHOL, V21, P917, DOI 10.1080/13854040600899724; Heaton R., 1993, WISCONSIN CARD SORTI; Heilbronner RL, 2009, CLIN NEUROPSYCHOL, V23, P1093, DOI 10.1080/13854040903155063; Hejl A, 2002, J NEUROL NEUROSUR PS, V73, P390, DOI 10.1136/jnnp.73.4.390; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Lehmann M, 2010, NEUROIMAGE, V49, P2264, DOI 10.1016/j.neuroimage.2009.10.056; Lindeboom J, 2003, VISUAL ASS TEST; Maioli F, 2007, ARCH GERONTOL GERIAT, V44, P233, DOI 10.1016/j.archger.2007.01.032; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Miller L, 2001, NEUROREHABILITATION, V16, P109; Mitchell AJ, 2009, ACTA PSYCHIAT SCAND, V119, P252, DOI 10.1111/j.1600-0447.2008.01326.x; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Olabarriaga SD, 2010, IEEE T INF TECHNOL B, V14, P979, DOI 10.1109/TITB.2010.2046742; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Petersen RC, 2004, J INTERN MED, V256, P183, DOI 10.1111/j.1365-2796.2004.01388.x; Petersen RC, 2007, SEMIN NEUROL, V27, P22, DOI 10.1055/s-2006-956752; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rosen G, 2004, POSTTRAUMATIC STRESS; Rubenzer S, 2009, PSYCHOL INJ LAW, V2, P114, DOI 10.1007/s12207-009-9045-4; Sheehan DV, 1998, J CLIN PSYCHIAT, V59, P22, DOI 10.4088/JCP.09m05305whi; Sollman MJ, 2011, ARCH CLIN NEUROPSYCH, V26, P774, DOI 10.1093/arclin/acr066; Spaan P. E., 2010, INT NEUR SOC POL NEU; Spaan PEJ, 2005, NEUROPSYCHOLOGY, V19, P629, DOI 10.1037/0894-4105.19.5.629; Stewart R, 2011, BRIT J PSYCHIAT, V198, P199, DOI 10.1192/bjp.bp.110.078683; Tae WS, 2008, NEURORADIOLOGY, V50, P569, DOI 10.1007/s00234-008-0383-9; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; van Egmond J, 2002, EUR PSYCHIAT, V17, P46, DOI 10.1016/S0924-9338(02)00622-3; Visser PJ, 2006, NEUROLOGY, V67, P1201, DOI 10.1212/01.wnl.0000238517.59286.c5; Whiteside DM, 2009, CLIN NEUROPSYCHOL, V23, P523, DOI 10.1080/13854040802389169; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO; World Health Organization, 1992, INT CLASS DIS 10 REV; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009; Zakzanis K. K., 2011, NEUROPSYCHOL REV, V13, P1; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	64	23	24	0	10	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	JAN 1	2013	35	1					59	70		10.1080/13803395.2012.751361			12	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	189YL	WOS:000322304100007	23228141				2021-06-18	
J	Schirmer-Mikalsen, K; Moen, KG; Skandsen, T; Vik, A; Klepstad, P				Schirmer-Mikalsen, K.; Moen, K. G.; Skandsen, T.; Vik, A.; Klepstad, P.			Intensive care and traumatic brain injury after the introduction of a treatment protocol: a prospective study	ACTA ANAESTHESIOLOGICA SCANDINAVICA			English	Article							SEVERE HEAD-INJURY; RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; INTRACRANIAL HYPERTENSION; EXTRACRANIAL COMPLICATIONS; DECOMPRESSIVE CRANIECTOMY; SEVERITY SCORE; HYPERGLYCEMIA; HYPOTHERMIA; MANAGEMENT	Background Traumatic brain injury (TBI) treatment protocols have been introduced in the intensive care unit (ICU) to avoid secondary brain injury. In this study, we aimed to evaluate the deviations from such a treatment protocol and the frequency of extracranial complications, and relate these findings to outcome. Methods During a 5-year period (20042009), 133 patients with severe TBI [Glasgow Coma Scale (GCS) score?=?8] were prospectively included. The following deviations from treatment goals were studied: intracranial pressure (ICP), blood pressure, haemoglobin, blood glucose, serum sodium, serum albumin, body temperature and extracranial complications during the ICU stay. Outcome was assessed using Glasgow Outcome Scale Extended score at 12 months. Results The frequencies of deviations from the treatment goals were: episodes of intracranial hypertension 69.5% (of monitored patients), hypotension 20.3%, anaemia 77.4%, hyperglycaemia 42.9%, hyponatremia 34.6%, hypoalbuminemia 30.8% and hyperthermia 54.9%. Pulmonary complications were common (pneumonia 72.2%, acute respiratory distress syndrome/acute lung injury 31.6%). Thrombocytopenia (4.5%), severe sepsis (3.0%), renal failure (0.8%) and liver failure (0.8%) were infrequent. Twenty-six (19.5%) patients died within the first 12 months due to the head injury. Age, GCS score, pupil dilation, Injury Severity Score (ISS), ICP?>?25?mmHg, hyperglycaemia and pneumonia predicted a worse outcome. Conclusions Deviations from the TBI treatment protocol were frequent. Pneumonia was the most frequent extracranial complication. Age, GCS score, pupil dilation, ISS, high ICP, hyperglycaemia and pneumonia predicted a worse outcome.	[Schirmer-Mikalsen, K.; Klepstad, P.] St Olavs Univ Hosp, Dept Anaesthesia & Acute Med, N-7006 Trondheim, Norway; [Moen, K. G.; Vik, A.] St Olavs Univ Hosp, Dept Neurosurg, N-7006 Trondheim, Norway; [Moen, K. G.; Skandsen, T.; Vik, A.] Norwegian Univ Sci & Technol, Dept Neurosci, Fac Med, N-7034 Trondheim, Norway; [Skandsen, T.] St Olavs Univ Hosp, Dept Phys Med & Rehabil, N-7006 Trondheim, Norway; [Klepstad, P.] Norwegian Univ Sci & Technol, Fac Med, Dept Circulat & Med Imaging, N-7034 Trondheim, Norway	Schirmer-Mikalsen, K (corresponding author), St Olavs Univ Hosp, Dept Anaesthesia & Acute Med, Postboks 3250 Sluppen, N-7006 Trondheim, Norway.	kari.schirmer@stolav.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	St. Olav University Hospital; Liaison Committee	Funded by the St. Olav University Hospital.; Kent Goran Moen has, during the study period, received a research grant from the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU).	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bilotta F, 2010, CURR OPIN ANESTHESIO, V23, P539, DOI 10.1097/ACO.0b013e32833e150a; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Clayton TJ, 2004, BRIT J ANAESTH, V93, P761, DOI 10.1093/bja/aeh249; Clifton GL, 2011, LANCET NEUROL, V10, P131, DOI 10.1016/S1474-4422(10)70300-8; Coester A, 2010, J TRAUMA, V68, P904, DOI 10.1097/TA.0b013e3181c9afc2; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cook DJ, 1998, ANN INTERN MED, V129, P433, DOI 10.7326/0003-4819-129-6-199809150-00002; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Foreman BP, 2007, J TRAUMA, V62, P946, DOI 10.1097/01.ta.0000229796.14717.3a; GENNARELLI TA, 1994, J TRAUMA, V37, P962, DOI 10.1097/00005373-199412000-00016; Grande PO, 2009, ACTA ANAESTH SCAND, V53, P1233, DOI 10.1111/j.1399-6576.2009.02074.x; Grande PO, 2011, J NEUROSURG ANESTH, V23, P251, DOI 10.1097/ANA.0b013e31821a8f10; Green DM, 2010, NEUROCRIT CARE, V13, P299, DOI 10.1007/s12028-010-9417-3; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Janssens U, 2000, INTENS CARE MED, V26, P1037, DOI 10.1007/s001340051316; Kramer AH, 2009, CRIT CARE, V13, DOI 10.1186/cc7916; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Li J, 2012, J NEUROTRAUM, V29, P96, DOI 10.1089/neu.2011.1753; Lingsma HF, 2010, LANCET NEUROL, V9, P543, DOI 10.1016/S1474-4422(10)70065-X; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Meier R, 2008, CRIT CARE, V12, DOI 10.1186/cc6974; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Ramesh VJ, 2011, J NEUROSURG ANESTH, V23, P183, DOI 10.1097/ANA.0b013e31821cb9ec; Rovlias A, 2000, NEUROSURGERY, V46, P335, DOI 10.1097/00006123-200002000-00015; Salim A, 2009, AM SURGEON, V75, P25; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Stein DM, 2011, J TRAUMA, V71, P364, DOI 10.1097/TA.0b013e31822820da; Stocchetti N, 2008, INTENS CARE MED, V34, P461, DOI 10.1007/s00134-007-0948-9; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Treggiari MM, 2004, CRIT CARE MED, V32, P327, DOI 10.1097/01.CCM.0000108870.09693.42; Tuettenberg J, 2009, J NEUROSURG, V110, P1200, DOI 10.3171/2008.10.JNS08293; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678	43	23	26	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-5172	1399-6576		ACTA ANAESTH SCAND	Acta Anaesthesiol. Scand.	JAN	2013	57	1					46	55		10.1111/j.1399-6576.2012.02785.x			10	Anesthesiology	Anesthesiology	053LA	WOS:000312271800007	23095138				2021-06-18	
J	Gu, LX; Chafi, MS; Ganpule, S; Chandra, N				Gu, Linxia; Chafi, Mehdi S.; Ganpule, Shailesh; Chandra, Namas			The influence of heterogeneous meninges on the brain mechanics under primary blast loading	COMPOSITES PART B-ENGINEERING			English	Article						Layered structures; Mechanical properties; Interface/interphase; Finite element analysis; Blast wave	RESPONSES; TISSUE	In the modeling of brain mechanics subjected to primary blast waves, there is currently no consensus on how many biological components to be used in the brain-meninges-skull complex, and what type of constitutive models to be adopted. The objective of this study is to determine the role of layered meninges in damping the dynamic response of the brain under primary blast loadings. A composite structures composed of eight solid relevant layers (including the pia, cerebrospinal fluid (CSF), dura maters) with different mechanical properties are constructed to mimic the heterogeneous human head. A hyper-viscoelastic material model is developed to better represent the mechanical response of the brain tissue over a large strain/high frequency range applicable for blast scenarios. The effect of meninges on the brain response is examined. Results show that heterogeneous composite structures of the head have a major influence on the intracranial pressure, maximum shear stress, and maximum principal strain in the brain, which is associated with traumatic brain injuries. The meninges serving as protective layers are revealed by mitigating the dynamic response of the brain. In addition, appreciable changes of the pressure and maximum shear stress are observed on the material interfaces between layers of tissues. This may be attributed to the alternation of shock wave speed caused by the impedance mismatch. (c) 2012 Elsevier Ltd. All rights reserved.	[Gu, Linxia; Chafi, Mehdi S.; Ganpule, Shailesh; Chandra, Namas] Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA; [Gu, Linxia] Nebraska Ctr Mat & Nanosci, Lincoln, NE 68588 USA	Gu, LX (corresponding author), Univ Nebraska, Dept Mech & Mat Engn, Lincoln, NE 68588 USA.	lgu2@unl.edu	gu, linxia/A-5645-2013	gu, linxia/0000-0003-2637-0299	US Army Research Office (ARO) [W911NF-08-1-0483]	This study is supported by the US Army Research Office (ARO), Contract No. W911NF-08-1-0483. The authors are grateful for Mr. Eric Cutler's help with proof reading.	Alley MD, 2011, NEUROIMAGE, V54, pS45, DOI 10.1016/j.neuroimage.2010.05.030; Arbogast KB, 1998, J BIOMECH, V31, P801, DOI 10.1016/S0021-9290(98)00068-2; ARBOGAST KB, 1997, P 41 STAPP CAR CRASH, P293; Bilston LE, 1997, BIORHEOLOGY, V34, P377, DOI 10.1016/S0006-355X(98)00022-5; BOWEN IG, 1968, ANN NY ACAD SCI, V152, P122, DOI 10.1111/j.1749-6632.1968.tb11971.x; BRANDS DWA, 2000, P 44 STAPP CAR CRASH, P249; Chafi MS, 2010, ANN BIOMED ENG, V38, P490, DOI 10.1007/s10439-009-9813-z; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chafi MS, 2009, INT J IMPACT ENG, V36, P1269, DOI 10.1016/j.ijimpeng.2009.03.007; Chen X, 2004, INT J SOLIDS STRUCT, V41, P4635, DOI 10.1016/j.ijsolstr.2004.02.064; Chen X, 2004, COMPOS SCI TECHNOL, V64, P1477, DOI 10.1016/j.compscitech.2003.10.024; Jin Xin, 2006, Stapp Car Crash J, V50, P637; Kleiven Svein, 2002, Stapp Car Crash J, V46, P123; Lippert SA, 2004, BIORHEOLOGY, V41, P681; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Nicolle S, 2005, BIORHEOLOGY, V42, P209; Pervin F, 2009, J BIOMECH, V42, P731, DOI 10.1016/j.jbiomech.2009.01.023; SHUCK LZ, 1972, J BASIC ENG-T ASME, V94, P905, DOI 10.1115/1.3425588; Taylor PA, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3118765; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Zaouk A, 2009, INTERACTION BLAST HE; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zoghi-Moghadam M, 2009, COMPUT METHOD BIOMEC, V12, P1, DOI 10.1080/10255840903064897	24	23	25	0	24	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1359-8368	1879-1069		COMPOS PART B-ENG	Compos. Pt. B-Eng.	DEC	2012	43	8					3160	3166		10.1016/j.compositesb.2012.04.014			7	Engineering, Multidisciplinary; Materials Science, Composites	Engineering; Materials Science	028DS	WOS:000310403600034		Green Published			2021-06-18	
J	Kobayashi, L; Costantini, TW; Coimbra, R				Kobayashi, Leslie; Costantini, Todd W.; Coimbra, Raul			Hypovolemic Shock Resuscitation	SURGICAL CLINICS OF NORTH AMERICA			English	Article						Hemorrhagic shock; Septic shock; Massive transfusion; Blood loss; Crystalloid	PROTHROMBIN COMPLEX CONCENTRATE; FRESH-FROZEN PLASMA; HYPERTONIC SALINE RESUSCITATION; MASSIVE BLOOD-TRANSFUSION; ACTIVATED FACTOR-VII; DAMAGE CONTROL RESUSCITATION; RECOMBINANT-FACTOR-VIIA; LIFE-THREATENING COAGULOPATHY; NATURAL COLLOID RESUSCITATION; TRAUMATIC BRAIN-INJURY	Several changes in the way patients with hemorrhagic shock are resuscitated have occurred over the past decades, including permissive hypotension, minimal crystalloid resuscitation, earlier blood transfusion, and higher plasma and platelet-to-red cell ratios. Hemostatic adjuncts, such as tranexamic acid and prothrombin complex, and the use of new methods of assessing coagulopathy are also being incorporated into resuscitation of the bleeding patient. These ideas have been incorporated by many trauma centers into institutional massive transfusion protocols, and adoption of these protocols has resulted in improvements in mortality and morbidity. This article discusses each of these new resuscitation strategies and the evidence supporting their use.	[Kobayashi, Leslie; Costantini, Todd W.; Coimbra, Raul] Univ Calif San Diego, Sch Med, Div Trauma Surg Crit Care & Burns, Dept Surg, San Diego, CA 92103 USA	Coimbra, R (corresponding author), Univ Calif San Diego, Sch Med, Div Trauma Surg Crit Care & Burns, Dept Surg, 200 W Arbor Dr 8896, San Diego, CA 92103 USA.	rcoimbra@ucsd.edu	Coimbra, Raul/AAP-3019-2020	Coimbra, Raul/0000-0002-3759-6851; Costantini, Todd/0000-0002-0215-5327			Alderson P, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001208.pub3, 10.1002/14651858.CD001208.pub4]; ALDERSON P, 2002, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001208; Allcock EC, 2011, J ROY ARMY MED CORPS, V157, P365, DOI 10.1136/jramc-157-04-03; American College of Surgeons Committee on Trauma, 2008, ADV TRAUM LIF SUPP D; Angle N, 1998, SHOCK, V9, P164, DOI 10.1097/00024382-199803000-00002; Behan LA, 2008, J NEUROL NEUROSUR PS, V79, P753, DOI 10.1136/jnnp.2007.132837; BICKELL WH, 1994, NEW ENGL J MED, V331, P1105, DOI 10.1056/NEJM199410273311701; Boffard KD, 2005, J TRAUMA, V59, P8, DOI 10.1097/01.TA.0000171453.37949.B7; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Boulis NM, 1999, NEUROSURGERY, V45, P1113, DOI 10.1097/00006123-199911000-00020; Brakenridge SC, 2011, J TRAUMA, V71, P299, DOI 10.1097/TA.0b013e318224d328; Brohi K, 2003, J TRAUMA, V54, P1127, DOI 10.1097/01.TA.0000069184.82147.06; Brown LM, 2011, J TRAUMA, V71, pS358, DOI 10.1097/TA.0b013e318227f152; Bruce D, 2008, CRIT CARE, V12, DOI 10.1186/cc6987; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2011, ANN SURG, V253, P431, DOI 10.1097/SLA.0b013e3181fcdb22; Bulger EM, 2010, JAMA-J AM MED ASSOC, V304, P1455, DOI 10.1001/jama.2010.1405; Cabrales P, 2007, SHOCK, V28, P461, DOI 10.1097/shk.0b013e31804880a1; Cap AP, 2011, J TRAUMA, V71, pS9, DOI 10.1097/TA.0b013e31822114af; Cartmill M, 2000, BRIT J NEUROSURG, V14, P458; CERVERA AL, 1975, J TRAUMA, V15, P498, DOI 10.1097/00005373-197506000-00008; Chapman SA, 2011, ANN PHARMACOTHER, V45, P869, DOI 10.1345/aph.1P605; Cinat ME, 1999, ARCH SURG-CHICAGO, V134, P964, DOI 10.1001/archsurg.134.9.964; Cohn SM, 2011, WORLD J SURG, V35, P430, DOI 10.1007/s00268-010-0875-8; Coimbra R, 1997, J TRAUMA, V42, P602, DOI 10.1097/00005373-199704000-00004; Collier B, 2010, J CRIT CARE, V25, DOI 10.1016/j.jcrc.2009.05.003; Como JJ, 2004, TRANSFUSION, V44, P809, DOI 10.1111/j.1537-2995.2004.03409.x; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cosgriff N, 1997, J TRAUMA, V42, P857, DOI 10.1097/00005373-199705000-00016; Cotton BA, 2006, SHOCK, V26, P115, DOI 10.1097/01.shk.0000209564.84822.f2; Cotton BA, 2011, ANN SURG, V254, P598, DOI 10.1097/SLA.0b013e318230089e; Cotton BA, 2011, J TRAUMA, V71, P407, DOI 10.1097/TA.0b013e31821e1bf0; Cotton BA, 2010, J TRAUMA, V69, pS33, DOI 10.1097/TA.0b013e3181e42411; Cotton BA, 2009, J TRAUMA, V67, P1004, DOI 10.1097/TA.0b013e3181bcb2a8; Cotton BA, 2009, J TRAUMA, V66, P41, DOI 10.1097/TA.0b013e31819313bb; Dart AB, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007594.pub2; Davenport R, 2011, CRIT CARE MED, V39, P2652, DOI 10.1097/CCM.0b013e3182281af5; Dentali F, 2011, THROMB HAEMOSTASIS, V106, P429, DOI 10.1160/TH11-01-0052; Dente CJ, 2009, J TRAUMA, V66, P1616, DOI 10.1097/TA.0b013e3181a59ad5; Dirks J, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-65; DuBose JJ, 2010, J TRAUMA, V68, P1172, DOI 10.1097/TA.0b013e3181d76d40; Duchesne JC, 2008, J TRAUMA, V65, P272, DOI 10.1097/TA.0b013e31817e5166; Duchesne JC, 2011, AM SURGEON, V77, P201; Duchesne JC, 2009, J TRAUMA, V67, P228; Duchesne JC, 2009, J TRAUMA, V67, P33, DOI 10.1097/TA.0b013e31819adb8e; ERRINGTON ML, 1971, J PHYSIOL-LONDON, V217, pP43; Finfer S, 2004, NEW ENGL J MED, V350, P2247; Fraga GP, 2010, J EMERG MED, V39, P253, DOI 10.1016/j.jemermed.2009.02.034; Gattas DJ, 2012, ANESTH ANALG, V114, P159, DOI 10.1213/ANE.0b013e318236b4d6; Gonzalez EA, 2007, J TRAUMA, V62, P112, DOI 10.1097/01.ta.0000250497.08101.8b; Grmec S, 2008, INT J EMERG MED, V1, P311, DOI 10.1007/s12245-008-0073-8; Gunter OL, 2008, J TRAUMA, V65, P527, DOI 10.1097/TA.0b013e3181826ddf; Hartog CS, 2011, INTENS CARE MED, V37, P1725, DOI 10.1007/s00134-011-2385-z; HARVEY MP, 1995, MED J AUSTRALIA, V163, P356, DOI 10.5694/j.1326-5377.1995.tb124628.x; Hauser CJ, 2010, J TRAUMA, V69, P489, DOI 10.1097/TA.0b013e3181edf36e; Healey MA, 1998, J TRAUMA, V45, P894, DOI 10.1097/00005373-199811000-00010; HEWSON JR, 1985, CRIT CARE MED, V13, P387, DOI 10.1097/00003246-198505000-00003; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Hsia CC, 2008, ANN SURG, V248, P61, DOI 10.1097/SLA.0b013e318176c4ec; Huber-Wagner S, 2007, VOX SANG, V92, P69, DOI 10.1111/j.1423-0410.2006.00858.x; Inaba K, 2010, J AM COLL SURGEONS, V211, P573, DOI 10.1016/j.jamcollsurg.2010.06.392; Inaba K, 2010, J AM COLL SURGEONS, V210, P957, DOI 10.1016/j.jamcollsurg.2010.01.031; Inaba K, 2008, J TRAUMA, V65, P1222, DOI 10.1097/TA.0b013e31818e8ff3; James MFM, 2011, BRIT J ANAESTH, V107, P693, DOI 10.1093/bja/aer229; Johansson PI, 2009, VOX SANG, V96, P111, DOI 10.1111/j.1423-0410.2008.01130.x; Kashuk JL, 2008, J TRAUMA, V65, P261, DOI 10.1097/TA.0b013e31817de3e1; Kheirabadi BS, 2008, J TRAUMA, V64, P1218, DOI 10.1097/TA.0b013e31816c5c6c; Kheirabadi BS, 2008, J TRAUMA, V64, P1228; KIVIOJA A, 1991, AM SURGEON, V57, P398; Krumrei NJ, 2012, J TRAUMA ACUTE CARE, V72, P211, DOI 10.1097/TA.0b013e318240507b; Leemann H, 2010, J TRAUMA, V69, P1403, DOI 10.1097/TA.0b013e3181faaa25; LESLIE SD, 1991, AM J CLIN PATHOL, V96, P770, DOI 10.1093/ajcp/96.6.770; Levi M, 2010, NEW ENGL J MED, V363, P1791, DOI 10.1056/NEJMoa1006221; Liberati A, 2006, INTERN EMERG MED, V1, P243, DOI 10.1007/BF02934748; Lissauer ME, 2011, AM J SURG, V202, P53, DOI 10.1016/j.amjsurg.2010.05.002; Lustenberger T, 2011, J TRAUMA, V71, P1144, DOI 10.1097/TA.0b013e318230e89b; Maegele M, 2007, INJURY, V38, P298, DOI 10.1016/j.injury.2006.10.003; Malone DL, 2006, J TRAUMA, V60, pS91, DOI 10.1097/01.ta.0000199549.80731.e6; Martini WZ, 2008, J TRAUMA, V65, P535, DOI 10.1097/TA.0b013e31818379a6; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; McLaughlin DF, 2008, J TRAUMA, V64, pS57, DOI 10.1097/TA.0b013e318160a566; MCLAUGHLIN DF, 2008, J TRAUMA, V64, pS63, DOI DOI 10.1097/TA.0B013E318160A566.[; McSwain N, 2011, J TRAUMA, V70, pS53, DOI 10.1097/TA.0b013e31821a5e5d; Mitra B, 2012, INJURY, V43, P33, DOI 10.1016/j.injury.2011.10.011; Moore FA, 2006, J TRAUMA, V61, P82, DOI 10.1097/01.ta.0000225933.08478.65; Moore FA, 2008, AM J SURG, V196, P948, DOI 10.1016/j.amjsurg.2008.07.043; Morales D, 1999, CIRCULATION, V100, P226, DOI 10.1161/01.CIR.100.3.226; Morrison CA, 2011, J TRAUMA, V70, P652, DOI 10.1097/TA.0b013e31820e77ea; Morrison JJ, 2012, ARCH SURG-CHICAGO, V147, P113, DOI 10.1001/archsurg.2011.287; Morse BC, 2011, AM SURGEON, V77, P1043; MURRAY DJ, 1988, ANESTHESIOLOGY, V69, P839, DOI 10.1097/00000542-198812000-00007; Myburgh J, 2007, NEW ENGL J MED, V357, P874; Nascimento B, 2011, J TRAUMA, V71, pS418, DOI 10.1097/TA.0b013e318232e591; Nienaber U, 2011, INJURY, V42, P697, DOI 10.1016/j.injury.2010.12.015; Niles SE, 2008, J TRAUMA, V64, P1459, DOI 10.1097/TA.0b013e318174e8bc; Nunez TC, 2009, J TRAUMA, V66, P346, DOI 10.1097/TA.0b013e3181961c35; Nystrup KB, 2011, SCAND J TRAUMA RESUS, V19, DOI 10.1186/1757-7241-19-52; O'Keeffe T, 2008, ARCH SURG-CHICAGO, V143, P686, DOI 10.1001/archsurg.143.7.686; OWENS TM, 1995, J TRAUMA, V39, P200, DOI 10.1097/00005373-199508000-00004; Pabinger I, 2008, J THROMB HAEMOST, V6, P622, DOI 10.1111/j.1538-7836.2008.02904.x; Perkins JG, 2009, J TRAUMA, V66, pS77, DOI 10.1097/TA.0b013e31819d8936; PHILLIPS TF, 1987, J TRAUMA, V27, P903, DOI 10.1097/00005373-198708000-00010; Plotkin AJ, 2008, J TRAUMA, V64, pS64, DOI 10.1097/TA.0b013e318160772d; Plurad DS, 2011, J TRAUMA, V71, P565, DOI 10.1097/TA.0b013e3182213d52; Rahbar MH, 2012, RESUSCITATION, V83, P459, DOI 10.1016/j.resuscitation.2011.09.019; Riskin DJ, 2009, J AM COLL SURGEONS, V209, P198, DOI 10.1016/j.jamcollsurg.2009.04.016; Rizoli SB, 2006, CRIT CARE, V10, DOI 10.1186/cc5133; Rizoli SB, 2006, ANN SURG, V243, P47, DOI 10.1097/01.sla.0000193608.93127.b1; Rugeri L, 2007, J THROMB HAEMOST, V5, P289, DOI 10.1111/j.1538-7836.2007.02319.x; Sambasivan CN, 2011, J TRAUMA, V71, pS329, DOI 10.1097/TA.0b013e318227edd3; Schick KS, 2009, CRIT CARE, V13, DOI 10.1186/cc8186; Schnuriger B, 2011, J TRAUMA, V70, P603, DOI 10.1097/TA.0b013e3182092abb; Schochl H, 2011, CRIT CARE, V15, DOI 10.1186/cc10539; Schochl H, 2011, CRIT CARE, V15, DOI 10.1186/cc10078; Schochl H, 2010, CRIT CARE, V14, DOI 10.1186/cc8948; Schreiber M, 2008, AM J SURG, V196, P958; Schreiber MA, 2007, J AM COLL SURGEONS, V205, P541, DOI 10.1016/j.jamcollsurg.2007.05.007; Schreiber MA, 2011, J TRAUMA, V70, pS13, DOI 10.1097/TA.0b013e31821a4ba5; SCHWARTZ J, 1981, ENDOCRINOLOGY, V109, P1778, DOI 10.1210/endo-109-5-1778; Shakur H, 2010, LANCET, V376, P23, DOI 10.1016/S0140-6736(10)60835-5; Shaz BH, 2010, TRANSFUSION, V50, P493, DOI 10.1111/j.1537-2995.2009.02414.x; Snyder CW, 2009, J TRAUMA, V66, P358, DOI 10.1097/TA.0b013e318196c3ac; Sondeen JL, 2011, TRANSFUSION, V51, P779, DOI 10.1111/j.1537-2995.2010.02928.x; Sperry JL, 2008, J TRAUMA, V65, P986, DOI 10.1097/TA.0b013e3181878028; Sperry JL, 2008, J TRAUMA, V64, P9, DOI 10.1097/TA.0b013e31815dd029; Spinella PC, 2008, CRIT CARE MED, V36, pS340, DOI 10.1097/CCM.0b013e31817e2ef9; Spinella PC, 2008, J TRAUMA, V64, pS69, DOI 10.1097/TA.0b013e318160ba2f; Spinella PC, 2007, CRIT CARE MED, V35, P2576, DOI 10.1097/01.CCM.0000285996.65226.A9; Spinella PC, 2009, J TRAUMA, V66, pS69, DOI 10.1097/TA.0b013e31819d85fb; Stadlbauer KH, 2003, ANESTHESIOLOGY, V98, P699, DOI 10.1097/00000542-200303000-00018; Stinger HK, 2008, J TRAUMA, V64, pS79, DOI 10.1097/TA.0b013e318160a57b; Tauber H, 2011, BRIT J ANAESTH, V107, P378, DOI 10.1093/bja/aer158; Teixeira PGR, 2009, J TRAUMA, V66, P693, DOI 10.1097/TA.0b013e31817e5c77; Thomas GOR, 2007, J TRAUMA, V62, P564, DOI 10.1097/TA.0b013e318031afc2; Van PY, 2010, J TRAUMA, V69, pS64, DOI 10.1097/TA.0b013e3181e453ec; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Voelckel WG, 2003, CRIT CARE MED, V31, P1160, DOI 10.1097/01.CCM.0000060014.75282.69; Wafaisade A, 2011, J TRAUMA, V70, P81, DOI 10.1097/TA.0b013e3182032e0b; Watson GA, 2009, J TRAUMA, V67, P221, DOI 10.1097/TA.0b013e3181ad5957; Wiedermann CJ, 2010, CRIT CARE, V14, DOI 10.1186/cc9308; WILSON RF, 1987, AM SURGEON, V53, P410; Woodruff SI, 2010, EMERG MED J, V27, P121, DOI 10.1136/emj.2008.060657; Yasaka M, 2002, THROMB RES, V108, P25, DOI 10.1016/S0049-3848(02)00402-4; YOUNES RN, 1992, SURGERY, V111, P380; Yucel N, 2006, J TRAUMA, V60, P1228, DOI 10.1097/01.ta.0000220386.84012.bf; Zink KA, 2009, AM J SURG, V197, P565, DOI 10.1016/j.amjsurg.2008.12.014	146	23	26	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0039-6109	1558-3171		SURG CLIN N AM	Surg. Clin.-North Am.	DEC	2012	92	6					1403	+		10.1016/j.suc.2012.08.006			22	Surgery	Surgery	058JI	WOS:000312629500005	23153876				2021-06-18	
J	Pontifex, MB; Broglio, SP; Drollette, ES; Scudder, MR; Johnson, CR; O'Connor, PM; Hillman, CH				Pontifex, Matthew B.; Broglio, Steven P.; Drollette, Eric S.; Scudder, Mark R.; Johnson, Chris R.; O'Connor, Phillip M.; Hillman, Charles H.			The Relation of Mild Traumatic Brain Injury to Chronic Lapses of Attention	RESEARCH QUARTERLY FOR EXERCISE AND SPORT			English	Article						cognitive control; concussion; sustained attention; vigilance	EXECUTIVE FUNCTIONS; PROFESSIONAL FOOTBALL; SUSTAINED ATTENTION; CONCUSSION; SENSITIVITY; PERFORMANCE; MEMORY; HIPPOCAMPUS; DYSFUNCTION; INHIBITION	We assessed the extent to which failures in sustained attention were associated with chronic mild traumatic brain injury (mTBI) deficits in cognitive control among college-age young adults with and without a history of sport-related concussion. Participants completed the ImPACT computer-based assessment and a modified flanker task. Results indicated that a history of mTBI, relative to healthy controls, was associated with inferior overall flanker task performance with a greater number of omission errors and more frequent sequentially occurring omission errors. Accordingly, these findings suggest that failures in the ability to maintain attentional vigilance may, in part, underlie mTBI-related cognition deficits.	[Pontifex, Matthew B.] Michigan State Univ, Dept Kinesiol, E Lansing, MI 48824 USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Drollette, Eric S.; Scudder, Mark R.; Johnson, Chris R.; O'Connor, Phillip M.; Hillman, Charles H.] Univ Illinois, Dept Kinesiol & Community Hlth, Urbana, IL 61801 USA	Pontifex, MB (corresponding author), Michigan State Univ, Dept Kinesiol, 27P IM Sports Circle, E Lansing, MI 48824 USA.	pontifex@msu.edu	Hillman, Charles/AAD-4828-2019	Hillman, Charles/0000-0002-3722-5612; Pontifex, Matthew/0000-0001-9819-9625	Mary Jane Neer Fund for Disability Research; University of Illinois Research Board; University of Illinois predoctoral fellowship through the NICHD Developmental Psychobiology and Neurobiology Training Grant [2 T32 HD007333]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007333] Funding Source: NIH RePORTER	This research was supported by grants from the Mary Jane Neer Fund for Disability Research, the University of Illinois Research Board, and a University of Illinois predoctoral fellowship through the NICHD Developmental Psychobiology and Neurobiology Training Grant (2 T32 HD007333) awarded to the first author. No conflicting financial interests exist. At the time of this study, the first author was with the University of Illinois at Urbana-Champaign. Please address correspondence concerning this article to Matthew B. Pontifex, Department of Kinesiology, 27P IM Sports Circle, Michigan State University, East Lansing, MI 488241049.	Bales JW, 2009, NEUROSCI BIOBEHAV R, V33, P981, DOI 10.1016/j.neubiorev.2009.03.011; Barkley RA, 1997, PSYCHOL BULL, V121, P65, DOI 10.1037/0033-2909.121.1.65; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Brocki KC, 2004, DEV NEUROPSYCHOL, V26, P571, DOI 10.1207/s15326942dn2602_3; Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Broglio SP, 2009, J NEUROTRAUM, V26, P1463, DOI [10.1089/neu.2008.0766, 10.1089/neu.2008-0766]; Caggiano DM, 2004, PSYCHON B REV, V11, P932, DOI 10.3758/BF03196724; Chen JK, 2008, ARCH GEN PSYCHIAT, V65, P81, DOI 10.1001/archgenpsychiatry.2007.8; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cicerone KD, 1997, CLIN NEUROPSYCHOL, V11, P266, DOI 10.1080/13854049708400455; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Davidson MC, 2006, NEUROPSYCHOLOGIA, V44, P2037, DOI 10.1016/j.neuropsychologia.2006.02.006; Diamond A., 2006, LIFESPAN COGNITION M, P70, DOI DOI 10.1093/ACPROF:OSO/9780195169539.003.0006; Dupuis F, 2000, NEUROREPORT, V11, P4087, DOI 10.1097/00001756-200012180-00035; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; ERIKSEN BA, 1974, PERCEPT PSYCHOPHYS, V16, P143, DOI 10.3758/BF03203267; ERIKSEN CW, 1979, PERCEPT PSYCHOPHYS, V25, P249, DOI 10.3758/BF03198804; FISK AD, 1981, HUM FACTORS, V23, P737; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Kaufman A.S., 1990, KAUFMAN BRIEF INTELL; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Leclercq M, 2002, APPLIED NEUROPSYCHOLOGY OF ATTENTION: THEORY DIAGNOSIS AND REHABILITATION, P257; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Meyer DE, 1997, PSYCHOL REV, V104, P3, DOI 10.1037/0033-295X.104.1.3; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Motulsky H., 1995, INTUITIVE BIOSTATIST; NORMAN DA, 1986, CONSCIOUSNESS SELF R, P1, DOI DOI 10.1007/978-1-4757-0629-1_1; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Parasuraman R, 1998, ATTENTIVE BRAIN, P221; PARASURAMAN R, 1979, SCIENCE, V205, P924, DOI 10.1126/science.472714; Pellman EJ, 2006, NEUROSURGERY, V58, P263, DOI 10.1227/01.NEU.0000200272.56192.62; Piland SG, 2010, J ATHL TRAINING, V45, P273, DOI 10.4085/1062-6050-45.3.273; Pontifex MB, 2007, CLIN NEUROPHYSIOL, V118, P570, DOI 10.1016/j.clinph.2006.09.029; Pontifex MB, 2009, MED SCI SPORT EXER, V41, P927, DOI 10.1249/MSS.0b013e3181907d69; Spencer KM, 1999, PSYCHOPHYSIOLOGY, V36, P364, DOI 10.1017/S0048577299970749; Tashlykov V, 2007, BRAIN RES, V1130, P197, DOI 10.1016/j.brainres.2006.10.032; Temple JG, 2000, HUM FACTORS, V42, P183, DOI 10.1518/001872000779656480; Warm JS, 2008, HUM FACTORS, V50, P433, DOI 10.1518/001872008X312152	45	23	23	0	30	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0270-1367	2168-3824		RES Q EXERCISE SPORT	Res. Q. Exerc. Sport	DEC	2012	83	4					553	559					7	Hospitality, Leisure, Sport & Tourism; Psychology, Applied; Psychology; Sport Sciences	Social Sciences - Other Topics; Psychology; Sport Sciences	062NB	WOS:000312925400009	23367818				2021-06-18	
J	Franschman, G; Verburg, N; Brens-Heldens, V; Andriessen, TMJC; Van der Naalt, J; Peerdeman, SM; Valk, JP; Hoogerwerf, N; Greuters, S; Schober, P; Vos, PE; Christiaans, HMT; Boer, C				Franschman, G.; Verburg, N.; Brens-Heldens, V.; Andriessen, T. M. J. C.; Van der Naalt, J.; Peerdeman, S. M.; Valk, J. P.; Hoogerwerf, N.; Greuters, S.; Schober, P.; Vos, P. E.; Christiaans, H. M. T.; Boer, C.			Effects of physician-based emergency medical service dispatch in severe traumatic brain injury on prehospital run time	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						Emergency medical service; Traumatic brain injury; Prehospital; Advanced life support; Mortality; Transportation; Mobile medical team	ON-SCENE TIMES; ADVANCED LIFE-SUPPORT; TEAM INVOLVEMENT; HEAD-INJURY; CARE; MORTALITY; IMPACT; HEMS	Introduction: Prehospital care by physician-based helicopter emergency medical services (P-HEMS) may prolong total prehospital run time. This has raised an issue of debate about the benefits of these services in traumatic brain injury (TBI). We therefore investigated the effects of P-HEMS dispatch on prehospital run time and outcome in severe TBI. Methods: Prehospital run times of 497 patients with severe TBI who were solely treated by a paramedic EMS (n = 125) or an EMS/P-HEMS combination (n = 372) were retrospectively analyzed. Other study parameters included the injury severity score (ISS), Glasgow Coma Scale (GCS), prehospital endotracheal intubation and predicted and observed outcome rates. Results: Patients who received P-HEMS care were younger and had higher ISS values than solely EMS-treated patients (10%; P = 0.04). The overall prehospital run time was 74 +/- 54 min, with similar out-of-hospital times for EMS and P-HEMS treated patients. Prehospital endotracheal intubation was more frequently performed in the P-HEMS group (88%) than in the EMS group (35%; P < 0.001). The prehospital run time for intubated patients was similar for P-HEMS (66 (51-80) min) and EMS-treated patients (59 (41-88 min). Unexpectedly, mortality probability scores and observed outcome scores were less favourable for EMS-treated patients when compared to patients treated by P-HEMS. Conclusion: P-HEMS dispatch does not increase prehospital run times in severe TBI, while it assures prehospital intubation of TBI patients by a well-trained physician. Our data however suggest that a subgroup of the most severely injured patients received prehospital care by an EMS, while international guidelines recommend advanced life support by a physician-based EMS in these cases. (C) 2012 Elsevier Ltd. All rights reserved.	[Franschman, G.; Verburg, N.; Greuters, S.; Schober, P.; Christiaans, H. M. T.; Boer, C.] Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, NL-1081 HV Amsterdam, Netherlands; [Verburg, N.; Peerdeman, S. M.] Vrije Univ Amsterdam, Med Ctr, Dept Neurosurg, NL-1081 HV Amsterdam, Netherlands; [Brens-Heldens, V.; Hoogerwerf, N.] Radboud Univ Nijmegen, Med Ctr, Dept Anesthesiol, Nijmegen, Netherlands; [Andriessen, T. M. J. C.; Vos, P. E.] Radboud Univ Nijmegen, Med Ctr, Dept Neurol, Nijmegen, Netherlands; [Van der Naalt, J.] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Groningen, Netherlands; [Valk, J. P.] Univ Med Ctr Groningen, Dept Anesthesiol, Groningen, Netherlands	Franschman, G (corresponding author), Vrije Univ Amsterdam, Med Ctr, Dept Anesthesiol, De Boelelaan 1117, NL-1081 HV Amsterdam, Netherlands.	g.franschman@vumc.nl	Verburg, Niels/ABA-6100-2020; Hoogerwerf, Nico/L-4388-2015; Schober, Patrick/G-7400-2012	Verburg, Niels/0000-0003-1048-1664; Hoogerwerf, Nico/0000-0003-1815-6989; Schober, Patrick/0000-0003-0814-081X; Boer, Christa/0000-0002-7781-6951	Department of Anaesthesiology of the VU University Medical Centre, Amsterdam, The Netherlands	This study was financially supported by the Department of Anaesthesiology of the VU University Medical Centre, Amsterdam, The Netherlands.	Aydin S, 2010, J TRAUMA, V69, P589, DOI 10.1097/TA.0b013e3181e74858; Brain Trauma Foundation, 2007, GUID PREH MAN TRAUM, VS12, pS1; Butler DP, 2010, EMERG MED J, V27, P692, DOI 10.1136/emj.2009.087486; De Jongh MA, 2012, INJURY; Di Bartolomeo S, 2001, ARCH SURG-CHICAGO, V136, P1293, DOI 10.1001/archsurg.136.11.1293; *FDN NAT AMB EM RO, 2007, LAND PROT AMB LPA7; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Franschman G, 2011, J TRAUMA, V71, P826, DOI 10.1097/TA.0b013e31820cebf0; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Lerner EB, 2001, ACAD EMERG MED, V8, P758, DOI 10.1111/j.1553-2712.2001.tb00201.x; Liberman M, 2000, J TRAUMA, V49, P584, DOI 10.1097/00005373-200010000-00003; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Osterwalder Joseph J, 2002, Prehosp Disaster Med, V17, P75; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Ringburg AN, 2007, J TRAUMA, V63, P258, DOI 10.1097/01.ta.0000240449.23201.57; Ryynanen OP, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-62; Schober P, 2011, J TRAUMA, V70, P1301, DOI 10.1097/TA.0b013e31820d20e8; Slagt C, 2001, Air Med J, V20, P17, DOI 10.1067/mmj.2001.115797; ten Duis HJ, 2003, INJURY, V34, P722, DOI 10.1016/S0020-1383(03)00162-1; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	21	23	24	0	4	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383			INJURY	Injury-Int. J. Care Inj.	NOV	2012	43	11					1838	1842		10.1016/j.injury.2012.05.020			5	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	014VR	WOS:000309404300011	22695322				2021-06-18	
J	Homaifar, BY; Brenner, LA; Forster, JE; Nagamoto, H				Homaifar, Beeta Y.; Brenner, Lisa A.; Forster, Jeri E.; Nagamoto, Herbert			Traumatic Brain Injury, Executive Functioning, and Suicidal Behavior: A Brief Report	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; suicide attempt; suicidal ideation; executive functioning; perseveration	DEPRESSION; RUMINATION; IDEATION; ATTEMPTERS; HISTORY; MODEL	Objective: The aim of this pilot study was to explore the relationship between executive dysfunction and suicidal behavior in two groups of participants: (Group 1, n = 18) veterans with traumatic brain injury (TBI) and a history of at least one suicide attempt (SA), and (Group 2, n = 29) veterans with TBI and no history of SA. Controlling for the severity of TBI, it was hypothesized that participants in Group 1 would perform more poorly than those in Group 2 on measures of executive functioning. Design: The primary outcome variable was decision making as assessed by performance on the Iowa Gambling Task (IGT). Secondary outcome variables included laboratory-measured impulsivity as measured by the Immediate and Delayed Memory Test (IMT/DMT), abstract reasoning as measured by the Wisconsin Card Sorting Test (WCST), and aggression as measured by the Lifetime History of Aggression (LHA) scale. Results: Among those in Group 1, time between TBI and first suicide attempt postinjury varied widely (months to nearly 30 years). Only the WCST perseverative errors score differed significantly between individuals with and without histories of one or more suicide attempts (SAs). Conclusion: Suggestions for future study of SA among those with TBI are provided. When working with individuals with TBI, clinicians are encouraged to incorporate suicide risk assessment into their practice. Augmenting this process with a measure of perseveration may be beneficial.	[Homaifar, Beeta Y.; Brenner, Lisa A.] VISN 19 MIRECC, Denver, CO 80220 USA; [Homaifar, Beeta Y.; Brenner, Lisa A.; Nagamoto, Herbert] Univ Colorado Denver, Sch Med, Dept Psychiat, Denver, CO 80210 USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Neurol, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Phys Med, Denver, CO USA; [Brenner, Lisa A.] Univ Colorado Denver, Sch Med, Dept Rehabil, Denver, CO USA; [Forster, Jeri E.] Univ Colorado Denver, Sch Med, Dept Pediat, Denver, CO USA; [Nagamoto, Herbert] Eastern Colorado Hlth Care Syst, Vet Affairs Med Ctr, Denver, CO USA	Homaifar, BY (corresponding author), VISN 19 MIRECC, 1055 Clermont St, Denver, CO 80220 USA.	beeta.homaifar@va.gov	Brenner, Lisa A./AAG-2442-2019				Allen LM, 2004, CARB COMPUTERIZED AS; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Beck A. T., 1996, BECK DEPRESSION INVE, VII; Brenner LA, 2009, REHABIL PSYCHOL, V54, P390, DOI 10.1037/a0017802; BROWN GL, 1979, PSYCHIAT RES, V1, P131, DOI 10.1016/0165-1781(79)90053-2; Davis RN, 2000, COGNITIVE THER RES, V24, P699, DOI 10.1023/A:1005591412406; Department of Veterans Affairs and Department of Defense, 2009, VA DOD CLIN PRACT GU; Dougherty DM, 2004, SUICIDE LIFE-THREAT, V34, P374, DOI 10.1521/suli.34.4.374.53738; Heaton R., 1993, WISCONSIN CARD SORTI; JANOFSKY JS, 1992, HOSP COMMUNITY PSYCH, V43, P132; Joiner T. E., 2005, WHY PEOPLE DIE SUICI; Jollant F, 2005, AM J PSYCHIAT, V162, P304, DOI 10.1176/appi.ajp.162.2.304; Keilp JG, 2001, AM J PSYCHIAT, V158, P735, DOI 10.1176/appi.ajp.158.5.735; Mann JJ, 1999, AM J PSYCHIAT, V156, P181; Marzuk PM, 2005, ACTA PSYCHIAT SCAND, V112, P294, DOI 10.1111/j.1600-0447.2005.00585.x; O'Connor RC, 2008, BEHAV RES THER, V46, P392, DOI 10.1016/j.brat.2008.01.007; Oquendo MA, 2004, J NERV MENT DIS, V192, P430, DOI 10.1097/01.nmd.0000126706.53615.7b; Oquendo MA, 2003, STANDARDIZED EVALUAT, P103; Rowland SM, 2005, BRAIN INJURY, V19, P77, DOI 10.1080/02699050410001719988; Rudd M.D., 2006, COGNITION SUICIDE TH, P355, DOI DOI 10.1037/11377-016; Simpson G, 2007, BRAIN INJURY, V21, P1335, DOI 10.1080/02699050701785542; Smith JM, 2006, SUICIDE LIFE-THREAT, V36, P443, DOI 10.1521/suli.2006.36.4.443; Smith JM, 2009, CLIN PSYCHOL REV, V29, P116, DOI 10.1016/j.cpr.2008.10.003; Teasdale TW, 2001, J NEUROL NEUROSUR PS, V71, P436, DOI 10.1136/jnnp.71.4.436; Thurman DJ., 1995, GUIDELINES SURVEILLA; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Watkins E, 2008, EMOTION, V8, P364, DOI 10.1037/1528-3542.8.3.364; Wells A, 1996, BEHAV RES THER, V34, P881, DOI 10.1016/S0005-7967(96)00050-2; Yurgelun-Todd DA, 2011, J HEAD TRAUMA REHAB, V26, P276, DOI 10.1097/HTR.0b013e31822251dc	29	23	23	1	15	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550			REHABIL PSYCHOL	Rehabil. Psychol.	NOV	2012	57	4					337	341		10.1037/a0030480			5	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	047EG	WOS:000311819900009	23181582				2021-06-18	
J	Levy, ML; Kasasbeh, AS; Baird, LC; Amene, C; Skeen, J; Marshall, L				Levy, Michael L.; Kasasbeh, Aimen S.; Baird, Lissa Catherine; Amene, Chiazo; Skeen, Jeff; Marshall, Larry			Concussions in Soccer: A Current Understanding	WORLD NEUROSURGERY			English	Article						Concussion; Head injury; Protective headgear; Soccer; Trauma	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; ATHLETIC HEAD-INJURIES; HIGH-SCHOOL; FOOTBALL PLAYERS; UNITED-STATES; PROTECTIVE HEADGEAR; CEREBRAL CONCUSSION; CONTACT-SPORTS; NEUROCOGNITIVE PERFORMANCE	OBJECTIVE: Traumatic brain injury (TBI) is a significant public health problem in the United States, with approximately 1.5-2 million TBIs occurring each year. However, it is believed that these figures underestimate the true toll of TBI. Soccer is the most popular sport in the world and has a following of millions in the United States. Soccer is a sport not traditionally identified as high-risk for concussions, yet several studies have shown that concussion rates in soccer are comparable to, and often exceed those of, other contact sports. As many as 22% of all soccer injuries are concussions. METHODS: Soccer is a sport not traditionally identified as high risk for concussions, yet several studies have shown that concussion rates in soccer are comparable to, and often exceed those of, other contact sports. As many as 22% of all soccer injuries are concussions. Head injury during soccer is usually the result of either "direct contact" or contact with the ball while "heading" the ball. Relationships between the number of headers sustained in a single season and the degree of cognitive impairment (attention and visual/verbal memory) have been demonstrated. It is also likely that multiple concussions may cause cumulative neuropsychologic impairment in soccer players. RESULTS: Although our understanding of risk factors for sports-related concussions is far from complete, there is great potential for prevention in sports-related concussions. Several measures must be taken to avert the development of concussions in soccer and, when they take place, reduce their effects. These include the development and testing of effective equipment during play, the maintenance of regulatory standards for all such equipment, educating young athletes on the safe and appropriate techniques used during play, and strict adherence to the rules of competition. CONCLUSIONS: In spite of such preventive measures, concussions in soccer will continue to occur. Considering the frequency of concussions in soccer, the serious sequelae of these concussions, and because almost half of concussed soccer players were noncompliant with recommended American Academy of Neurology return-to-play guidelines, further measures must be taken to protect players, in addition to understanding those criteria that result in removing an injured player from competition and the steps by which to safely return an athlete to competition after injury.	[Levy, Michael L.; Baird, Lissa Catherine; Amene, Chiazo; Skeen, Jeff] Rady Childrens Hosp San Diego, Div Pediat Neurosurg, San Diego, CA USA; [Levy, Michael L.; Baird, Lissa Catherine; Amene, Chiazo; Skeen, Jeff; Marshall, Larry] Univ Calif San Diego, Div Neurosurg, San Diego, CA 92103 USA; [Kasasbeh, Aimen S.] Univ Arizona, Grad Program Neurosci, Tucson, AZ USA	Levy, ML (corresponding author), Rady Childrens Hosp San Diego, Div Pediat Neurosurg, San Diego, CA USA.	mlevy@rchsd.org	Levy, Michael/AAL-4647-2020				Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Agel J, 2007, J ATHL TRAINING, V42, P270; American Academy of Pediatrics, 1988, PHYSICIAN SPORTSMED, V16, P165; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Anderson SJ, 2000, PEDIATRICS, V105, P659, DOI 10.1542/peds.105.3.640; [Anonymous], 1999, JAMA, V282, P974; [Anonymous], 1994, MMWR-MORBID MORTAL W, V43, P153; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Autti T, 1997, LANCET, V349, P1144, DOI 10.1016/S0140-6736(05)63019-X; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Baroff GS, 1998, J HEAD TRAUMA REHAB, V13, P45, DOI 10.1097/00001199-199804000-00007; Barth JT., 1989, MILD HEAD INJURY, P257; Baum KA, 1996, NEURORADIOLOGY, V38, P755, DOI 10.1007/s002340050342; Biros MH, 2009, ROSENS EMERGENCY MED; Blond L, 1999, BRIT J SPORT MED, V33, P110, DOI 10.1136/bjsm.33.2.110; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Boutin D, 2008, NEUROCASE, V14, P239, DOI 10.1080/13554790802247543; Broglio SP, 2003, J ATHL TRAINING, V38, P220; *C NEUR SURG, 1966, CLIN NEUROSURG, V12, P386; Cantu RC, 1997, CLIN SPORT MED, V16, P531, DOI 10.1016/S0278-5919(05)70038-7; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; CAPRUSO DX, 1992, NEUROL CLIN, V10, P879; Collie A, 2006, J NEUROL NEUROSUR PS, V77, P241, DOI 10.1136/jnnp.2005.073155; Collins MW, 2003, CLIN J SPORT MED, V13, P222, DOI 10.1097/00042752-200307000-00005; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2003, APPL NEUROPSYCHOL, V10, P12, DOI 10.1207/S15324826AN1001_3; Delaney JS, 2008, BRIT J SPORT MED, V42, P110, DOI 10.1136/bjsm.2007.037689; Delaney J Scott, 2005, Clin J Sport Med, V15, P216, DOI 10.1097/01.jsm.0000168077.74497.a4; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; Delaney JS, 2006, CLIN J SPORT MED, V16, P162, DOI 10.1097/00042752-200603000-00013; Delaney JS, 2004, CLIN J SPORT MED, V14, P80, DOI 10.1097/00042752-200403000-00005; Delaney JS, 2001, CLIN J SPORT MED, V11, P234, DOI 10.1097/00042752-200110000-00005; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dick R, 2007, J ATHL TRAINING, V42, P278; Dvorak J, 2000, AM J SPORT MED, V28, pS3; Dvorak J, 2007, BRIT J SPORT MED, V41, pI44, DOI 10.1136/bjsm.2007.037960; Elhammali N, 2010, INT J ORAL MAX SURG, V39, P857, DOI 10.1016/j.ijom.2010.04.006; Fields K, 1989, SPORTS MED, V17, P72; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; Fuller CW, 2005, BRIT J SPORT MED, V39, pI3, DOI 10.1136/bjsm.2005.018937; Gennarelli T.A., 1982, HEAD INJURY BASIC CL, P129; Gessel LM, 2007, J ATHL TRAINING, V42, P495; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; Hoshizaki TB, 2000, NEUROLOGICAL ATHLETI, P41; HOY K, 1992, AM J SPORT MED, V20, P318, DOI 10.1177/036354659202000314; IO Arizona Youth Soccer Association, HEAD INJ GUID PROC P; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; JANDA DH, 1995, AM J SPORT MED, V23, P340, DOI 10.1177/036354659502300316; Johnston KM, 2001, CLIN J SPORT MED, V11, P150, DOI 10.1097/00042752-200107000-00005; Johnston KM, 2000, CLIN J SPORT MED, V10, P209; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; KELLER CS, 1987, AM J SPORT MED, V15, P230, DOI 10.1177/036354658701500307; KELLY JP, 1991, JAMA-J AM MED ASSOC, V266, P2867, DOI 10.1001/jama.266.20.2867; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Killam C, 2005, ARCH CLIN NEUROPSYCH, V20, P599, DOI 10.1016/j.acn.2005.02.001; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Krauss Michael D, 2004, Curr Sports Med Rep, V3, P272; Langlois JA., 2004, TRAUMATIC BRAIN INJU; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lees K., 1988, SCI FOOTBALL, P385; Levy ML, 2004, NEUROSURGERY, V55, P649, DOI 10.1227/01.NEU.0000134598.06114.89; Levy ML, 2004, NEUROSURGERY, V55, P656, DOI 10.1227/01.NEU.0000134599.01917.AA; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; LINDSAY KW, 1980, BRIT MED J, V281, P789, DOI 10.1136/bmj.281.6243.789; Lovell MR, 1999, CLIN J SPORT MED, V9, P193, DOI 10.1097/00042752-199910000-00002; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Luhtanen P, 1994, FOOTBALL SOCCER; MADDOCKS DL, 1995, CLIN J SPORT MED, V5, P32, DOI 10.1097/00042752-199501000-00006; Maroon JC, 2000, NEUROSURGERY, V47, P659, DOI 10.1097/00006123-200009000-00027; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, MED SCI SPORT EXER, V32, P1980, DOI 10.1097/00005768-200012000-00002; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; MILLER JD, 1993, J NEUROL NEUROSUR PS, V56, P440, DOI 10.1136/jnnp.56.5.440; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman JA, 1993, ACCIDENTAL INJURY BI, P292; NEWMAN JA, 2000, P INT RES C BIOM IMP, P223; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu VC, 2002, NEUROSURGERY, V50, P195; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; Rabadi MH, 2011, CLIN J SPORT MED, V11, P194; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; Reilly T., 1976, J HUMAN MOVEMENT STU, V2, P87; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Sallis R. E., 2003, Medicine & Science in Sports & Exercise, V35, pS247, DOI 10.1097/00005768-200305001-01383; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; Schleimer Jonathan A, 2002, Curr Sports Med Rep, V1, P323; SCHMIDTOLSEN S, 1991, AM J SPORT MED, V19, P273, DOI 10.1177/036354659101900311; SCHNEIDER K, 1988, INT J SPORT BIOMECH, V4, P358, DOI 10.1123/ijsb.4.4.358; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Shetter A G, 1979, Adv Neurol, V22, P5; Smodlaka VN, 1984, PHYSICIAN SPORTSMED, V12, P127, DOI DOI 10.1080/00913847.1984.11701777; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; STEIN SC, 1993, BRAIN INJURY, V7, P425, DOI 10.3109/02699059309029685; STEPHENSON GC, 1992, INJURY, V23, P197, DOI 10.1016/S0020-1383(05)80045-2; Straume-Naesheim TM, 2009, NEUROSURGERY, V64, P719, DOI 10.1227/01.NEU.0000340681.12949.6D; SULLIVAN JA, 1980, AM J SPORT MED, V8, P325, DOI 10.1177/036354658000800505; TEASDALE G, 1974, LANCET, V2, P81; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Thurman DJ, 1998, J HEAD TRAUMA REHAB, V13, P1, DOI 10.1097/00001199-199804000-00003; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; TORG JS, 1985, MED SCI SPORT EXER, V17, P295; Tucker AM, 1997, SPORTS MED, V23, P21, DOI 10.2165/00007256-199723010-00003; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421; Voller B, 1999, BRAIN INJURY, V13, P821, DOI 10.1080/026990599121214; Warren WL, 1998, CLIN SPORT MED, V17, P13, DOI 10.1016/S0278-5919(05)70057-0; Webbe FM, 2003, APPL NEUROPSYCHOL, V10, P31, DOI 10.1207/S15324826AN1001_5; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Witol AD, 2003, ARCH CLIN NEUROPSYCH, V18, P397, DOI 10.1016/S0887-6177(02)00151-8; Yard EE, 2009, BRAIN INJURY, V23, P888, DOI 10.1080/02699050903283171; YARNELL PR, 1970, LANCET, V1, P863; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44	134	23	24	0	61	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	NOV	2012	78	5					535	544		10.1016/j.wneu.2011.10.032			10	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	049PP	WOS:000311996100037	22120567				2021-06-18	
J	Yang, SG; Ma, YH; Liu, Y; Que, HP; Zhu, CQ; Liu, SJ				Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun			Arachidonic Acid: A Bridge between Traumatic Brain Injury and Fracture Healing	JOURNAL OF NEUROTRAUMA			English	Article						arachidonic acid; fracture healing; metabonomics; serum; traumatic brain injury	DOCOSAHEXAENOIC ACID; CALLUS FORMATION; BONE-FRACTURE; PROSTAGLANDINS; MODEL; DIFFERENTIATION; MINERALIZATION; PROLIFERATION; EXPRESSION; REPAIR	Traumatic brain injury (TBI) is associated with enhanced osteogenesis. The aim of this study was to investigate the effect of serum from TBI rats on fracture healing. Results from this study showed that the serum from TBI rats enhanced the expression of bone gamma carboxyglutamate protein (BGLAP), and promoted in vitro proliferation of MC3T3-E1 cells, a mouse osteoblastic cell line. Furthermore, gas chromatography/mass spectrometry (GC/MS) coupled with multivariate statistical analysis was used to identify the changes in global serum metabolites after TBI. We found that arachidonic acid (AA) was significantly enhanced in serum metabolites in TBI subjects, while hydroxybutyric acid, leucine, malic acid, 5-oxyproline, isocitric acid, mannose, and uric acid were reduced. Finally, we examined the effects of AA on BGLAP expression and cell proliferation in MC3T3-E1 cells. We found that BGLAP expression and proliferation of osteoblasts were positively regulated in the presence of AA. These findings suggest that the increased AA in serum after TBI may play a key role in enhancing the speed of fracture healing.	[Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun] Inst Basic Med Sci, State Key Lab Prote, Beijing 100850, Peoples R China; [Yang, Shuguang; Ma, Yanhong; Liu, Yong; Que, Haiping; Zhu, Changqiang; Liu, Shaojun] Inst Basic Med Sci, Dept Neurobiol, Beijing 100850, Peoples R China; [Ma, Yanhong] 261st Hosp Chinese PLA, Dept Cardiol, Beijing, Peoples R China	Liu, SJ (corresponding author), Inst Basic Med Sci, State Key Lab Prote, Beijing 100850, Peoples R China.	liusj@bmi.ac.cn			Chinese National Key Project of Basic ResearchNational Basic Research Program of China [2009CB918301]; Chinese National Natural Science FoundationNational Natural Science Foundation of China (NSFC) [81000797]	This work was supported by the Chinese National Key Project of Basic Research (2009CB918301), and the Chinese National Natural Science Foundation (81000797).	BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; Cadosch D, 2009, J BONE JOINT SURG AM, V91A, P282, DOI 10.2106/JBJS.G.01613; Coetzee M, 2007, PROSTAG LEUKOTR ESS, V76, P35, DOI 10.1016/j.plefa.2006.10.001; Coetzee M, 2009, CELL BIOCHEM FUNCT, V27, P3, DOI 10.1002/cbf.1526; Colnot C, 2003, DEVELOPMENT, V130, P4123, DOI 10.1242/dev.00559; Fazzalari NL, 2011, OSTEOPOROSIS INT, V22, P2003, DOI 10.1007/s00198-011-1611-4; Feng B, 2007, J PROTEOME RES, V6, P2161, DOI 10.1021/pr0606326; GARLAND DE, 1980, J BONE JOINT SURG AM, V62, P1143, DOI 10.2106/00004623-198062070-00012; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Gerstenfeld LC, 2003, J CELL BIOCHEM, V88, P873, DOI 10.1002/jcb.10435; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Jagtap VR, 2011, INDIAN J CLIN BIOCHE, V26, P70, DOI 10.1007/s12291-010-0074-2; KAWAGUCHI H, 1995, CLIN ORTHOP RELAT R, P36; Kim JS, 1996, STROKE, V27, P1553, DOI 10.1161/01.STR.27.9.1553; KLEIN DC, 1970, ENDOCRINOLOGY, V86, P1436, DOI 10.1210/endo-86-6-1436; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; NAGATA T, 1994, CALCIFIED TISSUE INT, V55, P451, DOI 10.1007/BF00298559; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; Nicholson JK, 2002, NAT REV DRUG DISCOV, V1, P153, DOI 10.1038/nrd728; NORRDIN RW, 1990, PROSTAG LEUKOTR ESS, V41, P139, DOI 10.1016/0952-3278(90)90081-U; OWEN TA, 1990, J CELL PHYSIOL, V143, P420, DOI 10.1002/jcp.1041430304; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Rigaux P, 2005, JOINT BONE SPINE, V72, P146, DOI 10.1016/j.jbspin.2004.05.012; Schindeler A, 2008, SEMIN CELL DEV BIOL, V19, P459, DOI 10.1016/j.semcdb.2008.07.004; SIGAL E, 1991, AM J PHYSIOL, V260, pL13; Simon AM, 2002, J BONE MINER RES, V17, P963, DOI 10.1359/jbmr.2002.17.6.963; Simon AM, 2007, J BONE JOINT SURG AM, V89A, P500, DOI 10.2106/JBJS.F.00127; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Trentz OA, 2005, CRIT CARE MED, V33, P399, DOI 10.1097/01.CCM.0000152221.87477.21; UEDA K, 1980, J PEDIATR-US, V97, P834, DOI 10.1016/S0022-3476(80)80282-4; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013	34	23	24	0	31	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2012	29	17					2696	2705		10.1089/neu.2012.2442			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	047QU	WOS:000311856400011	22867040				2021-06-18	
J	Irintchev, A; Schachner, M				Irintchev, Andrey; Schachner, Melitta			The Injured and Regenerating Nervous System: Immunoglobulin Superfamily Members as Key Players	NEUROSCIENTIST			English	Article						close homologue of L1; injury; L1; myelin-associated glycoprotein; nervous system; neural cell adhesion molecule; peripheral nerve; regeneration; spinal cord	CELL-ADHESION MOLECULE; SPINAL-CORD-INJURY; MYELIN-ASSOCIATED GLYCOPROTEIN; PROMOTE FUNCTIONAL RECOVERY; NEURAL RECOGNITION MOLECULES; RETINAL GANGLION-CELLS; TRAUMATIC BRAIN-INJURY; EMBRYONIC STEM-CELLS; AXONAL REGENERATION; POLYSIALIC ACID	Understanding restricted functional recovery and designing efficient treatments to alleviate dysfunction after injury of the nervous system remain major challenges in neuroscience and medicine. Numerous molecules of potential significance in neural repair have been identified in vitro, but only few of these have proved to be of major importance in vivo up to now. Among the molecules involved in regeneration are several members of the immunoglobulin superfamily, most notably the neural cell adhesion molecules L1, its close homologue CHL1, and NCAM and, in particular, its polysialic acid glycan moiety. Sufficient evidence is now available to justify the statement that these molecules are major players not only in nervous system development but also in the adult during neural repair and synaptic plasticity. Importantly, insights into the functions of these molecules in promoting or inhibiting functional recovery have allowed the design and assessment of therapeutic approaches in animal models of central nervous system injury that could prove to be applicable in clinical settings.	[Irintchev, Andrey] Univ Jena, Dept Otorhinolaryngol, Neurosci Lab, D-07740 Jena, Germany; [Schachner, Melitta] Univ Hamburg, Zentrum Mol Neurobiol, Hamburg, Germany; [Schachner, Melitta] Rutgers State Univ, Dept Cell Biol & Neurosci, Keck Ctr Collaborat Neurosci, Piscataway, NJ USA	Irintchev, A (corresponding author), Univ Jena, Dept Otorhinolaryngol, Neurosci Lab, Lessingstr 2, D-07740 Jena, Germany.	andrey.irintchev@med.uni-jena.de	Irintchev, Andrey/A-2465-2011	Irintchev, Andrey/0000-0002-4637-1259			Apostolova I, 2006, J NEUROSCI, V26, P7849, DOI 10.1523/JNEUROSCI.1526-06.2006; Atwal JK, 2008, SCIENCE, V322, P967, DOI 10.1126/science.1161151; Aubert I, 1998, J COMP NEUROL, V399, P1; Ballermann M, 2006, EUR J NEUROSCI, V23, P1988, DOI 10.1111/j.1460-9568.2006.04726.x; Barclay AN, 2003, SEMIN IMMUNOL, V15, P215, DOI 10.1016/S1044-5323(03)00047-2; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Bartsch U, 1995, NEURON, V15, P1375, DOI 10.1016/0896-6273(95)90015-2; BARTSCH U, 1989, J COMP NEUROL, V284, P451, DOI 10.1002/cne.902840310; Becker C.G., 2007, MODEL ORGANISMS SPIN; Becker CG, 2007, J NEUROSCI RES, V85, P2793, DOI 10.1002/jnr.21121; Becker CG, 2004, J NEUROSCI, V24, P7837, DOI 10.1523/JNEUROSCI.2420-04.2004; Becker CG, 2001, EXP NEUROL, V169, P438, DOI 10.1006/exnr.2001.7657; Becker T, 2005, MOL CELL NEUROSCI, V30, P265, DOI 10.1016/j.mcn.2005.07.008; Bernreuther C, 2006, J NEUROSCI, V26, P11532, DOI 10.1523/JNEUROSCI.2688-06.2006; Blackmore M, 2006, J NEUROBIOL, V66, P348, DOI 10.1002/neu.20224; Blackmore M, 2006, J NEUROBIOL, V66, P1564, DOI 10.1002/neu.20311; Bonfanti L, 2006, PROG NEUROBIOL, V80, P129, DOI 10.1016/j.pneurobio.2006.08.003; Brummendorf T, 1996, CURR OPIN NEUROBIOL, V6, P584, DOI 10.1016/S0959-4388(96)80089-4; BRUSHART TME, 1988, J NEUROSCI, V8, P1026; Camand E, 2004, EUR J NEUROSCI, V20, P1161, DOI 10.1111/j.1460-9568.2004.03558.x; CAMPBELL DG, 1979, NATURE, V282, P341, DOI 10.1038/282341a0; Carenini S, 1999, GLIA, V27, P203, DOI 10.1002/(SICI)1098-1136(199909)27:3<203::AID-GLIA2>3.0.CO;2-7; Carmichael ST, 2006, ANN NEUROL, V59, P735, DOI 10.1002/ana.20845; Chaisuksunt V, 2000, NEUROSCIENCE, V100, P87, DOI 10.1016/S0306-4522(00)00254-2; Chaisuksunt V, 2000, J COMP NEUROL, V425, P382, DOI 10.1002/1096-9861(20000925)425:3<382::AID-CNE4>3.0.CO;2-N; Charles P, 2000, P NATL ACAD SCI USA, V97, P7585, DOI 10.1073/pnas.100076197; Charles P, 2002, BRAIN, V125, P1972, DOI 10.1093/brain/awf216; Chaudhry N, 2006, EXP NEUROL, V202, P238, DOI 10.1016/j.expneurol.2006.06.001; Chen J, 2005, J NEUROTRAUM, V22, P896, DOI 10.1089/neu.2005.22.896; Chen J, 2007, BRAIN, V130, P954, DOI 10.1093/brain/awm049; Chen S, 1999, J NEUROBIOL, V38, P428, DOI 10.1002/(SICI)1097-4695(19990215)38:3<428::AID-NEU10>3.0.CO;2-6; Chipman PH, 2010, EUR J NEUROSCI, V31, P238, DOI 10.1111/j.1460-9568.2009.07049.x; Courtine G, 2008, NAT MED, V14, P69, DOI 10.1038/nm1682; Cui YF, 2010, BRAIN, V133, P189, DOI 10.1093/brain/awp290; CUNNINGHAM BA, 1995, CURR OPIN CELL BIOL, V7, P628, DOI 10.1016/0955-0674(95)80103-0; Dahme M, 1997, NAT GENET, V17, P346, DOI 10.1038/ng1197-346; Descalzi G, 2009, MOL NEUROBIOL, V40, P253, DOI 10.1007/s12035-009-8085-9; Deumens R, 2007, NEUROSCI LETT, V420, P277, DOI 10.1016/j.neulet.2007.05.015; Di Filippo M, 2008, NEUROPHARMACOLOGY, V55, P353, DOI 10.1016/j.neuropharm.2008.01.012; Dityatev A, 2008, NEURON GLIA BIOL, V4, P197, DOI 10.1017/S1740925X09990111; Doherty P, 2000, MOL CELL NEUROSCI, V16, P283, DOI 10.1006/mcne.2000.0907; Dusart I, 1999, J COMP NEUROL, V408, P399; Duveau V, 2007, NEUROBIOL DIS, V26, P385, DOI 10.1016/j.nbd.2007.01.007; Duveau V, 2010, EUR J NEUROSCI, V32, P89, DOI 10.1111/j.1460-9568.2010.07272.x; El Maarouf A, 2006, P NATL ACAD SCI USA, V103, P16989, DOI 10.1073/pnas.0608036103; Emery DL, 2000, J COMP NEUROL, V424, P521; Fawcett J, 2009, PROG BRAIN RES, V175, P501, DOI 10.1016/S0079-6123(09)17534-9; Fey A, 2010, J NEUROTRAUM, V27, P815, DOI 10.1089/neu.2009.1217; Filbin MT, 2003, NAT REV NEUROSCI, V4, P703, DOI 10.1038/nrn1195; Fitch MT, 2008, EXP NEUROL, V209, P294, DOI 10.1016/j.expneurol.2007.05.014; Fox GB, 2001, J NEUROPATH EXP NEUR, V60, P132, DOI 10.1093/jnen/60.2.132; Franz CK, 2005, J NEUROSCI, V25, P2081, DOI 10.1523/JNEUROSCI.4880-04.2005; Franz CK, 2008, BRAIN, V131, P1492, DOI 10.1093/brain/awn039; Giger RJ, 2010, CSH PERSPECT BIOL, V2, DOI 10.1101/cshperspect.a001867; Guseva D, 2011, EXP NEUROL, V229, P339, DOI 10.1016/j.expneurol.2011.02.018; Guseva D, 2009, BRAIN, V132, P2180, DOI 10.1093/brain/awp160; Gwak YS, 2011, NEUROPHARMACOLOGY, V60, P799, DOI 10.1016/j.neuropharm.2010.12.030; HILDEBRAND C, 1985, BRAIN RES, V358, P163, DOI 10.1016/0006-8993(85)90960-6; Hillenbrand R, 1999, EUR J NEUROSCI, V11, P813, DOI 10.1046/j.1460-9568.1999.00496.x; Holm J, 1996, EUR J NEUROSCI, V8, P1613, DOI 10.1111/j.1460-9568.1996.tb01306.x; Horinouchi K, 2005, J COMP NEUROL, V482, P386, DOI 10.1002/cne.20398; Hortsch M, 2003, FRONT BIOSCI, V8, pD357, DOI 10.2741/1006; Hoschouer EL, 2009, EXP NEUROL, V216, P22, DOI 10.1016/j.expneurol.2008.10.025; Irving EA, 2005, J CEREBR BLOOD F MET, V25, P98, DOI 10.1038/sj.jcbfm.9600011; Jakovcevski I, 2007, NEUROSCIENCE, V149, P328, DOI 10.1016/j.neuroscience.2007.07.044; Jakovcevski I, 2007, J NEUROSCI, V27, P7222, DOI 10.1523/JNEUROSCI.0739-07.2007; Jucker M, 1996, NEUROSCIENCE, V75, P703, DOI 10.1016/0306-4522(96)00276-X; JUCKER M, 1995, MOL BRAIN RES, V28, P149, DOI 10.1016/0169-328X(94)00206-T; Jung M, 1997, MOL CELL NEUROSCI, V9, P116, DOI 10.1006/mcne.1997.0611; Karimi-Abdolrezaee S, 2010, J NEUROSCI, V30, P1657, DOI 10.1523/JNEUROSCI.3111-09.2010; Kim BG, 2006, EXP NEUROL, V198, P401, DOI 10.1016/j.expneurol.2005.12.010; Kim JE, 2004, NEURON, V44, P439, DOI 10.1016/j.neuron.2004.10.015; Kleene R, 2004, NAT REV NEUROSCI, V5, P195, DOI 10.1038/nrn1349; Klementiev B, 2008, EUR J NEUROSCI, V27, P2885, DOI 10.1111/j.1460-9568.2008.06245.x; KRUSE J, 1984, NATURE, V311, P153, DOI 10.1038/311153a0; LANGENFELDOSTER B, 1994, J NEUROCYTOL, V23, P591, DOI 10.1007/BF01191554; Lavdas AA, 2010, EXP NEUROL, V221, P206, DOI 10.1016/j.expneurol.2009.10.024; Lee JK, 2010, NEURON, V66, P663, DOI 10.1016/j.neuron.2010.05.002; Loers G, 2005, J NEUROCHEM, V92, P1463, DOI 10.1111/j.1471-4159.2004.02983.x; Loers G, 2007, J NEUROCHEM, V101, P865, DOI 10.1111/j.1471-4159.2006.04409.x; Lundborg G, 2007, ACTA PHYSIOL, V189, P207, DOI 10.1111/j.1748-1716.2006.01653.x; Maness PF, 2007, NAT NEUROSCI, V10, P19, DOI 10.1038/nn1827; Marino P, 2009, EXP NEUROL, V219, P163, DOI 10.1016/j.expneurol.2009.05.009; MARTINI R, 1994, J NEUROSCI, V14, P7180; MARTINI R, 1994, J NEUROCYTOL, V23, P1, DOI 10.1007/BF01189813; MARTINI R, 1988, J CELL BIOL, V106, P1735, DOI 10.1083/jcb.106.5.1735; Mason MRJ, 2003, EUR J NEUROSCI, V18, P789, DOI 10.1046/j.1460-9568.2003.02809.x; Mears S, 2003, J PERIPHER NERV SYST, V8, P91, DOI 10.1046/j.1529-8027.2003.03012.x; Mehanna A, 2010, MOL THER, V18, P34, DOI 10.1038/mt.2009.235; Mehanna A, 2009, BRAIN, V132, P1449, DOI 10.1093/brain/awp128; Meijs MFL, 2004, J NEUROTRAUM, V21, P1415, DOI 10.1089/neu.2004.21.1415; Mishra B, 2010, J NEUROSCI, V30, P12400, DOI 10.1523/JNEUROSCI.6407-09.2010; Murphy JA, 2009, INVEST OPHTH VIS SCI, V50, P861, DOI 10.1167/iovs.08-2334; Nakamura Y, 2011, J BIOL CHEM, V286, P1876, DOI 10.1074/jbc.M110.163493; Nikonenko AG, 2006, EUR J NEUROSCI, V23, P1839, DOI 10.1111/j.1460-9568.2006.04710.x; Omoto S, 2010, J NEUROSCI, V30, P13045, DOI 10.1523/JNEUROSCI.3228-10.2010; Ourednik V, 2009, STEM CELLS, V27, P2846, DOI 10.1002/stem.227; Papastefanaki F, 2007, BRAIN, V130, P2159, DOI 10.1093/brain/awm155; Quarles RH, 2007, J NEUROCHEM, V100, P1431, DOI 10.1111/j.1471-4159.2006.04319.x; Roonprapunt C, 2003, J NEUROTRAUM, V20, P871, DOI 10.1089/089771503322385809; Rougon G, 2003, ANNU REV NEUROSCI, V26, P207, DOI 10.1146/annurev.neuro.26.041002.131014; Runyan SA, 2007, NEUROSCIENCE, V150, P959, DOI 10.1016/j.neuroscience.2007.10.009; Sakai A, 2008, PAIN, V137, P378, DOI 10.1016/j.pain.2007.09.020; Schafer M, 1996, NEURON, V16, P1107, DOI 10.1016/S0896-6273(00)80137-3; Schmid RS, 2008, CURR OPIN NEUROBIOL, V18, P245, DOI 10.1016/j.conb.2008.07.015; Scholz T, 2009, J RECONSTR MICROSURG, V25, P339, DOI 10.1055/s-0029-1215529; Shapiro L, 2007, ANNU REV NEUROSCI, V30, P451, DOI 10.1146/annurev.neuro.29.051605.113034; Simova O, 2006, ANN NEUROL, V60, P430, DOI 10.1002/ana.20948; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; STYREN SD, 1995, EXP NEUROL, V131, P165, DOI 10.1016/0014-4886(95)90038-1; Teng YD, 1999, J NEUROSCI, V19, P7037, DOI 10.1523/JNEUROSCI.19-16-07037.1999; Tomita K, 2007, GLIA, V55, P1498, DOI 10.1002/glia.20566; Troncoso E, 2004, CEREB CORTEX, V14, P332, DOI 10.1093/cercor/bhg131; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Woolf CJ, 1999, LANCET, V353, P1959, DOI 10.1016/S0140-6736(99)01307-0; Woolhead CL, 1998, J COMP NEUROL, V391, P259; Wu B, 2009, J NEUROTRAUM, V26, P1847, DOI 10.1089/neu.2008.0551; Yamanaka H, 2007, EUR J NEUROSCI, V25, P1097, DOI 10.1111/j.1460-9568.2007.05344.x; Zhang S, 2010, NEUROCHEM INT, V56, P919, DOI 10.1016/j.neuint.2010.03.023; Zhang Y, 2000, MOL CELL NEUROSCI, V16, P71, DOI 10.1006/mcne.2000.0852; Zhang Y, 2005, P NATL ACAD SCI USA, V102, P14883, DOI 10.1073/pnas.0505164102; ZHANG Y, 1995, J COMP NEUROL, V361, P193, DOI 10.1002/cne.903610202; Zhang Y, 2008, RESTOR NEUROL NEUROS, V26, P81	123	23	26	0	8	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1073-8584			NEUROSCIENTIST	Neuroscientist	OCT	2012	18	5					452	466		10.1177/1073858411419047			15	Clinical Neurology; Neurosciences	Neurosciences & Neurology	011IC	WOS:000309157300004	21903634				2021-06-18	
J	Kemp, K; Gray, E; Wilkins, A; Scolding, N				Kemp, Kevin; Gray, Elizabeth; Wilkins, Alastair; Scolding, Neil			Purkinje cell fusion and binucleate heterokaryon formation in multiple sclerosis cerebellum	BRAIN			English	Article						Purkinje cells; multiple sclerosis; fusion; heterokaryon; cerebellum	BONE-MARROW-CELLS; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; HEMATOPOIETIC-CELLS; NEURONS; CORTEX; TRANSPLANTATION; DAMAGE; MICE	A major conceptual consideration in both endogenous and therapeutic central nervous system repair is how damaged (or senescent) neurons, given their often enormously complex and extensive network of connections, can possibly be replaced. The recent observation of fusion of circulating bone marrow cells with, in particular, cerebellar Purkinje cells, as well as the subsequent formation of stable heterokaryons, offers a tantalizing potential solution to this difficulty. Here, we have explored Purkinje cell fusion and heterokaryon formation in the human brain and the influence of central nervous system inflammation. We analysed post-mortem cerebellum tissue from patients who had multiple sclerosis and from appropriate controls. Purkinje cells were analysed for heterokaryon formation using immunohistochemistry techniques and chromosome composition using fluorescence in situ hybridization. For the first time in humans we show a disease-related increase in Purkinje cell fusion and heterokaryon formation. We have shown that heterokaryon formation takes place in control subjects, and that the frequency of this event is considerably increased in patients with multiple sclerosis, the prototypical inflammatory brain disease, with similar to 0.4% of Purkinje cells being binucleate heterokaryons. No mononucleate polyploid Purkinje cell heterokaryons were found. The observation that heterokaryon formation in the cerebellum occurs as part of the central nervous system inflammatory reaction suggests a potential mechanism of neural repair. It also suggests an exciting new avenue for therapeutic intervention, as enhancement or manipulation of fusion events may have a therapeutic role in cellular protection in multiple sclerosis.	[Kemp, Kevin; Gray, Elizabeth; Wilkins, Alastair; Scolding, Neil] Univ Bristol, Sch Clin Sci, Multiple Sclerosis & Stem Cell Grp, Bristol BS16 1JB, Avon, England	Kemp, K (corresponding author), Frenchay Hosp, Multiple Sclerosis & Stem Cell Labs, Burden Ctr, 1st Floor, Bristol BS16 1JB, Avon, England.	Kevin.Kemp@bristol.ac.uk	; Kemp, Kevin/B-9755-2017	Scolding, Neil/0000-0001-9177-1043; Kemp, Kevin/0000-0003-1465-1309	Ataxia UK; Burden Institute; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/J012580/1] Funding Source: researchfish; Parkinson&quot;s UKParkinson&apos;s UK [G-0909] Funding Source: researchfish	This work was carried out using a project grant from both Ataxia UK and The Burden Institute.	Alvarez-Dolado M, 2003, NATURE, V425, P968, DOI 10.1038/nature02069; Bae JS, 2007, STEM CELLS, V25, P1307, DOI 10.1634/stemcells.2006-0561; Blau HM, 2002, NATURE, V419, P437, DOI 10.1038/419437a; Chen KA, 2011, MOL CELL NEUROSCI, V47, P61, DOI 10.1016/j.mcn.2011.03.003; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Cogle CR, 2004, LANCET, V363, P1432, DOI 10.1016/S0140-6736(04)16102-3; Corti S, 2004, BRAIN, V127, P2518, DOI 10.1093/brain/awh273; Espejel S, 2009, ANN NEUROL, V66, P100, DOI 10.1002/ana.21670; Gray E, 2008, BRAIN PATHOL, V18, P86, DOI 10.1111/j.1750-3639.2007.00110.x; Johansson CB, 2008, NAT CELL BIOL, V10, P575, DOI 10.1038/ncb1720; Kemp K, 2011, NEUROPATH APPL NEURO, V37, P166, DOI 10.1111/j.1365-2990.2010.01122.x; Kozorovitskiy Y, 2003, NAT CELL BIOL, V5, P952, DOI 10.1038/ncb1103-952; Lagasse E, 2000, NAT MED, V6, P1229, DOI 10.1038/81326; Magrassi L, 2007, J NEUROSCI, V27, P9885, DOI 10.1523/JNEUROSCI.2539-07.2007; Mahmood A, 2005, NEUROSURGERY, V57, P1026, DOI 10.1227/01.NEU.0000181369.76323.50; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; Mahmood A, 2003, NEUROSURGERY, V53, P702; MANN DMA, 1978, J COMP NEUROL, V180, P345, DOI 10.1002/cne.901800210; Mezey E, 2003, P NATL ACAD SCI USA, V100, P1364, DOI 10.1073/pnas.0336479100; Miyata M, 1999, ACTA NEUROPATHOL, V98, P226, DOI 10.1007/s004010051073; Nern C, 2009, J NEUROSCI, V29, P3799, DOI 10.1523/JNEUROSCI.5848-08.2009; Nygren JM, 2008, NAT CELL BIOL, V10, P584, DOI 10.1038/ncb1721; Priller J, 2001, J CELL BIOL, V155, P733, DOI 10.1083/jcb.200105103; Singec I, 2008, NAT CELL BIOL, V10, P503, DOI 10.1038/ncb0508-503; TYRRELL T, 1992, PHILOS T ROY SOC B, V336, P239, DOI 10.1098/rstb.1992.0059; Valadi H, 2007, NAT CELL BIOL, V9, P654, DOI 10.1038/ncb1596; Vassilopoulos G, 2003, NATURE, V422, P901, DOI 10.1038/nature01539; Weimann JM, 2003, P NATL ACAD SCI USA, V100, P2088, DOI 10.1073/pnas.0337659100; Weimann JM, 2003, NAT CELL BIOL, V5, P959, DOI 10.1038/ncb1053; Wiersema A, 2008, STEM CELL RES, V1, P150, DOI 10.1016/j.scr.2008.02.001; Willenbring H, 2004, NAT MED, V10, P744, DOI 10.1038/nm1062; ZECEVIC N, 1976, J COMP NEUROL, V167, P27, DOI 10.1002/cne.901670103	32	23	25	0	4	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0006-8950	1460-2156		BRAIN	Brain	OCT	2012	135		10				2962	2972		10.1093/brain/aws226			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	025AX	WOS:000310156700007	22975392	Bronze			2021-06-18	
J	Storti, SF; Formaggio, E; Franchini, E; Bongiovanni, LG; Cerini, R; Fiaschi, A; Michel, CM; Manganotti, P				Storti, Silvia F.; Formaggio, Emanuela; Franchini, Enrica; Bongiovanni, Luigi G.; Cerini, Roberto; Fiaschi, Antonio; Michel, Christoph M.; Manganotti, Paolo			A multimodal imaging approach to the evaluation of post-traumatic epilepsy	MAGNETIC RESONANCE MATERIALS IN PHYSICS BIOLOGY AND MEDICINE			English	Article						Post-traumatic epilepsy; EEG-fMRI; Source localization	INDEPENDENT COMPONENT ANALYSIS; INTERICTAL EPILEPTIFORM DISCHARGES; EEG-FMRI COREGISTRATION; FUNCTIONAL MRI; WAVE DISCHARGES; FOCAL EPILEPSY; SPIKE; ACTIVATION; NETWORKS; BRAIN	Electroencephalography-functional magnetic resonance imaging (EEG-fMRI) coregistration and high-density EEG (hdEEG) can be combined to map noninvasively abnormal brain activation elicited by epileptic processes. By combining noninvasive imaging techniques in a multimodal approach, we sought to investigate pathophysiological mechanisms underlying epileptic activity in seven patients with severe traumatic brain injury. Standard EEG and fMRI data were acquired during a single scanning session. The EEG-fMRI data were analyzed using the general linear model and independent component analysis. Source localization of interictal epileptiform discharges (IEDs) was performed using 256-channel hdEEG. Blood oxygenation level dependent (BOLD) localizations were then compared to EEG source reconstruction. On hdEEG, focal source localization was detected in all seven patients; in six out of seven it was concordant with the expected epileptic activity as defined by EEG data and clinical evaluation; and in four out of seven in whom IEDs were recorded, BOLD signal changes were observed. These activities were partially concordant with the source localization. Multimodal integration of EEG-fMRI and hdEEG combining two different methods to localize the same epileptic foci appears to be a promising tool to noninvasively map abnormal brain activation in patients with post-traumatic brain injury.	[Storti, Silvia F.; Franchini, Enrica; Bongiovanni, Luigi G.; Fiaschi, Antonio; Manganotti, Paolo] Univ Verona, Sect Clin Neurol, Dept Neurol Neuropsychol Morphol & Movement Sci, Policlin GB Rossi, I-37134 Verona, Italy; [Formaggio, Emanuela; Fiaschi, Antonio; Manganotti, Paolo] IRCCS San Camillo, Dept Neurophysiol, Venice, Italy; [Cerini, Roberto] Univ Verona, Dept Pathol & Diagnost, I-37134 Verona, Italy; [Michel, Christoph M.] Univ Geneva, Univ Med Sch, Funct Brain Mapping Lab, Dept Fundamental Neurosci, Geneva, Switzerland	Storti, SF (corresponding author), Univ Verona, Sect Clin Neurol, Dept Neurol Neuropsychol Morphol & Movement Sci, Policlin GB Rossi, Ple LA Scuro 10, I-37134 Verona, Italy.	silviafrancesca.storti@univr.it	Storti, Silvia Francesca/K-3142-2016; Formaggio, Emanuela/N-2278-2019; Formaggio, Emanuela/K-1555-2016	Storti, Silvia Francesca/0000-0002-8605-803X; Formaggio, Emanuela/0000-0002-3417-0388; Formaggio, Emanuela/0000-0002-3417-0388	Center for Biomedical Imaging (CIBM) of the University of Geneva; Swiss Federal Institute of Technology, Lausanne (EPFL); Center for Biomedical Imaging (CIBM) of the University of Lausanne; University Hospital of Geneva, Switzerland; University Hospital of Lausanne, Switzerland; Cariverona, Verona, ItalyFondazione Cariverona	The development of CARTOOL is supported by the Center for Biomedical Imaging (CIBM) of the Universities of Geneva and Lausanne, the Swiss Federal Institute of Technology, Lausanne (EPFL), and the University Hospitals of Geneva and Lausanne, Switzerland. This study was supported by Cariverona, Verona, Italy.	Aghakhani Y, 2004, BRAIN, V127, P1127, DOI 10.1093/brain/awh136; Allen PJ, 1998, NEUROIMAGE, V8, P229, DOI 10.1006/nimg.1998.0361; Allen PJ, 2000, NEUROIMAGE, V12, P230, DOI 10.1006/nimg.2000.0599; Archer JS, 2003, NEUROIMAGE, V20, P1915, DOI 10.1016/S1053-8119(03)00294-5; Baudewig J, 2001, CLIN NEUROPHYSIOL, V112, P1196, DOI 10.1016/S1388-2457(01)00562-4; Beckmann CF, 2004, IEEE T MED IMAGING, V23, P137, DOI 10.1109/TMI.2003.822821; Benar CG, 2002, NEUROIMAGE, V17, P1182, DOI 10.1006/nimg.2002.1164; Borelli P, 2010, SEIZURE-EUR J EPILEP, V19, P605, DOI 10.1016/j.seizure.2010.09.001; Brodbeck V, 2011, BRAIN, V134, P2887, DOI 10.1093/brain/awr243; Cole DM, 2010, FRONT SYST NEUROSCI, V4, DOI 10.3389/fnsys.2010.00008; Cordes D, 2002, MAGN RESON IMAGING, V20, P305, DOI 10.1016/S0730-725X(02)00503-9; Cosottini M, 2010, MAGN RESON IMAGING, V28, P388, DOI 10.1016/j.mri.2009.11.011; Del Felice A, 2009, EPILEPSY RES, V85, P321, DOI 10.1016/j.eplepsyres.2009.03.025; Delorme A, 2004, J NEUROSCI METH, V134, P9, DOI 10.1016/j.jneumeth.2003.10.009; Formaggio E, 2011, NEUROIMAGE, V54, P2719, DOI 10.1016/j.neuroimage.2010.11.038; Formaggio E, 2008, BRAIN TOPOGR, V21, P100, DOI 10.1007/s10548-008-0058-1; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Goldman RI, 2000, CLIN NEUROPHYSIOL, V111, P1974, DOI 10.1016/S1388-2457(00)00456-9; Gotman J, 2005, P NATL ACAD SCI USA, V102, P15236, DOI 10.1073/pnas.0504935102; Gotman J, 2006, J MAGN RESON IMAGING, V23, P906, DOI 10.1002/jmri.20577; Greicius M, 2008, CURR OPIN NEUROL, V21, P424, DOI 10.1097/WCO.0b013e328306f2c5; Groening K, 2009, NEUROIMAGE, V46, P827, DOI 10.1016/j.neuroimage.2009.02.026; Guggisberg AG, 2011, NEUROIMAGE, V57, P1348, DOI 10.1016/j.neuroimage.2011.05.076; IVES JR, 1993, ELECTROEN CLIN NEURO, V87, P417, DOI 10.1016/0013-4694(93)90156-P; Jacobs J, 2007, EPILEPSIA, V48, P2068, DOI 10.1111/j.1528-1167.2007.01192.x; Kobayashi E, 2006, BRAIN, V129, P366, DOI 10.1093/brain/awh710; Lantz G, 2003, J CLIN NEUROPHYSIOL, V20, P311, DOI 10.1097/00004691-200309000-00003; Laufs H, 2007, HUM BRAIN MAPP, V28, P1023, DOI 10.1002/hbm.20323; Lemieux L, 2001, NEUROIMAGE, V14, P1097, DOI 10.1006/nimg.2001.0896; Lemieux L, 2001, NEUROIMAGE, V14, P780, DOI 10.1006/nimg.2001.0853; Li QF, 2009, EPILEPSY RES, V87, P160, DOI 10.1016/j.eplepsyres.2009.08.018; Logothetis NK, 2001, NATURE, V412, P150, DOI 10.1038/35084005; Luo C, 2010, EPILEPSY RES, V91, P133, DOI 10.1016/j.eplepsyres.2010.07.003; Manganotti P, 2008, MAGN RESON IMAGING, V26, P1089, DOI 10.1016/j.mri.2008.02.023; Mazzini L, 2003, EPILEPSIA, V44, P569, DOI 10.1046/j.1528-1157.2003.34902.x; McKeown MJ, 1998, HUM BRAIN MAPP, V6, P160, DOI 10.1002/(SICI)1097-0193(1998)6:3<160::AID-HBM5>3.3.CO;2-R; Menon V, 2005, INT REV NEUROBIOL, V66, P291, DOI 10.1016/S0074-7742(05)66010-2; Michel CM, 2004, CLIN NEUROPHYSIOL, V115, P2195, DOI 10.1016/j.clinph.2004.06.001; Moeller F, 2011, HUM BRAIN MAPP, V32, P209, DOI 10.1002/hbm.21010; Niedermeyer E., 2004, ELECTROENCEPHALOGRAP; Ogawa S, 2000, P NATL ACAD SCI USA, V97, P11026, DOI 10.1073/pnas.97.20.11026; Ossenblok P, 1999, IEEE ENG MED BIOL, V18, P67, DOI 10.1109/51.765191; Pesaresi I, 2011, MAGN RESON MATER PHY, V24, P285, DOI 10.1007/s10334-011-0263-x; Ritter P, 2006, NEUROSCI BIOBEHAV R, V30, P823, DOI 10.1016/j.neubiorev.2006.06.008; Rodionov R, 2007, NEUROIMAGE, V38, P488, DOI 10.1016/j.neuroimage.2007.08.003; Rosenkranz K, 2010, MAGN RESON MATER PHY, V23, P309, DOI 10.1007/s10334-009-0196-9; Salek-Haddadi A, 2006, BRAIN RES, V1088, P148, DOI 10.1016/j.brainres.2006.02.098; Siniatchkin M, 2010, BRAIN, V133, P2798, DOI 10.1093/brain/awq183; Spinelli L, 2000, BRAIN TOPOGR, V13, P115, DOI 10.1023/A:1026607118642; Storti SF, 2010, BRAIN TOPOGR, V23, P46, DOI 10.1007/s10548-009-0117-2; Thirion B, 2006, NEUROIMAGE, V29, P321, DOI 10.1016/j.neuroimage.2005.06.054; Thom M, 2011, BRAIN, V134, P2969, DOI 10.1093/brain/awr209; Vaudano AE, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006475; Volman V, 2011, J NEUROPHYSIOL, V106, P1933, DOI 10.1152/jn.00458.2011; Vulliemoz S, 2010, NEUROIMAGE, V49, P3219, DOI 10.1016/j.neuroimage.2009.11.055; Vulliemoz S, 2009, NEUROIMAGE, V46, P834, DOI 10.1016/j.neuroimage.2009.01.070; Vulliemoz S, 2010, EPILEPSIA, V51, P491, DOI 10.1111/j.1528-1167.2009.02342.x	57	23	24	0	13	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0968-5243			MAGN RESON MATER PHY	Magn. Reson. Mat. Phys. Biol. Med.	OCT	2012	25	5					345	360		10.1007/s10334-012-0316-9			16	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	012JH	WOS:000309231900003	22592963	Other Gold, Green Published			2021-06-18	
J	Wright, AD; Laing, AC				Wright, Alexander D.; Laing, Andrew C.			The influence of headform orientation and flooring systems on impact dynamics during simulated fall-related head impacts	MEDICAL ENGINEERING & PHYSICS			English	Article						Traumatic brain injury; Falls; Compliant floors; Injury Prevention; Head impact biomechanics; Aging	POSTURAL STABILITY; INJURY; HIP; BALANCE; BIOMECHANICS; ACCELERATION; POPULATION; CONCUSSION; PREDICTION; LOCOMOTION	Novel compliant flooring systems are a promising approach for reducing fall-related injuries in seniors, as they may provide up to 50% attenuation in peak force during simulated hip impacts while eliciting only minimal influences on balance. This study aimed to determine the protective capacity of novel compliant floors during simulated 'high severity' head impacts compared to common flooring systems. A headform was impacted onto a common Commercial-Carpet at 1.5, 2.5, and 3.5 m/s in front, back, and side orientations using a mechanical drop tower. Peak impact force applied to the headform (F-max), peak linear acceleration of the headform (g(max)) and Head Injury Criterion (HIC) were determined. For the 3.5 m/s trials, backwards-oriented impacts were associated with the highest F-max and HIC values (p < 0.001); accordingly, this head orientation was used to complete additional trials on three common floors (Resilient Rubber, Residential-Loop Carpet, Berber Carpet) and six novel compliant floors at each impact velocity. ANOVAs indicated that flooring type was associated with all parameters at each impact velocity (p < 0.001). Compared to impacts on the Commercial Carpet, Dunnett's post hoc indicated all variables were smaller (25-80%) for the novel compliant floors (p < 0.001), but larger for Resilient Rubber (31-159%, p < 0.01). This study demonstrates that during 'high severity' simulated impacts, novel compliant floors can substantially reduce the forces and accelerations applied to a headform compared to common floors including carpet and resilient rubber. In combination with reports of minimal balance impairments, these findings support the promise of novel compliant floors as a biomechanically effective strategy for reducing fall-related injuries including traumatic brain injuries and skull fractures. (c) 2011 IPEM. Published by Elsevier Ltd. All rights reserved.	[Laing, Andrew C.] Univ Waterloo, Dept Kinesiol, Fac Appl Hlth Sci, Injury Biomech & Aging Lab, Waterloo, ON N2L 3G1, Canada	Laing, AC (corresponding author), Univ Waterloo, Dept Kinesiol, Fac Appl Hlth Sci, Injury Biomech & Aging Lab, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	actlaing@uwaterloo.ca		Wright, Alexander D./0000-0001-6442-5583	Natural Sciences and Engineering Research Council of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC) [386544-2010]; Ontario Graduate Scholarship programOntario Graduate Scholarship	This research was funded in part by an operating grant obtained by ACL from the Natural Sciences and Engineering Research Council of Canada (NSERC; grant # 386544-2010). ADW was supported by the Ontario Graduate Scholarship program.	Adekoya Nelson, 2002, MMWR Surveill Summ, V51, P1; ASTM, 2004, F129204 ASTM; Chiu AYY, 2003, DISABIL REHABIL, V25, P45, DOI 10.1080/713813432; Cormier J, 2011, J BIOMECH ENG-T ASME, V133, DOI 10.1115/1.4003312; Coronado VG, 2005, J HEAD TRAUMA REHAB, V20, P215, DOI 10.1097/00001199-200505000-00005; Cory CZ, 2001, FORENSIC SCI INT, V123, P89, DOI 10.1016/S0379-0738(01)00523-0; Dickinson JI, 2002, GERONTOLOGIST, V42, P552, DOI 10.1093/geront/42.4.552; Dickinson JI, 2001, ENVIRON BEHAV, V33, P279, DOI 10.1177/00139160121972990; Dixon JL, 1993, ASTM STP, V2, P192; Duma SM, 2011, EXERC SPORT SCI REV, V39, P2, DOI 10.1097/JES.0b013e318203dfdb; Feng Y, 2010, J R SOC INTERFACE, V7, P1677, DOI 10.1098/rsif.2010.0210; Ferrell Richard B, 2002, Curr Psychiatry Rep, V4, P354; Funk JR, 2011, ANN BIOMED ENG, V39, P766, DOI 10.1007/s10439-010-0183-3; Gardner TN, 1998, MED ENG PHYS, V20, P57, DOI 10.1016/S1350-4533(97)00041-6; Gennarelli TA, 1984, BIOMECH IMPACT TRAUM, P103; Gill J, 2001, J GERONTOL A-BIOL, V56, pM438, DOI 10.1093/gerona/56.7.M438; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; GURDJIAN ES, 1966, J TRAUM, V6, P600, DOI 10.1097/00005373-196609000-00005; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2011, EXERC SPORT SCI REV, V39, P4, DOI 10.1097/JES.0b013e318201f53e; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Health Canada, 2002, CAN AG POP; Higgins M, 2007, J ATHL TRAINING, V42, P5; HODGSON VR, 1983, 27 STAPP CAR CRASH C; Hrysomallis C, 1999, 17 INT S BIOM SPORTS, P373; Ivancevic VG, 2009, COGN NEURODYNAMICS, V3, P281, DOI 10.1007/s11571-008-9070-0; King AI, 2000, ANNU REV BIOMED ENG, V2, P55, DOI 10.1146/annurev.bioeng.2.1.55; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Klenk J, 2011, MED ENG PHYS, V33, P368, DOI 10.1016/j.medengphy.2010.11.003; Laing AC, 2010, J BIOMECH, V43, P1898, DOI 10.1016/j.jbiomech.2010.03.025; Laing AC, 2009, ACCIDENT ANAL PREV, V41, P642, DOI 10.1016/j.aap.2009.03.001; Lord SR, 2000, GERONTOLOGY, V46, P306, DOI 10.1159/000022182; LORD SR, 1991, J GERONTOL, V46, pM69, DOI 10.1093/geronj/46.3.M69; Lundin-Olsson L, 1998, J AM GERIATR SOC, V46, P758, DOI 10.1111/j.1532-5415.1998.tb03813.x; Mack M G, 2000, Inj Prev, V6, P141, DOI 10.1136/ip.6.2.141; Mackay M, 2007, SADHANA-ACAD P ENG S, V32, P397, DOI 10.1007/s12046-007-0031-9; MacLellan MJ, 2006, EXP BRAIN RES, V173, P531, DOI 10.1007/s00221-006-0398-6; MAKI BE, 1990, J AM GERIATR SOC, V38, P1, DOI 10.1111/j.1532-5415.1990.tb01588.x; Marigold DS, 2005, J NEUROPHYSIOL, V94, P1733, DOI 10.1152/jn.00019.2005; Marjoux D, 2008, ACCIDENT ANAL PREV, V40, P1135, DOI 10.1016/j.aap.2007.12.006; McHenry BG, 2004, HIC ATB; McLean A. J., 1997, HEAD INJURY, P25; Minns Julian, 2004, Nurs Stand, V18, P33; Nabhani F, 2004, J MATER PROCESS TECH, V153, P139, DOI 10.1016/j.jmatprotec.2004.04.211; Nabhani F, 2002, J MATER PROCESS TECH, V124, P311, DOI 10.1016/S0924-0136(02)00200-5; NAHUM AM, 1975, LARYNGOSCOPE, V85, P140, DOI 10.1288/00005537-197501000-00011; NOCSAE, 2009, 00108M10 NOCSAE; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Pickett W, 2001, CAN MED ASSOC J, V165, P288; PODSIADLO D, 1991, J AM GERIATR SOC, V39, P142, DOI 10.1111/j.1532-5415.1991.tb01616.x; Prasad P, 1985, SAE GOV IND M; Redfern MS, 1997, HUM FACTORS, V39, P445, DOI 10.1518/001872097778827043; Robinovitch S.N., 2009, P 19 ANN M INT SOC P; Robinovitch SN, 1998, J ORTHOPAED RES, V16, P309, DOI 10.1002/jor.1100160306; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Rowson S, 2009, J BIOMECH ENG-T ASME, V131, DOI 10.1115/1.3130454; Shain KS, 2010, CLIN J SPORT MED, V20, P422, DOI 10.1097/JSM.0b013e3181f7db25; Simpson AHRW, 2004, AGE AGEING, V33, P242, DOI 10.1093/ageing/afh071; Singh Anita, 2006, Stapp Car Crash J, V50, P601; SMARTRISK, 2009, EC BURD INJ CAN; Sran MM, 2008, SPINE, V33, P1856, DOI 10.1097/BRS.0b013e31817bab05; Thomas KE, 2008, J SAFETY RES, V39, P269, DOI 10.1016/j.jsr.2008.05.001; Wright AD, 2011, ACCIDENT ANAL PREV, V43, P1480, DOI 10.1016/j.aap.2011.02.028; Zacker C, 1998, INT J TECHNOL ASSESS, V14, P446, DOI 10.1017/S0266462300011429; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749	67	23	23	0	18	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533	1873-4030		MED ENG PHYS	Med. Eng. Phys.	OCT	2012	34	8					1071	1078		10.1016/j.medengphy.2011.11.012			8	Engineering, Biomedical	Engineering	009MB	WOS:000309028800007	22172523				2021-06-18	
J	McLeod, TCV; Lam, KC; Bay, RC; Sauers, EL; Valier, ARS				McLeod, Tamara C. Valovich; Lam, Kenneth C.; Bay, R. Curtis; Sauers, Eric L.; Valier, Alison R. Snyder		Athletic Training Practice-Based R	Practice-Based Research Networks, Part II: A Descriptive Analysis of the Athletic Training Practice-Based Research Network in the Secondary School Setting	JOURNAL OF ATHLETIC TRAINING			English	Article						PBRN; adolescents; practice characteristics; professional practice; ICD-9; CPT	STATES HIGH-SCHOOL; CLINICAL-OUTCOMES ASSESSMENT; SPORTS-RELATED INJURIES; QUALITY-OF-LIFE; UNITED-STATES; PRACTICE PATTERNS; NORTH-CAROLINA; PHYSICAL-THERAPY; RISK-FACTORS; EPIDEMIOLOGY	Context: Analysis of health care service models requires the collection and evaluation of basic practice characterization data. Practice-based research networks (PBRNs) provide a framework for gathering data useful in characterizing clinical practice. Objective: To describe preliminary secondary school setting practice data from the Athletic Training Practice-Based Research Network (AT-PBRN). Design: Descriptive study. Setting: Secondary school athletic training facilities within the AT-PBRN. Patients or Other Participants: Clinicians (n = 22) and their patients (n = 2523) from the AT-PBRN. Main Outcome Measure(s): A Web-based survey was used to obtain data on clinical practice site and clinician characteristics. Patient and practice characteristics were obtained via deidentified electronic medical record data collected between September 1, 2009, and April 1, 2011. Descriptive data regarding the clinician and CPS practice characteristics are reported as percentages and frequencies. Descriptive analysis of patient encounters and practice characteristic data was performed, with the percentages and frequencies of the type of injuries recorded at initial evaluation, type of treatment received at initial evaluation, daily treatment, and daily sign-in procedures. Results: The AT-PBRN had secondary school sites in 7 states, and most athletic trainers at those sites (78.2%) had less than 5 years of experience. The secondary school sites within the AT-PBRN documented 2523 patients treated across 3140 encounters. Patients most frequently sought care for a current injury (61.3%), followed by preventive services (24.0%), and new injuries (14.7%). The most common diagnoses were ankle sprain/strain (17.9%), hip sprain/strain (12.5%), concussion (12.0%), and knee pain (2.5%). The most frequent procedures were athletic trainer evaluation (53.9%), hot- or cold-pack application (26.0%), strapping (10.3%), and therapeutic exercise (5.7%). The median number of treatments per injury was 3 (interquartile range = 2, 4; range = 2-19). Conclusions: These preliminary data describe services provided by clinicians within the AT-PBRN and demonstrate the usefulness of the PBRN model for obtaining such data.	[McLeod, Tamara C. Valovich; Sauers, Eric L.; Valier, Alison R. Snyder] AT Still Univ, Athlet Training Program, Mesa, AZ 85206 USA; [McLeod, Tamara C. Valovich; Lam, Kenneth C.; Bay, R. Curtis; Sauers, Eric L.; Valier, Alison R. Snyder] AT Still Univ, Dept Interdisciplinary Hlth Sci, Mesa, AZ USA	McLeod, TCV (corresponding author), AT Still Univ, Athlet Training Program, 5850 E Still Circle, Mesa, AZ 85206 USA.	tmcleod@atsu.edu	McLeod, Tamara/AAU-9435-2020; Lam, Kenny/ABB-9733-2020	Bay, Ralph/0000-0003-3525-9269; Lam, Kenneth/0000-0002-2185-0990			Albohm MJ, 1999, J REHABIL OUTCOMES M, V3, P51; American Medical Association, CPT CURR PROC TERM; Andrilla CHA, 2007, 109 WWAMI CTR HLTH W; Board of Certification, 2004, ROL DEL STUD; Borowski LA, 2008, AM J SPORT MED, V36, P2328, DOI 10.1177/0363546508322893; Brennan GP, 2006, PHYS THER, V86, P1251, DOI 10.2522/ptj.20050382; Collins CL, 2008, INJURY PREV, V14, P34, DOI 10.1136/ip.2007.017277; Collins CL, 2008, PEDIATRICS, V121, P1181, DOI 10.1542/peds.2007-2572; Collins CL, 2008, ARCH PEDIAT ADOL MED, V162, P49, DOI 10.1001/archpediatrics.2007.1; Comstock R. D., 2006, Morbidity and Mortality Weekly Report, V55, P1037; Darrow CJ, 2009, AM J SPORT MED, V37, P1798, DOI 10.1177/0363546509333015; del Aguila MA, 2005, J AM DENT ASSOC, V136, P790, DOI 10.14219/jada.archive.2005.0265; DeRouen TA, 2010, J AM DENT ASSOC, V141, P889, DOI 10.14219/jada.archive.2010.0289; Deshefy-Longhi T, 2008, J AM ACAD NURSE PRAC, V20, P281, DOI 10.1111/j.1745-7599.2008.00318.x; Downar C., 2001, PROFILING PROFESSION; Fernandez WG, 2007, ACAD EMERG MED, V14, P641, DOI [10.1197/j.aem.2007.03.1354, 10.1111/j.1553-2712.2007.tb01851.x]; Fox CH, 2006, J AM BOARD FAM MED, V19, P54, DOI 10.3122/jabfm.19.1.54; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Hootman JM, 2007, J ATHL TRAINING, V42, P170; KIRKLAND M, 2006, NATA NEWS        OCT, P40; Knowles SB, 2006, AM J EPIDEMIOL, V164, P1209, DOI 10.1093/aje/kwj337; McLeod TCV, 2009, J ATHL TRAINING, V44, P603, DOI 10.4085/1062-6050-44.6.603; Nagykaldi Z, 2007, J AM BOARD FAM MED, V20, P188, DOI 10.3122/jabfm.2007.02.060084; National Athletic Trainers' Association, 2011, ATHL TRAIN ED COMP; National Athletic Trainers' Association, 2008, NAT OUTC RES AN PROJ; National Federation of State High School Associations, 2010, NFHS 2009 2010 HIGH; National Institutes of Health, RES REP DAT HIPAA PR; Nelson AJ, 2007, J ATHL TRAINING, V42, P381; O'Malley KJ, 2005, HEALTH SERV RES, V40, P1620, DOI 10.1111/j.1475-6773.2005.00444.x; O'Neill L, 2005, MED CARE RES REV, V62, P339, DOI 10.1177/1077558705275424; Peabody JW, 2004, MED CARE, V42, P1066, DOI 10.1097/00005650-200411000-00005; Powell JW, 1999, J ATHL TRAINING, V34, P277; Ramirez M, 2006, AM J SPORT MED, V34, P1147, DOI 10.1177/0363546505284385; Rechel JA, 2008, J ATHL TRAINING, V43, P197, DOI 10.4085/1062-6050-43.2.197; Resnik L, 2003, PHYS THER, V83, P990, DOI 10.1093/ptj/83.11.990; Resnik L, 2003, PHYS THER, V83, P1090, DOI 10.1093/ptj/83.12.1090; Rindal DB, 2010, J DENT, V38, P1027, DOI 10.1016/j.jdent.2010.09.003; Sauers EL, 2012, J ATHL TRAIN, V47, pxx; Sauers EL, 2009, ATHL TRAIN SPORTS HL, V1, P244; Sauers EL, 2011, J SPORT REHABIL, V20, P100, DOI 10.1123/jsr.20.1.100; Sauers EL, 2011, J SPORT REHABIL, V20, P3, DOI 10.1123/jsr.20.1.3; Schulz MR, 2004, AM J EPIDEMIOL, V160, P937, DOI 10.1093/aje/kwh304; Schulz MR, 2004, AM J SPORT MED, V32, P396, DOI 10.1177/0363546503261715; Snyder AR, 2008, J ATHL TRAINING, V43, P428, DOI 10.4085/1062-6050-43.4.428; Snyder AR, 2007, ATHL TRAIN ED J, V2, P1; Steves R, 2004, J ATHL TRAINING, V39, P83; Trostler N, 2008, J AM DIET ASSOC, V108, P1060, DOI 10.1016/j.jada.2008.03.001; Valovich McLeod TC, 2008, J ATHL TRAINING, V43, P437, DOI DOI 10.404/1062-6050-43.4.437; Valovich McLeod TC, 2011, NATL SPORTS SAFETY S; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wasserman RC, 1998, PEDIATRICS, V102, P1350, DOI 10.1542/peds.102.6.1350; Weyer SM, 2010, J AM ACAD NURSE PRAC, V22, P156, DOI 10.1111/j.1745-7599.2009.00482.x; Yard EE, 2008, AM J SPORT MED, V36, P1930, DOI 10.1177/0363546508318047; Yardt EE, 2008, AM J SPORT MED, V36, P57, DOI 10.1177/0363546507307507	54	23	23	0	8	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	SEP-OCT	2012	47	5					557	566		10.4085/1062-6050-47.5.05			10	Sport Sciences	Sport Sciences	019KA	WOS:000309737300013	23068594	Green Published			2021-06-18	
J	Yurkiewicz, IR; Lappan, CM; Neely, ET; Hesselbrock, RR; Girard, PD; Alphonso, AL; Tsao, JW				Yurkiewicz, Ilana R.; Lappan, Charles M.; Neely, Edward T.; Hesselbrock, Roger R.; Girard, Philip D.; Alphonso, Aimee L.; Tsao, Jack W.			Outcomes from a US military neurology and traumatic brain injury telemedicine program	NEUROLOGY			English	Article								Objective: This study evaluated usage of the Army Knowledge Online (AKO) Telemedicine Consultation Program for neurology and traumatic brain injury (TBI) cases in remote overseas areas with limited access to subspecialists. We performed a descriptive analysis of quantity of consults, response times, sites where consults originated, military branches that benefitted, anatomic locations of problems, and diagnoses. Methods: This was a retrospective analysis that searched electronic databases for neurology consults from October 2006 to December 2010 and TBI consults from March 2008 to December 2010. Results: A total of 508 consults were received for neurology, and 131 consults involved TBI. For the most part, quantity of consults increased over the years. Meanwhile, response times decreased, with a mean response time of 8 hours, 14 minutes for neurology consults and 2 hours, 44 minutes for TBI consults. Most neurology consults originated in Iraq (67.59%) followed by Afghanistan (16.84%), whereas TBI consults mainly originated from Afghanistan (40.87%) followed by Iraq (33.91%). The most common consultant diagnoses were headaches, including migraines (52.1%), for neurology cases and mild TBI/concussion (52.3%) for TBI cases. In the majority of cases, consultants recommended in-theater management. After receipt of consultant's recommendation, 84 known neurology evacuations were facilitated, and 3 known neurology evacuations were prevented. Conclusions: E-mail-based neurology and TBI subspecialty teleconsultation is a viable method for overseas providers in remote locations to receive expert recommendations for a range of neurologic conditions. These recommendations can facilitate medically necessary patient evacuations or prevent evacuations for which on-site care is preferable. Neurology (R) 2012;79:1237-1243	[Tsao, Jack W.] USN, Bur Med & Surg, Washington, DC USA; [Tsao, Jack W.] Uniformed Serv Univ Hlth Sci, Dept Neurol, Bethesda, MD 20814 USA; [Yurkiewicz, Ilana R.] Harvard Univ, Sch Med, Boston, MA USA; [Lappan, Charles M.] Telehealth, So Reg Med Command, Off Surgeon Gen Teleconsultat Programs Project Ma, Ft Sam Houston, TX USA; [Neely, Edward T.; Alphonso, Aimee L.] Walter Reed Natl Mil Med Ctr, Dept Neurol, Bethesda, MD USA; [Hesselbrock, Roger R.] USAF, Sch Aerosp Med, Aerosp Med Consultat Div, Dayton, OH USA; [Girard, Philip D.] Dept Vet Affairs Ctr, Gainesville, FL USA	Tsao, JW (corresponding author), USN, Bur Med & Surg, Washington, DC USA.	jack.tsao@usuhs.edu			US ArmyUnited States Department of Defense	I.R. Yurkiewicz, C. M. Lappan, E. T. Neely, R. R. Hesselbrock, P. D. Girard, and A. L. Alphonso reports no disclosures. J.W. Tsao has received funding from the US Army to develop a military neurology telemedicine system. Go to Neurology.org for full disclosures.	Awareness, 2011, AW; Bergen P, 2006, WASHINGTON POST 1013; Defense and Veterans Brain Injury Center, 2011, DOD WORLDW NUMB TRAU; Miller TC, 2010, PROPUBLICA      0607; Summerall EL, 2010, TRAUMATIC BRAIN INJU; Vanden Brook T, 2009, US TODAY        0120	6	23	23	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0028-3878			NEUROLOGY	Neurology	SEP	2012	79	12					1237	1243		10.1212/WNL.0b013e31826aac33			7	Clinical Neurology	Neurosciences & Neurology	009WK	WOS:000309055900014	22955133				2021-06-18	
J	Chen, CC; Hsu, PW; Lee, ST; Chang, CN; Wei, KC; Wu, CT; Hsu, YH; Lin, TK; Lee, SC; Huang, YC				Chen, Ching-Chang; Hsu, Peng-Wei; Lee, Shih-Tseng; Chang, Chen-Nen; Wei, Kuo-Chen; Wu, Chieh-Tsai; Hsu, Yung-Hsin; Lin, Tzu-Kang; Lee, Sai-Cheung; Huang, Yin-Cheng			Brain surgery in patients with liver cirrhosis Clinical article	JOURNAL OF NEUROSURGERY			English	Article						Child-Turcotte-Pugh class; liver cirrhosis; brain surgery; prognostic factor; neurosurgery; complication	OPEN-HEART-SURGERY; ABDOMINAL OPERATIONS; RISK-FACTORS; MELD SCORE; TRAUMA; COAGULOPATHY; MORTALITY; SURVIVAL; OUTCOMES; INJURY	Object. Liver cirrhosis was identified as an independent predictor of poor outcomes in patients suffering trauma and in those undergoing major surgeries. The aim of this study was to report the authors' experiences treating patients with cirrhosis who undergo brain surgeries. Methods. Between 2004 and 2009, 121 consecutive patients with cirrhosis underwent 144 brain procedures. Patients were categorized as Child-Turcotte-Pugh (referred to as "Child") Class A, B, or C. The patient profiles, including the severity of cirrhosis, reason for surgery, complications, and prognosis factors, were analyzed. Results. In this retrospective study, the overall surgical complication rate for patients with cirrhosis was 52.1% and the mortality rate was 24.3%. For patients with acute traumatic brain injury (TB!), the complication, rebleeding, and mortality rates reached 84.4%, 68.8%, and 37.5%, respectively. Surgery for TBI was a significant risk factor for postoperative complications (p = 0.0002) and postoperative hemorrhage (p < 0.0001). Otherwise, according to the Child classification, the complication rate increased in a stepwise fashion from 38.7% to 60% to 84.2%, the rebleeding rate from 29.3% to 48.0% to 63.2%, and the mortality rate from 5.3% to 38% to 63.2% for Child A, B, and C, respectively. The Child classification was associated with higher risk of complications-Child B vs A OR 2.84(95% CI 1.28-6.29), Child C vs A OR 5.39 (95% CI 1.32-22.02). It was also associated with risk of death-Child C vs A OR 30.43 (95% CI 7.71-120.02), Child B vs A OR 10.88(95% CI 3.42-34.63). Conclusions. Liver cirrhosis is a poor comorbidity factor for brain surgery. The authors' results suggest that the Child classification used independently is a poor prognostic factor; in addition, grave outcomes were observed in patients with TBI. (http://thejns.org/doi/abs/10.3171/2012.4.JNS111338)	Chang Gung Univ, Dept Neurosurg, Kwei Shan, Taiwan; Chang Gung Mem Hosp Linkou, Kwei Shan, Taiwan	Huang, YC (corresponding author), Chang Gung Mem Hosp, 5 Fu Shin St, Tao Yuan 333, Taiwan.	ns3068@hotmail.com		Wu, Chieh-Tsai/0000-0002-8419-3764			An Y, 2007, EUR SURG RES, V39, P67, DOI 10.1159/000099145; Chen CC, 2009, CLIN NEUROL NEUROSUR, V111, P835, DOI 10.1016/j.clineuro.2009.08.013; Child CG., 1964, LIVER PORTAL HYPERTE, P50; Christmas AB, 2005, AM SURGEON, V71, P996; Dangleben DA, 2006, J AM COLL SURGEONS, V203, P908, DOI 10.1016/j.jamcollsurg.2006.08.001; Demetriades D, 2004, J AM COLL SURGEONS, V199, P538, DOI 10.1016/j.jamcollsurg.2004.06.017; DOBERNECK RC, 1983, AM J SURG, V146, P306, DOI 10.1016/0002-9610(83)90402-6; Fang JF, 2003, J TRAUMA, V54, P1131, DOI 10.1097/01.TA.0000066123.32997.BB; GARRISON RN, 1984, ANN SURG, V199, P648, DOI 10.1097/00000658-198406000-00003; Georgiou C, 2009, WORLD J SURG, V33, P1087, DOI 10.1007/s00268-009-9923-7; Gronbaek H, 2008, BMC GASTROENTEROL, V8, DOI 10.1186/1471-230X-8-16; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hess JR, 2008, J TRAUMA, V65, P748, DOI 10.1097/TA.0b013e3181877a9c; Huang HH, 2008, CLIN NEUROL NEUROSUR, V110, P253, DOI 10.1016/j.clineuro.2007.11.010; Kamath PS, 2003, LIVER TRANSPLANT, V9, P19, DOI 10.1053/jlts.2003.50031; Kamath PS, 2001, HEPATOLOGY, V33, P464, DOI 10.1053/jhep.2001.22172; Kaul V, 2000, Curr Treat Options Gastroenterol, V3, P433, DOI 10.1007/s11938-000-0030-y; Kremers WK, 2004, HEPATOLOGY, V39, P764, DOI 10.1002/hep.20083; Mansour A, 1997, SURGERY, V122, P730, DOI 10.1016/S0039-6060(97)90080-5; McCaughan GW, 2000, J GASTROEN HEPATOL, V15, pG90, DOI 10.1046/j.1440-1746.2000.02273.x; McCormick PA, 2000, BEST PRACT RES CL GA, V14, P1009, DOI 10.1053/bega.2000.0144; Shuja F, 2008, J TRAUMA, V65, P975, DOI 10.1097/TA.0b013e3181801cd9; SIRINEK KR, 1987, ARCH SURG-CHICAGO, V122, P271; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Teh SH, 2007, GASTROENTEROLOGY, V132, P1261, DOI 10.1053/j.gastro.2007.01.040; Thielmann M, 2010, EUR J CARDIO-THORAC, V38, P592, DOI 10.1016/j.ejcts.2010.02.042; TINKOFF G, 1990, ANN SURG, V211, P172, DOI 10.1097/00000658-199002000-00009; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; Wahlstrom K, 2000, AM SURGEON, V66, P1071; Zehtabchi S, 2008, RESUSCITATION, V76, P52, DOI 10.1016/j.resuscitation.2007.06.024	30	23	24	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	AUG	2012	117	2					348	353		10.3171/2012.4.JNS111338			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	978ST	WOS:000306766800028	22631693				2021-06-18	
J	Veremeyko, T; Starossom, SC; Weiner, HL; Ponomarev, ED				Veremeyko, Tatiana; Starossom, Sarah-Christine; Weiner, Howard L.; Ponomarev, Eugene D.			Detection of MicroRNAs in Microglia by Real-time PCR in Normal CNS and During Neuroinflammation	JOVE-JOURNAL OF VISUALIZED EXPERIMENTS			English	Article						Immunology; Issue 65; Neuroscience; Genetics; microglia; macrophages; microRNA; brain; mouse; real-time PCR; neuroinflammation	MACROPHAGES	Microglia are cells of the myeloid lineage that reside in the central nervous system (CNS) (1). These cells play an important role in pathologies of many diseases associated with neuroinflammation such as multiple sclerosis (MS) (2). Microglia in a normal CNS express macrophage marker CD11b and exhibit a resting phenotype by expressing low levels of activation markers such as CD45. During pathological events in the CNS, microglia become activated as determined by upregulation of CD45 and other markers3. The factors that affect microglia phenotype and functions in the CNS are not well studied. MicroRNAs (miRNAs) are a growing family of conserved molecules(similar to 22 nucleotides long) that are involved in many normal physiological processes such as cell growth and differentiation(4) and pathologies such as inflammation(5). MiRNAs downregulate the expression of certain target genes by binding complementary sequences of their mRNAs and play an important role in the activation of innate immune cells including macrophages(6) and microglia(7). In order to investigate miRNA-mediated pathways that define the microglial phenotype, biological function, and to distinguish microglia from other types of macrophages, it is important to quantitatively assess the expression of particular microRNAs in distinct subsets of CNS-resident microglia. Common methods for measuring the expression of miRNAs in the CNS include quantitative PCR from whole neuronal tissue and in situ hybridization. However, quantitative PCR from whole tissue homogenate does not allow the assessment of the expression of miRNA in microglia, which represent only 5-15% of the cells of neuronal tissue. Hybridization in situ allows the assessment of the expression of microRNA in specific cell types in the tissue sections, but this method is not entirely quantitative. In this report we describe a quantitative and sensitive method for the detection of miRNA by real-time PCR in microglia isolated from normal CNS or during neuroinflammation using experimental autoimmune encephalomyelitis (EAE), a mouse model for MS. The described method will be useful to measure the level of expression of microRNAs in microglia in normal CNS or during neuroinflammation associated with various pathologies including MS, stroke, traumatic injury, Alzheimer's disease and brain tumors.	[Veremeyko, Tatiana; Starossom, Sarah-Christine; Weiner, Howard L.; Ponomarev, Eugene D.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02138 USA	Ponomarev, ED (corresponding author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Ctr Neurol Dis, Cambridge, MA 02138 USA.	eponomarev@rics.bwh.harvard.edu	Ponomarev, Eugene D./K-1546-2013	Ponomarev, Eugene D./0000-0002-0871-8522; Starossom, Sarah/0000-0001-7935-9910	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS071039-01A1]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS071039] Funding Source: NIH RePORTER	The work was supported by the NIH R01 NS071039-01A1 research grant.	Basu Sreemanti, 2010, J Vis Exp, DOI 10.3791/1546; Caffarelli E, 2011, FRONT BIOSCI-LANDMRK, V16, P2682, DOI 10.2741/3880; Cardona AE, 2006, NAT PROTOC, V1, P1947, DOI 10.1038/nprot.2006.327; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; Gordon R, 2011, J NEUROSCI METH, V194, P287, DOI 10.1016/j.jneumeth.2010.11.001; Graeber M.B., 2011, FEBS LETT; He M, 2009, CELL MOL IMMUNOL, V6, P343, DOI 10.1038/cmi.2009.45; McCoy C.E., 2010, FRONT BIOSCI, V17, P2161; Moltzahn F, 2011, JOVE-J VIS EXP, DOI 10.3791/2552; Perruisseau-Carrier C, 2011, MOL NEUROBIOL, V43, P215, DOI 10.1007/s12035-011-8179-z; Ponomarev ED, 2005, J NEUROSCI RES, V81, P374, DOI 10.1002/jnr.20488; Ponomarev ED, 2011, NAT MED, V17, P64, DOI 10.1038/nm.2266; Tremblay ME, 2011, J NEUROSCI, V31, P16064, DOI 10.1523/JNEUROSCI.4158-11.2011	13	23	23	0	3	JOURNAL OF VISUALIZED EXPERIMENTS	CAMBRIDGE	1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA	1940-087X			JOVE-J VIS EXP	J. Vis. Exp.	JUL	2012		65							e4097	10.3791/4097			8	Multidisciplinary Sciences	Science & Technology - Other Topics	V36PJ	WOS:000209223200038	22872097	Green Published			2021-06-18	
J	Bartsch, AJ; Benzel, EC; Miele, VJ; Morr, DR; Prakash, V				Bartsch, Adam J.; Benzel, Edward C.; Miele, Vincent J.; Morr, Douglas R.; Prakash, Vikas			Boxing and mixed martial arts: preliminary traumatic neuromechanical injury risk analyses from laboratory impact dosage data	JOURNAL OF NEUROSURGERY			English	Article						concussion; traumatic brain injury; boxing; mixed martial arts; injury risk; severity index; rotation	PROFESSIONAL FOOTBALL; SOCCER HEADGEAR; BRAIN-INJURY; GAME IMPACTS; CONCUSSION; PERFORMANCE; HELMETS; RECONSTRUCTION; ACCELERATION; BIOMECHANICS	Object. In spite of ample literature pointing to rotational and combined impact dosage being key contributors to head and neck injury, boxing and mixed martial arts (MMA) padding is still designed to primarily reduce cranium linear acceleration. The objects of this study were to quantify preliminary linear and rotational head impact dosage for selected boxing and MMA padding in response to hook punches; compute theoretical skull, brain, and neck injury risk metrics; and statistically compare the protective effect of various glove and head padding conditions. Methods. An instrumented Hybrid III 50th percentile anthropomorphic test device (ATD) was struck in 54 pendulum impacts replicating hook punches at low (27-29 J) and high (54-58 J) energy. Five padding combinations were examined: unpadded (control), MMA glove-unpadded head, boxing glove unpadded head, unpadded pendulum-boxing headgear, and boxing glove-boxing headgear. A total of 17 injury risk parameters were measured or calculated. Results. All padding conditions reduced linear impact dosage. Other parameters significantly decreased, significantly increased, or were unaffected depending on padding condition. Of real-world conditions (MMA glove-bare head, boxing glove-bare head, and boxing glove-headgear), the boxing glove-headgear condition showed the most meaningful reduction in most of the parameters. In equivalent impacts, the MMA glove-bare head condition induced higher rotational dosage than the boxing glove-bare head condition. Finite element analysis indicated a risk of brain strain injury in spite of significant reduction of linear impact dosage. Conclusions. In the replicated hook punch impacts, all padding conditions reduced linear but not rotational impact dosage. Head and neck dosage theoretically accumulates fastest in MMA and boxing bouts without use of protective headgear. The boxing glove-headgear condition provided the best overall reduction in impact dosage. More work is needed to develop improved protective padding to minimize linear and rotational impact dosage and develop next-generation standards for head and neck injury risk. (http://thejns.org/doi/abs/10.3171/2011.12.JNS111478)	[Bartsch, Adam J.; Benzel, Edward C.] Cleveland Clin, Spine Res Lab, Cleveland, OH 44113 USA; [Benzel, Edward C.; Miele, Vincent J.] Cleveland Clin, Dept Neurol Surg, Neurol Inst, Cleveland, OH 44113 USA; [Bartsch, Adam J.; Benzel, Edward C.; Prakash, Vikas] Case Western Reserve Univ, Cleveland Traumat Neuromech Consortium, Cleveland, OH 44106 USA; [Prakash, Vikas] Case Western Reserve Univ, Dept Mech Engn, Cleveland, OH 44106 USA; [Morr, Douglas R.] Sci Expert Anal SEA Ltd, Columbus, OH USA; [Miele, Vincent J.] United Hosp Ctr Neurosurg & Spine Ctr, Clarksburg, WV USA	Bartsch, AJ (corresponding author), Cleveland Clin, Spine Res Lab, Luth2-C,1730 W 25th St, Cleveland, OH 44113 USA.	bartsca@ccf.org			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [AR050959]; Cleveland Clinic Center for Spine Health; Ohio Third Frontier; NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Arthritis & Musculoskeletal & Skin Diseases (NIAMS) [T32AR050959] Funding Source: NIH RePORTER	The authors report no conflict of interest concerning the materials or methods used in this study or the findings specified in this paper. They acknowledge assistance for the study from the National Institutes of Health Ruth L. Kirchstein T32 Training Grant AR050959, Cleveland Clinic Center for Spine Health, and Ohio Third Frontier. SEA, Ltd. provided use of the testing facility, impactor, instrumentation, data acquisition equipment, and Hybrid III ATD.	American Society for Testing and Materials, 2002, STAND TEST METH EQ P; Bandak FA, SIMON SIMULATED INJU; Broglio SP, 2003, J ATHL TRAINING, V38, P220; Casson IR, 2009, PHYS MED REH CLIN N, V20, P195, DOI 10.1016/j.pmr.2008.10.006; Caswell SV, 2002, J ATHL TRAINING, V37, P164; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Finan JD, 2008, TRAFFIC INJ PREV, V9, P483, DOI 10.1080/15389580802272427; Frechede B, 2009, MED SCI SPORT EXER, V41, P390, DOI 10.1249/MSS.0b013e318186b1c5; Gadd CW, 1966, P 10 STAPP CAR CRASH, V10, P164; Gilchrist A, 1996, ACCIDENT ANAL PREV, V28, P525, DOI 10.1016/0001-4575(96)00030-9; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Hrysomallis C, 2004, J SCI MED SPORT, V7, P156, DOI 10.1016/S1440-2440(04)80005-7; Knouse CL, 2003, J ATHL TRAINING, V38, P330; Lewis LM, 2001, ACAD EMERG MED, V8, P604, DOI 10.1111/j.1553-2712.2001.tb00171.x; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; McElhaney James H, 2005, Stapp Car Crash J, V49, pv; McIntosh A, 2004, BRIT J SPORT MED, V38, P46, DOI 10.1136/bjsm.2002.003103; McIntosh AS, 2000, BRIT J SPORT MED, V34, P337, DOI 10.1136/bjsm.34.5.337; Naunheim RS, 2003, ACAD EMERG MED, V10, P85, DOI 10.1197/aemj.10.1.85; Newman JA, 2005, J BIOMECH, V38, P1469, DOI 10.1016/j.jbiomech.2004.06.025; Newman JA, PROPOSED NEW BIOMECH; NOCSAE, STAND TEST METH EQ U; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; Ommaya AK, 2002, BRIT J NEUROSURG, V16, P220, DOI 10.1080/02688690220148824; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; SMITH PK, 1986, J HUM MOVEMENT STUD, V12, P153; Smith TA, 1973, P INT RES COUNC BIOM, V1, P271; Snell Memorial Foundation, STAND PROT HEADG US; Society of Automotive Engineers (SAE), 1995, J2111 SAE; Society of Automotive Engineers (SAE), 1994, J1733 SAE; Stojsih S, 2010, BRIT J SPORT MED, V44, P725, DOI 10.1136/bjsm.2008.052845; Takhounts E., 2003, STAPP CAR CRASH J, V47, P107, DOI DOI 10.4271/2003-22-0007; Thibault LE, 1990, ANN PROC ASS ADV AUT, V34, P337; Tierney RT, 2008, J ATHL TRAINING, V43, P578, DOI 10.4085/1062-6050-43.6.578; Versace J, 1971, P 15 STAPP CAR CRASH, DOI [DOI 10.4271/710881, 10.4271/710881]; Viano DC, 2006, NEUROSURGERY, V59, P591, DOI 10.1227/01.NEU.0000231851.97287.C2; Viano DC, 2005, NEUROSURGERY, V57, P1154, DOI 10.1227/01.NEU.0000187541.87937.D9; Walilko TJ, 2005, BRIT J SPORT MED, V39, P710, DOI 10.1136/bjsm.2004.014126; Withnall C, 2005, BRIT J SPORT MED, V39, pI49, DOI 10.1136/bjsm.2005.019182; Withnall C, 2005, BRIT J SPORT MED, V39, pI40, DOI 10.1136/bjsm.2005.019174; Zhang LY, 2004, J BIOMECH ENG-T ASME, V126, P226, DOI 10.1115/1.1691446	41	23	23	0	47	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	MAY	2012	116	5					1070	1080		10.3171/2011.12.JNS111478			11	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	929TO	WOS:000303088800023	22313361				2021-06-18	
J	Ibrahim, NG; Wood, J; Margulies, SS; Christian, CW				Ibrahim, Nicole G.; Wood, Joanne; Margulies, Susan S.; Christian, Cindy W.			Influence of age and fall type on head injuries in infants and toddlers	INTERNATIONAL JOURNAL OF DEVELOPMENTAL NEUROSCIENCE			English	Article						Falls; Brain injury; Mechanism; Age	TRAUMATIC BRAIN-INJURY; YOUNG-CHILDREN; POPULATION; MECHANISMS; HEIGHTS	Age-based differences in fall type and neuroanatomy in infants and toddlers may affect clinical presentations and injury patterns. Objective: Our goal is to understand the influence of fall type and age on injuries to help guide clinical evaluation. Design/Setting/Participants: Retrospectively, 285 children 0-48 months with accidental head injury from a fall and brain imaging between 2000 and 2006 were categorized by age (infan <= 1 year and toddler = 1-4 years) and fall type: low (<= 3 ft), intermediate (> 3 and < 10 ft), high height falls (>= 10 ft) and stair falls. Outcome Measures: Clinical manifestations were noted and head injuries separated into primary (bleeding) and secondary (hypoxia, edema). The influence of age and fall type on head injuries sustained was evaluated. Results: Injury patterns in children < 4 years varied with age. Despite similar injury severity scores, infants sustained more skull fractures than toddlers (71% vs. 39%). Of children with skull fractures, 11% had no evidence of scalp/facial soft tissue swelling. Of the patients with primary intracranial injury, 30% had no skull fracture and 8% had neither skull fracture nor cranial soft tissue injury. Low height falls resulted in primary intracranial injury without soft tissue or skull injury in infants (6%) and toddlers (16%). Conclusions: Within a given fall type, age-related differences in injuries exist between infants and toddlers. When interpreting a fall history, clinicians must consider the fall type and influence of age on resulting injury. For young children, intracranial injury is not always accompanied by external manifestations of their injury. (C) 2011 ISDN. Published by Elsevier Ltd. All rights reserved.	[Ibrahim, Nicole G.; Margulies, Susan S.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA; [Wood, Joanne; Christian, Cindy W.] Childrens Hosp Philadelphia, Dept Pediat, Philadelphia, PA 19104 USA	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA.	nicole.ibrahim@fda.hhs.gov; woodjo@email.chop.edu; margulie@seas.upenn.edu; Christian@email.chop.edu			NSF through the Center for Child Injury Prevention Studies (CChIPS); NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NIH RO1NS 39679]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679] Funding Source: NIH RePORTER	We acknowledge Dr. Michael Nance for the use of the Trauma Registry Database at CHOP. This work was funded by NSF through the Center for Child Injury Prevention Studies (CChIPS) and NINDS (NIH RO1NS 39679).	Agran PF, 2003, PEDIATRICS, V111, pE683, DOI 10.1542/peds.111.6.e683; CDC, 2004, 21 CDC, V52; CHADWICK DL, 1991, J TRAUMA, V31, P1353, DOI 10.1097/00005373-199110000-00006; Chang LT, 2007, J TRAUMA, V63, P70, DOI 10.1097/01.ta.0000219142.15584.b8; CHIAVIELLO CT, 1994, PEDIATRICS, V94, P679; DUHAIME AC, 1992, PEDIATRICS, V90, P179; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Hennrikus WL, 2003, CLIN ORTHOP RELAT R, P148, DOI 10.1097/01.blo.0000043059.62337.97; Holsti M, 2005, PEDIATR EMERG CARE, V21, P639, DOI 10.1097/01.pec.0000181426.25342.a9; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Johnson K, 2005, CLIN RADIOL, V60, P464, DOI 10.1016/j.crad.2004.09.013; Kim K A, 2000, Neurosurg Focus, V8, pe3; Lallier M, 1999, J PEDIATR SURG, V34, P1060, DOI 10.1016/S0022-3468(99)90564-X; LEHMAN D, 1993, PEDIATRICS, V92, P121; Murray JA, 2000, AM SURGEON, V66, P863; Park SH, 2004, YONSEI MED J, V45, P229, DOI 10.3349/ymj.2004.45.2.229; Pickett W, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.4.e365; Schutzman SA, 2001, ANN EMERG MED, V37, P65, DOI 10.1067/mem.2001.109440; Spady DW, 2004, PEDIATRICS, V113, P522, DOI 10.1542/peds.113.3.522; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; Wang MY, 2001, J PEDIATR SURG, V36, P1528, DOI 10.1053/jpsu.2001.27037	21	23	24	1	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0736-5748	1873-474X		INT J DEV NEUROSCI	Int. J. Dev. Neurosci.	MAY	2012	30	3			SI		201	206		10.1016/j.ijdevneu.2011.10.007			6	Developmental Biology; Neurosciences	Developmental Biology; Neurosciences & Neurology	936XH	WOS:000303622800005	22079853	Green Accepted, Green Published			2021-06-18	
J	Kim, DJ; Czosnyka, Z; Kasprowicz, M; Smieleweski, P; Baledent, O; Guerguerian, AM; Pickard, JD; Czosnyka, M				Kim, Dong-Joo; Czosnyka, Zofia; Kasprowicz, Magdalena; Smieleweski, Piotr; Baledent, Oliver; Guerguerian, Anne-Marie; Pickard, John D.; Czosnyka, Marek			Continuous Monitoring of the Monro-Kellie Doctrine: Is It Possible?	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood volume; cerebral compliance; compensatory mechanism; CSF compartment; traumatic brain injury; vascular compartment	PRESSURE-VOLUME INDEX; CEREBRAL PERFUSION-PRESSURE; FLUID PULSE PRESSURE; INTRACRANIAL-PRESSURE; CEREBROSPINAL-FLUID; HEAD-INJURY; BRAIN; AUTOREGULATION; HYDRODYNAMICS; CATS	The Monro-Kellie doctrine describes the principle of homeostatic intracerebral volume regulation, which stipulates that the total volume of the parenchyma, cerebrospinal fluid, and blood remains constant. Hypothetically, a slow shift (e. g., brain edema development) in the irregular vasomotion-driven exchanges of these compartmental volumes may lead to increased intracranial hypertension. To evaluate this paradigm in a clinical setting and measure the processes involved in the regulation of systemic intracranial volume, we quantified cerebral blood flow velocity (CBFv) in the middle cerebral artery, arterial blood pressure (ABP), and intracranial pressure (ICP), in 238 brain-injured subjects. Relative changes in compartmental compliances C-a (arterial) and C-i (combined venous and CSF compartments) were mathematically estimated using these raw signals through time series analysis; C-a and C-i were used to compute an index of cerebral compliance (ICC) as a moving correlation coefficient between C-a and C-i. Conceptually, a negative ICC would represent a functional Monro-Kellie doctrine by illustrating volumetric compensations between C-a and C-i. Clinical observations show that Lundberg A-waves and arterial hypertension were associated with negative ICC, whereas in refractory intracranial hypertension, a positive ICC was observed. In subjects who died, ICC was significantly greater than in survivors (0.46 +/- 0.027 versus 0.22 +/- 0.017; p < 0.01) over the first 5 days of intensive care. The mortality rate is 5% when ICC is less than 0, and 43% when above 0.7. ICC above 0.7 was associated with terminally elevated ICP (chi-square p = 0.026). We propose that the Monro-Kellie doctrine can be monitored in real time to illustrate the state of intracranial volume regulation.	[Kim, Dong-Joo] Korea Univ, Dept Brain & Cognit Engn, Seoul 136713, South Korea; [Kim, Dong-Joo; Czosnyka, Zofia; Smieleweski, Piotr; Pickard, John D.; Czosnyka, Marek] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; [Kim, Dong-Joo; Guerguerian, Anne-Marie] Univ Toronto, Hosp Sick Children, Dept Crit Care Med, Toronto, ON M5G 1X8, Canada; [Kasprowicz, Magdalena] Wroclaw Univ Technol, Inst Biomed Engn & Instrumentat, PL-50370 Wroclaw, Poland; [Baledent, Oliver] Amiens Univ Hosp, Dept Imaging & Biophys, Amiens, France	Kim, DJ (corresponding author), Korea Univ, Dept Brain, Seoul 136713, South Korea.	dongjookim@korea.ac.kr	baledent, olivier/AAQ-4489-2020	baledent, olivier/0000-0001-6028-6440; Kasprowicz, Magdalena/0000-0002-2271-7737	National Institute of Health Research Biomedical Research CentreNational Institute for Health Research (NIHR); Cambridge University Hospital Foundation Trust; Foundation of Polish Science; EC grant INTERREG; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0600986, G9439390, G0001237] Funding Source: researchfish; National Institute for Health ResearchNational Institute for Health Research (NIHR) [NF-SI-0508-10327] Funding Source: researchfish	The project was supported by the National Institute of Health Research Biomedical Research Centre, Cambridge University Hospital Foundation Trust-Neurosciences Theme and Senior Investigator Award (J.D.P.). M. K. is supported by the Foundation of Polish Science. M. C., Z.C., O.B., P. S., and J.D.P. are supported by EC grant INTERREG, interregional cooperation between the University of Picardie (Amiens) and the University of Cambridge, U.K.	Alperin N, 2005, J NEUROSURG, V103, P46, DOI 10.3171/jns.2005.103.1.0046; Avezaat C, 1984, CEREBROSPINAL FLUID; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Baledent O, 2006, J NEURORADIOLOGY, V33, P292, DOI 10.1016/S0150-9861(06)77287-X; BURTON AC, 1954, PHYSIOL REV, V34, P619; Carrera E., 2011, J NEUROTRAUMA; Czosnyka M, 1997, J NEUROL NEUROSUR PS, V63, P721, DOI 10.1136/jnnp.63.6.721; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; Czosnyka M, 2001, J NEUROSURG, V95, P756, DOI 10.3171/jns.2001.95.5.0756; Davson H., 1967, PHYSL CEREBROSPINAL; FRANK JI, 1995, NEUROLOGY, V45, P1286, DOI 10.1212/WNL.45.7.1286; GOPINATH SP, 1993, J NEUROSCI METH, V49, P11, DOI 10.1016/0165-0270(93)90104-Y; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; GREITZ D, 1992, NEURORADIOLOGY, V34, P370, DOI 10.1007/BF00596493; GUINANE JE, 1972, AM J PHYSIOL, V223, P425; GUINANE JE, 1974, NEUROLOGY, V24, P138, DOI 10.1212/WNL.24.2.138; GUINANE JE, 1975, NEUROLOGY, V25, P559, DOI 10.1212/WNL.25.6.559; Ito U, 1990, Adv Neurol, V52, P459; JENNETT B, 1975, LANCET, V1, P480; Kim DJ, 2009, PHYSIOL MEAS, V30, P647, DOI 10.1088/0967-3334/30/7/009; Kim DJ, 2009, NEUROSURGERY, V64, P494, DOI 10.1227/01.NEU.0000338434.59141.89; Kirkpatrick PJ, 1996, J NEUROL NEUROSUR PS, V60, P131, DOI 10.1136/jnnp.60.2.131; Koskinen LOD, 2005, NEUROSURGERY, V56, P693, DOI 10.1227/01.NEU.0000156609.95596.24; Luerssen T.G.S.P., 1989, INTRACRANIAL PRESSUR, P35; MARMAROU A, 1978, J NEUROSURG, V48, P332, DOI 10.3171/jns.1978.48.3.0332; Marmarou A., 1973, THEORETICAL EXPT EVA; Marmarou A.T., 1994, INTRACRANIAL PRESSUR, P15; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Miller JD, 1972, INTRACRANIAL PRESSUR, P270; Mokri B, 2001, NEUROLOGY, V56, P1746, DOI 10.1212/WNL.56.12.1746; Monro Alexander, 1783, OBSERVATIONS STRUCTU; Neff S, 1996, J NEUROSURG, V85, P1195; Newell DW, 1997, ACTA NEUROCHIR, V139, P804, DOI 10.1007/BF01411398; OSTERHOLM JL, 1970, J NEUROSURG, V32, P654, DOI 10.3171/jns.1970.32.6.0654; OVERGAARD J, 1976, J NEUROSURG, V45, P292, DOI 10.3171/jns.1976.45.3.0292; Pallet J., 2001, SPSS SURVIVAL MANUAL; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Piper I, 1999, BRIT J NEUROSURG, V13, P581, DOI 10.1080/02688699943097; POLLAY M, 1980, NEUROSURGERY, V6, P675, DOI 10.1227/00006123-198006000-00014; SKLAR FH, 1977, J NEUROSURG, V47, P670, DOI 10.3171/jns.1977.47.5.0670; SULLIVAN HG, 1977, J NEUROSURG, V47, P532, DOI 10.3171/jns.1977.47.4.0532; Toth M, 2000, PFLUG ARCH EUR J PHY, V439, P573, DOI 10.1007/s004240050980; Ursino M, 1997, J APPL PHYSIOL, V82, P1256	44	23	23	0	11	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAY	2012	29	7					1354	1363		10.1089/neu.2011.2018			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	933TC	WOS:000303384600009	21895518	Green Published			2021-06-18	
J	Kutzing, MK; Luo, V; Firestein, BL				Kutzing, Melinda K.; Luo, Vincent; Firestein, Bonnie L.			Protection from Glutamate-Induced Excitotoxicity by Memantine	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Microelectrode array; Memantine; NMDA receptor antagonist; Traumatic brain injury; Glutamate; Excitotoxicity	NMDA RECEPTOR ANTAGONISTS; TRAUMATIC BRAIN-INJURY; SEVERE ALZHEIMERS-DISEASE; SPINAL-CORD NEURONS; MICROELECTRODE ARRAYS; CORTICAL-NEURONS; POSTTRAUMATIC EPILEPSY; SYNCHRONOUS ACTIVITY; ACTIVATED CHANNELS; BLOCK	This study investigates whether the uncompetitive N-methyl-d-aspartic acid receptor antagonist, memantine, is able to protect dissociated cortical neurons from glutamate-induced excitotoxicity (GIE). Treatment with glutamate resulted in a significant loss of synchronization of neuronal activity as well as a significant increase in the duration of synchronized bursting events (SBEs). By administering memantine at the same time as glutamate, we were able to completely prevent these changes to the neuronal activity. Pretreatment with memantine was somewhat effective in preventing changes to the culture synchronization but was unable to fully protect the synchronization of electrical activity between neurons that showed high levels of synchronization prior to injury. Additionally, memantine pretreatment was unable to prevent the increase in the duration of SBEs caused by GIE. Thus, the timing of memantine treatment is important for conferring neuroprotection against glutamate-induced neurotoxicity. Finally, we found that GIE leads to a significant increase in the burst duration. Our data suggest that this may be due to an alteration in the inhibitory function of the neurons.	[Kutzing, Melinda K.; Luo, Vincent; Firestein, Bonnie L.] Rutgers State Univ, Dept Cell Biol & Neurosci, Piscataway, NJ 08854 USA; [Kutzing, Melinda K.] Rutgers State Univ, Grad Program Biomed Engn, Piscataway, NJ 08854 USA; [Firestein, Bonnie L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ 08854 USA	Firestein, BL (corresponding author), Rutgers State Univ, Dept Cell Biol & Neurosci, 604 Allison Rd, Piscataway, NJ 08854 USA.	fire-stein@biology.rutgers.edu		Firestein, Bonnie/0000-0002-1679-3565	New Jersey Commission on Brain Injury Research [09-3209-BIR-E-2]; National Institute of General Medical SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [5T32GM008339]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008339] Funding Source: NIH RePORTER	This work was funded by a grant from the New Jersey Commission on Brain Injury Research, #09-3209-BIR-E-2 to BLF. MLK was supported by Biotechnology Fellowship, Grant 5T32GM008339 from National Institute of General Medical Sciences.	Anitha M, 2011, MED HYPOTHESES, V76, P138, DOI 10.1016/j.mehy.2010.09.003; Bordji K, 2011, REV NEUROSCIENCE, V22, P285, DOI 10.1515/RNS.2011.029; CAVENESS WF, 1976, EPILEPSIA, V17, P207, DOI 10.1111/j.1528-1157.1976.tb03398.x; Cente M, 2009, CELL MOL NEUROBIOL, V29, P945, DOI 10.1007/s10571-009-9379-1; Chen HSV, 1998, NEUROSCIENCE, V86, P1121, DOI 10.1016/S0306-4522(98)00163-8; CHEN HSV, 1992, J NEUROSCI, V12, P4427; Chen HSV, 1997, J PHYSIOL-LONDON, V499, P27, DOI 10.1113/jphysiol.1997.sp021909; Chen HSV, 2006, J NEUROCHEM, V97, P1611, DOI 10.1111/j.1471-4159.2006.03991.x; Chiappalone M, 2003, BIOSENS BIOELECTRON, V18, P627, DOI 10.1016/S0956-5663(03)00041-1; Chiappalone M, 2007, INT J NEURAL SYST, V17, P87, DOI 10.1142/S0129065707000968; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; Dingledine R, 1999, PHARMACOL REV, V51, P7; Du YZ, 2007, GLIA, V55, P463, DOI 10.1002/glia.20472; Gopal KV, 2003, NEUROTOXICOL TERATOL, V25, P69, DOI 10.1016/S0892-0362(02)00321-5; Hales Chadwick M, 2010, J Vis Exp, DOI 10.3791/2056; Hardingham GE, 2002, NAT NEUROSCI, V5, P405, DOI 10.1038/nn835; Ikonomidou C, 2002, LANCET NEUROL, V1, P383, DOI 10.1016/S1474-4422(02)00164-3; Johnson JW, 2006, CURR OPIN PHARMACOL, V6, P61, DOI 10.1016/j.coph.2005.09.007; Kharlamov EA, 2011, EPILEPSY RES, V95, P20, DOI 10.1016/j.eplepsyres.2011.02.008; Kuszczyk M, 2010, PHARMACOL REP, V62, P1041, DOI 10.1016/S1734-1140(10)70366-2; Kutzing MK, 2011, ANN BIOMED ENG, V39, P2252, DOI 10.1007/s10439-011-0319-0; Leveille F, 2008, FASEB J, V22, P4258, DOI 10.1096/fj.08-107268; Li YL, 2007, BIOSENS BIOELECTRON, V22, P2976, DOI 10.1016/j.bios.2006.12.018; Lin CH, 2008, J NEUROCHEM, V104, P1415, DOI 10.1111/j.1471-4159.2007.05098.x; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; Lipton SA, 2006, NEURON, V50, P10, DOI 10.1016/j.neuron.2006.03.026; Lipton SA, 2006, NAT REV DRUG DISCOV, V5, P160, DOI 10.1038/nrd1958; LIPTON SA, 1993, TRENDS NEUROSCI, V16, P527, DOI 10.1016/0166-2236(93)90198-U; Lipton SA, 2007, NAT REV NEUROSCI, V8, P803, DOI 10.1038/nrn2229; Lowenstein DH, 2009, EPILEPSIA, V50, P4, DOI 10.1111/j.1528-1167.2008.02004.x; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; Morefield SI, 2000, BIOSENS BIOELECTRON, V15, P383, DOI 10.1016/S0956-5663(00)00095-6; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; Okamoto SI, 2009, NAT MED, V15, P1407, DOI 10.1038/nm.2056; Papadia S, 2008, NAT NEUROSCI, V11, P476, DOI 10.1038/nn2071; Rao VLR, 2001, BRAIN RES, V911, P96; Reisberg B, 2003, NEW ENGL J MED, V348, P1333, DOI 10.1056/NEJMoa013128; Rogawski MA, 2003, CNS DRUG REV, V9, P275, DOI 10.1111/j.1527-3458.2003.tb00254.x; ROGAWSKI MA, 1993, TRENDS PHARMACOL SCI, V14, P325, DOI 10.1016/0165-6147(93)90005-5; Sattler R, 1998, J NEUROCHEM, V71, P2349; Shew WL, 2010, J NEUROSCI METH, V192, P75, DOI 10.1016/j.jneumeth.2010.07.023; Sihver S, 2001, J NEUROCHEM, V78, P417, DOI 10.1046/j.1471-4159.2001.00428.x; Tani H, 2007, NEUROBIOL DIS, V25, P230, DOI 10.1016/j.nbd.2006.08.025; Tariot PN, 2004, JAMA-J AM MED ASSOC, V291, P317, DOI 10.1001/jama.291.3.317; Wilkinson D, 2007, DEMENT GERIATR COGN, V24, P138, DOI 10.1159/000105162; Willmore LJ, 2010, NEUROLOGY, V75, P202, DOI 10.1212/WNL.0b013e3181e8e94f; Wrighton DC, 2008, J PHYSIOL-LONDON, V586, P211, DOI 10.1113/jphysiol.2007.143164; Xia P, 2010, J NEUROSCI, V30, P11246, DOI 10.1523/JNEUROSCI.2488-10.2010; Ye ZC, 1998, GLIA, V22, P237, DOI 10.1002/(SICI)1098-1136(199803)22:3<237::AID-GLIA3>3.0.CO;2-2; ZEEVALK GD, 1992, J NEUROCHEM, V59, P1211, DOI 10.1111/j.1471-4159.1992.tb08430.x	51	23	24	0	6	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	MAY	2012	40	5					1170	1181		10.1007/s10439-011-0494-z			12	Engineering, Biomedical	Engineering	926DZ	WOS:000302812800017	22203191	Green Accepted			2021-06-18	
J	Wu, N; Zou, XT; Tian, Y; Fitek, J; Maffeo, M; Niezrecki, C; Chen, J; Wang, XW				Wu, Nan; Zou, Xiaotian; Tian, Ye; Fitek, John; Maffeo, Michael; Niezrecki, Christopher; Chen, Julie; Wang, Xingwei			An ultra-fast fiber optic pressure sensor for blast event measurements	MEASUREMENT SCIENCE AND TECHNOLOGY			English	Article						pressure sensor; fiber optic; traumatic brain injury; shock tube	TRAUMATIC BRAIN-INJURY; SHOCK; WAVE; DIAPHRAGM	Soldiers who are exposed to explosions are at risk of suffering traumatic brain injury (TBI). Since the causal relationship between a blast and TBI is poorly understood, it is critical to have sensors that can accurately quantify the blast dynamics and resulting wave propagation through a helmet and skull that are imparted onto and inside the brain. To help quantify the cause of TBI, it is important to record transient pressure data during a blast event. However, very few sensors feature the capabilities of tracking the dynamic pressure transients due to the rapid change of the pressure during blast events, while not interfering with the physical material layers or wave propagation. In order to measure the pressure transients efficiently, a pressure sensor should have a high resonant frequency and a high spatial resolution. This paper describes an ultra-fast fiber optic pressure sensor based on the Fabry-Perot principle for the application of measuring the rapid pressure changes in a blast event. A shock tube experiment performed in US Army Natick Soldier Research, Development and Engineering Center has demonstrated that the resonant frequency of the sensor is 4.12 MHz, which is relatively close to the designed theoretical value of 4.113 MHz. Moreover, the experiment illustrated that the sensor has a rise time of 120 ns, which demonstrates that the sensor is capable of observing the dynamics of the pressure transient during a blast event.	[Wu, Nan; Tian, Ye; Wang, Xingwei] Univ Massachusetts Lowell, Dept Elect & Comp Engn, Lowell, MA 01854 USA; [Zou, Xiaotian] Univ Massachusetts Lowell, Dept Biomed Engn & Biotechnol, Lowell, MA 01854 USA; [Fitek, John; Maffeo, Michael] USA, Natick Soldier Res Dev & Engn Ctr, Natick, MA 01760 USA; [Niezrecki, Christopher; Chen, Julie] Univ Massachusetts Lowell, Dept Mech Engn, Lowell, MA 01854 USA	Wu, N (corresponding author), Univ Massachusetts Lowell, Dept Elect & Comp Engn, 1 Univ Ave, Lowell, MA 01854 USA.	xingwei_wang@uml.edu	Tian, Ye/A-1090-2014; Zou, Xiaotian/J-8657-2013	Tian, Ye/0000-0002-0785-1145; 	Army Research LaboratoryUnited States Department of DefenseUS Army Research Laboratory (ARL) [W911NF-07-2-0081]	The authors are grateful for the collaboration with Natick Soldier Research, Development and Engineering Center for sharing the shock tube and the reference pressure sensors. The authors also appreciate the Army Research Laboratory for sponsoring this work (Nanomanufacturing of Multifunctional Sensors Award Number W911NF-07-2-0081).	Chavko M, 2007, J NEUROSCI METH, V159, P277, DOI 10.1016/j.jneumeth.2006.07.018; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Irwin RJ, 1999, J TRAUMA, V47, P105, DOI 10.1097/00005373-199907000-00023; MacPherson WN, 2000, MEAS SCI TECHNOL, V11, P95, DOI 10.1088/0957-0233/11/2/302; Moochhala SM, 2004, J TRAUMA, V56, P393, DOI 10.1097/01.TA.0000066181.50879.7A; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Parkes W, 2007, J MICROMECH MICROENG, V17, P1334, DOI 10.1088/0960-1317/17/7/016; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; Wang A, 2001, J LIGHTWAVE TECHNOL, V19, P1495, DOI 10.1109/50.956136; Wang WH, 2010, OPT EXPRESS, V18, P9006, DOI 10.1364/OE.18.009006; Wang WH, 2009, OPT EXPRESS, V17, P16613, DOI 10.1364/OE.17.016613; Wang XW, 2006, OPT LETT, V31, P885, DOI 10.1364/OL.31.000885; Watson S, 2006, MEAS SCI TECHNOL, V17, P1337, DOI 10.1088/0957-0233/17/6/008; Wightman JM, 2001, ANN EMERG MED, V37, P664, DOI 10.1067/mem.2001.114906; Wu N, 2010, PROC SPIE, V7574, DOI 10.1117/12.842034; Xu JC, 2005, OPT LETT, V30, P3269, DOI 10.1364/OL.30.003269; Xu JC, 2005, IEEE PHOTONIC TECH L, V17, P870, DOI 10.1109/LPT.2005.844013; Zhu YZ, 2005, IEEE PHOTONIC TECH L, V17, P447, DOI 10.1109/LPT.2004.839002	19	23	23	1	25	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0957-0233	1361-6501		MEAS SCI TECHNOL	Meas. Sci. Technol.	MAY	2012	23	5							055102	10.1088/0957-0233/23/5/055102			7	Engineering, Multidisciplinary; Instruments & Instrumentation	Engineering; Instruments & Instrumentation	929CR	WOS:000303039300016					2021-06-18	
J	Drabek, T; Janata, A; Jackson, EK; End, B; Stezoski, J; Vagni, VA; Janesko-Feldman, K; Wilson, CD; van Rooijen, N; Tisherman, SA; Kochanek, PM				Drabek, Tomas; Janata, Andreas; Jackson, Edwin K.; End, Brad; Stezoski, Jason; Vagni, Vincent A.; Janesko-Feldman, Keri; Wilson, Caleb D.; van Rooijen, Nico; Tisherman, Samuel A.; Kochanek, Patrick M.			Microglial depletion using intrahippocampal injection of liposome-encapsulated clodronate in prolonged hypothermic cardiac arrest in rats	RESUSCITATION			English	Article						Inflammation; Iba-1; Cardiac arrest; Brain ischemia; Resuscitation; Emergency preservation; Hypothermia	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; MINOCYCLINE TREATMENT; NEUROLOGICAL DYSFUNCTION; NEURONAL DEATH; TISSUE-DAMAGE; MACROPHAGES; CELLS; MECHANISM; BINDING	Trauma patients who suffer cardiac arrest (CA) from exsanguination rarely survive. Emergency preservation and resuscitation using hypothermia was developed to buy time for resuscitative surgery and delayed resuscitation with cardiopulmonary bypass (CPB), but intact survival is limited by neuronal death associated with microglial proliferation and activation. Pharmacological modulation of microglia may improve outcome following CA. Systemic injection of liposome-encapsulated clodronate (LEC) depletes macrophages. To test the hypothesis that intrahippocampal injection of LEC would attenuate local microglial proliferation after CA in rats, we administered LEC or PBS into the right or left hippocampus, respectively. After rapid exsanguination and 6 min no-flow, hypothermia was induced by ice-cold (IC) or room-temperature (RT) flush. Total duration of CA was 20 min. Pre-treatment (IC, RTpre) and post-treatment (RTpost) groups were studied, along with shams (cannulation only) and CPB controls. On day 7, shams and CPB groups showed neither neuronal death nor microglial activation. In contrast, the number of microglia in hippocampus in each individual group (IC, RTpre, RTpost) was decreased with LEC vs. PBS by similar to 34-46% (P < 0.05). Microglial proliferation was attenuated in the IC vs. RT groups (P < 0.05). Neuronal death did not differ between hemispheres or IC vs. RT groups. Thus, intrahippocampal injection of LEC attenuated microglial proliferation by similar to 40%, but did not alter neuronal death. This suggests that microglia may not play a pivotal role in mediating neuronal death in prolonged hypothermic CA. This novel strategy provides us with a tool to study the specific effects of microglia in hypothermic CA. (C) 2011 Elsevier Ireland Ltd. All rights reserved.	[Drabek, Tomas; Janata, Andreas; Jackson, Edwin K.; End, Brad; Stezoski, Jason; Vagni, Vincent A.; Janesko-Feldman, Keri; Wilson, Caleb D.; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Drabek, Tomas] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA 15260 USA; [Janata, Andreas; Tisherman, Samuel A.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Jackson, Edwin K.] Univ Pittsburgh, Dept Pharmacol & Clin Biol, Pittsburgh, PA 15219 USA; [van Rooijen, Nico] Vrije Univ, VUMC, Dept Mol Cell Biol, Fac Med, NL-1081 BT Amsterdam, Netherlands; [Tisherman, Samuel A.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA 15260 USA	Drabek, T (corresponding author), Univ Pittsburgh, Safar Ctr Resuscitat Res, 3434 5th Ave, Pittsburgh, PA 15260 USA.	drabekt@anes.upmc.edu	Van Rooijen, Nico/Z-1578-2019; Kochanek, Patrick M/D-2371-2015; Tisherman, Samuel A./AAK-9377-2020; Drabek, Tomas/AAJ-1595-2021	Kochanek, Patrick M/0000-0002-2627-913X; Tisherman, Samuel A./0000-0003-3810-3729; Drabek, Tomas/0000-0002-5702-4498; Jackson, Edwin/0000-0002-8101-6009	Department of Anesthesiology, University of PittsburghUniversity of Pittsburgh [09BGIA2310196]; Laerdal Foundation for Acute Medicine;  [NS070003];  [NS30318];  [NS38087]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, R21NS070003, P01NS030318, R01NS038087, P50NS030318] Funding Source: NIH RePORTER	This work was supported by the AHA Beginning Grant-in-Aid # 09BGIA2310196 (TD), Society of Cardiovascular Anesthesiologists Starter Grant (TD), a Seed Grant from The Department of Anesthesiology, University of Pittsburgh (TD), by the Laerdal Foundation for Acute Medicine (TD), and by NS070003, NS30318 and NS38087 (PMK).	Barbe E, 1996, J CELL SCI, V109, P2937; Bendel O, 2005, J CEREBR BLOOD F MET, V25, P1586, DOI 10.1038/sj.jcbfm.9600153; BERGH A, 1993, J ENDOCRINOL, V136, P407, DOI 10.1677/joe.0.1360407; Dehghani F, 2004, EXP NEUROL, V189, P241, DOI 10.1016/j.expneurol.2004.06.010; Drabek T, 2007, LIFE SCI, V81, P543, DOI 10.1016/j.lfs.2007.06.015; Drabek T, 2009, ANESTH ANALG, V109, P914, DOI 10.1213/ane.0b013e3181b0511e; Fan LW, 2006, EUR J NEUROSCI, V24, P341, DOI 10.1111/j.1460-9568.2006.04918.x; Fleisch H, 1989, Recent Results Cancer Res, V116, P1; Fox C, 2005, J CEREBR BLOOD F MET, V25, P1138, DOI 10.1038/sj.jcbfm.9600121; Frediani B, 2009, CLIN DRUG INVEST, V29, P359, DOI 10.2165/00044011-200929060-00001; GEHRMANN J, 1995, NEUROPATH APPL NEURO, V21, P277, DOI 10.1111/j.1365-2990.1995.tb01062.x; Gowing G, 2006, GLIA, V53, P331, DOI 10.1002/glia.20288; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hewlett KA, 2006, NEUROSCIENCE, V141, P27, DOI 10.1016/j.neuroscience.2006.03.071; Imai F, 2007, J CEREBR BLOOD F MET, V27, P488, DOI 10.1038/sj.jcbfm.9600362; Ito D, 2001, STROKE, V32, P1208, DOI 10.1161/01.STR.32.5.1208; Ito D, 1998, MOL BRAIN RES, V57, P1, DOI 10.1016/S0169-328X(98)00040-0; Kitamura Y, 2004, J PHARMACOL SCI, V94, P203, DOI 10.1254/jphs.94.203; Koshinaga M, 2007, HISTOL HISTOPATHOL, V22, P129, DOI 10.14670/HH-22.129; Lahoud-Rahme MS, 2009, RESUSCITATION, V80, P484, DOI 10.1016/j.resuscitation.2009.01.007; Lai AY, 2008, GLIA, V56, P259, DOI 10.1002/glia.20610; Lai AY, 2006, CAN J PHYSIOL PHARM, V84, P49, DOI 10.1139/y05-143; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lampl Y, 2007, NEUROLOGY, V69, P1404, DOI 10.1212/01.wnl.0000277487.04281.db; Lehenkari PP, 2002, MOL PHARMACOL, V61, P1255, DOI 10.1124/mol.61.5.1255; Liu JL, 2001, J CEREBR BLOOD F MET, V21, P361, DOI 10.1097/00004647-200104000-00005; Liu ZY, 2007, STROKE, V38, P146, DOI 10.1161/01.STR.0000251791.64910.cd; Marin-Teva JL, 2004, NEURON, V41, P535, DOI 10.1016/S0896-6273(04)00069-8; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; MICKLUS MJ, 1992, BIOCHIM BIOPHYS ACTA, V1124, P7, DOI 10.1016/0005-2760(92)90118-F; Nakajima Kazuyuki, 2004, Curr Drug Targets Cardiovasc Haematol Disord, V4, P65, DOI 10.2174/1568006043481284; Neumann J, 2008, J NEUROSCI, V28, P5965, DOI 10.1523/JNEUROSCI.0060-08.2008; NEUMAR RW, 1995, RESUSCITATION, V29, P249, DOI 10.1016/0300-9572(94)00827-3; Pavlakis N, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003474.pub2; Polfliet MMJ, 2001, J NEUROIMMUNOL, V116, P188, DOI 10.1016/S0165-5728(01)00282-X; Safar P, 2000, CRIT CARE MED, V28, pN214, DOI 10.1097/00003246-200011001-00012; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Schilling M, 2005, EXP NEUROL, V196, P290, DOI 10.1016/j.expneurol.2005.08.004; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Stirling DP, 2005, NEUROSCIENTIST, V11, P308, DOI 10.1177/1073858405275175; Stirling DP, 2004, J NEUROSCI, V24, P2182, DOI 10.1523/JNEUROSCI.5275-03.2004; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; VANROOIJEN N, 1990, CELL TISSUE RES, V260, P215, DOI 10.1007/BF00318625; vanRooijen N, 1996, J IMMUNOL METHODS, V193, P93, DOI 10.1016/0022-1759(96)00056-7; VANROOIJEN N, 1994, J IMMUNOL METHODS, V174, P83; VANROOIJEN N, 1989, J IMMUNOL METHODS, V124, P1, DOI 10.1016/0022-1759(89)90178-6; Wang JZ, 2004, J BIOL CHEM, V279, P19948, DOI 10.1074/jbc.M313629200; Xu L, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-7; Yamashima Tetsumori, 2007, Biotechnology Journal, V2, P596, DOI 10.1002/biot.200600219	50	23	23	0	10	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	APR	2012	83	4					517	526		10.1016/j.resuscitation.2011.09.016			10	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	930OO	WOS:000303149100034	21970817	Green Accepted			2021-06-18	
J	Hatic, H; Kane, MJ; Saykally, JN; Citron, BA				Hatic, Haris; Kane, Michael J.; Saykally, Jessica N.; Citron, Bruce A.			Modulation of Transcription Factor Nrf2 in an In Vitro Model of Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; in vitro studies; model of injury; neuronal cell death; traumatic brain injury	INDUCED CELL-DEATH; REDOX REGULATION; GENE-EXPRESSION; THIOREDOXIN; ACTIVATION; APOPTOSIS; DISEASE; ELEMENT; PATHOPHYSIOLOGY; ASTROCYTES	Traumatic brain injury (TBI) afflicts approximately 1.4 million people in the United States and TBIs have been labeled a major cause of death and disability on a global scale. Regulatory responses in a variety of neuronal loss conditions have supported the protective involvement of the nuclear factor (erythroid-derived 2)-like 2 (Nrf2) transcription factor. Nrf2 regulates antioxidant enzyme genes, and an increase in Nrf2 expression may counteract oxidative damage that results from TBI. Elevated Nrf2 may ultimately act through the upregulation of downstream target genes such as thioredoxin (Trx) and heat-shock protein-70 (HSP70) and this may reduce neuronal loss. We performed multiple mild biaxial stretch injuries to neuroblastoma cells in culture, and examined the effects of the Nrf2 activator, tert-butylhydroquinone (tBHQ). We also compared the stretch injury to oxidative insult. We confirmed that Trx and HSP70 were upregulated by treatment with tBHQ. We observed that tBHQ protected neurons from either insult, and that this was evident by different measures of cell viability and a decrease in annexin V binding. Neuronal health after insult was improved approximately 50% by tBHQ, indicating that neurons exposed to TBI in vitro can be protected.	[Hatic, Haris; Kane, Michael J.; Saykally, Jessica N.; Citron, Bruce A.] Bay Pines VA Healthcare Syst, Mol Biol Lab, Res & Dev 151, Bay Pines, FL 33744 USA; [Saykally, Jessica N.; Citron, Bruce A.] Univ S Florida, Dept Mol Med, Coll Med, Tampa, FL USA	Citron, BA (corresponding author), Bay Pines VA Healthcare Syst, Mol Biol Lab, Res & Dev 151, Bldg 22,Room 123,POB 4125, Bay Pines, FL 33744 USA.	bruce.citron@va.gov			Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development)US Department of Veterans Affairs; Bay Pines Foundation	We would like to thank Vedad Delic, Carrie Butler, and John S. Dennis for technical assistance and useful discussions. This study was supported by the Department of Veterans Affairs (Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development) and the Bay Pines Foundation. The contents do not represent the views of the Department of Veterans Affairs or the United States Government.	Aarskog NK, 2000, HUM GENET, V107, P494, DOI 10.1007/s004390000399; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Arner ESJ, 2000, EUR J BIOCHEM, V267, P6102, DOI 10.1046/j.1432-1327.2000.01701.x; Atkins CM, 2007, EXP NEUROL, V208, P145, DOI 10.1016/j.expneurol.2007.08.011; Borland MK, 2008, MOL NEURODEGENER, V3, DOI 10.1186/1750-1326-3-21; Brooks AR, 2002, PHYSIOL GENOMICS, V9, P27, DOI 10.1152/physiolgenomics.00075.2001; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Calabrese V, 2008, METHOD ENZYMOL, V441, P83, DOI 10.1016/S0076-6879(08)01206-8; Cha MK, 2009, J EXP CLIN CANC RES, V28, DOI 10.1186/1756-9966-28-93; CHIRGWIN JM, 1979, BIOCHEMISTRY-US, V18, P5294, DOI 10.1021/bi00591a005; Dennis JS, 2009, NEUROSCIENCE, V158, P745, DOI 10.1016/j.neuroscience.2008.10.030; Echemendia RJ, 2001, NEUROPSYCHOL REV, V11, P69, DOI 10.1023/A:1016651217141; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Endo H, 2008, ENVIRON HEALTH PERSP, V116, P873, DOI 10.1289/ehp.10696; Ewing-Cobbs L, 1998, BRAIN LANG, V61, P395, DOI 10.1006/brln.1997.1884; Foster JA, 1997, MOL BRAIN RES, V45, P207, DOI 10.1016/S0169-328X(96)00138-6; Gius D, 1999, TOXICOL LETT, V106, P93, DOI 10.1016/S0378-4274(99)00024-7; Greve MW, 2009, MT SINAI J MED, V76, P97, DOI 10.1002/msj.20104; Hattori I, 2002, REDOX REP, V7, P256, DOI 10.1179/135100002125000749; Heneka MT, 2001, J NEUROCHEM, V77, P568, DOI 10.1046/j.1471-4159.2001.00260.x; Hirota K, 1999, J BIOL CHEM, V274, P27891, DOI 10.1074/jbc.274.39.27891; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; HOLMGREN A, 1985, ANNU REV BIOCHEM, V54, P237, DOI 10.1146/annurev.biochem.54.1.237; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Ishii T, 2000, J BIOL CHEM, V275, P16023, DOI 10.1074/jbc.275.21.16023; Jaiswal AK, 2004, FREE RADICAL BIO MED, V36, P1199, DOI 10.1016/j.freeradbiomed.2004.02.074; Jakel RJ, 2007, BRAIN RES, V1144, P192, DOI 10.1016/j.brainres.2007.01.131; Jin W, 2009, J NEUROTRAUM, V26, P131, DOI 10.1089/neu.2008.0655; Kahle KT, 2009, PHYSIOLOGY, V24, P257, DOI 10.1152/physiol.00015.2009; Kane MJ, 2011, BRAIN RES, V1425, P123, DOI 10.1016/j.brainres.2011.09.047; Kane Michael J, 2009, Recent Pat CNS Drug Discov, V4, P190; Kaspar JW, 2009, FREE RADICAL BIO MED, V47, P1304, DOI 10.1016/j.freeradbiomed.2009.07.035; Kelly Stephen, 2002, Curr Med Res Opin, V18 Suppl 2, ps55, DOI 10.1185/030079902125000732; Kim YC, 2001, J BIOL CHEM, V276, P18399, DOI 10.1074/jbc.M100103200; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Li CQ, 2009, P NATL ACAD SCI USA, V106, P14547, DOI 10.1073/pnas.0907539106; Li J, 2005, TOXICOL SCI, V83, P313, DOI 10.1093/toxsci/kfi027; Masutani H, 2005, CELL DEATH DIFFER, V12, P991, DOI 10.1038/sj.cdd.4401625; Meaney DF, 2011, CLIN SPORT MED, V30, P19, DOI 10.1016/j.csm.2010.08.009; Niso-Santano M, 2010, FREE RADICAL BIO MED, V48, P1370, DOI 10.1016/j.freeradbiomed.2010.02.024; Powis G, 2001, ANNU REV BIOPH BIOM, V30, P421, DOI 10.1146/annurev.biophys.30.1.421; Saitoh M, 1998, EMBO J, V17, P2596, DOI 10.1093/emboj/17.9.2596; Shah ZA, 2007, NEUROSCIENCE, V147, P53, DOI 10.1016/j.neuroscience.2007.02.066; Shih AY, 2007, J NEUROCHEM, V101, P109, DOI 10.1111/j.1471-4159.2006.04345.x; Shih AY, 2005, J NEUROSCI, V25, P10321, DOI 10.1523/JNEUROSCI.4014-05.2005; Soundararajan R, 2008, J BIOL CHEM, V283, P2231, DOI 10.1074/jbc.M703583200; TAVARIA M, 1995, GENOMICS, V29, P266, DOI 10.1006/geno.1995.1242; Thurman D, 1999, JAMA-J AM MED ASSOC, V282, P954, DOI 10.1001/jama.282.10.954; Turturici G, 2011, BIOCHEM RES INT, V2011, DOI 10.1155/2011/618127; Ueno M, 1999, J BIOL CHEM, V274, P35809, DOI 10.1074/jbc.274.50.35809; Venugopal R, 1998, ONCOGENE, V17, P3145, DOI 10.1038/sj.onc.1202237; Watson WH, 2004, TOXICOL SCI, V78, P3, DOI 10.1093/toxsci/kfh050; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Zhang Y, 2007, CELL RES, V17, P363, DOI 10.1038/cr.2007.11	56	23	24	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2012	29	6					1188	1196		10.1089/neu.2011.1806			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	927ZL	WOS:000302949100019	22201269				2021-06-18	
J	Page, JL; Macpherson, AK; Middaugh-Bonney, T; Tator, CH				Page, Jessica L.; Macpherson, Alison K.; Middaugh-Bonney, Tara; Tator, Charles H.			Prevalence of helmet use by users of bicycles, push scooters, inline skates and skateboards in Toronto and the surrounding area in the absence of comprehensive legislation: an observational study	INJURY PREVENTION			English	Article								Background Legislation in the province of Ontario, Canada, mandates users under the age of 18 to wear a helmet when they ride a bicycle, and legislation has been shown to significantly increase rates of bicycle helmet use. Legislation does not exist in Ontario for older bicyclists or for users of other non-motorised modes of transportation, and there are no current data available regarding rates of helmet use in these categories. This study was designed to determine the prevalence of helmet use among users of bicycles, skateboards, push scooters and inline skates in Toronto, Ontario, and the surrounding area. Further analysis was performed to examine factors associated with helmet use. Methods We performed a cross-sectional, observational study. Three trained, stationary observers captured 6038 users of bicycles (5783), skateboards (77), inline skates (165) and push scooters (13) in the summer of 2009. Observations were separated into three time periods capturing commuters, midday users and recreational users. A general linear model was used to assess the factors associated with helmet use among bicyclists. Results Helmets were worn by 48.9% of all users observed and 50.0% of all bicyclists. Among bicyclists, females were more likely to wear helmets than males (prevalence ratio 1.27, 95% CI 1.17 to 1.36), while children were significantly more likely to wear helmets than adults (prevalence ratio 1.17, 95% CI 1.37 to 2.15). Significant behavioural variation was observed among users during the three observation periods (p<0.001), with commuters being the most likely to wear a helmet. Conclusion In the absence of comprehensive legislation encompassing all ages of users, only half of users of non-motorised, wheeled transportation devices are choosing to wear a helmet to protect against traumatic brain injury. Implementation of evidence-based strategies to increase helmet use, such as the introduction of legislation encompassing all ages and all equipment, is required.	[Tator, Charles H.] Univ Toronto, Dept Surg, Toronto, ON, Canada; [Page, Jessica L.] Univ Toronto, Fac Med, Toronto, ON, Canada; [Macpherson, Alison K.; Middaugh-Bonney, Tara] York Univ, Sch Kinesiol & Hlth Sci, Toronto, ON M3J 2R7, Canada	Tator, CH (corresponding author), Toronto Western Hosp, 12th Floor Rm 423,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	charles.tator@uhn.on.ca			Ontario Neurotrauma Foundation	This study was made possible by a summer scholarship for JL Page from the Ontario Neurotrauma Foundation. Thank you to Ajay Nadar for his assistance with data collection. Thanks to Dr Marieke Gardner for permitting inclusion of data from her 2006 study.	Adams J, 2001, Inj Prev, V7, P89, DOI 10.1136/ip.7.2.89; Beirness D J, 2001, Inj Prev, V7, P51, DOI 10.1136/ip.7.1.51; Dennis J, 2010, INJURY PREV, V16, P219, DOI 10.1136/ip.2009.025353; Gaines BA, 2004, J TRAUMA, V57, P111, DOI 10.1097/01.TA.0000082156.67895.C8; Hagel BE, 2006, INJURY PREV, V12, P262, DOI 10.1136/ip.2006.012112; Jacobsen PL, 2003, INJURY PREV, V9, P205, DOI 10.1136/ip.9.3.205; Khambalia A, 2005, PEDIATRICS, V116, P939, DOI 10.1542/peds.2005-0518; Macpherson A K, 2001, Inj Prev, V7, P228, DOI 10.1136/ip.7.3.228; Macpherson AK, 2006, INJURY PREV, V12, P231, DOI 10.1136/ip.2005.011379; Macpherson A, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005401.pub3; Rivara F P, 1999, Inj Prev, V5, P194; Robinson DL, 2006, BMJ-BRIT MED J, V332, P722, DOI 10.1136/bmj.332.7543.722-a; Saleh F, 2008, CATASTROPHIC INJURIE, P371; SMARTRISK, 2009, EC BURD INJ CAN, P24; Tator CH, 2008, CATASTROPHIC INJURIE, P79; Thompson DC, 2000, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD001855; Wesson DE, 2008, PEDIATRICS, V122, P605, DOI 10.1542/peds.2007-1776	17	23	23	0	14	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	APR	2012	18	2					94	97		10.1136/injuryprev-2011-040029			4	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	916RD	WOS:000302120000006	21873306				2021-06-18	
J	Bogart, E; Togher, L; Power, E; Docking, K				Bogart, Elise; Togher, Leanne; Power, Emma; Docking, Kimberley			Casual conversations between individuals with traumatic brain injury and their friends	BRAIN INJURY			English	Article						Traumatic brain injury; communication; discourse; conversation; friendship; exchange structure analysis	TRAINING COMMUNICATION PARTNERS; HEAD-INJURY; DISCOURSE; PEOPLE; SKILLS; INFORMATION; IMPACT	Primary objective: To investigate casual conversations with friends following severe traumatic brain injury (TBI). Methods: Nine participants with severe TBI were matched by age, gender and education to nine control participants. Each participant also invited a friend to partake in the study. Participants were recorded engaging in a brief casual conversation with a friend. The resulting discourse was analysed using Exchange Structure Analysis (ESA). Rates of information giving, information requesting and communication repair and negotiation were collated. Non-parametric statistical analyses were performed. Results: Participants with and without TBI obtained similar rates of information giving and information requesting. The friends of the participants with TBI produced significantly lower rates of information giving measures when compared to the controls, but achieved comparable rates of information requesting and communication repair and negotiation measures. Participants with TBI were observed to produce tangential language and to have difficulties identifying communication breakdown, asking questions and engaging in conversational joking. Conclusions: People with TBI are able to engage in casual conversations with friends in a similar way to matched controls. Friends of people with TBI are often restricted in contributing information in conversations. Further research is needed to specify the facilitative and restrictive communication behaviours so that they may be translated to clinical practise.	[Bogart, Elise; Togher, Leanne; Power, Emma; Docking, Kimberley] Univ Sydney, Fac Hlth Sci, Discipline Speech Pathol, Lidcombe, NSW 2141, Australia	Bogart, E (corresponding author), Univ Sydney, Fac Hlth Sci, Discipline Speech Pathol, C42 Cumberland Campus, Lidcombe, NSW 2141, Australia.	elise.bogart@sydney.edu.au	Power, Emma/A-9263-2015; Togher, Leanne/AAC-7083-2019	Power, Emma/0000-0002-2638-0406; Togher, Leanne/0000-0002-4518-6748			Adamovich B. B., 1992, SCALES COGNITIVE ABI; ALEXANDER MP, 1989, BRAIN LANG, V37, P656, DOI 10.1016/0093-934X(89)90118-1; Argyrous G, 2005, STAT RES GUIDE SPSS; Boles L, 1998, APHASIOLOGY, V12, P547, DOI 10.1080/02687039808249557; Bond F, 1997, BRAIN INJURY, V11, P319, DOI 10.1080/026990597123476; Brown Penelope, 1987, POLITENESS SOME UNIV, DOI [10.1017/CBO9780511813085, DOI 10.2307/3587263]; Coelho C. A., 2002, APHASIOLOGY, V16, P659, DOI [10.1080/02687030244000275, DOI 10.1080/02687030244000275]; Coelho CA, 2003, APHASIOLOGY, V17, P499, DOI 10.1080/02687030344000111; Coelho Carl, 2005, Seminars in Speech and Language, V26, P223, DOI 10.1055/s-2005-922102; Coelho Carl A., 2007, Seminars in Speech and Language, V28, P122, DOI 10.1055/s-2007-970570; Correll A, 2010, APHASIOLOGY, V24, P612, DOI 10.1080/02687030902732752; FLANAGAN S, 1995, BRAIN INJURY, V9, P321, DOI 10.3109/02699059509005773; Friedland D, 1998, BRAIN INJURY, V12, P1, DOI 10.1080/026990598122818; Godfrey HPD, 2000, APHASIOLOGY, V14, P433, DOI 10.1080/026870300401441; Halliday M., 1994, INTRO FUNCTIONAL GRA, V3rd; HARTLEY L L, 1991, Brain Injury, V5, P267, DOI 10.3109/02699059109008097; HARTLEY L L, 1992, Brain Injury, V6, P271, DOI 10.3109/02699059209029669; HUNT KW, 1970, MONOGR SOC RES CHILD, V35, P1; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jorgensen M, 2009, BRAIN INJURY, V23, P727, DOI 10.1080/02699050903133954; Kalpakjian CZ, 2004, AM J PHYS MED REHAB, V83, P255, DOI 10.1097/01.PHM.0000118033.07952.8C; Kilov AM, 2009, APHASIOLOGY, V23, P584, DOI 10.1080/02687030701855382; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Larkins B, 1999, ASIA PACIFIC J SPEEC, V4, P183; MCDONALD S, 1993, BRAIN LANG, V44, P28, DOI 10.1006/brln.1993.1003; McDonald S, 1999, COMMUNICATION DISORD; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Perneger TV, 1998, BRIT MED J, V316, P1236, DOI 10.1136/bmj.316.7139.1236; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Portney LG, 2009, FDN CLIN RES APPL PR; Poynton C., 1985, LANGUAGE GENDER MAKI; PRUTTING CA, 1987, J SPEECH HEAR DISORD, V52, P105, DOI 10.1044/jshd.5202.105; Rowlands A., 2000, BRAIN IMPAIR, V1, P151, DOI [10.1375/brim.1.2.151, DOI 10.1375/BRIM.1.2.151]; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Simmons-Mackie N, 2002, APHASIOLOGY, V16, P837, DOI 10.1080/02687030244000185; Snow P, 1998, BRAIN INJURY, V12, P911, DOI 10.1080/026990598121981; SPSS Inc, 2008, SPSS STAT REL 17 0 1; Tannen Deborah, 2005, CONVERSATIONAL STYLE; Tate RL, 1998, AUST NZ J PUBL HEAL, V22, P419, DOI 10.1111/j.1467-842X.1998.tb01406.x; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; Togher L, 1997, BRAIN INJURY, V11, P169, DOI 10.1080/026990597123629; Togher L, 1998, APHASIOLOGY, V12, P755, DOI 10.1080/02687039808249571; Togher L, 1996, DISABIL REHABIL, V18, P559, DOI 10.3109/09638289609166317; Togher L, 2000, APHASIOLOGY, V14, P365, DOI 10.1080/026870300401414; Togher L, 2004, APHASIOLOGY, V18, P313, DOI 10.1080/02687030344000535; TOGHER L, 2006, BRAIN IMPAIR, V7, P190, DOI DOI 10.1375/brim.7.3.190; Togher L, 2009, BRAIN IMPAIR, V10, P188, DOI 10.1375/brim.10.2.188; Van Leer E, 1999, J COMMUN DISORD, V32, P327, DOI 10.1016/S0021-9924(99)00008-8; VENTOLA E, 1979, J PRAGMATICS, V3, P267, DOI 10.1016/0378-2166(79)90034-1	49	23	23	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	MAR	2012	26	3					221	233		10.3109/02699052.2011.648711			13	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	899XD	WOS:000300849100003	22372410				2021-06-18	
J	Dahlin, AP; Hjort, K; Hillered, L; Sjodin, MOD; Bergquist, J; Wetterhall, M				Dahlin, Andreas P.; Hjort, Klas; Hillered, Lars; Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus			Multiplexed quantification of proteins adsorbed to surface-modified and non-modified microdialysis membranes	ANALYTICAL AND BIOANALYTICAL CHEMISTRY			English	Article						Microdialysis; On-surface enzymatic digestion (oSED); Mass spectrometry (MS); Cerebrospinal fluid (CSF); Interface/surface analysis; Tri-block copolymer surface modification	TRAUMATIC BRAIN-INJURY; HUMAN VENTRICULAR CSF; PROTEOMIC ANALYSIS; CEREBRAL MICRODIALYSIS; DIALYSIS MEMBRANES; SOLID-SURFACES; ADSORPTION; HEMODIALYSIS; POLYSULFONE; ACTIVATION	A simple and straightforward method for discovery and quantification of proteins adsorbed onto delicate and sensitive membrane surfaces is presented. The adsorbed proteins were enzymatically cleaved while still adsorbed onto the membranes using an on-surface enzymatic digestion (oSED). This was followed by isobaric tagging, nanoliquid chromatography, and tandem mass spectrometry. Protein adsorption on tri-block copolymer Poloxamer 407 surface-modified microdialysis (MD) membranes were compared with protein adsorption on unmodified MD membranes. Ventricular cerebrospinal fluid (vCSF) kept at 37 A degrees C was used as sample matrix. In total, 19 proteins were quantified in two biological replicates. The surface-modified membranes adsorbed 33% less proteins than control membranes and the most abundant proteins were subunits of hemoglobin and clusterin. The adsorption of clusterin on the modified membranes was on average 36% compared to control membranes. The most common protein in vCSF, Albumin, was not identified adsorbed to the surface at all. It was also experimentally verified that oSED, in conjunction with tandem mass spectrometry can be used to quantify femtomole amounts of proteins adsorbed on limited and delicate surfaces, such as MD membranes. The method has great potential and can be used to study much more complex protein adsorption systems than previously reported.	[Dahlin, Andreas P.; Hjort, Klas] Uppsala Univ, Dept Engn Sci, S-75121 Uppsala, Sweden; [Hillered, Lars] Uppsala Univ, Dept Neurosci, Div Neurosurg, Univ Uppsala Hosp, S-75185 Uppsala, Sweden; [Sjodin, Marcus O. D.; Bergquist, Jonas; Wetterhall, Magnus] Uppsala Univ, Dept Phys & Analyt Chem, SE-75124 Uppsala, Sweden	Dahlin, AP (corresponding author), Uppsala Univ, Dept Engn Sci, Box 534, S-75121 Uppsala, Sweden.	Andreas.Dahlin@angstrom.uu.se	Bergquist, Jonas/C-5894-2015	Dahlin, Andreas/0000-0002-0041-0902; Hillered, Lars/0000-0002-2808-9292; Bergquist, Jonas/0000-0002-4597-041X	Uppsala Berzelii Technology Centre for Neurodiagnostics; Swedish Governmental Agency for Innovation SystemsVinnova; Swedish Research CouncilSwedish Research CouncilEuropean Commission [P29797-1, 621-2008-3562]; Swedish Brain Foundation; Selander Foundation; Ahlen Foundation; Uppsala University Hospital	This study was supported by Uppsala Berzelii Technology Centre for Neurodiagnostics, with financing from the Swedish Governmental Agency for Innovation Systems and the Swedish Research Council Grant number P29797-1, 621-2008-3562, the Swedish Brain Foundation, the Selander Foundation, the Ahlen Foundation and the Uppsala University Hospital. We acknowledge CMA Microdialysis for material support.	Anderson JM, 2008, SEMIN IMMUNOL, V20, P86, DOI 10.1016/j.smim.2007.11.004; Bonomini M, 2006, J PROTEOME RES, V5, P2666, DOI 10.1021/pr060150u; Bruce SJ, 2009, ANAL CHEM, V81, P3285, DOI 10.1021/ac8024569; Currie EPK, 2003, ADV COLLOID INTERFAC, V100, P205, DOI 10.1016/S0001-8686(02)00061-1; Dahlin AP, 2010, ANAL CHEM, V82, P4376, DOI 10.1021/ac1007706; Dumortier G, 2006, PHARM RES-DORDR, V23, P2709, DOI 10.1007/s11095-006-9104-4; Hanrieder J, 2009, J NEUROSCI METH, V177, P469, DOI 10.1016/j.jneumeth.2008.10.038; Helmy A, 2009, J NEUROTRAUM, V26, P549, DOI 10.1089/neu.2008.0719; Hillered L, 2006, CURR OPIN CRIT CARE, V12, P112, DOI 10.1097/01.ccx.0000216576.11439.df; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; Ishikawa I, 2006, AM J NEPHROL, V26, P372, DOI 10.1159/000094779; Mares J, 2009, KIDNEY INT, V76, P404, DOI 10.1038/ki.2009.138; Mares J, 2009, J PROTEOME RES, V8, P1756, DOI 10.1021/pr800966w; Nakanishi K, 2001, J BIOSCI BIOENG, V91, P233, DOI 10.1016/S1389-1723(01)80127-4; NORDE W, 1986, ADV COLLOID INTERFAC, V25, P267, DOI 10.1016/0001-8686(86)80012-4; Rabe M, 2011, ADV COLLOID INTERFAC, V162, P87, DOI 10.1016/j.cis.2010.12.007; ROSENBERG ME, 1995, INT J BIOCHEM CELL B, V27, P633, DOI 10.1016/1357-2725(95)00027-M; Ross PL, 2004, MOL CELL PROTEOMICS, V3, P1154, DOI 10.1074/mcp.M400129-MCP200; Sjodin MOD, 2010, J CHROMATOGR B, V878, P2003, DOI 10.1016/j.jchromb.2010.05.036; Stenken JA, 2010, AAPS J, V12, P73, DOI 10.1208/s12248-009-9163-7; Wang XT, 2011, J BIOMAT SCI-POLYM E, V22, P1343, DOI 10.1163/092050610X508400; Wetterhall M, 2010, J CHROMATOGR B, V878, P1519, DOI 10.1016/j.jchromb.2010.04.003; Wisniewski N, 2001, J BIOMED MATER RES, V57, P513, DOI 10.1002/1097-4636(20011215)57:4<513::AID-JBM1197>3.0.CO;2-E	23	23	23	0	24	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	1618-2642			ANAL BIOANAL CHEM	Anal. Bioanal. Chem.	FEB	2012	402	6					2057	2067		10.1007/s00216-011-5614-y			11	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	892TL	WOS:000300308400008	22159469				2021-06-18	
J	Di Liberto, V; Makela, J; Korhonen, L; Olivieri, M; Tselykh, T; Malkia, A; Thi, HD; Belluardo, N; Lindholm, D; Mudo, G				Di Liberto, Valentina; Makela, Johanna; Korhonen, Laura; Olivieri, Melania; Tselykh, Timofey; Malkia, Annika; Hai Do Thi; Belluardo, Natale; Lindholm, Dan; Mudo, Giuseppa			Involvement of estrogen receptors in the resveratrol-mediated increase in dopamine transporter in human dopaminergic neurons and in striatum of female mice	NEUROPHARMACOLOGY			English	Article						RSV; Striatum; Dopaminergic neurons; DAT; Antiestrogen; Gene expression	RAT-BRAIN; MONOAMINE TRANSPORTERS; BETA IMMUNOREACTIVITY; DEPENDENT REGULATION; CELL-PROLIFERATION; ALZHEIMERS-DISEASE; SUBSTANTIA-NIGRA; UPTAKE SITES; PC12 CELLS; ER-ALPHA	Treatment with resveratrol (RSV) has been shown to protect vulnerable neurons after various brain injuries and in neurodegenerative diseases. The mechanisms for the effects of RSV in brain are not fully understood, but RSV may affect the expression of various gene products. RSV is structurally related to the synthetic estrogen, diethylstilbestrol so the effects of RSV may be gender-specific. Here we studied the role of RSV in the regulation of dopamine transporter (DAT) in the striatum using male and female mice. The basic levels of DAT in the striatum showed no sex difference, but the levels increased significantly by RSV (20 mg/kg i.p.) in female but not in male mice. Pretreatment of mice with the selective estrogen receptor (ER), ER alpha- and ER beta antagonist ICI 182,780, led to a complete block of RSV effect on DAT protein levels, suggesting that ERs are involved in the up-regulation of DAT by RSV. Similar data was also obtained in culture using human MESC2.10 and mouse SN4741 dopaminergic cells after treatment with RSV. Data further showed that RSV specifically induced gene transcription of DAT in the dopaminergic cells. These results show that estrogen receptors are involved in the up-regulation of DAT by RSV in the dopaminergic neurons, demonstrating a sex-dependent effect of RSV in the brain that may be of clinical importance. This article is part of a Special Issue entitled 'Post-Traumatic Stress Disorder'. (C) 2011 Elsevier Ltd. All rights reserved.	[Di Liberto, Valentina; Olivieri, Melania; Belluardo, Natale; Mudo, Giuseppa] Univ Palermo, Dept Expt Biomed & Clin Neurosci, Div Human Physiol, Mol Neurobiol Lab, IT-90134 Palermo, Italy; [Makela, Johanna; Korhonen, Laura; Tselykh, Timofey; Hai Do Thi; Lindholm, Dan] Univ Helsinki, Inst Biomed Biochem & Dev Biol, FIN-00014 Helsinki, Finland; [Tselykh, Timofey; Malkia, Annika; Hai Do Thi; Lindholm, Dan] Biomedicum 2 Helsinki, Minerva Med Res Inst, Helsinki, Finland	Mudo, G (corresponding author), Univ Palermo, Dept Expt Biomed & Clin Neurosci, Div Human Physiol, Mol Neurobiol Lab, Corso Tukory 129, IT-90134 Palermo, Italy.	giuseppa.mudo@unipa.it	Mudo', Giuseppa/G-7408-2011; Lindholm, Dan/B-3777-2014; Korhonen, Laura/AAW-3256-2020	Mudo', Giuseppa/0000-0002-3275-9981; Di Liberto, Valentina/0000-0002-8574-0061	Academy of FinlandAcademy of FinlandEuropean Commission; Sigrid Juselius FoundationSigrid Juselius Foundation; Finska Lakaresallskapet; Liv och Halsa; Finnish Parkinson Foundation; Minerva Foundation; Progetti di Ateneo (Universita di Palermo); Ateneo of Palermo	We thank J Lotharius and P Brundin for human MESC2.10, J Son and E Arenas for mouse SN4741 cells, and E. Lehto for skillful technical assistance. Supported by the Academy of Finland, Sigrid Juselius Foundation, Finska Lakaresallskapet, Liv och Halsa, The Finnish Parkinson Foundation, Minerva Foundation, and Progetti di Ateneo (Universita di Palermo). DLV and OM are supported by Ateneo of Palermo.	Anekonda TS, 2006, BRAIN RES REV, V52, P316, DOI 10.1016/j.brainresrev.2006.04.004; Anekonda TS, 2006, J NEUROCHEM, V96, P305, DOI 10.1111/j.1471-4159.2005.03492.x; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Baur JA, 2006, NAT REV DRUG DISCOV, V5, P493, DOI 10.1038/nrd2060; Beyer C, 2002, J STEROID BIOCHEM, V81, P319, DOI 10.1016/S0960-0760(02)00119-X; Blanchet J, 2008, PROG NEURO-PSYCHOPH, V32, P1243, DOI 10.1016/j.pnpbp.2008.03.024; Bosse R, 1997, MOL BRAIN RES, V46, P343, DOI 10.1016/S0169-328X(97)00082-X; Bowers JL, 2000, ENDOCRINOLOGY, V141, P3657, DOI 10.1210/en.141.10.3657; Brannvall K, 2002, MOL CELL NEUROSCI, V21, P512, DOI 10.1006/mcne.2002.1194; Chen C, 2000, ARCH PHARM RES, V23, P605, DOI 10.1007/BF02975249; Creutz LM, 2002, J COMP NEUROL, V446, P288, DOI 10.1002/cne.10207; Currie LJ, 2004, ARCH NEUROL-CHICAGO, V61, P886, DOI 10.1001/archneur.61.6.886; DAUVOIS S, 1993, J CELL SCI, V106, P1377; Dluzen D E, 2000, J Gend Specif Med, V3, P36; Dore S, 2005, NEUROSIGNALS, V14, P61, DOI 10.1159/000085386; Edwards DP, 2005, ANNU REV PHYSIOL, V67, P335, DOI 10.1146/annurev.physiol.67.040403.120151; El-Mowafy AM, 2002, MED PRIN PRACT, V11, P86, DOI 10.1159/000058013; Erixon-Lindroth N, 2005, PSYCHIAT RES-NEUROIM, V138, P1, DOI 10.1016/j.pscychresns.2004.09.005; Gainetdinov RR, 2003, ANNU REV PHARMACOL, V43, P261, DOI 10.1146/annurev.pharmtox.43.050802.112309; Garcia-Segura LM, 2001, PROG NEUROBIOL, V63, P29, DOI 10.1016/S0301-0082(00)00025-3; Gardiner SA, 2004, AM J GERIAT PSYCHIAT, V12, P621, DOI 10.1176/appi.ajgp.12.6.621; Gehm BD, 1997, P NATL ACAD SCI USA, V94, P14138, DOI 10.1073/pnas.94.25.14138; Gelinas S, 2002, J NEUROSCI RES, V70, P90, DOI 10.1002/jnr.10315; Hong SH, 2010, REPROD TOXICOL, V30, P469, DOI 10.1016/j.reprotox.2010.04.009; Howell A, 2000, CANCER, V89, P817, DOI 10.1002/1097-0142(20000815)89:4<817::AID-CNCR14>3.0.CO;2-6; Hulley SB, 2004, JAMA-J AM MED ASSOC, V291, P1769, DOI 10.1001/jama.291.14.1769; Jeng Yow-Jiun, 2009, J Mol Signal, V4, P2, DOI 10.1186/1750-2187-4-2; Jordan VC, 2003, J MED CHEM, V46, P1081, DOI 10.1021/jm020450x; Jourdain S, 2005, J NEUROENDOCRINOL, V17, P509, DOI 10.1111/j.1365-2826.2005.01337.x; Kairisalo M, 2011, NEUROSCI LETT, V488, P263, DOI 10.1016/j.neulet.2010.11.042; Klinge CM, 2005, J BIOL CHEM, V280, P7460, DOI 10.1074/jbc.M411565200; Koh SH, 2003, MOL BRAIN RES, V118, P72, DOI 10.1016/j.molbrainres.2003.07.003; Korhonen L, 2001, MOL CELL NEUROSCI, V17, P364, DOI 10.1006/mcne.2000.0935; Krishnan V, 2000, Vitam Horm, V60, P123, DOI 10.1016/S0083-6729(00)60018-3; Kuiper GGJM, 1998, ENDOCRINOLOGY, V139, P4252, DOI 10.1210/en.139.10.4252; Kurian MA, 2009, J CLIN INVEST, V119, P1595, DOI 10.1172/JCI39060; Laflamme N, 1998, J NEUROBIOL, V36, P357, DOI 10.1002/(SICI)1097-4695(19980905)36:3<357::AID-NEU5>3.0.CO;2-V; LANGCAKE P, 1977, EXPERIENTIA, V33, P151, DOI 10.1007/BF02124034; Le Saux M, 2006, J NEUROENDOCRINOL, V18, P25, DOI 10.1111/j.1365-2826.2005.01380.x; Levites Y, 2003, FASEB J, V17, P952, DOI 10.1096/fj.02-0881fje; Li LB, 2004, J BIOL CHEM, V279, P21012, DOI 10.1074/jbc.M311972200; Lotharius J, 2002, J BIOL CHEM, V277, P38884, DOI 10.1074/jbc.M205518200; Maggiolini M, 2010, J ENDOCRINOL, V204, P105, DOI 10.1677/JOE-09-0242; MORISSETTE M, 1993, J NEUROCHEM, V60, P1876, DOI 10.1111/j.1471-4159.1993.tb13415.x; MORISSETTE M, 1990, BRAIN RES BULL, V25, P419, DOI 10.1016/0361-9230(90)90231-N; Mueller SO, 2004, TOXICOL SCI, V80, P14, DOI 10.1093/toxsci/kfh147; Okawara M, 2007, BIOCHEM PHARMACOL, V73, P550, DOI 10.1016/j.bcp.2006.11.003; Patrone C, 1999, P NATL ACAD SCI USA, V96, P10905, DOI 10.1073/pnas.96.19.10905; Pedram A, 2002, J BIOL CHEM, V277, P50768, DOI 10.1074/jbc.M210106200; Peng J, 2009, ANTI-CANCER AGENT ME, V9, P481, DOI 10.2174/187152009788451833; Pozo-Guisado E, 2004, INT J CANCER, V109, P167, DOI 10.1002/ijc.11720; Ramassamy C, 2006, EUR J PHARMACOL, V545, P51, DOI 10.1016/j.ejphar.2006.06.025; Robb EL, 2011, FREE RADICAL BIO MED, V50, P821, DOI 10.1016/j.freeradbiomed.2010.12.038; Shimizu T, 2006, BIOCHEM PHARMACOL, V71, P742, DOI 10.1016/j.bcp.2005.12.018; Shughrue PJ, 1997, J COMP NEUROL, V388, P507, DOI 10.1002/(SICI)1096-9861(19971201)388:4<507::AID-CNE1>3.0.CO;2-6; Sokka AL, 2007, J NEUROSCI, V27, P901, DOI 10.1523/JNEUROSCI.4289-06.2007; Son JH, 1999, J NEUROSCI, V19, P10; Van den Bemd GJCM, 1999, BIOCHEM BIOPH RES CO, V261, P1, DOI 10.1006/bbrc.1999.0864; Wang Q, 2002, BRAIN RES, V958, P439, DOI 10.1016/S0006-8993(02)03543-6; Watson Cheryl S, 2006, J Mol Signal, V1, P5, DOI 10.1186/1750-2187-1-5; Wu F, 2008, J STEROID BIOCHEM, V110, P104, DOI 10.1016/j.jsbmb.2008.02.008; Yen GC, 2003, FREE RADICAL RES, V37, P509, DOI 10.1080/1071576031000083099; Zhang JQ, 2002, BRAIN RES, V935, P73, DOI 10.1016/S0006-8993(02)02460-5	63	23	24	0	7	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3908	1873-7064		NEUROPHARMACOLOGY	Neuropharmacology	FEB	2012	62	2					1011	1018		10.1016/j.neuropharm.2011.10.010			8	Neurosciences; Pharmacology & Pharmacy	Neurosciences & Neurology; Pharmacology & Pharmacy	909FZ	WOS:000301549300051	22041555				2021-06-18	
J	Murphy, JC; Gissane, C; Blake, C				Murphy, John C.; Gissane, Conor; Blake, Catherine			Injury in elite county-level hurling: a prospective study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							PROFESSIONAL RUGBY UNION; ICE HOCKEY INJURIES; DESCRIPTIVE EPIDEMIOLOGY; SURVEILLANCE SYSTEM; GAELIC FOOTBALL; SPORTS INJURIES; HAND INJURIES; NEW-ZEALAND; LEAGUE; PREVENTION	Objective To determine the incidence, prevalence and nature of sports injuries in elite male hurling players. Design Prospective study of county-grade hurling teams. Incidence, prevalence and descriptions of injuries were collated. Setting Four county teams during the 2007 season; January to September inclusive. Participants A total of 127 male players were followed over 34 weeks. Data were collected on a median (IQR) of 31 (30-32) players per team per week. The mean age was 23.3 +/- 2.5 years. Results There were 204 injuries to 104 players (82%, 95% CI (74 to 88)). Injury incidence rate during match-play (102.5 (84.4 to 123.2)) was 19 times higher than for training (5.3 (4.2 to 6.5)) (RR=19.5 (14.8 to 25.6)). The mean weekly prevalence of injury was 13.9% (12.5 to 14.8). Most injuries were new (n=170, 83.3%, (77.6 to 87.8)) and acute (n=165, 80.9% (74.9 to 85.7)). Muscle strain (n=86) accounted for 42.2% (35.6 to 49) of the total. 71% of injuries were to the lower limb (n=143, (63.5 to 76.0)) with hamstring strain (n=33, 16.5% (11.8 to 21.8)) predominating. Fractures constituted 7.4% injuries (n=15, 95% CI (4.5 to 11.8)), 12 of which were to the upper limb. There were three (1.5% (0.5 to 4.2)) eye injuries and one concussion injury (0.5% (0.1 to 2.7)). Conclusions These results provide data on hurling injuries using definitions that reflect international consensus statements. Injury incidence from match-play in particular is high compared with other sports. These findings have relevance for clinicians and coaches.	[Blake, Catherine] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Hlth Sci Ctr, Dublin 4, Ireland; [Murphy, John C.] Gael Athlet Assoc, Med Sci Comm, Dublin, Ireland; [Gissane, Conor] St Marys Univ Coll, Twickenham, England	Blake, C (corresponding author), Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Hlth Sci Ctr, Room A1-03, Dublin 4, Ireland.	c.blake@ucd.ie	Gissane, Conor/I-3661-2019; Blake, Catherine/M-6728-2016	Gissane, Conor/0000-0003-4677-3853; Blake, Catherine/0000-0002-0600-629X	Gaelic Athletic Association	Gaelic Athletic Association.	Agel J, 2007, J ATHL TRAINING, V42, P241; [Anonymous], 2007, SPSS 16 WIND REL 15; [Anonymous], VRP INJ SOFTW; Brooks JHM, 2005, BRIT J SPORT MED, V39, P757, DOI 10.1136/bjsm.2005.018135; Brooks JHM, 2005, BRIT J SPORT MED, V39, P767, DOI 10.1136/bjsm.2005.018408; BRYANT T, 2000, CONFIDENCE INTERVAL; Crowley P J, 1989, Br J Sports Med, V23, P183; CUDDIHY B, 1990, IRISH MED J, V83, P98; Dick R, 2007, J ATHL TRAINING, V42, P255; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Finch C, 2006, J SCI MED SPORT, V9, P3, DOI 10.1016/j.jsams.2006.02.009; Flynn TH, 2005, BRIT J SPORT MED, V39, P493, DOI 10.1136/bjsm.2004.013102; Fuller CW, 2008, BRIT J SPORT MED, V42, P452, DOI 10.1136/bjsm.2008.047035; GAA, 2009, OFF GUID 2; Kiely PD, 2003, INJURY, V34, P561, DOI 10.1016/S0020-1383(02)00050-5; King DA, 2009, CLIN J SPORT MED, V19, P277, DOI 10.1097/JSM.0b013e3181a7c6b0; Kuzuhara K, 2009, J ATHL TRAINING, V44, P208, DOI 10.4085/1062-6050-44.2.208; McIntyre MC, 2005, BRIT J SPORT MED, V39, P437, DOI 10.1136/bjsm.2004.013631; McLean JG, 1989, BRIT J SPORT MED, V23, P179; Newell M, 2006, Ir Med J, V99, P269; O'Connor K, 2006, Ir Med J, V99, P17; Orchard J, 2002, BRIT J SPORT MED, V36, P39, DOI 10.1136/bjsm.36.1.39; ORCHARD J, 1993, SPORT HLTH, V11, P39; OSULLIVAN ME, 1989, IRISH J MED SCI, V158, P79, DOI 10.1007/BF02942110; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Timpka T, 2007, SCAND J MED SCI SPOR, V17, P636, DOI 10.1111/j.1600-0838.2006.00623.x; Timpka T, 2002, MED SCI SPORT EXER, V34, P993, DOI 10.1097/00005768-200206000-00014; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Watson AWS, 1996, AM J SPORT MED, V24, P323, DOI 10.1177/036354659602400313; Watson AWS, 1999, J SPORT MED PHYS FIT, V39, P66; Wilson F, 2007, BRIT J SPORT MED, V41, P317, DOI 10.1136/bjsm.2006.033167	32	23	23	2	16	B M J PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	FEB	2012	46	2					138	142		10.1136/bjsm.2010.072132			5	Sport Sciences	Sport Sciences	879CY	WOS:000299308500014	20961917				2021-06-18	
J	Song, Y; Bi, L; Zhang, ZY; Huang, ZS; Hou, W; Lu, X; Sun, PX; Han, YS				Song, Yang; Bi, Long; Zhang, Zhenyu; Huang, Zhaosong; Hou, Wei; Lu, Xu; Sun, Pengxiao; Han, Yisheng			Increased levels of calcitonin gene-related peptide in serum accelerate fracture healing following traumatic brain injury	MOLECULAR MEDICINE REPORTS			English	Article						calcitonin gene-related peptide; traumatic brain injury; fracture healing	CEREBROSPINAL-FLUID; HEAD-INJURY; MODEL; BONE; RATS	The mechanisms responsible for the phenomenon of an accelerated speed of fracture healing in patients with traumatic brain injury (TBI) remain unclear. The present study was performed to test the hypothesis that TBI causes changes in calcitonin gene-related peptide (CGRP) levels in sera that enhance fracture healing. A standard closed femoral fracture was produced in rats, which were subjected to additional closed head trauma. The fracture healing was assessed 4 and 8 weeks later using micro-CT. Sera, brain tissues and muscles surrounding the fracture sites collected at 24,48, 72 and 168 h after injury were used to detect the expression of CGRP using ELISA, immunohistochemistry and RT-PCR. Micro-CT demonstrated that fracture healing and mineralization in the TBI-fracture group occurred earlier compared to the fracture-only group. ELISA analysis revealed a high concentration of CGRP in the TBI-fracture group (P<0.05), and immunohistochemistry assay and RT-PCR analysis revealed a significant increase in CGRP in the brain and muscle of the TBI-fracture group at 168 h after fracture (P<0.001). Our results indicate that the mechanism for the enhancement of fracture-healing secondary to traumatic brain injury is correlated to the high levels of CGRP, which may be released from the brain tissue into the serum.	[Song, Yang; Bi, Long; Zhang, Zhenyu; Huang, Zhaosong; Hou, Wei; Lu, Xu; Sun, Pengxiao; Han, Yisheng] Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China	Han, YS (corresponding author), Fourth Mil Med Univ, Xijing Hosp, Dept Orthoped, Xian 710032, Peoples R China.	yishenghan@hotmail.com			NSF of ChinaNational Natural Science Foundation of China (NSFC) [30872634, 30901532]	This study was supported by the NSF of China (Grant no. 30872634 and no. 30901532).	Arrieta-Cruz I, 2007, EXP NEUROL, V205, P449, DOI 10.1016/j.expneurol.2007.03.005; Banerjee Sugato, 2006, BMC Pharmacology, V6, P9, DOI 10.1186/1471-2210-6-9; BIDNER SM, 1990, J BONE JOINT SURG AM, V72A, P1144, DOI 10.2106/00004623-199072080-00004; Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; BONNARENS F, 1984, Journal of Orthopaedic Research, V2, P97, DOI 10.1002/jor.1100020115; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gangula PRR, 2000, BIOL REPROD, V62, P1033, DOI 10.1095/biolreprod62.4.1033; Gautschi OP, 2007, J NEUROTRAUM, V24, P154, DOI 10.1089/neu.2006.0166; Gautschi OP, 2009, ANZ J SURG, V79, P449, DOI 10.1111/j.1445-2197.2008.04803.x; Harzenetter MD, 2007, J IMMUNOL, V179, P607, DOI 10.4049/jimmunol.179.1.607; HOLLAND JP, 1994, STROKE, V25, P2055, DOI 10.1161/01.STR.25.10.2055; Huebner AK, 2008, ARCH BIOCHEM BIOPHYS, V473, P210, DOI 10.1016/j.abb.2008.02.013; Imai S, 2002, MICROSC RES TECHNIQ, V58, P61, DOI 10.1002/jemt.10119; Jones Kevin B, 2004, Iowa Orthop J, V24, P123; Klein BY, 1999, CALCIFIED TISSUE INT, V65, P217, DOI 10.1007/s002239900686; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Shih C, 1997, CLIN ORTHOP RELAT R, P335; Tanaka S, 2009, J CLIN INVEST, V119, P2879, DOI 10.1172/JCI40629; Valentijn K, 1997, BONE, V21, P269, DOI 10.1016/S8756-3282(97)00142-7; Vignery A, 1996, BONE, V18, P331, DOI 10.1016/8756-3282(96)00017-8	22	23	29	0	9	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997			MOL MED REP	Mol. Med. Rep.	FEB	2012	5	2					432	438		10.3892/mmr.2011.645			7	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	871DA	WOS:000298716900025	22038198	Bronze			2021-06-18	
J	Egede, LE; Dismuke, C; Echols, C				Egede, Leonard E.; Dismuke, Clara; Echols, Carrae			Racial/Ethnic Disparities in Mortality Risk Among US Veterans With Traumatic Brain Injury	AMERICAN JOURNAL OF PUBLIC HEALTH			English	Article							HEALTH-CARE-SYSTEM; RACIAL DISPARITIES; ETHNIC DISPARITIES; FUNCTIONAL OUTCOMES; ADMINISTRATIVE DATA; REHABILITATION; RACE; MODERATE; COHORT	Objectives. We examined the association of race/ethnicity with mortality risk in a national cohort of US veterans clinically diagnosed with traumatic brain injury. Methods. Between January 1, 2006 and December 31, 2006, we obtained data from a national cohort study of 7885 non-Hispanic White, 1748 Non-Hispanic Black, 314 Hispanic, and 4743 other or missing race/ethnicity veterans clinically diagnosed with traumatic brain injury in Veterans Affairs medical centers and community-based outpatient clinics. Results. Overall mortality at 48 months was 6.7% in Hispanic, 2.9% in non-Hispanic White, and 2.7% in non-Hispanic Black veterans. Compared with non-Hispanic White, Hispanic ethnicity was positively associated with a higher mortality risk (hazard ratio [HR]=2.33; 95% confidence interval [CI]=1.49, 3.64) in the race/ethnicity-only adjusted model. After adjusting for sociodemographic characteristics and comorbidities, Hispanic ethnicity continued to be positively associated (HR=1.61; 95% CI=1.00, 2.58) with a higher mortality risk relative to non-Hispanic White ethnicity. Conclusions. Hispanic ethnicity is positively associated with higher mortality risk among veterans clinically diagnosed with traumatic brain injury. More research is needed to understand the reasons for this disparity. (Am J Public Health. 2011;102:S266-S271. doi:10.2105/AJPH.2011.300176)	[Egede, Leonard E.; Dismuke, Clara] Med Univ S Carolina, Ctr Hlth Dispar Res, Charleston, SC 29425 USA; [Egede, Leonard E.; Dismuke, Clara; Echols, Carrae] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC USA	Egede, LE (corresponding author), Med Univ S Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280H,POB 250593, Charleston, SC 29425 USA.	egedel@musc.edu			Veterans Health Administration Health Services Research and Development (HSRD) [REA 08-261]; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K24DK093699] Funding Source: NIH RePORTER	This study was funded by the Veterans Health Administration Health Services Research and Development (HSR&D) program (grant REA 08-261).	[Anonymous], 2008, SAS STAT VERS 9 1 3; [Anonymous], 1980, INT CLASS DIS 9 REV; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Arthur M, 2008, MED CARE, V46, P192, DOI 10.1097/MLR.0b013e31815b9d8e; Berry C, 2010, J SURG RES, V163, P303, DOI 10.1016/j.jss.2010.03.018; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Carlson KF, 2010, J TRAUMA STRESS, V23, P17, DOI 10.1002/jts.20483; Catalano D, 2006, NEUROREHABILITATION, V21, P279; CORKIN S, 1984, ARCH NEUROL-CHICAGO, V41, P975, DOI 10.1001/archneur.1984.04050200081022; Deswal A, 2004, J AM COLL CARDIOL, V43, P778, DOI 10.1016/j.jacc.2003.10.033; Ellis C, 2009, ETHNIC DIS, V19, P161; Fischer HUS, 2010, MILITARY CASUALTY ST; Frei CR, 2010, BMC HEALTH SERV RES, V10, DOI 10.1186/1472-6963-10-143; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Helmer Drew, 2008, Prim Care Diabetes, V2, P73, DOI 10.1016/j.pcd.2008.02.004; Jha AK, 2001, JAMA-J AM MED ASSOC, V285, P297, DOI 10.1001/jama.285.3.297; Lynch CP, 2010, J GEN INTERN MED, V25, P1051, DOI 10.1007/s11606-010-1405-y; Mapppsy LKR, 2008, DIABETES CARE, V31, P880, DOI 10.2337/dc07-2215; Marrero MZ, 2002, CLIN PSYCHOL REV, V22, P463, DOI 10.1016/S0272-7358(01)00109-X; Martin CA, 2010, AM J SURG, V199, P210, DOI 10.1016/j.amjsurg.2009.05.001; McGinnis KA, 2003, AM J PUBLIC HEALTH, V93, P1728, DOI 10.2105/AJPH.93.10.1728; Pappadis MR, 2010, J HEAD TRAUMA REHABI; Proctor A, 2008, NEUROREHABILITATION, V23, P529; Quan HD, 2005, MED CARE, V43, P1130, DOI 10.1097/01.mlr.0000182534.19832.83; Saha S, 2008, J GEN INTERN MED, V23, P654, DOI 10.1007/s11606-008-0521-4; Sander AM, 2009, NEUROREHABILITATION, V24, P15, DOI 10.3233/NRE-2009-0450; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Sorani MD, 2009, J TRAUMA, V67, P75, DOI 10.1097/TA.0b013e31818234e8; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Volpp KG, 2007, HEALTH SERV RES, V42, P1613, DOI 10.1111/j.1475-6773.2006.00688.x; Wolinsky FD, 2006, BMC HEALTH SERV RES, V6, DOI 10.1186/1472-6963-6-131; Young BA, 2003, DIABETES CARE, V26, P2392, DOI 10.2337/diacare.26.8.2392	34	23	23	0	2	AMER PUBLIC HEALTH ASSOC INC	WASHINGTON	800 I STREET, NW, WASHINGTON, DC 20001-3710 USA	0090-0036	1541-0048		AM J PUBLIC HEALTH	Am. J. Public Health		2012	102			2			S266	S271		10.2105/AJPH.2011.300176			6	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	928FV	WOS:000302969500021	21852658	Green Published			2021-06-18	
J	French, LM; Lange, RT; Iverson, GL; Ivins, B; Marshall, K; Schwab, K				French, Louis M.; Lange, Rael T.; Iverson, Grant L.; Ivins, Brian; Marshall, Katherine; Schwab, Karen			Influence of Bodily Injuries on Symptom Reporting Following Uncomplicated Mild Traumatic Brain Injury in US Military Service Members	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						bodily injuries; mild traumatic brain injury; postconcussion symptoms; PTSD	POSTTRAUMATIC-STRESS-DISORDER; PERSISTENT POSTCONCUSSION SYNDROME; POST-CONCUSSION SYNDROME; CHRONIC PAIN; DEPRESSION; SOLDIERS; BLAST; IRAQ; REHABILITATION; AFGHANISTAN	Objective: To examine the relations among bodily injuries, traumatic stress, and postconcussion symptoms in a sample of combat-injured US service members who sustained a mild traumatic brain injury. Participants: One hundred and thirty-seven service members evaluated and treated at Walter Reed Army Medical Center following medical evacuation from the combat theater of Operation Enduring Freedom and Operation Iraqi Freedom. All had sustained an uncomplicated mild traumatic brain injury and concurrent bodily injuries. Procedure: Participants completed 2 symptom checklists within 3 months of injury. Severity of bodily injuries was quantified with a modified version of the Injury Severity Score that excluded intracranial injuries (ISS(mod)). Participants were classified into 4 ISS(mod) groups: minor (n = 17), moderate (n = 48), serious (n = 40), severe/critical (n = 32). Main outcome measures: Neurobehavioral Symptom Inventory (NBSI) and the Posttraumatic Stress Disorder Checklist-Civilian version (PCLC). Results: There was a significant negative association between ISSmod scores and the NBSI and PCLC total scores. There were significant main effects across the 4 groups for the NBSI and PCLC total scores. The highest NBSI and PCLC scores were consistently found in the ISSmod minor group, followed by the moderate, serious, and severe/critical groups. Conclusions: While it might be expected that greater comorbid physical injuries would be associated with greater symptom burden, in this study as the severity of bodily injuries increased, symptom burden decreased. Hypothesized explanations include: underreporting of symptoms; increased peer support; disruption of fear conditioning due to acute morphine use; or delayed expression of symptoms.	[French, Louis M.; Lange, Rael T.; Iverson, Grant L.; Ivins, Brian; Marshall, Katherine; Schwab, Karen] Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Washington, DC 20307 USA; [Lange, Rael T.; Iverson, Grant L.] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada; [French, Louis M.] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA	Lange, RT (corresponding author), Walter Reed Army Med Ctr, Def & Vet Brain Injury Ctr, Bldg 1,Room B207,6900 Georgia Ave NW, Washington, DC 20307 USA.	rlange@dvbic.org	french, louis/AAB-2083-2020	french, louis/0000-0002-9451-0604; Iverson, Grant/0000-0001-7348-9570			American Psychiatric Association, 1994, DIAGN STAT MAN MENT; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Benge JF, 2009, REHABIL PSYCHOL, V54, P270, DOI 10.1037/a0016736; Blanchard EB, 1996, BEHAV RES THER, V34, P669, DOI 10.1016/0005-7967(96)00033-2; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Bryant RA, 2010, AM J PSYCHIAT, V167, P312, DOI 10.1176/appi.ajp.2009.09050617; Bryant RA, 2009, BIOL PSYCHIAT, V65, P438, DOI 10.1016/j.biopsych.2008.10.032; Caplan LJ, 2010, J HEAD TRAUMA REHAB, V25, P447, DOI 10.1097/HTR.0b013e3181d5bdbd; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; Clark ME, 2009, PAIN MED, V10, P447, DOI 10.1111/j.1526-4637.2009.00590.x; DeRoon-Cassini TA, 2010, REHABIL PSYCHOL, V55, P1, DOI 10.1037/a0018601; Dobscha SK, 2009, PAIN MED, V10, P1200, DOI 10.1111/j.1526-4637.2009.00721.x; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gil S, 2005, AM J PSYCHIAT, V162, P963, DOI 10.1176/appi.ajp.162.5.963; Glaesser J, 2004, BMC PSYCHIATRY, V4, DOI 10.1186/1471-244X-4-5; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guez M, 2005, J CLIN EXP NEUROPSYC, V27, P151, DOI 10.1080/13803390490515487; Haldorsen T, 2003, APPL NEUROPSYCHOL, V10, P170, DOI 10.1207/S15324826AN1003_06; Helmer DA, 2009, PAIN MED, V10, P1174, DOI 10.1111/j.1526-4637.2009.00723.x; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson G.L., 2001, J FORENSIC NEUROPSYC, V2, P19, DOI [https://doi.org/10.1300/J151v02n01_02, DOI 10.1300/J151v02n01_02]; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; JAMISON RN, 1988, INT J PSYCHIAT MED, V18, P183; Kennedy JE, 2010, NEUROREHABILITATION, V26, P191, DOI 10.3233/NRE-2010-0555; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Managment of Concussion/nTBI Working Group, 2009, VA DOD CLIN PRACT GU; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Melcer T, 2010, MIL MED, V175, P147, DOI 10.7205/MILMED-D-09-00120; Mental Health Advisory Team V, 2011, OP IR FREED 06 08 IR; Messinger SD, 2009, DISABIL REHABIL, V31, P2130, DOI [10.3109/09638280902943223a, 10.3109/09638280902943223]; Mickeviciene D, 2004, EUR J NEUROL, V11, P411, DOI 10.1111/j.1468-1331.2004.00816.x; Mild Traumatic Brain Injury Committee, 1993, J HEAD TRAUMA REHAB, V8, P86; Owens BD, 2008, J TRAUMA, V64, P295, DOI 10.1097/TA.0b013e318163b875; Pasquina PF, 2008, J REHABIL RES DEV, V45, P953, DOI 10.1682/JRRD.2007.10.0163; Peleg K, 2003, AM J EMERG MED, V21, P258, DOI 10.1016/S0735-6757(03)00043-3; Quale AJ, 2009, INJURY, V40, P498, DOI 10.1016/j.injury.2008.11.006; Ramchand R, 2010, J TRAUMA STRESS, V23, P59, DOI 10.1002/jts.20486; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Stevenson M, 2001, Inj Prev, V7, P10, DOI 10.1136/ip.7.1.10; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; WARDEN DL, 2005, TXB TRAUMATIC BRAIN, P231; World Health Organization, 1992, ICD 10 INT STAT CLAS	50	23	23	0	11	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JAN-FEB	2012	27	1					63	74		10.1097/HTR.0b013e3182248344			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	879JV	WOS:000299326400007	21897286				2021-06-18	
J	Landon, J; Shepherd, D; Stuart, S; Theadom, A; Freundlich, S				Landon, Jason; Shepherd, Daniel; Stuart, Stacey; Theadom, Alice; Freundlich, Simone			Hearing every footstep: Noise sensitivity in individuals following traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Noise sensitivity; Traumatic brain injury; Post-concussive syndrome; Rehabilitation	HEAD-INJURY; PEOPLE; SELF; EXPERIENCE; DISABILITY; SYMPTOMS	Noise sensitivity is an important and under-researched symptom that can result from traumatic brain injury (TBI). Interpretative phenomenological analysis (IPA) was used to analyse the experiences of noise sensitivity of six individuals with TBI. The results revealed four major themes through which participants described a process of having to find information for themselves to understand what they were experiencing and their changed relationship with sounds. The participants also described feeling overwhelmed as they struggled to cope with the changes to their lives and being able to plan and take some control over their lives. The findings are of importance for both health professionals involved in rehabilitation and individuals recovering from TBI.	[Landon, Jason; Shepherd, Daniel; Stuart, Stacey; Theadom, Alice; Freundlich, Simone] Auckland Univ Technol, Dept Psychol, Auckland 1020, New Zealand	Landon, J (corresponding author), Auckland Univ Technol, Dept Psychol, Private Bag 92006, Auckland 1020, New Zealand.	Jason.landon@aut.ac.nz	Landon, Jason/AAD-3951-2019	Shepherd, Daniel/0000-0001-7089-7130; Theadom, Alice/0000-0003-0351-6216; Landon, Jason/0000-0002-3595-7430			ANDERSON EA, 1987, J CONSULT CLIN PSYCH, V55, P513, DOI 10.1037/0022-006X.55.4.513; Benedictus MR, 2010, ARCH PHYS MED REHAB, V91, P1436, DOI 10.1016/j.apmr.2010.06.019; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; COHEN F, 1973, PSYCHOSOM MED, V35, P375, DOI 10.1097/00006842-197309000-00002; Dang-Vu TT, 2010, CURR BIOL, V20, pR626, DOI 10.1016/j.cub.2010.06.032; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Gelech JM, 2011, QUAL HEALTH RES, V21, P62, DOI 10.1177/1049732310377454; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; HINKELDEY N S, 1990, Brain Injury, V4, P115, DOI 10.3109/02699059009026157; Howes H, 2005, PSYCHOL HEALTH, V20, P129, DOI 10.1080/0887044042000272903; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; JOB RFS, 1988, J ACOUST SOC AM, V83, P991, DOI 10.1121/1.396524; JOHNSTON M, 1980, PSYCHOL MED, V10, P145, DOI 10.1017/S0033291700039684; Johnston Marie, 1993, Annals of Behavioral Medicine, V15, P245; Jumisko Eija, 2005, J Neurosci Nurs, V37, P42; Jumisko E, 2009, J CLIN NURS, V18, P2273, DOI 10.1111/j.1365-2702.2008.02738.x; Landre N, 2006, ARCH CLIN NEUROPSYCH, V21, P255, DOI 10.1016/j.acn.2005.12.007; Lazarus R. S., 1987, EUR J PERSONALITY, V1, P141, DOI 10.1002/per.2410010304; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Miedema HME, 1999, J ACOUST SOC AM, V105, P3336, DOI 10.1121/1.424662; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; O'Callaghan C, 2006, NEUROPSYCHOL REHABIL, V16, P579, DOI 10.1080/09602010500368834; Paniak C, 2002, ARCH CLIN NEUROPSYCH, V17, P319, DOI 10.1016/S0887-6177(01)00115-9; Paterson J., 2002, REHABILITATION NURSI, V27, P13, DOI [10.1002/j.2048-7940.2002.tb01973.x, DOI 10.1002/J.2048-7940.2002.TB01973.X]; Patton MQ., 1990, QUALITATIVE EVALUATI; Pryor J, 2004, DISABIL REHABIL, V26, P974, DOI 10.1080/09638280410001702397; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Shotton L, 2007, BRAIN INJURY, V21, P857, DOI 10.1080/02699050701481621; Smith J., 2003, QUALITATIVE PSYCHOL; Smith JA, 1999, QUALITATIVE HLTH PSY; STANSFELD SA, 1992, PSYCHOL MED, P1, DOI 10.1017/S0033291716002336; Street RL, 2009, PATIENT EDUC COUNS, V74, P295, DOI 10.1016/j.pec.2008.11.015; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; YOUNG L, 1985, BRIT J CLIN PSYCHOL, V24, P303, DOI 10.1111/j.2044-8260.1985.tb00664.x	38	23	24	1	8	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2012	22	3					391	407		10.1080/09602011.2011.652496			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	936BV	WOS:000303566800004	22292864				2021-06-18	
J	Murphy, MP; Carmine, H				Murphy, Mary Pat; Carmine, Helen			Long-term health implications of individuals with TBI: A rehabilitation perspective	NEUROREHABILITATION			English	Article						Traumatic brain injury; health complications; nursing; healthy aging; chronic disease management	TRAUMATIC BRAIN-INJURY; GASTROESOPHAGEAL-REFLUX DISEASE; METABOLIC-SYNDROME; SLEEP DISORDERS; HEAD-INJURY; POSTTRAUMATIC SEIZURES; UNITED-STATES; COMMUNITY; PREVALENCE; MANAGEMENT	Individuals with acquired brain injuries often present with lifelong health challenges. Trauma to the body directly related to the injury, physical and medical sequelae resulting from the brain injury itself, and an increase in the observed onset of physical aging are among the problems which require consideration throughout their lives. For many rehabilitation professionals, issues related to medical stability and health maintenance are unfamiliar and intimidating. As both hospital stays shorten and an existing population of individuals with brain injuries' survival and life expectancy rates increase, rehabilitation professionals have been increasingly challenged by medical issues. Rehabilitation nurses are positioned to best navigate these issues and facilitate needed care coordination, early intervention, and ongoing education for individuals, their families, and other caregivers. This article describes common medical complications related to the initial and related disability and aging in individuals with brain injury including chronic and late emerging complications involving all body systems including spasticity and changing mobility, aspiration and dysphagia, incontinence, diabetes, and acute and chronic pain. Strategies for successful management of these issues in a home or community setting are also discussed. Special attention is paid to falls and fall prevention, issues specific to aging women, and nutrition and weight control. Ways to promote positive health behaviors to preserve function are also explored. Additionally, patient and family education as part of a lifetime management plan is discussed.	[Murphy, Mary Pat; Carmine, Helen] ReMed Recovery Care Ctr, Paoli, PA 19301 USA; [Murphy, Mary Pat; Carmine, Helen] Greater Philadelphia Chapter, Assoc Rehabil Nurses, Philadelphia, PA USA	Murphy, MP (corresponding author), ReMed Recovery Care Ctr, 16 Ind Blvd,Suite 203, Paoli, PA 19301 USA.	mmurphy@remed.com					Adler T., 2011, BRAIN INJURY PROFESS, V8, P22; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Asikainen I, 1999, EPILEPSIA, V40, P584, DOI 10.1111/j.1528-1157.1999.tb05560.x; Banotai A., 2011, ADV SPEECH LANGUAGE, V16, P6; Bittar RG, 2005, J CLIN NEUROSCI, V12, P12, DOI 10.1016/j.jocn.2004.03.025; Breed ST, 2004, ARCH PHYS MED REHAB, V85, pS61, DOI 10.1016/j.apmr.2003.08.115; Bushnik T, 2004, J HEAD TRAUMA REHAB, V19, P296, DOI 10.1097/00001199-200407000-00004; Castriotta RJ, 2009, J CLIN SLEEP MED, V5, P137; Castriotta RJ, 2001, ARCH PHYS MED REHAB, V82, P1403, DOI 10.1053/apmr.2001.26081; Chokroverty S, 2000, NEUROLOGY, V54, pS8; Chua K, 2003, BRAIN INJURY, V17, P469, DOI 10.1080/02699050210154268; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P1182, DOI 10.1016/S0003-9993(96)90145-8; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Fichtenberg NL, 2000, BRAIN INJURY, V14, P659; Flanagan S., 2008, BRAIN INJURY PROFESS, V5, P22; Ford ES, 2002, JAMA-J AM MED ASSOC, V287, P356, DOI 10.1001/jama.287.3.356; FUHRER MJ, 1993, ARCH PHYS MED REHAB, V74, P1172; Gohil B C, 2001, CNS Spectr, V6, P581; Gohil BC, 2001, CNS SPECTRUMS, V6, P589; GOLDSTEIN FC, 1994, J NEUROL NEUROSUR PS, V57, P961, DOI 10.1136/jnnp.57.8.961; Grundy SM, 2004, CIRCULATION, V109, P433, DOI 10.1161/01.CIR.0000111245.75752.C6; Hadjikoutis S, 2000, BRAIN, V123, P1863, DOI 10.1093/brain/123.9.1863; Harrison T, 2007, ADV NURS SCI, V30, P123, DOI 10.1097/01.ANS.0000271103.57290.6e; Harrison-Felix CL, 2009, ARCH PHYS MED REHAB, V90, P1506, DOI 10.1016/j.apmr.2009.03.015; Hart Robert P, 2003, Curr Pain Headache Rep, V7, P116, DOI 10.1007/s11916-003-0021-5; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P47, DOI 10.1097/00001199-199808000-00005; Hjemdahl P, 2002, CIRCULATION, V106, P2634, DOI 10.1161/01.CIR.0000041502.43564.79; Ishibe N, 2009, J HEAD TRAUMA REHAB, V24, P424, DOI 10.1097/HTR.0b013e3181c13426; Isomaa B, 2003, LIFE SCI, V73, P2395, DOI 10.1016/S0024-3205(03)00646-5; Ivanhoe CB, 2004, J HEAD TRAUMA REHAB, V19, P29, DOI 10.1097/00001199-200401000-00004; Jankovic J., 2007, PARKINSONS DIS MOVEM, P349; Kaltenbach T, 2006, ARCH INTERN MED, V166, P965, DOI 10.1001/archinte.166.9.965; Khoury RM, 1999, AM J GASTROENTEROL, V94, P2069; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Masel B.E., 2011, CHALLENGE, V5, P9; Masel B.E., 2011, CHALLENGE, V5, P28; Masel BE, 2001, ARCH PHYS MED REHAB, V82, P1526, DOI 10.1053/apmr.2001.26093; McGrath JC, 2008, CLIN REHABIL, V22, P635, DOI 10.1177/0269215507086432; Medley A, 2006, BRAIN INJURY, V20, P1403, DOI 10.1080/02699050601082057; Myers K. J., 2009, DYSTONIA PATIENT GUI, P117; Nosek MA, 2006, ARCH PHYS MED REHAB, V87, P320, DOI 10.1016/j.apmr.2005.11.003; O'Suilleabhain P, 2004, J HEAD TRAUMA REHAB, V19, P305, DOI 10.1097/00001199-200407000-00005; Oostra K, 1996, BRAIN INJURY, V10, P459, DOI 10.1080/026990596124313; Parcell DL, 2006, ARCH PHYS MED REHAB, V87, P278, DOI 10.1016/j.apmr.2005.10.024; Paterson WG, 1996, CAN FAM PHYSICIAN, V42, P925; PEET SM, 1995, BRIT MED J, V311, P1063, DOI 10.1136/bmj.311.7012.1063; Piesman M, 2007, AM J GASTROENTEROL, V102, P2128, DOI 10.1111/j.1572-0241.2007.01348.x; Pluskiewicz W, 1997, ULTRASOUND MED BIOL, V23, P553, DOI 10.1016/S0301-5629(97)00036-7; Safaz I, 2008, BRAIN INJURY, V22, P733, DOI 10.1080/02699050802304714; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Sander AM, 1999, ARCH PHYS MED REHAB, V80, P1303, DOI 10.1016/S0003-9993(99)90034-5; Shavelle RM, 2001, AM J PHYS MED REHAB, V80, P510, DOI 10.1097/00002060-200107000-00009; Thaxton L, 2002, J HEAD TRAUMA REHAB, V17, P335, DOI 10.1097/00001199-200208000-00007; US Department of Health & Human Services, 2004, BREAK BARR HLTH CAR; Verbrugge L., 2002, J DIS POL STUD, V12, P253, DOI DOI 10.1177/104420730201200405; Walker WC, 2004, J HEAD TRAUMA REHAB, V19, P72, DOI 10.1097/00001199-200401000-00007; Zagaria M.A., 2011, AM J NURSE PRACTITIO, V15, P63; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	58	23	23	0	20	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2012	31	1					85	94		10.3233/NRE-2012-0777			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	976SU	WOS:000306605900009	22523016				2021-06-18	
J	Murray, LL				Murray, Laura L.			Direct and indirect treatment approaches for addressing short-term or working memory deficits in aphasia	APHASIOLOGY			English	Article						Aphasia; Working memory; Short-term memory; Treatment; Memory training	DIRECT-CURRENT STIMULATION; TRAUMATIC BRAIN-INJURY; EXECUTIVE FUNCTION; SENTENCE COMPREHENSION; LANGUAGE PRODUCTION; PROCESSING SUPPORT; READING IMPAIRMENT; COGNITIVE FUNCTION; OLDER-ADULTS; MILD APHASIA	Background: A growing literature has documented that aphasia is frequently accompanied by deficits of short-term memory (STM) and working memory (WM), and that such memory impairments may negatively influence language abilities and aphasia treatment outcomes. Consequently, treating STM and WM impairments in individuals with aphasia should not only remediate these memory impairments but also positively affect their response to language therapy programmes. Aims: This paper critically reviews the aphasia literature pertaining to remediating, directly or indirectly, STM and WM deficits. Memory treatment protocols developed for other disordered as well as healthy populations are also discussed as possible therapy approaches to consider in future aphasia research. Main Contribution: Findings from a limited set of studies suggest that STM and WM impairments in individuals with aphasia do respond to treatment, and further that these treatments may also positively affect the language abilities of individuals with aphasia. Conclusions: Further research is warranted to establish the reliability and validity of these preliminary findings and to explore application of these treatments as well as those developed for nonaphasic populations to individuals representing a broader spectrum of aphasia types and severities.	Indiana Univ, Dept Speech & Hearing Sci, Bloomington, IN 47405 USA	Murray, LL (corresponding author), Indiana Univ, Dept Speech & Hearing Sci, 200 S Jordan, Bloomington, IN 47405 USA.	lmurray@indiana.edu					Aben L, 2008, J REHABIL MED, V40, P681, DOI 10.2340/16501977-0227; Adcock RA, 2009, SCHIZOPHRENIA BULL, V35, P1132, DOI 10.1093/schbul/sbp068; Alexander MP, 2006, J INT NEUROPSYCH SOC, V12, P236, DOI 10.1017/S1355617706060309; Baddeley A, 2003, J COMMUN DISORD, V36, P189, DOI 10.1016/S0021-9924(03)00019-4; Baker JM, 2010, STROKE, V41, P1229, DOI 10.1161/STROKEAHA.109.576785; Baldo JV, 2005, BRAIN LANG, V92, P240, DOI 10.1016/j.bandl.2004.06.103; Bartha L, 2003, BRAIN LANG, V85, P93, DOI 10.1016/S0093-934X(02)00502-3; Berry AS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0011537; Boggio PS, 2006, J NEUROL SCI, V249, P31, DOI 10.1016/j.jns.2006.05.062; Cahn BR, 2006, PSYCHOL BULL, V132, P180, DOI 10.1037/0033-2909.132.2.180; Caspari I, 1998, BRAIN COGNITION, V37, P205, DOI 10.1006/brcg.1997.0970; Catroppa C, 2006, Pediatr Rehabil, V9, P89, DOI 10.1080/13638490500155458; Chein JM, 2010, PSYCHON B REV, V17, P193, DOI 10.3758/PBR.17.2.193; Ciancarelli I, 2010, FUNCT NEUROL, V25, P81; Cicerone KD, 2002, BRAIN INJURY, V16, P185, DOI 10.1080/02699050110103959; Coelho CA, 2005, APHASIOLOGY, V19, P275, DOI 10.1080/02687030444000741; Colcombe S, 2003, PSYCHOL SCI, V14, P125, DOI 10.1111/1467-9280.t01-1-01430; Cornelissen K, 2003, J COGNITIVE NEUROSCI, V15, P444, DOI 10.1162/089892903321593153; Cowan N, 2008, PROG BRAIN RES, V169, P323, DOI 10.1016/S0079-6123(07)00020-9; Crosson B, 1999, NEUROPSYCHOLOGY, V13, P171, DOI 10.1037/0894-4105.13.2.171; Crosson B, 2007, J INT NEUROPSYCH SOC, V13, P582, DOI 10.1017/S1355617707070737; Dahlin E, 2009, RESTOR NEUROL NEUROS, V27, P405, DOI 10.3233/RNN-2009-0492; Deplanque D, 2009, J NEUROL NEUROSUR PS, V80, P942, DOI 10.1136/jnnp.2009.174490; Duval J, 2008, NEUROPSYCHOL REHABIL, V18, P430, DOI 10.1080/09602010701573950; Fabre C, 2002, INT J SPORTS MED, V23, P415, DOI 10.1055/s-2002-33735; Fillingham JK, 2005, INT J LANG COMM DIS, V40, P505, DOI 10.1080/13682820500138572; Francis DR, 2003, APHASIOLOGY, V17, P723, DOI 10.1080/02687030344000201; Frankel T, 2007, APHASIOLOGY, V21, P814, DOI 10.1080/02687030701192448; Fridriksson J, 2010, J NEUROSCI, V30, P11558, DOI 10.1523/JNEUROSCI.2227-10.2010; Friedmann N, 2003, BRAIN LANG, V86, P23, DOI 10.1016/S0093-934X(02)00530-8; GORDON WP, 1983, NEUROPSYCHOLOGIA, V21, P325, DOI 10.1016/0028-3932(83)90019-2; Holmes J, 2010, APPL COGNITIVE PSYCH, V24, P827, DOI 10.1002/acp.1589; Horowitz-Kraus T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0007141; Howard D., 2011, APHASIOLOGY; Jaeggi SM, 2008, P NATL ACAD SCI USA, V105, P6829, DOI 10.1073/pnas.0801268105; Jean L, 2010, AM J GERIAT PSYCHIAT, V18, P281, DOI 10.1097/JGP.0b013e3181c37ce9; Jha AP, 2010, EMOTION, V10, P54, DOI 10.1037/a0018438; Jo JM, 2009, AM J PHYS MED REHAB, V88, P404, DOI 10.1097/PHM.0b013e3181a0e4cb; Jolles DD, 2010, NEUROIMAGE, V52, P658, DOI 10.1016/j.neuroimage.2010.04.028; Jonides J, 1998, P NATL ACAD SCI USA, V95, P8410, DOI 10.1073/pnas.95.14.8410; Kalinyak-Fliszar M., APHASIOLOGY IN PRESS; Kesner RP, 2009, BEHAV NEUROSCI, V123, P1, DOI 10.1037/a0014004; Kirschen MP, 2006, BEHAV NEUROL, V17, P187, DOI 10.1155/2006/469132; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Klusmann V, 2010, J GERONTOL A-BIOL, V65, P680, DOI 10.1093/gerona/glq053; Koenig-Bruhin M, 2007, APHASIOLOGY, V21, P448, DOI 10.1080/02687030600670593; Kolk H. H. J., 2006, SYNTAX NONSENTENTIAL; Levaux MN, 2009, NEUROPSYCHOL REHABIL, V19, P244, DOI 10.1080/09602010802091829; Linebarger M, 2007, BRAIN LANG, V100, P53, DOI 10.1016/j.bandl.2006.09.001; Linebarger MC, 2004, COGN NEUROPSYCHOL, V21, P267, DOI 10.1080/02643290342000537; Linebarger MC, 2000, BRAIN LANG, V75, P416, DOI 10.1006/brln.2000.2378; Linebarger MC, 2001, NEUROPSYCHOL REHABIL, V11, P57, DOI 10.1080/09602010042000178; LORENZEN B, 2008, PERSPECT NEUROPHYS N, V18, P99, DOI DOI 10.1044/NNSLD18.3.99; Loukavenko EA, 2007, EUR J NEUROSCI, V26, P3267, DOI 10.1111/j.1460-9568.2007.05879.x; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Mahncke HW, 2006, P NATL ACAD SCI USA, V103, P12523, DOI 10.1073/pnas.0605194103; Majerus S, 2009, INTERACTIONS BETWEEN SHORT-TERM AND LONG-TERM MEMORY IN THE VERBAL DOMAIN, P244; Malouin F, 2004, ARCH PHYS MED REHAB, V85, P177, DOI 10.1016/S0003-9993(03)00771-8; Martin N., 2011, APHASIOLOGY; Martin Randi C., 2008, Seminars in Speech and Language, V29, P201, DOI 10.1055/s-0028-1082884; Mayer JF, 2002, APHASIOLOGY, V16, P727, DOI 10.1080/02687030143000870; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McDonald-Miszczak L, 1992, J GEN PSYCHOL, V47, P293; McDowell S, 1998, BRAIN, V121, P1155, DOI 10.1093/brain/121.6.1155; McGurk SR, 2007, AM J PSYCHIAT, V164, P1791, DOI 10.1176/appi.ajp.2007.07060906; Meinzer M, 2008, NEUROIMAGE, V39, P2038, DOI 10.1016/j.neuroimage.2007.10.008; Miniussi C, 2008, BRAIN STIMUL, V1, P326, DOI 10.1016/j.brs.2008.07.002; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Muller U, 1998, J NEUROSCI, V18, P2720; Murray L, 2004, APHASIOLOGY, V18, P785, DOI 10.1080/02687030444000273; Murray LL, 2006, J COMMUN DISORD, V39, P37, DOI 10.1016/j.jcomdis.2005.06.001; Murray LL, 2000, BRAIN LANG, V72, P40, DOI 10.1006/brln.1999.2281; Murray LL, 2004, J MED SPEECH-LANG PA, V12, pXXV; Murray LL, 1997, APHASIOLOGY, V11, P993, DOI 10.1080/02687039708249423; Ni W, 2000, J COGNITIVE NEUROSCI, V12, P120, DOI 10.1162/08989290051137648; Nicholas M, 2005, APHASIOLOGY, V19, P1052, DOI 10.1080/02687030544000245; Ohn SH, 2008, NEUROREPORT, V19, P43, DOI 10.1097/WNR.0b013e3282f2adfd; Olesen PJ, 2004, NAT NEUROSCI, V7, P75, DOI 10.1038/nn1165; Osaka N, 2004, NEUROIMAGE, V21, P623, DOI 10.1016/j.neuroimage.2003.09.069; Oswald Wolf D, 2006, Eur J Ageing, V3, P179, DOI 10.1007/s10433-006-0035-z; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Redick TS, 2006, APPL COGNITIVE PSYCH, V20, P713, DOI 10.1002/acp.1224; Ronnberg J, 1996, SCAND J PSYCHOL, V37, P46, DOI 10.1111/j.1467-9450.1996.tb00638.x; Rudner M, 2008, COGN PROCESS, V9, P19, DOI 10.1007/s10339-007-0183-x; Sander AM, 2007, AM J SPEECH-LANG PAT, V16, P316, DOI 10.1044/1058-0360(2007/036); Schmiedek F, 2010, FRONT AGING NEUROSCI, V2, DOI 10.3389/fnagi.2010.00027; Seniow J, 2009, J NEUROL SCI, V283, P91, DOI 10.1016/j.jns.2009.02.315; Serino A, 2007, BRAIN INJURY, V21, P11, DOI 10.1080/02699050601151811; Shipstead Z, 2010, PSYCHOL BELG, V50, P245, DOI 10.5334/pb-50-3-4-245; Sinotte MP, 2007, NEUROREHABILITATION, V22, P303; Smith PJ, 2010, PSYCHOSOM MED, V72, P239, DOI 10.1097/PSY.0b013e3181d14633; SOHLBERG MM, 2001, ATTENTION PROCESS TR, V2; Sung JE, 2009, APHASIOLOGY, V23, P1040, DOI 10.1080/02687030802592884; Swanson HL, 2010, J LEARN DISABIL-US, V43, P24, DOI 10.1177/0022219409338743; Takeuchi H, 2010, J NEUROSCI, V30, P3297, DOI 10.1523/JNEUROSCI.4611-09.2010; TOMPKINS CA, 1994, J SPEECH HEAR RES, V37, P896, DOI 10.1044/jshr.3704.896; Vallat C, 2005, BRAIN INJURY, V19, P1157, DOI 10.1080/02699050500110595; Vallat-Azouvi C, 2009, BRAIN INJURY, V23, P585, DOI 10.1080/02699050902970711; Vogt A, 2009, RESTOR NEUROL NEUROS, V27, P225, DOI 10.3233/RNN-2009-0473; Vukovic M, 2008, J COMMUN DISORD, V41, P531, DOI 10.1016/j.jcomdis.2008.04.001; Walker-Batson D, 2001, STROKE, V32, P2093, DOI 10.1161/hs0901.095720; Ween JE, 1996, NEUROLOGY, V47, P795, DOI 10.1212/WNL.47.3.795; Westerberg H, 2007, BRAIN INJURY, V21, P21, DOI 10.1080/02699050601148726; Westerberg H, 2007, PHYSIOL BEHAV, V92, P186, DOI 10.1016/j.physbeh.2007.05.041; Whiting E, 2007, J INT NEUROPSYCH SOC, V13, P972, DOI 10.1017/S1355617707071317; Zeidan F, 2010, CONSCIOUS COGN, V19, P597, DOI 10.1016/j.concog.2010.03.014	106	23	24	0	29	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0268-7038	1464-5041		APHASIOLOGY	Aphasiology		2012	26	3-4			SI		317	337		10.1080/02687038.2011.589894			21	Audiology & Speech-Language Pathology; Linguistics; Clinical Neurology; Rehabilitation	Audiology & Speech-Language Pathology; Linguistics; Neurosciences & Neurology; Rehabilitation	910OT	WOS:000301649800004					2021-06-18	
J	Ozen, LJ; Fernandes, MA				Ozen, Lana J.; Fernandes, Myra A.			Slowing Down after a Mild Traumatic Brain Injury: A Strategy to Improve Cognitive Task Performance?	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Head injury; Traumatic brain injury; Learning and memory; Attention; Executive functions; Everyday functioning; Anxiety	TIME PRESSURE MANAGEMENT; CLOSED-HEAD INJURY; POSTCONCUSSIVE SYNDROME; ATTENTION DEFICITS; DIAGNOSIS THREAT; LONG; SPEED; CONCUSSION; SYMPTOMS; FAILURES	Long-term persistent attention and memory difficulties following a mild traumatic brain injury (TBI) often go undetected on standard neuropsychological tests, despite complaints by mild TBI individuals. We conducted a visual Repetition Detection working memory task to digits, in which we manipulated task difficulty by increasing cognitive load, to identify subtle deficits long after a mild TBI. Twenty-six undergraduate students with a self-report of one mild TBI, which occurred at least 6 months prior, and 31 non-head-injured controls took part in the study. Participants were not informed until study completion that the study's purpose was to examine cognitive changes following a mild TBI, to reduce the influence of "diagnosis threat" on performance. Neuropsychological tasks did not differentiate the groups, though mild TBI participants reported higher state anxiety levels. On our working memory task, the mild TBI group took significantly longer to accurately detect repeated targets on our task, suggesting that slowed information processing is a long-term consequence of mild TBI. Accuracy was comparable in the low-load condition and, unexpectedly, mild TB1 performance surpassed that of controls in the high-load condition. Temporal analysis of target identification suggested a strategy difference between groups: mild TBI participants made a significantly greater number of accurate responses following the target's offset, and significantly fewer erroneous distracter responses prior to target onset, compared with controls. Results suggest that long after a mild TB!, high-functioning young adults invoke a strategy of delaying their identification of targets in order to maintain, and facilitate, accuracy on cognitively demanding tasks.	[Ozen, Lana J.; Fernandes, Myra A.] Univ Waterloo, Dept Psychol, Waterloo, ON N2L 3G1, Canada	Ozen, LJ (corresponding author), Univ Waterloo, Dept Psychol, 200 Univ Ave W, Waterloo, ON N2L 3G1, Canada.	lozen@uwaterloo.ca			National Sciences and Engineering Research Council of CanadaNatural Sciences and Engineering Research Council of Canada (NSERC)	This work was supported by a Discovery grant (M.A.F.) and a post-graduate scholarship (L.J.O.) from the National Sciences and Engineering Research Council of Canada.	Alves W., 1998, J HEAD TRAUMA REHAB, V8, P48, DOI DOI 10.1097/00001199-199309000-00007; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Beck AT., 1996, BECK DEPRESSION INVE, V2; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P215, DOI 10.1017/S1355617705050277; Bernstein DM, 2002, J INT NEUROPSYCH SOC, V8, P673, DOI 10.1017/S1355617702801400; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Bopp KL, 2007, J GERONTOL B-PSYCHOL, V62, pP239, DOI 10.1093/geronb/62.5.P239; BROADBENT DE, 1982, BRIT J CLIN PSYCHOL, V21, P1, DOI 10.1111/j.2044-8260.1982.tb01421.x; Chan RCK, 2002, J CLIN EXP NEUROPSYC, V24, P1081, DOI 10.1076/jcen.24.8.1081.8371; Cheyne JA, 2006, CONSCIOUS COGN, V15, P578, DOI 10.1016/j.concog.2005.11.009; Chiaravalloti ND, 2003, J CLIN EXP NEUROPSYC, V25, P489, DOI 10.1076/jcen.25.4.489.13878; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; Delis DC, 1987, CALIFORNIA VERBAL LE; Dischinger PC, 2009, J TRAUMA, V66, P289, DOI 10.1097/TA.0b013e3181961da2; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Frencham KAR, 2005, J CLIN EXP NEUROPSYC, V27, P334, DOI 10.1080/13803390490520328; Halstead WC, 1985, HALSTEAD REITAN NEUR; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Johansson B, 2009, BRAIN INJURY, V23, P1027, DOI 10.3109/02699050903421099; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Lachapelle J, 2008, BRAIN INJURY, V22, P265, DOI 10.1080/02699050801938983; Lavoie ME, 2004, J CLIN EXP NEUROPSYC, V26, P55, DOI 10.1076/jcen.26.1.55.23936; Madigan NK, 2000, J HEAD TRAUMA REHAB, V15, P943, DOI 10.1097/00001199-200006000-00007; Martin TA, 2000, REHABIL PSYCHOL, V45, P402, DOI 10.1037/0090-5550.45.4.402; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Mooney G, 2001, BRAIN INJURY, V15, P865, DOI 10.1080/02699050110065286; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Ozen LJ, 2011, J INT NEUROPSYCH SOC, V17, P219, DOI 10.1017/S135561771000144X; Pare N, 2009, NEUROPSYCHOL REHABIL, V19, P110, DOI 10.1080/09602010802106486; Potter DD, 2002, J INT NEUROPSYCH SOC, V8, P828, DOI 10.1017/S1355617702860118; REASON JT, 1982, ABSENT MINDED PSYCHO; Rohling ML, 2011, CLIN NEUROPSYCHOL, V25, P608, DOI 10.1080/13854046.2011.565076; Sivak S, 2008, BRAIN INJURY, V22, P193, DOI 10.1080/02699050801895431; Solbakk AK, 1999, PSYCHOPHYSIOLOGY, V36, P802; Spielberger C.D., 1970, STATE TRAIT ANXIETY; Suhr JA, 2005, J INT NEUROPSYCH SOC, V11, P23, DOI 10.1017/S1355617705050010; Suhr JA, 2002, J CLIN EXP NEUROPSYC, V24, P448, DOI 10.1076/jcen.24.4.448.1039; Tombaugh TN, 2007, ARCH CLIN NEUROPSYCH, V22, P25, DOI 10.1016/j.acn.2006.06.013; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Vanderploeg RD, 2007, J CLIN EXP NEUROPSYC, V29, P585, DOI 10.1080/13803390600826587; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wechsler D, 1997, WAIS 3 ADM SCORING M; Westcott MC, 2005, BRAIN INJURY, V19, P1261, DOI 10.1080/02699050500150104; Winkens I, 2009, CLIN REHABIL, V23, P79, DOI 10.1177/0269215508097855; Winkens I, 2009, ARCH PHYS MED REHAB, V90, P1672, DOI 10.1016/j.apmr.2009.04.016; Zhang K, 2010, EXP BRAIN RES, V204, P57, DOI 10.1007/s00221-010-2294-3	48	23	24	1	14	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JAN	2012	27	1					85	100		10.1093/arclin/acr087			16	Psychology, Clinical; Psychology	Psychology	885TE	WOS:000299802900008	22068441				2021-06-18	
J	Willeumier, K; Taylor, DV; Amen, DG				Willeumier, K.; Taylor, D. V.; Amen, D. G.			Elevated body mass in National Football League players linked to cognitive impairment and decreased prefrontal cortex and temporal pole activity	TRANSLATIONAL PSYCHIATRY			English	Article						body mass index (BMI); cognition; prefrontal cortex; single photon computed tomography (SPECT); temporal pole; waist-to-height ratio (WHtR)	HEALTHY-ADULTS; PROFESSIONAL FOOTBALL; AMERICAN FOOTBALL; LATE-LIFE; OBESITY; INDEX; ASSOCIATION; PREVALENCE; OVERWEIGHT; PERFORMANCE	Obesity is a risk factor for neurodegenerative disease and has been shown to adversely affect cognitive function. Professional athletes who participate in sports, which expose them to repetitive concussions, may be at heightened risk for cognitive impairment. Here, we investigated the effects of body mass as measured by waist-to-height ratio (WHtR) on regional cerebral blood flow using single-photon emission computed tomography imaging in 38 healthy weight (WHtR mean 49.34 +/- 2.8; age 58 +/- 9.6) and 38 overweight (WHtR mean 58.7 +/- 4.7; age 58 +/- 13.3) retired National Football League football players. After matching for age and position, we used a two sample t-test to determine the differences in blood flow in healthy versus overweight subjects. Statistical parametric mapping revealed a higher WHtR ratio is associated with decreased blood flow in Brodmann areas 8, 9 and 10, brain regions involved in attention, reasoning and executive function (P < 0.05, family-wise error) along with deficits in the temporal pole. Moreover, overweight athletes had significant decrease in attention (P = 0.01326), general cognitive proficiency (P = 0.012; Microcog: Assessment of Cognitive Functioning) and memory (P = 0.005; Mild Cognitive Impairment Screen). The association between elevated WHtR percentage and decreased blood flow in the prefrontal cortex and temporal pole may be correlated with the decreased performance on tests of attention and memory. These findings suggest that a weight management program may be critical to the health of athletes who have been exposed to mild brain trauma during their careers. Translational Psychiatry (2012) 2, e68; doi:10.1038/tp.2011.67; published online 17 January 2012	[Willeumier, K.; Taylor, D. V.; Amen, D. G.] Amen Clin, Newport Beach, CA 92660 USA	Amen, DG (corresponding author), Amen Clin, 4019 Westerly Pl,Suite 100, Newport Beach, CA 92660 USA.	docamen@amenclinic.com					Amen DG, 2011, J PSYCHOACTIVE DRUGS, V43, P1, DOI 10.1080/02791072.2011.566489; Amen DG, 2011, J NEUROPSYCH CLIN N, V23, P98, DOI 10.1176/appi.neuropsych.23.1.98; Anstey KJ, 2011, OBES REV, V12, pe426, DOI 10.1111/j.1467-789X.2010.00825.x; Ashburner J, 1999, HUM BRAIN MAPP, V7, P254, DOI 10.1002/(SICI)1097-0193(1999)7:4<254::AID-HBM4>3.0.CO;2-G; Boeka AG, 2008, ARCH CLIN NEUROPSYCH, V23, P467, DOI 10.1016/j.acn.2008.03.003; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; Friston K., 1995, HUM BRAIN MAPP, V2, P189, DOI [10.1002/hbm.460020402, DOI 10.1002/HBM.460020402]; Gazdzinski S, 2008, ANN NEUROL, V63, P652, DOI 10.1002/ana.21377; Gunstad J, 2007, COMPR PSYCHIAT, V48, P57, DOI 10.1016/j.comppsych.2006.05.001; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Harp JB, 2005, JAMA-J AM MED ASSOC, V293, P1061, DOI 10.1001/jama.293.9.1061-b; Kaiser GE, 2008, J STRENGTH COND RES, V22, P243, DOI 10.1519/JSC.0b013e31815f5d97; Laurson KR, 2007, JAMA-J AM MED ASSOC, V297, P363, DOI 10.1001/jama.297.4.363; Malina RM, 2007, J PEDIATR-US, V151, P378, DOI 10.1016/j.jpeds.2007.03.044; Mathews EM, 2008, J AM COLL HEALTH, V57, P33, DOI 10.3200/JACH.57.1.33-38; Medical Care Corporation, 2007, MILD COGN IMP SCREEN; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Miller EK, 2000, NAT REV NEUROSCI, V1, P59, DOI 10.1038/35036228; Omalu B, 2011, NEUROSURGERY, V69, P173, DOI 10.1227/NEU.0b013e318212bc7b; Omalu Bennet I, 2010, J Forensic Nurs, V6, P40, DOI 10.1111/j.1939-3938.2009.01064.x; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Raji CA, 2010, HUM BRAIN MAPP, V31, P353, DOI 10.1002/hbm.20870; Trenkle DL, 2007, J ALZHEIMERS DIS, V11, P323; Tucker AM, 2009, JAMA-J AM MED ASSOC, V301, P2111, DOI 10.1001/jama.2009.716; Volkow ND, 2009, OBESITY, V17, P60, DOI 10.1038/oby.2008.469; Walther K, 2010, HUM BRAIN MAPP, V31, P1052, DOI 10.1002/hbm.20916; Willeumier KC, 2011, OBESITY, V19, P1095, DOI 10.1038/oby.2011.16	27	23	23	0	10	NATURE PUBLISHING GROUP	NEW YORK	75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA	2158-3188			TRANSL PSYCHIAT	Transl. Psychiatr.	JAN	2012	2								e68	10.1038/tp.2011.67			6	Psychiatry	Psychiatry	971PZ	WOS:000306217600004	22832730	DOAJ Gold, Green Published			2021-06-18	
J	Callahan, BL; Ueda, K; Sakata, D; Plamondon, A; Murai, T				Callahan, Brandy L.; Ueda, Keita; Sakata, Daisuke; Plamondon, Andre; Murai, Toshiya			Liberal bias mediates emotion recognition deficits in frontal traumatic brain injury	BRAIN AND COGNITION			English	Article						Emotion; Recognition; Traumatic brain injury; Frontal lobe; Bias	FACIAL AFFECT RECOGNITION; PREFRONTAL CORTEX; HEAD-INJURY; DAMAGE; EXPRESSIONS; SCHIZOPHRENIA; COMMUNICATION; IMPAIRMENT; PERCEPTION; DEPRESSION	It is well-known that patients having sustained frontal-lobe traumatic brain injury (TBI) are severely impaired on tests of emotion recognition. Indeed, these patients have significant difficulty recognizing facial expressions of emotion, and such deficits are often associated with decreased social functioning and poor quality of life. As of yet, no studies have examined the response patterns which underlie facial emotion recognition impairment in TBI and which may lend clarity to the interpretation of deficits. Therefore, the present study aimed to characterize response patterns in facial emotion recognition in 14 patients with frontal TBI compared to 22 matched control subjects, using a task which required participants to rate the intensity of each emotion (happiness, sadness, anger, disgust, surprise and fear) of a series of photographs of emotional and neutral faces. Results first confirmed the presence of facial emotion recognition impairment in TBI, and further revealed that patients displayed a liberal bias when rating facial expressions, leading them to associate intense ratings of incorrect emotional labels to sad, disgusted, surprised and fearful facial expressions. These findings are generally in line with prior studies which also report important facial affect recognition deficits in TBI patients, particularly for negative emotions. (C) 2011 Elsevier Inc. All rights reserved.	[Callahan, Brandy L.; Plamondon, Andre] Univ Laval, Ecole Psychol, Quebec City, PQ G1V 0A6, Canada; [Callahan, Brandy L.] Univ Laval Robert Giffard, Ctr Rech, Quebec City, PQ G1J 2G3, Canada; [Ueda, Keita; Sakata, Daisuke; Murai, Toshiya] Kyoto Univ, Grad Sch Med, Dept Neuropsychiat, Sakyo Ku, Kyoto 6068507, Japan	Callahan, BL (corresponding author), Univ Laval, Ecole Psychol, Pavillon Felix Antoine Savard, Quebec City, PQ G1V 0A6, Canada.	brandy.callahan.1@ulaval.ca	Callahan, Brandy L/E-2483-2011	Callahan, Brandy/0000-0001-5617-2379	Alzheimer Society of Canada; Centre de recherche sur le cerveau, le comportement et la neuropsychiatrie; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23791328] Funding Source: KAKEN	Brandy Callahan is supported by a doctoral award from the Alzheimer Society of Canada and an additional research award from the Centre de recherche sur le cerveau, le comportement et la neuropsychiatrie.	Adolphs R, 2000, J NEUROSCI, V20, P2683; Adolphs R, 2003, BRAIN COGNITION, V52, P61, DOI 10.1016/S0278-2626(03)00009-5; Adolphs R, 1996, J NEUROSCI, V16, P7678; ADOLPHS R, 1994, NATURE, V372, P669, DOI 10.1038/372669a0; Babbage DR, 2011, NEUROPSYCHOLOGY, V25, P277, DOI 10.1037/a0021908; Bechara A, 2000, CEREB CORTEX, V10, P295, DOI 10.1093/cercor/10.3.295; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Benton A.L., 1983, CONTRIBUTIONS NEUROP; Bryson G, 1997, PSYCHIAT RES, V71, P105, DOI 10.1016/S0165-1781(97)00050-4; Croker V, 2005, BRAIN INJURY, V19, P787, DOI 10.1080/02699050500110033; Ekman P., 1976, PICTURES FACIAL AFFE; Fellows LK, 2003, BRAIN, V126, P1830, DOI 10.1093/brain/awg180; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Frenkel TI, 2009, COGNITION EMOTION, V23, P688, DOI 10.1080/02699930802076893; Fukui H, 2005, NEUROIMAGE, V24, P253, DOI 10.1016/j.neuroimage.2004.08.028; Gollan JK, 2008, PSYCHIAT RES, V159, P18, DOI 10.1016/j.psychres.2007.06.011; Halberstadt AG, 2011, J NONVERBAL BEHAV, V35, P35, DOI 10.1007/s10919-010-0099-5; Harlow JM, 1848, BOSTON MED SURG J, V39, P389, DOI DOI 10.1056/NEJM184812130392001; Hayes AF, 2009, COMMUN MONOGR, V76, P408, DOI 10.1080/03637750903310360; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P62, DOI 10.1016/j.neuropsychologia.2005.04.011; Henry JD, 2006, NEUROPSYCHOLOGIA, V44, P1623, DOI 10.1016/j.neuropsychologia.2006.03.020; Holmbeck GN, 2002, J PEDIATR PSYCHOL, V27, P87, DOI 10.1093/jpepsy/27.1.87; Hopkins MJ, 2002, BRAIN INJURY, V16, P245, DOI 10.1080/02699050110103346; Hornak J, 2003, BRAIN, V126, P1691, DOI 10.1093/brain/awg168; Hornak J, 1996, NEUROPSYCHOLOGIA, V34, P247, DOI 10.1016/0028-3932(95)00106-9; Ietswaart M, 2008, NEUROPSYCHOLOGIA, V46, P148, DOI 10.1016/j.neuropsychologia.2007.08.002; JACKSON HF, 1987, CORTEX, V23, P293, DOI 10.1016/S0010-9452(87)80039-4; Kohler CG, 2003, AM J PSYCHIAT, V160, P1768, DOI 10.1176/appi.ajp.160.10.1768; Kucharska-Pietura K, 2003, NEUROPSYCHOLOGIA, V41, P1082, DOI 10.1016/S0028-3932(02)00294-4; Lee SJ, 2009, PSYCHIAT INVEST, V6, P156, DOI 10.4306/pi.2009.6.3.156; Leppanen JM, 2004, PSYCHIAT RES, V128, P123, DOI 10.1016/j.psychres.2004.05.020; MacKinnon DP, 2002, PSYCHOL METHODS, V7, P83, DOI 10.1037/1082-989X.7.1.83; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Matsumoto D, 2007, INT J PSYCHOL, V42, P207, DOI 10.1080/00207590601050926; McDonald S, 2005, J INT NEUROPSYCH SOC, V11, P392, DOI 10.1017/S1355617705050447; McDonald S, 2004, NEUROPSYCHOLOGY, V18, P572, DOI 10.1037/0894-4105.18.3.572; Milders M, 2003, J CLIN EXP NEUROPSYC, V25, P157, DOI 10.1076/jcen.25.2.157.13642; Milders M, 2008, J INT NEUROPSYCH SOC, V14, P318, DOI 10.1017/S1355617708080351; Preacher KJ, 2008, BEHAV RES METHODS, V40, P879, DOI 10.3758/BRM.40.3.879; Radice-Neumann D, 2007, BRAIN INJURY, V21, P807, DOI 10.1080/02699050701504281; Rolls ET, 2008, PROG NEUROBIOL, V86, P216, DOI 10.1016/j.pneurobio.2008.09.001; Soussignan R, 2005, NEUROCASE, V11, P114, DOI 10.1080/13554790590922513; Spell LA, 2000, J NONVERBAL BEHAV, V24, P285, DOI 10.1023/A:1006675230193; Walz NC, 1996, AM J MENT RETARD, V101, P282; Wechsler D., 1981, WAIS R MANUAL WECHSL; Westermann S, 2010, J BEHAV THER EXP PSY, V41, P96, DOI 10.1016/j.jbtep.2009.10.007; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Zald DH, 2010, NEUROPSYCHOLOGIA, V48, P3377, DOI 10.1016/j.neuropsychologia.2010.08.012	48	23	23	0	15	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0278-2626			BRAIN COGNITION	Brain Cogn.	DEC	2011	77	3					412	418		10.1016/j.bandc.2011.08.017			7	Neurosciences; Psychology, Experimental	Neurosciences & Neurology; Psychology	855AG	WOS:000297535300011	21945238				2021-06-18	
J	Emery, CA; Kang, J; Schneider, KJ; Meeuwisse, WH				Emery, Carolyn A.; Kang, Jian; Schneider, Kathryn J.; Meeuwisse, Willem H.			Risk of injury and concussion associated with team performance and penalty minutes in competitive youth ice hockey	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT INJURY; CONSENSUS STATEMENT; BODY CHECKING; PARTICIPATION; RECOVERY; CALGARY; RULES	Objective To determine if there is an association between the risk of all injury or concussion and win-loss records or penalty minutes in competitive youth ice hockey players (ages 11-14). Design, setting, participants This is a secondary data analysis of a 2-year cohort study in Alberta and Quebec on the 2007/2008 (Pee Wee) and 2008/2009 (Bantam) seasons. Main outcome measures Incidence rate ratios (IRRs) were estimated based on Poisson regression for game-related injury and concussion and adjusted for cluster by team. Results A total of 140 teams from Alberta (n=2081) and 137 teams (n=2018) from Quebec were included in the analysis. There were 451 game-related injuries (121 concussions) from Alberta and 280 (62 concussions) from Quebec. For game-related injuries, the IRR between players from teams with more than 50% wins and players with less or equal to 50% wins was 0.78 (95% CI 0.64-0.95) for all injuries, 0.75 (95% CI 0.52-1.08) for concussions, 0.64 (95% CI 0.47-0.88) for injuries resulting in time loss of more than 7 days, and 0.74 (95% CI 0.39-1.40) for concussions resulting in time loss of more than 10 days; adjusting for clustering by team and other important risk factors (ie, province, age, level of play, previous injury, weight and position). There was no association found between the total penalty minutes per game and game-related injury or concussion. Conclusions There was a significant association found between team performance (ie, win/loss/tie record) and injury risk with a 22% lower injury rate and 36% lower injury rate resulting in less than 7 days time loss in Pee Wee and Bantam ice hockey teams winning more than 50% of all season games. Total penalty minutes per game were not associated with injury or concussion rates.	[Emery, Carolyn A.; Schneider, Kathryn J.; Meeuwisse, Willem H.] Univ Calgary, Fac Kinesiol, Roger Jackson Ctr Hlth & Wellness Res, Sport Injury Prevent Res Ctr, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Kang, Jian] Univ Calgary, Fac Med, Dept Pediat, Alberta Childrens Hosp, Calgary, AB T2N 1N4, Canada; [Emery, Carolyn A.; Meeuwisse, Willem H.] Univ Calgary, Fac Med, Dept Community Hlth Sci, Calgary, AB T2N 1N4, Canada	Emery, CA (corresponding author), Univ Calgary, Sport Med Ctr, 2500 Univ Dr NW, Calgary, AB T2N 1N4, Canada.	caemery@ucalgary.ca	Emery, Carolyn/AAI-2761-2020	Schneider, Kathryn/0000-0002-5951-5899	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); Max Bell Foundation; Hockey Calgary; Hockey Edmonton; Hockey Quebec; Hockey Alberta; Hockey Canada; Quebec Ministry of Education, Leisure and Sport; Alberta Heritage FoundationAlberta Heritage Foundation for Medical Research; Department of Pediatrics (Alberta Children's Hospital Foundation), Faculty of Medicine	This study was funded by the Canadian Institutes of Health Research and Max Bell Foundation. This research was possible due to the support from Hockey Calgary, Hockey Edmonton, Hockey Quebec, Hockey Alberta, Hockey Canada and the Quebec Ministry of Education, Leisure and Sport. This research could not have been completed without the support of many Pee Wee players, parents, coaches, team designates, physiotherapists, athletic therapists, student therapists and study physicians. Dr Carolyn Emery is supported by a Population Health Investigator Award from the Alberta Heritage Foundation, a New Investigator Award from the Canadian Institutes of Health Research and a Professorship in Pediatric Rehabilitation from the Department of Pediatrics (Alberta Children's Hospital Foundation), Faculty of Medicine.	Arnason A, 2004, MED SCI SPORT EXER, V36, P278, DOI 10.1249/01.MSS.0000113478.92945.CA; Benson Brian W, 2005, Med Sport Sci, V49, P86, DOI 10.1159/000085393; BERNARD D, 1993, ASTM STP, V1212, P44; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Brunelle JP, 2005, J SCI MED SPORT, V8, P294, DOI 10.1016/S1440-2440(05)80040-4; BRUST JD, 1992, AM J DIS CHILD, V146, P741, DOI 10.1001/archpedi.1992.02160180101026; Emery CA, 2009, PAED CHILD HEALT-CAN, V14, P439, DOI 10.1093/pch/14.7.439; Emery CA, 2006, CLIN J SPORT MED, V16, P20, DOI 10.1097/01.jsm.0000184638.72075.b7; Emery C, 2011, CAN MED ASSOC J, V183, P1249, DOI 10.1503/cmaj.101540; Emery CA, 2006, AM J SPORT MED, V34, P1960, DOI 10.1177/0363546506290061; Emery CA, 2010, JAMA-J AM MED ASSOC, V303, P2265, DOI 10.1001/jama.2010.755; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; Goodman D, 2001, MED SCI SPORT EXER, V33, P2004, DOI 10.1097/00005768-200112000-00005; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; Lau B, 2009, CLIN J SPORT MED, V19, P216, DOI 10.1097/JSM.0b013e31819d6edb; Makdissi M, 2009, BRIT J SPORT MED, V43, pI23, DOI 10.1136/bjsm.2009.058206; Marchie A, 2003, CAN MED ASSOC J, V169, P124; McCrory P, 2009, BRIT J SPORT MED, V43, pI76, DOI 10.1136/bjsm.2009.058248; Meeuwisse WH, 1998, CLIN J SPORT MED, V8, P164, DOI 10.1097/00042752-199807000-00003; REGNIER G, 1989, ASTM STP, V1050, P84; Roberts WO, 1996, ARCH PEDIAT ADOL MED, V150, P140, DOI 10.1001/archpedi.1996.02170270022003; ROY MA, 1989, PHYSICIAN SPORTSMED, V17, P119, DOI 10.1080/00913847.1989.11709735; *STATACORP, 2005, STAT STAT SOFTW COMP; Watson RC, 1996, CLIN J SPORT MED, V6, P108, DOI 10.1097/00042752-199604000-00008	25	23	23	0	11	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	DEC	2011	45	16					1289	1293		10.1136/bjsports-2011-090538			5	Sport Sciences	Sport Sciences	857BI	WOS:000297688500007	22117019				2021-06-18	
J	Hong, SQ; Zhang, HT; You, J; Zhang, MY; Cai, YQ; Jiang, XD; Xu, RX				Hong, Sun-Quan; Zhang, Hong-Tian; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang			Comparison of Transdifferentiated and Untransdifferentiated Human Umbilical Mesenchymal Stem Cells in Rats after Traumatic Brain Injury	NEUROCHEMICAL RESEARCH			English	Article						Cognitive function; Human umbilical mesenchymal stem cells; Neurotrophic factor; Transdifferentiation; Transplantation; Traumatic brain injury	MARROW STROMAL CELLS; SPINAL-CORD-INJURY; NEUROTROPHIC FACTORS; PROGENITOR CELLS; TRANSPLANTATION; THERAPY; STROKE; MODEL; IMPLANTATION; RECOVERY	Transdifferentiated and untransdifferentiated mesenchymal stem cells (MSCs) have shown therapeutic benefits in central nervous system (CNS) injury. However, it is unclear which would be more appropriate for transplantation. To address this question, we transplanted untransdifferentiated human umbilical mesenchymal stem cells (HUMSCs) and transdifferentiated HUMSCs (HUMSC-derived neurospheres, HUMSC-NSs) into a rat model of traumatic brain injury. Cognitive function, cell survival and differentiation, brain tissue morphology and neurotrophin expression were compared between groups. Significant improvements in cognitive function and brain tissue morphology were seen in the HUMSCs group compared with HUMSC-NSs group, which was accompanied by increased neurotrophin expression. Moreover, only few grafted cells survived in both the HUMSCs and HUMSC-NSs groups, with very few of the cells differentiating into neural-like cells. These findings indicate that HUMSCs are more appropriate for transplantation and their therapeutic benefits may be associated with neuroprotection rather than cell replacement.	[Hong, Sun-Quan; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China; [Hong, Sun-Quan; You, Jian; Zhang, Mao-Ying; Cai, Ying-Qian; Jiang, Xiao-Dan; Xu, Ru-Xiang] So Med Univ, Inst Neurosurg, Key Lab Brain Funct Repair & Regenerat Guangdong, Guangzhou 510282, Guangdong, Peoples R China; [Hong, Sun-Quan; Zhang, Hong-Tian; Xu, Ru-Xiang] Mil Gen Hosp Beijing PLA, Dept Neurosurg, Beijing 100700, Peoples R China	Jiang, XD (corresponding author), So Med Univ, Zhujiang Hosp, Dept Neurosurg, Guangzhou 510282, Guangdong, Peoples R China.	jxd_neuroscience@163.com; xuruxiang_neuron@126.com			Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [U0632008, 30772232, 30801184]; Foundation for Key Sci-Tech Research Projects of Guangdong [2008A030201019, 2007-05/06-70052]	The authors acknowledge Health & Biotech Company (Guangzhou, Guangdong, China) for them kindly present human umbilical mesenchymal stem cells. This work was supported by Natural Science Foundation of China (NSFC) (No. U0632008, 30772232, 30801184) and Foundation for Key Sci-Tech Research Projects of Guangdong (No. 2008A030201019, 2007-05/06-70052).	ABERCROMBIE M, 1946, ANAT REC, V94, P239, DOI 10.1002/ar.1090940210; Bath KG, 2006, COGN AFFECT BEHAV NE, V6, P79, DOI 10.3758/CABN.6.1.79; Boyce VS, 2007, J NEUROPHYSIOL, V98, P1988, DOI 10.1152/jn.00391.2007; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Fu YS, 2006, STEM CELLS, V24, P115, DOI 10.1634/stemcells.2005-0053; Gao JL, 2006, EXP NEUROL, V201, P281, DOI 10.1016/j.expneurol.2006.04.039; Gogel S, 2011, GENE THER, V18, P1, DOI 10.1038/gt.2010.130; Hains BC, 2004, EXP NEUROL, V188, P365, DOI 10.1016/j.expneurol.2004.04.001; Hayase M, 2009, J CEREBR BLOOD F MET, V29, P1409, DOI 10.1038/jcbfm.2009.62; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Kim HJ, 2010, J NEUROTRAUM, V27, P131, DOI [10.1089/neu.2008.0818, 10.1089/neu.2008-0818]; Koh SH, 2008, BRAIN RES, V1229, P233, DOI 10.1016/j.brainres.2008.06.087; Lee MW, 2007, BIOCHEM BIOPH RES CO, V358, P637, DOI 10.1016/j.bbrc.2007.04.181; Liao WB, 2009, TRANSPLANTATION, V87, P350, DOI 10.1097/TP.0b013e318195742e; PAXINOS G, 2005, RAT BRAIN STEREOTAXI, P98; Pisati F, 2007, CELL TRANSPLANT, V16, P41, DOI 10.3727/000000007783464443; Shang AJ, 2011, BRAIN RES, V1391, P102, DOI 10.1016/j.brainres.2011.03.019; Skardelly M, 2011, J NEUROTRAUM, V28, P401, DOI 10.1089/neu.2010.1526; Vaquero J, 2009, HISTOL HISTOPATHOL, V24, P107, DOI 10.14670/HH-24.107; Walker PA, 2010, REGEN MED, V5, P65, DOI 10.2217/RME.09.73; Walker PA, 2009, DIS MODEL MECH, V2, P23, DOI 10.1242/dmm.001198; Weiss ML, 2006, STEM CELLS, V24, P781, DOI 10.1634/stemcells.2005-0330; Yang CC, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003336; Zhang HT, 2009, NEUROSCI LETT, V458, P116, DOI 10.1016/j.neulet.2009.04.045; Zhang L, 2009, NEUROCHEM RES, V34, P2030, DOI 10.1007/s11064-009-9992-x; Zhang W, 2010, BRAIN RES, V1359, P256, DOI 10.1016/j.brainres.2010.08.072; Zurita M, 2008, NEUROSCI RES, V60, P275, DOI 10.1016/j.neures.2007.11.006	28	23	25	1	17	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	DEC	2011	36	12					2391	2400		10.1007/s11064-011-0567-2			10	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	841MN	WOS:000296516500024	21877237				2021-06-18	
J	Taha, AA; Badr, L; Westlake, C; Dee, V; Mudit, M; Tiras, KL				Taha, Asma A.; Badr, Lina; Westlake, Cheryl; Dee, Vivien; Mudit, Mathur; Tiras, Kathyrne L.			Effect of Early Nutritional Support on Intensive Care Unit Length of Stay and Neurological Status at Discharge in Children With Severe Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE NURSING			English	Article							HEAD-INJURY; OUTCOMES	Pediatric severe traumatic brain injury treatment guidelines for nutrition indicate that "there are insufficient data to support a treatment guideline for this topic" (P. D. Adelson et al., 2003). Based on adult studies, the guideline provided an option for practitioners to start nutritional support within 72 hours of admission and full replacement by day 7. This retrospective, descriptive correlation study examined the timing of nutritional supplement initiation and the timing of achieving full caloric intake in relation to length of stay (LOS) in the intensive care unit (ICU) and patient disposition status at discharge from hospital in children 8-18 years old. Median time to initiation of nutrition was 1.5 days (0.02-11.9 days), and full caloric goals were achieved in 3.4 days (0.5-19.6 days). Median ICU LOS was 2.1 days (0.01-97.9 days). Overall, 48% of patients were discharged home; 28% experienced mild, moderate, or severe disability; and 24% either died or survived in a vegetative state. Early initiation and achieving full caloric intake were both positively correlated with shorter LOS in the ICU (p < .01, Spearman's rho correlational matrix) and better disposition status at discharge from the hospital (p < .05, Kruskal-Wallis test).	[Taha, Asma A.; Tiras, Kathyrne L.] Calif State Univ San Bernardino, San Bernardino, CA 92407 USA; [Taha, Asma A.; Tiras, Kathyrne L.] Loma Linda Univ, Med Ctr, Loma Linda, CA USA; [Badr, Lina] Azusa Pacific Univ, MSN Program, Azusa, CA USA; [Badr, Lina] Azusa Pacific Univ, PNP Program, Azusa, CA USA; [Westlake, Cheryl] Azusa Pacific Univ, Int Program, Azusa, CA USA; [Westlake, Cheryl] Azusa Pacific Univ, Community Program, Azusa, CA USA; [Westlake, Cheryl] Azusa Pacific Univ, Nursing PhD Program, Azusa, CA USA; [Dee, Vivien] Azusa Pacific Univ, PhD Program, Azusa, CA USA; [Mudit, Mathur] Loma Linda Univ, Div Pediat Crit Care Med, Loma Linda, CA 92350 USA	Taha, AA (corresponding author), Calif State Univ San Bernardino, San Bernardino, CA 92407 USA.	ataha@llu.edu			Azusa Pacific University	This work was funded by a Doctoral Dissertation Grant-Nursing PhD Program, Azusa Pacific University.	Adelson P. D., 2003, PEDIAT CRITICAL C S3, V4, P68; Amorde-Spalding K., 2008, PEDIAT MANUAL CLIN D; Bratton SL, 2007, J NEUROTRAUM, V24, P77; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; FISER DH, 1992, J PEDIATR-US, V121, P68, DOI 10.1016/S0022-3476(05)82544-2; Fiser DH, 2000, CRIT CARE MED, V28, P1173, DOI 10.1097/00003246-200004000-00043; Gurgueira GL, 2005, JPEN-PARENTER ENTER, V29, P176, DOI 10.1177/0148607105029003176; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hulst JM, 2006, CURR OPIN CLIN NUTR, V9, P297, DOI 10.1097/01.mco.0000222115.91783.71; Ista Erwin, 2005, Crit Care Nurs Clin North Am, V17, P385, DOI 10.1016/j.ccell.2005.07.011; Joffe A, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD005144.pub2; Klodell CT, 2000, AM J SURG, V179, P168, DOI 10.1016/S0002-9610(00)00297-X; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lopez-Herce J, 2005, PEDIATR EMERG CARE, V21, P807; MOORE R, 1989, J TRAUMA, V29, P1633, DOI 10.1097/00005373-198912000-00007; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Paden M., 2002, INJURY LEADING CAUSE; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; PHILLIPS R, 1987, J NEUROSURG, V67, P846, DOI 10.3171/jns.1987.67.6.0846; Rhoney DH, 2002, NEUROL RES, V24, P613, DOI 10.1179/016164102101200456; Rogers EJ, 2003, NUTRITION, V19, P865, DOI 10.1016/S0899-9007(03)00170-9; Spalding HK, 2000, CRIT CARE MED, V28, P2041, DOI 10.1097/00003246-200006000-00060; Spinella PC, 2003, CRIT CARE MED, V31, P939, DOI 10.1097/01.CCM.0000053644.16336.52; Taylor SJ, 1999, CRIT CARE MED, V27, P2525, DOI 10.1097/00003246-199911000-00033; Thurman DJ, 2001, HEAD TRAUMA, P327; White JRM, 2001, CRIT CARE MED, V29, P534, DOI 10.1097/00003246-200103000-00011	26	23	24	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0888-0395	1945-2810		J NEUROSCI NURS	J. Neurosci. Nurs.	DEC	2011	43	6					291	297		10.1097/JNN.0b013e318234e9b2			7	Clinical Neurology; Nursing	Neurosciences & Neurology; Nursing	850PL	WOS:000297207700003	22089405				2021-06-18	
J	Sacco, K; Cauda, F; D'Agata, F; Duca, S; Zettin, M; Virgilio, R; Nascimbeni, A; Belforte, G; Eula, G; Gastaldi, L; Appendino, S; Geminiani, G				Sacco, Katiuscia; Cauda, Franco; D'Agata, Federico; Duca, Sergio; Zettin, Marina; Virgilio, Roberta; Nascimbeni, Alberto; Belforte, Guido; Eula, Gabriella; Gastaldi, Laura; Appendino, Silvia; Geminiani, Giuliano			A combined robotic and cognitive training for locomotor rehabilitation: evidences of cerebral functional reorganization in two chronic traumatic brain injured patients	FRONTIERS IN HUMAN NEUROSCIENCE			English	Article						motor training; cognitive training; motor imagery; locomotor rehabilitation; brain injury; robotic gait orthosis; functional magnetic resonance imaging; brain plasticity	DRIVEN GAIT ORTHOSIS; MOTOR IMAGERY; MENTAL PRACTICE; ANKLE DORSIFLEXION; STROKE PATIENTS; THERAPY; FMRI; CONNECTIVITY; ACTIVATION; PLASTICITY	It has been demonstrated that automated locomotor training can improve walking capabilities spinal cord-injured subjects but its effectiveness on brain damaged patients has not been well established. A possible explanation of the discordant results on the efficacy of robotic training in patients with cerebral lesions could be that these patients. besides stimulation of physiological motor patterns through passive leg movements, also need to train the cognitive aspects of motor control. Indeed another way to stimulated cerebral motor areas in paretic patients is to use the cognitive function of motor imagery. A promising possibility is thus to combine sensorimotor training with the use of motor imagery. The aim of this paper is to assess changes in brain activations after a combined sensorimotor and cognitive training for gait rehabilitation. The protocol consisted of the integrated use of a robotic gait orthosis prototype with locomotor imagery tasks. Assessment was conducted on two patients with chronic traumatic brain injury and major gait impairments, using functional magnetic resonance imaging. Physiatric functional scales were used to assess clinical outcomes. Results showed greater activation post-training in the sensorimotor and supplementary motor cortices, as well as enhanced functional connectivity within the motor network improvements in balance and, to a lesser extent, in gait outcomes were also found.	[Sacco, Katiuscia; Cauda, Franco; D'Agata, Federico; Geminiani, Giuliano] Univ Turin, Dept Psychol, Turin, Italy; [Sacco, Katiuscia; Cauda, Franco; D'Agata, Federico; Duca, Sergio; Geminiani, Giuliano] Koelliker Hosp, Dept Neuroradiol, Turin, Italy; [Sacco, Katiuscia; Geminiani, Giuliano] Neurosci Inst Turin, Turin, Italy; [Zettin, Marina; Virgilio, Roberta] Ctr Puzzle, Turin, Italy; [Nascimbeni, Alberto] Santa Croce Hosp, Physiatr Unit, Turin, Italy; [Belforte, Guido; Eula, Gabriella; Gastaldi, Laura; Appendino, Silvia] Politecn Torino, Dept Mech, Turin, Italy	Sacco, K (corresponding author), Univ Turin, Dept Psychol, Via Po 14, Turin, Italy.	katiuscia.sacco@unito.it	Cauda, Franco/G-5021-2010; Sacco, Katiuscia/J-2133-2012	Cauda, Franco/0000-0003-1526-8475; Sacco, Katiuscia/0000-0002-9660-5236; D'Agata, Federico/0000-0001-9432-0248	Piedmont RegionRegione Piemonte [4/2006]	This research was supported by the Piedmont Region, under the 2008 Human and Social Sciences grant, pursuant to Region Law no. 4/2006 (Regione Piemonte, bando Scienze Umane e Sociali 2008, L.R. n. 4/2006). The authors would like to thank the patients who participated in the study and their families.	Basford JR, 2003, ARCH PHYS MED REHAB, V84, P343, DOI 10.1053/apmr.2003.50034; Belforte G, 2001, MECHATRONICS, V11, P301, DOI 10.1016/S0957-4158(00)00017-9; Belforte G, 1997, SIMULATIONS IN BIOMEDICINE IV, P199; Berthoz A., 2000, BRAINS SENSE MOVEMEN; BOHANNON R W, 1989, Physiotherapy Canada, V41, P198; Colombo G, 2000, J REHABIL RES DEV, V37, P693; Colombo G, 2001, SPINAL CORD, V39, P252, DOI 10.1038/sj.sc.3101154; de Bode S, 2005, J CHILD NEUROL, V20, P64, DOI 10.1177/08830738050200011101; de Bode S, 2007, NEUROREHAB NEURAL RE, V21, P497, DOI 10.1177/1545968307299523; DECETY J, 1990, EUR ARCH PSY CLIN N, V240, P39, DOI 10.1007/BF02190091; Dickstein R, 2004, PHYS THER, V84, P1167, DOI 10.1093/ptj/84.12.1167; Dobkin BH, 2004, NEUROIMAGE, V23, P370, DOI 10.1016/j.neuroimage.2004.06.008; DRISKELL JE, 1994, J APPL PSYCHOL, V79, P481, DOI 10.1037/0021-9010.79.4.481; Dunsky A, 2006, INT J REHABIL RES, V29, P351, DOI 10.1097/MRR.0b013e328010f559; Enzinger C, 2008, STROKE, V39, P1507, DOI 10.1161/STROKEAHA.107.501999; Forrester LW, 2008, J REHABIL RES DEV, V45, P205, DOI 10.1682/JRRD.2007.02.0034; FRISTON KJ, 1993, J CEREBR BLOOD F MET, V13, P5, DOI 10.1038/jcbfm.1993.4; Hidler J, 2009, NEUROREHAB NEURAL RE, V23, P5, DOI 10.1177/1545968308326632; HOLDEN MK, 1986, PHYS THER, V66, P1530, DOI 10.1093/ptj/66.10.1530; Hornby TG, 2008, STROKE, V39, P1786, DOI 10.1161/STROKEAHA.107.504779; Husemann B, 2007, STROKE, V38, P349, DOI 10.1161/01.STR.0000254607.48765.cb; Jackson PL, 2004, NEUROREHAB NEURAL RE, V18, P106, DOI 10.1177/0888439004265249; Jackson PL, 2001, ARCH PHYS MED REHAB, V82, P1133, DOI 10.1053/apmr.2001.24286; Jezernik S, 2003, SPINAL CORD, V41, P657, DOI 10.1038/sj.sc.3101518; KARNI A, 1995, NATURE, V377, P155; Kelly C, 2006, ARCH PHYS MED REHAB, V87, pS20, DOI 10.1016/j.apmr.2006.08.333; LAWRENCE DG, 1968, BRAIN, V91, P1, DOI 10.1093/brain/91.1.1; Li X, 2008, PROCEEDINGS OF THE 11TH JOINT CONFERENCE ON INFORMATION SCIENCES; MAHONEY F I, 1965, Md State Med J, V14, P61; Malouin F, 2004, NEUROREHAB NEURAL RE, V18, P66, DOI 10.1177/0888439004266304; Malouin F, 2010, PHYS THER, V90, P240, DOI 10.2522/ptj.20090029; Mayr A, 2007, NEUROREHAB NEURAL RE, V21, P307, DOI 10.1177/1545968307300697; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Milton J, 2008, METHODS, V45, P336, DOI 10.1016/j.ymeth.2008.05.002; Nelles G, 2004, RESTOR NEUROL NEUROS, V22, P239; PASCUALLEONE A, 1994, SCIENCE, V263, P1287, DOI 10.1126/science.8122113; Phillips JP, 2007, DEV MED CHILD NEUROL, V49, P39, DOI 10.1017/S0012162207000102; Rossini P M, 2007, Eura Medicophys, V43, P241; Sacco K, 2006, NEUROIMAGE, V32, P1441, DOI 10.1016/j.neuroimage.2006.05.018; Sacco K, 2009, BRAIN RES, V1297, P124, DOI 10.1016/j.brainres.2009.08.049; Sahyoun C, 2004, NEUROIMAGE, V21, P568, DOI 10.1016/j.neuroimage.2003.09.065; Schwartz I, 2009, PM&R, V1, P516, DOI 10.1016/j.pmrj.2009.03.009; SIRIGU A, 1995, NEUROREPORT, V6, P997, DOI 10.1097/00001756-199505090-00012; Talairach J., 1988, COPLANAR STEREOTAXIC; Waldner A, 2009, FUNCT NEUROL, V24, P173; Westlake KP, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-18; Winchester P, 2005, NEUROREHAB NEURAL RE, V19, P313, DOI 10.1177/1545968305281515; Wirz M, 2005, ARCH PHYS MED REHAB, V86, P672, DOI 10.1016/j.apmr.2004.08.004; Yen CL, 2008, NEUROREHAB NEURAL RE, V22, P22, DOI 10.1177/1545968307301875	49	23	23	0	19	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-5161			FRONT HUM NEUROSCI	Front. Hum. Neurosci.	NOV 23	2011	5									10.3389/fnhum.2011.00146			9	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	882GS	WOS:000299552400001	22275890	DOAJ Gold, Green Published			2021-06-18	
J	Risbud, RM; Lee, C; Porter, BE				Risbud, Rashmi M.; Lee, Carolyn; Porter, Brenda E.			Neurotrophin-3 mRNA a putative target of miR21 following status epilepticus	BRAIN RESEARCH			English	Article						Epilepsy; Hippocampus; Pilocarpine; MicroRNA; Neurotrophin-3; miR21	TEMPORAL-LOBE EPILEPSY; TRAUMATIC BRAIN-INJURY; RAT HIPPOCAMPUS; DENTATE GYRUS; MICRORNA MATURATION; GENE-REGULATION; EXPRESSION; NT-3; BDNF; EPILEPTOGENESIS	Status epilepticus induces a cascade of protein expression changes contributing to the subsequent development of epilepsy. By identifying the cascade of molecular changes that contribute to the development of epilepsy we hope to be able to design therapeutics for preventing epilepsy. MicroRNAs influence gene expression by altering mRNA stability and/or translation and have been implicated in the pathology of multiple diseases. MiR21 and its co-transcript miR21*, microRNAs produced from either the 5' or 3' ends of the same precursor RNA strand, are increased in the hippocampus following status epilepticus. We have identified a miR21 binding site, in the 3' UTR of neurotrophin-3 that inhibits translation. Neurotrophin-3 mRNA levels decrease in the hippocampus following SE concurrent with the increase in miR21. MiR21 levels in cultured hippocampal neurons inversely correlate with neurotrophin-3 mRNA levels. Treatment of hippocampal neuronal cultures with excess K(+)Cl(-), a depolarizing agent mimicking the episode of status epilepticus, also results in an increase in miR21 and a decrease in neurotrophin-3 mRNA. MiR21 is a candidate for regulating neurotrophin-3 signaling in the hippocampus following status epilepticus. (C) 2011 Elsevier BM. All rights reserved.	[Risbud, Rashmi M.; Lee, Carolyn; Porter, Brenda E.] Childrens Hosp Philadelphia, Dept Pediat, Div Neurol, Philadelphia, PA 19104 USA; [Porter, Brenda E.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA	Porter, BE (corresponding author), Childrens Hosp Philadelphia, Dept Pediat, Div Neurol, 502C Abramson Res Bldg,3516 Civ Ctr Blvd, Philadelphia, PA 19104 USA.	porterb@email.chop.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS056222] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS056222] Funding Source: NIH RePORTER		Altman Naomi, 2005, Appl Bioinformatics, V4, P33, DOI 10.2165/00822942-200504010-00004; BENGZON J, 1993, NEUROSCIENCE, V53, P433, DOI 10.1016/0306-4522(93)90207-V; Binder DK, 2007, PROG BRAIN RES, V163, P371, DOI 10.1016/S0079-6123(07)63022-2; Buller B, 2010, FEBS J, V277, P4299, DOI 10.1111/j.1742-4658.2010.07818.x; CHENG B, 1994, BRAIN RES, V640, P56, DOI 10.1016/0006-8993(94)91857-0; Cummings DD, 1996, J NEUROSCI, V16, P5312; Davis BN, 2008, NATURE, V454, P56, DOI 10.1038/nature07086; Davis BN, 2010, MOL CELL, V39, P373, DOI 10.1016/j.molcel.2010.07.011; Elmer E, 1997, EXP NEUROL, V145, P93, DOI 10.1006/exnr.1997.6478; Gabriely G, 2008, MOL CELL BIOL, V28, P5369, DOI 10.1128/MCB.00479-08; He XP, 2004, NEURON, V43, P31, DOI 10.1016/j.neuron.2004.06.019; Hicks RR, 1997, MOL BRAIN RES, V48, P401, DOI 10.1016/S0169-328X(97)00158-7; Hu K, 2011, NEUROSCI LETT, V488, P252, DOI 10.1016/j.neulet.2010.11.040; Kim SY, 1998, EPILEPSY RES, V29, P211; Kulshreshtha R, 2007, MOL CELL BIOL, V27, P1859, DOI 10.1128/MCB.01395-06; Lin EJD, 2003, EUR J NEUROSCI, V18, P2087, DOI 10.1046/j.1460-9568.2003.02926.x; Lowenstein DH, 1996, J NEUROSCI, V16, P1759; Lu TX, 2009, J IMMUNOL, V182, P4994, DOI 10.4049/jimmunol.0803560; Mudo G, 1996, EPILEPSIA, V37, P198, DOI 10.1111/j.1528-1157.1996.tb00012.x; Nilsen TW, 2007, TRENDS GENET, V23, P243, DOI 10.1016/j.tig.2007.02.011; Noe F, 2008, BRAIN, V131, P1506, DOI 10.1093/brain/awn079; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Raol YH, 2006, J NEUROSCI, V26, P11342, DOI 10.1523/JNEUROSCI.3329-06.2006; Redell JB, 2011, J NEUROSCI RES, V89, P212, DOI 10.1002/jnr.22539; Sayed D, 2008, MOL BIOL CELL, V19, P3272, DOI 10.1091/mbc.E08-02-0159; SCHMIDTKASTNER R, 1995, EXP NEUROL, V136, P199, DOI 10.1006/exnr.1995.1096; Thomson JM, 2006, GENE DEV, V20, P2202, DOI 10.1101/gad.1444406; Thum T, 2008, NATURE, V456, P980, DOI 10.1038/nature07511; Tsai CA, 2003, NUCLEIC ACIDS RES, V31, DOI 10.1093/nar/gng052; van Rooij E, 2006, P NATL ACAD SCI USA, V103, P18255, DOI 10.1073/pnas.0608791103; Xu B, 2002, NEUROSCIENCE, V115, P1295, DOI 10.1016/S0306-4522(02)00384-6; Yang JT, 2005, EXP NEUROL, V192, P437, DOI 10.1016/j.expneurol.2004.12.023; Ziu MT, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0014724	33	23	29	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	NOV 18	2011	1424						53	59		10.1016/j.brainres.2011.09.039			7	Neurosciences	Neurosciences & Neurology	854IG	WOS:000297487600006	22019057	Green Accepted			2021-06-18	
J	Bernhard, M; Matthes, G; Kanz, KG; Waydhas, C; Fischbacher, M; Fischer, M; Bottiger, BW				Bernhard, M.; Matthes, G.; Kanz, K. G.; Waydhas, C.; Fischbacher, M.; Fischer, M.; Boettiger, B. W.			Emergency anesthesia, airway management and ventilation in major trauma. Background and key messages of the interdisciplinary S3 guidelines for major trauma patients	ANAESTHESIST			German	Article						Multiple trauma; Airway management; Endotracheal intubation; Capnography; Emergency anesthesia	RAPID-SEQUENCE INTUBATION; ADVANCED LIFE-SUPPORT; HOSPITAL ENDOTRACHEAL INTUBATION; CRITICALLY-ILL PATIENTS; IN-LINE STABILIZATION; TIDAL CARBON-DIOXIDE; ACUTE LUNG INJURY; TRACHEAL INTUBATION; BRAIN-INJURY; PREHOSPITAL AIRWAY	Patients with multiple trauma presenting with apnea or a gasping breathing pattern (respiratory rate < 6/min) require prehospital endotracheal intubation (ETI) and ventilation. Additional indications are hypoxia (SpO2 < 90% despite oxygen insufflation and after exclusion of tension pneumothorax), severe traumatic brain injury [Glasgow Coma Scale (GCS) < 9], trauma-associated hemodynamic instability [systolic blood pressure (SBP) < 90 mmHg] and severe chest trauma with respiratory insufficiency (respiratory rate > 29/min). The induction of anesthesia after preoxygenation is conducted as rapid sequence induction (analgesic, hypnotic drug, neuromuscular blocking agent). With the availability of ketamine as a viable alternative, the use of etomidate is not encouraged due to its side effects on adrenal function. An electrocardiogram (ECG), blood pressure measurement and pulse oximetry are needed to monitor the emergency anesthesia and the secured airway. Capnography is absolutely mandatory to confirm correct placement of the endotracheal tube and to monitor tube dislocations as well as ventilation and oxygenation in the prehospital and hospital setting. Because airway management is often complicated in trauma patients, alternative devices and a fiber-optic endoscope need to be available within the hospital. Use of these alternative measures for airway management and ventilation should be considered at the latest after a maximum of three unsuccessful intubation attempts. Emergency medical service (EMS) physicians should to be trained in emergency anesthesia, ETI and alternative methods of airway management on a regular basis. Within hospitals ETI, emergency anesthesia and ventilation are to be conducted by trained and experienced anesthesiologists. When a difficult airway or induction of anesthesia is expected, endotracheal intubation should be supervised or conducted by an anesthesiologist. Normoventilation should be the goal of mechanical ventilation. After arrival in the resuscitation room the ventilation will be controlled and guided with the help of arterial blood gas analyses. After temporary removal of a cervical collar, the cervical spine needs to be immobilized by means of manual in-line stabilization when securing the airway.	[Boettiger, B. W.] Univ Klinikum Koln AoR, Klin Anasthesiol & Operat Intens Med, D-50937 Cologne, Germany; [Bernhard, M.] Univ Klinikum Leipzig, Zent Notaufnahme Notaufnahmestn, Leipzig, Germany; [Matthes, G.] Ernst Moritz Arndt Univ Greifswald, Greifswald, Germany; [Matthes, G.] Unfallkrankenhaus Berlin, Klin Unfallchirurg & Orthopadie, Berlin, Germany; [Kanz, K. G.] Klinikum Univ, Chirurg Klin & Poliklin, Munich, Germany; [Waydhas, C.; Fischbacher, M.] Univ Klinikum Essen, Klin Unfallchirurg, Essen, Germany; [Fischer, M.] Kliniken Landkreises Goppingen gGmbH, Klin Anasthesiol Operat Intens Med Notfallmed & S, Klin Eichert, Goppingen, Germany	Bottiger, BW (corresponding author), Univ Klinikum Koln AoR, Klin Anasthesiol & Operat Intens Med, Kerpener Str 62, D-50937 Cologne, Germany.	bernd.boettiger@uk-koeln.de					Adnet F, 1998, ANN EMERG MED, V32, P454, DOI 10.1016/S0196-0644(98)70175-1; Albrecht E, 2006, EUR J TRAUMA, V32, P516, DOI DOI 10.1007/S00068-006-6001-Z; AMATO MBP, 1995, AM J RESP CRIT CARE, V152, P1835, DOI 10.1164/ajrccm.152.6.8520744; American College of Surgeons Committee on Trauma, 2008, ATLS STUD COURS MAN; Arbabi S, 2004, J TRAUMA, V56, P1029, DOI 10.1097/01.TA.0000123036.20919.4B; Aufmkolk M, 2003, UNFALLCHIRURG, V106, P746, DOI 10.1007/s00113-003-0640-7; Badjatia N, 2008, PREHOSP EMERG CARE, V12, pS1, DOI 10.1080/10903120701732052; Becke K, 2007, ANASTH INTENSIVMED, V9, P624; Berlac P, 2008, ACTA ANAESTH SCAND, V52, P897, DOI 10.1111/j.1399-6576.2008.01673.x; Berlot G, 2009, EUR J EMERG MED, V16, P312, DOI 10.1097/MEJ.0b013e32832d3aa1; Bernhard M, 2011, EUR J ANAESTH, V28, P75, DOI 10.1097/EJA.0b013e328342325a; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bonhomme V, 2009, CURR OPIN ANESTHESIO, V22, P579, DOI 10.1097/ACO.0b013e32832e7adb; Bratton SL, 2007, J NEUROTRAUMA S1, V24, P87; Braun U, 2004, ANASTH INTENSIVMED, V45, P302; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Bullock MR, 2007, J NEUROTRAUMA S1, V24, P87; Caplan RA, 2003, ANESTHESIOLOGY, V98, P1269; Caulfield EV, 2009, J TRAUMA, V66, P1577, DOI 10.1097/TA.0b013e3181a3931d; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chesnut RM, 1997, J TRAUMA, V42, pS4, DOI 10.1097/00005373-199705001-00002; Cobas MA, 2009, ANESTH ANALG, V109, P489, DOI 10.1213/ane.0b013e3181aa3063; Cogbill TH, 2008, J TRAUMA, V65, P994, DOI 10.1097/TA.0b013e318184ce12; Combes X, 2006, ACAD EMERG MED, V13, P828, DOI 10.1197/j.aem.2006.02.016; Cotton BA, 2008, ARCH SURG-CHICAGO, V143, P62, DOI 10.1001/archsurg.143.1.62; Cudnik MT, 2007, PREHOSP EMERG CARE, V11, P224, DOI 10.1080/10903120701205208; Davis DP, 2010, J TRAUMA, V69, P294, DOI 10.1097/TA.0b013e3181dc6c7f; Davis DP, 2003, J TRAUMA, V54, P444, DOI 10.1097/01.TA.0000053396.02126.CD; Deakin CD, 2010, RESUSCITATION, V81, P1305, DOI 10.1016/j.resuscitation.2010.08.017; Deakin CD, 2010, RESUSCITATION, V81, P539, DOI 10.1016/j.resuscitation.2010.02.001; Deutsche Gesellschaft fur Anasthesiologie und Intensivmedizin und Berufsverbande Deutscher Anasthesisten, 2007, ANASTH INTENSIVMED, V39, P470; Dewar D, 2009, INJURY, V40, P912, DOI 10.1016/j.injury.2009.05.024; DIN 75079 2002-08, 2004, DIN TASCH, V3, pS; DiRusso SM, 2005, J TRAUMA, V59, P84, DOI 10.1097/01.TA.0000171462.28379.F3; Dunham CM, 2003, J TRAUMA, V55, P162, DOI 10.1097/01.ta.0000083335.93868.2c; Dupanovic M, 2010, CURR OPIN ANESTHESIO, V23, P276, DOI 10.1097/ACO.0b013e3283360b4f; Eckstein M, 2000, J TRAUMA, V48, P643, DOI 10.1097/00005373-200004000-00010; Eich C, 2009, RESUSCITATION, V80, P888, DOI 10.1016/j.resuscitation.2009.05.008; El-Orbany M, 2010, ANESTH ANALG, V110, P1318, DOI 10.1213/ANE.0b013e3181d5ae47; EN 13718-2 (D), 2004, DIN TASCH, V3, P385; EN 1789: 1999, 2004, DIN TASCH, V3, pS; Fakhry SM, 2006, J TRAUMA, V60, P997, DOI 10.1097/01.ta.0000217285.94057.5e; Franschman G, 2009, RESUSCITATION, V80, P1147, DOI 10.1016/j.resuscitation.2009.06.029; Gausche M, 2000, JAMA-J AM MED ASSOC, V283, P783, DOI 10.1001/jama.283.6.783; Genzwurker H, 2007, ANAESTHESIST, V56, P665, DOI 10.1007/s00101-007-1194-9; Genzwurker HV, 2008, EUROANAESTHESIA; Gries A, 2008, ANAESTHESIST, V57, P562, DOI 10.1007/s00101-008-1373-3; Grmec S, 2004, EMERG MED J, V21, P518, DOI 10.1136/emj.2002.001974; Hager DN, 2005, AM J RESP CRIT CARE, V172, P1241, DOI 10.1164/rccm.200501-048CP; Heidegger T, 2005, BEST PRACT RES-CLIN, V19, P661, DOI 10.1016/j.bpa.2005.07.001; Helm M, 2006, BRIT J ANAESTH, V96, P67, DOI 10.1093/bja/aei275; Helm M, 2002, BRIT J ANAESTH, V88, P345, DOI 10.1093/bja/88.3.345; Henderson JJ, 2004, ANAESTHESIA, V59, P675, DOI 10.1111/j.1365-2044.2004.03831.x; Hildreth AN, 2008, J TRAUMA, V65, P573, DOI 10.1097/TA.0b013e31818255e8; Jabre P, 2009, LANCET, V374, P293, DOI 10.1016/S0140-6736(09)60949-1; Jeremitsky E, 2003, J TRAUMA, V54, P312, DOI 10.1097/01.TA.0000037876.37236.D6; Katz SH, 2001, ANN EMERG MED, V37, P32, DOI 10.1067/mem.2001.112098; Keel M, 2006, EUR J TRAUMA, V32, P387; Keul W, 2004, ANAESTHESIST, V53, P978, DOI 10.1007/s00101-004-0734-9; Klemen P, 2006, ACTA ANAESTH SCAND, V50, P1250, DOI 10.1111/J.1399-6576.2006.01039.X; Konrad C, 1998, ANESTH ANALG, V86, P635; Lackner CK, 2002, NOTFALL RETTUNGSMED, V5, P430; Lavery GG, 2008, CRIT CARE MED, V36, P2163, DOI 10.1097/CCM.0b013e31817d7ae1; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lee SW, 2009, J TRAUMA, V67, P526, DOI 10.1097/TA.0b013e3181866432; Liberman M, 2007, CURR OPIN CRIT CARE, V13, P691, DOI 10.1097/MCC.0b013e3282f1e77e; Manoach S, 2007, ANN EMERG MED, V50, P236, DOI 10.1016/j.annemergmed.2007.01.009; Morris C, 2009, ANAESTHESIA, V64, P532, DOI 10.1111/j.1365-2044.2008.05835.x; Mort TC, 2005, CRIT CARE MED, V33, P2672, DOI 10.1097/01.CCM.0000187131.67594.9E; Mort TC, 2004, ANESTH ANALG, V99, P607, DOI 10.1213/01.ANE.0000122825.04923.15; Mort TC, 2005, J CLIN ANESTH, V17, P255, DOI 10.1016/j.jclinane.2005.02.004; Mort TC, 2009, CRIT CARE MED, V37, P68, DOI 10.1097/CCM.0b013e318192845e; Muakkassa FF, 2010, J TRAUMA, V68, P1305, DOI 10.1097/TA.0b013e3181dcd137; Murray JA, 2000, J TRAUMA, V49, P1065, DOI 10.1097/00005373-200012000-00015; Mutzbauer TS, 2008, NOTFALL RETTUNGSMED, V11, P310, DOI 10.1007/s10049-008-1038-4; NAEMT, 2009, PRAKL TRAUM; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; Paal P, 2010, RESUSCITATION, V81, P148, DOI 10.1016/j.resuscitation.2009.10.023; Pelucio M, 1997, ACAD EMERG MED, V4, P563, DOI 10.1111/j.1553-2712.1997.tb03579.x; Ricard-Hibon A, 2002, EUR J ANAESTH, V19, P361, DOI 10.1017/S0265021502000583; RIVARA FP, 1989, JAMA-J AM MED ASSOC, V261, P566, DOI 10.1001/jama.261.4.566; Ruchholtz S, 2008, DTSCH ARZTEBL INT, V105, P225, DOI 10.3238/arztebl.2008.0225; Ruchholtz S, 2002, J TRAUMA, V52, P879, DOI 10.1097/00005373-200205000-00010; Santoni BG, 2009, ANESTHESIOLOGY, V110, P24, DOI 10.1097/ALN.0b013e318190b556; Schlechtriemen T, 2004, NOTFALL RETTUNGSMED, V7, P231; Schmidt UH, 2008, ANESTHESIOLOGY, V109, P973, DOI 10.1097/ALN.0b013e31818ddb90; Shah CV, 2008, CRIT CARE MED, V36, P2309, DOI 10.1097/CCM.0b013e318180dc74; Silvestri S, 2005, ANN EMERG MED, V45, P497, DOI 10.1016/j.annemergmed.2004.09.014; Sing RF, 1998, AM J EMERG MED, V16, P598, DOI 10.1016/S0735-6757(98)90227-3; Sise MJ, 2009, J TRAUMA, V66, P32, DOI 10.1097/TA.0b013e318191bb0c; Sloane C, 2000, J EMERG MED, V19, P259, DOI 10.1016/S0736-4679(00)00235-3; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Steinmann D, 2009, ANAESTHESIST, V58, P695, DOI 10.1007/s00101-009-1548-6; Stephens CT, 2009, ANESTH ANALG, V109, P866, DOI 10.1213/ane.0b013e3181ad87b0; Stiell IG, 2008, CAN MED ASSOC J, V178, P1141, DOI 10.1503/cmaj.071154; Stocchetti N, 1996, J TRAUMA, V40, P764, DOI 10.1097/00005373-199605000-00014; Thierbach A, 2004, ANAESTHESIST, V53, P543, DOI 10.1007/s00101-004-0679-z; Timmermann A, 2007, ANAESTHESIST, V56, P328, DOI 10.1007/s00101-007-1153-5; Timmermann A, 2009, ANAESTHESIST, V58, P663, DOI 10.1007/s00101-009-1570-8; Timmermann A, 2010, ANASTH INTENSIVMED S, V51, P7; Timmermann A, 2007, ANESTH ANALG, V104, P619, DOI 10.1213/01.ane.0000253523.80050.e9; Timmermann A, 2006, RESUSCITATION, V70, P179, DOI 10.1016/j.resuscitation.2006.01.010; Tracy S, 2006, J TRAUMA, V61, P1162, DOI 10.1097/01.ta.0000243887.90697.06; TRUPKA A, 1995, UNFALLCHIRURG, V98, P111; von Elm E, 2009, BRIT J ANAESTH, V103, P371, DOI 10.1093/bja/aep202; Wang H E, 2001, Prehosp Emerg Care, V5, P134, DOI 10.1080/10903120190939995; Wang HE, 2006, ACAD EMERG MED, V13, P372, DOI 10.1197/j.aem.2005.11.001; Wang HE, 2004, ANN EMERG MED, V44, P439, DOI 10.1016/j.annemergmed.2004.04.008; Wang HE, 2006, ANN EMERG MED, V47, P532, DOI 10.1016/j.annemergmed.2006.01.016; Wang HE, 2009, RESUSCITATION, V80, P50, DOI 10.1016/j.resuscitation.2008.08.016; Warner KJ, 2008, J TRAUMA, V64, P341, DOI 10.1097/TA.0b013e318160dfb3; Warner KJ, 2007, J TRAUMA, V62, P1330, DOI 10.1097/TA.0b013e31804a8032; Warner KJ, 2009, J TRAUMA, V67, P45, DOI 10.1097/TA.0b013e3181a92a70; Warner KJ, 2009, J TRAUMA, V66, P26, DOI 10.1097/TA.0b013e3181957a25; Wayne M A, 1999, Prehosp Emerg Care, V3, P107, DOI 10.1080/10903129908958916; Wolfl CG, 2009, UNFALLCHIRURG, V112, P846, DOI 10.1007/s00113-009-1685-z	116	23	24	0	9	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0003-2417	1432-055X		ANAESTHESIST	Anaesthesist	NOV	2011	60	11					1027	+		10.1007/s00101-011-1957-1			11	Anesthesiology	Anesthesiology	852NM	WOS:000297364700007	22089890				2021-06-18	
J	Friess, SH; Ralston, J; Eucker, SA; Helfaer, MA; Smith, C; Margulies, SS				Friess, Stuart H.; Ralston, Jill; Eucker, Stephanie A.; Helfaer, Mark A.; Smith, Colin; Margulies, Susan S.			Neurocritical Care Monitoring Correlates With Neuropathology in a Swine Model of Pediatric Traumatic Brain Injury	NEUROSURGERY			English	Article						Neurocritical care monitoring; Pediatric head injury; Swine; Traumatic brain injury model	CEREBRAL-BLOOD-FLOW; CLOSED-HEAD INJURY; TISSUE OXYGEN-TENSION; NEONATAL PIG; INTRACRANIAL-PRESSURE; CORTICAL IMPACT; AXONAL INJURY; CHILDREN; PIGLETS; AUTOREGULATION	BACKGROUND: Small-animal models have been used in traumatic brain injury (TBI) research to investigate the basic mechanisms and pathology of TBI. Unfortunately, successful TBI investigations in small-animal models have not resulted in marked improvements in clinical outcomes of TBI patients. OBJECTIVE: To develop a clinically relevant immature large-animal model of pediatric neurocritical care following TBI. METHODS: Eleven 4-week-old piglets were randomly assigned to either rapid axial head rotation without impact (n = 6) or instrumented sham (n = 5). All animals had an intracranial pressure monitor, brain tissue oxygen tension (PbtO(2)) probe, and cerebral microdialysis probe placed in the frontal lobe and data collected for 6 hours following injury. RESULTS: Injured animals had sustained elevations in intracranial pressure and lactate-pyruvate ratio (LPR), and decreased PbtO(2) compared with sham. PbtO(2) and LPR from separate frontal lobes had strong linear correlation in both sham and injured animals. Neuropathologic examination demonstrated significant axonal injury and infarct volumes in injured animals compared with sham at 6 hours postinjury. Averaged over time, PbtO(2) in both injured and sham animals had a strong inverse correlation with total injury volume. Average LPR had a strong correlation with total injury volume. CONCLUSION: LPR and PbtO(2) can be utilized as serial nonterminal secondary markers in our injury model for neuropathology, and as evaluation metrics for novel interventions and therapeutics in the acute postinjury period. This translational model bridges a vital gap in knowledge between TBI studies in small-animal models and clinical trials in the pediatric TBI population.	[Margulies, Susan S.] Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, Philadelphia, PA 19104 USA; [Friess, Stuart H.; Helfaer, Mark A.] Childrens Hosp Philadelphia, Dept Anesthesiol & Crit Care Med, Philadelphia, PA 19104 USA; [Smith, Colin] Western Gen Hosp, Dept Neuropathol, Edinburgh EH4 2XU, Midlothian, Scotland	Margulies, SS (corresponding author), Univ Penn, Dept Bioengn, Sch Engn & Appl Sci, 240 Skirkanich Hall,210 S 33rd St, Philadelphia, PA 19104 USA.	margulie@seas.upenn.edu	Eucker, Stephanie/AAL-1828-2021	Eucker, Stephanie/0000-0001-9986-5773; Smith, Colin/0000-0002-4507-5132	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K08-NS064051, R01-NS39679]; Endowed Chair in Critical Care Medicine; Children's Hospital of Philadelphia; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS039679, K08NS064051, U01NS069545] Funding Source: NIH RePORTER	This work was supported by NIH grant K08-NS064051 (to S. H. F.), the Endowed Chair in Critical Care Medicine, The Children's Hospital of Philadelphia (to M. A. H.), and NIH grant R01-NS39679 (to S. S. M.).	Adelson PD, 1997, PEDIATR NEUROSURG, V26, P200; Alessandri B, 2003, J NEUROTRAUM, V20, P1293, DOI 10.1089/089771503322686094; Armstead WM, 2010, CRIT CARE MED, V38, P1868, DOI 10.1097/CCM.0b013e3181e8ac1a; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Bhatia A, 2007, INTENS CARE MED, V33, P1263, DOI 10.1007/s00134-007-0678-z; BLOMQUIST HKS, 1986, J NEUROL NEUROSUR PS, V49, P536, DOI 10.1136/jnnp.49.5.536; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Charalambides C, 2010, CHILD NERV SYST, V26, P215, DOI 10.1007/s00381-009-1031-3; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Duhaime AC, 2007, PEDIATR CRIT CARE ME, V8, P71, DOI 10.1097/01.PCC.0000253552.60687.AC; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Eucker SA, 2011, EXP NEUROL, V227, P79, DOI 10.1016/j.expneurol.2010.09.015; Figaji AA, 2009, J NEUROSURG-PEDIATR, V4, P420, DOI 10.3171/2009.6.PEDS096; Figaji AA, 2009, CHILD NERV SYST, V25, P1335, DOI 10.1007/s00381-009-0821-y; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Friess SH, 2007, EXP NEUROL, V204, P234, DOI 10.1016/j.expneurol.2006.10.010; Friess SH, 2009, J NEUROTRAUM, V26, P1111, DOI [10.1089/neu.2008.0845, 10.1089/neu.2008-0845]; Hagberg H, 2002, DEV NEUROSCI-BASEL, V24, P364, DOI 10.1159/000069040; Hagberg H, 2002, MENT RETARD DEV D R, V8, P30, DOI 10.1002/mrdd.10007; Hamilton BE, 2007, PEDIATRICS, V119, P345, DOI 10.1542/peds.2006-3226; Hanneman SK, 2004, COMPARATIVE MED, V54, P36; HANNON JP, 1990, LAB ANIM SCI, V40, P293; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; LAM M, 1999, AM STAT ASS P BIOM S, P213; Manley GT, 2006, J NEUROTRAUM, V23, P128, DOI 10.1089/neu.2006.23.128; Raghupathi R, 2004, J NEUROTRAUM, V21, P307, DOI 10.1089/089771504322972095; Raghupathi R, 2002, J NEUROTRAUM, V19, P843, DOI 10.1089/08977150260190438; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Timaru-Kast R, 2008, J NEUROTRAUM, V25, P1107, DOI 10.1089/neu.2008.0517; Vajkoczy P, 2000, J NEUROSURG, V93, P265, DOI 10.3171/jns.2000.93.2.0265; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Wartenberg KE, 2007, CRIT CARE CLIN, V23, P507, DOI 10.1016/j.ccc.2007.06.002; WOOTTON R, 1982, BIOL NEONATE, V41, P209	35	23	23	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0148-396X			NEUROSURGERY	Neurosurgery	NOV	2011	69	5					1139	1147		10.1227/NEU.0b013e3182284aa1			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	832UV	WOS:000295835300042	21670716	Green Accepted, Green Published			2021-06-18	
J	Bahloul, M; Chaari, A; Dammak, H; Medhioub, F; Abid, L; Ksibi, H; Haddar, S; Kallel, H; Chelly, H; Ben Hamida, C; Bouaziz, M				Bahloul, Mabrouk; Chaari, Anis; Dammak, Hassen; Medhioub, Fatma; Abid, Leila; Ksibi, Hichem; Haddar, Sondes; Kallel, Hatem; Chelly, Hedi; Ben Hamida, Chokri; Bouaziz, Mounir			Post-traumatic pulmonary embolism in the intensive care unit	ANNALS OF THORACIC MEDICINE			English	Article						Anticoagulation; ICU; predictive factors; pulmonary embolism; trauma patients	TRAUMATIC BRAIN-INJURY; VENOUS THROMBOEMBOLISM; MAJOR TRAUMA; ACUTE PHYSIOLOGY; RISK-FACTORS; PROPHYLAXIS; SCORE; MANAGEMENT; DIAGNOSIS; HEPARIN	OBJECTIVE: To determine the predictive factors, clinical manifestations, and the outcome of patients with post-traumatic pulmonary embolism (PE) admitted in the intensive care unit (ICU). METHODS: During a four-year prospective study, a medical committee of six ICU physicians prospectively examined all available data for each trauma patient in order to classify patients according to the level of clinical suspicion of pulmonary thromboembolism. During the study period, all trauma patients admitted to our ICU were classified into two groups. The first group included all patients with confirmed PE; the second group included patients without clinical manifestations of PE. The diagnosis of PE was confirmed either by a high-probability ventilation/perfusion (V/Q) scan or by a spiral computed tomography (CT) scan showing one or more filling defects in the pulmonary artery or its branches. RESULTS: During the study period, 1067 trauma patients were admitted in our ICU. The diagnosis of PE was confirmed in 34 patients (3.2%). The mean delay of development of PE was 11.3 +/- 9.3 days. Eight patients (24%) developed this complication within five days of ICU admission. On the day of PE diagnosis, the clinical examination showed that 13 patients (38.2%) were hypotensive, 23 (67.7%) had systemic inflammatory response syndrome (SIRS), three (8.8%) had clinical manifestations of deep venous thrombosis (DVT), and 32 (94%) had respiratory distress requiring mechanical ventilation. In our study, intravenous unfractionated heparin was used in 32 cases (94%) and low molecular weight heparin was used in two cases (4%). The mean ICU stay was 31.6 +/- 35.7 days and the mean hospital stay was 32.7 +/- 35.3 days. The mortality rate in the ICU was 38.2% and the in-hospital mortality rate was 41%. The multivariate analysis showed that factors associated with poor prognosis in the ICU were the presence of circulatory failure (Shock) (Odds ratio (OR) = 9.96) and thrombocytopenia (OR = 32.5). Moreover, comparison between patients with and without PE showed that the predictive factors of PE were: Age > 40 years, a SAPS II score > 25, hypoxemia with PaO2/FiO(2) < 200 mmHg, the presence of spine fracture, and the presence of meningeal hemorrhage. CONCLUSION: Despite the high frequency of DVT in post-traumatic critically ill patients, symptomatic PE remains, although not frequently observed, because systematic screening is not performed. Factors associated with poor prognosis in the ICU are the presence of circulatory failure (shock) and thrombocytopenia. Predictive factors of PE are: Age > 40 years, a SAPS II score > 25, hypoxemia with PaO2/FiO(2) < 200, the presence of a spine fracture, and the presence of meningeal hemorrhage. Prevention is highly warranted.	[Bahloul, Mabrouk; Chaari, Anis; Dammak, Hassen; Medhioub, Fatma; Ksibi, Hichem; Kallel, Hatem; Chelly, Hedi; Ben Hamida, Chokri; Bouaziz, Mounir] Univ Hosp Sfax, Dept Intens Care, Sfax, Tunisia; [Abid, Leila] Univ Hosp Sfax, Dept Cardiol, Sfax, Tunisia; [Haddar, Sondes] Univ Hosp Sfax, Dept Radiol, Sfax, Tunisia	Bahloul, M (corresponding author), Hop Habib Bourguiba, Dept Med Intens Care, Route el Ain Km 1 3029, Sfax, Tunisia.	bahloulmab@yahoo.fr		Bahloul, Mabrouk/0000-0002-6488-8294			Bahloul M, 2010, ANN THORAC MED, V5, P97, DOI 10.4103/1817-1737.62473; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BARRITT DW, 1960, LANCET, V1, P1309; BONE RC, 1991, ANN INTERN MED, V114, P332, DOI 10.7326/0003-4819-114-4-332; Chin Paul, 2006, N Z Med J, V119, pU2052; Cohen AT, 2008, LANCET, V371, P387, DOI 10.1016/S0140-6736(08)60202-0; GEERTS WH, 1994, NEW ENGL J MED, V331, P1601, DOI 10.1056/NEJM199412153312401; Geerts WH, 1996, NEW ENGL J MED, V335, P701, DOI 10.1056/NEJM199609053351003; Goldhaber SZ, 2002, ANN INTERN MED, V136, P691, DOI 10.7326/0003-4819-136-9-200205070-00012; Goldhaber SZ, 1999, LANCET, V353, P1386, DOI 10.1016/S0140-6736(98)07534-5; Gruel Y, 2004, REV MED INTERNE, V25, P35, DOI 10.1016/S0248-8663(03)00109-7; HERMANN RE, 1961, AM J SURG, V102, P19, DOI 10.1016/0002-9610(61)90680-8; Ho KM, 2010, BRIT J ANAESTH, V105, P596, DOI 10.1093/bja/aeq254; KNAUS WA, 1981, CRIT CARE MED, V9, P591, DOI 10.1097/00003246-198108000-00008; Knudson M Margaret, 2004, Curr Opin Crit Care, V10, P539, DOI 10.1097/01.ccx.0000144941.09650.9f; KNUDSON MM, 1994, J TRAUMA, V37, P480, DOI 10.1097/00005373-199409000-00025; KNUDSON MM, 1992, J TRAUMA, V32, P2, DOI 10.1097/00005373-199201000-00002; Le Gal G, 2006, ANN INTERN MED, V144, P165, DOI 10.7326/0003-4819-144-3-200602070-00004; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Menaker J, 2007, J TRAUMA, V63, P620, DOI 10.1097/TA.0b013e31812f60aa; Menaker J, 2009, J TRAUMA, V67, P1244, DOI 10.1097/TA.0b013e31818c173a; Norwood SH, 2008, J TRAUMA, V65, P1021, DOI 10.1097/TA.0b013e31818a0e74; OMALLEY KF, 1990, J TRAUMA, V30, P748, DOI 10.1097/00005373-199006000-00018; Owings JT, 1997, ARCH SURG-CHICAGO, V132, P862; Paffrath T, 2010, INJURY, V41, P97, DOI 10.1016/j.injury.2009.06.010; Qureshi SS, 2001, CLIN EXP IMMUNOL, V125, P258, DOI 10.1046/j.1365-2249.2001.01596.x; Reiff DA, 2009, J TRAUMA, V66, P1436, DOI 10.1097/TA.0b013e31817fdf1c; Schultz DJ, 2004, J TRAUMA, V56, P727, DOI 10.1097/01.TA.0000119687.23542.EC; SIMPSON D, 1982, LANCET, V2, P450; Sing RF, 2006, J TRAUMA, V60, P732, DOI 10.1097/01.ta.0000210285.22571.66; STEIN PD, 1992, AM J CARDIOL, V69, P1239, DOI 10.1016/0002-9149(92)90944-T; Tapson VF, 2008, NEW ENGL J MED, V358, P1037, DOI 10.1056/NEJMra072753; Torbicki A, 2008, EUR HEART J, V29, P2276, DOI 10.1093/eurheartj/ehn310; Wells PS, 2000, THROMB HAEMOSTASIS, V83, P416	34	23	23	0	0	MEDKNOW PUBLICATIONS & MEDIA PVT LTD	MUMBAI	B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075, INDIA	1817-1737	1998-3557		ANN THORAC MED	Ann. Thorac. Med.	OCT-DEC	2011	6	4					199	206		10.4103/1817-1737.84773			8	Cardiac & Cardiovascular Systems; Respiratory System	Cardiovascular System & Cardiology; Respiratory System	820HX	WOS:000294897400004	21977064	DOAJ Gold, Green Published			2021-06-18	
J	Gonzalez, PG; Walker, MT				Gonzalez, Peter G.; Walker, Matthew T.			Imaging Modalities in Mild Traumatic Brain Injury and Sports Concussion	PM&R			English	Article							DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; POSITRON-EMISSION-TOMOGRAPHY; WHITE-MATTER INJURY; TECHNETIUM-99M-HMPAO SPECT; FUNCTIONAL MRI; COMPUTED-TOMOGRAPHY; ABNORMALITIES; CHILDREN; MODERATE	Mild traumatic brain injury is a significant public health issue that has been gaining considerable attention over the past few years. After injury, a large percentage of patients experience postconcussive symptoms that affect work and school performance and that carry significant medicolegal implications. Conventional imaging modalities (computed tomography and magnetic resonance imaging) are insensitive to microstructural changes and underestimate the degree of diffuse axonal injury and metabolic changes. Newer imaging techniques have attempted to better diagnose and characterize diffuse axonal injury and the metabolic and functional aspects of traumatic brain injury. The following review article summarizes the currently available imaging studies and describes the novel and more investigational techniques available for mild traumatic brain injury. A suggested algorithm is offered. PM R 2011;3:S413-S424	[Gonzalez, Peter G.] Eastern Virginia Med Sch, Dept Phys Med & Rehabil, Norfolk, VA 23507 USA; [Walker, Matthew T.] Northwestern Univ, Dept Radiol, Feinberg Sch Med, Chicago, IL 60611 USA	Gonzalez, PG (corresponding author), Eastern Virginia Med Sch, Dept Phys Med & Rehabil, 721 Fairfax Ave,3rd Floor, Norfolk, VA 23507 USA.	gonzalpg@evms.edu					Abdel-Dayem HM, 1998, CLIN NUCL MED, V23, P309, DOI 10.1097/00003072-199805000-00009; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bagley LJ, 2000, J MAGN RESON IMAGING, V11, P1, DOI 10.1002/(SICI)1522-2586(200001)11:1<1::AID-JMRI1>3.0.CO;2-H; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Centers for Disease Control and Prevention, 2003, C MILD TRAUM BRAIN I; Chen JK, 2008, CLIN J SPORT MED, V18, P241, DOI 10.1097/JSM.0b013e318170b59d; Chen JK, 2007, J NEUROL NEUROSUR PS, V78, P1231, DOI 10.1136/jnnp.2006.110395; Chen JK, 2004, NEUROIMAGE, V22, P68, DOI 10.1016/j.neuroimage.2003.12.032; Chen SHA, 2003, J NEUROL NEUROSUR PS, V74, P326, DOI 10.1136/jnnp.74.3.326; Cohen BA, 2007, AM J NEURORADIOL, V28, P907; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; Davis PC BJ, 2008, EXPERT PANEL NEUROLO; DOUSSET V, 1992, RADIOLOGY, V182, P483, DOI 10.1148/radiology.182.2.1732968; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Friedman SD, 1998, AM J NEURORADIOL, V19, P1879; Friedman SD, 1999, NEUROLOGY, V52, P1384, DOI 10.1212/WNL.52.7.1384; GALE SD, 1995, J NEUROTRAUM, V12, P151, DOI 10.1089/neu.1995.12.151; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holshouser BA, 2005, AM J NEURORADIOL, V26, P1276; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Huisman TAGM, 2003, J COMPUT ASSIST TOMO, V27, P5, DOI 10.1097/00004728-200301000-00002; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; HUMAYUN MS, 1989, NUCL MED COMMUN, V10, P335, DOI 10.1097/00006231-198905000-00004; ICHISE M, 1994, J NUCL MED, V35, P217; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; JACOBS A, 1994, J NUCL MED, V35, P942; Jacobs A, 1996, J NUCL MED, V37, P1605; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kuppermann N, 2008, PEDIATR RADIOL, V38, pS670, DOI 10.1007/s00247-008-0996-5; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; LEXA FJ, 1994, AM J NEURORADIOL, V15, P201; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; McGowan JC, 2000, AM J NEURORADIOL, V21, P875; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Niogi SN, 2008, AM J NEURORADIOL, V29, P967, DOI 10.3174/ajnr.A0970; Palchak MJ, 2003, ANN EMERG MED, V42, P492, DOI 10.1067/S0196-0644(03)00425-6; Parizel PM, 2005, EUR RADIOL, V15, P569, DOI 10.1007/s00330-004-2558-z; Ross BD, 1998, J MAGN RESON IMAGING, V8, P829, DOI 10.1002/jmri.1880080412; Rugg-Gunn FJ, 2001, J NEUROL NEUROSUR PS, V70, P530, DOI 10.1136/jnnp.70.4.530; Rutgers DR, 2008, AM J NEURORADIOL, V29, P1730, DOI 10.3174/ajnr.A1213; Schrader Harald, 2009, BMC Med Imaging, V9, P11, DOI 10.1186/1471-2342-9-11; Schwartz ES, 2010, PEDIATR RADIOL, V40, P50, DOI 10.1007/s00247-009-1451-y; Slobounov SM, 2010, EXP BRAIN RES, V202, P341, DOI 10.1007/s00221-009-2141-6; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004	59	23	23	0	4	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1934-1482	1934-1563		PM&R	PM&R	OCT	2011	3	10		3			S413	S424		10.1016/j.pmrj.2011.08.536			12	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	966YK	WOS:000305873100009	22035684				2021-06-18	
J	Lewis, MD; Bailes, J				Lewis, Michael D.; Bailes, Julian			Neuroprotection for the Warrior: Dietary Supplementation With Omega-3 Fatty Acids	MILITARY MEDICINE			English	Article							POLYUNSATURATED FATTY-ACIDS; CHRONIC TRAUMATIC ENCEPHALOPATHY; NATIONAL-FOOTBALL-LEAGUE; CARDIOVASCULAR RISK-FACTORS; RANDOMIZED CONTROLLED-TRIAL; DOSE DOCOSAHEXAENOIC ACID; NUTRITION SUPPORT THERAPY; CRITICAL-CARE MEDICINE; ILL PATIENT SOCIETY; SPINAL-CORD-INJURY	Nutrition has traditionally involved in supplying energy and hydration. An emerging concept developed by the authors is the concept of using omega-3 fatty acids (n-3 FAs) to increase the resilience of the brain. The n-3 FAs have numerous proven benefits including support of cardiovascular and psychiatric health. Docosahexaenoic acid in particular, is found in high concentrations in the brain. N-3 FAs provide benefits by exerting a protective mechanism at the cellular and neuronal levels including the modulation of inflammatory cascade following traumatic brain injury. Promising research and evolving clinical experience now indicate that n-3 FA is useful and effective for recovery following traumatic brain injury. More exciting is that new laboratory research shows the beneficial effects extend to when n-3 FA is given before injury. Given the safety profile, availability, and affordability of n-3 FA, Generally Recognized As Safe amounts of eicosapentaenoic acid and docosahexaenoic acid (up to 3,000 mg daily) should be considered for the athlete and soldier, not only for its general health benefits, but particularly also for those at risk or high exposure to brain impacts. A comprehensive, coordinated research program to evaluate the multiple uses of n-3 FA should be a high priority for the Department of Defense.	[Lewis, Michael D.] Def & Vet Brain Injury Ctr, Rockville, MD 20812 USA; [Bailes, Julian] W Virginia Univ, Dept Neurosurg, Morgantown, WV 26506 USA	Lewis, MD (corresponding author), Def & Vet Brain Injury Ctr, 11300 Rockville Pike,Suite 1100, Rockville, MD 20812 USA.						Agren JJ, 1997, PROSTAG LEUKOTR ESS, V57, P419, DOI 10.1016/S0952-3278(97)90421-X; Agren JJ, 1996, EUR J CLIN NUTR, V50, P765; Antalis CJ, 2006, PROSTAG LEUKOTR ESS, V75, P299, DOI 10.1016/j.plefa.2006.07.004; Appleton KM, 2010, AM J CLIN NUTR, V91, P757, DOI 10.3945/ajcn.2009.28313; Babcock AA, 2006, J NEUROSCI, V26, P12826, DOI 10.1523/JNEUROSCI.4937-05.2006; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; BAIRATI I, 1992, CIRCULATION, V85, P950, DOI 10.1161/01.CIR.85.3.950; Bays HE, 2007, AM J CARDIOL, V99, p35C, DOI 10.1016/j.amjcard.2006.11.020; Bazan NG, 2005, BRAIN PATHOL, V15, P159; Becker DJ, 2008, MAYO CLIN PROC, V83, P758, DOI 10.4065/83.7.758; BEHAN PO, 1990, ACTA NEUROL SCAND, V82, P209, DOI 10.1111/j.1600-0404.1990.tb04490.x; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; BLONK MC, 1990, AM J CLIN NUTR, V52, P120; Buydens-Branchey L, 2008, PROG NEURO-PSYCHOPH, V32, P568, DOI 10.1016/j.pnpbp.2007.10.020; Buydens-Branchey L, 2006, J CLIN PSYCHOPHARM, V26, P661, DOI 10.1097/01.jcp.0000246214.49271.f1; Calabresi L, 2000, ATHEROSCLEROSIS, V148, P387, DOI 10.1016/S0021-9150(99)00267-1; Calder P.C., 2010, J LIPID NUTR, V19, P233; Calder PC, 2003, BRAZ J MED BIOL RES, V36, P433, DOI 10.1590/S0100-879X2003000400004; Cantu RC, 2007, NEUROSURGERY, V61, P223, DOI 10.1227/01.NEU.0000255514.73967.90; Cao DH, 2004, PHARMACOL BIOCHEM BE, V79, P651, DOI 10.1016/j.pbb.2004.09.016; COBIAC L, 1991, AM J CLIN NUTR, V53, P1210; Colangelo LA, 2009, NUTRITION, V25, P1011, DOI 10.1016/j.nut.2008.12.008; Conquer JA, 1998, J LIPID RES, V39, P286; De Vriese SR, 2004, PROSTAG LEUKOTR ESS, V71, P13, DOI 10.1016/j.plefa.2003.12.002; DECATERINA R, 1990, CIRCULATION, V82, P428, DOI 10.1161/01.CIR.82.2.428; Deuster PA, 2009, MIL MED, V174, P671, DOI 10.7205/MILMED-D-04-4508; Devore EE, 2009, AM J CLIN NUTR, V90, P170, DOI 10.3945/ajcn.2008.27037; DYERBERG J, 1979, LANCET, V2, P433, DOI 10.1016/S0140-6736(79)91490-9; Ferretti A, 1998, J NUTR BIOCHEM, V9, P88, DOI 10.1016/S0955-2863(97)00172-1; Freeman MP, 2007, J CLIN PSYCHIAT, V68, P338; Freund-Levi Y, 2008, INT J GERIATR PSYCH, V23, P161, DOI 10.1002/gps.1857; Freund-Levi Y, 2006, ARCH NEUROL-CHICAGO, V63, P1402, DOI 10.1001/archneur.63.10.1402; Giza CC, 2001, J ATHL TRAINING, V36, P228; Gosselin N, 2006, NEUROSURGERY, V58, P1151, DOI 10.1227/01.NEU.0000215953.44097.FA; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Hartl R, 2008, J NEUROSURG, V109, P50, DOI 10.3171/JNS/2008/109/7/0050; Hallahan B, 2007, BRIT J PSYCHIAT, V190, P118, DOI 10.1192/bjp.bp.106.022707; HARKER LA, 1993, CIRCULATION, V87, P1017, DOI 10.1161/01.CIR.87.3.1017; Harris WS, 2008, CURR ATHEROSCLER REP, V10, P503, DOI 10.1007/s11883-008-0078-z; Heller AR, 2006, CRIT CARE MED, V34, P972, DOI 10.1097/01.CCM.0000206309.83570.45; Henry LC, 2010, J NEUROTRAUM, V27, P65, DOI 10.1089/neu.2009.0962; Heude B, 2003, AM J CLIN NUTR, V77, P803; Hibbeln Joseph R., 2009, V99, P17, DOI 10.1159/000192992; Hibbeln JR, 1998, LANCET, V351, P1213, DOI 10.1016/S0140-6736(05)79168-6; Hirayama T, 1990, LIFE STYLE MORTALITY; Hogyes E, 2003, NEUROSCIENCE, V119, P999, DOI 10.1016/S0306-4522(03)00198-2; Huan MM, 2004, BIOL PSYCHIAT, V56, P490, DOI 10.1016/j.biopsych.2004.06.028; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Huffman DM, 2004, EUR J APPL PHYSIOL, V92, P584, DOI 10.1007/s00421-004-1069-6; Iribarren C, 2004, EUR J CLIN NUTR, V58, P24, DOI 10.1038/sj.ejcn.1601739; Jonas WB, 2010, MILITARY MED, V175, P6, DOI DOI 10.7205/MILMED-D-10-00280; Jump DB, 2002, CURR OPIN LIPIDOL, V13, P155, DOI 10.1097/00041433-200204000-00007; Kaul N, 2008, J AM COLL NUTR, V27, P51, DOI 10.1080/07315724.2008.10719674; Keller D.D., 2007, J CLIN LIPIDOL, V1, P151; Kelley DS, 2007, AM J CLIN NUTR, V86, P324; Kim HY, 2010, PROSTAG LEUKOTR ESS, V82, P165, DOI 10.1016/j.plefa.2010.02.025; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Knapp HR, 1997, AM J CLIN NUTR, V65, P1687; KREMER JM, 1987, ANN INTERN MED, V106, P497, DOI 10.7326/0003-4819-106-4-497; LEAF A, 1994, CIRCULATION, V90, P2248, DOI 10.1161/01.CIR.90.5.2248; LEWIS M, 2011, J CLIN PSYC IN PRESS; Lim GP, 2005, J NEUROSCI, V25, P3032, DOI 10.1523/JNEUROSCI.4225-04.2005; Lin PY, 2007, J CLIN PSYCHIAT, V68, P1056, DOI 10.4088/JCP.v68n0712; Lonergan PE, 2004, J NEUROCHEM, V91, P20, DOI 10.1111/j.1471-4159.2004.02689.x; Maes M, 1996, J AFFECT DISORDERS, V38, P35, DOI 10.1016/0165-0327(95)00092-5; Marchioli R, 2001, LIPIDS, V36, pS119, DOI 10.1007/s11745-001-0694-8; Marklund N, 1997, NEUROREPORT, V8, P1457, DOI 10.1097/00001756-199704140-00026; Martindale RG, 2009, CRIT CARE MED, V37, P1757, DOI 10.1097/CCM.0b013e3181a40116; McClave SA, 2009, JPEN-PARENTER ENTER, V33, P277, DOI 10.1177/0148607109335234; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McNamara RK, 2007, BIOL PSYCHIAT, V62, P17, DOI 10.1016/j.biopsych.2006.08.026; Merched AJ, 2008, FASEB J, V22, P3595, DOI 10.1096/fj.08-112201; Micallef MA, 2009, ATHEROSCLEROSIS, V204, P476, DOI 10.1016/j.atherosclerosis.2008.09.020; Mills JD, 2011, J NEUROSURG, V114, P77, DOI 10.3171/2010.5.JNS08914; Mills JD, 2011, NEUROSURGERY, V68, P474, DOI 10.1227/NEU.0b013e3181ff692b; Monahan KD, 2004, HYPERTENSION, V44, P732, DOI 10.1161/01.HYP.0000145292.38579.f4; Montain SJ, 2010, MIL MED, V175, P65, DOI DOI 10.7205/MILMED-D-10-00127; Mori TA, 2006, CURR OPIN CLIN NUTR, V9, P95, DOI 10.1097/01.mco.0000214566.67439.58; Morris MC, 2003, ARCH NEUROL-CHICAGO, V60, P940, DOI 10.1001/archneur.60.7.940; Mozaffarian D, 2005, CIRCULATION, V112, P1945, DOI 10.1161/CIRCULATIONAHA.105.556886; Mullen M, 2010, MIL MED, V175, P1, DOI DOI 10.7205/MILMED-D-10-00246; Nelson GJ, 1997, LIPIDS, V32, P1129, DOI 10.1007/s11745-997-0145-6; Nelson GJ, 1997, LIPIDS, V32, P1137, DOI 10.1007/s11745-997-0146-5; Nestel P, 2002, AM J CLIN NUTR, V76, P326; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2010, AM J FOREN MED PATH, V31, P130, DOI 10.1097/PAF.0b013e3181ca7f35; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Pan HC, 2009, J NUTR BIOCHEM, V20, P715, DOI 10.1016/j.jnutbio.2008.06.014; Pauwels EKJ, 2009, DRUG NEWS PERSPECT, V22, P205, DOI 10.1358/dnp.2009.22.4.1367709; PHILLIPSON BE, 1985, NEW ENGL J MED, V312, P1210, DOI 10.1056/NEJM198505093121902; Roberts L, 2008, J AM COLL SURGEONS, V207, P276, DOI 10.1016/j.jamcollsurg.2008.02.015; ROGERS S, 1987, ATHEROSCLEROSIS, V63, P137, DOI 10.1016/0021-9150(87)90113-4; Ross BM, 2009, PROSTAG LEUKOTR ESS, V81, P309, DOI 10.1016/j.plefa.2009.10.004; Salem N, 2001, LIPIDS, V36, P945, DOI 10.1007/s11745-001-0805-6; Sanders TAB, 2006, BRIT J NUTR, V95, P525, DOI 10.1079/BJN20051658; Schaefer EJ, 2006, ARCH NEUROL-CHICAGO, V63, P1545, DOI 10.1001/archneur.63.11.1545; Singer P, 2004, PROSTAG LEUKOTR ESS, V71, P153, DOI 10.1016/j.plefa.2004.03.003; Stark KD, 2004, AM J CLIN NUTR, V79, P765; Sublette ME, 2006, AM J PSYCHIAT, V163, P1100, DOI 10.1176/appi.ajp.163.6.1100; Tanskanen A, 2001, ARCH GEN PSYCHIAT, V58, P512, DOI 10.1001/archpsyc.58.5.512; Tartibian B, 2009, CLIN J SPORT MED, V19, P115, DOI 10.1097/JSM.0b013e31819b51b3; Theobald HE, 2007, J NUTR, V137, P973; Theobald HE, 2004, AM J CLIN NUTR, V79, P558; Vagnozzi R, 2008, NEUROSURGERY, V62, P1286, DOI 10.1227/01.neu.0000333300.34189.74; van Gelder BM, 2007, AM J CLIN NUTR, V85, P1142; Vanschoonbeek K, 2004, ARTERIOSCL THROM VAS, V24, P1734, DOI 10.1161/01.ATV.0000137119.28893.0b; von Schacky C, 2009, PROSTAG LEUKOTR ESS, V81, P193, DOI 10.1016/j.plefa.2009.05.009; Walser B, 2008, EUR J APPL PHYSIOL, V104, P455, DOI 10.1007/s00421-008-0791-x; Wang HG, 1999, SCIENCE, V284, P339, DOI 10.1126/science.284.5412.339; Wang X, 2003, NEUROREPORT, V14, P2457, DOI 10.1097/00001756-200312190-00033; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Wu AG, 2007, J NEUROTRAUM, V24, P1587, DOI 10.1089/neu.2007.0313; Wurtman RJ, 2009, J NUTR HEALTH AGING, V13, P189, DOI 10.1007/s12603-009-0056-3; Yates A, 2009, SPORTS HEALTH, V1, P21, DOI 10.1177/1941738108326978; Youdim KA, 2000, INT J DEV NEUROSCI, V18, P383, DOI 10.1016/S0736-5748(00)00013-7	116	23	23	0	16	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0026-4075	1930-613X		MIL MED	Milit. Med.	OCT	2011	176	10					1120	1127		10.7205/MILMED-D-10-00466			8	Medicine, General & Internal	General & Internal Medicine	831EK	WOS:000295711300009	22128646	Bronze			2021-06-18	
J	Volman, V; Bazhenov, M; Sejnowski, TJ				Volman, Vladislav; Bazhenov, Maxim; Sejnowski, Terrence J.			Pattern of trauma determines the threshold for epileptic activity in a model of cortical deafferentation	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						computational model; epilepsy; homeostasis; traumatic brain injury; paroxysmal discharge	ACTIVITY-DEPENDENT MODULATION; HOMEOSTATIC PLASTICITY; QUANTAL AMPLITUDE; SYNAPTIC AMPA; EPILEPTOGENESIS; POTASSIUM; DYNAMICS; SEIZURES	Epileptic activity often occurs in the cortex after a latent period after head trauma; this delay has been attributed to the destabilizing influence of homeostatic synaptic scaling and changes in intrinsic properties. However, the impact of the spatial organization of cortical trauma on epileptogenesis is poorly understood. We addressed this question by analyzing the dynamics of a large-scale biophysically realistic cortical network model subjected to different patterns of trauma. Our results suggest that the spatial pattern of trauma can greatly affect the propensity for developing posttraumatic epileptic activity. For the same fraction of lesioned neurons, spatially compact trauma resulted in stronger posttraumatic elevation of paroxysmal activity than spatially diffuse trauma. In the case of very severe trauma, diffuse distribution of a small number of surviving intact neurons alleviated posttraumatic epileptogenesis. We suggest that clinical evaluation of the severity of brain trauma should take into account the spatial pattern of the injured cortex.	[Volman, Vladislav; Sejnowski, Terrence J.] Salk Inst Biol Studies, Howard Hughes Med Inst, Comp Neurobiol Lab, La Jolla, CA 92037 USA; [Volman, Vladislav; Sejnowski, Terrence J.] Univ Calif San Diego, Ctr Theoret Biol Phys, La Jolla, CA 92093 USA; [Bazhenov, Maxim] Univ Calif Riverside, Dept Cell Biol & Neurosci, Riverside, CA 92521 USA; [Sejnowski, Terrence J.] Univ Calif San Diego, Div Biol Sci, La Jolla, CA 92093 USA	Sejnowski, TJ (corresponding author), Salk Inst Biol Studies, Howard Hughes Med Inst, Comp Neurobiol Lab, La Jolla, CA 92037 USA.	terry@salk.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS059740, R01 NS060870]; Howard Hughes InstituteHoward Hughes Medical Institute; National Science FoundationNational Science Foundation (NSF) [NSF PHY0822283]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060870, R01NS059740] Funding Source: NIH RePORTER	This research was supported by National Institutes of Health Grants R01 NS059740 and R01 NS060870, the Howard Hughes Institute, and National Science Foundation sponsored Center for Theoretical Biological Physics NSF PHY0822283.	Barreto E, 2011, J BIOL PHYS, V37, P361, DOI 10.1007/s10867-010-9212-6; Bogaard A, 2009, J NEUROSCI, V29, P1677, DOI 10.1523/JNEUROSCI.5218-08.2009; Cressman JR, 2009, J COMPUT NEUROSCI, V26, P159, DOI 10.1007/s10827-008-0132-4; Desai NS, 2002, NAT NEUROSCI, V5, P783, DOI 10.1038/nn878; Diaz-Arrastia R, 2009, EPILEPSIA, V50, P14, DOI 10.1111/j.1528-1167.2008.02006.x; Echegoyen J, 2007, PLOS ONE, V2, DOI 10.1371/journal.pone.0000700; Frohlich F, 2008, J NEUROSCI, V28, P1709, DOI 10.1523/JNEUROSCI.4263-07.2008; Frohlich F, 2006, J NEUROSCI, V26, P6153, DOI 10.1523/JNEUROSCI.5509-05.2006; GRAFSTEIN B, 1957, ELECTROEN CLIN NEURO, V9, P723, DOI 10.1016/0013-4694(57)90096-2; HOFFMAN SN, 1994, J NEUROPHYSIOL, V71, P1762; Houweling AR, 2005, CEREB CORTEX, V15, P834, DOI 10.1093/cercor/bhh184; Jensen MS, 1997, J NEUROPHYSIOL, V77, P1224; Kilman V, 2002, J NEUROSCI, V22, P1328, DOI 10.1523/JNEUROSCI.22-04-01328.2002; Kollevold T, 1976, J Oslo City Hosp, V26, P99; LESCHINGER A, 1993, EXP BRAIN RES, V96, P230; Leslie KR, 2001, J NEUROSCI, V21, part. no.; Lissin DV, 1998, P NATL ACAD SCI USA, V95, P7097, DOI 10.1073/pnas.95.12.7097; Murthy VN, 2001, NEURON, V32, P673, DOI 10.1016/S0896-6273(01)00500-1; Netoff TI, 2004, J NEUROSCI, V24, P8075, DOI 10.1523/JNEUROSCI.1509-04.2004; Nita DA, 2006, J NEUROPHYSIOL, V95, P902, DOI 10.1152/jn.00742.2005; O'Brien RJ, 1998, NEURON, V21, P1067, DOI 10.1016/S0896-6273(00)80624-8; Pan EH, 1997, J NEUROPHYSIOL, V77, P2293; PRINCE DA, 1993, J NEUROPHYSIOL, V69, P1276; Rutherford LC, 1997, J NEUROSCI, V17, P4527; Steinlein OK, 2004, NAT REV NEUROSCI, V5, P400, DOI 10.1038/nrn1388; Topolnik L, 2003, CEREB CORTEX, V13, P883, DOI 10.1093/cercor/13.8.883; Turrigiano GG, 1999, TRENDS NEUROSCI, V22, P221, DOI 10.1016/S0166-2236(98)01341-1; Turrigiano GG, 1998, NATURE, V391, P892, DOI 10.1038/36103; Ullah G, 2009, J COMPUT NEUROSCI, V26, P171, DOI 10.1007/s10827-008-0130-6; Watt AJ, 2000, NEURON, V26, P659, DOI 10.1016/S0896-6273(00)81202-7	30	23	23	0	3	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 13	2011	108	37					15402	15407		10.1073/pnas.1112066108			6	Multidisciplinary Sciences	Science & Technology - Other Topics	819DF	WOS:000294804900080	21896754	Green Published, Bronze			2021-06-18	
J	Hisley, DM; Gurganus, JC; Drysdale, AW				Hisley, Dixie M.; Gurganus, James C.; Drysdale, Andrew W.			Experimental Methodology Using Digital Image Correlation to Assess Ballistic Helmet Blunt Trauma	JOURNAL OF APPLIED MECHANICS-TRANSACTIONS OF THE ASME			English	Article						ballistic impact; combat helmet; back face deformation; blunt criterion; digital image correlation		As modern helmets have become quite capable of defeating the penetration capabilities of ballistic threats, Soldiers may experience head injuries due to blunt trauma caused by helmet back face deformation (BFD). Possible resulting injuries include skull fracture, hematoma, concussion, contusion, diffuse axonal injury, etc. Some of these injuries have been associated with traumatic brain injury. In order to assess potential injury mechanisms prior to fielding new helmets, we have developed a means to experimentally replicate and measure helmet BFD that can be correlated to injury criteria. In this study, helmet performance test methodology is developed using a digital image correlation (DIC) technique. DIC provides the capability to measure dynamic displacements, thereby providing the ability to calculate deformation, velocity, and acceleration rates. We have shown that digital image correlation is an experimentation technique that accurately captures BFD area and rate of deformation for impacts against combat helmets. We used the DIC data to calculate a new metric; the available energy that could potentially impact a Soldier's head. Our study shows that DIC data upholds the hypothesis that helmet BFD mechanically loads the skull similar to a direct impact from a less-than-lethal projectile or blunt object impact. The available energy obtained from DIC measurements was used to calculate the blunt criterion (BC) for helmet standoff distances of 12.7 mm (0.5 in) and 19.1 mm (0.75 in), which in turn can provide a prediction of the probability of abbreviated injury scale (AIS) levels and, in particular, skull fracture. DIC can be used to provide dynamic helmet performance data that will allow increased understanding of BFD and quantitative assessment and validation of helmet performance results. Knowledge of the conditions leading to head trauma obtained through DIC experimentation should enable the selection of new energy-absorbing materials for helmets; thus, allowing new helmet design candidate performances to be objectively evaluated. Test data and characterization of helmet response could then be used to achieve improved warfighter survivability. [DOI: 10.1115/1.4004332]	[Hisley, Dixie M.; Gurganus, James C.; Drysdale, Andrew W.] USA, Res Lab, Syst Engn & Experimentat Branch, Aberdeen Proving Ground, MD 21005 USA	Hisley, DM (corresponding author), USA, Res Lab, Syst Engn & Experimentat Branch, Aberdeen Proving Ground, MD 21005 USA.	dixie.hisley@us.army.mil; james.gurganus@us.army.mil; andrew.drysdale@us.army.mil			Survivability and Lethality Analysis Directorate of the Army Research Laboratory	Funding for this research was provided by the TILV program, Survivability and Lethality Analysis Directorate of the Army Research Laboratory. The authors would also like to acknowledge the efforts of Scott Williams and Joseph Lee in the completion of this work. This material is declared a work of the U. S. Government and is not subject to copyright protection in the United States. Approved for public release; distribution is unlimited.	BIR CA, 2000, THESIS WAYNE STATE U; Cannon L, 2001, J R Army Med Corps, V147, P87; CARROLL AW, 1978, ANN SURG, V188, P753, DOI 10.1097/00000658-197812000-00007; COLLINS J, 2007, ARLTR4116; Department of Defense, 1997, MILSTD662F DEP DEF; *GOM, 2009, AR V6 1 US MAN GOM O; *H P WHIT LAB INC, 1995, HPWTP040101B H P WHI; Mahoney PF, 2005, BALLISTIC TRAUMA PRA; MCENTIRE B, 2005, CR200512 USAARL; *NAT I JUST, 1981, 010601 NIJ; Raymond D, 2009, J BIOMECH, V42, P2479, DOI 10.1016/j.jbiomech.2009.07.018; Sturdivan L., 2005, J TRAUMA, V56, P651; Sturdivan L., 2010, COMMUNICATION; WEERASOORIYA T, 2008, P 2008 INT C EXP EXP; Yu J.H., 2010, ARLTR5333	15	23	23	1	18	ASME	NEW YORK	TWO PARK AVE, NEW YORK, NY 10016-5990 USA	0021-8936	1528-9036		J APPL MECH-T ASME	J. Appl. Mech.-Trans. ASME	SEP	2011	78	5							051022	10.1115/1.4004332			7	Mechanics	Mechanics	806GT	WOS:000293795000022					2021-06-18	
J	Asgari, S; Bergsneider, M; Hamilton, R; Vespa, P; Hu, X				Asgari, Shadnaz; Bergsneider, Marvin; Hamilton, Robert; Vespa, Paul; Hu, Xiao			Consistent Changes in Intracranial Pressure Waveform Morphology Induced by Acute Hypercapnic Cerebral Vasodilatation	NEUROCRITICAL CARE			English	Article						Intracranial pressure; Hemodynamic signal; Cerebral vasodilation; Hypercapnia; Waveform morphology	TRAUMATIC BRAIN-INJURY; PULSE PRESSURE; BLOOD-FLOW; AUTOREGULATION; ALGORITHM; DYNAMICS; FEATURES	Intracranial pressure (ICP) remains a pivotal physiological signal for managing brain injury and subarachnoid hemorrhage (SAH) patients in neurocritical care units. Given the vascular origin of the ICP, changes in ICP waveform morphology could be used to infer cerebrovascular changes. Clinical validation of this association in the setting of brain trauma, and SAH is challenging due to the multi-factorial influences on, and uncertainty of, the state of the cerebral vasculature. To gain a more controlled setting, in this articel, we study ICP signals recorded in four uninjured patients undergoing a CO2 inhalation challenge in which hypercapnia induced acute cerebral vasodilatation. We apply our morphological clustering and analysis of intracranial pressure (MOCAIP) algorithm to identify six landmarks on individual ICP pulses (based on the three established ICP sub-peaks; P1, P2, and P3) and extract 128 ICP morphological metrics. Then by comparing baseline, test, and post-test data, we assess the consistency and rate of change for each individual metric. Acute vasodilatation causes consistent changes in a total of 72 ICP pulse morphological metrics and the P2 sub-region responds to cerebral vascular changes in the most consistent way with the greatest change as compared to P1 and P3 sub-regions. Since the dilation/constriction of the cerebral vasculature resulted in detectable consistent changes in ICP MOCIAP metrics, by an extended monitoring practice of ICP that includes characterizing ICP pulse morphology, one can potentially detect cerebrovascular changes, continuously, for patients under neurocritical care.	[Asgari, Shadnaz; Bergsneider, Marvin; Hamilton, Robert; Vespa, Paul; Hu, Xiao] Univ Calif Los Angeles, David Geffen Sch Med, Neural Syst & Dynam Lab, Dept Neurosurg, Los Angeles, CA 90095 USA; [Bergsneider, Marvin; Hamilton, Robert; Hu, Xiao] Univ Calif Los Angeles, Henry Samueli Sch Engn & Appl Sci, Biomed Engn Grad Program, Los Angeles, CA 90095 USA; [Vespa, Paul] Univ Calif Los Angeles, David Geffen Sch Med, Neurocrit Care Program, Dept Neurosurg, Los Angeles, CA 90095 USA	Hu, X (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Neural Syst & Dynam Lab, Dept Neurosurg, 18-265 Semel,10833 Le Conte Ave,Box 703919, Los Angeles, CA 90095 USA.	xhu@mednet.ucla.edu			R01 award [NS054881, NS066008];  [NS059797]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS054881, R01NS066008, R21NS059797] Funding Source: NIH RePORTER	This work is partially supported by NS059797 and R01 awards NS054881 and NS066008.	Afonso VX, 1999, IEEE T BIO-MED ENG, V46, P192, DOI 10.1109/10.740882; Asgari S, 2010, IEEE T INF TECHNOL B, V14, P166, DOI 10.1109/TITB.2009.2034845; Asgari S, 2009, PHYSIOL MEAS, V30, P1211, DOI 10.1088/0967-3334/30/11/006; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; Brown AW, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2007.12.001; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; Czosnyka M, 1996, ACTA NEUROCHIR, V138, P531, DOI 10.1007/BF01411173; CZOSNYKA M, 1996, ACTA NEUROCHIR WIEN, V138, P541; Fan JY, 2008, AM J CRIT CARE, V17, P545; Gega A., 1980, INTRACRANIAL PRESSUR, P188; Germon K, 1988, J Neurosci Nurs, V20, P344; Hamilton R., 2009, C P IEEE ENG MED BIO, P4331; Hiler M, 2006, J NEUROSURG, V104, P731, DOI 10.3171/jns.2006.104.5.731; Hu X, 2008, PHYSIOL MEAS, V29, P459, DOI 10.1088/0967-3334/29/4/004; Hu X, 2010, IEEE T BIO-MED ENG, V57, P1070, DOI 10.1109/TBME.2009.2037607; Hu X, 2010, PHYSIOL MEAS, V31, P679, DOI 10.1088/0967-3334/31/5/006; Hu X, 2009, IEEE T BIO-MED ENG, V56, P696, DOI 10.1109/TBME.2008.2008636; Hu X, 2009, J CEREBR BLOOD F MET, V29, P688, DOI 10.1038/jcbfm.2008.160; Kasprowicz M, 2010, J NEUROSCI METH, V190, P310, DOI 10.1016/j.jneumeth.2010.05.015; Kaufman L., 2005, FINDING GROUPS DATA; Lavinio A, 2009, INTENS CARE MED, V35, P546, DOI 10.1007/s00134-008-1311-5; March K, 1990, J Neurosci Nurs, V22, P375; MILLER J D, 1987, Neurological Research, V9, P193; Muwaswes M, 1985, J Neurosurg Nurs, V17, P238; NORNES H, 1977, ACTA NEUROCHIR, V38, P177, DOI 10.1007/BF01401089; NORTH B, 1997, HEAD INJURY, P209; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; SCALZO F, 2010, ARTIF INTELL M UNPUB; Scalzo F, 2010, BIOMED ENG ONLINE, V9, DOI 10.1186/1475-925X-9-61; Scalzo F, 2009, MED BIOL ENG COMPUT, V47, P967, DOI 10.1007/s11517-009-0505-5; YOSHIHARA M, 1995, J NEUROSURG, V82, P386, DOI 10.3171/jns.1995.82.3.0386	33	23	25	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933			NEUROCRIT CARE	Neurocrit. Care	AUG	2011	15	1					55	62		10.1007/s12028-010-9463-x			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	789XI	WOS:000292552100009	21052864	Green Accepted			2021-06-18	
J	Degeneffe, CE; Chan, F; Dunlap, L; Man, D; Sung, C				Degeneffe, Charles Edmund; Chan, Fong; Dunlap, Laura; Man, David; Sung, Connie			Development and Validation of the Caregiver Empowerment Scale: A Resource for Working With Family Caregivers of Persons With Traumatic Brain Injury	REHABILITATION PSYCHOLOGY			English	Article						traumatic brain injury; family; empowerment; caregiving; social support	QUALITY-OF-LIFE; PSYCHOMETRIC VALIDATION; ADULT SIBLINGS; INDIVIDUALS; RELIABILITY; PREDICTORS; PROGRAM; PEOPLE; MEMBER; NEEDS	To use multitrait analysis to determine the measurement structure of the Caregiver Empowerment Scale (CES). Participants: An American sample of 87 adult primary family caregivers of persons with traumatic brain injury (TBI). Results: A four-factor structure was identified including factor 1 (Advocacy Self-Efficacy), factor 2 (Community Self-Efficacy), factor 3 (Caregiver Self-Efficacy), and factor 4 (Personal Self-Efficacy). Conclusions: The CES provides clinicians and researchers a means to assess self-perceived coping abilities of family caregivers of persons with TBI.	[Degeneffe, Charles Edmund] San Diego State Univ, Rehabil Counseling Program, Dept Adm Rehabil & Postsecondary Educ, Interwork Inst, San Diego, CA 92108 USA; [Chan, Fong; Sung, Connie] Univ Wisconsin, Dept Rehabil Psychol & Special Educ, Madison, WI 53706 USA; [Dunlap, Laura] ACT Med Grp, Raleigh, NC USA; [Man, David] Hong Kong Polytech Univ, Dept Rehabil Sci, Hong Kong, Hong Kong, Peoples R China	Degeneffe, CE (corresponding author), San Diego State Univ, Rehabil Counseling Program, Dept Adm Rehabil & Postsecondary Educ, Interwork Inst, 3590 Camino del Rio N, San Diego, CA 92108 USA.	cdegenef@mail.sdsu.edu					Bishop M, 2006, AUST J REHABIL COUNS, V12, P73, DOI 10.1375/jrc.12.2.73; Catalano D, 2010, AUST J REHABIL COUNS, V16, P57, DOI 10.1375/jrc.16.2.57; Chapin MH, 2004, DISABIL REHABIL, V26, P1135, DOI 10.1080/09638280410001714772; Cheing GLY, 2010, INT J REHABIL RES, V33, P88, DOI 10.1097/MRR.0b013e32832e9884; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Chronister J, 2010, NEUROREHABILITATION, V27, P49, DOI 10.3233/NRE-2010-0580; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; Degeneffe CE, 2009, AUST J REHABIL COUNS, V15, P12, DOI 10.1375/jrc.15.1.12; Degeneffe CE, 2008, J REHABIL, V74, P10; Degeneffe CE, 2010, BRAIN INJURY, V24, P1416, DOI 10.3109/02699052.2010.514317; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; EAMES P, 1990, REHABILITATION ADULT, P410; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; GREENBERG JS, 1993, GERONTOLOGIST, V33, P542, DOI 10.1093/geront/33.4.542; HAYS RD, 1990, BEHAV RES METH INS C, V22, P167, DOI 10.3758/BF03203140; KENDALL E, 2003, J VOCAT REHABIL, V19, P31; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kolakowski-Hayner S, 2001, J HEAD TRAUMA REHAB, V16, P1; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; KREUTZER JS, 1992, ARCH PHYS MED REHAB, V73, P771; Kreutzer JS, 1989, FAMILY NEEDS QUESTIO; Kritsotakis G, 2010, EUR J CANCER CARE, V19, P45, DOI 10.1111/j.1365-2354.2007.00910.x; Man D, 1999, BRAIN INJURY, V13, P433, DOI 10.1080/026990599121485; Man DWK, 2003, BRAIN INJURY, V17, P437, DOI 10.1080/0269905031000070152; Man DWK, 1998, BRAIN INJURY, V12, P245, DOI 10.1080/026990598122728; Man DWK, 2001, BRAIN INJURY, V15, P961, DOI 10.1080/02699050110065664; McKinlay WW, 1988, J HEAD TRAUMA REHAB, p[3, 64]; Rosenthal M., 1989, TRAUMATIC BRAIN INJU, P191; Rubin S. E., 2003, PROFESSIONAL REHABIL, V11, P54; Santa-Barbara J, 1983, CANADIAN J COMMUNITY, V2, P91, DOI [10.7870/cjcmh-1983-0018, DOI 10.7870/CJCMH-1983-0018]; Serio CD, 1997, BRAIN INJURY, V11, P1, DOI 10.1080/026990597123764; Steffen AM, 2002, J GERONTOL B-PSYCHOL, V57, pP74, DOI 10.1093/geronb/57.1.P74; Stewart AL, 1992, MEASURING FUNCTIONIN; Vangel SJ, 2011, J HEAD TRAUMA REHAB, V26, P20, DOI 10.1097/HTR.0b013e318204a70d; WARE JE, 1997, MAP R WINDOWS MULTIT; Watt T, 2009, QUAL LIFE RES, V18, P483, DOI 10.1007/s11136-009-9460-8; Zeiss A., 1999, J CLIN GEROPSYCHOLOG, V5, P221, DOI [10.1023/A:1022955817074, DOI 10.1023/A:1022955817074]; Zimmerman MA, 1998, REHABIL PSYCHOL, V43, P3, DOI 10.1037/0090-5550.43.1.3	38	23	24	0	12	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	AUG	2011	56	3					243	250		10.1037/a0024465			8	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	809TD	WOS:000294078700009	21787096				2021-06-18	
J	Ross, LM; Register-Mihalik, JK; Mihalik, JP; McCulloch, KL; Prentice, WE; Shields, EW; Guskiewicz, KM				Ross, Luke M.; Register-Mihalik, Johna K.; Mihalik, Jason P.; McCulloch, Karen L.; Prentice, William E.; Shields, Edgar W.; Guskiewicz, Kevin M.			Effects of a Single-Task Versus a Dual-Task Paradigm on Cognition and Balance in Healthy Subjects	JOURNAL OF SPORT REHABILITATION			English	Article						postural stability; concussion; attention	POSTURAL STABILITY; ATTENTIONAL DEMANDS; CONCUSSION; YOUNG; PERFORMANCE; RECOVERY; DEFICITS; SYSTEM; FOCUS; ADVANTAGES	Context: Recent evidence has revealed deficiencies in the ability to divide attention after concussion. Objective: To examine the effects of a single vs a dual task on cognition and balance in healthy subjects and to examine reliability of 2 dual-task paradigms while examining the overall feasibility of the tasks. Design: Pretest-posttest experimental design. Setting: Sports medicine research laboratory. Patients: 30 healthy, recreationally active college students. Intervention: Subjects performed balance and cognitive tasks under the single- and dual-task conditions during 2 test sessions 14 d apart. Main Outcome Measures: The procedural reaction-time (PRT) test of the Automated Neuropsychological Assessment Metrics (eyes-closed tasks) and an adapted Procedural Auditory Task (PAT; eyes-open tasks) were used to assess cognition. The NeuroCom Sensory Organization Test (SOT) and the Balance Error Scoring System (BESS) were used to assess balance performance. Five 2-way, within-subject ANOVAs and a paired-samples t test were used to analyze the data. ICCs were used to assess reliability across 2 test sessions. Results: On the SOT, performance significantly improved between test sessions (F-1.29 = 35.695, P < .001) and from the single to the dual task (F-1.29 = 9.604, P = .004). On the PRT, performance significantly improved between test sessions (F-1.29 = 57.252, P < .001) and from the single to the dual task (F-1.29 = 7.673, P = .010). No differences were seen on the BESS and the PAT. Reliability across test sessions ranged from moderate to poor for outcome measure. Conclusions: The BESS appears to be a more reliable and functional tool in dual-task conditions as a result of its increased reliability and clinical applicability. In addition, the BESS is more readily available to clinicians than the SOT.	[Ross, Luke M.; Prentice, William E.; Shields, Edgar W.] Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA; [Register-Mihalik, Johna K.; Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC USA; [McCulloch, Karen L.] Univ N Carolina, Div Phys Therapy, Chapel Hill, NC USA	Ross, LM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Chapel Hill, NC 27515 USA.			Mihalik, Jason/0000-0001-6085-8322; Guskiewicz, Kevin/0000-0002-8682-2130			Andersson G, 2002, BRAIN RES BULL, V58, P135, DOI 10.1016/S0361-9230(02)00770-0; Bleiberg J, 1998, J HEAD TRAUMA REHAB, V13, P36, DOI 10.1097/00001199-199804000-00006; Bleiberg J, 2004, NEUROSURGERY, V54, P1073, DOI 10.1227/01.NEU.0000118820.33396.6A; Broglio SP, 2005, MED SCI SPORT EXER, V37, P689, DOI 10.1249/01.MSS.0000159019.14919.09; Broglio SP, 2007, J ATHL TRAINING, V42, P509; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2007, NEUROSURGERY, V60, P1050, DOI 10.1227/01.NEU.0000255479.90999.C0; Butter CM, 2003, PROG BRAIN RES, V144, P183, DOI 10.1016/S0079-6123(03)14401-3; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Chien CW, 2007, ARCH PHYS MED REHAB, V88, P374, DOI 10.1016/j.apmr.2006.11.019; Drew AS, 2007, NEUROSCI LETT, V417, P61, DOI 10.1016/j.neulet.2007.02.038; Fan J, 2002, J COGNITIVE NEUROSCI, V14, P340, DOI 10.1162/089892902317361886; Guskiewicz KM, 2004, J ATHL TRAINING, V39, P280; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Guskiewicz KM, 2001, CLIN J SPORT MED, V11, P182, DOI 10.1097/00042752-200107000-00009; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Muller MLTM, 2007, EXP BRAIN RES, V183, P447, DOI 10.1007/s00221-007-1065-2; Otani S, 2003, J PHYSIOL-PARIS, V97, P423, DOI 10.1016/j.jphysparis.2004.01.002; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Pellecchia GL, 2003, GAIT POSTURE, V18, P29, DOI 10.1016/S0966-6362(02)00138-8; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; POSNER MI, 1990, ANNU REV NEUROSCI, V13, P25, DOI 10.1146/annurev.ne.13.030190.000325; Rankin JK, 2000, J GERONTOL A-BIOL, V55, pM112, DOI 10.1093/gerona/55.3.M112; Redfern MS, 2001, GAIT POSTURE, V14, P211, DOI 10.1016/S0966-6362(01)00144-8; Register-Mihalik JK, 2008, NEUROSURGERY, V63, P76, DOI 10.1227/01.NEU.0000335073.39728.CE; Riemann BL, 2000, J ATHL TRAINING, V35, P19; Siu KC, 2008, AGING CLIN EXP RES, V20, P349, DOI 10.1007/BF03324867; Siu KC, 2008, EXP BRAIN RES, V184, P115, DOI 10.1007/s00221-007-1087-9; Siu KC, 2007, GAIT POSTURE, V25, P121, DOI 10.1016/j.gaitpost.2006.02.002; Sosnoff JJ, 2007, EXP AGING RES, V33, P399, DOI 10.1080/03610730701525311; Swan L, 2004, BRIT J PSYCHOL, V95, P31, DOI 10.1348/000712604322779442; Valovich TC, 2003, J ATHL TRAINING, V38, P51; van Donkelaar P, 2006, EXERC SPORT SCI REV, V34, P77, DOI 10.1249/00003677-200604000-00007; Wrisley DM, 2007, ARCH PHYS MED REHAB, V88, P1049, DOI 10.1016/j.apmr.2007.05.003; Wulf G, 1999, RES Q EXERCISE SPORT, V70, P120, DOI 10.1080/02701367.1999.10608029; Wulf G, 2000, RES Q EXERCISE SPORT, V71, P229, DOI 10.1080/02701367.2000.10608903; Wulf G, 2001, RES Q EXERCISE SPORT, V72, P335, DOI 10.1080/02701367.2001.10608970; Wulf G, 2007, RES Q EXERCISE SPORT, V78, P384, DOI 10.5641/193250307X13082505158336	45	23	24	0	26	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	AUG	2011	20	3					296	310		10.1123/jsr.20.3.296			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	807AY	WOS:000293864100004	21828382				2021-06-18	
J	Yu, LJ; Stokell, R; Treleaven, J				Yu, Li-Ju; Stokell, Raina; Treleaven, Julia			The effect of neck torsion on postural stability in subjects with persistent whiplash	MANUAL THERAPY			English	Article						Balance; Whiplash; Neck torsion	JOINT POSITION ERROR; BACK-PAIN PATIENTS; STANDING BALANCE; SENSORY CONDITIONS; DIZZINESS; INJURY; POSTUROGRAPHY; DISABILITY; DISORDERS; SELECTION	Dysfunction of cervical receptors in neck disorders has been shown to lead to disturbances in postural stability. The neck torsion manoeuvre used in the smooth pursuit neck torsion (SPNT) test is thought to be a specific measure of neck afferent dysfunction on eye movement in those with neck pain. This study aimed to determine whether neck torsion could change balance responses in those with persistent whiplash-associated disorders (WADs). Twenty subjects with persistent WAD and 20 healthy controls aged between 18 and 50 years stood on a computerised force plate with eyes closed in comfortable stance under 5 conditions: neutral head, head turned to left and right and neck torsion to left and right. Root mean square (rms) amplitude of sway was measured in the anterioreposterior (AP) and medial -lelateral (ML) directions. The whiplash group had significantly greater rms amplitude in the AP direction following neck torsion compared to the control group (p < 0.03). The results show that the neck torsion manoeuvre may lead to greater postural deficits in individuals with persistent WAD and provides further evidence of neck torsion to identify abnormal cervical afferent input, as an underlying cause of balance disturbances in WAD. Further research is warranted. Crown Copyright (C) 2011 Published by Elsevier Ltd. All rights reserved.	[Yu, Li-Ju; Stokell, Raina; Treleaven, Julia] Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia	Treleaven, J (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Physiotherapy, Brisbane, Qld 4072, Australia.	j.treleaven@uq.edu.au	Treleaven, Julia M/F-8734-2010; Treleaven, Julia/N-1379-2019	Treleaven, Julia M/0000-0002-6258-3972; Treleaven, Julia/0000-0002-6258-3972			ALUND M, 1991, ACTA OTO-LARYNGOL, P601; della Volpe R, 2006, GAIT POSTURE, V24, P349, DOI 10.1016/j.gaitpost.2005.10.009; El-Kahky AM, 2000, ACTA OTO-LARYNGOL, V120, P508, DOI 10.1080/000164800750046018; Field S, 2008, MANUAL THER, V13, P183, DOI 10.1016/j.math.2006.12.005; Horak F., 1996, POSTURAL ORIENTATION; KARLBERG M, 1995, ACTA OTO-LARYNGOL, P440; Karlberg M, 1996, J VESTIBUL RES-EQUIL, V6, P37; Madeleine P, 2004, ARCH PHYS MED REHAB, V85, P432, DOI 10.1016/j.apmr.2003.03.003; MALLINSON AI, 1996, J MUSCULOSKELET PAIN, V4, P105, DOI DOI 10.1300/J094V04N04_10; McIlroy WE, 1997, CLIN BIOMECH, V12, P66, DOI 10.1016/S0268-0033(96)00040-X; McPartland JM, 1997, J MANIP PHYSIOL THER, V20, P24; Michaelson P, 2003, J REHABIL MED, V35, P229, DOI 10.1080/16501970306093; Mientjes MIV, 1999, CLIN BIOMECH, V14, P710, DOI 10.1016/S0268-0033(99)00025-X; Prieto TE, 1996, IEEE T BIO-MED ENG, V43, P956, DOI 10.1109/10.532130; Rocchi L, 2004, MED BIOL ENG COMPUT, V42, P71, DOI 10.1007/BF02351013; Rocchi L, 2002, J NEUROL NEUROSUR PS, V73, P267, DOI 10.1136/jnnp.73.3.267; RUBIN AM, 1995, AM J OTOL, V16, P216; Schieppati M, 2003, NEUROSCIENCE, V121, P277, DOI 10.1016/S0306-4522(03)00439-1; SHUMWAYCOOK A, 1986, PHYS THER, V66, P1548, DOI 10.1093/ptj/66.10.1548; Sjostrom H, 2003, SPINE, V28, P1725, DOI 10.1097/00007632-200308010-00018; Speers RA, 1998, GAIT POSTURE, V7, P207, DOI 10.1016/S0966-6362(98)00006-X; Spitzer W, 1995, SPINE, V20, P1, DOI DOI 10.1097/00007632-199504151-00001; Tesio L, 1999, AM J PHYS MED REHAB, V78, P233, DOI 10.1097/00002060-199905000-00009; Tjell C, 1998, AM J OTOL, V19, P76; Tjell C, 2003, J WHIPLASH ASS DISOR, V1, P9; Treleaven J, 2006, MANUAL THER, V11, P99, DOI 10.1016/j.math.2005.04.003; Treleaven J, 2005, J REHABIL MED, V37, P219, DOI 10.1080/16501970410024299; Treleaven J, 2005, J REHABIL MED, V37, P224, DOI 10.1080/16501970510027989; Treleaven J, 2005, GAIT POSTURE, V21, P395, DOI 10.1016/j.gaitpost.2004.04.008; Treleaven J, 2003, J REHABIL MED, V35, P36, DOI 10.1080/16501970306109; Treleaven J, 2008, ARCH PHYS MED REHAB, V89, P522, DOI 10.1016/j.apmr.2007.11.002; VERNON H, 1991, J MANIP PHYSIOL THER, V14, P409; Vuillerme N, 2005, NEUROSCI LETT, V378, P135, DOI 10.1016/j.neulet.2004.12.024; Vuillerme N, 2009, EXP BRAIN RES, V192, P723, DOI 10.1007/s00221-008-1639-7	34	23	24	0	8	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	1356-689X			MANUAL THER	Man. Ther.	AUG	2011	16	4					339	343		10.1016/j.math.2010.12.006			5	Rehabilitation	Rehabilitation	798XH	WOS:000293245000006	21256074				2021-06-18	
J	Abdanipour, A; Tiraihi, T; Mirnajafi-Zadeh, J				Abdanipour, Alireza; Tiraihi, Taki; Mirnajafi-Zadeh, Javad			Improvement of the pilocarpine epilepsy model in rat using bone marrow stromal cell therapy	NEUROLOGICAL RESEARCH			English	Article						Epilepsy; Pilocarpine; Epileptogenesis; Convulsion; Bone marrow stromal cells	TEMPORAL-LOBE EPILEPSY; SPONTANEOUS RECURRENT SEIZURES; TRAUMATIC BRAIN-INJURY; MESENCHYMAL STEM-CELLS; ADULT-RAT; STATUS EPILEPTICUS; INTRACTABLE EPILEPSY; TRANSPLANTATION; HIPPOCAMPUS; NEURONS	Objective: Temporal lobe epilepsy is one of the most common types of epilepsy. Cytotherapy was tried for several neurological disorders. In this investigation, bone marrow stromal cells (BMSCs) were used in order to evaluate the recovery of epileptic rats induced by pilocarpine. Methods: The rats were divided into four groups: a negative control, treated groups, and epileptic rats treated with the vehicle only. The animals in the chronic phase were monitored for three weeks using Racine scale. BMSCs were labeled with BrdU and injected intravenously. After 6 weeks, the rats were killed and processed in paraffin as well as immunohistochemical techniques. Results: The results of the behavioral test showed that the number of seizures significantly decreased in treatment groups. Histopathology of the tissues from the untreated rats showed cell death and neurophagia. The numerical density of neurons per area was significantly higher in the treated groups than in the untreated ones. BMSCs localized in the hippocampus of the treated animals. Discussion: The results showed that there is structural and functional improvement in the epileptic rats treated with BMSCs.	[Abdanipour, Alireza; Tiraihi, Taki] Tarbiat Modares Univ, Dept Anat Sci, Sch Med Sci, Tehran, Iran; [Tiraihi, Taki] Khatam Al Anbia Hosp, Shafa Neurosci Res Ctr, Tehran, Iran; [Mirnajafi-Zadeh, Javad] Tarbiat Modares Univ, Dept Physiol, Sch Med Sci, Tehran, Iran	Tiraihi, T (corresponding author), Tarbiat Modares Univ, Dept Anat Sci, Sch Med Sci, POB 14155-4838, Tehran, Iran.	takialtr@modares.ac.ir	Mirnajafi-Zadeh, Javad/W-5379-2019; abdanipour, Alireza/I-4964-2016	Mirnajafi-Zadeh, Javad/0000-0003-3946-9052; abdanipour, Alireza/0000-0002-2975-3423			Aherne W. A., 1982, MORPHOMETRY; Bahadori MH, 2001, J NEUROCYTOL, V30, P125, DOI 10.1023/A:1011935122963; Baptiste DC, 2007, PROG BRAIN RES, V161, P217, DOI 10.1016/S0079-6123(06)61015-7; Barker Roger A, 2004, NeuroRx, V1, P472, DOI 10.1007/BF03206631; Barry Frank P, 2003, Novartis Found Symp, V249, P86; Bianco P, 2001, STEM CELLS, V19, P180, DOI 10.1634/stemcells.19-3-180; Bjorklund A, 2000, NAT NEUROSCI, V3, P537, DOI 10.1038/75705; Black IB, 2001, BLOOD CELL MOL DIS, V27, P632, DOI 10.1006/bcmd.2001.0423; Browne T, 2008, HDB EPILEPSY; Carpentino JE, 2008, J NEUROSCI RES, V86, P512, DOI 10.1002/jnr.21514; Castillo CG, 2008, BEHAV BRAIN RES, V193, P17, DOI 10.1016/j.bbr.2008.04.023; CAVALHEIRO EA, 1991, EPILEPSIA, V32, P778, DOI 10.1111/j.1528-1157.1991.tb05533.x; CAVAZOS JE, 1994, J NEUROSCI, V14, P3106; Chawla S, 2002, PEDIATR NEUROL, V27, P186, DOI 10.1016/S0887-8994(02)00416-2; Chen Q, 2005, J NEUROSCI RES, V80, P611, DOI 10.1002/jnr.20494; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chen Y, 2006, CELL MOL LIFE SCI, V63, P1649, DOI 10.1007/s00018-006-6019-5; Chopp M, 2002, LANCET NEUROL, V1, P92, DOI 10.1016/S1474-4422(02)00040-6; Chopp M, 2006, ADV EXP MED BIOL, V585, P49; Chu K, 2004, BRAIN RES, V1023, P213, DOI 10.1016/j.brainres.2004.07.045; Clarke Emer, 2005, Methods Mol Biol, V290, P173; Costa-Ferro ZSM, 2010, SEIZURE-EUR J EPILEP, V19, P84, DOI 10.1016/j.seizure.2009.12.003; Dezawa M, 2005, EXPERT OPIN BIOL TH, V5, P427, DOI 10.1517/14712598.5.4.427; Dezawa M, 2006, CELL MOL LIFE SCI, V63, P2764, DOI 10.1007/s00018-006-6191-7; Glien M, 2001, EPILEPSY RES, V46, P111, DOI 10.1016/S0920-1211(01)00272-8; Grisolia JS, 2001, EPILEPSY BEHAV, V2, P318, DOI 10.1006/ebeh.2001.0230; Guttinger M, 2005, EPILEPSIA, V46, P1162, DOI 10.1111/j.1528-1167.2005.61804.x; Habisch HJ, 2007, J NEURAL TRANSM, V114, P1395, DOI 10.1007/s00702-007-0748-y; Harvey RL, 2003, PHYS MED REH CLIN N, V14, P143; Hattiangady B, 2006, NEUROSCIENCE, V139, P1369, DOI 10.1016/j.neuroscience.2006.01.058; Hattiangady B, 2008, EXP NEUROL, V212, P468, DOI 10.1016/j.expneurol.2008.04.040; Hauser WA, 2008, EPILEPSIA, V49, P8, DOI 10.1111/j.1528-1167.2008.01443.x; Hermann A, 2004, J CELL SCI, V117, P4411, DOI 10.1242/jcs.01307; Hermann Andreas, 2006, Expert Opin Biol Ther, V6, P653, DOI 10.1517/14712598.6.7.653; Hokari M, 2008, J NEUROSCI RES, V86, P1024, DOI 10.1002/jnr.21572; Huber A, 2001, P NATL ACAD SCI USA, V98, P7611, DOI 10.1073/pnas.131102898; Jacobs MP, 2001, NEUROLOGY, V57, P1536, DOI 10.1212/WNL.57.9.1536; Khalatbary AR, 2007, NEUROL RES, V29, P21, DOI 10.1179/016164107X165642; Kobayashi M, 2003, J NEUROSCI, V23, P2440; Labouyrie E, 1999, AM J PATHOL, V154, P405, DOI 10.1016/S0002-9440(10)65287-X; Leroy C, 2003, EXP NEUROL, V182, P361, DOI 10.1016/S0014-4886(03)00122-5; Li TF, 2007, BRAIN, V130, P1276, DOI 10.1093/brain/awm057; Loscher W, 2008, TRENDS NEUROSCI, V31, P62, DOI 10.1016/j.tins.2007.11.012; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Mahmood A, 2003, NEUROSURGERY, V53, P697, DOI 10.1227/01.NEU.0000079333.61863.AA; MCKAY IS, 2004, PHARM BIOCH BEHAV, V78, P111; Meletis K, 2003, TRENDS NEUROSCI, V26, P292, DOI 10.1016/S0166-2236(03)00125-5; Nolte MW, 2008, NEUROBIOL DIS, V31, P342, DOI 10.1016/j.nbd.2008.05.010; Olstorn H, 2007, NEUROSURGERY, V60, P1089, DOI 10.1227/01.NEU.0000255461.91892.0D; Parent JM, 1997, J NEUROSCI, V17, P3727; Pugliatti M, 2007, EPILEPSIA, V48, P2224; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Rao MS, 2007, NEUROBIOL DIS, V27, P117, DOI 10.1016/j.nbd.2007.03.016; Raza M, 2001, BRAIN RES, V903, P1, DOI 10.1016/S0006-8993(01)02127-8; Rigoulot MA, 2004, J PHARMACOL EXP THER, V308, P787, DOI 10.1124/jpet.103.057091; Rodi N, 2004, TRENDS MOL MED, V10, P93, DOI 10.1016/j.molmed.2004.01.010; Rosenow F, 2007, EPILEPSIA, V48, P82, DOI 10.1111/j.1528-1167.2007.01359.x; Ruschenschmidt T, 2005, EPILEPSIA, V46, P174, DOI 10.1111/j.1528-1167.2005.01028.x; Sanchez-Ramos JR, 2002, J NEUROSCI RES, V69, P880, DOI 10.1002/jnr.10337; Savitz SI, 2002, ANN NEUROL, V52, P266, DOI 10.1002/ana.60000; Seshi B, 2000, BLOOD CELL MOL DIS, V26, P234, DOI 10.1006/bcmd.2000.0301; Shetty AK, 2007, STEM CELLS, V25, P2396, DOI 10.1634/stemcells.2007-0313; Shyu WC, 2007, STROKE, V38, P367, DOI 10.1161/01.STR.0000254463.24655.14; TAKI TM, 1984, AM J ANAT, V171, P415, DOI 10.1002/aja.1001710406; Thompson KW, 2005, NEUROSCIENCE, V133, P1029, DOI 10.1016/j.neuroscience.2005.03.003; Turner DA, 2003, NEUROSURGERY, V52, P632, DOI 10.1227/01.NEU.0000047825.91205.E6; TURSKI L, 1989, SYNAPSE, V3, P154, DOI 10.1002/syn.890030207; Vaquero J, 2006, NEUROSCI LETT, V398, P129, DOI 10.1016/j.neulet.2005.12.072; Woodbury D, 2000, J NEUROSCI RES, V61, P364, DOI 10.1002/1097-4547(20000815)61:4<364::AID-JNR2>3.0.CO;2-C; Zaman V, 2003, HIPPOCAMPUS, V13, P618, DOI 10.1002/hipo.10091	70	23	25	0	15	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	JUL	2011	33	6					625	632		10.1179/1743132810Y.0000000018			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	783ML	WOS:000292087300009	21708072				2021-06-18	
J	Kahalley, LS; Conklin, HM; Tyc, VL; Wilson, SJ; Hinds, PS; Wu, SJ; Xiong, XP; Hudson, MM				Kahalley, Lisa S.; Conklin, Heather M.; Tyc, Vida L.; Wilson, Stephanie J.; Hinds, Pamela S.; Wu, Shengjie; Xiong, Xiaoping; Hudson, Melissa M.			ADHD and Secondary ADHD Criteria Fail to Identify Many At-Risk Survivors of Pediatric ALL and Brain Tumor	PEDIATRIC BLOOD & CANCER			English	Article						ADHD; attention; cancer; children; cognitive assessment; hyperactivity; oncology	CONTINUOUS PERFORMANCE-TEST; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; DEFICIT HYPERACTIVITY DISORDER; SLUGGISH COGNITIVE TEMPO; LONG-TERM SURVIVORS; CLOSED-HEAD INJURY; DOUBLE-BLIND; NEUROPSYCHOLOGICAL PERFORMANCE; CHILDHOOD-CANCER; CHILDREN	Background. Post-treatment attention problems experienced by pediatric cancer survivors have been described as similar to symptoms of Attention-Deficit/Hyperactivity Disorder (ADHD) experienced in physically healthy children. Accordingly, the objectives of this study were to: (a) estimate the rate of occurrence of ADHD and secondary ADHD (SADHD) in a sample of pediatric cancer survivors, (b) compare the rate of ADHD/SADHD among survivors to the prevalence of ADHD in the general population, and (c) examine clinical correlates of ADHD/SADHD in this sample. Procedure. Survivors of pediatric ALL or brain tumor (n = 100) participated in an assessment of attention including a Computerized Performance Measure [Conners' Continuous Performance test-II (CPT-II)], parent and self-report measures (Conners 3), and a structured diagnostic interview for ADHD and other psychological disorders [Diagnostic Interview for Children and Adolescents-IV (DICA-IV)]. Results. Binomial tests revealed that the rate of ADHD/SADHD in our sample (9%) was significantly greater than the lower limits of ADHD prevalence among children in the US (3%; P < 0.001), while no difference was identified compared to the upper limits of ADHD prevalence (7%; P > 0.05). Many additional survivors (> 25% of the sample) obtained clinical elevations on Conners 3 scales but did not meet ADHD/SADHD criteria. Conclusions. Attentional deficits experienced by pediatric cancer survivors do not appear to resemble the clinical presentation of ADHD or SADHD. Many survivors with cognitive and behavioral difficulties related to attention were not identified using this diagnostic approach. Findings offer needed clarification to guide researchers and clinicians in conceptualizing, assessing, and intervening on attentional late effects. Pediatr Blood Cancer 2011;57:110-118. (C) 2011 Wiley-Liss, Inc.	[Kahalley, Lisa S.] Baylor Coll Med, Dept Pediat, Psychol Sect, Houston, TX 77030 USA; [Conklin, Heather M.; Tyc, Vida L.; Wilson, Stephanie J.] St Jude Childrens Res Hosp, Dept Psychol, Memphis, TN 38105 USA; [Hinds, Pamela S.] Childrens Natl Med Ctr, Dept Nursing Res & Qual Outcomes, Washington, DC 20010 USA; [Hinds, Pamela S.] George Washington Univ, Dept Pediat, Washington, DC 20052 USA; [Wu, Shengjie; Xiong, Xiaoping] St Jude Childrens Res Hosp, Dept Biostat, Memphis, TN 38105 USA; [Hudson, Melissa M.] St Jude Childrens Res Hosp, Dept Oncol, Div Canc Survivorship, Memphis, TN 38105 USA	Kahalley, LS (corresponding author), Texas Childrens Hosp, 1102 Bates,Suite 730, Houston, TX 77030 USA.	lskahall@texaschildrens.org	Hudson, Melissa M/N-4441-2018; Hinds, Pamela/W-8115-2019; Conklin, Heather M/N-2696-2018	Hudson, Melissa M/0000-0001-6984-2407; 	National Institute of Drug AbuseUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [F32DA024503]; NIH Cancer CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [CA21765]; American Lebanese Syrian Associated Charities (ALSAC)American Lebanese Syrian Associated Charities (ALSAC); NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R25CA023944, P30CA021765] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [F32DA024503] Funding Source: NIH RePORTER	Grant sponsor: National Institute of Drug Abuse; Grant number: F32DA024503; Grant sponsor: NIH Cancer Center Support CORE Grant; Grant number: CA21765; Grant sponsor: American Lebanese Syrian Associated Charities (ALSAC).	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Agay N, 2010, PSYCHOPHARMACOLOGY, V210, P511, DOI 10.1007/s00213-010-1853-4; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Anderson V, 1997, Pediatr Rehabil, V1, P63; Anderson V, 2006, J INT NEUROPSYCH SOC, V12, P519, DOI 10.1017/S135561770606067X; Barkley RA, 2006, ATTENTION DEFICIT HY; Butler RW, 2005, J PEDIATR PSYCHOL, V30, P65, DOI 10.1093/jpepsy/jsi017; Carlson CL, 2002, J CLIN CHILD ADOLESC, V31, P123, DOI 10.1207/153744202753441738; Conklin HM, 2007, J PEDIATR PSYCHOL, V32, P1127, DOI 10.1093/jpepsy/jsm045; Conklin HM, 2010, J PEDIATR PSYCHOL, V35, P144, DOI 10.1093/jpepsy/jsp044; Conners C.K., 2008, CONNERS MANUAL; Conners CK, 2000, MHS STAFF CONNERS CO; Edwards MC, 2007, J ABNORM CHILD PSYCH, V35, P393, DOI 10.1007/s10802-007-9098-3; Epstein JN, 1998, CLIN NEUROPSYCHOL, V12, P155, DOI 10.1076/clin.12.2.155.2000; Fossen A, 1998, PEDIATR HEMAT ONCOL, V15, P479, DOI 10.3109/08880019809018309; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Hartman CA, 2004, J ABNORM CHILD PSYCH, V32, P491, DOI 10.1023/B:JACP.0000037779.85211.29; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Holmquist LA, 2002, J CLIN PSYCHOL MED S, V9, P315, DOI 10.1023/A:1020791018897; Homer CJ, 2000, PEDIATRICS, V105, P1158; Kaplan S, 2004, J Atten Disord, V8, P45, DOI 10.1177/108705470400800202; KAVALE K, 1982, J LEARN DISABIL-US, V15, P280, DOI 10.1177/002221948201500508; KLORMAN R, 1984, PSYCHOPHARMACOL BULL, V20, P3; Krull KR, 2008, J PEDIATR-US, V152, P101, DOI 10.1016/j.jpeds.2007.05.047; LAHEY BB, 1988, J AM ACAD CHILD PSY, V27, P330, DOI 10.1097/00004583-198805000-00011; Langer T, 2002, MED PEDIATR ONCOL, V38, P320, DOI 10.1002/mpo.10055; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Lockwood KA, 1999, J PEDIATR PSYCHOL, V24, P55, DOI 10.1093/jpepsy/24.1.55; Mackie S, 2007, AM J PSYCHIAT, V164, P647, DOI 10.1176/appi.ajp.164.4.647; Maddrey AM, 2005, J NEURO-ONCOL, V72, P245, DOI 10.1007/s11060-004-3009-z; Max JE, 2004, DEV NEUROPSYCHOL, V25, P159, DOI 10.1207/s15326942dn2501&2_9; McClellan JM, 2000, J AM ACAD CHILD PSY, V39, P19, DOI 10.1097/00004583-200001000-00013; McGee RA, 2000, J ABNORM CHILD PSYCH, V28, P415, DOI 10.1023/A:1005127504982; Merchant TE, 2002, INT J RADIAT ONCOL, V53, P1271, DOI 10.1016/S0360-3016(02)02828-6; Moleski M, 2000, ARCH CLIN NEUROPSYCH, V15, P603, DOI 10.1016/S0887-6177(99)00050-5; Mostofsky SH, 2002, BIOL PSYCHIAT, V52, P785, DOI 10.1016/S0006-3223(02)01412-9; Mulhern RK, 2004, J CLIN ONCOL, V22, P4795, DOI 10.1200/JCO.2004.04.128; Mulhern RK, 2004, J INT NEUROPSYCH SOC, V10, P180, DOI 10.1017/S135561770410204X; Patel SK, 2007, PEDIATR BLOOD CANCER, V49, P970, DOI 10.1002/pbc.21151; PELOQUIN LJ, 1986, J ABNORM PSYCHOL, V95, P88, DOI 10.1037/0021-843X.95.1.88; Peterson CC, 2008, PEDIATR BLOOD CANCER, V51, P99, DOI 10.1002/pbc.21544; Pineda DA, 2007, EUR CHILD ADOLES PSY, V16, P337, DOI 10.1007/s00787-007-0605-4; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Reeves CB, 2007, J PEDIATR PSYCHOL, V32, P1050, DOI 10.1093/jpepsy/jsm063; Reeves CB, 2006, J PEDIATR PSYCHOL, V31, P272, DOI 10.1093/jpepsy/jsj019; RIS MD, 1994, J CLIN EXP NEUROPSYC, V16, P21, DOI 10.1080/01688639408402615; Rodgers J, 1999, ARCH DIS CHILD, V80, P318, DOI 10.1136/adc.80.4.318; Rogers R, 2001, HDB DIAGNOSTIC STRUC; Thompson SJ, 2001, J CLIN ONCOL, V19, P1802, DOI 10.1200/JCO.2001.19.6.1802; Troy L, 2000, PSYCHO-ONCOL, V9, P29, DOI 10.1002/(SICI)1099-1611(200001/02)9:1<29::AID-PON428>3.3.CO;2-Q; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007	53	23	23	0	10	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1545-5009	1545-5017		PEDIATR BLOOD CANCER	Pediatr. Blood Cancer	JUL	2011	57	1					110	118		10.1002/pbc.22998			9	Oncology; Hematology; Pediatrics	Oncology; Hematology; Pediatrics	762DL	WOS:000290452400019	21337681	Green Accepted			2021-06-18	
J	Kieffer-Kristensen, R; Teasdale, TW; Bilenberg, N				Kieffer-Kristensen, Rikke; Teasdale, Thomas W.; Bilenberg, Niels			Post-traumatic stress symptoms and psychological functioning in children of parents with acquired brain injury	BRAIN INJURY			English	Article						Children; caregiver; post-traumatic stress disorder; family; prevention	SOMATICALLY ILL PARENTS; EVENT SCALE CRIES; CANCER-PATIENTS; PSYCHOSOCIAL CONSEQUENCES; BEHAVIORAL-PROBLEMS; NATIONAL-SURVEY; REVISED IMPACT; BREAST-CANCER; FOLLOW-UP; FAMILY	Introduction/objectives: The effect of parental brain injury on children has been relatively little investigated. This study examines post-traumatic stress symptoms (PSS) and psychological functioning in children with a parent with an acquired brain injury. Participants, materials and methods: The participants were 35 patients with acquired brain injury, their spouses and children aged 7-14 years recruited from out-patient brain injury rehabilitation units across Denmark. Children self-reported psychological functioning using the Becks Youth Inventory (BYI) and Child Impact of Events revised (CRIES) measuring PSS symptoms. Emotional and behavioural problems among the children were also identified by the parents using the Achenbach's Child Behaviour Checklist (CBCL). A matched control group, consisting of 20 children of parents suffering from diabetes, was recruited from the National Danish Diabetes Register. Results: Post-traumatic stress symptoms above cut-off score (<30) were found (CRIES) in 46% of the children in the brain injury group compared to 10% in the diabetes group. The parents in the brain injury group reported more emotional and behavioural problems in their children when compared to published norms (CBCL). Conclusions: When parents have acquired brain injury, their children appear to be at a substantial risk for developing post-traumatic stress symptoms. These results indicate the need for a child-centred family support service to reduce the risk of children being traumatized by parental brain injury, with a special focus on the relational changes within the family.	[Kieffer-Kristensen, Rikke; Teasdale, Thomas W.] Univ Copenhagen, Dept Psychol, DK-1353 Copenhagen, Denmark; [Bilenberg, Niels] Univ So Denmark, Dept Child, Odense, Denmark; [Bilenberg, Niels] Univ So Denmark, Dept Adolescence Psychiat, Odense, Denmark	Kieffer-Kristensen, R (corresponding author), Univ Copenhagen, Dept Psychol, Oster Farimagsgade 2A, DK-1353 Copenhagen, Denmark.	rikke.kieffer@psy.ku.dk	Bilenberg, Niels/I-6027-2014	Bilenberg, Niels/0000-0002-5838-556X			ACHENBACH TM, 1991, MONOGR SOC RES CHILD, V56, pR5; Alderfer MA, 2003, J PEDIATR PSYCHOL, V28, P281, DOI 10.1093/jpepsy/jsg016; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; ARMISTEAD L, 1995, CLIN PSYCHOL REV, V15, P409, DOI 10.1016/0272-7358(95)00023-I; BECK JS, 2001, BECK YOUTH INVENTORY; Bilenberg N, 1999, ACTA PSYCHIAT SCAND, V100, P2, DOI 10.1111/j.1600-0447.1999.tb10703.x; Birenbaum L K, 1999, Oncol Nurs Forum, V26, P1639; BOWLBY J, 1969, ATTACHTMENT LOSS; Butera-Prinzi F, 2004, BRAIN INJURY, V18, P83, DOI 10.1080/0269905031000118500; Compas BE, 1996, HEALTH PSYCHOL, V15, P167, DOI 10.1037/0278-6133.15.3.167; Dyregrov A, 1996, SCAND J PSYCHOL, V37, P339, DOI 10.1111/j.1467-9450.1996.tb00667.x; Edwards L, 2008, PSYCHO-ONCOL, V17, P1039, DOI 10.1002/pon.1323; ETH S, 1985, 137 ANN M AM PSYCH A; Giannopoulou L, 2006, PERS INDIV DIFFER, V40, P1027, DOI 10.1016/j.paid.2005.11.002; Gosling J, 1999, BRAIN INJURY, V13, P785; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Huizinga GA, 2003, PSYCHO-ONCOL, V12, pS209; KOBAK R, 1999, HDB ATTACHMENT THEOR, P21; KOBAK R, 2006, HDB DEV PSYCHOPATHOL, P333; Kreutzer JS, 2007, NEUROREHABILITATION, V22, P53; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; LECLERE FB, 1994, J MARRIAGE FAM, V56, P457, DOI 10.2307/353112; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; ODDY M, 1978, BRIT J PSYCHIAT, V133, P507, DOI 10.1192/bjp.133.6.507; Perlesz A, 2000, J HEAD TRAUMA REHAB, V15, P909, DOI 10.1097/00001199-200006000-00005; Perrin S, 2005, BEHAV COGN PSYCHOTH, V33, P487, DOI 10.1017/S1352465805002419; Perrin S, 2000, J CHILD PSYCHOL PSYC, V41, P277, DOI 10.1017/S0021963099005454; PESSAR LF, 1993, BRAIN INJURY, V7, P231, DOI 10.3109/02699059309029675; Ponsford J, 2010, J INT NEUROPSYCH SOC, V16, P306, DOI 10.1017/S1355617709991342; Pynoos R., 1992, BEREAVEMENT CARE, V11, P2, DOI DOI 10.1080/02682629208657280; Pynoos RS, 2009, J TRAUMA STRESS, V22, P391, DOI 10.1002/jts.20450; Romer G, 2007, PRAX KINDERPSYCHOL K, V56, P870, DOI 10.13109/prkk.2007.56.10.870; RUTTER M, 1966, I PSYCHIAT MAUDSLEY, V16; Sanchez L, 1994, Ann Clin Psychiatry, V6, P39, DOI 10.3109/10401239409148838; Schmitt F, 2008, J CLIN ONCOL, V26, P5877, DOI 10.1200/JCO.2007.12.8132; SHAW JA, 1995, J AM ACAD CHILD PSY, V34, P1185, DOI 10.1097/00004583-199509000-00016; Smith P, 2003, PERS INDIV DIFFER, V34, P315, DOI 10.1016/S0191-8869(02)00047-8; Smith P, 2002, J TRAUMA STRESS, V15, P147, DOI 10.1023/A:1014812209051; Steck B, 2007, EUR CHILD ADOLES PSY, V16, P199, DOI 10.1007/s00787-006-0589-5; Stoppelbein L, 2000, J AM ACAD CHILD PSY, V39, P1112, DOI 10.1097/00004583-200009000-00010; Stoppelbein LA, 2006, J PEDIATR PSYCHOL, V31, P367, DOI 10.1093/jpepsy/jsj055; Teasdale TW, 2005, BRAIN INJURY, V19, P1049, DOI 10.1080/02699050500110421; Thastum M, 2009, SCAND J PSYCHOL, V50, P47, DOI 10.1111/j.1467-9450.2008.00690.x; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; URBACH JR, 1991, PSYCHOSOMATICS, V32, P24, DOI 10.1016/S0033-3182(91)72108-7; Uysal S, 1998, J HEAD TRAUMA REHAB, V13, P57, DOI 10.1097/00001199-199812000-00007; Visser A, 2007, ACTA ONCOL, V46, P67, DOI 10.1080/02841860600949560; Visser-Meily A, 2005, J REHABIL MED, V37, P236, DOI 10.1080/16501970510025990; Watson M, 2006, BRIT J CANCER, V94, P43, DOI 10.1038/sj.bjc.6602887; Webster G, 2007, CLIN REHABIL, V21, P1097, DOI 10.1177/0269215507079833; Yule W, 2001, J CLIN PSYCHIAT, V62, P23	52	23	23	0	9	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUL	2011	25	7-8					752	760		10.3109/02699052.2011.579933			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	769RJ	WOS:000291035600011	21604930				2021-06-18	
J	Bjelobaba, I; Parabucki, A; Lavrnja, I; Stojkov, D; Dacic, S; Pekovic, S; Rakic, L; Stojiljkovic, M; Nedeljkovic, N				Bjelobaba, Ivana; Parabucki, Ana; Lavrnja, Irena; Stojkov, Danijela; Dacic, Sanja; Pekovic, Sanja; Rakic, Ljubisa; Stojiljkovic, Mirjana; Nedeljkovic, Nadezda			Dynamic Changes in the Expression Pattern of Ecto-5 '-Nucleotidase in the Rat Model of Cortical Stab Injury	JOURNAL OF NEUROSCIENCE RESEARCH			English	Article						brain; ecto-5 '-nucleotidase; purinergic systems; ATP; astrocytes	SYNAPTIC PLASMA-MEMBRANES; P2 PURINERGIC RECEPTORS; EXTRACELLULAR ATP; BRAIN-INJURY; IN-VIVO; REACTIVE ASTROCYTES; GENE-EXPRESSION; CEREBRAL-CORTEX; UP-REGULATION; ADENOSINE	Traumatic injury induces massive release of ATP in the extracellular space, where it influences numerous aspects of neuronal, astrocytic, and microglial responses to injury by activating P2X and P2Y receptors. The extracellular ATP actions are controlled by the ectonucleotidase enzyme pathway, which hydrolyses ATP to adenosine at all neuronal and nonneuronal cell types. Adenosine activates its P1 receptors, which have important neuroprotective roles. The rate-limiting enzyme in the ectonucleotidase pathway is ecto-5 '-nucleotidase (e-5NT), which catalyzes the final step of dephosphorylation of AMP to adenosine. The aim of the present study was to characterize the expression pattern and cellular distribution of e-5NT in the perilesioned cortex at 4 hr and 1, 2, 7, and 15 days after unilateral cortical stab injury (CSI). Immunoblot and immunohistochemical studies showed that overall e-5NT expression was lower 4 hr and 1 day postinjury and then gradually increased above the control levels. Double-immunofluorescence studies further showed in control tissue the presence of the enzyme in the membranes surrounding neuronal somata and apical dendrites and less frequently in astrocytes. CSI caused a rapid (after 4 hr) and irreversible loss of the enzyme from neurons, accounting for a decrease in the overall enzyme expression. This was accompanied with a gradual increase in e-5NT-positive astrocytes, accounting for up-regulation of the enzyme levels in the injured area. Thus, CSI induced dynamic changes in the expression pattern of e-5NT that modify the ATP/adenosine ratio and the extent of P1 and P2 receptors activation and, therefore, outcome of the pathological processes after CSI. (C) 2011 Wiley-Liss, Inc.	[Nedeljkovic, Nadezda] Univ Belgrade, Fac Biol, Inst Physiol & Biochem, Dept Gen Physiol & Biophys, Belgrade 11001, Serbia; [Bjelobaba, Ivana; Parabucki, Ana; Lavrnja, Irena; Stojkov, Danijela; Pekovic, Sanja; Stojiljkovic, Mirjana] Univ Belgrade, Inst Biol Res Sinisa Stankovic, Dept Neurobiol, Belgrade 11001, Serbia; [Rakic, Ljubisa] Serbian Acad Arts & Sci, Belgrade, Serbia	Nedeljkovic, N (corresponding author), Univ Belgrade, Fac Biol, Inst Physiol & Biochem, Dept Gen Physiol & Biophys, Studentski Trg 3, Belgrade 11001, Serbia.	nnedel@bio.bg.ac.rs	Lavrnja, Irena/ABA-1558-2020; Bjelobaba, Ivana/ABA-1538-2020	Lavrnja, Irena/0000-0002-0607-5594; Bjelobaba, Ivana/0000-0002-7649-0304; Savic, Danijela/0000-0001-7411-4527	Serbian Ministry of Science and TechnologyMinistry of Science, Serbia [41014]	Contract grant sponsor: Serbian Ministry of Science and Technology; Contract grant number: 41014.	Abbracchio MP, 1998, JPN J PHARMACOL, V78, P113, DOI 10.1254/jjp.78.113; Amadio S, 2002, NEUROPHARMACOLOGY, V42, P489, DOI 10.1016/S0028-3908(01)00197-6; Bjelobaba I, 2010, NEUROSCIENCE, V170, P107, DOI 10.1016/j.neuroscience.2010.06.063; Bonan CD, 2000, NEUROCHEM RES, V25, P775, DOI 10.1023/A:1007557205523; Bonan CD, 2000, EPILEPSY RES, V39, P229, DOI 10.1016/S0920-1211(00)00095-4; Braun N, 1998, J NEUROSCI, V18, P4891; Burnstock G, 2008, NAT REV DRUG DISCOV, V7, P575, DOI 10.1038/nrd2605; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; Cunha Rodrigo A, 2005, Purinergic Signal, V1, P111, DOI 10.1007/s11302-005-0649-1; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Maria R, 1999, NATURE, V401, P489, DOI 10.1038/46809; Di Virgilio F, 2009, TRENDS NEUROSCI, V32, P79, DOI 10.1016/j.tins.2008.11.003; Edwards FA, 1996, CIBA F SYMP, V198, P278; Franke H, 2006, INT J DEV NEUROSCI, V24, P123, DOI 10.1016/j.ijdevneu.2005.11.016; Franke H, 2006, PFLUG ARCH EUR J PHY, V452, P622, DOI 10.1007/s00424-006-0071-8; GRAY EG, 1962, J ANAT, V96, P79; Gyoneva S, 2009, PARKINSONISM RELAT D, V15, pS195, DOI 10.1016/S1353-8020(09)70813-2; Hansen KR, 1995, GENE, V167, P307, DOI 10.1016/0378-1119(95)00574-9; Haynes SE, 2006, NAT NEUROSCI, V9, P1512, DOI 10.1038/nn1805; Heinemeyer T, 1998, NUCLEIC ACIDS RES, V26, P362, DOI 10.1093/nar/26.1.362; Honda S, 2001, J NEUROSCI, V21, P1975, DOI 10.1523/JNEUROSCI.21-06-01975.2001; INOUE K, 1995, NEUROREPORT, V6, P437; JAMES S, 1993, J NEUROCHEM, V60, P219, DOI 10.1111/j.1471-4159.1993.tb05841.x; Kalsi K, 2002, MOL CELL BIOCHEM, V232, P113, DOI 10.1023/A:1014806916844; Koizumi S, 2007, NATURE, V446, P1091, DOI 10.1038/nature05704; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Lehto MT, 2002, BIOCHEMISTRY-US, V41, P1398, DOI 10.1021/bi011579w; Letho MT, 1998, BIOCHEM J, V332, P101, DOI 10.1042/bj3320101; MARKWELL MAK, 1978, ANAL BIOCHEM, V87, P206, DOI 10.1016/0003-2697(78)90586-9; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; Melani A, 2005, NEUROCHEM INT, V47, P442, DOI 10.1016/j.neuint.2005.05.014; Nagy AK, 1997, MOL CHEM NEUROPATHOL, V31, P135, DOI 10.1007/BF02815238; Narravula S, 2000, J IMMUNOL, V165, P5262, DOI 10.4049/jimmunol.165.9.5262; Neary Joseph T, 2006, Novartis Found Symp, V276, P131; Neary JT, 2006, J NEUROSCI RES, V84, P515, DOI 10.1002/jnr.20969; Neary JT, 2005, MOL NEUROBIOL, V31, P95, DOI 10.1385/MN:31:1-3:095; Neary JT, 2005, J NEUROTRAUM, V22, P491, DOI 10.1089/neu.2005.22.491; Neary JT, 2003, J NEUROSCI, V23, P2348, DOI 10.1523/jneurosci.23-06-02348.2003; Nedeljkovic N, 2005, INT J DEV NEUROSCI, V23, P45, DOI 10.1016/j.ijdevneu.2004.09.001; Nedeljkovic N, 1998, GEN PHYSIOL BIOPHYS, V17, P3; Nedeljkovic N, 2006, CELL BIOL INT, V30, P541, DOI 10.1016/j.cellbi.2006.03.001; Nedeljkovic N, 2008, NEUROCHEM RES, V33, P873, DOI 10.1007/s11064-007-9529-0; O'Dell DM, 2000, J NEUROSCI, V20, P4821; Ochiishi T, 1999, J COMP NEUROL, V411, P301; Ohsawa K, 2007, GLIA, V55, P604, DOI 10.1002/glia.20489; OREGAN MH, 1992, BRAIN RES, V582, P22, DOI 10.1016/0006-8993(92)90312-W; Ridet JL, 1997, TRENDS NEUROSCI, V20, P570, DOI 10.1016/S0166-2236(97)01139-9; Sofroniew MV, 2005, NEUROSCIENTIST, V11, P400, DOI 10.1177/1073858405278321; Stone TW, 2007, METAB BRAIN DIS, V22, P337, DOI 10.1007/s11011-007-9064-3; Takenouchi T, 2009, CRIT REV IMMUNOL, V29, P335, DOI 10.1615/CritRevImmunol.v29.i4.40; Tarumoto T, 2000, BLOOD, V96, P1716, DOI 10.1182/blood.V96.5.1716.h8001716_1716_1722; Verkhratsky A, 2009, MOL NEUROBIOL, V39, P190, DOI 10.1007/s12035-009-8063-2; Villa RF, 2002, NEUROCHEM RES, V27, P861, DOI 10.1023/A:1020381829107; Wang M, 2005, J NEUROCHEM, V95, P630, DOI 10.1111/j.1471-4159.2005.03408.x; Xiang ZH, 2006, J NEUROSCI RES, V83, P91, DOI 10.1002/jnr.20709; Yegutkin GG, 2008, BBA-MOL CELL RES, V1783, P673, DOI 10.1016/j.bbamcr.2008.01.024; Zimmermann H, 2000, N-S ARCH PHARMACOL, V362, P299, DOI 10.1007/s002100000309	57	23	23	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0360-4012	1097-4547		J NEUROSCI RES	J. Neurosci. Res.	JUN	2011	89	6					862	873		10.1002/jnr.22599			12	Neurosciences	Neurosciences & Neurology	749OI	WOS:000289477500009	21337375				2021-06-18	
J	Nishihara, T; Ochi, M; Sugimoto, K; Takahashi, H; Yano, H; Kumon, Y; Ohnishi, T; Tanaka, J				Nishihara, Tasuku; Ochi, Michihisa; Sugimoto, Kana; Takahashi, Hisaaki; Yano, Hajime; Kumon, Yoshiaki; Ohnishi, Takanori; Tanaka, Junya			Subcutaneous injection containing IL-3 and GM-CSF ameliorates stab wound-induced brain injury in rats	EXPERIMENTAL NEUROLOGY			English	Article						Macrophage; Traumatic brain injury; IL-3; GM-CSF; Subcutaneous injection; Iba1; NG2	COLONY-STIMULATING FACTOR; NG2 PROTEOGLYCAN; IN-VITRO; CELLS; MICROGLIA; ISCHEMIA; PROGESTERONE; HIPPOCAMPAL; NEURONS; PROFILE	Macrophage-like cells densely accumulate in stab wound-induced brain lesions in rats. Many of these cells express the macrophage marker Iba1 and the oligodendrocyte progenitor cell marker NG2 chondroitin sulfate proteoglycan (NG2), and have been termed BINCs (brain Iba1(+)/NG2(+) cells). Results from our previous study showed that BINCs elicit neuroprotective action, and agents inducing BINC activation or proliferation are expected to ameliorate traumatic brain injuries (TBIs). In the present study, TBI was established by inserting a needle into the cerebrum and moving the needle in a longitudinal, fan-like movement. Isolated BINCs from these stab lesions expressed mRNAs encoding receptors for interleukin-3 (IL-3) and granulocyte/macrophage colony-stimulating factor (GM-CSF). When this mixture of cytokines was added to the cultured BINCs, expression of mRNAs encoding insulin-like growth factor-1, hepatocyte growth factor, and proliferating cell nuclear antigen increased. The cytokine mixture induced enhanced wound healing in BINCs-brain cell co-cultures in vitro. Stab wounds in the rats resulted in significant brain tissue loss at 2 months post-lesion. However, tissue loss was reduced by 40% when the combination of IL-3 and GM-CSF was subcutaneously injected 7 times (once per day) beginning at 2 or 3 days post-lesion (dpl). BINCs are highly proliferative and an intraperitoneal injection of 5-fluorouracil (5FU) at 2 dpl eliminated the BINCs, resulting in death of the rats. The cytokine mixture injection significantly reduced mortality of the 5FU-treated rats. These results suggest that the combination of IL-3 and GM-CSF serves as a promising agent to ameliorate TBI via action on BINCs. (C) 2011 Elsevier Inc. All rights reserved.	[Nishihara, Tasuku; Ochi, Michihisa; Sugimoto, Kana; Takahashi, Hisaaki; Yano, Hajime; Kumon, Yoshiaki; Ohnishi, Takanori; Tanaka, Junya] Ehime Univ, Ehime Proteomed Res Ctr, Dept Basic & Clin Neurosci, Toon, Ehime 7910295, Japan; [Nishihara, Tasuku; Ochi, Michihisa; Sugimoto, Kana; Takahashi, Hisaaki; Yano, Hajime; Tanaka, Junya] Ehime Univ, Grad Sch Med, Dept Mol & Cellular Physiol, Toon, Ehime 7910295, Japan; [Kumon, Yoshiaki; Ohnishi, Takanori] Ehime Univ, Grad Sch Med, Dept Neurosurg, Toon, Ehime 7910295, Japan	Tanaka, J (corresponding author), Ehime Univ, Ehime Proteomed Res Ctr, Dept Basic & Clin Neurosci, Toon, Ehime 7910295, Japan.	jtanaka@m.ehime-u.ac.jp	Tanaka, Junya/Y-1033-2019	Tanaka, Junya/0000-0003-1056-5948	Setsuro Fujii Memorial; The Osaka Foundation for Promotion of Fundamental Medical Research; Ehime University; Ministry of Education, Culture, Sports, Science and Technology of JapanMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT); Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [23592092, 23592130, 22390037, 23659688, 20570192] Funding Source: KAKEN	This study was supported by grants from the Setsuro Fujii Memorial, The Osaka Foundation for Promotion of Fundamental Medical Research, and Ehime University and was also supported by Grants-in-Aid for scientific research from the Ministry of Education, Culture, Sports, Science and Technology of Japan (Program for Enhancing Systematic Education in Graduate School).	ANTMAN KH, 1990, YALE J BIOL MED, V63, P387; Barreda DR, 2004, DEV COMP IMMUNOL, V28, P509, DOI 10.1016/j.dci.2003.09.010; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Berezovskaya O, 1996, ACTA NEUROPATHOL, V92, P479, DOI 10.1007/s004010050550; Bethel A, 1997, STROKE, V28, P609, DOI 10.1161/01.STR.28.3.609; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; CHENG B, 1991, NEURON, V7, P1031, DOI 10.1016/0896-6273(91)90347-3; Gibson CL, 2008, BRAIN, V131, P318, DOI 10.1093/brain/awm183; Immonen RJ, 2009, EXP NEUROL, V215, P29, DOI 10.1016/j.expneurol.2008.09.009; Mammis A, 2009, SURG NEUROL, V71, P527, DOI 10.1016/j.surneu.2008.02.040; Matsumoto H, 2007, J NEUROSCI RES, V85, P994, DOI 10.1002/jnr.21198; Matsumoto H, 2008, J CEREBR BLOOD F MET, V28, P149, DOI 10.1038/sj.jcbfm.9600519; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Minambres E, 2008, J NEUROTRAUM, V25, P581, DOI 10.1089/neu.2007.0398; Nakano-Doi A, 2010, STEM CELLS, V28, P1292, DOI 10.1002/stem.454; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; Raivich G, 1998, J COMP NEUROL, V395, P342, DOI 10.1002/(SICI)1096-9861(19980808)395:3<342::AID-CNE6>3.0.CO;2-2; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Sayeed I, 2009, PROG BRAIN RES, V175, P219, DOI 10.1016/S0079-6123(09)17515-5; Schabitz WR, 2008, J CEREBR BLOOD F MET, V28, P29, DOI 10.1038/sj.jcbfm.9600496; Sen AP, 2010, NEUROTHERAPEUTICS, V7, P91, DOI 10.1016/j.nurt.2009.10.014; Smirkin A, 2010, J CEREBR BLOOD F MET, V30, P603, DOI 10.1038/jcbfm.2009.233; Tanaka J, 1998, GLIA, V24, P198, DOI 10.1002/(SICI)1098-1136(199810)24:2<198::AID-GLIA5>3.3.CO;2-S; Toth ZE, 2008, BLOOD, V111, P5544, DOI 10.1182/blood-2007-10-119073; Utagawa A, 2008, EXP NEUROL, V211, P283, DOI 10.1016/j.expneurol.2008.02.001; Vink R, 2004, EXPERT OPIN INV DRUG, V13, P1263, DOI 10.1517/13543784.13.10.1263; Wen TC, 1998, J EXP MED, V188, P635, DOI 10.1084/jem.188.4.635; Yokoyama A, 2006, GLIA, V53, P754, DOI 10.1002/glia.20332; Zhao LR, 2007, STROKE, V38, P2584, DOI 10.1161/STROKEAHA.106.476457	30	23	24	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2011	229	2					507	516		10.1016/j.expneurol.2011.04.006			10	Neurosciences	Neurosciences & Neurology	774XF	WOS:000291419400036	21515263				2021-06-18	
J	Christidi, F; Bigler, ED; McCauley, SR; Schnelle, KP; Merkley, TL; Mors, MB; Li, XQ; Macleod, M; Chu, ZL; Hunter, JV; Levin, HS; Clifton, GL; Wilde, EA				Christidi, Foteini; Bigler, Erin D.; McCauley, Stephen R.; Schnelle, Kathleen P.; Merkley, Tricia L.; Mors, Matthew B.; Li, Xiaoqi; Macleod, Marianne; Chu, Zili; Hunter, Jill V.; Levin, Harvey S.; Clifton, Guy L.; Wilde, Elisabeth A.			Diffusion Tensor Imaging of the Perforant Pathway Zone and Its Relation to Memory Function in Patients with Severe Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						diffusion tensor imaging; memory; perforant pathway; traumatic brain injury	MILD COGNITIVE IMPAIRMENT; CLOSED-HEAD-INJURY; AXONAL INJURY; HIPPOCAMPAL ATROPHY; CORPUS-CALLOSUM; NEURONAL INJURY; IN-VIVO; MODERATE; DAMAGE; MRI	Based on the importance of the perforant pathway (PP) for normal hippocampal function, the vulnerability of temporal structures, and significant memory impairment in patients with traumatic brain injury (TBI), we investigated in vivo changes in the PP zone, hippocampus, and temporal lobe white and gray matter using diffusion tensor imaging (DTI) and volumetric analysis, and any specific relations with memory performance (Verbal Selective Reminding Test, Rey-Osterrieth Complex Figure Test), in 14 patients with severe TBI. Compared to a demographically-similar control group, our patients had significantly decreased fractional anisotropy (FA) and higher apparent diffusion coefficient (ADC) for the PP zone bilaterally, and higher ADC bilaterally in the hippocampus. Volumetric analysis revealed significantly decreased volumes in both hippocampi and temporal gray matter bilaterally. Consistent long-term retrieval (CLTR) and delayed recall were significantly related to (1) right and left PP zone ADC, (2) left hippocampus ADC, and (3) left hippocampal volume. Nonverbal memory (immediate and delayed recall) was significantly associated with (1) right and left PP zone ADC, (2) left hippocampal volume, and (3) gray (immediate recall) and white (immediate recall, bilaterally; delayed recall, left) matter temporal volumes. Advanced neuroimaging analysis can detect in vivo changes in the PP zone and temporal structures in patients with severe TBI, with these changes being highly associated with memory impairment.	[Christidi, Foteini] Natl & Kapodistrian Univ, Eginit Hosp, Sch Med, Postgrad Program Clin Neuropsychol, Athens, Greece; [Christidi, Foteini] Natl & Kapodistrian Univ, Eginit Hosp, Sch Med, Neuropsychol Lab,Dept Neurol 1, Athens, Greece; [Bigler, Erin D.; Merkley, Tricia L.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA; [Bigler, Erin D.; Mors, Matthew B.] Brigham Young Univ, Dept Neurosci, Provo, UT 84602 USA; [Bigler, Erin D.] Univ Utah, Dept Psychiat, Salt Lake City, UT USA; [Bigler, Erin D.] Univ Utah, Utah Brain Inst, Salt Lake City, UT USA; [Clifton, Guy L.] Univ Texas Houston, Sch Med, Dept Neurosurg, Vivian L Smith Ctr Neurol Res, Houston, TX USA; [Chu, Zili; Hunter, Jill V.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.; Wilde, Elisabeth A.] Baylor Coll Med, Dept Neurol, Houston, TX 77030 USA; [Chu, Zili; Hunter, Jill V.] Texas Childrens Hosp, Dept Pediat Radiol, Houston, TX 77030 USA; [McCauley, Stephen R.; Levin, Harvey S.; Wilde, Elisabeth A.] Michael E DeBakey VA Med Ctr, Houston, TX USA	Wilde, EA (corresponding author), Baylor Coll Med, Dept Phys Med & Rehabil, 1709 Dryden Rd,Suite 1200, Houston, TX 77030 USA.	ewilde@bcm.edu	Merkley, Tricia/AAN-2989-2020	Merkley, Tricia/0000-0002-0897-8391	Dana Foundation; Medical School, National and Kapodistrian University of Athens, Greece; University of Texas Health Science Center at Houston, Texas	Funding for this project was provided by a grant from the Dana Foundation (PI: Wilde). We also gratefully acknowledge the organization committee of the clinical neuropsychology program of the Medical School, National and Kapodistrian University of Athens, Greece, and The University of Texas Health Science Center at Houston, Texas (A. C. Papanicolaou, D. Vassilopoulos; I. Evdokimidis, I. Zalonis, S. G. Papageorgiou, C. Potagas, and N. Smyrnis) for their financial assistance to author F. C. We wish to acknowledge the contribution of Dr. Ramon Arrastia-Diaz for his assistance in developing the DTI protocol for the perforant pathway. We thank Jonathan Chia, Vipulkumar Patel, and Dr. Ponnada Narayana for their assistance in the development and implementation of the MR sequences. We also wish to acknowledge the assistance of Ragini Yallampalli in manuscript preparation. Finally, we wish to thank the participants of this study.	Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Anderson CA, 2010, NEUROREHABILITATION, V26, P47, DOI 10.3233/NRE-2010-0535; Arciniegas DB, 2001, J NEUROPSYCH CLIN N, V13, P213, DOI 10.1176/appi.neuropsych.13.2.213; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ariza M, 2006, BRAIN INJURY, V20, P1053, DOI 10.1080/02699050600909862; Augustinack JC, 2010, FRONT HUM NEUROSCI, V4, DOI [10.3389/fnhum.2010.00042, 10.3389/fnhum.2010.000421985]; Azouvi P, 2009, PROG BRAIN RES, V177, P89, DOI 10.1016/S0079-6123(09)17708-7; Baldwin SA, 1997, J NEUROTRAUM, V14, P385, DOI 10.1089/neu.1997.14.385; Bendlin BB, 2008, NEUROIMAGE, V42, P503, DOI 10.1016/j.neuroimage.2008.04.254; BIASCA N, 2007, PROG BRAIN RES, V161, P719; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, 2009, AM PSYCHIAT PUBLISHI, P229; Bigler ED, 2007, NEUROPSYCHOLOGY, V21, P515, DOI 10.1037/0894-4105.21.5.515; Bigler ED, 2010, BRAIN IMAGING BEHAV, V4, P270, DOI 10.1007/s11682-010-9105-0; Bigler ED, 2010, NEUROIMAGE, V50, P1017, DOI 10.1016/j.neuroimage.2010.01.003; BLACHSTEIN H, 1993, NEUROPSYCHOLOGY, V7, P530, DOI DOI 10.1037/0894-4105.7.4.530; Bramlett HM, 1999, J NEUROSURG, V91, P653, DOI 10.3171/jns.1999.91.4.0653; Carbonnel WS, 1999, ACTA NEUROPATHOL, V98, P396, DOI 10.1007/s004010051100; COHEN J, 1988, STAT POWER ANAL BEHA, P412; Conti AC, 1998, J NEUROSCI, V18, P5663; Di Paola M, 2008, HIPPOCAMPUS, V18, P719, DOI 10.1002/hipo.20432; Diaz-Arrastia R, 2000, ARCH NEUROL-CHICAGO, V57, P1611, DOI 10.1001/archneur.57.11.1611; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Garnett MR, 2000, BRAIN, V123, P1403, DOI 10.1093/brain/123.7.1403; Geddes DM, 2003, EXP NEUROL, V184, P420, DOI 10.1016/S0014-4886(03)00254-1; Golarai G, 2001, J NEUROSCI, V21, P8523; Gozal E, 2001, NEUROSCI LETT, V305, P197, DOI 10.1016/S0304-3940(01)01853-5; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; Hoschl C, 2001, EUR ARCH PSY CLIN N, V251, P81; Holmberg P, 2009, CURR NEUROVASC RES, V6, P1; HOOGENRAAD F, 2002, MULTICENTER EVALUATI; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; HYMAN BT, 1986, ANN NEUROL, V20, P472, DOI 10.1002/ana.410200406; Inglese M, 2005, J NEUROSURG, V103, P298, DOI 10.3171/jns.2005.103.2.0298; Jones DK, 1999, MAGNET RESON MED, V42, P515, DOI 10.1002/(SICI)1522-2594(199909)42:3<515::AID-MRM14>3.3.CO;2-H; Kadar T, 1998, J NEURAL TRANSM, V105, P987, DOI 10.1007/s007020050107; Kalus P, 2006, NEUROIMAGE, V30, P713, DOI 10.1016/j.neuroimage.2005.10.035; Kantarci K, 2005, NEUROLOGY, V64, P902, DOI 10.1212/01.WNL.0000153076.46126.E9; KOTAPKA MJ, 1994, J NEUROTRAUM, V11, P317, DOI 10.1089/neu.1994.11.317; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Larrabee GJ, 2000, CLIN NEUROPSYCHOL, V14, P110, DOI 10.1076/1385-4046(200002)14:1;1-8;FT110; LEVIN HS, 1990, J CLIN EXP NEUROPSYC, V12, P129, DOI 10.1080/01688639008400960; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1998, J NEUROL NEUROSUR PS, V5, P1294; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; LEZAK MD, 1979, CORTEX, V15, P63, DOI 10.1016/S0010-9452(79)80007-6; MAPOU RL, 1992, HDB HEAD TRAUMA EARL, V75, P75; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Meyers J., 1995, REY COMPLEX FIGURE T; MILLIS SR, 1994, J CLIN EXP NEUROPSYC, V16, P498, DOI 10.1080/01688639408402661; Mori S, 2006, NEURON, V51, P527, DOI 10.1016/j.neuron.2006.08.012; NETSCH T, 2001, INT C COMP VIS; O'Sullivan M, 2004, J NEUROL NEUROSUR PS, V75, P441, DOI 10.1136/jnnp.2003.014910; Ouyang YB, 2007, J NEUROSCI, V27, P4253, DOI 10.1523/JNEUROSCI.0211-07.2007; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; RempelClower NL, 1996, J NEUROSCI, V16, P5233; Rogalski EJ, 2009, BEHAV NEUROL, V21, P51, DOI [10.3233/BEN-2009-0235, 10.1155/2009/408037]; Ropper A.H., 2009, ADAMS VICTORS PRINCI; Salat DH, 2009, NEUROIMAGE, V48, P21, DOI 10.1016/j.neuroimage.2009.06.074; Salmond CH, 2006, NEUROIMAGE, V29, P117, DOI 10.1016/j.neuroimage.2005.07.012; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Scheff SW, 2006, J ALZHEIMERS DIS, V9, P101; Shimamura M, 2005, NEUROSCIENCE, V131, P87, DOI 10.1016/j.neuroscience.2004.10.041; Sick TJ, 1998, BRAIN RES, V785, P287, DOI 10.1016/S0006-8993(97)01418-2; Stark C., 2007, HIPPOCAMPUS BOOK, P549; Strauss E., 2006, COMPENDIUM NEUROPSYC, P811; Sugiyama K, 2007, BRAIN INJURY, V21, P413, DOI 10.1080/02699050701311042; TAFT WC, 1992, J NEUROTRAUM, V9, P281, DOI 10.1089/neu.1992.9.281; Tate DF, 2000, LEARN MEMORY, V7, P442, DOI 10.1101/lm.33000; TEASDALE G, 1974, LANCET, V2, P81; Tomaiuolo F, 2004, J NEUROL NEUROSUR PS, V75, P1314, DOI 10.1136/jnnp.2003.017046; Vakil E, 2005, J CLIN EXP NEUROPSYC, V27, P977, DOI 10.1080/13803390490919245; Van Petten C, 2004, NEUROPSYCHOLOGIA, V42, P1394, DOI 10.1016/j.neuropsychologia.2004.04.006; Vanderploeg RD, 2001, J CLIN EXP NEUROPSYC, V23, P185, DOI 10.1076/jcen.23.2.185.1210; Vespa PM, 2010, NEUROLOGY, V75, P792, DOI 10.1212/WNL.0b013e3181f07334; Wallister TW, 2008, WORLD PSYCHIATRY, V7, P3; Wang JY, 2008, ARCH NEUROL-CHICAGO, V65, P619, DOI 10.1001/archneur.65.5.619; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2007, DEV MED CHILD NEUROL, V49, P294, DOI 10.1111/j.1469-8749.2007.00294.x; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wolkowitz OM, 2007, NEUROCASE, V13, P189, DOI 10.1080/13554790701475468; Yassa MA, 2010, P NATL ACAD SCI USA, V107, P12687, DOI 10.1073/pnas.1002113107; Yoshimura S, 2003, J CLIN INVEST, V112, P1202, DOI 10.1172/JCI200316618; Zec RF, 2001, J CLIN EXP NEUROPSYC, V23, P671, DOI 10.1076/jcen.23.5.671.1247; ZOLAMORGAN S, 1993, ANNU REV NEUROSCI, V16, P547, DOI 10.1146/annurev.ne.16.030193.002555	88	23	23	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2011	28	5					711	725		10.1089/neu.2010.1644			15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	762JI	WOS:000290472100272	21381986				2021-06-18	
J	Savage, WJ; Barron-Casella, E; Fu, ZM; Dulloor, P; Williams, L; Crain, BJ; White, DA; Jennings, JM; Van Eyk, JE; Debaun, MR; Everett, A; Casella, JF				Savage, William J.; Barron-Casella, Emily; Fu, Zongming; Dulloor, Pratima; Williams, Lisa; Crain, Barbara J.; White, Desiree A.; Jennings, Jacky M.; Van Eyk, Jennifer E.; Debaun, Michael R.; Everett, Allen; Casella, James F.			Plasma glial fibrillary acidic protein levels in children with sickle cell disease	AMERICAN JOURNAL OF HEMATOLOGY			English	Article							TRAUMATIC BRAIN-INJURY; NEURON-SPECIFIC ENOLASE; TRANSFUSION SIT TRIAL; ACUTE ISCHEMIC-STROKE; CEREBROSPINAL-FLUID; EARLY-DIAGNOSIS; SERUM; MARKERS; RELEASE; ANEMIA	To determine if glial fibrillary acidic protein (GFAP) is associated with brain injury in children with sickle cell disease (SCD), we measured plasma GFAP among cross-sectional groups of unselected children with SCD, subsets of children with SCD and normal brain MRI or MRI evidence of cerebral infarct, healthy pediatric controls, and adults with brain injury. Children with SCD had higher plasma GFAP than healthy pediatric controls (mean concentrations 0.14 +/- 0.37 vs. 0.07 +/- 0.08 ng/mL; P = 0.003); also, 16.0% (16/100) of children with SCD and cerebral infarct had GFAP elevations above the 95th percentile of healthy pediatric controls (P = 0.04). Although not statistically significant, children with SCD and cerebral infarct had more elevated GFAP levels than with SCD and no infarct (16/100, 16.0% vs. 14/168, 8.3%; P = 0.07). Children with SCD and acute brain ischemia had a higher proportion of elevated GFAP than SCD children with normal MRI (3/6, 50% vs. 8.3%; P = 0.01). GFAP was associated with elevated systolic blood pressure in the preceding year and correlated positively with white blood cell count and negatively with age and performance IQ. Plasma GFAP is elevated among children with SCD and may be associated with subclinical brain injury.	[Savage, William J.; Casella, James F.] JHUSOM, Div Transfus Med, Baltimore, MD 21117 USA; [Savage, William J.; Barron-Casella, Emily; Fu, Zongming; Williams, Lisa; Casella, James F.] JHUSOM, Div Pediat Hematol, Baltimore, MD USA; [Dulloor, Pratima; Everett, Allen] JHUSOM, Div Pediat Cardiol, Baltimore, MD USA; [Crain, Barbara J.] JHUSOM, Div Neuropathol, Baltimore, MD USA; [White, Desiree A.] Washington Univ, Dept Psychol, Sch Med, St Louis, MO 63130 USA; [Jennings, Jacky M.] JHUSOM, Div Gen Pediat & Adolescent Med, Baltimore, MD USA; [Van Eyk, Jennifer E.] JHUSOM, Div Cardiol, Baltimore, MD USA; [Debaun, Michael R.] Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63130 USA; [Debaun, Michael R.] Washington Univ, Sch Med, Dept Biostat, St Louis, MO 63130 USA; [Debaun, Michael R.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63130 USA	Savage, WJ (corresponding author), Carnegie 667,600 N Wolfe St, Baltimore, MD 21287 USA.	wsavage1@jhmi.edu		jennings, jacky/0000-0002-3789-5122	SIT Trial investigators [1U54HL090515, R01 HL091759, 5K12HL087169]; NHLBI Proteomic InitiativeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [N01-HV-28,120, 1U54RR023561, 5U01NS042804, 5K01DA022298, 5T15HL086386]; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR000052] Funding Source: NIH RePORTER; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R01HL091759, K12HL087169, U54HL090515, T15HL086386] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS042804] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [K01DA022298] Funding Source: NIH RePORTER	Grant sponsor: SIT Trial investigators; Grant numbers: 1U54HL090515, R01 HL091759, 5K12HL087169. Grant sponsor: NHLBI Proteomic Initiative; Grant numbers: N01-HV-28,120, 1U54RR023561, 5U01NS042804, 5K01DA022298, 5T15HL086386	Allard L, 2005, CLIN CHEM, V51, P2043, DOI 10.1373/clinchem.2005.053942; Armstrong FD, 1996, PEDIATRICS, V97, P864; BEMBEA MM, 2010, PEDIAT CRIT CARE MED; Casella JF, 2010, PEDIATR HEMAT ONCOL, V27, P69, DOI 10.3109/08880010903360367; Herrmann M, 2000, STROKE, V31, P2670, DOI 10.1161/01.STR.31.11.2670; Hesse C, 2001, NEUROSCI LETT, V297, P187, DOI 10.1016/S0304-3940(00)01697-9; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Jauch EC, 2006, STROKE, V37, P2508, DOI 10.1161/01.STR.0000242290.01174.9e; Kinney TR, 1999, PEDIATRICS, V103, P640, DOI 10.1542/peds.103.3.640; LEWIS SA, 1984, P NATL ACAD SCI-BIOL, V81, P2743, DOI 10.1073/pnas.81.9.2743; Nylen K, 2006, J NEUROL SCI, V240, P85, DOI 10.1016/j.jns.2005.09.007; Ohene-Frempong K, 1998, BLOOD, V91, P288; PERSSON L, 1987, STROKE, V18, P911, DOI 10.1161/01.STR.18.5.911; Rashid P, 2003, STROKE, V34, P2741, DOI 10.1161/01.STR.0000092488.40085.15; Rivers CS, 2006, STROKE, V37, P1418, DOI 10.1161/01.STR.0000221294.90068.c4; SARNAIK S, 2009, ELEVATED SYSTOLIC BL; Schwamm LH, 1998, STROKE, V29, P2268, DOI 10.1161/01.STR.29.11.2268; Vendt BA, 2009, J DIGIT IMAGING, V22, P326, DOI 10.1007/s10278-008-9114-3; Vichinsky EP, 2010, JAMA-J AM MED ASSOC, V303, P1823, DOI 10.1001/jama.2010.562; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Wang W, 2001, J PEDIATR-US, V139, P391, DOI 10.1067/mpd.2001.116935; Wunderlich MT, 2006, EUR J NEUROL, V13, P1118, DOI 10.1111/j.1468-1331.2006.01435.x; Zimmermann-Ivol CG, 2004, MOL CELL PROTEOMICS, V3, P66, DOI 10.1074/mcp.M300066-MCP200	23	23	23	0	4	WILEY-BLACKWELL	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0361-8609			AM J HEMATOL	Am. J. Hematol.	MAY	2011	86	5					427	429		10.1002/ajh.21995			3	Hematology	Hematology	766CB	WOS:000290756300010	21523806	Bronze, Green Accepted			2021-06-18	
J	Yuge, L; Sasaki, A; Kawahara, Y; Wu, S; Matsumoto, M; Manabe, T; Kajiume, T; Takeda, M; Magaki, T; Takahashi, T; Kurisu, K; Matsumoto, M				Yuge, Louis; Sasaki, Akira; Kawahara, Yumi; Wu, Shu-liang; Matsumoto, Masaya; Manabe, Tomotaka; Kajiume, Teruyuki; Takeda, Masaaki; Magaki, Takuro; Takahashi, Tetsuya; Kurisu, Kaoru; Matsumoto, Masayasu			Simulated Microgravity Maintains the Undifferentiated State and Enhances the Neural Repair Potential of Bone Marrow Stromal Cells	STEM CELLS AND DEVELOPMENT			English	Article							MESENCHYMAL STEM-CELLS; CEREBRAL-ISCHEMIA MODEL; TRAUMATIC BRAIN-INJURY; THERAPEUTIC BENEFIT; FUNCTIONAL RECOVERY; PROGENITOR CELLS; ADULT-RAT; DIFFERENTIATION; EXPRESSION; GROWTH	Recently, regenerative medicine with bone marrow stromal cells (BMSCs) has gained significant attention for the treatment of central nervous system diseases. Here, we investigated the activity of BMSCs under simulated microgravity conditions. Mouse BMSCs (mBMSCs) were isolated from C57BL/6 mice and harvested in 1G condition. Subjects were divided into 4 groups: cultured under simulated microgravity and 1G condition in growth medium and neural differentiation medium. After 7 days of culture, the mBMSCs were used for morphological analysis, reverse transcription (RT)-polymerase chain reaction, immunostaining analysis, and grafting. Neural-induced mBMSCs cultured under 1G conditions exhibited neural differentiation, whereas those cultured under simulated microgravity did not. Moreover, under simulated microgravity conditions, mBMSCs could be cultured in an undifferentiated state. Next, we intravenously injected cells into a mouse model of cerebral contusion. Graft mBMSCs cultured under simulated microgravity exhibited greater survival in the damaged region, and the motor function of the grafted mice improved significantly. mBMSCs cultured under simulated microgravity expressed CXCR4 on their cell membrane. Our study indicates that culturing cells under simulated microgravity enhances their survival rate by maintaining an undifferentiated state of cells, making this a potentially attractive method for culturing donor cells to be used in grafting.	[Yuge, Louis; Sasaki, Akira; Wu, Shu-liang; Matsumoto, Masaya; Manabe, Tomotaka] Hiroshima Univ, Grad Sch Hlth Sci, Div Bioenvironm Adaptat Sci, Minami Ku, Hiroshima 7348551, Japan; [Yuge, Louis; Kawahara, Yumi] Space Biolabs YK, Hiroshima, Japan; [Kawahara, Yumi; Takahashi, Tetsuya; Matsumoto, Masayasu] Hiroshima Univ, Grad Sch Biomed Sci, Dept Clin Neurosci & Therapeut, Hiroshima 7348551, Japan; [Kajiume, Teruyuki] Hiroshima Univ, Grad Sch Biomed Sci, Dept Pediat, Hiroshima 7348551, Japan; [Takeda, Masaaki; Magaki, Takuro; Kurisu, Kaoru] Hiroshima Univ, Grad Sch Biomed Sci, Dept Neurosurg, Hiroshima 7348551, Japan	Yuge, L (corresponding author), Hiroshima Univ, Grad Sch Hlth Sci, Div Bioenvironm Adaptat Sci, Minami Ku, 1-2-3 Kasumi, Hiroshima 7348551, Japan.	ryuge@hiroshima-u.ac.jp			American Society for Gravitational and Space Biology at NASA Ames Research Center, San Francisco; Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [20500447, 21591085, 23592127] Funding Source: KAKEN	The authors thank Dr. Masaru Okabe at Osaka University for kindly providing GFP mice; Mr. Ryuji Hirose, Mr. Toshimasa Ochiai, and Mr. Eiji Matsubara, Mitsubishi Heavy Industries, Ltd., for providing information and suggestions; and Dr. Araceli Espinosa-Jeffrey and Prof. Jean de Vellis at Department of Neurobiology, Semel Institute for Neuroscience, UCLA, for their comments during data analysis and preparation of the manuscript. This study received the award from the 23rd Annual Meeting of the American Society for Gravitational and Space Biology at NASA Ames Research Center, San Francisco, October 27, 2007.	Bang OY, 2005, ANN NEUROL, V57, P874, DOI 10.1002/ana.20501; Carlsson SIM, 2003, BBA-MOL CELL RES, V1642, P173, DOI 10.1016/j.bbamcr.2003.08.003; Chen JL, 2000, NEUROPHARMACOLOGY, V39, P711, DOI 10.1016/S0028-3908(00)00006-X; Chen JL, 2001, STROKE, V32, P1005, DOI 10.1161/01.STR.32.4.1005; Chen XG, 2002, NEUROPATHOLOGY, V22, P275, DOI 10.1046/j.1440-1789.2002.00450.x; Chiba S, 2004, J NEUROL SCI, V219, P107, DOI 10.1016/j.jns.2004.01.006; Cook JL, 1998, MOL BRAIN RES, V55, P9, DOI 10.1016/S0169-328X(97)00350-1; Crigler L, 2006, EXP NEUROL, V198, P54, DOI 10.1016/j.expneurol.2005.10.029; Gonzalez R, 2007, BIOCHEM BIOPH RES CO, V362, P491, DOI 10.1016/j.bbrc.2007.08.033; Higashibata Akira, 2006, BMC Biochemistry, V7, DOI 10.1186/1471-2091-7-19; Hirasaka K, 2005, BBA-MOL CELL RES, V1743, P130, DOI 10.1016/j.bbamcr.2004.09.013; Honma T, 2006, EXP NEUROL, V199, P56, DOI 10.1016/j.expneurol.2005.05.004; Hung SC, 2004, INT J CANCER, V110, P313, DOI 10.1002/ijc.20126; Iihoshi S, 2004, BRAIN RES, V1007, P1, DOI 10.1016/j.brainres.2003.09.084; Ji JF, 2004, STEM CELLS, V22, P415, DOI 10.1634/stemcells.22-3-415; Katano H, 1998, BRAIN RES, V800, P69, DOI 10.1016/S0006-8993(98)00493-4; Lu D, 2001, NEUROREPORT, V12, P559, DOI 10.1097/00001756-200103050-00025; Lu J, 2006, NEUROSCI LETT, V398, P12, DOI 10.1016/j.neulet.2005.12.053; Masada T, 2001, J CEREBR BLOOD F MET, V21, P22, DOI 10.1097/00004647-200101000-00004; Morita-Fujimura Y, 1999, NEUROSCIENCE, V93, P1465, DOI 10.1016/S0306-4522(99)00231-6; Nomura T, 2005, NEUROSCIENCE, V136, P161, DOI 10.1016/j.neuroscience.2005.06.062; Plett PA, 2004, EXP HEMATOL, V32, P773, DOI 10.1016/j.exphem.2004.03.014; Qu RJ, 2007, NEUROPATHOLOGY, V27, P355, DOI 10.1111/j.1440-1789.2007.00792.x; Roche S, 2007, J CELL BIOCHEM, V101, P271, DOI 10.1002/jcb.21185; Shen LH, 2007, J CEREBR BLOOD F MET, V27, P6, DOI 10.1038/sj.jcbfm.9600311; Shichinohe H, 2004, BRAIN RES PROTOC, V13, P166, DOI 10.1016/j.brainresprot.2004.04.004; Takeda M, 2009, NEUROSCI LETT, V463, P54, DOI 10.1016/j.neulet.2009.07.045; Yi L, 2005, GLIA, V49, P407, DOI 10.1002/glia.20126; Yuge L, 2003, IN VITRO CELL DEV-AN, V39, P89; Yuge L, 2006, STEM CELLS DEV, V15, P921, DOI 10.1089/scd.2006.15.921; Zhang XH, 2006, BIOCHEM BIOPH RES CO, V351, P853, DOI 10.1016/j.bbrc.2006.10.125	31	23	23	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	MAY	2011	20	5					893	900		10.1089/scd.2010.0294			8	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	759NT	WOS:000290255300013	20828292				2021-06-18	
J	Cecil, S; Chen, PM; Callaway, SE; Rowland, SM; Adler, DE; Chen, JW				Cecil, Sandy; Chen, Patrick M.; Callaway, Sarah E.; Rowland, Susan M.; Adler, David E.; Chen, Jefferson W.			Traumatic Brain Injury Advanced Multimodal Neuromonitoring From Theory to Clinical Practice	CRITICAL CARE NURSE			English	Article							CEREBRAL-BLOOD-FLOW; MODERATE HYPOTHERMIA; TISSUE OXYGEN; MICRODIALYSIS; AUTOREGULATION; METABOLISM; MANAGEMENT; PRESSURE; THERAPY; GLUCOSE	Traumatic brain injury accounts for nearly 1.4 million injuries and 52 000 deaths annually in the United States. Intensive bedside neuromonitoring is critical in preventing secondary ischemic and hypoxic injury common to patients with traumatic brain injury in the days following trauma. Advancements in multimodal neuromonitoring have allowed the evaluation of changes in markers of brain metabolism (eg, glucose, lactate, pyruvate, and glycerol) and other physiological parameters such as intracranial pressure, cerebral perfusion pressure, cerebral blood flow, partial pressure of oxygen in brain tissue, blood pressure, and brain temperature. This article highlights the use of multimodal monitoring in the intensive care unit at a level I trauma center in the Pacific Northwest. The trends in and significance of metabolic, physiological, and hemodynamic factors in traumatic brain injury are reviewed, the technical aspects of the specific equipment used to monitor these parameters are described, and how multimodal monitoring may guide therapy is demonstrated. As a clinical practice, multimodal neuromonitoring shows great promise in improving bedside therapy in patients with traumatic brain injury, ultimately leading to improved neurological outcomes. (Critical Care Nurse. 2011;31:25-37)	[Cecil, Sandy; Callaway, Sarah E.] Legacy Emanuel Med Ctr, Surg Intens Care Unit, Portland, OR USA; [Chen, Patrick M.] Dartmouth Coll, Hanover, NH 03755 USA	Cecil, S (corresponding author), 2801 N Gantenbein Ave, Portland, OR 97227 USA.	scecil@lhs.org	chen, jeff/AAR-7375-2020; Chen, Patrick M./AAX-9264-2020	chen, jeff/0000-0003-0624-6864; Chen, Patrick M./0000-0003-4505-964X			Bader Mary Kay, 2006, J Neurosci Nurs, V38, P248; Bellander BM, 2004, INTENS CARE MED, V30, P2166, DOI 10.1007/s00134-004-2461-8; Botteri M, 2008, CRIT CARE MED, V36, P3089, DOI 10.1097/CCM.0b013e31818bd7df; Bratton SL, 2008, J NEUROTRAUM, V25, P276; Buggy DJ, 2000, BRIT J ANAESTH, V84, P615, DOI 10.1093/bja/84.5.615; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Carter BG, 2008, CHILD NERV SYST, V24, P245, DOI 10.1007/s00381-007-0461-z; Chang JJJ, 2009, CRIT CARE MED, V37, P283, DOI 10.1097/CCM.0b013e318192fbd7; Chesnut RM, 1998, SURG NEUROL, V50, P187, DOI 10.1016/S0090-3019(98)00075-5; *CODM SHURTL INC, 2008, HEMEDEX POCK REF GUI; Czosnyka M, 2009, NEUROCRIT CARE, V10, P373, DOI 10.1007/s12028-008-9175-7; Diller KR, 2009, ANNU REV BIOMED ENG, V11, P135, DOI 10.1146/annurev-bioeng-061008-124908; DOBERSTEIN C, 1996, NEUROTRAUMA, P539; Gallagher CN, 2009, NEUROSURGERY, V64, P555, DOI 10.1227/01.NEU.0000338430.49461.D2; Goodman JC, 2009, CURR OPIN CRIT CARE, V15, P110, DOI 10.1097/MCC.0b013e328325d142; Gwinnutt CL, 2005, ANAEST INTENS CARE M, V6, P153, DOI 10.1383/anes.6.5.153.65040; Hillered L, 2005, J NEUROTRAUM, V22, P3, DOI 10.1089/neu.2005.22.3; *INT NEUROSCIENCES, 2004, LIC IMC COMPL NEUR D; *INT NEUROSCIENCES, 2004, CAM US MAN; Jenkinson MD, 2009, J NEUROSURG, V110, P861, DOI 10.3171/2008.10.JNS17667; Johnston Andrew J, 2002, Curr Opin Crit Care, V8, P121, DOI 10.1097/00075198-200204000-00006; Meixensberger J, 2003, J NEUROL NEUROSUR PS, V74, P760, DOI 10.1136/jnnp.74.6.760; Molina CA, 2009, ANN NEUROL, V66, P28, DOI 10.1002/ana.21723; Narotam PK, 2006, J PEDIATR SURG, V41, P505, DOI 10.1016/j.jpedsurg.2005.11.069; Oddo M, 2008, CRIT CARE MED, V36, P3233, DOI 10.1097/CCM.0b013e31818f4026; Peerdeman SM, 2000, INTENS CARE MED, V26, P662, DOI 10.1007/s001340051230; Peerdeman SM, 2003, J NEUROL, V250, P797, DOI 10.1007/s00415-003-1079-z; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; Phan N, 2009, J NEUROTRAUM, V26, pA66; Presciutti M, 2009, J NEUROSCI NURS, V41, P131, DOI 10.1097/JNN.0b013e3181a23e7d; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sahuquillo J, 2004, CURR PHARM DESIGN, V10, P2193, DOI 10.2174/1381612043384051; Saqqur M, 2007, CRIT CARE MED, V35, pS216, DOI 10.1097/01.CCM.0000260633.66384.FB; Shardlow E, 2008, ANAEST INTENS CARE M, V9, P222, DOI 10.1016/j.mpaic.2008.03.009; Steiner LA, 2006, BRIT J ANAESTH, V97, P26, DOI 10.1093/bja/ael110; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; TISDALL MM, 2008, BRIT J ANAESTH, V97, P18; Ungerstedt U, 2004, CURR PHARM DESIGN, V10, P2145, DOI 10.2174/1381612043384105; VAJKOCZY P, 2007, EUR NEUROL DIS, V7, P6; WALTERS FJ, 1998, UPDATE ANAESTH, V8; WEINBERG AD, 1993, ANN EMERG MED, V22, P370, DOI 10.1016/S0196-0644(05)80467-6; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Wolfe TJ, 2009, CURR NEUROL NEUROSCI, V9, P477, DOI 10.1007/s11910-009-0070-1; Zauner A, 2002, NEUROSURGERY, V51, P289, DOI 10.1097/00006123-200208000-00003; Zhao H, 2007, J CEREBR BLOOD F MET, V27, P1879, DOI 10.1038/sj.jcbfm.9600540	46	23	26	0	4	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	0279-5442	1940-8250		CRIT CARE NURSE	Crit. Care Nurse	APR	2011	31	2					25	36		10.4037/ccn2010226			12	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	744AX	WOS:000289065500086	20592189				2021-06-18	
J	Colantonio, A; Gerber, G; Bayley, M; Deber, R; Yin, JL; Kim, H				Colantonio, Angela; Gerber, Gary; Bayley, Mark; Deber, Raisa; Yin, Junlang; Kim, Hwan			DIFFERENTIAL PROFILES FOR PATIENTS WITH TRAUMATIC AND NON-TRAUMATIC BRAIN INJURY	JOURNAL OF REHABILITATION MEDICINE			English	Article						brain injuries; rehabilitation; treatment outcome	FUNCTIONAL INDEPENDENCE MEASURE; SPINAL-CORD-INJURY; REHABILITATION; RELIABILITY	Objective: To profile the demographic, clinical and environmental characteristics of persons with acquired brain injury receiving inpatient rehabilitation services in Canada. Design: This study utilizes data from the Canadian Institute for Health Information's National Rehabilitation Reporting System, between April 2001 and March 2006. The data were collected from publicly insured institutions providing inpatient rehabilitation across Canada. The main outcome measures examined were demographic and clinical characteristics. Participants: Adults with brain injury by traumatic (n=2675) vs non-traumatic causes (n=2759). Results: Approximately half of acquired brain injury patients receiving inpatient rehabilitation had non-traumatic causes of brain injury. Traumatic brain injury patients were more likely to be younger, male, from rural areas, and to make greater gains in rehabilitation. Differences were found in the types and numbers of comorbidities. However, patients from these 2 groups had similar lengths of rehabilitation stay. Conclusion: These findings support a differential profile of patients by brain injury aetiology. This has relevance for staff training, resource allocation and future research.	[Colantonio, Angela; Bayley, Mark; Yin, Junlang; Kim, Hwan] Univ Toronto, Toronto Rehabil Inst, Toronto, ON M5G 1V7, Canada; [Gerber, Gary] Univ Toronto, W Pk Healthcare Ctr, Toronto, ON M5G 1V7, Canada; [Deber, Raisa] Univ Toronto, Dept Hlth Policy Management & Evaluat, Toronto, ON M5G 1V7, Canada	Colantonio, A (corresponding author), Univ Toronto, Toronto Rehabil Inst, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca		Colantonio, Angela/0000-0003-2094-4765; Bayley, Mark/0000-0001-7860-9463; Deber, Raisa/0000-0003-0598-3926	Ontario Ministry of Health and Long Term CareMinistry of Health and Long-Term Care, Ontario; Toronto Rehabilitation Institute Foundation; Ontario Neurotrauma Foundation	We acknowledge support from a grant from the Ontario Ministry of Health and Long Term Care to the Toronto Rehabilitation Institute and the Toronto Rehabilitation Institute Foundation. We acknowledge support from a grant from the Ontario Neurotrauma Foundation. We thank the Canadian Institute for Health Information for providing access to National Rehabilitation Reporting System data and for use of the FIM (R) instrument. The FIM (R) instrument, data-set and impairment codes referenced herein arc the property of Uniform Data System for Medical Rehabilitation, a division of UB Foundation Activities, Inc.	*CAN I HLTH INF, 2005, INP REH CAN 2003 200; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; Corrigan JD, 2007, ARCH PHYS MED REHAB, V88, P418, DOI 10.1016/j.apmr.2007.01.010; Cullen NK, 2008, BRAIN INJURY, V22, P1013, DOI 10.1080/02699050802530581; Granger CV, 1998, ARCH PHYS MED REHAB, V79, P235, DOI 10.1016/S0003-9993(98)90000-4; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HEINEMANN AW, 1993, ARCH PHYS MED REHAB, V74, P566, DOI 10.1016/0003-9993(93)90153-2; McKinley WO, 2001, AM J PHYS MED REHAB, V80, P693, DOI 10.1097/00002060-200109000-00010; McKinley WO, 2000, AM J PHYS MED REHAB, V79, P138, DOI 10.1097/00002060-200003000-00005; Mechanda K, 2007, POSTAL CODES MAP GEO; Ottenbacher KJ, 2004, JAMA-J AM MED ASSOC, V292, P1687, DOI 10.1001/jama.292.14.1687; Ottenbacher KJ, 1996, ARCH PHYS MED REHAB, V77, P1226, DOI 10.1016/S0003-9993(96)90184-7; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700	13	23	23	0	7	FOUNDATION REHABILITATION INFORMATION	UPPSALA	TRADGARDSGATAN 14, UPPSALA, SE-753 09, SWEDEN	1650-1977			J REHABIL MED	J. Rehabil. Med.	MAR	2011	43	4					311	315		10.2340/16501977-0783			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	743ID	WOS:000289011000006	21347507	DOAJ Gold, Green Published			2021-06-18	
J	Nation, AD; Nelson, NG; Yard, EE; Comstock, RD; McKenzie, LB				Nation, Adam D.; Nelson, Nicolas G.; Yard, Ellen E.; Comstock, R. Dawn; McKenzie, Lara B.			Football-Related Injuries Among 6-to 17-Year-Olds Treated in US Emergency Departments, 1990-2007	CLINICAL PEDIATRICS			English	Article						football; children; adolescents; injury; emergency department	YOUTH FOOTBALL; HIGH-SCHOOL; RISK-FACTORS; PLAYERS; COLLEGIATE; EPIDEMIOLOGY; CONCUSSION	Football is one of the most popular youth sports in the United States despite the high rate of injuries. Previously published studies have investigated football-related injuries that occurred in organized play but have excluded those that occurred during unorganized play. Through use of the National Electronic Injury Surveillance System database, cases of football-related injuries were identified for analysis. Sample weights were used to calculate national estimates. An estimated 5 252 721 children and adolescents 6 to 17 years old were treated in US emergency departments for football-related injuries. The annual number of cases increased by 26.5% over the 18-year study period. The 12- to 17-year-old age group accounted for 77.8% of all injuries and had nearly twice the odds of sustaining a concussion. The findings suggest the need for increased prevention efforts to lower the risk of football-related injury in children and adolescents.	[McKenzie, Lara B.] Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, Columbus, OH 43205 USA; [Comstock, R. Dawn; McKenzie, Lara B.] Ohio State Univ, Columbus, OH 43210 USA	McKenzie, LB (corresponding author), Nationwide Childrens Hosp, Res Inst, Ctr Injury Res & Policy, 700 Childrens Dr, Columbus, OH 43205 USA.	lara.mckenzie@nationwidechildrens.org	McKenzie, Lara/C-5122-2012	McKenzie, Lara/0000-0003-2889-0001			Adickes MS, 2004, SPORTS MED, V34, P201, DOI 10.2165/00007256-200434030-00005; Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Bergeron MF, 2005, MED SCI SPORT EXER, V37, P1421, DOI 10.1249/01.mss.0000174891.46893.82; BRAUNWART B, 1889, JOURNEY CAMP ORIGINS; Bulut M, 2006, EMERG MED J, V23, P540, DOI 10.1136/emj.2005.029439; Dick R, 2007, J ATHL TRAINING, V42, P221; Dompier TP, 2007, J ATHL TRAINING, V42, P395; GOLDBERG B, 1988, PEDIATRICS, V81, P255; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; Langburt W, 2001, J CHILD NEUROL, V16, P83, DOI 10.1177/088307380101600203; MAGGIO FP, 2007, NOTRE DAME GAME CHAN; Malina RM, 2006, CLIN J SPORT MED, V16, P214, DOI 10.1097/00042752-200605000-00005; *NAT FOOTB LEAG, NAT FOOTB LEAG HIST; Pincivero DM, 1997, SPORTS MED, V23, P247, DOI 10.2165/00007256-199723040-00004; *POP WARN LITTL SC, 2008, POP WARN LITTL SCHOL; Powell JW, 1999, J ATHL TRAINING, V34, P277; Schroeder T., 2001, NEISS SAMPLE DESIGN; Shankar PR, 2007, AM J SPORT MED, V35, P1295, DOI 10.1177/0363546507299745; SMITH RA, 1981, J SPORTS HIST, V8, P15; Stocker B D, 1997, J Ky Med Assoc, V95, P458; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; TEITZ CC, 1987, J BONE JOINT SURG AM, V69A, P2, DOI 10.2106/00004623-198769010-00002; Turbeville SD, 2003, AM J SPORT MED, V31, P276, DOI 10.1177/03635465030310022001; Turbeville SD, 2003, AM J SPORT MED, V31, P974, DOI 10.1177/03635465030310063801; Tyler TF, 2006, AM J SPORT MED, V34, P471, DOI 10.1177/0363546505280429; *US BUR CENS, NAT POP EST 2000S; *US BUR CENS, 1990, INT EST US POP AG SE; *US CONS PROD SAF, 2009, NEISS COD MAN; US Consumer Product Safety Commission, 2000, NAT EL INJ SURV SYST; Zemper Eric D., 1994, Journal of Athletic Training, V29, P44; 2007, 2007 SUPERSTUDY SPOR	31	23	23	0	14	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAR	2011	50	3					200	207		10.1177/0009922810388511			8	Pediatrics	Pediatrics	718TG	WOS:000287148500006	21127078				2021-06-18	
J	Wang, JP; Zhao, YZ; Liu, CL; Jiang, C; Zhao, CY; Zhu, ZJ				Wang, Jianping; Zhao, Yuanzheng; Liu, Chunling; Jiang, Chao; Zhao, Chunyan; Zhu, Zhongjun			Progesterone inhibits inflammatory response pathways after permanent middle cerebral artery occlusion in rats	MOLECULAR MEDICINE REPORTS			English	Article						adhesion molecule; cerebral ischemia; macrophage; neutrophil; pregnancy hormone	TRAUMATIC BRAIN-INJURY; EXPRESSION; ALLOPREGNANOLONE; MECHANISMS; ISCHEMIA; RECOVERY; DEFICITS; PROTEIN	Recent studies have indicated that progesterone (PROG) reduces the expression of inflammatory factors in brain tissue. The present study was designed to investigate whether PROG inhibits the inflammatory response and the infiltration of inflammatory cells in the brain. One hundred and seventy-six adult male Sprague-Dawley rats were randomly divided into four groups: a sham-operated (control) group, a permanent middle cerebral artery occlusion (pMCAO) group, a vehicle-treated group and a PROG-treated group. After pMCAO, the rats received an initial intraperitoneal injection of PROG (8 mg/kg) or vehicle at 1 h post-occlusion, followed by subcutaneous injections at 6, 24 and 48 h. The expression levels of intercellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and CD68 in the brain were measured by immunohistochemistry and Western blotting. The level of myeloperoxidase (MPO) activity was detected by spectrophotometry. The rats were sacrificed 72 h after surgery and isolated brain was sectioned into coronal slices and stained with 2,3,5-triphenyltetrazolium chloride (TTC). Western blotting and spectrophotometry revealed that the expression levels of ICAM-1, VCAM-1, CD68 and MPO were reduced in the brain tissue of PROG-treated rats. In addition, PROG-treated rats showed a substantial reduction in the infarct volume compared to vehicle controls. PROG effectively inhibited the inflammatory response and reduced the infiltration of leukocytes in the ischemic brain by inhibiting the expression of ICAM-1 and VCAM-1.	[Wang, Jianping; Zhao, Yuanzheng; Jiang, Chao; Zhao, Chunyan; Zhu, Zhongjun] Zhengzhou Univ, Affiliated Hosp 1, Zhengzhou 450052, Henan, Peoples R China; [Liu, Chunling] Zhengzhou Univ, Cerebrovasc Dis Inst, Zhengzhou 450052, Henan, Peoples R China	Zhao, YZ (corresponding author), Zhengzhou Univ, Affiliated Hosp 1, 3 Kangfuqian St, Zhengzhou 450052, Henan, Peoples R China.	zhaoyuanzheng@126.com			School of Basic Medical Sciences, Zhengzhou University	The study was supported by Mrs. Xiuhua Ren at the School of Basic Medical Sciences, Zhengzhou University.	Alkayed NJ, 2000, STROKE, V31, P161, DOI 10.1161/01.STR.31.1.161; Cai WY, 2008, NEUROPHARMACOLOGY, V55, P127, DOI 10.1016/j.neuropharm.2008.04.023; Carrithers MD, 2000, BRAIN, V123, P1092, DOI 10.1093/brain/123.6.1092; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Djebaili M, 2004, NEUROSCIENCE, V123, P349, DOI 10.1016/j.neuroscience.2003.09.023; Ferenbach D, 2008, KIDNEY INT, V74, P5, DOI 10.1038/ki.2008.189; Frijns CJM, 2002, STROKE, V33, P2115, DOI 10.1161/01.STR.0000021902.33129.69; Gibson CL, 2005, EXP NEUROL, V193, P522, DOI 10.1016/j.expneurol.2005.01.009; Gibson CL, 2004, J CEREBR BLOOD F MET, V24, P805, DOI 10.1097/01.WCB.0000125365.83980.00; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; He J, 2004, EXP NEUROL, V189, P404, DOI 10.1016/j.expneurol.2004.06.008; He J, 2004, RESTOR NEUROL NEUROS, V22, P19; Hu ZY, 2009, CURR MED CHEM, V16, P1418, DOI 10.2174/092986709787846523; Ishikawa M, 2003, STROKE, V34, P1777, DOI 10.1161/01.STR.0000074921.17767.F2; Ishrat T, 2009, BRAIN RES, V1257, P94, DOI 10.1016/j.brainres.2008.12.048; Jiang C, 2009, INFLAMM RES, V58, P619, DOI 10.1007/s00011-009-0032-8; Mani SK, 2006, MOL ENDOCRINOL, V20, P1322, DOI 10.1210/me.2005-0466; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; Postler E, 1997, GLIA, V19, P27, DOI 10.1002/(SICI)1098-1136(199701)19:1<27::AID-GLIA3>3.0.CO;2-7; Sayeed L, 2007, RESTOR NEUROL NEUROS, V25, P151; Smith S, 2004, CONTRACT THEORY, P4; Takaba H, 2004, CELL MOL NEUROBIOL, V24, P589, DOI 10.1023/B:CEMN.0000036400.55503.5e; VAGEROVA K, 2008, ANESTH ANALG, V107, P201; Vemuganti R, 2004, STROKE, V35, P179, DOI 10.1161/01.STR.0000106479.53235.3E; WARD PA, 1991, AM J MED, V91, pS89, DOI 10.1016/0002-9343(91)90290-E; YANG J, 2001, CHINESE PHARMACOL B, V17, P9; ZHANG RL, 1995, BRAIN RES, V682, P182, DOI 10.1016/0006-8993(95)00346-R; 叶心国, 2005, [中华物理医学与康复杂志, Chinese Journal of Physical Medicine and Rehabilitation], V27, P442	28	23	23	0	4	SPANDIDOS PUBL LTD	ATHENS	POB 18179, ATHENS, 116 10, GREECE	1791-2997	1791-3004		MOL MED REP	Mol. Med. Rep.	MAR-APR	2011	4	2					319	324		10.3892/mmr.2011.418			6	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	727GK	WOS:000287785800020	21468571	Bronze			2021-06-18	
J	Li, S; Rymer, WZ				Li, Sheng; Rymer, William Zev			Voluntary Breathing Influences Corticospinal Excitability of Nonrespiratory Finger Muscles	JOURNAL OF NEUROPHYSIOLOGY			English	Article							TRANSCRANIAL MAGNETIC STIMULATION; SOMATOSENSORY-EVOKED POTENTIALS; CEREBRAL BLOOD-FLOW; MOTOR IMAGERY; VOLITIONAL INSPIRATION; RESPIRATORY AFFERENTS; BRAIN ACTIVATION; ISOMETRIC FORCE; HUMANS; DIAPHRAGM	Li S, Rymer WZ. Voluntary breathing influences corticospinal excitability of nonrespiratory finger muscles. J Neurophysiol 105: 512-521, 2011. First published December 15, 2010; doi:10.1152/jn.00946.2010. The present study aimed to investigate neurophysiologic mechanisms mediating the newly discovered phenomenon of respiratory-motor interactions and to explore its potential clinical application for motor recovery. First, young and healthy subjects were instructed to breathe normally (NORM); to exhale (OUT) or inhale (IN) as fast as possible in a self-paced manner; or to voluntarily hold breath (HOLD). In experiment 1 (n = 14), transcranial magnetic stimulation (TMS) was applied during 10% maximal voluntary contraction (MVC) finger flexion force production or at rest. The motor-evoked potentials (MEPs) were recorded from flexor digitorum superficialis (FDS), extensor digitorum communis (EDC), and abductor digiti minimi (ADM) muscles. Similarly, in experiment 2 (n = 11), electrical stimulation (ES) was applied to FDS or EDC during the described four breathing conditions while subjects maintained 10%MVC of finger flexion or extension and at rest. In the exploratory clinical experiments (experiment 3), four patients with chronic neurological disorders (three strokes, one traumatic brain injury) received a 30-min session of breathing-controlled ES to the impaired EDC. In experiment 1, the EDC MEP magnitudes increased significantly during IN and OUT at both 10%MVC and rest; the FDS MEPs were enhanced only at 10%MVC, whereas the ADM MEP increased only during OUT, compared with NORM for both at rest and 10%MVC. No difference was found between NORM and HOLD for all three muscles. In experiment 2, when FDS was stimulated, force response was enhanced during both IN and OUT, but only at 10% MVC. When EDC was stimulated, force response increased at both 10% MVC and rest, only during IN, but not OUT. The averaged response latency was 83 ms for the finger extensors and 79 ms for the finger flexors. After a 30-min intervention of ES to EDC triggered by forced inspiration in experiment 3, we observed a significant reduction in finger flexor spasticity. The spasticity reduction lasted for >= 4 wk in all four patients. TMS and ES data, collectively, support the phenomenon that there is an overall respiration-related enhancement on the motor system, with a strong inspiration-finger extension coupling during voluntary breathing. As such, breathing-controlled electrical stimulation (i.e., stimulation to finger extensors delivered during the voluntary inspiratory phase) could be applied for enhancing finger extension strength and finger flexor spasticity reduction in poststroke patients.	[Li, Sheng] Univ Texas Hlth Sci Ctr Houston, Dept Phys Med & Rehabil, Houston, TX 77030 USA; [Li, Sheng] Inst Rehabil & Res, Motor Recovery Lab, Houston, TX USA; [Rymer, William Zev] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Rymer, William Zev] Rehabil Inst Chicago, Sensory Motor Performance Program, Chicago, IL 60611 USA	Li, S (corresponding author), Univ Texas Hlth Sci Ctr Houston, Dept Phys Med & Rehabil, Houston, TX 77030 USA.	sheng.li@uth.tmc.edu			National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS-060774]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS060774] Funding Source: NIH RePORTER	This study was supported in part by the National Institute of Neurological Disorders and Stroke Grant R01-NS-060774.	AMINOFF MJ, 1971, J PHYSIOL-LONDON, V215, P557, DOI 10.1113/jphysiol.1971.sp009485; Bakhtiary AH, 2008, CLIN REHABIL, V22, P418, DOI 10.1177/0269215507084008; Balzamo E, 1997, NEUROSCI LETT, V236, P127, DOI 10.1016/S0304-3940(97)00782-9; Balzamo E, 1999, NEUROSCI LETT, V270, P157, DOI 10.1016/S0304-3940(99)00482-6; BRASILNETO JP, 1992, J CLIN NEUROPHYSIOL, V9, P132, DOI 10.1097/00004691-199201000-00014; Chae John, 2003, Phys Med Rehabil Clin N Am, V14, pS93, DOI 10.1016/S1047-9651(02)00051-7; COLEBATCH JG, 1991, J PHYSIOL-LONDON, V443, P91, DOI 10.1113/jphysiol.1991.sp018824; Corfield DR, 1998, RESP PHYSIOL, V114, P109, DOI 10.1016/S0034-5687(98)00083-8; Danion F, 2003, CLIN NEUROPHYSIOL, V114, P1445, DOI 10.1016/S1388-2457(03)00105-6; DAVIS JN, 1972, EXP NEUROL, V34, P78, DOI 10.1016/0014-4886(72)90189-6; DICK JPR, 1987, NEUROSCI LETT, V75, P349, DOI 10.1016/0304-3940(87)90548-9; Evans KC, 1999, J PHYSIOL-LONDON, V520, P383, DOI 10.1111/j.1469-7793.1999.00383.x; Filippi MM, 2000, BRAIN RES, V881, P159, DOI 10.1016/S0006-8993(00)02837-7; Fink GR, 1995, J PHYSIOL-LONDON, V489, P663, DOI 10.1113/jphysiol.1995.sp021081; Fontanari P, 1996, NEUROSCI LETT, V210, P130, DOI 10.1016/0304-3940(96)12564-7; GANDEVIA SC, 1987, J PHYSIOL-LONDON, V384, P109, DOI 10.1113/jphysiol.1987.sp016445; GANDEVIA SC, 1989, RESP PHYSIOL, V77, P203, DOI 10.1016/0034-5687(89)90007-8; Guz A, 1997, RESP PHYSIOL, V109, P197, DOI 10.1016/S0034-5687(97)00050-9; Haouzi P, 2006, RESP PHYSIOL NEUROBI, V152, P169, DOI 10.1016/j.resp.2005.08.004; Hara Y, 2000, ARCH PHYS MED REHAB, V81, P418, DOI 10.1053/mr.2000.3872; Ikeda ER, 2009, J STRENGTH COND RES, V23, P127, DOI 10.1519/JSC.0b013e31818eb256; Kamper DG, 2001, MUSCLE NERVE, V24, P673, DOI 10.1002/mus.1054; LAHUERTA J, 1992, J NEUROL NEUROSUR PS, V55, P1142, DOI 10.1136/jnnp.55.12.1142; Li S, 2004, J NEUROSCI, V24, P9674, DOI 10.1523/JNEUROSCI.2781-04.2004; Li S, 2004, COGNITIVE BRAIN RES, V20, P273, DOI 10.1016/j.cogbrainres.2004.03.003; Li S, 2007, EXP BRAIN RES, V179, P517, DOI 10.1007/s00221-006-0809-8; Li S, 2007, NEUROSCI LETT, V412, P243, DOI 10.1016/j.neulet.2006.11.013; Li S, 2006, MUSCLE NERVE, V34, P651, DOI 10.1002/mus.20592; Li S, 2009, CLIN NEUROPHYSIOL, V120, P1154, DOI 10.1016/j.clinph.2008.12.045; Li ZM, 2001, J BIOMECH, V34, P1097, DOI 10.1016/S0021-9290(01)00061-6; Macey KE, 2004, J APPL PHYSIOL, V97, P1897, DOI 10.1152/japplphysiol.00359.2004; Macey PM, 2003, RESP PHYSIOL NEUROBI, V138, P275, DOI 10.1016/j.resp.2003.09.002; Maluf KS, 2007, CLIN NEUROPHYSIOL, V118, P2063, DOI 10.1016/j.clinph.2007.06.009; MASKILL D, 1991, J PHYSIOL-LONDON, V443, P105, DOI 10.1113/jphysiol.1991.sp018825; Plum F., 1981, REGULATION BREATHI 2, P989; RAMSAY SC, 1993, J PHYSIOL-LONDON, V461, P85, DOI 10.1113/jphysiol.1993.sp019503; Sharshar T, 2004, J PHYSIOL-LONDON, V560, P897, DOI 10.1113/jphysiol.2004.061150; Smejkal V, 1999, PHYSIOL RES, V48, P21; Smejkal V, 2000, PHYSIOL RES, V49, P659; Yue GH, 2000, MUSCLE NERVE, V23, P376, DOI 10.1002/(SICI)1097-4598(200003)23:3<376::AID-MUS9>3.0.CO;2-2; ZIFKO UA, 1995, MUSCLE NERVE, V18, P1487, DOI 10.1002/mus.880181224	41	23	23	6	13	AMER PHYSIOLOGICAL SOC	BETHESDA	9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA	0022-3077			J NEUROPHYSIOL	J. Neurophysiol.	FEB	2011	105	2					512	521		10.1152/jn.00946.2010			10	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	718OG	WOS:000287133200002	21160006	Green Published			2021-06-18	
J	Scherer, MR; Shelhamer, MJ; Schubert, MC				Scherer, Matthew R.; Shelhamer, Mark J.; Schubert, Michael C.			Characterizing high-velocity angular vestibulo-ocular reflex function in service members post-blast exposure	EXPERIMENTAL BRAIN RESEARCH			English	Article						Blast; Traumatic brain injury; Angular vestibulo-ocular reflex; Scleral search coil	DYNAMIC VISUAL-ACUITY; INJURY-INDUCED NEUROTRAUMA; PASSIVE HEAD MOVEMENTS; VESTIBULAR NEURITIS; BLAST INJURY; BRAIN-INJURY; SEARCH-COIL; COMPENSATION; RESPONSES; NEURONS	Blasts (explosions) are the most common mechanism of injury in modern warfare. Traumatic brain injury (TBI) and dizziness are common sequelae associated with blasts, and many service members (SMs) report symptoms worsen with activity. The purpose of this study was to measure angular vestibulo-ocular reflex gain (aVOR) of blast-exposed SMs with TBI during head impulse testing. We also assessed their symptoms during exertion. Twenty-four SMs recovering from TBI were prospectively assigned to one of two groups based on the presence or absence of dizziness. Wireless monocular scleral search coil and rate sensor were used to characterize active and passive yaw and pitch head and eye rotations. Visual analog scale (VAS) was used to monitor symptoms during fast walking/running. For active yaw head impulses, aVOR gains were significantly lower in the symptomatic group (0.79 +/- A 0.15) versus asymptomatic (0.87 +/- A 0.18), but not for passive head rotation. For pitch head rotation, the symptomatic group had both active (0.915 +/- A 0.24) and passive (0.878 +/- A 0.22) aVOR gains lower than the asymptomatic group (active 1.03 +/- A 0.27, passive 0.97 +/- A 0.23). Some SMs had elevated aVOR gain. VAS scores for all symptoms were highest during exertion. Our data suggest symptomatic SMs with TBI as a result of blast have varied aVOR gain during high-velocity head impulses and provide compelling evidence of pathology affecting the vestibular system. Potential loci of injury in this population include the following: disruption of pathways relaying vestibular efference signals, differential destruction of type I vestibular hair cells, or selective damage to irregular afferent pathways-any of which may explain the common discrepancy between reports of vestibular-like symptoms and laboratory testing results. Significantly reduced pitch aVOR in symptomatic SMs and peak symptom severity during exertional testing support earlier findings in the chronic blast-exposed active duty SMs.	[Scherer, Matthew R.; Shelhamer, Mark J.; Schubert, Michael C.] Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA; [Shelhamer, Mark J.] Johns Hopkins Sch Med, Dept Biomed Engn, Baltimore, MD 21287 USA; [Scherer, Matthew R.] Univ Maryland, Sch Med, Dept Phys Therapy & Rehabil Sci, Baltimore, MD 21201 USA	Schubert, MC (corresponding author), Johns Hopkins Sch Med, Dept Otolaryngol Head & Neck Surg, Baltimore, MD 21287 USA.	mschube1@jhmi.edu			NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K23 DC007926-04] Funding Source: Medline; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K23DC007926] Funding Source: NIH RePORTER		ABELN W, 1981, BRAIN RES, V222, P458, DOI 10.1016/0006-8993(81)91055-6; Aw ST, 2001, NEUROLOGY, V57, P768, DOI 10.1212/WNL.57.5.768; Black FO, 1996, AM J OTOL, V17, P401; BRANTBERG K, 1990, AM J OTOLARYNG, V11, P345, DOI 10.1016/0196-0709(90)90066-5; Cernak I, 1996, J TRAUMA, V40, pS100, DOI 10.1097/00005373-199603001-00023; Cernak I, 2001, J TRAUMA, V50, P695, DOI 10.1097/00005373-200104000-00017; Cernak I, 2001, BRAIN INJURY, V15, P593, DOI 10.1080/02699050010009559; Cullen KE, 2004, CURR OPIN NEUROBIOL, V14, P698, DOI 10.1016/j.conb.2004.10.002; Cullen KE, 2004, J NEUROPHYSIOL, V91, P1919, DOI 10.1152/jn.00988.2003; Della Santina CC, 2002, ARCH OTOLARYNGOL, V128, P1044, DOI 10.1001/archotol.128.9.1044; Department of Veterans Affairs/ Department of Defense ( VA/ DoD), 2009, VA DOD CLIN PRACT GU; Eggert Thomas, 2007, Dev Ophthalmol, V40, P15; FERNANDEZ C, 1976, J NEUROPHYSIOL, V39, P970; Furman JM, 2000, PHYS THER, V80, P179, DOI 10.1093/ptj/80.2.179; Goldberg J.M., 1985, Progress in Clinical and Biological Research, V176, P231; Gottshall K, 2009, ASS RES OT MIDW M BA; Gottshall KR, 2010, J NEUROL PHYS THER, V34, P94, DOI 10.1097/NPT.0b013e3181dead12; GROSSMAN GE, 1988, EXP BRAIN RES, V70, P470; Herdman SJ, 2003, ARCH OTOLARYNGOL, V129, P819, DOI 10.1001/archotol.129.8.819; Hoffer M, 2008, VESTIBULAR DIFFERENC; Hoffer Michael E, 2009, Int Tinnitus J, V15, P115; Hoffer ME, 2010, OTOL NEUROTOL, V31, P232, DOI 10.1097/MAO.0b013e3181c993c3; Hullar TE, 2005, J NEUROPHYSIOL, V93, P2777, DOI 10.1152/jn.01002.2004; Husni EA, 1966, JAMA-J AM MED ASSOC, V196, P101; Klam F, 2003, ANN NY ACAD SCI, V1004, P271, DOI 10.1196/annals.1303.024; Kocsis JD, 2009, J REHABIL RES DEV, V46, P667, DOI 10.1682/JRRD.2008.08.0100; Leigh J., 2006, NEUROLOGY EYE MOVEME; Mitchell J, 2004, MANUAL THER, V9, P220, DOI 10.1016/j.math.2004.03.005; NADOL JB, 1995, OTOLARYNG HEAD NECK, V112, P162, DOI 10.1016/S0194-5998(95)70316-0; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Park HJ, 2005, ACTA OTO-LARYNGOL, V125, P852, DOI 10.1080/00016480510033667; Roberts D, 2008, PROCEEDINGS OF THE EYE TRACKING RESEARCH AND APPLICATIONS SYMPOSIUM (ETRA 2008), P197, DOI 10.1145/1344471.1344519; ROBINSON DA, 1963, IEEE T BIO-MED ENG, VBM10, P137, DOI 10.1109/TBMEL.1963.4322822; Roy FD, 2004, LARYNGOSCOPE, V114, P1190, DOI 10.1097/00005537-200407000-00011; Roy JE, 2001, J NEUROSCI, V21, P2131, DOI 10.1523/JNEUROSCI.21-06-02131.2001; Scherer M, 2007, MIL MED, V172, P731, DOI 10.7205/MILMED.172.7.731; Scherer M, 2008, J VESTIBUL RES-EQUIL, V18, P147; Scherer MR, 2009, PHYS THER, V89, P980, DOI 10.2522/ptj.20080353; SCHUBERT M, 2009, ASS RES OT MIDW M BA; Schubert MC, 2004, PHYS THER, V84, P373, DOI 10.1093/ptj/84.4.373; Schubert MC, 2008, ARCH PHYS MED REHAB, V89, P500, DOI 10.1016/j.apmr.2007.11.010; Schubert MC, 2006, JARO-J ASSOC RES OTO, V7, P329, DOI 10.1007/s10162-006-0047-6; Strupp M, 1998, NEUROLOGY, V51, P838, DOI 10.1212/WNL.51.3.838; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; VONHOLST E, 1950, NATURWISSENSCHAFTEN, V37, P464, DOI 10.1007/BF00622503; Walker MF, 1999, ANN NY ACAD SCI, V871, P205, DOI 10.1111/j.1749-6632.1999.tb09186.x; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Wiener SI, 2002, COGNITIVE BRAIN RES, V14, P75, DOI 10.1016/S0926-6410(02)00062-9	48	23	24	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0014-4819			EXP BRAIN RES	Exp. Brain Res.	FEB	2011	208	3					399	410		10.1007/s00221-010-2490-1			12	Neurosciences	Neurosciences & Neurology	705GU	WOS:000286117700008	21113582	Green Accepted			2021-06-18	
J	Zhu, WJ; Zhang, J; Zhang, ZG				Zhu, Wenjing; Zhang, Jing; Zhang, Zigui			Effects of Fluoride on Synaptic Membrane Fluidity and PSD-95 Expression Level in Rat Hippocampus	BIOLOGICAL TRACE ELEMENT RESEARCH			English	Article						Fluoride; Hippocampus; Membrane fluidity; Neurotoxicity; Oxidative stress; PSD-95	TRAUMATIC BRAIN-INJURY; OXIDATIVE STRESS; PROTEIN; NEUTROPHILS; FLUOROSIS; RECEPTOR; DENSITY; NEURONS; SYSTEM; AREAS	The objective of this study is to investigate the neurotoxicity of drinking water fluorosis on rat hippocampus. Just weaning male Sprague-Dawley rats were randomly divided into four groups and given 15, 30, and 60 mg/L NaF solution and distilled water, respectively, for 9 months. The fluidity of brain synaptic membrane and expression level of postsynaptic density 95 (PSD-95) were tested. Results showed that the fluidity of brain synaptic membrane decreased gradually with increasing of fluoride concentration, and it was significantly decreased (P < 0.05) in moderate-fluoride group compared with control group, and expression level of PSD-95 was significantly decreased (P < 0.01) in moderate-fluoride group when compared with that of control group. These results indicate that decrease of synaptic membrane fluidity and PSD-95 expression level may be the molecular basis of central nervous system damage caused by fluoride intoxication; PSD-95 in CA3 region of hippocampus is probably a target molecule for fluoride.	[Zhu, Wenjing; Zhang, Jing; Zhang, Zigui] Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Peoples R China	Zhang, ZG (corresponding author), Zhejiang Normal Univ, Inst Ecol, Jinhua 321004, Peoples R China.	zzg@zjnu.cn			National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [30871295]; Natural Science Foundation of Zhejiang ProvinceNatural Science Foundation of Zhejiang Province [Y207751]	This research was sponsored by the National Natural Science Foundation of China (Grant No. 30871295) and Natural Science Foundation of Zhejiang Province (Grant No. Y207751).	Bhatnagar Maheep, 2002, Indian Journal of Experimental Biology, V40, P546; Cayabyab FS, 2000, EUR J NEUROSCI, V12, P1949, DOI 10.1046/j.1460-9568.2000.00083.x; Chen P, 2007, MOL PHARMACOL, V72, P40, DOI 10.1124/mol.107.034942; Choubisa SL, 2009, FLUORIDE, V42, P210; CULLIS PR, 1985, BIOCH LIPIDS MEMBRAN, P25; de la Monte SM, 2000, CELL MOL LIFE SCI, V57, P1471, DOI 10.1007/PL00000630; DELLABIANCA V, 1988, BIOCHEM BIOPH RES CO, V150, P955, DOI 10.1016/0006-291X(88)90722-X; Ehrlich I, 2007, P NATL ACAD SCI USA, V104, P4176, DOI 10.1073/pnas.0609307104; ERIK K, 1987, CLIN CHEM, V33, P253; Gao Q, 2008, TOXICOL IN VITRO, V22, P837, DOI 10.1016/j.tiv.2007.12.017; Gascon S, 2008, MOL PSYCHIATR, V13, P99, DOI 10.1038/sj.mp.4002017; Gorczyca D, 2007, J NEUROSCI, V27, P1033, DOI 10.1523/JNEUROSCI.3160-06.2007; Guan ZZ, 1998, NEUROTOXICOL TERATOL, V20, P537, DOI 10.1016/S0892-0362(97)00136-0; He Y, 2008, FLUORIDE, V41, P192; HENSLEY K, 1994, FREE RADICAL BIO MED, V17, P321, DOI 10.1016/0891-5849(94)90018-3; Krapivinsky G, 2006, NEURON, V52, P485, DOI 10.1016/j.neuron.2006.09.033; Lang SB, 2007, J NEUROSCI, V27, P1097, DOI 10.1523/JNEUROSCI.3590-06.2007; Lechuga-Sancho AM, 2006, ENDOCRINOLOGY, V147, P5314, DOI 10.1210/en.2006-0766; Li G, 2000, FLUORIDE, V33, P14; Matzilevich DA, 2002, J NEUROSCI RES, V67, P646, DOI 10.1002/jnr.10157; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; Ranjan R, 2009, FLUORIDE, V42, P88; Scheff SW, 2005, J NEUROTRAUM, V22, P719, DOI 10.1089/neu.2005.22.719; Shila S, 2005, TOXICOLOGY, V210, P25, DOI 10.1016/j.tox.2005.01.003; Su JJ, 2006, J NEUROL SCI, V243, P21, DOI 10.1016/j.jns.2005.11.006; TOPER R, 1987, BIOCHIM BIOPHYS ACTA, V931, P262, DOI 10.1016/0167-4889(87)90215-1; Trivedi MH, 2009, FLUORIDE, V42, P29; Tsuriel S, 2006, PLOS BIOL, V4, P1572, DOI 10.1371/journal.pbio.0040271; Wu AG, 2006, EXP NEUROL, V197, P309, DOI 10.1016/j.expneurol.2005.09.004; Yi JH, 2006, NEUROCHEM INT, V48, P394, DOI 10.1016/j.neuint.2005.12.001; Zhang ZG, 2008, FLUORIDE, V41, P139	31	23	23	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0163-4984	1559-0720		BIOL TRACE ELEM RES	Biol. Trace Elem. Res.	FEB	2011	139	2					197	203		10.1007/s12011-010-8654-9			7	Biochemistry & Molecular Biology; Endocrinology & Metabolism	Biochemistry & Molecular Biology; Endocrinology & Metabolism	706DQ	WOS:000286198100009	20217272				2021-06-18	
J	Beller, JA; Gurkoff, GG; Berman, RF; Lyeth, BG				Beller, Justin A.; Gurkoff, Gene G.; Berman, Robert F.; Lyeth, Bruce G.			Pharmacological enhancement of glutamate transport reduces excitotoxicity in vitro	RESTORATIVE NEUROLOGY AND NEUROSCIENCE			English	Article						Pharmacology; neurodegeneration; ceftriaxone; group II mGluR	TRAUMATIC BRAIN-INJURY; DEPENDENT TRANSCRIPTIONAL REGULATION; PROTEIN-KINASE-C; GROUP-II; SURFACE EXPRESSION; NEUROTRANSMITTER TRANSPORTERS; RECEPTOR ACTIVATION; NEURONAL INJURY; MOUSE MODEL; GLAST	Purpose: Glutamate transporters are responsible for removing glutamate from the extracellular space and have the potential to protect neurons from excitotoxicity. In the present study, the effects of ceftriaxone and (2R, 4R)-APDC (APDC) on the protein expression of GLAST and GLT-1, the rate of glutamate uptake, and neuroprotection were evaluated in a cell culture model of glutamate excitotoxicity. Methods: Mixed neuron/astrocyte cultures were prepared from 1 day old rat pups. Protein levels of GLAST and GLT-1 glutamate transporters were quantified using In-Cell Western techniques after acute or 5-day treatment with either ceftriaxone or APDC. Glutamate uptake was measured using Michaelis-Menten kinetics to evaluate the effects of 5-day treatment with ceftriaxone or APDC. Neuronal cell death in response to a 10-minute 1 mM glutamate challenge was measured following 5-day treatment with either ceftriaxone or APDC. Results: Five-day treatment with 100 mu M ceftriaxone significantly increased both GLAST and GLT-1 protein levels 31.3% and 47.5% above control, respectively, increased the V(max) 29.3%, increased the K(m) of glutamate uptake 117.9%, and reduced neuronal death 22.0% after a 1 mM glutamate challenge. Five-day treatment with 1 mM APDC significantly increased GLAST protein levels 27.6%, increased the V(max) 92.4%, increased the K(m) of glutamate transport 118.9%, and decreased neuronal death 36.8% after a 1 mM glutamate challenge. Conclusions: Chronic treatment with ceftriaxone or APDC provided neuroprotection from glutamate excitotoxicity while increasing GLAST and GLT-1 protein levels and increasing glutamate uptake. These compounds may have therapeutic potential in chronic excitotoxic neurodegenerative diseases.	[Beller, Justin A.; Gurkoff, Gene G.; Berman, Robert F.; Lyeth, Bruce G.] Univ Calif Davis, Dept Neurol Surg, Davis, CA 95618 USA; [Gurkoff, Gene G.] Univ Calif Davis, NSF Ctr Biophoton Sci & Technol, Sacramento, CA 95817 USA; [Beller, Justin A.] Univ Kentucky, Coll Med, Spinal Cord & Brain Injury Res Ctr, Lexington, KY USA	Lyeth, BG (corresponding author), Univ Calif Davis, Dept Neurol Surg, 1 Shields Ave, Davis, CA 95618 USA.	bglyeth@ucdavis.edu		Lyeth, Bruce/0000-0003-4811-1474	National Institutes of Health NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 29995, NS 45136]; National Institute of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [5 T32 ES07059]; Center for Biophotonics Science and Technology [PHY 0120999]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007059] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS029995, R01NS045136] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health NINDS NS 29995, NS 45136 and the National Institute of Environmental Health Sciences 5 T32 ES07059. This work was also supported by the Center for Biophotonics Science and Technology, a designated NSF Science and Technology Center, managed by the University of California, Davis, under Cooperative Agreement number PHY 0120999. We would like to thank Robert Hunt, Emily Doisy, and Kimberly Katleba for their expert technical assistance on this project.	Agrawal N, 2005, P NATL ACAD SCI USA, V102, P3777, DOI 10.1073/pnas.0500055102; Allen JW, 1999, J PHARMACOL EXP THER, V290, P112; Benarroch EE, 2010, NEUROLOGY, V74, P259, DOI 10.1212/WNL.0b013e3181cc89e3; Bergles DE, 1998, J NEUROSCI, V18, P7709; Bristol LA, 1996, ANN NEUROL, V39, P676, DOI 10.1002/ana.410390519; CASADO M, 1993, J BIOL CHEM, V268, P27313; Conradt M, 1997, J NEUROCHEM, V68, P1244, DOI 10.1046/j.1471-4159.1997.68031244.x; Gegelashvili G, 1996, NEUROREPORT, V8, P261, DOI 10.1097/00001756-199612200-00052; Gegelashvili G, 2001, Prog Brain Res, V132, P267; Gegelashvili G, 2000, NEUROCHEM INT, V37, P163, DOI 10.1016/S0197-0186(00)00019-X; Harrison PJ, 2008, J PSYCHOPHARMACOL, V22, P308, DOI 10.1177/0269881108089818; Kalandadze A, 2002, J BIOL CHEM, V277, P45741, DOI 10.1074/jbc.M203771200; KANAI Y, 1993, FASEB J, V7, P1450; Kelso ML, 2011, NEUROSCI LETT, V488, P60, DOI 10.1016/j.neulet.2010.11.003; Kohara A, 2008, BRAIN RES, V1191, P168, DOI 10.1016/j.brainres.2007.11.035; Lee SG, 2008, J BIOL CHEM, V283, P13116, DOI 10.1074/jbc.M707697200; Lewerenz J, 2009, J NEUROCHEM, V111, P332, DOI 10.1111/j.1471-4159.2009.06347.x; Lipski J, 2007, NEUROSCIENCE, V146, P617, DOI 10.1016/j.neuroscience.2007.02.003; Lopez-Bayghen E, 2004, J NEUROCHEM, V91, P200, DOI 10.1111/j.1471-4159.2004.02706.x; Lyeth BG, 2001, EXP NEUROL, V169, P191, DOI 10.1006/exnr.2001.7643; Mafra RA, 2003, BRAZ J MED BIOL RES, V36, P951, DOI 10.1590/S0100-879X2003000700018; Meldrum BS, 2000, J NUTR, V130, p1007S, DOI 10.1093/jn/130.4.1007S; Melzer N, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0003149; Mendez JA, 2004, J NEUROCHEM, V88, P835, DOI 10.1046/j.1471-4159.2003.02206.x; Nickell J, 2007, NEUROBIOL AGING, V28, P1737, DOI 10.1016/j.neurobiolaging.2006.07.015; Ramirez-Sotelo G, 2007, NEUROCHEM RES, V32, P73, DOI 10.1007/s11064-006-9227-3; Ramos KM, 2010, NEUROSCIENCE, V169, P1888, DOI 10.1016/j.neuroscience.2010.06.014; Robinson MB, 2002, J NEUROCHEM, V80, P1, DOI 10.1046/j.0022-3042.2001.00698.x; Rosas S, 2007, J NEUROCHEM, V101, P1134, DOI 10.1111/j.1471-4159.2007.04517.x; Rothstein JD, 1996, NEUROLOGY, V47, pS19, DOI 10.1212/WNL.47.4_Suppl_2.19S; Rothstein JD, 1996, NEURON, V16, P675, DOI 10.1016/S0896-6273(00)80086-0; Rothstein JD, 2005, NATURE, V433, P73, DOI 10.1038/nature03180; Shahlaie K, 2010, J NEUROTRAUM, V27, P175, DOI 10.1089/neu.2009.1003; Sheldon AL, 2007, NEUROCHEM INT, V51, P333, DOI 10.1016/j.neuint.2007.03.012; Torres-Salazar D, 2007, MOL PHARMACOL, V72, P1100, DOI 10.1124/mol.107.041020; Verma R, 2010, EUR J PHARMACOL, V638, P65, DOI 10.1016/j.ejphar.2010.04.021; Vernon AC, 2008, NEUROREPORT, V19, P475, DOI 10.1097/WNR.0b013e3282f602df; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; Xu NJ, 2003, J NEUROSCI, V23, P4775; Yang DN, 2004, NEUROSCI LETT, V357, P159, DOI 10.1016/j.neulet.2003.11.074; Zelenaia O, 2000, MOL PHARMACOL, V57, P667; Zeng LH, 2010, NEUROBIOL DIS, V37, P764, DOI 10.1016/j.nbd.2009.12.020; Zhong C, 2006, J NEUROCHEM, V97, P1015, DOI 10.1111/j.1471-4159.2006.03786.x; Zwienenberg M, 2001, NEUROSURGERY, V48, P1119, DOI 10.1097/00006123-200105000-00031	44	23	23	0	4	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0922-6028			RESTOR NEUROL NEUROS	Restor. Neurol. Neurosci.		2011	29	5					331	346		10.3233/RNN-2011-603			16	Neurosciences	Neurosciences & Neurology	814VW	WOS:000294486300005	21846950				2021-06-18	
J	Bercaw, EL; Hanks, RA; Millis, SR; Gola, TJ				Bercaw, Edwin L.; Hanks, Robin A.; Millis, Scott R.; Gola, Thomas J.			Changes in Neuropsychological Performance after Traumatic Brain Injury from Inpatient Rehabilitation to 1-Year Follow-Up in Predicting 2-Year Functional Outcomes	CLINICAL NEUROPSYCHOLOGIST			English	Article						Cognitive recovery; Rehabilitation; Serial assessment; Longitudinal; Recovery of function; Brain injury outcomes	SEVERE HEAD-INJURY; FALSE DISCOVERY RATE; RECOVERY; MODERATE; INTEGRATION; ATTENTION; SEVERITY	The present study explored the predictive value of interval change in neuropsychological performance at three time-points following moderate-to-severe TBI (inpatient rehabilitation, 1-year, and 2-year follow-up) on functional outcome measures collected at 2-year follow-up. Symmetrized percent change scores were calculated and used to predict scores on functional measures using linear regression while controlling for age and injury severity. Results showed that change in performance from inpatient to 1-year on total list learning (CVLT-II or RAVLT) and oral SDMT significantly predicted 2-year ratings of functional status. By comparison, most neuropsychological measures taken at 1-year follow-up also accounted for unique variance in 2-year functional outcomes. These results indicate that changes in learning and processing speed during the first year of recovery are sensitive indicators when predicting long-term disability and degree of functional independence, though absolute performance at 1 year is also highly associated with functional outcome at 2 years post-injury.	[Bercaw, Edwin L.] Rehabil Inst Michigan, Dept Rehabil Psychol & Neuropsychol, Detroit, MI USA; [Hanks, Robin A.; Millis, Scott R.; Gola, Thomas J.] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI USA	Bercaw, EL (corresponding author), 1250 S Tamiami Trail,Suite 201, Sarasota, FL 34239 USA.	ed.bercaw@gmail.com			U.S. Department of Education - National Institute of Disability and Rehabilitation ResearchUS Department of Education [H133A080044]	This study was supported, in part, by a grant from the U.S. Department of Education - National Institute of Disability and Rehabilitation Research (H133A080044).	Bate AJ, 2001, CLIN NEUROPSYCHOL, V15, P405, DOI 10.1076/clin.15.3.405.10279; Benjamini Y, 2001, BEHAV BRAIN RES, V125, P279, DOI 10.1016/S0166-4328(01)00297-2; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Berry DA, 2006, AM STAT, V60, P27, DOI 10.1198/000313006X90684; Boake C, 2001, ARCH PHYS MED REHAB, V82, P761, DOI 10.1053/apmr.2001.23753; Christensen BK, 2008, ARCH PHYS MED REHAB, V89, pS3, DOI 10.1016/j.apmr.2008.10.002; Chu BC, 2007, J CLIN EXP NEUROPSYC, V29, P617, DOI 10.1080/13803390600878893; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Delis DC, 2000, CALIFORNIA VERBAL LE; DIKMEN S, 1990, J CLIN EXP NEUROPSYC, V12, P507, DOI 10.1080/01688639008400997; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dikmen SS, 1999, J INT NEUROPSYCH SOC, V5, P346, DOI 10.1017/S1355617799544056; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Gladsjo JA, 1999, NORMS LETT CATEGORY; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; HALL K, 1985, ARCH PHYS MED REHAB, V66, P35; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P1030, DOI 10.1016/S0003-9993(99)90056-4; Hanks RA, 2008, ARCH PHYS MED REHAB, V89, P950, DOI 10.1016/j.apmr.2008.01.011; Hoofien D, 2002, BRAIN INJURY, V16, P9, DOI 10.1080/02699050110088227; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; JOHNSON SC, 1994, NEUROPSYCHOLOGY, V8, P301; Kersel DA, 2001, BRAIN INJURY, V15, P283, DOI 10.1080/02699050010005887; KlOve H, 1963, MED CLIN N AM; Kreutzer JS, 1993, J HEAD TRAUMA REHAB, V8, P47; Langlois JA., 2004, TRAUMATIC BRAIN INJU; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; Millis S R, 1994, Int J Neurosci, V79, P165; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Novack T., 2000, ORIENTATION LOG; PONSFORD J, 1992, J CLIN EXP NEUROPSYC, V14, P822, DOI 10.1080/01688639208402865; Ponsford J, 2008, J INT NEUROPSYCH SOC, V14, P233, DOI 10.1017/S1355617708080272; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rohling ML, 2003, CLIN NEUROPSYCHOL, V17, P289, DOI 10.1076/clin.17.3.289.18086; Ross S R, 1997, Appl Neuropsychol, V4, P165, DOI 10.1207/s15324826an0403_4; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Ruttan L, 2008, ARCH PHYS MED REHAB, V89, pS69, DOI 10.1016/j.apmr.2008.07.007; Sawrie S M, 1996, J Int Neuropsychol Soc, V2, P556; Schretlen DJ, 2003, INT REV PSYCHIATR, V15, P341, DOI 10.1080/09540260310001606728; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Smith A., 1982, SYMBOL DIGIT MODALIT; Spikman JM, 1999, J CLIN EXP NEUROPSYC, V21, P585, DOI 10.1076/jcen.21.5.585.874; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Till C, 2008, ARCH PHYS MED REHAB, V89, pS25, DOI 10.1016/j.apmr.2008.07.004; Uniform Data System for Medical Rehabilitation, 1997, GUID UN DAT SET MED; Wilson JTL, 2000, J NEUROL NEUROSUR PS, V69, P204, DOI 10.1136/jnnp.69.2.204	50	23	23	0	15	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2011	25	1					72	89		10.1080/13854046.2010.532813			18	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	722FM	WOS:000287417100005	21120763				2021-06-18	
J	Borg, J; Roe, C; Nordenbo, A; Andelic, N; de Boussard, C; af Geijerstam, JL				Borg, Jorgen; Roe, Cecilie; Nordenbo, Annette; Andelic, Nada; de Boussard, Catharina; af Geijerstam, Jean-Luc			Trends and Challenges in the Early Rehabilitation of Patients with Traumatic Brain Injury A Scandinavian Perspective	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Traumatic Brain Injury; Incidence; Risk; Acute Rehabilitation; Early Rehabilitation	RANDOMIZED CONTROLLED-TRIAL; POST-CONCUSSION SYMPTOMS; MILD HEAD-INJURY; FOLLOW-UP; EARLY INTERVENTION; LIFE SATISFACTION; NORTHERN SWEDEN; UNITED-STATES; DISABILITY; NORWAY		[Borg, Jorgen; de Boussard, Catharina] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Stockholm, Sweden; [Roe, Cecilie; Andelic, Nada] Oslo Univ Hosp, Dept Phys Med & Rehabil, Oslo, Norway; [Nordenbo, Annette] Copenhagen Univ Hosp Glostrup, Dept Neurorehabil, Traumat Brain Injury Unit, Hvidovre, Denmark; [af Geijerstam, Jean-Luc] Karolinska Hosp, Dept Med, Clin Epidemiol Unit, S-10401 Stockholm, Sweden; [af Geijerstam, Jean-Luc] Swedish Council Hlth Technol Assessment, Stockholm, Sweden	Borg, J (corresponding author), Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Stockholm, Sweden.			Borg, Jorgen/0000-0002-2372-7478; Andelic, Nada/0000-0002-3719-4406			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; ANDELIC N, 2008, BRAIN INJ S1, V22, P87; Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andelic Nada, 2010, J Trauma Manag Outcomes, V4, P6, DOI 10.1186/1752-2897-4-6; Andelic N, 2010, DISABIL REHABIL, V32, P1122, DOI 10.3109/09638280903410722; Andersson EE, 2007, ACTA NEUROCHIR, V149, P151, DOI 10.1007/s00701-006-1082-0; Baguley IJ, 2009, AM J PHYS MED REHAB, V88, P615, DOI 10.1097/PHM.0b013e3181aeab96; Bener A, 2010, BRAIN INJURY, V24, P74, DOI 10.3109/02699050903508192; Borg J, 2004, J REHABIL MED, V36, P76, DOI 10.1080/16501960410023840; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cicerone KD, 2005, ARCH PHYS MED REHAB, V86, P1681, DOI 10.1016/j.apmr.2005.03.024; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Engberg AW, 2006, ACTA NEUROL SCAND, V113, P178, DOI 10.1111/j.1600-0404.2005.00570.x; Engberg AW, 2001, EUR J EPIDEMIOL, V17, P437, DOI 10.1023/A:1013733107520; Eriksson G, 2006, J REHABIL MED, V38, P159, DOI 10.1080/16501970500415322; Heskestad B, 2010, SCAND J TRAUMA RESUS, V18, DOI 10.1186/1757-7241-18-10; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Indredavik B, 2003, CEREBROVASC DIS, V15, P19, DOI 10.1159/000068213; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jacobsson LJ, 2009, ACTA NEUROL SCAND, V120, P389, DOI 10.1111/j.1600-0404.2009.01238.x; Jakola AS, 2007, ACTA NEUROL SCAND, V115, P398, DOI 10.1111/j.1600-0404.2007.00827.x; JOHANSSON E, 1991, SCAND J REHABIL MED, V23, P179; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kleiven Svein, 2003, Inj Control Saf Promot, V10, P173, DOI 10.1076/icsp.10.3.173.14552; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Krakau K, 2007, NUTRITION, V23, P308, DOI 10.1016/j.nut.2007.01.010; Krakau K, 2006, BRAIN INJURY, V20, P345, DOI 10.1080/02699050500487571; Langhorne P, 1995, Rev Neurol, V23, P394; Lannsjo M, 2009, BRAIN INJURY, V23, P213, DOI 10.1080/02699050902748356; Lindberg PG, 2007, NEUROREHAB NEURAL RE, V21, P315, DOI 10.1177/1545968306296965; Lovstad M, 2010, J HEAD TRAUMA REHAB, V25, P349, DOI 10.1097/HTR.0b013e3181cec841; Lundin A, 2006, BRAIN INJURY, V20, P799, DOI 10.1080/02699050600744327; Mazaux JM, 1998, DISABIL REHABIL, V20, P435, DOI 10.3109/09638289809166108; Monti MM, 2010, NEW ENGL J MED, V362, P579, DOI 10.1056/NEJMoa0905370; Muller Kay, 2006, Tidsskr Nor Laegeforen, V126, P1205; Nestvold K, 2005, ACTA NEUROL SCAND, V112, P13, DOI 10.1111/j.1600-0404.2005.00344.x; NESTVOLD K, 1988, NEUROEPIDEMIOLOGY, V7, P134, DOI 10.1159/000110147; Paniak C, 2000, BRAIN INJURY, V14, P219; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Schirmer-Mikalsen K, 2007, ACTA ANAESTH SCAND, V51, P1194, DOI 10.1111/j.1399-6576.2007.01372.x; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Skandsen T, 2008, CLIN REHABIL, V22, P653, DOI 10.1177/0269215508089067; Skandsen T, 2010, J NEUROSURG, V113, P556, DOI 10.3171/2009.9.JNS09626; Sorbo AK, 2009, INT J REHABIL RES, V32, P139, DOI 10.1097/MRR.0b013e328325a5d1; Soreide K, 2007, WORLD J SURG, V31, P2092, DOI 10.1007/s00268-007-9226-9; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stein SC, 2010, J NEUROTRAUM, V27, P1343, DOI 10.1089/neu.2009.1206; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Summers CR, 2009, MT SINAI J MED, V76, P105, DOI 10.1002/msj.20100; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Tengvar Christer, 2006, Lakartidningen, V103, P3685; Terent A, 2009, J NEUROL NEUROSUR PS, V80, P881, DOI 10.1136/jnnp.2008.169102; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; Wade DT, 1997, J NEUROL NEUROSUR PS, V62, P478, DOI 10.1136/jnnp.62.5.478; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246	65	23	23	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	JAN	2011	90	1					65	73		10.1097/PHM.0b013e3181fc80e7			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	695ZW	WOS:000285412700009	21169746				2021-06-18	
J	Lewis, MW; Babbage, DR; Leathem, JM				Lewis, Mark W.; Babbage, Duncan R.; Leathem, Janet M.			Assessing executive performance during cognitive rehabilitation	NEUROPSYCHOLOGICAL REHABILITATION			English	Article						Executive functioning; Neuropsychological assessment; Ecological validity; Cognitive rehabilitation	TRAUMATIC BRAIN INJURY; ECOLOGICAL VALIDITY; INTERNATIONAL CLASSIFICATION; OUTCOME MEASURES; HEALTH; EVERYDAY; DYSFUNCTION; DISABILITY; TESTS; PREDICTION	Executive functioning influences a host of other cognitive processes and people who attend neuropsychological services are more likely to display executive dysfunction than any other cognitive deficit (Stuss Levine, 2002). Impairment in executive functioning disrupts a person's ability to effectively employ their intact areas of functioning, and undermines effective self-management of other areas of dysfunction, hampering attempts to employ compensatory strategies. Therefore, assessment of a person's executive functioning is a high priority as part of a comprehensive neurorehabilitation plan. Guided by the International Classification of Functioning, Disability, and Health model (ICF model; Peterson, 2005), we suggest that an important development in the field is moving to formal assessment of executive performance in functional contexts, in addition to more traditional assessment of executive impairment. We outline a number of existing studies in this area, review current measures that can provide clinicians with useful information on these issues, and discuss how this research could be further advanced.	[Babbage, Duncan R.] Massey Univ, Sch Psychol, Wellington 6140, New Zealand	Babbage, DR (corresponding author), Massey Univ, Sch Psychol, POB 756, Wellington 6140, New Zealand.	D.R.Babbage@massey.ac.nz		Babbage, Duncan/0000-0002-9259-9246			ACHENBACH TM, 1987, PSYCHOL BULL, V101, P213, DOI 10.1037/0033-2909.101.2.213; Baguena N., 2006, Annales de Readaptation et de Medecine Physique, V49, P234, DOI 10.1016/j.annrmp.2006.02.007; Bamdad MJ, 2003, BRAIN INJURY, V17, P1011, DOI 10.1080/0269905031000110553; BAUM C, 1993, AM J OCCUP THER, V47, P431, DOI 10.5014/ajot.47.5.431; BENTON AL, 1968, NEUROPSYCHOLOGIA, V6, P53, DOI 10.1016/0028-3932(68)90038-9; BETTCHER BM, 2008, 36 ANN INT NEUR SOC; Bilbao A, 2003, NEUROREHABILITATION, V18, P239; Birnboim N.J.S., 2001, SCAND J OCCUP THER, V8, P193, DOI [10.1080/110381201317166559, DOI 10.1080/110381201317166559]; BOYD TM, 1993, APPL COGNITIVE PSYCH, V7, P171, DOI 10.1002/acp.2350070208; Burgess PW, 2006, J INT NEUROPSYCH SOC, V12, P194, DOI 10.1017/S1355617706060310; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; BURGESS PW, 1996, BEHAV AASSESSMENT DY; Chaytor N, 2006, ARCH CLIN NEUROPSYCH, V21, P217, DOI 10.1016/j.acn.2005.12.002; Chaytor N, 2003, NEUROPSYCHOL REV, V13, P181, DOI 10.1023/B:NERV.0000009483.91468.fb; Chevignard M, 2000, CORTEX, V36, P649, DOI 10.1016/S0010-9452(08)70543-4; Chevignard MP, 2008, NEUROPSYCHOL REHABIL, V18, P461, DOI 10.1080/09602010701643472; Chevignard MP, 2009, DEV NEUROREHABIL, V12, P76, DOI 10.1080/17518420902777019; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; COMALLI PE, 1962, J GENET PSYCHOL, V100, P47, DOI 10.1080/00221325.1962.10533572; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, VI; Fisher AG, 2001, ASSESSMENT MOTOR PRO, V2; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Gioia GA, 2010, STUD NEUROPSYCHOL NE, P179; Hall KM, 2001, ARCH PHYS MED REHAB, V82, P367, DOI 10.1053/apmr.2001.21525; Hall KM., 1993, J HEAD TRAUMA REHAB, V8, DOI [DOI 10.1097/00001199-199308020-00008, 10.1097/00001199-199308020-00008]; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hoskin K. M., 2005, PSYCHIAT PSYCHOL LAW, V12, P56, DOI [http://dx.doi.org/10.1375/pplt.2005.12.1.56, DOI 10.1375/PPLT.2005.12.1.56]; Kertesz A, 1997, CAN J NEUROL SCI, V24, P29, DOI 10.1017/S0317167100021053; Knight C, 2002, NEUROPSYCHOL REHABIL, V12, P231, DOI 10.1080/09602010244000039; Kottorp A, 2003, J INTELL DISABIL RES, V47, P597, DOI 10.1046/j.1365-2788.2003.00475.x; Lamberts KF, 2010, J CLIN EXP NEUROPSYC, V32, P56, DOI 10.1080/13803390902806550; LEWIS MW, 2009, C AUSTR FAC REH MED; LEWIS MW, 2008, J INT NEUROPSYCH SOC, V14, P186; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; LONG CJ, 1996, ECOLOGICAL VALIDITY, P1; MAHONEY F I, 1965, Md State Med J, V14, P61; Malec JF, 2000, J HEAD TRAUMA REHAB, V15, P670, DOI 10.1097/00001199-200002000-00006; Malloy PF, 2001, FRONTAL SYSTEMS BEHA; Manchester D, 2004, BRAIN INJURY, V18, P1067, DOI 10.1080/02699050410001672387; MCCUE M, 1998, HUMAN BRAIN FUNCT, P113; McLellan D.L., 1991, CLIN NEUROL NEUROSUR, V1, P768; MCPHEETERS HL, 1984, COMMUNITY MENT HLT J, V20, P44; Mitchell M, 2008, J CLIN EXP NEUROPSYC, V30, P683, DOI 10.1080/13803390701679893; NEISTADT ME, 1992, OCCUP THER J RES, V12, P242, DOI 10.1177/153944929201200404; Norris G, 2000, NEUROPSYCHOL REHABIL, V10, P33, DOI 10.1080/096020100389282; Oddy M, 1999, NEUROPSYCHOL REHABIL, V9, P373, DOI 10.1080/096020199389446; Odhuba RA, 2005, BRIT J CLIN PSYCHOL, V44, P269, DOI 10.1348/014466505X29431; Peterson DB, 2005, REHABIL PSYCHOL, V50, P105, DOI 10.1037/0090-5550.50.2.105; PIOTROWSKI C, 1989, PROF PSYCHOL-RES PR, V20, P423; Rabin LA, 2007, CLIN NEUROPSYCHOL, V21, P727, DOI 10.1080/13854040600888776; Ready RE, 2001, CLIN NEUROPSYCHOL, V15, P314, DOI 10.1076/clin.15.3.314.10269; Reed GM, 2005, REHABIL PSYCHOL, V50, P122, DOI 10.1037/0090-5550.50.2.122; Sbordone R. J., 1996, ECOLOGICAL VALIDITY, P15; Sbordone RJ, 1999, STUD NEUROPSYCHOL DE, P227; Schwartz MF, 2002, NEUROPSYCHOL REHABIL, V12, P311, DOI 10.1080/09602010244000084; Semkovska M, 2004, SCHIZOPHR RES, V69, P289, DOI 10.1016/j.schres.2003.07.005; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; SHALLICE T, 1978, CORTEX, V14, P294, DOI 10.1016/S0010-9452(78)80055-0; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Skinner A, 2006, CLIN REHABIL, V20, P609, DOI 10.1191/0269215506cr981oa; Spikman JM, 2010, J INT NEUROPSYCH SOC, V16, P118, DOI 10.1017/S1355617709991020; Spinella M, 2005, INT J NEUROSCI, V115, P649, DOI 10.1080/00207450590524304; Spooner DM, 2006, ARCH CLIN NEUROPSYCH, V21, P327, DOI 10.1016/j.acn.2006.04.004; Stuss DT, 2002, ANNU REV PSYCHOL, V53, P401, DOI 10.1146/annurev.psych.53.100901.135220; Teasdale TW, 1997, BRAIN INJURY, V11, P543, DOI 10.1080/026990597123250; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; Turner-Stokes L, 1999, CLIN REHABIL, V13, P277, DOI 10.1191/026921599676896799; Van der Elst W, 2008, ARCH CLIN NEUROPSYCH, V23, P787, DOI 10.1016/j.acn.2008.09.002; VANDERLINDEN M, 1992, COGNITIVE NEUROPSYCH, V9, P301, DOI 10.1080/02643299208252063; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson B. A., 1996, ECOLOGICAL VALIDITY, P413; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood RL, 2006, ARCH CLIN NEUROPSYCH, V21, P429, DOI 10.1016/j.acn.2005.06.014; World Health Organization, 2001, INT CLASS FUNCT DIS	77	23	23	0	19	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2011	21	2					145	163	PII 932225604	10.1080/09602011.2010.543867			19	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	733NZ	WOS:000288270700001	21229458				2021-06-18	
J	MacGregor, AJ; Dougherty, AL; Morrison, RH; Quinn, KH; Galarneau, MR				MacGregor, Andrew J.; Dougherty, Amber L.; Morrison, Rosemary H.; Quinn, Kimberly H.; Galarneau, Michael R.			Repeated concussion among US military personnel during Operation Iraqi Freedom	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						blast; combat; concussion; concussive injury; deployment; head injury; head trauma; military; multiple; severity; traumatic brain injury	TRAUMATIC BRAIN-INJURY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; AFGHANISTAN; PLAYERS	Concussions are a predominant injury of the conflicts in Iraq and Afghanistan. The aims of this study were to describe repeated concussive events among U.S. military personnel injured in Operation Iraqi Freedom and examine subsequent healthcare utilization. We reviewed clinical records from the Expeditionary Medical Encounter Database to identify servicemembers with repeat concussions. We abstracted demographic and injury-specific variables, calculated time between events, and identified healthcare utilization from electronic medical databases. Overall, 113 personnel experienced more than one concussion between 2004 and 2008. A majority of these incidents were blast related. The median time between events was 40 days, with 20% experiencing a second event within 2 weeks of the first and 87% within 3 months. Time between events was not associated with severity of the second event. Greater severity of the second concussive event was associated with higher postinjury utilization of mental health and neurology services. This study is one of the first to describe repeated concussions in a combat setting. We found that repeated concussions occur within a short interval among deployed personnel, although the effects of the first event are unclear. Further research is needed to define the effect of repeated concussions on the health of combat veterans.	[MacGregor, Andrew J.; Dougherty, Amber L.; Morrison, Rosemary H.; Quinn, Kimberly H.; Galarneau, Michael R.] USN, Hlth Res Ctr, Dept Med Modeling Simulat & Mission Support, San Diego, CA 92106 USA	Dougherty, AL (corresponding author), USN, Hlth Res Ctr, 140 Sylvester Rd, San Diego, CA 92106 USA.	amber.dougherty@med.navy.mil		MacGregor, Andrew/0000-0003-1020-7390	Department of DefenseUnited States Department of Defense [PT090804, 61024]	This material was based on work supported by the Congressionally Directed Medical Research Programs, Department of Defense (proposal PT090804 under work unit 61024).	BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Barth JT, 1989, MILD HEAD INJURY; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Commission on Professional Hospital Activities, 1977, INT CLASS DIS; Galarneau MR, 2006, MIL MED, V171, P691, DOI 10.7205/MILMED.171.8.691; Gennarelli TA, 2005, ABBREVIATED INJURY S; Gondusky JS, 2005, MIL MED, V170, P546, DOI 10.7205/MILMED.170.6.546; GRONWALL D, 1975, LANCET, V2, P995; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Jordan BD, 2000, SEMIN NEUROL, V20, P179, DOI 10.1055/s-2000-9826; Macciocchi SN, 2001, J ATHL TRAINING, V36, P303; MacGregor AJ, 2010, J HEAD TRAUMA REHAB, V25, P1, DOI 10.1097/HTR.0b013e3181c2993d; Martin EM, 2008, AM J NURS, V108, P40, DOI 10.1097/01.NAJ.0000315260.92070.3f; McAllister T., 2005, TXB TRAUMATIC BRAIN, P279; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pellman E, 2004, NEUROSURGERY, V55, P860, DOI 10.1227/01.NEU.0000137657.00146.7D; RAND, 2008, INVISIBLE WOUNDS WAR; SALCIDO R, 1992, Brain Injury, V6, P293, DOI 10.3109/02699059209029671; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Teasdale TW, 2003, J NEUROL NEUROSUR PS, V74, P933, DOI 10.1136/jnnp.74.7.933; Thornton AE, 2008, J CLIN EXP NEUROPSYC, V30, P398, DOI 10.1080/13803390701443662; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; Zeitzer MB, 2008, AAOHN J, V56, P347, DOI 10.3928/08910162-20080801-03	28	23	23	0	3	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	10					1269	1277		10.1682/JRRD.2011.01.0013			9	Rehabilitation	Rehabilitation	V28XL	WOS:000208713400013	22234670	Bronze			2021-06-18	
J	Peng, QY; Park, HS; Shah, P; Wilson, N; Ren, YP; Wu, YN; Liu, J; Gaebler-Spira, DJ; Zhang, LQ				Peng, Qiyu; Park, Hyung-Soon; Shah, Parag; Wilson, Nicole; Ren, Yupeng; Wu, Yi-Ning; Liu, Jie; Gaebler-Spira, Deborah J.; Zhang, Li-Qun			Quantitative evaluations of ankle spasticity and stiffness in neurological disorders using manual spasticity evaluator	JOURNAL OF REHABILITATION RESEARCH AND DEVELOPMENT			English	Article						catch angle; cerebral palsy; contracture; manual spasticity evaluator; neurological disorders; quantitative measurement; range of motion; spasticity; Tardieu scale; velocity	MODIFIED ASHWORTH SCALE; MODIFIED TARDIEU SCALE; CEREBRAL-PALSY; BRAIN-INJURY; INTERRATER RELIABILITY; MUSCLE SPASTICITY; CHILDREN; MANAGEMENT; VELOCITY; SYSTEM	Spasticity and contracture are major sources of disability in people with neurological impairments that have been evaluated using various instruments: the Modified Ashworth Scale, tendon reflex scale, pendulum test, mechanical perturbations, and passive joint range of motion (ROM). These measures generally are either convenient to use in clinics but not quantitative or they are quantitative but difficult to use conveniently in clinics. We have developed a manual spasticity evaluator (MSE) to evaluate spasticity/contracture quantitatively and conveniently, with ankle ROM and stiffness measured at a controlled low velocity and joint resistance and Tardieu catch angle measured at several higher velocities. We found that the Tardieu catch angle was linearly related to the velocity, indicating that increased resistance at higher velocities was felt at further stiffer positions and, thus, that the velocity dependence of spasticity may also be position-dependent. This finding indicates the need to control velocity in spasticity evaluation, which is achieved with the MSE. Quantitative measurements of spasticity, stiffness, and ROM can lead to more accurate characterizations of pathological conditions and outcome evaluations of interventions, potentially contributing to better healthcare services for patients with neurological disorders such as cerebral palsy, spinal cord injury, traumatic brain injury, and stroke.	[Peng, Qiyu; Park, Hyung-Soon; Shah, Parag; Wilson, Nicole; Ren, Yupeng; Wu, Yi-Ning; Liu, Jie; Gaebler-Spira, Deborah J.; Zhang, Li-Qun] Rehabil Inst Chicago, Chicago, IL 60611 USA; [Park, Hyung-Soon; Gaebler-Spira, Deborah J.; Zhang, Li-Qun] Northwestern Univ, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Park, Hyung-Soon] NIH, Clin Res Ctr, Dept Rehabil Med, Bethesda, MD 20892 USA; [Liu, Jie; Zhang, Li-Qun] Northwestern Univ, Dept Biomed Engn, Chicago, IL 60611 USA	Zhang, LQ (corresponding author), Rehabil Inst Chicago, 345 E Super St,Suite 1406, Chicago, IL 60611 USA.	l-zhang@northwestern.edu	Park, Hyung-Soon/B-3334-2010; Wilson, Nicole A/C-4049-2008; peng, qiyu/G-1586-2013	Park, Hyung-Soon/0000-0003-4274-7420; Wilson, Nicole A/0000-0002-0844-1885; Wu, Yi-Ning/0000-0001-8369-6717; Gaebler-Spira, Deborah/0000-0001-6827-4241	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-HD044295]; National Institute on Disability and Rehabilitation Research [H133S080074]; National Science FoundationNational Science Foundation (NSF) [CBET-0854498, IIP-0750515]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD044295] Funding Source: NIH RePORTER	This material was based on work supported with resources from the National Institutes of Health (grant R01-HD044295), National Institute on Disability and Rehabilitation Research (grant H133S080074), and National Science Foundation (grants CBET-0854498 and IIP-0750515).	Allison SC, 1996, INT J REHABIL RES, V19, P67, DOI 10.1097/00004356-199603000-00007; Bell KR, 1998, PRINCIPLES OF NEUROLOGIC REHABILITATION, P309; BOHANNON RW, 1987, PHYS THER, V67, P206, DOI 10.1093/ptj/67.2.206; Boyd RN, 1999, EUR J NEUROL, V6, pS23, DOI 10.1111/j.1468-1331.1999.tb00031.x; Chung SG, 2005, ARCH PHYS MED REHAB, V86, P318, DOI 10.1016/j.apmr.2004.04.048; Damiano DL, 2002, DEV MED CHILD NEUROL, V44, P112, DOI 10.1017/S0012162201001761; Gracies JM, 2010, ARCH PHYS MED REHAB, V91, P421, DOI 10.1016/j.apmr.2009.11.017; Hesse S, 2003, CURR OPIN NEUROL, V16, P705, DOI 10.1097/00019052-200312000-00010; Lance J W, 1981, Clin Exp Neurol, V18, P27; Liu J, 2010, P AM SOC BIOM ANN M; Mehrholz J, 2005, CLIN REHABIL, V19, P751, DOI 10.1191/0269215505cr889oa; Moseley A, 1991, Aust J Physiother, V37, P175, DOI 10.1016/S0004-9514(14)60540-7; Nef T, 2009, NEURODEGENER DIS, V6, P240, DOI 10.1159/000262444; Park HS, 2008, IEEE T NEUR SYS REH, V16, P245, DOI 10.1109/TNSRE.2008.920067; Rymer W., 1994, PHYS MED REHABIL, V8, P441; Sanger TD, 2003, PEDIATRICS, V111, DOI 10.1542/peds.111.1.e89; Sherman Kristen Brewer, 2006, Phys Med Rehabil Clin N Am, V17, P473, DOI 10.1016/j.pmr.2005.11.007; Singer BJ, 2003, CLIN BIOMECH, V18, P157, DOI 10.1016/S0268-0033(02)00173-0; Sunnerhagen KS, 2010, J NEUROL NEUROSUR PS, V81, P2, DOI 10.1136/jnnp.2009.189068; TARDIEU C, 1989, PHYS THER, V69, P656, DOI 10.1093/ptj/69.8.656; Tederko Piotr, 2007, Ortop Traumatol Rehabil, V9, P467; Wu YN, 2010, DEV MED CHILD NEUROL, V52, P563, DOI 10.1111/j.1469-8749.2009.03602.x; Yam WKL, 2006, J CHILD NEUROL, V21, P1031, DOI 10.2310/7010.2006.00222; YOUNG RR, 1994, NEUROLOGY, V44, P12; Zafonte R, 2004, J HEAD TRAUMA REHAB, V19, P89, DOI 10.1097/00001199-200403000-00002; Zhang LQ, 2002, IEEE T NEUR SYS REH, V10, P149, DOI 10.1109/TNSRE.2002.802857	26	23	26	1	14	JOURNAL REHAB RES & DEV	BALTIMORE	DEPT OF VETERANS AFFAIRS REHABIL RES & DEVELOP CTR 103 SOUTH GAY STREET, BALTIMORE, MD 21202-4051 USA	0748-7711	1938-1352		J REHABIL RES DEV	J. Rehabil. Res. Dev.		2011	48	4					473	481		10.1682/JRRD.2010.04.0053			9	Rehabilitation	Rehabilitation	774GB	WOS:000291372200013	21674395	Bronze, Green Accepted			2021-06-18	
J	Araujo, IM; Carreira, BP; Carvalho, CM; Carvalho, AP				Araujo, Ines M.; Carreira, Bruno P.; Carvalho, Caetana M.; Carvalho, Arselio P.			Calpains and Delayed Calcium Deregulation in Excitotoxicity	NEUROCHEMICAL RESEARCH			English	Article						Neuronal death; Excitotoxicity; Neurodegeneration; Sodium-calcium exchanger; Glutamate; Calpain	ACUTE GLUTAMATE EXCITOTOXICITY; BRAIN-INJURY; HIPPOCAMPAL-NEURONS; NA+/CA2+ EXCHANGE; CA1 NEURONS; MITOCHONDRIAL DEPOLARIZATION; REPERFUSION INJURY; STATUS EPILEPTICUS; IN-VITRO; INHIBITOR	Overactivation of glutamate receptors results in neurodegeneration in a variety of brain pathologies, including ischemia, epilepsy, traumatic brain injury and slow-progressing neurodegenerative disorders. In all these pathologies, it is well accepted that the calcium-dependent cysteine proteases calpains are key players in the mechanisms of neuronal cell death. Many research groups have been actively pursuing to establish a link between the deregulation of intracellular Ca2+ homeostasis associated with excitotoxicity and calpain activity. It is well established that these two events are connected and interact synergistically to promote neurodegeneration, but whether calpain activity depends on or contributes to Ca2+ deregulation is still under debate.	[Araujo, Ines M.; Carreira, Bruno P.; Carvalho, Caetana M.; Carvalho, Arselio P.] Univ Coimbra, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal	Araujo, IM (corresponding author), Univ Coimbra, Ctr Neurosci & Cell Biol, P-3004517 Coimbra, Portugal.	inaraujo@cnc.cj.uc.pt	Araujo, Ines M/F-4703-2012	Araujo, Ines M/0000-0002-2438-0111; Carreira, Bruno P./0000-0002-7874-6545	Foundation for Science and Technology (FCT), PortugalPortuguese Foundation for Science and Technology [PTDC/SAU-NEU/102612/2008, PTDC/SAU-NMC/112183/2009]; FCTPortuguese Foundation for Science and TechnologyEuropean Commission [SFRH/BD/23754/2005]	This work was funded by Foundation for Science and Technology (FCT), Portugal, Grants PTDC/SAU-NEU/102612/2008 and PTDC/SAU-NMC/112183/2009. Bruno P. Carreira is funded by a fellowship provided by FCT (SFRH/BD/23754/2005).	Abramov AY, 2008, BBA-BIOENERGETICS, V1777, P953, DOI 10.1016/j.bbabio.2008.04.017; Abramov AY, 2010, BBA-GEN SUBJECTS, V1800, P297, DOI 10.1016/j.bbagen.2009.08.002; Araujo IM, 2007, CELL DEATH DIFFER, V14, P1635, DOI 10.1038/sj.cdd.4402171; Araujo IM, 2008, J NEUROCHEM, V105, P666, DOI 10.1111/j.1471-4159.2007.05181.x; Araujo IM, 2005, CNS NEUROL DISORD-DR, V4, P319, DOI 10.2174/1568007054546126; Arundine M, 2003, CELL CALCIUM, V34, P325, DOI 10.1016/S0143-4160(03)00141-6; Bano D, 2005, CELL, V120, P275, DOI 10.1016/j.cell.2004.11.049; Bevers MB, 2008, J CEREBR BLOOD F MET, V28, P655, DOI 10.1038/sj.jcbfm.9600595; Bevers MB, 2010, EXP NEUROL, V224, P170, DOI 10.1016/j.expneurol.2010.03.007; Brustovetsky T, 2010, J NEUROSCI RES, V88, P1317, DOI 10.1002/jnr.22295; Budd SL, 1996, J NEUROCHEM, V67, P2282; Czeiter E, 2009, MOLECULES, V14, P5115, DOI 10.3390/molecules14125115; Dietz RM, 2007, HIPPOCAMPUS, V17, P1049, DOI 10.1002/hipo.20336; FRANDSEN A, 1993, J NEUROCHEM, V60, P1202, DOI 10.1111/j.1471-4159.1993.tb03278.x; Gerencser AA, 2009, J NEUROCHEM, V110, P990, DOI 10.1111/j.1471-4159.2009.06194.x; Higuchi M, 2005, J BIOL CHEM, V280, P15229, DOI 10.1074/jbc.M500939200; Kawamura M, 2005, BRAIN RES, V1037, P59, DOI 10.1016/j.brainres.2004.12.050; Khodorov B, 2004, PROG BIOPHYS MOL BIO, V86, P279, DOI 10.1016/j.pbiomolbio.2003.10.002; KIEDROWSKI L, 1994, NEURON, V12, P295, DOI 10.1016/0896-6273(94)90272-0; Kiedrowski L, 2007, J NEUROCHEM, V100, P915, DOI 10.1111/j.1471-4159.2006.04308.x; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Li PA, 1998, NEUROSCI LETT, V247, P17, DOI 10.1016/S0304-3940(98)00266-3; Liu J, 2008, SCI SIGNAL, V1, DOI 10.1126/scisignal.123tr3; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Matsuda T, 2001, J PHARMACOL EXP THER, V298, P249; Molinaro P, 2008, J NEUROSCI, V28, P1179, DOI 10.1523/JNEUROSCI.4671-07.2008; Nicholls DG, 1998, BIOFACTORS, V8, P287, DOI 10.1002/biof.5520080317; Nicholls DG, 1998, BBA-BIOENERGETICS, V1366, P97, DOI 10.1016/S0005-2728(98)00123-6; Nicholls DG, 1999, BIOCHEM SOC SYMP, V66, P55, DOI 10.1042/bss0660055; NICHOLLS DG, 1986, BRIT MED BULL, V42, P353, DOI 10.1093/oxfordjournals.bmb.a072152; Pilitsis JG, 2001, BRAIN RES, V916, P192, DOI 10.1016/S0006-8993(01)02896-7; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Sattler R, 1996, BRAIN RES, V719, P239, DOI 10.1016/0006-8993(96)00125-4; Schroder UH, 1999, NEUROPHARMACOLOGY, V38, P319, DOI 10.1016/S0028-3908(98)00198-1; Storozhevykh TP, 2010, NEUROCHEM RES, V35, P323, DOI 10.1007/s11064-009-0058-x; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; Vergun O, 1999, J PHYSIOL-LONDON, V519, P451, DOI 10.1111/j.1469-7793.1999.0451m.x; Wang SH, 2008, BRAIN RES BULL, V76, P90, DOI 10.1016/j.brainresbull.2007.12.006; Zhao XR, 2008, J NEUROTRAUM, V25, P1195, DOI 10.1089/neu.2008.0635	41	23	24	1	8	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190			NEUROCHEM RES	Neurochem. Res.	DEC	2010	35	12			SI		1966	1969		10.1007/s11064-010-0323-z			4	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	695IX	WOS:000285364900013	21110090				2021-06-18	
J	Bastian, JD; Buchler, L; Meyer, DC; Siebenrock, KA; Keel, MJB				Bastian, Johannes Dominik; Buechler, Lorenz; Meyer, Dominik Christoph; Siebenrock, Klaus Arno; Keel, Marius Johann Baptist			Surgical Hip Dislocation for Osteochondral Transplantation as a Salvage Procedure for a Femoral Head Impaction Fracture	JOURNAL OF ORTHOPAEDIC TRAUMA			English	Article						anterior hip dislocation; surgical hip dislocation; osteochondral autograft; impaction fracture	ARTICULAR-CARTILAGE DEFECTS; AUTOLOGOUS TRANSPLANTATION; TRAUMATIC DISLOCATION; ANTERIOR DISLOCATION; JOINT; OSSIFICATION; IMPINGEMENT; REPLACEMENT; ALLOGRAFTS; OSTEOTOMY	Obturator anterior hip dislocation is very rare. Poor results are described in patients with additional large transchondral fractures and treatment of these injuries remains challenging. Appropriate treatment recommendations are missing in the literature. This case report introduces surgical hip dislocation for osteochondral autograft transplantation with graft harvest from the nonweightbearing area of the head-neck junction as a salvage procedure in a large femoral head defect. We report the treatment and outcome of a 48-year-old man who sustained an anterior dislocation of the left hip after a motorcycle accident. After initial closed reduction in the emergency room, imaging analysis revealed a large osteochondral defect of the femoral head within the weightbearing area (10 x 20 mm, depth: 5 mm). The hip was exposed with a surgical hip dislocation using a trochanteric osteotomy. An osteochondral autograft was harvested from a nonweightbearing area of the femoral head and transferred into the defect. The patient was prospectively examined clinically and radiologically. Two years postoperatively, the patient was free of pain and complaints. The function of the injured hip was comparable to that of the contralateral, healthy hip and showed satisfying radiologic results. Surgical hip dislocation with a trochanteric flip osteotomy is a simple, one-step technique that allows full inspection of the hip to treat osteochondral femoral defects by osteochondral transplantation. The presented technique, used as a salvage procedure in a large femoral head defect, yielded good clinical and satisfying radiologic outcomes at the midterm.	[Bastian, Johannes Dominik; Buechler, Lorenz; Siebenrock, Klaus Arno; Keel, Marius Johann Baptist] Univ Bern, Dept Orthoped Surg, Inselspital, CH-3010 Bern, Switzerland; [Meyer, Dominik Christoph] Univ Zurich, Dept Orthoped, Zurich, Switzerland	Bastian, JD (corresponding author), Univ Bern, Dept Orthoped Surg, Inselspital, Freiburgstr 3, CH-3010 Bern, Switzerland.	johannesbastian@gmx.de		Siebenrock, Klaus Arno/0000-0003-3627-4313; Buchler, Lorenz/0000-0002-6779-6432			Al-Shaikh RA, 2002, FOOT ANKLE INT, V23, P381, DOI 10.1177/107110070202300502; Ansah P, 2007, J BONE JOINT SURG AM, V89A, P2188, DOI 10.2106/JBJS.F.00299; Bastian JD, 2009, OSTEOARTHR CARTILAGE, V17, P539, DOI 10.1016/j.joca.2008.08.005; Bastian JD, 2009, CLIN ORTHOP RELAT R, V467, P732, DOI 10.1007/s11999-008-0649-x; Beck M, 2009, CLIN ORTHOP RELAT R, V467, P769, DOI 10.1007/s11999-008-0653-1; BELLAMY N, 1988, J RHEUMATOL, V15, P1833; BROOKER AF, 1973, J BONE JOINT SURG AM, VA 55, P1629; Bugbee WD, 1999, CLIN SPORT MED, V18, P67, DOI 10.1016/S0278-5919(05)70130-7; Croft SJ, 2006, EMERG MED J, V23, DOI 10.1136/emj.2005.031013; DELEE JC, 1980, J BONE JOINT SURG AM, V62, P960, DOI 10.2106/00004623-198062060-00012; DREINHOFER KE, 1994, J BONE JOINT SURG BR, V76B, P6; DUSSAULT RG, 1980, RADIOLOGY, V135, P627, DOI 10.1148/radiology.135.3.7384446; Egli RJ, 2003, BONE, V33, P352, DOI 10.1016/S8756-3282(03)00192-3; EPSTEIN HC, 1973, CLIN ORTHOP RELAT R, P116; ERB RE, 1995, AM J ROENTGENOL, V165, P1215, DOI 10.2214/ajr.165.5.7572506; Espinosa N, 2006, J BONE JOINT SURG AM, V88A, P925, DOI 10.2106/JBJS.E.00290; Espinosa Norman, 2007, J Bone Joint Surg Am, V89 Suppl 2 Pt.1, P36, DOI 10.2106/JBJS.F.01123; Ferguson SJ, 2003, J BIOMECH, V36, P171, DOI 10.1016/S0021-9290(02)00365-2; FRIEDLAENDER GE, 1992, ORTHOPEDICS, V15, P1171; Ganz R, 2001, J BONE JOINT SURG BR, V83B, P1119, DOI 10.1302/0301-620X.83B8.11964; Gautier E, 2000, J BONE JOINT SURG BR, V82B, P679, DOI 10.1302/0301-620X.82B5.10426; Gudas R, 2006, KNEE SURG SPORT TR A, V14, P834, DOI 10.1007/s00167-006-0067-0; Guo JJ, 2010, INT ORTHOP, V34, P319, DOI 10.1007/s00264-009-0849-3; HADDAD RJ, 1990, J BONE JOINT SURG BR, V72, P2; Hangody L, 2008, INJURY, V39, pS32, DOI 10.1016/j.injury.2008.01.041; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; Hart R, 2003, ARTHROSCOPY, V19, DOI 10.1016/j.arthro.2003.10.025; Henle P, 2007, INJURY, V38, P478, DOI 10.1016/j.injury.2007.01.023; HOROWITZ MC, 1991, J BONE JOINT SURG AM, V73A, P1157, DOI 10.2106/00004623-199173080-00004; Horowitz MC, 1996, CLIN ORTHOP RELAT R, P25; Keel M, 2005, EUR J TRAUMA, V2, P138; Krueger A, 2007, ARTHROSCOPY, V23, P1285, DOI 10.1016/j.arthro.2007.07.002; Labler L, 2009, J TRAUMA, V66, P749, DOI 10.1097/TA.0b013e318171971a; Mardones RA, 2005, J BONE JOINT SURG AM, V87A, P273, DOI 10.2106/JBJS.D.01793; MEYERS MH, 1985, CLIN ORTHOP RELAT R, P111; Ohlendorf C, 1996, J ORTHOPAED RES, V14, P413, DOI 10.1002/jor.1100140311; Philippon MJ, 2009, ARTHROSCOPY, V25, P169, DOI 10.1016/j.arthro.2008.09.013; Rittmeister M, 2005, ORTHOPADE, V34, P320, DOI 10.1007/s00132-005-0776-y; Sahin V, 2003, J TRAUMA, V54, P520, DOI 10.1097/01.TA.0000020394.32496.52; Scheibel M, 2004, J BONE JOINT SURG BR, V86B, P991, DOI 10.1302/0301-620X.86B7.14941; Siebenrock KA, 2002, J ORTHOP TRAUMA, V16, P543, DOI 10.1097/00005131-200209000-00002; Siebenrock KA, 1998, J ORTHOP TRAUMA, V12, P387, DOI 10.1097/00005131-199808000-00004; Sirlin CB, 2001, RADIOLOGY, V219, P35, DOI 10.1148/radiology.219.1.r01ap0435; Sotereanos Nicholas G, 2008, Orthopedics, V31, P177, DOI 10.3928/01477447-20080201-33; Stevenson S, 1996, CLIN ORTHOP RELAT R, P86; TEHRANZADEH J, 1990, AM J ROENTGENOL, V155, P1049, DOI 10.2214/ajr.155.5.2120934; THOMPSON VP, 1951, J BONE JOINT SURG AM, V33-A, P746, DOI 10.2106/00004623-195133030-00023; Tonnis D, 1999, J BONE JOINT SURG AM, V81A, P1747; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Zahiri CA, 1998, J ARTHROPLASTY, V13, P890, DOI 10.1016/S0883-5403(98)90195-4	50	23	26	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0890-5339	1531-2291		J ORTHOP TRAUMA	J. Orthop. Trauma	DEC	2010	24	12					E113	E118		10.1097/BOT.0b013e3181dfbb52			6	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	679HF	WOS:000284151800001	21076245				2021-06-18	
J	Kawai, N; Maeda, Y; Kudomi, N; Yamamoto, Y; Nishiyama, Y; Tamiya, T				Kawai, Nobuyuki; Maeda, Yukito; Kudomi, Nobuyuki; Yamamoto, Yuka; Nishiyama, Yoshihiro; Tamiya, Takashi			Focal Neuronal Damage in Patients with Neuropsychological Impairment after Diffuse Traumatic Brain Injury: Evaluation Using C-11-Flumazenil Positron Emission Tomography with Statistical Image Analysis	JOURNAL OF NEUROTRAUMA			English	Article						cognitive function; flumazenil; neuronal loss; positron emission tomography; traumatic brain injury	CEREBRAL GLUCOSE-METABOLISM; ACUTE VEGETATIVE STATE; HEAD-INJURY; AXONAL INJURY; FDG-PET; DEFICITS; HYPOMETABOLISM; PERFORMANCE; SEVERITY; ATROPHY	This study was conducted to identify the regional neuronal damage occurring in patients with neuropsychological impairment following diffuse traumatic brain injury (TBI) compared with normal control subjects. In addition, measures of the neuropsychological tests were correlated with regional C-11-flumazenil (FMZ) binding potential (BP) reductions to clarify the relationship between cognitive impairment and regional neuronal damage. We performed C-11-flumazenil positron emission tomography (FMZ-PET) studies using three-dimensional stereotactic surface projection (3D-SSP) statistical image analysis in eight diffuse axonal injury (DAI) patients (mean age 29.1 +/- 11.1 years, range 19-46 years). All patients underwent assessment with the Wechsler Adult Intellectual Scale-Third Edition (WAIS-III) to evaluate general intelligence. Twenty healthy control subjects (mean age 24.4 +/- 2.8 years, range 22-30 years) were also studied to obtain a normal database for 3D-SSP. Group comparisons showed significant regional low FMZ uptake in the bilateral medial frontal gyri, the anterior cingulate gyri, and the thalamus. Individual analysis also showed decreased FMZ uptake in these regions; however, the distribution and extent of low FMZ uptake were different in each individual patient. Full-scale IQ (FIQ) and performance IQ (PIQ) negatively correlated with the degree of FMZ BP reduction (BZR index) in the right thalamus. FIQ, verbal IQ (VIQ), and PIQ also negatively correlated with the BZR index in the left medial frontal gyrus. DAI uniformly induced neuronal damage in the medial frontal cortex and the thalamus, which may be related to underlying cognitive impairments in diffuse TBI patients. Future studies to confirm a common area of focal neuronal damage and a direct correlation with neuropsychological testing may validate the use of FMZ-PET for the functional diagnosis of neuropsychological impairments after TBI.	[Kawai, Nobuyuki; Tamiya, Takashi] Kagawa Univ, Fac Med, Dept Neurol Surg, Miki, Kagawa 7610793, Japan; [Maeda, Yukito; Yamamoto, Yuka; Nishiyama, Yoshihiro] Kagawa Univ, Fac Med, Dept Radiol, Miki, Kagawa 7610793, Japan; [Kudomi, Nobuyuki] Kagawa Univ, Fac Med, Dept Med Phys, Miki, Kagawa 7610793, Japan	Kawai, N (corresponding author), Kagawa Univ, Fac Med, Dept Neurol Surg, 1750-1 Miki Cho, Miki, Kagawa 7610793, Japan.	nobu@kms.ac.jp			Japan Society for the Promotion of ScienceMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of Science; General Insurance Association of Japan	This work was supported in part by grants from the Grant-in-Aid for Scientific Research from the Japan Society for the Promotion of Science, and the General Insurance Association of Japan. The authors appreciate the excellent technical support of the radiological technologist at our institution.	ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; Anderson CV, 1996, J NEUROTRAUM, V13, P35, DOI 10.1089/neu.1996.13.35; Bigler ED, 2001, J HEAD TRAUMA REHAB, V16, P117, DOI 10.1097/00001199-200104000-00003; Buki A, 2006, ACTA NEUROCHIR, V148, P181, DOI 10.1007/s00701-005-0674-4; DEVINSKY O, 1995, BRAIN, V118, P279, DOI 10.1093/brain/118.1.279; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FRISTON KJ, 1990, J CEREBR BLOOD F MET, V10, P458, DOI 10.1038/jcbfm.1990.88; FRISTON KJ, 1991, J CEREBR BLOOD F MET, V11, P690, DOI 10.1038/jcbfm.1991.122; Gale S D, 1995, J Int Neuropsychol Soc, V1, P17; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gross H, 1996, J NEUROPSYCH CLIN N, V8, P324; Haier RJ, 2004, NEUROIMAGE, V23, P425, DOI 10.1016/j.neuroimage.2004.04.025; Heiss WD, 2000, STROKE, V31, P366, DOI 10.1161/01.STR.31.2.366; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; ICHISE M, 1994, J NUCL MED, V35, P217; Kato T, 2007, J NEUROTRAUM, V24, P919, DOI 10.1089/neu.2006.0203; Klumpers UMH, 2008, J CEREBR BLOOD F MET, V28, P579, DOI 10.1038/sj.jcbfm.9600554; Kuroda S, 2004, J NUCL MED, V45, P943; Lifshitz J, 2007, J NEUROPATH EXP NEUR, V66, P218, DOI 10.1097/01.jnen.0000248558.75950.4d; Little DM, 2010, NEUROLOGY, V74, P558, DOI 10.1212/WNL.0b013e3181cff5d5; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Maxwell WL, 2004, BRAIN, V127, P2470, DOI 10.1093/brain/awh294; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; MINOSHIMA S, 1995, J NUCL MED, V36, P1238; MINOSHIMA S, 1994, J NUCL MED, V35, pP33; Mizumura S, 2003, ANN NUCL MED, V17, P289, DOI 10.1007/BF02988523; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; Nakayama N, 2006, J NEUROL NEUROSUR PS, V77, DOI 10.1136/jnnp.2005.080523; Rudolf J, 2002, EUR J NEUROL, V9, P671, DOI 10.1046/j.1468-1331.2002.00468.x; Rudolf J, 2000, LANCET, V355, P115, DOI 10.1016/S0140-6736(99)04280-4; SAMSON Y, 1985, EUR J PHARMACOL, V110, P247, DOI 10.1016/0014-2999(85)90218-3; Sidaros A, 2009, NEUROIMAGE, V44, P1, DOI 10.1016/j.neuroimage.2008.08.030; Stamatakis EA, 2002, J NUCL MED, V43, P476; Uzan M, 2003, J NEUROL NEUROSUR PS, V74, P33, DOI 10.1136/jnnp.74.1.33; Yamauchi H, 2007, ANN NEUROL, V61, P454, DOI 10.1002/ana.21104; Yamauchi H, 2009, STROKE, V40, P3730, DOI 10.1161/STROKEAHA.109.560011; Zhang J, 2010, J NEUROTRAUM, V27, P35, DOI 10.1089/neu.2009.1049	37	23	24	0	10	MARY ANN LIEBERT INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	DEC	2010	27	12					2131	2138		10.1089/neu.2010.1464			8	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	691PN	WOS:000285093400002	21138392				2021-06-18	
J	Thaler, S; Choragiewicz, TJ; Rejdak, R; Fiedorowicz, M; Turski, WA; Tulidowicz-Bielak, M; Zrenner, E; Schuettauf, F; Zarnowski, T				Thaler, Sebastian; Choragiewicz, Tomasz J.; Rejdak, Robert; Fiedorowicz, Michal; Turski, Waldemar A.; Tulidowicz-Bielak, Maria; Zrenner, Eberhart; Schuettauf, Frank; Zarnowski, Tomasz			Neuroprotection by acetoacetate and beta-hydroxybutyrate against NMDA-induced RGC damage in rat-possible involvement of kynurenic acid	GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY			English	Article						beta-hydroxybutyrate; Acetoacetate; Retinal ganglion cells; Kynurenic acid; Neuroprotection	RETINAL GANGLION-CELLS; ASPARTATE-INDUCED NEUROTOXICITY; TRAUMATIC BRAIN-INJURY; INHIBITION IN-VIVO; KETOGENIC DIET; KETONE-BODIES; THERAPEUTIC INTERVENTION; GLYCOLYSIS INHIBITION; NEUROTROPHIC FACTOR; ENERGY-METABOLISM	Purpose This study investigated the effects of systemically administered lithium acetoacetate (ACA) and sodium beta-hydroxybutyrate (BHB) in a rat model of N-methyl-D-aspartate (NMDA)-induced damage of retinal ganglion cells (RGC). Additionally, the influence of ACA and BHB on kynurenic acid (KYNA) production was assessed in vitro in bovine retinal slices. Methods Female adult Brown Norway rats in groups of 5-8 animals were used. ACA and BHB were administered intraperitoneally once a day for 21 consecutive days, and phosphate buffered saline (PBS) was administered to control animals. After 2 weeks, the animals received intraocular NMDA (2 mu l of a 10 mM solution in PBS) or intraocular PBS as a control. On day 19, retinal ganglion cells were labeled retrogradely with hydroxystilbamidine. Two days later, RGC density (cells per mm(2)) was assessed on retinal flatmounts. Additionaly, bovine retinal slices were incubated with NMDA and ACA or BHB at concentrations of 1.0 mM and 3.0 mM, and de novo KYNA production was measured using HPLC. Results Intraperitoneal ACA (250 mg/kg) or BHB (291.2 mg/kg) significantly protected RGC against NMDA-induced neurodegeneration. De novo KYNA production in bovine retinal slices was lowered by NMDA. Both ACA and BHB at a concentration of 3.0 mM significantly reduced the effects of NMDA. Conclusions ACA and BHB had a significant dose-dependent neuroprotective effect on RGC in a rat model of NMDA-induced RGC damage. Both ketone bodies also significantly attenuated NMDA-induced reduction of retinal KYNA production in vitro, suggesting that this mechanism may be essential for the neuroprotective effects of ACA and BHB in vivo. Our results imply that ketone bodies may represent an additional treatment option in chronic neurodegenerative disorders of the eye.	[Zarnowski, Tomasz] Med Univ, Dept Ophthalmol, PL-20079 Lublin, Poland; [Thaler, Sebastian; Choragiewicz, Tomasz J.; Rejdak, Robert; Fiedorowicz, Michal; Zrenner, Eberhart; Schuettauf, Frank] Univ Tubingen, Ctr Ophthalmol, Tubingen, Germany; [Choragiewicz, Tomasz J.; Rejdak, Robert; Tulidowicz-Bielak, Maria; Zarnowski, Tomasz] Med Univ, Tadeusz Krwawicz Chair Ophthalmol, PL-20079 Lublin, Poland; [Choragiewicz, Tomasz J.; Rejdak, Robert; Tulidowicz-Bielak, Maria; Zarnowski, Tomasz] Med Univ, Hosp Eye, PL-20079 Lublin, Poland; [Rejdak, Robert; Fiedorowicz, Michal] PAS Med Res Ctr, Dept Expt Pharmacol, Warsaw, Poland; [Turski, Waldemar A.] Inst Agr Med, Dept Toxicol, Lublin, Poland	Zarnowski, T (corresponding author), Med Univ, Dept Ophthalmol, Chmielna 1, PL-20079 Lublin, Poland.	zarnowskit@poczta.onet.pl	Fiedorowicz, Michal/L-1538-2018; Fiedorowicz, Michal/O-9779-2019; Zarnowski, Tomasz/AAM-6460-2020	Fiedorowicz, Michal/0000-0001-5755-3608; Fiedorowicz, Michal/0000-0001-5755-3608; Turski, Waldemar/0000-0002-5805-5106; Zarnowski, Tomasz/0000-0002-6978-7417	EUEuropean Commission [LSHG-CT-2005-512036]; Kerstan FoundationEuropean Commission	Supported by the EU (integrated project EVI-GENORET LSHG-CT-2005-512036).; MF and TC received support from the Kerstan Foundation in the form of a research fellowship. The authors thank Dr T. Kocki (Lublin, Poland) for technical assistance and Dr M. Gasior (USA) for valuable help in designing the experiments.	Bough KJ, 2006, ANN NEUROL, V60, P223, DOI 10.1002/ana.20899; Casson RJ, 2006, CLIN EXP OPHTHALMOL, V34, P54, DOI 10.1111/j.1442-9071.2006.01146.x; COYLE JT, 1993, SCIENCE, V262, P689, DOI 10.1126/science.7901908; Dardzinski BJ, 2000, PEDIATR RES, V48, P248, DOI 10.1203/00006450-200008000-00021; DEVIVO DC, 1978, ANN NEUROL, V3, P331, DOI 10.1002/ana.410030410; Donevan SD, 2003, EPILEPSIA, V44, P1274, DOI 10.1046/j.1528-1157.2003.07203.x; Dong CJ, 2008, INVEST OPHTH VIS SCI, V49, P4515, DOI 10.1167/iovs.08-2078; Gasior M, 2006, BEHAV PHARMACOL, V17, P431, DOI 10.1097/00008877-200609000-00009; Haces ML, 2008, EXP NEUROL, V211, P85, DOI 10.1016/j.expneurol.2007.12.029; Hodgkins PS, 1998, DEV NEUROSCI-BASEL, V20, P408, DOI 10.1159/000017338; Hodgkins PS, 1998, EUR J NEUROSCI, V10, P1986, DOI 10.1046/j.1460-9568.1998.00208.x; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Kashiwaya Y, 2000, P NATL ACAD SCI USA, V97, P5440, DOI 10.1073/pnas.97.10.5440; Kido N, 2000, BRAIN RES, V884, P59, DOI 10.1016/S0006-8993(00)02887-0; Klocker N, 1998, J NEUROSCI, V18, P1038; Lipton SA, 2007, CURR DRUG TARGETS, V8, P621, DOI 10.2174/138945007780618472; Maalouf M, 2007, NEUROSCIENCE, V145, P256, DOI 10.1016/j.neuroscience.2006.11.065; Massieu L, 2003, NEUROSCIENCE, V120, P365, DOI 10.1016/S0306-4522(03)00266-5; Massieu L, 2001, NEUROSCIENCE, V106, P669, DOI 10.1016/S0306-4522(01)00323-2; Masuda R, 2005, J NEUROSCI RES, V80, P501, DOI 10.1002/jnr.20464; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Mejia-Toiber J, 2006, NEUROCHEM RES, V31, P1399, DOI 10.1007/s11064-006-9189-5; Morizane C, 1997, EUR J PHARMACOL, V328, P45, DOI 10.1016/S0014-2999(97)83026-9; Noh HS, 2006, J NEUROSCI RES, V83, P702, DOI 10.1002/jnr.20736; Pernet V, 2007, J NEUROCHEM, V103, P1481, DOI 10.1111/j.1471-4159.2007.04843.x; Pierre K, 2005, J NEUROCHEM, V94, P1, DOI 10.1111/j.1471-4159.2005.03168.x; Prins ML, 2004, J NEUROCHEM, V90, P666, DOI 10.1111/j.1471-4159.2004.02542.x; Schuettauf F, 2005, GRAEF ARCH CLIN EXP, V243, P1036, DOI 10.1007/s00417-005-1152-7; Schuettauf F, 2006, EXP EYE RES, V83, P1128, DOI 10.1016/j.exer.2006.05.021; Seki M, 2008, PROG BRAIN RES, V173, P495, DOI 10.1016/S0079-6123(08)01134-5; SHIBATA K, 1988, J CHROMATOGR-BIOMED, V430, P376, DOI 10.1016/S0378-4347(00)83173-4; SILIPRANDI R, 1992, VISUAL NEUROSCI, V8, P567, DOI 10.1017/S0952523800005666; Sinha SR, 2005, NEUROLOGIST, V11, P161, DOI 10.1097/01.nrl.0000160818.58821.d2; Suzuki M, 2001, JPN J PHARMACOL, V87, P143, DOI 10.1254/jjp.87.143; Thio LL, 2000, NEUROLOGY, V54, P325, DOI 10.1212/WNL.54.2.325; Tieu K, 2003, J CLIN INVEST, V112, P892, DOI 10.1172/JCI200318797; Tsukada H, 2005, NEUROPSYCHOPHARMACOL, V30, P1861, DOI 10.1038/sj.npp.1300732; TURSKI WA, 1988, BRAIN RES, V454, P164, DOI 10.1016/0006-8993(88)90815-3; Veech RL, 2001, IUBMB LIFE, V51, P241; Zarnowski T, 2006, J NEURAL TRANSM, V113, P1367, DOI 10.1007/s00702-005-0423-0; Zhao Z, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-29; Ziegler DR, 2003, NEUROCHEM RES, V28, P1793, DOI 10.1023/A:1026107405399	42	23	23	0	7	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0721-832X	1435-702X		GRAEF ARCH CLIN EXP	Graefes Arch. Clin. Exp. Ophthalmol.	DEC	2010	248	12					1729	1735		10.1007/s00417-010-1425-7			7	Ophthalmology	Ophthalmology	687WW	WOS:000284810000007	20532550	Green Published, Other Gold			2021-06-18	
J	Turner, B; Fleming, J; Parry, J; Vromans, M; Cornwell, P; Gordon, C; Ownsworth, T				Turner, Ben; Fleming, Jennifer; Parry, Julie; Vromans, Monique; Cornwell, Petrea; Gordon, Cassandra; Ownsworth, Tamara			Caregivers of Adults With Traumatic Brain Injury: The Emotional Impact of Transition From Hospital to Home	BRAIN IMPAIRMENT			English	Article						rehabilitation; brain injury; discharge; anxiety; depression; stress	ANXIETY STRESS SCALES; QUALITY-OF-LIFE; STROKE PATIENTS; FAMILY CAREGIVERS; INFORMAL CAREGIVERS; 1ST MONTH; BURDEN; CARE; PREDICTORS; DEPRESSION	Primary Objective: To explore levels of depression, anxiety, stress and strain symptomatology experienced by caregivers of adults with traumatic brain injury (FBI) during the phase of transition from hospital to home. Research Design: Prospective study with data collected at three time-points: pre-discharge, 1-month post-discharge, and 3-months post-discharge. Methods and Procedures: Twenty-nine caregivers of adults with TBI (mean age 48 years), recruited on patient discharge from rehabilitation, completed the Caregiver Strain Index and the Depression, Anxiety and Stress Scale at the three time points. Results. Paired t tests showed significantly lower levels of caregiver strain at one month compared to pre-discharge, and significantly less strain and depression symptoms at 3-month follow-up compared to pre-discharge. Non-significant reductions were observed in level of stress and anxiety across the follow-up time points. Independent group t tests found that female caregivers experienced greater strain than male caregivers at 3 months post-discharge, and caregivers who were immediate family members of the patient experienced greater anxiety than those who were spouses/partners of the patient at 1-month follow-up. Conclusions. The rate of depressive symptoms in caregivers of people with TBI was greater than the general population, and strain was prevalent during the transition period. The results suggest more specific caregiver support and preparation is needed before patient discharge from hospital, and that adequate time spent in rehabilitation is beneficial for caregiver wellbeing.	[Turner, Ben] Acquired Brain Injury Outreach Serv, Brisbane, Qld, Australia; [Turner, Ben; Fleming, Jennifer; Parry, Julie; Vromans, Monique; Cornwell, Petrea; Gordon, Cassandra] Univ Queensland, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; [Fleming, Jennifer] Princess Alexandra Hosp, Occupat Therapy Dept, Brisbane, Qld 4102, Australia; [Gordon, Cassandra; Ownsworth, Tamara] Griffith Univ, Sch Psychol, Brisbane, Qld 4111, Australia; [Fleming, Jennifer] Ctr Functioning & Hlth Res, Queensland Hlth, Australia	Turner, B (corresponding author), Acquired Brain Injury Outreach Serv, POB 6053, Buranda, Qld 4102, Australia.	Ben_J_Turner@health.qld.gov.au	Fleming, Jennifer M/B-4436-2011; Cornwell, Petrea/AAE-5547-2019	Ownsworth, Tamara/0000-0003-1835-7094	Australian Postgraduate AwardAustralian Government	The first author was in receipt of an Australian Postgraduate Award at the time of conducting this research. The authors thank two anonymous reviewers for useful comments during the preparation of the manuscript.	Antony MM, 1998, PSYCHOL ASSESSMENT, V10, P176, DOI 10.1037/1040-3590.10.2.176; *AUSTR BUR STAT, 1998, AUSTR STAND CLASS OC; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bugge C, 1999, STROKE, V30, P1517, DOI 10.1161/01.STR.30.8.1517; Bull MJ., 1992, QUAL HLTH RES, V2, P27, DOI [10.1177/104973239200200103, DOI 10.1177/104973239200200103]; Chumbler NR, 2004, INT J GERIATR PSYCH, V19, P944, DOI 10.1002/gps.1187; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd, pXXI; COPE D N, 1991, Brain Injury, V5, P111, DOI 10.3109/02699059109008083; Crawford JR, 2003, BRIT J CLIN PSYCHOL, V42, P111, DOI 10.1348/014466503321903544; Davis LC, 2009, J HEAD TRAUMA REHAB, V24, P145, DOI 10.1097/HTR.0b013e3181a0b291; Devilly G.J, 2007, EFFECT SIZE GENERATO; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; Elliott TR, 2001, J COUNS PSYCHOL, V48, P223, DOI 10.1037//0022-0167.48.2.223; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Fraser C, 1999, J Neurosci Nurs, V31, P9; Gan C, 2006, BRAIN INJURY, V20, P587, DOI 10.1080/02699050600743725; GEORGE LK, 1986, GERONTOLOGIST, V26, P253, DOI 10.1093/geront/26.3.253; Grant JS, 2004, BRAIN INJURY, V18, P797, DOI 10.1080/02699050410001671766; Han B, 1999, STROKE, V30, P1478, DOI 10.1161/01.STR.30.7.1478; Hankey GJ, 2004, BMJ-BRIT MED J, V328, P1085, DOI 10.1136/bmj.328.7448.1085; Kalra L, 2004, BMJ-BRIT MED J, V328, P1099, DOI 10.1136/bmj.328.7448.1099; Kasuya RT, 2000, POSTGRAD MED, V108, P119, DOI 10.3810/pgm.2000.12.1324; Khan F, 2003, MED J AUSTRALIA, V178, P290, DOI 10.5694/j.1326-5377.2003.tb05199.x; King RB, 2001, RES NURS HEALTH, V24, P307, DOI 10.1002/nur.1032; Kreutzer JS, 2009, ARCH PHYS MED REHAB, V90, P939, DOI 10.1016/j.apmr.2009.01.010; Lovibond S.H., 1995, MANUAL DEPRESSION AN; Low JTS, 1999, SOC SCI MED, V49, P711, DOI 10.1016/S0277-9536(99)00194-X; Marosszeky NEV, 1997, PTA PROTOCOL GUIDELI; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; McCullagh E, 2005, STROKE, V36, P2181, DOI 10.1161/01.STR.0000181755.23914.53; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; MITCHLEY M, 1996, CLIN REHABIL, V10, P3; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Norup A, 2010, BRAIN INJURY, V24, P81, DOI 10.3109/02699050903508200; NOVACK TA, 1991, J HEAD TRAUMA REHAB, V6, P69, DOI DOI 10.1097/00001199-199112000-00014; Olofsson A, 2005, CLIN REHABIL, V19, P433, DOI 10.1191/0269215505cr788oa; Ownsworth T, 2009, BRAIN IMPAIR, V10, P149, DOI 10.1375/brim.10.2.149; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; ROBINSON BC, 1983, J GERONTOL, V38, P344, DOI 10.1093/geronj/38.3.344; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Schlossberg N. K., 1984, COUNSELLING ADULTS T; Slade T., 2007, MENTAL HLTH AUSTR; Stuckey JC, 1996, GERONTOLOGIST, V36, P686, DOI 10.1093/geront/36.5.686; TEASDALE B, 1974, LANCET, P281; Tooth L, 2005, BRAIN INJURY, V19, P963, DOI 10.1080/02699050500110785; Turner BJ, 2008, DISABIL REHABIL, V30, P1153, DOI 10.1080/09638280701532854; *UB FDN ACT INC UN, 1997, FIM INSTR; van den Heuvel ETP, 2001, CLIN REHABIL, V15, P669, DOI 10.1191/0269215501cr446oa; Yee JL, 2000, GERONTOLOGIST, V40, P147, DOI 10.1093/geront/40.2.147	49	23	23	0	15	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1443-9646	1839-5252		BRAIN IMPAIR	Brain Impair.	DEC	2010	11	3					281	292		10.1375/brim.11.3.281			12	Clinical Neurology; Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	710VJ	WOS:000286544800004		Green Published			2021-06-18	
J	Musacchio, MJ; Smith, AP; McNeal, CA; Munoz, L; Rothenberg, DM; von Roenn, KA; Byrne, RW				Musacchio, Michael J., Jr.; Smith, Adam P.; McNeal, Christopher A.; Munoz, Lorenzo; Rothenberg, David M.; von Roenn, Kelvin A.; Byrne, Richard W.			Neuro-Critical Care Skills Training Using a Human Patient Simulator	NEUROCRITICAL CARE			English	Article						Neurocritical care; Human patient simulator; Neurosurgical training	PERFORMANCE; VALIDITY	Neurosurgical trainees regularly encounter critical care situations. Traditionally, education was accomplished through lecture and experience. Increasingly, human patient simulators (HPS) are employed, allowing trainees to sharpen skills in a safe and realistic environment. We describe our experience using HPS in neurosurgical training. We developed a critical care training program for residents and medical students using HPS. We used a hi-fidelity, lifelike Human Patient Simulator (TM) (HPS (TM)) produced by Medical Education Technologies, Inc.(TM) to simulate realistic scenarios for trainee education. Topics included spinal shock, closed head injury, and cerebral vasospasm. A three-way evaluation model was employed to test validity, including pre- and post-exercise testing, survey feedback, and videotaped replay. The simulation exercises were conducted by a neuro-critical care attending, a senior neurosurgical resident, and a HPS technician. We currently have 29 participants. On a 20-point critical care multiple-choice exam for these participants, average improvement has been 4.5 points or 25%. In subgroup analysis, average improvement was 4.75 points (24%) amongst neurosurgery residents, 3.07 points (18%) amongst neurology residents, 7 points (38%) amongst general surgery residents, and 7 points (38%) amongst senior medical students. Post-exercise evaluations were overwhelmingly positive. Neurosurgical critical care education is important for safe and effective care for patients. Clinical experience and didactic lectures help trainees obtain a solid knowledge base, but do not provide the benefit for learning in a fail-safe environment. Through the use of HPS, we have enhanced the critical care education of our trainees.	[Musacchio, Michael J., Jr.; Smith, Adam P.; Munoz, Lorenzo; von Roenn, Kelvin A.; Byrne, Richard W.] Rush Univ, Med Ctr, Dept Neurosurg, Chicago, IL 60612 USA; [McNeal, Christopher A.] Rush Univ, Simulat Lab, Chicago, IL 60612 USA; [Rothenberg, David M.] Rush Univ, Med Ctr, Dept Anesthesiol, Chicago, IL 60612 USA	Smith, AP (corresponding author), Rush Univ, Med Ctr, Dept Neurosurg, 1725 W Harrison Ave,Suite 1115, Chicago, IL 60612 USA.	adam_smith@rush.edu	Byrne, Richard/Q-9644-2019				Boulet JR, 2003, ANESTHESIOLOGY, V99, P1270, DOI 10.1097/00000542-200312000-00007; CHOPRA V, 1994, BRIT J ANAESTH, V73, P293, DOI 10.1093/bja/73.3.293; Croley WC, 2007, CRIT CARE MED, V35, pS117, DOI 10.1097/01.CCM.0000252917.25301.18; Devitt JH, 1998, ANESTH ANALG, V86, P1160, DOI 10.1097/00000539-199806000-00004; Devitt JH, 2001, ANESTHESIOLOGY, V95, P36, DOI 10.1097/00000542-200107000-00011; Grenvik Ake, 2004, Curr Opin Crit Care, V10, P233, DOI 10.1097/01.ccx.0000132654.52131.32; Hammond Jeffrey, 2004, Curr Opin Crit Care, V10, P325, DOI 10.1097/01.ccx.0000140950.47361.c9; Lighthall GK, 2003, CRIT CARE MED, V31, P2437, DOI 10.1097/01.CCM.0000089645.94121.42; Maran NJ, 2003, MED EDUC, V37, P22, DOI 10.1046/j.1365-2923.37.s1.9.x; Schwid HA, 2002, ANESTHESIOLOGY, V97, P1434, DOI 10.1097/00000542-200212000-00015; Steadman RH, 2006, CRIT CARE MED, V34, P151, DOI 10.1097/01.CCM.0000190619.42013.94; Tsai TC, 2003, MED EDUC, V37, P72, DOI 10.1046/j.1365-2923.37.s1.3.x; Weller JM, 2003, BRIT J ANAESTH, V90, P43, DOI 10.1093/bja/aeg002	13	23	24	0	4	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	OCT	2010	13	2					169	175		10.1007/s12028-010-9405-7			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	653LS	WOS:000282093500002	20625852				2021-06-18	
J	Powers, WJ				Powers, William J.			Intracerebral Hemorrhage and Head Trauma Common Effects and Common Mechanisms of Injury	STROKE			English	Article; Proceedings Paper	27th Princeton Conference 2010	APR 22-24, 2010	Boston, MA			intracerebral hemorrhage; traumatic brain injury; cerebral oxygen metabolism; cerebral glucose metabolism	BRAIN-INJURY; CEREBRAL METABOLISM; DYSFUNCTION; HYPERVENTILATION; GLUCOSE	Nontraumatic intracerebral hemorrhage (ICH) remains a devastating condition with 30-day mortality rates of 35% to 52%. Until the pathophysiology of this condition is better understood, it will not be possible to develop effective therapies. Studies of cerebral blood flow and metabolism in patients with acute ICH show similar abnormalities to those that occur in patients with traumatic brain injury, thus raising the question of whether there are common mechanisms of injury shared by the 2 conditions. In both ICH and traumatic brain injury, there is an early reduction in the cerebral metabolic rate of oxygen without ischemia, mitochondrial dysfunction, and transient focal increases in regional glucose metabolism that occur after a few days. ICH and traumatic brain injury share barotrauma from pressure waves that propagate through the intracranial contents as a common mechanism of brain injury. Recent data demonstrating contralateral hemispheric damage in patients with acute ICH provide further support for this theory of common injury mechanisms. (Stroke. 2010;41[suppl 1]:S107-S110.)	Univ N Carolina, Dept Neurol, Chapel Hill, NC 27599 USA	Powers, WJ (corresponding author), Univ N Carolina, Dept Neurol, CB 7025,Room 2131,170 Manning Dr, Chapel Hill, NC 27599 USA.	powersw@neurology.unc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS044885, K23 NS044885, NS35966, P50 NS055977, P01 NS035966] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS035966, K23NS044885, P50NS055977, P50NS035966] Funding Source: NIH RePORTER		Adams RE, 1998, NEUROLOGY, V50, P519, DOI 10.1212/WNL.50.2.519; Bazarian JJ, 2007, J NEUROTRAUM, V24, P1447, DOI 10.1089/neu.2007.0241; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BERING EA, 1956, SURG GYNECOL OBSTET, V102, P134; Bolanos JP, 2009, ADV DRUG DELIVER REV, V61, P1299, DOI 10.1016/j.addr.2009.05.009; Broderick J, 2007, STROKE, V38, P2001, DOI 10.1161/STROKEAHA.107.183689; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; Hattori N, 2004, J NUCL MED, V45, P775; HEISS WD, 1992, J CEREBR BLOOD F MET, V12, P193, DOI 10.1038/jcbfm.1992.29; Kim-Han JS, 2006, STROKE, V37, P2457, DOI 10.1161/01.STR.0000240674.99945.4e; Maas AIR, 2007, J NEUROTRAUM, V24, P303, DOI 10.1089/neu.2006.0033; Mayer AR, 2010, NEUROLOGY, V74, P643, DOI 10.1212/WNL.0b013e3181d0ccdd; Morgenstern LB, 2005, STROKE, V36, pE23, DOI 10.1161/01.STR.0000155685.77775.4c; PAPO I, 1979, NEUROSURGERY, V4, P504, DOI 10.1227/00006123-197906000-00002; POUNGVARIN N, 1991, BRIT MED J, V302, P1565, DOI 10.1136/bmj.302.6792.1565; Sarrafzadeh A, 2005, J NEURORADIOLOGY, V32, P348, DOI 10.1016/S0150-9861(05)83168-2; SETTE G, 1989, BRAIN, V112, P931, DOI 10.1093/brain/112.4.931; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; WISE RJS, 1983, ANN NEUROL, V14, P627, DOI 10.1002/ana.410140605; Xing L, 2010, STROKE, V41, pE212; Xu YQ, 2010, J CEREBR BLOOD F MET, V30, P883, DOI 10.1038/jcbfm.2009.263; Zazulia AR, 2010, STROKE, V41, pE211; Zazulia AR, 2009, STROKE, V40, P1638, DOI 10.1161/STROKEAHA.108.536037; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	26	23	24	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	OCT	2010	41	10		1			S107	S110		10.1161/STROKEAHA.110.595058			4	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	655DR	WOS:000282224300029	20876480	Green Accepted, Bronze			2021-06-18	
J	Elhammali, N; Bremerich, A; Rustemeyer, J				Elhammali, N.; Bremerich, A.; Rustemeyer, J.			Demographical and clinical aspects of sports-related maxillofacial and skull base fractures in hospitalized patients	INTERNATIONAL JOURNAL OF ORAL AND MAXILLOFACIAL SURGERY			English	Article						maxillofacial fracture; skull base fracture; sports-related injury; concomitant injury; midface fracture; mandible fracture	FACIAL FRACTURES; INJURIES; SOCCER; PREVENTION; PROTECTION; ETIOLOGY	As many as 30% of all maxillofacial fractures (MFFs) and skull base fractures (SBFs) are reported to be sports-related. Participation in sporting activities has grown worldwide and the number of cases of sports-related injuries has also increased. The aim of this study was to evaluate the data of 3596 patients hospitalized by MFF or SBF over a 6-year period; 147 (4%) of these cases were sports-related (mean age 29.7 +/- 12.8 years). The highest incidence was found in patients aged 20-29 years (35%), and the fractures resulted mostly from ball sports (74%), especially soccer (59%) and handball (8%). The injuries involved different areas, with a significant prevalence of the midface complex (67%) compared with the mandible region (29%) and the skull base (4%). The commonest diagnoses associated with MFF and SBF were brain concussion (19%), laceration of the skin and soft tissue (16%), and dental injury (8%). Surgery was required for 88% of midface fractures. In cases of mandible fractures 52% were supplied with osteosynthesis. This study identified the significant number of severe sports-related injuries that occur each year, suggesting that changes of rules and safety standards are needed for the prevention of such injuries.	[Elhammali, N.; Bremerich, A.; Rustemeyer, J.] Ctr Hosp, Dept Cranio & Maxillofacial Surg, Bremen, Germany; [Elhammali, N.] Altahadi Univ, Sirte, Libya	Rustemeyer, J (corresponding author), Klinikum Bremen Mitte, Dept Cranio & Maxillofacial Surg, D-28177 Bremen, Germany.	janrustem@gmx.de					Adirim TA, 2003, SPORTS MED, V33, P75, DOI 10.2165/00007256-200333010-00006; Antoun JS, 2008, J ORAL MAXIL SURG, V66, P504, DOI 10.1016/j.joms.2007.08.018; Bak MJ, 2004, J ORAL MAXIL SURG, V62, P1209, DOI 10.1016/j.joms.2004.06.034; Carroll SM, 1996, IRISH MED J, V89, P188; Cascone P, 2008, J CRANIOFAC SURG, V19, P772, DOI 10.1097/SCS.0b013e31816b1ad4; Cerulli G, 2002, J CRANIOFAC SURG, V13, P627, DOI 10.1097/00001665-200209000-00006; Chalmers DJ, 1998, SPORTS MED, V25, P339, DOI 10.2165/00007256-199825050-00006; Chalmers DJ, 2002, INJURY PREV, V8, pIV22, DOI 10.1136/ip.8.suppl_4.iv22; Conn JM, 2003, INJURY PREV, V9, P117, DOI 10.1136/ip.9.2.117; De Gioanni P P, 2000, Minerva Stomatol, V49, P21; Delilbasi C, 2004, ORAL SURG ORAL MED O, V97, P23, DOI 10.1016/j.tripleo.2003.10.008; DELOES M, 1995, INT J SPORTS MED, V16, P134, DOI 10.1055/s-2007-972980; Dempsey RL, 2005, INJURY PREV, V11, P91, DOI 10.1136/ip.2004.006205; Exadaktylos AK, 2004, BRIT J SPORT MED, V38, P750, DOI 10.1136/bjsm.2003.008581; Fasola A O, 2000, Afr J Med Med Sci, V29, P215; Gassner R, 1999, J ORAL MAXIL SURG, V57, P1068, DOI 10.1016/S0278-2391(99)90327-0; Hill CM, 1998, BRIT J ORAL MAX SURG, V36, P44, DOI 10.1016/S0266-4356(98)90747-1; Kelly KD, 2001, CLIN J SPORT MED, V11, P77, DOI 10.1097/00042752-200104000-00003; LIM LH, 1993, AUST NZ J SURG, V63, P784, DOI 10.1111/j.1445-2197.1993.tb00341.x; MacAfee K A 2nd, 1994, Penn Dent J (Phila), V93, P16; Maladiere E, 2001, INT J ORAL MAX SURG, V30, P291, DOI 10.1054/ijom.2001.0059; Marshall SW, 2003, JAMA-J AM MED ASSOC, V289, P568, DOI 10.1001/jama.289.5.568; Motamedi MHK, 2003, J ORAL MAXIL SURG, V61, P61, DOI 10.1053/joms.2003.50049; Mourouzis C, 2005, INT J ORAL MAX SURG, V34, P635, DOI 10.1016/j.ijom.2005.01.008; Papakosta V, 2008, DENT TRAUMATOL, V24, P193, DOI 10.1111/j.1600-9657.2007.00536.x; Roccia F, 2008, J CRANIOFAC SURG, V19, P377, DOI 10.1097/SCS.0b013e318163e3d7; SANE J, 1988, INT J ORAL MAX SURG, V17, P122, DOI 10.1016/S0901-5027(88)80165-6; SMITH AM, 1993, MAYO CLIN PROC, V68, P939, DOI 10.1016/S0025-6196(12)62265-4; Tanaka N, 1996, J ORAL MAXIL SURG, V54, P715, DOI 10.1016/S0278-2391(96)90688-6; Ueeck BA, 2004, J ORAL MAXIL SURG, V62, P693, DOI 10.1016/j.joms.2003.12.010	30	23	25	0	4	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0901-5027	1399-0020		INT J ORAL MAX SURG	Int. J. Oral Maxillofac. Surg.	SEP	2010	39	9					857	862		10.1016/j.ijom.2010.04.006			6	Dentistry, Oral Surgery & Medicine; Surgery	Dentistry, Oral Surgery & Medicine; Surgery	674QE	WOS:000283761500004	20462740				2021-06-18	
J	Iverson, GL				Iverson, Grant L.			Clinical and Methodological Challenges With Assessing Mild Traumatic Brain Injury in the Military	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain injury; concussion; epidemiology; screening; surveillance	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION-SYNDROME; DISSOCIATIVE SYMPTOMS; FOOTBALL PLAYERS; CHRONIC PAIN; HEAD-INJURY; CONCUSSION; IRAQ; DEPRESSION; DEPLOYMENT	Background: A vast majority of traumatic brain injuries sustained by military personnel are mild in severity. In 2008, the United States Department of Defense officially mandated a screening program designed to identify deployment-related mild traumatic brain injuries and associated residual symptoms. Objective: This article reviews this screening program, illustrates the clinical and methodological challenges associated with screening, and makes recommendations for improving the process of screening for mild traumatic brain injuries and related symptoms.	[Iverson, Grant L.] Univ British Columbia, Dept Psychiat, Vancouver, BC V6T 2A1, Canada; [Iverson, Grant L.] British Columbia Mental Hlth & Addict Serv, Vancouver, BC, Canada	Iverson, GL (corresponding author), Univ British Columbia, Dept Psychiat, 2255 Wesbrook Mall, Vancouver, BC V6T 2A1, Canada.	giverson@interchange.ubc.ca		Iverson, Grant/0000-0001-7348-9570			*ARM FORC HLTH SUR, 2008, MED SURVEILL MON REP, V10, P2; Belanger HG, 2010, J INT NEUROPSYCH SOC, V16, P194, DOI 10.1017/S1355617709990841; Birmes P, 2003, AM J PSYCHIAT, V160, P1337, DOI 10.1176/appi.ajp.160.7.1337; CARDENA E, 1993, AM J PSYCHIAT, V150, P474; Covassin T, 2008, J ATHL TRAINING, V43, P119, DOI 10.4085/1062-6050-43.2.119; De Beaumont L, 2007, BRAIN INJURY, V21, P631, DOI 10.1080/02699050701426931; *DEF VET BRAIN INJ, TBI NUMB; Delaney JS, 2000, CLIN J SPORT MED, V10, P9, DOI 10.1097/00042752-200001000-00003; Fear NT, 2009, PSYCHOL MED, V39, P1379, DOI 10.1017/S0033291708004595; FREINKEL A, 1994, AM J PSYCHIAT, V151, P1335; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; Gunstad J, 2004, ARCH CLIN NEUROPSYCH, V19, P391, DOI 10.1016/S0887-6177(03)00073-8; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Harvey AG, 1999, J TRAUMA STRESS, V12, P673, DOI 10.1023/A:1024773202939; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Iverson GL, 2006, ARCH CLIN NEUROPSYCH, V21, P303, DOI 10.1016/j.acn.2005.12.008; Iverson GL, 2009, CLIN NEUROPSYCHOL, V23, P1299, DOI 10.1080/13854040903153902; KARZMARK P, 1995, BRAIN INJURY, V9, P21, DOI 10.3109/02699059509004567; Machulda MM, 1998, ARCH CLIN NEUROPSYCH, V13, P415, DOI 10.1016/S0887-6177(97)00031-0; MADAKASIRA S, 1987, J NERV MENT DIS, V175, P286, DOI 10.1097/00005053-198705000-00008; McCauley SR, 2001, J CLIN EXP NEUROPSYC, V23, P792, DOI 10.1076/jcen.23.6.792.1016; Meares S, 2008, J NEUROL NEUROSUR PS, V79, P300, DOI 10.1136/jnnp.2007.126565; Mental Health Advisory Team (MHAT-V), OP IR FREED 06 08 IR; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V55, P200, DOI 10.1136/jnnp.55.3.200; Morgan CA, 2001, AM J PSYCHIAT, V158, P1239, DOI 10.1176/appi.ajp.158.8.1239; RADANOV BP, 1992, SPINE, V17, P127, DOI 10.1097/00007632-199202000-00001; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schwab KA, 2007, J HEAD TRAUMA REHAB, V22, P377, DOI 10.1097/01.HTR.0000300233.98242.87; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tanielian T, 2008, INVISIBLE WOUNDS WAR; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Trahan DE, 2001, ARCH CLIN NEUROPSYCH, V16, P435, DOI 10.1016/S0887-6177(00)00051-2; Vanderploeg RD, 2009, ARCH PHYS MED REHAB, V90, P1084, DOI 10.1016/j.apmr.2009.01.023; Wilde EA, 2004, J NEUROTRAUM, V21, P137, DOI 10.1089/089771504322778604; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3; Zemper ED, 2003, AM J PHYS MED REHAB, V82, P653, DOI 10.1097/01.PHM.0000083666.74494.BA	43	23	23	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2010	25	5					313	319		10.1097/HTR.0b013e3181d6f9bd			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	649JR	WOS:000281765400003	20220528				2021-06-18	
J	Melo, JRT; Di Rocco, F; Blanot, S; Laurent-Vannier, A; Reis, RC; Baugnon, T; Sainte-Rose, C; Olveira, J; Zerah, M; Meyer, P				Melo, Jose Roberto Tude; Di Rocco, Federico; Blanot, Stephane; Laurent-Vannier, Anne; Reis, Rodolfo Casimiro; Baugnon, Thomas; Sainte-Rose, Christian; Olveira-Filho, Jamary; Zerah, Michel; Meyer, Philippe			Acute hyperglycemia is a reliable outcome predictor in children with severe traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Pediatric; Head injury; Hyperglycemia; Prognosis; Outcome	SEVERE HEAD-INJURY; INTENSIVE INSULIN THERAPY; CRITICALLY-ILL PATIENTS; PROGNOSTIC FACTORS; EPIDEMIOLOGY; METABOLISM; EXPERIENCE; MANAGEMENT; MORTALITY; IMPACT	Hyperglycemia in the acute phase after trauma could adversely affect outcome in children with severe traumatic brain injury (TBI). The goal of this study was to identify the relationship between acute spontaneous hyperglycemia and outcome in children with severe TBI at hospital discharge and 6 months later. A retrospective analysis of blood glucose levels in children with severe TBI at a Pediatric level I Trauma Center, between January 2000 and December 2005. Hyperglycemia was considered for a cut-off value of 11.1 mmol/l (200 mg/dl). Outcome was measured with Glasgow Outcome Scale (GOS) at hospital discharge and at 6 months. A multiple logistic regression analysis, the Student's t test and the chi (2) test were done. Hyperglycemia was noted within the first 48 h in 34% of the patients. Mortality (70% vs 14%, p < 10(-5)) was more frequent in hyperglycemic children and bad outcome upon hospital discharge in those who remained hyperglycemic during the first 48 h of hospitalization. GOS after 6 months demonstrated that those normoglycemic children had a better outcome (95%) than those who developed hyperglycemia during the first 48 h (83%, p = 0.01) after trauma. Hyperglycemia could be considered as a marker of brain injury and when present upon admission, could reflect extensive brain damage with frequently associated mortality and bad outcome. The inability to maintain normal blood glucose levels during the first 48 h could be a predictive factor of bad outcome. Avoiding hyperglycemia in the initial phase could be a major issue in children with severe TBI.	[Melo, Jose Roberto Tude; Reis, Rodolfo Casimiro; Olveira-Filho, Jamary] Univ Fed Bahia, Sch Med, Postgrad Program Med & Hlth, BR-40296200 Salvador, BA, Brazil; [Melo, Jose Roberto Tude; Di Rocco, Federico; Sainte-Rose, Christian; Zerah, Michel] Univ Descartes Paris 5, Hop Necker Enfants Malad, AP HP, Dept Pediat Neurosurg, Paris, France; [Blanot, Stephane; Baugnon, Thomas; Meyer, Philippe] Univ Descartes Paris 5, Hop Necker Enfants Malad, AP HP, Pediat Surg Crit Care Unit, Paris, France; [Laurent-Vannier, Anne] Hop Natl Rehabil St Maurice, St Maurice, France	Melo, JRT (corresponding author), Univ Fed Bahia, Sch Med, Postgrad Program Med & Hlth, Alameda Jasmins 200 702 B Cidade Jardim, BR-40296200 Salvador, BA, Brazil.	robertotude@gmail.com	DI ROCCO, Federico/C-6343-2015; Meyer, Philippe/ABE-4242-2020; ZERAH, Michel/E-6473-2012	Meyer, Philippe/0000-0002-3829-6631; Di Rocco, Federico/0000-0003-2145-5533	CAPES Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES)	The authors acknowledge Mrs. Adeline Noiriat, secretary of the Department of Pediatric Neurosurgery-Hopital Necker-Enfants Malades.; CAPES Brazil (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), Exchange Program for PhD studies, is a source of support.; This study is supported in part by a grant from Direction Regionale de la Recherche Clinique Assistance Publique Hopitaux de Paris PHRC 2003 No. AOM 03018.	Alexandrou G, 2010, PEDIATRICS, V125, pE584, DOI 10.1542/peds.2009-0449; Anderson VA, 2001, PEDIATR NEUROSURG, V34, P138, DOI 10.1159/000056009; Bardella IJ, 1999, AM FAM PHYSICIAN, V60, P1743; Bilotta F, 2009, ANESTHESIOLOGY, V110, P611, DOI 10.1097/ALN.0b013e318198004b; Bochicchio GV, 2007, J TRAUMA, V63, P1353, DOI 10.1097/TA.0b013e31815b83c4; Bochicchio GV, 2005, J TRAUMA, V58, P921, DOI 10.1097/01.TA.0000162141.26392.07; Chiaretti A, 2002, CHILD NERV SYST, V18, P129, DOI 10.1007/s00381-002-0558-3; Chiaretti A, 1998, CHILD NERV SYST, V14, P455, DOI 10.1007/s003810050259; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Danzl D, 2002, SEMIN RESP CRIT CARE, V23, P57, DOI 10.1055/s-2002-20589; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; Ducrocq SC, 2006, PEDIATR CRIT CARE ME, V7, P461, DOI 10.1097/01.PCC.0000235245.49129.27; DURR JA, 1992, DIABETES, V41, P627, DOI 10.2337/diabetes.41.5.627; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; GAILLARD M, 1989, ANN PEDIATR-PARIS, V36, P194; Grinkeviciute DE, 2007, MEDICINA-LITHUANIA, V43, P861, DOI 10.3390/medicina43110111; Hirsch IB, 2002, J CLIN ENDOCR METAB, V87, P975, DOI 10.1210/jc.87.3.975; JENNETT B, 1975, CIBA F SYMP, V34, P3; Jeremitsky E, 2005, J TRAUMA, V58, P47, DOI 10.1097/01.TA.0000135158.42242.B1; KUSHNER M, 1990, ANN NEUROL, V28, P129, DOI 10.1002/ana.410280204; Laird AM, 2004, J TRAUMA, V56, P1058, DOI 10.1097/01.TA.0000123267.39011.9F; LAM AM, 1991, J NEUROSURG, V75, P545, DOI 10.3171/jns.1991.75.4.0545; Marton E, 2007, CHILD NERV SYST, V23, P873, DOI 10.1007/s00381-007-0314-9; MICHAUD LJ, 1991, J TRAUMA, V31, P1356, DOI 10.1097/00005373-199110000-00007; Orliaguet GA, 2008, PEDIATR ANESTH, V18, P455, DOI 10.1111/j.1460-9592.2008.02507.x; Piazza O, 2007, PEDIATR NEUROSURG, V43, P258, DOI 10.1159/000103304; Pierrot M, 2003, ANN FR ANESTH, V22, P12, DOI 10.1016/S0750-7658(02)00003-5; Pillai S, 2001, PEDIATR NEUROSURG, V34, P98, DOI 10.1159/000056002; ROSNER MJ, 1984, J NEUROSURG, V61, P76, DOI 10.3171/jns.1984.61.1.0076; Sung J, 2005, J TRAUMA, V59, P80, DOI 10.1097/01.TA.0000171452.96585.84; Tentillier E, 2004, ANN FR ANESTH, V23, P109, DOI 10.1016/j.annfar.2003.11.019; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vinchon M, 2003, PEDIATR NEUROSURG, V39, P122, DOI 10.1159/000071648	33	23	26	0	2	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	SEP	2010	152	9					1559	1565		10.1007/s00701-010-0680-z			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	642UO	WOS:000281246500017	20461419				2021-06-18	
J	Timmons, SD				Timmons, Shelly D.			Current trends in neurotrauma care	CRITICAL CARE MEDICINE			English	Article						neurotrauma; neurocritical care; traumatic brain injury; hypertonic saline; decompressive craniotomy; hypothermia; beta-blockers	TRAUMATIC BRAIN-INJURY; HYPERTONIC SALINE RESUSCITATION; SEVERE HEAD-INJURY; LACTATED RINGERS SOLUTION; TISSUE OXYGEN-TENSION; EARLY DECOMPRESSIVE CRANIECTOMY; MILD HYPOTHERMIA THERAPY; REFRACTORY INTRACRANIAL HYPERTENSION; 7.5-PERCENT SODIUM-CHLORIDE; CEREBRAL PERFUSION-PRESSURE	Severe traumatic brain injury remains a significant cause of mortality and morbidity worldwide. The use of therapeutic interventions such as hypertonic saline administration and decompressive craniectomy have solid foundations and can improve outcomes, although questions remain about patient selection, optimal timing, and comparisons to other treatments. Hypothermia, while having promise, has not definitively been shown to benefit patients with traumatic brain injury, although clinical trials are underway. The use of beta-blockers in traumatic brain injury has been proposed as a neuroprotective measure, but data are lacking to support widespread clinical use. Brain tissue oxygenation monitoring is gaining widespread acceptance as a safe tool to provide additional information both to guide therapeutic interventions and to further elucidate mechanisms of secondary brain injury. Evidence is also mounting that guided therapy using brain tissue oxygenation in addition to intracranial pressure and cerebral perfusion pressure monitoring leads to better outcomes after traumatic brain injury. (Crit Care Med 2010; 38[Suppl.]: S431-S444)	Univ Tennessee, Hlth Sci Ctr, Div Neurotrauma, Semmes Murphey Neurol & Spine Inst, Memphis, TN 38163 USA	Timmons, SD (corresponding author), Univ Tennessee, Hlth Sci Ctr, Div Neurotrauma, Semmes Murphey Neurol & Spine Inst, Memphis, TN 38163 USA.						Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; AARABI B, 2009, FOCUS, V26, pE8; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Adamo MA, 2009, J NEUROSURG-PEDIATR, V3, P334, DOI 10.3171/2008.12.PEDS08310; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS12; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; Alam HB, 2000, J SURG RES, V94, P145, DOI 10.1006/jsre.2000.6011; Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; Alderson P, 2004, COCHRANE DB SYST REV, DOI [DOI 10.1002/14651858.CD001048.PUB2, 10.1002/14651858.CD001048.pub2]; Alessandri B, 2004, J NEUROSCI METH, V139, P161, DOI 10.1016/j.jneumeth.2004.04.021; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Artru F, 1998, NEUROL RES, V20, pS48; Bardt TF, 1998, ACT NEUR S, V71, P153; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bayir H, 2009, CRIT CARE MED, V37, P689, DOI 10.1097/CCM.0b013e318194abf2; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Berger S, 2002, J TRAUMA, V53, P558, DOI 10.1097/00005373-200209000-00027; BERTONE JJ, 1990, AM J VET RES, V51, P999; BERTONE JJ, 1992, AM J VET RES, V53, P1844; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P126; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS14, DOI 10.1089/neu.2007.9994; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS21; Brasel KJ, 2008, J AM COLL SURGEONS, V206, P220, DOI 10.1016/j.jamcollsurg.2007.07.020; Bratton SL, 2008, J NEUROTRAUM, V25, P276; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; Bulger EM, 2008, ARCH SURG-CHICAGO, V143, P139, DOI 10.1001/archsurg.2007.41; Bulger EM, 2007, ANN SURG, V245, P635, DOI 10.1097/01.sla.0000251367.44890.ae; Bullock MR, 2006, NEUROSURGERY S, V58, pSi; Cairns Chris J S, 2002, Curr Opin Crit Care, V8, P106, DOI 10.1097/00075198-200204000-00003; Chen HI, 2008, NEUROSURGERY, V63, P880, DOI 10.1227/01.NEU.0000327882.10629.06; Childs C, 2006, NEUROCRIT CARE, V5, P10, DOI 10.1385/NCC:5:1:10; Christian E, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E9; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; Clausen T, 2004, BRAIN RES, V1019, P113, DOI 10.1016/j.brainres.2004.05.099; CLIBBARO S, 2007, SURG NEUROL, V68, P632; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1992, J NEUROTRAUM, V9, pS487; Clifton GL, 2001, J NEUROSURG, V95, P751, DOI 10.3171/jns.2001.95.5.0751; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Coplin WM, 2001, J TRAUMA, V50, P1050, DOI 10.1097/00005373-200106000-00013; Coplin WM, 2001, NEUROL RES, V23, P277, DOI 10.1179/016164101101198433; Cormio M, 1999, J NEUROTRAUM, V16, P927, DOI 10.1089/neu.1999.16.927; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Cudd TA, 1998, SHOCK, V10, P32, DOI 10.1097/00024382-199807000-00006; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; De Luca GP, 2000, ACTA NEUROCHIR SUPPL, V76, P401; Deb S, 1999, J TRAUMA, V46, P582, DOI 10.1097/00005373-199904000-00005; DEFIGUEIREDO LFP, 1995, CARDIOVASC SURG, V3, P679; Dine CJ, 2009, EMERG MED CLIN N AM, V27, P137, DOI 10.1016/j.emc.2008.07.003; Dings J, 1998, NEUROL RES, V20, pS71; Dings J, 1997, NEUROL RES, V19, P241, DOI 10.1080/01616412.1997.11740806; Diringer MN, 2007, J NEUROSURG, V106, P526, DOI 10.3171/jns.2007.106.4.526; Einhaus S L, 1996, J Tenn Med Assoc, V89, P81; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Elliott MB, 2009, BRAIN RES, V1305, P183, DOI 10.1016/j.brainres.2009.09.104; Fakhry SM, 2004, J TRAUMA, V56, P492, DOI 10.1097/01.TA.0000115650.07193.66; FANCONY G, 2008, CRIT CARE MED, V36, P295; Figaji AA, 2003, CHILD NERV SYST, V19, P666, DOI 10.1007/s00381-003-0804-3; Figaji AA, 2008, NEUROSURGERY, V63, P83, DOI 10.1227/01.NEU.0000335074.39728.00; Figaji AA, 2008, NEUROSURG FOCUS, V25, DOI 10.3171/FOC.2008.25.10.E4; Froelich M, 2009, CRIT CARE MED, V37, P1433, DOI 10.1097/CCM.0b013e31819c1933; GAAB MR, 1990, ACT NEUR S, V51, P326; Gal R, 2002, CLIN NEUROL NEUROSUR, V104, P318, DOI 10.1016/S0303-8467(02)00023-9; Gooch MR, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS0962; Gopinath SP, 1999, CRIT CARE MED, V27, P2337, DOI 10.1097/00003246-199911000-00003; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GRAND PO, 2000, SCHWEIZ MED WOCHENSC, V30, P1538; Grant FC, 1939, ANN SURG, V110, P488, DOI 10.1097/00000658-193910000-00002; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Gupta AK, 1999, ANESTH ANALG, V88, P549, DOI 10.1097/00000539-199903000-00016; Harris OA, 2002, ARCH NEUROL-CHICAGO, V59, P1077, DOI 10.1001/archneur.59.7.1077; Harris OA, 2009, J NEUROSURG, V110, P1256, DOI 10.3171/2009.1.JNS081320; Hartl R, 1997, ACT NEUR S, V70, P40; Hejazi N, 2002, EUR J PEDIATR, V161, P99, DOI 10.1007/s00431-001-0864-x; Hemphill JC, 2005, AM J NEURORADIOL, V26, P1095; Hemphill JC, 2001, NEUROSURGERY, V48, P377, DOI 10.1097/00006123-200102000-00028; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; Henker RA, 1998, NEUROSURGERY, V42, P1071, DOI 10.1097/00006123-199805000-00071; Hlatky R, 2008, J NEUROSURG, V108, P53, DOI 10.3171/JNS/2008/108/01/0053; Ho CL, 2008, J NEUROSURG, V108, P943, DOI 10.3171/JNS/2008/108/5/0943; Hoelper BM, 2005, ACTA NEUROCHIR, V147, P767, DOI 10.1007/s00701-005-0512-8; Holcroft J W, 1989, Prog Clin Biol Res, V299, P331; HOLCROFT JW, 1987, ANN SURG, V206, P279, DOI 10.1097/00000658-198709000-00006; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; HUANG PP, 1995, ANN SURG, V221, P543, DOI 10.1097/00000658-199505000-00012; Hukkelhoven CWPM, 2002, J NEUROSURG, V97, P549, DOI 10.3171/jns.2002.97.3.0549; Hutchinson Peter, 2007, Neurosurg Focus, V22, pE14; Hutchison JS, 2008, NEW ENGL J MED, V358, P2447, DOI 10.1056/NEJMoa0706930; Imberti R, 2005, J NEUROSURG, V102, P455, DOI 10.3171/jns.2005.102.3.0455; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Jaeger M, 2005, ACTA NEUROCHIR, V147, P51, DOI 10.1007/s00701-004-0408-z; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; KERR FWL, 1968, MAYO CLIN PROC, V43, P852; Kerwin AJ, 2009, J TRAUMA, V67, P277, DOI 10.1097/TA.0b013e3181acc726; Kiening KL, 1997, NEUROL RES, V19, P233, DOI 10.1080/01616412.1997.11740805; Kilpatrick MM, 2000, NEUROSURGERY, V47, P850, DOI 10.1097/00006123-200010000-00011; Kontopoulos V, 2002, ACTA NEUROCHIR, V144, P791, DOI 10.1007/s00701-002-0948-z; Kunze E, 1998, ACT NEUR S, V71, P16; Leal-Noval SR, 2006, INTENS CARE MED, V32, P1733, DOI 10.1007/s00134-006-0376-2; Lescot T, 2006, CRIT CARE MED, V34, P3029, DOI 10.1097/01.CCM.0000243797.42346.64; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; Liu WG, 2006, J INT MED RES, V34, P58, DOI 10.1177/147323000603400107; MANINGAS PA, 1989, AM J SURG, V157, P528, DOI 10.1016/0002-9610(89)90654-5; Marion DW, 2006, NEUROSURGERY, V58, P655; Marion DW, 2004, CRIT CARE MED, V32, pS43, DOI 10.1097/01.CCM.0000110731.69637.16; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARMAROU A, 1992, J NEUROTRAUM, V9, pS327; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Martini RP, 2009, J NEUROSURG, V111, P644, DOI 10.3171/2009.2.JNS08998; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; Mayzler O, 2006, J NEUROSURG ANESTH, V18, P24, DOI 10.1097/01.ana.0000188358.41284.cb; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Meier U, 2000, ACTA NEUROCHIR SUPPL, V76, P475; MELLERGARD P, 1990, NEUROSURGERY, V27, P654, DOI 10.1227/00006123-199010000-00029; MELLERGARD P, 1992, NEUROSURGERY, V31, P671; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; Messina AR, 2003, ELECTR POW SYST RES, V64, P17, DOI 10.1016/S0378-7796(02)00151-7; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Munch E, 2000, NEUROSURGERY, V47, P315; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Narotam PK, 2009, J NEUROSURG, V111, P672, DOI 10.3171/2009.4.JNS081150; Narotam PK, 2008, J NEUROSURG, V109, P1065, DOI 10.3171/JNS.2008.109.12.1065; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Nortje J, 2008, CRIT CARE MED, V36, P273, DOI 10.1097/01.CCM.0000292014.60835.15; Oddo M, 2009, J NEUROL NEUROSUR PS, V80, P916, DOI 10.1136/jnnp.2008.156596; OGATA H, 1993, CIRC SHOCK, V41, P113; Pascual JL, 2003, J TRAUMA, V54, pS133, DOI 10.1097/01.TA.0000064526.33647.63; Pascual JL, 2003, J TRAUMA, V54, P121, DOI 10.1097/00005373-200301000-00015; Pascual JL, 2002, ANN SURG, V236, P634, DOI 10.1097/00000658-200211000-00014; PASCUAL JMS, 1992, CRIT CARE MED, V20, P200, DOI 10.1097/00003246-199202000-00009; Pascual JL, 2008, AM SURGEON, V74, P253; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Piepgras A, 1998, NEUROSURGERY, V42, P311, DOI 10.1097/00006123-199802000-00058; Pinto FCG, 2006, J TRAUMA, V60, P758, DOI 10.1097/01.ta.0000214581.89316.73; Polderman KH, 2008, LANCET, V371, P1955, DOI 10.1016/S0140-6736(08)60837-5; Polderman KH, 2004, INTENS CARE MED, V30, P1860, DOI 10.1007/s00134-004-2383-5; Polderman KH, 2002, INTENS CARE MED, V28, P1563, DOI 10.1007/s00134-002-1511-3; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PROUGH DS, 1985, CRIT CARE MED, V13, P407, DOI 10.1097/00003246-198505000-00008; Qiu Wu-si, 2005, Chin J Traumatol, V8, P27; Qiu Wu-si, 2006, Chin J Traumatol, V9, P238; Qiu W, 2007, J CRIT CARE, V22, P229, DOI 10.1016/j.jcrc.2006.06.011; Qiu WS, 2006, J CLIN NEUROSCI, V13, P995, DOI 10.1016/j.jocn.2006.02.027; Quigley A, 2009, BRAIN RES, V1304, P138, DOI 10.1016/j.brainres.2009.09.062; Qureshi AI, 1999, J TRAUMA, V47, P659, DOI 10.1097/00005373-199910000-00009; RAMIRES JAF, 1992, CIRC SHOCK, V37, P220; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; RANSOHOFF J, 1971, J NEUROL NEUROSUR PS, V34, P106, DOI 10.1136/jnnp.34.1.106-a; Reithmeier T, 2005, CHILD NERV SYST, V21, P249, DOI 10.1007/s00381-004-1044-x; RESNICK DK, 1994, NEUROSURGERY, V34, P252, DOI 10.1227/00006123-199402000-00007; Rhee P, 2000, CRIT CARE MED, V28, P74, DOI 10.1097/00003246-200001000-00012; Rhee P, 1998, J TRAUMA, V44, P313, DOI 10.1097/00005373-199802000-00014; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Rockswold GL, 2009, NEUROSURGERY, V65, P1035, DOI 10.1227/01.NEU.0000359533.16214.04; Rockswold SB, 2010, J NEUROSURG, V112, P1080, DOI 10.3171/2009.7.JNS09363; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rossi S, 2001, J NEUROL NEUROSUR PS, V71, P448, DOI 10.1136/jnnp.71.4.448; Rozet I, 2007, ANESTHESIOLOGY, V107, P697, DOI 10.1097/01.anes.0000286980.92759.94; Rubiano AM, 2009, ULUS TRAVMA ACIL CER, V15, P28; Ruf B, 2003, CRIT CARE, V7, pR133, DOI 10.1186/cc2361; Sahuquillo J, 2009, INTENS CARE MED, V35, P890, DOI 10.1007/s00134-008-1357-4; Sakowitz OW, 2007, J TRAUMA, V62, P292, DOI 10.1097/01.ta.0000203560.03937.2d; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; SCHMALL LM, 1990, EQUINE VET J, V22, P273, DOI 10.1111/j.2042-3306.1990.tb04266.x; SCHMALL LM, 1990, EQUINE VET J, V22, P278, DOI 10.1111/j.2042-3306.1990.tb04267.x; SCHMOKER JD, 1991, J TRAUMA, V31, P1607, DOI 10.1097/00005373-199112000-00007; Schneider GH, 2002, ACT NEUR S, V81, P77; Sell SL, 2008, ANESTHESIOLOGY, V108, P873, DOI 10.1097/ALN.0b013e31816c8a15; Shackford SR, 1998, J TRAUMA, V44, P50, DOI 10.1097/00005373-199801000-00004; Shackford SR, 1997, J TRAUMA, V42, pS48, DOI 10.1097/00005373-199705001-00009; Sheikh AA, 1996, CRIT CARE MED, V24, P1226, DOI 10.1097/00003246-199607000-00027; SHIGEMORI M, 1980, ACTA NEUROCHIR, V54, P61, DOI 10.1007/BF01401944; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Shiozaki T, 2001, J NEUROSURG, V94, P50, DOI 10.3171/jns.2001.94.1.0050; Simma B, 1998, CRIT CARE MED, V26, P1265, DOI 10.1097/00003246-199807000-00032; Skoglund TS, 2006, J NEUROTRAUM, V23, P1502, DOI 10.1089/neu.2006.23.1502; Smith MJ, 2005, CRIT CARE MED, V33, P1104, DOI 10.1097/01.CCM.0000162685.60609.49; Smrcka M, 2005, ACT NEUR S, V95, P273; Soukiasian HJ, 2002, AM SURGEON, V68, P1066; Soustiel JF, 2006, BRAIN RES, V1101, P136, DOI 10.1016/j.brainres.2006.05.045; SPIERS JP, 1993, CIRC SHOCK, V40, P29; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stiefel MF, 2005, J NEUROSURG, V103, P805, DOI 10.3171/jns.2005.103.5.0805; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; Stiefel MF, 2006, J NEUROSURG, V105, P281, DOI 10.3171/ped.2006.105.4.281; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Stocchetti N, 2002, INTENS CARE MED, V28, P1555, DOI 10.1007/s00134-002-1513-1; Stone JG, 1997, NEUROSURGERY, V41, P20, DOI 10.1097/00006123-199707000-00007; Subrato D, 2000, J TRAUMA, V49, P47, DOI 10.1097/00005373-200007000-00007; Sydenham E, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001048.pub3; Tateishi A, 1998, NEUROSURGERY, V42, P1065, DOI 10.1097/00006123-199805000-00066; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Taylor Edward E, 2008, Proc (Bayl Univ Med Cent), V21, P120; Taylor G, 1996, J PEDIATR SURG, V31, P65, DOI 10.1016/S0022-3468(96)90321-8; TEASDALE G, 1974, LANCET, V2, P81; Thompson HJ, 2003, NEUROBIOL DIS, V12, P163, DOI 10.1016/S0969-9961(02)00030-X; Thompson HJ, 2003, J NEUROL NEUROSUR PS, V74, P614, DOI 10.1136/jnnp.74.5.614; Thorat JD, 2008, J CLIN NEUROSCI, V15, P143, DOI 10.1016/j.jocn.2006.08.014; TIMMONS SD, NEUROLOGICAL SURG CO; Timofeev I, 2008, J NEUROSURG, V108, P66, DOI 10.3171/JNS/2008/108/01/0066; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Tokutomi T, 2009, J TRAUMA, V66, P166, DOI 10.1097/TA.0b013e318157dbec; Tolias CM, 2004, J NEUROSURG, V101, P435, DOI 10.3171/jns.2004.101.3.0435; Tortorici MA, 2007, CRIT CARE MED, V35, P2196, DOI 10.1097/01.CCM.0000281517.97507.6E; Ucar T, 2005, J NEUROTRAUM, V22, P1311, DOI 10.1089/neu.2005.22.1311; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Valadka AB, 1998, CRIT CARE MED, V26, P1576, DOI 10.1097/00003246-199809000-00029; Valadka AB, 2002, ACT NEUR S, V81, P299; Valadka AB, 2000, J TRAUMA, V49, P1, DOI 10.1097/00005373-200007000-00001; van den Brink WA, 2000, NEUROSURGERY, V46, P868, DOI 10.1097/00006123-200004000-00018; vanSantbrink H, 1996, NEUROSURGERY, V38, P21, DOI 10.1097/00006123-199601000-00007; Varon J, 2008, CHEST, V133, P1267, DOI 10.1378/chest.07-2190; VASSAR MJ, 1991, ARCH SURG-CHICAGO, V126, P1065; VASSAR MJ, 1993, J TRAUMA, V34, P622, DOI 10.1097/00005373-199305000-00003; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; Wade CE, 1997, SURGERY, V122, P609, DOI 10.1016/S0039-6060(97)90135-5; WALSH JC, 1991, J SURG RES, V50, P284, DOI 10.1016/0022-4804(91)90192-O; Wang H, 2004, J NEUROSURG, V100, P272, DOI 10.3171/jns.2004.100.2.0272; Ware ML, 2005, NEUROSURGERY, V57, P727, DOI 10.1227/01.NEU.0000175726.08903.OA; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Whitfield PC, 2001, BRIT J NEUROSURG, V15, P500, DOI 10.1080/02688690120105110; Whitfield PC, 2001, NEUROSURGERY, V49, P225, DOI 10.1097/00006123-200107000-00042; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; WISNER DH, 1990, J TRAUMA, V30, P75, DOI 10.1097/00005373-199001000-00011; Woertgen C, 2004, ACTA NEUROCHIR, V146, P691, DOI 10.1007/s00701-004-0280-x; WORTHLEY LIG, 1988, J NEUROSURG, V68, P478, DOI 10.3171/jns.1988.68.3.0478; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P616, DOI 10.2176/nmc.33.616; YAMAURA A, 1979, Neurologia Medico-Chirurgica, V19, P717, DOI 10.2176/nmc.19.717; Yan Y, 2001, Chin J Traumatol, V4, P8; Yan Y, 2010, J CLIN NEUROSCI, V17, P196, DOI 10.1016/j.jocn.2009.05.022; Yang XF, 2008, ACTA NEUROCHIR, V150, P1241, DOI 10.1007/s00701-008-0145-9; Yilmaz N, 2007, BRAIN RES, V1164, P132, DOI 10.1016/j.brainres.2007.06.017; YOUNES RN, 1992, SURGERY, V111, P380; Zhi DS, 2003, SURG NEUROL, V59, P381, DOI 10.1016/S0090-3019(03)00148-4; ZHU V, 2003, CHIN J TRAUMATOL, V6, P152; ZORNOW MH, 1989, J TRAUMA, V29, P484, DOI 10.1097/00005373-198904000-00011; Zygun DA, 2009, CRIT CARE MED, V37, P1074, DOI 10.1097/CCM.0b013e318194ad22	252	23	23	0	7	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	SEP	2010	38	9		S			S431	S444		10.1097/CCM.0b013e3181ec57ab			14	Critical Care Medicine	General & Internal Medicine	647FB	WOS:000281602100004	20724876				2021-06-18	
J	Guerrero, AF; Alfonso, A				Guerrero, Arthur F.; Alfonso, Abel			Traumatic Brain Injury-Related Hypopituitarism: A Review and Recommendations for Screening Combat Veterans	MILITARY MEDICINE			English	Article							ANTERIOR-PITUITARY FUNCTION; DIABETES-INSIPIDUS; STALK RUPTURE; ACUTE-PHASE; DYSFUNCTION; INSUFFICIENCY; CHILD	Recent civilian data obtained in those sustaining head injuries, has found a high prevalence of pituitary dysfunction. Currently, there is no data available in the military population. We reviewed the literature for traumatic brain injury (TBI)-related hypopituitarism and found that the prevalence of anterior hypopituitarism may be as high as 30-80% after 24-36 months. Since many of the symptoms of hypopituitarism are similar to those of TBI, it is important to make clinicians caring for combat veterans aware of its occurrence. Herein, we provide an overview of the literature and recommendations for hormonal testing when TBI-related hypopituitarism is suspected.	[Guerrero, Arthur F.; Alfonso, Abel] Walter Reed Army Med Ctr, Dept Internal Med, Endocrinol Diabet & Metab Serv, Washington, DC 20307 USA	Guerrero, AF (corresponding author), Walter Reed Army Med Ctr, Dept Internal Med, Endocrinol Diabet & Metab Serv, 6900 Georgia Ave NW, Washington, DC 20307 USA.						Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Agha Amar, 2005, Am J Med, V118, P1416; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; BISTRITZER T, 1981, AM J DIS CHILD, V135, P966, DOI 10.1001/archpedi.1981.02130340070022; Bondanelli M, 2005, EUR J ENDOCRINOL, V152, P679, DOI 10.1530/eje.1.01895; Bondanelli M, 2004, J NEUROTRAUM, V21, P685, DOI 10.1089/0897715041269713; Chen YC, 2009, J NEUROTRAUM, V26, P861, DOI 10.1089/neu.2008.0645; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Dusick J. R., 2008, PITUITARY; Ghigo E, 2005, BRAIN INJURY, V19, P711, DOI 10.1080/02699050400025315; Giordano Giulio, 2005, Pituitary, V8, P227, DOI 10.1007/s11102-006-6045-1; GIRARD J, 1977, J PEDIATR-US, V90, P241, DOI 10.1016/S0022-3476(77)80637-9; HALIMI P, 1988, J COMPUT ASSIST TOMO, V12, P135, DOI 10.1097/00004728-198801000-00026; Iglesias P, 1996, J ENDOCRINOL INVEST, V19, P320, DOI 10.1007/BF03347870; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Kleindienst A, 2009, J NEUROTRAUM, V26, P1435, DOI 10.1089/neu.2008.0601; KLINGBEIL GEG, 1985, ARCH PHYS MED REHAB, V66, P44; Klose M, 2007, CLIN ENDOCRINOL, V67, P598, DOI 10.1111/j.1365-2265.2007.02931.x; Lew HL, 2005, J REHABIL RES DEV, V42, pXIII, DOI 10.1682/JRRD.2005.07.0124; MASSOL J, 1987, NEURORADIOLOGY, V29, P299, DOI 10.1007/BF00451773; Mayorga MA, 1997, TOXICOLOGY, V121, P17, DOI 10.1016/S0300-483X(97)03652-4; MILLER WL, 1980, NEW ENGL J MED, V302, P724, DOI 10.1056/NEJM198003273021305; Schneider M, 2008, CLIN ENDOCRINOL, V68, P206, DOI 10.1111/j.1365-2265.2007.03020.x; Scott SG, 2006, J AM OSTEOPATH ASSOC, V106, P265; Tanriverdi F, 2008, CLIN ENDOCRINOL, V68, P573, DOI 10.1111/j.1365-2265.2007.03070.x; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009	31	23	23	0	6	ASSOC MILITARY SURG US	BETHESDA	9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA	0026-4075			MIL MED	Milit. Med.	AUG	2010	175	8					574	580		10.7205/MILMED-D-09-00189			7	Medicine, General & Internal	General & Internal Medicine	632VB	WOS:000280456000008	20731261	Bronze			2021-06-18	
J	Krause, JS; Saunders, LL; Newman, S				Krause, James S.; Saunders, Lee L.; Newman, Susan			Posttraumatic Stress Disorder and Spinal Cord Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Depression; Factor analysis, statistical; Rehabilitation; Spinal cord injuries; Stress disorders, post-traumatic	TRAUMATIC BRAIN-INJURY; RISK-FACTORS; EVENT SCALE; DEPRESSION; PREVALENCE; DISTRESS; VETERANS; ALCOHOL; IMPACT; LOCUS	Objectives: To identify the prevalence of posttraumatic stress disorder (PTSD) after spinal cord injury (SCI) in a sample averaging over 2 decades postinjury at assessment. Related objectives are to confirm the factor structure, compare subscales with those reported in a nonclinical sample, and identify the relationship of PTSD with depression. Design: Survey. Setting: A medical university in the Southeastern United States. Participants: Participants were initially identified through specialty hospitals in the Midwest and Southeastern United States. A cohort of adults (N=927) with traumatic SCI of at least 1 year duration at enrollment in 2002 to 2003 and a minimum of 7 years at the time of assessment completed the study materials. Interventions: Not applicable. Main Outcomes Measures: PTSD was measured by the Purdue Posttraumatic Stress Disorder Scale-Revised, and depression was measured by the Patient Health Questionnaire 9-item. Results: PTSD was reported by less than 10% of the participants. Item endorsement decreased as a function of years postinjury, primarily because of low rates of endorsement among those 21 or more years postinjury. Confirmatory factor analysis did not result in an acceptable fit for subscales, item sets, or factors previously reported in the literature. Participants scored higher than a nonclinical sample (reported in the literature) on the arousal and avoidance subscales but lower on the re-experiencing subscale. Item endorsements were lower for the first set of items that relate directly to the SCI itself, with the highest item endorsement for "have difficulty remembering important aspects of event." PTSD rarely occurred in the absence of a depressive disorder. Conclusions: PTSD does not appear to be highly prevalent in long-term SCI survivors, and endorsement of items related to re-experiencing and even recalling the injury are rare. Because SCI often is accompanied by mild traumatic brain injury, difficulty recalling the event may have an organic rather than psychologic component.	[Krause, James S.] Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, Charleston, SC 29425 USA	Krause, JS (corresponding author), Med Univ S Carolina, Dept Hlth Sci & Res, Coll Hlth Profess, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.	krause@musc.edu			Department of Education, National Institute of Disability and Rehabilitation Research [H133G060126]	Supported by the Department of Education, National Institute of Disability and Rehabilitation Research (grant no. H133G060126). The contents of this publication do not necessarily represent the policy of the Department of Education, and you should not assume endorsement by the Federal Government.	Agar E, 2006, BEHAV COGN PSYCHOTH, V34, P437, DOI 10.1017/S1352465806002943; American Psychiatric Association (APA), 1994, DIAGN STAT MAN MENT, V4th; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Browne M.W., 1993, TESTING STRUCTURAL E, P136, DOI DOI 10.1177/0049124192021002005; Chung MC, 2007, PSYCHIAT RES, V152, P253, DOI 10.1016/j.psychres.2004.09.013; Chung MC, 2006, J AFFECT DISORDERS, V93, P229, DOI 10.1016/j.jad.2006.02.021; Foa EB, 1997, PSYCHOL ASSESSMENT, V9, P445, DOI 10.1037/1040-3590.9.4.445; Garrison A, 2004, J SPINAL CORD MED, V27, P111, DOI 10.1080/10790268.2004.11753740; Goldman RL, 2008, REHABIL PSYCHOL, V53, P162, DOI 10.1037/0090-5550.53.2.162; Hartsough D. M., 1988, SCREENING SCALE ESTI; Hatcher MB, 2009, BRIT J HEALTH PSYCH, V14, P541, DOI 10.1348/135910708X373445; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Joseph S, 2000, J TRAUMA STRESS, V13, P101, DOI 10.1023/A:1007777032063; Jurisic B, 2009, CRISIS, V30, P34, DOI 10.1027/0227-5910.30.1.34; Kennedy P, 2003, BRIT J CLIN PSYCHOL, V42, P41, DOI 10.1348/014466503762842002; Kennedy P, 2001, SPINAL CORD, V39, P1, DOI 10.1038/sj.sc.3101100; Kessler RC, 2005, ARCH GEN PSYCHIAT, V62, P593, DOI 10.1001/archpsyc.62.6.593; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kulka R. A., 1990, TRAUMA VIETNAM WAR G; LAUTERBACH D, 1996, ASSESSMENT, V3, P17, DOI DOI 10.1177/107319119600300102; Lude P, 2005, SPINAL CORD, V43, P102, DOI 10.1038/sj.sc.3101688; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Martz E, 2005, REHABIL PSYCHOL, V50, P149, DOI 10.1037/0090-5550.50.2.149; MCFALL ME, 1991, PSYCHOSOCIAL PROCESS, V4, P88; Migliorini C, 2008, AUST NZ J PSYCHIAT, V42, P309, DOI 10.1080/00048670801886080; National Spinal Cord Injury Statistical Center (NSCISC), 2009, ANN STAT REP; Nielsen MS, 2003, SPINAL CORD, V41, P296, DOI 10.1038/sj.sc.3101427; Nielsen MS, 2003, REHABIL PSYCHOL, V48, P289, DOI 10.1037/0090-5550.48.4.289; Orsillo S. M., 2001, PRACTITIONERS GUIDE, P255, DOI DOI 10.1007/0-306-47628-2_20; Radnitz C., 2000, INT J REHABILITATION, V5, P195, DOI DOI 10.1023/A:1012903406285; Radnitz CL, 2000, J ANXIETY DISORD, V14, P313, DOI 10.1016/S0887-6185(00)00025-6; Radnitz CL, 1998, J TRAUMA STRESS, V11, P505, DOI 10.1023/A:1024404729251; Tate DG, 2004, ARCH PHYS MED REHAB, V85, P1837, DOI 10.1016/j.apmr.2004.02.022; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; *US DEP VET AFF, 2009, NAT CTR PTSD CLIN AD; *US DEP VET AFF, 2010, PTSD CHECKL; Weiss DS, 1996, IMPACT EVENTS SCALE, P399	38	23	24	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	AUG	2010	91	8					1182	1187		10.1016/j.apmr.2010.05.012			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	642BT	WOS:000281178900005	20684898				2021-06-18	
J	Levine, RL; Hergenroeder, GW; Francis, JL; Miller, CC; Hursting, MJ				Levine, Robert L.; Hergenroeder, Georgene W.; Francis, John L.; Miller, Charles C.; Hursting, Marcie J.			Heparin-platelet factor 4 antibodies in intensive care patients: an observational seroprevalence study	JOURNAL OF THROMBOSIS AND THROMBOLYSIS			English	Article						Heparin; Platelet factor 4; Antibody; Prevalence; Heparin-induced thrombocytopenia	CRITICALLY-ILL PATIENTS; INDUCED THROMBOCYTOPENIA; THROMBOSIS; RISK; ASSOCIATION; POPULATION; PREVALENCE; FREQUENCY; ARTERIAL	Heparin-platelet factor 4 (PF4) antibodies mediate heparin-induced thrombocytopenia (HIT) and, irrespective of thrombocytopenia, are associated with poorer outcomes in some patients. The prevalence of heparin-PF4 antibodies, including platelet-activating ones, in patients in the medical, neurotrauma, or shock-trauma intensive care unit (ICU) remains unclear. In this single-center, observational study, heparin-PF4 antibodies (IgG/A/M) were measured by ELISA in 185 adults (median APACHE II score, 16) admitted to the medical (n = 27), neurotrauma (n = 96), or shock-trauma (n = 62) ICU and after 7 +/- A 2 days. Seropositive patients and heparin-treated patients with unexplained, new-onset thrombocytopenia were also tested for platelet-activating antibodies using a serotonin release assay (SRA). Of 185 patients, seropositivity occurred in 20 patients (10.8%; 95% CI 6.7-16.2%) at admission and 54 (29.2%, 95% CI 22.8-36.3%) after 7 days (P < 0.001). Platelet-activating antibodies occurred in 4 seropositive patients at admission and 9 seropositive patients after 7 days (including in 1 patient at each assessment), each without thrombocytopenia or new thrombosis. Of 12 seropositive patients with platelet-activating antibodies, 6 had an ELISA optical density (OD) > 1.0. ELISA-positive, SRA-negative, suspected HIT occurred in 1 patient. Heparin-PF4 antibodies are present in 10.8% of medical, neurotrauma, or shock-trauma ICU patients at admission and increase significantly to 29.2% within 7 days. Approximately 17-20% of seropositive ICU patients, often those with an ELISA OD > 1.0, have platelet-activating heparin-PF4 antibodies.	[Hursting, Marcie J.] Clin Sci Consulting, Austin, TX 78746 USA; [Hergenroeder, Georgene W.] Univ Texas Med Sch Houston, Dept Neurosurg, Houston, TX USA; [Levine, Robert L.] Methodist Hosp, Houston, TX 77030 USA; [Francis, John L.] Florida Hosp Inst Translat Res, Orlando, FL USA	Hursting, MJ (corresponding author), Clin Sci Consulting, 3001 Loveland Cove, Austin, TX 78746 USA.	mhursting@sprintmail.com		Hergenroeder, Georgene/0000-0002-6170-2191	GlaxoSmithKlineGlaxoSmithKline	This study was supported by a grant from GlaxoSmithKline. Dr. Levine and Dr. Francis have received grant support and consultancy fees from GlaxoSmithKline. Dr. Hursting has received consultancy fees from GlaxoSmithKline. Ms. Hergenroeder and Dr. Miller have no conflicts of interest related to this study.	Arepally GM, 2008, J THROMB THROMBOLYS, V26, P55, DOI 10.1007/s11239-008-0217-y; Bennett-Guerrero E, 2005, J THORAC CARDIOV SUR, V130, P1567, DOI 10.1016/j.jtcvs.2005.07.052; Calaitges JG, 1999, J VASC SURG, V29, P779, DOI 10.1016/S0741-5214(99)70203-X; Crowther MA, 2005, J CRIT CARE, V20, P348, DOI 10.1016/j.jcrc.2005.09.008; Dattalo P., 2008, DETERMINING SAMPLE S; de la Vega LP, 2005, MAYO CLIN PROC, V80, P995, DOI 10.4065/80.8.995; Everett BM, 2007, ANN THORAC SURG, V83, P592, DOI 10.1016/j.athoracsur.2006.09.040; Francis JL, 2004, SEMIN THROMB HEMOST, V30, P359, DOI 10.1055/s-2004-831049; Geerts WH, 2008, CHEST, V133, p381S, DOI 10.1378/chest.08-0656; Gettings EM, 2006, CRIT CARE, V10, DOI 10.1186/cc5100; Greinacher A, 2005, BLOOD, V106, P2921, DOI 10.1182/blood-2005-05-1824; Hirsh J, 2004, ARCH INTERN MED, V164, P361, DOI 10.1001/archinte.164.4.361; Hourigan LA, 2002, J HEART LUNG TRANSPL, V21, P1283, DOI 10.1016/S1053-2498(02)00458-8; Kearon C, 2008, CHEST, V133, p454S, DOI 10.1378/chest.08-0658; Keeling D, 2006, BRIT J HAEMATOL, V133, P259, DOI 10.1111/j.1365-2141.2006.06018.x; Kress DC, 2007, ANN THORAC SURG, V83, P1737, DOI 10.1016/j.athoracsur.2006.12.011; Levy JH, 2007, HEMATOL ONCOL CLIN N, V21, P65, DOI 10.1016/j.hoc.2006.11.003; Lo GK, 2007, AM J HEMATOL, V82, P1037, DOI 10.1002/ajh.21032; Mascelli MA, 2005, J THROMB THROMBOLYS, V18, P171, DOI 10.1007/s11239-005-0342-9; Mattioli A V, 2000, Ital Heart J, V1, P39; Mullen MP, 2008, ANESTH ANALG, V107, P371, DOI 10.1213/ane.0b013e3181734604; Napolitano LM, 2006, CRIT CARE MED, V34, P2898, DOI 10.1097/01.CCM.0000248723.18068.90; Risch L, 2003, BLOOD COAGUL FIBRIN, V14, P113, DOI 10.1097/00001721-200301000-00020; Schmugge M, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.1.e10; Scott JR, 2007, J BURN CARE RES, V28, P71, DOI 10.1097/BCR.0b013E31802C8929; Selleng K, 2007, CRIT CARE MED, V35, P1165, DOI 10.1097/01.CCM.0000259538.02375.A5; Shalansky SJ, 2002, PHARMACOTHERAPY, V22, P803, DOI 10.1592/phco.22.11.803.33634; Verma AK, 2003, PHARMACOTHERAPY, V23, P745, DOI 10.1592/phco.23.6.745.32188; Warkentin TE, 2000, BLOOD, V96, P1703, DOI 10.1182/blood.V96.5.1703.h8001703_1703_1708; Warkentin TE, 2008, CHEST, V133, p340S, DOI 10.1378/chest.08-0677; Warkentin TE, 2008, AM J MED, V121, P632, DOI 10.1016/j.amjmed.2008.03.012; Williams RT, 2003, CIRCULATION, V107, P2307, DOI 10.1161/01.CIR.0000066696.57519.AF; Zwicker JI, 2004, J THROMB HAEMOST, V2, P2133, DOI 10.1111/j.1538-7836.2004.01039.x	33	23	26	0	1	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0929-5305	1573-742X		J THROMB THROMBOLYS	J. Thromb. Thrombolysis	AUG	2010	30	2					142	148		10.1007/s11239-009-0425-0			7	Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease	Cardiovascular System & Cardiology; Hematology	630GZ	WOS:000280262500004	19911252				2021-06-18	
J	Rienstra, A; Spaan, PEJ; Schmand, B				Rienstra, A.; Spaan, P. E. J.; Schmand, B.			Validation of Symptom Validity Tests Using a "Child-model" of Adult Cognitive Impairments	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						symptom validity testing; validity; Amsterdam Short-Term Memory test; Word Memory Test; Test of Memory Malingering; Word Completion Memory Test	WORD MEMORY TEST; TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL TESTS; RECOGNITION MEMORY; MALINGERING TOMM; TEST-PERFORMANCE; CLAIMANTS; FAMILIAR; SAMPLE; SPAN	Validation studies of symptom validity tests (SVTs) in children are uncommon. However, since children's cognitive abilities are not yet fully developed, their performance may provide additional support for the validity of these measures in adult populations. Four SVTs, the Test of Memory Malingering (TOMM), the Word Memory Test (WMT), the Amsterdam Short-Term Memory (ASTM) test, and the Word Completion Memory Test (WCMT), along with several neuropsychological instruments were administered to 48 Dutch school children aged 7-12. All children scored above the established adult cut-offs on the TOMM and the WMT. They could pass the ASTM test if their reading skills were at a level equivalent to that of 9 year olds. All children passed our criterion of a negative WCMT score. However, the WCMT does seem sensitive to the level of verbal fluency. Implications for the applicability of these SVTs in adult populations are discussed.	[Rienstra, A.; Schmand, B.] Univ Amsterdam, Acad Med Ctr, Dept Neurol, NL-1105 AZ Amsterdam, Netherlands; [Rienstra, A.; Spaan, P. E. J.; Schmand, B.] Univ Amsterdam, Dept Psychon, Amsterdam, Netherlands	Rienstra, A (corresponding author), Acad Med Ctr, Dept Neurol H2 222, POB 22660, NL-1100 DD Amsterdam, Netherlands.	a.rienstra@amc.uva.nl		Spaan, Pauline/0000-0001-5858-2419	Psychology Research Institute University of Amsterdam	This work was supported by Psychology Research Institute University of Amsterdam.	ALLEN LM, 1999, 1999 COMPUTERIZED AS; Anglin J. M., 1993, MONOGR SOC RES CHILD, V58, pi, DOI [10.2307/1166112, DOI 10.2307/1166112]; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Baayen R. H., 1995, The CELEX lexical database. Linguistic data consortium; BARON IS, 1995, PEDIAT NEUROPSYCHOLO; Benton A., 1976, MULTILINGUAL APHASIA; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Blaskewitz N, 2008, ARCH CLIN NEUROPSYCH, V23, P379, DOI 10.1016/j.acn.2008.01.008; Bolan B, 2002, J CLIN EXP NEUROPSYC, V24, P154, DOI 10.1076/jcen.24.2.154.1000; Brandt KR, 2005, APPL COGNITIVE PSYCH, V19, P1113, DOI 10.1002/acp.1163; Brockhaus R, 2004, NERVENARZT, V75, P882, DOI 10.1007/s00115-003-1592-4; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; CERCY SP, 1997, CLIN ASSESSMENT MALI; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Courtney JC, 2003, CHILD NEUROPSYCHOL, V9, P109, DOI 10.1076/chin.9.2.109.14507; Donders J, 2005, CHILD NEUROPSYCHOL, V11, P221, DOI 10.1080/09297040490917298; FAUST D, 1988, PROF PSYCHOL-RES PR, V19, P508, DOI 10.1037/0735-7028.19.5.508; Flaro L, 2000, ARCH CLIN NEUROPSYCH, V15, P840, DOI 10.1016/S0887-6177(00)80344-3; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gorissen M, 2005, SCHIZOPHR RES, V78, P199, DOI 10.1016/j.schres.2005.02.016; Green P, 2003, CHILD NEUROPSYCHOL, V9, P189, DOI 10.1076/chin.9.3.189.16460; Green P, 1999, BRAIN INJURY, V13, P813, DOI 10.1080/026990599121205; Hall H. V., 1996, DETECTING MALINGERIN, P3; Hartman DE, 2002, ARCH CLIN NEUROPSYCH, V17, P709, DOI 10.1016/S0887-6177(01)00172-X; Hilsabeck R. C., 1997, WORD COMPLETION MEMO; Hilsabeck RC, 2001, ARCH CLIN NEUROPSYCH, V16, P669, DOI 10.1016/S0887-6177(00)00077-9; Howe LLS, 2007, ARCH CLIN NEUROPSYCH, V22, P753, DOI 10.1016/j.acn.2007.06.003; HULME C, 1991, J MEM LANG, V30, P685, DOI 10.1016/0749-596X(91)90032-F; Iverson G. L., 1999, J COGNITIVE REHABILI, V17, P4; Iverson GL, 2000, J HEAD TRAUMA REHAB, V15, P829, DOI 10.1097/00001199-200004000-00006; Iverson GL, 1996, J CLIN EXP NEUROPSYC, V18, P38, DOI 10.1080/01688639608408260; JACOBY LL, 1991, J MEM LANG, V30, P513, DOI 10.1016/0749-596X(91)90025-F; KOHNSTAMM GA, 1981, NIEUWE STREEFLIJST W; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lu PH, 2002, CLIN NEUROPSYCHOL, V16, P90, DOI 10.1076/clin.16.1.90.8328; MacAllister WS, 2009, CHILD NEUROPSYCHOL, V15, P521, DOI 10.1080/09297040902748226; Macciocchi SN, 2006, ARCH CLIN NEUROPSYCH, V21, P395, DOI 10.1016/j.acn.2006.06.003; Mathias CW, 2002, ASSESSMENT, V9, P301, DOI 10.1177/1073191102009003009; Merten T, 2005, ARCH CLIN NEUROPSYCH, V20, P719, DOI 10.1016/j.acn.2005.04.004; Merten T, 2007, J CLIN EXP NEUROPSYC, V29, P308, DOI 10.1080/13803390600693607; Nagle AM, 2006, ARCH CLIN NEUROPSYCH, V21, P777, DOI 10.1016/j.acn.2006.06.011; PHAF RH, 1991, SPONTANEOUS COMPLETI; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Reitan R. M., 1992, TRAIL MAKING TEST MA; Rienstra A, 2009, ARCH CLIN NEUROPSYCH, V24, P255, DOI 10.1093/arclin/acp035; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Rueda MR, 2004, NEUROPSYCHOLOGIA, V42, P1029, DOI 10.1016/j.neuropsychologia.2003.12.012; Schagen S, 1997, J CLIN EXP NEUROPSYC, V19, P43, DOI 10.1080/01688639708403835; Schmand B., 2004, AMSTERDAM SHORT TERM; Slick DJ, 2004, ARCH CLIN NEUROPSYCH, V19, P465, DOI 10.1016/j.acn.2003.04.001; Stevens A, 2008, PSYCHIAT RES, V157, P191, DOI 10.1016/j.psychres.2007.01.003; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Tombaugh TN, 1996, TEST MEMORY MALINGER; Verhoeven L, 1995, DRIE MINUTEN TOETS H; Wechsler D., 1991, WECHSLER INTELLIGENC; Wechsler D, 1997, WAIS 3 ADM SCORING M; Weinborn M, 2003, J CLIN EXP NEUROPSYC, V25, P979, DOI 10.1076/jcen.25.7.979.16481	59	23	25	0	5	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	AUG	2010	25	5					371	382		10.1093/arclin/acq035			12	Psychology, Clinical; Psychology	Psychology	627BN	WOS:000280013100003	20484327	Bronze			2021-06-18	
J	Weishaupt, N; Silasi, G; Colbourne, F; Fouad, K				Weishaupt, Nina; Silasi, Gergely; Colbourne, Frederick; Fouad, Karim			Secondary Damage in the Spinal Cord after Motor Cortex Injury in Rats	JOURNAL OF NEUROTRAUMA			English	Article						spinal cord injury; stroke; traumatic brain injury; wallerian degeneration	CENTRAL-NERVOUS-SYSTEM; WALLERIAN DEGENERATION; RHESUS-MONKEY; FLUORO-JADE; BRAIN; ACTIVATION; RESPONSES; RECOVERY; INNATE; CNS	When neurons within the motor cortex are fatally injured, their axons, many of which project into the spinal cord, undergo wallerian degeneration. Pathological processes occurring downstream of the cortical damage have not been extensively studied. We created a focal forelimb motor cortex injury in rats and found that axons from cell bodies located in the hindlimb motor cortex (spared by the cortical injury) become secondarily damaged in the spinal cord. To assess axonal degeneration in the spinal cord, we quantified silver staining in the corticospinal tract (CST) at 1 week and 4 weeks after the injury. We found a significant increase in silver deposition at the thoracic spinal cord level at 4 weeks compared to 1 week post-injury. At both time points, no degenerating neurons could be found in the hindlimb motor cortex. In a separate experiment, we showed that direct injury of neurons within the hindlimb motor cortex caused marked silver deposition in the thoracic CST at 1 week post-injury, and declined thereafter. Therefore, delayed axonal degeneration in the thoracic spinal cord after a focal forelimb motor cortex injury is indicative of secondary damage at the spinal cord level. Furthermore, immunolabeling of spinal cord sections showed that a local inflammatory response dominated by partially activated Iba-1-positive microglia is mounted in the CST, a viable mechanism to cause the observed secondary degeneration of fibers. In conclusion, we demonstrate that following motor cortex injury, wallerian degeneration of axons in the spinal cord leads to secondary damage, which is likely mediated by inflammatory processes.	[Fouad, Karim] Univ Alberta, Fac Rehabil Med, Edmonton, AB T6G 2G4, Canada; [Weishaupt, Nina; Silasi, Gergely; Colbourne, Frederick; Fouad, Karim] Univ Alberta, Ctr Neurosci, Edmonton, AB T6G 2G4, Canada; [Colbourne, Frederick] Univ Alberta, Dept Psychol, Edmonton, AB T6G 2G4, Canada	Fouad, K (corresponding author), Univ Alberta, Fac Rehabil Med, 3-87 Corbett Hall, Edmonton, AB T6G 2G4, Canada.	karim.fouad@ualberta.ca	Colbourne, Frederick/ABB-7774-2020	Colbourne, Frederick/0000-0002-9567-2082; Fouad, Karim/0000-0003-3654-7852; Silasi, Gergely/0000-0003-1036-1304	Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR) [MOP 77530, MOP 97781]; Alberta Heritage Foundation for Medical ResearchAlberta Heritage Foundation for Medical Research [sti 200600442, sti 200600018]	This work was supported by the Canadian Institutes of Health Research (MOP 77530 to K. F. and MOP 97781 to F. C.), and the Alberta Heritage Foundation for Medical Research (sti 200600442 to K. F. and sti 200600018 to F. C.). F. C. and K. F. are Alberta Heritage Foundation for Medical Research Senior Scholars.	Basiri M, 2010, BRAIN RES BULL, V81, P43, DOI 10.1016/j.brainresbull.2009.11.002; Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bolton DAE, 2006, BEHAV BRAIN RES, V168, P272, DOI 10.1016/j.bbr.2005.11.017; Choo AM, 2008, EXP NEUROL, V212, P490, DOI 10.1016/j.expneurol.2008.04.038; Crutcher KA, 2006, J NEUROIMMUNE PHARM, V1, P195, DOI 10.1007/s11481-006-9021-7; Czeiter E, 2008, J NEUROTRAUM, V25, P205, DOI 10.1089/neu.2007.0331; Dirnagl U, 2004, E SCHERING RES FDN W, V47, P87; Fu D, 2004, NEUROSCIENCE, V125, P819, DOI 10.1016/j.neuroscience.2004.02.012; Hagg T, 2006, J NEUROTRAUM, V23, P264, DOI 10.1089/neu.2006.23.263; Hausmann O, 2003, SPINAL CORD, V41, P369, DOI 10.1038/sj.sc.3101483; IIZUKA H, 1989, STROKE, V20, P1396, DOI 10.1161/01.STR.20.10.1396; Ishida Y, 2002, SPINE, V27, P1652, DOI 10.1097/00007632-200208010-00011; Kanazawa H, 2002, J BIOL CHEM, V277, P20026, DOI 10.1074/jbc.M109218200; Kolb B, 1997, NEUROSCIENCE, V76, P1139, DOI 10.1016/S0306-4522(96)00448-4; KOSHINAGA M, 1995, J NEUROTRAUM, V12, P209, DOI 10.1089/neu.1995.12.209; Moisse K, 2006, BBA-MOL BASIS DIS, V1762, P1083, DOI 10.1016/j.bbadis.2006.03.001; Moisse K, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-29; Nagamoto-Combs K, 2007, J NEUROTRAUM, V24, P1719, DOI 10.1089/neu.2007.0377; Nagamoto-Combs K, 2010, J NEUROTRAUM, V27, P565, DOI 10.1089/neu.2009.0966; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Prewitt CMF, 1997, EXP NEUROL, V148, P433, DOI 10.1006/exnr.1997.6694; Rapalino O, 1998, NAT MED, V4, P814, DOI 10.1038/nm0798-814; Schmued LC, 2000, TOXICOL PATHOL, V28, P91, DOI 10.1177/019262330002800111; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Schwartz M, 2003, J CEREBR BLOOD F MET, V23, P385, DOI 10.1097/01.WCB.0000061881.75234.5E; Schwartz M, 1999, TRENDS NEUROSCI, V22, P295, DOI 10.1016/S0166-2236(99)01405-8; Shi FJ, 2009, J NEUROTRAUM, V26, P2083, DOI [10.1089/neu.2008.0706, 10.1089/neu.2008-0706]; Stence N, 2001, GLIA, V33, P256, DOI 10.1002/1098-1136(200103)33:3<256::AID-GLIA1024>3.0.CO;2-J; Vargas ME, 2007, ANNU REV NEUROSCI, V30, P153, DOI 10.1146/annurev.neuro.30.051606.094354; Wang L, 2009, NEUROPATHOLOGY, V29, P230, DOI 10.1111/j.1440-1789.2008.00969.x; Whishaw IQ, 2000, NEUROPHARMACOLOGY, V39, P788, DOI 10.1016/S0028-3908(99)00259-2; Windle V, 2006, EXP NEUROL, V201, P324, DOI 10.1016/j.expneurol.2006.04.012; Xue MZ, 2000, STROKE, V31, P1721, DOI 10.1161/01.STR.31.7.1721; Ye XM, 2001, BRAIN RES PROTOC, V8, P104, DOI 10.1016/S1385-299X(01)00086-1; Zhao HG, 2008, BRAIN RES, V1246, P158, DOI 10.1016/j.brainres.2008.08.096; Zilles K., 1985, CORTEX RAT STEREOTAX	36	23	23	1	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG	2010	27	8					1387	1397		10.1089/neu.2010.1346			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	639OU	WOS:000280984900004	20515316				2021-06-18	
J	Ferguson, S; Mouzon, B; Kayihan, G; Wood, M; Poon, F; Doore, S; Mathura, V; Humphrey, J; O'Steen, B; Hayes, R; Roses, A; Mullan, M; Crawford, F				Ferguson, S.; Mouzon, B.; Kayihan, G.; Wood, M.; Poon, F.; Doore, S.; Mathura, V.; Humphrey, J.; O'Steen, B.; Hayes, R.; Roses, A.; Mullan, M.; Crawford, F.			APOLIPOPROTEIN E GENOTYPE AND OXIDATIVE STRESS RESPONSE TO TRAUMATIC BRAIN INJURY	NEUROSCIENCE			English	Article						APOE; traumatic brain injury; microarray; oxidative stress; transgenic	CLOSED-HEAD INJURY; ONSET ALZHEIMERS-DISEASE; NITRIC-OXIDE PRODUCTION; NF-KAPPA-B; TRANSGENIC MICE; APOE GENOTYPE; DEFICIENT MICE; PROTEIN; ALLELE; ACTIVATION	Traumatic Brain Injury (TBI) is known to result in oxidative stress, and as variation at the Apolipoprotein E (APOE) gene has been shown to influence outcome following TBI, but through as yet unclear mechanisms, we used transgenic APOE mouse models to examine the relationship between APOE genotype and oxidative stress following TBI. We administered a controlled cortical impact (CCI) injury or sham injury to transgenic mice expressing either human APOE3 or APOE4 on a murine APOE-deficient background. RNA was prepared from the ipsilateral hippocampi and cortices retrieved at 24 h and 1 month post-TBI. Microarray analysis was performed on unpooled samples from three mice per group to determine the genomic response to TBI and to specifically investigate the response of genes involved in oxidative stress mechanisms. Our data demonstrated TBI-induced expression of many more anti-oxidant related genes in the APOE3 mice, suggesting a potential anti-oxidative role for ApoE3 compared to ApoE4. However, in an additional cohort of mice we isolated the ipsilateral hippocampi, cortices, and cerebella at 1 month after TBI or sham injury for immunohistochemical analysis of markers of oxidative stress: the formation and presence of carbonyls (indication of general oxidative modification), 3-nitrotyrosine (3NT; specific to protein modification), or 4-hydroxyl-2-nonenal (HNE; specific to lipid peroxidation). Although we observed significant increases in all three markers of oxidative stress in response to injury, and genotype was a significant factor for carbonyl and 3NT, we found no significant interaction between genotype and injury. This may be due to the overwhelming effect of injury compared to genotype in our ANOVA, but nonetheless suggests that an influence on oxidative stress response is not the primary mechanism behind the APOE-genotype dependent effects on outcome following TBI. (C) 2010 IBRO. Published by Elsevier Ltd. All rights reserved.	[Ferguson, S.; Mouzon, B.; Kayihan, G.; Wood, M.; Poon, F.; Doore, S.; Mathura, V.; Humphrey, J.; Mullan, M.; Crawford, F.] Roskamp Inst, Sarasota, FL 34243 USA; [O'Steen, B.] Univ Florida, McKnight Brain Inst, Ctr Traumat Brain Injury Studies, Gainesville, FL USA; [Hayes, R.] Banyan Biomarkers, Alachua, FL 32615 USA; [Roses, A.] Duke Univ, R David Thomas Execut Training Ctr, Durham, NC USA	Ferguson, S (corresponding author), Roskamp Inst, 2040 Whitfield Ave, Sarasota, FL 34243 USA.	sferguson@rfdn.org		Mullan, Michael/0000-0002-1473-7527; Doore, Sarah/0000-0002-7672-2355	VA Merit awardUS Department of Veterans Affairs; Roskamp Foundation; DoDUnited States Department of Defense [W81XWH-07-1-0700]	This work was supported by a VA Merit award to FC, by the Roskamp Foundation and in part by DoD contract W81XWH-07-1-0700 (FC).	Alberghini A, 2005, J BIOL CHEM, V280, P30120, DOI 10.1074/jbc.M500971200; Ates O, 2007, MOL CELL BIOCHEM, V294, P137, DOI 10.1007/s11010-006-9253-0; Beni SM, 2004, FASEB J, V18, P149, DOI 10.1096/fj.03-0323fje; BERGER R, 1995, SOMAT CELL MOLEC GEN, V21, P121, DOI 10.1007/BF02255787; Brigelius-Flohe R, 2006, BIOL CHEM, V387, P1329, DOI 10.1515/BC.2006.166; Colton CA, 2004, J NEUROIMMUNOL, V147, P62, DOI 10.1016/j.jneuroim.2003.10.015; Crawford F, 2009, NEUROSCIENCE, V159, P1349, DOI 10.1016/j.neuroscience.2009.01.033; Crawford FC, 2002, NEUROLOGY, V58, P1115, DOI 10.1212/WNL.58.7.1115; Crawford FC, 2007, BRAIN RES, V1185, P45, DOI 10.1016/j.brainres.2007.09.042; de Haan JB, 1998, J BIOL CHEM, V273, P22528, DOI 10.1074/jbc.273.35.22528; Edenberg HJ, 2008, HUM MOL GENET, V17, P963, DOI 10.1093/hmg/ddm368; Glabe CG, 2006, NEUROBIOL AGING, V27, P570, DOI 10.1016/j.neurobiolaging.2005.04.017; Haddad JJ, 2002, J NEUROIMMUNOL, V133, P1, DOI 10.1016/S0165-5728(02)00357-0; Hicdonmez T, 2006, NEUROCHEM RES, V31, P473, DOI 10.1007/s11064-006-9040-z; Hirota K, 2000, BIOCHEM BIOPH RES CO, V274, P177, DOI 10.1006/bbrc.2000.3106; Huebbe P, 2007, MOL NUTR FOOD RES, V51, P1510, DOI 10.1002/mnfr.200700194; Jaffrey SR, 1998, NEURON, V20, P115, DOI 10.1016/S0896-6273(00)80439-0; Jakobsson PJ, 1997, J BIOL CHEM, V272, P22934, DOI 10.1074/jbc.272.36.22934; Jofre-Monseny L, 2008, MOL NUTR FOOD RES, V52, P131, DOI 10.1002/mnfr.200700322; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Juurlink B H, 1998, J Spinal Cord Med, V21, P309; Kharrazi H, 2008, CLIN BIOCHEM, V41, P932, DOI 10.1016/j.clinbiochem.2008.05.001; Kurooka H, 1997, GENOMICS, V39, P331, DOI 10.1006/geno.1996.4493; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lauderback CM, 2001, BIOCHEMISTRY-US, V40, P2548, DOI 10.1021/bi002312k; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; Lomnitski L, 2000, EXP TOXICOL PATHOL, V52, P177; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Marcourakis T, 2008, CELL BIOCHEM FUNCT, V26, P852, DOI 10.1002/cbf.1516; Matsubara K, 2002, NEUROTOXICOL TERATOL, V24, P593, DOI 10.1016/S0892-0362(02)00212-X; Mauri M, 2006, FUNCT NEUROL, V21, P223; Mazur-Kolecka B, 2003, BRAIN RES, V983, P48, DOI 10.1016/S0006-8993(03)03026-9; Milojevic J, 2007, J AM CHEM SOC, V129, P4282, DOI 10.1021/ja067367+; Miyata M, 1996, NAT GENET, V14, P55, DOI 10.1038/ng0996-55; Mori T, 2003, J NEUROPATH EXP NEUR, V62, P280, DOI 10.1093/jnen/62.3.280; OKAMURA N, 1990, J CLIN INVEST, V85, P1583, DOI 10.1172/JCI114608; OKUIZUMI K, 1994, NAT GENET, V7, P10, DOI 10.1038/ng0594-10b; Ozturk E, 2008, PROG NEURO-PSYCHOPH, V32, P81, DOI 10.1016/j.pnpbp.2007.07.016; Pedersen WA, 2000, J NEUROCHEM, V74, P1426, DOI 10.1046/j.1471-4159.2000.0741426.x; Pombo CM, 1997, J BIOL CHEM, V272, P29372, DOI 10.1074/jbc.272.46.29372; Pombo CM, 1996, EMBO J, V15, P4537, DOI 10.1002/j.1460-2075.1996.tb00831.x; Pun PBL, 2009, FREE RADICAL RES, V43, P348, DOI 10.1080/10715760902751902; Ramassamy C, 2000, NEUROBIOL DIS, V7, P23, DOI 10.1006/nbdi.1999.0273; Ramassamy C, 2001, MOL BRAIN RES, V86, P76, DOI 10.1016/S0169-328X(00)00268-0; Sabo T, 2000, NEUROSCIENCE, V101, P879, DOI 10.1016/S0306-4522(00)00438-3; SAUNDERS AM, 1993, LANCET, V342, P710, DOI 10.1016/0140-6736(93)91709-U; Sharapova TA, 2009, CONTEMP PROBL ECOL+, V2, P72, DOI 10.1134/S1995425509010123; SORBI S, 1995, NAT MED, V1, P852, DOI 10.1038/nm0995-852; Spinazzola A, 2006, NAT GENET, V38, P570, DOI 10.1038/ng1765; Sroussi HY, 2009, FEMS IMMUNOL MED MIC, V55, P55, DOI 10.1111/j.1574-695X.2008.00498.x; TEESDALE GM, 1997, LANCET, V350, P1069; VANDUIJN CM, 1994, NAT GENET, V7, P74, DOI 10.1038/ng0594-74; Wei YH, 2002, EXP BIOL MED, V227, P671; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; White F, 2001, NEUROBIOL DIS, V8, P611, DOI 10.1006/nbdi.2001.0401; Xiong Ye, 2004, J Stroke Cerebrovasc Dis, V13, P129, DOI 10.1016/j.jstrokecerebrovasdis.2004.05.001; Xiong YQ, 2007, J NEUROCHEM, V100, P639, DOI 10.1111/j.1471-4159.2006.04312.x; Xu PT, 1996, NEUROBIOL DIS, V3, P229, DOI 10.1006/nbdi.1996.0023; Zorov DB, 2006, BBA-BIOENERGETICS, V1757, P509, DOI 10.1016/j.bbabio.2006.04.029	59	23	24	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience	JUL 14	2010	168	3					811	819		10.1016/j.neuroscience.2010.01.031			9	Neurosciences	Neurosciences & Neurology	608UM	WOS:000278611500022	20105454				2021-06-18	
J	Barker, LA; Andrade, J; Morton, N; Romanowski, CAJ; Bowles, DP				Barker, L. A.; Andrade, J.; Morton, N.; Romanowski, C. A. J.; Bowles, D. P.			Investigating the 'latent' deficit hypothesis: Age at time of head injury, implicit and executive functions and behavioral insight	NEUROPSYCHOLOGIA			English	Article						Developmental; Trajectory; Cognition; Awareness	TRAUMATIC BRAIN-INJURY; UNDERSTANDING AWARENESS DEFICITS; SELF-AWARENESS; DEVELOPMENTAL DIFFERENCES; ADOLESCENT BRAIN; CHILDHOOD; PERFORMANCE; MATURATION; COGNITION; VALIDITY	This study investigated the 'latent deficit' hypothesis in two groups of head-injured patients with predominantly frontal lesions, those injured prior to steep morphological and corresponding functional maturational periods for frontal networks (<= age 25), and those injured >28 years. The latent deficit hypothesis proposes that early injuries produce enduring cognitive deficits manifest later in the lifespan with graver consequences for behavior than adult injuries, particularly after frontal pathology (Eslinger, Grattan, Damasio & Damasio, 1992). Implicit and executive deficits both contribute to behavioral insight after frontal head injury (Barker, Andrade, Romanowski, Morton, & Wasti, 2006). On the basis of morphological and behavioral data, we hypothesized that early injury would confer greater vulnerability to impairment on tasks associated with frontal regions than later injury. Patients completed experimental tasks of implicit cognition, executive function measures and the DEX measure of behavioral insight (Behavioral Assessment of the Dysexecutive Syndrome: Wilson, Alderman, Burgess, Emslie, & Evans, 1996). The Early Injury group were more impaired on implicit cognition tasks compared to controls that Late Injury patients. There were no marked group differences on most executive function measures. Executive ability only contributed to behavioral awareness in the Early Injury Group. Findings showed that age at injury moderates the relationship between executive and implicit cognition and behavioral insight and that early injuries result in long-standing deficits to functions associated with frontal regions partially supporting the latent deficit hypothesis. (C) 2010 Elsevier Ltd. All rights reserved.	[Barker, L. A.; Bowles, D. P.] Sheffield Hallam Univ, Dept Psychol, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England; [Andrade, J.] Univ Plymouth, Sch Psychol, Plymouth PL4 8AA, Devon, England; [Morton, N.] Tickhill Rd Hosp, Rotherham Doncaster S Humber Mental Hlth NHS Fdn, Neurorehabil Serv, Doncaster DN4 8QL, England; [Romanowski, C. A. J.] Royal Hallamshire Hosp, Dept Acad Radiol, Sheffield S10 2JF, S Yorkshire, England	Barker, LA (corresponding author), Sheffield Hallam Univ, Dept Psychol, Brain Behav & Cognit Grp, Sheffield S10 2BP, S Yorkshire, England.	l.barker@shu.ac.uk	Andrade, Jackie/H-1215-2013	Andrade, Jackie/0000-0002-6626-7192	PPP Foundation [577/365]	This research was funded by the PPP Foundation (grant no. 577/365). The authors wish to thank participants who took part in the study and Dr Howard Jackson of the Transitional Rehabilitation Unit, St. Helens. This study was performed in accordance with the ethical standards laid down in the 1964 Declaration of Helsinki.	Anderson SW, 1999, NAT NEUROSCI, V2, P1032; Anderson SW, 2000, DEV NEUROPSYCHOL, V18, P281, DOI 10.1207/S1532694202Anderson; Anderson V, 2005, PEDIATRICS, V116, P1374, DOI 10.1542/peds.2004-1728; Anderson VA, 2001, DEV NEUROPSYCHOL, V20, P385, DOI 10.1207/S15326942DN2001_5; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Andrade J, 2001, BRIT J ANAESTH, V86, P189, DOI 10.1093/bja/86.2.189; Andres P, 2002, NEUROPSYCHOLOGIA, V40, P835, DOI 10.1016/S0028-3932(01)00182-8; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Barker LA, 2006, NEUROPSYCHOLOGIA, V44, P1413, DOI 10.1016/j.neuropsychologia.2005.12.005; Barker LA, 2006, J EXP PSYCHOL LEARN, V32, P636, DOI 10.1037/0278-7393.32.3.636; Barker LA, 2004, NEUROCASE, V10, P233, DOI 10.1080/13554790490495096; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Beldarrain MG, 2002, EXP BRAIN RES, V142, P529, DOI 10.1007/s00221-001-0935-2; Bennett PC, 2005, J INT NEUROPSYCH SOC, V11, P606, DOI 10.1017/S1355617705050721; Benton A, 1989, MULTILINGUAL APHASIA; Blakemore SJ, 2006, J CHILD PSYCHOL PSYC, V47, P296, DOI 10.1111/j.1469-7610.2006.01611.x; BO J, 2009, EXPT BRAIN RES, V190, P317; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; Burgess PW, 1998, J INT NEUROPSYCH SOC, V4, P547, DOI 10.1017/S1355617798466037; Chan RCK, 2008, J NEUROL NEUROSUR PS, V79, P86, DOI 10.1136/jnnp.2007.117184; COHEN J, 1993, BEHAV RES METH INSTR, V25, P257, DOI 10.3758/BF03204507; Craik FIM, 1999, PSYCHOL SCI, V10, P26, DOI 10.1111/1467-9280.00102; D'Argembeau A, 2005, NEUROIMAGE, V25, P616, DOI 10.1016/j.neuroimage.2004.11.048; Damasio AR, 1996, PHILOS T R SOC B, V351, P1413, DOI 10.1098/rstb.1996.0125; DAMASIO H, 1990, LESION ANAL NEUROPSY; DEMIR OE, 2009, DEVELOPMENTAL SCI, P1; Eslinger PJ, 2004, BRAIN COGNITION, V55, P84, DOI 10.1016/s0278-2626(03)00281-1; Eslinger PJ, 2000, DEV NEUROPSYCHOL, V18, P297, DOI 10.1207/S1532694203Eslinger; ESLINGER PJ, 1997, DEV PREFRONTAL CORTE; Ewing-Cobbs L, 2006, J NEUROSURG, V105, P287, DOI 10.3171/ped.2006.105.4.287; Fay TB, 2009, NEUROPSYCHOLOGY, V23, P271, DOI 10.1037/a0014936; Flashman LA, 2002, NEUROREHABILITATION, V17, P285; Frith CD, 2008, NEURON, V60, P503, DOI 10.1016/j.neuron.2008.10.032; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P333, DOI 10.1097/00001199-200507000-00005; Hart T, 2009, NEUROPSYCHOL REHABIL, V19, P161, DOI 10.1080/09602010802188393; Hayes BK, 1996, J EXP CHILD PSYCHOL, V63, P22, DOI 10.1006/jecp.1996.0041; Heaton R. K, 1981, WISCONSIN CARD SORTI; Hebb D.O., 1949, ORG BEHAV NEUROPSYCH; Honda M, 1998, BRAIN, V121, P2159, DOI 10.1093/brain/121.11.2159; Huizinga M, 2006, NEUROPSYCHOLOGIA, V44, P2017, DOI 10.1016/j.neuropsychologia.2006.01.010; Jaccard J., 2003, SAGE U PAPERS SERIES; Jimenez L, 2001, Q J EXP PSYCHOL-A, V54, P345, DOI 10.1080/02724980042000200; Johnston MV, 2009, DEV DISABIL RES REV, V15, P94, DOI 10.1002/ddrr.64; Kennard MA, 1940, ARCH NEURO PSYCHIATR, V44, P377, DOI 10.1001/archneurpsyc.1940.02280080137008; Kolb B., 1995, BRAIN PLASTICITY BEH; Kolb B., 1990, FUNDAMENTALS HUMAN N; Lebel C, 2008, NEUROIMAGE, V40, P1044, DOI 10.1016/j.neuroimage.2007.12.053; LEVIN HS, 1991, DEV NEUROPSYCHOL, V7, P377, DOI 10.1080/87565649109540499; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Lieberman MD, 2000, PSYCHOL BULL, V126, P109, DOI 10.1037/0033-2909.126.1.109; Lin CCH, 2000, J CLIN EXP NEUROPSYC, V22, P69, DOI 10.1076/1380-3395(200002)22:1;1-8;FT069; Meulemans T, 1998, J EXP CHILD PSYCHOL, V69, P199, DOI 10.1006/jecp.1998.2442; Miyake A, 2000, COGNITIVE PSYCHOL, V41, P49, DOI 10.1006/cogp.1999.0734; Morris R., 2004, COGNITIVE NEUROPSYCH, V2nd; MORTON N, 2010, BRAIN INJURY, V24, P38; NISSEN MJ, 1987, COGNITIVE PSYCHOL, V19, P1, DOI 10.1016/0010-0285(87)90002-8; O'Keeffe F, 2007, J INT NEUROPSYCH SOC, V13, P38, DOI 10.1017/S1355617707070075; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Ownsworth T, 2005, J HEAD TRAUMA REHAB, V20, P315, DOI 10.1097/00001199-200507000-00004; Ownsworth T, 2006, NEUROPSYCHOL REHABIL, V16, P415, DOI 10.1080/09602010500505641; Ownsworth TL, 2000, CLIN NEUROPSYCHOL, V14, P76, DOI 10.1076/1385-4046(200002)14:1;1-8;FT076; Paus T, 2005, TRENDS COGN SCI, V9, P60, DOI 10.1016/j.tics.2004.12.008; Paus T, 2008, NAT REV NEUROSCI, V9, P947, DOI 10.1038/nrn2513; Ponsford J, 2004, COGNITIVE BEHAV REHA; Riddle WR, 2008, J MAGN RESON IMAGING, V28, P320, DOI 10.1002/jmri.21450; Romine CB, 2005, APPL NEUROPSYCHOL, V12, P190, DOI 10.1207/s15324826an1204_2; Rosen HJ, 2010, NEUROIMAGE, V49, P3358, DOI 10.1016/j.neuroimage.2009.11.041; SCHACTER DL, 1990, J CLIN EXP NEUROPSYC, V12, P155, DOI 10.1080/01688639008400962; Schmitz TW, 2006, NEUROPSYCHOLOGIA, V44, P762, DOI 10.1016/j.neuropsychologia.2005.07.012; Seger CA, 1997, CONSCIOUS COGN, V6, P108, DOI 10.1006/ccog.1996.0285; Seidler RD, 2005, EXP BRAIN RES, V165, P114, DOI 10.1007/s00221-005-2284-z; Shallice, 1997, HAYLING BRIXTON TEST; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sosin DM, 1996, PEDIATRICS, V98, P868; Sowell ER, 2003, NAT NEUROSCI, V6, P309, DOI 10.1038/nn1008; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Steinberg L, 2007, CURR DIR PSYCHOL SCI, V16, P55, DOI 10.1111/j.1467-8721.2007.00475.x; STUSS D, 2007, T ROYAL SOC LONDON B, V362, P901; Sullivan JR, 2009, APPL NEUROPSYCHOL, V16, P62, DOI 10.1080/09084280802644243; Thomas KM, 2004, J COGNITIVE NEUROSCI, V16, P1339, DOI 10.1162/0898929042304688; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Tranel D, 2000, DEV NEUROPSYCHOL, V18, P273, DOI 10.1207/S1532694201Tranel; Vaidya CJ, 2007, NEUROPSYCHOLOGY, V21, P497, DOI 10.1037/0894-4105.21.4.497; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 1997, WAIS 3 ADM SCORING M; WILLIAMS D, 1992, BRAIN COGNITION, V20, P196, DOI 10.1016/0278-2626(92)90069-X; Wilson, 1991, NATL ADULT READING T; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wise K, 2005, BRAIN INJURY, V19, P765, DOI 10.1080/0269905050019977; Wong PS, 1997, CONSCIOUS COGN, V6, P519, DOI 10.1006/ccog.1997.0322; ZAJONC RB, 1980, AM PSYCHOL, V35, P151, DOI 10.1037/0003-066X.35.2.151; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	93	23	23	0	15	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JUL	2010	48	9					2550	2563		10.1016/j.neuropsychologia.2010.05.001			14	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	634ID	WOS:000280573300015	20470806	Green Accepted			2021-06-18	
J	Hagen, EM; Eide, GE; Rekand, T; Gilhus, NE; Gronning, M				Hagen, E. M.; Eide, G. E.; Rekand, T.; Gilhus, N. E.; Gronning, M.			Traumatic spinal cord injury and concomitant brain injury: a cohort study	ACTA NEUROLOGICA SCANDINAVICA			English	Article						epidemiology; etiology; incidence; traumatic brain injury; traumatic spinal cord injury	BLOOD-ALCOHOL LEVEL; HEAD-INJURY; CLASSIFICATION; EPIDEMIOLOGY; PREDICTORS; MORTALITY; MODERATE; SWEDEN	Objective - To assess the temporal trends in the incidence and demographic characteristics of traumatic spinal cord injury (TSCI) with clinical concomitant traumatic brain injury (TBI), in an unselected, geographically defined cohort, 1952-2001. Material and methods - The patients were identified from hospital records. TBI was classified as none, mild, moderate, and severe. Results - Of 336 patients, 157 (46.7%) patients had a clinical concomitant TBI. Clinical TBI was classified as mild in 30.1%, moderate in 11.0% and severe in 5.7%. The average annual incidence increased from 3.3 per million in the first decade to 10.7 per million in the last. Alcohol was the strongest risk factor of clinical TBI (OR = 3.69) followed by completeness of TSCI (OR = 2.18). Conclusions - The incidence of TSCI with concomitant TBI has increased during the last 50 years. Alcohol and completeness of injury are strong risk factors. Increased awareness of dual diagnoses is necessary.	[Hagen, E. M.; Rekand, T.; Gilhus, N. E.; Gronning, M.] Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway; [Hagen, E. M.; Gilhus, N. E.; Gronning, M.] Univ Bergen, Dept Clin Med, Bergen, Norway; [Eide, G. E.] Haukeland Hosp, Clin Res Ctr, N-5021 Bergen, Norway; [Eide, G. E.] Univ Bergen, Dept Publ Hlth & Primary Hlth Care, Bergen, Norway	Hagen, EM (corresponding author), Haukeland Hosp, Dept Neurol, N-5021 Bergen, Norway.	ellen.merete.hagen@helse-bergen.no	Rekand, Tiina/A-6201-2008; Rekand, Tiina/V-7189-2019; Hagen, Ellen Merete/F-8841-2014	Rekand, Tiina/0000-0002-2506-9501; Hagen, Ellen Merete/0000-0002-6925-6747			Abelson-Mitchell N, 2008, J CLIN NURS, V17, P46, DOI 10.1111/j.1365-2702.2007.01941.x; Ahlm K, 2009, ACCIDENT ANAL PREV, V41, P129, DOI 10.1016/j.aap.2008.10.002; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; AYYOUB Z, 2003, SPINAL CORD MED PRIN, P509; Barker RN, 2009, SPINAL CORD, V47, P149, DOI 10.1038/sc.2008.82; Bombardier CH, 1998, BRAIN INJURY, V12, P725, DOI 10.1080/026990598122124; Butcher I, 2007, J NEUROTRAUM, V24, P281, DOI 10.1089/neu.2006.0030; Cunningham RM, 2002, ALCOHOL ALCOHOLISM, V37, P236, DOI 10.1093/alcalc/37.3.236; DEVIVO MJ, 2003, SPINAL CORD MED PRIN, P79; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Hagen EM, 2010, SPINAL CORD, V48, P313, DOI 10.1038/sc.2009.133; Hagen EM, 2009, SPINAL CORD, V47, P367, DOI 10.1038/sc.2008.118; Hagen EM, 2010, J NEUROL NEUROSUR PS, V81, P368, DOI 10.1136/jnnp.2009.178798; Hagen EM, 2005, ACTA NEUROL SCAND, V112, P42, DOI 10.1111/j.1600-0404.2005.00430.x; Holly LT, 2002, J NEUROSURG, V96, P285, DOI 10.3171/spi.2002.96.3.0285; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Jacobsson LJ, 2007, ACTA NEUROL SCAND, V116, P300, DOI 10.1111/j.1600-0404.2007.00896.x; Kleinbaum D. G., 2002, LOGISTIC REGRESSION; KRAUS JF, 1975, J CHRON DIS, V28, P471, DOI 10.1016/0021-9681(75)90057-0; Lydersen S, 2009, STAT MED, V28, P1159, DOI 10.1002/sim.3531; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; Macciocchi SN, 2004, AM J PHYS MED REHAB, V83, P22, DOI 10.1097/01.PHM.0000104661.86307.91; Macciocchi S, 2008, ARCH PHYS MED REHAB, V89, P1350, DOI 10.1016/j.apmr.2007.11.055; Maynard FM, 1997, SPINAL CORD, V35, P266, DOI 10.1038/sj.sc.3100432; Rehn M, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-1; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Stockwell T, 2002, J STUD ALCOHOL, V63, P372, DOI 10.15288/jsa.2002.63.372; Sundstrom T, 2007, J NEUROTRAUM, V24, P147, DOI 10.1089/neu.2006.0099; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Tolonen A, 2007, J REHABIL MED, V39, P622, DOI 10.2340/16501977-0101; Turner AP, 2006, REHABIL PSYCHOL, V51, P78, DOI 10.1037/0090-5550.51.1.78; ZAFONTE RD, 2002, SPINAL CORD MED, P261	33	23	24	0	4	WILEY-BLACKWELL	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	0001-6314			ACTA NEUROL SCAND	Acta Neurol. Scand.	JUL	2010	122			190			51	57		10.1111/j.1600-0404.2010.01376.x			7	Clinical Neurology	Neurosciences & Neurology	605IO	WOS:000278341400010	20586736				2021-06-18	
J	Hung, CJ; Yao, CL; Cheng, FC; Wu, ML; Wang, TH; Hwang, SM				Hung, Chi-Jen; Yao, Chao-Ling; Cheng, Fu-Chou; Wu, Mei-Ling; Wang, Tzu-Hao; Hwang, Shiaw-Min			Establishment of immortalized mesenchymal stromal cells with red fluorescence protein expression for in vivo transplantation and tracing in the rat model with traumatic brain injury	CYTOTHERAPY			English	Article						mesenchymal stromal cells; non-viral transfection; red fluorescent protein; telomerase reverse transcriptase; traumatic brain injury	HUMAN BONE-MARROW; STEM-CELLS; GENE-THERAPY; LIFE-SPAN; EX-VIVO; TELOMERASE; TISSUE; PROLIFERATION; KINETICS	Background aims. Human mesenchymal stromal cells (hMSC) play a crucial role in tissue engineering and regenerative medicine, and have important clinical potential for cell therapy. However, many hMSC studies have been restricted by limited cell numbers and difficult detection in vivo. To expand the lifespan, hMSC are usually immortalized by virus-mediated gene transfer. However, these genetically modified cells easily lose critical phenotypes and stable genotypes because of insertional mutagenesis. Methods. We used a non-viral transfection method to establish human telomerase reverse transcriptase-immortalized cord blood hMSC (hTERT-cbMSC). We also established red fluorescent protein (RFP)-expressing hTERT-cbMSC (hTERT/RFP-cbMSC) by the same non-viral transfection method, and these cells were injected into a rat model with traumatic brain injury for in vivo detection analysis. Results. The hTERT-cbMSC could grow more than 200 population doublings with a stable doubling time and maintained differentiation capacities. hTERT/RFP-cbMSC could proliferate efficiently within 2 weeks at the injury location and could be detected easily under a fluorescent microscope. Importantly, both hTERT-cbMSC and hTERT/RFP-cbMSC showed no chromosomal abnormalities by karyotype analysis and no tumor formation in severe combined immunodeficient (SCID) mice by transplantation assay. Conclusions. We have developed immortalized cbMSC with hTERT expression and RFP expression, which will be useful tools for stem cell research and translational study.	[Hung, Chi-Jen; Yao, Chao-Ling; Wu, Mei-Ling; Hwang, Shiaw-Min] Food Ind Res & Dev Inst, Bioresource Collect & Res Ctr, Hsinchu 30062, Taiwan; [Yao, Chao-Ling] Yuan Ze Univ, Dept Chem Engn & Mat Sci, Chungli, Taiwan; [Cheng, Fu-Chou] Vet Gen Hosp, Dept Med Res, Taichung, Taiwan; [Wang, Tzu-Hao] Chang Gung Mem Hosp, Genom Med Res Core Lab, Tao Yuan, Taiwan	Hwang, SM (corresponding author), Food Ind Res & Dev Inst, Bioresource Collect & Res Ctr, 331 Shih Pin Rd, Hsinchu 30062, Taiwan.	hsm@firdi.org.tw					Abdallah BM, 2005, BIOCHEM BIOPH RES CO, V326, P527, DOI 10.1016/j.bbrc.2004.11.059; Aluigi M, 2006, STEM CELLS, V24, P454, DOI 10.1634/stemcells.2005-0198; Banfi A, 2000, EXP HEMATOL, V28, P707, DOI 10.1016/S0301-472X(00)00160-0; Bhakta S, 2006, CARDIOVASC REVASCULA, V7, P19, DOI 10.1016/j.carrev.2005.10.008; Bleiziffer O, 2007, J CELL MOL MED, V11, P206, DOI 10.1111/j.1582-4934.2007.00027.x; Blesch A, 2004, METHODS, V33, P164, DOI 10.1016/j.ymeth.2003.11.005; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bodnar AG, 1998, SCIENCE, V279, P349, DOI 10.1126/science.279.5349.349; Bocker W, 2008, J CELL MOL MED, V12, P1347, DOI [10.1111/j.1582-4934.2008.0299.x, 10.1111/j.1582-4934.2008.00299.x]; Bokhoven M, 2009, J VIROL, V83, P283, DOI 10.1128/JVI.01865-08; Bruder SP, 1997, J CELL BIOCHEM, V64, P278, DOI 10.1002/(SICI)1097-4644(199702)64:2<278::AID-JCB11>3.0.CO;2-F; Burns JS, 2005, CANCER RES, V65, P3126, DOI 10.1158/0008-5472.CAN-04-2218; Campisi J, 1997, EUR J CANCER, V33, P703, DOI 10.1016/S0959-8049(96)00058-5; Chang YJ, 2006, STEM CELLS, V24, P679, DOI 10.1634/stemcells.2004-0308; Check E, 2002, NATURE, V420, P116, DOI 10.1038/420116a; Erices A, 2000, BRIT J HAEMATOL, V109, P235, DOI 10.1046/j.1365-2141.2000.01986.x; Finnie JW, 2002, VET PATHOL, V39, P679, DOI 10.1354/vp.39-6-679; FRIEDENSTEIN AJ, 1976, EXP HEMATOL, V4, P267; Gao X, 2007, AAPS J, V9, pE92, DOI 10.1208/aapsj0901009; Greider CW, 1998, P NATL ACAD SCI USA, V95, P90, DOI 10.1073/pnas.95.1.90; GREIDER CW, 1990, BIOESSAYS, V12, P363, DOI 10.1002/bies.950120803; HARLEY CB, 1990, NATURE, V345, P458, DOI 10.1038/345458a0; Hill JM, 2003, CIRCULATION, V108, P1009, DOI 10.1161/01.CIR.0000084537.66419.7A; Huang GP, 2008, J CELL BIOCHEM, V103, P1256, DOI 10.1002/jcb.21502; Huang Q, 2007, MECH AGEING DEV, V128, P25, DOI 10.1016/j.mad.2006.11.006; in 'tAnker PS, 2003, BLOOD, V102, P1548, DOI 10.1182/blood-2003-04-1291; Marshall E, 1999, SCIENCE, V286, P2244, DOI 10.1126/science.286.5448.2244; Morales CP, 1999, NAT GENET, V21, P115, DOI 10.1038/5063; Phinney DG, 2007, STEM CELLS, V25, P2896, DOI 10.1634/stemcells.2007-0637; Pittenger MF, 1999, SCIENCE, V284, P143, DOI 10.1126/science.284.5411.143; Prockop DJ, 1997, SCIENCE, V276, P71, DOI 10.1126/science.276.5309.71; Qu CS, 2008, BRAIN RES, V1208, P234, DOI 10.1016/j.brainres.2008.02.042; Serakinci N, 2004, ONCOGENE, V23, P5095, DOI 10.1038/sj.onc.1207651; Simonsen JL, 2002, NAT BIOTECHNOL, V20, P592, DOI 10.1038/nbt0602-592; Sobajima S, 2008, SPINE J, V8, P888, DOI 10.1016/j.spinee.2007.09.011; Terai M, 2005, MOL BIOL CELL, V16, P1491, DOI 10.1091/mbc.E04-07-0652; Thomas M, 2003, APPL MICROBIOL BIOT, V62, P27, DOI 10.1007/s00253-003-1321-8; Williams JT, 1999, AM SURGEON, V65, P22; Zuk PA, 2001, TISSUE ENG, V7, P211, DOI 10.1089/107632701300062859	39	23	24	0	14	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1465-3249	1477-2566		CYTOTHERAPY	Cytotherapy	JUL	2010	12	4					455	465		10.3109/14653240903555827			11	Cell & Tissue Engineering; Biotechnology & Applied Microbiology; Cell Biology; Hematology; Medicine, Research & Experimental	Cell Biology; Biotechnology & Applied Microbiology; Hematology; Research & Experimental Medicine	631EO	WOS:000280329600003	20230225				2021-06-18	
J	Kaye, AJ; Gallagher, R; Callahan, JM; Nance, ML				Kaye, Adam J.; Gallagher, Rachel; Callahan, James M.; Nance, Michael L.			Mild Traumatic Brain Injury in the Pediatric Population: The Role of the Pediatrician in Routine Follow-Up	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Mild traumatic brain injury; Pediatrics; Head trauma; Follow-up care; Primary care	SPORT-RELATED CONCUSSION; CLOSED-HEAD INJURY; CHILDREN; PREDICTION; MANAGEMENT; SYMPTOMS	Background: Traumatic brain injury is common in children. Fortunately, most patients suffer mild traumatic brain injury ( MTBI). Appropriate guidelines for follow-up care are not well established. We sought to determine practice experience and preferences of general pediatricians related to follow-up care of MTBI. Methods: Members of the American Academy of Pediatrics Council of Community Pediatrics and general pediatricians in the Pennsylvania Chapter of the American Academy of Pediatrics participated in a web-based survey regarding practice setting, level of comfort caring for patients with MTBI, and referral patterns for such patients. Results: A total of 298 pediatricians responded. An urban or suburban practice setting was reported by 83.3% with a wide distribution in practice experience ( 0 - 10 years 40.5%, 11 - 20 years 24.5%, >21 years 35%). Most respondents ( 54.5%) had cared for at least 2 to 5 patients with MTBI in the past 6 months but only 8% had seen >10 patients. Fifty-nine percent had not participated in continuing medical education activities related to MTBI and 62.2% did not use neurocognitive tests. The majority ( 89%) thought that they were the appropriate provider for follow-up; this declined to 61.2% for patients with loss of consciousness and only 5.4% if patients had persistent symptoms. Neurologists ( 75%) were the consultant of choice for referral. Increased practice experience was associated with an increased comfort in determining return to play status. Conclusion: In this survey, pediatricians thought that they were the most appropriate clinicians to follow-up patients with MTBI. However, most accepted this responsibility without the benefit of specific continuing medical education or using neurocognitive tests. Ensuring the availability of appropriate resources for pediatricians to care for these patients is important.	[Nance, Michael L.] Childrens Hosp Philadelphia, Dept Surg, Philadelphia, PA 19104 USA; [Kaye, Adam J.] Hosp Univ Penn, Dept Surg, Philadelphia, PA 19104 USA; [Gallagher, Rachel] Childrens Hosp, Dept Med, Div Emergency Med, Boston, MA 02115 USA; [Callahan, James M.] Univ Penn, Sch Med, Dept Pediat, Div Emergency Med, Philadelphia, PA 19104 USA	Nance, ML (corresponding author), Childrens Hosp Philadelphia, Dept Surg, 34th & Civ Ctr Blvd, Philadelphia, PA 19104 USA.	nance@email.chop.edu					Bergman DA, 1999, PEDIATRICS, V104, P1407; Blinman TA, 2009, J PEDIATR SURG, V44, P1223, DOI 10.1016/j.jpedsurg.2009.02.027; *CAN PED SOC, 2006, PEDIAT CHILD HLTH, V11, P420; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cohen JS, 2009, CURR OPIN PEDIATR, V21, P288, DOI 10.1097/MOP.0b013e32832b1195; Demorest RA, 2005, PEDIATRICS, V115, P28, DOI 10.1542/peds.2004-0266; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Haydel MJ, 2003, ANN EMERG MED, V42, P507, DOI 10.1067/S0196-0644(03)00512-2; King NS, 1999, BRIT J CLIN PSYCHOL, V38, P15, DOI 10.1348/014466599162638; Kirkwood MW, 2006, PEDIATRICS, V117, P1359, DOI 10.1542/peds.2005-0994; Langlois JA, 2005, J HEAD TRAUMA REHAB, V20, P229, DOI 10.1097/00001199-200505000-00006; McCrory Paul, 2005, Clin J Sport Med, V15, P48; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; Nance ML, 2009, ANN SURG, V249, P859, DOI 10.1097/SLA.0b013e3181a41ae5; *NAT CTR INJ PREV, 2003, FACTS PHYS MILD TRAU; Purcell L, 2008, CLIN PEDIATR, V47, P106, DOI 10.1177/0009922807306053; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Thiessen ML, 2006, PEDIATR CLIN N AM, V53, P1, DOI 10.1016/j.pcl.2005.09.004; Thompson Matthew D, 2003, Semin Pediatr Neurol, V10, P130, DOI 10.1016/S1071-9091(03)00021-4; ACUTE CONCUSSION EVA	21	23	23	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	2010	68	6					1396	1400		10.1097/TA.0b013e3181cf7d1b			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	610ES	WOS:000278714600024	20539184				2021-06-18	
J	Li, Y; Hawkins, BE; DeWitt, DS; Prough, DS; Maret, W				Li, Yuan; Hawkins, Bridget E.; DeWitt, Douglas S.; Prough, Donald S.; Maret, Wolfgang			The relationship between transient zinc ion fluctuations and redox signaling in the pathways of secondary cellular injury: Relevance to traumatic brain injury	BRAIN RESEARCH			English	Article						Zinc; Pheochromocytoma (PC12) cells; Traumatic brain injury; Rapid stretch injury; Oxidative stress; Metallothionein	STRETCH-INDUCED INJURY; NITRIC-OXIDE; OXIDATIVE STRESS; METALLOTHIONEIN; CELLS; HIPPOCAMPUS; PATHOPHYSIOLOGY; HOMEOSTASIS; ACTIVATION; MECHANISMS	A major obstacle that hampers the design of drug therapy for traumatic brain injury is the incomplete understanding of the biochemical pathways that lead to secondary cellular injury and contribute to cell death. One such pathway involves reactive species that generate potentially cytotoxic zinc ion fluctuations as a major executor of neuronal, and possibly glial, cell death. Whether zinc ions released during traumatic brain injury are toxic or protective is controversial but can be approached by investigating the exact concentrations of free zinc ions, the thresholds of compromised zinc buffering capacity, and the mechanism of cellular homeostatic control of zinc. Rapidly stretch-injured rat pheochromocytoma (PC12) cells express cellular zinc ion fluctuations that depend on the production of nitric oxide. Chelation of cellular zinc ions after rapid stretch injury, however, increases cellular reactive oxygen species. In a rat model of traumatic brain injury, parasagittal fluid percussion, analysis of the metal load of metallothionein was used as an indicator of changes in cellular zinc ion concentrations. The combined results from the cellular and in vivo investigations caution against interpreting zinc ion fluctuations in the early phase (24 h) after injury as a primarily cytotoxic event. (C) 2010 Elsevier B.V. All rights reserved.	[Li, Yuan; Maret, Wolfgang] Univ Texas Med Branch, Div Human Nutr, Dept Prevent Med & Community Hlth, Galveston, TX 77555 USA; [Hawkins, Bridget E.; DeWitt, Douglas S.; Prough, Donald S.; Maret, Wolfgang] Univ Texas Med Branch, Dept Anesthesiol, Galveston, TX 77555 USA	Li, Y (corresponding author), Harvard Univ, Sch Publ Hlth, Dept Genet & Complex Dis, 677 Huntington Ave,Bldg 2,Rm 133, Boston, MA 02115 USA.	yuan@hsph.harvard.edu	Hawkins, Bridget/H-4933-2015; Prough, Donald S/G-5793-2013	Hawkins, Bridget/0000-0002-1887-3657; Prough, Donald S/0000-0001-7994-532X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS042849]; National Institutes of Environmental Health SciencesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [ES007254]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [T32ES007254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS042849] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health grant NS042849 (to DSP), and in part by a predoctoral fellowship (to BEH) from the National Institutes of Environmental Health Sciences training grant ES007254. We thank Margaret A. Parsley for her technical assistance and Dr. Alai Tan for help with the statistical analyses.	Adamo AM, 2010, NEUROTOX RES, V17, P1, DOI 10.1007/s12640-009-9067-4; Ahmed SM, 2000, J NEUROCHEM, V74, P1951, DOI 10.1046/j.1471-4159.2000.741951000000000.x; Aizenman E, 2000, J NEUROCHEM, V75, P1878, DOI 10.1046/j.1471-4159.2000.0751878.x; Aras MA, 2009, J NEUROCHEM, V110, P106, DOI 10.1111/j.1471-4159.2009.06106.x; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Atahan E, 2010, BIOL TRACE ELEM RES, V137, P206, DOI 10.1007/s12011-009-8568-6; Beauchamp K, 2008, MOL MED, V14, P731, DOI 10.2119/2008-00050.Beauchamp; Bossy-Wetzel E, 2004, NEURON, V41, P351, DOI 10.1016/S0896-6273(04)00015-7; Bozym RA, 2006, ACS CHEM BIOL, V1, P103, DOI 10.1021/cb500043a; Bramlett HM, 2007, PROG BRAIN RES, V161, P125, DOI 10.1016/S0079-6123(06)61009-1; Bramlett HM, 2004, J CEREBR BLOOD F MET, V24, P133, DOI 10.1097/01.WCB.0000111614.19196.04; Calderone A, 2004, J NEUROSCI, V24, P9903, DOI 10.1523/JNEUROSCI.1713-04.2004; Choi DW, 1998, ANNU REV NEUROSCI, V21, P347, DOI 10.1146/annurev.neuro.21.1.347; Cima RR, 2006, AM J PHYSIOL-GASTR L, V290, pG250, DOI 10.1152/ajpgi.00501.2004; Cortese MM, 2008, FREE RADICAL BIO MED, V44, P2002, DOI 10.1016/j.freeradbiomed.2008.02.013; Cuajungco MP, 2003, BRAIN RES REV, V41, P44, DOI 10.1016/S0165-0173(02)00219-9; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Dietrich A, 1998, BEHAV NEUROSCI, V112, P1043, DOI 10.1037/0735-7044.112.5.1043; DIETRICH WD, 1994, J NEUROTRAUM, V11, P629, DOI 10.1089/neu.1994.11.629; Dineley KE, 2003, J NEUROCHEM, V85, P563, DOI 10.1046/j.1471-4159.2003.01678.x; Dineley KE, 2008, J NEUROCHEM, V106, P2184, DOI 10.1111/j.1471-4159.2008.05536.x; Doering P, 2007, NEUROSCIENCE, V150, P93, DOI 10.1016/j.neuroscience.2007.09.066; ELLIS EF, 1995, J NEUROTRAUM, V12, P325, DOI 10.1089/neu.1995.12.325; Enriquez P, 2004, CURR PHARM DESIGN, V10, P2131; Fekete A, 2008, FREE RADICAL BIO MED, V44, P1010, DOI 10.1016/j.freeradbiomed.2007.11.022; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frederickson CJ, 2004, NEUROSCIENTIST, V10, P18, DOI 10.1177/1073858403255840; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Goforth PB, 2004, J NEUROTRAUM, V21, P719, DOI 10.1089/0897715041269704; Grady CL, 2003, HIPPOCAMPUS, V13, P572, DOI 10.1002/hipo.10114; GREENE LA, 1976, P NATL ACAD SCI USA, V73, P2424, DOI 10.1073/pnas.73.7.2424; Haase H, 2004, ANAL BIOCHEM, V333, P19, DOI 10.1016/j.ab.2004.04.039; Hall ED, 1988, J NEUROTRAUM, V5, P81, DOI 10.1089/neu.1988.5.81; Hamm RJ, 1996, J NEUROTRAUM, V13, P41, DOI 10.1089/neu.1996.13.41; Hao Q, 2005, J ALZHEIMERS DIS, V8, P161; Hellmich HL, 2008, NEUROSCI LETT, V440, P155, DOI 10.1016/j.neulet.2008.05.068; Hellmich HL, 2004, NEUROSCI LETT, V355, P221, DOI 10.1016/j.neulet.2003.10.074; KATAYAMA T, 1990, ANGIOLOGY, V41, P479, DOI 10.1177/000331979004100610; Kesner RP, 2006, BIOL PSYCHOL, V73, P3, DOI 10.1016/j.biopsycho.2006.01.004; Kochanek PM, 2008, CURR OPIN CRIT CARE, V14, P135, DOI 10.1097/MCC.0b013e3282f57564; Koh JY, 1996, SCIENCE, V272, P1013, DOI 10.1126/science.272.5264.1013; Krezel A, 2007, BIOCHEM J, V402, P551, DOI 10.1042/BJ20061044; Krezel A, 2006, J BIOL INORG CHEM, V11, P1049, DOI 10.1007/s00775-006-0150-5; Lee JY, 2008, J NEUROSCI, V28, P10919, DOI 10.1523/JNEUROSCI.3421-08.2008; Li Y, 2008, J ANAL ATOM SPECTROM, V23, P1055, DOI 10.1039/b802220h; Li Y, 2009, EXP CELL RES, V315, P2463, DOI 10.1016/j.yexcr.2009.05.016; Liaudet L, 1998, J INFECT DIS, V177, P127, DOI 10.1086/513813; MARET W, 1995, NEUROCHEM INT, V27, P111, DOI 10.1016/0197-0186(94)00173-R; Maret W, 1998, P NATL ACAD SCI USA, V95, P3478, DOI 10.1073/pnas.95.7.3478; MARET W, 1994, P NATL ACAD SCI USA, V91, P237, DOI 10.1073/pnas.91.1.237; Maret W, 1999, P NATL ACAD SCI USA, V96, P1936, DOI 10.1073/pnas.96.5.1936; Maret W, 2008, EXP GERONTOL, V43, P363, DOI 10.1016/j.exger.2007.11.005; Maret W, 2006, ANTIOXID REDOX SIGN, V8, P1419, DOI 10.1089/ars.2006.8.1419; Maret W, 2009, CHEM REV, V109, P4682, DOI 10.1021/cr800556u; Mathew BP, 1999, J NEUROTRAUM, V16, P1177, DOI 10.1089/neu.1999.16.1177; MCALLISTER TW, 1992, PSYCHIAT CLIN N AM, V15, P395; MCCLAIN CJ, 1986, J NEUROSURG, V64, P224, DOI 10.3171/jns.1986.64.2.0224; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Sensi SL, 2009, NAT REV NEUROSCI, V10, P780, DOI 10.1038/nrn2734; Spahl DU, 2003, P NATL ACAD SCI USA, V100, P13952, DOI 10.1073/pnas.2335190100; St Croix CM, 2002, AM J PHYSIOL-LUNG C, V282, pL185, DOI 10.1152/ajplung.00267.2001; Suh SW, 2000, BRAIN RES, V852, P268, DOI 10.1016/S0006-8993(99)02095-8; Turan B, 1997, AM J PHYSIOL-HEART C, V272, pH2095; Yang Y, 2001, P NATL ACAD SCI USA, V98, P5556, DOI 10.1073/pnas.101123298; Young B, 1996, J NEUROTRAUM, V13, P25, DOI 10.1089/neu.1996.13.25; Zhang L, 1996, SCIENCE, V274, P1921, DOI 10.1126/science.274.5294.1921	66	23	23	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	MAY 12	2010	1330						131	141		10.1016/j.brainres.2010.03.034			11	Neurosciences	Neurosciences & Neurology	599FP	WOS:000277896800013	20303343	Green Accepted			2021-06-18	
J	Gardner, A; Shores, EA; Batchelor, J				Gardner, Andrew; Shores, E. Arthur; Batchelor, Jennifer			Reduced Processing Speed in Rugby Union Players Reporting Three or More Previous Concussions	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						Sports-related concussion; Computerized neuropsychological tests	SPORTS-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HIGH-SCHOOL; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; RECOVERY; HISTORY; MANAGEMENT; RETURN	The issue pertaining to the effect of multiple self-reported sports-related concussions on cognitive function is controversial. Although this topic has received increased attention in the literature recently, the issue remains unresolved. Evidence supporting a detrimental cognitive effect has been reported at a sub-concussive level and following one, two, and three or more previous concussions. However, numerous studies have been unable to replicate these findings. Additionally, discrepancies between neuropsychological testing formats have been identified, where studies utilizing traditional tests tend to support the notion of detrimental cognitive effects whereas studies with computerized tests have tended to demonstrate no effect. The present study sought to examine possible detrimental cognitive effects in a sample of adult male rugby union players who reported a history of three or more concussions (n = 34) compared with those who reported no previous concussions (n = 39). A computerized neuropsychological battery and a traditional neuropsychological measure of processing speed were administered for this purpose. Findings revealed that there were differences between groups on two processing speed measures from both traditional and computerized tests. Athletes with a history of multiple concussions performed significantly lower on these measures than those with no history of concussion. These results provide further evidence to suggest that a history of three or more self-reported concussions in active athletes may have a detrimental effect on cognitive function. Future research may focus on identifying moderating factors in an attempt to resolve some of the conflicting findings and identify potential athletes at risk for sustaining cognitive deficits.	[Gardner, Andrew; Shores, E. Arthur; Batchelor, Jennifer] Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia	Shores, EA (corresponding author), Macquarie Univ, Dept Psychol, N Ryde, NSW 2109, Australia.	arthur.shores@mq.edu.au	Gardner, Andrew/J-5162-2013	Shores, Edwin A/0000-0003-1553-5131; Batchelor, Jennifer/0000-0003-4438-4993	Macquarie University	Supported by Macquarie University Postgraduate Research Fund.	Broglio SP, 2006, BRIT J SPORT MED, V40, P802, DOI 10.1136/bjsm.2006.028019; Bruce JM, 2009, NEUROSURGERY, V64, P100, DOI 10.1227/01.NEU.0000336310.47513.C8; Cantu RC, 2003, CLIN SPORT MED, V22, P593, DOI 10.1016/S0278-5919(02)00095-9; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Collie A, 2006, BRIT J SPORT MED, V40, P550, DOI 10.1136/bjsm.2005.019802; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; Collins MW, 2002, NEUROSURGERY, V51, P1175, DOI 10.1097/00006123-200211000-00011; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; Echemendia RJ, 2003, APPL NEUROPSYCHOL, V10, P48, DOI 10.1207/S15324826AN1001_7; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gaetz M, 2000, BRAIN INJURY, V14, P1077; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hollis SJ, 2009, AM J SPORT MED, V37, P2328, DOI 10.1177/0363546509341032; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2006, BRIT J SPORT MED, V40, P72, DOI 10.1136/bjsm.2005.020651; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, J INT NEUROPSYCH SOC, V10, P904, DOI 10.1017/S1355617704106139; Iverson GL, 2004, BRAIN INJURY, V18, P433, DOI 10.1080/02699050310001617352; Lovell M, 2004, CLIN SPORT MED, V23, P421, DOI 10.1016/j.csm.2004.04.001; Lovell M, 2009, CLIN SPORT MED, V28, P95, DOI 10.1016/j.csm.2008.08.008; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2009, J SCI MED SPORT, V12, P340, DOI 10.1016/j.jsams.2009.02.004; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Moser RS, 2005, NEUROSURGERY, V57, P300, DOI 10.1227/01.NEU.0000166663.98616.E4; Moser RS, 2002, ARCH CLIN NEUROPSYCH, V17, P91, DOI 10.1016/S0887-6177(01)00108-1; Pellman EJ, 2004, NEUROSURGERY, V55, P1290, DOI 10.1227/01.NEU.0000149244.97560.91; Rabadi MH, 2001, CLIN J SPORT MED, V11, P194, DOI 10.1097/00042752-200107000-00011; Randolph C, 2005, J ATHL TRAINING, V40, P139; Shuttleworth-Rdwards AB, 2008, ARCH CLIN NEUROPSYCH, V23, P511, DOI 10.1016/j.acn.2008.05.002; Slobounov S, 2007, NEUROSURGERY, V61, P338, DOI 10.1227/01.NEU.0000280001.03578.FF; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Wall SE, 2006, J NEUROL NEUROSUR PS, V77, P518, DOI 10.1136/jnnp.2004.061044; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D, 1997, WAIS 3 ADM SCORING M	35	23	23	0	19	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	0887-6177	1873-5843		ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	MAY	2010	25	3					174	181		10.1093/arclin/acq007			8	Psychology, Clinical; Psychology	Psychology	587MC	WOS:000276995600002	20202986	Bronze			2021-06-18	
J	Gao, GY; Oda, Y; Wei, EP; Povlishock, JT				Gao, Guoyi; Oda, Yasutaka; Wei, Enoch P.; Povlishock, John T.			The adverse pial arteriolar and axonal consequences of traumatic brain injury complicated by hypoxia and their therapeutic modulation with hypothermia in rat	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						brain arterioles; DAI rat; hypothermia; hypoxia; traumatic brain injury	TO-MODERATE HYPOTHERMIA; POSTTRAUMATIC HYPOTHERMIA; MILD HYPOTHERMIA; CEREBRAL MICROCIRCULATION; SECONDARY INSULTS; PROGNOSTIC VALUE; RELAXING FACTOR; CATS; HYPOTENSION; IMPACT	This study examined the effect of posttraumatic hypoxia on cerebral vascular responsivity and axonal damage, while also exploring hypothermia's potential to attenuate these responses. Rats were subjected to impact acceleration injury (IAI) and equipped with cranial windows to assess vascular reactivity to topical acetylcholine, with postmortem analyses using antibodies to amyloid precursor protein to assess axonal damage. Animals were subjected to hypoxia alone, IAI and hypoxia, IAI and hypoxia before induction of moderate hypothermia (33 degrees C), IAI and hypoxia induced during hypothermic intervention, and IAI and hypoxia initiated after hypothermia. Hypoxia alone had no impact on vascular reactivity or axonal damage. Acceleration injury and posttraumatic hypoxia resulted in dramatic axonal damage and altered vascular reactivity. When IAI and hypoxia were followed by hypothermic intervention, no axonal or vascular protection ensued. However, when IAI was followed by hypoxia induced during hypothermia, axonal and vascular protection followed. When this same hypoxic insult followed the use of hypothermia, no benefit ensued. These studies show that early hypoxia and delayed hypoxia exert damaging axonal and vascular consequences. Although this damage is attenuated by hypothermia, this follows only when hypoxia occurs during hypothermia, with no benefit found if the hypoxic insult proceeds or follows hypothermia. Journal of Cerebral Blood Flow & Metabolism (2010) 30, 628-637; doi: 10.1038/jcbfm.2009.235; published online 11 November 2009	[Gao, Guoyi; Oda, Yasutaka; Wei, Enoch P.; Povlishock, John T.] Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, Richmond, VA 23298 USA; [Gao, Guoyi] Shanghai Jiao Tong Univ, Sch Med, Renji Hosp, Dept Neurosurg, Shanghai 200030, Peoples R China; [Oda, Yasutaka] Yamaguchi Univ, Adv Med Emergency & Crit Care Ctr, Yamaguchi, Japan	Povlishock, JT (corresponding author), Virginia Commonwealth Univ, Med Ctr, Dept Anat & Neurobiol, POB 980709, Richmond, VA 23298 USA.	jtpovlis@vcu.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS 057175, HD 055813]	This study was supported by NIH Grants NS 057175 and HD 055813. No portion of the paper has been presented previously.	Clifton GL, 2009, J NEUROTRAUM, V26, P393, DOI 10.1089/neu.2008.0556; Dietrich WD, 2009, J NEUROTRAUM, V26, P301, DOI 10.1089/neu.2008.0806; DIETRICH WD, 1992, J NEUROTRAUM, V9, pS475; ELLIS EF, 1983, PROSTAGLANDINS, V26, P917, DOI 10.1016/0090-6980(83)90154-5; Geeraerts T, 2008, INTENS CARE MED, V34, P551, DOI 10.1007/s00134-007-0863-0; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; ISHIGE N, 1987, NEUROSURGERY, V20, P854, DOI 10.1227/00006123-198706000-00006; ISHIGE N, 1987, NEUROSURGERY, V20, P848, DOI 10.1227/00006123-198706000-00005; Jiang JY, 2007, CURR OPIN CRIT CARE, V13, P153, DOI 10.1097/MCC.0b013e32807f2a80; Jiang JY, 2009, J NEUROTRAUM, V26, P399, DOI 10.1089/neu.2008.0525; Jiang JY, 2004, NEUROSURGERY, V54, P713, DOI 10.1227/01.NEU.0000109535.58429.49; JIANG JY, 1991, J NEUROSURG, V74, P492, DOI 10.3171/jns.1991.74.3.0492; Jiang JY, 2006, J CEREBR BLOOD F MET, V26, P771, DOI 10.1038/sj.jcbfm.9600253; Koizumi H, 1998, J NEUROSURG, V89, P303, DOI 10.3171/jns.1998.89.2.0303; KONTOS HA, 1992, J NEUROTRAUM, V9, P349, DOI 10.1089/neu.1992.9.349; KONTOS HA, 1988, AM J PHYSIOL, V255, pH1259; LEVASSEUR JE, 1975, STROKE, V6, P308, DOI 10.1161/01.STR.6.3.308; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marmarou CR, 2005, J NEUROTRAUM, V22, P1066, DOI 10.1089/neu.2005.22.1066; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McHugh GS, 2007, J NEUROTRAUM, V24, P287, DOI 10.1089/neu.2006.0031; Murray GD, 2007, J NEUROTRAUM, V24, P329, DOI 10.1089/neu.2006.0035; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Povlishock J T, 1980, Adv Exp Med Biol, V131, P227; Povlishock JT, 2009, J NEUROTRAUM, V26, P333, DOI 10.1089/neu.2008.0604; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; Reed AR, 2002, SAMJ S AFR MED J, V92, P221; Robertson CL, 2000, CRIT CARE MED, V28, P3218, DOI 10.1097/00003246-200009000-00017; Rockswold GL, 2006, J NEUROSURG, V104, P170, DOI 10.3171/jns.2006.104.1.170; ROSNER G, 2003, JEMS, V28, P118; Rosner Gregg, 2003, JEMS, V28, P100; Schneider A, 2008, ANAESTHESIST, V57, P197, DOI 10.1007/s00101-008-1311-4; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P26, DOI 10.1136/jnnp.66.1.26; Stahel PF, 2008, INTENS CARE MED, V34, P402, DOI 10.1007/s00134-007-0889-3; Stone JR, 1999, ACTA NEUROPATHOL, V97, P335, DOI 10.1007/s004010050996; Suehiro E, 2003, J NEUROTRAUM, V20, P381, DOI 10.1089/089771503765172336; Suehiro E, 2001, J NEUROSURG, V94, P493, DOI 10.3171/jns.2001.94.3.0493; Thomas S, 2000, ACT NEUR S, V76, P397; WEI EP, 1992, STROKE, V23, P1623, DOI 10.1161/01.STR.23.11.1623; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; WEI EP, 1981, CIRC RES, V48, P95, DOI 10.1161/01.RES.48.1.95; Yamamoto M, 1999, J NEUROTRAUM, V16, P487, DOI 10.1089/neu.1999.16.487	42	23	23	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAR	2010	30	3					628	637		10.1038/jcbfm.2009.235			10	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	563DV	WOS:000275108900017	19904286	Bronze, Green Published			2021-06-18	
J	Sahin, S; Erturer, E; Ozturk, I; Toker, S; Seckin, F; Akman, S				Sahin, Suner; Erturer, Erden; Ozturk, Irfan; Toker, Serdar; Seckin, Faik; Akman, Senol			Radiographic and functional results of osteosynthesis using the proximal femoral nail antirotation (PFNA) in the treatment of unstable intertrochanteric femoral fractures	ACTA ORTHOPAEDICA ET TRAUMATOLOGICA TURCICA			English	Article						Bone nails; femoral neck fractures/surgery; fracture fixation, intramedullary/instrumentation/methods; hip fractures/surgery	PERTROCHANTERIC HIP-FRACTURES; TROCHANTERIC FRACTURES; SCREW-PLATE; FIXATION; FEMUR; FAILURE; GAMMA; ELEMENT	Objectives: We evaluated the radiographic and functional results of the proximal femoral nail antirotation (PFNA) system in patients with unstable intertrochanteric femoral fractures. Methods: The study included 45 patients (25 women, 20 men; mean age 72 years; range 27 to 97 years) who underwent osteosynthesis using the PFNA for unstable intertrochanteric femoral fractures. The fractures were in the right hip in 25 patients, and in the left hip in 20 patients. The fractures were classified according to the AO system. One patient had an open fracture due to firearm injury (Gustilo-Anderson 3A). The patients underwent surgery within a mean of eight days (range 2 to 21 days) from injury. The mean hospital stay was 13.5 days (range 4 to 25 days). Closed reduction was achieved in all the patients. The results were assessed clinically and radiographically. The neck-shaft angle of the femur (collodiaphysial angle) and the tip-apex distance were measured. The position of the helical screw within the femoral head was determined using the method of Cleveland and Bosworth. Clinical evaluation was made using the Harris hip score. Perioperative and postoperative complications were recorded. The mean follow-up period was 17.3 months (range 6 to 23 months). Results: The mean operation time was 37.8 min (range 22 to.118 min) and the mean blood loss was 225 ml (range 150 to 450 ml). During surgery, femoral shaft fracture occurred in three patients, and greater trochanter fracture occurred in nine patients. Union was obtained in all the patients. Reduction was poor in four patients (8.9%), acceptable in seven patients (15.6%), and good in 34 patients (75.6%). The mean collodiaphysial angle was 136.7 degrees (range 125 degrees to 148 degrees). The tip-apex distance was <25 mm in 36 patients (80%), and >= 25 mm in nine patients (20%). The position of the helical screw in the femoral head was appropriate in 38 patients (84.4%). Postoperative complications included secondary varus (n=2, 4.4%), calcification at the tip of the greater trochanter (n=7, 15.5%), sensitivity over the fascia lata (n=7), medial thigh pain (n=11, 24.4%), and screw cut-out (n=1, 2.2%). Nine patients developed femoral shortness (mean 9.4 mm; range 8 to 113 mm). Screws showed lateral displacement in five patients (11.1%), which was less than 5 mm in four patients. Secondary surgery was required in four patients (8.9%). The mean Harris hip score was 77.8. Harris hip scores were very good in 11 patients (24.4%), good in 19 patients (42.2%), moderate in nine patients (20%), and poor in six patients (13.3%). Conclusion: Due to advantages of high union rate, early postoperative mobilization, and short operation time, PFNA osteosynthesis is the method of choice for surgical treatment of unstable intertrochanteric femoral fractures.	[Toker, Serdar] Dumlupinar Univ, Fac Med, Dept Orthoped & Traumatol, TR-43270 Kutahya, Turkey; [Sahin, Suner; Erturer, Erden; Ozturk, Irfan; Seckin, Faik; Akman, Senol] Sisli Etfal Training & Res Hosp, Dept Orthoped & Traumatol, Istanbul, Turkey	Toker, S (corresponding author), Dumlupinar Univ, Fac Med, Dept Orthoped & Traumatol, Tavsanli Yolu 10 Km, TR-43270 Kutahya, Turkey.	tokerserdar@hotmail.com	Toker, Serdar/L-7990-2013; erturer, erden/AAO-2634-2020	erturer, erden/0000-0003-4489-5937			Al-yassari G, 2002, INJURY, V33, P395, DOI 10.1016/S0020-1383(02)00008-6; Banan H, 2002, INJURY, V33, P401, DOI 10.1016/S0020-1383(02)00054-2; BAUMGAERTNER MR, 1995, J BONE JOINT SURG AM, V77A, P1058, DOI 10.2106/00004623-199507000-00012; Boldin C, 2003, ACTA ORTHOP SCAND, V74, P53, DOI 10.1080/00016470310013662; Brunner A, 2008, J ORTHOP TRAUMA, V22, P731, DOI 10.1097/BOT.0b013e3181893b1b; CLEVELAND M, 1947, J BONE JOINT SURG, V29, P1049; Dodds SD, 2004, CURR OPIN ORTHOP, V15, P12; Domingo LJ, 2001, INT ORTHOP, V25, P298; DOPPELT SH, 1980, ORTHOP CLIN N AM, V11, P507; Ekstrom W, 2007, J ORTHOP TRAUMA, V21, P18, DOI 10.1097/BOT.0b013e31802b41cf; Fogagnolo F, 2004, ARCH ORTHOP TRAUM SU, V124, P31, DOI 10.1007/s00402-003-0586-9; Gotfried Y, 2000, J ORTHOP TRAUMA, V14, P490, DOI 10.1097/00005131-200009000-00005; Gotfried Y, 2004, CLIN ORTHOP RELAT R, P82, DOI 10.1097/01.blo.0000132264.14046.c2; Haidukewych GT, 2001, J BONE JOINT SURG AM, V83A, P643, DOI 10.2106/00004623-200105000-00001; HARRIS WH, 1969, J BONE JOINT SURG AM, VA 51, P737, DOI 10.2106/00004623-196951040-00012; Hay D, 2003, J BONE JOINT SURG BR, V85B, P1037, DOI 10.1302/0301-620X.85B7.14372; HORNBY R, 1989, J BONE JOINT SURG BR, V71, P619; JACOBS RR, 1980, CLIN ORTHOP RELAT R, P62; KAUFER H, 1980, CLIN ORTHOP RELAT R, P53; Kesmezacar Hayrettin, 2005, Acta Orthop Traumatol Turc, V39, P287; Lenich A, 2006, ARCH ORTHOP TRAUM SU, V126, P706, DOI 10.1007/s00402-006-0117-6; Menezes DFA, 2005, CLIN ORTHOP RELAT R, P221, DOI 10.1097/01.blo.0000176448.00020.fa; Mereddy P, 2009, INJURY, V40, P428, DOI 10.1016/j.injury.2008.10.014; Parker MJ, 1996, INT ORTHOP, V20, P163, DOI 10.1007/s002640050055; Pervez H, 2004, INJURY, V35, P994, DOI 10.1016/j.injury.2003.10.028; RHA JD, 1993, INT ORTHOP, V17, P320; Sadowski C, 2002, J BONE JOINT SURG AM, V84A, P372, DOI 10.2106/00004623-200203000-00007; Schipper IB, 2004, J BONE JOINT SURG BR, V86B, P86, DOI 10.1302/0301-620X.86B1.14455; Schipper IB, 2002, CLIN ORTHOP RELAT R, P277, DOI 10.1097/01.blo.0000026575.55792.eb; Seral B, 2004, INJURY, V35, P130, DOI 10.1016/S0020-1383(03)00076-7; Siegmeth AW, 2005, J BONE JOINT SURG BR, V87B, P1123, DOI 10.1302/0301-620X.87B8; Simmermacher RKJ, 2008, INJURY, V39, P932, DOI 10.1016/j.injury.2008.02.005; SIMPSON AHRW, 1989, INJURY, V20, P227, DOI 10.1016/0020-1383(89)90120-4; Sommers MB, 2004, J ORTHOP TRAUMA, V18, P361, DOI 10.1097/00005131-200407000-00006; STEINBERG GG, 1988, ORTHOPEDICS, V11, P265; Takigami I, 2008, BULL HOSP JT DIS, V66, P276; Tyllianakis Minos, 2004, Acta Orthop Belg, V70, P444; WOLFGANG GL, 1982, CLIN ORTHOP RELAT R, P148	38	23	43	0	14	TURKISH ASSOC ORTHOPAEDICS TRAUMATOLOGY	ISTANBUL	TIP FAKULTESI ORTOPEDI VE TRAVMATOLOJI KLINIGI, ISTANBUL, TOPKAPI 34390, TURKEY	1017-995X			ACTA ORTHOP TRAUMATO	Acta Orthop. Traumatol. Turc.	MAR-APR	2010	44	2					127	134		10.3944/AOTT.2010.2237			8	Orthopedics	Orthopedics	641OL	WOS:000281137600008	20676015	DOAJ Gold			2021-06-18	
J	Aviv, RI; Tomlinson, G; Kendall, B; Thakkar, C; Valentine, A				Aviv, Richard I.; Tomlinson, George; Kendall, Brian; Thakkar, Chandrashekhar; Valentine, Alan			Cavum Septi Pellucidi in Boxers	CANADIAN ASSOCIATION OF RADIOLOGISTS JOURNAL-JOURNAL DE L ASSOCIATION CANADIENNE DES RADIOLOGISTES			English	Article						Cavum pellucidi; Boxers; Head injury	TRAUMATIC BRAIN-INJURY; PROFESSIONAL BOXERS; SOCCER PLAYERS; VERGAE; DAMAGE; CT	Objective: Controversy exists over the significance of the isolated finding of cavum septi pellucidi (CSP) and its prevalence rate in healthy individuals and in professional boxers. Few magnetic resonance imaging (MRI) studies have looked at large cohorts of boxers. The aim of this study was to identify the prevalence and extent of a CSP among professional boxers and to compare these with a control group. Methods: MRI studies of 164 male boxers scanned for annual British boxing board license renewal were reviewed and compared with 43 control patients. CSP prevalence, size, and extent were recorded. Extent was classified as type 1, anterior to the fornix; type 2, extending up to the fornix; and type 3, extending into the cavum vergae. Parenchymal abnormalities were documented, and the Evan's ratio was used as an indication of brain atrophy. Results: A CSP was present in 40% of controls and 49% of boxers. There was a trend to a higher CSP prevalence in boxers (P = .099). No control patient had type 2 or 3 extension (P < .0009), as opposed to 30% and 16% prevalence in boxers. Three boxers increased their extent over serial imaging. No difference in CSP size was established between the 2 groups (P= .43), but there was an association between progressive scans and increased CSP size over time in boxers, independent of age (P = .05). Eight boxers demonstrated a CSP on a subsequent scan not seen on an earlier scan. Conclusion: The prevalence of a CSP is high among both control patients and boxers. There is a trend to a larger CSP with increasing number of scans without evidence of atrophy and independent of age. Boxers also have a greater posterior extent than controls. The findings may be explained by sudden increases in intracranial pressure that forced cerebrospinal fluid (CSF) through small defects in the septal leaflets, which result in an increase in size and or extent of a CSP.	[Aviv, Richard I.] Sunnybrook Med Ctr, Div Neuroradiol, Sunnybrook Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada; [Kendall, Brian; Valentine, Alan] Royal Free Hosp, London NW3 2QG, England; [Thakkar, Chandrashekhar] Royal London Hosp, London E1 1BB, England; [Tomlinson, George] Toronto Gen Res Inst, Div Clin Decis Making & Hlth Care, Toronto, ON, Canada	Aviv, RI (corresponding author), Sunnybrook Med Ctr, Div Neuroradiol, Sunnybrook Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.	Richard.aviv@sunnybrook.ca	Tomlinson, George A/L-5432-2016	Tomlinson, George A/0000-0002-9328-6399			Bodensteiner JB, 1997, SPORTS MED, V24, P361, DOI 10.2165/00007256-199724060-00002; Cabanis E A, 1986, Acta Radiol Suppl, V369, P365; CASSON IR, 1984, JAMA-J AM MED ASSOC, V251, P2663, DOI 10.1001/jama.251.20.2663; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DAVIE CA, 1995, J NEUROL NEUROSUR PS, V58, P688, DOI 10.1136/jnnp.58.6.688; HAGLUND Y, 1990, ACTA NEUROL SCAND, V82, P353; HARVEY PKP, 1974, LANCET, V2, P928; JORDAN BD, 1990, JAMA-J AM MED ASSOC, V263, P1670, DOI 10.1001/jama.263.12.1670; JORDAN BD, 1992, RADIOLOGY, V185, P509, DOI 10.1148/radiology.185.2.1410364; MACPHERSON P, 1988, NEURORADIOLOGY, V30, P506, DOI 10.1007/BF00339691; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; MAWDSLEY C, 1963, LANCET, V2, P795; MILLER ME, 1986, ARCH NEUROL-CHICAGO, V43, P821, DOI 10.1001/archneur.1986.00520080061022; Moseley IF, 2000, NEURORADIOLOGY, V42, P1, DOI 10.1007/s002340050001; NAKANO S, 1981, J COMPUT ASSIST TOMO, V5, P348, DOI 10.1097/00004728-198106000-00006; PAYNE EE, 1968, NEUROCHIRURGIA, V11, P173; SCHWIDDE JT, 1952, AMA ARCH NEUROL PSY, V67, P625, DOI 10.1001/archneurpsyc.1952.02320170043006; SHAW CM, 1969, BRAIN, V92, P213, DOI 10.1093/brain/92.1.213; SPILLANE J D, 1962, Br Med J, V2, P1205; Zhang LJ, 2003, AM J NEURORADIOL, V24, P52	21	23	24	0	2	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0846-5371			CAN ASSOC RADIOL J	Can. Assoc. Radiol. J.-J. Assoc. Can. Radiol.	FEB	2010	61	1					29	32		10.1016/j.carj.2009.09.002			4	Radiology, Nuclear Medicine & Medical Imaging	Radiology, Nuclear Medicine & Medical Imaging	554AT	WOS:000274408600006	19854608				2021-06-18	
J	Ahmadi, SA; Meier, U; Lemcke, J				Ahmadi, Sebastian A.; Meier, Ullrich; Lemcke, Johannes			Detailed long-term outcome analysis after decompressive craniectomy for severe traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; decompressive craniectomy; TBI; outcome	SF-36 HEALTH SURVEY; SEVERE HEAD-INJURY; QUALITY-OF-LIFE; FUNCTIONAL INDEPENDENCE MEASURE; BECK DEPRESSION INVENTORY; BARTHEL INDEX; FOLLOW-UP; DISABILITY; SCALE; ADULTS	Objective: To assess detailed long-term clinical outcome at least 1 year after decompressive craniectomy ( DC) in patients with severe traumatic brain injury (TBI). Methods: One hundred and thirty-one patients with severe TBI underwent DC between September 1997 and September 2005. Outcome was measured using the Glasgow Outcome Scale (GOS). Detailed outcome analysis was performed using Glasgow Outcome Scale Extended, Short-Form 36 (SF-36), Beck Depression Inventory, Trail Making Test B (TMT-B), Digit-Symbol Test (DST) and Barthel Index (BI). Results: Sixty-three patients (48.1%) died during their initial hospital stay, 27 (20.6%) were discharged in a vegetative state, 32 (24.4%) with severe disability and nine (6.9%) with moderate disability ( GOS 3 and 4, respectively). At time of follow-up 75 patients (67.7%) were either dead or in a vegetative state. Thirty patients with GOS > 2 were recruited for a detailed outcome analysis: Major depression, neurologic deficits and impaired TMT-B and DST performances were common and significantly more prevalent than in normative controls. Yet, patients reported only modestly reduced SF-36 and high BI scores. Conclusions: Despite multiple health-related problems after DC, many patients proved highly functional in activities of daily living and reported qualities of life not significantly inferior to that of healthy individuals. Depression was common and requires to be addressed with patients and caregivers. Better targeted therapies could improve neuropsychological and psychiatric outcomes in this complex cohort.	[Ahmadi, Sebastian A.] Univ Klinikum Dusseldorf, Neurochirurg Klin, D-40225 Dusseldorf, Germany; [Ahmadi, Sebastian A.; Meier, Ullrich; Lemcke, Johannes] Unfallkrankenhaus Berlin, Dept Neurosurg, Berlin, Germany	Ahmadi, SA (corresponding author), Univ Klinikum Dusseldorf, Neurochirurg Klin, Moorenstr 5, D-40225 Dusseldorf, Germany.	ahmadi@med.uni-duesseldorf.de		Lemcke, Johannes/0000-0002-8073-1625			Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Aarabi B, 2009, NEUROSURGERY, V64, P927, DOI 10.1227/01.NEU.0000341907.30831.D2; Ayuso-Mateos JL, 2001, BRIT J PSYCHIAT, V179, P308, DOI 10.1192/bjp.179.4.308; BAK JS, 1980, J CONSULT CLIN PSYCH, V48, P395, DOI 10.1037/0022-006X.48.3.395; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bullinger M, 2002, RESTOR NEUROL NEUROS, V20, P111; BULLINGER M, 1995, SOC SCI MED, V41, P1359, DOI 10.1016/0277-9536(95)00115-N; Bullinger M., 1998, SF 36 FRAGEBOGEN ZUM; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Colantonio A, 1998, ARCH PHYS MED REHAB, V79, P550, DOI 10.1016/S0003-9993(98)90072-7; Cooper DJ, 2008, J CRIT CARE, V23, P387, DOI 10.1016/j.jcrc.2007.05.002; Danish SF, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.3.FOCUS945; DAVIES ADM, 1968, J CLIN PSYCHOL, V24, P98; Draper K, 2008, NEUROPSYCHOLOGY, V22, P618, DOI 10.1037/0894-4105.22.5.618; Emanuelson I, 2003, ACTA NEUROL SCAND, V108, P332, DOI 10.1034/j.1600-0404.2003.00155.x; FANN JR, 1995, AM J PSYCHIAT, V152, P1493; Findler M, 2001, BRAIN INJURY, V15, P715, DOI 10.1080/02699050010013941; Gomez PA, 2000, ACTA NEUROCHIR, V142, P373, DOI 10.1007/s007010050445; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Hellawell DJ, 1999, BRAIN INJURY, V13, P489; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoofien D, 2001, BRAIN INJURY, V15, P189; Howard JL, 2008, J TRAUMA, V65, P380, DOI 10.1097/TA.0b013e31817c50d4; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Hutchinson P J, 2004, Curr Opin Crit Care, V10, P101, DOI 10.1097/00075198-200404000-00004; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Kwon S, 2004, STROKE, V35, P918, DOI 10.1161/01.STR.0000119385.56094.32; Langeluddecke PM, 2003, CLIN NEUROPSYCHOL, V17, P273, DOI 10.1076/clin.17.2.273.16499; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Lasa L, 2000, J AFFECT DISORDERS, V57, P261, DOI 10.1016/S0165-0327(99)00088-9; Lemcke J, 2010, ACTA NEUROCHIR SUPPL, V106, P231, DOI 10.1007/978-3-211-98811-4_43; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Lezak MD., 2004, NEUROPSYCHOLOGICAL A, V4th ed, P1016; Lippert-Gruner M, 2003, BRAIN INJURY, V17, P49, DOI 10.1080/0269905021000010230; MAHONEY F I, 1965, Md State Med J, V14, P61; McDermott S, 2005, DISABIL REHABIL, V27, P117, DOI 10.1080/09638280400007380; Morgalla MH, 2008, J NEUROSURG, V109, P685, DOI 10.3171/JNS/2008/109/10/0685; Nestvold K, 2009, BRAIN INJURY, V23, P15, DOI 10.1080/02699050802530540; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Paniak C, 1999, J HEAD TRAUMA REHAB, V14, P211, DOI 10.1097/00001199-199906000-00002; Perino C, 2001, BRAIN INJURY, V15, P139, DOI 10.1080/026990501458371; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P193, DOI 10.1136/jnnp.72.2.193; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; REITAN RM, 1992, TRAIL MAKING TEST MA, P10; Richter P, 1998, PSYCHOPATHOLOGY, V31, P160, DOI 10.1159/000066239; RICKELS E, 2006, SCHADELHIRN VERLETZU; *RKI, 2000, BGS98 RKI; Sangha H, 2005, INT J REHABIL RES, V28, P135, DOI 10.1097/00004356-200506000-00006; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schneider GH, 2002, ACT NEUR S, V81, P77; Spreen O, 1998, COMPENDIUM NEUROPSYC, P736; STEWART AL, 1992, MEASURING FUNCTIONIN, P449; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Tewes U, 1991, HDB TESTANWEISUNG; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; Tombaugh TN, 2004, ARCH CLIN NEUROPSYCH, V19, P203, DOI 10.1016/S0887-6177(03)00039-8; TREMEL SJE, 2003, THESIS HUMBOLDT U BE, P122; Turner-Stokes L, 2002, DISABIL REHABIL, V24, P383, DOI 10.1080/096382801101550; WARE JE, 1992, MED CARE, V30, P473, DOI 10.1097/00005650-199206000-00002; Ware JE, 2000, SPINE, V25, P3130, DOI 10.1097/00007632-200012150-00008; Wechsler D., 1981, WAIS R MANUAL WECHSL; Wechsler D., 1955, MANUAL WECHSLER ADUL; Whitnall L, 2006, J NEUROL NEUROSUR PS, V77, P640, DOI 10.1136/jnnp.2005.078246; Williams RF, 2009, J TRAUMA, V66, P1570, DOI 10.1097/TA.0b013e3181a594c4; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wittchen HU, 2002, HUM PSYCHOPHARM CLIN, V17, pS1, DOI 10.1002/hup.398; Woldag H, 2006, FORTSCHR NEUROL PSYC, V74, P367, DOI 10.1055/s-2006-932142; Zakzanis KK, 2005, NEUROPSYCHOLOGIA, V43, P1878, DOI 10.1016/j.neuropsychologia.2005.03.013	76	23	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	13-14					1539	1549		10.3109/02699052.2010.523049			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	691QV	WOS:000285096800003	20973624				2021-06-18	
J	Alla, S; Sullivan, SJ; McCrory, P; Schneiders, AG; Handcock, P				Alla, Sridhar; Sullivan, S. John; McCrory, Paul; Schneiders, Anthony G.; Handcock, Phil			Does exercise evoke neurological symptoms in healthy subjects?	JOURNAL OF SCIENCE AND MEDICINE IN SPORT			English	Article						Brain concussion; Neurological manifestations; Postconcussion symptoms; Exercise; Athletic injuries; Return-to-play	SPORTS-RELATED CONCUSSION; EXERTION	Concussion is a common injury in collision sports and is evidenced by a variety of signs and symptoms. The recording of neurological symptoms is an important component of screening for a concussion and in return-to-play decisions. However similar symptoms are prevalent in the general population and are reported to be associated with participation in physical activities. The purpose of this study was to document the neurological symptoms reported by healthy individuals following controlled bouts of exercise. A crossover randomised design with 2 levels of exercise intensity, moderate intensity and high intensity, each of 15 min duration was used. Participants completed a standardised postconcussion symptom checklist prior to exercise (pre), immediately following exercise (post-1) and again after 15 min of rest (post-2). 60 participants were recruited into the study. A summed symptom score was calculated and analysed with a 2-way repeated measures ANOVA procedure. The intensity x time interaction (F(2,118) = 23.94, p < 0.001) demonstrated a significant increase in symptom scores for the high intensity condition immediately following exercise (p < 0.001). Although the moderate intensity showed a similar trend this was not significant. These findings suggest that sports medicine professionals need to be aware of the effect of exercise on symptom reporting when assessing and in making return-to-play decisions. (C) 2009 Sports Medicine Australia. Published by Elsevier Ltd. All rights reserved.	[Alla, Sridhar; Sullivan, S. John; Schneiders, Anthony G.] Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand; [McCrory, Paul] Univ Melbourne, Ctr Hlth Exercise & Sports Med, Melbourne, Vic 3010, Australia; [Handcock, Phil] Univ Otago, Sch Phys Educ, Christchurch, New Zealand	Alla, S (corresponding author), Univ Otago, Ctr Physiotherapy Res, Christchurch, New Zealand.	allsr357@student.otago.ac.nz	McCrory, Paul/Q-8688-2019; Handcock, Phil/P-2400-2019; Schneiders, Anthony/F-4212-2015	Handcock, Phil/0000-0002-0753-1117; Schneiders, Anthony/0000-0002-1583-3879; McCrory, Paul/0000-0003-4850-0568			BORG G, 1987, EUR J APPL PHYSIOL O, V56, P679, DOI 10.1007/BF00424810; Covassin T, 2007, BRIT J SPORT MED, V41, P370, DOI 10.1136/bjsm.2006.032334; Duthie G, 2003, SPORTS MED, V33, P973, DOI 10.2165/00007256-200333130-00003; Iverson GL, 2003, APPL NEUROPSYCHOL, V10, P137, DOI 10.1207/S15324826AN1003_02; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; Schneiders AG, 2008, BRIT J SPORT MED, V42, P1011, DOI 10.1136/bjsm.2007.041665; Susco TM, 2004, J ATHL TRAINING, V39, P241	8	23	23	0	7	SPORTS MEDICINE AUSTRALIA	MITCHELL	3-5 CHENEY PL, PO BOX 78, MITCHELL, ACT 2911, AUSTRALIA	1440-2440			J SCI MED SPORT	J. Sci. Med. Sport	JAN	2010	13	1					24	26		10.1016/j.jsams.2008.12.629			3	Sport Sciences	Sport Sciences	547AX	WOS:000273858300006	19231284				2021-06-18	
J	Bie, XD; Han, J; Dai, HB				Bie, Xiao-Dong; Han, Jue; Dai, Hai-Bin			Effects of hydroxysafflor yellow A on the experimental traumatic brain injury in rats	JOURNAL OF ASIAN NATURAL PRODUCTS RESEARCH			English	Article						hydroxysafflor yellow A; traumatic brain injury; ATPase; SOD; t-PA; MMP-9	ISCHEMIA-REPERFUSION INJURY; OXIDATIVE STRESS; MITOCHONDRIAL DAMAGE; MECHANISMS; PROTECTS; HEART	This paper explores the effects of hydroxysafflor yellow A (HSYA) on traumatic brain injury (TBI). Rats were divided into four groups: control, TBI, TBI combined with HSYA, and TBI combined with nimodipine. Saline, HSYA, or nimodipine was i.v. injected at 30min before and 6h after the onset of TBI. The contusion volume of brain, mitochondrial ATPase activity, brain malondialdehyde (MDA) content, and the concentrations of tissue plasminogen activator (t-PA) and plasminogen activator inhibitor-1 (PAI-1) in the blood plasma were investigated. The results showed that the inhibitory rate of HSYA at a dose of 4mg/kg was 59.2% compared with the TBI group. After the insult by TBI for 48h, the activity of Na+, K+-ATPase, Ca2+-ATPase, and Mg2+-ATPase decreased to 31, 35, and 38% of control group. HSYA increased these ATPase activities by 162, 96, and 131% of TBI group. HSYA also increased superoxide dismutase activity and decreased MDA content in the right parietal lobe adjacent to contusion foci in TBI rats. HSYA enhanced the t-PA activity by 64.64%, decreased the PAI-1 activity by 71.88%, and decreased the MMP-9 expression to 49.11% in the hippocampus of the TBI group at 12h. In conclusion, HSYA may exert a potential therapeutic strategy to improve the outcome following TBI injury.	[Dai, Hai-Bin] Zhejiang Univ, Dept Pharm, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China; [Bie, Xiao-Dong] Zhejiang Univ, Dept Tradit Chinese Med, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China; [Han, Jue] Zhanongkou Community Med Care Ctr, Hangzhou 310004, Zhejiang, Peoples R China	Dai, HB (corresponding author), Zhejiang Univ, Dept Pharm, Affiliated Hosp 2, Coll Med, Hangzhou 310009, Zhejiang, Peoples R China.	haibindai@zju.edu.cn		Dai, Haibin/0000-0002-5768-2714	Zhejiang Provincial Natural Science Foundation of ChinaNatural Science Foundation of Zhejiang Province [Y207256]; Zhejiang Provincial Scientific Foundation of China [2008C33061]; Zhejiang Province Traditional Chinese Medicine Foundation of China [2004C092, 2008YA021]	This project was supported by grants from the Zhejiang Provincial Natural Science Foundation of China (Y207256), the Zhejiang Provincial Scientific Foundation of China (2008C33061), and the Zhejiang Province Traditional Chinese Medicine Foundation of China (2004C092, 2008YA021).	Anup R, 1999, INDIAN J BIOCHEM BIO, V36, P266; Biros M H, 2001, Curr Opin Crit Care, V7, P444, DOI 10.1097/00075198-200112000-00012; Blaustein M. P., 1977, AM J PHYSIOL, V1, P165; Borges N, 2004, INT J NEUROSCI, V114, P217, DOI 10.1080/00207450490249419; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; CORDIS GA, 1993, J CHROMATOGR, V632, P97, DOI 10.1016/0021-9673(93)80031-3; ENGELKE M, 1992, PHARMACOL TOXICOL, V71, P343, DOI 10.1111/j.1600-0773.1992.tb00559.x; Jang YY, 2000, PHARMACOL RES, V42, P361, DOI 10.1006/phrs.2000.0705; Kohler HP, 2000, NEW ENGL J MED, V342, P1792, DOI 10.1056/NEJM200006153422406; Kowaltowski AJ, 1999, FREE RADICAL BIO MED, V26, P463, DOI 10.1016/S0891-5849(98)00216-0; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; Liu YN, 2008, CLIN EXP PHARMACOL P, V35, P211, DOI 10.1111/j.1440-1681.2007.04814.x; Marklund N, 2006, CURR PHARM DESIGN, V12, P1645, DOI 10.2174/138161206776843340; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; MESELHY MR, 1993, CHEM PHARM BULL, V41, P1796, DOI 10.1248/cpb.41.1796; Seckin Sule, 2001, Research Communications in Molecular Pathology and Pharmacology, V109, P299; Tian JW, 2008, PHARMACOLOGY, V82, P121, DOI 10.1159/000141653; Tian JW, 2005, NEUROSCI LETT, V374, P92, DOI 10.1016/j.neulet.2004.10.030; Turrens JF, 1997, BIOSCIENCE REP, V17, P3, DOI 10.1023/A:1027374931887; Wang HC, 2007, EXP NEUROL, V206, P59, DOI 10.1016/j.expneurol.2007.03.031; Wei XB, 2005, NEUROSCI LETT, V386, P58, DOI 10.1016/j.neulet.2005.05.069; Wei YH, 2002, EXP BIOL MED, V227, P671; Zhu HB, 2005, J ASIAN NAT PROD RES, V7, P607, DOI 10.1080/10286020310001625120; Zhu HB, 2003, PLANTA MED, V69, P429, DOI 10.1055/s-2003-39714	25	23	24	0	9	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	1028-6020			J ASIAN NAT PROD RES	J. Asian Nat. Prod. Res.		2010	12	3					239	247	PII 920383890	10.1080/10286020903510636			9	Plant Sciences; Chemistry, Applied; Chemistry, Medicinal; Pharmacology & Pharmacy	Plant Sciences; Chemistry; Pharmacology & Pharmacy	594WJ	WOS:000277569900011	20390772				2021-06-18	
J	Kean, J; Trzepacz, PT; Murray, LL; Abell, M; Trexler, L				Kean, Jacob; Trzepacz, Paula T.; Murray, Laura L.; Abell, Malene; Trexler, Lance			Initial validation of a brief provisional diagnostic scale for delirium	BRAIN INJURY			English	Article						Posttraumatic amnesia; delirium; traumatic brain injury; rehabilitation	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC AMNESIA; ACUTE CONFUSION; COGNITIVE TEST; HEAD-INJURIES; RATING-SCALE; REHABILITATION; REVISED-98; CONCUSSION; SEVERITY	Primary objective: The Delirium Diagnostic Tool-Provisional (DDT-Pro) is a newly developed provisional diagnostic tool for delirium presented here. This study evaluated its accuracy and validity in a population of participants with acquired brain injury (ABI). Research design: Cross-sectional study. Methods: Thirty-six patients with ABI, including traumatic brain injury (TBI; n = 29) and intraparenchymal haemorrhage (ICH; n = 7) were assessed at admission to inpatient rehabilitation using the DDT-Pro, the Delirium Rating Scale-Revised 98 (DRS-R98) and DSM-IV-TR diagnostic criteria for delirium. Results: Using receiver operating characteristic (ROC) analysis, the estimate of accuracy, the area under the curve (AUC), was 0.994, and the DDT-Pro accurately classified 35/36 (97%) observations vs the DSM-IV-TR gold standard. The DDTPro correlated well with the DRS-R98 both in terms of raw score (r -0.913, p < 0.0001) and estimates of the duration of delirium (r = 0.975, p < 0.0001). Conclusions: The DDT-Pro is supported as a measure of delirium following ABI. Further validation in ABI and other medical populations is recommended.	[Kean, Jacob; Murray, Laura L.] Indiana Univ, Dept Speech & Hearing Sci, Bloomington, IN 47405 USA; [Kean, Jacob; Trexler, Lance] Rehabil Hosp Indiana, Indianapolis, IN USA; [Trzepacz, Paula T.] Eli Lilly & Co, Neurosci, Indianapolis, IN USA; [Trzepacz, Paula T.] Indiana Univ Sch Med, Dept Psychiat, Indianapolis, IN USA; [Abell, Malene] Indiana Univ, Dept Psychol & Brain Sci, Bloomington, IN USA; [Trexler, Lance] Indiana Univ Sch Med, Dept Phys Med & Rehabil, Indianapolis, IN USA	Kean, J (corresponding author), 4141 Shore Dr, Indianapolis, IN 46254 USA.	jakean@indiana.edu	Trzepacz, Paula/AAQ-3330-2021	Kean, Jacob/0000-0002-8577-0586			Alderson AL, 2003, ARCH PHYS MED REHAB, V84, P668, DOI 10.1016/S0003-9993(03)04842-6; *AM PSYCH PUBL, 2000, AM PSYCH PUBL STAT M; Burns A, 2004, J NEUROL NEUROSUR PS, V75, P362, DOI 10.1136/jnnp.2003.023366; EWERT J, 1989, ARCH NEUROL-CHICAGO, V46, P911, DOI 10.1001/archneur.1989.00520440105027; Franco JG, 2009, PSYCHOSOMATICS, V50, P255, DOI 10.1176/appi.psy.50.3.255; Hart RP, 1996, PSYCHOSOMATICS, V37, P533, DOI 10.1016/S0033-3182(96)71517-7; HSU LM, 1994, MULTIVAR BEHAV RES, V29, P127, DOI 10.1207/s15327906mbr2902_1; KATZ DI, 1992, J HEAD TRAUMA REHAB, V7, P1; Kennedy RE, 2003, PSYCHOSOMATICS, V44, P283, DOI 10.1176/appi.psy.44.4.283; Lipowski ZJ., 1990, DELIRIUM ACUTE CONFU; McFall RM, 1999, ANNU REV PSYCHOL, V50, P215, DOI 10.1146/annurev.psych.50.1.215; Meagher DJ, 2007, BRIT J PSYCHIAT, V190, P135, DOI 10.1192/bjp.bp.106.023911; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Nakase-Thompson R, 2004, BRAIN INJURY, V18, P131, DOI 10.1080/0269905031000149542; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; ROCKWOOD K, 1994, J AM GERIATR SOC, V42, P252, DOI 10.1111/j.1532-5415.1994.tb01747.x; Rolfson D B, 1999, Int Psychogeriatr, V11, P431, DOI 10.1017/S1041610299006043; RUSSELL WR, 1946, BRAIN, V69, P280, DOI 10.1093/brain/69.4.280; Russell WR, 1932, BRAIN, V55, P549, DOI 10.1093/brain/55.4.549; RYAN K, 2007, VALIDATION CONFUSION; Sherer M, 2005, ARCH PHYS MED REHAB, V86, P896, DOI 10.1016/j.apmr.2004.09.029; Sherer M, 2008, ARCH PHYS MED REHAB, V89, P42, DOI 10.1016/j.apmr.2007.08.128; *SPSS INC, 2008, SPSS 17 WIND; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; Symonds C P, 1937, Proc R Soc Med, V30, P1081; Symonds CP, 1935, LANCET, V1, P486; Symonds CP, 1928, BRIT MED J, V1928, P829, DOI 10.1136/bmj.2.3540.829; Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229; TRZEPACZ PT, 2004, TXB TRAUMATIC BRAIN; TRZEPACZ T, 2002, ESSENTIALS NEUROPSYC, V4, P525; Weir N, 2006, BRAIN INJURY, V20, P927, DOI 10.1080/02699050600832684; YOUDEN WJ, 1950, CANCER, V3, P32, DOI 10.1002/1097-0142(1950)3:1<32::AID-CNCR2820030106>3.0.CO;2-3	32	23	23	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2010	24	10					1222	1230		10.3109/02699052.2010.498008			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100009	20645705				2021-06-18	
J	Pahatouridis, D; Alexiou, GA; Zigouris, A; Mihos, E; Drosos, D; Voulgaris, S				Pahatouridis, Dimitrios; Alexiou, George A.; Zigouris, Andreas; Mihos, Evaggelos; Drosos, Dimitrios; Voulgaris, Spyridon			Coagulopathy in moderate head injury. The role of early administration of low molecular weight heparin	BRAIN INJURY			English	Article						Moderate head injury; coagulopathy; disseminated intravascular coagulation; low molecular weight heparin; Intravascular microthrombosis; deep venous thrombosis	DISSEMINATED INTRAVASCULAR COAGULATION; BRAIN-INJURY; TRAUMA; SYSTEM	Introduction: Abnormalities in blood coagulation are relatively common after traumatic brain injury (TBI). We prospectively studied the safety of the early antithrombotic prophylaxis with low molecular weight heparin. Methods: We prospectively evaluated 61 patients with moderate TBI. Patients requiring surgical treatment and/or with injuries in other systems were excluded. Coagulation studies included among others prothrombin time (PT), plasma fibrinogen levels and D-dimer levels. Blood samples were collected on admission and 24 h, 48 h, and 72 h later. Prophylaxis was started within 24 hours with tinzaparin. Results: In 42 of 61 patients a form of disseminated intravascular coagulation (DIC) was detected. The severity of head injury was correlated with the severity of the coagulation disorders. The PT was prolonged in the first two days. Plasma fibrinogen levels dropped initially and increased to above normal values 2-3 days later. D-dimer levels were significantly elevated and in 19 patients remained elevated throughout the study period. Clinical manifestations of DIC were not observed. Conclusions: Patients with moderate TBI are at a serious risk of developing brain intravascular microthrombosis. Our study supports the early use of low molecular weight heparin.	[Pahatouridis, Dimitrios; Alexiou, George A.; Zigouris, Andreas; Mihos, Evaggelos; Drosos, Dimitrios; Voulgaris, Spyridon] Univ Hosp Ioannina, Dept Neurosurg, Ioannina, Greece	Alexiou, GA (corresponding author), Aetideon 52, Holargos 11561, Attikis, Greece.	alexiougrg@yahoo.gr		Alexiou, George/0000-0003-0257-4481			AUER L, 1978, ACTA NEUROCHIR, V43, P51, DOI 10.1007/BF01809225; BROWD SR, 2004, PROPHYLAXIS DEEP VEN, V17; GRAHAM DI, 1971, LANCET, V1, P265; Haagh W A J J M, 2006, Ned Tijdschr Geneeskd, V150, P2530; Hess JR, 2006, J TRAUMA, V60, pS12, DOI 10.1097/01.ta.0000199545.06536.22; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; KARRICK MM, 2005, J TRAUMA, V58, P725; Keller M S, 2001, Semin Pediatr Surg, V10, P12, DOI 10.1053/spsu.2001.19381; Kleindienst A, 2003, ACTA NEUROCHIR, V145, P1085, DOI 10.1007/s00701-003-0142-y; May AK, 1997, AM SURGEON, V63, P233; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; REILLY P, 2005, HEAD INJURY PATHOPHY; Sawauchi S, 2001, NEUROL SURG TOKYO, V29, P131; Stein SC, 2004, NEUROCRIT CARE, V1, P479, DOI 10.1385/NCC:1:4:479; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Taylor FB, 2001, THROMB HAEMOSTASIS, V86, P1327; WAFAISADE A, 2009, NEUROCRIT CARE  1006	18	23	25	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2010	24	10					1189	1192		10.3109/02699052.2010.490510			4	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	667MJ	WOS:000283197100005	20642324				2021-06-18	
J	Preissig, CM; Rigby, MR				Preissig, Catherine M.; Rigby, Mark R.			A disparity between physician attitudes and practice regarding hyperglycemia in pediatric intensive care units in the United States: a survey on actual practice habits	CRITICAL CARE			English	Article							GLUCOSE CONTROL; INSULIN THERAPY; MORTALITY; VARIABILITY; MANAGEMENT; MORBIDITY; DEATH	Introduction: Hyperglycemia is common in critically ill patients and is associated with increased morbidity and mortality. Strict glycemic control improves outcomes in some adult populations and may have similar effects in children. While glycemic control has become standard care in adults, little is known regarding hyperglycemia management strategies used by pediatric critical care practitioners. We sought to assess both the beliefs and practice habits regarding glycemic control in pediatric intensive care units (ICUs) in the United States (US). Methods: We surveyed 30 US pediatric ICUs from January to May 2009. Surveys were conducted by phone between the investigators and participating centers and consisted of a 22-point questionnaire devised to assess physician perceptions and center-specific management strategies regarding glycemic control. Results: ICUs included a cross section of centers throughout the US. Fourteen out of 30 centers believe all critically ill hyperglycemic adults should be treated, while 3/30 believe all critically ill children should be treated. Twenty-nine of 30 believe some subsets of adults with hyperglycemia should be treated, while 20/30 believe some subsets of children should receive glycemic control. A total of 70%, 73%, 80%, 27%, and 40% of centers believe hyperglycemia adversely affects outcomes in cardiac, trauma, traumatic brain injury, general medical, and general surgical pediatric patients, respectively. However, only six centers use a standard, uniform approach to treat hyperglycemia at their institution. Sixty percent of centers believe hypoglycemia is more dangerous than hyperglycemia. Seventy percent listed fear of management-induced hypoglycemia as a barrier to glycemic control at their center. Conclusions: Considerable disparity exists between physician beliefs and actual practice habits regarding glycemic control among pediatric practitioners, with few centers reporting the use of any consistent standard approach to screening and management. Physicians wishing to practice glycemic control in their critically ill pediatric patients may want to consider adopting center-wide uniform approaches to improve safety and efficacy of treatment.	[Preissig, Catherine M.] Med Ctr Cent Georgia, Dept Pediat, Div Pediat Crit Care Med, Macon, GA 31201 USA; [Preissig, Catherine M.; Rigby, Mark R.] Emory Univ, Sch Med, Dept Pediat, Div Pediat Crit Care, Atlanta, GA 30322 USA	Preissig, CM (corresponding author), Med Ctr Cent Georgia, Dept Pediat, Div Pediat Crit Care Med, 777 Hemlock St, Macon, GA 31201 USA.	preissig.catherine@mccg.org					*ACE ADA TASK FORC, 2009, ENDOCR PRACT, V15, P1; [Anonymous], 2005, DIABETES CARE, V28, pS4; Branco Ricardo G, 2005, Pediatr Crit Care Med, V6, P470, DOI 10.1097/01.PCC.0000161284.96739.3A; Brunkhorst FM, 2008, NEW ENGL J MED, V358, P125, DOI 10.1056/NEJMoa070716; Clausen TD, 2005, DIABETES CARE, V28, P990; Cochran A, 2003, J TRAUMA, V55, P1035, DOI 10.1097/01.TA.0000031175.96507.48; Faustino EV, 2005, J PEDIATR-US, V146, P30, DOI 10.1016/j.jpeds.2004.08.076; Finfer S, 2009, NEW ENGL J MED, V360, P1283, DOI 10.1056/NEJMoa0810625; Finney SJ, 2003, JAMA-J AM MED ASSOC, V290, P2041, DOI 10.1001/jama.290.15.2041; Griesdale DEG, 2009, CAN MED ASSOC J, V180, P821, DOI 10.1503/cmaj.090206; Hays SP, 2006, PEDIATRICS, V118, P1811, DOI 10.1542/peds.2006-0628; Hirshberg E, 2008, PEDIATR CRIT CARE ME, V9, P361, DOI 10.1097/PCC.0b013e318172d401; Hirshberg E, 2008, CHEST, V133, P1328, DOI 10.1378/chest.07-2702; *I HEALTHC IMPR, MAINT AD GLYC CONTR; Inzucchi SE, 2006, NEW ENGL J MED, V355, P1903, DOI 10.1056/NEJMcp060094; Klein GW, 2008, J PEDIATR-US, V153, P379, DOI 10.1016/j.jpeds.2008.04.012; Krinsley JS, 2004, MAYO CLIN PROC, V79, P992, DOI 10.4065/79.8.992; Nayak P, 2009, PEDIATR CRIT CARE ME, V10, P303, DOI 10.1097/PCC.0b013e318198b012; Odetola FO, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1920; Preissig CM, 2008, PEDIATR CRIT CARE ME, V9, P581, DOI 10.1097/PCC.0b013e31818d36cb; Preissig CM, 2009, J PEDIATR-US, V155, P734, DOI 10.1016/j.jpeds.2009.05.007; Wiener RS, 2008, JAMA-J AM MED ASSOC, V300, P933, DOI 10.1001/jama.300.8.933; Srinivasan Vijay, 2004, Pediatr Crit Care Med, V5, P329, DOI 10.1097/01.PCC.0000128607.68261.7C; Van den Berghe G, 2006, NEW ENGL J MED, V354, P449, DOI 10.1056/NEJMoa052521; Van den Berghe G, 2001, NEW ENGL J MED, V345, P1359, DOI 10.1056/NEJMoa011300; Vlasselaers D, 2009, LANCET, V373, P547, DOI 10.1016/S0140-6736(09)60044-1; Wintergerst KA, 2006, PEDIATRICS, V118, P173, DOI 10.1542/peds.2005-1819; Yung M, 2008, PEDIATR CRIT CARE ME, V9, P147, DOI 10.1097/PCC.0b013e3181668c22; 2004, CRIT CARE MED, V32, P281	29	23	23	0	2	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1466-609X	1364-8535		CRIT CARE	Crit. Care		2010	14	1							R11	10.1186/cc8865			8	Critical Care Medicine	General & Internal Medicine	587KD	WOS:000276989800045	20128893	DOAJ Gold, Green Published			2021-06-18	
J	Hayes, GM				Hayes, Galina M.			Severe seizures associated with traumatic brain injury managed by controlled hypothermia, pharmacologic coma, and mechanical ventilation in a dog	JOURNAL OF VETERINARY EMERGENCY AND CRITICAL CARE			English	Article						canine; cooling; head trauma	SEVERE HEAD-INJURY; THERAPEUTIC HYPOTHERMIA; INTRACRANIAL-PRESSURE; MODERATE HYPOTHERMIA; STATUS EPILEPTICUS; MODEL	Objective To describe the management and outcome of a dog presenting with intractable seizures associated with traumatic brain injury. Case Summary A spayed female Wheaten Terrier was presented to an emergency clinic with neurologic deficits (modified Glasgow coma scale of 10) shortly after a road traffic accident. Seizures were uncontrolled despite aggressive pharmacologic intervention. Controlled hypothermia to achieve a rectal temperature of 33-35 degrees C (91.4-95 degrees F) was initiated as a protective measure to reduce intracranial pressure and cerebral metabolic rate, and to assist with seizure control. Intubation and mechanical ventilation were required to protect the airway and manage hypercapnia associated with hypoventilation. The patient went on to make a full recovery, although behavioral changes were noted by the owners for an 8-week period following injury. New or Unique Information Provided To the author's knowledge, this is the first instance of therapeutic hypothermia reported in the veterinary literature. A short review of this treatment modality is provided.	[Hayes, Galina M.] Western Vet Specialist Ctr, Emergency Dept, Calgary, AB T3C 0J8, Canada	Hayes, GM (corresponding author), Univ Guelph, Ontario Vet Coll, Dept Clin Studies, Guelph, ON N1G 2W1, Canada.	galina@uoguelph.ca					Abate MG, 2008, MINERVA ANESTESIOL, V74, P425; ALDERSON P, 2004, COCHRANE DB SYST REV, V18; BAGLEY RS, 1995, J AM VET MED ASSOC, V207, P588; BRATTON SL, 2007, J NEUROTRAUM, V24, P21; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; Chesnut Randall M., 1997, Emergency Medicine Clinics of North America, V15, P581, DOI 10.1016/S0733-8627(05)70319-9; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cohen SM, 2005, TXB CRITICAL CARE, P377; Ganong WE, 2005, REV MED PHYSL, P597; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; GRAHAM DI, 1995, BRAIN PATHOL, V5, P397, DOI 10.1111/j.1750-3639.1995.tb00618.x; KAUFMANN AM, 1992, J NEUROSURG, V77, P584, DOI 10.3171/jns.1992.77.4.0584; LOTHMAN E, 1990, NEUROLOGY, V40, P13; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; Matsushita Y, 2001, CRIT CARE MED, V29, P2060, DOI 10.1097/00003246-200111000-00004; McIntyre LA, 2003, JAMA-J AM MED ASSOC, V289, P2992, DOI 10.1001/jama.289.22.2992; Moore FA, 2004, LANCET, V363, P1988, DOI 10.1016/S0140-6736(04)16415-5; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Parviainen I, 2006, INTENS CARE MED, V32, P1075, DOI 10.1007/s00134-006-0154-1; Peterson K, 2008, J NEUROTRAUM, V25, P62, DOI 10.1089/neu.2007.0424; Platt SR, 2001, J VET INTERN MED, V15, P581, DOI 10.1892/0891-6640(2001)015&lt;0581:TPVOTM&gt;2.3.CO;2; Polderman KH, 2009, CRIT CARE MED, V37, P1101, DOI 10.1097/CCM.0b013e3181962ad5; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; POMERANZ S, 1993, J NEUROSURG, V79, P241, DOI 10.3171/jns.1993.79.2.0241; Ract C, 2007, INTENS CARE MED, V33, P645, DOI 10.1007/s00134-007-0558-6; Stocchetti N, 2007, INTENS CARE MED, V33, P1682, DOI 10.1007/s00134-007-0798-5; Sturges BK., 2009, SMALL ANIMAL CRITICA, P883; Syring RS, 2001, J AM VET MED ASSOC, V218, P1124, DOI 10.2460/javma.2001.218.1124	29	23	23	0	17	WILEY-BLACKWELL PUBLISHING, INC	MALDEN	COMMERCE PLACE, 350 MAIN ST, MALDEN 02148, MA USA	1479-3261			J VET EMERG CRIT CAR	J. Vet. Emerg. Crit. Care	DEC	2009	19	6					629	634		10.1111/j.1476-4431.2009.00478.x			6	Veterinary Sciences	Veterinary Sciences	530KQ	WOS:000272590400013	20017770				2021-06-18	
J	Jin, W; Wang, HD; Hu, ZG; Yan, W; Chen, G; Yin, HX				Jin, Wei; Wang, Han-Dong; Hu, Zhi-gang; Yan, Wei; Chen, Gang; Yin, Hong-Xia			Transcription Factor Nrf2 Plays a Pivotal Role in Protection Against Traumatic Brain Injury-Induced Acute Intestinal Mucosal Injury in Mice	JOURNAL OF SURGICAL RESEARCH			English	Article						nuclear factor E2-related factor 2; traumatic brain injury; intestine; inflammation; oxidative stress	ABERRANT CRYPT FOCI; OXIDATIVE STRESS; ENHANCES SUSCEPTIBILITY; NRF2-DEFICIENT MICE; HEAD-INJURY; RATS; CHEMOPREVENTION; CARCINOGENESIS; ANTIOXIDANT; INDUCTION	Background. Traumatic brain injury (TBI) can induce an acute intestinal mucosal injury. Nuclear factor erythroid 2-related factor 2 (Nrf2) has a unique role in many physiological stress processes, but its contribution to intestinal mucosal injury after TBI remains to be determined. Materials and Methods. Wildtype Nrf2 (+/+) and Nrf2 (-/-) deficient mice were subjected to a moderately severe weight-drop impact head injury. Intestinal mucosal morphological changes, plasma endotoxin, intestinal permeability, apoptosis, inflammatory cytokines, and antioxidant/detoxifying enzymes were measured at 24 hours after TBI. Results. Nrf2 deficient mice were found to be more susceptible to TBI-induced acute intestinal mucosal injury, as characterized by the higher increase in gut structure damage, plasma endotoxin, intestinal permeability, and apoptosis after TBI. This exacerbation of intestinal mucosal injury in Nrf2 deficient mice was associated with increased intestinal mRNA and protein expression of inflammatory cytokines such as tumor necrosis factor-alpha, interleukin-1 beta and interleukin-6, and with decreased intestinal mRNA expression and activity levels of antioxidant and detoxifying enzymes including NAD(P)H: quinone oxidoreductase 1 (NQO1) and glutathione S-transferase alpha-1 (GST-alpha 1), compared with their wildtype Nrf2 ( +/+) counterparts after TBI. Conclusions. We show for the first time that mice lacking Nrf2 are more susceptible to TBI-induced acute intestinal mucosal injury. Our data suggests that Nrf2 plays an important role in protecting TBI-induced intestinal mucosal injury, possibly by regulating of inflammatory cytokines and inducing of antioxidant and detoxifying enzymes. (C) 2009 Elsevier Inc. All rights reserved.	[Jin, Wei; Wang, Han-Dong; Hu, Zhi-gang; Chen, Gang; Yin, Hong-Xia] Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, Nanjing 210002, Jiangsu Prov, Peoples R China; [Yan, Wei] Zhejiang Univ, Sch Med, Affiliated Hosp 2, Dept Neurosurg, Hangzhou 310003, Zhejiang, Peoples R China	Wang, HD (corresponding author), Nanjing Univ, Dept Neurosurg, Sch Med, Jinling Hosp, 305 E Zhongshan Rd, Nanjing 210002, Jiangsu Prov, Peoples R China.	hdwang_jw@yahoo.com.cn	Yin, Hong/AAC-5784-2020	Yan, Wei/0000-0002-1123-0835	Jinling Hospital of China	The authors acknowledge support for this work by grants from Jinling Hospital of China. They thank Dr. Bo Wu and Dr. Geng-bao Feng for technical assistance.	Begleiter A, 2003, CANCER EPIDEM BIOMAR, V12, P566; BENSON AM, 1980, P NATL ACAD SCI-BIOL, V77, P5216, DOI 10.1073/pnas.77.9.5216; Braun S, 2002, MOL CELL BIOL, V22, P5492, DOI 10.1128/MCB.22.15.5492-5505.2002; Chen G, 2008, J SURG RES, V147, P92, DOI 10.1016/j.jss.2007.05.029; Chen XL, 2004, CURR PHARM DESIGN, V10, P879, DOI 10.2174/1381612043452901; Chung FL, 2000, CARCINOGENESIS, V21, P2287, DOI 10.1093/carcin/21.12.2287; Doig CJ, 1998, AM J RESP CRIT CARE, V158, P444, DOI 10.1164/ajrccm.158.2.9710092; HALL ED, 1985, J NEUROSURG, V62, P882, DOI 10.3171/jns.1985.62.6.0882; Hang CH, 2005, J SURG RES, V123, P188, DOI 10.1016/j.jss.2004.08.002; Hang CH, 2003, WORLD J GASTROENTERO, V9, P2776; Hang CH, 2007, J SURG RES, V137, P53, DOI 10.1016/j.jss.2006.06.026; HECHT SS, 1995, J CELL BIOCHEM, P195; Itoh K, 1997, BIOCHEM BIOPH RES CO, V236, P313, DOI 10.1006/bbrc.1997.6943; Jain AK, 2005, J BIOL CHEM, V280, P29158, DOI 10.1074/jbc.M502083200; Kelly VP, 2000, CANCER RES, V60, P957; Khor TO, 2006, CANCER RES, V66, P11580, DOI 10.1158/0008-5472.CAN-06-3562; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Lee JM, 2005, FASEB J, V19, P1061, DOI 10.1096/fj.04-2591hyp; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; McMahon M, 2001, CANCER RES, V61, P3299; Osburn WO, 2007, INT J CANCER, V121, P1883, DOI 10.1002/ijc.22943; Osburn WO, 2006, ARCH BIOCHEM BIOPHYS, V454, P7, DOI 10.1016/j.abb.2006.08.005; Owuor ED, 2002, BIOCHEM PHARMACOL, V64, P765, DOI 10.1016/S0006-2952(02)01137-1; Pilitsis JG, 2001, NEUROL RES, V23, P227, DOI 10.1179/016164101101198389; Pool-Zobel B, 2005, MUTAT RES-FUND MOL M, V591, P74, DOI 10.1016/j.mrfmmm.2005.04.020; Ramos-Gomez M, 2001, P NATL ACAD SCI USA, V98, P3410, DOI 10.1073/pnas.051618798; Rangasamy T, 2005, J EXP MED, V202, P47, DOI 10.1084/jem.20050538; Rangasamy T, 2004, J CLIN INVEST, V114, P1248, DOI 10.1172/JCI200421146; ROSS D, 1993, CANCER METAST REV, V12, P83, DOI 10.1007/BF00689803; Sasaki M, 2007, J CLIN BIOCHEM NUTR, V40, P1, DOI 10.3164/jcbn.40.1; Shapiro TA, 2001, CANCER EPIDEM BIOMAR, V10, P501; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; Soffler C, 2007, VET CLIN N AM-EQUINE, V23, P135, DOI 10.1016/j.cveq.2006.11.004; SUGIE S, 1994, CARCINOGENESIS, V15, P1555, DOI 10.1093/carcin/15.8.1555; Thimmulappa RK, 2006, J CLIN INVEST, V116, P984, DOI 10.1172/JCI25790	35	23	29	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	DEC	2009	157	2					251	260		10.1016/j.jss.2008.08.003			10	Surgery	Surgery	583CL	WOS:000276650200018	19394962				2021-06-18	
J	Laalo, JP; Kurki, TJ; Sonninen, PH; Tenovuo, OS				Laalo, Jussi P.; Kurki, Timo J.; Sonninen, Pirkko H.; Tenovuo, Olli S.			Reliability of Diagnosis of Traumatic Brain Injury by Computed Tomography in the Acute Phase	JOURNAL OF NEUROTRAUMA			English	Article						CT scanning; head trauma; traumatic brain injury	RADIOLOGY RESIDENT INTERPRETATIONS; ACUTE INTRACRANIAL HEMORRHAGE; DIFFUSE AXONAL INJURY; MINOR HEAD-INJURY; EMERGENCY-DEPARTMENT; CT; S100B; MILD; MR; SERUM	The purpose of our study was to determine the accuracy and reliability of the computed tomographic (CT) diagnosis of acute traumatic brain injury (TBI) and to evaluate the inter-observer variation of CT reports of acute TBI between two experienced neuroradiologists and a neuroradiologist in training. One hundred cranial CT examinations of suspected TBI were chosen randomly from those taken during 1 year at a university central hospital, with institutional ethics committee approval. Two neuroradiologists and one neuroradiologist in training read the scans independently and were blinded to the clinical data. The original reports of radiologists on call, who were either radiology residents or general radiologists, were reviewed. Main outcome measures were false-positive and false-negative findings, and the congruency of different readers' reports. The reference standard was a group consensus formed by three neuroradiologists. Radiologists on call missed a significant number of brain contusions (67%), but with regard to intraventricular and subarachnoid hemorrhages and edema, their accuracy was moderate. They reported practically no false-positive brain contusion findings, and all readers found subdural hemorrhages reliably. The two experienced neuroradiologists had the smallest number of false-negative findings, but their reports differed significantly. Of the other neuroradiologists' mistakes, 75% were false-positive, nearly all of these concerning contusions, whereas the other made random mistakes. In conclusion, there was a marked variation between readers in the detection of brain contusion findings on acute brain CT. Experience increased accuracy, yet even between the reports of the most experienced readers, there were marked differences.	[Laalo, Jussi P.; Sonninen, Pirkko H.] Turku Univ, Cent Hosp, Med Imaging Ctr, Turku 20521, Finland; [Tenovuo, Olli S.] Turku Univ, Cent Hosp, Dept Neurol, Turku, Finland; [Kurki, Timo J.; Sonninen, Pirkko H.] Pulssi Med Imaging Ctr, Turku, Finland	Laalo, JP (corresponding author), Turku Univ, Cent Hosp, Med Imaging Ctr, PL 52, Turku 20521, Finland.	jlaalo@utu.fi		Kurki, Timo/0000-0001-5532-3534			af Geijerstam JL, 2006, BMJ-BRIT MED J, V333, P465, DOI 10.1136/bmj.38918.669317.4F; ALFARO D, 1995, ANN EMERG MED, V25, P169, DOI 10.1016/S0196-0644(95)70319-5; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Brandstack N, 2006, BRAIN INJURY, V20, P409, DOI 10.1080/02699050500487951; Branstetter BF, 2007, ACAD RADIOL, V14, P201, DOI 10.1016/j.acra.2006.11.001; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chan T, 2008, ACAD RADIOL, V15, P290, DOI 10.1016/j.acra.2007.09.022; Chan T, 2007, COMPUT MED IMAG GRAP, V31, P285, DOI 10.1016/j.compmedimag.2007.02.010; Cooper VF, 2008, ACAD RADIOL, V15, P1198, DOI 10.1016/j.acra.2008.02.011; Davis P C, 2000, Radiology, V215 Suppl, P507; Erly WK, 2003, AM J ROENTGENOL, V180, P1727, DOI 10.2214/ajr.180.6.1801727; Ezaki Y, 2006, ACTA NEUROCHIR, V148, P547, DOI 10.1007/s00701-005-0692-2; Filippi CG, 2008, RADIOLOGY, V249, P972, DOI 10.1148/radiol.2493071543; Fiser SM, 1998, AM SURGEON, V64, P1088; GRANT JM, 1991, LANCET, V337, P215, DOI 10.1016/0140-6736(91)92169-3; HESSELINK JR, 1988, AM J ROENTGENOL, V150, P1133; HILLMAN BJ, 1976, AM J ROENTGENOL, V127, P807, DOI 10.2214/ajr.127.5.807; Huber-Wagner S, 2009, LANCET, V373, P1455, DOI 10.1016/S0140-6736(09)60232-4; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Kleindienst A, 2006, J NEUROTRAUM, V23, P1185, DOI 10.1089/neu.2006.23.1185; Kuhlmann J. N., 2008, Morphologie, V92, P68, DOI 10.1016/j.morpho.2008.06.002; Le AH, 2007, EMERG RADIOL, V14, P311, DOI 10.1007/s10140-007-0645-6; Livingston DH, 2000, ANN SURG, V232, P126, DOI 10.1097/00000658-200007000-00018; Lobato RD, 1997, ACTA NEUROCHIR, V139, P385, DOI 10.1007/BF01808871; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Muller K, 2007, J TRAUMA, V62, P1452, DOI 10.1097/TA.0b013e318047bfaa; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Pelinka LE, 2004, J NEUROTRAUM, V21, P1553, DOI 10.1089/0897715042441846; Rieger M, 2009, J TRAUMA, V66, P648, DOI 10.1097/TA.0b013e31816275f3; Rogers JM, 2007, BRAIN INJURY, V21, P1321, DOI 10.1080/02699050701765700; Routsi C, 2006, SHOCK, V26, P20, DOI 10.1097/01.shk.0000209546.06801.d7; Ruchhjoltz S, 2002, CHIRURG, V73, P1005, DOI 10.1007/s00104-002-0429-1; Ryan LM, 2003, INT REV PSYCHIATR, V15, P310, DOI 10.1080/09540260310001606692; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Sistrom C, 2008, ACAD RADIOL, V15, P934, DOI 10.1016/j.acra.2008.02.013; Smith JS, 2007, J TRAUMA, V63, P75, DOI 10.1097/01.ta.0000245991.42871.87; Strub WM, 2007, AM J NEURORADIOL, V28, P1679, DOI 10.3174/ajnr.A0653; Strub WM, 2006, EMERG RADIOL, V13, P19, DOI 10.1007/s10140-006-0498-4; Unden J, 2005, BRIT J NEUROSURG, V19, P43, DOI 10.1080/02688690500089381; van der Naalt J, 1999, ANN NEUROL, V46, P70, DOI 10.1002/1531-8249(199907)46:1<70::AID-ANA11>3.0.CO;2-L; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wardlaw JM, 2002, J NEUROL NEUROSUR PS, V72, P188, DOI 10.1136/jnnp.72.2.188; Wurmb TE, 2009, J TRAUMA, V66, P658, DOI 10.1097/TA.0b013e31817de3f4; Wysoki MG, 1998, RADIOLOGY, V208, P125, DOI 10.1148/radiology.208.1.9646802; Yuh EL, 2008, J NEUROTRAUM, V25, P1163, DOI 10.1089/neu.2008.0590	45	23	23	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	DEC	2009	26	12					2169	2178		10.1089/neu.2009.1011			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	536AI	WOS:000273013200004	19691423				2021-06-18	
J	Li, YZ; Bondada, V; Joshi, A; Geddes, JW				Li, Yanzhang; Bondada, Vimala; Joshi, Aashish; Geddes, James W.			Calpain 1 and Calpastatin expression is developmentally regulated in rat brain	EXPERIMENTAL NEUROLOGY			English	Article						Calcium; Apoptosis; Necrosis; Cell death; Injury	APOPTOSIS-INDUCING FACTOR; CELL-DEATH; MU-CALPAIN; HYPOXIA-ISCHEMIA; TRAUMATIC BRAIN; DIFFERENTIAL EXPRESSION; POSTNATAL DEVELOPMENT; CEREBRAL-CORTEX; NEURONAL DEATH; INJURY	Calpains and caspases are cysteine endopeptidases which share many similar substrates. Caspases are essential for caspase-dependent apoptotic death where calpains may play an augmentive role, while calpains are strongly implicated in necrotic cell death morphologies. Previous studies have demonstrated a down-regulation in the expression of many components of the caspase-dependent cell death pathway during CNS development. We therefore sought to determine if there is a corresponding upregulation of calpains. The major CNS calpains are the g-and m-isoforms, composed of the unique 80 kDa calpain 1 and 2 subunits, respectively, and the shared 28 kDa small subunit. In rat brain, relative protein and mRNA levels of calpain 1, calpain 2, caspase 3, and the endogenous calpain inhibitor-calpastatin, were evaluated using western blot and real-time RT-PCR. The developmental time points examined ranged from embryonic day IS until postnatal day 90. Calpain 1 and calpastatin protein and mRNA levels were low at early developmental time points and increased dramatically by P30. Conversely, caspase-3 expression was greatest at E18, and was rapidly downregulated by P30. Calpain 2 protein and mRNA levels were relatively constant throughout the E18-P90 age range examined. The inverse relationship of calpain I and caspase 3 levels during CNS development is consistent with the shift from caspase-dependent to caspase-independent cell death mechanisms following CNS injury in neonatal vs. adult rat brain. (C) 2009 Elsevier Inc. All rights reserved.	[Geddes, James W.] Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, SCoBIRC, Lexington, KY 40536 USA; [Joshi, Aashish; Geddes, James W.] Univ Kentucky, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Geddes, JW (corresponding author), Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, SCoBIRC, B477 BBSRB,741 S Limestone St, Lexington, KY 40536 USA.	jgeddes@uky.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [PO1AG10836, PO1NS058484, P30NS051220]; Kentucky Spinal Cord and Brain Injury Research Trust; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P30NS051220, P01NS058484] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P01AG010836] Funding Source: NIH RePORTER	The funding for this research was provided by NIH grants PO1AG10836, PO1NS058484, and P30NS051220; and support from the Kentucky Spinal Cord and Brain Injury Research Trust.	AGHAJANIAN G. K., 1967, BRAIN RES, V6, P716, DOI 10.1016/0006-8993(67)90128-X; Azam M, 2001, MOL CELL BIOL, V21, P2213, DOI 10.1128/MCB.21.6.2213-2220.2001; Badugu R, 2008, J BIOL CHEM, V283, P3409, DOI 10.1074/jbc.M706851200; Bittigau P, 2004, EXP TOXICOL PATHOL, V56, P83, DOI 10.1016/j.etp.2004.04.006; Bittigau P, 2003, NEUROTOX RES, V5, P475, DOI 10.1007/BF03033158; Blaschke AJ, 1996, DEVELOPMENT, V122, P1165; BLOMGREN K, 1989, NEUROCHEM RES, V14, P1149, DOI 10.1007/BF00965622; Cao GD, 2007, J NEUROSCI, V27, P9278, DOI 10.1523/JNEUROSCI.2826-07.2007; CHAKRABARTI AK, 1993, DEV BRAIN RES, V71, P107, DOI 10.1016/0165-3806(93)90111-M; de la Rosa EJ, 2000, TRENDS NEUROSCI, V23, P454, DOI 10.1016/S0166-2236(00)01628-3; Dong YN, 2006, J NEUROCHEM, V99, P206, DOI 10.1111/j.1471-4159.2006.04096.x; Dutt P, 2006, BMC DEV BIOL, V6, DOI 10.1186/1471-213X-6-3; EAYRS JT, 1959, J ANAT, V93, P385; Erecinska M, 2004, PROG NEUROBIOL, V73, P397, DOI 10.1016/j.pneurobio.2004.06.003; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Garcia M, 2005, BIOCHEM BIOPH RES CO, V338, P1241, DOI 10.1016/j.bbrc.2005.10.081; Gill R, 2002, J CEREBR BLOOD F MET, V22, P420, DOI 10.1097/00004647-200204000-00006; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Honda M, 2008, AM J PHYSIOL-CELL PH, V294, pC957, DOI 10.1152/ajpcell.00505.2007; Honda S, 2004, J BIOL CHEM, V279, P10615, DOI 10.1074/jbc.M308841200; Hu BR, 2000, J CEREBR BLOOD F MET, V20, P1294, DOI 10.1097/00004647-200009000-00003; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Joshi A, 2009, EXP NEUROL, V218, P221, DOI 10.1016/j.expneurol.2009.04.013; Kar P, 2008, ARCH BIOCHEM BIOPHYS, V470, P176, DOI 10.1016/j.abb.2007.11.018; Kar P, 2007, ARCH BIOCHEM BIOPHYS, V466, P290, DOI 10.1016/j.abb.2007.07.022; Kuchay SM, 2007, MOL CELL BIOL, V27, P6038, DOI 10.1128/MCB.00522-07; Liu CL, 2004, NEUROSCIENCE, V127, P113, DOI 10.1016/j.neuroscience.2004.03.062; Liu WF, 2002, J BIOL CHEM, V277, P8273, DOI 10.1074/jbc.M110768200; Liu XL, 2004, ANNU REV PHARMACOL, V44, P349, DOI 10.1146/annurev.pharmtox.44.101802.121804; Lu T, 2002, BBA-MOL CELL RES, V1590, P16, DOI 10.1016/S0167-4889(02)00193-3; Madden SD, 2007, INT J DEV BIOL, V51, P415, DOI 10.1387/ijdb.062263sm; Naga KK, 2007, J NEUROSCI, V27, P7469, DOI 10.1523/JNEUROSCI.0646-07.2007; Pang Z, 2003, J NEUROPATH EXP NEUR, V62, P633, DOI 10.1093/jnen/62.6.633; Polster BM, 2005, J BIOL CHEM, V280, P6447, DOI 10.1074/jbc.M413269200; PorteraCailliau C, 1997, J COMP NEUROL, V378, P88, DOI 10.1002/(SICI)1096-9861(19970203)378:1<88::AID-CNE5>3.0.CO;2-G; PorteraCailliau C, 1997, J COMP NEUROL, V378, P70; PYSH JJ, 1970, BRAIN RES, V18, P325, DOI 10.1016/0006-8993(70)90332-X; Raghupathi R, 2004, BRAIN PATHOL, V14, P215, DOI 10.1111/j.1750-3639.2004.tb00056.x; Raynaud F, 2008, INT J DEV BIOL, V52, P383, DOI 10.1387/ijdb.072448fr; Raynaud P, 2005, ARCH BIOCHEM BIOPHYS, V437, P69, DOI 10.1016/j.abb.2005.02.026; Shimohama S, 2001, BIOCHEM BIOPH RES CO, V289, P1063, DOI 10.1006/bbrc.2001.6108; SIMONSON L, 1985, BRAIN RES, V327, P153, DOI 10.1016/0006-8993(85)91509-4; STURROCK RR, 1974, J ANAT, V117, P37; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Suzuki K, 2004, DIABETES, V53, pS12, DOI 10.2337/diabetes.53.2007.S12; Syntichaki P, 2002, NATURE, V419, P939, DOI 10.1038/nature01108; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yeo W, 2004, DEV BIOL, V274, P233, DOI 10.1016/j.ydbio.2004.07.026; Zhu C, 2005, CELL DEATH DIFFER, V12, P162, DOI 10.1038/sj.cdd.4401545	51	23	24	0	2	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	DEC	2009	220	2					316	319		10.1016/j.expneurol.2009.09.004			4	Neurosciences	Neurosciences & Neurology	528FV	WOS:000272428700014	19751724	Green Accepted			2021-06-18	
J	Farias, S; Frey, LC; Murphy, RC; Heidenreich, KA				Farias, Santiago; Frey, Lauren C.; Murphy, Robert C.; Heidenreich, Kim A.			Injury-Related Production of Cysteinyl Leukotrienes Contributes to Brain Damage following Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cysteinyl leukotrienes; inflammation; mass spectrometry; traumatic brain injury	FOCAL CEREBRAL-ISCHEMIA; ARACHIDONIC-ACID; MOLECULAR-CLONING; RAT-BRAIN; BIOSYNTHESIS; RECEPTOR; MICE; 5-LIPOXYGENASE; NEUTROPHILS; METABOLISM	The leukotrienes belong to a family of biologically active lipids derived from arachidonate that are often involved in inflammatory responses. In the central nervous system, a group of leukotrienes, known as the cysteinyl leukotrienes, is generated in brain tissue in response to a variety of acute brain injuries. Although the exact clinical significance of this excess production remains unclear, the cysteinyl leukotrienes may contribute to injury-related disruption of the brain-blood barrier and exacerbate secondary injury processes. In the present study, the formation and role of cysteinyl leukotrienes was explored in the fluid percussion injury model of traumatic brain injury in rats. The results showed that levels of the cysteinyl leukotrienes were elevated after fluid percussion injury with a maximal formation 1 hour after the injury. Neutrophils contributed to cysteinyl leukotriene formation in the injured brain hemisphere, potentially through a transcellular biosynthetic mechanism. Furthermore, pharmacological reduction of cysteinyl leukotriene formation after the injury, using MK-886, resulted in reduction of brain lesion volumes, suggesting that the cysteinyl leukotrienes play an important role in traumatic brain injury.	[Farias, Santiago; Murphy, Robert C.; Heidenreich, Kim A.] Univ Colorado Denver, Dept Pharmacol, Aurora, CO 80045 USA; [Farias, Santiago; Frey, Lauren C.; Murphy, Robert C.; Heidenreich, Kim A.] Univ Colorado Denver, Neurosci Program, Aurora, CO 80045 USA; [Frey, Lauren C.] Colorado Injury Control & Res Ctr, Ft Collins, CO USA; [Heidenreich, Kim A.] Eastern Colorado Hlth Care Syst, VA Res Serv, Denver, CO USA	Heidenreich, KA (corresponding author), Univ Colorado Denver, Dept Pharmacol, Anschutz Med Campus,MS 8303,12800 E 19th Ave,POB, Aurora, CO 80045 USA.	kim.heidenreich@uchsc.edu			Colorado TBI Trust Fund; Colorado Injury Control and Research Center; Eastern Colorado Health Care System; National Institute of Heart, Lung and BloodUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [HL25785]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [HL025785]; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [R37HL025785, R01HL025785] Funding Source: NIH RePORTER	This project was supported by grants from the Colorado TBI Trust Fund Research Program, the Colorado Injury Control and Research Center, the Eastern Colorado Health Care System, the National Institute of Heart, Lung and Blood (HL25785), and the National Institutes of Health (HL025785). The authors wish to thank Erin Genova and Storey Wilson (Pathology Department, UCDenver) for their help with the histological studies, and Aaron Lepkin and Cheri Unkart for their help with the behavioral testing.	BABA T, 1991, J CEREBR BLOOD F MET, V11, P638, DOI 10.1038/jcbfm.1991.115; Ballerini P, 2005, INT J IMMUNOPATH PH, V18, P255, DOI 10.1177/039463200501800208; Beray-Berthat V, 2003, BRAIN RES, V987, P32, DOI 10.1016/S0006-8993(03)03224-4; BORGEAT P, 1979, J BIOL CHEM, V254, P7865; Boyce JA, 2005, CHEM IMMUNOL ALLERGY, V87, P59, DOI 10.1159/000087571; Busse W, 2005, CHEST, V127, P1312, DOI 10.1378/chest.127.4.1312; Capra V, 2004, PHARMACOL RES, V50, P1, DOI 10.1016/j.phrs.2003.12.012; CHIAMULERA C, 1993, BRAIN RES, V606, P251, DOI 10.1016/0006-8993(93)90992-V; Ciceri P, 2001, BRIT J PHARMACOL, V133, P1323, DOI 10.1038/sj.bjp.0704189; Deutsch J, 1997, NEUROCHEM RES, V22, P759, DOI 10.1023/A:1022030306359; Dhillon HS, 1996, J NEUROTRAUM, V13, P781, DOI 10.1089/neu.1996.13.781; Evans JF, 2008, TRENDS PHARMACOL SCI, V29, P72, DOI 10.1016/j.tips.2007.11.006; Farias SE, 2008, J LIPID RES, V49, P1990, DOI 10.1194/jlr.M800200-JLR200; Farias SE, 2007, J NEUROCHEM, V103, P1310, DOI 10.1111/j.1471-4159.2007.04830.x; Feldmann H, 1979, Acta Neurochir Suppl (Wien), V28, P74; Fiala JC, 2005, J MICROSC-OXFORD, V218, P52, DOI 10.1111/j.1365-2818.2005.01466.x; Finkelstein EA., 2006, INCIDENCE EC BURDEN; FISHER H, 2008, CRS REP C WASH DC; Frey LC, 2009, J NEUROSCI METH, V177, P267, DOI 10.1016/j.jneumeth.2008.10.022; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Goldlust EJ, 1996, STROKE, V27, P1657, DOI 10.1161/01.STR.27.9.1657; GUHLMANN A, 1989, J EXP MED, V170, P1905, DOI 10.1084/jem.170.6.1905; Haeggstrom JZ, 2004, J BIOL CHEM, V279, P50639, DOI 10.1074/jbc.R400027200; Hall LM, 1998, J AM SOC MASS SPECTR, V9, P527, DOI 10.1016/S1044-0305(98)00013-0; Hu H, 2005, ACTA PHARMACOL SIN, V26, P685, DOI 10.1111/j.1745-7254.2005.00092.x; JATANA M, 2006, J NEUROINFLAMM, V11, P3; Kitagawa K, 2004, BRAIN RES, V1004, P198, DOI 10.1016/j.brainres.2004.01.018; Lam BK, 2003, PROSTAG LEUKOTR ESS, V69, P111, DOI 10.1016/S0952-3278(03)00071-1; LANGOIS JA, 2006, TRAUMATIC BRAIN INJU; Leslie CC, 2004, PROSTAG LEUKOTR ESS, V70, P373, DOI 10.1016/j.plefa.2003.12.012; LEVIN HS, 1995, J NEUROTRAUM, V12, P913, DOI 10.1089/neu.1995.12.913; LEWIS RA, 1990, NEW ENGL J MED, V323, P645; Luo M, 2003, P NATL ACAD SCI USA, V100, P12165, DOI 10.1073/pnas.2133253100; Lynch KR, 1999, NATURE, V399, P789; Maekawa A, 2008, P NATL ACAD SCI USA, V105, P16695, DOI 10.1073/pnas.0808993105; Marmarou Anthony, 2007, Neurosurg Focus, V22, pE1; Murphy RC, 2007, BIOCHEM J, V405, P379, DOI 10.1042/BJ20070289; Nothacker HP, 2000, MOL PHARMACOL, V58, P1601; PALMBLAD J, 1984, J IMMUNOL, V132, P3041; Perri BR, 1997, J NEUROTRAUM, V14, P15, DOI 10.1089/neu.1997.14.15; Phillis John W., 2003, Critical Reviews in Neurobiology, V15, P61, DOI 10.1615/CritRevNeurobiol.v15.i1.30; Provost P, 1998, BRIT J PHARMACOL, V123, P251, DOI 10.1038/sj.bjp.0701611; Rao AM, 1999, NEUROCHEM RES, V24, P1225, DOI 10.1023/A:1020916905312; Rouzer C A, 1986, Adv Prostaglandin Thromboxane Leukot Res, V16, P3; Sarau HM, 1999, MOL PHARMACOL, V56, P657; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Schuhmann MU, 2003, NEUROL RES, V25, P481, DOI 10.1179/016164103101201896; Soares HD, 1995, J NEUROSCI, V15, P8223; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Uz T, 2008, NEUROSCI LETT, V436, P269, DOI 10.1016/j.neulet.2008.03.041; Wang ML, 2006, BIOCHEM BIOPH RES CO, V350, P399, DOI 10.1016/j.bbrc.2006.09.057; Warden DL, 2005, J NEUROTRAUM, V22, P1178; Yu GL, 2005, PHARMACOLOGY, V73, P31, DOI 10.1159/000081072; Zhang WP, 2004, NEUROSCI LETT, V363, P247, DOI 10.1016/j.neulet.2004.03.088	54	23	24	0	5	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2009	26	11					1977	1986		10.1089/neu.2009.0877			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	523CO	WOS:000272049600013	19886806	Green Published			2021-06-18	
J	Scharbrodt, W; Stein, M; Schreiber, V; Boker, DK; Oertel, MF				Scharbrodt, Wolfram; Stein, Marco; Schreiber, Vanessa; Boeker, Dieter-Karsten; Oertel, Matthias F.			The prediction of long-term outcome after subarachnoid hemorrhage as measured by the Short Form-36 Health Survey	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Glasgow Outcome Scale score; SF-36; Subarachnoid hemorrhage; Outcome	QUALITY-OF-LIFE; GOOD NEUROLOGICAL RECOVERY; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL VASOSPASM; INTRACRANIAL ANEURYSMS; PSYCHOSOCIAL OUTCOMES; COOPERATIVE ANEURYSM; SCALE; PROGNOSIS	The Glasgow Outcome Scale (GOS) score is widely used to assess Outcome after a subarachnoid hemorrhage (SAH). Patients who have recovered fully or with a mild disability (GOS scores 4 and 5) frequently complain about difficulties in conducting their daily activities. The Short Form-36 (SF-36) Health Survey is a questionnaire that assesses outcomes in multiple categories. This study was conducted to compare the quality of outcome assessment between the SF-36 Health Survey and COS scores. A total of 128 patients with SAH (all data expressed as mean +/- standard deviation) aged 53.1 +/- 12.1 years, and a mean Hunt and Hess grade on admission of 2 +/- 1, were retrospectively included in the Study. Medical charts were reviewed to assess previous medical history, location of the aneurysm and the presence of vasospasm. The SF-36 and GOS scores were collected in structured interviews approximately 5 years (+/- 2 years) after the SAH. The SF-36 data were compared to a historical healthy control cohort of 2,474 individuals. The results showed that 52% of patients experienced a favourable outcome after SAH (GOS scores 4 and 5). Vasospasm was recorded in 25% of patients. However, the average SF-36 results were lower in all tested categories for patients after SAH than the healthy normal controls. None of the SF-36 categories except physical function correlated significantly with the GOS score. Aneurysm location did not have an impact on SF-36 data. Patients after a SAH assessed as COS score 5 are significantly impaired in social functioning and general health. We conclude that patients continue to suffer neuropsychological deficits years after a SAH. The GOS score is a rough outcome measure that primarily focuses on physical functioning. SF-36 is a useful tool to include in the neuropsychological Outcome assessment of patients with SAH. (C) 2009 Elsevier Ltd. All rights reserved.	[Scharbrodt, Wolfram; Stein, Marco; Schreiber, Vanessa; Boeker, Dieter-Karsten; Oertel, Matthias F.] Univ Hosp Giessen, Dept Neurosurg, D-35385 Giessen, Germany	Oertel, MF (corresponding author), Univ Hosp Giessen, Dept Neurosurg, Klin Str 29, D-35385 Giessen, Germany.	matthias.oertel@neuro.med.uni-giessen.de					ADAMS HP, 1987, NEUROLOGY, V37, P1586, DOI 10.1212/WNL.37.10.1586; Buchanan KM, 2000, NEUROSURGERY, V46, P831, DOI 10.1097/00006123-200004000-00012; Cedzich C, 2005, ZBL NEUROCHIR, V66, P112, DOI 10.1055/s-2005-836477; Dikmen S, 2001, J NEUROTRAUM, V18, P127, DOI 10.1089/08977150150502578; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Hackett ML, 2000, NEUROLOGY, V55, P658, DOI 10.1212/WNL.55.5.658; Hop JW, 1998, STROKE, V29, P798, DOI 10.1161/01.STR.29.4.798; Hop JW, 2001, J NEUROSURG, V95, P957, DOI 10.3171/jns.2001.95.6.0957; HUNT WE, 1968, J NEUROSURG, V28, P14, DOI 10.3171/jns.1968.28.1.0014; HUTTER BO, 1993, NEUROSURGERY, V33, P999; Hutter BO, 2001, J NEUROSURG, V94, P241, DOI 10.3171/jns.2001.94.2.0241; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1975, CIBA F SYMP, V4, P3; KASSELL NF, 1983, NEUROSURGERY, V13, P479, DOI 10.1227/00006123-198311000-00001; KASSELL NF, 1982, NEUROSURGERY, V11, P337, DOI 10.1227/00006123-198209000-00001; Katati MJ, 2007, CEREBROVASC DIS, V24, P66, DOI 10.1159/000103118; Kim DH, 2005, STROKE, V36, P792, DOI 10.1161/01.STR.0000157594.58180.97; King W A, 1994, Neurosurg Clin N Am, V5, P767; Kreitschmann-Andermahr I, 2007, CLIN ENDOCRINOL, V66, P833, DOI 10.1111/j.1365-2265.2007.02821.x; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; Oertel M, 2002, J NEUROSURG, V97, P1045, DOI 10.3171/jns.2002.97.5.1045; Ohkuma H, 2001, STROKE, V32, P1176, DOI 10.1161/01.STR.32.5.1176; Powell J, 2004, J NEUROL NEUROSUR PS, V75, P1119, DOI 10.1136/jnnp.2002.000414; Powell J, 2002, J NEUROL NEUROSUR PS, V72, P772, DOI 10.1136/jnnp.72.6.772; Ransom ER, 2007, NEUROCRIT CARE, V6, P174, DOI 10.1007/s12028-007-0019-7; Rosengart AJ, 2007, J NEUROSURG, V107, P253, DOI 10.3171/JNS-07/08/0253; Satz P, 1998, BRAIN INJURY, V12, P555, DOI 10.1080/026990598122322; Schuiling WJ, 2005, STROKE, V36, P578, DOI 10.1161/01.STR.0000154862.33213.73; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; WARE JE, 1987, J CHRON DIS, V40, P473; Ware JE., 1993, SF 36 HLTH SURVEY MA; Wik Kirsten E, 2005, Tidsskr Nor Laegeforen, V125, P152	33	23	23	0	7	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2009	16	11					1409	1413		10.1016/j.jocn.2009.01.011			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	509YB	WOS:000271054100004	19581094				2021-06-18	
J	Blum, J; Hansen, M; Rommens, PM				Blum, Jochen; Hansen, Matthias; Rommens, Pol Maria			Angle-Stable Intramedullary Nailing of Proximal Humerus Fractures with the PHN (Proximal Humeral Nail)	OPERATIVE ORTHOPADIE UND TRAUMATOLOGIE			German	Article						Proximal humerus fracture; Intramedullary nailing; Angular stability; Internal fixation	SHAFT FRACTURES; INTERNAL-FIXATION; DISPLACED FRACTURES; 4-PART FRACTURES; OPEN REDUCTION; STABILIZATION; ANTEGRADE; 3-PART; HEAD	Stable fixation of two- and three-part fractures of the proximal humerus through minimally invasive operative technique and rapid bone healing as well as restoration of original anatomy. Early functional training with the goal of restoration of former mobility and daily activities. Unstabile two- and three-part fractures of the proximal humerus (AO classification: 11-A2, 11-A3, 11-B1, 11-B2, 11-B3). Subcapital nonunion of the humerus. Pathologic fractures. Pediatric fractures of the proximal humerus. Fractures of the proximal humerus types 11-C2 und 11-C3 according to the AO classification. Active local infection, e.g., after former operation. Closed reduction. Anterior acromial incision, splitting of the deltoid muscle and the rotator cuff. Opening of the medullary canal with the awl. Nail introduction. Spiral blade introduction in cannulated technique through stab incision. Distal interlocking through aiming device, angle-stable blocking of nail and blade through end cap. Postoperative fixation in Gilchrist sling until 2nd postoperative day; then physiotherapy respecting fracture type and stability, local swelling, patient's age and compliance, and concomitant injuries. 151 proximal humeral fractures were treated with a proximal humeral nail (PHN). 108 patients could be followed up 1 year postoperatively. Significant complications were perforation of the articular surface through bolts or blades (n = 8), implant-related pain (n = 10), fragment dislocation (n = 2), nonunion (n = 2), humeral head necrosis (n = 3), and superficial infection (n = 1). 1 year after the operation, the Constant-Murley Score showed a median value of 75.3 in the injured shoulder and of 89.9 in the uninjured shoulder. The DASH (Disability of the Arm, Shoulder and Hand) Score was 5.9 preoperatively and 9.3 at 1 year postoperatively. The worst results regarding the Constant-Murley Score as well as the DASH Score were found in C-type fractures.	[Blum, Jochen; Hansen, Matthias] Johannes Gutenberg Univ Mainz, Klinikum Worms, Akad Lehrkrankenhaus, Klin Unfall Hand & Wiederherstellungschirurg, D-67550 Worms, Germany; [Rommens, Pol Maria] Univ Kliniken Mainz, Klin & Poliklin Unfallchirurg, Mainz, Germany	Blum, J (corresponding author), Johannes Gutenberg Univ Mainz, Klinikum Worms, Akad Lehrkrankenhaus, Chefarzt Klin Unfall Hand & Wiederherstellungschi, D-67550 Worms, Germany.	Jochen.blum@klinikum-worms.de	Hansen, Matthias/AAH-7248-2021				Blum J, 2002, UNFALLCHIRURG, V105, P9, DOI 10.1007/s113-002-8158-5; Blum J, 2001, J ORTHOP TRAUMA, V15, P342, DOI 10.1097/00005131-200106000-00007; Blum J, 1998, UNFALLCHIRURG, V101, P342, DOI 10.1007/s001130050279; BLUM J, 2000, SURG TECHNIQUES ORTH, P10; BLUM J, 2003, AKTUEL TRAUMATOL, V33, P7; BLUM J, 2006, OSTEO TRAUMA CARE, V14, P34; Blum J, 2007, EUR J TRAUMA EMERG S, V33, P149, DOI 10.1007/s00068-007-7035-3; CONSTANT CR, 1987, CLIN ORTHOP RELAT R, P160; ESSER RD, 1994, CLIN ORTHOP RELAT R, V299, P244; FLATOW EL, 1991, J BONE JOINT SURG AM, V73A, P1213, DOI 10.2106/00004623-199173080-00011; Germann G, 1999, Handchir Mikrochir Plast Chir, V31, P149, DOI 10.1055/s-1999-13902; Hessmann MH, 2005, J TRAUMA, V58, P1194, DOI 10.1097/01.TA.0000170400.68994.AB; Hessmann MH, 2001, CHIRURG, V72, P1235, DOI 10.1007/s001040170026; HESSMANN MH, 2003, EUR J TRAUMA, V29, P253; Hintermann B, 2000, J BONE JOINT SURG BR, V82B, P1107, DOI 10.1302/0301-620X.82B8.10330; HORAKI HS, 1975, CLIN ORTHOP RELAT R, V112, P250; JIHVANG K, 1996, CLIN ORTHOP RELAT R, V327, P225; KOCIALKOWSKI A, 1990, INJURY, V21, P209, DOI 10.1016/0020-1383(90)90003-D; Lill H, 2001, CHIRURG, V72, P1224, DOI 10.1007/s001040170025; LIND T, 1989, ARCH ORTHOP TRAUM SU, V108, P285, DOI 10.1007/BF00932316; Mittlmeier TWF, 2003, J BONE JOINT SURG AM, V85A, P136, DOI 10.2106/00004623-200300004-00019; Resch H, 1997, J BONE JOINT SURG BR, V79B, P295, DOI 10.1302/0301-620X.79B2.6958; RESCH H, 2001, INJURY S1, V32; ROMMENS PM, 1995, J BONE JOINT SURG BR, V77B, P84; ROMMENS PM, 1998, CLIN ORTHOP RELAT R, V350, P26; ROMMENS PM, 1998, TECHNIQUES ORTHOPAED, V13, P51; ROSE SH, 1982, CLIN ORTHOP RELAT R, V168, P24	27	23	25	0	3	URBAN & VOGEL	MUNICH	NEUMARKTER STRASSE 43, D-81673 MUNICH, GERMANY	0934-6694	1439-0981		OPER ORTHOP TRAUMATO	Oper. Orthopade Traumatol.	SEP	2009	21	3					296	311		10.1007/s00064-009-1806-4			16	Orthopedics	Orthopedics	498ZJ	WOS:000270185400006	19779685				2021-06-18	
J	Levy, A; Bercovich-Kinori, A; Alexandrovich, AG; Tsenter, J; Trembovler, V; Lund, FE; Shohami, E; Stein, R; Mayo, L				Levy, Ayelet; Bercovich-Kinori, Adi; Alexandrovich, Alexander G.; Tsenter, Jeanna; Trembovler, Victoria; Lund, Frances E.; Shohami, Esther; Stein, Reuven; Mayo, Lior			CD38 Facilitates Recovery from Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						CD38; head trauma; microglia	CLOSED-HEAD-INJURY; CYCLIC ADP-RIBOSE; NEURONAL CELL-DEATH; OBJECT RECOGNITION; IN-VIVO; T-CELL; REACTIVE ASTROCYTES; SIGNAL-TRANSDUCTION; COGNITIVE DEFICITS; RESIDENT MICROGLIA	Traumatic brain injury (TBI) is a major cause of death and disability worldwide. It causes progressive tissue atrophy and consequent neurological dysfunctions. TBI is accompanied by neuroinflammation, a process mediated largely by microglia. CD38 is an ectoenzyme that promotes transmembrane signaling via the synthesis of potent calcium mobilizing agents or via its receptor activity. CD38 is expressed in the brain in various cell types including microglia. In previous studies, we showed that CD38 regulates microglial activation and response to chemokines. In view of the important role of neuroinflammation in TBI and the effects of CD38 on microglial responses, the present study examines the role of CD38 in the recovery of mice from closed head injury (CHI), a model of focal TBI. For this purpose, CD38-deficient and wild-type (WT) mice were subjected to a similar severity of CHI and the effect of the injury on neurobehavioral and cognitive functions was assessed by the Neurological Severity Score (NSS) and the Object Recognition Test, at various time points post-injury. The results show that recovery after CHI (as indicated by the NSS) was significantly lower in CD38-deficient mice than in WT mice and that the object recognition performance after injury was significantly impaired in injured CD38-deficient mice than in WT mice. In addition, we also observed that the amount of activated microglia/macrophages at the injury site was significantly lower in CD38-deficient mice compared with WT mice. Taken together, our findings indicate that CD38 plays a beneficial role in the recovery of mice from CHI and that this effect is mediated, at least in part, via the effect of CD38 on microglia responses.	[Levy, Ayelet; Bercovich-Kinori, Adi; Stein, Reuven; Mayo, Lior] Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, IL-69978 Ramat Aviv, Israel; [Alexandrovich, Alexander G.; Tsenter, Jeanna; Trembovler, Victoria; Shohami, Esther] Hebrew Univ Jerusalem, Dept Pharmacol, Jerusalem, Israel; [Lund, Frances E.] Univ Rochester, Dept Med, Div Allergy Immunol & Rheumatol, Rochester, NY USA	Stein, R (corresponding author), Tel Aviv Univ, George S Wise Fac Life Sci, Dept Neurobiol, IL-69978 Ramat Aviv, Israel.	reuvens@post.tau.ac.il		Mayo, Lior/0000-0002-1296-6692	Israel Science FoundationIsrael Science Foundation [643/02]; Israel Ministry of Science, Culture Sport; Adams Super-Center for Brain Research; Adams Super-Center for Brain Research [2007061]; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 AI063399]; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [R01AI063399] Funding Source: NIH RePORTER	This work was supported by the Israel Science Foundation (643/02 to R. S.), Israel Ministry of Science, Culture & Sport (Eshkol Foundation to L. M.), Adams Super-Center for Brain Research (to R. S.), U. S.-Israel Binational Science Foundation (2007061 to R. S.), and National Institutes of Health(R01 AI063399 to F. E. L.).	Adriouch S, 2007, J IMMUNOL, V179, P186, DOI 10.4049/jimmunol.179.1.186; AIHARA N, 1995, J NEUROTRAUM, V12, P53, DOI 10.1089/neu.1995.12.53; Akirav I, 2006, CEREB CORTEX, V16, P1759, DOI 10.1093/cercor/bhj114; AKIYAMA H, 1994, BRAIN RES, V635, P257, DOI 10.1016/0006-8993(94)91447-8; Allan SM, 2001, NAT REV NEUROSCI, V2, P734, DOI 10.1038/35094583; Arque G, 2008, PLOS ONE, V3, DOI 10.1371/journal.pone.0002575; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Biegon A, 2004, P NATL ACAD SCI USA, V101, P5117, DOI 10.1073/pnas.0305741101; Broadbent NJ, 2004, P NATL ACAD SCI USA, V101, P14515, DOI 10.1073/pnas.0406344101; Ceni C, 2003, BIOCHEM J, V370, P175, DOI 10.1042/BJ20020604; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; Cockayne DA, 1998, BLOOD, V92, P1324, DOI 10.1182/blood.V92.4.1324.416k26_1324_1333; Dammermann W, 2005, J BIOL CHEM, V280, P21394, DOI 10.1074/jbc.M413085200; Deaglio S, 2001, LEUKEMIA RES, V25, P1, DOI 10.1016/S0145-2126(00)00093-X; Ennaceur A, 2005, BEHAV BRAIN RES, V159, P247, DOI 10.1016/j.bbr.2004.11.006; ENNACEUR A, 1988, BEHAV BRAIN RES, V31, P47, DOI 10.1016/0166-4328(88)90157-X; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Floyd CL, 2007, PROG BRAIN RES, V161, P61, DOI 10.1016/S0079-6123(06)61005-4; Franco L, 2006, J NEUROCHEM, V99, P165, DOI 10.1111/j.1471-4159.2006.04031.x; Frasca L, 2006, BLOOD, V107, P2392, DOI 10.1182/blood-2005-07-2913; Garden GA, 2006, J NEUROIMMUNE PHARM, V1, P127, DOI 10.1007/s11481-006-9015-5; Gregorini A, 2006, CELL BIOL INT, V30, P727, DOI 10.1016/j.cellbi.2006.05.004; Grosjean MB, 2007, HISTOL HISTOPATHOL, V22, P235, DOI 10.14670/HH-22.235; Grossman R, 2003, NEUROIMAGE, V20, P1971, DOI 10.1016/j.neuroimage.2003.06.003; Guo Z, 2000, NEUROLOGY, V54, P1316, DOI 10.1212/WNL.54.6.1316; Guse AH, 2004, CURR MED CHEM, V11, P847, DOI 10.2174/0929867043455602; Hanisch UK, 2007, NAT NEUROSCI, V10, P1387, DOI 10.1038/nn1997; HOWARD M, 1993, SCIENCE, V262, P1056, DOI 10.1126/science.8235624; Krebs C, 2005, J IMMUNOL, V174, P3298, DOI 10.4049/jimmunol.174.6.3298; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; KUMAGAI MA, 1995, J EXP MED, V181, P1101, DOI 10.1084/jem.181.3.1101; Ladeby R, 2005, BRAIN RES REV, V48, P196, DOI 10.1016/j.brainresrev.2004.12.009; Laird MD, 2008, NEUROSIGNALS, V16, P154, DOI 10.1159/000111560; Lalancette-Hebert M, 2007, J NEUROSCI, V27, P2596, DOI 10.1523/JNEUROSCI.5360-06.2007; Lee HC, 2000, CHEM IMMUNOL, V75, P39; Lee HC, 2004, CURR MOL MED, V4, P227, DOI 10.2174/1566524043360753; Lund FE, 1999, J IMMUNOL, V162, P2693; Lund FE, 1998, IMMUNOL REV, V161, P79, DOI 10.1111/j.1600-065X.1998.tb01573.x; Lund FE, 2006, INT IMMUNOL, V18, P1029, DOI 10.1093/intimm/dxl037; Lye TC, 2000, NEUROPSYCHOL REV, V10, P115, DOI 10.1023/A:1009068804787; Malavasi F, 2008, PHYSIOL REV, V88, P841, DOI 10.1152/physrev.00035.2007; Matsumori Y, 2006, NEUROBIOL DIS, V22, P187, DOI 10.1016/j.nbd.2005.10.015; Mayo L, 2007, CELL DEATH DIFFER, V14, P183, DOI 10.1038/sj.cdd.4401989; Mayo L, 2008, J IMMUNOL, V181, P92, DOI 10.4049/jimmunol.181.1.92; MIZUGUCHI M, 1995, BRAIN RES, V697, P235, DOI 10.1016/0006-8993(95)00885-T; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Nadler Y, 2008, GLIA, V56, P552, DOI 10.1002/glia.20638; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Panikashvili D, 2001, NATURE, V413, P527, DOI 10.1038/35097089; Partida-Sanchez S, 2001, NAT MED, V7, P1209, DOI 10.1038/nm1101-1209; Partida-Sanchez S, 2004, J IMMUNOL, V172, P1896, DOI 10.4049/jimmunol.172.3.1896; Partida-Sanchez S, 2003, MICROBES INFECT, V5, P49, DOI 10.1016/S1286-4579(02)00055-2; Perraud AL, 2001, NATURE, V411, P595, DOI 10.1038/35079100; Plassman BL, 2000, NEUROLOGY, V55, P1158, DOI 10.1212/WNL.55.8.1158; Reshef A, 2008, J NEUROTRAUM, V25, P569, DOI 10.1089/neu.2007.0341; Schmidt OI, 2005, BRAIN RES REV, V48, P388, DOI 10.1016/j.brainresrev.2004.12.028; Schreiber V, 2006, NAT REV MOL CELL BIO, V7, P517, DOI 10.1038/nrm1963; Schuber F, 2004, CURR MOL MED, V4, P249, DOI 10.2174/1566524043360708; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shein NA, 2008, BRAIN RES, V1244, P132, DOI 10.1016/j.brainres.2008.09.032; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; Silvennoinen O, 1996, J IMMUNOL, V156, P100; Simard AR, 2007, J COMP NEUROL, V504, P716, DOI 10.1002/cne.21469; Soulet D, 2008, CURR OPIN PHARMACOL, V8, P508, DOI 10.1016/j.coph.2008.04.002; Stahel PF, 2000, J CEREBR BLOOD F MET, V20, P369, DOI 10.1097/00004647-200002000-00019; Streit WJ, 2002, GLIA, V40, P133, DOI 10.1002/glia.10154; Streit WJ, 2000, TOXICOL PATHOL, V28, P28, DOI 10.1177/019262330002800104; Tsenter J, 2008, J NEUROTRAUM, V25, P324, DOI 10.1089/neu.2007.0452; WAXWEILER RJ, 1995, J NEUROTRAUM, V12, P509, DOI 10.1089/neu.1995.12.509; Wyss-Coray T, 2006, NAT MED, V12, P1005, DOI 10.1038/nml1484; Yamada M, 1997, BRAIN RES, V756, P52, DOI 10.1016/S0006-8993(97)00117-0; Yatsiv I, 2002, J CEREBR BLOOD F MET, V22, P971, DOI 10.1097/00004647-200208000-00008; Ying WH, 2008, ANTIOXID REDOX SIGN, V10, P179, DOI 10.1089/ars.2007.1672; Ying WJ, 2007, FRONT BIOSCI-LANDMRK, V12, P2728, DOI 10.2741/2267	76	23	25	0	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	SEP	2009	26	9					1521	1533		10.1089/neu.2008.0746			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	489NG	WOS:000269426200009	19257806	Green Published			2021-06-18	
J	Bishop, FS; Finn, MA; Samuelson, M; Schmidt, RH				Bishop, Frank S.; Finn, Michael A.; Samuelson, Mical; Schmidt, Richard H.			Endovascular balloon angioplasty for treatment of posttraumatic venous sinus thrombosis Case report	JOURNAL OF NEUROSURGERY			English	Article						dural venous sinus thrombosis; balloon angioplasty; trauma; endovascular treatment	SUPERIOR SAGITTAL SINUS; CLOSED-HEAD-INJURY; DEPRESSED SKULL FRACTURE; INTRACRANIAL HYPERTENSION; MECHANICAL THROMBOLYSIS; THROMBECTOMY; UROKINASE; INFUSION; OCCLUSION; CHILDREN	In severe cases, posttraumatic cerebral sinus thrombosis can result in venous congestion and persistent intracranial hypertension refractory to both conventional medical therapy and surgical decompression. The authors report a unique case of a patient Successfully treated with endovascular mechanical thrombolysis using balloon angioplasty for clinically significant posttraumatic venous sinus thrombosis and review the reported treatments for cerebral venous sinus occlusive disease. This 18-year-old man Suffered severe closed head injury from a fall while skateboarding. A head CT scan demonstrated basilar skull fractures involving the left jugular foramen. A CT angiogram revealed thrombosis of the left transverse sinus and occlusion of the sigmoid sinus and internal jugular vein. Despite treatment with anticoagulation therapy and decompressive hemi- and suboccipital craniectomies, intracranial hypertension remained refractory. Serial angiography demonstrated progressive sinus Occlusion. Endovascular balloon thrombolysis of the left transverse and sigmoid sinuses resulted in immediate reduction of intracranial pressures and improved sinus patency. Intracranial pressure measurements remained low after the procedure. The patient eventually improved neurologically, was able to follow commands and walk, and was discharged to a rehabilitation facility for further recovery. Anticoagulation therapy, Surgical decompression, and endovascular thrombolysis have been reported as treatment modalities for clinically significant posttraumatic venous sinus thrombosis. In this case, endovascular mechanical thrombolysis with balloon angioplasty resulted in resolution of thrombus and successful immediate reduction of intracranial pressure. This treatment may be considered in patients with critically elevated intracranial pressure from posttraumatic venous sinus occlusion refractory to other treatment measures. (DOI: 10.3171/2009.2.JNS08491)	[Bishop, Frank S.; Finn, Michael A.; Samuelson, Mical; Schmidt, Richard H.] Univ Utah, Dept Neurosurg, Sch Med, Salt Lake City, UT 84132 USA	Schmidt, RH (corresponding author), Univ Utah, Dept Neurosurg, Sch Med, 175 N Med Dr E, Salt Lake City, UT 84132 USA.	neuropub@hsc.utah.edu					Canhao P, 2003, CEREBROVASC DIS, V15, P159, DOI 10.1159/000068833; Chaloupka JC, 1999, NEUROSURGERY, V45, P650, DOI 10.1097/00006123-199909000-00045; Chow K, 2000, STROKE, V31, P1420, DOI 10.1161/01.STR.31.6.1420; Curtin KR, 2004, AM J NEURORADIOL, V25, P1807; D'Alise MD, 1998, SURG NEUROL, V49, P430, DOI 10.1016/S0090-3019(97)00182-1; EINHAUPL KM, 1991, LANCET, V338, P597, DOI 10.1016/0140-6736(91)90607-Q; Gurley MB, 1996, J ENDOVASC SURG, V3, P306, DOI 10.1583/1074-6218(1996)003<0306:SSTAWI>2.0.CO;2; Kasner S E, 1998, J Stroke Cerebrovasc Dis, V7, P421, DOI 10.1016/S1052-3057(98)80126-2; Kirsch J, 2007, NEUROSURGERY, V60, P577, DOI 10.1227/01.NEU.0000255339.26027.68; Kobayashi S, 2004, J CLIN NEUROSCI, V11, P322, DOI 10.1016/S0967-5868(03)00149-8; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; Novak Z, 2000, AM J NEURORADIOL, V21, P143; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; PERSSON L, 1990, NEUROSURGERY, V26, P117, DOI 10.1227/00006123-199001000-00016; Philips MF, 1999, J NEUROSURG, V90, P65, DOI 10.3171/jns.1999.90.1.0065; Prasad RS, 2006, J PEDIAT HEMATOL ONC, V28, P196, DOI 10.1097/01.mph.0000210408.66803.f2; Soleau SW, 2003, NEUROSURGERY, V52, P534, DOI 10.1227/01.NEU.0000047815.21786.C1; Stiefel D, 2000, EUR J PEDIATR SURG, V10, P41, DOI 10.1055/s-2008-1072321; STRINGER WL, 1983, NEUROSURGERY, V12, P95; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008; Tamimi A, 2005, PEDIATR NEUROSURG, V41, P237, DOI 10.1159/000087480; Tsai FY, 2007, CARDIOVASC INTER RAD, V30, P675, DOI 10.1007/s00270-007-9046-1; vandenBrink WA, 1996, NEUROSURGERY, V38, P1044, DOI 10.1097/00006123-199605000-00039; VINES F, 1971, RADIOLOGY, V98, P9, DOI 10.1148/98.1.9; Wasay M, 2001, STROKE, V32, P2310, DOI 10.1161/hs1001.096192; Yamashita S, 2005, NEUROL MED-CHIR, V45, P635, DOI 10.2176/nmc.45.635; Yokota H, 2006, J NEUROSURG, V104, P849, DOI 10.3171/jns.2006.104.5.849	27	23	24	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2009	111	1					17	21		10.3171/2009.2.JNS08491			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	462VA	WOS:000267383900005	19326975				2021-06-18	
J	Sorani, MD; Lee, M; Kim, H; Meeker, M; Manley, GT				Sorani, Marco D.; Lee, Michaela; Kim, Helen; Meeker, Michele; Manley, Geoffrey T.			Race\Ethnicity and Outcome After Traumatic Brain Injury at a Single, Diverse Center	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						Race; Ethnicity; Traumatic brain injury; Mortality; Glasgow Outcome Scale	SEVERE HEAD-INJURY; ENDOTRACHEAL INTUBATION; FUNCTIONAL OUTCOMES; RACIAL DISPARITIES; REHABILITATION; FIELD; COMA; AGE; MANAGEMENT; MODERATE	Background: Many factors may predict mortality and disability after traumatic brain injury (TBI), including age and injury severity. However, the role of race\ethnicity has typically been studied tangentially or in homogeneous settings. We investigated whether race\ethnicity was associated with medical outcomes at a single, diverse center. Methods: We retrospectively identified patients with TBI older than 17 years with blunt injuries admitted to a Level I trauma center from 2001 to 2004. Glasgow Outcome Scale (GOS) was used to determine outcome at discharge. We performed multivariable logistic regression on two measures of outcome by dichotomizing Glasgow Outcome Scale scores. Results: We identified 357 patients with TBI from five categories: whites (46.2%), Asians (19.9%), Hispanics (17.9%), blacks (10.9%), and other\ unknown (5.0%). Without adjusting for other factors, Asians experienced higher mortality (odds ratio [OR] = 2.25, p = 0.01) compared with whites but not degree of disability. After adjusting for age and Injury Severity Score, a weaker trend remained for higher mortality in Asians (OR = 1.38, p = 0.35), and after excluding cases of assault, the finding was again significant (OR = 2.00, p = 0.04). We also confirmed the recently reported OR of higher mortality among blacks (OR = 1.30). Hispanics seemed to do slightly better at discharge. Conclusions: The question of whether and how race plays a role in TBI is controversial. At a single, diverse center, we found that mortality is associated with race, age, and Injury Severity Score. Future clinical studies will benefit from detailed genotypic and phenotypic data and should balance larger sample sizes with ethnic diversity.	[Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA 94110 USA; [Sorani, Marco D.] Univ Calif San Francisco, Program Biol & Med Informat, San Francisco, CA 94110 USA; [Kim, Helen] Univ Calif San Francisco, Dept Anesthesiol, San Francisco, CA 94110 USA; [Lee, Michaela; Meeker, Michele; Manley, Geoffrey T.] San Francisco Gen Hosp, San Francisco, CA 94110 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurosurg, 1001 Potrero Ave Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS049691, NS050173]; UCSF Brain and Spinal Injury Center; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS050173, F31NS049691] Funding Source: NIH RePORTER	Supported by NIH grants NS049691 (to M.S.) and NS050173 (to G.T.M.) and by the UCSF Brain and Spinal Injury Center.	Arango-Lasprilla JC, 2007, ARCH PHYS MED REHAB, V88, P11, DOI 10.1016/j.apmr.2006.10.029; Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; *ASS ADV AUT MED C, 1990, ABBR INJ SCAL 1990 R; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bazarian JJ, 2003, ACAD EMERG MED, V10, P1209, DOI 10.1197/S1069-6563(03)00491-3; Bochicchio GV, 2003, J TRAUMA, V54, P307, DOI 10.1097/01.TA.0000046252.97590.BE; Bowman SM, 2007, MED CARE, V45, P686, DOI 10.1097/MLR.0b013e31803dcdf3; Brown CVR, 2006, J TRAUMA, V61, P572, DOI 10.1097/01.ta.0000200842.19740.38; Burchard EG, 2004, AM J RESP CRIT CARE, V169, P386, DOI 10.1164/rccm.200309-1293OC; Burnett DM, 2000, BRAIN INJURY, V14, P713; Chi JH, 2006, J TRAUMA, V61, P1134, DOI 10.1097/01.ta.0000196644.64653.d8; Collins JK, 2004, NUTR J, V3, DOI 10.1186/1475-2891-3-15; COOPER PR, 2000, HEAD INJURY; Davis DP, 2006, J TRAUMA, V60, P985, DOI 10.1097/01.ta.0000205860.96209.1c; Elf K, 2002, CRIT CARE MED, V30, P2129, DOI 10.1097/00003246-200209000-00029; Farin A, 2003, J NEUROSURG, V98, P32, DOI 10.3171/jns.2003.98.1.0032; Gargiullo P, 2002, JAMA-J AM MED ASSOC, V287, P1391; Groswasser Z, 1998, BRAIN INJURY, V12, P805, DOI 10.1080/026990598122197; Haider AH, 2007, J TRAUMA, V62, P1259, DOI 10.1097/TA.0b013e31803c760e; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; Hartl R, 2006, J TRAUMA, V60, P1250, DOI 10.1097/01.ta.0000203717.57821.8d; Hemphill JC, 2004, STROKE, V35, P1130, DOI 10.1161/01.STR.0000125858.71051.ca; JENNETT B, 1975, LANCET, V1, P480; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; Jordan BD, 2007, NEUROCHEM RES, V32, P905, DOI 10.1007/s11064-006-9251-3; Kim H, 2007, STROKE, V38, P2430, DOI 10.1161/STROKEAHA.107.485573; Livingston DH, 2005, J TRAUMA, V59, P1298, DOI 10.1097/01.ta.0000196002.03681.18; Marwick C, 2000, JAMA-J AM MED ASSOC, V283, P989, DOI 10.1001/jama.283.8.989; Moles DR, 1999, BRIT J ORAL MAX SURG, V37, P301, DOI 10.1054/bjom.1998.0040; Mosenthal AC, 2004, J TRAUMA, V56, P1042, DOI 10.1097/01.TA.0000127767.83267.33; Munro PT, 2002, BRIT MED J, V325, P1001, DOI 10.1136/bmj.325.7371.1001; Mushkudiani NA, 2007, J NEUROTRAUM, V24, P259, DOI 10.1089/neu.2006.0028; Nathens AB, 2001, JAMA-J AM MED ASSOC, V285, P1164, DOI 10.1001/jama.285.9.1164; Odebode TO, 2004, PEDIATR SURG INT, V20, P348, DOI 10.1007/s00383-004-1196-5; Parry-Jones BL, 2006, NEUROPSYCHOL REHABIL, V16, P537, DOI 10.1080/09602010500231875; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; Riechers RG, 2005, J NEUROTRAUM, V22, P1327, DOI 10.1089/neu.2005.22.1327; Risch N., 2002, GENOME BIOL, V3, P2007, DOI [DOI 10.1186/GB-2002-3-7-COMMENT2007, DOI 10.1186/GB-2002-3-7-C0MMENT2007]; Sander AM, 2007, NEUROREHABILITATION, V22, P9; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Shigemori M, 2002, NEUROL RES, V24, P41, DOI 10.1179/016164102101199521; SLEE VN, 1978, ANN INTERN MED, V88, P424, DOI 10.7326/0003-4819-88-3-424; Smits M, 2005, JAMA-J AM MED ASSOC, V294, P1519, DOI 10.1001/jama.294.12.1519; SNIEZEK JE, 1989, JAMA-J AM MED ASSOC, V262, P2270, DOI 10.1001/jama.262.16.2270; TEASDALE G, 1976, ACTA NEUROCHIR, V34, P45, DOI 10.1007/BF01405862; Timofeev I, 2006, ACTA NEUROCHIR SUPPL, V96, P11; *US BUR CENS, 2003, US CENS BUR GUID PRE; Wall SP, 2005, ACAD EMERG MED, V12, P862, DOI 10.1197/j.aem.2005.05.003; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; Willis F, 2003, J NATL MED ASSOC, V95, P71; Winchell RJ, 1997, ARCH SURG-CHICAGO, V132, P592; 2001, RACIAL ETHNIC DIVERS; SFGH 2004 ANN REPORT; 2007, WHAT IS TRAUMATIC BR	55	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUL	2009	67	1					75	80		10.1097/TA.0b013e31818234e8			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	470CZ	WOS:000267953100013	19590312				2021-06-18	
J	Kelly, P; MacCormick, J; Strange, R				Kelly, Patrick; MacCormick, Judith; Strange, Rebecca			Non-accidental head injury in New Zealand: The outcome of referral to statutory authorities	CHILD ABUSE & NEGLECT			English	Article						Child abuse; Non-accidental head injury; Shaken baby syndrome; Child neglect; Substantiation; Risk factors; Recurrence; Legal system	SHAKEN-BABY-SYNDROME; TRAUMATIC BRAIN-INJURY; RISK-FACTORS; MALTREATMENT; CHILDREN; CHALLENGES; INFANTS; ABUSE	Objectives: To describe the outcome of referral to the statutory authorities for infants under 2 years with non-accidental head injury (NAHI), and to establish whether the authorities held sufficient information to develop a risk profile for these cases. Methods: Retrospective review of cases admitted to hospital in Auckland, New Zealand from 1988 to 1998. Records from the hospital admission, child protective services and Police were reviewed, up to 19 years from diagnosis. Results: Of 39 infants, 33 survived to leave hospital. Documentation of risk factors was erratic, and sometimes incongruent between agencies. Inter-agency case conferences took place in 17/39 (44%). The Department of Child, Youth and Family Services (CYF) used an informal family agreement to secure safety in 15/33 survivors (45%). Family Group Conferences occurred in 17/33 (52%). Nine of 33 were placed permanently outside the home (27%), two (6%) with unrelated caregivers. Charges were laid in 18/39 cases (46%). Fifteen cases came to trial, with 14 convictions (36%). Of the survivors, 44% were later renotified to CYF. There was no obvious relationship between type of intervention and re-notification. Conclusions: Ensuring the safety of an infant with NAHI, and identifying and taking appropriate action with regard to the offender, are complex tasks. In New Zealand, data collection is often incomplete and inter-agency practice and collaboration is variable. Although the rate of prosecution was relatively high by international standards, many children were later notified again for further concerns of abuse or neglect, Suggesting that our interventions have been only partially successful. Practice implications: This paper suggests that all infants admitted to hospital with non-accidental head injury should become part of a prospective inter-agency research study, using a standardised data collection instrument. This should include the systematic collection of all data known or suspected to be associated with risk of child abuse, and incorporate long-term prospective follow-up, regardless of child protective or legal outcomes. Without large numbers followed prospectively and according to sound methodology, it is difficult to prove which forms of intervention are better than others at reducing the risk of further abuse. (C) 2009 Elsevier Ltd. All rights reserved.	[Kelly, Patrick; MacCormick, Judith] Starship Childrens Hosp, Te Puaruruhau Child Abuse Assessment Unit, Auckland 1, New Zealand; [Strange, Rebecca] Auckland Dist Hlth Board & Child Youth & Family L, Auckland, New Zealand	Kelly, P (corresponding author), Starship Childrens Hosp, Te Puaruruhau Child Abuse Assessment Unit, Pk Rd,Private Bag 92024, Auckland 1, New Zealand.			Kelly, Patrick/0000-0002-8813-8877			ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; *AUCKL DISTR HLTH, 2007, LEG ISS REL CHILDR; Barlow KM, 2005, PEDIATRICS, V116, pE174, DOI 10.1542/peds.2004-2739; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Barr RG, 2006, CHILD ABUSE NEGLECT, V30, P7, DOI 10.1016/j.chiabu.2005.06.009; Barr RG, 2008, AM J PREV MED, V34, pS106, DOI 10.1016/j.amepre.2008.01.021; BROWN MJA, 2000, CARE PROTECTION IS A; *CAB HLTH FAM SERV, 2007, REP CHILD AB NEGL; Caton A, 2000, SOCIAL WORK NOW, V17, P28; Chadwick DL, 1998, PEDIATRICS, V101, P321, DOI 10.1542/peds.101.2.321; CONNOLLY M, 2006, PRACTICE NOTE CHIEF; *DEP CHILD YOUTH F, 2001, LETS STOP CHILD AB T; *DEP SOC WELF, 1999, STAT REP YEAR END 19; Dias MS, 2005, PEDIATRICS, V115, DOI 10.1542/peds.2004-1896; DOOLAN M, 1991, PREVENTING JUVENILE; Dyer C, 2005, BRIT MED J, V331, P253, DOI 10.1136/bmj.331.7511.253; Ellaway BA, 2004, ARCH DIS CHILD, V89, P845, DOI 10.1136/adc.2003.035493; Ellison K, 2008, MICH HIST REV, V34, P162; Haviland J, 1997, ARCH DIS CHILD, V77, P504, DOI 10.1136/adc.77.6.504; Hindley N, 2006, ARCH DIS CHILD, V91, P744, DOI 10.1136/adc.2005.085639; Hobbs C, 2005, ARCH DIS CHILD, V90, P952, DOI 10.1136/adc.2003.037739; Hussey JM, 2005, CHILD ABUSE NEGLECT, V29, P479, DOI 10.1016/j.chiabu.2003.12.005; Jayawant S, 1998, BMJ-BRIT MED J, V317, P1558, DOI 10.1136/bmj.317.7172.1558; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KELLY P, 2004, NZ MED J, V117, P1047; Kelly P, 2008, J PAEDIATR CHILD H, V44, P99, DOI 10.1111/j.1440-1754.2007.01234.x; King WJ, 2003, CAN MED ASSOC J, V168, P155; KIRO C, 2006, INT C FAM GROUP C; *LAW COMM, 2003, LAW COMM PUBL, V282; Mansell J., 2006, SOC POLICY J N Z, V28, P97; Minns RA, 2008, AM J PREV MED, V34, pS126, DOI 10.1016/j.amepre.2008.01.016; National Society for the Prevention of Cruelty to Children, 2002, WHICH YOU DID IT PRO; *NZ CHILDR YOUNG P, 1996, BREAK CYCL INT PROT; *OFF CHILDR COMM, 2006, SAF CHILDR HOSP; *OFF COMM CHILDR, 2003, REP INV DEATHS SJ AP; Office of the Commissioner for Children, 2000, FIN REP INV DEATH RI; OREILLY L, 1997, CASE REV VK WATSON; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Reijneveld SA, 2004, LANCET, V364, P1340, DOI 10.1016/S0140-6736(04)17191-2; RENOUF J, 1990, CHILDREN YOUNG PERSO; Ricci L, 2003, CHILD ABUSE NEGLECT, V27, P271, DOI 10.1016/S0145-2134(03)00006-1; ROBERTSON JP, 1996, 5 OFF COMM CHILDR; Runyan DK, 2008, AM J PREV MED, V34, pS112, DOI 10.1016/j.amepre.2008.01.011; Sibert JR, 2002, CHILD ABUSE NEGLECT, V26, P267, DOI 10.1016/S0145-2134(01)00324-6; Sidebotham P, 2006, CHILD ABUSE NEGLECT, V30, P497, DOI 10.1016/j.chiabu.2005.11.005; Smith JAS, 2005, J PAEDIATR CHILD H, V41, P513, DOI 10.1111/j.1440-1754.2005.00694.x; Stiffman MN, 2002, PEDIATRICS, V109, P615, DOI 10.1542/peds.109.4.615; Theodore AD, 2005, PEDIATRICS, V115, pE331, DOI 10.1542/peds.2004-1033; WATT E, 2003, HIST YOUTH JUSTICE 2; Wirtz SJ, 2008, AM J PREV MED, V34, pS134, DOI 10.1016/j.amepre.2007.11.004; Wu SS, 2004, CHILD ABUSE NEGLECT, V28, P1253, DOI 10.1016/j.chiabu.2004.07.005	52	23	25	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134	1873-7757		CHILD ABUSE NEGLECT	Child Abuse Negl.	JUN	2009	33	6					393	401		10.1016/j.chiabu.2008.09.008			9	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	459QN	WOS:000267118800012	19481802				2021-06-18	
J	Burke, HS; Degeneffe, CE; Olney, MF				Burke, Hillary S.; Degeneffe, Charles E.; Olney, Marjorie F.			A New Disability for Rehabilitation Counselors: Iraq War Veterans with Traumatic Brain Injury and Post-Traumatic Stress Disorder	JOURNAL OF REHABILITATION			English	Article							EXPOSURE THERAPY; VIRTUAL-REALITY	Traumatic brain injury (TBI) and post-traumatic stress disorder (PTSD) are considered the "signature" injuries of military personnel serving in the Iraq war. An alarming number of returning veterans are incurring a combination of these two disabilities. TBI and PTSD combined presents an array of challenges for injured persons that are experienced differently by those separately affected by TBI or PTSD. Hence, the combination of TBI and PTSD presents a new disability classification for the rehabilitation counseling profession. There is an acute need to develop and facilitate specialized care and rehabilitative services for veterans impacted by this nascent disability. We highlight neurobiological, behavioral, and physiological characteristics associated with combat-incurred TBI/PTSD injuries. Additionally, we offer recommendations for rehabilitation counseling professionals and researchers to consider in response to our review of the current system of veteran care, common barriers to rehabilitation and societal re-integration, and available resources for military personnel impacted by TBI and PTSD.	[Burke, Hillary S.; Degeneffe, Charles E.; Olney, Marjorie F.] San Diego State Univ, San Diego, CA 92182 USA	Degeneffe, CE (corresponding author), San Diego State Univ, 5500 Campanile Dr, San Diego, CA 92182 USA.	cdegenef@mail.sdsu.edu					*ARM NEWS SERV, 2007, ARM LAUNCH CHAIN TEA; BERGFELD C, 2006, BUSINESS WEEK   0706; Bilmes Linda J., 2008, WASHINGTON POST 0309; *CA COMM FDN, 2008, INV WOUNDS WAR PSYCH; CRAINE M, 2008, 2007 COMP GRANT TRAI; *DEF LINK, 2008, OP IR FREED US CAS S; Defense and Veterans Brain Injury Center, 2007, DVBIC FACT SHEET; Degeneffe CE, 2001, HEALTH SOC WORK, V26, P257, DOI 10.1093/hsw/26.4.257; DePalma RG, 2005, NEW ENGL J MED, V352, P1335, DOI 10.1056/NEJMra042083; Fairweather A., 2007, DEFINING NEW AGE VET; *FORC HLTH PROT RE, TBI PTSD QUICK FACTS; Hall L.K., 2008, COUNSELING MILITARY; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; *IR BOD COUNT, 2008, DOC CIV DEATHS VIOL; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kraft Heidi S., 2007, RULE NUMBER 2 LESSON; LEE C, 2008, WASHINGTON POST 0516; Levin A., 2008, PSYCHIAT NEWS, V43, P23; Litz B. T., UNIQUE CIRCUMSTANCES; McNally R. J., 1999, PTSD RES Q, V10, P1; *PAT UK, 2007, STRESS PTSD; Paunovic N, 2001, BEHAV RES THER, V39, P1183, DOI 10.1016/S0005-7967(00)00093-0; Perna RB, 2003, J HEAD TRAUMA REHAB, V18, P201; Rao V, 2002, PSYCHIAT CLIN N AM, V25, P43, DOI 10.1016/S0193-953X(03)00052-2; Rosenthal M, 2000, HANDBOOK OF REHABILITATION PSYCHOLOGY, P49, DOI 10.1037/10361-003; Sherman MD, 2006, J MARITAL FAM THER, V32, P479, DOI 10.1111/j.1752-0606.2006.tb01622.x; Summerall E. L, 2008, TRAUMATIC BRAIN INJU; Taber KH, 2006, J NEUROPSYCH CLIN N, V18, P141, DOI 10.1176/appi.neuropsych.18.2.141; *US DEP DEF, 2008, OP IR FRED MIL DEATH; *US DEP VET AFF, 2007, VA POL SYST CAR ADM; *US DEP VET AFF, 2007, VA POL SYST CAR FREQ; *US DEP VET AFF, 2007, VA POL SYST CAR FAC; Walshe DG, 2003, CYBERPSYCHOL BEHAV, V6, P329, DOI 10.1089/109493103322011641; Warden D, 2006, J HEAD TRAUMA REHAB, V21, P398, DOI 10.1097/00001199-200609000-00004; WILLIS A, 2007, TRENDS TREATMENT AM; WONG E, 2008, NY TIMES        0215; Wood DP, 2007, CYBERPSYCHOL BEHAV, V10, P309, DOI 10.1089/cpb.2006.9951; Woodruff L, 2007, INSTANT FAMILYS JOUR; YEOMAN B, 2008, WOUNDED VETS COME HO; 2007, CBS NEWS        1113	40	23	23	0	15	NATL REHABILITATION ASSOC-NRA	ALEXANDRIA	633 S WASHINGTON ST, ALEXANDRIA, VA 22314-4109 USA	0022-4154			J REHABIL	J. Rehabil.	APR-JUN	2009	75	3			SI		5	14					10	Rehabilitation	Rehabilitation	472TC	WOS:000268154100002					2021-06-18	
J	Bickerdike, MJ; Thomas, GB; Batchelor, DC; Sirimanne, ES; Leong, W; Lin, H; Sieg, F; Wen, J; Brimble, MA; Harris, PW; Gluckman, PD				Bickerdike, Michael J.; Thomas, Gregory B.; Batchelor, David C.; Sirimanne, Ernest S.; Leong, Wing; Lin, Hai; Sieg, Frank; Wen, Jingyuan; Brimble, Margaret A.; Harris, Paul W.; Gluckman, Peter D.			NNZ-2566: A Gly-Pro-Glu analogue with neuroprotective efficacy in a rat model of acute focal stroke	JOURNAL OF THE NEUROLOGICAL SCIENCES			English	Article						Neuroprotection; Stroke; Ischaemia; Hypoxia; Apoptosis	N-TERMINAL TRIPEPTIDE; GLYCINE-PROLINE-GLUTAMATE; GROWTH-FACTOR-I; CEREBRAL-ARTERY OCCLUSION; OKADAIC ACID; PHARMACOLOGICAL EVALUATION; GPE; BRAIN; ISCHEMIA; LESION	The N-terminal cleavage product of human insulin-like growth factor-1 (IGF-1) in the brain is the tripeptide molecule Glypromate (R) (Gly-Pro-Glu). Glypromate (R) has demonstrated neuroprotective effects in numerous in vitro and in vivo models of brain injury and is in clinical trials for the prevention of cognitive impairment following cardiac surgery. NNZ-2566 is a structural analogue of Glypromate (R), resulting from alpha-methylation of the proline moiety, which has improved the elimination half-life and oral bioavailability over the parent peptide. fit vivo, NNZ-2566 reduces injury size in rats subjected to focal stroke. An intravenous infusion of NNZ-2566 of 4 h duration (3-10 mg/kg/h), initiated 3 h after endothelin-induced middle-cerebral artery constriction, significantly reduced infarct area as assessed on day 5. Neuroprotective efficacy in the MCAO model was also observed following oral administration of the drug (30-60 mg/kg), when formulated as a microemulsion. In vitro, NNZ-2566 significantly attenuates apoptotic cell death in primary striatal cultures, suggesting attenuation of apoptosis is one mechanism of action underlying its neuroprotective effects. NNZ-2566 is currently in clinical trials for the treatment of cognitive deficits following traumatic brain injury, and these data further support the development of the drug as a neuroprotective agent for acute brain injury. (c) 2008 Elsevier B.V. All rights reserved.	[Bickerdike, Michael J.; Thomas, Gregory B.; Batchelor, David C.; Sirimanne, Ernest S.; Leong, Wing; Lin, Hai; Sieg, Frank; Gluckman, Peter D.] Neuren Pharmaceut Ltd, Auckland 1011, New Zealand; [Wen, Jingyuan] Univ Auckland, Dept Pharm, Auckland 1, New Zealand; [Brimble, Margaret A.; Harris, Paul W.] Univ Auckland, Dept Med Chem, Auckland 1, New Zealand; [Gluckman, Peter D.] Univ Auckland, Liggins Inst, Auckland 1, New Zealand	Bickerdike, MJ (corresponding author), Neuren Pharmaceut Ltd, 57 Wellington St,Freemans Bay, Auckland 1011, New Zealand.	mbickerdike@neurenpharma.com		Sieg, Frank/0000-0001-9637-3239; Brimble, Margaret/0000-0002-7086-4096			AGNATI LF, 1991, ITAL J NEUROL SCI, V12, P49; Aguado-Liera D, 2004, NEUROREPORT, V15, P1979, DOI 10.1097/00001756-200408260-00029; Alexi T, 1999, EXP NEUROL, V159, P84, DOI 10.1006/exnr.1999.7168; De Diego SA, 2006, BIOORG MED CHEM LETT, V16, P3396, DOI 10.1016/j.bmcl.2006.04.033; Baker AM, 2005, NEUROPEPTIDES, V39, P81, DOI 10.1016/j.npep.2004.11.001; Batchelor DC, 2003, ANAL BIOCHEM, V323, P156, DOI 10.1016/j.ab.2003.08.032; Biernaskie J, 2001, MAGNET RESON MED, V46, P827, DOI 10.1002/mrm.1263; Brimble MA, 2005, BIOORGAN MED CHEM, V13, P519, DOI 10.1016/j.bmc.2004.10.006; Cagnoli CM, 1996, J MOL NEUROSCI, V7, P65, DOI 10.1007/BF02736849; Callaway JK, 1999, STROKE, V30, P2704, DOI 10.1161/01.STR.30.12.2704; CARLSSONSKWIRUT C, 1986, FEBS LETT, V201, P46, DOI 10.1016/0014-5793(86)80568-3; De Diego SAA, 2006, BIOORG MED CHEM LETT, V16, P1392, DOI 10.1016/j.bmcl.2005.11.040; De Diego SAA, 2005, BIOORG MED CHEM LETT, V15, P2279, DOI 10.1016/j.bmcl.2005.03.015; Gresle MM, 2006, BRAIN RES, V1110, P13, DOI 10.1016/j.brainres.2006.06.111; Guan J, 2004, NEUROPHARMACOLOGY, V47, P892, DOI 10.1016/j.neuropharm.2004.07.002; Guan J, 2000, BRAIN RES, V859, P286, DOI 10.1016/S0006-8993(00)01988-0; HARRIS KA, 1993, ANN NEUROL, V33, P77, DOI 10.1002/ana.410330113; Harris PWR, 2006, J LABELLED COMPD RAD, V49, P571, DOI 10.1002/jlcr.1075; Harris PWR, 2005, TETRAHEDRON, V61, P10018, DOI 10.1016/j.tet.2005.08.026; Kanwar JR, 2004, BRAIN, V127, P1313, DOI 10.1093/brain/awh156; Krishnamurthi R, 2004, NEUROREPORT, V15, P1601, DOI 10.1097/01.wnr.0000127461.15985.07; Lai MYH, 2005, BIOORGAN MED CHEM, V13, P533, DOI 10.1016/j.bmc.2004.10.004; Newman MF, 2006, LANCET, V368, P694, DOI 10.1016/S0140-6736(06)69254-4; NILSSONHAKANSSON L, 1993, NEUROREPORT, V4, P1111; Raja PV, 2004, CNS SPECTRUMS, V9, P763, DOI 10.1017/S1092852900022409; ROUSSEL S, 1992, HYPERTENSION, V19, P40, DOI 10.1161/01.HYP.19.1.40; SARA VR, 1989, BIOCHEM BIOPH RES CO, V165, P766, DOI 10.1016/S0006-291X(89)80032-4; Saura J, 1999, NEUROREPORT, V10, P161, DOI 10.1097/00001756-199901180-00031; SHARKEY J, 1993, J CEREBR BLOOD F MET, V13, P865, DOI 10.1038/jcbfm.1993.108; SHARKEY J, 1994, J AUTONOM NERV SYST, V49, pS177; Sizonenko SV, 2001, BRAIN RES, V922, P42, DOI 10.1016/S0006-8993(01)03148-1; Souid-Mensi G, 2008, TOXICON, V51, P1338, DOI 10.1016/j.toxicon.2008.03.002; Svedin P, 2007, DEV NEUROSCI-BASEL, V29, P393, DOI 10.1159/000105480; Trotter NS, 2005, BIOORGAN MED CHEM, V13, P501, DOI 10.1016/j.bmc.2004.10.005; Zhao XR, 2005, STROKE, V36, P129, DOI 10.1161/01.STR.0000149624.87661.18	35	23	25	1	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0022-510X	1878-5883		J NEUROL SCI	J. Neurol. Sci.	MAR 15	2009	278	1-2					85	90		10.1016/j.jns.2008.12.003			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	411ZF	WOS:000263692300017	19157421				2021-06-18	
J	Frey, LC; Hellier, J; Unkart, C; Lepkin, A; Howard, A; Hasebroock, K; Serkova, N; Liang, LP; Patel, M; Soltesz, I; Staley, K				Frey, Lauren C.; Hellier, Jennifer; Unkart, Cheri; Lepkin, Aaron; Howard, Allyson; Hasebroock, Kendra; Serkova, Natalie; Liang, LiPing; Patel, Manisha; Soltesz, Ivan; Staley, Kevin			A novel apparatus for lateral fluid percussion injury in the rat	JOURNAL OF NEUROSCIENCE METHODS			English	Article						Lateral fluid percussion injury; Rat; Experimental TBI; Picospritzer	TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC EPILEPSY; EXPERIMENTAL-MODELS; CELL LOSS; HYPEREXCITABILITY; HIPPOCAMPUS	Lateral fluid percussion injury (LFPI) is the most commonly used experimental model of human traumatic brain injury (TBI). To date, investigators using this model have produced injury using a pendulum-and-piston-based device (PPBD) to drive fluid against an intact dural surface. Two disadvantages of this method, however, are (1) the necessary reliance on operator skill to position and release the pendulum, and (2) reductions in reproducibility due to variable friction between the piston's o-rings and the cylinder. To counteract these disadvantages, we designed a low-priced, novel, fluid percussion apparatus that delivers a pressure pulse of air to a standing column of fluid, forcing it against the intact dural surface. The pressure waveforms generated by this apparatus are similar to those reported in the LFPI/PPBD literature and had little variation in appearance between trials. In addition, our apparatus produced an acute and chronic TBI syndrome similar to that in the LFPI/PPBD literature, as quantified by histological changes, MRI structural changes and chronic behavioral sequelae. (C) 2008 Elsevier B.V. All rights reserved.	[Frey, Lauren C.; Unkart, Cheri; Lepkin, Aaron] Univ Colorado, Dept Neurol, Denver, CO USA; [Hellier, Jennifer] Univ Colorado Denver, Neurosci Program, Denver, CO USA; [Hasebroock, Kendra; Serkova, Natalie] Univ Colorado Denver, Dept Anesthesiol, Denver, CO USA; [Liang, LiPing; Patel, Manisha] Univ Colorado Denver, Dept Pharmaceut Sci, Denver, CO USA; [Soltesz, Ivan] Univ Calif Irvine, Dept Anat & Neurobiol, Irvine, CA 92717 USA; [Staley, Kevin] Harvard Univ, Sch Med, Dept Neurol, Cambridge, MA 02138 USA; [Howard, Allyson] Stanford Univ, Dept Neurosurg, Stanford, CA 94305 USA	Frey, LC (corresponding author), POB 6510,Mail Stop F727, Aurora, CO 80045 USA.	lauren.frey@uchsc.edu			National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS-35915]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS035915, R37NS035915, R29NS035915] Funding Source: NIH RePORTER	This work was supported by the Colorado Injury Control Research Center and the National Institutes of Health (NS-35915, I.S.).	Coulter DA, 1996, EPILEPSY RES, V26, P81, DOI 10.1016/S0920-1211(96)00044-7; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; Fujimoto ST, 2004, NEUROSCI BIOBEHAV R, V28, P365, DOI 10.1016/j.neubiorev.2004.06.002; Gallyas F, 2002, ACTA NEUROPATHOL, V103, P36, DOI 10.1007/s004010100424; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; LAURER HL, 1999, CURRENT OPINIONS NEU, P715; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MCCAMAN RE, 1977, BRAIN RES, V136, P141, DOI 10.1016/0006-8993(77)90138-X; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Morales DM, 2005, NEUROSCIENCE, V136, P971, DOI 10.1016/j.neuroscience.2005.08.030; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; Pitkanen A, 2006, J NEUROTRAUM, V23, P241, DOI 10.1089/neu.2006.23.241; Rangel P, 2005, ARQ NEURO-PSIQUIAT, V63, P972, DOI 10.1590/S0004-282X2005000600013; Ratzliff ADH, 2002, TRENDS NEUROSCI, V25, P140, DOI 10.1016/S0166-2236(00)02122-6; Santhakumar V, 2003, J NEUROSCI, V23, P5865; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Santhakumar V, 2005, J NEUROPHYSIOL, V93, P437, DOI 10.1152/jn.00777.2004; Schallert Timothy, 2006, NeuroRx, V3, P497, DOI 10.1016/j.nurx.2006.08.001; Statler KD, 2006, BRAIN RES, V1076, P216, DOI 10.1016/j.brainres.2005.12.106; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Statler KD, 2001, J NEUROTRAUM, V18, P1195, DOI 10.1089/089771501317095232; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; SULLIVAN HG, 1976, J NEUROSURG, V45, P520, DOI 10.3171/jns.1976.45.5.0520; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Toth Z, 1997, J NEUROSCI, V17, P8106; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	27	23	26	1	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270	1872-678X		J NEUROSCI METH	J. Neurosci. Methods	MAR 15	2009	177	2					267	272		10.1016/j.jneumeth.2008.10.022			6	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	407VV	WOS:000263393300002	19022291	Green Accepted			2021-06-18	
J	Gonzalez, SL; Lopez-Costa, JJ; Labombarda, F; Deniselle, MCG; Guennoun, R; Schumacher, M; De Nicola, AF				Gonzalez, Susana L.; Jose Lopez-Costa, Juan; Labombarda, Florencia; Gonzalez Deniselle, Maria Claudia; Guennoun, Rachida; Schumacher, Michael; De Nicola, Alejandro F.			Progesterone Effects on Neuronal Ultrastructure and Expression of Microtubule-associated Protein 2 (MAP2) in Rats with Acute Spinal Cord Injury	CELLULAR AND MOLECULAR NEUROBIOLOGY			English	Article						Chromatolysis; Electron microscopy; MAP2; Motoneuron; Neuroprotection; Progesterone; Spinal cord injury	TRAUMATIC BRAIN-INJURY; NEUROTROPHIC FACTOR EXPRESSION; AMYOTROPHIC-LATERAL-SCLEROSIS; MYELIN BASIC-PROTEIN; VENTRAL HORN NEURONS; NEUROACTIVE STEROIDS; SENSORY NEURONS; MOTOR-NEURONS; SCHWANN-CELLS; DEGENERATION	(1) Following acute spinal cord injury, progesterone modulates several molecules essential for motoneuron function, although the morphological substrates for these effects are unknown. (2) The present study analyzed morphological changes in motoneurons distal to the lesion site from rats with or without progesterone treatment. We employed electron microscopy to study changes in nucleus and cytoplasm and immunohistochemistry for the microtubule-associated protein 2 (MAP2) for changes in cytoskeleton. (3) After spinal cord injury, the nucleoplasm appeared more finely dispersed resulting in reduced electron opacity and the nucleus adopted an eccentric position. Changes of perikarya included dissolution of Nissl bodies and dissociation of polyribosomes (chromatolysis). After progesterone treatment for 3 days, the deafferented motoneurons now presented a clumped nucleoplasm, a better-preserved rough endoplasmic reticulum and absence of chromatolysis. Progesterone partially prevented development of nuclear eccentricity. Whereas 50% of injured motoneurons showed nuclear eccentricity, only 16% presented this phenotype after receiving progesterone. Additionally, injured rats showed reduced immunostaining for MAP2 in dendrites, pointing to cytoskeleton abnormalities, whereas progesterone treatment attenuated the injury-induced loss of MAP2. (4) Our data indicated that progesterone maintained in part neuronal ultrastructure, attenuated chromatolysis, and preclude the loss of MAP2, suggesting a protective effect during the early phases of spinal cord injury.	[Gonzalez, Susana L.; Labombarda, Florencia; Gonzalez Deniselle, Maria Claudia; De Nicola, Alejandro F.] Inst Biol & Med Expt, Lab Neuroendocrine Biochem, RA-1428 Buenos Aires, DF, Argentina; [Gonzalez, Susana L.; Labombarda, Florencia; Gonzalez Deniselle, Maria Claudia; De Nicola, Alejandro F.] Univ Buenos Aires, Dept Human Biochem, Fac Med, Buenos Aires, DF, Argentina; [Jose Lopez-Costa, Juan] Univ Buenos Aires, Inst Biol Celular & Neurociencias Prof Eduardo De, Fac Med, Buenos Aires, DF, Argentina; [Guennoun, Rachida; Schumacher, Michael] Univ Paris 11, F-94276 Le Kremlin Bicetre, France; [Guennoun, Rachida; Schumacher, Michael] INSERM, UMR 788, F-94276 Le Kremlin Bicetre, France	De Nicola, AF (corresponding author), Inst Biol & Med Expt, Lab Neuroendocrine Biochem, Obligado 2490, RA-1428 Buenos Aires, DF, Argentina.	denicola@dna.uba.ar	Schumacher, Michael/G-3581-2013; Guennoun, Rachida/F-2420-2011	Schumacher, Michael/0000-0001-6117-5371; Guennoun, Rachida/0000-0002-9219-7300	FONCYTFONCyT [25610]; National Research Council of ArgentinaConsejo Nacional de Investigaciones Cientificas y Tecnicas (CONICET) [5542]; University of Buenos AiresUniversity of Buenos Aires [M022, M808]	The authors acknowledge the support of FONCYT (BID OC AR PICT 2004 # 25610), the National Research Council of Argentina (CONICET, PIP 5542), and the University of Buenos Aires (M022 and M808). We deeply thank Ms. Mariana Lopez Ravasio for electron microscopic techniques and Juan Pablo Corazza for help with photography.	Acheson A, 1996, PHILOS T ROY SOC B, V351, P417, DOI 10.1098/rstb.1996.0037; Azbill RD, 1997, BRAIN RES, V765, P283, DOI 10.1016/S0006-8993(97)00573-8; Azcoitia I, 2003, NEUROBIOL AGING, V24, P853, DOI 10.1016/S0197-4580(02)00234-8; Bareyre FM, 2003, TRENDS NEUROSCI, V26, P555, DOI 10.1016/j.tins.2003.08.004; BARR ML, 1948, J COMP NEUROL, V89, P93, DOI 10.1002/cne.900890203; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; Bjugn R, 1997, EXP NEUROL, V148, P179, DOI 10.1006/exnr.1997.6610; CACERES A, 1988, MOL BRAIN RES, V3, P233, DOI 10.1016/0169-328X(88)90046-0; CRAGG BG, 1970, BRAIN RES, V23, P1, DOI 10.1016/0006-8993(70)90345-8; Cutler SM, 2007, J NEUROTRAUM, V24, P1475, DOI 10.1089/neu.2007.0294; Davies AM, 1996, NEUROCHEM RES, V21, P749, DOI 10.1007/BF02532296; De Nicola AF, 2006, J MOL NEUROSCI, V28, P3, DOI 10.1385/JMN:28:1:3; Deniselle MCG, 2005, EXP NEUROL, V195, P518, DOI 10.1016/j.expneurol.2005.06.015; Deniselle MCG, 2002, J STEROID BIOCHEM, V83, P199, DOI 10.1016/S0960-0760(02)00262-5; Desarnaud F, 1998, J NEUROCHEM, V71, P1765; di Michele F, 2000, NEUROSCI LETT, V284, P65, DOI 10.1016/S0304-3940(00)00965-4; Di Stefano G, 2006, REJUV RES, V9, P94; EIDELBERG E, 1989, BRAIN RES BULL, V22, P39, DOI 10.1016/0361-9230(89)90125-1; Farah CA, 2005, J BIOL CHEM, V280, P9439, DOI 10.1074/jbc.M412304200; Fee DB, 2007, BRAIN RES, V1137, P146, DOI 10.1016/j.brainres.2006.12.024; Fontaine-Lenoir V, 2006, P NATL ACAD SCI USA, V103, P4711, DOI 10.1073/pnas.0600113103; Fukumitsu H, 1997, NEUROSCI LETT, V238, P107, DOI 10.1016/S0304-3940(97)00852-5; Garay L, 2007, J STEROID BIOCHEM, V107, P228, DOI 10.1016/j.jsbmb.2007.03.040; Ghoumari AM, 2003, J NEUROCHEM, V86, P848, DOI 10.1046/j.1471-4159.2003.01881.x; GOLD BG, 1991, J NEUROSCI, V11, P943; Deniselle MCG, 2007, EXP NEUROL, V203, P406, DOI 10.1016/j.expneurol.2006.08.019; Gonzalez SL, 2005, J STEROID BIOCHEM, V94, P143, DOI 10.1016/j.jsbmb.2005.01.016; Gonzalez SL, 2004, NEUROSCIENCE, V125, P605, DOI 10.1016/j.neuroscience.2004.02.024; Grossman KJ, 2004, BRAIN RES, V1008, P29, DOI 10.1016/j.brainres.2004.02.022; Hayashi T, 1998, STROKE, V29, P1007, DOI 10.1161/01.STR.29.5.1007; HAYES RL, 1995, J NEUROTRAUM, V12, P933, DOI 10.1089/neu.1995.12.933; Ibanez C, 2003, PROG NEUROBIOL, V71, P49, DOI 10.1016/j.pneurobio.2003.09.002; Jamieson SMF, 2007, NEUROTOXICOLOGY, V28, P1092, DOI 10.1016/j.neuro.2007.04.009; Kaur P, 2007, J NEUROSCI RES, V85, P2441, DOI 10.1002/jnr.21370; Kikuchi H, 1999, ACTA NEUROPATHOL, V97, P13, DOI 10.1007/s004010050950; KOENIG HL, 1995, SCIENCE, V268, P1500, DOI 10.1126/science.7770777; Kupina NC, 2003, EXP NEUROL, V180, P55, DOI 10.1016/S0014-4886(02)00048-1; Labombarda F, 2006, ENDOCRINOLOGY, V147, P1847, DOI 10.1210/en.2005-0955; Labombarda F, 2006, J NEUROTRAUM, V23, P181, DOI 10.1089/neu.2006.23.181; Labombarda F, 2003, J NEUROCHEM, V87, P902, DOI 10.1046/j.1471-4159.2003.02055.x; Labombarda F, 2002, J NEUROTRAUM, V19, P343, DOI 10.1089/089771502753594918; Leist M, 2001, NAT REV MOL CELL BIO, V2, P589, DOI 10.1038/35085008; Magnaghi V, 2001, BRAIN RES REV, V37, P360, DOI 10.1016/S0165-0173(01)00140-0; MARSH HN, 1993, J NEUROSCI, V13, P4281; McIlwain DL, 2005, BMC NEUROSCI, V6, DOI 10.1186/1471-2202-6-19; Melcangi RC, 2006, J MOL NEUROSCI, V28, P1, DOI 10.1385/JMN:28:1:1; MIRANDA RC, 1993, P NATL ACAD SCI USA, V90, P6439, DOI 10.1073/pnas.90.14.6439; NACIMIENTO W, 1995, ACTA NEUROPATHOL, V90, P552; Patte-Mensah C, 2004, J COMP NEUROL, V477, P286, DOI 10.1002/cne.20251; PRICE DL, 1972, J CELL BIOL, V53, P24, DOI 10.1083/jcb.53.1.24; Reyna-Neyra A, 2002, BRAIN RES BULL, V58, P607, DOI 10.1016/S0361-9230(02)00829-8; Roof RL, 1997, MOL CHEM NEUROPATHOL, V31, P1, DOI 10.1007/BF02815156; Siegel S., 1989, NONPARAMETRIC STAT B; Sperandio S, 2000, P NATL ACAD SCI USA, V97, P14376, DOI 10.1073/pnas.97.26.14376; Springer JE, 1997, J NEUROCHEM, V69, P1592, DOI 10.1046/j.1471-4159.1997.69041592.x; Stein DG, 2005, ANN NY ACAD SCI, V1052, P152, DOI 10.1196/annals.1347.011; Thomas AJ, 1999, SPINE, V24, P2134, DOI 10.1097/00007632-199910150-00013; WAKAYAMA I, 1992, BRAIN RES, V586, P12, DOI 10.1016/0006-8993(92)91365-L; Wright DW, 2007, ANN EMERG MED, V49, P391, DOI 10.1016/j.annemergmed.2006.07.932; Yu WR, 2000, ACTA NEUROPATHOL, V100, P546, DOI 10.1007/s004010000206; Zeman RJ, 2004, EXP NEUROL, V187, P460, DOI 10.1016/j.expneurol.2004.03.006; Zhang SX, 2000, J NEUROPATH EXP NEUR, V59, P287, DOI 10.1093/jnen/59.4.287	62	23	28	0	4	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0272-4340	1573-6830		CELL MOL NEUROBIOL	Cell. Mol. Neurobiol.	FEB	2009	29	1					27	39		10.1007/s10571-008-9291-0			13	Cell Biology; Neurosciences	Cell Biology; Neurosciences & Neurology	403XA	WOS:000263114100004	18584320				2021-06-18	
J	Shahlaie, K; Boggan, JE; Latchaw, RE; Ji, C; Muizelaar, JP				Shahlaie, Kiarash; Boggan, James E.; Latchaw, Richard E.; Ji, Cheng; Muizelaar, J. Paul			Posttraumatic Vasospasm Detected by Continuous Brain Tissue Oxygen Monitoring: Treatment with Intraarterial Verapamil and Balloon Angioplasty	NEUROCRITICAL CARE			English	Article						Vasospasm; Traumatic brain injury; Brain tissue oxygen; PbtO2; Angioplasty; Verapamil	CEREBRAL-BLOOD-FLOW; SEVERE HEAD-INJURY; TRAUMATIC SUBARACHNOID HEMORRHAGE; TRANSCRANIAL DOPPLER ULTRASOUND; INTRACRANIAL ARTERIAL SPASM; TIME-COURSE; HEMODYNAMIC DISTURBANCES; CT-SCAN; VELOCITY; NIMODIPINE	Posttraumatic vasospasm (PTV) is a relatively common event following traumatic brain injury (TBI) that has been strongly correlated with worse neurological outcome in many studies. However, vasospasm continues to be an under-recognized source of secondary injury following TBI, and currently published guidelines do not address screening or management strategies for PTV. Brain tissue oxygen (PbtO2) monitoring probes allow for continuous screening for cerebral hypoxia following TBI, but their use as a monitor for PTV has not been previously described. Case report and literature review. We present a case of PTV identified by persistent low PbtO2 despite aggressive medical therapy. Computed tomography and digital subtraction angiography confirmed severe cerebral arterial vasospasm involving both anterior and posterior circulations. The patient was successfully treated with serial intraarterial therapy including balloon angioplasty and verapamil infusion. Posttraumatic vasospasm should be included in the differential diagnosis of cerebral hypoxia (e.g., low PbtO2) following TBI. Management strategies for PTV may include early, aggressive intraarterial therapies including drug infusion and balloon angioplasty.	[Shahlaie, Kiarash; Boggan, James E.; Muizelaar, J. Paul] Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sch Med, Sacramento, CA 95817 USA; [Latchaw, Richard E.; Ji, Cheng] Univ Calif Davis, Med Ctr, Dept Radiol, Sacramento, CA 95817 USA	Shahlaie, K (corresponding author), Univ Calif Davis, Med Ctr, Dept Neurol Surg, Sch Med, 4860 Y St,Suite 3740, Sacramento, CA 95817 USA.	krshahlaie@ucdavis.edu					Armin SS, 2006, NEUROL RES, V28, P445, DOI 10.1179/016164106X115053; Armonda RA, 2006, NEUROSURGERY, V59, P1215, DOI 10.1227/01.NEU.0000249190.46033.94; ARSENI C, 1971, ACTA NEUROCHIR, V24, P25, DOI 10.1007/BF01403138; ARUTIUNOV AI, 1974, J NEUROSURG, V40, P459, DOI 10.3171/jns.1974.40.4.0459; BAILEY I, 1991, ACTA NEUROCHIR, V110, P97, DOI 10.1007/BF01400674; Bakshi A, 1998, NATL MED J INDIA, V11, P220; BRAAKMAN R, 1994, J NEUROSURG, V80, P797; *BRAIN TRAUM FDN, 2007, J NEUROTRAUMA S1, V24, pS65; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; Cairns CJS, 2003, ANAESTH INTENS CARE, V31, P87, DOI 10.1177/0310057X0303100117; CHAN KH, 1992, SURG NEUROL, V38, P433, DOI 10.1016/0090-3019(92)90111-Y; CHAN KH, 1992, NEUROSURGERY, V30, P697; CHAN KH, 1993, ACTA NEUROCHIR, P81; COLUMELLA F, 1963, ACTA RADIOL DIAGN, V1, P239, DOI 10.1177/028418516300100217; Compton J S, 1987, Br J Neurosurg, V1, P435, DOI 10.3109/02688698708999633; Devlin JW, 2000, NEUROSURGERY, V47, P1243, DOI 10.1097/00006123-200011000-00048; Doppenberg EMR, 1998, ACT NEUR S, V71, P166; Doppenberg EMR, 1998, SURG NEUROL, V49, P650, DOI 10.1016/S0090-3019(97)00355-8; Dorhout SM, 2008, STROKE, V39, P514, DOI 10.1161/STROKEAHA.107.496802; Echlin FA, 1942, ARCH NEURO PSYCHIATR, V47, P77, DOI 10.1001/archneurpsyc.1942.02290010087007; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; FRENIDENFELT H, 1963, ACTA RADIOL, V1, P278; GAETANI P, 1994, J NEUROL NEUROSUR PS, V57, P66, DOI 10.1136/jnnp.57.1.66; GOMEZ CR, 1991, SURG NEUROL, V35, P30, DOI 10.1016/0090-3019(91)90198-I; GROLIMUND P, 1988, LANCET, V1, P1173; Hadani M, 1997, J NEUROTRAUM, V14, P629, DOI 10.1089/neu.1997.14.629; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; HARDERS AG, 1987, J NEUROSURG, V66, P718, DOI 10.3171/jns.1987.66.5.0718; Hoelper BM, 2003, NEUROSURGERY, V52, P970, DOI 10.1227/01.NEU.0000053033.98317.A3; JAKOBSEN M, 1990, ACTA NEUROL SCAND, V82, P311; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KISTLER JP, 1983, NEUROLOGY, V33, P424, DOI 10.1212/WNL.33.4.424; Kochanowicz J, 2006, NEURORADIOLOGY, V48, P31, DOI 10.1007/s00234-005-0009-4; KORDESTANI RK, 1995, NEUROSURG CLIN N AM, V6, P657; Kostron H, 1985, Neurochirurgia (Stuttg), V28 Suppl 1, P103; KOSTRON H, 1984, Neurological Research, V6, P29; Lee JH, 1997, J NEUROSURG, V87, P221, DOI 10.3171/jns.1997.87.2.0221; Lee KH, 2006, NEUROCRIT CARE, V4, P68, DOI 10.1385/NCC:4:1:068; LEWIS WH, 1968, ANN MO BOT GARD, V55, P31, DOI 10.2307/2394818; LINDEGAARD KF, 1989, ACTA NEUROCHIR, V100, P12, DOI 10.1007/BF01405268; MACPHERS.P, 1973, J NEUROL NEUROSUR PS, V36, P1069, DOI 10.1136/jnnp.36.6.1069; MACPHERSON P, 1978, J NEUROL NEUROSUR PS, V41, P122, DOI 10.1136/jnnp.41.2.122; MARSHALL LF, 1978, J NEUROSURG, V48, P560, DOI 10.3171/jns.1978.48.4.0560; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; MARTIN NA, 1992, J NEUROSURG, V77, P575, DOI 10.3171/jns.1992.77.4.0575; MARTIN NA, 1995, J NEUROTRAUM, V12, P897, DOI 10.1089/neu.1995.12.897; Mattioli C, 2003, J NEUROSURG, V98, P37, DOI 10.3171/jns.2003.98.1.0037; Meixensberger J, 2003, NEUROL RES, V25, P445, DOI 10.1179/016164103101201823; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; Muench E, 2007, CRIT CARE MED, V35, P1844, DOI 10.1097/01.CCM.0000275392.08410.DD; Muizelaar JP, 1999, J NEUROSURG, V91, P51, DOI 10.3171/jns.1999.91.1.0051; MUTTAQIN Z, 1991, NEUROSURG REV, V14, P321, DOI 10.1007/BF00383273; Newell D W, 1992, Clin Neurosurg, V39, P348; Oertel M, 2005, J NEUROSURG, V103, P812, DOI 10.3171/jns.2005.103.5.0812; Ojha BK, 2005, SURG NEUROL, V64, P174, DOI 10.1016/j.surneu.2004.11.030; PASQUALIN A, 1984, NEUROSURGERY, V15, P855, DOI 10.1227/00006123-198412000-00015; Radhakrishnan D, 1997, ANAESTHESIA, V52, P489, DOI 10.1111/j.1365-2044.1997.112-az0105.x; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Romner B, 1996, J NEUROSURG, V85, P90, DOI 10.3171/jns.1996.85.1.0090; Rosenthal G, 2008, CRIT CARE MED, V36, P1917, DOI 10.1097/CCM.0b013e3181743d77; Rozsa L, 1989, Radiol Diagn (Berl), V30, P151; SANDER D, 1993, J NEUROL SCI, V119, P1, DOI 10.1016/0022-510X(93)90185-2; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; SEIFERT V, 1995, J NEUROSURG, V82, P55, DOI 10.3171/jns.1995.82.1.0055; Soustiel JF, 2004, SURG NEUROL, V62, P201, DOI 10.1016/j.surneu.2003.10.037; Soustiel JF, 2002, ACTA NEUROCHIR, V144, P137, DOI 10.1007/s007010200016; Soustiel JF, 2002, STROKE, V33, P72, DOI 10.1161/hs0102.100484; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; SUWANWELA C, 1972, J NEUROSURG, V36, P314, DOI 10.3171/jns.1972.36.3.0314; SYMON L, 1967, J NEUROL NEUROSUR PS, V30, P497, DOI 10.1136/jnnp.30.6.497; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; TEASDALE G, 1990, ACT NEUR S, V51, P315; Vajkoczy P, 2003, J NEUROSURG, V98, P1227, DOI 10.3171/jns.2003.98.6.1227; Vajramani GV, 1999, BRIT J NEUROSURG, V13, P468, DOI 10.1080/02688699908540620; Vath A, 2002, ACT NEUR S, V81, P307; WADWORTH AN, 1992, DRUG AGING, V2, P262, DOI 10.2165/00002512-199202040-00002; WEBER M, 1990, NEUROSURGERY, V27, P106, DOI 10.1227/00006123-199007000-00015; WEIR B, 1978, J NEUROSURG, V48, P173, DOI 10.3171/jns.1978.48.2.0173; Wilensky Eileen Maloney, 2005, J Neurosci Nurs, V37, P278; Wilkins R H, 1990, Neurosurg Clin N Am, V1, P329; WILKINS RH, 1970, J NEUROSURG, V32, P626, DOI 10.3171/jns.1970.32.6.0626; Xiao Xingyi, 2002, Chin J Traumatol, V5, P380; Yamada K, 1998, NEUROSURGERY, V43, P153, DOI 10.1097/00006123-199807000-00101; Zubkov AY, 1999, J NEUROTRAUM, V16, P763, DOI 10.1089/neu.1999.16.763; Zubkov ZY, 2000, SURG NEUROL, V53, P126; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P41, DOI 10.1016/0022-510X(95)00178-X; ZURYNSKI YA, 1995, J NEUROL SCI, V134, P33, DOI 10.1016/0022-510X(95)00172-9; ZWIENENBERGLEE M, 2006, NEUROSURGERY S3, V59, pS3, DOI DOI 10.1227/01.NEU.000023952.07760.59; ZWIENENBERGLEE M, 2003, NEUROSURGERY, V59, pS139	90	23	24	1	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	FEB	2009	10	1					61	69		10.1007/s12028-008-9138-z			9	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	397GZ	WOS:000262652200009	18807219				2021-06-18	
J	Arango-Lasprilla, JC; Ketchum, JM; Gary, K; Hart, T; Corrigan, J; Forster, L; Mascialino, G				Arango-Lasprilla, Juan Carlos; Ketchum, Jessica M.; Gary, Kelli; Hart, Tessa; Corrigan, John; Forster, Lauren; Mascialino, Guido			Race/ethnicity differences in satisfaction with life among persons with traumatic brain injury	NEUROREHABILITATION			English	Article						Satisfaction with life; TBI; Race/ethnicity	COMMUNITY INTEGRATION; OUTCOMES; MODEL; RACE; DISABILITY; RETURN; WORK; CARE	Objective: To determine differences in life satisfaction at 1-year post-TBI among Caucasian, African American, Hispanic, and Asian individuals with TBI, after adjusting for covariates that significantly differ between ethnic groups and/or affect the Satisfaction with Life Scale (SWLS) at one year post-injury. Design: Retrospective study. Setting: Longitudinal dataset of the TBI Model Systems National Database. Participants: 3,368 individuals with moderate to severe TBI (2478 Caucasian, 629 African American, 180 Hispanic, and 81 Asian/Pacific Islander) hospitalized between 1989 and 2005. Main Outcome Measures: Satisfaction with Life Total score at 1 year post injury. Results: African Americans had 3.21 units lower SWLS scores one year post-injury than Asian/Pacific Islanders (95% CI = 0.61-5.81) and 1.99 units lower SWLS scores than Caucasians (95% CI = 0.97-3.00) after controlling for marital status, employment at admission, cause of injury, FIM at discharge, and LOS in acute care. Conclusions: African Americans have poorer self-reported life satisfaction than Caucasians and Asians one year after TBI. This effect is not due to pre-injury marital or employment status, cause of injury, nor injury severity or functional status. Further research on the factors which might explain these differences is warranted, so that targeted rehabilitation programs can be designed and implemented that enhance quality of life for all individuals who have suffered a TBI.	[Arango-Lasprilla, Juan Carlos; Gary, Kelli; Forster, Lauren] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA 23219 USA; [Ketchum, Jessica M.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA 23219 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Corrigan, John] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Mascialino, Guido] Mt Sinai Sch Med, Dept Rehabil Med, New York, NY USA	Arango-Lasprilla, JC (corresponding author), Virginia Commonwealth Univ, Dept Phys Med & Rehabil, 730 E Broad St,4th Floor,Room 4230A, Richmond, VA 23219 USA.	jcarangolasp@vcu.edu	Ketchum, Jessica/AAE-8200-2020; Corrigan, John D./E-2921-2011	MASCIALINO, GUIDO/0000-0001-7408-6546; Ketchum, Jessica/0000-0002-5566-3691	PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [H133A070036, H133P040006] Funding Source: Medline		Allison D., 1991, BEHAV THERAPIST, V5, P15; Alston RJ, 1996, J REHABIL, V62, P16; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Arango-Lasprilla JC, 2007, BRAIN INJURY, V21, P701, DOI 10.1080/02699050701481597; Boulware LE, 2003, PUBLIC HEALTH REP, V118, P358, DOI 10.1016/S0033-3549(04)50262-5; BROWN SD, 2004, J ANTIMICROB CHEM S1, V54, P7; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Casagrande SS, 2007, J GEN INTERN MED, V22, P389, DOI 10.1007/s11606-006-0057-4; Cicerone KD, 2007, J HEAD TRAUMA REHAB, V22, P257, DOI 10.1097/01.HTR.0000290970.56130.81; Corrigan JD, 1998, ARCH PHYS MED REHAB, V79, P298, DOI 10.1016/S0003-9993(98)90010-7; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Dahmer E., 1993, J HEAD TRAUMA REHAB, V8, P12, DOI [10.1097/00001199-199308020-00004, DOI 10.1097/00001199-199308020-00004]; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Doig E, 2001, BRAIN INJURY, V15, P747, DOI 10.1080/02699050110034343; GERHART K, 1917, J TRAUMA, V55, P1045; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hart T, 2005, J HEAD TRAUMA REHAB, V20, P158, DOI 10.1097/00001199-200503000-00004; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; Hicken BL, 2002, J REHABIL RES DEV, V39, P359; Hoofien D, 2001, BRAIN INJURY, V15, P189; JORGE RE, 1994, J NEUROSURG, V81, P726, DOI 10.3171/jns.1994.81.5.0726; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; LASPRILLA JCA, 2008, BRAIN INJURY, P1; LoBello SC, 2003, J REHABIL RES DEV, V40, P293, DOI 10.1682/JRRD.2003.07.0293; Machamer JE, 2003, J HEAD TRAUMA REHAB, V18, P387, DOI 10.1097/00001199-200309000-00001; Mailhan L, 2005, BRAIN INJURY, V19, P227, DOI 10.1080/02699050410001720149; Mazaux JM, 2002, ACT NEUR S, V79, P49; Mellick D, 2003, BRAIN INJURY, V17, P55, DOI 10.1080/0269905021000010159; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; PAVOT W, 1993, SOC INDIC RES, V28, P1, DOI 10.1007/BF01086714; Pierce CA, 2006, AM J PHYS MED REHAB, V85, P889, DOI 10.1097/01.phm.0000242615.43129.ae; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P69; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Sherer M, 2003, J HEAD TRAUMA REHAB, V18, P408, DOI 10.1097/00001199-200309000-00003; Shermer CR, 2007, J TRAUMA, V63, P1268; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Warren L, 1996, J REHABIL RES DEV, V33, P404	40	23	23	0	11	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2009	24	1					5	14		10.3233/NRE-2009-0449			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	412DS	WOS:000263704400002	19208953				2021-06-18	
J	Bekinschtein, TA; Golombek, DA; Simonetta, SH; Coleman, MR; Manes, FF				Bekinschtein, T. A.; Golombek, D. A.; Simonetta, S. H.; Coleman, M. R.; Manes, F. F.			Circadian rhythms in the vegetative state	BRAIN INJURY			English	Article						vegetative state; circadian rhythms; body temperature; guidelines	HYPOXIA; CLOCK; TEMPERATURE; SCALE; GENES; BRAIN	Objective: To evaluate whether vegetative state patients maintain circadian rhythms. Research design: An observational study of five single cases. Methods and procedures: Five chronic vegetative state patients underwent clinical and neurological evaluations and 2-week continuous temperature measurements. Main outcomes and results: The two patients with traumatic brain injury showed well-formed circadian temperature rhythms and had more reflexive behaviours and relatively low cortical and sub-cortical atrophy, whereas the three patients from anoxic-hypoxic origin demonstrated no cycles or rhythmic behaviour. Conclusions: The presence of periods of wakefulness does not imply preserved sleep-wake cycling capacity, nor preserved circadian rhythms and it should not be taken as a distinguishing feature for the definition of the vegetative state.	[Bekinschtein, T. A.] MRC, Cognit & Brain Sci Unit, Cambridge CB2 7EF, England; [Bekinschtein, T. A.; Manes, F. F.] Inst Cognit Neurol INECO, Buenos Aires, DF, Argentina; [Bekinschtein, T. A.; Manes, F. F.] Raul Carrea Inst Neurol Res, Buenos Aires, DF, Argentina; [Bekinschtein, T. A.; Coleman, M. R.] Addenbrookes Hosp, Impaired Consciousness Res Grp, Cambridge, England; [Golombek, D. A.; Simonetta, S. H.] Quilmes Univ, Chronobiol Lab, Buenos Aires, DF, Argentina; [Manes, F. F.] Favaloro Univ, Inst Neurosci, Buenos Aires, DF, Argentina	Bekinschtein, TA (corresponding author), MRC, Cognit & Brain Sci Unit, 15 Chaucer Rd, Cambridge CB2 7EF, England.	tristan.bekinschtein@mrc-cbu.cam.ac.uk		Bekinschtein, Tristan/0000-0001-5501-8628; Golombek, Diego/0000-0002-6291-5586	Antorchas Foundation (TAB) and PICT (DAG)	This research was supported by the following grants: Antorchas Foundation (TAB) and PICT (DAG). We thank the patients and their families for their participation.	Alster Jason, 1993, Brain Injury, V7, P191, DOI 10.3109/02699059309029672; ASHWAL S, 1994, NEW ENGL J MED, V330, P1572; Auer R. N., 2002, GREENFIELDS NEUROPAT; BEKINSCHTEIN TA, 2006, THESIS U BUENOS AIRE; Bekinschtein T, 2009, PROG BRAIN RES, V177, P171, DOI 10.1016/S0079-6123(09)17712-9; Bozek K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0004882; Chilov D, 2001, FASEB J, V15, P2613, DOI 10.1096/fj.01-0092com; Davidson AJ, 2003, J BIOL RHYTHM, V18, P430, DOI 10.1177/0748730403256066; Dominguez-Rodriguez A, 2006, AM J CARDIOL, V97, P1162, DOI 10.1016/j.amjcard.2005.11.033; Fukudome Y, 1996, AM J PHYSIOL-REG I, V270, pR1109; Galton CJ, 2001, J NEUROL NEUROSUR PS, V70, P165, DOI 10.1136/jnnp.70.2.165; Ghorbel MT, 2003, MOL CELL NEUROSCI, V22, P396, DOI 10.1016/S1044-7431(02)00019-2; Giacino JT, 2004, ARCH PHYS MED REHAB, V85, P2020, DOI 10.1016/j.apmr.2004.02.033; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; Isono M, 2002, BRAIN INJURY, V16, P705, DOI 10.1080/02699050210127303; Pattoneri Paolo, 2005, J Clin Hypertens (Greenwich), V7, P734, DOI 10.1111/j.1524-6175.2005.04780.x; PONCET L, 1999, AM J PHYSIOL, V277, P66; Rosato E, 2007, CIRCADIAN RHYTHMS ME; The Royal College of Physicians, 2003, VEG STAT GUID DIAGN; Veasey SC, 2004, SLEEP, V27, P194, DOI 10.1093/sleep/27.2.194; VOGEL HP, 1990, CLIN ENDOCRINOL, V33, P631	21	23	23	0	6	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	11					915	919	PII 915243110	10.1080/02699050903283197			5	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300008	20100128				2021-06-18	
J	Broglio, SP; Sosnoff, JJ; Rosengren, KS; McShane, K				Broglio, Steven P.; Sosnoff, Jacob J.; Rosengren, Karl S.; McShane, Kate			A Comparison of Balance Performance: Computerized Dynamic Posturography and a Random Motion Platform	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Posture; Rehabilitation	POSTURAL CONTROL; DEVELOPMENTAL PERSPECTIVE; SENSORY ORGANIZATION; PARKINSONS-DISEASE; CONCUSSION; STABILITY; GAIT; DISORDERS; DEFICITS	Objective: To establish the clinical utility of the PROPRIO 5000 as a balance assessment device by establishing convergent validity with the NeuroCom sensory organization test (SOT). Design: Cross-sectional. Setting: Balance research laboratory. Participants: Young adults (N=40; 21.1 +/- 1.4y). Interventions: Not applicable. Main Outcome Measures: Performance on each of the 6 NeuroCom SOT testing conditions and PROPRIO 5000 dynamic motion analysis score. Results: Correlational analyses between output variables yielded significant relationships between the dynamic motion analysis score from the 0 to 10 second (r=-.38), 10 to 20 second (r=-.34), and 20 to 30 second (r=-.35) intervals and the SOT composite balance score. Conclusions: The initial stages of the PROPRIO 5000 and the NeuroCom SOT battery may evaluate similar aspects of postural control. However, as the magnitude of PROPRIO perturbations increased, the relationship between the devices diverged and the complete PROPRIO assessment is not thought to pair with the SOT assessment. Differences between the 2 devices may be associated with varying degrees of test difficulty and the necessary Postural control strategies involved in responding to continual balance perturbations (PROPRIO 5000) or to different sensory inputs (SOT).	[Broglio, Steven P.; Sosnoff, Jacob J.; Rosengren, Karl S.; McShane, Kate] Univ Illinois, Dept Kinesiol & Community Hlth, Champaign, IL USA; [Rosengren, Karl S.] Univ Illinois, Dept Psychol, Champaign, IL USA	Broglio, SP (corresponding author), Dept Kinesiol & Community Hlth, 906 Goodwin Ave, Urbana, IL 61801 USA.	broglio@uiuc.edu	Sosnoff, Jacob/P-3397-2019	Sosnoff, Jacob/0000-0002-0286-9207; Rosengren, Karl/0000-0003-1448-1282			Amiridis IG, 2003, NEUROSCI LETT, V350, P137, DOI 10.1016/S0304-3940(03)00878-4; Arokoski JPA, 2006, GAIT POSTURE, V23, P45, DOI 10.1016/j.gaitpost.2004.11.017; Black FO, 2001, CURR OPIN OTOLARYNGO, V9, P314, DOI DOI 10.1097/00020840-200110000-00011; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Catena RD, 2007, GAIT POSTURE, V25, P406, DOI 10.1016/j.gaitpost.2006.05.006; Doyle RJ, 2007, GAIT POSTURE, V25, P166, DOI 10.1016/j.gaitpost.2006.03.004; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Frzovic D, 2000, ARCH PHYS MED REHAB, V81, P215, DOI 10.1053/apmr.2000.0810215; GAGON I, 2006, PHYS OCCUP THER PEDI, V26, P23; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; HIRABAYASHI S, 1995, BRAIN DEV-JPN, V17, P111, DOI 10.1016/0387-7604(95)00009-Z; Hirsch MA, 2003, ARCH PHYS MED REHAB, V84, P1109, DOI 10.1016/S0003-9993(03)00046-7; Horak F, 1996, HDB PHYSL 12, P255; Horak FB, 2006, AGE AGEING, V35, P7, DOI 10.1093/ageing/afl077; KUO AD, 1993, PROG BRAIN RES, V97, P349; *LOG INC, 1992, 3D MOUS HEAD TRACK T; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; Morton SM, 2004, NEUROSCIENTIST, V10, P247, DOI 10.1177/1073858404263517; Nallegowda M, 2004, AM J PHYS MED REHAB, V83, P898, DOI 10.1097/01.PHM.0000146505.18244.43; Nashner L, 1993, HDB BALANCE FUNCTION, P261; NASHNER LM, 1990, NEUROL CLIN, V8, P331, DOI 10.1016/S0733-8619(18)30359-1; NASHNER LM, 1982, J NEUROSCI, V2, P536; Nashner LM., 1997, HDB BALANCE FUNCTION, P280; Peterka R J, 1990, J Vestib Res, V1, P73; Peterson CL, 2003, CLIN J SPORT MED, V13, P230, DOI 10.1097/00042752-200307000-00006; Romberg MH, 1853, MANUAL NERVOUS DIS M; Rosengren KS, 2007, GAIT POSTURE, V25, P215, DOI 10.1016/j.gaitpost.2006.03.009; Schapira AHV, 2004, JAMA-J AM MED ASSOC, V291, P358, DOI 10.1001/jama.291.3.358; Shimada H, 2003, AM J PHYS MED REHAB, V82, P511, DOI 10.1097/01.PHM.0000064726.59036.CB; SHUMWAYCOOK A, 1985, J MOTOR BEHAV, V17, P131; SIMS EL, J APPL BIOM IN PRESS; Whitney SL, 2006, ARCH PHYS MED REHAB, V87, P402, DOI 10.1016/j.apmr.2005.11.002	32	23	24	0	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JAN	2009	90	1					145	150		10.1016/j.apmr.2008.06.025			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	397IY	WOS:000262657600020	19154841				2021-06-18	
J	Fridman, EA; Calvar, J; Bonetto, M; Gamzu, E; Krimchansky, BZ; Meli, F; Leiguarda, RC; Zafonte, R				Fridman, Esteban A.; Calvar, Jorge; Bonetto, Mariana; Gamzu, Elkan; Krimchansky, Ben Zion; Meli, Francisco; Leiguarda, Ramon C.; Zafonte, Ross			Fast awakening from minimally conscious state with apomorphine	BRAIN INJURY			English	Article						Brain injury; minimally conscious; dopaminergic; apomorphine; diffusion tensor	TRAUMATIC BRAIN-INJURY; PARKINSONS-DISEASE; VEGETATIVE STATE; SUBCUTANEOUS APOMORPHINE; FOLLOW-UP; BROMOCRIPTINE; LEVODOPA; THERAPY; SCALE; COMA	Background: Traumatic brain injury (TBI) can induce long-term severe disorders of consciousness. Evidence suggests an underlying dopaminergic deficit. Dopamine agonists may therefore play an important role in recovery of consciousness. Objective: To explore the response to continuous subcutaneous administration of apomorphine in a patient who had remained in minimally conscious state for 104 days and to evaluate the anatomical substrate of the effect. Design: A prospective, open-label, daily treatment, dose-escalation single case clinical study, with retrospective diffusion tensor image (DTI) evaluation. Results: On the fist day of treatment, the patient was able to move his limbs on command and answer yes/no questions which had not been the case prior to apomorphine administration. Subsequently there was a full recovery of consciousness and substantial functional recovery that was sustained even after apomorphine discontinuation. At the highest dose, mild dyskinesias were observed. These resolved with a lowering of the dose. DTI demonstrated a decrease of thalamocortical and corticothalamic projections in this MCS patient compared to normal volunteers. Conclusion: Although this is an open-label single-patient case report, the data are consistent with the theory that a dopaminergic deficit underlies MCS and that it may be overcome with apomorphine administration.	[Fridman, Esteban A.; Bonetto, Mariana] FLENI, Neurol Res Inst, Dept Neurol, Neurorehabil Sect & Spast Clin, RA-2325 Buenos Aires, DF, Argentina; [Fridman, Esteban A.; Meli, Francisco; Leiguarda, Ramon C.] FLENI, Neurol Res Inst, Dept Neurosci, Neurorehabil Sect & Spast Clin, RA-2325 Buenos Aires, DF, Argentina; [Fridman, Esteban A.; Calvar, Jorge] Consejo Nacl Invest Cient & Tecn, RA-1033 Buenos Aires, DF, Argentina; [Krimchansky, Ben Zion] Lowenstein Rehabil Hosp, Dept Neurol, Ranaana, Israel; [Zafonte, Ross] Harvard Univ, Sch Med, Spaulding Rehabil Hosp, Boston, MA USA	Fridman, EA (corresponding author), FLENI, Neurol Res Inst, Dept Neurol, Neurorehabil Sect & Spast Clin, RA-2325 Buenos Aires, DF, Argentina.	efridman@fleni.org.ar		Fridman, Esteban/0000-0001-7879-8874	NeuroHealing Pharmaceuticals Inc; Research Department of the Institute for Neurological Research-FLENI	Funding for this study came from NeuroHealing Pharmaceuticals Inc and the Research Department of the Institute for Neurological Research-FLENI. We specially thank Professor Brent Masel for his helpful comments on the manuscript, Claudia Navarro for all her efforts at the ANMAT (Argentinean Drugs Administrative Office) and manuscript edition.	Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Freeman A, 2001, ANN NEUROL, V50, P321, DOI 10.1002/ana.1119; Giacino JT, 2002, NEUROLOGY, V58, P349, DOI 10.1212/WNL.58.3.349; GROENEWEGEN HJ, 1994, TRENDS NEUROSCI, V17, P52, DOI 10.1016/0166-2236(94)90074-4; HUGHES AJ, 1991, NEUROLOGY, V41, P1723, DOI 10.1212/WNL.41.11.1723; Jenner P, 2003, CURR OPIN NEUROL, V16, pS3, DOI 10.1097/00019052-200312001-00002; Jiang HY, 2006, COMPUT METH PROG BIO, V81, P106, DOI 10.1016/j.cmpb.2005.08.004; Katzenschlager R, 2005, MOVEMENT DISORD, V20, P151, DOI 10.1002/mds.20276; Kolls BJ, 2006, CLIN NEUROPHARMACOL, V29, P292, DOI 10.1097/01.WNF.0000220824.57769.E5; Matsuda W, 2003, J NEUROL NEUROSUR PS, V74, P1571, DOI 10.1136/jnnp.74.11.1571; MONTASTRUC JL, 1989, J NEUROL NEUROSUR PS, V52, P773, DOI 10.1136/jnnp.52.6.773; Nicola SM, 2000, ANNU REV NEUROSCI, V23, P185, DOI 10.1146/annurev.neuro.23.1.185; NUTT JG, 1984, NEW ENGL J MED, V310, P483, DOI 10.1056/NEJM198402233100802; Owen AM, 2006, SCIENCE, V313, P1402, DOI 10.1126/science.1130197; Pahwa R, 2007, J NEUROL SCI, V258, P137, DOI 10.1016/j.jns.2007.03.013; Passler MA, 2001, ARCH PHYS MED REHAB, V82, P311, DOI 10.1053/apmr.2001.20831; POEWE WH, 1986, NEUROLOGY, V36, P1528, DOI 10.1212/WNL.36.11.1528; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Schiff ND, 2007, NATURE, V448, P600, DOI 10.1038/nature06041; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wisor JP, 2001, J NEUROSCI, V21, P1787; Zafonte RD, 2000, J HEAD TRAUMA REHAB, V15, P1179, DOI 10.1097/00001199-200010000-00014; Zafonte RD, 1998, BRAIN INJURY, V12, P617; Zafonte RD, 2001, J HEAD TRAUMA REHAB, V16, P112, DOI 10.1097/00001199-200102000-00014	26	23	24	0	7	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	2					172	177	PII 908449772	10.1080/02699050802649662			6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	403LD	WOS:000263083200012	19191097				2021-06-18	
J	Gerring, JP; Grados, MA; Slomine, B; Christensen, JR; Salorio, CF; Cole, WR; Vasa, RA				Gerring, Joan P.; Grados, Marco A.; Slomine, Beth; Christensen, James R.; Salorio, Cynthia F.; Cole, Wesley R.; Vasa, Roma A.			Disruptive behaviour disorders and disruptive symptoms after severe paediatric traumatic brain injury	BRAIN INJURY			English	Article						Traumatic brain injury; oppositional defiant disorder; conduct disorder	CLOSED-HEAD-INJURY; ATTENTION-DEFICIT/HYPERACTIVITY DISORDER; POSTTRAUMATIC-STRESS-DISORDER; OPPOSITIONAL DEFIANT DISORDER; DISABILITY RATING-SCALE; OVERT AGGRESSION SCALE; PRELIMINARY EFFICACY; CONDUCT DISORDER; DEVELOPMENTAL PSYCHOPATHOLOGY; SUBSEQUENT DEVELOPMENT	Objective: To determine pre-injury prevalence and post-injury incidence of DSM-III-R oppositional defiant disorder (ODD) and conduct disorder (CD), increase in disruptive symptoms after severe paediatric traumatic brain injury (TBI) and risk factors associated with development of these disturbances. Methods: Ninety-four children were followed 1 one year after severe TBI. Assessments of pre-injury and 1-year psychiatric status were ascertained by parent report. The 1-year incidence of disruptive behaviour disorders/symptoms was the main outcome measure. Results: The pre-injury prevalence of ODD and CD in the TBI sample was 6% and 8%, respectively, the prevalence of pre-injury CD being significantly higher than in a reference population. The incidence of new-onset ODD and CD 1-year post-injury was 9% and 8%, respectively, the incidence of new-onset CD being significantly higher than in a reference population. ODD symptoms and total number of disruptive symptoms increased significantly over the first post-injury year. Significant risk factors for disruptive disorders/symptoms included higher pre-injury psychosocial adversity, delinquency ratings and affective lability. Conclusions: Pre-injury conduct disorder is a significant risk factor for post-injury disruptive behaviours. New-onset CD and disruptive symptoms are consequences of TBI at 1-year post-injury. Risk factors for these post-injury disturbances are similar to risk factors in non-TBI populations.	[Gerring, Joan P.; Grados, Marco A.; Slomine, Beth; Christensen, James R.; Salorio, Cynthia F.; Cole, Wesley R.; Vasa, Roma A.] Johns Hopkins Bayview Med Ctr, Baltimore, MD 21224 USA	Gerring, JP (corresponding author), Johns Hopkins Bayview Med Ctr, D2E,4940 Eastern Ave, Baltimore, MD 21224 USA.	jgerring@jhmi.edu		Grados, Marco/0000-0002-6189-6264	NIMHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER	This work was supported by NIMH grant K20 MH-00997.	ACHENBACH TM, 1993, EMPIRICALLY BASED TA; Alderman N, 1997, BRAIN INJURY, V11, P503, DOI 10.1080/713802182; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andrews TK, 1998, BRAIN INJURY, V12, P133, DOI 10.1080/026990598122755; BLACKER D, 2000, AM PSYCHIAT ASS TASK, P1; Breslau N, 2006, ARCH GEN PSYCHIAT, V63, P1238, DOI 10.1001/archpsyc.63.11.1238; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; Cole WR, 2008, BRAIN INJURY, V22, P932, DOI 10.1080/02699050802454808; DISCALA C, 1991, ARCH PHYS MED REHAB, V72, P662; EDELBROCK C, 1985, CHILD DEV, V56, P265, DOI 10.2307/1130193; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Gerring JP, 2002, J AM ACAD CHILD PSY, V41, P157, DOI 10.1097/00004583-200202000-00009; Gerson AC, 1996, PSYCHIAT RES, V65, P189, DOI 10.1016/S0165-1781(96)02851-X; Goldstrohm SL, 2005, ARCH CLIN NEUROPSYCH, V20, P675, DOI 10.1016/j.acn.2005.02.005; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Grados MA, 2008, DEPRESS ANXIETY, V25, P398, DOI 10.1002/da.20398; Guttmann-Steinmetz S, 2006, J AM ACAD CHILD PSY, V45, P440, DOI 10.1097/01.chi.0000196422.42599.63; Herskovits EH, 1999, RADIOLOGY, V213, P389, DOI 10.1148/radiology.213.2.r99nv45389; Herskovits EH, 2003, NEUROIMAGE, V19, P1664, DOI 10.1016/S1053-8119(03)00231-3; Herskovits EH, 2002, RADIOLOGY, V224, P345, DOI 10.1148/radiol.2242011439; Hill J, 2002, J CHILD PSYCHOL PSYC, V43, P133, DOI 10.1111/1469-7610.00007; Hinshaw S P, 1994, Prog Exp Pers Psychopathol Res, P3; HINSHAW SP, 1993, DEV PSYCHOPATHOL, V5, P31, DOI 10.1017/S0954579400004247; Hinshaw SP, 2002, J ABNORM CHILD PSYCH, V30, P431, DOI 10.1023/A:1019808712868; Hollingshead AA, 1975, 4 FACTOR INDEX UNPUB; Jensen PS, 1999, J AM ACAD CHILD PSY, V38, P1569, DOI 10.1097/00004583-199912000-00019; Lahey BB, 1996, J AM ACAD CHILD PSY, V35, P855, DOI 10.1097/00004583-199607000-00011; LANGLEY J, 1983, Journal of Pediatric Psychology, V8, P181, DOI 10.1093/jpepsy/8.2.181; LECKMAN JF, 1982, ARCH GEN PSYCHIAT, V39, P879; Loeber R, 2000, DEV PSYCHOPATHOL, V12, P737, DOI 10.1017/S0954579400004107; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 1997, BRAIN INJURY, V11, P699; Max JE, 1998, J NERV MENT DIS, V186, P325, DOI 10.1097/00005053-199806000-00001; Moffitt TE, 2008, J CHILD PSYCHOL PSYC, V49, P3, DOI 10.1111/j.1469-7610.2007.01823.x; OSBERG JS, 1990, AM J PHYS MED REHAB, V69, P67, DOI 10.1097/00002060-199004000-00004; Paris R., 1974, CLIN NEUROPSYCHOLOGY, P179; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Reich W, 2000, J AM ACAD CHILD PSY, V39, P59, DOI 10.1097/00004583-200001000-00017; Rowe R, 2002, J CHILD PSYCHOL PSYC, V43, P365, DOI 10.1111/1469-7610.00027; Salorio CF, 2005, J INT NEUROPSYCH SOC, V11, P686, DOI 10.1017/S1355617705050885; Salorio CF, 2008, PEDIATR CRIT CARE ME, V9, P47, DOI 10.1097/01.PCC.0000298638.66240.0E; Shaffer D, 1996, J AM ACAD CHILD PSY, V35, P865, DOI 10.1097/00004583-199607000-00012; Slifer KJ, 2009, DEV DISABIL RES REV, V15, P144, DOI 10.1002/ddrr.60; Slomine BS, 2005, J INT NEUROPSYCH SOC, V11, P645, DOI 10.1017/S1355617705050769; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; Speltz ML, 1999, J AM ACAD CHILD PSY, V38, P838, DOI 10.1097/00004583-199907000-00013; Stouthamer-Loeber M, 2002, J CONSULT CLIN PSYCH, V70, P111, DOI 10.1037//0022-006X.70.1.111; SZATMARI P, 1994, INT J METHOD PSYCH, V4, P231; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Vasa RA, 2002, J AM ACAD CHILD PSY, V41, P148, DOI 10.1097/00004583-200202000-00008; Wade SL, 2009, J HEAD TRAUMA REHAB, V24, P239, DOI 10.1097/HTR.0b013e3181ad6680; Wade SL, 2008, J HEAD TRAUMA REHAB, V23, P369, DOI 10.1097/01.HTR.0000341432.67251.48; Wade SL, 2006, J HEAD TRAUMA REHAB, V21, P57, DOI 10.1097/00001199-200601000-00006; YUDOFSKY SC, 1986, AM J PSYCHIAT, V143, P35	59	23	23	0	32	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.		2009	23	12					944	955		10.3109/02699050903285531			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	529YL	WOS:000272555200002	19831491				2021-06-18	
J	Minor, LB; Lasker, DM				Minor, Lloyd B.; Lasker, David M.			Tonic and phasic contributions to the pathways mediating compensation and adaptation of the vestibulo-ocular reflex	JOURNAL OF VESTIBULAR RESEARCH-EQUILIBRIUM & ORIENTATION			English	Article; Proceedings Paper	Symposium on Vestibular Compensation held at the 32nd Annual Midwinter Meeting of the Association-for-Research-in-Otolaryngology	FEB 14-19, 2009	Baltimore, MD	Assoc Res Otolaryngol		Regular afferent; irregular afferent; labyrinthectomy; vestibular; semicircular canals; mathematical model; high acceleration head movement; vestibular hypofunction; retinal slip error	HIGH-ACCELERATION ROTATIONS; SQUIRREL-MONKEY; HIGH-FREQUENCY; VESTIBULAR-NERVE; RESPONSES; HEAD; COMPONENTS; CHINCHILLA; AFFERENTS; DYNAMICS	Processes of vestibular compensation mediate recovery of many aspects of vestibular dysfunction following unilateral vestibular injury. The VOR in response to high-frequency, high-acceleration head movements, however, retains an enduring asymmetry. Head movements that are inhibitory with respect to semicircular canals on the intact side lead to a diminished VOR whereas head movements that are excitatory for semicircular canals on the intact side lead to a VOR that returns close to normal. We review our work directed toward understanding the processes of VOR compensation to high-frequency, high-acceleration head movements and the related topic of adaptation to changes in the visual requirements for a compensatory VOR. Our work has shown that the processes of both compensation and adaptation to these stimuli can be described by a mathematical model with inputs from tonic and phasic components. We have further shown that the dynamics of regular afferents have close resemblance to the tonic pathway whereas the dynamics of irregular afferents match those of the phasic pathway.	[Minor, Lloyd B.; Lasker, David M.] Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Baltimore, MD 21205 USA	Lasker, DM (corresponding author), Johns Hopkins Univ, Dept Otolaryngol Head & Neck Surg, Sch Med, Ross Bldg,Suite 710,720 Rutland Ave, Baltimore, MD 21205 USA.	dlasker@jhmi.edu			NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC002390] Funding Source: NIH RePORTER; NIDCD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01 DC002390-05, R01 DC002390-09, R01 DC-02390, R01 DC002390-06, R01 DC002390-08, R01 DC002390-07, R01 DC002390] Funding Source: Medline		Aw ST, 1996, J NEUROPHYSIOL, V76, P4021, DOI 10.1152/jn.1996.76.6.4021; BAIRD RA, 1988, J NEUROPHYSIOL, V60, P182; Baloh RW, 2003, NEW ENGL J MED, V348, P1027, DOI 10.1056/NEJMcp021154; Carey JP, 2007, OTOL NEUROTOL, V28, P356, DOI 10.1097/01.mao.0000253284.40995.d8; Carey JP, 2002, JARO-J ASSOC RES OTO, V3, P430, DOI 10.1007/s101620010053; Clendaniel RA, 2002, J NEUROPHYSIOL, V88, P3534, DOI 10.1152/jn.00404.2002; Clendaniel RA, 2001, J NEUROPHYSIOL, V86, P1594; Collewijn H, 2000, J NEUROPHYSIOL, V84, P376; Cremer PD, 1998, BRAIN, V121, P699, DOI 10.1093/brain/121.4.699; CULLEN KE, 2010, J VESTIB RES UNPUB; Curthoys I S, 1995, J Vestib Res, V5, P67; HALMAGYI GM, 1988, ARCH NEUROL-CHICAGO, V45, P737, DOI 10.1001/archneur.1988.00520310043015; HALMAGYI GM, 1990, EXP BRAIN RES, V81, P479, DOI 10.1007/BF02423496; HONRUBIA V, 1984, AM J OTOLARYNG, V5, P15, DOI 10.1016/S0196-0709(84)80016-2; Hullar TE, 2005, J NEUROPHYSIOL, V93, P2777, DOI 10.1152/jn.01002.2004; Hullar TE, 1999, J NEUROPHYSIOL, V82, P2000; Huterer M, 2002, J NEUROPHYSIOL, V88, P13, DOI 10.1152/jn.2002.88.1.13; JENKINS HA, 1985, LARYNGOSCOPE, V95, P1224; Lasker DM, 1999, J NEUROPHYSIOL, V82, P1271; Lasker DM, 2002, ANN NY ACAD SCI, V956, P324, DOI 10.1111/j.1749-6632.2002.tb02831.x; Lasker DM, 2000, J NEUROPHYSIOL, V83, P2482; LISBERGER SG, 1986, J NEUROSCI, V6, P346; LISBERGER SG, 1984, SCIENCE, V225, P74, DOI 10.1126/science.6610214; Minor LB, 1999, NEUROLOGY, V53, P2158, DOI 10.1212/WNL.53.9.2158; Minor LB, 1999, J NEUROPHYSIOL, V82, P1254; PAIGE GD, 1989, ACTA OTO-LARYNGOL, V108, P1, DOI 10.3109/00016488909107385; Palla A, 2004, JARO-J ASSOC RES OTO, V5, P427, DOI 10.1007/s10162-004-4035-4; SMITH PF, 1988, BRAIN RES BRAIN RES, V14, P308; Straka H, 2009, ANN NY ACAD SCI, V1164, P37, DOI 10.1111/j.1749-6632.2008.03740.x; Ushio M., 2009, Society for Neuroscience Abstract Viewer and Itinerary Planner, V39; ZEE DS, BASIC APPL ASPECTS V, P125	31	23	23	0	7	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0957-4271	1878-6464		J VESTIBUL RES-EQUIL	J. Vestib. Res.-Equilib. Orientat.		2009	19	5-6					159	170		10.3233/VES-2009-0353			12	Neurosciences; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	603PJ	WOS:000278220200003	20495233	Green Accepted			2021-06-18	
J	Park, HK; Joo, WI; Chough, CK; Cho, CB; Lee, KJ; Rha, HK				Park, Hae-Kwan; Joo, Won-Il; Chough, Chung-Kee; Cho, Chul-Beom; Lee, Kyung-Jin; Rha, Hyoung-Kyun			The clinical efficacy of repeat brain computed tomography in patients with traumatic intracranial haemorrhage within 24 hours after blunt head injury	BRITISH JOURNAL OF NEUROSURGERY			English	Article						head trauma; intracranial haemorrhage; computed tomography; epidural haematoma	FOLLOW-UP; CT; MANAGEMENT; HEMATOMAS; UTILITY; SCAN	This study was performed to determine the usefulness of repeated brain computed tomography (CT) within 24 hours of blunt head trauma in patients with traumatic intracranial haemorrhages (ICH) and who were initially treated nonsurgically. Factors associated with the worsening of lesions on repeat CT were evaluated. Medical records of all blunt head trauma patients with traumatic ICH admitted to our hospital from January 2003 to December 2006 were retrospectively reviewed. Patients older than 16 years of age with an initial Glasgow Coma Scale (GCS) of 8 or greater were included. From the results of the repeat CT, patients were categorized as Group 1 (improved or unchanged condition) or Group 2 (worsened condition). A total of 168 patients (mean age of 44.8 +/- 19.2; mean admission GCS of 13.42 +/- 2.07; male to female ratio 2.1:1) were included. In 161 patients, repeat CT was obtained on a routine basis. In the remaining 7, it was prompted by a worsening neurological condition. The mean time from initial to repeat CT was 10.10 +/- 7.25 hours. Based on the results of the repeat CT, 108 patients were included in Group 1 and 60 in Group 2. The mean initial GCS was lower in patients from Group 2 versus those from Group 1 (11.9 +/- 2.6 compared with 14.3 +/- 0.96; p < 0.001). After repeat CT, 28 (47%) of the patients in Group 2 underwent neurosurgical interventions. Of the 28 surgically treated patients from Group 2, 6 (10%) exhibited neurological worsening and 22 (37%) appeared neurologically stable. According to our data, we suggest that routine repeat CT within 24 hours after blunt head trauma might minimize potential neurological deterioration in patients with either a GCS lower than 12 or with an epidural haematoma or multiple lesions as indicated on initial CT.	[Park, Hae-Kwan; Joo, Won-Il; Chough, Chung-Kee; Cho, Chul-Beom; Lee, Kyung-Jin; Rha, Hyoung-Kyun] Catholic Univ Korea, Dept Neurosurg, St Marys Hosp, Seoul 150713, South Korea	Joo, WI (corresponding author), Catholic Univ Korea, Dept Neurosurg, St Marys Hosp, 62 Youido Dong, Seoul 150713, South Korea.	jwi@catholic.ac.kr					Brown CVR, 2007, J TRAUMA, V62, P1339, DOI 10.1097/TA.0b013e318054e25a; Chao A, 2001, J TRAUMA, V51, P870, DOI 10.1097/00005373-200111000-00008; COPE DN, 1988, ARCH PHYS MED REHAB, V69, P483; FRENCH BN, 1997, SURG NEUROL, V4, P171; Lee TT, 1997, ACTA NEUROCHIR, V139, P1042, DOI 10.1007/BF01411558; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; ROBERSON FC, 1979, SURG NEUROL, V12, P161; Schuster R, 2005, AM SURGEON, V71, P701; Servadei E, 2000, BRIT J NEUROSURG, V14, P110; SMITH HK, 1991, NEUROSURGERY, V29, P258, DOI 10.1227/00006123-199108000-00016; Stearley H E, 1998, Am J Crit Care, V7, P282; Sullivan TP, 1999, AM J NEURORADIOL, V20, P107; WADDELL G, 1975, BRIT MED J, V2, P417, DOI 10.1136/bmj.2.5968.417; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89	15	23	25	0	0	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0268-8697	1360-046X		BRIT J NEUROSURG	Br. J. Neurosurg.		2009	23	6					617	621		10.3109/02688690902999302			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	585TK	WOS:000276851900011	19922276				2021-06-18	
J	Saunders, LL; Selassie, AW; Hill, EG; Nicholas, JS; Horner, MD; Corrigan, JD; Lackland, DT				Saunders, Lee L.; Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Horner, Michael David; Corrigan, John D.; Lackland, Daniel T.			A population-based study of repetitive traumatic brain injury among persons with traumatic brain injury	BRAIN INJURY			English	Article						Brain injuries; epilepsy; seizures; epidemiology; survival analysis	PROFESSIONAL FOOTBALL PLAYERS; RECURRENT CONCUSSION; SOCIOECONOMIC-STATUS; UNITED-STATES; HEAD TRAUMA; RATES; HOSPITALIZATION; COLLEGIATE; SEIZURES; OUTCOMES	Primary objective: The objective was to estimate and compare the hazards of repetitive traumatic brain injury (RTBI) events as a function of the index TBI severity, in a cohort of TBI hospital discharges include in the South Carolina Traumatic Brain Injury Follow-up Registry. Research design: Retrospective cohort. Methods and procedures: There were 4357 persons with TBI who were followed from the index hospital discharge through 31 December 2005 for RTBI events through the statewide hospital discharge (HD) and emergency department (ED) records. Prentice, Williams, Peterson total time/conditional probability model (PWP-CP) for recurrent events survival analysis was used to assess RTBI as a function of index TBI severity. Main outcomes and results: Index TBI severity approached significance in its relationship with RTBI, with persons with a severe index TBI experiencing events at a higher rate than those with a mild/moderate index TBI. Among the other covariates evaluated, epilepsy/seizure disorder, race, gender, payer status, cause of injury and having a prior history of TBI were associated with RTBI. Conclusions: While TBI severity approached significance with RTBI, other variables, such as epilepsy/seizure disorder, seem to have a more significant relationship with RTBI.	[Saunders, Lee L.] Med Univ S Carolina, Dept Hlth Sci & Res, Charleston, SC 29425 USA; [Selassie, Anbesaw W.; Hill, Elizabeth G.; Nicholas, Joyce S.; Lackland, Daniel T.] Med Univ S Carolina, Dept Biostat Bioinformat & Epidemiol, Charleston, SC 29425 USA; [Horner, Michael David] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA; [Horner, Michael David] Ralph H Johnson Dept Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA; [Corrigan, John D.] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA	Saunders, LL (corresponding author), Med Univ S Carolina, Dept Hlth Sci & Res, 77 President St,Suite 117,MSC 700, Charleston, SC 29425 USA.	saundel@musc.edu			Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU421926]	This study was supported by Grant No. U17/CCU421926 from the Division of Injury Response, National Center for Injury Prevention and Control (CIPC), Centers for Disease Control and Prevention (CDC) ( PI: Anbesaw W. Selassie). The study was performed pursuant to a jointly financed cooperative arrangement between the NCPIC, the National Center for Chronic Disease Prevention and Health Promotion, CDC and the Social Security Administration (SSA), Office of Disability Income and Support Programs. The opinions and conclusions expressed are solely the authors' and should not be construed as representing the opinions or policy of CDC, SSA, or any agency of the federal government.	ALBRIGHT JP, 1985, AM J SPORT MED, V13, P147, DOI 10.1177/036354658501300301; ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; Annegers JF, 1998, NEW ENGL J MED, V338, P20, DOI 10.1056/NEJM199801013380104; *ASS ADV AUT MED, 1990, ABBR INJ SCAL; Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Betz ME, 2005, ANN EMERG MED, V46, P544, DOI 10.1016/j.annemergmed.2005.07.009; Birken CS, 2006, CAN MED ASSOC J, V175, P867, DOI 10.1503/cmaj.051207; Bruns TJ, 2003, EPILEPSIA, V44, P2, DOI 10.1046/j.1528-1157.44.s10.3.x; Butler J, 2001, CENTRAL NERVOUS SYST; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cubbin C, 2002, ANNU REV PUBL HEALTH, V23, P349, DOI 10.1146/annurev.publhealth.23.100901.140548; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; d'Errico A, 2007, OCCUP ENVIRON MED, V64, P325, DOI 10.1136/oem.2006.027839; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Guskiewicz KM, 2000, AM J SPORT MED, V28, P643, DOI 10.1177/03635465000280050401; HOSMER DW, 2008, APPL SURV AN REGR MO; Kelly J., 1997, MMWR-MORBID MORTAL W, V46, P224; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LIN D, 1993, J AM STAT ASSOC, V84, P1074; Pickelsimer EE, 2006, J HEAD TRAUMA REHAB, V21, P491, DOI 10.1097/00001199-200611000-00004; PRENTICE RL, 1981, BIOMETRIKA, V68, P373, DOI 10.1093/biomet/68.2.373; *S CAR STAT BUDG C, 2006, S CAR POP REP; Schofield PW, 2006, BRAIN INJURY, V20, P499, DOI 10.1080/02699050600664749; Selassie AW, 2008, J HEAD TRAUMA REHAB, V23, P123, DOI 10.1097/01.HTR.0000314531.30401.39; Swaine BR, 2007, PEDIATRICS, V119, P749, DOI 10.1542/peds.2006-1186; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Walker R, 2003, J PSYCHOACTIVE DRUGS, V35, P343, DOI 10.1080/02791072.2003.10400017; Whiteneck G, 2004, ARCH PHYS MED REHAB, V85, pS73, DOI 10.1016/j.apmr.2003.08.107	33	23	23	0	9	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2009	23	11					866	872	PII 915242880	10.1080/02699050903283213			7	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	498JY	WOS:000270137300002	20100122				2021-06-18	
J	Shein, NA; Grigoriadis, N; Horowitz, M; Umschwief, G; Alexandrovich, AG; Simeonidou, C; Grigoriadis, S; Touloumi, O; Shohami, E				Shein, Na'ama A.; Grigoriadis, Nikolaos; Horowitz, Michal; Umschwief, Gali; Alexandrovich, Alexander G.; Simeonidou, Constantina; Grigoriadis, Savuas; Touloumi, Olga; Shohami, Esther			Microglial involvement in neuroprotection following experimental traumatic brain injury in heat-acclimated mice	BRAIN RESEARCH			English	Article						Cytokines; Glia; Neuroprotection; Neurotrophin; Preconditioning	EXPRESSION; ERYTHROPOIETIN; DISEASE; MODEL; RAT	Brain-derived neurotrophic factor (BDNF) conveys neuroprotection in various settings of experimental central nervous system injury. Using a model of endogenous neuroprotection, induced in mice by chronic exposure to moderate ambient heat (heat acclimation, HA), we have previously shown that neuroprotection following traumatic brain injury involves reduced post-injury tumor necrosis factor alpha (TNF alpha) expression. As glial cells play a pivotal role in post-injury inflammation on one hand, and are also capable of inducing neuroprotection by harboring trophic factors and BDNF in particular, the effects of injury and HA on overall BDNF content at the trauma area, gliosis and glial BDNF expression were investigated. Western blotting indicated higher overall BDNF levels in HA sham-operated mice. Following injury, a decrease was observed in the HA group only, reaching levels similar to normothermic mice. Immunohistochemical studies demonstrated BDNF-positive resting microglia in non-injured HA but not normothermic animals. Post-injury astrocytosis and microglial immunoreactivity were enhanced in the HA group. Particularly, an increase in the amount of ramified microglia was observed within the penumbra, accompanied by a concomitant decrease in globular microglia, a major source of pro-inflammatory mediators. BDNF labeling on and around microglia and their processes was intensified in HA mice. Furthermore, BDNF immunoreactivity in HA mice was evident in the degenerated edges of axons. These findings, taken together with the growing body of evidence indicating the neuroprotective potential of both BDNF and microglia, suggest a possible role of these cells in HA-induced neuroprotection. (C) 2008 Elsevier B.V. All rights reserved.	[Shein, Na'ama A.; Horowitz, Michal; Umschwief, Gali] Hebrew Univ Jerusalem, Dept Physiol, IL-91905 Jerusalem, Israel; [Shein, Na'ama A.; Umschwief, Gali; Alexandrovich, Alexander G.; Shohami, Esther] Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91905 Jerusalem, Israel; [Grigoriadis, Nikolaos; Touloumi, Olga] AHEPA Univ Hosp, Dept Neurol, Thessaloniki, Greece; [Simeonidou, Constantina] AHEPA Univ Hosp, Dept Physiol, Thessaloniki, Greece; [Grigoriadis, Nikolaos; Simeonidou, Constantina; Touloumi, Olga] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece; [Grigoriadis, Savuas] Hebrew Univ Jerusalem, Hadassah Univ Hosp, Dept Neurosurg, Jerusalem, Israel	Horowitz, M (corresponding author), Hebrew Univ Jerusalem, Dept Physiol, IL-91905 Jerusalem, Israel.	horowitz@cc.huji.ac.il; esty@cc.huji.ac.il					Sharma HS, 2006, ACTA NEUROCHIR SUPPL, V96, P329; Shein NA, 2005, J CEREBR BLOOD F MET, V25, P1456, DOI 10.1038/sj.jcbfm.9600142; Shein NA, 2008, J NEUROTRAUM, V25, P112, DOI 10.1089/neu.2007.0358; Shein NA, 2007, PROG BRAIN RES, V161, P353, DOI 10.1016/S0079-6123(06)61025-X; Shein NA, 2007, BRAIN RES, V1185, P313, DOI 10.1016/j.brainres.2007.09.024; Shohami E, 1997, J NEUROIMMUNOL, V72, P169, DOI 10.1016/S0165-5728(96)00181-6; SHOHAMI E, 1994, ACTA NEUROCHIR, P443; Simic G, 2000, EXP NEUROL, V165, P12, DOI 10.1006/exnr.2000.7448; Smith DH, 2003, NEUROMOL MED, V4, P59, DOI 10.1385/NMM:4:1-2:59; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Vavrek R, 2006, BRAIN, V129, P1534, DOI 10.1093/brain/awl087; Zuccato C, 2001, SCIENCE, V293, P493, DOI 10.1126/science.1059581	12	23	23	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	DEC 9	2008	1244						132	141		10.1016/j.brainres.2008.09.032			10	Neurosciences	Neurosciences & Neurology	384YH	WOS:000261779600014	18835383				2021-06-18	
J	Abate, MG; Trivedi, M; Fryer, TD; Smielewski, P; Chatfield, DA; Williams, GB; Aigbirhio, F; Carpenter, TA; Pickard, JD; Menon, DK; Coles, JP				Abate, M. Giulia; Trivedi, Monica; Fryer, Tim D.; Smielewski, Piotr; Chatfield, Doris A.; Williams, Guy B.; Aigbirhio, Franklin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.; Coles, Jonathan P.			Early Derangements in Oxygen and Glucose Metabolism Following Head Injury: The Ischemic Penumbra and Pathophysiological Heterogeneity	NEUROCRITICAL CARE			English	Article						Head injury; Oxygen metabolism; Glucose metabolism; Ischemia; Positron emission tomography; Traumatic penumbra	CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; BLOOD-FLOW; HYPERVENTILATION; O-15; BURDEN; DAMAGE	Introduction Conclusive evidence of cerebral ischemia following head injury has been elusive. We aimed to use O-15 and (18)Fluorodeoxyglucose positron emission tomography (PET) to investigate pathophysiological derangements following head injury. Results Eight patients underwent PET within 24 h of injury to map cerebral blood flow (CBF), cerebral oxygen metabolism (CMRO2), oxygen extraction fraction (OEF), and cerebral glucose metabolism (CMRglc). Physiological regions of interest (ROI) were generated for each subject using a range of OEF values from very low (< 10), low (10-30), normal range (30-50), high (50-70), and critically high (70%). We applied these ROIs to each subject to generate data that would examine the balance between blood flow and metabolism across the injured brain independent of structural injury. Discussion Compared to the normal range, brain regions with higher OEF demonstrate a progressive CBF reduction (P < 0.01), CMRO2 increase (P < 0.05), and no change in CMRglc, while regions with lower OEF are associated with reductions in CBF, CMRO2, and CMRglc (P < 0.01). Although all subjects demonstrate a decrease in CBF with increases in OEF > 70%, CMRO2 and CMRglc were generally unchanged. One subject demonstrated a reduction in CBF and small fall in CMRO2 within the high OEF region (> 70%), combined with a progressive increase in CMRglc. Conclusions The low CBF and maintained CMRO2 in the high OEF ROIs is consistent with classical cerebral ischemia and the presence of an 'ischemic penumbra' following early head injury, while the metabolic heterogeneity that we observed suggests significant pathophysiological complexity. Other mechanisms of energy failure are clearly important and further study is required to delineate the processes involved.	[Abate, M. Giulia; Trivedi, Monica; Fryer, Tim D.; Chatfield, Doris A.; Williams, Guy B.; Aigbirhio, Franklin; Carpenter, T. Adrian; Pickard, John D.; Menon, David K.; Coles, Jonathan P.] Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; [Abate, M. Giulia; Trivedi, Monica; Chatfield, Doris A.; Menon, David K.; Coles, Jonathan P.] Addenbrookes Hosp, Div Anaesthesia, Cambridge CB2 2QQ, England; [Abate, M. Giulia] Univ Milano Bicocca, Coll Med, HS Gerardo, I-20052 Monza, Italy; [Smielewski, Piotr; Pickard, John D.] Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England	Coles, JP (corresponding author), Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Box 65, Cambridge CB2 2QQ, England.	jpc44@wbic.cam.ac.uk		Smielewski, Peter/0000-0001-5096-3938	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0600986, G0001237] Funding Source: Medline		BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; Coles JP, 2007, CRIT CARE MED, V35, P568, DOI 10.1097/01.CCM.0000254066.37187.88; Coles JP, 2006, J CEREBR BLOOD F MET, V26, P48, DOI 10.1038/sj.jcbfm.9600179; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P202, DOI 10.1097/01.WCB.0000103022.98348.24; Coles JP, 2004, J CEREBR BLOOD F MET, V24, P191, DOI 10.1097/01.WCB.0000100045.07481.DE; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Diringer MN, 2000, J NEUROSURG, V92, P7, DOI 10.3171/jns.2000.92.1.0007; FRACKOWIAK RSJ, 1980, J COMPUT ASSIST TOMO, V4, P727, DOI 10.1097/00004728-198012000-00001; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HUANG SC, 1980, AM J PHYSIOL, V238, pE69; JENNETT B, 1975, LANCET, V1, P480; Johnston AJ, 2005, CRIT CARE MED, V33, P189, DOI 10.1097/01.CCM.0000149837.09225.BD; KINAHAN PE, 1989, IEEE T NUCL SCI, V36, P964, DOI 10.1109/23.34585; LAMMERTSMA AA, 1987, J CEREBR BLOOD F MET, V7, P372, DOI 10.1038/jcbfm.1987.75; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Menon DK, 2004, CRIT CARE MED, V32, P1384, DOI 10.1097/01.CCM.0000127777.16609.08; MILLER JD, 1985, BRIT J ANAESTH, V57, P120, DOI 10.1093/bja/57.1.120; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; PHELPS ME, 1979, J NUCL MED, V20, P328; Rodriguez-Baeza A, 2003, ANAT REC PART A, V273A, P583, DOI 10.1002/ar.a.10069; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Schwarzmaier S, 2006, J NEUROTRAUM, V23, P769; Smielewski Peter, 2002, J Clin Monit Comput, V17, P427, DOI 10.1023/A:1026293611455; Stein SC, 2004, NEUROSURGERY, V54, P687, DOI 10.1227/01.NEU.0000108641.98845.88; TEASDALE G, 1974, LANCET, V2, P81; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6	28	23	24	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	DEC	2008	9	3					319	325		10.1007/s12028-008-9119-2			7	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	367HC	WOS:000260542100007	18563636				2021-06-18	
J	Fan, JY; Kirkness, C; Vicini, P; Burr, R; Mitchell, P				Fan, Jun-Yu; Kirkness, Catherine; Vicini, Paolo; Burr, Robert; Mitchell, Pamela			INTRACRANIAL PRESSURE WAVEFORM MORPHOLOGY AND INTRACRANIAL ADAPTIVE CAPACITY	AMERICAN JOURNAL OF CRITICAL CARE			English	Article							CEREBRAL PERFUSION-PRESSURE; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; INTRA-CRANICAL PRESSURE; FLUID PULSE PRESSURE; VOLUME INDEX; INTENSIVE-CARE; HYPERTENSION; DYNAMICS; PATIENT	Background Intracranial hypertension due to primary and secondary injuries is a prime concern when providing care to patients with severe traumatic brain injury. Increases in intracranial pressure vary depending on compensatory processes within the craniospinal space, also referred to as intracranial adaptive capacity. In patients with traumatic brain injury and decreased intracranial adaptive capacity, intracranial pressure increases disproportionately in response to a variety of stimuli. However, no well-validated measures are available in clinical practice to predict the development of such an increase. Objectives To examine whether P2 elevation, quantified by determining the P2: P1 ratio (>= 0.8) of the intracranial pressure pulse waveform, is a unique predictor of disproportionate increases in intracranial pressure on a beat-by-beat basis in the 30 minutes preceding the elevation in patients with severe traumatic brain injury, within 48 hours after deployment of an intracranial pressure monitor. Methods A total of 38 patients with severe traumatic brain injury were sampled from a randomized controlled trial of cerebral perfusion pressure management in patients with traumatic brain injury or subarachnoid hemorrhage. Results The P2 elevation was not only present before the disproportionate increase in pressure, but also appeared in the comparison data set (within-subject without such a pressure increase). Conclusions P2 elevation is not a reliable clinical indicator to predict an impending disproportionate increase in intracranial pressure. (American Journal of Critical Care. 2008;17:545-554)	[Fan, Jun-Yu] Chang Gung Inst Technol, Dept Nursing, Tao Yuan 333, Taiwan; [Fan, Jun-Yu] Chang Gung Mem Hosp, Tao Yuan, Taiwan; [Vicini, Paolo] Univ Washington, Dept Bioengn, Seattle, WA 98195 USA; [Mitchell, Pamela] Univ Washington, Sch Nursing, Seattle, WA 98195 USA	Fan, JY (corresponding author), Chang Gung Inst Technol, Dept Nursing, 261 Wen Hwa 1st Rd, Tao Yuan 333, Taiwan.	jyfan@gw.cgit.edu.tw			National Institute of Nursing ResearchUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01 NR04901]; NATIONAL INSTITUTE OF NURSING RESEARCHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Nursing Research (NINR) [R01NR004901] Funding Source: NIH RePORTER	The study from which the data were obtained was funded by grant R01 NR04901 from the National Institute of Nursing Research to Pamela H. Mitchell and Catherine Kirkness, principal investigators.	AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; AVEZAAT CJJ, 1986, ACTA NEUROCHIR, V79, P13, DOI 10.1007/BF01403461; AVEZAAT CJJ, 1986, NEUROSURG REV, V9, P113, DOI 10.1007/BF01743061; BRAY RS, 1986, INTRACRANIAL PRESSUR, V6, P260; CARDOSO ER, 1983, J NEUROSURG, V59, P817, DOI 10.3171/jns.1983.59.5.0817; Chesnut R M, 1995, New Horiz, V3, P366; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOPP M, 1980, J NEUROSURG, V53, P516, DOI 10.3171/jns.1980.53.4.0516; CONTANT CF, 1995, J NEUROSCI METH, V57, P15, DOI 10.1016/0165-0270(94)00106-Q; CZOSNYKA M, 1988, ACTA NEUROCHIR, V93, P140, DOI 10.1007/BF01402897; Czosnyka M, 2004, J NEUROL NEUROSUR PS, V75, P813, DOI 10.1136/jnnp.2003.033126; CZOSNYKA M, 1990, ACTA NEUROCHIR, V105, P112, DOI 10.1007/BF01669992; Gega A, 1980, INTRACRANIAL PRESSUR, P188; Germon K, 1988, J Neurosci Nurs, V20, P344; GRAY WJ, 1987, J NEUROSURG, V67, P369, DOI 10.3171/jns.1987.67.3.0369; GRAY WJ, 1987, J NEUROSURG, V67, P377, DOI 10.3171/jns.1987.67.3.0377; Hickey J, 2003, CLIN PRACTICE NEUROL; HIRAI O, 1984, SURG NEUROL, V21, P67, DOI 10.1016/0090-3019(84)90404-X; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Kirkness C J, 2000, J Neurosci Nurs, V32, P271; Kirkness CJ, 2006, AM J CRIT CARE, V15, P600; Kirkness CJ, 2005, ACTA NEUROCHIR SUPPL, V95, P13; KLASSEN P A, 1991, Neurological Research, V13, P194; Lang E W, 1995, New Horiz, V3, P400; Langlois JA, 2006, TRAUMATIC BRAIN INJU; LEECH P, 1974, J NEUROL NEUROSUR PS, V37, P1093, DOI 10.1136/jnnp.37.10.1093; LUNDBERG N, 1960, Acta Psychiatr Scand Suppl, V36, P1; March K, 1990, J Neurosci Nurs, V22, P375; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; MILLER J D, 1987, Neurological Research, V9, P198; Miller J D, 1975, Clin Neurosurg, V22, P76; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, J NEUROTRAUM, V9, pS317; MILLER JD, 1973, ARCH NEUROL-CHICAGO, V28, P265, DOI 10.1001/archneur.1973.00490220073011; Miller JD, 1972, INTRACRANIAL PRESSUR, P270; Mitchell P H, 1986, J Neurosci Nurs, V18, P170; MITCHELL PH, 1981, NURS RES, V30, P212; Mitchell PH, 2002, ACT NEUR S, V81, P163; MITCHELL PH, 1978, NURS RES, V27, P4; MITCHELL PH, 1986, NURS CLIN N AM, V21, P563; MITCHELL PH, 1998, INTRACRANIAL PRESSUR, P420; Muwaswes M, 1985, J Neurosurg Nurs, V17, P238; NORNES H, 1977, ACTA NEUROCHIR, V38, P177, DOI 10.1007/BF01401089; Piper I, 1997, HEAD INJURY; PITTS LH, 1980, INTRACRANIAL PRESSUR, V4, P5; PORTNOY HD, 1994, PEDIATR NEUROSURG, V20, P92, DOI 10.1159/000120771; PORTNOY HD, 1981, NEUROSURGERY, V9, P14, DOI 10.1227/00006123-198107000-00004; Rauch M E, 1990, J Neurosci Nurs, V22, P173; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; Rising C J, 1993, J Neurosci Nurs, V25, P302; ROBERTSON CS, 1989, J NEUROSURG, V71, P673, DOI 10.3171/jns.1989.71.5.0673; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TSEMENTZIS SA, 1982, ACTA NEUROCHIR, V65, P153, DOI 10.1007/BF01405841; WILLIS ML, 1991, THESIS U WASHINGTON; Yau Y, 2002, ACTA NEUROCHIR SUPPL, V81, P167	56	23	26	0	8	AMER ASSOC CRITICAL CARE NURSES	ALISO VIEJO	101 COLUMBIA, ALISO VIEJO, CA 92656 USA	1062-3264			AM J CRIT CARE	Am. J. Crit. Care	NOV 1	2008	17	6					545	554					10	Critical Care Medicine; Nursing	General & Internal Medicine; Nursing	367OK	WOS:000260561100010	18978239				2021-06-18	
J	Urbach, A; Redecker, C; Witte, OW				Urbach, Anja; Redecker, Christoph; Witte, Otto W.			Induction of Neurogenesis in the Adult Dentate Gyrus by Cortical Spreading Depression	STROKE			English	Article						spreading depression; neurogenesis; dentate gyrus; cognition	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; HIPPOCAMPAL NEUROGENESIS; SUBVENTRICULAR ZONE; NMDA RECEPTOR; PROGENITOR CELLS; BLOOD-FLOW; RAT; NEURONS; CORTEX	Background and Purpose-Spreading depression (SD) is an epiphenomenon of neurological disorders, like stroke or traumatic brain injury. These diseases have been associated with an increased neurogenesis in the adult rodent dentate gyrus. Such proliferative activity can also be induced by conditions that-like SD-coincide with a disturbed neuronal excitability, eg, epilepsy. Thus we hypothesized that SD might likewise influence hippocampal neurogenesis and potentially act as mediator of injury-induced neurogenesis. Methods-Repetitive cortical SD were induced by epidural application of 3 mol/L KCl. At different time points thereafter dentate gyrus neurogenesis was investigated by means of intraperitoneal bromodeoxyuridine injections and immunocytochemistry. Spatial learning and memory was tested in a Morris water maze. Results-Cortical SD significantly increased proliferative activity in the ipsilateral subgranular zone on days 2 and 4. We detected about 280% more newborn cells in the dentate gyrus of rats that received bromodeoxyuridine during the first week after SD and were allowed to recover for 6 weeks. Most of these cells expressed the mature neuronal marker NeuN. The mitogenic action of SD was suppressed by systemic administration of the NMDA receptor antagonist MK-801. Behavioral performance of SD animals in the Morris water maze did not improve significantly. Conclusions-From our data we postulate that the increased dentate gyrus neurogenesis observed after brain injury may at least partly be mediated by SD-like epiphenomena. Furthermore they indicate that even a strongly enhanced dentate gyrus neurogenesis may occur without significant improvements in hippocampus-dependent spatial learning and memory. (Stroke. 2008; 39: 3064-3072.)	[Urbach, Anja; Redecker, Christoph; Witte, Otto W.] Univ Jena, Dept Neurol, D-07747 Jena, Germany	Urbach, A (corresponding author), Univ Jena, Dept Neurol, Erlanger Allee 101-FZL, D-07747 Jena, Germany.	anja.urbach@med.uni-jena.de	Witte, Otto/P-4127-2018	Witte, Otto/0000-0003-2101-4105	Federal Ministry for Education and ResearchFederal Ministry of Education & Research (BMBF) [01GI9905, 01GZ0306]	This work was supported by the Federal Ministry for Education and Research (grants 01GI9905 and 01GZ0306).	Arvidsson A, 2001, EUR J NEUROSCI, V14, P10, DOI 10.1046/j.0953-816x.2001.01611.x; Back T, 2000, ANN NEUROL, V47, P485, DOI 10.1002/1531-8249(200004)47:4<485::AID-ANA12>3.3.CO;2-#; Bernabeu R, 2000, J CEREBR BLOOD F MET, V20, P1669, DOI 10.1097/00004647-200012000-00006; Biebl M, 2000, NEUROSCI LETT, V291, P17, DOI 10.1016/S0304-3940(00)01368-9; CAMERON HA, 1995, J NEUROSCI, V15, P4687; Chun SK, 2006, NEUROBIOL LEARN MEM, V86, P322, DOI 10.1016/j.nlm.2006.05.005; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Drapeau E, 2003, P NATL ACAD SCI USA, V100, P14385, DOI 10.1073/pnas.2334169100; FABRICIUS M, 1993, BRAIN RES, V612, P61, DOI 10.1016/0006-8993(93)91644-8; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Gage FH, 1998, J NEUROBIOL, V36, P249, DOI 10.1002/(SICI)1097-4695(199808)36:2<249::AID-NEU11>3.0.CO;2-9; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1999, P NATL ACAD SCI USA, V96, P5263, DOI 10.1073/pnas.96.9.5263; Hadjikhani N, 2001, P NATL ACAD SCI USA, V98, P4687, DOI 10.1073/pnas.071582498; Hartings JA, 2003, J NEUROSCI, V23, P11602; Hermann DM, 1999, RESTOR NEUROL NEUROS, V14, P103; Jakubs K, 2006, NEURON, V52, P1047, DOI 10.1016/j.neuron.2006.11.004; Jin KL, 2001, P NATL ACAD SCI USA, V98, P4710, DOI 10.1073/pnas.081011098; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Kempermann G, 2002, EUR J NEUROSCI, V16, P129, DOI 10.1046/j.1460-9568.2002.02042.x; Kokaia Z, 2003, CURR OPIN NEUROBIOL, V13, P127, DOI 10.1016/S0959-4388(03)00017-5; Lauritzen M, 2001, CEPHALALGIA, V21, P757, DOI 10.1046/j.1468-2982.2001.00244.x; LOIS C, 1993, P NATL ACAD SCI USA, V90, P2074, DOI 10.1073/pnas.90.5.2074; Madsen TM, 2000, BIOL PSYCHIAT, V47, P1043, DOI 10.1016/S0006-3223(00)00228-6; Markakis EA, 1999, J COMP NEUROL, V406, P449; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; MAYEVSKY A, 1991, J CEREBR BLOOD F MET, V11, P829, DOI 10.1038/jcbfm.1991.142; MESHI D, 2006, NAT NEUROSCI; MIES G, 1993, J NEUROCHEM, V60, P360, DOI 10.1111/j.1471-4159.1993.tb05860.x; MIES G, 1993, NEUROREPORT, V4, P709, DOI 10.1097/00001756-199306000-00027; MORRIS RGM, 1981, LEARN MOTIV, V12, P239, DOI 10.1016/0023-9690(81)90020-5; Nacher J, 2001, EUR J NEUROSCI, V13, P512, DOI 10.1046/j.0953-816x.2000.01424.x; NEDERGAARD M, 1988, BRAIN RES, V449, P395, DOI 10.1016/0006-8993(88)91062-1; Parent JM, 1997, J NEUROSCI, V17, P3727; Paxinos G., 2004, RAT NERVOUS SYSTEM, VThird; Raber J, 2004, RADIAT RES, V162, P39, DOI 10.1667/RR3206; Sharp FR, 2002, DEV BRAIN RES, V134, P23, DOI 10.1016/S0165-3806(01)00286-3; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V410, P372, DOI 10.1038/35066584; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Urbach A, 2006, EUR J NEUROSCI, V24, P841, DOI 10.1111/j.1460-9568.2006.04862.x; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; van Praag H, 2002, NATURE, V415, P1030, DOI 10.1038/4151030a; Wernsmann B, 2006, EUR J NEUROSCI, V23, P1103, DOI 10.1111/j.1460-9568.2006.04643.x; Yanamoto H, 2005, STROKE, V36, P1544, DOI 10.1161/01.STR.0000169903.09253.c7; Zhao CM, 2006, J NEUROSCI, V26, P3, DOI 10.1523/JNEUROSCI.3648-05.2006	47	23	24	1	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	NOV	2008	39	11					3064	3072		10.1161/STROKEAHA.108.518076			9	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	365SC	WOS:000260427100025	18802207	Bronze			2021-06-18	
J	Wu, AP; Davidson, T				Wu, Amy P.; Davidson, Terence			Posttraumatic anosmia secondary to central nervous system injury	AMERICAN JOURNAL OF RHINOLOGY			English	Article						Anosmia; closed head injury; MRI; nervous system diseases; olfaction disorders; olfactory bulb; olfactory tracts; trauma	OLFACTORY DYSFUNCTION	Background: The presumed pathogenesis of posttraumatic anosmia is stretching or shearing of the olfactory nerves in a coup-contracoup head contusion. Direct injury to the brain is an alternate mechanism of injury. In this study we report a case where direct injury to the brain is the probable mechanism of injury. Methods: A case report was performed. Results: A 55-year-old man presented with loss of smell beginning I month after a closed head injury with loss of consciousness. The MRI showed posttraumatic scarring in the region of the olfactory bulbs. Conclusion: This case suggests that central nervous system injury to the olfactory bulbs and tracts may be a mechanism of posttraumatic anosmia.	Univ Calif San Diego, Med Ctr, Div Otolaryngol Head & Neck Surg, San Diego, CA 92103 USA; Vet Adm San Diego Hlth Care Syst, San Diego, CA USA	Davidson, T (corresponding author), Univ Calif San Diego, Sch Med, 9500 Gilman Dr,Evergreen,MC 0617, La Jolla, CA 92093 USA.	tdavidson@ucsd.edu					Doty RL, 1997, ARCH NEUROL-CHICAGO, V54, P1131, DOI 10.1001/archneur.1997.00550210061014; Kern RC, 2000, LARYNGOSCOPE, V110, P2106, DOI 10.1097/00005537-200012000-00025; Reiter ER, 2004, OTOLARYNG CLIN N AM, V37, P1167, DOI 10.1016/j.otc.2004.06.005; Wise JB, 2006, ANN OTO RHINOL LARYN, V115, P124, DOI 10.1177/000348940611500208; Yousem DM, 1996, AM J NEURORADIOL, V17, P1171	5	23	23	0	5	OCEAN SIDE PUBLICATIONS INC	PROVIDENCE	95 PITMAN ST, PROVIDENCE, RI 02906 USA	1050-6586			AM J RHINOL	Am. J. Rhinol.	NOV-DEC	2008	22	6					606	607		10.2500/ajr.2008.22.3238			2	Otorhinolaryngology	Otorhinolaryngology	391AU	WOS:000262205600008	19178798				2021-06-18	
J	Karger, B; Rand, S; Fracasso, T; Pfeiffer, H				Karger, B.; Rand, S.; Fracasso, T.; Pfeiffer, H.			Bloodstain pattern analysis - Casework experience	FORENSIC SCIENCE INTERNATIONAL			English	Article						Bloodstain distribution pattern; Casework; Interpretation	CLOSE-RANGE SHOTS; BACKSPATTER; DISTANCE; SPATTER; HEAD	The morphology of bloodstain distribution patterns at the crime scene carries vital information for a reconstruction of the events. Contrary to experimental work, case reports where the reconstruction has been verified have rarely been published. This is the reason why a series Of four illustrative cases is presented where bloodstain pattern analysis at the crime scene made a reconstruction of the events possible and where this reconstruction was later verified by a confession of the offender. The cases include various types of bloodstains such as contact and smear stains, drop stains, arterial blood spatter and splash stains from both impact and cast-off pattern. Problems frequently encountered in practical casework are addressed, such as unfavourable environmental conditions or combinations of different bloodstain patterns. It is also demonstrated that the analysis of bloodstain morphology can support individualisation of stains by directing the selection of a limited number of stains from a complex pattern for DNA analysis. The complexity of real situations suggests a step-by-step approach starting with a Comprehensive view of the overall picture. This is followed by a differentiation and analysis of single bloodstain patterns and a search for informative details. It is ideal when the expert inspecting the crime scene has also performed the autopsy, but he definitely must have detailed knowledge of the injuries of the deceased/injured and of the possible mechanisms of production. (C) 2008 Elsevier Ireland Ltd. All rights reserved.	[Karger, B.; Rand, S.; Fracasso, T.; Pfeiffer, H.] Univ Munster, Inst Med Legale, D-48149 Munster, Germany	Karger, B (corresponding author), Univ Munster, Inst Med Legale, Rontgenstr 62, D-48149 Munster, Germany.	karger@uni-muenster.de					Anderson S, 2005, FORENSIC SCI INT, V148, P37, DOI 10.1016/j.forsciint.2004.04.071; Balthazard V., 1939, ANN MED LEG CRIMINOL, V19, P265; BRINKMANN B, 1985, Z RECHTSMED, V94, P237; Brinkmann B, 1986, Beitr Gerichtl Med, V44, P67; Burnett BR, 1997, J FORENSIC SCI, V42, P519; DeForest PR., 1990, J FORENSIC SCI, V35, P1491; Du Chesne Alfred, 1993, Archiv fuer Kriminologie, V192, P159; Hulse-Smith L, 2007, J FORENSIC SCI, V52, P65, DOI 10.1111/j.1556-4029.2006.00298.x; Karger B, 1996, INT J LEGAL MED, V109, P66, DOI 10.1007/BF01355519; Karger B, 1998, INT J LEGAL MED, V111, P17; Karger B, 1997, INT J LEGAL MED, V110, P27; Kleiber M, 2001, FORENSIC SCI INT, V119, P260, DOI 10.1016/S0379-0738(00)00363-7; Knock C, 2007, J FORENSIC SCI, V52, P1044, DOI 10.1111/j.1556-4029.2007.00505.x; LOCHTE T, 1933, DTSCH Z GERICHTL MED, V22, P387; MacDonell HL., 1982, BLOODSTAIN PATTERN I, P16; PIZZOLA PA, 1986, J FORENSIC SCI, V31, P50; PIZZOLA PA, 1986, J FORENSIC SCI, V31, P36; Rand S, 1986, Beitr Gerichtl Med, V44, P75; RAYMOND MA, 1986, FORENSIC SCI INT, V31, P189, DOI 10.1016/0379-0738(86)90187-8; Raymond MA, 1996, SCI JUSTICE, V36, P153, DOI 10.1016/S1355-0306(96)72590-X; Raymond MA, 1996, SCI JUSTICE, V36, P161, DOI 10.1016/S1355-0306(96)72591-1; RISENBATT RR, 1995, J FORENSIC SCI, V40, P139; Rowe WF, 2006, FORENSIC SCI INT, V161, P47, DOI 10.1016/j.forsciint.2005.10.023; STEPHENS BG, 1983, J FORENSIC SCI, V28, P437; WHITE B, 1986, CAN SOC FORENSIC SCI, V19, P3; Willis C, 2001, FORENSIC SCI INT, V123, P1, DOI 10.1016/S0379-0738(01)00506-0; Wilson CI, 2004, AM J FOREN MED PATH, V25, P80, DOI 10.1097/01.paf.0000113857.07024.fa; Yen K, 2003, AM J FOREN MED PATH, V24, P132, DOI 10.1097/01.paf.0000065164.92878.2f; ZWEIDINGER R A, 1973, Journal of Forensic Sciences, V18, P296	29	23	24	1	139	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0379-0738	1872-6283		FORENSIC SCI INT	Forensic Sci.Int.	OCT 25	2008	181	1-3					15	20		10.1016/j.forsciint.2008.07.010			6	Medicine, Legal	Legal Medicine	377WC	WOS:000261281500003	18790581				2021-06-18	
J	Tran, TY; Dunne, IE; German, JW				Tran, Timothy Y.; Dunne, Irie E.; German, John W.			Beta blockers exposure and traumatic brain injury: a literature review	NEUROSURGICAL FOCUS			English	Article						adrenergic receptor; beta blocker; brain injury; catecholamine; trauma	CEREBRAL-BLOOD-FLOW; HEART-RATE-VARIABILITY; CARDIOVASCULAR MORBIDITY; INTRACRANIAL-PRESSURE; ADRENERGIC-BLOCKADE; TROPONIN ELEVATION; ENERGY-METABOLISM; IMPROVED OUTCOMES; TARGETED THERAPY; LUND CONCEPT	Traumatic brain injury (TBI) continues to carry a significant public health burden and is anticipated to worsen worldwide over the next century. Recently the authors of several articles have suggested that exposure to beta blockers may improve mortality rates following TBI. The exact mechanism through which beta blockers mediate this effect is unknown. In this paper, the authors review the literature regarding the safety of beta blockers in patients with TBI. The findings of several recent retrospective cohort studies are examined and implications for future investigation are discussed. Future questions to be addressed include: the specific indications for the use of beta blockers in patients with TBI, the optimal type and dose of beta blocker given, the end point of beta blocker therapy, and the safety of beta blockers in cases of severe TBIs.	[Tran, Timothy Y.; Dunne, Irie E.; German, John W.] Albany Med Coll, Dept Surg, Div Neurosurg, Albany, NY 12108 USA	German, JW (corresponding author), Albany Med Coll, Dept Surg, Div Neurosurg, 47 New Scotland Ave, Albany, NY 12108 USA.	jwgerman@hotmail.com					ALEXANDER RW, 1975, NATURE, V258, P437, DOI 10.1038/258437a0; Arbabi S, 2004, J TRAUMA, V56, P265, DOI 10.1097/01.TA.0000109859.91202.C8; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; ASGEIRSSON B, 1995, ACTA ANAESTH SCAND, V39, P347, DOI 10.1111/j.1399-6576.1995.tb04075.x; Babuin L, 2005, CAN MED ASSOC J, V173, P1191, DOI 10.1503/cmaj/051291; BRYAN RM, 1990, AM J PHYSIOL, V259, pH269; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; Di Angelantonio E, 2005, J NEUROL NEUROSUR PS, V76, P76, DOI 10.1136/jnnp.2004.041491; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; Friese RS, 2008, J TRAUMA, V64, P1061, DOI 10.1097/TA.0b013e3181684cf0; Gebhard F, 2000, ARCH SURG-CHICAGO, V135, P291, DOI 10.1001/archsurg.135.3.291; Gisvold SE, 2001, ACTA ANAESTH SCAND, V45, P399, DOI 10.1034/j.1399-6576.2001.045004399.x; Grande PO, 2002, ACTA ANAESTH SCAND, V46, P929, DOI 10.1034/j.1399-6576.2002.460802.x; GRANDE PO, 1989, INTENS CARE MED, V15, P523, DOI 10.1007/BF00273564; HAMILL RW, 1987, ANN NEUROL, V21, P438, DOI 10.1002/ana.410210504; Hays A, 2006, NEUROLOGY, V66, P1330, DOI 10.1212/01.wnl.0000210523.22944.9b; Herndon DN, 2001, NEW ENGL J MED, V345, P1223, DOI 10.1056/NEJMoa010342; Hesdorffer DC, 2007, J TRAUMA, V63, P841, DOI 10.1097/TA.0b013e318123fc21; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; JOYCE JN, 1992, SYNAPSE, V10, P228, DOI 10.1002/syn.890100306; KRAUS J, 1985, J NEUROSURG, V63, P537, DOI 10.3171/jns.1985.63.4.0537; Lampert R, 2003, AM J CARDIOL, V91, P137, DOI 10.1016/S0002-9149(02)03098-9; Maier B, 2007, SHOCK, V28, P668, DOI 10.1097/shk.0b013e318123e64e; Mangano DT, 1996, NEW ENGL J MED, V335, P1713, DOI 10.1056/NEJM199612053352301; Mautes AEM, 2001, ACTA NEUROCHIR, V143, P51, DOI 10.1007/s007010170138; MOREL DR, 1984, INTENS CARE MED, V10, P133, DOI 10.1007/BF00265802; Morganti-Kossmann MC, 2007, INJURY, V38, P1392, DOI 10.1016/j.injury.2007.10.005; MOSS E, 1995, BRIT J ANAESTH, V74, P635, DOI 10.1093/bja/74.6.635; Naidech AM, 2005, CIRCULATION, V112, P2851, DOI 10.1161/CIRCULATIONAHA.105.533620; Naredi S, 2001, ACTA ANAESTH SCAND, V45, P402, DOI 10.1034/j.1399-6576.2001.045004402.x; Naredi S, 1998, INTENS CARE MED, V24, P446, DOI 10.1007/s001340050594; Nilsson F, 1997, ACTA ANAESTH SCAND, V41, P1257, DOI 10.1111/j.1399-6576.1997.tb04641.x; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; PAYEN D, 1990, CRIT CARE MED, V18, P392, DOI 10.1097/00003246-199004000-00008; Peden M., 2004, WORLD REPORT ROAD TR; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; Riordan WP, 2007, J TRAUMA, V63, P503, DOI 10.1097/TA.0b013e3181271c34; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schmalbruch IK, 2002, STROKE, V33, P251, DOI 10.1161/hs0102.101233; Seekamp A, 1998, J TRAUMA, V44, P874, DOI 10.1097/00005373-199805000-00022; Stahl N, 2001, INTENS CARE MED, V27, P1215, DOI 10.1007/s001340101004; Su CF, 2005, CLIN NEUROPHYSIOL, V116, P1273, DOI 10.1016/j.clinph.2005.01.010; Wahlstrom MR, 2005, INTENS CARE MED, V31, P832, DOI 10.1007/s00134-005-2632-2; Wallace A, 1998, ANESTHESIOLOGY, V88, P7, DOI 10.1097/00000542-199801000-00005; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; WOOLF PD, 1987, J NEUROSURG, V66, P875, DOI 10.3171/jns.1987.66.6.0875; WOOLF PD, 1988, AM J PHYSIOL, V254, pE287; WOOLF PD, 1983, J CLIN ENDOCR METAB, V56, P246, DOI 10.1210/jcem-56-2-246; Zygun DA, 2005, CRIT CARE MED, V33, P654, DOI 10.1097/01.ccm.0000155911.01844.54	52	23	24	0	0	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1092-0684			NEUROSURG FOCUS	Neurosurg. Focus	OCT	2008	25	4							E8	10.3171/FOC.2008.25.10.E8			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	355HX	WOS:000259701100008	18828706	Bronze			2021-06-18	
J	Buckman, JE; Bates, ME; Morgenstern, J				Buckman, Jennifer E.; Bates, Marsha E.; Morgenstern, Jon			Social support and cognitive impairment in clients receiving treatment for alcohol- and drug-use disorders: A replication study	JOURNAL OF STUDIES ON ALCOHOL AND DRUGS			English	Article; Proceedings Paper	115th Annual Convention of the American-Psychological-Association	AUG 17-20, 2007	San Francisco, CA	Amer Psychol Assoc			TRAUMATIC BRAIN-INJURY; QUALITY-OF-LIFE; NETWORKS; MECHANISMS; ABSTINENCE; PREVENTION; RETENTION; RECOVERY; OUTCOMES; FRIENDS	Objective: The influence that social network members exert on the drinking behaviors of alcohol-dependent individuals may represent a behavioral change process that is sensitive to co-occurring cognitive impairment and operates outside treatment to promote or impede outcomes. This study was aimed at extending earlier research support for this hypothesis by assessing impairment in memory as well as executive functions in a more heterogeneous population with alcohol- and/or drug-use disorders. Method: Latent class analysis was used as a person-centered approach to characterize the nature and extent of social support for abstinence from alcohol and drug use in 122 men and women entering treatment for substance-use disorders. Substance use, executive dysfunction, and memory impairments were compared across latent classes at four points during the first year after treatment entry The interrelationship of impairment and social support on treatment outcomes was also examined. Results: Three independent social support classes-(1) Frequent Positive Support, (2) Limited Positive Support, and (3) Negative Support-were identified. The Frequent Positive Support class demonstrated the most frequent substance use and greatest executive impairment at treatment entry but-by the end of treatment-showed pronounced improvements in both. In addition, less recovery of executive function by the end of treatment predicted better 12-month substance-use outcomes in the Frequent Positive Support class, whereas it predicted poorer outcomes in the Negative Support class. Conclusions: The results offer further evidence for the heightened importance of informal social network processes in the treatment outcomes of persons with severe and ongoing deficits in executive functioning.	[Bates, Marsha E.] Rutgers State Univ, Ctr Alcohol Studies, Piscataway, NJ 08854 USA; [Morgenstern, Jon] Columbia Univ, Med Ctr, Dept Psychiat, New York, NY USA	Bates, ME (corresponding author), Rutgers State Univ, Ctr Alcohol Studies, 607 Allison Rd, Piscataway, NJ 08854 USA.	mebates@rci.rutgers.edu	Bates, Marsha/AAD-6426-2020	Buckman, Jennifer/0000-0002-1898-5499	NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K02AA000325, R01AA011594, P50AA008747] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [K02 AA00325, P50 AA08747, R01 AA11594, R01 AA011594, K02 AA000325] Funding Source: Medline		ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Aharonovich E, 2003, DRUG ALCOHOL DEPEN, V71, P207, DOI 10.1016/S0376-8716(03)00092-9; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bartsch AJ, 2007, BRAIN, V130, P36, DOI 10.1093/brain/awl303; Bates ME, 2006, PSYCHOL ADDICT BEHAV, V20, P241, DOI 10.1037/0893-164X.20.3.241; Bates ME, 2005, ALCOHOL CLIN EXP RES, V29, P367, DOI 10.1097/01.ALC.0000156131.88125.2A; Bates ME, 1999, ASSESSMENT OF NEUROPSYCHOLOGICAL FUNCTIONS IN PSYCHIATRIC DISORDERS, P373; Bates ME, 2002, PSYCHOL ADDICT BEHAV, V16, P35, DOI 10.1037//0893-164X.16.1.35; Beattie MC, 1999, ADDICT BEHAV, V24, P593, DOI 10.1016/S0306-4603(98)00120-8; Benton A., 1976, MULTILINGUAL APHASIA; Buckman JF, 2007, J STUD ALCOHOL DRUGS, V68, P738, DOI 10.15288/jsad.2007.68.738; CARLIN AS, 1996, NEUROPSYCHOLOGICAL A, P486; Clifford P.R., 1991, MANUAL ADM IMPORTANT; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; DELIS D, 1987, CALIFORNIA VERBAL LE; DONOVAN DM, 2000, NIAAA PROJECT MATCH, V8, P62; FALSSTEWART W, 1992, J CLIN PSYCHOL, V48, P539, DOI 10.1002/1097-4679(199207)48:4<539::AID-JCLP2270480416>3.0.CO;2-I; Giancola PR, 1998, RECENT DEV ALCOHOL, V14, P227, DOI 10.1007/0-306-47148-5_10; Golden C., 1978, STROOP COLOR WORD TE; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; KAPLAN SP, 1990, REHABIL COUNS BULL, V34, P16; Knight DK, 1996, J SUBST ABUSE, V8, P417, DOI 10.1016/S0899-3289(96)90003-6; Knight R. G., 1994, CLIN NEUROPSYCHOLOGY; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Little RJA, 1987, STAT ANAL MISSING DA; LONGABAUGH R, 1993, J STUD ALCOHOL, V54, P465, DOI 10.15288/jsa.1993.54.465; LONGABAUGH R, 2001, PROJECT MATCH MONOGR, V8, P260; Manuel JK, 2007, J STUD ALCOHOL DRUGS, V68, P871, DOI 10.15288/jsad.2007.68.871; Marlatt GA, 1985, RELAPSE PREVENTION, P128; McCrady BS, 2004, PSYCHOL ADDICT BEHAV, V18, P113, DOI 10.1037/0893-164X.18.2.113; McCutcheon A., 1987, LATENT CLASS ANAL; Mohr CD, 2001, J STUD ALCOHOL, V62, P637, DOI 10.15288/jsa.2001.62.637; Morgenstern J, 1999, J STUD ALCOHOL, V60, P846, DOI 10.15288/jsa.1999.60.846; Morgenstern J, 1996, J STUD ALCOHOL, V57, P53, DOI 10.15288/jsa.1996.57.53; Morgenstern J, 1997, J CONSULT CLIN PSYCH, V65, P768, DOI 10.1037/0022-006X.65.5.768; Muthen L.K., 1998, MPLUS COMPREHENSIVE; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; NIXON SJ, 1995, ALCOHOL HEALTH RES W, V19, P97; PFEFFERBAUM A, 1995, ALCOHOL CLIN EXP RES, V19, P1177, DOI 10.1111/j.1530-0277.1995.tb01598.x; Prigatano GP, 1996, COGNITIVE REHABILITA, P223; Reitan RM., 1985, HALSTEAD REITAN NEUR; Richter S S, 1991, J Subst Abuse, V3, P371; Rogers RD, 2001, CURR OPIN NEUROBIOL, V11, P250, DOI 10.1016/S0959-4388(00)00204-X; RUSSELL EW, 1987, J CONSULT CLIN PSYCH, V55, P898, DOI 10.1037/0022-006X.55.6.898; SIDDALL JW, 1988, INT J ADDICT, V23, P1241, DOI 10.3109/10826088809058855; SIMON HA, 1975, COGNITIVE PSYCHOL, V7, P268, DOI 10.1016/0010-0285(75)90012-2; SOBELL LC, 1992, MEASURING ALCOHOL CONSUMPTION, P41, DOI 10.1007/978-1-4612-0357-5_3; Spreen O., 1998, COMPENDIUM NEUROPSYC; Sussman S, 1996, J PSYCHOACTIVE DRUGS, V28, P169, DOI 10.1080/02791072.1996.10524389; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Winkler D, 2006, J HEAD TRAUMA REHAB, V21, P8, DOI 10.1097/00001199-200601000-00002; Witkiewitz K, 2004, AM PSYCHOL, V59, P224, DOI 10.1037/0003-066X.59.4.224; Ylvisaker M, 2003, J HEAD TRAUMA REHAB, V18, P7, DOI 10.1097/00001199-200301000-00005; Zachary R., 1986, SHIPLEY I LIVING SCA; Zywiak WH, 2002, J STUD ALCOHOL, V63, P114	57	23	23	0	9	ALCOHOL RES DOCUMENTATION INC CENT ALCOHOL STUD RUTGERS UNIV	PISCATAWAY	C/O DEIRDRE ENGLISH, 607 ALLISON RD, PISCATAWAY, NJ 08854-8001 USA	1937-1888			J STUD ALCOHOL DRUGS	J. Stud. Alcohol Drugs	SEP	2008	69	5					738	746		10.15288/jsad.2008.69.738			9	Substance Abuse; Psychology	Substance Abuse; Psychology	348IW	WOS:000259205200013	18781249	Green Published			2021-06-18	
J	Mas, E; Michel, F; Guy, A; Bultel, V; Falquet, Y; Chardon, P; Rossi, JC; Cristol, JP; Durand, T				Mas, Emilie; Michel, Francoise; Guy, Alexandre; Bultel, Valerie; Falquet, Yoan; Chardon, Patrick; Rossi, Jean-Claude; Cristol, Jean Paul; Durand, Thierry			Quantification of urinary F-2-isoprostanes with 4(RS)-F-4t-neuroprostane as an internal standard using gas chromatography-mass spectrometry - Application to polytraumatized patients	JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES			English	Article						isoprostanes; GC-MS; 15-F-2t-IsoP; 4(RS)-F-4t-NeuroP; polytraurnatized patients	TRAUMATIC BRAIN-INJURY; PERFORMANCE LIQUID-CHROMATOGRAPHY; PEROXIDATION IN-VIVO; LIPID-PEROXIDATION; 8-EPI-PROSTAGLANDIN F2-ALPHA; DOCOSAHEXAENOIC ACID; CEREBROSPINAL-FLUID; OXIDATIVE STRESS; 8-ISO-PROSTAGLANDIN F2-ALPHA; PROSTANOIDS F2-ISOPROSTANES	Isoprostanes are a family of prostaglandin isomers produced from oxidation of polyunsaturated fatty acids through a non-enzymatic free radical-catalyzed mechanism. Quantification of F-2-isoprostanes (F-2-IsoPs) provides a good index of oxidative stress and allows non-invasive assessment of lipid peroxidation in vivo. Since "interferences peaks" at m/z 573 co-elute with d(4)-15-F-2t-IsoP preferentially used, we propose a new GC-NICI-MS approach to quantify urinary F-2-IsoPs by using 4(RS)-F-4t-neuroprostane as the internal standard. This method was applied to quantify urinary F-2-IsoPs excretion in healthy volunteers and polytraumatized patients. Our results showed a significant increase (p < 0.0001) in urinary F-2-IsoPs in polytraumatized patients compared with healthy volunteers (4.73 +/- 2.75 ng/mg vs. 0.811 +/- 0.359 ng/mg creatinine). (c) 2008 Elsevier B.V. All rights reserved.	[Mas, Emilie; Michel, Francoise; Rossi, Jean-Claude] Lapeyronie Hosp, Dept Biochem, F-34295 Montpellier 5, France; [Guy, Alexandre; Bultel, Valerie; Rossi, Jean-Claude; Durand, Thierry] CNRS, IBMM, UM 1, Fac Pharm,UMR 5247,UM 2, Montpellier, France; [Falquet, Yoan; Chardon, Patrick] Lapeyronie Hosp, Dept Anesthesiol & Crit Care Med, Montpellier, France	Michel, F (corresponding author), Lapeyronie Hosp, Dept Biochem, 371 Ave Doyen Gaston Giraud, F-34295 Montpellier 5, France.	francoise-michel@chu-montpellier.fr					Arneson KO, 2007, METHOD ENZYMOL, V433, P127, DOI 10.1016/S0076-6879(07)33007-3; Bachi A, 1996, FREE RADICAL BIO MED, V20, P619, DOI 10.1016/0891-5849(95)02087-X; Basu S, 2005, ANTIOXID REDOX SIGN, V7, P221, DOI 10.1089/ars.2005.7.221; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Bessard J, 2001, J CHROMATOGR B, V754, P333, DOI 10.1016/S0378-4347(00)00621-6; Bohnstedt KC, 2005, J CHROMATOGR B, V827, P39, DOI 10.1016/j.jchromb.2005.02.023; Cracowski JL, 2002, TRENDS PHARMACOL SCI, V23, P360, DOI 10.1016/S0165-6147(02)02053-9; Cuzzorcrea S, 2004, CURR MED CHEM, V11, P1147, DOI 10.2174/0929867043365396; Davies SS, 2006, ANAL BIOCHEM, V348, P185, DOI 10.1016/j.ab.2005.10.012; Durand T, 2001, BIOORG MED CHEM LETT, V11, P2495, DOI 10.1016/S0960-894X(01)00473-5; Durand T, 2000, TETRAHEDRON LETT, V41, P3859, DOI 10.1016/S0040-4039(00)00508-6; Durant R, 2004, SHOCK, V22, P34, DOI 10.1097/01.shk.0000129197.46212.7e; Fessel JP, 2002, P NATL ACAD SCI USA, V99, P16713, DOI 10.1073/pnas.252649099; HELMERSSON J, 1999, ESSENT FATTY ACIDS, V61, P203; Keel M, 2005, INJURY, V36, P691, DOI 10.1016/j.injury.2004.12.037; Klein T, 1997, J PHARMACOL EXP THER, V282, P1658; Lawson JA, 1998, J BIOL CHEM, V273, P29295, DOI 10.1074/jbc.273.45.29295; Lawson JA, 2006, J LIPID RES, V47, P2515, DOI 10.1194/jlr.M600327-JLR200; Lee CYJ, 2004, BIOCHEM BIOPH RES CO, V320, P696, DOI 10.1016/j.bbrc.2004.06.015; Lenz A, 2007, INJURY, V38, P1336, DOI 10.1016/j.injury.2007.10.003; Li HW, 1999, P NATL ACAD SCI USA, V96, P13381, DOI 10.1073/pnas.96.23.13381; Milne GL, 2008, J BIOL CHEM, V283, P15533, DOI 10.1074/jbc.R700047200; Montine TJ, 2002, ANN NEUROL, V52, P175, DOI 10.1002/ana.10272; Montuschi P, 2004, FASEB J, V18, P1791, DOI 10.1096/fj.04-2330rev; Mori TA, 1999, ANAL BIOCHEM, V268, P117, DOI 10.1006/abio.1998.3037; Morrow JD, 1999, METHOD ENZYMOL, V300, P3; MORROW JD, 1992, P NATL ACAD SCI USA, V89, P10721, DOI 10.1073/pnas.89.22.10721; MORROW JD, 1992, J CLIN INVEST, V90, P2502, DOI 10.1172/JCI116143; MORROW JD, 1994, METHOD ENZYMOL, V233, P163; Murai Y, 2000, PROSTAG OTH LIPID M, V62, P173, DOI 10.1016/S0090-6980(00)00061-7; Musiek ES, 2004, J CHROMATOGR B, V799, P95, DOI 10.1016/j.jchromb.2003.10.036; NOUROOZZADEH J, 1995, J CHROMATOGR B, V667, P199, DOI 10.1016/0378-4347(95)00035-H; Ohashi N, 2000, J CHROMATOGR B, V746, P17, DOI 10.1016/S0378-4347(00)00201-2; Pratico D, 2004, CHEM PHYS LIPIDS, V128, P165, DOI 10.1016/j.chemphyslip.2003.09.012; Pratico D, 2001, TRENDS ENDOCRIN MET, V12, P243, DOI 10.1016/S1043-2760(01)00411-8; Pratico D, 2002, J NEUROCHEM, V80, P894, DOI 10.1046/j.0022-3042.2002.00777.x; Proudfoot J, 1999, ANAL BIOCHEM, V272, P209, DOI 10.1006/abio.1999.4187; Schwedhelm E, 2000, J CHROMATOGR B, V744, P99, DOI 10.1016/S0378-4347(00)00236-X; Song WL, 2008, J BIOL CHEM, V283, P6, DOI 10.1074/jbc.M706124200; Tsikas D, 1998, J CHROMATOGR B, V716, P7, DOI 10.1016/S0378-4347(98)00275-8; Tsikas D, 2003, J CHROMATOGR B, V794, P237, DOI 10.1016/S1570-0232(03)00457-4; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005; Walter MF, 2000, ANAL BIOCHEM, V280, P73, DOI 10.1006/abio.1999.4476; WANG ZY, 1995, J PHARMACOL EXP THER, V275, P94	46	23	23	0	7	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	1570-0232			J CHROMATOGR B	J. Chromatogr. B	SEP 1	2008	872	1-2					133	140		10.1016/j.jchromb.2008.07.037			8	Biochemical Research Methods; Chemistry, Analytical	Biochemistry & Molecular Biology; Chemistry	356FT	WOS:000259764800017	18706873				2021-06-18	
J	Hata, JS; Shelsky, CR; Hindman, BJ; Smith, TC; Simmons, JS; Todd, MM				Hata, J. Steven; Shelsky, Constance R.; Hindman, Bradley J.; Smith, Thomas C.; Simmons, Jonathan S.; Todd, Michael M.			A prospective, observational clinical trial of fever reduction to reduce systemic oxygen consumption in the setting of acute brain injury	NEUROCRITICAL CARE			English	Article						fever; oxygen consumption; brain injuries; hypothermia; shivering; critical care	BODY-TEMPERATURE; ACUTE STROKE; THERAPEUTIC HYPOTHERMIA; METABOLIC-RATE; HEAD-INJURY; HYPERTHERMIA; MEPERIDINE; THRESHOLD; INCREASES; MORTALITY	Introduction Fever after acute brain injury appears to be a detrimental factor, associated with impaired neurological outcomes. This study assessed physiological changes in systemic oxygen consumption (VO2) during cutaneous cooling after severe brain injury. Methods This prospective, observational, clinical study evaluated ten, critically ill, brain-injured patients requiring mechanical ventilation with a core body temperature of greater or equal to 38 degrees C. Febrile patients failing to defervesce after acetaminophen underwent indirect calorimetry for a 1-hour baseline period followed by a 4 h cooling period. The Arctic Sun (R) Temperature Management System (Medivance (R)) directed core temperature to a goal of 36 degrees C. Results The patients had a mean age of 32 years (95% CI 23, 40), Glasgow Coma Scale of 6 (95% CI 5,7), and APACHE 2 score of 19 (95% CI 15, 22), with 8 of 10 patients suffering traumatic brain injuries. The baseline 1-h core temperature was significantly reduced from 38.6 degrees +/- 0.9 to 36.3 degrees +/- 1.2 degrees C (P < 0.0001) over 4 h. Two cohorts were identified based upon the presence or absence of shivering. Within the non-shivering cohort, systemic VO2 was significantly reduced from 415 +/- 123 to 308 +/- 115 ml/min (-27 +/- 18%) (P < 0.05). In contrast, those with shivering showed no significant reduction in VO2, despite significantly decreasing core temperature. The overall percentage change of VCO2 correlated with VO2 (r(2) = 0.91). Conclusion Fever reduction in acute brain injury appears to significantly reduce systemic VO2, but is highly dependent on shivering control.	[Hata, J. Steven] Univ Iowa Hosp & Clin, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA; [Hata, J. Steven; Simmons, Jonathan S.] Univ Iowa, Roy J & Lucille A Carver Coll Med, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA	Hata, JS (corresponding author), Univ Iowa Hosp & Clin, Dept Anesthesia, Div Crit Care, Iowa City, IA 52242 USA.	steven-hata@uiowa.edu	Hata, J./ABI-1484-2020	Simmons, Jonathan/0000-0003-2806-0331; Hindman, Bradley/0000-0003-2242-7980	Medivance(R)	Financial support: Medivance (R) provided grant support for this investigation	Al-Senani FM, 2004, RESUSCITATION, V62, P143, DOI 10.1016/j.resuscitation.2004.02.016; Albrecht RF, 1998, MAYO CLIN PROC, V73, P629; Arroliga A, 2005, CHEST, V128, P496, DOI 10.1378/chest.128.2.496; Bernard SA, 2002, NEW ENGL J MED, V346, P557, DOI 10.1056/NEJMoa003289; BUSIJA DW, 1988, AM J PHYSIOL, V255, pH343; Castillo J, 1998, STROKE, V29, P2455, DOI 10.1161/01.STR.29.12.2455; De Witte J, 2002, ANESTHESIOLOGY, V96, P467, DOI 10.1097/00000542-200202000-00036; Eicher DJ, 2005, PEDIATR NEUROL, V32, P11, DOI 10.1016/j.pediatrneurol.2004.06.014; FRANK SM, 1995, ANESTHESIOLOGY, V82, P83, DOI 10.1097/00000542-199501000-00012; Geffroy A, 2004, INTENS CARE MED, V30, P785, DOI 10.1007/s00134-004-2280-y; Ginsberg MD, 2003, STROKE, V34, P214, DOI 10.1161/01.STR.0000048846.09677.62; Gluckman PD, 2005, LANCET, V365, P663, DOI 10.1016/S0140-6736(05)17946-X; Gozzoli V, 2004, INTENS CARE MED, V30, P401, DOI 10.1007/s00134-003-2087-2; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iaizzo PA, 1999, J NEUROSURG ANESTH, V11, P231, DOI 10.1097/00008506-199910000-00002; Jiang JY, 2002, J NEUROTRAUM, V19, P869, DOI 10.1089/08977150260190456; Kammersgaard LP, 2002, STROKE, V33, P1759, DOI 10.1161/01.STR.0000019910.90280.F1; Kasner SE, 2002, STROKE, V33, P130, DOI 10.1161/hs0102.101477; LANIER WL, 1989, ANESTHESIOLOGY, V71, P87, DOI 10.1097/00000542-198907000-00016; Lenhardt R, 1999, AM J MED, V106, P550, DOI 10.1016/S0002-9343(99)00068-6; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P210, DOI 10.1164/ajrccm.151.1.7812556; MANTHOUS CA, 1995, AM J RESP CRIT CARE, V151, P10, DOI 10.1164/ajrccm.151.1.7812538; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATTHEWS DSF, 1995, ARCH DIS CHILD, V72, P507, DOI 10.1136/adc.72.6.507; Mayer SA, 2001, NEUROLOGY, V56, P292, DOI 10.1212/WNL.56.3.292; Mayer SA, 2004, CRIT CARE MED, V32, P2508, DOI 10.1097/01.CCM.0000147441.39670.37; Mokhtarani M, 2001, ANESTH ANALG, V93, P1233, DOI 10.1097/00000539-200111000-00038; Nemoto EM, 2005, ADV EXP MED BIOL, V566, P83; Oliveira J, 2001, NEUROLOGY, V56, P1299, DOI 10.1212/WNL.56.10.1299; RALLEY FE, 1988, CAN J ANAESTH, V35, P332, DOI 10.1007/BF03010851; RAURICH JM, 1994, JPEN-PARENTER ENTER, V18, P521, DOI 10.1177/0148607194018006521; Reith J, 1996, LANCET, V347, P422, DOI 10.1016/S0140-6736(96)90008-2; ROSA G, 1995, ACTA ANAESTH SCAND, V39, P90, DOI 10.1111/j.1399-6576.1995.tb05598.x; Sessler DI, 2001, ANESTHESIOLOGY, V95, P531, DOI 10.1097/00000542-200108000-00040; Shankaran S, 2005, NEW ENGL J MED, V353, P1574, DOI 10.1056/NEJMcps050929; SLADEN RN, 1995, J CARDIOTHOR VASC AN, V9, P147, DOI 10.1016/S1053-0770(05)80185-5; Sweney MT, 2001, ANESTHESIOLOGY, V95, P1089, DOI 10.1097/00000542-200111000-00011; Talke P, 1997, ANESTHESIOLOGY, V87, P835, DOI 10.1097/00000542-199710000-00017	39	23	23	0	5	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	AUG	2008	9	1					37	44		10.1007/s12028-007-9015-1			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	340PM	WOS:000258657500008	17985248				2021-06-18	
J	Vilar-Lopez, R; Gomez-Rio, M; Santiago-Ramajo, S; Rodriguez-Fernandez, A; Puente, AE; Perez-Garcia, M				Vilar-Lopez, Raquel; Gomez-Rio, Manuel; Santiago-Ramajo, Sandra; Rodriguez-Fernandez, Antonio; Puente, Antonio E.; Perez-Garcia, Miguel			Malingering detection in a Spanish population with a known-groups design	ARCHIVES OF CLINICAL NEUROPSYCHOLOGY			English	Article						malingering; TOMM; Dot Counting Test; Spanish speakers; poor effort; insufficient effort	TRAUMATIC BRAIN-INJURY; DOT COUNTING TEST; FORENSIC NEUROPSYCHOLOGY; CLINICAL-NEUROPSYCHOLOGY; HEAD-INJURY; MEMORY; PERFORMANCE; TOMM; TESTS; RATES	Malingering detection has become a topic of increased interest in the US over the last years. However, this development has not been matched in Europe. For example, in Spain there is insufficient evidence to support the use of reliable and valid malingering tests. In this study, we tested the applicability of two malingering detection tests (Test of Memory Malingering (TOMM) and Dot Counting Test) in a Spanish sample. The sample included three groups of patients (30 non-compensation seeking, 14 compensation seeking non-suspected of malingering, and 10 suspected of malingering) and a group of analog students (n = 54). Tests' results were able to discriminate between the groups of malingerers (both patients and analogs) and non-malingerers (both compensation seeking and non-compensation seeking). However, the TOMM achieved a higher overall classification rate than the Dot Counting Test. Our results encourage the use of the TOMM as an indicator of malingering with Spanish population. (C) 2008 National Academy of Neuropsychology. Published by Elsevier Ltd. All rights reserved.	[Vilar-Lopez, Raquel; Santiago-Ramajo, Sandra; Perez-Garcia, Miguel] Univ Granada, Dept Personalidad Evaluac & Tratamiento Psicol, Granada, Spain; [Gomez-Rio, Manuel; Rodriguez-Fernandez, Antonio] Hosp Univ Virgen Nieves, Nucl Med Serv, Granada, Spain; [Puente, Antonio E.] Univ N Carolina, Wilmington, NC 28401 USA; [Perez-Garcia, Miguel] Univ Granada, Inst Neurosci, E-18071 Granada, Spain	Vilar-Lopez, R (corresponding author), Univ Granada, Dept Personalidad Evaluac & Tratamiento Psicol, Granada, Spain.	raquelvilarlopez@hotmail.com	Vilar-Lopez, Raquel/I-7847-2016; Rodriguez-Fernandez, Antonio/AAB-3469-2019; Garcia, Miguel Perez/F-9630-2010; Santiago-Ramajo, Sandra/H-6801-2015	Vilar-Lopez, Raquel/0000-0001-9639-0143; Garcia, Miguel Perez/0000-0003-4775-7556; Santiago-Ramajo, Sandra/0000-0002-6358-6155			Alejandre, 1998, TAVEC TEST APRENDIZA; Ashendorf L, 2004, ARCH CLIN NEUROPSYCH, V19, P125, DOI 10.1016/S0887-6177(02)00218-4; Bianchini KJ, 2001, CLIN NEUROPSYCHOL, V15, P19, DOI 10.1076/clin.15.1.19.1907; Bigler ED, 2006, ARCH CLIN NEUROPSYCH, V21, P503, DOI 10.1016/j.acn.2006.03.008; Binks PG, 1997, ARCH CLIN NEUROPSYCH, V12, P41, DOI 10.1016/S0887-6177(96)00019-4; Boone KB, 2002, ARCH CLIN NEUROPSYCH, V17, P625, DOI 10.1016/S0887-6177(01)00166-4; BRICKENKAMP R, 1962, TEST D2; Bush SS, 2005, ARCH CLIN NEUROPSYCH, V20, P419, DOI 10.1016/j.acn.2005.02.002; Cato MA, 2002, CLIN NEUROPSYCHOL, V16, P524, DOI 10.1076/clin.16.4.524.13901; Constantinou M, 2005, ARCH CLIN NEUROPSYCH, V20, P191, DOI 10.1016/j.acn.2004.06.002; Constantinou M, 2003, CHILD NEUROPSYCHOL, V9, P81, DOI 10.1076/chin.9.2.81.14505; Duncan A, 2005, ASSESSMENT, V12, P123, DOI 10.1177/1073191105275512; Etherton JL, 2005, ARCH CLIN NEUROPSYCH, V20, P375, DOI 10.1016/j.acn.2004.09.007; Frederick RI, 1994, NEUROPSYCHOLOGY, V8, P118, DOI 10.1037/0894-4105.8.1.118; Gavett BE, 2005, APPL NEUROPSYCHOL, V12, P1, DOI 10.1207/s15324826an1201_1; Gervais RO, 2004, ARCH CLIN NEUROPSYCH, V19, P475, DOI 10.1016/j.acn.2003.05.001; Gierok SD, 2005, ARCH CLIN NEUROPSYCH, V20, P755, DOI 10.1016/j.acn.2005.04.008; Golden C., 1978, STROOP COLOR WORD TE; Greiffenstein M.F., 1994, PSYCHOL ASSESSMENT, V6, P218, DOI [https://doi.org/10.1037/1040-3590.6.3.218, DOI 10.1037/1040-3590.6.3.218]; Greve KW, 2006, J CLIN EXP NEUROPSYC, V28, P1176, DOI 10.1080/13803390500263550; Greve KW, 2006, ARCH CLIN NEUROPSYCH, V21, P117, DOI 10.1016/j.acn.2005.06.009; Haber AH, 2006, CLIN NEUROPSYCHOL, V20, P524, DOI 10.1080/13854040590967595; Hilsabeck RC, 2005, ARCH CLIN NEUROPSYCH, V20, P1025, DOI 10.1016/j.acn.2005.05.003; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Larrabee G.J., 2005, FORENSIC NEUROPSYCHO; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Lee A, 2000, CLIN NEUROPSYCHOL, V14, P303, DOI 10.1076/1385-4046(200008)14:3;1-P;FT303; LEZACK MD, 1995, NEUROPSYCHOLOGICAL A; MCCAFFREY RJ, 1997, PRACTICE FORENSIC NE; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Moore BA, 2004, BRAIN INJURY, V18, P975, DOI 10.1080/02699050410001672350; O'Bryant SE, 2004, ARCH CLIN NEUROPSYCH, V19, P489, DOI 10.1016/j.acn.2003.07.001; Powell MR, 2004, ARCH CLIN NEUROPSYCH, V19, P693, DOI 10.1016/j.acn.2004.04.001; Ramirez RM, 2004, REV NEUROLOGIA, V38, P28, DOI 10.33588/rn.3801.2003533; Rees LM, 1998, PSYCHOL ASSESSMENT, V10, P10, DOI 10.1037/1040-3590.10.1.10; Rees LM, 2001, ARCH CLIN NEUROPSYCH, V16, P501, DOI 10.1016/S0887-6177(00)00064-0; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Rose FE, 1998, ARCH CLIN NEUROPSYCH, V13, P349, DOI 10.1016/S0887-6177(97)00025-5; SEISDEDOS N, 2000, CAMBIOS TEST FLEXIBI; Slick D., 1997, VICTORIA SYMPTOM VAL; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P481, DOI 10.1076/clin.16.4.481.13914; Sweet JJ, 2002, CLIN NEUROPSYCHOL, V16, P109, DOI 10.1076/clin.16.2.109.13237; Tan JE, 2002, CLIN NEUROPSYCHOL, V16, P495, DOI 10.1076/clin.16.4.495.13909; Teichner G, 2004, ARCH CLIN NEUROPSYCH, V19, P455, DOI 10.1016/S0887-6177(03)00078-7; Tombaugh TN, 1996, TEST MEMORY MALINGER; Vilar-Lopez R, 2007, ARCH CLIN NEUROPSYCH, V22, P379, DOI 10.1016/j.acn.2007.01.012; Wechsler D., 1997, WECHSLER ADULT INTEL; Willison J, 2006, ARCH CLIN NEUROPSYCH, V21, P41, DOI 10.1016/j.acn.2005.07.005; Wolfson D., 1993, HALSTEAD REITAN NEUR; Yanez YT, 2006, ARCH CLIN NEUROPSYCH, V21, P161, DOI 10.1016/j.acn.2005.07.009; Zakzanis KK, 2001, ARCH CLIN NEUROPSYCH, V16, P653, DOI 10.1016/S0887-6177(00)00076-7	53	23	24	0	5	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0887-6177			ARCH CLIN NEUROPSYCH	Arch. Clin. Neuropsychol.	JUL	2008	23	4					365	377		10.1016/j.acn.2008.01.007			13	Psychology, Clinical; Psychology	Psychology	320CJ	WOS:000257211000001	18343087	Bronze			2021-06-18	
J	Straume-Naesheim, TM; Andersen, TE; Jochum, M; Dvorak, J; Bahr, R				Straume-Naesheim, Truls Martin; Andersen, Thor Einar; Jochum, Marianne; Dvorak, Jiri; Bahr, Roald			Minor head trauma in soccer and serum levels of S100B	NEUROSURGERY			English	Article						brain injury; closed head trauma; S100 proteins; soccer	NEURON-SPECIFIC ENOLASE; POST-CONCUSSION SYMPTOMS; BRAIN-INJURY; S-100B PROTEIN; NEUROPSYCHOLOGICAL IMPAIRMENT; BIOCHEMICAL MARKERS; FOOTBALL SOCCER; ELITE PLAYERS; DAMAGE S-100B; ELIMINATION	OBJECTIVE: To compare the serum levels of S100B after head trauma with the effect of heading, high-intensity exercise, and playing in a league match. Heading and head trauma in soccer have been suspected to cause brain impairment. The protein S100B is a marker of acute neuronal tissue damage. METHODS: Baseline S100B was measured in 535 Norwegian professional soccer players. Two hundred twenty-eight head impacts were registered from 352 league matches. Three teams (n = 48) performed a high-intensity exercise session without heading and a low-intensity session with heading exercises. A blood sample was drawn from each participant within 1 hour (131) after the session, and another sample (1312) was drawn after a match or training session. The players were assigned to four groups: Head Impact (n = 65), Match Control (match participants without head impact, n = 49), High-intensity Exercise (n = 35), and Heading (n = 36). RESULTS: Serum S100B increased from baseline to B1 for all groups. The increase for the match groups (Head Impact and Match Control) was significantly higher than for both training groups. However, no significant differences between the Head Impact and Match Control groups or between the two training groups were found. A total of 39 players (33.9%) had elevated B1 values (>= 0.12 ng/ml) after a match, but these findings were equally distributed between the Match Control and Head Impact groups. CONCLUSION: Both soccer training and soccer matches cause a transient increase in S100B. There is a possible additive effect of activity with high intensity and heading, but minor head impacts do not seem to cause an additional increase.	[Straume-Naesheim, Truls Martin; Andersen, Thor Einar; Bahr, Roald] Norwegian Sch Sports Sci, Dept Sports Med, Oslo SportsTrauma & Res Ctr, NO-0806 Oslo, Norway; [Jochum, Marianne] Univ Munich, Dept Clin Chem & Clin Biochem, Munich, Germany; [Dvorak, Jiri] Med Assessment & Res Ctr, Dept Neurol, Schulthess Clin, Int Federat Assoc Football, Zurich, Switzerland	Straume-Naesheim, TM (corresponding author), Norwegian Sch Sports Sci, Dept Sports Med, Oslo SportsTrauma & Res Ctr, POB 4014 Ulleval Stad, NO-0806 Oslo, Norway.	truls.straume-nesheim@nih.no	Bahr, Roald/B-6964-2014	Bahr, Roald/0000-0001-5725-4237; Andersen, Thor Einar/0000-0003-4172-4518			ABDULRAHMAN A, 1979, ACTA PHYSIOL SCAND, V107, P227, DOI 10.1111/j.1748-1716.1979.tb06467.x; Andersen TE, 2004, BRIT J SPORT MED, V38, P690, DOI 10.1136/bjsm.2003.009357; Andersen TE, 2004, BRIT J SPORT MED, V38, P626, DOI 10.1136/bjsm.2003.007955; Anderson RE, 2002, ACTA ANAESTH SCAND, V46, P1179; Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Arnason A, 2004, MED SCI SPORT EXER, V36, P278, DOI 10.1249/01.MSS.0000113478.92945.CA; Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Babbs C F, 2001, ScientificWorldJournal, V1, P281; Biberthaler P, 2006, SHOCK, V25, P446, DOI 10.1097/01.shk.0000209534.61058.35; Biberthaler P, 2002, EUR J MED RES, V7, P164; Biberthaler P, 2001, WORLD J SURG, V25, P93, DOI 10.1007/s002680020370; Biberthaler P, 2001, SHOCK, V16, P97, DOI 10.1097/00024382-200116020-00002; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; de boussard CN, 2004, BRAIN INJURY, V18, P671, DOI 10.1080/02699050310001646215; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P727, DOI 10.1136/jnnp.73.6.727; Delaney TS, 2002, CLIN J SPORT MED, V12, P331, DOI 10.1097/00042752-200211000-00003; Dietrich Mde O, 2004, CLIN J SPORT MED, V14, p[368, 368]; Dietrich MO, 2003, CAN J APPL PHYSIOL, V28, P710, DOI 10.1139/h03-054; Donato R, 1999, BBA-MOL CELL RES, V1450, P191, DOI 10.1016/S0167-4889(99)00058-0; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Fehrenbach E, 2006, SPORTS MED, V36, P373, DOI 10.2165/00007256-200636050-00001; Fuller CW, 2006, CLIN J SPORT MED, V16, P97, DOI 10.1097/00042752-200603000-00003; FULLER CW, 2005, BR J SPORTS MED S1, V39, P3; Guskiewicz KM, 2002, AM J SPORT MED, V30, P630; HAIMOTO H, 1987, LAB INVEST, V57, P489; Hanin I, 1996, NAT MED, V2, P1307, DOI 10.1038/nm1296-1307; Ingebrigtsen T, 1999, NEUROSURGERY, V45, P468, DOI 10.1097/00006123-199909000-00010; Ingebrigtsen T, 2003, RESTOR NEUROL NEUROS, V21, P171; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; Korfias S, 2006, CURR MED CHEM, V13, P3719, DOI 10.2174/092986706779026129; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; Matser JT, 2001, J CLIN EXP NEUROPSYC, V23, P770, DOI 10.1076/jcen.23.6.770.1029; Mussack T, 2003, EUR J MED RES, V8, P457; Mussack T, 2002, CRIT CARE MED, V30, P2669, DOI 10.1097/00003246-200212000-00010; Mussack T, 2002, SHOCK, V18, P395, DOI 10.1097/00024382-200211000-00002; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2006, CLIN CHEM LAB MED, V44, P1140, DOI 10.1515/CCLM.2006.190; Otto M, 2000, INT J SPORTS MED, V21, P551, DOI 10.1055/s-2000-8480; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pershin Boris B, 2002, Russ J Immunol, V7, P2; Powell JW, 1999, J ATHL TRAINING, V34, P277; Raabe A, 1999, NEUROSURGERY, V45, P477, DOI 10.1097/00006123-199909000-00012; REILLY T, 2003, SCI SOCCER, P59; Rothoerl RD, 1998, J TRAUMA, V45, P765, DOI 10.1097/00005373-199810000-00025; Rutherford A, 2003, NEUROPSYCHOL REV, V13, P153, DOI 10.1023/A:1025525613477; Savola O, 2003, EUR J NEUROL, V10, P175, DOI 10.1046/j.1468-1331.2003.00552.x; Scaccianoce S, 2004, BRAIN RES, V1004, P208, DOI 10.1016/j.brainres.2004.01.028; SHARMA HS, 1991, NEUROSCI RES, V10, P211; Stalnacke BM, 2006, BRIT J SPORT MED, V40, P313, DOI 10.1136/bjsm.2005.021584; Stalnacke BM, 2005, J REHABIL MED, V37, P300, DOI 10.1080/16501970510032910; Stalnacke BM, 2004, BRAIN INJURY, V18, P899, DOI 10.1080/02699050410001671865; Stalnacke BM, 2003, CLIN J SPORT MED, V13, P292; Stapert S, 2005, EUR NEUROL, V53, P22, DOI 10.1159/000083678; Steinacker JM, 2004, EUR J APPL PHYSIOL, V91, P382, DOI 10.1007/s00421-003-0960-x; Stranjalis G, 2004, J NEUROTRAUM, V21, P1070, DOI 10.1089/0897715041651088; STRAUMENAESHEIM TM, 2005, BR J SPORTS MED S1, V39, P70; Stroick M, 2006, CURR MED CHEM, V13, P3053, DOI 10.2174/092986706778521751; Townend W, 2006, J NEUROTRAUM, V23, P149, DOI 10.1089/neu.2006.23.149; Townend WJ, 2002, J NEUROL NEUROSUR PS, V73, P542, DOI 10.1136/jnnp.73.5.542; TYSVAER AT, 1992, SPORTS MED, V14, P200, DOI 10.2165/00007256-199214030-00006; Unden J, 2005, J TRAUMA, V58, P59, DOI 10.1097/01.TA.0000130613.35877.75; Watson P, 2005, AM J PHYSIOL-REG I, V288, pR1689, DOI 10.1152/ajpregu.00676.2004; ZIMMER DB, 1995, BRAIN RES BULL, V37, P417, DOI 10.1016/0361-9230(95)00040-2	67	23	25	0	6	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0148-396X	1524-4040		NEUROSURGERY	Neurosurgery	JUN	2008	62	6					1297	1305		10.1227/01.neu.0000333301.34189.3d			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	334MS	WOS:000258226500027	18824996	Green Accepted			2021-06-18	
J	Kramer, ME; Chiu, CYP; Walz, NC; Holland, SK; Yuan, WH; Karunanayaka, P; Wade, SL				Kramer, Megan E.; Chiu, C. -Y. Peter; Walz, Nicolay Chertkoff; Holland, Scott K.; Yuan, Weihong; Karunanayaka, Prasanna; Wade, Shari L.			Long-term neural processing of attention following early childhood traumatic brain injury: fMRI and neurobehavioral outcomes	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						childhood brain disorder; continuous performance test; brain imaging; children; head injury; neuropsychology	CONTINUOUS PERFORMANCE-TEST; WORKING-MEMORY LOAD; SUSTAINED ATTENTION; DEFICIT/HYPERACTIVITY DISORDER; RETROSPECTIVE ESTIMATION; SELF-REGULATION; HEAD-INJURY; CHILDREN; ADOLESCENTS; ACTIVATION	Attentional deficits are common and significant sequelae of pediatric traumatic brain injury (TBI). However. little is known about how file underlying neural processes that Support different components of attention are affected. The present Study examined brain activation patterns using fMRI ill a group Of young children who sustained a TBI ill early childhood (n = 5: mean age = 9.4) and a group of age-matched control children with orthopedic injuries (OI) (n=8) during a continuous performance task (CPT). Four children ill the TBI group had moderate injuries. and one had a severe injury. Performance oil the CPT task did not differ between groups. Both TBI and 01 children activated similar networks of brain regions relevant to sustained attention processing, but the TBI group demonstrated several areas of significantly greater activation relative to controls. including frontal and parietal regions. These findings of over-activation of the relevant attention network in the TBI group contrast with those obtained in imaging studies of Attention-Deficit/Hyperactivity Disorder where under-activation of the attention network has been documented. This Study provides evidence that young children's brains function differently following it traumatic brain injury, and that these differences persist for years after the injury.	[Kramer, Megan E.; Chiu, C. -Y. Peter] Univ Cincinnati, Dept Psychol, Cincinnati, OH 45221 USA; [Chiu, C. -Y. Peter] Univ Cincinnati, Dept Commun Sci & Disorders, Cincinnati, OH 45221 USA; [Walz, Nicolay Chertkoff; Holland, Scott K.; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, Cincinnati, OH USA; [Walz, Nicolay Chertkoff; Holland, Scott K.; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Holland, Scott K.; Yuan, Weihong; Karunanayaka, Prasanna] Cincinnati Childrens Hosp Med Ctr, Childrens Hosp Res Fdn, Cincinnati, OH USA	Kramer, ME (corresponding author), Univ Cincinnati, Dept Psychol, 101A Dyer Hall,ML 0376, Cincinnati, OH 45221 USA.	kramerm2@email.uc.edu		Holland, Scott/0000-0003-3719-0875; Kramer, Megan/0000-0002-8813-7217	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [RO1-HD044279]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD); National Center for Research Resources, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01 RR 08084]; U.S. National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1HD044279]; US National Institute of Child Health and Human Development.United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [RO1-HD38578]; Association of Volunteers of the Convalescent Hospital for Children; Cincinnati Children's Hospital Medical Center; University of Cincinnati; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R01HD042729] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R43HD044279, R01HD038578] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [M01RR008084] Funding Source: NIH RePORTER	The authors thank Vincent Schmithorst. Ph.D. for programming consultation, and Caleb Adler, M.D. for use of the CPT-IP paradigm. This work was Supported in part by (1) NIH grant RO1-HD044279 from the National Council on Medical Rehabilitation Research in the National Institute of Child Health and Human Development; (2) UPHS GCRC Grant #M01 RR 08084 from the National Center for Research Resources, NIH (3) NIH grant RO1HD044279 from the U.S. National Institute of Child Health and Human Development; and (4) NIH grant RO1-HD38578 from the US National Institute of Child Health and Human Development. Funding for the fMRI scans was provided by the Association of Volunteers of the Convalescent Hospital for Children, Cincinnati Children's Hospital Medical Center. The first author was supported by a University Dean's Distinguished Dissertation Award sponsored by the University of Cincinnati.	Achenbach T. M., 1991, MANUAL CHILD BEHAV C; Adler CM, 2005, BIPOLAR DISORD, V7, P577, DOI 10.1111/j.1399-5618.2005.00257.x; Anderson V, 1998, BRAIN INJURY, V12, P937, DOI 10.1080/026990598121990; Anderson V, 2005, BRAIN INJURY, V19, P699, DOI 10.1080/02699050400025281; Anderson V, 2001, J CLIN EXP NEUROPSYC, V23, P705, DOI 10.1076/jcen.23.6.705.1015; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; Borgaro S, 2003, J CLIN EXP NEUROPSYC, V25, P283, DOI 10.1076/jcen.25.2.283.13646; Catroppa C, 2005, J INT NEUROPSYCH SOC, V11, P84, DOI 10.1017/S1355617705050101; Catroppa C, 2003, DEV NEUROPSYCHOL, V23, P359, DOI 10.1207/S15326942DN2303_3; Catroppa C, 1999, CHILD NEUROPSYCHOL, V5, P251, DOI 10.1076/0929-7049(199912)05:04;1-R;FT251; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; CORNBLATT BA, 1989, PSYCHIAT RES, V29, P65, DOI 10.1016/0165-1781(89)90188-1; Dennis M., 1995, TRAUMATIC HEAD INJUR, P165; Elliott C.D., 1990, DIFFERENTIAL ABILITY; EPSTEIN JN, NEUROIMAGIN IN PRESS; Ewing-Cobbs L, 1998, CHILD NEUROPSYCHOL, V4, P35, DOI 10.1076/chin.4.1.35.3194; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; Ganesalingam K, 2007, J INT NEUROPSYCH SOC, V13, P298, DOI 10.1017/S1355617707070324; Ganesalingam K, 2006, J INT NEUROPSYCH SOC, V12, P609, DOI 10.1017/S1355617706060796; HU XP, 1995, MAGNET RESON MED, V34, P201, DOI 10.1002/mrm.1910340211; Karunanayaka PR, 2007, NEUROREHABILITATION, V22, P355; Le TH, 1996, MAGNET RESON MED, V35, P290, DOI 10.1002/mrm.1910350305; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Manly T., 1999, TEACH TEST EVERYDAY; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1041, DOI 10.1097/01.chi.0000173292.05817.f8; Max JE, 2005, J AM ACAD CHILD PSY, V44, P443, DOI 10.1097/01.chi.0000156661.38576.0f; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MIRSKY A F, 1991, Neuropsychology Review, V2, P109, DOI 10.1007/BF01109051; Muzik O, 2000, NEUROIMAGE, V12, P538, DOI 10.1006/nimg.2000.0651; Newsome MR, 2007, NEUROCASE, V13, P16, DOI 10.1080/13554790601186629; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; POLVISHOCK JT, 2005, J HEAD TRAUMA REHAB, V20, P76; Robin DA, 1999, APHASIOLOGY, V13, P701, DOI 10.1080/026870399401812; ROSVOLD HE, 1956, J CONSULT PSYCHOL, V20, P343, DOI 10.1037/h0043220; Rothbart MK, 2001, CHILD DEV, V72, P1394, DOI 10.1111/1467-8624.00355; Rothbart MK, 2001, DEV COGN NEUROSCI, P353; Rubia K, 2005, AM J PSYCHIAT, V162, P1067, DOI 10.1176/appi.ajp.162.6.1067; Scheibel RS, 2007, NEUROREHAB NEURAL RE, V21, P36, DOI 10.1177/1545968306294730; Scheibel RS, 2003, BRAIN INJURY, V17, P919, DOI 10.1080/0269905031000110472; Schmithorst VJ, 2001, IEEE T MED IMAGING, V20, P535, DOI 10.1109/42.929619; Smith AB, 2006, AM J PSYCHIAT, V163, P1044, DOI 10.1176/appi.ajp.163.6.1044; Strakowski SM, 2004, NEUROPSYCHOPHARMACOL, V29, P1734, DOI 10.1038/sj.npp.1300492; Talairach J., 1988, COPLANAR STEREOTACTI; Tamm L, 2006, AM J PSYCHIAT, V163, P1033, DOI 10.1176/appi.ajp.163.6.1033; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Thevenaz P, 1998, IEEE T IMAGE PROCESS, V7, P27, DOI 10.1109/83.650848; Wassenberg R, 2004, BRAIN INJURY, V18, P751, DOI 10.1080/02699050410001671775; Wilke M, 2002, HUM BRAIN MAPP, V17, P48, DOI 10.1002/hbm.10053; WORSLEY KJ, 1995, NEUROIMAGE, V2, P173, DOI 10.1006/nimg.1995.1023; Xiong JH, 1995, HUM BRAIN MAPP, V3, P287, DOI 10.1002/hbm.460030404; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yeates KO, 2000, PEDIAT NEUROPSYCHOLO	56	23	23	0	8	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	MAY	2008	14	3					424	435		10.1017/S1355617708080545			12	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	338VK	WOS:000258537300008	18419841	Green Accepted, Bronze			2021-06-18	
J	Morris, S; Ridley, S; Lecky, FE; Munro, V; Christensen, MC				Morris, S.; Ridley, S.; Lecky, F. E.; Munro, V.; Christensen, M. C.			Determinants of hospital costs associated with traumatic brain injury in England and Wales	ANAESTHESIA			English	Article; Proceedings Paper	Meeting of the European-Association-for-Trauma-and-Emergency-Surgery/European-Trauma-Society Congress	MAY, 2007	Graz, AUSTRIA	European Assoc Trauma & Emergency Surg, European Trauma Soc			HEAD-INJURY; CARE; PREDICTION; MODERATE; OUTCOMES; EUROPE	Using data from the Trauma Audit Research Network, we investigated the costs of acute care in patients >= 18 years of age hospitalised for traumatic brain injury between January 2000 and December 2005 in England and Wales. Traumatic brain injury patients were defined and stratified using the Abbreviated Injury Scale. A total of 6484 traumatic brain injury patients were identified; 22.3% had an Abbreviated Injury Scale score of three, 38.0% of four and 39.7% of five. Median age (IQR) was 42 years (28-59) and 76.7% were men. Primary cause of injury was motor vehicle collisions (42.4%) followed by falls (38.0%). In total 23.7% of the patients died before discharge. Hospitalisation costs averaged 15 pound 462 (SD 16 pound 844). Costs varied significantly by age, Glasgow Coma Score, Injury Severity Score, coexisting injuries of the thorax, spine and lower limb, hospital mortality, availability of neurosurgical services, and specialty of attendants seen in the Accident and Emergency department.	[Morris, S.] Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England; [Ridley, S.] Glan Clwyd Gen Hosp, Rhyl LL18 5UJ, Denbigh, Wales; [Lecky, F. E.] Univ Manchester, Salford M6 8HD, Lancs, England; [Munro, V.] Novo Nordisk Ltd, Crawley RH11 9RT, W Sussex, England; [Christensen, M. C.] Novo Nordisk AS, DK-2880 Bagsvaerd, Denmark	Morris, S (corresponding author), Brunel Univ, Hlth Econ Res Grp, Uxbridge UB8 3PH, Middx, England.	stephen.morris@brunel.ac.uk		Morris, Stephen/0000-0002-5828-3563			Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; Boake C, 2005, NEUROSURGERY, V56, P994, DOI 10.1227/01.NEU.0000158319.38230.C3; Bouamra O, 2006, J TRAUMA, V61, P701, DOI 10.1097/01.ta.0000197175.91116.10; Brell M, 2001, NEUROCIRUGIA, V12, P105; CURTIS L, 2004, UNIT COSTS HLTH SOCI; Department of Health, 2005, NHS REF COSTS 2004 A; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Firsching R, 2001, WORLD J SURG, V25, P1221; Hyam JA, 2006, CRIT CARE, V10, DOI 10.1186/cc5066; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; Lecky FE, 2002, EMERG MED J, V19, P520, DOI 10.1136/emj.19.6.520; McGarry LJ, 2002, J TRAUMA, V53, P1152, DOI 10.1097/00005373-200212000-00020; Morris S, 2007, ANAESTHESIA, V62, P43, DOI 10.1111/j.1365-2044.2006.04896.x; *NAT I HLTH CLIN E, 2004, TECHN APPR GUID, V83, P13; National Institute for Health and Clinical Excellence, 2003, HEAD INJ TRIAG ASS I; Patel HC, 2005, LANCET, V366, P1538, DOI 10.1016/S0140-6736(05)67626-X; *ROYAL COLL SURG, 1999, REP WORK PART MAN PA; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y	18	23	23	0	10	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0003-2409			ANAESTHESIA	Anaesthesia	MAY	2008	63	5					499	508		10.1111/j.1365-2044.2007.05432.x			10	Anesthesiology	Anesthesiology	287PB	WOS:000254927900009	18412648	Bronze			2021-06-18	
J	Stylianos, S; Ford, HR				Stylianos, Steven; Ford, Henri R.			Outcomes in pediatric trauma care	SEMINARS IN PEDIATRIC SURGERY			English	Article						Pediatric trauma; Processes of care; Quality	EVIDENCE-BASED GUIDELINES; BLUNT SPLENIC INJURIES; NONOPERATIVE MANAGEMENT; PRACTICE PATTERNS; ISOLATED SPLEEN; CHILDREN; ADULT; SURGEONS; CENTERS; FRACTURES	Variation in clinical practice patterns has attracted the attention of specialty organizations, payers, government health agencies, and the public. Such variation raises concerns about efficacy and cost relative to the care provided. Consequently, the establishment of national benchmarks has become an increasing priority in trauma care as well as elsewhere in the health sector. Comparing treatment of pediatric injury by hospital type or physician expertise has often created more controversy than conformity. Three key components that help define quality of care include infrastructure, process, and outcome. This report will highlight outcomes studies in pediatric trauma care, often comparing outcomes by physician and hospital expertise. We will discuss pediatric trauma mortality and outcomes in abdominal, closed head, and orthopedic injuries with an emphasis on functional outcomes. Much of the data are derived from large regional and national databases, which are increasingly available and useful in the analysis of specific aspects of our health care delivery system. (C) 2008 Elsevier Inc. All rights reserved.	[Stylianos, Steven] Miami Childrens Hosp, Dept Pediat Surg, Miami, FL 33155 USA; [Ford, Henri R.] Univ So Calif, Keck Sch Med, Childrens Hosp Los Angeles, Dept Surg, Los Angeles, CA 90033 USA	Stylianos, S (corresponding author), Miami Childrens Hosp, Dept Pediat Surg, 3200 SW 60th Court,Suite 201, Miami, FL 33155 USA.	steven.stylianos@mch.com			Department of Health and Human Services, Maternal and Child Health Bureau [HO3MC0006]	Dr. Stylianos was supported in part by Grant #HO3MC0006 from the Department of Health and Human Services, Maternal and Child Health Bureau.	Birkmeyer JD, 1998, SURGERY, V124, P917, DOI 10.1016/S0039-6060(98)70017-0; Bowman SM, 2005, JAMA-J AM MED ASSOC, V294, P2611, DOI 10.1001/jama.294.20.2611; DAMELIO LF, 1995, AM SURGEON, V61, P968; Davis DH, 2005, PEDIATRICS, V115, P89, DOI 10.1542/peds.2004-0508; Densmore JC, 2006, J PEDIATR SURG, V41, P92, DOI 10.1016/j.jpedsurg.2005.10.013; Farrell Louise Szypulski, 2004, Pediatr Crit Care Med, V5, P5, DOI 10.1097/01.PCC.0000102223.77194.D7; Figaji AA, 2006, SAMJ S AFR MED J, V96, P969; FORTUNE JB, 1992, J TRAUMA, V33, P130, DOI 10.1097/00005373-199207000-00024; Frumiento C, 2000, J PEDIATR SURG, V35, P985, DOI 10.1053/jpsu.2000.6948; Hall JR, 1996, J PEDIATR SURG, V31, P72, DOI 10.1016/S0022-3468(96)90322-X; Heyworth BE, 2004, J PEDIATR ORTHOPED, V24, P455, DOI 10.1097/01241398-200409000-00001; Holmes JH, 2005, J TRAUMA, V59, P1309, DOI 10.1097/01.ta.0000197366.38404.79; Jacobs IA, 2001, AM SURGEON, V67, P149; KELLER MS, 1995, J PEDIATR SURG, V30, P221, DOI 10.1016/0022-3468(95)90564-2; KNUDSON MM, 1992, J TRAUMA, V32, P729, DOI 10.1097/00005373-199206000-00009; Mooney DP, 2005, J TRAUMA, V58, P108, DOI 10.1097/01.TA.0000153746.76095.03; Mooney DP, 2004, J TRAUMA, V56, P328, DOI 10.1097/01.TA.0000053737.16542.FB; Mooney DP, 1998, J PEDIATR SURG, V33, P1076, DOI 10.1016/S0022-3468(98)90534-6; Myers JG, 2000, J TRAUMA, V48, P801, DOI 10.1097/00005373-200005000-00002; Osler TM, 2001, J TRAUMA, V50, P96, DOI 10.1097/00005373-200101000-00017; Potoka DA, 2001, J TRAUMA, V51, P824, DOI 10.1097/00005373-200111000-00002; Potoka DA, 2000, J TRAUMA, V49, P237, DOI 10.1097/00005373-200008000-00009; RHODES M, 1993, J TRAUMA, V35, P384, DOI 10.1097/00005373-199309000-00009; Segui-Gomez M, 2003, J PEDIATR SURG, V38, P1162, DOI 10.1016/S0022-3468(03)00262-8; SIMS CA, BLUNT SOLID IN PRESS; Smith JT, 1999, J PEDIATR ORTHOPED, V19, P553, DOI 10.1097/00004694-199907000-00027; Stylianos S, 2006, J AM COLL SURGEONS, V202, P247, DOI 10.1016/j.jamcollsurg.2005.10.012; Stylianos S, 2002, J PEDIATR SURG, V37, P453, DOI 10.1053/jpsu.2002.30860; Stylianos S, 2000, J PEDIATR SURG, V35, P164, DOI 10.1016/S0022-3468(00)90003-4; Todd SR, 2004, J TRAUMA, V57, P1065, DOI 10.1097/01.TA.0000103988.66443.0E; Vitale MG, 2005, J PEDIATR ORTHOPED, V25, P581, DOI 10.1097/01.bpo.0000175112.91122.41; Winthrop AL, 2005, J TRAUMA, V58, P468, DOI 10.1097/01.TA.0000153940.23471.B7	32	23	26	0	3	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1055-8586	1532-9453		SEMIN PEDIATR SURG	Semin. Pediatr. Surg.	MAY	2008	17	2					110	115		10.1053/j.sempedsurg.2008.02.006			6	Pediatrics; Surgery	Pediatrics; Surgery	408CU	WOS:000263412100006	18395660				2021-06-18	
J	Foley, LM; Hitchens, TK; Melick, JA; Bayir, H; Ho, C; Kochanek, PM				Foley, Lesley M.; Hitchens, T. Kevin; Melick, John A.; Bayir, Huelya; Ho, Chien; Kochanek, Patrick M.			Effect of inducible nitric oxide synthase on cerebral blood flow after experimental traumatic brain injury in mice	JOURNAL OF NEUROTRAUMA			English	Article						arterial spin labeling; head injury; iNOS; magnetic resonance imaging; perfusion	CONTROLLED CORTICAL IMPACT; SELECTIVE-INHIBITION; EXPRESSION; PERFUSION; DEFICIENT; NO; NEUROPROTECTION; NEUROGENESIS; ANGIOGENESIS; ATTENUATION	Inducible nitric oxide synthase (iNOS) has been suggested to play a complex role in the response to central nervous system insults such as traumatic brain injury (TBI) and cerebral ischemia. In the current study, we quantified maps of regional cerebral blood flow (CBF) using an arterial spin-labeling magnetic resonance imaging (MRI) technique, at 24 and 72 h after experimental TBI in iNOS knockout (KO) and wild-type (WT) mice. Our hypothesis was that iNOS would contribute to the level of CBF at 72 h after experimental TBI in mice. Comparing anatomical brain regions of interest (ROIs) at 24-h post controlled cortical impact (CCI), there were significant reductions in CBF in the hemisphere, cortex, and contusion-rich area of the cortex of injured animals versus naive, regardless of genotype. Regional assessment of CBF at 72 h after injury demonstrated that recovery of CBF was reduced in the ipsilateral hippocampus, thalamus, and amygdala/piriform cortex in iNOS KO versus WT mice by 26%, 15%, and 21%, respectively; this attenuated recovery was restricted to structures outside the contusion. These regions with reduced CBF in iNOS KO mice represented ROIs where CBF in the WT was either numerically or statistically greater than that seen in respective WT naive, suggesting a contribution of iNOS to delayed posttraumatic hyperemia. However, pixel analysis denoted that the contribution of iNOS to CBF at 72 h was not limited to hyperemia flows. In conclusion, iNOS plays a role in the recovery of CBF after CCI in mice. Questions remain if this effect represents a homeostatic component of CBF recovery, pathologic vasodilatation linked to inflammation, or NO-mediated facilitation of angiogenesis.	[Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin; Ho, Chien] Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; [Melick, John A.; Bayir, Huelya; Kochanek, Patrick M.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, Pittsburgh, PA 15260 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Dept Crit Care Med, 3434 5th Ave, Pittsburgh, PA 15260 USA.	kochanekpm@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Ho, Chien/O-6112-2016	Kochanek, Patrick M/0000-0002-2627-913X; Ho, Chien/0000-0002-4094-9232	NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41EB001977] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, P01NS030318] Funding Source: NIH RePORTER; NIBIB NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [P41 EB-001977] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318] Funding Source: Medline		ABRAMOFF MD, 2005, J BIOPHOTONICS INT, V11, P36; Bayir H, 2005, J CEREBR BLOOD F MET, V25, P673, DOI 10.1038/sj.jcbfm.9600068; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Cullis ER, 2006, MICROVASC RES, V71, P76, DOI 10.1016/j.mvr.2006.01.004; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; Foley LM, 2005, MAGN RESON MED, V54, P798, DOI 10.1002/mrm.20621; Gahm C, 2000, NEUROSURGERY, V46, P169; Hayashi T, 2003, J CEREBR BLOOD F MET, V23, P166, DOI 10.1097/00004647-200302000-00004; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; HERSCOVITCH P, 1985, J CEREBR BLOOD F MET, V5, P65, DOI 10.1038/jcbfm.1985.9; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUANG ZH, 1994, SCIENCE, V265, P1883, DOI 10.1126/science.7522345; IADECOLA C, 1995, AM J PHYSIOL-REG I, V268, pR286; Iadecola C, 1997, J NEUROSCI, V17, P9157; Iadecola C, 1996, STROKE, V27, P1373, DOI 10.1161/01.STR.27.8.1373; Jafarian-Tehrani M, 2005, NITRIC OXIDE-BIOL CH, V12, P61, DOI 10.1016/j.niox.2004.12.001; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; Kawano T, 2007, J CEREBR BLOOD F MET, V27, P1453, DOI 10.1038/sj.jcbfm.9600449; Louin G, 2006, NEUROPHARMACOLOGY, V50, P182, DOI 10.1016/j.neuropharm.2005.08.020; Okamoto H, 1998, STROKE, V29, P1209, DOI 10.1161/01.STR.29.6.1209; Pearse DD, 2003, J NEUROPATH EXP NEUR, V62, P1096, DOI 10.1093/jnen/62.11.1096; Petrov T, 2000, ACTA NEUROPATHOL, V100, P196, DOI 10.1007/s004019900167; Sidman R. L., 1971, ATLAS MOUSE BRAIN SP; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Steiner J, 2004, NITRIC OXIDE-BIOL CH, V10, P162, DOI 10.1016/j.niox.2004.03.005; Stoffel M, 2000, ACTA NEUROCHIR SUPPL, V76, P357; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wada K, 1998, J NEUROSURG, V89, P807, DOI 10.3171/jns.1998.89.5.0807; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; Willmot M, 2005, FREE RADICAL BIO MED, V39, P412, DOI 10.1016/j.freeradbiomed.2005.03.028; Zhang RL, 2002, STROKE, V33, P2675, DOI 10.1161/01.STR.0000034399.95249.59; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323; Zhao P, 2004, ANESTHESIOLOGY, V101, P695, DOI 10.1097/00000542-200409000-00018; Zhu DY, 2003, J NEUROSCI, V23, P223	38	23	25	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	APR	2008	25	4					299	310		10.1089/neu.2007.0471			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	282PL	WOS:000254579600003	18373480				2021-06-18	
J	Li, YF; Bai, Y				Li, Yingfeng; Bai, Yong			Comparison of characteristics between fatal and injury accidents in the highway construction zones	SAFETY SCIENCE			English	Article						accident; construction zone; highway; characteristics; safety		Highway construction zone safety has been a research focus in many countries for many decades. In the United States, regardless of the research efforts devoted, highway construction zones remain a serious safety concerti for government agencies, legislatures, the highway industry, and the traveling pub lic. In this study, the fatal and injury accidents between 1992 and 2004 in Kansas highway construction zones were examined systematically and their major characteristics were compared. The results showed significant differences between fatal and injury accidents in the construction zones. The researchers found that: (1) head-on was the dominant type for fatal accidents while rear-end was the dominant injury accident type; (2) a large percent of fatal accidents involved trucks while a majority of injury accidents involved light-duty vehicles only; (3) disregarded traffic control, alcohol impairment, and speeding caused a much larger proportion of fatal accidents while followed too close caused a much higher percentage of injury accidents; and (4) unfavorable light conditions and complicated road geometries contributed to causing a larger percentage of fatal accidents than to causing injury accidents. Based on the study results, practical safety countermeasures targeted at different severity of accidents are recommended in terms of construction zone traffic control and public education. (c) 2007 Elsevier Ltd. All rights reserved.	[Li, Yingfeng; Bai, Yong] Univ Kansas, Dept Civil Environm & Architectural Engn, Lawrence, KS 66045 USA	Li, YF (corresponding author), Univ Kansas, Dept Civil Environm & Architectural Engn, 1530 W l5th St,2160 Learned Hall, Lawrence, KS 66045 USA.	Lyf537@ku.edu; ybai@ku.edu	Bai, Yong/AAN-8674-2020	Bai, Yong/0000-0002-2814-0422			*AASHTO, 1987, SUMM REP WORK ZON CR; BAI Y, 2003, P 33 ANN M SE DEC SC, P367; Bai Y., 2006, KU0501 KTRAN U KANS; BAI Y, 2002, P FALL M AM SOC CIV; BENEKOHAL RF, 1995, 1509 TRANSP RES BOAR, P55; CHAMBLESS J, 2002, ITE J I TRANSPORTATI, P46; Daniel J, 2000, TRANSPORT RES REC, P18, DOI 10.3141/1715-03; *FHWA, 2006, HIGHW STAT 2004 3; *FHWA, 2004, WORK ZON SAF FACTS S; Garber N.J., 1990, 90R12 VTRC; Garber NJ, 2002, 02R12 VTRC; GRAHAM J, 1977, FHWARD7780 FHWA; Ha T. J., 1995, TRANSP RES REC, V1509, P38; HARGROVES BT, 1981, TRANSPORT ENG-J ASCE, V107, P525; HILL RW, 2003, THESIS TEXAS TU; LI Y, 2006, P CIW W99 INT C GLOB; Mohan S. B., 2002, PRACT PERIOD STRUCT, V7, P68, DOI DOI 10.1061/(ASCE)1084-0680(2002)7:2(68); Nemeth Z. A., 1978, TRANSPORT RES REC, V672, P19; PAL R, 1919, 1529 TRANSP RES BOAR, P43; Pigman JG, 1990, TRANSPORT RES REC, V1270, P12; ROUPHAIL NM, 1988, 1163 TRANSP RES BOAR, P4; SCHROCK DS, 2004, FHWATX05040281 US DE; Sorock GS, 1996, ACCIDENT ANAL PREV, V28, P131, DOI 10.1016/0001-4575(95)00055-0; THOMPSON SK, 2002, SAMPLING, P11; ULLMAN GL, 1990, FHWATX9011082 FHWA; *UT, 2005, TESTS IND US 2 WAY C; Wang J., 1996, TRANSPORT RES REC, V1529, P54, DOI DOI 10.3141/1529-07	27	23	23	0	10	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0925-7535	1879-1042		SAFETY SCI	Saf. Sci.	APR	2008	46	4					646	660		10.1016/j.ssci.2007.06.019			15	Engineering, Industrial; Operations Research & Management Science	Engineering; Operations Research & Management Science	313NV	WOS:000256748200007		Green Published			2021-06-18	
J	Elovic, EP; Jasey, NN; Eisenberg, ME				Elovic, Elie Paul; Jasey, Neil N., Jr.; Eisenberg, Michal E.			The use of atypical Antipsychotics after traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						agitation; atypical antipsychotic; aripiprazole; behavior; clozapine; olanzapine; quetiapine; risperidone; traumatic brain injuiy; ziprasidone	DRUGS; RISPERIDONE; QUETIAPINE; SCHIZOPHRENIA; ZIPRASIDONE; CLOZAPINE		[Elovic, Elie Paul; Jasey, Neil N., Jr.; Eisenberg, Michal E.] Univ Med & Dent New Jersey, New Jersey Med Sch, Kessler Med Rehabil Res & Educ Ctr, Dept Phys Med & Rehabil,Traumat Brain Injury Res, W Orange, NJ 07052 USA	Elovic, EP (corresponding author), Univ Med & Dent New Jersey, New Jersey Med Sch, Kessler Med Rehabil Res & Educ Ctr, Dept Phys Med & Rehabil,Traumat Brain Injury Res, W Orange, NJ 07052 USA.	eelovic@kmrrec.org					Akdede BBK, 2005, PROG NEURO-PSYCHOPH, V29, P233, DOI 10.1016/j.pnpbp.2004.11.005; Alderfer BS, 2006, J NEUROPSYCH CLIN N, V18, P551, DOI 10.1176/appi.neuropsych.18.4.551; Arciniegas DB, 2003, INT REV PSYCHIATR, V15, P328, DOI 10.1080/09540260310001606719; Cosi C, 2005, BRAIN RES, V1043, P32, DOI 10.1016/j.brainres.2005.02.072; Elovic EP, 2003, J HEAD TRAUMA REHAB, V18, P177, DOI 10.1097/00001199-200303000-00008; Gardner DM, 2005, CAN MED ASSOC J, V172, P1703, DOI 10.1503/cmaj.1041064; GOLDSTEIN LB, 1995, NEUROLOGY, V45, P865, DOI 10.1212/WNL.45.5.865; Horacek J, 2006, CNS DRUGS, V20, P389, DOI 10.2165/00023210-200620050-00004; JESTE DV, 2007, NEUROPSYCHOPHARMACOL; Kim E, 2006, J NEUROPSYCH CLIN N, V18, P547, DOI 10.1176/appi.neuropsych.18.4.547; Kurosawa S, 2007, J NEURAL TRANSM, V114, P1121, DOI 10.1007/s00702-007-0747-z; McGurk Susan R, 2004, MedGenMed, V6, P27; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; Mizoguchi Y, 2002, J NEUROPSYCH CLIN N, V14, P87, DOI 10.1176/appi.neuropsych.14.1.87-a; Newcomer JW, 2005, CNS DRUGS, V19, P1; Noe E, 2007, BEHAV NEUROL, V18, P7, DOI 10.1155/2007/529076; Oster TJ, 2007, CNS SPECTRUMS, V12, P764, DOI 10.1017/S1092852900015455; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; Silver BV, 2003, BRAIN INJURY, V17, P237, DOI 10.1080/0269905021000013192; Stahl S.M., 2000, ESSENTIAL PSYCHOPHAR; TAHIR R, 2007, US PHARM, V32, pHS3; U.S. Food and Drug Administration, 2005, DEATHS ANT ELD PAT B; Weiser M, 2000, SCHIZOPHR RES, V46, P81, DOI 10.1016/S0920-9964(00)00025-6	23	23	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	MAR-APR	2008	23	2					132	135		10.1097/01.HTR.0000314532.07530.e5			4	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	280KW	WOS:000254426700008	18362767				2021-06-18	
J	Vilela, MD				Vilela, Marcelo Duarte			Delayed paradoxical herniation after a decompressive craniectomy: case report	SURGICAL NEUROLOGY			English	Article						lumbar puncture; decompressive craniectomy; paradoxical herniation; blood patch; cranioplasty	TRAUMATIC BRAIN-INJURY; CEREBROSPINAL-FLUID; INTRACRANIAL HYPOTENSION; PUNCTURE; DRAINAGE; SURGERY	Background: Paradoxical herniation can occur as a complication of lumbar puncture in patients who had a decompressive craniectomy. The supposed mechanism is the development of a negative pressure gradient that allows the brain to shift toward the infratentorial space with subsequent herniation. Trendelenburg position plus early cranioplasty has been the suggested treatment to eliminate the gradient. Case Description: A 53-year-old woman had a decompressive hemicraniectomy for SAH-related swelling. A lumbar puncture was performed on postoperative day 5 to rule out infection. She remained neurologically stable until 6 weeks later, when she deteriorated because of a paradoxical herniation. Head positioning and cranioplasty were only temporarily helpful. She developed a second episode of decline a few days later due to an extraaxial CSF collection. A lumbar blood patch plus drainage of the collection successfully allowed full neurologic recovery. Conclusions: Cranioplasty and head positioning alone might not be sufficient to eliminate the negative pressure gradient. A blood patch should be part of the management of paradoxical herniation. (c) 2008 Elsevier Inc. All rights reserved.	Univ Washington, Harborview Med Ctr, Dept Neurol Surg, Seattle, WA 98104 USA	Vilela, MD (corresponding author), Univ Washington, Harborview Med Ctr, Dept Neurol Surg, 325 9Th Ave, Seattle, WA 98104 USA.	mdvilela@u.washington.edu					Albanese J, 2003, CRIT CARE MED, V31, P2535, DOI 10.1097/01.CCM.0000089927.67396.F3; ANDRIEU JM, 1995, IMMUNOL TODAY, V16, P5, DOI 10.1016/0167-5699(95)80062-X; Binder DK, 2002, NEUROSURGERY, V51, P830, DOI 10.1227/01.NEU.0000024286.95876.2F; Bloch J, 2003, J NEUROL NEUROSUR PS, V74, P992, DOI 10.1136/jnnp.74.7.992; Carter BS, 1997, NEUROSURGERY, V40, P1168, DOI 10.1097/00006123-199706000-00010; Ebel H, 1999, CHILD NERV SYST, V15, P84, DOI 10.1007/s003810050337; Harscher S, 2006, ACTA NEUROCHIR, V148, P31, DOI 10.1007/s00701-005-0617-0; Heuer GG, 2004, J NEUROSURG, V101, P408, DOI 10.3171/jns.2004.101.3.0408; Klimo P, 2004, J NEUROSURG, V100, P215, DOI 10.3171/jns.2004.100.2.0215; Komotar RJ, 2005, NEUROSURGERY, V57, P286, DOI 10.1227/01.NEU.0000166661.96546.33; Mori K, 2004, SURG NEUROL, V62, P420, DOI 10.1016/j.surneu.2003.12.017; OVELESE AA, 2005, NEUROSURGERY, V57, P594; Rutigliano D, 2006, J PEDIATR SURG, V41, P83, DOI 10.1016/j.jpedsurg.2005.10.010; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; Samadani U, 2003, NEUROSURGERY, V52, P148, DOI 10.1097/00006123-200301000-00019; Schievink WI, 2006, JAMA-J AM MED ASSOC, V295, P2286, DOI 10.1001/jama.295.19.2286; Schwab S, 1998, NERVENARZT, V69, P896, DOI 10.1007/s001150050360; Smith ER, 2002, NEUROSURGERY, V51, P117, DOI 10.1097/00006123-200207000-00018; SNOW RB, 1991, NEUROSURGERY, V28, P880, DOI 10.1227/00006123-199106000-00016; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; Vakharia SB, 1997, ANESTH ANALG, V84, P585, DOI 10.1097/00000539-199703000-00022; van Crevel H, 2002, J NEUROL, V249, P129, DOI 10.1007/PL00007855	22	23	26	0	1	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	0090-3019			SURG NEUROL	Surg. Neurol.	MAR	2008	69	3					293	296		10.1016/j.surneu.2007.01.027			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	275SJ	WOS:000254091600016	17586009				2021-06-18	
J	Cremer, OL				Cremer, O. L.			Does ICP monitoring make a difference in neurocritical care?	EUROPEAN JOURNAL OF ANAESTHESIOLOGY			English	Article; Proceedings Paper	Brain Annual Meeting	MAY 09-12, 2007	Brescia, ITALY			head injury; intracranial pressure monitoring; blood pressure; intracerebral; outcome	SEVERE HEAD-INJURY; TRAUMATIC BRAIN-INJURY; INTRACRANIAL-PRESSURE MONITORS; CEREBRAL PERFUSION-PRESSURE; INTENSIVE-CARE; HEMORRHAGIC COMPLICATIONS; NEUROSURGICAL CENTERS; PULMONARY-ARTERY; CLINICAL-TRIALS; MANAGEMENT	Raised intracranial pressure and low cerebral perfusion pressure are associated with ischaemia and poor outcome after brain injury. Therefore, many management protocols target these variables. However, there are no randomized controlled trials that have demonstrated the effectiveness of intracranial pressure-guided care in severely head-injured patients. Observational studies of such therapy have yielded inconsistent results, ranging from decreased mortality to no effect or increased morbidity or mortality. A recent cohort study supports the notion that the possible benefits of intracranial pressure monitoring after traumatic brain injury are small - if present - and would exceed a number needed for the treatment of 16. Furthermore, intracranial pressure monitoring and aggressive management of intracranial pressure and cerebral perfusion pressure have been associated with increased lengths of stay in the neurocritical care unit, conceivable costs and possibly an increased rate of complications. Against this background, there is sufficient clinical equipoise to warrant an adequately powered randomized controlled trial to compare intracranial pressure-guided care with supportive critical care without intracranial pressure monitoring in patients with severe traumatic brain injury. However, the realization of such a trial is likely to be problematic for a number of reasons, not least of which them firmly held biases of many clinicians.	Univ Utrecht Hosp, Dept Intens Care, NL-3508 GA Utrecht, Netherlands	Cremer, OL (corresponding author), Univ Utrecht Hosp, Dept Intens Care, POB 85500, NL-3508 GA Utrecht, Netherlands.	o.l.cremer@umcutrecht.nl	Cremer, Olaf L/G-3855-2016	Cremer, Olaf L/0000-0003-4264-1108			AUCOIN PJ, 1986, AM J MED, V80, P369, DOI 10.1016/0002-9343(86)90708-4; Bekar A, 1998, NEUROSURG REV, V21, P254, DOI 10.1007/BF01105781; Blaha M, 2005, J NEUROL NEUROSUR PS, V76, P147, DOI 10.1136/jnnp.2003.030817; Blaha M, 2003, PEDIATR NEUROSURG, V39, P27, DOI 10.1159/000070877; *BRAIN T FDN, 2000, MAN PROGN SEV TRAUM; *BRAIN TRAU FDN, GUID MAN SEV TRAUM I; Bulger EM, 2002, CRIT CARE MED, V30, P1870, DOI 10.1097/00003246-200208000-00033; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Cremer OL, 2005, CRIT CARE MED, V33, P2207, DOI 10.1097/01.CCM.0000181300.99078.B5; Cremer OL, 2001, LANCET, V357, P117, DOI 10.1016/S0140-6736(00)03547-9; Cremer OL, 2006, J TRAUMA, V61, P1484, DOI 10.1097/01.ta.0000195981.63776.ba; Crockard H A, 1976, Surg Neurol, V5, P151; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Eker C, 1998, CRIT CARE MED, V26, P1881, DOI 10.1097/00003246-199811000-00033; FREEMAN R, 1990, NEW ENGL J MED, V322, P624, DOI 10.1056/NEJM199003013220910; Gelabert-Gonzalez M, 2006, ACTA NEUROCHIR, V148, P435, DOI 10.1007/s00701-005-0683-3; GELPKE GJ, 1983, J NEUROSURG, V59, P745, DOI 10.3171/jns.1983.59.5.0745; Grande PO, 1997, J TRAUMA, V42, pS23, DOI 10.1097/00005373-199705001-00005; JENNETT B, 1977, J NEUROL NEUROSUR PS, V40, P291, DOI 10.1136/jnnp.40.3.291; Kornecki A, 2002, CHILD NERV SYST, V18, P375, DOI 10.1007/s00381-002-0613-0; Lane PL, 2000, CAN J SURG, V43, P442; Lee TT, 1998, ACTA NEUROCHIR, V140, P41, DOI 10.1007/s007010050055; Maas AIR, 2004, ACT NEUR S, V89, P113; Maitinez-Manas RM, 2000, J NEUROL NEUROSUR PS, V69, P82, DOI 10.1136/jnnp.69.1.82; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; McKeating EG, 1998, BRIT J NEUROSURG, V12, P7; MILLER J D, 1987, Neurological Research, V9, P193; MINDERMANN T, 1992, ACTA NEUROCHIR, V116, P60, DOI 10.1007/BF01541255; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murphy LS, 1999, BRIT J NEUROSURG, V13, P564, DOI 10.1080/02688699943060; NARAYAN RK, 1982, J NEUROSURG, V56, P650, DOI 10.3171/jns.1982.56.5.0650; Natale Renato, 2003, J Obstet Gynaecol Can, V25, P1007; Odetola FO, 2006, PEDIATRICS, V117, P1893, DOI 10.1542/peds.2005-2179; Patel HC, 2002, INTENS CARE MED, V28, P547, DOI 10.1007/s00134-002-1235-4; Roberts I, 1998, J NEUROL NEUROSUR PS, V65, P729, DOI 10.1136/jnnp.65.5.729; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sahjpaul R, 2000, CAN J NEUROL SCI, V27, P143; Sahuquillo J, 1999, J NEUROSURG, V90, P16, DOI 10.3171/jns.1999.90.1.0016; Sandham JD, 2003, NEW ENGL J MED, V348, P5, DOI 10.1056/NEJMoa021108; Shigemori M, 2002, NEUROL RES, V24, P41, DOI 10.1179/016164102101199521; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; Stocchetti N, 2001, INTENS CARE MED, V27, P400, DOI 10.1007/s001340000825; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Vincent JL, 2005, CRIT CARE MED, V33, P1392, DOI 10.1097/01.CCM.0000166890.93559.2D; Wheeler AP, 2006, NEW ENGL J MED, V354, P2213; Wilkins IA, 2001, ANAESTHESIA, V56, P350, DOI 10.1046/j.1365-2044.2001.01708.x; 2000, J NEUROTRAUMA, V17, P479	50	23	23	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0265-0215	1365-2346		EUR J ANAESTH	Eur. J. Anaesth.		2008	25			42			87	93		10.1017/S0265021507003237			7	Anesthesiology	Anesthesiology	283AY	WOS:000254610100015	18289423				2021-06-18	
J	Gfroerer, SD; Wade, SL; Wu, M				Gfroerer, Susan Davies; Wade, Shari L.; Wu, Michelle			Parent perceptions of school-based support for students with traumatic brain injuries	BRAIN INJURY			English	Article						traumatic brain injury; parent perception; return to school; school services; school support	HEAD-INJURY; PREDICTORS; RECOVERY; SEQUELAE; TERM; TBI	Primary objective: To determine whether parents believe schools provided necessary support to their children who sustained traumatic brain injuries. Research design: Interview, to determine parent perceptions. Methods and procedure: Sixty-six primary caregivers of school-age children who experienced a TBI within the previous 2 years were interviewed regarding what types of special support were needed by and provided for their children during the 3 months immediately following school re-entry. They then rated how difficult it was to obtain support or services from the school and how satisfied they were with the support or services. Main outcomes and results: The majority of participants did not perceive the need for school-based services, even when the injury was severe. Almost all students whose parents perceived a need for an adjusted schedule were granted that accommodation, but few students received school-based counselling or behavioural support. Conclusions: Results indicated that participants perceived relatively few school-based supports, particularly given the actual academic, behavioural and social challenges experienced by children who have sustained a TBI. Schools and hospitals must take steps to ensure appropriate post-head injury support services.	[Gfroerer, Susan Davies] Univ Dayton, Dept Counselor Educ & Human Serv, Dayton, OH 45469 USA; [Wade, Shari L.; Wu, Michelle] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH USA; [Wade, Shari L.] Univ Cincinnati, Cincinnati, OH USA	Gfroerer, SD (corresponding author), Univ Dayton, Dept Counselor Educ & Human Serv, 300 Coll Pk, Dayton, OH 45469 USA.	gfroersd@notes.udayton.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [HD40942-02, R21 HD040942] Funding Source: Medline; PHS HHSUnited States Department of Health & Human ServicesUnited States Public Health Service [R49 CCR523224] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD040942] Funding Source: NIH RePORTER		Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2006, NEUROPSYCHOLOGY, V20, P42, DOI 10.1037/0894-4105.20.1.42; BOLL TJ, 1997, HDB CLIN CHILD NEURO, P140; CLARK E, 1992, SCHOOL PSYCHOL REV, V21, P246; CLARK E, 1997, CHILDRENS NEEDS, V2, P815; Dykeman B, 2003, J INSTRUCTIONAL PSYC, P225; Ewing-Cobbs L, 1990, TRAUMATIC BRAIN INJU, P107; EWINGCOBBS L, 1989, J PEDIATR PSYCHOL, V14, P531, DOI 10.1093/jpepsy/14.4.531; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; FLETCHERJANZEN E, 1997, HDB CHILD CLIN NEURO, P452; Glang A, 2004, NEUROREHABILITATION, V19, P219; GLANG A, 2006, J HEAD TRAUMA REHAB, V21, P408; JELLINGER K, 1983, PEDIAT HEAD TRAUMA, P87; KIM YM, 2000, EARLY CHILD DEV CARE, V160, P133; Leith KH, 2004, BRAIN INJURY, V18, P1191, DOI 10.1080/02699050410001719943; LEVIN HS, 1995, TRAUMATIC HEAD INJUR, P70; Mohr JD, 2005, PREV SCH FAIL, V49, P53, DOI 10.3200/PSFL.49.4.53-57; *NAT INF CTR CHILD, 2004, FS18 NICCYD; Peck CA, 2004, RES PRACT PERS SEV D, V29, P135, DOI 10.2511/rpsd.29.2.135; RAVET J, 2007, RES PAPERS ED, V22, P333, DOI DOI 10.1080/02671520701497589; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; Savage Ronald C, 2005, Pediatr Rehabil, V8, P92; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Stancin T, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e34; Taylor HG, 1999, NEUROPSYCHOLOGY, V13, P76, DOI 10.1037/0894-4105.13.1.76; TAYLOR HG, 1997, J INT NEUROPSYCH SOC, V3, P1; Teeter P.A., 1997, CHILD NEUROPSYCHOLOG; TELZROW CF, 1987, J LEARN DISABIL, V20, P536, DOI 10.1177/002221948702000905; TONKS J, 2007, BRAIN IMPAIR, V8, P143, DOI DOI 10.1375/BRIM.8.2.143; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514	31	23	23	0	4	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2008	22	9					649	656		10.1080/02699050802227162			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	336NS	WOS:000258371600002	18608201	Green Accepted			2021-06-18	
J	Gronovist, J; Haggman-Henrikson, B; Eriksson, PO				Gronovist, Johan; Haggman-Henrikson, Birgitta; Eriksson, Per-Olof			Impaired jaw function and eating difficulties in Whiplash-associated disorders	SWEDISH DENTAL JOURNAL			English	Article						Chewing; eating behaviour; jaw; neck; whiplash injuries	HEAD-NECK MOVEMENTS; CERVICAL-SPINE DISORDERS; TEMPOROMANDIBULAR DISORDERS; STOMATOGNATHIC SYSTEM; SYMPTOMS; DYSFUNCTION; PAIN; PREVALENCE; MODULATION; INJURY	Eating requires mouth opening, biting, chewing and swallowing and should be performed without dysfunction or pain. Previous studies have shown that jaw opening-closing movements are the result of coordinated activation of both jaw and neck muscles,with simultaneous movements in the temporomandibular, atlanto-occipital and cervical spine joints. Consequently, it can be assumed that pain or dysfunction in any of the three joint systems involved could impair jaw activities. In fact, recent findings support this hypothesis by showing an association between neck injury and reduced amplitudes, speed and coordination of integrated jaw-neck movements. This study investigated the possible association between neck injury and disturbed eating behaviour. Fifty Whiplash-associated disorders (WAD) patients with pain and dysfunction in the jaw-face region and 50 healthy age-and sex-matched controls without any history of neck injury participated in the study. All participants were assessed by a questionnaire, which contained 26 items about eating behaviour jaw pain and dysfunction. For the WAD group there were significant differences in jaw pain and dysfunction and eating behaviour before and after the accident, but no significant differences between WAD before and healthy. The healthy and the WAD group before the accident reported no or few symptoms. The WAD patients after the accident reported pain and dysfunction during mouth opening, biting, chewing, swallowing and yawning and felt fatigue, stiffness and numbness in the jaw-face region. In addition, a majority also reported avoiding tough food and big pieces of food, and taking breaks during meals. Altogether, these observations suggest an association between neck injury and disturbed jaw function and therefore impaired eating behaviour. A clinical implication is that examination of jaw function should be recommended as part of the assessment and rehabilitation of WAD patients.	[Gronovist, Johan; Haggman-Henrikson, Birgitta; Eriksson, Per-Olof] Umea Univ, Clin Oral Physiol Fac Med, Muscle & Motor Control & MotoRehab Lab, SE-90187 Umea, Sweden	Eriksson, PO (corresponding author), Umea Univ, Clin Oral Physiol Fac Med, Muscle & Motor Control & MotoRehab Lab, SE-90187 Umea, Sweden.	per-olof.eriksson@odont.umu.se	Haggman-Henrikson, Birgitta/C-6998-2008	Haggman-Henrikson, Birgitta/0000-0001-6088-3739	Department of Odontology; Faculty of Medicine, Umea University; Public Dental Health Service, Vasterbotten, Sweden; RTP (The Swedish Association of Survivors of Traffic Accidents and Polio)	Supported by the Department of Odontology and the Faculty of Medicine, Umea University, the Public Dental Health Service, Vasterbotten, Sweden, and RTP (The Swedish Association of Survivors of Traffic Accidents and Polio).	Capra NF, 2000, PAIN, V86, P151, DOI 10.1016/S0304-3959(00)00231-1; Ciancaglini R, 1999, SCAND J REHABIL MED, V31, P17; CLARK GT, 1987, J AM DENT ASSOC, V115, P251, DOI 10.14219/jada.archive.1987.0231; De Laat A, 1998, Clin Oral Investig, V2, P54, DOI 10.1007/s007840050045; DeWijer A, 1996, J ORAL REHABIL, V23, P742, DOI 10.1046/j.1365-2842.1996.d01-187.x; DeWijer A, 1996, J ORAL REHABIL, V23, P733, DOI 10.1046/j.1365-2842.1996.00427.x; Egermark I, 2001, ACTA ODONTOL SCAND, V59, P40, DOI 10.1080/000163501300035788; Elfving L, 2002, SWED DENT J, V26, P9; Eriksson PO, 2007, ARCH ORAL BIOL, V52, P404, DOI 10.1016/j.archoralbio.2006.12.016; Eriksson PO, 2000, J DENT RES, V79, P1378, DOI 10.1177/00220345000790060501; Eriksson PO, 2004, EUR J ORAL SCI, V112, P25, DOI 10.1111/j.0909-8836.2004.00098.x; Eriksson PO, 1998, J ORAL REHABIL, V25, P859, DOI 10.1046/j.1365-2842.1998.00333.x; ERIKSSON PO, 2005, CONNS CURRENT THERAP, P1128; Feine JS, 2006, J ORAL REHABIL, V33, P301, DOI 10.1111/j.1365-2842.2006.01614.x; Ferrari R, 2005, ANN RHEUM DIS, V64, P1337, DOI 10.1136/ard.2004.034447; Freeman MD, 1999, SPINE, V24, P86, DOI 10.1097/00007632-199901010-00022; Haggman-Henrikson B, 2006, J DENT RES, V85, P1001, DOI 10.1177/154405910608501105; Haggman-Henrikson B, 2004, J DENT RES, V83, P864, DOI 10.1177/154405910408301108; Haggman-Henrikson B, 2002, J DENT RES, V81, P747, DOI 10.1177/154405910208101105; Haggman-Henrikson B, 2004, J DENT RES, V83, P946, DOI 10.1177/154405910408301211; HEISE AP, 1992, J ORAL MAXIL SURG, V50, P825, DOI 10.1016/0278-2391(92)90273-3; Hellstrom F, 2000, J DENT RES, V79, P1815, DOI 10.1177/00220345000790101401; HU JW, 1993, PAIN, V55, P243, DOI 10.1016/0304-3959(93)90153-G; Igarashi N, 2000, BRAIN RES, V871, P151, DOI 10.1016/S0006-8993(00)02433-1; Johansson H, 1999, AM J IND MED, P104; Kasch H, 2002, J OROFAC PAIN, V16, P118; KIRVESKARI P, 1988, ACTA ODONTOL SCAND, V46, P281, DOI 10.3109/00016358809004778; Klobas L, 2004, SWED DENT J, V28, P29; Magnusson T, 2000, J OROFAC PAIN, V14, P310; Ro JY, 2001, PAIN, V92, P117, DOI 10.1016/S0304-3959(00)00477-2; Sale H, 2007, J AM DENT ASSOC, V138, P1084, DOI 10.14219/jada.archive.2007.0320; SPITZER WO, 1995, SPINE, V20, pS1; Visscher CM, 2001, EUR J ORAL SCI, V109, P76, DOI 10.1034/j.1600-0722.2001.00996.x; Zafar H, 2006, SWED DENT J, V30, P9; Zafar H, 2000, ARCH ORAL BIOL, V45, P675, DOI 10.1016/S0003-9969(00)00032-7; Zeredo JL, 2003, J DENT RES, V82, P402, DOI 10.1177/154405910308200515; Zeredo JL, 2002, J DENT RES, V81, P39, DOI 10.1177/154405910208100109	37	23	23	0	2	SWEDISH DENTAL JOURNAL	STOCKHOLM	BOX 1217, SE-111 82 STOCKHOLM, SWEDEN	0347-9994			SWED DENT J	Swed. Dent. J.		2008	32	4					171	178					8	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	389HC	WOS:000262082500003	19172918				2021-06-18	
J	Salvatore, C; Marco, M; Antonio, R; Salvatore, I; Eugenio, B				Salvatore, Chibbaro; Marco, Marsella; Antonio, Romano; Salvatore, Ippolito; Eugenio, Benericem			Combined internal uncusectomy and decompressive craniectomy for the treatment of severe closed head injury: experience with 80 cases	JOURNAL OF NEUROSURGERY			English	Article						decompressive craniectomy; raised intracranial pressure; tentorial incision; severe head trauma; transtentorial herniation; uncoparahippocampectomy	ACUTE SUBDURAL HEMATOMA; TRANSTENTORIAL HERNIATION; INTRACRANIAL-PRESSURE; TEMPORAL LOBECTOMY; CEREBRAL EDEMA; MANAGEMENT; CRANIOTOMY; RECOVERY; COMA	Object. Transtentorial brain herniation is a major cause of morbidity and death following severe closed head injury. The purpose of this study was to evaluate the efficacy of selective uncoparahippocampectomy and tentorial splitting as an adjuvant method of treating otherwise uncontrollable elevated intracranial pressure (ICP) while attempting to prevent or minimize the devastating consequences caused by transtentorial herniation. Methods. The authors retrospectively reviewed data from a series of 80 consecutive cases of severe closed head injury (Glasgow Coma Scale [GCS] score < 8) treated in their neurosurgical unit. All patients had elevated ICP and downward tentorial herniation, as documented with ICP monitoring, and clinical examination and computed tomography, respectively. Given the evidence of acute and ongoing neurological deterioration, all patients were treated with selective uncoparahippocampectomy and tentorial edge incision followed by wide decompressive craniectomy and duraplasty. Results. All injuries were caused by blunt trauma with signs of acute and/or progressive increased ICP causing downward transtentorial herniation. Fifty-eight patients were male and 22 were female with a mean age of 35 years and a mean preoperative GCS score of 5. Based on the current American Association of Neurological Surgeons guidelines for head trauma, an intraparenchymal ICP device (Camino, Integra) was placed in all patients who had a GCS score < 8, and ICP was consistently > 20 cm H2O. Whenever possible, risks and benefits were explained to family members, and then surgery was per-formed within 3-16 hours (median 6 hours). At a mean follow-up of 30 months, the outcome was favorable (Glasgow Outcome Scale [GOS] score of 4 or 5) in 60 patients (75%) and unfavorable (GOS score of 3) in 8 (10%), whereas the remaining 12 patients (15%) died at some point during the postoperative course. There was no survivor patient in a vegetative state. A younger age had a significant effect on positive outcome (p < 0.0005), as did an earlier operation (p < 0.04). The preoperative neurological status as assessed using the GCS as well as pupillary reactivity had no significant effect on outcome (p = 0.054 and p > 0.05, respectively). Conclusions. A selective uncoparahippocampectomy with a tentorial edge incision and a wide decompressive craniectomy with duraplasty can be an effective adjuvant form of aggressive treatment to improve outcome in patients with severe closed head injury, especially in those who are younger if they are treated promptly.	[Salvatore, Chibbaro; Antonio, Romano; Salvatore, Ippolito; Eugenio, Benericem] Univ Hosp, Dept Neurosurg, Parma, Italy; [Marco, Marsella] Univ Hosp, Dept Neurosurg, Tucson, AZ USA	Salvatore, C (corresponding author), Via Enrico Toti 19, I-34100 Trieste, Italy.	schibbaro@hotmail.com	Chibbaro, Salvatore/AAI-6368-2020				ADAMS JH, 1976, NEUROPATH APPL NEURO, V2, P323, DOI 10.1111/j.1365-2990.1976.tb00506.x; ANDREWS BT, 1991, NEUROSURGERY, V29, P227, DOI 10.1227/00006123-199108000-00010; BECKER DP, 1977, J NEUROSURG, V47, P491, DOI 10.3171/jns.1977.47.4.0491; BLINKOV SM, 1992, J NEUROSURG, V76, P973, DOI 10.3171/jns.1992.76.6.0973; BRITT RH, 1978, NEUROSURGERY, V2, P195, DOI 10.1227/00006123-197805000-00001; BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CLARK K, 1968, J NEUROSURG, V29, P367, DOI 10.3171/jns.1968.29.4.0367; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Cooper P R, 1976, Surg Neurol, V5, P25; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; CUSHING HW, 1908, J HOPKINS HOSP B, V19, P48; FREEDMAN H, 1952, J NEUROSURG, V9, P52, DOI 10.3171/jns.1952.9.1.0052; GOWER DJ, 1988, NEUROSURGERY, V23, P417, DOI 10.1227/00006123-198810000-00002; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; KJELLBERG RN, 1971, J NEUROSURG, V34, P488, DOI 10.3171/jns.1971.34.4.0488; LANGFITT TW, 1964, J NEUROSURG, V21, P989, DOI 10.3171/jns.1964.21.11.0989; MARSHALL LF, 1991, J NEUROSURG, V75, pS28, DOI 10.3171/sup.1991.75.1s.0s28; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1992, GREENFIELDS NEUROPAT, P69; MOODY RA, 1968, J NEUROSURG, V29, P586, DOI 10.3171/jns.1968.29.6.0586; MUNRO D, 1952, NEW ENGL J MED, V247, P699, DOI 10.1056/NEJM195211062471901; NUSSBAUM ES, 1991, NEUROSURGERY, V29, P62, DOI 10.1227/00006123-199107000-00010; RANSOHOFF J, 1971, J NEUROSURG, V34, P70, DOI 10.3171/jns.1971.34.1.0070; REICH JB, 1993, ANN NEUROL, V33, P159, DOI 10.1002/ana.410330205; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Sarabia R, 1988, Acta Neurochir Suppl (Wien), V42, P40; SCOVILLE WB, 1979, ACTA NEUROCHIR, V47, P149, DOI 10.1007/BF01406400; STABLEIN DM, 1980, NEUROSURGERY, V6, P243; VENES JL, 1975, J NEUROSURG, V42, P429, DOI 10.3171/jns.1975.42.4.0429; VOLLMER DG, 1991, J NEUROSURG, V75, pS37, DOI 10.3171/sup.1991.75.1s.0s37; WALKER AE, 1960, J NEUROSURG, V26, P184	33	23	32	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JAN	2008	108	1					74	79		10.3171/JNS/2008/108/01/0074			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	248AI	WOS:000252123300010	18173313				2021-06-18	
J	Cohen, O; De La Zerda, DJ; Beygui, R; Hekmat, D; Laks, H				Cohen, O.; De La Zerda, D. J.; Beygui, R.; Hekmat, D.; Laks, H.			Donor brain death mechanisms and outcomes after heart transplantation	TRANSPLANTATION PROCEEDINGS			English	Article							INTRACRANIAL-PRESSURE; GRADUAL INCREASE; ACTIVATION; EXPERIENCE; INJURY; IMPACT	We sought to explore whether the cause of donor brain death influenced recipient outcomes after cardiac transplantation. In retrospect, 358 consecutive donors provided cardiac allografts to adult patients undergoing orthotopic heart transplantation at a single urban US medical center from January 2000 through December 2005. Alternate recipients were excluded. Mechanism and cause of donor brain injury and death were divided into five categories: anoxia (nontraumatic) (n = 36), blunt head trauma (n = 220), penetrating head trauma (n = 83), brain tumor/infection (n = 7), and cerebrovascular event (n = 12). The five subgroups were categorized as traumatic or nontraumatic. The end points of the study were causes of early and late mortality, survival, and rejection rate. There were 59 deaths in the 6-year period. Total and short-term recipient mortality were found to be statistically higher among heart transplant recipients when the donors suffered from traumatic brain death compared to those whose brain death etiology was nontraumatic (P =.045, P =.033, respectively). Rejection rate was similar in all groups (P =.497). In conclusion, donor traumatic brain death was found to be a valid risk factor for recipient mortality after heart transplantation. Caution should be used when evaluating such donors, particularly in the presence of other risk factors.	[Cohen, O.; De La Zerda, D. J.; Beygui, R.; Hekmat, D.; Laks, H.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiac Surg, Los Angeles, CA 90095 USA	Cohen, O (corresponding author), Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiac Surg, Box 951741,62-182 CHS, Los Angeles, CA 90095 USA.	oved.cohen@gmail.com	cohen, oved/AAI-7068-2020				Anyanwu AC, 2003, J HEART LUNG TRANSPL, V22, P281, DOI 10.1016/S1053-2498(02)00490-4; Baroldi G, 1997, J HEART LUNG TRANSPL, V16, P994; Billingham M, 2005, J HEART LUNG TRANSPL, V24, P1709, DOI 10.1016/j.healun.2005.03.018; Billingham M E, 1990, J Heart Transplant, V9, P587; Birks EJ, 2000, TRANSPLANTATION, V70, P1498, DOI 10.1097/00007890-200011270-00018; BUSSON M, 1995, TRANSPLANT P, V27, P1662; Ciccone AM, 2002, J THORAC CARDIOV SUR, V123, P429, DOI 10.1067/mtc.2002.120732; Goel Radha, 2005, Congest Heart Fail, V11, P99; Marelli D, 2002, ANN THORAC SURG, V74, P1558, DOI 10.1016/S0003-4975(02)03933-4; MARELLI D, 2000, CLIN TRANSPL, V10, P297; McCarthy JF, 1998, ANN THORAC SURG, V65, P1574, DOI 10.1016/S0003-4975(98)00138-6; Mehra MR, 2004, J AM COLL CARDIOL, V43, P806, DOI 10.1016/j.jacc.2003.08.059; NOVITZKY D, 1988, TRANSPLANTATION, V45, P964, DOI 10.1097/00007890-198805000-00025; Plenz G, 2002, J AM COLL CARDIOL, V39, P1508, DOI 10.1016/S0735-1097(02)01791-6; POWNER DJ, 1992, J HEART LUNG TRANSPL, V11, P1046; Pratschke J, 1999, TRANSPLANTATION, V67, P343, DOI 10.1097/00007890-199902150-00001; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Takada M, 1998, TRANSPLANTATION, V65, P1533, DOI 10.1097/00007890-199806270-00001; Taylor DO, 2003, J HEART LUNG TRANSPL, V22, P616, DOI 10.1016/S1053-2498(03)00186-4; Tsai FC, 2002, J HEART LUNG TRANSPL, V21, P623, DOI 10.1016/S1053-2498(01)00425-9; VANLOON J, 1993, J NEUROSURG, V79, P705, DOI 10.3171/jns.1993.79.5.0705; WAHLERS T, 1991, J HEART LUNG TRANSPL, V10, P22; Wilhelm MJ, 2000, J HEART LUNG TRANSPL, V19, P414, DOI 10.1016/S1053-2498(00)00073-5; Wilhelm MJ, 2000, CIRCULATION, V102, P2426, DOI 10.1161/01.CIR.102.19.2426	24	23	24	0	0	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0041-1345	1873-2623		TRANSPL P	Transplant. Proc.	DEC	2007	39	10					2964	2969		10.1016/j.transproceed.2007.08.102			6	Immunology; Surgery; Transplantation	Immunology; Surgery; Transplantation	246WG	WOS:000252037900004	18089301				2021-06-18	
J	Smits, M; Hunink, MGM; Nederkoorn, PJ; Dekker, HM; Vos, PE; Kool, DR; Hofman, PAM; Twijnstra, A; de Haan, GG; Tanghe, HLJ; Dippel, DWJ				Smits, M.; Hunink, M. G. M.; Nederkoorn, P. J.; Dekker, H. M.; Vos, P. E.; Kool, D. R.; Hofman, P. A. M.; Twijnstra, A.; de Haan, G. G.; Tanghe, H. L. J.; Dippel, D. W. J.			A history of loss of consciousness or post-traumatic amnesia in minor head injury: "conditio sine qua non" or one of the risk factors?	JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY			English	Article							TRAUMATIC INTRACRANIAL HEMATOMA; COMPUTED-TOMOGRAPHY; BRAIN INJURY; MILD; MANAGEMENT; METAANALYSIS; ADULTS; RULE; GUIDELINES; DIAGNOSIS	Objective: A history of loss of consciousness (LOC) or post-traumatic amnesia (PTA) is commonly considered a prerequisite for minor head injury (MHI), although neurocranial complications also occur when LOC/PTA are absent, particularly in the presence of other risk factors. The purpose of this study was to evaluate whether known risk factors for complications after MHI in the absence of LOC/PTA have the same predictive value as when LOC/PTA are present. Methods: A prospective multicentre study was performed in four university hospitals between February 2002 and August 2004 of consecutive blunt head injury patients (>= 16 years) presenting with a normal level of consciousness and a risk factor. Outcome measures were any neurocranial traumatic CT finding and neurosurgical intervention. Common odds ratios (OR) were estimated for each of the risk factors and tested for homogeneity. Results: 2462 patients were included: 1708 with and 754 without LOC/PTA. Neurocranial traumatic findings on CT were present in 7.5% and were more common when LOC/PTA was present (8.7%). Neurosurgical intervention was required in 0.4%, irrespective of the presence of LOC/PTA. ORs were comparable across the two subgroups (p>0.05), except for clinical evidence of a skull fracture, with high ORs both when LOC/PTA was present (OR = 37, 95% CI 17 to 80) or absent (OR = 6.9, 95% CI 1.8 to 27). LOC and PTA had significant ORs of 1.9 (95% CI 1.0 to 2.7) and 1.7 (95% CI 1.3 to 2.3), respectively. Conclusion: Known risk factors have comparable ORs in MHI patients with or without LOC or PTA. MHI patients without LOC or PTA need to be explicitly considered in clinical guidelines.	[Smits, M.; Tanghe, H. L. J.] Erasmus Univ, Med Ctr, Dept Radiol, Rotterdam, Netherlands; [Hunink, M. G. M.] Erasmus Univ, Med Ctr, Dept Radiol, Dept Epidemiol & Biostat, Rotterdam, Netherlands; [de Haan, G. G.] Erasmus Univ, Med Ctr, Dept Med Informat, Rotterdam, Netherlands; [Dippel, D. W. J.] Erasmus Univ, Med Ctr, Dept Neurol, Rotterdam, Netherlands; [Dekker, H. M.] Univ Med Ctr Nijmegen St Radboud, Dept Radiol, Nijmegen, Netherlands; [Vos, P. E.] Univ Med Ctr Nijmegen St Radboud, Dept Neurol, Nijmegen, Netherlands; [Kool, D. R.] Acad Med Ctr, Dept Radiol, Amsterdam, Netherlands; [Nederkoorn, P. J.] Acad Med Ctr, Dept Neurol, Amsterdam, Netherlands; [Hofman, P. A. M.] Univ Hosp Maastricht, Dept Radiol, Maastricht, Netherlands; [Twijnstra, A.] Univ Hosp Maastricht, Dept Neurol, Maastricht, Netherlands	Hunink, MGM (corresponding author), Erasmus Univ, Med Ctr, Dept Epidemiol, Dept Radiol, Rotterdam, Netherlands.	m.hunink@erasmusmc.nl	Dippel, Diederik/AAJ-2192-2020; Vos, Pieter/A-6043-2012; Dekker, H.M./L-4262-2015; Smits, Marion/E-4795-2011; Smits, Marion/AAB-3985-2019	Dippel, Diederik/0000-0002-9234-3515; Smits, Marion/0000-0001-5563-2871			ALTMAN DG, 1999, PRACTICAL STAT MED R, P268; Batchelor J, 2002, EMERG MED J, V19, P515, DOI 10.1136/emj.19.6.515; BORCZUK P, 1995, ANN EMERG MED, V25, P731, DOI 10.1016/S0196-0644(95)70199-0; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; de Kruijk JR, 2001, BRAIN INJURY, V15, P117, DOI 10.1080/026990501458353; Dunham CM, 1996, J TRAUMA, V41, P679, DOI 10.1097/00005373-199610000-00014; Dunning J, 2004, J NEUROTRAUM, V21, P877, DOI 10.1089/0897715041526122; Fabbri A, 2005, J NEUROTRAUM, V22, P1419, DOI 10.1089/neu.2005.22.1419; Geijerstam JLA, 2003, ACTA NEUROCHIR, V145, P843, DOI 10.1007/s00701-003-0115-1; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Hofman PAM, 2000, J NEUROL NEUROSUR PS, V68, P416, DOI 10.1136/jnnp.68.4.416; HOSMER DW, 1989, APPL LOGISTIC REGRES, P74; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Hunink MGM, 2005, RADIOLOGY, V235, P375, DOI 10.1148/radiol.2352040727; Ibanez J, 2004, J NEUROSURG, V100, P825, DOI 10.3171/jns.2004.100.5.0825; Ingebrigtsen T, 2000, J TRAUMA, V48, P760, DOI 10.1097/00005373-200004000-00029; Kay A, 2001, WORLD J SURG, V25, P1210, DOI 10.1007/s00268-001-0084-6; KLAUBER MR, 1989, NEUROSURGERY, V24, P31, DOI 10.1227/00006123-198901000-00005; KLINE R, 1998, METHODOLOGY SOCIAL S, P74; Miller Erik C., 1997, Journal of Emergency Medicine, V15, P453, DOI 10.1016/S0736-4679(97)00071-1; MILLER JD, 1990, NEUROSURGERY, V27, P669, DOI 10.1227/00006123-199011000-00001; NICE, HEAD INJ TRIAG ASS I; Servadei F, 2001, J NEUROTRAUM, V18, P657, DOI 10.1089/089771501750357609; SHACKFORD SR, 1992, J TRAUMA, V33, P385, DOI 10.1097/00005373-199209000-00009; *SIGN, EARL MAN PAT HEAD IN; SMITS M, 2007, RADIOLOGY; Smits M, 2007, ANN INTERN MED, V146, P397, DOI 10.7326/0003-4819-146-6-200703200-00004; Sonis J, 1998, Fam Med, V30, P584; STEIN SC, 1992, J TRAUMA, V33, P11, DOI 10.1097/00005373-199207000-00003; Stiell IG, 2001, ANN EMERG MED, V38, P317, DOI 10.1067/mem.2001.116795; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; TEASDALE GM, 1990, BRIT MED J, V300, P363, DOI 10.1136/bmj.300.6721.363; TWIJNSTRA A, GUIDELINES DIAGNOSIS; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x	36	23	25	0	2	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0022-3050	1468-330X		J NEUROL NEUROSUR PS	J. Neurol. Neurosurg. Psychiatry	DEC	2007	78	12					1359	1364		10.1136/jnnp.2007.117143			6	Clinical Neurology; Psychiatry; Surgery	Neurosciences & Neurology; Psychiatry; Surgery	240CD	WOS:000251563700016	17470468	Green Published			2021-06-18	
J	Dean, NP; Boslaugh, S; Adelson, D; Pineda, JA; Leonard, JR				Dean, Nathan P.; Boslaugh, Susan; Adelson, David; Pineda, Jose A.; Leonard, Jeffrey R.			Physician agreement with evidence-based recommendations for the treatment of severe traumatic brain injury in children	JOURNAL OF NEUROSURGERY			English	Article						guideline; intracranial hypertension; pediatric neurosurgery; survey; traumatic brain injury	INTRACRANIAL-PRESSURE; CARE	Object. The aim of this study was to evaluate physician agreement with published recommendations and guidelines for the management of severe traumatic brain injury (TBI) in children and to identify markers associated with physician responses matching published guidelines. Methods. An Internet survey was created based on recommendations and guidelines published in 2003 and was sent to US physicians and neurosurgeons caring for pediatric patients with severe TBI. Agreement with each recommendation was tabulated. Characteristics of the surveyed physicians and their institutions were compared to identify markers of conformity with first-tier recommendations (intracranial pressure [ICP] treatment threshold, monitoring cerebral perfusion pressure, use of sedation/neuromuscular blockade, and use of hyperosmolar therapy). Results. One hundred ninety-four US physicians responded: 36 neurosurgeons and 158 nonsurgeons. Overall, physician responses matched most recommendations more than 60% of the time. The serum osmolality threshold of hypertonic saline., use of prophylactic hyperventilation, and differences in ICP thresholds based on a child's age comprised the recommendations with the least agreement. No physician variable was linked to increased agreement with first-tier recommendations. Conclusions. Overall, physician responses coincided with the published guidelines and recommendations. Examples of variable conformance most likely reflect the paucity of available data and lack of randomized controlled trials in the field of severe TBI.	Washington Univ, Sch Med, Dept Pediat, St Louis, MO 63110 USA; Washington Univ, Sch Med, Dept Neurosurg, St Louis, MO 63110 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA	Dean, NP (corresponding author), Childrens Natl Med Ctr, Div Pediat Crit Care, 111 Michigan Ave NW, Washington, DC 20010 USA.	ndean@cnmc.org	Pineda, Jose/W-2806-2019				Adelson P David, 2003, Pediatr Crit Care Med, V4, pS2, DOI 10.1097/01.CCM.0000066600.71233.01; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS25; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS40; Diringer MN, 2004, NEUROCRIT CARE, V1, P219, DOI 10.1385/NCC:1:2:219; Dominguez TE, 2004, CRIT CARE MED, V32, P1438, DOI 10.1097/01.CCM.0000124860.91886.C2; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Hesdorffer DC, 2002, J TRAUMA, V52, P1202, DOI 10.1097/00005373-200206000-00031; Jankowitz BT, 2006, DEV NEUROSCI-BASEL, V28, P264, DOI 10.1159/000094153; Keenan Heather T, 2005, Pediatr Crit Care Med, V6, P537, DOI 10.1097/01.PCC.0000164638.44600.67; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kornecki A, 2002, CHILD NERV SYST, V18, P375, DOI 10.1007/s00381-002-0613-0; Langlois JA, 2006, TRAUMATIC BRAIN INJU; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; Segal S, 2001, INTENS CARE MED, V27, P236, DOI 10.1007/s001340000717	14	23	23	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085			J NEUROSURG	J. Neurosurg.	NOV	2007	107	5		S			387	391		10.3171/PED-07/11/387			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	233GT	WOS:000251079200005	18459901				2021-06-18	
J	Henninger, N; Sicard, KM; Li, ZX; Kulkarni, P; Dutzmann, S; Urbanek, C; Schwab, S; Fisher, M				Henninger, Nils; Sicard, Kenneth M.; Li, Zhixin; Kulkarni, Praveen; Duetzmann, Stephan; Urbanek, Christian; Schwab, Stefan; Fisher, Marc			Differential recovery of behavioral status and brain function assessed with functional magnetic resonance imaging after mild traumatic brain injury in the rat	CRITICAL CARE MEDICINE			English	Article						apparent diffusion coefficient; cerebral concussion; diffusion weighted imaging; functional magnetic resonance imaging; perfusion weighted imaging; pixel-by-pixel analysis	CEREBRAL-BLOOD-FLOW; APPARENT DIFFUSION-COEFFICIENT; CONTROLLED CORTICAL IMPACT; WATER DIFFUSION; WALLERIAN DEGENERATION; IN-VIVO; PERFUSION; MRI; METABOLISM; TISSUE	Objective: The relationship between cerebral integrity, recovery of brain function, and neurologic status after mild traumatic brain injury is incompletely characterized. Design. Prospective and randomized study in rodents. Setting: University laboratory. Subjects: Male Wistar rats (290-310 g). Interventions: In rats, quantitative diffusion weighted imaging (DWI), perfusion weighted imaging (PWI), T2-weighted imaging (T2WI), and functional magnetic resonance imaging (fMRI) were performed up to 21 days after weight-induced, closed-head, mild traumatic brain injury (MTBI, n = 6) or sham operation (n = 6). Pixel-by-pixel analysis and region of interest analysis were used to evaluate structural (apparent diffusion coefficient [ADC] and basal cerebral blood flow [bCBF]) and functional magnetic resonance signal changes within the brain, respectively. Quantitative fMRI signal changes were correlated with behavioral measures. Measurements and Main Results. Despite normal appearing DWI and T2WI findings following MTBI, persistent hypoperfusion developed that was not associated with cytotoxic edema. In contrast, the ADC was significantly increased by -5% at 1 and 7 days post-MTBI. Post-MTBI fMRI responses to hypercapnia and forepaw stimulation were significantly impaired and showed a differential recovery rate between and within investigated region of interests. Significant dysfunction in forepaw placement test persisted up to day I and correlated significantly with fMRI signal changes in the primary somatosensory and motor cortices. Conclusions. MTBI produced distinct changes on multimodal MRI and behavioral variables acutely and chronically. Following MTBI, fMRI and ADC-bCBF pixel-by-pixel analysis identified subtle structural and functional alterations in the brain that appeared completely normal on conventional DWI and T2WI after concussion injury. The former techniques may therefore provide great potential for understanding mild traumatic brain injury, identifying mechanisms underlying recovery, and investigating specific interventions to enhance functional outcome.	Univ Massachusetts, Sch Med, Dept Internal Med, Worcester, MA 01605 USA; Med Coll Wisconsin, Dept Biol, Milwaukee, WI 53226 USA; Ctr Comparat Neurolmaging, Dept Psychiat, Worcester, MA USA; Goethe Univ Frankfurt, Dept Neurosurg, D-6000 Frankfurt, Germany; Klinikum Stadt Ludwigshafen, Dept Neurol, Ludwigshafen, Germany; Univ Erlangen Nurnberg, Dept Neurol, Erlangen, Germany	Henninger, N (corresponding author), Univ Massachusetts, Sch Med, Dept Internal Med, Worcester, MA 01605 USA.	henningn@ummhc.org		Henninger, Nils/0000-0002-3883-5623; Kulkarni, Praveen/0000-0002-8876-4544			Adams A, 2001, BCS CONF SERIES, P49; Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Barzo P, 1997, J NEUROSURG, V87, P900, DOI 10.3171/jns.1997.87.6.0900; Beaulieu C, 1996, MAGNET RESON MED, V36, P627, DOI 10.1002/mrm.1910360419; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bennett SAL, 1998, NEUROREPORT, V9, P161; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Chen SF, 2004, J CEREBR BLOOD F MET, V24, P1025, DOI 10.1097/01.WCB.0000129415.34520.47; CRUZ J, 1995, CRIT CARE MED, V23, P1412, DOI 10.1097/00003246-199508000-00016; DERYCK M, 1992, BRAIN RES, V573, P44; Dewitt DS, 2003, J NEUROTRAUM, V20, P795, DOI 10.1089/089771503322385755; Duhaime AC, 2006, J NEUROSURG, V104, P259, DOI 10.3171/ped.2006.104.4.259; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Goetz P, 2004, J NEUROTRAUM, V21, P645, DOI 10.1089/0897715041269731; Hakumaki JM, 1998, CANCER RES, V58, P3791; HANSTOCK CC, 1994, STROKE, V25, P843, DOI 10.1161/01.STR.25.4.843; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Henninger N, 2005, EXP NEUROL, V195, P447, DOI 10.1016/j.expneurol.2005.06.013; HENNINGER N, 2007, J CEREB BLOOD FLOW M; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hughes DG, 2004, NEURORADIOLOGY, V46, P550, DOI 10.1007/s00234-004-1227-x; Iverson GL, 2005, CURR OPIN PSYCHIATR, V18, P301, DOI 10.1097/01.yco.0000165601.29047.ae; Jantzen KJ, 2004, AM J NEURORADIOL, V25, P738; Kurca E, 2006, NEURORADIOLOGY, V48, P661, DOI 10.1007/s00234-006-0109-9; Liu ZHM, 2004, MAGN RESON MED, V52, P277, DOI 10.1002/mrm.20148; Londono A, 2003, AM J NEURORADIOL, V24, P1582; McAllister TW, 2001, NEUROIMAGE, V14, P1004, DOI 10.1006/nimg.2001.0899; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; Nakashima T, 2007, AM J NEURORADIOL, V28, P236; NEDD K, 1993, BRAIN INJURY, V7, P469, DOI 10.3109/02699059309008174; Pierpaoli C, 2001, NEUROIMAGE, V13, P1174, DOI 10.1006/nimg.2001.0765; Shen Q, 2004, J CEREBR BLOOD F MET, V24, P280, DOI 10.1097/01.WCB.0000110048.43905.E5; Sicard K, 2003, J CEREBR BLOOD F MET, V23, P472, DOI 10.1097/01.WCB.0000054755.93668.20; Sicard KM, 2006, J CEREBR BLOOD F MET, V26, P1451, DOI 10.1038/sj.jcbfm.9600299; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; Valonen PK, 2004, J MAGN RESON IMAGING, V19, P389, DOI 10.1002/jmri.20026; Virley D, 2000, J CEREBR BLOOD F MET, V20, P563, DOI 10.1097/00004647-200003000-00015; ZHANG JQ, 2003, 11 SCI M INT SOC MAG	39	23	25	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	NOV	2007	35	11					2607	2614		10.1097/01.CCM.0000286395.79654.8D			8	Critical Care Medicine	General & Internal Medicine	224CN	WOS:000250423500019	17828037				2021-06-18	
J	Kerner, A; Schlenk, F; Sakowitz, O; Haux, D; Sarrafzadeh, A				Kerner, Antje; Schlenk, Florian; Sakowitz, Oliver; Haux, Daniel; Sarrafzadeh, Asita			Impact of hyperglycemia on neurological deficits and extracellular glucose levels in aneurysmal subarachnoid hemorrhage patients	NEUROLOGICAL RESEARCH			English	Article						glucose; hyperglycemia; cerebral metabolism; microdialysis; subarachnoid hemorrhage	TRAUMATIC BRAIN-INJURY; POOR-GRADE PATIENTS; INTRACEREBRAL MICRODIALYSIS; CEREBRAL MICRODIALYSIS; BEDSIDE MICRODIALYSIS; METABOLISM; VASOSPASM; ISCHEMIA; VALUES; SCALE	Objective: Hyperglycemia after aneurysmal subarachnoid hemorrhage (SAH) is associated with serious complications. Blood glucose may indicate a target for therapy to prevent delayed ischemic neurological deficits (DIND) and improve outcome. The objective of this study was to investigate energy metabolism in the extracellular/cerebrospinal fluid and blood in relation to outcome. Methods: Prospective non-randomized study was carried out in the intensive care unit (ICU) of university hospital (n = 170 aneurysmal SAH patients, age: 51.0 +/- 12.6 years old). Following approval by the ethics committee, a microdialysis catheter was inserted into the vascular territory of the aneurysm after clipping. Patients were studied for 165 +/- 84 hours and classified according to the presence of neurological symptoms as asymptomatic (n = 66) and symptomatic (n = 104): acute focal neurological deficits (AFND, n = 61) and delayed ischemic neurological deficits (DIND, n = 43). The microdialysates were analysed hourly for energy metabolites. Daily morning blood glucose and cerebrospinal fluid (CSF) levels (glucose and lactate) were determined. Six-month Glasgow outcome scale (GOS) was assessed. Results: Hyperglycemia on admission and high blood glucose levels on the following days were significantly related to the presence of symptoms, most pronounced in patients with poor outcome (p<0.05). In symptomatic patients (high blood glucose), the lowest extracellular fluid (ECF) glucose concentrations were found, most pronounced in the AFND group (1.0 +/- 1.2 mmol/l). The anaerobic metabolites lactate, lactate/pyruvate ratio (LPR) and lactate/glucose ratio (LGR) were higher in symptomatic patients (p<0.001) indicating cerebral metabolic distress. CSF concentrations of glucose and lactate were of no specific value. Conclusion: This study confirms the relevance of hyperglycemia to neurological outcome in SAH patients. Cerebral glucose was significantly lower in AFND patients despite hyperglycemic blood levels. More detailed works are necessary to select risk patients for optimized targeted therapy to avoid insulin-induced cerebral metabolic crisis.	Univmed Berlin, Virchow Med Ctr, Dept Neurosurg, Berlin, Germany; Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany	Sarrafzadeh, A (corresponding author), Humboldt Univ, Charite Virchow Med Ctr, Clin Neurosurg, Augustenburger Platz 1, D-13353 Berlin, Germany.	asita.sarrafzadeh@charite.de					Alberti O, 2000, CLIN NEUROL NEUROSUR, V102, P78, DOI 10.1016/S0303-8467(00)00067-6; Badjatia N, 2005, CRIT CARE MED, V33, P1603, DOI 10.1097/01.CCM.0000168054.60538.2B; Bell DA, 2005, BRIT J NEUROSURG, V19, P21, DOI 10.1080/02688690500089423; Claassen J, 2004, CRIT CARE MED, V32, P832, DOI 10.1097/01.CCM.0000114830.48833.8A; Diaz-Parejo P, 2003, INTENS CARE MED, V29, P544, DOI 10.1007/s00134-003-1669-3; DRAKE CG, 1988, J NEUROSURG, V68, P985; Enblad P, 1997, J NEUROL NEUROSUR PS, V62, P512, DOI 10.1136/jnnp.62.5.512; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Frontera JA, 2006, STROKE, V37, P199, DOI 10.1161/01.STR.0000194960.73883.0f; Germanson TP, 1998, SURG NEUROL, V49, P155, DOI 10.1016/S0090-3019(97)00337-6; Hutchinson PJ, 2000, J NEUROSURG, V93, P37, DOI 10.3171/jns.2000.93.1.0037; Hutchinson PJ, 2005, PHYSIOL MEAS, V26, P423, DOI 10.1088/0967-3334/26/4/008; Hutchinson PJA, 2000, ACT NEUR S, V76, P431; JENNETT B, 1975, LANCET, V1, P480; Juvela S, 2005, J NEUROSURG, V102, P998, DOI 10.3171/jns.2005.102.6.0998; LANZINO G, 1993, J NEUROSURG, V79, P885, DOI 10.3171/jns.1993.79.6.0885; Mees SMD, 2003, NEUROLOGY, V61, P1132, DOI 10.1212/01.WNL.0000090466.68866.02; Mocco J, 2006, NEUROSURGERY, V59, P529, DOI 10.1227/01.NEU.0000228680.22550.A2; Nilsson OG, 1999, NEUROSURGERY, V45, P1176, DOI 10.1097/00006123-199911000-00032; Reinstrup P, 2000, NEUROSURGERY, V47, P701, DOI 10.1097/00006123-200009000-00035; Sarrafzadeh A, 2004, J NEUROSURG, V100, P400, DOI 10.3171/jns.2004.100.3.0400; Sarrafzadeh AS, 2003, BRIT J NEUROSURG, V17, P340, DOI 10.1080/02688690310001601234; Sarrafzadeh AS, 2002, CRIT CARE MED, V30, P1062, DOI 10.1097/00003246-200205000-00018; Sato M, 2006, ACTA NEUROCHIR, V148, P623, DOI 10.1007/s00701-005-0717-x; Unterberg AW, 2001, J NEUROSURG, V94, P740, DOI 10.3171/jns.2001.94.5.0740; Valadka AB, 1998, J NEUROTRAUM, V15, P509, DOI 10.1089/neu.1998.15.509; Vespa P, 2006, CRIT CARE MED, V34, P850, DOI 10.1097/01.CCM.0000201875.12245.6F; Vespa P, 2005, J CEREBR BLOOD F MET, V25, P763, DOI 10.1038/sj.jcbfm.9600073; Vespa PM, 2003, J CEREBR BLOOD F MET, V23, P865, DOI 10.1097/01.WCB.0000076701.45782.EF	29	23	25	0	1	MANEY PUBLISHING	LEEDS	STE 1C, JOSEPHS WELL, HANOVER WALK, LEEDS LS3 1AB, W YORKS, ENGLAND	0161-6412			NEUROL RES	Neurol. Res.	OCT	2007	29	7					647	653		10.1179/016164107X248983			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	234MJ	WOS:000251167900003	18173901				2021-06-18	
J	Blizzard, CA; Haas, MA; Vickers, JC; Dickson, TC				Blizzard, C. A.; Haas, M. A.; Vickers, J. C.; Dickson, T. C.			Cellular dynamics underlying regeneration of damaged axons differs from initial axon development	EUROPEAN JOURNAL OF NEUROSCIENCE			English	Article						brain injury; cytoskeleton; growth cone; growth factor; live-cell imaging	GROWTH CONE MOTILITY; SPINAL-CORD-INJURY; ALZHEIMERS-DISEASE; CORTICAL-NEURONS; IN-VITRO; NEUROTROPHIC FACTOR; TRAUMATIC BRAIN; CEREBRAL-CORTEX; GUIDANCE; CYTOSKELETAL	While long-distance regeneration may be limited in mammalian species, it is becoming apparent that damaged mature neurons retain some capacity for attempted regeneration and that the adult CNS is not entirely inhibitory to axon growth. Our investigations show that there are critical intrinsic features of postinjury axonal regeneration that differ from initial axon development, and that these distinct differences may account for the limited and inappropriate regenerative response that currently characterizes the mature CNS. We compared the neurochemical and dynamic characteristics of developing axons to relatively mature regenerating axons, utilizing an in vitro model of axonal transection to long-term cultured rat cortical neurons. Immunolabelling studies revealed that regenerating and developing axons have a similar localization of cytoskeletal proteins, but the tips of regenerating axons, although morphologically similar, were smaller with reduced fillopodial extension, relative to developmental growth cones. Live imaging demonstrated that regenerating axons exhibited significantly less outgrowth than developmental neurites. Furthermore, growth cones of regenerating axons had a significant reduction in pausing, considered vital for interstitial branching and pathfinding, than did developmental growth cones. In addition, unlike developing axons, the regenerating axons were unresponsive to the growth factors BDNF and GDNF. Thus, although similar in their cytoskeletal composition, the growth cones of regenerative sprouts differed from their developmental counterparts in their size, their dynamic behaviour and their ability to respond to critical growth factors. These intrinsic differences may account for the inability of post-traumatic locally sprouting axons to make accurate pathway decisions and successfully respond to trauma.	Univ Tasmania, Menzies Res Inst, Neuro Repair Grp, Hobart, Tas 7001, Australia	Dickson, TC (corresponding author), Univ Tasmania, Menzies Res Inst, Neuro Repair Grp, Private Bag 29, Hobart, Tas 7001, Australia.	Tracey.Dickson@utas.edu.au	Vickers, James C/J-7464-2014	Vickers, James C/0000-0001-5671-4879; Blizzard, Catherine/0000-0002-8683-2937; Dickson, Tracey/0000-0002-9196-1661; Haas, Matilda/0000-0002-5149-0471			Airaksinen MS, 2002, NAT REV NEUROSCI, V3, P383, DOI 10.1038/nrn812; Bakshi A, 2006, EUR J NEUROSCI, V23, P2119, DOI 10.1111/j.1460-9568.2006.04743.x; Bareyre FM, 2004, NAT NEUROSCI, V7, P269, DOI 10.1038/nn1195; Barnabe-Heider F, 2003, J NEUROSCI, V23, P5149; Blackmore M, 2006, J NEUROBIOL, V66, P348, DOI 10.1002/neu.20224; Brandt R, 1998, CELL TISSUE RES, V292, P181, DOI 10.1007/s004410051049; Cai DM, 1999, NEURON, V22, P89, DOI 10.1016/S0896-6273(00)80681-9; Carmichael ST, 2003, CURR OPIN NEUROL, V16, P699, DOI 10.1097/00019052-200312000-00009; Chuckowree JA, 2004, NEUROSCIENTIST, V10, P280, DOI 10.1177/1073858404263511; Chuckowree JA, 2003, J NEUROSCI, V23, P3715; Dent EW, 2003, NEUROSCIENTIST, V9, P343, DOI 10.1177/1073858403252683; Dent EW, 2003, NEURON, V40, P209, DOI 10.1016/S0896-6273(03)00633-0; Dickson TC, 1999, EXP NEUROL, V156, P100, DOI 10.1006/exnr.1998.7010; Dickson TC, 2000, J NEUROTRAUM, V17, P1095, DOI 10.1089/neu.2000.17.1095; Dickson TC, 2005, NEUROBIOL DIS, V18, P286, DOI 10.1016/j.nbd.2004.10.001; Dickson TC, 2007, NEUROREPORT, V18, P283, DOI 10.1097/WNR.0b013e3280143cdb; Fawcett JW, 2006, J NEUROTRAUM, V23, P371, DOI 10.1089/neu.2006.23.371; Goldberg JL, 2002, SCIENCE, V296, P1860, DOI 10.1126/science.1068428; Gomes RA, 2006, J NEUROSCI, V26, P11487, DOI 10.1523/JNEUROSCI.2364-06.2006; Gordon-Weeks PR, 2004, J NEUROBIOL, V58, P70, DOI 10.1002/neu.10266; Haas MA, 2004, EUR J NEUROSCI, V20, P1436, DOI 10.1111/j.1460-9568.2004.03620.x; Hafidi A, 2004, J COMP NEUROL, V470, P80, DOI 10.1002/cne.20003; HALLORAN MC, 1994, J NEUROSCI, V14, P2161; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Hortsch M, 1996, NEURON, V17, P587, DOI 10.1016/S0896-6273(00)80192-0; Jones SL, 2006, J NEUROBIOL, V66, P1630, DOI 10.1002/neu.20309; Kalil K, 2000, J NEUROBIOL, V44, P145, DOI 10.1002/1097-4695(200008)44:2<145::AID-NEU5>3.3.CO;2-O; Kalil K, 1996, PROG BRAIN RES, V108, P31, DOI 10.1016/S0079-6123(08)62530-3; King CE, 1997, NEUROREPORT, V8, P1663; King CE, 2001, NEUROPATH APPL NEURO, V27, P115, DOI 10.1046/j.1365-2990.2001.00317.x; KORSCHING S, 1993, J NEUROSCI, V13, P2739; LI D, 1995, EUR J NEUROSCI, V7, P1164, DOI 10.1111/j.1460-9568.1995.tb01106.x; LURIE DI, 1994, J COMP NEUROL, V344, P559, DOI 10.1002/cne.903440406; Mason CA, 1997, J NEUROSCI, V17, P1086; McKinney RA, 1997, NAT MED, V3, P990, DOI 10.1038/nm0997-990; Niwa H, 2002, NEUROCHEM RES, V27, P485, DOI 10.1023/A:1019896502774; Salin P, 1995, J NEUROSCI, V15, P8234; Skaliora I, 2000, J NEUROSCI, V20, P3650; Suter DM, 2000, J NEUROBIOL, V44, P97, DOI 10.1002/1097-4695(200008)44:2<97::AID-NEU2>3.3.CO;2-L; Swanwick CC, 2004, J COMP NEUROL, V478, P405, DOI 10.1002/cne.20295; Szebenyi G, 1998, J NEUROSCI, V18, P7930; TessierLavigne M, 1996, SCIENCE, V274, P1123, DOI 10.1126/science.274.5290.1123; Tucker KL, 2001, NAT NEUROSCI, V4, P29; Vickers JC, 2000, PROG NEUROBIOL, V60, P139, DOI 10.1016/S0301-0082(99)00023-4; Woodhouse A, 2005, NEUROTOX RES, V7, P5, DOI 10.1007/BF03033772; Yiu G, 2006, NAT REV NEUROSCI, V7, P617, DOI 10.1038/nrn1956; Zhang GX, 2005, NEUROREHAB NEURAL RE, V19, P46, DOI 10.1177/1545968305274577; Zhou FQ, 2004, J NEUROBIOL, V58, P84, DOI 10.1002/neu.10278; Zhou LJ, 2003, J NEUROSCI RES, V74, P221, DOI 10.1002/jnr.10718	49	23	23	0	6	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0953-816X	1460-9568		EUR J NEUROSCI	Eur. J. Neurosci.	SEP	2007	26	5					1100	1108		10.1111/j.1460-9568.2007.05750.x			9	Neurosciences	Neurosciences & Neurology	205QT	WOS:000249130400003	17767489				2021-06-18	
J	Jokel, R; De Nil, L; Sharpe, K				Jokel, Regina; De Nil, Luc; Sharpe, Katie			Speech disfluencies in adults with neurogenic stuttering associated with stroke and traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							RIGHT-HEMISPHERE LESION; INFARCTION; BEHAVIOR; FLUENCY; DISEASE; SYMPTOM; DAMAGE	This study is part of a larger project aimed at exploring the speech, language, cognitive, psychosocial, and medical characteristics of adult neurogenic stuttering. In the present article, speech disfluency patterns in adults with neurogenic stuttering in two diagnostic groups, traumatic brain injury and stroke, were compared. The results revealed that people with neurogenic stuttering do not present as a homogeneous group but that they may present with different speech disfluency characteristics, as well as etiology-dependent self-perceptions. It is anticipated that the observations in the present article ultimately will lead to a greater understanding of the neural mechanisms underlying speech fluency and will result in more effective diagnostic and interventional approaches.	Univ Toronto, Dept Speech Language Pathol, Bayrest Ctr Geriatr Care, Toronto, ON M5G 1V7, Canada; Univ Toronto, Dept Speech Language Pathol, Toronto Western Res Inst, Sick Kids Res Inst, Toronto, ON, Canada; Catholic Univ Louvain, B-3000 Louvain, Belgium	Jokel, R (corresponding author), Univ Toronto, Dept Speech Language Pathol, Bayrest Ctr Geriatr Care, Rehabil Sci Bldg,Univ Ave,Room 160, Toronto, ON M5G 1V7, Canada.	r.jokel@utoronto.ca					ABE K, 1993, J NEUROL NEUROSUR PS, V56, P1024, DOI 10.1136/jnnp.56.9.1024; Ackerman H, 1996, APHASIOLOGY, V10, P409, DOI 10.1080/02687039608248420; ANDREWS G, 1974, J SPEECH HEAR DISORD, V39, P312, DOI 10.1044/jshd.3903.312; ARDILA A, 1986, BRAIN LANG, V27, P239, DOI 10.1016/0093-934X(86)90018-0; Ardila A, 1999, NEUROCASE, V5, P435; BIJLEVELD H, 1994, FOLIA PHONIATR LOGO, V46, P250, DOI 10.1159/000266323; BLOODSTEIN O, 1995, HDB SHUTTERING; BLOOM CM, 1973, J SPEECH HEAR RES, V16, P518, DOI 10.1044/jshr.1603.518; Boberg E., 1985, COMPREHENSIVE STUTTE; BRUTTEN GJ, 1980, P 18 C INT ASS LOG P; CANTER GJ, 1971, BRIT J DISORD COMMUN, V6, P139; Carluer L, 2000, MOVEMENT DISORD, V15, P343, DOI 10.1002/1531-8257(200003)15:2<343::AID-MDS1026>3.0.CO;2-I; Ciabarra AM, 2000, J NEUROL NEUROSUR PS, V69, P546, DOI 10.1136/jnnp.69.4.546; COMMODORE RW, 1978, J FLUENCY DISORD, V3, P1, DOI 10.1016/0094-730X(78)90002-5; CRAIG AR, 1984, BRIT J MED PSYCHOL, V57, P173, DOI 10.1111/j.2044-8341.1984.tb01597.x; DALE P, 1977, J FLUENCY DISORD, V2, P311, DOI 10.1016/0094-730X(77)90036-5; Fabbro F, 1999, NEUROLINGUISTICS BIL; Fairbanks G, 1954, J SPEECH HEAR DISORD, V19, P133, DOI 10.1044/jshd.1902.133; FLEET WS, 1985, NEUROLOGY, V35, P1343, DOI 10.1212/WNL.35.9.1343; FOLSTEIN M, 1975, J PSYCHIAT RES, V12, P187; GRANDIN CB, 1998, NEUROIMAGE, V7, pS159; Grant AC, 1999, ARCH NEUROL-CHICAGO, V56, P624, DOI 10.1001/archneur.56.5.624; Hagiwara H, 2000, Rinsho Shinkeigaku, V40, P605; Hall N. E., 2004, THEORY RES THERAPY F, P363; Helm-Estabrooks N., 1993, STUTTERING RELATED D, P205; Helm-Estabrooks Nancy, 1998, Seminars in Speech and Language, V19, P23, DOI 10.1055/s-2008-1064032; HELMESTABROOKS N, 1986, NEUROLOGY, V36, P1109, DOI 10.1212/WNL.36.8.1109; HORNER J, 1983, BRAIN LANG, V18, P71, DOI 10.1016/0093-934X(83)90007-X; Howell P, 1999, J SPEECH LANG HEAR R, V42, P345, DOI 10.1044/jslhr.4202.345; Jankelowitz DL, 1996, J COMMUN DISORD, V29, P223, DOI 10.1016/0021-9924(95)00050-X; Kim KHS, 1997, NATURE, V388, P171, DOI 10.1038/40623; KNOPMAN DS, 1983, NEUROLOGY, V33, P1170, DOI 10.1212/WNL.33.9.1170; LEBRUN Y, 1983, J FLUENCY DISORD, V8, P161, DOI 10.1016/0094-730X(83)90029-3; LEBRUN Y, 1985, J FLUENCY DISORD, V10, P137, DOI 10.1016/0094-730X(85)90021-X; LEBRUN Y, 1987, ACTA NEUROCHIR, V85, P103, DOI 10.1007/BF01456105; LEBRUN Y, 1983, J FLUENCY DISORD, V8, P323, DOI 10.1016/0094-730X(83)90012-8; LEBRUN Y, 1990, J FLUENCY DISORD, V15, P251, DOI 10.1016/0094-730X(90)90040-Y; LUDLOW CL, 1987, ANN NEUROL, V22, P60, DOI 10.1002/ana.410220114; MANNING WH, 2001, CLIN DECISION MAKING; MARAIST JA, 1957, J SPEECH HEAR DISORD, V22, P385, DOI 10.1044/jshd.2203.385; MARKET KE, 1990, J FLUENCY DISORD, V15, P21, DOI 10.1016/0094-730X(90)90029-R; MAZZUCCHI GM, 1981, BRIT J DISORDERS COM, V16, P19; NASS R, 1994, DEV MED CHILD NEUROL, V36, P73; NWOKAH EE, 1988, J FLUENCY DISORD, V13, P357, DOI 10.1016/0094-730X(88)90004-6; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Pillai JJ, 2003, NEUROIMAGE, V19, P565, DOI 10.1016/S1053-8119(03)00151-4; Riley GD, 1994, STUTTERING SEVERITY; Ringo C. C., 1995, J MED SPEECH-LANG PA, V3, P111; ROSENBEK J, 1978, BRAIN LANG, V6, P82, DOI 10.1016/0093-934X(78)90046-9; Stewart T, 1996, EUR J DISORDER COMM, V31, P1; Thacker RC, 1996, J FLUENCY DISORD, V21, P227, DOI 10.1016/S0094-730X(96)00025-3; Tsumoto T, 1999, NEUROL SURG TOKYO, V27, P79; Van Borsel J, 1998, J FLUENCY DISORD, V23, P49, DOI 10.1016/S0094-730X(98)00002-3; Van Borsel J, 2001, J COMMUN DISORD, V34, P385, DOI 10.1016/S0021-9924(01)00057-0; Van Riper C, 1955, STUTTERING CHILDREN, P199; WILSON M, 1988, BEHAV RES METH INSTR, V20, P6, DOI 10.3758/BF03202594; WINGATE ME, 1964, J SPEECH HEAR DISORD, V29, P484, DOI 10.1044/jshd.2904.484; Yaruss JS, 1998, AM J SPEECH-LANG PAT, V7, P25, DOI 10.1044/1058-0360.0702.25	58	23	23	0	12	DELMAR LEARNING	CLIFTON PARK	EXECUTIVE WOODS, 5 MAXWELL DR, CLIFTON PARK, NY 12065 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	2007	15	3					243	261					19	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	211FH	WOS:000249509200007					2021-06-18	
J	Gross, J; Machulik, A; Amarjargal, N; Moller, R; Ungethum, U; Kuban, RJ; Fuchs, FU; Andreeva, N; Fuchs, J; Henke, W; Pohl, EE; Szczepek, AJ; Haupt, H; Mazurek, B				Gross, Johann; Machulik, Astrid; Amarjargal, Nyamaa; Moller, Renate; Ungethuem, Ute; Kuban, Ralf-Juergen; Fuchs, Frank-Uwe; Andreeva, Nadezhda; Fuchs, Julia; Henke, Wolfgang; Pohl, Elena E.; Szczepek, Agnieszka J.; Haupt, Heidemarie; Mazurek, Birgit			Expression of apoptosis-related genes in the organ of Corti, modiolus and stria vascularis of newborn rats	BRAIN RESEARCH			English	Article						apoptosis; cochlea; culture; gene expression; microarray; rat	TRAUMATIC BRAIN-INJURY; EXTRACELLULAR-SUPEROXIDE DISMUTASE; CELL-DEATH; BCL-2 FAMILY; OXIDATIVE STRESS; MESSENGER-RNA; HEARING-LOSS; AUDITORY NEURONS; CASPASE ACTIVITY; SPIRAL GANGLION	Cell death in the inner ear tissues is an important mechanism leading to hearing impairment. Here, using microarrays and real-time RT-PCR we analyzed expression of selected apoptosis -related genes in rat's inner ear. We determined the gene expression in tissues freshly isolated from neonatal rats (3-5 days old) and compared it to that of explants cultured for 24 h under normoxic or hypoxic conditions. For the analyses, we used pooled samples of the organ of Corti (OC), modiolus (MOD) and stria. vascularis (SV), respectively. We observed region-specific changes in gene expression between the fresh tissues and the normoxic culture. In the OC, expression of the proapoptotic genes caspase-2, caspase-3, caspase-6 and calpain-1 was downregulated. In the MOD, the antioxidative defense SOD-2 and SOD-3 were upregulated. In the SV, caspase-2, caspase-6, calpain-1 and SOD-3 were downregulated and SOD-2 upregulated. We speculate that these changes could reflect survival shift in transcriptome of inner ear explants tissues under in vitro conditions. With the exception of SOD-2, hypoxic culture conditions induced the same changes in gene expression as the normoxic conditions indicating that culture preparation is likely the dominating factor, which modifies the gene expression pattern. We conclude that various culture conditions induce different expression pattern of apoptosis -related genes in the organotypic cochlear cultures, as compared to fresh tissues. This transcriptional pattern may reflect the survival ability of specific tissues and could become a tempting target for a pharmacological intervention in inner ear diseases. (c) 2007 Elsevier B.V. All rights reserved.	Univ Med Berlin, Mol Biol Res Lab, Dept Othorhinolaryngol, Charite, D-10117 Berlin, Germany; Acad Med Sci, Brain Res Inst, Moscow, Russia; Inst Cell & Neurobiol, Berlin, Germany	Gross, J (corresponding author), Univ Med Berlin, Mol Biol Res Lab, Dept Othorhinolaryngol, Charite, CharitePl 1, D-10117 Berlin, Germany.	johann.gross@charite.de	Pohl, Elena E./A-4025-2009; Szczepek, Agnieszka J./C-1434-2019; Szczepek, Agnieszka/AAK-8514-2021	Pohl, Elena E./0000-0002-0604-5950; Szczepek, Agnieszka/0000-0002-9292-6606; Amarjargal, Nyamaa/0000-0002-8541-8662			Andreeva N, 2006, NEUROSCI LETT, V396, P86, DOI 10.1016/j.neulet.2005.11.013; Arundine M, 2004, J NEUROSCI, V24, P8106, DOI 10.1523/JNEUROSCI.1362-04.2004; Brockhaus F, 1999, BIOCHEM J, V338, P295, DOI 10.1042/0264-6021:3380295; Chaitidis P, 2005, CYTOKINE, V30, P366, DOI 10.1016/j.cyto.2005.02.004; Chen MHJ, 2006, NEUROSCI LETT, V397, P69, DOI 10.1016/j.neulet.2005.12.011; Cheng AG, 1999, BRAIN RES, V850, P234, DOI 10.1016/S0006-8993(99)01983-6; Cheng Alan G, 2005, Curr Opin Otolaryngol Head Neck Surg, V13, P343, DOI 10.1097/01.moo.0000186799.45377.63; Chong ZZ, 2005, PROG NEUROBIOL, V75, P207, DOI 10.1016/j.pneurobio.2005.02.004; CIANCIO G, 1988, J HISTOCHEM CYTOCHEM, V36, P1147, DOI 10.1177/36.9.2457047; Dhar-Mascareno M, 2005, FREE RADICAL BIO MED, V38, P1311, DOI 10.1016/j.freeradbiomed.2005.01.017; Endo T, 2005, LARYNGOSCOPE, V115, P2016, DOI 10.1097/01.mlg.0000183020.32435.59; Fan TJ, 2005, ACTA BIOCH BIOPH SIN, V37, P719, DOI 10.1111/j.1745-7270.2005.00108.x; Feghali J G, 1998, Ear Nose Throat J, V77, P282; Fuentes-Prior P, 2004, BIOCHEM J, V384, P201, DOI 10.1042/BJ20041142; Gao J, 1999, J NEURAL TRANSM, V106, P111, DOI 10.1007/s007020050143; Gates GA, 2005, LANCET, V366, P1111, DOI 10.1016/S0140-6736(05)67423-5; Ginham R, 2001, NEUROSCI LETT, V302, P113, DOI 10.1016/S0304-3940(01)01687-1; Gramsbergen JB, 2002, BRAIN RES, V935, P47, DOI 10.1016/S0006-8993(02)02451-4; Greijer AE, 2004, J CLIN PATHOL, V57, P1009, DOI 10.1136/jcp.2003.015032; Gross J, 2005, HEARING RES, V204, P183, DOI 10.1016/j.heares.2005.02.001; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Henderson D, 2006, EAR HEARING, V27, P1, DOI 10.1097/01.aud.0000191942.36672.f3; Hernandez-Saavedra D, 2005, BIOMED PHARMACOTHER, V59, P204, DOI 10.1016/j.biopha.2005.03.001; Huang YH, 2001, TRENDS MOL MED, V7, P355, DOI 10.1016/S1471-4914(01)02049-4; Ito A, 2000, FEBS LETT, V470, P360, DOI 10.1016/S0014-5793(00)01351-X; Jin KL, 2002, J NEUROCHEM, V81, P25, DOI 10.1046/j.1471-4159.2002.00781.x; Jin KL, 2001, J NEUROCHEM, V77, P1508, DOI 10.1046/j.1471-4159.2001.00361.x; Julien JP, 1998, PROG NUCLEIC ACID RE, V61, P1, DOI 10.1016/S0079-6603(08)60823-5; Kim HN, 1996, ACTA OTO-LARYNGOL, V116, P805, DOI 10.3109/00016489609137930; Kim R, 2005, BIOCHEM BIOPH RES CO, V333, P336, DOI 10.1016/j.bbrc.2005.04.161; Kirby J, 2002, HUM MOL GENET, V11, P2061, DOI 10.1093/hmg/11.17.2061; Kirkegaard M, 2006, NEUROSCIENCE, V142, P425, DOI 10.1016/j.neuroscience.2006.06.037; Lakhani SA, 2006, SCIENCE, V311, P847, DOI 10.1126/science.1115035; Lee JE, 2004, ORL-J OTO-RHIN-LARYN, V66, P111, DOI 10.1159/000079329; Lee SJ, 2007, CELL DEATH DIFFER, V14, P1106, DOI 10.1038/sj.cdd.4402111; LEFEBVRE PP, 1991, BRAIN RES, V567, P306, DOI 10.1016/0006-8993(91)90809-A; Lefebvre PP, 2002, AUDIOL NEURO-OTOL, V7, P165, DOI 10.1159/000058304; Lindsten T, 2005, NEUROSCIENTIST, V11, P10, DOI 10.1177/1073858404269267; Lowenheim H, 1999, HEARING RES, V128, P16, DOI 10.1016/S0378-5955(98)00181-6; MacLachan TK, 2002, P NATL ACAD SCI USA, V99, P9492, DOI 10.1073/pnas.132241599; Marciano PG, 2004, J NEUROSCI, V24, P2866, DOI 10.1523/JNEUROSCI.5051-03.2004; Mazurek B, 2003, HEARING RES, V182, P2, DOI 10.1016/S0378-5955(03)00134-5; Mou K, 1997, J COMP NEUROL, V386, P529; Mou K, 1997, HEARING RES, V103, P47, DOI 10.1016/S0378-5955(96)00163-3; Nicotera TM, 2004, AUDIOL NEURO-OTOL, V9, P353, DOI 10.1159/000081284; Nicotera TM, 2003, JARO-J ASSOC RES OTO, V4, P466, DOI 10.1007/s10162-002-3038-2; Noraberg J, 1999, BRAIN RES PROTOC, V3, P278, DOI 10.1016/S1385-299X(98)00050-6; Nozik-Grayck E, 2005, INT J BIOCHEM CELL B, V37, P2466, DOI 10.1016/j.biocel.2005.06.012; Ohlemiller KK, 2006, BRAIN RES, V1091, P89, DOI 10.1016/j.brainres.2006.03.017; Ohlemiller KK, 2004, J COMP NEUROL, V479, P103, DOI 10.1002/cne.20326; Orita Y, 2002, OTOL NEUROTOL, V23, P34, DOI 10.1097/00129492-200201000-00009; Pfaffl MW, 2002, NUCLEIC ACIDS RES, V30, DOI 10.1093/nar/30.9.e36; Pfaffl MW, 2001, NUCLEIC ACIDS RES, V29, DOI 10.1093/nar/29.9.e45; Pfister Bryan, 2004, Mech Chem Biosyst, V1, P233; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; Ripoll C, 1997, J NEUROSCI METH, V73, P123, DOI 10.1016/S0165-0270(96)02217-0; Riva C, 2007, EXP GERONTOL, V42, P327, DOI 10.1016/j.exger.2006.10.014; Roucou X, 2005, CELL DEATH DIFFER, V12, P783, DOI 10.1038/sj.cdd.4401629; SCHUKNECHT HF, 1993, ANN OTO RHINOL LARYN, V102, P1; Shroff EH, 2007, CELL CYCLE, V6, P807, DOI 10.4161/cc.6.7.4044; Singh AB, 2002, KIDNEY INT, V62, P106, DOI 10.1046/j.1523-1755.2002.00427.x; Soane L, 2005, J BIOENERG BIOMEMBR, V37, P179, DOI 10.1007/s10863-005-6590-8; SOBKOWICZ HM, 1993, ACTA OTO-LARYNGOL, P3; Spudich A, 2005, NEUROBIOL DIS, V20, P442, DOI 10.1016/j.nbd.2005.04.002; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Tamada Y, 2005, BRAIN RES, V1050, P148, DOI 10.1016/j.brainres.2005.05.048; Van De Water TR, 2004, OTOL NEUROTOL, V25, P627, DOI 10.1097/00129492-200407000-00035; Vousden KH, 2002, NAT REV CANCER, V2, P594, DOI 10.1038/nrc864; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Whitlon DS, 2006, NEUROSCIENCE, V138, P653, DOI 10.1016/j.neuroscience.2005.11.030; Yao XF, 1996, HEARING RES, V96, P199, DOI 10.1016/0378-5955(96)00050-0; Yokota M, 2003, BRAIN RES, V984, P122, DOI 10.1016/S0006-8993(03)03121-4; Zelko IN, 2005, ENDOCRINOLOGY, V146, P332, DOI 10.1210/en.2004-1007; Zelko IN, 2002, FREE RADICAL BIO MED, V33, P337, DOI 10.1016/S0891-5849(02)00905-X; Zhang Y, 2000, J NEUROSCI, V20, P8384, DOI 10.1523/JNEUROSCI.20-22-08384.2000; Zhong H, 1999, BIOCHEM BIOPH RES CO, V259, P523, DOI 10.1006/bbrc.1999.0815; Zou H, 1997, CELL, V90, P405, DOI 10.1016/S0092-8674(00)80501-2	77	23	26	0	5	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	AUG 8	2007	1162						56	68		10.1016/j.brainres.2007.05.061			13	Neurosciences	Neurosciences & Neurology	202BS	WOS:000248877100007	17612509				2021-06-18	
J	Wright, G; Bell, A; McGlashan, G; Vincent, C; Welbury, RR				Wright, Graeme; Bell, Aileen; McGlashan, Gregor; Vincent, Carolyn; Welbury, Richard R.			Dentoalveolar trauma in Glasgow: an audit of mechanism and injury	DENTAL TRAUMATOLOGY			English	Article						tooth injuries; tooth fractures; tooth avulsion; child; dental audit	DENTAL INJURIES; PERMANENT INCISORS; CHILDREN; PREVALENCE; TURKEY; UNIVERSITY; DENTISTRY; ANKARA	Traumatic dental injuries in children often require multiple follow-up visits to the dentist and may have long-term consequences for the developing dentition. The aim of this audit was to examine age, gender, location, time of year, mechanism of injury and type of injury sustained in relation to dentoalveolar trauma in children attending the paediatric dental trauma clinic at Glasgow Dental Hospital from 2002 to 2004, and to compare our findings with data in the published literature. Males suffered 60% of all dental trauma, 79% of sporting injuries and 85% of assaults. The injuries in males were more severe, representing 65% of enamel dentine and pulp fractures, 100% of crown root fractures and 66% of crown root and pulp fractures. A peak for trauma was seen in the 8-11-year-old group (43%). The majority of injuries in the under four age group resulted from falls (87%). Taken as a whole, falls accounted for 49%, sports related injuries 18%, bicycle and scooter 13%, assault 7%, and road traffic accidents 1.5% of all injuries. They also accounted for a far higher percentage of intrusive luxations (67%). The largest proportion of injuries occurred during the summer months (33%). Sixty-four percent of children suffered trauma to more than one tooth. Fifty-eight percent of injuries involved the dental hard tissues and pulp and the majority of these (82%) were crown fractures. Most subjects (82%) suffered trauma to their periodontal tissues, (26% concussion or subluxation, 26% lateral luxation and 23% avulsion). Injuries to the supporting bone were uncommon. Sixty-six percent of all injuries occurred outdoors. Our findings were similar to a number of published studies, but in contrast to several others. More consistency is required in the collection and reporting of trauma data to be able to draw meaningful conclusions by comparison.	Glasgow Dent Hosp & Sch, Dept Paediat Dent, Glasgow, Lanark, Scotland; Glasgow Dent Hosp & Sch, Dept Oral Surg, Glasgow, Lanark, Scotland	Welbury, RR (corresponding author), Glasgow Dent Hosp & Sch, Dept Paediat Dent, Glasgow, Lanark, Scotland.	r.r.welbury@dental.gla.ac.uk		Welbury, Richard/0000-0002-9322-2440			Altay N, 2001, DENT TRAUMATOL, V17, P201; Borssen E, 1997, ENDOD DENT TRAUMATOL, V13, P276; Canakci V, 2003, DENT TRAUMATOL, V19, P248, DOI 10.1034/j.1600-9657.2003.00199.x; da Silva AC, 2004, DENT TRAUMATOL, V20, P6, DOI 10.1111/j.1600-4469.2004.00212.x; Gabris K, 2001, DENT TRAUMATOL, V17, P103, DOI 10.1034/j.1600-9657.2001.017003103.x; Gassner R, 2003, J CRANIO MAXILL SURG, V31, P51, DOI 10.1016/S1010-5182(02)00168-3; Glendor U, 2000, Swed Dent J Suppl, V140, P1; Kramer PF, 2003, DENT TRAUMATOL, V19, P299, DOI 10.1046/j.1600-4469.2003.00203.x; Locker D, 2005, CAN J PUBLIC HEALTH, V96, P73, DOI 10.1007/BF03404023; Rajab LD, 2003, DENT TRAUMATOL, V19, P6, DOI 10.1034/j.1600-9657.2003.00131.x; Saroglu I, 2002, DENT TRAUMATOL, V18, P299, DOI 10.1034/j.1600-9657.2002.00093.x; Skaare AB, 2003, DENT TRAUMATOL, V19, P304, DOI 10.1046/j.1600-4469.2003.00211.x; Tapias MA, 2003, DENT TRAUMATOL, V19, P119, DOI 10.1034/j.1600-9657.2003.00141.x; Wood EB, 2002, AUST DENT J, V47, P142, DOI 10.1111/j.1834-7819.2002.tb00318.x; Zaragoza AA, 1998, J DENT CHILD, V65, P492; Zerfowski M, 1998, Clin Oral Investig, V2, P120, DOI 10.1007/s007840050056	16	23	25	0	11	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	1600-4469			DENT TRAUMATOL	Dent. Traumatol.	AUG	2007	23	4					226	231		10.1111/j.1600-9657.2006.00430.x			6	Dentistry, Oral Surgery & Medicine	Dentistry, Oral Surgery & Medicine	197CX	WOS:000248532400007	17635356				2021-06-18	
J	Larson, MJ; Kelly, KG; Stigge-Kaufman, DA; Schmalfuss, IM; Perlstein, WM				Larson, Michael J.; Kelly, Kiesa G.; Stigge-Kaufman, David A.; Schmalfuss, Ilona M.; Perlstein, William M.			Reward context sensitivity impairment following severe TBI: An event-related potential investigation	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						traumatic brain injury (TBI); event-related potential (ERP); feedback; rehabilitation; feedback related negativity (FRN); error related negativity (ERN); contingency	TRAUMATIC BRAIN-INJURY; CLOSED-HEAD-INJURY; COGNITIVE CONTROL; DECISION-MAKING; NEGATIVITY REFLECTS; SOCIAL-ADJUSTMENT; DEFICITS; BAD; FEEDBACK; MODERATE	Many rehabilitation protocols following traumatic brain injury (TBI) utilize reinforcement and reward to influence behavior and facilitate recovery; however, previous studies suggest survivors of severe TBI demonstrate impairments in contingency utilization and sensitivity. The precise neurobiological mechanisms underlying these deficits have not been thoroughly explored. but can be examined using the "feedback-related negativity" (FRN)-an event-related potential (ERP) component evoked following performance or response feedback (e.g., whether a monetary reward is obtained) with a larger FRN following unfavorable than favorable outcomes-particularly when unfavorable feedback occurs in the context of high reward probability. We examined ERPs elicited by favorable (monetary gain: "reward") and unfavorable (no monetary gain: "non-reward") feedback during a guessing task where probability of reward outcome was manipulated in survivors of severe TBI and demographically matched healthy participants. Consistent with previous findings, controls showed larger amplitude FRN to non-reward feedback and the largest amplitude FRN following a non-reward when reward probability context was greatest. In contrast. FRN in TBI participants did not significantly differentiate non-reward from reward trials and their FRN was largest to reward trials in the low reward probability context. Findings implicate an electrophysiological marker of impaired reward context sensitivity following severe TBI.	Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32610 USA; Tennessee State Univ, Dept Psychol, Nashville, TN 37203 USA; N Florida S Georgia Vet Adm, Gainesville, FL USA; Univ Florida, Gainesville, FL USA; Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, McKnight Brain Inst, Gainesville, FL 32611 USA	Perlstein, WM (corresponding author), Univ Florida, Dept Clin & Hlth Psychol, HSC Box 100165, Gainesville, FL 32610 USA.	wmp@phhp.ufl.edu	Larson, Michael J/C-8543-2012	Larson, Michael J/0000-0002-8199-8065	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R21MH073076, K01MH001857] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31NS053335] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K01 MH01857, R21 MH073076] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F31 NS053335] Funding Source: Medline		Bechara A, 2004, BRAIN COGNITION, V55, P30, DOI 10.1016/j.bandc.2003.04.001; Bechara A, 2000, BRAIN, V123, P2189, DOI 10.1093/brain/123.11.2189; BECHARA A, 1994, COGNITION, V50, P7, DOI 10.1016/0010-0277(94)90018-3; Bechara A, 1996, CEREB CORTEX, V6, P215, DOI 10.1093/cercor/6.2.215; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BERG P, 1994, ELECTROEN CLIN NEURO, V90, P229, DOI 10.1016/0013-4694(94)90094-9; BERTRAND O, 1985, ELECTROEN CLIN NEURO, V62, P462, DOI 10.1016/0168-5597(85)90058-9; BIGLER, 1990, TRAUMATIC BRAIN INJU; BOND MR, 1986, NEUROPSYCHOLOGICAL A, P347; Bush G, 2000, TRENDS COGN SCI, V4, P215, DOI 10.1016/S1364-6613(00)01483-2; CLARK JH, 1924, J PHYSL OPTICS, V5, P269; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; FUSTER JM, 1997, PREFRONTAL CORTEX AN; Gehring WJ, 2002, SCIENCE, V295, P2279, DOI 10.1126/science.1066893; Gerstenbrand F, 2001, BRAIN INJURY, V15, P95; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Hajcak G, 2006, BIOL PSYCHOL, V71, P148, DOI 10.1016/j.biopsycho.2005.04.001; Holroyd C.B, 2004, ERRORS CONFLICTS BRA, P211, DOI [10.1037/0033-295X.109.4.679, DOI 10.1037/0033-295X.109.4.679]; Holroyd CB, 2004, PSYCHOPHYSIOLOGY, V41, P245, DOI 10.1111/j.1469-8986.2004.00152.x; Holroyd CB, 2003, NEUROREPORT, V14, P2481, DOI 10.1097/00001756-200312190-00037; Holroyd CB, 2002, PSYCHOL REV, V109, P679, DOI [10.1037//0033-295X.109.4.679, 10.1037/0033-295X.109.4.679]; Holroyd CB, 2006, BRAIN RES, V1105, P93, DOI 10.1016/j.brainres.2005.12.015; Ille N, 2002, J CLIN NEUROPHYSIOL, V19, P113, DOI 10.1097/00004691-200203000-00002; ILLE N, 1997, BIOMED TECH S, V42, P80; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; King NS, 1997, CLIN REHABIL, V11, P13, DOI 10.1177/026921559701100104; Larson MJ, 2006, J CLIN EXP NEUROPSYC, V28, P968, DOI 10.1080/13803390600646860; Larson MJ, 2006, NEUROREPORT, V17, P329, DOI 10.1097/01.wnr.0000199461.01542.db; LARSON MJ, UNPUB PERFORMANCE MO; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; Levine B, 2000, J INT NEUROPSYCH SOC, V6, P299, DOI 10.1017/S1355617700633052; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Mcallister TW, 2004, BRAIN INJURY, V18, P331, DOI 10.1080/02699050310001617370; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; MILLER LA, 1992, NEUROPSYCHOLOGIA, V30, P69, DOI 10.1016/0028-3932(92)90015-E; Napolitano E, 2005, MED SCI MONITOR, V11, pRA212; Nieuwenhuis S, 2005, EUR J NEUROSCI, V21, P3161, DOI 10.1111/j.1460-9568.2005.04152.x; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Park NW, 2003, NEUROCASE, V9, P51, DOI 10.1076/neur.9.1.51.14371; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Plenger PM, 1996, ARCH PHYS MED REHAB, V77, P536, DOI 10.1016/S0003-9993(96)90291-9; Rolls ET, 2000, CEREB CORTEX, V10, P284, DOI 10.1093/cercor/10.3.284; Ruchsow M, 2002, NEUROSCI LETT, V325, P203, DOI 10.1016/S0304-3940(02)00288-4; Salmond CH, 2005, J NEUROTRAUM, V22, P613, DOI 10.1089/neu.2005.22.613; Schlund MW, 2002, BRAIN INJURY, V16, P347, DOI 10.1080/02699050110103977; Schlund MW, 2002, BRAIN INJURY, V16, P527, DOI 10.1080/02699050110113679; Schlund MW, 2001, BRAIN INJURY, V15, P1061, DOI 10.1080/02699050110086887; Schlund MW, 2000, BRAIN INJURY, V14, P573, DOI 10.1080/026990500120475; Seignourel PJ, 2005, NEUROPSYCHOLOGY, V19, P578, DOI 10.1037/0894-4105.19.5.578; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; Soeda A, 2005, NEURORADIOLOGY, V47, P501, DOI 10.1007/s00234-005-1372-x; Speilberger C. D., 1983, MANUAL STATE TRAIT A; Tateno A, 2003, J NEUROPSYCH CLIN N, V15, P155, DOI 10.1176/appi.neuropsych.15.2.155; TEASDALE G, 1974, LANCET, V2, P81; van Meel CS, 2005, NEUROPSYCHOLOGIA, V43, P1946, DOI 10.1016/j.neuropsychologia.2005.03.018; van Veen V, 2004, BRAIN COGNITION, V56, P267, DOI 10.1016/j.bandc.2004.06.007; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; Yasuda A, 2004, NEUROREPORT, V15, P2561, DOI 10.1097/00001756-200411150-00027	61	23	24	0	12	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	JUL	2007	13	4					615	625		10.1017/S1355617707070762			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	186GJ	WOS:000247766800007	17521495				2021-06-18	
J	Ribbers, GM				Ribbers, G. M.			Traumatic Brain Injury Rehabilitation in the Netherlands: Dilemmas and Challenges	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Netherlands; rehabilitation; traumatic brain injury		Traumatic brain injury (TBI) is the number one cause of mortality and morbidity in young adults in modern Western societies. This article discusses TBI rehabilitation in the Netherlands. Facts and figures on rehabilitation as well as on the epidemiology of TBI and its silent epidemic in the Netherlands are presented. The Dutch healthcare system is described, and strengths and weaknesses of TBI rehabilitation are discussed.	[Ribbers, G. M.] Rijndam Rehabil Ctr, NL-3001 KD Rotterdam, Netherlands; [Ribbers, G. M.] Erasmus MC, Rotterdam, Netherlands	Ribbers, GM (corresponding author), Rijndam Rehabil Ctr, POB 23181, NL-3001 KD Rotterdam, Netherlands.	g.ribbers@rijndam.nl	Ribbers, Gerard/N-3623-2019; Ribbers, Gerard M/C-1454-2014	Ribbers, Gerard M/0000-0002-6114-349X			Andlin-Sobocki P, 2005, EUR J NEUROL, V12, P1, DOI 10.1111/j.1468-1331.2005.01202.x; Berg J, 2005, EUR J NEUROL, V12, P85, DOI 10.1111/j.1468-1331.2005.01200.x; *CTR BUR STAT VOOR, 2006, GEZ ZORG CIJF; Dobkin BH, 2005, NEW ENGL J MED, V352, P1677, DOI 10.1056/NEJMcp043511; DURGIN CJ, 1993, STAFF DEV CLIN INTER; Eilander HJ, 2005, BRAIN INJURY, V19, P425, DOI 10.1080/02699050400025299; Fleminger S, 2005, BRIT MED J, V331, P1419, DOI 10.1136/bmj.331.7530.1419; GOLDSTEIN M, 1990, ANN NEUROL, V27, P327, DOI 10.1002/ana.410270315; HORN LJ, 1995, MED REHABILITATION T; *INSP GEZ, 1997, EEN DEUR VERD COORD; *LAND COORD PUNT N, 1996, PUBL LAND COORD PUNT; Matser EJT, 2000, PHYSICIAN SPORTSMED, V28, P87, DOI 10.3810/psm.2000.01.645; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; *MIN HLTH WELF SPO, 2004, INT PUBL SER HLTH E, V1; *MIN HLTH WELF SPO, 2004, NEW HLTH INS SYST BR; OUDEJANS SCC, 2005, HDB KWALITEIT ZORG, V46, P46; *PRISM, 2004, PUBL PRISM; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; van Baalen B, 2006, CLIN REHABIL, V20, P686, DOI 10.1191/0269215506cre982oa; VANBALEN HGG, 1997, THESIS KATHOLIEKE U; VANBEECK EF, 1998, THESIS ERASMUS MED C; VANDENBRINK WA, 2000, THESIS ERASMUS MED C; 1997, PROBLEMATIEK MENSEN; 2006, REVALICLATIE BRANCHE	24	23	23	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2007	22	4					234	238		10.1097/01.HTR.0000281839.07968.32			5	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	V87BQ	WOS:000205885400007	17667066				2021-06-18	
J	Nehrt, A; Rodgers, R; Shapiro, S; Borgens, R; Shi, R				Nehrt, A.; Rodgers, R.; Shapiro, S.; Borgens, R.; Shi, R.			The critical role of voltage-dependent calcium channel in axonal repair following mechanical trauma	NEUROSCIENCE			English	Article						axon; neurotrauma; membrane integrity; membrane; depolarization; resealing; guinea pig	MAMMALIAN SPINAL-CORD; WHITE-MATTER; NEURITE TRANSECTION; NERVE MEMBRANES; CA2+ CHANNELS; CUT END; INJURY; DEGENERATION; DISRUPTION; NEURONS	Membrane disruption following mechanical injury likely plays a critical role in the pathology of spinal cord trauma. It is known that intracellular calcium is a key factor that is essential to membrane resealing. However, the differential role of calcium influx through the injury site and through voltage dependent calcium channels (VDCC) has not been examined in detail. Using a well-established ex vivo guinea-pig spinal cord white matter preparation, we have found that axonal membrane resealing was significantly inhibited following transection or compression in the presence of cadmium, a non-specific calcium channel blocker, or nimodipine, a specific L-type calcium channel blocker. Membrane resealing was assessed by the changes of membrane potential and compound action potential (CAP), and exclusion of horseradish peroxidase 60 min following trauma. Furthermore, I mu M BayK 8644, a VDCC agonist, significantly enhanced membrane resealing. Interestingly, this effect was completely abolished when the concentration of BayK 8644 was increased to 30 mu M. These data suggest that VDCC play a critical role in membrane resealing. Further, there is likely an appropriate range of calcium influx through VDCC which ensures effective axonal membrane resealing. Since elevated intracellular calcium has also been linked to axonal deterioration, blockage of VDCC is proposed to be a clinical treatment for various injuries. The knowledge gained in this study will likely help us better understand the role of calcium in various CNS trauma, which is critical for designing new approaches or perhaps optimizing the effectiveness of existing methods in the treatment of CNS trauma. (C) 2007 IBRO. Published by Elsevier Ltd. All rights reserved.	Purdue Univ, Weldon Sch Biomed Engn, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA	Shi, R (corresponding author), Purdue Univ, Weldon Sch Biomed Engn, Ctr Paralysis Res, Dept Basic Med Sci, W Lafayette, IN 47907 USA.	riyi@purdue.edu			NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03 HD041371-02, R03 HD041371-01A1, R03 HD041371] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R03HD041371] Funding Source: NIH RePORTER		Agrawal SK, 2000, NEUROSCIENCE, V99, P179, DOI 10.1016/S0306-4522(00)00165-2; Borgens RB, 2000, FASEB J, V14, P27; BORGENS RB, 1980, P NATL ACAD SCI-BIOL, V77, P1209, DOI 10.1073/pnas.77.2.1209; Cano-Abad MF, 2001, J BIOL CHEM, V276, P39695, DOI 10.1074/jbc.M102334200; Cocucci E, 2004, MOL BIOL CELL, V15, P5356, DOI 10.1091/mbc.E04-07-0577; Coorssen JR, 1996, EMBO J, V15, P3787, DOI 10.1002/j.1460-2075.1996.tb00752.x; Detrait E, 2000, J NEUROBIOL, V44, P382, DOI 10.1002/1097-4695(20000915)44:4<382::AID-NEU2>3.0.CO;2-Q; Eddleman CS, 2000, BIOPHYS J, V79, P1883, DOI 10.1016/S0006-3495(00)76438-1; Eddleman CS, 1997, P NATL ACAD SCI USA, V94, P4745, DOI 10.1073/pnas.94.9.4745; Fern R, 1996, J NEUROPHYSIOL, V76, P3264; FERN R, 1995, J NEUROPHYSIOL, V74, P369; Fiskum G, 2000, J NEUROTRAUM, V17, P843, DOI 10.1089/neu.2000.17.843; Fitzpatrick MO, 1998, J NEUROL NEUROSUR PS, V64, P285, DOI 10.1136/jnnp.64.3.285; GEORGE EB, 1995, J NEUROSCI, V15, P6445; GROSS GW, 1983, J NEUROSCI, V3, P1979; GROSS GW, 1987, EXP BRAIN RES, V67, P52, DOI 10.1007/BF00269452; Imaizumi T, 1999, BRAIN RES, V817, P84, DOI 10.1016/S0006-8993(98)01214-1; KRAUSE TL, 1994, J NEUROSCI, V14, P6638; Kulbatski I, 2004, J NEUROTRAUM, V21, P357, DOI 10.1089/089771504322972130; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Lucas J H, 1985, Cent Nerv Syst Trauma, V2, P231; Luo J, 2002, SPINAL CORD, V40, P656, DOI 10.1038/sj.sc.3101363; Mason RP, 1999, J NEUROCHEM, V72, P1448, DOI 10.1046/j.1471-4159.1999.721448.x; Maxwell WL, 1999, J NEUROTRAUM, V16, P273, DOI 10.1089/neu.1999.16.273; McNeil PL, 2003, ANNU REV CELL DEV BI, V19, P697, DOI 10.1146/annurev.cellbio.19.111301.140101; McNeil PL, 2001, NAT CELL BIOL, V3, pE124, DOI 10.1038/35074652; Ouardouz M, 2005, NEUROPHARMACOLOGY, V48, P566, DOI 10.1016/j.neuropharm.2004.12.007; Peasley MA, 2002, AM J PHYSIOL-CELL PH, V283, pC980, DOI 10.1152/ajpcell.00591.2001; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POINTILLART V, 1993, J NEUROTRAUM, V10, P201, DOI 10.1089/neu.1993.10.201; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; QUARDOUZ M, 2003, NEURON, V40, P53; Ray SK, 2003, BRAIN RES REV, V42, P169, DOI 10.1016/S0165-0173(03)00152-8; Rhee RY, 1996, INT ANGIOL, V15, P153; Rodriguez A, 1997, J CELL BIOL, V137, P93, DOI 10.1083/jcb.137.1.93; Sattler R, 1996, BRAIN RES, V719, P239, DOI 10.1016/0006-8993(96)00125-4; SCHANNE FAX, 1979, SCIENCE, V206, P700, DOI 10.1126/science.386513; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; SCHLAEPFER WW, 1973, J CELL BIOL, V59, P456, DOI 10.1083/jcb.59.2.456; Shi R, 1999, J NEUROPHYSIOL, V81, P2406; Shi R, 2001, J NEUROCYTOL, V30, P829, DOI 10.1023/A:1019645505848; Shi R, 2000, J NEUROCYTOL, V29, P633, DOI 10.1023/A:1010879219775; Shi R, 2002, NEUROSCIENCE, V110, P765, DOI 10.1016/S0306-4522(01)00596-6; Shi R, 1996, J NEUROPHYSIOL, V76, P1572; Shi R, 2000, NEUROSCIENCE, V98, P157, DOI 10.1016/S0306-4522(00)00096-8; SHI R, 2002, J NEUROTRAUM, V19, P1394; Shi RY, 1989, J NEUROTRAUM, V6, P261, DOI 10.1089/neu.1989.6.261; Shi RY, 2000, J NEUROPHYSIOL, V84, P1763; Shi RY, 2004, J NEUROCYTOL, V33, P203, DOI 10.1023/B:NEUR.0000030695.76840.19; SPIRA ME, 1993, J NEUROBIOL, V24, P300, DOI 10.1002/neu.480240304; STEINHARDT RA, 1994, SCIENCE, V263, P390, DOI 10.1126/science.7904084; STOKES BT, 1983, EXP NEUROL, V80, P561, DOI 10.1016/0014-4886(83)90307-2; STRAUTMAN AF, 1990, J NEUROSCI, V10, P3564; Terasaki M, 1997, J CELL BIOL, V139, P63, DOI 10.1083/jcb.139.1.63; Ueda K, 1997, J NEUROCHEM, V68, P265; XIE XY, 1991, J NEUROSCI, V11, P3257; YAWO H, 1983, SCIENCE, V222, P1351, DOI 10.1126/science.6658457; YAWO H, 1985, J NEUROSCI, V5, P1626; YOUNG W, 1982, BRAIN RES, V253, P105, DOI 10.1016/0006-8993(82)90677-1; YOUNG W, 1986, BRAIN RES, V365, P42, DOI 10.1016/0006-8993(86)90720-1; Young W, 1992, J NEUROTRAUMA S1, V9, P9; ZIV NE, 1993, EUR J NEUROSCI, V5, P657, DOI 10.1111/j.1460-9568.1993.tb00531.x	62	23	28	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522	1873-7544		NEUROSCIENCE	Neuroscience	JUN 8	2007	146	4					1504	1512		10.1016/j.neuroscience.2007.02.015			9	Neurosciences	Neurosciences & Neurology	176RB	WOS:000247101500008	17448606	Green Accepted			2021-06-18	
J	Hart, T; Hanks, R; Bogner, JA; Millis, S; Esselman, P				Hart, Tessa; Hanks, Robin; Bogner, Jennifer A.; Millis, Scott; Esselman, Peter			Blame attribution in intentional and unintentional traumatic brain injury: Longitudinal changes and impact on subjective well-being	REHABILITATION PSYCHOLOGY			English	Article						brain injuries; violence; psychological outcome; intentional TBI; blame attribution	SPINAL-CORD-INJURY; GLASGOW OUTCOME SCALE; LIFE SATISFACTION; REHABILITATION OUTCOMES; STRESS-DISORDER; RISK-FACTORS; SET-POINT; VIOLENCE; RESPONSIBILITY; DISABILITY	Objective: Examine longitudinal changes in attribution of blame to self and others, and concern over cause of injury, in both intentional (violence-related) and unintentional (accidental) traumatic brain injury (TBI); investigate the relation of these factors to subjective well-being outcomes at I year post-TBI. Study Design: Prospective, multicenter, observational study with longitudinal component. Participants: 99 men with unintentional TBI and 25 men with intentional TBI who sustained moderate to severe injuries, received inpatient rehabilitation, and provided data in both acute rehabilitation and 1-year follow-up. Measures: Blame Attribution Questionnaire, General Health Questionnaire-30, Neurobehavioral Functioning Inventory-Revised Depression Scale, Satisfaction With Life Scale, community participation measures. Results: At both time points, participants with intentional TBI blamed others more while those with unintentional TBI blamed themselves more (trend). Other-blame at I year predicted depression but not life satisfaction. Self-blame was not a significant predictor of depression or life satisfaction. Increasing concern over cause/blame for injury from acute rehabilitation to follow-up was associated with high levels of emotional distress. Conclusion: Blame attribution issues may be markers of TBI-related emotional distress regardless of injury etiology, particularly when others are blamed for the injury and/or concerns over cause of injury do not resolve over time.	Moss Rehabil Res Inst, Philadelphia, PA 19141 USA; Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48202 USA; Wayne State Univ, Sch Med, Rehabil Inst Michigan, Detroit, MI 48202 USA; Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA	Hart, T (corresponding author), Moss Rehabil Res Inst, 1200 W Tabor Rd, Philadelphia, PA 19141 USA.	thart@einstein.edu	Bogner, Jennifer/E-2773-2011				Alicke MD, 2000, PSYCHOL BULL, V126, P556, DOI 10.1037//0033-2909.126.4.556; ATHELSTAN GT, 1979, REHABIL COUNS BULL, V22, P311; Bogner JA, 2001, ARCH PHYS MED REHAB, V82, P571, DOI 10.1053/apmr.2001.22340; BULMAN RJ, 1977, J PERS SOC PSYCHOL, V35, P351, DOI 10.1037/0022-3514.35.5.351; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; *CDCP, 1998, BEHAV RISK FACT SURV; Celano Marianne, 2002, Child Maltreat, V7, P65, DOI 10.1177/1077559502007001006; Centers for Disease Control and Prevention, 1999, TRAUM BRAIN INJ US R; CORRIGAN J, 2000, INTRO SATISFACTION L; Corrigan J D, 1994, NeuroRehabilitation, V4, P109, DOI 10.3233/NRE-1994-4207; Corrigan JD, 2004, J HEAD TRAUMA REHAB, V19, P445, DOI 10.1097/00001199-200411000-00003; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Corrigan JD, 2003, PROBLEMATIC SUBSTANC; Delahanty DL, 1997, J CONSULT CLIN PSYCH, V65, P560, DOI 10.1037/0022-006X.65.4.560; Diener E, 2000, AM PSYCHOL, V55, P34, DOI 10.1037/0003-066X.55.1.34; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dijkers MP, 2004, ARCH PHYS MED REHAB, V85, pS21, DOI 10.1016/j.apmr.2003.08.119; Dikmen SS, 2004, ARCH PHYS MED REHAB, V85, P1457, DOI 10.1016/j.apmr.2003.12.041; Esselman PC, 2004, ARCH PHYS MED REHAB, V85, P1445, DOI 10.1016/j.apmr.2003.10.018; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Goldberg D., 1978, MANUAL GEN HLTH QUES; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Hart T, 2003, REHABIL PSYCHOL, V48, P86, DOI 10.1037/0090-5550.48.2.86; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; HEINEMANN AW, 1988, REHABIL PSYCHOL, V33, P195, DOI 10.1037//0090-5550.33.4.195; Hickling EJ, 1999, J TRAUMA STRESS, V12, P345, DOI 10.1023/A:1024784711484; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kreutzer JS., 1999, NEUROBEHAVIORAL FUNC; Lambert JF, 2004, J NERV MENT DIS, V192, P304, DOI 10.1097/01.nmd.0000120890.16617.af; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lucas RE, 2003, J PERS SOC PSYCHOL, V84, P527, DOI 10.1037/0022-3514.84.3.527; Lucas RE, 2004, PSYCHOL SCI, V15, P8, DOI 10.1111/j.0963-7214.2004.01501002.x; Lyubomirsky S, 2001, AM PSYCHOL, V56, P239, DOI 10.1037/0003-066X.56.3.239; Machamer JE, 2003, J HEAD TRAUMA REHAB, V18, P387, DOI 10.1097/00001199-200309000-00001; McDowell I., 1996, MEASURING HLTH, V2nd ed.; Myers DG, 2000, AM PSYCHOL, V55, P56, DOI 10.1037/0003-066X.55.1.56; Pavot W., 1993, PSYCHOL ASSESSMENT, V5, P164, DOI DOI 10.1037/1040-3590.5.2.164; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REIDY K, 1994, ARCH PHYS MED REHAB, V75, P837, DOI 10.1016/0003-9993(94)90106-6; Richards JS, 1997, REHABIL PSYCHOL, V42, P115, DOI 10.1037/0090-5550.42.2.115; SCHULZ R, 1985, J PERS SOC PSYCHOL, V48, P1162, DOI 10.1037/0022-3514.48.5.1162; SHOLOMSKAS DE, 1990, J APPL SOC PSYCHOL, V20, P548, DOI 10.1111/j.1559-1816.1990.tb00427.x; *US DEP HLTH HUM S, 1998, NAT HOUSE SURV DRUG; VANDENBOUT J, 1988, J CLIN PSYCHOL, V44, P17, DOI 10.1002/1097-4679(198801)44:1<17::AID-JCLP2270440104>3.0.CO;2-J; Wagner AK, 2000, J TRAUMA, V49, P404, DOI 10.1097/00005373-200009000-00004; Warren L, 1996, J REHABIL RES DEV, V33, P404; WEBB CR, 1995, ARCH PHYS MED REHAB, V76, P1113, DOI 10.1016/S0003-9993(95)80118-9; Willer B., 1993, J HEAD TRAUMA REHAB, V8, P75, DOI DOI 10.1097/00001199-199308020-00009; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	52	23	23	0	10	EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA	0090-5550	1939-1544		REHABIL PSYCHOL	Rehabil. Psychol.	MAY	2007	52	2					152	161		10.1037/0090-5550.52.2.152			10	Psychology, Clinical; Rehabilitation	Psychology; Rehabilitation	167EL	WOS:000246433900004					2021-06-18	
J	Baskin, JH; Edersheim, JG; Price, BH				Baskin, Joseph H.; Edersheim, Judith G.; Price, Bruce H.			Is a picture worth a thousand words? Neuroimaging in the courtroom	AMERICAN JOURNAL OF LAW & MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; EMISSION-TOMOGRAPHY; EPILEPSY; BEHAVIOR; DEFICITS; VIOLENCE; PSYCHOPATHY; MURDERERS; MATTER; DEATH		Univ Massachusetts, Sch Med, Dept Psychiat, Amherst, MA 01003 USA; Massachusetts Gen Hosp, Dept Psychiat, Law & Psychiat Serv, Boston, MA 02114 USA	Baskin, JH (corresponding author), Univ Massachusetts, Sch Med, Dept Psychiat, Amherst, MA 01003 USA.						[Anonymous], 2006, NATURE, V441, P907, DOI 10.1038/441907a; Appelbaum PS, 2002, PSYCHIATR SERV, V53, P389, DOI 10.1176/appi.ps.53.4.389; Bassarath L, 2001, CAN J PSYCHIAT, V46, P728; BEAR D, 1991, NEUROLOGICAL PERSPEC, pS3; Benning TB, 2003, BRIT J PSYCHIAT, V183, P563, DOI 10.1192/bjp.183.6.563; Benuzzi F, 2004, BRAIN RES BULL, V63, P269, DOI 10.1016/j.brainresbull.2004.03.005; Blair RJR, 2003, BRIT J PSYCHIAT, V182, P5, DOI 10.1192/bjp.182.1.5; Blakemore C, 2005, LANCET, V366, P2035, DOI 10.1016/S0140-6736(05)67816-6; BOBAN M, BRAIN, V129, pE42; Bonilha L, 2003, J NEUROL NEUROSUR PS, V74, P1627, DOI 10.1136/jnnp.74.12.1627; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Brower MC, 2000, EPILEPSY BEHAV, V1, P145, DOI 10.1006/ebeh.2000.0069; BRUFKIN JL, 2001, TRAUMA VIOLENCE ABUS, V6, P181; BUCKSBAUM MS, 2004, AM J PSYCHIAT, V161, P2178; Bufkin JL, 2005, TRAUMA VIOLENCE ABUS, V6, P176, DOI 10.1177/1524838005275089; Chio A, 2003, NEUROLOGY, V61, P1412, DOI 10.1212/01.WNL.0000094383.65150.07; Chronister RB, 1997, FUNDAMENTAL NEUROSCI, P443; Cohen-Gadol AA, 2005, J NEUROSURG, V102, P902, DOI 10.3171/jns.2005.102.5.0902; CUMMINGS JL, 2003, NEUROPSYCHIATRY BEHA, P7; DAMASIO H, 1994, SCIENCE, V264, P1102, DOI 10.1126/science.8178168; FENSTER JM, 2003, MAVERICKS MIRACLES M, P190; Filley C. M., 2000, NEUROPSY NEUROPSY BE, V14, P1; FIX JD, 1995, HIGH YIELD NEUROANAT; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; FREEMAN LZ, 1965, AM J PSYCHIAT, V120, P708; Gatzke-Kopp LM, 2001, J NEUROPSYCH CLIN N, V13, P486, DOI 10.1176/appi.neuropsych.13.4.486; GEORGE W, LIE BEHIND LIE DETEC, pCH4; GIBSON M, 2002, BORN CRIME CESARE LO, P19; GOLDSTEIN MA, 2004, MAGNETIC RESONANCE I, P21; GOULD SJ, 1977, EVER SINCE DARWIN RE, P224; GOULD SJ, 1981, MISMEASURE MAN, P124; HEINSEN H, BRAIN, V129, pE43; HELEN S, 1996, J NUCL MED, V37, P18; ICHISE M, 1994, J NUCL MED, V35, P217; Kantarci K, 2003, NEUROIMAG CLIN N AM, V13, P197, DOI 10.1016/S1052-5149(03)00025-X; KAUFMAN DM, 2001, CLIN NEUROLOGY PSYCH, P123; KICHL KA, 2001, BIOL PSYCHIAT, V50, P677; Kozel FA, 2005, BIOL PSYCHIAT, V58, P605, DOI 10.1016/j.biopsych.2005.07.040; Kulynych J, 1997, STANFORD LAW REV, V49, P1249, DOI 10.2307/1229252; Laakso MP, 2001, BEHAV BRAIN RES, V118, P187, DOI 10.1016/S0166-4328(00)00324-7; Lee Bruce, 2005, NeuroRx, V2, P372; Lee TMC, 2005, NEUROIMAGE, V28, P305, DOI 10.1016/j.neuroimage.2005.06.051; LEVINE B, 2006, J NEUROTRAUM, V23, P1411; Levine B, 2006, J NEUROTRAUM, V23, P1396, DOI 10.1089/neu.2006.23.1396; LEWIS DO, 1988, AM J PSYCHIAT, V145, P584; LEWIS DO, 1986, AM J PSYCHIAT, V143, P838; LEWIS DO, 2006, J AM ACAD PSYCHIAT L, V32, P408; Marsh L, 2000, EPILEPSY BEHAV, V1, P160, DOI 10.1006/ebeh.2000.0061; Masdeu JC, 2005, J NEUROL SCI, V236, P55, DOI 10.1016/j.jns.2005.05.001; MASS P, 1997, UNDERBROSS, P185; Max JE, 2000, J INT NEUROPSYCH SOC, V6, P279, DOI 10.1017/S1355617700633039; McAllister TW, 2001, J CLIN EXP NEUROPSYC, V23, P775, DOI 10.1076/jcen.23.6.775.1026; Mendez ME, 2005, J NEUROPSYCH CLIN N, V17, P413, DOI 10.1176/appi.neuropsych.17.3.413; Mendez MF, 2006, J NEUROL NEUROSUR PS, V77, P4, DOI 10.1136/jnnp.2005.072496; Miller BL, 1997, BRIT J PSYCHIAT, V170, P150, DOI 10.1192/bjp.170.2.150; Miller BL, 2007, NEUROLOGY, V68, P68, DOI 10.1212/01.wnl.0000251313.89403.b3; MORSE SJ, 1996, SEMINAR CLIN NEUROPS, P222; Mosconi Lisa, 2005, Eur J Nucl Med Mol Imaging, V32, P486, DOI 10.1007/s00259-005-1762-7; Nakaji P, 2003, PEDIATRICS, V112, pE430, DOI 10.1542/peds.112.5.e430; NOVELLINE RA, 2004, SQUIRES FUNDAMENTALS, P602; Pearson H, 2006, NATURE, V441, P918, DOI 10.1038/441918a; PRICE BH, 1990, BRAIN, V113, P1383, DOI 10.1093/brain/113.5.1383; Pridmore S, 2005, AUST NZ J PSYCHIAT, V39, P856, DOI 10.1111/j.1440-1614.2005.01679.x; Raine A, 2000, ARCH GEN PSYCHIAT, V57, P119, DOI 10.1001/archpsyc.57.2.119; Raine A, 1996, ARCH GEN PSYCHIAT, V53, P544; Raine A, 1997, BIOL PSYCHIAT, V42, P495, DOI 10.1016/S0006-3223(96)00362-9; Raine A, 1998, BEHAV SCI LAW, V16, P319, DOI 10.1002/(SICI)1099-0798(199822)16:3<319::AID-BSL311>3.0.CO;2-G; Reid William H, 2003, J Psychiatr Pract, V9, P388, DOI 10.1097/00131746-200309000-00008; Relkin N, 1996, SEMINARS CLIN NEUROP, V1, P172; RESTAK RM, 1992, SCIENCES, V32, P16, DOI 10.1002/j.2326-1951.1992.tb02400.x; SHEPHERD GM, 1999, INFORM PROCESSING DE, V393; STEFAN SJ, 2006, BRAIN, V128, P2626; Stein DJ, 2005, CNS SPECTRUMS, V10, P88, DOI 10.1017/S1092852900019404; Tiihonen J, 1997, EUR J NUCL MED, V24, P1253, DOI 10.1007/s002590050149; TONKONOGY JM, 1991, NEUROPSYCHIATRY, V3, P189; Turner R, 1998, EXP BRAIN RES, V123, P5, DOI 10.1007/s002210050538; van Elst LT, 2000, BRAIN, V123, P234, DOI 10.1093/brain/123.2.234; VATZ RE, 2004, US TODAY MAGAZIN MAR, P26; VOLKOW ND, 1987, BRIT J PSYCHIAT, V151, P668, DOI 10.1192/bjp.151.5.668; Warriner Erin M, 2006, Curr Psychiatry Rep, V8, P73, DOI 10.1007/s11920-006-0083-2; WEIGER WA, 1988, J PSYCHIAT RES, V22, P85, DOI 10.1016/0022-3956(88)90073-8; Wild J, 2005, NATURE, V437, P457, DOI 10.1038/437457a; Wilson J, 1996, J NUCL MED, V37, P1256; Yang YL, 2005, BRIT J PSYCHIAT, V187, P320, DOI 10.1192/bjp.187.4.320; 2007, HARV U GAZETTE  FEB, P1	85	23	23	0	5	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0098-8588	2375-835X		AM J LAW MED	Am. J. Law Med.		2007	33	2-3					239	269		10.1177/009885880703300205			31	Law	Government & Law	205WO	WOS:000249145500005	17910159				2021-06-18	
J	Blais, MC; Boisvert, JM				Blais, Marie Claude; Boisvert, Jean-Marie			Psychological adjustment and marital satisfaction following head injury. Which critical personal characteristics should both partners develop?	BRAIN INJURY			English	Article						traumatic brain injury; personal characteristics; psychological and marital adjustment	TRAUMATIC BRAIN-INJURY; COPING STRATEGIES; SELF-AWARENESS; FAMILY CAREGIVERS; DYADIC ADJUSTMENT; HOSPITAL ANXIETY; DEPRESSION; DISTRESS; SCALE; STRESS	Primary objective and research design: Using a correlational design, this study verifies the relationships between personal characteristics of individuals with TBI and their spouses and their level of psychological and marital adjustment. Methods and procedure: Seventy individuals with TBI and their spouses in the post-acute rehabilitation phase completed self-report questionnaires assessing the predictive variables ( coping and social problem- solving strategies; perceived communication skills) and the criteria variables of psychological and marital adjustment. Main outcomes and results: In the target group, the characteristics most strongly related to adjustment variables were an effective attitude towards problems, infrequent use of avoidance coping strategies, and a positive perception of one's spouse's communication skills. Individuals with TBI and their spouses report significantly lower scores on some of these personal characteristics, compared to those of a matched control group of 70 couples from the general population. Conclusions: Specific personal characteristics are critical for psychological and marital adjustment following TBI. This knowledge may be of relevance for detecting couples at risk for developing difficulties in the post-acute rehabilitation phase. Rehabilitation interventions targeting the personal characteristics identified as critical for the adjustment process could help to prevent these difficulties.	Univ Quebec Trois Rivieres, Dept Psychol, Trois Rivieres, PQ G9A 5H7, Canada; Univ Laval, Sch Psychol, Quebec City, PQ, Canada	Blais, MC (corresponding author), Univ Quebec Trois Rivieres, Dept Psychol, CP 500,Pavillon, Trois Rivieres, PQ G9A 5H7, Canada.	Marie-Claude.Blais1@uqtr.ca					Anson K, 2006, BRAIN INJURY, V20, P167, DOI 10.1080/02699050500442956; Bach LJ, 2006, NEUROPSYCHOL REHABIL, V16, P397, DOI 10.1080/09602010500412830; Beaudry M, 2004, J DIVORCE REMARRIAGE, V42, P85, DOI [DOI 10.1300/J087V42N01_04, 10.1300/J087v42n01_04]; Bjelland I, 2002, J PSYCHOSOM RES, V52, P69, DOI 10.1016/S0022-3999(01)00296-3; Blais MC, 2005, BRAIN INJURY, V19, P1223, DOI 10.1080/02699050500309387; Bodenmann G, 2001, SWISS J PSYCHOL, V60, P3, DOI 10.1024//1421-0185.60.1.3; BOUCHARD G, 1995, CAN J BEHAV SCI, V27, P371, DOI 10.1037/0008-400X.27.3.371; BOYD LA, 1977, J COUNS PSYCHOL, V24, P540; Bravo G, 1996, CAN J AGING, V15, P112, DOI 10.1017/S0714980800013325; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Carnes S.L., 2005, FAM SYST HEALTH, V23, P186, DOI DOI 10.1037/1091-7527.23.2.186; Chronister J, 2006, REHABIL PSYCHOL, V51, P190, DOI 10.1037/0090-5550.51.3.190; Cohen S., 1995, MEASURING STRESS GUI, P3; Crane DR, 2000, AM J FAM THER, V28, P53, DOI 10.1080/019261800261815; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; D'Zurilla T. J., 1990, PYCSHOLOGICAL ASSESS, V2, P156, DOI DOI 10.1037/1040-3590.2.2.156; Douglas JM, 1996, BRAIN INJURY, V10, P819, DOI 10.1080/026990596123936; DUGAS M, 1996, THERAPIE COMPORTEMEN, V6, P59; DUGAS MJ, 1995, COGNITIVE THER RES, V19, P109, DOI 10.1007/BF02229679; DUPUY HJ, 1978, SELF REPRESENTATION; DZURILLA TJ, 1995, COGNITIVE THER RES, V19, P547, DOI 10.1007/BF02230513; DZURILLA TJ, 1995, BEHAV THER, V26, P409, DOI 10.1016/S0005-7894(05)80091-7; EDWARDS DW, 1978, EVALUATION QUART, V2, P275, DOI 10.1177/0193841X7800200206; Elliott TR, 1999, REHABIL PSYCHOL, V44, P104, DOI 10.1037/0090-5550.44.1.104; ELLIOTT TR, 1991, COGNITIVE THER RES, V15, P387, DOI 10.1007/BF01173033; ELLIOTT TR, 1995, J COUNS PSYCHOL, V42, P105, DOI 10.1037/0022-0167.42.1.105; Engberg AW, 2004, BRAIN INJURY, V18, P533, DOI 10.1080/02699050310001645829; Evans CC, 2005, J HEAD TRAUMA REHAB, V20, P488, DOI 10.1097/00001199-200511000-00002; Ey S, 1998, J PSYCHOSOC ONCOL, V16, P59; Fazio A.F., 1977, CONCURRENT VALIDATIO; Finset A, 2000, BRAIN INJURY, V14, P887; FOLKMAN S, 1986, J PERS SOC PSYCHOL, V50, P992, DOI 10.1037/0022-3514.50.5.992; Folkman S., 1988, WAYS COPING QUESTION; Freeston MH, 1997, PSYCHOL REP, V81, P419, DOI 10.2466/pr0.1997.81.2.419; GADOURY M, 1999, CADRE REFERENCE CLIN; Gortner ET, 1998, J CONSULT CLIN PSYCH, V66, P377, DOI 10.1037/0022-006X.66.2.377; GOSSELIN P, 2002, J THERAPIE COMPORTEM, V12, P49; GOTTMAN J, 1977, J MARRIAGE FAM, V39, P461, DOI 10.2307/350902; GROVER KJ, 1984, PSYCHOL REP, V54, P629, DOI 10.2466/pr0.1984.54.2.629; Hiott DW, 2002, NEUROREHABILITATION, V17, P345; Jacobson NS, 2000, J CONSULT CLIN PSYCH, V68, P351, DOI 10.1037/0022-006X.68.2.351; Julien D, 2000, CAN J BEHAV SCI, V32, P84, DOI 10.1037/h0087103; Karlovits T, 1999, BRAIN INJURY, V13, P845; KOSCIULEK JF, 1994, REHABIL PSYCHOL, V39, P215, DOI 10.1037/0090-5550.39.4.215; Kosciulek JF, 1997, BRAIN INJURY, V11, P821, DOI 10.1080/026990597123034; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; Lazarus R.S., 1984, HDB BEHAV MED, P282; LEZAK MD, 1988, J CLIN EXP NEUROPSYC, V10, P111, DOI 10.1080/01688638808405098; LINN RT, 1994, BRAIN INJURY, V8, P135, DOI 10.3109/02699059409150965; LOCKE HJ, 1959, MARRIAGE FAM LIVING, V21, P251, DOI 10.2307/348022; MALIA K, 1995, BRAIN INJURY, V9, P607, DOI 10.3109/02699059509008219; MARKMAN HJ, 1993, CLIN PSYCHOL REV, V13, P29, DOI 10.1016/0272-7358(93)90006-8; MARKMAN HJ, 1993, J CONSULT CLIN PSYCH, V61, P70, DOI 10.1037/0022-006X.61.1.70; MARKMAN HJ, 1984, MARITAL INTERACTION, P233; MARKMAN HJ, 1987, UNDERSTANDING MAJOR, P266; MARKMAN HJ, 1984, MARITAL INTERACTION; Martell C. R., 2001, DEPRESSION CONTEXT S; MIGNEAULT S, 2002, THESIS QUEBEC CANADA; Minnes P, 2000, BRAIN INJURY, V14, P737; MISHARA B, 1987, TRADUCTION FRANCAISE; MITCHELL SE, 1983, PSYCHOL REP, V53, P545, DOI 10.2466/pr0.1983.53.2.545; MONK M, 1981, CLIN INVEST MED, V4, P183; Moore A D, 1989, Brain Inj, V3, P171, DOI 10.3109/02699058909004549; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOORE AD, 1995, BRAIN INJURY, V9, P109, DOI 10.3109/02699059509008185; Perlesz A, 1999, REHABIL PSYCHOL, V44, P6, DOI 10.1037/0090-5550.44.1.6; Port A, 2002, BRAIN INJURY, V16, P277, DOI 10.1080/02699050110103274; PTACEK JT, 1994, J PSYCHOSOC ONCOL, V12, P47, DOI 10.1300/J077V12N03_04; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rath JF, 2003, NEUROPSYCHOL REHABIL, V13, P461, DOI 10.1080/09602010343000039; RENICK MJ, 1992, FAM RELAT, V41, P141, DOI 10.2307/584825; ROY R, 1985, INT J FAM THER, V7, P271, DOI 10.1007/BF00924028; Rutterford NA, 2006, J INT NEUROPSYCH SOC, V12, P359, DOI 10.1017/S1355617706060450; Sander AM, 1997, BRAIN INJURY, V11, P235, DOI 10.1080/026990597123548; Savard J, 1998, J PERS ASSESS, V71, P349, DOI 10.1207/s15327752jpa7103_5; SCHUMM WR, 1986, J MARRIAGE FAM, V48, P381, DOI 10.2307/352405; SCHUMM WR, 1983, PSYCHOL REP, V53, P583, DOI 10.2466/pr0.1983.53.2.583; SCHUMM WR, 1983, PSYCHOL REP, V53, P567, DOI 10.2466/pr0.1983.53.2.567; SPANIER GB, 1976, J MARRIAGE FAM, V38, P15, DOI 10.2307/350547; STEBBINS P, 1997, AUSTR J REHABILITATI, V3, P30; Tomberg T, 2005, BRAIN INJURY, V19, P1181, DOI 10.1080/02699050500150153; TURK DC, 1992, REHABIL PSYCHOL, V37, P259, DOI 10.1037/h0079108; WARE JE, 1979, CONCEPTUALIZATION ME, V3; Wells R, 2005, BRAIN INJURY, V19, P1105, DOI 10.1080/02699050500150062; White M. B., 1994, FAMILY PERSPECTIVE, V28, P53; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460; WRIGHT J, 1985, INTERVENTION AUPRES; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x; Ziino C, 2006, J INT NEUROPSYCH SOC, V12, P100, DOI 10.1017/S1355617706060139	93	23	23	0	13	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.		2007	21	4					357	372		10.1080/02699050701311075			16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	168IY	WOS:000246518600002	17487634				2021-06-18	
J	Durham, SR; Duhaime, AC				Durham, Susan R.; Duhaime, Ann-Christine			Maturation-dependent response of the immature brain to experimental subdural hematoma	JOURNAL OF NEUROTRAUMA			English	Article						age; animal studies; models of injury; pediatric brain injury; traumatic brain injury	INFLICTED HEAD-INJURY; AXONAL INJURY; NEUROPATHOLOGY; CHILDREN; TRAUMA; DAMAGE; INFANTS; MODEL	In children less than 2 years of age, the radiographic finding of a subdural hematoma (SDH) in the absence of trauma is highly suggestive of inflicted head injury. Little is understood about the unique pathophysiologic response of the immature brain to a SDH. The goal of the current study was to develop an experimental SDH model to determine whether there is a maturation-dependent response of the immature brain to SDH. Fifteen domestic Yorkshire piglets of three different age groups (five each of 5-days, 1-month, and 4-months old) were selected for study. A volume of blood equal to 10% of the intracranial volume (4.5 cc in the 5-day old, 5.4 cc in the 1-month old, and 9.4 cc in the 4-month old) was injected through a right frontal burr hole. Histologic analysis, including hematoxylin and eosin staining and TUNEL staining, was performed at 7 days survival. A significant difference in percentage of injured hemisphere was noted between the 5-day old group and the 1- and 4-month old animals (p = 0.0382). The number of TUNEL-positive cells/HPF increased significantly with increasing animal age (p = 0.0450). The current study demonstrates a significant maturation-dependent response of the immature brain to SDH, with the youngest animals being quite resistant to a SDH alone. This model will allow further study of additional cerebral insults, such as the addition of apnea or seizures, which may act synergistically along with a SDH to overwhelm the innate neuroprotective capacity of the immature brain to traumatic injury.	Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA	Durham, SR (corresponding author), Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.	srd@hitchcock.org					Barlow KM, 1999, ACTA PAEDIATR, V88, P734; Biousse V, 2002, AM J OPHTHALMOL, V133, P249, DOI 10.1016/S0002-9394(01)01366-6; CALDER IM, 1984, J CLIN PATHOL, V37, P1095, DOI 10.1136/jcp.37.10.1095; Dias MS, 1998, PEDIATR NEUROSURG, V29, P77, DOI 10.1159/000028694; DICKERSON JW, 1967, PROC R SOC SER B-BIO, V166, P384, DOI 10.1098/rspb.1967.0002; Duhaime A.C., 1993, J NEUROTRAUMA S1, V10, pS59; Duhaime AC, 1996, PEDIATR NEUROSURG, V24, P292, DOI 10.1159/000121058; Duhaime AC, 2003, J NEUROSURG, V99, P542, DOI 10.3171/jns.2003.99.3.0542; DUHAIME AC, 1994, J NEUROTRAUM, V11, P669, DOI 10.1089/neu.1994.11.669; Duhaime AC, 1996, J NEUROTRAUM, V13, P79, DOI 10.1089/neu.1996.13.79; Duhaime AC, 2000, J NEUROSURG, V93, P455, DOI 10.3171/jns.2000.93.3.0455; Durham SR, 2000, PEDIATR NEUROSURG, V33, P76, DOI 10.1159/000028980; Ewing-Cobbs L, 2000, CHILD NERV SYST, V16, P25, DOI 10.1007/s003810050006; FLYNN TJ, 1984, NEUROCHEM RES, V9, P935, DOI 10.1007/BF00964525; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; Gilles EE, 1998, PEDIATR NEUROL, V19, P119, DOI 10.1016/S0887-8994(98)00038-1; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; Haseler LJ, 1997, PEDIATRICS, V99, P4, DOI 10.1542/peds.99.1.4; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; LINDENBERG R, 1969, ARCH PATHOL, V87, P298; Lo T Y M, 2003, Pediatr Rehabil, V6, P47, DOI 10.1080/1363849031000109516; MILLER JD, 1990, NEUROSURGERY, V27, P433, DOI 10.1227/00006123-199009000-00016; PAMPIGLIONE G, 1971, P ROY SOC MED, V64, P429, DOI 10.1177/003591577106400441; Parizel PM, 2003, PEDIATR RADIOL, V33, P868, DOI 10.1007/s00247-003-1025-3; Ransom GH, 2003, CHILD ABUSE NEGLECT, V27, P381, DOI 10.1016/S0145-2134(03)00025-5; Sasaki M, 2001, J NEUROTRAUM, V18, P1241, DOI 10.1089/089771501317095278; Sawauchi S, 2003, J NEUROTRAUM, V20, P613, DOI 10.1089/089771503322144536; Sawauchi S, 2002, ACT NEUR S, V81, P243; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; Shaver EG, 1996, PEDIATR NEUROSURG, V25, P123, DOI 10.1159/000121109; Suh DY, 2001, NEUROSURGERY, V49, P309, DOI 10.1097/00006123-200108000-00011; THOMAS JM, 1971, GROWTH, V35, P259; Tomita Y, 2000, ACTA NEUROCHIR SUPPL, V76, P213	34	23	23	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2007	24	1					5	14		10.1089/neu.2006.0054			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	131GX	WOS:000243858100002	17263666				2021-06-18	
J	Noe, E; Ferri, J; Trenor, C; Chirivella, J				Noe, Enrique; Ferri, Joan; Trenor, Carlos; Chirivella, Javier			Efficacy of ziprasidone in controlling agitation during post-traumatic amnesia	BEHAVIOURAL NEUROLOGY			English	Article						posttraumatic amnesia; traumatic brain injury; ziprasidone; neuroleptics; agitation	TRAUMATIC BRAIN-INJURY; CLOSED HEAD-INJURY; RESTLESSNESS; RISPERIDONE; OLANZAPINE; CLOZAPINE	Objectives: to provide our initial experience with ziprasidone in the management of behaviour problems of patients with traumatic brain injury (TBI) during the period of post-traumatic amnesia (PTA). Patients: Five patients with a mean age of 26.8 +/- 9.8 years who had suffered a severe TBI (Glasgow Coma Scale score < 8; length of coma: 16 +/- 7.1 days; and length of PTA: 62.4 +/- 14.8 days) were included in the study. Agitation was assessed by the Agitated Behaviour Scale (ABS) prior to the administration of ziprasidone, after two weeks of initiating treatment and at the moment of discontinuing ziprasidone. Results: ABS Total score decreased from 27.2 +/- 3 to 18 +/- 1.2 after two weeks of treatment. The same decrease was also noticed in each one of the subscales (dishinhibition, aggressiveness and lability). Mean dose of the drug was 52.8 +/- 27.11 mg/day (range: 20-80 mg), with the highest dose ranging between 40 and 80 mg (64 +/- 21.9 mg). Maximum period of administration of ziprasidone was 48.2 +/- 14.8 days (range: 35-68 days). No clinical or electrocardiographic side effects were reported. Conclusion: This study shows the efficacy of ziprasidone in controlling agitation during the PTA period. Despite the small size of our sample, ziprasidone reduced symptoms of agitation quickly and with good tolerability, safety and no side effects.	Inst Valenciano Neurorehabil IVAN, Serv Dano Cerebral Hosp NISA, Valencia, Spain	Noe, E (corresponding author), Hosp Valencia Mar, Inst Valenciano Neurorehabil IVAN, C Rio Tajo 1, Valencia 46011, Spain.	enoe@comv.es		Noe Sebastian, Enrique/0000-0002-2547-8727			BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P917; Butler PV, 2000, AUST NZ J PSYCHIAT, V34, P684, DOI 10.1046/j.1440-1614.2000.00758.x; GOLDBERG TE, 1994, J CLIN PSYCHIAT, V55, P88; Heinrich TW, 2004, GEN HOSP PSYCHIAT, V26, P490, DOI 10.1016/j.genhosppsych.2004.08.001; Keck P E Jr, 2001, Expert Opin Pharmacother, V2, P1033; Krieger D, 2003, NEUROREHABILITATION, V18, P205; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LLINAS RJ, 1995, NEUROLOGIA, V10, P14; Matza LS, 2005, CNS DRUGS, V19, P499, DOI 10.2165/00023210-200519060-00003; MICHALS ML, 1993, J CLIN PSYCHOPHARM, V13, P198; Mizoguchi Y, 2002, J NEUROPSYCH CLIN N, V14, P87, DOI 10.1176/appi.neuropsych.14.1.87-a; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; REYES RL, 1981, ARCH PHYS MED REHAB, V62, P20; Richard I., 2003, Annales de Readaptation et de Medecine Physique, V46, P49, DOI 10.1016/S0168-6054(02)00353-7; Sallee FR, 2000, J AM ACAD CHILD PSY, V39, P292, DOI 10.1097/00004583-200003000-00010; Schreiber S, 1998, INT CLIN PSYCHOPHARM, V13, P273, DOI 10.1097/00004850-199811000-00006; Silver BV, 2003, BRAIN INJURY, V17, P237, DOI 10.1080/0269905021000013192; Stahl SM, 2003, J CLIN PSYCHIAT, V64, P6	19	23	23	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	0953-4180			BEHAV NEUROL	Behav. Neurol.		2007	18	1					7	11		10.1155/2007/529076			5	Clinical Neurology	Neurosciences & Neurology	151OL	WOS:000245299900002	17297214	DOAJ Gold, Green Published			2021-06-18	
J	Rees, RJ; Bellon, ML				Rees, Roger J.; Bellon, Michelle L.			Post concussion syndrome ebb and flow: Longitudinal effects and management	NEUROREHABILITATION			English	Article						concussion; post concussion syndrome; minimal brain damage; psychological difficulties; neurological impairment	TRAUMATIC BRAIN-INJURY; CHRONIC-FATIGUE-SYNDROME; MILD HEAD-INJURY; POSTTRAUMATIC-STRESS-DISORDER; SELF-AWARENESS; POSTCONCUSSION SYNDROME; MEMORY IMPAIRMENT; SYMPTOMS; REHABILITATION; DEFINITION	This research identified persistent post concussion symptoms (PCS) in a group of 20 adult subjects. PCS generally lasted for two years with a mean of 3.35 years. Typical symptoms included physical and cognitive fatigue, depressive behaviors, sensitivity to noise, social withdrawal, irritability, concentration and problem solving difficulties, loss of libido and much difficulty making decisions at even the simplest strategic level. They represented a hard core group for whom the original symptoms persisted well beyond the 6 month period. Participants identified their PCS according to sensory, somatic affective and cognitive items immediately following their trauma (01) and two years later (02). Counseling and psychotherapy intervention took place between 01 and 02. Items on the PCS schedules and the Beck Depression Inventory (II) demonstrated significant decline in the presence of overall symptoms most noticeably in reduction of agitation, irritability and suicidal wishes. However, subjects throughout generally experienced the feeling that they were being punished which equated with behaviors comparable with learned helplessness. The PCS group considered themselves to be different people after trauma. They had different goals, changing lifestyle, relationships and employment and were more often in a dependent state. Comparability with other conditions such as PTSD and chronic fatigue syndrome (CFS) was demonstrated by individuals who experienced persistent and invasive post concussion symptoms.	Flinders Univ S Australia, Sch Med, Adelaide, SA 5001, Australia	Rees, RJ (corresponding author), Flinders Univ S Australia, Sch Med, Sturt Rd,Bedford Pk,GPO BOX 2100, Adelaide, SA 5001, Australia.	rees1@iinet.net.au		Bellon, Michelle/0000-0003-2551-1846			ABBEY SE, 1991, AM J PSYCHIAT, V148, P1638; Adler P. A., 1994, HDB QUALITATIVE RES, P337; ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; ANDERSON ID, 1990, J TRAUMA, V30, P974, DOI 10.1097/00005373-199008000-00005; Atkinson P., 1994, HDB QUALITATIVE RES, P248; Beck A.T., 1987, BECK DEPRESSION INVE; BECKER M, 1995, PHARMACOECONOMICS, V7, P229, DOI 10.2165/00019053-199507030-00006; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Binder LM, 1996, AM J PSYCHIAT, V153, P7; Blanchard EB, 1996, BEHAV RES THER, V34, P775, DOI 10.1016/0005-7967(96)00038-1; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BOHNEN N, 1992, NEUROSURGERY, V30, P692; BORNSTEIN RA, 1989, J NEUROSURG, V70, P509, DOI 10.3171/jns.1989.70.4.0509; BRISON S, 2002, AFERMATH VIOLENCE RE; Bryant RA, 1999, J NERV MENT DIS, V187, P302, DOI 10.1097/00005053-199905000-00006; Bryant RA, 2003, AM J PSYCHIAT, V160, P585, DOI 10.1176/appi.ajp.160.3.585; CICERONE KD, 1995, J HEAD TRAUMA REHAB, V10, P1, DOI 10.1097/00001199-199510030-00002; CICERONE KD, 2000, TRAUMATIC BRAIN INJU, P95; COREY G, 1992, THEORY PRACTICE COUN, P140; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Deb S, 1998, J NEUROL NEUROSUR PS, V65, P899, DOI 10.1136/jnnp.65.6.899; DELUCA J, 1995, J NEUROL NEUROSUR PS, V58, P38, DOI 10.1136/jnnp.58.1.38; DeLuca J, 2004, REHABIL PSYCHOL, V49, P62, DOI 10.1037/0090-5550.49.1.62; DEVINSKY O, 1992, BEHAV NEUROLOGY 100; Evans JJ, 1998, J INT NEUROPSYCH SOC, V4, P399, DOI 10.1017/S1355617798003993; Fontana A., 1994, HDB QUALITATIVE RES, P361; GERBERICH SG, 1983, AM J PUBLIC HEALTH, V73, P1370, DOI 10.2105/AJPH.73.12.1370; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Gray T., 1989, NEUROPEPTIDES STRESS, P92; GREIFFENSTEIN MF, 1995, CLIN NEUROPSYCHOL, V9, P230, DOI 10.1080/13854049508400485; GRONWALL D, 1974, LANCET, V2, P605; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; HAGEN C, 1979, REHABILTATION HEAD I; HILTON J, 1877, LECT REST PAIN; Hirt ER, 1996, J PERS SOC PSYCHOL, V71, P245, DOI 10.1037/0022-3514.71.2.245; ISEN AM, 1983, SOC COGNITION, V2, P18, DOI 10.1521/soco.1983.2.1.18; ISEN AM, 2000, HDB EMOTIONS, P417; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P74, DOI DOI 10.1097/00001199-199309000-00009; King NS, 2003, BRIT J PSYCHIAT, V183, P276, DOI 10.1192/bjp.183.4.276; KRAUS JF, 1996, NEUROTRAUMA, P13; Larrabee GJ, 2000, CLIN GUIDE NEUROPSYC, P301; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; Levin H. S., 1987, NEUROBEHAVIORAL RECO, P262; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A, P97; LIDVALL F, 1974, ACTA NEUROL SCAND, V20, P56; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; MARION DW, 1995, MED REHABILITATION T, P29; MATEER CA, 1992, PHYSICAL MED REHABIL, V6, P143; Mayou RA, 2000, BRIT J PSYCHIAT, V177, P540, DOI 10.1192/bjp.177.6.540; MIDDELBOE T, 1991, ACTA NEUROL SCAND, V85, P687; MILLER L, 1993, PSYCHOTHERAPY BRAIN, P173; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Ownsworth T, 2004, NEUROPSYCHOL REHABIL, V14, P535, DOI 10.1080/09602010343000538; Ownsworth TL, 2002, BRAIN INJURY, V16, P291, DOI 10.1080/02699050110103986; PALLANT J, 2001, SPSS SURVIVAL MANUAL, P180; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; RASKIN NJ, 1995, CURRENT PSYCHOTHERAP, P128; RESS RJ, 2005, INTERUPTED LIVES REH; RESS RJ, 1997, PLATEAUS SUMMITS TRA; RIMEL RW, 1982, NEUROSURGERY, V11, P344, DOI 10.1227/00006123-198209000-00002; Roman DD, 1991, CLIN NEUROPSYCHOL, V5, P33; Ruff RM, 1999, BRAIN INJURY, V13, P943; SCHLUEDERBERG A, 1992, ANN INTERN MED, V117, P325, DOI 10.7326/0003-4819-117-4-325; SCHMALING KB, 1994, PSYCHOSOM MED, V56, P383, DOI 10.1097/00006842-199409000-00001; SOHLBERG MM, 2001, COGNITIVE REHABILITA, P453; STONER HB, 1994, BRAIN CONTROL RESPON, P3; SYMONDS C, 1962, LANCET, V1, P1; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Tiersky LA, 1997, J CLIN EXP NEUROPSYC, V19, P560, DOI 10.1080/01688639708403744; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; Wilson BA, 1996, MEMORY, V4, P465, DOI 10.1080/741940776; Wrightson P, 1999, MILD HEAD INJURY GUI	76	23	23	1	15	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2007	22	3					229	242					14	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	216NM	WOS:000249884800009	17917173				2021-06-18	
J	Roche, NL; Moody, A; Szabo, K; Fleming, JM; Shum, DHK				Roche, Nadine L.; Moody, Anna; Szabo, Krisztina; Fleming, Jennifer M.; Shum, David H. K.			Prospective memory in adults with traumatic brain injury: An analysis of perceived reasons for remembering and forgetting	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							SELF-AWARENESS; REHABILITATION; DEFICITS	Reasons for prospective remembering and forgetting after traumatic brain injury (TBI) were investigated using Ellis' (1996) five phases of prospective memory as a framework. Participants were 38 individuals with severe TBI and 34 controls. Participants self-rated their perceived reasons for prospective remembering and forgetting using section C of the Comprehensive Assessment of Prospective Memory (CAPM). Significant others also rated participants using the same scale. Analyses were conducted to examine the effect of group membership (TBI or control) on reported reasons for prospective remembering and forgetting. Findings highlighted the TBI group's difficulties with encoding, performance interval, and execution phases of prospective remembering.	Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia; Griffith Univ, Sch Psychol & Appl Cognit Neurosci Res, Nathan, Qld 4111, Australia	Fleming, JM (corresponding author), Univ Queensland, Sch Hlth & Rehabil Sci, Div Occupat Therapy, Brisbane, Qld 4072, Australia.	j.fleming@uq.edu.au	Fleming, Jennifer M/B-4436-2011; Shum, David/A-3914-2008	Shum, David/0000-0002-4810-9262			Andrewes DG, 1998, NEUROPSYCHOL REHABIL, V8, P377, DOI 10.1080/713755582; Baddeley A. D., 2002, HDB MEMORY DISORDERS, P3; Bogod NM, 2003, J INT NEUROPSYCH SOC, V9, P450, DOI 10.1017/S1355617703930104; BRADSHAW JL, 1995, CLIN NEUROPSYCHOLOGY; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; Cohen G, 1993, MEMORY CURRENT ISSUE; Cohen Gillian, 1996, MEMORY REAL WORLD; DALLABARBA G, 1993, HDB NEUROPSYCHOLOGY, V8, P239; DOBBS AR, 1996, PROSPECTIVE MEMORY T, P199; EINSTEIN GO, 1990, J EXP PSYCHOL LEARN, V16, P717, DOI 10.1037/0278-7393.16.4.717; Ellis J, 2000, APPL COGNITIVE PSYCH, V14, pS1, DOI 10.1002/acp.767; Ellis JA., 1996, PROSPECTIVE MEMORY T, P1; Fleming J, 1999, OCCUP THER J RES, V19, P3, DOI 10.1177/153944929901900101; Fleming JM, 2005, BRAIN INJURY, V19, P1, DOI 10.1080/02699050410001720059; Fleming JM, 1996, BRAIN INJURY, V10, P1; Fortune N, 1999, DEFINITION INCIDENCE; GLISKY EL, 1996, PROSPECTIVE MEMORY T, P249; GOLDSTEIN LH, 1992, BRIT J CLIN PSYCHOL, V31, P75, DOI 10.1111/j.2044-8260.1992.tb00969.x; Groot YCT, 2002, J INT NEUROPSYCH SOC, V8, P645, DOI 10.1017/S1355617702801321; Hannon R, 1995, REHABIL PSYCHOL, V40, P289, DOI 10.1037/0090-5550.40.4.289; Hart T, 2002, J HEAD TRAUMA REHAB, V17, P556, DOI 10.1097/00001199-200212000-00007; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; HERRMANN DJ, 1982, PSYCHOL BULL, V92, P434, DOI 10.1037/0033-2909.92.2.434; Hutchinson J, 1997, TOP LANG DISORD, V18, P45, DOI 10.1097/00011363-199711000-00006; Kinsella G, 1996, BRAIN INJURY, V10, P499, DOI 10.1080/026990596124214; LEVIN HS, 1995, J NEUROTRAUM, V12, P601, DOI 10.1089/neu.1995.12.601; Mateer C. A., 1999, COGNITIVE NEUROREHAB, P314; Mateer C.A., 1987, J HEAD TRAUMA REHAB, V2, P74, DOI [10.1097/00001199-198709000-00009, DOI 10.1097/00001199-198709000-00009]; O'Connell ME, 2003, NEUROREHABILITATION, V18, P9; PARENTE R, 1991, COGNITIVE REHABILITA, P147; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; Roche NL, 2002, BRAIN INJURY, V16, P931, DOI 10.1080/02699050210138581; Shum D, 1999, J CLIN EXP NEUROPSYC, V21, P49, DOI 10.1076/jcen.21.1.49.943; Shum D., 2002, BRAIN IMPAIR, V3, DOI [https://doi.org/10.1375/brim.3.1.1, DOI 10.1375/BRIM.3.1.1]; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Stuss DT, 1992, NEUROPSY NEUROPSY BE, V5; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; THOMPSON SBN, 1996, BRIT J OCCUPATIONAL, V59, P418; van den Broek MD, 2000, BRAIN INJURY, V14, P455; Varney N. R., 1993, J HEAD TRAUMA REHAB, V8, P32, DOI DOI 10.1097/00001199-199303000-00005; WAUGH N, 1999, THESIS GRIFFITH U QU; Wilson BA, 2003, STUD NEUROPSYCHOL DE, P71; WINOGRAD E, 1987, PRACTICAL ASPECTS ME, V1, P348	43	23	24	0	9	ROUTLEDGE JOURNALS, TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0960-2011	1464-0694		NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.		2007	17	3					314	334		10.1080/09602010600831004			21	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	165IQ	WOS:000246298500003	17474059				2021-06-18	
J	De Monte, VE; Geffen, GM; Massavelli, BM				De Monte, Veronica Eileen; Geffen, Gina Malke; Massavelli, Bronwyn May			The effects of post-traumatic amnesia on information processing following mild traumatic brain injury	BRAIN INJURY			English	Article						post-traumatic amnesia; mild-traumatic brain injury; severity; information processing; verbal recall	HEAD-INJURY; RAPID SCREEN; CONCUSSION; SYMPTOMS	Primary objective: The aim of this study was to determine whether a single measurement of level of PTA could distinguish patients more severely injured from those less so, by investigating the effect of PTA on psychometric test performance. Methods and procedures: Ninety patients with mTBI completed a word recall test, a spoken version of the Speed of Comprehension test and the Digit Symbol Substitution Test (Digit Symbol), within 24 hours of injury. These patients were divided into two groups, based on the presence (n = 42) or absence (n = 48) of PTA at the time of testing. PTA was measured with an eight-item orientation scale. Main outcomes and results: An independent groups design showed that patients with mTBI in PTA recalled fewer words after two presentations and after a delay and completed fewer symbols in 90 seconds on Digit Symbol than patients with mTBI not in PTA. Discriminant function analysis was applied to explore whether classifying severity of injury in terms of number of orientation questions answered would be useful. Conclusions: These results indicate that for individuals with mTBI in PTA, speed of information processing and verbal memory are impaired. A single brief administration of orientation questions may be sufficient to provide an index of severity of mTBI within the first 24 hours.	Univ Queensland, Cognit Psychophysiol Lab, Med Sch, Herston, Qld 4006, Australia	Geffen, GM (corresponding author), Univ Queensland, Cognit Psychophysiol Lab, Med Sch, Edith Cavell Bldg,Herston Rd, Herston, Qld 4006, Australia.	geffen@psy.uq.edu.au					Baddeley A.D., 1992, SPEED CAPACITY LANGU; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Borg J, 2004, J REHABIL MED, V36, P61, DOI 10.1080/16501960410023822; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Comerford VE, 2002, J CLIN EXP NEUROPSYC, V24, P409, DOI 10.1076/jcen.24.4.409.1044; De Monte VE, 2005, J CLIN EXP NEUROPSYC, V27, P224, DOI 10.1080/13803390490515766; De Monte VE, 2004, J CLIN EXP NEUROPSYC, V26, P628, DOI 10.1080/13803390490504443; De Monte VE., 2005, BRAIN IMPAIR, V6, P109, DOI [10.1375/brim.2005.6.2.109, DOI 10.1375/BRIM.2005.6.2.109]; Feinstein A, 2002, J NEUROPSYCH CLIN N, V14, P25, DOI 10.1176/appi.neuropsych.14.1.25; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Geffen G., 1994, AUST OCCUP THER J, V41, P31, DOI DOI 10.1111/J.1440-1630.1994.TB01809.X; GELDER BC, 2000, DISS ABSTR INT B, V60, P3563; HintonBayre AD, 1997, J CLIN EXP NEUROPSYC, V19, P275, DOI 10.1080/01688639708403857; HOFFMAN LM, 2000, DISS ABSTR INT B, V61, P2763; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kwapil KJ., 2003, BRAIN IMPAIR, V4, P155; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Peloso PM, 2004, J REHABIL MED, V36, P106, DOI 10.1080/16501960410023868; Shores E A, 1995, Appl Neuropsychol, V2, P167; Smith-Seemiller L, 2003, BRAIN INJURY, V17, P199, DOI 10.1080/0269905021000030823; Tabachnick B., 2001, USING MULTIVARIATE S; Trenerry M.R., 1989, STROOP NEUROPSYCHOLO; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wilson BA, 1999, BRAIN INJURY, V13, P505, DOI 10.1080/026990599121412	29	23	23	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	2006	20	13-14					1345	1354		10.1080/02699050601082073			10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	130GF	WOS:000243787100004	17378226				2021-06-18	
J	Chen, Q; Wang, S; Thompson, SN; Hall, ED; Guttmann, RP				Chen, Qinghua; Wang, Susan; Thompson, Stephanie N.; Hall, Edward D.; Guttmann, Rodney P.			Identification and characterization of PEBP as a calpain substrate	JOURNAL OF NEUROCHEMISTRY			English	Article						Alzheimer's disease; calpain; phosphatidylethanolamine-binding protein; proteasome	FOCAL CEREBRAL-ISCHEMIA; TRAUMATIC BRAIN-INJURY; PEPTIDE (HCNP)-RELATED COMPONENTS; ALZHEIMERS-DISEASE; IN-SITU; CORTICAL-NEURONS; PROSTATE-CANCER; ALPHA-SYNUCLEIN; CELL-MIGRATION; RAT-BRAIN	Calpains are calcium- and thiol-dependent proteases whose dysregulation has been implicated in a number of diseases and conditions such as cardiovascular dysfunction, ischemic stroke, and Alzheimer's disease (AD). While the effects of calpain activity are evident, the precise mechanism(s) by which dysregulated calpain activity results in cellular degeneration are less clear. In order to determine the impact of calpain activity, there is a need to identify the range of specific calpain substrates. Using an in vitro proteomics approach we confirmed that phosphatidylethanolamine-binding protein (PEBP) as a novel in vitro and in situ calpain substrate. We also observed PEBP proteolysis in a model of brain injury in which calpain is clearly activated. In addition, with evidence of calpain dysregulation in AD, we quantitated protein levels of PEBP in postmortem brain samples from the hippocampus of AD and age-matched controls and found that PEBP levels were approximately 20% greater in AD. Finally, with previous evidence that PEBP may act as a serine protease inhibitor, we tested PEBP as an inhibitor of the proteasome and found that PEBP inhibited the chymostrypsin-like activity of the proteasome by similar to 30%. Together these data identify PEBP as a potential in vivo calpain substrate and indicate that increased PEBP levels may contribute to impaired proteasome function.	Univ Kentucky, Dept Gerontol, Lexington, KY 40536 USA; Univ Kentucky, Spinal Cord & Brain Injury Res Ctr, Lexington, KY 40536 USA; Univ Kentucky, Dept Physiol, Lexington, KY 40536 USA; Univ Kentucky, Sanders Brown Ctr Aging, Lexington, KY 40536 USA	Guttmann, RP (corresponding author), Univ Kentucky, Dept Gerontol & Physiol, 800 S Limestone,Room 305 SB, Lexington, KY 40536 USA.	rodneyg@uky.edu	Hall, Edward D/F-8930-2013; guttmann, rodney/AAN-8880-2021	guttmann, rodney/0000-0001-5553-3099	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS047635] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS047635] Funding Source: NIH RePORTER		Adamec E, 2002, ACTA NEUROPATHOL, V104, P92, DOI 10.1007/s00401-002-0528-6; BARTUS RT, 1994, J CEREBR BLOOD F MET, V14, P537, DOI 10.1038/jcbfm.1994.67; BARTUS RT, 1995, NEUROL RES, V17, P249, DOI 10.1080/01616412.1995.11740322; Bence NF, 2001, SCIENCE, V292, P1552, DOI 10.1126/science.292.5521.1552; Bi RF, 2000, J BIOL CHEM, V275, P26477, DOI 10.1074/jbc.M003763200; Bi XN, 1998, BRAIN RES, V790, P245, DOI 10.1016/S0006-8993(98)00067-5; BLOMGREN K, 1995, BRAIN RES, V684, P143, DOI 10.1016/0006-8993(95)00399-B; CRESSMAN CM, 1995, FEBS LETT, V367, P223, DOI 10.1016/0014-5793(95)00543-I; Dong YZ, 2006, FASEB J, V20, P331, DOI 10.1096/fj.05-4524fje; Franco SJ, 2005, J CELL SCI, V118, P3829, DOI 10.1242/jcs.02562; Fu Z, 2006, PROSTATE, V66, P248, DOI 10.1002/pros.20319; Fukada K, 2004, MOL CELL PROTEOMICS, V3, P1211, DOI 10.1074/mcp.M400094-MCP200; Gafni J, 2004, J BIOL CHEM, V279, P20211, DOI 10.1074/jbc.M401267200; GEDDES JW, 1995, NEUROBIOL AGING, V16, P651, DOI 10.1016/0197-4580(95)00062-J; Goffredo D, 2002, J BIOL CHEM, V277, P39594, DOI 10.1074/jbc.C200353200; Goll DE, 2003, PHYSIOL REV, V83, P731, DOI 10.1152/physrev.00029.2002; Guttmann RP, 1998, J BIOL CHEM, V273, P13331, DOI 10.1074/jbc.273.21.13331; Guttmann RP, 1997, J BIOL CHEM, V272, P2005, DOI 10.1074/jbc.272.3.2005; Guttmann RP, 2002, J PHARMACOL EXP THER, V302, P1023, DOI 10.1124/jpet.102.036962; Guttmann RP, 2001, J NEUROCHEM, V78, P1083, DOI 10.1046/j.1471-4159.2001.00493.x; Hagan S, 2005, CLIN CANCER RES, V11, P7392, DOI 10.1158/1078-0432.CCR-05-0283; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Hengst U, 2001, J BIOL CHEM, V276, P535, DOI 10.1074/jbc.M002524200; HONG SC, 1994, STROKE, V25, P663, DOI 10.1161/01.STR.25.3.663; HONG SC, 1994, BRAIN RES, V661, P43, DOI 10.1016/0006-8993(94)91178-9; Huttenlocher A, 1997, J BIOL CHEM, V272, P32719, DOI 10.1074/jbc.272.52.32719; JOHNSON GVW, 1989, BIOCHEM BIOPH RES CO, V163, P1505, DOI 10.1016/0006-291X(89)91150-9; Johnson GVW, 1997, BIOESSAYS, V19, P1011, DOI 10.1002/bies.950191111; Keller JN, 2000, J NEUROCHEM, V75, P436, DOI 10.1046/j.1471-4159.2000.0750436.x; Kim MH, 2003, EXP NEUROL, V183, P109, DOI 10.1016/S0014-4886(03)00132-8; Kupina NC, 2001, J NEUROTRAUM, V18, P1229, DOI 10.1089/089771501317095269; Liu MC, 2006, BIOCHEM J, V394, P715, DOI 10.1042/BJ20050905; LODISH HF, 1990, J BIOL CHEM, V265, P10893; Mamoune A, 2003, CANCER RES, V63, P4632; Marcum JL, 2005, BIOCHEM BIOPH RES CO, V334, P342, DOI 10.1016/j.bbrc.2005.06.089; Markgraf CG, 1998, STROKE, V29, P152, DOI 10.1161/01.STR.29.1.152; Mathews PM, 2002, J BIOL CHEM, V277, P36415, DOI 10.1074/jbc.M205208200; McCollum AT, 2004, J NEUROSCI RES, V76, P104, DOI 10.1002/jnr.20059; MELLONI E, 1989, TRENDS NEUROSCI, V12, P438, DOI 10.1016/0166-2236(89)90093-3; Minger SL, 1998, BRAIN RES, V810, P181, DOI 10.1016/S0006-8993(98)00921-4; Mishizen-Eberz AJ, 2003, J NEUROCHEM, V86, P836, DOI 10.1046/j.1471-4159.2003.01878.x; MITAKE S, 1995, NEUROPATH APPL NEURO, V21, P35, DOI 10.1111/j.1365-2990.1995.tb01026.x; Mitake S, 1996, NEUROPATH APPL NEURO, V22, P440, DOI 10.1111/j.1365-2990.1996.tb00918.x; Mitake Shigehisa, 1997, Kaohsiung Journal of Medical Sciences, V13, P10; MURACHI T, 1981, ADV ENZYME REGUL, V19, P407; Neumar RW, 2003, J BIOL CHEM, V278, P14162, DOI 10.1074/jbc.M212255200; Neumar RW, 2001, EXP NEUROL, V170, P27, DOI 10.1006/exnr.2001.7708; Otsuka Y, 1996, NEUROCHEM RES, V21, P369, DOI 10.1007/BF02531654; Perkins DN, 1999, ELECTROPHORESIS, V20, P3551, DOI 10.1002/(SICI)1522-2683(19991201)20:18<3551::AID-ELPS3551>3.0.CO;2-2; Pettigrew LC, 1996, J CEREBR BLOOD F MET, V16, P1189, DOI 10.1097/00004647-199611000-00013; Posmantur R, 1997, NEUROSCIENCE, V77, P875, DOI 10.1016/S0306-4522(96)00483-6; RAMI A, 1993, BRAIN RES, V609, P67, DOI 10.1016/0006-8993(93)90856-I; Robinson A, 1996, CAN MED ASSOC J, V154, P193; Saatman KE, 2000, J CEREBR BLOOD F MET, V20, P66, DOI 10.1097/00004647-200001000-00010; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Schoenwaelder SM, 1997, J BIOL CHEM, V272, P24876, DOI 10.1074/jbc.272.40.24876; SIMAN R, 1984, P NATL ACAD SCI-BIOL, V81, P3572, DOI 10.1073/pnas.81.11.3572; SIMAN R, 1983, J NEUROCHEM, V41, P950, DOI 10.1111/j.1471-4159.1983.tb09039.x; Snyder H, 2003, J BIOL CHEM, V278, P11753, DOI 10.1074/jbc.M208641200; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sullivan PG, 1999, J NEUROSCI, V19, P6248; Sun AY, 1999, CLIN NEUROPHARMACOL, V22, P164; Tsugu Y, 1998, EUR J NEUROL, V5, P561, DOI 10.1046/j.1468-1331.1998.560561.x; WANG KKW, 1989, BIOCHEM J, V262, P693, DOI 10.1042/bj2620693; Wells A, 2005, INT REV CYTOL, V245, P1, DOI 10.1016/S0074-7696(05)45001-9; Yadavalli R, 2004, J BIOL CHEM, V279, P21948, DOI 10.1074/jbc.M400793200; Yamazaki T, 1997, BIOCHEMISTRY-US, V36, P8377, DOI 10.1021/bi970209y; Zalewska T, 1996, FOLIA NEUROPATHOL, V34, P121; Zhang JW, 1998, J NEUROCHEM, V71, P240; ZHANG L, 1999, J BIOL CHEM, V274, P8699; Zhang SX, 2003, J NEUROTRAUM, V20, P59, DOI 10.1089/08977150360517182	71	23	25	0	5	BLACKWELL PUBLISHING	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DQ, OXON, ENGLAND	0022-3042			J NEUROCHEM	J. Neurochem.	NOV	2006	99	4					1133	1141		10.1111/j.1471-4159.2006.04160.x			9	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	098ZS	WOS:000241562900009	17018026	Bronze			2021-06-18	
J	Rice, J; Philbin, N; Handrigan, M; Hall, C; McGwin, G; Ahlers, S; Pearce, LB; Arnaud, F; McCarron, R; Freilich, D				Rice, Jennifer; Philbin, Nora; Handrigan, Michael; Hall, Carrie; McGwin, Gerald; Ahlers, Stephen; Pearce, L. B.; Arnaud, Francoise; McCarron, Richard; Freilich, Daniel			Vasoactivity of bovine polymerized hemoglobin (HBOC-201) in swine with traumatic hemorrhagic shock with and without brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article						hemoglobin based oxygen carrier; HBOC-201; hemorrhagic shock; resuscitation; blood pressure; vasoactivity; hypoperfusion	CROSS-LINKED HEMOGLOBIN; DELAYED EVACUATION; BLOOD SUBSTITUTE; OXYGEN CARRIER; LIVER-INJURY; VOLUME RESUSCITATION; HETASTARCH HEX; MODEL; TRANSFUSION; MULTICENTER	Background: We previously reported that bovine polymerized hemoglobin (HBOC- 201) improved outcome in swine with hemorrhagic shock (HS) with and without traumatic brain injury (TBI). Herein, we add analyses of blood pressure (BP) responses, associated physiologic data, and HS fluid infusion guidelines. Methods: HBOC-201 versus standard fluid resuscitation was compared in four anesthetized invasively monitored swine models: moderate controlled HS, severe controlled HS, severe uncontrolled HS (liver injury), and severe uncontrolled HS/TBI (liver/parietal brain injuries). Pigs received fluid for hypotension and tachycardia, and were followed up to 6 (HS alone) or 72 hours (HS/TBI). The change in mean arterial pressure (Delta MAP) response severity was stratified and analyzed based on infusion number and HS severity, using Student's t and Fisher's exact tests. Results: HBOC-201 vasoactivity resulted in higher MAP in all studies. Among HBOC-201 pigs, Delta MAP responses were significant for the first two infusions and inversely related to HS severity. Among controls, ANUP responses remained significant through the fourth infusion in controlled HS models, and through the first in severe uncontrolled HS/TBI; none were significant in severe uncontrolled HS. Delta MAP was higher with HBOC-201 through the first infusion in moderate controlled HS, the fifth in severe uncontrolled HS, and the second in severe uncontrolled HS/TBI; there were no group differences in severe controlled HS. No severe MAP responses occurred. Higher Delta MAP severity did not impact outcome. Hypotension satisfied fluid reinfusion criteria less consistently than tachycardia. Overall, HBOC-201 improved physiologic parameters and survival without causing hypoperfusion; in severe HS, perfusion improved. Conclusions: In swine with HS :t TBI, HBOC-201 had mild to moderate vasoactivity, resulting in significant ANUP responses mainly after initial infusions, no severe/adverse responses, and improved outcome. Our data suggest that use of physiologic parameters (e.g., tachycardia), in addition to hypotension to guide fluid reinfusion during HS resuscitation with HBOC-201, will minimize hypoperfusion risk and maximize potential benefit.	USN, Med Res Ctr, Combat Casualty Directorate, Silver Spring, MD 20910 USA; Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA; Biopure Corp, Cambridge, MA USA	Freilich, D (corresponding author), USN, Med Res Ctr, Combat Casualty Directorate, Silver Spring, MD 20910 USA.	freilichd@nmrc.navy.mil					ABASSI Z, 1997, J LAB CLIN MED, V129, P580; Baldwin AL, 2002, AM J PHYSIOL-HEART C, V283, pH1292, DOI 10.1152/ajpheart.00221.2002; Butler FK, 2001, MIL MED, V166, P625; Doyle MP, 1999, J BIOL CHEM, V274, P2583, DOI 10.1074/jbc.274.4.2583; ENZAN K, 1991, J APPL PHYSIOL, V71, P2231; Fitzpatrick CM, 2004, J AM COLL SURGEONS, V199, P693, DOI 10.1016/j.jamcollsurg.2004.07.025; Freilich E, 2002, ARTIF CELL BLOOD SUB, V30, P83, DOI 10.1081/BIO-120003190; Gould SA, 2002, J AM COLL SURGEONS, V195, P445, DOI 10.1016/S1072-7515(02)01335-2; Gould SA, 1996, WORLD J SURG, V20, P1200; Greenburg AG, 2004, J AM COLL SURGEONS, V198, P373, DOI 10.1016/j.jamcollsurg.2003.11.020; Gulati A, 1996, CRIT CARE MED, V24, P137, DOI 10.1097/00003246-199601000-00023; Gurney J, 2004, J TRAUMA, V57, P726, DOI 10.1097/01.TA.0000147520.84792.B4; Handrigan MT, 2005, SHOCK, V23, P337, DOI 10.1097/01.shk.0000156667.04628.1f; HOYT DB, 1994, J TRAUMA, V37, P426, DOI 10.1097/00005373-199409000-00016; Johnson T, 2006, CRIT CARE MED, V34, P1464, DOI 10.1097/01.CCM.0000215824.85190.89; Katz LM, 2002, RESUSCITATION, V54, P77, DOI 10.1016/S0300-9572(02)00053-9; Kerner T, 2003, INTENS CARE MED, V29, P378, DOI 10.1007/s00134-002-1622-x; Knudson MM, 2003, J TRAUMA, V54, P242, DOI 10.1097/01.TA.0000037776.28201.75; Kochanek Kenneth D, 2004, Natl Vital Stat Rep, V52, P1; LaMuraglia GM, 2000, J VASC SURG, V31, P299, DOI 10.1016/S0741-5214(00)90161-7; Lee SK, 2002, ACAD EMERG MED, V9, P969; Levy JH, 2002, J THORAC CARDIOV SUR, V124, P35, DOI 10.1067/mtc.2002.121505; LUNA GK, 1989, AM J SURG, V157, P512, DOI 10.1016/0002-9610(89)90649-1; Manning JE, 2001, CRIT CARE MED, V29, P2067, DOI 10.1097/00003246-200111000-00005; Manning JE, 2000, SHOCK, V13, P152, DOI 10.1097/00024382-200013020-00010; Maxwell RA, 2000, J TRAUMA, V49, P200, DOI 10.1097/00005373-200008000-00005; McNeil JD, 2001, J TRAUMA, V50, P1063, DOI 10.1097/00005373-200106000-00015; Moisan S, 1998, CAN J PHYSIOL PHARM, V76, P434, DOI 10.1139/cjpp-76-4-434; Philbin N, 2005, RESUSCITATION, V66, P367, DOI 10.1016/j.resuscitation.2005.03.019; RICE J, 2006, 35 CRIT CAR C SOC CR; Rice J, 2006, SHOCK, V26, P302, DOI 10.1097/01.shk.0000226338.48033.c2; Rogers FB, 1997, ARCH SURG-CHICAGO, V132, P376; Sampei K, 2005, AM J PHYSIOL-HEART C, V289, pH1191, DOI 10.1152/ajpheart.00251.2005; Sampson JB, 2003, J TRAUMA, V55, P747, DOI 10.1097/01.TA.0000084519.47163.77; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; SHARMA AC, 1995, CRIT CARE MED, V23, P874, DOI 10.1097/00003246-199505000-00016; Sloan EP, 1999, JAMA-J AM MED ASSOC, V282, P1857, DOI 10.1001/jama.282.19.1857; Sprung J, 2002, ANESTH ANALG, V94, P799, DOI 10.1097/00000539-200204000-00006; THOMPSON D, 1990, ANN EMERG MED, V19, P268, DOI 10.1016/S0196-0644(05)82042-6; Tsai AG, 2003, AM J PHYSIOL-HEART C, V285, pH1411, DOI 10.1152/ajpheart.00307.2003; Victorino GP, 2003, J AM COLL SURGEONS, V196, P679, DOI 10.1016/S1072-7515(03)00128-5; VLAHAKES GJ, 1990, J THORAC CARDIOV SUR, V100, P379; WANG Y, 1993, AM REV RESPIR DIS, V147, P927, DOI 10.1164/ajrccm/147.4.927; York GB, 2003, J TRAUMA, V55, P873, DOI 10.1097/01.TA.0000092681.17874.6F	44	23	23	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	NOV	2006	61	5					1085	1099		10.1097/01.ta.0000236640.62893.fa			15	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	105TB	WOS:000242054100010	17099513				2021-06-18	
J	O'Callaghan, C; Powell, T; Oyebode, J				O'Callaghan, Catherine; Powell, Theresa; Oyebode, Jan			An exploration of the experience of gaining awareness of deficit in people who have suffered a traumatic brain injury	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							IMPAIRED SELF-AWARENESS; ALZHEIMERS-DISEASE; HEAD-INJURY; ANOSOGNOSIA; MODEL; UNAWARENESS; DYSFUNCTION; NARRATIVES; KNOWLEDGE; ILLNESS	Gaining awareness of deficits was explored in 10 people with moderate to severe traumatic brain injury (TBI) using a semi-structured interview and interpretative phenomenological analysis. Eight master themes emerged from the transcripts. Knowledge of deficits was acquired through personal discovery and the reactions of others, often outside the rehabilitation environment. Rehabilitation provided explanations and a normalising and supportive environment that facilitated people in acknowledging their deficits. Most participants spontaneously referred to denial and saw this as an active cognitive and behavioural process that both helped and hindered recovery. The emotional reaction to learning about deficits was described largely in terms of fear and loss and resonates with psychological models of grief.	Univ Birmingham, Dept Clin Psychol, Birmingham B15 2TT, W Midlands, England	Powell, T (corresponding author), Univ Birmingham, Dept Clin Psychol, Birmingham B15 2TT, W Midlands, England.	t.powell@bham.ac.uk		Powell, Theresa/0000-0002-3351-9453; Oyebode, Jan/0000-0002-0263-8740			Abreu BC, 2001, ARCH PHYS MED REHAB, V82, P49, DOI 10.1053/apmr.2001.9167; Agnew SK, 1998, AGING MENT HEALTH, V2, P7, DOI 10.1080/13607869856876; Barco P.P., 1991, COGNITIVE REHABILITA, P129; BISIACH E, 1986, NEUROPSYCHOLOGIA, V24, P471, DOI 10.1016/0028-3932(86)90092-8; Chittum WR, 1996, BRAIN INJURY, V10, P763; Clare L, 2004, BRIT J CLIN PSYCHOL, V43, P155, DOI 10.1348/014466504323088033; Conneeley A. L., 2003, BRIT J OCCUPATIONAL, V66, P440; Crisp R., 1994, J APPL REHABILITATIO, V25, P16; Crisp R., 1993, DISABILITY HANDICAP, V8, P393, DOI [DOI 10.1080/02674649366780371, 10.1080/02674649366780371]; Crosson B., 1989, J HEAD TRAUMA REHAB, V4, P46, DOI [10.1097/00001199-198909000-00008, DOI 10.1097/00001199-198909000-00008]; Dalla Barba G, 1999, NEUROCASE, V5, P59, DOI 10.1093/neucas/5.1.59; DEATON AV, 1986, REHABIL PSYCHOL, V31, P231, DOI 10.1037//0090-5550.31.4.231; Dirette D, 2002, BRAIN INJURY, V16, P861, DOI 10.1080/02699050210131902; Fleming JM, 1996, BRAIN INJURY, V10, P1; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldbeck R, 1997, J PSYCHOSOM RES, V43, P575, DOI 10.1016/S0022-3999(97)00168-2; Goldstein K, 1942, EFFECTS BRAIN INJURI; Goldstein K., 1939, ORGANISM; Goldstein K, 1952, PSYCHIATR, V15, P245, DOI 10.1080/00332747.1952.11022878; Katz Noomi, 2002, Can J Occup Ther, V69, P281; Kortte KB, 2003, REHABIL PSYCHOL, V48, P131, DOI 10.1037/0090-5550.48.3.131; LEVINE J, 1994, J PSYCHOSOM RES, V38, P99, DOI 10.1016/0022-3999(94)90083-3; LEVINE J, 1975, J CONSULT CLIN PSYCH, V43, P751; MALAN DH, 1995, INDIVIDUAL PSYCHOTHE; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; Meredith K., 1999, J COGNITIVE REHABILI, V17, P10; Nochi M, 1998, QUAL HEALTH RES, V8, P665, DOI 10.1177/104973239800800507; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; Nochi M, 1998, SOC SCI MED, V46, P869, DOI 10.1016/S0277-9536(97)00211-6; PERSINGER MA, 1993, PSYCHOL REP, V72, P1059, DOI 10.2466/pr0.1993.72.3c.1059; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1998, CLIN NEUROPSYCHOL, V12, P56, DOI 10.1076/clin.12.1.56.1721; Prigatano GP, 1997, NEUROPSY NEUROPSY BE, V10, P135; Prigatano GP., 1999, PRINCIPLES NEUROPSYC; Rubin SS, 1999, DEATH STUD, V23, P681, DOI 10.1080/074811899200731; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; Sherer M, 1998, NEUROREHABILITATION, V10, P25, DOI 10.3233/NRE-1998-10104; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SMITH JA, 2001, QUALITATIVE PSYCHOL, P51; TINDALL C, 1994, QUALITATIVE METHODSE; Toglia J, 2000, NEUROREHABILITATION, V15, P57; Wallace CA, 2000, BRAIN INJURY, V14, P549; Zhou J, 1996, J HEAD TRAUMA REHAB, V11, P51, DOI 10.1097/00001199-199602000-00007	44	23	23	0	12	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	OCT	2006	16	5					579	593		10.1080/09602010500368834			15	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	096FI	WOS:000241362600004	16952894				2021-06-18	
J	Rangel-Castillo, L; Robertson, CS				Rangel-Castillo, Leonardo; Robertson, Claudia S.			Management of intracranial hypertension	CRITICAL CARE CLINICS			English	Article							TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; CEREBRAL BLOOD-FLOW; INTRA-CRANICAL PRESSURE; DECOMPRESSIVE CRANIECTOMY; CONTROLLED-TRIAL; PERFUSION-PRESSURE; CLINICAL-TRIAL; SUBARACHNOID HEMORRHAGE; 20-PERCENT MANNITOL	Effective treatment of intracranial hypertension involves meticulous avoidance of factors that precipitate or aggravate increased intracranial pressure. When intracranial pressure becomes elevated, it is important to rule out new mass lesions that should be surgically evacuated. Medical management of increased intracranial pressure should include sedation and paralysis, drainage of cerebrospinal fluid, and osmotherapy with either mannitol or hypertonic saline. For intracranial hypertension refractory to initial medical management, barbiturate coma, hypothermia, or decompressive craniectomy should be considered. Steroids are not indicated and may be harmful in the treatment of intracranial hypertension resulting from traumatic brain injury.	Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Robertson, CS (corresponding author), Baylor Coll Med, Dept Neurosurg, 1 Baylor Plaza, Houston, TX 77030 USA.	claudiar@bcm.tmc.edu			NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER		Aarabi B, 2006, J NEUROSURG, V104, P469, DOI 10.3171/jns.2006.104.4.469; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS28; Adelson P David, 2003, Pediatr Crit Care Med, V4, pS19; Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Albanese J, 1999, CRIT CARE MED, V27, P407, DOI 10.1097/00003246-199902000-00050; ANDREWS BT, 1988, J NEUROSURG, V69, P518, DOI 10.3171/jns.1988.69.4.0518; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bader MK, 2005, AACN ADV CRIT CARE, V16, P526, DOI 10.1097/00044067-200510000-00009; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Biousse V, 2003, AM J OPHTHALMOL, V135, P437, DOI 10.1016/S0002-9394(02)02062-7; Bor-Seng-Shu E, 2006, J NEUROSURG, V104, P93, DOI 10.3171/jns.2006.104.1.93; BRUCE DA, 1981, J NEUROSURG, V54, P170, DOI 10.3171/jns.1981.54.2.0170; Caricato A, 2005, J TRAUMA, V58, P571, DOI 10.1097/01.TA.0000152806.19198.DB; Cherian L, 2004, J NEUROTRAUM, V21, P1196; Cheung A, 2005, NEUROCRIT CARE, V3, P216, DOI 10.1385/NCC:3:3:216; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Coles JP, 2004, BRAIN, V127, P2479, DOI 10.1093/brain/awh268; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Cruz J, 2004, J NEUROSURG, V100, P376, DOI 10.3171/jns.2004.100.3.0376; Cruz J, 2001, NEUROSURGERY, V49, P864; Czosnyka M, 1996, NEUROSURGERY, V38, P219, DOI 10.1097/00006123-199601000-00053; Dietrich WD, 1996, NEUROSURGERY, V38, P533, DOI 10.1097/00006123-199603000-00023; Digre K, 2005, NEUROLOGY, V64, P1827; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; DOCZI T, 1993, ACTA NEUROCHIR, V121, P1, DOI 10.1007/BF01405174; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Edwards P, 2005, LANCET, V365, P1957; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; ENGBERG M, 1989, ACTA ANAESTH SCAND, V33, P642, DOI 10.1111/j.1399-6576.1989.tb02983.x; Feigin VL, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004583.pub2; FELDMAN Z, 1992, J NEUROSURG, V76, P207, DOI 10.3171/jns.1992.76.2.0207; Friedman DI, 2005, AM J CLIN DERMATOL, V6, P29, DOI 10.2165/00128071-200506010-00004; GOBIET W, 1975, ACTA NEUROCHIR, V32, P13, DOI 10.1007/BF01405899; GOPINATH SP, 1995, NEUROSURGERY, V36, P1137, DOI 10.1227/00006123-199506000-00011; GUDEMAN SK, 1979, J NEUROSURG, V51, P301, DOI 10.3171/jns.1979.51.3.0301; Hebert PC, 1999, NEW ENGL J MED, V340, P409, DOI 10.1056/NEJM199902113400601; Hutchinson PJ, 2006, ACTA NEUROCHIR SUPPL, V96, P17; Jacob S, 2005, HEADACHE, V45, P75, DOI 10.1111/j.1526-4610.2005.05013.x; JONES PA, 1994, J NEUROSURG ANESTH, V6, P4; Joseph DK, 2004, J TRAUMA, V57, P687, DOI 10.1097/01.TA.0000140645.84897.F2; Kaal ECA, 2004, CURR OPIN ONCOL, V16, P593, DOI 10.1097/01.cco.0000142076.52721.b3; KISHORE PRS, 1981, AM J ROENTGENOL, V137, P829, DOI 10.2214/ajr.137.4.829; Knapp JM, 2005, AACN ADV CRIT CARE, V16, P199, DOI 10.1097/00044067-200504000-00011; LANGFITT TW, 1965, NEUROLOGY, V15, P622, DOI 10.1212/WNL.15.7.622; Lee ST, 1997, CAN J NEUROL SCI, V24, P40, DOI 10.1017/S0317167100021077; LUNDBERG N, 1965, J NEUROSURG, V22, P581, DOI 10.3171/jns.1965.22.6.0581; Marchuk G, 2005, CAN J NEUROL SCI, V32, pS22; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MAYHALL CG, 1984, NEW ENGL J MED, V310, P553, DOI 10.1056/NEJM198403013100903; MESSETER K, 1986, J NEUROSURG, V64, P231, DOI 10.3171/jns.1986.64.2.0231; Miller J D, 1982, J R Coll Surg Edinb, V27, P292; Miller J D, 1979, Int Anesthesiol Clin, V17, P19, DOI 10.1097/00004311-197917020-00005; MUIZELAAR JP, 1984, J NEUROSURG, V61, P700, DOI 10.3171/jns.1984.61.4.0700; MUIZELAAR JP, 1988, J NEUROSURG, V69, P923, DOI 10.3171/jns.1988.69.6.0923; Nates JL, 1997, ANAESTH INTENS CARE, V25, P502, DOI 10.1177/0310057X9702500509; Ng I, 2004, NEUROSURGERY, V54, P593, DOI 10.1227/01.NEU.0000108639.16783.39; NORDSTROM CH, 1988, J NEUROSURG, V68, P424, DOI 10.3171/jns.1988.68.3.0424; NORTH JB, 1974, ARCH NEUROL-CHICAGO, V31, P338, DOI 10.1001/archneur.1974.00490410086010; OSULLIVAN MG, 1994, J NEUROSURG, V80, P46, DOI 10.3171/jns.1994.80.1.0046; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; PRIELIPP RC, 1995, ANESTH ANALG, V81, P3, DOI 10.1097/00000539-199507000-00002; ROBERTSON CS, 1983, J NEUROSURG, V59, P455, DOI 10.3171/jns.1983.59.3.0455; ROSNER MJ, 1986, J NEUROSURG, V65, P636, DOI 10.3171/jns.1986.65.5.0636; Sahuquillo J, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003983.pub2; SATO M, 1991, ACTA NEUROCHIR, V110, P174, DOI 10.1007/BF01400687; SAUL TG, 1981, J NEUROSURG, V54, P596, DOI 10.3171/jns.1981.54.5.0596; SCHALEN W, 1992, ACTA NEUROCHIR, V117, P153, DOI 10.1007/BF01400613; Schramm WM, 1998, ANESTH ANALG, V86, P123, DOI 10.1097/00000539-199801000-00025; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SELHORST JB, 1985, NEUROSURGERY, V16, P357, DOI 10.1227/00006123-198503000-00013; Stiefel MF, 2004, J NEUROSURG, V101, P241, DOI 10.3171/jns.2004.101.2.0241; Stocchetti N, 2005, CHEST, V127, P1812, DOI 10.1378/chest.127.5.1812; Taneda M, 1996, J NEUROSURG, V84, P762, DOI 10.3171/jns.1996.84.5.0762; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEMPKIN NR, 1990, NEW ENGL J MED, V323, P497; UNTERBERG A, 1993, NEUROSURGERY, V32, P17, DOI 10.1227/00006123-199301000-00003; Vespa PM, 1999, J NEUROSURG, V91, P750, DOI 10.3171/jns.1999.91.5.0750; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WELCH K, 1980, J NEUROSURG, V52, P693, DOI 10.3171/jns.1980.52.5.0693; Yundt KD, 1997, CRIT CARE CLIN, V13, P163, DOI 10.1016/S0749-0704(05)70300-6; Zabramski JM, 2003, J NEUROSURG, V98, P725, DOI 10.3171/jns.2003.98.4.0725	82	23	24	0	1	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0749-0704	1557-8232		CRIT CARE CLIN	Crit. Care Clin.	OCT	2006	22	4					713	+		10.1016/j.ccc.2006.06.003			21	Critical Care Medicine	General & Internal Medicine	138AJ	WOS:000244334500009	17239751				2021-06-18	
J	Taupin, P				Taupin, Philippe			Adult neurogenesis in mammals	CURRENT OPINION IN MOLECULAR THERAPEUTICS			English	Article						adult brain; central nervous system; CNS; homeostasis; neural stem cells; neuroadaptation; neurogenesis; plasticity; regeneration	GRANULE CELL NEUROGENESIS; TRAUMATIC BRAIN-INJURY; CENTRAL-NERVOUS-SYSTEM; NEURAL STEM-CELLS; RAT DENTATE GYRUS; HIPPOCAMPAL NEUROGENESIS; SUBSTANTIA-NIGRA; OLFACTORY-BULB; ENRICHED ENVIRONMENT; SUBVENTRICULAR ZONE	With the recent confirmation that neurogenesis occurs in the adult brain, and that neural stem cells reside in the adult central nervous system (CNS), the function of newly generated neuronal cells in the adult brain is the source of intense research and debate. Neurogenesis is modulated by a wide variety of physiopathological conditions and environmental stimuli, offering the possibility that newly generated neuronal cells might be functionally associated with the response to these processes. Newly generated neuronal cells in the hippocampus have also been implicated in mechanisms of learning, memory and depression. However, a number of studies have challenged some of these findings, and the roles of newly generated neuronal cells in the functioning of the CNS remain to be fully understood. Neurogenesis has been shown to increase bilaterally in the adult brain and new neuronal cells are generated at sites of degeneration in the brain during disease and after injuries. Taken together, these findings suggest that new neuronal cells may be involved in processes such as homeostasis of brain tissue, regeneration, plasticity, and neuroadaptation.	Natl Univ Singapore, Natl Inst Neurosci, Singapore 308433, Singapore	Taupin, P (corresponding author), Natl Univ Singapore, Natl Inst Neurosci, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore.	obgpjt@nus.edu.sg					ALTMAN J, 1969, J COMP NEUROL, V137, P433, DOI 10.1002/cne.901370404; ALTMAN J, 1965, J COMP NEUROL, V124, P319, DOI 10.1002/cne.901240303; Alvarez-Buylla A, 2004, NEURON, V41, P683, DOI 10.1016/S0896-6273(04)00111-4; Anderson V, 2000, PEDIATR NEUROSURG, V32, P282, DOI 10.1159/000028956; Arvidsson A, 2002, NAT MED, V8, P963, DOI 10.1038/nm747; ATEN JA, 1992, HISTOCHEM J, V24, P251, DOI 10.1007/BF01046839; Banasr M, 2004, NEUROPSYCHOPHARMACOL, V29, P450, DOI 10.1038/sj.npp.1300320; Brezun JM, 1999, NEUROSCIENCE, V89, P999, DOI 10.1016/S0306-4522(98)00693-9; Brown J, 2003, EUR J NEUROSCI, V17, P2042, DOI 10.1046/j.1460-9568.2003.02647.x; Burns KA, 2005, EUR J NEUROSCI, V21, P803, DOI 10.1111/j.1460-9568.2005.03907.x; Carrette O, 2003, PROTEOMICS, V3, P1486, DOI 10.1002/pmic.200300470; CAVINESS VS, 1995, TRENDS NEUROSCI, V18, P379, DOI 10.1016/0166-2236(95)93933-O; CAVINESS VS, 1973, J COMP NEUROL, V151, P113, DOI 10.1002/cne.901510203; Chen Y, 2005, EXP NEUROL, V196, P87, DOI 10.1016/j.expneurol.2005.07.010; Cramer SC, 2000, NEUROPHARMACOLOGY, V39, P842, DOI 10.1016/S0028-3908(99)00258-0; Curtis MA, 2005, NEUROSCIENCE, V132, P777, DOI 10.1016/j.neuroscience.2004.12.051; Curtis MA, 2003, P NATL ACAD SCI USA, V100, P9023, DOI 10.1073/pnas.1532244100; Danilov AI, 2006, EUR J NEUROSCI, V23, P394, DOI 10.1111/j.1460-9568.2005.04563.x; Dash PK, 2001, J NEUROSCI RES, V63, P313, DOI 10.1002/1097-4547(20010215)63:4<313::AID-JNR1025>3.0.CO;2-4; Eriksson PS, 1998, NAT MED, V4, P1313, DOI 10.1038/3305; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Frielingsdorf H, 2004, P NATL ACAD SCI USA, V101, P10177, DOI 10.1073/pnas.0401229101; Gould E, 1999, NAT NEUROSCI, V2, P260, DOI 10.1038/6365; Gould E, 1998, P NATL ACAD SCI USA, V95, P3168, DOI 10.1073/pnas.95.6.3168; GRATZNER HG, 1982, SCIENCE, V218, P474, DOI 10.1126/science.7123245; Grote HE, 2005, EUR J NEUROSCI, V22, P2081, DOI 10.1111/j.1460-9568.2005.04365.x; Hayes NL, 2002, DEV BRAIN RES, V134, P77, DOI 10.1016/S0165-3806(01)00324-8; Jackson-Guilford J, 2000, NEUROSCI LETT, V293, P91, DOI 10.1016/S0304-3940(00)01502-0; Jacobs BL, 2000, MOL PSYCHIATR, V5, P262, DOI 10.1038/sj.mp.4000712; Jiang W, 2001, STROKE, V32, P1201, DOI 10.1161/01.STR.32.5.1201; Jin K, 2003, MOL CELL NEUROSCI, V24, P171, DOI 10.1016/S1044-7431(03)00159-3; Jin KL, 2004, P NATL ACAD SCI USA, V101, P343, DOI 10.1073/pnas.2634794100; Kempermann G, 1997, NATURE, V386, P493, DOI 10.1038/386493a0; Koketsu D, 2006, EXP NEUROL, V199, P92, DOI 10.1016/j.expneurol.2006.03.012; Kotloski R, 2002, PROG BRAIN RES, V135, P95; Kuhn HG, 1996, J NEUROSCI, V16, P2027; Leuner B, 2004, J NEUROSCI, V24, P7477, DOI 10.1523/JNEUROSCI.0204-04.2004; Lie DC, 2002, J NEUROSCI, V22, P6639; Liu JL, 1998, J NEUROSCI, V18, P7768; Madsen TM, 2003, NEUROSCIENCE, V119, P635, DOI 10.1016/S0306-4522(03)00199-4; Malberg JE, 2003, NEUROPSYCHOPHARMACOL, V28, P1562, DOI 10.1038/sj.npp.1300234; Malberg JE, 2000, J NEUROSCI, V20, P9104, DOI 10.1523/jneurosci.20-24-09104.2000; Meshi D, 2006, NAT NEUROSCI, V9, P729, DOI 10.1038/nn1696; MILLER MW, 1988, BRAIN RES, V457, P44, DOI 10.1016/0006-8993(88)90055-8; Mohapel P, 2005, NEUROSCIENCE, V132, P767, DOI 10.1016/j.neuroscience.2004.11.056; Nilsson M, 1999, J NEUROBIOL, V39, P569, DOI 10.1002/(SICI)1097-4695(19990615)39:4<569::AID-NEU10>3.0.CO;2-F; Parent JM, 1999, J NEUROSCI, V19, P4508; Parent JM, 1997, J NEUROSCI, V17, P3727; Parent JM, 2002, J NEUROSCI, V22, P3174, DOI 10.1523/JNEUROSCI.22-08-03174.2002; Parent JM, 1998, NEUROSCI LETT, V247, P9, DOI 10.1016/S0304-3940(98)00269-9; Parent JM, 2002, ANN NEUROL, V52, P802, DOI 10.1002/ana.10393; Pencea V, 2001, EXP NEUROL, V172, P1, DOI 10.1006/exnr.2001.7768; Perna RB, 2003, J HEAD TRAUMA REHAB, V18, P201; Rhodes JS, 2004, BEHAV NEUROSCI, V118, P305, DOI 10.1037/0735-7044.118.2.305; Ribotta MG, 2004, ACTA NEUROCHIR SUPPL, V89, P87; Sanai N, 2004, NATURE, V427, P740, DOI 10.1038/nature02301; Santarelli L, 2003, SCIENCE, V301, P805, DOI 10.1126/science.1083328; Sawabini KA, 2004, PARKINSONISM RELAT D, V10, pS37, DOI 10.1016/j.parkreldis.2004.02.002; Sawamoto K, 2006, SCIENCE, V311, P629, DOI 10.1126/science.1119133; SHIBUI S, 1989, J HISTOCHEM CYTOCHEM, V37, P1007, DOI 10.1177/37.7.2659659; Shors TJ, 2002, HIPPOCAMPUS, V12, P578, DOI 10.1002/hipo.10103; Shors TJ, 2001, NATURE, V414, P938, DOI 10.1038/414938a; Slevin JT, 2005, J NEUROSURG, V102, P216, DOI 10.3171/jns.2005.102.2.0216; Song SH, 2002, NATURE, V417, P39, DOI 10.1038/417039a; Taupin P, 2000, NEURON, V28, P385, DOI 10.1016/S0896-6273(00)00119-7; Taupin P, 2002, J NEUROSCI RES, V69, P745, DOI 10.1002/jnr.10378; Taupin P, 2005, MED SCI MONITOR, V11, pRA247; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; van Praag H, 1999, NAT NEUROSCI, V2, P266; van Praag H, 2000, NAT REV NEUROSCI, V1, P191, DOI 10.1038/35044558; Vega CJ, 2005, NAT METHODS, V2, P167, DOI 10.1038/NMETH741; Wang R, 2004, NEUROSCIENCE, V126, P305, DOI 10.1016/j.neuroscience.2004.03.048; Watt FM, 2000, SCIENCE, V287, P1427, DOI 10.1126/science.287.5457.1427; Witte OW, 1998, CURR OPIN NEUROL, V11, P655, DOI 10.1097/00019052-199812000-00008; Zhao M, 2003, P NATL ACAD SCI USA, V100, P7925, DOI 10.1073/pnas.1131955100	75	23	23	0	3	THOMSON REUTERS (SCIENTIFIC) LTD	LONDON	77 HATTON GARDEN, LONDON, EC1N 8JS, ENGLAND	1464-8431	2040-3445		CURR OPIN MOL THER	Curr. Opin. Mol. Ther.	AUG	2006	8	4					345	351					7	Biotechnology & Applied Microbiology; Medicine, Research & Experimental	Biotechnology & Applied Microbiology; Research & Experimental Medicine	069DG	WOS:000239425200010	16955698				2021-06-18	
J	Soustiel, JF; Vlodausky, E; Zaaroor, M				Soustiel, Jean F.; Vlodausky, Eugene; Zaaroor, Menashe			Relative effects of mannitol and hypertonic saline on calpain activity, apoptosis and polymorphonuclear infiltration in traumatic focal brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; hypertonic saline; apoptosis; neuroinflammation	CEREBRAL-BLOOD-FLOW; POSTTRAUMATIC INTRACRANIAL HYPERTENSION; SEVERE HEAD-INJURY; HYPERBARIC-OXYGEN THERAPY; PROTEIN-KINASE P38; CEREBROSPINAL-FLUID; 20-PERCENT MANNITOL; CONTROLLED-TRIAL; SODIUM-CHLORIDE; SPINAL-FLUID	The purpose of this study was to compare the relative effects of mannitol and hypertonic saline (HTS) on calpain activity, apoptosis and neuroinflammatory response induced by experimental cortical contusion. Four groups of 5 Sprague-Dawley male rats were submitted to focal brain injury produced by exposing the parietal cortex to dynamic cortical deformation. Groups were defined by rescucitation fluids administered 30 min post-injury as follows: group 1-0.9% normal saline 2 ml/kg; group 2-mannitol 20% 0.5 g/kg; group 3-HTS 2 ml/kg; group 4-HTS 4 mVkg. At 72 h, animals were sacrificed. Paraffin-mounted sections of were stained for p-Calpain, TUNEL, active caspase 3 and myeloperoxidase. There was no difference in the lesion size between the different groups. In contrast, there was a significant reduction in calpain and apoptosis activity and in the neuroinflammatory response in animals receiving HTS. Although mannitol proved to significantly decrease the neuroinflammatory response and calpain activity, it did not affect apoptosis, and its effect was significantly less than that of HTS. Importantly, the effect of HTS was mostly independent from the infused volume. our results show that HTS promotes cell survival and reduces secondary brain damage following TBI. This protective effect was evidenced at rather small infused volumes, proved to encompass several cellular and molecular mechanisms involved in secondary cell death and could not be related to relief of intracranial pressure. These findings suggest that the high osmolality of HTS may have protective effects besides its impact on brain edema.	Technion Israel Inst Technol, Acute Brain Injury Res Lab, Haifa, Israel; Technion Israel Inst Technol, AB Rappaport Fac Med, Haifa, Israel; Rambam Med Ctr, Dept Pathol, Haifa, Israel	Soustiel, JF (corresponding author), Rambam Med Ctr, Dept Neurosurg, Bat Galim,POB 9602, IL-31096 Haifa, Israel.	j_soustiel@rambam.health.gov.il; e_viodavsky@rambam.health.gov.il					ALBERICO AM, 1987, J NEUROSURG, V67, P648, DOI 10.3171/jns.1987.67.5.0648; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; BERGER S, 1995, NEUROSURGERY, V37, P98, DOI 10.1227/00006123-199507000-00015; Bhardwaj Anish, 2004, Curr Opin Crit Care, V10, P126, DOI 10.1097/00075198-200404000-00009; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; BUCKELL M, 1964, LANCET, V2, P1151; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; Chen Y, 2004, J LEUKOCYTE BIOL, V76, P245, DOI 10.1189/jlb.0204066; Chen YM, 2003, J CEREBR BLOOD F MET, V23, P137, DOI 10.1097/01.WCB.0000044631.80210.3C; Ciesla DJ, 2001, J TRAUMA, V50, P206, DOI 10.1097/00005373-200102000-00004; Ciesla DJ, 2000, J TRAUMA, V48, P388, DOI 10.1097/00005373-200003000-00004; Cooper DJ, 2004, JAMA-J AM MED ASSOC, V291, P1350, DOI 10.1001/jama.291.11.1350; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dietrich WD, 2004, ACTA NEUROCHIR SUPPL, V89, P69; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Doppenberg EMR, 2004, J NEUROSURG ANESTH, V16, P87, DOI 10.1097/00008506-200401000-00019; Doyle JA, 2001, J TRAUMA, V50, P367, DOI 10.1097/00005373-200102000-00030; Farkas O, 2005, ACTA NEUROCHIR, V147, P855, DOI 10.1007/s00701-005-0559-6; Feuerstein GZ, 1997, ANN NY ACAD SCI, V825, P179, DOI 10.1111/j.1749-6632.1997.tb48428.x; FISHER B, 1992, J NEUROSURG ANESTH, V4, P4, DOI 10.1097/00008506-199201000-00002; Hartl R, 1997, J TRAUMA, V42, pS41, DOI 10.1097/00005373-199705001-00008; Hausmann R, 1999, INT J LEGAL MED, V112, P227, DOI 10.1007/s004140050241; JAGGI JL, 1990, J NEUROSURG, V72, P176, DOI 10.3171/jns.1990.72.2.0176; Junger H, 2003, J MOL NEUROSCI, V21, P111, DOI 10.1385/JMN:21:2:111; Junger WG, 1998, J CLIN INVEST, V101, P2768, DOI 10.1172/JCI1354; Kampfl A, 1996, J NEUROCHEM, V67, P1575; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; Kinoshita K, 2002, J NEUROTRAUM, V19, P681, DOI 10.1089/08977150260139075; Krep H, 2004, RESUSCITATION, V63, P73, DOI 10.1016/j.resuscitation.2004.03.023; LANGFITT TW, 1961, NEUROLOGY, V11, P196, DOI 10.1212/WNL.11.3.196; Lenzlinger PM, 2001, MOL NEUROBIOL, V24, P169; LUNDBERG N, 1959, Acta Psychiatr Scand Suppl, V34, P1; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mirski MA, 2000, J NEUROSURG ANESTH, V12, P334, DOI 10.1097/00008506-200010000-00006; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morganti-Kossmann MC, 2001, SHOCK, V16, P165, DOI 10.1097/00024382-200116030-00001; Murao Y, 2003, SHOCK, V20, P23, DOI 10.1097/01.shk.0000078832.57685.6c; Nath R, 1996, NEUROREPORT, V8, P249, DOI 10.1097/00001756-199612200-00050; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; O'Dell DM, 2000, J NEUROSCI, V20, P4821; OBRIST WD, 1984, J NEUROSURG, V61, P241, DOI 10.3171/jns.1984.61.2.0241; Ogden AT, 2005, NEUROSURGERY, V57, P207, DOI 10.1227/01.NEU.0000166533.79031.D8; Otto VI, 2001, NEUROREPORT, V12, P2059, DOI 10.1097/00001756-200107030-00053; Palzur E, 2004, J NEUROTRAUM, V21, P41, DOI 10.1089/089771504772695931; Pike BR, 2004, J CEREBR BLOOD F MET, V24, P98, DOI 10.1097/01.WCB.0000098520.11962.37; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Qureshi AI, 1998, CRIT CARE MED, V26, P440, DOI 10.1097/00003246-199803000-00011; Qureshi AI, 2000, CRIT CARE MED, V28, P1556, DOI 10.1097/00003246-200005000-00049; Ringger NC, 2004, J NEUROTRAUM, V21, P829, DOI 10.1089/0897715041526177; RINK A, 1995, AM J PATHOL, V147, P1575; ROSNER MJ, 1990, J TRAUMA, V30, P933, DOI 10.1097/00005373-199008000-00001; Royo NC, 1999, NEUROREPORT, V10, P1363, DOI 10.1097/00001756-199904260-00038; SAUL TG, 1982, J NEUROSURG, V56, P498, DOI 10.3171/jns.1982.56.4.0498; Schatzmann C, 1998, ACT NEUR S, V71, P31; Shires GT, 2005, AM J SURG, V189, P85, DOI 10.1016/j.amjsurg.2004.06.040; Shreiber DI, 1999, J NEUROPATH EXP NEUR, V58, P153, DOI 10.1097/00005072-199902000-00005; Smith FM, 2000, ACTA NEUROPATHOL, V100, P537, DOI 10.1007/s004010000222; Soustiel JF, 2005, J NEUROTRAUM, V22, P345, DOI 10.1089/neu.2005.22.345; SQUIER MKT, 1994, J CELL PHYSIOL, V159, P229, DOI 10.1002/jcp.1041590206; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Suarez JI, 1998, CRIT CARE MED, V26, P1118, DOI 10.1097/00003246-199806000-00038; Tseng MY, 2003, STROKE, V34, P1389, DOI 10.1161/01.STR.0000071526.45277.44; Valadka AB, 2000, CRIT CARE MED, V28, P1245, DOI 10.1097/00003246-200004000-00069; VASSAR MJ, 1993, ARCH SURG-CHICAGO, V128, P1003; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF; Vlodavsky E, 2006, NEUROPATH APPL NEURO, V32, P40, DOI 10.1111/j.1365-2990.2005.00698.x; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Weed LH, 1919, AM J PHYSIOL, V48, P531; WISE BL, 1968, J NEUROSURG, V28, P124, DOI 10.3171/jns.1968.28.2.0124; WISE BL, 1962, J NEUROSURG, V19, P1038, DOI 10.3171/jns.1962.19.12.1038	71	23	27	0	5	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993	1872-6240		BRAIN RES	Brain Res.	JUL 26	2006	1101						136	144		10.1016/j.brainres.2006.05.045			9	Neurosciences	Neurosciences & Neurology	070RK	WOS:000239541000017	16787640				2021-06-18	
J	Tehranian, R; Rose, ME; Vagni, V; Griffith, RP; Wu, SS; Maits, S; Zhang, XP; Clark, RSB; Dixon, CE; Kochanek, PM; Bernard, O; Graham, SH				Tehranian, Roya; Rose, Marie E.; Vagni, Vincent; Griffith, R. P.; Wu, Shasha; Maits, Sara; Zhang, Xiaopeng; Clark, Robert S. B.; Dixon, C. Edward; Kochanek, Patrick M.; Bernard, Ora; Graham, Steven H.			Transgenic mice that overexpress the anti-apoptotic Bcl-2 protein have improved histological outcome but unchanged behavioral outcome after traumatic brain injury	BRAIN RESEARCH			English	Article						traumatic brain injury; transgenic mice; Bcl-2; apoptosis	CEREBRAL-ARTERY OCCLUSION; PROGRAMMED CELL-DEATH; NEURONAL DEATH; SPATIAL PROFILE; EXPRESSION; RAT; MECHANISMS; ISCHEMIA; PROTEOLYSIS; CALPAIN	Increasing evidence suggests that apoptosis is a contributing factor to neuronal cell death in traumatic brain injury (TBI). There is increased expression, cleavage and activation of caspases as well as other proteins known to regulate apoptosis in neurons after TBI. These proteins include the proto-oncogene Bcl-2 which belongs to a family of proteins with both pro- and anti-apoptotic properties. To investigate the role of apoptosis in TBI and the importance of Bcl-2 protein on the severity and outcome of injury, Bcl-2 overexpressing transgenic and wild-type control mice were subjected to the controlled cortical impact model of TBI. There was no significant difference in the cleavage of caspase-3 or caspase-9 detected by Western blotting of hippocampal samples from transgenic or wild-type mice after TBI. Bcl-2 transgenic mice had smaller contusion volumes and increased numbers of surviving neurons in CA2 but not other regions of hippocampus compared to wild-type controls. By contrast, there was no difference in motor function determined by the round beam balance and wire grip tests between transgenic and wild-type mice after TBI. Cognitive function assessed by the Morris water maze was also not different between groups. These results suggest that overexpression of Bcl-2 is only partially neuroprotective and other members of this protein family may prove to be more important in protecting neurons from cell death.	VA Pittsburgh Healthcare Syst 151UH, Ctr Geriatr Res Educ & Clin, Pittsburgh, PA 15206 USA; Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Neurosurg, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15261 USA	Graham, SH (corresponding author), VA Pittsburgh Healthcare Syst 151UH, Ctr Geriatr Res Educ & Clin, 7108 Highland Dr, Pittsburgh, PA 15206 USA.	steven.graham@med.va.gov	Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS30318] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P01NS030318, P50NS030318] Funding Source: NIH RePORTER		BEDERSON JB, 1986, STROKE, V17, P472, DOI 10.1161/01.STR.17.3.472; Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; CARONLESLIE LAM, 1994, FASEB J, V8, P639; Chen J, 2000, J CEREBR BLOOD F MET, V20, P1033, DOI 10.1097/00004647-200007000-00002; Clark RSB, 2000, J NEUROCHEM, V74, P740, DOI 10.1046/j.1471-4159.2000.740740.x; Clark RSB, 2001, J NEUROTRAUM, V18, P675, DOI 10.1089/089771501750357627; Clark RSB, 1997, J NEUROSCI, V17, P9172; Conti AC, 1998, J NEUROSCI, V18, P5663; Danial NN, 2004, CELL, V116, P205, DOI 10.1016/S0092-8674(04)00046-7; Datta SR, 2000, MOL CELL, V6, P41, DOI 10.1016/S1097-2765(00)00006-X; DeVries AC, 2001, P NATL ACAD SCI USA, V98, P11824, DOI 10.1073/pnas.201215298; DIETRICH WD, 1994, ACTA NEUROPATHOL, V87, P250, DOI 10.1007/BF00296740; FARLIE PG, 1995, P NATL ACAD SCI USA, V92, P4397, DOI 10.1073/pnas.92.10.4397; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; Gennarelli TA, 1996, NEUROPATH APPL NEURO, V22, P509, DOI 10.1111/j.1365-2990.1996.tb01126.x; Gillardon F, 1996, MOL BRAIN RES, V40, P254, DOI 10.1016/0169-328X(96)00059-9; Gilman CP, 2002, NEUROMOL MED, V2, P197, DOI 10.1385/NMM:2:2:197; Graham SH, 2000, J NEUROTRAUM, V17, P831, DOI 10.1089/neu.2000.17.831; Henry-Mowatt J, 2004, ONCOGENE, V23, P2850, DOI 10.1038/sj.onc.1207534; HOCKENBERY D, 1990, NATURE, V348, P334, DOI 10.1038/348334a0; JACOBSON MD, 1995, NATURE, V374, P814, DOI 10.1038/374814a0; Knoblach SM, 2004, J CEREBR BLOOD F MET, V24, P1119, DOI 10.1097/01.WCB.0000138664.17682.32; Lawrence MS, 1997, J CEREBR BLOOD F MET, V17, P740; LINNIK MD, 1995, STROKE, V26, P1670, DOI 10.1161/01.STR.26.9.1670; LINNIK MD, 1995, STROKE, V26, P1675; MARTINOU JC, 1994, NEURON, V13, P1017, DOI 10.1016/0896-6273(94)90266-6; McIntosh TK, 1998, NEUROPATH APPL NEURO, V24, P251; Monuki ES, 2001, NAT NEUROSCI, V4, P1199, DOI 10.1038/nn752; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Offen D, 1998, P NATL ACAD SCI USA, V95, P5789, DOI 10.1073/pnas.95.10.5789; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Raghupathi R, 1998, J CEREBR BLOOD F MET, V18, P1259, DOI 10.1097/00004647-199811000-00013; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; RINK A, 1995, AM J PATHOL, V147, P1575; Satchell MA, 2003, J NEUROCHEM, V85, P697, DOI 10.1046/j.1471-4159.2003.01707.x; Shacka JJ, 2005, CNS NEUROL DISORD-DR, V4, P25, DOI 10.2174/1568007053005127; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Wennersten A, 2003, ACTA NEUROPATHOL, V105, P281, DOI 10.1007/s00401-002-0649-y; Whalen MJ, 1999, J CEREBR BLOOD F MET, V19, P835, DOI 10.1097/00004647-199908000-00002; Willis SN, 2005, GENE DEV, V19, P1294, DOI 10.1101/gad.1304105; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yakovlev AG, 1997, J NEUROSCI, V17, P7415	44	23	24	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	JUL 26	2006	1101						126	135		10.1016/j.brainres.2006.05.049			10	Neurosciences	Neurosciences & Neurology	070RK	WOS:000239541000016	16782076				2021-06-18	
J	Flaherty, EG				Flaherty, Emalee G.			Analysis of caretaker histories in abuse: Comparing initial histories with subsequent confessions	CHILD ABUSE & NEGLECT			English	Article						physical child abuse; abusive head trauma; perpetrator confessions	TRAUMATIC BRAIN-INJURY; CHILD MALTREATMENT; RISK-FACTORS; UNITED-STATES; HEAD-INJURY; PARENTS; PERPETRATOR; ALCOHOL; INFANTS	Objective: We hypothesize that perpetrators of abuse include elements of truth in their initial history and that an analysis of perpetrator confessions can teach professionals how to identify these initial truths. Methods: The information from a consecutive sample of perpetrators' confessions concerning 41 children hospitalized because of injuries caused by child abuse was reviewed. The details about the injuries contained in the confessions were compared with the details provided when these children initially presented for medical care. Information about the perpetrator's gender and relationship to the child, the victim's age and gender, type of injury, family risk factors, the trigger of the abusive event, the circumstances surrounding the event, and the type of trauma were collected. Results: A total of 45 perpetrators abused 41 children; 76% of perpetrators were male; 56% were the child's father; 34% were the child's mother. The perpetrators initially provided no explanation about how 68% of the children received an injury. In 91% of their initial histories, the perpetrators provided some element of truth about the circumstances or triggering event for the abuse. In 67% of confessions, crying was the circumstance that triggered the abuse. Mothers were more likely to describe the situation that triggered the abuse (85% of mothers versus 58% of fathers, p = ns), while fathers were more likely to describe accurately the circumstances surrounding the abuse (79% of fathers versus 62% of mothers, p = ns). Conclusions: Perpetrators of abuse provide initial truths in their presenting history. Child abuse professionals must take a careful history from all caretakers and "listen" for the "elements of truth." These truths are the child's behavior or circumstance that increased stress and triggered the abuse. Employing this method in a careful analysis of confessions can make a significant contribution to the capacity to identify child abuse. In addition, more information about the role of triggers may help to focus child abuse prevention strategies. (c) 2006 Elsevier Ltd. All rights reserved.	Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, Chicago, IL 60614 USA	Flaherty, EG (corresponding author), Northwestern Univ, Feinberg Sch Med, Childrens Mem Hosp, 2300 Childrens Pl,Box 16, Chicago, IL 60614 USA.						BILLMIRE ME, 1985, PEDIATRICS, V75, P340; Brewster AL, 1998, CHILD ABUSE NEGLECT, V22, P91, DOI 10.1016/S0145-2134(97)00132-4; Brown J, 1998, CHILD ABUSE NEGLECT, V22, P1065, DOI 10.1016/S0145-2134(98)00087-8; Cadzow SP, 1999, CHILD ABUSE NEGLECT, V23, P845, DOI 10.1016/S0145-2134(99)00063-0; DAVIS HW, 1995, COMT PEDIAT, V12, P94; FELDMAN KW, 2001, PEDIATRICS; Hettler J, 2003, PEDIATRICS, V111, P602, DOI 10.1542/peds.111.3.602; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KELLEHER K, 1994, AM J PUBLIC HEALTH, V84, P1586, DOI 10.2105/AJPH.84.10.1586; Knapp J F, 1998, Pediatr Rev, V19, P316, DOI 10.1542/pir.19-9-316; Kotch JB, 1999, CHILD ABUSE NEGLECT, V23, P305, DOI 10.1016/S0145-2134(99)00003-4; Krugman R D, 1983, Pediatrician, V12, P68; Overpeck MD, 1998, NEW ENGL J MED, V339, P1211, DOI 10.1056/NEJM199810223391706; Reece RM, 2000, ARCH PEDIAT ADOL MED, V154, P11; Rivara FP, 1997, JAMA-J AM MED ASSOC, V278, P569, DOI 10.1001/jama.278.7.569; SCHMITT BD, 1987, CHILD ABUSE NEGLECT, V11, P421, DOI 10.1016/0145-2134(87)90015-9; Sidebotham P, 2001, CHILD ABUSE NEGLECT, V25, P1177, DOI 10.1016/S0145-2134(01)00261-7; *SPSS INC, SPSS WIND COMP VERS; Starling SP, 2004, ARCH PEDIAT ADOL MED, V158, P454, DOI 10.1001/archpedi.158.5.454; STARLING SP, 1995, PEDIATRICS, V95, P259; Tzioumi D, 1998, CHILD ABUSE NEGLECT, V22, P1105, DOI 10.1016/S0145-2134(98)00093-3; *US DEP HHS, 2002, CHILD MALTR 2000; *US DEP HHS, 1996, CHILD NEGL CAS LEV D	23	23	23	0	3	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0145-2134			CHILD ABUSE NEGLECT	Child Abuse Negl.	JUL	2006	30	7					789	798		10.1016/j.chiabu.2005.12.008			10	Family Studies; Psychology, Social; Social Work	Family Studies; Psychology; Social Work	070SO	WOS:000239544400005	16844217				2021-06-18	
J	Shore, PM; Hand, LL; Roy, L; Trivedi, P; Kochanek, PM; Adelson, PD				Shore, Paul M.; Hand, Linda L.; Roy, Lonnie; Trivedi, Prernal; Kochanek, Patrick M.; Adelson, P. David			Reliability and validity of the Pediatric Intensity Level of Therapy (PILOT) scale: A measure of the use of intracranial pressure-directed therapies	CRITICAL CARE MEDICINE			English	Article						head injury; clinical research; therapeutic intensity; child abuse; nonaccidental trauma; hypothermia; barbiturates; decompressive craniectomy; scale development	TRAUMATIC BRAIN-INJURY; CEREBRAL BLOOD-FLOW; SEVERE HEAD-INJURY; GLASGOW COMA SCALE; LENGTH-OF-STAY; DECOMPRESSIVE CRANIECTOMY; 20-PERCENT MANNITOL; RANDOMIZED TRIAL; PRACTICAL SCALE; VOLUME INDEX	Objective. To test the reliability and validity of the Pediatric Intensity Level of Therapy (PILOT) scale, a novel measure of overall therapeutic effort directed at controlling intracranial pressure (ICP) in the setting of severe (Glasgow Coma Scale of :5 8) pediatric traumatic brain injury (TBI). Design. Case-control study via retrospective review of medical records. Setting. Tertiary-care, university-based children's hospital intensive care unit. Patients., Randomly selected patients <= 18 yrs old admitted to the intensive care unit in 2002-2003 with severe TBI (cases: group 1, n = 27), mild-moderate TBI (control: group 2, n = 30), extracranial trauma (control: group 3, n = 29), or nontraumatic illnesses (control: group 4, n = 27). Interventions., None. Measurements and Main Results. A 38-point scale was developed to quantify daily ICP-directed therapeutic effort. All currently recommended therapies are represented. Demographic and physiologic data were collected on all patients. A total of 24 of 27 patients with severe TBI received ICP-directed therapy; three did not because of judgments of futility. No control patients received ICP-directed therapy. The PILOT scale score was assessed for the first 7 days posttrauma or postadmission. Interrater reliability was 0.91 (intraclass correlation coefficient) and intrarater reliability was 0.94. The highest PILOT scale scores were in patients with severe TBI (11.7 +/- 5.6 vs. 1.3 +/- 1.7 vs. 2.0 +/- 2.1 vs. 1.9 +/- 1.8 for groups 1, 2, 3 and 4, respectively [mean +/- SD]; p <.001 by analysis of variance/ Bonferroni). Patients with severe TBI who received ICP-directed therapy had higher PILOT scale scores (12.6 +/- 5.3 vs. 5.0 +/- 3.0, p =.001) than those who did not. Pearson's correlation coefficients of mean PILOT scale scores with measures of injury severity, outcome, and ICP were as follows: Glasgow Coma Scales score, -0.73 (P <.001); overall Injury Severity Score, 0.37 (p <.001); Injury Severity Score (head component only), 0.53 (p <.001); 6-month Glasgow Outcome Scale, -0.26 (p =.006); ICP burden (hours per day with ICP above treatment threshold), 0.59 (p =.002); and mean ICP, 0.41 (p=.044). Conclusions: The PILOT scale score can be obtained retrospectively and has good reliability. It can discriminate patients receiving ICP-directed therapy, even among patients with severe TBI, and correlates with measures of injury severity, outcome, and ICP in an expected way. Thus, it seems to be a valid measure of the use of ICP-directed therapy, although prospective, multiple-center validation is recommended.	Univ Texas, SW Med Ctr, Dallas, TX 75390 USA; Childrens Med Ctr, Dallas, TX 75235 USA; Childrens Hosp Pittsburgh, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Pittsburgh, PA 15260 USA; Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Shore, PM (corresponding author), Univ Texas, SW Med Ctr, Dallas, TX 75390 USA.		Adelson, David/W-2083-2019; Kochanek, Patrick M/D-2371-2015	Kochanek, Patrick M/0000-0002-2627-913X	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T-32 HD 40686] Funding Source: Medline		Alexander RH, 1993, ADV TRAUMA LIFE SUPP; Allen Elizabeth M., 1996, P809; Association for the Advancement of Automotive Medicine, 1990, ABBR INJ SCAL 1990 R; Battison C, 2005, CRIT CARE MED, V33, P196, DOI 10.1097/01.CCM.0000150269.65485.A6; Bedell EA, 1998, ANESTH ANALG, V87, P751; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; Biestro A, 1997, ACTA NEUROCHIR, V139, P725, DOI 10.1007/BF01420045; BOUMA GJ, 1992, J NEUROSURG, V77, P15, DOI 10.3171/jns.1992.77.1.0015; Brown SA, 2001, AM J PHYS MED REHAB, V80, P196, DOI 10.1097/00002060-200103000-00009; BULLOCK MR, 2000, J NEUROTRAUM, V17, P451; BULLOCK MR, 2000, J NEUROTRAUM, V17, P527; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS49; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS45; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS53; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS38; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS56; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS34; CARNEY NA, 2003, PEDIAT CRIT CARE MED, V4, pS40; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; Cruz J, 2002, NEUROSURGERY, V51, P628, DOI 10.1097/00006123-200209000-00006; Cruz J, 2001, NEUROSURGERY, V49, P864; Cullen D J, 1974, Crit Care Med, V2, P57, DOI 10.1097/00003246-197403000-00001; Diringer MN, 2004, CRIT CARE MED, V32, P1489, DOI 10.1097/01.CCM.0000129484.61912.84; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; Fortune JB, 1995, J TRAUMA, V39, P1091, DOI 10.1097/00005373-199512000-00014; Guerra WKW, 1999, J NEUROSURG, V90, P187, DOI 10.3171/jns.1999.90.2.0187; Henderson WR, 2003, INTENS CARE MED, V29, P1637, DOI 10.1007/s00134-003-1848-2; HSIANG JK, 1994, CRIT CARE MED, V22, P1471, DOI 10.1097/00003246-199409000-00019; JAMES HE, 1980, ACTA NEUROCHIR, V51, P161, DOI 10.1007/BF01406742; JENNETT B, 1975, LANCET, V1, P480; Khanna S, 2000, CRIT CARE MED, V28, P1144, DOI 10.1097/00003246-200004000-00038; LEVIN AB, 1979, NEUROSURGERY, V5, P570, DOI 10.1227/00006123-197911000-00005; MARION DW, 1994, J TRAUMA, V36, P89, DOI 10.1097/00005373-199401000-00014; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MARMAROU A, 1991, J NEUROSURG, V75, pS21, DOI 10.3171/sup.1991.75.1s.0s21; MASET AL, 1987, J NEUROSURG, V67, P832, DOI 10.3171/jns.1987.67.6.0832; Munch E, 2000, NEUROSURGERY, V47, P315; Natale JE, 2000, CRIT CARE MED, V28, P2608, DOI 10.1097/00003246-200007000-00071; Peterson B, 2000, CRIT CARE MED, V28, P1136, DOI 10.1097/00003246-200004000-00037; PLETS C, 1989, AM J CARDIOL, V63, pC40, DOI 10.1016/0002-9149(89)90405-0; Polin RS, 1997, NEUROSURGERY, V41, P84, DOI 10.1097/00006123-199707000-00018; ROBERTS I, 2003, COCHRANE DB SYST REV, V2; Robertson Charlene M. T., 2001, Pediatr Crit Care Med, V2, P145, DOI 10.1097/00130478-200104000-00009; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; SEGATORE M, 1992, HEART LUNG, V21, P548; SHAPIRO K, 1982, J NEUROSURG, V56, P819, DOI 10.3171/jns.1982.56.6.0819; Shore PM, 2004, J NEUROTRAUM, V21, P1113; Skippen P, 1997, CRIT CARE MED, V25, P1402, DOI 10.1097/00003246-199708000-00031; Soukup J, 2002, NEUROL RES, V24, P161, DOI 10.1179/016164102101199710; Taylor A, 2001, CHILD NERV SYST, V17, P154, DOI 10.1007/s003810000410; TEASDALE G, 1974, LANCET, V2, P81; Tokutomi T, 2003, NEUROSURGERY, V52, P102, DOI 10.1097/00006123-200301000-00013; Unterberg AW, 1997, J TRAUMA, V42, pS32, DOI 10.1097/00005373-199705001-00006; Vialet R, 2003, CRIT CARE MED, V31, P1683, DOI 10.1097/01.CCM.0000063268.91710.DF	57	23	23	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	JUL	2006	34	7					1981	1987		10.1097/01.CCM.0000220765.22184.ED			7	Critical Care Medicine	General & Internal Medicine	058BN	WOS:000238639300017	16691131				2021-06-18	
J	Wu, S; Fang, CX; Kim, J; Ren, J				Wu, Shan; Fang, Cindy X.; Kim, Jihye; Ren, Jun			Enhanced pulmonary inflammation following experimental intracerebral hemorrhage	EXPERIMENTAL NEUROLOGY			English	Article						intracerebral hemorrhage; brain; lung; inflammation; cytokine	TRAUMATIC BRAIN-INJURY; CONTUSION; BLOOD; RATS	The association between brain damage and respiratory dysfunction has been recognized although mechanistic link between the two is still poorly defined. Intracerebral hemorrhage is accompanied by brain injury, stroke, and parenchymal hematoma formation with surrounding inflammation. Increase intracranial pressure as a result of intracerebral hemorrhage may promote localized activation of cytokines and coagulation system including tissue factor release. However, whether intracerebral hemorrhage triggers inflammation in noncerebral organs has not been elucidated. The aim of the present study was to examine the impact of intracerebral hemorrhage on lung inflammatory response. Intracerebral hemorrhage was induced by stereotaxic intrastriatal administration of bacterial collagenase. Expression of intracellular adhesion molecule-1 (ICAM-1), I kappa B-alpha, tissue factor, tumor necrosis factor-alpha (TNF-alpha), and interleukin-1 beta (IL-1 beta) was evaluated by Western blot analysis. Our results revealed that intracerebral hemorrhage upregulated expression of ICAM-I and tissue factor in both brain and lung, whereas it enhanced TNF-alpha and IL-I beta mainly in brain within 6 and 24 h of the brain injury. Levels of I kappa B-alpha remained unchanged in brain and lung tissues. Appearance of inflammatory markers in the lung was accompanied by morphological pulmonary damage. These data suggest that intracerebral hemorrhage may trigger acute inflammatory response in both brain and lung. (c) 2006 Elsevier Inc. All rights reserved.	Univ Wyoming, Div Pharmaceut Sci, Laramie, WY 82071 USA; Univ Wyoming, Ctr Cardiovasc Res & Alternat Med, Laramie, WY 82071 USA	Ren, J (corresponding author), Univ Wyoming, Div Pharmaceut Sci, 1000 E Univ Ave,Dept 3375, Laramie, WY 82071 USA.	jren@uwyo.edu					Aronowski J, 2005, NEUROL RES, V27, P268, DOI 10.1179/016164105X25225; Chen HI, 1995, BIOL SIGNAL, V4, P186; Cifu DX, 1996, ARCH PHYS MED REHAB, V77, P883, DOI 10.1016/S0003-9993(96)90274-9; Donnelly SC, 1996, ANN INTERN MED, V125, P191, DOI 10.7326/0003-4819-125-3-199608010-00005; Earle SA, 2005, SURGERY, V138, P431, DOI 10.1016/j.surg.2005.06.026; Fisher AJ, 1999, LANCET, V353, P1412, DOI 10.1016/S0140-6736(99)00494-8; Garnier Y, 2003, J SOC GYNECOL INVEST, V10, P450, DOI 10.1016/S1071-5576(03)00150-3; Goel Radha, 2005, Congest Heart Fail, V11, P99; Gong C, 2000, BRAIN RES, V871, P57, DOI 10.1016/S0006-8993(00)02427-6; Jean WC, 1998, NEUROSURGERY, V43, P1382, DOI 10.1097/00006123-199812000-00076; Knoferl MW, 2003, SHOCK, V19, P519, DOI 10.1097/01.shk.0000070739.34700.f6; Lampl Y, 2005, CEREBROVASC DIS, V20, P433, DOI 10.1159/000088981; NISHINO A, 1994, ACTA NEUROCHIR, P86; Orliaguet C, 2000, ANN FR ANESTH, V19, P164; Owens R, 2005, NEONATAL NETW, V24, P55, DOI 10.1891/0730-0832.24.3.55; PASINETTI GM, 1992, EXP NEUROL, V118, P117, DOI 10.1016/0014-4886(92)90028-O; PAXINOS G, 1985, J NEUROSCI METH, V13, P139, DOI 10.1016/0165-0270(85)90026-3; Pyeron A M, 2001, J Neurosci Nurs, V33, P203; Ren J, 2006, FRONT BIOSCI-LANDMRK, V11, P15, DOI 10.2741/1776; SCHRANZ D, 1983, MONATSSCHR KINDERH, V131, P109; SHIVALKAR B, 1993, CIRCULATION, V87, P230, DOI 10.1161/01.CIR.87.1.230; Whalen MJ, 1999, CRIT CARE MED, V27, P1014, DOI 10.1097/00003246-199905000-00049; Xue MZ, 2000, NEUROSCI LETT, V283, P230, DOI 10.1016/S0304-3940(00)00971-X	23	23	28	0	1	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUL	2006	200	1					245	249		10.1016/j.expneurol.2006.01.027			5	Neurosciences	Neurosciences & Neurology	070EL	WOS:000239503000026	16516197				2021-06-18	
J	Wood, RL; Liossi, C				Wood, Rodger L.; Liossi, Christina			Neuropsychological and neurobehavioral correlates of aggression following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							LONG-TERM SURVIVORS; BLUNT HEAD-INJURY; IMPULSIVE AGGRESSION; RELATIVES; SEQUELAE; BEHAVIOR; DEFICITS; IMPACT	This study aimed to establish the neuropsychological and neurobehavioral pro. le of individuals who develop aggression following traumatic brain injury. In a prospective cohort study, 134 brain-injured individuals who exhibited aggression were compared to 153 individuals who had sustained comparable injuries but were not aggressive. In the aggressive group, specific deficits were identified in verbal memory and visuo-perceptual skills. Compared to normative data, this group had impaired executive-attention function. It is tentatively suggested that significant impairment in verbal memory and visuospatial abilities against a background of diminished executive-attention functioning is associated with the development of aggression after brain injury, especially when other risk factors such as low premorbid IQ, low socioeconomic status, and male gender are present.	Univ Southampton, Sch Psychol, Southampton S017 1BJ, Hants, England; Swansea Univ, Swansea, W Glam, Wales	Liossi, C (corresponding author), Univ Southampton, Sch Psychol, Southampton S017 1BJ, Hants, England.	cliossi@soton.ac.uk		Liossi, Christina/0000-0003-0627-6377			Baddeley A.D., 1992, SPEED CAPACITY LANGU; Barratt ES, 1997, BIOL PSYCHIAT, V41, P1045, DOI 10.1016/S0006-3223(96)00175-8; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Brower MC, 2001, J NEUROL NEUROSUR PS, V71, P720, DOI 10.1136/jnnp.71.6.720; Cohen RA, 2003, J INT NEUROPSYCH SOC, V9, P760, DOI 10.1017/S1355617703950090; COHEN RA, 1999, VIOLENCE VICT, V4, P397; DEMPSTER AP, 1977, J ROY STAT SOC B MET, V39, P1, DOI 10.1111/j.2517-6161.1977.tb01600.x; Erdfelder E, 1996, BEHAV RES METH INS C, V28, P1, DOI 10.3758/BF03203630; ESLINGER PJ, 1995, NEUROREHABILITATION, V5, P161, DOI 10.3233/NRE-1995-5206; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Greve KW, 2002, PERS INDIV DIFFER, V32, P639, DOI 10.1016/S0191-8869(01)00066-6; Greve KW, 2001, BRAIN INJURY, V15, P255; Halstead WC, 1985, HALSTEAD REITAN NEUR; Koechlin E, 1999, NATURE, V399, P148; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Linares-Orama N, 2005, J COMMUN DISORD, V38, P311, DOI 10.1016/j.jcomdis.2005.02.006; LITTLE RJA, 1988, J AM STAT ASSOC, V83, P1198, DOI 10.2307/2290157; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MOFFITT TE, 1990, CRIME JUSTICE, V12, P99, DOI 10.1086/449165; Morgan AB, 2000, CLIN PSYCHOL REV, V20, P113, DOI 10.1016/S0272-7358(98)00096-8; NELSON H, 1991, NATL ADULT READING R; Paschall MJ, 2002, AGGRESS VIOLENT BEH, V7, P215, DOI 10.1016/S1359-1789(00)00044-6; PETRIDES M, 1995, ANN NY ACAD SI, V15, P85; ROSENBAUM A, 1994, J CONSULT CLIN PSYCH, V62, P1187, DOI 10.1037/0022-006X.62.6.1187; Ruff CC, 2003, NEUROPSYCHOLOGIA, V41, P1241, DOI 10.1016/S0028-3932(03)00016-2; Shallice, 1997, HAYLING BRIXTON TEST; SHALLICE T, 1991, BRAIN, V114, P727, DOI 10.1093/brain/114.2.727; *SPSS INC, 2004, SPSS REF GUID; Stanford MS, 1997, PERS INDIV DIFFER, V23, P961, DOI 10.1016/S0191-8869(97)00120-7; Wechsler D., 1997, WECHSLER ADULT MEMOR; Wechsler D, 1997, WAIS 3 ADM SCORING M; Wilson BA, 1996, BEHAV ASSESSMENT DYS; Wood R. L., 1987, BRAIN INJURY REHABIL; Wood RL, 2005, BRAIN INJURY, V19, P845, DOI 10.1080/02699050500058778; Wood RL, 2004, NEUROPSYCHOL REHABIL, V14, P329, DOI 10.1080/09602010343000255; Wood RL, 2001, NEUROBEHAVIORAL DISA; YEUDALL LT, 1997, CANADIAN MENTAL HLTH, V25, P7	40	23	23	0	7	AMER PSYCHIATRIC PUBLISHING, INC	WASHINGTON	800 MAINE AVE SW, SUITE 900, WASHINGTON, DC 20024 USA	0895-0172	1545-7222		J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	SUM	2006	18	3					333	341		10.1176/appi.neuropsych.18.3.333			9	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	081AC	WOS:000240288600004	16963582				2021-06-18	
J	Cameron, CM; Purdie, DM; Kliewer, EV; McClure, RJ				Cameron, Cate M.; Purdie, David M.; Kliewer, Erich V.; McClure, Rod J.			Mental health: A cause or consequence of injury? A population-based matched cohort study	BMC PUBLIC HEALTH			English	Article							TRAUMATIC BRAIN-INJURY; SATISFACTION 12 MONTHS; SPINAL-CORD-INJURY; GENERAL HEALTH; WORK STATUS; FOLLOW-UP; ASSOCIATION; COMORBIDITY; DISORDERS; MORTALITY	Background: While a number of studies report high prevalence of mental health problems among injured people, the temporal relationship between injury and mental health service use has not been established. This study aimed to quantify this relationship using 10 years of follow-up on a population-based cohort of hospitalised injured adults. Methods: The Manitoba Injury Outcome Study is a retrospective population-based matched cohort study that utilised linked administrative data from Manitoba, Canada, to identify an inception cohort ( 1988 - 1991) of hospitalised injured cases (ICD-9-CM 800 - 995) aged 18 - 64 years (n = 21,032), which was matched to a non-injured population-based comparison group ( n = 21,032). Pre-injury comorbidity and post-injury mental health data were obtained from hospital and physician claims records. Negative Binomial regression was used to estimate adjusted rate ratios (RRs) to measure associations between injury and mental health service use. Results: Statistically significant differences in the rates of mental health service use were observed between the injured and non-injured, for the pre-injury year and every year of the follow-up period. The injured cohort had 6.56 times the rate of post-injury mental health hospitalisations (95% CI 5.87, 7.34) and 2.65 times the rate of post-injury mental health physician claims ( 95% CI 2.53, 2.77). Adjusting for comorbidities and pre-existing mental health service use reduced the hospitalisations RR to 3.24 ( 95% CI 2.92, 3.60) and the physician claims RR to 1.53 ( 95% CI 1.47, 1.59). Conclusion: These findings indicate the presence of pre-existing mental health conditions is a potential confounder when investigating injury as a risk factor for subsequent mental health problems. Collaboration with mental health professionals is important for injury prevention and care, with ongoing mental health support being a clearly indicated service need by injured people and their families. Public health policy relating to injury prevention and control needs to consider mental health strategies at the primary, secondary and tertiary level.	Griffith Univ, Sch Med, Meadowbrook, Australia; Queensland Inst Med Res, Brisbane, Qld 4006, Australia; CancerCare Manitoba, Dept Epidemiol, Winnipeg, MB, Canada; CancerCare Manitoba, Canc Registry, Winnipeg, MB, Canada; Univ Manitoba, Dept Community Hlth Sci, Winnipeg, MB R3T 2N2, Canada; Univ Sydney, Sch Publ Hlth, Sydney, NSW 2006, Australia; Univ Queensland, Sch Populat Hlth, St Lucia, Qld 4067, Australia	Cameron, CM (corresponding author), Griffith Univ, Sch Med, Meadowbrook, Australia.	cate.cameron@griffith.edu.au; davidpurdie@fastmail.fm; erich.kliewer@cancercare.mb.ca; r.mcclure@griffith.edu.au		McClure, Roderick/0000-0002-9067-8282; Cameron, Cate/0000-0003-1476-5744			Bombardier CH, 2004, ARCH PHYS MED REHAB, V85, P1749, DOI 10.1016/j.apmr.2004.07.348; Cameron CM, 2005, J TRAUMA, V59, P639, DOI 10.1097/01.ta.0000183222.79685.23; CAMERON DJ, 1983, INT J IMMUNOPHARMACO, V5, P345, DOI 10.1016/0192-0561(83)90038-3; Carrico CJ, 2000, J TRAUMA, V48, P848; COHEN MM, 1995, MED CARE S, V33, P42; Darnall BD, 2005, ARCH PHYS MED REHAB, V86, P650, DOI 10.1016/j.apmr.2004.10.028; Dryden DM, 2004, SPINAL CORD, V42, P513, DOI 10.1038/sj.sc.3101629; Dryden DM, 2005, NEUROEPIDEMIOLOGY, V25, P55, DOI 10.1159/000086284; DUFORT GG, 1993, J NERV MENT DIS, V181, P467, DOI 10.1097/00005053-199308000-00001; Dunn LT, 2000, BRIT J NEUROSURG, V14, P219; Field CA, 2001, J TRAUMA, V50, P13, DOI 10.1097/00005373-200101000-00002; GARDNER W, 1995, PSYCHOL BULL, V118, P392, DOI 10.1037/0033-2909.118.3.392; Greenspan AI, 2002, J TRAUMA, V53, P709, DOI 10.1097/00005373-200210000-00015; Klabunde CN, 2002, MED CARE, V40, P26; Koven R, 2005, PREV MED, V41, P240, DOI 10.1016/j.ypmed.2004.11.009; Macmillan PJ, 2002, BRAIN INJURY, V16, P41, DOI 10.1080/0269905011008812; McCullagh P., 1989, GEN LINEAR MODELS; MCEVOY S, 2004, SCI BASIS INJURY PRE, P62; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; MORRIS JA, 1990, J TRAUMA, V30, P1476, DOI 10.1097/00005373-199012000-00006; O'Donnell ML, 2004, AM J PSYCHIAT, V161, P507, DOI 10.1176/appi.ajp.161.3.507; O'Donnell ML, 2003, CLIN PSYCHOL REV, V23, P587, DOI 10.1016/S0272-7358(03)00036-9; Patterson DR, 2003, J BURN CARE REHABIL, V24, P347, DOI 10.1097/01.BCR.0000086070.91033.7F; Roos LL, 1999, J CLIN EPIDEMIOL, V52, P39, DOI 10.1016/S0895-4356(98)00126-7; Roos LL, 1997, HEALTH SERV RES, V32, P229; ROOS LL, 1997, HEALTH SERV RES, V32, P239; ROOS N, 1995, MED CARE, V33, P12; ROOS NP, 1995, MED CARE S, V33, P20; Rothman K.J., 1998, MODERN EPIDEMIOLOGY, V2nd ed.; Schneeweiss S, 2000, INT J EPIDEMIOL, V29, P891, DOI 10.1093/ije/29.5.891; Silver JM, 2001, BRAIN INJURY, V15, P935, DOI 10.1080/02699050110065295; *STAT CAN, 2002, CAN COMM HLTH SURV M; Wadsworth EJK, 2005, HUM PSYCHOPHARM CLIN, V20, P391, DOI 10.1002/hup.709; Watts R, 1999, BRAIN INJURY, V13, P113, DOI 10.1080/026990599121773; Young TK, 2000, AM J PUBLIC HEALTH, V90, P1466, DOI 10.2105/AJPH.90.9.1466; Zatzick D, 2004, J TRAUMA, V57, P360, DOI 10.1097/01.TA.0000141332.43183.7F	36	23	23	0	4	BIOMED CENTRAL LTD	LONDON	MIDDLESEX HOUSE, 34-42 CLEVELAND ST, LONDON W1T 4LB, ENGLAND	1471-2458			BMC PUBLIC HEALTH	BMC Public Health	MAY 2	2006	6								114	10.1186/1471-2458-6-114			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	069GD	WOS:000239433500001	16650287	DOAJ Gold, Green Published			2021-06-18	
J	Huang, PS; Tang, GJ; Chen, CH; Kou, YR				Huang, PS; Tang, GJ; Chen, CH; Kou, YR			Whole-body moderate hypothermia confers protection from wood smoke-induced acute lung injury in rats: The therapeutic window	CRITICAL CARE MEDICINE			English	Article						smoke inhalation injury; acute lung injury; induced hypothermia; pulmonary inflammation; bronchoalveolar lavage fluid; cytokines	RESPIRATORY-DISTRESS-SYNDROME; PROMISING TREATMENT MODALITY; TRAUMATIC BRAIN-INJURY; MILD HYPOTHERMIA; OXIDATIVE STRESS; CARDIOPULMONARY BYPASS; INHALATION INJURY; ENDOTOXEMIC RATS; LIPID-PEROXIDATION; ISCHEMIA	objective: Toxic smoke inhalation causes acute lung injury. We studied the efficacy and therapeutic window of whole-body hypothermia in rats with wood smoke-induced acute lung injury. Design: Randomized, controlled study. Setting. Research laboratory. Subjects: Anesthetized, paralyzed, and artificially ventilated rats (n = 100) were used. Interventions. Air or wood smoke (30 breaths) was delivered into the lung using a respirator. Immediately after challenge, the rat's colonic temperature was kept a) 37 degrees C (normothermia, NT) for I (NT-1-Air and NT-1-Smoke), 2.5 (NT-2.5-Air and NT-2.5-Smoke), or 5 hrs (NT-5-Air and NT-5-Smoke) in six groups; b) 30 degrees C (hypothermia, HT) for 2.5 (HT-2.5-Smoke) or 5 hrs (HT-5-Air and HT-5-Smoke) in three groups; c) 30 degrees C for the first 2.5 hrs followed by 37 degrees C for another 2.5 hrs (HT-NT-5-Smoke) in one group; or d) 37 degrees C for the first 2.5 hrs followed by 30 degrees C for another 2.5 hrs (NT-HT-5-Smoke) in on group. Measurements and Main Results. Various acute lung injury indexes were assessed at 1, 2.5, or 5 hrs after challenge. In the air group, whole-body hypothermia did not affect the level of lung lipid peroxidation and the amount of proteins, total and differential cell counts, and concentrations of tumor necrosis factor-et and interleukin-1 beta in bronchoalveolar lavage fluid. In the smoke groups, these acute lung injury indexes were increased showing that NT-5-Smoke > NT-2.5-Smoke > NT-1-Smoke. Whole-body hypothermia prevented increases in these acute lung injury indexes in the HT-2.5-Smoke and HT-5-Smoke groups. The efficacy of whole-body hypothermia in the HT-NT-5-Smoke group was superior to that in the NT-HT-5-Smoke group and similar to that in the HT-5-Smoke group. Whole-body hypothermia also alleviated smoke-induced poor gas exchange, pulmonary edema, and pathohistologic injurious signs. Conclusions: Whole-body hypothermia confers protection from wood smoke-induced acute lung injury in rats by suppressing oxidant bronchoalveolar damage and pulmonary inflammation. Early and short-period (2 hrs) application of whole-body hypothermia provides favorable therapeutic effects.	Natl Yang Ming Univ, Sch Med, Inst Physiol, Taipei 11221, Taiwan; Vet Gen Hosp, I Lan Hosp, DOH, Ilan, Taiwan; Mackay Mem Hosp, Dept Surg, Thorac Surg Div, Taipei, Taiwan	Kou, YR (corresponding author), Natl Yang Ming Univ, Sch Med, Inst Physiol, Taipei 11221, Taiwan.	yrkou@ym.edu.tw		Kou, Yu Ru/0000-0002-4681-9009			Adachi M, 2001, PEDIATR RES, V50, P590, DOI 10.1203/00006450-200111000-00010; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Allen BS, 2003, J THORAC CARDIOV SUR, V125, P625, DOI 10.1067/mtc.2003.96; Attuwaybi BO, 2003, J SURG RES, V115, P48, DOI 10.1016/S0022-4804(03)00313-5; BARROW RE, 1990, J APPL PHYSIOL, V68, P2165; Bernard SA, 2003, CRIT CARE MED, V31, P2041, DOI 10.1097/01.CCM.0000069731.18472.61; BLACK PR, 1976, J SURG RES, V20, P49, DOI 10.1016/0022-4804(76)90083-4; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; Chiang CH, 1999, AM J RESP CRIT CARE, V160, P1319, DOI 10.1164/ajrccm.160.4.9811079; Cullen KE, 1997, J BIOL CHEM, V272, P1742, DOI 10.1074/jbc.272.3.1742; FLETCHER BL, 1973, ANAL BIOCHEM, V52, P1, DOI 10.1016/0003-2697(73)90327-8; Gazmuri RJ, 2003, CRIT CARE MED, V31, P2811, DOI 10.1097/01.CCM.0000099344.57796.F3; GILSTON A, 1983, INTENS CARE MED, V9, P37, DOI 10.1007/BF01693705; GOSS JR, 1995, J NEUROTRAUM, V12, P159, DOI 10.1089/neu.1995.12.159; Gundersen Y, 2001, ACTA ANAESTH SCAND, V45, P994, DOI 10.1034/j.1399-6576.2001.450812.x; Guven H, 2002, J TRAUMA, V53, P66, DOI 10.1097/00005373-200207000-00014; Hassoun HT, 2002, SURGERY, V132, P369, DOI 10.1067/msy.2002.125722; Hildebrand F, 2004, AM J SURG, V187, P363, DOI 10.1016/j.amjsurg.2003.12.016; Honore PM, 2001, CRIT CARE MED, V29, P1903, DOI 10.1097/00003246-200110000-00009; Horiguchi T, 2003, J NEUROTRAUM, V20, P511, DOI 10.1089/089771503765355577; HURST JM, 1985, CRIT CARE MED, V13, P771, DOI 10.1097/00003246-198509000-00019; JANSSENS SP, 1994, J APPL PHYSIOL, V77, P888; Javadpour M, 1998, BRIT J SURG, V85, P943; Jeng MJ, 2003, CRIT CARE MED, V31, P1166, DOI 10.1097/01.CCM.0000059312.90697.32; Khandoga A, 2003, FREE RADICAL BIO MED, V35, P901, DOI 10.1016/S0891-5849(03)00430-1; Kimmel EC, 1999, DRUG CHEM TOXICOL, V22, P91, DOI 10.3109/01480549909029726; Kimura A, 2002, CRIT CARE MED, V30, P1499, DOI 10.1097/00003246-200207000-00017; Koh Y, 1999, Respirology, V4, P325, DOI 10.1046/j.1440-1843.1999.00200.x; KOU YR, 1994, J APPL PHYSIOL, V76, P2333; Laffon M, 1999, AM J RESP CRIT CARE, V160, P1443, DOI 10.1164/ajrccm.160.5.9901097; LEI BP, 1994, STROKE, V25, P147, DOI 10.1161/01.STR.25.1.147; Lim CM, 2004, INTENS CARE MED, V30, P1638, DOI 10.1007/s00134-004-2336-z; Lim CM, 2003, LUNG, V181, P23, DOI 10.1007/s00408-002-0111-x; Lim CM, 2003, INTENS CARE MED, V29, P453, DOI 10.1007/s00134-002-1529-6; Lin YS, 2000, EUR J PHARMACOL, V394, P139, DOI 10.1016/S0014-2999(00)00126-6; Lin YS, 2001, EUR J PHARMACOL, V425, P141, DOI 10.1016/S0014-2999(01)01184-0; Maier CM, 2002, NEUROBIOL DIS, V11, P28, DOI 10.1006/nbdi.2002.0513; Marion DW, 1996, CRIT CARE MED, V24, pS81; Matsuoka Koji, 2003, Pancreas, V26, pe12, DOI 10.1097/00006676-200301000-00024; Murakami K, 2003, NEWS PHYSIOL SCI, V18, P125, DOI 10.1152/nips.01427.2002; Ning XH, 2002, J APPL PHYSIOL, V92, P2200, DOI 10.1152/japplphysiol.01035.2001; Park MS, 2004, TOXICOLOGY, V195, P97, DOI 10.1016/j.tox.2003.09.005; Patel S, 2000, J AM COLL SURGEONS, V191, P650, DOI 10.1016/S1072-7515(00)00736-5; Polderman KH, 2004, INTENS CARE MED, V30, P556, DOI 10.1007/s00134-003-2152-x; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Qing M, 2003, CRIT CARE MED, V31, P2769, DOI 10.1097/01.CCM.0000098858.64868.9C; Qing M, 2001, SHOCK, V15, P372, DOI 10.1097/00024382-200115050-00007; Sarcia PJ, 2003, SHOCK, V20, P41, DOI 10.1097/01.shk.0000071080.50028.f2; Satas S, 2003, BIOL NEONATE, V83, P146, DOI 10.1159/000067958; Scumpia PO, 2002, AM J PHYSIOL-LUNG C, V283, pL1231, DOI 10.1152/ajplung.00102.2002; Sievers HH, 2002, ANN THORAC SURG, V74, P1167, DOI 10.1016/S0003-4975(02)03853-5; Sutcliffe IT, 2001, J CEREBR BLOOD F MET, V21, P1310, DOI 10.1097/00004647-200111000-00007; Suzuki S, 2004, CRIT CARE MED, V32, P144, DOI 10.1097/01.CCM.0000098857.14923.44; Taniguchi T, 2004, ANESTH ANALG, V98, P1114, DOI 10.1213/01.ANE.0000100740.07331.A2; TOLEDOPEREYRA LH, 1977, ANN THORAC SURG, V23, P487, DOI 10.1016/S0003-4975(10)64176-8; TRABER DL, 1992, AM REV RESPIR DIS, V146, pS15, DOI 10.1164/ajrccm/146.5_Pt_2.S15; TRABER DL, 1986, RESP INJURY SMOKE IN, P61; VILLAR J, 1993, RESUSCITATION, V26, P183, DOI 10.1016/0300-9572(93)90178-S; Wang GJ, 2002, NEUROSCIENCE, V114, P1081, DOI 10.1016/S0306-4522(02)00350-0; WETTERBERG T, 1992, ACTA ANAESTH SCAND, V36, P490, DOI 10.1111/j.1399-6576.1992.tb03504.x; Xu LJ, 2002, J CEREBR BLOOD F MET, V22, P21, DOI 10.1097/00004647-200201000-00003; YOUN YK, 1992, FREE RADICAL BIO MED, V12, P409; Zar HA, 1999, ANESTHESIOLOGY, V90, P1103, DOI 10.1097/00000542-199904000-00025	63	23	26	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	APR	2006	34	4					1160	1167		10.1097/01.CCM.0000207342.50559.0F			8	Critical Care Medicine	General & Internal Medicine	025YH	WOS:000236303000033	16484924				2021-06-18	
J	Ates, O; Ondul, S; Onal, C; Buyukkiraz, M; Somay, H; Cayli, SR; Gogusgeren, MA; Okrakdogen, M; Kocak, A; Yologlu, S; Berkman, Z; Tevruz, M				Ates, O; Ondul, S; Onal, C; Buyukkiraz, M; Somay, H; Cayli, SR; Gogusgeren, MA; Okrakdogen, M; Kocak, A; Yologlu, S; Berkman, Z; Tevruz, M			Post-traumatic early epilepsy in pediatric age group with emphasis on influential factors	CHILDS NERVOUS SYSTEM			English	Article; Proceedings Paper	18th Congress of the European-Society-for-Pediatric-Neurosurgery	JUN 14-18, 2002	KIRUNA, SWEDEN	European Soc Pediat Neurosurg		pediatric; head injury; posttraumatic epilepsy; early epilepsy; diphenylhydantoin	SEVERE HEAD-INJURY; EARLY SEIZURES; CHILDREN; PREDICTORS; PHENYTOIN; TRAUMA	Objective: Posttraumatic epilepsy in the pediatric age group is mostly seen within the first week. An acute posttraumatic epileptic fit, which may induce secondary insults, should be hindered. The aim of the study is to define the risk factors for posttraumatic early epilepsy (PTEE) and the indications for prophylactic therapy. Methods: In this survey, a total of 1,785 pediatric patients-under the age of 16-are studied. The majority of the patients (1,655) were treated in Haydarpa Numune Hospital within the years 1993-1999. The rest, which consists of 130 patients, were treated in Inonu University Turgut Ozal Medical Center between the years 2001 and 2003. The patients were categorized according to age, gender, neurological manifestations, type of trauma, cranial pathology, number and type of epileptic fits, the interval between trauma and convulsion, electroencephalogram findings, and antiepileptic therapy. All these factors were challenged due to their effect on the evolution of PTEE. Results: Only 149 cases had PTEE (8.4%). There was no correlation between gender and the incidence of PTEE. The data showed that 11.7% of the patients at or under the age of 3 (p=0.00072), 30.8% of the patients with severe head injury (Glasgow Coma Scale=3-8; Children's Coma Scale = 3-8; p=0.00000), 19.3% of the patients with depressed skull fractures (p=0.00038), 13.7% of the patients with intraparenchymal hemorrhage (p=0.0000072), and 21.6% of the patients with cerebral edema (p=0.000008) had PTEE. Only 20% of the patients with PTEE had a Glasgow Outcome Scale (GOS) of 3 or less (p=0.0000075). Conclusion: Those patients at or under the age of 3, with severe head injury, cerebral edema, intraparenchymal hemorrhage, or depressed skull fracture, have a higher incidence of PTEE. Moreover, because the GOS of these patients are prone to be worse, antiepileptic therapy in acute stage may be effective in preventing the secondary brain damage.	Inonu Univ, Turgut Ozal Med Ctr, Sch Med, Dept Neurosurg, TR-44069 Malatya, Turkey; Haydarpasa Numune Hosp, Dept Neurosurg, Istanbul, Turkey; Inonu Univ Sch Med, Dept Biostat, Malatya, Turkey	Ates, O (corresponding author), Inonu Univ, Turgut Ozal Med Ctr, Sch Med, Dept Neurosurg, TR-44069 Malatya, Turkey.	atesozkan@hotmail.com	Yologlu, Saim/ABI-8014-2020	Yologlu, Saim/0000-0002-9619-3462			ANNEGERS JF, 1980, NEUROLOGY, V30, P683, DOI 10.1212/WNL.30.7.683; BERGER MS, 1985, J NEUROSURG, V62, P194, DOI 10.3171/jns.1985.62.2.0194; *BRAIN TRAUM FDN, 2000, J NEUROTRAUM, V17, P549, DOI DOI 10.1089/NEU.2000.17.549; CAVENESS WF, 1961, EPILEPSIA, V2, P123; Chiaretti A, 2000, CHILD NERV SYST, V16, P862, DOI 10.1007/s003810000368; DESAI BT, 1983, EPILEPSIA, V24, P289, DOI 10.1111/j.1528-1157.1983.tb04892.x; Frey LC, 2003, EPILEPSIA, V44, P11, DOI 10.1046/j.1528-1157.44.s10.4.x; HAHN YS, 1988, NEUROSURGERY, V22, P864, DOI 10.1227/00006123-198805000-00008; HEEVER CMV, 1989, J NEUROSURG, V71, P186; HENDRICK EB, 1968, J TRAUM, V8, P547; JENNETT B, 1974, ARCH NEUROL-CHICAGO, V30, P394, DOI 10.1001/archneur.1974.00490350052008; JENNETT B, 1965, BRIT MED J, V2, P1215; KAPLAN HA, 1961, EPILEPSIA, V2, P111; Lee ST, 1995, ACTA NEUROCHIR, V137, P151, DOI 10.1007/BF02187187; LEWIS RJ, 1993, ANN EMERG MED, V22, P1114, DOI 10.1016/S0196-0644(05)80974-6; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; MARSHALL C, 1961, EPILEPSIA, V2, P138; MCQUEEN JK, 1983, J NEUROL NEUROSUR PS, V46, P899, DOI 10.1136/jnnp.46.10.899; MOSHE SL, 1987, EPILEPSIA S1, V28, P3; Ong LC, 1996, J PAEDIATR CHILD H, V32, P173, DOI 10.1111/j.1440-1754.1996.tb00917.x; PohlmannEden B, 1997, ACTA NEUROL SCAND, V95, P257, DOI 10.1111/j.1600-0404.1997.tb00206.x; RAPPORT RL, 1973, J NEUROSURG, V38, P159, DOI 10.3171/jns.1973.38.2.0159; RISH BL, 1973, J NEUROSURG, V38, P155, DOI 10.3171/jns.1973.38.2.0155; SADIKOGLU S, 1988, DERGISI, V3, P240; SALAZAR AM, 1985, NEUROLOGY, V35, P1406, DOI 10.1212/WNL.35.10.1406; Schierhout G, 1998, J NEUROL NEUROSUR PS, V64, P108, DOI 10.1136/jnnp.64.1.108; TEMKIN NR, 1990, NEW ENGL J MED, V323, P497, DOI 10.1056/NEJM199008233230801; Tuncer R, 1989, TURK NEUROSURG, V1, P23; WALKER AE, 1970, EPILEPSIA, V11, P17, DOI 10.1111/j.1528-1157.1970.tb03861.x; WEISS GH, 1972, J NEUROSURG, V37, P164, DOI 10.3171/jns.1972.37.2.0164; YABLON SA, 1993, ARCH PHYS MED REHAB, V74, P983; YOUNG B, 1983, J NEUROSURG, V58, P231, DOI 10.3171/jns.1983.58.2.0231	32	23	25	1	8	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2006	22	3					279	284		10.1007/s00381-005-1177-6			6	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	015IV	WOS:000235546000012	15889309				2021-06-18	
J	Moor, E; Shohami, E; Kanevsky, E; Grigoriadis, N; Symeonidou, C; Kohen, R				Moor, E; Shohami, E; Kanevsky, E; Grigoriadis, N; Symeonidou, C; Kohen, R			Impairment of the ability of the injured aged brain in elevating urate and ascorbate	EXPERIMENTAL GERONTOLOGY			English	Article						aging; ascorbic acid; uric acid; axonal injury; microdialysis; traumatic brain injury; closed head injury; low molecular weight antioxidants	CLOSED-HEAD-INJURY; OXIDATIVE STRESS; EXTRACELLULAR ASCORBATE; IN-VIVO; FOREBRAIN ISCHEMIA; RAT-BRAIN; RELEASE; ANTIOXIDANTS; GLUTAMATE; ACID	Urate and ascorbate play a major role in the defense mechanism of the brain against oxidative damage induced by traumatic brain injury. The severity and extent of brain damage are known to increase with age. This may be due to different basal levels of endogenous antioxidants, and/or to impaired ability of the old brain to recruit and elevate the levels of antioxidants following injury. To investigate this hypothesis, we measured basal ascorbate and urate levels in the hippocampus, using microdialysis in young, adults and old rats, and performed closed head injury (CHI) in young (5-6 weeks) and old rats (19-20 months). Basal ascorbate, but not urate levels in old rats were significantly lower than in the adults. The ability of the old rats to increase ascorbate levels after CHI was significantly lower than that of the young ones, as indicated by lower levels of ascorbate and urate in the dialysate of old rats. This lower level of antioxidant mobilization in the old brain may explain the extended damage found in histology. Evaluation of hippocampal cell loss (p < 0.05) and axonal degeneration in the corpus callosum showed more extensive damage in old as compared to young rats (chi(2)=4.25; p < 0.05). These findings shed more light on the susceptibility of old rat brain to CHI-induced oxidative damage. (c) 2006 Elsevier Inc. All rights reserved.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel; Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel; Aristotle Univ Thessaloniki, AHEPA Univ Hosp, Dept Neurol, GR-54006 Thessaloniki, Greece; Aristotle Univ Thessaloniki, Fac Med, Dept Physiol, GR-54006 Thessaloniki, Greece	Kohen, R (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmaceut, IL-91120 Jerusalem, Israel.	ronko@cc.huji.ac.il					AMES BN, 1981, P NATL ACAD SCI-BIOL, V78, P6858, DOI 10.1073/pnas.78.11.6858; Armstead WM, 2002, DEV BRAIN RES, V139, P19, DOI 10.1016/S0165-3806(02)00511-4; Bashore TR, 2002, PSYCHOL BULL, V128, P151, DOI 10.1037/0033-2909.128.1.151; Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; BECKER BF, 1993, FREE RADICAL BIO MED, V14, P615, DOI 10.1016/0891-5849(93)90143-I; Beckman KB, 1998, PHYSIOL REV, V78, P547; BeitYannai E, 1997, J CEREBR BLOOD F MET, V17, P273, DOI 10.1097/00004647-199703000-00004; Beni-Adani L, 2001, J PHARMACOL EXP THER, V296, P57; Berry EM, 1999, MED HYPOTHESES, V53, P397, DOI 10.1054/mehy.1998.0786; Butterfield DA, 2001, TRENDS MOL MED, V7, P548, DOI 10.1016/S1471-4914(01)02173-6; Chen Y, 1996, J NEUROTRAUM, V13, P557, DOI 10.1089/neu.1996.13.557; COHEN G, 1994, ANN NY ACAD SCI, V738, P8; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; Elangovan V, 2000, J NEUROTRAUM, V17, P1013, DOI 10.1089/neu.2000.17.1013; Esposito E, 2002, NEUROBIOL AGING, V23, P719, DOI 10.1016/S0197-4580(02)00078-7; Fan P, 2003, J NEUROTRAUM, V20, P437, DOI 10.1089/089771503765355513; Glantz L, 2005, EXP NEUROL, V192, P117, DOI 10.1016/j.expneurol.2004.11.012; Goldstein FC, 2001, J CLIN EXP NEUROPSYC, V23, P739, DOI 10.1076/jcen.23.6.739.1028; Hall ED, 2005, J NEUROTRAUM, V22, P252, DOI 10.1089/neu.2005.22.252; Halliwell B, 1996, ANNU REV NUTR, V16, P33, DOI 10.1146/annurev.nu.16.070196.000341; HALLIWELL B, 1987, FEBS LETT, V213, P9, DOI 10.1016/0014-5793(87)81455-2; HARMAN D, 1956, J GERONTOL, V11, P298, DOI 10.1093/geronj/11.3.298; HILLERED L, 1988, NEUROSCI LETT, V95, P286, DOI 10.1016/0304-3940(88)90672-6; HILLERED L, 1990, NEUROSCI LETT, V113, P328, DOI 10.1016/0304-3940(90)90606-A; JAVOUHEY E, 2005, IN PRESS ACCIDENT AN; Joseph JA, 2000, MECH AGEING DEV, V116, P141, DOI 10.1016/S0047-6374(00)00128-7; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; Litchfield S, 2001, ACTA NEUROPATHOL, V101, P17; Lomnitski L, 2000, EXP TOXICOL PATHOL, V52, P177; Maier CM, 2002, NEUROSCIENTIST, V8, P323, DOI 10.1177/107385840200800408; Martindale JL, 2002, J CELL PHYSIOL, V192, P1, DOI 10.1002/jcp.10119; Miele M, 2000, BRIT J PHARMACOL, V129, P582, DOI 10.1038/sj.bjp.0703066; MIELE M, 1994, NEUROSCIENCE, V62, P87, DOI 10.1016/0306-4522(94)90316-6; Miele M, 1996, J NEUROSCI METH, V70, P15, DOI 10.1016/S0165-0270(96)00094-5; Moor E, 2001, NEUROSCI LETT, V316, P169, DOI 10.1016/S0304-3940(01)02394-1; MOTCHNIK PA, 1994, METHOD ENZYMOL, V234, P115; Nyska A, 2002, TOXICOL PATHOL, V30, P620, DOI 10.1080/01926230290166724; SEVANIAN A, 1991, AM J CLIN NUTR, V54, pS1129, DOI 10.1093/ajcn/54.6.1129s; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SVENSSON L, 1993, BRAIN RES, V609, P36, DOI 10.1016/0006-8993(93)90851-D; Tayag EC, 1996, BRAIN RES, V733, P287, DOI 10.1016/0006-8993(96)00669-5; van der Loo B, 2003, BIOCHEM BIOPH RES CO, V303, P483, DOI 10.1016/S0006-291X(03)00360-7; Wei YH, 1998, P SOC EXP BIOL MED, V217, P53; Wei YH, 2002, EXP BIOL MED, V227, P671; Yusa T, 2000, NEUROSCI LETT, V293, P123, DOI 10.1016/S0304-3940(00)01501-9; Yusa T, 2001, BRAIN RES, V897, P104, DOI 10.1016/S0006-8993(01)02099-6	47	23	25	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0531-5565	1873-6815		EXP GERONTOL	Exp. Gerontol.	MAR	2006	41	3					303	311		10.1016/j.exger.2005.12.006			9	Geriatrics & Gerontology	Geriatrics & Gerontology	030RY	WOS:000236653300009	16459044				2021-06-18	
J	Caricato, A; Pennisi, M; Mancino, A; Vigna, G; Sandroni, C; Arcangeli, A; Antonelli, M				Caricato, A; Pennisi, M; Mancino, A; Vigna, G; Sandroni, C; Arcangeli, A; Antonelli, M			Levels of vancomycin in the cerebral interstitial fluid after severe head injury	INTENSIVE CARE MEDICINE			English	Article						blood-brain barrier; cerebral interstitial fluid; cerebral posttraumatic hemorrhage; microdialysis; severe head injury; vancomycin	BLOOD-BRAIN-BARRIER; CEREBROSPINAL-FLUID; MICRODIALYSIS; PHARMACOKINETICS; SAMPLES; KILL	Objective:To evaluate the concentrations of vancomycin in the cerebral interstitial fluid after intravenous administration by multiple boli. Design:Prospective non randomized study. Setting:University hospital general ICU. Patients:Four patients undergone to craniotomy for evacuation of cerebral posttraumatic hemorrhage, who developed pneumonia 4-7 days from the injury. Methods:Two microdialysis catheters were placed in each patient: one in the edematous brain surrounding the focal lesion and one in the subcutaneous tissue of abdomen. Levels of vancomycin were measured in serum and in the microdialysates samples. Results:Plasmatic concentration of 10-15 mu g/ml in the trough level was obtained after four administrations of vancomycin. Levels of vancomycin in the subcutaneous tissue was above minimum inhibitory concentrations in all patients after the second administration. Mean serum/brain ratio was 8%. Cerebral interstitial concentration of vancomycin was never above minimum inhibitory concentrations; its maximum value was 1.2 mu g/ml. Conclusions:In edematous brain close to a posttraumatic hemorrhage the levels of vancomycin do not differ from that in healthy subjects. At these plasmatic concentrations cerebral interstitial levels of vancomycin were insufficient while subcutaneous interstitial levels were effective for clinical use.	Univ Sacred Heart, Sch Med, Dept Anesthesia & Intens Care, I-00168 Rome, Italy	Caricato, A (corresponding author), Univ Sacred Heart, Sch Med, Dept Anesthesia & Intens Care, Lgo A Gemelli 1, I-00168 Rome, Italy.	anselmo.caricato@fastwebnet.it	Antonelli, Massimo/K-9915-2016; Antonelli, Massimo/F-9848-2010; Sandroni, Claudio/A-7320-2019	Antonelli, Massimo/0000-0003-3007-1670; Sandroni, Claudio/0000-0002-8878-2611; mancino, aldo/0000-0003-4556-8647; PENNISI, Mariano Alberto/0000-0001-8761-5144			Abbott NJ, 1996, MOL MED TODAY, V2, P106, DOI 10.1016/1357-4310(96)88720-X; ACKERMAN BH, 1992, ANTIMICROB AGENTS CH, V36, P1766, DOI 10.1128/AAC.36.8.1766; Albanese J, 2000, ANTIMICROB AGENTS CH, V44, P1356, DOI 10.1128/AAC.44.5.1356-1358.2000; Begg EJ, 1999, BRIT J CLIN PHARMACO, V47, P23, DOI 10.1046/j.1365-2125.1999.00850.x; Bouw R, 2001, ACTA ANAESTH SCAND, V45, P390, DOI 10.1034/j.1399-6576.2001.045003390.x; *BRIT NAT FORM, 2005, BRIT NAT FORM, V49; Davies MI, 2000, ADV DRUG DELIVER REV, V45, P169, DOI 10.1016/S0169-409X(00)00114-9; de Lange ECM, 2002, CLIN PHARMACOKINET, V41, P691, DOI 10.2165/00003088-200241100-00001; Eftekhar B, 2004, J NEUROSURG, V101, P757, DOI 10.3171/jns.2004.101.5.0757; Iwamoto T, 2003, BIOL PHARM BULL, V26, P876; Lutsar I, 1998, CLIN INFECT DIS, V27, P1117, DOI 10.1086/515003; Mackie CE, 1997, J PHARMACEUT BIOMED, V15, P917, DOI 10.1016/S0731-7085(96)01924-3; MOELLERING RC, 1981, ANN INTERN MED, V94, P343, DOI 10.7326/0003-4819-94-3-343; PEETERMANS WE, 1990, ANTIMICROB AGENTS CH, V34, P1869, DOI 10.1128/AAC.34.10.1869; Plock N, 2005, BIOMED CHROMATOGR, V19, P237, DOI 10.1002/bmc.446; Povlishock J.T, 1998, INTRO BLOOD BRAIN BA, P441; Rocha LL, 1997, J NEUROCHEM, V68, P616; STRATTON CW, 1987, ANTIMICROB AGENTS CH, V31, P1210, DOI 10.1128/AAC.31.8.1210; STRAUSBAUGH LJ, 1981, J ANTIMICROB CHEMOTH, V6, P363; Tobin CM, 2002, J ANTIMICROB CHEMOTH, V50, P713, DOI 10.1093/jac/dkf212	20	23	27	0	2	SPRINGER	NEW YORK	233 SPRING STREET, NEW YORK, NY 10013 USA	0342-4642			INTENS CARE MED	Intensive Care Med.	FEB	2006	32	2					325	328		10.1007/s00134-005-0015-3			4	Critical Care Medicine	General & Internal Medicine	011EH	WOS:000235250300024	16432677				2021-06-18	
J	Salmond, CH; Menon, DK; Chatfield, DA; Pickard, JD; Sahakian, BJ				Salmond, C. H.; Menon, D. K.; Chatfield, D. A.; Pickard, J. D.; Sahakian, B. J.			Changes over time in cognitive and structural profiles of head injury survivors	NEUROPSYCHOLOGIA			English	Article						head injury; acetylcholine; MRI; neuropsychology	TRAUMATIC BRAIN-INJURY; SUSTAINED ATTENTION; DEFICITS	Survivors of traumatic head injury often suffer chronic cognitive deficits. Considerable evidence implicates the cholinergic system in these deficits. Recently, we reported cognitive and structural abnormalities in a cohort of head injured survivors consistent with this hypothesis [see Salmond, C. H., Chatfield, D. A., Menon, D. K., Pickard, J. D., & Sahakian, B. J. (2005). Cognitive Sequelae of Head Injury: Involvement of Basal Forebrain and associated structures. Brain, 128(1), 189-200]. The stability of the cognitive and structural MRI profiles was investigated in a longitudinal study. Twenty-one survivors of moderate-severe head injury completed two comprehensive neuropsychological assessments and two structural MRI scans at least six months apart. A cohort of controls also completed these investigations. The results revealed that the cognitive and structural profiles are relatively stable from six months post-injury forward up to 3 years post-injury. Deficits in memory, attention and reaction time were found, with relative preservation of working memory, consistent with abnormalities in the cholinergic system. These findings suggest that cholinergic enhancers may be an effective treatment for cognitive deficits post-head injury in survivors up to three years post-injury. (c) 2006 Elsevier Ltd. All rights reserved.	Univ Cambridge, Addenbrookes Hosp, Wolfson Brain Imaging Ctr, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Anaesthet, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Neurosurg, Cambridge CB2 2QQ, England; Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 2QQ, England	Salmond, CH (corresponding author), Inst Psychiat, Addict Sci Bldg,4 Windsor Walk, London SE5 8AF, England.	Claire.Salmond@iop.kcl.ac.uk	Sahakian, Barbara/AAW-1198-2020	Sahakian, Barbara/0000-0001-7352-1745	Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G9439390, G0001354, G0001237, G0600986] Funding Source: Medline; Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [G0001354B] Funding Source: researchfish		Arciniegas David B, 2003, Curr Psychiatry Rep, V5, P391, DOI 10.1007/s11920-003-0074-5; BECK A, 1970, DEPRESSION CAUSES TE; Dewar D, 1996, J NEUROTRAUM, V13, P181, DOI 10.1089/neu.1996.13.181; Dikmen SS, 2003, ARCH PHYS MED REHAB, V84, P1449, DOI 10.1016/S0003-9993(03)00287-9; Dixon CE, 1997, EXP NEUROL, V146, P479, DOI 10.1006/exnr.1997.6557; Dockree PM, 2004, COGNITIVE BRAIN RES, V20, P403, DOI 10.1016/j.cogbrainres.2004.03.019; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; Girard D, 1996, BRAIN INJURY, V10, P663, DOI 10.1080/026990596124089; Good CD, 2001, NEUROIMAGE, V14, P21, DOI 10.1006/nimg.2001.0786; Hammond FM, 2004, J HEAD TRAUMA REHAB, V19, P314, DOI 10.1097/00001199-200407000-00006; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Nelson HE, 1982, NATL ADULT READING T; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Reinvang I, 2000, NEUROPSYCHOLOGIA, V38, P995, DOI 10.1016/S0028-3932(99)00153-0; Robertson IH, 1997, NEUROPSYCHOLOGIA, V35, P747, DOI 10.1016/S0028-3932(97)00015-8; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; Timmerman ME, 1999, NEUROPSYCHOLOGIA, V37, P467, DOI 10.1016/S0028-3932(98)00085-2; Zhang L, 2004, ARCH PHYS MED REHAB, V85, P1050, DOI 10.1016/j.apmr.2003.10.014	19	23	23	0	8	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932			NEUROPSYCHOLOGIA	Neuropsychologia		2006	44	10					1995	1998		10.1016/j.neuropsychologia.2006.03.013			4	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	068VS	WOS:000239403200037	16620889				2021-06-18	
J	Kochanek, PM; Hendrich, KS; Jackson, EK; Wisniewski, SR; Melick, JA; Shore, PM; Janesko, KL; Zacharia, L; Ho, C				Kochanek, PM; Hendrich, KS; Jackson, EK; Wisniewski, SR; Melick, JA; Shore, PM; Janesko, KL; Zacharia, L; Ho, C			Characterization of the effects of adenosine receptor agonists on cerebral blood flow in uninjured and traumatically injured rat brain using continuous arterial spin-labeled magnetic resonance imaging	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						A(1) receptor; A(2A) receptor; CGS 21680; 2-chloroadenosine; perfusion; traumatic brain injury	CONTROLLED CORTICAL IMPACT; POSITRON EMISSION TOMOGRAPHY; AMYGDALA-KINDLED SEIZURES; AMINO-ACID RELEASE; PROTEIN-KINASE-C; A(2A) RECEPTOR; L-ARGININE; GLUCOSE-UTILIZATION; CGS 21680; PERFUSION	Hypoperfusion after traumatic brain injury may exacerbate damage. Adenosine, a vasodilator, regulates cerebral blood flow (CBF). Treatment with adenosine receptor agonists has shown benefit in experimental CNS trauma; however, their effects on CBF after injury remain undefined. We used magnetic resonance imaging to assess CBF in uninjured rats both early and at 24 h after intrahippocampal administration of either the nonselective adenosine receptor agonist 2-chloroadenosine (2-CA, 12 nmol) or the A(2A)-receptor agonist 2-p-(2-carboxyethyl)-phenethylamino-5'-N-ethylcarbox-amidoadenosine (CGS 21680, 6 nmol). We also assessed the effects of these agents on cerebral metabolic rate for glucose (CMRglu). We then assessed the effect of 2-CA on CBF at 3.5 to 5 h after controlled cortical impact (CCI). Injection of 2-CA into uninjured rat brain produced marked increases in CBF in ipsilateral hippocampus and cortex versus vehicle (P<0.05); CBF increases persisted even at 24 h. Measurement of hippocampal levels of 2-CA showed persistent increases to 24 h. CGS 21680 produced even more marked global increases in CBF than seen with 2-CA (2-6-fold versus vehicle, P<0.05 in 10/12 regions of interest (ROIs)). Neither agonist altered CMRglu versus vehicle. After CCI, 2-CA increased CBF in ipsilateral hippocampal and hemispheric ROIs (P<0.05 versus vehicle), but the response was attenuated at severe injury levels. We report marked increases in CBF after injection of adenosine receptor agonists into uninjured rat brain despite unaltered CMRglu. 2-Chloroadenosine produced enduring increases in CBF in uninjured brain and attenuated posttraumatic hypoperfusion. Future studies of adenosine-related therapies in CNS injury should address the role of CBF.	Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; Carnegie Mellon Univ, Pittsburgh NMR Ctr Biomed Res, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA; Univ Pittsburgh, Sch Med, Sch Publ Hlth, Pittsburgh, PA USA; Carnegie Mellon Univ, Dept Biol Sci, Pittsburgh, PA 15213 USA	Kochanek, PM (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, 3434 5th Ave,Suite 201, Pittsburgh, PA 15260 USA.	Kochanekpm@ccm.upmc.edu	Ho, Chien/O-6112-2016; Kochanek, Patrick M/D-2371-2015	Ho, Chien/0000-0002-4094-9232; Kochanek, Patrick M/0000-0002-2627-913X; Zacharia, Lefteris/0000-0002-0327-2373; Wisniewski, Stephen/0000-0002-3877-9860; Jackson, Edwin/0000-0002-8101-6009	NCRR NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [RR 03631, RR 10962] Funding Source: Medline; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD 40686] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 30318, NS 38087] Funding Source: Medline; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [P41RR003631, R01RR010962] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P20NS030318, P50NS030318, R01NS038087, P01NS030318] Funding Source: NIH RePORTER		AbdulGhani AS, 1997, EUR J PHARMACOL, V326, P7, DOI 10.1016/S0014-2999(97)00139-8; Aden U, 2003, STROKE, V34, P739, DOI 10.1161/01.STR.0000060204.67672.8B; Armstead WM, 2003, BRAIN RES, V971, P153, DOI 10.1016/S0006-8993(03)02287-X; Armstead WM, 1999, AM J PHYSIOL-HEART C, V277, pH1884; Armstead WM, 1998, J NEUROTRAUM, V15, P721, DOI 10.1089/neu.1998.15.721; Bell MJ, 1998, J NEUROTRAUM, V15, P163, DOI 10.1089/neu.1998.15.163; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Chen JF, 2001, J NEUROSCI, V21, part. no., DOI 10.1523/JNEUROSCI.21-10-j0001.2001; Cheng P, 1999, J POROUS MEDIA, V2, P19, DOI 10.1615/JPorMedia.v2.i1.20; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 2003, J NEUROTRAUM, V20, P77, DOI 10.1089/08977150360517209; Coney AM, 1998, J PHYSIOL-LONDON, V509, P507, DOI 10.1111/j.1469-7793.1998.507bn.x; Cunha RA, 1996, N-S ARCH PHARMACOL, V353, P261, DOI 10.1007/BF00168627; Cunha RA, 2000, NEUROSCI LETT, V289, P127, DOI 10.1016/S0304-3940(00)01295-7; DESARRO G, 1991, EUR J PHARMACOL, V194, P145, DOI 10.1016/0014-2999(91)90098-B; DETRE JA, 1992, MAGNET RESON MED, V23, P37, DOI 10.1002/mrm.1910230106; DeWitt DS, 1997, J NEUROTRAUM, V14, P223, DOI 10.1089/neu.1997.14.223; Dixon AK, 1997, J NEUROCHEM, V69, P315; Dixon CE, 1999, J NEUROTRAUM, V16, P109, DOI 10.1089/neu.1999.16.109; DUNWIDDIE TV, 1982, J PHARMACOL EXP THER, V220, P70; EVANS MC, 1987, NEUROSCI LETT, V83, P287, DOI 10.1016/0304-3940(87)90101-7; Forbes ML, 1997, J CEREBR BLOOD F MET, V17, P865, DOI 10.1097/00004647-199708000-00005; Golding EM, 2002, PHYSIOL MEAS, V23, P615, DOI 10.1088/0967-3334/23/4/302; HEADRICK JP, 1994, J CEREBR BLOOD F MET, V14, P853, DOI 10.1038/jcbfm.1994.107; Hendrich KS, 1999, MAGN RESON MED, V42, P673, DOI 10.1002/(SICI)1522-2594(199910)42:4<673::AID-MRM8>3.0.CO;2-B; Higashi H, 2002, J NEUROSURG, V96, P117, DOI 10.3171/jns.2002.96.1.0117; HOVDA DA, 1995, J NEUROTRAUM, V12, P903, DOI 10.1089/neu.1995.12.903; HUTCHISON AJ, 1989, J PHARMACOL EXP THER, V251, P47; IBAYASHI S, 1991, J CEREBR BLOOD F MET, V11, P72, DOI 10.1038/jcbfm.1991.8; JACOBSON KA, 1997, PURINERGIC APPROACHE, P103; Joshi S, 2002, ANESTH ANALG, V94, P393, DOI 10.1097/00000539-200202000-00031; KALARIA RN, 1988, J CEREBR BLOOD F MET, V8, P32, DOI 10.1038/jcbfm.1988.5; Kelly DF, 2000, J NEUROTRAUM, V17, P261, DOI 10.1089/neu.2000.17.261; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Kochanek PM, 2001, MAGNET RESON MED, V45, P924, DOI 10.1002/mrm.1123; Kroppenstedt SN, 2002, J NEUROTRAUM, V19, P1421, DOI 10.1089/089771502320914651; MCBEAN DE, 1989, J CEREBR BLOOD F MET, V9, P548, DOI 10.1038/jcbfm.1989.78; NEHLIG A, 1994, EUR J PHARMACOL, V258, P57, DOI 10.1016/0014-2999(94)90057-4; Ngai AC, 2001, AM J PHYSIOL-HEART C, V280, pH2329; OREGAN MH, 1992, NEUROSCI LETT, V138, P169, DOI 10.1016/0304-3940(92)90498-V; Pedata F, 2001, ANN NY ACAD SCI, V939, P74; Popoli P, 2002, J NEUROSCI, V22, P1967, DOI 10.1523/JNEUROSCI.22-05-01967.2002; Pourgholami MH, 1997, BRAIN RES, V775, P37, DOI 10.1016/S0006-8993(97)00769-5; Shin HK, 2000, AM J PHYSIOL-HEART C, V278, pH339; SIMPSON RE, 1992, J NEUROCHEM, V58, P1683, DOI 10.1111/j.1471-4159.1992.tb10041.x; SOKOLOFF L, 1977, J NEUROCHEM, V28, P897, DOI 10.1111/j.1471-4159.1977.tb10649.x; SOLLEVI A, 1987, J CEREBR BLOOD F MET, V7, P673, DOI 10.1038/jcbfm.1987.121; SORICELLI A, 1995, STROKE, V26, P1572, DOI 10.1161/01.STR.26.9.1572; Stange K, 1997, ACTA PHYSIOL SCAND, V160, P117, DOI 10.1046/j.1365-201X.1997.00113.x; Statler KD, 2000, J NEUROTRAUM, V17, P1179, DOI 10.1089/neu.2000.17.1179; STRUPP JP, 1996, NEUROIMAGE, V3, P607; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; TSENG CJ, 1988, HYPERTENSION, V11, P191, DOI 10.1161/01.HYP.11.2.191; VANWYLEN DGL, 1989, J CEREBR BLOOD F MET, V9, P556, DOI 10.1038/jcbfm.1989.79; Varma MR, 2002, BRAIN RES, V951, P191, DOI 10.1016/S0006-8993(02)03161-X; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; WILLIAMS DS, 1992, P NATL ACAD SCI USA, V89, P212, DOI 10.1073/pnas.89.1.212; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; YU L, 2004, NAT MED, V10, P1; ZHANG WG, 1995, MAGNET RESON MED, V33, P370, DOI 10.1002/mrm.1910330310; ZHANG WG, 1993, MAGNET RESON MED, V29, P416, DOI 10.1002/mrm.1910290323	64	23	24	0	4	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2005	25	12					1596	1612		10.1038/sj.jcbfm.9600154			17	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	020UZ	WOS:000235939600004	15931163	Bronze			2021-06-18	
J	Lyons, JM; Pearl, JM; McLean, KM; Akhter, SA; Wagner, CJ; Pandalai, PK; Duffy, JY				Lyons, JM; Pearl, JM; McLean, KM; Akhter, SA; Wagner, CJ; Pandalai, PK; Duffy, JY			Glucocorticoid administration reduces cardiac dysfunction after brain death in pigs	JOURNAL OF HEART AND LUNG TRANSPLANTATION			English	Article							CARDIOPULMONARY BYPASS; PHYSIOLOGICAL-CHANGES; DONOR; HEARTS; TRANSPLANTATION; HEMODYNAMICS; PRESERVATION; ACTIVATION; CHILDREN; SURGERY	Background: Traumatic brain injury and subsequent brain death (BD) account for nearly half of all organ donors, yet only 33% of available hearts are transplanted. Alterations in multiple physiologic pathways after BD can lead to cardiac dysfunction and exclusion from transplantation. Triple hormone resuscitation with methylprednisolone, thyroid hormone and vasopressin has had inconsistent results in the effort to reduce cardiac dysfunction associated with BD, but individual analysis of these agents is limited. The hypothesis was that glucocorticoid administration alone could reduce BD-associated cardiac dysfunction. Methods: Crossbred pigs (25 to 35 kg) had BD induced by sub-dural balloon inflation. Hemodynamics were measured for 360 minutes after BD. Negative cerebral perfusion pressures and decreased laser Doppler cerebral blood flow confirmed BD. Animals (n = 5/treatment group) received: saline (Group 1); 30 mg/kg methylprednisolone 2 hours before BD (Group 2); or 30 mg/kg methylprednisolone 1 hour after BD (Group 3). Repeated measures analysis of variance and unpaired t-tests were used for appropriate comparisons. Results: Left ventricular (LV) pre-load recruitable stroke work (PRSW) decreased in untreated Group I over time (p < 0.001), whereas PRSW in animals treated with glucocorticoids, Groups 2 and 3, was not different from baseline at 360 minutes after BD. Diastolic function measured as LV -dP/dt (minimum derivative of the change in pressure over time) and tau (time constant of isovolumic relaxation) was also preserved 360 minutes after brain death by glucocorticoids in Groups 2 and 3 (p > 0.05). Oxygen delivery 360 minutes after BD was higher in Group 2 compared with Group 1 (p = 0.02) and Group 3 (p = 0.006). Conclusions: Glucocorticoid therapy before or after BD preserved IV systolic and diastolic function. Glucocorticoids administered after brain death might increase the number of hearts available for transplant by reducing brain death-associated cardiac dysfunction.	Cincinnati Childrens Hosp, Ctr Med, Div Cardiothorac Surg, Cincinnati, OH 45229 USA; Univ Cincinnati, Coll Med, Dept Surg, Cincinnati, OH 45267 USA; Univ Cincinnati, Coll Med, Dept Pediat, Cincinnati, OH 45267 USA	Duffy, JY (corresponding author), Cincinnati Childrens Hosp, Ctr Med, Div Cardiothorac Surg, 3333 Burnet Ave,ML2004, Cincinnati, OH 45229 USA.	jodie.duff@cchmc.org		Pandalai, Prakash/0000-0002-2729-0058			Akhter SA, 1997, P NATL ACAD SCI USA, V94, P12100, DOI 10.1073/pnas.94.22.12100; Bittner HB, 1996, J HEART LUNG TRANSPL, V15, P764; Duffy Jodie Y, 2004, Pediatr Crit Care Med, V5, P28, DOI 10.1097/01.PCC.0000102382.92024.04; Duval ELIM, 1999, EUR J PEDIATR, V158, P387, DOI 10.1007/s004310051098; Follette DM, 1998, J HEART LUNG TRANSPL, V17, P423; Herijgers P, 1996, TRANSPLANTATION, V62, P330, DOI 10.1097/00007890-199608150-00005; MERTES PM, 1994, TRANSPLANTATION, V58, P414, DOI 10.1097/00007890-199408270-00004; Nishimura H, 1997, HEART VESSELS, V12, P84, DOI 10.1007/BF02820871; NOVITZKY D, 1988, TRANSPLANTATION, V45, P964, DOI 10.1097/00007890-198805000-00025; Pearl JM, 2004, ANN THORAC SURG, V77, P994, DOI 10.1016/j.athoracsur.2003.09.067; Pearl JM, 2002, ANN THORAC SURG, V74, P830, DOI 10.1016/S0003-4975(02)03843-2; Pratschke J, 2001, ANN SURG, V234, P732, DOI 10.1097/00000658-200112000-00004; Rosendale JD, 2003, TRANSPLANTATION, V75, P1336, DOI 10.1097/01.TP.0000062839.58826.6D; Rosengard BR, 2002, AM J TRANSPLANT, V2, P701, DOI 10.1034/j.1600-6143.2002.20804.x; Ryan JB, 2003, J HEART LUNG TRANSPL, V22, P922, DOI 10.1016/S1053-2498(02)00558-2; Smith M, 2004, J HEART LUNG TRANSPL, V23, pS217, DOI 10.1016/j.healun.2004.06.017; Szabo G, 1998, J HEART LUNG TRANSPL, V17, P921; Szabo G, 2004, J HEART LUNG TRANSPL, V23, pS223, DOI 10.1016/j.healun.2004.04.005; Szabo G, 1999, WORLD J SURG, V23, P36, DOI 10.1007/s002689900562; Tarnok A, 1999, PEDIATR CARDIOL, V20, P113, DOI 10.1007/s002469900417; Wilhelm MJ, 2000, CIRCULATION, V102, P2426, DOI 10.1161/01.CIR.102.19.2426; Zaroff Jonathan G., 2002, Circulation, V106, P836, DOI 10.1161/01.CIR.0000025587.40373.75	22	23	23	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1053-2498	1557-3117		J HEART LUNG TRANSPL	J. Heart Lung Transplant.	DEC	2005	24	12					2249	2254		10.1016/j.healun.2005.07.010			6	Cardiac & Cardiovascular Systems; Respiratory System; Surgery; Transplantation	Cardiovascular System & Cardiology; Respiratory System; Surgery; Transplantation	998HH	WOS:000234308700037	16364878				2021-06-18	
J	Zagorac, D; Yamaura, K; Zhang, C; Roman, RJ; Harder, DR				Zagorac, D; Yamaura, K; Zhang, C; Roman, RJ; Harder, DR			The effect of superoxide anion on autoregulation of cerebral blood flow	STROKE			English	Article						free radicals; cerebral blood flow	CA2+-ACTIVATED K+ CHANNELS; NITRIC-OXIDE; BRAIN-INJURY; IMPAIRED AUTOREGULATION; POTASSIUM CHANNELS; EXPERIMENTAL-MODEL; HYDROGEN-PEROXIDE; HYPERTENSION; ENDOTHELIUM; MECHANISMS	Background and Purpose - Recent studies have suggested that autoregulation of cerebral blood flow (CBF) is impaired after traumatic and ischemic brain injury. Given that the levels of superoxide anion (O-2(.-)) are increased in these conditions, we postulate that O-2(.-) contributes to the impairment of CBF autoregulation. Methods - CBF was monitored with laser Doppler flowmetry during increases in blood pressure. Results - During the control period, CBF was well autoregulated after the increase in mean arterial pressure (MAP) from 98 +/- 3 to 140 +/- 6 mm Hg. The autoregulation index (AI;Delta CBF/Delta MAP) averaged 0.25 +/- 0.02 (n = 6). O-2(.-) in the brain was then increased by subdural perfusion of xanthine/xanthine oxidase (different concentrations) and catalase. Low concentrations of O-2(.-) decreased basal CBF by 10 +/- 1.6% but had no effect on autoregulation (AI, 0.19 +/- 0.02; n = 6). Higher concentrations of O-2(.-) (0.2 mmol/L xanthine and either 3 or 20 mU xanthine oxidase) increased basal CBF by 30 +/- 2% and 42 +/- 4%, respectively, and impaired autoregulation of CBF (AI, 0.55 +/- 0.03 and 0.76 +/- 0.02; n = 6). Inclusion of superoxide dismutase in the O-2(.-)-generating system restored autoregulation (AI, 0.28 +/- 0.05; n = 6). Neither inhibition of NO synthase nor the addition of deferioxamine had any effect on the ability of higher concentrations of O-2(.-) to impair autoregulation of CBF (AI, 0.65 +/- 0.07 and 0.72 +/- 0.05 respectively; n = 6). O-2(.-) also increased the activity of K-Ca channels in cerebral vascular smooth muscle cells (VSMCs; n = 8). Conclusion - These results suggest that O-2(.-) increases basal CBF and impairs autoregulation of CBF, likely through the activation of KCa channels in cerebral VSMCs.	Med Coll Wisconsin, Dept Physiol, Milwaukee, WI 53226 USA; Med Coll Wisconsin, Cardiovasc Res Ctr, Milwaukee, WI 53226 USA; Clement Zablocki VA Med Ctr, Milwaukee, WI USA	Harder, DR (corresponding author), Med Coll Wisconsin, Dept Physiol, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.	dharder@mcw.edu			NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [P01HL059996, P01HL068769, R37HL033833, R01HL033833] Funding Source: NIH RePORTER; NHLBI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [5PO1 HL068769-04, HL33833-21, 2PO1 HL059996-06A1] Funding Source: Medline		Benov L, 1998, FREE RADICAL BIO MED, V25, P826, DOI 10.1016/S0891-5849(98)00163-4; DiChiara TJ, 1997, J NEUROSCI, V17, P4942; Engelborghs K, 2000, J NEUROTRAUM, V17, P667, DOI 10.1089/089771500415418; Faraci FM, 1998, PHYSIOL REV, V78, P53; Gebremedhin D, 2000, CIRC RES, V87, P60, DOI 10.1161/01.RES.87.1.60; GRYGLEWSKI RJ, 1986, NATURE, V320, P454, DOI 10.1038/320454a0; HARDER DR, 1985, ANN BIOMED ENG, V13, P335, DOI 10.1007/BF02584252; HARDER DR, 1994, AM J PHYSIOL, V266, pH2098; Hoagland KM, 2003, HYPERTENSION, V41, P697, DOI 10.1161/01.HYP.0000047881.15426.DC; Hodges GR, 2000, FREE RADICAL BIO MED, V29, P434, DOI 10.1016/S0891-5849(00)00298-7; Hong KW, 2001, AM J PHYSIOL-HEART C, V281, pH308; Iida Y, 2000, STROKE, V31, P2224, DOI 10.1161/01.STR.31.9.2224; Irikura K, 1996, STROKE, V27, P1399, DOI 10.1161/01.STR.27.8.1399; Kourie JI, 1998, AM J PHYSIOL-CELL PH, V275, pC1; Milhorat T H, 1989, Neurol Res, V11, P29; Paterno R, 2000, AM J PHYSIOL-HEART C, V278, pH2003; PAULSON OB, 1990, CEREBROVAS BRAIN MET, V2, P161; Prat R, 1998, ACT NEUR S, V71, P123; Rey FE, 2002, CIRCULATION, V106, P2497, DOI 10.1161/01.CIR.0000038108.71560.70; Szentivanyi M, 2000, HYPERTENSION, V35, P418, DOI 10.1161/01.HYP.35.1.418; Tarpey MM, 2001, CIRC RES, V89, P224, DOI 10.1161/hh1501.094365; Tschudi MR, 1996, HYPERTENSION, V27, P32, DOI 10.1161/01.HYP.27.1.32; Wang ZW, 1997, J GEN PHYSIOL, V110, P35, DOI 10.1085/jgp.110.1.35; Wei EP, 1996, AM J PHYSIOL-HEART C, V271, pH1262; WEI EP, 1985, AM J PHYSIOL, V248, P157; Wolin MS, 2000, ARTERIOSCL THROM VAS, V20, P1430, DOI 10.1161/01.ATV.20.6.1430	26	23	23	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	DEC	2005	36	12					2589	2594		10.1161/01.STR.0000189997.84161.95			6	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	986LZ	WOS:000233452400024	16293785	Green Published, Bronze			2021-06-18	
J	Crisp, R				Crisp, R			Key factors related to vocational outcome: Trends for six disability groups	JOURNAL OF REHABILITATION			English	Article							SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; PSYCHOSOCIAL RISK-FACTORS; SEVERE MENTAL-ILLNESS; LOW-BACK-PAIN; COMMUNITY INTEGRATION; MYOCARDIAL-INFARCTION; EMPLOYMENT STATUS; FOLLOW-UP; ACUTE PREDICTORS	This paper reviewed empirical studies published since 1987 and identified variables related to employment outcomes for six disability groups. These groups included persons with spinal cord injuries, traumatic brain injuries, amputations, chronic pain, myocardial infarction / coronary artery bypass grafting, and severe mental illness. The five key factors that were most consistently related to vocational outcome were: severity of disability, socio-demographic factors, psychosocial factors, psychological factors, and enduring employment status. While severity of disability continues to be an important factor, there was less of a medical than psychosocial flavor evident. The key predictors of vocational outcome were socio-demographic (i.e., age, education, race/ethnicity, litigation/financial compensation), psychosocial (e.g, coping strategies, social support) and psychological factors (in particular, depressive symptoms). Socio-demographic factors that identified clients at high risk of long-term employment, and related access and equity were issues frequently reported. Enduring employment status had recently emerged as an area of interest to researchers. Implications for vocational rehabilitation service providers were discussed.	CRS Australia, Croydon, Vic 3136, Australia	Crisp, R (corresponding author), CRS Australia, POB 1172, Croydon, Vic 3136, Australia.	ross.crisp@crsrehab.gov.au					American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Blyth FM, 2003, PAIN, V103, P41, DOI 10.1016/S0304-3959(02)00380-9; Bond GR, 2001, J CONSULT CLIN PSYCH, V69, P489, DOI 10.1037//0022-006X.69.3.489; Boudrez H, 2000, ACTA CARDIOL, V55, P341, DOI 10.2143/AC.55.6.2005765; Brooks N, 1987, Brain Inj, V1, P5, DOI 10.3109/02699058709034439; Cattelani R, 2002, BRAIN INJURY, V16, P51, DOI 10.1080/02699050110088821; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Cook J. A., 2003, J VOCATIONAL REHABIL, V18, P25; COPE DN, 1995, BRAIN INJURY, V9, P649, DOI 10.3109/02699059509008224; CRISP R, 1992, J REHABIL, V58, P27; CRISP R, 1990, J REHABIL, V56, P28; Crook J, 2002, J OCCUP REHABIL, V12, P277, DOI 10.1023/A:1020278708861; Crowther RE, 2001, BMJ-BRIT MED J, V322, P204, DOI 10.1136/bmj.322.7280.204; Curran CA, 2000, J HEAD TRAUMA REHAB, V15, P1256, DOI 10.1097/00001199-200012000-00006; DEVIVO MJ, 1987, ARCH PHYS MED REHAB, V68, P494; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; Dunn DS, 1996, REHABIL PSYCHOL, V41, P285, DOI 10.1037/0090-5550.41.4.285; Elinson L, 2004, PSYCHIAT SERV, V55, P29, DOI 10.1176/appi.ps.55.1.29; Elliott TR, 1996, ARCH PHYS MED REHAB, V77, P816, DOI 10.1016/S0003-9993(96)90263-4; Ericsson M, 2002, DISABIL REHABIL, V24, P334, DOI 10.1080/09638280110096241; Felmingham KL, 2001, ARCH PHYS MED REHAB, V82, P435, DOI 10.1053/apmr.2001.21985; Fisher K, 2003, INT J REHABIL RES, V26, P51, DOI 10.1097/00004356-200303000-00007; Fleming J, 1999, BRAIN INJURY, V13, P417; FRANK RG, 1987, J CONSULT CLIN PSYCH, V55, P727; Gatchel RJ, 1995, SPINE, V20, P2702, DOI 10.1097/00007632-199512150-00011; Glenn MB, 2001, BRAIN INJURY, V15, P811, DOI 10.1080/02699050010025777; Haldorsen EMH, 1998, SPINE, V23, P1202, DOI 10.1097/00007632-199806010-00004; Hammen C, 2000, J CONSULT CLIN PSYCH, V68, P220, DOI 10.1037/0022-006X.68.2.220; Hansson L, 1993, Qual Assur Health Care, V5, P41; Hess DW, 2000, ARCH PHYS MED REHAB, V81, P359, DOI 10.1016/S0003-9993(00)90084-4; Ide M, 2002, ARCH PHYS MED REHAB, V83, P1394, DOI 10.1053/apmr.2002.35095; JENSEN MP, 1991, J CONSULT CLIN PSYCH, V69, P655; Johnstone B, 2003, BRAIN INJURY, V17, P95, DOI 10.1080/0269905021000010212; Kemp B, 1999, REHABIL PSYCHOL, V44, P235, DOI 10.1037/0090-5550.44.3.235; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Krause JS, 1998, REHABIL PSYCHOL, V43, P41, DOI 10.1037/0090-5550.43.1.41; Krause JS, 1996, REHABIL COUNS BULL, V39, P244; Krause JS, 1998, ARCH PHYS MED REHAB, V79, P615, DOI 10.1016/S0003-9993(98)90033-8; Krause JS, 1996, ARCH PHYS MED REHAB, V77, P737; Krause JS, 1997, ARCH PHYS MED REHAB, V78, P651, DOI 10.1016/S0003-9993(97)90432-9; Krause JS, 2003, ARCH PHYS MED REHAB, V84, P1282, DOI 10.1016/S0003-9993(03)00265-X; Krause JS, 1999, REHABIL PSYCHOL, V44, P354, DOI 10.1037/0090-5550.44.4.354; Krause JS, 1997, REHABIL PSYCHOL, V42, P31, DOI 10.1037/0090-5550.42.1.31; Krause JS, 2000, ARCH PHYS MED REHAB, V81, P1099, DOI 10.1053/apmr.2000.7167; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Kreutzer JS, 2001, BRAIN INJURY, V15, P563, DOI 10.1080/02699050010009108; LIVINGSTON DH, 1994, J TRAUMA, V37, P495, DOI 10.1097/00005373-199409000-00027; MACDONALD MR, 1987, ARCH PHYS MED REHAB, V68, P339; MAELAND JG, 1987, J PSYCHOSOM RES, V31, P471, DOI 10.1016/0022-3999(87)90005-5; MCMORDIE W R, 1990, Brain Injury, V4, P57, DOI 10.3109/02699059009026149; MCSHANE SL, 1993, REHABIL PSYCHOL, V38, P27, DOI 10.1037/0090-5550.38.1.27; MILHOUS RL, 1989, ARCH PHYS MED REHAB, V70, P589; Mittag O, 2001, SOC SCI MED, V52, P1441, DOI 10.1016/S0277-9536(00)00250-1; MOORE A D, 1992, Brain Injury, V6, P89, DOI 10.3109/02699059209008129; MOWBRAY CT, 1995, PSYCHIATR REHABIL J, V19, P17, DOI 10.1037/h0095444; Mueser KT, 1997, J NERV MENT DIS, V185, P419, DOI 10.1097/00005053-199707000-00001; Mullins J, 1997, J REHABIL, V63, P21; Myrtek M, 1997, INT J CARDIOL, V59, P291, DOI 10.1016/S0167-5273(97)02925-2; O'Connell MJ, 2000, REHABIL PSYCHOL, V45, P212, DOI 10.1037/0090-5550.45.2.212; Ormel J, 2000, ARCH GEN PSYCHIAT, V57, P381, DOI 10.1001/archpsyc.57.4.381; Petrie KJ, 1996, BRIT MED J, V312, P1191; Pezzin LE, 2000, ARCH PHYS MED REHAB, V81, P292, DOI 10.1053/apmr.2000.0810292; PONSFORD JL, 1995, BRAIN INJURY, V9, P11, DOI 10.3109/02699059509004566; Putzke JD, 2002, ARCH PHYS MED REHAB, V83, P1603, DOI 10.1053/apmr.2002.35115; Rainville J, 1997, SPINE, V22, P2016, DOI 10.1097/00007632-199709010-00016; RAO N, 1990, Brain Injury, V4, P49, DOI 10.3109/02699059009026148; RINTALA DH, 1994, REHABIL PSYCHOL, V39, P15, DOI 10.1037/h0080311; Roessler RT, 2002, REHABIL COUNS BULL, V45, P207, DOI 10.1177/00343552020450040301; Rohe DE, 1998, J VOCAT BEHAV, V52, P45, DOI 10.1006/jvbe.1996.1560; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; ROST K, 1992, ARCH INTERN MED, V152, P381, DOI 10.1001/archinte.152.2.381; RUFF RM, 1993, BRAIN INJURY, V7, P101, DOI 10.3109/02699059309008164; Russinova Z, 2002, INT REV PSYCHIATR, V14, P303, DOI 10.1080/0954026021000016941; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; Sander AM, 1996, J HEAD TRAUMA REHAB, V11, P70, DOI 10.1097/00001199-199610000-00007; SCHLEIFER SJ, 1989, ARCH INTERN MED, V149, P1785, DOI 10.1001/archinte.149.8.1785; Schoppen T, 2001, ARCH PHYS MED REHAB, V82, P239, DOI 10.1053/apmr.2001.18231; Schultz IZ, 2002, SPINE, V27, P2720, DOI 10.1097/00007632-200212010-00012; SHANKAR J, 2003, AUSTR E J ADV MENTAL, V2; SHERBOURNE CD, 1995, J CONSULT CLIN PSYCH, V63, P345, DOI 10.1037/0022-006X.63.3.345; Sherer M, 2002, CLIN NEUROPSYCHOL, V16, P157, DOI 10.1076/clin.16.2.157.13238; Sherer M, 2002, ARCH PHYS MED REHAB, V83, P183, DOI 10.1053/apmr.2002.28802; Soderman E, 2003, SOC SCI MED, V56, P193, DOI 10.1016/S0277-9536(02)00024-2; Suter PB, 2002, PAIN, V100, P249, DOI 10.1016/S0304-3959(02)00238-5; Trieschmann R.B., 1988, SPINAL CORD INJURIES, V2nd edition; Tsang H, 2000, J REHABIL, V66, P19; Vahle VJ, 2000, ARCH PHYS MED REHAB, V81, pS53, DOI 10.1053/apmr.2000.20625; Ville I, 1996, INT J REHABIL RES, V19, P241, DOI 10.1097/00004356-199609000-00005; Waghorn G, 2002, J REHABIL, V68, P40; Waghorn G., 1999, J VOCATIONAL REHABIL, V13, P153; WEED R, 1997, J REHABILITATION OUT, V1, P35; Whyte AS, 2002, DISABIL REHABIL, V24, P462, DOI 10.1080/09638280110105213; YOUNG ME, 1994, REHABIL COUNS BULL, V37, P229	93	23	23	0	14	NATL REHABILITATION ASSOC-NRA	ALEXANDRIA	633 S WASHINGTON ST, ALEXANDRIA, VA 22314-4109 USA	0022-4154			J REHABIL	J. Rehabil.	OCT-DEC	2005	71	4					30	37					8	Rehabilitation	Rehabilitation	990ZM	WOS:000233781900005					2021-06-18	
J	Nagel, BJ; Barlett, VC; Schweinsburg, AD; Tapert, SF				Nagel, BJ; Barlett, VC; Schweinsburg, AD; Tapert, SF			Neuropsychological predictors of BOLD response during a spatial working memory task in adolescents: What can performance tell us about fMRI response patterns?	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article; Proceedings Paper	31st Annual Meeting of the International-Neuropsychological-Society	FEB 05-08, 2003	HONOLULU, HI	Int Neuropsychol Soc			DEFICIT HYPERACTIVITY DISORDER; TRAUMATIC BRAIN-INJURY; FUNCTIONAL MRI; ALCOHOL DEPENDENCE; EXECUTIVE FUNCTION; SUBSTANCE-ABUSE; FAMILY-HISTORY; NEURAL BASIS; TERM-MEMORY; DATA SETS	The relationship between standardized neuropsychological test performance and functional magnetic resonance imaging (fMRI) response during cognitive tasks is largely unknown. This exploratory investigation examined the relationship between neuropsychological test performance and fMRI response to a spatial working memory (SWM) task among 49 typically developing adolescents. Participants were administered a variety of neuropsychological tests in the domains of working memory, visuospatial skills, executive functioning, attention, learning and memory, visuomotor skills and processing speed, and language functioning. Neuropsychological domain scores were used to predict fMRI response during a SWM task. Results suggest that in many brain regions, neuropsychological performance negatively predicts fMRI response, suggesting that those teens with better neuropsychological abilities required fewer neural resources to adequately perform the task. This study provides further understanding of how neuropsychological abilities relate to neural activity during fMRI tasks, and provides an important link between neuropsychological and fMRI research.	VA San Diego Healthcare Syst, La Jolla, CA 92161 USA; Vet Med Res Fdn, San Diego, CA USA; Univ Calif San Diego, Sch Arts & Sci, Dept Psychol, San Diego, CA 92103 USA; Univ Calif San Diego, Dept Psychiat, Sch Med, San Diego, CA 92103 USA	Tapert, SF (corresponding author), VA San Diego Healthcare Syst, 151B,3350 La Jolla Village Dr, La Jolla, CA 92161 USA.	stapert@ucsd.edu	Tapert, Susan/AAE-8208-2020; Dager, Alecia D/V-5798-2017		NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA013419, R21AA012519] Funding Source: NIH RePORTER; NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01 AA013419, R01 AA13419, R01 AA013419-01, R21 AA12519] Funding Source: Medline		Adams JW, 1997, J EXP CHILD PSYCHOL, V67, P21, DOI 10.1006/jecp.1997.2397; Akshoomoff NA, 1997, INT REV NEUROBIOL, V41, P575, DOI 10.1016/S0074-7742(08)60371-2; Alloway TP., 1997, DEV MEMORY CHILDHOOD, P163; Baddeley A. D., 1986, WORKING MEMORY; BANDETTINI PA, 1993, MAGNET RESON MED, V30, P161, DOI 10.1002/mrm.1910300204; Botvinick MM, 2001, PSYCHOL REV, V108, P624, DOI 10.1037//0033-295X.108.3.624; Braver TS, 1997, NEUROIMAGE, V5, P49, DOI 10.1006/nimg.1996.0247; BROWN SA, 1989, ADDICT BEHAV, V14, P291, DOI 10.1016/0306-4603(89)90060-9; Brown SA, 1998, J STUD ALCOHOL, V59, P427, DOI 10.15288/jsa.1998.59.427; Cabeza R, 2000, J COGNITIVE NEUROSCI, V12, P1, DOI 10.1162/08989290051137585; Callicott JH, 1999, CEREB CORTEX, V9, P20, DOI 10.1093/cercor/9.1.20; Cox RW, 1999, MAGNET RESON MED, V42, P1014, DOI 10.1002/(SICI)1522-2594(199912)42:6<1014::AID-MRM4>3.0.CO;2-F; Cox RW, 1996, COMPUT BIOMED RES, V29, P162, DOI 10.1006/cbmr.1996.0014; Daneman M, 1996, PSYCHON B REV, V3, P422, DOI 10.3758/BF03214546; de Jong PF, 1998, J EXP CHILD PSYCHOL, V70, P75, DOI 10.1006/jecp.1998.2451; Delis D, 1994, MANUAL CALIFORNIA VE; Delis DC., 2001, MANUAL DELIS KAPLAN; FORMAN SD, 1995, MAGNET RESON MED, V33, P636, DOI 10.1002/mrm.1910330508; Friston KJ, 1996, MAGNET RESON MED, V35, P346, DOI 10.1002/mrm.1910350312; Gathercole SE, 1999, TRENDS COGN SCI, V3, P410, DOI 10.1016/S1364-6613(99)01388-1; Gathercole SE, 2004, APPL COGNITIVE PSYCH, V18, P1, DOI 10.1002/acp.934; Glabus MF, 2003, CEREB CORTEX, V13, P1352, DOI 10.1093/cercor/bhg082; Golden C., 1978, STROOP COLOR WORD TE; Horwitz B, 2000, NEUROIMAGE, V12, P434, DOI 10.1006/nimg.2000.0632; Johnson SC, 2001, J INT NEUROPSYCH SOC, V7, P55, DOI 10.1017/S135561770171106X; Kalechstein AD, 1998, CLIN NEUROPSYCHOL, V12, P339, DOI 10.1076/clin.12.3.339.1991; Kindermann SS, 2004, SCHIZOPHR RES, V68, P203, DOI 10.1016/j.schres.2003.08.010; Klingberg T, 2002, J COGNITIVE NEUROSCI, V14, P1, DOI 10.1162/089892902317205276; Kondo H, 2004, NEUROIMAGE, V21, P2, DOI 10.1016/j.neuroimage.2003.09.046; Kwon H, 2002, P NATL ACAD SCI USA, V99, P13336, DOI 10.1073/pnas.162486399; LEATHER CV, 1994, J EXP CHILD PSYCHOL, V58, P88, DOI 10.1006/jecp.1994.1027; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lewis SJG, 2004, EUR J NEUROSCI, V19, P755, DOI 10.1111/j.1460-9568.2004.03108.x; LOGIE RH, 1994, MEM COGNITION, V22, P395, DOI 10.3758/BF03200866; Luciana M, 1998, NEUROPSYCHOLOGIA, V36, P273, DOI 10.1016/S0028-3932(97)00109-7; McAllister TW, 1999, NEUROLOGY, V53, P1300, DOI 10.1212/WNL.53.6.1300; MCCARTHY G, 1994, P NATL ACAD SCI USA, V91, P8690, DOI 10.1073/pnas.91.18.8690; McInnes A, 2003, J ABNORM CHILD PSYCH, V31, P427, DOI 10.1023/A:1023895602957; MEYER CH, 1992, MAGNET RESON MED, V28, P202, DOI 10.1002/mrm.1910280204; MEYER CH, 1987, P 6 ANN M SOC MAGN R; Nelson CA, 2000, DEV PSYCHOL, V36, P109, DOI 10.1037/0012-1649.36.1.109; Niendam TA, 2003, AM J PSYCHIAT, V160, P2060, DOI 10.1176/appi.ajp.160.11.2060; NOLL DC, 1992, MAGNET RESON MED, V25, P319, DOI 10.1002/mrm.1910250210; NOLL DC, 1995, JMRI-J MAGN RESON IM, V5, P49, DOI 10.1002/jmri.1880050112; Osaka N, 2004, NEUROIMAGE, V21, P623, DOI 10.1016/j.neuroimage.2003.09.069; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; Pickering S. J., 2003, ED CHILD PSYCHOL, V20, P109, DOI DOI 10.1037/A0036633; Ranganath C, 2003, NEUROPSYCHOLOGIA, V41, P378, DOI 10.1016/S0028-3932(02)00169-0; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; RICE JP, 1995, ALCOHOL CLIN EXP RES, V19, P1018, DOI 10.1111/j.1530-0277.1995.tb00983.x; Rypma B, 2002, J COGNITIVE NEUROSCI, V14, P721, DOI 10.1162/08989290260138627; Shaffer D, 2000, J AM ACAD CHILD PSY, V39, P28, DOI 10.1097/00004583-200001000-00014; Shallice T, 2002, DEV NEUROPSYCHOL, V21, P43, DOI 10.1207/S15326942DN2101_3; Speck O, 2000, NEUROREPORT, V11, P2581, DOI 10.1097/00001756-200008030-00046; Swanson HL, 2003, J EXP CHILD PSYCHOL, V85, P1, DOI 10.1016/S0022-0965(03)00043-2; Talairach J., 1988, COPLANAR STEREOTAXIC; Tapert S. F., 2001, Alcoholism Clinical and Experimental Research, V25, p80A; Tapert SF, 2000, ADDICTION, V95, P1043, DOI 10.1046/j.1360-0443.2000.95710436.x; Tapert SF, 1999, J INT NEUROPSYCH SOC, V5, P481, DOI 10.1017/S1355617799566010; Tapert SF, 2002, J INT NEUROPSYCH SOC, V8, P873, DOI 10.1017/S1355617702870011; Thomas KM, 1999, NEUROIMAGE, V10, P327, DOI 10.1006/nimg.1999.0466; Thompson AP, 1998, PSYCHOL REP, V82, P1339, DOI 10.2466/PR0.82.3.1339-1346; WARD BD, 1997, SIMULTANEOUS INFEREN; Wechsler D., 1997, MANUAL WECHSLER ADUL; Wechsler D., 2011, WECHLSER ABBREVIATED; Wechsler D., 1981, WAIS R MANUAL WECHSL; WECHSLER D, 1993, MANUAL WECHSLER INTE; Wilkinson G. S., 1993, WIDE RANGE ACHIEVEME; WONG EC, 2000, P INT SOC MAGN RESON, V8, P683	69	23	24	0	7	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1380-3395	1744-411X		J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	OCT	2005	27	7					823	839		10.1080/13803390490919038			17	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	970GN	WOS:000232293400004	16183616	Green Accepted			2021-06-18	
J	Salorio, CF; Slomine, BS; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP				Salorio, CF; Slomine, BS; Grados, MA; Vasa, RA; Christensen, JR; Gerring, JP			Neuroanatomic correlates of CVLT-C performance following pediatric traumatic brain injury	JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY			English	Article						TBI (traumatic brain injury); memory; children; magnetic resonance imaging; diffuse brain injury; neuropsychological test	CLOSED-HEAD-INJURY; VERBAL-LEARNING TEST; CHILDRENS VERSION; MEMORY FUNCTION; AXONAL DAMAGE; 1ST YEAR; ADOLESCENTS; SEVERITY; MRI; RECOVERY	Traumatic brain injury (TBI) frequently results in memory problems, and the degree of memory impairment is related to injury severity and is commonly associated with lesions in frontal and temporal brain areas. This study examined the relationship among injury severity, brain lesions, and memory in children with moderate to severe TBI using Donders' (1999) 5-factor model of performance on the California Verbal Learning Test-Children's Version (CVLT-C). Seventy-six children underwent magnetic resonance imaging (MRI) scans 3 months post-TBI and testing 1 year post-TBI. Results showed injury severity (Glasgow Coma Scale) was not predictive of performance on 4 of the 5 factors. Volume of frontal and/or temporal brain lesions was significantly predictive of performance on 3 of the 5 factors. Unexpectedly, lesion volume outside these areas (extra-frontotemporal) was predictive of performance on all 5 factors. In contrast, Verbal IQ at 1 year was most strongly associated with preinjury factors (socioeconomic status and special education involvement), although extra-frontotemporal lesions also contributed to the variability in this measure. Results suggest that in children with moderate to severe TBI, extra-frontal/temporal lesions are predictive of memory outcome 1 year postinjury above and beyond initial severity or frontal/temporal contusions. This finding may relate to widespread diffuse axonal injury, which potentially disconnects brain circuits mediating memory following moderate to severe TBI.	Kennedy Krieger Inst, Dept Pediat Rehabil, Baltimore, MD 21205 USA; Johns Hopkins Univ, Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD USA; Johns Hopkins Univ, Sch Med, Dept Pediat, Baltimore, MD USA	Salorio, CF (corresponding author), Kennedy Krieger Inst, Dept Pediat Rehabil, 707 N Broadway, Baltimore, MD 21205 USA.	salorio@kennedykrieger.org		Grados, Marco/0000-0002-6189-6264	EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD007414] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20MH000997] Funding Source: NIH RePORTER; NICHD NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [5-T32-HD0741410] Funding Source: Medline; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [K20 MH-00997] Funding Source: Medline		Adams JH, 1999, J CLIN PATHOL, V52, P804, DOI 10.1136/jcp.52.11.804; ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Alexander MP, 2003, BRAIN, V126, P1493, DOI 10.1093/brain/awg128; American Psychiatric Association, 1987, DIAGN STAT MAN MENT; AUERBACH SH, 1986, J HEAD TRAUMA REHAB, V1, P1, DOI DOI 10.1097/00001199-198609000-00004; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; Catroppa C, 2002, BRAIN INJURY, V16, P369, DOI 10.1080/02699050110104444; Delis D, 1994, CALIFORNIA VERBAL LE; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Donders J, 1999, DEV NEUROPSYCHOL, V15, P395, DOI 10.1080/87565649909540757; Donders J, 2004, J INT NEUROPSYCH SOC, V10, P482, DOI 10.1017/S1355617704104025; ESLINGER PJ, 1985, NEUROLOGY, V35, P1731, DOI 10.1212/WNL.35.12.1731; EWINGCOBBS L, 1990, NEUROSURGERY, V27, P683, DOI 10.1227/00006123-199011000-00003; EWINGCOBBS L, 1998, TRAUMATIC BRAIN INJU, P11; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; Gerring J, 2000, BRAIN INJURY, V14, P205; Gerring JP, 1998, J AM ACAD CHILD PSY, V37, P647, DOI 10.1097/00004583-199806000-00015; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Grados MA, 2001, J NEUROL NEUROSUR PS, V70, P350, DOI 10.1136/jnnp.70.3.350; Hoffman N, 2000, ARCH CLIN NEUROPSYCH, V15, P47, DOI 10.1016/S0887-6177(98)00156-5; HOLLINGSHEAD AB, 1975, UNPUB 4 FACTOR INDEX; *ISG TECHN, 1995, ALL SOFTW; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; JAFFE KM, 1992, ARCH PHYS MED REHAB, V73, P540; JAFFE KM, 1993, ARCH PHYS MED REHAB, V74, P587, DOI 10.1016/0003-9993(93)90156-5; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; KAUFMANN PM, 1993, J CHILD NEUROL, V8, P348, DOI 10.1177/088307389300800410; Levin H S, 1997, J Int Neuropsychol Soc, V3, P598; Levin HS, 1996, DEV NEUROPSYCHOL, V12, P17, DOI 10.1080/87565649609540638; LEVIN HS, 1982, NEUROSURGERY, V11, P668, DOI 10.1227/00006123-198211000-00009; LEVIN HS, 1988, NEUROSURGERY, V22, P1043, DOI 10.1227/00006123-198806010-00012; LEVIN HS, 1989, NEUROSURGERY, V24, P223, DOI 10.1227/00006123-198902000-00011; LEVIN HS, 1993, ARCH NEUROL-CHICAGO, V50, P897, DOI 10.1001/archneur.1993.00540090008004; Levin HS, 2001, NEUROPSYCHOLOGIA, V39, P122, DOI 10.1016/S0028-3932(00)00111-1; LEVIN HS, 1994, J CHILD NEUROL, V9, P81, DOI 10.1177/088307389400900121; Mandzia JL, 2004, HUM BRAIN MAPP, V21, P1, DOI 10.1002/hbm.10140; Massagli TL, 1996, ARCH PHYS MED REHAB, V77, P125, DOI 10.1016/S0003-9993(96)90156-2; Medana IM, 2003, BRAIN, V126, P515, DOI 10.1093/brain/awg061; MENDELSOHN D, 1992, CHILD NERV SYST, V8, P445, DOI 10.1007/BF00274405; Miller LJ, 2003, REHABIL PSYCHOL, V48, P237, DOI 10.1037/0090-5550.48.4.237; Roman MJ, 1998, J CLIN EXP NEUROPSYC, V20, P245, DOI 10.1076/jcen.20.2.245.1168; SLIFER KJ, 1993, J APPL BEHAV ANAL, V26, P469, DOI 10.1901/jaba.1993.26-469; Slomine BS, 2002, BRAIN INJURY, V16, P759, DOI 10.1080/02699050210127286; SQUIRE LR, 1989, J NEUROSCI, V9, P828; STUSS D T, 1981, Journal of Clinical Neuropsychology, V3, P13, DOI 10.1080/01688638108403110; Talairach TM, 1988, COPLANAR STEREOTAXIC; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; TEASDALE G, 1974, LANCET, V2, P81; Vasa RA, 2004, BIOL PSYCHIAT, V55, P208, DOI 10.1016/S0006-3223(03)00708-X; Verger K, 2001, BRAIN INJURY, V15, P211; Wechsler D., 1991, WECHSLER INTELLIGENC; Weis S, 2004, CEREB CORTEX, V14, P256, DOI 10.1093/cercor/bhg125; WELNER Z, 1987, J AM ACAD CHILD PSY, V26, P649, DOI 10.1097/00004583-198709000-00007; WILSON J T L, 1990, Brain Injury, V4, P349; Yeates K O, 1995, J Int Neuropsychol Soc, V1, P78; Yeates KO, 2000, SCI PRACT NEUROPSYCH, P92; Yeates KO, 2002, NEUROPSYCHOLOGY, V16, P514, DOI 10.1037//0894-4105.16.4.514; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012	60	23	23	0	7	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	1355-6177	1469-7661		J INT NEUROPSYCH SOC	J. Int. Neuropsychol. Soc.	OCT	2005	11	6					686	696		10.1017/S1355617705050885			11	Clinical Neurology; Neurosciences; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	980NQ	WOS:000233025600004	16248904				2021-06-18	
J	Mackenzie, JA; McMillan, TM				Mackenzie, JA; McMillan, TM			Knowledge of post-concussional syndrome in naive lay-people, general practitioners and people with minor traumatic brain injury	BRITISH JOURNAL OF CLINICAL PSYCHOLOGY			English	Article							HEAD-INJURY; POSTCONCUSSIVE SYMPTOMS; RANDOMIZED-TRIAL; BASE RATES; MISCONCEPTIONS; STRESS; PHYSIOGENESIS; PSYCHOGENESIS; ABILITY	Background. Expectations about effects of minor traumatic brain injury (MTBI) may play a role in maintaining symptoms, the ability to simulate post-concussion syndrome (PCS) and the extent to which professionals might associate patient complaints with MTBI. In turn, expectations will be related to knowledge about MTBI. This study investigates knowledge of PCS in people with MTBI compared with general practitioners (GPs) and lay-people, using recall (a vignette) and symptom guessing or recognition (checklists). Methods. Thirty GPs, 30 people with MTBI, and 30 lay-people generated symptoms from a vignette describing a MTB1. They then completed a PCS checklist or a checklist containing PCS and 'bogus' items pertaining to the vignette. Results. Only 1 of 90 participants reported enough PCS symptoms to indicate 'caseness' from the vignette alone. Using checklists, more GPs (60%) than controls (20%) ticked enough symptoms to attain PCS'caseness'. Few people with MTB1 who did not themselves achieve PCS 'caseness' by self-report using checklists achieved Icaseness' using the vignette and checklists. The frequency of non-physical symptom reporting was higher than for physical symptom reporting. The addition of 'bogus' items to checklists did not affect responding. Conclusions. It is unlikely that pre-injury expectations about MTBI maintain PCS symptoms. PCS was difficult to simulate without prompting, even by GPs and PCS,cases'. The use of 'caseness', rather than simple symptom scores, and further development of checklists with 'bogus' items may provide a more valid assessment of MTBI effects. GPs may benefit from further information about PCS and available treatments.	Univ Glasgow, Dept Psychol Med, Glasgow G12 8QQ, Lanark, Scotland	McMillan, TM (corresponding author), Univ Glasgow, Gartnavel Royal Hosp, 1055 Great Western Rd, Glasgow G12 0XH, Lanark, Scotland.	t.m.mcmillan@clinmed.gla.ac.uk					Anderson Shirley I., 1993, Brain Injury, V7, P309, DOI 10.3109/02699059309034957; AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; BADDELEY AD, 1992, MANUAL SPEED CAPACIT; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BLEEKER JK, 1995, PSYCHOTHER PSYCHOSOM, V63, P151, DOI 10.1159/000288952; Burges C, 2001, BRIT J CLIN PSYCHOL, V40, P209, DOI 10.1348/014466501163544; FOX DD, 1995, NEUROPSYCHOLOGY, V9, P606, DOI 10.1037/0894-4105.9.4.606; Gasquoine P G, 2000, Appl Neuropsychol, V7, P83, DOI 10.1207/S15324826AN0702_3; Gouvier W D, 1988, Arch Clin Neuropsychol, V3, P273, DOI 10.1016/0887-6177(88)90019-4; GOUVIER WD, 1992, ARCH CLIN NEUROPSYCH, V7, P193, DOI 10.1016/0887-6177(92)90162-G; Gunstad J, 2001, J INT NEUROPSYCH SOC, V7, P323, DOI 10.1017/S1355617701733061; Iverson GL, 1997, BRAIN INJURY, V11, P783, DOI 10.1080/026990597122990; JACOBSON RR, 1995, J PSYCHOSOM RES, V39, P675, DOI 10.1016/0022-3999(95)00006-5; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; LEESHALEY PR, 1993, ARCH CLIN NEUROPSYCH, V8, P203, DOI 10.1016/0887-6177(93)90036-Z; LEESHALEY PR, 1994, J CLIN PSYCHOL, V50, P252, DOI 10.1002/1097-4679(199403)50:2<252::AID-JCLP2270500217>3.0.CO;2-T; LeesHaley PR, 1997, BRAIN INJURY, V11, P791; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; McMillan T, 2003, STUD NEUROPSYCHOL DE, P271; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MITTENBERG W, 1992, J NEUROL NEUROSUR PS, V41, P611; ODDY M, 1978, J NEUROL NEUROSUR PS, V41, P611, DOI 10.1136/jnnp.41.7.611; Oddy M, 2003, HDB NEUROLOGICAL REH, P453; Paniak C, 1998, BRAIN INJURY, V12, P1011, DOI 10.1080/026990598121927; Paniak C, 2000, BRAIN INJURY, V14, P219; Ruff RM, 1996, BRAIN INJURY, V10, P551, DOI 10.1080/026990596124124; Sawchyn JM, 2000, ARCH CLIN NEUROPSYCH, V15, P1, DOI 10.1016/S0887-6177(98)00041-9; *SCOTT INT GUID NE, 2000, SCOTT INT GUID NETW; Springer JA, 1997, J HEAD TRAUMA REHAB, V12, P41, DOI 10.1097/00001199-199706000-00005; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Wade DT, 1998, J NEUROL NEUROSUR PS, V65, P177, DOI 10.1136/jnnp.65.2.177; WILLER B, 1993, ARCH CLIN NEUROPSYCH, V8, P461, DOI 10.1016/0887-6177(93)90009-P; WONG JL, 1994, ARCH CLIN NEUROPSYCH, V9, P411, DOI 10.1016/0887-6177(94)90004-3	35	23	24	0	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0144-6657	2044-8260		BRIT J CLIN PSYCHOL	Br. J. Clin. Psychol.	SEP	2005	44		3				417	424		10.1348/014466505X35696			8	Psychology, Clinical	Psychology	969IF	WOS:000232227100009	16238886				2021-06-18	
J	Xu, GY; Hughes, MG; Zhang, LP; Cain, L; McAdoo, DJ				Xu, GY; Hughes, MG; Zhang, LP; Cain, L; McAdoo, DJ			Administration of glutamate into the spinal cord at extracellular concentrations reached post-injury causes functional impairments	NEUROSCIENCE LETTERS			English	Article						activity box; excitotoxicity; functional impairment; glutamate; microdialysis; oligodendrocyte; spinal cord injury	MODEL COMBINING MICRODIALYSIS; EXCITATORY AMINO-ACIDS; RAT STRIATUM; CHRONIC INFUSION; IMPACT INJURY; TISSUE LOSS; NEUROTOXICITY; ELECTROPHYSIOLOGY; NEUROCHEMISTRY; EXCITOTOXICITY	In vivo experiments addressing the role of released glutamate in damage caused by neurotrauma seldom administer glutamate itself because it usually produces relatively little damage when administered into central nervous system (CNS) tissue in vivo. However, because of recent observations that glutamate administered into the spinal cord at the levels attained following spinal cord injury (SCI) kills neurons and oligodendrocytes, we tested the effects of administering glutamate at those concentrations on locomotor function. The Basso-Beattie-Bresnahan (BBB) test and activity box measures demonstrated that those glutainate concentrations produce lasting functional impairments. Several parameters provided by the activity box provided sensitive measures of the degree of post-SCI impairment, demonstrating their substantial potential for evaluating outcomes of SCI. Results obtained also enhance evidence that glutainate toxicity contributes to secondary damage following SO and suggest that damage to white matter is an important contributor to such damage. (c) 2005 Elsevier Ireland Ltd. All rights reserved.	Univ Texas, Med Branch, Dept Neurosci & Cell Biol, Galveston, TX 77555 USA	McAdoo, DJ (corresponding author), Univ Texas, Med Branch, Dept Neurosci & Cell Biol, 301 Univ Blvd, Galveston, TX 77555 USA.	djmcadoo@utmb.edu			NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS011255, P01NS039161] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS39161, NS11255] Funding Source: Medline		BASSO DM, 1995, J NEUROTRAUM, V12, P1, DOI 10.1089/neu.1995.12.1; CAIN LD, IN PRESS J NEUROTRAU; FADEN AI, 1990, EUR J PHARMACOL, V175, P165, DOI 10.1016/0014-2999(90)90227-W; FADEN AI, 1988, ANN NEUROL, V23, P623, DOI 10.1002/ana.410230618; Houghton AK, 1997, NEUROREPORT, V8, P3795, DOI 10.1097/00001756-199712010-00028; KOHLER C, 1981, BRAIN RES, V211, P485, DOI 10.1016/0006-8993(81)90978-1; Li SX, 2000, J NEUROSCI, V20, P1190, DOI 10.1523/JNEUROSCI.20-03-01190.2000; Liu D, 1999, NEUROSCIENCE, V93, P1383, DOI 10.1016/S0306-4522(99)00278-X; LIU DX, 1991, BRAIN RES, V547, P344, DOI 10.1016/0006-8993(91)90984-4; LIU DX, 1993, J NEUROTRAUM, V10, P349, DOI 10.1089/neu.1993.10.349; LIU DX, 1994, MOL CHEM NEUROPATHOL, V23, P77, DOI 10.1007/BF02815402; Magnuson DSK, 1999, EXP NEUROL, V156, P191, DOI 10.1006/exnr.1999.7016; MANGANO RM, 1983, BRAIN RES BULL, V10, P47, DOI 10.1016/0361-9230(83)90073-4; McAdoo DJ, 1999, EXP NEUROL, V159, P538, DOI 10.1006/exnr.1999.7166; McAdoo DJ, 2005, BRAIN RES, V1038, P92, DOI 10.1016/j.brainres.2005.01.024; McAdoo DJ, 2000, BRAIN RES, V865, P283, DOI 10.1016/S0006-8993(00)02296-4; MCBEAN GJ, 1985, J NEUROCHEM, V44, P247, DOI 10.1111/j.1471-4159.1985.tb07137.x; MCBEAN GJ, 1984, BRAIN RES, V290, P372, DOI 10.1016/0006-8993(84)90959-4; Mills CD, 2002, EXP NEUROL, V173, P153, DOI 10.1006/exnr.2001.7828; Mills CD, 2001, J NEUROTRAUM, V18, P1091, DOI 10.1089/08977150152693773; PANTER SS, 1990, ANN NEUROL, V27, P96, DOI 10.1002/ana.410270115; Plunkett JA, 2001, EXP NEUROL, V168, P144, DOI 10.1006/exnr.2000.7604; SORKIN LS, 1988, J NEUROSCI METH, V23, P131, DOI 10.1016/0165-0270(88)90185-9; Teng YD, 1997, J NEUROSCI, V17, P4359; Wada S, 1999, J NEUROSURG, V91, P98, DOI 10.3171/spi.1999.91.1.0098; WAXMAN SG, 1989, J NEUROL SCI, V91, P1, DOI 10.1016/0022-510X(89)90072-5; Wrathall JR, 1997, EXP NEUROL, V145, P565, DOI 10.1006/exnr.1997.6506; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; Xu GY, 2004, EXP NEUROL, V187, P329, DOI 10.1016/j.expneurol.2004.01.029; XU GY, 2004, P 34 ANN M SOC NEUR; YEZIERSKI RP, 1993, J NEUROTRAUM, V10, P445, DOI 10.1089/neu.1993.10.445	31	23	25	0	0	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0304-3940	1872-7972		NEUROSCI LETT	Neurosci. Lett.	AUG 26	2005	384	3					271	276		10.1016/j.neulet.2005.04.100			6	Neurosciences	Neurosciences & Neurology	944XF	WOS:000230463700013	15925447				2021-06-18	
J	Sen, J; Belli, A; Petzold, A; Russo, S; Keir, G; Thompson, EJ; Smith, M; Kitchen, N				Sen, J; Belli, A; Petzold, A; Russo, S; Keir, G; Thompson, EJ; Smith, M; Kitchen, N			Extracellular fluid S100B in the injured brain: a future surrogate marker of acute brain injury?	ACTA NEUROCHIRURGICA			English	Article						acute brain injury; microdialysis; S100B; monitoring; marker	CEREBROSPINAL-FLUID; SERUM S100B	The authors describe the measurement of S100B protein in brain extracellular fluid (ECF) of patients with acute brain injury (traumatic brain injury and subarachnoid haemorrhage) using the technique of microdialysis. To our knowledge, this is the first report of S100B measurement in the human brain. Acute Brain Injury (ABI) is a leading cause of death and disability and the need for a practical and sensitive biochemical marker for monitoring these patients is urgent. The calcium binding astrocyte protein, S100B, may be a candidate for this role. Previous serum studies have shown S100B to be a sensitive predictor of mortality and rise in intracranial pressure in ABI, but it has never before been measured directly within the brain. The ECF reflects the local biochemistry of the brain parenchyma, and the use of intracerebral microdialysis opens up the possibility of studying many novel surrogate markers of injury in the laboratory, in addition to the conventional markers it measures at the bedside (lactate, pyruvate, glucose, and glycerol). In this preliminary report of two cases, the authors demonstrate the quantification of S100B in ECF microdialysate, and investigate whether changes in hourly S100B profile can be related to secondary brain injury. It is shown that extracellular concentrations of S100B change markedly in response to secondary brain injury. Further investigation is required to determine whether extracellular S100B measurement in ABI could assist in patient management.	UCL Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Surg Intens Care Unit, London WC1N 3BG, England; Victor Horsley Dept Neurosurg, London, England; Inst Neurol, Dept Neuroimmunol, London WC1N 3BG, England	Sen, J (corresponding author), UCL Natl Hosp Neurol & Neurosurg, Dept Neurosurg, Surg Intens Care Unit, Queen Sq, London WC1N 3BG, England.	j.sen@ion.ucl.ac.uk	Smith, Martin/B-2616-2009; Petzold, Axel/C-1090-2009; Belli, Antonio/I-3799-2015	Petzold, Axel/0000-0002-0344-9749; Belli, Antonio/0000-0002-3211-9933			Anderson RE, 2001, NEUROSURGERY, V48, P1255, DOI 10.1097/00006123-200106000-00012; Donato R, 2001, INT J BIOCHEM CELL B, V33, P637, DOI 10.1016/S1357-2725(01)00046-2; Green AJE, 1997, J IMMUNOL METHODS, V205, P35, DOI 10.1016/S0022-1759(97)00050-1; Petzold A, 2003, BRAIN RES BULL, V61, P281, DOI 10.1016/S0361-9230(03)00091-1; Petzold A, 2002, CRIT CARE MED, V30, P2705, DOI 10.1097/00003246-200212000-00015; TAKAYASU M, 1985, J NEUROSURG, V63, P417, DOI 10.3171/jns.1985.63.3.0417; UNGERSTEDT U, 1991, J INTERN MED, V230, P365, DOI 10.1111/j.1365-2796.1991.tb00459.x	7	23	23	0	0	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268			ACTA NEUROCHIR	Acta Neurochir.	AUG	2005	147	8					897	900		10.1007/s00701-005-0526-2			4	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	950FY	WOS:000230844200028	15824882				2021-06-18	
J	Cooper, EB; Scherder, EJA; Cooper, JB				Cooper, EB; Scherder, EJA; Cooper, JB			Electrical treatment of reduced consciousness: Experience with coma and Alzheimer's disease	NEUROPSYCHOLOGICAL REHABILITATION			English	Article; Proceedings Paper	Conference of the International-Neuropsychological-Society	JUL 16-19, 2003	Berlin, GERMANY	Int Neuropsychol Soc			NERVE-STIMULATION TENS; TRAUMATIC BRAIN-INJURY; SEVERE HEAD-INJURY; MEDIAN NERVE; AFFECTIVE BEHAVIOR; CINGULATE CORTEX; BASAL FOREBRAIN; LOCUS-COERULEUS; MEMORY; CT	The right median nerve can be stimulated electrically to help arouse the central nervous system for persons with reduced levels of consciousness. The mechanisms of central action include increased cerebral blood flow and raised levels of dopamine. There is 11 years of experience in the USA of using nerve stimulation for acute coma after traumatic brain injury There is a much longer period of experience by neurosurgeons in Japan with implanted electrodes on the cervical spinal cord for persons in the persistent vegetative state (PVS). But the use of right median nerve electrical stimulation (RMNS) for patients in the subacute and chronic phases of coma is relatively new. Surface electrical stimulation to treat anoxic brain injury as well as traumatic brain injury is evolving. Novel applications of electrical stimulation in Amsterdam have produced cognitive behavioural effects in persons with early and mid-stage Alzheimer's disease employing transcutaneous electrical nerve stimulation (TENS). Improvements in short-term memory and speech fluency have also been noted. Regardless of the aetiology of the coma or reduced level of awareness, electrical stimulation may serve as a catalyst to enhance central nervous system functions. It remains for the standard treatments and modalities to retrain the injured brain emerging from reduced levels of consciousness.	Univ Virginia, Dept Neurol Surg, Charlottesville, VA USA; E Carolina Univ, Dept Phys Med & Rehabil, Brody Sch Med, Greenville, NC USA; Vrije Univ Amsterdam, Dept Neuropsychol, Amsterdam, Netherlands; Univ Groningen, Dept Human Movement Sci, Groningen, Netherlands; Virginia Commonwealth Univ Med Coll Virginia, Dept Neurol, Richmond, VA USA	Cooper, EB (corresponding author), 1001 N Queen St, Kinston, NC 28501 USA.	edwincooper@earthlink.net					Blackman JA, 2003, J HEAD TRAUMA REHAB, V18, P493, DOI 10.1097/00001199-200311000-00003; Buitrago MM, 2004, EXP BRAIN RES, V158, P336, DOI 10.1007/s00221-004-1906-1; Cedazo-Minguez A, 2001, J CELL MOL MED, V5, P254, DOI 10.1111/j.1582-4934.2001.tb00159.x; Cifu DX, 2003, ARCH PHYS MED REHAB, V84, P1441, DOI 10.1016/S0003-9993(03)00272-7; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; COOPER E, IN PRESS ELECT TREAT; COOPER E, 1996, P AM INP OUTP SYST A; Cooper E B Jr, 1973, Surg Forum, V24, P477; Cooper EB, 2003, ACT NEUR S, V87, P7; COOPER J, 1996, THESIS E CAROLINA U; Cooper JB, 1999, BRAIN INJURY, V13, P261, DOI 10.1080/026990599121638; Critchley HD, 2003, BRAIN, V126, P2139, DOI 10.1093/brain/awg216; DAVEY M, 2004, COMMUNICATION; DORAISWAMY M, 2003, PSYCHOPHARMACOLOGY B, V37, P41; Dringenberg HC, 2003, NEUROSCIENCE, V119, P839, DOI 10.1016/S0306-4522(03)00197-0; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; Ezrokhi VL, 1999, NEUROSCIENCE, V88, P741, DOI 10.1016/S0306-4522(98)00232-2; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; GERSH MR, 1992, ELECTROTHERAPY REHAB, P260; Gobbo OL, 2004, BEHAV BRAIN RES, V152, P231, DOI 10.1016/j.bbr.2003.10.017; GREENAMYRE JT, 1988, PROG NEURO-PSYCHOPH, V12, P421, DOI 10.1016/0278-5846(88)90102-9; Hayashi N., 1997, SOC TREAT COMA, V6, P133; Ho GJ, 2002, NEUROREPORT, V13, P1825, DOI 10.1097/00001756-200210070-00028; Hynd MR, 2004, NEUROCHEM INT, V45, P583, DOI 10.1016/j.neuint.2004.03.007; Kampfl A, 1998, LANCET, V351, P1763, DOI 10.1016/S0140-6736(97)10301-4; KANNO T, 1989, PACE, V12, P733, DOI 10.1111/j.1540-8159.1989.tb02724.x; KANNO T, 1995, UNPUB DORSAL COLUMN; KANNO T, 2000, SOC TREATMENT COMA, V9, P23; KANNO T, 1992, SOC TREATMENT COMA, V1, P67; KAPUR N, 1994, J NEUROL NEUROSUR PS, V57, P1334, DOI 10.1136/jnnp.57.11.1334; Kayama Y, 1998, EUR UROL, V33, P12, DOI 10.1159/000052235; KIDO DK, 1992, RADIOLOGY, V182, P777, DOI 10.1148/radiology.182.3.1535893; Klintsova AY, 1999, CURR OPIN NEUROBIOL, V9, P203, DOI 10.1016/S0959-4388(99)80028-2; KOKAIA Z, 1994, NEUROREPORT, V5, P1241, DOI 10.1097/00001756-199406020-00021; Kwan CL, 2000, PAIN, V85, P359, DOI 10.1016/S0304-3959(99)00287-0; Le Bars PL, 2002, NEUROPSYCHOBIOLOGY, V45, P19, DOI 10.1159/000048668; LEGORATTISANCHEZ MO, 1989, BRAIN RES BULL, V23, P283, DOI 10.1016/0361-9230(89)90210-4; Liu JT, 2003, ACTA NEUROCHIR SUPPL, V87, P11; Luijpen MW, 2003, REV NEUROSCIENCE, V14, P343; MARSHALL F, 1996, NEUROSURGERY, P2717; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; MONTGOMERY G, 1989, DISCOVER, V10, P58; Moriya T, 2000, SOC TREAT COMA, V9, P159; MORIYA T, 1999, SOC TREAT COMA, V8, P111; OKUMA I, 2001, SOC TREATMENT COMA, V10, P67; PARENT A, 1996, CARPENTERS HUMAN NEU, P381; Peri CV, 2001, BRAIN INJURY, V15, P903, DOI 10.1080/02699050110065709; Salehi A, 1999, J NEURAL TRANSM, V106, P955, DOI 10.1007/s007020050216; Sauvage M, 2001, NEUROSCIENCE, V104, P643, DOI 10.1016/S0306-4522(01)00137-3; SCHELTENS P, 1992, J NEUROL NEUROSUR PS, V55, P967, DOI 10.1136/jnnp.55.10.967; SCHERDER EJA, 1995, BEHAV BRAIN RES, V67, P211, DOI 10.1016/0166-4328(94)00115-V; Scherder EJA, 2003, CHINESE J PHYSIOL, V46, P143; Scherder EJA, 1999, BEHAV BRAIN RES, V101, P105, DOI 10.1016/S0166-4328(98)00150-8; Scherder EJA, 2001, BRAIN INJURY, V15, P545, DOI 10.1080/02699050010007399; SCHERDER EJA, 1992, J CLIN EXP NEUROPSYC, V14, P951, DOI 10.1080/01688639208402546; Scherder EJA, 1998, BIOL PSYCHIAT, V43, P417, DOI 10.1016/S0006-3223(97)00208-4; Scherder EJA, 1999, BIOL PSYCHIAT, V45, P743, DOI 10.1016/S0006-3223(98)00072-9; SCHERDER EJA, 2004, UNPUB EFFECTS RIGHT; SCHERDER EJA, 1996, CHILDRENS HOSP Q, V8, P187; Shinotoh H, 2003, ANN NY ACAD SCI, V985, P411; Spiegel J, 1999, CLIN NEUROPHYSIOL, V110, P47, DOI 10.1016/S0168-5597(98)00043-4; SWAAB DF, 2004, HDB CLIN NEUROLOGY, V80; TOUTANT SM, 1984, J NEUROSURG, V61, P691, DOI 10.3171/jns.1984.61.4.0691; van Dijk KRA, 2002, REV NEUROSCIENCE, V13, P257; Van Someren EJW, 1998, ALZ DIS ASSOC DIS, V12, P114, DOI 10.1097/00002093-199806000-00010; YAMAMOTO K, 1997, SOC TREATMENT COMA, V6, P117; Yokoyama T, 1996, SOC TREAT COMA, V5, P117	67	23	40	1	6	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JUL-SEP	2005	15	3-4					389	405		10.1080/09602010443000317			17	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	965PE	WOS:000231961900024	16350980	Green Published			2021-06-18	
J	Rondina, C; Videtta, W; Petroni, G; Lujan, S; Schoon, P; Mori, LB; Matkovich, J; Carney, N; Chesnut, R				Rondina, C; Videtta, W; Petroni, G; Lujan, S; Schoon, P; Mori, LB; Matkovich, J; Carney, N; Chesnut, R			Mortality and morbidity from moderate to severe traumatic brain injury in Argentina	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						Argentina; outcomes; rehabilitation; traumatic brain injury	DISABILITY RATING-SCALE; HEAD; COMA	After adopting the Guidelines for the Management of Severe Head Injury, critical care physicians in Argentina reduced the mortality rate of patients with traumatic brain injury (TBI). However, there is no in-hospital or postdischarge rehabilitation services for persons with TBI in Argentina. Thus, severely disabled survivors were being discharged to home without follow-up or long-term care. Objectives: The objectives of this project were to establish a structure for conducting research about TBI in Argentina, and to conduct a prospective, observational study of outcomes from TBI in hospitals that had adopted the acute care guidelines. The goal was to document outcomes for people treated in a medical system that does not provide TBI rehabilitation. The focus of this report is mortality and morbidity during the acute care and hospital ward treatment of TBI in Argentina. Methods: We established a data-collection system in 5 hospitals in Argentina, using instruments and protocols developed by the NIDRR-funded TBI Model System program. Data-collection intervals were established to be comparable with intervals used in the TBI Model System program. The Argentine team consists of 11 neurocritical care physicians and I project manager/translator. All patient evaluation, data collection and entry, quality control, and local administration were conducted by this group. Results: Over 31 months, 278 patients were entered into the study. Approximately 61% were discharged from acute care directly to home. The in-hospital mortality rate was 31%. Seventy-six percent of expired patients died from secondary complications such as sepsis and pneumonia, and 93% while in the hospital. Discussion: TBI is a major public health concern in Argentina. However, rehabilitation for TBI is not a part of this country's medical system. The greatest proportion of expired patients in the Argentine sample died of secondary complications such as pneumonia or sepsis, which may have been avoided employing basic medical rehabilitation. The next research questions to be addressed in this population should be designed to identify solutions to the immediate need for rehabilitation, including treatment efficacy questions as well as questions about systems for delivering treatments.	Hosp Emergencias Dr Clemente Alvarez, RA-2000 Rosario, Santa Fe, Argentina; Hosp Nacl Professor A Posadas, Buenos Aires, DF, Argentina; Hosp Interzonal Gen Agudos Professor Dr Luis Guem, Buenos Aires, DF, Argentina; Oregon Hlth & Sci Univ, Portland, OR 97201 USA; Univ Washington, Harborview Hosp, Seattle, WA 98195 USA	Rondina, C (corresponding author), Hosp Emergencias Dr Clemente Alvarez, Rueda 1100, RA-2000 Rosario, Santa Fe, Argentina.			Chesnut, Randall/0000-0001-6377-3666			Adelson PD, 2003, CRIT CARE MED, V31, pS418, DOI 10.1097/00003246-200306006-00002; ADELSON PD, 2003, TRAUMA, V54, pS235; Boake C, 1996, ARCH PHYS MED REHAB, V77, P765, DOI 10.1016/S0003-9993(96)90254-3; Bond M R, 1979, Acta Neurochir Suppl (Wien), V28, P126; BULLOCK R, 1996, GUIDELINES MANAGEMEN; Carney Nancy A, 2003, Pediatr Crit Care Med, V4, pS1; *COMM TRAUM AM COL, 1999, RES OPT CAR INJ PAT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; GOUVIER WD, 1987, ARCH PHYS MED REHAB, V68, P94; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P84, DOI 10.1097/00002060-199304000-00005; Kreutzer JS, 1996, ARCH PHYS MED REHAB, V77, P116, DOI 10.1016/S0003-9993(96)90155-0; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; MARSHALL LF, 1983, J NEUROSURG, V59, P285, DOI 10.3171/jns.1983.59.2.0285; NEIRA JA, 2001, MED INTENSIVA, V18, P92; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; Verdejo G, 2000, Epidemiol Bull, V21, P7	17	23	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2005	20	4					368	376		10.1097/00001199-200507000-00008			9	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	941MV	WOS:000230219800008	16030443				2021-06-18	
J	Eftekharpour, E; Karimi-Abdolrezaee, S; Sinha, K; Velumian, AA; Kwiecien, JM; Fehlings, MG				Eftekharpour, E; Karimi-Abdolrezaee, S; Sinha, K; Velumian, AA; Kwiecien, JM; Fehlings, MG			Structural and functional alterations of spinal cord axons in adult Long Evans Shaker (LES) dysmyelinated rats	EXPERIMENTAL NEUROLOGY			English	Article						Caspr; western blotting; real-time PCR; compound action potential; K+ channels	K+ CHANNELS; MOLECULAR ARCHITECTURE; PARANODAL JUNCTIONS; POTASSIUM CHANNELS; MYELINATED AXONS; PROTEIN CASPR; LOCALIZATION; EXPRESSION; CONTACTIN; INJURY	Abnormal formation or loss of myelin is a distinguishing feature of many neurological disorders and contributes to the pathobiology of neurotrauma. In this study we characterize the functional and molecular changes in CNS white matter in Long Evans Shaker (LES) rats. These rats have a spontaneous Mutation Of the gene encoding myelin basic protein which results in severe dysmyelination of the central nervous system (CNS), providing a unique model for demyelinating/dysmyelinating disorders. To date, the functional and molecular changes in CNS white matter in this model are not well understood. We have used in vivo somatosensory evoked potential (SSEP), in vitro compound action potential (CAP) recording in isolated dorsal columns, confocal immunohistochemistry, Western blotting and real-time PCR to examine the electrophysiological, molecular and cellular changes in spinal cord white matter in LES rats. We observed that dysmyelination is associated with dispersed labeling of Kv1.1 and Kv1.2 K+ channel subunits, as well as Caspr, a protein normally confined to paranodes, along the LES rat spinal cord axons. Abnormal electrophysiological properties including attenuation of CAP amplitude and conduction velocity, high frequency conduction failure and enhanced sensitivity to K+ channel blockers 4-aminopyridine and dendrotoxin-I were observed in spinal cord axons from LES rats. Our results in LES rats clarify some of the key molecular, cellular and functional consequences of dysmyelination and myelin-axon interactions. Further understanding of these issues in this model could provide critical insights for neurological disorders characterized by demyelination. (c) 2005 Elsevier Inc. All rights reserved.	Univ Toronto, Toronto Western Hosp, Hlth Network, Div Neurosurg, Toronto, ON M5T 2S8, Canada; Univ Toronto, Inst Med Sci, Toronto, ON M5T 2S8, Canada; McMaster Univ, Toronto Western Res Inst, Krembil Neurosci Ctr, Div Cell & Mol Biol, Hamilton, ON, Canada; McMaster Univ, Dept Pathol & Mol Med, Hamilton, ON, Canada	Fehlings, MG (corresponding author), Univ Toronto, Toronto Western Hosp, Hlth Network, Div Neurosurg, Room 4W-449,399 Bathurst St, Toronto, ON M5T 2S8, Canada.	michael.fehlings@uhn.on.ca		Eftekharpour, Eftekhar/0000-0002-2849-3754; Karimi-Abdolrezaee, Soheila/0000-0002-0683-2663; Fehlings, Michael/0000-0002-5722-6364			Arroyo EJ, 2002, J NEUROSCI, V22, P1726, DOI 10.1523/JNEUROSCI.22-05-01726.2002; Arroyo EJ, 2001, CELL TISSUE RES, V305, P53, DOI 10.1007/s004410100403; Arroyo EJ, 2000, HISTOCHEM CELL BIOL, V113, P1, DOI 10.1007/s004180050001; Baracskay KL, 2002, J NEUROSCI RES, V70, P645, DOI 10.1002/jnr.10418; Bhat MA, 2001, NEURON, V30, P369, DOI 10.1016/S0896-6273(01)00294-X; BLIGHT AR, 1989, BRAIN RES BULL, V22, P47, DOI 10.1016/0361-9230(89)90126-3; Boyle MET, 2001, NEURON, V30, P385, DOI 10.1016/S0896-6273(01)00296-3; CHIU SY, 1981, J PHYSIOL-LONDON, V313, P415, DOI 10.1113/jphysiol.1981.sp013674; Craner MJ, 2003, BRAIN, V126, P1552, DOI 10.1093/brain/awg153; DELANEY KH, 1995, LAB ANIM SCI, V45, P547; Dodson PD, 2002, J NEUROSCI, V22, P6953; Dupree JL, 1999, J CELL BIOL, V147, P1145, DOI 10.1083/jcb.147.6.1145; EFTEKHARPOUR E, 2003, 21 NAT NEUR SOC BIL, P425; Einheber S, 1997, J CELL BIOL, V139, P1495, DOI 10.1083/jcb.139.6.1495; Fehlings MG, 1997, J NEUROSCI METH, V71, P215, DOI 10.1016/S0165-0270(96)00147-1; Fehlings MG, 1996, BRAIN RES, V736, P135, DOI 10.1016/0006-8993(96)00667-1; FEHLINGS MG, 1988, ELECTROEN CLIN NEURO, V69, P65, DOI 10.1016/0013-4694(88)90036-3; Girault JA, 2002, CURR OPIN NEUROBIOL, V12, P476, DOI 10.1016/S0959-4388(02)00370-7; Gollan L, 2003, J CELL BIOL, V163, P1213, DOI 10.1083/jcb.200309147; Gollan L, 2002, J CELL BIOL, V157, P1247, DOI 10.1083/jcb.200203050; Karimi-Abdolrezaee S, 2004, EUR J NEUROSCI, V19, P577, DOI 10.1111/j.0953-816X.2004.03164.x; Kwiecien JM, 1998, J NEUROCYTOL, V27, P581, DOI 10.1023/A:1006922227791; Mathis C, 2001, DEVELOPMENT, V128, P4881; Menegoz M, 1997, NEURON, V19, P319, DOI 10.1016/S0896-6273(00)80942-3; Nashmi R, 2000, EUR J NEUROSCI, V12, P491, DOI 10.1046/j.1460-9568.2000.00926.x; Nashmi R, 1997, J NEUROTRAUM, V14, P151, DOI 10.1089/neu.1997.14.151; Nashmi R, 2001, NEUROSCIENCE, V104, P235, DOI 10.1016/S0306-4522(01)00009-4; Nie DY, 2003, EMBO J, V22, P5666, DOI 10.1093/emboj/cdg570; O'Connor LT, 1999, J NEUROSCI, V19, P3404; Peles E, 2000, CURR OPIN NEUROBIOL, V10, P558, DOI 10.1016/S0959-4388(00)00122-7; PRIVAT A, 1979, NEUROSCI LETT, V12, P107, DOI 10.1016/0304-3940(79)91489-7; Rasband M, 1998, J NEUROSCI, V18, P36; Rasband MN, 2001, J COMP NEUROL, V429, P166, DOI 10.1002/1096-9861(20000101)429:1<166::AID-CNE13>3.0.CO;2-Y; Rasband MN, 1999, J NEUROCYTOL, V28, P319, DOI 10.1023/A:1007057512576; Rios JC, 2000, J NEUROSCI, V20, P8354, DOI 10.1523/JNEUROSCI.20-22-08354.2000; Schmittgen TD, 2000, ANAL BIOCHEM, V285, P194, DOI 10.1006/abio.2000.4753; Sobko A, 1998, J NEUROSCI, V18, P10398; Tait S, 2000, J CELL BIOL, V150, P657, DOI 10.1083/jcb.150.3.657; Wang H, 1995, NEURON, V15, P1337, DOI 10.1016/0896-6273(95)90012-8; WANG H, 1993, NATURE, V365, P75, DOI 10.1038/365075a0; WANG H, 1994, J NEUROSCI, V14, P4588; Waxman SG, 2002, J REHABIL RES DEV, V39, P233; ZELLER NK, 1984, P NATL ACAD SCI-BIOL, V81, P18, DOI 10.1073/pnas.81.1.18	43	23	24	0	5	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0014-4886	1090-2430		EXP NEUROL	Exp. Neurol.	JUN	2005	193	2					334	349		10.1016/j.expneurol.2005.01.019			16	Neurosciences	Neurosciences & Neurology	926PK	WOS:000229134900007	15869936				2021-06-18	
J	Ferman, TJ; Lucas, JA; Ivnik, RJ; Smith, GE; Willis, FB; Petersen, RC; Graff-Radford, NR				Ferman, TJ; Lucas, JA; Ivnik, RJ; Smith, GE; Willis, FB; Petersen, RC; Graff-Radford, NR			Mayo's Older African American Normative Studies: Auditory Verbal Learning Test norms for African American elders	CLINICAL NEUROPSYCHOLOGIST			English	Article							WHITE COMMUNITY RESIDENTS; NEUROPSYCHOLOGICAL TEST-PERFORMANCE; MILD COGNITIVE IMPAIRMENT; CLOSED-HEAD-INJURY; ALZHEIMERS-DISEASE; HIPPOCAMPAL ATROPHY; MEMORY; DEMENTIA; SPECIFICITY; SENSITIVITY	The Auditory Verbal Learning Test (AVLT) is frequently used in clinical practice to assess for memory dysfunction in the elderly. Aspart of the Mayo Older African Americans Normative Studies (MOAANS), we provide age and education adjusted normative data for the AVLT. The sample consists of 306 self-identified African Americans who are cognitively normal, community-dwelling and ranging in age from 56 through 94. Additional summary indices are included in the normative data, including learning efficiency, delayed recall, percent retention, and an index representing recognition memory corrected for false-positive identifications. Given the importance of using a normative reference sample that closely represents the population of interest, the current norms should provide clinically useful data for evaluating African American elders, especially those who were educated in the southern United States.	Mayo Fdn, Dept Psychiat & Psychol, Jacksonville, FL USA; Mayo Fdn, Dept Family Med, Jacksonville, FL USA; Mayo Fdn, Dept Neurol, Jacksonville, FL USA; Mayo Fdn, Dept Psychiat & Psychol, Rochester, MN USA; Mayo Fdn, Dept Neurol, Rochester, MN USA	Lucas, JA (corresponding author), Mayo Clin, 4500 San Pablo Rd, Jacksonville, FL 32224 USA.	jlucas@mayo.edu		Smith, Glenn/0000-0003-1506-9484	NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50 AG16574] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P50AG016574] Funding Source: NIH RePORTER		Albert SM, 1999, AM J PUBLIC HEALTH, V89, P95, DOI 10.2105/AJPH.89.1.95; BIGLER ED, 1989, J CLIN PSYCHOL, V45, P277, DOI 10.1002/1097-4679(198903)45:2<277::AID-JCLP2270450216>3.0.CO;2-M; BUTTERS N, 1995, ANNU REV PSYCHOL, V46, P493; FILLENBAUM G, 1990, J CLIN EPIDEMIOL, V43, P651, DOI 10.1016/0895-4356(90)90035-N; Fillenbaum GG, 1998, J CLIN EPIDEMIOL, V51, P587, DOI 10.1016/S0895-4356(98)00024-9; Fillenbaum GG, 2001, J INT NEUROPSYCH SOC, V7, P502, DOI 10.1017/S1355617701744062; Gainotti G, 1998, ALZ DIS ASSOC DIS, V12, P152, DOI 10.1097/00002093-199809000-00006; GEFFEN GM, 1994, BRAIN INJURY, V8, P405, DOI 10.3109/02699059409150992; GUILMETTE TJ, 1995, NEUROPSYCHOLOGY, V9, P338, DOI 10.1037/0894-4105.9.3.338; Harris ME, 2002, J CLIN EXP NEUROPSYC, V24, P214, DOI 10.1076/jcen.24.2.214.995; HENDRIE HC, 1995, AM J PSYCHIAT, V152, P1485; Heun R, 1997, DEMENT GERIATR COGN, V8, P329, DOI 10.1159/000106651; HEYMAN A, 1991, ARCH NEUROL-CHICAGO, V48, P594, DOI 10.1001/archneur.1991.00530180046016; Ivnik RJ, 1992, CLIN NEUROPSYCHOL, V6, P83; JANOWSKY JS, 1989, BEHAV NEUROSCI, V103, P548, DOI 10.1037/0735-7044.103.3.548; Lezak M.D., 1983, NEUROPSYCHOLOGICAL A; Lucas JA, 2005, CLIN NEUROPSYCHOL, V19, P162, DOI 10.1080/13854040590945265; Lucas MD, 1996, J CLIN EXP NEUROPSYC, V18, P88, DOI 10.1080/01688639608408265; Manly JJ, 2002, J INT NEUROPSYCH SOC, V8, P341, DOI 10.1017/S1355617702813157; MANLY JJ, 1998, NEUROLOGY, V50, P1; MICELI G, 1981, Journal of Clinical Neuropsychology, V3, P53, DOI 10.1080/01688638108403113; Petersen RC, 2000, NEUROLOGY, V54, P581, DOI 10.1212/WNL.54.3.581; Petersen RC, 1999, ARCH NEUROL-CHICAGO, V56, P303, DOI 10.1001/archneur.56.3.303; Rey A, 1964, EXAMEN CLIN PSYCHOL; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; ROSENBERG SJ, 1984, J CLIN PSYCHOL, V40, P785, DOI 10.1002/1097-4679(198405)40:3<785::AID-JCLP2270400325>3.0.CO;2-4; Sencakova D, 2001, ARCH NEUROL-CHICAGO, V58, P1593, DOI 10.1001/archneur.58.10.1593; Simard M, 1999, DRUG AGING, V14, P197, DOI 10.2165/00002512-199914030-00004; Smith GE, 1996, AGING NEUROPSYCHOL C, V3, P141, DOI 10.1080/13825589608256619; Taylor E.M., 1959, PSYCHOL APPRAISAL CH; TERESI JA, 1995, J CLIN EPIDEMIOL, V48, P473, DOI 10.1016/0895-4356(94)00159-N; Tierney M. C., 1994, PSYCHOL ASSESSMENT, V6, P129, DOI DOI 10.1037/1040-3590.6.2.129; Tierney MC, 2001, ARCH NEUROL-CHICAGO, V58, P1654, DOI 10.1001/archneur.58.10.1654; Tierney MC, 1996, NEUROLOGY, V46, P661, DOI 10.1212/WNL.46.3.661; Welsh KA, 1995, NEUROLOGY, V45, P2207, DOI 10.1212/WNL.45.12.2207	35	23	24	2	5	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	1385-4046	1744-4144		CLIN NEUROPSYCHOL	Clin. Neuropsychol.	JUN	2005	19	2					214	228		10.1080/13854040590945300			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	932LN	WOS:000229555300056	16019705				2021-06-18	
J	Pickett, W; Streight, S; Simpson, K; Brison, RJ; Cusimano, M				Pickett, W; Streight, S; Simpson, K; Brison, RJ; Cusimano, M			Head injuries in youth soccer players presenting to the emergency department	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; NEUROPSYCHOLOGICAL IMPAIRMENT; FOOTBALL PLAYERS; DAMAGE	Background: There has been recent concern about neuropsychological injuries experienced by soccer players, particularly related to the purposeful heading of the ball. There are few population based analyses examining whether this is a legitimate concern. Objectives: To explore, using an existing injury surveillance system, one of many parts of this issue: acute injuries requiring emergency medical care experienced by youth soccer players. Methods: Descriptive epidemiological analysis of emergency department injury surveillance data (1996-2001) for youths aged 10-24 years from the Kingston sites of the Canadian Hospital Injury Reporting and Prevention Program. Results: A total of 1714 cases of soccer injury were identified (mean 286 a year); 235 (13.7%) involved diagnoses of injuries to the head. Leading mechanical factors resulting in head injury were contact with other players or persons (153/235; 65.1%) and balls (62/235; 26.4%). Heading was reported in 4/62 (6%) of the ball contact injuries, and attempted heading was reported in 15/153 (9.8%) of the cases involving person to person contact. Unspecified head to head contact between players was reported in 39 cases. Conclusions: Minor head injuries that result in emergency medical treatment do not happen often in youth soccer, and very few can be attributed to the purposeful heading of the ball. Player contact injuries appear to be a more important injury control concern. This study informs one of many aspects of the soccer heading injury debate.	Queens Univ, Dept Emergency Med, Kingston, ON K7L 2V7, Canada; Queens Univ, Dept Epidemiol & Community Hlth, Kingston, ON K7L 2V7, Canada; St Michaels Univ Hosp, Div Neurosurg, Toronto, ON M5B 1A6, Canada	Pickett, W (corresponding author), Queens Univ, Kingston Gen Hosp, Dept Emergency Med, Angada 3, Kingston, ON K7L 2V7, Canada.	simpsonk@kgh.kari.net; injuryprevention@smh.toronto.on.ca	Cusimano, Michael/X-4059-2019				Barnes BC, 1998, AM J SPORT MED, V26, P433, DOI 10.1177/03635465980260031601; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Broglio SP, 2003, J ATHL TRAINING, V38, P220; *CAN SOCC ASS, COACH GRASS ROOTS IT; Downs DS, 2002, J SPORT MED PHYS FIT, V42, P103; Filipe JAC, 2003, ARCH OPHTHALMOL-CHIC, V121, P687; Guskiewicz KM, 2002, AM J SPORT MED, V30, P157, DOI 10.1177/03635465020300020201; HAGLUND Y, 1993, AM J SPORT MED, V21, P97, DOI 10.1177/036354659302100117; *HLTH CAN, 1996, CAN HOSP INJ REP PRE; Horn EP, 2000, RETINA-J RET VIT DIS, V20, P604, DOI 10.1097/00006982-200011000-00003; Janda David H, 2002, Inj Control Saf Promot, V9, P25, DOI 10.1076/icsp.9.1.25.3324; Jordan SE, 1996, AM J SPORT MED, V24, P205, DOI 10.1177/036354659602400216; Kirkendall DT, 2001, J ATHL TRAINING, V36, P328; Kirkendall DT, 2001, SPORTS MED, V31, P369, DOI 10.2165/00007256-200131050-00006; LOBNES JH, 1996, SOCCER SPORTS MED SC, P71; Mackenzie S G, 1999, Inj Prev, V5, P208; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; Matser JT, 1998, NEUROLOGY, V51, P791, DOI 10.1212/WNL.51.3.791; McCrory PR, 2003, BRIT MED J, V327, P351, DOI 10.1136/bmj.327.7411.351; Naunheim RS, 2000, J TRAUMA, V48, P938, DOI 10.1097/00005373-200005000-00020; Nilsson S, 1978, Am J Sports Med, V6, P358, DOI 10.1177/036354657800600608; Pickett W, 2000, Inj Prev, V6, P9, DOI 10.1136/ip.6.1.9; Powell JW, 1999, JAMA-J AM MED ASSOC, V282, P958, DOI 10.1001/jama.282.10.958; Prabhu VC, 2002, NEUROSURGERY, V50, P195; Putukian M, 2000, CLIN J SPORT MED, V10, P104, DOI 10.1097/00042752-200004000-00004; Queen RM, 2003, MED SCI SPORT EXER, V35, P2069, DOI 10.1249/01.MSS.0000099081.20125.A5; SORTLAND O, 1989, NEURORADIOLOGY, V31, P44; Tysvaer A, 1981, Br J Sports Med, V15, P163; TYSVAER AT, 1989, ACTA NEUROL SCAND, V80, P151, DOI 10.1111/j.1600-0404.1989.tb03858.x; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; TYSVAER AT, 1989, AM J SPORT MED, V17, P573, DOI 10.1177/036354658901700421	31	23	23	0	8	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	APR 1	2005	39	4					226	231		10.1136/bjsm.2004.013169			6	Sport Sciences	Sport Sciences	911CV	WOS:000227980000019	15793093	Green Published, Bronze			2021-06-18	
J	Fujisawa, H; Yonaha, H; Okumoto, K; Uehara, H; Ie, T; Nagata, Y; Suehiro, E; Suzuki, M				Fujisawa, H; Yonaha, H; Okumoto, K; Uehara, H; Ie, T; Nagata, Y; Suehiro, E; Suzuki, M			Mutism after evacuation of acute subdural hematoma of the posterior fossa	CHILDS NERVOUS SYSTEM			English	Article						acute subdural hematoma; posterior fossa; mutism; head injury	TRANSIENT CEREBELLAR MUTISM; CHILDREN; SPEECH	Case report: A 7-year-old boy was involved in a road traffic accident. A computed tomography scan revealed an acute subdural hematoma (ASDH) of the posterior fossa, traumatic subarachnoid hemorrhage, and distortion of the brain stem. Removal of the ASDH was completed 3.5 h after injury. After extubation, the patient rapidly recovered consciousness. He was able to follow commands, although he did not speak. He began to utter 14 days after the injury. His speech became normal 39 days after injury. A magnetic resonance imaging scan revealed a post-contusional change in the right cerebellum and an ischemic lesion in the pons. Discussion: Immediate removal of the hematoma is the only therapy for patients with ASDH of the posterior fossa. Although any lesions of the dentate nucleus, red nucleus, thalamus, cerebral cortex, and pons, all of which are involved in this case, are able to cause mutism, his mutism was primarily caused by the severe ASDH of the posterior fossa. The transient nature of this syndrome suggests that the cause of the mutism is trauma-related edema and/or transient ischemia of these structures.	Yamaguchi Univ, Sch Med, Dept Neurosurg, Yamaguchi 7558505, Japan; Okinawa Prefectural Yaeyama Hosp, Dept Surg, Ishigaki, Japan; Okinawa Prefectural Yaeyama Hosp, Dept Radiol, Ishigaki, Japan	Fujisawa, H (corresponding author), Yamaguchi Univ, Sch Med, Dept Neurosurg, 1-1-1 Minami Kogushi, Yamaguchi 7558505, Japan.	hirofuji@yamaguchi-u.ac.jp	Suehiro, Eiichi/I-5852-2019				Coplin WM, 1997, BRAIN LANG, V59, P473, DOI 10.1006/brln.1997.1790; Hecimovic I, 1999, SURG NEUROL, V51, P247, DOI 10.1016/S0090-3019(97)00473-4; KINGMA A, 1994, ACTA NEUROCHIR, V131, P74, DOI 10.1007/BF01401456; Koh S, 1997, PEDIATR NEUROL, V16, P218, DOI 10.1016/S0887-8994(97)00018-0; MAHONEY F I, 1965, Md State Med J, V14, P61; Miyakita Y, 1999, ACTA NEUROCHIR, V141, P209, DOI 10.1007/s007010050288; Niskikawa M, 1998, NEUROL MED-CHIR, V38, P569, DOI 10.2176/nmc.38.569; RAFTOPOULOS C, 1990, CLIN NEUROL NEUROSUR, V92, P57, DOI 10.1016/0303-8467(90)90008-S; Sinha AK, 1998, CHILD NERV SYST, V14, P460, DOI 10.1007/s003810050261; Turgut M, 1998, CHILD NERV SYST, V14, P161, DOI 10.1007/s003810050204; Wang MC, 2002, J NEUROSURG, V96, P607, DOI 10.3171/jns.2002.96.3.0607; YOKOTA H, 1990, Neurological Surgery, V18, P67	12	23	24	0	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	MAR	2005	21	3					234	236		10.1007/s00381-004-0999-y			3	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	902OY	WOS:000227367600012	15290193				2021-06-18	
J	Morelli, V; Espinoza, L				Morelli, V; Espinoza, L			Groin injuries and groin pain in athletes: Part 2	PRIMARY CARE			English	Article							ACETABULAR LABRAL TEARS; OSTEITIS PUBIS; FEMORAL-HEAD; AVASCULAR NECROSIS; MAGNETIC-RESONANCE; HIP PAIN; CORE DECOMPRESSION; ILIOPSOAS TENDON; LIGAMENTUM TERES; STRESS-FRACTURES	Sports injuries to the hip and groin region have been noted in 5% to 9% of high school athletes [1,2]. These injuries occur most commonly in athletes participating in sports involving side-to-side cutting, quick accelerations and decelerations, and sudden directional changes. Symptoms may range from intermittent episodes of mild discomfort to severe and chronic career-ending pain. Groin injuries may result from a variety of causes. Although this article deals mainly with athletic etiologies, the physician must keep in mind that many other medical conditions may also affect the groin. Differential diagnosis of nonathletic causes of groin pain is outlined below: Intra-abdominal disorders (eg, aneurysm, appendicitis, diverticulosis, inflammatory bowel disease) Genitourinary abnormalities (eg, urinary tract infection, lymphadenitis, prostatitis, scrotal and testicular abnormalities, gynecologic abnormalities, nephrolithiasis) Referred lumbosacral pain (eg, lumbar disc disease) Hip joint disorders (eg, Legg-Calve-Perthes disease, synovitis, slipped femoral capital epiphysis in younger patients and osteochondritis dissecans of femoral head, osteoarthritis) Because of these overlapping medical conditions and because the anatomy of the region is so complex, a team approach is optimal. In the National Institute for Groin Injuries, primary care sports physicians coordinate input from a team of urologists, neurologists, radiologists, interventional radiologists, orthopedists, general surgeons, gynecologists, physical therapists, and gastroenterologists. The primary care physician, in addition to performing a focused history and physical examination, should have an understanding of the diagnostic imaging available and a working knowledge of the sensitivities and specificities of each test. After generating a complete differential diagnosis, appropriate referral when needed, and formulation of a treatment plan, the coordinating physician must diligently maintain oversight of the athlete's response to initial conservative management. This is paramount not only because of the difficulty of diagnosis, but also because 27% to 90% of patients presenting with groin pain have more than one coexisting injury [3,4]. As the authors will illustrate, these coexisting injuries are thought to arise due to the close proximity of anatomical elements in the region, predisposing one insult to naturally involve adjacent structures. Alternatively, an initial injury may alter the delicate biomechanics of the hip and groin, leading to secondary overuse injuries. Whatever the reason, it is common for one injury to be properly diagnosed and be improving with treatment, while at the same time a concomitant injury may have gone entirely undiagnosed and untreated, leaving both the athlete and physician frustrated if proper monitoring and re-evaluation are not done. In the second of this two-part series, disorders of the os pubis, stress fractures and various hip pathologies are reviewed as causes of groin pain.	Louisiana State Univ, Hlth Sci Ctr, Primary Care Sports Med Fellowship, Kenner, LA 70065 USA; Louisiana State Univ, Hlth Sci Ctr, Orthopaed Residency Program, Kenner, LA 70065 USA	Morelli, V (corresponding author), Louisiana State Univ, Hlth Sci Ctr, Primary Care Sports Med Fellowship, 200 W Esplanade Ave,Suite 412, Kenner, LA 70065 USA.	morellivincent@yahoo.com					Assouline-Dayan Y, 2002, SEMIN ARTHRITIS RHEU, V32, P94, DOI 10.1053/sarh.2002.33724; Baber YF, 1999, J BONE JOINT SURG BR, V81B, P600, DOI 10.1302/0301-620X.81B4.8803; Barile A, 2000, Radiol Med, V100, P216; Bencardino Jenny T, 2003, Top Magn Reson Imaging, V14, P145, DOI 10.1097/00002142-200304000-00004; Byrd JWT, 2004, ARTHROSCOPY, V20, P385, DOI 10.1016/j.arthro.2004.01.025; Byrd JWT, 2001, CLIN SPORT MED, V20, P801; Combs JA, 1998, MED SCI SPORT EXER, V30, P1561, DOI 10.1097/00005768-199811000-00001; COOPER DE, 1991, AM J SPORT MED, V19, P322, DOI 10.1177/036354659101900319; COVENTRY MB, 1961, JAMA-J AM MED ASSOC, V178, P898, DOI 10.1001/jama.1961.03040480028006; Deetz S., 1981, J APPLIED COMMUNICAT, V9, P1, DOI DOI 10.1080/00909888109360284; DIPAOLA J D, 1991, Arthroscopy, V7, P101, DOI 10.1016/0749-8063(91)90087-E; DORRELL JH, 1986, J BONE JOINT SURG BR, V68, P400; EDWARDS DJ, 1995, J BONE JOINT SURG BR, V77B, P374; EKBERG O, 1988, SPORTS MED, V6, P56, DOI 10.2165/00007256-198806010-00006; Eskridge C, 1997, J Perinatol, V17, P321; Farjo LA, 1999, ARTHROSCOPY, V15, P132, DOI 10.1053/ar.1999.v15.015013; FRICKER PA, 1991, SPORTS MED, V12, P266, DOI 10.2165/00007256-199112040-00005; Fricker PA, 1997, BRIT J SPORT MED, V31, P97, DOI 10.1136/bjsm.31.2.97; GLUECK CJ, 1995, AM J HEMATOL, V48, P213, DOI 10.1002/ajh.2830480402; GLUECK CJ, 1994, AM J HEMATOL, V45, P156, DOI 10.1002/ajh.2830450212; GRACE JN, 1989, J BONE JOINT SURG AM, V71A, P358, DOI 10.2106/00004623-198971030-00008; HARRIS NH, 1974, BRIT MED J, V4, P211, DOI 10.1136/bmj.4.5938.211; HEDSTROM SA, 1982, AM J SPORT MED, V10, P44, DOI 10.1177/036354658201000111; Hill PF, 1996, J BONE JOINT SURG BR, V78B, P383; HOLT MA, 1995, AM J SPORT MED, V23, P601, DOI 10.1177/036354659502300515; IKEDA T, 1988, J BONE JOINT SURG BR, V70, P13; Ishizaka M, 1997, CLIN ORTHOP RELAT R, P140, DOI 10.1097/00003086-199704000-00016; JACOBSON T, 1990, AM J SPORT MED, V18, P470, DOI 10.1177/036354659001800504; Janzen DL, 1996, CAN ASSOC RADIOL J, V47, P202; Johnston CAM, 1998, SPORTS MED, V25, P271, DOI 10.2165/00007256-199825040-00005; Karlsson J, 1997, SPORTS MED ARTHROSC, V5, P268; Kelly BT, 2003, AM J SPORT MED, V31, P1020, DOI 10.1177/03635465030310060701; Knight A, 2001, CAN MED ASSOC J, V165, P397; KOO KH, 1995, J BONE JOINT SURG BR, V77B, P870; Lage LA, 1996, ARTHROSCOPY, V12, P269, DOI 10.1016/S0749-8063(96)90057-2; LAORR A, 1995, SKELETAL RADIOL, V24, P239; Lavernia C J, 1999, J Am Acad Orthop Surg, V7, P250; LEE JK, 1988, RADIOLOGY, V169, P217, DOI 10.1148/radiology.169.1.3420261; Lynch SA, 1999, SPORTS MED, V28, P137, DOI 10.2165/00007256-199928020-00006; Maksymowych WP, 2001, J RHEUMATOL, V28, P2754; McCarthy J, 2003, CLIN ORTHOP RELAT R, P38, DOI 10.1097/01.blo.0000043042.84315.17; McCarthy JC, 2001, CLIN ORTHOP RELAT R, P25; McCarthy JC, 2001, J ARTHROPLASTY, V16, P81, DOI 10.1054/arth.2001.28370; Mitchell B, 2003, CLIN J SPORT MED, V13, P152, DOI 10.1097/00042752-200305000-00005; MONT MA, 1995, J BONE JOINT SURG AM, V77A, P459, DOI 10.2106/00004623-199503000-00018; Moore RS, 1998, J BONE JOINT SURG AM, V80A, P1043, DOI 10.2106/00004623-199807000-00013; Narvani AA, 2003, KNEE SURG SPORT TR A, V11, P403, DOI 10.1007/s00167-003-0390-7; NOCCION SL, 2003, DELEE DREZS ORTHOPAE, P1443; Ohashi K, 1997, RADIOL CLIN N AM, V35, P591; Pauli S, 2002, BRIT J SPORT MED, V36, P71, DOI 10.1136/bjsm.36.1.71; PETTINE KA, 1991, AM J SPORT MED, V19, P96, DOI 10.1177/036354659101900118; Rao J, 2001, CLIN SPORT MED, V20, P791, DOI 10.1016/S0278-5919(05)70285-4; Reichert-Penetrat S, 2001, DERMATOLOGY, V203, P356, DOI 10.1159/000051794; Renstrom PAFH, 1997, SPORTS MED ARTHROSC, V5, P247; Rijnen WHC, 2003, CLIN ORTHOP RELAT R, P74, DOI 10.1097/01.blo.0000096823.67494.64; Rolf C, 1997, SPORTS MED ARTHROSC, V5, P301; Roos HP, 1997, SPORTS MED ARTHROSC, V5, P292; Ross JJ, 2003, MEDICINE, V82, P340, DOI 10.1097/01.md.0000091180.93122.1c; Schmid MR, 2003, RADIOLOGY, V226, P382, DOI 10.1148/radiol.2262020019; Shin AY, 1996, AM J SPORT MED, V24, P168, DOI 10.1177/036354659602400209; Steinberg ME, 2001, CLIN ORTHOP RELAT R, P71; STEINBERG ME, 1995, J BONE JOINT SURG BR, V77B, P34; STULBERG BN, 1991, CLIN ORTHOP RELAT R, P140; Weaver CJ, 2002, AM J ROENTGENOL, V178, P973, DOI 10.2214/ajr.178.4.1780973; Westlin N, 1997, SPORTS MED ARTHROSC, V5, P280; Williams J G, 1978, Br J Sports Med, V12, P129; Williams PR, 2000, AM J SPORT MED, V28, P350, DOI 10.1177/03635465000280031101	67	23	23	0	18	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399 USA	0095-4543			PRIMARY CARE	Primary Care	MAR	2005	32	1					185	+		10.1016/j.pop.2004.11.012			17	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	925JF	WOS:000229048700010	15831318				2021-06-18	
J	Henry, GK				Henry, GK			Probable malingering and performance on the test of variables of attention	CLINICAL NEUROPSYCHOLOGIST			English	Article							TRAUMATIC BRAIN-INJURY; VERBAL-LEARNING TEST; HEAD-INJURY; ATTORNEYS	Fifty subjects with mild head injury involved in personal injury litigation and 2 subjects referred for evaluation of their disability status underwent comprehensive neuropsychological examination including the Test of Variables of Attention (TOVA). Group status was determined by performance on symptom validity testing. Twenty-six subjects who failed symptom validity testing formed the probable malingering (PM) group, while 26 subjects who passed symptom validity testing comprised the not malingering (NM) group. Subjects in the PM group performed significantly worse on all TOVA variables relative to subjects in the NM group. Discriminant function analyses revealed that TOVA omission errors >= 3 errors was the best predictor of group status. Malingering research employing a group of probable clinical malingerers has direct generalizability to real-world settings.	Los Angeles Neuropsychol Grp, Los Angeles, CA 90025 USA	Henry, GK (corresponding author), Los Angeles Neuropsychol Grp, 1950 Sawtelle Blvd,Suite 342, Los Angeles, CA 90025 USA.	GHenry0249@aol.com					Cohen J, 1988, STAT POWER BEHAV SCI; CONDER R, 1992, COMPUTERIZED ASSESSM; DIKMEN SS, 1995, NEUROPSYCHOLOGY, V9, P80, DOI 10.1037/0894-4105.9.1.80; Essig SM, 2001, ARCH CLIN NEUROPSYCH, V16, P271, DOI 10.1016/S0887-6177(99)00065-7; Green P, 1996, WORD MEMORY TEST; Greenberg L., 1996, TEST VARIABLES ATTEN; Greiffenstein M F, 1996, J Int Neuropsychol Soc, V2, P477; Guilmette TJ, 2004, ARCH CLIN NEUROPSYCH, V19, P183, DOI 10.1016/S0887-6177(03)00025-8; Kreutzer JS, 2003, J HEAD TRAUMA REHAB, V18, P128, DOI 10.1097/00001199-200303000-00004; Larrabee GJ, 2003, CLIN NEUROPSYCHOL, V17, P410, DOI 10.1076/clin.17.3.410.18089; Leark RA, 2002, ARCH CLIN NEUROPSYCH, V17, P335, DOI 10.1016/S0887-6177(01)00118-4; Millis SR, 1995, PSYCHOL ASSESSMENT, V7, P463; Millis SR, 2001, J HEAD TRAUMA REHAB, V16, P343, DOI 10.1097/00001199-200108000-00005; Mittenberg W, 1996, ARCH CLIN NEUROPSYCH, V11, P271, DOI 10.1016/0887-6177(95)00040-2; Mittenberg W, 2002, J CLIN EXP NEUROPSYC, V24, P1094, DOI 10.1076/jcen.24.8.1094.8379; Mittenberg W, 2001, CLIN NEUROPSYCHOL, V15, P440; Neter J., 1996, APPL LINEAR REGRESSI, V3rd ed; Rogers R, 2003, ASSESSMENT, V10, P160, DOI 10.1177/1073191103010002007; Rogers R., 1997, CLIN ASSESSMENT MALI, P398; Slick DJ, 1999, CLIN NEUROPSYCHOL, V13, P545, DOI 10.1076/1385-4046(199911)13:04;1-Y;FT545; Suhr JA, 1999, J CLIN EXP NEUROPSYC, V21, P701, DOI 10.1076/jcen.21.5.701.868; Sweet JJ, 2000, ARCH CLIN NEUROPSYCH, V15, P105, DOI 10.1016/S0887-6177(98)00153-X; Tombaugh TN, 1996, TEST MEMORY MALINGER; WETTER MW, 1995, PROF PSYCHOL-RES PR, V26, P474, DOI 10.1037/0735-7028.26.5.474	24	23	23	0	4	TAYLOR & FRANCIS INC	PHILADELPHIA	325 CHESTNUT ST, SUITE 800, PHILADELPHIA, PA 19106 USA	1385-4046			CLIN NEUROPSYCHOL	Clin. Neuropsychol.	FEB	2005	19	1					121	129		10.1080/13854040490516604			9	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	912YF	WOS:000228115300009	15814483				2021-06-18	
J	Cherington, M				Cherington, M			Spectrum of neurologic complications of lightning injuries	NEUROREHABILITATION			English	Article						lightning injuries; post-hypoxic encephalopathy; myelopathy; delayed syndromes; keraunoparalysis; neurorehabilitation; safety recommendations	SPINAL-CORD-INJURY; TRAUMATIC BRAIN-INJURY; LICHTENBERG FIGURES; ELECTRICAL INJURIES; STRIKE; ENCEPHALOPATHY	Lightning is responsible for a wide spectrum of neurologic complications. Many of the persistent symptoms require long-term neurorehabilitation. The lightning-related neurologic conditions are divided into four categories. Category I consists of signs and symptoms that are temporary and usually benign. Category II conditions are prolonged or permanent produced by significant central nervous system lesions. Two of the most devastating complications are lightning-related encephalopathy and myelopathy. The disabilities that accompany these lesions call for concentrated neurorehabilitation. A large number of patients are afflicted with neurobehavioral symptoms that may last for months or years. Category III contains delayed neurologic syndromes. Category IV encompasses neurologic lesions that are not directly activated by the lightning strike but are the result of trauma secondary to falls or blasts effects. The sensible course for individuals at risk is to learn and follow lightning safety recommendations.	St Anthony Hosp, Lightning Data Ctr, Denver, CO 80204 USA	Cherington, M (corresponding author), St Anthony Hosp, Lightning Data Ctr, 4231 W 16th Ave, Denver, CO 80204 USA.	Lightningdatacenter@Centura.org					Abrahamson J, 2000, NATURE, V403, P519, DOI 10.1038/35000525; ANDREWS C, 1995, SEMIN NEUROL, V15, P296, DOI 10.1055/s-2008-1041035; BLUMBERG MS, 2002, BODY HEAT; Brewer KL, 2004, ACAD EMERG MED, V11, P125, DOI 10.1197/j.aem.2003.09.010; Bychkov VL, 2002, PHILOS T ROY SOC A, V360, P37, DOI 10.1098/rsta.2001.0918; Chang BS, 2003, NEUROLOGY, V60, P10, DOI 10.1212/01.WNL.0000031432.05543.14; Charcot JM, 1889, B MED PARIS, V3, P1323; CHARCOT JM, 1890, WIEN MED WOCH, V40; CHERINGTON M, 1993, NEUROLOGY, V43, P1437, DOI 10.1212/WNL.43.7.1437; Cherington M, 2003, J BURN CARE REHABIL, V24, P175, DOI 10.1097/01.BCR.0000066783.15017.A4; Cherington M, 2003, INJURY, V34, P367, DOI 10.1016/S0020-1383(02)00313-3; Cherington M, 2003, NEUROLOGY, V60, P182, DOI 10.1212/01.WNL.0000033801.15204.B5; CHERINGTON M, 1995, SEMIN NEUROL, V15, P233, DOI 10.1055/s-2008-1041028; Cherington M, 2002, J TRAUMA, V52, P579, DOI 10.1097/00005373-200203000-00031; CHERINGTON M, 1990, PHYSICIAN SPORTSMED, V18, P58, DOI 10.1080/00913847.1990.11710113; CHERINGTON M, 1992, ANN EMERG MED, V21, P575, DOI 10.1016/S0196-0644(05)82529-6; Cherington M, 1999, 11 C APPL CLIM DALL, V10, P379; COHEN JA, 1995, SEMIN NEUROL, V15, P413; COOPER MA, 1980, ANN EMERG MED, V9, P134, DOI 10.1016/S0196-0644(80)80268-X; Coubrough Valerie, 2002, Axone, V23, P14; Critchley M, 1934, LANCET, V1, P68; Critchley Macdonald, 1932, Bristol Med Chir J (1883), V49, P285; CURRAN EB, 1997, SR193 NOAA NWS, P1; Curt A, 2004, SPINAL CORD, V42, P1, DOI 10.1038/sj.sc.3101558; DAVIDSON GS, 1988, ACTA NEUROPATHOL, V77, P104, DOI 10.1007/BF00688250; DMITRIEV MT, 1986, ORTOP TRAVMATOL PROT, V11, P66; Duff K, 2001, NEUROPSYCHOL REV, V11, P101, DOI 10.1023/A:1016623318049; Gilliam FG, 2004, NEUROLOGY, V62, P23, DOI 10.1212/WNL.62.1.23; Gunnarsson T, 2003, CURR OPIN NEUROL, V16, P717, DOI 10.1097/00019052-200312000-00012; Jafari H, 2001, J NEUROL NEUROSUR PS, V71, P265, DOI 10.1136/jnnp.71.2.265; LICHTENBERG R, 1993, J AM COLL CARDIOL, V21, P531, DOI 10.1016/0735-1097(93)90699-2; LOPEZ RE, 1993, B AM METEOROL SOC, V74, P2171, DOI 10.1175/1520-0477(1993)074<2171:TUOLIA>2.0.CO;2; LOPEZ RE, 1995, SEMIN NEUROL, V15, P286, DOI 10.1055/s-2008-1041034; MANN H, 1983, AM J NEURORADIOL, V4, P976; New PW, 2004, ARCH PHYS MED REHAB, V85, P87, DOI 10.1016/S0003-9993(03)00378-2; OZGUN B, 1995, AM J NEURORADIOL, V16, P1370; PRIMEAU M, 1995, SEMIN NEUROL, V15, P279, DOI 10.1055/s-2008-1041033; Resnik BI, 1996, AM J FOREN MED PATH, V17, P99, DOI 10.1097/00000433-199606000-00002; SHARMA M, 1978, BRIT MED J, V2, P1464, DOI 10.1136/bmj.2.6150.1464-a; Shmatov ML, 2003, J PLASMA PHYS, V69, P507, DOI 10.1017/S002237780300237X; Singer S, 2002, PHILOS T R SOC A, V360, P5, DOI 10.1098/rsta.2001.0916; STANLEY LD, 1985, NEUROSURGERY, V16, P686, DOI 10.1227/00006123-198505000-00020; STEINBAUM S, 1994, J TRAUMA, V36, P113, DOI 10.1097/00005373-199401000-00019; TENDUIS HJ, 1985, BURNS, V12, P54, DOI 10.1016/0305-4179(85)90183-4; TENDUIS HJ, 1987, BURNS, V13, P141, DOI 10.1016/0305-4179(87)90104-5; Tsuei BJ, 2004, INJURY, V35, P7, DOI 10.1016/S0020-1383(03)00309-7; WEERAMANTHRI TS, 1991, J ROY SOC MED, V84, P687; Wilson FC, 2003, NEUROREHABILITATION, V18, P291; Yarnell PR, 1995, SEMIN NEUROL, V15, P391, DOI 10.1055/s-2008-1041050; Zimmermann C, 2002, ANN EMERG MED, V39, P660, DOI 10.1067/mem.2002.124439	50	23	24	0	1	IOS PRESS	AMSTERDAM	NIEUWE HEMWEG 6B, 1013 BG AMSTERDAM, NETHERLANDS	1053-8135	1878-6448		NEUROREHABILITATION	Neurorehabilitation		2005	20	1					3	8					6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	912UL	WOS:000228105300002	15798349				2021-06-18	
J	Cristofori, L; Tavazzi, B; Gambin, R; Vagnozzi, R; Signoretti, S; Arnorini, AM; Fazzina, G; Lazzarino, G				Cristofori, L; Tavazzi, B; Gambin, R; Vagnozzi, R; Signoretti, S; Arnorini, AM; Fazzina, G; Lazzarino, G			Biochemical analysis of the cerebrospinal fluid: evidence for catastrophic energy failure and oxidative damage preceding brain death in severe head injury: a case report	CLINICAL BIOCHEMISTRY			English	Article						cerebrospinal fluid; energy metabolism; high-performance liquid chromatography; oxidative stress; traumatic brain injury	LIPID-PEROXIDATION; MITOCHONDRIAL DYSFUNCTION; GLUTAMATE; CHILDREN; INFANTS; ACID; RATS	Objectives: To compare biochemical and clinical parameters in a case of fatal severe traumatic brain injury (TBI) with secondary insult. Design and methods: A TBI patient was catheterized for intracranial pressure (ICP) monitoring and cerebrospinal fluid (CSF) analysis of ascorbate, malondialdehyde, oxypurines, and nucleosides. Results: Oxidative brain damage preceded ATP catabolite increment in the CSF even with ICP below 20 mm Hg. Sustained oxidative stress caused irreversible energy state derangement followed by a refractory ICP rise. Massive oxypurine and nucleoside release was recorded 36 h before brain death. Conclusions: Molecular events, detected by biochemical CSF analysis and preceding modification of clinical parameters in severe TBI with secondary insult, are discussed. (C) 2004 The Canadian Society of Clinical Chemists. All rights reserved.	Univ Catania, Dept Chem Sci, Biochem Lab, I-95125 Catania, Italy; Univ Hosp Verona, Dept Neurosurg, Verona, Italy; Catholic Univ Rome, Inst Biochem & Clin Biochem, Rome, Italy; Univ Roma Tor Vergata, Dept Neurosci, Chair Neurosurg, Rome, Italy; San Camillo Hosp, Dept Neurosci, Div Neurosurg, Rome, Italy	Lazzarino, G (corresponding author), Univ Catania, Dept Chem Sci, Biochem Lab, Viale A Doria 6, I-95125 Catania, Italy.	lazzarig@mbox.unict.it	TAVAZZI, BARBARA/AAB-9830-2019; Signoretti, stefano/AAL-5631-2020; lazzarino, giuseppe/K-2277-2015	TAVAZZI, BARBARA/0000-0001-8743-0895; Signoretti, stefano/0000-0002-8086-1622; AMORINI, Angela Maria/0000-0003-3525-9955; lazzarino, giuseppe/0000-0002-5917-7279			Bayir H, 2002, PEDIATR RES, V51, P571, DOI 10.1203/00006450-200205000-00005; Cristofori L, 2001, J INVEST MED, V49, P450, DOI 10.2310/6650.2001.33790; DIPIERRO D, 1995, ANAL BIOCHEM, V231, P407, DOI 10.1006/abio.1995.0071; LAZZARINO G, 1991, ANAL BIOCHEM, V197, P191, DOI 10.1016/0003-2697(91)90378-7; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Signoretti S, 2001, J NEUROTRAUM, V18, P977, DOI 10.1089/08977150152693683; SMITH SL, 1994, J NEUROTRAUM, V11, P393, DOI 10.1089/neu.1994.11.393; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; Vagnozzi R, 1999, J NEUROTRAUM, V16, P903, DOI 10.1089/neu.1999.16.903; Varma S, 2003, J NEUROTRAUM, V20, P781, DOI 10.1089/089771503767870005	10	23	23	0	0	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0009-9120	1873-2933		CLIN BIOCHEM	Clin. Biochem.	JAN	2005	38	1					97	100		10.1016/j.clinbiochem.2004.09.013			4	Medical Laboratory Technology	Medical Laboratory Technology	890IZ	WOS:000226506200017	15607325				2021-06-18	
J	Hirshberg, LM; Chiu, SF; Frazier, JA				Hirshberg, LM; Chiu, SF; Frazier, JA			Emerging brain-based interventions for children and adolescents: overview and clinical perspective	CHILD AND ADOLESCENT PSYCHIATRIC CLINICS OF NORTH AMERICA			English	Article							PSYCHOTHERAPY; DISORDER	Electroencephalogram biofeedback (EBF), repetitive transcranial magnetic stimulation (rTMS), and vagal nerve stimulation (VNS) are emerging interventions that attempt to directly impact brain function through neurostimulation and neurofeedback mechanisms. This article provides a brief overview of each of these techniques, summarizes the relevant research findings, and examines the implications of this research for practice standards based on the guidelines for recommending evidence based treatments as developed by the American Academy of Child and Adolescent Psychiatry for attention deficit hyperactivity disorder (ADHD). EBF meets the "Clinical Guidelines" standard for ADHD, seizure disorders, anxiety, depression, and traumatic brain injury. VNS meets this same standard for treatment of refractory epilepsy and meets the lower "Options" standard for several other disorders. rTMS meets the standard for "Clinical Guidelines" for bipolar disorder, unipoloar disorder, and schizophrenia. Several conditions are discussed regarding the use of evidence based thinking related to these emerging interventions and future directions.	Neurodev Ctr, Providence, RI 02903 USA; Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02912 USA; Univ Calif Davis, Dept Psychiat & Behav Sci, Sacramento, CA 95817 USA; Harvard Univ, Cambridge Hosp, Sch Med, Dept Psychiat, Cambridge, MA 02193 USA	Hirshberg, LM (corresponding author), Neurodev Ctr, 260 W Exchange St,Suite 302, Providence, RI 02903 USA.	lhirshberg@cox.net					Akshoomoff N, 2002, DEV PSYCHOPATHOL, V14, P613, DOI 10.1017/S0954579402003115; Barry RJ, 2003, CLIN NEUROPHYSIOL, V114, P184, DOI 10.1016/S1388-2457(02)00363-2; Benson K, 2000, NEW ENGL J MED, V342, P1878, DOI 10.1056/NEJM200006223422506; BLECKER C, 2004, HUM BRAIN MAPP C BUD; Britton A, 1998, HEAL TECHNOL ASSESS, V2, P1, DOI [10.1136/bmj.317.7167.1258a, DOI 10.1136/BMJ.317.7167.1258A]; Chambless D. L., 1998, CLIN PSYCHOL-UK, V51, P3, DOI DOI 10.1037/E619622010-001; Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7; Concato J, 2000, NEW ENGL J MED, V342, P1887, DOI 10.1056/NEJM200006223422507; DeCharms RC, 2004, NEUROIMAGE, V21, P436, DOI 10.1016/j.neuroimage.2003.08.041; Finitzo T, 2000, PEDIATRICS, V106, P798; GRINYATSENKO VA, 2001, HUM PHYSL, V27, P5; Hamilton JD, 2004, J AM ACAD CHILD PSY, V43, P105, DOI 10.1097/00004583-200401000-00020; Iakovenko E A, 2003, Fiziol Cheloveka, V29, P61; Jarusiewicz B., 2002, J NEUROTHER, V6, P39, DOI [DOI 10.1300/J184V06N04_05, 10.1300/J184v06n04_05]; Kiyatkin EA, 2002, EUR J NEUROSCI, V16, P164, DOI 10.1046/j.1460-9568.2002.02066.x; Kraemer HC, 2003, J AM ACAD CHILD PSY, V42, P1524, DOI 10.1097/00004583-200312000-00022; KROPOTOV JD, INT J PSYCHOPHYSIOL; Lambert MJ, 2001, PSYCHOTHERAPY, V38, P357, DOI 10.1037/0033-3204.38.4.357; LaVaque T.J., 2002, J NEUROTHERAPY, V6, P11; LEVANT R, CLIN PSYCHOL SCI PRA; Lewine JD, 2002, AM J PSYCHIAT, V159, P1689, DOI 10.1176/appi.ajp.159.10.1689; Nock MK, 2004, J AM ACAD CHILD PSY, V43, P777, DOI 10.1097/01.chi.0000120023.14101.58; Pascual-Marqui RD, 2002, METHOD FIND EXP CLIN, V24, P91; Ponomarev V. A., 1999, HUM PHYSL, V25, P143; Rieppi R, 2002, J AM ACAD CHILD PSY, V41, P269, DOI 10.1097/00004583-200203000-00006; Rohan M, 2004, AM J PSYCHIAT, V161, P93, DOI 10.1176/appi.ajp.161.1.93; SCHAMOWSKI F, 2004, HUM BRAIN MAPP C BUD; SELIGMAN MEP, 1995, AM PSYCHOL, V50, P965, DOI 10.1037/0003-066X.50.12.965; Shevelev IA, 1998, PROG NEUROBIOL, V56, P269, DOI 10.1016/S0301-0082(98)00038-0; Swerdlow B., 1991, HEADACHE Q-CURR TREA, V2, P96; Toomim H., 1999, BIOFEEDBACK, V27, P10; Weingarten K, 1998, FAM PROCESS, V37, P3, DOI 10.1111/j.1545-5300.1998.00003.x; Westen D, 2001, J CONSULT CLIN PSYCH, V69, P875, DOI 10.1037//0022-006X.69.6.875; Winterer G, 2004, AM J PSYCHIAT, V161, P490, DOI 10.1176/appi.ajp.161.3.490	34	23	23	0	22	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1056-4993	1558-0490		CHILD ADOL PSYCH CL	Child Adolesc. Psychiatr. N. Am.	JAN	2005	14	1					1	+		10.1016/j.chc.2004.07.011			20	Psychiatry	Psychiatry	883CS	WOS:000225988400003	15564050				2021-06-18	
J	Mussack, T; Briegel, J; Schelling, G; Biberthaler, P; Jochum, M				Mussack, T; Briegel, J; Schelling, G; Biberthaler, P; Jochum, M			Effect of stress doses of hydrocortisone on S-100B vs. interleukin-8 and polymorphonuclear elastase levels in human septic shock	CLINICAL CHEMISTRY AND LABORATORY MEDICINE			English	Article						cerebral ischemia; hydrocortisone; inflammation; septic shock; S-100B	SYSTEMIC INFLAMMATORY RESPONSE; TRAUMATIC BRAIN-INJURY; NEUROLOGICAL COMPLICATIONS; NEUROBIOCHEMICAL MARKERS; ORGAN FAILURE; DOUBLE-BLIND; HEAD TRAUMA; PROTEIN; SERUM; SEPSIS	Stress doses of hydrocortisone a re known to have immunomodulatory effects in patients with hyperdynamic septic shock. The prognosis correlates with the presence and severity of septic encephalopathy. However, neurological evaluation is influenced by the use of analgesia sedation during artificial ventilation. The objective of this study was to demonstrate the effect of stress doses of hydrocortisone during the initial phase of human septic shock on the serum values of the neurospecific protein S-100B in comparison to the inflammation markers interleukin (IL)-8 in serum and polymorphonuclear (PMN) elastase in plasma. A total of 24 consecutive patients, who met the American College of Chest Physicians/Society of Critical Care Medicine criteria for septic shock, were enrolled in this prospective, randomized, double-blind, single-center trial. The severity of illness at recruitment was graded using the Acute Physiology and Chronic Health Evaluation 11 and the Simplified Acute Physiology Score 11 scoring systems. Multi-organ dysfunction syndrome was described by the Sepsis-related Organ Failure Assessment (SOFA) score. All patients were prospectively randomized to receive either stress doses of hydrocortisone or placebo. Hydrocortisone was started in 12 patients with a loading dose of 100 mg and followed by a continuous infusion of 0.18 mg/kg/h for 6 days. Median S-100B serum levels of the hydrocortisone group decreased from 0.32 ng/mL at study entry to 0.07 ng/mL 6 days later without significant differences compared to the placebo group. Initial IL-8 serum levels were significantly higher in the hydrocortisone group up to 12 h after study entry, and significantly decreased from 715 to 17 pg/mL at the end of the observation period. Median PMN elastase plasma levels were not affected by hydrocortisone infusion. Patients with initial S-100B serum levels >0.50 ng/mL revealed significantly higher SOFA scores up to 30 h, IL-8 serum levels up to 12 h, and PMN elastase plasma levels up to 36 h after study entry than those patients with <= 0.50 ng/mL. These effects were independent of the amount of fluid correction for hemodilution. Starting S-100B, IL-8 and PMN elastase values of the hydrocortisone group were within the ranges already known in patients with out-of-hospital cardiac arrest or severe traumatic brain injury. Stress doses of hydrocortisone resulted in a significant reduction in IL-8 serum, but not in S-100B serum and PMN elastase plasma concentrations in patients with hyperdynamic septic shock. For the first time, a similar extent of S-100B increase in serum of septic patients at the time of diagnosis was shown as reported for cardiac arrest or severe traumatic brain injury.	Univ Munich Klinikum, Dept Surg Innenstadt, D-80336 Munich, Germany; Univ Munich Klinikum, Dept Anesthesiol Grosshadern, D-80336 Munich, Germany; Univ Munich Klinikum, Dept Clin Chem & Clin Biochem Innenstadt, D-80336 Munich, Germany	Mussack, T (corresponding author), Univ Munich Klinikum, Dept Surg Innenstadt, Nussbaumstr 20, D-80336 Munich, Germany.	thomas.mussack@med.uni-muenchen.de	Schelling, Gustav/U-2603-2018; Briegel, Josef/AAG-3774-2019	Schelling, Gustav/0000-0002-6538-0652; 			Anderson RE, 2001, ANN THORAC SURG, V71, P1512, DOI 10.1016/S0003-4975(01)02399-2; Annane D, 2002, JAMA-J AM MED ASSOC, V288, P862, DOI 10.1001/jama.288.7.862; Astudillo R, 1996, Eur J Cardiothorac Surg, V10, P1107, DOI 10.1016/S1010-7940(96)80358-7; Barie PS, 1998, J TRAUMA, V44, P1108, DOI 10.1097/00005373-199806000-00032; BARIE PS, 1994, J TRAUMA, V37, P660, DOI 10.1097/00005373-199410000-00022; BASTOS PG, 1993, CRIT CARE MED, V21, P1459, DOI 10.1097/00003246-199310000-00012; Bertsch T, 2001, CLIN CHEM LAB MED, V39, P319, DOI 10.1515/CCLM.2001.050; Blomquist S, 1997, J CARDIOTHOR VASC AN, V11, P699, DOI 10.1016/S1053-0770(97)90160-9; Bollaert PE, 1998, CRIT CARE MED, V26, P645, DOI 10.1097/00003246-199804000-00010; BOLTON CF, 1993, ANN NEUROL, V33, P94, DOI 10.1002/ana.410330115; Bolton CF, 1996, CRIT CARE MED, V24, P1408, DOI 10.1097/00003246-199608000-00022; BONE RC, 1992, CHEST, V101, P1644, DOI 10.1378/chest.101.6.1644; BRIEGEL J, 1994, CLIN INVESTIGATOR, V72, P782; Briegel J, 1999, CRIT CARE MED, V27, P723, DOI 10.1097/00003246-199904000-00025; Briegel J, 2001, J AM SOC NEPHROL, V12, pS70; BRIEGEL J, 1991, LANCET, V338, P507, DOI 10.1016/0140-6736(91)90575-A; Danielson D, 2001, Curr Opin Crit Care, V7, P367, DOI 10.1097/00075198-200110000-00009; Eidelman LA, 1996, JAMA-J AM MED ASSOC, V275, P470, DOI 10.1001/jama.275.6.470; ENDO S, 1995, J INFLAMM, V45, P136; HAIMOTO H, 1987, LAB INVEST, V57, P489; Herrmann M, 2000, J NEUROTRAUM, V17, P113, DOI 10.1089/neu.2000.17.113; Hollenberg SM, 2004, CRIT CARE MED, V32, P1928, DOI 10.1097/01.CCM.0000139761.05492.D6; Hund E, 2001, J NEUROL, V248, P929, DOI 10.1007/s004150170043; Hund E, 1999, CRIT CARE MED, V27, P2544, DOI 10.1097/00003246-199911000-00036; Jonsson H, 2000, J CARDIOTHOR VASC AN, V14, P698, DOI 10.1053/jcan.2000.18444; Keh D, 2003, AM J RESP CRIT CARE, V167, P512, DOI 10.1164/rccm.200205-446OC; Lindner A, 1998, INTERNIST, V39, P485, DOI 10.1007/s001080050200; MARSHALL JC, 1995, CRIT CARE MED, V23, P1638, DOI 10.1097/00003246-199510000-00007; METINKO AP, 1992, J CLIN INVEST, V90, P791, DOI 10.1172/JCI115953; MUNCK A, 1984, ENDOCR REV, V5, P25, DOI 10.1210/edrv-5-1-25; Mussack T, 2000, ACT NEUR S, V76, P393; Mussack T, 2001, RESUSCITATION, V49, P193, DOI 10.1016/S0300-9572(00)00346-4; Pelinka LE, 2003, BRIT J ANAESTH, V91, P595, DOI 10.1093/bja/aeg225; Pelinka LE, 2003, SHOCK, V19, P195, DOI 10.1097/00024382-200303000-00001; Rosen H, 1998, STROKE, V29, P473, DOI 10.1161/01.STR.29.2.473; Schwarz S, 1997, NERVENARZT, V68, P292, DOI 10.1007/s001150050127; Stanimirovic D, 2000, BRAIN PATHOL, V10, P113; USUI A, 1989, CLIN CHEM, V35, P1942; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; WAAGE A, 1988, IMMUNOLOGY, V63, P299; WEISS SJ, 1989, NEW ENGL J MED, V320, P365; Westaby S, 1996, ANN THORAC SURG, V61, P88, DOI 10.1016/0003-4975(95)00904-3; Wheeler AP, 1999, NEW ENGL J MED, V340, P207, DOI 10.1056/NEJM199901213400307; Wiesmann M, 1997, ACTA NEUROCHIR, V139, P1155, DOI 10.1007/BF01410976; Wunderlich MT, 1999, STROKE, V30, P1190, DOI 10.1161/01.STR.30.6.1190; YOUNG GB, 1990, CLIN INVEST MED, V13, P297	46	23	23	0	2	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	1434-6621	1437-4331		CLIN CHEM LAB MED	Clin. Chem. Lab. Med.		2005	43	3					259	268		10.1515/CCLM.2005.044			10	Medical Laboratory Technology	Medical Laboratory Technology	912FN	WOS:000228063100001	15843228				2021-06-18	
J	Muthukumar, N				Muthukumar, N			Uncommon cause of sinus thrombosis following closed mild head injury in a child	CHILDS NERVOUS SYSTEM			English	Article						antiphospholipid antibodies; cerebral venous thrombosis; fracture; magnetic resonance venography; mild head injury; thrombophilia		Object: Sinus thrombosis following a closed mild head injury is rare. A case of dural sinus thrombosis following a mild closed head injury due to an uncommon cause is reported. Methods: A 7-year-old child presented with GCS 15 after a road traffic accident. CT revealed an occipital fracture. Ten days later the child developed signs of increased intracranial pressure. An MR venogram at this time revealed thrombosis of the transverse sinus with hypoplasia of the contralateral transverse and sigmoid sinuses. The patient's anitiphospholipid antibody titres were elevated. The patient was treated with anticoagulants and improved. Conclusions: The role of inherited and acquired procoagulant factors in the aetiology of sinus thrombosis is increasingly being recognized. When a patient presents with sinus thrombosis after a closed mild head injury, it is necessary to investigate for the presence of risk factors for thrombophilia as it has implications for the long-term management of the patient.	Madurai Med Coll, Dept Neurosurg, Madurai 625020, Tamil Nadu, India	Muthukumar, N (corresponding author), Madurai Med Coll, Dept Neurosurg, Muruganagam,138,Anna Nagar, Madurai 625020, Tamil Nadu, India.	prasan86@eth.net					ABRAMSON N, 2001, SOUTH MED J, V94, P997; Brors M, 2001, NEURORADIOLOGY, V43, P144, DOI 10.1007/PL00006045; D'Alise MD, 1998, SURG NEUROL, V49, P430, DOI 10.1016/S0090-3019(97)00182-1; Ferrera PC, 1998, AM J EMERG MED, V16, P382, DOI 10.1016/S0735-6757(98)90134-6; Kuether TA, 1998, NEUROSURGERY, V42, P1163, DOI 10.1097/00006123-199805000-00129; Levine JS, 2002, NEW ENGL J MED, V346, P752, DOI 10.1056/NEJMra002974; Ochagavia AR, 1996, LANCET, V347, P1564, DOI 10.1016/S0140-6736(96)90721-7; RICH C, 1993, STROKE, V24, P603, DOI 10.1161/01.STR.24.4.603; Satoh H, 2000, NEUROL MED-CHIR, V40, P361, DOI 10.2176/nmc.40.361; Stiefel D, 2000, EUR J PEDIATR SURG, V10, P41, DOI 10.1055/s-2008-1072321; TAHA JM, 1993, NEUROSURGERY, V32, P541, DOI 10.1227/00006123-199304000-00008	11	23	25	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0256-7040	1433-0350		CHILD NERV SYST	Childs Nerv. Syst.	JAN	2005	21	1					86	88		10.1007/s00381-004-0926-2			3	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	889RN	WOS:000226460200019	15168052				2021-06-18	
J	Talbert, DG				Talbert, DG			Paroxysmal cough injury, vascular rupture and 'shaken baby syndrome'	MEDICAL HYPOTHESES			English	Article							RESPIRATORY-DISTRESS SYNDROME; BLOOD-FLOW VELOCITY; INTRAVENTRICULAR HEMORRHAGE; PULMONARY; INFANTS	It is widely assumed that subdural and retinal haemorrhage in infants can only result from traumatic rupture of vulnerable blood vessels. An alternative aetiology, that of vascular rupture resulting from excessive intraluminal pressure, is presented in three disease conditions. (1) Perlman et al., studying premature neonates requiring mechanical ventilation for respiratory distress syndrome, observed "cough-like" fluctuations in oesophageal pressure greater than 18 cms H2O, whose timing matched fluctuations in anterior cerebral artery flow. When 14 out of 24 neonates were paralysed (to prevent abdominal muscle activity) intraventricular haemorrhage developed in all 10 controls but in only one of the paralysed group during paralysis. (2) New analysis of pressure data extracted from a previous study of prolonged expiratory apnoea showed alveolar collapse induced 100 mmHg intrathoracic cough pressure surges. Superior vena cava pressures up to 50 mmHg were implied, and radial artery systolic pressures over 180 mmHg recorded. (3) Bordetella pertussis bacteria attach to cilia in the airways, but do not invade the underlying tissue. The irritation causes the powerful coughing paroxysms of whooping cough. Brain haemorrhages and retinal detachment have been observed to result from the high intravascular pressures produced. The data suggest that any source of intense airway irritation not easily removed (laryngeal infection, inhalation of regurgitated feed, fluff, smoke, etc.) could induce similar bleeding, a paroxysmal cough injury (PCI). Additional objective evidence of inflicted trauma is necessary to distinguish between 'shaken baby syndrome' and PCI. (C) 2004 Elsevier Ltd. All rights reserved.	Univ London Imperial Coll Sci Technol & Med, Queen Charlottes Hosp, Sch Med, Inst Reprod & Dev Biol, London W12 0NN, England	Talbert, DG (corresponding author), Univ London Imperial Coll Sci Technol & Med, Queen Charlottes Hosp, Sch Med, Inst Reprod & Dev Biol, Du Cane Rd, London W12 0NN, England.	d.talbert@imperial.ac.uk					BANNISTER R, 1996, OXFORD TXB MED, P3881; GANONG WF, 1987, REV MED PHYSL, P493; Geddes JF, 2003, NEUROPATH APPL NEURO, V29, P14, DOI 10.1046/j.1365-2990.2003.00434.x; HEISTAD DD, 1983, HDB PHYSL 2, V3, P137; LINNEMANN CC, 1996, OXFORD TXB MED, V7, P587; Lumb AB, 2000, NUNNS APPL RESP PHYS, P82; MCKENDRICK GDW, 1978, PRICES TXB PRACTICE, P49; MORSE SI, 1979, TXB MED, V203, P341; PERLMAN J, 1988, PEDIATRICS, V81, P399; PERLMAN JM, 1983, NEW ENGL J MED, V309, P204, DOI 10.1056/NEJM198307283090402; PERLMAN JM, 1985, NEW ENGL J MED, V312, P1353, DOI 10.1056/NEJM198505233122104; SADUN AS, 1988, DUANES CLIN OPTHALMO, V4, P1; SOUTHALL DP, LANCET, P571; SOUTHALL DP, 1987, CURRENT TOPICS PULMO, P210; SOUTHALL DP, 1990, ARCH DIS CHILD, V65, P935; WEST JB, 1991, J APPL PHYSIOL, V70, P1731; WIDDICOMBE JG, 1982, J EXP BIOL, V100, P41; WIDDICOMBE JG, 1986, RESP SYSTEM 1, V2, P363	18	23	23	1	3	CHURCHILL LIVINGSTONE	EDINBURGH	JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND	0306-9877			MED HYPOTHESES	Med. Hypotheses		2005	64	1					8	13		10.1016/j.mehy.2004.07.017			6	Medicine, Research & Experimental	Research & Experimental Medicine	876FH	WOS:000225481400002	15533602				2021-06-18	
J	Jokinen, H; Kalska, H; Ylikoski, R; Hietanen, M; Mantyla, R; Pohjasvaara, T; Kaste, M; Erkinjuntti, T				Jokinen, H; Kalska, H; Ylikoski, R; Hietanen, M; Mantyla, R; Pohjasvaara, T; Kaste, M; Erkinjuntti, T			Medial temporal lobe atrophy and memory deficits in elderly stroke patients	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						aging; cognition; medial temporal lobe atrophy; memory; stroke	PROBABLE ALZHEIMERS-DISEASE; TRAUMATIC BRAIN INJURY; VASCULAR DEMENTIA; COGNITIVE IMPAIRMENT; ENTORHINAL CORTEX; ISCHEMIC-STROKE; LEWY BODIES; MRI; HIPPOCAMPAL; DEPRESSION	Medial temporal lobe atrophy (MTA) and its role in memory deficits have been studied extensively in patients with various dementias and non-degenerative neurologic diseases. In stroke patients MTA is a significant risk factor for dementia. However, its role in memory decline in non-demented stroke patients is not yet known. Our aim was to evaluate the relationship between MTA and cognitive functions in a large cohort of elderly patients, who underwent a comprehensive neuropsychologic examination and magnetic resonance imaging 3 months after an ischemic stroke. The study sample (n = 260) was divided into three groups according to the severity of MTA. After adjusting for age, volume of infarcts and cortical atrophy, we found that patients with moderate to severe MTA performed significantly worse in tests of learning, story recall, visual reproduction, block design and mental speed. In contrast, the groups did not differ in tests of digit span, flexibility, verbal fluency and conceptualization. Our conclusion is that in aged stroke patients, MTA is associated with poor performance in specific cognitive domains. The most vulnerable domains are memory and visuospatial functions, whereas verbal and executive functions seem to be unrelated to MTA.	Univ Helsinki, Cent Hosp, Dept Neurol, Unit Neuropsychol, FIN-00029 Helsinki, Finland; Univ Helsinki, Dept Psychol, SF-00100 Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Radiol, Helsinki, Finland; Univ Helsinki, Cent Hosp, Dept Neurol, Memory Res Unit, Helsinki, Finland; Lohja Dist Hosp, Helsinki, Finland	Jokinen, H (corresponding author), Univ Helsinki, Cent Hosp, Dept Neurol, Unit Neuropsychol, POB 302, FIN-00029 Helsinki, Finland.	hanna.jokinen@helsinki.fi	Jokinen, Hanna/AAG-5863-2019	Jokinen, Hanna/0000-0001-7889-1120; Kaste, Markku/0000-0001-6557-6412			*AM PSYCH ASS, 1987, AM PSYCH ASS COMM NO; Barba R, 2001, CEREBROVASC DIS, V11, P216, DOI 10.1159/000047642; Barber R, 1999, NEUROLOGY, V52, P1153, DOI 10.1212/WNL.52.6.1153; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bigler ED, 2002, AM J NEURORADIOL, V23, P255; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; DESMOND PM, 1994, AUST NZ J MED, V24, P547, DOI 10.1111/j.1445-5994.1994.tb01756.x; DEWEER B, 1995, J NEUROL NEUROSUR PS, V58, P590, DOI 10.1136/jnnp.58.5.590; Du AT, 2002, NEUROLOGY, V58, P1635, DOI 10.1212/WNL.58.11.1635; Eichenbaum H, 1997, ANNU REV PSYCHOL, V48, P547, DOI 10.1146/annurev.psych.48.1.547; ERKINJUNTTI T, 1993, ARCH NEUROL-CHICAGO, V50, P305, DOI 10.1001/archneur.1993.00540030069017; Fein G, 2000, NEUROLOGY, V55, P1626, DOI 10.1212/WNL.55.11.1626; FULD PA, 1982, FULD OBJECT MEMORY E; Goodglass H., 1983, ASSESSMENT APHASIA R; Hashimoto M, 1998, NEUROLOGY, V51, P357, DOI 10.1212/WNL.51.2.357; Henon H, 1998, J NEUROL NEUROSUR PS, V65, P641, DOI 10.1136/jnnp.65.5.641; Kalaria RN, 2000, NEUROBIOL AGING, V21, P321, DOI 10.1016/S0197-4580(00)00125-1; Kril JJ, 2002, J NEUROL NEUROSUR PS, V72, P747, DOI 10.1136/jnnp.72.6.747; Laakso MP, 2000, BIOL PSYCHIAT, V47, P1056, DOI 10.1016/S0006-3223(99)00306-6; Laakso MP, 1996, NEUROLOGY, V46, P678, DOI 10.1212/WNL.46.3.678; LENCZ T, 1992, ANN NEUROL, V31, P629, DOI 10.1002/ana.410310610; Leskela M, 1999, EUR J NEUROL, V6, P653, DOI 10.1046/j.1468-1331.1999.660653.x; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; Mantyla R, 2000, STROKE, V31, P695, DOI 10.1161/01.STR.31.3.695; MILLER LA, 1993, ARCH NEUROL-CHICAGO, V50, P391, DOI 10.1001/archneur.1993.00540040051014; Mizuno K, 2000, J NEUROL SCI, V173, P18, DOI 10.1016/S0022-510X(99)00289-0; Mori E, 1997, J NEUROL NEUROSUR PS, V63, P214, DOI 10.1136/jnnp.63.2.214; OBrien JT, 1997, PSYCHOL MED, V27, P1267, DOI 10.1017/S0033291797005606; Pohjasvaara T, 1999, J NEUROL NEUROSUR PS, V67, P742, DOI 10.1136/jnnp.67.6.742; Pohjasvaara T, 2000, ARCH NEUROL-CHICAGO, V57, P1295, DOI 10.1001/archneur.57.9.1295; Pohjasvaara T, 1997, STROKE, V28, P785, DOI 10.1161/01.STR.28.4.785; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; SASS KJ, 1990, NEUROLOGY, V40, P1694, DOI 10.1212/WNL.40.11.1694; SCHELTENS P, 1992, J NEUROL NEUROSUR PS, V55, P967, DOI 10.1136/jnnp.55.10.967; SCOVILLE WB, 1957, J NEUROL NEUROSUR PS, V20, P11, DOI 10.1136/jnnp.20.1.11; SQUIRE LR, 1991, SCIENCE, V253, P1380, DOI 10.1126/science.1896849; Visser PJ, 2002, J NEUROL NEUROSUR PS, V72, P491; Wahlund LO, 2000, J NEUROL NEUROSUR PS, V69, P630, DOI 10.1136/jnnp.69.5.630; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WMS R WECHSLER MEMOR; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223	41	23	23	0	1	BLACKWELL PUBLISHING LTD	OXFORD	9600 GARSINGTON RD, OXFORD OX4 2DG, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	DEC	2004	11	12					825	832		10.1111/j.1468-1331.2004.00870.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	878AA	WOS:000225616900005	15667413				2021-06-18	
J	Sommer, JL; Witkiewicz, PM				Sommer, JL; Witkiewicz, PM			The therapeutic challenges of dual diagnosis: TBI/SCI	BRAIN INJURY			English	Article							SPINAL-CORD-INJURY; HEAD-INJURY	Rehabilitation centres provide therapeutic intervention to both patients with traumatic brain injury (TBI) and spinal cord injury (SCI). Patients with a dual diagnosis of TBI and SCI present a challenge to the rehabilitation professional. Previous studies indicate an incidence of concomitant TBI and SCI to be between 24-59%. Many research articles discuss how a diagnosis of TBI is often missed during the medical examination of a person with a suspected SCI. This article will focus on the implications of dual diagnosis encountered during the rehabilitation process. A case study is used to highlight the challenges presented by the cognitive impairments of a TBI in combination with the motoric deficits of SCI. Management strategies utilised by the rehabilitation team are discussed.	Virginia Commonwealth Univ, Med Ctr, North Hosp, Rehabil & Res Ctr, Richmond, VA 23298 USA	Sommer, JL (corresponding author), Virginia Commonwealth Univ, Med Ctr, North Hosp, Rehabil & Res Ctr, 1st Floor,13th & Marshall St,POB 960661, Richmond, VA 23298 USA.	jsommer@mail2.vcu.edu					*ASIA, 1992, STAND NEUR FUNCT CLA; DAVIDOFF G, 1985, ARCH PHYS MED REHAB, V66, P41; DAVIDOFF GN, 1992, ARCH PHYS MED REHAB, V73, P275; Elovic E, 1999, TOP SPINAL CORD INJ, V5, P1, DOI DOI 10.1310/V75J-RE76-20GH-X7BY; Fee FA, 1995, SCI PSYCHOSOCIAL PRO, V8, P106; GRIEVE J, 1999, NEUROPSYCHOLOGY OCCU; GUTMAN SA, 2001, CE18 AOTA CONT ED; Hammond MC, 2000, YES YOU CAN GUIDE SE; Iida H, 1999, J TRAUMA, V46, P450, DOI 10.1097/00005373-199903000-00018; Lemke D M, 1995, SCI Nurs, V12, P40; NEIMIER JP, 1 STEPS REC BRAIN IN; NOLDELOPEZ G, 1995, ADV REHABILITATION, V4, P65; PEDRETTI LW, 1996, OCCUPATIONAL THERAPY, P765; POVOLNY MA, 1993, J REHABIL, V59, P22; *RANCH LOS AM MED, 1980, LEV COGN FUNCT; RICHARDS JS, 1991, ARCH PHYS MED REHAB, V72, P275; RICKER HJ, 1999, TOPICS SPINAL CORD I, V5, P76; Ricker J.H., 1999, TOP SPINAL CORD INJ, V5, P76; Stutts M, 1991, NEUROREHABILITATION, V1; TROSPER RM, 2000, SCI PSYCHOSOCIAL PRO, V13, P1; WAGNER KA, 1984, ASIA ABSTR DIG, P1096; Watanabe T, 1999, TOP SPINAL CORD INJ, V5, P83; WILMOT CB, 1985, ARCH PHYS MED REHAB, V66, P227, DOI 10.1016/0003-9993(85)90148-0; Wilson BA, 1996, J HEAD TRAUMA REHAB, V11, P54, DOI 10.1097/00001199-199604000-00006	24	23	23	0	1	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	2004	18	12					1297	1308		10.1080/02699050410001672288			12	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	871BW	WOS:000225105300010	15666572				2021-06-18	
J	Denes, Z				Denes, Z			The influence of severe malnutrition on rehabilitation in patients with severe head injury	DISABILITY AND REHABILITATION			English	Article								Objective: The purpose of the study was to evaluate the consequences of severe malnutrition in patients with severe head injury during rehabilitation. Patients and methods: The data were collected from medical records of patients admitted to the neurorehabilitation unit over the last 5 years. Twenty of 1850 patients had severe malnutrion, the body mass index (BMI) of these patients were under 15 (10 - 14) kg/m(2). The majority of patients suffered traumatic brain damage (17/20). Thirteen patients arrived with percutaneous endoscopic gastrotomy / PEG, three nasogastric tube in 3 cases we placed PEG. The nutritional strategy included a high-calorie diet, by means of bolus feeding five times during the day, continuous feeding during the night; the daily intake target being more than 2500 kcal. Results: During rehabilitation treatment the majority of patients (13/20) revealed weight gain with a rate of 0.5-2 kg/week. The following complications were treated during the rehabilitation phase: 20 pressure sores, 20 contractures, 11 urinal infections, 6 cases of pneumonia, 2 of purulent bronchitis, 6 of sepsis, 1 penoscrotal abscess, epidydymitis, and 1 case of purulent arthritis. The patients required total assistance at the time of admission. At discharge 10 patients remained completely dependent, 6 patients needed minimal assistance, and 4 patients could perform daily activities independently. The average length of stay in our unit was 78/6 - 150/days. Conclusion: Patients with head injury suffering from severe malnutrition exhibit serious complications at the time of admission as well as during rehabilitation treatment. The patients were very difficult to mobilize. The length of stay at the rehabilitation unit was 28 days longer when complicated by malnutrition, than head injuries showing normal nutritional status. These findings underline the importance of adequate nutrition in patients with head injury in both the acute ward and in the rehabilitation unit.	Natl Inst Med Rehabil, H-1528 Budapest, Hungary	Denes, Z (corresponding author), Natl Inst Med Rehabil, 12 Szanatorium 19, H-1528 Budapest, Hungary.	z.denes@rehabint.hu					Annoni JM, 1998, DISABIL REHABIL, V20, P308, DOI 10.3109/09638289809166086; BROOKE MM, 1989, J NEUROL REHABIL, V3, P27; DENES Z, 1997, REHABILITACIO, V7, P2; MAHONEY F I, 1965, Md State Med J, V14, P61; SACKS GS, 1995, JPEN-PARENTER ENTER, V19, P387, DOI 10.1177/0148607195019005387; *STAT U NEW YORK B, 1990, GUID US UN DAT SET M; Suchner U, 1996, NUTRITION, V12, P13, DOI 10.1016/0899-9007(95)00016-X; WEEKES E, 1996, JPEN, V24, P31	8	23	25	0	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	OCT 7	2004	26	19					1163	1165		10.1080/09638280412331270380			3	Rehabilitation	Rehabilitation	852QR	WOS:000223772000007	15371030				2021-06-18	
J	Dedoukou, X; Spyridopoulos, T; Kedikoglou, S; Alexe, DM; Dessypris, N; Petridou, E				Dedoukou, X; Spyridopoulos, T; Kedikoglou, S; Alexe, DM; Dessypris, N; Petridou, E			Incidence and risk factors of fall injuries among infants	ARCHIVES OF PEDIATRICS & ADOLESCENT MEDICINE			English	Article							YOUNG-CHILDREN; ABUSE	Objective: To assess the incidence of fall injuries among infants in Greece, overall and by type of nursery equipment. Design: Review of data from a large injury database. Setting: The Emergency Department Injury Surveillance System in Greece. Patients: A total of 2672 injured infants. Interventions: Specially trained health visitors performed in-person interviews with the children's guardians, using a preceded questionnaire. The results of an independent survey of 777 mothers of noninjured children younger than 2 years attending the same emergency departments were used to allow quantification of the role of specific nursery equipment in the causation of infant fall injuries. Main Outcome Measures: Annual rate of injury by falling in infants, overall and by cause. Results: About 4400 infant fall injuries occur annually in Greece, corresponding to an annual incidence rate of 44 injuries per 1000 infants. The incidence of falls increases with increasing infant age. A high percentage of severe injuries was detected, most of them concussions (14.3%) and fractures (9.4%). Approximately 10% of infants with fall-related injuries required hospitalization. More than 36% of fall injuries involved nursery equipment. Infant walker use was associated with a higher incidence of falls (about 9 per 1000 infant-years), and these falls occasionally involved stairs and caused serious injuries. Infant bouncers, strollers, and changing tables were all associated with a similar incidence of falls (about 4 per 1000 infant-years). Conclusions: Falls are a common cause of serious infant injuries, and nursery equipment is frequently involved in the injury-causing event.	Univ Athens, Sch Med, Dept Hyg & Epidemiol, Athens 11527, Greece; Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA	Petridou, E (corresponding author), Univ Athens, Sch Med, Dept Hyg & Epidemiol, 75 Mikras Asias Str, Athens 11527, Greece.	epetrid@med.uoa.gr		PETRIDOU, ELENI/0000-0003-3695-3439			[Anonymous], Leading causes of death.; Bull MJ, 2001, PEDIATRICS, V108, P790; CHIAVIELLO CT, 1994, PEDIATRICS, V93, P974; Conners GP, 2002, PATIENT EDUC COUNS, V46, P169, DOI 10.1016/S0738-3991(01)00210-5; DALTON HJ, 1990, AM J DIS CHILD, V144, P875, DOI 10.1001/archpedi.1990.02150320039022; Dessypris N, 2002, J Cancer Epidemiol Prev, V7, P123; Emanuelson I, 2003, Inj Control Saf Promot, V10, P139, DOI 10.1076/icsp.10.3.139.14553; Krug EG, 2000, AM J PUBLIC HEALTH, V90, P523, DOI 10.2105/AJPH.90.4.523; Kypri K, 2001, J PAEDIATR CHILD H, V37, P603, DOI 10.1046/j.1440-1754.2001.0776b.x; Macgregor D M, 2000, Inj Prev, V6, P291, DOI 10.1136/ip.6.4.291; Mathers LJ, 1998, ACAD EMERG MED, V5, P1064, DOI 10.1111/j.1553-2712.1998.tb02663.x; Mayr JM, 1999, ACTA PAEDIATR, V88, P319, DOI 10.1080/08035259950170105; *NAT CTR INJ PREV, 2001, UN FALL DEATHS RAT 1; *NAT STAT SERV GRE, 1998, NAT MOV POP GREEC, P129; Petridou E, 1996, Inj Prev, V2, P118, DOI 10.1136/ip.2.2.118; Powell EC, 2002, AMBUL PEDIATR, V2, P276, DOI 10.1367/1539-4409(2002)002<0276:IADOHC>2.0.CO;2; Ridenour MV, 1999, PERCEPT MOTOR SKILL, V88, P669; SHENDUT IH, 1995, MED J MALAYSIA, V50, P192; Smith GA, 1997, PEDIATRICS, V100, DOI 10.1542/peds.100.2.e1; Tarantino CA, 1999, PEDIATR EMERG CARE, V15, P5, DOI 10.1097/00006565-199902000-00002; THOMAS SA, 1991, PEDIATRICS, V88, P471; Trogan I, 2001, ARCH DIS CHILD, V85, P289, DOI 10.1136/adc.85.4.289; WATSON WL, 1993, J PAEDIATR CHILD H, V29, P228, DOI 10.1111/j.1440-1754.1993.tb00493.x; *WHO, 2003, WORLD HLTH REP 2002; Wickham T, 2002, ARCH DIS CHILD, V86, P168, DOI 10.1136/adc.86.3.168; World Health Organization, 2014, WHO STAT INF SYST WH; 10 LEADING CAUSES HO; FALL PREVENTION CHIL; FALL PREVENTION INFA	29	23	24	0	3	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	1072-4710	1538-3628		ARCH PEDIAT ADOL MED	Arch. Pediatr. Adolesc. Med.	OCT	2004	158	10					1002	1006		10.1001/archpedi.158.10.1002			5	Pediatrics	Pediatrics	859PA	WOS:000224279200010	15466690	Bronze, Green Accepted			2021-06-18	
J	Crookes, BA; Cohn, SM; Bonet, H; Burton, EA; Nelson, J; Majetschak, M; Varon, AJ; Linden, JM; Proctor, KG				Crookes, BA; Cohn, SM; Bonet, H; Burton, EA; Nelson, J; Majetschak, M; Varon, AJ; Linden, JM; Proctor, KG			Building a better fluid for emergency resuscitation of traumatic brain injury	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	62nd Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 11-13, 2003	MINNEAPOLIS, MN	Amer Assoc Surg Trauma		Hemorrhagic Shock; adenosine; ATL-146e; A2A receptor; Hextend Swine	ADENOSINE RECEPTOR AGONISTS; SPINAL-CORD ISCHEMIA; REPERFUSION INJURY; HEMORRHAGIC-SHOCK; REDUCES PARALYSIS; A(2A) AGONIST; SALINE; PROTECTION; RABBIT; INFLAMMATION	Hextend (HEX) is a colloid solution that is FDA-approved for volume expansion during surgery. ATL-146e is a novel adenosine A2A receptor agonist that has anti-inflammatory, neuroprotective, and coronary vasodilator properties. Three series of experiments were designed to evaluate the therapeutic potential of HEX ATL-146e for emergency resuscitation from traumatic brain injury (TBI) + hemorrhagic hypotension. Methods: In the first two studies in vivo, anesthetized, ventilated pigs (30-45 kg) received a fluid percussion TBI, 45% arterial hemorrhage, and 30 minutes shock period. In Series 1, resuscitation consisted of unlimited crystalloid (n = 8) or HEX (n = 8) to correct systolic arterial pressure > 100 mm Hg and heart rate < 100 bpm for the first 60 minutes ("emergency phase"), and then maintain cerebral perfusion pressure (CPP) > 70 mm Hg for 60-240 minutes. In Series 2 (n = 31), resuscitation consisted of a 1 L bolus of HEX + ATL-146e (10 ng/kg/min, n = 10) or HEX +placebo (n = 10) followed by crystalloid to the same endpoints. In Series 3 in vivo, the hemodynamic response evoked by 0, 10, 50, or 100 ng/kg/min ATL-146e was measured before or 60 minutes after HEX resuscitation from 45% hemorrhage. Results: Following TBI+hemorrhage, there were 4/22 deaths in series 1 and 11/31 deaths in series 2. In those alive at 30 minutes, mean arterial pressure, cardiac index, mixed venous 02 saturation, and cerebral venous 0, saturation were all reduced by 40-60%, while heart rate and lactate were increased 2-5 fold. With no resuscitation (n = 2), there was minimal hemodynamic compensation and progressive acidosis. Upon resuscitation, these values corrected but intracranial pressure progressively rose from <5 nun Hg to 15-20 nun Hg. Series 1: With HEX m = 8) versus crystalloid (n = 8), CPP was less labile, acid/base was maintained, and the fluid requirement was reduced by 60% (all p < 0.05) Series 2: With ATL-146e (n = 10) versus placebo (n = 10), stroke volume and cardiac output were improved by 40-60%, and the fluid requirement was reduced by 30% (all p < 0.05). Series 3: ATL-146e caused a dose-related increase (p < 0.05) in stroke volume after, but not before, hemorrhage. The effects on preload, afterload, and heart rate were similar before and after hemorrhage. Conclusions: HEX alone is a safe and efficacious low volume alternative to initial crystalloid resuscitation after TBI. An adenosine A2A agonist combined with I L of HEX safely and effectively counteracted a decrease in cardiac performance noted after TBI + hemorrhage without causing hypotension or bradycardia.	Univ Miami, Sch Med, Dept Surg, Div Trauma, Miami, FL 33101 USA; Univ Miami, Sch Med, Dept Surg, Div Surg Crit Care, Miami, FL USA; Univ Miami, Sch Med, Dept Anesthesiol, Miami, FL USA; Univ Miami, Sch Med, Dept Med, Miami, FL USA; Univ Virginia, Sch Med, Charlottesville, VA 22908 USA	Proctor, KG (corresponding author), Univ Miami, Sch Med, Dept Surg, Div Trauma, Miami, FL 33101 USA.	kproctor@miami.edu	Linden, Joel/AAH-5690-2020				Bell MJ, 2001, CRIT CARE MED, V29, P399, DOI 10.1097/00003246-200102000-00033; Bowen TE, 1988, EMERGENCY WAR SURG; *BRAIN TRAUM FDN, GUID PREH MAN TRAUM; Cassada DC, 2002, J VASC SURG, V35, P994, DOI 10.1067/mva.2002.123091; Cassada DC, 2002, J TRAUMA, V53, P225, DOI 10.1097/00005373-200208000-00005; Cassada DC, 2001, ANN THORAC SURG, V72, P1245, DOI 10.1016/S0003-4975(01)03057-0; Cassada DC, 2001, J VASC SURG, V34, P482, DOI 10.1067/mva.2001.117996; Cassada DC, 2001, SURGERY, V130, P230, DOI 10.1067/msy.2001.115838; Cassada DC, 2002, ANN THORAC SURG, V74, P846, DOI 10.1016/S0003-4975(02)03793-1; Dunwiddie TV, 2001, ANNU REV NEUROSCI, V24, P31, DOI 10.1146/annurev.neuro.24.1.31; Fabian MJ, 2002, J TRAUMA, V53, P864, DOI 10.1097/00005373-200211000-00010; Gan TJ, 1999, ANESTH ANALG, V88, P992, DOI 10.1097/00000539-199905000-00005; Gibson JB, 2002, SHOCK, V17, P234, DOI 10.1097/00024382-200203000-00013; Glass TF, 1999, J NEUROTRAUM, V16, P771, DOI 10.1089/neu.1999.16.771; Glass TF, 2001, J NEUROTRAUM, V18, P57, DOI 10.1089/089771501750055776; Glover DK, 2001, CIRCULATION, V104, P1181, DOI 10.1161/hc3601.093983; Hartl R, 1997, ACT NEUR S, V70, P126; Kelly ME, 2003, J TRAUMA, V55, P94, DOI 10.1097/01.TA.0000029042.37577.A6; KING DR, IN PRESS SURGERY; Linden J, 2001, ANNU REV PHARMACOL, V41, P775, DOI 10.1146/annurev.pharmtox.41.1.775; Mangano DT, 1997, JAMA-J AM MED ASSOC, V277, P325, DOI 10.1001/jama.277.4.325; MATTOX KL, 1991, ANN SURG, V213, P482, DOI 10.1097/00000658-199105000-00014; MAZZONI MC, 1990, CIRC SHOCK, V31, P407; McPherson JA, 2001, ARTERIOSCL THROM VAS, V21, P791, DOI 10.1161/01.ATV.21.5.791; MENASCHE P, 1995, J THORAC CARDIOV SUR, V110, P1096, DOI 10.1016/S0022-5223(05)80179-5; Murphree LJ, 2002, MOL PHARMACOL, V61, P455, DOI 10.1124/mol.61.2.455; Obata T, 2002, LIFE SCI, V71, P2083, DOI 10.1016/S0024-3205(02)01993-8; Ongini E, 2001, FARMACO, V56, P87, DOI 10.1016/S0014-827X(01)01024-2; Peirce SM, 2001, AM J PHYSIOL-HEART C, V281, pH67; POPE A, 1999, FLUID RES STAT SCI T; Rieger JM, 2001, J MED CHEM, V44, P531, DOI 10.1021/jm0003642; Riou LM, 2002, J AM COLL CARDIOL, V40, P1687, DOI 10.1016/S0735-1097(02)02372-0; Robertson CS, 1999, CRIT CARE MED, V27, P2086, DOI 10.1097/00003246-199910000-00002; Stone TW, 2002, ADV EXP MED BIOL, V513, P249; Wade CE, 1997, J TRAUMA, V42, pS61, DOI 10.1097/00005373-199705001-00011; Wilkes NJ, 2002, ANESTH ANALG, V94, P538, DOI 10.1097/00000539-200203000-00011; Wilkes NJ, 2001, ANESTH ANALG, V93, P811, DOI 10.1097/00000539-200110000-00003	37	23	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	SEP	2004	57	3					547	554		10.1097/01.TA.0000135162.85859.4C			8	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	859YH	WOS:000224303800017	15454801				2021-06-18	
J	Fujihara, S; Brucki, SMD; Rocha, MSG; Carvalho, AA; Piccolo, AC				Fujihara, S; Brucki, SMD; Rocha, MSG; Carvalho, AA; Piccolo, AC			Prevalence of presenile dementia in a tertiary outpatient clinic	ARQUIVOS DE NEURO-PSIQUIATRIA			English	Article						presenile dementia; vascular dementia; Alzheimer's disease; epidemiology	INTERNATIONAL WORKSHOP; VASCULAR DEMENTIA; FRONTOTEMPORAL DEMENTIA; ALZHEIMERS-DISEASE; DIAGNOSIS; SERVICES; CRITERIA; BRAZIL; YOUNG	There are very few reports about prevalence of presenile dementia in Brazil. We reviewed files of patients evaluated with early onset of cognitive impairment in our institution. Among 141 patients (61% males) there was no difference between gender by age at onset or at first evaluation. We have observed an increasing number of patients after 50 years. The most frequent causes were: vascular dementia (36.9%), Alzheimer's disease (20.3%) and traumatic brain injury (9.2%). There was difference among dementia type by age of onset and first evaluation, educational level and length of dementia. These results may be compared with those from other neurologic services in order to replicate or confirm these results.	Hosp Santa Marcelina, Sao Paulo, Brazil	Fujihara, S (corresponding author), Rua Humberto Primo 740-123, BR-04018032 Sao Paulo, Brazil.	sbrucki@uol.com.br	ROCHA, MARIA SHEILA G/G-6645-2012; ROCHA, MARIA SHEILA GUIMARAES/AAK-7584-2020; Brucki, Sonia MD/B-5736-2014; Brucki, Sonia/L-4201-2019	ROCHA, MARIA SHEILA G/0000-0003-4312-3994; ROCHA, MARIA SHEILA GUIMARAES/0000-0003-4312-3994; Brucki, Sonia MD/0000-0002-8303-6732; Brucki, Sonia/0000-0002-8303-6732			Brucki SMD, 2003, ARQ NEURO-PSIQUIAT, V61, P777, DOI 10.1590/S0004-282X2003000500014; BRUN A, 1994, J NEUROL NEUROSUR PS, V57, P416; CAIXETA L, 2003, ARQ NEUROPSIQUIAT S2, V61, pS19; CANINEU PR, 2003, ARQ NEURO-PSIQUIAT, V61, pS21; DELANY N, 1995, INT J GERIATR PSYCH, V10, P597, DOI 10.1002/gps.930100710; Elberling TV, 2002, NEUROLOGY, V59, P1259, DOI 10.1212/WNL.59.8.1259; ENGELHARDT E, 2001, ARQ NEUROPSIQUIAT S3, V59, pS3; Harvey RJ, 2003, J NEUROL NEUROSUR PS, V74, P1206, DOI 10.1136/jnnp.74.9.1206; Harvey RJ, 1998, YOUNG ONSET DEMENTIA; HOFFMAN A, 1991, INT J EPIDEMIOL, V20, P736; Ikeda M, 2001, NEUROLOGY, V57, P839, DOI 10.1212/WNL.57.5.839; JORM AF, 1987, ACTA PSYCHIAT SCAND, V76, P465, DOI 10.1111/j.1600-0447.1987.tb02906.x; KOKMEN E, 1989, NEUROLOGY, V39, P773, DOI 10.1212/WNL.39.6.773; MCGONIGAL G, 1993, BRIT MED J, V306, P680, DOI 10.1136/bmj.306.6879.680; McKeith IG, 1996, NEUROLOGY, V47, P1113, DOI 10.1212/WNL.47.5.1113; McKeith IG, 1999, NEUROLOGY, V53, P902, DOI 10.1212/WNL.53.5.902; MCKHANN G, 1984, NEUROLOGY, V34, P939, DOI 10.1212/WNL.34.7.939; NEWENS AJ, 1993, PSYCHOL MED, V23, P631, DOI 10.1017/S0033291700025411; Panegyres PK, 2000, MED J AUSTRALIA, V173, P279, DOI 10.5694/j.1326-5377.2000.tb125651.x; Petersen RC, 2001, NEUROLOGY, V56, P1133, DOI 10.1212/WNL.56.9.1133; ROMAN GC, 1993, NEUROLOGY, V43, P250, DOI 10.1212/WNL.43.2.250; Silva DW, 2002, ARQ NEURO-PSIQUIAT, V60, P996; Takada LT, 2003, ARQ NEURO-PSIQUIAT, V61, P925, DOI 10.1590/S0004-282X2003000600007; TREVES T, 1986, ARCH NEUROL-CHICAGO, V43, P26, DOI 10.1001/archneur.1986.00520010022014; Vale FAC, 2002, ARQ NEURO-PSIQUIAT, V60, P548, DOI 10.1590/S0004-282X2002000400006; Varma AR, 2002, ACTA NEUROL SCAND, V105, P261, DOI 10.1034/j.1600-0404.2002.1o148.x; Woodburn K J, 1999, Health Bull (Edinb), V57, P384	27	23	28	0	4	ASSOC ARQUIVOS NEURO- PSIQUIATRIA	SAO PAULO SP	PR AMADEU AMARAL 47/33, 01327-010 SAO PAULO SP, BRAZIL	0004-282X	1678-4227		ARQ NEURO-PSIQUIAT	Arq. Neuro-Psiquiatr.	SEP	2004	62	3A					592	595		10.1590/S0004-282X2004000400005			4	Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	853AV	WOS:000223799400005	15334214	DOAJ Gold			2021-06-18	
J	Reinert, M; Schaller, B; Widmer, HR; Seiler, R; Bullock, R				Reinert, M; Schaller, B; Widmer, HR; Seiler, R; Bullock, R			Influence of oxygen therapy on glucose-lactate metabolism after diffuse brain injury	JOURNAL OF NEUROSURGERY			English	Article						severe head injury; oxygen; glucose; lactate; rat	SEVERE HEAD-INJURY; FREE-RADICAL PRODUCTION; CEREBRAL-BLOOD-FLOW; ADULT-MOUSE BRAIN; INSPIRED OXYGEN; INTRACRANIAL-PRESSURE; PROLONGED ANESTHESIA; HYPERBARIC-OXYGEN; SUBDURAL-HEMATOMA; GLUTAMATE RELEASE	Object. Severe traumatic brain injury (TBI) imposes a huge metabolic load on brain tissue, which can be summarized initially as a state of hypermetabolism and hyperglycolysis. In experiments O-2 consumption has been shown to increase early after trauma, especially in the presence of high lactate levels and forced O-2 availability. In recent clinical studies the effect of increasing O-2 availability on brain metabolism has been analyzed. By their nature, however, clinical trauma models suffer from a heterogeneous injury distribution. The aim of this study was to analyze, in a standardized diffuse brain injury model, the effect of increasing the fraction of inspired O-2 on brain glucose and lactate levels, and to compare this effect with the metabolism of the noninjured sham-operated brain. Methods. A diffuse severe TBI model developed by Foda and Maramarou, et al., in which a 420-g weight is dropped from a height of 2 m was used in this study. Forty-one male Wistar rats each weighing approximately 300 g were included. Anesthesized rats were monitored by placing a femoral arterial line for blood pressure and blood was drawn for a blood gas analysis. Two time periods were defined: Period A was defined as preinjury and Period B as postinjury. During Period B two levels of fraction of inspired oxygen (FiO(2)) were studied: air (FiO(2) 0.21) and oxygen (FiO(2) 1). Four groups were studied including sham-operated animals: air-air-sham (AAS); air-O-2-sham (AOS); air-air-trauma (AAT); and air-O-2-trauma (AOT). In six rats the effect of increasing the FiO(2) on serum glucose and lactate was analyzed. During Period B lactate values in the brain determined using microdialysis were significantly lower (p < 0.05) in the AOT group than in the AAT group and glucose values in the brain determined using microdialysis were significantly higher (p < 0.04). No differences were demonstrated in the other groups. Increasing the FiO(2) had no significant effect on the serum levels of glucose and lactate. Conclusions. Increasing the FiO(2) influences dialysate glucose and lactate levels in injured brain tissue. Using an FiO(2) of 1 influences brain metabolism in such a way that lactate is significantly reduced and glucose significantly increased. No changes in dialysate glucose and lactate values were found in the noninjured brain.	Univ Bern, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland; Univ Bern, Dept Neurol Surg, Bern, Switzerland; Virginia Commonwealth Univ, Med Coll Virginia, Dept Neurosurg, Richmond, VA 23298 USA	Reinert, M (corresponding author), Univ Bern, Inselspital, Dept Neurol, CH-3010 Bern, Switzerland.	michael.reinert@neurochirurgie-bern.ch	Reinert, Michael/E-4964-2011; Reinert, Michael/AAA-3929-2019; Widmer, Hans Rudolf/O-5172-2017	Reinert, Michael/0000-0002-0971-9543; Widmer, Hans Rudolf/0000-0003-3378-8765; Schaller, Benoit/0000-0002-6861-2340			AGARDH CD, 1991, INT J DEV NEUROSCI, V9, P127, DOI 10.1016/0736-5748(91)90003-5; BARBER RE, 1970, NEW ENGL J MED, V283, P1478, DOI 10.1056/NEJM197012312832702; Bergsneider M, 1997, J NEUROSURG, V86, P241, DOI 10.3171/jns.1997.86.2.0241; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; CAO W, 1988, NEUROSCI LETT, V88, P233, DOI 10.1016/0304-3940(88)90132-2; Cater HL, 2001, J PHYSIOL-LONDON, V531, P459, DOI 10.1111/j.1469-7793.2001.0459i.x; Chen T, 2000, J NEUROTRAUM, V17, P135, DOI 10.1089/neu.2000.17.135; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Clausen T, 2001, BRAIN RES, V908, P35, DOI 10.1016/S0006-8993(01)02566-5; Clausen T, 2001, CURR PHARM DESIGN, V7, P1517, DOI 10.2174/1381612013397267; DAUGHERTY WP, 2001, J NEUROTRAUM, V18, P1185; Doppenberg EMR, 1998, J NEUROTRAUM, V15, P337, DOI 10.1089/neu.1998.15.337; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; FOLZ R, 1997, LUNG SCI FDN, P2713; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; HEMPEL FG, 1977, J APPL PHYSIOL, V43, P873; INGLIS F, 1992, J NEUROTRAUM, V9, P75, DOI 10.1089/neu.1992.9.75; INGLIS FM, 1990, ACT NEUR S, V51, P277; Kuroda Y, 1997, ANESTHESIOLOGY, V87, P527, DOI 10.1097/00000542-199709000-00011; Kuroda Y, 1996, ANESTHESIOLOGY, V84, P555, DOI 10.1097/00000542-199603000-00010; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; Magistretti PJ, 1999, NEWS PHYSIOL SCI, V14, P177, DOI 10.1152/physiologyonline.1999.14.5.177; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; Marshall L F, 1995, New Horiz, V3, P573; Menzel M, 1999, J NEUROSURG ANESTH, V11, P240, DOI 10.1097/00008506-199910000-00003; Menzel M, 1999, J NEUROSURG, V91, P1, DOI 10.3171/jns.1999.91.1.0001; MINK RB, 1995, CRIT CARE MED, V23, P1398, DOI 10.1097/00003246-199508000-00014; Morimoto T, 1996, J CEREBR BLOOD F MET, V16, P92, DOI 10.1097/00004647-199601000-00011; MUIZELAAR JP, 1991, J NEUROSURG, V75, P731, DOI 10.3171/jns.1991.75.5.0731; Murakami N, 2001, CRIT CARE MED, V29, P814, DOI 10.1097/00003246-200104000-00027; Oshima T, 2003, EUR J ANAESTH, V20, P543, DOI 10.1097/00003643-200307000-00005; Pellerin L, 2002, DIABETES NUTR METAB, V15, P268; Pellerin L, 2003, NEUROCHEM INT, V43, P331, DOI 10.1016/S0197-0186(03)00020-2; Pellerin L, 2003, J PHYSIOL-LONDON, V546, P325, DOI 10.1113/jphysiol.2002.035105; PELLERIN L, 1994, P NATL ACAD SCI USA, V91, P10625, DOI 10.1073/pnas.91.22.10625; Pierre K, 2000, NEUROSCIENCE, V100, P617, DOI 10.1016/S0306-4522(00)00294-3; Pierre K, 2002, J CEREBR BLOOD F MET, V22, P586, DOI 10.1097/00004647-200205000-00010; REASONER DK, 1990, BRIT J ANAESTH, V65, P210, DOI 10.1093/bja/65.2.210; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; Reinert M, 2003, ACTA NEUROCHIR, V145, P341, DOI 10.1007/s00701-003-0027-0; Schurr A, 1999, J NEUROSCI, V19, P34; Schurr A, 2002, INT J MOL MED, V10, P131, DOI 10.3892/ijmm.10.2.131; Schurr A, 2001, BRAIN RES, V895, P268, DOI 10.1016/S0006-8993(01)02082-0; SCHURR A, 1988, SCIENCE, V240, P1326, DOI 10.1126/science.3375817; SINGER MM, 1970, NEW ENGL J MED, V283, P1473, DOI 10.1056/NEJM197012312832701; SUTTON RL, 1994, ACTA NEUROCHIR, P446; Tseng MT, 2003, NEUROL RES, V25, P83, DOI 10.1179/016164103101200978; van den Brink WA, 1998, ACT NEUR S, V71, P190; VANDEWATER JM, 1970, NEW ENGL J MED, V283, P621, DOI 10.1056/NEJM197009172831203; Young B, 1996, JAMA-J AM MED ASSOC, V276, P538, DOI 10.1001/jama.276.7.538	51	23	26	0	4	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	AUG	2004	101	2					323	329		10.3171/jns.2004.101.2.0323			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	842JQ	WOS:000223000600024	15309926				2021-06-18	
J	Ariza, M; Mataro, M; Poca, MA; Junque, C; Garnacho, A; Amoros, S; Sahuquillo, J				Ariza, M; Mataro, M; Poca, MA; Junque, C; Garnacho, A; Amoros, S; Sahuquillo, J			Influence of extraneurological insults on ventricular enlargement and neuropsychological functioning after moderate and severe traumatic brain injury	JOURNAL OF NEUROTRAUMA			English	Article						head injury; hypoxia; neuropsychology; outcome; ventricular enlargement	SEVERE HEAD-INJURY; CEREBRAL PERFUSION-PRESSURE; COMA DATA-BANK; INTRACRANIAL HYPERTENSION; COMPUTED-TOMOGRAPHY; COGNITIVE SEQUELAE; PRACTICAL SCALE; PROGNOSIS; RECOVERY; MEMORY	Extraneurological insults secondary to TBI such as hypotension or hypoxia have been associated with mortality and morbidity. The purpose of this study was to investigate the influence of systemic complications on both neuropsychological outcome and cerebral atrophy. Fifty-seven patients selected from 122 consecutive admissions were studied. Data on the type and severity of injury as well as other systemic insults were collected prior to and during the first 3 days of hospitalization. These data included the presence or absence of a hypoxic episode during the pre-hospital period, the presence and degree of hypoxia, hypercapnia, anemia, hypotension and intracranial hypertension, pupillary reactivity, Glasgow Coma Scale score and coma duration. From the last control CT scan image, performed 6 months post-injury, four different indexes of ventricular dilatation were calculated. Neuropsychological assessment at 6 months included tests of verbal and visual memory, visuoconstructive functions, fine motor speed, and frontal lobe functions. Our results showed that hypoxia and hypotension were related to neuropsychological outcome and long-term ventricular enlargement. Hypoxic episodes prior to hospitalization were related to third ventricle dilatation and to adverse neurological and cognitive outcomes, especially to attention, motor speed, mental flexibility, fluency and verbal memory impairments, suggesting fronto-striatal and hippocampal dysfunction. We conclude that the effect of extraneurological insults on brain structure and function may be as important as the severity of the primary injury.	Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, Barcelona 08035, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Res Unit, Barcelona 08035, Spain; Univ Barcelona, Hosp Gen Valle Hebron, Neurotraumatol Intens Care Unit, Barcelona 08035, Spain; Univ Barcelona, Dept Psychiat & Clin Psychobiol, E-08007 Barcelona, Spain	Sahuquillo, J (corresponding author), Univ Barcelona, Hosp Gen Valle Hebron, Dept Neurosurg, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.	sahuquillo@homemail.com	Sahuquillo, Juan/B-3577-2008; Garnacho, Angel/A-9309-2013; Mataro, Maria/B-4524-2011; Junque, Carme/B-4400-2011; Ariza, Mar/F-2754-2019; Poca, Maria A./B-8475-2008	Sahuquillo, Juan/0000-0003-0713-5875; Mataro, Maria/0000-0002-9946-2656; Junque, Carme/0000-0002-6381-3063; Poca, Maria A./0000-0002-3831-0536; Ariza, Mar/0000-0003-1020-6945			Benton A., 1994, MULTILINGUAL APHASIA; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Blatter DD, 1997, AM J NEURORADIOL, V18, P1; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; Combes P, 1996, INTENS CARE MED, V22, P1391, DOI 10.1007/s001340050269; CORTBUS F, 1994, ACTA NEUROCHIR, V130, P117, DOI 10.1007/BF01405511; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; Fujioka M, 2000, CEREBROVASC DIS, V10, P2, DOI 10.1159/000016018; GILCHRIST E, 1979, ARCH NEUROL-CHICAGO, V36, P355, DOI 10.1001/archneur.1979.00500420065008; JANE JA, 1982, CLIN NEUR, V29, P346; JENNETT B, 1975, LANCET, V1, P480; KlOve H, 1963, MED CLIN N AM; Lannoo E, 1998, INTENS CARE MED, V24, P236, DOI 10.1007/s001340050556; Lannoo E, 2000, J NEUROTRAUM, V17, P403, DOI 10.1089/neu.2000.17.403; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lezak MD, 1995, NEUROPSYCHOLOGICAL A; Maneru C, 2001, NEUROLOGY, V57, P1115, DOI 10.1212/WNL.57.6.1115; MARMAROU A, 1991, J NEUROSURG, V75, pS59, DOI 10.3171/sup.1991.75.1s.0s59; Mataro M, 2001, J NEUROTRAUM, V18, P869, DOI 10.1089/089771501750451794; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; MILLER JD, 1977, J NEUROSURG, V47, P503, DOI 10.3171/jns.1977.47.4.0503; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; MILLER JD, 1978, JAMA-J AM MED ASSOC, V240, P439, DOI 10.1001/jama.240.5.439; REIDERGROSWASSER I, 1993, AM J ROENTGENOL, V160, P147, DOI 10.2214/ajr.160.1.8416613; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Resnick DK, 1997, J TRAUMA, V42, P1108, DOI 10.1097/00005373-199706000-00021; REY A, 1959, TEST COPIE REPRODUCT; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RUFF RM, 1991, J NEUROSURG, V75, pS50, DOI 10.3171/sup.1991.75.1s.0s50; Smith A., 1991, SYMBOL DIGIT MODALIT; TABADDOR K, 1984, NEUROSURGERY, V14, P701, DOI 10.1227/00006123-198406000-00010; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1988, J NEUROL NEUROSUR PS, V51, P1452, DOI 10.1136/jnnp.51.11.1452; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WILSON B, 1991, Brain Injury, V5, P189, DOI 10.3109/02699059109008089; YOUNG B, 1981, J NEUROSURG, V54, P300, DOI 10.3171/jns.1981.54.3.0300	45	23	23	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					864	876		10.1089/0897715041526203			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800004	15307899				2021-06-18	
J	Kneafsey, R; Gawthorpe, D				Kneafsey, R; Gawthorpe, D			Head injury: long-term consequences for patients and families and implications for nurses	JOURNAL OF CLINICAL NURSING			English	Article						brain injury; narrative review; nursing	TRAUMATIC BRAIN-INJURY; PERCEPTIONS; DISABILITY	Background. Head injury as a result of trauma is an important cause of long-term disability. Recently published guidance from the National Institute for Clinical Excellence on Acute Head Injuries and a forthcoming National Service Framework for Long-Term Neurological Conditions provides renewed focus on this practice speciality. Aims and objectives. This article presents a narrative review of a range of quantitative and qualitative studies that have explored the impact of head injury and postinjury disabilities on patients' and families lives. Results. Patients may experience a range of physical, emotional, cognitive, social and behavioural problems after head injury that will have a significant impact on both their own and their families' everyday lives. It is important that the behavioural, physical and psychological aspects of head injury are addressed. Carers may be vulnerable to stress and anxiety as a result of their caring role. Conclusions. It is often in the longer term that the true complexity and impact of head injury may become apparent. Ongoing support, from a range of services, will be required to assist both patient and family to cope with their circumstances. Ensuring that practice is evidence based, it is necessary to conduct further research, both to explore the effectiveness of current service provision and investigate those aspects deemed important by patients and carers. Relevance to clinical practice. As nurses play an important role in both the acute and long-term care and support of those who have suffered a head injury, it is vital that they are aware of the wide ranging needs with which patients and families may present.	Univ Salford, Sch Nursing, Manchester M30 ONN, Lancs, England	Kneafsey, R (corresponding author), Univ Salford, Sch Nursing, Peel House,Albert St, Manchester M30 ONN, Lancs, England.	r.kneafsey@salford.ac.uk					Acorn S., 1993, CANADIAN J REHABILIT, V7, P149; ANNELLS M, 1999, NURSE RES, V6, P5; [Anonymous], 2000, COMPR CRIT CAR REV A; BLACK N, 1994, J EPIDEMIOL COMMUN H, V48, P425, DOI 10.1136/jech.48.5.425-a; BLOSSER J, 1995, J HEAD TRAUMA REHAB, V10, P46, DOI 10.1097/00001199-199504000-00006; BREWIN J, 2001, BRIT J THERAPY REHAB, V8, P218; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; Brooks N., 1987, J HEAD TRAUMA REHABI, V2, P1, DOI [10.1097/00001199-198709000-00003, DOI 10.1097/00001199-198709000-00003]; Bullock MR, 1996, J NEUROTRAUM, V13, P641, DOI 10.1089/neu.1996.13.641; CHESNUT RM, 1999, REHABILITATION TRAUM, P1; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; CONNOLLY D, 2001, BR J OCCUP THER, V64, P41, DOI DOI 10.1177/030802260106400108; *CRIT REV ADV GROU, 1996, INTRO SYST REV SCH H; DARRACH W, 2000, J NEUROSURGICAL PSYC, V68, P8; Darragh AR, 2001, AM J OCCUP THER, V55, P191, DOI 10.5014/ajot.55.2.191; Davies C, 2000, BRIT J THERAPY REHAB, V7, P521; DeJong G., 1990, J HEAD TRAUMA REHAB, V5, P9, DOI [https://doi.org/10.1097/00001199-199003000-00004, DOI 10.1097/00001199-199003000-00004]; *DEP HLTH, 2001, GOV RESP HLTH SEL CO; *DEP HLTH, 1996, HIDD DIS REP SSI TRA; Department of Health, 2001, NURS CONTR PROV COMP; FLEMINGER S, 2003, COCHRANE LIB; GRAVELL R, 2002, HEAD INJURY REHABILI; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Hassan N, 2002, CLIN REHABIL, V16, P534, DOI 10.1191/0269215502cr523oa; HEMMINGWAY S, 1997, NURSING STANDARD, V12, P40; Hodgkinson D W, 1994, Eur J Emerg Med, V1, P9, DOI 10.1097/00063110-199403000-00003; JENNETT B, 1981, J NEUROL NEUROSUR PS, V44, P285, DOI 10.1136/jnnp.44.4.285; JENNETT B, 1976, LANCET, V1, P1031; Johnson D, 1999, J HYDROL ENG, V4, P117, DOI 10.1061/(ASCE)1084-0699(1999)4:2(117); Johnson R., 1996, CLIN REHABIL, V10, P173, DOI [DOI 10.1177/026921559601000215, 10.1177/026921559601000215]; Long AF, 2002, J ADV NURS, V37, P70, DOI 10.1046/j.1365-2648.2002.02059.x; Long AF, 2002, NURS EDUC TODAY, V22, P136, DOI 10.1054/nedt.2001.0671; LONG AF, 2001, RES REPORTS SERIES N, V19; Marshall LF, 1998, J NEUROSURG, V89, P519, DOI 10.3171/jns.1998.89.4.0519; Marshall LF, 2000, NEUROSURGERY, V47, P546, DOI 10.1097/00006123-200009000-00002; MCDOWELL I, 1995, CLIN REHABIL, V9, P150; Mead D., 2001, NURSE RES, DOI [10.7748/nr2001.07.8.4.4.c6162, DOI 10.7748/NR2001.07.8.4.4.C6162]; Mysiw WJ, 1997, ARCH PHYS MED REHAB, V78, P213, DOI 10.1016/S0003-9993(97)90266-5; *NAT I CLIN EXC, 2003, HEAD INJ TRIAG ASS I; *NHS EX, 1997, REH GUID HOLD REP; Nichols KA, 1993, PSYCHOL CARE PHYS IL; Nochi M, 2000, SOC SCI MED, V51, P1795, DOI 10.1016/S0277-9536(00)00111-8; PICKETHAUBER R, 2000, J NEUROSCIENCE NURSI, V32, P22; Polgar S., 1995, INTRO RES HLTH SCI; Rosenthal M, 1998, ARCH PHYS MED REHAB, V79, P90, DOI 10.1016/S0003-9993(98)90215-5; *ROYAL COLL SURG, 1999, WORK PART MAN PAT HE; SANTBRINK H, 1996, NEUROSURGERY, V38, P21; SERIO CD, 1995, J HEAD TRAUMA REHAB, V10, P32, DOI 10.1097/00001199-199504000-00005; SULLIVAN J, 2000, J NEUROSCIENCE NURSI, V32, P4; Swift TL, 2001, BRAIN INJURY, V15, P149, DOI 10.1080/026990501458380; TEASDALE G, 1974, LANCET, V2, P81; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; Watanabe Y, 2000, CLIN REHABIL, V14, P172, DOI 10.1191/026921500666833742; WESTCOTT E, 1998, NURSING TIMES RES, V3, P421; WILLER BS, 1991, ARCH PHYS MED REHAB, V72, P460	55	23	23	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0962-1067	1365-2702		J CLIN NURS	J. Clin. Nurs.	JUL	2004	13	5					601	608		10.1111/j.1365-2702.2004.00903.x			8	Nursing	Nursing	827VV	WOS:000221932700009	15189413				2021-06-18	
J	Ringger, NC; Tolentino, PJ; McKinsey, DM; Pike, BR; Wang, KKW; Hayes, RL				Ringger, NC; Tolentino, PJ; McKinsey, DM; Pike, BR; Wang, KKW; Hayes, RL			Effects of injury severity on regional and temporal mRNA expression levels of calpains and caspases after traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						apoptosis; injury magnitude; neuronal death; proteases; RT-PCR	CORTICAL IMPACT INJURY; FOCAL CEREBRAL-ISCHEMIA; NEURONAL CELL-DEATH; SEPTOHIPPOCAMPAL CULTURES; MITOCHONDRIAL DYSFUNCTION; DIFFERENTIAL EXPRESSION; DNA FRAGMENTATION; SPATIAL PROFILE; AXONAL INJURY; HEAD-INJURY	Despite a preponderance of studies demonstrating gene expression and/or enzymatic activation of calpain and caspase proteases after traumatic brain injury (TBI), no studies have examined the effects of injury magnitude on expression levels of these cell death effectors after TBI. Determination of the degree to which injury severity affects specific expression profiles is critical to understanding the relevant pathways contributing to post-trauma pathology and for developing targeted therapeutics. This investigation tested the hypothesis that different injury magnitudes (1.0, 1.2, and 1.6 mm) cause alterations in the regional and temporal patterns of mRNA expression of calpain-related (calpain-1 and -2, calpastatin) and caspase-related (caspases -3, -8, -9, BID) gene products after cortical impact in rats. Quantitative RT-PCR was used to compare effects of injury severity on mRNA levels in ipsilateral (injured) cortex and hippocampus, 6 h to 5 days post-injury. TBI caused increases in mRNA expression of all proteins examined, with the highest expression detected in the cortex. Generally, injury magnitude and levels of gene expression were positively correlated. High levels of gene induction were observed with BID, caspase-3, and -8, while caspase-9 mRNA had the lowest level of induction. Interestingly, although calpains are activated within minutes of TBI, calpain mRNA expression was highest 72 h to 5 days post-TBI. This study is the first analysis of the regional and temporal expression of calpains and caspases after TBI. These data provide insight into the inter-relationship of these two protease families and on the distinct but overlapping cascades of cell death after TBI.	Univ Florida, Eyelyn F & William L McKnight Brain Inst, Dept Neurosci, Gainesville, FL 32611 USA; Univ Florida, Eyelyn F & William L McKnight Brain Inst, Dept Neurosurg, Gainesville, FL 32611 USA; Univ Florida, Eyelyn F & William L McKnight Brain Inst, Dept Psychiat, Gainesville, FL 32611 USA; Univ Florida, Eyelyn F & William L McKnight Brain Inst, Ctr Traumat Brain Injuries, Gainesville, FL 32611 USA; NIGMS, NIH, Bethesda, MD USA	Ringger, NC (corresponding author), 100 S Newell Dr,L1-100 POB, Gainesville, FL 32610 USA.	ringger@ufbi.ufl.edu	Pike, Bruce/K-5562-2014	Pike, Bruce/0000-0001-8924-683X; Wang, Kevin/0000-0002-9343-6473			Beer R, 2001, J NEUROCHEM, V78, P862, DOI 10.1046/j.1471-4159.2001.00460.x; Beer R, 2000, J NEUROCHEM, V75, P1264, DOI 10.1046/j.1471-4159.2000.0751264.x; Benchoua A, 2001, J NEUROSCI, V21, P7127, DOI 10.1523/JNEUROSCI.21-18-07127.2001; Blomgren K, 2001, J BIOL CHEM, V276, P10191, DOI 10.1074/jbc.M007807200; BONFOCO E, 1995, P NATL ACAD SCI USA, V92, P7162, DOI 10.1073/pnas.92.16.7162; Budihardjo I, 1999, ANNU REV CELL DEV BI, V15, P269, DOI 10.1146/annurev.cellbio.15.1.269; Buki A, 2000, J NEUROSCI, V20, P2825; Chan SL, 1999, J NEUROSCI RES, V58, P167, DOI 10.1002/(SICI)1097-4547(19991001)58:1<167::AID-JNR16>3.3.CO;2-B; Chen M, 2001, J BIOL CHEM, V276, P30724, DOI 10.1074/jbc.M103701200; CHERIAN L, 1994, J NEUROTRAUM, V11, P573, DOI 10.1089/neu.1994.11.573; Conti AC, 1998, J NEUROSCI, V18, P5663; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Eldadah BA, 2000, J NEUROTRAUM, V17, P811, DOI 10.1089/neu.2000.17.811; Faddis BT, 1997, J NEUROSCI, V17, P951; Fan L, 1996, MOL BRAIN RES, V36, P287, DOI 10.1016/0169-328X(95)00274-V; FINEMAN I, 1993, BRAIN RES, V624, P94, DOI 10.1016/0006-8993(93)90064-T; Franz G, 2002, J CEREBR BLOOD F MET, V22, P951, DOI 10.1097/00004647-200208000-00006; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; Gibson UEM, 1996, GENOME RES, V6, P995, DOI 10.1101/gr.6.10.995; GOODMAN JC, 1994, J NEUROTRAUM, V11, P587, DOI 10.1089/neu.1994.11.587; Gwag BJ, 1999, NEUROSCIENCE, V90, P1339, DOI 10.1016/S0306-4522(98)00508-9; Harrison DC, 2001, MOL BRAIN RES, V89, P133, DOI 10.1016/S0169-328X(01)00058-4; Heid CA, 1996, GENOME RES, V6, P986, DOI 10.1101/gr.6.10.986; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lenzlinger PM, 2002, J NEUROIMMUNOL, V122, P167, DOI 10.1016/S0165-5728(01)00466-0; Matsushita K, 2000, J NEUROSCI, V20, P6879, DOI 10.1523/JNEUROSCI.20-18-06879.2000; McGinnis KM, 1999, BIOCHEM BIOPH RES CO, V263, P94, DOI 10.1006/bbrc.1999.1315; MEANEY DF, 1994, J NEUROTRAUM, V11, P599, DOI 10.1089/neu.1994.11.599; NATHANIEL PD, 2000, 18 ANN NAT NEUR SOC; Newcomb JK, 1999, EXP NEUROL, V158, P76, DOI 10.1006/exnr.1999.7071; Newcomb JK, 1999, J NEUROTRAUM, V16, P1, DOI 10.1089/neu.1999.16.1; Newcomb-Fernandez JK, 2001, J CEREBR BLOOD F MET, V21, P1281, DOI 10.1097/00004647-200111000-00004; Pike BR, 1998, J NEUROSCI RES, V52, P505, DOI 10.1002/(SICI)1097-4547(19980601)52:5<505::AID-JNR3>3.3.CO;2-Y; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Pike BR, 2000, J NEUROTRAUM, V17, P283, DOI 10.1089/neu.2000.17.283; Plesnila N, 2001, P NATL ACAD SCI USA, V98, P15318, DOI 10.1073/pnas.261323298; Raghupathi R, 2000, J NEUROTRAUM, V17, P927, DOI 10.1089/neu.2000.17.927; Rami A, 2000, BRAIN RES, V866, P299, DOI 10.1016/S0006-8993(00)02301-5; Shi YX, 2000, AM J PHYSIOL-RENAL, V279, pF509; SHOHAMI E, 1994, J CEREBR BLOOD F MET, V14, P615, DOI 10.1038/jcbfm.1994.76; Sullivan PG, 1998, J NEUROTRAUM, V15, P789, DOI 10.1089/neu.1998.15.789; Thompson M. B., 2000, Journal of Neurotrauma, V17, P953; Tolentino PJ, 2002, J NEUROCHEM, V80, P579, DOI 10.1046/j.0022-3042.2001.00726.x; Verweij BH, 2000, J NEUROSURG, V93, P829, DOI 10.3171/jns.2000.93.5.0829; Verweij BH, 1997, NEUROL RES, V19, P334, DOI 10.1080/01616412.1997.11740821; Wang KKW, 2000, TRENDS NEUROSCI, V23, P20, DOI 10.1016/S0166-2236(99)01479-4; Witkowski JM, 2002, BLOOD, V100, P1802, DOI 10.1182/blood-2001-11-0073; Xiong Y, 1997, J NEUROTRAUM, V14, P907, DOI 10.1089/neu.1997.14.907; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhao X, 1999, NEUROCHEM RES, V24, P371, DOI 10.1023/A:1020933616351	51	23	25	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JUL	2004	21	7					829	841		10.1089/0897715041526177			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	842AE	WOS:000222973800001	15307896				2021-06-18	
J	Fricke, ST; Vink, R; Chiodo, C; Cernak, I; Ileva, L; Faden, AI				Fricke, ST; Vink, R; Chiodo, C; Cernak, I; Ileva, L; Faden, AI			Consistent and reproducible slice selection in rodent brain using a novel stereotaxic device for MRI	JOURNAL OF NEUROSCIENCE METHODS			English	Article						stereotaxic; rat; mouse; magnetic resonance spectroscopy; CT; neurotrauma; stroke; PET	RAT-BRAIN; HIPPOCAMPUS; INJURY	Typically small animal radiological images are obtained after placing the animal in the center of the imaging device using beds or platforms, and then adjusting the position after obtaining a scout image. Such a process does not permit the reproducible visualization of the same anatomical plane with repeated examinations. We have developed a device that allows stereotaxic placement of an animal in precisely the same position for repeated examinations. The instrument incorporates a full range of physiological monitoring and life support systems including temperature control, anesthesia delivery and respiratory monitoring. Using magnetic resonance imaging (MRI), the accuracy and reliability of this device is demonstrated in a rat traumatic brain injury (TBI) model. (C) 2004 Elsevier B.V. All rights reserved.	Georgetown Univ, Dept Neurosci, Washington, DC 20057 USA; Univ Adelaide, Dept Pathol, Adelaide, SA, Australia; ASI Instruments Inc, Warren, MI USA	Fricke, ST (corresponding author), Georgetown Univ, Dept Neurosci, Res Bldg,Room WB-01,POB 571464, Washington, DC 20057 USA.	stf2@georgetown.edu	Cernak, Ibolja/A-6399-2008; AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667; Ibolja, Cernak/0000-0003-3214-698X			Faden AI, 2003, J CEREBR BLOOD F MET, V23, P342, DOI 10.1097/01.WCB.0000046143.31247.FD; KAMIRYO T, 1995, ACTA NEUROCHIR, V133, P87, DOI 10.1007/BF01404955; KARGER CP, 1995, INT J RADIAT ONCOL, V33, P485, DOI 10.1016/0360-3016(95)00066-8; Khubchandani M, 2003, MAGNET RESON MED, V49, P962, DOI 10.1002/mrm.10441; Lahti KM, 1998, J NEUROSCI METH, V82, P75, DOI 10.1016/S0165-0270(98)00037-5; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Ohl F, 1999, J NEUROSCI METH, V88, P189, DOI 10.1016/S0165-0270(99)00028-X; Wolf OT, 2002, BRAIN RES PROTOC, V10, P41	8	23	23	0	6	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0165-0270			J NEUROSCI METH	J. Neurosci. Methods	JUN 15	2004	136	1					99	102		10.1016/j.jneumeth.2004.01.003			4	Biochemical Research Methods; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	822VF	WOS:000221567800010	15126050				2021-06-18	
J	Chieregato, A; Fainardi, E; Servadei, F; Tanfani, A; Pugliese, G; Pascarella, R; Targa, L				Chieregato, A; Fainardi, E; Servadei, F; Tanfani, A; Pugliese, G; Pascarella, R; Targa, L			Centrifugal distribution of regional cerebral blood flow and its time course in traumatic intracerebral hematomas	JOURNAL OF NEUROTRAUMA			English	Article						cerebral blood flow; head injury; ischemia; time course; traumatic contusions; traumatic hematomas; xenon-CT	HEAD-INJURED PATIENTS; BRAIN-INJURY; XENON-CT; CONTUSIONS; ISCHEMIA; HEMORRHAGE; EDEMA; PERFUSION; CONSCIOUSNESS; HYPOPERFUSION	Cerebral blood flow (CBF) alterations following post-traumatic contusions have been demonstrated in recent papers. We evaluated regional CBF (rCBF) by means of Xenon-enhanced computerized tomography (Xe-CT) in 29 traumatic intracerebral hematomas, from 22 patients with severe head injury (GCS less than or equal to 8). Fifty traumatic hematoma/Xe-CT CBF measurements were obtained from 39 Xe-CT studies performed during the acute phase (corresponding to the first 20 days post-injury). The rCBF was measured in three different regions of interest: the hemorrhagic core, the perihematoma edematous low-density area, and a I-cm rim of perihematoma normal-appearing brain tissue, surrounding the edematous low-density area. We found a centrifugal improvement of rCBF as well as a decrease in the rates of CBF levels below 18 mL/100 g/min from the core to the periphery (p < 0.0001), which persisted over time. Ischemic rCBF values were detected in the perihematoma low-density area only in 24% of the traumatic hematomas. The time course of rCBF levels showed a reduced flow in the first 24 h, with a recovery of flow from day 2 to day 4, followed by another reduced flow (p < 0.0001) both in the perihematoma edematous low-density area and in the non-lesioned tissue. Our findings suggest that the only area with persistent ischemic values was the hemorrhagic core. Low rCBF levels seen in the perihematoma low-density area may only be ascribed partially to ischemia and can possibly recover over time. These results could encourage a surgical approach based on an early evacuation of the hemorrhagic core associated to a preservation of the surrounding edematous tissue.	Osped Gen Provinciale M Bufalini, Unita Operat Anestesia & Rianimazone, I-47023 Cesena, Italy; Arcispedale St Anna, Ferrara, Italy	Chieregato, A (corresponding author), Osped Gen Provinciale M Bufalini, Unita Operat Anestesia & Rianimazone, Viale Ghirotti 286, I-47023 Cesena, Italy.	achiere@ausl-cesena.emr.it	Pascarella, Rosario/AAL-2639-2021	Pascarella, Rosario/0000-0002-0512-9298; Servadei, Franco/0000-0002-3595-3464			ALEXANDER MJ, 1994, ACTA NEUROCHIR, P479; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bullock MR, 2002, NEUROSURGERY, V50, P788; BULLOCK R, 1988, SURG NEUROL, V29, P101, DOI 10.1016/0090-3019(88)90065-1; BULLOCK R, 1990, ACT NEUR S, V51, P286; BULLOCK R, 1991, J NEUROL NEUROSUR PS, V54, P427, DOI 10.1136/jnnp.54.5.427; BULLOCK R, 1989, SURG NEUROL, V32, P181, DOI 10.1016/0090-3019(89)90176-6; Bullock RM, 2000, J NEUROTRAUM, V17, P449; Carhuapoma JR, 2002, AM J NEURORADIOL, V23, P1322; CHESNUT R, 1999, TRAUMATIC BRAIN INJU, P81; Chieregato A, 2003, ACTA NEUROCHIR SUPPL, V86, P333; CRUZ J, 1994, J NEUROSURG, V80, P143, DOI 10.3171/jns.1994.80.1.0143; Diringer MN, 2002, J NEUROSURG, V96, P103, DOI 10.3171/jns.2002.96.1.0103; Furuya Y, 2003, NEUROSURGERY, V52, P340, DOI 10.1227/01.NEU.0000043931.83041.AA; GUR D, 1985, STROKE, V16, P871, DOI 10.1161/01.STR.16.5.871; Hattori N, 2003, ACTA NEUROCHIR SUPPL, V86, P49; Hoelper BM, 2000, ACTA NEUROCHIR SUPPL, V76, P21; JENNETT B, 1975, LANCET, V1, P480; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Katayama Y, 2003, ACTA NEUROCHIR SUPPL, V86, P323; KATAYAMA Y, 1990, ACT NEUR S, V51, P308; Kawamata T, 2002, ACTA NEUROCHIR SUPPL, V81, P281; KUSHI H, 1994, ACTA NEUROCHIR, P472; Levasseur JE, 2000, J NEUROTRAUM, V17, P101, DOI 10.1089/neu.2000.17.101; LOU HC, 1987, ANN NEUROL, V22, P289, DOI 10.1002/ana.410220302; Maas AIR, 1997, ACTA NEUROCHIR, V139, P286, DOI 10.1007/BF01808823; MADSEN FF, 1990, ACTA NEUROCHIR, V106, P24, DOI 10.1007/BF01809329; Maeda T, 2003, ACT NEUR S, V86, P329; Marchal G, 1999, J CEREBR BLOOD F MET, V19, P467, DOI 10.1097/00004647-199905000-00001; MARION DW, 1995, QUANTITATIVE CEREBRAL BLOOD FLOW MEASUREMENTS USING STABLE XENON/CT: CLINICAL APPLICATIONS, P283; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Mathew P, 1996, J NEUROSURG, V85, P860, DOI 10.3171/jns.1996.85.5.0860; McLaughlin MR, 1996, J NEUROSURG, V85, P871, DOI 10.3171/jns.1996.85.5.0871; Pindzola RR, 1998, NEUROSURGERY, V43, P1488; Portella G, 2000, ACT NEUR S, V76, P273; RIBAS GC, 1992, J NEUROTRAUM, V9, pS265; Schellinger PD, 2003, STROKE, V34, P1674, DOI 10.1161/01.STR.0000076010.10696.55; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei F, 2000, NEUROSURGERY, V46, P70; Siddique MS, 2002, J NEUROSURG, V96, P736, DOI 10.3171/jns.2002.96.4.0736; SOLONIUK D, 1986, J TRAUMA, V26, P787, DOI 10.1097/00005373-198609000-00003; Steiner LA, 2003, J CEREBR BLOOD F MET, V23, P1371, DOI 10.1097/01.WCB.0000090861.67713.10; SUTTON LN, 1990, ACT NEUR S, V51, P397; TEASDALE G, 1974, LANCET, V2, P81; TENJIN H, 1990, NEUROSURGERY, V26, P971, DOI 10.1227/00006123-199006000-00009; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Verweij BH, 2000, J NEUROSURG, V93, P815, DOI 10.3171/jns.2000.93.5.0815; Verweij BH, 2001, J NEUROSURG, V95, P569, DOI 10.3171/jns.2001.95.4.0569; von Oettingen G, 2002, NEUROSURGERY, V50, P781, DOI 10.1097/00006123-200204000-00019; von Oettingen G, 2000, NEURORADIOLOGY, V42, P168, DOI 10.1007/s002340050039; WOLFSON SK, 1990, STROKE, V21, P751, DOI 10.1161/01.STR.21.5.751; Xi GH, 1998, STROKE, V29, P2580, DOI 10.1161/01.STR.29.12.2580; Zazulia AR, 2001, J CEREBR BLOOD F MET, V21, P804, DOI 10.1097/00004647-200107000-00005	56	23	26	0	2	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUN	2004	21	6					655	666		10.1089/0897715041269669			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	836EG	WOS:000222537600002	15253794				2021-06-18	
J	Man, DWK; Lee, EWT; Tong, ECH; Yip, SCS; Lui, WF; Lam, CS				Man, DWK; Lee, EWT; Tong, ECH; Yip, SCS; Lui, WF; Lam, CS			Health services needs and quality of life assessment of individuals with brain injuries: a pilot cross-sectional study	BRAIN INJURY			English	Article							CLOSED-HEAD INJURY; COMMUNITY INTEGRATION; NEGATIVE AFFECT; FOLLOW-UP; SATISFACTION; SCALES; REHABILITATION; DISABILITY; ADULTS	Background and purpose: Quality of Life (QoL) studies have received a substantial amount of attention in medical and rehabilitative practices. However, there is still a paucity of studies in the area, especially on persons with brain injuries (BI). This pilot study, on the QoL of individuals with brain injuries in Hong Kong, attempts to fill this void. It is hoped that the finding of this study will guide the development of programmes and services to people with brain injuries. Methods: Through the Self-help Group for People with Brain Damage in Hong Kong, 35 subjects (22 men and 13 women) were successfully recruited to participate in this study by convenience sampling. Demographic data were collected through face-to-face interviews guided by a questionnaire and QoL data were gathered using the Comprehensive Quality of Life Scale-Intellectual/Cognitive Disability-5th edition (ComQol-15). The general emotional condition of the participants over the past 2 months was measured by a validated Chinese version of the Positive and Negative Affect Scale (PANAS). The participants' ratings on the importance of and their satisfaction with 20 health services areas were also collected. Results: Preliminary results show that the overall mean quality of life score, as measured by ComQol-15, was slightly less than two-thirds of the maximum score. Among the seven QoL domains, health and safety received some of the highest scores, while the lowest scores were obtained in the area of material well-being, place in community and productivity. People whose injuries had occurred relatively recently (less than 5 years ago) were found to have higher intimacy QoL scores than their counterparts injured more than 5 years ago. In the domain of safety, persons with a brain injury who were employed scored significantly higher than those who were not. Positive affect scores and the total affect of PANAS scores correlated significantly with the overall QoL scores. Moreover, persons with a brain injury usually felt satisfied with the services they valued as important. The top five most important services were medical services, occupational therapy, physiotherapy, vocational counselling and social work. Discussion and conclusion: The QoL profile of people with brain injuries in Hong Kong was initially obtained and low scores in the ComQoL were identified in the domains of material well-being, community activities and responsibility and productivity. These might be the consequences of their physical and cognitive limitations due to brain injury. This implies that appropriate interventions to improve their daily life conditions and their social integration would be necessary to improve their QoL. On the other hand, the BI sample also rated relatively high scores in other ComQoL areas such as safety and health, reflecting a good living environment and probably good health care services. Those whose brain injuries had occurred less than 5 years ago tended to have a higher ComQoL intimacy score than those whose injuries occurred more than 5 years ago. In other words, their social relationships may deteriorate with the longer period post-injury so that this group may need more supportive services. In the safety domain, it was found that subjects who were employed after their brain injury scored significantly higher than those who were not, which matched studies about the significant contribution of work towards life satisfaction. The satisfaction of their needs in the services they received, which may affect their QoL, was also investigated. It is clear that they valued the medical and rehabilitation services they received and felt satisfied with them.	Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China; IIT, Chicago, IL 60616 USA	Man, DWK (corresponding author), Hong Kong Polytech Univ, Hong Kong, Hong Kong, Peoples R China.	rsdavid@polyu.edu.hk					Asikainen I, 1998, BRAIN INJURY, V12, P95, DOI 10.1080/026990598122737; BAGOZZI RP, 1993, J PERS SOC PSYCHOL, V65, P836, DOI 10.1037/0022-3514.65.4.836; BECONA E, 1933, JUEGO COMPULSIVE COM; BOYLE GJ, 1991, PERS INDIV DIFFER, V12, P291, DOI 10.1016/0191-8869(91)90115-R; BRWON I, 1996, QUALITY LIFE HLTH PR, P3; Burleigh SA, 1998, AM J OCCUP THER, V52, P45, DOI 10.5014/ajot.52.1.45; Collins R, 2000, J HEAD TRAUMA REHAB, V15, P1139, DOI 10.1097/00001199-200010000-00007; Corrigan JD, 2001, J HEAD TRAUMA REHAB, V16, P543, DOI 10.1097/00001199-200112000-00003; Cummins RA, 1997, J APPL RES INTELLECT, V10, P199, DOI 10.1111/j.1468-3148.1997.tb00017.x; Cummins RA, 1996, SOC INDIC RES, V38, P303, DOI 10.1007/BF00292050; CUMMINS RA, 1999, URBAN QUALITY LIFE C, P325; CUMMINS RA, 1996, DIRECTORY INSTRUMENT, P1; CUMMINS RA, 1994, EDUC PSYCHOL MEAS, V54, P378; DAWSON DR, 1995, BRAIN INJURY, V9, P339, DOI 10.3109/02699059509005774; Dawson DR, 2000, BRAIN COGNITION, V44, P35; DePalma J A, 2001, Crit Care Nurs Q, V23, P42; Donnelly KZ, 2000, BRAIN COGNITION, V44, P21; Glover A, 2003, DISABIL REHABIL, V25, P750, DOI 10.1080/0963828021000058503; Goldstein FC, 1999, J NEUROPSYCH CLIN N, V11, P38, DOI 10.1176/jnp.11.1.38; Groswasser Z, 1999, NEUROPSYCHOL REHABIL, V9, P493, DOI 10.1080/096020199389545; Health and Welfare Bureau, 1999, HONG KONG REH PROGR; HEINEMANN AW, 1995, J HEAD TRAUMA REHAB, V10, P54, DOI 10.1097/00001199-199508000-00006; *HLTH WELF BUR, 2000, CONS DOC HLTH CAR RE, P5; *HLTH WELF BUR, 1999, HARV REP IMPR HONG K; Hoofien D, 2001, BRAIN INJURY, V15, P189; KAITARO T, 1995, BRAIN INJURY, V9, P713, DOI 10.3109/02699059509008227; KALPAKJIAN CZ, 2000, DISS ABSTR INT, V61, P6709; KLONOFF PS, 1986, J CLIN EXP NEUROPSYC, V8, P469, DOI 10.1080/01688638608405171; LO SK, 2000, 1 NAT QUAL LIF S GUA; Man DWK, 2003, BRAIN INJURY, V17, P775, DOI 10.1080/0269905031000088577; Man DWK, 2001, BRAIN INJURY, V15, P961, DOI 10.1080/02699050110065664; O'Neill J, 1998, J HEAD TRAUMA REHAB, V13, P68, DOI 10.1097/00001199-199808000-00007; Olver JH, 1996, BRAIN INJURY, V10, P841, DOI 10.1080/026990596123945; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; RENWICK R, 1996, QUALITY LIFE HLTH PR, P26; Seibert PS, 2002, BRAIN INJURY, V16, P837, DOI 10.1080/02699050210131939; Steadman-Pare D, 2001, J HEAD TRAUMA REHAB, V16, P330, DOI 10.1097/00001199-200108000-00004; TABOLT LR, 2000, BRAIN COGNITION, V44, P39; TENNANT A, 1995, BRAIN INJURY, V9, P595, DOI 10.3109/02699059509008218; THOMAS DF, 2001, J APPL REHABILITATIO, V32, P17; THOMSEN IV, 1990, NEUROBEHAVIOURAL SEQUELAE OF TRAUMATIC BRAIN INJURY, P52; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WATSON D, 1988, J PERS SOC PSYCHOL, V54, P1063, DOI 10.1037/0022-3514.54.6.1063	43	23	24	0	6	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JUN	2004	18	6					577	591		10.1080/02699050310001646143			15	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	811DX	WOS:000220753700005	15204338				2021-06-18	
J	Lee, JS; Han, YM; Yoo, DS; Choi, SJ; Choi, BH; Kim, JH; Kim, YH; Huh, PW; Ko, YJ; Rha, HK; Cho, KS; Kim, DS				Lee, JS; Han, YM; Yoo, DS; Choi, SJ; Choi, BH; Kim, JH; Kim, YH; Huh, PW; Ko, YJ; Rha, HK; Cho, KS; Kim, DS			A molecular basis for the efficacy of magnesium treatment following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						fluid percussion injury; gene expression; magnesium ion; traumatic brain injury	DNA STRAND BREAKS; EXPRESSION; NICKEL(II); APOPTOSIS; EXCISION; REPAIR; BAX; P53	Magnesium ions have been shown to be a promising treatment for brain lesions caused by traumatic brain injury (TBI), as well as for the associated acute neurodegeneration and progressive functional deficits. This study investigated the effects of magnesium on the expression of the cell death/survival related proteins following TBI. Male Sprague-Dawley (SD) rats (n = 66, 280-320 g body weight) were subjected to sham surgery alone (n = 14), or to the surgery followed by a lateral fluid percussion brain injury of moderate severity (n = 52, 2.4-2.7 atm). The injured rats were randomly treated with an intravenous bolus of magnesium chloride (n = 26, 125 mumol) or saline vehicle (n = 26). The coronal brain sections were quantitatively analyzed for cell apoptosis and the expression of p53-related proteins, Bcl-2, cyclin D1 and PCNA at 1, 2, and 4 days post-injury by immunohistochemistry or in situ hybridization. Tissue damage was observed primarily in the ipsilateral cortex of the injured region with the induction of apoptosis and p53 mRNA level at 2 days after TBI. The expression of p53 and responding proteins (p21(WAF1/C1P1), Mdm2 and Bax) showed a temporal pattern similar to the apoptotic events in the time course experiments. They were induced in the early time points of days 1-2, decreasing by day 4 after TBI. In contrast, the expression of the cell survival related proteins-Bcl-2, cyclin D1, and PCNA-was most significant at day 4 post-injury, when the rate of apoptosis decreased. Magnesium treatment resulted in a reduction in apoptosis and expression of p53-related proteins. However, it had only a slight additive effect on the expression of the survival related proteins in the same time-course. These results provide a molecular basis for the efficiency of magnesium in treating TBI-induced tissue damage.	Catholic Univ Korea, Coll Med, Dept Rehabil Med, Seoul 137701, South Korea; Catholic Univ Korea, Coll Med, Catholic Neurosci Ctr, Seoul 137701, South Korea; Catholic Univ Korea, Uijongbu St Marys Hosp, Dept Neurosurg, Uijongbu, South Korea	Ko, YJ (corresponding author), Catholic Univ Korea, Coll Med, Dept Rehabil Med, 505 Banpo Dong, Seoul 137701, South Korea.	yjko@catholic.ac.kr					Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Bush TG, 1999, NEURON, V23, P297, DOI 10.1016/S0896-6273(00)80781-3; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; ELDEIRY WS, 1994, CANCER RES, V54, P1169; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; FREEMAN RS, 1994, NEURON, V12, P343, DOI 10.1016/0896-6273(94)90276-3; Graham D I, 1993, Acta Neurochir Suppl (Wien), V57, P41; GU Y, 1993, NATURE, V366, P707, DOI 10.1038/366707a0; Hartmann M, 1998, CARCINOGENESIS, V19, P617, DOI 10.1093/carcin/19.4.617; HARTWIG A, 1994, CANCER RES, V54, P4045; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Jordan J, 1997, J NEUROSCI, V17, P1397; JUDITH KM, 1999, EXP NEUROL, V159, P584; Kawabata H, 1997, BIOCHEM BIOPH RES CO, V233, P133, DOI 10.1006/bbrc.1997.6362; LAPLACA MC, 1998, J NEUROTRAUM, V15, P878; Li Y, 1997, BRAIN RES, V765, P301, DOI 10.1016/S0006-8993(97)00524-6; LITTEFIELD NA, 1994, CELL BIOL TOXICOL, V10, P127, DOI 10.1007/BF00756493; LYDALL D, 1995, SCIENCE, V270, P1488, DOI 10.1126/science.270.5241.1488; MATSUMOTO Y, 1995, SCIENCE, V269, P699, DOI 10.1126/science.7624801; MAYER ML, 1984, NATURE, V309, P261, DOI 10.1038/309261a0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; MCINTOSH TK, 1994, CEREBROVAS BRAIN MET, V6, P109; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; MICHALOVITZ D, 1990, CELL, V62, P671, DOI 10.1016/0092-8674(90)90113-S; MIYASHITA T, 1995, CELL, V80, P293; NELSON WG, 1994, MOL CELL BIOL, V14, P1815, DOI 10.1128/MCB.14.3.1815; Pravdenkova SV, 1996, BRAIN RES, V729, P151, DOI 10.1016/0006-8993(96)00222-3; Raghupathi R, 1998, J NEUROTRAUM, V15, P555, DOI 10.1089/neu.1998.15.555; RAGHUPATHI R, 1997, J CEREB BLOOD FLOW M, V17, pS494; Ravishankar S, 2001, BRAIN RES, V901, P23, DOI 10.1016/S0006-8993(01)02109-6; SENSOL SK, 1999, BRAIN RES, V818, P23; SMITH ML, 1994, SCIENCE, V266, P1376, DOI 10.1126/science.7973727; Vink R, 2003, NEUROSCI LETT, V336, P41, DOI 10.1016/S0304-3940(02)01244-2	35	23	24	0	0	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAY	2004	21	5					549	561		10.1089/089771504774129883			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	821LK	WOS:000221461900006	15165363				2021-06-18	
J	Lai, YC; Kochanek, PM; Adelson, PD; Janesko, K; Ruppel, RA; Clark, RSB				Lai, YC; Kochanek, PM; Adelson, PD; Janesko, K; Ruppel, RA; Clark, RSB			Induction of the stress response after inflicted and non-inflicted traumatic brain injury in infants and children	JOURNAL OF NEUROTRAUMA			English	Article						cerebrospinal fluid; child abuse; head injury; heat shock protein; shaken baby syndrome	HEAT-SHOCK-PROTEIN; NITRIC-OXIDE SYNTHASE; IMMATURE RAT MODEL; CEREBROSPINAL-FLUID; MESSENGER-RNA; C-FOS; EXPRESSION; HSP70; GENE; APOPTOSIS	Rapid induction of 72-kD heat shock protein (Hsp70) is a key component of the stress response and is seen after a variety of insults to the brain including experimental hyperthermia, ischemia, seizures, and traumatic brain injury (TBI). Little is known about the endogenous stress response in pediatric patients after brain injury. Accordingly, the concentration of Hsp70 was determined in 61 cerebrospinal fluid (CSF) samples from 20 infants and children after TBI. Peak Hsp70 level were increased in TBI patients vs. controls.(4.60 [1.49-78.99] vs. 2.18 [1.38-4.25] ng/mL, respectively, median (range), p = 0.01) and occurred most often on day 1 after injury. Strikingly, CSF levels of Hsp70 were positively and independently associated with inflicted vs. non-inflicted TBI (7.03 [2.30-27.22] vs. 2.06 [1.06-78.99] ng/mL, respectively, p = 0.05). Endogenous Hsp70 expression was confirmed by Western blot and immunocytochemistry using brain tissue samples removed from patients who underwent decompressive craniotomy for refractory intracranial hypertension or at autopsy. These data suggest that the endogenous stress response, as measured and quantified by the Hsp70 concentration in CSF, occurs in infants and children after TBI. The endogenous stress response is more robust in victims of child abuse, compared with patients with accidental TBI, supporting age-dependence or a difference in either injury frequency, duration, severity, or mechanism in this subgroup of TBI patients. Further studies are needed to determine the role of Hsp70 in both non-inflicted and inflicted TBI in infants and children.	Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15213 USA; Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; St Vincents Hosp, Dept Pediat, Indianapolis, IN USA	Clark, RSB (corresponding author), Univ Pittsburgh, Childrens Hosp Pittsburgh, Sch Med, Dept Crit Care Med, Main Tower 6840 3705 5th Ave, Pittsburgh, PA 15213 USA.	clarkrs@ccm.upmc.edu	Kochanek, Patrick M/D-2371-2015; Adelson, David/W-2083-2019	Kochanek, Patrick M/0000-0002-2627-913X; Lai, Yi-Chen/0000-0002-9450-5506			ALEXANDER R, 1990, AM J DIS CHILD, V144, P58, DOI 10.1001/archpedi.1990.02150250068033; Amick Jonathan E., 2001, Pediatr Crit Care Med, V2, P260, DOI 10.1097/00130478-200107000-00013; Asea A, 2002, J BIOL CHEM, V277, P15028, DOI 10.1074/jbc.M200497200; Asea A, 2000, NAT MED, V6, P435; Avishai-Eliner S, 2001, J NEUROENDOCRINOL, V13, P799, DOI 10.1046/j.1365-2826.2001.00698.x; Beere HM, 2000, NAT CELL BIOL, V2, P469; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bell MJ, 1999, CRIT CARE MED, V27, P493, DOI 10.1097/00003246-199903000-00023; Berger RP, 2002, J NEUROTRAUM, V19, P1405, DOI 10.1089/089771502320914633; Berger RP, 2002, PEDIATRICS, V109, DOI 10.1542/peds.109.2.e31; Bertrand N, 2000, J CEREBR BLOOD F MET, V20, P1056, DOI 10.1097/00004647-200007000-00005; BLAKE MJ, 1991, AM J PHYSIOL, V260, P663; BURDON RH, 1993, MOL ASPECTS MED, V14, P83, DOI 10.1016/0098-2997(93)90020-E; Chen MZ, 1998, J NEUROTRAUM, V15, P171, DOI 10.1089/neu.1998.15.171; Clark RSB, 1996, PEDIATR RES, V39, P784, DOI 10.1203/00006450-199605000-00007; Clark RSB, 1999, FASEB J, V13, P813; CLARK RSB, 1994, J NEUROTRAUM, V11, P499, DOI 10.1089/neu.1994.11.499; Clark RSB, 2000, J PEDIATR-US, V137, P197, DOI 10.1067/mpd.2000.106903; DUHAIME AC, 1987, J NEUROSURG, V66, P409, DOI 10.3171/jns.1987.66.3.0409; DunnMeynell AA, 1997, BRAIN RES, V761, P25, DOI 10.1016/S0006-8993(97)00210-2; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; Dutcher SA, 1998, J NEUROTRAUM, V15, P421, DOI 10.1089/neu.1998.15.421; Gilles EE, 1996, PEDIATR NEUROL, V15, P114, DOI 10.1016/0887-8994(96)00153-1; Gilliland MGF, 1998, J FORENSIC SCI, V43, P723; GIULIAN D, 1989, J NEUROSCI, V9, P4416; Guzhova I, 2001, BRAIN RES, V914, P66, DOI 10.1016/S0006-8993(01)02774-3; Hoehn B, 2001, J CEREBR BLOOD F MET, V21, P1303, DOI 10.1097/00004647-200111000-00006; Jenny C, 1999, JAMA-J AM MED ASSOC, V281, P621, DOI 10.1001/jama.281.7.621; Kochanek Patrick M., 2000, Pediatr Crit Care Med, V1, P4, DOI 10.1097/00130478-200007000-00003; LEVIN HS, 1992, NEUROSURGERY, V31, P435, DOI 10.1227/00006123-199209000-00008; Lindsberg PJ, 1996, J CEREBR BLOOD F MET, V16, P82, DOI 10.1097/00004647-199601000-00010; Massa SM, 1996, CEREBROVAS BRAIN MET, V8, P95; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Morris ST, 2000, ANIM SCI, V70, P363, DOI 10.1017/S1357729800054825; Panjwani NN, 2002, J IMMUNOL, V168, P2997, DOI 10.4049/jimmunol.168.6.2997; Planas AM, 1997, PROG NEUROBIOL, V51, P607, DOI 10.1016/S0301-0082(97)00004-X; RAGHUPATHI R, 1995, J CEREBR BLOOD F MET, V15, P467, DOI 10.1038/jcbfm.1995.58; Ravagnan L, 2001, NAT CELL BIOL, V3, P839, DOI 10.1038/ncb0901-839; ROGUE PJ, 1993, FEBS LETT, V334, P351, DOI 10.1016/0014-5793(93)80710-C; Ruppel RA, 2002, NEUROSURG CLIN N AM, V13, P169, DOI 10.1016/S1042-3680(01)00005-5; Ruppel RA, 2001, J PEDIATR-US, V138, P18, DOI 10.1067/mpd.2001.110979; Schwartz M, 2001, TRENDS MOL MED, V7, P252, DOI 10.1016/S1471-4914(01)01993-1; Seidberg NA, 2003, J NEUROCHEM, V84, P514, DOI 10.1046/j.1471-4159.2003.01547.x; SIMON RP, 1991, J NEUROSCI, V11, P881; Sinz EH, 1999, J CLIN INVEST, V104, P647, DOI 10.1172/JCI6670; Srivastava P, 2002, ANNU REV IMMUNOL, V20, P395, DOI 10.1146/annurev.immunol.20.100301.064801; Truettner J, 1999, J NEUROTRAUM, V16, P471, DOI 10.1089/neu.1999.16.471; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Whalen MJ, 2000, CRIT CARE MED, V28, P929, DOI 10.1097/00003246-200004000-00003	49	23	23	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	MAR	2004	21	3					229	237		10.1089/089771504322972022			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	806CI	WOS:000220411600001	15115598				2021-06-18	
J	Adickes, MS; Stuart, MJ				Adickes, MS; Stuart, MJ			Youth football injuries	SPORTS MEDICINE			English	Article							HIGH-SCHOOL FOOTBALL; YOUNG ATHLETE; SPORTS; PITFALLS	A paucity of literature exists on the subject of youth football with the majority of research concentrating on athletes of high-school age or older. Youth football participants include those athletes who compete in organised football prior to high school. Injury rate and severity for youth players is surprisingly low when compared with those competitors who have passed through puberty. As children mature they become bigger, faster and stronger, which is accompanied by an increased injury risk. Quarterbacks and running backs are injured almost five times more often than offensive linemen and linebackers. The knee is the most common site of injury followed by the ankle, wrist and hand. Fortunately, traumatic brain and cervical spine injuries are exceedingly rare. In this article, we review the youth football literature, identify the most common injuries by anatomical location, discuss the differential diagnoses and outline treatment options.	Mayo Clin, Dept Orthoped Surg, Rochester, MN 55905 USA	Stuart, MJ (corresponding author), Mayo Clin, Dept Orthoped Surg, 200 1st St,SW, Rochester, MN 55905 USA.						Culpepper M I, 1983, Phys Sportsmed, V11, P117, DOI 10.1080/00913847.1983.11708662; DAGIAU RF, 1980, AM J SPORT MED, V8, P257, DOI 10.1177/036354658000800408; DELEE JC, 1992, AM J SPORT MED, V20, P575, DOI 10.1177/036354659202000515; GARRICK JG, 1978, PEDIATRICS, V61, P465, DOI 10.1542/peds.61.3.465; Godshall R W, 1975, J Sports Med, V3, P139; GOLDBERG B, 1984, PHYSICIAN SPORTSMED, V12, P122; HALPERN B, 1987, AM J SPORT MED, V15, P316, DOI 10.1177/036354658701500404; HANKIN FM, 1990, HAND CLIN, V6, P429; Iobst CA, 2000, CLIN SPORT MED, V19, P621, DOI 10.1016/S0278-5919(05)70229-5; LECLERC S, 2002, ANN EMERG MED, V40, P442; LINDER MM, 1995, CLIN J SPORT MED, V5, P167, DOI 10.1097/00042752-199507000-00006; Metzl JD, 1999, PEDIATR EMERG CARE, V15, P363, DOI 10.1097/00006565-199910000-00018; MORETZ A, 1978, J OKLA ST MED ASSOC, V71, P85; Perron AD, 2001, AM J EMERG MED, V19, P413, DOI 10.1053/ajem.2001.24464; PRAGER BI, 1989, AM J SPORT MED, V17, P681, DOI 10.1177/036354658901700516; Radelet MA, 2002, PEDIATRICS, V110, DOI 10.1542/peds.110.3.e28; ROSER LA, 1970, CLIN ORTHOP RELAT R, P219; SAAL JA, 1991, SPORTS MED, V12, P132, DOI 10.2165/00007256-199112020-00005; Stuart MJ, 2002, MAYO CLIN PROC, V77, P317, DOI 10.4065/77.4.317; THOMPSON N, 1987, AM J SPORT MED, V15, P117, DOI 10.1177/036354658701500204; Title CI, 2002, ORTHOP CLIN N AM, V33, P587, DOI 10.1016/S0030-5898(02)00006-8	21	23	23	0	8	ADIS INTERNATIONAL LTD	AUCKLAND	41 CENTORIAN DR, PRIVATE BAG 65901, MAIRANGI BAY, AUCKLAND 10, NEW ZEALAND	0112-1642			SPORTS MED	Sports Med.		2004	34	3					201	207		10.2165/00007256-200434030-00005			7	Sport Sciences	Sport Sciences	802WN	WOS:000220193700005	14987128				2021-06-18	
J	Fujita, R; Ueda, H				Fujita, R; Ueda, H			Protein kinase C-mediated cell death mode switch induced by high glucose	CELL DEATH AND DIFFERENTIATION			English	Article						necrosis; apoptosis; glucose; protein kinase C; ATP	TRAUMATIC BRAIN-INJURY; SODIUM-POTASSIUM ATPASE; CEREBRAL BLOOD-FLOW; CORTICAL-NEURONS; CYTOCHROME-C; BCL-2 FAMILY; PHOSPHOLIPASE-C; NERVOUS-SYSTEM; APOPTOSIS; NECROSIS	Cortical neurons rapidly die in necrosis due to poor glucose uptake in the low-density (LD) culture under serum-free condition without any supplements. The scanning and transmission electron microscopical analyses characterized the necrosis by membrane disruption, mitochondrial swelling and loss of cytoplasmic electron density. High-glucose treatment delayed the neuronal death by suppressing necrosis, but induced apoptosis through increase in Bax levels, cytochrome c release, caspase-3 activation and DNA ladder formation. Although pyruvate as well as high glucose inhibited necrotic cell death and rapid decrease in cellular ATP levels, possibly related to decreased [(3)H]-2-deoxy glucose uptake under the serum-free condition, it did not induce apoptosis. Protein kinase C inhibitors blocked these changes related to the cell death mode switch. Several neurotrophic factors did not affect the necrosis, but potentiated high-glucose-induced survival activity, while inhibiting cytochrome c release. All these results suggest that high-glucose treatment causes neuronal cell death mode switch by inhibiting necrosis, while inducing apoptosis, which is prevented by neurotrophic factors.	Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, Nagasaki 8528521, Japan	Ueda, H (corresponding author), Nagasaki Univ, Grad Sch Biomed Sci, Div Mol Pharmacol & Neurosci, 1-14 Bunkyo Machi, Nagasaki 8528521, Japan.	ueda@net.nagasaki-u.ac.jp		Ueda, Hiroshi/0000-0002-8002-0137			Ansari K, 1999, J BIOL CHEM, V274, P30052, DOI 10.1074/jbc.274.42.30052; Ashkenazi A, 1998, SCIENCE, V281, P1305, DOI 10.1126/science.281.5381.1305; Becker KJ, 1998, CURR OPIN NEUROL, V11, P45, DOI 10.1097/00019052-199802000-00008; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; Bredesen DE, 1995, ANN NEUROL, V38, P839, DOI 10.1002/ana.410380604; Dirnagl U, 1999, TRENDS NEUROSCI, V22, P391, DOI 10.1016/S0166-2236(99)01401-0; Eguchi Y, 1997, CANCER RES, V57, P1835; Faden AI, 1996, PHARMACOL TOXICOL, V78, P12, DOI 10.1111/j.1600-0773.1996.tb00173.x; Fujita R, 2003, CELL DEATH DIFFER, V10, P782, DOI 10.1038/sj.cdd.4401239; Fujita R, 2001, CELL MOL NEUROBIOL, V21, P317, DOI 10.1023/A:1012645920229; FUJITA R, 2002, SFN 32 ANN M, P15; Furlan M, 1996, ANN NEUROL, V40, P216, DOI 10.1002/ana.410400213; GAVRIELI Y, 1992, J CELL BIOL, V119, P493, DOI 10.1083/jcb.119.3.493; Green DR, 1998, SCIENCE, V281, P1309, DOI 10.1126/science.281.5381.1309; Ha HC, 1999, P NATL ACAD SCI USA, V96, P13978, DOI 10.1073/pnas.96.24.13978; Hamabe W, 2000, CELL MOL NEUROBIOL, V20, P695, DOI 10.1023/A:1007050808754; HOSSMANN KA, 1994, ANN NEUROL, V36, P557, DOI 10.1002/ana.410360404; Kaufmann SH, 2001, TRENDS CELL BIOL, V11, P526, DOI 10.1016/S0962-8924(01)02173-0; KERR JFR, 1972, BRIT J CANCER, V26, P239, DOI 10.1038/bjc.1972.33; Kluck RM, 1997, SCIENCE, V275, P1132, DOI 10.1126/science.275.5303.1132; KOIVISTO UM, 1991, J BIOL CHEM, V266, P2615; Kouroku Y, 1998, BIOCHEM BIOPH RES CO, V247, P780, DOI 10.1006/bbrc.1998.8815; Lee Y, 1999, J BIOL CHEM, V274, P19792, DOI 10.1074/jbc.274.28.19792; LEES GJ, 1994, BRAIN RES, V649, P225, DOI 10.1016/0006-8993(94)91068-5; LEES GJ, 1990, NEUROSCI LETT, V120, P159, DOI 10.1016/0304-3940(90)90027-7; Leist M, 1997, J EXP MED, V185, P1481, DOI 10.1084/jem.185.8.1481; MacManus JP, 1997, J CEREBR BLOOD F MET, V17, P815, DOI 10.1038/aj.jcbfm.9590266; Marzo I, 1998, SCIENCE, V281, P2027, DOI 10.1126/science.281.5385.2027; MUIZELAAR JP, 1994, CAN J NEUROL SCI, V21, pS6, DOI 10.1017/S0084255900003685; Nakagawa T, 2000, NATURE, V403, P98, DOI 10.1038/47513; Nicotera P, 1997, CELL DEATH DIFFER, V4, P435, DOI 10.1038/sj.cdd.4400265; Osuga H, 2000, P NATL ACAD SCI USA, V97, P10254, DOI 10.1073/pnas.170144197; Putcha GV, 2001, NEURON, V29, P615, DOI 10.1016/S0896-6273(01)00238-0; Richter C, 1996, FEBS LETT, V378, P107, DOI 10.1016/0014-5793(95)01431-4; RINK A, 1995, AM J PATHOL, V147, P1575; Senatorov VV, 2000, J PHYSIOL-LONDON, V525, P343, DOI 10.1111/j.1469-7793.2000.00343.x; Shimizu S, 1999, NATURE, V399, P483, DOI 10.1038/20959; Tisi R, 2002, FEBS LETT, V520, P133, DOI 10.1016/S0014-5793(02)02806-5; Towne JE, 2001, J BIOL CHEM, V276, P18657, DOI 10.1074/jbc.M100322200; Tsujimoto Y, 1997, CELL DEATH DIFFER, V4, P429, DOI 10.1038/sj.cdd.4400262; Tsujimoto Y, 2000, FEBS LETT, V466, P6, DOI 10.1016/S0014-5793(99)01761-5; VERMES I, 1995, J IMMUNOL METHODS, V184, P39, DOI 10.1016/0022-1759(95)00072-I; Xue Y, 1998, EMBO J, V17, P1996, DOI 10.1093/emboj/17.7.1996; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yang J, 1997, SCIENCE, V275, P1129, DOI 10.1126/science.275.5303.1129; Yoshida A, 1999, BIOCHEM BIOPH RES CO, V259, P78, DOI 10.1006/bbrc.1999.0627; Yoshida A, 2000, INT J MOL MED, V6, P329; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	50	23	24	0	0	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1350-9047			CELL DEATH DIFFER	Cell Death Differ.	DEC	2003	10	12					1336	1347		10.1038/sj.cdd.4401300			12	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	745ZA	WOS:000186720300007	12934062	Bronze			2021-06-18	
J	Davis, DP; Patel, PM				Davis, Daniel P.; Patel, Piyush M.			Ischemic preconditioning in the brain	CURRENT OPINION IN ANESTHESIOLOGY			English	Article						cerebral ischemia preconditioning; ischemic preconditioning; volatile anesthetics	FOCAL CEREBRAL-ISCHEMIA; RAT CORTICAL-NEURONS; PROTEIN-KINASE-II; BICUCULLINE EVOKED SEIZURES; LONG-TERM SURVIVAL; NITRIC-OXIDE; 3-NITROPROPIONIC ACID; TRANSIENT EPISODE; IN-VITRO; SUBCELLULAR-DISTRIBUTION	Purpose of review Brain ischemia is responsible for significant morbidity and mortality associated with cardiovascular surgery, and is the end result of multiple disease states, including cardiac arrest, stroke, and traumatic brain injury. Despite significant resources dedicated to developing neuroprotective strategies, little progress has been made in this regard. Neuronal ischemic preconditioning is an endogenous neuroprotective strategy that provides sustained and robust ischemic tolerance. Identification of the mechanisms responsible for mediating the preconditioning response may offer novel therapeutic targets and further our understanding of the natural adaptations to brain injury. Recent findings Recent research efforts have elucidated many intracellular signaling pathways that ultimately lead to ischemic tolerance after a preconditioning stimulus. Most of these are associated with glutamate receptor signal transduction, the intracellular kinases, and several transcription regulators. Microarray analysis has identified several gene families that warrant further investigation to identify novel candidates for neuroprotective therapies. These include genes involved in synaptic architecture and signal propagation, cell cycle and transcription regulators, and mediators of apoptosis such as the heat shock proteins and anti-apoptotic mitochondrial proteins. Summary Neuronal ischemic preconditioning is an endogenous mechanism that leads to robust neuroprotection from ischemia. Identification of the upstream pathways that initiate preconditioning and candidate genes that mediate this phenomenon may offer novel therapeutic targets, with applicability to a variety of disease states and perioperative complications.	[Patel, Piyush M.] VA Med Ctr, Anesthesia Serv 125, San Diego, CA 92161 USA; [Davis, Daniel P.] Univ Calif San Diego, Dept Emergency Med, San Diego, CA 92103 USA; [Patel, Piyush M.] Univ Calif San Diego, Dept Anesthesiol, San Diego, CA 92103 USA	Patel, PM (corresponding author), VA Med Ctr, Anesthesia Serv 125, 3350 La Jolla Village Dr, San Diego, CA 92161 USA.	ppatel@ucsd.edu			National Institutes of Health (USA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; SAEM (Society for Academic Emergency Medicine)	This study was supported by a grant from the National Institutes of Health (USA) to P.M.P. and from SAEM (Society for Academic Emergency Medicine) to D.P.D.	Abe H, 2000, NEUROSCI LETT, V295, P54, DOI 10.1016/S0304-3940(00)01577-9; Aizenman E, 2000, J PHARMACOL EXP THER, V295, P572; Bauer B, 1999, BASIC RES CARDIOL, V94, P31, DOI 10.1007/s003950050124; Belayev L, 1996, NEUROREPORT, V8, P55, DOI 10.1097/00001756-199612200-00012; Bhardwaj A, 2001, STROKE, V32, P1920, DOI 10.1161/01.STR.32.8.1920; Blanck TJJ, 2000, ANESTHESIOLOGY, V93, P1285, DOI 10.1097/00000542-200011000-00023; Blondeau N, 2001, J NEUROSCI, V21, P4668, DOI 10.1523/JNEUROSCI.21-13-04668.2001; Bond A, 1999, EUR J PHARMACOL, V380, P91, DOI 10.1016/S0014-2999(99)00523-3; Bossenmeyer-Pourie C, 2000, PEDIATR RES, V47, P385, DOI 10.1203/00006450-200003000-00017; Brambrink AM, 2000, J CEREBR BLOOD F MET, V20, P1425, DOI 10.1097/00004647-200010000-00004; Bruer U, 1997, FEBS LETT, V414, P117, DOI 10.1016/S0014-5793(97)00954-X; Centeno JM, 1999, BRAIN RES, V836, P62, DOI 10.1016/S0006-8993(99)01610-8; Corbett D, 1997, BRAIN RES, V760, P129, DOI 10.1016/S0006-8993(97)00294-1; Corbett D, 1998, PROG NEUROBIOL, V54, P531, DOI 10.1016/S0301-0082(97)00078-6; Dawson VL, 2000, TRENDS PHARMACOL SCI, V21, P423, DOI 10.1016/S0165-6147(00)01560-1; Deplanque D, 2000, STROKE, V31, P1465; Dowden J, 1999, STROKE, V30, P1240, DOI 10.1161/01.STR.30.6.1240; Emerson MR, 1999, BRAIN RES, V825, P189, DOI 10.1016/S0006-8993(99)01195-6; Furuya K, 2001, J CEREBR BLOOD F MET, V21, P226, DOI 10.1097/00004647-200103000-00006; Gidday JM, 1999, J CEREBR BLOOD F MET, V19, P331, DOI 10.1097/00004647-199903000-00011; Ginis I, 2002, J CEREBR BLOOD F MET, V22, P142, DOI 10.1097/00004647-200202000-00002; Ginis I, 1999, AM J PHYSIOL-CELL PH, V276, pC1171; GLAZIER SS, 1994, J CEREBR BLOOD F MET, V14, P545, DOI 10.1038/jcbfm.1994.68; Gonzalez-Zulueta M, 2000, P NATL ACAD SCI USA, V97, P436, DOI 10.1073/pnas.97.1.436; HANYU S, 1993, ACTA NEUROPATHOL, V86, P16, DOI 10.1007/BF00454893; HEURTEAUX C, 1995, P NATL ACAD SCI USA, V92, P4666, DOI 10.1073/pnas.92.10.4666; Johns L, 2000, BIOCHEM BIOPH RES CO, V276, P134, DOI 10.1006/bbrc.2000.3443; Kapinya KJ, 2002, NEUROREPORT, V13, P1431, DOI 10.1097/00001756-200208070-00017; Kapinya KJ, 2002, STROKE, V33, P1889, DOI 10.1161/01.STR.0000020092.41820.58; KATO H, 1992, BRAIN RES BULL, V29, P559, DOI 10.1016/0361-9230(92)90123-F; Katsura K, 2001, NEUROL RES, V23, P751, DOI 10.1179/016164101101199126; Kirino T, 2002, J CEREBR BLOOD F MET, V22, P1283, DOI 10.1097/01.WCB.0000040942.89393.88; Kitagawa K, 1997, NEUROSCIENCE, V81, P989, DOI 10.1016/S0306-4522(97)00229-7; Kurkinen K, 2001, NEUROREPORT, V12, P269, DOI 10.1097/00001756-200102120-00018; Kuroiwa T, 2000, NEUROSCI LETT, V283, P145, DOI 10.1016/S0304-3940(00)00937-X; Mabuchi T, 2001, J NEUROSCI, V21, P9204, DOI 10.1523/JNEUROSCI.21-23-09204.2001; Masada T, 2001, J CEREBR BLOOD F MET, V21, P22, DOI 10.1097/00004647-200101000-00004; Matsushima K, 1996, J CEREBR BLOOD F MET, V16, P221, DOI 10.1097/00004647-199603000-00006; Matsuyama K, 1997, ANN THORAC SURG, V63, P1315, DOI 10.1016/S0003-4975(97)00104-5; Mori T, 2000, NEUROPATH APPL NEURO, V26, P31, DOI 10.1046/j.1365-2990.2000.00215.x; MURRY CE, 1986, CIRCULATION, V74, P1124, DOI 10.1161/01.CIR.74.5.1124; Nagata A, 1998, ANESTH ANALG, V87, P1416, DOI 10.1097/00000539-199812000-00040; Nishio S, 2000, J NEUROSURG, V93, P845, DOI 10.3171/jns.2000.93.5.0845; Nishio S, 1999, ANN NY ACAD SCI, V890, P26, DOI 10.1111/j.1749-6632.1999.tb07978.x; Ohno M, 1996, BRAIN RES BULL, V40, P229, DOI 10.1016/0361-9230(96)00050-0; Premkumar A, 2002, J NEUROCHEM, V82, P345, DOI 10.1046/j.1471-4159.2002.00966.x; Puisieux F, 2000, EUR J PHARMACOL, V389, P71, DOI 10.1016/S0014-2999(99)00893-6; Rauca C, 2000, BRAIN RES, V868, P147, DOI 10.1016/S0006-8993(00)02388-X; Ravati A, 2001, J NEUROCHEM, V78, P909, DOI 10.1046/j.1471-4159.2001.00463.x; Rejdak K, 2000, EPILEPSY RES, V41, P213, DOI 10.1016/S0920-1211(00)00143-1; Rejdak K, 2000, J NEURAL TRANSM, V107, P1263, DOI 10.1007/s007020070016; Rejdak K, 2000, J NEURAL TRANSM, V107, P947, DOI 10.1007/s007020070044; Reshef A, 1998, ADV EXP MED BIOL, V431, P365; Rubino A, 2000, TRENDS PHARMACOL SCI, V21, P225, DOI 10.1016/S0165-6147(00)01483-8; Shamloo M, 1999, J CEREBR BLOOD F MET, V19, P173; Shamloo M, 2000, NEUROSCIENCE, V96, P665, DOI 10.1016/S0306-4522(99)00586-2; Shamloo M, 1999, NEUROSCIENCE, V93, P81, DOI 10.1016/S0306-4522(99)00137-2; Skaper SD, 2001, ANN NY ACAD SCI, V939, P11; Taga K, 1997, ANESTHESIOLOGY, V87, P918, DOI 10.1097/00000542-199710000-00027; Tan SE, 2002, NEUROPHARMACOLOGY, V42, P540, DOI 10.1016/S0028-3908(02)00004-7; Tauskela JS, 1999, BRAIN RES, V827, P143, DOI 10.1016/S0006-8993(99)01322-0; Toyoda T, 2000, J NEUROSURG, V92, P435, DOI 10.3171/jns.2000.92.3.0435; Tremblay R, 2000, J NEUROSCI, V20, P7183; Vannucci RC, 1998, J NEUROCHEM, V71, P1215; von Arnim CAF, 2001, NEUROSCI LETT, V299, P130, DOI 10.1016/S0304-3940(00)01762-6; Wang XK, 2000, J CEREBR BLOOD F MET, V20, P15, DOI 10.1097/00004647-200001000-00004; Weih M, 1999, NEUROSCI LETT, V272, P207, DOI 10.1016/S0304-3940(99)00594-7; Whitfield PC, 1999, BRAIN RES, V818, P450, DOI 10.1016/S0006-8993(98)01342-0; Xiong LZ, 2003, ANESTH ANALG, V96, P233, DOI 10.1097/00000539-200301000-00047; Zhan RZ, 2002, ANESTHESIOLOGY, V97, P896, DOI 10.1097/00000542-200210000-00022; Zvara DA, 1999, ANN THORAC SURG, V68, P874, DOI 10.1016/S0003-4975(99)00559-7	71	23	28	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0952-7907	1473-6500		CURR OPIN ANESTHESIO	Curr. Opin. Anesthesiol.	OCT	2003	16	5					447	452		10.1097/00001503-200310000-00002			6	Anesthesiology	Anesthesiology	V24WJ	WOS:000208440200002	17021495				2021-06-18	
J	Ursino, M; Giulloni, M				Ursino, M; Giulloni, M			Quantitative assessment of cerebral autoregulation from transcranial Doppler pulsatility: a computer simulation study	MEDICAL ENGINEERING & PHYSICS			English	Article						cerebral autoregulation; cerebral perfusion pressure; intracranial pressure; mathematical model; Transcranial Doppler	HUMAN INTRACRANIAL HYDRODYNAMICS; TRAUMATIC BRAIN INJURY; FLUID PULSE PRESSURE; BLOOD-FLOW VELOCITY; SEVERE HEAD-INJURY; MATHEMATICAL-MODEL; AUTO-REGULATION; CO2 REACTIVITY; ULTRASOUND; DYNAMICS	Transcranial Doppler (TCD) ultrasonography is largely used today to achieve non-invasive assessment of cerebral autoregulation and cerebrovascular reactivity in neurosurgical patients. Recent experimental and clinical studies suggest that not only the pattern of mean velocity, but also velocity pulse amplitude alterations during changes in cerebral perfusion pressure (CPP) contain information on autoregulation status. The aim of this work is to investigate the relationship between cerebral autoregulation and TCD pulsatility by means of a comprehensive mathematical model of intracranial dynamics and cerebrovascular regulation. Simulation results, performed using different values of the most important clinical parameters of the model (autoregulation strength, cerebrospinal fluid (CSF) outflow resistance and intracranial elastance coefficient) show that velocity pulse amplitude increases with a reduction in CPP in patients with intact autoregulation, whereas changes in velocity pulsatility are modest in patients with weak autoregulation. Finally, velocity pulse amplitude decreases during a CPP reduction in patients with impaired autoregulation. Moreover, the relationship between the velocity pulse amplitude changes and autoregulation strength is almost linear in a wide range of CPP values, and is scarcely affected by changes in CSF circulation and intracranial elasticity. Starting from these results, we suggest a new quantitative index to assess autoregulation strength, i.e. G(aut)% = (s-b)/a, where G(aut)% is autoregulation strength (100% means intact autoregulation, 0% means impaired autoregulation), a similar or equal to -0.03; bsimilar or equal to1.5 and s is the slope of the relationship percentage changes of velocity pulse amplitude to arterial pressure pulse amplitude vs. CPP changes'. (C) 2003 IPEM. Published by Elsevier Science Ltd. All rights reserved.	Univ Bologna, Dipartimento Elettron Informat & Sistemist, I-40136 Bologna, Italy; Bellaria Hosp, Dept Neurosurg, Bologna, Italy	Ursino, M (corresponding author), Univ Bologna, Dipartimento Elettron Informat & Sistemist, Viale Risorgimento 2, I-40136 Bologna, Italy.			Ursino, Mauro/0000-0002-0911-0308			AASLID R, 1982, J NEUROSURG, V57, P769, DOI 10.3171/jns.1982.57.6.0769; AUER LM, 1987, J NEUROSURG, V67, P263, DOI 10.3171/jns.1987.67.2.0263; AVEZAAT CJJ, 1979, J NEUROL NEUROSUR PS, V42, P687, DOI 10.1136/jnnp.42.8.687; AVEZAAT CJJ, 1983, INTRACRANIAL PRESSUR, V5, P326; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHAN KH, 1992, J NEUROSURG, V77, P55, DOI 10.3171/jns.1992.77.1.0055; Czosnyka M, 1997, NEUROSURGERY, V41, P11, DOI 10.1097/00006123-199707000-00005; CZOSNYKA M, 1994, NEUROSURGERY, V35, P287, DOI 10.1227/00006123-199408000-00015; Enevoldsen E, 1986, Acta Neurochir Suppl (Wien), V36, P133; ENEVOLDSEN EM, 1978, J NEUROSURG, V48, P689, DOI 10.3171/jns.1978.48.5.0689; GILLER CA, 1991, ACTA NEUROCHIR, V108, P7, DOI 10.1007/BF01407660; Junger EC, 1997, J NEUROSURG, V86, P425, DOI 10.3171/jns.1997.86.3.0425; Kelly DF, 1997, J NEUROSURG, V86, P633, DOI 10.3171/jns.1997.86.4.0633; KONTOS HA, 1978, AM J PHYSIOL, V234, P371; KOSTELJANETZ M, 1986, NEUROSURGERY, V18, P17, DOI 10.1227/00006123-198601000-00004; Lodi CA, 1998, AM J PHYSIOL-HEART C, V274, pH1729; MACKENZIE ET, 1979, STROKE, V10, P711, DOI 10.1161/01.STR.10.6.711; MARMAROU A, 1975, J NEUROSURG, V43, P523, DOI 10.3171/jns.1975.43.5.0523; MARMAROU A, 1991, J NEUROSURG S, V75, P59; Martin NA, 1997, J NEUROSURG, V87, P9, DOI 10.3171/jns.1997.87.1.0009; Milnor WR, 1982, HEMODYNAMICS; MUIZELAAR JP, 1989, J NEUROSURG, V71, P72, DOI 10.3171/jns.1989.71.1.0072; NELSON RJ, 1992, NEUROSURGERY, V31, P705; NORNES H, 1977, ACTA NEUROCHIR, V38, P177, DOI 10.1007/BF01401089; Panerai RB, 1998, PHYSIOL MEAS, V19, P305, DOI 10.1088/0967-3334/19/3/001; STEIGER HJ, 1994, NEUROSURGERY, V34, P79; STRANDGAARD S, 1984, STROKE, V15, P413, DOI 10.1161/01.STR.15.3.413; TIECKS FP, 1995, STROKE, V26, P1014, DOI 10.1161/01.STR.26.6.1014; Ursino M, 1998, AM J PHYSIOL-HEART C, V274, pH1715; URSINO M, 1991, ANN BIOMED ENG, V19, P15, DOI 10.1007/BF02368459; URSINO M, 1995, IEEE T BIO-MED ENG, V42, P529, DOI 10.1109/10.387192; URSINO M, 1988, ANN BIOMED ENG, V16, P379, DOI 10.1007/BF02364625; URSINO M, 1988, ANN BIOMED ENG, V16, P403, DOI 10.1007/BF02364626; Ursino M, 2001, ANN BIOMED ENG, V29, P563, DOI 10.1114/1.1380423	34	23	25	0	5	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	1350-4533			MED ENG PHYS	Med. Eng. Phys.	OCT	2003	25	8					655	666		10.1016/S1350-4533(02)00251-5			12	Engineering, Biomedical	Engineering	722MK	WOS:000185379200005	12900181				2021-06-18	
J	Baker-Price, L; Persinger, MA				Baker-Price, L; Persinger, MA			Intermittent burst-firing weak (1 microTesla) magnetic fields reduce psychometric depression in patients who sustained closed head injuries: A replication and electroencephalographic validation	PERCEPTUAL AND MOTOR SKILLS			English	Article								14 patients who reported chronic depression more than one year after closed head injuries were exposed to weak (1 microTesla), burst-firing magnetic fields either across the temporal lobes or over the left frontal lobe. The treatment was for 30 min. once per week for 6 wk. The reduction in depression scores after 5 wk. of treatments and after 6 wk. of no treatment (follow-up) accommodated 54% of the variance for both groups. The changes in depression scores did not differ significantly between the two groups (temporal vs frontal). Following treatment, the frequency of complex partial epileptic-like experiences decreased significantly only for the 7 who received the bilateral stimulation over the temporal lobes. Quantitative bipolar electroencephalographic measurements over the occipital, prefrontal, and temporal regions showed increased power within the 16-Hz to 18-Hz range 6 wk. after termination of treatment for those 7 patients who received the burst-firing magnetic fields bilaterally over the temporal lobes but not over the left prefrontal region.	Laurentian Univ, Clin Neurosci Lab, Sudbury, ON P3E 2C6, Canada	Persinger, MA (corresponding author), Laurentian Univ, Clin Neurosci Lab, Ramsey Lake Rd, Sudbury, ON P3E 2C6, Canada.						BakerPrice LA, 1996, PERCEPT MOTOR SKILL, V83, P491, DOI 10.2466/pms.1996.83.2.491; Beck A.T., 1987, BECK DEPRESSION INVE; BUREAU YRJ, 1995, ELECTRO MAGNETOBIOL, V14, P1, DOI 10.3109/15368379509028464; GODDARD GV, 1986, LIMBIC SYSTEM FUNCTI, P95; Pearlson Godfrey D., 1995, P1019; Persinger MA, 2000, PERCEPT MOTOR SKILL, V90, P659, DOI 10.2466/PMS.90.2.659-674; Roberts RJ, 1990, NEUROPSYCHOLOGY, V4, P65; Speer AM, 2000, BIOL PSYCHIAT, V48, P1133, DOI 10.1016/S0006-3223(00)01065-9; TEBANO MT, 1988, ELECTROEN CLIN NEURO, V70, P185, DOI 10.1016/0013-4694(88)90118-6; TSANG EW, 2002, INT J BIOELECTROMAGN, V2, P263; Videbech P, 2000, ACTA PSYCHIAT SCAND, V101, P11, DOI 10.1034/j.1600-0447.2000.101001011.x; Wassermann EM, 2001, CLIN NEUROPHYSIOL, V112, P1367, DOI 10.1016/S1388-2457(01)00585-5; ZHONGQI N, 1998, P 20 ANN INT C IEEE, V20, P3275	13	23	23	0	0	PERCEPTUAL MOTOR SKILLS	MISSOULA	PO BOX 9229, MISSOULA, MT 59807 USA	0031-5125			PERCEPT MOTOR SKILL	Percept. Mot. Skills	JUN	2003	96	3	1				965	974		10.2466/PMS.96.3.965-974			10	Psychology, Experimental	Psychology	687JA	WOS:000183372000035	12831278				2021-06-18	
J	Toschlog, EA; MacElligot, J; Sagraves, SG; Schenarts, PJ; Bard, MR; Goettler, CE; Rotondo, MF; Swanson, MS				Toschlog, EA; MacElligot, J; Sagraves, SG; Schenarts, PJ; Bard, MR; Goettler, CE; Rotondo, MF; Swanson, MS			The relationship of Injury Severity Score and Glasgow Coma Score to rehabilitative potential in patients suffering traumatic brain injury	AMERICAN SURGEON			English	Article; Proceedings Paper	71st Annual Meeting of the Southeastern Surgical Congress	FEB 09-11, 2003	SAVANNAH, GEORGIA	SE Surg Congress			FUNCTIONAL INDEPENDENCE MEASURE; SEVERE HEAD-INJURY; PREDICTION; DISABILITY; VARIABLES; SYSTEMS; SCALE	The predictive utility of the Injury Severity Score (ISS) and Glasgow Coma Score (GCS) in relation to rehabilitative potential and functional outcome in traumatic brain injury (TBI) is untested. The purpose of this study was to define the relationship of ISS and GCS to rehabilitative potential using the functional independence measure (FIM) score. Trauma and inpatient rehabilitation (IR) registries were queried for demographic, disposition, and injury scoring data. FIM scores at admission (A) and discharge (D) were assessed including IR FIM gain (G). Analysis of variance was used to examine the relationship of ISS and GCS to FIM with predictive utility investigated through bivariate analysis. Of 5488 patients admitted to a Level I trauma center (1999-2000) 1437 suffered TBI with 285 (20%) entering IR. Compared with low-ISS patients the high-ISS patients had significantly lower FIM-A and FIM-D, but FIM-G was static. GCS results were similar, excluding FIM-G which was significantly higher for GCS less than or equal to8 compared with GCS >8. Bivariate analysis revealed no ISS correlation with FIM-G (r = 0.16) and a weak GCS correlation (FIM-G r = -0.15). As prospective predictive measures ISS and GCS correlate weakly with rehabilitative potential in TBI patients. Severely injured patients including those with severe TBI have a rehabilitative gain toward functional independence that is similar to that of when compared with those less severely injured.	E Carolina Univ, Brody Sch Med, Univ Hlth Syst Eastern N Carolina, Ctr Excellence Trauma & Surg Crit Care,Dept Surg, Greenville, NC 27858 USA	Toschlog, EA (corresponding author), E Carolina Univ, Brody Sch Med, Univ Hlth Syst Eastern N Carolina, Ctr Excellence Trauma & Surg Crit Care,Dept Surg, Greenville, NC 27858 USA.						Alvarez M, 1998, CRIT CARE MED, V26, P142, DOI 10.1097/00003246-199801000-00030; Bouillon B, 1997, J TRAUMA, V42, P652, DOI 10.1097/00005373-199704000-00012; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; CHAMPION HR, 1989, J TRAUMA, V29, P623, DOI 10.1097/00005373-198905000-00017; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Corrigan JD, 1997, ARCH PHYS MED REHAB, V78, P828, DOI 10.1016/S0003-9993(97)90195-7; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; DISCALA C, 1992, AM J PHYS MED REHAB, V71, P145, DOI 10.1097/00002060-199206000-00004; GRANGER CV, 1993, AM J PHYS MED REHAB, V72, P33, DOI 10.1097/00002060-199302000-00008; HAMILTON BB, 1994, SCAND J REHABIL MED, V26, P115; HAMILTON BB, 1986, GUIDE USE UNIFORM DA; HART AC, 2001, INT CLASSIFICATION D; Marik PE, 2002, CHEST, V122, P699, DOI 10.1378/chest.122.2.699; PRICE DJE, 1972, INJURY-BR J ACCIDENT, V3, P218, DOI 10.1016/0020-1383(72)90104-0; *RES FDN STAT U NE, 1990, GUID US UN DAT SET M; TEASDALE G, 1974, LANCET, V2, P81; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P13; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; Wagner AK, 2000, AM J PHYS MED REHAB, V79, P235, DOI 10.1097/00002060-200005000-00004; Wagner AK, 2000, J TRAUMA, V49, P411, DOI 10.1097/00005373-200009000-00005; WAXMAN K, 1991, ARCH SURG-CHICAGO, V126, P1237; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P364, DOI 10.1097/00002060-199609000-00012; Zafonte RD, 1996, AM J PHYS MED REHAB, V75, P456, DOI 10.1097/00002060-199611000-00011	24	23	24	0	4	SOUTHEASTERN SURGICAL CONGRESS	ATLANTA	141 WEST WIEUCA RD, STE B100, ATLANTA, GA 30342 USA	0003-1348			AM SURGEON	Am. Surg.	JUN	2003	69	6					491	497					7	Surgery	Surgery	693RV	WOS:000183732900012	12852506				2021-06-18	
J	Hurley, SD; Coleman, PD				Hurley, SD; Coleman, PD			Facial nerve axotomy in aged and young adult rats: analysis of the glial response	NEUROBIOLOGY OF AGING			English	Article						microglia; astrocytes; T cells	FIBRILLARY ACIDIC PROTEIN; TRAUMATIC BRAIN INJURY; SEVERE HEAD-INJURY; MICROGLIAL CELLS; MESSENGER-RNA; ADHESION MOLECULES; OUTCOME PREDICTION; WHITE-MATTER; SPINAL-CORD; EXPRESSION	With increasing age, there is a trend towards greater morbidity and injury extent with brain injury. Because several reports have suggested that microglia and astrocytes have an exacerbated response to brain injury in the aged, we set out to explore glial responses to facial nerve axotomy. This model was chosen because the glial responses are well-characterized in young rats and there is no perturbation of the blood-brain barrier (BBB). Immunohistochemistry was performed for glial fibrillary acidic protein (GFAP), leukocyte common antigen, type 3 complement receptor, and major histocompatability complex classes I and II. Quantitative analysis showed that age does not affect the glial response to axotomy in the lesioned facial nucleus; however, an aging-related contralateral effect with enhanced GFAP-labeling was observed. Interestingly, despite a lack of infiltrating neutrophils, a T cell influx was observed in both young and aged rats. Overall, these results suggest that neutrophil extravasion and BBB breakdown are underappreciated with regards to aging and injury exacerbation. (C) 2002 Elsevier Science Inc. All rights reserved.	Univ Rochester, Alzheimers Dis Ctr, Rochester, NY 14642 USA; Univ Rochester, Ctr Aging & Dev Biol, Rochester, NY 14642 USA	Hurley, SD (corresponding author), Dept Neurobiol & Anat, 601 Elmwood Ave,POB 603, Rochester, NY 14642 USA.				NIA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [T32 AG00107, AG1096, P30 AG08665] Funding Source: Medline; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [P30AG008665, T32AG000107] Funding Source: NIH RePORTER		Bailly Y., 1990, HEMOPOIETIC SYSTEM, P27; BLINZING.K, 1968, Z ZELLFORSCH MIK ANA, V85, P145, DOI 10.1007/BF00325030; BRONSON RT, 1993, BRAIN RES, V609, P124, DOI 10.1016/0006-8993(93)90864-J; Carlos TM, 1997, J LEUKOCYTE BIOL, V61, P279; DAVIS M, 1995, STROKE, V26, P1072, DOI 10.1161/01.STR.26.6.1072; FEARNSIDE MR, 1993, BRIT J NEUROSURG, V7, P267, DOI 10.3109/02688699309023809; Gordon MN, 1997, J COMP NEUROL, V388, P106; GOSS JR, 1995, J NEUROCHEM, V64, P1351; GRAEBER MB, 1988, J NEUROCYTOL, V17, P209, DOI 10.1007/BF01674208; GRAEBER MB, 1986, J NEUROCYTOL, V15, P363; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; GRAEBER MB, 1988, J NEUROSCI RES, V21, P18, DOI 10.1002/jnr.490210104; HAMM RJ, 1991, J NEUROSURG, V75, P916, DOI 10.3171/jns.1991.75.6.0916; HANSEN LA, 1987, NEUROBIOL AGING, V8, P1, DOI 10.1016/0197-4580(87)90051-0; Hickey WF, 1999, SEMIN IMMUNOL, V11, P125, DOI 10.1006/smim.1999.0168; Kyrkanides S, 2001, J NEUROIMMUNOL, V119, P269, DOI 10.1016/S0165-5728(01)00404-0; LUERSSEN TG, 1988, J NEUROSURG, V68, P409, DOI 10.3171/jns.1988.68.3.0409; Major DE, 1997, NEUROBIOL AGING, V18, P523, DOI 10.1016/S0197-4580(97)00102-4; Morgan TE, 1999, NEUROSCIENCE, V89, P687, DOI 10.1016/S0306-4522(98)00334-0; NICHOLS NR, 1993, NEUROBIOL AGING, V14, P421, DOI 10.1016/0197-4580(93)90100-P; Nogawa S, 1998, P NATL ACAD SCI USA, V95, P10966, DOI 10.1073/pnas.95.18.10966; OCALLAGHAN JP, 1991, NEUROBIOL AGING, V12, P171, DOI 10.1016/0197-4580(91)90057-Q; OGURA K, 1994, NEUROREPORT, V5, P1224, DOI 10.1097/00001756-199406020-00016; Olschowka JA, 1997, BRAIN BEHAV IMMUN, V11, P273, DOI 10.1006/brbi.1997.0506; OLSSON T, 1992, AUTOIMMUNITY, V13, P117, DOI 10.3109/08916939209001912; Ono J, 2001, J CLIN NEUROSCI, V8, P120, DOI 10.1054/jocn.2000.0732; PENNINGS JL, 1993, ARCH SURG-CHICAGO, V128, P787; PERRY VH, 1993, GLIA, V7, P60, DOI 10.1002/glia.440070111; Pohjasvaara T, 1997, STROKE, V28, P729, DOI 10.1161/01.STR.28.4.729; Raivich G, 1998, J NEUROSCI, V18, P5804; RIOHORTEGA P, 1932, CYTOLOGY CELLULAR PA, P481; Rothweiler B, 1998, ARCH PHYS MED REHAB, V79, P881, DOI 10.1016/S0003-9993(98)90082-X; SCHWAB CW, 1992, ARCH SURG-CHICAGO, V127, P701; Searle S.R., 1992, VARIANCE COMPONENTS; SELLADURAI BM, 1992, BRIT J NEUROSURG, V6, P549, DOI 10.3109/02688699209002372; Sheffield LG, 1998, NEUROBIOL AGING, V19, P47, DOI 10.1016/S0197-4580(97)00168-1; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Signorini DF, 1999, J NEUROL NEUROSUR PS, V66, P20, DOI 10.1136/jnnp.66.1.20; Sloane JA, 1999, NEUROBIOL AGING, V20, P395, DOI 10.1016/S0197-4580(99)00066-4; Streit WJ, 1996, NEUROTOXICOLOGY, V17, P671; STREIT WJ, 1989, EXP NEUROL, V105, P115, DOI 10.1016/0014-4886(89)90111-8; Streit WJ, 1998, EXP NEUROL, V152, P74, DOI 10.1006/exnr.1998.6835; Streit WJ, 1997, J MOL MED-JMM, V75, P130, DOI 10.1007/s001090050097; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; STREIT WJ, 1988, GLIA, V1, P301, DOI 10.1002/glia.440010502; Stuesse SL, 2000, NEUROSCI LETT, V287, P121, DOI 10.1016/S0304-3940(00)01142-3; Sutherland GR, 1996, STROKE, V27, P1663, DOI 10.1161/01.STR.27.9.1663; Teasdale G, 1979, Acta Neurochir Suppl (Wien), V28, P140; Thorvaldsen P, 1999, STROKE, V30, P2529, DOI 10.1161/01.STR.30.12.2529; Vollmer DG, 1991, J NEUROSURG S, V75, P37; WANG XK, 1995, J NEUROTRAUM, V12, P825, DOI 10.1089/neu.1995.12.825; WOOD GS, 1981, J HISTOCHEM CYTOCHEM, V29, P1196, DOI 10.1177/29.10.7028859; Zhang RL, 1999, STROKE, V30, P624, DOI 10.1161/01.STR.30.3.624	53	23	24	0	1	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0197-4580			NEUROBIOL AGING	Neurobiol. Aging	MAY-JUN	2003	24	3					511	518	PII S0197-4580(02)00097-0	10.1016/S0197-4580(02)00097-0			8	Geriatrics & Gerontology; Neurosciences	Geriatrics & Gerontology; Neurosciences & Neurology	654FT	WOS:000181484100012	12600726				2021-06-18	
J	Hoane, MR; Knotts, AA; Akstulewicz, SL; Aquilano, M; Means, LW				Hoane, MR; Knotts, AA; Akstulewicz, SL; Aquilano, M; Means, LW			The behavioral effects of magnesium therapy on recovery of function following bilateral anterior medial cortex lesions in the rat	BRAIN RESEARCH BULLETIN			English	Article						brain injury; DMTS; cognitive deficits; working memory; reference memory; sensorimotor behavior	TRAUMATIC BRAIN INJURY; SENSORIMOTOR CORTEX; FACILITATE RECOVERY; COGNITIVE DEFICITS; PREFRONTAL CORTEX; NMDA ANTAGONISTS; CORTICAL DAMAGE; WORKING-MEMORY; FRONTAL-CORTEX; DRUGS	Magnesium (Mg++) therapy has been shown to be neuroprotective and to facilitate recovery of motor and sensorimotor function in a variety of animal models of traumatic brain injury. However, few studies have investigated the efficacy of Mg++ therapy on cognitive impairments following injury. The present study evaluated the ability of magnesium chloride (MgCl2) to facilitate recovery of function following bilateral anterior medial cortex lesions (bAMC). Rats received electrolytic bAMC lesions or sham surgery and were then treated with 1 mmol/kg, i.P. MgCl2, 2 mmol/kg, i.p. MgCl2, or 1.0 ml/kg, i.p. 0.9% saline. Drug treatment was administered 15 min following injury with subsequent injections administered at 24 and 12 h. Rats were tested on a battery of behavioral tests that measured both cognitive (reference and working memory in the Morris Water Maze (MWM) and spatial delayed matching-to-sample (DMTS)) and sensorimotor performance (bilateral tactile adhesive removal). The results indicated that bAMC lesions produced significant cognitive impairments in reference memory and working memory in the MWM, DMTS and sensorimotor impairments compared to shams. Mg++ therapy exhibited a dose-dependent effect in facilitating recovery of function. Administration of 2 mmol of MgCl2 significantly improved performance on the bilateral adhesive tactile removal test, DMTS and working memory tests. The 1 mmol dose of MgCl2 reduced the initial deficit on the tactile adhesive removal test and reduced the working memory impairment on the second day of testing. These results suggest Mg++ therapy improves cognitive performance following injury in a dose-dependent manner. (C) 2003 Elsevier Science Inc. All rights reserved.	E Carolina Univ, Dept Psychol, Brain Injury Lab, Greenville, NC 27858 USA; E Carolina Univ, Program Neurosci, Greenville, NC 27858 USA	Hoane, MR (corresponding author), E Carolina Univ, Dept Psychol, Brain Injury Lab, Rawl 218, Greenville, NC 27858 USA.			Hoane, Michael/0000-0001-7779-2657			Aikawa J., 1981, MAGNESIUM ITS BIOL S; Bara M, 1984, MAGNESIUM, V3, P212; Bareyre FM, 1999, J NEUROCHEM, V73, P271, DOI 10.1046/j.1471-4159.1999.0730271.x; BARTH TM, 1990, BEHAV BRAIN RES, V39, P73, DOI 10.1016/0166-4328(90)90122-U; Barth TM, 1998, RESTORATIVE NEUROLOGY, P121; CLOUGHHELFMAN C, 1991, FREE RADICAL RES COM, V15, P177, DOI 10.3109/10715769109049138; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; Feldman Z, 1996, J NEUROSURG, V85, P131, DOI 10.3171/jns.1996.85.1.0131; GARFINKEL L, 1985, Magnesium, V4, P60; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; GUNTHER T, 1984, MAGNESIUM-B, V6, P77; Heath DL, 1996, BRAIN RES, V738, P150, DOI 10.1016/0006-8993(96)00957-2; Heath DL, 1999, J PHARMACOL EXP THER, V288, P1311; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; Heath DL, 1999, MAGNESIUM RES, V12, P269; Hoane MR, 2000, BRAIN RES BULL, V53, P175, DOI 10.1016/S0361-9230(00)00327-0; Hoane MR, 1998, BRAIN RES BULL, V45, P45, DOI 10.1016/S0361-9230(97)00288-8; Hoane MR, 1997, RESTOR NEUROL NEUROS, V11, P71, DOI 10.3233/RNN-1997-111208; Hoane MR, 2002, PHYSIOL BEHAV, V76, P271, DOI 10.1016/S0031-9384(02)00714-X; Hoane MR, 2001, MAGNESIUM RES, V14, P51; Janis LS, 1998, J NEUROTRAUM, V15, P105, DOI 10.1089/neu.1998.15.105; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; Kesner RP, 1996, CEREB CORTEX, V6, P311, DOI 10.1093/cercor/6.2.311; KOLB B, 1984, BRAIN RES REV, V8, P65, DOI 10.1016/0165-0173(84)90018-3; Lindner MD, 1999, BEHAV BRAIN RES, V102, P1, DOI 10.1016/S0166-4328(98)00160-0; MCINTOSH TK, 1989, BRAIN RES, V482, P252, DOI 10.1016/0006-8993(89)91188-8; McIntosh TK, 1988, J NEUROTRAUM, V5, P17, DOI 10.1089/neu.1988.5.17; Means LW, 2001, PHYSIOL BEHAV, V74, P613, DOI 10.1016/S0031-9384(01)00621-7; MEANS LW, 1993, NEUROSCI PROTOCOLS, V93, P1; MEANS LW, 1993, NEUROBEHAVIORAL PLAS, P67; Muir JK, 1999, EXP NEUROL, V159, P584, DOI 10.1006/exnr.1999.7187; OKIYAMA K, 1995, J NEUROCHEM, V64, P802; PAXINOS G, 1997, RAT BRAIN STEREOTAXI; Ragozzino ME, 2001, NEUROSCI LETT, V308, P145, DOI 10.1016/S0304-3940(01)02020-1; Regan RF, 1998, J NEUROCHEM, V70, P77; Saatman KE, 2001, J NEUROPATH EXP NEUR, V60, P183, DOI 10.1093/jnen/60.2.183; SCHALLERT T, 1990, STROKE, V21, P143; SMITH DH, 1993, NEUROSCI LETT, V157, P211, DOI 10.1016/0304-3940(93)90739-8; Smith JS, 2000, NEURAL PLAST, V7, P73, DOI 10.1155/NP.2000.73; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1990, Magnes Res, V3, P163; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; Voorhies AC, 2002, BEHAV BRAIN RES, V133, P237, DOI 10.1016/S0166-4328(02)00029-3	45	23	24	0	2	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0361-9230			BRAIN RES BULL	Brain Res. Bull.	APR 15	2003	60	1-2					105	114		10.1016/S0361-9230(03)00022-4			10	Neurosciences	Neurosciences & Neurology	677MC	WOS:000182811200010	12725898				2021-06-18	
J	Hoshino, S; Kobayashi, S; Furukawa, T; Asakura, T; Teramoto, A				Hoshino, S; Kobayashi, S; Furukawa, T; Asakura, T; Teramoto, A			Multiple immunostaining methods to detect traumatic axonal injury in the rat fluid-percussion brain injury model	NEUROLOGIA MEDICO-CHIRURGICA			English	Article; Proceedings Paper	59th Annual Meeting of the Japan-Neurosurgical-Society	OCT, 2000	FUKUOKA, JAPAN	Japan Neurosurg Soc		axonal injury; beta-amyloid precursor protein; head injury; immunohistochemistry; neurofilament; rat	AMYLOID PRECURSOR PROTEIN; HEAD-INJURY; ALZHEIMERS-DISEASE; NEUROFILAMENT SUBUNITS; BETA-PROTEIN; APP; ANTIBODIES; DIAGNOSIS; MARKER; IMMUNOREACTIVITY	Immunohistochemistry using beta-amyloid precursor protein (APP) N-terminus antibodies is routinely used to detect traumatic axonal injury (TAI). The temporal and regional distributions of APP C- and N-terminus immunoreactivity were investigated in rats with experimental brain injury and compared to distribution of neurofilament (NF) immunoreactivity. Male Sprague-Dawley rats underwent right lateral fluid-percussion (FP) brain injury or sham injury. Six FP injury rats and two control rats were transcardially fixed with 10% formalin at 1, 6, 24, and 48 hours, and 1 and 2 weeks after injury and serial 6 pm-thick paraffin sections were prepared. At 6 hours after injury, APP C-terminus immunostaining labeled small neurons and axonal deposits in the injured parasagittal cortex, striatum, thalami, and dorsal medulla, whereas APP N-terminus and NF immunostaining showed few axonal deposits in the parasagittal cortex. At 24-48 hours post-injury, marked axonal damage, including axonal swelling and bulbs, was observed in the injured cerebral hemisphere, cerebellar white matter, and medulla. NF immunostaining was most sensitive for axonal damage in the injured deep cortical layers, cerebellum, and medulla. At 1-2 weeks after injury, APP N-terminus immunostaining mainly showed dot-like axonal profiles in the injured thalamus. APP C-terminus immunoreactivity may serve as an early marker of TAI, and the C-terminal fragments of APP may be involved in the evolution of TAI because C-terminal fragments of APP are neurotoxic and pro-apoptotic. Multiple immunostaining methods may be required to fully recognize the extent of TAI.	Chiba Hokusoh Hosp, Nippon Med Sch, Dept Neurosurg, Chiba, Japan; Nippon Med Coll, Dept Neurosurg, Tokyo 113, Japan	Hoshino, S (corresponding author), Heiwadai Hosp, Dept Neurosurg, Abiko, Chiba, Japan.						ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Aplin AE, 1996, J NEUROCHEM, V67, P699; Barnes NY, 1998, J NEUROSCI, V18, P5869; Bramlett HM, 1997, J NEUROPATH EXP NEUR, V56, P1132, DOI 10.1097/00005072-199710000-00007; BUXBAUM JD, 1990, P NATL ACAD SCI USA, V87, P6003, DOI 10.1073/pnas.87.15.6003; Chen XH, 1999, J NEUROPATH EXP NEUR, V58, P588, DOI 10.1097/00005072-199906000-00003; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; DYRKS T, 1988, EMBO J, V7, P949, DOI 10.1002/j.1460-2075.1988.tb02900.x; FUKUCHI KI, 1994, EXP NEUROL, V127, P253, DOI 10.1006/exnr.1994.1101; Fukuda K, 1996, J NEUROTRAUM, V13, P255, DOI 10.1089/neu.1996.13.255; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 1997, NEUROPATH APPL NEURO, V23, P339, DOI 10.1046/j.1365-2990.1997.4498044.x; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GRADY MS, 1993, J NEUROPATH EXP NEUR, V52, P143, DOI 10.1097/00005072-199303000-00007; HILBICH C, 1993, J BIOL CHEM, V268, P26571; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Lu DC, 2000, NAT MED, V6, P397; MarquezSterling NR, 1997, J NEUROSCI, V17, P140; McKenzie KJ, 1996, ACTA NEUROPATHOL, V92, P608, DOI 10.1007/s004010050568; Oehmichen M, 1998, FORENSIC SCI INT, V95, P67, DOI 10.1016/S0379-0738(98)00075-9; PEERLESS SJ, 1967, CAN MED ASSOC J, V96, P577; Pierce JES, 1996, J NEUROSCI, V16, P1083; SHERRIFF FE, 1994, NEUROREPORT, V5, P1085, DOI 10.1097/00001756-199405000-00016; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; SISODIA SS, 1990, SCIENCE, V248, P492, DOI 10.1126/science.1691865; SLUNT HH, 1994, J BIOL CHEM, V269, P2637; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; STRICH SJ, 1956, J NEUROL NEUROSUR PS, V19, P163, DOI 10.1136/jnnp.19.3.163; Thornhill S, 2000, BRIT MED J, V320, P1631, DOI 10.1136/bmj.320.7250.1631; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006; YANKNER BA, 1989, SCIENCE, V245, P417, DOI 10.1126/science.2474201; YOSHIKAWA K, 1992, NATURE, V359, P64, DOI 10.1038/359064a0	38	23	30	0	0	JAPAN NEUROSURGICAL SOC	TOKYO	C/O AKAMON-MAE IWATA BLDG, 5-27-8 HONGO, BUNKYO-KU, TOKYO, 113-0033, JAPAN	0470-8105			NEUROL MED-CHIR	Neurol. Med.-Chir.	APR	2003	43	4					165	173		10.2176/nmc.43.165			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	669JN	WOS:000182348300001	12760494	Bronze			2021-06-18	
J	Furukawa, T; Hoshino, S; Kobayashi, S; Asakura, T; Takahashi, M; Atsumi, T; Teramoto, A				Furukawa, T; Hoshino, S; Kobayashi, S; Asakura, T; Takahashi, M; Atsumi, T; Teramoto, A			The glutamate AMPA receptor antagonist, YM872, attenuates cortical tissue loss, regional cerebral edema, and neurological motor deficits after experimental brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						AMPA receptor antagonist; excitotoxicity; glutamate; neuroprotection; traumatic brain injury	LATERAL FLUID-PERCUSSION; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; NEURONAL DEATH; POSTTRAUMATIC HYPOTHERMIA; EXTRACELLULAR POTASSIUM; ARTERY OCCLUSION; MESSENGER-RNA; AMINO-ACIDS; ISCHEMIA	A massive increase in extracellular glutamate is thought to contribute to brain damage after traumatic brain injury. We examined the neuroprotective effect of the AMPA receptor antagonist YM872 in a rat head injury model using the fluid-percussion procedure. Male Sprague-Dawley rats were subjected to right lateral (parasagittal) fluid-percussion brain injury or sham injury. At 15 min postinjury, they received either YM872 (20 mg/kg/h, 20 mg/3 mL) or normal saline (vehicle) intravenously for 4 h. The administration of YM872 significantly improved the composite neuroscore at 1 and 2 weeks postinjury (p < 0.05), and markedly reduced the volume of tissue loss in the injured cortex (p < 0.05). It also significantly reduced cerebral edema in the ipsilateral parietal cortex at 48 h postinjury (p < 0.01). These results indicate that the posttraumatic administration of YM872 may be neuroprotective by ameliorating cortical tissue loss and regional cerebral edema, and suggest the importance of AMPA receptors in traumatic brain damage involving secondary injury processes.	Nippon Med Coll, Dept Neurosurg, Tokyo 113, Japan; Nippon Med Coll, Dept Crit Care Med, Tokyo 113, Japan; Chiba Hokusoh Hosp, Nippon Med Sch, Dept Neurosurg, Chiba, Japan; Yamanouchi Pharmaceut Co Ltd, Inst Drug Discovery Res, Pharmacol Labs, Ibaraki, Japan	Hoshino, S (corresponding author), Heiwadai Hosp, Dept Neurosurg, 834-28 Abiko, Chiba 2701101, Japan.						Belayev L, 2001, J NEUROTRAUM, V18, P1031, DOI 10.1089/08977150152693728; Bernert H, 1996, P NATL ACAD SCI USA, V93, P5235, DOI 10.1073/pnas.93.11.5235; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; BULLOCK R, 1992, J NEUROTRAUM, V9, pS442; CHOI DW, 1995, TRENDS NEUROSCI, V18, P58; CHOI DW, 1987, J NEUROSCI, V7, P357; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Goforth PB, 1999, J NEUROSCI, V19, P7367, DOI 10.1523/JNEUROSCI.19-17-07367.1999; Gorter JA, 1997, J NEUROSCI, V17, P6179; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HICKS RR, 1994, BRAIN RES, V655, P91, DOI 10.1016/0006-8993(94)91601-2; Hoshino S, 1996, BRAIN RES, V711, P73, DOI 10.1016/0006-8993(95)01329-6; Hoshino S, 1998, NEUROREPORT, V9, P1879, DOI 10.1097/00001756-199806010-00039; Ikonomidou C, 2000, P NATL ACAD SCI USA, V97, P12885, DOI 10.1073/pnas.220412197; Kamegai J, 2001, ENDOCRINOLOGY, V142, P4154, DOI 10.1210/en.142.9.4154; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; Kawasaki-Yatsugi S, 1998, BRAIN RES, V793, P39, DOI 10.1016/S0006-8993(98)00108-5; KawasakiYatsugi S, 1997, JPN J PHARMACOL, V74, P253, DOI 10.1254/jjp.74.253; Kohara A, 1998, J PHARM PHARMACOL, V50, P795, DOI 10.1111/j.2042-7158.1998.tb07142.x; Marmarou A, 2000, J NEUROSURG, V93, P183, DOI 10.3171/jns.2000.93.2.0183; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MINAMISAWA H, 1990, STROKE, V21, P758, DOI 10.1161/01.STR.21.5.758; Morris GF, 1999, J NEUROSURG, V91, P737, DOI 10.3171/jns.1999.91.5.0737; MORRIS RGM, 1986, NATURE, V319, P774, DOI 10.1038/319774a0; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; Okiyama K, 1998, BRAIN RES, V792, P291, DOI 10.1016/S0006-8993(98)00158-9; Okiyama K, 1997, J NEUROTRAUM, V14, P211, DOI 10.1089/neu.1997.14.211; OLNEY JW, 1991, SCIENCE, V254, P1515, DOI 10.1126/science.1835799; Osteen CL, 2001, J NEUROTRAUM, V18, P141, DOI 10.1089/08977150150502587; Ozawa S, 1998, PROG NEUROBIOL, V54, P581, DOI 10.1016/S0301-0082(97)00085-3; PALMER AM, 1993, J NEUROCHEM, V61, P2015, DOI 10.1111/j.1471-4159.1993.tb07437.x; Paxinos G, 1986, RAT BRAIN STEREOTAXI; Reinert M, 2000, J NEUROSURG, V93, P800, DOI 10.3171/jns.2000.93.5.0800; SANGER DJ, 1991, PSYCHOPHARMACOLOGY, V104, P27, DOI 10.1007/BF02244550; SHAPIRA Y, 1990, Journal of Neurotrauma, V7, P131, DOI 10.1089/neu.1990.7.131; Shimizu-Sasamata M, 1998, STROKE, V29, P2141, DOI 10.1161/01.STR.29.10.2141; SMITH DH, 1993, J NEUROSCI, V13, P5383; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Takahashi M, 1998, J PHARMACOL EXP THER, V287, P559; Takahashi M, 1998, J PHARMACOL EXP THER, V284, P467; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Turski L, 1998, P NATL ACAD SCI USA, V95, P10960, DOI 10.1073/pnas.95.18.10960; Tymianski M, 1996, NEUROSURGERY, V38, P1176; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; WRATHALL JR, 1994, J NEUROSCI, V14, P6598; XUE D, 1994, J CEREBR BLOOD F MET, V14, P251, DOI 10.1038/jcbfm.1994.32; Young W, 1992, J NEUROTRAUMA S1, V9, P9	53	23	24	0	3	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	MAR	2003	20	3					269	278		10.1089/089771503321532851			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	661GU	WOS:000181883500005	12820681				2021-06-18	
J	Reichard, RR; White, CL; Hladik, CL; Dolinak, D				Reichard, RR; White, CL; Hladik, CL; Dolinak, D			Beta-amyloid precursor protein staining in nonhomicidal pediatric medicolegal autopsies	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article; Proceedings Paper	77th Annual Meeting of the American-Association-of-Neuropathologists	JUN 21-24, 2001	CHICAGO, ILLINOIS	Amer Assoc Neuropathologists		autopsy; beta-amyloid precursor protein; brain; immunohistochemistry; sudden infant death syndrome (SIDS); pediatric	CENTRAL-NERVOUS-SYSTEM; DIFFUSE AXONAL INJURY; ALZHEIMERS-DISEASE; HEAD-INJURY; REACTIVE ASTROCYTES; EXPRESSION; BRAIN; RAT; APP; NEUROPATHOLOGY	Immunohistochemical staining for beta-amyloid precursor protein (betaAPP) has been validated as a marker for axonal injury in adults surviving greater than or equal to2 hours after white matter damage. The significance of betaAPP staining in pediatric brains and spinal cords is not as well established. We evaluated the white matter immunoreactivity for betaAPP from a variety of pediatric medicolegal autopsies: natural disease (non-Sudden Infant Death Syndrome [SIDS]), SIDS, motor vehicle accidents, drowning, near-drowning, overlay, carbon monoxide toxicity, miscellaneous trauma, and mechanical asphyxia. The cases of carbon monoxide toxicity, motor vehicle accidents (death at scene), drowning (with resuscitation), and a natural (non-SIDS) death had no significant white matter staining. The traumatic deaths with a significant survival interval, a variety of natural deaths, the near-drowning case, and surprisingly, all SIDS had detectable betaAPP white matter immunostaining. These results demonstrate that features other than traumatic axonal injury, such as metabolic insults and hypoxic-ischemic injury secondary to vascular compromise, must contribute to betaAPP immunostaining. In addition, we describe a variety of betaAPP-immunoreactive structures not previously reported in the pediatric population. This study illustrates that betaAPP immunostaining enhances detection of a variety of white matter changes, and provides a basis for interpretation of these results.	Univ Texas, Hlth Sci Ctr, SW Med Sch, Dept Pathol,Neuropathol Lab, Dallas, TX 75235 USA; Univ Texas, Hlth Sci Ctr, SW Med Sch, Dept Pathol,Immunohistochem Lab, Dallas, TX 75235 USA; SW Inst Forens Sci, Dallas, TX USA	Reichard, RR (corresponding author), 922 Varian Way, Palo Alto, CA 94304 USA.		White, Charles L/AAJ-1858-2021	White, Charles L/0000-0002-3870-2804			ARAI H, 1991, ANN NEUROL, V30, P686, DOI 10.1002/ana.410300509; BLUMBERGS PC, 1994, LANCET, V344, P1055, DOI 10.1016/S0140-6736(94)91712-4; CORIA F, 1992, NEUROPATH APPL NEURO, V18, P27, DOI 10.1111/j.1365-2990.1992.tb00762.x; Dolinak D, 2000, NEUROPATH APPL NEURO, V26, P448, DOI 10.1046/j.1365-2990.2000.00273.x; Dolinak D, 2000, ACTA NEUROPATHOL, V100, P553, DOI 10.1007/s004010000218; GARDELLA JE, 1992, LAB INVEST, V67, P303; Geddes JF, 2000, NEUROPATH APPL NEURO, V26, P105, DOI 10.1046/j.1365-2990.2000.026002105.x; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; GENTLEMAN SM, 1995, ACTA NEUROPATHOL, V89, P537; Gleckman AM, 1999, ARCH PATHOL LAB MED, V123, P146; IKEDA K, 1990, BRAIN RES, V527, P140, DOI 10.1016/0006-8993(90)91072-O; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Maxwell WL, 1997, J NEUROTRAUM, V14, P419, DOI 10.1089/neu.1997.14.419; MITA S, 1989, AM J PATHOL, V134, P1253; NAVES FJ, 1994, NEUROSCI LETT, V181, P73, DOI 10.1016/0304-3940(94)90563-0; Nihashi T, 2001, ACTA NEUROCHIR, V143, P287, DOI 10.1007/s007010170109; Obonai T, 1998, PEDIATR NEUROL, V19, P23, DOI 10.1016/S0887-8994(98)00008-3; OHTA M, 1993, DEV BRAIN RES, V75, P151, DOI 10.1016/0165-3806(93)90019-7; OKUDA R, 1994, ACTA NEUROPATHOL, V87, P161, DOI 10.1007/BF00296186; Panegyres PK, 1997, NEUROPEPTIDES, V31, P523, DOI 10.1016/S0143-4179(97)90000-7; Shannon P, 1998, ACTA NEUROPATHOL, V95, P625, DOI 10.1007/s004010050849; SHAW CM, 1989, J CHILD NEUROL, V4, P39, DOI 10.1177/088307388900400106; SIMAN R, 1989, NEURON, V3, P275, DOI 10.1016/0896-6273(89)90252-3; TRAPP BD, 1994, J NEUROSCI RES, V37, P538, DOI 10.1002/jnr.490370413; WILLIAMS G, 1999, DISCOVERY, V1, P11	27	23	23	0	1	AMER ASSN NEUROPATHOLOGISTS INC	LAWRENCE	1041 NEW HAMPSHIRE ST, LAWRENCE, KS 66044 USA	0022-3069			J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	MAR	2003	62	3					237	247		10.1093/jnen/62.3.237			11	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	653QM	WOS:000181448400003	12638728	Bronze			2021-06-18	
J	Feinstein, A; Hershkop, S; Ouchterlony, D; Jardine, A; McCullagh, S				Feinstein, A; Hershkop, S; Ouchterlony, D; Jardine, A; McCullagh, S			Posttraumatic amnesia and recall of a traumatic event following traumatic brain injury	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article							CLOSED-HEAD INJURY; ACUTE STRESS DISORDER; GENERAL HEALTH; PREDICTORS; ACCIDENTS; IMPACT; MEMORY	The relationship between posttraumatic amnesia (PTA) and symptoms of posttraumatic stress disorder (PTSD) was examined in 282 outpatients at a mean of 53 days after traumatic brain injury (TBI). Patients were assessed for TBI severity, intrusive and avoidant PTSD-type symptoms, and psychological distress, and were stratified into four comparison groups by duration of PTA. Levels of PTSD-type symptoms and psychological distress did not differ significantly between groups. Even patients with PTA >1 week reported intrusive and avoidant PTSD-type symptoms. However, when patients were stratified into those with PTA of <1 hour or >1 hour, the former were more likely to report such symptoms. TBI patients with brief PTA are more likely to experience PTSD-type reactions, but severe TBI with prolonged PTA is not incompatible with such reactions in a subset of patients. Possible mechanisms that could account for this finding are discussed.	Sunnybrook & Womens Coll, Dept Psychiat, Hlth Sci Ctr, Toronto, ON M4N 3M5, Canada	Feinstein, A (corresponding author), Sunnybrook & Womens Coll, Dept Psychiat, Hlth Sci Ctr, 2075 Bayview Ave, Toronto, ON M4N 3M5, Canada.		Jardine, Alan/L-5770-2019				American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Bryant RA, 1998, AM J PSYCHIAT, V155, P625, DOI 10.1176/ajp.155.5.625; Bryant RA, 1996, J TRAUMA STRESS, V9, P621; BRYANT RA, 1995, PSYCHOL MED, V25, P869, DOI 10.1017/S0033291700035121; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Ellenberg JH, 1996, ARCH NEUROL-CHICAGO, V53, P782, DOI 10.1001/archneur.1996.00550080104018; FEINSTEIN A, 1991, PSYCHOL MED, V21, P85, DOI 10.1017/S0033291700014689; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; GOLDBERG DP, 1979, PSYCHOL MED, V9, P139, DOI 10.1017/S0033291700021644; GRISBY J, 1993, BRAIN INJURY, V7, P507; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Harvey AG, 1998, J NERV MENT DIS, V186, P333, DOI 10.1097/00005053-199806000-00002; Harvey AG, 1998, BRAIN INJURY, V12, P147, DOI 10.1080/026990598122773; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; HORTON AM, 1993, PERCEPT MOTOR SKILL, V76, P243, DOI 10.2466/pms.1993.76.1.243; King NS, 1997, J NEUROL NEUROSUR PS, V62, P82, DOI 10.1136/jnnp.62.1.82; Krikorian R, 1998, J NEUROPSYCH CLIN N, V10, P359, DOI 10.1176/jnp.10.3.359; LAYTON BS, 1995, CLIN NEUROPSYCHOL, V9, P2, DOI 10.1080/13854049508402050; MAYOU R, 1993, BRIT MED J, V307, P647, DOI 10.1136/bmj.307.6905.647; McMillan TM, 1996, BRAIN INJURY, V10, P749, DOI 10.1080/026990596124016; McMillan TM, 1996, J NEUROL NEUROSUR PS, V60, P422, DOI 10.1136/jnnp.60.4.422; MCMILLAN TM, 1991, BRIT J PSYCHIAT, V159, P431, DOI 10.1192/bjp.159.3.431; McNeil J E, 1996, Cogn Neuropsychiatry, V1, P239, DOI 10.1080/135468096396532; MIDDELBOE T, 1992, ACTA NEUROL SCAND, V85, P5; Ohry A, 1996, BRAIN INJURY, V10, P687, DOI 10.1080/026990596124106; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P16, DOI DOI 10.1001/ARCHNEUR.1961.00450130006002; SBORDONE RJ, 1995, BRAIN INJURY, V9, P405, DOI 10.3109/02699059509005780; Warden DL, 1997, J NEUROPSYCH CLIN N, V9, P18; 1961, LANCET, V2, P1445	29	23	24	0	2	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	WIN	2002	14	1					25	30		10.1176/appi.neuropsych.14.1.25			6	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	517BD	WOS:000173590500005	11884651				2021-06-18	
J	Maekawa, S; Aibiki, M; Si, QS; Nakamura, Y; Shirakawa, Y; Kataoka, K				Maekawa, S; Aibiki, M; Si, QS; Nakamura, Y; Shirakawa, Y; Kataoka, K			Differential effects of lowering culture temperature on mediator release from lipopolysaccharide-stimulated neonatal rat microglia	CRITICAL CARE MEDICINE			English	Article						lipopolysaccharide; mediator; microglia; temperature reduction	TRAUMATIC BRAIN-INJURY; MILD HYPOTHERMIA THERAPY; NITRIC-OXIDE PRODUCTION; PROTEIN-KINASE-C; POSTISCHEMIC HYPOTHERMIA; MODERATE HYPOTHERMIA; ACTIVATED MICROGLIA; CEREBRAL-ISCHEMIA; ARTERY OCCLUSION; ASTROCYTES	Objective: Therapeutic moderate hypothermia has the potential for neuronal protection against brain injury. Microglia, a type of immune-related cell in the brain, may play a certain role in neuronal damage subsequent to injury. We examined the effects of culture temperature changes from 37degreesC to 33degreesC or 30degreesC on mediator release, including nitric oxide, interleukin-6, and tumor necrosis factor-alpha from lipopolysaccharide-stimulated microglia harvested from neonatal rats. Design: Laboratory study. Setting: University medical school. Subjects: Microglial cells isolated from primary cultures of rat brains. Interventions: The production of nitric oxide was measured by a nitrite accumulation method in a culture medium, whereas cytokines, interleukin-6, and tumor necrosis factor-alpha were measured by enzyme-linked immunosorbent assay. Measurement and Main Results: At 30degreesC and 33degreesC, nitric oxide production stimulated by Iipopolysaccha ride decreased to 10 and 30% of control (37degreesC), respectively, 24 hrs after the stimulation, and the decrease was sustained for 48 hrs. Interleukin-6 production at 30degreesC and 33degreesC was also reduced to 30% of control 6 hrs after the activation. Such responses lasted throughout the study. However, tumor necrosis factor-alpha release at 30degreesC and 33degreesC was depressed for only 6 hrs after stimulation, followed by subsequent elevation to concentrations similar to those at 37degreesC. Microglial morphologic activation, showing changes from, round to bipolar, reached a peak at 6 hrs in the 37degreesC group, returning to round 12 hrs after lipopolysaccharide application. In 30degreesC and 33degreesC, the zenith was detected at 6 hrs, with activation remaining even 12 hrs after the stimulation, suggesting prolongation of the microglial response to lipopolysaccha ride, which was inconsistent with changes in tumor necrosis factor release. Conclusions: Decreasing culture temperature inhibits the production of nitric oxide and interleukin-6 from activated microglia. Differences were found in the degree or time course change between tumor necrosis factor-alpha and the other mediators. Also, the time course of morphologic changes in microglia was dependent on culture temperature. Further studies are required to define the mechanisms for such differences in mediator release from cooled microglia and also to clarify the inconsistency between morphologic change and its function in the cell.	Ehime Univ, Sch Med, Dept Emergency Med, Shigenobu, Ehime 7910295, Japan; Albert Einstein Coll Med, Dept Pathol, Bronx, NY 10467 USA; Kanazawa Univ, Fac Pharmacol, Kanazawa, Ishikawa 920, Japan	Aibiki, M (corresponding author), Ehime Univ, Sch Med, Dept Emergency Med, 454 Shitsukawa, Shigenobu, Ehime 7910295, Japan.						Abraham H, 2000, BRAIN RES, V862, P63, DOI 10.1016/S0006-8993(00)02072-2; Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aibiki M, 2000, CRIT CARE MED, V28, P3902, DOI 10.1097/00003246-200012000-00029; BANATI RB, 1993, GLIA, V7, P111, DOI 10.1002/glia.440070117; CHAO CC, 1995, CLIN IMMUNOL IMMUNOP, V77, P358, DOI 10.1006/clin.1995.1163; CHAO CC, 1992, J IMMUNOL, V149, P2736; Clifton GL, 2001, NEW ENGL J MED, V344, P556, DOI 10.1056/NEJM200102223440803; Colbourne F, 2000, J CEREBR BLOOD F MET, V20, P1702, DOI 10.1097/00004647-200012000-00009; Ding MZ, 1997, J BIOL CHEM, V272, P11327; Fabrizi C, 2001, J BIOL CHEM, V276, P25692, DOI 10.1074/jbc.M100133200; Goghari V, 2000, NEUROSCI LETT, V281, P83, DOI 10.1016/S0304-3940(00)00824-7; Hemmer K, 2001, NEUROCHEM INT, V38, P557, DOI 10.1016/S0197-0186(00)00119-4; Holzer M, 2002, NEW ENGL J MED, V346, P549; Iadecola C, 1997, ANN NY ACAD SCI, V835, P203, DOI 10.1111/j.1749-6632.1997.tb48631.x; Inamasu J, 2000, J NEUROIMMUNOL, V109, P66, DOI 10.1016/S0165-5728(00)00211-3; Janabi N, 1996, J IMMUNOL, V157, P2129; Jiang JY, 2000, J NEUROSURG, V93, P546, DOI 10.3171/jns.2000.93.4.0546; KATHLEEN MB, 1992, BRAIN RES, V587, P250; LEE SC, 1993, J IMMUNOL, V150, P2659; LIU MK, 1994, J IMMUNOL, V153, P2642; Minghetti L, 1998, PROG NEUROBIOL, V54, P99, DOI 10.1016/S0301-0082(97)00052-X; Nakamura Y, 1999, NEUROSCI RES, V35, P95, DOI 10.1016/S0168-0102(99)00071-1; Nakamura Y, 2001, NEUROCHEM INT, V38, P1, DOI 10.1016/S0197-0186(00)00067-X; NATHAN C, 1992, FASEB J, V6, P3051; NISHIZUKA Y, 1984, SCIENCE, V225, P1365, DOI 10.1126/science.6147898; PETERSON PK, 1994, J INFECT DIS, V170, P457, DOI 10.1093/infdis/170.2.457; Phanithi PB, 2000, NEUROPATHOLOGY, V20, P273, DOI 10.1046/j.1440-1789.2000.00346.x; Shiozaki T, 1999, J NEUROSURG, V91, P185, DOI 10.3171/jns.1999.91.2.0185; Si QS, 1997, NEUROSCIENCE, V81, P223, DOI 10.1016/S0306-4522(97)00172-3; Si QS, 1996, EXP NEUROL, V137, P345, DOI 10.1006/exnr.1996.0035; Si QS, 1998, BRAIN RES, V812, P97, DOI 10.1016/S0006-8993(98)00954-8; Zhao ML, 2001, J NEUROIMMUNOL, V115, P182, DOI 10.1016/S0165-5728(00)00463-X	32	23	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	DEC	2002	30	12					2700	2704		10.1097/00003246-200212000-00014			5	Critical Care Medicine	General & Internal Medicine	633AP	WOS:000180257300014	12483061				2021-06-18	
J	Kroppenstedt, SN; Sakowitz, OW; Thomale, UW; Unterberg, AW; Stover, JF				Kroppenstedt, SN; Sakowitz, OW; Thomale, UW; Unterberg, AW; Stover, JF			Influence of norepinephrine and dopamine on cortical perfusion, EEG activity, extracellular glutamate, and brain edema in rats after controlled cortical impact injury	JOURNAL OF NEUROTRAUMA			English	Article						blood pressure elevation; catecholamines; cerebral blood flow; microdialysis; secondary brain damage; traumatic brain injury	CEREBRAL BLOOD-FLOW; CEREBROSPINAL-FLUID GLUTAMATE; SENSORIMOTOR CORTEX ABLATION; AMINO-ACID; RELAXING FACTOR; HEAD TRAUMA; RECEPTORS; RECOVERY; NEURONS; RELEASE	Following traumatic brain injury, catecholamines given to ameliorate cerebral perfusion may induce brain damage via cerebral arteriolar constriction and increased neuronal excitation. In the present study the acute effects of norepinephrine and dopamine on pericontusional cortical perfusion (rCBF), electroencephalographic (EEG) activity, extracellular glutamate, and brain edema were investigated in rats following controlled cortical impact injury (CCI). rCBF, cerebral perfusion pressure (CPP), EEG activity, and glutamate were determined before, during, and after infusing norepinephrine or dopamine, increasing MABP to 120 mm Hg for 90 min at 4 h after CCI. Control rats received physiological saline. At 8 h after CCI, hemispheric swelling and water content were determined gravimetrically. Following CCI, rCBF was significantly decreased. In parallel to elevating MABP and CPP, rCBF was significantly increased by norepinephrine and dopamine, being mostly pronounced with norepinephrine (+44% vs. +29%). In controls, rCBF remained diminished (-45%). EEG activity was significantly increased by norepinephrine and dopamine, while pericontusional glutamate was only elevated by norepinephrine (28 +/- 6 vs. 8 +/- 4 muM). Brain edema was not increased compared to control rats. Despite significantly increasing MABP and CPP to the same extent, norepinephrine and dopamine seem to differentially influence pericontusional cortical perfusion and glutamatergic transmission. In addition to the pressure-passive increase in CPP local cerebral effects seem to account for the sustained norepinephrine-induced increase in pericontusional cortical perfusion. The significantly elevated pericontusional glutamate concentrations in conjunction with the increased EEG activity suggest a sustained metabolically driven increase in cortical perfusion during norepinephrine infusion.	Humboldt Univ, Charite, Virchow Med Ctr, Dept Neurosurg, Berlin, Germany	Kroppenstedt, SN (corresponding author), Humboldt Univ, Charite, Virchow Med Ctr, Dept Neurosurg, Berlin, Germany.	skroppen@charite.de					ALTURA BM, 1980, BRIT J PHARMACOL, V69, P543, DOI 10.1111/j.1476-5381.1980.tb07900.x; BASAR E, 1975, BIOL CYBERN, V20, P137, DOI 10.1007/BF00342634; Baskaya MK, 1997, NEUROSCI LETT, V226, P33; Beaumont A, 2001, J NEUROTRAUM, V18, P1359, DOI 10.1089/08977150152725650; Berridge CW, 1999, NEUROSCIENCE, V93, P1263, DOI 10.1016/S0306-4522(99)00276-6; Berridge CW, 1996, J NEUROSCI, V16, P7010; BOYESON MG, 1990, PHARMACOL BIOCHEM BE, V35, P497, DOI 10.1016/0091-3057(90)90279-Q; BRYAN RM, 1995, ANESTH ANALG, V80, P687, DOI 10.1097/00000539-199504000-00007; Cherian L, 1999, CRIT CARE MED, V27, P2512, DOI 10.1097/00003246-199911000-00031; Cherian L, 1996, J NEUROTRAUM, V13, P371, DOI 10.1089/neu.1996.13.371; DeWitt D S, 1995, New Horiz, V3, P376; DIRNAGL U, 1994, AM J PHYSIOL, V267, pH296; Dunn-Meynell AA, 1998, BRAIN RES, V800, P245, DOI 10.1016/S0006-8993(98)00524-1; FEENEY DM, 1990, CAN J PSYCHOL, V44, P233, DOI 10.1037/h0084243; FLINT RS, 1985, BRAIN RES BULL, V15, P197, DOI 10.1016/0361-9230(85)90136-4; GARTHWAITE J, 1988, NATURE, V336, P385, DOI 10.1038/336385a0; Giri BK, 2000, STROKE, V31, P961, DOI 10.1161/01.STR.31.4.961; Golding EM, 1999, CLIN EXP HYPERTENS, V21, P299, DOI 10.3109/10641969909068668; HANSSON E, 1992, BRAIN RES BULL, V29, P297, DOI 10.1016/0361-9230(92)90060-B; Huda K, 2001, NEUROSCI LETT, V307, P175, DOI 10.1016/S0304-3940(01)01960-7; IADECOLA C, 1993, BRAIN RES, V606, P148, DOI 10.1016/0006-8993(93)91583-E; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Kikuchi K, 2000, BRAIN RES, V860, P130, DOI 10.1016/S0006-8993(00)02034-5; Kochanek OM, 1995, J NEUROTRAUM, V12, P1015, DOI 10.1089/neu.1995.12.1015; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; Kroppenstedt SN, 1999, J NEUROSURG, V90, P520, DOI 10.3171/jns.1999.90.3.0520; Kroppenstedt SN, 2000, CRIT CARE MED, V28, P3792, DOI 10.1097/00003246-200012000-00004; LAWTHO D, 1993, EUR J NEUROSCI, V5, P1494, DOI 10.1111/j.1460-9568.1993.tb00217.x; LIU J, 1993, ARCH BIOCHEM BIOPHYS, V302, P118, DOI 10.1006/abbi.1993.1189; MCINTOSH TK, 1994, J NEUROCHEM, V63, P1426; Myburgh JA, 1998, ACT NEUR S, V71, P19; Nemoto EM, 1996, ANESTH ANALG, V83, P1262, DOI 10.1097/00000539-199612000-00023; Noh JS, 1999, EXP NEUROL, V159, P217, DOI 10.1006/exnr.1999.7144; PALMER RMJ, 1987, NATURE, V327, P524, DOI 10.1038/327524a0; PRASAD MR, 1992, J NEUROTRAUM, V9, P269, DOI 10.1089/neu.1992.9.269; ROSNER MJ, 1995, J NEUROSURG, V83, P949, DOI 10.3171/jns.1995.83.6.0949; Santhakumar V, 2001, ANN NEUROL, V50, P708, DOI 10.1002/ana.1230; Sebban C, 1999, BRIT J PHARMACOL, V128, P1045, DOI 10.1038/sj.bjp.0702894; Soehle M, 2001, J NEUROSCI METH, V110, P91, DOI 10.1016/S0165-0270(01)00422-8; Stibick DL, 2001, J NEUROTRAUM, V18, P303, DOI 10.1089/08977150151070955; Stover JF, 2000, NEUROSCI LETT, V288, P25, DOI 10.1016/S0304-3940(00)01187-3; SUTIN J, 1992, BRAIN RES BULL, V29, P277, DOI 10.1016/0361-9230(92)90057-5; SUTTON RL, 1992, RESTOR NEUROL NEUROS, V4, P1, DOI 10.3233/RNN-1992-4101; Talmor D, 1998, ANESTH ANALG, V87, P574, DOI 10.1097/00000539-199809000-00014; Troadec JD, 2001, J NEUROCHEM, V79, P200, DOI 10.1046/j.1471-4159.2001.00556.x; Unterberg AW, 1997, ACT NEUR S, V70, P106; von Essen C, 1972, J Pharm Pharmacol, V24, P668; Yamakura T, 2001, ANNU REV PHARMACOL, V41, P23, DOI 10.1146/annurev.pharmtox.41.1.23	49	23	26	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV	2002	19	11					1421	1432		10.1089/089771502320914651			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	620JD	WOS:000179529500003	12490007				2021-06-18	
J	Beal, AL; Scheltema, KE; Beilman, GJ; Deuser, WE				Beal, AL; Scheltema, KE; Beilman, GJ; Deuser, WE			Hypokalemia following trauma	SHOCK			English	Article						wounds and injuries-complications; head injury; resuscitation; electrolytes; Injury Severity Score (ISS); Length of Stay (LOS); Traumatic Brain Injury JBI); Glasgow Coma Score (GCS)	SERUM POTASSIUM; SEVERITY	Frequent hypokalemia was noted immediately after trauma, and it was hypothesized that hypokalemia occurred more frequently in the more severely injured. A retrospective trauma registry and chart review was done on 546 trauma patients looking at admission potassium, a variety of lab tests related to potassium, specific injuries, hospital/ICU lengths of stay, and general patient demographics. Admission hypokalemia (K < 3.6 meq/l) was more frequent in those with closed head injuries (41.1% vs. 27.5%, P < .001) and in those who suffered spinal cord injuries (54.5% vs. 33.6%, P < .05). Hyperglycemia was more frequent with admission hypokalemia (45.2% vs. 29.7%, P < .001). Hypokalemia occurred more frequently in younger patients (28.6 vs. 37.7 y, P < .001). Also, the pediatric group, ages 5-14, had admission hypolkalemia more frequently than those ages 15-59, or those ages > 59. (54.9% vs. 34.5% vs. 16.7%, P < .001). Glasgow Coma Scores (GCS) were significantly lower(12.0 vs. 13.5, P < .001) and Injury Severity Scores (ISS) were higher (17.4 vs. 13.4, P < .001), with admission hypokalemia. Additionally, hypokalemia was a positive predictor of ISS (P = .05). Hypokalemic patients more likely needed a ventilator, (26.6% vs. 16.5%, P < .01) but did not have significantly more ventilator days (P > .05). Subsequently, hypokalemic patients had longer ICU lengths of stay (LOS) (2.6 vs. 1.5 days, P < .005) and longer hospital LOS (8.5 vs. 5.6 days, P < .001). When stratified into categories of "severe": (K < 3.1 meq/l), "moderate": (K = 3.1-3.3 meq/l), and "mild": (K = 3.4-3.5 meq/l) hypokalemia, those with severe hypokalemia had significantly lower GCS (10.0 vs. 13.1, p < .05), higher serum glucose levels (167 vs. 137 mg/dl, P < .05), lower creatinine levels (.77 vs. .95 mg/dl, P < .05), and longer hospital lengths of stay (13.1 days vs. 7.6 days, P < .05 results).	N Mem Hlth Care, Robbinsdale, MN 55441 USA; Univ Minnesota, Minneapolis, MN 55414 USA	Beal, AL (corresponding author), N Mem Hlth Care, 3300 Oakdale Ave, Robbinsdale, MN 55441 USA.			Beilman, Gregory/0000-0001-5036-3027			CLAUSEN T, 1983, ACTA MED SCAND, P111; EPSTEIN FH, 1983, NEW ENGL J MED, V309, P1450, DOI 10.1056/NEJM198312083092308; Gabow PA, 1992, RENAL ELECTROLYTE DI, P231; Grace G T, 1988, Curr Surg, V45, P463; Lazar L, 1997, J PEDIATR SURG, V32, P88, DOI 10.1016/S0022-3468(97)90102-0; MORELL V, 1993, SOUTHERN MED J, V86, P658, DOI 10.1097/00007611-199306000-00014; POMERANZ S, 1989, ACTA NEUROCHIR, V97, P62, DOI 10.1007/BF01577741; SHIN B, 1986, ANESTHESIOLOGY, V65, P90, DOI 10.1097/00000542-198607000-00018; SMITH JS, 1978, SURG GYNECOL OBSTET, V147, P18; TEPAS JJ, 1988, J TRAUMA, V28, P425, DOI 10.1097/00005373-198804000-00001; VANEK VW, 1994, SOUTHERN MED J, V87, P41, DOI 10.1097/00007611-199401000-00010; WILLIAMS ME, 1985, NEW ENGL J MED, V312, P823, DOI 10.1056/NEJM198503283121304	12	23	29	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	AUG	2002	18	2					107	110		10.1097/00024382-200208000-00002			4	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	617VR	WOS:000179382000002	12166770				2021-06-18	
J	Morgan, A; Ward, E; Murdoch, B; Bilbie, K				Morgan, A; Ward, E; Murdoch, B; Bilbie, K			Acute characteristics of pediatric dysphagia subsequent to traumatic brain injury: Videofluoroscopic assessment	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						acute; dysphagia; swallowing impairment; traumatic brain injury; videofluoroscopy	SWALLOWING DISORDERS; HEAD TRAUMA; CHILDREN; PHYSIOLOGY; OUTCOMES; ADULTS	Objective: To document the acute characteristics of swallowing impairment in a group of children post moderate/severe traumatic brain injury (TBI) by means of videofluoroscopy. Participants: Eighteen children with moderate/severe TBI. Main Outcome Measure: Videofluoroscopy at an average of 27.7 days post-injury. Results: Subjects demonstrated a range of dysphagia severity levels: mild-moderate (n = 8), moderate (n = 6), moderate-severe (n = 3), and severe (n = 1) and had a combination of oral and pharyngeal phase characteristics. More specifically; observable features or physiological impairments that were identified included reduced lingual control, hesitancy of tongue movement, repetitive tongue pumping, the presence of aspiration (including silent aspiration), delayed swallow reflex trigger, reduced laryngeal elevation and closure, and reduced peristalsis. Conclusions: These data highlight the diversity of swallowing deficits and dysphagia severity levels in children following TBI and suggest that the former are consistent with a pattern of oropharyngeal impairments.	Univ Queensland, Dept Speech Pathol & Audiol, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia; Univ Queensland, Mater Childrens Hosp, Speech Pathol Dept, Brisbane, Qld 4101, Australia	Morgan, A (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Sch Hlth & Rehabil Sci, Brisbane, Qld 4072, Australia.		Ward, Elizabeth/F-9652-2010; Bolton, Kate/AAH-2756-2020; Murdoch, Bruce E/C-1397-2012; Morgan, Angela/J-5235-2017	Ward, Elizabeth/0000-0002-2680-8978; Morgan, Angela/0000-0003-1147-7405			ARVEDSON J, 1994, INT J PEDIATR OTORHI, V28, P173, DOI 10.1016/0165-5876(94)90009-4; Arvedson JC, 1998, PEDIAT VIDEOFLUOROSC; BECK T J, 1990, Dysphagia, V5, P118, DOI 10.1007/BF02412634; CASAS MJ, 1995, DYSPHAGIA, V10, P155, DOI 10.1007/BF00260969; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cook I J, 1989, Dysphagia, V4, P8, DOI 10.1007/BF02407397; Darrow DH, 1998, OTOLARYNG CLIN N AM, V31, P405, DOI 10.1016/S0030-6665(05)70061-X; Derkay CS, 1998, OTOLARYNG CLIN N AM, V31, P397, DOI 10.1016/S0030-6665(05)70060-8; Dodds W J, 1989, Dysphagia, V3, P171, DOI 10.1007/BF02407219; DODDS WJ, 1990, AM J ROENTGENOL, V154, P953, DOI 10.2214/ajr.154.5.2108569; EKBERG O, 1982, BRIT J RADIOL, V55, P258, DOI 10.1259/0007-1285-55-652-258; EKBERG O, 1982, ACTA OTO-LARYNGOL, V93, P123, DOI 10.3109/00016488209130862; EVANSMORRIS S, 1981, NORMAL ACQUISITION F; Friedman B, 2000, DYSPHAGIA, V15, P153, DOI 10.1007/s004550010018; GELFAND MD, 1981, GASTROENTEROLOGY, V80, P1154; Halper AS, 1999, J HEAD TRAUMA REHAB, V14, P486, DOI 10.1097/00001199-199910000-00009; Langmore SE, 1998, DYSPHAGIA, V13, P69, DOI 10.1007/PL00009559; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; Logemann J.A., 1993, MANUAL VIDEOFLUOROGR; LOGEMANN JA, 1989, ARCH PHYS MED REHAB, V70, P767; LOGEMANN JA, 1990, NEUROLOGY, V40, P1136, DOI 10.1212/WNL.40.7.1136; Logemann JA, 1994, J HEAD TRAUMA REHAB, V9, P43; Loughlin G M, 1989, Dysphagia, V3, P126; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; Mackay LE, 1999, J HEAD TRAUMA REHAB, V14, P435, DOI 10.1097/00001199-199910000-00004; MANDELSTAM P, 1970, GASTROENTEROLOGY, V58, P32; MORGAN A, 2001, ASIA PACIFIC J SPEEC, V1, P9; Morgan AS, 1999, J HEAD TRAUMA REHAB, V14, P454, DOI 10.1097/00001199-199910000-00006; NEWMAN LA, 1991, INVEST RADIOL, V26, P870, DOI 10.1097/00004424-199110000-00005; O'Donoghue S, 1999, FOLIA PHONIATR LOGO, V51, P158, DOI 10.1159/000021494; O'Neil KH, 1999, DYSPHAGIA, V14, P139, DOI 10.1007/PL00009595; Ott DJ, 1998, DYSPHAGIA, V13, P148; Palmer Jeffrey B., 1993, Dysphagia, V8, P209, DOI 10.1007/BF01354540; Perlman A L, 1994, Dysphagia, V9, P90; PUTNAM PE, 1992, PEDIATRICS, V89, P871; ROBBINS J, 1992, GASTROENTEROLOGY, V103, P823, DOI 10.1016/0016-5085(92)90013-O; Rowe LA, 1999, J HEAD TRAUMA REHAB, V14, P497, DOI 10.1097/00001199-199910000-00010; Schurr MJ, 1999, J TRAUMA, V46, P817, DOI 10.1097/00005373-199905000-00009; Tracy J F, 1989, Dysphagia, V4, P90, DOI 10.1007/BF02407151; Ylvisaker M, 1989, J HEAD TRAUMA REHAB, V4, P51	41	23	25	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	2002	17	3					220	241		10.1097/00001199-200206000-00004			22	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	552WE	WOS:000175642400004	12086576				2021-06-18	
J	Canedo, A; Grix, MC; Nicoletti, J				Canedo, A; Grix, MC; Nicoletti, J			An analysis of assessment instruments for the minimally responsive patient (MRP): clinical observations	BRAIN INJURY			English	Article							BRAIN-INJURED PATIENTS; COMA; SCALE; REHABILITATION; CONSCIOUSNESS; RECOVERY; STATES	The purpose for presenting these cases is to report on clinical observations that way have relevance for improvement in individuals responding minimally to their environment as a result of a severe traumatic brain injury. Specifically, the authors observe that there is a sub-group of minimally responsive patients who, when given sensory stimulation, show,in increase in responding that is being under-reported with current assessment instruments. Further, subtle changes in responding can occur over a wide temporal gradient and under-reporting of said changes may result in the premature cessation of a beneficial therapeutic intervention. Advantages and disadvantages of the instruments that have been developed to specifically assess responses to sensory stimulation are discussed. The authors' observations suggest that clinical findings do not correlate with assessment scores. These provisory observations indicate that there is a need to develop methodologically sound tools that will accurately monitor individuals throughout the rehabilitative process.	Jamaica Hosp, Brady Inst, Jamaica, NY USA; Pk Terrace Care Ctr, Traumat Brain Injury Programme, Rego Pk, NY USA	Grix, MC (corresponding author), 233 7th St,3rd Floor,Suite 5, Garden City, NY 11530 USA.						ANSELL BJ, 1991, J SPEECH HEAR RES, V34, P1017, DOI 10.1044/jshr.3405.1017; Ansell BJ, 1989, W NEUROSENSORY STIMU; Burke D, 2000, BRAIN INJURY, V14, P463; DAVIS JM, 1995, J MICROCOLUMN SEP, V7, P3, DOI 10.1002/mcs.1220070102; GIACINO J, 1992, JFK COMA RECOVERY SC; Gill-Thwaites H, 1999, NEUROPSYCHOL REHABIL, V9, P305, DOI 10.1080/096020199389392; Hagen C, 1979, REHABILITATION HEAD; HALL M E, 1992, Brain Injury, V6, P435, DOI 10.3109/02699059209008139; HORN S, 1993, NEUROPSYCHOL REHABIL, V3, P121; Kater K M, 1989, West J Nurs Res, V11, P20, DOI 10.1177/019394598901100103; LEWINN EB, 1978, LANCET, V2, P156; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; ODell MW, 1996, NEUROREHABILITATION, V6, P45, DOI 10.3233/NRE-1996-6106; Rader M.A., 1989, SENSORY STIMULATION; RAPPAPORT M, 1992, ARCH PHYS MED REHAB, V73, P628; Shiel A, 2000, WESSEX HEAD INJURY M; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; Sosnowski C, 1994, J Neurosci Nurs, V26, P336; TEASDALE G, 1974, LANCET, V2, P81; Teasdale GM, 2000, INTENS CARE MED, V26, P153, DOI 10.1007/s001340050037; WILSON GJ, 1993, STRENGTH COND COACH, V1, P3; Wood R L, 1992, Brain Inj, V6, P411, DOI 10.3109/02699059209008137; WOOD RL, 1993, NEUROPSYCHOL REHABIL, V3, P177	23	23	24	0	0	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	MAY	2002	16	5					453	461		10.1080/02699050110119853			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	553TX	WOS:000175692500007	12097227				2021-06-18	
J	Preston, E; Webster, J				Preston, E; Webster, J			Differential passage of [C-14]sucrose and [H-3]inulin across rat blood-brain barrier after cerebral ischemia	ACTA NEUROPATHOLOGICA			English	Article						cerebral ischemia; blood-brain barrier; cerebrovascular injury; stroke	FOREBRAIN ISCHEMIA; PERMEABILITY; EDEMA; PERMEATION; TRANSPORT; SUCROSE; INULIN	The biophysical nature of blood-brain barrier (BBB) opening after ischemic or hemorrhagic stroke or traumatic brain injury is unresolved. Ultrastructural (electron micrograph) investigations of experimental BBB injury commonly indicate the abnormal presence of vesicles or tubular structures in cerebrovascular endothelial cells, suggesting the likelihood of convective, fluid-phase transport of blood substances into brain. We measured transfer constants (K(i)s) for the simultaneous passage of two intravenously delivered tracers ([C-14]sucrose, Mol wt=342. [H-3]inulin approximate to5,000) across the intact BBB in the rat, and 24 h after global cerebral ischemia (16-20 min duration) or 24, 48 or 72 h after focal ischemia (2 h duration). In both ischemia models, the upward increment in K-i (DeltaK(i)) for sucrose, indicating the extra injury-related tracer flux into brain, significantly exceeded that for inulin, as might be expected with faster diffusion of the smaller molecule through injury pores or channels. This inequality of DeltaK(i)s did not suggest a major role for convective, fluid-phase transport by endothelial vesicular or tubular structures and a predominance of diffusional transport was indicated.	Natl Res Council Canada, Inst Biol Sci, Ottawa, ON K1A 0R6, Canada	Preston, E (corresponding author), Natl Res Council Canada, Inst Biol Sci, M54 Montreal Rd, Ottawa, ON K1A 0R6, Canada.	ed.preston@nrc.ca					AMTORP O, 1980, ACTA PHYSIOL SCAND, V110, P337, DOI 10.1111/j.1748-1716.1980.tb06678.x; BROADWELL RD, 1989, ACTA NEUROPATHOL, V79, P117, DOI 10.1007/BF00294368; BUCHAN AM, 1992, STROKE, V23, P273, DOI 10.1161/01.STR.23.2.273; COLE DJ, 1991, ACTA NEUROPATHOL, V82, P266, DOI 10.1007/BF00308811; CURRY FE, 1984, HDB PHYSL CARDIOVASC, V4, P309, DOI DOI 10.1152/JAPPLPHYSIOL.00389.2006; DIETRICH WD, 1990, J NEUROPATH EXP NEUR, V49, P486, DOI 10.1097/00005072-199009000-00004; DIETRICH WD, 1988, J NEUROPATH EXP NEUR, V47, P443, DOI 10.1097/00005072-198807000-00005; HSU CY, 1989, ANN NY ACAD SCI, V559, P282; Huang ZG, 1999, CAN J NEUROL SCI, V26, P298, DOI 10.1017/S0317167100000421; JOHSHITA H, 1990, STROKE, V21, P1051, DOI 10.1161/01.STR.21.7.1051; KLATZO I, 1994, ACTA NEUROCHIR, P3; LOSSINSKY AS, 1983, ACTA NEUROPATHOL, V61, P239, DOI 10.1007/BF00691992; LUCCHESI KJ, 1990, AM J PHYSIOL, V258, pH695; MAYHAN WG, 1985, AM J PHYSIOL, V248, pH712; OHNO K, 1978, AM J PHYSIOL, V235, pH299; PARDRIDGE WM, 1991, PEPTIDE DRUG DELIVER, P149; PRESTON E, 1990, ACT NEUR S, V51, P174; PRESTON E, 1983, J NEUROSCI METH, V9, P45, DOI 10.1016/0165-0270(83)90108-5; Preston E, 1998, BRAIN RES BULL, V45, P111, DOI 10.1016/S0361-9230(97)00278-5; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; PRESTON E, 1993, NEUROSCI LETT, V149, P75, DOI 10.1016/0304-3940(93)90351-K; Preston E, 1997, BRAIN RES, V761, P4, DOI 10.1016/S0006-8993(97)00323-5; SAMPAOLO S, 1991, ACTA NEUROPATHOL, V82, P107, DOI 10.1007/BF00293952; SMITH KA, 1984, ANNU REV IMMUNOL, V2, P319, DOI 10.1146/annurev.iy.02.040184.001535; Stewart PA, 2000, CELL MOL NEUROBIOL, V20, P149, DOI 10.1023/A:1007026504843; Vaz R, 1998, ACTA NEUROCHIR, V140, P76, DOI 10.1007/s007010050061; Xue D., 1998, Society for Neuroscience Abstracts, V24, P1955; ZIYLAN YZ, 1983, EXP NEUROL, V79, P845, DOI 10.1016/0014-4886(83)90047-X	28	23	24	0	1	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.	MAR	2002	103	3					237	242		10.1007/s004010100458			6	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	528KV	WOS:000174243700006	11907803				2021-06-18	
J	Zhao, H; Huang, HW; Wu, GC; Cao, XD				Zhao, H; Huang, HW; Wu, GC; Cao, XD			Effect of orphanin FQ on interleukin-1 beta mRNA transcripts in the rat CNS	NEUROSCIENCE			English	Article						orphanin FQ; interleukin-1 beta; neurommurne; neuron; astrocyte; microglia	CENTRAL-NERVOUS-SYSTEM; OPIOID RECEPTOR; NOCICEPTIN/ORPHANIN FQ; MICROGLIA; INJURY; CELLS; BRAIN	To elucidate the mechanism of orphanin FQ on neuroimmune modulation, the relationship between orphanin FQ and interleukin-1beta in the rat CNS in vivo and in vitro was investigated. In our experiments, it was found that orphanin FQ and interleukin-1beta mRNA transcripts showed a similar distribution in cerebral cortex, hippocampus and hypothalamus. By using the in situ hybridization technique, down-regulation of interleukin-1beta mRNA transcripts by central administration of orphanin FQ was further identified in the traumatic animal model. Similar inhibitory effects were also observed on the number of microglia in the CNS. The effects produced by orphanin FQ were abolished by combination with its receptor (OP4)-specific antagonist [Phe(1)Psi(CH2-NH)Gly(2)]nociceptin-(1-13)-NH2, which suggested that the function of orphanin FQ might be attributable to the OP4 pathway. However, the effect on the number of astrocytes in the CNS remained unchanged, despite evidence that OP4 is expressed on astrocytes as well as on neurons and microglia. When analyzed by reverse transcription-polymerase chain reaction, interleukin-1beta gene expression was observed to be enhanced and inhibited in primary neuron and microglial cell cultures exposed to orphanin FQ respectively. Interleukin-1beta gene expression in astrocyte cultures was not affected by treatment with orphanin FQ. Our findings suggest that the neuroimmune function of orphanin FQ might be dependent on interleukin-1beta derived from microglia, and the interaction between microglia and neurons. (C) 2002 IBRO. Published by Elsevier Science Ltd. All rights reserved.	Fudan Univ, Shanghai Med Coll, Dept Neurobiol, Natl Key Lab Med Neurobiol, Shanghai 200032, Peoples R China; Fudan Univ, Huashan Hosp, Dept Hand Surg, Shanghai 200032, Peoples R China	Cao, XD (corresponding author), Fudan Univ, Shanghai Med Coll, Dept Neurobiol, Natl Key Lab Med Neurobiol, Shanghai 200032, Peoples R China.						Aldskogius H, 1998, PROG NEUROBIOL, V55, P1, DOI 10.1016/S0301-0082(97)00093-2; Anton B, 1996, J COMP NEUROL, V368, P229; BAN EM, 1993, NEUROSCIENCE, V52, P725, DOI 10.1016/0306-4522(93)90421-B; Buzas B, 1998, J NEUROCHEM, V71, P556; Calo G, 2000, BRIT J PHARMACOL, V129, P1261, DOI 10.1038/sj.bjp.0703219; DINARELLO CA, 1991, BLOOD, V77, P1627; Du LN, 1998, ACUPUNCTURE ELECTRO, V23, P1; GIULIAN D, 1986, J EXP MED, V164, P594, DOI 10.1084/jem.164.2.594; HALFORD WP, 1995, J NEUROIMMUNOL, V59, P91, DOI 10.1016/0165-5728(95)00030-6; Henderson G, 1997, TRENDS PHARMACOL SCI, V18, P293, DOI 10.1016/S0165-6147(97)90645-3; Ikeda K, 1998, J COMP NEUROL, V399, P139, DOI 10.1002/(SICI)1096-9861(19980914)399:1<139::AID-CNE11>3.0.CO;2-C; Koster A, 1999, P NATL ACAD SCI USA, V96, P10444, DOI 10.1073/pnas.96.18.10444; LANDIS DMD, 1994, ANNU REV NEUROSCI, V17, P133, DOI 10.1146/annurev.ne.17.030194.001025; LU LM, 1997, ACTA PHYSL SIN, V49, P235; MEUNIER JC, 1995, NATURE, V377, P532, DOI 10.1038/377532a0; Meunier JC, 1997, EUR J PHARMACOL, V340, P1, DOI 10.1016/S0014-2999(97)01411-8; Mogil JS, 1996, NEUROSCIENCE, V75, P333, DOI 10.1016/0306-4522(96)00338-7; Mrak RE, 2000, J NEUROPATH EXP NEUR, V59, P471, DOI 10.1093/jnen/59.6.471; Peluso J, 1998, J NEUROIMMUNOL, V81, P184, DOI 10.1016/S0165-5728(97)00178-1; REINSCHEID RK, 1995, SCIENCE, V270, P792, DOI 10.1126/science.270.5237.792; Sheng JG, 1998, ACTA NEUROPATHOL, V95, P229, DOI 10.1007/s004010050792; Stoll G, 1999, PROG NEUROBIOL, V58, P233, DOI 10.1016/S0301-0082(98)00083-5; Wang AJ, 1996, ACTA PHYSL SIN, V48, P348; WANG J, 2001, CHIN J NEUROSCI, V17, P368; ZHAO H, 2001, ACTA PHYSL SIN, V53, P209	25	23	24	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2002	114	4					1019	1031	PII S0306-4522(02)00233-6	10.1016/S0306-4522(02)00233-6			13	Neurosciences	Neurosciences & Neurology	613LZ	WOS:000179134900019	12379256				2021-06-18	
J	Wildering, WC; Hermann, PM; Bulloch, AGM				Wildering, WC; Hermann, PM; Bulloch, AGM			Lymnaea epidermal growth factor promotes axonal regeneration in CNS organ culture	JOURNAL OF NEUROSCIENCE			English	Article						neurotrophic factor; epidermal growth factor; axonal regeneration; invertebrate; mollusk; CNS; L-EGF; peripheral nerve regeneration; neurotrauma	CENTRAL-NERVOUS-SYSTEM; SENSORY NEURONS; FACTOR-ALPHA; RECEPTOR; INJURY; CELLS; CONNECTIONS; ACTIVATION; EXPRESSION; INTEGRINS	Members of the epidermal growth factor (EGF) family are frequently implicated in the injury response of the mammalian nervous system. Although this implication is supported by extensive molecular evidence, it is not underpinned by conclusive functional data. Recently, we found that expression of an EGF homolog from the pond snail Lymnaea stagnalis (L-EGF) is upregulated after axotomy in the adult CNS, suggesting a role for this molecule in the injury response of the CNS. In the present study we asked whether L-EGF can promote axonal regeneration of three types of identified neurons in organ-cultured CNS. Treatment with purified L-EGF substantially enhanced axonal regeneration of all three types of neurons, an effect inhibited by submicromolar doses of PD153035, a specific EGF receptor (EGFR) tyrosine kinase inhibitor. In addition, PD153035 and K252a, a nonspecific kinase inhibitor, also reduced the degree of axonal regeneration that occurs without L-EGF supplementation, indicating that L-EGF or other EGFR ligands synthesized in the CNS participate in the regenerative response. An intriguing aspect of these results is that axonal regeneration of different, intrinsically L-EGF responsive and unresponsive neurons occurred in a coordinated manner. This observation suggests that indirect in addition to direct actions contribute to the beneficial effect of L-EGF. In conclusion, we provide functional evidence that an EGF homolog can promote axonal regeneration, substantiating existing molecular evidence implicating the EGF family in peripheral nerve regeneration and emphasizes the therapeutic potential of these molecules.	Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Physiol & Biophys,Neurosci Res Grp, Calgary, AB T2N 4N1, Canada	Wildering, WC (corresponding author), Univ Calgary, Fac Med, Hlth Sci Ctr, Dept Physiol & Biophys,Neurosci Res Grp, 3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada.	wilderin@ucalgary.ca		Wildering, Willem/0000-0001-9120-5930			ALLISON P, 1985, PROC R SOC SER B-BIO, V226, P135, DOI 10.1098/rspb.1985.0088; Ambron RT, 1996, MOL NEUROBIOL, V13, P61, DOI 10.1007/BF02740752; CHALAZONITIS A, 1992, J NEUROSCI, V12, P583; DUBUISSON AS, 1993, J RECONSTR MICROSURG, V9, P341, DOI 10.1055/s-2007-1006741; Ebadi M, 1997, NEUROCHEM INT, V30, P347, DOI 10.1016/S0197-0186(96)00071-X; Fainzilber M, 1996, SCIENCE, V274, P1540, DOI 10.1126/science.274.5292.1540; FERRARI G, 1991, J NEUROSCI RES, V30, P493, DOI 10.1002/jnr.490300306; FREDMAN SM, 1987, J NEUROSCI METH, V20, P181, DOI 10.1016/0165-0270(87)90050-1; Frostick SP, 1998, MICROSURG, V18, P397, DOI 10.1002/(SICI)1098-2752(1998)18:7<397::AID-MICR2>3.0.CO;2-F; FRY DW, 1994, SCIENCE, V265, P1093, DOI 10.1126/science.8066447; Fu SY, 1997, MOL NEUROBIOL, V14, P67, DOI 10.1007/BF02740621; Goldberg JL, 2000, ANNU REV NEUROSCI, V23, P579, DOI 10.1146/annurev.neuro.23.1.579; Hermann PM, 2000, BEHAV NEUROSCI, V114, P410, DOI 10.1037//0735-7044.114.2.410; Hermann PM, 2000, J NEUROSCI, V20, P6355, DOI 10.1523/JNEUROSCI.20-17-06355.2000; Ide C, 1996, NEUROSCI RES, V25, P101; JANSE C, 1979, MALACOLOGIA, V18, P485; JANSE C, 1986, MECH AGEING DEV, V35, P179, DOI 10.1016/0047-6374(86)90008-4; Juliano Rudy, 1996, Bioessays, V18, P911, DOI 10.1002/bies.950181110; Justicia C, 1999, J CEREBR BLOOD F MET, V19, P128; KENIGSBERG RL, 1995, J NEUROSCI RES, V41, P734, DOI 10.1002/jnr.490410604; Kimpinski K, 2001, J NEUROSCI RES, V63, P486, DOI 10.1002/jnr.1043; KITS KS, 1990, NEUROSCI LETT, V109, P253, DOI 10.1016/0304-3940(90)90003-R; Klaassen LJ, 1998, NEUROBIOL AGING, V19, P341, DOI 10.1016/S0197-4580(98)00065-7; KNUSEL B, 1992, J NEUROCHEM, V59, P1987; KRUK PJ, 1992, J NEUROSCI RES, V31, P401, DOI 10.1002/jnr.490310302; Logan Ann, 1994, Progress in Growth Factor Research, V5, P379, DOI 10.1016/0955-2235(94)00008-9; McAllister AK, 1996, NEURON, V17, P1057, DOI 10.1016/S0896-6273(00)80239-1; Meyer-Franke A, 1998, NEURON, V21, P681, DOI 10.1016/S0896-6273(00)80586-3; MOFFETT SB, 1995, PROG NEUROBIOL, V46, P289, DOI 10.1016/0301-0082(95)00007-I; Moro L, 1998, EMBO J, V17, P6622, DOI 10.1093/emboj/17.22.6622; MORRISON RS, 1988, J NEUROSCI RES, V21, P71, DOI 10.1002/jnr.490210111; Peng H, 1998, J CEREBR BLOOD F MET, V18, P349, DOI 10.1097/00004647-199804000-00002; PLOPPER GE, 1995, MOL BIOL CELL, V6, P1349; Porter JC, 1998, TRENDS CELL BIOL, V8, P390, DOI 10.1016/S0962-8924(98)01344-0; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RAO G, 1986, J NEUROSCI METH, V16, P251, DOI 10.1016/0165-0270(86)90050-6; Riese DJ, 1998, BIOESSAYS, V20, P41, DOI 10.1002/(SICI)1521-1878(199801)20:1<41::AID-BIES7>3.0.CO;2-V; RODGERS W, 1998, READING UNDERSTANDIN, P169; RUEGG UT, 1989, TRENDS PHARMACOL SCI, V10, P218, DOI 10.1016/0165-6147(89)90263-0; Shafer OT, 1998, P ROY SOC B-BIOL SCI, V265, P2171, DOI 10.1098/rspb.1998.0555; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Terenghi G, 1999, J ANAT, V194, P1, DOI 10.1046/j.1469-7580.1999.19410001.x; TOMA JG, 1992, J NEUROSCI, V12, P2504; VONBERNHARDI R, 1995, J NEUROBIOL, V27, P353, DOI 10.1002/neu.480270308; Wildering W. C., 1997, Society for Neuroscience Abstracts, V23, P57; Xian CJ, 1999, MOL NEUROBIOL, V20, P157, DOI 10.1007/BF02742440; Xian CJ, 1999, EXP NEUROL, V157, P317, DOI 10.1006/exnr.1999.7063; Yamada M, 1997, PROG NEUROBIOL, V51, P19, DOI 10.1016/S0301-0082(96)00046-9	48	23	25	0	2	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474	1529-2401		J NEUROSCI	J. Neurosci.	DEC 1	2001	21	23					9345	9354		10.1523/JNEUROSCI.21-23-09345.2001			10	Neurosciences	Neurosciences & Neurology	494BL	WOS:000172258400031	11717368	Green Published, Bronze			2021-06-18	
J	Yorkston, KM; Spencer, K; Duffy, J; Beukelman, D; Golper, LA; Miller, R; Strand, E; Sullivan, M				Yorkston, KM; Spencer, K; Duffy, J; Beukelman, D; Golper, LA; Miller, R; Strand, E; Sullivan, M			Evidence-based medicine and practice guidelines: Application to the field of speech-language pathology	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							CLINICAL-PRACTICE GUIDELINES; TRAUMATIC BRAIN INJURY; TREATMENT EFFICACY; COGNITIVE REHABILITATION; CRITICAL-APPRAISAL; RESEARCH DESIGNS; QUALITY; CARE; DISORDERS; OUTCOMES	Medical speech-language pathology is turning to the tools of evidence-based medicine and practice guidelines as a mean of assisting in decision making and improving the quality of services to individuals with neurologic communication disorders. Evidence-based practice is an approach to decision making in which the clinician uses the best evidence available to decide upon the option that best suits their patients. Practice guidelines are explicit statements that assist practitioners and patients to make decisions about appropriate health care for specific clinical conditions. Trends leading to a proliferation of guidelines along with a critical review of their development and application to the field of speech-language pathology are provided. Development of evidence-based practice guidelines for the management of dysarthria is reviewed including descriptions of the writing committee and the panel of experts, development of the questions to be addressed, types of evidence included, and methods for rating the evidence.	Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; Univ Washington, Dept Speech & Hearing Sci, Seattle, WA 98195 USA; Mayo Clin, Dept Neurol, Div Speech Pathol, Rochester, MN USA; Univ Nebraska, Dept Special Educ & Commun Disorders, Lincoln, NE USA; Vanderbilt Bill Wilkerson Ctr, Dept Speech & Hearing Sci, Nashville, TN USA; Vet Adm Puget Sound Hlth Syst, Dept Rehabil Med, Seattle, WA USA; Univ Nebraska, Munroe Meyer Inst Genet & Rehabil, Omaha, NE 68182 USA	Yorkston, KM (corresponding author), Univ Washington, Dept Rehabil Med, Box 356490, Seattle, WA 98195 USA.						AESCHLEMAN SR, 1991, REHABIL PSYCHOL, V36, P43, DOI 10.1037/0090-5550.36.1.43; *AM SPEECH LANG HE, 1998, PREF PRACT PATT PROF; Baum H. M., 1998, J MED SPEECH-LANG PA, V6, P55; BYNG S, 1998, MEASURING OUTCOMES S, P558; Carney N, 1999, J HEAD TRAUMA REHAB, V14, P277, DOI 10.1097/00001199-199906000-00008; Chambless DL, 1998, J CONSULT CLIN PSYCH, V66, P7, DOI 10.1037/0022-006X.66.1.7; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Coelho CA, 1996, J SPEECH HEAR RES, V39, pS5, DOI 10.1044/jshr.3905.s5; COOKE JP, 1996, CONT ENDOCRINOL, V1, P3; CROSBIE J, 1993, J CONSULT CLIN PSYCH, V61, P966, DOI 10.1037/0022-006X.61.6.966; *DHHS, 1994, FED REGISTER, V59, P19723; FIELD MJ, 1992, GUIDELINES CLIN PRAC, P426; Forbes SA, 1997, ARCH PHYS MED REHAB, V78, P1112, DOI 10.1016/S0003-9993(97)90137-4; FRATTALI CM, 1998, MEASURING OUTCOMES S, P1; Gallagher TM, 1998, FOLIA PHONIATR LOGO, V50, P165, DOI 10.1159/000021459; Garrard J, 1999, HLTH SCI LIT REV MAD; Glass G.V., 1976, EDUC RES, P3, DOI DOI 10.3102/0013189X005010003; Gray JAM, 1997, EVIDENCE BASED HEALT; GREENER J, 2000, COCHRANE LIB; GRESHAM GE, 1995, AHCRP PUBLICATION; Grilli R, 2000, LANCET, V355, P103, DOI 10.1016/S0140-6736(99)02171-6; Hadorn DC, 1996, J CLIN EPIDEMIOL, V49, P749, DOI 10.1016/0895-4356(96)00019-4; Hayes O W, 1994, J Am Osteopath Assoc, V94, P732; Holland AL, 1996, J SPEECH HEAR RES, V39, pS27, DOI 10.1044/jshr.3905.s27; Johnston MV, 1998, REHABILITATION MED P, P287; KEARNS K P, 1990, Seminars in Speech and Language, V11, P273, DOI 10.1055/s-2008-1064258; Lohr K N, 1994, Int J Qual Health Care, V6, P17; Lohr KN, 1998, HEALTH POLICY, V46, P1, DOI 10.1016/S0168-8510(98)00044-X; LOHR KN, 1995, J LAW MED ETHICS, V23, P49, DOI 10.1111/j.1748-720X.1995.tb01330.x; Miller RG, 1999, NEUROLOGY, V52, P1311, DOI 10.1212/WNL.52.7.1311; Olswang L. B., 1998, MEASURING OUTCOMES S, P134; Olswang L. B., 1990, TREATMENT EFFICACY R, P99; OLSWANG LB, 1993, J FLUENCY DISORD, V18, P125, DOI 10.1016/0094-730X(93)90002-L; Owens D K, 1993, Jt Comm J Qual Improv, V19, P248; Ringel SP, 1996, ARCH NEUROL-CHICAGO, V53, P867, DOI 10.1001/archneur.1996.00550090065012; ROBEY RR, 1999, CLIN APH C KEY W FLO; Sackett D., 1997, EVIDENCE BASED MED; Shaneyfelt TM, 1999, JAMA-J AM MED ASSOC, V281, P1900, DOI 10.1001/jama.281.20.1900; Solodky C, 1998, MED CARE, V36, pAS13, DOI 10.1097/00005650-199808001-00003; Stason WB, 1997, MED CARE, V35, pJS68, DOI 10.1097/00005650-199706001-00013; STASON WB, 1997, MED CARE S, V35, pJS78; Strand E. A., 1994, MOTOR SPEECH DISORDE, P37; Streiner DL, 1998, CAN J PSYCHIAT, V43, P737, DOI 10.1177/070674379804300709; TROMBLY C, 1995, AM J OCCUP THER, V49, P711, DOI 10.5014/ajot.49.7.711; West RR, 2000, POSTGRAD MED J, V76, P383, DOI 10.1136/pmj.76.897.383; WHURR R, 1992, EUR J DISORDER COMM, V27, P1; Woolf SH, 2000, J FAM PRACTICE, V49, P1081; Yorkston KM, 1996, J SPEECH HEAR RES, V39, pS46, DOI 10.1044/jshr.3905.s46	48	23	23	0	8	SINGULAR PUBLISHING GROUP INC	CLIFTON PARK	5 MAXWELL DR, CLIFTON PARK, NY 12065 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	DEC	2001	9	4					243	256					14	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	502YW	WOS:000172771200006					2021-06-18	
J	Cheliout-Heraut, F; Rubinsztajn, R; Ioos, C; Estournet, B				Cheliout-Heraut, F; Rubinsztajn, R; Ioos, C; Estournet, B			Prognostic value of evoked potentials and sleep recordings in the prolonged comatose state of children. Preliminary data	NEUROPHYSIOLOGIE CLINIQUE-CLINICAL NEUROPHYSIOLOGY			English	Article						anoxic coma; children; evoked potentials; sleep recordings; traumatic coma; wake-sleep cycle	SEVERE HEAD-INJURY; BRAIN-STEM; PREDICTION; PATIENT; ELECTROENCEPHALOGRAM; ABNORMALITIES; PATTERNS; ARREST; COMAS; EEG	Objectives - Sleep recordings and evoked potentials (EPs) were, used in five comatose children to evaluate their predictive value for outcome following a severe comatose state. Methods and subjects - The protocol included EEG, Brainstem Evoked Responses (BERs), Somatosensory Evoked Potentials (SEPs) and polysomnography. From 10 to 15 days post-coma (D10 to D15), EEG and clinical examinations were carried out every second day, then one day in four from 15 to 30 days post-coma (D15 to D30), and one day in seven from D30 to six months (M6). Evoked potentials and Polysomnography were recorded on D10-D15 or D30 in the second month (M2) and in M6. Of the five children, three were in anoxic coma and two in traumatic coma. All had extensive lesions and a Glasgow Coma Scale (GCS) score of less than five. The results of the EEG, polysomnographic and EP recordings were compared to the clinical outcome. Results and conclusion - In the three anoxic comas we observed BER abnormalities and the absence of SEP N20 associated with wide cortical lesions with brainstem extension. Sleep recordings showed major alterations of the wake-sleep cycle without any improvement in M6, Abnormalities included loss of the normal REM-sleep pattern associated with alteration of NREM sleep and periods of increase in motor activity without EEG arousal. This sleep pattern appeared to be associated with involvement of the brainstem. in the two traumatic comas, alterations of the early cortical SEP responses were less severe and the BERs were normal. Some sleep spindles were observed as well as the persistence of sleep cycles in the first weeks post-coma. The combined use of EEG, EPs and polysomnography improved the outcome prediction in comparison with the use of just one modality. EPs and sleep recordings were far superior to clinical evaluation and to GCS in the appreciation of the functional status of comatose children. The reappearence of sleep patterns is considered to be of favorable prognosis for outcome of the coma state, as is the presence of sleep spindles in post-trauma coma. This study showed that EPs and sleep recordings help to further distinguish between patients with good or bad outcomes. (C) 2001 Editions scientifiques et medicales Elsevier SAS.	Hop Raymond Poincare, Serv Explorat Fonctionnelles, F-92380 Garches, France; Hop Raymond Poincare, Serv Pediat, F-92380 Garches, France	Cheliout-Heraut, F (corresponding author), Hop Raymond Poincare, Serv Explorat Fonctionnelles, 104 Blvd R Poincare, F-92380 Garches, France.						BECA J, 1995, J PEDIATR-US, V126, P44, DOI 10.1016/S0022-3476(95)70498-1; BERGAMASCO B, 1968, ELECTROEN CLIN NEURO, V24, P374, DOI 10.1016/0013-4694(68)90198-3; BRICOLO A, 1976, CLIN ELECTROENCEPHAL, V7, P184, DOI 10.1177/155005947600700402; BRITT CW, 1981, NEUROLOGY, V31, P393; BRUNKO E, 1987, ELECTROEN CLIN NEURO, V66, P15, DOI 10.1016/0013-4694(87)90133-7; BRUNKO E, 1985, ELECTROEN CLIN NEURO, V62, P338, DOI 10.1016/0168-5597(85)90042-5; CHATRIAN GE, 1963, ELECTROENCEPHALOGR C, V13, P272; Cheliou-Heraut F., 1992, Neurophysiologie Clinique, V22, P269, DOI 10.1016/S0987-7053(05)80259-X; Courjon J, 1971, Rev Electroencephalogr Neurophysiol Clin, V1, P133, DOI 10.1016/S0370-4475(71)80054-0; EVANS BM, 1995, J NEUROL NEUROSUR PS, V59, P17, DOI 10.1136/jnnp.59.1.17; Facco E, 1998, ELECTROEN CLIN NEURO, V107, P332, DOI 10.1016/S0013-4694(98)00080-7; FELDMAN MH, 1971, NEUROLOGY, V21, P459, DOI 10.1212/WNL.21.5.459; FREEMON FR, 1974, ELECTROEN CLIN NEURO, V36, P657, DOI 10.1016/0013-4694(74)90232-6; GEORGE B, 1986, NEUROCHIRURGIA, V29, P45; GIUBILEI F, 1995, J NEUROL NEUROSUR PS, V58, P484, DOI 10.1136/jnnp.58.4.484; GREENBERG RP, 1981, J NEUROSURG, V55, P227, DOI 10.3171/jns.1981.55.2.0227; Guerit J. M., 1993, Neurophysiologie Clinique, V23, P209, DOI 10.1016/S0987-7053(05)80231-X; Guerit JM, 1999, NEUROPHYSIOL CLIN, V29, P301, DOI 10.1016/S0987-7053(99)90044-8; GUILLEMINAULT C, 1973, ELECTROEN CLIN NEURO, V34, P177, DOI 10.1016/0013-4694(73)90045-X; GUTLING E, 1995, NEUROLOGY, V45, P915, DOI 10.1212/WNL.45.5.915; HANSOTIA P, 1981, NEUROLOGY, V31, P83, DOI 10.1212/WNL.31.1.83; HULIHAN JF, 1994, NEUROLOGY, V44, P758, DOI 10.1212/WNL.44.4.758; HUME AL, 1981, ANN NEUROL, V10, P411, DOI 10.1002/ana.410100503; HUTCHINSON DO, 1991, ELECTROEN CLIN NEURO, V78, P228, DOI 10.1016/0013-4694(91)90037-5; JANKEL WR, 1985, J CLIN NEUROPHYSIOL, V2, P1, DOI 10.1097/00004691-198501000-00001; JENNETT B, 1975, LANCET, V1, P480; JOUET M, 1961, REV NEUROL, V105, P181; MARKAND ON, 1976, NEUROLOGY, V26, P769, DOI 10.1212/WNL.26.8.769; MUNARI C, 1981, ELECTROEN CLIN NEURO, V51, P170, DOI 10.1016/0013-4694(81)90006-7; NAQUET R, 1967, REV NEUROL-FRANCE, V117, P512; PAMPIGLIONE G, 1968, Lancet, P1261; Plum F, 1982, DIAGNOSIS STUPOR COM; Rechtschaffen A, 1968, MANUAL STANDARDIZED; ROSENBERG C, 1984, ARCH NEUROL-CHICAGO, V41, P835, DOI 10.1001/archneur.1984.04050190041012; RUMPL E, 1980, EEG-EMG-Z ELEK ELEKT, V11, P43; Sleigh JW, 1999, J NEUROSURG, V91, P577, DOI 10.3171/jns.1999.91.4.0577; TURAZZI S, 1977, LANCET, V2, P62; WALSER H, 1985, ARCH NEUROL-CHICAGO, V42, P32, DOI 10.1001/archneur.1985.04060010038013; WALSER H, 1981, EEG-EMG-Z ELEK ELEKT, V12, P198; WILKUS RJ, 1971, ARCH NEUROL-CHICAGO, V24, P538, DOI 10.1001/archneur.1971.00480360072009; Zandbergen EGJ, 1998, LANCET, V352, P1808, DOI 10.1016/S0140-6736(98)04076-8	41	23	24	0	2	ELSEVIER FRANCE-EDITIONS SCIENTIFIQUES MEDICALES ELSEVIER	ISSY-LES-MOULINEAUX	65 RUE CAMILLE DESMOULINS, CS50083, 92442 ISSY-LES-MOULINEAUX, FRANCE	0987-7053	1769-7131		NEUROPHYSIOL CLIN	Neurophysiol. Clin.-Clin. Neurophysiol.	OCT	2001	31	5					283	292		10.1016/S0987-7053(01)00270-2			10	Clinical Neurology; Neurosciences; Physiology	Neurosciences & Neurology; Physiology	492GW	WOS:000172160900001	11817270				2021-06-18	
J	Kushner, DS				Kushner, DS			Concussion in sports: Minimizing the risk for complications	AMERICAN FAMILY PHYSICIAN			English	Article							HEAD-INJURY; CONTACT-SPORTS; MILD; GUIDELINES; MANAGEMENT; TRAUMA	Mild traumatic brain injury, or concussion, is a common consequence of collisions, falls and other forms of contact in sports. Concussion may be defined as an acute trauma-induced alteration of mental function lasting fewer than 24 hours, with or without preceding loss of consciousness. The physician's responsibilities in assessing an athlete with concussion include determining the need for emergency intervention and offering guidance about the athlete's ability to return to play. Concussion may be complicated by cerebral edema related to the second impact syndrome, cumulative neuropsychologic deficits, intracranial bleeding or the postconcussion syndrome. The risk of complications is increased in athletes who prematurely return to play and in those with prolonged loss of consciousness or post-traumatic amnesia. An athlete with prolonged loss of consciousness or signs and symptoms that worsen or persist after a concussion should be evaluated in the emergency department. An athlete should not be allowed to resume sports participation until all symptoms of a concussion have resolved.	Univ Miami, Sch Med, Dept Neurol, Miami, FL 33101 USA	Kushner, DS (corresponding author), Univ Miami, Sch Med, Dept Neurol, POB 016960, Miami, FL 33101 USA.		Kushner, David S./AAW-4951-2020	Kushner, David S./0000-0001-6090-6304			Bergman DA, 1999, PEDIATRICS, V104, P1407; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; *COL MED SOC, 1991, GUID MAN CONC SPORTS; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; DACEY RG, 1986, J NEUROSURG, V65, P203, DOI 10.3171/jns.1986.65.2.0203; DACEY RG, 1993, HEAD INJURY, P159; GRONWALL D, 1975, LANCET, V2, P995; HAAS DC, 1986, BRAIN, V109, P251, DOI 10.1093/brain/109.2.251; HARRISON D W, 1990, Journal of Emergency Medicine, V8, P21, DOI 10.1016/0736-4679(90)90381-5; JENNETT B, 1973, SCOT MED J, V18, P8, DOI 10.1177/003693307301800103; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1998, J HEAD TRAUMA REHAB, V13, P53, DOI 10.1097/00001199-199804000-00008; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Kushner D, 1998, ARCH INTERN MED, V158, P1617, DOI 10.1001/archinte.158.15.1617; Lawler KA, 1996, J HEAD TRAUMA REHAB, V11, P18, DOI 10.1097/00001199-199612000-00005; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LIAU LM, 1996, NEUROLOGICAL SURG, P1549; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; RUBIN W, 1990, NEUROL CLIN, V8, P225, DOI 10.1016/S0733-8619(18)30352-9; SAUNDERS RL, 1984, JAMA-J AM MED ASSOC, V252, P538, DOI 10.1001/jama.252.4.538; STEIN SC, 1990, NEUROSURGERY, V26, P638, DOI 10.1227/00006123-199004000-00012; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014; YAMAMOTO LG, 1988, CLIN PEDIATR, V27, P479, DOI 10.1177/000992288802701003	25	23	23	0	3	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X			AM FAM PHYSICIAN	Am. Fam. Physician	SEP 15	2001	64	6					1007	1014					8	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	475UU	WOS:000171188200012	11578022				2021-06-18	
J	Loganovsky, KN; Yuryev, KL				Loganovsky, KN; Yuryev, KL			EEG patterns in persons exposed to ionizing radiation as a result of the Chernobyl accident: Part 1: Conventional EEG analysis	JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES			English	Article								Prospective conventional EEG study was carried out 3-5 and 10-13 years after the Chernobyl accident (1986) in patients who had acute radiation sickness and in emergency workers in 1986 ("liquidators"). Control groups comprised healthy volunteers; veterans of the Afghanistan war with posttraumatic stress disorder; veterans with mild traumatic brain injury; and patients with dyscirculatory encephalopathy. In 3-5 years after irradiation, there were irritated EEG changes with paroxysmal activity shifted to the left frontotemporal region (cortical-limbic overactivation) that were transformed 10-13 Years after irradiation toward a low-voltage EEG pattern with excess of fast (beta) and slow (delta) activity together with depression of alpha and theta activity (organic brain damage with inhibition of the cortical-limbic system). Quantitative EEG is likely to be very informative for investigation of dose-effect relationships.	Ukraine Acad Med Sci, Res Ctr Radiat Med, Int Clin Radiol, Dept Neurol,WHO Collaborating Ctr, Kiev, Ukraine	Loganovsky, KN (corresponding author), 16D Heroes Stalingrad St,Apt 173, UA-04210 Kiev, Ukraine.		Loganovsky, Konstantin/E-2136-2016	Loganovsky, Konstantin/0000-0002-0680-8882			ABRAMS R, 1988, ELECTROCONVULSIVE TH; BRUMBACK RA, 1981, ELECTROENCEPHALOGR C, V52, P128; CHAYANOV NV, 1992, 3 INT C BRAIN EL TOP; DANIEL W, 1995, BIOSTATISTICS FDN AN; Danilov V M, 1994, Fiziol Zh Im I M Sechenova, V80, P88; Danysz J, 1903, CR HEBD ACAD SCI, V136, P461; Danysz J, 1903, CR HEBD ACAD SCI, V137, P1296; DAVIS H, 1939, A RES NERV MENT DIS, V19, P50; DAVYDOV BI, 1987, RAD BIOL, V8; EDISON TA, 1896, SAN FRANCISCO CHRON, V19, P1; Flor-Henry P., 1983, CEREBRAL BASIS PSYCH; FlorHenry P, 1988, EEG MENTAL ACTIVITIE, P182; Futagi Y, 1998, ELECTROEN CLIN NEURO, V106, P392, DOI 10.1016/S0013-4694(98)00002-9; GANGLOFF H, 1962, EFFECTS IONIZING RAD, P123; GOROVITZ LM, 1906, BIOL SIGNIFICANCE RA; GRIGORIEV YG, 1963, RAD DAMAGES COMPENSA; HALEY TJ, 1962, EFFECTS IONIZING RAD, P171; Holahan Jr EV, 1987, MILITARY RADIOBIOLOG, P87; Hughes JR, 1999, J NEUROPSYCH CLIN N, V11, P190, DOI 10.1176/jnp.11.2.190; HUNT WA, 1987, MILITARY RADIOBIOLOG, P321; *IAEA, 1996, NAT REP UKR 10 YEARS; *IAEA, 1992, INT CHERN PROJ TECHN; *IAEA, 1961, P INT S VIENN; IZUMI C, 1955, FOLIO PSYCHIAT NEURO, V9, P229; Kimeldorf D. J., 1965, IONIZING RAD NEURAL; KINDSELSKY LP, 1995, CHERNOBYL CATASTROPH, P447; KONUMA M, 1961, Nagasaki Igakkai Zasshi, V36, P706; KONUMA M, 1954, JAPANESE MED J, V1544, P5; KONUMA M, 1967, HIROSHIMA MED J, V20, P231; KUZMA JW, 1984, BASIC STAT HLTH SCI; LEBEDINSKY AV, 1960, IONIZING RAD INFLUEN; LIKHTAREV I, 1996, BFS SKK SEM 10 YEARS; LIKHTAREV IA, 1994, HEALTH PHYS, V66, P643, DOI 10.1097/00004032-199406000-00004; LIVANOV MN, 1962, SOME PROBLEMS IONIZI; LOGANOVSKII KN, 1999, SOTSIALNAYA KLIN PSI, V1, P5; Loganovsky KN, 2000, ZH NEVROPATOL PSIKH, V100, P15; Loganovsky KN, 1995, P INT C MENT HLTH CO, P52; LONDON ES, 1903, BERLIN CLIN WEEKLY, V23, P523; MICKLEY GA, 1987, MILITARY RADIOBIOLOG, P303; NEMENOV MI, 1950, ROENTGENTHERAPY EXPO; Niedermeyer E., 1993, ELECTROENCEPHALOGRAP; NOSHCHENKO AG, 1994, VRACHEBNOE DELO, V2, P16; NOSHCHENKO AG, 1990, BIOL RADIOECOLOGICAL, P218; Nyagu AI, 1998, NEUROPSYCHIATRIC EFF; Nyagu AI, 1997, UKRAINIAN MED J, V2, P33; NYAGU AI, 1996, EXCLUSION ZONE, V3, P175; Nyagu AI, 1996, INT C 1 DEC CHERN BO, P347; NYAGU AI, 1999, 11 WORLD PSYCH C HAM, P161; Nyagu AI, 1999, INT J RAD MED, V2, P3; NYAGU AI, 1992, ZH NEVROPATOL PSYKHI, V94, P72; Nyagu AI, 1997, INT C SEV SPAIN NOV, P261; Oddie SD, 1998, NEUROSCI BIOBEHAV R, V22, P221, DOI 10.1016/S0149-7634(97)00003-1; PEYMER SI, 1985, REPORTS ACAD SCI UNI, V284, P1481; SOSNOVSKAYA F M, 1971, Zhurnal Nevropatologii i Psikhiatrii Imeni S. S. Korsakova, V71, P205; SYNEK VM, 1983, CLIN ELECTROENCEPHAL, V14, P102, DOI 10.1177/155005948301400211; TARKHANOV IR, 1896, HOSP NEWSPAPER BOTKI, V34, P785; TARKHANOV IR, 1896, HOSP NEWSPAPER BOTKI, V33, P753; TRAUGOTT NN, 1968, ESSAYS HUMAN PSYCHOP; TROCHERIE S, 1984, NATO, V2, P633; USHAKOV IB, 1997, CHERNOBYL RAD PSYCHO; Viatleva O A, 1996, Zh Nevrol Psikhiatr Im S S Korsakova, V96, P41; WAGEMAKER G, 1996, DIAGNOSIS TREATMENT; YAAR I, 1982, J NEUROL NEUROSUR PS, V45, P166, DOI 10.1136/jnnp.45.2.166; YURYEV KL, 1999, UKRAINIAN MED J, V4, P137; ZHAVORONKOVA LA, 1994, ZH VYSSH NERV DEYAT+, V44, P159; ZHAVORONKOVA LA, 1998, P 2 INT C LONG TERM, P233; Zhavoronkova Ludmila A., 1995, Brain Topography, V8, P161, DOI 10.1007/BF01199779; Zhirmunskaya E. A., 1991, CLIN ELECTROENCEPHAL; ZHUKOVSKY MO, 1903, REV PSYCHIAT NEUROPA, V11, P801	69	23	27	0	2	AMER PSYCHIATRIC PRESS, INC	WASHINGTON	1400 K ST, N W, STE 1101, WASHINGTON, DC 20005 USA	0895-0172			J NEUROPSYCH CLIN N	J. Neuropsychiatr. Clin. Neurosci.	FAL	2001	13	4					441	458		10.1176/appi.neuropsych.13.4.441			18	Clinical Neurology; Neurosciences; Psychiatry	Neurosciences & Neurology; Psychiatry	501VX	WOS:000172707700002	11748314				2021-06-18	
J	Mataro, M; Poca, MA; Sahuquillo, J; Pedraza, S; Ariza, M; Amoros, S; Junque, C				Mataro, M; Poca, MA; Sahuquillo, J; Pedraza, S; Ariza, M; Amoros, S; Junque, C			Neuropsychological outcome in relation to the traumatic coma data bank classification of computed tomography imaging	JOURNAL OF NEUROTRAUMA			English	Article						computerized tomography; head injury; neuropsychology; outcome	SEVERE HEAD-INJURY; INTRACRANIAL HYPERTENSION; VENTRICULAR ENLARGEMENT; BRAIN-LESIONS; EARLY INDEXES; SCALE; MILD; CT; EXPERIENCE; MANAGEMENT	The Traumatic Coma Data Bank (TCDB) classification of CT (computed tomography) scan has been related to the general outcome and intracranial pressure evolution. Our aim was to analyse the relationship of this classification with neuropsychological outcome and late indices of ventricular dilatation. Fifty-seven patients with a moderate or severe head injury (mean admission Glasgow Coma Scale Score, 7.7) were studied from 122 consecutive cases. There were 49 males and 8 females (mean age, 27.7 years). Subjects were classified into TCDB categories on the basis of their most serious acute CT scan finding. From the last control CT scan image, performed at a mean of 6.12 months postinjury, several measures of ventricular dilatation were calculated. Neuropsychological assessment at 6-month included tests of verbal and visual memory, visuoconstructive functions, fine motor speed, and frontal lobe functions. Patients with diffuse injury type I showed better neuropsychological outcome than patients with more severe diffuse injuries and those with mass lesions. Within the diffuse injury groups, the degree of diffuse damage was related to measures of verbal memory and attention and cognitive flexibility. Ventricular enlargement was more evident in patients with mass lesions and it decreased in the remaining groups as the severity of diffuse injury diminished. These results show that there is a relationship between acute intracranial lesion diagnosis according to TCDB classification and neuropsychological results and ventricular dilatation indices at 6 months postinjury.	Vall Hebron Univ Hosp, Dept Neurosurg, Barcelona 08035, Spain; Vall Hebron Univ Hosp, Neurotraumatol Res Unit, Barcelona, Spain; Hosp Univ Josep Trueta, Neuroradiol Unit, Girona, Spain; Univ Barcelona, Dept Psychiat & Clin Psychophysiol, Barcelona, Spain	Poca, MA (corresponding author), Vall Hebron Univ Hosp, Dept Neurosurg, Passeig Vall Hebron 119-129, Barcelona 08035, Spain.		pedraza, salvador/AAC-1728-2019; Sahuquillo, Juan/B-3577-2008; Mataro, Maria/B-4524-2011; Poca, Maria A./B-8475-2008; Ariza, Mar/F-2754-2019; Junque, Carme/B-4400-2011	pedraza, salvador/0000-0003-2517-4413; Sahuquillo, Juan/0000-0003-0713-5875; Mataro, Maria/0000-0002-9946-2656; Poca, Maria A./0000-0002-3831-0536; Junque, Carme/0000-0002-6381-3063; Ariza, Mar/0000-0003-1020-6945			ALEXANDRE A, 1983, J NEUROSURG, V59, P751, DOI 10.3171/jns.1983.59.5.0751; Benton A., 1976, MULTILINGUAL APHASIA; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; BIGLER ED, 1996, NEUROIMAGING, V2, P261; BROOKS DN, 1980, J NEUROL NEUROSUR PS, V43, P529, DOI 10.1136/jnnp.43.6.529; BUSCHKE H, 1974, NEUROLOGY, V24, P1019, DOI 10.1212/WNL.24.11.1019; CLIFTON GL, 1992, NEUROSURGERY, V31, P975, DOI 10.1227/00006123-199211000-00028; CORDOBES F, 1986, ACTA NEUROCHIR, V81, P27, DOI 10.1007/BF01456261; CULLUM CM, 1985, INT J NEUROSCI, V28, P279, DOI 10.3109/00207458508985395; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; EISENBERG HM, 1990, J NEUROSURG, V73, P688, DOI 10.3171/jns.1990.73.5.0688; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GROSWASSER Z, 1987, SURG NEUROL, V27, P331, DOI 10.1016/0090-3019(87)90007-3; JENKINS A, 1986, LANCET, V2, P445; JENNETT B, 1975, LANCET, V1, P480; KAKARIEKA A, 1994, ACTA NEUROCHIR, V129, P1, DOI 10.1007/BF01400864; KlOve H, 1963, MED CLIN N AM; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1988, J NEUROL NEUROSUR PS, V51, P1294, DOI 10.1136/jnnp.51.10.1294; LEVIN HS, 1990, J NEUROSURG, V73, P699, DOI 10.3171/jns.1990.73.5.0699; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; LEVIN HS, 1981, ARCH NEUROL-CHICAGO, V38, P623, DOI 10.1001/archneur.1981.00510100051007; LEVIN HS, 1991, NEUROSURGERY, V28, P196, DOI 10.1227/00006123-199102000-00004; LEVIN HS, 1987, J NEUROSURG, V66, P706, DOI 10.3171/jns.1987.66.5.0706; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LEVIN HS, 1991, ARCH NEUROL-CHICAGO, V48, P580, DOI 10.1001/archneur.1991.00530180032013; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; MACPHERSON P, 1986, J NEUROL NEUROSUR PS, V49, P29, DOI 10.1136/jnnp.49.1.29; MARSHALL LF, 1991, J NEUROSURG S, V75, P28; Marshall SB, 1991, J NEUROSURG S, V75, P14; Mataro M, 2000, J NEUROL NEUROSUR PS, V68, P615, DOI 10.1136/jnnp.68.5.615; MEYERS CA, 1983, J NEUROL NEUROSUR PS, V46, P1092, DOI 10.1136/jnnp.46.12.1092; MILLER JD, 1981, J NEUROSURG, V54, P289, DOI 10.3171/jns.1981.54.3.0289; Poca MA, 1998, ACT NEUR S, V71, P27; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; ROSS BL, 1994, AM J PHYS MED REHAB, V73, P341, DOI 10.1097/00002060-199409000-00007; RYE A, 1959, TEST COPIE REPROD ME; SERVADEI F, 1995, NEUROSURGERY, V37, P899, DOI 10.1227/00006123-199511000-00008; Smith A., 1991, SYMBOL DIGIT MODALIT; SmithSeemiller L, 1997, BRAIN INJURY, V11, P191; TEASDALE G, 1982, BRIT MED J, V285, P1695, DOI 10.1136/bmj.285.6356.1695; Teasdale GM, 1998, J NEUROTRAUM, V15, P587, DOI 10.1089/neu.1998.15.587; UZZELL BP, 1986, J NEUROSURG, V65, P630, DOI 10.3171/jns.1986.65.5.0630; UZZELL BP, 1987, NEUROSURGERY, V20, P396, DOI 10.1227/00006123-198703000-00007; VILKKI J, 1988, J NEUROL NEUROSUR PS, V51, P1452, DOI 10.1136/jnnp.51.11.1452; Vollmer D G, 1991, Neurosurg Clin N Am, V2, P437; WILBERGER JE, 1987, NEUROSURGERY, V20, P571, DOI 10.1227/00006123-198704000-00011; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; WILSON JTL, 1988, J NEUROL NEUROSUR PS, V51, P391, DOI 10.1136/jnnp.51.3.391	53	23	24	0	1	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	SEP	2001	18	9					869	879		10.1089/089771501750451794			11	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	471TP	WOS:000170945000003	11565599				2021-06-18	
J	Fischer, K; Zhang, F; Angel, MF; Lineaweaver, WC				Fischer, K; Zhang, F; Angel, MF; Lineaweaver, WC			Injuries associated with mandible fractures sustained in motor vehicle collisions	PLASTIC AND RECONSTRUCTIVE SURGERY			English	Article							FACIAL FRACTURES; MAXILLOFACIAL INJURIES	Motor vehicle collisions are second only to altercations as the most common cause of mandible fractures. This article details in a retrospectively studied group the incidence of isolated mandible fractures and associated injuries in patients who were involved in motor vehicle collisions. This group consisted of 148 patients with mandible fractures listed in the University of Mississippi's trauma registry during the past 5 years. In almost all patients, associated injuries occurred with mandible fractures that were caused by motor vehicle collisions, with an incidence of 99.3 percent. Facial and head lacerations and facial fractures were the leading associated injuries, occurring in more than half of the patients who had a mandible fracture. Closed head injury is the major life-threatening associated injury and cause of mortality. The life-threatening injuries occurred in 64.8 percent of patients in this study. The mortality rate in this group of patients was 8.1 percent. These data suggest that mandible fractures from motor vehicle collisions should never be viewed as an isolated injury but rather as part of a spectrum of significant and sometimes life-threatening injuries that require thorough trauma evaluation at the time of presentation.	Univ Mississippi, Med Ctr, Dept Surg, Div Plast Surg, Jackson, MS 39216 USA	Lineaweaver, WC (corresponding author), Univ Mississippi, Med Ctr, Dept Surg, Div Plast Surg, 2500 N State St, Jackson, MS 39216 USA.						ALLAN BP, 1990, INT J ORAL MAX SURG, V19, P268, DOI 10.1016/S0901-5027(05)80417-5; Azevedo AB, 1998, J TRAUMA, V45, P1084, DOI 10.1097/00005373-199812000-00020; Bayles SW, 1997, ARCH OTOLARYNGOL, V123, P1304; DAVIDOFF G, 1988, ANN EMERG MED, V17, P6, DOI 10.1016/S0196-0644(88)80492-X; FRIDRICH KL, 1992, J ORAL MAXIL SURG, V50, P586, DOI 10.1016/0278-2391(92)90438-6; HAUG HZ, 1992, J ORAL MAXIL SURG, V50, P218, DOI 10.1016/0278-2391(92)90315-Q; HAUG RH, 1994, J ORAL MAXIL SURG, V52, P729, DOI 10.1016/0278-2391(94)90488-X; HAUG RH, 1990, J ORAL MAXIL SURG, V48, P926, DOI 10.1016/0278-2391(90)90004-L; LIM LH, 1993, BRIT J PLAST SURG, V46, P635, DOI 10.1016/0007-1226(93)90191-D; LUCE EA, 1979, PLAST RECONSTR SURG, V63, P26, DOI 10.1097/00006534-197901000-00005; Marciani RD, 1999, J ORAL MAXIL SURG, V57, P119, DOI 10.1016/S0278-2391(99)90221-5; Murray J F, 1975, Clin Plast Surg, V2, P131; *NAT CTR HLTH STAT, 1987, INT CLASS DIS ICD 9, V1, P146; OLSON RA, 1982, J ORAL MAXIL SURG, V40, P23, DOI 10.1016/S0278-2391(82)80011-6; Poole G V, 1991, J Miss State Med Assoc, V32, P83; REATH DB, 1989, J TRAUMA, V29, P806, DOI 10.1097/00005373-198906000-00018; Surkin J, 2000, SPINE, V25, P716, DOI 10.1097/00007632-200003150-00011	17	23	25	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0032-1052	1529-4242		PLAST RECONSTR SURG	Plast. Reconstr. Surg.	AUG	2001	108	2					328	331		10.1097/00006534-200108000-00006			4	Surgery	Surgery	456RW	WOS:000170096900006	11496169				2021-06-18	
J	Regner, A; Alves, LB; Chemale, I; Costa, MS; Friedman, G; Achaval, M; Leal, L; Emanuelli, T				Regner, A; Alves, LB; Chemale, I; Costa, MS; Friedman, G; Achaval, M; Leal, L; Emanuelli, T			Neurochemical characterization of traumatic brain injury in humans	JOURNAL OF NEUROTRAUMA			English	Article						GFAP; human; glutamate; traumatic brain injury	D-ASPARTATE RECEPTOR; FIBRILLARY ACIDIC PROTEIN; CENTRAL-NERVOUS-SYSTEM; SEVERE HEAD-INJURY; BINDING-SITES; L-<H-3>GLUTAMATE BINDING; GLUTAMATE NEUROTOXICITY; EXTRACELLULAR GLUTAMATE; <H-3>MK-801 BINDING; HUMAN CEREBELLUM	Trauma is the leading cause of death in individuals between the ages of 1 and 44 years. And, in the case of severe head injury mortality can reach as high as 35-70%. Despite this fact, there has been little progress in the development of effective pharmacological agents to protect brain injured patients. To date, there is little data on the mechanisms involved in neuronal cellular insult after severe head injury, especially in humans. Glutamate acts both as a primary excitatory neurotransmitter and a potential neurotoxin within the mammalian brain. Evidence indicates that hyperactivity of the glutamate system contributes to neuronal death in brain trauma. Also, in animal models of neurotrauma, this neural injury is followed by gliosis which has been linked to the severity of brain injury. To investigate the glutamate system in brain trauma, we carried out [H-3]glutamate and [H-3]MK801 (a noncompetitive NMDA-receptor antagonist) binding and [H-3]glutamate uptake assays in human cerebral cortex preparations obtained from severely brain injured and control victims. Additionally, to investigate gliosis following brain injury, we performed GFAP immunohistochemistry. There were no significant differences in [H-3]glutamate binding (affinity or density of sites) between the control and head injured groups. In contrast, cerebral cortical [H-3]MK801 binding revealed both a significant increase in the density of sites (B-max) and a decrease in the dissociation constant (Kd) in the head injured group when compared to controls. There were no significant differences in [H-3]glutamate uptake between groups. The injured brains presented an increased number of GFAP-positive astrocytes and more intense GFAP reaction in comparison to control brains. In the context of traumatic brain injury, our results encourage further investigation into compounds capable of selective modulation of NMDA receptor subtype in humans while also therapeutically manipulating glial cell responses following brain trauma.	Univ Fed Rio Grande Sul, Dept Biochem, Porto Alegre, RS, Brazil; Univ Fed Rio Grande Sul, Dept Morphol Sci, Porto Alegre, RS, Brazil; Hosp Pronto Socorro Porto Alegre, Emergency Room, Porto Alegre, RS, Brazil; Hosp Pronto Socorro Porto Alegre, Neurosurg Unit, Porto Alegre, RS, Brazil; Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Emergency Care Unit, Porto Alegre, RS, Brazil; Univ Fed Rio Grande Sul, Hosp Clin Porto Alegre, Intens Care Unit, Porto Alegre, RS, Brazil; Univ Fed Santa Maria, Dept Food Technol & Sci, BR-97119900 Santa Maria, RS, Brazil	Regner, A (corresponding author), Univ Fed Rio Grande Sul, Dept Biochem, Porto Alegre, RS, Brazil.		Emanuelli, Tatiana/AAX-9075-2020; Friedman, Gilberto/F-7212-2015; Friedman, Gilberto/F-7208-2015; Regner, Andrea/M-2596-2014	Emanuelli, Tatiana/0000-0003-0168-3416; Friedman, Gilberto/0000-0001-9369-2488; Regner, Andrea/0000-0002-6657-7991			Alessandri B, 1999, ACT NEUR S, V75, P21; Baldwin SA, 1996, GLIA, V16, P266; Bridges RJ, 1999, CURR PHARM DESIGN, V5, P363; BROCKER B, 1991, CURR CONCEPTS IMAGIN, V1, P387; Bullock MR, 1999, NEUROSURGERY, V45, P207, DOI 10.1097/00006123-199908000-00001; Bullock R, 1998, J NEUROSURG, V89, P507, DOI 10.3171/jns.1998.89.4.0507; Chan H, 1999, NEUROCHEM RES, V24, P1397, DOI 10.1023/A:1022532623281; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; CHOI DW, 1988, J NEUROSCI, V8, P185; CHOI DW, 1990, ANNU REV NEUROSCI, V13, P171, DOI 10.1146/annurev.neuro.13.1.171; CHOI DW, 1992, J NEUROBIOL, V23, P1261, DOI 10.1002/neu.480230915; COWBURN RF, 1988, J NEUROCHEM, V50, P1872, DOI 10.1111/j.1471-4159.1988.tb02491.x; COX JA, 1989, BRAIN RES, V499, P267, DOI 10.1016/0006-8993(89)90774-9; CROSS A, 1986, J NEUROCHEM, V47, P1463, DOI 10.1111/j.1471-4159.1986.tb00779.x; Dietrich WD, 1999, J NEUROTRAUM, V16, P567, DOI 10.1089/neu.1999.16.567; DRINGEN R, 1993, BRAIN RES, V623, P208, DOI 10.1016/0006-8993(93)91429-V; Duhaime AC, 1996, NEUROTRAUMA, P365; Eclancher F, 1996, BRAIN RES, V737, P201, DOI 10.1016/0006-8993(96)00732-9; Emanuelli T, 1998, BIOCHEM MOL BIOL INT, V44, P1265; FADEN AI, 1992, TRENDS PHARMACOL SCI, V13, P29, DOI 10.1016/0165-6147(92)90013-V; Hertz L, 1999, J NEUROSCI RES, V57, P417, DOI 10.1002/(SICI)1097-4547(19990815)57:4<417::AID-JNR1>3.3.CO;2-E; HUBBARD CM, 1989, BRAIN RES, V486, P170, DOI 10.1016/0006-8993(89)91290-0; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KAWAMATA T, 1992, J CEREBR BLOOD F MET, V12, P12, DOI 10.1038/jcbfm.1992.3; Knipper M, 1997, NEUROCHEM INT, V31, P659, DOI 10.1016/S0197-0186(97)00009-0; KRAUS JF, 1996, NEUROTRAUMA, P13; LaPlaca MC, 1998, J NEUROSCI RES, V52, P220, DOI 10.1002/(SICI)1097-4547(19980415)52:2<220::AID-JNR10>3.0.CO;2-B; LIPTON SA, 1994, NEW ENGL J MED, V330, P613; LOWRY OH, 1951, J BIOL CHEM, V193, P265; LYNCH DR, 1994, CURR OPIN NEUROL, V7, P510, DOI 10.1097/00019052-199412000-00007; Marion D W, 1999, Clin Neurosurg, V45, P184; Merchant RE, 1999, ANN NY ACAD SCI, V890, P42, DOI 10.1111/j.1749-6632.1999.tb07979.x; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; NAGY A, 1984, J NEUROCHEM, V43, P1114, DOI 10.1111/j.1471-4159.1984.tb12851.x; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; NILSSON P, 1990, J CEREBR BLOOD F MET, V10, P631, DOI 10.1038/jcbfm.1990.115; NORENBERG MD, 1994, J NEUROPATH EXP NEUR, V53, P213, DOI 10.1097/00005072-199405000-00001; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Peng TI, 1998, MOL PHARMACOL, V53, P974; PIGGOTT MA, 1992, J NEUROCHEM, V58, P1001, DOI 10.1111/j.1471-4159.1992.tb09354.x; PIGGOTT MA, 1992, BRAIN RES, V588, P277, DOI 10.1016/0006-8993(92)91586-4; Porco JA, 2000, COMB CHEM HIGH T SCR, V3, P93, DOI 10.2174/1386207003331715; PROCTER AW, 1991, J NEUROCHEM, V56, P299, DOI 10.1111/j.1471-4159.1991.tb02596.x; PROCTER AW, 1989, J NEUROCHEM, V53, P698, DOI 10.1111/j.1471-4159.1989.tb11760.x; Reinert MM, 1999, NEUROL RES, V21, P330, DOI 10.1080/01616412.1999.11740940; Rocha E, 1998, NEUROREPORT, V9, P3971, DOI 10.1097/00001756-199812010-00037; STEELE JE, 1991, J NEUROCHEM, V56, P1248, DOI 10.1111/j.1471-4159.1991.tb11418.x; SUN FY, 1994, BRAIN RES, V661, P63, DOI 10.1016/0006-8993(94)91181-9; Trotti D, 1998, TRENDS PHARMACOL SCI, V19, P328, DOI 10.1016/S0165-6147(98)01230-9; Tsacopoulos M, 1996, J NEUROSCI, V16, P877; TSIOTOS P, 1989, BRAIN RES, V481, P87, DOI 10.1016/0006-8993(89)90487-3; TSUNG IP, 1998, MOL PHARMACOL, V53, P974; VALADKA AB, 1996, TRAUMA, P267; VALADKA AB, 2000, TRAUMA, P377; Vandenberg RJ, 1998, CLIN EXP PHARMACOL P, V25, P393, DOI 10.1111/j.1440-1681.1998.tb02221.x; VARGAS F, 1993, GEN PHARMACOL, V24, P1257, DOI 10.1016/0306-3623(93)90378-B; Vespa P, 1998, J NEUROSURG, V89, P971, DOI 10.3171/jns.1998.89.6.0971; VIJAYAN VK, 1990, MOL CHEM NEUROPATHOL, V13, P107, DOI 10.1007/BF03159912; Wood AM, 1998, J NEUROCHEM, V70, P677	59	23	26	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	AUG	2001	18	8					783	792		10.1089/089771501316919148			10	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	464AG	WOS:000170509600004	11526984				2021-06-18	
J	Rizzo, AA; Buckwalter, JG; McGee, JS; Bowerly, T; van der Zaag, C; Neumann, U; Thiebaux, M; Kim, L; Pair, J; Chua, C				Rizzo, AA; Buckwalter, JG; McGee, JS; Bowerly, T; van der Zaag, C; Neumann, U; Thiebaux, M; Kim, L; Pair, J; Chua, C			Virtual environments for assessing and rehabilitating cognitive/functional performance - A review of projects at the USC Integrated Media Systems Center	PRESENCE-TELEOPERATORS AND VIRTUAL ENVIRONMENTS			English	Article							MENTAL ROTATION; GENDER DIFFERENCES; SEX-DIFFERENCES; DEMENTIA; ABILITY	Virtual reality (VR) technology offers new options for the creation of sophisticated tools that could be applied in the areas of assessment and rehabilitation of cognitive and functional processes. VR systems allow for the precise presentation and control of dynamic, multisensory, three-dimensional (3-D) stimulus environments, as well as the recording of all behavioral responses that occur within them. Assessment and rehabilitation scenarios that would be difficult if not impossible to deliver using conventional neuropsychological methods are now being developed that take advantage of these VR assets. If empirical studies demonstrate effectiveness, virtual environments (VEs) could be of considerable value for better understanding, measuring, and treating persons with impairments due to traumatic brain injury, neurological disorders, and learning disabilities. This article describes the progress of a VR research program at the USC Integrated Media Systems Center and Information Sciences Institute that has developed and investigated the use of a series of VEs designed to target (i) molecular visuospatial skills using a 3-D, projection-based ImmersaDesk system, and (ii) attention (and soon memory and executive functioning) processes within ecologically valid functional scenarios utilizing a head-mounted display (HMD). Results from completed research, rationales and methodology of works in progress, and our plan for future work is presented. Our primary vision has been to develop VR systems that target cognitive processes and functional skills that are of relevance to a wide range of patient populations with central nervous system (CNS) dysfunction, as well as for the assessment of unimpaired performance. We have also sought to select cognitive/functional targets that intuitively appear well matched to the specific assets available with currently available VR technology.	Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA 90089 USA; So Calif Permanente Med Grp, Dept Res & Evaluat, Pasadena, CA 91101 USA; Fuller Grad Sch Psychol, Pasadena, CA 91101 USA; Univ So Calif, Sch Gerontol, Los Angeles, CA 90089 USA; Univ So Calif, Inst Informat Sci, Marina Del Rey, CA 90292 USA	Rizzo, AA (corresponding author), Univ So Calif, Integrated Media Syst Ctr, Los Angeles, CA 90089 USA.		McGee, Jocelyn/ABA-7532-2020				Army Individual Test Battery, 1944, MAN DIR SCOR; BENTON A L, 1978, Archives of Neurology, V35, P364; Brown DJ, 1997, COMMUN ACM, V40, P72, DOI 10.1145/257874.257891; CASEY MB, 1995, DEV PSYCHOL, V31, P697, DOI 10.1037/0012-1649.31.4.697; COLE KC, 1998, LOS ANGELES TIM 0314, pA19; COLE KC, 1998, LOS ANGELES TIM 0314, pA1; Delgado AR, 1996, MEM COGNITION, V24, P504, DOI 10.3758/BF03200938; DELIS D, 1983, CALIFORNIA VERBAL LE; GAINOTTI G, 1992, J CLIN EXP NEUROPSYC, V14, P239, DOI 10.1080/01688639208402826; GOUCHIE C, 1991, PSYCHONEUROENDOCRINO, V16, P323, DOI 10.1016/0306-4530(91)90018-O; KAMPEN DL, 1994, OBSTET GYNECOL, V83, P979, DOI 10.1097/00006250-199406000-00017; Kennedy R. S., 1993, Int'l. J. Aviat. Psychol., V3, P203, DOI [DOI 10.1207/S15327108IJAP0303_3, 10.1207/s15327108ijap0303_3]; KENNEDY RS, 1984, MOTION HIST QUESTION; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; MASTERS MS, 1993, BEHAV GENET, V23, P337, DOI 10.1007/BF01067434; McGee JS, 2000, CYBERPSYCHOL BEHAV, V3, P469, DOI 10.1089/10949310050078931; MCGEORGE P, 2000, COMMUNICATION   1212; Miller BL, 1997, NEUROLOGY, V48, P937, DOI 10.1212/WNL.48.4.937; Mitrushina M., 1999, HDB NORMATIVE DATA N; *NAT I DIS REH RES, NOT FIN LONG RANG PL; *NAT SCI FDN, PA98168 NSF; NEWCOMBE N, 1983, SEX ROLES, V9, P530; Nunnally J. C., 1993, PSYCHOMETRIC THEORY, V3rd; PETERS M, 1995, BRAIN COGNITION, V28, P39, DOI 10.1006/brcg.1995.1032; PUGNETTI L, 1995, COMPUT BIOL MED, V25, P213, DOI 10.1016/0010-4825(94)00040-W; Qubeck WJ, 1997, PERCEPT MOTOR SKILL, V85, P323; RICHARDSON JTE, 1994, PERCEPT MOTOR SKILL, V78, P435, DOI 10.2466/pms.1994.78.2.435; Rizzo AA, 2000, CYBERPSYCHOL BEHAV, V3, P483, DOI 10.1089/10949310050078940; RIZZO AA, 1997, VIRTUAL REALITY NEUR, P123; RIZZO AA, IN PRESS HDB VIRTUAL; ROSE FD, 1996, P 1 EUR C DIS VIRT R, P5; Sattler JM, 1988, ASSESSMENT CHILDREN; SHEPARD RN, 1971, SCIENCE, V171, P701, DOI 10.1126/science.171.3972.701; Signorino M, 1996, ARCH GERONTOL GERIAT, V23, P139, DOI 10.1016/0167-4943(96)00714-5; SILVERMAN I, 1993, ETHOL SOCIOBIOL, V14, P257, DOI 10.1016/0162-3095(93)90021-9; Stephanidis C, 1998, INT J HUM-COMPUT INT, V10, P107, DOI 10.1207/s15327590ijhc1002_2; VANDENBERG SG, 1978, PERCEPT MOTOR SKILL, V47, P599, DOI 10.2466/pms.1978.47.2.599; VOYER D, 1995, PSYCHOL BULL, V117, P250, DOI 10.1037/0033-2909.117.2.250; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wohlschlager A, 1998, J EXP PSYCHOL HUMAN, V24, P397, DOI 10.1037/0096-1523.24.2.397	41	23	23	0	15	M I T PRESS	CAMBRIDGE	FIVE CAMBRIDGE CENTER, CAMBRIDGE, MA 02142 USA	1054-7460			PRESENCE-TELEOP VIRT	Presence-Teleoper. Virtual Env.	AUG	2001	10	4					359	374		10.1162/1054746011470226			16	Computer Science, Cybernetics; Computer Science, Software Engineering	Computer Science	492AT	WOS:000172143800003					2021-06-18	
J	Johannes, S; Wieringa, BM; Nager, W; Muller-Vahl, KR; Dengler, R; Munte, TF				Johannes, S; Wieringa, BM; Nager, W; Muller-Vahl, KR; Dengler, R; Munte, TF			Electrophysiological measures and dual-task performance in Tourette syndrome indicate deficient divided attention mechanisms	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						attention; audition; event-related potentials; Tourette syndrome; vision	EVENT-RELATED POTENTIALS; COGNITIVE BRAIN POTENTIALS; AUDITORY ODDBALL TASKS; CLOSED-HEAD-INJURY; FUNCTIONAL NEUROANATOMY; SUSTAINED ATTENTION; INTRACRANIAL ERPS; CHILDREN; DISORDER; TARGET	Tourette syndrome has been associated with impairments of attentional functions such as distractability, even in subjects without co-morbid attention deficit hyperactivity disorder. Based on the results of earlier research we hypothesized that Tourette syndrome patients might employ altered control mechanisms of attentional processes and have concurrent difficulties in allocating their attentional resources among competing tasks. Event-related brain potentials (ERPs) were recorded in a group of Tourette syndrome patients and in a matched control group during a dual task experiment. This experiment required the simultaneous detection of visual and auditory target stimuli which were manipulated to yield two different difficulty levels each of which were varied orthogonally. The behavioural parameters confirmed the intended performance differences between difficult-to-detect targets and easy-to-detect targets. This was paralleled by lower amplitudes and longer latencies of the corresponding P3b-ERP subcomponents. Although Tourette syndrome patients were unimpaired in overall performance they showed an increased interference of visual task demands with auditory target perception. In parallel they also exhibited a reduced amplitude of the P3b component to auditory targets. The findings show that Tourette syndrome patients are not generally impaired in their dual task performance. The allocation of attentional resources to competing tasks however, is altered. We speculate that this may be related to deficient inhibitory functions.	Hannover Med Sch, Dept Neurol, D-30623 Hannover, Germany; Otto Von Guericke Univ, Dept Neuropsychol, Magdeburg, Germany; Med Hsch Hannover, Dept Clin Psychiat & Psychotherapy, Hannover, Germany	Johannes, S (corresponding author), Hannover Med Sch, Dept Neurol, D-30623 Hannover, Germany.		Munte, Thomas/C-2077-2014	Muller-Vahl, Kirsten/0000-0002-7181-7419			Adcock RA, 2000, P NATL ACAD SCI USA, V97, P3567, DOI 10.1073/pnas.060588897; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Barcelo F, 2000, NEUROPSYCHOLOGIA, V38, P1342, DOI 10.1016/S0028-3932(00)00046-4; Bornstein R A, 1991, J Neuropsychiatry Clin Neurosci, V3, P157; Bourke PA, 1997, Q J EXP PSYCHOL-A, V50, P821; Chao LL, 1997, NEUROBIOL AGING, V18, P87, DOI 10.1016/S0197-4580(96)00161-3; Clark VP, 2000, J NEUROPHYSIOL, V83, P3133; Clarke JM, 1999, CLIN NEUROPHYSIOL, V110, P1226, DOI 10.1016/S1388-2457(99)00064-4; Clarke JM, 1999, CLIN NEUROPHYSIOL, V110, P1210, DOI 10.1016/S1388-2457(99)00063-2; DRAKE ME, 1992, CLIN ELECTROENCEPHAL, V23, P19, DOI 10.1177/155005949202300106; Ebmeier KP, 1995, ELECTROEN CLIN NEURO, V95, P434, DOI 10.1016/0013-4694(95)00173-5; Garcia-Larrea L, 1998, EVOKED POTENTIAL, V108, P260, DOI 10.1016/S0168-5597(97)00085-3; GEORGIOU N, 1995, BRAIN, V118, P1305, DOI 10.1093/brain/118.5.1305; Halgren E, 1998, ELECTROEN CLIN NEURO, V106, P156, DOI 10.1016/S0013-4694(97)00119-3; HILLYARD SA, 1983, ANNU REV PSYCHOL, V34, P33, DOI 10.1146/annurev.ps.34.020183.000341; Isreal J B, 1980, Prog Brain Res, V54, P416, DOI 10.1016/S0079-6123(08)61653-2; JENNINGS JR, 1976, PSYCHOPHYSIOLOGY, V13, P277; Johannes S, 1997, EUR J NEUROL, V4, P152, DOI 10.1111/j.1468-1331.1997.tb00321.x; Klem G H, 1999, Electroencephalogr Clin Neurophysiol Suppl, V52, P3; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Linden DEJ, 1999, CEREB CORTEX, V9, P815, DOI 10.1093/cercor/9.8.815; Nash AJ, 1996, INT J PSYCHOPHYSIOL, V23, P171, DOI 10.1016/S0167-8760(96)00049-9; Oades RD, 1996, BIOL PSYCHOL, V43, P163, DOI 10.1016/0301-0511(96)05189-7; Oades RD, 2000, PSYCHIAT RES, V93, P165, DOI 10.1016/S0165-1781(00)00105-0; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; Ozonoff S, 1998, J CHILD PSYCHOL PSYC, V39, P1109, DOI 10.1111/1469-7610.00415; Palumbo D, 1997, ARCH NEUROL-CHICAGO, V54, P475, DOI 10.1001/archneur.1997.00550160101023; PICTON TW, 1992, J CLIN NEUROPHYSIOL, V9, P456, DOI 10.1097/00004691-199210000-00002; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; Sheppard DM, 1999, CLIN PSYCHOL REV, V19, P531, DOI 10.1016/S0272-7358(98)00059-2; Sherman EMS, 1998, J CLIN EXP NEUROPSYC, V20, P644, DOI 10.1076/jcen.20.5.644.1118; Shucard DW, 1997, NEUROPSYCHOLOGY, V11, P147, DOI 10.1037/0894-4105.11.1.147; Spencer T, 1998, J CHILD PSYCHOL PSYC, V39, P1037, DOI 10.1017/S0021963098002984; Stablum F, 1996, CORTEX, V32, P261, DOI 10.1016/S0010-9452(96)80050-5; STEPHENSON WA, 1951, ELECTROEN CLIN NEURO, V3, P237, DOI 10.1016/0013-4694(51)90017-X; *TOUR SYNDR CLASS, 1994, NEUROLOGY, V50, P1013; VANWOERKOM TCAM, 1994, ACTA NEUROL SCAND, V90, P116; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Vilkki J, 1996, NEUROPSYCHOLOGIA, V34, P1051, DOI 10.1016/0028-3932(96)00028-0; WICKENS C, 1983, SCIENCE, V221, P1080, DOI 10.1126/science.6879207; Yamazaki T, 2000, BRAIN TOPOGR, V12, P159, DOI 10.1023/A:1023467806268; Yoshiura T, 1999, NEUROREPORT, V10, P1683, DOI 10.1097/00001756-199906030-00011; Ziemann U, 1997, AM J PSYCHIAT, V154, P1277	43	23	26	1	4	BLACKWELL SCIENCE LTD	OXFORD	P O BOX 88, OSNEY MEAD, OXFORD OX2 0NE, OXON, ENGLAND	1351-5101			EUR J NEUROL	Eur. J. Neurol.	MAY	2001	8	3					253	260		10.1046/j.1468-1331.2001.00199.x			8	Clinical Neurology; Neurosciences	Neurosciences & Neurology	430EK	WOS:000168561000009	11328334				2021-06-18	
J	Dijkstra, S; Geisert, EE; Dijkstra, CD; Bar, PR; Joosten, EAJ				Dijkstra, S; Geisert, EE; Dijkstra, CD; Bar, PR; Joosten, EAJ			CD81 and microglial activation in vitro: proliferation, phagocytosis and nitric oxide production	JOURNAL OF NEUROIMMUNOLOGY			English	Article						microglia; tetraspanins; CD81; trauma, nervous system; spinal cord injuries	NECROSIS-FACTOR-ALPHA; ANTIPROLIFERATIVE ANTIBODY; ALPHA-3-BETA-1 INTEGRIN; CELL-ADHESION; TARGET; MYELIN; BRAIN; MACROPHAGE; ASTROCYTES; EXPRESSION	CD81 (TAPA), a member of the tetraspanin family of proteins, is upregulated by astrocytes and microglia after traumatic injury to the rat central nervous system (CNS). To further understand the role of CD81 in the microglial response to injury, we analysed the functional effects of a CD81 antibody, AMP1, on cultured rat microglia. We found that AMP1 suppressed microglial proliferation in a dose-dependent manner. Furthermore, AMP1 stimulated myelin phagocytosis, probably by opsonizing the myelin. The phagocytosis of latex beads, as well as the production of nitric oxide, were not significantly influenced by AMP1. These data indicate that CD81 is involved in an important subset of microglial effector functions after CNS injury. (C) 2001 Elsevier Science B.V. All rights reserved.	UMC Utrecht, Dept Expt Neurol, NL-3508 GA Utrecht, Netherlands; Univ Tennessee, Memphis Coll Med, Dept Anat & Neurobiol, Memphis, TN 38163 USA; Free Univ Amsterdam, Fac Med, Dept Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands	Dijkstra, S (corresponding author), UMC Utrecht, Dept Expt Neurol, POB 85500, NL-3508 GA Utrecht, Netherlands.	s.dijkstra@neuro.azu.nl	bar, peter/A-2897-2009				Aderem A, 1999, ANNU REV IMMUNOL, V17, P593, DOI 10.1146/annurev.immunol.17.1.593; Altomonte M, 1996, SCAND J IMMUNOL, V43, P367; ANTON ES, 1995, J NEUROSCI, V15, P584; Berditchevski F, 1997, J BIOL CHEM, V272, P2595, DOI 10.1074/jbc.272.5.2595; BRADBURY LE, 1992, J IMMUNOL, V149, P2841; Bruce AJ, 1996, NAT MED, V2, P788, DOI 10.1038/nm0796-788; Clarke K, 1998, Mol Vis, V4, P3; Dijkstra S, 2000, J COMP NEUROL, V428, P266, DOI 10.1002/1096-9861(20001211)428:2<266::AID-CNE6>3.0.CO;2-0; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; GEISERT EE, 1991, NEUROSCI LETT, V133, P262, DOI 10.1016/0304-3940(91)90584-G; Geisert EE, 1996, J NEUROSCI, V16, P5478; GIULIAN D, 1986, J NEUROSCI, V6, P2163; GRAEBER MB, 1988, NEUROSCI LETT, V85, P317, DOI 10.1016/0304-3940(88)90585-X; Hellendall RP, 1997, J NEUROIMMUNOL, V74, P19, DOI 10.1016/S0165-5728(96)00202-0; HOL EM, 1994, BRAIN RES, V662, P109, DOI 10.1016/0006-8993(94)90802-8; Kopczynski CC, 1996, SCIENCE, V271, P1867, DOI 10.1126/science.271.5257.1867; Kreutzberg GW, 1996, TRENDS NEUROSCI, V19, P312, DOI 10.1016/0166-2236(96)10049-7; Ledeboer A, 2000, GLIA, V30, P134, DOI 10.1002/(SICI)1098-1136(200004)30:2<134::AID-GLIA3>3.0.CO;2-3; Levy S, 1998, ANNU REV IMMUNOL, V16, P89, DOI 10.1146/annurev.immunol.16.1.89; Maecker HT, 1997, J EXP MED, V185, P1505, DOI 10.1084/jem.185.8.1505; Maecker HT, 1997, FASEB J, V11, P428; MATSUMOTO AK, 1993, J EXP MED, V178, P1407, DOI 10.1084/jem.178.4.1407; MERRILL JE, 1993, J IMMUNOL, V151, P2132; OREN R, 1990, MOL CELL BIOL, V10, P4007, DOI 10.1128/MCB.10.8.4007; Peduzzi JD, 1999, EXP NEUROL, V160, P460, DOI 10.1006/exnr.1999.7234; Penas PF, 2000, J INVEST DERMATOL, V114, P1126, DOI 10.1046/j.1523-1747.2000.00998.x; Pileri P, 1998, SCIENCE, V282, P938, DOI 10.1126/science.282.5390.938; RAIVICH G, 1994, EUR J NEUROSCI, V6, P1615, DOI 10.1111/j.1460-9568.1994.tb00552.x; Raivich G, 1999, BRAIN RES REV, V30, P77, DOI 10.1016/S0165-0173(99)00007-7; RIESKE E, 1989, BRAIN RES, V492, P1, DOI 10.1016/0006-8993(89)90883-4; SAKAI N, 1995, J NEUROCHEM, V65, P895; SCHICK MR, 1993, J IMMUNOL, V151, P1918; Schwab ME, 1996, PHYSIOL REV, V76, P319; Smith ME, 1999, NEUROCHEM RES, V24, P261, DOI 10.1023/A:1022566121967; Smith ME, 1998, J NEUROSCI RES, V54, P68, DOI 10.1002/(SICI)1097-4547(19981001)54:1<68::AID-JNR8>3.0.CO;2-F; SMITH ME, 1993, J NEUROSCI RES, V35, P480, DOI 10.1002/jnr.490350504; Stangel M, 2000, J NEUROIMMUNOL, V106, P137, DOI 10.1016/S0165-5728(00)00210-1; Stipp CS, 2000, J CELL SCI, V113, P1871; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Streit WJ, 1999, PROG NEUROBIOL, V57, P563, DOI 10.1016/S0301-0082(98)00069-0; Sullivan CD, 1998, J COMP NEUROL, V396, P366; Todd SC, 1996, J EXP MED, V184, P2055, DOI 10.1084/jem.184.5.2055; Van der Goes A, 1999, J NEUROIMMUNOL, V101, P61, DOI 10.1016/S0165-5728(99)00133-2; van der Goes A, 1998, J NEUROIMMUNOL, V92, P67, DOI 10.1016/S0165-5728(98)00175-1; vanderLaan LJW, 1996, J NEUROIMMUNOL, V70, P145, DOI 10.1016/S0165-5728(96)00110-5; von Zahn J, 1997, NEUROREPORT, V8, P3851, DOI 10.1097/00001756-199712220-00003; Yanez-Mo M, 1998, J CELL BIOL, V141, P791, DOI 10.1083/jcb.141.3.791; ZIELASEK J, 1992, CELL IMMUNOL, V141, P111, DOI 10.1016/0008-8749(92)90131-8	48	23	25	0	0	ELSEVIER	AMSTERDAM	RADARWEG 29, 1043 NX AMSTERDAM, NETHERLANDS	0165-5728	1872-8421		J NEUROIMMUNOL	J. Neuroimmunol.	MAR 1	2001	114	1-2					151	159		10.1016/S0165-5728(01)00240-5			9	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	413WN	WOS:000167634700018	11240026				2021-06-18	
J	Yakovlev, AG; Di, X; Movsesyan, V; Mullins, PGM; Wang, GP; Boulares, H; Zhang, JH; Xu, M; Faden, AI				Yakovlev, AG; Di, X; Movsesyan, V; Mullins, PGM; Wang, GP; Boulares, H; Zhang, JH; Xu, M; Faden, AI			Presence of DNA fragmentation and lack of neuroprotective effect in DFP45 knockout mice subjected to traumatic brain injury	MOLECULAR MEDICINE			English	Article							CASPASE-ACTIVATED DNASE; FOCAL CEREBRAL-ISCHEMIA; CORTICAL IMPACT INJURY; CLOSED-HEAD INJURY; CA2+/MG2+-DEPENDENT ENDONUCLEASE; CELL-DEATH; DEPENDENT ENDONUCLEASE; CHROMATIN CONDENSATION; NEURONAL APOPTOSIS; INHIBITION	Background: Apoptosis plays an important pathophysiologic role in neuronal cell loss and associated neurologic deficits following traumatic brain injury (TBI). DNA fragmentation represents one of the characteristic biochemical features of neuronal apoptosis and is observed after experimental TBI. DFF45 and DFF40 are essential for DNA fragmentation in various models of apoptosis. Materials and Methods: We used mice deficient in DFF45 and wild-type controls. Oligonucleosomal DNA fragmentation induced by TBI was analyzed using in vivo and in vitro assays. Expression and integrity of DFF45 and DFF40 proteins was assessed by Western analysis. Other outcome measurements included neurologic scoring, learning/memory tests, lesion volume measurements (MRI), and assessment of cell viability in vitro among others. Results: We compared the effects of controlled cortical impact (CCI) trauma in DFF45 knockout mice and wild-type controls. Analysis of TBI-induced DNA fragmentation in brain cortex from wild-type and DFF45 knockout mice indicates that, although somewhat delayed, oligonucleosomal cleavage of DNA occurs after TBI in DFF45 knockout mice. DFF45 knockouts showed no significant differences in behavioral outcomes or lesion volumes after TBI as compared to wild-type controls. Using an in vitro reconstitution system, we also demonstrated that cleavage of DFF45 by caspase-3 is not sufficient for DNA fragmentation induced by protein extracts from rat brain cortex. We found that endonuclease activity induced in rat brain cortex following TBI depends on the presence of Mg2+ and Ca2+, but is not inhibited by Zn2+. Primary neuronal cultures from DFF45 knockouts failed to show DNA laddering in response to staurosporine, but did show prominent, albeit delayed, DNA fragmentation following treatment with etoposide. In contrast, primary neurons from wildtype animals demonstrated marked DNA fragmentation following treatment with staurosporine or etoposide. Conclusions: The results of this study suggest that, in addition to DFF45/40, other endonucleases may be essential for chromatin degradation during neuronal apoptosis in adult brain after TBI.	Georgetown Univ, Dept Neurosci, Washington, DC 20007 USA; Georgetown Univ, Dept Biochem & Mol Biol, Washington, DC 20007 USA; Univ Cincinnati, Coll Med, Dept Cell Biol Neurobiol & Anat, Cincinnati, OH 45221 USA	Faden, AI (corresponding author), Georgetown Univ, Dept Neurosci, Res Bldg,Room Ep12,3970 Reservoir Rd NW, Washington, DC 20007 USA.	fadena@giccs.georgetown.edu	zhang, jianhua/D-3404-2009	Zhang, Jianhua/0000-0002-2128-9574; Mullins, Paul/0000-0002-1339-6361	NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS 38941, NS 36537] Funding Source: Medline		Adjei PN, 1996, J CLIN INVEST, V98, P2588, DOI 10.1172/JCI119078; Adjei PN, 1997, J CLIN INVEST, V100, P951; Albensi BC, 2000, EXP NEUROL, V162, P61, DOI 10.1006/exnr.2000.7256; Andrew DJ, 1999, IMMUNOPHARMACOLOGY, V41, P1, DOI 10.1016/S0162-3109(98)00049-6; Assaf Y, 1999, J NEUROTRAUM, V16, P1165, DOI 10.1089/neu.1999.16.1165; BARRY MA, 1993, ARCH BIOCHEM BIOPHYS, V300, P440, DOI 10.1006/abbi.1993.1060; BATISTATOU A, 1993, J CELL BIOL, V122, P523, DOI 10.1083/jcb.122.3.523; Bhattacharya R, 1997, TOXICOLOGY, V123, P207, DOI 10.1016/S0300-483X(97)00130-3; Buki A, 2000, J NEUROSCI, V20, P2825; Cigola E, 1997, EXP CELL RES, V231, P363, DOI 10.1006/excr.1997.3477; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; COHEN JJ, 1984, J IMMUNOL, V132, P38; Colicos MA, 1996, BRAIN RES, V739, P120, DOI 10.1016/S0006-8993(96)00824-4; CSERNANSKY CA, 1994, J NEUROSCI RES, V38, P101, DOI 10.1002/jnr.490380113; Di Stefano G, 2000, J NEUROL NEUROSUR PS, V69, P210, DOI 10.1136/jnnp.69.2.210; Eldadah BA, 1997, J NEUROSCI, V17, P6105; Eldadah BA, 1996, NUCLEIC ACIDS RES, V24, P4092, DOI 10.1093/nar/24.20.4092; Elger B, 1997, EUR J PHARMACOL, V336, P7, DOI 10.1016/S0014-2999(97)01217-X; Enari M, 1998, NATURE, V393, P396, DOI 10.1038/30782; Enari M, 1998, NATURE, V391, P43; ENARI M, 1995, EMBO J, V14, P5201, DOI 10.1002/j.1460-2075.1995.tb00204.x; Fox GB, 1998, J NEUROTRAUM, V15, P1037, DOI 10.1089/neu.1998.15.1037; Fox GB, 1998, J NEUROTRAUM, V15, P599, DOI 10.1089/neu.1998.15.599; Fraser MJ, 1996, J CELL SCI, V109, P2343; GIANNAKIS C, 1991, BIOCHEM BIOPH RES CO, V181, P915, DOI 10.1016/0006-291X(91)91278-K; Halenbeck R, 1998, CURR BIOL, V8, P537, DOI 10.1016/S0960-9822(98)79298-X; Heiduschka P, 2000, NEUROPHARMACOLOGY, V39, P889, DOI 10.1016/S0028-3908(99)00245-2; HOCKINGS PD, 1995, JMRI-J MAGN RESON IM, V5, P437, DOI 10.1002/jmri.1880050412; ISHIDA R, 1974, BIOCHEM BIOPH RES CO, V56, P703, DOI 10.1016/0006-291X(74)90662-7; Khodarev NN, 1996, J IMMUNOL, V156, P922; Kimura C, 1998, EXP CELL RES, V239, P411, DOI 10.1006/excr.1997.3912; LI Y, 1995, J CEREBR BLOOD F MET, V15, P389, DOI 10.1038/jcbfm.1995.49; LINNIK MD, 1993, STROKE, V24, P2002, DOI 10.1161/01.STR.24.12.2002; Liu XS, 1998, P NATL ACAD SCI USA, V95, P8461, DOI 10.1073/pnas.95.15.8461; Liu XS, 1997, CELL, V89, P175, DOI 10.1016/S0092-8674(00)80197-X; Los M, 2000, BIOCHEMISTRY-US, V39, P7365, DOI 10.1021/bi000158w; Loubinoux I, 1997, STROKE, V28, P419, DOI 10.1161/01.STR.28.2.419; Matsushita K, 1996, BRAIN RES, V743, P362, DOI 10.1016/S0006-8993(96)01112-2; McCarty JS, 1999, BIOCHEM BIOPH RES CO, V264, P176, DOI 10.1006/bbrc.1999.1497; McConkey David J., 1996, Scanning Microscopy, V10, P777; MCCONKEY DJ, 1989, FASEB J, V3, P1843; McIlroy D, 1999, ONCOGENE, V18, P4401, DOI 10.1038/sj.onc.1202868; McIntosh T K, 1987, Cent Nerv Syst Trauma, V4, P119; Mitamura S, 1998, BIOCHEM BIOPH RES CO, V243, P480, DOI 10.1006/bbrc.1998.8122; MOGIL RJ, 1994, J IMMUNOL, V152, P1674; MORRIS R, 1984, J NEUROSCI METH, V11, P47, DOI 10.1016/0165-0270(84)90007-4; Nagata S, 2000, EXP CELL RES, V256, P12, DOI 10.1006/excr.2000.4834; NEWMEYER DD, 1991, METHOD CELL BIOL, V36, P607; NICHOLSON DW, 1995, NATURE, V376, P37, DOI 10.1038/376037a0; NIKONOVA L V, 1989, Biokhimiya, V54, P1709; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; RIBEIRO JM, 1993, BIOCHEMISTRY-US, V32, P9129, DOI 10.1021/bi00086a018; RINK A, 1995, AM J PATHOL, V147, P1575; Robertson JD, 2000, J STRUCT BIOL, V129, P346, DOI 10.1006/jsbi.2000.4254; Sakahira H, 2000, J BIOL CHEM, V275, P8091, DOI 10.1074/jbc.275.11.8091; Sakahira H, 1998, NATURE, V391, P96; SHIOKAWA D, 1994, EUR J BIOCHEM, V226, P23, DOI 10.1111/j.1432-1033.1994.tb20022.x; Shiokawa D, 1998, BIOCHEM J, V332, P713, DOI 10.1042/bj3320713; Slane JM, 2000, BRAIN RES, V867, P70, DOI 10.1016/S0006-8993(00)02258-7; Tang D, 1998, J BIOL CHEM, V273, P28549, DOI 10.1074/jbc.273.44.28549; Thornberry NA, 1998, SCIENCE, V281, P1312, DOI 10.1126/science.281.5381.1312; Urbano A, 1998, J BIOL CHEM, V273, P34820, DOI 10.1074/jbc.273.52.34820; VERHAEGEN S, 1995, BIOCHEM PHARMACOL, V50, P1021, DOI 10.1016/0006-2952(95)00233-P; Wohrl W, 1999, BIOCHEM BIOPH RES CO, V254, P552, DOI 10.1006/bbrc.1998.9982; Wolf BB, 1999, J BIOL CHEM, V274, P30651, DOI 10.1074/jbc.274.43.30651; Wright SC, 1997, J EXP MED, V186, P1107, DOI 10.1084/jem.186.7.1107; Wright SC, 1997, FASEB J, V11, P843; Wyllie A H, 1980, Int Rev Cytol, V68, P251; Wyllie A H, 1992, Semin Immunol, V4, P389; WYLLIE AH, 1984, J PATHOL, V142, P67, DOI 10.1002/path.1711420112; Yakovlev AG, 2000, J BIOL CHEM, V275, P21302, DOI 10.1074/jbc.M001087200; Yakovlev AG, 1997, J NEUROSCI, V17, P7415; Zhang C, 1999, J NEUROCHEM, V73, P1650, DOI 10.1046/j.1471-4159.1999.0731650.x; Zhang JH, 1999, J BIOL CHEM, V274, P37450, DOI 10.1074/jbc.274.52.37450; Zhang JH, 1998, P NATL ACAD SCI USA, V95, P12480, DOI 10.1073/pnas.95.21.12480; ZHIVOTOVSKY B, 1994, INT ARCH ALLERGY IMM, V105, P333, DOI 10.1159/000236778; ZHIVOTOVSKY B, 1993, EXP CELL RES, V207, P163, DOI 10.1006/excr.1993.1176	77	23	24	0	1	SPRINGER	NEW YORK	ONE NEW YORK PLAZA, SUITE 4600, NEW YORK, NY, UNITED STATES	1076-1551	1528-3658		MOL MED	Mol. Med.	MAR	2001	7	3					205	216		10.1007/BF03401955			12	Biochemistry & Molecular Biology; Cell Biology; Medicine, Research & Experimental	Biochemistry & Molecular Biology; Cell Biology; Research & Experimental Medicine	418QU	WOS:000167903500008	11471558	DOAJ Gold, Green Published			2021-06-18	
J	Zafonte, RD; Wood, DL; Harrison-Felix, CL; Millis, SR; Valena, NV				Zafonte, RD; Wood, DL; Harrison-Felix, CL; Millis, SR; Valena, NV			Severe penetrating head injury: A study of outcomes	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Glasgow Coma Scale; head injuries; penetrating; wounds; gunshot; rehabilitation	TRAUMATIC BRAIN INJURY; CIVILIAN GUNSHOT WOUNDS; CRANIOCEREBRAL INJURIES; MODEL SYSTEMS; COMA; MANAGEMENT; VIOLENCE; SCALE	Objective: To determine and describe the demographics and functional outcomes of persons who require inpatient rehabilitation for severe penetrating head injury resulting from a gunshot wound to the head. Design: Data were collected prospectively from the time of admission to acute care through discharge from inpatient rehabilitation. Setting: Two sites: an urban, level I, acute care, trauma center and an inpatient rehabilitation hospital with a specialized brain injury unit. Participants: Twenty-seven persons with severe penetrating head injury. Main Outcome Measures: The FIM(TM) instrument, the Disability Rating Scale (DRS), and the length of stay (LOS). Results: Demographic data showed our population to be similar to other groups of persons at high risk for violent injury. Eighty-five percent of the subjects were men with a mean age of 34 years. The majority were African American (93%), reflective of our general patient population. Average acute care LOS was 31 days and average rehabilitation LOS was 44 days. Average FIM gain was 40.2 and, on average, DRS scores improved 7.6 points from rehabilitation admission to discharge. All study participants made enough progress to be discharged to private residences. Conclusion: Although the mortality rate is high among patients with penetrating head injury, those who survive to receive inpatient rehabilitation can achieve functional improvement.	Univ Pittsburgh, Dept Phys Med & Rehabil, Pittsburgh, PA 15215 USA; Wayne State Univ, Rehabil Inst Michigan, Detroit, MI USA; Craig Hosp, Englewood, CO USA; Kessler Med Rehabil Res & Educ Corp, W Orange, NJ USA; HealthSouth, Houston, TX USA	Zafonte, RD (corresponding author), Univ Pittsburgh, Dept Phys Med & Rehabil, 3471 5th Ave,Ste 901, Pittsburgh, PA 15215 USA.	zafonteRD@msx.upmc.edu					AARABI B, 1990, NEUROSURGERY, V27, P692, DOI 10.1227/00006123-199011000-00004; ALDRICH EF, 1992, SURG NEUROL, V38, P418, DOI 10.1016/0090-3019(92)90109-Z; Ansari SA, 1998, BRIT J NEUROSURG, V12, P340; Carey ME, 1990, J NEUROTRAUM, V7, P13, DOI 10.1089/neu.1990.7.13; *CDCP, 1997, 1997 US INJ MORT STA; CLARK WC, 1986, J NEUROSURG, V65, P9, DOI 10.3171/jns.1986.65.1.0009; COWEN TD, 1995, ARCH PHYS MED REHAB, V76, P797, DOI 10.1016/S0003-9993(95)80542-7; GRAHM TW, 1990, NEUROSURGERY, V27, P696, DOI 10.1227/00006123-199011000-00005; Hall KM, 1996, J HEAD TRAUMA REHAB, V11, P27, DOI 10.1097/00001199-199610000-00004; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1986, NEUROSURGERY, V18, P689, DOI 10.1227/00006123-198606000-00002; KAUFMAN HH, 1993, NEUROSURGERY, V32, P962, DOI 10.1227/00006123-199306000-00013; LEVI L, 1990, ISRAEL J MED SCI, V26, P548; LEVY ML, 1994, NEUROSURGERY, V35, P77, DOI 10.1227/00006123-199407000-00012; MILLIS SR, 1995, BRAIN INJURY, V9, P509, DOI 10.3109/02699059509008210; NAGIB MG, 1986, NEUROSURGERY, V18, P533, DOI 10.1227/00006123-198605000-00003; RAIMONDI AJ, 1970, J NEUROSURG, V32, P647, DOI 10.3171/jns.1970.32.6.0647; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; SICCARDI D, 1991, SURG NEUROL, V35, P455, DOI 10.1016/0090-3019(91)90179-D; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V273, P1778, DOI 10.1001/jama.273.22.1778; *STAT U NY BUFF UB, 1993, GUID UN DAT SET MED; STONE JL, 1995, J TRAUMA, V38, P851, DOI 10.1097/00005373-199506000-00002; VALENA N, 1997, AM J PHYS MED REHABI, V76, P163; Zafonte RD, 1997, BRAIN INJURY, V11, P403	27	23	24	0	2	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAR	2001	82	3					306	310		10.1053/apmr.2001.18226			5	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	407RG	WOS:000167284100003	11245750				2021-06-18	
J	Hentschel, S; Hader, W; Boyd, M				Hentschel, S; Hader, W; Boyd, M			Head injuries in skiers and snowboarders in British Columbia	CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES			English	Article							ALPINE SKIING INJURIES; SPINE	Background: At the Vancouver General Hospital Neurosurgical Service there have been a significant number of seriously brain injured snowboarders, seemingly out of proportion to the number of skiers. The purpose of this study was to determine whether snowboarders suffered more serious head injuries than skiers in the Vancouver catchment area. Methods: The British Columbia Trauma Registry was searched for patients incurring head injuries while skiing or snowboarding on British Columbia mountains during the period from January 1992 to December 1997. Patients were included if they were admitted to hospital and underwent neurosurgical consultation. Results: A total of 40 skiers and 14 snowboarders met the above criteria. Of the skiers, 15% sustained a severe head injury by Glasgow Coma Score, another 30% sustaining moderate head injuries, while 29% of snowboarders had a severe injury and 36% a moderate injury. A concussion was present in 60% of the skiers and 21% of the snowboarders. Snowboarders suffered an intracranial hemorrhage in 71% of the cases compared to 28% of the skiers. A craniotomy was performed acutely in 10% of skiers and in 29% of snowboarders, Three deaths occurred as a direct result of head injury, one while snowboarding. All but one of the surviving skiers were able to return home, whereas four of 13 surviving snowboarders required additional inpatient rehabilitation or transfer to another acute hospital for ongoing care. Conclusions: Snowboarders suffer more significant head injuries compared to skiers in this series and are much more likely than skiers to require an intracranial procedure. In our opinion, this indicates that additional safety measures, in particular the use of mandatory helmets, should be considered by ski areas and their patrons.	Univ British Columbia, Vancouver Hosp, Dept Surg, Div Neurosurg, Vancouver, BC V5Z 1M9, Canada; Hlth Sci Ctr, Vancouver, BC V5Z 1M9, Canada	Hentschel, S (corresponding author), Div Neurosurg, Dept Surg, 3rd Floor,910 W 10th Ave, Vancouver, BC V5Z 4E3, Canada.						ABULABAN RB, 1991, CAN MED ASSOC J, V145, P1097; BLADIN C, 1995, SPORTS MED, V19, P358, DOI 10.2165/00007256-199519050-00005; Chow TK, 1996, J TRAUMA, V41, P321, DOI 10.1097/00005373-199608000-00021; Davidson TM, 1996, WESTERN J MED, V164, P231; Davidson TM, 1996, WESTERN J MED, V164, P310; FURRER M, 1995, J TRAUMA, V39, P737, DOI 10.1097/00005373-199510000-00024; KIP P, 1995, ORTHOPEDICS, V18, P737; MYLES ST, 1992, CAN J SURG, V35, P643; Nakaguchi H, 1999, J TRAUMA, V46, P1066, DOI 10.1097/00005373-199906000-00017; PRALL JA, 1995, INJURY, V26, P539, DOI 10.1016/0020-1383(95)00085-N; Prall JA, 1995, J TRAUMA, V39, P1115, DOI 10.1097/00005373-199512000-00018; Sacco DE, 1998, J TRAUMA, V44, P654, DOI 10.1097/00005373-199804000-00016; Sutherland AG, 1996, INJURY, V27, P423, DOI 10.1016/0020-1383(96)00026-5	13	23	23	1	6	CANADIAN J NEUROL SCI INC	CALGARY	PO BOX 4220, STATION C EDITORIAL & SUBSCRIPTION SERV, CALGARY, AB T2T 5N1, CANADA	0317-1671			CAN J NEUROL SCI	Can. J. Neurol. Sci.	FEB	2001	28	1					42	46					5	Clinical Neurology	Neurosciences & Neurology	403AM	WOS:000167020400007	11252293				2021-06-18	
J	Gosepath, K; Nafe, B; Ziegler, E; Mann, WJ				Gosepath, K; Nafe, B; Ziegler, E; Mann, WJ			Neurofeedback training as a therapy for tinnitus	HNO			German	Article						therapy of tinnitus; neurofeedback; electrical activity of the brain tinnitusquestionaire; biofeedback	AUDITORY-CORTEX; BIOFEEDBACK; MECHANISMS; DIAGNOSIS; SYSTEM	Background and objective: Biofeedback is known as a possibility to control physiologic processes like body temperature or heart frequency. Neurofeedback is a form of biofeedback linked to aspects of the electrical activity of the brain such as frequency, location or amplitude of specific EEG activity. It has been successfully used in patients with closed head injury, hyperactivity disorder or epilepsy. Patients/methods: In this study 40 patients with tinnitus were treated with neurofeedback. They trained to upregulate the amplitude of their alpha -activity and downregulate the amplitude of beta -activity during muscle relaxation and acoustic orientation on sounds or music in order to suppress their tinnitus. Results: After 15 sessions of training 24 patients with a duration of their tinnitus for an average of 1 year showed significant increase of alpha -amplitudes while 16 patients with duration of their tinnitus on an average of 7 years showed a decrease of beta -amplitudes without any change in alpha -activity. After the training all patients had a significant reduction of the score in the tinnitusquestionaire of Gobel and Hiller. In a control-group of 15 persons without tinnitus we didn't see any changes of alpha- or beta -amplitudes during the same training. Conclusions: In conclusion neurofeedback is a new therapy for patients with tinnitus. Patients get the possibility of selfcontrol and therefore of influence on their disease.	Romerwallklin, Klin Neurootol Erkrankungen, D-55131 Mainz, Germany	Gosepath, K (corresponding author), Romerwallklin, Klin Neurootol Erkrankungen, Romerwall 51-55, D-55131 Mainz, Germany.						Andersson G, 1999, BRIT J AUDIOL, V33, P201, DOI 10.3109/03005369909090101; Arnold W, 1996, ORL J OTO-RHINO-LARY, V58, P195, DOI 10.1159/000276835; BISCHOFF C, 1995, PSYCHOTHERAPEUT, V40, P179; EBE M, 1994, LEITFADEN EEG PRAXIS, P68; GOEBEL G, 1995, OTO RHINO LARYN NOVA, V5, P178, DOI 10.1159/000313202; GOEBEL G, 1994, DIAGNOSTICA, V40, P155; HAZELL JWP, 1990, J OTOLARYNGOL, V19, P11; HAZELL JWP, 1995, TINNITUS MECH, P57; Hoke ES, 1998, AUDIOL NEURO-OTOL, V3, P300, DOI 10.1159/000013802; HOKE M, 1989, HEARING RES, V37, P281, DOI 10.1016/0378-5955(89)90028-2; HOKE M, 1991, ACTA OTO-LARYNGOL, P176; HOUSE JW, 1981, J LARYNGOL OTOL, P178; JASTREBOFF PJ, 1993, BRIT J AUDIOL, V27, P7, DOI 10.3109/03005369309077884; JASTREBOFF PJ, 1990, NEUROSCI RES, V8, P221, DOI 10.1016/0168-0102(90)90031-9; KIRSCH CA, 1989, PSYCHOSOM MED, V51, P209, DOI 10.1097/00006842-198903000-00009; KIRSCH CA, 1987, BIOFEEDBACK SELF-REG, V12, P295, DOI 10.1007/BF00998721; Kotchoubey B, 1999, CLIN NEUROPHYSIOL, V110, P683, DOI 10.1016/S1388-2457(99)00005-X; KRONER B, 1981, BIOFEEDBACK THERAPIE, P112; Lenarz T, 1998, LARYNGO RHINO OTOL, V77, P54, DOI 10.1055/s-2007-996932; Lockwood AH, 1998, NEUROLOGY, V50, P114, DOI 10.1212/WNL.50.1.114; Lubar JF, 1997, APPL PSYCHOPHYS BIOF, V22, P111, DOI 10.1023/A:1026276228832; LUBAR JF, 1995, BIOFEEDBACK SELF-REG, V20, P83, DOI 10.1007/BF01712768; Norena A, 1999, CLIN NEUROPHYSIOL, V110, P666, DOI 10.1016/S1388-2457(98)00034-0; OLSCHEWSKI A, 1996, PROGR MUSKELENTSPANN; Sataloff RT, 1996, AM J OTOL, V17, P909; SCHAAF H, 2000, RETRAINING TINNITUST, P82; SEIFERT AR, 1975, BIOL PSYCHOL, V3, P157, DOI 10.1016/0301-0511(75)90033-2; Shulman A, 1996, P 5 INT TINN SEM POR, P539; STERMAN MB, 1972, ELECTROEN CLIN NEURO, V33, P89, DOI 10.1016/0013-4694(72)90028-4; Sterman MB, 1996, BIOFEEDBACK SELF-REG, V21, P3, DOI 10.1007/BF02214147; WallhausserFranke E, 1997, NEUROREPORT, V8, P725, DOI 10.1097/00001756-199702100-00029; WallhausserFranke E, 1996, NEUROREPORT, V7, P1585, DOI 10.1097/00001756-199607080-00010; WILHELM K, 1999, PSYCHOL HEUTE, V26, P18; Zenner HP, 1998, HNO, V46, P699, DOI 10.1007/s001060050299	34	23	23	1	12	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0017-6192	1433-0458		HNO	HNO	JAN	2001	49	1					29	+		10.1007/s001060050704			7	Otorhinolaryngology	Otorhinolaryngology	398DK	WOS:000166741100006	11219406				2021-06-18	
J	Green, P; Iverson, GL				Green, P; Iverson, GL			Validation of the computerized assessment of response bias in litigating patients with head injuries	CLINICAL NEUROPSYCHOLOGIST			English	Article							MEMORY TEST; DEFICIT; BRAIN	The detection of malingering in neuropsychological assessment requires valid measures of incomplete effort. The Computerized Assessment of Response Bias (CARB) is a digit-recognition procedure desiged to detect poor effort during a neuropsychological evaluation. We examined the CARB performance of a consecutive series of litigating patients (N = 119) with a full range of head-injury severity, from trivial to severe. Patients with trivial or mild head injuries performed more poorly than did patients with frank brain injuries. Specifically, patients with moderate to severe traumatic brain injuries obtained higher total scores and demonstrated briefer response latencies than did patients with trivial or mild head injuries.	Univ British Columbia, Dept Psychiat, Vancouver, BC, Canada; Riverview Hosp, Port Coquitlam, BC, Canada	Green, P (corresponding author), Neurobehav Assoc, 17107-107 Ave, Edmonton, AB, Canada.			Iverson, Grant/0000-0001-7348-9570			Binder Laurence M, 1990, Clin Neuropsychol, V4, P25, DOI 10.1080/13854049008401494; BINDER LM, 1987, J CLIN EXP NEUROPSYC, V9, P167, DOI 10.1080/01688638708405357; BRADY JP, 1961, ARCH GEN PSYCHIAT, V4, P331; CONDER R, 1992, COMPUTERIZED ASSESSM; GROSZ HJ, 1965, ARCH GEN PSYCHIAT, V13, P255; HISCOCK M, 1989, J CLIN EXP NEUROPSYC, V11, P967, DOI 10.1080/01688638908400949; MILLER H, 1972, LANCET, V1, P580; MILLIS SR, 1992, CLIN NEUROPSYCHOL, V6, P406; PANKRATZ L, 1983, PERCEPT MOTOR SKILL, V57, P367, DOI 10.2466/pms.1983.57.2.367; PANKRATZ L, 1975, J CONSULT CLIN PSYCH, V43, P421, DOI 10.1037/h0076722; PANKRATZ L, 1987, ARCH NEUROL-CHICAGO, V44, P798, DOI 10.1001/archneur.1987.00520200006007; PRIGATANO GP, 1993, J CLIN EXP NEUROPSYC, V15, P537, DOI 10.1080/01688639308402577; ROSE FE, 1995, CLIN NEUROPSYCHOL, V9, P124, DOI 10.1080/13854049508401594; SLICK D, 1994, J CLIN EXP NEUROPSYC, V16, P472, DOI 10.1080/01688639408402657; TEASDALE G, 1974, LANCET, V2, P81; THEODOR LH, 1973, J ABNORM PSYCHOL, V82, P552, DOI 10.1037/h0035362; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Western SL, 1996, ARCH CLIN NEUROPSYCH, V11, P557, DOI 10.1016/0887-6177(95)00043-7; Willis SC., 1991, PSYCHOL ASSESSMENT J, V3, P175, DOI [10.1037/1040-3590.3.2.175, DOI 10.1037/1040-3590.3.2.175]	19	23	23	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0920-1637			CLIN NEUROPSYCHOL	Clin. Neuropsychol.		2001	15	4					492	497		10.1076/clin.15.4.492.1887			6	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	535QR	WOS:000174656100007	11935450				2021-06-18	
J	Grenander, A; Bredbacka, S; Rydvall, A; Aroch, R; Edner, G; Koskinen, LOD; Olivecrona, M				Grenander, A; Bredbacka, S; Rydvall, A; Aroch, R; Edner, G; Koskinen, LOD; Olivecrona, M			Antithrombin treatment in patients with traumatic brain injury - A pilot study	JOURNAL OF NEUROSURGICAL ANESTHESIOLOGY			English	Article						antithrombin; coagulopathy; D-dimer; fibrin, soluble; injury, brain; thrombin-antithrombin complex	DISSEMINATED INTRAVASCULAR COAGULATION; SEVERE HEAD-INJURY; SOLUBLE FIBRIN; THROMBIN; ASSAY; ABNORMALITIES; COAGULOPATHY; PROCOAGULANT; HEMORRHAGE; PLASMA	This study will determine if early administration of antithrombin concentrate to patients with traumatic brain injury (TBI) can inhibit or significantly shorten the time of coagulopathy. The progress of brain injury monitored by computed tomographic scan (CT) was also assessed, as was the time needed for intensive care and outcome related to Glasgow outcome scale (GOS). Twenty-eight patients with isolated brain trauma verified with CT were included in either of two parallel groups. The Glasgow coma score (GCS) was mean 7.5, and median 7.0; signifying a moderate to severe traumatic brain injury but with a mortality of only 3.5 %. The patients randomized to antithrombin treatment received a total of 100 U/kg BW during 24 hours. To measure hypercoagulability, soluble fibrin (SF), D-dimer (D-d), and thrombin-antithrombin complex (TAT) were assessed together with antithrombin (AT) and routine coagulation tests. Before treatment, SF, D-d, and TAT were markedly increased in both groups. Soluble fibrin and D-dimer (measured after treatment began) appeared to decrease faster in the AT group, and there was a statistically significant difference between the groups at 36 hours for SF and at 36 hours, 48 hours, and at Day 3 for D-d. Thrombin-antithrombin complex levels were very high in both groups but, surprisingly, showed no significant difference between the groups. The authors conclude that antithrombin concentrate administered to patients with severe TBI resulted in a marginal reduction of hypercoagulation. We could not detect any obvious influence by antithrombin on brain injury progress, on CT, or on outcome or time needed for intensive care.	Karolinska Hosp, Dept Anesthesia & Intens Care, S-17176 Stockholm, Sweden; Karolinska Hosp, Dept Neurol Surg, S-17176 Stockholm, Sweden; Univ Umea Hosp, Dept Anesthesiol & Intens Care, S-90185 Umea, Sweden; Univ Umea Hosp, Dept Neurol Surg, S-90185 Umea, Sweden	Grenander, A (corresponding author), Karolinska Hosp, Dept Anesthesia & Intens Care, S-17176 Stockholm, Sweden.		Koskinen, Lars-Owe/AAQ-8957-2020	Koskinen, Lars-Owe/0000-0003-3528-8502			ABILDGAARD U, 1977, THROMB RES, V11, P549, DOI 10.1016/0049-3848(77)90208-0; ASGEIRSSON B, 1994, INTENS CARE MED, V20, P260, DOI 10.1007/BF01708961; Bick RL, 1998, SEMIN THROMB HEMOST, V24, P3, DOI 10.1055/s-2007-994971; BREDBACKA S, 1994, J NEUROSURG ANESTH, V6, P75; CUNNINGHAM DD, 1993, THROMB HAEMOSTASIS, V70, P168; ELMS MJ, 1983, THROMB HAEMOSTASIS, V50, P591; Frebelius S, 1996, ARTERIOSCL THROM VAS, V16, P1292, DOI 10.1161/01.ATV.16.10.1292; Hoots WK, 1997, SEMIN THROMB HEMOST, V23, P3; Hulka F, 1996, ARCH SURG-CHICAGO, V131, P923; JENNETT B, 1975, LANCET, V1, P480; KAUFMAN HH, 1980, NEUROSURGERY, V7, P445, DOI 10.1227/00006123-198011000-00003; KAUFMAN HH, 1984, NEUROSURGERY, V15, P34, DOI 10.1227/00006123-198407000-00008; KAUFMAN HH, 1985, CENTRAL NERVOUS SYST, P187; KEARNEY TJ, 1992, J TRAUMA, V32, P608, DOI 10.1097/00005373-199205000-00012; Lee KR, 1996, ACTA NEUROCHIR, V138, P396, DOI 10.1007/BF01420301; Marshall SB, 1991, J NEUROSURG S, V75, P14; MILLER RS, 1994, J TRAUMA, V37, P442, DOI 10.1097/00005373-199409000-00019; MULLERBERGHAUS G, 1989, SEMIN THROMB HEMOST, V15, P58, DOI 10.1055/s-2007-1002690; OLSON JD, 1989, NEUROSURGERY, V24, P825, DOI 10.1227/00006123-198906000-00007; PELZER H, 1988, THROMB HAEMOSTASIS, V59, P101; PIEK J, 1992, J NEUROSURG, V77, P901, DOI 10.3171/jns.1992.77.6.0901; Scherer RU, 1998, CRIT CARE MED, V26, P149, DOI 10.1097/00003246-199801000-00031; STEIN SC, 1992, NEUROSURGERY, V30, P160, DOI 10.1227/00006123-199202000-00002; TOUHO H, 1986, NEUROSURGERY, V19, P523, DOI 10.1227/00006123-198610000-00005; VANDERSANDE JJ, 1981, J NEUROSURG, V54, P21, DOI 10.3171/jns.1981.54.1.0021; WIMAN B, 1986, THROMB HAEMOSTASIS, V55, P189	26	23	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	0898-4921			J NEUROSURG ANESTH	J. Neurosurg. Anesthesiol.	JAN	2001	13	1					49	56		10.1097/00008506-200101000-00010			8	Anesthesiology; Clinical Neurology; Surgery	Anesthesiology; Neurosciences & Neurology; Surgery	384GZ	WOS:000165935600009	11145479				2021-06-18	
J	Marschark, M; Richtsmeier, LM; Richardson, JTE; Crovitz, HF; Henry, J				Marschark, M; Richtsmeier, LM; Richardson, JTE; Crovitz, HF; Henry, J			Intellectual and emotional functioning in college students following mild traumatic brain injury in childhood and adolescence	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognitive impairment; college students; emotional functioning; fluency; memory impairment; study behavior; Symptom Checklist-90-Revised; traumatic brain injury	CLOSED-HEAD-INJURY; POSTTRAUMATIC AMNESIA; POSTCONCUSSION SYNDROME; BEHAVIOR PROBLEMS; WORKING-MEMORY; UNITED-STATES; CHILDREN; PERFORMANCE; CONCUSSION; SEQUELAE	Objective: To investigate whether college students with a history of mild traumatic brain injury (TBI) in childhood or adolescence show residual deficits in intellectual functioning, approaches to studying, or emotional stability. Design: Participants with a history of mild TBI and two control groups. Setting: Volunteers were recruited from students taking an introductory psychology course. Participants: 79 students with a history of mild TBI, 75 students with a history of general anesthesia, and 93 students with no history of either TBI or general anesthesia. Main Outcome Measures: Participants carried out tests of verbal memory, nonverbal memory, verbal fluency, and nonverbal fluency; in addition, they completed a short form of the Approaches to Studying Inventory and the symptom Checklist-90-Revised (SCL-90-R). Results: In comparison with the two control groups, the students with a history of mild TBI produced similar scores on the cognitive tests and similar orientations to studying. However, they showed a significantly higher level of emotional distress on the SCL-90-R. Conclusion: College students with a history of mild TBI in childhood or adolescence are intellectually unimpaired and approach their studying in a similar manner to their uninjured classmates. Nevertheless, they report more severe distress in terms of their general personal and emotional functioning.	Rochester Inst Technol, Natl Tech Inst Deaf, Ctr Res Teaching & Learning, Rochester, NY 14623 USA; Rochester Inst Technol, Med Ctr, Rochester, NY 14623 USA; Brunel Univ, Dept Human Sci, Uxbridge UB8 3PH, Middx, England; Duke Univ, Dept Psychol, Durham, NC 27706 USA; Univ N Carolina, Dept Psychol, Greensboro, NC 27412 USA	Marschark, M (corresponding author), Rochester Inst Technol, Natl Tech Inst Deaf, Ctr Res Teaching & Learning, Rochester, NY 14623 USA.			Richardson, John/0000-0002-6267-0603	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS027243] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS27243] Funding Source: Medline		ALEXANDER MP, 1995, NEUROLOGY, V45, P1253, DOI 10.1212/WNL.45.7.1253; AMPHOUX M, 1977, REV MED TRAVAIL, V5, P53; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1996, PHILOS T ROY SOC B, V351, P1397, DOI 10.1098/rstb.1996.0123; BADDELEY A, 1987, NEUROBEHAVIORAL RECO; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; Bijur P., 1995, TRAUMATIC HEAD INJUR; BIJUR PE, 1990, PEDIATRICS, V86, P337; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P432, DOI 10.1080/01688639708403871; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BROWN SJ, 1994, J NEUROPSYCH CLIN N, V6, P15; CAPLAN PJ, 1997, GENDER DIFFERENCES H; CARLSSON GS, 1987, J NEUROSURG, V67, P197, DOI 10.3171/jns.1987.67.2.0197; Caveness W F, 1979, Adv Neurol, V22, P1; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CORKIN SH, 1987, NEUROBEHAVIORAL RECO; CROVITZ HF, 1983, CORTEX, V19, P407, DOI 10.1016/S0010-9452(83)80009-4; Derogatis L.R, 1975, SCL 90 R; DEROGATIS LR, 1977, J CLIN PSYCHOL, V33, P981, DOI 10.1002/1097-4679(197710)33:4<981::AID-JCLP2270330412>3.0.CO;2-0; DEROGATIS LR, 1976, BRIT J PSYCHIAT, V128, P280, DOI 10.1192/bjp.128.3.280; Derogatis LR., 1977, SCL 90 R ADM SCORING, V1; DICESARE A, 1990, COGNITIVE REHABILITA, V8, P14; Dikmen S, 1976, Trans Am Neurol Assoc, V101, P72; Entwistle Noel, 1983, UNDERSTANDING STUDEN; FORRESTER G, 1994, BRAIN INJURY, V8, P175, DOI 10.3109/02699059409150969; Gibbs G., 1992, IMPROVING QUALITY ST; Gordon WR, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199812000-00006; Graves EJ, 1997, VITAL HLTH STAT, V13; Greenwood R, 1997, LANCET, V349, P1041, DOI 10.1016/S0140-6736(05)62288-X; GRONWALL D, 1975, LANCET, V2, P995; GRONWALL D, 1980, Journal of Clinical Neuropsychology, V2, P51, DOI 10.1080/01688638008403780; Gronwall D.M., 1974, PSYCHOL EFFECTS CONC; HEISKANEN O, 1974, DEV MED CHILD NEUROL, V16, P11; HOWIESON DB, 1995, HDB MEMORY DISORDERS; Jennett B, 1981, MANAGEMENT HEAD INJU; JORESKOG KG, 1971, PSYCHOMETRIKA, V36, P409, DOI 10.1007/BF02291366; KALSBEEK WD, 1980, J NEUROSURG, V53, pS19; Kant R, 1997, BRAIN INJURY, V11, P115, DOI 10.1080/026990597123700; King NS, 1997, J NEUROL NEUROSUR PS, V62, P38, DOI 10.1136/jnnp.62.1.38; Kinsella G J, 1997, J Int Neuropsychol Soc, V3, P608; KLONOFF H, 1974, CLIN NEUROPSYCHOLOGY; Kolb B., 1990, FUNDAMENTALS HUMAN N; Kraus JF, 1996, NEUROL CLIN, V14, P435, DOI 10.1016/S0733-8619(05)70266-8; KRAUS JF, 1993, HEAD INJURY; Levin HS, 1989, MILD HEAD INJURY; Levine B, 1998, J INT NEUROPSYCH SOC, V4, P247, DOI 10.1017/S1355617798002471; Light R, 1998, J CONSULT CLIN PSYCH, V66, P1023; MARSCHARK M, 1989, J EXP PSYCHOL LEARN, V15, P710, DOI 10.1037/0278-7393.15.4.710; MAYOU R, 1986, BRIT J PSYCHIAT, V149, P172, DOI 10.1192/bjp.149.2.172; MCMILLAN TM, 1987, J NEUROL NEUROSUR PS, V50, P393, DOI 10.1136/jnnp.50.4.393; Mittenberg W, 1997, NEUROPSYCHOLOGY, V11, P447, DOI 10.1037/0894-4105.11.3.447; MONTANELLI RG, 1976, PSYCHOMETRIKA, V41, P341, DOI 10.1007/BF02293559; NIES KJ, 1994, ARCH CLIN NEUROPSYCH, V9, P501, DOI 10.1016/0887-6177(94)90041-8; ODONNELL WE, 1984, J CLIN PSYCHOL, V40, P241, DOI 10.1002/1097-4679(198401)40:1<241::AID-JCLP2270400147>3.0.CO;2-6; PAIVIO A, 1968, J EXP PSYCHOL MONO 2, V76; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Richardson J. T. E., 2000, RES STUDENT LEARNING; RICHARDSON JTE, 1985, COGNITIVE NEUROPSYCH, V2, P149, DOI 10.1080/02643298508252864; RICHARDSON JTE, 1994, HIGH EDUC, V27, P449, DOI 10.1007/BF01384904; Richardson JTE, 1996, BEHAV RES METH INSTR, V28, P12, DOI 10.3758/BF03203631; RICHARDSON JTE, 1990, STUD HIGH EDUC, V15, P155, DOI 10.1080/03075079012331377481; RICHARDSON JTE, 2000, CLIN NEUROPSYCHOLOGI; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RIVARA JB, 1994, ARCH PHYS MED REHAB, V75, P369, DOI 10.1016/0003-9993(94)90157-0; RODIN G, 1991, DEPRESSION MENTALLY; ROSENTHAL R, 1988, ARTIFACT BEHAV RES; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTHERFORD WH, 1989, MILD HEAD INJURY; Satz P, 1997, PSYCHOL BULL, V122, P107, DOI 10.1037/0033-2909.122.2.107; Satz P, 1999, J CLIN EXP NEUROPSYC, V21, P620, DOI 10.1076/jcen.21.5.620.870; SEGALOWITZ SJ, 1991, J LEARN DISABIL, V24, P551, DOI 10.1177/002221949102400907; Smed A, 1997, ACTA NEUROL SCAND, V95, P73, DOI 10.1111/j.1600-0404.1997.tb00072.x; Spikman JM, 1996, J CLIN EXP NEUROPSYC, V18, P755, DOI 10.1080/01688639608408298; Stewart DP, 1996, ACAD EMERG MED, V3, P21, DOI 10.1111/j.1553-2712.1996.tb03297.x; STUSS DT, 1985, NEUROSURGERY, V17, P41, DOI 10.1227/00006123-198507000-00007; Stuss DT, 1999, J NEUROSURG, V90, P635, DOI 10.3171/jns.1999.90.4.0635; STUSS DT, 1987, FRONTAL LOBES REVIS; Tabachnick BG, 2013, USING MULTIVARIATE S; Thurman DJ, 1999, J HEAD TRAUMA REHAB, V14, P602, DOI 10.1097/00001199-199912000-00009; TRANEL D, 1994, HDB NEUROPSYCHOLOGY, V9; VANZOMEREN AH, 1984, CLOSED HEAD INJURY P; VARNEY NR, 1995, J HEAD TRAUMA REHAB, V10, P18; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; Wallis BJ, 1998, CEPHALALGIA, V18, P101, DOI 10.1046/j.1468-2982.1998.1802101.x; Wallis BJ, 1996, PAIN, V66, P223, DOI 10.1016/0304-3959(96)03044-8; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; WOESSNER R, 1995, J HEAD TRAUMA REHAB, V10, P78, DOI 10.1097/00001199-199504000-00009; Yeates KO, 1999, J HEAD TRAUMA REHAB, V14, P337, DOI 10.1097/00001199-199908000-00003	91	23	24	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	DEC	2000	15	6					1227	1245		10.1097/00001199-200012000-00004			19	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	378ZX	WOS:000165617400004	11056405				2021-06-18	
J	Lanham, RA; Weissenburger, JE; Schwab, KA; Rosner, MM				Lanham, RA; Weissenburger, JE; Schwab, KA; Rosner, MM			A longitudinal investigation of the concordance between individuals with traumatic brain injury and family or friend ratings on the Katz Adjustment Scale	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						awareness; concordance; DVHIP; Katz Adjustment Scale (KAS); Neurobehavioral Rating Scale (NBRS); traumatic brain injury	CLOSED-HEAD-INJURY; IMPAIRED AWARENESS; BEHAVIORAL LIMITATIONS; SIGNIFICANT OTHERS; PRACTICAL SCALE; RELATIVES; REHABILITATION; CONSCIOUSNESS; QUESTIONNAIRE; DYSFUNCTION	Changes in the level of agreement (concordance) between self and family or friend reporting on the Katz Adjustment Scale (KAS) from 6 to 12 months postinjury were assessed in 55 individuals with traumatic brain injury (IwTBI). Although the concordance between self and family/friend reports significantly increased over the course of recovery, possibly reflecting improvements in awareness, the concordance showed limited relationship to measures of injury severity and neuropsychological functioning. Concordance did not significantly relate to clinicians' ratings of inaccurate insight and self-appraisal on the awareness item from the Neurobehavioral Rating Scale (NBRS). Clinicians' ratings of awareness demonstrated only limited relationship to measures of injury severity and neuropsychological functioning, as well. Although similar results in the literature have been interpreted as demonstrating that awareness, defined as concordance, is possibly a unique construct separate from injury severity and neuropsychological functioning, an alternative hypothesis is presented concerning other noninjury factors that may affect the level of agreement in problem reporting between IwTBI and family/friend informants.	Vet Affairs Med Ctr, Def & Vet Head Injury Program, Dept Traumat Brain Injury, Minneapolis, MN USA; Walter Reed Army Med Ctr, Def & Vet Head Injury Program, Washington, DC 20307 USA; Wilford Hall USAF Med Ctr, Henry M Jackson Fdn, Def & Vet Head Injury Program, Lackland AFB, TX 78236 USA	Lanham, RA (corresponding author), Vet Affairs Med Ctr, Def & Vet Head Injury Program, Dept Traumat Brain Injury, Minneapolis, MN USA.						BENYISHAY Y, 1985, SEMIN NEUROL, V5, P252, DOI 10.1055/s-2008-1041522; CAVALLO M M, 1992, Brain Injury, V6, P327, DOI 10.3109/02699059209034947; CURTISS G, 1999, UNPUB FACTOR STRUCTU; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; Flashman L. A., 1998, SEMINARS CLIN NEUROP, V3, P201; Fleming JM, 1998, J HEAD TRAUMA REHAB, V13, P39, DOI 10.1097/00001199-199810000-00006; FLEMING JM, 1996, BRAIN INJURY, V10, P15; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; Freeston MH, 1997, PSYCHOL REP, V81, P419, DOI 10.2466/pr0.1997.81.2.419; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; Goldberg E., 1991, AWARENESS DEFICIT BR, P152; GOREN DA, 1993, BRAIN INJURY, V7, P219; Hanks RA, 1999, ARCH PHYS MED REHAB, V80, P991, DOI 10.1016/S0003-9993(99)90049-7; Heilbronner R L, 1989, Brain Inj, V3, P387, DOI 10.3109/02699058909004562; Heilman K., 1991, AWARENESS DEFICIT BR, P53; HENDRYX PM, 1989, ARCH PHYS MED REHAB, V70, P526; Herbert CM, 1989, CLIN REHABIL, V3, P125; JACKSON DN, 1961, EDUC PSYCHOL MEAS, V21, P771, DOI 10.1177/001316446102100402; JACKSON H F, 1992, Brain Injury, V6, P109, DOI 10.3109/02699059209029650; KATZ MM, 1963, PSYCHOL REP, V13, P503, DOI 10.2466/pr0.1963.13.2.503; KAY T, 1995, J HEAD TRAUMA REHAB, V10, P12, DOI 10.1097/00001199-199504000-00004; Lam C S, 1988, Brain Inj, V2, P235, DOI 10.3109/02699058809150947; Leathem JM, 1998, J CLIN EXP NEUROPSYC, V20, P694, DOI 10.1076/jcen.20.5.694.1122; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; Lewis L., 1991, AWARENESS DEFICIT BR, P223; LEZAK MD, 1978, J CLIN PSYCHIAT, V39, P592; LEZAK MD, 1983, NEUROPSYCHOLOGICAL A; Malec JF, 1997, J HEAD TRAUMA REHAB, V12, P1, DOI 10.1097/00001199-199706000-00002; MALIA K, 1997, J COGN REHABIL, V5, P10; McCrae RR, 1998, J PERS, V66, P285, DOI 10.1111/1467-6494.00013; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; MCKINLAY WW, 1984, J CLIN NEUROPSYCHOL, V6, P87, DOI 10.1080/01688638408401199; Meana M, 1997, OBSTET GYNECOL, V90, P583, DOI 10.1016/S0029-7844(98)80136-1; Mesulam M., 1985, PRINCIPLES BEHAV NEU; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; Prigatano G. P., 1991, BNI Q, V7, P27; Prigatano G. P., 1986, NEUROPSYCHOLOGICAL R; Prigatano George P, 1993, Clin Neuropsychol, V7, P123, DOI 10.1080/13854049308401514; Prigatano GP, 1996, CLIN NEUROPSYCHOL, V10, P191, DOI 10.1080/13854049608406680; PRIGATANO GP, 1990, ARCH PHYS MED REHAB, V71, P1058; Prigatano GP, 1998, J HEAD TRAUMA REHAB, V13, P29, DOI 10.1097/00001199-199810000-00005; Prigatano GP, 1991, AWARENESS DEFICIT BR, P111; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P1; RANSEEN JD, 1990, INT J CLIN NEUROPSYC, V12, P29; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P353, DOI 10.1016/S0003-9993(97)90225-2; Sander AM, 1997, ARCH PHYS MED REHAB, V78, P138, DOI 10.1016/S0003-9993(97)90254-9; Sbordone RJ, 1998, BRAIN INJURY, V12, P505, DOI 10.1080/026990598122467; Seel RT, 1997, ARCH PHYS MED REHAB, V78, P1254, DOI 10.1016/S0003-9993(97)90340-3; Sherer M, 1998, J INT NEUROPSYCH SOC, V4, P380, DOI 10.1017/S1355617798003804; Sherer M, 1998, BRAIN INJURY, V12, P63, DOI 10.1080/026990598122863; Sherer M, 1998, J HEAD TRAUMA REHAB, V13, P52, DOI 10.1097/00001199-199810000-00007; SHERER M, 1997, J INT NEUROPSYCH SOC, V3, P75; Snyder DK, 1997, MANUAL MARITAL SATIS; Spangenberg JJ, 1999, J PSYCHOL, V133, P253, DOI 10.1080/00223989909599738; Strong J., 1995, BRIT J OCCUPATIONAL, V58, P55, DOI DOI 10.1177/030802269505800204; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; SUNDERLAND A, 1984, J CLIN NEUROPSYCHOL, V6, P127, DOI 10.1080/01688638408401204; TEASDALE G, 1974, LANCET, V2, P81; Tepper S, 1996, BRAIN INJURY, V10, P575, DOI 10.1080/026990596124142; Weinstein EA, 1955, DENIAL ILLNESS	61	23	23	0	5	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704 USA	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	2000	15	5					1123	1138		10.1097/00001199-200010000-00006			16	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	359DT	WOS:000089596800006	10970933				2021-06-18	
J	Mrazik, M; Ferrara, MS; Peterson, CL; Elliott, RE; Courson, RW; Clanton, MD; Hynd, GW				Mrazik, M; Ferrara, MS; Peterson, CL; Elliott, RE; Courson, RW; Clanton, MD; Hynd, GW			Injury severity and neuropsychological and balance outcomes of four college athletes	BRAIN INJURY			English	Article							MILD HEAD-INJURY; FOOTBALL PLAYERS; STANDARDIZED ASSESSMENT; SOCCER PLAYERS; CONCUSSION; SPORTS; MANAGEMENT	Recent evidence suggests significant short-term neurocognitive deficits following mild traumatic brain injury (MTBI) in sports. However, sequelae of mild head injuries is complicated by many factors including a history of multiple head injuries and injury severity. Few studies have considered the influence these variables may have on proper classification of a MTBI and their meaning for return-to-play guidelines. This study presents the short-term neuropsychological and balance outcomes of four college athletes who sustained mild head injuries of different severity (grade I, grade II, grade III and multiple head injured with a grade II based on American Academy of Neurology guidelines). The results demonstrated that self-report symptoms of concussion were slow to resolve in the grade III and multiple concussed individuals. For neuropsychological testing, Trails A & B, Symbol Digit Modalities Test and Digits Span Backwards were the most sensitive in identifying differences between the injuries. For balance assessments using the Neurocom Smart Balance System, the Sensory Organization Test and Reaction Time were also important variables in detecting differences among the various injuries. When these data are used together, it can assist physicians in determining safe return-to-play for athletes who sustain MTBI. There are contradindications in the numerous grading systems and return-to-play guidelines for MTBI. The results from this study provides new evidence which can be assimilated into a valid grading scale for MTBI sustained in sport.	Univ Georgia, Athens, GA 30602 USA	Mrazik, M (corresponding author), Univ Georgia, 300 River Rd, Athens, GA 30602 USA.	mmrazik@coe.uga.edu					Barth JT, 1989, MILD HEAD INJURY; Benton AL, 1978, MULTILINGUAL APHASIA; Brandt J., 1991, CLIN NEUROPSYCHOL, V5, P125, DOI 10.1080/13854049108403297.; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; *CO MED SOC, 1991, REP SPORTS MED COMM; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CREMONAMETEYARD SL, 1994, NEUROPSYCHOLOGIA, V32, P649, DOI 10.1016/0028-3932(94)90026-4; Delaney JS, 1999, CLIN J SPORT MED, V9, P121; FORDSMITH CD, 1995, ARCH PHYS MED REHAB, V76, P77, DOI 10.1016/S0003-9993(95)80047-6; Geurts ACH, 1999, ARCH PHYS MED REHAB, V80, P144, DOI 10.1016/S0003-9993(99)90111-9; GRONWALL D, 1975, LANCET, V2, P995; GUESKIEWICZ KM, 1995, THESIS U VIRGINIA; Guskiewicz KM, 1997, MED SCI SPORT EXER, V29, pS213; Guskiewicz KM, 1996, J SPORT REHABIL, V5, P45, DOI 10.1123/jsr.5.1.45; Ingebrigtsen Tor, 1996, Tidsskrift for den Norske Laegeforening, V116, P3594; JORDAN BD, 1993, MED ASPECTS BOXING; Kelly JP, 1997, NEUROLOGY, V48, P575, DOI 10.1212/WNL.48.3.575; Kelly JP, 1997, NEUROLOGY, V48, P581; Lahat E, 1996, PEDIATR NEUROL, V15, P299, DOI 10.1016/S0887-8994(96)00221-4; Lovell MR, 1998, J HEAD TRAUMA REHAB, V13, P9, DOI 10.1097/00001199-199804000-00004; Matser EJT, 1999, JAMA-J AM MED ASSOC, V282, P971, DOI 10.1001/jama.282.10.971; McCrea M, 1997, NEUROLOGY, V48, P586, DOI 10.1212/WNL.48.3.586; McCrea M, 1998, J HEAD TRAUMA REHAB, V13, P27, DOI 10.1097/00001199-199804000-00005; Nelson W. E., 1984, PHYSICIAN SPORTSMED, V12, P103; Putukian M, 1996, PHYSICIAN SPORTSMED, V24, P25, DOI 10.3810/psm.1996.11.1283; ROOS R, 1996, PHYSICIAN SPORTSMEDI, V24; Smith A., 1982, SYMBOL DIGIT MODALIT; Spreen O., 1991, COMPENDIUM NEUROPSYC; TYSVAER AT, 1991, AM J SPORT MED, V19, P56, DOI 10.1177/036354659101900109; Wechsler D, 1974, WECHSLER MEMORY SCAL; Wechsler D., 1997, WECHSLER MEMORY SCAL, VIII; Wojtys EM, 1999, AM J SPORT MED, V27, P676, DOI 10.1177/03635465990270052401	32	23	23	0	10	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	OCT	2000	14	10					921	931		10.1080/026990500445736			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	364QG	WOS:000089902900006	11076137				2021-06-18	
J	Burnett, DM; Silver, TM; Kolakowsky-Hayner, SA; Cifu, DX				Burnett, DM; Silver, TM; Kolakowsky-Hayner, SA; Cifu, DX			Functional outcome for African Americans and Hispanics treated at a traumatic brain injury model systems centre	BRAIN INJURY			English	Article							RACE; REHABILITATION; COMMUNITY; IMPACT; STROKE	Objective: To describe the demographics, incidence and functional outcome for African Americans and Hispanics treated at a traumatic brain injury (TBI) model systems centre. Design: Retrospective data analysis of patients admitted to an acute inpatient rehabilitation national TBI model systems centre. Setting: A tertiary care university medical centre participating in the NIDRR Traumatic Brain Injury Model Systems project. Subjects: Eighty-seven patients with TBI admitted to a Model Systems acute intensive interdisciplinary rehabilitation setting between 1989-1999. Information was extracted from the National TBI Model Systems data base for demographics such as age, race, education, gender, marital and employment status, sponsorship, injury aetiology and severity. Outcome measures: Functional outcome was determined using the Functional Independence Measure (FIM), and the Disability Rating Scale (DRS) at the time of admission and discharge. Results: Descriptive statistics were completed using SPSS. African American (94.3%) and Hispanic (5.7%) patients were injured most often as a result of motor vehicle accidents (48.8%). Males comprised 86.2% of this population, which had an average age of 34.5 years (SD = 13.1). On admission, average GCS score was 7.8 (SD = 3.6), average DRS was 13.5 (SD = 5.8), and average FIM total score was 49.8 (SD = 26.5). Average length of unconsciousness was 5.2 days (SD = 27.9), while average length of post-traumatic amnesia was 41.9 days (SD = 59.3). At the time of injury, 78.2% of the patients were not married. The majority of patients (97.7%) had private residences and 88.5% returned to their original home. Most patients had at least a high school education or passed a high school equivalent exam (49.4%) and were employed (70.1%) at the time of injury. Only 7% of the patients had a history of prior TBI. With regard to substance use, only 34.2% of patients reported pre-morbid illicit drug use. However, 50.5% met criteria for heavy or moderate alcohol use rates. Only 35.6% of patients reported a pre-morbid history of arrests, with the average number of arrests equal to 4.5 (SD = 10.2). Within this population, the number of drug or alcohol related arrests was 4.8 (SD = 13.5). Conclusions: Unmarried African American males, with an average age of 35 years, predominated at this institution. The primary mechanism of injury was motor vehicle accidents. The majority of patients had, at least, a high school education or passed an equivalency exam, were employed at the time of their injury and were discharged to their prior private residence. While half of the patients met criteria for moderate-to-heavy alcohol consumption, only one-third of the patients reported a history of premorbid illicit drug use. This descriptive analysis supports the need for further investigation of minority populations that sustain TBI and will enhance the accuracy of implications that minority status may have on functional outcome.	Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, Richmond, VA 23298 USA	Kolakowsky-Hayner, SA (corresponding author), Virginia Commonwealth Univ, Med Coll Virginia, Dept Phys Med & Rehabil, POB 980542, Richmond, VA 23298 USA.		Kolakowsky-Hayner, Stephanie A./I-9858-2019	Kolakowsky-Hayner, Stephanie A./0000-0002-6228-9909; Cifu, David/0000-0003-1600-9387			COOPER KD, 1983, NEUROEPIDEMIOLOGY, V9, P70; Ditunnio John F. Jr., 1995, P170; FRANKOWSKI RF, 1985, CENTRAL NERVOUS SYST; HALL KM, 1994, ARCH PHYS MED REHAB, V75, pSC10; HOWARD G, 1994, STROKE, V25, P120; KLATSKY AL, 1991, AM J PUBLIC HEALTH, V811, P423; LILLIEBLANTON M, 1995, NATIONS INTEREST EQU; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rosenthal M, 1996, J HEAD TRAUMA REHAB, V11, P40, DOI 10.1097/00001199-199610000-00005; SAAB PG, 1991, J HYPERTENS, V9, P249, DOI 10.1097/00004872-199103000-00009; SACCO RL, 1991, STROKE, V22, P305, DOI 10.1161/01.STR.22.3.305; Twigg AR, 1998, NEUROREHABILITATION, V11, P249, DOI 10.3233/NRE-1998-11308; ZWEIFLER RM, 1995, STROKE, V26, P245, DOI 10.1161/01.STR.26.2.245	13	23	23	0	3	TAYLOR & FRANCIS LTD	LONDON	11 NEW FETTER LANE, LONDON EC4P 4EE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	2000	14	8					713	718					6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	342XT	WOS:000088672000004	10969889				2021-06-18	
J	Blau, S; Kohen, R; Bass, P; Rubinstein, A				Blau, S; Kohen, R; Bass, P; Rubinstein, A			Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis	DIGESTIVE DISEASES AND SCIENCES			English	Article						experimental colitis; dinitrobenzene sulfonic-acid; low-molecular-weight antioxidants; glutathione; oxidative stress; cyclic voltammetry	TRINITROBENZENE SULFONIC-ACID; REACTIVE OXYGEN METABOLITES; INDUCED OXIDATIVE STRESS; HAPTEN-INDUCED MODEL; EPITHELIAL L2 CELLS; CLOSED-HEAD INJURY; BOWEL-DISEASE; CYCLIC VOLTAMMETRY; GLUTATHIONE SYNTHESIS; FREE-RADICALS	Tissue antioxidant status is altered as a response to oxidative stress. This oxidative stress, caused by reactive oxygen species, is associated with inflammatory bowel disease (IBD). Our aim was to examine the relationship between total tissue low-molecular-weight antioxidant (LMWA) profile and inflammation severity in dinitrobenzene sulfonic acid (DNBS) experimental colitis in the rat. Rats were treated with three doses of DNBS: 1. 10, and 20 mg. Inflammation severity was assessed by tissue colonic wet weight, macroscopic evaluation, and tissue myeloperoxidase (MPO) activity. The capacity of water-soluble LMWA was assessed by measuring the reducing power of the tissues with cyclic voltammetry (CV) and by measuring ti;sue levels of reduced glutathione. While typical markers of inflammation (MPO, macroscopic examination, and colonic wet weight) indicated DNBS dose dependency, such dependency could not be demonstrated for the tissue LMWA as measured by reduced glutathione levels and by the tissues' reducing power. Mild colonic inflammation (induced by ethanol or by 1 mg of DNBS) caused an increase in the overall capacity of water-soluble LMWA. However, severe inflammation (induced by 20 mg of DNBS) caused a reduction in the tissue LMWA capacity. An intermediate dose of DNBS (10 mg) caused moderate inflammation, but did not cause a significant change in the tissue LMWA compared with a saline control treatment. In conclusion, LMWA changed in a biphasic pattern reflective of the severity of mucosal colonic inflammation. It is suggested that: low dose of DNBS (1 mg) and topical alcohol (25% v/v) caused an adaptation effect to the mild oxidative stress associated with mild inflammation. This resulted in an increase in the LMWA. A higher dose of DNBS (20 mg) caused more severe inflammation with an overall reduction in LMWA, The increased efflux of reactive oxygen species, associated with severe inflammation, led to an overall consumption of the tissue LMWA, which masked the increase in LMWA caused by the mild oxidative stress.	Hebrew Univ Jerusalem, Sch Pharm, Fac Med, IL-91120 Jerusalem, Israel; Univ Wisconsin, Sch Pharm, Madison, WI 53706 USA	Rubinstein, A (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Fac Med, POB 12065, IL-91120 Jerusalem, Israel.			Rubinstein, Abraham/0000-0001-6212-3725			ARNAIZ SL, 1995, FREE RADICAL BIO MED, V19, P303, DOI 10.1016/0891-5849(95)00023-Q; BANNAI S, 1991, BIOCHIM BIOPHYS ACTA, V1092, P175, DOI 10.1016/0167-4889(91)90153-O; Blau S, 1999, MOL CELL BIOCHEM, V194, P185, DOI 10.1023/A:1006994800272; BRADFORD MM, 1976, ANAL BIOCHEM, V72, P248, DOI 10.1016/0003-2697(76)90527-3; BRODY LL, 1996, DIGEST DIS SCI, V41, P2078; BUFFINTON GD, 1995, FREE RADICAL BIO MED, V19, P911, DOI 10.1016/0891-5849(95)94362-H; BUFFINTON GD, 1995, FREE RADICAL RES, V22, P131, DOI 10.3109/10715769509147535; Chamulitrat W, 1997, BBA-GEN SUBJECTS, V1336, P73, DOI 10.1016/S0304-4165(97)00012-3; Chevion S, 1997, FREE RADICAL BIO MED, V22, P411, DOI 10.1016/S0891-5849(96)00337-1; Choi J, 1997, BIOCHEM PHARMACOL, V53, P987, DOI 10.1016/S0006-2952(96)00867-2; DeMedina FS, 1996, J PHARMACOL EXP THER, V278, P771; GRISHAM MB, 1994, LANCET, V344, P859, DOI 10.1016/S0140-6736(94)92831-2; GRISHAM MB, 1991, GASTROENTEROLOGY, V101, P540, DOI 10.1016/0016-5085(91)90036-K; GRISHAM MB, 1986, AM J PHYSIOL, V251, pG567; GRISHAM MB, 1990, METHOD ENZYMOL, V186, P729; Halliwell B, 1989, FREE RADICALS BIOL M; HARRIS ML, 1992, PHARMACOL THERAPEUT, V53, P375, DOI 10.1016/0163-7258(92)90057-7; Hawkins JV, 1997, DIGEST DIS SCI, V42, P1969, DOI 10.1023/A:1018887832465; IRIARTE WLZ, 1996, SCAND J GASTROENTERO, V31, P985; KESHAVARZIAN A, 1992, J LAB CLIN MED, V120, P778; KESHAVARZIAN A, 1992, GASTROENTEROLOGY, V103, P177, DOI 10.1016/0016-5085(92)91111-G; KOHEN R, 1992, EXP GERONTOL, V27, P161, DOI 10.1016/0531-5565(92)90040-7; KOHEN R, 1993, J PHARMACOL TOXICOL, V29, P185, DOI 10.1016/1056-8719(93)90024-9; Kohen R, 1999, METHOD ENZYMOL, V300, P285; Kohen R, 1997, ARCH GERONTOL GERIAT, V24, P103, DOI 10.1016/S0167-4943(96)00744-3; KRAWISZ JE, 1984, GASTROENTEROLOGY, V87, P1344; LIU RY, 1992, J QINGHAI NORMAL U, V1, P1; Loguercio C, 1996, DIGEST DIS SCI, V41, P1204, DOI 10.1007/BF02088238; Lomnitski L, 1997, PHARMACOL BIOCHEM BE, V56, P669, DOI 10.1016/S0091-3057(96)00412-1; LUCK MS, 1993, J PHARMACOL EXP THER, V264, P984; Moghadasian MH, 1996, DIGEST DIS SCI, V41, P791, DOI 10.1007/BF02213136; MORRIS GP, 1989, GASTROENTEROLOGY, V96, P795, DOI 10.1016/0016-5085(89)90904-9; MULDER TPJ, 1991, GUT, V32, P1146, DOI 10.1136/gut.32.10.1146; OBRIEN PJ, 1990, XENOBIOTICA, V20, P945, DOI 10.3109/00498259009046910; OGINO T, 1989, BIOCHIM BIOPHYS ACTA, V1006, P131, DOI 10.1016/0005-2760(89)90334-2; OSBORNE DL, 1994, J CLIN INVEST, V94, P1910, DOI 10.1172/JCI117541; Romero IA, 1996, TOXICOL APPL PHARM, V139, P94, DOI 10.1006/taap.1996.0146; SARKAR S, 1995, J TRACE ELEM MED BIO, V9, P144, DOI 10.1016/S0946-672X(11)80038-6; SHI MM, 1994, J BIOL CHEM, V269, P26512; SHI MM, 1994, AM J PHYSIOL-LUNG C, V267, pL414; Shohami E, 1999, J NEUROTRAUM, V16, P365, DOI 10.1089/neu.1999.16.365; SIMMONDS NJ, 1992, GASTROENTEROLOGY, V103, P186, DOI 10.1016/0016-5085(92)91112-H; TANNAHILL CL, 1995, GASTROENTEROLOGY, V109, P800, DOI 10.1016/0016-5085(95)90387-9; VANDERVLIET A, 1992, FREE RADICAL BIO MED, V12, P499, DOI 10.1016/0891-5849(92)90103-N; VERSPAGET HW, 1991, SCAND J GASTROENTERO, V26, P44, DOI 10.3109/00365529109111229; WALLACE JL, 1995, J PHARMACOL TOXICOL, V33, P237, DOI 10.1016/1056-8719(95)00001-X; WOODS JS, 1995, BIOCHEM PHARMACOL, V50, P1719, DOI 10.1016/0006-2952(95)02075-6; YANNAI EB, 1997, J CEREB BLOOD FLOW M, V17, P273	48	23	23	0	2	SPRINGER	DORDRECHT	VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS	0163-2116	1573-2568		DIGEST DIS SCI	Dig. Dis. Sci.	JUN	2000	45	6					1180	1187		10.1023/A:1005510321278			8	Gastroenterology & Hepatology	Gastroenterology & Hepatology	330QF	WOS:000087972200022	10877235				2021-06-18	
J	Kurowski, K; Chandran, S				Kurowski, K; Chandran, S			The preparticipation athletic evaluation	AMERICAN FAMILY PHYSICIAN			English	Article							HYPERTROPHIC CARDIOMYOPATHY; INJURY	A comprehensive medical history that includes questions about a personal and family history of cardiovascular disease is the most important initial component of the preparticipation athletic evaluation. Additional questions should focus on any history of neurologic or musculoskeletal problems. A limited physical examination should emphasize cardiac auscultation with provocative maneuvers to screen for hypertrophic cardiomyopathy. This condition is the most common cause of sudden death in young male athletes. Other components of the physical examination include an evaluation of the spine and extremities. Screening tests such as electrocardiography. treadmill stress testing and urinalysis are not indicated in the absence of symptoms or a significant history of risk factors. Specific conditions that would exclude or limit athletic participation include hypertrophic cardiomyopathy. long QT interval syndrome, concussion. significant knee injury, sickle cell disease and uncontrolled seizures. Overall. about 1 percent of athletes who are screened are completely disqualified from sports participation.	Finch Univ Hlth Sci Chicago Med Sch, Dept Family Med, N Chicago, IL 60064 USA	Kurowski, K (corresponding author), Finch Univ Hlth Sci Chicago Med Sch, Dept Family Med, N Chicago, IL 60064 USA.						ABBOTT H G, 1969, Archives of Physical Medicine and Rehabilitation, V50, P326; [Anonymous], 1988, PEDIATRICS, V81, P737; [Anonymous], 1996, Med Sci Sports Exerc, V28, P1445; [Anonymous], 1995, SPORTSMEDICINE DIGES, V17, P3; ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; BARROW GW, 1988, AM J SPORT MED, V16, P209, DOI 10.1177/036354658801600302; Cantu RC, 1998, CLIN SPORT MED, V17, P37, DOI 10.1016/S0278-5919(05)70059-4; Cantu RC, 1998, CLIN SPORT MED, V17, P137, DOI 10.1016/S0278-5919(05)70068-5; Corrado D, 1998, NEW ENGL J MED, V339, P364, DOI 10.1056/NEJM199808063390602; GOTT VL, 1986, NEW ENGL J MED, V314, P1070, DOI 10.1056/NEJM198604243141702; Grafe MW, 1997, CLIN SPORT MED, V16, P569, DOI 10.1016/S0278-5919(05)70043-0; Krowchuk DP, 1997, PEDIATR ANN, V26, P37, DOI 10.3928/0090-4481-19970101-09; Lerakis S, 1997, AM J MED SCI, V314, P324; MARON BJ, 1994, MED SCI SPORT EXER, V26, pS261; Maron BJ, 1997, LANCET, V350, P1330; Maron BJ, 1999, JAMA-J AM MED ASSOC, V281, P650, DOI 10.1001/jama.281.7.650; Maron BJ, 1996, JAMA-J AM MED ASSOC, V276, P199, DOI 10.1001/jama.276.3.199; MARON BJ, 1999, JAMA-J AM MED ASSOC, V281, P2288; *NAT HIGH BLOOD PR, 1997, NIH PUBL; SMITH DM, 1997, PREPARTICIPATION PHY; Smith J, 1998, MAYO CLIN PROC, V73, P419; STOCK JG, 1991, AM FAM PHYSICIAN, V44, P515; THOMPSON PD, 1994, MED SCI SPORT EXER, V26, pS271; *US PREV SERV TASK, 1996, GUID CLIN PREV SERV, P8; VANCAMP SP, 1995, MED SCI SPORT EXER, V27, P641; WELDER AA, 1993, J PHARMACOL TOXICOL, V29, P61, DOI 10.1016/1056-8719(93)90052-G; Wiggins DL, 1997, CLIN SPORT MED, V16, P593, DOI 10.1016/S0278-5919(05)70044-2	27	23	23	0	3	AMER ACAD FAMILY PHYSICIANS	KANSAS CITY	8880 WARD PARKWAY, KANSAS CITY, MO 64114-2797 USA	0002-838X	1532-0650		AM FAM PHYSICIAN	Am. Fam. Physician	MAY 1	2000	61	9					2683	2690					8	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	314TF	WOS:000087073100014	10821150				2021-06-18	
J	Cullinane, DC; Jenkins, JM; Reddy, S; VanNatta, T; Eddy, VA; Bass, JG; Chen, A; Schwartz, M; Lavin, P; Morris, JA				Cullinane, DC; Jenkins, JM; Reddy, S; VanNatta, T; Eddy, VA; Bass, JG; Chen, A; Schwartz, M; Lavin, P; Morris, JA			Anterior ischemic optic neuropathy: A complication after systemic inflammatory response syndrome	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	59th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma	SEP 16-18, 1999	BOSTON, MASSACHUSETTS	Amer Assoc Surgery Trauma			CARDIOPULMONARY BYPASS; SURGERY; HYPOTENSION; PATHOGENESIS; VISION	Background: Patients are surviving previously fatal injuries, Unique morbidities are occurring in these survivors. Anterior ischemic optic neuropathy represents a previously unrecognized cause of blindness in the trauma victim. We hypothesize that this phenomenon is caused by unique characteristics of optic edema/ pressure or decreased blood flow associated with massive resuscitation. Methods: Between November of 1991 and August of 1998, there were 18,199 admissions to our trauma center. Of this group, 350 patients required massive volume resuscitation (> 20 liters infused over first 24 hours). Patients having closed head injuries, facial fractures or direct orbital trauma were excluded from study. The following variables were studied: demographics, injury severity (Injury Severity; Score, highest lactate, worst base deficit, and lowest pH) crystalloid and transfusion requirements, ventilator requirements (PEEP) Results: Of the 350 patients with massive resuscitation, 9 patients were diagnosed with anterior ischemic optic neuropathy (2.6%). Of these, seven patients required celiotomy (78%). Six of the seven celiotomy patients had damage control celiotomies and abdominal compartment syndrome (86%). One patient had a repair of a subclavian artery; one had a complex acetabular repair. Blindness was unilateral in five patients and bilateral in four. All nine patients had evidence of global hypoperfusion, systemic inflammatory response, massive resuscitation, and high ventilatory support; one patient required cardiopulmonary resuscitation. Conclusion: Prone positioning is known to be associated with an increased intraocular pressure. We postulate that the combination of massive resuscitation and prone positioning will increase the incidence of anterior ischemic optic neuropathy. As such,,ve recommend that prone positioning for adult respiratory, distress syndrome be reserved for only those patients at risk of death.	Vanderbilt Univ, Med Ctr, Nashville, TN USA	Cullinane, DC (corresponding author), Mayo Clin, Dept Surg, 200 1st St SW, Rochester, MN 55907 USA.			Cullinane, Daniel/0000-0002-0414-1949			Bloomfield GL, 1996, J TRAUMA, V40, P936, DOI 10.1097/00005373-199606000-00012; BOGHEN DR, 1975, BRAIN, V98, P689, DOI 10.1093/brain/98.4.689; BROWN RH, 1994, ANESTHESIOLOGY, V80, P222, DOI 10.1097/00000542-199401000-00033; CHISHOLM IA, 1969, BRIT J OPHTHALMOL, V53, P289, DOI 10.1136/bjo.53.5.289; CONNOLLY SE, 1994, AM J OPHTHALMOL, V117, P235, DOI 10.1016/S0002-9394(14)73082-X; CULLEN JF, 1967, BRIT J OPHTHALMOL, V51, P513, DOI 10.1136/bjo.51.8.513; DORO S, 1985, ARCH OPHTHALMOL-CHIC, V103, P1143; Eddy V, 1997, SURG CLIN N AM, V77, P801, DOI 10.1016/S0039-6109(05)70585-5; FEIT RH, 1984, AM J OPHTHALMOL, V98, P105, DOI 10.1016/0002-9394(84)90196-X; HAYREH SS, 1987, OPHTHALMOLOGY, V94, P1488; JOHNSON MW, 1987, OPHTHALMOLOGY, V94, P1577; JOHNSON MW, 1994, OPHTHALMOLOGY, V94, P1557; Jolliet P, 1998, CRIT CARE MED, V26, P1977, DOI 10.1097/00003246-199812000-00023; KATZ DM, 1994, ARCH OPHTHALMOL-CHIC, V112, P925, DOI 10.1001/archopht.1994.01090190073024; LARKIN DFP, 1987, BRIT J OPHTHALMOL, V71, P344, DOI 10.1136/bjo.71.5.344; LOCKET S, 1949, BRIT J OPHTHALMOL, V33, P543, DOI 10.1136/bjo.33.9.543; MORRIS JA, 1996, CURR PROB SURG, V33, P609; PINCUS F, 1919, ARCH CLIN EXP OPHTHA, V98, P152; RIZZO JF, 1987, AM J OPHTHALMOL, V103, P808; SERVILLA KS, 1986, AM J KIDNEY DIS, V8, P61, DOI 10.1016/S0272-6386(86)80156-1; Shaked G, 1998, J TRAUMA, V44, P923, DOI 10.1097/00005373-199805000-00032; SWEENEY PJ, 1982, NEUROLOGY, V32, P560, DOI 10.1212/WNL.32.5.560; WEINSTEIN JM, 1983, INVEST OPHTH VIS SCI, V24, P1559; WILSON JF, 1991, ARCH OTOLARYNGOL, V117, P1304	24	23	25	1	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	MAR	2000	48	3					381	386		10.1097/00005373-200003000-00003			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	295QT	WOS:000085979900005	10744273				2021-06-18	
J	Bublak, P; Schubert, T; Matthes-von Cramon, G; von Cramon, DY				Bublak, P; Schubert, T; Matthes-von Cramon, G; von Cramon, DY			Differential demands on working memory for guiding a simple action sequence: Evidence from closed-head-injured subjects	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							DUAL-TASK-PERFORMANCE; CENTRAL EXECUTIVE DEFICIT; TRAUMATIC BRAIN INJURY; FRONTAL-LOBE; INDIVIDUAL-DIFFERENCES; PARKINSONS-DISEASE; DIVIDED ATTENTION; INFORMATION; PERCEPTION; BEHAVIOR	In the present study, a working memory paradigm was used to assess coordinative abilities required for the flexible control of a sequence of actions. Subjects had to maintain and recall a list of digits that functioned as an ensemble of activity cues used for guiding a sequence of forced-choice responses. In three task conditions, the demand on the selection of the activity cues was varied parametrically to manipulate the requirement of coordinating maintenance and processing operations of working memory for guiding the response sequences. A comparison between subjects suffering from severe closed head injury (CHI) and matched controls in a blocked presentation of task conditions revealed that patients, in contrast to controls, did not preplan the sequence by rearranging the ensemble of activity cues prior to execution of the action sequence. Patients' performance was more comparable to controls tested in a random presentation in which preplanning was not possible. Our results further suggest that patients are less efficient in selecting activity cues from working memory, especially in more demanding situations when activity cues have to be completely reordered for guiding a sequence of actions. These results point to an executive dysfunction in CHI subjects that may contribute to the deficits known as inflexible and rigid behavior.	Max Planck Inst Cognit Neurosci, Dept Neurol, Leipzig, Germany; Univ Leipzig, Daycare Clin Cognit Neurol, D-7010 Leipzig, Germany	Bublak, P (corresponding author), Univ Munich, Inst Psychol & Neuropsychol, Leopoldstr 13, D-80802 Munich, Germany.			Schubert, Torsten/0000-0002-6514-6145			Alderman N, 1996, NEUROPSYCHOL REHABIL, V6, P161, DOI 10.1080/713755505; Alloway TP., 1997, DEV MEMORY CHILDHOOD, P163; Azouvi P, 1996, J CLIN EXP NEUROPSYC, V18, P317, DOI 10.1080/01688639608408990; Baddeley A, 1997, NEUROPSYCHOLOGY, V11, P187, DOI 10.1037/0894-4105.11.2.187; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baddeley A. D., 1986, WORKING MEMORY; BADDELEY AD, 1991, BRAIN, V114, P2521, DOI 10.1093/brain/114.6.2521; BROUWER WH, 1989, CORTEX, V25, P219, DOI 10.1016/S0010-9452(89)80038-3; BROWN RG, 1991, BRAIN, V114, P215; CARLSON RA, 1993, J EXP PSYCHOL HUMAN, V19, P531; Cicerone KD, 1996, BRAIN INJURY, V10, P79, DOI 10.1080/026990596124566; COWAN N, 1988, PSYCHOL BULL, V104, P163, DOI 10.1037/0033-2909.104.2.163; Cowey CM, 1996, MEMORY, V4, P19, DOI 10.1080/741940668; CREMONAMETEYARD SL, 1992, NEUROPSYCHOLOGIA, V30, P123, DOI 10.1016/0028-3932(92)90022-E; DALRYMPLEALFORD JC, 1994, J NEUROL NEUROSUR PS, V57, P360, DOI 10.1136/jnnp.57.3.360; DANEMAN M, 1980, J VERB LEARN VERB BE, V19, P450, DOI 10.1016/S0022-5371(80)90312-6; DARK VJ, 1990, MEM COGNITION, V18, P119, DOI 10.3758/BF03197088; Duncan J, 1996, COGNITIVE PSYCHOL, V30, P257, DOI 10.1006/cogp.1996.0008; DUNCAN J, 1986, COGNITIVE NEUROPSYCH, V3, P271, DOI 10.1080/02643298608253360; Ferraro FR, 1996, BRAIN COGNITION, V32, P429, DOI 10.1006/brcg.1996.0075; Fuster J, 1989, PREFRONTAL CORTEX; FUSTER JM, 1985, HUM NEUROBIOL, V4, P169; Garavan H, 1998, MEM COGNITION, V26, P263, DOI 10.3758/BF03201138; HARTMAN A, 1992, CLIN REHABIL, V6, P133; JEANNEROD M, 1997, COGNITIVE NEUROSCIEN; JUST MA, 1992, PSYCHOL REV, V99, P122, DOI 10.1037/0033-295X.99.1.122; MAPOU RL, 1992, HDB HEAD TRAUMA ACUT, P75; MAYR U, 1993, J EXP PSYCHOL LEARN, V19, P1297, DOI 10.1037/0278-7393.19.6.1297; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; Mecklinger A, 1999, J CLIN EXP NEUROPSYC, V21, P606, DOI 10.1076/jcen.21.5.606.873; Owen AM, 1996, BRAIN, V119, P1597, DOI 10.1093/brain/119.5.1597; OWEN AM, 1990, NEUROPSYCHOLOGIA, V28, P1021, DOI 10.1016/0028-3932(90)90137-D; PETRIDES M, 1982, NEUROPSYCHOLOGIA, V20, P249, DOI 10.1016/0028-3932(82)90100-2; Ponsford J., 1995, TRAUMATIC BRAIN INJU; Salthouse TA, 1996, PSYCHOL REV, V103, P403, DOI 10.1037/0033-295X.103.3.403; STABLUM F, 1994, CORTEX, V30, P603, DOI 10.1016/S0010-9452(13)80238-9; Veltman JC, 1996, NEUROPSYCHOLOGY, V10, P357, DOI 10.1037/0894-4105.10.3.357; VONCRAMON DY, 1994, NEUROPSYCHOL REHABIL, V4, P399, DOI 10.1080/09602019408401608; VONCRAMON DY, 1992, NEUROPSYCHOLOGICAL R; WENGER JL, 1995, J EXP PSYCHOL HUMAN, V21, P170; WIEGERSMA S, 1990, NEUROPSYCHOLOGIA, V28, P95, DOI 10.1016/0028-3932(90)90089-7; YEE PL, 1991, COGNITIVE PSYCHOL, V23, P615, DOI 10.1016/0010-0285(91)90007-B	42	23	23	0	4	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.		2000	22	2					176	190		10.1076/1380-3395(200004)22:2;1-1;FT176			15	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	310QF	WOS:000086838300002	10779832				2021-06-18	
J	Cheney, JA; Brown, AL; Bareyre, FM; Russ, AB; Weisser, JD; Ensinger, HA; Leusch, A; Raghupathi, R; Saatman, KE				Cheney, JA; Brown, AL; Bareyre, FM; Russ, AB; Weisser, JD; Ensinger, HA; Leusch, A; Raghupathi, R; Saatman, KE			The novel compound LOE 908 attenuates acute neuromotor dysfunction but not cognitive impairment or cortical tissue loss following traumatic brain injury in rats	JOURNAL OF NEUROTRAUMA			English	Article						behavior; brain injury; cation channels; cognition; motor function	CHANNEL BLOCKER; CEREBRAL EDEMA; HEAD-INJURY; CALCIUM; DEFICITS; MOTOR; NEUROTOXICITY; CONSEQUENCES; INHIBITION; RECOVERY	Experimental traumatic brain injury (TBI) initiates massive disturbances in Ca2+ concentrations in the brain that may contribute to neuronal damage. Intracellular Ca2+ may be elevated via influx through voltage-operated cation channels, ligand-gated ionotropic channels, and store-operated cation channels (SOCs). In the present study, we evaluated the neurobehavioral and histological effects of acute posttraumatic administration of (R,S)-(3,4-dihydro-6,7-dimethoxy-isoquinoline-1-yl)-2-phenyl-N,N-di[2-(2,3,4-trimethoxyphenyl)ethyl]-acetamide (LOE 908), a broad spectrum inhibitor of voltage-operated cation channels and SOCs. Male Sprague-Dawley rats (n = 53) were trained in the Morris water maze, anesthetized (60 mg/kg pentobarbital, i.p.), and subjected to lateral fluid percussion brain injury (2.5-2.7 atm; n = 38) or surgery without injury (n = 15). At 15 min postinjury, animals were randomized to receive intravenous administration of either a high dose of LOE 908 (4 mg/kg bolus followed by 160 mg/kg over 24 h; n = 13), a low dose of LOE 908 (2 mg/kg bolus followed by 80 mg/kg over 24 h; n = 12), or vehicle (n = 13). Uninjured controls received the high dose of LOE 908 (n = 8) or vehicle (n = 7). Treatment with either dose of LOE 908 significantly improved neuromotor function at 48 h postinjury when compared to vehicle treatment. Although a significant deficit in visuospatial memory was observed in brain-injured animals at this timepoint when compared to uninjured animals, neither dose of LOE 908 attenuated injury-induced cognitive dysfunction. Histological evaluation revealed that neither dose of LOE 908 affected cortical lesion size at 48 h postinjury. These data suggest that broad spectrum cation channel blockers may be beneficial in the treatment of neurological motor dysfunction when administered in the acute posttraumatic period.	Univ Penn, Dept Neurosurg, Philadelphia, PA 19104 USA; Boehringer Ingelheim Pharma KG, D-6507 Ingelheim, Germany	Saatman, KE (corresponding author), Univ Penn, Dept Neurosurg, 105C Hayden Hall,3320 Smith Walk, Philadelphia, PA 19104 USA.				NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01GM034690] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS008803, R01NS026818] Funding Source: NIH RePORTER; NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [R01-GM34690] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01-NS26818, P50-NS08803] Funding Source: Medline		Bramlett HM, 1997, BRAIN RES, V762, P195, DOI 10.1016/S0006-8993(97)00387-9; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; BROWN DSO, 1992, ARCH PHYS MED REHAB, V73, P758; CHOI DW, 1988, TRENDS NEUROSCI, V11, P465, DOI 10.1016/0166-2236(88)90200-7; CHOI DW, 1987, J NEUROSCI, V7, P369; Clark RSB, 1997, J NEUROTRAUM, V14, P179, DOI 10.1089/neu.1997.14.179; Conti AC, 1998, J NEUROSCI, V18, P5663; CORTEZ SC, 1989, BRAIN RES, V482, P271, DOI 10.1016/0006-8993(89)91190-6; Di X, 1996, J NEUROTRAUM, V13, P497, DOI 10.1089/neu.1996.13.497; DIETRICH WD, 1994, J NEUROTRAUM, V11, P289, DOI 10.1089/neu.1994.11.289; Encabo A, 1996, BRIT J PHARMACOL, V119, P702, DOI 10.1111/j.1476-5381.1996.tb15729.x; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENTILE N, 1993, J NEUROTRAUM, V10, pS193; Guluma KZ, 1999, J NEUROTRAUM, V16, P311, DOI 10.1089/neu.1999.16.311; Hicks R, 1996, ACTA NEUROPATHOL, V91, P236, DOI 10.1007/s004010050421; HoehnBerlage M, 1997, J CEREBR BLOOD F MET, V17, P534, DOI 10.1097/00004647-199705000-00007; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KRAUS JF, 1993, HEAD INJURY; KRAUTWURST D, 1993, MOL PHARMACOL, V43, P655; LOWENSTEIN DH, 1992, J NEUROSCI, V12, P4846; MATTSON MP, 1994, J NEUROTRAUM, V11, P3, DOI 10.1089/neu.1994.11.3; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; McIntosh TK, 1997, NEUROSCIENTIST, V3, P169, DOI 10.1177/107385849700300310; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1993, J CEREBR BLOOD F MET, V13, P183, DOI 10.1038/jcbfm.1993.22; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; PAXINOS G, 1990, STEREOTAXIC ATLAS RA; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1994, J NEUROTRAUM, V11, P723, DOI 10.1089/neu.1994.11.723; PUTNEY JW, 1990, CELL CALCIUM, V11, P611, DOI 10.1016/0143-4160(90)90016-N; RINK A, 1995, AM J PATHOL, V147, P1575; Rzigalinski BA, 1998, J NEUROCHEM, V70, P2377; Saatman KE, 1996, P NATL ACAD SCI USA, V93, P3428, DOI 10.1073/pnas.93.8.3428; Saatman KE, 1997, EXP NEUROL, V147, P418, DOI 10.1006/exnr.1997.6629; SHAPIRA Y, 1989, Neurological Research, V11, P169; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SIMPSON PB, 1995, TRENDS NEUROSCI, V18, P299, DOI 10.1016/0166-2236(95)93919-O; SMITH DH, 1994, NEUROSCI LETT, V168, P151, DOI 10.1016/0304-3940(94)90438-3; SMITH DH, 1993, J NEUROSCI, V13, P5383; Smith DH, 1991, J NEUROTRAUM, V8, P259, DOI 10.1089/neu.1991.8.259; SOARES HD, 1992, J NEUROCHEM, V58, P1845, DOI 10.1111/j.1471-4159.1992.tb10061.x; Soares HD, 1995, J NEUROSCI, V15, P8223; SUN FY, 1995, BRAIN RES, V673, P133, DOI 10.1016/0006-8993(94)01413-C; Swaine BR, 1996, BRAIN INJURY, V10, P347, DOI 10.1080/026990596124368; TOULMOND S, 1993, BRAIN RES, V620, P24, DOI 10.1016/0006-8993(93)90266-P; VONTSCHARNER V, 1986, NATURE, V324, P369, DOI 10.1038/324369a0; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WES PD, 1995, P NATL ACAD SCI USA, V92, P9652, DOI 10.1073/pnas.92.21.9652; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; Young W, 1992, J NEUROTRAUMA S1, V9, P9; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8; Zitt C, 1996, NEURON, V16, P1189, DOI 10.1016/S0896-6273(00)80145-2	52	23	23	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538 USA	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	2000	17	1					83	91		10.1089/neu.2000.17.83			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	278WR	WOS:000085012400007	10674760				2021-06-18	
J	Cheng, C; Reynolds, IJ				Cheng, C; Reynolds, IJ			Subcellular localization of glutamate-stimulated intracellular magnesium concentration changes in cultured rat forebrain neurons using confocal microscopy	NEUROSCIENCE			English	Article						intracellular magnesium; Mg2+; NMDA receptor; magindo-1; confocal microscopy	RECEPTOR-MEDIATED NEUROTOXICITY; TRAUMATIC BRAIN INJURY; CORTICAL-NEURONS; NERVOUS-SYSTEM; FREE MG-2+; IN-VITRO; CALCIUM; MG2+; CHANNELS; ISCHEMIA	Glutamate can stimulate increases in intracellular magnesium concentration ([Mg2+](i)) and induce neurotoxicity, both independent of Ca2+ changes. Although Mg2+ is essential within the cell, very little is known about how it is regulated, especially in neurons. Therefore we used the Auorescenr indicator, magindo(-1) and confocal microscopy to examine possible intracellular pools of Mg2+ in cultured neurons that can be dynamically regulated by glutamate. The magindo-1 fluorescence signal was present throughout the cell body and extends into the neuronal processes. The magindo-1 405 nm/490 nm ratio signal was similar in the cytoplasm and nucleus, suggesting that resting [Mg2+](i) is uniform across the neuron. The addition of 100 mu M glutamate/10 mu M glycine in an extracellular Ca2+- and Na+-free buffer stimulated an increase in [Mg2+](i) in both the nuclear and cytoplasmic regions of similar magnitude and duration. This glutamate exposure also stimulated a [Mg2+](i) increase in neuronal processes which was inhibited by the N-methyl-D-aspartate receptor antagonist, MK-801 (10 mu M) The glutamate-stimulated [Mg2+](i) increase in both the cell body and neuronal processes was dependent on the extracellular Mg2+ concentration. These findings suggest glutamate-stimulated [Mg2+](i) changes may not only impact cytoplasmic processes, but also directly trigger nuclear events involved, for example, in neuronal injury. (C) 1999 IBRO. Published by Elsevier Science Ltd.	Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA	Reynolds, IJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Pharmacol, Pittsburgh, PA 15261 USA.		Reynolds, Ian Jeffery/ABH-3197-2020; Reynolds, Ian/C-4358-2008	Reynolds, Ian/0000-0003-3028-5070	NIGMS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM 08424] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS34138] Funding Source: Medline; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM008424] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS034138] Funding Source: NIH RePORTER		AGUS ZS, 1991, ANNU REV PHYSIOL, V53, P299, DOI 10.1146/annurev.ph.53.030191.001503; Bara M, 1984, Magnesium, V3, P215; BROCARD JB, 1993, NEURON, V11, P751, DOI 10.1016/0896-6273(93)90084-5; CHOI DW, 1988, NEURON, V1, P623, DOI 10.1016/0896-6273(88)90162-6; CHOI DW, 1987, J PHARMACOL EXP THER, V242, P713; CHOI DW, 1987, J NEUROSCI, V7, P369; CHOI DW, 1987, J NEUROSCI, V7, P357; EBEL H, 1980, J CLIN CHEM CLIN BIO, V18, P257; GARFINKEL L, 1985, Magnesium, V4, P60; GUNTHER T, 1986, MAGNESIUM, V5, P53; Hartnett KA, 1997, J NEUROCHEM, V68, P1836; Heath DL, 1999, J NEUROSURG, V90, P504, DOI 10.3171/jns.1999.90.3.0504; HELPERN JA, 1993, NEUROLOGY, V43, P1577, DOI 10.1212/WNL.43.8.1577; HYRE K, 1997, J NEUROSCI, V17, P6669; KELEPOURIS E, 1993, MINER ELECTROL METAB, V19, P277; LATTANZIO FA, 1991, BIOCHEM BIOPH RES CO, V177, P184, DOI 10.1016/0006-291X(91)91966-G; Lipp P, 1997, EMBO J, V16, P7166, DOI 10.1093/emboj/16.23.7166; LUCAS DR, 1957, ARCH OPHTHALMOL-CHIC, V58, P193; MCINTOSH TK, 1990, J NEUROCHEM, V55, P1170, DOI 10.1111/j.1471-4159.1990.tb03122.x; MICHAELS RL, 1990, J NEUROSCI, V10, P283; MIYASHIRO K, 1994, P NATL ACAD SCI USA, V91, P10800, DOI 10.1073/pnas.91.23.10800; MORELLE B, 1994, ANAL BIOCHEM, V218, P170, DOI 10.1006/abio.1994.1156; OLNEY JW, 1969, SCIENCE, V164, P719, DOI 10.1126/science.164.3880.719; PAINE PL, 1975, NATURE, V254, P109, DOI 10.1038/254109a0; PETRALIA RS, 1994, J NEUROSCI, V14, P6102; PETRALIA RS, 1994, J NEUROSCI, V14, P667; Pivovarova NB, 1999, J NEUROSCI, V19, P6372; POPOV EG, 1988, ARCH BIOCHEM BIOPHYS, V261, P91, DOI 10.1016/0003-9861(88)90107-5; RAJDEV S, 1994, NEUROSCIENCE, V62, P667, DOI 10.1016/0306-4522(94)90468-5; REYNOLDS IJ, 1996, SOC NEUR ABSTR, V22, P68; ROMANI A, 1992, ARCH BIOCHEM BIOPHYS, V298, P1, DOI 10.1016/0003-9861(92)90086-C; Rout Michael P., 1994, Trends in Cell Biology, V4, P357, DOI 10.1016/0962-8924(94)90085-X; Sebille S, 1996, BIOCHEM BIOPH RES CO, V227, P743, DOI 10.1006/bbrc.1996.1579; SILVERMAN HS, 1994, AM J PHYSIOL, V266, pC222; Stout AK, 1996, J PHYSIOL-LONDON, V492, P641, DOI 10.1113/jphysiol.1996.sp021334; Stout AK, 1999, NEUROSCIENCE, V89, P91, DOI 10.1016/S0306-4522(98)00441-2; Taylor CP, 1999, J NEUROSCI, V19, P619; TYMIANSKI M, 1993, J NEUROSCI, V13, P2085; VINK R, 1987, BIOCHEM BIOPH RES CO, V149, P594, DOI 10.1016/0006-291X(87)90409-8; VINK R, 1990, J NEUROSCI, V10, P3524; Vink R, 1996, J NEUROCHEM, V66, P2477; VINK R, 1988, J BIOL CHEM, V263, P757; VINK R, 1991, MG2PLUS EXCITABLE ME, P125; WHITE RJ, 1995, J NEUROSCI, V15, P1318	44	23	24	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0306-4522			NEUROSCIENCE	Neuroscience		2000	95	4					973	979					7	Neurosciences	Neurosciences & Neurology	277EL	WOS:000084919700005	10682704				2021-06-18	
J	Halper, AS; Cherney, LR; Cichowski, K; Zhang, M				Halper, AS; Cherney, LR; Cichowski, K; Zhang, M			Dysphagia after head trauma: The effect of cognitive-communicative impairments on functional outcomes	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cognition; communication; dysphagia; outcomes; swallowing; traumatic brain injury	BRAIN INJURY; NEUROGENIC DYSPHAGIA; ADULTS	This article discusses the impact of cognitive-communicative and behavior problems on oral intake. Data on the swallowing outcomes of a group of patients in an acute rehabilitation facility are presented. These data illustrate the relationships among severity of dysphagia, admission and discharge Functional Independence Measure (FIM(TM)) scores, admission and discharge cognitive FIM(TM) scores and length of stay. Two case studies that describe the effect of cognitive-communicative disorders on dysphagia are provided.	Rehabil Inst Chicago, Educ & Training Ctr, Chicago, IL 60611 USA; Northwestern Univ, Sch Med, Chicago, IL USA; Northwestern Univ, Evanston, IL USA	Halper, AS (corresponding author), Rehabil Inst Chicago, Educ & Training Ctr, 345 E Super, Chicago, IL 60611 USA.						American Speech-Language-Hearing Association, 1987, ASHA, V29, P53; AVERYSMITH W, 1994, AM J OCCUP THER, V48, P235, DOI 10.5014/ajot.48.3.235; BROWN G E, 1992, Dysphagia, V7, P138, DOI 10.1007/BF02493445; Cherney LR, 1996, SEMIN NEUROL, V16, P349, DOI 10.1055/s-2008-1040993; Cherney LR, 1989, J HEAD TRAUMA REHAB, V4, P42; Cherney LR, 1994, CLIN MANAGEMENT DYSP; FIELD LH, 1989, BRAIN INJURY, V3, P9; Hagen C, 1981, TOP LANG DIS, V1, P73; Halper AS, 1991, CLIN MANAGEMENT COMM; LAZARUS C, 1987, ARCH PHYS MED REHAB, V68, P79; Lazarus CL, 1989, J HEAD TRAUMA REHAB, V4, P34; LOGEMANN J A, 1990, Dysphagia, V4, P202, DOI 10.1007/BF02407266; LOGEMANN JA, 1995, J SPEECH HEAR RES, V38, P556, DOI 10.1044/jshr.3803.556; Mackay LE, 1999, ARCH PHYS MED REHAB, V80, P365, DOI 10.1016/S0003-9993(99)90271-X; *REH I CHIC, 1996, REH I CHIC FUNCT ASS; Sohlberg M. M., 1989, INTRO COGNITIVE REHA; *STAT U NEW YORK B, 1996, GUID UN DAT SET MED; TEASDALE G, 1974, LANCET, V2, P81; Tippett DC, 1987, DYSPHAGIA, V1, P221; WINSTEIN CJ, 1983, PHYS THER, V63, P1992, DOI 10.1093/ptj/63.12.1992; YUEN HK, 1992, AM J OCCUP THER, V46, P943, DOI 10.5014/ajot.46.10.943	21	23	26	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	OCT	1999	14	5					486	496		10.1097/00001199-199910000-00009			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	245MW	WOS:000083113600009	10653944				2021-06-18	
J	Goozee, JV; Murdoch, BE; Theodoros, DG				Goozee, JV; Murdoch, BE; Theodoros, DG			Electropalatographic assessment of articulatory timing characteristics in dysarthria following traumatic brain injury	JOURNAL OF MEDICAL SPEECH-LANGUAGE PATHOLOGY			English	Article							CLOSED-HEAD INJURY; EPG DATA REDUCTION; SPEECH DISORDERS; VOWEL DISTORTION; SPEAKERS; CONTACT	Electropalatography (EPG) is an instrumental technique that records the location and timing of tongue-to-palate contacts during speech (Hardcastle, 1984; Hardcastle, Gibbon, & Jones, 1991a; Hardcastle, Jones, Knight, Trudgeon, & Calder, 1989). Such a technique would be valuable in objectively assessing the articulatory disturbances exhibited by individuals with dysarthria following traumatic brain injury (TBI). To date, however, only a limited number of studies have reported using EPG for this purpose. The aims of the present study were to use EPG to assess the articulatory timing characteristics exhibited by three male subjects (aged 23, 27, and 29 years) with dysarthria following severe TBI and to examine the EPG results in relation to perceptual and physiological (nonspeech) findings. A word list, consisting of the lingual consonants, / t, d, s, z, k, g /, in the word-initial position of single-syllable real words of CV and CVC construction (where V = / a /), was read aloud three times by each subject while wearing an EPG palate. The results obtained by the TBI subjects were compared with a non-neurologically impaired control and are discussed in a series of three case discussions. Both longer and shorter consonant phase durations were exhibited, as were the features of undershooting and overshooting. The findings demonstrated that electropalatography provides greater insight into the nature of the underlying articulatory disturbances exhibited by individuals with dysarthria following TBI.	Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, St Lucia, Qld 4067, Australia	Murdoch, BE (corresponding author), Univ Queensland, Dept Speech Pathol & Audiol, Motor Speech Res Unit, St Lucia, Qld 4067, Australia.		Theodoros, Deborah/F-1362-2010; Murdoch, Bruce E/C-1397-2012				BARLOW SM, 1988, ASS RES OT ABSTR, V11, P218; BARRY RM, 1993, CLIN LINGUIST PHONET, V7, P275, DOI 10.1080/02699209308985567; BARRY RM, 1995, CLIN LINGUIST PHONET, V9, P311, DOI 10.3109/02699209508985339; BARRY RM, 1995, CASE STUDIES CLIN LI, P181; Byrd D, 1996, J PHONETICS, V24, P209, DOI 10.1006/jpho.1996.0012; BYRD D, 1995, J SPEECH HEAR RES, V38, P821, DOI 10.1044/jshr.3804.821; DAGENAIS PA, 1994, J PHONETICS, V22, P225, DOI 10.1016/S0095-4470(19)30202-5; DAGENAIS PA, 1995, J COMMUN DISORD, V28, P303, DOI 10.1016/0021-9924(95)00059-1; Darley F., 1975, MOTOR SPEECH DISORDE; DOCHERTY G, 1993, SPEECH RES LAB WORK, V7, P8; Duffy J. R., 2020, MOTOR SPEECH DISORDE; DWORKIN JP, 1986, J COMMUN DISORD, V19, P115, DOI 10.1016/0021-9924(86)90015-8; FLETCHER SG, 1989, J SPEECH HEAR RES, V32, P736, DOI 10.1044/jshr.3204.736; FLETCHER SG, 1991, J ACOUST SOC AM, V89, P850, DOI 10.1121/1.1894646; GOLDSTEIN P, 1994, CLIN LINGUIST PHONET, V8, P201, DOI 10.3109/02699209408985307; HARDCASTLE W, 1989, CLIN LINGUIST PHONET, V3, P1, DOI 10.3109/02699208908985268; HARDCASTLE W, 1976, PHYSL SPEECH PRODUCT; HARDCASTLE WJ, 1991, J PHONETICS, V19, P251, DOI 10.1016/S0095-4470(19)30343-2; HARDCASTLE WJ, 1991, BRIT J DISORD COMMUN, V26, P41; HARDCASTLE WJ, 1985, BRIT J DISORD COMMUN, V20, P249; HARDCASTLE WJ, 1984, PHONETICS LABORATORY, V4, P1; HARDCASTLE WJ, 1997, INSTRUMENTAL CLIN PH, P149; HIROSE H, 1986, FOLIA PHONIATR, V38, P61, DOI 10.1159/000265824; KENT RD, 1975, J SPEECH HEAR DISORD, V40, P467, DOI 10.1044/jshd.4004.467; Linebaugh C. E., 1984, DYSARTHRIAS PHYSL AC, P197; Marquardt TP, 1990, TRAUMATIC BRAIN INJU, P181; MCCLEAN MD, 1987, J SPEECH HEAR RES, V30, P276, DOI 10.1044/jshr.3002.276; Murdoch B. E., 1987, AUSTR J HUMAN COMMUN, V15, P15; NETSELL R, 1975, J SPEECH HEAR DISORD, V40, P170, DOI 10.1044/jshd.4002.170; NGUYEN N, 1996, QMC WORKING PAPERS S, V1, P5; Peterson H. A., 1994, APPRAISAL DIAGNOSIS; ROBIN DA, 1991, DYSARTHRIA AND APRAXIA OF SPEECH, P173; THEODOROS DG, 1994, BRAIN INJURY, V8, P101, DOI 10.3109/02699059409150963; THEODOROS DG, 1995, BRAIN INJURY, V9, P237, DOI 10.3109/02699059509008196; THOMPSON BE, 1984, EXP FLUIDS, V2, P47; VOGEL M, 1983, FOLIA PHONIATR, V35, P294, DOI 10.1159/000265705; Yorkston K.M., 1981, ASSESSMENT INTELLIGI; ZIEGLER W, 1986, BRIT J DISORD COMMUN, V21, P173; ZIEGLER W, 1983, PHONETICA, V40, P63; ZIEGLER W, 1983, PHONETICA, V40, P312, DOI 10.1159/000261698	40	23	23	0	2	SINGULAR PUBLISHING GROUP INC	SAN DIEGO	401 WEST A ST, STE 325, SAN DIEGO, CA 92101-7904 USA	1065-1438			J MED SPEECH-LANG PA	J. Med. Speech-Lang. Pathol.	SEP	1999	7	3					209	222					14	Audiology & Speech-Language Pathology; Clinical Neurology	Audiology & Speech-Language Pathology; Neurosciences & Neurology	235JJ	WOS:000082538300004					2021-06-18	
J	Newburn, G; Edwards, R; Thomas, H; Collier, J; Fox, K; Collins, C				Newburn, G; Edwards, R; Thomas, H; Collier, J; Fox, K; Collins, C			Moclobemide in the treatment of major depressive disorder (DSM-3) following traumatic brain injury	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; SOCIAL-ADJUSTMENT; CHRONIC PAIN; MOOD; REHABILITATION; AMITRIPTYLINE; COMPLAINTS; FLUOXETINE; RELATIVES; SEQUELAE	Major depression (MDD) following traumatic brain injury (TBI) is a common phenomenon. There are no adequate studies in the literature defining optimum treatments for this condition following TBI. The opportunity arose to analyse a group of patients who were included in a larger study of an antidepressant (moclobemide). As the treatment, but not the delivery, was known, this has the status of an open study. Twenty-six patients with major depression of late onset (mean 4.67 years post-TBI) were identified (18 male, 8 female), with a mean age at injury 28.49 years. The group was moderately depressed with Hamilton Depression score (HAM-D) of 23.385 and moderately anxious with Hamilton Anxiety score (HAM-A) of 21.231. Mean HAM-D reduction was 81% and HAM-A reduction 81%. Of the 26 subjects 23 were defined as responders. Onset of action was rapid, with 17 responding by day 3. Irritability scores showed a mean reduction of 57% and pain scores a reduction of 39%. It is concluded that moclobemide may be an effective treatment for MDD following TBI, but properly controlled studies must be carried out to confirm this.	Rotorua Rehabil Ctr, Rotorua, New Zealand; Mem Hosp, Dept Psychiat, Hastings, New Zealand; Anglesea Clin, Hamilton, New Zealand; Sunnyside Hosp, Christchurch, New Zealand	Newburn, G (corresponding author), Rotorua Rehabil Ctr, POB 614, Rotorua, New Zealand.						Beetar JT, 1996, ARCH PHYS MED REHAB, V77, P1298, DOI 10.1016/S0003-9993(96)90196-3; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; CASSIDY JW, 1989, J HEAD TRAUMA REHAB, V4, P67; Da Prada M, 1988, J Neural Transm Suppl, V26, P31; DINAN TG, 1992, ACTA PSYCHIAT SCAND, V85, P292, DOI 10.1111/j.1600-0447.1992.tb01472.x; FAVA M, 1991, PSYCHOPHARMACOL BULL, V27, P275; FEDEROFF JP, 1992, AM J PSYCHIAT, V149, P918; Gualtari CT, 1991, BRAIN INJURY, V5, P219; JACOBS HE, 1988, ARCH PHYS MED REHAB, V69, P425; JORGE RE, 1993, J NEUROPSYCH CLIN N, V5, P43; JORGE RE, 1993, J NERV MENT DIS, V181, P91, DOI 10.1097/00005053-199302000-00004; JORGE RE, 1993, J AFFECT DISORDERS, V27, P233, DOI 10.1016/0165-0327(93)90047-N; KINSELLA G, 1988, PSYCHOL MED, V18, P57, DOI 10.1017/S0033291700001884; KRAGHSORENSEN P, 1995, J CLIN PSYCHOPHAR S2, V15, P24; Lahz S, 1996, ARCH PHYS MED REHAB, V77, P889, DOI 10.1016/S0003-9993(96)90275-0; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; MCKINLAY WW, 1981, J NEUROL NEUROSUR PS, V44, P527, DOI 10.1136/jnnp.44.6.527; NEWBURN GM, 1990, AUST NZ J PSYCHIAT, V24, P475, DOI 10.3109/00048679009062902; NEWBURN GM, 1995, J CLIN PSYCHOPHAR S2, V15, P10; ODDY M, 1985, J NEUROL NEUROSUR PS, V48, P564, DOI 10.1136/jnnp.48.6.564; PRIGITANO GP, 1986, NEUROPSYCHOLOGICAL R; ROBINSON RG, 1981, ANN NEUROL, V9, P447, DOI 10.1002/ana.410090506; Robinson Robert G., 1994, P219; ROSE ED, 1981, ARCH GEN PSYCHIAT, V38, P1344; RUTHERFORD WH, 1977, LANCET, V1, P1; SARAN AS, 1985, J CLIN PSYCHIAT, V46, P335; SCHALEN W, 1994, BRAIN INJURY, V8, P49, DOI 10.3109/02699059409150958; SCHOENHUBER R, 1988, J NEUROL NEUROSUR PS, V51, P722, DOI 10.1136/jnnp.51.5.722; Silver J. M., 1991, NEUROPSY NEUROPSY BE, V4, P12; SILVER JM, 1992, AM PSYCHIAT PRESS TX, P363; STARKSTEIN SE, 1987, BRAIN, V110, P1045, DOI 10.1093/brain/110.4.1045; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; TYERMAN A, 1984, INT J REHABIL RES, V7, P11, DOI 10.1097/00004356-198403000-00002; UOMOTO JM, 1993, ARCH PHYS MED REHAB, V74, P61; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; Varney NR, 1987, NEUROPSYCHOLOGY, V1, P7, DOI 10.1037//0894-4105.1.1.7; VERSIANI M, 1989, BRIT J PSYCHIAT, V155, P72, DOI 10.1192/S0007125000297523; WEDDELL R, 1980, PSYCHOL MED, V10, P257, DOI 10.1017/S0033291700044019; WILLIAMS R, 1993, INT CLIN PSYCHOPHARM, V7, P155, DOI 10.1097/00004850-199300730-00006	40	23	23	0	4	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	AUG	1999	13	8					637	642					6	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	239YW	WOS:000082799200007	10901691				2021-06-18	
J	Shimonkevitz, R; Bar-Or, D; Harris, L; Dole, K; McLaughlin, L; Yukl, R				Shimonkevitz, R; Bar-Or, D; Harris, L; Dole, K; McLaughlin, L; Yukl, R			Transient monocyte release of interleukin-10 in response to traumatic brain injury	SHOCK			English	Article						cytokines; trauma; traumatic brain injury; monocyte; IL-10; IFN gamma; TGF beta	HEAD-INJURY; CYTOKINE PRODUCTION; CELLS; ACTIVATION; EXPRESSION; PATTERNS; SEVERITY; HUMANS; TISSUE; SEPSIS	A significant component of the immune response to trauma results in the systemic presence of cytokines which have the potential to suppress the patient's immune response to infection and contribute to post-injury complications. We assayed peripheral blood leukocytes obtained from 10 patients with head trauma to determine their production of interleukin (IL). Serum was assayed for the presence of IL-10, TGF beta(1), and IFN gamma by ELISA. Peripheral blood leukocytes were screened for intracellular IL-10 and lFN gamma by fluorescence-activated flow cytometry, and cytokine-specific mRNA was detected by the polymerase chain reaction. We detected an immediate, but transient, presence of IL-10 in the sera of all 10 patients who suffered head trauma. IL-10-specific intracytoplasmic immunofluorescence was also detected immediately after injury in peripheral blood monocytes, but not in lymphocytes or granulocytes. IL-10-specific mRNA was detected in peripheral blood leukocytes in only 50% of patients immediately after injury, when the highest serum levels of IL-10 were observed. Our data indicates that release of pre-formed IL-10 by monocytes contributes to the presence of IL-10 found in patient peripheral blood immediately after head injury.	Swedish Med Ctr, HealthOne, Trauma Res Dept, Englewood, CO 80110 USA; Swedish Med Ctr, HealthOne, Trauma Serv, Englewood, CO 80110 USA	Shimonkevitz, R (corresponding author), Swedish Med Ctr, HealthOne, Trauma Res Dept, Room 4-454,501 E Hampden Ave, Englewood, CO 80110 USA.		Bar-Or, David/AAE-9328-2020				Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; CHERNOFF AE, 1995, J IMMUNOL, V154, P5492; CIOFFI WG, 1993, ARCH SURG-CHICAGO, V128, P1260; CRARY B, 1983, J IMMUNOL, V131, P1178; De AK, 1997, CLIN IMMUNOL IMMUNOP, V82, P73, DOI 10.1006/clin.1996.4289; DONNELLY SC, 1994, RESUSCITATION, V28, P87, DOI 10.1016/0300-9572(94)90077-9; Dutcher SA, 1998, J NEUROTRAUM, V15, P411, DOI 10.1089/neu.1998.15.411; FIORENTINO DF, 1989, J EXP MED, V170, P2081, DOI 10.1084/jem.170.6.2081; FIORENTINO DF, 1991, J IMMUNOL, V146, P3444; Groux H, 1996, J EXP MED, V184, P19, DOI 10.1084/jem.184.1.19; Hauser CJ, 1997, J TRAUMA, V42, P895, DOI 10.1097/00005373-199705000-00021; HAUSER CJ, 1995, SHOCK, V4, P247, DOI 10.1097/00024382-199510000-00003; HERSHMAN MJ, 1990, BRIT J SURG, V77, P204, DOI 10.1002/bjs.1800770225; HOYT DB, 1990, J TRAUMA, V30, P759, DOI 10.1097/00005373-199007000-00001; Knoblach SM, 1998, EXP NEUROL, V153, P143, DOI 10.1006/exnr.1998.6877; Lindner H, 1997, TRANSPLANTATION, V64, P1370, DOI 10.1097/00007890-199711150-00023; MorgantiKossman MC, 1997, MOL PSYCHIATR, V2, P133, DOI 10.1038/sj.mp.4000227; Neidhardt R, 1997, J TRAUMA, V42, P863, DOI 10.1097/00005373-199705000-00017; OTT L, 1994, J NEUROTRAUM, V11, P447, DOI 10.1089/neu.1994.11.447; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; Puyana JC, 1998, J TRAUMA, V44, P1037, DOI 10.1097/00005373-199806000-00017; Selzman CH, 1998, SHOCK, V10, P309, DOI 10.1097/00024382-199811000-00001; Sherry RM, 1996, J TRAUMA, V40, P613, DOI 10.1097/00005373-199604000-00016; Thornton FJ, 1997, SHOCK, V8, P391, DOI 10.1097/00024382-199712000-00001; Woiciechowsky C, 1998, NAT MED, V4, P808, DOI 10.1038/nm0798-808	25	23	23	0	0	BIOMEDICAL PRESS	AUGUSTA	1021 15TH ST, BIOTECH PARK STE 9,, AUGUSTA, GA 30901 USA	1073-2322			SHOCK	Shock	JUL	1999	12	1					10	16		10.1097/00024382-199907000-00002			7	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	216BQ	WOS:000081421000002	10468046				2021-06-18	
J	Ishikawa, K; Tanaka, H; Takaoka, M; Ogura, H; Shiozaki, T; Hosotsubo, H; Shimazu, T; Yoshioka, T; Sugimoto, H				Ishikawa, K; Tanaka, H; Takaoka, M; Ogura, H; Shiozaki, T; Hosotsubo, H; Shimazu, T; Yoshioka, T; Sugimoto, H			Granulocyte colony-stimulating factor ameliorates life-threatening infections after combined therapy with barbiturates and mild hypothermia in patients with severe head injuries	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	58th Annual Meeting of the American-Association-for-the-Surgery-of-Trauma/Trauma-Association-of-Canada	SEP 24-27, 1998	BALTIMORE, MD	Amer Assoc Surg Trauma, Trauma Assoc Canada		granulocyte colony-stimulating factor (G-CSF); head injury; infection; leukopenia; hypothermia	TRAUMATIC BRAIN INJURY; NEUTROPHIL MIGRATION; MODERATE HYPOTHERMIA; CHEMI-LUMINESCENCE; SEPSIS; ACCUMULATION; SUPPRESSION; VOLUNTEERS; FILGRASTIM; MODULATION	Objective: The objective of this study was to clarify the effects of recombinant human granulocyte colony-stimulating factor (rhG-CSF) administration on infections in patients with severe head injuries after combined therapy with high-dose barbiturates and mild hypothermia. Patients and Methods: Since 1996, we have administered rhG-CSF to eight patients with severe head injuries for 5 days (group G), Their treatment results were compared with those of 22 patients cared for earlier without rhG-CSF treatment (group N), All patients in both groups met the criteria of total leukocyte count (TLC) less than 5,000/mm(3), C-reactive protein (CRP) over 10 mg/dL, and the presence of an infectious complication. Changes in the TLC, CRP, respiratory index, intracranial pressure, and infectious condition were evaluated in both groups. In addition, the nucleated cell count a:nd differentiation from bone marrow aspiration, neutrophil functions, serum concentrations of interleukin-6, and plasma concentration of leukocyte elastase were evaluated in group G, Results: In group G, TLC, nucleated cell count, and neutrophil functions significantly increased, whereas CRP, respiratory index, and interleukin-6 decreased reciprocally. There was no deterioration of intracranial pressure and leukocyte elastase, Consequently, seven of the eight patients in group G recovered from life-threatening infections, and none of the eight patients died. However, in group N, CRP and respiratory index remained high and TLC did not increase as much as it did in group G, Infections continued after 5 days in 17 of the 22 patients, 7 of whom died from severe infections during hospitalization, Conclusion: Administration of rhG-CSF ameliorated life-threatening infections without causing lung injury or increasing brain swelling in patients with severe head injuries who were treated with combined therapy involving high-dose barbiturates and mild hypothermia.	Osaka Univ, Sch Med, Dept Traumatol, Suita, Osaka 5650871, Japan; Osaka Prefectural Nakakawachi Med Ctr Acute Med, Osaka, Japan; Osaka Prefectural Gen Hosp, Dept Emergency Med, Osaka, Japan	Ishikawa, K (corresponding author), Osaka Univ, Sch Med, Dept Traumatol, 2-15 Yamadaoka, Suita, Osaka 5650871, Japan.						BIAGAS KV, 1992, J NEUROTRAUM, V9, P363, DOI 10.1089/neu.1992.9.363; BIGGAR WD, 1986, J APPL PHYSIOL, V60, P1186; BIGGAR WD, 1984, INFECT IMMUN, V46, P857, DOI 10.1128/IAI.46.3.857-859.1984; BIGGAR WD, 1983, INFECT IMMUN, V40, P708, DOI 10.1128/IAI.40.2.708-712.1983; BOHN DJ, 1986, CRIT CARE MED, V14, P529, DOI 10.1097/00003246-198606000-00002; CANCIO LC, 1994, RESUSCITATION, V28, P9, DOI 10.1016/0300-9572(94)90049-3; CLIFTON GL, 1993, J NEUROTRAUM, V10, P263, DOI 10.1089/neu.1993.10.263; DALE DC, 1995, J INFECT DIS, V172, P1061, DOI 10.1093/infdis/172.4.1061; DEHAAS M, 1994, BLOOD, V84, P3885, DOI 10.1182/blood.V84.11.3885.bloodjournal84113885; Esposito C, 1998, CRIT CARE MED, V26, P636, DOI 10.1097/00003246-199804000-00005; FREWEN TC, 1982, J PEDIATR-US, V100, P663, DOI 10.1016/S0022-3476(82)80782-8; GABRILOVE JL, 1988, J CLIN INVEST, V82, P1454, DOI 10.1172/JCI113751; GILMORE GL, 1995, EXP HEMATOL, V23, P1319; GOLDFARB MA, 1975, AM J SURG, V129, P255, DOI 10.1016/0002-9610(75)90234-2; GORGEN I, 1992, J IMMUNOL, V149, P918; HARTUNG T, 1995, BLOOD, V85, P2482, DOI 10.1182/blood.V85.9.2482.bloodjournal8592482; HARTUNG T, 1997, SHOCK S1, V7, P81; Heard SO, 1998, CRIT CARE MED, V26, P748, DOI 10.1097/00003246-199804000-00027; Ishikawa K, 1998, J TRAUMA, V44, P1047, DOI 10.1097/00005373-199806000-00018; ISHIKAWA K, 1997, 4 INT C IMM CONS TRA, P661; KAWAKAMI M, 1990, BLOOD, V76, P1962; KRESS HG, 1989, ACTA ANAESTH SCAND, V33, P122, DOI 10.1111/j.1399-6576.1989.tb02873.x; Kurz A, 1996, NEW ENGL J MED, V334, P1209, DOI 10.1056/NEJM199605093341901; LIESCHKE GJ, 1992, NEW ENGL J MED, V327, P99; Mamelak AN, 1996, J TRAUMA, V41, P91, DOI 10.1097/00005373-199607000-00014; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; MATSUO Y, 1994, STROKE, V25, P1469, DOI 10.1161/01.STR.25.7.1469; METCALF D, 1991, SCIENCE, V254, P529, DOI 10.1126/science.1948028; MOONEY DP, 1988, ARCH SURG-CHICAGO, V123, P1353; MOORE MAS, 1991, ANNU REV IMMUNOL, V9, P159; NEUWELT EA, 1982, J NEUROSURG, V56, P254, DOI 10.3171/jns.1982.56.2.0254; Niitsu N, 1997, BRIT J CANCER, V76, P1661, DOI 10.1038/bjc.1997.614; OREILLY M, 1992, J TRAUMA, V33, P679, DOI 10.1097/00005373-199211000-00014; Pajkrt D, 1997, BLOOD, V90, P1415, DOI 10.1182/blood.V90.4.1415.1415_1415_1424; Patton JH, 1998, J TRAUMA, V44, P750, DOI 10.1097/00005373-199805000-00002; ROILIDES E, 1991, J INFECT DIS, V163, P579, DOI 10.1093/infdis/163.3.579; SCHALEN W, 1992, ACTA ANAESTH SCAND, V36, P369, DOI 10.1111/j.1399-6576.1992.tb03483.x; Schops P, 1997, PHYS MED REHAB KUROR, V7, P80, DOI 10.1055/s-2008-1061865; SHENAQ SA, 1986, ANN CLIN LAB SCI, V16, P130; Shiozaki T, 1998, J NEUROSURG, V89, P206, DOI 10.3171/jns.1998.89.2.0206; SHIOZAKI T, 1993, J NEUROSURG, V79, P363, DOI 10.3171/jns.1993.79.3.0363; Tanaka H, 1996, J TRAUMA, V40, P718, DOI 10.1097/00005373-199605000-00006; TEASDALE G, 1974, LANCET, V2, P81; UHL MW, 1994, J NEUROTRAUM, V11, P303, DOI 10.1089/neu.1994.11.303; VALERIUS T, 1993, BLOOD, V82, P931; vanEeden SF, 1997, AM J PHYSIOL-HEART C, V272, pH1717; WEISBART RH, 1988, NATURE, V332, P647, DOI 10.1038/332647a0; Weiss M, 1996, CYTOKINE, V8, P260, DOI 10.1006/cyto.1996.0035; WHITE IWC, 1983, CAN ANAESTH SOC J, V30, P506, DOI 10.1007/BF03007085	50	23	23	0	0	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0022-5282	1529-8809		J TRAUMA	J. Trauma-Injury Infect. Crit. Care	JUN	1999	46	6					999	1007		10.1097/00005373-199906000-00004			9	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	205BR	WOS:000080801900005	10372615				2021-06-18	
J	Carson, JD; Roberts, MA; White, AL				Carson, JD; Roberts, MA; White, AL			The epidemiology of women's rugby injuries	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						epidemiology; rugby; women, wounds and injuries	SOCCER; BASKETBALL; PLAYERS	Objective: The purpose of this study was to identify all injuries to members of an elite women's rugby team and to compare these injuries with published data on injuries in other women's contact and collision sports. Design: This was a prospective cohort observational study conducted using a monthly log completed by the team's certified athletic therapist to closely monitor attendance at practices and games along with the type and severity of injuries. Setting: Rugby games and practices held in Ontario, Quebec, and the Netherlands. Participants: Forty members of the Ontario Women's Senior Provincial Rugby Team over the 1997 season and the 1998 World Championships. Main Outcome Measures: An injury was defined as a rugby-related event that kept a player out of practice or competition for >24 hours or required the attention of a physician (e.g., suturing lacerations) and in addition included all dental, eye, and nerve injuries and concussions. Results: There were a total of 35 injuries in 4,958 player-hours and 2,926 athletic exposures. This resulted in a rugby injury rate of 7.1 +/- 0.4 per 1,000 player-hours and 12.0 +/- 2 per 1,000 athletic exposures. Conclusion: The incidence of injuries in women's rugby is comparable with that in other women's contact and collision sports, indicating that the sport may be safer than stated in the literature and media.	Univ Toronto, Womens Coll Hosp, Sport Ctr Adv Res & Educ, Toronto, ON M5S 1B2, Canada; York Univ, Sports Med Clin, Toronto, ON M3J 2R7, Canada; Univ Waterloo, Fac Appl Hlth Sci, Waterloo, ON N2L 3G1, Canada	Carson, JD (corresponding author), Univ Toronto, Womens Coll Hosp, Sport Ctr Adv Res & Educ, 76 Grenville St, Toronto, ON M5S 1B2, Canada.						ARENDT E, 1995, AM J SPORT MED, V23, P694, DOI 10.1177/036354659502300611; ARENDT EA, 1994, CLIN SPORT MED, V13, P483; CAMPBELL H, 1995, LANCET, V346, P188; CANTU RC, 1986, PHYSICIAN SPORTSMED, V14, P75, DOI 10.1080/00913847.1986.11709197; COAKLEY JJ, 1990, SPORT SOC; ENGSTROM B, 1991, AM J SPORT MED, V19, P372, DOI 10.1177/036354659101900408; GARRAWAY M, 1995, LANCET, V345, P1485; GIBBS N, 1994, SPORTS MED, V18, P438, DOI 10.2165/00007256-199418060-00007; HAGERTY E, 1994, RUGBY, P20; Jakoet I, 1998, S AFR MED J, V88, P45; KUJALA UM, 1995, BRIT MED J, V311, P1465, DOI 10.1136/bmj.311.7018.1465; Levy AS, 1997, AM J SPORT MED, V25, P360, DOI 10.1177/036354659702500315; MEEWISSE WH, 1994, CLIN J SPORT MED, V4, P166; MICHELI LJ, 1989, SPROTS CARE FITNESS, P11; *NAT COLL ATHL ASS, 1994, NCAA REP 1993 94 MEN; *NAT COLL ATHL ASS, 1993, NCAA REP 1992 93 SOF; *NAT COLL ATHL ASS, 1996, NCAA REP 1995 96 SOC; Pieter W., 1994, Journal of Sports Traumatology and Related Research, V16, P49; Silver J R, 1992, Br J Sports Med, V26, P253; STEINBERG P, 1998, RUGBY, P24; WEIR MA, 1996, MED SCI SPORTS EXERC, V28, P1171; Young K., 1995, Journal of Sport and Social Issues, V19, P45, DOI 10.1177/019372395019001004; YOUNG K, 1994, SOCIOL SPORT J, V11, P175, DOI 10.1123/ssj.11.2.175; ZELISKO JA, 1982, AM J SPORT MED, V10, P297, DOI 10.1177/036354658201000507; 1994, RUGBY, V20, P4; 1998, RUGBY, V24, P4	26	23	24	0	3	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	APR	1999	9	2					75	78		10.1097/00042752-199904000-00006			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	216PV	WOS:000081451800006	10442621				2021-06-18	
J	Jeong, BY				Jeong, BY			Comparisons of variables between fatal and nonfatal accidents in manufacturing industry	INTERNATIONAL JOURNAL OF INDUSTRIAL ERGONOMICS			English	Article						accident analysis; manufacturing industry; occupational deaths and injuries	INFORMATION; SYSTEM	This study concerns with the comparisons of variables between fatal and nonfatal accidents in Korean manufacturing industries. The national industrial accident statistics for the years 1991-1994 were extracted from the annual publications of Ministry of Labor. These data were used to compare the distributions of fatal and nonfatal injuries in terms of company size, injured person's age, work experience, accident time, activity at time of accident, accident type, injury type, injured body part, and accident agency. Results show that the distributions of the fatal injuries are statistically different from those of the nonfatal injuries: (1) nonfatal injuries occur more frequently in the younger workers, while deaths occur more frequently in the older workers; (2) the proportion of death occurring in night shift is greater than that of nonfatal injuries; (3) 'caught in and between objects' is the most common type of accident, but the second common type of accident is 'awkward or sudden movement' in the nonfatal injuries, instead of 'falls from a height' in deaths; and (4) 'fracture' is the leading caused injury and death, but the second leading type of injury is 'contusion or bruise' in the nonfatal injuries and 'cerebral concussion' in deaths.	Hansung Univ, Dept Ind Engn, Sungbuk Gu, Seoul 136792, South Korea	Jeong, BY (corresponding author), Hansung Univ, Dept Ind Engn, Sungbuk Gu, 389 Samsun Dong, Seoul 136792, South Korea.		Jeong, Byung Yong/Q-6377-2018	Jeong, Byung Yong/0000-0001-6837-1324			ANDERSSON R, 1983, ERGONOMICS, V26, P33, DOI 10.1080/00140138308963310; BIERINGSORENSEN F, 1985, ERGONOMICS, V28, P5; BUCK PC, 1985, ERGONOMICS, V28, P949, DOI 10.1080/00140138508963217; HETTINGER T, 1985, ERGONOMICS, V28, P17, DOI 10.1080/00140138508963106; Hogg RV., 1997, PROBABILITY STAT INF; Jeong BY, 1997, INT J IND ERGONOM, V20, P301; METZLER F, 1985, ERGONOMICS, V28, P21, DOI 10.1080/00140138508963107; *MIN LAB, 1972, ANN AN IND ACC; NICHOLSON AS, 1985, ERGONOMICS, V28, P31, DOI 10.1080/00140138508963109; Surry J, 1968, IND ACCIDENT RES HUM; ZUIDEMA H, 1985, ERGONOMICS, V28, P45, DOI 10.1080/00140138508963110	11	23	23	0	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0169-8141			INT J IND ERGONOM	Int. J. Ind. Ergon.	MAR 20	1999	23	5-6					565	572					8	Engineering, Industrial; Ergonomics	Engineering	162XP	WOS:000078372700019					2021-06-18	
J	Beardmore, S; Tate, R; Liddle, B				Beardmore, S; Tate, R; Liddle, B			Does information and feedback improve children's knowledge and awareness of deficits after traumatic brain injury?	NEUROPSYCHOLOGICAL REHABILITATION			English	Article							HEAD-INJURY; DYSFUNCTION; SEQUELAE; SCALE	A frequent observation in adults suffering severe traumatic brain injury (TBI) is that many minimise or appear unaware of their deficits. Few data exist for children, but an initial study by Jacobs (1993) found that knowledge in children after TBI was poor, and this raised issues relating to awareness of deficit. The present study had two aims: (1) to investigate the extent of deficient knowledge and awareness in children and adolescents after severe TBI; (2) to develop an intervention designed to improve knowledge of TBI and awareness of deficit and evaluate its efficacy. Initial evaluation with 21 participants, aged between 9 and 16 years, found a very poor understanding of TBI and some were unaware of their deficits. Subjects were randomly assigned to either an injury-information or attention-placebo session. The results of two-way repeated-measures analyses of variance indicated that the intervention session was not successful in increasing the children's knowledge or awareness of deficit. These findings are discussed in the context of possible causes of poor knowledge and unawareness and implications for rehabilitation practice.	Univ Sydney, Dept Psychol, Sydney, NSW 2006, Australia; Royal N Shore Hosp, Sydney, NSW, Australia							Abidin R.R., 1990, PARENTING STRESS IND; Achenbach T. M., 1991, MANUAL CHILD BEHAV C; *AUSTR COMM REH SE, 1993, ACQ BRAIN IMP INF PA; BEAUMONT M, EPILEPSY ED MANUAL T; BERNARD ME, 1987, YOU CAN DO WHAT EVER; BOGAN J, 1991, STUDENT BRAIN INJURY; BURBACH DJ, 1986, HEALTH PSYCHOL, V5, P307, DOI 10.1037/0278-6133.5.3.307; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Chittum WR, 1996, BRAIN INJURY, V10, P763; CRAFT AW, 1975, HDB CLIN NEUROLOGY, V23, P445; FAY GC, 1994, ARCH PHYS MED REHAB, V75, P733; Fleming JM, 1996, BRAIN INJURY, V10, P1; FLETCHER JM, 1988, HDB PEDIATRIC PSYCHO, P258; FORDYCE DJ, 1986, REHABIL PSYCHOL, V31, P217, DOI 10.1037//0090-5550.31.4.217; GODFREY HPD, 1993, J CLIN EXP NEUROPSYC, V15, P503, DOI 10.1080/01688639308402574; *HEAD INJ COUNC AU, 1994, BRAIN INJ INF KIT; *HEADW QUEENSL INC, CHILDR HEAD INJ SER; *HUNT BRAIN INJ RE, 1996, WHY DID HAV HAPP OUR; JACOBS MP, 1993, NEUROPSYCHOL REHABIL, V3, P341, DOI 10.1080/09602019308401446; JOHNSON CN, 1982, CHILD DEV, V53, P222, DOI 10.2307/1129656; JOHNSON DA, 1992, BRIT J EDUC PSYCHOL, V62, P404, DOI 10.1111/j.2044-8279.1992.tb01033.x; KLONOFF H, 1993, J NEUROL NEUROSUR PS, V56, P410, DOI 10.1136/jnnp.56.4.410; Langer K.G., 1992, NEUROPSYCHOL REHABIL, V2, P59, DOI [https://doi.org/10.1080/09602019208401395, DOI 10.1080/09602019208401395]; LEHMKUHL G, 1990, BRAIN BEHAV CHILD PS, P267; MAROSSZEKY NEV, 1993, CLIN NEUROPSYCHOL, V7, P85, DOI 10.1080/13854049308401890; MCGLYNN SM, 1989, J CLIN EXP NEUROPSYC, V11, P143, DOI 10.1080/01688638908400882; NEUHAUSER C, 1978, AM J ORTHOPSYCHIAT, V48, P335, DOI 10.1111/j.1939-0025.1978.tb01321.x; NOCKLEBY DM, 1987, INT J CLIN NEUROPSYC, V9, P145; ODDY M, 1993, NEUROPSYCHOL REHABIL, V3, P301, DOI 10.1080/09602019308401444; PERROTT SB, 1991, DEV NEUROPSYCHOL, V7, P69, DOI 10.1080/87565649109540477; PIERS EV, 1984, PIERSHARRIS CHILDREN; Prigatano G. P., 1990, CLIN NEUROPSYCHOL, V4, P163, DOI [10.1080/13854049008401509, DOI 10.1080/13854049008401509]; Prigatano GP, 1986, NEUROPSYCHOL REHABIL, P96; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; SPIRITO A, 1988, J PEDIATR PSYCHOL, V13, P555, DOI 10.1093/jpepsy/13.4.555; Stuss DT., 1991, AWARENESS DEFICIT BR, P63; Wilson B. A., 1985, RIVERMEAD BEHAV MEMO	38	23	23	0	4	PSYCHOLOGY PRESS	HOVE	27 CHURCH RD, HOVE BN3 2FA, EAST SUSSEX, ENGLAND	0960-2011			NEUROPSYCHOL REHABIL	Neuropsychol. Rehabil.	JAN	1999	9	1					45	62		10.1080/713755588			18	Neurosciences; Psychology	Neurosciences & Neurology; Psychology	159ZG	WOS:000078205400003					2021-06-18	
S	Filbert, MG; Forster, JS; Smith, CD; Ballough, GPH		Trembly, B; Slikker, W		Filbert, MG; Forster, JS; Smith, CD; Ballough, GPH			Neuroprotective effects of HU-211 on brain damage resulting from soman-induced seizures	NEUROPROTECTIVE AGENTS: FOURTH INTERNATIONAL CONFERENCE	ANNALS OF THE NEW YORK ACADEMY OF SCIENCES		English	Article; Proceedings Paper	4th International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	NOV 15-19, 1998	ANNAPOLIS, MARYLAND	US FDA, Natl Ctr Toxicol Res, Dept Vet Affairs Med Ctr			CLOSED-HEAD INJURY; MICROTUBULE-ASSOCIATED PROTEIN-2; NMDA ANTAGONIST; RAT-BRAIN; IMMUNOREACTIVITY; PROTECTS; LIGHT	Neuroprotective effects of HU-211 (dexanabinol), a synthetic nonpsychotropic analog of tetrahydrocannabinol, on brain damage resulting from soman-induced seizures were examined in male Sprague-Dawleg rats challenged with 1.6 LD50 soman, At 5 or 40 min after onset of seizures, the rats were given an intraperitoneal injection of 25 mg/kg HU-211, All, rats that received soman showed electrocorticographic (ECoG) evidence of sustained: seizures and status epilepticus for 4-6 hr, HU-211 had no effect: on either the strength or duration of seizure activity, Administration of HU-211 at 5 min after seizure onset reduced median lesion volume 86% (as assessed by microtubule-associated protein 2 (MAP2)-negative staining), and when administered 40 min post-onset, the reduction in necrosis was 81.5% despite the presence of continuous seizures for 4-5 hr, These observations were corroborated by hemotoxylin and eosin (H&E) histopathological assessment that showed a significant reduction in piriform cortical neuronal damage in HU-211-treated animals, It is concluded that HU-211 provides considerable neuroprotection against brain damage produced by soman-induced seizures.	USA, Med Res Inst Chem Def, Aberdeen Proving Ground, MD 21010 USA	Filbert, MG (corresponding author), USA, Med Res Inst Chem Def, 3100 Ricketts Point Rd, Aberdeen Proving Ground, MD 21010 USA.						BALLOUGH GPH, 1995, J NEUROSCI METH, V61, P23, DOI 10.1016/0165-0270(95)00019-Q; Ballough GPH, 1998, MOL CHEM NEUROPATHOL, V34, P1, DOI 10.1007/BF02815133; BARJOSEPH A, 1994, MOL CHEM NEUROPATHOL, V23, P125, DOI 10.1007/BF02815406; BERNHARDT R, 1984, J COMP NEUROL, V226, P203, DOI 10.1002/cne.902260205; BIEGON A, 1995, NEUROL RES, V17, P275, DOI 10.1080/01616412.1995.11740326; BRAITMAN DJ, 1989, BRAIN RES BULL, V23, P145, DOI 10.1016/0361-9230(89)90173-1; CLIFFORD D, 1989, EXP NEUROL, V10, P272; CLIFFORD DB, 1990, EPILEPSIA, V31, P382, DOI 10.1111/j.1528-1157.1990.tb05492.x; ESHHAR N, 1995, EUR J PHARMACOL, V283, P19, DOI 10.1016/0014-2999(95)00271-L; ESHHAR N, 1993, NEUROREPORT, V5, P237, DOI 10.1097/00001756-199312000-00013; FIX AS, 1993, EXP NEUROL, V123, P204, DOI 10.1006/exnr.1993.1153; HICKS RR, 1995, BRAIN RES, V678, P151, DOI 10.1016/0006-8993(95)00179-T; HSU SM, 1981, J HISTOCHEM CYTOCHEM, V29, P577, DOI 10.1177/29.4.6166661; LABRUYERE J, 1986, Society for Neuroscience Abstracts, V12, P344; Matus Andrew, 1994, V13, P155; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; OLNEY JW, 1983, NATURE, V301, P520, DOI 10.1038/301520a0; Shih TM, 1997, J APPL TOXICOL, V17, P255, DOI 10.1002/(SICI)1099-1263(199707)17:4<255::AID-JAT441>3.0.CO;2-D; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; Shohami E, 1997, J CEREBR BLOOD F MET, V17, P1007, DOI 10.1097/00004647-199710000-00002; SMITH G G, 1987, Society for Neuroscience Abstracts, V13, P1031; SPARENBORG S, 1992, NEUROPHARMACOLOGY, V31, P357, DOI 10.1016/0028-3908(92)90068-Z; Striem S., 1996, Society for Neuroscience Abstracts, V22, P196; TAYLOR P, 1996, PHARMACOL BASIS THER, P161; WATSON RE, 1986, PEPTIDES, V7, P155, DOI 10.1016/0196-9781(86)90076-8	25	23	23	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-222-3	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1999	890						505	514		10.1111/j.1749-6632.1999.tb08032.x			10	Biochemistry & Molecular Biology; Multidisciplinary Sciences; Clinical Neurology; Pharmacology & Pharmacy	Biochemistry & Molecular Biology; Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BP50F	WOS:000085330700048	10668456				2021-06-18	
J	Potter, DD; Barrett, K				Potter, DD; Barrett, K			Assessment of mild head injury with ERPs and neuropsychological tasks	JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						head injury; attention; memory; P3b; P3a; Nd; PASAT	EVENT-RELATED POTENTIALS; AUDITORY ODDBALL TASK; SEQUELAE; SYMPTOMS; CONCUSSION; ATTENTION; P300; DEFICITS; MEMORY	Mild head injury can result in the development of persistent symptoms including impairments of memory and: attention in a small but significant minority. The problem in assessing these difficulties in such cases is the likely interaction of psychogenic and organic causes. The aim of the present research:is to more,accurately characterize the nature of these cognitive deficits. Twelve asymptomatic volunteers, who;had experienced a mild head injury in the last 3.5 years, were compared to a matched control group. ERPs were recorded during the performance of the paced auditory serial addition task (PASAT) and a 3-stimulus auditory "oddball" task. Verbal paired associate, Trails A and B, Digit Symbol, Rey Figure Recall, NART, and Digit Span were also administered. The mild head injured group showed evidence of a mild impairment of episodic memory, slowing of attention shifting, but no changes in reaction time or error rates in either the "oddball" task or the PASAT. Although there was no-evidence of impairment of brain orienting responses in the 3-stimulus auditory oddball task there was evidence of reduced frontal negativity associated with changes in task demand in the PASAT This particular ERP feature appears similar to those associated with activation of selective attention mechanisms, thus suggesting that these asymptomatic individuals may be showing signs of a mild. impairment of allocation of attention resources.	Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland; Haywood Hosp, Neurobehav Unit, Stoke On Trent, Staffs, England; Univ Keele, Dept Psychol, Keele ST5 5BG, Staffs, England	Potter, DD (corresponding author), Univ Dundee, Dept Psychol, Dundee DD1 4HN, Scotland.						BARIBEAU J, 1990, PSYCHOPHYSIOLOGICAL, P161; BARRETT K, 1994, J ACCID EMERG MED, V11, P79; BARTH JT, 1983, NEUROSURGERY, V13, P529, DOI 10.1227/00006123-198311000-00008; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; Bohnen N., 1992, Brain Injury, V6, P481, DOI 10.3109/02699059209008145; BOHNEN N, 1992, ACTA NEUROL SCAND, V85, P116, DOI 10.1111/j.1600-0404.1992.tb04009.x; BOHNEN N, 1992, NEUROSURGERY, V30, P692; CAMPBELL KB, 1995, HDB NEUROPSYCHOLOGY, V10; CAMPBELL KB, 1990, NEW TRENDS ADV TECHN, P202; CAMPBELL KB, 1986, CEREBRAL PSYCHOPHYSI, P486; CRAIK F, 1993, 34 ANN M PSYCH SOC W; CURRY SH, 1980, MOTIVATION MOTOR SEN, P507; DAVIDOFF DA, 1988, COGNITIVE REHABILITA, V6, P8; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; ELSON LM, 1994, SEMIN NEUROL, V14, P8, DOI 10.1055/s-2008-1041053; EVANS RW, 1992, NEUROL CLIN, V10, P815; FISHER JM, 1994, SEMIN NEUROL, V14, P53, DOI 10.1055/s-2008-1041059; GENTILINI M, 1989, MILD HEAD INJURY, P163; GOODMAN JC, 1994, SEMIN NEUROL, V14, P19, DOI 10.1055/s-2008-1041054; Gronwall D, 1986, J HEAD TRAUMA REHAB, V1, P53, DOI DOI 10.1097/00001199-198606000-00009; Gronwall D, 1989, MILD HEAD INJURY, P153; HALL S, 1991, PERCEPT MOTOR SKILL, V72, P1295, DOI 10.2466/PMS.72.4.1295-1298; HAYES S, 1994, NEW STATESMAN SOC, V7, P14; HEINZE HJ, 1992, NEUROPSYCHOLOGIA, V30, P495, DOI 10.1016/0028-3932(92)90054-P; HUGENHOLTZ H, 1988, NEUROSURGERY, V22, P853, DOI 10.1227/00006123-198805000-00006; JENNETT B, 1981, BRIT MED J, V282, P101, DOI 10.1136/bmj.282.6258.101; Johnson R., 1988, ADV PSYCHOPHYSIOLOGY, V3, P69; Kaplan E., 1991, WAIS R NEUROPSYCHOLO; King N, 1997, BRIT J CLIN PSYCHOL, V36, P161, DOI 10.1111/j.2044-8260.1997.tb01405.x; KNIGHT RT, 1984, ELECTROEN CLIN NEURO, V59, P9, DOI 10.1016/0168-5597(84)90016-9; LEININGER BE, 1990, J NEUROL NEUROSUR PS, V53, P293, DOI 10.1136/jnnp.53.4.293; Miller E, 1970, Cortex, V6, P121; Miller L., 1993, PSYCHOTHERAPY BRAIN; NAATANEN R, 1990, BEHAV BRAIN SCI, V13, P201, DOI 10.1017/S0140525X00078407; Nelson HE, 1982, NATL ADULT READING T; NEWCOMBE F, 1994, J NEUROL NEUROSUR PS, V57, P709, DOI 10.1136/jnnp.57.6.709; Osterrieth PA, 1944, ARCH PSYCHOLOGIE, V30, P206; OTOOLE DM, 1987, PSYCHOPHYSIOLOGY, V24, P487, DOI 10.1111/j.1469-8986.1987.tb00325.x; PACKARD RC, 1994, SEMIN NEUROL, V14, P74, DOI 10.1055/s-2008-1041062; PARASURAMAN R, 1991, J CLIN EXP NEUROPSYC, V13, P789, DOI 10.1080/01688639108401090; POLICH J, 1995, BIOL PSYCHOL, V41, P103, DOI 10.1016/0301-0511(95)05130-9; Potter D, 1996, J PSYCHOPHYSIOL, V10, P79; POTTER DD, 1994, MAPP COGN TIM SPAC C; PRATAPCHAND R, 1988, ACTA NEUROL SCAND, V78, P185, DOI 10.1111/j.1600-0404.1988.tb03643.x; RUFF RM, 1986, SAN DIEGO NEUROPSYCH; RUGG MD, 1988, J NEUROL NEUROSUR PS, V51, P691, DOI 10.1136/jnnp.51.5.691; RUGG MD, 1993, NEUROPSYCHOLOGIA, V31, P373, DOI 10.1016/0028-3932(93)90161-R; RUGG MD, 1989, BRAIN, V112, P489, DOI 10.1093/brain/112.2.489; Rugg MD., 1994, COGNITIVE ELECTROPHY, P124, DOI 10.1007/978-1-4612-0283-7%5F5; Rutherford W. H., 1989, MILD HEAD INJURY, P217; SCHOENHUBER R, 1989, MILD HEAD INJURY, P142; SEGALOWITZ SJ, 1992, J CLIN EXP NEUROPSYC, V14, P545, DOI 10.1080/01688639208402844; SEMLITSCH HV, 1986, PSYCHOPHYSIOLOGY, V23, P695, DOI 10.1111/j.1469-8986.1986.tb00696.x; Spreen O., 1991, COMPENDIUM NEUROPSYC; SQUIRES NK, 1975, ELECTROEN CLIN NEURO, V38, P387, DOI 10.1016/0013-4694(75)90263-1; Van Zomeren A. H., 1984, CLOSED HEAD INJURY P, P74; VANPETTEN C, 1991, J COGNITIVE NEUROSCI, V3, P129; VANZOMEREN AH, 1985, J NEUROL NEUROSUR PS, V48, P21, DOI 10.1136/jnnp.48.1.21; VERLEGER R, 1988, BEHAV BRAIN SCI, V11, P343, DOI 10.1017/S0140525X00058015; Verleger R, 1997, PSYCHOPHYSIOLOGY, V34, P131, DOI 10.1111/j.1469-8986.1997.tb02125.x; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; Woods DL., 1990, EVENT RELATED BRAIN, P178; YOUNG WB, 1994, SEMIN NEUROL, V14, P46, DOI 10.1055/s-2008-1041058	64	23	24	0	3	HOGREFE & HUBER PUBLISHERS	GOTTINGEN	ROHNSWEG 25, D-37085 GOTTINGEN, GERMANY	0269-8803			J PSYCHOPHYSIOL	J. Psychophysiol.		1999	13	3					173	189		10.1027//0269-8803.13.3.173			17	Psychology, Biological; Neurosciences	Psychology; Neurosciences & Neurology	236RA	WOS:000082611300005					2021-06-18	
J	Ricci, R; Vaishnavi, S; Chatterjee, A				Ricci, R; Vaishnavi, S; Chatterjee, A			A deficit of intermediate vision: Experimental observations and theoretical implications	NEUROCASE			English	Article						attention; object recognition; visual agnosia; simultanagnosia; pre-attentive vision	MONKEY VISUAL-CORTEX; OBJECT RECOGNITION; CONTOUR PERCEPTION; NEGLECT; SPOTLIGHT; ATTENTION; DISCRIMINATION; SPECIALIZATION; MECHANISMS; DESIGN	The nervous system constructs visual representations hierarchically. Elementary features are extracted from the visual scene and grouped to form candidate objects, which may then be selected for attentional scrutiny. We wished to learn if intermediate vision (pre-attentive and effortless grouping processes) can be damaged selectively and, if so, what the consequences of such damage might be. We present a patient with significant visual disabilities following a traumatic brain injury. Her early vision was preserved. However, she had a deficit of intermediate vision as evidenced by an inability to: (i) link visual attributes into perceptual wholes effortlessly, (ii) search for visual targets pre-attentively and (iii) accurately perceive illusory contours. By contrast, she could deploy attention both panoramically and selectively. She also recognized real objects and described pictures. We conclude that intermediate vision can be damaged selectively. Attention can be deployed on a visual scene which has not been pre-attentively parsed. Grouping processes are not needed to recognize objects, Our findings suggest that the hierarchical organization of visual processing is more interactive than implied by serial feed-forward models.	Univ Alabama, Dept Neurol, Birmingham, AL 35294 USA; Univ Turin, Dept Psychol, Turin, Italy		a_chatterjee@email.neuro.uab.edu		Ricci, Raffaella/0000-0003-3422-2552			ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; BARLOW HB, 1981, PROC R SOC SER B-BIO, V212, P1, DOI 10.1098/rspb.1981.0022; BERGEN JR, 1983, NATURE, V303, P696, DOI 10.1038/303696a0; CHATTERJEE A, 1994, NEUROPSY NEUROPSY BE, V7, P267; Coslett HB, 1995, NEUROCASE, V1, P305; COSLETT HB, 1991, BRAIN, V114, P1523, DOI 10.1093/brain/114.4.1523; DELIS DC, 1986, NEUROPSYCHOLOGIA, V24, P205, DOI 10.1016/0028-3932(86)90053-9; DRIVER J, 1992, NATURE, V360, P73, DOI 10.1038/360073a0; Farah M, 1990, VISUAL AGNOSIA; Goodglass H., 1972, ASSESSMENT APHASIA R; GRABOWECKY M, 1993, J COGNITIVE NEUROSCI, V5, P288, DOI 10.1162/jocn.1993.5.3.288; GROSOF DH, 1993, NATURE, V365, P550, DOI 10.1038/365550a0; Grossberg S, 1997, TRENDS NEUROSCI, V20, P106, DOI 10.1016/S0166-2236(96)01002-8; HALLIGAN PW, 1994, COGNITIVE NEUROPSYCH, V11, P167, DOI 10.1080/02643299408251973; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY, P279; HYVARINEN L, 1993, PV16 COLOR TEST QUAN; James W., 1890, PRINCIPLES PSYCHOL; KANIZSA G, 1976, SCI AM, V234, P48, DOI 10.1038/scientificamerican0476-48; KARTSOUNIS LD, 1991, NEUROPSYCHOLOGIA, V29, P969, DOI 10.1016/0028-3932(91)90061-C; LIVINGSTONE MS, 1987, J NEUROSCI, V7, P3416; Marr D., 1982, VISION COMPUTATIONAL; NAVON D, 1977, COGNITIVE PSYCHOL, V9, P353, DOI 10.1016/0010-0285(77)90012-3; Nawrot M, 1996, VISION RES, V36, P1141, DOI 10.1016/0042-6989(95)00173-5; PELLI DG, 1988, CLIN VISION SCI, V2, P187; PETERHANS E, 1989, J NEUROSCI, V9, P1749; Stark ME, 1997, NEUROPSYCHOLOGIA, V35, P1233, DOI 10.1016/S0028-3932(97)00049-3; THAISS L, 1992, CORTEX, V28, P601; TREISMAN AM, 1980, COGNITIVE PSYCHOL, V12, P97, DOI 10.1016/0010-0285(80)90005-5; VANESSEN DC, 1992, SCIENCE, V255, P419, DOI 10.1126/science.1734518; VANESSEN DC, 1990, COLD SPRING HARB SYM, V55, P679; Vecera SP, 1997, NEUROPSYCHOLOGY, V11, P30, DOI 10.1037/0894-4105.11.1.30; VONDERHEYDT R, 1989, J NEUROSCI, V9, P1731; Warrington E. K., 1991, VISUAL OBJECT SPATIA; WEISKRANTZ L, 1974, BRAIN, V97, P709, DOI 10.1093/brain/97.1.709; Wilson B., 1987, BEHAV INATTENTION TE; ZEKI SM, 1978, NATURE, V274, P423, DOI 10.1038/274423a0	36	23	23	0	3	OXFORD UNIV PRESS	OXFORD	GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND	1355-4794			NEUROCASE	Neurocase		1999	5	1					1	12					12	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	169VT	WOS:000078770300001					2021-06-18	
J	Leahy, BJ; Lam, CS				Leahy, BJ; Lam, CS			Neuropsychological testing and functional outcome for individuals with traumatic brain injury	BRAIN INJURY			English	Article							HEAD-INJURIES; REHABILITATION; VARIABLES	The relationship between performance on neuropsychological measures and the vocational and independent living functioning of individuals with traumatic brain injury was examined. The Wechsler Adult intelligence Scale-Revised (WAIS-R) IQ and Stroop Color and Word Test scores differentiated individuals who required no assistance with activities of daily living from those requiring some level of assistance. Only the Stroop Color and Word Test scores differentiated individuals who were competitively employed or engaged in degree-oriented education from those who were unemployed or in sheltered or supported employment. Wechsler Memory Scale-Revised (WMS-R) scores did not differentiate these groups.	IIT, Inst Psychol, Chicago, IL 60616 USA	Lam, CS (corresponding author), IIT, Inst Psychol, 3101 S Dearborn, Chicago, IL 60616 USA.						Acker MB, 1989, NEUROPSYCHOLOGY, V3, P123, DOI 10.1037//0894-4105.3.3.123; BISHARA S N, 1992, Brain Injury, V6, P373, DOI 10.3109/02699059209034952; BORNSTEIN RA, 1988, CLIN NEUROPSYCHOL, V2, P107, DOI DOI 10.1080/13854048808520093; BROOKS DN, 1972, J NERV MENT DIS, V155, P350; CALLAHAN D, 1991, PSYCHOL SOCIAL IMPAC, P295; CHELUNG GJ, 1989, ADV PSYCHOL ASSESS, P65; DIKMEN SS, 1994, ARCH NEUROL-CHICAGO, V51, P177, DOI 10.1001/archneur.1994.00540140087018; EISENBERG HM, 1985, CENTRAL NERVOUS SYST, P271; Evans RW, 1992, J HEAD TRAUMA REHAB, V7, P24; EZRACHI O, 1991, J HEAD TRAUMA REHAB, V0006, P00071, DOI DOI 10.1097/00001199-199109000-00010; FABIANO RJ, 1995, REHABIL PSYCHOL, V40, P223, DOI 10.1037/0090-5550.40.3.223; Golden C., 1978, STROOP COLOR WORD TE; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HUMPHREY M, 1980, INJURY, V12, P107, DOI 10.1016/0020-1383(80)90133-3; JONES M, 1990, DEFINING VALUE CASE; KARZMARK P, 1992, Brain Injury, V6, P213, DOI 10.3109/02699059209029662; Kaufman A. S., 1990, ASSESSING ADOLESCENT; LAM CS, 1991, REHABIL COUNS BULL, V35, P68; LEVIN HS, 1979, J NEUROSURG, V50, P412, DOI 10.3171/jns.1979.50.4.0412; LEZAK MD, 1986, REHABIL PSYCHOL, V31, P241, DOI 10.1037//0090-5550.31.4.241; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; LISHMAN WA, 1968, BRIT J PSYCHIAT, V114, P373, DOI 10.1192/bjp.114.509.373; LOKKEBERG AR, 1984, J NEUROSURG, V61, P254, DOI 10.3171/jns.1984.61.2.0254; MANDLEBERG IA, 1976, J NEUROL NEUROSUR PS, V39, P1001, DOI 10.1136/jnnp.39.10.1001; Naugle RI, 1990, TRAUMATIC BRAIN INJU, P69; PAPASTRAT LA, 1992, J HEAD TRAUMA REHAB, V7, P11; PUTNAM SH, 1992, CLIN NEUROPSYCHOL, V6, P383; RYAN T V, 1992, Brain Injury, V6, P175, DOI 10.3109/02699059209029656; SPETTELL CM, 1991, ARCH PHYS MED REHAB, V72, P320; Wechsler, 1981, WAIS R MANUAL; Wechsler D., 1987, WECHSLER MEMORY SCAL; WEHMAN PH, 1995, J HEAD TRAUMA REHAB, V10, P27; Wilson B. A., 1993, APPL PREV PSYCHOL, V2, P209, DOI [DOI 10.1016/S0962-1849(05)80091-5, 10.1016/S0962-1849(05)80091-5]; ZEIGLER EA, 1987, J REHABIL, V53, P50	34	23	23	0	3	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON EC4A 3DE, ENGLAND	0269-9052			BRAIN INJURY	Brain Inj.	DEC	1998	12	12					1025	1035		10.1080/026990598121936			11	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	150BW	WOS:000077643400003	9876862				2021-06-18	
J	Roncone, R; Rossi, L; Muiere, E; Impallomeni, M; Matteucci, M; Giacomelli, R; Tonietti, G; Casacchia, M				Roncone, R; Rossi, L; Muiere, E; Impallomeni, M; Matteucci, M; Giacomelli, R; Tonietti, G; Casacchia, M			The Italian version of the family assessment device	SOCIAL PSYCHIATRY AND PSYCHIATRIC EPIDEMIOLOGY			English	Article							TRAUMATIC BRAIN INJURY; SUICIDAL-BEHAVIOR; MAJOR DEPRESSION; MAINTENANCE CHEMOTHERAPY; COMMUNITY MANAGEMENT; AFTERCARE TREATMENT; EXPRESSED EMOTION; CONTROLLED TRIAL; POOR ADJUSTMENT; CHRONIC ILLNESS	The aim of the study was to evaluate in a heterogeneous Italian sample (n = 340) the psyche metric properties of the Italian version of the Family Assessment Device (FAD), a 60-item questionnaire assessing family functioning. The questionnaire was administered to psychiatric (n = 116), medical (n = 114) and non-clinical samples (n = 110). In a sample of 30 non-clinical subjects the temporal stability of the FAD was investigated. The results showed a good temporal stability for Problem Solving, General Functioning, Communication, and Affective Responsiveness scales, and a good internal reliability of the scale. Factor analysis of the Italian version provided discrepancies with the hypothesized structure of the instrument, leading to the identification of seven slightly different dimensions. The proposed seven-factor model of the instrument did not provide a good fit to our data. The results of our study suggest the need for a major improvement in the adaptation of the FAD in the Italian setting.	Univ Aquila, Dept Psychiat, I-67100 Laquila, Italy; Univ Aquila, Dept Internal Med, I-67100 Laquila, Italy	Roncone, R (corresponding author), Univ Aquila, Dept Psychiat, Blocco 11,Via Vetoio, I-67100 Laquila, Italy.	rroncone@webacl.it	Roncone, Rita/H-3095-2012	Giacomelli, Roberto/0000-0003-0670-9638; RONCONE, Rita/0000-0002-1206-0970			ARPIN K, 1990, J CLIN EPIDEMIOL, V43, P373, DOI 10.1016/0895-4356(90)90123-7; BERNBAUM M, 1993, J CLIN PSYCHOL, V49, P670, DOI 10.1002/1097-4679(199309)49:5<670::AID-JCLP2270490509>3.0.CO;2-F; BERTRANDO P, 1992, BRIT J PSYCHIAT, V161, P223, DOI 10.1192/bjp.161.2.223; BROWN GW, 1972, BRIT J PSYCHIAT, V121, P241, DOI 10.1192/bjp.121.3.241; BROWNE GB, 1990, MED CARE, V28, P43, DOI 10.1097/00005650-199001000-00006; EPSTEIN NB, 1983, J MARITAL FAM THER, V9, P171, DOI 10.1111/j.1752-0606.1983.tb01497.x; FALLOON IRH, 1982, NEW ENGL J MED, V306, P1437, DOI 10.1056/NEJM198206173062401; FALLOON IRH, 1985, ARCH GEN PSYCHIAT, V42, P887; FOWLER PC, 1981, J CLIN PSYCHOL, V37, P160, DOI 10.1002/1097-4679(198101)37:1<160::AID-JCLP2270370132>3.0.CO;2-Q; FRANCESCONI A, 1993, RIABILITAZIONE PSICH, P189; GOWERS SG, 1995, J CHILD PSYCHOL PSYC, V36, P993, DOI 10.1111/j.1469-7610.1995.tb01345.x; Halvorsen J G, 1991, Fam Pract Res J, V11, P21; HOGARTY GE, 1991, ARCH GEN PSYCHIAT, V48, P340; HOGARTY GE, 1986, ARCH GEN PSYCHIAT, V43, P633; JOFFE RT, 1988, AM J PSYCHIAT, V145, P1420; Joreskog K., 1988, LISREL 7 GUIDE PROGR; Kabacoff R.I., 1990, J FAMILY PSYCHOL, V3, P431, DOI [10.1037/h0080547, DOI 10.1037/H0080547]; KEITNER G I, 1986, International Journal of Family Psychiatry, V7, P11; KEITNER GI, 1987, PSYCHIATRY, V50, P242, DOI 10.1080/00332747.1987.11024356; KEITNER GI, 1987, COMPR PSYCHIAT, V28, P54; KEITNER GI, 1995, AM J PSYCHIAT, V152, P1002; KING CA, 1993, J AM ACAD CHILD PSY, V32, P1198, DOI 10.1097/00004583-199311000-00013; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEFF J, 1985, BRIT J PSYCHIAT, V146, P594, DOI 10.1192/bjp.146.6.594; LIEPMAN MR, 1989, FAM PROCESS, V28, P239, DOI 10.1111/j.1545-5300.1989.00239.x; MARTIN G, 1995, ACTA PSYCHIAT SCAND, V92, P336, DOI 10.1111/j.1600-0447.1995.tb09594.x; MCKAY JR, 1993, J SUBST ABUSE TREAT, V10, P17, DOI 10.1016/0740-5472(93)90094-I; MILLER IW, 1994, FAM PROCESS, V33, P53, DOI 10.1111/j.1545-5300.1994.00053.x; MILLER IW, 1986, COMPR PSYCHIAT, V27, P302, DOI 10.1016/0010-440X(86)90006-4; MILLER IW, 1985, J MARITAL FAM THER, V11, P345, DOI 10.1111/j.1752-0606.1985.tb00028.x; NORTH C, 1995, BRIT J PSYCHIAT, V167, P673, DOI 10.1192/bjp.167.5.673; NORUSIS MJ, 1995, SPSS WINDOWS VERSION; OATES RK, 1994, J AM ACAD CHILD PSY, V33, P945, DOI 10.1097/00004583-199409000-00003; Reeber B J, 1992, Rehabil Nurs, V17, P332; Rivara JB, 1996, ARCH PHYS MED REHAB, V77, P754, DOI 10.1016/S0003-9993(96)90253-1; SAWYER MG, 1988, J MARITAL FAM THER, V14, P287, DOI 10.1111/j.1752-0606.1988.tb00748.x; STEVENSONHINDE J, 1995, FAM PROCESS, V34, P337, DOI 10.1111/j.1545-5300.1995.00337.x; TARRIER N, 1988, BRIT J PSYCHIAT, V153, P532, DOI 10.1192/bjp.153.4.532; TARRIER N, 1989, BRIT J PSYCHIAT, V154, P625, DOI 10.1192/bjp.154.5.625; WALLER G, 1990, BRIT J PSYCHIAT, V156, P546, DOI 10.1192/bjp.156.4.546	41	23	25	0	6	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0933-7954	1433-9285		SOC PSYCH PSYCH EPID	Soc. Psychiatry Psychiatr. Epidemiol.	SEP	1998	33	9					451	461		10.1007/s001270050079			11	Psychiatry	Psychiatry	118JK	WOS:000075834600007	9766172				2021-06-18	
J	Obrenovitch, TP				Obrenovitch, TP			Neuroprotective strategies: Voltage-gated Na+-channel down-modulation versus presynaptic glutamate release inhibition	REVIEWS IN THE NEUROSCIENCES			English	Article						neuroprotection; neuronal death; glutamate; excitotoxicity; voltage-gated Na+-channels; Na+-channel blockers; riluzole	TRAUMATIC BRAIN INJURY; FOCAL CEREBRAL-ISCHEMIA; HIGH EXTRACELLULAR GLUTAMATE; CAT CAUDATE-NUCLEUS; MODERATE HYPOTHERMIA; RAT STRIATUM; AMINO-ACIDS; TIME-COURSE; AREA CA1; RILUZOLE	Insufficient ATP production relative to cellular requirements is the key factor detrimental to neurons in neurological disorders associated with deficient oxygen/glucose supply or mitochondrial dysfunction, As a large part of the energy consumed by brain cells is used to maintain the Na+ gradient across the cellular membrane, reduction of energy demand by down-modulation of voltage-gated Na+-channels is a rational strategy for neuroprotection against these conditions, Preservation of the inward Na+ gradient is likely to be also beneficial as it is an essential driving force for vital ion exchanges and transport mechanisms (e.g. Ca2+-homeostasis and cell volume regulation). From these elements, I propose that use-dependent Na+-channel blockers increase the resilience of nerve cells to the primary insult and/or subsequent deleterious events, and that reduced efflux of glutamate and other compounds is only a consequence of cellular stress attenuation, The widespread hypothesis that down-modulation of Na+-channels is neuroprotective primarily through reduction of presynaptic glutamate release conflicts with strong experimental evidence.	Univ Bradford, Sch Pharm, Postgrad Studies Pharmacol, Bradford BD7 1DP, W Yorkshire, England							AMES A, 1992, J NEUROSCI, V12, P840, DOI 10.1523/jneurosci.12-03-00840.1992; Asai S, 1996, NEUROREPORT, V7, P1092, DOI 10.1097/00001756-199604100-00028; ASTRUP J, 1982, J NEUROSURG, V56, P482, DOI 10.3171/jns.1982.56.4.0482; Back T, 1996, J CEREBR BLOOD F MET, V16, P202, DOI 10.1097/00004647-199603000-00004; Balkan S, 1997, ACTA NEUROL SCAND, V95, P140, DOI 10.1111/j.1600-0404.1997.tb00085.x; Bareyre F, 1997, J NEUROTRAUM, V14, P839, DOI 10.1089/neu.1997.14.839; BECQUET D, 1990, BRAIN RES, V519, P82, DOI 10.1016/0006-8993(90)90063-H; BENAVIDES J, 1985, NEUROPHARMACOLOGY, V24, P1085, DOI 10.1016/0028-3908(85)90196-0; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; CARAFOLI E, 1987, ANNU REV BIOCHEM, V56, P395, DOI 10.1146/annurev.bi.56.070187.002143; CHERAMY A, 1986, NEUROSCIENCE, V19, P1081, DOI 10.1016/0306-4522(86)90124-7; Claus JJ, 1998, NEUROBIOL AGING, V19, P57, DOI 10.1016/S0197-4580(98)00004-9; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; Crumrine RC, 1997, STROKE, V28, P2230, DOI 10.1161/01.STR.28.11.2230; Culmsee C, 1998, EUR J PHARMACOL, V342, P193, DOI 10.1016/S0014-2999(97)01499-4; Doble A, 1996, NEUROLOGY, V47, pS233, DOI 10.1212/WNL.47.6_Suppl_4.233S; ERECINSKA M, 1989, J CEREBR BLOOD F MET, V9, P2, DOI 10.1038/jcbfm.1989.2; Gill R, 1997, INT REV NEUROBIOL, V40, P197; GOZLAN H, 1994, J NEUROPHYSIOL, V72, P3017; Hamm RJ, 1996, J NEUROTRAUM, V13, P325, DOI 10.1089/neu.1996.13.325; Hille B., 1991, IONIC CHANNELS EXCIT; Hsu KS, 1997, BRIT J PHARMACOL, V122, P671, DOI 10.1038/sj.bjp.0701409; Humm JL, 1998, BRAIN RES, V783, P286, DOI 10.1016/S0006-8993(97)01356-5; Iijima T, 1998, J NEUROTRAUM, V15, P277, DOI 10.1089/neu.1998.15.277; Izumi Y, 1998, J CEREBR BLOOD F MET, V18, P97, DOI 10.1097/00004647-199801000-00010; Kawaguchi K, 1997, BRAIN RES, V749, P131, DOI 10.1016/S0006-8993(96)01311-X; Koizumi H, 1997, BRAIN RES, V747, P304, DOI 10.1016/S0006-8993(96)01240-1; Lang F, 1998, PHYSIOL REV, V78, P247; LEKIEFFRE D, 1993, NEUROSCIENCE, V56, P93, DOI 10.1016/0306-4522(93)90565-W; Lesch KP, 1997, J NEURAL TRANSM-SUPP, P155; MacIver MB, 1996, ANESTHESIOLOGY, V85, P626, DOI 10.1097/00000542-199609000-00023; Marion DW, 1997, NEW ENGL J MED, V336, P540, DOI 10.1056/NEJM199702203360803; MARTIN D, 1993, EUR J PHARMACOL, V250, P473, DOI 10.1016/0014-2999(93)90037-I; Mecocci P, 1997, MOL CHEM NEUROPATHOL, V31, P53, DOI 10.1007/BF02815160; Miele M, 1996, J PHYSIOL-LONDON, V497, P745, DOI 10.1113/jphysiol.1996.sp021805; MoralesVillagran A, 1996, NEUROCHEM INT, V28, P35, DOI 10.1016/0197-0186(95)00064-F; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Obrenovitch TP, 1998, N-S ARCH PHARMACOL, V357, P225, DOI 10.1007/PL00005161; OBRENOVITCH TP, 1990, J NEUROPHYSIOL, V64, P1125; Obrenovitch TP, 1997, J NEUROTRAUM, V14, P677, DOI 10.1089/neu.1997.14.677; Obrenovitch TP, 1996, ACT NEUR S, V66, P50; OBRENOVITCH TP, 1995, CEREBROVAS BRAIN MET, V7, P1; Obrenovitch TP, 1997, PROG NEUROBIOL, V51, P39, DOI 10.1016/S0301-0082(96)00049-4; OBRENOVITCH TP, 1993, J NEUROCHEM, V61, P178, DOI 10.1111/j.1471-4159.1993.tb03553.x; OBRENOVITCH TP, 1997, REV CONTEMP PHARMACO, V8, P227; OGATA T, 1992, J NEUROCHEM, V58, P1957, DOI 10.1111/j.1471-4159.1992.tb10075.x; ORREGO F, 1993, NEUROSCIENCE, V56, P539, DOI 10.1016/0306-4522(93)90355-J; Peluffo H, 1997, NEUROSCI LETT, V228, P207, DOI 10.1016/S0304-3940(97)00384-4; REDDY NL, 1995, BIOORG MED CHEM LETT, V5, P2259; REEVES TM, 1995, EXP BRAIN RES, V106, P248; Rutledge EM, 1996, J NEUROSCI, V16, P7803; SANCHEZARMASS S, 1994, J NEUROPHYSIOL, V71, P2236; Schulz JB, 1996, NEUROSCIENCE, V71, P1043, DOI 10.1016/0306-4522(95)00527-7; Segovia G, 1997, NEUROCHEM RES, V22, P1491, DOI 10.1023/A:1021958613125; Shaw PJ, 1997, J NEUROL, V244, pS3, DOI 10.1007/BF03160574; Small DL, 1997, INT REV NEUROBIOL, V40, P137; SOLLNER T, 1994, TRENDS NEUROSCI, V17, P344, DOI 10.1016/0166-2236(94)90178-3; Takahashi M, 1997, J EXP BIOL, V200, P401; Thoresen M, 1997, ACTA PAEDIATR, V86, P1029, DOI 10.1111/j.1651-2227.1997.tb14799.x; Tibbs GR, 1996, J NEUROCHEM, V67, P389; Timmerman W, 1997, SYNAPSE, V27, P242, DOI 10.1002/(SICI)1098-2396(199711)27:3<242::AID-SYN9>3.0.CO;2-D; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UEDA Y, 1992, STROKE, V23, P253, DOI 10.1161/01.STR.23.2.253; Umemiya M, 1995, BRIT J PHARMACOL, V116, P3227, DOI 10.1111/j.1476-5381.1995.tb15128.x; Urenjak J, 1996, PHARMACOL REV, V48, P21; URENJAK J, 1991, PHARMACOLOGY, V43, P26, DOI 10.1159/000138824; URENJAK J, 1997, REV CONTEMP PHARMACO, V8, P237; Wada E, 1998, J COMP NEUROL, V393, P493; WAHL F, 1994, J NEUROCHEM, V63, P1003; Wahl F, 1997, BRAIN RES, V756, P247, DOI 10.1016/S0006-8993(97)00144-3; WALDMEIER PC, 1995, NEUROLOGY, V45, P1907, DOI 10.1212/WNL.45.10.1907; Warner DS, 1996, ANESTHESIOLOGY, V84, P1475, DOI 10.1097/00000542-199606000-00024; XIE YX, 1994, BRAIN RES, V652, P216, DOI 10.1016/0006-8993(94)90230-5; Zhang C, 1998, J NEUROSCI RES, V52, P342, DOI 10.1002/(SICI)1097-4547(19980501)52:3<342::AID-JNR10>3.0.CO;2-8	74	23	23	0	3	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	JUL-DEC	1998	9	3					203	211					9	Neurosciences	Neurosciences & Neurology	130CD	WOS:000076500800003	9833651				2021-06-18	
J	Matthews, MA; Carey, ME; Soblosky, JS; Davidson, JF; Tabor, SL				Matthews, MA; Carey, ME; Soblosky, JS; Davidson, JF; Tabor, SL			Focal brain injury and its effects on cerebral mantle, neurons, and fiber tracks	BRAIN RESEARCH			English	Article						brain injury; neural degeneration; fiber track degeneration; neurobehavior	DIFFUSE AXONAL INJURY; NEOCORTICAL DAMAGE; MOTOR CORTEX; HEAD-INJURY; RAT; ORGANIZATION; DEGENERATION; DENDRITES; STRIATUM; MODEL	Following a mild cortical impact injury delivered by a piston to the right sensorimotor cortex of the anesthetized rat, we evaluated mantle loss, neuronal changes, and fiber track degeneration by deOlmos silver stains up to 8 weeks after injury. Darkened neurons indicating damage (chromatolysis) occurred widely throughout both hemispheres and were seen from 1 h to 8 weeks after injury. This effect might have occurred from pressure wave damage from piston impact, brain displacement or deafferentation. Cerebral mantle loss was variable but fiber track degeneration related to projection and corticofugal descending tracks associated with the right sensorimotor system was rather constant. Unexpectedly, considerable fiber track degeneration occurred within the cerebellum, especially the inferior vermis. Cells directly under the piston face were surprisingly well-preserved but axon degeneration studies showed that these apparently intact neuronal cell bodies were surrounded by a dense network of degenerating fiber tracks. The intact cells, therefore, may have been functionally cut off from the rest of the brain owing to interruption of their efferents and afferents. The increased susceptibility of axons compared to cell bodies seen with this focal injury is similar to that observed with diffuse brain injury. The early appearing, severe and widespread axon damage we observed suggests that amelioration of focal traumatic brain injury will have to be directed promptly to the preservation of axons as well as cell bodies. (C) 1998 Elsevier Science B.V. All rights reserved.	Louisiana State Univ, Med Ctr, Dept Neurosurg, Brain Protect Res Lab, New Orleans, LA 70112 USA; Louisiana State Univ, Med Ctr, Dept Anat, New Orleans, LA 70112 USA	Carey, ME (corresponding author), Louisiana State Univ, Med Ctr, Dept Neurosurg, Brain Protect Res Lab, 1542 Tulane Ave, New Orleans, LA 70112 USA.						BUSTO R, 1987, J CEREBR BLOOD F MET, V7, P729, DOI 10.1038/jcbfm.1987.127; CAMMERMEYER JAN, 1961, ACTA NEUROPATHOL, V1, P245; CLIFTON GL, 1991, J CEREBR BLOOD F MET, V11, P114, DOI 10.1038/jcbfm.1991.13; de Olmos JS, 1981, NEUROANATOMICAL TRAC, P117; DEOLMOS JS, 1994, NEUROTOXICOL TERATOL, V16, P545, DOI 10.1016/0892-0362(94)90033-7; DIXON C E, 1988, Journal of Neurotrauma, V5, P91, DOI 10.1089/neu.1988.5.91; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Doppenberg EMR, 1997, J NEUROTRAUM, V14, P71, DOI 10.1089/neu.1997.14.71; EBRAHIMI A, 1992, NEUROSCI RES, V14, P39, DOI 10.1016/S0168-0102(05)80005-7; ERB DE, 1988, ACTA NEUROPATHOL, V76, P347, DOI 10.1007/BF00686971; Frankowski R F, 1986, Adv Psychosom Med, V16, P153; FRIEDE RL, 1960, J NEUROPATH EXP NEUR, V19, P266, DOI 10.1097/00005072-196004000-00007; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P109; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; HALL RD, 1974, BRAIN RES, V66, P23, DOI 10.1016/0006-8993(74)90076-6; Homayoun P, 1997, J NEUROCHEM, V69, P199; JONES TA, 1994, J NEUROSCI, V14, P2140; JONES TA, 1992, BRAIN RES, V581, P156, DOI 10.1016/0006-8993(92)90356-E; JONES TA, 1992, BEHAV BRAIN RES, V51, P1, DOI 10.1016/S0166-4328(05)80306-7; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; LIGHTHALL J W, 1990, Journal of Neurotrauma, V7, P65, DOI 10.1089/neu.1990.7.65; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MAXWELL WL, 1992, ACTA NEUROPATHOL, V84, P289; MAXWELL WL, 1988, ACTA NEUROPATHOL, V76, P395, DOI 10.1007/BF00686977; MCGEORGE AJ, 1989, NEUROSCIENCE, V29, P503, DOI 10.1016/0306-4522(89)90128-0; NEAFSEY EJ, 1986, BRAIN RES REV, V11, P77, DOI 10.1016/0165-0173(86)90011-1; Paxinos G, 1986, RAT BRAIN STEREOTAXI; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Povlishock JT, 1997, J NEUROPATH EXP NEUR, V56, P347, DOI 10.1097/00005072-199704000-00003; POVLISHOCK JT, 1992, BRAIN PATHOL, V2, P1; POVLISHOCK JT, 1986, ACTA NEUROPATHOL, V70, P53, DOI 10.1007/BF00689514; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P41; ROULLIER EM, 1991, NEUROSCI LETT, V125, P93; SCHLAEPFER WW, 1974, BRAIN RES, V69, P203, DOI 10.1016/0006-8993(74)90002-X; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; STRICH SJ, 1961, LANCET, V2, P443; SUTTON RL, 1993, J NEUROTRAUM, V10, P135, DOI 10.1089/neu.1993.10.135; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; TOULMOND S, 1993, BRAIN RES, V620, P32, DOI 10.1016/0006-8993(93)90267-Q; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	44	23	27	0	1	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	MAY 25	1998	794	1					1	18		10.1016/S0006-8993(98)00107-3			18	Neurosciences	Neurosciences & Neurology	ZX048	WOS:000074475000001	9630470				2021-06-18	
J	Ulus, IH; Ozyurt, G; Korfali, E				Ulus, IH; Ozyurt, G; Korfali, E			Decreased serum choline concentrations in humans after surgery, childbirth, and traumatic head injury	NEUROCHEMICAL RESEARCH			English	Article						choline; serum choline; surgical stress; pregnancy; childbirth stress; traumatic injury; head trauma	RAT CORPUS STRIATUM; TYROSINE-HYDROXYLASE; ACETYLCHOLINE-RELEASE; CONSCIOUS RATS; BETA-ENDORPHIN; BRAIN; STIMULATION; METABOLITES; DEFICIENCY; INDUCTION	The serum levels of choline decreased by approximately 50% in patients having a surgery under general as well as epidural anesthesia. The decrease is lasts for two days after surgery. Intravenous administration of succinylcholine, either by a single bolus injection or by a slow continuous infusion, increased the serum choline levels several folds during surgery. In these patients, a significant decrease in the serum choline levels was observed one and two days after surgery. In 16 pregnant women at the term, serum choline levels were higher than the value observed in 19 nonpregnant women. The serum choline levels decreased by about 40% or 60% after having a childbirth either by vaginal delivery or caesarean section, respectively. Serum choline levels in blood obtained from 9 patients with traumatic head injury were significantly lower than the observed levels in blood samples obtained from healthy volunteers. These observations show that serum choline levels increase during pregnancy and decrease during stressful situations in humans.	Uludag Univ, Fac Med, Dept Pharmacol & Clin Pharmacol, TR-16059 Bursa, Turkey; Uludag Univ, Fac Med, Dept Anaesthesiol & Reanimat, TR-16059 Bursa, Turkey; Uludag Univ, Fac Med, Dept Neurosurg, TR-16059 Bursa, Turkey	Ulus, IH (corresponding author), Uludag Univ, Fac Med, Dept Pharmacol & Clin Pharmacol, TR-16059 Bursa, Turkey.		Ulus, Ismail/D-5340-2015				ALTURA BM, 1978, P SOC EXP BIOL MED, V158, P77; BLUSZTAJN JK, 1983, SCIENCE, V221, P614, DOI 10.1126/science.6867732; BOUAZIZ H, 1995, ANESTH ANALG, V80, P1140, DOI 10.1097/00000539-199506000-00012; BUCHMAN AL, 1994, CLIN PHARMACOL THER, V55, P277, DOI 10.1038/clpt.1994.28; BURT ME, 1980, LANCET, V2, P638; BUYUKUYSAL RL, 1995, EUR J PHARMACOL, V281, P179, DOI 10.1016/0014-2999(95)00241-C; CONLAY LA, 1992, INT J SPORTS MED, V13, pS141, DOI 10.1055/s-2007-1024619; CONLAY LA, 1986, NEW ENGL J MED, V315, P892; Eisenach JC, 1996, ANESTH ANALG, V82, P621, DOI 10.1097/00000539-199603000-00034; FARBER SA, 1993, BRAIN RES, V607, P177, DOI 10.1016/0006-8993(93)91504-L; GARNER SC, 1995, J NUTR, V125, P2851; GROWDON JH, 1977, NEW ENGL J MED, V297, P524, DOI 10.1056/NEJM197709082971002; HELLER JH, 1953, SCIENCE, V118, P353, DOI 10.1126/science.118.3065.353; HolmesMcNary MQ, 1997, DEV BRAIN RES, V101, P9, DOI 10.1016/S0165-3806(97)00044-8; HolmesMcNary MQ, 1996, AM J CLIN NUTR, V64, P572; JOHNSON DA, 1992, LIFE SCI, V51, P1597, DOI 10.1016/0024-3205(92)90622-V; LINDAHL S, 1983, ACTA ANAESTH SCAND, V27, P50, DOI 10.1111/j.1399-6576.1983.tb01904.x; LOPEZ G, 1987, NEUROCHEM INT, V11, P293; LOPEZ G-COVIELLA I, 1992, Journal of Nutritional Biochemistry, V3, P313; LOPEZCOVIELLA I, 1995, J NEUROCHEM, V65, P889; LOY R, 1991, ADV EXP MED BIOL, V295, P373; MAIRE JCE, 1985, J PHYSIOL-PARIS, V80, P189; MECK WH, 1988, DEV PSYCHOBIOL, V21, P339, DOI 10.1002/dev.420210405; MECK WH, 1989, BEHAV NEUROSCI, V103, P1234, DOI 10.1037/0735-7044.103.6.1234; MILLINGTON WR, 1982, J NEUROCHEM, V38, P1748, DOI 10.1111/j.1471-4159.1982.tb06658.x; PANCHERI P, 1984, NEUROENDOCRINOL LETT, V6, P295; RENNICK B, 1976, KIDNEY INT, V10, P329, DOI 10.1038/ki.1976.116; ROHLFS EM, 1993, J NUTR, V123, P1762; Savci V, 1996, BRAIN RES, V709, P97, DOI 10.1016/0006-8993(95)01308-3; Savci V, 1996, EUR J PHARMACOL, V309, P275, DOI 10.1016/0014-2999(96)00330-5; SAVCI V, 1995, J NEUROCHEM, V64, P378; SHEARD NF, 1986, AM J CLIN NUTR, V43, P219; SHEARD NF, 1994, J NUTR BIOCHEM, V5, P303, DOI 10.1016/0955-2863(94)90036-1; SLACK BE, 1989, FIDIA RES SERIES, V20, P233; STHAXHOLDT O, 1981, ACTA ANAESTH SCAND, V25, P434, DOI 10.1111/j.1399-6576.1981.tb01681.x; ULUS IH, 1989, BRAIN RES, V484, P217, DOI 10.1016/0006-8993(89)90364-8; ULUS IH, 1976, SCIENCE, V194, P1060, DOI 10.1126/science.10629; ULUS IH, 1978, J PHARMACOL EXP THER, V204, P676; ULUS IH, 1977, P NATL ACAD SCI USA, V74, P798, DOI 10.1073/pnas.74.2.798; ULUS IH, 1995, BRIT J PHARMACOL, V116, P1911, DOI 10.1111/j.1476-5381.1995.tb16682.x; WANG FL, 1975, ANAL BIOCHEM, V63, P195, DOI 10.1016/0003-2697(75)90204-3; WECKER L, 1980, BRAIN RES, V184, P234, DOI 10.1016/0006-8993(80)90605-8; WURTMAN RJ, 1992, TRENDS NEUROSCI, V15, P117, DOI 10.1016/0166-2236(92)90351-8; ZEISEL SH, 1995, J NUTR, V125, P3049; ZEISEL SH, 1991, FASEB J, V5, P2093; ZEISEL SH, 1990, J NUTR BIOCHEM, V1, P332, DOI 10.1016/0955-2863(90)90001-2	46	23	23	0	0	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0364-3190	1573-6903		NEUROCHEM RES	Neurochem. Res.	MAY	1998	23	5					727	732		10.1023/A:1022455325657			6	Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	ZG369	WOS:000072994700020	9566612				2021-06-18	
J	Chen, Y; Shohami, E; Bass, R; Weinstock, M				Chen, Y; Shohami, E; Bass, R; Weinstock, M			Cerebro-protective effects of ENA713, a novel acetylcholinesterase inhibitor, in closed head injury in the rat	BRAIN RESEARCH			English	Article						closed-head injury; brain edema; blood-brain barrier; neurological deficit; acetylcholinesterase inhibitor; rat	CONCUSSIVE BRAIN INJURY; TRANSIENT ISCHEMIA; GERBIL BRAIN; PERMEABILITY; HYPOTHERMIA; HU-211	Focal ischemic brain damage and diffuse brain swelling occur in severe cases of traumatic head injury. Ischemia decreases brain acetylcholine (ACh) levels and head trauma upregulates acetylcholinesterase (AChE) in experimental animal models. The present study determined whether a brain-selective AChE inhibitor, ENA713, given once, up to 2 h after closed head injury (CHI) could reduce the vasogenic edema and accelerate recovery from neurological deficits induced by the injury in rats. ENA713 1-5 mg/kg produced a dose-related inhibition of AChE ranging from 40-85% in the cortex and hippocampus. Doses of 1, 2 and 5 mg/kg, significantly reduced the motor and neurological deficits and speeded recovery, as indicated by measurements made 7 and 14 days after injury. The two larger doses were still effective when injected 1 or 2 h after CHI. The acceleration by ENA713 of recovery of motor function was independent of its reduction in body temperature and was prevented by the simultaneous injection of mecamylamine (2.5 mg/kg), but not by scopolamine (0.2 or 1 mg/kg). Edema in the contused hemisphere (24 h after injury) and disruption of the blood brain barrier (4 h after injury) were significantly reduced (about 50%) by doses of 2 and 5 mg/kg, but not by 1 mg/kg. The data support the hypothesis that ENA713 exerts a neuroprotective effect in brain injury by preventing the decrease in cholinergic activity in cerebral vessels and in neurones. (C) 1998 Elsevier Science B.V.	Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel	Weinstock, M (corresponding author), Hebrew Univ Jerusalem, Sch Pharm, Dept Pharmacol, IL-91120 Jerusalem, Israel.						Adams J H, 1983, Acta Neurochir Suppl (Wien), V32, P15; BAGHDOYAN HA, 1984, BRAIN RES, V306, P39, DOI 10.1016/0006-8993(84)90354-8; BeitYannai E, 1996, BRAIN RES, V717, P22, DOI 10.1016/0006-8993(95)01492-6; BULLOCK R, 1991, VINKEN BRUYNS HDB CL, V24, P249; CANCIO LC, 1994, RESUSCITATION, V28, P9, DOI 10.1016/0300-9572(94)90049-3; CLEMENT JG, 1993, PHARMACOL BIOCHEM BE, V44, P689, DOI 10.1016/0091-3057(93)90187-X; DAUPHIN F, 1995, PHARMACOL THERAPEUT, V67, P385, DOI 10.1016/0163-7258(95)00022-4; DIXON CE, 1994, NEUROSCI LETT, V180, P127, DOI 10.1016/0304-3940(94)90503-7; ELLMAN GL, 1961, BIOCHEM PHARMACOL, V7, P88, DOI 10.1016/0006-2952(61)90145-9; GORMAN LK, 1989, J NEUROTRAUM, V6, P203; GRIEG ME, 1949, SCIENCE, V110, P237; HARDEBO JE, 1984, ACTA NEUROL SCAND, V70, P438; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; LOBATO RD, 1988, J NEUROSURG, V68, P417, DOI 10.3171/jns.1988.68.3.0417; LYETH BG, 1988, BRAIN RES, V448, P88, DOI 10.1016/0006-8993(88)91104-3; LYETH BG, 1988, BRAIN RES, V452, P39, DOI 10.1016/0006-8993(88)90006-6; SADOSHIMA S, 1995, J CEREBR BLOOD F MET, V15, P845, DOI 10.1038/jcbfm.1995.105; SAIJA A, 1988, Journal of Neurotrauma, V5, P161, DOI 10.1089/neu.1988.5.161; SHAPIRA Y, 1993, ANESTH ANALG, V77, P141; SHAPIRA Y, 1988, CRIT CARE MED, V16, P258, DOI 10.1097/00003246-198803000-00010; SHOHAMI E, 1993, J NEUROTRAUM, V10, P109, DOI 10.1089/neu.1993.10.109; SHOHAMI E, 1995, BRAIN RES, V674, P55, DOI 10.1016/0006-8993(94)01433-I; Shohami E, 1996, ISR J MED SCI S, V32, pS9; TANAKA K, 1994, NEUROCHEM RES, V19, P117, DOI 10.1007/BF00966804; TANAKA K, 1995, NEUROCHEM RES, V20, P663, DOI 10.1007/BF01705533; TRANCARD J, 1989, BRAIN RES, V476, P213, DOI 10.1016/0006-8993(89)91241-9; TSUJIMOTO S, 1993, ACTA NEUROCHIR, V124, P127, DOI 10.1007/BF01401134; UYAMA O, 1988, J CEREBR BLOOD F MET, V8, P282, DOI 10.1038/jcbfm.1988.59; WEINSTOCK M, 1994, J NEURAL TRANSM-SUPP, P219; Weinstock M., 1986, ADV BEHAV BIOL, P539; ZAUNER A, 1995, J NEUROTRAUM, V12, P547, DOI 10.1089/neu.1995.12.547	31	23	23	0	0	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0006-8993			BRAIN RES	Brain Res.	FEB 16	1998	784	1-2					18	24		10.1016/S0006-8993(97)00982-7			7	Neurosciences	Neurosciences & Neurology	ZC505	WOS:000072586800003	9518537				2021-06-18	
J	Hills, EC; Geldmacher, DS				Hills, EC; Geldmacher, DS			The effect of character and array type on visual spatial search quality following traumatic brain injury	BRAIN INJURY			English	Article							ATTENTION; NEGLECT; PERFORMANCE; DOMINANCE	Disorder; of visuomotor function are common following traumatic brain injury (TBI), but spatially directed visual attention has received little study in this population. 'Cancellation' testing is a common, bedside method for assessing directed attention, which can provide information on how task properties influence visual scanning and search following severe TBI. Groups of 20 individuals after severe TBI and 21 healthy control subjects were matched for age and education. Participants performed finger tapping tests to assess motor speed as well as four cancellation tests employing letter and geometric figure stimuli in random and structured arrays. Control and TBI groups differed significantly on measures of accuracy, task completion time, and search quality. There was no significant effect of stimulus or array type on accuracy or time. Figure targets in a higher search quality, suggesting a right hemispheric dominance effect on these tasks. The findings support a deficit in visuomotor scanning performance in TBI beyond a purely motor effect. Interactions between stimulus and array types suggest that hemispheric cooperation is required for the optimal performance of these tasks, and that interhemispheric communication may be preferentially compromised by TBI.	John F Kennedy Med Ctr, JFK Johnson Rehabil Inst, Dept Rehabil Med, Edison, NJ USA; John F Kennedy Med Ctr, JFK Johnson Rehabil Inst, Ctr Head Injuries, Edison, NJ USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Neurol, New Brunswick, NJ 08903 USA; Univ Med & Dent New Jersey, Robert Wood Johnson Med Sch, Dept Rehabil Med, New Brunswick, NJ 08903 USA	Geldmacher, DS (corresponding author), Alzheimer Ctr, 12200 Fairhill Rd, Cleveland, OH 44120 USA.						ALBERT ML, 1973, NEUROLOGY, V23, P658, DOI 10.1212/WNL.23.6.658; DIMOND SJ, 1979, CORTEX, V15, P43, DOI 10.1016/S0010-9452(79)80005-2; FOLDI NS, 1992, J GERONTOL, V47, pP146, DOI 10.1093/geronj/47.3.P146; GELDMACHER D, 1997, J INT NEUROPSYCH SOC, V3, P16; Geldmacher DS, 1996, BRAIN COGNITION, V32, P405, DOI 10.1006/brcg.1996.0073; Geldmacher DS, 1997, BRAIN INJURY, V11, P59, DOI 10.1080/026990597123818; GELDMACHER DS, 1994, NEUROPSY NEUROPSY BE, V7, P275; GELDMACHER DS, 1995, J INT NEUROPSYCH SOC, V1, P129; Hagen C., 1972, LEVELS COGNITIVE FUN; HEILMAN KM, 1980, NEUROLOGY, V30, P327, DOI 10.1212/WNL.30.3.327; HEILMAN KM, 1993, CLIN NEUROPSYCHOLOGY, P279; LEVIN HS, 1988, SCAND J REHABIL MED, P33; MARK VW, 1997, J INT NEUROPSYCH SOC, V3, P72; MCNENY R, 1990, NEUROREHABILITATION, V1, P72; MESUSLAM MM, 1985, PRINCIPLES BEHAV NEU; PONSFORD JL, 1988, J CLIN EXP NEUROPSYC, V10, P693, DOI 10.1080/01688638808402808; POSNER MI, 1984, J NEUROSCI, V4, P1863; POSNER MI, 1987, NEUROBEHAVIORAL RECO, P390; Shum D. H. K., 1990, CLIN NEUROPSYCHOL, V4, P151, DOI DOI 10.1080/13854049008401508; STUSS DT, 1989, J NEUROL NEUROSUR PS, V52, P742, DOI 10.1136/jnnp.52.6.742; vansZomeren AH, 1987, NEUROBEHAVIORAL RECO, P398; VILLARDITA C, 1983, ARCH NEUROL-CHICAGO, V40, P737, DOI 10.1001/archneur.1983.04050110055008; WEINTRAUB S, 1987, ARCH NEUROL-CHICAGO, V44, P621, DOI 10.1001/archneur.1987.00520180043014; WHITEHEAD R, 1991, J COGNITIVE NEUROSCI, V3, P329, DOI 10.1162/jocn.1991.3.4.329	24	23	23	0	1	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	JAN	1998	12	1					69	76		10.1080/026990598122872			8	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YT347	WOS:000071592500007	9483339				2021-06-18	
J	Frosch, S; Gruber, A; Jones, C; Myers, S; Noel, E; Westerlund, A; Zavisin, T				Frosch, S; Gruber, A; Jones, C; Myers, S; Noel, E; Westerlund, A; Zavisin, T			The long term effects of traumatic brain injury on the roles of caregivers	BRAIN INJURY			English	Article							FOLLOW-UP	This study was conducted to identify the long term effects of traumatic brain injury (TBI) on the roles of caregivers. The subjects consisted of 155 caregivers of survivors with TBI who were randomly selected from 15 midwestern stale brain injury association databases. A questionnaire was developed by the researchers to determine factors affecting role changes of caregivers. The Role Checklist, by Barris, Oakley and Kielhofner, was also included with the questionnaire. Both were mailed to each selected caregiver and used for data gathering. The data obtained were analysed to determine existing trends in the data. Graphs were utilized to depict the trends that was identified. The following trends and conclusions established by this research include: (a) behavioural effects of the survivor with a TBI are associated with the number of role changes experienced by caregivers; (b) participation in support systems is associated with the number of role changes experienced by caregivers; and (c) caregivers who care for a person with a TBI in the home will show a larger number of role changes than those who do not provide direct care for a person with a TBI.	UNIV INDIANAPOLIS, OCCUPAT THERAPY DEPT, INDIANAPOLIS, IN 46227 USA							American Heritage Dictionary, 1985, AM HERITAGE DICT; BAILEY D, 1991, RES HLTH PROFESSIONA; BARRIS R, 1987, MENTAL HLTH ASSESSME, P73; BROOKS N, 1986, J NEUROL NEUROSUR PS, V49, P764, DOI 10.1136/jnnp.49.7.764; Campbell C H, 1988, Rehabil Nurs, V13, P320; FAHY TJ, 1967, LANCET, V2, P475; HALL KM, 1994, ARCH PHYS MED REHAB, V75, P876, DOI 10.1016/0003-9993(94)90112-0; HALLETT JD, 1984, AM J OCCUPATIONAL TH, V48, P241; Krause Joan H., 1991, J HEAD TRAUMA REHAB, V6, P1; KREUTZER JS, 1994, BRAIN INJURY, V8, P211, DOI 10.3109/02699059409150974; LEACH LR, 1994, BRAIN INJURY, V8, P599, DOI 10.3109/02699059409151012; Thomsen I V, 1974, Scand J Rehabil Med, V6, P180; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILLIAMS SJ, 1993, INTRO HLTH SERVICES, P361	14	23	27	0	0	TAYLOR & FRANCIS INC	PHILADELPHIA	530 WALNUT STREET, STE 850, PHILADELPHIA, PA 19106 USA	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	DEC	1997	11	12					891	906					16	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	YG767	WOS:A1997YG76700005	9413623				2021-06-18	
J	Georgoulis, AD; Papageorgiou, CD; Makris, CA; Moebius, UG; Soucacos, PN				Georgoulis, AD; Papageorgiou, CD; Makris, CA; Moebius, UG; Soucacos, PN			Anterior cruciate ligament reconstruction with the press-fit technique - 2-5 years followed-up of 42 patients	ACTA ORTHOPAEDICA SCANDINAVICA			English	Article								42 patients underwent anterior cruciate ligament (ACL) reconstruction with the press-fit technique. The ACL was reconstructed with a bone-tendon-bone graft from the medial third of the patellar tendon.The graft was stabilized without screws in the femur and tibia by press-fit. To imitate the anatomical functioning of the ACL, the femoral bone block was placed with the tendon close to the over-the-top position. The tibial block was then placed in a trough on the tibia, so that the ligament fibres were parallel and tight during extension and slightly inverted during flexion. At evaluation mean 41 (25-61) months postoperatively, the mean Lysholm score was 93 (80-100) points, the mean activity level was 6 (3-10) points, and the mean translation of the tibia head, measured by the KT-1000 arthrometer (side-to-side difference), was 2 (0-7) mm. Only 3 of the patients suffered loss of extension (5 degrees). Patients who underwent reconstruction at least 4 months after the injury had better results than those who were operated earlier. The press-fit method allowed for anatomic substitution of the ACL with a stable graft without the disadvantages associated with screws. This method gave early postoperative functioning of the knee and good mid-term results.		Georgoulis, AD (corresponding author), UNIV IOANNINA,SCH MED,DEPT ORTHOPAED SURG,GR-45110 IOANNINA,GREECE.		Papageorgiou, Christos/AAI-5325-2021; Makris, Christos/AAN-2146-2021	Makris, Christos/0000-0003-2571-7449			Bernard M, 1996, UNFALLCHIRURG, V99, P332; BERNARD M, 1992, 1 WORLD C SPORTS TRA; BRADLEY J, 1988, J BONE JOINT SURG BR, V70, P94; CERULLO G, 1993, ARTHROSCOPY, V9, P712, DOI 10.1016/S0749-8063(05)80515-8; DANIEL DM, 1994, CRUCIAL LIGAMENTS, P387; DIJAN P, 1994, KNEE SURG SPORTS TRA, V2, P207; FAHEY M, 1994, AM J SPORT MED, V22, P410, DOI 10.1177/036354659402200318; Feagin J A Jr, 1976, Am J Sports Med, V4, P95, DOI 10.1177/036354657600400301; FEAGIN JA, 1994, CRUCIAL LIGAMENTS, P269; FEAGIN JA, 1995, SPORTS EXERCISE INJU, V1, P176; FRIEDMANN RL, 1994, CLIN ORTHOPAEDICS, V306, P163; GEORGOULIS AD, 1996, HEID KREUZB S 28 30; GIRGIS FG, 1975, CLIN ORTHOPAEDICS, V106, P216; HERTEL P, 1994, ARTHROSKOPISCHE VERS; HOWELL SM, 1993, J BONE JOINT SURG AM, V75A, P1044, DOI 10.2106/00004623-199307000-00011; JOHNSON LL, 1994, CRUCIAL LIGAMENTS DI, P555; KUROSAKA M, 1987, AM J SPORT MED, V15, P225, DOI 10.1177/036354658701500306; LAIS E, 1991, THESIS FREIE U BERLI; LINSALATA JC, 1996, 2 WORLD C SPORTS TRA; LYSHOLM J, 1982, AM J SPORT MED, V10, P150, DOI 10.1177/036354658201000306; NOULIS G, 1875, THESIS FM PARIS, P1; PAESSLER HH, 1992, AM J SPORT MED, V20, P95, DOI 10.1177/036354659202000122; SACHS RA, 1989, AM J SPORT MED, V17, P760, DOI 10.1177/036354658901700606; Schulte K., 1995, ARTHROSCOPY, V11, P372; SHAFFER B, 1993, ARTHROSCOPY, V9, P633, DOI 10.1016/S0749-8063(05)80499-2; TEGNER Y, 1985, CLIN ORTHOP RELAT R, P00043; Torg J S, 1976, Am J Sports Med, V4, P84, DOI 10.1177/036354657600400206; Xerogeanes J W, 1995, Knee Surg Sports Traumatol Arthrosc, V3, P9, DOI 10.1007/BF01553518	28	23	23	0	0	SCANDINAVIAN UNIVERSITY PRESS	OSLO	PO BOX 2959 TOYEN, JOURNAL DIVISION CUSTOMER SERVICE, N-0608 OSLO, NORWAY	0001-6470			ACTA ORTHOP SCAND	Acta Orthop. Scand.	OCT	1997	68			275			42	45		10.1080/17453674.1997.11744742			4	Orthopedics	Orthopedics	YF063	WOS:A1997YF06300011	9385264	Bronze			2021-06-18	
J	Persel, CS; Persel, CH; Ashley, MJ; Krych, DK				Persel, CS; Persel, CH; Ashley, MJ; Krych, DK			The use of noncontingent reinforcement and contingent restraint to reduce physical aggression and self-injurious behaviour in a traumatically brain injured adult	BRAIN INJURY			English	Article							CLOSED HEAD-INJURY; DIFFERENTIAL REINFORCEMENT; MANAGEMENT; DISORDERS; AGITATION	Many different intervention programmes for reducing undesirable behaviour with people with traumatic brain injury (TBI) have been investigated in recent years. The purpose of this study was to examine the potential of using noncontingent reinforcement (NCR) in combination with contingent restraint to reduce severe behaviour. The subject (E.L.) was a 40-year-old male with TBI admitted to a rehabilitation long-term care programme. E.L. had a history of physical aggression (PA) and self-injurious behaviour (SIB). Assessment conditions included a descriptive analysis, response scatterplot and Self-Injury Trauma (SIT) Scale. Attention was identified as the maintaining positive reinforcement for PA and SIE. Treatment conditions were compared using a reversal (ABAB) design. Attention (NCR) was delivered on a fixed-time schedule that was not dependent on the subject's behaviour. Contingent restraint was applied when E.L. exhibited PA or SIE that was dangerous to himself or others. During treatment, PA occurred over 4 times less often and SIE over 2.5 times less often. Results demonstrated that PA and SIE were sensitive to NCR. NCR can be an effective procedure for reducing severe behaviour maintained by socially-mediated positive reinforcement.	CTR NEURO SKILLS,IRVING,TX	Persel, CS (corresponding author), CTR NEURO SKILLS,DEPT RES & DEV,2658 MT VERNON AVE,BAKERSFIELD,CA 93306, USA.						ALBERTO PA, 1990, APPL BEHAV ANAL TEAC; BAER DM, 1968, J APPL BEHAV ANAL, V1, P91, DOI 10.1901/jaba.1968.1-91; BLACKERBY WF, 1988, J HEAD TRAUMA REHAB, V3, P33; BROOKE MM, 1992, ARCH PHYS MED REHAB, V73, P320, DOI 10.1016/0003-9993(92)90003-F; CORRIGAN JD, 1988, ARCH PHYS MED REHAB, V69, P487; DAVIS JR, 1994, BRAIN INJURY, V8, P589, DOI 10.3109/02699059409151011; DENNYBROWN D, 1945, JAMA-J AM MED ASSOC, V127, P429, DOI 10.1001/jama.1945.02860080001001; GERVASIO AH, 1995, NEUROREHABILITATION, V5, P309, DOI 10.3233/NRE-1995-5405; GIBBS JW, 1985, BEHAV MODIF, V9, P3, DOI 10.1177/01454455850091001; IWATA BA, 1990, J APPL BEHAV ANAL, V23, P99, DOI 10.1901/jaba.1990.23-99; IWATA BA, 1982, ANAL INTERVENTION DE, V2, P1; JACOBS HE, 1993, BEHAV ANAL GUID BRAI; Konarski E. A., 1989, BEHAV RESIDENTIAL TR, V4, P45; LAVIGNA GW, 1986, ALTENATIVE PUNISHMEN; LEVIN HS, 1978, ARCH NEUROL-CHICAGO, V35, P720, DOI 10.1001/archneur.1978.00500350024005; Marcus BA, 1996, J APPL BEHAV ANAL, V29, P43, DOI 10.1901/jaba.1996.29-43; NEVIN JA, 1990, J EXP ANAL BEHAV, V53, P359, DOI 10.1901/jeab.1990.53-359; REPP AC, 1976, J APPL BEHAV ANAL, V9, P501, DOI 10.1901/jaba.1976.9-501; ROMANCZYK RG, 1986, ADV LEARNING BEHAV D, P29; SMITH P, 1983, PROF ASS RESP TRAIN; Spreat S., 1986, BEHAVIORAL RESIDENTI, V1, P57; TOUCHETTE PE, 1985, J APPL BEHAV ANAL, V18, P343, DOI 10.1901/jaba.1985.18-343; Treadwell K, 1996, J HEAD TRAUMA REHAB, V11, P62, DOI 10.1097/00001199-199602000-00008; UOMOTO JM, 1992, ARCH PHYS MED REHAB, V73, P674; VanReekum R, 1996, BRAIN INJURY, V10, P319, DOI 10.1080/026990596124340; VOLLMER TR, 1993, J APPL BEHAV ANAL, V26, P9, DOI 10.1901/jaba.1993.26-9; YUEN HK, 1996, BRAIN INJURY, V3, P229; Zencius A H, 1989, Brain Inj, V3, P199, DOI 10.3109/02699058909004553	28	23	23	2	10	TAYLOR & FRANCIS LTD	LONDON	ONE GUNPOWDER SQUARE, LONDON, ENGLAND EC4A 3DE	0269-9052			BRAIN INJURY	Brain Inj.	OCT	1997	11	10					751	760					10	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XY415	WOS:A1997XY41500006	9354251				2021-06-18	
J	Karger, B; DuChesne, A; Ortmann, C; Brinkmann, B				Karger, B; DuChesne, A; Ortmann, C; Brinkmann, B			Unusual self-inflicted injuries simulating a criminal offence	INTERNATIONAL JOURNAL OF LEGAL MEDICINE			English	Article						self-inflicted injuries; atypical injuries; wound morphology		A total of 14 cases with self-inflicted injuries intended to simulate a criminal offence are reported. Typical characteristics of self-infliction such as superficiality, localisation at the anterior aspect, parallel course or avoidance of areas with high sensitivity to pain are substantiated by most of the cases analysed. However, the majority of cases also comprised atypical features including large hematomas of the extremities, a gaping cut wound, lip laceration, hematoma of the eyelids, concussion of the brain, large burn injuries and signs of bonding. Therefore, atypical injuries, which are either found in isolation or in combination with typical injury patterns, cannot exclude self-infliction. Initially, most ''victims'' did not intend to report the matter to the police but the persons whose affection was to be obtained made the report. Psychopathological motivations are predominant but rational motives such as attempted insurance fraud also occur.		Karger, B (corresponding author), UNIV MUNSTER,INST LEGAL MED,VON ESMARCH STR 86,D-48149 MUNSTER,GERMANY.						HOLITZNER WV, 1993, Z PSYCHOSOM MED PSYC, V39, P319; HOLZER FJ, 1969, ARCH KRIMINOL, V143, P1; HOLZER FJ, 1969, ARCH KRIMINOL, V143, P96; KNIGHT BH, 1968, MED SCI LAW, V8, P264, DOI 10.1177/002580246800800409; Konig H G, 1987, Arch Kriminol, V180, P13; LOCHTE T, 1913, VIERTELJAHRESSCHR S, V45, P261; MAYER J, 1937, HDB ARTEFAKTE; MCKERRACHER DW, 1968, BRIT J PSYCHIAT, V114, P829, DOI 10.1192/bjp.114.512.829; METTER D, 1989, MED SACH, V1, P14; POLLAK S, 1987, Archiv fuer Kriminologie, V179, P81; PUSCHEL K, 1994, HAUTNAH PADIATR, V6, P170; SACHSSE U, 1987, FORUM PSYCHOANAL, V3, P51; SCHULZ F, 1981, Aktuelle Dermatologie, V7, P10; SMITH S, 1949, FORENSIC MED, P168; SNEDDON I, 1975, BRIT MED J, V3, P527, DOI 10.1136/bmj.3.5982.527; STRASSMANN F, 1910, VJSCHR GERICHTL ME S, V39, P3	16	23	23	0	2	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0937-9827			INT J LEGAL MED	Int. J. Legal Med.	SEP	1997	110	5					267	272		10.1007/s004140050083			6	Medicine, Legal	Legal Medicine	XT496	WOS:A1997XT49600007	9297583				2021-06-18	
J	Butler, K; Rourke, BP; Fuerst, DR; Fisk, JL				Butler, K; Rourke, BP; Fuerst, DR; Fisk, JL			A typology of psychosocial functioning in pediatric closed-head injury	CHILD NEUROPSYCHOLOGY			English	Article; Proceedings Paper	24th Annual Meeting of the International-Neuropsychological-Society	FEB 15-17, 1996	CHICAGO, IL	Int Neuropsychol Soc, US PHS, Natl Inst Aging, Alzheimers Dis Cooperat Study			LEARNING-DISABLED CHILDREN; PERSONALITY SUBTYPES; ADJUSTMENT; SEQUELAE; CRITERIA	A typology of psychosocial functioning following pediatric closed-head injury (CHI) was derived by subjecting Personality Inventory for Children Revised (PIC-R) profiles to cluster analyses. Participants (N = 128) aged 6 to 16 years were classified into mild, moderate, and severe injury groups based on loss of consciousness (LOG), Glasgow Coma Scale (GCS), and so forth. On average, subjects were injured at 8.78 years of age and were assessed 2.12 years following their injury. Using four hierarchical-agglomerative clustering techniques, a seven-subtype typology was derived that overlapped, in part, with typologies previously reported for children with learning disabilities (LD). Based on clinical scale elevations of the mean PIC-R profiles, the subtypes were labeled Normal, Cognitive Deficit, Somatic Concern, Mild Anxiety, Internalized Psychopathology, Antisocial, and Social Isolation. Statistically significant relationships were found between psychosocial subtype membership and (a) injury severity, and (b) age at injury. Children assigned to the Social Isolation subtype were more likely to have severe CHI, and to have been injured at younger ages. Children tested after longer intervals since sustaining their CHI also tended to be assigned to the Social Isolation subtype. This subtype had elevations on the PIC-R cognitive triad and Psychosis scales, and may represent a persistent pattern of psychosocial disturbance following childhood CHI.	UNIV WINDSOR,WINDSOR,ON N9B 3P4,CANADA; YALE UNIV,NEW HAVEN,CT 06520; WAYNE STATE UNIV,SCH MED,DETROIT,MI 48202; HENRY FORD HOSP,DETROIT,MI							ACHENBACH TM, 1983, MANUAL CHILD BEHAVIO; ACHENBACH TM, 1986, TEACHERS REPORT FORM; Aldenderfer M.S., 1984, CLUSTER ANAL; ASARNOW RF, 1991, J PEDIATR PSYCHOL, V16, P543, DOI 10.1093/jpepsy/16.5.543; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; BUTLER K, 1997, UNPUB NEUROPSYCHOLOG; CASEY R, 1986, PEDIATRICS, V78, P497; CHADWICK O, 1981, Journal of Clinical Neuropsychology, V3, P101, DOI 10.1080/01688638108403117; CONNERS C, 1973, PSYCHOPHARMACOLOGY B, V9, P24; DIKMEN SS, 1989, MILD HEAD INJURY, P229; DONDERS J, 1992, J ABNORM CHILD PSYCH, V20, P233, DOI 10.1007/BF00916690; Fletcher J.M., 1985, NEUROPSYCHOLOGY LEAR, P187; FLETCHER JM, 1990, J CONSULT CLIN PSYCH, V58, P93, DOI 10.1037/0022-006X.58.1.93; FUERST DR, 1989, J CONSULT CLIN PSYCH, V57, P275, DOI 10.1037/0022-006X.57.2.275; FUERST DR, 1990, J CONSULT CLIN PSYCH, V58, P657, DOI 10.1037/0022-006X.58.5.657; FUERST DR, 1993, J ABNORM CHILD PSYCH, V21, P597, DOI 10.1007/BF00916445; Fuerst DR, 1995, CHILD NEUROPSYCHOL, V1, P38, DOI 10.1080/09297049508401341; FUERST DR, 1991, THESIS U WINDSOR ONT; GDOWSKI CL, 1985, J ABNORM PSYCHOL, V94, P346, DOI 10.1037/0021-843X.94.3.346; HUBERT L, 1985, J CLASSIF, V2, P193, DOI 10.1007/BF01908075; KNIGHTS R M, 1991, Brain Injury, V5, P339, DOI 10.3109/02699059109008107; KNIGHTS RM, 1981, NEUROPSYCHOLOGICAL A, P335; Lachar D, 1982, PERSONALITY INVENTOR; LACOMBE JA, 1991, PSYCHOL ASSESSMENT J, V3, P678; LEVIN HS, 1989, MILD HEAD INJURY, P189; Lorr M., 1983, CLUSTER ANAL SOCIAL; MILLIGAN GW, 1986, MULTIVAR BEHAV RES, V21, P441, DOI 10.1207/s15327906mbr2104_5; MOREY LC, 1984, EDUC PSYCHOL MEAS, V44, P33, DOI 10.1177/0013164484441003; PORTER JE, 1985, NEUROPSYCHOLOGY LEAR, P257; RAND WM, 1971, J AM STAT ASSOC, V66, P846, DOI 10.2307/2284239; Rourke B. P., 1991, LEARNING DISABILITIE; ROURKE BP, 1986, NEUROPSYCHOLOGICAL A; Rourke BP, 1989, NONVERBAL LEARNING D; Rutherford W. H., 1989, MILD HEAD INJURY, P217; RUTTER M, 1981, AM J PSYCHIAT, V138, P1533; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SARLE WS, 1985, SAS USERS GUIDE STAT, P255; SHAFFER D, 1975, CIBA FDN S, P191; SOKAL ROBERT R., 1958, UNIV KANSAS SCI BULL, V38, P1409; SOrensen T, 1948, K DANSKE VIDENSK SEL, V5, P1; Sparrow S., 1984, VINELAND ADAPTIVE BE; WARD JH, 1963, J AM STAT ASSOC, V58, P236, DOI 10.2307/2282967; WINOGRON HW, 1984, J CLIN NEUROPSYCHOL, V6, P269, DOI 10.1080/01688638408401218; WIRT RD, 1977, MULTIDIMENSIONAL DES; WIRT RD, 1984, MULTIDIMENSIONAL DES	45	23	23	0	3	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	0929-7049			CHILD NEUROPSYCHOL	Child Neuropsychol.	AUG	1997	3	2					98	133		10.1080/09297049708401371			36	Clinical Neurology	Neurosciences & Neurology	XR523	WOS:A1997XR52300002					2021-06-18	
J	Prat, R; Markiv, V; Dujovny, M; Misra, M				Prat, R; Markiv, V; Dujovny, M; Misra, M			Evaluation of cerebral autoregulation following diffuse brain injury in rats	NEUROLOGICAL RESEARCH			English	Article						autoregulation; diffuse brain injury; laser-Doppler flowmetry; arterial pressure; cerebral perfusion pressure	LASER-DOPPLER FLOWMETRY; BLOOD-FLOW VELOCITY; HEAD-INJURY; PERFUSION-PRESSURE; MAGNETIC-RESONANCE; MODEL; PH	The normal cerebral circulation has the ability to maintain a stable cerebral blood flow over a wide range of cerebral perfusion pressures and this is known as cerebral autoregulation. This autoregulation may be impaired in the injured brain. Closed head injury was induced in 28 Sprague-Dawley rats weighing 400-450 g. Four groups were studied: control group, head injured rat from meter height using 350 g, 400 g and 450 g respectively. CBF, volume velocity was monitored using laser-Doppler flowmetry together with monitoring of ICP and arterial blood pressure. Correlation to assess the relationship between CBF and CPP was done in each animal every hour. if correlation coefficient was > 0.85 and CPP was within normal range, loss of autoregulation was hypothesized. Chi square test, ANOVA test and unpaired Student's t-test were done and significant level of p<0.05 was established. Mean CBF in injured rats was significantly lower than controls (p=0.028) at the fifth hour. CBV was lower in the group of 450 g 1 m impact than in controls at 3 h (p=0.04). Velocity in the group of all injured rats, was significantly lower than in controls at 3 h (p=0.032) and at 4 h (p=0.027). Loss of autoregulation was seen during first four hours after trauma in all groups of rats who sustained injury. Statistical significant difference (p=0.041) in loss of autoregulation between injured and control animals was seen. No loss of autoregulation was observed in the control group. In conclusion CBF and CPP provide information about loss of autoregulation in diffuse brain injury. Decrease in CBF and increase of ICP is observed as a result of loss of cerebral autoregulation. Knowledge of loss of autoregulation could give important information and help in the management of head injured patients.	UNIV ILLINOIS, DEPT NEUROSURG, CHICAGO, IL 60612 USA							AASLID R, 1989, STROKE, V20, P45, DOI 10.1161/01.STR.20.1.45; Arbit E, 1996, NEUROSURG CLIN N AM, V7, P741; CZOSNYKA M, 1994, ACTA NEUROCHIR, P468; DICKMAN CA, 1991, NEUROSURGERY, V28, P467, DOI 10.1227/00006123-199103000-00026; DIRNAGL U, 1989, J CEREBR BLOOD F MET, V9, P589, DOI 10.1038/jcbfm.1989.84; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DUJOVNY M, 1994, NEUROSURGERY, V34, P935; Fabricius M, 1996, J CEREBR BLOOD F MET, V16, P156, DOI 10.1097/00004647-199601000-00018; FLORENCE G, 1992, J CEREBR BLOOD F MET, V12, P674, DOI 10.1038/jcbfm.1992.92; FODA MAA, 1994, J NEUROSURG, V80, P301, DOI 10.3171/jns.1994.80.2.0301; Gennarelli TA, 1993, HEAD INJURY, P137; Giulioni M, 1996, NEUROSURGERY, V39, P1005, DOI 10.1097/00006123-199611000-00024; HABERL RL, 1993, ACTA NEUROCHIR, P64; HABERL RL, 1989, AM J PHYSIOL, V256, pH1247; HABERL RL, 1989, AM J PHYSIOL, V256, pH1255; HERNANDEZAVILA G, 1995, AM J NEURORADIOL, V16, P1618; ITO J, 1996, NEUROSURGERY, V84, P97; KEMPSKI O, 1995, INT J MICROCIRC, V15, P37, DOI 10.1159/000178947; KIRKPATRICK PJ, 1994, J NEUROL NEUROSUR PS, V57, P1382, DOI 10.1136/jnnp.57.11.1382; LAM AM, 1992, BRIT J ANAESTH, V68, P424, DOI 10.1093/bja/68.4.424; Lam JMK, 1997, J NEUROSURG, V86, P438, DOI 10.3171/jns.1997.86.3.0438; Lang E W, 1994, Neurosurg Clin N Am, V5, P573; Lang E W, 1995, New Horiz, V3, P400; LIGHTHALL J W, 1989, Journal of Neurotrauma, V6, P83, DOI 10.1089/neu.1989.6.83; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; MARSHALL LF, 1983, J NEUROSURG, V59, P276, DOI 10.3171/jns.1983.59.2.0276; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MENDELOW AD, 1985, J NEUROSURG, V63, P43, DOI 10.3171/jns.1985.63.1.0043; MEYERSON BA, 1991, NEUROSURGERY, V29, P750, DOI 10.1227/00006123-199111000-00018; MISRA M, IN PRESS POSTURAL CH; NAWASHIRO H, 1995, J NEUROTRAUM, V12, P189, DOI 10.1089/neu.1995.12.189; NILSSON B, 1977, J NEUROSURG, V47, P274, DOI 10.3171/jns.1977.47.2.0274; SAHUQUILLO J, 1993, ACTA NEUROCHIR, V122, P204, DOI 10.1007/BF01405530; SKARPHEDINSSON JO, 1988, ACTA PHYSIOL SCAND, V134, P133, DOI 10.1111/j.1748-1716.1988.tb08469.x; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; Yamakami Iwao, 1993, Neurologia Medico-Chirurgica, V33, P7, DOI 10.2176/nmc.33.7; YAMAKI T, 1994, J NEUROTRAUM, V11, P613, DOI 10.1089/neu.1994.11.613; Yamaki T, 1996, J TRAUMA, V40, P50, DOI 10.1097/00005373-199601000-00010	38	23	23	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0161-6412	1743-1328		NEUROL RES	Neurol. Res.	AUG	1997	19	4					393	402		10.1080/01616412.1997.11740832			10	Clinical Neurology; Neurosciences	Neurosciences & Neurology	XQ220	WOS:A1997XQ22000009	9263220				2021-06-18	
J	Ying, WH				Ying, WH			Deleterious network: A testable pathogenetic concept of Alzheimer's disease	GERONTOLOGY			English	Article						Alzheimer's disease; pathogenesis; amyloid precursor protein metabolism; oxidative damage; energy metabolism; calcium homeostasis	AMYLOID-BETA-PEPTIDE; AMYOTROPHIC-LATERAL-SCLEROSIS; FREE-RADICAL THEORY; CALCIUM CHANNELS; HEAD-INJURY; CELL-DEATH; NEUROFIBRILLARY TANGLES; PARKINSONISM-DEMENTIA; HIPPOCAMPAL-NEURONS; GLUCOSE-METABOLISM	Cumulative evidence has indicated that a deleterious network is formed on the basis of close interactions among abnormal amyloid precursor protein (APP) metabolism, oxidative damage, compromised energy metabolism and impaired calcium homeostasis. A unifying hypothesis - the deleterious network hypothesis of Alzheimer's disease (AD)- proposes that the deleterious network, not any single factor, is the common pathway of AD. Aging and multiple genetic or environmental factors could trigger the network by promoting the occurrence of one or more of the key detrimental factors, leading to a number of pathological changes of the disorder. This new hypothesis appears to unify some major theories of AD, providing a sound basis for consistent explanations to a large variety of the observations about the disorder. In this article up-to-date delineation of the novel theory is given. Three types of studies are also proposed for further determining the validity of the new hypothesis. Based on this theory, it is suggested that combinative applications of the approaches which can reduce the incidence of the four key pathological factors could become a new therapeutic strategy of AD.		Ying, WH (corresponding author), UNIV NEW MEXICO,SCH MED,DEPT PHYSIOL,BASIC MED SCI BLDG 234,ALBUQUERQUE,NM 87131, USA.						ARISPE N, 1993, P NATL ACAD SCI USA, V90, P567, DOI 10.1073/pnas.90.2.567; BANDY B, 1990, FREE RADICAL BIO MED, V8, P523, DOI 10.1016/0891-5849(90)90152-9; BEAL MF, 1992, ANN NEUROL, V31, P119, DOI 10.1002/ana.410310202; BEHL C, 1994, CELL, V77, P817, DOI 10.1016/0092-8674(94)90131-7; BENSHACHAR D, 1991, J NEUROCHEM, V57, P2133, DOI 10.1111/j.1471-4159.1991.tb06432.x; BLANCO P, 1994, NEUROSCI LETT, V165, P5, DOI 10.1016/0304-3940(94)90696-3; BRAAK H, 1996, ACTA NEUROL SCAND, V165, P3; BROUILLET E, 1995, P NATL ACAD SCI USA, V92, P7105, DOI 10.1073/pnas.92.15.7105; BUSCIGLIO J, 1995, NEURON, V14, P879, DOI 10.1016/0896-6273(95)90232-5; BUSCIGLIO J, 1995, NATURE, V378, P776, DOI 10.1038/378776a0; CHENG B, 1992, EXP NEUROL, V117, P114, DOI 10.1016/0014-4886(92)90120-F; CORTOPASSI G, 1995, BBA-MOL BASIS DIS, V1271, P171, DOI 10.1016/0925-4439(95)00025-Y; DAVIGNON J, 1988, ARTERIOSCLEROSIS, V8, P1, DOI 10.1161/01.ATV.8.1.1; Davis Robert E., 1996, Neurology, V46, pA276; DYRKS T, 1992, J BIOL CHEM, V267, P18210; EISEN A, 1992, CAN J NEUROL SCI, V19, P117, DOI 10.1017/S0317167100041482; ELLIS WG, 1974, NEUROLOGY, V24, P101, DOI 10.1212/WNL.24.2.101; Forster MJ, 1996, P NATL ACAD SCI USA, V93, P4765, DOI 10.1073/pnas.93.10.4765; FRATIGLIONI L, 1996, ACTA NEUROL SCAND  S, V165, P33; Frederikse PH, 1996, J BIOL CHEM, V271, P10169, DOI 10.1074/jbc.271.17.10169; GABUZDA D, 1994, J BIOL CHEM, V269, P13623; GIBBSON GE, 1984, J NEUROCHEM, V37, P978; GITTER BD, 1995, P NATL ACAD SCI USA, V92, P10738, DOI 10.1073/pnas.92.23.10738; Goodman YD, 1996, J NEUROCHEM, V66, P1836; GREENLUND LJS, 1995, NEURON, V14, P303, DOI 10.1016/0896-6273(95)90287-2; HARDY JA, 1992, SCIENCE, V256, P184, DOI 10.1126/science.1566067; HARMAN D, 1993, AGE, V16, P23, DOI 10.1007/BF02436127; HASHAM MI, 1994, CAN J PHYSIOL PHARM, V72, P728, DOI 10.1139/y94-104; HEBBEL RP, 1986, BIOCHIM BIOPHYS ACTA, V862, P8, DOI 10.1016/0005-2736(86)90463-3; HEIZMANN CW, 1992, TRENDS NEUROSCI, V15, P259, DOI 10.1016/0166-2236(92)90067-I; HENSLEY K, 1994, P NATL ACAD SCI USA, V91, P3270, DOI 10.1073/pnas.91.8.3270; HENSLEY K, 1995, J NEUROCHEM, V65, P2146; HOYER S, 1995, DRUG AGING, V6, P210, DOI 10.2165/00002512-199506030-00004; HOYER S, 1991, ANN NY ACAD SCI, V640, P65; Hsiao K, 1996, SCIENCE, V274, P99, DOI 10.1126/science.274.5284.99; HUTCHIN T, 1995, P NATL ACAD SCI USA, V92, P6892, DOI 10.1073/pnas.92.15.6892; KANEKO I, 1995, J NEUROCHEM, V65, P2585; KHACHATURIAN ZS, 1994, ANN NY ACAD SCI, V747, P1; KONTOS HA, 1985, CIRC RES, V57, P142, DOI 10.1161/01.RES.57.1.142; KONTOS HA, 1986, J NEUROSURG, V64, P803, DOI 10.3171/jns.1986.64.5.0803; KOROTZER AR, 1995, EUR J PHARM-MOLEC PH, V288, P125, DOI 10.1016/0922-4106(95)90006-3; KOWALTOWSKI AJ, 1995, AM J PHYSIOL-CELL PH, V269, pC141; Lippa CF, 1996, NEUROLOGY, V46, P406, DOI 10.1212/WNL.46.2.406; Lizasoain I, 1996, BIOCHEM J, V314, P877, DOI 10.1042/bj3140877; LLINAS R, 1993, P NATL ACAD SCI USA, V90, P11743, DOI 10.1073/pnas.90.24.11743; MARK RJ, 1995, J NEUROSCI, V15, P6239; Masliah E, 1996, J NEUROSCI, V16, P5795; MATTSON MP, 1993, BRAIN RES, V602, P21, DOI 10.1016/0006-8993(93)90236-G; MATTSON MP, 1995, BRAIN RES, V676, P219, DOI 10.1016/0006-8993(95)00148-J; MATTSON MP, 1993, BRAIN RES, V621, P35, DOI 10.1016/0006-8993(93)90295-X; MATTSON MP, 1990, NEURON, V4, P105, DOI 10.1016/0896-6273(90)90447-N; Maurice T, 1996, BRAIN RES, V706, P181, DOI 10.1016/0006-8993(95)01032-7; MAYEUX R, 1995, NEUROLOGY, V45, P555, DOI 10.1212/WNL.45.3.555; MCCORMACK JG, 1985, BIOCHEM J, V231, P581, DOI 10.1042/bj2310581; MECOCCI P, 1993, ANN NEUROL, V34, P609, DOI 10.1002/ana.410340416; Mecocci P, 1996, NEUROSCI LETT, V207, P129, DOI 10.1016/0304-3940(96)12509-X; MeierRuge W, 1996, REV NEUROSCIENCE, V7, P1; MEIERRUGE W, 1994, GERONTOLOGY, V40, P246; Montine TJ, 1996, J NEUROPATH EXP NEUR, V55, P202, DOI 10.1097/00005072-199602000-00009; NADLER V, 1995, BRAIN RES, V685, P1, DOI 10.1016/0006-8993(95)00367-Y; OHKURA T, 1994, ENDOCR J, V41, P361, DOI 10.1507/endocrj.41.361; PACIFICI RE, 1991, GERONTOLOGY, V37, P166; PARKER WD, 1994, NEUROLOGY, V44, P1090, DOI 10.1212/WNL.44.6.1090; PIKE CJ, 1992, NEUROREPORT, V3, P769, DOI 10.1097/00001756-199209000-00012; POLVIKOSKI T, 1995, NEW ENGL J MED, V333, P1242, DOI 10.1056/NEJM199511093331902; QUERFURTH HW, 1994, BIOCHEMISTRY-US, V33, P4550, DOI 10.1021/bi00181a016; Reiman EM, 1996, NEW ENGL J MED, V334, P752, DOI 10.1056/NEJM199603213341202; ROBERTS GW, 1994, J NEUROL NEUROSUR PS, V57, P419, DOI 10.1136/jnnp.57.4.419; RODER HM, 1991, J NEUROSCI, V11, P3325; RODER HM, 1993, BIOCHEM BIOPH RES CO, V193, P639, DOI 10.1006/bbrc.1993.1672; SAITO KI, 1993, P NATL ACAD SCI USA, V90, P2628, DOI 10.1073/pnas.90.7.2628; Scheuner D, 1996, NAT MED, V2, P864, DOI 10.1038/nm0896-864; SCHWAB C, 1995, ACTA NEUROPATHOL, V90, P287; SCHWEERS O, 1995, P NATL ACAD SCI USA, V92, P8463, DOI 10.1073/pnas.92.18.8463; SHIMOHAMA S, 1993, NEUROLOGY, V43, P1407, DOI 10.1212/WNL.43.7.1407; SLANSKY I, 1995, NEURORADIOLOGY, V37, P270; SMITH CD, 1991, P NATL ACAD SCI USA, V88, P10540, DOI 10.1073/pnas.88.23.10540; Smith MA, 1996, NATURE, V382, P120, DOI 10.1038/382120b0; SOHAL RS, 1993, P NATL ACAD SCI USA, V90, P7255, DOI 10.1073/pnas.90.15.7255; SOHAL RS, 1989, MECH AGEING DEV, V49, P129, DOI 10.1016/0047-6374(89)90096-1; SPENCER PS, 1987, SCIENCE, V237, P517, DOI 10.1126/science.3603037; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Thibault O, 1996, SCIENCE, V272, P1017, DOI 10.1126/science.272.5264.1017; Thomas T, 1996, NATURE, V380, P168, DOI 10.1038/380168a0; TODOKI K, 1992, AM J PHYSIOL, V262, pH806; TRONCOSO JC, 1993, BRAIN RES, V613, P313, DOI 10.1016/0006-8993(93)90918-D; TRUMP BF, 1995, FASEB J, V9, P219; VANRENSBURG SJ, 1995, MED HYPOTHESES, V44, P268, DOI 10.1016/0306-9877(95)90178-7; VANRENSBURG SJ, 1993, NEUROREPORT, V4, P1269, DOI 10.1097/00001756-199309000-00015; Vito P, 1996, SCIENCE, V271, P521, DOI 10.1126/science.271.5248.521; VOLTERRA A, 1994, J NEUROSCI, V14, P2924; WEI EP, 1980, CIRC RES, V46, P37, DOI 10.1161/01.RES.46.1.37; Yamatsuji T, 1996, SCIENCE, V272, P1349, DOI 10.1126/science.272.5266.1349; YAN SD, 1995, NAT MED, V1, P693, DOI 10.1038/nm0795-693; Yan SD, 1996, NATURE, V382, P685, DOI 10.1038/382685a0; Ying W, 1996, MED HYPOTHESES, V47, P307, DOI 10.1016/S0306-9877(96)90071-7; Ying W, 1996, MED HYPOTHESES, V46, P421, DOI 10.1016/S0306-9877(96)90021-3; YING W, IN PRESS MED HYPOTHE; ZOCCARATO F, 1993, BIOCHIM BIOPHYS ACTA, V1176, P208, DOI 10.1016/0167-4889(93)90046-R	99	23	31	0	2	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	0304-324X			GERONTOLOGY	Gerontology	JUL-AUG	1997	43	4					242	253					12	Geriatrics & Gerontology	Geriatrics & Gerontology	XG398	WOS:A1997XG39800007	9222753				2021-06-18	
J	Nabors, NA; Millis, SR; Rosenthal, M				Nabors, NA; Millis, SR; Rosenthal, M			Use of the neurobehavioral cognitive status examination (Cognistat) in traumatic brain injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article							STROKE PATIENTS; REHABILITATION	Objective: To examine the relationship between the Neurobehavioral Cognitive Status Examination (Cognistat) and established neuropsychological measures of related constructs in a traumatic brain injury (TBI) sample. Design: A retrospective study of 45 patients who were administered Cognistat as part of a neuropsychological evaluation. Setting: A tertiary care rehabilitation center. Patients: Forty-five TBI patients admitted to an inpatient rehabilitation unit from January 1994 through December 1995 and referred for a neuropsychological evaluation. Main Outcome Measure: Cognistat, a neuropsychological screening measure, that assesses orientation, attention, language, memory, calculation, construction, and reasoning. Pearson zero-order correlations were calculated between Cognistat subtests and selected standard neuropsychological measures. It was hypothesized that Cognistat would be associated with the standard neuropsychological measures. Results: The following Cognistat subtests were significantly associated with standard neuropsychological measures: Cognistat Memory with the California Verbal Learning Test and Logical Memory, Cognistat Comprehension with the Token Test, Cognistat Construction with Block Design, and Cognistat Attention with Trails A. No significant relationship was found between Cognistat reasoning subtests and the Wisconsin Card Sorting Test. Conclusion: Consistent with the hypotheses, Cognistat subtests were significantly associated with standard neuropsychological measures of related cognitive constructs. These findings suggest that general statements regarding specific domains of cognitive functioning can be made using Cognistat subtest scores.	WAYNE STATE UNIV,SCH MED,DEPT PHYS MED & REHABIL,DETROIT,MI	Nabors, NA (corresponding author), REHABIL INST MICHIGAN,261 MACK BLVD,DETROIT,MI 48201, USA.						Benton AL, 1983, MULTILINGUAL APHASIA; Cammermeyer M, 1988, J Neurosci Nurs, V20, P314; DELIS D, 1987, CALIFORNIA VERBAL LE; Fields S D, 1992, Int Psychogeriatr, V4, P93, DOI 10.1017/S1041610292000929; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; FULLERTON KJ, 1986, LANCET, V327, P430; GRESHAM GE, 1995, AHCPR PUBLICATION; Heaton R.K., 1991, COMPREHENSIVE NORMS; Heaton R. K, 1981, WISCONSIN CARD SORTI; KIERNAN RJ, 1987, ANN INTERN MED, V107, P481, DOI 10.7326/0003-4819-107-4-481; LAMARRE CJ, 1994, J PSYCHIATR NEUROSCI, V19, P103; LEVIN HS, 1979, J NERV MENT DIS, V167, P675, DOI 10.1097/00005053-197911000-00004; LOGUE PE, 1994, J NERV MENT DIS, V181, P341; LUXENBERG JS, 1986, ARCH PHYS MED REHAB, V67, P796; MITRUSHINA M, 1994, HOSP COMMUNITY PSYCH, V45, P252; MYSIW WJ, 1989, AM J PHYS MED REHAB, V68, P168, DOI 10.1097/00002060-198908000-00003; *NO CAL NEUR GROUP, 1988, MAN NEUR COGN STAT E; Oehlert ME, 1996, REHABIL PSYCHOL, V41, P162; OSMON DC, 1992, ARCH PHYS MED REHAB, V73, P414; Reitan R.M., 1993, HALSTEADREITAN NEURO; Roper BL, 1996, NEUROPSY NEUROPSY BE, V9, P54; ROTHLIND JC, 1995, 1995 ANN M AM PSYCH; TEADALE G, 1974, LANCET, V2, P81; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Wiederman Michael W., 1995, Clinical Gerontologist, V15, P35, DOI 10.1300/J018v15n04_04	26	23	26	0	2	ASPEN PUBL INC	FREDERICK	7201 MCKINNEY CIRCLE, FREDERICK, MD 21704	0885-9701			J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUN	1997	12	3					79	84		10.1097/00001199-199706000-00008			6	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	XC699	WOS:A1997XC69900008					2021-06-18	
J	Worzniak, M; Fetters, MD; Comfort, M				Worzniak, M; Fetters, MD; Comfort, M			Methylphenidate in the treatment of coma	JOURNAL OF FAMILY PRACTICE			English	Article						methylphenidate; coma; brain injuries; Glascow Coma Scale		While there is significant morbidity and mortality involving patients in semicomatose and comatose states, the care of such patients has traditionally been limited to supportive measures. We report two cases of patients treated with methylphenidate hydrochloride: the first, a patient in a semicomatose state resulting from traumatic brain injury, and the second, a patient in a comatose state secondary to a subdural hematoma that occurred after a fall. Treatment with methylphenidate may provide neurostimulations by augmenting the activity of injured neuronal tissue within the reticular activating system, and by amplifying the net effect of the reduced number of viable neurons. Methylphenidate is a low-cost, potentially efficacious intervention for reducing the duration of comas, for preventing life-threatening and costly complications of prolonged unconsciousness, and for promoting early ambulation and recovery. Further research using more rigorous research designs to ascertain the effectiveness of methylphenidate in the treatment of patients in semicomatose and comatose states is needed.	UNIV MICHIGAN,MED CTR,DEPT FAMILY PRACTICE,ANN ARBOR,MI	Worzniak, M (corresponding author), OAKWOOD HOSP & MED CTR,FAMILY PRACTICE RESIDENCY PROGRAM,FAMILY PRACTICE RESIDENCY,DEARBORN,MI 48123, USA.						BOET J, 1971, ARCH HOSP VARGAS, V13, P103; DING YS, 1994, SYNAPSE, V18, P152, DOI 10.1002/syn.890180207; DUCOURS JL, 1990, NUCL MED COMMUN, V11, P361, DOI 10.1097/00006231-199005000-00003; GUYTON AC, 1991, TXB MED PHYSIOL, P648; HOAGLAND RJ, 1965, AM J MED SCI, V249, P623; JENETT B, 1976, J NEUROL NEUROSUR PS, V39, P647; Kaelin DL, 1996, ARCH PHYS MED REHAB, V77, P6, DOI 10.1016/S0003-9993(96)90211-7; KAPLAN HI, 1993, POCKET HDB PSYCHIAT, P168; KRAUS MF, 1995, INT J PSYCHIAT MED, V25, P39, DOI 10.2190/BXRM-3M58-WBC5-A7EL; LICHTIGFELD FJ, 1990, CLIN NEUROPHARMACOL, V13, P459, DOI 10.1097/00002826-199010000-00007; SATEL SL, 1989, J CLIN PSYCHIAT, V50, P241; SCHLEISSNER LA, 1966, CALIF MED, V105, P41	12	23	23	0	2	APPLETON & LANGE	E NORWALK	25 VAN ZANT ST, E NORWALK, CT 06855	0094-3509			J FAM PRACTICE	J. Fam. Pract.	MAY	1997	44	5					495	498					6	Primary Health Care; Medicine, General & Internal	General & Internal Medicine	WY588	WOS:A1997WY58800016	9152268				2021-06-18	
J	Weise, K; Schwab, E; Scheufele, TM				Weise, K; Schwab, E; Scheufele, TM			Elbow injuries in childhood	UNFALLCHIRURG			English	Article						elbow joint injuries; child; adolescence	ACCIDENTS	Fractures and dislocations of the elbow are some of the most common injuries in childhood and adolescence. The majority occur in sport and play activities, e.g., a fall from gymnastics apparatus or a bike, or from popular sports items, such as skateboards or in-line skates. The injuries can be divided into pure dislocations of the joint and fractures of the distal humerus, proximal radius and ulna, or combinations of both. In addition, extra- and intraarticular fracture types are defined, with the latter as partial or complete joint lesions. Dislocations of the elbow joint or the radial head can occur as single injuries or in combination with a fracture. Supracondylar fractures and avulsion fractures of the medial epicondyle are the most frequent extraarticular lesions of the distal humerus. Fractures of the lateral condyle prevail is incomplete intraarticular lesions. In the forearm, radial head and neck fractures are predominant while typical and atypical Monteggia injuries have a special status. The complex joint construction and the age-dependent appearance of the epiphyseal ossification centers sometimes make a correct radiological diagnosis difficult. The trauma history and an exact, clinical examination help to verify the injury, as do comparative X-ray studies of the uninjured side when necessary (but not routinely). Unlike other anatomical areas, most el bow injuries-even in the growing skeleton are treated operatively. Hereby, the growth plates have to be respected using minimal amounts of small implants. Additional immobilization in a cast for 2-4 weeks is necessary in most cases but does not lead to a functional deficit - in contrast to adults. The implants should be removed as early as possible, Despite all therapeutic efforts, a significant number of late sequelae, such as malunions and functional impairment, can be seen. The rate of long-term complications increases in cases of untreated displacement of fragments or joint instability. Corrective measures are performed only in selected cases and after the growth plates are closed, Our own treatment regime is demonstrated using exemplary clinical cases of the different injuries and the results of a long-term follow-up study on sports injuries of the elbow in children. Errors in diagnosis and therapy, as well as possible com plications, are pointed out.		Weise, K (corresponding author), BERUFSGENOSSENSCHAFTLICHE UNFALLKLIN TUBINGEN,SCHNARRENBERGSTR 95,D-72076 TUBINGEN,GERMANY.						HEFTI F, 1981, ORTHOPADE, P274; JONASCH E, 1981, VERLETZUNGEN KINDERN; MEULI HC, 1981, ORTHOPADE, V10, P256; MORGER R, 1972, Z KINDERCHIR, V11, P717; PAAR Q, 1989, MUNCHEN MED WOCHEN, V131, P550; PFISTER A, 1985, TRAINING SPORT PRAVE, pS206; RODEGERDTS U, 1978, ORTHOP PRAX, V14, P98; SCHEUFELE TM, 1990, THESIS EBERHARD KARL; SCHMIDT B, 1989, Z KINDERCHIR, V44, P357; SCHULITZ KP, 1975, ARCH ORTHOP TRAUM SU, V81, P225, DOI 10.1007/BF00416948; SCHUMACHER G, 1978, ORTHOP PRAX, V14, P82; STEINBRUCK K, 1983, ORTHOP PRAX, V19, P927; VINZ H, 1989, Beitraege zur Orthopaedie und Traumatologie, V36, P169; VINZ H, 1989, Beitraege zur Orthopaedie und Traumatologie, V36, P153; von Laer L, 1989, OPER ORTHOP TRAUMATO, V1, P163; VONLAER L, 1981, ORTHOPADE, V10, P264; VONLAER L, 1991, FRAKTUREN LUXATIONEN; VONLAER L, 1993, CHIR PRAX, V47, P117; VONLAER LR, 1990, KORREKTUREINGRIFFE W, P174; WEBER BG, 1978, FRAKTURENBEHANDLUNG; WEISE K, 1995, CHIRURG OPERATIONSLE, V9; WIESENBERG S, 1983, CHIR PRAX, V31, P555; WIRTH CH, 1978, ORTHOP PRAX, V14, P103	23	23	23	0	7	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0177-5537			UNFALLCHIRURG	Unfallchirurg	APR	1997	100	4					255	269		10.1007/s001130050117			19	Emergency Medicine; Surgery	Emergency Medicine; Surgery	WX385	WOS:A1997WX38500002	9229775				2021-06-18	
J	Reeves, TM; Zhu, J; Povlishock, JT; Phillips, LL				Reeves, TM; Zhu, J; Povlishock, JT; Phillips, LL			The effect of combined fluid percussion and entorhinal cortical lesions on long-term potentiation	NEUROSCIENCE			English	Article						traumatic brain injury; deafferentation; combined injuries; long-term potentiation; hippocampus; receptor plasticity	TRAUMATIC BRAIN INJURY; EXCITATORY AMINO-ACIDS; NUCLEUS-REUNIENS-THALAMI; DENTATE GYRUS; RAT; REINNERVATION; HIPPOCAMPUS; RECOVERY; DEFICITS; PATHWAY	Among the pathological processes initiated by traumatic brain injury are excessive neuroexcitation and target cell deafferentation. The current study examines the contribution of these injury components, separately as well as their combined effect, on postinjury alterations in the capacity for long-term potentiation and the immunolocalization of N-methyl-D-aspartate receptors and GABA. Adult rats underwent central fluid percussion traumatic brain injury, electrolytic bilateral entorhinal cortex lesions, or a combined injury of both procedures separated by 24 h. At two or 15 days postinjury, the capacity for long-term potentiation of the Schaffer collateral-commissural input to CA1 was measured in acute electrophysiological recordings. Entorhinal cortical lesions resulted in time-dependent increases in the effectiveness of tetanic stimulation to elevate population postsynaptic potentials and population spike amplitudes. These lesions also resulted in a marked intensification in the density of iv-methyl-D-aspartate receptors in the CA1 stratum lacunosum-moleculare. All injury conditions that included fluid percussion as a component (alone or in combined injuries) produced a persistent impairment in long-term potentiation of the evoked population postsynaptic potentials. Thus, in combined injuries, the presence of concussion-induced neuroexcitation attenuated deafferentation-induced response increases. Both N-methyl-D-aspartate receptor and GABA immunobinding following combined injuries were also reduced relative to those observed following entorhinal lesions alone. The present results suggest that a process of receptor plasticity, possibly involving reactive synaptogenesis, may contribute to postdeafferentation enhancements of long-term potentiation, and that a traumatic brain insult will attenuate these enhancements. This interaction of different injury components suggests that recovery of function following brain injury may be enhanced by pharmacological reduction of neuroexcitation during postinjury intervals of reactive receptor plasticity. (C) 1997 IBRO.	VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DIV NEUROSURG,RICHMOND,VA 23298	Reeves, TM (corresponding author), VIRGINIA COMMONWEALTH UNIV,MED COLL VIRGINIA,DEPT ANAT,RICHMOND,VA 23298, USA.				NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [NS20193, NS12587, NS01750] Funding Source: Medline; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P50NS012587, K17NS001750, P01NS012587, R01NS020193] Funding Source: NIH RePORTER		Adams JH, 1992, GREENFIELDS NEUROPAT, P106; CHAVEZNORIEGA LE, 1989, NEUROSCI LETT, V104, P58, DOI 10.1016/0304-3940(89)90329-7; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; COTMAN CW, 1978, NEURONAL PLASTICITY, P227; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; ERB DE, 1991, EXP BRAIN RES, V83, P253; FADEN AI, 1989, SCIENCE, V244, P798, DOI 10.1126/science.2567056; HAMM RJ, 1992, J NEUROTRAUM, V9, P11, DOI 10.1089/neu.1992.9.11; HAYES RL, 1988, J NEUROTRAUM, V5, P287; HERKENHAM M, 1978, J COMP NEUROL, V177, P589, DOI 10.1002/cne.901770405; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KOTAPKA MJ, 1992, ACTA NEUROPATHOL, V83, P530, DOI 10.1007/BF00310031; LYETH BG, 1990, BRAIN RES, V526, P249, DOI 10.1016/0006-8993(90)91229-A; LYNCH G, 1983, NATURE, V305, P719, DOI 10.1038/305719a0; McIntosh TK, 1989, J NEUROTRAUM, V6, P247, DOI 10.1089/neu.1989.6.247; MIYAZAKI S, 1992, BRAIN RES, V585, P335, DOI 10.1016/0006-8993(92)91232-4; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PANTER SS, 1992, NEUROSCI LETT, V136, P165, DOI 10.1016/0304-3940(92)90040-E; PERSSON L, 1992, J NEUROSURG, V76, P72, DOI 10.3171/jns.1992.76.1.0072; PHILLIPS LL, 1994, J NEUROTRAUM, V11, P641, DOI 10.1089/neu.1994.11.641; PHILLIPS LL, 1992, J NEUROTRAUM, V9, P323, DOI 10.1089/neu.1992.9.323; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1995, AXON, P505; REEVES TM, 1995, EXP BRAIN RES, V106, P248; REEVES TM, 1986, EXP BRAIN RES, V65, P167; REEVES TM, 1988, EXP NEUROL, V102, P37, DOI 10.1016/0014-4886(88)90076-3; SHU SY, 1988, NEUROSCI LETT, V85, P169, DOI 10.1016/0304-3940(88)90346-1; STEWARD O, 1989, Journal of Neurotrauma, V6, P99, DOI 10.1089/neu.1989.6.99; WILSON RC, 1979, BRAIN RES, V176, P65, DOI 10.1016/0006-8993(79)90870-9; WILSON RC, 1981, J NEUROPHYSIOL, V46, P324; WOUTERLOOD FG, 1990, J COMP NEUROL, V296, P179, DOI 10.1002/cne.902960202; YAGHMAI A, 1992, J NEUROPATH EXP NEUR, V51, P158, DOI 10.1097/00005072-199203000-00006	32	23	23	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0306-4522			NEUROSCIENCE	Neuroscience	MAR	1997	77	2					431	444		10.1016/S0306-4522(96)00486-1			14	Neurosciences	Neurosciences & Neurology	WK428	WOS:A1997WK42800013	9472402				2021-06-18	
S	Doppenberg, EMR; Choi, SC; Bullock, R		Slikker, W		Doppenberg, EMR; Choi, SC; Bullock, R			Clinical trials in traumatic brain injury - What can we learn from previous studies?	NEUROPROTECTIVE AGENTS - THIRD INTERNATIONAL CONFERENCE	Annals of the New York Academy of Sciences		English	Article; Proceedings Paper	3rd International Conference on Neuroprotective Agents - Clinical and Experimental Aspects	SEP 09-12, 1996	VARENNA, ITALY	New York Acad Sci, FDA, Natl Ctr Toxicol Res, Arkansas, Dept Vet Affairs Med Ctr, Togus, Maine			SEVERE HEAD-INJURY; ACUTE SUBDURAL-HEMATOMA; CONJUGATED SUPEROXIDE-DISMUTASE; KALLIKREIN-KININ SYSTEM; FLUID-PERCUSSION MODEL; CEREBRAL BLOOD-FLOW; THERAPEUTIC HYPOTHERMIA; SUBARACHNOID HEMORRHAGE; AXONAL CHANGE; ISCHEMIA		VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DEPT BIOSTAT, RICHMOND, VA 23298 USA	Doppenberg, EMR (corresponding author), VIRGINIA COMMONWEALTH UNIV, MED COLL VIRGINIA, DIV NEUROSURG, POB 980631, RICHMOND, VA 23298 USA.						ADAMS JH, 1983, ACTA NEUROCHIR, V32, pS15; ASTRUP J, 1981, STROKE, V12, P723, DOI 10.1161/01.STR.12.6.723; BOUMA GJ, 1992, J NEUROSURG, V77, P360, DOI 10.3171/jns.1992.77.3.0360; BRANSTON NM, 1974, EXP NEUROL, V45, P195, DOI 10.1016/0014-4886(74)90112-5; BROADDUS WC, 1996, 46 ANN M C NEUR SURG; Bullock R., 1995, NEUROCHEMICAL MONITO, P64; CHOI SC, 1996, DISCOVERIES HEAD TRA, P67; CLIFTON GL, 1993, NEUROSURGERY, V33, P34; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; Di X, 1996, RESTOR NEUROL NEUROS, V9, P231, DOI 10.3233/RNN-1996-9406; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; Drummond ME, 1987, METHODS EC EVALUATIO; EISENBERG HM, 1988, J NEUROSURG, V69, P15, DOI 10.3171/jns.1988.69.1.0015; GENNARELLI TA, 1994, J NEUROTRAUM, V11, P357, DOI 10.1089/neu.1994.11.357; GRAHAM DI, 1985, BRIT J ANAESTH, V57, P3, DOI 10.1093/bja/57.1.3; GRUMME T, 1995, RES EXP MED, V195, P217, DOI 10.1007/BF02576791; Harders A, 1996, J NEUROSURG, V85, P82, DOI 10.3171/jns.1996.85.1.0082; JONES TH, 1981, J NEUROSURG, V54, P773, DOI 10.3171/jns.1981.54.6.0773; Kassell NF, 1996, J NEUROSURG, V84, P221, DOI 10.3171/jns.1996.84.2.0221; KATAYAMA Y, 1990, J NEUROSURG, V73, P889, DOI 10.3171/jns.1990.73.6.0889; KURODA Y, 1992, NEUROSURGERY, V31, P1062, DOI 10.1227/00006123-199212000-00012; LANDOLT H, 1994, ACTA NEUROCHIR, P475; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; MAIERHAUFF K, 1984, J NEUROSURG, V61, P97, DOI 10.3171/jns.1984.61.1.0097; MARION DW, 1993, J NEUROSURG, V79, P354, DOI 10.3171/jns.1993.79.3.0354; Marion DW, 1996, CRIT CARE MED, V24, pS81; MARMAROU A, 1996, ACTA NEUROCHIR S, V66, P188; MARMAROU A, 1993, J NEUROTRAUM, V10, pS61; MARSHALL LF, 1995, J NEUROTRAUM, V12, P929, DOI 10.1089/neu.1995.12.929; MCCLELLAN DR, 1986, COMA TRAUMATIQUE; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MUIZELAAR JP, 1993, J NEUROSURG, V78, P375, DOI 10.3171/jns.1993.78.3.0375; MUIZELAAR JP, 1994, ADV EXP MED BIOL, V366, P389; OMMAYA AK, 1966, SCIENCE, V153, P211, DOI 10.1126/science.153.3732.211; PALMER AM, 1993, J NEUROTRAUM, V10, P363, DOI 10.1089/neu.1993.10.363; PETTUS EH, 1994, J NEUROTRAUM, V11, P507, DOI 10.1089/neu.1994.11.507; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; SCHRODER ML, 1994, J NEUROSURG, V80, P324, DOI 10.3171/jns.1994.80.2.0324; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; SCHWARTZ ML, 1984, CAN J NEUROL SCI, V11, P434, DOI 10.1017/S0317167100045960; STEIN SC, 1996, NEUROTRAUMA, P755; TEASDALE G, 1992, J NEUROTRAUM, V9, pS545; Tsuchida E, 1996, J NEUROSURG, V85, P104, DOI 10.3171/jns.1996.85.1.0104; UNTERBERG A, 1986, J NEUROSURG, V64, P269, DOI 10.3171/jns.1986.64.2.0269; UNTERBERG A, 1984, J NEUROSURG, V61, P87, DOI 10.3171/jns.1984.61.1.0087; WARD JD, 1985, J NEUROSURG, V62, P383, DOI 10.3171/jns.1985.62.3.0383; WEI EP, 1993, AM J PHYSIOL, V265, pH1439; Whitehead J., 1983, DESIGN ANAL SEQUENTI; WOLF AL, 1993, J NEUROSURG, V78, P54, DOI 10.3171/jns.1993.78.1.0054; YOSHINO A, 1991, BRAIN RES, V561, P106, DOI 10.1016/0006-8993(91)90755-K	50	23	23	0	2	NEW YORK ACAD SCIENCES	NEW YORK	2 EAST 63RD ST, NEW YORK, NY 10021 USA	0077-8923		1-57331-093-X; 1-57331-092-1	ANN NY ACAD SCI	Ann.NY Acad.Sci.		1997	825						305	322		10.1111/j.1749-6632.1997.tb48441.x			18	Multidisciplinary Sciences; Neurosciences; Pharmacology & Pharmacy	Science & Technology - Other Topics; Neurosciences & Neurology; Pharmacology & Pharmacy	BJ99G	WOS:A1997BJ99G00027	9369996				2021-06-18	
J	Vink, R; Golding, EM; Williams, JP; McIntosh, TK				Vink, R; Golding, EM; Williams, JP; McIntosh, TK			Blood glucose concentration does not affect outcome in brain trauma: A P-31 MRS study	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						magnesium; nuclear magnetic resonance; magnetic resonance spectroscopy; brain injury; lactic acidosis	NUCLEAR-MAGNETIC-RESONANCE; FREE MAGNESIUM; INJURY; PH; SPECTROSCOPY; DAMAGE; RATS; MECHANISM; ISCHEMIA; ACIDOSIS	Effects of blood glucose concentration on biochemical and neurologic outcome following lateral fluid percussion-induced traumatic injury of moderate severity (2.8 atm) in rats were studied using radioactive phosphorus (P-31) magnetic resonance spectroscopy (MRS) and a battery of tests designed to evaluate posttraumatic neurologic motor function. Prior to injury, male Sprague-Dawley rats (n = 18) were randomly assigned to receive either dextrose, 2 ml 50% (wt/vol), zinc insulin (10 IU/kg) or no treatment, thus dividing the animals into hyperglycemic, hypoglycemic, and normoglycemic groups, respectively. Animals were then injured, monitored for 4 h by P-31 MRS before being allowed to recover, and assessed for posttraumatic motor function. Following brain injury, there was no difference in brain intracellular pH between groups over the 4-h posttraumatic MRS monitoring period. Similarly, intracellular free magnesium, cytosolic phosphorylation potential, and neurologic outcome posttrauma were not significantly different between groups. We conclude that, unlike models of ischemia, blood glucose concentration may not be a significant factor affecting outcome in traumatic brain injury.	UNIV PENN, SCH MED, DIV NEUROSURG, PHILADELPHIA, PA 19104 USA	Vink, R (corresponding author), JAMES COOK UNIV N QUEENSLAND, DIV BIOCHEM & HUMAN PHYSIOL, TOWNSVILLE, QLD 4811, AUSTRALIA.		AM, Robert Vink/S-5616-2019; Vink, Robert/J-7351-2012	AM, Robert Vink/0000-0002-4885-0667; Vink, Robert/0000-0002-4885-0667	NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS026818] Funding Source: NIH RePORTER; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS26818] Funding Source: Medline		ANDERSEN BJ, 1992, BRAIN RES, V585, P184, DOI 10.1016/0006-8993(92)91205-S; BOCK JL, 1987, BIOCHIM BIOPHYS ACTA, V928, P8, DOI 10.1016/0167-4889(87)90079-6; DIEMER NH, 1981, NEUROPATH APPL NEURO, V7, P217, DOI 10.1111/j.1365-2990.1981.tb00091.x; DUCKROW RB, 1981, J NEUROSURG, V54, P607, DOI 10.3171/jns.1981.54.5.0607; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; GUPTA RK, 1978, J BIOL CHEM, V253, P6172; Hayes RL, 1988, J NEUROTRAUM, V5, P259, DOI 10.1089/neu.1988.5.259; HENQUIN JC, 1983, NATURE, V301, P73, DOI 10.1038/301073a0; HOVDA DA, 1992, CENTRAL NERVOUS SYST, P47; LAWSON JWR, 1979, J BIOL CHEM, V254, P6528; MALLOY CR, 1986, BIOCHIM BIOPHYS ACTA, V885, P1, DOI 10.1016/0167-4889(86)90032-7; MCINTOSH TK, 1987, J NEUROCHEM, V49, P1530; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; MYERS RE, 1973, J NEUROPATHOL EXP NE, V35, P301; PETROFF OAC, 1985, NEUROLOGY, V35, P781, DOI 10.1212/WNL.35.6.781; PLUM F, 1983, NEUROLOGY, V33, P222, DOI 10.1212/WNL.33.2.222; REHNCRONA S, 1980, ACTA PHYSIOL SCAND, V110, P435, DOI 10.1111/j.1748-1716.1980.tb06692.x; SIESJO BK, 1988, NEUROCHEM PATHOL, V9, P31; VEECH RL, 1979, J BIOL CHEM, V254, P6538; VINK R, 1987, J CEREBR BLOOD F MET, V7, P563, DOI 10.1038/jcbfm.1987.106; VINK R, 1993, MOL CHEM NEUROPATHOL, V18, P279, DOI 10.1007/BF03160120; Vink R, 1988, J NEUROTRAUM, V5, P315, DOI 10.1089/neu.1988.5.315; Vink R, 1990, J NEUROTRAUM, V7, P21, DOI 10.1089/neu.1990.7.21; WARNER DS, 1987, STROKE, V18, P464, DOI 10.1161/01.STR.18.2.464; YAMAKAMI I, 1989, J CEREBR BLOOD F MET, V9, P117, DOI 10.1038/jcbfm.1989.16; Yuan XQ, 1988, J NEUROTRAUM, V5, P289, DOI 10.1089/neu.1988.5.289	26	23	23	0	0	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	JAN	1997	17	1					50	53		10.1097/00004647-199701000-00007			4	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	VZ028	WOS:A1997VZ02800007	8978386	Bronze			2021-06-18	
J	Thurman, DJ; Jeppson, L; Burnett, CL; Beaudoin, DE; Rheinberger, MM; Sniezek, JE				Thurman, DJ; Jeppson, L; Burnett, CL; Beaudoin, DE; Rheinberger, MM; Sniezek, JE			Surveillance of traumatic brain injuries in Utah	WESTERN JOURNAL OF MEDICINE			English	Article							HEAD-INJURY; POPULATION; COUNTY; COMA	From 1990 through 1992 we conducted surveillance of cases requiring hospital admission and of fatal cases of traumatic brain injury among residents of Utah and found an annual incidence rate of 108.8 per 100,000 population. The greatest number of injuries occurred among men and persons aged 15 to 24 years. Motor vehicles were the leading cause of injury, followed by falls and assaults, The incidence rate we found is substantially lower than previously published rates of traumatic brain injury, This may be the result of a decrease in the incidence of these injuries in the decade since earlier studies were done, as well as changing hospital admission criteria that serve to exclude less severe cases of injury, Despite the apparent decline in rates, our findings indicate the continued importance of traumatic brain injury as a public health problem and the need to develop more effective prevention strategies that will address the major causes of these injuries.	UTAH DEPT HLTH,DIV COMMUNITY & FAMILY HLTH SERV,SALT LAKE CITY,UT 84116	Thurman, DJ (corresponding author), CTR DIS CONTROL & PREVENT,NATL CTR INJURY PREVENT & CONTROL,MAILSTOP F41,4770 BUFORD HWY NE,ATLANTA,GA 30341, USA.			Thurman, David/0000-0002-0533-7062			ANNEGERS JF, 1980, NEUROLOGY, V30, P912, DOI 10.1212/WNL.30.9.912; *CDC, 1995, INJ MORT NAT SUMM IN; Centers for Disease Control (CDC), 1988, MMWR Suppl, V37, P1; COOPER K D, 1983, Neuroepidemiology, V2, P70, DOI 10.1159/000110512; FIFE D, 1987, AM J PUBLIC HEALTH, V77, P810, DOI 10.2105/AJPH.77.7.810; FIFE D, 1986, AM J PUBLIC HEALTH, V76, P773, DOI 10.2105/AJPH.76.7.773; Fleiss JL, 1981, STATISTICAL METHODS; Frankowski RF, 1985, CENTRAL NERVOUS SYST, P33; *HLTH CAR FIN ADM, 1989, INT CLASS DIS; JAGGER J, 1984, J TRAUMA, V24, P40, DOI 10.1097/00005373-198401000-00006; JENNETT B, 1975, LANCET, V1, P480; JENNETT B, 1977, LANCET, V1, P878; KALSBEEK WD, 1980, J NEUROSURG S, pS19; KLAUBER MR, 1981, AM J EPIDEMIOL, V113, P500, DOI 10.1093/oxfordjournals.aje.a113125; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; Kraus JF, 1993, HEAD INJURY, P1; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; MacKenzie E J, 1989, Md Med J, V38, P725; SOSIN DM, 1995, JAMA-J AM MED ASSOC, V278, P1778; TEASDALE G, 1974, LANCET, V2, P81; Thurman DJ., 1995, GUIDELINES SURVEILLA; WHITMAN S, 1984, AM J EPIDEMIOL, V119, P570, DOI 10.1093/oxfordjournals.aje.a113774; WILLIAMS DH, 1990, NEUROSURGERY, V27, P422, DOI 10.1227/00006123-199009000-00014	23	23	23	0	1	CALIFORNIA PHYSICIAN MAGAZINE	SAN FRANCISCO	C/O DONNA TAYLOR, EDITOR, PO BOX 7690, SAN FRANCISCO, CA 94102-7690	0093-0415			WESTERN J MED	West. J. Med.	OCT	1996	165	4					192	196					5	Medicine, General & Internal	General & Internal Medicine	VU111	WOS:A1996VU11100001	8987423				2021-06-18	
J	Gurney, JG; PrestonMartin, S; McDaniel, AM; Mueller, BA; Holly, EA				Gurney, JG; PrestonMartin, S; McDaniel, AM; Mueller, BA; Holly, EA			Head injury as a risk factor for brain tumors in children: Results from a multicenter case-control study	EPIDEMIOLOGY			English	Article						brain neoplasms; cancer; children; etiology; head injury; neurology; traumatic brain injury	EXPLORATORY CASE-CONTROL; MALIGNANT GLIOMA; TRAUMA; CANCER; GLIOBLASTOMA	We evaluated the risk of brain tumor occurrence in relation to previous head injury in a population-based case control study of 540 children with a primary brain tumor and 801 control children. The risk of a brain tumor among children with a previous head injury that resulted in medical attention was slightly elevated when compared with children with no re ported head injury [odds ratio (OR)=1.4; 95% confidence limits (CL)=1.0, 1.9]. This effect was stronger when;we restricted the head-injured group to the few children with loss of consciousness (OR=1.6; 95% CL=0.6, 3.9) or an overnight admission to a hospital (OR=1.7; 95% CL 0.7, 4.6), relative to those with no head injury. We observed no appreciable association between brain tumor occurrence and birth injury involving the head or a forceps delivery. Among the few children with either a birth injury or forceps delivery and a subsequent head injury, we observed approximately twofold elevations in risk. The OR was 2.6 (95% CL=1.1, 6.9) for those with a birth injury and subsequent head injury, relative to those with neither a birth injury nor head injury. Our results provide only weak evidence in support of head injury as an etiologic agent for brain tumor occurrence in children, although most of our exposed group had only mild head injury.	WAYNE STATE UNIV,SCH MED,KARMANOS CANC INST,DETROIT,MI					DIVISION OF CANCER PREVENTION AND CONTROLUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [N01CN005230] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P01CA017054, R01CA047082] Funding Source: NIH RePORTER; NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [CA17054, CA47082, N01-CN-05230] Funding Source: Medline		ANNEGERS JF, 1979, NEUROSURGERY, V4, P203, DOI 10.1227/00006123-197903000-00001; BRESLOW NE, 1980, IARC SCI PUB, V32; BUNIN GR, 1994, CANCER EPIDEM BIOMAR, V3, P197; BURCH JD, 1987, J NATL CANCER I, V78, P601; CARPENTER AV, 1987, AM J PUBLIC HEALTH, V77, P1180, DOI 10.2105/AJPH.77.9.1180; CUSHING H, 1938, MENINGIOMAS THEIR CL; Gruss P, 1993, Zentralbl Neurochir, V54, P186; HARTGE P, 1984, AM J EPIDEMIOL, V120, P825, DOI 10.1093/oxfordjournals.aje.a113955; HOCHBERG F, 1984, NEUROLOGY, V34, P1511, DOI 10.1212/WNL.34.11.1511; HOWE GR, 1989, CANCER RES, V49, P4349; KUIJTEN RR, 1989, CANCER RES, V49, P4349; Linn Shai, 1995, Annals of Epidemiology, V5, P440, DOI 10.1016/1047-2797(95)00059-3; MCCREDIE M, 1994, INT J CANCER, V56, P11; PAL J, 1989, J TRAUMA, V29, P746, DOI 10.1097/00005373-198906000-00008; PEREZDIAZ C, 1985, SURG NEUROL, V24, P581, DOI 10.1016/0090-3019(85)90278-2; PRESTONMARTIN S, 1990, CANCER RES, V50, P7415; PRESTONMARTIN S, 1982, CANCER RES, V42, P5240; PRESTONMARTIN S, 1983, J NATL CANCER I, V70, P863; RYAN P, 1992, INT J CANCER, V51, P20, DOI 10.1002/ijc.2910510105; SCHIFFER J, 1985, NEUROSURGERY, V14, P84; SCHLEHOFER B, 1992, CANCER, V69, P2541, DOI 10.1002/1097-0142(19920515)69:10<2541::AID-CNCR2820691025>3.0.CO;2-H; SCHMITT HP, 1983, FORTSCHR NEUROL PSYC, V51, P227, DOI 10.1055/s-2007-1002228; SMITH CML, 1984, NEUROPATH APPL NEURO, V10, P235, DOI 10.1111/j.1365-2990.1984.tb00354.x; TROOST D, 1984, CLIN NEUROPATHOL, V3, P139; WITZMANN A, 1981, NEUROCHIRURGIA, V24, P202	25	23	24	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1044-3983			EPIDEMIOLOGY	Epidemiology	SEP	1996	7	5					485	489		10.1097/00001648-199609000-00005			5	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	VC739	WOS:A1996VC73900006	8862978				2021-06-18	
J	Russell, MB; Olesen, J				Russell, MB; Olesen, J			Migraine associated with head trauma	EUROPEAN JOURNAL OF NEUROLOGY			English	Article						migraine associated with head trauma; aetiology; genetics	INJURY; RISK; SEX	Migraine associated with head trauma i.e. onset of migraine in close temporal relation to a head trauma was analyzed in a large population based survey of 4000 forty-year-old males and females. Of the 29 people with migraine associated with head trauma, 20 had migraine without aura associated with head trauma, six had migrainous disorder without aura associated with head trauma and three had migraine with aura associated with head trauma. Eleven had a significant head trauma (loss of consciousness or posttraumatic amnesia lasting more than 10 minutes) and 18 had a minor head trauma. The overall lifetime prevalence of migraine associated with head trauma was 1.4% with a male-female ratio of 1:2.4. The symptomatology of migraine associated and unassociated with head trauma was not different. The first degree relatives of probands with migraine associated with head trauma were blindly interviewed by a physician. The first degree relatives of probands with migraine without aura associated with head trauma had a significantly lower risk of migraine without aura than first degree relatives of probands with migraine without aura unassociated with head trauma. We conclude that migraine without aura associated and unassociated with head trauma have a different aetiology. Thus, it is very likely that a head trauma may cause migraine without aura. The mechanisms involved in trauma induced migraine without aura are unknown.	UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT INTERNAL MED C,GLOSTRUP POPULAT STUDIES,DK-2600 GLOSTRUP,DENMARK	Russell, MB (corresponding author), UNIV COPENHAGEN,GLOSTRUP HOSP,DEPT NEUROL,DK-2600 GLOSTRUP,DENMARK.						BEHRMAN S, 1977, INJURY, V9, P74, DOI 10.1016/0020-1383(77)90059-6; Cartlidge N E, 1981, HEAD INJURY; Guthkelch A N, 1977, Neurosurgery, V1, P101; HAAS DC, 1969, J NEUROL NEUROSUR PS, V32, P548, DOI 10.1136/jnnp.32.6.548; JENSEN OK, 1990, CEPHALALGIA, V10, P285, DOI 10.1046/j.1468-2982.1990.1006285.x; LEONE M, 1994, CEPHALALGIA, V14, P280, DOI 10.1046/j.1468-2982.1994.1404280.x; MATTHEWS WB, 1972, BRIT MED J, V2, P326, DOI 10.1136/bmj.2.5809.326; RASMUSSEN BK, 1992, NEUROLOGY, V42, P1225, DOI 10.1212/WNL.42.6.1225; RASMUSSEN BK, 1992, CEPHALALGIA, V12, P221, DOI 10.1046/j.1468-2982.1992.1204221.x; RUSSELL MB, 1995, INT J EPIDEMIOL, V24, P612, DOI 10.1093/ije/24.3.612; RUSSELL MB, 1995, BRIT MED J, V311, P541, DOI 10.1136/bmj.311.7004.541; Russell MB, 1996, CEPHALALGIA, V16, P156, DOI 10.1046/j.1468-2982.1996.1603156.x; RUSSELL MB, 1995, HUM GENET, V96, P726, DOI 10.1007/BF00210307; RUSSELL MB, 1966, CEPHALALGIA, V16, P239; SELBY G, 1960, J NEUROL NEUROSUR PS, V23, P23, DOI 10.1136/jnnp.23.1.23; SNOEK JW, 1984, BRAIN, V107, P15, DOI 10.1093/brain/107.1.15; VOHANKA S, 1990, ACTIV NERV SUPER, V32, P179; WEISS HD, 1991, HEADACHE, V31, P451, DOI 10.1111/j.1526-4610.1991.hed3107451.x; WEISS KM, 1982, J CHRON DIS, V35, P539, DOI 10.1016/0021-9681(82)90073-X; 1988, CEPHALALGIA S7, V8, P1	20	23	23	0	0	RAPID SCIENCE PUBLISHERS	LONDON	2-6 BOUNDARY ROW, LONDON, ENGLAND SE1 8NH	1351-5101			EUR J NEUROL	Eur. J. Neurol.	SEP	1996	3	5					424	428		10.1111/j.1468-1331.1996.tb00243.x			5	Clinical Neurology; Neurosciences	Neurosciences & Neurology	VP378	WOS:A1996VP37800002					2021-06-18	
J	Johnson, SC; Pinkston, JB; Bigler, ED; Blatter, DD				Johnson, SC; Pinkston, JB; Bigler, ED; Blatter, DD			Corpus callosum morphology in normal controls and traumatic brain injury: Sex differences, mechanisms of injury, and neuropsychological correlates	NEUROPSYCHOLOGY			English	Article							HEMISPHERIC DISCONNECTION SYNDROME; DIFFUSE AXONAL INJURY; CLOSED HEAD-INJURY; MORPHOMETRIC ANALYSIS; MR; GENDER; SIZE; LATERALIZATION; SCHIZOPHRENIA; PERFORMANCE	This study examined the relative cross-sectional area of the corpus callosum (CC) from MRI scans of 166 normal controls and 97 patients who have suffered traumatic brain injury (TBI). The issue of sex differences in the normal CC is addressed with regard to methodological limitations of many previous conflicting reports. Women had larger CC relative to cranial Volume than did men, and this appears to be more than simply an artifact of larger heads in men. The TBI sample showed selective atrophy most notable in the genu and isthmus of the CC, which may reflect cortical degeneration ir om common sites of injury or Wallerian degeneration secondary to diffuse axonal injury al sites other than the CC itself. The splenium of the CC was significantly related to functioning on the Digit Symbol task for the female TBI patients. The observed differences between gender on CC morphology and function may reflect global differences in brain organization.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LDS HOSP,SALT LAKE CITY,UT				Johnson, Sterling/0000-0002-8501-545X			ABOITIZ F, 1992, BRAIN, V115, P1521, DOI 10.1093/brain/115.5.1521; ABOITIZ F, 1992, BRAIN RES, V598, P143, DOI 10.1016/0006-8993(92)90178-C; Bigler E, 1990, TRAUMATIC BRAIN INJU, P13; BIGLER ED, 1996, INT NEUR SOC 24 ANN; BIGLER ED, 1988, DIAGNOSTIC CLIN NEUR; BINDER JR, 1992, BRAIN, V115, P1807, DOI 10.1093/brain/115.6.1807; *BIOM IM RES, 1994, ANALYZE VERS 7 0 COM; BLATTER DD, IN PRESS AM J NEUROR; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; Bogen J.E., 1993, CLIN NEUROPSYCHOLOGY, P337; BOLDRINI P, 1992, CORTEX, V28, P135, DOI 10.1016/S0010-9452(13)80172-4; Braun CMJ, 1989, NEUROPSYCHOLOGY, V3, P91; Burke H. L, 1994, NEUROPSYCHOLOGY, V8, P563; Buxbaum LJ, 1995, NEUROCASE, V1, P3, DOI 10.1080/13554799508402342; BYNE W, 1988, BEHAV NEUROSCI, V102, P222, DOI 10.1037/0735-7044.102.2.222; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARKE S, 1989, J COMP NEUROL, V280, P213, DOI 10.1002/cne.902800205; DELACOSTE MC, 1985, J NEUROPATH EXP NEUR, V44, P578, DOI 10.1097/00005072-198511000-00004; DELACOSTEUTAMSING C, 1982, SCIENCE, V216, P1431, DOI 10.1126/science.7089533; DEMETER S, 1988, HUM NEUROBIOL, V6, P219; DENENBERG VH, 1991, BRAIN RES, V548, P126, DOI 10.1016/0006-8993(91)91113-F; DRIESEN NR, 1995, PSYCHOBIOLOGY, V23, P240; FISHMAN PS, 1993, J NEUROTRAUM, V10, P457, DOI 10.1089/neu.1993.10.457; GALABURDA AM, 1990, NEUROPSYCHOLOGIA, V28, P529, DOI 10.1016/0028-3932(90)90032-J; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; HABIB M, 1991, BRAIN COGNITION, V16, P41, DOI 10.1016/0278-2626(91)90084-L; HAUSER P, 1989, BIOL PSYCHIAT, V26, P659, DOI 10.1016/0006-3223(89)90100-5; Heaton R.K., 1991, COMPREHENSIVE NORMS; HINES M, 1992, BEHAV NEUROSCI, V106, P3, DOI 10.1037/0735-7044.106.1.3; HYND GW, 1995, ARCH NEUROL-CHICAGO, V52, P32, DOI 10.1001/archneur.1995.00540250036010; HYND GW, 1991, J LEARN DISABIL, V24, P141, DOI 10.1177/002221949102400302; INOUE Y, 1990, AM J NEURORADIOL, V11, P897; JERNIGAN TL, 1990, ARCH NEUROL-CHICAGO, V47, P27, DOI 10.1001/archneur.1990.00530010035015; JOHNSON SC, 1994, BRAIN RES BULL, V35, P373, DOI 10.1016/0361-9230(94)90116-3; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KERTESZ A, 1987, NEUROLOGY, V37, P1385, DOI 10.1212/WNL.37.8.1385; KIMURA D, 1992, SCI AM, V267, P119; KING AI, 1995, J NEUROTRAUM, V12, P651, DOI 10.1089/neu.1995.12.651; LAISSY JP, 1993, AM J NEURORADIOL, V14, P145; LASSONDE M, 1990, BRAIN LANG, V38, P195, DOI 10.1016/0093-934X(90)90110-3; LAW DJ, 1993, PSYCHOL SCI, V4, P35, DOI 10.1111/j.1467-9280.1993.tb00553.x; LEVIN HS, 1990, J NEUROSURG, V73, P77, DOI 10.3171/jns.1990.73.1.0077; LEVIN HS, 1989, J NEUROL NEUROSUR PS, V52, P1162, DOI 10.1136/jnnp.52.10.1162; LEZAK MD, 1995, NEUROPSYCHOLOGICAL A; OKUSKY J, 1988, ANN NEUROL, V24, P379, DOI 10.1002/ana.410240305; OLDFIELD RC, 1971, NEUROPSYCHOLOGIA, V9, P97, DOI 10.1016/0028-3932(71)90067-4; OPPENHEIM JS, 1987, ANN NEUROL, V21, P604, DOI 10.1002/ana.410210615; Pandya D. N., 1986, 2 HEMISPHERES ONE BR, P47; PETERS M, 1988, CAN J PSYCHOL, V42, P313, DOI 10.1037/h0084195; Pozzilli C, 1994, J Neuroimaging, V4, P218; RAMAEKERS G, 1991, CHILDS CORPUS CALLOS, P40; RASBAND W, 1994, IMAGE VERS 1 55 COMP; REINARZ SJ, 1988, AM J ROENTGENOL, V151, P791, DOI 10.2214/ajr.151.4.791; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; ROSSI A, 1989, AM J PSYCHIAT, V146, P99; RUBENS AB, 1977, ARCH NEUROL-CHICAGO, V34, P750, DOI 10.1001/archneur.1977.00500240038006; SEYMOUR SE, 1994, BRAIN, V117, P105, DOI 10.1093/brain/117.1.105; SHAYWITZ BA, 1995, NATURE, V373, P607, DOI 10.1038/373607a0; Smith A., 1982, SYMBOL DIGIT MODALIT; SPERRY R, 1982, SCIENCE, V217, P1223, DOI 10.1126/science.7112125; STRAUSS E, 1994, J CLIN EXP NEUROPSYC, V16, P79, DOI 10.1080/01688639408402618; STRICH SJ, 1961, LANCET, V2, P443; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WEIS S, 1993, AM J NEURORADIOL, V14, P637; WITELSON SF, 1985, SCIENCE, V229, P665, DOI 10.1126/science.4023705; WITELSON SF, 1991, BRAIN RES, V545, P175, DOI 10.1016/0006-8993(91)91284-8; WITELSON SF, 1989, BRAIN, V112, P799, DOI 10.1093/brain/112.3.799	68	23	23	0	8	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242	0894-4105			NEUROPSYCHOLOGY	Neuropsychology	JUL	1996	10	3					408	415		10.1037/0894-4105.10.3.408			8	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	UY062	WOS:A1996UY06200012					2021-06-18	
J	Padula, WV; Argyris, S				Padula, WV; Argyris, S			Post trauma vision syndrome and visual midline shift syndrome	NEUROREHABILITATION			English	Article						post trauma vision syndrome; visual midline shift syndrome; vision; traumatic brain injury; cerebrovascular accident		Following a neurological event such as a traumatic brain injury (TBI), cerebrovascular accident (CVA), multiple sclerosis (MS), etc. Vision imbalances can occur between affecting the focal and ambient visual process that can affect balance, posture, ambulation, reading, attention, concentration and cognitive function in general. Post Trauma Vision Syndrome (PTVS) and Visual Midline Shift Syndrome (VMSS) can be the cause of these difficulties. This paper discusses the symptoms and characteristics of these syndromes as well as methods of treatment.		Padula, WV (corresponding author), GUILDFORD MED CTR,POB 1408,652 BOSTON POST RD,GUILFORD,CT 06347, USA.						LIEBOWITZ HW, IN PRESS ORG REPRESE; Padula W. V., 1988, BEHAV VISION APPROAC; PADULA WV, 1994, BRAIN INJURY, V8, P125, DOI 10.3109/02699059409150964; THOMAS J, 1992, LECT NEUR REH ASS S; TREVARTHEN C, 1973, BRAIN, V96, P547, DOI 10.1093/brain/96.3.547	5	23	23	0	6	ELSEVIER SCI IRELAND LTD	CLARE	CUSTOMER RELATIONS MANAGER, BAY 15, SHANNON INDUSTRIAL ESTATE CO, CLARE, IRELAND	1053-8135			NEUROREHABILITATION	Neurorehabilitation	JUN	1996	6	3					165	171		10.1016/1053-8135(96)00162-X			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	UK480	WOS:A1996UK48000002	24525768				2021-06-18	
J	Fujii, DEM; Ahmed, I				Fujii, DEM; Ahmed, I			Psychosis secondary to traumatic brain injury	NEUROPSYCHIATRY NEUROPSYCHOLOGY AND BEHAVIORAL NEUROLOGY			English	Article						traumatic brain injury; psychosis; seizure; temporal lobe abnormality	PSYCHIATRIC SEQUELAE; HEAD TRAUMA	The records of 15 inpatients with a history of delusions or hallucinations after sustaining traumatic brain injury were procured from the archives of a state hospital. Studies of brain function and structure such as electroencephalogram (EEG), computerized EEG, single photon emission computerized tomography (SPECT), CT, and MRI were examined to investigate the relationship between lesion site and the presence of secondary psychosis. Although the majority of subjects had bilateral abnormalities on imaging studies, the modal lesion area was the right temporal area, followed closely by the left temporal and frontal areas. The majority of the patients also had a history of seizures and/or temporal lobe abnormalities on EEG studies. The results of our studies are generally consistent with those described in the literature.	UNIV HAWAII,DEPT PSYCHIAT,KANEOHE,HI	Fujii, DEM (corresponding author), HAWAII STATE HOSP,DEPT NEUROPSYCHOL,45-710 KEAAHALA RD,KANEOHE,HI 96744, USA.						ACHTE KA, 1969, ACTA PSYCHIAT SCAND, V45, P1, DOI 10.1111/j.1600-0447.1969.tb06197.x; [Anonymous], 1987, DIAGNOSTIC STAT MANU, V3rd; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CUMMINGS JL, 1988, PSYCHOSOMATICS, V29, P16, DOI 10.1016/S0033-3182(88)72418-4; Davison K, 1969, BRIT J PSYCHIATRY SP, V4, P113; GUR RC, 1992, ARCH GEN PSYCHIAT, V49, P409; Hillbom E., 1960, ACTA PSYCHIATRICA S, VS142, P1; KOUFEN DI, 1987, EUR ARCH PSY NEUR SC, V237, P2; LISHMAN WA, 1973, PSYCHOL MED, V3, P304, DOI 10.1017/S003329170004959X; RIMMEL J, 1990, REHABILITATION ADULT; Smeltzer D., 1994, NEUROPSYCHIATRY TRAU; THOMSEN IV, 1984, J NEUROL NEUROSUR PS, V47, P260, DOI 10.1136/jnnp.47.3.260; WILCOX JA, 1987, PSYCHIAT RES, V21, P303, DOI 10.1016/0165-1781(87)90013-8	13	23	23	0	0	LIPPINCOTT-RAVEN PUBL	PHILADELPHIA	227 EAST WASHINGTON SQ, PHILADELPHIA, PA 19106	0894-878X			NEUROPSY NEUROPSY BE	Neuropsychiatr. Neuropsychol. Behav. Neurol.	APR	1996	9	2					133	138					6	Clinical Neurology; Psychiatry; Psychology	Neurosciences & Neurology; Psychiatry; Psychology	UB299	WOS:A1996UB29900008					2021-06-18	
J	Charnley, G; Judet, T; deLoubresse, CG; Mollaret, O				Charnley, G; Judet, T; deLoubresse, CG; Mollaret, O			Excision of heterotopic ossification around the knee following brain injury	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article								We present the results of five patients who underwent resection of heterotopic ossification around the knee following traumatic brain injury. All the patients had improved function and no pain at a minimum of 1 year follow up, irrespective of their preoperative neurological status. Oar philosophy for such surgery is outlined and, although the surgical goals may seem small, the outcome for any individual patient may be considerable.	HOP TENON,F-75020 PARIS,FRANCE							AYERS D, 1991, CLIN ORTHOPAEDICS, V265, P87; BOSSE MJ, 1988, J BONE JOINT SURG AM, V70A, P1231, DOI 10.2106/00004623-198870080-00016; DEJERINE MME, 1918, ANN MED, V5, P497; GARLAND DE, 1991, CLIN ORTHOP RELAT R, P59; GARLAND DE, 1985, J BONE JOINT SURG AM, V67A, P1261, DOI 10.2106/00004623-198567080-00019; GARLAND DE, 1988, CLIN ORTHOP RELAT R, V233, P86; GARLAND DE, 1991, CLIN ORTHOPAEDICS, V263, P13; MOLLARET O, 1991, THESIS U PARIS; Moore T J, 1993, J Orthop Trauma, V7, P11, DOI 10.1097/00005131-199302000-00003; ROBERTS JB, 1979, J BONE JOINT SURG AM, V61, P760, DOI 10.2106/00004623-197961050-00018	10	23	25	0	0	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0020-1383			INJURY	Injury-Int. J. Care Inj.	MAR	1996	27	2					125	128		10.1016/0020-1383(95)00180-8			4	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	TY672	WOS:A1996TY67200011	8730387				2021-06-18	
J	Wekesa, M; Asembo, JM; Njororai, WWS				Wekesa, M; Asembo, JM; Njororai, WWS			Injury surveillance in a rugby tournament	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						injuries; rugby football		Objective-To investigate injuries in international rugby football. Methods-All injuries that led to temporary stoppage of the game or to the substitution of a player during the Rugby World Cup prequalifying tournament were recorded. Six matches were played, involving the Arabian Gulf, Kenya, Namibia, and Zimbabwe. Results-47 injuries were recorded, giving an injury rate of eight per match. The number of injuries decreased from 38.3% in the first matches to 23.4% in the final ones. The most serious injury was a concussion and the majority of the injuries affected soft tissues. Anatomically, the lower limbs suffered most injuries (46.8%), followed by the head (21.3%), trunk (17.0%), and upper limbs (12.8%). Slightly more injuries occurred in the defensive half of the field of play (53.2%) than in the offensive half (46.8%). More injuries occurred in the second half (61.7%) than in the first half (38.3%). Conclusions-Protective equipment should be introduced to minimise the number and seriousness of injuries in rugby.	EXERCISE & SPORTS CONSULTANCY,NAIROBI,KENYA; KENYA POLYTECH,SPORTS & GAMES DEPT,NAIROBI,KENYA; KENYATTA UNIV,DEPT PHYS EDUC,NAIROBI,KENYA			Simiyu, Wycliffe W. Njororai/AAD-7565-2019	Simiyu, Wycliffe W. Njororai/0000-0002-3164-4269			Blonstein J L, 1974, Trans Med Soc Lond, V90, P20; CLARK DR, 1991, 2 WORLD C SCI FOOTB; DAVIES JE, 1978, BRIT MED J, V2, P1759, DOI 10.1136/bmj.2.6154.1759; DORAN GA, 1984, J SPORT MED PHYS FIT, V24, P90; DURKIN TE, 1977, BRIT J SPORT MED, V11, P72; HAMMACHER ER, 1991, 2 WORLD C SCI FOOTB; HARDIKER RJ, 1981, SPORT FITNESS SPORTS, P118; HOLLMANN W, 1990, SPORTSMEDIZIN ARBEIT; Micheli L J, 1974, J Sports Med, V2, P93; NIELSEN AB, 1989, AM J SPORT MED, V17, P803, DOI 10.1177/036354658901700614; NIELSEN AB, 1988, INT J SPORTS MED, V9, P341, DOI 10.1055/s-2007-1025037; NOAKES TD, 1991, 2 WORLD C SCI FOOTB; REILLY T, 1981, J SPORT MED PHYS FIT, V21, P186; ROY SP, 1974, S AFR MED J, V48, P234; VANDERNEUT HW, 1991, 2 WORLD C SCI FOOTB; VANHEERDEN JJ, 1976, S AFR MED J, V50, P1374; WEKESA M, 1993, E AFR MED J, V70, P671; WEKESA M, 1993, MEDICUS, V12, P8	18	23	23	0	3	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	MAR	1996	30	1					61	63		10.1136/bjsm.30.1.61			3	Sport Sciences	Sport Sciences	UB727	WOS:A1996UB72700016	8665122	Green Published, Bronze			2021-06-18	
J	Anderson, CV; Wood, DMG; Bigler, ED; Blatter, DD				Anderson, CV; Wood, DMG; Bigler, ED; Blatter, DD			Lesion volume, injury severity, and thalamic integrity following head injury	JOURNAL OF NEUROTRAUMA			English	Article						traumatic brain injury; magnetic resonance; lesion volume	AXONAL INJURY	Magnetic resonance scans of 63 TBI patients were analyzed to examine the relationship between injury severity, lesion volume (nonthalamic cortical/subcortical lesions), ventricle-to-brain ratio (VER), and thalamic volume. For comparison, 33 normal control subjects were used. Patients with visible nonthalamic structural lesions showed significantly smaller thalamic volumes than patients without visible lesions or control subjects. Results also indicated that patients with visible lesions had significantly more severe injuries than patients without lesions. Patients with moderate-severe injuries had significantly smaller thalamic volumes and greater VBRs than patients with mild-moderate injuries. Although several variables related to thalamic volume, the presence of nonthalamic lesions was sufficient to result in smaller thalamic volume. Decreased thalamic volume following head injury suggests that subcortical brain structures may be susceptible to transneuronal degeneration following cortical lesions, and that this can be detected by in vivo MR-based volumetric analysis.	BRIGHAM YOUNG UNIV,DEPT PSYCHOL,PROVO,UT 84602; LATTER DAY ST HOSP,DEPT RADIOL,SALT LAKE CITY,UT 84143							ANDERSON CV, 1995, J NEUROPSYCH CLIN N, V7, P42; BIGLER ED, 1994, FUNCTIONAL NEUROIMAG, P121; Bigler Erin D., 1993, Brain Injury, V7, P125, DOI 10.3109/02699059309008166; BLATTER DD, 1995, AM J NEURORADIOL, V16, P241; BLUMBERGS PC, 1989, J NEUROL NEUROSUR PS, V52, P838, DOI 10.1136/jnnp.52.7.838; CHRISTMAN CW, 1994, J NEUROTRAUM, V11, P173, DOI 10.1089/neu.1994.11.173; CLARKE LP, 1995, MAGN RESON IMAGING, V13, P343, DOI 10.1016/0730-725X(94)00124-L; GALE SD, 1994, NEUROPSY NEUROPSY BE, V7, P160; Gean A, 1994, IMAGING HEAD TRAUMA; JESSELL TM, 1991, PRINCIPLES NEURAL SC, P258; Johnson SC, 1994, NEUROPSYCHOLOGY, V8, P307, DOI DOI 10.1037/0894-4105.8.3.301; KUCHARCZYK J, 1994, MAGNETIC RESONANCE I; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; MATTHEWS MA, 1973, J NEUROCYTOL, V2, P265, DOI 10.1007/BF01104030; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; PRAYER LM, 1994, MAGNETIC RESONANCE N, P441; ROBB RA, 1995, 3 DIMENSIONAL BIOMED; ROSENTHAL M, 1993, TRAUMATIC BRAIN INJU; ROSS DT, 1993, J NEUROTRAUM, V10, P151, DOI 10.1089/neu.1993.10.151; ROSS DT, 1990, NEUROSCIENCE, V35, P525, DOI 10.1016/0306-4522(90)90327-Z; Steward O, 1989, PRINCIPLES CELLULAR; WHITE RJ, 1992, NEW ENGL J MED, V327, P1507; WILSON JTL, 1992, J HEAD TRAUMA REHAB, V7, P29	25	23	23	0	2	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	JAN	1996	13	1					35	40		10.1089/neu.1996.13.35			6	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TW167	WOS:A1996TW16700005	8714861				2021-06-18	
J	Feehan, M; Waller, AE				Feehan, M; Waller, AE			Precompetition injury and subsequent tournament performance in full-contact taekwondo	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article						taekwondo; injury; performance; regulation	MARTIAL ARTS	Objective - To determine the pattern of injuries sustained by taekwondo competitors, and how previous injury affects performance in sporting competition. Methods - Competitors at a major New Zealand full-contact taekwondo tournament were given a comprehensive questionnaire immediately before competition. Self reports of injuries sustained through taekwondo in the previous 12 months were determined. Results - No significant sex differences were found. The injury prevalence was high, but comparatively less than reported for other contact sports such as rugby football. However, one in 20 injuries was a closed head injury. No significant associations between prior injury and tournament outcome were found. Conclusions - Taekwondo can be a source of disabling injury, However, the fact that prior injury did not appear to be associated with impaired competition performance may militate against acceptance of control and regulation by competitors and coaches.	UNIV N CAROLINA,SCH MED,DEPT EMERGENCY MED,CHAPEL HILL,NC	Feehan, M (corresponding author), JOHNS HOPKINS UNIV,SCH HYG & PUBL HLTH,FAC SOCIAL & BEHAV SCI,DEPT HLTH POLICY & MANAGEMENT,BALTIMORE,MD 21205, USA.						Birrer R, 1981, Phys Sportsmed, V9, P97, DOI 10.1080/00913847.1981.11711013; Birrer R B, 1983, Br J Sports Med, V17, P131; BIRRER RB, 1988, AM J SPORT MED, V16, P408, DOI 10.1177/036354658801600418; Cho S. H., 1968, KOREAN KARATE FREE F; CHUN R, 1982, ADVANCING TAE KWON D; FISHER RA, 1941, STATISTICAL METHODS; GERRARD DF, 1994, BRIT J SPORT MED, V28, P229, DOI 10.1136/bjsm.28.4.229; Johannsen H V, 1988, Br J Sports Med, V22, P113; LUCAS J, 1992, J PHYS ED RECREA APR; McLatchie G, 1981, Br J Sports Med, V15, P84; OLER M, 1991, J TRAUMA, V31, P251, DOI 10.1097/00005373-199131020-00017; Park Y. H., 1989, TAE KWON DO ULTIMATE; SERINA ER, 1991, J BIOMECH, V10, P951; Siana J E, 1986, Br J Sports Med, V20, P165; Snedecor G. W., 1980, STATISTICAL METHODS; WALLER AE, 1994, BRIT J SPORT MED, V28, P223, DOI 10.1136/bjsm.28.4.223; Zemper E D, 1989, Br J Sports Med, V23, P161	17	23	24	0	4	BUTTERWORTH-HEINEMANN LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, OXON, ENGLAND OX5 1GB	0306-3674			BRIT J SPORT MED	Br. J. Sports Med.	DEC	1995	29	4					258	262		10.1136/bjsm.29.4.258			5	Sport Sciences	Sport Sciences	TQ222	WOS:A1995TQ22200011	8808541	Bronze, Green Published			2021-06-18	
J	Ildan, F; Polat, S; Oner, A; Isbir, T; Cetinalp, E; Kaya, M; Karadayi, A				Ildan, F; Polat, S; Oner, A; Isbir, T; Cetinalp, E; Kaya, M; Karadayi, A			The effect of the treatment of high-dose methylprednisolone on Na+-K+/Mg+2 ATPase activity and lipid peroxidation and ultrastructural findings following cerebral contusion in rat	SURGICAL NEUROLOGY			English	Article						brain; injury; methylprednisolone; Na+-K+/Mg+2 ATPase; lipid peroxidation; ultrastructural study	SPINAL-CORD TRAUMA; (NA+ + K+)-ATPASE; STEROID-THERAPY; INJURY; CAT; SYSTEM; OXYGEN; CORTEX; EDEMA	BACKGROUND Although use of corticosteroid in the management of head trauma has caused a great deal of controversy, corticosteroids have long been an adjunct in the management of severe closed head injury. The glucocorticoid steroid methylprednisolone (MP) has been proven to have significant antioxidant effect when administered in an antioxidant-high dose after central nervous system injury. METHODS The sodium-potassium activated and magnesium dependent adenosine-5'-triphosphatase (Na+-K+/Mg+2 ATPase EC.3.6.1.3.) activity, lipid peroxidation, and early ultrastructural findings were determined during the immediate posttraumatic period in rats. Mechanical brain injury was produced when a calibrated weight-drop device is allowed to fall on to the skull's convexity over the right hemisphere, 1 to 2 mm lateral from the midline. In group I, rats were used to determine Na+-K+/Mg+2 ATPase activity, the extent of lipid peroxidation, by measuring the level of malondialdehyde content and normal ultrastructural findings in two different brain areas (cerebral cortex and brain stem), In group II, physiologic saline was administered right after trauma in the same amount as methylprednisolone. In group III rats, methylprednisolone (30 mg/kg) was administered intravenously right after trauma. RESULTS Na+-K+/Mg+2 ATPase activity significantly decreased in the cerebral cortex and in brain stem within 2 hours after trauma (p < 0.05), There was significant difference in malondialdehyde content between groups II and III (p < 0.05). Methylprednisolone treatment reduced malondialdehyde content and induced the recovery of Na+-K+/Mg+2 activity. CONCLUSIONS These data suggest that inactivation of Na+-K+/Mg+2 ATPase is closely correlated to changes of lipid peroxidation and the alteration of the ultrastructural findings in the early phases after head trauma, The glucocorticoid steroid methylprednisolone has been proven to have significant effect in inactivation of Na+-K+/Mg+2 ATPase with significant reduction of malondialdehyde content.	CUKUROVA UNIV, SCH MED, DEPT HISTOL, Balcali, TURKEY; CUKUROVA UNIV, SCH MED, DEPT BIOCHEM, Balcali, TURKEY	Ildan, F (corresponding author), CUKUROVA UNIV, SCH MED, DEPT NEUROSURG 01330, Balcali, TURKEY.		POLAT, Sait/J-3812-2018	POLAT, Sait/0000-0003-1646-8831			ANDERSON DK, 1982, J NEUROSURG, V56, P106, DOI 10.3171/jns.1982.56.1.0106; BOURKE RS, 1979, NEURAL TRAUMA, P95; BRAUGHLER JM, 1985, J NEUROCHEM, V44, P1282, DOI 10.1111/j.1471-4159.1985.tb08755.x; BRAUGHLER JM, 1989, FREE RADICAL BIO MED, V6, P289, DOI 10.1016/0891-5849(89)90056-7; BRAUGHLER JM, 1982, J NEUROSURG, V56, P838, DOI 10.3171/jns.1982.56.6.0838; CAMPBELL JB, 1974, J NEUROSURG, V40, P726, DOI 10.3171/jns.1974.40.6.0726; CLASEN RA, 1979, STROKE, V10, P670, DOI 10.1161/01.STR.10.6.670; CLENDENON NR, 1978, NEUROLOGY, V28, P78, DOI 10.1212/WNL.28.1.78; CLENDENON NR, 1978, J NEUROSURG, V49, P563, DOI 10.3171/jns.1978.49.4.0563; Clendenon NR, 1979, NEURAL TRAUMA, P115; DELATORRE JC, 1975, NEUROLOGY, V25, P508, DOI 10.1212/WNL.25.6.508; DEMOPOULOS HB, 1980, ACTA PHYSIOL SCAND, P91; ELLIS EF, 1981, J NEUROCHEM, V37, P892, DOI 10.1111/j.1471-4159.1981.tb04476.x; EMERSON TE, 1979, SURG GYNECOL OBSTET, V148, P361; EMERSON TE, 1977, P SOC EXP BIOL MED, V156, P378; GAUDET RJ, 1979, BIOCHEM BIOPH RES CO, V86, P893, DOI 10.1016/0006-291X(79)91796-0; GREEN BA, 1980, SURG NEUROL, V13, P91; HALL ED, 1982, SURG NEUROL, V18, P320, DOI 10.1016/0090-3019(82)90140-9; HALL ED, 1981, EXP NEUROL, V73, P321, DOI 10.1016/0014-4886(81)90067-4; HALL ED, 1982, J NEUROSURG, V57, P247, DOI 10.3171/jns.1982.57.2.0247; HALL ED, 1992, J NEUROTRAUM, V9, P33; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; KOVACHICH GB, 1981, BRAIN RES, V206, P229, DOI 10.1016/0006-8993(81)90122-0; KOVACHICH GB, 1980, J NEUROCHEM, V35, P1449, DOI 10.1111/j.1471-4159.1980.tb09022.x; LOWRY OH, 1951, J BIOL CHEM, V193, P265; Millonig G., 1961, J APPL PHYS, V32, P1637; MONCADA S, 1979, NEW ENGL J MED, V300, P1142, DOI 10.1056/NEJM197905173002006; OHKAWA H, 1979, ANAL BIOCHEM, V95, P351, DOI 10.1016/0003-2697(79)90738-3; ORTEGA BD, 1972, STEROIDS BRAIN EDEMA, P167; PRYOR WA, 1976, LIPIDS, V11, P370, DOI 10.1007/BF02532843; READING HW, 1980, Q J EXP PHYSIOL CMS, V65, P105, DOI 10.1113/expphysiol.1980.sp002495; READING HW, 1979, BIOCHEM PHARMACOL, V28, P3471, DOI 10.1016/0006-2952(79)90089-3; SELIGMAN ML, 1979, PHOTOCHEM PHOTOBIOL, V29, P549, DOI 10.1111/j.1751-1097.1979.tb07089.x; SELIGMAN ML, 1977, LIPIDS, V12, P945, DOI 10.1007/BF02533316; SUN AY, 1972, BIOCHIM BIOPHYS ACTA, V266, P350, DOI 10.1016/0005-2736(72)90093-4; TORNHEIM PA, 1978, J NEUROSURG, V48, P220, DOI 10.3171/jns.1978.48.2.0220; WHEELER KP, 1975, BIOCHEM J, V146, P713, DOI 10.1042/bj1460713; YOUNG W, 1982, J NEUROSURG, V57, P667, DOI 10.3171/jns.1982.57.5.0667	38	23	28	0	3	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	0090-3019			SURG NEUROL	Surg. Neurol.	DEC	1995	44	6					573	580					8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	TX871	WOS:A1995TX87100028	8669035				2021-06-18	
J	KERR, C				KERR, C			DYSNOMIA FOLLOWING TRAUMATIC BRAIN INJURY - AN INFORMATION-PROCESSING APPROACH TO ASSESSMENT	BRAIN INJURY			English	Article							WORD MATCHING TASKS; CLOSED HEAD-INJURY; ALZHEIMERS-DISEASE; SEMANTIC ERRORS; RETRIEVAL; APHASIA; DEFICITS; COMPREHENSION; IMPAIRMENT; DISORDERS	Current cognitive neuropsychological models of language have contributed to a greater understanding of the language processing components involved in the simple task of picture naming. The naming abilities of a group of 20 patients who had sustained a traumatic brain injury (TBI) were assessed with the purpose of more accurately describing the precise processing mechanisms underlying the dysnomia. Performance of the TBI group on the Boston Naming Test was analysed for error pattern and compared to a group of controls (n = 20) matched for age, sex and years of education. TBI subjects performed significantly poorer than controls, despite an unexpectedly high rate of naming 'error' in controls. TBI and control subjects showed marked similarity in overall error pattern. The results of a more comprehensive language-processing assessment is reported for a subgroup of six clearly dysnomic TBI subjects. Conclusions are drawn regarding the possible functional locus of the naming impairment in each case, and the contribution of current cognitive neuropsychological studies in anemia rehabilitation is discussed.		KERR, C (corresponding author), ROYAL REHABIL CTR, DEPT SPEECH PATHOL, SYDNEY, NSW 2112, AUSTRALIA.						BUTTERWORTH B, 1984, NEUROPSYCHOLOGIA, V22, P409, DOI 10.1016/0028-3932(84)90036-8; CARAMAZZA A, 1989, COGNITIVE APPROACHES, P383; COLTHEART M, COGNITIVE NEUROPSYCH, P1; COOK K, 1991, P NEWCASTLE TYNE S T, P1; ELLIS AW, 1988, HUMAN COGNITIVE NEUR; GAINOTTI G, 1976, BRIT J DISORD COMMUN, V11, P57; GAINOTTI G, 1986, BRAIN LANG, V3, P359; GROHER M, 1977, J SPEECH HEAR RES, V20, P212, DOI 10.1044/jshr.2002.212; HADAR U, 1987, CORTEX, V23, P505, DOI 10.1016/S0010-9452(87)80011-4; HARTLEY LL, 1990, APHASIOLOGY, V4, P353, DOI 10.1080/02687039008249088; HEILMAN KM, 1971, J NEUROL NEUROSUR PS, V34, P265, DOI 10.1136/jnnp.34.3.265; Hillis A. E., 1991, CLIN APHASIOLOGY, V19, P255; HONEY K, 1994, IN PRESS MINISTERIAL; HOWARD D, 1984, COGN NEUROPSYCHOL, V1, P163, DOI 10.1080/02643298408252021; HOWARD D, 1985, BRAIN, V108, P817; HOWARD D, 1989, COGNITIVE APPROACHES, P383; HUFF FJ, 1986, BRAIN LANG, V28, P235, DOI 10.1016/0093-934X(86)90103-3; JORDAN F M, 1990, Brain Injury, V4, P27; Kaplan E., 1983, BOSTON NAMING TEST; KAY J, 1987, BRAIN, V110, P613, DOI 10.1093/brain/110.3.613; KAY J, 1989, PSYCHOLINGUISTIC ASS; KREMIN H, 1993, FOUNDATIONS OF APHASIA REHABILITATION, P261; LESSER R, 1993, FOUNDATIONS OF APHASIA REHABILITATION, P249; LESSER R, 1989, COGNITIVE APPROACHES, P65; LEVIN HS, 1976, J NEUROL NEUROSUR PS, V39, P1062, DOI 10.1136/jnnp.39.11.1062; LI EC, 1991, NEUROPSYCHOLOGIA, V29, P1083; LYLE DM, 1990, COMMUNITY HEALTH ST, V14, P118; MARSHALL J, 1990, APHASIOLOGY, V4, P167, DOI 10.1080/02687039008249068; MARTIN A, 1983, BRAIN LANG, V19, P124, DOI 10.1016/0093-934X(83)90059-7; MITCHUM CC, 1990, APHASIOLOGY, V4, P261, DOI 10.1080/02687039008249079; MURDOCH BE, 1987, BRAIN LANG, V31, P122, DOI 10.1016/0093-934X(87)90064-2; Nettleton J., 1991, J NEUROLINGUIST, V6, P139, DOI [10.1016/0911-6044(91)90004-3, DOI 10.1016/0911-6044(91)90004-3]; NICHOLAS LE, 1989, APHASIOLOGY, V3, P569, DOI 10.1080/02687038908249023; Norusis M.J., 1993, SPSS WINDOWS BASE SY; PRING T, 1990, APHASIOLOGY, V4, P479, DOI 10.1080/02687039008248788; RAYMER AM, 1993, APHASIOLOGY, V7, P27, DOI 10.1080/02687039308249498; SARNO MT, 1980, J NERV MENT DIS, V168, P685, DOI 10.1097/00005053-198011000-00008; SHALLICE T, 1986, COGNITIVE NEUROPSYCH, P111; SHORES EA, 1986, MED J AUSTRALIA, V144, P569, DOI 10.5694/j.1326-5377.1986.tb112311.x; Siegel S., 1956, NONPARAMETRIC STAT B; SILVERI MC, 1989, APHASIOLOGY, V3, P423, DOI 10.1080/02687038908249004; TEASDALE G, 1974, LANCET, V2, P81; THOMSEN IV, 1975, J NEUROL NEUROSUR PS, V38, P713, DOI 10.1136/jnnp.38.7.713	43	23	23	2	3	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV-DEC	1995	9	8					777	796		10.3109/02699059509008234			20	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	TH499	WOS:A1995TH49900003	8605511				2021-06-18	
J	MARSHALL, LF; MARSHALL, SB				MARSHALL, LF; MARSHALL, SB			PITFALLS AND ADVANCES FROM THE INTERNATIONAL TIRILAZAD TRIAL IN MODERATE AND SEVERE HEAD-INJURY	JOURNAL OF NEUROTRAUMA			English	Article						TRAUMATIC BRAIN INJURY; INTERNATIONAL TIRILAZAD TRIAL; TRIAL DESIGN; FEASIBILITY	LIPID-PEROXIDATION; U74006F	This manuscript reviews current experience with a large-scale clinical trial of the nonglucocorticoid 21-aminosteroid compound, tirilazad mesylate (U-74,006F). The trial itself now encompasses 15 countries with all central coordination conducted in the Data Coordinating Center at the University of California, San Diego. To date, the conduct of this trial has shown that diverse groups of clinicians in multiple countries have been able to work together to adhere to a tightly defined research protocol. Despite the success in initiating and conducting this trial, however, there have been several unanticipated problems that have complicated its progress. In this regard, difficulties have been associated with the use of mean Glasgow coma scores for data analysis. Similarly, a prospective identification of the risk variables was found necessary to preclude the potential for serious errors in data analysis. Lastly, a differential effect of the drug was noted in women compared to men in the European subarachnoid hemorrhage trial where a significant improvement in outcome was observed in males. This differential response appears to be linked to drug metabolism, but the problem may be further compounded by improper dosing because of failure to weigh many patients. Women appear to be routinely underdosed because their weights are routinely underestimated. Overall, this paper shows the feasibility of conducting such a large scale international trial, while also highlighting some of the potential pitfalls and problems that should be avoided in future trials of this nature.	UNIV CALIF SAN DIEGO,SAN DIEGO MED CTR,DIV NEUROSURG,SAN DIEGO,CA 92103	MARSHALL, LF (corresponding author), UNIV CALIF SAN DIEGO,SAN DIEGO MED CTR,NEUROL SERV,200 W ARBOR DR,SAN DIEGO,CA 92103, USA.						BRAUGHLER JM, 1987, J BIOL CHEM, V262, P10438; GAUTILLE T, UNPUB; HALL ED, 1988, J NEUROSURG, V68, P456, DOI 10.3171/jns.1988.68.3.0456; HALL ED, 1988, STROKE, V19, P997, DOI 10.1161/01.STR.19.8.997; HALL ED, 1988, STROKE, P340; KASSELL ND, 1993, OCT P WORLD C NEUR A; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14	7	23	23	0	0	MARY ANN LIEBERT INC PUBL	LARCHMONT	2 MADISON AVENUE, LARCHMONT, NY 10538	0897-7151			J NEUROTRAUM	J. Neurotrauma	OCT	1995	12	5					929	932		10.1089/neu.1995.12.929			4	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	TE646	WOS:A1995TE64600019	8594222				2021-06-18	
J	ALTURA, BM; MEMON, ZS; ALTURA, BT; CRACCO, RQ				ALTURA, BM; MEMON, ZS; ALTURA, BT; CRACCO, RQ			ALCOHOL-ASSOCIATED ACUTE HEAD TRAUMA IN HUMAN-SUBJECTS IS ASSOCIATED WITH EARLY DEFICITS IN SERUM IONIZED MG AND CA	ALCOHOL			English	Article						BRAIN TRAUMA; ALCOHOL ABUSE; DIVALENT CATIONS; ION-SELECTIVE ELECTRODES; MOTOR VEHICLE ACCIDENTS	FATAL INJURIES; BRAIN INJURY; EMERGENCY; CONSUMPTION; GLUTAMATE; ACCIDENT; BLOOD	Acute head trauma (AHT) (caused by motor vehicle accidents that did not produce loss of consciousness or observed brain lesions on CT scan, or falls) was found to result in early (1-8 h after injury) serum deficits in ionized magnesium (IMg2+) and ionized calcium (ICa2+) assessed with ion-selective electrodes (ISEs). Total Mg (TMg) and other electrolytes as well as serum biochemical analytes were an within the normal reference ranges. AHT patients with acute alcohol intoxication (BAG greater than or equal to 150 mg/dl) or alcohol abuse (BAG > 200 mg/dl) demonstrated deficits (15-35% less than normal) in IMg2+, but serum TMg levels were normal as were electrolytes and serum biochemical analytes. AHT patients with alcohol intoxication or alcohol abuse required hospitalization for 1-3 days prior to release, whereas AHT patients without alcohol intoxication were released in less than 24 h. The ICa2+/IMg2+ ratio, a sign of increased vascular tone and vascular reactivity, was significantly elevated in AHT patients with alcohol intoxication but not in AHT patients without alcohol intoxication or abuse. These serum divalent cation changes early after traumatic brain injury could be of considerable practicable diagnostic value in the assessment of alcohol-associated head injury. Use of ion-selective electrodes to accurately measure IMg2+ could serve as a logical basis for monitoring the response of the body to AHT.	SUNY HLTH SCI CTR,DEPT MED,BROOKLYN,NY 11203; SUNY HLTH SCI CTR,DEPT NEUROL,BROOKLYN,NY 11203	ALTURA, BM (corresponding author), SUNY HLTH SCI CTR,DEPT PHYSIOL,BOX 31,450 CLARKSON AVE,BROOKLYN,NY 11203, USA.				NIAAA NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [AA-08674] Funding Source: Medline; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [R01AA008674] Funding Source: NIH RePORTER		Altura B M, 1984, Alcohol, V1, P325, DOI 10.1016/0741-8329(84)90056-9; Altura B. M., 1992, Magnesium and Trace Elements, V10, P122; Altura B T, 1984, Magnesium, V3, P195; Altura B. T., 1992, Magnesium and Trace Elements, V10, P90; Altura Bella T., 1994, Scandinavian Journal of Clinical and Laboratory Investigation, V54, P53, DOI 10.3109/00365519409095211; ALTURA BM, 1983, SCIENCE, V220, P331, DOI 10.1126/science.6836278; ALTURA BM, 1981, FED PROC, V40, P2672; ALTURA BM, 1993, ALCOHOL, V10, P563, DOI 10.1016/0741-8329(93)90084-2; ALTURA BM, 1991, CLIN RES, V39, pA394; ALTURA BM, ALCOHOL, V12, P131; ALTURA BT, 1992, METHOD FIND EXP CLIN, V14, P297; ALTURA BT, 1994, SCAND J CLIN LAB INV, V54, P21, DOI 10.3109/00365519409095208; ALTURA BT, 1980, NEUROSCI LETT, V20, P323, DOI 10.1016/0304-3940(80)90168-8; ALTURA BT, 1982, MAGNESIUM EXP CLIN R, V1, P277; BABU AR, IN PRESS BRAIN RES B; BECKER DP, 1985, CENTRAL NERVOUS SYST; BOUMA GJ, 1991, J NEUROSURG, V75, P685, DOI 10.3171/jns.1991.75.5.0685; CHERPITEL CJS, 1989, DRUG ALCOHOL DEPEN, V24, P195; CHERPITEL CJS, 1989, J STUD ALCOHOL, V50, P155, DOI 10.15288/jsa.1989.50.155; ECKARDT MJ, 1981, JAMA-J AM MED ASSOC, V246, P648, DOI 10.1001/jama.246.6.648; FLINK EB, 1954, J LAB CLIN MED, V43, P169; GOODMAN RA, 1991, J STUD ALCOHOL, V52, P156, DOI 10.15288/jsa.1991.52.156; HUANG QF, 1994, AM J PHYSIOL, V266, pR158; HURST PM, 1973, J SAFETY RES, V5, P130; IKEDA Y, 1990, NEUROSURGERY, V27, P1; JENNETT B, 1976, LANCET, V1, P1031; JENNETT B, 1975, LANCET, V1, P280; JONES GA, 1989, ALCOHOL HEALTH RES W, V13, P105; MARSHALL LF, 1990, CURR OPIN NEUROL NEU, V3, P4; NOWAK L, 1984, NATURE, V307, P462, DOI 10.1038/307462a0; PERRINE MW, 1989, SURGEON GENERALS WORKSHOP ON DRUNK DRIVING, P35; ROTHMAN SM, 1986, ANN NEUROL, V19, P105, DOI 10.1002/ana.410190202; SMITH SM, 1989, AM J PREV MED, V5, P296; YATES DW, 1987, J ROY SOC MED, V80, P486, DOI 10.1177/014107688708000810; YATES DW, 1987, BRIT J ADDICT, V82, P163; ZHANG A, 1992, BIOCHIM BIOPHYS ACTA, V1134, P25, DOI 10.1016/0167-4889(92)90024-6; ZHANG A, 1994, EUR J PHARMACOL, V248, P229	37	23	23	0	1	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD, ENGLAND OX5 1GB	0741-8329			ALCOHOL	Alcohol	SEP-OCT	1995	12	5					433	437		10.1016/0741-8329(95)00026-N			5	Substance Abuse; Pharmacology & Pharmacy; Toxicology	Substance Abuse; Pharmacology & Pharmacy; Toxicology	RV112	WOS:A1995RV11200006	8519438				2021-06-18	
J	TWUM, M; PARENTE, R				TWUM, M; PARENTE, R			ROLE OF IMAGERY AND VERBAL LABELING IN THE PERFORMANCE OF PAIRED ASSOCIATES TASKS BY PERSONS WITH CLOSED-HEAD INJURY	JOURNAL OF CLINICAL AND EXPERIMENTAL NEUROPSYCHOLOGY			English	Article							MNEMONIC AID; MEMORY; AMNESIA; RECALL	The facilitating effects of visual imagery and verbal labeling strategies on learning and retention were examined with 60 survivors of closed-head injury. Because individuals without known neurological deficits use cognitive strategies when learning new materials, we expected that head-injured subjects could also be taught to use these strategies. Subjects were asked to memorize the verbal and visual paired associates stimulus items from the revised Wechsler Memory Scale-Revised (WMS-R). One group of subjects received mental imagery instructions to help them learn the verbal paired associates. Another group received verbal labeling training to help them learn the visual paired associates. Subjects who received imagery but not verbal labeling instructions were able to recall more paired associations than those who did not receive imagery. Those subjects who received verbal labeling but not imagery instructions recalled more visual paired associations than those who did not. Subjects who received learning instructions also showed better retention of the learned information.	TOWSON STATE UNIV,DEPT PSYCHOL,TOWSON,MD 21204			Parente, Frederick/W-2570-2019	Parente, Frederick/0000-0002-2784-3433			BADDELEY AD, 1973, NEUROPSYCHOLOGIA, V11, P159, DOI 10.1016/0028-3932(73)90003-1; BOWER GH, 1970, J VERB LEARN VERB BE, V9, P529, DOI 10.1016/S0022-5371(70)80096-2; BOWER GH, 1970, AM SCI, V58, P496; BROOKS DN, 1983, REHABILITATION HEAD, P185; BROWN RW, 1954, J ABNORM SOC PSYCH, V49, P454, DOI 10.1037/h0057814; CERMAK L S, 1975, Cortex, V11, P163; CERMAK LS, 1976, NEUROPSYCHOLOGIA, V14, P311, DOI 10.1016/0028-3932(76)90025-7; CROVITZ HF, 1979, CORTEX, V15, P131, DOI 10.1016/S0010-9452(79)80013-1; CULLUM CM, 1986, J CLIN EXP NEUROPSYC, V8, P437, DOI 10.1080/01688638608401333; CULLUM CM, 1990, TRAUMATIC BRAIN INJU, P129; CUTTING J, 1978, CORTEX, V14, P485, DOI 10.1016/S0010-9452(78)80024-0; DOPKINS S, 1990, CORTEX, V26, P189, DOI 10.1016/S0010-9452(13)80350-4; ELLIS HC, 1968, J EXP PSYCHOL, V78, P401, DOI 10.1037/h0026453; GLASGOW RE, 1977, J CLIN PSYCHOL, V33, P1049, DOI 10.1002/1097-4679(197710)33:4<1049::AID-JCLP2270330429>3.0.CO;2-V; GRIMM BH, 1986, HDB CLIN NEUROPSYCHO, V2, P495; GROSSMAN A, 1979, INT NEUROPSYCHOLOGY; HARRELL M, 1992, COGNITIVE REHABILITA; HITCH GJ, 1991, J EXP CHILD PSYCHOL, V51, P220, DOI 10.1016/0022-0965(91)90033-O; HOWES JL, 1983, NEUROPSYCHOLOGIA, V21, P341, DOI 10.1016/0028-3932(83)90020-9; JONES MK, 1974, NEUROPSYCHOLOGIA, V12, P21, DOI 10.1016/0028-3932(74)90023-2; Kolb B., 1990, FUNDAMENTALS HUMAN N; KOVNER R, 1983, J CLIN NEUROPSYCHOL, V5, P65, DOI 10.1080/01688638308401151; KREUTZER J, 1992, ANN REV HEAD INJURY; LENG NRC, 1988, CORTEX, V24, P33, DOI 10.1016/S0010-9452(88)80015-7; LEWINSOHN PM, 1977, J CONSULT CLIN PSYCH, V45, P717, DOI 10.1037/0022-006X.45.5.717; Moffat N., 1984, CLIN MANAGEMENT MEMO, P63; PAIVIO A, 1969, PSYCHOL REV, V76, P241, DOI 10.1037/h0027272; PARENTE R, 1993, APPL COGNITIVE PSYCH, V7, P585, DOI 10.1002/acp.2350070704; PARENTE R, 1991, RETRAINING MEMORY TE; PARENTE R, 1991, COGNITIVE REHABILITA, P147; PATTEN BM, 1972, ARCH NEUROL-CHICAGO, V26, P25, DOI 10.1001/archneur.1972.00490070043006; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; Schacter DL, 1986, CLIN NEUROPSYCHOLOGY, P257; SHEWAN CM, 1974, PERCEPT MOTOR SKILL, V38, P255, DOI 10.2466/pms.1974.38.1.255; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; WOOD RL, 1984, CLIN MANAGEMENT MEMO, P148	37	23	23	0	0	SWETS ZEITLINGER PUBLISHERS	LISSE	P O BOX 825, 2160 SZ LISSE, NETHERLANDS	1380-3395			J CLIN EXP NEUROPSYC	J. Clin. Exp. Neuropsychol.	AUG	1994	16	4					630	639		10.1080/01688639408402674			10	Psychology, Clinical; Clinical Neurology; Psychology	Psychology; Neurosciences & Neurology	NW682	WOS:A1994NW68200015	7962364				2021-06-18	
J	RIVARA, FP				RIVARA, FP			EPIDEMIOLOGY AND PREVENTION OF PEDIATRIC TRAUMATIC BRAIN INJURY	PEDIATRIC ANNALS			English	Article										RIVARA, FP (corresponding author), HARBORVIEW INJURY PREVENT & RES CTR,MAILSTOP ZX-10,325 9TH AVE,SEATTLE,WA 98104, USA.							0	23	23	0	0	SLACK INC	THOROFARE	6900 GROVE RD, THOROFARE, NJ 08086	0090-4481			PEDIATR ANN	Pediatr. Annu.	JAN	1994	23	1					12	17		10.3928/0090-4481-19940101-06			6	Pediatrics	Pediatrics	MU563	WOS:A1994MU56300003	8152860				2021-06-18	
J	JOHNSON, DA; ROETHIGJOHNSTON, K; RICHARDS, D				JOHNSON, DA; ROETHIGJOHNSTON, K; RICHARDS, D			BIOCHEMICAL AND PHYSIOLOGICAL-PARAMETERS OF RECOVERY IN ACUTE SEVERE HEAD-INJURY - RESPONSES TO MULTISENSORY STIMULATION	BRAIN INJURY			English	Article							CHILDREN	We investigated the efficacy of applying a programme of multisensory stimulation to patients with severe diffuse traumatic brain injury, during their admission to a tertiary neurosurgical intensive care unit. We attempted to determine the nature and extent of any physiological or biochemical changes occurring as a result of the multisensory stimulation in the initial period of their comatose state. The findings were inconclusive with no significant treatment effect demonstrated.	ATKINSON MORLEYS HOSP, DEPT PSYCHOL, LONDON SW20, ENGLAND; ROYAL SUSSEX CTY HOSP, DEPT CLIN BIOCHEM, BRIGHTON BN2 5BE, E SUSSEX, ENGLAND							Barrie-Shevlin P, 1987, Nursing (Lond), V3, P597; BUCHWALD JS, 1975, UCLA FORUM MED SCI, V18, P315; CAMPBELL AGM, 1984, BMJ-BRIT MED J, V289, P1022, DOI 10.1136/bmj.289.6451.1022; CLIFTON GL, 1983, J NEUROSURG, V59, P447, DOI 10.3171/jns.1983.59.3.0447; ENGEL GL, 1980, AM J PSYCHIAT, V137, P535; Evans B M, 1979, Acta Neurochir Suppl (Wien), V28, P52; EVANS BM, 1976, J NEUROL NEUROSUR PS, V39, P392, DOI 10.1136/jnnp.39.4.392; FERRY PC, 1986, ARCH NEUROL-CHICAGO, V43, P281, DOI 10.1001/archneur.1986.00520030067017; FOWLES DC, 1981, PSYCHOPHYSIOLOGY, V18, P232, DOI 10.1111/j.1469-8986.1981.tb03024.x; Freeman E A, 1992, Brain Inj, V6, P95, DOI 10.3109/02699059209008130; FREEMAN EA, 1987, CATASTROPHE COMA; Johnson D. W., 1989, COOPERATION COMPETIT, P23; JOHNSON DA, IN PRESS BRIT J NEUR; JOHNSON LC, 1967, ELECTROEN CLIN NEURO, V22, P11, DOI 10.1016/0013-4694(67)90004-1; KOLB B, 1992, MECHANISMS RECOVERY, P169; KRAEMER GW, 1985, TRENDS NEUROSCI, V8, P339, DOI 10.1016/0166-2236(85)90118-3; LEFEVER FF, 1986, J CLIN EXPT NEUROPSY, V8, P4; LEVINE M, 1976, NEUROPSYCHOLOGY LEAR, P3; LEWINN EB, 1978, LANCET, V2, P156; LEWINN EB, 1980, ROY SOC HEALTH J, V100, P19, DOI 10.1177/146642408010000107; MILLER C, 1985, MED WORLD NEWS, V25, P69; MITCHELL S, 1990, Brain Injury, V4, P273, DOI 10.3109/02699059009026177; OKEN BS, 1985, CENTRAL NERVOUS SYST, P177; PIERCE J P, 1990, Brain Injury, V4, P191, DOI 10.3109/02699059009026165; Quine S, 1988, Brain Inj, V2, P139, DOI 10.3109/02699058809150938; Reivich M, 1983, Hum Neurobiol, V2, P25; RISBERG J, 1986, EXPT TECHNIQUES HUMA, P514; ROSE F D, 1988, Medical Science Research, V16, P257; ROSE FD, 1992, RESTOR NEUROL NEUROS, V4, P241, DOI 10.3233/RNN-1992-4401; ROSE FD, 1992, MECHANISMS RECOVERY, P187; Rosenzwelg M., 1980, RECOVERY FUNCTION TH, P127; Roy C S, 1890, J Physiol, V11, P85; SHARAV T, 1986, MENT RETARD, V24, P81; STEIN DG, 1981, FUNCTIONAL RECOVERY, P424; SUEDFELD P, 1979, RES PSYCHOL MED, P89; TEASDALE G, 1974, LANCET, V2, P81; Teuber H L, 1975, Ciba Found Symp, P159; VANWOERKOM TCAM, 1982, EUR NEUROL, V21, P227, DOI 10.1159/000115485; WALKER JB, 1975, DEV NEUROPSYCHOL, P160; WILL B, 1992, MECHANISMS RECOVERY, P79; Williams D, 1941, BRAIN, V64, P223, DOI 10.1093/brain/64.4.223; WILLIAMS PD, 1986, INT J NURS STUD, V23, P21, DOI 10.1016/0020-7489(86)90035-0; WILSON S L, 1991, Brain Injury, V5, P393, DOI 10.3109/02699059109008112; WOOD R L, 1991, Brain Injury, V5, P401, DOI 10.3109/02699059109008113; YANKO J, 1985, HEAD INJURY REHABILI, P141	45	23	23	0	2	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0269-9052	1362-301X		BRAIN INJURY	Brain Inj.	NOV-DEC	1993	7	6					491	499		10.3109/02699059309008176			9	Neurosciences; Rehabilitation	Neurosciences & Neurology; Rehabilitation	MA173	WOS:A1993MA17300003	7903180				2021-06-18	
J	RUIJS, MBM; GABREELS, FJM; KEYSER, A				RUIJS, MBM; GABREELS, FJM; KEYSER, A			THE RELATION BETWEEN NEUROLOGICAL TRAUMA PARAMETERS AND LONG-TERM OUTCOME IN CHILDREN WITH CLOSED-HEAD INJURY	EUROPEAN JOURNAL OF PEDIATRICS			English	Article						CLOSED HEAD INJURY; COMA; POSTTRAUMATIC AMNESIA; RESIDUAL SEQUELAE	YOUNG-CHILDREN; COMA SCALE; SEQUELAE; ADOLESCENTS; CONCUSSION; PROGNOSIS; SYMPTOMS	In a study of 54 children with closed head injury, the relation between neurological severity indicators and the occurrence of long-term sequelae was investigated. Patient data were recorded during the clinical phase and during a 2 year follow up period. A correlation analysis identified early predictors for the occurrence of long-term sequelae. In particular, the duration of coma and of post-traumatic amnesia correlated strongly with the occurrence of neurological, behavioural and intellectual residual sequelae but not with the more subjective complaints.	ST RADBOUD HOSP,DEPT CHILD NEUROL,NIJMEGEN,NETHERLANDS	RUIJS, MBM (corresponding author), ST RADBOUD HOSP,INST NEUROL,POB 9101,6500 HB NIJMEGEN,NETHERLANDS.						ARTIOLA I, 1980, J NEUROL NEUROSUR PS, V43, P377; BINDER LM, 1986, J CLIN EXP NEUROPSYC, V8, P323, DOI 10.1080/01688638608401325; BLACK P, 1981, BRAIN DYSFUNCTION CH; BRAAKMAN R, 1980, NEUROSURGERY, V6, P362, DOI 10.1227/00006123-198004000-00002; BROWN G, 1981, PSYCHOL MED, V11, P63, DOI 10.1017/S0033291700053289; CHADWICK O, 1981, PSYCHOL MED, V11, P49, DOI 10.1017/S0033291700053277; Denker P., 1944, NY STATE J MED, V44, P379; DIKMEN S, 1986, J NEUROL NEUROSUR PS, V49, P1227, DOI 10.1136/jnnp.49.11.1227; FARMER MY, 1987, PEDIATR NEUROSCI, V13, P304, DOI 10.1159/000120348; FISHER CM, 1966, NEUROLOGY, V16, P826, DOI 10.1212/WNL.16.8.826; FISHER CM, 1982, NEUROLOGY, V32, P667, DOI 10.1212/WNL.32.6.667; GRONWALL D, 1974, LANCET, V2, P605; HEISKANEN O, 1970, ACTA NEUROL SCAND, V46, P343, DOI 10.1111/j.1600-0404.1970.tb05798.x; HJERN B, 1962, ARCH DIS CHILD, V37, P113, DOI 10.1136/adc.37.192.113; JENNETT B, 1976, NEW ZEAL MED J, V84, P144; LEVATI A, 1982, J NEUROSURG, V57, P779, DOI 10.3171/jns.1982.57.6.0779; LEVIN HS, 1979, CHILD BRAIN, V5, P281; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; REILLY PL, 1988, CHILD NERV SYST, V4, P30; RIMEL RW, 1981, NEUROSURGERY, V9, P221, DOI 10.1227/00006123-198109000-00001; RUIJS MBM, 1992, DEV MED CHILD NEUROL, V34, P885; RUIJS MBM, 1990, CLIN NEUROL NEUROSUR, V92, P323, DOI 10.1016/0303-8467(90)90058-D; RUSSELL WR, 1961, ARCH NEUROL-CHICAGO, V5, P4, DOI 10.1001/archneur.1961.00450130006002; RUSSELL WR, 1971, TRAUMATIC AMNESIAS; RUTHERFORD WH, 1977, LANCET, V1, P1; RUTHERFORD WH, 1979, INJURY, V10, P225, DOI 10.1016/0020-1383(79)90015-9; RUTTER M, 1980, PSYCHOL MED, V10, P633, DOI 10.1017/S0033291700054933; SCHACTER DL, 1977, CORTEX, V13, P150, DOI 10.1016/S0010-9452(77)80006-3; SIMPSON D, 1982, LANCET, V2, P450; TEASDALE G, 1974, LANCET, V2, P81	30	23	24	0	4	SPRINGER VERLAG	NEW YORK	175 FIFTH AVE, NEW YORK, NY 10010	0340-6199			EUR J PEDIATR	Eur. J. Pediatr.	OCT	1993	152	10					844	847		10.1007/BF02073384			4	Pediatrics	Pediatrics	LY422	WOS:A1993LY42200015	8223789				2021-06-18	
J	HARRINGTON, DE; MALEC, J; CICERONE, K; KATZ, HT				HARRINGTON, DE; MALEC, J; CICERONE, K; KATZ, HT			CURRENT PERCEPTIONS OF REHABILITATION PROFESSIONALS TOWARDS MILD TRAUMATIC BRAIN INJURY	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						MINOR HEAD INJURY; POSTCONCUSSION SYNDROME; POSTTRAUMATIC HEAD SYNDROME; TRAUMATIC HEAD INJURY			COASTLINE COMMUNITY COLL,NEWPORT BEACH,CA; JOHNSON REHABIL INST,EDISON,NJ; MAYO CLIN & MAYO FDN,ROCHESTER,MN 55905; REHABIL INST NEW ORLEANS,NEW ORLEANS,LA							Alves W. M., 1986, J HEAD TRAUMA REHAB, V1, P1; AUBREY JB, 1989, J NEUROL NEUROSUR PS, V52, P842, DOI 10.1136/jnnp.52.7.842; AUERBACK AH, 1967, DIS NERV SYST, V29, P110; BENTON AL, 1989, MILD HEAD INJURY; BINDER LM, 1986, J CLIN EXPER NEUROPS, V8, P321; ERICKSEN JE, 1882, CONCUSSION SPINE NER; GENNARELLI TA, 1986, J HEAD TRAUMA REHAB, V1, P23; KRAUS JF, 1984, AM J EPIDEMIOL, V119, P186, DOI 10.1093/oxfordjournals.aje.a113737; MCMORDIE WR, 1988, CLIN NEUROPSYCHOL, V2, P198; PAGE H, 1885, INJURIES SPINE SPINA; RUTHERFORD WH, 1989, MILD HEAD INJURY; TRIMBLE MR, 1981, POST TRAUMATIC NEURO; Walton G. L., 1881, BOSTON MED SURG J, V109, P337, DOI 10.1056/NEJM188310111091501	13	23	23	0	2	W B SAUNDERS CO	PHILADELPHIA	INDEPENDENCE SQUARE WEST CURTIS CENTER, STE 300, PHILADELPHIA, PA 19106-3399	0003-9993			ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUN	1993	74	6					579	586		10.1016/0003-9993(93)90155-4			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	LG423	WOS:A1993LG42300004	8503747				2021-06-18	
J	WHITE, BC; KRAUSE, GS				WHITE, BC; KRAUSE, GS			BRAIN INJURY AND REPAIR MECHANISMS - THE POTENTIAL FOR PHARMACOLOGICAL THERAPY IN CLOSED-HEAD TRAUMA	ANNALS OF EMERGENCY MEDICINE			English	Article; Proceedings Paper	SYMP ON NEUROTRAUMA : CONCEPTS, CURRENT PRACTICE AND EMERGING THERAPIES	JUN 11-12, 1992	DEARBORN, MI	WAYNE STATE UNIV SCH MED, DEPT EMERGENCY MED		BRAIN INJURY; TRAUMA, CLOSED-HEAD		Rotational acceleration from closed-head trauma produces shear-strain brain injury at the interface of gray and white matter. The initial injury is followed by progressive damage involving three key phenomena: progression of subtle focal axonal damage to axonal transection between six and 12 hours after injury, progressive development of tissue microhemorrhages between 12 and 96 hours after injury, and development of tissue and cerebral spinal fluid lactic acidosis that does not appear to be explained by tissue ischemia. All of these phenomena could be explained by trauma-induced tissue depolarization, activation of phospholipases and the release of free arachidonic acid, radical generation by metabolism of arachidonate, and lipid peroxidation with consequent membrane degradation and partial mitochondrial uncoupling. Because of terminal differentiation, neurons may have a limited membrane repair capability that might be stimulated by growth factors. Other potential therapeutic interventions include calmodulin inhibitors, iron chelators, and free radical scavengers.		WHITE, BC (corresponding author), DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT EMERGENCY MED,4201 ST ANTOINE,DETROIT,MI 48201, USA.							0	23	23	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.	JUN	1993	22	6					970	979		10.1016/S0196-0644(05)82737-4			10	Emergency Medicine	Emergency Medicine	LE338	WOS:A1993LE33800003	8503535				2021-06-18	
J	DOUCET, JP; BAZAN, NG				DOUCET, JP; BAZAN, NG			EXCITABLE-MEMBRANES, LIPID MESSENGERS, AND IMMEDIATE-EARLY GENES - ALTERATION OF SIGNAL TRANSDUCTION IN NEUROMODULATION AND NEUROTRAUMA	MOLECULAR NEUROBIOLOGY			English	Article; Proceedings Paper	SATELLITE SYMP ON MOLECULAR EVENTS IN NEUROTRANSMISSION, AT THE 13TH BIENNIAL MEETING OF THE INTERNATIONAL SOC FOR NEUROCHEMISTRY	JUL 20-22, 1991	SYDNEY, AUSTRALIA	INT SOC NEUROCHEM			PLATELET-ACTIVATING-FACTOR; LONG-TERM POTENTIATION; FREE FATTY-ACIDS; RAT CEREBRAL-CORTEX; ARACHIDONIC-ACID; C-FOS; FACTOR PAF; ELECTROCONVULSIVE SHOCK; SUBCELLULAR-LOCALIZATION; ENDOTHELIAL-CELLS		LOUISIANA STATE UNIV,MED CTR,SCH MED,LSU EYE CTR,2020 GRAVIER ST,SUITE B,NEW ORLEANS,LA 70112; LOUISIANA STATE UNIV,MED CTR,SCH MED,LSU NEUROSCI CTR,NEW ORLEANS,LA 70112			Bazan, Nicolas/AAN-4121-2020	Bazan, Nicolas/0000-0002-9243-5444			ABATE C, 1991, ONCOGENE, V6, P2179; ABRAHAM W, 1992, MOL NEUROBIOL, V5, P1; ARAI A, 1992, EUR J NEUROSCI, V4, P411, DOI 10.1111/j.1460-9568.1992.tb00890.x; AVELDANO MI, 1975, J NEUROCHEM, V25, P919, DOI 10.1111/j.1471-4159.1975.tb04432.x; AVELDANO MI, 1974, FEBS LETT, V40, P53, DOI 10.1016/0014-5793(74)80892-6; AVELDANO MI, 1975, BRAIN RES, V100, P99, DOI 10.1016/0006-8993(75)90244-9; BARBOUR B, 1989, NATURE, V342, P918, DOI 10.1038/342918a0; BARTEL DP, 1989, GENE DEV, V3, P304, DOI 10.1101/gad.3.3.304; BAUDRY M, 1991, DEV BRAIN RES, V61, P265, DOI 10.1016/0165-3806(91)90140-E; Bazan N G, 1980, Adv Neurol, V28, P197; Bazan N G, 1976, Adv Exp Med Biol, V72, P317; BAZAN NG, 1991, LIPIDS, V26, P1236, DOI 10.1007/BF02536539; BAZAN NG, 1970, BIOCHIM BIOPHYS ACTA, V218, P1, DOI 10.1016/0005-2760(70)90086-X; BAZAN NG, 1970, LIFE SCI, V9, P501, DOI 10.1016/0024-3205(70)90205-5; BAZAN NG, 1971, ACTA PHYSIOL LAT AM, V21, P101; BAZAN NG, 1984, BIOCHEM BIOPH RES CO, V125, P741, DOI 10.1016/0006-291X(84)90601-6; BAZAN NG, 1971, LIPIDS, V6, P211, DOI 10.1007/BF02533041; BAZAN NG, 1987, MOL MECHANISMS NEURO, P45; BAZAN NG, 1986, BASIC MECH EPILEPSIE, V47, P209; BAZAN NG, 1971, LIPIDS, V6, P212; BIRKLE DL, 1984, BIOCHIM BIOPHYS ACTA, V795, P564, DOI 10.1016/0005-2760(84)90187-5; BIRKLE DL, 1988, J NEUROCHEM, V51, P1900, DOI 10.1111/j.1471-4159.1988.tb01175.x; BIRKLE DL, 1987, J NEUROCHEM, V48, P1768, DOI 10.1111/j.1471-4159.1987.tb05735.x; BLANK ML, 1981, J BIOL CHEM, V256, P175; BLASQUEZ C, 1990, EUR J PHARMACOL, V177, P145, DOI 10.1016/0014-2999(90)90264-7; BOSISIO E, 1976, PROSTAGLANDINS, V11, P773, DOI 10.1016/0090-6980(76)90186-6; BRAQUET P, 1989, J LIPID MEDIATOR, V1, P75; BRAQUET P, 1987, PHARMACOL REV, V39, P97; BRAQUET P, 1990, ADV PROSTAGLANDIN TH, V21, P929; BRATTON DL, 1991, BIOCHIM BIOPHYS ACTA, V1062, P24, DOI 10.1016/0005-2736(91)90330-B; BRAUGHLER JM, 1992, J NEUROTRAUM, V9, pS1; BRAUGHLER JM, 1985, J NEUROCHEM, V45, P1288, DOI 10.1111/j.1471-4159.1985.tb05555.x; BUSSOLINO F, 1986, J BIOL CHEM, V261, P6502; BUSSOLINO F, 1989, J LIPID MEDIATOR, V1, P283; BUSSOLINO F, 1988, J NEUROCHEM, V51, P1755, DOI 10.1111/j.1471-4159.1988.tb01155.x; CENEDELLA RJ, 1975, LIPIDS, V10, P290, DOI 10.1007/BF02532702; CHILTON FH, 1984, J BIOL CHEM, V259, P2014; CHRISTY B, 1989, P NATL ACAD SCI USA, V86, P8737, DOI 10.1073/pnas.86.22.8737; CHRISTY BA, 1988, P NATL ACAD SCI USA, V85, P7857, DOI 10.1073/pnas.85.21.7857; CLARK G, 1992, IN PRESS NEURON; CLEMENTS MP, 1991, NEUROSCIENCE, V45, P379, DOI 10.1016/0306-4522(91)90235-G; COLE AJ, 1990, J NEUROCHEM, V55, P1920, DOI 10.1111/j.1471-4159.1990.tb05777.x; COLLINGRIDGE GL, 1983, J PHYSIOL-LONDON, V334, P33, DOI 10.1113/jphysiol.1983.sp014478; DAVIS H, 1984, PSYCHOL BULL, V95, P518; DECALDIRONI MIA, 1979, NEUROCHEM RES, V4, P213; DELCERRO S, 1990, BEHAV NEURAL BIOL, V54, P213, DOI 10.1016/0163-1047(90)90595-W; DIENEL GA, 1984, J NEUROCHEM, V43, P913, DOI 10.1111/j.1471-4159.1984.tb12825.x; DOEBBER TW, 1987, P NATL ACAD SCI USA, V84, P7557, DOI 10.1073/pnas.84.21.7557; DOMINGO MT, 1988, BIOCHEM BIOPH RES CO, V151, P730, DOI 10.1016/S0006-291X(88)80341-3; DOUCET JP, 1990, MOL NEUROBIOL, V4, P27, DOI 10.1007/BF02935584; DUMUIS A, 1988, NATURE, V336, P68, DOI 10.1038/336068a0; EDGAR AD, 1982, J NEUROCHEM, V39, P1111, DOI 10.1111/j.1471-4159.1982.tb11503.x; FRANCEL PC, 1992, J NEUROTRAUM, V9, pS27; FRANCESCANGELI E, 1989, BIOCHEM BIOPH RES CO, V161, P107, DOI 10.1016/0006-291X(89)91567-2; FRERICHS KU, 1990, J NEUROSURG, V73, P223, DOI 10.3171/jns.1990.73.2.0223; GILBOE DD, 1991, J NEUROCHEM, V56, P311, DOI 10.1111/j.1471-4159.1991.tb02597.x; GIUSTO NM, 1983, NEUROCHEM PATHOL, V1, P17; GLASER KB, 1990, J BIOL CHEM, V265, P8658; HARRIS RA, 1985, FED PROC, V44, P858; HENSON PM, 1987, PLATELET ACTIVATING, P255; HERSCHMAN HR, 1991, ANNU REV BIOCHEM, V60, P281, DOI 10.1146/annurev.biochem.60.1.281; HERSCHMAN HR, 1989, TRENDS BIOCHEM SCI, V14, P455, DOI 10.1016/0968-0004(89)90105-9; HILLERRED L, 1990, NEW TRENDS LIPID MED, V4, P190; HO YS, 1987, J EXP MED, V165, P1524, DOI 10.1084/jem.165.6.1524; HYMAN BT, 1982, J NEUROCHEM, V38, P650, DOI 10.1111/j.1471-4159.1982.tb08680.x; IKEDA M, 1986, J NEUROCHEM, V47, P123; JORGENSEN MB, 1989, BRAIN RES, V484, P393, DOI 10.1016/0006-8993(89)90388-0; JUNIER MP, 1988, ENDOCRINOLOGY, V123, P72, DOI 10.1210/endo-123-1-72; KACZMAREK L, 1992, BEHAV NEURAL BIOL, V57, P263, DOI 10.1016/0163-1047(92)90276-A; KATO K, 1991, BRAIN RES, V563, P94, DOI 10.1016/0006-8993(91)91519-7; KAWASAKI T, 1987, BIOCHIM BIOPHYS ACTA, V920, P85, DOI 10.1016/0005-2760(87)90314-6; KENTROTI S, 1991, J NEUROSCI RES, V28, P497, DOI 10.1002/jnr.490280406; KINDY M, 1991, J MOL NEUROSCI, V27, P217; KOCHANEK PM, 1988, J CEREBR BLOOD F MET, V8, P546, DOI 10.1038/jcbfm.1988.95; KORNECKI E, 1988, SCIENCE, V240, P1792, DOI 10.1126/science.3381103; KORNECKI E, 1984, SCIENCE, V226, P1454, DOI 10.1126/science.6150550; KUMAR R, 1988, BIOCHIM BIOPHYS ACTA, V963, P375, DOI 10.1016/0005-2760(88)90304-9; LAPETINA E, 1989, ARACHIDONIC ACID MET, V59, P153; LAZAREWICZ JW, 1983, NEUROCHEM INT, V5, P471, DOI 10.1016/0197-0186(83)90077-3; LEE TC, 1988, J BIOL CHEM, V263, P1755; LEE TC, 1986, J BIOL CHEM, V261, P5373; LINDEN DJ, 1987, J NEUROSCI, V7, P3783; LINDSBERG PJ, 1990, STROKE, V21, P1452, DOI 10.1161/01.STR.21.10.1452; LUSTIG HS, 1992, NEUROSCI LETT, V139, P15, DOI 10.1016/0304-3940(92)90847-Z; MAIER JAM, 1990, J BIOL CHEM, V265, P10805; MARCHESELLI V L, 1991, Society for Neuroscience Abstracts, V17, P349; MARCHESELLI VL, 1990, J BIOL CHEM, V265, P9140; MARCHESELLI VL, 1992, T AM SOC NEUROCHHEM, V23, P329; MARCHESELLI VL, 1991, T AM SOC NEUROCHEM, V22, P187; MARION J, 1978, PROSTAGLANDINS, V16, P99, DOI 10.1016/0090-6980(78)90206-X; MASSICOTTE G, 1990, BRAIN RES, V537, P49, DOI 10.1016/0006-8993(90)90338-C; MASSICOTTE G, 1990, NEUROSCI LETT, V118, P245, DOI 10.1016/0304-3940(90)90638-P; MAZER B, 1991, J IMMUNOL, V146, P1914; MILLER B, 1992, NATURE, V355, P722, DOI 10.1038/355722a0; MILLER LG, 1991, RES COMMUN CHEM PATH, V74, P253; MONTAROLO PG, 1986, SCIENCE, V234, P1249, DOI 10.1126/science.3775383; MORGAN JI, 1987, SCIENCE, V237, P192, DOI 10.1126/science.3037702; MORGAN JI, 1991, ANNU REV NEUROSCI, V14, P421, DOI 10.1146/annurev.ne.14.030191.002225; NIETO ML, 1991, J BIOL CHEM, V266, P18699; OBENAUS A, 1989, NEUROSCI LETT, V98, P172, DOI 10.1016/0304-3940(89)90505-3; OBERPICHLER H, 1990, J CEREBR BLOOD F MET, V10, P133, DOI 10.1038/jcbfm.1990.17; OKADA D, 1989, NEUROSCI LETT, V100, P141, DOI 10.1016/0304-3940(89)90674-5; ONODERA H, 1989, NEUROSCI LETT, V98, P101, DOI 10.1016/0304-3940(89)90381-9; PANETTA T, 1987, BIOCHEM BIOPH RES CO, V149, P580, DOI 10.1016/0006-291X(87)90407-4; PELLERIN L, 1991, NEUROCHEM RES, V16, P983, DOI 10.1007/BF00965841; POLITI LE, 1985, NEUROCHEM PATHOL, V3, P249; RAMESHA CS, 1986, J BIOL CHEM, V261, P7592; RANSONE LJ, 1990, ANNU REV CELL BIOL, V6, P539, DOI 10.1146/annurev.cellbio.6.1.539; RECORD M, 1989, J CELL BIOCHEM, V40, P353, DOI 10.1002/jcb.240400311; REDDY TS, 1987, J NEUROSCI RES, V18, P449, DOI 10.1002/jnr.490180311; ROUGEOT C, 1990, NEUROENDOCRINOLOGY, V51, P315; RUSTENBECK I, 1991, BIOCHIM BIOPHYS ACTA, V1069, P99, DOI 10.1016/0005-2736(91)90109-L; SAFFEN DW, 1988, P NATL ACAD SCI USA, V85, P7795, DOI 10.1073/pnas.85.20.7795; SAMIEI M, 1991, J BIOL CHEM, V266, P14889; SAWYER DB, 1989, BIOCHIM BIOPHYS ACTA, V987, P129, DOI 10.1016/0005-2736(89)90464-1; SCHULAM PG, 1991, J IMMUNOL, V146, P1642; SHENG M, 1988, MOL CELL BIOL, V8, P2787, DOI 10.1128/MCB.8.7.2787; SHENG M, 1990, NEURON, V4, P571, DOI 10.1016/0896-6273(90)90115-V; SHUKLA SD, 1992, FASEB J, V6, P2296; SIESJO BK, 1990, EUR NEUROL, V30, P3, DOI 10.1159/000117184; SIESJO BK, 1982, J NEUROCHEM, V39, P796, DOI 10.1111/j.1471-4159.1982.tb07962.x; SIESJO BK, 1989, J CEREBR BLOOD F MET, V9, P127, DOI 10.1038/jcbfm.1989.20; SNYDER F, 1990, AM J PHYSIOL, V259, pC697; SOGOS V, 1990, J NEUROSCI RES, V27, P706, DOI 10.1002/jnr.490270431; SPINNEWYN B, 1987, PROSTAGLANDINS, V34, P337, DOI 10.1016/0090-6980(87)90079-7; SQUINTO SP, 1990, J MOL NEUROSCI, V2, P79, DOI 10.1007/BF02876914; SQUINTO SP, 1989, J NEUROSCI RES, V24, P558, DOI 10.1002/jnr.490240414; STEWART AG, 1989, BRIT J PHARMACOL, V98, P141, DOI 10.1111/j.1476-5381.1989.tb16874.x; STEWART AG, 1989, BRIT J PHARMACOL, V96, P503, DOI 10.1111/j.1476-5381.1989.tb11845.x; STEWART AG, 1990, P NATL ACAD SCI USA, V87, P3215, DOI 10.1073/pnas.87.8.3215; STOLL LL, 1989, CELL REGUL, V1, P13; SUGA K, 1990, J BIOL CHEM, V265, P12363; SUKHATME VP, 1988, CELL, V53, P37, DOI 10.1016/0092-8674(88)90485-0; TESSNER TG, 1989, J BIOL CHEM, V264, P4794; TRIPATHI YB, 1991, LIFE SCI, V49, P1761, DOI 10.1016/0024-3205(91)90319-7; VALLARI DS, 1990, ARCH BIOCHEM BIOPHYS, V276, P538, DOI 10.1016/0003-9861(90)90756-O; WARDLOW ML, 1986, J IMMUNOL, V136, P3441; WEBER C, 1991, BIOCHIM BIOPHYS ACTA, V1133, P38, DOI 10.1016/0167-4889(91)90239-T; WILLIAMS JH, 1989, NEUROSCI LETT, V107, P301, DOI 10.1016/0304-3940(89)90835-5; WIRTHMUELLER U, 1990, BIOCHEM BIOPH RES CO, V170, P556, DOI 10.1016/0006-291X(90)92127-L; WOODARD DS, 1987, J BIOL CHEM, V262, P2520; YOREK MA, 1984, J NEUROCHEM, V42, P254, DOI 10.1111/j.1471-4159.1984.tb09726.x; YOSHIDA S, 1980, J NEUROSURG, V53, P323, DOI 10.3171/jns.1980.53.3.0323; YOUNG W, 1992, J NEUROTRAUM, V9, pS9; YUE TL, 1991, J PHARMACOL EXP THER, V257, P374; YUE TL, 1990, J NEUROCHEM, V54, P1809, DOI 10.1111/j.1471-4159.1990.tb01239.x; YUE TL, 1991, NEUROSCIENCE, V41, P177, DOI 10.1016/0306-4522(91)90208-6; ZLATANOVA J, 1990, TRENDS BIOCHEM SCI, V15, P273, DOI 10.1016/0968-0004(90)90053-E	148	23	23	0	0	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512	0893-7648			MOL NEUROBIOL	Mol. Neurobiol.	WIN	1992	6	4					407	424		10.1007/BF02757944			18	Neurosciences	Neurosciences & Neurology	KJ813	WOS:A1992KJ81300008	1337456				2021-06-18	
J	GRAHAM, CJ; KITTREDGE, D; STUEMKY, JH				GRAHAM, CJ; KITTREDGE, D; STUEMKY, JH			INJURIES ASSOCIATED WITH CHILD SAFETY SEAT MISUSE	PEDIATRIC EMERGENCY CARE			English	Article						CHILD SAFETY SEAT; TRAUMA; MOTOR VEHICLE ACCIDENTS		The charts of 370 children under the age of two years who presented to a pediatric emergency department between September 1988 and August 1989 were reviewed. Twenty-seven patients (7% of the total) had injuries associated with child safety seat (CSS) misuse. Thirteen were infants and toddlers injured as motor vehicle occupants when improperly restrained-CSS harness not properly connected (8), use of an improper device (3), and CSS not anchored to the car seat (2). Fourteen were infants under one year of age who were injured falling in their CSS. Injuries included minor head trauma (17), linear skull fracture (5), concussion (1), femoral fracture (1), depressed skull fracture with epidural hematoma (1), cervical vertebral fracture (1), and intraventricular hemorrhage (1). Nine patients were hospitalized. Injuries associated with CSS misuse may be more common than previously recognized and can result in significant injury. Educational efforts should focus on correct usage.		GRAHAM, CJ (corresponding author), ARKANSAS CHILDRENS HOSP,PEDIAT EMERGENCY MED SECT,800 MARSHALL ST,LITTLE ROCK,AR 72202, USA.							0	23	23	0	3	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	0749-5161			PEDIATR EMERG CARE	Pediatr. Emerg. Care	DEC	1992	8	6					351	353		10.1097/00006565-199212000-00012			3	Emergency Medicine; Pediatrics	Emergency Medicine; Pediatrics	KC060	WOS:A1992KC06000012	1454645				2021-06-18	
J	LEE, JP; LUI, TN; CHANG, CN				LEE, JP; LUI, TN; CHANG, CN			ACUTE POSTTRAUMATIC INTRAVENTRICULAR HEMORRHAGE ANALYSIS OF 25 PATIENTS WITH EMPHASIS ON FINAL OUTCOME	ACTA NEUROLOGICA SCANDINAVICA			English	Article						COMPUTED TOMOGRAPHY; HEAD INJURY; INTRAVENTRICULAR HEMORRHAGE; SHEARING INJURY		A series of 25 patients suffering acute post-traumatic intraventricular hemorrhage (IVH) after closed head injury is reviewed. Post-traumatic IVH was associated with other brain lesion in most cases; intracerebral lesions with contusion, subdural hematoma, and epidural hematoma coexisted with post-traumatic IVH in ten, three, and one instance, respectively. In six cases, no CT abnormality other than IVH was noted. The final outcome in this series is poor, only 10 (40%) patients made a functional survival. Four different groups of IVH were proposed according to the CT scan findings: deep nuclei hemorrhage, brain stem injury, white matter hemorrhage and isolated IVH. The group of isolated IVH usually got a good outcome. The abnormal motor response, abnormal pupil reaction and impaired oculocephalic response were reliable parameters for poor prognosis.	CHANG GUNG MED COLL, DIV NEUROSURG, TAIPEI, TAIWAN	LEE, JP (corresponding author), CHANG GUNG MEM HOSP, DEPT SURG, DIV NEUROSURG, 199 TUNG HWA N RD, TAIPEI 10591, TAIWAN.						ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; CARLSSON CA, 1968, J NEUROSURG, V29, P242, DOI 10.3171/jns.1968.29.3.0242; CORDOBES F, 1983, J NEUROSURG, V58, P217, DOI 10.3171/jns.1983.58.2.0217; DANZIGER A, 1979, J TRAUMA, V19, P1, DOI 10.1097/00005373-197901000-00001; DAVIS KR, 1977, SEMIN ROENTGENOL, V12, P53, DOI 10.1016/0037-198X(77)90056-6; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DOLINSKAS CA, 1977, AM J ROENTGENOL, V129, P681, DOI 10.2214/ajr.129.4.681; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; FRENCH BN, 1977, SURG NEUROL, V7, P171; FUJITSU K, 1988, NEUROSURGERY, V23, P423, DOI 10.1227/00006123-198810000-00003; Gennarelli T A, 1981, Acta Neuropathol Suppl, V7, P23; GRAEB DA, 1982, RADIOLOGY, V143, P91, DOI 10.1148/radiology.143.1.6977795; GUTTERMAN P, 1970, J NEUROSURG, V32, P330, DOI 10.3171/jns.1970.32.3.0330; JENNETT B, 1979, NEUROSURGERY, V4, P283, DOI 10.1227/00006123-197904000-00001; JENNETT B, 1975, LANCET, V1, P480; Kerr P, 1985, Clin Exp Neurol, V21, P123; KIM CH, 1981, SURG NEUROL, V16, P415, DOI 10.1016/0090-3019(81)90233-0; KOBAYASHI S, 1985, CHILD NERV SYST, V1, P18, DOI 10.1007/BF00706725; MERINODEVILLASANTE J, 1976, AM J ROENTGENOL, V126, P765, DOI 10.2214/ajr.126.4.765; OLIFF M, 1978, J COMPUT ASSIST TOMO, V2, P625, DOI 10.1097/00004728-197811000-00020; PAGNI CA, 1973, J NEUROSURG SCI, V17, P289; PIEK J, 1986, ACTA NEUROCHIR, V83, P105, DOI 10.1007/BF01402386; Stewart W A, 1973, Surg Neurol, V1, P303; TEASDALE G, 1974, LANCET, V2, P81; TSAI FY, 1978, J COMPUT ASSIST TOMO, V2, P323, DOI 10.1097/00004728-197807000-00018; VAPALAHTI M, 1971, BMJ-BRIT MED J, V3, P404, DOI 10.1136/bmj.3.5771.404; ZIMMERMAN RA, 1978, RADIOLOGY, V127, P393, DOI 10.1148/127.2.393; ZUCCARELLO M, 1981, ACTA NEUROCHIR, V55, P283, DOI 10.1007/BF01808444	29	23	24	0	0	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0001-6314	1600-0404		ACTA NEUROL SCAND	Acta Neurol. Scand.	AUG	1991	84	2					85	90		10.1111/j.1600-0404.1991.tb04913.x			6	Clinical Neurology	Neurosciences & Neurology	GE152	WOS:A1991GE15200002	1950456				2021-06-18	
J	HOEKSTRA, SM; BENDER, JS; LEVISON, MA				HOEKSTRA, SM; BENDER, JS; LEVISON, MA			THE MANAGEMENT OF LARGE SOFT-TISSUE DEFECTS FOLLOWING CLOSE-RANGE SHOTGUN INJURY	JOURNAL OF TRAUMA-INJURY INFECTION AND CRITICAL CARE			English	Article; Proceedings Paper	20TH ANNUAL MEETING OF THE WESTERN TRAUMA ASSOC	FEB 26-MAR 02, 1990	CRESTED BUTTE, CO	W TRAUMA ASSOC			WOUNDS; SCORE	Large soft-tissue defects following close-range shotgun blasts remain a major technical challenge to trauma surgeons. During the period 1980 through 1988, 43 patients who survived greater than 48 hours following this injury were managed in our center. The locations of their soft-tissue defects were: extremity, 22; abdomen/chest, 18; and head/neck, three. All patients underwent immediate surgical exploration and wide debridement of all devitalized tissue along with repair of associated injuries. Management included mandatory frequent dressing changes, debridement, irrigation in the operating room, and the perioperative administration of broad-spectrum antibiotics. Four patients whose abdominal wall defects could not be initially closed had temporary placement of rayon cloth to prevent evisceration. Overall, four patients underwent delayed primary closure, eight were covered with split-thickness skin grafts, nine had closure with myocutaneous flaps, and 19 closed by secondary intent. Two patients, who were transferred to us following initial management, developed wound sepsis due to inadequate debridement and both eventually required amputation as did one patient who developed early myonecrosis following lengthy arterial repair. Frequent operative dressing changes, adequate debridement, and irrigation minimize sepsis following close-range shotgun blasts and should be the treatment of choice for this devastating injury. Techniques of wound closure need to be individualized to the particular situation.	DETROIT RECEIVING HOSP & UNIV HLTH CTR,DEPT SURG,DETROIT,MI; WAYNE STATE UNIV,DETROIT,MI 48202							BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; Bell M J, 1971, J Trauma, V11, P522, DOI 10.1097/00005373-197106000-00010; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; DEMUTH WE, 1971, J TRAUM, V11, P219, DOI 10.1097/00005373-197103000-00003; LEDGERWOOD A, 1973, AM J SURG, V125, P690, DOI 10.1016/0002-9610(73)90166-9; LEDGERWOOD AM, 1977, SURG CLIN N AM, V57, P111; PARADIES LH, 1966, J BONE JOINT SURG AM, VA 48, P425, DOI 10.2106/00004623-196648030-00002; ROBERTS RM, 1984, SURGERY, V96, P902; RODGERS CM, 1988, SURG CLIN N AM, V68, P823; SCHMITT HJ, 1970, SURG GYNECOL OBSTETR, V130, P682; SHEPARD GH, 1980, J TRAUMA, V20, P1065, DOI 10.1097/00005373-198012000-00011; SHERMAN R T, 1963, J Trauma, V3, P76, DOI 10.1097/00005373-196301000-00007	12	23	24	0	0	WILLIAMS & WILKINS	BALTIMORE	351 WEST CAMDEN ST, BALTIMORE, MD 21201-2436	1079-6061			J TRAUMA	J. Trauma-Injury Infect. Crit. Care	DEC	1990	30	12					1489	1493		10.1097/00005373-199012000-00008			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	EP971	WOS:A1990EP97100008	2258959				2021-06-18	
J	GREEN, ED; SIMSON, LR; KELLERMAN, HH; HOROWITZ, RN; STURNER, WQ				GREEN, ED; SIMSON, LR; KELLERMAN, HH; HOROWITZ, RN; STURNER, WQ			CARDIAC CONCUSSION FOLLOWING SOFTBALL BLOW TO THE CHEST	ANNALS OF EMERGENCY MEDICINE			English	Article										GREEN, ED (corresponding author), EDWARD W SPARROW HOSP,DEPT EMERGENCY MED,LANSING,MI 48909, USA.							0	23	24	0	1	MOSBY-YEAR BOOK INC	ST LOUIS	11830 WESTLINE INDUSTRIAL DR, ST LOUIS, MO 63146-3318	0196-0644			ANN EMERG MED	Ann. Emerg. Med.		1980	9	3					155	157		10.1016/S0196-0644(80)80272-1			3	Emergency Medicine	Emergency Medicine	JG879	WOS:A1980JG87900009	7362107				2021-06-18	
J	STREIFLER, M; HOFMAN, S				STREIFLER, M; HOFMAN, S			SINISTRAD MIRROR WRITING AND READING AFTER BRAIN CONCUSSION IN A BI-SYSTEMIC (ORIENTO-OCCIDENTAL) POLYGLOT	CORTEX			English	Article									ICHILOV HOSP, MUNICIPAL GOVT MED CTR, DEPT NEUROL, TEL AVIV, ISRAEL; TEL AVIV UNIV, SCH MED, TEL AVIV, ISRAEL							BEELEY AL, 1918, EXPT STUDY LEFT HAND; BENTON AL, 1965, CAN PSYCHOLOGIST, V6, P332, DOI 10.1037/h0083084; Carmichael L, 1932, J GEN PSYCHOL, V6, P296, DOI 10.1080/00221309.1932.9711876; CRITCHLEY M, 1927, MIRROR WRITING; Critchley M., 1970, APHASIOLOGY OTHER AS; CRITCHLEY M, 1964, DEVELOPMENTAL DYSLEX; DENNYBROWN D, 1952, BRAIN, V75, P433; Faust C, 1947, NERVENARZT, V18, P103; Fildes LG, 1923, B J PSYCHOL-GEN SECT, V14, P57, DOI 10.1111/j.2044-8295.1923.tb00112.x; Fox JC, 1926, BRAIN, V49, P333, DOI 10.1093/brain/49.3.333; Fraenkel M, 1908, ARCH PSYCHIAT NERVEN, V43, P1275, DOI 10.1007/BF01812132; Gordon H, 1920, BRAIN, V43, P313; HALPERN L, 1944, HAREFUAH, V26, P105; Head H., 1926, APHASIA KINDRED DISO, V1; HERRMANN G, 1926, AGRPHIE IHRE LOKALDI; Kleist K., 1934, GEHIRNPATHOLOGIE; NEBLETT HC, 1941, SO MED SURG, P103; NEWNHAM R, 1971, ABOUT CHINESE; Oblu N, 1967, Stud Cercet Neurol, V12, P187; Orton S., 1937, READING WRITING SPEE; Orton ST, 1943, ARCH OPHTHALMOL-CHIC, V30, P707; Orton ST, 1928, J AMER MED ASSOC, V90, P1095, DOI 10.1001/jama.1928.02690410007003; PARK GE, 1953, J PEDIATR-US, V42, P120, DOI 10.1016/S0022-3476(53)80117-4; POETZL O, 1928, APHASIELEHRE STANDPU, V1; STRAUSS H, 1942, CITED INDIRECTLY; TOWE, 1967, CITED INDIRECTLY; TRUEMAN RH, 1965, POSTGRAD MED, V38, P469, DOI 10.1080/00325481.1965.11695681; WALSH FB, 1957, CLINICAL NEUROOPHTHA	28	23	23	0	2	ELSEVIER MASSON, CORPORATION OFFICE	PARIS	65 CAMILLE DESMOULINS CS50083 ISSY-LES-MOULINEAUX, 92442 PARIS, FRANCE	0010-9452	1973-8102		CORTEX	Cortex		1976	12	4					356	364		10.1016/S0010-9452(76)80039-1			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	CW512	WOS:A1976CW51200006	1009772				2021-06-18	
J	RINDER, L; OLSSON, Y				RINDER, L; OLSSON, Y			STUDIES ON VASULAR PERMEABILITY CHANGES IN EXPERIMENTAL BRAIN CONCUSSION .2. DURATION OF ALTERED PERMEABILITY	ACTA NEUROPATHOLOGICA			English	Article																AIRD RB, 1952, J NEUROSURG, V9, P331, DOI 10.3171/jns.1952.9.4.0331; ALLEN TH, 1948, AM J PHYSIOL, V154, P27; BAKAY L, 1964, J NEUROPATH EXP NEUR, V23, P393, DOI 10.1097/00005072-196407000-00001; Bakay L, 1965, CEREBRAL EDEMA; Broman T, 1955, ACTA PSYCH NEUROL, V30, P115, DOI 10.1111/j.1600-0447.1955.tb06051.x; Broman T., 1949, PERMEABILITY CEREBRO; BROMAN T, 1961, ACTA PSYCHIAT SCAND, V36, P69; BROWN GW, 1954, AMA ARCH NEUROL PSY, V71, P707, DOI 10.1001/archneurpsyc.1954.02320420035004; CASSEN B, 1960, AM J PHYSIOL, V198, P1296; CAVENESS WF, 1966, HEAD INJURY C P   ED, P203; CAVENESS WF, 1966, HEAD INJURY       ED, P260; CAVENESS WF, 1966, HEAD INJURY C P   ED, P383; CAVENESS WF, 1966, HEAD INJURY       ED, P172; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; CHASON JL, 1966, J TRAUM, V6, P767, DOI 10.1097/00005373-196611000-00008; COURVILLE CB, 1953, COMMOTIO CEREBRI; DAVID H, 1965, Dtsch Z Gesamte Gerichtl Med, V56, P177, DOI 10.1007/BF00577083; DAVID H, 1967, ACTA NEUROPATH BERL, V9, P212; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; DOBBING J, 1961, PHYSIOL REV, V41, P130; DURET H, THESIS PARIS; EICHELBERGER L, 1949, AM J PHYSIOL, V156, P129; FAAS FH, 1968, J NEUROSURG, V28, P137, DOI 10.3171/jns.1968.28.2.0137; FRIEDE RL, 1960, J NEUROPATH EXP NEUR, V19, P266, DOI 10.1097/00005072-196004000-00007; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; FUJITA I, 1966, WAKYAMA MED REP, V11, P75; GERLACH J, 1953, Z NATURFORSCH B, V8, P578, DOI 10.1515/znb-1953-1006; GROAT R, 1950, J NEUROPATH EXP NEUR, V9, P150, DOI 10.1097/00005072-195004000-00003; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; GROSS AG, 1958, J NEUROSURG, V15, P548, DOI 10.3171/jns.1958.15.5.0548; GURDJIAN ES, 1961, J NEUROSURG, V18, P58, DOI 10.3171/jns.1961.18.1.0058; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; GURDJIAN ES, 1965, 7 P STAPP CAR CRASH, P470; GUTTINGER W, 1950, Z NATURFORSCH A, V5, P622; HAMBERGER A, 1966, Z ZELLFORSCH MIK ANA, V70, P386, DOI 10.1007/BF00336504; HAMBERGER A, 1966, J NEUROPATH EXP NEUR, V25, P68, DOI 10.1097/00005072-196601000-00004; HOLLISTER NR, AD203385 ASTIA DOC; HOLLISTER NR, 1958, WADC58193 TECHN REP; ISHII S, 1959, J NEUROSURG, V16, P152, DOI 10.3171/jns.1959.16.2.0152; JAKOB A, 1913, HISTOLOGISCHE HISTOP, V5, P182; KLATZO I, 1967, J NEUROPATH EXP NEUR, V26, P1, DOI 10.1097/00005072-196701000-00001; KLATZO I, 1958, J NEUROPATH EXP NEUR, V17, P548, DOI 10.1097/00005072-195810000-00002; Klatzo I, 1965, Prog Brain Res, V15, P73; KLATZO I, 1964, J NEUROPATH EXP NEUR, V23, P18, DOI 10.1097/00005072-196401000-00002; KLATZO I, 1967, 1965 P S BRAIN ED ED, P554; KLATZO IGOR, 1962, ACTA NEUROPATHOLOGICA, V2, P144; KLATZO IGOR, 1965, ACTA NEUROPATHOL, V5, P161; KLUVER H, 1953, J NEUROPATH EXP NEUR, V12, P400; LANGFITT TW, 1966, HEAD INJURY, P172; Lee JC, 1960, NEUROLOGY, V10, P814, DOI 10.1212/WNL.10.9.814; LEE JC, 1966, ARCH NEUROL-CHICAGO, V14, P36, DOI 10.1001/archneur.1966.00470070040005; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; LINDGREN S, 1967, J TRAUM, V7, P493, DOI 10.1097/00005373-196707000-00001; LINDGREN SO, 1966, ACTA CHIR SCAND S360; LINDGREN STEN, 1965, BIOPHYSIK, V2, P320; LOEW F, 1958, Dtsch Z Nervenheilkd, V178, P358, DOI 10.1007/BF02388077; Meessen H, 1949, CYTOARCHITECTONIC AT; MEYER JS, 1955, ELECTROEN CLIN NEURO, V7, P529, DOI 10.1016/0013-4694(55)90078-X; Miller GG, 1927, ARCH SURG-CHICAGO, V14, P891, DOI 10.1001/archsurg.1927.01130160100005; Ommaya A K, 1966, Ann R Coll Surg Engl, V39, P317; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1966, HEAD INJURY, P260; PETERS G, 1943, ZBL NEUROCHIR, V8, P172; Pilcher C, 1937, ARCH SURG-CHICAGO, V35, P512, DOI 10.1001/archsurg.1937.01190150095009; PILCHER C, 1941, SURG GYNECOL OBSTET, V72, P755; QUADBECK G, 1955, Z NATURFORSCH PT B, V10, P168, DOI 10.1515/znb-1955-0310; RAIMONDI AJ, 1962, ACTA NEUROPATH BERL, V2, P177; Rawson RA, 1943, AM J PHYSIOL, V138, P0708; RENGACHERY SS, 1967, J NEUROSURG, V26, P614, DOI 10.3171/jns.1967.26.6.0614; RINDER L, IN PRESS; RINDER L, TO BE PUBLISHED; ROWBATHAM GF, 1964, ACUTE INJURIES HEAD; SCHEINKER IM, 1947, J NEUROSURG, V4, P255, DOI 10.3171/jns.1947.4.3.0255; SCHILLER AA, 1953, J GEN PHYSIOL, V36, P489, DOI 10.1085/jgp.36.4.489; SCHMIDT H., 1964, ACTA NEUROPATHOL, V4, P46; SCHRODER J. M., 1965, ACTA NEURO PATHOL, V5, P82; SELLIER K, 1963, HEFTE UNFALLHEILK; SEVERY DM, 1965, 7 P STAPP CAR CRA ED, P470; SJOVALL H, 1943, ACTA PATH MICROB S48; STEINWALL O, 1966, J NEUROPATH EXP NEUR, V25, P542, DOI 10.1097/00005072-196610000-00004; STEINWALL O, 1965, ACTA NEUROL SCAN S13, V41, P1; STREICHER E, 1964, ARCH NEUROL-CHICAGO, V11, P444, DOI 10.1001/archneur.1964.00460220106014; TANI EHCHI, 1965, ACTA NEUROPATHOL, V4, P507; THOMAS LM, 1967, J NEUROSURG, V26, P316, DOI 10.3171/jns.1967.26.3.0316; UNTERHARNSCHEIDT.F, 1963, MONOGRAPHIEN GESAMTG, P103; VONGIERKE HE, 1966, HEAD INJURY C P, P383; WARD AA, 1966, HEAD INJURY C P, P203; White JC, 1943, ANN SURG, V119, P619, DOI 10.1097/00000658-194310000-00010; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; WINDLE WF, 1946, J NEUROSURG, V3, P157, DOI 10.3171/jns.1946.3.2.0157	91	23	23	0	0	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0001-6322	1432-0533		ACTA NEUROPATHOL	Acta Neuropathol.		1968	11	3					201	+					1	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	B9000	WOS:A1968B900000002	5709760				2021-06-18	
J	CHASON, JL; FERNANDO, OU; HODGSON, VR; THOMAS, LM; GURDJIAN, ES				CHASON, JL; FERNANDO, OU; HODGSON, VR; THOMAS, LM; GURDJIAN, ES			EXPERIMENTAL BRAIN CONCUSSION - MORPHOLOGIC FINDINGS AND A NEW CYTOLOGIC HYPOTHESIS	JOURNAL OF TRAUMA			English	Article																Brunner H, 1925, MSCHR OHRENHEILK, V59, P697; BRUNNER H, 1925, MONATSCHR OHRENH, V59, P763; BRUNNER H, 1925, MONATSCHR OHRENH, V59, P922; CANNON WB, 1902, AM J PHYSIOL, V6, P91; CHASON JL, 1958, J NEUROSURG, V15, P135, DOI 10.3171/jns.1958.15.2.0135; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; COURVILLE CB, 1953, COMMOTIO CEREBRI, P67; DELISI L, 1915, RIV SPER FRENIATR, V41, P249; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; DENNYBROWN D, 1961, ARCH NEUROL-CHICAGO, V5, P1; DILUZENBERGER A, 1898, NEUROL ZBL, V17, P363; Dixon KC, 1940, LANCET, V2, P360; FRIEDE RL, 1961, ARCH NEUROL-CHICAGO, V4, P449, DOI 10.1001/archneur.1961.00450100097012; GREENFIELD JG, 1939, P ROY SOC MED, V32, P43; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; GURDJIAN ES, 1965, CLIN NEUROSURG, V12, P390; Handler P, 1942, J BIOL CHEM, V143, P49; JACOBSON KB, 1957, J BIOPHYS BIOCHEM CY, V3, P31, DOI 10.1083/jcb.3.1.31; Jakob A., 1912, HISTOL HISTOPATH ARB, V5, P182; KAUFMAN BT, 1960, BIOCHIM BIOPHYS ACTA, V39, P332, DOI 10.1016/0006-3002(60)90171-2; KORNBERG A, 1948, J BIOL CHEM, V176, P665; Mann PJG, 1941, NATURE, V147, P326, DOI 10.1038/147326a0; Mann PJG, 1941, BIOCHEM J, V35, P502, DOI 10.1042/bj0350502; MCILWAIN H, 1944, BIOCHEM J, V44, P470; MCILWAIN HN, 1962, PRACTICAL NEUROCHEMI, P214; MURTHY MRV, 1963, BIOCHIM BIOPHYS ACTA, V78, P71, DOI 10.1016/0006-3002(63)91610-X; QUASTEL JH, 1953, BIOCHIM BIOPHYS ACTA, V10, P256; ROCKOFF SD, 1964, AMER J ROENTGENOL RA, V91, P1026; ROWBOTHAM G F, 1964, Acta Neurochir (Wien), V12, P339, DOI 10.1007/BF01402102; Scagliosi G., 1898, VIRCHOWS ARCH, V152, P487; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; SUNG SC, 1952, J BIOL CHEM, V197, P175; Trotter W, 1924, LANCET, V1, P935; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	35	23	23	0	0							J TRAUM			1966	6	6					767	&		10.1097/00005373-196611000-00008			0	Emergency Medicine; Surgery	Emergency Medicine; Surgery	86024	WOS:A19668602400010	5925020				2021-06-18	
J	CHASON, JL; HARDY, WG; WEBSTER, JE; GURDJIAN, ES				CHASON, JL; HARDY, WG; WEBSTER, JE; GURDJIAN, ES			ALTERATIONS IN CELL STRUCTURE OF THE BRAIN ASSOCIATED WITH EXPERIMENTAL CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article																Brunner H, 1925, MSCHR OHRENHEILK, V59, P697; BRUNNER H, 1925, MONATSCHR OHRENH, V59, P763; BRUNNER H, 1925, MONATSCHR OHRENH, V59, P922; CHASON JL, 1957, J NEUROPATH EXP NEUR, V16, P102, DOI 10.1097/00005072-195701000-00012; CHASON JL, 1955, EXCERPTA MED, V8, P854; COURVILLE CB, 1953, COMMOTIO CEREBRI CER, V14, P47; DELISI L, 1915, RIV SPER FRENIATR, V41, P249; DELUZENBERGER A, 1898, NEUROL ZBL, V17, P363; Dunlap CB, 1924, AM J PSYCHIAT, V3, P403; GRINKER RR, 1934, NEUROLOGY, V9, P792; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Gurdjian ES, 1944, J NEUROSURG, V1, P393, DOI 10.3171/jns.1944.1.6.0393; GURDJIAN ES, 1953, NEUROLOGY, V3, P417, DOI 10.1212/WNL.3.6.417; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; Jakob A., 1912, HISTOL HISTOPATH ARB, V5, P182; KOENIG RS, 1952, J NEUROPATH EXP NEUR, V11, P69, DOI 10.1097/00005072-195201000-00008; LINDENBERG R, 1956, AM J PATHOL, V32, P1147; MINKOWSKI M, 1930, SCHWEIZER MED WCHNSC, V60, P701; NEUBURGER K, 1929, KRANKHEITSFORSCHUNG, V7, P219; OSNATO M, 1926, ARCH NEUROL PSYCHIAT, V16, P667; Rand CW, 1934, ARCH NEURO PSYCHIATR, V31, P527, DOI 10.1001/archneurpsyc.1934.02250030067004; RAND CW, 1947, J NEUROPATH EXP NEUR, V6, P1; Rand CW, 1931, ARCH SURG-CHICAGO, V23, P357, DOI 10.1001/archsurg.1931.01160090002001; RAND CW, 1946, ARCH NEURO PSYCHIATR, V55, P79, DOI 10.1001/archneurpsyc.1946.02300130003001; Scagliosi G., 1898, VIRCHOWS ARCH, V152, P487; SCHMAUS H, 1890, VIRCHOWS ARCH PATH A, V122, P470; Scott WW, 1940, ARCH NEURO PSYCHIATR, V43, P270, DOI 10.1001/archneurpsyc.1940.02280020078006; Walker AE, 1944, J NEUROSURG, V1, P103, DOI 10.3171/jns.1944.1.2.0103; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561	29	23	23	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1958	15	2					135	139		10.3171/jns.1958.15.2.0135			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WG961	WOS:A1958WG96100003	13514511				2021-06-18	
J	WARD, AA				WARD, AA			PHYSIOLOGICAL BASIS OF CONCUSSION	JOURNAL OF NEUROSURGERY			English	Article																BORNSTEIN MB, 1946, J NEUROPHYSIOL, V9, P349; Denny-Brown D, 1941, BRAIN, V64, P93, DOI 10.1093/brain/64.2-3.93; FOLTZ EL, 1953, J NEUROSURG, V10, P342, DOI 10.3171/jns.1953.10.4.0342; FOLTZ EL, 1956, J NEUROSURG, V13, P145, DOI 10.3171/jns.1956.13.2.0145; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P591, DOI 10.1001/archneurpsyc.1952.02320230017002; FRENCH JD, 1953, AMA ARCH NEUROL PSY, V69, P519, DOI 10.1001/archneurpsyc.1953.02320280107010; FRENCH JD, 1952, AMA ARCH NEUROL PSY, V68, P577, DOI 10.1001/archneurpsyc.1952.02320230003001; GURDJIAN ES, 1954, NEUROLOGY, V4, P674, DOI 10.1212/WNL.4.9.674; SACHS E, 1957, J NEUROSURG, V14, P22, DOI 10.3171/jns.1957.14.1.0022; WARD A, 1950, J NEUROSURG, V7, P398, DOI 10.3171/jns.1950.7.5.0398	10	23	23	0	1	AMER ASSOC NEUROLOGICAL SURGEONS	CHARLOTTESVILLE	UNIV VIRGINIA, 1224 WEST MAIN ST, STE 450, CHARLOTTESVILLE, VA 22903	0022-3085			J NEUROSURG	J. Neurosurg.		1958	15	2					129	134		10.3171/jns.1958.15.2.0129			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	WG961	WOS:A1958WG96100002	13514510				2021-06-18	
J	WINDLE, WF; GROAT, RA				WINDLE, WF; GROAT, RA			DISAPPEARANCE OF NERVE CELLS AFTER CONCUSSION	ANATOMICAL RECORD			English	Article																DENNYBROWN D, 1945, PHYSIOL REV, V25, P296; GROAT RA, 1945, SURG GYNECOL OBSTET, V81, P63; GROAT RA, 1945, J NEUROSURG, V2, P26, DOI 10.3171/jns.1945.2.1.0026; Groat RA, 1944, AM J PHYSIOL, V141, P0117; KOENIG H, 1945, STAIN TECHNOL, V20, P13, DOI 10.3109/10520294509107124; Windle W. F., 1944, SURG GYNECOL AND OBSTET, V79, P561; Windle WF, 1943, STAIN TECHNOL, V18, P77, DOI 10.3109/10520294309105794; WINDLE WF, 1944, 70TH T AM NEUR ASS A, P117	8	23	23	0	2	WILEY-LISS	NEW YORK	DIV JOHN WILEY & SONS INC, 605 THIRD AVE, NEW YORK, NY 10158-0012	0003-276X			ANAT REC	Anat. Rec.		1945	93	2					201	209		10.1002/ar.1090930210			9	Anatomy & Morphology	Anatomy & Morphology	YA563	WOS:A1945YA56300009	21003323				2021-06-18	
J	Zwirner, J; Scholze, M; Waddell, JN; Ondruschka, B; Hammer, N				Zwirner, Johann; Scholze, Mario; Waddell, John Neil; Ondruschka, Benjamin; Hammer, Niels			Mechanical Properties of Human Dura Mater in Tension - An Analysis at an Age Range of 2 to 94 Years	SCIENTIFIC REPORTS			English	Article							SKULL-BRAIN MODEL; HUMAN HEAD; IMPACT; BLAST; INJURIES; FRACTURE; GUNSHOT; EPIDEMIOLOGY; POSTMORTEM; THICKNESS	Realistic human head models are of great interest in traumatic brain injury research and in the forensic pathology courtroom and teaching. Due to a lack of biomechanical data, the human dura mater is underrepresented in head models. This study provides tensile data of 73 fresh human cranial dura mater samples retrieved from an area between the anterior middle and the posterior middle meningeal artery. Tissues were adapted to their native water content using the osmotic stress technique. Tensile tests were conducted under quasi-static uniaxial testing conditions with simultaneous digital image correlation. Human temporal dura mater is mechanically highly variable with regards to its elastic modulus of 70 +/- 44 MPa, tensile strength of 7 +/- 4 MPa, and maximum strain of 11 +/- 3 percent. Mechanical properties of the dura mater did not vary significantly between side nor sex and decreased with the age of the cadaver. Both elastic modulus and tensile strength appear to have constant mechanical parameters within the first 139 hours post mortem. The mechanical properties provided by this study can help to improve computational and physical human head models. These properties under quasi-static conditions do not require adjustments for side nor sex, whereas adjustments of tensile properties accompanied with normal aging may be of interest.	[Zwirner, Johann; Hammer, Niels] Univ Otago, Dept Anat, Dunedin, New Zealand; [Scholze, Mario] Tech Univ Chemnitz, Inst Mat Sci & Engn, Chemnitz, Germany; [Waddell, John Neil] Univ Otago, Sir John Walsh Res Inst, Fac Dent, Dunedin, New Zealand; [Ondruschka, Benjamin] Univ Leipzig, Inst Legal Med, Leipzig, Germany; [Hammer, Niels] Univ Leipzig, Dept Orthoped & Trauma Surg, Leipzig, Germany; [Hammer, Niels] Fraunhofer IWU, Dresden, Germany; [Hammer, Niels] Med Univ Graz, Dept Anat, Graz, Austria	Zwirner, J; Hammer, N (corresponding author), Univ Otago, Dept Anat, Dunedin, New Zealand.; Hammer, N (corresponding author), Univ Leipzig, Dept Orthoped & Trauma Surg, Leipzig, Germany.; Hammer, N (corresponding author), Fraunhofer IWU, Dresden, Germany.; Hammer, N (corresponding author), Med Univ Graz, Dept Anat, Graz, Austria.	medijo@gmx.de; niels.hammer@medunigraz.at		Scholze, Mario/0000-0002-0120-2478	German Research Foundation (DFG)German Research Foundation (DFG); University of Leipzig	The authors would like to thank Marlene Black for her help with plastination for "Figure 1" and Miss Joanna Tomlinson for proofreading the paper as a native speaker. We acknowledge support from the German Research Foundation (DFG) and the University of Leipzig within the program of Open Access Publishing.	Asgharpour Z, 2014, J MECH BEHAV BIOMED, V33, P16, DOI 10.1016/j.jmbbm.2013.02.010; BANDAK FA, 1995, J NEUROTRAUM, V12, P679, DOI 10.1089/neu.1995.12.679; Carr D, 2015, INT J LEGAL MED, V129, P505, DOI 10.1007/s00414-014-1073-2; Chafi MS, 2009, P I MECH ENG H, V223, P1003, DOI 10.1243/09544119JEIM631; Chauvet D, 2010, NEUROSURG REV, V33, P287, DOI 10.1007/s10143-010-0261-x; De Kegel D, 2018, J MECH BEHAV BIOMED, V79, P122, DOI 10.1016/j.jmbbm.2017.12.023; Fam MD, 2018, J NEUROL SURG PART B, V79, P614, DOI 10.1055/s-0038-1651501; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gu LX, 2012, COMPOS PART B-ENG, V43, P3160, DOI 10.1016/j.compositesb.2012.04.014; Haimann MCJ, 1998, J ANAT, V192, P99; Hammer N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0105037; Hong JY, 2011, SPINE J, V11, P1121, DOI 10.1016/j.spinee.2011.11.001; Horgan TJ, 2003, INT J CRASHWORTHINES, V8, P353, DOI 10.1533/cras.8.4.353.19278; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Keene DD, 2016, J ROY ARMY MED CORPS, V162, P355, DOI 10.1136/jramc-2015-000490; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Kozerska Magdalena, 2015, Folia Med Cracov, V55, P33; Li ZG, 2011, ANN BIOMED ENG, V39, P2984, DOI 10.1007/s10439-011-0409-z; Liang ZY, 2015, APPL BIONICS BIOMECH, V2015, P1, DOI 10.1155/2015/837585; MacManus DB, 2017, ACTA BIOMATER, V57, P384, DOI 10.1016/j.actbio.2017.05.022; Mahoney PF, 2017, INT J LEGAL MED, V131, P1043, DOI 10.1007/s00414-017-1557-y; Maikos JT, 2008, J NEUROTRAUM, V25, P38, DOI 10.1089/neu.2007.0348; Majdan M, 2016, LANCET PUBLIC HEALTH, V1, pE76, DOI 10.1016/S2468-2667(16)30017-2; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; Maxeiner H, 2009, RECHTSMEDIZIN, V19, P111, DOI 10.1007/s00194-008-0585-9; MCGARVEY KA, 1984, BIOMATERIALS, V5, P109, DOI 10.1016/0142-9612(84)90011-5; Moore DF, 2009, NEUROIMAGE, V47, pT10, DOI 10.1016/j.neuroimage.2009.02.019; Ondruschka B, 2018, J NEUROTRAUM, V35, P2044, DOI 10.1089/neu.2017.5441; PATIN DJ, 1993, ANESTH ANALG, V76, P535; Protasoni M, 2011, J NEUROSURG, V114, P1723, DOI 10.3171/2010.12.JNS101732; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Scholze M, 2018, SCI REP-UK, V8, DOI 10.1038/s41598-018-29583-4; Schyma C, 2012, INT J LEGAL MED, V126, P607, DOI 10.1007/s00414-012-0704-8; Shetye SS, 2014, J MECH BEHAV BIOMED, V34, P146, DOI 10.1016/j.jmbbm.2014.02.014; Tan LB, 2014, INT J NUMER METH BIO, V30, P1476, DOI 10.1002/cnm.2668; Taylor CA, 2017, MMWR SURVEILL SUMM, V66, P1, DOI 10.15585/mmwr.ss6609a1; Thali MJ, 2002, AM J FOREN MED PATH, V23, P223, DOI 10.1097/00000433-200209000-00003; Thali MJ, 2002, FORENSIC SCI INT, V125, P195, DOI 10.1016/S0379-0738(01)00639-9; Thali MJ, 2002, FORENSIC SCI INT, V125, P178, DOI 10.1016/S0379-0738(01)00637-5; Thali MJ, 2002, FORENSIC SCI INT, V127, P168, DOI 10.1016/S0379-0738(02)00117-2; van Noort R, 1981, Clin Phys Physiol Meas, V2, P197, DOI 10.1088/0143-0815/2/3/003; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; Viano DC, 2005, NEUROSURGERY, V57, P891, DOI 10.1227/01.NEU.0000186950.54075.3B; Wolpers C., 1944, KLIN WOCHENSCHR, V23, P169, DOI 10.1007/BF01773402; Yue X., 2010, FINITE ELEMENT ANAL; Zhang L, 2001, Stapp Car Crash J, V45, P369; Zwirner J, 2017, INT J LEGAL MED, V131, P1581, DOI 10.1007/s00414-017-1580-z	47	22	23	3	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	NOV 13	2019	9								16655	10.1038/s41598-019-52836-9			11	Multidisciplinary Sciences	Science & Technology - Other Topics	JM3PD	WOS:000496129600004	31723169	DOAJ Gold, Green Published			2021-06-18	
J	Stemper, BD; Shah, AS; Harezlak, J; Rowson, S; Mihalik, JP; Duma, SM; Riggen, LD; Brooks, A; Cameron, KL; Campbell, D; DiFiori, JP; Giza, CC; Guskiewicz, KM; Jackson, J; McGinty, GT; Svoboda, SJ; McAllister, TW; Broglio, SP; McCrea, M; Hoy, AM; Hazzard, JB; Kelly, LA; Ortega, JD; Port, N; Putukian, M; Langford, TD; Tierney, R; Goldman, JT; Benjamin, HJ; Buckley, T; Kaminski, TW; Clugston, JR; Schmidt, JD; Feigenbaum, LA; Eckner, JT; Guskiewicz, K; Miles, JD; Anderson, S; Master, CL; Collins, M; Kontos, AP; Bazarian, JJ; Chrisman, SPO; McGinty, G; O'Donnell, P; Cameron, K; Susmarski, A; Duma, S; Rowson, S; Bullers, CT; Miles, CM; Dykhuizen, BH; Lintner, L				Stemper, Brian D.; Shah, Alok S.; Harezlak, Jaroslaw; Rowson, Steven; Mihalik, Jason P.; Duma, Stefan M.; Riggen, Larry D.; Brooks, Alison; Cameron, Kenneth L.; Campbell, Darren; DiFiori, John P.; Giza, Christopher C.; Guskiewicz, Kevin M.; Jackson, Jonathan; McGinty, Gerald T.; Svoboda, Steven J.; McAllister, Thomas W.; Broglio, Steven P.; McCrea, Michael; Hoy, April Marie (Reed); Hazzard, Joseph B., Jr.; Kelly, Louise A.; Ortega, Justus D.; Port, Nicholas; Putukian, Margot; Langford, T. Dianne; Tierney, Ryan; Goldman, Joshua T.; Benjamin, Holly J.; Buckley, Thomas; Kaminski, Thomas W.; Clugston, James R.; Schmidt, Julianne D.; Feigenbaum, Luis A.; Eckner, James T.; Guskiewicz, Kevin; Miles, Jessica Dysart; Anderson, Scott; Master, Christina L.; Collins, Micky; Kontos, Anthony P.; Bazarian, Jeffrey J.; Chrisman, Sara P. O.; McGinty, Gerald; O'Donnell, Patrick; Cameron, Kenneth; Susmarski, Adam; Duma, Stefan; Rowson, Steve; Bullers, Christopher Todd; Miles, Christopher M.; Dykhuizen, Brian H.; Lintner, Laura		CARE Consortium Investigators	Comparison of Head Impact Exposure Between Concussed Football Athletes and Matched Controls: Evidence for a Possible Second Mechanism of Sport-Related Concussion	ANNALS OF BIOMEDICAL ENGINEERING			English	Article						Repetitive head impact exposure; Subconcussive; Traumatic brain injury; Sport-related concussion	WHITE-MATTER INTEGRITY; PROFESSIONAL FOOTBALL; RECURRENT CONCUSSION; CEREBRAL CONCUSSION; INJURY; PLAYERS; BIOMECHANICS; IMPAIRMENT; VALIDATION; KINEMATICS	Studies of football athletes have implicated repetitive head impact exposure in the onset of cognitive and brain structural changes, even in the absence of diagnosed concussion. Those studies imply accumulating damage from successive head impacts reduces tolerance and increases risk for concussion. Support for this premise is that biomechanics of head impacts resulting in concussion are often not remarkable when compared to impacts sustained by athletes without diagnosed concussion. Accordingly, this analysis quantified repetitive head impact exposure in a cohort of 50 concussed NCAA Division I FBS college football athletes compared to controls that were matched for team and position group. The analysis quantified the number of head impacts and risk weighted exposure both on the day of injury and for the season to the date of injury. 43% of concussed athletes had the most severe head impact exposure on the day of injury compared to their matched control group and 46% of concussed athletes had the most severe head impact exposure for the season to the date of injury compared to their matched control group. When accounting for date of injury or season to date of injury, 72% of all concussed athletes had the most or second most severe head impact exposure compared to their matched control group. These trends associating cumulative head impact exposure with concussion onset were stronger for athletes that participated in a greater number of contact activities. For example, 77% of athletes that participated in ten or more days of contact activities had greater head impact exposure than their matched control group. This unique analysis provided further evidence for the role of repetitive head impact exposure as a predisposing factor for the onset of concussion. The clinical implication of these findings supports contemporary trends of limiting head impact exposure for college football athletes during practice activities in an effort to also reduce risk of concussive injury.	[Stemper, Brian D.] Marquette Univ, Joint Dept Biomed Engn, Milwaukee, WI 53233 USA; [Stemper, Brian D.] Med Coll Wisconsin, Milwaukee, WI 53226 USA; [Stemper, Brian D.; Shah, Alok S.; McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA; [Stemper, Brian D.; Shah, Alok S.; McCrea, Michael] Zablocki Vet Affairs Med Ctr, Milwaukee, WI USA; [Harezlak, Jaroslaw; Riggen, Larry D.] Indiana Univ, Dept Epidemiol & Biostat, Sch Publ Hlth, Bloomington, IN USA; [Rowson, Steven; Duma, Stefan M.] Virginia Tech, Dept Biomed Engn & Mech, Blacksburg, VA USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Steve Tisch BrainSPORT Program, Dept Neurosurg, Los Angeles, CA 90095 USA; [Giza, Christopher C.] Univ Calif Los Angeles, David Geffen Sch Med, Steve Tisch BrainSPORT Program, Dept Pediat, Los Angeles, CA 90095 USA; [DiFiori, John P.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Family Med & Orthopaed, Div Sports Med & Nonoperat Orthopaed, Los Angeles, CA 90095 USA; [Brooks, Alison] Univ Wisconsin, Sch Med & Publ Hlth, Dept Orthoped, Madison, WI USA; [Mihalik, Jason P.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27515 USA; [Cameron, Kenneth L.; Svoboda, Steven J.] US Mil Acad, John A Feagin Jr Sports Med Fellowship, Keller Army Hosp, West Point, NY 10996 USA; [Campbell, Darren; Jackson, Jonathan; McGinty, Gerald T.] US Air Force Acad, Dept Sports Med, Colorado Springs, CO 80840 USA; [McAllister, Thomas W.] Indiana Sch Med, Dept Psychiat, Indianapolis, IN USA; [Broglio, Steven P.] Univ Michigan, Sch Kinesiol, Ann Arbor, MI 48109 USA; [Hoy, April Marie (Reed)] Azusa Pacific Univ, Azusa, CA 91702 USA; [Hazzard, Joseph B., Jr.] Bloomsburg Univ, Bloomsburg, PA USA; [Kelly, Louise A.] Calif Lutheran Univ, Thousand Oaks, CA USA; [Ortega, Justus D.] Humboldt State Univ, Arcata, CA USA; [Port, Nicholas] Indiana Univ, Bloomington, IN 47405 USA; [Putukian, Margot] Princeton Univ, Princeton, NJ 08544 USA; [Langford, T. Dianne; Tierney, Ryan] Temple Univ, Philadelphia, PA 19122 USA; [Giza, Christopher C.; Goldman, Joshua T.] Univ Calif Los Angeles, Los Angeles, CA USA; [Benjamin, Holly J.] Univ Chicago, Chicago, IL 60637 USA; [Buckley, Thomas; Kaminski, Thomas W.] Univ Delaware, Newark, DE 19716 USA; [Clugston, James R.] Univ Florida, Gainesville, FL 32611 USA; [Schmidt, Julianne D.] Univ Georgia, Athens, GA 30602 USA; [Feigenbaum, Luis A.] Univ Miami, Coral Gables, FL 33124 USA; [Eckner, James T.] Univ Michigan, Ann Arbor, MI 48109 USA; [Mihalik, Jason P.; Guskiewicz, Kevin] Univ North Carolina Chapel Hill, Chapel Hill, NC USA; [Miles, Jessica Dysart] Univ North Georgia, Dahlonega, GA USA; [Anderson, Scott] Univ Oklahoma, Norman, OK 73019 USA; [Master, Christina L.] Univ Penn, Philadelphia, PA 19104 USA; [Collins, Micky; Kontos, Anthony P.] Univ Pittsburgh, Med Ctr, Pittsburgh, PA 15260 USA; [Bazarian, Jeffrey J.] Univ Rochester, Rochester, NY 14627 USA; [Chrisman, Sara P. O.] Univ Washington, Seattle, WA 98195 USA; [Brooks, Alison] Univ Wisconsin Madison, Madison, WI USA; [McGinty, Gerald] US Air Force Acad, Colorado Springs, CO 80840 USA; [O'Donnell, Patrick] US Coast Guard Acad, New London, CT USA; [Cameron, Kenneth] US Mil Acad, West Point, NY USA; [Susmarski, Adam] US Naval Acad, Annapolis, MD 21402 USA; [Duma, Stefan; Rowson, Steve] Virginia Tech, Blacksburg, VA USA; [Bullers, Christopher Todd; Miles, Christopher M.] Wake Forest Univ, Winston Salem, NC 27101 USA; [Dykhuizen, Brian H.] Wilmington Coll, Southwest, OH USA; [Lintner, Laura] Winston Salem Univ, Winston Salem, NC USA	Stemper, BD (corresponding author), Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA.	bstemper@mcw.edu	Buckley, Thomas A/B-7525-2016; Stemper, Brian/AAX-7611-2020; Rowson, Steven/B-1270-2012; Harezlak, Jaroslaw/P-8557-2014	Buckley, Thomas A/0000-0002-0515-0150; Rowson, Steven/0000-0002-3227-0596; Harezlak, Jaroslaw/0000-0002-3070-7686; Cameron, Kenneth/0000-0002-6276-4482	Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - National Collegiate Athletic Association (NCAA); Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium - Department of Defense (DoD); U.S. Army Medical Research Acquisition Activity, Chandler Street, Ford Detrick MD; Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program [W81XWH-14-2-0151]; UCLA	This investigation was made possible, in part, with support from the Grand Alliance Concussion Assessment, Research, and Education (CARE) Consortium, funded, by the National Collegiate Athletic Association (NCAA) and the Department of Defense (DoD). The U.S. Army Medical Research Acquisition Activity, 820 Chandler Street, Ford Detrick MD 21702-5014 is the awarding and administering acquisition office. This work was supported by the Office of the Assistant Secretary of Defense for Health Affairs through the Psychological Health and Traumatic Brain Injury Program under Award NO W81XWH-14-2-0151. Opinions, interpretations, conclusions and recommendations are those of the authors and are not necessarily endorsed by the Department of Defense (DHP funds). The authors have no other financial conflicts of interest to disclose. UCLA would like to acknowledge the Tisch BrainSPORT program which provided funds to purchase the HIT System for their team. The team would also like to acknowledge the HIT System operators that participated in this study: Julia Ford (UNC), Gus Hendricks (UCLA), Quinn Lukens (UW), Brett Griesemer (VT), Alex Black (VT), Lewis Young (VT), Dom Calhoun (USAFA), and Sean Roach (USMA). Results of this study are presented clearly, honestly, and without fabrication, falsification, or inappropriate data manipulation. Results of the present study do not constitute endorsement by ACSM. The conclusions herein are those of the authors. They do not represent official policy of the Department of the Air Force or the Department of Defense. CARE Consortium Investigators are listed alphabetically by institution: April Marie (Reed) Hoy, MS, ATC (Azusa Pacific University); Joseph B. Hazzard Jr, EdD, ATC (Bloomsburg University); Louise A. Kelly, PhD (California Lutheran University); Justus D. Ortega, PhD (Humboldt State University); Nicholas Port, PhD (Indiana University); Margot Putukian MD (Princeton University); T. Dianne Langford, PhD, and Ryan Tierney, PhD, ATC (Temple University); Christopher C. Giza, MD and Joshua T. Goldman, MD, MBA (University of California, Los Angeles); Holly J. Benjamin MD (University of Chicago); Thomas Buckley, EdD, ATC, and Thomas W. Kaminski, PhD, ATC (University of Delaware); James R. Clugston, MD, MS (University of Florida); Julianne D. Schmidt, PhD, ATC (University of Georgia); Luis A. Feigenbaum, DPT, ATC (University of Miami); James T. Eckner, MD, MS (University of Michigan); Kevin Guskiewicz, PhD, ATC, and Jason P. Mihalik, PhD, CAT(C), ATC (University of North Carolina at Chapel Hill); Jessica Dysart Miles, PhD, ATC (University of North Georgia); Scott Anderson, ATC (University of Oklahoma); Christina L. Master, MD (University of Pennsylvania); Micky Collins, PhD, and Anthony P. Kontos, PhD (University of Pittsburgh Medical Center); Jeffrey J. Bazarian, MD, MPH (University of Rochester); Sara P.O. Chrisman, MD, MPH (University of Washington); Alison Brooks, MD, MPH (University of Wisconsin-Madison); Jonathan Jackson, MD, and Gerald McGinty, DPT (United States Air Force Academy); Patrick O'Donnell, MHA (United States Coast Guard Academy); Kenneth Cameron, PhD, MPH, ATC (United States Military Academy); Adam Susmarski, MD (United States Naval Academy); Stefan Duma, PhD and Steve Rowson, PhD (Virginia Tech); Christopher Todd Bullers, MD, and Christopher M. Miles, MD (Wake Forest University); Brian H. Dykhuizen, MS, ATC (Wilmington College); Laura Lintner DO (Winston-Salem University).	Baugh CM, 2015, J NEUROTRAUM, V32, P314, DOI 10.1089/neu.2014.3582; Bazarian JJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094734; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P747, DOI 10.1249/MSS.0b013e3182793067; Beckwith JG, 2012, ANN BIOMED ENG, V40, P237, DOI 10.1007/s10439-011-0422-2; Belson K, NY TIMES; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Breedlove KM., 2014, ATHLETIC TRAIN SPORT, V6, P119, DOI [10.3928/19425864-20140507-02, DOI 10.3928/19425864-20140507-02]; Broglio SP, 2017, J NEUROTRAUM, V34, P2675, DOI 10.1089/neu.2016.4767; Broglio SP, 2017, SPORTS MED, V47, P1437, DOI 10.1007/s40279-017-0707-1; Broglio SP, 2013, AM J SPORT MED, V41, P2877, DOI 10.1177/0363546513502458; Broglio SP, 2011, J NEUROTRAUM, V28, P2069, DOI 10.1089/neu.2011.1825; Broglio SP, 2010, MED SCI SPORT EXER, V42, P2064, DOI 10.1249/MSS.0b013e3181dd9156; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Crisco JJ, 2010, J ATHL TRAINING, V45, P549, DOI 10.4085/1062-6050-45.6.549; Davenport EM, 2014, J NEUROTRAUM, V31, P1617, DOI 10.1089/neu.2013.3233; Duhaime AC, 2012, J NEUROSURG, V117, P1092, DOI 10.3171/2012.8.JNS112298; Duma SM, 2005, CLIN J SPORT MED, V15, P3, DOI 10.1097/00042752-200501000-00002; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Giza Christopher C, 2014, Neurosurgery, V75 Suppl 4, pS24, DOI 10.1227/NEU.0000000000000505; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2007, NEUROSURGERY, V61, P1244, DOI 10.1227/01.neu.0000306103.68635.1a; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Gysland SM, 2012, ANN BIOMED ENG, V40, P14, DOI 10.1007/s10439-011-0421-3; Holbourn AHS, 1943, LANCET, V2, P438; Jadischke R, 2013, J BIOMECH, V46, P2310, DOI 10.1016/j.jbiomech.2013.05.030; Kleiven S, 2003, J NEUROTRAUM, V20, P365, DOI 10.1089/089771503765172327; Koerte IK, 2012, JAMA-J AM MED ASSOC, V308, P1859, DOI 10.1001/jama.2012.13735; Laurer HL, 2001, J NEUROSURG, V95, P859, DOI 10.3171/jns.2001.95.5.0859; MARGULIES SS, 1992, J BIOMECH, V25, P917, DOI 10.1016/0021-9290(92)90231-O; Martini D, 2013, MED SCI SPORT EXER, V45, P755, DOI 10.1249/MSS.0b013e3182798758; McAllister TW, 2012, NEUROLOGY, V78, P1777, DOI 10.1212/WNL.0b013e3182582fe7; McAllister TW, 2014, NEUROLOGY, V82, P63, DOI 10.1212/01.wnl.0000438220.16190.42; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Miller JR, 2007, AM J SPORT MED, V35, P1284, DOI 10.1177/0363546507300261; OMMAYA AK, 1964, J NEUROSURG, V21, P249, DOI 10.3171/jns.1964.21.4.0249; OMMAYA AK, 1971, J BIOMECH, V4, P13, DOI 10.1016/0021-9290(71)90011-X; OMMAYA AK, 1973, J NEUROSURG, V39, P152, DOI 10.3171/jns.1973.39.2.0152; OMMAYA AK, 1974, BRAIN, V97, P633, DOI 10.1093/brain/97.1.633; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P40; Rowson S, 2018, J NEUROTRAUM, V35, P681, DOI 10.1089/neu.2017.5169; Rowson S, 2013, ANN BIOMED ENG, V41, P873, DOI 10.1007/s10439-012-0731-0; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Rowson S, 2011, J APPL BIOMECH, V27, P8, DOI 10.1123/jab.27.1.8; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Stemper BD, 2014, PROG NEUROL SURG, V28, P14, DOI 10.1159/000358748; Swartz EE, 2015, J ATHL TRAINING, V50, P1219, DOI 10.4085/1062-6050-51.1.06; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Urban JE, 2013, ANN BIOMED ENG, V41, P2474, DOI 10.1007/s10439-013-0861-z; Waljas M, 2015, J NEUROTRAUM, V32, P534, DOI 10.1089/neu.2014.3339; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	55	22	22	1	2	SPRINGER	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0090-6964	1573-9686		ANN BIOMED ENG	Ann. Biomed. Eng.	OCT	2019	47	10			SI		2057	2072		10.1007/s10439-018-02136-6			16	Engineering, Biomedical	Engineering	JQ0HT	WOS:000498636800003	30362082	Green Published, Other Gold			2021-06-18	
J	Callcut, RA; Kornblith, LZ; Conroy, AS; Robles, AJ; Meizoso, JP; Namias, N; Meyer, DE; Haymaker, A; Truitt, MS; Agrawal, V; Haan, JM; Lightwine, KL; Porter, JM; San Roman, JL; Biffl, WL; Hayashi, MS; Sise, MJ; Badiee, J; Recinos, G; Inaba, K; Schroeppel, TJ; Callaghan, E; Dunn, JA; Godin, S; McIntyre, RC; Peltz, ED; O'Neill, PJ; Diven, CF; Scifres, AM; Switzer, EE; West, MA; Storrs, S; Cullinane, DC; Cordova, JF; Moore, EE; Moore, HB; Privette, AR; Eriksson, EA; Cohen, MJ; Manning, RJ; Gutierrez, T; Deramo, P; Dunne, CE; Wong, MD; Krell, RV; Cross, AM; Butler, C; Moore, C; Rumford, R				Callcut, Rachael A.; Kornblith, Lucy Z.; Conroy, Amanda S.; Robles, Anamaria J.; Meizoso, Jonathan P.; Namias, Nicholas; Meyer, David E.; Haymaker, Amanda; Truitt, Michael S.; Agrawal, Vaidehi; Haan, James M.; Lightwine, Kelly L.; Porter, John M.; San Roman, Janika L.; Biffl, Walter L.; Hayashi, Michael S.; Sise, Michael J.; Badiee, Jayraan; Recinos, Gustavo; Inaba, Kenji; Schroeppel, Thomas J.; Callaghan, Emma; Dunn, Julie A.; Godin, Samuel; McIntyre, Robert C.; Peltz, Erik D.; O'Neill, Patrick J.; Diven, Conrad F.; Scifres, Aaron M.; Switzer, Emily E.; West, Michaela A.; Storrs, Sarah; Cullinane, Daniel C.; Cordova, John F.; Moore, Ernest E.; Moore, Hunter B.; Privette, Alicia R.; Eriksson, Evert A.; Cohen, Mitchell Jay; Manning, Ronald J.; Gutierrez, Tim; Deramo, Paul; Dunne, Casey E.; Wong, Monica D.; Krell, Regina V.; Cross, Alisa M.; Butler, Cressilee; Moore, Cindy; Rumford, Richelle		Western Trauma Assoc Multictr	The why and how our trauma patients die: A prospective Multicenter Western Trauma Association study	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article; Proceedings Paper	48th Annual Meeting of the Western-Trauma-Association (WTA)	FEB 15-MAR 03, 2018	Whistler, CANADA	Western Trauma Assoc		Hemorrhage; cause of death; exsanguination	BLOOD-CELL TRANSFUSION; PREHOSPITAL DEATHS; MORTALITY; IMPACT	BACKGROUND: Historically, hemorrhage has been attributed as the leading cause (40%) of early death. However, a rigorous, real-time classification of the cause of death (COD) has not been performed. This study sought to prospectively adjudicate and classify COD to determine the epidemiology of trauma mortality. METHODS: Eighteen trauma centers prospectively enrolled all adult trauma patients at the time of death during December 2015 to August 2017. Immediately following death, attending providers adjudicated the primary and contributing secondary COD using standardized definitions. Data were confirmed by autopsies, if performed. RESULTS: One thousand five hundred thirty-six patients were enrolled with a median age of 55 years (interquartile range, 32-75 years), 74.5% were male. Penetrating mechanism (n = 412) patients were younger (32 vs. 64, p < 0.0001) and more likely to be male (86.7% vs. 69.9%, p < 0.0001). Falls were the most common mechanism of injury (26.6%), with gunshot wounds second (24.3%). The most common overall primary COD was traumatic brain injury (TBI) (45%), followed by exsanguination (23%). Traumatic brain injury was nonsurvivable in 82.2% of cases. Blunt patients were more likely to have TBI (47.8% vs. 37.4%, p < 0.0001) and penetrating patients exsanguination (51.7% vs. 12.5%, p < 0.0001) as the primary COD. Exsanguination was the predominant prehospital (44.7%) and early COD (39.1%) with TBI as the most common later. Penetrating mechanism patients died earlier with 80.1% on day 0 (vs. 38.5%, p < 0.0001). Most deaths were deemed disease-related (69.3%), rather than by limitation of further aggressive care (30.7%). Hemorrhage was a contributing cause to 38.8% of deaths that occurred due to withdrawal of care. CONCLUSION: Exsanguination remains the predominant early primary COD with TBI accounting for most deaths at later time points. Timing and primary COD vary significantly by mechanism. Contemporaneous adjudication of COD is essential to elucidate the true understanding of patient outcome, center performance, and future research. Copyright (c) 2019 Wolters Kluwer Health, Inc. All rights reserved.	[Callcut, Rachael A.; Kornblith, Lucy Z.; Conroy, Amanda S.; Robles, Anamaria J.] Univ Calif San Francisco, Zuckerberg San Francisco Gen Hosp, Dept Surg, San Francisco, CA 94143 USA; [Meizoso, Jonathan P.; Namias, Nicholas] Univ Miami, Jackson Mem Hosp, Miller Sch Med, Dept Surg, Miami, FL 33136 USA; [Meyer, David E.; Haymaker, Amanda] Univ Texas Hlth Sci Ctr Houston, McGovern Med Sch, Dept Surg, Houston, TX 77030 USA; [Truitt, Michael S.; Agrawal, Vaidehi] Methodist Dallas Med Ctr, Div Trauma & Acute Care, Dallas, TX USA; [Haan, James M.; Lightwine, Kelly L.] Univ Kansas, Sch Med, Dept Trauma, Via Christi Hlth,Wichita Campus, Wichita, KS 67214 USA; [Porter, John M.; San Roman, Janika L.] Cooper Univ Hosp, Div Trauma, Camden, NJ USA; [Biffl, Walter L.] Scripps Mem Hosp La Jolla, Dept Surg, La Jolla, CA USA; [Hayashi, Michael S.] Univ Hawaii, Queens Med Ctr, Dept Surg, Honolulu, HI 96822 USA; [Sise, Michael J.; Badiee, Jayraan] Scripps Mercy Hosp, Trauma Serv, San Diego, CA USA; [Recinos, Gustavo; Inaba, Kenji] Los Angeles Cty Univ Southern Calif Med Ctr, Div Surg Crit Care & Trauma, Los Angeles, CA USA; [Schroeppel, Thomas J.; Callaghan, Emma] Univ Colorado Hlth, Dept Surg, Mem Hosp, Colorado Springs, CO USA; [Dunn, Julie A.; Godin, Samuel] Univ Colorado Hlth North, Med Ctr Rockies, Dept Surg, Loveland, CO USA; [McIntyre, Robert C.; Peltz, Erik D.] Univ Colorado, Sch Med, Dept Surg, Aurora, CO USA; [O'Neill, Patrick J.; Diven, Conrad F.] Abrazo Med Grp, Dept Trauma & Gen Surg, Abrazo West Campus, Goodyear, AZ USA; [Scifres, Aaron M.; Switzer, Emily E.] Univ Oklahoma, Dept Surg, Oklahoma City, OK USA; [West, Michaela A.; Storrs, Sarah] North Mem Hlth Hosp, Div Trauma & Emergency Acute Care Surg, Robbinsdale, MN USA; [Cullinane, Daniel C.; Cordova, John F.] Marshfield Clin Fdn Med Res & Educ, Dept Surg, Marshfield, WI USA; [Moore, Ernest E.; Moore, Hunter B.] Univ Colorado, Denver Hlth Med Ctr, Dept Surg, Denver, CO 80202 USA; [Privette, Alicia R.; Eriksson, Evert A.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA; [Cohen, Mitchell Jay] Denver Hlth Med Ctr, Dept Surg, Denver, CO USA; [Cohen, Mitchell Jay] Univ Colorado, Med Ctr, Aurora, CO USA	Callcut, RA (corresponding author), Zuckerberg San Francisco Gen Hosp, Dept Surg, Ward 3A,1001 Potrero Ave, San Francisco, CA 94110 USA.	Rachael.Callcut@ucsf.edu	Meizoso, Jonathan/AAF-5777-2019; Agrawal, Vaidehi/B-8282-2019; INABA, KENJI/AAC-8532-2020; Wong, Monica D/D-9016-2017	Meizoso, Jonathan/0000-0002-6616-6682; Agrawal, Vaidehi/0000-0002-1958-630X; Wong, Monica D/0000-0001-7041-9518; Meyer, David/0000-0002-3816-0160; West, Michaela A/0000-0002-6598-4114; Hayashi, Michael/0000-0001-9743-4945	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K01ES026834]; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K01ES026834] Funding Source: NIH RePORTER	Dr. Callcut is supported by NIH K01ES026834.	Brown JB, 2015, J AM COLL SURGEONS, V220, P797, DOI 10.1016/j.jamcollsurg.2015.01.006; Cohen MJ, 2012, ANN SURG, V255, P379, DOI 10.1097/SLA.0b013e318235d9e6; Cripps MW, 2013, J TRAUMA ACUTE CARE, V75, pS255, DOI 10.1097/TA.0b013e31829a24b4; Davis JS, 2014, J TRAUMA ACUTE CARE, V77, P213, DOI 10.1097/TA.0000000000000292; Demetriades D, 2005, J AM COLL SURGEONS, V201, P343, DOI 10.1016/j.jamcollsurg.2005.05.003; Demetriades D, 2004, J AM COLL SURGEONS, V198, P20, DOI 10.1016/j.jamcollsurg.2003.09.003; Fox EE, 2017, SHOCK, V47, P567, DOI 10.1097/SHK.0000000000000788; Holcomb JB, 2015, JAMA-J AM MED ASSOC, V313, P471, DOI 10.1001/jama.2015.12; Nardi G, 2015, CRIT CARE, V19, DOI 10.1186/s13054-015-0817-9; Oliver GJ, 2017, INJURY, V48, P985, DOI 10.1016/j.injury.2017.02.026; Oyeniyi BT, 2017, INJURY, V48, P5, DOI 10.1016/j.injury.2016.10.037; Pang JM, 2008, INJURY, V39, P102, DOI 10.1016/j.injury.2007.05.022; Pfeifer R, 2009, INJURY, V40, P907, DOI 10.1016/j.injury.2009.05.006; Powell EK, 2016, J TRAUMA ACUTE CARE, V81, P458, DOI 10.1097/TA.0000000000001078; Rhee P, 2014, ANN SURG, V260, P13, DOI 10.1097/SLA.0000000000000600; SAUAIA A, 1995, J TRAUMA, V38, P185, DOI 10.1097/00005373-199502000-00006; Trunkey DD, 1988, SCI AM, V4, P1; Valdez C, 2016, J SURG RES, V200, P604, DOI 10.1016/j.jss.2015.08.031; Weireter LJ, 2014, AM SURGEON, V80, P764	19	22	22	0	1	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	MAY	2019	86	5					864	870		10.1097/TA.0000000000002205			7	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	HW6KW	WOS:000466799900015	30633095	Green Accepted			2021-06-18	
J	Carlson, AP; Abbas, M; Alunday, RL; Qeadan, F; Shuttleworth, CW				Carlson, Andrew P.; Abbas, Mohammad; Alunday, Robert L.; Qeadan, Fares; Shuttleworth, C. William			Spreading depolarization in acute brain injury inhibited by ketamine: a prospective, randomized, multiple crossover trial	JOURNAL OF NEUROSURGERY			English	Article						subarachnoid hemorrhage; vasospasm; spreading depression; spreading depolarization; delayed cerebral ischemia; vascular disorders; traumatic brain injury	SUBARACHNOID HEMORRHAGE; NMDA RECEPTOR; DEPRESSION; ISCHEMIA; CLUSTERS; SEDATION	OBJECTIVE Retrospective clinical data and case studies support a therapeutic effect of ketamine in suppression of spreading depolarization (SD) following brain injury. Preclinical data strongly support efficacy in terms of frequency of SD as well as recovery from electrocorticography (ECoG) depression. The authors present the results of the first prospective controlled clinical trial testing the role of ketamine used for clinical sedation on occurrence of SD. METHODS Ten patients with severe traumatic brain injury (TBI) or aneurysmal subarachnoid hemorrhage (SAH) were recruited for this pilot trial. A standard ECoG strip was placed at the time of craniotomy, and the patients were then placed on an alternating every-6-hour schedule of ketamine or other sedation agent. The order of treatment was randomized. The ketamine dose was adjusted to clinical effect or maintained at a subanesthetic basal dose (0.1 mg/kg/hr) if no sedation was required. SD was scored using standard criteria, blinded to ketamine dosing. Occurrence of SD was compared with the hourly dose of ketamine to determine the effect of ketamine on SD occurrence. RESULTS Successful ECoG recordings were obtained in all 10 patients: 8 with SAH and 2 with TBI. There were a total of 1642 hours of observations with adequate ECoG: 833 hours off ketamine and 809 hours on ketamine. Analysis revealed a strong dose-dependent effect such that hours off ketamine or on doses of less than 1.15 mg/kg/hr were associated with an increased risk of SD compared with hours on doses of 1.15 mg/kg/hr or more (OR 13.838, 95% CI 1.99-1000). This odds ratio decreased with lower doses of 1.0 mg/kg/hr (OR 4.924, 95% CI 1.337-43.516), 0.85 mg/kg/ hr (OR 3.323, 95% CI 1.139-16.074), and 0.70 mg/kg/hr (OR 2.725, 95% CI 1.068-9.898) to a threshold of no effect at 0.55 mg/kg/hr (OR 1.043, 95% CI 0.565-2.135). When all ketamine data were pooled (i.e., on ketamine at any dose vs off ketamine), a nonsignificant overall trend toward less SD during hours on ketamine (chi(2) = 3.86, p = 0.42) was observed. CONCLUSIONS Ketamine effectively inhibits SD over a wide range of doses commonly used for sedation, even in nonintubated patients. These data also provide the first prospective evidence that the occurrence of SD can be influenced by clinical intervention and does not simply represent an unavoidable epiphenomenon after injury. These data provide the basis for future studies assessing clinical improvement with SD-directed therapy.	[Carlson, Andrew P.; Abbas, Mohammad; Alunday, Robert L.] Univ New Mexico, Sch Med, Dept Neurosurg, Albuquerque, NM 87131 USA; [Qeadan, Fares] Univ New Mexico, Sch Med, Dept Internal Med, Albuquerque, NM 87131 USA; [Shuttleworth, C. William] Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA	Carlson, AP (corresponding author), Univ New Mexico, Albuquerque, NM 87131 USA.	andrewcarlson@salud.unm.edu	Carlson, Andrew P/B-4369-2012; Qeadan, Fares/ABD-3131-2020; Qeadan, Fares/B-9482-2014	Carlson, Andrew P/0000-0003-2189-3699; Qeadan, Fares/0000-0002-3376-220X	National Center for Advancing Translational Sciences pilot grant [1UL1TR001449-01]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS106901, GM109089]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001449] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P20GM109089] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS106901, R01NS051288] Funding Source: NIH RePORTER	Support was provided by the National Center for Advancing Translational Sciences pilot grant no. 1UL1TR001449-01 to the Clinical Translational Science Center (to A.P.C.) and NIH grants nos. NS106901 and GM109089 (to C.W.S.).	Agresti A., 2011, INT ENCY STAT SCI; Aiba I, 2012, J PHYSIOL-LONDON, V590, P5877, DOI 10.1113/jphysiol.2012.234476; ARMITAGE P, 1955, BIOMETRICS, V11, P375, DOI 10.2307/3001775; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Carlson AP, 2012, NEUROL RES, V34, P223, DOI 10.1179/1743132811Y.0000000077; COCHRAN WG, 1954, BIOMETRICS, V10, P417, DOI 10.2307/3001616; De Pinto Mario, 2008, J Opioid Manag, V4, P54; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2017, J CEREBR BLOOD F MET, V37, P1595, DOI 10.1177/0271678X16654496; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Duque JC, 2008, J VET PHARMACOL THER, V31, P344, DOI 10.1111/j.1365-2885.2008.00965.x; Feuerstein D, 2010, J CEREBR BLOOD F MET, V30, P1343, DOI 10.1038/jcbfm.2010.17; GORELOVA NA, 1987, ELECTROEN CLIN NEURO, V66, P440, DOI 10.1016/0013-4694(87)90213-6; Hartings JA, 2017, J CEREBR BLOOD F MET, V37, P1571, DOI 10.1177/0271678X16654495; Hartings JA, 2014, ANN NEUROL, V76, P681, DOI 10.1002/ana.24256; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hertle DN, 2012, BRAIN, V135, P2390, DOI 10.1093/brain/aws152; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; MARRANNES R, 1988, BRAIN RES, V457, P226, DOI 10.1016/0006-8993(88)90690-7; Nakamura H, 2010, BRAIN, V133, P1994, DOI 10.1093/brain/awq117; Reinhart KM, 2018, EXP NEUROL, V305, P121, DOI 10.1016/j.expneurol.2018.04.007; Riker RR, 1999, CRIT CARE MED, V27, P1325, DOI 10.1097/00003246-199907000-00022; Roberts DJ, 2011, CRIT CARE MED, V39, P2743, DOI 10.1097/CCM.0b013e318228236f; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Sanchez-Porras R, 2014, NEUROPHARMACOLOGY, V84, P52, DOI 10.1016/j.neuropharm.2014.04.018; Schiefecker AJ, 2015, NEUROCRIT CARE, V22, P293, DOI 10.1007/s12028-014-0050-4; Somjen GG, 2001, PHYSIOL REV, V81, P1065; Strayer RJ, 2009, AM J EMERG MED, V27, P512, DOI 10.1016/j.ajem.2009.01.020; Vollenweider FX, 1997, EUR NEUROPSYCHOPHARM, V7, P25, DOI 10.1016/S0924-977X(96)00042-9; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; 2015, ANN EMERG MED, V65, P43, DOI DOI 10.1016/J.ANNEMERGMED.2014.06.018	36	22	22	1	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAY	2019	130	5					1513	1519		10.3171/2017.12.JNS171665			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HW0VW	WOS:000466401100013	29799344	Green Accepted, Bronze			2021-06-18	
J	Elkin, BS; Gabler, LF; Panzer, MB; Siegmund, GP				Elkin, Benjamin S.; Gabler, Lee F.; Panzer, Matthew B.; Siegmund, Gunter P.			Brain tissue strains vary with head impact location: A possible explanation for increased concussion risk in struck versus striking football players	CLINICAL BIOMECHANICS			English	Article						Football; Brain; Finite element model; Concussion	FINITE-ELEMENT MODEL; PROFESSIONAL FOOTBALL; INJURY; RESPONSES; SEVERITY; VALIDATION; CRITERIA; SPORTS	Background: On-field football helmet impacts over a large range of severities have caused concussions in some players but not in other players. One possible explanation for this variability is the struck player's helmet impact location. Methods: We examined the effect of impact location on regional brain tissue strain when input energy was held constant. Laboratory impacts were performed at 12 locations distributed over the helmet and the resulting head kinematics were simulated in two finite element models of the brain: the Simulated Injury Monitor and the Global Human Body Model Consortium brain model. Findings: Peak kinematics, injury metrics and brain strain varied significantly with impact location. Differences in impact location explained 33 to 37% of the total variance in brain strain for the whole brain and cerebrum, considerably more than the variance explained by impact location for the peak resultant head kinematics (8 to 23%) and slightly more than half of the variance explained by the difference in closing speed (57 to 61%). Both finite element models generated similar strain results, with minor variations for impacts that generated multiaxial rotations, larger variations in brainstem strains for some impact locations and a small bias for the cerebellum. Interpretation: Based on this experimental and computational simulation study, impact location on the football helmet has a large effect on regional brain tissue strain. We also found that the lowest strains consistently occurred in impacts to the crown and forehead, helmet locations commonly associated with the striking player.	[Elkin, Benjamin S.] MEA Forens Engineers & Scientists, Toronto, ON, Canada; [Gabler, Lee F.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, Charlottesville, VA USA; [Siegmund, Gunter P.] MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada; [Siegmund, Gunter P.] Univ British Columbia, Sch Kinesiol, Vancouver, BC, Canada; [Elkin, Benjamin S.] MEA Forens Engineers & Scientists Ltd, 22 Voyager Court South, Toronto, ON, Canada; [Gabler, Lee F.; Panzer, Matthew B.] Univ Virginia, Ctr Appl Biomech, 4040 Lewis & Clark Dr, Charlottesville, VA 22911 USA	Siegmund, GP (corresponding author), MEA Forens Engineers & Scientists, 11-11151 Horseshoe Way, Richmond, BC V7A 4S5, Canada.	gunter.siegmund@meaforensic.com	Siegmund, Gunter P/B-7003-2013	Siegmund, Gunter/0000-0003-2387-941X			Bandak FA, 1994, SAE T, V103, P1708, DOI [10.4271/942215, DOI 10.4271/942215]; Beckwith JG, 2013, MED SCI SPORT EXER, V45, P737, DOI 10.1249/MSS.0b013e3182792ed7; Cater HL, 2006, J BIOMECH, V39, P2810, DOI 10.1016/j.jbiomech.2005.09.023; Eckner JT, 2014, AM J SPORT MED, V42, P566, DOI 10.1177/0363546513517869; Elkin BS, 2007, STAPP CAR CRASH JO, V51, P127; Funk J R, 2007, Annu Proc Assoc Adv Automot Med, V51, P343; Funk JR, 2012, ANN BIOMED ENG, V40, P79, DOI 10.1007/s10439-011-0400-8; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Gennarelli Thomas A, 1987, P 31 STAPP CAR CRASH, DOI [10.4271/872197, DOI 10.4271/872197]; Greenwald RM, 2008, NEUROSURGERY, V62, P789, DOI 10.1227/01.neu.0000318162.67472.ad; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Hodgson V. R., 1983, 831618 SAE, DOI [10.4271/831618, DOI 10.4271/831618]; Holbourn AHS, 1943, LANCET, V2, P438; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Ji SB, 2014, BIOMECH MODEL MECHAN, V13, P1121, DOI 10.1007/s10237-014-0562-z; Ji SB, 2014, ANN BIOMED ENG, V42, P11, DOI 10.1007/s10439-013-0907-2; Jin X, 2017, J BIOMECH ENG-T ASME, V139, DOI 10.1115/1.4037399; Kleiven S, 2006, INT J CRASHWORTHINES, V11, P65, DOI 10.1533/ijcr.2005.0384; Kleiven S., 2005, P IRCOBI C PRAG CZEC, P41; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McIntosh AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-005078; Miller LE, 2017, COMPUT METHOD BIOMEC, V20, P1273, DOI 10.1080/10255842.2017.1340462; Morrison B, 2011, ANNU REV BIOMED ENG, V13, P91, DOI 10.1146/annurev-bioeng-071910-124706; Panzer MB, 2012, ANN BIOMED ENG, V40, P1530, DOI 10.1007/s10439-012-0519-2; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Rowson S, 2012, ANN BIOMED ENG, V40, P1, DOI 10.1007/s10439-011-0392-4; Siegmund GP, 2016, ANN BIOMED ENG, V44, P1257, DOI 10.1007/s10439-015-1420-6; Siegmund GP, 2014, ANN BIOMED ENG, V42, P1834, DOI 10.1007/s10439-014-1052-2; Takhounts E. G., 2011, P 22 ENH SAF VEH C; Takhounts Erik G, 2013, Stapp Car Crash J, V57, P243; Takhounts EG, 2008, STAPP CAR C, V52, P1; Viano DC, 2007, NEUROSURGERY, V61, P313, DOI 10.1227/01.NEU.0000279969.02685.D0; Viceconti M, 2005, CLIN BIOMECH, V20, P451, DOI 10.1016/j.clinbiomech.2005.01.010; Weaver AA, 2012, ANN BIOMED ENG, V40, P2005, DOI 10.1007/s10439-012-0553-0; Wonnacott M., 2010, 2010010136 SAE; Zhang LY, 2001, J NEUROTRAUM, V18, P21, DOI 10.1089/089771501750055749; Zhao W, 2015, IRCOBI C LYON FRANC, P208	40	22	22	0	12	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0268-0033	1879-1271		CLIN BIOMECH	Clin. Biomech.	APR	2019	64				SI		49	57		10.1016/j.clinbiomech.2018.03.021			9	Engineering, Biomedical; Orthopedics; Sport Sciences	Engineering; Orthopedics; Sport Sciences	HY6ON	WOS:000468249700008	29625747				2021-06-18	
J	Chao, HL; Lin, C; Zuo, Q; Liu, YL; Xiao, MQ; Xu, XP; Li, Z; Bao, ZY; Chen, HM; You, YP; Kochanek, PM; Yin, HY; Liu, N; Kagan, VE; Bayir, H; Ji, J				Chao, Honglu; Lin, Chao; Zuo, Qiang; Liu, Yinlong; Xiao, Mengqing; Xu, Xiupeng; Li, Zheng; Bao, Zhongyuan; Chen, Huimei; You, Yongping; Kochanek, Patrick M.; Yin, Huiyong; Liu, Ning; Kagan, Valerian E.; Bayir, Hulya; Ji, Jing			Cardiolipin-Dependent Mitophagy Guides Outcome after Traumatic Brain Injury	JOURNAL OF NEUROSCIENCE			English	Article						apoptosis; autophagy; cardiolipin; mitophagy; neuroprotection; phospholipid	DYNAMIN-RELATED PROTEIN-1; AUTOPHAGIC CELL-DEATH; PHOSPHOLIPID SCRAMBLASE-3; MITOCHONDRIAL FISSION; PATHWAY; ELIMINATION; PARKIN; SIGNAL; MICE; DRP1	Mitochondrial energy production is essential for normal brain function. Traumatic brain injury (TBI) increases brain energy demands, results in the activation of mitochondrial respiration, associated with enhanced generation of reactive oxygen species. This chain of events triggers neuronal apoptosis via oxidation of a mitochondria-specific phospholipid, cardiolipin (CL). One pathway through which cells can avoid apoptosis is via elimination of damaged mitochondria by mitophagy. Previously, we showed that externalization of CL to the mitochondrial surface acts as an elimination signal in cells. Whether CL-mediated mitophagy occurs in vivo or its significance in the disease processes are not known. In this study, we showed that TBI leads to increased mitophagy in the human brain, which was also detected using TBI models in male rats. Knockdown of CL synthase, responsible for de novo synthesis of CL, or phospholipid scramblase-3, responsible for CL translocat ion to the outer mitochondrial membrane, significantly decreased TBI-induced mitophagy. Inhibition of mitochondrial clearance by 3-methyladenine, mdivi-1, or phospholipid scramblase-3 knockdown after TBI led to a worse outcome, suggesting that mitophagy is beneficial. Together, our findings indicate that TBI-induced mitophagy is an endogenous neuroprotective process that is directed by CL, which marks damaged mitochondria for elimination, thereby limiting neuronal death and behavioral deficits.	[Chao, Honglu; Lin, Chao; Liu, Yinlong; Xu, Xiupeng; Li, Zheng; Bao, Zhongyuan; You, Yongping; Liu, Ning; Ji, Jing] Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China; [Zuo, Qiang] Nanjing Med Univ, Affiliated Hosp 1, Dept Orthoped, Nanjing 210029, Jiangsu, Peoples R China; [Chao, Honglu; Kagan, Valerian E.; Bayir, Hulya; Ji, Jing] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA; [Chao, Honglu; Kochanek, Patrick M.; Bayir, Hulya; Ji, Jing] Univ Pittsburgh, Dept Crit Care Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15219 USA; [Xiao, Mengqing; Yin, Huiyong] Chinese Acad Sci, Shanghai Inst Biol Sci, Inst Nutr Sci, Key Lab Food Safety Res, Shanghai 200031, Peoples R China; [Xiao, Mengqing; Yin, Huiyong] Univ Chinese Acad Sci, CAS, Beijing 100049, Peoples R China; [Xiao, Mengqing; Yin, Huiyong] Shanghai Tech Univ, Sch Life Sci & Technol, Shanghai 201210, Peoples R China; [Chen, Huimei] Nanjing Univ, Sch Med, Dept Med Genet, Nanjing 210093, Jiangsu, Peoples R China; [Chen, Huimei] Jiangsu Key Lab Mol Med, Nanjing 210029, Jiangsu, Peoples R China; [Yin, Huiyong] Minist Hlth, Key Lab Food Safety Risk Assessment, Beijing 100022, Peoples R China; [Kagan, Valerian E.] IM Sechenov Moscow State Med Univ, Lab Nav Redox Lipid, Moscow 119991, Russia; [Kagan, Valerian E.] IM Sechenov Moscow State Med Univ, Dept Human Pathol, Moscow 119991, Russia; [Bayir, Hulya] Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA	Ji, J (corresponding author), Nanjing Med Univ, Affiliated Hosp 1, Dept Neurosurg, Nanjing 210029, Jiangsu, Peoples R China.; Bayir, H; Ji, J (corresponding author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Dept Environm & Occupat Hlth, Pittsburgh, PA 15219 USA.; Bayir, H (corresponding author), Childrens Hosp Pittsburgh, Childrens Neurosci Inst, Pittsburgh, PA 15224 USA.	bayihx@ccm.upmc.edu; jijing@njmu.edu.cn		Kagan, Valerian E./0000-0002-7245-1885	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS061817, NS076511]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81300998, 81471269]; Jiangsu Province's Natural Science FoundationNatural Science Foundation of Jiangsu Province [BK20160047, BK20160044]; Jiangsu Province; Priority Academic Program Development of Jiangsu Higher Education Institutions; NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Allergy & Infectious Diseases (NIAID) [U19AI068021] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS061817, R01NS076511] Funding Source: NIH RePORTER	This work was supported by NIH Grants (NS061817, NS076511) to H.B., National Natural Science Foundation of China (81300998, 81471269) to J.J., Jiangsu Province's Natural Science Foundation (BK20160047, BK20160044) to J.J., and Jiangsu Province and the Priority Academic Program Development of Jiangsu Higher Education Institutions.	Bayir H, 2007, ANN NEUROL, V62, P154, DOI 10.1002/ana.21168; Burman JL, 2017, J CELL BIOL, V216, P3231, DOI 10.1083/jcb.201612106; Cavallucci V, 2014, CELL DEATH DIS, V5, DOI 10.1038/cddis.2014.511; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Chu CT, 2014, AUTOPHAGY, V10, P376, DOI 10.4161/auto.27191; Chu CT, 2013, NAT CELL BIOL, V15, P1197, DOI 10.1038/ncb2837; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Feng Y, 2017, NEUROCHEM RES, V42, P3296, DOI 10.1007/s11064-017-2372-z; Fischer TD, 2016, FRONT SYST NEUROSCI, V10, DOI [10.3389/fnsys.2016.00029, 10.3389/fnsys.2010.00020]; Galluzzi L, 2016, NAT REV NEUROSCI, V17, P467, DOI 10.1038/nrn.2016.51; Gao YY, 2017, AM J TRANSL RES, V9, P887; Geisler S, 2010, NAT CELL BIOL, V12, P119, DOI 10.1038/ncb2012; He Y, 2007, J CELL BIOCHEM, V101, P1210, DOI 10.1002/jcb.21243; Huang CY, 2017, J NEUROIMMUNOL, V313, P61, DOI 10.1016/j.jneuroim.2017.10.011; Iyer SS, 2013, IMMUNITY, V39, P311, DOI 10.1016/j.immuni.2013.08.001; Ji J, 2012, NAT NEUROSCI, V15, P1407, DOI 10.1038/nn.3195; Ji J, 2012, J NEUROTRAUM, V29, P776, DOI 10.1089/neu.2010.1602; Jin YC, 2016, WORLD NEUROSURG, V88, P433, DOI 10.1016/j.wneu.2015.10.055; Kagan VE, 2016, CELL DEATH DIFFER, V23, P1140, DOI 10.1038/cdd.2015.160; Kagan VE, 2009, FREE RADICAL BIO MED, V46, P1439, DOI 10.1016/j.freeradbiomed.2009.03.004; Kagan VE, 2005, NAT CHEM BIOL, V1, P223, DOI 10.1038/nchembio727; Kilbaugh TJ, 2015, EXP NEUROL, V271, P136, DOI 10.1016/j.expneurol.2015.05.009; Klionsky DJ, 2016, AUTOPHAGY, V12, P1, DOI 10.1080/15548627.2015.1100356; Kowalczyk JE, 2009, NEUROCHEM INT, V55, P157, DOI 10.1016/j.neuint.2009.01.009; Kroemer G, 2008, NAT REV MOL CELL BIO, V9, P1004, DOI 10.1038/nrm2529; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Liu HD, 2013, NEUROL SCI, V34, P1173, DOI 10.1007/s10072-012-1214-7; Liu JH, 2003, MOL CANCER RES, V1, P892; Liu JH, 2003, CANCER RES, V63, P1153; Liu JH, 2008, BIOCHEMISTRY-US, V47, P4518, DOI 10.1021/bi701962c; Liu Y, 2015, CELL DEATH DIFFER, V22, P367, DOI 10.1038/cdd.2014.143; Liu YL, 2017, J NEUROTRAUM, V34, P2119, DOI 10.1089/neu.2016.4764; Liu Y, 2017, BEHAV BRAIN RES, V331, P135, DOI 10.1016/j.bbr.2017.04.024; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; Mukhida K, 2005, MED HYPOTHESES, V64, P1120, DOI 10.1016/j.mehy.2004.12.020; Osier ND, 2016, FRONT NEUROL, V7, DOI 10.3389/fneur.2016.00134; Park E, 2008, CAN MED ASSOC J, V178, P1163, DOI 10.1503/cmaj.080282; Pickrell AM, 2015, NEURON, V85, P257, DOI 10.1016/j.neuron.2014.12.007; Preau S, 2016, ANTIOXID REDOX SIGN, V24, P529, DOI 10.1089/ars.2015.6421; Qian W, 2013, EXPERT OPIN THER TAR, V17, P997, DOI 10.1517/14728222.2013.823160; Rosdah AA, 2016, PHARMACOL RES PERSPE, V4, DOI 10.1002/prp2.235; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Scafidi S, 2010, DEV NEUROSCI-BASEL, V32, P480, DOI 10.1159/000323178; Schneider CA, 2012, NAT METHODS, V9, P671, DOI 10.1038/nmeth.2089; Shellington DK, 2011, CRIT CARE MED, V39, P494, DOI 10.1097/CCM.0b013e318206b1fa; Smith CM, 2011, NEUROBIOL DIS, V43, P52, DOI 10.1016/j.nbd.2010.09.014; Smith G, 2017, DEV NEUROBIOL, V77, P1260, DOI 10.1002/dneu.22519; Sun Y, 2012, J BIOL CHEM, V287, P40652, DOI 10.1074/jbc.M112.419721; Tang YC, 2016, PROTEIN CELL, V7, P699, DOI 10.1007/s13238-016-0307-0; Twig G, 2008, EMBO J, V27, P433, DOI 10.1038/sj.emboj.7601963; Wang CX, 2017, CELL BIOL INT, V41, P1039, DOI 10.1002/cbin.10820; Wang Z, 2012, J MOL NEUROSCI, V46, P192, DOI 10.1007/s12031-011-9575-6; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wu Q, 2017, HISTOL HISTOPATHOL, V32, P551, DOI 10.14670/HH-11-841; Wu YT, 2010, J BIOL CHEM, V285, P10850, DOI 10.1074/jbc.M109.080796; Yamashita S, 2016, J CELL BIOL, V215, P649, DOI 10.1083/jcb.201605093; Zhang XN, 2013, AUTOPHAGY, V9, P1321, DOI 10.4161/auto.25132; Zuo W, 2014, NEUROPHARMACOLOGY, V86, P103, DOI 10.1016/j.neuropharm.2014.07.002	59	22	23	2	7	SOC NEUROSCIENCE	WASHINGTON	11 DUPONT CIRCLE, NW, STE 500, WASHINGTON, DC 20036 USA	0270-6474			J NEUROSCI	J. Neurosci.	MAR 6	2019	39	10					1930	1943		10.1523/JNEUROSCI.3415-17.2018			14	Neurosciences	Neurosciences & Neurology	HN7WJ	WOS:000460403400014	30626699	Bronze, Green Published			2021-06-18	
J	Corley, J; Lepard, J; Barthelemy, E; Ashby, JL; Park, KB				Corley, Jacquelyn; Lepard, Jacob; Barthelemy, Ernest; Ashby, Joanna L.; Park, Kee B.			Essential Neurosurgical Workforce Needed to Address Neurotrauma in Low- and Middle-Income Countries	WORLD NEUROSURGERY			English	Article						Global neurosurgery; Low-and middle-income countries; Neurotrauma; Traumatic brain injury; Traumatic spinal injury	SURGICAL CARE; EMERGENCY NEUROSURGERY; MODELING STRATEGY; GENERAL SURGEONS; ACCESS; HEALTH	BACKGROUND: Among all trauma-related injuries globally, traumatic brain injury (TBI) and traumatic spine injury (TSI) account for the largest proportion of cases. Where previously data was lacking, recent efforts have been initiated to better quantify the extent of neurotrauma in low-and middle-income countries (LMICs). This information is vital to understand the current neurosurgical deficit so that resources and efforts can be focused on where they are needed most. The purpose of this study is to determine the minimum number of neurosurgeons to address the neurotrauma demand in LMICs and evaluate current evidence to support facility needs so that policy-based recommendations can be made to prioritize development initiatives to scale up neurosurgical services. METHODS: Using existing data regarding the incidence of TBI and TSI in LMICs and current neurosurgical workforce and estimates of case load capacity, the minimum number of neurosurgeons needed to address neurotrauma per population was calculated. Evidence was gathered regarding necessary hospital facilities and disbursement patterns based on time needed to intervene effectively for neurotrauma. RESULTS: There are 4,897,139 total operative cases of TBI and TSI combined in LMICs annually. At minimum, there needs to be 1 neurosurgeon only performing neurotrauma cases per approximately 212,000 people. Evidence suggests that patients should be within 4 hours of a neurosurgical facility at the very least. CONCLUSIONS: The development of neurotrauma systems is essential to address the large burden of neurotrauma in LMICs. The minimum requirements for neurosurgical workforce is 1 neurotrauma surgeon per 212,000 people.	[Corley, Jacquelyn; Lepard, Jacob; Barthelemy, Ernest; Ashby, Joanna L.; Park, Kee B.] Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA; [Corley, Jacquelyn] Duke Dept Neurosurg, Durham, NC 27704 USA; [Lepard, Jacob] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA; [Lepard, Jacob] Boston Childrens Hosp, Boston, MA USA; [Barthelemy, Ernest] Icahn Sch Med Mt Sinai, Dept Neurosurg, New York, NY 10029 USA; [Ashby, Joanna L.] Univ Glasgow, Med Sch, Glasgow, Lanark, Scotland	Corley, J (corresponding author), Harvard Med Sch, Global Neurosurg Initiat, Program Global Surg & Social Change, Boston, MA 02115 USA.; Corley, J (corresponding author), Duke Dept Neurosurg, Durham, NC 27704 USA.	jacorley21@gmail.com					Albutt K, 2018, PLOS ONE, V13, DOI 10.1371/journal.pone.0195986; Alkire BC, 2015, LANCET GLOB HEALTH, V3, pE316, DOI 10.1016/S2214-109X(15)70115-4; Bagan M, 2010, WORLD NEUROSURG, V73, P289, DOI 10.1016/j.wneu.2010.03.007; Cairo SB, 2018, PEDIATR SURG INT, V34, P467, DOI 10.1007/s00383-018-4238-0; Chao TE, 2015, WORLD J SURG, V39, P2140, DOI 10.1007/s00268-014-2905-4; Dewan MC, 2019, J NEUROSURG, V130, P1055, DOI 10.3171/2017.11.JNS171500; El Khamlichi Abdeslam, 2014, World Neurosurg, V81, P234, DOI 10.1016/j.wneu.2013.10.051; Esquivel MM, 2016, JAMA SURG, V151, P1064, DOI 10.1001/jamasurg.2016.2303; Haglund MM, 2011, WORLD J SURG, V35, P1175, DOI 10.1007/s00268-011-1080-0; Kanyi JK, 2018, WORLD J SURG, V42, P40, DOI 10.1007/s00268-017-4143-z; Kempthorne P, 2017, ANESTH ANALG, V125, P981, DOI 10.1213/ANE.0000000000002258; Kumar R, 2018, WORLD NEUROSURG, V113, pE345, DOI 10.1016/j.wneu.2018.02.033; Luck T, 2015, ANZ J SURG, V85, P610, DOI 10.1111/ans.13138; Meara JG, 2015, LANCET, V386, P569, DOI 10.1016/S0140-6736(15)60160-X; Muniz SA, 2017, J TRAUMA NURS, V24, P306, DOI 10.1097/JTN.0000000000000310; Rose J, 2015, LANCET GLOB HEALTH, V3, pS13, DOI 10.1016/S2214-109X(15)70087-2; Rubiano AM, 2015, NATURE, V527, pS193, DOI 10.1038/nature16035; Santos MM, 2018, WORLD NEUROSURG, V113, P425, DOI 10.1016/j.wneu.2018.01.084; Treacy PJ, 2005, ANZ J SURG, V75, P852, DOI 10.1111/j.1445-2197.2005.03549.x; Weiser TG, 2008, LANCET, V372, P139, DOI 10.1016/S0140-6736(08)60878-8; World Health Organization, 2008, TASK SHIFT GLOB REC	21	22	22	0	0	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2019	123						295	299		10.1016/j.wneu.2018.12.042			5	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	HR2II	WOS:000462958400151	30579006				2021-06-18	
J	Yauger, YJ; Bermudez, S; Moritz, KE; Glaser, E; Stoica, B; Byrnes, KR				Yauger, Young J.; Bermudez, Sara; Moritz, Kasey E.; Glaser, Ethan; Stoica, Bogdan; Byrnes, Kimberly R.			Iron accentuated reactive oxygen species release by NADPH oxidase in activated microglia contributes to oxidative stress in vitro	JOURNAL OF NEUROINFLAMMATION			English	Article						BV2; Iron sulfate; Neuronal toxicity; Microglial polarization; Neuroinflammation	TRAUMATIC BRAIN-INJURY; LIPID-PEROXIDATION; ACCUMULATION; EXPRESSION; SUSCEPTIBILITY; NEUROTOXICITY; DEFEROXAMINE; INFLAMMATION; SPECIFICITY; INVOLVEMENT	Background: Excessive iron contributes to oxidative stress after central nervous system injury. NADPH oxidase (NOX) enzymes are upregulated in microglia after pro-inflammatory activation and contribute to oxidative stress. The relationship between iron, microglia, NOX, and oxidative stress is currently unclear. Methods: We evaluated the effects of iron on lipopolysaccharide (LPS)-activated microglia and its secondary effect within neuronal co-cultures. Further, NOX2 and four specific inhibitors were tested to evaluate the relationship with the reactive oxygen species (ROS)-producing enzymes. Results: An iron dose-dependent increase in ROS production among microglia treated with LPS was identified. Interestingly, despite this increase in ROS, inflammatory polarization alterations were not detected among the microglia after exposure to iron and LPS. Co-culture experimentation between primary neurons and exposed microglia (iron and LPS) significantly reduced neuronal cell number at 24 h, suggesting a profound neurotoxic effect despite the lack of a change in polarization phenotype. NOX2 and NOX4 inhibition significantly reduced ROS production among microglia exposed to iron and LPS and reduced neuronal damage and death in response to microglial co-culture. Conclusions: In conclusion, iron significantly increased ROS production and neurotoxicity without exacerbating LP-activated microglia phenotype in vitro, suggesting that iron contributes to microglia-related oxidative stress, and this may be a viable therapeutic target for injury or neurodegeneration. Further, this study highlights both NOX2 and NOX4 as potential therapeutic targets in the treatment of iron-induced microglia-related inflammation and neurotoxicity.	[Yauger, Young J.; Moritz, Kasey E.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Neurosci Grad Program, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Bermudez, Sara; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA; [Glaser, Ethan; Stoica, Bogdan] Univ Maryland, Sch Med, Dept Anesthesiol, 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA; [Glaser, Ethan; Stoica, Bogdan] Univ Maryland, Sch Med, Ctr Shock Trauma & Anesthesiol Res STAR, 655 W Baltimore St,Room 6-015, Baltimore, MD 21201 USA	Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Neurosci Grad Program, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.; Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, Room C2099,4301 Jones Bridge Rd, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu		Byrnes, Kimberly/0000-0002-7501-7734	Tri Service Nursing Research Program (TSNRP) [HU0001-15-1-TS16]	This research was completely funded by the Tri Service Nursing Research Program (TSNRP) grant number HU0001-15-1-TS16.	Aguirre P, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0144848; Bedard K, 2007, PHYSIOL REV, V87, P245, DOI 10.1152/physrev.00044.2005; BLASI E, 1990, J NEUROIMMUNOL, V27, P229, DOI 10.1016/0165-5728(90)90073-V; BRAUGHLER JM, 1986, J BIOL CHEM, V261, P282; BRIDGES RA, 1959, AMA J DIS CHILD, V97, P387, DOI 10.1001/archpedi.1959.02070010389004; Chang EF, 2005, J CEREBR BLOOD F MET, V25, P1401, DOI 10.1038/sj.jcbfm.9600147; Chenais B, 2002, J NEUROCHEM, V81, P615, DOI 10.1046/j.1471-4159.2002.00864.x; Cooney SJ, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-155; Das A, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0644-1; Das KP, 2004, NEUROTOXICOL TERATOL, V26, P397, DOI 10.1016/j.ntt.2004.02.006; Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z; Ghosh M, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-015-0463-9; GLOBUS MYT, 1995, J NEUROCHEM, V65, P1704; Haleagrahara N, 2013, J TOXICOL SCI, V38, P25, DOI 10.2131/jts.38.25; HALL ED, 1994, ANN NY ACAD SCI, V738, P15; Hall ED, 2016, J BIOENERG BIOMEMBR, V48, P169, DOI 10.1007/s10863-015-9600-5; Iles KE, 2002, IMMUNOL RES, V26, P95, DOI 10.1385/IR:26:1-3:095; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Ke Y, 2007, PROG NEUROBIOL, V83, P149, DOI 10.1016/j.pneurobio.2007.07.009; Khan M, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-78; Kroner A, 2014, NEURON, V83, P1098, DOI 10.1016/j.neuron.2014.07.027; Lazarus RC, 2015, FREE RADICAL BIO MED, V78, P89, DOI 10.1016/j.freeradbiomed.2014.10.507; Li YP, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0740-2; Loane DJ, 2016, EXP NEUROL, V275, P316, DOI 10.1016/j.expneurol.2015.08.018; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Mehhase J, 2006, BBA-MOL CELL RES, V1763, P854, DOI 10.1016/j.bbamcr.2006.04.012; Nakamura T, 2005, BRAIN RES, V1039, P30, DOI 10.1016/j.brainres.2005.01.036; Nisenbaum EJ, 2014, J NEUROTRAUM, V31, P301, DOI 10.1089/neu.2013.3102; Nishio S, 1997, ACT NEUR S, V70, P84; Piga R, 2007, NEUROTOXICOLOGY, V28, P67, DOI 10.1016/j.neuro.2006.07.006; Plesnila N, 2016, CURR OPIN PHARMACOL, V26, P110, DOI 10.1016/j.coph.2015.10.008; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Song N, 2007, J NEUROSCI RES, V85, P3118, DOI 10.1002/jnr.21430; Stansley B, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-115; Sung YM, 2016, PAK J PHARM SCI, V29, P1087; Tamashiro TT, 2012, JOVE-J VIS EXP, DOI 10.3791/3814; Urrutia P, 2013, J NEUROCHEM, V126, P541, DOI 10.1111/jnc.12244; von Leden RE, 2017, J NEUROTRAUM, V34, P755, DOI 10.1089/neu.2016.4486; Wagner KR, 2002, DEV NEUROSCI-BASEL, V24, P154, DOI 10.1159/000065703; Wang QS, 2014, GLIA, V62, P2034, DOI 10.1002/glia.22724; Yakovlev AG, 2001, J NEUROSCI, V21, P7439; You LH, 2015, NEUROSCIENCE, V284, P234, DOI 10.1016/j.neuroscience.2014.09.071; Zhang GX, 2016, NEUROCHEM RES, V41, P2948, DOI 10.1007/s11064-016-2013-y; Zhang LJ, 2013, NEUROL SCI, V34, P639, DOI 10.1007/s10072-012-1090-1; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504; Zhu YQ, 2017, PARKINSONISM RELAT D, V36, P76, DOI 10.1016/j.parkreldis.2017.01.003; Zucca FA, 2017, PROG NEUROBIOL, V155, P96, DOI 10.1016/j.pneurobio.2015.09.012	47	22	23	0	9	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND		1742-2094		J NEUROINFLAMM	J. Neuroinflamm.	FEB 18	2019	16								41	10.1186/s12974-019-1430-7			15	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	HM1IC	WOS:000459202900004	30777083	DOAJ Gold, Green Published			2021-06-18	
J	Covassin, T; Savage, JL; Bretzin, AC; Fox, ME				Covassin, Tracey; Savage, Jennifer L.; Bretzin, Abigail C.; Fox, Meghan E.			Sex differences in sport-related concussion long-term outcomes	INTERNATIONAL JOURNAL OF PSYCHOPHYSIOLOGY			English	Article						Sex differences; Neurocognitive; Electrophysiology; Symptoms	TRAUMATIC BRAIN-INJURY; NEUROCOGNITIVE PERFORMANCE; SOCCER PLAYERS; BASE-LINE; REPORTING BEHAVIORS; SYMPTOMS; RECOVERY; GENDER; MANAGEMENT; BALANCE	Approximately 1.6 to 3.8 million recreational and sports-related concussions (SRC) occur each year in the Unites States. Research suggest that female athletes are at a greater risk for a SRC compared to male athletes competing in comparable sports (i.e., soccer, basketball). Moreover, female athletes have reported more total symptoms and greater neurocognitive impairments following a SRC. Female athletes have been found to report greater symptom provocation as measured by the Vestibular/Ocular Motor Screening (VOMS), and increased brain activation compared to males. There is a scarcity of research on long-term effects of SRC in male and female athletes. Therefore, the aim of this review article is to summarize the existing literature on sex differences in acute and sub-acute SRC outcomes.	[Covassin, Tracey; Savage, Jennifer L.; Bretzin, Abigail C.] Michigan State Univ, Dept Kinesiol, 308 W Circle Dr, E Lansing, MI 48824 USA; [Fox, Meghan E.] Grand Valley State Univ, Allendale, MI 49401 USA	Covassin, T (corresponding author), Michigan State Univ, Dept Kinesiol, 308 W Circle Dr, E Lansing, MI 48824 USA.	covassin@msu.edu	Savage, Jennifer/C-4680-2018	Bretzin, Abigail/0000-0003-3730-2849			Baker J. G, 2015, CLIN PEDIAT; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Beatty WW, 2003, J CLIN EXP NEUROPSYC, V25, P1065, DOI 10.1076/jcen.25.8.1065.16732; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Berz K, 2013, PHYSICIAN SPORTSMED, V41, P58, DOI 10.3810/psm.2013.05.2015; Boden BP, 1998, AM J SPORT MED, V26, P238, DOI 10.1177/03635465980260021301; Brooks BL, 2014, J HEAD TRAUMA REHAB, V29, P257, DOI 10.1097/HTR.0000000000000016; Broshek DK, 2005, J NEUROSURG, V102, P856, DOI 10.3171/jns.2005.102.5.0856; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Colvin AC, 2009, AM J SPORT MED, V37, P1699, DOI 10.1177/0363546509332497; Covassin T, 2006, BRIT J SPORT MED, V40, P923, DOI 10.1136/bjsm.2006.029496; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2013, TRANSL STROKE RES, V4, P420, DOI 10.1007/s12975-012-0228-z; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; Covassin T, 2011, CLIN SPORT MED, V30, P125, DOI 10.1016/j.csm.2010.08.001; Covassin T, 2010, J NEUROL NEUROSUR PS, V81, P597, DOI 10.1136/jnnp.2009.193797; Ellemberg D, 2007, CLIN J SPORT MED, V17, P369, DOI 10.1097/JSM.0b013e31814c3e3e; EMERSON CS, 1993, BRAIN RES, V608, P95, DOI 10.1016/0006-8993(93)90778-L; Fakhran S, 2014, RADIOLOGY, V272, P815, DOI 10.1148/radiol.14132512; Frommer LJ, 2011, J ATHL TRAINING, V46, P76, DOI 10.4085/1062-6050-46.1.76; Halpern D. F., 2000, SEX DIFFERENCES COGN; Heaton RK., 1996, NEUROPSYCHOL ASSESS, V2, P141; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; HIDDEMA F, 1963, Psychiatr Neurol Neurochir, V66, P517; Hsu HL, 2015, RADIOLOGY, V276, P828, DOI 10.1148/radiol.2015142549; Kerr Z. Y, 2016, JAMA PEDIAT; Kerr ZY, 2016, AM J SPORT MED, V44, P220, DOI 10.1177/0363546515612082; Kimura D, 2002, PSYCHOL REP, V91, P1137, DOI 10.2466/PR0.91.7.1137-1142; Kontos A. P, 2015, BRAIN IMAGING BEHAV, P1, DOI DOI 10.1007/S11682-015-9412-6; Kostyun RO, 2015, SPORTS HEALTH, V7, P52, DOI 10.1177/1941738114555075; Laibow R. E., 2001, Journal of Neurotherapy, V5, P45, DOI 10.1300/J184v05n04_04; Lau BC, 2011, AM J SPORT MED, V39, P1209, DOI 10.1177/0363546510392016; Leddy JJ, 2016, PHYS MED REH CLIN N, V27, P437, DOI 10.1016/j.pmr.2015.12.003; LEWIS RS, 1987, BRAIN COGNITION, V6, P142, DOI 10.1016/0278-2626(87)90115-1; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lipton RB, 2001, HEADACHE, V41, P638, DOI 10.1046/j.1526-4610.2001.041007638.x; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2010, J HEAD TRAUMA REHAB, V25, P283, DOI 10.1097/HTR.0b013e3181e67923; McLeod TCV, 2015, BRAIN INJURY, V29, P175, DOI 10.3109/02699052.2014.965206; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Miller JH, 2016, J NEUROSURG-PEDIATR, V17, P491, DOI 10.3171/2015.8.PEDS14332; NCAA, 2016, NCAA PART RAT 2014 2; NFHS, 2016, PART HIGH SCH SPORTS; Ono K. E, 2015, AM J SPORTS MED; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Ponsford J, 2012, NEUROPSYCHOLOGY, V26, P304, DOI 10.1037/a0027888; Rabinowitz AR, 2015, J NEUROTRAUM, V32, P1488, DOI 10.1089/neu.2014.3555; Register-Mihalik J. K, 2010, ASSESSMENT HIGH SCH; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Schneider K. J, 2010, BR J SPORTS MED; Slobounov S, 2012, CLIN NEUROPHYSIOL, V123, P1755, DOI 10.1016/j.clinph.2011.12.022; Slobounov S, 2009, CLIN NEUROPHYSIOL, V120, P862, DOI 10.1016/j.clinph.2009.03.009; Sufrinko A. M, 2016, CLIN J SPORT MED; Tierney RT, 2005, MED SCI SPORT EXER, V37, P272, DOI 10.1249/01.MSS.0000152734.47516.AA; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wallace J, 2017, J ATHL TRAINING, V52, P228, DOI 10.4085/1062-6050-52.1.07; Weiss EM, 2003, PERS INDIV DIFFER, V35, P863, DOI 10.1016/S0191-8869(02)00288-X; Westfall DR, 2015, J PEDIATR REHAB MED, V8, P297, DOI 10.3233/PRM-150348; Zuckerman SL, 2016, NEUROSURG FOCUS, V40, DOI 10.3171/2016.1.FOCUS15593; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634; Zuckerman SL, 2012, J NEUROSURG-PEDIATR, V10, P504, DOI 10.3171/2012.8.PEDS12139	63	22	22	0	11	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0167-8760	1872-7697		INT J PSYCHOPHYSIOL	Int. J. Psychophysiol.	OCT	2018	132		A		SI		9	13		10.1016/j.ijpsycho.2017.09.010			5	Psychology, Biological; Neurosciences; Physiology; Psychology; Psychology, Experimental	Psychology; Neurosciences & Neurology; Physiology	GV7GC	WOS:000446289000003	28927725				2021-06-18	
J	Stephenson, EL; Yong, VW				Stephenson, Erin L.; Yong, V. Wee			Pro-inflammatory roles of chondroitin sulfate proteoglycans in disorders of the central nervous system	MATRIX BIOLOGY			English	Article						Extracellular matrix; Inflammation; Metalloproteinases; Multiple sclerosis; Spinal cord injury	SPINAL-CORD-INJURY; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; NF-KAPPA-B; EXTRACELLULAR-MATRIX; MULTIPLE-SCLEROSIS; PERINEURONAL NETS; CELL-ACTIVATION; P-SELECTIN; PTP-SIGMA; HEPARAN-SULFATE	The extracellular matrix of the central nervous system is an interconnected network of proteins and sugars. It is crucial for homeostasis, but its remodeling in neurological diseases impacts both injury and repair. Here we introduce an extracellular matrix family member that participates in immune-matrix interactions, the chondroitin sulfate proteoglycans. Chondroitin sulfate proteoglycans integrate signals from the microenvironment to activate immune cells, and they boost inflammatory responses by binding immunological receptors including toll-like receptors, selectins, CD44, and beta 1 integrin. Chondroitin sulfate proteoglycans also bind signaling molecules for immune cells such as cytokines and chemokines, and they activate matrix-degrading enzymes. Chondroitin sulfate proteoglycans accumulate in the damaged CNS, including during traumatic brain/spinal cord injury and multiple sclerosis, and they help drive pathogenesis. This Review aims to give new insights into the remodeling of chondroitin sulfate proteoglycans during inflammation, and how these matrix glycoproteins are able to drive neuroinflammation. (C) 2018 Elsevier B.V. All rights reserved.	Hotchkiss Brain Inst, Calgary, AB, Canada; [Yong, V. Wee] Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada	Yong, VW (corresponding author), Univ Calgary, 3330 Hosp Dr, Calgary, AB T2N 4N1, Canada.	vyong@ucalgary.ca			Canadian Institutes of Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [363459]; Multiple Sclerosis Society of Canada [2697]; Alberta Innovates Health Solutions, CRIO Team program [201300669]; CIHR Vanier program; Alberta Innovates Health Solutions; Canada Research Chair programCanada Research Chairs	The authors' research has been supported by operating grants from the Canadian Institutes of Health Research (CIHR) (363459), the Multiple Sclerosis Society of Canada (2697), and the Alberta Innovates Health Solutions (201300669) CRIO Team program. ES acknowledges studentship support from the CIHR Vanier program and Alberta Innovates Health Solutions. VWY has salary support from the Canada Research Chair (Tier 1) program.	Adair-Kirk TL, 2008, INT J BIOCHEM CELL B, V40, P1101, DOI 10.1016/j.biocel.2007.12.005; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Akiyama H, 2004, BIOCHEM J, V382, P269, DOI 10.1042/BJ20031851; Bandtlow CE, 2000, PHYSIOL REV, V80, P1267; Bartus K, 2014, J NEUROSCI, V34, P4822, DOI 10.1523/JNEUROSCI.4369-13.2014; Beggah AT, 2005, NEUROSCIENCE, V133, P749, DOI 10.1016/j.neuroscience.2005.03.005; Brambilla R, 2005, J EXP MED, V202, P145, DOI 10.1084/jem.20041918; Brocke S, 1999, P NATL ACAD SCI USA, V96, P6896, DOI 10.1073/pnas.96.12.6896; Burnside ER, 2014, NEUROPATH APPL NEURO, V40, P26, DOI 10.1111/nan.12114; Busch SA, 2009, J NEUROSCI, V29, P9967, DOI 10.1523/JNEUROSCI.1151-09.2009; Carulli D, 2006, J COMP NEUROL, V494, P559, DOI 10.1002/cne.20822; Chang AS, 2012, ANN NEUROL, V72, P918, DOI 10.1002/ana.23693; Deepa SS, 2002, J BIOL CHEM, V277, P43707, DOI 10.1074/jbc.M207105200; Dickendesher TL, 2012, NAT NEUROSCI, V15, P703, DOI 10.1038/nn.3070; Didangelos A, 2014, J NEUROSCI, V34, P16424, DOI 10.1523/JNEUROSCI.2927-14.2014; Dyck S, 2018, J NEUROINFLAMM, V15, DOI 10.1186/s12974-018-1128-2; Dyck SM, 2015, EXP NEUROL, V269, P169, DOI 10.1016/j.expneurol.2015.04.006; Ebert S, 2008, J LEUKOCYTE BIOL, V84, P736, DOI 10.1189/jlb.0208138; Ellyard JI, 2007, J BIOL CHEM, V282, P15238, DOI 10.1074/jbc.M608046200; Engelhardt B, 2005, TRENDS IMMUNOL, V26, P485, DOI 10.1016/j.it.2005.07.004; Feliu A, 2017, J NEUROSCI, V37, P8385, DOI 10.1523/JNEUROSCI.2900-16.2017; Fisher D, 2011, J NEUROSCI, V31, P14051, DOI 10.1523/JNEUROSCI.1737-11.2011; Frevert CW, 2003, AM J RESP CELL MOL, V28, P464, DOI 10.1165/rcmb.2002-0084OC; Fry EJ, 2007, NEURON, V53, P649, DOI 10.1016/j.neuron.2007.02.009; Fry EJ, 2010, GLIA, V58, P423, DOI 10.1002/glia.20934; Furst CM, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061407; Galtrey CM, 2008, EUR J NEUROSCI, V27, P1373, DOI 10.1111/j.1460-9568.2008.06108.x; Gamier P., 2003, IMMUNOL LETT, V85, P53; Garcia-Alias G, 2012, EXP NEUROL, V235, P26, DOI 10.1016/j.expneurol.2011.09.009; Gerwien H, 2016, SCI TRANSL MED, V8, DOI 10.1126/scitranslmed.aaf8020; Gill S, 2010, ANAT REC, V293, P968, DOI 10.1002/ar.21094; Gogolla N, 2009, SCIENCE, V325, P1258, DOI 10.1126/science.1174146; Grimpe B, 2004, J NEUROSCI, V24, P1393, DOI 10.1523/JNEUROSCI.4986-03.2004; Heindryckx F., 2018, MATRIX BIOL; Hirose J, 2001, J BIOL CHEM, V276, P5228, DOI 10.1074/jbc.M007542200; Hoogewerf AJ, 1997, BIOCHEMISTRY-US, V36, P13570, DOI 10.1021/bi971125s; Hurt-Camejo E, 1999, J BIOL CHEM, V274, P18957, DOI 10.1074/jbc.274.27.18957; Iida J, 2007, BIOCHEM J, V403, P553, DOI 10.1042/BJ20061176; Iozzo RV, 2005, NAT REV MOL CELL BIO, V6, P646, DOI 10.1038/nrm1702; Ishikawa H, 1999, SPINE, V24, P1071, DOI 10.1097/00007632-199906010-00005; Jones LL, 2003, EXP NEUROL, V182, P399, DOI 10.1016/S0014-4886(03)00087-6; Kang I, 2017, J BIOL CHEM, V292, P51, DOI 10.1074/jbc.M116.753186; Kawashima H, 2002, J BIOL CHEM, V277, P12921, DOI 10.1074/jbc.M200396200; Kawashima H, 2000, J BIOL CHEM, V275, P35448, DOI 10.1074/jbc.M003387200; Keough MB, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11312; Kim S, 2009, NATURE, V457, P102, DOI 10.1038/nature07623; Kishimoto TK, 2008, NEW ENGL J MED, V358, P2457, DOI 10.1056/NEJMoa0803200; Korin B, 2017, NAT NEUROSCI, V20, P1300, DOI 10.1038/nn.4610; Kuipers HF, 2016, P NATL ACAD SCI USA, V113, P1339, DOI 10.1073/pnas.1525086113; Kuschert GSV, 1999, BIOCHEMISTRY-US, V38, P12959, DOI 10.1021/bi990711d; Lang BT, 2015, NATURE, V518, P404, DOI 10.1038/nature13974; Lau LW, 2013, NAT REV NEUROSCI, V14, P722, DOI 10.1038/nrn3550; Lau LW, 2012, ANN NEUROL, V72, P419, DOI 10.1002/ana.23599; Malla N, 2013, FEBS J, V280, P2870, DOI 10.1111/febs.12291; Miller RT, 2017, MATRIX BIOL, V57-58, P366, DOI 10.1016/j.matbio.2016.07.001; Miyamoto K, 2014, GLYCOBIOLOGY, V24, P469, DOI 10.1093/glycob/cwu014; Mohan H, 2010, BRAIN PATHOL, V20, P966, DOI 10.1111/j.1750-3639.2010.00399.x; Morawski M, 2004, EXP NEUROL, V188, P309, DOI 10.1016/j.expneurol.2004.04.017; NAUJOKAS MF, 1993, CELL, V74, P257, DOI 10.1016/0092-8674(93)90417-O; Petersen F, 1998, J IMMUNOL, V161, P4347; Pizzorusso T, 2002, SCIENCE, V298, P1248, DOI 10.1126/science.1072699; Potter-Perigo S, 2010, AM J RESP CELL MOL, V43, P109, DOI 10.1165/rcmb.2009-0081OC; Pozzi A, 2017, MATRIX BIOL, V57-58, P1, DOI 10.1016/j.matbio.2016.12.009; Ra HJ, 2009, J BIOL CHEM, V284, P27924, DOI 10.1074/jbc.M109.035147; Rachmilewitz J, 1998, BLOOD, V92, P223, DOI 10.1182/blood.V92.1.223.413k15_223_229; Rauch U, 2007, BIOCHEM SOC T, V35, P656, DOI 10.1042/BST0350656; Ringer P, 2017, MATRIX BIOL, V64, P6, DOI 10.1016/j.matbio.2017.03.004; Rolls A, 2006, FASEB J, V20, P547, DOI 10.1096/fj.05-4540fje; Rolls A, 2008, PLOS MED, V5, P1262, DOI 10.1371/journal.pmed.0050171; ROSAMOND S, 1987, J IMMUNOL, V139, P1946; Saigoh K, 2016, NEUROSCI RES, V108, P55, DOI 10.1016/j.neures.2016.01.002; Sajad M, 2011, J MOL NEUROSCI, V43, P531, DOI 10.1007/s12031-010-9476-0; Sashinami H, 2012, LIFE SCI, V91, P1263, DOI 10.1016/j.lfs.2012.09.022; Satoh JI, 2005, J NEUROPATH EXP NEUR, V64, P129, DOI 10.1093/jnen/64.2.129; Schuksz M, 2008, P NATL ACAD SCI USA, V105, P13075, DOI 10.1073/pnas.0805862105; Shen YJ, 2009, SCIENCE, V326, P592, DOI 10.1126/science.1178310; Shijo T, 2018, J NEUROSCI RES, V96, P222, DOI 10.1002/jnr.24127; Singh V., 2015, NEUROINFLAMMATION, V2; Sobel RA, 2001, J NEUROPATH EXP NEUR, V60, P1198, DOI 10.1093/jnen/60.12.1198; Sorokin L, 2010, NAT REV IMMUNOL, V10, P712, DOI 10.1038/nri2852; Stephenson EL, 2018, BRAIN, V141, DOI 10.1093/brain/awy033; Tan GK, 2014, ACTA BIOMATER, V10, P2684, DOI 10.1016/j.actbio.2014.02.025; Tang XF, 2003, J NEUROSCI RES, V71, P427, DOI 10.1002/jnr.10523; Troeberg L, 2014, CHEM BIOL, V21, P1300, DOI 10.1016/j.chembiol.2014.07.014; Uchimura K, 2002, J BIOL CHEM, V277, P1443, DOI 10.1074/jbc.M104719200; Wang JY, 2002, P NATL ACAD SCI USA, V99, P14362, DOI 10.1073/pnas.222536599; Warford J, 2014, BIOCHEM BIOPH RES CO, V443, P524, DOI 10.1016/j.bbrc.2013.11.119; Warford JR, 2018, ACTA NEUROPATHOL COM, V6, DOI 10.1186/s40478-017-0506-9; Wight TN, 2017, MATRIX BIOL, V60-61, P38, DOI 10.1016/j.matbio.2016.12.001; Winberg JO, 2003, EUR J BIOCHEM, V270, P3996, DOI 10.1046/j.1432-1033.2003.03788.x; Wu YJ, 2002, J BIOL CHEM, V277, P12294, DOI 10.1074/jbc.M110748200; Yang R, 2002, SCAND J IMMUNOL, V55, P2, DOI 10.1046/j.0300-9475.2001.01033.x; Yong V. W., 2001, METALLOPROTEINASES B; Zhang WX, 2015, CARBOHYD POLYM, V123, P331, DOI 10.1016/j.carbpol.2015.01.059; Zheng PS, 2004, J CELL SCI, V117, P5887, DOI 10.1242/jcs.01516; Zhou JH, 2010, J NEUROIMMUNOL, V223, P55, DOI 10.1016/j.jneuroim.2010.04.002; ZIMMERMANN DR, 1989, EMBO J, V8, P2975, DOI 10.1002/j.1460-2075.1989.tb08447.x	97	22	23	3	33	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0945-053X	1569-1802		MATRIX BIOL	Matrix Biol.	OCT	2018	71-72				SI		432	442		10.1016/j.matbio.2018.04.010			11	Biochemistry & Molecular Biology; Cell Biology	Biochemistry & Molecular Biology; Cell Biology	GW6ZH	WOS:000447113100030	29702175				2021-06-18	
J	Xia, YG; Pu, HJ; Leak, RK; Shi, YJ; Mu, HF; Hu, XM; Lu, ZY; Foley, LM; Hitchens, TK; Dixon, CE; Bennett, MVL; Chen, J				Xia, Yuguo; Pu, Hongjian; Leak, Rehana K.; Shi, Yejie; Mu, Hongfeng; Hu, Xiaoming; Lu, Zhengyu; Foley, Lesley M.; Hitchens, T. Kevin; Dixon, C. Edward; Bennett, Michael V. L.; Chen, Jun			Tissue plasminogen activator promotes white matter integrity and functional recovery in a murine model of traumatic brain injury	PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA			English	Article						white matter; head injury; trauma; contusion; alteplase	CHONDROITIN SULFATE PROTEOGLYCAN; CENTRAL-NERVOUS-SYSTEM; PREVENTS IMPAIRMENT; CEREBRAL AUTOREGULATION; THERAPEUTIC STRATEGIES; ENDOGENOUS TPA; AXONAL INJURY; STROKE; INTRANASAL; MICE	Recombinant tissue plasminogen activator (tPA) is a Food and Drug Administration-approved thrombolytic treatment for ischemic stroke. tPA is also naturally expressed in glial and neuronal cells of the brain, where it promotes axon outgrowth and synaptic plasticity. However, there are conflicting reports of harmful versus neuroprotective effects of tPA in acute brain injury models. Furthermore, its impact on white matter integrity in preclinical traumatic brain injury (TBI) has not been thoroughly explored, although white matter disruption is a better predictor of long-term clinical outcomes than focal lesion volumes. Here we show that the absence of endogenous tPA in knockout mice impedes long-term recovery of white matter and neurological function after TBI. tPA-knockout mice exhibited greater asymmetries in forepaw use, poorer sensorimotor balance and coordination, and inferior spatial learning and memory up to 35 d after TBI. White matter damage was also more prominent in tPA knockouts, as shown by diffusion tensor imaging, histological criteria, and electrophysiological assessments of axon conduction properties. Replenishment of tPA through intranasal application of the recombinant protein in tPA-knockout mice enhanced neurological function, the structural and functional integrity of white matter, and postinjury compensatory sprouting in corticofugal projections. tPA also promoted neurite outgrowth in vitro, partly through the epidermal growth factor receptor. Both endogenous and exogenous tPA protected against white matter injury after TBI without increasing intracerebral hemorrhage volumes. These results unveil a previously unappreciated role for tPA in the protection and/or repair of white matter and long-term functional recovery after TBI.	[Xia, Yuguo; Pu, Hongjian; Shi, Yejie; Mu, Hongfeng; Hu, Xiaoming; Lu, Zhengyu; Chen, Jun] Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA; [Xia, Yuguo; Pu, Hongjian; Shi, Yejie; Mu, Hongfeng; Hu, Xiaoming; Lu, Zhengyu; Chen, Jun] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Leak, Rehana K.] Duquesne Univ, Sch Pharm, Grad Sch Pharmaceut Sci, Pittsburgh, PA 15282 USA; [Hu, Xiaoming; Dixon, C. Edward; Chen, Jun] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA; [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, Anim Imaging Ctr, Pittsburgh, PA 15203 USA; [Dixon, C. Edward] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Bennett, Michael V. L.] Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA	Chen, J (corresponding author), Univ Pittsburgh, Pittsburgh Inst Brain Disorders & Recovery, Pittsburgh, PA 15213 USA.; Chen, J (corresponding author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Chen, J (corresponding author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15261 USA.; Bennett, MVL (corresponding author), Albert Einstein Coll Med, Dominick P Purpura Dept Neurosci, Bronx, NY 10461 USA.	michael.bennett@einstein.yu.edu; chenj2@upmc.edu	Pu, Hongjian/AAW-3322-2020; Shi, Yejie/C-2355-2018; Leak, Rehana K/I-2607-2019	Shi, Yejie/0000-0001-7502-9201; Leak, Rehana K/0000-0003-2817-7417	NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS095029, NS108695]; US Department of Veterans Affairs (VA) Merit ReviewUS Department of Veterans Affairs [BX003377]; VA Senior Research Career Scientist Award; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS108695, R01NS095029] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01BX003377] Funding Source: NIH RePORTER	We thank Carol Culver for editorial assistance and Patricia Strickler for administrative support. This project was supported by NIH Grants NS095029 and NS108695 (to M.V.L.B. and J.C.), and US Department of Veterans Affairs (VA) Merit Review BX003377 (to J.C.). J.C. is the Richard King Mellon Professor of Neurology and a recipient of a VA Senior Research Career Scientist Award. M.V.L.B. is the Sylvia and Robert S. Olnick Professor of Neuroscience.	Adibhatla RM, 2008, CNS NEUROL DISORD-DR, V7, P243, DOI 10.2174/187152708784936608; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Armstead WM, 2018, J NEUROSCI RES, V96, P128, DOI 10.1002/jnr.24112; Armstead WM, 2016, STROKE, V47, P2096, DOI 10.1161/STROKEAHA.116.012678; Armstead WM, 2013, J NEUROTRAUM, V30, P1898, DOI 10.1089/neu.2013.2962; Armstead WM, 2012, J NEUROTRAUM, V29, P1794, DOI 10.1089/neu.2012.2328; Armstrong RC, 2016, NEUROPHARMACOLOGY, V110, P654, DOI 10.1016/j.neuropharm.2015.04.029; BABHAIR SA, 1990, RES COMMUN CHEM PATH, V67, P241; Bertrand T, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.296; Bigler ED, 2001, ARCH CLIN NEUROPSYCH, V16, P95; Brown AW, 2011, J NEUROTRAUM, V28, P167, DOI 10.1089/neu.2010.1400; Chevilley A, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00415; Christrup LL, 2008, CLIN THER, V30, P469, DOI 10.1016/j.clinthera.2008.03.001; Correa F, 2011, J EXP MED, V208, P1229, DOI 10.1084/jem.20101880; Crumrine R Christian, 2011, Exp Transl Stroke Med, V3, P10, DOI 10.1186/2040-7378-3-10; Dhuria SV, 2010, J PHARM SCI-US, V99, P1654, DOI 10.1002/jps.21924; Echeverry R, 2010, J CLIN INVEST, V120, P2194, DOI 10.1172/JCI41722; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Gravanis I, 2008, EXPERT OPIN THER TAR, V12, P159, DOI 10.1517/14728222.12.2.159 ; Hacke W, 2008, NEW ENGL J MED, V359, P1317, DOI 10.1056/NEJMoa0804656; Haile WB, 2012, J CEREBR BLOOD F MET, V32, P57, DOI 10.1038/jcbfm.2011.106; Hanson LR, 2008, BMC NEUROSCI, V9, DOI 10.1186/1471-2202-9-S3-S5; Harris NG, 2009, J NEUROSCI RES, V87, P2937, DOI 10.1002/jnr.22115; Hijazi N, 2015, BLOOD, V125, P2558, DOI 10.1182/blood-2014-08-588442; Huang YY, 1996, P NATL ACAD SCI USA, V93, P8699, DOI 10.1073/pnas.93.16.8699; Hynds DL, 1999, EXP NEUROL, V160, P244, DOI 10.1006/exnr.1999.7212; Kaur J, 2004, J CEREBR BLOOD F MET, V24, P945, DOI 10.1097/01.WCB.0000137868.50767.E8; Kim YH, 1999, SCIENCE, V284, P647, DOI 10.1126/science.284.5414.647; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kozlovskaya L, 2014, J CONTROL RELEASE, V189, P133, DOI 10.1016/j.jconrel.2014.06.053; KRYSTOSEK A, 1981, SCIENCE, V213, P1532, DOI 10.1126/science.7197054; Lee TW, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00396; Lemarchand E, 2016, CELL DEATH DIFFER, V23, P123, DOI 10.1038/cdd.2015.76; Leonetti C, 2017, MOL NEURODEGENER, V12, DOI 10.1186/s13024-017-0160-5; Li LJ, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0165637; Liot G, 2006, J NEUROCHEM, V98, P1458, DOI 10.1111/j.1471-4159.2006.03982.x; Liu ZW, 2012, NEUROBIOL DIS, V45, P804, DOI 10.1016/j.nbd.2011.11.004; Loane DJ, 2010, TRENDS PHARMACOL SCI, V31, P596, DOI 10.1016/j.tips.2010.09.005; Mao LL, 2017, BRAIN, V140, P1914, DOI 10.1093/brain/awx111; Meng YL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0106238; Mesulam MM, 1998, BRAIN, V121, P1013, DOI 10.1093/brain/121.6.1013; Minor K, 2009, J NEUROCHEM, V109, P706, DOI 10.1111/j.1471-4159.2009.05977.x; National Research Council, 2011, GUIDE CARE USE LAB A; Nusbaum F, 2017, FRONT NEUROSCI-SWITZ, V11, DOI 10.3389/fnins.2017.00173; Papadopoulos CM, 2002, ANN NEUROL, V51, P433, DOI 10.1002/ana.10144; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Seeds NW, 2003, J NEUROSCI, V23, P7368; Shen LH, 2011, STROKE, V42, P459, DOI 10.1161/STROKEAHA.110.593863; Sidaros A, 2008, BRAIN, V131, P559, DOI 10.1093/brain/awm294; Stein SC, 2009, J NEUROTRAUM, V26, P1585, DOI [10.1089/neu.2008.0720, 10.1089/neu.2008-0720]; Thorne RG, 2004, NEUROSCIENCE, V127, P481, DOI 10.1016/j.neuroscience.2004.05.029; Tomkins AJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16026; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Tsirka SE, 2002, BIOCHEM SOC T, V30, P222, DOI 10.1042/bst0300222; VERSTRAETE M, 1985, J PHARMACOL EXP THER, V235, P506; Wang GH, 2015, P NATL ACAD SCI USA, V112, P2853, DOI 10.1073/pnas.1501441112; Yepes M, 2004, EXP BIOL MED, V229, P1097; Yi JH, 2012, J COMP NEUROL, V520, P3295, DOI 10.1002/cne.23156; Zou T, 2006, J NEUROPATH EXP NEUR, V65, P78, DOI 10.1097/01.jnen.0000195942.25163.f5	59	22	22	0	9	NATL ACAD SCIENCES	WASHINGTON	2101 CONSTITUTION AVE NW, WASHINGTON, DC 20418 USA	0027-8424			P NATL ACAD SCI USA	Proc. Natl. Acad. Sci. U. S. A.	SEP 25	2018	115	39					E9230	E9238		10.1073/pnas.1810693115			9	Multidisciplinary Sciences	Science & Technology - Other Topics	GU7XK	WOS:000445545200024	30201709	Green Published, Bronze			2021-06-18	
J	Hess, ER; Homme, JL; Kharbanda, AB; Tzimenatos, L; Louie, JP; Cohen, DM; Nigrovic, LE; Westphal, JJ; Shah, ND; Inselman, J; Ferrara, MJ; Herrin, J; Montori, VM; Kupperrnann, N				Hess, Erik R.; Homme, James L.; Kharbanda, Anupam B.; Tzimenatos, Leah; Louie, Jeffrey P.; Cohen, Daniel M.; Nigrovic, Lise E.; Westphal, Jessica J.; Shah, Nilay D.; Inselman, Jonathan; Ferrara, Michael J.; Herrin, Jeph; Montori, Victor M.; Kupperrnann, Nathan			Effect of the Head Computed Tomography Choice Decision Aid in Parents of Children With Minor Head Trauma A Cluster Randomized Trial	JAMA NETWORK OPEN			English	Article							PHYSICIAN; NUMERACY; TRUST	IMPORTANCE The Pediatric Emergency Care Applied Research Network prediction rules for minor head trauma identify children at very low, intermediate, and high risk of clinically important traumatic brain injuries (ciTBIs) and recommend no computed tomography (CT) for those at very low risk. However, the prediction rules provide little guidance in the choice of home observation or CT in children at intermediate risk for ciTBI. OBJECTIVE To compare a decision aid with usual care in parents of children at intermediate risk for ciTBI. DESIGN, SETTINGS, AND PARTICIPANTS This cluster randomized trial was conducted in 7 geographically diverse US emergency departments (EDs) from April 1, 2014, to September 30, 2016. Eligible participants were emergency clinicians, children ages 2 to 18 years with minor head trauma at intermediate risk for ciTBI, and their parents. INTERVENTIONS Clinicians were randomly assigned (1:1ratio) to shared decision-making facilitated by the Head CT Choice decision aid or to usual care. MAIN OUTCOMES AND MEASURES The primary outcome, selected by parent stakeholders, was knowledge of their child's risk for ciTBI and the available diagnostic options. Secondary outcomes included decisional conflict, parental involvement in decision-making, the ED CT rate, 7-day health care utilization, and missed ciTBI. RESULTS A total of 172 clinicians caring for 971 children (493 decision aid; 478 usual care) with minor head trauma at intermediate risk for ciTBI were enrolled. The patient mean (SD) age was 6.7 (7.1) years, 575 (59%) were male, and 253 (26%) were of nonwhite race. Parents in the decision aid arm compared with the usual care arm had greater knowledge (mean [SD] questions correct: 6.2 [2.0] vs 5.3 [2.0]; mean difference, 0.9; 95% CI, 0.6-1.3), had less decisional conflict (mean [SD] decisional conflict score, 14.8 [15.5] vs 19.2 [16.6]; mean difference, -4.4; 95% CI, -7.3 to -2.4), and were more involved in CT decision-making (observing patient involvement [OPTION] scores: mean [SD], 25.0 [8.5] vs 13.3 [6.5]; mean difference, 11.7; 95% CI, 9.6-13.9). Although the ED CT rate did not significantly differ (decision aid, 22% vs usual care, 24%; odds ratio, 0.81; 95% CI, 0.51-1.27), the mean number of imaging tests was lower in the decision aid arm 7 days after injury. No child had a missed ciTBI. CONCLUSIONS AND RELEVANCE Use of a decision aid in parents of children at intermediate risk of ciTBI increased parent knowledge, decreased decisional conflict, and increased involvement in decision-making. The intervention did not significantly reduce the ED CT rate but safely decreased health care utilization 7 days after injury.	[Hess, Erik R.] Univ Alabama Birmingham, Dept Emergency Med, 619 19th St S, Birmingham, AL 35249 USA; [Hess, Erik R.; Ferrara, Michael J.] Mayo Clin, Dept Emergency Med, Coll Med, Rochester, MN USA; [Hess, Erik R.; Montori, Victor M.] Mayo Clin, Knowledge & Evaluat Res Unit, Coll Med, Rochester, MN USA; [Homme, James L.] Mayo Clin, Div Pediat Emergency Med, Dept Emergency Med, Rochester, MN USA; [Homme, James L.] Mayo Clin, Dept Pediat, Div Pediat Emergency Med, Rochester, MN USA; [Kharbanda, Anupam B.; Kupperrnann, Nathan] Childrens Hosp & Clin Minnesota, Dept Pediat Emergency Med, Minneapolis, MN USA; [Tzimenatos, Leah] Univ Calif Davis Hlth, Sacramento, CA USA; [Louie, Jeffrey P.] Univ Minnesota, Dept Pediat, Div Emergency Med, Minneapolis, MN 55455 USA; [Cohen, Daniel M.] Nationwide Childrens Hosp, Div Emergency Med, Columbus, OH USA; [Nigrovic, Lise E.] Boston Childrens Hosp, Div Emergency Med, Boston, MA USA; [Shah, Nilay D.] Mayo Clin, Dept Hlth Sci Res, Div Hlth Care Policy & Res, Coll Med, Rochester, MN USA; [Shah, Nilay D.; Inselman, Jonathan] Mayo Clin, Robert D & Patricia E Kern Ctr Sci Healthcare Del, Rochester, MN USA; [Ferrara, Michael J.] Mayo Clin, Dept Surg, Coll Med, Div Trauma Crit Care & Gen Surg, Rochester, MN USA; [Herrin, Jeph] Yale Univ, Sch Med, New Haven, CT USA; [Kupperrnann, Nathan] Univ Calif Davis, Sch Med, Dept Pediat, Sacramento, CA 95817 USA	Hess, ER (corresponding author), Univ Alabama Birmingham, Dept Emergency Med, 619 19th St S, Birmingham, AL 35249 USA.	ehess@uabmc.edu			Patient-Centered Outcomes Research Institute AwardPatient-Centered Outcomes Research Institute - PCORI [12-11-4435]	This study was funded from contract 12-11-4435 through a Patient-Centered Outcomes Research Institute Award.	Allen Donner, 2000, DESIGN ANAL CLUSTER; Atabaki SM, 2016, ACAD EMERG MED, V23, P566, DOI 10.1111/acem.12923; Coyne I, 2016, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008970.pub3; Elwyn G, 2005, HEALTH EXPECT, V8, P34, DOI 10.1111/j.1369-7625.2004.00311.x; Fagerlin A, 2007, MED DECIS MAKING, V27, P672, DOI 10.1177/0272989x07304449; Faul M, 2010, TRAUMATIC BRAIN INJU, DOI [10.15620/cdc.55710272989X07304449, DOI 10.15620/CDC.55710272989X07304449]; Hess EP, 2016, BMJ-BRIT MED J, V355, DOI 10.1136/bmj.i6165; Hess EP, 2014, TRIALS, V15, DOI 10.1186/1745-6215-15-253; Hess EP, 2012, CIRC-CARDIOVASC QUAL, V5, P251, DOI 10.1161/CIRCOUTCOMES.111.964791; Karanicolas PJ, 2009, J CLIN EPIDEMIOL, V62, P479, DOI 10.1016/j.jclinepi.2008.02.009; Kuppermann N, 2009, LANCET, V374, P1160, DOI 10.1016/S0140-6736(09)61558-0; LeBlanc A, 2015, JAMA INTERN MED, V175, P1761, DOI 10.1001/jamainternmed.2015.5214; LeBlanc A, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0128063; McNaughton C, 2011, ACAD EMERG MED, V18, P1148, DOI 10.1111/j.1553-2712.2011.01210.x; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Moseley KL, 2006, AMBUL PEDIATR, V6, P58, DOI 10.1016/j.ambp.2005.08.001; OCONNOR AM, 1995, MED DECIS MAKING, V15, P25, DOI 10.1177/0272989X9501500105; Quayle KS, 2014, NEW ENGL J MED, V371, P1945, DOI 10.1056/NEJMc1407902; Schulz KF, 2010, ANN INTERN MED, V152, P726, DOI 10.7326/0003-4819-152-11-201006010-00232; Stacey D, 2011, COCHRANE DB SYST REV, DOI [10.1002/14651858.CD001431.pub2, 10.1002/14651858.CD001431.pub3, 10.1002/14651858.CD001431.pub4]; Thom DH, 2002, FAM PRACT, V19, P476, DOI 10.1093/fampra/19.5.476	21	22	22	1	5	AMER MEDICAL ASSOC	CHICAGO	330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA	2574-3805			JAMA NETW OPEN	JAMA Netw. Open	SEP	2018	1	5							e182430	10.1001/jamanetworkopen.2018.2430			13	Medicine, General & Internal	General & Internal Medicine	HD6JU	WOS:000452645200010	30646167	DOAJ Gold, Green Published			2021-06-18	
J	Zhu, W; Ding, YX; Kong, W; Li, T; Chen, HG				Zhu, Wei; Ding, Yuexia; Kong, Wei; Li, Tuo; Chen, Hongguang			Docosahexaenoic Acid (DHA) Provides Neuroprotection in Traumatic Brain Injury Models via Activating Nrf2-ARE Signaling	INFLAMMATION			English	Article						traumatic brain injury; Nrf2/ARE pathway; docosahexaenoic acid (DHA); immunofluorescence	CLOSED-HEAD INJURY; HUMAN CANCER-CELLS; OXIDATIVE STRESS; ANTIOXIDANT RESPONSE; HIPPOCAMPAL; EXPRESSION; APOPTOSIS; AUTOPHAGY; DEFENSE; PATHWAY	In this study, we explored the neuroprotective effects of docosahexaenoic acid (DHA) in traumatic brain injury (TBI) models. In this study, we first confirmed that DHA was neuroprotective against TBI via the NSS test and Morris water maze experiment. Western blot was conducted to identify the expression of Bax, caspase-3, and Bcl-2. And the cell apoptosis of the TBI models was validated by TUNEL staining. Relationships between nuclear factor erythroid 2-related factor 2-antioxidant response element (Nrf2-ARE) pathway-related genes and DHA were explored by RT-PCR and Western blot. Rats of the DHA group performed remarkably better than those of the TBI group in both NSS test and water maze experiment. DHA conspicuously promoted the expression of Bcl-2 and diminished that of cleaved caspase-3 and Bax, indicating the anti-apoptotic role of DHA. Superoxide dismutase (SOD) activity and cortical malondialdehyde content, glutathione peroxidase (GPx) activity were renovated in rats receiving DHA treatment, implying that the neuroprotective influence of DHA was derived from lightening the oxidative stress caused by TBI. Moreover, immunofluorescence and Western blot experiments revealed that DHA facilitated the translocation of Nrf2 to the nucleus. DHA administration also notably increased the expression of the downstream factors NAD(P)H:quinone oxidoreductase (NQO-1) and heme oxygenase 1(HO-1). DHA exerted neuroprotective influence on the TBI models, potentially through activating the Nrf2- ARE pathway.	[Zhu, Wei; Kong, Wei; Li, Tuo; Chen, Hongguang] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, 20 East Yuhuangding Rd, Yantai 264000, Shandong, Peoples R China; [Ding, Yuexia] Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Pharm, Yantai 264000, Shandong, Peoples R China	Zhu, W (corresponding author), Qingdao Univ, Affiliated Yantai Yuhuangding Hosp, Dept Neurosurg, 20 East Yuhuangding Rd, Yantai 264000, Shandong, Peoples R China.	weilifengshike@163.com					Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; BANG HY, 2017, MOLECULES, V22, DOI DOI 10.3390/M0LECULES22060969; Brooks JC, 2013, ARCH PHYS MED REHAB, V94, P2203, DOI 10.1016/j.apmr.2013.07.005; Casanas-Sanchez Veronica, 2015, Front Physiol, V6, P203, DOI 10.3389/fphys.2015.00203; Casanas-Sanchez V, 2014, J NEUROCHEM, V131, P470, DOI 10.1111/jnc.12833; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; De Smedt-Peyrusse V, 2008, J NEUROCHEM, V105, P296, DOI 10.1111/j.1471-4159.2007.05129.x; Ding K, 2014, FREE RADICAL BIO MED, V73, P1, DOI 10.1016/j.freeradbiomed.2014.04.031; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gu Y, 2015, NEUROSCIENCE, V291, P331, DOI 10.1016/j.neuroscience.2014.09.073; Huang HC, 2002, J BIOL CHEM, V277, P42769, DOI 10.1074/jbc.M206911200; Jing K, 2011, AUTOPHAGY, V7, P1348, DOI 10.4161/auto.7.11.16658; Kang KS, 2010, PLOS ONE, V5, DOI 10.1371/journal.pone.0010296; Lee JM, 2004, J BIOCHEM MOL BIOL, V37, P139; Li LL, 2015, CELL MOL NEUROBIOL, V35, P615, DOI 10.1007/s10571-015-0166-x; Liu ZW, 2017, NEUROCHEM RES, V42, P1375, DOI 10.1007/s11064-017-2186-z; Ou WJ, 2017, FREE RADICAL BIO MED, V112, P597, DOI 10.1016/j.freeradbiomed.2017.09.002; Ovey IS, 2015, NEUROSCIENCE, V284, P225, DOI 10.1016/j.neuroscience.2014.09.078; Riz I, 2016, ONCOTARGET, V7, P66360, DOI 10.18632/oncotarget.11960; Saw CLL, 2013, FOOD CHEM TOXICOL, V62, P869, DOI 10.1016/j.fct.2013.10.023; Smith JA, 2013, NEUROCHEM INT, V62, P764, DOI 10.1016/j.neuint.2013.02.013; Song JH, 2000, J NUTR, V130, P3028; Stephenson JA, 2013, J LIPIDS, V2013, DOI 10.1155/2013/261247; Villeneuve NF, 2010, ANTIOXID REDOX SIGN, V13, P1699, DOI 10.1089/ars.2010.3211; Wang S, 2014, J NUTR BIOCHEM, V25, P515, DOI 10.1016/j.jnutbio.2013.12.011; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu AG, 2011, J NEUROTRAUM, V28, P2113, DOI 10.1089/neu.2011.1872; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang YQ, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00580; Zgorzynska E, 2017, PHARMACOL REP, V69, P935, DOI 10.1016/j.pharep.2017.04.009; Zhang L, 2017, SCI REP-UK, V7, DOI 10.1038/srep46763	33	22	22	0	11	SPRINGER/PLENUM PUBLISHERS	NEW YORK	233 SPRING ST, NEW YORK, NY 10013 USA	0360-3997	1573-2576		INFLAMMATION	Inflammation	AUG	2018	41	4					1182	1193		10.1007/s10753-018-0765-z			12	Cell Biology; Immunology	Cell Biology; Immunology	GO1PO	WOS:000439725900007	29663102				2021-06-18	
J	Howell, DR; Osternig, LR; Chou, LS				Howell, David R.; Osternig, Louis R.; Chou, Li-Shan			Detection of Acute and Long-Term Effects of Concussion: Dual-Task Gait Balance Control Versus Computerized Neurocognitive Test	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Attention; Concussion; Locomotion; Postual balance; Rehabilitation	SPORTS-RELATED CONCUSSION; MANAGEMENT PRACTICE PATTERNS; TRAUMATIC BRAIN-INJURY; POSTURAL CONTROL; YOUNG-ADULTS; SINGLE-TASK; HIGH-SCHOOL; RECOVERY; ADOLESCENTS; PERFORMANCE	Objective: To examine the acute (within 72h of injury) and long-term (2mo postinjury) independent associations between objective dual-task gait balance and neurocognitive measurements among adolescents and young adults with a concussion and matched controls. Design: Longitudinal case-control. Setting: Motion analysis laboratory. Participants: A total of 95 participants completed the study: 51 who sustained a concussion (mean age, 17.5 +/- 3.3y; 71% men) and 44 controls (mean age, 17.7 +/- 2.9y; 72% men). Participants who sustained a concussion underwent a dual-task gait analysis and computerized neurocognitive testing within 72 hours of injury and again 2 months later. Uninjured controls also completed the same test protocol in similar time increments. Interventions: Not applicable. Main Outcome Measures: We compared dual-task gait balance control and computerized neurocognitive test performance between groups using independent samples t tests. Multivariable binary logistic regression models were then constructed for each testing time to determine the association between group membership (concussion vs control), dual-task gait balance control, and neurocognitive function. Results: Medial-lateral center-of-mass displacement during dual-task gait was independently associated with group membership at the initial test (adjusted odds ratio [aOR], 2.432; 95% confidence interval [CI], 1.269-4.661) and 2-month follow-up test (aOR, 1.817; 95% CI, 1.014-3.256) tests, Visual memory composite scores were significantly associated with group membership at the initial hour postinjury time point (aOR,.953; 95% CI,.833.998). However, the combination of computerized neurocognitive test variables did not predict dual-task gait balance control for participants with concussion, and no single neurocognitive variable was associated with dual-task gait balance control at either testing time. Conclusions: Dual-task assessments concurrently evaluating gait and cognitive performance may allow for the detection of persistent deficits beyond those detected by computerized neurocognitive deficits alone. (C) 2018 by the American Congress of Rehabilitation Medicine	[Howell, David R.] Childrens Hosp Colorado, Ctr Sports Med, Aurora, CO USA; [Howell, David R.] Univ Colorado, Sch Med, Dept Orthoped, Aurora, CO USA; [Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Osternig, Louis R.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, Eugene, OR 97403 USA	Chou, LS (corresponding author), Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu		Chou, Li-Shan/0000-0002-2777-7034; Howell, David/0000-0002-2955-0191	Department of Defense TATRC Award [W81XWH-11-1-0717]; Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	Supported by the Department of Defense TATRC Award (award no. W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology.	Baker CS, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12252; Baugh CM, 2016, AM J SPORT MED, V44, P1391, DOI 10.1177/0363546516635639; Beauchet Olivier, 2006, Psychol Neuropsychiatr Vieil, V4, P215; Benedict PA, 2015, J NEUROL SCI, V353, P111, DOI 10.1016/j.jns.2015.04.029; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Cross M, 2016, BRIT J SPORT MED, V50, P926, DOI 10.1136/bjsports-2015-094982; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Guskiewicz KM, 2011, PM&R, V3, pS445, DOI 10.1016/j.pmrj.2011.08.009; Halterman CI, 2006, BRAIN, V129, P747, DOI 10.1093/brain/awh705; Howel DR, 2017, J APPL BIOMECH, V33, P24, DOI 10.1123/jab.2015-0323; Howell D, 2015, J BIOMECH, V48, P3364, DOI 10.1016/j.jbiomech.2015.06.014; Howell DR, 2018, J SCI MED SPORT, V21, P358, DOI 10.1016/j.jsams.2017.08.004; Howell DR, 2017, J SCI MED SPORT, V20, P622, DOI 10.1016/j.jsams.2016.11.020; Howell DR, 2017, GAIT POSTURE, V54, P284, DOI 10.1016/j.gaitpost.2017.03.034; Howell DR, 2017, J NEUROTRAUM, V34, P838, DOI 10.1089/neu.2016.4609; Howell DR, 2016, GAIT POSTURE, V49, P176, DOI 10.1016/j.gaitpost.2016.07.008; Howell DR, 2016, J HEAD TRAUMA REHAB, V31, P262, DOI 10.1097/HTR.0000000000000176; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2005, J CLIN EXP NEUROPSYC, V27, P683, DOI 10.1081/13803390490918435; Iverson GL, 2004, ARCH CLIN NEUROPSYCH, V19, P961; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Iverson G, 2007, CLIN J SPORT MED, V17, P31; Kelly KC, 2014, J ATHL TRAINING, V49, P665, DOI 10.4085/1062-6050-49.3.25; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Manaseer T. S., 2017, CLIN J SPORT MED; McClincy MP, 2006, BRAIN INJURY, V20, P33, DOI 10.1080/02699050500309817; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Meehan WP, 2012, PEDIATRICS, V129, P38, DOI 10.1542/peds.2011-1972; Moser RS, 2007, ARCH CLIN NEUROPSYCH, V22, P909, DOI 10.1016/j.acn.2007.09.004; Nelson LD, 2016, J INT NEUROPSYCH SOC, V22, P24, DOI 10.1017/S1355617715001101; Oldham JR, 2016, GAIT POSTURE, V49, P437, DOI 10.1016/j.gaitpost.2016.07.327; Parker TM, 2007, BRIT J SPORT MED, V41, P868, DOI 10.1136/bjsm.2006.033761; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Sambasivan K, 2015, J PEDIATR REHAB MED, V8, P335, DOI 10.3233/PRM-150351; Shumway-Cook A, 2000, J GERONTOL A-BIOL, V55, pM10; Stache S, 2016, CLIN J SPORT MED, V26, P381, DOI 10.1097/JSM.0000000000000270; SUTHERLAND DH, 1980, J BONE JOINT SURG AM, V62, P336, DOI 10.2106/00004623-198062030-00004; Toledo E, 2012, NEUROSCI BIOBEHAV R, V36, P1510, DOI 10.1016/j.neubiorev.2012.03.007; Vos PE, 2010, NEUROLOGY, V75, P1786, DOI 10.1212/WNL.0b013e3181fd62d2	48	22	22	1	12	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	JUL	2018	99	7					1318	1324		10.1016/j.apmr.2018.01.025			7	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	GL9JZ	WOS:000437552100009	29457997				2021-06-18	
J	Kerr, ZY; Thomas, LC; Simon, JE; McCrea, M; Guskiewicz, KM				Kerr, Zachary Y.; Thomas, Leah C.; Simon, Janet E.; McCrea, Michael; Guskiewicz, Kevin M.			Association Between History of Multiple Concussions and Health Outcomes Among Former College Football Players 15-Year Follow-up From the NCAA Concussion Study (1999-2001)	AMERICAN JOURNAL OF SPORTS MEDICINE			English	Article						epidemiology; college sports; traumatic brain injury; health-related quality of life	QUALITY-OF-LIFE; STATES HIGH-SCHOOL; RECURRENT CONCUSSION; COGNITIVE IMPAIRMENT; DEPRESSION; PATIENT; SPORTS; RISK; COMORBIDITIES; QUESTIONNAIRE	Background: Previous research has examined associations between concussion history and adverse health outcomes among former professional football players. Less is known about the potential effects of concussion among former college football players without additional exposure at the professional level. Purpose: To examine the association between concussion and adverse health outcomes in a cohort of former college football players without exposure to professional football, 15 years after their playing careers ended. Study Design: Cross-sectional study; Level of evidence, 3. Methods: A sample of 204 former collegiate football players (23.4% of eligible athletes with available contact information)all of whom played at least 1 season of football from 1999 to 2001 in the National Collegiate Athletic Association (NCAA) and had no professional football exposurecompleted a general health survey that assessed lifetime concussion history and included the following: the Veterans RAND 36 Item Health Survey, containing a physical composite score (PCS) and mental composite score (MCS); the depression module of the Patient Health Questionnaire; and the 4-item CAGE alcohol dependence questionnaire (for cutting down, annoyance by criticism, guilty feeling, and eye-openers). Multivariable binomial regression models estimated adjusted prevalence ratios (PRs) with 95% CIs while controlling for demographics and playing history covariates through forward selection model building. Results: Most participants reported a concussion history (84.3%). Overall, 22.1% and 39.2% of participants reported a PCS and an MCS <50, respectively (indicating worse health than the US national average); 19.1% reported Patient Health Questionnaire scores >= 10 (indicating moderate/severe depression); and 24.8% reported CAGE scores >= 2 (indicating alcohol dependence). The prevalence of having an MCS <50 was higher among those reporting >= 3 versus 0 concussions (PR, 2.5; 95% CI, 1.3-4.9). Controlling for body mass index (BMI), the prevalence of moderate/severe depression was higher among those reporting >= 3 versus 0 concussions (PR, 4.2; 95% CI, 1.0-16.3). Controlling for BMI, the prevalence of having a PCS <50 was higher among those reporting 3 versus 1 or 2 concussions (PR, 2.6; 95% CI, 1.3-5.0) but not 0 concussions (PR, 1.5; 95% CI, 0.6-3.6). No associations were found for alcohol dependence. Conclusion: Associations between a history of multiple concussions and adverse health outcomes were found among former collegiate football players without professional football exposure but were limited to those reporting >= 3 prior concussions. Because only 23.4% of eligible athletes responded to the survey, the possibility of ascertainment bias exists, and our findings should thus be interpreted with some caution. Continued examination within nonprofessional football populations is needed, but findings highlight the need for prevention efforts to reduce concussion incidence.	[Kerr, Zachary Y.; Thomas, Leah C.; Simon, Janet E.; McCrea, Michael; Guskiewicz, Kevin M.] Univ N Carolina, Chapel Hill, NC 27515 USA; [Kerr, Zachary Y.; Thomas, Leah C.; Guskiewicz, Kevin M.] Univ N Carolina, Dept Exercise & Sport Sci, Campus Box 8700, Chapel Hill, NC 27599 USA; [Kerr, Zachary Y.; Thomas, Leah C.; Guskiewicz, Kevin M.] Univ N Carolina, Matthew Gfeller Sport Related Traumat Brain Injur, Chapel Hill, NC 27515 USA; [Kerr, Zachary Y.; Thomas, Leah C.; Guskiewicz, Kevin M.] Univ N Carolina, Ctr Study Retired Athletes, Chapel Hill, NC 27515 USA; [Simon, Janet E.] Ohio Univ, Sch Appl Hlth & Wellness, Div Athlet Training, Athens, OH 45701 USA; [McCrea, Michael] Med Coll Wisconsin, Dept Neurosurg, Milwaukee, WI 53226 USA	Guskiewicz, KM (corresponding author), Univ N Carolina, Dept Exercise & Sport Sci, Campus Box 8700, Chapel Hill, NC 27599 USA.	gus@email.unc.edu			National Collegiate Athletic Association's Sport Science Institute	This research was funded in part by a grant from the National Collegiate Athletic Association's Sport Science Institute, in which K.M.G. and M.M. served as co-principal investigators.	Baugh CM, 2015, AM J SPORT MED, V43, P47, DOI 10.1177/0363546514553090; BERNADT MW, 1982, LANCET, V1, P325; Centers for Disease Control and Prevention (CDC), 2009, NAT HLTH NUTR EX SUR; COUNCIL SPORTS MED FITNESS, 2015, PEDIATRICS, V136, pE1419, DOI 10.1542/peds.2015-3282; Didehbani N, 2013, ARCH CLIN NEUROPSYCH, V28, P418, DOI 10.1093/arclin/act028; ESPN, 2011, IVY LEAG LIM FULL CO; ESPN, 2013, PAC 12 LIM CONT PRAC; EWING JA, 1984, JAMA-J AM MED ASSOC, V252, P1905, DOI 10.1001/jama.252.14.1905; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Green L., 2014, LEGAL PERSPECTIVES R; Greenland S, 2004, AM J EPIDEMIOL, V160, P301, DOI 10.1093/aje/kwh221; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Hair J.F., 1995, MULTIVARIATE DATA AN, V4th ed.; Harrell Frank E., 2001, REGRESSION MODELING; Hassan MK, 2003, INT J OBESITY, V27, P1227, DOI 10.1038/sj.ijo.0802396; JAESCHKE R, 1989, CONTROL CLIN TRIALS, V10, P407, DOI 10.1016/0197-2456(89)90005-6; Jones B., 2015, STATES ADOPT PLANS L; Kazis LE, 2006, J AMBUL CARE MANAG, V29, P310, DOI 10.1097/00004479-200610000-00007; Kazis Lewis E, 2004, J Ambul Care Manage, V27, P263; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115594578; Kerr ZY, 2015, ORTHOP J SPORTS MED, V3, DOI 10.1177/2325967115610545; Kerr ZY, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114544107; Kerr Zachary Y, 2014, Inj Epidemiol, V1, P28; Kerr ZY, 2012, AM J SPORT MED, V40, P2206, DOI 10.1177/0363546512456193; Kilcoyne KG, 2014, SPORTS HEALTH, V6, P402, DOI 10.1177/1941738113491545; KITCHENS JM, 1994, JAMA-J AM MED ASSOC, V272, P1782, DOI 10.1001/jama.272.22.1782; Kocalevent RD, 2013, GEN HOSP PSYCHIAT, V35, P551, DOI 10.1016/j.genhosppsych.2013.04.006; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Kroshus E, 2014, BRIT J SPORT MED, V48, P135, DOI 10.1136/bjsports-2013-092498; Lincoln AE, 2011, AM J SPORT MED, V39, P958, DOI 10.1177/0363546510392326; Lowe B, 2004, MED CARE, V42, P1194, DOI 10.1097/00005650-200412000-00006; Maddigan SL, 2005, QUAL LIFE RES, V14, P1311, DOI 10.1007/s11136-004-6640-4; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; Montenigro PH, 2017, J NEUROTRAUM, V34, P328, DOI 10.1089/neu.2016.4413; National Collegiate Athletic Association, 2014, 2014 15 SPORTS MED H; National Collegiate Athletic Association, 2014, FOOTB PRACT GUID; Smith AW, 2008, HEALTH CARE FINANC R, V29, P41; Spiegelman D, 2005, AM J EPIDEMIOL, V162, P199, DOI 10.1093/aje/kwi188; Stamm JM, 2015, NEUROLOGY, V84, P1114, DOI 10.1212/WNL.0000000000001358; Strand V, 2004, CLIN EXP RHEUMATOL, V22, pS57; Strand V, 2008, AM J MANAG CARE, V14, P239; Strand Vibeke, 2004, Curr Rheumatol Rep, V6, P20, DOI 10.1007/s11926-004-0080-6; Swallen KC, 2005, PEDIATRICS, V115, P340, DOI 10.1542/peds.2004-0678; Ware JE., 2001, SF 36 PHYS MENTAL HL, V2; Yan LJL, 2004, OBES RES, V12, P69, DOI 10.1038/oby.2004.10; Zou GY, 2004, AM J EPIDEMIOL, V159, P702, DOI 10.1093/aje/kwh090; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	50	22	22	2	15	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0363-5465	1552-3365		AM J SPORT MED	Am. J. Sports Med.	JUN	2018	46	7					1733	1741		10.1177/0363546518765121			9	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	GH7IJ	WOS:000433616400029	29620911				2021-06-18	
J	Gellerfors, M; Fevang, E; Backman, A; Kruger, A; Mikkelsen, S; Nurmi, J; Rognas, L; Sandstrom, E; Skallsjo, G; Svensen, C; Gryth, D; Lossius, HM				Gellerfors, M.; Fevang, E.; Backman, A.; Kruger, A.; Mikkelsen, S.; Nurmi, J.; Rognas, L.; Sandstrom, E.; Skallsjo, G.; Svensen, C.; Gryth, D.; Lossius, H. M.			Pre-hospital advanced airway management by anaesthetist and nurse anaesthetist critical care teams: a prospective observational study of 2028 pre-hospital tracheal intubations	BRITISH JOURNAL OF ANAESTHESIA			English	Article						airway management; emergency medical services; intubation; intratracheal	RAPID-SEQUENCE INTUBATION; TRAUMATIC BRAIN-INJURY; EMERGENCY MEDICAL-SERVICES; CLINICAL-PRACTICE; ADVERSE EVENTS; PHYSICIAN; MULTICENTER; HYPOTENSION; GUIDELINES; STATEMENT	Background: Pre-hospital tracheal intubation success and complication rates vary considerably among provider categories. The purpose of this study was to estimate the success and complication rates of pre-hospital tracheal intubation performed by physician anaesthetist or nurse anaesthetist pre-hospital critical care teams. Methods: Data were prospectively collected from critical care teams staffed with a physician anaesthetist or a nurse anaesthetist according to the Utstein template for pre-hospital advanced airway management. The patients served by six ambulance helicopters and six rapid response vehicles in Denmark, Finland, Norway, and Sweden from May 2015 to November 2016 were included. Results: The critical care teams attended to 32 007 patients; 2028 (6.3%) required pre-hospital tracheal intubation. The overall success rate of pre-hospital tracheal intubation was 98.7% with a median intubation time of 25 s and an on-scene time of 25 min. The majority (67.0%) of the patients' tracheas were intubated by providers who had performed >2500 tracheal intubations. The success rate of tracheal intubation on the first attempt was 84.5%, and 95.9% of intubations were completed after two attempts. Complications related to pre-hospital tracheal intubation were recorded in 10.9% of the patients. Intubations after rapid sequence induction had a higher success rate compared with intubations without rapid sequence induction (99.4% vs 98.1%; P=0.02). Physicians had a higher tracheal intubation success rate than nurses (99.0% vs 97.6%; P=0.03). Conclusions: When performed by experienced physician anaesthetists and nurse anaesthetists, pre-hospital tracheal intubation was completed rapidly with high success rates and a low incidence of complications.	[Gellerfors, M.; Svensen, C.] Karolinska Inst, Dept Clin Sci & Educ, Sect Anaesthesiol & Intens Care, Stockholm, Sweden; [Gellerfors, M.] Swedish Air Ambulance SLA, Mora, Sweden; [Gellerfors, M.; Svensen, C.] Soder Sjukhuset, Dept Anaesthesiol & Intens Care, Stockholm, Sweden; [Gellerfors, M.] Swedish Armed Forces, SAE Medevac Helicopter, Linkoping, Sweden; [Fevang, E.; Kruger, A.; Lossius, H. M.] Norwegian Air Ambulance Fdn, Dept Res & Dev, Drobak, Norway; [Fevang, E.] Stavanger Univ Hosp, Dept Anaesthesiol & Intens Care, Stavanger, Norway; [Backman, A.] Karolinska Inst, Ctr Resuscitat Sci, Stockholm, Sweden; [Kruger, A.] Norwegian Univ Sci & Technol, Dept Emergency Med & Prehosp Serv, St Olavs Univ Hosp, Trondheim, Norway; [Mikkelsen, S.] Odense Univ Hosp, Mobile Emergency Care Unit, Dept Anaesthesiol & Intens Care Med, Odense, Denmark; [Nurmi, J.] Helsinki Univ Hosp, Dept Emergency Med & Serv, Helsinki, Finland; [Nurmi, J.] Univ Helsinki, Dept Emergency Med, Helsinki, Finland; [Rognas, L.] Cent Denmark Reg, Prehosp Crit Care Serv Aarhus, Dept Prehosp Crit Care Serv, Pregosp Emergency Med Serv, Aarhus, Denmark; [Sandstrom, E.] Reg Jamtland Harjedalen, Helicopter Emergency Med Serv, Ostersund, Sweden; [Skallsjo, G.] Vastra Gotalandsreg, Helicopter Emergency Med Serv, Gothenburg, Sweden; [Gryth, D.] Karolinska Inst, Sect Anaesthesiol & Intens Care Med, Dept Physiol & Pharmacol, Stockholm, Sweden; [Gryth, D.] Karolinska Univ Hosp, Perioperat Med & Intens Care, Stockholm, Sweden; [Lossius, H. M.] Univ Stavanger, Dept Hlth Sci, Stavanger, Norway	Gellerfors, M (corresponding author), Karolinska Inst, Dept Clin Sci & Educ, Sect Anaesthesiol & Intens Care, Stockholm, Sweden.; Gellerfors, M (corresponding author), Swedish Air Ambulance SLA, Mora, Sweden.; Gellerfors, M (corresponding author), Soder Sjukhuset, Dept Anaesthesiol & Intens Care, Stockholm, Sweden.; Gellerfors, M (corresponding author), Swedish Armed Forces, SAE Medevac Helicopter, Linkoping, Sweden.	mikael.gellerfors@ki.se	Mikkelsen, Soren/R-1890-2019; Rognas, Leif/AAI-9373-2020; Rognas, Leif/AAF-6182-2020	Mikkelsen, Soren/0000-0002-5187-7027; Rognas, Leif/0000-0002-2542-565X; 	Swedish Medical Association; ALF-Grant Stockholm County Council; Laerdahl Foundation	Swedish Medical Association, ALF-Grant Stockholm County Council, and the Laerdahl Foundation.	Adnet F, 1998, ANN EMERG MED, V32, P454, DOI 10.1016/S0196-0644(98)70175-1; Bossers SM, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0141034; Bowles TM, 2011, BRIT J ANAESTH, V107, P687, DOI 10.1093/bja/aer251; Breckwoldt J, 2012, RESUSCITATION, V83, P434, DOI 10.1016/j.resuscitation.2011.10.011; Chesters A, 2014, EMERG MED J, V31, P65, DOI 10.1136/emermed-2012-201846; Crewdson K, 2017, CRIT CARE, V21, DOI 10.1186/s13054-017-1603-7; Davis DP, 2006, CRIT CARE MED, V34, P1202, DOI 10.1097/01.CCM.0000208359.74623.1C; Haltmeier T, 2017, EUR J TRAUMA EMERG S, V43, P731, DOI 10.1007/s00068-016-0718-x; Harris T, 2011, EMERG MED J, V28, P225, DOI 10.1136/emj.2009.088302; Heffner AC, 2012, J CRIT CARE, V27, P587, DOI 10.1016/j.jcrc.2012.04.022; Helm M, 2013, ACTA ANAESTH SCAND, V57, P199, DOI 10.1111/aas.12032; Hossfeld B, 2016, EUR J ANAESTH, V33, P881, DOI 10.1097/EJA.0000000000000533; Jensen AG, 2010, ACTA ANAESTH SCAND, V54, P922, DOI 10.1111/j.1399-6576.2010.02277.x; Kruger AJ, 2013, ACTA ANAESTH SCAND, V57, P1175, DOI 10.1111/aas.12181; Lansom Joshua D, 2016, Air Med J, V35, P295, DOI 10.1016/j.amj.2016.04.019; Lecky F, 2008, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001429.pub2; Lin CC, 2008, AM J EMERG MED, V26, P845, DOI 10.1016/j.ajem.2007.11.027; Lockey D, 2014, BRIT J ANAESTH, V113, P220, DOI 10.1093/bja/aeu227; Lockey DJ, 2017, ANAESTHESIA, V72, P379, DOI 10.1111/anae.13779; Lossius HM, 2002, ACTA ANAESTH SCAND, V46, P771, DOI 10.1034/j.1399-6576.2002.460703.x; Newton A, 2008, J TRAUMA, V64, P487, DOI 10.1097/TA.0b013e31802e7476; Pakkanen T, 2016, SCAND J TRAUMA RESUS, V24, DOI 10.1186/s13049-016-0256-x; Rehn M, 2016, ACTA ANAESTH SCAND, V60, P852, DOI 10.1111/aas.12746; ROGNAS L, 2013, SCAND J TRAUMA RESUS, V21; Sollid SJM, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-58; Soti A, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-014-0081-z; Sunde GA, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0136-9; von Elm E, 2007, BMJ-BRIT MED J, V335, P806; von Vopelius-Feldt J, 2013, EUR J EMERG MED, V20, P382, DOI 10.1097/MEJ.0b013e32835b08b7	29	22	22	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0007-0912	1471-6771		BRIT J ANAESTH	Br. J. Anaesth.	MAY	2018	120	5					1103	1109		10.1016/j.bja.2017.12.036			7	Anesthesiology	Anesthesiology	GN4SU	WOS:000439023600067	29661387	Green Accepted, Green Published, Other Gold			2021-06-18	
J	Skandsen, T; Einarsen, CE; Normann, I; Bjoralt, S; Karlsen, RH; McDonagh, D; Nilsen, TL; Akslen, AN; Haberg, AK; Vik, A				Skandsen, Toril; Einarsen, Cathrine Elisabeth; Normann, Ingunn; Bjoralt, Stine; Karlsen, Rune Hatlestad; McDonagh, David; Nilsen, Tom Lund; Akslen, Andreas Nylenna; Haberg, Asta Kristine; Vik, Anne			The epidemiology of mild traumatic brain injury: the Trondheim MTBI follow-up study	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Cohort studies; Mild traumatic brain injury; CT; Medical care; Epidemiology	ACUTE ALCOHOL-USE; HEAD-INJURY; EMERGENCY-DEPARTMENT; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; POPULATION; TBI; MULTICENTER; HOSPITALS; SEVERITY	Background: Mild traumatic brain injury (MTBI) is a frequent medical condition, and some patients report long-lasting problems after MTBI. In order to prevent MTBI, knowledge of the epidemiology is important and potential bias in studies should be explored. Aims of this study were to describe the epidemiological characteristics of MTBI in a Norwegian area and to evaluate the representativeness of patients successfully enrolled in the Trondheim MTBI follow-up study. Methods: During 81 weeks in 2014 and 2015, all persons aged 16-60 years, presenting with possible MTBI to the emergency department (ED) at St. Olavs Hospital, Trondheim University Hospital or to Trondheim municipal outpatient ED, were evaluated for participation in the follow-up study. Patients were identified by CT referrals and patient lists. Patients who were excluded or missed for enrolment in the follow-up study were recorded. Results: We identified 732 patients with MTBI. Median age was 28 years, and fall was the most common cause of injury. Fifty-three percent of injuries occurred during the weekend. Only 29% of MTBI patients were hospitalised. Study specific exclusion criteria were present in 23%. We enrolled 379 in the Trondheim MTBI follow-up study. In this cohort, Glasgow Coma Scale score was 15 at presentation in 73%; 45% of patients were injured under the influence of alcohol. Patients missed for inclusion were significantly more often outpatients, females, injured during the weekend, and suffering violent injuries, but differences between enrolled and not enrolled patients were small. Conclusion: Two thirds of all patients with MTBI in the 16-60 age group were treated without hospital admission, patients were often young, and half of the patients presented during the weekend. Fall was the most common cause of injury, and patients were commonly injured under the influence of alcohol, which needs to be addressed when considering strategies for prevention. The Trondheim MTBI follow-up study comprised patients who were highly representative for the underlying epidemiology of MTBI.	[Skandsen, Toril; Einarsen, Cathrine Elisabeth; Normann, Ingunn; Bjoralt, Stine; Karlsen, Rune Hatlestad; Akslen, Andreas Nylenna; Haberg, Asta Kristine; Vik, Anne] Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Fac Med & Hlth Sci, Trondheim, Norway; [Skandsen, Toril; Einarsen, Cathrine Elisabeth; Karlsen, Rune Hatlestad] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway; [McDonagh, David] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Orthopaed, Trondheim, Norway; [McDonagh, David] Trondheim Kommune, Municipal Emergency Dept, Trondheim, Norway; [Haberg, Asta Kristine] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Radiol & Nucl Med, Trondheim, Norway; [Vik, Anne] Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Neurosurgery, Trondheim, Norway; [Nilsen, Tom Lund] NTNU, Fac Med & Hlth Sci, Dept Publ Hlth & Nursing, Trondheim, Norway	Skandsen, T (corresponding author), Norwegian Univ Sci & Technol, Dept Neuromed & Movement Sci, Fac Med & Hlth Sci, Trondheim, Norway.; Skandsen, T (corresponding author), Trondheim Reg & Univ Hosp, St Olavs Hosp, Dept Phys Med & Rehabil, Trondheim, Norway.	toril.skandsen@ntnu.no	Skandsen, Toril/P-6767-2014	Skandsen, Toril/0000-0001-5495-9338	Liaison Committee	The study was funded by the Liaison Committee between the Central Norway Regional Health Authority (RHA) and the Norwegian University of Science and Technology (NTNU). Toril Skandsen, Rune H. Karlsen and Cathrine E. Einarsen received separate research grants from the same committee.	Andelic N, 2008, NEUROEPIDEMIOLOGY, V30, P120, DOI 10.1159/000120025; Andersson EH, 2003, ACTA NEUROL SCAND, V107, P256, DOI 10.1034/j.1600-0404.2003.00112.x; Borges G, 2006, B WORLD HEALTH ORGAN, V84, P453, DOI 10.2471/BLT.05.027466; Borges G, 2006, ADDICTION, V101, P993, DOI 10.1111/j.1360-0443.2006.01462.x; Bye EK, 2010, DRUG ALCOHOL REV, V29, P131, DOI 10.1111/j.1465-3362.2009.00117.x; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; de Koning ME, 2017, BRAIN INJURY, V31, P1102, DOI 10.1080/02699052.2017.1296193; Koning ME, 2017, J NEUROTRAUM, V34, P257, DOI 10.1089/neu.2015.4377; EDNA TH, 1984, SCAND J SOC MED, V12, P7, DOI 10.1177/140349488401200103; Engberg AW, 2004, ACTA NEUROL SCAND, V110, P281, DOI 10.1111/j.1600-0404.2004.00323.x; Fabbri A, 2008, J NEUROL NEUROSUR PS, V79, P567, DOI 10.1136/jnnp.2007.120162; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Foks KA, 2017, J NEUROTRAUM, V34, P2529, DOI 10.1089/neu.2016.4919; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Heskestad B, 2009, SCAND J TRAUMA RESUS, V17, DOI 10.1186/1757-7241-17-6; Ingebrigtsen T, 1998, NEUROEPIDEMIOLOGY, V17, P139, DOI 10.1159/000026165; Isokuortti H, 2016, J NEUROTRAUM, V33, P232, DOI 10.1089/neu.2015.3888; Kerr Zachary Y, 2014, N C Med J, V75, P8; Korley FK, 2016, J HEAD TRAUMA REHAB, V31, P379, DOI 10.1097/HTR.0000000000000187; Luoto TM, 2013, J NEUROTRAUM, V30, P11, DOI 10.1089/neu.2012.2611; Maas AIR, 2017, LANCET NEUROL, V16, P987, DOI 10.1016/S1474-4422(17)30371-X; Maas AIR, 2015, NEUROSURGERY, V76, P67, DOI 10.1227/NEU.0000000000000575; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Pedersen K, 2015, NEUROEPIDEMIOLOGY, V45, P20, DOI 10.1159/000381780; Peloso PM, 2004, J REHABIL MED, V36, P22, DOI 10.1080/16501960410023714; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Rossow I, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-1076; Scheenen ME, 2016, J NEUROTRAUM, V33, P339, DOI 10.1089/neu.2015.3926; STEIN SC, 1995, BRAIN INJURY, V9, P437, DOI 10.3109/02699059509008203; Styrke J, 2007, J NEUROTRAUM, V24, P1425, DOI 10.1089/neu.2007.0266; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970	37	22	22	0	1	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	APR 27	2018	26								34	10.1186/s13049-018-0495-0			9	Emergency Medicine	Emergency Medicine	GE6IT	WOS:000431330700002	29703222	DOAJ Gold, Green Published			2021-06-18	
J	Casili, G; Campolo, M; Paterniti, I; Lanza, M; Filippone, A; Cuzzocrea, S; Esposito, E				Casili, Giovanna; Campolo, Michela; Paterniti, Irene; Lanza, Marika; Filippone, Alessia; Cuzzocrea, Salvatore; Esposito, Emanuela			Dimethyl Fumarate Attenuates Neuroinflammation and Neurobehavioral Deficits Induced by Experimental Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						inflammation; NF-kappa B; Nrf-2; oxidative stress; TBI	REMITTING MULTIPLE-SCLEROSIS; NF-KAPPA-B; NITRIC-OXIDE; INFLAMMATION; INHIBITOR; PROTECTS; NEURODEGENERATION; NEUROPROTECTION; EPIDEMIOLOGY; MITOCHONDRIA	Traumatic brain injury (TBI) is a serious neuropathology that causes secondary injury mechanisms, including dynamic interplay between ischemic, inflammatory, and cytotoxic processes. Fumaric acid esters (FAEs) showed beneficial effects in pre-clinical models of neuroinflammation and toxic oxidative stress, so the aim of the present work was to evaluate the potential beneficial effects of dimethyl fumarate (DMF), the most pharmacologically effective molecules among the FAEs, in a mouse model of TBI induced by controlled cortical impact (CCI). Mice were administered DMF orally at the doses of 1, 10, and 30 mg/kg 1 h and 4 h after CCI. We performed histological, molecular, and immunohistochemistry analysis on the traumatic penumbral areas of the brain 24 h after CCI. DMF treatment notably reduced histological damage and behavioral impairments, reducing neurodegeneration as evidenced by assessments of neuronal loss, Fluoro-Jade C, and TUNEL staining; also, treatment with DMF blocked the apoptosis process increasing B-cell lymphoma 2 (Bcl-2) expression in injured cortex. Further, DMF treatment up-regulated antioxidant Kelch-like ECH-associated protein 1/nuclear factor erythroid 2-related factor pathway, inducing activation of manganese superoxide dismutase and heme-oxygenase-1 and reducing 4-hydroxy-2-nonenal staining. Also, regulating the NF-kappa B pathway, DMF treatment decreased the severity of inflammation through a modulation of neuronal nitric oxide synthase, interleukin 1, tumor necrosis factor, cyclooxygenase 2, and myeloperoxidase activity, reducing ionized calcium-binding adapter molecule 1 and glial fibrillary acidic protein expression. Our results support the thesis that DMF may be an effective neuroprotectant after brain trauma and warrants further study.	[Casili, Giovanna; Campolo, Michela; Paterniti, Irene; Lanza, Marika; Filippone, Alessia; Cuzzocrea, Salvatore; Esposito, Emanuela] Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy; [Cuzzocrea, Salvatore] St Louis Univ, Dept Pharmacol & Physiol Sci, St Louis, MO USA	Esposito, E (corresponding author), Univ Messina, Dept Chem Biol Pharmaceut & Environm Sci, Viale Ferdinando Stagno DAlcontres 31, I-98166 Messina, Italy.	eesposito@unime.it	Campolo, Michela/K-6432-2016	Cuzzocrea, Salvatore/0000-0001-6131-3690			Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Ahmad A, 2012, BRAIN BEHAV IMMUN, V26, P1310, DOI 10.1016/j.bbi.2012.07.021; Arent AM, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/723060; Bao F, 2012, J NEUROTRAUM, V29, P2375, DOI 10.1089/neu.2012.2408; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Bellanti F, 2013, REDOX BIOL, V1, P340, DOI 10.1016/j.redox.2013.05.003; Biswas SK, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/5698931; Block ML, 2005, PROG NEUROBIOL, V76, P77, DOI 10.1016/j.pneurobio.2005.06.004; Bomprezzi R, 2015, THER ADV NEUROL DISO, V8, P20, DOI 10.1177/1756285614564152; Bruschetta Giuseppe, 2017, Front Neurosci, V11, P6, DOI 10.3389/fnins.2017.00006; Campolo M, 2017, ANTIOXID REDOX SIGN, V27, P453, DOI 10.1089/ars.2016.6800; Campolo M, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0196-1; Campolo M, 2013, FASEB J, V27, P4489, DOI 10.1096/fj.13-234716; Casili G, 2016, J CROHNS COLITIS, V10, P472, DOI 10.1093/ecco-jcc/jjv231; Cernak I, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00209; Cheng G, 2012, BRIT J PHARMACOL, V167, P699, DOI 10.1111/j.1476-5381.2012.02025.x; Cheng ZG, 2013, ASIAN PAC J TROP MED, V6, P305, DOI 10.1016/S1995-7645(13)60061-9; Cherian L, 2004, BRAIN PATHOL, V14, P195, DOI 10.1111/j.1750-3639.2004.tb00053.x; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Cordaro M, 2017, J NEUROTRAUM, V34, P3027, DOI 10.1089/neu.2016.4678; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cryan JF, 2005, NEUROSCI BIOBEHAV R, V29, P571, DOI 10.1016/j.neubiorev.2005.03.009; De la Fuente M, 2009, CURR PHARM DESIGN, V15, P3003, DOI 10.2174/138161209789058110; DeLong WG, 2004, CLIN ORTHOP RELAT R, P57, DOI 10.1097/01.blo.0000130840.64528.1e; Esposito E, 2014, PHARMACOL RES, V86, P26, DOI 10.1016/j.phrs.2014.05.009; Esposito E, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041880; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; Hickey RW, 2007, PEDIATR RES, V62, P271, DOI 10.1203/PDR.0b013e3180db2902; Jin W, 2009, J SURG RES, V157, P251, DOI 10.1016/j.jss.2008.08.003; Jorge RE, 2005, J HEAD TRAUMA REHAB, V20, P475, DOI 10.1097/00001199-200511000-00001; Kappos L, 2008, LANCET, V372, P1463, DOI 10.1016/S0140-6736(08)61619-0; Kawai T, 2007, TRENDS MOL MED, V13, P460, DOI 10.1016/j.molmed.2007.09.002; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Kontos H A, 1986, Cent Nerv Syst Trauma, V3, P257; Leinhase I, 2006, BMC NEUROSCI, V7, DOI 10.1186/1471-2202-7-55; Liu YZ, 2015, J NEUROSURG, V123, P915, DOI 10.3171/2014.11.JNS132348; Loane DJ, 2014, J NEUROPATH EXP NEUR, V73, P14, DOI 10.1097/NEN.0000000000000021; Longbrake EE., 2015, MULT SCLER J EXP TRA, V1, DOI 10.1177/2055217315596994; Mendez-David I, 2015, NEUROSCI LETT, V597, P121, DOI 10.1016/j.neulet.2015.04.036; Mestas J, 2004, J IMMUNOL, V172, P2731, DOI 10.4049/jimmunol.172.5.2731; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Molina-Holgado E, 2000, BRIT J PHARMACOL, V131, P152, DOI 10.1038/sj.bjp.0703557; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Murphy MP, 2009, BIOCHEM J, V417, P1, DOI 10.1042/BJ20081386; Nakamura M, 1999, J COMP NEUROL, V412, P681, DOI 10.1002/(SICI)1096-9861(19991004)412:4<681::AID-CNE9>3.0.CO;2-F; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; PELLOW S, 1985, J NEUROSCI METH, V14, P149, DOI 10.1016/0165-0270(85)90031-7; Raghupathi R, 2003, J NEUROTRAUM, V20, P421, DOI 10.1089/089771503765355504; Ryu S, 2015, EXP NEUROBIOL, V24, P31, DOI 10.5607/en.2015.24.1.31; Sahuquillo J, 2001, CURR PHARM DESIGN, V7, P1475, DOI 10.2174/1381612013397311; Sandberg M, 2014, NEUROPHARMACOLOGY, V79, P298, DOI 10.1016/j.neuropharm.2013.11.004; Schwarzbold Marcelo, 2008, Neuropsychiatr Dis Treat, V4, P797; Signoretti S, 2004, J NEUROTRAUM, V21, P1154, DOI 10.1089/neu.2004.21.1154; Sullivan PG, 2011, J NEUROTRAUM, V28, P311, DOI 10.1089/neu.2010.1646; Vandermeeren M, 2001, J INVEST DERMATOL, V116, P124, DOI 10.1046/j.1523-1747.2001.00211.x; Viatour P, 2005, TRENDS BIOCHEM SCI, V30, P43, DOI 10.1016/j.tibs.2004.11.009; Wada K, 1998, NEUROSURGERY, V43, P1427, DOI 10.1097/00006123-199812000-00096; Wang L, 2005, ANN CLIN LAB SCI, V35, P79; Wieloch T, 2006, CURR OPIN NEUROBIOL, V16, P258, DOI 10.1016/j.conb.2006.05.011; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2009, EXPERT OPIN EMERG DR, V14, P67, DOI [10.1517/14728210902769601, 10.1517/14728210902769601 ]; Yao Y, 2016, TRANSL STROKE RES, V7, P535, DOI 10.1007/s12975-016-0496-0; Yokoyama H, 2008, NEUROL SCI, V29, P293, DOI 10.1007/s10072-008-0986-2; Yu GL, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0583-x; Zhang XD, 2015, BMC BIOINFORMATICS, V16, DOI 10.1186/s12859-015-0519-y; Zhao XR, 2007, STROKE, V38, P3280, DOI 10.1161/STROKEAHA.107.486506; Zhao XR, 2015, STROKE, V46, P1923, DOI 10.1161/STROKEAHA.115.009398	71	22	22	0	1	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JUL	2018	35	13					1437	1451		10.1089/neu.2017.5260		APR 2018	15	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	GJ4CQ	WOS:000430444900001	29361881				2021-06-18	
J	Khetani, S; Kollath, VO; Kundra, V; Nguyen, MD; Debert, C; Sen, A; Karan, K; Sanati-Nezhad, A				Khetani, Sultan; Kollath, Vinayaraj Ozhukil; Kundra, Varun; Minh Dang Nguyen; Debert, Chantel; Sen, Arindom; Karan, Kunal; Sanati-Nezhad, Amir			Polyethylenimine Modified Graphene-Oxide Electrochemical Immunosensor for the Detection of Glial Fibrillary Acidic Protein in Central Nervous System Injury	ACS SENSORS			English	Article						central nervous system injury; glial fibrillary acidic protein; biomarkers; graphene electrode; polyethylenimine; immunosensor; electrochemical impedance spectroscopy	TRAUMATIC BRAIN-INJURY; SPINAL-CORD-INJURY; CEREBROSPINAL-FLUID; SUSPENDED GRAPHENE; BLOOD BIOMARKERS; ANTICANCER DRUG; SPECTROSCOPY; DIAGNOSTICS; MICROCHIP; ELECTRODE	Glial fibrillary acidic protein (GFAP) is as an intermediate filament protein expressed by certain cells in the central nervous system (CNS). GFAP has been recognized as a reliable biomarker of CNS injury. However, due to the absence of rapid and easy-to-use assays for the detection of CNS injury biomarkers, measuring GFAP levels to identify CNS injury has not attained widespread clinical implementation. In the present work, we developed a polyethylenimine (PEI) coated graphene screen-printed electrode and used it for highly sensitive immunosensing of GFAP. Covalent binding of GFAP antibody to the PEI-modified electrode surface along with electrochemical impedance spectroscopy was used for detecting the change in the electrical conductivity of the electrodes. A highly linear response was recorded for various GFAP concentrations. Quantitative, selective, and label-free detection was achieved in the dynamic range of 1 pg mL(-1) to 100 ng mL(-1) for GFAP spiked in phosphate buffer saline, artificial cerebrospinal fluid, and human blood serum. The performance of the immunosensor was further validated and correlated by testing samples with the commercially available enzyme-linked immunosorbent assay method. This functionalized electrode could be used clinically for rapid detection and monitoring of CNS injury.	[Khetani, Sultan; Kundra, Varun; Sanati-Nezhad, Amir] Univ Calgary, Dept Mech & Mfg Engn, BioMEMS & Bioinspired Microfluid Lab, Calgary, AB T2N 1N4, Canada; [Sen, Arindom; Sanati-Nezhad, Amir] Univ Calgary, Schulich Sch Engn, Ctr Bioengn Res & Educ, Calgary, AB T2N 1N4, Canada; [Khetani, Sultan; Sen, Arindom; Sanati-Nezhad, Amir] Univ Calgary, Biomed Engn Grad Program, Calgary, AB T2N 1N4, Canada; [Sen, Arindom] Univ Calgary, Schulich Sch Engn, Pharmaceut Prod Res Facil, Calgary, AB T2N 1N4, Canada; [Kollath, Vinayaraj Ozhukil; Sen, Arindom; Karan, Kunal] Univ Calgary, Dept Chem & Petr Engn, Calgary, AB T2N 1N4, Canada; [Minh Dang Nguyen] Univ Calgary, Alberta Children Hosp, Res Inst Child & Maternal Hlth, Dept Clin Neurosci,Hotchkiss Brain Inst, Calgary, AB T2N 1N4, Canada; [Debert, Chantel] Univ Calgary, Foothills Med Ctr, Div Phys Med & Rehabil, Dept Clin Neurosci, Calgary, AB T2H 2T9, Canada	Sanati-Nezhad, A (corresponding author), Univ Calgary, Dept Mech & Mfg Engn, BioMEMS & Bioinspired Microfluid Lab, Calgary, AB T2N 1N4, Canada.; Sanati-Nezhad, A (corresponding author), Univ Calgary, Schulich Sch Engn, Ctr Bioengn Res & Educ, Calgary, AB T2N 1N4, Canada.; Sanati-Nezhad, A (corresponding author), Univ Calgary, Biomed Engn Grad Program, Calgary, AB T2N 1N4, Canada.	amir.sanatinezhad@ucalgary.ca	Karan, Kunal/N-3983-2019; Ozhukil Kollath, Vinayaraj/D-7792-2015	Karan, Kunal/0000-0001-5432-8050; Debert, Chantel/0000-0002-2704-0438; Sen, Arindom/0000-0002-8994-8601; Ozhukil Kollath, Vinayaraj/0000-0001-9814-339X	Natural Sciences and Engineering Research of Canada (NSERC)Natural Sciences and Engineering Research Council of Canada (NSERC); Alberta Prion Research Institute (APRI); CMC Microsystems, Canada; Alberta Innovates BioSolution (AIBS); University of Calgary	The authors acknowledge Natural Sciences and Engineering Research of Canada (NSERC); Alberta Prion Research Institute (APRI), CMC Microsystems, Canada; and Alberta Innovates BioSolution (AIBS) for supporting this research. V.O.K. acknowledges University of Calgary for Eyes High Postdoctoral Scholarship. We would also like to thank Farbod Ehsan Hosseini, and Udit Shrivastava for inputs and suggestions for this work.	Arya SK, 2013, LANGMUIR, V29, P6770, DOI 10.1021/la401109r; Bell J, 2004, NATURE, V429, P453, DOI 10.1038/nature02624; Bolotin KI, 2008, SOLID STATE COMMUN, V146, P351, DOI 10.1016/j.ssc.2008.02.024; Bunch JS, 2008, NANO LETT, V8, P2458, DOI 10.1021/nl801457b; Cummins BM, 2016, BIOTECHNOL ADV, V34, P161, DOI 10.1016/j.biotechadv.2016.01.005; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Du X, 2008, NAT NANOTECHNOL, V3, P491, DOI 10.1038/nnano.2008.199; Elias DC, 2009, SCIENCE, V323, P610, DOI 10.1126/science.1167130; Haselwood BA, 2015, BIOSENS BIOELECTRON, V67, P752, DOI 10.1016/j.bios.2014.09.032; Honda M, 2010, J TRAUMA, V69, P104, DOI 10.1097/TA.0b013e3181bbd485; Horcas I, 2007, REV SCI INSTRUM, V78, DOI 10.1063/1.2432410; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Ju L, 2011, NAT NANOTECHNOL, V6, P630, DOI [10.1038/NNANO.2011.146, 10.1038/nnano.2011.146]; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Khetani S., 2016, CMBES P, V39, P1; Khetani S, 2017, SENSOR ACTUAT B-CHEM, V247, P163, DOI 10.1016/j.snb.2017.02.169; Kollath VO, 2016, PHYS CHEM CHEM PHYS, V18, P26144, DOI 10.1039/c6cp04457c; Kollath VO, 2013, ADV ENG MATER, V15, P295, DOI 10.1002/adem.201200177; Kwon BK, 2010, J NEUROTRAUM, V27, P669, DOI 10.1089/neu.2009.1080; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee C, 2008, SCIENCE, V321, P385, DOI 10.1126/science.1157996; Lequin RM, 2005, CLIN CHEM, V51, P2415, DOI 10.1373/clinchem.2005.051532; Liu Y, 2013, ELECTROANAL, V25, P1050, DOI 10.1002/elan.201200525; Lu HL, 2015, RSC ADV, V5, P64925, DOI 10.1039/c5ra11528k; North SH, 2012, ANNU REV ANAL CHEM, V5, P35, DOI 10.1146/annurev-anchem-062011-143105; Pouw MH, 2014, SPINAL CORD, V52, P428, DOI 10.1038/sc.2014.26; Pouw MH, 2009, SPINAL CORD, V47, P519, DOI 10.1038/sc.2008.176; Pradhan R, 2014, BIOSENS BIOELECTRON, V55, P44, DOI 10.1016/j.bios.2013.11.060; Pumera M, 2011, MATER TODAY, V14, P308, DOI 10.1016/S1369-7021(11)70160-2; Ricci F, 2012, ELECTROCHIM ACTA, V84, P74, DOI 10.1016/j.electacta.2012.06.033; Safavieh M, 2017, NANOSCALE, V9, P1852, DOI 10.1039/c6nr06417e; Safavieh M, 2016, BIOSENS BIOELECTRON, V80, P230, DOI 10.1016/j.bios.2016.01.060; Schedin F, 2007, NAT MATER, V6, P652, DOI 10.1038/nmat1967; Shahim P, 2014, JAMA NEUROL, V71, P684, DOI 10.1001/jamaneurol.2014.367; Shao YY, 2010, ELECTROANAL, V22, P1027, DOI 10.1002/elan.200900571; Silva NA, 2014, PROG NEUROBIOL, V114, P25, DOI 10.1016/j.pneurobio.2013.11.002; Tang XW, 2006, NANO LETT, V6, P1632, DOI 10.1021/nl060613v; Tuteja SK, 2015, BIOSENS BIOELECTRON, V66, P129, DOI 10.1016/j.bios.2014.10.072; Valente KP, 2017, DRUG DISCOV TODAY, V22, P1654, DOI 10.1016/j.drudis.2017.06.010; Vashist SK, 2014, SCI REP-UK, V4, DOI 10.1038/srep04407; Walt DR, 2005, SCIENCE, V308, P217, DOI 10.1126/science.1108161; WANG Y, 1990, CHEM MATER, V2, P557, DOI 10.1021/cm00011a018; Yokobori S, 2015, WORLD NEUROSURG, V83, P867, DOI 10.1016/j.wneu.2013.03.012; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zetterberg H, 2013, NAT REV NEUROL, V9, P201, DOI 10.1038/nrneurol.2013.9; 2013, INT PERSP SPIN CORD, P1	46	22	22	5	38	AMER CHEMICAL SOC	WASHINGTON	1155 16TH ST, NW, WASHINGTON, DC 20036 USA	2379-3694			ACS SENSORS	ACS Sens.	APR	2018	3	4					844	851		10.1021/acssensors.8b00076			15	Chemistry, Multidisciplinary; Chemistry, Analytical; Nanoscience & Nanotechnology	Chemistry; Science & Technology - Other Topics	GE4DT	WOS:000431165200015	29516727				2021-06-18	
J	Ryan, NP; Genc, S; Beauchamp, MH; Yeates, KO; Hearps, S; Catroppa, C; Anderson, VA; Silk, TJ				Ryan, N. P.; Genc, S.; Beauchamp, M. H.; Yeates, K. O.; Hearps, S.; Catroppa, C.; Anderson, V. A.; Silk, T. J.			White matter microstructure predicts longitudinal social cognitive outcomes after paediatric traumatic brain injury: a diffusion tensor imaging study	PSYCHOLOGICAL MEDICINE			English	Article						Brain injuries; childhood; diffusion tensor imaging; social cognition; theory of mind	DEFAULT MODE NETWORK; UNCINATE FASCICULUS; PRAGMATIC LANGUAGE; SPATIAL STATISTICS; CORPUS-CALLOSUM; EARLY-CHILDHOOD; DTI FINDINGS; CHILDREN; CONNECTIVITY; MIND	Background. Deficits in social cognition may be among the most profound and disabling sequelae of paediatric traumatic brain injury (TBI); however, the neuroanatomical correlates of longitudinal outcomes in this domain remain unexplored. This study aimed to characterize social cognitive outcomes longitudinally after paediatric TBI, and to evaluate the use of sub-acute diffusion tensor imaging (DTI) to predict these outcomes. Methods. The sample included 52 children with mild complex-severe TBI who were assessed on cognitive theory of mind (ToM), pragmatic language and affective ToM at 6-and 24-months post-injury. For comparison, 43 typically developing controls (TDCs) of similar age and sex were recruited. DTI data were acquired sub-acutely (mean = 5.5 weeks post-injury) in a subset of 65 children (TBI = 35; TDC = 30) to evaluate longitudinal prospective relationships between white matter microstructure assessed using Tract-Based Spatial Statistics and social cognitive outcomes. Results. Whole brain voxel-wise analysis revealed significantly higher mean diffusivity (MD), axial diffusivity (AD) and radial diffusivity (RD) in the sub-acute TBI group compared with TDC, with differences observed predominantly in the splenium of the corpus callosum (sCC), sagittal stratum (SS), dorsal cingulum (DC), uncinate fasciculus (UF) and middle and superior cerebellar peduncles (MCP & SCP, respectively). Relative to TDCs, children with TBI showed poorer cognitive ToM, affective ToM and pragmatic language at 6-months post-insult, and those deficits were related to abnormal diffusivity of the sCC, SS, DC, UF, MCP and SCP. Moreover, children with TBI showed poorer affective ToM and pragmatic language at 24-months post-injury, and those outcomes were predicted by sub-acute alterations in diffusivity of the DC and MCP. Conclusions. Abnormal microstructure within frontal-temporal, limbic and cerebro-cerebellar white matter may be a risk factor for long-term social difficulties observed in children with TBI. DTI may have potential to unlock early prognostic markers of long-term social outcomes.	[Ryan, N. P.; Hearps, S.; Catroppa, C.; Anderson, V. A.] Murdoch Childrens Res Inst, Australian Ctr Child Neuropsychol Studies, Melbourne, Vic, Australia; [Ryan, N. P.; Catroppa, C.; Anderson, V. A.] Royal Childrens Hosp, Dept Psychol, Melbourne, Vic, Australia; [Ryan, N. P.; Catroppa, C.; Anderson, V. A.] Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia; [Genc, S.; Silk, T. J.] Murdoch Childrens Res Inst, Dev Imaging, Melbourne, Vic, Australia; [Genc, S.; Anderson, V. A.; Silk, T. J.] Univ Melbourne, Dept Paediat, Melbourne, Vic, Australia; [Beauchamp, M. H.] Univ Montreal, Dept Psychol, Montreal, PQ, Canada; [Beauchamp, M. H.] Ste Justine Res Ctr, Montreal, PQ, Canada; [Yeates, K. O.] Hotchkiss Brain Inst, Dept Psychol, Calgary, AB, Canada; [Yeates, K. O.] Univ Calgary, Alberta Childrens Hosp, Res Inst, Calgary, AB, Canada	Ryan, NP (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Melbourne, Vic, Australia.; Ryan, NP (corresponding author), Univ Melbourne, Melbourne Sch Psychol Sci, Parkville, Vic 3052, Australia.	nicholas.ryan@unimelb.edu.au	Ryan, Nicholas/K-5445-2019; Hearps, Stephen/L-6853-2016; Yeates, Keith/AAJ-4223-2020; Silk, Tim/K-4295-2019	Ryan, Nicholas/0000-0002-0878-8889; Genc, Sila/0000-0002-4624-7071; Yeates, Keith/0000-0001-7680-2892; Silk, Tim/0000-0002-7290-512X	Victoria Neurotrauma Initiative, Australia [CO6E1]; Victorian Government Operational Infrastructure Support Program; Australian Postgraduate AwardAustralian Government; MCRI Ph.D. scholarship; NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed GrantNational Health and Medical Research Council of Australia; NHMRC Senior Practitioner FellowshipNational Health and Medical Research Council of Australia	This work was supported by a grant from the Victoria Neurotrauma Initiative (CO6E1), Australia; the Victorian Government Operational Infrastructure Support Program; an Australian Postgraduate Award, MCRI Ph.D. scholarship, and NHMRC Moving Ahead Centre for Research Excellence in Brain Injury Recovery Seed Grant to NR; and an NHMRC Senior Practitioner Fellowship to VA. The funding bodies did not play a role in the design of the study, collection, analysis and interpretation of the data, or writing of the manuscript.	Adamson C, 2013, BRAIN INJURY, V27, P454, DOI 10.3109/02699052.2012.750756; Adolphs R, 2009, ANNU REV PSYCHOL, V60, P693, DOI 10.1146/annurev.psych.60.110707.163514; Ameis SH, 2015, CORTEX, V62, P158, DOI 10.1016/j.cortex.2014.10.014; Amodio DM, 2006, NAT REV NEUROSCI, V7, P268, DOI 10.1038/nrn1884; Anderson V, 2013, J INT NEUROPSYCH SOC, V19, P539, DOI 10.1017/S1355617712001543; Ashwal S, 2014, J CHILD NEUROL, V29, P1704, DOI 10.1177/0883073814538504; Aung Wint Yan, 2013, Imaging Med, V5, P427; Bach M, 2014, NEUROIMAGE, V100, P358, DOI 10.1016/j.neuroimage.2014.06.021; Beauchamp MH, 2011, J NEUROTRAUM, V28, P915, DOI 10.1089/neu.2010.1712; Beauchamp MH, 2010, PSYCHOL BULL, V136, P39, DOI 10.1037/a0017768; Beauchamp MH, 2009, J NEUROTRAUM, V26, P1645, DOI [10.1089/neu.2009.0916, 10.1089/neu.2009-0916]; Bellerose J, 2015, J INT NEUROPSYCH SOC, V21, P483, DOI 10.1017/S1355617715000569; Bigler ED, 2013, NEUROPSYCHOLOGY, V27, P438, DOI 10.1037/a0032837; Bigler ED, 2010, NEUROLOGY, V74, P626, DOI 10.1212/WNL.0b013e3181d3e43a; Blakemore SJ, 2008, NAT REV NEUROSCI, V9, P267, DOI 10.1038/nrn2353; Burnett S, 2009, ANN NY ACAD SCI, V1167, P51, DOI 10.1111/j.1749-6632.2009.04509.x; Caeyenberghs K, 2011, NEUROREHAB NEURAL RE, V25, P492, DOI 10.1177/1545968310394870; Caeyenberghs K, 2010, HUM BRAIN MAPP, V31, P992, DOI 10.1002/hbm.20911; Carrington SJ, 2009, HUM BRAIN MAPP, V30, P2313, DOI 10.1002/hbm.20671; Catroppa C, 2015, J NEUROTRAUM, V32, P109, DOI 10.1089/neu.2013.3276; Chiong W, 2013, BRAIN, V136, P1929, DOI 10.1093/brain/awt066; Choudhury S, 2006, SOC COGN AFFECT NEUR, V1, P165, DOI 10.1093/scan/nsl024; D'Mello AM, 2015, FRONT NEUROSCI-SWITZ, V9, DOI 10.3389/fnins.2015.00408; Davis CL, 2016, NEUROCASE, V22, P22, DOI 10.1080/13554794.2015.1024137; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dennis M, 2013, DEV COGN NEUROS-NETH, V5, P25, DOI 10.1016/j.dcn.2012.11.006; Dennis M, 2013, J INT NEUROPSYCH SOC, V19, P34, DOI 10.1017/S1355617712000884; Dennis M, 2012, J INT NEUROPSYCH SOC, V18, P908, DOI 10.1017/S1355617712000756; Dumontheil I, 2010, DEVELOPMENTAL SCI, V13, P331, DOI 10.1111/j.1467-7687.2009.00888.x; Ewing-Cobbs L, 2008, NEUROIMAGE, V42, P1305, DOI 10.1016/j.neuroimage.2008.06.031; Ewing-Cobbs L, 2012, INT J DEV NEUROSCI, V30, P247, DOI 10.1016/j.ijdevneu.2011.07.004; Genc S, 2017, J NEUROTRAUM, V34, P798, DOI 10.1089/neu.2016.4584; Giedd JN, 1999, NAT NEUROSCI, V2, P861, DOI 10.1038/13158; Gilliam M, 2011, BIOL PSYCHIAT, V69, P839, DOI 10.1016/j.biopsych.2010.11.024; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Harrison P., 2003, ADAPTIVE BEHAV ASSES; Hayes JP, 2016, J INT NEUROPSYCH SOC, V22, P120, DOI 10.1017/S1355617715000740; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Huisman TAGM, 2004, AM J NEURORADIOL, V25, P370; Jalbrzikowski M, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00393; Kennedy DP, 2012, TRENDS COGN SCI, V16, P559, DOI 10.1016/j.tics.2012.09.006; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Levin HS, 2011, DEV NEUROPSYCHOL, V36, P273, DOI 10.1080/87565641.2010.549885; Liu PC, 2016, AIP ADV, V6, DOI 10.1063/1.4954997; Mahoney CJ, 2011, BRIT J PSYCHIAT, V198, P365, DOI 10.1192/bjp.bp.110.082677; McDonald S, 2013, J INT NEUROPSYCH SOC, V19, P528, DOI 10.1017/S1355617713000039; Miyata J, 2010, SCHIZOPHR RES, V119, P232, DOI 10.1016/j.schres.2009.12.038; Newcombe V, 2009, BRIT J NEUROSURGERY, V21, P340; Ochsner KN, 2004, J COGNITIVE NEUROSCI, V16, P1746, DOI 10.1162/0898929042947829; Oishi K, 2015, ANN NEUROL, V77, P68, DOI 10.1002/ana.24300; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Phan KL, 2009, BIOL PSYCHIAT, V66, P691, DOI 10.1016/j.biopsych.2009.02.028; Philippi CL, 2009, J NEUROSCI, V29, P15089, DOI 10.1523/JNEUROSCI.0796-09.2009; Pugliese L, 2009, NEUROIMAGE, V47, P427, DOI 10.1016/j.neuroimage.2009.05.014; Roberts RM, 2014, DEV NEUROPSYCHOL, V39, P600, DOI 10.1080/87565641.2014.973958; Roberts RM, 2016, DEV NEUROPSYCHOL, V41, P176, DOI 10.1080/87565641.2016.1186167; Robinson KE, 2014, J NEUROTRAUM, V31, P1835, DOI 10.1089/neu.2014.3422; Ryan NP, 2015, HUM BRAIN MAPP, V36, P1677, DOI 10.1002/hbm.22729; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Ryan NP, 2013, INT J DEV NEUROSCI, V31, P811, DOI 10.1016/j.ijdevneu.2013.10.002; Schmahmann J, 2009, FIBER PATHWAYS BRAIN; Secord, 1989, TEST LANGUAGE COMPET; Sethi A, 2015, CORTEX, V62, P11, DOI 10.1016/j.cortex.2014.07.018; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; Sun SW, 2006, MAGN RESON MED, V55, P302, DOI 10.1002/mrm.20774; Supekar K, 2010, NEUROIMAGE, V52, P290, DOI 10.1016/j.neuroimage.2010.04.009; Tartaglia MC, 2012, J NEUROL, V259, P1071, DOI 10.1007/s00415-011-6300-x; Tasker RC, 2005, PEDIATR RES, V58, P302, DOI 10.1203/01.PDR.0000169965.08854.25; TEASDALE G, 1974, LANCET, V2, P81; Tesink CMJY, 2009, BRAIN, V132, P1941, DOI 10.1093/brain/awp103; Thompson PM, 2005, INT REV NEUROBIOL, V67, P285, DOI 10.1016/S0074-7742(05)67009-2; Tlustos SJ, 2011, J INT NEUROPSYCH SOC, V17, P1132, DOI 10.1017/S1355617711001202; Tournier JD, 2008, NEUROIMAGE, V42, P617, DOI 10.1016/j.neuroimage.2008.05.002; Van Overwalle F, 2015, HUM BRAIN MAPP, V36, P5137, DOI 10.1002/hbm.23002; Van Overwalle F, 2016, NEUROIMAGE, V124, P248, DOI 10.1016/j.neuroimage.2015.09.001; Veeramuthu V, 2015, J NEUROTRAUM, V32, P1497, DOI 10.1089/neu.2014.3750; VOGEL S, 1992, ED ALTERNATIVES STUD; Von Der Heide RJ, 2013, BRAIN, V136, P1692, DOI 10.1093/brain/awt094; Wakana S, 2007, NEUROIMAGE, V36, P630, DOI 10.1016/j.neuroimage.2007.02.049; Wilde EA, 2005, J NEUROTRAUM, V22, P333, DOI 10.1089/neu.2005.22.333; Wilde EA, 2006, J NEUROTRAUM, V23, P1412, DOI 10.1089/neu.2006.23.1412; Wilde EA, 2016, J NEUROTRAUM, V33, P2000, DOI 10.1089/neu.2015.4212; Wilde EA, 2012, BRAIN IMAGING BEHAV, V6, P404, DOI 10.1007/s11682-012-9150-y; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Wozniak JR, 2006, NEUROSCI BIOBEHAV R, V30, P762, DOI 10.1016/j.neubiorev.2006.06.003; Wu TC, 2010, DEV NEUROSCI-BASEL, V32, P361, DOI 10.1159/000317058; Yuan W, 2007, AM J NEURORADIOL, V28, P1919, DOI 10.3174/ajnr.A0698; Zupan B, 2017, BRAIN IMPAIR, V18, P36, DOI 10.1017/BrImp.2016.22	90	22	24	1	10	CAMBRIDGE UNIV PRESS	NEW YORK	32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA	0033-2917	1469-8978		PSYCHOL MED	Psychol. Med.	MAR	2018	48	4					679	691		10.1017/S0033291717002057			13	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	GB8OZ	WOS:000429336500013	28780927				2021-06-18	
J	Weaver, LK; Wilson, SH; Lindblad, AS; Churchill, S; Deru, K; Price, RC; Williams, CS; Orrison, WW; Walker, JM; Meehan, A; Mirow, S				Weaver, Lindell K.; Wilson, Steffanie H.; Lindblad, Anne S.; Churchill, Susan; Deru, Kayla; Price, Robert C.; Williams, Chris S.; Orrison, William W.; Walker, James M.; Meehan, Anna; Mirow, Susan		BIMA Study Team	Hyperbaric oxygen for post-concussive symptoms in United States military service members: a randomized clinical trial	UNDERSEA AND HYPERBARIC MEDICINE			English	Article							TRAUMATIC BRAIN-INJURY; PERSISTENT POSTCONCUSSION SYMPTOMS; OF-DEFENSE TRIALS; HEAD-INJURY; SLEEP-DISORDERS; TBI ISSUES; RELIABILITY; DESIGN; QUESTIONNAIRE; VALIDITY	Background: In prior military randomized trials, participants with persistent symptoms after mild traumatic brain injury (TBI) reported improvement regardless of receiving hyperbaric oxygen (HBO2) or sham intervention. This study's objectives were to identify outcomes for future efficacy trials and describe changes by intervention. Methods: This Phase II, randomized, double-blind, sham-controlled trial enrolled military personnel with mild TBI and persistent post-concussive symptoms. Participants were randomized to receive 40 HBO2 (1.5 atmospheres absolute (ATA), >99% oxygen, 60 minutes) or sham chamber sessions (1.2 ATA, room air, 60 minutes) over 12 weeks. Participants and evaluators were blinded to allocation. Outcomes assessed at baseline, 13 weeks and six months included symptoms, quality of life, neuropsychological, neurological, electroencephalography, sleep, auditory, vestibular, autonomic, visual, neuroimaging, and laboratory testing. Participants completed 12-month questionnaires. Intention-to-treat results are reported. Results: From 9/11/2012 to 5/19/2014, 71 randomized participants received HBO2 (n=36) or sham (n=35). At baseline, 35 participants (49%) met post-traumatic stress disorder (PTSD) criteria. By the Neurobehavioral Symptom Inventory, the HBO2 group had improved 13-week scores (mean change -3.6 points, P=0.03) compared to sham (+3.9 points). In participants with PTSD, change with HBO2 was more pronounced (-8.6 vs. +4.8 points with sham, P=0.02). PTSD symptoms also improved in the HBO2 group, and more so in the subgroup with PTSD. Improvements regressed at six and 12 months. Hyperbaric oxygen improved some cognitive processing speed and sleep measures. Participants with PTSD receiving HBO2 had improved functional balance and reduced vestibular complaints at 13 weeks. Conclusions: By 13 weeks, HBO2 improved post-concussive and PTSD symptoms, cognitive processing speed, sleep quality, and balance function, most dramatically in those with PTSD. Changes did not persist beyond six months. Several outcomes appeared sensitive to change; additional studies are warranted.	[Weaver, Lindell K.; Churchill, Susan; Deru, Kayla] Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA; [Weaver, Lindell K.; Churchill, Susan; Deru, Kayla] Intermt LDS Hosp, Salt Lake City, UT 84143 USA; [Weaver, Lindell K.; Mirow, Susan] Univ Utah, Sch Med, Salt Lake City, UT 84112 USA; [Wilson, Steffanie H.; Lindblad, Anne S.] Emmes Corp, Rockville, MD USA; [Price, Robert C.] Evans Army Community Hosp, Ft Carson, CO USA; [Williams, Chris S.; Orrison, William W.; Walker, James M.; Meehan, Anna; Mirow, Susan] Lovelace Biomed Res, Albuquerque, NM USA	Weaver, LK (corresponding author), Intermt Med Ctr, Div Hyperbar Med, Murray, UT 84107 USA.; Weaver, LK (corresponding author), Intermt LDS Hosp, Salt Lake City, UT 84143 USA.; Weaver, LK (corresponding author), Univ Utah, Sch Med, Salt Lake City, UT 84112 USA.	lindell.weaver@imail.org			U.S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-15-D-0039-0003]	This work is supported by the U.S. Army Medical Research and Materiel Command under Contract No. W81XWH-15-D-0039-0003.	Allen RP, 2003, SLEEP MED, V4, P101, DOI 10.1016/S1389-9457(03)00010-8; Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Anic-Labat S, 1999, SLEEP, V22, P77; [Anonymous], 2008, BALANCE FUNCTION ASS; Badke MB, 2004, ARCH PHYS MED REHAB, V85, P227, DOI 10.1016/j.apmr.2003.06.006; Basco MR, 2000, AM J PSYCHIAT, V157, P1599, DOI 10.1176/appi.ajp.157.10.1599; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Becker S, 2003, J COGNITIVE NEUROSCI, V15, P821, DOI 10.1162/089892903322370744; Benedict R, 1996, REVISION BRIEF VISUO; BERG KO, 1992, CAN J PUBLIC HEALTH, V83, pS7; Bishop GD, 1998, PERS INDIV DIFFER, V24, P867, DOI 10.1016/S0191-8869(98)00024-5; Boussi-Gross R, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079995; Bush K, 1998, ARCH INTERN MED, V158, P1789, DOI 10.1001/archinte.158.16.1789; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Casscells SW, 2007, TRAUMATIC BRAIN INJU; Centers for Disease Control and Prevention Department of Defense VA Leadership Panel, 2013, C TRAUM BRAIN INJ US; Chiu WT, 2006, J NEUROTRAUM, V23, P1609, DOI 10.1089/neu.2006.23.1609; Chung F, 2014, J CLIN SLEEP MED, V10, P951, DOI 10.5664/jcsm.4022; Cifu DX, 2015, J HEAD TRAUMA REHAB, V30, P21, DOI 10.1097/HTR.0000000000000036; Cifu DX, 2014, J REHABIL RES DEV, V51, P1047, DOI 10.1682/JRRD.2014.01.0013; Cifu DX, 2014, ANN NEUROL, V75, P277, DOI 10.1002/ana.24067; Cifu DX, 2014, J HEAD TRAUMA REHAB, V29, P11, DOI 10.1097/HTR.0b013e3182a6aaf0; Clark JF, 2017, CLIN J SPORT MED, V27, P457, DOI 10.1097/JSM.0000000000000381; Corrigan JD, 2007, J HEAD TRAUMA REHAB, V22, P318, DOI 10.1097/01.HTR.0000300227.67748.77; Crapo RO, 2002, AM J RESP CRIT CARE, V166, P111, DOI 10.1164/rccm.166/1/111; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Doty RL, 1996, LARYNGOSCOPE, V106, P353, DOI 10.1097/00005537-199603000-00021; Edwards R H, 1977, Physiotherapy, V63, P51; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Felipe L, 2014, INT ARCH OTORHINOLAR, V18, P77, DOI 10.1055/s-0033-1352503; Figueroa XA, 2016, NEUROLOGY, V87, P1400, DOI 10.1212/WNL.0000000000003146; Flaherty S A, 1996, AANA J, V64, P133; FURMAN JM, 1995, OTOLARYNG HEAD NECK, V112, P8, DOI 10.1016/S0194-5998(95)70300-4; Golden C., 1978, MANUAL STROOP COLOR; Grieger TA, 2006, AM J PSYCHIAT, V163, P1777, DOI 10.1176/appi.ajp.163.10.1777; Guilfoyle MR, 2010, J NEUROTRAUM, V27, P2173, DOI 10.1089/neu.2010.1353; Hanna-Pladdy B, 2002, J NEUROL NEUROSUR PS, V73, P574, DOI 10.1136/jnnp.73.5.574; Harch PG, 2013, UNDERSEA HYPERBAR M, V40, P469; Harch PG, 2012, J NEUROTRAUM, V29, P168, DOI 10.1089/neu.2011.1895; Hirvonen TP, 1999, J VESTIBUL RES-EQUIL, V9, P119; HODDES E, 1973, PSYCHOPHYSIOLOGY, V10, P431, DOI 10.1111/j.1469-8986.1973.tb00801.x; Hoge C, 2015, JAMA INTERN MED, V175, P53, DOI 10.1001/jamainternmed.2014.3375; Hurst H, 2004, J MANIP PHYSIOL THER, V27, P26, DOI 10.1016/j.jmpt.2003.11.003; Kabat MH, 2001, CLIN NEUROPSYCHOL, V15, P498, DOI 10.1076/clin.15.4.498.1882; King N, 2014, NEUROREHABILITATION, V34, P741, DOI 10.3233/NRE-141072; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kothari Mihir T., 2005, Indian Journal of Ophthalmology, V53, P43; Lee C T, 1998, SPUMS J, V28, P125; LEVIN HS, 1987, J NEUROSURG, V66, P234, DOI 10.3171/jns.1987.66.2.0234; Masel BE, 2010, J NEUROTRAUM, V27, P1529, DOI 10.1089/neu.2010.1358; McCrary BF, 2013, UNDERSEA HYPERBAR M, V40, P443; Meehan A, 2016, UNDERSEA HYPERBAR M, V43, P567; Miller RS, 2015, JAMA INTERN MED, V175, P43, DOI 10.1001/jamainternmed.2014.5479; Mirow S, 2016, UNDERSEA HYPERBAR M, V43, P531; Mitchell SJ, 2014, DIVING HYPERB MED, V44, P228; Moher D., 2010, BMJ, V340; Morgenthaler T, 2007, SLEEP, V30, P519, DOI 10.1093/sleep/30.4.519; OLEARY DP, 1990, NEUROL CLIN, V8, P297, DOI 10.1016/S0733-8619(18)30357-8; Orrison WW, 2009, J NEUROTRAUM, V26, P689, DOI 10.1089/neu.2008.0636; RADLOFF L S, 1977, Applied Psychological Measurement, V1, P385, DOI 10.1177/014662167700100306; Ruff RM, 1996, ARCH CLIN NEUROPSYCH, V11, P329, DOI 10.1016/0887-6177(95)00033-X; Ruffolo LF, 2000, CLIN NEUROPSYCHOL, V14, P223, DOI 10.1076/1385-4046(200005)14:2;1-Z;FT223; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Scorza KA, 2013, UNDERSEA HYPERBAR M, V40, P548; Shandley S, 2017, UNDERSEA HYPERBAR M, V44, P257; Skipper LD, 2016, UNDERSEA HYPERBAR M, V43, P601; Smits M, 2011, NEURORADIOLOGY, V53, P553, DOI 10.1007/s00234-010-0774-6; TANG DI, 1993, BIOMETRICS, V49, P23, DOI 10.2307/2532599; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tombaugh TN, 1997, PSYCHOL ASSESSMENT, V9, P260, DOI 10.1037/1040-3590.9.3.260; Walker JM, 2016, UNDERSEA HYPERBAR M, V43, P549; Walker WC, 2014, NEUROREHAB NEURAL RE, V28, P420, DOI 10.1177/1545968313516869; Weaver LK, 2016, UNDERSEA HYPERBAR M, V43, P485; Weaver LK, 2013, UNDERSEA HYPERBAR M, V40, P471; Weaver LK, 2012, UNDERSEA HYPERBAR M, V39, P807; Wechsler D., 2001, WECHSLER TEST ADULT; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Williams CS, 2016, UNDERSEA HYPERBAR M, V43, P511; Williams CS, 2016, UNDERSEA HYPERBAR M, V43, P521; Wilson SH, 2016, UNDERSEA HYPERBAR M, V43, P615; Wilson SH, 2016, UNDERSEA HYPERBAR M, V43, P585; Wolf EG, 2015, UNDERSEA HYPERBAR M, V42, P313; Wolf EG, 2012, UNDERSEA HYPERBAR M, V39, P1075; Wolf G, 2012, J NEUROTRAUM, V29, P2606, DOI 10.1089/neu.2012.2549; Zaloshnja E, 2008, J HEAD TRAUMA REHAB, V23, P394, DOI 10.1097/01.HTR.0000341435.52004.ac	85	22	23	0	9	UNDERSEA & HYPERBARIC MEDICAL SOC INC	DURHAM	21 WEST COLONY PLACE, STE 280, DURHAM, NC 27705 USA	1066-2936			UNDERSEA HYPERBAR M	Undersea Hyperb. Med.	MAR-APR	2018	45	2					129	156					28	Marine & Freshwater Biology; Medicine, Research & Experimental	Marine & Freshwater Biology; Research & Experimental Medicine	GF0XQ	WOS:000431655500001	29734566				2021-06-18	
J	Yi, Y; Li, E; Sun, G; Yan, HQ; Foley, LM; Andrzejczuk, LA; Attarwala, IY; Hitchens, TK; Kiselyov, K; Dixon, CE; Sun, DD				Yi, Yan; Li, Eric; Sun, George; Yan, Hong Q.; Foley, Lesley M.; Andrzejczuk, Liwia A.; Attarwala, Insiya Y.; Hitchens, T. Kevin; Kiselyov, Kirill; Dixon, C. Edward; Sun, Dandan			Effects of DHA on Hippocampal Autophagy and Lysosome Function After Traumatic Brain Injury	MOLECULAR NEUROBIOLOGY			English	Article						Autophagy; Cortical contusion injury; Docosahexaenoic acid; Lysosome; Microglial polarization; Secondary injury	OXIDATIVE STRESS; CELL-SURVIVAL; CATHEPSIN-D; PROTEIN; RAT; BIOSYNTHESIS; BIOGENESIS; EXPRESSION; TRANSIENT; MODEL	Traumatic brain injury (TBI) triggers endoplasmic reticulum (ER) stress and impairs autophagic clearance of damaged organelles and toxic macromolecules. In this study, we investigated the effects of the post-TBI administration of docosahexaenoic acid (DHA) on improving hippocampal autophagy flux and cognitive functions of rats. TBI was induced by cortical contusion injury in Sprague-Dawley rats, which received DHA (16 mg/kg in DMSO, intraperitoneal administration) or vehicle DMSO (1 ml/kg) with an initial dose within 15 min after the injury, followed by a daily dose for 3 or 7 days. First, RT-qPCR reveals that TBI induced a significant elevation in expression of autophagy-related genes in the hippocampus, including SQSTM1/p62 (sequestosome 1), lysosomal-associated membrane proteins 1 and 2 (Lamp1 and Lamp2), and cathepsin D (Ctsd). Upregulation of the corresponding autophagy-related proteins was detected by immunoblotting and immunostaining. In contrast, the DHA-treated rats did not exhibit the TBI-induced autophagy biogenesis and showed restored CTSD protein expression and activity. T-2-weighted images and diffusion tensor imaging (DTI) of ex vivo brains showed that DHA reduced both gray matter and white matter damages in cortical and hippocampal tissues. DHA-treated animals performed better than the vehicle control group on the Morris water maze test. Taken together, these findings suggest that TBI triggers sustained stimulation of autophagy biogenesis, autophagy flux, and lysosomal functions in the hippocampus. Swift post-injury DHA administration restores hippocampal lysosomal biogenesis and function, demonstrating its therapeutic potential.	[Yi, Yan] Dalian Med Univ, Hosp 2, Dept Neurol, Dalian 116027, Peoples R China; [Yi, Yan; Li, Eric; Sun, George; Attarwala, Insiya Y.; Sun, Dandan] Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward] Univ Pittsburgh, Brain Trauma Res Ctr, Dept Neurosurg, Pittsburgh, PA 15213 USA; [Yan, Hong Q.; Dixon, C. Edward; Sun, Dandan] Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA; [Foley, Lesley M.; Hitchens, T. Kevin] Univ Pittsburgh, Anim Imaging Ctr, Pittsburgh, PA 15213 USA; [Andrzejczuk, Liwia A.; Kiselyov, Kirill] Univ Pittsburgh, Dept Biol Sci, Pittsburgh, PA 15213 USA; [Hitchens, T. Kevin] Univ Pittsburgh, Dept Neurobiol, Pittsburgh, PA 15213 USA	Sun, DD (corresponding author), Univ Pittsburgh, Dept Neurol, Pittsburgh, PA 15213 USA.; Sun, DD (corresponding author), Vet Affairs Pittsburgh Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15213 USA.	sund@upmc.edu		Andrzejczuk, Livia A./0000-0001-5585-6189	Chinese Dalian Municipal Bureau Study Abroad Research Award; National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01NS089051]; US Department of Veterans Affairs VA [RRD] [B6761R]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS089051] Funding Source: NIH RePORTER	This work was supported in part by the National Institutes of Health [R01NS089051] (DS) and the US Department of Veterans Affairs VA [RR&D#B6761R] (CED). Y.Y. was supported by the Chinese Dalian Municipal Bureau Study Abroad Research Award.	Ariza M, 2006, NEUROPSYCHOLOGIA, V44, P1956, DOI 10.1016/j.neuropsychologia.2005.11.007; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Calandria JM, 2015, CELL DEATH DIFFER, V22, P1363, DOI 10.1038/cdd.2014.233; CARLSSON SR, 1988, J BIOL CHEM, V263, P18911; Colletti GA, 2012, J BIOL CHEM, V287, P8082, DOI 10.1074/jbc.M111.285536; Dixon CE, 1999, RESTOR NEUROL NEUROS, V14, P285; DIXON CE, 1991, J NEUROSCI METH, V39, P253; GIESELMANN V, 1983, J CELL BIOL, V97, P1, DOI 10.1083/jcb.97.1.1; Harvey LD, 2015, ASN NEURO, V7, DOI 10.1177/1759091415618969; Johansson I, 2015, AUTOPHAGY, V11, P1636, DOI 10.1080/15548627.2015.1061170; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Mayurasakorn K, 2011, CURR OPIN CLIN NUTR, V14, P158, DOI 10.1097/MCO.0b013e328342cba5; Nakanishi H, 2001, J NEUROSCI, V21, P7526; Ogata M, 2006, MOL CELL BIOL, V26, P9220, DOI 10.1128/MCB.01453-06; Pankiv S, 2007, J BIOL CHEM, V282, P24131, DOI 10.1074/jbc.M702824200; Park Y, 2015, J NEUROTRAUM, V32, P1449, DOI 10.1089/neu.2014.3694; Pena KA, 2015, BIOCHEM J, V470, P65, DOI 10.1042/BJ20140645; Pettersen K, 2016, FREE RADICAL BIO MED, V90, P158, DOI 10.1016/j.freeradbiomed.2015.11.018; ROSENFELD MG, 1982, J CELL BIOL, V93, P135, DOI 10.1083/jcb.93.1.135; RUDENKO G, 1995, STRUCTURE, V3, P1249, DOI 10.1016/S0969-2126(01)00260-X; Saftig P, 2009, NAT REV MOL CELL BIO, V10, P623, DOI 10.1038/nrm2745; Sardiello M, 2009, SCIENCE, V325, P473, DOI 10.1126/science.1174447; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Schober ME, 2016, J NEUROTRAUM, V33, P390, DOI 10.1089/neu.2015.3945; Tanida I, 2004, INT J BIOCHEM CELL B, V36, P2503, DOI 10.1016/j.biocel.2004.05.009; Yao XL, 2006, NEUROSCI LETT, V409, P65, DOI 10.1016/j.neulet.2006.09.015; Zhang XZ, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms10938; Zhao Jiang, 2015, Journal of China Agricultural University, V20, P1	30	22	22	1	15	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	0893-7648	1559-1182		MOL NEUROBIOL	Mol. Neurobiol.	MAR	2018	55	3					2454	2470		10.1007/s12035-017-0504-8			17	Neurosciences	Neurosciences & Neurology	FY5TG	WOS:000426897800052	28365875	Green Accepted			2021-06-18	
J	Chan, C; Iverson, GL; Purtzki, J; Wong, K; Kwan, V; Gagnon, I; Silverberg, ND				Chan, Catherine; Iverson, Grant L.; Purtzki, Jacqueline; Wong, Kathy; Kwan, Vivian; Gagnon, Isabelle; Silverberg, Noah D.			Safety of Active Rehabilitation for Persistent Symptoms After Pediatric Sport-Related Concussion: A Randomized Controlled Trial	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Adolescent health; Athletic injuries; Craniocerebral trauma; Physical therapy modalities; Post-concussion syndrome; Rehabilitation	POSTCONCUSSIVE SYMPTOMS; PSYCHOMETRIC PROPERTIES; RECOVERY; CHILDREN; SCALES; ADOLESCENTS; RELIABILITY; VALIDITY; IMPACT; SLOW	Objectives: To examine the safety and tolerability of an active rehabilitation program for adolescents who are slow to recover from a sport-related concussion, and secondarily to estimate the treatment effect for this intervention. Design: Single-site, parallel, open-label, randomized controlled trial comparing treatment as usual (TAU) to TAU plus active rehabilitation. Setting: Outpatient concussion clinic. Participants: Adolescents (N=19) aged 12 to 18 years with postconcussion symptoms lasting >= 1 month after a sports-related concussion. Interventions: TAU consisted of symptom management and return-to-play advice, return-to-school facilitation, and physiatry consultation. The active rehabilitation program involved in-clinic subsymptom threshold aerobic training, coordination exercises, and visualization and imagery techniques with a physiotherapist (mean, 3.4 sessions) as well as a home exercise program, over 6 weeks. Main Outcome Measures: A blinded assessor systematically monitored for predetermined adverse events in weekly telephone calls over the 6-week intervention period. The treating physiotherapist also recorded in-clinic symptom exacerbations during aerobic training. The Post Concussion Symptom Scale was the primary efficacy outcome. Results: Nineteen participants were randomized, and none dropped out of the study. Of the 12 adverse events detected (6 in each group), 10 were symptom exacerbations from 1 weekly telephone assessment to the next, and 2 were emergency department visits. Four adverse events were referred to an external safety committee and deemed unrelated to the study procedures. In-clinic symptom exacerbations occurred in 30% (9/30) of aerobic training sessions, but resolved within 24 hours in all instances. In linear mixed modeling, active rehabilitation was associated with a greater reduction on the Post-Concussion Symptom Scale than TAU only. Conclusions: The results support the safety, tolerability, and potential efficacy of active rehabilitation for adolescents with persistent postconcussion symptoms. (C) 2017 by the American Congress of Rehabilitation Medicine	[Chan, Catherine; Purtzki, Jacqueline; Wong, Kathy] GF Strong Rehab Ctr, Vancouver, BC, Canada; [Chan, Catherine; Wong, Kathy] Univ British Columbia, Dept Phys Therapy, Vancouver, BC, Canada; [Iverson, Grant L.] Harvard Med Sch, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] A Red Sox Fdn, Home Base, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp Program, Boston, MA USA; [Iverson, Grant L.] MassGeneral Hosp Children, Sport Concuss Program, Boston, MA USA; [Purtzki, Jacqueline; Silverberg, Noah D.] Univ British Columbia, Div Phys Med & Rehabil, Vancouver, BC, Canada; [Wong, Kathy] Univ British Columbia, Dept Occupat Sci & Occupat Therapy, Vancouver, BC, Canada; [Kwan, Vivian] Univ Calgary, Calgary, AB, Canada; [Gagnon, Isabelle] McGill Univ, Montreal, PQ, Canada; [Gagnon, Isabelle] Montreal Childrens Hosp, Montreal, PQ, Canada; [Silverberg, Noah D.] Vancouver Coastal Hlth Res Inst, Rehabil Res Program, Vancouver, BC, Canada	Silverberg, ND (corresponding author), Rehabil Res Program, 4255 Laurel St, Vancouver, BC V5Z 2G9, Canada.	noah.silverberg@vch.ca		Iverson, Grant/0000-0001-7348-9570	Vancouver Coastal Health Research Institute	Supported by a Team Grant Award from the Vancouver Coastal Health Research Institute. Clinical Trial Registration No.: NCT02031068.	Alsalaheen B, 2016, SPORTS MED, V46, P1487, DOI 10.1007/s40279-016-0532-y; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Chrisman SPD, 2017, NEUROREHABILITATION, V40, P493, DOI 10.3233/NRE-161436; Cordingley D, 2016, J NEUROSURG-PEDIATR, V18, P693, DOI 10.3171/2016.5.PEDS16139; DiFazio M, 2016, CLIN PEDIATR, V55, P443, DOI 10.1177/0009922815589914; Gagnon I, 2016, SCAND J MED SCI SPOR, V26, P299, DOI 10.1111/sms.12441; Gagnon I, 2009, BRAIN INJURY, V23, P956, DOI 10.3109/02699050903373477; Griesbach GS, 2004, NEUROSCIENCE, V125, P129, DOI 10.1016/j.neuroscience.2004.01.030; Grool AM, 2016, JAMA-J AM MED ASSOC, V316, P2504, DOI 10.1001/jama.2016.17396; Imhoff S, 2016, J SPORTS MED, V2016, P5127374, DOI DOI 10.1155/2016/5127374; Irwin DE, 2010, QUAL LIFE RES, V19, P595, DOI 10.1007/s11136-010-9619-3; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Iverson GL, 2003, CLIN NEUROPSYCHOL, V17, P460, DOI 10.1076/clin.17.4.460.27934; Julious SA, 2005, PHARM STAT, V4, P287, DOI 10.1002/pst.185; Kurowski BG, 2017, J HEAD TRAUMA REHAB, V32, P79, DOI 10.1097/HTR.0000000000000238; Leddy JJ, 2007, NEUROREHABILITATION, V22, P199; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Leddy JJ, 2010, CLIN J SPORT MED, V20, P21, DOI 10.1097/JSM.0b013e3181c6c22c; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, J NEUROSURG, V98, P296, DOI 10.3171/jns.2003.98.2.0296; Maerlender A, 2015, DEV NEUROPSYCHOL, V40, P273, DOI 10.1080/87565641.2015.1067706; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; McCrory P, 2017, BRIT J SPORT MED, V51, P838, DOI 10.1136/bjsports-2017-097699; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2012, J ATHL TRAINING, V47, P221; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Mychasiuk R, 2016, EUR J NEUROSCI, V44, P2407, DOI 10.1111/ejn.13360; Schneider KJ, 2017, BRIT J SPORT MED, V51, DOI 10.1136/bjsports-2016-097475; Schneider KJ, 2014, BRIT J SPORT MED, V48, P1294, DOI 10.1136/bjsports-2013-093267; Silverberg ND, 2016, JAMA PEDIATR, V170, P946, DOI 10.1001/jamapediatrics.2016.1187; Stallard N, 2012, STAT MED, V31, P1031, DOI 10.1002/sim.4357; Steer, 2005, BECK YOUTH INVENTORI; Sullivan K, 2011, J HEAD TRAUMA REHAB, V26, P170, DOI 10.1097/HTR.0b013e3181e47f95; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Varni JW, 2008, QUAL LIFE RES, V17, P105, DOI 10.1007/s11136-007-9282-5; Varni JW, 2014, QUAL LIFE RES, V23, P1233, DOI 10.1007/s11136-013-0544-0; Varni JW, 2010, J PAIN, V11, P1109, DOI 10.1016/j.jpain.2010.02.005; Varni JW, 2009, PEDIATR CLIN N AM, V56, P843, DOI 10.1016/j.pcl.2009.05.016; Wells EM, 2016, J CHILD NEUROL, V31, P86, DOI 10.1177/0883073815570152; Wiebe DJ, 2016, JAMA PEDIATR, V170, P1108, DOI 10.1001/jamapediatrics.2016.1979	41	22	23	0	29	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2018	99	2					242	249		10.1016/j.apmr.2017.09.108			8	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	FU7YX	WOS:000424069800004	28989074				2021-06-18	
J	Ishii, N; Tsubouchi, H; Miura, A; Yanagi, S; Ueno, H; Shiomi, K; Nakazato, M				Ishii, Nobuyuki; Tsubouchi, Hironobu; Miura, Ayako; Yanagi, Shigehisa; Ueno, Hiroaki; Shiomi, Kazutaka; Nakazato, Masamitsu			Ghrelin alleviates paclitaxel-induced peripheral neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions in mice	EUROPEAN JOURNAL OF PHARMACOLOGY			English	Article						Ghrelin; Growth hormone secretagogue receptor; Paclitaxel; Chemotherapy-induced peripheral neuropathy; Peripheral neuropathic pain; PC12	TRAUMATIC BRAIN-INJURY; CONTRIBUTES; APOPTOSIS; PREVENTS; HORMONE; DISEASE; DRUG; STIMULATION; MECHANISMS; INDUCTION	Paclitaxel is an effective chemotherapeutic agent, but has some treatment-limiting adverse effects that markedly decrease patients' quality of life. Peripheral neuropathy is one of these, and no treatment for it has been established yet. Ghrelin, an endogenous ligand for the growth hormone secretagogue receptor, is secreted from the stomach and has widespread effects on multiple systems. We investigated the pharmacological potential of ghrelin in preventing paclitaxel-induced peripheral neuropathy using wild-type mice, ghrelin-null mice, and growth hormone secretagogue receptor-null mice. In wild-type mice, ghrelin administration alleviated mechanical and thermal hypersensitivity, and partially prevented neuronal loss of small unmyelinated intraepidermal nerve fibers but not large myelinated nerve fibers. Moreover, ghrelin administration decreased plasma oxidative and nitrosative stress and increased the expression of uncoupling protein 2 (UCP2) and superoxide dismutase 2 (SOD2) in the dorsal root ganglia, which are mitochondrial antioxidant proteins, and peroxisome proliferator-activated receptor gamma coactivator 1-alpha (PGC-1 alpha), a regulator of mitochondrial number. Both ghrelin-null mice and growth hormone secretagogue receptor-null mice developed more severe nerve injuries than wild-type mice. Our results suggest that ghrelin administration exerts a protective effect against paclitaxel-induced neuropathy by reducing oxidative stress and enhancing mitochondrial anti-oxidant functions, and that endogenous ghrelin has a neuroprotective effect that is mediated by ghrelin/growth hormone secretagogue receptor signaling. Ghrelin could be a promising therapeutic agent for the management of this intractable disease.	[Ishii, Nobuyuki; Tsubouchi, Hironobu; Miura, Ayako; Yanagi, Shigehisa; Ueno, Hiroaki; Shiomi, Kazutaka; Nakazato, Masamitsu] Univ Miyazaki, Fac Med, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, Miyazaki, Japan	Tsubouchi, H (corresponding author), Univ Miyazaki, Dept Internal Med, Div Neurol Respirol Endocrinol & Metab, 5200 Kihara, Kiyotake, Miyazaki 8891692, Japan.	hironobu_tsubouchi@med.miyazaki-u.ac.jp	ISHII, Nobuyuki/AAI-6966-2020	ISHII, Nobuyuki/0000-0003-1302-4151	Grants-in-Aid for Scientific ResearchMinistry of Education, Culture, Sports, Science and Technology, Japan (MEXT)Japan Society for the Promotion of ScienceGrants-in-Aid for Scientific Research (KAKENHI) [17K16051] Funding Source: KAKEN		Andrews ZB, 2008, NATURE, V454, P846, DOI 10.1038/nature07181; Andrews ZB, 2009, J NEUROSCI, V29, P14057, DOI 10.1523/JNEUROSCI.3890-09.2009; Andrews ZB, 2005, NAT REV NEUROSCI, V6, P829, DOI 10.1038/nrn1767; Bernardi P, 2006, FEBS J, V273, P2077, DOI 10.1111/j.1742-4658.2006.05213.x; Bobylev I, 2015, NEUROBIOL DIS, V82, P321, DOI 10.1016/j.nbd.2015.07.006; Boyette-Davis J, 2011, PAIN, V152, P308, DOI 10.1016/j.pain.2010.10.030; Carozzi VA, 2015, NEUROSCI LETT, V596, P90, DOI 10.1016/j.neulet.2014.10.014; CHAPLAN SR, 1994, J NEUROSCI METH, V53, P55, DOI 10.1016/0165-0270(94)90144-9; Dobutovic B, 2014, ARCH MED SCI, V10, P806, DOI 10.5114/aoms.2014.44872; Duggett NA, 2016, NEUROSCIENCE, V333, P13, DOI 10.1016/j.neuroscience.2016.06.050; Erriquez J, 2009, CELL CALCIUM, V46, P197, DOI 10.1016/j.ceca.2009.07.003; Fujimura K, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0094373; Garcia JM, 2008, ENDOCRINOLOGY, V149, P455, DOI 10.1210/en.2007-0828; Giuliani D, 2014, NEUROBIOL AGING, V35, P537, DOI 10.1016/j.neurobiolaging.2013.08.030; Kawai S, 2011, EXP ANIM TOKYO, V60, P481, DOI 10.1538/expanim.60.481; Ko MH, 2002, NEUROBIOL DIS, V11, P155, DOI 10.1006/nbdi.2002.0537; Ko MH, 2014, NEUROPEPTIDES, V48, P109, DOI 10.1016/j.npep.2014.02.001; Kojima M, 2006, NAT CLIN PRACT ENDOC, V2, P80, DOI 10.1038/ncpendmet0080; Kojima M, 1999, NATURE, V402, P656, DOI 10.1038/45230; Konaka K, 2017, J PHARM HEALTH CARE, V3, DOI 10.1186/s40780-017-0090-y; Kyoraku I, 2009, BIOCHEM BIOPH RES CO, V389, P405, DOI 10.1016/j.bbrc.2009.08.171; Li Y, 2013, ENDOCRINE, V43, P376, DOI 10.1007/s12020-012-9761-5; Liu XY, 2013, INFLAMMATION, V36, P1286, DOI 10.1007/s10753-013-9667-2; Lopez NE, 2012, BRAIN RES, V1489, P140, DOI 10.1016/j.brainres.2012.10.031; Masocha W, 2016, SCI REP-UK, V6, DOI 10.1038/srep21582; Masocha W, 2014, SCI REP-UK, V4, DOI 10.1038/srep06719; Nakazato M, 2001, NATURE, V409, P194, DOI 10.1038/35051587; Polomano RC, 2001, PAIN, V94, P293, DOI 10.1016/S0304-3959(01)00363-3; Qi L, 2014, ANN SURG, V260, P169, DOI 10.1097/SLA.0000000000000328; Qin Y, 2014, LIVER INT, V34, P567, DOI 10.1111/liv.12286; ROWINSKY EK, 1995, NEW ENGL J MED, V332, P1004, DOI 10.1056/NEJM199504133321507; Sato T, 2008, REGUL PEPTIDES, V145, P7, DOI 10.1016/j.regpep.2007.09.010; Sommer C, 1998, BRAIN RES, V784, P154, DOI 10.1016/S0006-8993(97)01327-9; Sun YX, 2004, P NATL ACAD SCI USA, V101, P4679, DOI 10.1073/pnas.0305930101; Tofthagen Cindy, 2010, Clin J Oncol Nurs, V14, pE22, DOI 10.1188/10.CJON.E22-E28; Tsuchimochi W, 2013, EUR J PHARMACOL, V702, P187, DOI 10.1016/j.ejphar.2013.01.035; Tsujino H, 2000, MOL CELL NEUROSCI, V15, P170, DOI 10.1006/mcne.1999.0814; Wu ZD, 1999, CELL, V98, P115, DOI 10.1016/S0092-8674(00)80611-X; Xu ZW, 2008, TOXICOLOGY, V247, P133, DOI 10.1016/j.tox.2008.02.018; Zeng M, 2015, INFLAMMATION, V38, P683, DOI 10.1007/s10753-014-9977-z; Zhang HJ, 2013, J PAIN, V14, P1031, DOI 10.1016/j.jpain.2013.03.012; Zhang HM, 2016, J PAIN, V17, P775, DOI 10.1016/j.jpain.2016.02.011	42	22	23	0	8	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0014-2999	1879-0712		EUR J PHARMACOL	Eur. J. Pharmacol.	JAN 15	2018	819						35	42		10.1016/j.ejphar.2017.11.024			8	Pharmacology & Pharmacy	Pharmacology & Pharmacy	FS2SQ	WOS:000419629200005	29154935				2021-06-18	
J	Yuan, Q; Yu, J; Wu, X; Sun, YR; Li, ZQ; Du, ZY; Wu, XH; Hu, J				Yuan, Qiang; Yu, Jian; Wu, Xing; Sun, Yi-rui; Li, Zhi-qi; Du, Zhuo-ying; Wu, Xue-hai; Hu, Jin			Prognostic value of coagulation tests for in-hospital mortality in patients with traumatic brain injury	SCANDINAVIAN JOURNAL OF TRAUMA RESUSCITATION & EMERGENCY MEDICINE			English	Article						Traumatic brain injury; Coagulopathy; Coagulation tests; Mortality; Prediction model	HEAD-INJURY; COAGULOPATHY; MODELS; PROGRESSION; IMPACT	Background: Coagulopathy is commonly observed after traumatic brain injury (TBI). However, it is not known whether using the standard independent predictors in conjunction with coagulation tests would improve their prognostic value. We determined the incidence of TBI-associated coagulopathy in patients with isolated TBI (iTBI), evaluated the prognostic value of coagulation tests for in-hospital mortality, and tested their predictive power for in-hospital mortality in patients with iTBI. Methods: We conducted a retrospective, observational database study on 2319 consecutive patients with iTBI who attended the Huashan Hospital Department of the Neurosurgery Neurotrauma Center at Fudan University in China between December 2004 and June 2015. Two models based on the admission characteristics were developed: model A included predictors such as age, Glasgow Coma Scale (GCS) score, pupil reactivity, type of injury, and hemoglobin and glucose levels, while model B included the predictors from model A as well as coagulation test results. A total of 1643 patients enrolled between December 2004 and December 2011 were used to derive the prognostic models, and 676 patients enrolled between January 2012 and June 2015 were used to validate the models. Results: Overall, 18.6% (n = 432) of the patients developed coagulopathy after iTBI. The prevalence of acute traumatic coagulopathy is associated with the severity of brain injury. The percentage of platelet count <100x109/L, international normalized ratio (INR) > 1.25, the prothrombin time (PT)>14 s, activated partial thromboplastin time (APTT) > 36 s, D-dimer >5 mg/L and fibrinogen (FIB) < 1.5 g/L was also closely related to the severity of brain injury, significance being found among three groups. Age, pupillary reactivity, GCS score, epidural hematoma (EDH), and glucose levels were independent prognostic factors for in-hospital mortality in model A, whereas age, pupillary reactivity, GCS score, EDH, glucose levels, INR >1.25, and APTT >36 s exhibited strong prognostic effects in model B. Discrimination and calibration were good for the development group in both prediction models. However, the external validation test showed that calibration was better in mode ! B than in mode ! A for patients from the validation population (Hosmer-Lemeshow test, p = 0.152 vs. p = 0.046, respectively). Conclusions: Coagulation tests can improve the predictive power of the standard mode ! for in-hospital mortality after TBI.	[Yuan, Qiang; Yu, Jian; Wu, Xing; Sun, Yi-rui; Li, Zhi-qi; Du, Zhuo-ying; Wu, Xue-hai; Hu, Jin] Fudan Univ, Huashan Hosp, Dept Neurosurg, 12 Wulumuqi Zhong Rd, Shanghai 200040, Peoples R China	Hu, J (corresponding author), Fudan Univ, Huashan Hosp, Dept Neurosurg, 12 Wulumuqi Zhong Rd, Shanghai 200040, Peoples R China.	yq123abc20146@163.com; hujindn@126.com			National Natural Science Foundation of China (NSFC)National Natural Science Foundation of China (NSFC) [81471241, 81271375, 81171133]	This work was supported by the National Natural Science Foundation of China (NSFC Grants 81471241, 81271375 and 81171133).	Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Cap AP, 2011, J TRAUMA, V71, pS78, DOI 10.1097/TA.0b013e3182218cd8; Manoel ALD, 2015, NEUROCRIT CARE, V22, P34, DOI 10.1007/s12028-014-0026-4; Dewall Jeremy, 2010, JEMS, V35, P54, DOI 10.1016/S0197-2510(10)70095-4; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Epstein DS, 2015, BRIT J NEUROSURG, V29, P118, DOI 10.3109/02688697.2014.950632; Epstein DS, 2014, INJURY, V45, P819, DOI 10.1016/j.injury.2014.01.011; Genet GF, 2013, J NEUROTRAUM, V30, P301, DOI 10.1089/neu.2012.2612; Halpern CH, 2008, J NEUROTRAUM, V25, P997, DOI 10.1089/neu.2008.0548; Harhangi BS, 2008, ACTA NEUROCHIR, V150, P165, DOI 10.1007/s00701-007-1475-8; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Kuo JR, 2004, J CLIN NEUROSCI, V11, P710, DOI 10.1016/j.jocn.2003.10.011; Kushimoto S, 2001, NEUROSURGERY, V49, P1084, DOI 10.1097/00006123-200111000-00011; Laroche M, 2012, NEUROSURGERY, V70, P1334, DOI 10.1227/NEU.0b013e31824d179b; Lustenberger T, 2010, INJURY, V41, P924, DOI 10.1016/j.injury.2010.04.019; Maas Andrew I R, 2015, Handb Clin Neurol, V128, P455, DOI 10.1016/B978-0-444-63521-1.00029-7; MacLeod JBA, 2003, J TRAUMA, V55, P39, DOI 10.1097/01.TA.0000075338.21177.EF; McCully SP, 2013, SEMIN THROMB HEMOST, V39, P896, DOI 10.1055/s-0033-1357484; Mushkudiani NA, 2008, J CLIN EPIDEMIOL, V61, P331, DOI 10.1016/j.jclinepi.2007.06.011; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Perel Pablo, 2006, BMC Med Inform Decis Mak, V6, P38, DOI 10.1186/1472-6947-6-38; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Steyerberg EW, 2008, BRIT MED J, V336, P789, DOI 10.1136/bmj.39542.610000.3A; Talving P, 2009, J TRAUMA, V66, P55, DOI 10.1097/TA.0b013e318190c3c0; Van Beek JGM, 2007, J NEUROTRAUM, V24, P315, DOI 10.1089/neu.2006.0034; Wafaisade A, 2010, NEUROCRIT CARE, V12, P211, DOI 10.1007/s12028-009-9281-1; West KL, 2011, J NEUROSURG, V114, P9, DOI 10.3171/2010.7.JNS091857; Yuan F, 2012, J TRAUMA ACUTE CARE, V73, P137, DOI 10.1097/TA.0b013e31824b00ac; Zehtahchi S, 2008, J TRAUMA, V65, P1571, DOI 10.1097/TA.0b013e31818c9c33	29	22	24	1	3	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1757-7241			SCAND J TRAUMA RESUS	Scand. J. Trauma Resusc. Emerg. Med.	JAN 5	2018	26								3	10.1186/s13049-017-0471-0			9	Emergency Medicine	Emergency Medicine	FS2PO	WOS:000419620800002	29304855	DOAJ Gold, Green Published			2021-06-18	
J	Baugh, CM; Weintraub, GS; Gregory, AJ; Djoko, A; Dompier, TP; Kerr, ZY				Baugh, Christine M.; Weintraub, Gil S.; Gregory, Andrew J.; Djoko, Aristarque; Dompier, Thomas P.; Kerr, Zachary Y.			Descriptive Epidemiology of Injuries Sustained in National Collegiate Athletic Association Men's and Women's Volleyball, 2013-2014 to 2014-2015	SPORTS HEALTH-A MULTIDISCIPLINARY APPROACH			English	Article						volleyball; injury epidemiology; college; concussion	SURVEILLANCE SYSTEM; PROSPECTIVE COHORT; UNITED-STATES; SPORTS; CONCUSSION; PLAYERS	Background: There were 18,844 volleyball players in the National Collegiate Athletic Association (NCAA) in the 2014-2015 academic year. Little research has examined sex-based differences among these athletes. Purpose: To examine injury epidemiology in NCAA men's and women's volleyball athletes. Study Design: Descriptive epidemiology study. Methods: Injury surveillance data from the 2013-2014 through 2014-2015 academic years were obtained from the NCAA Injury Surveillance Program for 6 men's and 33 women's collegiate volleyball teams. Injury rates per 1000 athlete-exposures (AEs) and injury rate ratios (IRRs) with 95% CIs were calculated. Time-loss (TL) injuries resulted in participation restriction for at least 24 hours, and non-time-loss (NTL) injuries resulted in participation restriction of less than 24 hours. Results: Overall, 83 and 510 injuries were reported in men and women, respectively, leading to injury rates of 4.69 and 7.07 per 1000 AEs. The injury rate was greater in women than men (IRR, 1.51; 95% CI, 1.19-1.90). TL injury rates were 1.75 and 2.62 per 1000 AEs for men and women, respectively. The ankle was the most commonly injured body part among TL injuries (men, 25.8%; women, 24.3%); the knee was the most commonly injured body part among NTL injuries (men, 25.5%; women, 16.3%). Among TL injuries, common diagnoses included sprains (men, 25.8%; women, 31.2%) and concussions (men, 19.4%; women, 14.8%). Most TL concussions were due to ball contact (men, 83.3%; women, 53.6%). Compared with men, women had a greater NTL overuse injury rate (IRR, 3.47; 95% CI, 1.61-7.46). Compared with women, men had a greater TL injury rate associated with ball contact (IRR, 2.24; 95% CI, 1.07-4.68). Conclusion: There are differences in injury patterns and rates between male and female intercollegiate volleyball players. Although a limited-contact sport, a notable number of concussions were sustained, mostly from ball contact.	[Baugh, Christine M.] Harvard Univ, Interfac Initiat Hlth Policy, Cambridge, MA 02138 USA; [Weintraub, Gil S.] Harvard Med Sch, Boston, MA USA; [Gregory, Andrew J.] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA; [Djoko, Aristarque] Datalys Ctr Sports Injury Res & Prevent, Indianapolis, IN USA; [Dompier, Thomas P.] Lebanon Valley Coll, Dept Athlet Training, Annville, PA USA; [Kerr, Zachary Y.] Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA	Kerr, ZY (corresponding author), Univ North Carolina Chapel Hill, Dept Exercise & Sport Sci, 313 Woollen Gym,CB 8700, Chapel Hill, NC 27599 USA.	zkerr@email.unc.edu	Baugh, Christine/AAG-2324-2020	Baugh, Christine/0000-0002-9340-6338	NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH019733] Funding Source: NIH RePORTER; NIMH NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH019733] Funding Source: Medline		Agel J, 2007, J ATHL TRAINING, V42, P295; Bahr R, 1997, SCAND J MED SCI SPOR, V7, P172, DOI 10.1111/j.1600-0838.1997.tb00135.x; Bere T, 2015, BRIT J SPORT MED, V49, P1132, DOI 10.1136/bjsports-2015-094959; Frey C, 2010, FOOT ANKLE INT, V31, P296, DOI 10.3113/FAI.2010.0296; Hartig DE, 1999, AM J SPORT MED, V27, P173, DOI 10.1177/03635465990270021001; Hreljac A, 2000, MED SCI SPORT EXER, V32, P1635; Kerr ZY, 2015, MMWR-MORBID MORTAL W, V64, P1330, DOI 10.15585/mmwr.mm6448a2; Kerr ZY, 2014, J ATHL TRAINING, V49, P552, DOI 10.4085/1062-6050-49.3.58; Kerr ZY, 2014, BRAIN INJURY, V28, P1009, DOI 10.3109/02699052.2014.904049; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Marar M, 2012, AM J SPORT MED, V40, P747, DOI 10.1177/0363546511435626; Reeser JC, 2015, SPORTS HEALTH, V7, P504, DOI 10.1177/1941738115600143; Verhagen EALM, 2004, BRIT J SPORT MED, V38, P477, DOI 10.1136/bjsm.2003.005785; Zuckerman SL, 2015, AM J SPORT MED, V43, P2654, DOI 10.1177/0363546515599634	14	22	22	0	18	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1941-7381	1941-0921		SPORTS HEALTH	Sports Health	JAN-FEB	2018	10	1					60	69		10.1177/1941738117733685			10	Sport Sciences	Sport Sciences	FQ4DC	WOS:000418306800009	28985702	Green Published			2021-06-18	
J	Chong, CD; Berisha, V; Chiang, CC; Ross, K; Schwedt, TJ				Chong, Catherine D.; Berisha, Visar; Chiang, Chia-Chun; Ross, Katherine; Schwedt, Todd J.			Less Cortical Thickness in Patients With Persistent Post-Traumatic Headache Compared With Healthy Controls: An MRI Study	HEADACHE			English	Article						cortical thickness; concussion; magnetic resonance imaging; migraine; post-traumatic headache; traumatic brain injury	TRAUMATIC BRAIN-INJURY; TRAIT ANXIETY; SEGMENTATION; INVENTORY; ACCURATE; REGIONS; STATE	ObjectiveTo investigate differences in cortical thickness in patients with persistent post-traumatic headache (PPTH) relative to healthy controls and to interrogate whether cortical morphology relates to headache burden (headache frequency, years with post-traumatic headache, PTH) in patients with PPTH. BackgroundPTHs are one of the most common symptoms following concussion. In some patients, PTHs continue for longer than three months and are classified as PPTH. This study has two main goals: (1) To delineate the neuropathology of PPTH, by interrogating differences in cortical thickness in patients with PPTH relative to healthy controls. (2) To interrogate potential associations between brain morphology and headache burden in patients with PPTH by examining whether cortical thickness relates to frequency of headaches or years lived with PTH. MethodsAdults with PPTH diagnosed according to ICHD 3 beta diagnostic criteria and healthy controls underwent brain MRI on a 3 Tesla scanner. Vertex-by-vertex whole brain estimates of cortical thickness were automatically calculated using FreeSurfer v5.3. Differences in cortical thickness in patients with PPTH relative to healthy controls were determined using a general linear model design. Associations were explored between regional clusters where patients with PPTH showed cortical thickness differences compared with healthy controls with headache frequency and years lived with PPTH. ResultsThis study included 33 patients with PPTH and 33 healthy control subjects (healthy controls: median age=33.0, IQR=15.5; patients with PPTH: median age=36.0, IQR=20.5; P=.56). Patients with PPTH had less cortical thickness relative to healthy controls in the left and right superior frontal, caudal middle frontal, and precentral cortex as well as less cortical thickness in the right supramarginal, right superior and inferior parietal, and right precuneus region (P<.05, Monte Carlo corrected for multiple comparisons). There were no regions where patients with PPTH had more cortical thickness relative to healthy controls. A correlation analysis of regions that showed less cortical thickness in patients with PPTH demonstrated a negative correlation between left and right superior frontal thickness with headache frequency (P<.05). There was no association between regional cortical thickness and years lived with PPTH. ConclusionCompared with healthy controls, patients with PPTH had less cortical thickness in bilateral frontal regions and right hemisphere parietal regions. For patients with PPTH, more frequent headaches were related to less thickness in the left and right superior frontal regions, potentially indicating that brain morphology changes in the superior frontal regions in patients with PPTH are modified by headache frequency.	[Chong, Catherine D.; Chiang, Chia-Chun; Schwedt, Todd J.] Mayo Clin, Dept Neurol, Phoenix, AZ USA; [Berisha, Visar] Arizona State Univ, Sch Elect Comp & Energy Engn, Tempe, AZ USA; [Berisha, Visar] Arizona State Univ, Dept Speech & Hearing Sci, Tempe, AZ 85287 USA; [Ross, Katherine] Phoenix VA Hlth Care Syst, Audiol & Speech Pathol Serv, Phoenix, AZ USA	Chong, CD (corresponding author), Mayo Clin, Neurol, 5777 East Mayo Blvd, Phoenix, AZ 85054 USA.	chong.catherine@mayo.edu		Berisha, Visar/0000-0001-8804-8874; Chiang, Chia-Chun/0000-0001-7802-7172	U.S. Department of DefenseUnited States Department of Defense [W81XWH-15-1-0286]; NIH Clinical CenterUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K23NS070891]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [K23NS070891] Funding Source: NIH RePORTER	U.S. Department of Defense, Grant/Award Number: W81XWH-15-1-0286; NIH Clinical Center, Grant/Award Number: K23NS070891.	Addolorato G, 1999, J PSYCHOSOM RES, V46, P283, DOI 10.1016/S0022-3999(98)00109-3; Albaugh MD, 2015, J PEDIATR-US, V166, P394, DOI 10.1016/j.jpeds.2014.10.016; Apkarian AV, 2011, PAIN, V152, pS49, DOI 10.1016/j.pain.2010.11.010; Baliki MN, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0026010; Beck AT, 1996, J PERS ASSESS, V67, P588, DOI 10.1207/s15327752jpa6703_13; CDC, 2003, C MILD TRAUM BRAIN I; Chong CD, 2017, NEUROIMAGE-CLIN, V13, P223, DOI 10.1016/j.nicl.2016.10.023; Chong CD, 2017, CEPHALALGIA, V37, P828, DOI 10.1177/0333102416652091; Chong CD, 2014, CEPHALALGIA, V34, P1115, DOI 10.1177/0333102414531157; D'souza Maria M, 2015, Indian J Radiol Imaging, V25, P404, DOI 10.4103/0971-3026.169445; Dale AM, 1999, NEUROIMAGE, V9, P179, DOI 10.1006/nimg.1998.0395; Dean PJ, 2015, BRAIN INJURY, P1; Desikan RS, 2006, NEUROIMAGE, V31, P968, DOI 10.1016/j.neuroimage.2006.01.021; Dikmen S, 2010, J INT NEUROPSYCH SOC, V16, P401, DOI 10.1017/S1355617710000196; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fischl B, 2004, CEREB CORTEX, V14, P11, DOI 10.1093/cercor/bhg087; Fischl B, 2001, IEEE T MED IMAGING, V20, P70, DOI 10.1109/42.906426; Fischl B, 2002, NEURON, V33, P341, DOI 10.1016/S0896-6273(02)00569-X; Ghodadra A, 2016, AM J NEURORADIOL, V37, P274, DOI 10.3174/ajnr.A4505; Gronenschild EHBM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038234; Hagler DJ, 2006, NEUROIMAGE, V33, P1093, DOI 10.1016/j.neuroimage.2006.07.036; Hayasaka S, 2003, NEUROIMAGE, V20, P2343, DOI 10.1016/j.neuroimage.2003.08.003; Jaramillo CA, 2016, HEADACHE, V56, P528, DOI 10.1111/head.12726; Jensen KB, 2013, ARTHRITIS RHEUM-US, V65, P3293, DOI 10.1002/art.38170; KNIGHT RG, 1983, BRIT J CLIN PSYCHOL, V22, P245, DOI 10.1111/j.2044-8260.1983.tb00610.x; Lange RT, 2015, ARCH CLIN NEUROPSYCH, V30, P7, DOI 10.1093/arclin/acu060; Lucas S., 2015, BRAIN NEUROTRAUMA MO; Merkley TL, 2008, J NEUROTRAUM, V25, P1343, DOI 10.1089/neu.2008.0615; Michael AP, 2015, J NEUROTRAUM, V32, P1751, DOI 10.1089/neu.2015.3918; Riederer F, 2017, HEADACHE, V57, P255, DOI 10.1111/head.12993; Schwedt TJ, 2015, HEADACHE, V55, P762, DOI 10.1111/head.12584; Schwedt TJ, 2014, CEPHALALGIA, V34, P947, DOI 10.1177/0333102414526069; Schwedt TJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099791; Segonne F, 2004, NEUROIMAGE, V22, P1060, DOI 10.1016/j.neuroimage.2004.03.032; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; Spielberger CD., 1989, MANUAL STATE TRAIT A, V2; Tate DF, 2014, BRAIN IMAGING BEHAV, V8, P102, DOI 10.1007/s11682-013-9257-9; Theeler B, 2013, HEADACHE, V53, P881, DOI 10.1111/head.12123; Torelli P, 2004, CEPHALALGIA, V24, P29, DOI 10.1111/j.1468-2982.2004.00633.x; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Walker WC, 2013, CEPHALALGIA, V33, P998, DOI 10.1177/0333102413482197; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492	42	22	22	0	7	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0017-8748	1526-4610		HEADACHE	Headache	JAN	2018	58	1					53	61		10.1111/head.13223			9	Clinical Neurology	Neurosciences & Neurology	FR4WP	WOS:000419067600005	29139130	Green Accepted, Bronze			2021-06-18	
J	Liang, JW; Wu, SH; Xie, WX; He, HF				Liang, Jinwei; Wu, Shanhu; Xie, Wenxi; He, Hefan			Ketamine ameliorates oxidative stress-induced apoptosis in experimental traumatic brain injury via the Nrf2 pathway	DRUG DESIGN DEVELOPMENT AND THERAPY			English	Article						traumatic brain injury; ketamine; oxidative stress; Nrf2; apoptosis	PROVIDES NEUROPROTECTION; AUTOPHAGY; RATS; ANTIOXIDANT; PROTECTS	Background: Ketamine can act as a multifunctional neuroprotective agent by inhibiting oxidative stress, cellular dysfunction, and apoptosis. Although it has been proven to be effective in various neurologic disorders, the mechanism of the treatment of traumatic brain injury (TBI) is not fully understood. The aim of this study was to investigate the neuroprotective function of ketamine in models of TBI and the potential role of the nuclear factor erythroid 2-related factor 2 (Nrf2) pathway in this putative protective effect. Materials and methods: Wild-type male mice were randomly assigned to five groups: Sham group, Sham + ketamine group, TBI group, TBI + vehicle group, and TBI + ketamine group. Marmarou's weight drop model in mice was used to induce TBI, after which either ketamine or vehicle was administered via intraperitoneal injection. After 24 h, the brain samples were collected for analysis. Results: Ketamine significantly ameliorated secondary brain injury induced by TBI, including neurological deficits, brain water content, and neuronal apoptosis. In addition, the levels of malondialdehyde (MDA), glutathione peroxidase (GPx), and superoxide dismutase (SOD) were restored by the ketamine treatment. Western blotting and immunohistochemistry showed that ketamine significantly increased the level of Nrf2. Furthermore, administration of ketamine also induced the expression of Nrf2 pathway-related downstream factors, including hemeoxygenase-1 and quinine oxidoreductase-1, at the pre- and post-transcriptional levels. Conclusion: Ketamine exhibits neuroprotective effects by attenuating oxidative stress and apoptosis after TBI. Therefore, ketamine could be an effective therapeutic agent for the treatment of TBI.	[Liang, Jinwei; Wu, Shanhu; Xie, Wenxi; He, Hefan] Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 248 East St, Quanzhou, Fujian, Peoples R China	He, HF (corresponding author), Fujian Med Univ, Affiliated Hosp 2, Dept Anesthesiol, 248 East St, Quanzhou, Fujian, Peoples R China.	fjhehefan@126.com			Fujian Province Natural Science FoundationNatural Science Foundation of Fujian Province [2016J01520]	This work was supported by grants from the Fujian Province Natural Science Foundation (No 2016J01520 from Professor Hehe Fan).	Bell JD, 2017, ANESTH ANALG, V124, P1237, DOI 10.1213/ANE.0000000000001856; Bergamo P, 2011, MOL NUTR FOOD RES, V55, pS248, DOI 10.1002/mnfr.201100295; Brown BP, 2015, NEUROSCIENCE, V290, P31, DOI 10.1016/j.neuroscience.2014.12.076; Chang LC, 2013, CNS NEUROSCI THER, V19, P390, DOI 10.1111/cns.12077; Cheng T, 2016, FREE RADICAL BIO MED, V92, P15, DOI 10.1016/j.freeradbiomed.2015.12.027; Ding K, 2015, NEUROCHEM INT, V91, P46, DOI 10.1016/j.neuint.2015.10.008; Eisenried A, 2017, PAIN, V158, P2181, DOI 10.1097/j.pain.0000000000001019; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Gao YY, 2017, AM J TRANSL RES, V9, P887; Gao YY, 2016, J SURG RES, V206, P67, DOI 10.1016/j.jss.2016.07.014; Halima B, 2018, J MED FOOD, V21, P70, DOI 10.1089/jmf.2017.0039; Lee DS, 2016, MOL MED REP, V13, P4911, DOI 10.3892/mmr.2016.5129; Lee JM, 2003, BBA-GENE STRUCT EXPR, V1629, P92, DOI 10.1016/j.bbaexp.2003.08.006; Liu ZW, 2017, NEUROCHEM RES, V42, P1375, DOI 10.1007/s11064-017-2186-z; Luggya TS, 2017, AFR HEALTH SCI, V17, P500, DOI 10.4314/ahs.v17i2.25; MARCOUX FW, 1988, BRAIN RES, V452, P329, DOI 10.1016/0006-8993(88)90037-6; Mas MF, 2017, PHYS MED REH CLIN N, V28, P829, DOI 10.1016/j.pmr.2017.06.014; McGirr A, 2017, BRAIN, V140, P2210, DOI 10.1093/brain/awx142; Mollayeva T, 2017, BMJ OPEN, V7, DOI 10.1136/bmjopen-2017-018626; Nakagami Y, 2016, OXID MED CELL LONGEV, V2016, DOI 10.1155/2016/7469326; Okonkwo DO, 2017, CRIT CARE MED, V45, P1907, DOI 10.1097/CCM.0000000000002619; Ozay R, 2017, WORLD NEUROSURG, V97, P407, DOI 10.1016/j.wneu.2016.09.115; Park JM, 2015, J CLIN BIOCHEM NUTR, V56, P132, DOI 10.3164/jcbn.14-76; Qin MZ, 2015, INT J CLIN EXP PATHO, V8, P12943; Reus GZ, 2017, PHARMACOL REP, V69, P1094, DOI 10.1016/j.pharep.2017.04.021; Romano R, 2017, J BREATH RES, V12; Sharma S, 2017, PLOS GENET, V13, DOI 10.1371/journal.pgen.1006804; Syatkin SP, 2016, B EXP BIOL MED+, V161, P703, DOI 10.1007/s10517-016-3489-9; Vazquez GH, 2017, CNS NEUROL DISORD-DR, V16, P858, DOI 10.2174/1871527316666170728165648; Xie YL, 2017, BIOMED PHARMACOTHER, V91, P70, DOI 10.1016/j.biopha.2017.04.070; Zanos P, 2016, NATURE, V533, P481, DOI 10.1038/nature17998; Zhai XF, 2016, NEUROIMMUNOMODULAT, V23, P179, DOI 10.1159/000448716; Zhou X, 2014, BIOL PHARM BULL, V37, P1282, DOI 10.1248/bpb.b14-00083; Zhu Min-min, 2007, Zhonghua Yi Xue Za Zhi, V87, P1308	34	22	23	0	2	DOVE MEDICAL PRESS LTD	ALBANY	PO BOX 300-008, ALBANY, AUCKLAND 0752, NEW ZEALAND	1177-8881			DRUG DES DEV THER	Drug Des. Dev. Ther.		2018	12						845	853		10.2147/DDDT.S160046			9	Chemistry, Medicinal; Pharmacology & Pharmacy	Pharmacology & Pharmacy	GD2JU	WOS:000430326700001	29713142	DOAJ Gold, Green Published			2021-06-18	
S	McKee, AC; Abdolmohammadi, B; Stein, TD		Hainline, B; Stern, RA		McKee, Ann C.; Abdolmohammadi, Bobak; Stein, Thor D.			The neuropathology of chronic traumatic encephalopathy	SPORTS NEUROLOGY	Handbook of Clinical Neurology		English	Article; Book Chapter							BRAIN-INJURY; DEMENTIA-PUGILISTICA; ALZHEIMERS-DISEASE; NEUROFIBRILLARY TANGLES; TAU PATHOLOGY; PUNCH-DRUNK; HEAD-INJURY; CONSENSUS; CRITERIA; PHOSPHORYLATION	Chronic traumatic encephalopathy (CTE) is a neurodegenerative tauopathy associated with repetitive head trauma, including concussion and subconcussion. CTE was first recognized in boxers nearly a century ago as "dementia pugilistica" or "punch drunk," but has been recently identified in contact sports athletes (including American football, ice hockey, soccer, baseball, rugby, boxing, and wrestling) and military veterans exposed to blast. Similar to many other neurodegenerative diseases, CTE is diagnosed conclusively only by neuropathologic examination of brain tissue. CTE is characterized by the buildup of hyperphosphorylated tau as neurofibrillary tangles, abnormal neurites, and inclusions in astrocytes around small blood vessels with a tendency to occur in clusters at the sulcal depths of the cortex. Using the McKee criteria, a consensus panel of expert neuropathologists confirmed CTE as a unique neurodegenerative disease with a pathognomonic CTE lesion that has only been found in individuals exposed to brain trauma. Recently, 177 instances of CTE were reported in a convenience sample of 202 former American football players, including 110 of 111 former National Football League players (99%), 48 of 53 former college football players (91%), and 3 of 14 former high school players (21%), by far the largest case series ever reported. Significant increases in active microglia and inflammation also occur after repetitive head impact injury and in CTE. A preliminary study showed that inflammatory cytokines were elevated in the brain tissue and cerebrospinal fluid of individuals with pathologically confirmed CTE compared to controls and individuals with Alzheimer disease, which may some day be useful in diagnosis of CTE during life. Although many fundamental questions remain to be answered regarding CTE, postmortem analysis of tissue from brain donors and tissue-based research have accelerated and expanded our current understanding of CTE and its pathogenesis. Guided by the neuropathologic findings, current research efforts are underway to develop biomarkers to diagnose CTE and effective ways to treat the disorder during life.	[McKee, Ann C.; Stein, Thor D.] VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA; [McKee, Ann C.; Abdolmohammadi, Bobak; Stein, Thor D.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA; [McKee, Ann C.; Abdolmohammadi, Bobak; Stein, Thor D.] Boston Univ, Sch Med, Dept Pathol, Boston, MA 02118 USA; [McKee, Ann C.; Abdolmohammadi, Bobak; Stein, Thor D.] Boston Univ, CTE Ctr, Boston, MA 02215 USA	McKee, AC (corresponding author), VA Boston Healthcare Syst, 150 S Huntington Ave, Boston, MA 02130 USA.	amckee@bu.edu	Lang, Steven/AAE-8102-2021	Lang, Steven/0000-0003-1669-9146			Armstrong RA, 2017, OPTOMETRY VISION SCI, V94, P33, DOI 10.1097/OPX.0000000000000911; Bieniek K, 2014, BRAIN PATHOL, V84; Bieniek KF, 2015, ACTA NEUROPATHOL, V130, P877, DOI 10.1007/s00401-015-1502-4; Braak H, 2003, NEUROBIOL AGING, V24, P197, DOI 10.1016/S0197-4580(02)00065-9; BRAAK H, 1991, ACTA NEUROPATHOL, V82, P239, DOI 10.1007/BF00308809; Cairns NJ, 2007, ACTA NEUROPATHOL, V114, P5, DOI 10.1007/s00401-007-0237-2; Cherry JD, 2016, ACTA NEUROPATHOL COM, V4, DOI 10.1186/s40478-016-0382-8; Cherry JJ, 2017, PLOS ONE, V12, DOI 10.1371/journal.pone.0185079; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; COURVILLE CYRIL B., 1962, BULL LOS ANGELES NEUROL SOC, V27, P160; Crane PK, 2016, JAMA NEUROL, V73, P1062, DOI 10.1001/jamaneurol.2016.1948; Critchley M, 1949, PUNCH DRUNK SYNDROME; Gardner RC, 2015, ANN NEUROL, V77, P987, DOI 10.1002/ana.24396; Geddes JF, 1999, ACTA NEUROPATHOL, V98, P171, DOI 10.1007/s004010051066; Geddes JF, 1996, NEUROPATH APPL NEURO, V22, P12, DOI 10.1111/j.1365-2990.1996.tb00840.x; Goldstein LE, 2012, SCI TRANSL MED, V4, DOI 10.1126/scitranslmed.3003716; Hay JR, 2015, J NEUROPATH EXP NEUR, V74, P1147, DOI [10.1093/jnen/74.12.1147, 10.1097/NEN.0000000000000261]; HOF PR, 1991, ACTA NEUROPATHOL, V82, P321, DOI 10.1007/BF00308819; HOF PR, 1992, ACTA NEUROPATHOL, V85, P23, DOI 10.1007/BF00304630; Holleran L, 2017, ACTA NEUROPATHOL, V133, P367, DOI 10.1007/s00401-017-1686-x; Huber BR, 2016, NEUROSCIENCE, V319, P206, DOI 10.1016/j.neuroscience.2016.01.022; Hyman BT, 1997, J NEUROPATH EXP NEUR, V56, P1095, DOI 10.1097/00005072-199710000-00002; Jafari S, 2013, MOVEMENT DISORD, V28, P1222, DOI 10.1002/mds.25458; Jordan B, 1992, MED ASPECTS BOXING; Kanaan NM, 2016, J NEUROPATH EXP NEUR, V75, P19, DOI 10.1093/jnen/nlv001; Kovacs GG, 2016, ACTA NEUROPATHOL, V131, P87, DOI 10.1007/s00401-015-1509-x; Lee PC, 2012, NEUROLOGY, V79, P2061, DOI 10.1212/WNL.0b013e3182749f28; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Ling HL, 2015, ACTA NEUROPATHOL, V130, P891, DOI 10.1007/s00401-015-1496-y; Marchi N, 2004, CLIN CHIM ACTA, V342, P1, DOI 10.1016/j.cccn.2003.12.008; Marchi N, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0056805; Martland HS, 1928, J AMER MED ASSOC, V91, P1103, DOI 10.1001/jama.1928.02700150029009; McKee AC, 2016, ACTA NEUROPATHOL, V131, P75, DOI 10.1007/s00401-015-1515-z; McKee AC, 2014, ALZHEIMERS DEMENT, V10, pS242, DOI 10.1016/j.jalz.2014.04.003; McKee AC, 2014, ACTA NEUROPATHOL, V127, P29, DOI 10.1007/s00401-013-1230-6; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; McKee AC, 2010, J NEUROPATH EXP NEUR, V69, P918, DOI 10.1097/NEN.0b013e3181ee7d85; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Mez J, 2017, JAMA-J AM MED ASSOC, V318, P360, DOI 10.1001/jama.2017.8334; Millspaugh J., 1937, US NAVAL MED B, V35, P297; MIRRA SS, 1991, NEUROLOGY, V41, P479, DOI 10.1212/WNL.41.4.479; Mufson EJ, 2018, J NEUROTRAUM, V35, P1260, DOI 10.1089/neu.2017.5368; Mufson EJ, 2016, BRAIN INJURY, V30, P1399, DOI 10.1080/02699052.2016.1219058; Omalu B, 2011, NEUROSURG FOCUS, V31, DOI 10.3171/2011.9.FOCUS11178; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Parker HL, 1934, J NEUROL PSYCHOPATHO, V15, P20; Perry DC, 2016, J NEUROSURG, V124, P511, DOI 10.3171/2015.2.JNS14503; ROBERTS GW, 1990, LANCET, V335, P918, DOI 10.1016/0140-6736(90)90520-F; Stein TD, 2015, ACTA NEUROPATHOL, V130, P21, DOI 10.1007/s00401-015-1435-y; Stein TD, 2014, ALZHEIMERS RES THER, V6, DOI 10.1186/alzrt234; Tagge CA, 2018, BRAIN, V141, P422, DOI 10.1093/brain/awx350; Thal Dietmar R, 2006, Sci Aging Knowledge Environ, V2006, pre1, DOI 10.1126/sageke.2006.6.re1; Williams DJ, 1996, PATHOLOGY, V28, P102, DOI 10.1080/00313029600169653; Woerman AL, 2016, P NATL ACAD SCI USA, V113, pE8187, DOI 10.1073/pnas.1616344113; Zhukareva V, 2001, ACTA NEUROPATHOL, V101, P518	56	22	22	0	5	ELSEVIER	AMSTERDAM	Radarweg 29, PO Box 211, AMSTERDAM, NETHERLANDS	0072-9752		978-0-44-463955-4; 978-0-444-63954-7	HAND CLINIC			2018	158						297	307		10.1016/B978-0-444-63954-7.00028-8			11	Clinical Neurology; Sport Sciences	Neurosciences & Neurology; Sport Sciences	BP1MW	WOS:000540371100030	30482357				2021-06-18	
J	McNutt, MK; Kale, AC; Kitagawa, RS; Turkmani, AH; Fields, DW; Baraniuk, S; Gill, BS; Cotton, BA; Moore, LJ; Wade, CE; Day, A; Holcomb, JB				McNutt, Michelle K.; Kale, A. Cozette; Kitagawa, Ryan S.; Turkmani, Ali H.; Fields, David W.; Baraniuk, Sarah; Gill, Brijesh S.; Cotton, Bryan A.; Moore, Laura J.; Wade, Charles E.; Day, Arthur; Holcomb, John B.			Management of blunt cerebrovascular injury (BCVI) in the multisystem injury patient with contraindications to immediate anti-thrombotic therapy	INJURY-INTERNATIONAL JOURNAL OF THE CARE OF THE INJURED			English	Article						BCVI; Stroke; Traumatic brain injury (TBI); Solid organ injury; Antithrombotic therapy	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; HEMORRHAGIC NEUROLOGIC INJURY; SCREENING CRITERIA; APPROPRIATE ROLE; TRAUMA PATIENTS; STROKE RATE; DIAGNOSIS; ANTICOAGULATION; ASSOCIATION; GUIDELINES	Introduction: Practice management guidelines for screening and treatment of patients with blunt cerebrovascular injury (BCVI) have been associated with a decreased risk of ischemic stroke. Treatment: of patients with BCVI and multisystem injuries that delays immediate antithrombotic therapy remains controversial. The purpose of this study was to determine the timing of BCVI treatment initiation, the incidence of stroke, and bleeding complications as a result of antithrombotic therapy in patients with isolated BCVI in comparison to those with BCVI complicated by multisystem injuries. Materials and methods: This study was a retrospective review of all adult blunt trauma patients admitted to a level 1 trauma center from 2009 to 2014 with a diagnosis of BCVI. Results: A total of 28,305 blunt trauma patients were admitted during the study period. Of these, 323 (1.1%) had 481 BCEVIs and were separated into two groups. Isolated BCVI was reported in 111 (34.4%) patients and 212 (65.6%) patients had accompanying multisystem injuries (traumatic brain injury (TBI), solid organ injury, or spinal cord injury) that contraindicated immediate antithrombotic therapy. Treatment: started in patients with isolated BCVI at a median time of 30.3 (15, 52) hours after injury in contrast to 62.4 (38, 97) hours for those with multisystem injuries (p<0.001). The incidence of stroke was identical (9.9%) between groups and no bleeding complications related to antithrombotic therapy were identified. Conclusion: The lack of bleeding complications and equivalent stroke rates between groups suggests that the presence of TBI, solid organ injury, and spinal cord injury are not contraindications to anti-thrombotic therapy for stroke prevention in patients with BCVI. (c) 2017 Elsevier Ltd. All rights reserved.	[McNutt, Michelle K.; Cotton, Bryan A.; Moore, Laura J.; Holcomb, John B.] Univ Texas Hlth Sci Ctr Houston, Mem Hermann Hosp, Red Duke Trauma Inst, Dept Surg, Houston, TX 77030 USA; [Kale, A. Cozette; Fields, David W.] Univ Texas Houston, Sch Med, McGovern Med Sch, Houston, TX USA; [Kitagawa, Ryan S.; Day, Arthur] Univ Texas Hlth Sci Ctr Houston, Texas Med Ctr, Mischer Neurosci Inst, Dept Neurosurg, Houston, TX 77030 USA; [Turkmani, Ali H.] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA; [Baraniuk, Sarah] Ctr Translat Injury Res CeTIR, Houston, TX USA; [Gill, Brijesh S.] Univ Texas Hlth Sci Ctr Houston, Dept Surg, Houston, TX 77030 USA; [Wade, Charles E.] Univ Texas Hlth Sci Ctr Houston, Ctr Translat Injury Res CeTIR, Dept Surg, Houston, TX 77030 USA	McNutt, MK (corresponding author), FACS, 6431 Fannin St,MSB 4-278, Houston, TX 77030 USA.	Michelle.K.McNutt@uth.tmc.edu; Alixandra.C.Kale@uth.tmc.edu; Ryan.S.Kitagawa@uth.tmc.edu; Ali.HassounTurkmani@uth.tmc.edu; David.W.Fields@uth.tmc.edu; Mary.Baraniuk@uth.tmc.edu; Brijesh.S.Gill@uth.tmc.edu; Bryan.A.Cotton@uth.tmc.edu; Laura.J.Moore@uth.tmc.edu; Charles.E.Wade@uth.tmc.edu; Arthur.L.Day@uth.tmc.edu; John.Holcomb@uth.tmc.edu		holcomb, john/0000-0001-8312-9157			[Anonymous], 2002, BLUNT VASCULAR NECK, P1, DOI [10.1097/01.TA.0000022083.35916.8A, DOI 10.1097/01.TA.0000022083.35916.8A]; Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2006, J TRAUMA, V60, P1204, DOI 10.1097/01.ta.0000220435.55791.ce; Biffl W, 2012, J TRAUMA ACUTE CARE, V72, P345; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Bromberg WJ, 2011, J TRAUMA, V70, P1063; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brott TG, 2012, J AM COLL CARDIOL, V60, P566, DOI [10.1016/j.jacc.2010.11.006, 10.1016/j.jacc.2012.06.006]; Bruns BR, 2014, J TRAUMA ACUTE CARE, V76, P691, DOI 10.1097/TA.0b013e3182ab1b4d; Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P539; Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P330, DOI 10.1097/TA.0b013e31823de8a0; Callcut RA, 2012, J TRAUMA ACUTE CARE, V72, P338, DOI 10.1097/TA.0b013e318243d978; Cothren CC, 2009, ARCH SURG-CHICAGO, V144, P685, DOI 10.1001/archsurg.2009.111; Cothren CC, 2005, AM J SURG, V190, P845, DOI 10.1016/j.amsurg.2005.08.007; Cothren CC, 2004, ARCH SURG-CHICAGO, V139, P540, DOI 10.1001/archsurg.139.5.540; DiCocco JM, 2011, ANN SURG, V253, P444, DOI 10.1097/SLA.0b013e31820d946b; Eastman AL, 2009, J TRAUMA, V67, P551, DOI 10.1097/TA.0b013e3181b84408; Emmett KP, 2011, J TRAUMA, V70, P1058, DOI 10.1097/TA.0b013e318213f849; Goodwin RB, 2009, J TRAUMA, V67, P1046, DOI 10.1097/TA.0b013e3181b83b63; Malhotra AK, 2007, ANN SURG, V246, P632, DOI 10.1097/SLA.0b013e3181568cab; Miller PR, 2001, J TRAUMA, V51, P1; Miller PR, PROSPECTIVE SCREENIN; Paulus EM, 2014, J TRAUMA ACUTE CARE, V76, P279, DOI 10.1097/TA.0000000000000101; Roberts DJ, 2013, ANN SURG, V257, P621, DOI 10.1097/SLA.0b013e318288c514; Stein DM, 2009, J TRAUMA, V66, P132, DOI 10.1097/TA.0b013e318142d146; Wahl WL, 2002, J TRAUMA, V52, P896, DOI 10.1097/00005373-200205000-00012; Wang AC, 2012, J TRAUMA ACUTE CARE, V72, P1599, DOI 10.1097/TA.0b013e318246ead4; Wei CW, 2010, CAN J NEUROL SCI, V37, P574, DOI 10.1017/S0317167100010726	28	22	22	0	1	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0020-1383	1879-0267		INJURY	Injury-Int. J. Care Inj.	JAN	2018	49	1					67	74		10.1016/j.injury.2017.07.036			8	Critical Care Medicine; Emergency Medicine; Orthopedics; Surgery	General & Internal Medicine; Emergency Medicine; Orthopedics; Surgery	FS9VT	WOS:000422767800011	28789779				2021-06-18	
J	Misquitta, K; Dadar, M; Tarazi, A; Hussain, MW; Alatwi, MK; Ebraheem, A; Multani, N; Khodadadi, M; Goswami, R; Wennberg, R; Tator, C; Green, R; Colella, B; Davis, KD; Mikulis, D; Grinberg, M; Sato, C; Rogaeva, E; Collins, DL; Tartaglia, MC				Misquitta, Karen; Dadar, Mahsa; Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Multani, Namita; Khodadadi, Mozhgan; Goswami, Ruma; Wennberg, Richard; Tator, Charles; Green, Robin; Colella, Brenda; Davis, Karen Deborah; Mikulis, David; Grinberg, Mark; Sato, Christine; Rogaeva, Ekaterina; Collins, D. Louis; Tartaglia, Maria Carmela			The relationship between brain atrophy and cognitive-behavioural symptoms in retired Canadian football players with multiple concussions	NEUROIMAGE-CLINICAL			English	Article						Sport-related concussion; Mild traumatic brain injury; Deformation based morphometry; Aging	CHRONIC TRAUMATIC ENCEPHALOPATHY; DEFORMATION-BASED MORPHOMETRY; HEAD-INJURY; RECURRENT CONCUSSION; HIPPOCAMPAL VOLUME; LEAGUE PLAYER; MILD; MRI; SEGMENTATION; ASSOCIATION	Multiple concussions, particularly in contact sports, have been associated with cognitive deficits, psychiatric impairment and neurodegenerative diseases like chronic traumatic encephalopathy. We used volumetric and deformation-based morphometric analyses to test the hypothesis that repeated concussions may be associated with smaller regional brain volumes, poorer cognitive performance and behavioural symptoms among former professional football players compared to healthy controls. This study included fifty-three retired Canadian Football League players, 25 age-and education-matched healthy controls, and controls from the Cambridge Centre for Aging and Neuroscience database for validation. Volumetric analyses revealed greater hippocampal atrophy than expected for age in former athletes with multiple concussions than controls and smaller left hippocampal volume was associated with poorer verbal memory performance in the former athletes. Deformation-based morphometry confirmed smaller bilateral hippocampal volume that was associated with poorer verbal memory performance in athletes. Repeated concussions may lead to greater regional atrophy than expected for age.	[Misquitta, Karen; Multani, Namita; Grinberg, Mark; Sato, Christine; Rogaeva, Ekaterina; Tartaglia, Maria Carmela] Univ Toronto, Tanz Ctr Res Neurodegenerat Dis, Krembil Discovery Tower,60 Leonard Ave, Toronto, ON M5T 0S8, Canada; [Dadar, Mahsa; Collins, D. Louis] McConnell Brain Imaging Ctr, Montreal Neurol Inst, 3801 Rue Univ, Montreal, PQ H3A 2B4, Canada; [Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Multani, Namita; Khodadadi, Mozhgan; Goswami, Ruma; Wennberg, Richard; Tator, Charles; Green, Robin; Colella, Brenda; Davis, Karen Deborah; Mikulis, David; Tartaglia, Maria Carmela] Toronto Western Hosp, Canadian Concuss Ctr, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Tarazi, Apameh; Hussain, Mohammed W.; Alatwi, Mohammed K.; Ebraheem, Ahmed; Khodadadi, Mozhgan; Wennberg, Richard; Tator, Charles; Tartaglia, Maria Carmela] Toronto Western Hosp, Krembil Neurosci Ctr, Div Neurol, 399 Bathurst St, Bathurst, ON M5T 2S8, Canada; [Goswami, Ruma; Davis, Karen Deborah] Toronto Western Hosp, Krembil Neurosci Ctr, Div Brain Imaging & Behav Syst Neurosci, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Tator, Charles] Univ Toronto, Dept Surg, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada; [Tator, Charles] Toronto Western Hosp, Krembil Neurosci Ctr, Div Neurosurg, 399 Bathurst St, Bathurst, ON M5T 2S8, Canada; [Green, Robin; Colella, Brenda] Univ Hlth Network, Toronto Rehabil Inst, 550 Univ Ave, Toronto, ON M5G 2A2, Canada; [Mikulis, David] Toronto Western Hosp, Dept Med Imaging, 399 Bathurst St, Toronto, ON M5T 2S8, Canada; [Misquitta, Karen; Tator, Charles; Green, Robin; Davis, Karen Deborah; Mikulis, David; Tartaglia, Maria Carmela] Univ Toronto, Inst Med Sci, 1 Kings Coll Circle, Toronto, ON M5S 1A8, Canada	Tartaglia, MC (corresponding author), Tanz Ctr Res Neurodegenerat Dis, Krembil Discovery Tower,60 Leonard Ave, Toronto, ON M5T 0S8, Canada.	carmela.tartaglia@uhn.ca	Mikulis, David J/H-5167-2019	Alatwi, Mohammed/0000-0002-0163-6698; Mikulis, David/0000-0003-3956-0892; Green, Robin/0000-0001-9451-3963; Dadar, Mahsa/0000-0003-4008-2672	Physicians' Services Incorporated Foundation; Toronto General and Western Hospital Foundation; UK Biotechnology and Biological Sciences Research CouncilUK Research & Innovation (UKRI)Biotechnology and Biological Sciences Research Council (BBSRC) [BB/H008217/1]; UK Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC); University of Cambridge, UKUniversity of Cambridge; CIHRCanadian Institutes of Health Research (CIHR); Andre Carron Family	This study was funded by the Physicians' Services Incorporated Foundation and the Toronto General and Western Hospital Foundation through specific donations to the Canadian Concussion Centre. We thank Leo Ezerins of the CFLAA for his help in recruiting participants. Data collection and sharing for this project was provided by the Cambridge Centre for Aging and Neuroscience (CamCAN). CamCAN funding was provided by the UK Biotechnology and Biological Sciences Research Council (grant number BB/H008217/1), together with support from the UK Medical Research Council and University of Cambridge, UK. KM funded by CIHR. DLC received a grant from the Andre Carron Family. DLC and MCT contributed to study concept and design. KM, MD, AT, MWH, MKA, AE, NM, MK, R Goswami, RW, CT, R Green, BC, KD, MG, CS, ER, DM, and MCT contributed to data acquisition and analysis. KM, MD and MCT contributed to preparing the manuscript. We thank all the participants for the generous contribution of their time.	Abner EL, 2014, DEMENT GERIATR COGN, V37, P294, DOI 10.1159/000355478; Ashburner J, 1998, HUM BRAIN MAPP, V6, P348, DOI 10.1002/(SICI)1097-0193(1998)6:5/6<348::AID-HBM4>3.3.CO;2-G; Bigler ED, 1997, AM J NEURORADIOL, V18, P11; Cantu RC, 2001, J ATHL TRAINING, V36, P244; Cole JH, 2015, ANN NEUROL, V77, P571, DOI 10.1002/ana.24367; Collins DL, 2010, NEUROIMAGE, V52, P1355, DOI 10.1016/j.neuroimage.2010.04.193; COLLINS DL, 1995, COMP IMAG VIS, V3, P139; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Collins DL, 1997, INT J PATTERN RECOGN, V11, P1271, DOI 10.1142/S0218001497000597; CORSELLIS JA, 1973, PSYCHOL MED, V3, P270, DOI 10.1017/S0033291700049588; Coupe P, 2008, IEEE T MED IMAGING, V27, P425, DOI 10.1109/TMI.2007.906087; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Debette S, 2011, NEUROLOGY, V77, P461, DOI 10.1212/WNL.0b013e318227b227; Dempsey RJ, 2003, J NEUROSURG, V98, P867, DOI 10.3171/jns.2003.98.4.0867; Fjell AM, 2013, NEUROBIOL AGING, V34, P2239, DOI 10.1016/j.neurobiolaging.2013.04.006; FRISK V, 1990, NEUROPSYCHOLOGIA, V28, P349, DOI 10.1016/0028-3932(90)90061-R; Gaser C, 2001, NEUROIMAGE, V13, P1140, DOI 10.1006/nimg.2001.0771; Goswami R, 2016, BRAIN STRUCT FUNCT, V221, P1911, DOI 10.1007/s00429-015-1012-0; Green REA, 2014, FRONT HUM NEUROSCI, V8, DOI 10.3389/fnhum.2014.00067; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz KM, 2005, NEUROSURGERY, V57, P719, DOI 10.1227/01.NEU.0000175725.75780.DD; HICKS RR, 1993, J NEUROTRAUM, V10, P405, DOI 10.1089/neu.1993.10.405; Hiploylee C, 2017, J NEUROTRAUM, V34, P1511, DOI 10.1089/neu.2016.4677; Ilvesmaki T, 2014, BRAIN, V137, P1876, DOI 10.1093/brain/awu095; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levine B, 2008, NEUROLOGY, V70, P771, DOI 10.1212/01.wnl.0000304108.32283.aa; MacKenzie JD, 2002, AM J NEURORADIOL, V23, P1509; MALIA K, 1995, BRAIN INJURY, V9, P697, DOI 10.3109/02699059509008226; Matthies S, 2012, WORLD J BIOL PSYCHIA, V13, P75, DOI 10.3109/15622975.2010.541282; Maxwell WL, 2003, J NEUROPATH EXP NEUR, V62, P272, DOI 10.1093/jnen/62.3.272; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Mckee AC, 2009, J NEUROPATH EXP NEUR, V68, P709, DOI 10.1097/NEN.0b013e3181a9d503; Meier TB, 2016, HUM BRAIN MAPP, V37, P833, DOI 10.1002/hbm.23072; Merritt VC, 2018, ARCH CLIN NEUROPSYCH, V33, P36, DOI 10.1093/arclin/acx051; Morey L.C, 1991, PSYCHOL ASSESSMENT R; Multani N, 2016, J NEUROL, V263, P1332, DOI 10.1007/s00415-016-8141-0; Omalu BI, 2006, NEUROSURGERY, V59, P1086, DOI 10.1227/01.NEU.0000245601.69451.27; Omalu Bennet I, 2010, J Forensic Nurs, V6, P130, DOI 10.1111/j.1939-3938.2010.01078.x; Omalu BI, 2005, NEUROSURGERY, V57, P128, DOI 10.1227/01.NEU.0000163407.92769.ED; Rabinowitz AR, 2014, PSYCHIAT CLIN N AM, V37, P1, DOI 10.1016/j.psc.2013.11.004; Rey A, 1964, EXAMEN CLIN PSYCHOL; SAUNDERS AM, 1993, NEUROLOGY, V43, P1467, DOI 10.1212/WNL.43.8.1467; Shafto MA, 2014, BMC NEUROL, V14, DOI 10.1186/s12883-014-0204-1; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Sled JG, 1998, IEEE T MED IMAGING, V17, P87, DOI 10.1109/42.668698; SMITH ML, 1981, NEUROPSYCHOLOGIA, V19, P781, DOI 10.1016/0028-3932(81)90090-7; Spreen O., 1991, COMPENDIUM NEUROPSYC; Strain JF, 2015, JAMA NEUROL, V72, P773, DOI 10.1001/jamaneurol.2015.0206; Tajima-Pozo K, 2015, ACTA NEUROPSYCHIATR, V27, P362, DOI 10.1017/neu.2015.34; Taylor JR, 2017, NEUROIMAGE, V144, P262, DOI 10.1016/j.neuroimage.2015.09.018; Tremblay S, 2014, CLIN NEUROPHYSIOL, V125, P1371, DOI 10.1016/j.clinph.2013.11.040; Tremblay S, 2013, CEREB CORTEX, V23, P1159, DOI 10.1093/cercor/bhs102; Wilde EA, 2006, BRAIN INJURY, V20, P695, DOI 10.1080/02699050600744079; Zagorchev L, 2016, J NEUROTRAUM, V33, P29, DOI 10.1089/neu.2014.3831	55	22	22	0	3	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	2213-1582			NEUROIMAGE-CLIN	NeuroImage-Clin.		2018	19						551	558		10.1016/j.nicl.2018.05.014			8	Neuroimaging	Neurosciences & Neurology	GQ7PL	WOS:000441936300057	29984163	DOAJ Gold, Green Published			2021-06-18	
S	Raine, A		Widiger, T; Cannon, TD		Raine, Adrian			Antisocial Personality as a Neurodevelopmental Disorder	ANNUAL REVIEW OF CLINICAL PSYCHOLOGY, VOL 14	Annual Review of Clinical Psychology		English	Article; Book Chapter						psychopathy; conduct disorder; imaging; epigenetics; neurocognition; prevention	CALLOUS-UNEMOTIONAL TRAITS; AGE 3 YEARS; MATERNAL CIGARETTE-SMOKING; TRAUMATIC BRAIN-INJURY; PRENATAL EXPOSURE; BEHAVIOR PROBLEMS; PSYCHOPATHIC TRAITS; EXTERNALIZING BEHAVIOR; CORTICAL THICKNESS; PREFRONTAL CORTEX	Although antisocial personality disorder (APD) is one of the most researched personality disorders, it is still surprisingly resistant to treatment. This lack of clinical progress may be partly due to the failure to view APD as a neurodevelopmental disorder and to consider early interventions. After first defining what constitutes a neurodevelopmental disorder, this review evaluates the extent to which APD meets neurodevelopmental criteria, covering structural and functional brain imaging, neurocognition, genetics and epigenetics, neurochemistry, and early health risk factors. Prevention and intervention strategies for APD are then outlined, focusing on addressing early biological and health systems, followed by forensic and clinical implications. It is argued both that APD meets criteria for consideration as a neurodevelopmental disorder and that consideration should be given both to the possibility that early onset conduct disorder is neurodevelopmental in nature, and also to the inclusion of psychopathy as a specifier in future Diagnostic and Statistical Manual revisions of APD.	[Raine, Adrian] Univ Penn, Dept Criminol, Philadelphia, PA 19104 USA; [Raine, Adrian] Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA; [Raine, Adrian] Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA	Raine, A (corresponding author), Univ Penn, Dept Criminol, Philadelphia, PA 19104 USA.; Raine, A (corresponding author), Univ Penn, Dept Psychiat, Philadelphia, PA 19104 USA.; Raine, A (corresponding author), Univ Penn, Dept Psychol, Philadelphia, PA 19104 USA.	araine@sas.upenn.edu					American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Archer J, 2005, AGGRESS VIOLENT BEH, V10, P241, DOI 10.1016/j.avb.2004.01.001; Astill RG, 2012, PSYCHOL BULL, V138, P1109, DOI 10.1037/a0028204; Barkataki I, 2006, BEHAV BRAIN RES, V169, P239, DOI 10.1016/j.bbr.2006.01.009; Beach SRH, 2011, PSYCHOSOM MED, V73, P83, DOI 10.1097/PSY.0b013e3181fdd074; Bechara A, 1997, SCIENCE, V275, P1293, DOI 10.1126/science.275.5304.1293; Berryessa CM, 2015, J MENT HEALTH RES IN, V8, P140, DOI 10.1080/19315864.2015.1040176; Bishop D. V. M., 2008, RUTTERS CHILD ADOLES, P32, DOI DOI 10.1002/9781444300895.CH3.PP.32-41; Blair RJR, 2008, PHILOS T R SOC B, V363, P2557, DOI 10.1098/rstb.2008.0027; Blair RJR, 2013, NAT REV NEUROSCI, V14, P786, DOI 10.1038/nrn3577; Boivin MJ, 2015, NATURE, V527, pS155, DOI 10.1038/nature16029; Bos PA, 2016, PSYCHONEUROENDOCRINO, V68, P194, DOI 10.1016/j.psyneuen.2016.03.006; Brook M, 2013, J ABNORM PSYCHOL, V122, P156, DOI 10.1037/a0030261; Bublitz MH, 2012, NICOTINE TOB RES, V14, P388, DOI 10.1093/ntr/ntr191; Buckholtz JW, 2010, NAT NEUROSCI, V13, P419, DOI 10.1038/nn.2510; Casement MD, 2014, DEV COGN NEUROS-NETH, V8, P18, DOI 10.1016/j.dcn.2013.12.003; Caspi A, 1996, ARCH GEN PSYCHIAT, V53, P1033; Caspi A, 2006, NAT REV NEUROSCI, V7, P583, DOI 10.1038/nrn1925; Cecil KM, 2008, PLOS MED, V5, P741, DOI 10.1371/journal.pmed.0050112; Checknita D, 2015, BRIT J PSYCHIAT, V206, P216, DOI 10.1192/bjp.bp.114.144964; Choy O, 2016, STOCKH CRIM S STOCKH; Dadds MR, 2014, DEV PSYCHOPATHOL, V26, P33, DOI 10.1017/S0954579413000497; Damasio A., 1994, DESCARTESERROR EMOTI; Decety J, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00489; Ducharme S, 2011, BIOL PSYCHIAT, V70, P283, DOI 10.1016/j.biopsych.2011.03.015; Duke AA, 2013, PSYCHOL BULL, V139, P1148, DOI 10.1037/a0031544; Esbensen AJ, 2016, INT REV RES DEV DISA, V51, P153, DOI 10.1016/bs.irrdd.2016.07.005; Fairchild G, 2011, AM J PSYCHIAT, V168, P624, DOI 10.1176/appi.ajp.2010.10081184; Fazel S, 2011, PLOS MED, V8, DOI 10.1371/journal.pmed.1001150; Frick PJ, 2003, DEV PSYCHOL, V39, P246, DOI 10.1037/0012-1649.39.2.246; Gajos JM, 2016, NEUROSCI BIOBEHAV R, V69, P147, DOI 10.1016/j.neubiorev.2016.07.017; Gao Y, 2010, AM J PSYCHIAT, V167, P56, DOI 10.1176/appi.ajp.2009.09040499; Gao Y, 2009, CAN J PSYCHIAT, V54, P813, DOI 10.1177/070674370905401204; Genkinger JM, 2015, ENVIRON RES, V140, P136, DOI 10.1016/j.envres.2015.03.017; Gibbon S, 2010, COCHRANE DB SYST REV, V6; Glenn AL, 2014, NAT REV NEUROSCI, V15, P54, DOI 10.1038/nrn3640; Glenn AL, 2010, BIOL PSYCHIAT, V67, P52, DOI 10.1016/j.biopsych.2009.06.018; Goldstein AN, 2014, ANNU REV CLIN PSYCHO, V10, P679, DOI 10.1146/annurev-clinpsy-032813-153716; Grafman J, 1996, NEUROLOGY, V46, P1231, DOI 10.1212/WNL.46.5.1231; Gregory S, 2012, ARCH GEN PSYCHIAT, V69, P962, DOI 10.1001/archgenpsychiatry.2012.222; Guillemin C, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086822; Haghighi A, 2013, JAMA PSYCHIAT, V70, P98, DOI 10.1001/archgenpsychiatry.2012.1101; Hanson JL, 2015, BIOL PSYCHIAT, V77, P314, DOI 10.1016/j.biopsych.2014.04.020; Herpers PCM, 2014, DEV PSYCHOPATHOL, V26, P245, DOI 10.1017/S0954579413000527; Holzel BK, 2011, PSYCHIAT RES-NEUROIM, V191, P36, DOI 10.1016/j.pscychresns.2010.08.006; Hofvander B, 2009, BMC PSYCHIATRY, V9, DOI 10.1186/1471-244X-9-35; Hyde LW, 2014, J ABNORM PSYCHOL, V123, P214, DOI 10.1037/a0035467; Jiang WX, 2017, SCI REP-UK, V7, DOI 10.1038/srep43002; Jiang WX, 2016, NEUROSCIENCE, V337, P143, DOI 10.1016/j.neuroscience.2016.08.052; Joseph J, 2014, HUM BRAIN MAPP, V35, P659, DOI 10.1002/hbm.22209; Khalifa N, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007667.pub2; Kiehl KA, 2006, PSYCHIAT RES, V142, P107, DOI 10.1016/j.psychres.2005.09.013; Kirk U, 2015, SOC COGN AFFECT NEUR, V10, P752, DOI 10.1093/scan/nsu112; Klein RG, 2012, ARCH GEN PSYCHIAT, V69, P1295, DOI 10.1001/archgenpsychiatry.2012.271; Koenigs M, 2011, MOL PSYCHIATR, V16, P792, DOI 10.1038/mp.2010.124; Kolla NJ, 2015, NEUROPSYCHOPHARMACOL, V40, P2596, DOI 10.1038/npp.2015.106; Kopsida E, 2016, FRONT NEUROSCI-SWITZ, V10, DOI 10.3389/fnins.2016.00066; Krueger RF, 2002, J ABNORM PSYCHOL, V111, P411, DOI 10.1037//0021-843X.111.3.411; Kumari V, 2014, AUST NZ J PSYCHIAT, V48, P153, DOI 10.1177/0004867413512690; Kumari V, 2009, SCHIZOPHR RES, V110, P47, DOI 10.1016/j.schres.2009.01.009; Larkby CA, 2011, J AM ACAD CHILD PSY, V50, P262, DOI 10.1016/j.jaac.2010.12.004; Li XR, 2010, HUM BRAIN MAPP, V31, P410, DOI 10.1002/hbm.20875; Liljegren M, 2015, JAMA NEUROL, V72, P295, DOI 10.1001/jamaneurol.2014.3781; Liu JH, 2004, AM J PSYCHIAT, V161, P2005, DOI 10.1176/appi.ajp.161.11.2005; Liu JH, 2015, INT J MOL SCI, V16, P18129, DOI 10.3390/ijms160818129; Liu JH, 2014, NUTRIENTS, V6, P530, DOI 10.3390/nu6020530; Liu JH, 2011, AGGRESS VIOLENT BEH, V16, P63, DOI 10.1016/j.avb.2010.12.003; Liu JH, 2009, J RES ADOLESCENCE, V19, P93, DOI 10.1111/j.1532-7795.2009.00583.x; Loeber R, 2000, J ABNORM CHILD PSYCH, V28, P353, DOI 10.1023/A:1005169026208; Marsh AA, 2008, NEUROSCI BIOBEHAV R, V32, P454, DOI 10.1016/j.neubiorev.2007.08.003; Marsh AA, 2011, PSYCHIAT RES-NEUROIM, V194, P279, DOI 10.1016/j.pscychresns.2011.07.008; Matthys W, 2012, CLIN CHILD FAM PSYCH, V15, P234, DOI 10.1007/s10567-012-0118-7; McNamara RK, 2010, AM J CLIN NUTR, V91, P1060, DOI 10.3945/ajcn.2009.28549; Meyer-Lindenberg A, 2006, P NATL ACAD SCI USA, V103, P6269, DOI 10.1073/pnas.0511311103; Millan MJ, 2013, NEUROPHARMACOLOGY, V68, P2, DOI 10.1016/j.neuropharm.2012.11.015; MOFFITT TE, 1993, PSYCHOL REV, V100, P674, DOI 10.1037/0033-295X.100.4.674; Moffitt TE, 2015, AM J PSYCHIAT, V172, P967, DOI 10.1176/appi.ajp.2015.14101266; Moffitt TE, 2015, CRIMINOLOGY, V53, P121, DOI 10.1111/1745-9125.12061; Montoya ER, 2013, PSYCHONEUROENDOCRINO, V38, P1362, DOI 10.1016/j.psyneuen.2012.12.001; Morales S, 2016, DEVELOPMENTAL SCI, V19, P853, DOI 10.1111/desc.12320; Narayan VM, 2007, AM J PSYCHIAT, V164, P1418, DOI 10.1176/appi.ajp.2007.06101631; Neugebauer R, 1999, JAMA-J AM MED ASSOC, V282, P455, DOI 10.1001/jama.282.5.455; O'Brien TC, 2013, NEUROTOXICOL TERATOL, V40, P67, DOI 10.1016/j.ntt.2013.09.002; OBrien BS, 1996, J ABNORM CHILD PSYCH, V24, P223, DOI 10.1007/BF01441486; Ogilvie JM, 2011, CRIMINOLOGY, V49, P1063, DOI 10.1111/j.1745-9125.2011.00252.x; Olds D, 1998, JAMA-J AM MED ASSOC, V280, P1238, DOI 10.1001/jama.280.14.1238; Olfson M, 2015, JAMA PSYCHIAT, V72, P867, DOI 10.1001/jamapsychiatry.2015.0500; Orff HJ, 2009, J HEAD TRAUMA REHAB, V24, P155, DOI 10.1097/HTR.0b013e3181a0b281; Pansky B., 1988, REV NEUROSCIENCE; Pappadopulos E, 2006, J CAN ACAD CHILD ADO, V15, P27; Pardini DA, 2014, BIOL PSYCHIAT, V75, P73, DOI 10.1016/j.biopsych.2013.04.003; Patrick C.J., 2007, PERSONALITY DISORDER, P109; Peterson BS, 2015, JAMA PSYCHIAT, V72, P531, DOI 10.1001/jamapsychiatry.2015.57; Pratt TC, 2016, CRIMINOLOGY, V54, P587, DOI 10.1111/1745-9125.12115; Provencal N, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089839; Pujara M, 2014, SOC COGN AFFECT NEUR, V9, P794, DOI 10.1093/scan/nst054; Raine A, 2002, J ABNORM CHILD PSYCH, V30, P311, DOI 10.1023/A:1015754122318; Raine A, 2003, AM J PSYCHIAT, V160, P1627, DOI 10.1176/appi.ajp.160.9.1627; Raine A, 2002, DEV PSYCHOPATHOL, V14, P25, DOI 10.1017/S0954579402001025; Raine A, 2001, PSYCHOPHYSIOLOGY, V38, P254, DOI 10.1111/1469-8986.3820254; Raine A, 2006, SOC COGN AFFECT NEUR, V1, P203, DOI 10.1093/scan/nsl033; Raine A, 2006, ANNU REV CLIN PSYCHO, V2, P291, DOI 10.1146/annurev.clinpsy.2.022305.095318; Raine A, 2017, J CHILD PSYCHOL PSYC, V58, P728, DOI 10.1111/jcpp.12693; Raine A, 2015, J CHILD PSYCHOL PSYC, V56, P509, DOI 10.1111/jcpp.12314; Raine A, 2010, BRIT J PSYCHIAT, V197, P186, DOI 10.1192/bjp.bp.110.078485; Raine Adrian, 2013, ANATOMY VIOLENCE BIO; Rautiainen MR, 2016, TRANSL PSYCHIAT, V6, DOI 10.1038/tp.2016.155; Rosenstrom T, 2017, BEHAV GENET, V47, P265, DOI 10.1007/s10519-016-9833-z; Sadeh A, 2015, DEV NEUROPSYCHOL, V40, P122, DOI 10.1080/87565641.2014.973498; Samuelson M, 2007, PRISON J, V87, P254, DOI 10.1177/0032885507303753; Sarkar S, 2016, PLOS ONE, V11, DOI 10.1371/journal.pone.0155475; SARWAR M, 1989, AM J NEURORADIOL, V10, P989; Semiz UB, 2008, TURK PSIKIYATR DERG, V19, P373; Shao YC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112222; Silva, 2001, SEX DIFFERENCES ANTI; Storebo OJ, 2016, J ATTEN DISORD, V20, P815, DOI 10.1177/1087054713512150; Swayze VW, 1997, PEDIATRICS, V99, P232, DOI 10.1542/peds.99.2.232; Timonen M, 2002, PSYCHIAT RES, V113, P217, DOI 10.1016/S0165-1781(02)00269-X; Toro R, 2008, NEUROPSYCHOPHARMACOL, V33, P1019, DOI 10.1038/sj.npp.1301484; Tottenham N, 2016, NEUROSCI BIOBEHAV R, V70, P217, DOI 10.1016/j.neubiorev.2016.07.030; Treit S, 2013, J NEUROSCI, V33, P10098, DOI 10.1523/JNEUROSCI.5004-12.2013; Tremblay RE, 2010, J CHILD PSYCHOL PSYC, V51, P341, DOI 10.1111/j.1469-7610.2010.02211.x; Tuvblad C, 2014, PSYCHOL ASSESSMENT, V26, P704, DOI 10.1037/a0036711; Vassos E, 2014, MOL PSYCHIATR, V19, P471, DOI 10.1038/mp.2013.31; Viding E, 2005, J CHILD PSYCHOL PSYC, V46, P592, DOI 10.1111/j.1469-7610.2004.00393.x; Wakschlag L, 2017, AM J PSYCHIAT; Wang DS, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0039501; White SF, 2013, J CHILD PSYCHOL PSYC, V54, P575, DOI 10.1111/j.1469-7610.2012.02603.x; WIDIGER TA, 2006, HDB PSYCHOPATHY, P156; Wilson HA, 2014, INT J FORENSIC MENT, V13, P36, DOI 10.1080/14999013.2014.890682; Yang YL, 2015, PSYCHIAT RES-NEUROIM, V231, P333, DOI 10.1016/j.pscychresns.2015.01.017; Yang YL, 2012, NEUROREPORT, V23, P702, DOI 10.1097/WNR.0b013e328355a62a; Yang YL, 2009, PSYCHIAT RES-NEUROIM, V174, P81, DOI 10.1016/j.pscychresns.2009.03.012; Yang YL, 2009, ARCH GEN PSYCHIAT, V66, P986, DOI 10.1001/archgenpsychiatry.2009.110; Yoo SS, 2007, CURR BIOL, V17, pR877, DOI 10.1016/j.cub.2007.08.007; Yorifuji T, 2017, ENVIRON INT, V99, P192, DOI 10.1016/j.envint.2016.11.016; Zhang HM, 2017, ENVIRON HEALTH PERSP, V125, P746, DOI 10.1289/EHP478	137	22	24	4	29	ANNUAL REVIEWS	PALO ALTO	4139 EL CAMINO WAY, PO BOX 10139, PALO ALTO, CA 94303-0897 USA	1548-5943			ANNU REV CLIN PSYCHO	Annu. Rev. Clin. Psychol.		2018	14						259	289		10.1146/annurev-clinpsy-050817084819			31	Psychology, Clinical; Psychology	Psychology	BK2KR	WOS:000433057100010	29401045				2021-06-18	
J	Simon, DW; Aneja, RK; Alexander, H; Bell, MJ; Bayir, H; Kochanek, PM; Clark, RSB				Simon, Dennis W.; Aneja, Rajesh K.; Alexander, Henry; Bell, Michael J.; Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.			Minocycline Attenuates High Mobility Group Box 1 Translocation, Microglial Activation, and Thalamic Neurodegeneration after Traumatic Brain Injury in Post-Natal Day 17 Rats	JOURNAL OF NEUROTRAUMA			English	Article						HMGB1; microglia; minocycline; neuroinflammation; traumatic brain injury	CEREBROSPINAL-FLUID; CYTOCHROME-C; NEUROPROTECTION; CHILDREN; STATES; MICE; DYSAUTONOMIA; IMPAIRMENT; APOPTOSIS; HMGB1	In response to cell injury, the danger signal high mobility group box-1 (HMGB) is released, activating macrophages by binding pattern recognition receptors. We investigated the role of the anti-inflammatory drug minocycline in attenuating HMGB1 translocation, microglial activation, and neuronal injury in a rat model of pediatric traumatic brain injury (TBI). Post-natal day 17 Sprague-Dawley rats underwent moderate-severe controlled cortical impact (CCI). Animals were randomized to treatment with minocycline (90mg/kg, intraperitoneally) or vehicle (saline) at 10min and 20h after injury. Shams received anesthesia and craniotomy. We analyzed HMGB1 translocation (protein fractionation and Western blotting), microglial activation (Iba-1 immunohistochemistry), neuronal death (Fluoro-Jade-B [FJB] immunofluorescence), and neuronal cell counts (unbiased stereology). Behavioral assessments included motor and Morris-water maze testing. Nuclear to cytosolic translocation of HMGB1 in the injured brain was attenuated in minocycline versus vehicle-treated rats at 24h (p<0.001). Treatment with minocycline reduced microglial activation in the ipsilateral cortex, hippocampus, and thalamus (p<0.05 vs. vehicle, all regions); attenuated neurodegeneration (FJB-positive neurons) at seven days (p<0.05 vs. vehicle); and increased thalamic neuronal survival at 14 days (naive 22773 +/- 1012 cells/mm(3), CCI + vehicle 11753 +/- 464, CCI + minocycline 17047 +/- 524; p<0.001). Minocycline-treated rats demonstrated delayed motor recovery early after injury but had no injury effect on Morris-water maze whereas vehicle-treated rats performed worse than sham on the final two days of testing (both p<0.05 vs. vehicle). Minocycline globally attenuated HMGB1 translocation and microglial activation in injured brain in a pediatric TBI model and afforded selective thalamic neuroprotection. The HMGB1 translocation and thalamic injury may represent novel mechanistic and regional therapeutic targets in pediatric TBI.	[Simon, Dennis W.; Aneja, Rajesh K.; Bell, Michael J.; Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA USA; [Simon, Dennis W.; Aneja, Rajesh K.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Pediat, Pittsburgh, PA 15261 USA; [Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15261 USA; [Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Dept Anesthesiol, Pittsburgh, PA 15261 USA; [Bayir, Hulya] Univ Pittsburgh, Sch Med, Dept Environm & Occupat Hlth, Pittsburgh, PA USA; [Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Clin & Translat Sci Inst, Pittsburgh, PA USA; [Alexander, Henry; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Simon, DW (corresponding author), Childrens Hosp Pittsburgh, 4401 Penn Ave, Pittsburgh, PA 15224 USA.	dennis.simon2@chp.edu			NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS38620, U01 NS081041]; NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32 HD40686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER	Support was received from NINDS grants R01 NS38620 and U01 NS081041; and NICHD T32 HD40686.	Alano CC, 2006, P NATL ACAD SCI USA, V103, P9685, DOI 10.1073/pnas.0600554103; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Au AK, 2012, J NEUROTRAUM, V29, P2013, DOI 10.1089/neu.2011.2171; Baguley IJ, 2008, NEUROCRIT CARE, V8, P293, DOI 10.1007/s12028-007-9021-3; Baguley IJ, 2014, J NEUROTRAUM, V31, P1515, DOI 10.1089/neu.2013.3301; Bell MJ, 1997, J NEUROTRAUM, V14, P451, DOI 10.1089/neu.1997.14.451; Bittigau D, 1999, ANN NEUROL, V45, P724, DOI 10.1002/1531-8249(199906)45:6<724::AID-ANA6>3.0.CO;2-P; Bramlett HM, 1997, ACTA NEUROPATHOL, V93, P190, DOI 10.1007/s004010050602; Bye N, 2007, EXP NEUROL, V204, P220, DOI 10.1016/j.expneurol.2006.10.013; Cascio A, 2004, ANTIMICROB AGENTS CH, V48, P2739, DOI 10.1128/AAC.48.7.2739-2741.2004; Cernak I, 2010, DEV NEUROSCI-BASEL, V32, P442, DOI 10.1159/000320085; Chhor V, 2017, BRAIN BEHAV IMMUN, V63, P197, DOI 10.1016/j.bbi.2016.11.001; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Elewa HF, 2006, PHARMACOTHERAPY, V26, P515, DOI 10.1592/phco.26.4.515; Fagan SC, 2004, EXP NEUROL, V186, P248, DOI 10.1016/j.expneurol.2003.12.006; Hanlon LA, 2016, J NEUROPATH EXP NEUR, V75, P214, DOI 10.1093/jnen/nlv021; Hayakawa K, 2008, STROKE, V39, P951, DOI 10.1161/STROKEAHA.107.495820; Homsi S, 2010, J NEUROTRAUM, V27, P911, DOI 10.1089/neu.2009.1223; Hu XR, 2010, EUR J PHARMACOL, V638, P84, DOI 10.1016/j.ejphar.2010.03.059; Jenkins LW, 2002, J NEUROTRAUM, V19, P715, DOI 10.1089/08977150260139101; Jin XM, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041892; Kabadi SV, 2012, NEUROTHERAPEUTICS, V9, P405, DOI 10.1007/s13311-011-0095-4; Kikuchi K, 2009, BIOCHEM BIOPH RES CO, V385, P132, DOI 10.1016/j.bbrc.2009.04.041; Kirk KA, 2012, DEV MED CHILD NEUROL, V54, P759, DOI 10.1111/j.1469-8749.2012.04322.x; Kovesdi Erzsebet, 2012, Front Neurol, V3, P111, DOI 10.3389/fneur.2012.00111; Kumar A, 2013, NEUROBIOL AGING, V34, P1397, DOI 10.1016/j.neurobiolaging.2012.11.013; Laird MD, 2014, GLIA, V62, P26, DOI 10.1002/glia.22581; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lu B, 2013, PROTEIN CELL, V4, P163, DOI 10.1007/s13238-012-2118-2; Mejia ROS, 2001, NEUROSURGERY, V48, P1393; Merianda TT, 2015, J NEUROSCI, V35, P5693, DOI 10.1523/JNEUROSCI.3397-14.2015; Morrison Wynne E, 2004, Pediatr Crit Care Med, V5, P145, DOI 10.1097/01.PCC.0000112373.71645.2A; Newell E, 2015, PEDIATR CRIT CARE ME, V16, P549, DOI 10.1097/PCC.0000000000000400; Okuma Y, 2014, NEUROPHARMACOLOGY, V85, P18, DOI 10.1016/j.neuropharm.2014.05.007; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Plane JM, 2010, ARCH NEUROL-CHICAGO, V67, P1442, DOI 10.1001/archneurol.2010.191; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Simon DW, 2017, NAT REV NEUROL, V13, P171, DOI 10.1038/nrneurol.2017.13; Siopi E, 2012, NEUROSCI LETT, V511, P110, DOI 10.1016/j.neulet.2012.01.051; Stackman RW, 2012, J NEUROSCI, V32, P10211, DOI 10.1523/JNEUROSCI.4868-11.2012; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Tang MK, 2010, J CEREBR BLOOD F MET, V30, P119, DOI 10.1038/jcbfm.2009.194; Vaccari JPD, 2014, J CEREBR BLOOD F MET, V34, P369, DOI 10.1038/jcbfm.2013.227; Walko TD, 2014, MOL MED, V20, P612, DOI 10.2119/molmed.2014.00156; Wallisch J. S., 2017, NEUROCRIT CARE; Whalen MJ, 1999, J NEUROTRAUM, V16, P299, DOI 10.1089/neu.1999.16.299; Wiley CA, 2016, J NEUROTRAUM, V33, P1866, DOI 10.1089/neu.2015.4272	47	22	23	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN	2018	35	1					130	138		10.1089/neu.2017.5093			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	FS1WO	WOS:000419569700015	28699371	Green Published			2021-06-18	
J	Hung, TH; Shyue, SK; Wu, CH; Chen, CC; Lin, CC; Chang, CF; Chen, SF				Hung, Tai-Ho; Shyue, Song-Kun; Wu, Chun-Hu; Chen, Chien-Cheng; Lin, Chao-Chang; Chang, Che-Feng; Chen, Szu-Fu			Deletion or inhibition of soluble epoxide hydrolase protects against brain damage and reduces microglia-mediated neuroinflammation in traumatic brain injury	ONCOTARGET			English	Article						soluble epoxide hydrolase; traumatic brain injury; microglia; inflammation; AUDA	NITRIC-OXIDE SYNTHASE; N-TERMINAL DOMAIN; P38 MAPK PATHWAYS; SUBARACHNOID HEMORRHAGE; INFLAMMATORY RESPONSES; THERAPEUTIC TARGET; CEREBRAL-ISCHEMIA; CORTICAL IMPACT; PPAR-GAMMA; C-FOS	Traumatic brain injury (TBI) induces a series of inflammatory processes that contribute to neuronal damage. The present study investigated the involvement of soluble epoxide hydrolase (sEH) in neuroinflammation and brain damage in mouse TBI and in microglial cultures. The effects of genetic deletion of sEH and treatment with an sEH inhibitor, 12-(3-adamantan-1-yl-ureido)-dodecanoic acid (AUDA), on brain damage and inflammatory responses were evaluated in mice subjected to controlled cortical impact. The anti-inflammatory mechanism of sEH inhibition/deletion was investigated in vitro. TBI-induced an increase in sEH protein level in the injured cortex from 1 h to 4 days and sEH was expressed in microglia. Genetic deletion of sEH significantly attenuated functional deficits and brain damage up to 28 days post-TBI. Deletion of sEH also reduced neuronal death, apoptosis, brain edema, and BBB permeability at 1 and 4 day(s). These changes were associated with markedly reduced microglial/macrophage activation, neutrophil infiltration, matrix metalloproteinase-9 activity, inflammatory mediator expression at 1 and 4 day(s), and epoxyeicosatrienoic acid (EET) degradation at 1 and 4 day(s). Administration of AUDA attenuated brain edema, apoptosis, inflammatory mediator upregulation and EET degradation at 4 days. In primary microglial cultures, AUDA attenuated both LPS-or IFN-Upsilon-stimulated nitric oxide (NO) production and reduced LPS-or IFN-Upsilon-induced p38 MAPK and NF-kappa B signaling. Deletion of sEH also reduced IFN-Upsilon-induced NO production. Moreover, AUDA attenuated N2A neuronal death induced by BV2 microglial-conditioned media. Our results suggest that inhibition of sEH may be a potential therapy for TBI by modulating the cytotoxic functions of microglia.	[Hung, Tai-Ho] Chang Gung Univ, Chang Gung Mem Hosp Taipei, Dept Obstet & Gynecol, Taoyuan, Taiwan; [Hung, Tai-Ho] Chang Gung Univ, Coll Med, Taoyuan, Taiwan; [Shyue, Song-Kun] Acad Sinica, Inst Biomed Sci, Taipei, Taiwan; [Wu, Chun-Hu] Natl Def Med Ctr, Grad Inst Life Sci, Taipei, Taiwan; [Chen, Chien-Cheng; Lin, Chao-Chang; Chen, Szu-Fu] Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan; [Chang, Che-Feng] Yale Univ, Sch Med, Dept Neurol, New Haven, CT 06510 USA; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Phys, Taipei, Taiwan; [Chen, Szu-Fu] Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan	Chen, SF (corresponding author), Cheng Hsin Gen Hosp, Dept Phys Med & Rehabil, Taipei, Taiwan.; Chen, SF (corresponding author), Natl Def Med Ctr, Dept Phys, Taipei, Taiwan.; Chen, SF (corresponding author), Natl Def Med Ctr, Dept Biophys, Taipei, Taiwan.	szufuchen@yahoo.com.tw	Hung, Tai-Ho/C-7584-2011; Shyue, Song-Kun/Q-2583-2018; Hung, Tai-Ho/ABD-1800-2020; WU, CHUN-HU/P-3958-2018	Shyue, Song-Kun/0000-0002-1057-8696; Chang, Che-Feng/0000-0002-3211-1739; WU, CHUN-HU/0000-0001-6851-7936; Hung, Tai-Ho/0000-0003-2354-7060	Ministry of Science and Technology of TaiwanMinistry of Science and Technology, Taiwan [MOST 101-2314-B-350-001-MY3, MOST 103-2314-B-182A-009-MY2]; Cheng Hsin General Hospital Foundation [CHGH104-29, CHGH104-30]	This study was supported by grants from the Ministry of Science and Technology of Taiwan (no. MOST 101-2314-B-350-001-MY3 and MOST 103-2314-B-182A-009-MY2) and Cheng Hsin General Hospital Foundation (no. CHGH104-29 and CHGH104-30).	Batchelor PE, 1999, J NEUROSCI, V19, P1708; Chang CF, 2011, AM J PATHOL, V178, P1749, DOI 10.1016/j.ajpath.2010.12.023; Chen CC, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0115694; Chen CC, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0030294; Chen SF, 2008, BRIT J PHARMACOL, V155, P1279, DOI 10.1038/bjp.2008.345; Chen SF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0045763; Chen XJ, 2016, MOL NEUROBIOL, V53, P1565, DOI 10.1007/s12035-015-9118-1; Cipriani R, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0308-6; Colton CA, 2009, J NEUROIMMUNE PHARM, V4, P399, DOI 10.1007/s11481-009-9164-4; Cronin A, 2003, P NATL ACAD SCI USA, V100, P1552, DOI 10.1073/pnas.0437829100; Cummins PM, 2012, MOL CELL BIOL, V32, P242, DOI 10.1128/MCB.06029-11; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Gao YX, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0040258; Greter M, 2015, FRONT IMMUNOL, V6, DOI 10.3389/fimmu.2015.00249; Haase G, 2008, CURR OPIN NEUROBIOL, V18, P284, DOI 10.1016/j.conb.2008.07.013; Holmin S, 1998, NEUROSURGERY, V42, P291, DOI 10.1097/00006123-199802000-00047; Hou HH, 2015, SCI REP-UK, V5, DOI 10.1038/srep13524; Hou HH, 2012, CARDIOVASC RES, V93, P120, DOI 10.1093/cvr/cvr267; Hu XM, 2015, NAT REV NEUROL, V11, P56, DOI 10.1038/nrneurol.2014.207; Hung YW, 2015, BRAIN BEHAV IMMUN, V43, P118, DOI 10.1016/j.bbi.2014.07.016; Iliff JJ, 2010, PROSTAG OTH LIPID M, V91, P68, DOI 10.1016/j.prostaglandins.2009.06.004; Imig JD, 2009, NAT REV DRUG DISCOV, V8, P794, DOI 10.1038/nrd2875; Jara JH, 2007, J NEUROCHEM, V100, P1407, DOI 10.1111/j.1471-4159.2006.04330.x; Karve IP, 2016, BRIT J PHARMACOL, V173, P692, DOI 10.1111/bph.13125; Khan MAH, 2013, HYPERTENSION, V62, P905, DOI 10.1161/HYPERTENSIONAHA.113.01949; Kim JH, 2010, J NEUROCHEM, V115, P1161, DOI 10.1111/j.1471-4159.2010.07004.x; Koistinaho M, 2002, GLIA, V40, P175, DOI 10.1002/glia.10151; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Liao YL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0068963; Liu Y, 2005, P NATL ACAD SCI USA, V102, P16747, DOI 10.1073/pnas.0508081102; Liu Y, 2016, J MOL NEUROSCI, V58, P254, DOI 10.1007/s12031-015-0670-y; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Lotocki G, 2006, EUR J NEUROSCI, V24, P2283, DOI 10.1111/j.1460-9568.2006.05123.x; Marmarou A, 2003, ACT NEUR S, V86, P7; Martini RP, 2014, J NEUROSURG, V121, P1359, DOI 10.3171/2014.7.JNS131990; McConeghy KW, 2012, CNS DRUGS, V26, P613, DOI 10.2165/11634020-000000000-00000; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Morin C, 2010, AM J RESP CELL MOL, V43, P564, DOI 10.1165/rcmb.2009-0155OC; Nag S, 2009, NEUROPATH APPL NEURO, V35, P417, DOI 10.1111/j.1365-2990.2008.01009.x; Nag S, 2009, ACTA NEUROPATHOL, V118, P197, DOI 10.1007/s00401-009-0541-0; POVLISHOCK JT, 1978, BRAIN RES, V153, P223, DOI 10.1016/0006-8993(78)90404-3; Qin XC, 2015, MOL NEUROBIOL, V52, P187, DOI 10.1007/s12035-014-8833-3; Raghupathi R, 1996, MOL BRAIN RES, V37, P134, DOI 10.1016/0169-328X(95)00289-5; Raghupathi R, 2002, NEUROSCIENCE, V110, P605, DOI 10.1016/S0306-4522(01)00461-4; Revermann M, 2010, CURR OPIN PHARMACOL, V10, P173, DOI 10.1016/j.coph.2009.12.002; Sanders WG, 2012, AM J PHYSIOL-CELL PH, V303, pC278, DOI 10.1152/ajpcell.00386.2011; Shlosberg D, 2010, NAT REV NEUROL, V6, P393, DOI 10.1038/nrneurol.2010.74; Siler DA, 2015, STROKE, V46, P1916, DOI 10.1161/STROKEAHA.114.008560; Simpkins AN, 2009, AM J PATHOL, V174, P2086, DOI 10.2353/ajpath.2009.080544; Siopi E, 2013, NEUROPHARMACOLOGY, V67, P183, DOI 10.1016/j.neuropharm.2012.11.009; Skovira JW, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0769-2; Smith KR, 2005, P NATL ACAD SCI USA, V102, P2186, DOI 10.1073/pnas.0409591102; Srivastava K, 2012, CELL MOL NEUROBIOL, V32, P319, DOI 10.1007/s10571-011-9777-z; Strauss KI, 2013, PROSTAG OTH LIPID M, V104, P18, DOI 10.1016/j.prostaglandins.2012.07.005; Sun J, 2016, J MOL NEUROSCI, V59, P90, DOI 10.1007/s12031-016-0717-8; Svensson C, 2011, BIOCHEM BIOPH RES CO, V406, P488, DOI 10.1016/j.bbrc.2011.02.083; Tanaka H, 2008, BBA-GENE REGUL MECH, V1779, P17, DOI 10.1016/j.bbagrm.2007.11.005; Taylor RA, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/746068; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Wagner EF, 2009, NAT REV CANCER, V9, P537, DOI 10.1038/nrc2694; Wu CH, 2016, J NEUROINFLAMM, V13, DOI 10.1186/s12974-016-0524-8; Wu CH, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113397; YANG K, 1994, BRAIN RES, V664, P141, DOI 10.1016/0006-8993(94)91964-X; Yuan L, 2016, NEUROPATH APPL NEURO, V42, P607, DOI 10.1111/nan.12291; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang WR, 2008, STROKE, V39, P2073, DOI 10.1161/STROKEAHA.107.508325; Zhang Y, 2017, J NEUROCHEM, V140, P814, DOI 10.1111/jnc.13933; Zhao JB, 2011, NEUROSCI LETT, V498, P147, DOI 10.1016/j.neulet.2011.05.001; Zhou C, 2016, CELL PHYSIOL BIOCHEM, V39, P721, DOI 10.1159/000445663; Zhou DX, 2014, CELL SIGNAL, V26, P192, DOI 10.1016/j.cellsig.2013.11.004; Zhou HZ, 2012, J NEUROPATH EXP NEUR, V71, P348, DOI 10.1097/NEN.0b013e31824ea078; Zweckberger K, 2006, J NEUROTRAUM, V23, P1083, DOI 10.1089/neu.2006.23.1083	72	22	23	1	3	IMPACT JOURNALS LLC	ORCHARD PARK	6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA		1949-2553		ONCOTARGET	Oncotarget	NOV 28	2017	8	61					103236	103260		10.18632/oncotarget.21139			25	Oncology; Cell Biology	Oncology; Cell Biology	FS1TY	WOS:000419562500041	29262558	Other Gold, Green Published			2021-06-18	
J	Mann, AP; Scodeller, P; Hussain, S; Braun, GB; Molder, T; Toome, K; Ambasudhan, R; Teesalu, T; Lipton, SA; Ruoslahti, E				Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; Molder, Tarmo; Toome, Kadri; Ambasudhan, Rajesh; Teesalu, Tambet; Lipton, Stuart A.; Ruoslahti, Erkki			Identification of a peptide recognizing cerebrovascular changes in mouse models of Alzheimer's disease	NATURE COMMUNICATIONS			English	Article							TISSUE GROWTH-FACTOR; CEREBRAL AMYLOID ANGIOPATHY; PLURIPOTENT STEM-CELLS; REACTIVE ASTROCYTES; ENDOTHELIAL-CELLS; INVADING FIBROBLASTS; PARKINSONS-DISEASE; SPINAL-CORD; EXPRESSION; THERAPY	Cerebrovascular changes occur in Alzheimer's disease (AD). Using in vivo phage display, we searched for molecular markers of the neurovascular unit, including endothelial cells and astrocytes, in mouse models of AD. We identified a cyclic peptide, CDAGRKQKC (DAG), that accumulates in the hippocampus of hAPP-J20 mice at different ages. Intravenously injected DAG peptide homes to neurovascular unit endothelial cells and to reactive astrocytes in mouse models of AD. We identified connective tissue growth factor (CTGF), a matricellular protein that is highly expressed in the brain of individuals with AD and in mouse models, as the target of the DAG peptide. We also showed that exogenously delivered DAG homes to the brain in mouse models of glioblastoma, traumatic brain injury, and Parkinson's disease. DAG may potentially be used as a tool to enhance delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.	[Mann, Aman P.; Scodeller, Pablo; Hussain, Sazid; Braun, Gary B.; Ruoslahti, Erkki] Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA; [Scodeller, Pablo; Molder, Tarmo; Toome, Kadri; Teesalu, Tambet] Univ Tartu, Inst Biomed & Translat Med, Canc Biol Lab, EE-50411 Tartu, Estonia; [Hussain, Sazid] AivoCode Inc, La Jolla, CA 92037 USA; [Ambasudhan, Rajesh; Lipton, Stuart A.] Scintillon Inst, Neurodegenerat Dis Ctr, San Diego, CA 92121 USA; [Lipton, Stuart A.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA; [Ruoslahti, Erkki] Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA	Ruoslahti, E (corresponding author), Sanford Burnham Prebys Med Discovery Inst, Canc Res Ctr, La Jolla, CA 92037 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Ctr Nanomed, Santa Barbara, CA 93106 USA.; Ruoslahti, E (corresponding author), Univ Calif Santa Barbara, Dept Cell Mol & Dev Biol, Santa Barbara, CA 93106 USA.	ruoslahti@sbpdiscovery.org	Scodeller, Pablo/AAH-7694-2019	Scodeller, Pablo/0000-0003-0745-2467	NCI GrantUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30 CA30199]; Defense Advanced Research Projects Agency (DARPA)United States Department of DefenseDefense Advanced Research Projects Agency (DARPA) [N66001-14-1-4010]; European Research CouncilEuropean Research Council (ERC)European Commission [291910]; Wellcome Trust International FellowshipWellcome Trust [WT095077MA]; European Union through the European Regional Development FundEuropean Commission [2014-2020.4.01.15-0012]; NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 HD29587, R01 NS086890, DP1 DA041722, P30 NS076411]; Distinguished Investigator Award of the Brain & Behavior Research Foundation; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [P01HD029587] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [P30CA030199] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS097867, R01NS086890, P30NS076411] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG058013, R01AG056259, RF1AG057409] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [DP1DA041722] Funding Source: NIH RePORTER	We thank Prof. R. Bjerkvig at University of Bergen for sharing the P13 glioma cells, Prof. Lawrence Goldstein at UCSD for AD hiPSCs; Nima Dolatabadi, Daniel Joseph and James Parker at the Scintillon Institute for assistance in studies involving hiPSC differentiation; Tracy Fang Newmeyer for help with animal studies; Venkata R. Kotamraju for peptide synthesis; and the New York Brain Bank at Columbia University for sharing human AD brain tissues. Proteomics analysis and histology was performed by proteomics and histology core respectively at Sanford Burnham Prebys, supported by the NCI Grant, P30 CA30199. This work was supported in part by the Defense Advanced Research Projects Agency (DARPA) under Cooperative Agreement N66001-14-1-4010 (to E.R.). The findings and views expressed are those of the authors and do not reflect the official policy or position of the Department of Defense or the U.S. Government. T.T. was supported by grants from the European Research Council (No. 291910), the Wellcome Trust International Fellowship (WT095077MA), and by European Union through the European Regional Development Fund (Project No. 2014-2020.4.01.15-0012). R. A. and S.A.L. were supported by NIH grants P01 HD29587, R01 NS086890, DP1 DA041722, and P30 NS076411, and by a Distinguished Investigator Award of the Brain & Behavior Research Foundation.	Agemy L, 2011, P NATL ACAD SCI USA, V108, P17450, DOI 10.1073/pnas.1114518108; Baloyannis SJ, 2012, J NEUROL SCI, V322, P117, DOI 10.1016/j.jns.2012.07.010; BJERKVIG R, 1990, J NEUROSURG, V72, P463, DOI 10.3171/jns.1990.72.3.0463; Bougnaud S, 2016, ONCOTARGET, V7, P31955, DOI 10.18632/oncotarget.7454; Braun GB, 2014, NAT MATER, V13, P904, DOI [10.1038/NMAT3982, 10.1038/nmat3982]; Chen ZL, 1997, CELL, V91, P917, DOI 10.1016/S0092-8674(00)80483-3; Chesselet MF, 2012, NEUROTHERAPEUTICS, V9, P297, DOI 10.1007/s13311-012-0104-2; Conrad S, 2005, J NEUROSURG-SPINE, V2, P319, DOI 10.3171/spi.2005.2.3.0319; Dadosh T, 2009, MATER LETT, V63, P2236, DOI 10.1016/j.matlet.2009.07.042; de la Torre JC, 2014, NEW ENGL J MED, V370, P1459, DOI 10.1056/NEJMc1402193; de la Torre JC, 2002, STROKE, V33, P1152, DOI 10.1161/01.STR.0000014421.15948.67; De Winter P, 2008, GROWTH FACTORS, V26, P80, DOI 10.1080/08977190802025602; Farkas E, 2001, PROG NEUROBIOL, V64, P575, DOI 10.1016/S0301-0082(00)00068-X; Hoshi A, 2011, EXP NEUROL, V227, P89, DOI 10.1016/j.expneurol.2010.09.016; Israel MA, 2012, NATURE, V482, P216, DOI 10.1038/nature10821; Jacobsen JS, 2006, P NATL ACAD SCI USA, V103, P5161, DOI 10.1073/pnas.0600948103; Jun JI, 2011, NAT REV DRUG DISCOV, V10, P945, DOI 10.1038/nrd3599; Lin TX, 2009, NAT METHODS, V6, P805, DOI [10.1038/nmeth.1393, 10.1038/NMETH.1393]; Lippmann ES, 2012, NAT BIOTECHNOL, V30, P783, DOI 10.1038/nbt.2247; Mann AP, 2016, NAT COMMUN, V7, DOI 10.1038/ncomms11980; Marchesi VT, 2011, FASEB J, V25, P5, DOI 10.1096/fj.11-0102ufm; Meyer EP, 2008, P NATL ACAD SCI USA, V105, P3587, DOI 10.1073/pnas.0709788105; Milner E, 2014, STROKE, V45, P3064, DOI 10.1161/STROKEAHA.114.006078; Montagne A, 2015, NEURON, V85, P296, DOI 10.1016/j.neuron.2014.12.032; MULLAN M, 1992, NAT GENET, V1, P345, DOI 10.1038/ng0892-345; Navarro JRG, 2013, ANALYST, V138, P583, DOI 10.1039/c2an36135c; Ruoslahti E, 2002, NAT REV CANCER, V2, P83, DOI 10.1038/nrc724; Ruoslahti E, 2012, ADV MATER, V24, P3747, DOI 10.1002/adma.201200454; Schwab JM, 2000, NEUROPATH APPL NEURO, V26, P434, DOI 10.1046/j.1365-2990.2000.00271.x; Schwab JM, 2001, J NEUROTRAUM, V18, P377, DOI 10.1089/089771501750170930; Sengillo JD, 2013, BRAIN PATHOL, V23, P303, DOI 10.1111/bpa.12004; Sevigny J, 2016, NATURE, V537, P50, DOI 10.1038/nature19323; Simunovic F, 2009, BRAIN, V132, P1795, DOI 10.1093/brain/awn323; Spliet WGM, 2003, ACTA NEUROPATHOL, V106, P449, DOI 10.1007/s00401-003-0741-y; Talantova M, 2013, P NATL ACAD SCI USA, V110, pE2518, DOI 10.1073/pnas.1306832110; Teesalu T, 2012, METHOD ENZYMOL, V503, P35, DOI 10.1016/B978-0-12-396962-0.00002-1; Teesalu T, 2009, P NATL ACAD SCI USA, V106, P16157, DOI 10.1073/pnas.0908201106; Ueberham U, 2003, NEUROSCIENCE, V116, P1, DOI 10.1016/S0306-4522(02)00670-X; Verkhratsky A, 2010, NEUROTHERAPEUTICS, V7, P399, DOI 10.1016/j.nurt.2010.05.017; Weller RO, 2009, ACTA NEUROPATHOL, V118, P87, DOI 10.1007/s00401-009-0498-z; Wisniewski JR, 2009, NAT METHODS, V6, P359, DOI [10.1038/NMETH.1322, 10.1038/nmeth.1322]; Wright AL, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0059586; Xie D, 2004, CLIN CANCER RES, V10, P2072, DOI 10.1158/1078-0432.CCR-0659-03; Zhong ZH, 2009, J CLIN INVEST, V119, P3437, DOI 10.1172/JCI38476; Zlokovic BV, 2011, NAT REV NEUROSCI, V12, P723, DOI 10.1038/nrn3114	45	22	22	0	22	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2041-1723			NAT COMMUN	Nat. Commun.	NOV 10	2017	8								1403	10.1038/s41467-017-01096-0			11	Multidisciplinary Sciences	Science & Technology - Other Topics	FM2YM	WOS:000414869200002	29123083	DOAJ Gold, Green Published			2021-06-18	
J	Camacho-Soto, A; Warden, MN; Searles Nielsen, S; Salter, A; Brody, DL; Prather, H; Racette, BA				Camacho-Soto, Alejandra; Warden, Mark N.; Searles Nielsen, Susan; Salter, Amber; Brody, David L.; Prather, Heidi; Racette, Brad A.			Traumatic brain injury in the prodromal period of Parkinson's disease: A large epidemiological study using medicare data	ANNALS OF NEUROLOGY			English	Article								ObjectiveStudies suggest a greater risk of Parkinson's disease (PD) after traumatic brain injury (TBI), but it is possible that the risk of TBI is greater in the prodromal period of PD. We aimed to examine the time-to-TBI in PD patients in their prodromal period compared to population-based controls. MethodsWe identified 89,790 incident PD cases and 118,095 comparable controls aged>65 years in 2009 using Medicare claims data. Using data from the preceding 5 years, we compared time-to-TBI in PD patients in their prodromal period to controls. We estimated hazard ratios (HRs) and 95% confidence intervals (CIs) for TBI in a Cox regression, while adjusting for age, sex, race/ethnicity, modified Charlson comorbidity index, smoking, and alcohol use. ResultsRisk of TBI was greater in PD patients in their prodromal period across all age and sex groups, with HRs consistently increasing with proximity to PD diagnosis. HRs ranged from 1.64 (95% CI, 1.52, 1.77) 5 years preceding diagnosis to 3.93 (95% CI, 3.74, 4.13) in the year before. The interaction between PD, TBI, and time was primarily observed for TBI attributed to falls. Motor dysfunction and cognitive impairment, suggested by corresponding International Classification of Diseases, Ninth Revision codes, partially mediated the PD-TBI association. InterpretationThere is a strong association between PD and a recent TBI in the prodromal period of PD. This association strengthens as PD diagnosis approaches and may be a result of undetected nonmotor and motor symptoms, but confirmation will be required. Ann Neurol 2017;82:744-754	[Camacho-Soto, Alejandra; Warden, Mark N.; Searles Nielsen, Susan; Brody, David L.; Prather, Heidi; Racette, Brad A.] Washington Univ, Dept Neurol, Sch Med, Campus Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA; [Salter, Amber] Washington Univ, Div Biostat, St Louis, MO USA; [Prather, Heidi] Washington Univ, Sch Med, Dept Orthoped Surg, St Louis, MO USA; [Racette, Brad A.] Univ Witwatersrand, Sch Publ Hlth, Fac Hlth Sci, Johannesburg, South Africa	Racette, BA (corresponding author), Washington Univ, Dept Neurol, Sch Med, Campus Box 8111,660 South Euclid Ave, St Louis, MO 63110 USA.	racetteb@wustl.edu	Prather, Heidi/AAN-8851-2021	Searles Nielsen, Susan/0000-0001-7768-4736	Rehabilitation Medicine Scientist Training Program [5K12 HD001097-19]; NIEHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K24ES017765-07]; Michael J. Fox Foundation; American Parkinson Disease Association; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Environmental Health Sciences (NIEHS) [K24ES017765] Funding Source: NIH RePORTER	This study was supported by the Rehabilitation Medicine Scientist Training Program, 5K12 HD001097-19 (to A.C.S.) and NIEHS K24ES017765-07 (to B.A.R.), the Michael J. Fox Foundation (to B.A.R., S.S.N., and M.N.W.), and the American Parkinson Disease Association (to B.A.R., S.S.N., and M.N.W.).		0	22	22	0	3	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0364-5134	1531-8249		ANN NEUROL	Ann. Neurol.	NOV	2017	82	5					744	754		10.1002/ana.25074			11	Clinical Neurology; Neurosciences	Neurosciences & Neurology	FN3UG	WOS:000415925900009	29024046	Green Accepted			2021-06-18	
J	Renno, WM; Benov, L; Khan, KM				Renno, Waleed M.; Benov, Ludmil; Khan, Khalid M.			Possible role of antioxidative capacity of (-)-epigallocatechin-3-gallate treatment in morphological and neurobehavioral recovery after sciatic nerve crush injury	JOURNAL OF NEUROSURGERY-SPINE			English	Article						EGCG; oxidative stress; neuroregeneration; neuroprotection; stereological analysis; rat	GREEN TEA POLYPHENOL; EPIGALLOCATECHIN-GALLATE EGCG; TRAUMATIC BRAIN-INJURY; NON-SERRATED CLAMP; SPINAL-CORD; PERIPHERAL-NERVES; NEUROPATHIC PAIN; NEURODEGENERATIVE DISEASES; NRF2-MEDIATED ANTIOXIDANT; QUANTITATIVE ASSESSMENT	OBJECTIVE This study examined the capacity of the major polyphenolic green tea extract (-)-epigallocatechin-3-gallate (EGCG) to suppress oxidative stress and stimulate the recovery and prompt the regeneration of sciatic nerve after crush injury. METHODS Adult male Wistar rats were randomly assigned to one of 4 groups: 1) Naive, 2) Sham (sham injury, surgical control group), 3) Crush (sciatic nerve crush injury treated with saline), and 4) Crush+EGCG (sciatic nerve crush injury treated with intraperitoneally administered EGCG, 50 mg/kg). All animals were tested for motor and sensory neurobehavioral parameters throughout the study. Sciatic nerve and spinal cord tissues were harvested and processed for morphometric and stereological analysis. For the biochemical assays, the time points were Day 1, Day 7, Day 14, and Day 28 after nerve injury. RESULTS After sciatic nerve crush injury, the EGCG-treated animals (Crush+EGCG group) showed significantly better recovery of foot position and toe spread and 50% greater improvement in motor recovery than the saline-treated animals (Crush group). The Crush+EGCG group displayed an early hopping response at the beginning of the 3rd week postinjury. Animals in the Crush+EGCG group also showed a significant reduction in mechanical allodynia and hyperalgesia latencies and significant improvement in recovery from nociception deficits in both heat withdrawal and tail flick withdrawal latencies compared with the Crush group. In both the Crush+EGCG and Crush groups, quantitative evaluation revealed significant morphological evidence of neuroregeneration according to the following parameters: mean ncross-sectional area of axons,myelin thickness in the sciatic nerve (from Week 4 to Week 8), increase of myelin basic protein concentration and gene expression in both the injured sciatic nerve and spinal cord, and fiber diameter to axon diameter ratio and myelin thickness to axon diameter ratio at Week 2 after sciatic nerve injury. However, the axon area remained much smaller in both the Crush+EGCG and Crush groups compared with the Sham and Naive groups. The number of axons per unit area was significantly decreased in the Crush+ EGCG and Crush groups compared with controls. Sciatic nerve injury produced generalized oxidative stress manifested as a significant increase of isoprostanes in the urine and decrease of the total antioxidant capacity (TAC) of the blood from Day 7 until Day 14. EGCG-treated rats showed significantly less increase of isoprostanes than saline-treated animals and also showed full recovery of TAC levels by Day 14 after nerve injury. In spinal cord tissue analysis, EGCG-treated animals showed induced glutathione reductase and suppressed induction of heme oxygenase 1 gene expression compared with nontreated animals. CONCLUSIONS EGCG treatment suppressed the crush-induced production of isoprostanes and stimulated the recovery of the TAC and was associated with remarkable alleviation of motor and sensory impairment and significant histomorphological evidence of neuronal regeneration following sciatic nerve crush injury in rats. The findings of this study suggest that EGCG can be used as an adjunctive therapeutic remedy for nerve injury. However, further investigations are needed to establish the antioxidative mechanism involved in the regenerative process after nerve injury. Only upregulation of glutathione reductase supports the idea that EGCG is acting indirectly via induction of enzymes or transcription factors.	[Renno, Waleed M.; Khan, Khalid M.] Kuwait Univ, Fac Med, Dept Anat, POB 24923, Safat 13110, Kuwait; [Benov, Ludmil] Kuwait Univ, Fac Med, Dept Biochem, Safat, Kuwait	Renno, WM (corresponding author), Kuwait Univ, Fac Med, Dept Anat, POB 24923, Safat 13110, Kuwait.	wrenno@hsc.edu.kw	Benov, Ludmil/AAD-3714-2020	Benov, Ludmil/0000-0002-0205-0146	Animal Resource Center, Health Science Center, Kuwait University; Kuwait University Research Administration [MA01/11]; Research Sector OMICSRU grant [SRUL02/13]	We would like to thank Mr. Jijin Kumar, Mrs. Preethi George, Mrs. Sinu Joe, Mrs. Soumya Jose, and Mrs. Shabeeba Pattillath for their excellent technical assistance. Also, we acknowledge the support of the Animal Resource Center, Health Science Center, Kuwait University. This work was funded by Kuwait University Research Administration (grant No. MA01/11) and Research Sector OMICSRU grant SRUL02/13.	Akhtar N, 2011, ARTHRITIS RES THER, V13, DOI 10.1186/ar3368; An SS, 2014, KOREAN J ANESTHESIOL, V67, P123, DOI 10.4097/kjae.2014.67.2.123; Aslan H, 2006, OBES SURG, V16, P1526, DOI 10.1381/096089206778869942; Baluchnejadmojarad T, 2012, IRAN J PHARM RES, V11, P1243; Belanger E, 2011, BIOMED OPT EXPRESS, V2, P2698, DOI 10.1364/BOE.2.002698; Bin Choi Y, 2004, BRAIN RES, V1019, P47, DOI 10.1016/j.brainres.2004.05.079; Cai J, 2014, J NUTR BIOCHEM, V25, P716, DOI 10.1016/j.jnutbio.2014.02.012; Canan S, 2008, NEUROPATH APPL NEURO, V34, P638, DOI 10.1111/j.1365-2990.2008.00938.x; Canan S, 2008, INT J DEV NEUROSCI, V26, P733, DOI 10.1016/j.ijdevneu.2008.07.005; Chen WQ, 2010, EXP BIOL MED, V235, P577, DOI 10.1258/ebm.2010.009329; Chen WQ, 2009, BEHAV BRAIN RES, V202, P71, DOI 10.1016/j.bbr.2009.03.017; Choi JI, 2012, NEUROSCI LETT, V510, P53, DOI 10.1016/j.neulet.2011.12.070; De Vry J, 2004, EUR J PHARMACOL, V491, P137, DOI 10.1016/j.ejphar.2004.03.051; Francisco Jairo Silva, 2004, Braz. oral res., V18, P100, DOI 10.1590/S1806-83242004000200002; FRIEDE RL, 1985, J NEUROL NEUROSUR PS, V48, P749, DOI 10.1136/jnnp.48.8.749; Gan L, 2014, BBA-MOL BASIS DIS, V1842, P1208, DOI 10.1016/j.bbadis.2013.12.011; Geuna S, 2005, MICROSC RES TECHNIQ, V66, P270, DOI 10.1002/jemt.20167; Geuna S, 2001, ANAT EMBRYOL, V204, P1, DOI 10.1007/s004290100188; Gundersen RY, 2005, ACTA ANAESTH SCAND, V49, P1108, DOI 10.1111/j.1399-6576.2005.00786.x; Hadlock TA, 1999, J PERIPHER NERV SYST, V4, P258; Haque AM, 2008, J NUTR BIOCHEM, V19, P619, DOI 10.1016/j.jnutbio.2007.08.008; He M, 2009, BIOL PHARM BULL, V32, P55, DOI 10.1248/bpb.32.55; Higdon JV, 2003, CRIT REV FOOD SCI, V43, P89, DOI 10.1080/10408690390826464; Hirata K, 2000, EUR J NEUROSCI, V12, P4147, DOI 10.1046/j.1460-9568.2000.00307.x; Huang GS, 2010, RHEUMATOL INT, V30, P1197, DOI 10.1007/s00296-009-1128-8; Itoh T, 2011, NEUROMOL MED, V13, P300, DOI 10.1007/s12017-011-8162-x; JACOBS JM, 1985, BRAIN, V108, P897, DOI 10.1093/brain/108.4.897; Jiang J, 2012, INT J MOL MED, V29, P946, DOI 10.3892/ijmm.2012.924; Kaplan S, 2005, J NEUROSCI METH, V145, P277, DOI 10.1016/j.jneumeth.2005.02.012; Keilhoff G, 2007, DEV NEUROBIOL, V67, P1382, DOI 10.1002/dneu.20384; Kuang X, 2012, EUR J PHARMACOL, V676, P51, DOI 10.1016/j.ejphar.2011.11.037; Kubo K, 2009, J PHARMACOL EXP THER, V331, P162, DOI 10.1124/jpet.109.156034; Lee JS, 2012, BMC COMPLEM ALTERN M, V12, DOI 10.1186/1472-6882-12-124; Lee SY, 2003, BRAIN RES BULL, V61, P399, DOI 10.1016/S0361-9230(03)00139-4; Leong Daniel J, 2014, Arthritis Res Ther, V16, P508, DOI 10.1186/s13075-014-0508-y; Liu MY, 2014, MOL NEUROBIOL, V49, P1350, DOI 10.1007/s12035-013-8608-2; Luis AL, 2007, J NEUROSCI METH, V163, P92, DOI 10.1016/j.jneumeth.2007.02.017; Mandel S, 2004, J NEUROCHEM, V88, P1555, DOI 10.1046/j.1471-4159.2003.02291.x; Mendonca AC, 2003, J NEUROSCI METH, V129, P183, DOI 10.1016/S0165-0270(03)00207-3; Moore AM, 2012, J NEUROSCI METH, V204, P19, DOI 10.1016/j.jneumeth.2011.10.011; Mozaffar T, 2009, J ORTHOP RES, V27, P114, DOI 10.1002/jor.20704; Na HK, 2008, ARCH BIOCHEM BIOPHYS, V476, P171, DOI 10.1016/j.abb.2008.04.003; Na HK, 2008, FOOD CHEM TOXICOL, V46, P1271, DOI 10.1016/j.fct.2007.10.006; Ownby SL, 2014, J INFLAMM-LOND, V11, DOI 10.1186/1476-9255-11-8; Paine A, 2010, BIOCHEM PHARMACOL, V80, P1895, DOI 10.1016/j.bcp.2010.07.014; Peng PH, 2010, EXP EYE RES, V90, P528, DOI 10.1016/j.exer.2010.01.007; Raposo D, 2015, BRAIN RES BULL, V110, P68, DOI 10.1016/j.brainresbull.2014.12.004; Renno WM, 2006, NUTR NEUROSCI, V9, P41, DOI 10.1080/10284150600576705; Renno WM, 2016, NEUROPHARMACOLOGY, V102, P1, DOI 10.1016/j.neuropharm.2015.10.029; Renno WM, 2015, J NEUROTRAUM, V32, P170, DOI 10.1089/neu.2014.3491; Renno WM, 2014, NEUROPHARMACOLOGY, V77, P100, DOI 10.1016/j.neuropharm.2013.09.013; Renno WM, 2013, NEUROCHEM INT, V62, P221, DOI 10.1016/j.neuint.2012.12.018; Renno WM, 2012, N-S ARCH PHARMACOL, V385, P807, DOI 10.1007/s00210-012-0758-7; Rezai-Zadeh K, 2005, J NEUROSCI, V25, P8807, DOI 10.1523/JNEUROSCI.1521-05.2005; Ronchi G, 2014, J PERIPHER NERV SYST, V19, P224, DOI 10.1111/jns.12090; Savastano LE, 2014, J NEUROSCI METH, V227, P166, DOI 10.1016/j.jneumeth.2014.01.020; Senggunprai L, 2014, PHYTOTHER RES, V28, P841, DOI 10.1002/ptr.5061; Sergent T, 2010, CHEM-BIOL INTERACT, V188, P659, DOI 10.1016/j.cbi.2010.08.007; Shirai N, 2004, ANN NUTR METAB, V48, P51, DOI 10.1159/000075305; Srividhya R, 2008, INT J DEV NEUROSCI, V26, P217, DOI 10.1016/j.ijdevneu.2007.12.003; Stylianou E, 1998, INT J BIOCHEM CELL B, V30, P1075, DOI 10.1016/S1357-2725(98)00081-8; Sutherland BA, 2006, J NUTR BIOCHEM, V17, P291, DOI 10.1016/j.jnutbio.2005.10.005; THALHAMMER JG, 1995, ANESTHESIOLOGY, V82, P1013, DOI 10.1097/00000542-199504000-00026; Tiwari V, 2011, EUR J PAIN, V15, P286, DOI 10.1016/j.ejpain.2010.07.005; TURGUT M, 2010, J BRACHIAL PLEX PERI, V5; Tyurin VA, 2000, J NEUROCHEM, V75, P2178, DOI 10.1046/j.1471-4159.2000.0752178.x; Unal B, 2005, BRAIN RES, V1048, P228, DOI 10.1016/j.brainres.2005.05.001; Unno K, 2004, EXP GERONTOL, V39, P1027, DOI 10.1016/j.exger.2004.03.033; van Praag H, 2007, J NEUROSCI, V27, P5869, DOI 10.1523/JNEUROSCI.0914-07.2007; Varejao ASP, 2004, J NEUROTRAUM, V21, P1652, DOI 10.1089/neu.2004.21.1652; Varejao ASP, 2004, NEUROL RES, V26, P186, DOI 10.1179/016164104225013833; Wang T, 2014, INT J MOL MED, V33, P994, DOI 10.3892/ijmm.2014.1635; Weinreb O, 2009, GENES NUTR, V4, P283, DOI 10.1007/s12263-009-0143-4; Xie J, 2010, NEUROSCI LETT, V479, P26, DOI 10.1016/j.neulet.2010.05.020; Yoo KY, 2010, PHYTOTHER RES, V24, P1065, DOI 10.1002/ptr.3083	75	22	22	0	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1547-5654	1547-5646		J NEUROSURG-SPINE	J. Neurosurg.-Spine	NOV	2017	27	5					593	613		10.3171/2016.10.SPINE16218			21	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	FL6LV	WOS:000414357100016	28777065	Bronze			2021-06-18	
J	Kuo, BJ; Vaca, SD; Vissoci, JRN; Staton, CA; Xu, L; Muhumuza, M; Ssenyonjo, H; Mukasa, J; Kiryabwire, J; Nanjula, L; Muhumuza, C; Rice, HE; Grant, GA; Haglund, MM				Kuo, Benjamin J.; Vaca, Silvia D.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Xu, Linda; Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Nanjula, Lydia; Muhumuza, Christine; Rice, Henry E.; Grant, Gerald A.; Haglund, Michael M.			A prospective neurosurgical registry evaluating the clinical care of traumatic brain injury patients presenting to Mulago National Referral Hospital in Uganda	PLOS ONE			English	Article							LOW-INCOME; BURDEN; IMPACT; OUTCOMES	Background Traumatic Brain Injury (TBI) is disproportionally concentrated in low-and middle-income countries (LMICs), with the odds of dying from TBI in Uganda more than 4 times higher than in high income countries (HICs). The objectives of this study are to describe the processes of care and determine risk factors predictive of poor outcomes for TBI patients presenting to Mulago National Referral Hospital (MNRH), Kampala, Uganda. Methods We used a prospective neurosurgical registry based on Research Electronic Data Capture (REDCap) to systematically collect variables spanning 8 categories. Univariate and multivariate analysis were conducted to determine significant predictors of mortality. Results 563 TBI patients were enrolled from 1 June-30 November 2016. 102 patients (18%) received surgery, 29 patients (5.1%) intended for surgery failed to receive it, and 251 patients (45%) received non-operative management. Overall mortality was 9.6%, which ranged from 4.7% for mild and moderate TBI to 55% for severe TBI patients with GCS 3-5. Within each TBI severity category, mortality differed by management pathway. Variables predictive of mortality were TBI severity, more than one intracranial bleed, failure to receive surgery, high dependency unit admission, ventilator support outside of surgery, and hospital arrival delayed by more than 4 hours. Conclusions The overall mortality rate of 9.6% in Uganda for TBI is high, and likely underestimates the true TBI mortality. Furthermore, the wide-ranging mortality (3-82%), high ICU fatality, and negative impact of care delays suggest shortcomings with the current triaging practices. Lack of surgical intervention when needed was highly predictive of mortality in TBI patients. Further research into the determinants of surgical interventions, quality of step-up care, and prolonged care delays are needed to better understand the complex interplay of variables that affect patient outcome. These insights guide the development of future interventions and resource allocation to improve patient outcomes.	[Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Haglund, Michael M.] Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA; [Kuo, Benjamin J.; Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.; Rice, Henry E.; Haglund, Michael M.] Duke Univ, Global Hlth Inst, Durham, NC 27708 USA; [Kuo, Benjamin J.] Duke Natl Univ Singapore, Med Sch, Singapore, Singapore; [Vaca, Silvia D.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA; [Vaca, Silvia D.; Xu, Linda; Grant, Gerald A.] Stanford Ctr Innovat Global Hlth, Palo Alto, CA USA; [Vissoci, Joao Ricardo Nickenig; Staton, Catherine A.] Duke Univ, Med Ctr, Dept Emergency Med, Durham, NC USA; [Xu, Linda; Grant, Gerald A.] Stanford Univ, Med Ctr, Dept Neurosurg, Palo Alto, CA 94304 USA; [Muhumuza, Michael; Ssenyonjo, Hussein; Mukasa, John; Kiryabwire, Joel; Nanjula, Lydia] Mulago Hosp, Dept Neurosurg, Kampala, Uganda; [Muhumuza, Christine] Makerere Univ, Sch Publ Hlth, Kampala, Uganda; [Rice, Henry E.] Duke Univ, Med Ctr, Dept Surg, Durham, NC 27710 USA; [Haglund, Michael M.] Duke Univ, Dept Neurosurg, Med Ctr, Durham, NC 27708 USA	Haglund, MM (corresponding author), Duke Univ, Div Global Neurosurg & Neurol, Durham, NC 27708 USA.; Haglund, MM (corresponding author), Duke Univ, Global Hlth Inst, Durham, NC 27708 USA.; Haglund, MM (corresponding author), Duke Univ, Dept Neurosurg, Med Ctr, Durham, NC 27708 USA.	michael.haglund@dm.duke.edu		Staton, Catherine/0000-0002-6468-2894	Duke Department of Neurosurgery; Duke Division of Global Neurosurgery and Neurology; Duke Global Health Institute; Duke-NUS Medical School; Stanford Medical Scholars Program; FOGARTY INTERNATIONAL CENTERUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Fogarty International Center (FIC) [K01TW010000] Funding Source: NIH RePORTER	Funding was provided by the Duke Department of Neurosurgery, Duke Division of Global Neurosurgery and Neurology, Duke Global Health Institute, Duke-NUS Medical School, and Stanford Medical Scholars Program. No funding bodies had any role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.	Abdelgadir J, 2017, WORLD NEUROSURG, V101, P651, DOI 10.1016/j.wneu.2017.02.048; Bhalla K, 2009, INJURY PREV, V15, P150, DOI 10.1136/ip.2008.020826; Bhalla K, 2009, PLOS MED, V6, P22, DOI 10.1371/journal.pmed.1000001; CDC, 2016, TRAUMATIC BRAIN INJU; Chandran A, 2010, EPIDEMIOL REV, V32, P110, DOI 10.1093/epirev/mxq009; Demyttenaere SV, 2009, CAN J SURG, V52, pE146; Di Saverio S, 2014, LANGENBECK ARCH SURG, V399, P109, DOI 10.1007/s00423-013-1143-9; Gagne M, 2017, J TRAUMA ACUTE CARE, V82, P374, DOI 10.1097/TA.0000000000001319; Gupta D, 2016, WORLD NEUROSURG, V89, P169, DOI 10.1016/j.wneu.2015.12.097; Hofman K, 2005, AM J PUBLIC HEALTH, V95, P13, DOI 10.2105/AJPH.2004.039354; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jayaraman S, 2011, WORLD J SURG, V35, P505, DOI 10.1007/s00268-010-0871-z; Kim YJ, 2011, J EMERG NURS, V37, P328, DOI 10.1016/j.jen.2010.04.017; Krishnamoorthy V, 2015, J INTENSIVE CARE, P1; Kwizera Arthur, 2012, BMC Res Notes, V5, P475, DOI 10.1186/1756-0500-5-475; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lozano R, 2012, LANCET, V380, P2095, DOI 10.1016/S0140-6736(12)61728-0; Mwita CC, 2016, J NEUROSCI RURAL PRA, V7, P97, DOI 10.4103/0976-3147.165390; Opondo EA, 2009, ANN AFRICAN SURG, P1; Selassie AW, 2011, J TRAUMA, V71, P1226, DOI 10.1097/TA.0b013e318226ecfc; Staton CA, 2015, INT J INJ CONTROL SA, P1; Tobi KU, 2016, SOUTH AFR J ANAESTH, V22, P135, DOI 10.1080/22201181.2016.1206293; Tran TM, 2015, WORLD NEUROSURG, V83, P269, DOI 10.1016/j.wneu.2014.12.028; Ubos. Uganda National Household Survey 2009/ 2010, 2010, UGAUBOSUBOS2012V01, P222; World Health Organization, 2015, INJURY PREV, P318	25	22	22	0	1	PUBLIC LIBRARY SCIENCE	SAN FRANCISCO	1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA	1932-6203			PLOS ONE	PLoS One	OCT 31	2017	12	10							e0182285	10.1371/journal.pone.0182285			16	Multidisciplinary Sciences	Science & Technology - Other Topics	FL2ZD	WOS:000414088900001	29088217	DOAJ Gold, Green Published			2021-06-18	
J	Teh, DBL; Prasad, A; Jiang, WX; Ariffin, MZ; Khanna, S; Belorkar, A; Wong, L; Liu, XG; All, AH				Teh, Daniel Boon Loong; Prasad, Ankshita; Jiang, Wenxuan; Ariffin, Mohd. Zacky; Khanna, Sanjay; Belorkar, Abha; Wong, Limsoon; Liu, Xiaogang; All, Angelo H.			Transcriptome Analysis Reveals Neuroprotective aspects of Human Reactive Astrocytes induced by Interleukin 1 beta	SCIENTIFIC REPORTS			English	Article							SPINAL-CORD-INJURY; NEURITE OUTGROWTH; SULFATE PROTEOGLYCAN; AXONAL REGENERATION; FUNCTIONAL RECOVERY; SCAR FORMATION; GROWTH; EXPRESSION; MATRIX; CELLS	Reactive astrogliosis is a critical process in neuropathological conditions and neurotrauma. Although it has been suggested that it confers neuroprotective effects, the exact genomic mechanism has not been explored. The prevailing dogma of the role of astrogliosis in inhibition of axonal regeneration has been challenged by recent findings in rodent model's spinal cord injury, demonstrating its neuroprotection and axonal regeneration properties. We examined whether their neuroprotective and axonal regeneration potentials can be identify in human spinal cord reactive astrocytes in vitro. Here, reactive astrogliosis was induced with IL1 beta. Within 24 hours of IL1 beta induction, astrocytes acquired reactive characteristics. Transcriptome analysis of over 40000 transcripts of genes and analysis with PFSnet subnetwork revealed upregulation of chemokines and axonal permissive factors including FGF2, BDNF, and NGF. In addition, most genes regulating axonal inhibitory molecules, including ROBO1 and ROBO2 were downregulated. There was no increase in the gene expression of "Chondroitin Sulfate Proteoglycans" (CSPGs') clusters. This suggests that reactive astrocytes may not be the main CSPG contributory factor in glial scar. PFSnet analysis also indicated an upregulation of "Axonal Guidance Signaling" pathway. Our result suggests that human spinal cord reactive astrocytes is potentially neuroprotective at an early onset of reactive astrogliosis.	[Teh, Daniel Boon Loong; All, Angelo H.] Natl Univ Singapore, Singapore Inst Neurotechnol SINAPSE, 28 Med Dr,5-COR, Singapore 117456, Singapore; [Prasad, Ankshita] Natl Univ Singapore, Dept Biomed Engn, E4,4 Engn Dr 3, Singapore 117583, Singapore; [Jiang, Wenxuan] Natl Univ Singapore, Dept Orthopaed Surg, 1E Kent Ridge Rd, Singapore 119228, Singapore; [Ariffin, Mohd. Zacky; Khanna, Sanjay] Natl Univ Singapore, Yong Loo Lin Sch Med, Dept Physiol, Singapore, Singapore; [Belorkar, Abha; Wong, Limsoon] Natl Univ Singapore, Dept Comp Sci, 13 Comp Dr, Singapore 117417, Singapore; [Liu, Xiaogang] Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore; [All, Angelo H.] Dept Biomed Engn, 701C Rutland Ave 720, Baltimore, MD 21205 USA; [All, Angelo H.] Johns Hopkins Sch Med, 701C Rutland Ave 720, Baltimore, MD 21205 USA; [All, Angelo H.] Johns Hopkins Sch Med, Dept Neurol, 701C Rutland Ave 720, Baltimore, MD 21205 USA	All, AH (corresponding author), Natl Univ Singapore, Singapore Inst Neurotechnol SINAPSE, 28 Med Dr,5-COR, Singapore 117456, Singapore.; Liu, XG (corresponding author), Natl Univ Singapore, Dept Chem, 3 Sci Dr 3, Singapore 117543, Singapore.; All, AH (corresponding author), Dept Biomed Engn, 701C Rutland Ave 720, Baltimore, MD 21205 USA.; All, AH (corresponding author), Johns Hopkins Sch Med, 701C Rutland Ave 720, Baltimore, MD 21205 USA.; All, AH (corresponding author), Johns Hopkins Sch Med, Dept Neurol, 701C Rutland Ave 720, Baltimore, MD 21205 USA.	xiaogangliu@nus.edu.sg; hmn@jhu.edu	Ariffin, Mohammed Zacky/ABF-9613-2020; Wong, Limsoon/E-5033-2010; LIU, XIAOGANG/A-8038-2011; Wong, Limsoon/W-3611-2019; Loong, Daniel Teh Boon/AAF-6660-2019	Ariffin, Mohammed Zacky/0000-0002-6228-3830; Wong, Limsoon/0000-0003-1241-5441; LIU, XIAOGANG/0000-0003-2517-5790; Wong, Limsoon/0000-0003-1241-5441; Loong, Daniel Teh Boon/0000-0002-4560-8568; Khanna, Sanjay/0000-0002-7304-6259	Singapore's Ministry of Education Tier 1Ministry of Education, Singapore [R-175-000-137-112]; Singapore Institute for Neurotechnology Seed Fund [R-175-000-121-733]; State of Maryland, USA [2013-MSCRFII-0109-00]	We would like to thank Ms. Low Kay En and Ms Tan Soon Huat from Electron Microscopy Unit, Yong Loo Lin School of Medicine, and Ms. Tan Shu Ying from the Confocal Microscopy Unity of National University of Singapore, for their technical assistance. This work is supported by the R-175-000-137-112 (Singapore's Ministry of Education Tier 1), R-175-000-121-733 (Singapore Institute for Neurotechnology Seed Fund), (2013-MSCRFII-0109-00, PI: A. ALL) State of Maryland, USA.	Ahmed G, 2011, J NEUROSCI, V31, P14018, DOI 10.1523/JNEUROSCI.0943-11.2011; Allan SM, 2005, NAT REV IMMUNOL, V5, P629, DOI 10.1038/nri1664; Alto LT, 2009, NAT NEUROSCI, V12, P1106, DOI 10.1038/nn.2365; Anderson MA, 2016, NATURE, V532, P195, DOI 10.1038/nature17623; Austin JW, 2012, J NEUROCHEM, V122, P344, DOI 10.1111/j.1471-4159.2012.07789.x; Baydyuk M, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00254; Beaudet MJ, 2015, SCI REP-UK, V5, DOI 10.1038/srep16763; Bin Goh WW, 2016, J PROTEOME RES, V15, P3167, DOI 10.1021/acs.jproteome.6b00402; Chandrasekaran A, 2016, FRONT CELL NEUROSCI, V10, DOI 10.3389/fncel.2016.00215; Chen A, 2013, BIOMED REP, V1, P167, DOI 10.3892/br.2012.48; Dawes JM, 2011, SCI TRANSL MED, V3, DOI 10.1126/scitranslmed.3002193; Dickson BJ, 2002, SCIENCE, V298, P1959, DOI 10.1126/science.1072165; Edwards TJ, 2014, CELL REP, V8, P272, DOI 10.1016/j.celrep.2014.06.008; Faulkner JR, 2004, J NEUROSCI, V24, P2143, DOI 10.1523/JNEUROSCI.3547-03.2004; Gao DH, 2010, CELL MOL BIOL LETT, V15, P582, DOI 10.2478/s11658-010-0029-x; Gaudet AD, 2014, EXP NEUROL, V258, P24, DOI 10.1016/j.expneurol.2013.11.020; Gautier L, 2004, BIOINFORMATICS, V20, P307, DOI 10.1093/bioinformatics/btg405; Hansson E, 2015, NEUROCHEM RES, V40, P372, DOI 10.1007/s11064-014-1363-6; Harel NY, 2006, NAT REV NEUROSCI, V7, P603, DOI 10.1038/nrn1957; Harlow EG, 2010, NEURON, V65, P385, DOI 10.1016/j.neuron.2010.01.024; Herx LM, 2001, J NEUROPATH EXP NEUR, V60, P961, DOI 10.1093/jnen/60.10.961; Hill JJ, 2012, P NATL ACAD SCI USA, V109, P9155, DOI 10.1073/pnas.1205697109; Ito M, 2009, J NEUROTRAUM, V26, P41, DOI 10.1089/neu.2008.0646; Jankovski A, 1996, J COMP NEUROL, V371, P376; John GR, 2002, NAT MED, V8, P1115, DOI 10.1038/nm781; Kanehisa M, 2000, NUCLEIC ACIDS RES, V28, P27, DOI 10.1093/nar/28.1.27; Klapka N, 2006, J NEUROTRAUM, V23, P422, DOI 10.1089/neu.2006.23.422; Lafortune L, 1996, J NEUROPATH EXP NEUR, V55, P515, DOI 10.1097/00005072-199605000-00003; Lim K, 2014, BIOINFORMATICS, V30, P189, DOI 10.1093/bioinformatics/btt625; Linker RA, 2011, BRAIN, V134, P678, DOI 10.1093/brain/awq386; Liu XD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0075804; Livak KJ, 2001, METHODS, V25, P402, DOI 10.1006/meth.2001.1262; Lu P, 2007, EXP NEUROL, V203, P8, DOI 10.1016/j.expneurol.2006.07.030; M'Dahoma S, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0102027; Malin D, 2009, J CELL SCI, V122, P995, DOI 10.1242/jcs.040378; Min SK, 2015, SCI REP-UK, V5, DOI 10.1038/srep14418; Minor K, 2008, NEUROBIOL DIS, V32, P88, DOI 10.1016/j.nbd.2008.06.009; Mirshafiey Abbas, 2014, Sultan Qaboos Univ Med J, V14, pe13; Molina-Holgado F, 2000, J NEUROIMMUNOL, V111, P1, DOI 10.1016/S0165-5728(00)00344-1; Nakanishi K, 2006, J BIOL CHEM, V281, P24970, DOI 10.1074/jbc.M601498200; Oberheim NA, 2012, METHODS MOL BIOL, V814, P23, DOI 10.1007/978-1-61779-452-0_3; Orre M, 2014, NEUROBIOL AGING, V35, P1, DOI 10.1016/j.neurobiolaging.2013.07.008; Ozdinler PH, 2006, NAT NEUROSCI, V9, P1371, DOI 10.1038/nn1789; Paniagua-Torija B, 2015, NEUROSCIENCE, V284, P283, DOI 10.1016/j.neuroscience.2014.10.013; Plantman S, 2008, MOL CELL NEUROSCI, V39, P50, DOI 10.1016/j.mcn.2008.05.015; Rajagopalan S, 2004, NAT CELL BIOL, V6, P756, DOI 10.1038/ncb1156; Rao VTS, 2016, J NEUROPATH EXP NEUR, V75, P156, DOI 10.1093/jnen/nlv016; Roybon L, 2013, CELL REP, V4, P1035, DOI 10.1016/j.celrep.2013.06.021; Santos-Galindo Maria, 2011, Biol Sex Differ, V2, P7, DOI 10.1186/2042-6410-2-7; Sato A, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-65; SCHNITZER J, 1981, J CELL BIOL, V90, P435, DOI 10.1083/jcb.90.2.435; Selvaraj P, 2015, MOL CELL NEUROSCI, V68, P222, DOI 10.1016/j.mcn.2015.08.005; Skuljec J, 2011, J NEUROPATH EXP NEUR, V70, P758, DOI 10.1097/NEN.0b013e3182294fad; Sofroniew MV, 2010, ACTA NEUROPATHOL, V119, P7, DOI 10.1007/s00401-009-0619-8; Sofroniew MV, 2009, TRENDS NEUROSCI, V32, P638, DOI 10.1016/j.tins.2009.08.002; Spisak S, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0046215; Szebenyi G, 2001, J NEUROSCI, V21, P3932, DOI 10.1523/JNEUROSCI.21-11-03932.2001; Tarassishin L, 2014, GLIA, V62, P999, DOI 10.1002/glia.22657; Teller P, 2009, SURG CLIN N AM, V89, P599, DOI 10.1016/j.suc.2009.03.006; Tom VJ, 2004, J NEUROSCI, V24, P9282, DOI 10.1523/JNEUROSCI.2120-04.2004; Tselnicker IF, 2014, BIOCHEM SOC T, V42, P1263, DOI 10.1042/BST20140166; Tsiperson V, 2015, ASN NEURO, V7, DOI 10.1177/1759091414566878; von Boyen GBT, 2004, GUT, V53, P222, DOI 10.1136/gut.2003.012625; Walsh FS, 1997, ANNU REV CELL DEV BI, V13, P425, DOI 10.1146/annurev.cellbio.13.1.425; Wang SM, 2016, MOL NEUROBIOL, V53, P5912, DOI 10.1007/s12035-015-9486-6; Wang W., 2016, DRUG DISCOVERY TODAY; Wang YJ, 2014, PLOS ONE, V9, DOI [10.1371/journal.pone.0110024, 10.1371/journal.pone.0085234]; White RE, 2008, EXP NEUROL, V214, P10, DOI 10.1016/j.expneurol.2008.06.012; Wu D, 2005, J NEUROCYTOL, V34, P459, DOI 10.1007/s11068-006-8998-4; Yang ZS, 2006, J NEUROSCI, V26, P3829, DOI 10.1523/JNEUROSCI.4247-05.2006; Zachary I, 2005, NEUROSIGNALS, V14, P207, DOI 10.1159/000088637; Zamanian JL, 2012, J NEUROSCI, V32, P6391, DOI 10.1523/JNEUROSCI.6221-11.2012; Zhang J, 2003, J RECONSTR MICROSURG, V19, P467	73	22	23	0	11	NATURE RESEARCH	BERLIN	HEIDELBERGER PLATZ 3, BERLIN, 14197, GERMANY	2045-2322			SCI REP-UK	Sci Rep	OCT 25	2017	7								13988	10.1038/s41598-017-13174-w			12	Multidisciplinary Sciences	Science & Technology - Other Topics	FK7PS	WOS:000413700200027	29070875	DOAJ Gold, Green Published			2021-06-18	
J	Nissinen, J; Andrade, P; Natunen, T; Hiltunen, M; Malm, T; Kanninen, K; Soares, JI; Shatillo, O; Sallinen, J; Ndode-Ekane, XE; Pitkanen, A				Nissinen, Jari; Andrade, Pedro; Natunen, Teemu; Hiltunen, Mikko; Malm, Tarja; Kanninen, Katja; Soares, Joana I.; Shatillo, Olena; Sallinen, Jukka; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla			Disease-modifying effect of atipamezole in a model of post-traumatic epilepsy	EPILEPSY RESEARCH			English	Article						alpha 2-Adrenoceptor; Beam walking; Cannabinoid 1 receptor antagonist; Composite neuroscore; Epileptogenesis; Lateral fluid-percussion; Memory; Seizure susceptibility; Somato-motor performance; SR141716A	TRAUMATIC BRAIN-INJURY; CB1 RECEPTOR ANTAGONIST; FREELY-MOVING RATS; SELECTIVE ALPHA(2)-ADRENOCEPTOR ANTAGONIST; LONG-TERM HYPEREXCITABILITY; FOCAL CEREBRAL-ISCHEMIA; ELECTRICAL-STIMULATION; STATUS EPILEPTICUS; NEURONAL DAMAGE; FRONTAL-CORTEX	Treatment of TBI remains a major unmet medical need, with 2.5 million new cases of traumatic brain injury (TBI) each year in Europe and 1.5 million in the USA. This single-center proof-of-concept preclinical study tested the hypothesis that pharmacologic neurostimulation with proconvulsants, either atipamezole, a selective alpha(2)-adrenoceptor antagonist, or the cannabinoid receptor 1 antagonist SR141716A, as monotherapy would improve functional recovery after TBI. A total of 404 adult Sprague-Dawley male rats were randomized into two groups: sham-injured or lateral fluid-percussion induced TBI. The rats were treated with atipamezole (started at 30 min or 7 d after TBI) or SR141716A (2 min or 30 min post-TBI) for up to 9 wk. Total follow-up time was 14 wk after treatment initiation. Outcome measures included motor (composite neuroscore, beam-walking) and cognitive performance (Morris water-maze), seizure susceptibility, spontaneous seizures, and cortical and hippocampal pathology. All injured rats exhibited similar impairment in the neuroscore and beam-walking tests at 2 d post-TBI. Atipamezole treatment initiated at either 30 min or 7 d post-TBI and continued for 9 wk via subcutaneous osmotic minipumps improved performance in both the neuroscore and beam-walking tests, but not in the Morris water-maze spatial learning and memory test. Atipamezole treatment initiated at 7 d post-TBI also reduced seizure susceptibility in the pentylenetetrazol test 14 wk after treatment initiation, although it did not prevent the development of epilepsy. SR141716A administered as a single dose at 2 min post-TBI or initiated at 30 min post-TBI and continued for 9 wk had no recovery-enhancing or antiepileptogenic effects. Mechanistic studies to assess the alpha(2)-adrenoceptor subtype specificity of the disease-modifying effects of atipametzole revealed that genetic ablation of alpha(2A)-noradrenergic receptor function in Adra2A mice carrying an N79P point mutation had antiepileptogenic effects after TBI. On the other hand, blockade of alpha(2C)-adrenoceptors using the receptor subtype specific antagonist ORM-12741 had no favorable effects on the post-TBI outcome. Finally, to assess whether regulation of the post-injury inflammatory response by atipametzole in glial cells contributed to a favorable outcome, we investigated the effect of atipamezole on spontaneous and/or lipopolysaccharide-stimulated astroglial or microglial cytokine release in vitro. We observed no effect. Our data demonstrate that a 9-wk administration of alpha 2A-noradrenergic antagonist, atipamezole, is recovery-enhancing after TBI.	[Nissinen, Jari; Andrade, Pedro; Malm, Tarja; Kanninen, Katja; Shatillo, Olena; Ndode-Ekane, Xavier Ekolle; Pitkanen, Asla] Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland; [Natunen, Teemu; Hiltunen, Mikko] Univ Eastern Finland, Inst Biomed, POB 1627, FI-70211 Kuopio, Finland; [Natunen, Teemu; Hiltunen, Mikko] Kuopio Univ Hosp, Dept Neurol, POB 1627, FI-70211 Kuopio, Finland; [Soares, Joana I.] Univ Porto, Inst Invest & Inovacao Saude, Oporto, Portugal; [Soares, Joana I.] Univ Porto, Inst Biol Mol & Celular, Oporto, Portugal; [Soares, Joana I.] Univ Porto, Programa Doutoral Neurociencias, Oporto, Portugal; [Sallinen, Jukka] Orion Corp Orion Pharma, POB 425,Tengstrominkatu 8, Turku 20101, Finland	Pitkanen, A (corresponding author), Univ Eastern Finland, AI Virtanen Inst Mol Sci, Dept Neurobiol, POB 1627, FI-70211 Kuopio, Finland.	asla.pitkanen@uef.fi	; Andrade, Pedro/N-8410-2018	Ndode-Ekane, Xavier Ekolle/0000-0001-5682-5632; Soares, Joana I./0000-0002-3549-6873; Andrade, Pedro/0000-0001-9118-8341; Malm, Tarja/0000-0002-9530-7472	CURE (Citizens United for Research in Epilepsy); Academy of FinlandAcademy of FinlandEuropean Commission	We thank Mr. Jarmo Hartikainen and Mrs. Merja Lukkari for excellent technical assistance. This study was supported by CURE (Citizens United for Research in Epilepsy) (AP) and The Academy of Finland (AP). Atipamezole was a gift from Orion Pharma.	Aoki C, 1998, CEREB CORTEX, V8, P269, DOI 10.1093/cercor/8.3.269; Barbelivien A, 2002, NEUROPHARMACOLOGY, V42, P117, DOI 10.1016/S0028-3908(01)00150-2; BIEGON A, 1992, EUR J PHARMACOL, V224, P27, DOI 10.1016/0014-2999(92)94814-C; Birder LA, 1999, J PHYSIOL-LONDON, V515, P533, DOI 10.1111/j.1469-7793.1999.533ac.x; Biters L. V., 2002, J COMP NEUROL, V444, P63; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Chen K, 2007, J NEUROSCI, V27, P46, DOI 10.1523/JNEUROSCI.3966-06.2007; Chen YJ, 2014, P NATL ACAD SCI USA, V111, P17296, DOI 10.1073/pnas.1409513111; Chi XJ, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0554-5; Christopoulou FD, 2011, J CLIN PHARM THER, V36, P10, DOI 10.1111/j.1365-2710.2010.01164.x; Citraro R, 2013, EPILEPSY RES, V106, P74, DOI 10.1016/j.eplepsyres.2013.06.004; Comelli F, 2010, EUR J PHARMACOL, V637, P62, DOI 10.1016/j.ejphar.2010.03.061; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Costa B, 2005, PAIN, V116, P52, DOI 10.1016/j.pain.2005.03.043; Deshpande LS, 2007, NEUROSCI LETT, V411, P11, DOI 10.1016/j.neulet.2006.09.046; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; Echegoyen J, 2009, EPILEPSY RES, V85, P123, DOI 10.1016/j.eplepsyres.2009.02.019; FEENEY DM, 1985, BRAIN RES, V342, P352, DOI 10.1016/0006-8993(85)91135-7; Fisher RS, 2014, EPILEPSIA, V55, P475, DOI 10.1111/epi.12550; Flugge G, 2003, EUR J NEUROSCI, V17, P917, DOI 10.1046/j.1460-9568.2003.02510.x; Gobert A, 1998, NEUROSCIENCE, V84, P413, DOI 10.1016/S0306-4522(97)00565-4; Gobert A, 1997, J NEUROCHEM, V69, P2616; Goldstein LB, 1999, REV NEUROL-FRANCE, V155, P731; Goldstein LB, 1997, PHARMACOL BIOCHEM BE, V58, P1151, DOI 10.1016/S0091-3057(97)00324-9; Gribble FM, 2010, NEW ENGL J MED, V362, P361, DOI 10.1056/NEJMcibr0911499; Haapalinna A, 1997, N-S ARCH PHARMACOL, V356, P570, DOI 10.1007/PL00005092; Halonen T, 1996, EUR J PHARMACOL, V299, P69, DOI 10.1016/0014-2999(95)00835-7; HALONEN T, 1995, BRAIN RES, V693, P217, DOI 10.1016/0006-8993(95)00744-B; Haltiner AM, 1997, ARCH PHYS MED REHAB, V78, P835, DOI 10.1016/S0003-9993(97)90196-9; Hammond FM, 2004, NEUROREHABILITATION, V19, P25; Herrick AL, 2014, RHEUMATOLOGY, V53, P948, DOI 10.1093/rheumatology/ket421; Hutchinson DS, 2011, J NEUROCHEM, V117, P915, DOI 10.1111/j.1471-4159.2011.07261.x; Jansson CC, 1998, MOL PHARMACOL, V53, P963; Janumpalli S, 1998, J NEUROSCI, V18, P2004; Jolkkonen J, 2000, EUR J PHARMACOL, V400, P211, DOI 10.1016/S0014-2999(00)00409-X; Katz DI, 1998, ARCH PHYS MED REHAB, V79, P488, DOI 10.1016/S0003-9993(98)90060-0; Kharatishvili I, 2006, NEUROSCIENCE, V140, P685, DOI 10.1016/j.neuroscience.2006.03.012; Kharatishvili I, 2010, EPILEPSY RES, V90, P47, DOI 10.1016/j.eplepsyres.2010.03.007; LAITINEN KSM, 1995, EUR J PHARMACOL, V285, P255, DOI 10.1016/0014-2999(95)00410-M; Lehto J, 2015, SYNAPSE, V69, P172, DOI 10.1002/syn.21798; LEVIN BE, 1994, RESTOR NEUROL NEUROS, V7, P5, DOI 10.3233/RNN-1994-7102; Herrera-Garcia AM, 2014, J IMMUNOL, V193, P3023, DOI 10.4049/jimmunol.1400255; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; Ndode-Ekane XE, 2010, NEUROSCIENCE, V166, P312, DOI 10.1016/j.neuroscience.2009.12.002; Ndode-Ekane XE, 2017, J NEUROTRAUM, V34, P459, DOI 10.1089/neu.2016.4404; OHLSSON AL, 1995, STROKE, V26, P644, DOI 10.1161/01.STR.26.4.644; OKIYAMA K, 1992, J NEUROSURG, V77, P607, DOI 10.3171/jns.1992.77.4.0607; Oliviero A, 2012, EUR NEUROPSYCHOPHARM, V22, P27, DOI 10.1016/j.euroneuro.2011.04.004; Olli-Lahdesmaki T, 1999, J NEUROSCI, V19, P9281; Peeters W, 2015, ACTA NEUROCHIR, V157, P1683, DOI 10.1007/s00701-015-2512-7; Pertovaara A, 2005, CNS DRUG REV, V11, P273; Pitkanen A, 2004, EPILEPSY RES, V61, P119, DOI 10.1016/j.eplepsyres.2004.07.005; Pitkanen A, 2014, NEUROTHERAPEUTICS, V11, P286, DOI 10.1007/s13311-014-0260-7; Piwnica D, 2014, J DERMATOL SCI, V75, P49, DOI 10.1016/j.jdermsci.2014.04.002; Puurunen K, 2001, NEUROPHARMACOLOGY, V40, P597, DOI 10.1016/S0028-3908(00)00182-9; RACINE RJ, 1972, ELECTROEN CLIN NEURO, V32, P281, DOI 10.1016/0013-4694(72)90177-0; Ren X., 2016, J NEUROIMMUNE PHARM, P1; Roosevelt RW, 2006, BRAIN RES, V1119, P124, DOI 10.1016/j.brainres.2006.08.048; SARA SJ, 1991, NEUROSCI LETT, V126, P1, DOI 10.1016/0304-3940(91)90356-X; Smith DC, 2005, J NEUROTRAUM, V22, P1485, DOI 10.1089/neu.2005.22.1485; Sukegawa S, 2014, ANESTH ANALG, V118, P473, DOI 10.1213/ANE.0000000000000060; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; VIRTANEN R, 1989, ARCH INT PHARMACOD T, V297, P190; Waltereit R, 2003, MOL NEUROBIOL, V27, P99, DOI 10.1385/MN:27:1:99; Wang XT, 2014, EUR J PHARMACOL, V724, P16, DOI 10.1016/j.ejphar.2013.12.026; Wang X, 2016, BRAIN RES, V1646, P174, DOI 10.1016/j.brainres.2016.05.055; Yao H, 2015, SCI REP-UK, V5, DOI 10.1038/srep16849	68	22	22	1	3	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0920-1211	1872-6844		EPILEPSY RES	Epilepsy Res.	OCT	2017	136						18	34		10.1016/j.eplepsyres.2017.07.005			17	Clinical Neurology	Neurosciences & Neurology	FI8MD	WOS:000412255800004	28753497	Green Accepted			2021-06-18	
J	Davies, MAM; Judge, AD; Delmestri, A; Kemp, SPT; Stokes, KA; Arden, NK; Newton, JL				Davies, Madeleine A. M.; Judge, Andrew D.; Delmestri, Antonella; Kemp, Simon P. T.; Stokes, Keith A.; Arden, Nigel K.; Newton, Julia L.			Health amongst former rugby union players: A cross-sectional study of morbidity and health-related quality of life	SCIENTIFIC REPORTS			English	Article							BONE-MINERAL DENSITY; PHYSICAL-ACTIVITY; GENERAL-POPULATION; OSTEOARTHRITIS; INJURIES; EQ-5D; RISK; RELIABILITY; CONCUSSION; BENEFITS	In the general population, physical activity is associated with improved health outcomes. However, long-term sports participation may be associated with adverse outcomes, particularly at the elite level. The aims of this study were to assess morbidity and health-related quality of life (HrQoL) amongst former rugby players, compared to an age-standardised general population sample. A cross-sectional study of former elite, male, rugby players (n = 259) was undertaken, and standardised morbidity ratios (SMR) calculated, assessing morbidity prevalence relative to English Longitudinal Study of Aging participants (ELSA, n = 5186). HrQoL, measured using the EQ-5D, was compared to a Health Survey for England (HSE, n = 2981) sample. In SMR analyses of participants aged 50+, diabetes was significantly lower amongst former players, (0.28, 95% CI 0.11-0.66), whereas osteoarthritis (4.00, 95% CI 3.32-4.81), joint replacement (6.02, 95% CI 4.66-7.77), osteoporosis (2.69, 95% CI 1.35-5.38), and anxiety (2.00, 95% CI 1.11-3.61) were significantly higher. More problems in HrQoL were reported amongst former players within the domains of mobility (p < 0.001), self-care (p = 0.041), usual activities (p < 0.001) and pain/discomfort (p < 0.001). Morbidity and HrQoL differ between players and the general population, with higher musculoskeletal morbidity and lower diabetes amongst former players. The magnitude of musculoskeletal morbidity may warrant proactive osteoarthritis management within this population.	[Davies, Madeleine A. M.; Judge, Andrew D.; Delmestri, Antonella; Arden, Nigel K.; Newton, Julia L.] Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Oxford, England; [Kemp, Simon P. T.] Rugby Football Union, Twickenham, England; [Stokes, Keith A.] Univ Bath, Dept Hlth, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Bath, Avon, England	Arden, NK (corresponding author), Univ Oxford, Nuffield Dept Orthopaed Rheumatol & Musculoskelet, Arthrit Res UK Ctr Sport Exercise & Osteoarthrit, Oxford, England.	nigel.arden@ndorms.ox.ac.uk	; Stokes, Keith/C-2605-2009	Kemp, Simon/0000-0002-3250-2713; Davies, Madeleine/0000-0002-6047-7340; Stokes, Keith/0000-0002-5049-2838; Arden, Nigel/0000-0002-3452-3382; Delmestri, Antonella/0000-0003-0388-3403	National Institute of Aging in the United StatesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Office for National Statistics; Arthritis Research UK Centre for Sport, Exercise and OsteoarthritisVersus Arthritis; Rugby Football Union	The authors gratefully acknowledge Tim Stevens and Sally Wright at Oxford University Rugby Football Club, Ian Minto and Nykki Webber at Cambridge University Rugby Football Club, and Philip Lay for all their guidance and assistance during Oxbridge recruitment. We also gratefully acknowledge Bill Treadwell and the England Rugby Internationals Club Committee for their guidance and assistance with English International player recruitment and Richard Bryan at the Rugby Players Association for his continued support. We would like to thank our Project Steering Group for their insight and contributions throughout the duration of the project, particularly our lay representatives. We would also like to thank the players who have contributed to player involvement in the study, and are indebted to the participants who have given their time and continued to inspire this player health study. ELSA data were made available through the UK Data Archive. ELSA was developed by a team of researchers based at the NatCen Social Research, University College London and the Institute for Fiscal Studies. The data were collected by NatCen Social Research. The funding is provided by the National Institute of Aging in the United States, and a consortium of UK government departments coordinated by the Office for National Statistics. The developers and funders of ELSA and the Archive do not bear any responsibility for the analyses or interpretations presented here. The study was supported financially by the Arthritis Research UK Centre for Sport, Exercise and Osteoarthritis (Grant reference 20194) and also received funding from the Rugby Football Union.	Bayram N, 2008, SOC PSYCH PSYCH EPID, V43, P667, DOI 10.1007/s00127-008-0345-x; Bennell K, 2012, NAT REV RHEUMATOL, V8, P747, DOI 10.1038/nrrheum.2012.119; Blair SN, 2009, BRIT J SPORT MED, V43, P1; Brilleman S. L., 2013, BR J GEN PRACT, V63; Brooks JHM, 2008, CLIN SPORT MED, V27, P51, DOI 10.1016/j.csm.2007.09.001; Caine DJ, 2011, BRIT J SPORT MED, V45, P298, DOI 10.1136/bjsm.2010.081984; Carter M, 2015, BMJ-BRIT MED J, V350, DOI 10.1136/bmj.h26; Conaghan PG, 2002, BRIT J SPORT MED, V36, P330, DOI 10.1136/bjsm.36.5.330; Conner-Spady BL, 2015, QUAL LIFE RES, V24, P1775, DOI 10.1007/s11136-014-0910-6; Cosh S., 2012, QUAL RES SPORT EXERC, V5, P1; Curtis Gannon L, 2017, J Clin Med Res, V9, P375, DOI 10.14740/jocmr3001w; Cutler D.M, 2012, OXFORD HDB HLTH EC; Daghestani HN, 2015, OSTEOARTHR CARTILAGE, V23, P1890, DOI 10.1016/j.joca.2015.02.009; Davies Madeleine A M, 2017, Res Involv Engagem, V3, P8, DOI 10.1186/s40900-017-0055-1; DAWBER TR, 1963, ANN NY ACAD SCI, V107, P539, DOI 10.1111/j.1749-6632.1963.tb13299.x; Decq P, 2016, ACTA NEUROCHIR, V158, P289, DOI 10.1007/s00701-015-2681-4; Deshpande AD, 2008, PHYS THER, V88, P1254, DOI 10.2522/ptj.20080020; Egan E, 2006, BONE, V38, P227, DOI 10.1016/j.bone.2005.08.024; Ekstrand J, 2011, BRIT J SPORT MED, V45, P553, DOI 10.1136/bjsm.2009.060582; Elloumi M, 2006, INT J SPORTS MED, V27, P351, DOI 10.1055/s-2005-865742; Fagard RH, 1999, MED SCI SPORT EXER, V31, pS624, DOI 10.1097/00005768-199911001-00022; Fransen M, 1999, RHEUMATOLOGY, V38, P807, DOI 10.1093/rheumatology/38.9.807; Godlee F., 2015, BMJ-BRIT MED J, V350; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HART DJ, 1994, ANN RHEUM DIS, V53, P158, DOI 10.1136/ard.53.3.158; HELMRICH SP, 1991, NEW ENGL J MED, V325, P147, DOI 10.1056/NEJM199107183250302; Hume PA, 2017, SPORTS MED, V47, P1209, DOI 10.1007/s40279-016-0608-8; Janssen MF, 2011, DIABETIC MED, V28, P395, DOI 10.1111/j.1464-5491.2010.03136.x; Jeon CY, 2007, DIABETES CARE, V30, P744, DOI 10.2337/dc06-1842; Johnson JA, 1998, QUAL LIFE RES, V7, P155, DOI 10.1023/A:1008809610703; Johnson JA, 2000, MED CARE, V38, P115, DOI 10.1097/00005650-200001000-00013; KING NA, 2005, EUROPEAN J SPORTS SC, V5, P73, DOI DOI 10.1080/17461390500148466; Kohl HW, 2001, MED SCI SPORT EXER, V33, pS472, DOI 10.1097/00005768-200106001-00017; Lee AJ, 2001, BRIT J SPORT MED, V35, P38, DOI 10.1136/bjsm.35.1.38; Lohmander LS, 2007, AM J SPORT MED, V35, P1756, DOI 10.1177/0363546507307396; Marmot M, 2016, ENGLISH LONGITUDINAL, P5050; Marshall SW, 2001, J ATHL TRAINING, V36, P334; McKenna J, 2007, SPORT EDUC SOC, V12, P19, DOI 10.1080/13573320601081500; McMillan TM, 2017, J NEUROL NEUROSUR PS, V88, P505, DOI 10.1136/jnnp-2016-314279; Melzer K, 2004, CURR OPIN CLIN NUTR, V7, P641, DOI 10.1097/00075197-200411000-00009; Morel J, 2001, OSTEOPOROSIS INT, V12, P152, DOI 10.1007/s001980170148; Multiple sclerosis in adults: management, 2014, CLIN GUIDELINE; Musumeci G, 2015, INT J MOL SCI, V16, P6093, DOI 10.3390/ijms16036093; NatCen Social Research, 2016, HLTH SURV ENGL; Orchard JW, 2006, J SCI MED SPORT, V9, P459, DOI 10.1016/j.jsams.2006.05.001; Patricios JS, 2014, BRIT J SPORT MED, V48, P76, DOI 10.1136/bjsports-2013-093031; Pickard AS, 2008, RESP MED, V102, P519, DOI 10.1016/j.rmed.2007.11.016; Public Health England, 2014, AUTH, P1; Roberts SP, 2013, BMJ OPEN, V3, DOI 10.1136/bmjopen-2013-003998; Rothman K. J., 1986, MODERN EPIDEMIOLOGY; van Reenen M, 2015, EQ 5D 5L USER GUIDE; Wang YF, 2005, AM J CLIN NUTR, V81, P555; Warburton DER, 2006, CAN MED ASSOC J, V174, P801, DOI 10.1503/cmaj.051351; Williams S, 2013, SPORTS MED, V43, P1043, DOI 10.1007/s40279-013-0078-1	54	22	22	0	14	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	SEP 28	2017	7								11786	10.1038/s41598-017-12130-y			11	Multidisciplinary Sciences	Science & Technology - Other Topics	FI5CI	WOS:000411998400001	28959048	DOAJ Gold, Green Published, Green Accepted			2021-06-18	
J	Adams, WM; Scarneo, SE; Casa, DJ				Adams, William M.; Scarneo, Samantha E.; Casa, Douglas J.			State-Level Implementation of Health and Safety Policies to Prevent Sudden Death and Catastrophic Injuries Within Secondary School Athletics	ORTHOPAEDIC JOURNAL OF SPORTS MEDICINE			English	Article						sudden cardiac death; exertional heat stroke; traumatic head injuries; emergency action plans; preparticipation examination	ASSOCIATION POSITION STATEMENT; TASK-FORCE; PRACTICES RECOMMENDATIONS; CONSENSUS STATEMENT; CARDIAC-ARREST; SPORT; CONCUSSION; MANAGEMENT; PROGRAMS	Background: Sudden death and catastrophic injuries during sport can be attenuated with the implementation of evidence-based health and safety policies. However, the extent of the implementation of these policies within secondary school athletics is unknown. Purpose: To provide an assessment of the implementation of health and safety policies pertaining to the leading causes of sudden death and catastrophic injuries in sport within secondary school athletics in the United States. Study Design: Descriptive epidemiology study. Methods: A rubric for evidence-based practices for preventing the leading causes of death and catastrophic injuries in sport was created. The rubric comprised 5 equally weighted sections for sudden cardiac arrest, head injuries, exertional heat stroke, appropriate medical coverage, and emergency preparedness. State high school athletic association (SHSAA) policies, enacted legislation, and Department of Education policies were extensively reviewed for all 50 states and the District of Columbia. States meeting the specific criteria in the rubric, which required policies to be mandated for all SHSAA member schools, were awarded credit; the weighted scores were tabulated to calculate an aggregate score. States were then ranked from 1 (best) to 51 (worst) based on the aggregate score achieved. Results: The median score on the rubric was 47.1% (range, 23.00%-78.75%). States ranked 1 through 10 (from 78.75% to 56.98%) were North Carolina, Kentucky, Massachusetts, New Jersey, South Dakota, Missouri, Washington, Hawaii, Wisconsin, and Georgia, respectively. States ranked 11 through 20 (from 56.03% to 50.55%) were Arkansas, New York, Mississippi, West Virginia, Oregon, Illinois, Tennessee, Arizona, Texas, and District of Columbia, respectively. States ranked 21 through 30 (from 49.40% to 44.00%) were Virginia, Pennsylvania, Florida, New Mexico, Alabama, Maine, Rhode Island, Indiana, Nevada, and Utah, respectively. States ranked 31 through 40 (from 43.93% to 39.80%) were Ohio, Delaware, Alaska, Vermont, Louisiana, Maryland, Oklahoma, Connecticut, Idaho, and South Carolina, respectively. States ranked 41 through 51 (from 38.73% to 23.00%) were Michigan, North Dakota, Nebraska, New Hampshire, Kansas, Wyoming, Minnesota, Montana, Iowa, California, and Colorado, respectively. Conclusion: State scores ranged from 23.00% to 78.75% for the implementation of evidence-based best practices for preventing the leading causes of sudden death and catastrophic injuries (sudden cardiac arrest, traumatic head injuries, exertional heat stroke, and exertional sickling) in sport. Continued advocacy for the development and implementation of policies at the secondary school level surrounding sudden death and catastrophic injuries is warranted to optimize the health and safety of these student athletes.	[Adams, William M.; Scarneo, Samantha E.; Casa, Douglas J.] Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, 2095 Hillside Rd,Box U-1110, Storrs, CT 06269 USA	Casa, DJ (corresponding author), Univ Connecticut, Korey Stringer Inst, Dept Kinesiol, 2095 Hillside Rd,Box U-1110, Storrs, CT 06269 USA.	douglas.casa@uconn.edu					Adams WM, 2016, J ATHL TRAINING, V51, P358, DOI 10.4085/1062-6050-51.4.14; Adams WM, 2017, J ATHL TRAIN S6, V52, pS103; Adams WM, 2016, J ATHL TRAIN S, V51, pS167; Almeraya A, 2017, J ATHL TRAIN S6, V52, pS50; Andersen JC, 2002, J ATHL TRAINING, V37, P99; Anderson S, 2017, J ATHL TRAINING, V52, P145, DOI 10.4085/1062-6050-52.3.02; [Anonymous], 2016, 2014 15 HIGH SCH ATH; Attanasio SM, 2016, J ATHL TRAIN S6, V51, pS; Bernhardt DT, 2010, PPE PREPARTICIPATION; Boden BP, 2013, AM J SPORT MED, V41, P1108, DOI 10.1177/0363546513478572; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Casa DJ, 2015, J ATHL TRAINING, V50, P986, DOI 10.4085/1062-6050-50.9.07; Casa DJ, 2013, J ATHL TRAINING, V48, P546, DOI 10.4085/1062-6050-48.4.12; Casa DJ, 2012, J ATHL TRAINING, V47, P477, DOI 10.4085/1062-6050-47.4.08; Casa DJ, 2012, J ATHL TRAINING, V47, P96; Casa DJ, 2009, J ATHL TRAINING, V44, P332, DOI 10.4085/1062-6050-44.3.332; Colgate B, 2017, 2017 FOOTBALL RULES; Demartini JK, 2015, MED SCI SPORT EXER, V47, P240, DOI 10.1249/MSS.0000000000000409; Drezner JA, 2007, PREHOSP EMERG CARE, V11, P253, DOI 10.1080/10903120701204839; Drezner JA, 2013, BRIT J SPORT MED, V47, P1179, DOI 10.1136/bjsports-2013-092786; Finn AL, 2017, J ATHL TRAIN S6, V52, pS314; Hopkins B, 2016, 2016 17 NFHS WRESTLI; Kerr ZY, 2016, ORTHOP J SPORTS MED, V4, DOI 10.1177/2325967116648441; Koski M, 2017, 2017 FIELD HOCKEY RU; Lawler EC, 2017, J HEALTH ECON, V52, P45, DOI 10.1016/j.jhealeco.2017.01.002; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; National Athletic Trainers' Association, 2003, APPR MED CAR SEC SCH; National Center for Catastrophic Sport Injury Research, 2015, CAT SPORTS INJ RES 3; National Federation of State High School Associations, 2017, RUL WRIT PROC; Rynkiewicz KM, 2017, J ATHL TRAIN S6, V52, pS77; Scarneo SE, 2017, J ATHL TRAIN S6, V52, pS22; Schuster D, 2016, 2016 17 NFHS ICE HOC; Weaver J, 2017, 2017 NFHS BOYS LACRO	33	22	22	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	2325-9671			ORTHOP J SPORTS MED	Orthop. J. Sports Med.	SEP 18	2017	5	9							2325967117727262	10.1177/2325967117727262			8	Orthopedics; Sport Sciences	Orthopedics; Sport Sciences	FH5HZ	WOS:000411197600001	28951881	DOAJ Gold, Green Published			2021-06-18	
J	Hammond, FM; Malec, JF; Zafonte, RD; Sherer, M; Bogner, J; Dikmen, S; Whitney, MP; Bell, KR; Perkins, SM; Moser, EA				Hammond, Flora M.; Malec, James F.; Zafonte, Ross D.; Sherer, Mark; Bogner, Jennifer; Dikmen, Sureyya; Whitney, Marybeth P.; Bell, Kathleen R.; Perkins, Susan M.; Moser, Elizabeth A.			Potential Impact of Amantadine on Aggression in Chronic Traumatic Brain Injury	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						aggression; amantadine; anger; brain injuries	NEUROPSYCHIATRIC INVENTORY; PHARMACOLOGICAL MANAGEMENT; BEHAVIOR; INTERVENTION; IRRITABILITY; THERAPY; COMMON; SCALE; STATE	Objective: To assess the effects of amantadine on anger and aggression among individuals with a chronic traumatic brain injury (TBI). Methods: A cohort of 118 persons with chronic TBI (>6 months postinjury) and moderate-severe aggression selected from a larger cohort of 168 participants enrolled in a parallel-group, randomized, double-blind, placebo-controlled trial of amantadine 100 mg twice daily (n = 82) versus placebo (n = 86) for treatment of irritability were studied. Anger and aggression were measured at treatment days 0, 28, and 60 using observerrated and participant-rated State-Trait Anger Expression Inventory-2 (STAXI-2) and Neuropsychiatric Inventory-Agitation/Aggression domain (NPI-A) Most Problematic and Distress scores. Results: Participant-rated day 60 NPI-A Most Problematic (adjusted P = .0118) and NPI-A Distress (adjusted P = .0118) were statistically significant between the 2 groups, but STAXI-2 differences were not significant after adjustment for multiple comparisons. Substantial improvements were noted in both amantadine and placebo groups (70% vs 56% improving at least 3 points on day 60 Observer NPI-A; P = .11). Conclusion: Amantadine 100 mg twice daily in this population with chronic TBI appears to be beneficial in decreasing aggression from the perspective of the individual with TBI. No beneficial impact on anger was found. Trial Registration: clinicaltrials.gov Identifier: NCT00779324; http://www.clinicaltrials.gov/ct2/show/NCT00779324?term=irritability&rank=6.	[Hammond, Flora M.; Malec, James F.; Perkins, Susan M.; Moser, Elizabeth A.] Indiana Univ Sch Med, 4141 Shore Dr, Indianapolis, IN 46254 USA; [Hammond, Flora M.; Malec, James F.] Rehabil Hosp Indiana, Indianapolis, IN USA; [Zafonte, Ross D.] Harvard Med Sch, Massachusetts Gen Hosp, Spaulding Rehabil Hosp, Boston, MA USA; [Zafonte, Ross D.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA; [Sherer, Mark] TIRR Mem Hermann, Houston, TX USA; [Bogner, Jennifer] Ohio State Univ, Dept Phys Med & Rehabil, Columbus, OH 43210 USA; [Dikmen, Sureyya; Bell, Kathleen R.] Univ Washington, Seattle, WA 98195 USA; [Whitney, Marybeth P.] Carolinas Hlth Care Syst, Carolinas Rehabil, Dept Phys Med & Rehabil, Charlotte, NC USA; [Bell, Kathleen R.] Univ Texas Southwestern Med Ctr Dallas, Dallas, TX 75390 USA	Hammond, FM (corresponding author), Indiana Univ Sch Med, 4141 Shore Dr, Indianapolis, IN 46254 USA.	hammond@rhin.com		Bell, Kathleen/0000-0002-0928-2046	US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability, Independent Living, and Rehabilitation Research [H133A080035]	The research reported in this article was supported by US Department of Education, Office of Special Education and Rehabilitative Services, National Institute on Disability, Independent Living, and Rehabilitation Research grant H133A080035. This support included the funds to purchase amantadine. The study sponsor had no role in the design and conduct of this study; the collection, management, analysis, and interpretation of the data; or the preparation review, or approval of the manuscript.	Anson K, 2006, BRAIN INJURY, V20, P1, DOI 10.1080/02699050500309791; Arciniegas DB, 2014, PSYCHIAT CLIN N AM, V37, P31, DOI 10.1016/j.psc.2013.12.001; Baguley IJ, 2006, J HEAD TRAUMA REHAB, V21, P45, DOI 10.1097/00001199-200601000-00005; Beck AT., 1996, BECK DEPRESSION INVE, V2; Berry DA, 1996, J NATL CANCER I, V88, P1606, DOI 10.1093/jnci/88.22.1606; Chew E, 2009, J REHABIL RES DEV, V46, P851, DOI 10.1682/JRRD.2008.09.0120; CUMMINGS JL, 1994, NEUROLOGY, V44, P2308, DOI 10.1212/WNL.44.12.2308; Evans CC, 2008, J HEAD TRAUMA REHAB, V23, P329, DOI 10.1097/01.HTR.0000336845.06704.bc; Finniss DG, 2010, LANCET, V375, P686, DOI 10.1016/S0140-6736(09)61706-2; Fleminger S, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003299.pub2; Hall KT, 2015, TRENDS MOL MED, V21, P285, DOI 10.1016/j.molmed.2015.02.009; Hammond FM, 2015, J NEUROTRAUM, V32, P1230, DOI 10.1089/neu.2014.3803; Hammond FM, 2014, J HEAD TRAUMA REHAB, V29, P391, DOI 10.1097/01.HTR.0000438116.56228.de; HOLM S, 1979, SCAND J STAT, V6, P65; Kaufer DI, 1998, J AM GERIATR SOC, V46, P210, DOI 10.1111/j.1532-5415.1998.tb02542.x; Kilmer RP, 2006, REHABIL PSYCHOL, V51, P232, DOI 10.1037/0090-5550.51.3.232; Medd J, 2000, NEUROPSYCHOL REHABIL, V10, P185, DOI 10.1080/096020100389246; Miciak M, 2012, SCAND J CARING SCI, V26, P394, DOI 10.1111/j.1471-6712.2011.00923.x; Neumann D, 2017, J HEAD TRAUMA REHAB, V32, P205, DOI 10.1097/HTR.0000000000000261; Rybin D, 2015, STAT MED, V34, P2281, DOI 10.1002/sim.6494; Sabaz M, 2014, J HEAD TRAUMA REHAB, V29, pE19, DOI 10.1097/HTR.0b013e31828dc590; Spahn JM, 2010, J AM DIET ASSOC, V110, P879, DOI 10.1016/j.jada.2010.03.021; Spielberger C.D., 1999, STATE TRAIT ANGER EX; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573	24	22	22	0	6	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	SEP-OCT	2017	32	5					308	318		10.1097/HTR.0000000000000342			11	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FG2DW	WOS:000409893800011	28891908				2021-06-18	
J	Yin, HY; Song, SW; Pan, XD				Yin, Haiyan; Song, Shuwen; Pan, Xudong			Knockdown of miR-155 protects microglia against LPS-induced inflammatory injury via targeting RACK1: a novel research for intracranial infection	JOURNAL OF INFLAMMATION-LONDON			English	Article						Intracranial inflammation; miR-155; Inflammation; Cell injury; Microglia; RACK1	KAPPA-B ACTIVATION; NITRIC-OXIDE; MICRORNAS; ROLES; DYSREGULATION; PATHWAY; DEATH	Background: Intracranial infection, one of the complications of traumatic brain injury, is usually associated with inflammation. Several microRNAs (miRNAs), including miR-155, have been reported to be critical modulators in peripheral and central nervous system inflammation. In this study, we investigated the role of miR-155 in lipopolysaccharide (LPS)-induced inflammatory injury in mouse microglia BV2 cells. Results: The expression level of miR-155 was significantly up-regulated after LPS stimulation in BV2 cells. LPS administration decreased BV2 cell viability, promoted apoptosis and increased the release of pro-inflammatory cytokines; while miR-155 knockdown rescued BV2 cell from LPS-induced injury. RACK1 was a directly target of miR-155. Interestingly, miR-155 knockdown did not attenuate LPS-induced inflammatory injury when RACK1 was knocked down. The mechanistic study indicated that miR-155 knockdown deactivated MAPK/NF-kappa B and mTOR signaling pathways under LPS-treated conditions. Conclusions: Knockdown of miR-155 protected mouse microglia BV2 cells from LPS-induced inflammatory injury via targeting RACK1 and deactivating MAPK/NF-kappa B and mTOR signaling pathways.	[Yin, Haiyan] Jining Med Univ, Affiliated Hosp, Dept Neurol, Jining 272000, Peoples R China; [Song, Shuwen] Jining 1 Peoples Hosp, Dept Infect Dis, Jining 272000, Peoples R China; [Pan, Xudong] Qingdao Univ, Affiliated Hosp, Dept Neurol, 16,Jiangsu Rd, Qingdao 266000, Peoples R China	Pan, XD (corresponding author), Qingdao Univ, Affiliated Hosp, Dept Neurol, 16,Jiangsu Rd, Qingdao 266000, Peoples R China.	panxudong012@126.com					Bartel DP, 2004, CELL, V116, P281, DOI 10.1016/S0092-8674(04)00045-5; Beveridge NJ, 2012, NEUROBIOL DIS, V46, P263, DOI 10.1016/j.nbd.2011.12.029; Bhalala OG, 2013, NAT REV NEUROL, V9, P328, DOI 10.1038/nrneurol.2013.67; Bi XL, 2005, INT IMMUNOPHARMACOL, V5, P185, DOI 10.1016/j.intimp.2004.08.008; Bluml S, 2011, ARTHRITIS RHEUM-US, V63, P1281, DOI 10.1002/art.30281; Bodea LG, 2014, J NEUROSCI, V34, P8546, DOI 10.1523/JNEUROSCI.5002-13.2014; Cardoso AL, 2012, IMMUNOLOGY, V135, P73, DOI 10.1111/j.1365-2567.2011.03514.x; Cullen BR, 2009, NATURE, V457, P421, DOI 10.1038/nature07757; Fan K, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0268-x; Faraoni I, 2009, BBA-MOL BASIS DIS, V1792, P497, DOI 10.1016/j.bbadis.2009.02.013; Foerster BR, 2007, ACTA RADIOL, V48, P875, DOI 10.1080/02841850701477728; Geaghan M, 2015, BIOL PSYCHIAT, V78, P231, DOI 10.1016/j.biopsych.2014.12.009; Graeber MB, 2010, ACTA NEUROPATHOL, V119, P89, DOI 10.1007/s00401-009-0622-0; Harrison-Felix C, 2006, J HEAD TRAUMA REHAB, V21, P22, DOI 10.1097/00001199-200601000-00003; Hermanto U, 2002, MOL CELL BIOL, V22, P2345, DOI 10.1128/MCB.22.7.2345-2365.2002; Hutchison ER, 2009, NEUROMOL MED, V11, P153, DOI 10.1007/s12017-009-8086-x; Jin HM, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/ar4531; Kaminska B, 2005, BBA-PROTEINS PROTEOM, V1754, P253, DOI 10.1016/j.bbapap.2005.08.017; Kiely PA, 2008, J BIOL CHEM, V283, P22952, DOI 10.1074/jbc.M800802200; Kurowska-Stolarska M, 2011, P NATL ACAD SCI USA, V108, P11193, DOI 10.1073/pnas.1019536108; Lawrence T, 2009, CSH PERSPECT BIOL, V1, DOI 10.1101/cshperspect.a001651; LAWSON LJ, 1990, NEUROSCIENCE, V39, P151, DOI 10.1016/0306-4522(90)90229-W; Lee JM, 2004, J BIOL CHEM, V279, P53725, DOI 10.1074/jbc.M407627200; Lin C, 2015, CHIN J TRAUMATOL, V18, P81, DOI 10.1016/j.cjtee.2014.10.007; Jimenez CM, 2013, WORLD NEUROSURG, V79, P749, DOI 10.1016/j.wneu.2012.06.025; Miller BH, 2010, BRAIN RES, V1338, P89, DOI 10.1016/j.brainres.2010.03.035; Mor E, 2011, NUCLEIC ACIDS RES, V39, P3710, DOI 10.1093/nar/gkq1325; Mullins ME, 2011, RADIOL CLIN N AM, V49, P47, DOI 10.1016/j.rcl.2010.08.002; Murugaiyan G, 2011, J IMMUNOL, V187, P2213, DOI 10.4049/jimmunol.1003952; Russo I, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0449-7; Saugstad JA, 2010, J CEREBR BLOOD F MET, V30, P1564, DOI 10.1038/jcbfm.2010.101; Seddiki N, 2014, IMMUNOLOGY, V142, P32, DOI 10.1111/imm.12227; Shukla Girish C, 2011, Mol Cell Pharmacol, V3, P83; Slezak-Prochazka I, 2010, RNA, V16, P1087, DOI 10.1261/rna.1804410; Streit WJ, 2004, J NEUROINFLAMM, V1, DOI 10.1186/1742-2094-1-14; Syed SAM, 2015, FASEB J, V29, P634; Weichhart T, 2008, IMMUNITY, V29, P565, DOI 10.1016/j.immuni.2008.08.012; Weichhart T, 2011, BLOOD, V117, P4273, DOI 10.1182/blood-2010-09-310888; Wu D, 2013, FRONT PHYSIOL, V4, DOI 10.3389/fphys.2013.00055; Xin Q, 2015, J IMMUNOL, V194, P5437, DOI 10.4049/jimmunol.1403028; Yao F, 2014, CELL RES, V24, P359, DOI 10.1038/cr.2013.162; Zhang WZ, 2008, J BIOL CHEM, V283, P16416, DOI 10.1074/jbc.M802360200	42	22	22	0	5	BMC	LONDON	CAMPUS, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	1476-9255			J INFLAMM-LOND	J. Inflamm.-Lond.	AUG 9	2017	14								17	10.1186/s12950-017-0162-7			12	Immunology	Immunology	FD6FN	WOS:000407624500001	28804270	DOAJ Gold, Green Published			2021-06-18	
J	Ferguson, NM; Sarnaik, A; Miles, D; Shafi, N; Peters, MJ; Truemper, E; Vavilala, MS; Bell, MJ; Wisniewski, SR; Luther, JF; Hartman, AL; Kochanek, PM				Ferguson, Nikki Miller; Sarnaik, Ajit; Miles, Darryl; Shafi, Nadeem; Peters, Mark J.; Truemper, Edward; Vavilala, Monica S.; Bell, Michael J.; Wisniewski, Stephen R.; Luther, James F.; Hartman, Adam L.; Kochanek, Patrick M.		Investigators Approaches Decisions	Abusive Head Trauma and Mortality-An Analysis From an International Comparative Effectiveness Study of Children With Severe Traumatic Brain Injury	CRITICAL CARE MEDICINE			English	Article						abusive head injury; comparative effectiveness research; pediatric neurocritical care; pediatric traumatic brain injury; secondary injuries	OPERATIONAL CASE-DEFINITION; YOUNG-CHILDREN; UNITED-STATES; OUTCOMES; INFANTS; NEUROPATHOLOGY; DEMOGRAPHICS; BURDEN; DEATH; APNEA	Objectives: Small series have suggested that outcomes after abusive head trauma are less favorable than after other injury mechanisms. We sought to determine the impact of abusive head trauma on mortality and identify factors that differentiate children with abusive head trauma from those with traumatic brain injury from other mechanisms. Design: First 200 subjects from the Approaches and Decisions in Acute Pediatric Traumatic Brain Injury Trial-a comparative effectiveness study using an observational, cohort study design. Setting: PICUs in tertiary children's hospitals in United States and abroad. Patients: Consecutive children (age < 18 yr) with severe traumatic brain injury (Glasgow Coma Scale <= 8; intracranial pressure monitoring). Interventions: None. Measurements and Main Results: Demographics, injury-related scores, prehospital, and resuscitation events were analyzed. Children were dichotomized based on likelihood of abusive head trauma. A total of 190 children were included (n = 35 with abusive head trauma). Abusive head trauma subjects were younger (1.87 +/- 0.32 vs 9.23 +/- 0.39 yr; p < 0.001) and a greater proportion were female (54.3% vs 34.8%; p = 0.032). Abusive head trauma were more likely to 1) be transported from home (60.0% vs 33.5%; p < 0.001), 2) have apnea (34.3% vs 12.3%; p = 0.002), and 3) have seizures (28.6% vs 7.7%; p < 0.001) during prehospital care. Abusive head trauma had a higher prevalence of seizures during resuscitation (31.4 vs 9.7%; p = 0.002). After adjusting for covariates, there was no difference in mortality (abusive head trauma, 25.7% vs nonabusive head trauma, 18.7%; hazard ratio, 1.758; p = 0.60). A similar proportion died due to refractory intracranial hypertension in each group (abusive head trauma, 66.7% vs nonabusive head trauma, 69.0%). Conclusions: In this large, multicenter series, children with abusive head trauma had differences in prehospital and in-hospital secondary injuries which could have therapeutic implications. Unlike other traumatic brain injury populations in children, female predominance was seen in abusive head trauma in our cohort. Similar mortality rates and refractory intracranial pressure deaths suggest that children with severe abusive head trauma may benefit from therapies including invasive monitoring and adherence to evidence-based guidelines.	[Ferguson, Nikki Miller] Virginia Commonwealth Univ, Dept Pediat, Richmond, VA USA; [Sarnaik, Ajit] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA; [Miles, Darryl] Univ Texas Southwestern, Dept Pediat, Dallas, TX USA; [Shafi, Nadeem] Univ Tennessee, Dept Pediat, Memphis, TN USA; [Peters, Mark J.] Great Ormond St Hosp Sick Children, Dept Pediat, London, England; [Truemper, Edward] Univ Nebraska, Dept Pediat, Omaha, NE 68182 USA; [Vavilala, Monica S.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA; [Bell, Michael J.; Kochanek, Patrick M.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Wisniewski, Stephen R.; Luther, James F.] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA; [Hartman, Adam L.] NINDS, Off Clin Res, Bldg 36,Rm 4D04, Bethesda, MD 20892 USA	Bell, MJ (corresponding author), Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Peters, Mark/AAD-7518-2019; Ferguson, Nikki Miller/AAA-4548-2020; Hartman, Adam/W-9782-2019	Peters, Mark/0000-0003-3653-4808; Hartman, Adam/0000-0001-5672-3409; Bennett, Tellen/0000-0003-1483-4236; Edwards, Richard/0000-0001-8415-2180; Figaji, Anthony/0000-0002-3357-6490	National Institute of Neurological Disorders and Stroke of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01 NS081041]; National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; University of PittsburghUniversity of Pittsburgh; Approaches and Decisions in Acute Pediatric Traumatic Brain Injury Trial; NIH via Childrens' Hospital Pittsburgh; NIH, Pittsburgh Children's Hospital; University of Nebraska College of Medicine, Gerber Foundation grant; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [U54HD079123] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS081041] Funding Source: NIH RePORTER	Supported, in part, by the National Institute of Neurological Disorders and Stroke of the National Institutes of Health under Award Number U01 NS081041. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.; Drs. Miller Ferguson's and Sarnaik's institution received funding from the National Institute of Neurological Disorders and Stroke (NINDS)/National Institutes of Health (NIH), and they received support for article research from the NIH. Dr. Miles's institution received funding from the University of Pittsburgh, and he received support for article research from the NIH. Dr. Shafi's institution received funding from Approaches and Decisions in Acute Pediatric Traumatic Brain Injury Trial (PI: Michael Bell, UPMC), and he received support for article research from the NIH. Dr. Peters' institution received funding from the NIH via Childrens' Hospital Pittsburgh (per patient payments and initial set-up costs), and he received support for article research from the NIH; he disclosed funding from providing expert witness services to criminal and family courts in the United Kingdom concerning causation and timing of head trauma (for both prosecution and defense). Dr. Truemper's institution received funding from the NIH, Pittsburgh Children's Hospital, the University of Nebraska College of Medicine, Gerber Foundation grant (coinvestigator in determination of embolic burden in infants with CHD undergoing corrective or palliative	Acker SN, 2014, J PEDIATR SURG, V49, P338, DOI 10.1016/j.jpedsurg.2013.10.008; Adamo MA, 2009, J NEUROSURG-PEDIATR, V4, P414, DOI 10.3171/2009.6.PEDS0939; Armstead WM, 2010, BRAIN RES, V1330, P142, DOI 10.1016/j.brainres.2010.03.024; Bechtel K, 2004, PEDIATRICS, V114, P165, DOI 10.1542/peds.114.1.165; Bennett TD, 2012, ARCH PEDIAT ADOL MED, V166, P641, DOI 10.1001/archpediatrics.2012.322; Berger RP, 2016, PEDIATRICS, V138, DOI 10.1542/peds.2015-3756; Chang DC, 2004, J TRAUMA, V57, P1189, DOI 10.1097/01.TA.0000145076.05111.E1; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Davies FC, 2015, EMERG MED J, V32, P921, DOI 10.1136/emermed-2015-205285; Deans KJ, 2013, J TRAUMA ACUTE CARE, V75, P157, DOI 10.1097/TA.0b013e3182984acb; Diaz-Olavarrieta C, 2011, CHILD ABUSE NEGLECT, V35, P915, DOI 10.1016/j.chiabu.2011.05.017; Du LN, 2004, J BIOL CHEM, V279, P38563, DOI 10.1074/jbc.M405461200; Duval J, 2008, J CHILD NEUROL, V23, P663, DOI 10.1177/0883073808314161; Ewing-Cobbs L, 1998, PEDIATRICS, V102, P300, DOI 10.1542/peds.102.2.300; Ferguson NM, 2016, PEDIATR CRIT CARE ME, V17, P444, DOI 10.1097/PCC.0000000000000709; Geddes JF, 2001, BRAIN, V124, P1299, DOI 10.1093/brain/124.7.1299; Geddes JF, 2001, BRAIN, V124, P1290, DOI 10.1093/brain/124.7.1290; GOLDSTEIN B, 1993, CRIT CARE MED, V21, P1328, DOI 10.1097/00003246-199309000-00016; Greiner MV, 2015, J CHILD NEUROL, V30, P1778, DOI 10.1177/0883073815580285; Hymel KP, 2007, PEDIATRICS, V119, P922, DOI 10.1542/peds.2006-3111; Johnson DL, 1995, PEDIATR NEUROSURG, V23, P305, DOI 10.1159/000120976; Keenan HT, 2008, AM J PREV MED, V34, pS120, DOI 10.1016/j.amepre.2007.11.001; Keenan HT, 2006, PEDIATRICS, V117, P317, DOI 10.1542/peds.2005-0979; Keenan HT, 2004, PEDIATRICS, V114, P633, DOI 10.1542/peds.2003-1020-L; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; Kemp AM, 2003, ARCH DIS CHILD, V88, P472, DOI 10.1136/adc.88.6.472; Kesler H, 2008, J NEUROSURG-PEDIATR, V1, P351, DOI 10.3171/PED/2008/1/5/351; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; KRIEL RL, 1989, PEDIATR NEUROL, V5, P296, DOI 10.1016/0887-8994(89)90021-0; Liesemer K, 2011, J NEUROTRAUM, V28, P755, DOI 10.1089/neu.2010.1518; Lind K, 2016, CHILD ABUSE NEGLECT, V51, P358, DOI 10.1016/j.chiabu.2015.08.001; Makaroff KL, 2003, DEV MED CHILD NEUROL, V45, P497, DOI 10.1017/S0012162203000926; Matschke J, 2015, INT J LEGAL MED, V129, P105, DOI 10.1007/s00414-014-1060-7; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Nuno M, 2015, J NEUROSURG PEDIAT, P1; Parks S, 2012, INJURY PREV, V18, P392, DOI 10.1136/injuryprev-2011-040234; Parks SE, 2012, INJURY PREV, V18, P193, DOI 10.1136/injuryprev-2011-040128; Peterson C, 2015, CHILD MALTREATMENT, V20, P162, DOI 10.1177/1077559515583549; Peterson C, 2014, PEDIATRICS, V134, P91, DOI 10.1542/peds.2014-0117; Piteau SJ, 2012, PEDIATRICS, V130, P315, DOI 10.1542/peds.2011-1545; Scavarda D, 2010, CHILD NERV SYST, V26, P1555, DOI 10.1007/s00381-010-1150-x; Shein SL, 2012, J PEDIATR-US, V161, P716, DOI 10.1016/j.jpeds.2012.03.046; Siriussawakul A, 2011, PEDIATR ANESTH, V21, P141, DOI 10.1111/j.1460-9592.2010.03498.x; Xiang J, 2013, BRAIN INJURY, V27, P1555, DOI 10.3109/02699052.2013.831126	45	22	22	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0090-3493	1530-0293		CRIT CARE MED	Crit. Care Med.	AUG	2017	45	8					1398	1407		10.1097/CCM.0000000000002378			10	Critical Care Medicine	General & Internal Medicine	FA5FY	WOS:000405469600040	28430697	Green Accepted			2021-06-18	
J	Tucker, R; Raftery, M; Fuller, GW; Hester, B; Kemp, S; Cross, MJ				Tucker, Ross; Raftery, Martin; Fuller, Gordon Ward; Hester, Ben; Kemp, Simon; Cross, Matthew J.			A video analysis of head injuries satisfying the criteria for a head injury assessment in professional Rugby Union: a prospective cohort study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORTS INJURIES; TACKLE INJURIES; CONCUSSION; EPIDEMIOLOGY; PREVENTION; MANAGEMENT; TIME	Objectives Concussion is the most common match injury in professional Rugby Union, accounting for 25% of match injuries. The primary prevention of head injuries requires that the injury mechanism be known so that interventions can be targeted to specifically overall incidence by focusing on characteristics with the greatest propensity to cause a head injury. Methods 611 head injury assessment (HIA) events in professional Rugby Union over a 3-year period were analysed, with specific reference to match events, position, time and nature of head contact. Results 464 (76%) of HIA events occur during tackles, with the tackler experiencing a significantly greater propensity for an HIA than the ball carrier (1.40 HIAs/1000 tackles for the tackler vs 0.54 HIAs/1000 tackles for the ball carrier, incidence rate ratio (IRR) 2.59). Propensity was significantly greater for backline players than forwards (IRR 1.54, 95% CI 1.28 to 1.84), but did not increase over the course of the match. Head to head contact accounted for the most tackler HIAs, with the greatest propensity. Conclusions By virtue of its high propensity and frequency, the tackle should be the focus for interventions that may include law change and technique education. A specific investigation of the characteristics of the tackle is warranted to refine the approach to preventative strategies.	[Tucker, Ross; Raftery, Martin; Hester, Ben] World Rugby Pty Ltd, Dublin, Ireland; [Fuller, Gordon Ward] Univ Sheffield, Sch Hlth & Related Res, Sheffield, S Yorkshire, England; [Kemp, Simon; Cross, Matthew J.] Rugby Football Union, London, England; [Cross, Matthew J.] Univ Bath, Dept Hlth, Bath, Avon, England	Tucker, R (corresponding author), World Rugby Pty Ltd, Dublin, Ireland.	Ross.tucker@mweb.co.za		Kemp, Simon/0000-0002-3250-2713; Fuller, Gordon Ward/0000-0001-8532-3500	National Institute for Health ResearchNational Institute for Health Research (NIHR) [CL-2015-04-005] Funding Source: researchfish		Bahr R, 2003, BRIT J SPORT MED, V37, P384, DOI 10.1136/bjsm.37.5.384; Batten J, 2016, BRIT J SPORT MED, V50, P1293, DOI 10.1136/bjsports-2015-095949; Burger N, 2016, BRIT J SPORT MED, V50, P932, DOI 10.1136/bjsports-2015-095295; Freitag A, 2015, BRIT J SPORT MED, V49, P511, DOI 10.1136/bjsports-2014-093684; Fuller CW, 2007, BRIT J SPORT MED, V41, P862, DOI 10.1136/bjsm.2007.037499; Fuller CW, 2015, BRIT J SPORT MED, V49, P478, DOI 10.1136/bjsports-2013-093381; Fuller CW, 2010, BRIT J SPORT MED, V44, P159, DOI 10.1136/bjsm.2008.050864; Fuller GW, 2017, J SCI MED SPORT, V20, P246, DOI 10.1016/j.jsams.2016.07.008; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Garraway WM, 1999, BRIT J SPORT MED, V33, P37, DOI 10.1136/bjsm.33.1.37; Hendricks S, 2015, EUR J SPORT SCI, V15, P557, DOI 10.1080/17461391.2015.1046192; Hollis SJ, 2011, BRIT J SPORT MED, V45, P997, DOI 10.1136/bjsm.2010.079707; Kemp S, ENGLAND PROFESSIONAL; Kemp SPT, 2008, CLIN J SPORT MED, V18, P227, DOI 10.1097/JSM.0b013e31816a1c9a; Makdissi M, 2016, J SCI MED SPORT, V19, P958, DOI 10.1016/j.jsams.2016.02.014; Mc Fie S, 2016, CLIN J SPORT MED, V26, P398, DOI 10.1097/JSM.0000000000000276; Pellman EJ, 2004, NEUROSURGERY, V54, P81, DOI 10.1227/01.NEU.0000097267.54786.54; Quarrie KL, 2008, AM J SPORT MED, V36, P1705, DOI 10.1177/0363546508316768; Raftery M, 2016, BRIT J SPORT MED, V50, P642, DOI 10.1136/bjsports-2016-095959; Roberts SP, 2014, ORTHOP J SPORTS MED, V2, DOI 10.1177/2325967114562781; VANMECHELEN W, 1992, SPORTS MED, V14, P82, DOI 10.2165/00007256-199214020-00002; Wilson B D, 1999, J Sci Med Sport, V2, P153, DOI 10.1016/S1440-2440(99)80195-9	22	22	22	0	21	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	AUG	2017	51	15					1147	1151		10.1136/bjsports-2017-097883			5	Sport Sciences	Sport Sciences	FA9US	WOS:000405792300011	28663217	Green Accepted			2021-06-18	
J	Teng, ZP; Guo, ZD; Zhong, JJ; Cheng, CJ; Huang, ZJ; Wu, Y; Tang, S; Luo, C; Peng, X; Wu, HT; Sun, XC; Jiang, L				Teng, Zhipeng; Guo, Zongduo; Zhong, Jianjun; Cheng, Chongjie; Huang, Zhijian; Wu, Yue; Tang, Shuang; Luo, Chao; Peng, Xing; Wu, Haitao; Sun, Xiaochuan; Jiang, Li			ApoE Influences the Blood-Brain Barrier Through the NF-kappa B/MMP-9 Pathway After Traumatic Brain Injury	SCIENTIFIC REPORTS			English	Article							APOLIPOPROTEIN-E; MATRIX METALLOPROTEINASES; SUBARACHNOID HEMORRHAGE; MMP-9; APOPTOSIS; MODEL; IMPAIRMENT; DISRUPTION; ACTIVATION; INTEGRITY	Apolipoprotein E (ApoE), encoded by the ApoE gene (APOE), influences the outcomes of traumatic brain injury (TBI), but the mechanism remains unclear. The present study aimed to investigate the effects of different ApoEs on the outcome of TBI and to explore the possible mechanisms. Controlled cortical impact (CCI) was performed on APOE epsilon 3 (E3) and APOE epsilon 4 (E4) transgenic mice, APOE-KO (KO) mice, and wild type (WT) mice to construct an in vivo TBI model. Neurological deficits, blood brain barrier (BBB) permeability and brain edema were detected at days 1, 3, and 7 after TBI. The results revealed no significant differences among the four groups at day 1 or day 3 after injury, but more severe deficits were found in E4 and KO mice than in E3 and WT mice. Furthermore, a significant loss of tight junction proteins was observed in E4 and KO mice compared with E3 and WT mice at day 7. Additionally, more expression and activation of NF-kappa B and MMP-9 were found in E4 mice compared with E3 mice. Different ApoEs had distinct effects on neuro-function and BBB integrity after TBI. ApoE3, but not E4, might inhibit the NF-kappa B/MMP-9 pathway to alleviate BBB disruption and improve TBI outcomes.	[Guo, Zongduo; Zhong, Jianjun; Cheng, Chongjie; Huang, Zhijian; Wu, Yue; Sun, Xiaochuan; Jiang, Li] Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China; [Teng, Zhipeng; Luo, Chao; Peng, Xing] Chongqing Tradit Chinese Med Hosp, Dept Neurosurg, Chongqing, Peoples R China; [Wu, Haitao] Zunyi Med Coll, Dept Neurosurg, Affiliated Hosp, Zunyi, Guizhou, Peoples R China; [Tang, Shuang] Suining Cent Hosp, Dept Neurosurg, Suining, Sichuan, Peoples R China	Jiang, L (corresponding author), Chongqing Med Univ, Dept Neurosurg, Affiliated Hosp 1, Chongqing, Peoples R China.	156313147@qq.com		Huang, Zhijian/0000-0002-8241-0761; sun, xiao chuan/0000-0001-6992-332X	National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81100865, 81571159]; National Key Clinical Specialty Construction Project of China [2011170]; Chongqing Key Discipline [40010200010008]; Guizhou Science and Technology Department [2332]	This work was supported by grants from the National Natural Science Foundation of China (No. 81100865 and 81571159) and the National Key Clinical Specialty Construction Project of China (No. 2011170), Chongqing Key Discipline (No. 40010200010008) and a grant from the Guizhou Science and Technology Department (2013, 2332).	Batra A, 2010, J CEREBR BLOOD F MET, V30, P1188, DOI 10.1038/jcbfm.2010.1; Bell RD, 2012, NATURE, V485, P512, DOI 10.1038/nature11087; Candelario-Jalil E, 2011, STROKE, V42, P1345, DOI 10.1161/STROKEAHA.110.600825; Cao F, 2016, J NEUROTRAUM, V33, P175, DOI 10.1089/neu.2015.3887; Chen LG, 2015, EXP CELL RES, V334, P294, DOI 10.1016/j.yexcr.2015.03.004; Chen YJ, 2014, BIOCHEM PHARMACOL, V92, P530, DOI 10.1016/j.bcp.2014.09.026; Cheng CJ, 2015, TRANSL STROKE RES, V6, P446, DOI 10.1007/s12975-015-0426-6; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Fullerton SM, 2001, EXP NEUROL, V169, P13, DOI 10.1006/exnr.2001.7631; Ghajar J, 2000, LANCET, V356, P923, DOI 10.1016/S0140-6736(00)02689-1; Guo ZD, 2015, NEUROL SCI, V36, P1241, DOI 10.1007/s10072-015-2092-6; Guo ZD, 2010, NEUROL RES, V32, P715, DOI 10.1179/016164109X12478302362491; Guo ZD, 2010, NEUROL SCI, V31, P143, DOI 10.1007/s10072-009-0192-x; Hafezi-Moghadam A, 2007, AM J PHYSIOL-CELL PH, V292, pC1256, DOI 10.1152/ajpcell.00563.2005; Halliday MR, 2016, J CEREBR BLOOD F MET, V36, P216, DOI 10.1038/jcbfm.2015.44; Jha R, 2014, STROKE, V45, P1040, DOI 10.1161/STROKEAHA.113.004627; Jia F, 2014, J NEUROTRAUM, V31, P1225, DOI 10.1089/neu.2013.3230; Jiang L, 2015, NEUROSCIENCE, V301, P375, DOI 10.1016/j.neuroscience.2015.06.005; Jiang Y, 2006, NEUROSCI LETT, V408, P155, DOI 10.1016/j.neulet.2006.08.082; Lee CS, 2009, ARTERIOSCL THROM VAS, V29, P472, DOI 10.1161/ATVBAHA.108.176230; Nishitsuji K, 2011, J BIOL CHEM, V286, P17536, DOI 10.1074/jbc.M111.225532; ROSENBERG GA, 1995, J NEUROTRAUM, V12, P833, DOI 10.1089/neu.1995.12.833; Unterberg AW, 2004, NEUROSCIENCE, V129, P1021, DOI 10.1016/j.neuroscience.2004.06.046; Verghese PB, 2011, LANCET NEUROL, V10, P241, DOI 10.1016/S1474-4422(10)70325-2; Zheng MH, 2014, J MOL NEUROSCI, V54, P282, DOI 10.1007/s12031-014-0291-x; Zhong JJ, 2017, NEUROSCIENCE, V343, P434, DOI 10.1016/j.neuroscience.2016.05.033; Zhou S, 2013, FEBS LETT, V587, P254, DOI 10.1016/j.febslet.2012.12.003; Zlokovic BV, 2013, JAMA NEUROL, V70, P440, DOI 10.1001/jamaneurol.2013.2152	28	22	23	0	5	NATURE PUBLISHING GROUP	LONDON	MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND	2045-2322			SCI REP-UK	Sci Rep	JUL 27	2017	7								6649	10.1038/s41598-017-06932-3			8	Multidisciplinary Sciences	Science & Technology - Other Topics	FB8CH	WOS:000406366000007	28751738	DOAJ Gold, Green Published			2021-06-18	
J	Ho, J; Zhou, Z; Li, XG; Kleiven, S				Ho, Johnson; Zhou, Zhou; Li, Xiaogai; Kleiven, Svein			The peculiar properties of the faix and tentorium in brain injury biomechanics	JOURNAL OF BIOMECHANICS			English	Article						Biomechanics; Falx; Tentorium; Traumatic brain injuries; Diffuse axonal injuries	DIFFUSE AXONAL INJURY; MAXIMUM PRINCIPAL STRAIN; HEAD; IMPACT; CONCUSSION; MATER; DURA	The influence of the faix and tentorium on brain injury biomechanics during impact was studied with finite element (FE) analysis. Three detailed 3D FE head models were created based on the images of a healthy, normal size head. Two of the models contained the addition of falx and tentorium with material properties from previously published experiments. Impact loadings from a reconstructed concussive case in a sport accident were applied to the two players involved. The results suggested that the faix and tentorium could induce large strains to the surrounding brain tissues, especially to the corpus callosum and brainstem. The tentorium seemed to constrain the motion of the cerebellum while inducing large strain in the brainstem in both players involved in the accident (one player had mainly coronal head rotation and the other had both coronal and transversal rotations). Since changed strain levels were observed in the brainstem and corpus callosum, which are classical sites for diffuse axonal injuries (DAI), we confirmed the importance of using accurate material properties for falx and tentorium in a FE head model when studying traumatic brain injuries. (C) 2017 Published by Elsevier Ltd.	[Ho, Johnson; Zhou, Zhou; Li, Xiaogai; Kleiven, Svein] KTH Royal Inst Technol, Neuron Engn, Stockholm, Sweden	Kleiven, S (corresponding author), KTH Flemingsberg, Halsovagen 11C, SE-14157 Huddinge, Sweden.	sveink@kth.se		zhou, zhou/0000-0002-3910-0418; Li, Xiaogai/0000-0001-8522-4705			Adams JH, 2000, BRAIN, V123, P1327, DOI 10.1093/brain/123.7.1327; Aimedieu P, 2004, J NEUROSURG, V100, P111, DOI 10.3171/jns.2004.100.1.0111; [Anonymous], 2007, LS DYNA KEYW US MAN; Bradshaw DRS, 2001, J BIOMECH, V34, P85, DOI 10.1016/S0021-9290(00)00135-4; Chen Y, 2010, ACTA MECH, V213, P155, DOI 10.1007/s00707-009-0274-0; Dick R, 2007, J ATHL TRAINING, V42, P221; Gabler LF, 2016, ANN BIOMED ENG, V44, P3705, DOI 10.1007/s10439-016-1697-0; GALFORD JE, 1970, J BIOMECH, V3, P211, DOI 10.1016/0021-9290(70)90007-2; Gennarelli T A, 1983, Acta Neurochir Suppl (Wien), V32, P1; GENNARELLI TA, 1989, J NEUROSURG, V71, P244, DOI 10.3171/jns.1989.71.2.0244; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; Giordano Chiara, 2016, Stapp Car Crash J, V60, P363; Golman A., 2013, P 41 INT WORKSH; Hardy W N, 2001, Stapp Car Crash J, V45, P337; Hardy WN, 2007, STAPP CAR CRASH JO, V51, P17; Ho J, 2009, INT J CRASHWORTHINES, V14, P555, DOI 10.1080/13588260902895708; Ho J, 2009, J BIOMECH, V42, P2074, DOI 10.1016/j.jbiomech.2009.06.051; Ji SB, 2015, J NEUROTRAUM, V32, P441, DOI 10.1089/neu.2013.3268; Kleiven Svein, 2013, Front Bioeng Biotechnol, V1, P15; Kleiven S, 2007, STAPP CAR CRASH JO, V51, P81; Li XG, 2017, BIOMECH MODEL MECHAN, V16, P823, DOI 10.1007/s10237-016-0855-5; Mao HJ, 2013, J BIOMECH ENG-T ASME, V135, DOI 10.1115/1.4025101; McAllister TW, 2012, ANN BIOMED ENG, V40, P127, DOI 10.1007/s10439-011-0402-6; Miller R., 1998, FINITE ELEMENT MODEL; Netter F. H., 1953, COMPILATION PAINTING; Newman J A, 2000, Stapp Car Crash J, V44, P215; Nishimoto T, 1998, J BIOMECH ENG-T ASME, V120, P140, DOI 10.1115/1.2834294; Pedersen K, 2015, NEUROEPIDEMIOLOGY, V45, P20, DOI 10.1159/000381780; VANNOORT R, 1981, BIOMATERIALS, V2, P41, DOI 10.1016/0142-9612(81)90086-7; VOIGT GE, 1977, ACTA NEUROPATHOL, V39, P201, DOI 10.1007/BF00691698; Wilcox Ruth K, 2003, J Orthop Sci, V8, P432, DOI 10.1007/s10776-003-0644-9	31	22	22	0	10	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0021-9290	1873-2380		J BIOMECH	J. Biomech.	JUL 26	2017	60						243	247		10.1016/j.jbiomech.2017.06.023			5	Biophysics; Engineering, Biomedical	Biophysics; Engineering	FE5YN	WOS:000408287300033	28673666				2021-06-18	
J	Cancelliere, C; Coronado, VG; Taylor, CA; Xu, L				Cancelliere, Carol; Coronado, Victor G.; Taylor, Christopher A.; Xu, Likang			Epidemiology of Isolated Versus Nonisolated Mild Traumatic Brain Injury Treated in Emergency Departments in the United States, 2006-2012: Sociodemographic Characteristics	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						brain concussion; brain injuries; epidemiology; hospital emergency service	ADMINISTRATIVE DATA; DIAGNOSIS; ACCURACY; ADULTS; CODES	Objectives: To describe the frequencies and rates of mild traumatic brain injury (mTBI) emergency department (ED) visits, analyze the trend across the years, and compare sociodemographic characteristics of visits by mTBI type (ie, mTBI as the only injury, or present along with other injuries). Design: Population-based descriptive study using data from the Nationwide Emergency Department Sample (2006-2012). Methods: Joinpoint regression was used to calculate the average annual percent changes of mTBI incidence rates. Characteristics between isolated and nonisolated visits were compared, and the odds ratios were reported. Results: The rate per 100 000 population of mTBI ED visits in the United States increased significantly from 569.4 (in 2006) to 807.9 (in 2012). The highest rates were observed in 0-to 4-year-olds, followed by male 15-to 24-year-olds and females 65 years and older; the lowest rates were among 45-to 64-year-olds. The majority (70%) of all visits were nonisolated and occurred more frequently in residents of metropolitan areas. Falls were the leading external cause. Most visits were privately insured or covered by Medicare/Medicaid, and the injury occurred on weekdays in predominantly metropolitan hospitals in the South region. Conclusions: The burden of mTBI in US EDs is high. Most mTBI ED visits present with other injuries. Awareness of sociodemographic factors associated with nonisolated mTBI may help improve diagnosis in US EDs. This information has implications for resource planning and mTBI screening in EDs.	[Cancelliere, Carol] Univ Toronto, Inst Hlth Policy Management & Evaluat, Hlth Sci Bldg,155 Coll St,Ste 425, Toronto, ON, Canada; [Taylor, Christopher A.; Xu, Likang] Natl Ctr Injury Prevent & Control, Atlanta, GA USA; [Coronado, Victor G.] Ctr Dis Control & Prevent, Atlanta, GA USA	Cancelliere, C (corresponding author), Univ Toronto, Inst Hlth Policy Management & Evaluat, Hlth Sci Bldg,155 Coll St,Ste 425, Toronto, ON, Canada.	carol@427health.com	Taylor, Christopher A/D-2067-2013	Taylor, Christopher A/0000-0002-0937-5461	Intramural CDC HHS [CC999999] Funding Source: Medline		Abrams Gary M, 2015, Continuum (Minneap Minn), V21, P188, DOI 10.1212/01.CON.0000461092.86865.a4; Adachi H, 2015, INTERV NEURORADIOL, V21, P719, DOI 10.1177/1591019915609120; Adamson BC, 2015, ARCH PHYS MED REHAB, V96, P1329, DOI 10.1016/j.apmr.2015.01.005; [Anonymous], 2014, JOINP REGR PROGR VER; [Anonymous], 2014, INTR NEDS; [Anonymous], 2013, HCUP NEDS DESCR DAT; Bay E, 2011, ADV EMERG NURS J, V33, P71, DOI 10.1097/TME.0b013e318207e851; Bazarian JJ, 2006, ACAD EMERG MED, V13, P31, DOI 10.1197/j.aem.2005.07.038; Bazarian JJ, 2005, BRAIN INJURY, V19, P85, DOI 10.1080/02699050410001720158; Bazarian JJ, 2005, EMERG MED J, V22, P473, DOI 10.1136/emj.2004.019273; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS201, DOI 10.1016/j.apmr.2013.10.010; Cancelliere Carol, 2014, Arch Phys Med Rehabil, V95, pS210, DOI 10.1016/j.apmr.2013.06.035; Carlson KF, 2013, BRAIN INJURY, V27, P640, DOI 10.3109/02699052.2013.771795; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS278, DOI 10.1016/j.apmr.2013.08.295; Centers for Disease Control and Prevention, HLTH US 2012 IN INJ; Centers for Disease Control and Prevention, 2012, BRIDG RAC POP EST DA; Centers for Disease Control and Prevention National Center for Injury Prevention and Control, 2010, TRAUM BRAIN INJ FACT; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; Cubbin C, 2000, AM J PUBLIC HEALTH, V90, P70, DOI 10.2105/AJPH.90.1.70; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M., 2010, TRAUMATIC BRAIN INJU, P1; Hung Ryan, 2014, Arch Phys Med Rehabil, V95, pS174, DOI 10.1016/j.apmr.2013.08.301; Krainin Benjamin M, 2011, J Spec Oper Med, V11, P38; Leibson CL, 2011, EPIDEMIOLOGY, V22, P836, DOI 10.1097/EDE.0b013e318231d535; Leute PJF, 2015, EUR J TRAUMA EMERG S, V41, P299, DOI 10.1007/s00068-014-0429-0; Marin JR, 2014, JAMA-J AM MED ASSOC, V311, P1917, DOI 10.1001/jama.2014.3979; National Center for Injury Prevention and Control, 2003, REP C MILD TRAUM BRA; Powell JM, 2008, ARCH PHYS MED REHAB, V89, P1550, DOI 10.1016/j.apmr.2007.12.035; Selassie AW, 2004, AM J EMERG MED, V22, P465, DOI 10.1016/j.ajem.2004.07.024; Stuart B, 2012, J EMERG NURS, V38, P435, DOI 10.1016/j.jen.2011.04.006; Voss JD, 2015, CURR PAIN HEADACHE R, V19, DOI 10.1007/s11916-015-0506-z	33	22	22	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2017	32	4					E37	E46		10.1097/HTR.0000000000000260			10	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	FA2KB	WOS:000405269200005	28489698	Green Accepted			2021-06-18	
J	Girard, R; Fam, MD; Zeineddine, HA; Tan, H; Mikati, AG; Shi, CB; Jesselson, M; Shenkar, R; Wu, MJ; Cao, Y; Hobson, N; Larsson, HBW; Christoforidis, GA; Awad, IA				Girard, Romuald; Fam, Maged D.; Zeineddine, Hussein A.; Tan, Huan; Mikati, Abdul Ghani; Shi, Changbin; Jesselson, Michael; Shenkar, Robert; Wu, Meijing; Cao, Ying; Hobson, Nicholas; Larsson, Henrik B. W.; Christoforidis, Gregory A.; Awad, Issam A.			Vascular permeability and iron deposition biomarkers in longitudinal follow-up of cerebral cavernous malformations	JOURNAL OF NEUROSURGERY			English	Article						cerebral cavernous malformation; biomarker; dynamic contrast-enhanced quantitative permeability; quantitative susceptibility mapping; iron; vascular disorders	SOMATIC MUTATIONS; CCM PATHOGENESIS; DISEASE; RELIABILITY; HEMORRHAGE; SEVERITY; LESION; MODEL; ECHO; MRI	OBJECTIVE Vascular permeability and iron leakage are central features of cerebral cavernous malformation (CCM) pathogenesis. The authors aimed to correlate prospective clinical behavior of CCM lesions with longitudinal changes in biomarkers of dynamic contrast-enhanced quantitative permeability (DCEQP) and quantitative susceptibility mapping (QSM) assessed by MRI. METHODS Forty-six patients with CCMs underwent 2 or more permeability and/or susceptibility studies in conjunction with baseline and follow-up imaging and clinical surveillance during a mean 12.05 months of follow-up (range 2.4-31.27 months). Based on clinical and imaging features, cases/lesions were classified as stable, unstable, or recovering. Associated and predictive changes in quantitative permeability and susceptibility were investigated. RESULTS Lesional mean permeability and QSM values were not significantly different in stable versus unstable lesions at baseline. Mean lesional permeability in unstable CCMs with lesional bleeding or growth increased significantly (+85.9% change; p = 0.005), while mean permeability in stable and recovering lesions did not significantly change. Mean lesional QSM values significantly increased in unstable lesions (+44.1% change; p = 0.01), decreased slightly with statistical significance in stable lesions (-3.2% change; p = 0.003), and did not significantly change in recovering lesions. Familial cases developing new lesions during the follow-up period showed a higher background brain permeability at baseline (p = 0.001), as well as higher regional permeability (p = 0.003) in the area that would later develop a new lesion as compared with the homologous contralateral brain region. CONCLUSIONS In vivo assessment of vascular permeability and iron deposition on MRI can serve as objective and quantifiable biomarkers of disease activity in CCMs. This may be applied in natural history studies and may help calibrate clinical trials. The 2 techniques are likely applicable in other disorders of vascular integrity and iron leakage such as aging, hemorrhagic microangiopathy, and traumatic brain injury.	[Girard, Romuald; Fam, Maged D.; Zeineddine, Hussein A.; Tan, Huan; Mikati, Abdul Ghani; Shi, Changbin; Jesselson, Michael; Shenkar, Robert; Wu, Meijing; Cao, Ying; Hobson, Nicholas; Awad, Issam A.] Univ Chicago Med, Sect Neurosurg, Neurovasc Surg Program, Chicago, IL USA; [Larsson, Henrik B. W.] Univ Copenhagen, Funct Imaging Unit, Dept Clin Physiol Nucl Med & PET, Rigshosp Glostrup Inst Clin Med,Fac Hlth Sci, Copenhagen, Denmark; [Larsson, Henrik B. W.] Norwegian Univ Technol & Sci, Dept Circulat & Med Imaging, Trondheim, Norway; [Christoforidis, Gregory A.] Univ Chicago Med, Dept Radiol, Chicago, IL USA	Awad, IA (corresponding author), Univ Chicago Med, Sect Neurosurg, 5841 S Maryland Ave,MC3026 Neurosurg J341, Chicago, IL 60637 USA.	iawad@uchicago.edu	Shenkar, Robert/AAC-7065-2020	Girard, Romuald/0000-0002-5893-9315	NIH, William and Judith Davis Fund in Neurovascular Surgery Research [R21NS087328]; Safadi Translational Fellowship; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R21NS087328] Funding Source: NIH RePORTER	This work was partially supported by a grant from the NIH (R21NS087328) to Dr. Awad by the William and Judith Davis Fund in Neurovascular Surgery Research, and by a grant from the Safadi Translational Fellowship to Dr. Girard.	Abdulrauf SI, 1999, NEUROSURGERY, V44, P41, DOI 10.1097/00006123-199901000-00020; Akers AL, 2009, HUM MOL GENET, V18, P919, DOI 10.1093/hmg/ddn430; Awad IA, 2005, SURG NEUROL, V63, P317, DOI 10.1016/j.surneu.2004.12.032; Choquet H, 2014, CEREBROVASC DIS, V38, P440, DOI 10.1159/000369200; de Champfleur NM, 2011, NEUROSURGERY, V68, P641, DOI 10.1227/NEU.0b013e31820773cf; de Rochefort L, 2010, MAGN RESON MED, V63, P194, DOI 10.1002/mrm.22187; de Souza JM, 2008, AM J NEURORADIOL, V29, P154, DOI 10.3174/ajnr.A0748; Flemming KD, 2015, J CLIN NEUROSCI, V22, P969, DOI 10.1016/j.jocn.2015.01.007; Gault J, 2005, STROKE, V36, P872, DOI 10.1161/01.STR.0000157586.20479.fd; Gault J, 2006, NEUROSURGERY, V59, P1278, DOI 10.1227/01.NEU.0000249188.38409.03; Gault J, 2009, NEUROSURGERY, V65, P138, DOI 10.1227/01.NEU.0000348049.81121.C1; Gibson CC, 2015, CIRCULATION, V131, P289, DOI 10.1161/CIRCULATIONAHA.114.010403; Girard R, 2016, BIOMARK MED, V10, P255, DOI 10.2217/bmm.15.118; Gunel M, 1996, NEW ENGL J MED, V334, P946, DOI 10.1056/NEJM199604113341503; Hanley JA, 2003, AM J EPIDEMIOL, V157, P364, DOI 10.1093/aje/kwf215; Hart BL, 2013, TRANSL STROKE RES, V4, P500, DOI 10.1007/s12975-013-0285-y; Horne MA, 2016, LANCET NEUROL, V15, P166, DOI 10.1016/S1474-4422(15)00303-8; Huberty C.J., 1994, APPL DISCRIMINANT AN; JOHNSON EW, 1995, GENOME RES, V5, P368, DOI 10.1101/gr.5.4.368; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Larsson HBW, 2009, MAGN RESON MED, V62, P1270, DOI 10.1002/mrm.22136; Lehnhardt FG, 2005, ARCH NEUROL-CHICAGO, V62, P653, DOI 10.1001/archneur.62.4.653; Liu T, 2011, MAGN RESON MED, V66, P777, DOI 10.1002/mrm.22816; Liu T, 2011, NMR BIOMED, V24, P1129, DOI 10.1002/nbm.1670; McDonald DA, 2014, HUM MOL GENET, V23, P4357, DOI 10.1093/hmg/ddu153; McDonald DA, 2012, STROKE, V43, P571, DOI 10.1161/STROKEAHA.111.625467; McDonald DA, 2011, HUM MOL GENET, V20, P211, DOI 10.1093/hmg/ddq433; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Mikati AG, 2015, J CEREBR BLOOD F MET, V35, P1632, DOI 10.1038/jcbfm.2015.98; Mikati AG, 2014, STROKE, V45, P598, DOI 10.1161/STROKEAHA.113.003548; Petersen TA, 2010, AM J NEURORADIOL, V31, P377, DOI 10.3174/ajnr.A1822; Porter PJ, 1997, J NEUROSURG, V87, P190, DOI 10.3171/jns.1997.87.2.0190; Rencher AC., 2012, METHODS MULTIVARIATE, V3rd Edition; Rigby AS, 2000, DISABIL REHABIL, V22, P339, DOI 10.1080/096382800296575; Salman RAS, 2008, STROKE, V39, P3222, DOI 10.1161/STROKEAHA.108.515544; Shenkar R, 2015, GENET MED, V17, P188, DOI 10.1038/gim.2014.97; Sim J, 2005, PHYS THER, V85, P257; STEIGER HJ, 1987, NEUROSURGERY, V21, P879, DOI 10.1227/00006123-198712000-00016; Stockton RA, 2010, J EXP MED, V207, P881, DOI 10.1084/jem.20091258; Tan H, 2016, AJNR AM J NEURORADIO; Tan H, 2014, INVEST RADIOL, V49, P498, DOI 10.1097/RLI.0000000000000043; Whitehead KJ, 2009, NAT MED, V15, P462, DOI 10.1038/nm0409-462c; Yadla S, 2010, NEUROSURG FOCUS, V29, DOI 10.3171/2010.5.FOCUS10121; ZWEIG MH, 1993, CLIN CHEM, V39, P561	44	22	22	0	2	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	JUL	2017	127	1					102	110		10.3171/2016.5.JNS16687			9	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EY6JB	WOS:000404087500016	27494817	Green Accepted			2021-06-18	
J	Vargas, E; Barrett, DW; Saucedo, CL; Huang, LD; Abraham, JA; Tanaka, H; Haley, AP; Gonzalez-Lima, F				Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Huang, Li-Da; Abraham, Jacob A.; Tanaka, Hirofumi; Haley, Andreana P.; Gonzalez-Lima, F.			Beneficial neurocognitive effects of transcranial laser in older adults	LASERS IN MEDICAL SCIENCE			English	Article						Brain photobiomodulation; Infrared laser; Attention; Memory; EEG; fMRI	CYTOCHROME-C-OXIDASE; NEAR-INFRARED LIGHT; COGNITIVE ENHANCEMENT; STIMULATION; PHOTOBIOMODULATION; THERAPY; OXYGENATION; HUMANS; MEMORY	Transcranial infrared laser stimulation (TILS) at 1064 nm, 250 mW/cm(2) has been proven safe and effective for increasing neurocognitive functions in young adults in controlled studies using photobiomodulation of the right prefrontal cortex. The objective of this pilot study was to determine whether there is any effect from TILS on neurocognitive function in older adults with subjective memory complaint at risk for cognitive decline (e.g., increased carotid artery intima-media thickness or mild traumatic brain injury). We investigated the cognitive effects of TILS in older adults (ages 49-90, n = 12) using prefrontal cortex measures of attention (psychomotor vigilance task (PVT)) and memory (delayed match to sample (DMS)), carotid artery intima-media thickness (measured by ultrasound), and evaluated the potential neural mechanisms mediating the cognitive effects of TILS using exploratory brain studies of electroencephalography (EEG, n = 6) and functional magnetic resonance imaging (fMRI, n = 6). Cognitive performance, age, and carotid artery intima-media thickness were highly correlated, but all participants improved in all cognitive measures after TILS treatments. Baseline vs. chronic (five weekly sessions, 8 min each) comparisons of mean cognitive scores all showed improvements, significant for PVT reaction time (p < 0.001), PVT lapses (p < 0.001), and DMS correct responses (p < 0.05). The neural studies also showed for the first time that TILS increases resting-state EEG alpha, beta, and gamma power and promotes more efficient prefrontal blood-oxygen-level-dependent (BOLD)-fMRI response. Importantly, no adverse effects were found. These preliminary findings support the use of TILS for larger randomized clinical trials with this non-invasive approach to augment neurocognitive function in older people to combat aging-related and vascular disease-related cognitive decline.	[Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Haley, Andreana P.; Gonzalez-Lima, F.] Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA; [Vargas, Enrique; Barrett, Douglas W.; Saucedo, Celeste L.; Haley, Andreana P.; Gonzalez-Lima, F.] Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA; [Huang, Li-Da; Abraham, Jacob A.] Univ Texas Austin, Dept Elect Engn, Austin, TX 78712 USA; [Tanaka, Hirofumi] Univ Texas Austin, Dept Kinesiol & Hlth Educ, Austin, TX 78712 USA	Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Dept Psychol, Austin, TX 78712 USA.; Gonzalez-Lima, F (corresponding author), Univ Texas Austin, Inst Neurosci, Austin, TX 78712 USA.	gonzalezlima@utexas.edu	Abraham, Jacob/ABD-1017-2020	Abraham, Jacob/0000-0002-5336-5631; Gonzalez-Lima, Francisco/0000-0001-9856-0775	National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21 AG055772]; Darrell K. Royal Research Fund for Alzheimer's Disease; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [R21AG050898] Funding Source: NIH RePORTER	This study was supported in part by grants from the National Institute on Aging (R21 AG055772) and the Darrell K. Royal Research Fund for Alzheimer's Disease.	Anders JJ, 2015, PHOTOMED LASER SURG, V33, P183, DOI 10.1089/pho.2015.9848; Anders JJ, 2014, LASER SURG MED, V46, P34, DOI 10.1002/lsm.22212; Barrett DW, 2013, NEUROSCIENCE, V230, P13, DOI 10.1016/j.neuroscience.2012.11.016; Basar E, 2013, INT J PSYCHOPHYSIOL, V90, P99, DOI 10.1016/j.ijpsycho.2013.07.005; Blanco N. J., 2015, J NEUROPSYCHOL; Blanco NJ, 2017, NEUROBIOL LEARN MEM, V139, P69, DOI 10.1016/j.nlm.2016.12.016; Disner SG, 2016, BRAIN STIMUL, V9, P780, DOI 10.1016/j.brs.2016.05.009; Gonzales MM, 2014, INT J OBESITY, V38, P1193, DOI 10.1038/ijo.2014.5; Gonzalez-Lima F, 2014, BIOCHEM PHARMACOL, V88, P584, DOI 10.1016/j.bcp.2013.11.010; Gonzalez-Lima F, 2014, FRONT SYST NEUROSCI, V8, DOI 10.3389/fnsys.2014.00036; Haley AP, 2007, J NEUROIMAGING, V17, P227, DOI 10.1111/j.1552-6569.2007.00110.x; Hamblin MR, 2016, BBA CLIN, V6, P113, DOI 10.1016/j.bbacli.2016.09.002; Hwang J, 2016, LASER MED SCI, V31, P1151, DOI 10.1007/s10103-016-1962-3; Karu TI, 2005, J PHOTOCH PHOTOBIO B, V81, P98, DOI 10.1016/j.jphotobiol.2005.07.002; Mochizuki-Oda N, 2002, NEUROSCI LETT, V323, P207, DOI 10.1016/S0304-3940(02)00159-3; Naeser MA, 2016, PHOTOMED LASER SURG, V34, P610, DOI 10.1089/pho.2015.4037; Nguyen-Thanh HT, 2009, AM J CARDIOL, V104, P1383, DOI 10.1016/j.amjcard.2009.07.005; Palva S, 2011, FRONT PSYCHOL, V2, DOI 10.3389/fpsyg.2011.00204; Rojas JC, 2017, HDB LOW LEVEL LASER, P1057; Rojas JC, 2013, BIOCHEM PHARMACOL, V86, P447, DOI 10.1016/j.bcp.2013.06.012; Rojas JC, 2012, J ALZHEIMERS DIS, V32, P741, DOI 10.3233/JAD-2012-120817; Rojas JC, 2011, EYE BRAIN, V3, P49, DOI 10.2147/EB.S21391; Rojas JC, 2008, J NEUROSCI, V28, P13511, DOI 10.1523/JNEUROSCI.3457-08.2008; Schiffer F, 2009, BEHAV BRAIN FUNCT, V5, DOI 10.1186/1744-9081-5-46; Tanaka M, 2012, BEHAV BRAIN FUNCT, V8, DOI 10.1186/1744-9081-8-48; Tian FH, 2016, LASER SURG MED, V48, P343, DOI 10.1002/lsm.22471; Wang X, 2017, J CEREB BLO IN PRESS; Wang XL, 2016, SCI REP-UK, V6, DOI 10.1038/srep30540; Wong-Riley MTT, 2005, J BIOL CHEM, V280, P4761, DOI 10.1074/jbc.M409650200	29	22	24	0	27	SPRINGER LONDON LTD	LONDON	236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND	0268-8921	1435-604X		LASER MED SCI	Lasers Med. Sci.	JUL	2017	32	5					1153	1162		10.1007/s10103-017-2221-y			10	Engineering, Biomedical; Surgery	Engineering; Surgery	EX8AS	WOS:000403471600022	28466195	Green Accepted			2021-06-18	
J	McKendy, KM; Lee, LF; Boulva, K; Deckelbaum, DL; Mulder, DS; Razek, TS; Grushka, JR				McKendy, Katherine M.; Lee, Lawrence F.; Boulva, Kerianne; Deckelbaum, Dan L.; Mulder, David S.; Razek, Tarek S.; Grushka, Jeremy R.			Epidural analgesia for traumatic rib fractures is associated with worse outcomes: a matched analysis	JOURNAL OF SURGICAL RESEARCH			English	Article						Trauma; Rib fractures; Epidural; Analgesia; Respiratory complications	BLUNT THORACIC TRAUMA; PAIN MANAGEMENT; MORBIDITY; FIXATION; SURGERY; BENEFIT; INJURY; DEATH	Background: The optimal method of pain control for patients with traumatic rib fractures is unknown. The aim of this study was to determine the effect of epidural analgesia on respiratory complications and in-hospital mortality in patients with rib fractures. Methods: Adult patients at a level I trauma center with >= 1 rib fracture from blunt trauma were included (2004-2013). Those with a blunt-penetrating mechanism, traumatic brain injury, or underwent a laparotomy or thoracotomy were excluded. Patients who were treated with epidural analgesia (EPI) were compared with those were not treated with epidural analgesia (NEPI) using coarsened exact matching. Primary outcomes were respiratory complications (pneumonia, deep vein thrombosis/pulmonary embolus, and respiratory failure) and 30-d in-hospital mortality. Secondary outcomes were total hospital and intensive care unit length of stay, and duration of ventilator support. Results: About 1360 patients (EPI: 329 and NEPI: 1031) met inclusion criteria (mean age: 54.2 y; standard deviation [SD]: 19.7; 68% male). The mean number of rib fractures was 4.8 (SD: 3.3; 21% bilateral) with a high total burden of injury (mean Injury Severity Score: 19.9 [SD: 8.9]). The overall incidence of respiratory complications was 13% and mortality was 4%. After matching, 204 EPI patients were compared with 204 NEPI patients, with no differences in baseline characteristics. EPI patients experienced more respiratory complications (19% versus 10%, P = 0.009), but no differences in 30-d mortality (5% versus 2%, P = 0.159), duration of mechanical ventilation (EPI: 148 h [SD: 167] versus NEPI: 117 h [SD: 187], P = 0.434), or duration of intensive care unit length of stay (6.5 d [SD: 7.6] versus 5.8 d [SD: 9.1], P = 0.626). Hospital stay was higher in the EPI group (16.6 d [SD: 19.6] vs 12.7 d [SD: 15.2], P = 0.026). Conclusions: Epidural analgesia is associated with increased respiratory complications without providing mortality benefit after traumatic rib fractures. Alternate analgesic strategies should be investigated to treat these severely injured patients. (C) 2017 Elsevier Inc. All rights reserved.	[McKendy, Katherine M.; Lee, Lawrence F.; Boulva, Kerianne; Deckelbaum, Dan L.; Razek, Tarek S.; Grushka, Jeremy R.] McGill Univ, Hlth Ctr, Dept Surg, Div Gen Surg, Montreal, PQ, Canada; [Mulder, David S.] McGill Univ, Hlth Ctr, Dept Surg, Div Thorac Surg, Montreal, PQ, Canada	Grushka, JR (corresponding author), McGill Univ, Hlth Ctr, Dept Crit Care Med, Div Gen,Acute Care & Trauma Surg, 1650 Cedar Ave,L9-411, Montreal, PQ H3G 1A4, Canada.	jeremy.grushka@mcgill.ca					Battle CE, 2012, INJURY, V43, P8, DOI 10.1016/j.injury.2011.01.004; Bergeron E, 2003, J TRAUMA, V54, P478, DOI 10.1097/01.TA.0000037095.83469.4C; Blackwell M, 2009, STATA J, V9, P524, DOI 10.1177/1536867X0900900402; Blecher GE, 2008, INJURY, V39, P586, DOI 10.1016/j.injury.2007.10.021; Bugaev N, 2016, J TRAUMA ACUTE CARE, V81, P699, DOI 10.1097/TA.0000000000001169; Bulger EM, 2004, SURGERY, V136, P426, DOI 10.1016/j.surg.2004.05.019; Bulger EM, 2000, J TRAUMA, V48, P1040, DOI 10.1097/00005373-200006000-00007; Carrier FM, 2009, CAN J ANAESTH, V56, P230, DOI 10.1007/s12630-009-9052-7; Crawford ME, 1996, ANESTH ANALG, V83, P1028, DOI 10.1097/00000539-199611000-00022; Farquhar J, 2016, CAN J SURG, V59, P299, DOI 10.1503/cjs.000515; Flagel BT, 2005, SURGERY, V138, P717, DOI 10.1016/j.surg.2005.07.022; Gage A, 2014, J TRAUMA ACUTE CARE, V76, P39, DOI 10.1097/TA.0b013e3182ab1b08; Galvagno SM, 2016, J TRAUMA ACUTE CARE, V81, P936, DOI 10.1097/TA.0000000000001209; Gordy S, 2014, AM J SURG, V207, P659, DOI 10.1016/j.amjsurg.2013.12.012; Hashemzadeh S, 2011, J CARDIOVASC THORAC, V3, P87, DOI 10.5681/jcvtr.2011.019; Holcomb JB, 2003, J AM COLL SURGEONS, V196, P549, DOI 10.1016/S1072-7515(02)01894-X; Leinicke JA, 2013, ANN SURG, V258, P914, DOI 10.1097/SLA.0b013e3182895bb0; LUCHETTE FA, 1994, J TRAUMA, V36, P865, DOI 10.1097/00005373-199406000-00018; Majak P, 2016, CURR OPIN CRIT CARE, V22, P572, DOI 10.1097/MCC.0000000000000364; Marik PE, 2016, CRIT CARE MED, V44, P1920, DOI 10.1097/CCM.0000000000001483; Ng JM, 2002, ANN ACAD MED SINGAP, V31, P509; Pratt WB, 2008, J GASTROINTEST SURG, V12, P1207, DOI 10.1007/s11605-008-0467-1; SHACKFORD SR, 1994, J TRAUMA, V36, P869; Shelley CL, 2016, J TRAUMA ACUTE CARE, V81, P463, DOI 10.1097/TA.0000000000001147; Simon BJ, 2005, J TRAUMA, V59, P1256, DOI 10.1097/01.ta.0000178063.77946.f5; Stevens GA, 2010, POPUL HEALTH METR, V8, DOI 10.1186/1478-7954-8-6; Sugimoto M, 2016, J HEPATO-BIL-PAN SCI, V23, P102, DOI 10.1002/jhbp.307; Uchida K, 2016, EUR J TRAUMA EMERG S; Wells AR, 2013, POPUL HEALTH MANAG, V16, P35, DOI 10.1089/pop.2011.0104; Yeh DD, 2012, INJURY, V43, P1667, DOI 10.1016/j.injury.2012.05.022; Zaw AA, 2015, AM SURGEON, V81, P950; ZIEGLER DW, 1994, J TRAUMA, V37, P975, DOI 10.1097/00005373-199412000-00018	32	22	22	0	3	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0022-4804	1095-8673		J SURG RES	J. Surg. Res.	JUN 15	2017	214						117	123		10.1016/j.jss.2017.02.057			7	Surgery	Surgery	FA3RX	WOS:000405363200016	28624032				2021-06-18	
J	Au, AK; Aneja, RK; Bayir, H; Bell, MJ; Janesko-Feldman, K; Kochanek, PM; Clark, RSB				Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.			Autophagy Biomarkers Beclin 1 and p62 are Increased in Cerebrospinal Fluid after Traumatic Brain Injury	NEUROCRITICAL CARE			English	Article						Autophagy; Autophagic flux; Traumatic brain injury; Biomarkers; Pediatrics; Cerebrospinal fluid; Outcome	CELL-DEATH; NEURODEGENERATIVE DISEASE; APOPTOSIS; MICE; PROTEIN; SYSTEM; SECRETION; PATHOLOGY; RAPAMYCIN; PATHWAY	Background Autophagy is a process that recycles damaged proteins and organelles. Beclin 1 is involved in the nucleation phase, while p62 is consumed during the elongation phase. We hypothesized that these autophagy biomarkers are increased in cerebrospinal fluid (CSF) after traumatic brain injury (TBI) in children and associated with unfavorable outcome. Methods Thirty children with severe TBI had CSF collected on days 1, 3, and 7. Patients without TBI or meningoencephalitis served as controls. Beclin 1 and p62 were measured by ELISA. Outcome was assigned 6 months after injury (Glasgow Outcome Scale score; GOS). Results Mean and peak CSF beclin 1 and p62 levels were increased compared to controls (P < 0.05). Peak p62 levels were higher in patients with unfavorable versus favorable outcome (0.79 +/- 1.03 vs. 0.17 +/- 0.54 ng/ml, respectively; mean +/- SD, P = 0.002) and were independently associated with outcome when controlling for age and initial Glasgow Coma Scale score (P = 0.019; AUC 0.88, 95% CI 0.76, 1.00). Conclusion Beclin 1 and p62 are increased in CSF after TBI, suggesting increased autophagy with impairment of, and/or exceeding the capacity for, autophagic flux. The association of increased p62 with unfavorable outcome suggests that autophagy in excess of the capacity to clear degradation products may be deleterious after TBI.	[Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Dept Crit Care Med, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA; [Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Janesko-Feldman, Keri; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, UPMC, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA; [Au, Alicia K.; Aneja, Rajesh K.; Bayir, Hulya; Bell, Michael J.; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Med Ctr, Dept Pediat, Safar Ctr Resuscitat Res, Pittsburgh, PA USA; [Bell, Michael J.] Univ Pittsburgh, Med Ctr, Dept Neurol Surg, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Au, AK (corresponding author), Univ Pittsburgh, Med Ctr, Safar Ctr Resuscitat Res, Dept Crit Care Med, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA.; Au, AK (corresponding author), Univ Pittsburgh, Med Ctr, Childrens Hosp Pittsburgh, UPMC, 4401 Penn Ave,Fac Pavil,Suite 2000, Pittsburgh, PA 15224 USA.	auak@upmc.edu			Children's Hospital of Pittsburgh Scientific Program;  [R01 NS38620]	Funding was provided by R01 NS38620 and the Children's Hospital of Pittsburgh Scientific Program.	Axe EL, 2008, J CELL BIOL, V182, P685, DOI 10.1083/jcb.200803137; Boland B, 2008, J NEUROSCI, V28, P6926, DOI 10.1523/JNEUROSCI.0800-08.2008; Bove J, 2011, NAT REV NEUROSCI, V12, P437, DOI 10.1038/nrn3068; Brandner S, 2013, EUR NEUROL, V70, P189, DOI 10.1159/000352032; Clark RSB, 2008, AUTOPHAGY, V4, P88, DOI 10.4161/auto.5173; Deisenhammer F, 2006, EUR J NEUROL, V13, P913, DOI 10.1111/j.1468-1331.2006.01493.x; DeKosky ST, 2013, NAT REV NEUROL, V9, P192, DOI 10.1038/nrneurol.2013.36; Diskin T, 2005, J NEUROTRAUM, V22, P750, DOI 10.1089/neu.2005.22.750; Dupont N, 2011, EMBO J, V30, P4701, DOI 10.1038/emboj.2011.398; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Ghavami S, 2014, PROG NEUROBIOL, V112, P24, DOI 10.1016/j.pneurobio.2013.10.004; Hara T, 2006, NATURE, V441, P885, DOI 10.1038/nature04724; He CC, 2010, CURR OPIN CELL BIOL, V22, P140, DOI 10.1016/j.ceb.2010.01.001; Jiang S, 2013, J INNATE IMMUN, V5, P471, DOI 10.1159/000346707; Jin ZY, 2009, CELL, V137, P721, DOI 10.1016/j.cell.2009.03.015; Kang R, 2011, CELL DEATH DIFFER, V18, P571, DOI 10.1038/cdd.2010.191; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Komatsu M, 2006, NATURE, V441, P880, DOI 10.1038/nature04723; Komatsu M, 2012, PHARMACOL RES, V66, P457, DOI 10.1016/j.phrs.2012.07.004; Li HH, 2015, J TRANSL MED, V13, DOI 10.1186/s12967-015-0726-3; Liang XH, 1998, J VIROL, V72, P8586, DOI 10.1128/JVI.72.11.8586-8596.1998; Lipinski MM, 2015, ANTIOXID REDOX SIGN, V23, P565, DOI 10.1089/ars.2015.6306; Liu CL, 2008, J CEREBR BLOOD F MET, V28, P674, DOI 10.1038/sj.jcbfm.9600587; Liu Y, 2013, P NATL ACAD SCI USA, V110, P20364, DOI 10.1073/pnas.1319661110; Luo CL, 2011, NEUROSCIENCE, V184, P54, DOI 10.1016/j.neuroscience.2011.03.021; McKnight NC, 2014, PLOS GENET, V10, DOI 10.1371/journal.pgen.1004626; Mizushima N, 2011, ANNU REV CELL DEV BI, V27, P107, DOI 10.1146/annurev-cellbio-092910-154005; Nezis IP, 2012, ANTIOXID REDOX SIGN, V17, P786, DOI 10.1089/ars.2011.4394; Nickel W, 2009, NAT REV MOL CELL BIO, V10, P148, DOI 10.1038/nrm2617; Nixon RA, 2006, TRENDS NEUROSCI, V29, P528, DOI 10.1016/j.tins.2006.07.003; Ponpuak M, 2015, CURR OPIN CELL BIOL, V35, P106, DOI 10.1016/j.ceb.2015.04.016; Puy V, 2016, FRONT AGING NEUROSCI, V8, DOI 10.3389/fnagi.2016.00154; Rubinszfein DC, 2005, AUTOPHAGY, V1, P11, DOI 10.4161/auto.1.1.1513; Sadasivan S, 2008, BIOCHEM BIOPH RES CO, V373, P478, DOI 10.1016/j.bbrc.2008.05.031; Sakai K, 2014, AM J FOREN MED PATH, V35, P38, DOI 10.1097/PAF.0000000000000067; Sarkar C, 2014, AUTOPHAGY, V10, P2208, DOI 10.4161/15548627.2014.981787; Satchell MA, 2005, J CEREBR BLOOD F MET, V25, P919, DOI 10.1038/sj.jcbfm.9600088; Seibenhener ML, 2004, MOL CELL BIOL, V24, P8055, DOI 10.1128/MCB.24.18.8055-8068.2004; Seibenhener ML, 2013, BIOCHIM BIOPHYS ACTA, V3, P452; Sommer JB, 2002, EUR NEUROL, V47, P224, DOI 10.1159/000057904; Stepkowski TM, 2011, FREE RADICAL BIO MED, V50, P1186, DOI 10.1016/j.freeradbiomed.2011.01.033; Thorburn J, 2009, CELL DEATH DIFFER, V16, P175, DOI 10.1038/cdd.2008.143; Zhou FF, 2011, FEBS J, V278, P403, DOI 10.1111/j.1742-4658.2010.07965.x; Zhou YL, 2016, INT J BIOL SCI, V12, P87, DOI 10.7150/ijbs.13229	44	22	25	0	6	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA	1541-6933	1556-0961		NEUROCRIT CARE	Neurocrit. Care	JUN	2017	26	3					348	355		10.1007/s12028-016-0351-x			8	Critical Care Medicine; Clinical Neurology	General & Internal Medicine; Neurosciences & Neurology	EV9JA	WOS:000402101100005	28000126				2021-06-18	
J	Lewis, LM; Schloemann, DT; Papa, L; Fucetola, RP; Bazarian, J; Lindburg, M; Welch, RD				Lewis, Lawrence M.; Schloemann, Derek T.; Papa, Linda; Fucetola, Robert P.; Bazarian, Jeffrey; Lindburg, Miranda; Welch, Robert D.			Utility of Serum Biomarkers in the Diagnosis and Stratification of Mild Traumatic Brain Injury	ACADEMIC EMERGENCY MEDICINE			English	Article							FIBRILLARY ACIDIC PROTEIN; CONCUSSION SYMPTOMS QUESTIONNAIRE; C-TERMINAL HYDROLASE; MINOR HEAD-INJURY; INTRACRANIAL LESIONS; NEUROSURGICAL INTERVENTION; COLLABORATING-CENTER; COMPUTED-TOMOGRAPHY; TASK-FORCE; S100B	Objective: The objective was to compare test characteristics of a single serum concentration of glial fibrillary acidic protein (GFAP), S-100 beta, and ubiquitin carboxyl terminal hydrolase L1 (UCH-L1), obtained within 6 hours of head injury, to diagnose mild traumatic brain injury (mTBI) in head-injured subjects. Methods: Adults aged 18 to 80 years who presented to one of seven EDs with a blunt closed head injury underwent head CT within 4 hours of injury and had blood drawn for biomarker analysis within 6 hours of injury were eligible. Subjects were considered to have mTBI if they had an initial Glasgow Coma Scale (GCS) > 13 and met one or more of the following criteria: loss of consciousness (LOC), posttraumatic amnesia, or confusion. Subjects with mTBI and an abnormal head computed tomography (CT) scan were categorized as complicated mTBI; those with a normal head CT were categorized as uncomplicated mTBI; and subjects with a GCS = 15, no LOC, no posttraumatic amnesia, and no confusion were considered to not have a mTBI. Biomarker concentration measurements for GFAP and UCH-L1 were performed using an enzyme-linked immunosorbent assay. S-100 beta concentration was determined using an electrochemiluminescence immunoassay. Median biomarker concentration for each group was compared using the Kruskal-Wallis test. Logistic regression was used to determine area under the receiver operating curve (AUC) for each of the three biomarkers. Sensitivity, specificity, negative predictive value (NPV), positive predictive value (PPV), and negative and positive likelihood ratios (LRs) for the three biomarkers to differentiate between complicated mTBI, uncomplicated mTBI, and no mTBI were calculated. Results: A total of 247 subjects were enrolled and had adequate clinical and biomarker information for analysis. A total of 188 met criteria for mTBI, with 34 (18.1%) having an acute abnormality on CT (complicated mTBI). The mean (+/- SD) age of the study population was 45.8 (+/- 17.3) years, and 59.9% were male. Median serum concentrations for all biomarkers were significantly different between groups, lowest in the no mTBI group, and progressively increasing in the uncomplicated and complicated mTBI groups (p < 0.0001). All three biomarkers were significant classifiers of mTBI versus no mTBI, with the following AUCs: GFAP, 0.70; S-100 beta, 0.69; and UCHL1, 0.65 (p = 0.17). Sensitivity for mTBI was highest for S-100 beta (96.5%). NPVs ranged from 31% for UCH-L1 to 35% for GFAP. PPVs ranged from 75.5% for S-100 beta to 96.5% for GFAP. Negative LR ranged from 0.59 for GFAP to 0.71 for UCH-L1, with positive LR ranging from 1.0 for both UCH-L1 and S-100 beta to 8.7 for GFAP. Conclusion: A single serum concentration of GFAP, UCH-L1, or S-100 beta within 6 hours of head injury may be useful in identifying and stratifying the severity of brain injury in emergency department patients with head trauma, but cannot reliably exclude a diagnosis of concussion. A positive GFAP was associated with the presence of concussion.	[Lewis, Lawrence M.; Schloemann, Derek T.; Lindburg, Miranda] Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63130 USA; [Fucetola, Robert P.] Washington Univ, Sch Med, Dept Neurol, St Louis, MO 63110 USA; [Papa, Linda] Orlando Reg Med Ctr Inc, Dept Emergency Med, Orlando, FL USA; [Bazarian, Jeffrey] Univ Rochester, Sch Med, Dept Emergency Med, Rochester, NY USA; [Welch, Robert D.] Wayne State Univ, Dept Emergency Med, Detroit, MI USA	Lewis, LM (corresponding author), Washington Univ, Sch Med, Div Emergency Med, St Louis, MO 63130 USA.	lewisl@wustl.edu			U. S. Army Medical Research and Materiel CommandU.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-06-1-0517, W81XWH-10-C-0251]; Washington University; Banyan Biomarkers, Inc.; Orlando Regional Medical Center; University of Rochester School of Medicine; Wayne State University	This work is supported by the U. S. Army Medical Research and Materiel Command under Contract W81XWH-06-1-0517 and Contract W81XWH-10-C-0251. The views, opinions, and/or findings contained in this report are those of the authors and should not be construed as an official Department of the Army position, policy, or decision unless so designated by other documentation. LL reports grant money to Washington University to conduct research conceived and sponsored by Banyan Biomarkers, Inc. LP reports grant money to Orlando Regional Medical Center to conduct research conceived and sponsored by Banyan Biomarkers, Inc. She has also served as an unpaid consultant for Banyan Biomarkers, Inc. JB reports grant money to the University of Rochester School of Medicine to conduct research conceived and sponsored by Banyan Biomarkers, Inc. RW reports grant money to Wayne State University to conduct research conceived and sponsored by Banyan Biomarkers, Inc. None of the authors received consulting fees, and none have ownership in this company or other biomarker companies. DS and ML report no conflicts of interest.	Bossuyt PM, 2003, ANN INTERN MED, V138, P40, DOI 10.7326/0003-4819-138-1-200301070-00010; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Collins MW, 1999, JAMA-J AM MED ASSOC, V282, P964, DOI 10.1001/jama.282.10.964; CRITCHLOW DE, 1991, COMMUN STAT THEORY, V20, P127; Culotta VP, 1996, NEUROSURGERY, V38, P245, DOI 10.1097/00006123-199602000-00002; de Guise E, 2010, CLIN NEUROPSYCHOL, V24, P1113, DOI 10.1080/13854046.2010.506199; Dwass M., 1960, CONTRIBUTIONS PROBAB; Eyres S, 2005, CLIN REHABIL, V19, P878, DOI 10.1191/0269215505cr905oa; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gomez PA, 1996, BRIT J NEUROSURG, V10, P453, DOI 10.1080/02688699647078; Holm L, 2005, J REHABIL MED, V37, P137, DOI 10.1080/16501970510027321; Hsiang JNK, 1997, J NEUROSURG, V87, P234, DOI 10.3171/jns.1997.87.2.0234; Karr JE, 2014, NEUROPSYCHOLOGY, V28, P321, DOI 10.1037/neu0000037; Kay T, 1993, J HEAD TRAUMA REHAB, V8, P86, DOI DOI 10.1097/00001199-199309000-00010; Kelly JP, 1997, NEUROLOGY, V48, P581; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Lange RT, 2009, BRAIN INJURY, V23, P83, DOI 10.1080/02699050802635281; McCrory P, 2005, BRIT J SPORT MED, V39, pI78, DOI 10.1136/bjsm.2005.018614; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; Metting Z, 2012, NEUROLOGY, V78, P1428, DOI 10.1212/WNL.0b013e318253d5c7; Missler U, 1999, CLIN CHEM, V45, P138; Mondello S, 2012, NEUROSURGERY, V70, P666, DOI 10.1227/NEU.0b013e318236a809; National Hospital Discharge Survey (NHDS) 2010; National Hospital Ambulatory Medical Care Survey (NHAMCS) 2010; National Vital Statistics System (NVSS), 2010, ALL DAT SOURC MAINT; Osafo N, 2014, 40 ANN E ATL STUD RE; Papa L, 2014, J NEUROTRAUM, V31, P1815, DOI 10.1089/neu.2013.3245; Papa L, 2012, ANN EMERG MED, V59, P471, DOI 10.1016/j.annemergmed.2011.08.021; Papa L, 2012, J TRAUMA ACUTE CARE, V72, P1335, DOI 10.1097/TA.0b013e3182491e3d; Poli-de-Figueiredo Luiz F, 2006, Clinics, V61, P41, DOI 10.1590/S1807-59322006000100008; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Steel R.D.G.A., 1960, TECHNOMETRICS, V2, P197, DOI DOI 10.1080/00401706.1960.10489894; Swann I, 1999, TRAUMA, V1, P143; Thurman DJ., 1995, GUIDELINES SURVEILLA; Unden J, 2010, J HEAD TRAUMA REHAB, V25, P228, DOI 10.1097/HTR.0b013e3181e57e22; Welch RD, 2016, J NEUROTRAUM, V33, P203, DOI 10.1089/neu.2015.4149; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Zhou XH, 2009, STAT METHODS DIAGNOS; Zongo D, 2012, ANN EMERG MED, V59, P209, DOI 10.1016/j.annemergmed.2011.07.027	37	22	23	0	9	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1069-6563	1553-2712		ACAD EMERG MED	Acad. Emerg. Med.	JUN	2017	24	6					710	720		10.1111/acem.13174			11	Emergency Medicine	Emergency Medicine	FA2BC	WOS:000405244600007	28170122	Bronze			2021-06-18	
J	Compas, BE; Jaser, SS; Reeslund, K; Patel, N; Yarboi, J				Compas, Bruce E.; Jaser, Sarah S.; Reeslund, Kristen; Patel, Niral; Yarboi, Janet			Neurocognitive Deficits in Children With Chronic Health Conditions	AMERICAN PSYCHOLOGIST			English	Article						children; adolescents; chronic health conditions; neurocognitive problems	LONG-TERM SURVIVORS; ACUTE LYMPHOBLASTIC-LEUKEMIA; CHILDHOOD-CANCER SURVIVOR; CONGENITAL HEART-DISEASE; SICKLE-CELL-DISEASE; WHITE-MATTER VOLUME; ADULT SURVIVORS; EDUCATIONAL-IMPLICATIONS; COGNITIVE FUNCTION; EXECUTIVE FUNCTION	Over 4 million children in the United States suffer from chronic health conditions, including cancer, sickle cell disease, and diabetes. Because of major advances in the early identification and treatment of these conditions, survival rates for these children continue to rise, and the majority now lives into adulthood. However, increases in survival have come with costs related to long-term effects of disease processes and treatments. Foremost among these consequences is impairment in brain development and neurocognitive function that may affect a substantial portion of children with chronic health conditions and follow many into adulthood. Impaired cognitive function may contribute to impairment in educational and occupational attainment, mental health, and quality of life for children with chronic conditions. Despite the significance and scope of this problem, advances in the identification and understanding of neurocognitive problems and the delivery of effective clinical care have been hindered in part because research has been "siloed"-conducted on each chronic condition in isolation. This review examines, for the first time, neurocognitive problems in a selected set of 6 chronic pediatric health conditions-leukemia, brain tumors, sickle cell disease, congenital heart disease, Type 1 diabetes, and traumatic brain injury-to define the magnitude of the problem and identify directions for future research and clinical care. Psychologists from many areas of specialization, including pediatric psychology, educational and school psychology, neuropsychology, behavioral medicine, and adult primary care, are uniquely positioned to contribute to every phase of this work, including research, identification, and intervention.	[Compas, Bruce E.; Reeslund, Kristen; Yarboi, Janet] Vanderbilt Univ, Dept Psychol & Human Dev, Peabody 552, Nashville, TN 37203 USA; [Jaser, Sarah S.; Patel, Niral] Vanderbilt Univ, Dept Pediat, Nashville, TN USA	Compas, BE (corresponding author), Vanderbilt Univ, Dept Psychol & Human Dev, Peabody 552, Nashville, TN 37203 USA.	bruce.compas@vanderbilt.edu	Jaser, Sarah/J-7872-2019	Patel, Niral/0000-0001-9690-4255	National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD075005]; National Cancer InstituteUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA175840]; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [DP3DK097678]; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32 MH018921]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21HD075005] Funding Source: NIH RePORTER; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R21CA175840] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [T32MH018921] Funding Source: NIH RePORTER	Preparation of this article was supported in part by grants from the National Institute of Child Health and Human Development (R21HD075005; Bruce E. Compas), the National Cancer Institute (R21CA175840; Bruce E. Compas), the National Institute of Diabetes and Digestive and Kidney Diseases (DP3DK097678; Sarah S. Jaser), and a training grant from the National Institute of Mental Health (T32 MH018921).	Allman C, 2013, CHILD NEUROPSYCHOL, V19, P97, DOI 10.1080/09297049.2011.639756; Andreotti C, 2015, J CHILD NEUROL, V30, P1349, DOI 10.1177/0883073814563140; Annett RD, 2015, PEDIATR BLOOD CANCER, V62, pS460, DOI 10.1002/pbc.25749; [Anonymous], 2016, DIABETES CARE, V39, pS1, DOI 10.2337/dc16-S001; Asato MR, 2010, CEREB CORTEX, V20, P2122, DOI 10.1093/cercor/bhp282; Babikian T, 2009, NEUROPSYCHOLOGY, V23, P283, DOI 10.1037/a0015268; Boulet SLGS, 2010, CONGENITAL HEART DEF, P493; Campbell LK, 2007, PEDIATR BLOOD CANCER, V49, P65, DOI 10.1002/pbc.20860; Carey ME, 2008, AM J NEURORADIOL, V29, P792, DOI 10.3174/ajnr.A0904; Centers for Disease Control and Prevention, 2014, NAT DIAB STAT REP ES; Centers for Disease Control and Prevention, 2015, CONG HEART DEF CHDS; Cheung YT, 2015, NEUROSCI BIOBEHAV R, V53, P108, DOI 10.1016/j.neubiorev.2015.03.016; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conklin HM, 2015, J CLIN ONCOL, V33, P3894, DOI 10.1200/JCO.2015.61.6672; Conklin HM, 2010, J CLIN ONCOL, V28, P4465, DOI 10.1200/JCO.2010.28.4026; Cousino MK, 2013, J PEDIATR PSYCHOL, V38, P809, DOI 10.1093/jpepsy/jst049; Cox CL, 2016, J CANCER SURVIV, V10, P743, DOI 10.1007/s11764-016-0520-0; Deary IJ, 2012, ANNU REV PSYCHOL, V63, P453, DOI 10.1146/annurev-psych-120710-100353; Desrocher M, 2004, CHILD NEUROPSYCHOL, V10, P36, DOI 10.1076/chin.10.1.36.26241; Doan SN, 2011, DEV PSYCHOPATHOL, V23, P873, DOI 10.1017/S0954579411000368; Evans GW, 2009, P NATL ACAD SCI USA, V106, P6545, DOI 10.1073/pnas.0811910106; Fisher L, 2014, AM PSYCHOL, V69, P355, DOI 10.1037/a0036101; Gurney JG, 2009, J CLIN ONCOL, V27, P2390, DOI 10.1200/JCO.2008.21.1458; Halfon N, 2010, JAMA-J AM MED ASSOC, V303, P665, DOI 10.1001/jama.2010.130; Hanson JL, 2012, J NEUROSCI, V32, P7917, DOI 10.1523/JNEUROSCI.0307-12.2012; Hardy KK, 2013, PSYCHO-ONCOLOGY, V22, P1856, DOI 10.1002/pon.3222; Hood KK, 2014, J ADOLESCENT HEALTH, V55, P498, DOI 10.1016/j.jadohealth.2014.03.011; Kadan-Lottick NS, 2010, JNCI-J NATL CANCER I, V102, P881, DOI 10.1093/jnci/djq156; Kamdar KY, 2011, PEDIATR BLOOD CANCER, V57, P454, DOI 10.1002/pbc.23162; Karsdorp PA, 2007, J PEDIATR PSYCHOL, V32, P527, DOI 10.1093/jpepsy/jsl047; Kernan CL, 2012, EPILEPSIA, V53, P2156, DOI 10.1111/j.1528-1167.2012.03706.x; King AA, 2014, AM J HEMATOL, V89, P162, DOI 10.1002/ajh.23604; Kirchhoff AC, 2011, CANCER-AM CANCER SOC, V117, P3033, DOI 10.1002/cncr.25867; Kolb B., 2008, COGNITIVE NEUROREHAB, P6; Koller K, 2004, ENVIRON HEALTH PERSP, V112, P987, DOI 10.1289/ehp.6941; Krull KR, 2013, J CLIN ONCOL, V31, P4407, DOI 10.1200/JCO.2012.48.2315; Krull KR, 2013, J CLIN ONCOL, V31, P2182, DOI 10.1200/JCO.2012.46.7944; Krull KR, 2012, J CLIN ONCOL, V30, P3618, DOI 10.1200/JCO.2012.42.6841; Kucera M, 2011, PSYCHOL SCHOOLS, V48, P587, DOI 10.1002/pits.20573; Kunin-Batson A, 2011, PEDIATR BLOOD CANCER, V57, P1197, DOI 10.1002/pbc.22982; Lane DA, 2002, HEART, V88, P71, DOI 10.1136/heart.88.1.71; Liu F, 2015, NEURO-ONCOLOGY, V17, P604, DOI 10.1093/neuonc/nou306; Marino BS, 2012, CIRCULATION, V126, P1143, DOI 10.1161/CIR.0b013e318265ee8a; Mazaika PK, 2016, DIABETES, V65, P476, DOI 10.2337/db15-1242; Ment LR, 2003, JAMA-J AM MED ASSOC, V289, P705, DOI 10.1001/jama.289.6.705; Morton PD, 2015, TRENDS NEUROSCI, V38, P353, DOI 10.1016/j.tins.2015.04.001; Naguib JM, 2009, J PEDIATR PSYCHOL, V34, P271, DOI 10.1093/jpepsy/jsn074; National Institute of Child Health and Human Development, 2014, EK SHRIV NAT I CHILD; Neville HJ, 2013, P NATL ACAD SCI USA, V110, P12138, DOI 10.1073/pnas.1304437110; Nisbett RE, 2012, AM PSYCHOL, V67, P130, DOI 10.1037/a0026699; Olson K, 2016, CHILD NEUROPSYCHOL, V22, P509, DOI 10.1080/09297049.2015.1049941; Pang JWY, 2008, PEDIATR BLOOD CANCER, V50, P104, DOI 10.1002/pbc.21226; Panigrahy A, 2015, NEUROIMAGE-CLIN, V7, P438, DOI 10.1016/j.nicl.2015.01.013; Pavone P, 2001, NEUROLOGY, V56, P1047, DOI 10.1212/WNL.56.8.1047; Perrin JM, 2007, JAMA-J AM MED ASSOC, V297, P2755, DOI 10.1001/jama.297.24.2755; Raver CC, 2013, DEV PSYCHOL, V49, P292, DOI 10.1037/a0028343; Reddick WE, 2006, CANCER-AM CANCER SOC, V106, P941, DOI 10.1002/cncr.21679; Reddick WE, 2003, CANCER-AM CANCER SOC, V97, P2512, DOI 10.1002/cncr.11355; Riggs L, 2014, J INT NEUROPSYCH SOC, V20, P168, DOI 10.1017/S135561771300129X; Robinson KE, 2015, CHILD NEUROPSYCHOL, V21, P779, DOI 10.1080/09297049.2014.924492; Robinson KE, 2014, NEUROPSYCHOLOGY, V28, P791, DOI 10.1037/neu0000077; Robinson KE, 2010, PEDIATR BLOOD CANCER, V55, P525, DOI 10.1002/pbc.22568; Robinson KE, 2010, PEDIATR BLOOD CANCER, V54, P585, DOI 10.1002/pbc.22362; Robison LL, 2009, J CLIN ONCOL, V27, P2308, DOI 10.1200/JCO.2009.22.3339; Rosoff PM, 2006, NEW ENGL J MED, V355, P1522, DOI 10.1056/NEJMp068168; Schatz J, 2002, J PEDIATR PSYCHOL, V27, P739, DOI 10.1093/jpepsy/27.8.739; Sheehan VA, 2014, BLOOD, V124, DOI 10.1182/blood.V124.21.2716.2716; Simko LC, 2006, J CARDIOVASC NURS, V21, P85, DOI 10.1097/00005082-200603000-00003; Studer M, 2014, NEUROLOGY, V82, P784, DOI 10.1212/WNL.0000000000000162; Thies KM, 1999, J SCHOOL HEALTH, V69, P392, DOI 10.1111/j.1746-1561.1999.tb06354.x; Thigpen J. C., 2016, NEUROONCOLOGY PRACTI; United States. Bureau of the Census, 2011, 2010 CENSUS BRIEFS; van der Lee JH, 2007, JAMA-J AM MED ASSOC, V297, P2741, DOI 10.1001/jama.297.24.2741; VONRHEIN M, 2011, THE JOURNAL OF PEDIA, V158, P984, DOI DOI 10.1016/J.JPEDS.2010.11.040; Wiener L, 2015, PEDIATR BLOOD CANCER, V62, pS419, DOI 10.1002/pbc.25675; Zagorsky JL, 2007, INTELLIGENCE, V35, P489, DOI 10.1016/j.intell.2007.02.003; Zebrack BJ, 2004, J CLIN ONCOL, V22, P999, DOI 10.1200/JCO.2004.06.148	77	22	22	1	16	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0003-066X	1935-990X		AM PSYCHOL	Am. Psychol.	MAY-JUN	2017	72	4					326	338		10.1037/amp0000042			13	Psychology, Multidisciplinary	Psychology	EU1EO	WOS:000400756800002	28481580	Bronze, Green Accepted			2021-06-18	
J	Fishman, M; Taranto, E; Perlman, M; Quinlan, K; Benjamin, HJ; Ross, LF				Fishman, Michael; Taranto, Eleanor; Perlman, Meryl; Quinlan, Kyran; Benjamin, Holly J.; Ross, Lainie Friedman			Attitudes and Counseling Practices of Pediatricians Regarding Youth Sports Participation and Concussion Risks	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; DOCTOR; CHILD; IF; EPIDEMIOLOGY; MANAGEMENT; KNOWLEDGE; FOOTBALL	Objective To examine attitudes and practices of pediatricians toward sports-related head trauma and youth participation in tackle football and ice hockey. Study design A respondent-anonymous electronic survey was distributed 3 times to members of the American Academy of Pediatrics Section of Bioethics, Council on Injury, Violence, and Poison Prevention, and Council on Sports Medicine and Fitness. Results Of 791 eligible pediatricians, 227 (29%) responded. Most respondents (189/223;85%) treat sportsrelated concussions, among whom 83% (137/165) reported access to an established return-to-play protocol within their practice. Virtually all (160/166;96%) reported increased parental awareness/concern regarding concussions and 85% (139/163) reported increased visits for head trauma. Overall, 77% (140/183) would not allow their son to play tackle football and 35% (64/181) and 34% (63/184) would not allow their son or daughter, respectively, to participate in ice hockey. Most respondents endorsed limiting or eliminating tackling (143/176; 81%) and checking (144/179; 80%) from practice. Respondents were evenly divided in their support for counseling against youth participation in full-contact sports, with 48% in favor (87/180). Conclusions Most respondents would not allow their own child to play tackle football and endorsed limiting or eliminating tackling in practice. The American Academy of Pediatrics should consider recommending restrictions on tackling in football to support the current concussion concerns of its members.	[Fishman, Michael; Taranto, Eleanor] Univ Chicago, Pritzker Sch Med, Chicago, IL 60637 USA; [Perlman, Meryl; Ross, Lainie Friedman] Univ Chicago, MacLean Ctr Clin Med Eth, Chicago, IL 60637 USA; [Quinlan, Kyran] Rush Univ, Dept Pediat, Med Ctr, Chicago, IL 60612 USA; [Benjamin, Holly J.; Ross, Lainie Friedman] Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 6082, Chicago, IL 60637 USA; [Benjamin, Holly J.] Univ Chicago, Dept Orthoped Surg & Rehabil Med, Chicago, IL 60637 USA	Ross, LF (corresponding author), Univ Chicago, Dept Pediat, 5841 S Maryland Ave,MC 6082, Chicago, IL 60637 USA.	Lross@uchicago.edu		Ross, Lainie/0000-0002-7395-3000	University of Chicago Pritzker School of Medicine Summer Research Project; National Institute of Diabetes and Digestive and Kidney DiseasesUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [T35DK062719-29]	Supported by the University of Chicago Pritzker School of Medicine Summer Research Project (to M.F. and E.T.). Also supported by National Institute of Diabetes and Digestive and Kidney Diseases (T35DK062719-29 [to E.T].). The authors declare no conflicts of interest.	Anderson AJ, 2000, PEDIATRICS, V105, P657; Anderson BL, 2016, CLIN J SPORT MED, V26, P206, DOI 10.1097/JSM.0000000000000214; Arbogast KB, 2016, JAMA PEDIAT, V170, P1; Bachynski KE, 2016, NEW ENGL J MED, V374, P405, DOI 10.1056/NEJMp1513993; Bachynski KE, 2014, J LAW MED ETHICS, V42, P323, DOI 10.1111/jlme.12149; Benson BW, 2013, BRIT J SPORT MED, V47, P321, DOI 10.1136/bjsports-2013-092216; Brenner JS, 2014, PEDIATRICS, V133, P1151, DOI 10.1542/peds.2014-0692; Centers for Disease Control and Prevention (CDC), 2003, MMWR Morb Mortal Wkly Rep, V52, P785; COUNCIL SPORTS MED FITNESS, 2015, PEDIATRICS, V136, pE1419, DOI 10.1542/peds.2015-3282; Daneshvar DH, 2011, CLIN SPORT MED, V30, P1, DOI 10.1016/j.csm.2010.08.006; Gaw CE, 2016, BMC EMERG MED, V16, DOI 10.1186/s12873-016-0071-8; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Hagel BE, 2006, CAN MED ASSOC J, V175, P155, DOI 10.1503/cmaj.051531; Halstead M, 2003, PEDIATRICS, V126, P597; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; Jinguji TM, 2011, PHYS MED REH CLIN N, V22, P565, DOI 10.1016/j.pmr.2011.08.001; Kirschen MP, 2014, NEUROLOGY, V83, P352, DOI 10.1212/WNL.0000000000000613; Kon AA, 2006, PEDIATRICS, V118, P393, DOI 10.1542/peds.2005-2655; Kontos AP, 2016, PEDIATRICS, V137, DOI 10.1542/peds.2015-1633; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Macpherson A, 2006, PEDIATRICS, V117, pE143, DOI 10.1542/peds.2005-1163; Meehan WP, 2013, CLIN J SPORT MED, V23, P339, DOI 10.1097/JSM.0b013e318291d3b3; Metzl JD, 2006, PEDIATRICS, V117, P1813, DOI 10.1542/peds.2006-0480; Register-Mihalik JK, 2013, J ATHL TRAINING, V48, P645, DOI 10.4085/1062-6050-48.3.20; Rice SG, 2000, PEDIATRICS, V107, P1205; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Ross LF, 2003, J CLIN ETHIC, V14, P59; Schneider DK, 2016, BRIT J SPORT MED, P1; Truog R, 2003, J CLIN ETHIC, V14, P63; Truog RD, 1999, PEDIATRICS, V103, P153, DOI 10.1542/peds.103.1.153; Zonfrillo MR, 2012, PEDIATRICS, V130, P1120, DOI 10.1542/peds.2012-1431	31	22	22	0	15	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	MAY	2017	184						19	25		10.1016/j.jpeds.2017.01.048			8	Pediatrics	Pediatrics	EU5WH	WOS:000401104300006	28238481				2021-06-18	
J	Olson, EA; Cui, JL; Fukunaga, R; Nickerson, LD; Rauch, SL; Rosso, IM				Olson, Elizabeth A.; Cui, Jiaolong; Fukunaga, Rena; Nickerson, Lisa D.; Rauch, Scott L.; Rosso, Isabelle M.			Disruption of white matter structural integrity and connectivity in posttraumatic stress disorder: A TBSS and tractography study	DEPRESSION AND ANXIETY			English	Article						anterior cingulate cortex; diffusion tensor imaging; inferior longitudinal fasciculus; posttraumatic stress disorder; probabilistic tractography	TRAUMATIC BRAIN-INJURY; ANTERIOR CINGULATE; HIPPOCAMPAL VOLUME; PTSD; ABNORMALITIES; VETERANS; EXPOSURE; CORTEX; ADULTS; NEUROCIRCUITRY	BackgroundMost studies of brain white matter (WM) in posttraumatic stress disorder (PTSD) have focused on combat trauma, and often were confounded by neurological and substance dependence comorbidity. This study used tract-based spatial statistics (TBSS) and probabilistic tractography to characterize WM microstructure in a mixed-sex community sample of PTSD patients exposed to diverse and multiple traumas, and in trauma-exposed normal comparison (TENC) subjects. MethodsTBSS compared diffusion measures between 20 adults with DSM-IV PTSD and 17 TENC, using a whole-brain voxel-wise approach. Probabilistic tractography using Freesurfer's TRACULA was employed to measure diffusion tensor imaging (DTI) metrics within anatomically defined pathways. DTI metrics were compared between groups and correlated with PTSD symptom severity and trauma load. ResultsControlling for age, sex, and motion, PTSD subjects had significantly reduced fractional anisotropy (FA) in a left frontal lobe cluster compared with TENC, at p < .05, family-wise error corrected. Tractography identified significant group differences in the inferior longitudinal fasciculus (ILF), including lower FA and higher radial diffusivity in PTSD compared with TENC. Within the PTSD group, FA values were not correlated with symptom severity or trauma load. Results remained significant after removing participants using psychotropic medication or those with comorbid major depression. ConclusionsPTSD patients had reduced WM integrity in left hemisphere frontal WM and temporal-occipital WM tracts, compared to trauma-exposed controls. Reduced frontal FA is consistent with compromised top-down attentional control and emotion regulation in PTSD, while reduced ILF FA may be related to sensory processing and gating abnormalities in this disorder.	[Olson, Elizabeth A.; Cui, Jiaolong; Fukunaga, Rena; Rauch, Scott L.; Rosso, Isabelle M.] McLean Hosp, Ctr Depress Anxiety & Stress Res, Belmont, MA 02478 USA; [Olson, Elizabeth A.; Fukunaga, Rena; Nickerson, Lisa D.; Rauch, Scott L.; Rosso, Isabelle M.] Harvard Med Sch, Dept Psychiat, Boston, MA USA; [Nickerson, Lisa D.] McLean Hosp, McLean Imaging Ctr, Belmont, MA 02478 USA	Rosso, IM (corresponding author), McLean Hosp, Anxiety & Traumat Stress Disorders Lab, Mailstop 334,115 Mill St, Belmont, MA 02478 USA.	irosso@hms.harvard.edu	Olson, Elizabeth/M-7981-2018; Rosso, Isabelle M/AAA-6166-2019	Olson, Elizabeth/0000-0003-4617-8050; 	Dana Foundation; National Institute of Mental HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [5R01MH096987]; NATIONAL INSTITUTE OF MENTAL HEALTHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Mental Health (NIMH) [R01MH096987] Funding Source: NIH RePORTER	Grant sponsor: Dana Foundation; Grant sponsor: National Institute of Mental Health (5R01MH096987).	Abe O, 2006, PSYCHIAT RES-NEUROIM, V146, P231, DOI 10.1016/j.pscychresns.2006.01.004; Adenauer H, 2011, BMC NEUROSCI, V12, DOI 10.1186/1471-2202-12-127; Admon R, 2013, HUM BRAIN MAPP, V34, P2808, DOI 10.1002/hbm.22100; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; BASSER PJ, 1994, BIOPHYS J, V66, P259, DOI 10.1016/S0006-3495(94)80775-1; Bierer LM, 2015, PSYCHONEUROENDOCRINO, V51, P567, DOI 10.1016/j.psyneuen.2014.11.007; BLAKE DD, 1995, J TRAUMA STRESS, V8, P75, DOI 10.1002/jts.2490080106; Breslau N, 1998, ARCH GEN PSYCHIAT, V55, P626, DOI 10.1001/archpsyc.55.7.626; Bryant RA, 2008, J PSYCHIATR NEUROSCI, V33, P142; Catani C, 2009, EUR ARCH PSY CLIN N, V259, P340, DOI 10.1007/s00406-009-0006-4; Catani M, 2003, BRAIN, V126, P2093, DOI 10.1093/brain/awg203; Choi J, 2012, NEUROIMAGE, V59, P1071, DOI 10.1016/j.neuroimage.2011.09.033; Clark CR, 2009, CLIN EEG NEUROSCI, V40, P84, DOI 10.1177/155005940904000208; Corbo V, 2005, BIOL PSYCHIAT, V58, P119, DOI 10.1016/j.biopsych.2005.02.032; Daniels JK, 2013, DEPRESS ANXIETY, V30, P207, DOI 10.1002/da.22044; Davenport ND, 2015, HUM BRAIN MAPP, V36, P1053, DOI 10.1002/hbm.22685; De Bellis MD, 2015, DEV PSYCHOPATHOL, V27, P1555, DOI 10.1017/S0954579415000942; Durkee CA, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0080952; Fani N, 2012, NEUROPSYCHOPHARMACOL, V37, P2740, DOI 10.1038/npp.2012.146; First MB., 2002, STRUCTURED CLIN INTE; Hagmann P, 2006, RADIOGRAPHICS, V26, pS205, DOI 10.1148/rg.26si065510; Hakamata Y, 2007, NEUROSCI RES, V59, P383, DOI 10.1016/j.neures.2007.08.012; Helpman L, 2016, NEUROIMAGE-CLIN, V12, P715, DOI 10.1016/j.nicl.2016.10.007; Herringa R, 2012, PSYCHIAT RES-NEUROIM, V203, P139, DOI 10.1016/j.pscychresns.2012.02.005; Isaac L, 2015, BIOL PSYCHOL, V105, P20, DOI 10.1016/j.biopsycho.2014.12.011; Jovanovic T, 2010, AM J PSYCHIAT, V167, P648, DOI 10.1176/appi.ajp.2009.09071074; Karl A, 2006, NEUROSCI BIOBEHAV R, V30, P1004, DOI 10.1016/j.neubiorev.2006.03.004; Kennis M, 2015, NEUROPSYCHOPHARMACOL, V40, P2434, DOI 10.1038/npp.2015.94; Kessler RC, 2000, J CLIN PSYCHIAT, V61, P4; Kim MJ, 2005, NEUROREPORT, V16, P1049, DOI 10.1097/00001756-200507130-00004; Kim SJ, 2006, NEUROPSYCHOBIOLOGY, V54, P120, DOI 10.1159/000098262; Kubany ES, 2000, PSYCHOL ASSESSMENT, V12, P210, DOI 10.1037//1040-3590.12.2.210; Levin HS, 2010, J NEUROTRAUM, V27, P683, DOI 10.1089/neu.2009.1073; Li L, 2014, NEUROSCI BIOBEHAV R, V43, P163, DOI 10.1016/j.neubiorev.2014.04.003; Long ZL, 2013, J AFFECT DISORDERS, V150, P798, DOI 10.1016/j.jad.2013.03.004; Milad MR, 2009, BIOL PSYCHIAT, V66, P1075, DOI 10.1016/j.biopsych.2009.06.026; Mueller-Pfeiffer C, 2013, NEUROIMAGE-CLIN, V3, P531, DOI 10.1016/j.nicl.2013.08.009; Nardo D, 2010, J PSYCHIATR RES, V44, P477, DOI 10.1016/j.jpsychires.2009.10.014; Neylan TC, 1999, BIOL PSYCHIAT, V46, P1656, DOI 10.1016/S0006-3223(99)00047-5; O'Doherty DCM, 2015, PSYCHIAT RES-NEUROIM, V232, P1, DOI 10.1016/j.pscychresns.2015.01.002; Pineles SL, 2016, PSYCHOPHYSIOLOGY, V53, P1377, DOI 10.1111/psyp.12679; Rauch SL, 2006, BIOL PSYCHIAT, V60, P376, DOI 10.1016/j.biopsych.2006.06.004; Rauch SL, 2003, NEUROREPORT, V14, P913, DOI 10.1097/01.wnr.0000071767.24455.10; Roine U, 2015, MOL AUTISM, V6, DOI 10.1186/2040-2392-6-4; Sanjuan PM, 2013, PSYCHIAT RES-NEUROIM, V214, P260, DOI 10.1016/j.pscychresns.2013.09.002; Sarica A, 2014, J NEUROSCI METH, V224, P79, DOI 10.1016/j.jneumeth.2013.12.014; Schuff N, 2011, NEUROIMAGE, V54, pS62, DOI 10.1016/j.neuroimage.2010.05.024; Shin LM, 2010, NEUROPSYCHOPHARMACOL, V35, P169, DOI 10.1038/npp.2009.83; Smith SM, 2004, NEUROIMAGE, V23, pS208, DOI 10.1016/j.neuroimage.2004.07.051; Smith SM, 2006, NEUROIMAGE, V31, P1487, DOI 10.1016/j.neuroimage.2006.02.024; Smith SM, 2009, NEUROIMAGE, V44, P83, DOI 10.1016/j.neuroimage.2008.03.061; SOLOMON SD, 1992, JAMA-J AM MED ASSOC, V268, P633, DOI 10.1001/jama.268.5.633; Song SK, 2003, NEUROIMAGE, V20, P1714, DOI 10.1016/j.neuroimage.2003.07.005; Sun YW, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0083473; Thomaes K, 2010, J CLIN PSYCHIAT, V71, P1636, DOI 10.4088/JCP.08m04754blu; Woon FL, 2010, PROG NEURO-PSYCHOPH, V34, P1181, DOI 10.1016/j.pnpbp.2010.06.016; Yeatman JD, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0049790; Yendiki A, 2014, NEUROIMAGE, V88, P79, DOI 10.1016/j.neuroimage.2013.11.027; Yendiki Anastasia, 2011, Front Neuroinform, V5, P23, DOI 10.3389/fninf.2011.00023; Zhang L, 2011, J AFFECT DISORDERS, V133, P294, DOI 10.1016/j.jad.2011.03.040	60	22	22	0	4	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1091-4269	1520-6394		DEPRESS ANXIETY	Depress. Anxiety	MAY	2017	34	5					437	445		10.1002/da.22615			9	Psychology, Clinical; Psychiatry; Psychology	Psychology; Psychiatry	ET5NJ	WOS:000400330100007	28294462	Green Accepted			2021-06-18	
J	Winkler, MKL; Dengler, N; Hecht, N; Hartings, JA; Kang, EJ; Major, S; Martus, P; Vajkoczy, P; Woitzik, J; Dreier, JP				Winkler, Maren K. L.; Dengler, Nora; Hecht, Nils; Hartings, Jed A.; Kang, Eun J.; Major, Sebastian; Martus, Peter; Vajkoczy, Peter; Woitzik, Johannes; Dreier, Jens P.			Oxygen availability and spreading depolarizations provide complementary prognostic information in neuromonitoring of aneurysmal subarachnoid hemorrhage patients	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						Spreading depolarization; spreading depression; subarachnoid hemorrhage; vasospasm; stroke; oxygen availability	TRAUMATIC BRAIN-INJURY; HUMAN CEREBRAL-CORTEX; PERIINFARCT DEPOLARIZATIONS; ANOXIC DEPOLARIZATION; NEUROCRITICAL CARE; MALIGNANT STROKE; DEPRESSION; HYPEROXIA; ISCHEMIA; SLICES	Multimodal neuromonitoring in neurocritical care increasingly includes electrocorticography to measure epileptic events and spreading depolarizations. Spreading depolarization causes spreading depression of activity (=isoelectricity) in electrically active tissue. If the depression is long-lasting, further spreading depolarizations occur in still isoelectric tissue where no activity can be suppressed. Such spreading depolarizations are termed isoelectric and are assumed to indicate energy compromise. However, experimental and clinical recordings suggest that long-lasting spreading depolarization-induced depression and isoelectric spreading depolarizations are often recorded outside of the actual ischemic zones, allowing the remote diagnosis of delayed cerebral ischemia after aneurysmal subarachnoid hemorrhage. Here, we analyzed simultaneous electrocorticography and tissue partial pressure of oxygen recording in 33 aneurysmal subarachnoid hemorrhage patients. Multiple regression showed that both peak total depression duration per recording day and mean baseline tissue partial pressure of oxygen were independent predictors of outcome. Moreover, tissue partial pressure of oxygen preceding spreading depolarization was similar and differences in tissue partial pressure of oxygen responses to spreading depolarization were only subtle between isoelectric spreading depolarizations and spreading depressions. This further supports that, similar to clustering of spreading depolarizations, long spreading depolarization-induced periods of isoelectricity are useful to detect energy compromise remotely, which is valuable because the exact location of future developing pathology is unknown at the time when the neurosurgeon implants recording devices.	[Winkler, Maren K. L.; Kang, Eun J.; Major, Sebastian; Dreier, Jens P.] Charite, Ctr Stroke Res Berlin, Berlin, Germany; [Dengler, Nora; Hecht, Nils; Vajkoczy, Peter; Woitzik, Johannes] Charite, Dept Neurosurg, Berlin, Germany; [Hartings, Jed A.] Univ Cincinnati, Dept Neurosurg, Cincinnati, OH USA; [Kang, Eun J.; Major, Sebastian; Dreier, Jens P.] Charite, Dept Expt Neurol, Berlin, Germany; [Major, Sebastian; Dreier, Jens P.] Charite, Dept Neurol, Berlin, Germany; [Martus, Peter] Univ Tubingen, Inst Clin Epidemiol & Appl Biometry, Tubingen, Germany	Dreier, JP (corresponding author), Charite, Ctr Stroke Res Berlin, Charite Campus Mitte, Charite Pl 1, D-10117 Berlin, Germany.	jens.dreier@charite.de	Major, Sebastian/I-1838-2019	Major, Sebastian/0000-0003-0970-1308; Dengler, Nora F./0000-0001-7783-8053; Hartings, Jed/0000-0001-8583-3471	Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin)Federal Ministry of Education & Research (BMBF) [01 EO 0801, BCCN 01GQ1001C B2]; Era-Net Neuron [01EW1212]; Deutsche ForschungsgemeinschaftGerman Research Foundation (DFG) [DFG DR 323/5-1]	The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Supported by the Bundesministerium fur Bildung und Forschung (Center for Stroke Research Berlin, 01 EO 0801; BCCN 01GQ1001C B2) and Era-Net Neuron 01EW1212 to Dr. Dreier and Deutsche Forschungsgemeinschaft (DFG DR 323/5-1) to Drs. Dreier, Martus, Woitzik and Vajkoczy.	AITKEN PG, 1988, NEUROSCI LETT, V89, P187, DOI 10.1016/0304-3940(88)90379-5; Beynon C, 2012, J NEUROTRAUM, V29, P2109, DOI 10.1089/neu.2012.2365; Bohman LE, 2011, NEUROCRIT CARE, V14, P361, DOI 10.1007/s12028-011-9526-7; Bosche B, 2010, ANN NEUROL, V67, P607, DOI 10.1002/ana.21943; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS65; Brenner M, 2012, ARCH SURG-CHICAGO, V147, P1042, DOI 10.1001/archsurg.2012.1560; Bruce DA, 2000, CHILD NERV SYST, V16, P724, DOI 10.1007/s003810000336; Carter RE, 2013, J NEUROCHEM, V125, P673, DOI 10.1111/jnc.12237; Chong DJ, 2005, J CLIN NEUROPHYSIOL, V22, P79, DOI 10.1097/01.WNP.0000158699.78529.AF; Citerio G, 2015, CURR OPIN CRIT CARE, V21, P113, DOI 10.1097/MCC.0000000000000179; Claassen J, 2013, ANN NEUROL, V74, P53, DOI 10.1002/ana.23859; Davis DP, 2009, J NEUROTRAUM, V26, P2217, DOI 10.1089/neu.2009.0940; Dijkhuizen RM, 1999, BRAIN RES, V840, P194, DOI 10.1016/S0006-8993(99)01769-2; Diringer MN, 2008, CURR OPIN CRIT CARE, V14, P167, DOI 10.1097/MCC.0b013e3282f57552; Dohmen C, 2008, ANN NEUROL, V63, P720, DOI 10.1002/ana.21390; Dreier JP, 2006, BRAIN, V129, P3224, DOI 10.1093/brain/awl297; Dreier JP, 2015, NEURON, V86, P902, DOI 10.1016/j.neuron.2015.04.004; Dreier JP, 2012, BRAIN, V135, P259, DOI 10.1093/brain/awr303; Dreier JP, 2011, NAT MED, V17, P439, DOI 10.1038/nm.2333; Dreier JP, 2009, BRAIN, V132, P1866, DOI 10.1093/brain/awp102; Drenckhahn C, 2012, BRAIN, V135, P853, DOI 10.1093/brain/aws010; Eross L, 2009, J NEUROSURG, V110, P327, DOI 10.3171/2008.6.JNS17611; Fabricius M, 2006, BRAIN, V129, P778, DOI 10.1093/brain/awh716; Fabricius M, 2008, CLIN NEUROPHYSIOL, V119, P1973, DOI 10.1016/j.clinph.2008.05.025; FISHER CM, 1980, NEUROSURGERY, V6, P1, DOI 10.1227/00006123-198001000-00001; Hartings JA, 2006, J CEREBR BLOOD F MET, V26, P696, DOI 10.1038/sj.jcbfm.9600223; Hartings JA, 2011, LANCET NEUROL, V10, P1058, DOI 10.1016/S1474-4422(11)70243-5; Hartings JA, 2011, BRAIN, V134, P1529, DOI 10.1093/brain/awr048; HERNANDEZCACERES J, 1987, BRAIN RES, V437, P360, DOI 10.1016/0006-8993(87)91652-0; Hinzman JM, 2014, BRAIN, V137, P2960, DOI 10.1093/brain/awu241; Kager H, 2002, J NEUROPHYSIOL, V88, P2700, DOI 10.1152/jn.00237.2002; Kilgannon JH, 2011, CIRCULATION, V123, P2717, DOI 10.1161/CIRCULATIONAHA.110.001016; LAURITZEN M, 1992, J CEREBR BLOOD F MET, V12, P223, DOI 10.1038/jcbfm.1992.32; Lauritzen M, 2011, J CEREBR BLOOD F MET, V31, P17, DOI 10.1038/jcbfm.2010.191; Leao AAP, 1944, J NEUROPHYSIOL, V7, P359; Lindquist BE, 2012, NEUROSCIENCE, V223, P365, DOI 10.1016/j.neuroscience.2012.07.053; Muller M, 1998, BRAIN RES, V812, P1, DOI 10.1016/S0006-8993(98)00812-9; Narotam PK, 2014, J NEUROTRAUM, V31, P630, DOI 10.1089/neu.2013.3104; Nortje J, 2006, BRIT J ANAESTH, V97, P95, DOI 10.1093/bja/ael137; Oddo M, 2014, NEUROCRIT CARE, V21, P103, DOI 10.1007/s12028-014-0024-6; Oliveira-Ferreira AI, 2010, J CEREBR BLOOD F MET, V30, P1504, DOI 10.1038/jcbfm.2010.40; Park S, 2011, NEUROCRIT CARE, V15, P469, DOI 10.1007/s12028-011-9540-9; Piilgaard H, 2009, J CEREBR BLOOD F MET, V29, P1517, DOI 10.1038/jcbfm.2009.73; Quintard H, 2015, NEUROCRIT CARE, V22, P243, DOI 10.1007/s12028-014-0062-0; Ramakrishna R, 2008, J NEUROSURG, V109, P1075, DOI 10.3171/JNS.2008.109.12.1075; Rincon F, 2014, J NEUROL NEUROSUR PS, V85, P799, DOI 10.1136/jnnp-2013-305505; Sakowitz OW, 2013, STROKE, V44, P220, DOI 10.1161/STROKEAHA.112.672352; Sakowitz OW, 2009, STROKE, V40, pE519, DOI 10.1161/STROKEAHA.109.549303; Schatlo B, 2010, NEUROSURGERY, V67, P721, DOI 10.1227/01.NEU.0000378024.70848.8F; Seule M, 2015, NEUROCRIT CARE, V23, P108, DOI 10.1007/s12028-015-0111-3; Sjoberg F, 2013, J INTERN MED, V274, P505, DOI 10.1111/joim.12139; SOLENSKI NJ, 1995, CRIT CARE MED, V23, P1007, DOI 10.1097/00003246-199506000-00004; Spiotta AM, 2010, J NEUROSURG, V113, P571, DOI 10.3171/2010.1.JNS09506; Stiefel MF, 2006, J NEUROSURG, V105, P568, DOI 10.3171/jns.2006.105.4.568; STOLTENBURGDIDI.G, 1987, STROKE MICROCIRCULAT, P471; Strong AJ, 2002, STROKE, V33, P2738, DOI 10.1161/01.STR.0000043073.69602.09; Takano T, 2007, NAT NEUROSCI, V10, P754, DOI 10.1038/nn1902; Vergouwen MDI, 2011, J CEREBR BLOOD F MET, V31, P1545, DOI 10.1038/jcbfm.2011.56; von Bornstadt D, 2015, NEURON, V85, P1117, DOI 10.1016/j.neuron.2015.02.007; Woitzik J, 2013, NEUROLOGY, V80, P1095, DOI 10.1212/WNL.0b013e3182886932; Wolf Stefan, 2012, Acta Neurochir Suppl, V114, P161, DOI 10.1007/978-3-7091-0956-4_30	61	22	22	0	1	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	MAY	2017	37	5					1841	1856		10.1177/0271678X16641424			16	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	ET8CG	WOS:000400525200021	27025768	Green Published, Bronze			2021-06-18	
J	Zhao, B; Zheng, ZB				Zhao, Bing; Zheng, Zebao			Insulin Growth Factor 1 Protects Neural Stem Cells Against Apoptosis Induced by Hypoxia Through Akt/Mitogen-Activated Protein Kinase/Extracellular Signal-Regulated Kinase (Akt/MAPK/ERK) Pathway in Hypoxia-Ishchemic Encephalopathy	MEDICAL SCIENCE MONITOR			English	Article						Apoptosis; Cell Survival; Insulin-Like Growth Factor Binding Protein 1; MAP Kinases; Neural Stem Cells; Phosphatidylinositol 3-Kinases	FACTOR-I; ISCHEMIC ENCEPHALOPATHY; TREATMENT OPTIONS; RECEPTOR; DIFFERENTIATION; PROLIFERATION; INVOLVEMENT; HYPOTHERMIA; OXYGEN; MODEL	Background: Insulin growth factor 1 (IGF-1) is reported to modulate cell growth and acts as potential therapy for traumatic brain injury. This study was designed to investigate the effect of IGF-1 on hypoxia-induced apoptosis in neural stem cells (NSCs). Material/Methods: A hypoxia model was constructed using NSCs separated from the hippocampus of rat. NSCs were divided into four groups: cells under normoxic conditions that acted as controls (C group), cells under hypoxia (H group), cells under hypoxia with IGF-1 (HI group), and cells under hypoxia with IGF-1 as well as picropodophyllin (PPP), which acts as an inhibitor of the IGF-1 receptor (HIP group). The cell viability and apoptosis were respectively measured by 3-(4,5-dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay and flow cytometry. Finally, the phosphorylation levels of apoptosis-associated proteins and key kinases in the phosphatidylinositol3- kinase (PI3K)/AKT and the mitogen-activated protein kinase/extracellular signal-regulated kinase (MAPK/ERK) pathways were detected by Western blot analysis. Results: In comparison with the H group, the cell viability was increased while the cell apoptosis was reduced by IGF1 in the HI group. Besides, the expression levels of Bax, cytochrome c, and activated caspase-3 were all improved in the H group, and the remarkable differences were eliminated in the HI group compared with the C group. The expression level of Bcl-2 was the opposite. Additionally, down-regulations of phosphorylated AKT, MAPK, and ERK induced by hypoxia were all improved by IGF-1. All the influences of IGF-1 were weakened by addition of PPP. Conclusions: IGF-1 increased cell viability while decreasing apoptosis in hypoxic NSCs through the PI3K/AKT and MAPK/ERK pathways.	[Zhao, Bing; Zheng, Zebao] Jining 1 Peoples Hosp, Dept Children Rehabil, Jining, Shandong, Peoples R China	Zheng, ZB (corresponding author), Jining 1 Peoples Hosp, Dept Children Rehabil, Jining, Shandong, Peoples R China.	zhengzebao604@126.com					Bath C, 2013, STEM CELL RES, V10, P349, DOI 10.1016/j.scr.2013.01.004; Chalak LF, 2014, J PEDIATR-US, V164, P468, DOI 10.1016/j.jpeds.2013.10.067; Chipuk JE, 2010, MOL CELL, V37, P299, DOI 10.1016/j.molcel.2010.01.025; Dai Y, 2014, BRAIN DEV-JPN, V36, P228, DOI 10.1016/j.braindev.2013.04.007; Ezashi T, 2005, P NATL ACAD SCI USA, V102, P4783, DOI 10.1073/pnas.0501283102; Girnita A, 2006, CLIN CANCER RES, V12, P1383, DOI 10.1158/1078-0432.CCR-05-1106; Haiyan H, 2016, EVID-BASED COMPL ALT, V2016, P3106980; Higgins RD, 2011, J PEDIATR-US, V159, P851, DOI 10.1016/j.jpeds.2011.08.004; Huat TJ, 2014, BMC NEUROSCI, V15, DOI 10.1186/1471-2202-15-91; Kurinczuk JJ, 2010, EARLY HUM DEV, V86, P329, DOI 10.1016/j.earlhumdev.2010.05.010; Li Y, 2013, ASIAN PAC J CANCER P, V14, P4599, DOI 10.7314/APJCP.2013.14.8.4599; Llambi F, 2011, MOL CELL, V44, P517, DOI 10.1016/j.molcel.2011.10.001; Loison F, 2014, J CLIN INVEST, V124, P4445, DOI 10.1172/JCI76246; Ma JC, 2010, J SURG RES, V160, P90, DOI 10.1016/j.jss.2008.08.016; Merchant NM, 2015, EXPERT OPIN ORPHAN D, V3, P357, DOI 10.1517/21678707.2015.1021776; Molyneaux BJ, 2007, NAT REV NEUROSCI, V8, P427, DOI 10.1038/nrn2151; Neubauer JA, 2004, J APPL PHYSIOL, V96, P367, DOI 10.1152/japplphysiol.00831.2003; Papademetrio DL, 2015, TARGETED ONCOLOGY, V11, P1; PUCILOWSKA JB, 1993, J CLIN ENDOCR METAB, V77, P1516, DOI 10.1210/jc.77.6.1516; RINDERKNECHT E, 1978, J BIOL CHEM, V253, P2769; Rink C, 2011, ANTIOXID REDOX SIGN, V14, P1889, DOI 10.1089/ars.2010.3474; Rubovitch V, 2010, NEUROBIOL DIS, V38, P299, DOI 10.1016/j.nbd.2010.01.021; SELL C, 1995, CANCER RES, V55, P303; Shoemaker LD, 2016, MOL CELL PROTEOMICS, V15, P344, DOI 10.1074/mcp.O115.052704; Studer L, 2000, J NEUROSCI, V20, P7377; Supeno NE, 2013, INT J MED SCI, V10, P522, DOI 10.7150/ijms.5325; Valenciano A, 2012, TRANSL ONCOL, V5, P1, DOI 10.1593/tlo.11265; Van LH, 2013, PEDIATRICS, V131, P88; Vasilcanu R, 2008, ONCOGENE, V27, P1629, DOI 10.1038/sj.onc.1210797; Vhaouari P, 2005, ARCH DIS CHILD-FETAL, V90, P257; Xiang L, 2007, MED HYPOTHESES, V69, P629; Yan Y, 2012, HISTOCHEM CELL BIOL, V137, P513; Yu ML, 2015, CELL BIOL INT, V39, P910, DOI 10.1002/cbin.10466; [袁丽丽 Yuan Lili], 2008, [神经解剖学杂志, Chinese Journal of Neuroanatomy], V24, P343; Zhang XL, 2014, J CHEM-NY, V2014, DOI 10.1155/2014/249485; Zhu LL, 2005, MOL NEUROBIOL, V31, P231, DOI 10.1385/MN:31:1-3:231	36	22	22	0	5	INT SCIENTIFIC LITERATURE, INC	SMITHTOWN	361 FOREST LANE, SMITHTOWN, NY 11787 USA	1643-3750			MED SCI MONITOR	Med. Sci. Monitor	APR 19	2017	23						1872	1879		10.12659/MSM.901055			8	Medicine, Research & Experimental	Research & Experimental Medicine	ES3AH	WOS:000399398900001	28420864	Green Published			2021-06-18	
J	Hagos, FT; Daood, MJ; Ocque, JA; Nolin, TD; Bayir, H; Poloyac, SM; Kochanek, PM; Clark, RSB; Empey, PE				Hagos, Fanuel T.; Daood, Monica J.; Ocque, Jacob A.; Nolin, Thomas D.; Bayir, Hulya; Poloyac, Samuel M.; Kochanek, Patrick M.; Clark, Robert S. B.; Empey, Philip E.			Probenecid, an organic anion transporter 1 and 3 inhibitor, increases plasma and brain exposure of N-acetylcysteine	XENOBIOTICA			English	Article						Antioxidant; inhibitor; n-acetylcysteine; organic anion tranporter; pharmacokinetics; probenecid; transporter	CEREBROSPINAL-FLUID; GLUTATHIONE; PHARMACOKINETICS; BARRIER; MECHANISM; BENZYLPENICILLIN; FEXOFENADINE; ELIMINATION; ZIDOVUDINE; CLEARANCE	1. N-acetylcysteine (NAC) is being investigated as an antioxidant for several conditions including traumatic brain injury, but the mechanism by which it crosses membrane barriers is unknown. We have attempted to understand how the transporter inhibitor, probenecid, affects NAC pharmacokinetics and to evaluate the interaction of NAC with transporters. 2. Juvenile Sprague-Dawley rats were administered NAC alone or in combination with probenecid intraperitoneally. Plasma and brain samples were collected serially and NAC concentrations were measured. Transporter studies were conducted with human embryonic kidney-293 cells that overexpress organic anion transporter (OAT)1 or OAT3 and with human multi-drug resistance-associatedprotein (MRP)1 or MRP4 membrane vesicles. 3. NAC area under the curve was increased in plasma (1.65-fold) and brain (2.41-fold) by probenecid. The apparent plasma clearance was decreased by 65%. Time- and concentration-dependent NAC uptake that was inhibitable by probenecid was observed with OAT1 and OAT3. No uptake of NAC was observed with MRP1 or MRP4. 4. Our results indicate for the first time that NAC is substrate for OAT1 and OAT3 and that probenecid increases NAC plasma and brain exposure in vivo. These data provide insight regarding how NAC crosses biological barriers and suggest a promising therapeutic strategy to increase NAC exposure.	[Hagos, Fanuel T.; Poloyac, Samuel M.] Univ Pittsburgh, Ctr Clin Pharmaceut Sci, Sch Pharm, Dept Pharmaceut Sci, Pittsburgh, PA USA; [Hagos, Fanuel T.; Daood, Monica J.; Ocque, Jacob A.; Nolin, Thomas D.; Poloyac, Samuel M.; Empey, Philip E.] Univ Pittsburgh, Ctr Clin Pharmaceut Sci, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Dept Crit Care Med, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Univ Pittsburgh, Safar Ctr Resuscitat Res, Sch Med, Pittsburgh, PA USA; [Bayir, Hulya; Kochanek, Patrick M.; Clark, Robert S. B.] Childrens Hosp Pittsburgh UPMC, Pittsburgh, PA USA	Empey, PE (corresponding author), Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, 335 Sutherland Dr,Room 205, Pittsburgh, PA 15261 USA.	pempey@pitt.edu	Empey, Philip/L-9604-2019; Nolin, Thomas/AAB-7311-2020	Empey, Philip/0000-0001-7474-2339; Nolin, Thomas/0000-0003-4339-1382	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS069247, TR000146]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000146] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS069247] Funding Source: NIH RePORTER	This work was supported by the National Institutes of Health NS069247 and TR000146. The authors have no conflicts of interest related to this study.	Atkuri KR, 2007, CURR OPIN PHARMACOL, V7, P355, DOI 10.1016/j.coph.2007.04.005; BORGSTROM L, 1986, EUR J CLIN PHARMACOL, V31, P217, DOI 10.1007/BF00606662; Cotgreave I A, 1997, Adv Pharmacol, V38, P205; Dodd S, 2008, EXPERT OPIN BIOL TH, V8, P1955, DOI 10.1517/14728220802517901 ; Donovan MD, 2015, J PHARM PHARMACOL, V67, P501, DOI 10.1111/jphp.12341; Erdman AR, 2006, AM J PHYSIOL-RENAL, V290, pF905, DOI 10.1152/ajprenal.00272.2005; Erickson MA, 2012, BRAIN BEHAV IMMUN, V26, P1085, DOI 10.1016/j.bbi.2012.07.003; Farr SA, 2003, J NEUROCHEM, V84, P1173, DOI 10.1046/j.1471-4159.2003.01580.x; Giustarini D, 2012, BIOCHEM PHARMACOL, V84, P1522, DOI 10.1016/j.bcp.2012.09.010; Grandjean EM, 2000, CLIN THER, V22, P209, DOI 10.1016/S0149-2918(00)88479-9; Harada D, 2001, ANAL BIOCHEM, V290, P251, DOI 10.1006/abio.2000.4980; Hoffer ME, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054163; HURST GA, 1967, AM REV RESPIR DIS, V96, P962; Kalvass JC, 2013, CLIN PHARMACOL THER, V94, P80, DOI 10.1038/clpt.2013.34; Kikuchi R, 2003, J PHARMACOL EXP THER, V306, P51, DOI 10.1124/jpet.103.049197; Koh AS, 2002, MOL PHARMACOL, V62, P921, DOI 10.1124/mol.62.4.921; Kusuhara Hiroyuki, 2005, NeuroRx, V2, P73, DOI 10.1007/BF03206644; LASKIN OL, 1982, ANTIMICROB AGENTS CH, V21, P804, DOI 10.1128/AAC.21.5.804; Loscher W, 2005, PROG NEUROBIOL, V76, P22, DOI 10.1016/j.pneurobio.2005.04.006; Maeda K, 2014, EUR J PHARM SCI, V59, P94, DOI 10.1016/j.ejps.2014.04.004; Margulies S, 2016, J NEUROTRAUM, V33, P101, DOI 10.1089/neu.2014.3855; MCLELLAN LI, 1995, CARCINOGENESIS, V16, P2099, DOI 10.1093/carcin/16.9.2099; Minematsu T, 2008, DRUG METAB DISPOS, V36, P1496, DOI 10.1124/dmd.107.019828; Neuwelt EA, 2001, CANCER RES, V61, P7868; Offen D, 2004, J NEUROCHEM, V89, P1241, DOI 10.1111/j.1471-4159.2004.02428.x; OLSSON B, 1988, EUR J CLIN PHARMACOL, V34, P77, DOI 10.1007/BF01061422; Pombrio JM, 2001, MOL PHARMACOL, V60, P1091; PRESCOTT LF, 1979, BRIT MED J, V2, P1097, DOI 10.1136/bmj.2.6198.1097; Rushworth GF, 2014, PHARMACOL THERAPEUT, V141, P150, DOI 10.1016/j.pharmthera.2013.09.006; Samuni Y, 2013, BBA-GEN SUBJECTS, V1830, P4117, DOI 10.1016/j.bbagen.2013.04.016; SAWCHUK RJ, 1990, PHARMACEUT RES, V7, P332, DOI 10.1023/A:1015854902915; Shimizu M, 2005, DRUG METAB DISPOS, V33, P1477, DOI 10.1124/dmd.105.004622; Tachikawa M, 2012, J NEUROCHEM, V123, P750, DOI 10.1111/jnc.12018; Tahara H, 2006, DRUG METAB DISPOS, V34, P743, DOI 10.1124/dmd.105.008375; Versantvoort CHM, 1995, INT J CANCER, V63, P855, DOI 10.1002/ijc.2910630617; WONG SL, 1993, J PHARMACOL EXP THER, V264, P899; Zhou J, 2015, J PHARM SCI-US, V104, P2619, DOI 10.1002/jps.24482	37	22	23	0	8	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	0049-8254	1366-5928		XENOBIOTICA	Xenobiotica	APR	2017	47	4					346	353		10.1080/00498254.2016.1187777			8	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	EM5JK	WOS:000395347600009	27278858	Green Accepted			2021-06-18	
J	Hoover, EC; Souza, PE; Gallun, FJ				Hoover, Eric C.; Souza, Pamela E.; Gallun, Frederick J.			Auditory and Cognitive Factors Associated with Speech-in-Noise Complaints following Mild Traumatic Brain Injury	JOURNAL OF THE AMERICAN ACADEMY OF AUDIOLOGY			English	Article						auditory processing disorder; hearing impairment; postconcussive syndrome; traumatic brain injury	HEARING-LOSS; FREQUENCY-SELECTIVITY; SENSITIVITY; RECEPTION; SEQUELAE; MEMORY; INFORMATION; VETERANS; RELEASE; SCALE	Background: Auditory complaints following mild traumatic brain injury (MTBI) are common, but few studies have addressed the role of auditory temporal processing in speech recognition complaints. Purpose: In this study, deficits understanding speech in a background of speech noise following MTBI were evaluated with the goal of comparing the relative contributions of auditory and nonauditory factors. Research Design: A matched-groups design was used in which a group of listeners with a history of MTBI were compared to a group matched in age and pure-tone thresholds, as well as a control group of young listeners with normal hearing (YNH). Study Sample: Of the 33 listeners who participated in the study, 13 were included in the MTBI group (mean age = 46.7 yr), 11 in the Matched group (mean age = 49 yr), and 9 in the YNH group (mean age = 20.8 yr). Data Collection and Analysis: Speech-in-noise deficits were evaluated using subjective measures as well as monaural word (Words-in-Noise test) and sentence (Quick Speech-in-Noise test) tasks, and a binaural spatial release task. Performance on these measures was compared to psychophysical tasks that evaluate monaural and binaural temporal fine-structure tasks and spectral resolution. Cognitive measures of attention, processing speed, and working memory were evaluated as possible causes of differences between MTBI and Matched groups that might contribute to speech-in-noise perception deficits. Results: A high proportion of listeners in the MTBI group reported difficulty understanding speech in noise (84%) compared to the Matched group (9.1%), and listeners who reported difficulty were more likely to have abnormal results on objective measures of speech in noise. No significant group differences were found between the MTBI and Matched listeners on any of the measures reported, but the number of abnormal tests differed across groups. Regression analysis revealed that a combination of auditory and auditory processing factors contributed to monaural speech-in-noise scores, but the benefit of spatial separation was related to a combination of working memory and peripheral auditory factors across all listeners in the study. Conclusions: The results of this study are consistent with previous findings that a subset of listeners with MTBI has objective auditory deficits. Speech-in-noise performance was related to a combination of auditory and nonauditory factors, confirming the important role of audiology in MTBI rehabilitation. Further research is needed to evaluate the prevalence and causal relationship of auditory deficits following MTBI.	[Hoover, Eric C.] Univ S Florida, Dept Commun Sci & Disorders, Tampa, FL 33620 USA; [Souza, Pamela E.] Northwestern Univ, Dept Commun Sci & Disorders, Evanston, IL USA; [Souza, Pamela E.] Northwestern Univ, Knowles Hearing Ctr, Evanston, IL USA; [Gallun, Frederick J.] Oregon Hlth & Sci Univ, Natl Ctr Rehabilitat Auditory Res, Portland VA Med Ctr & Otolaryngol, Portland, OR 97201 USA; [Gallun, Frederick J.] Oregon Hlth & Sci Univ, Head & Neck Surg Dept, Portland, OR 97201 USA	Hoover, EC (corresponding author), Univ S Florida, Dept Commun Sci & Disorders, Tampa, FL 33620 USA.	erichoover@usf.edu	Gallun, Frederick J./G-3792-2012	Gallun, Frederick J./0000-0002-4145-2199	NIH grantsUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 DC60014, R01 DC12289]; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [R01DC012289, R01DC006014] Funding Source: NIH RePORTER	This work was supported by NIH grants R01 DC60014 and R01 DC12289 (to author P.E.S.)	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; Anonymous, 2006, Morbidity and Mortality Weekly Report, V55, P201; Bergemalm PO, 2005, INT J AUDIOL, V44, P39, DOI 10.1080/14992020400022546; Bergemalm PO, 2001, ACTA OTO-LARYNGOL, V121, P724, DOI 10.1080/00016480152583674; BERNSTEIN LR, 1982, J ACOUST SOC AM, V71, P147, DOI 10.1121/1.387254; Bolia RS, 2000, J ACOUST SOC AM, V107, P1065, DOI 10.1121/1.428288; COCKRELL J L, 1992, Brain Injury, V6, P261, DOI 10.3109/02699059209029667; Cox RM, 1997, EAR HEARING, V18, P388, DOI 10.1097/00003446-199710000-00004; Dean PJA, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00030; Frisina RD, 2001, HEARING RES, V158, P1, DOI 10.1016/S0378-5955(01)00296-9; Gallun FJ, J REHABIL R IN PRESS; Gallun FJ, 2013, FRONT NEUROSCI-SWITZ, V7, DOI 10.3389/fnins.2013.00252; Gallun FJ, 2012, J REHABIL RES DEV, V49, P1005, DOI 10.1682/JRRD.2012.03.0038; Gygi B, 2012, ACTA ACUST UNITED AC, V98, P142, DOI 10.3813/AAA.918500; Hall RCW, 2005, PSYCHOSOMATICS, V46, P195, DOI 10.1176/appi.psy.46.3.195; Hartmann WM, 2011, J ACOUST SOC AM, V130, P292, DOI 10.1121/1.3596475; Hoffer ME, 2013, PSYCHIAT ANN, V43, P318, DOI 10.3928/00485713-20130703-06; Hoofien D, 2001, BRAIN INJURY, V15, P189; Hoover E, 2014, J ACOUST SOC AM, V135, P2166, DOI DOI 10.1121/1.4877039; Hoover EC, 2015, SIG 6 PERSPECT HEAR, V19, P12; Hopkins K, 2011, J ACOUST SOC AM, V130, P334, DOI 10.1121/1.3585848; Hopkins K, 2010, INT J AUDIOL, V49, P940, DOI 10.3109/14992027.2010.512613; HUMES LE, 2010, THE AGING AUDITORY S, P211, DOI DOI 10.1007/978-1-4419-0993-0_8; Jury MA, 2001, NEW ZEAL MED J, V114, P286; Killion MC, 2000, HEAR J, V53, P46; Krause MO, 2014, BRAIN INJURY, V28, P1473, DOI 10.3109/02699052.2014.920520; LEVITT H, 1971, J ACOUST SOC AM, V49, P467, DOI 10.1121/1.1912375; Lew HL, 2007, J REHABIL RES DEV, V44, P921, DOI 10.1682/JRRD.2007.09.0140; Mangels JA, 2002, NEUROPSYCHOLOGIA, V40, P2369, DOI 10.1016/S0028-3932(02)00084-2; McArdle RA, 2006, J AM ACAD AUDIOL, V17, P157, DOI 10.3766/jaaa.17.3.2; McArdle Rachel A, 2005, J Am Acad Audiol, V16, P726, DOI 10.3766/jaaa.16.9.9; Moore BCJ, 2006, J ACOUST SOC AM, V119, P480, DOI 10.1121/1.2139070; Moore BCJ, 2009, INT J AUDIOL, V48, P161, DOI 10.1080/14992020802475235; Musiek Frank E, 2004, J Am Acad Audiol, V15, P117, DOI 10.3766/jaaa.15.2.3; Noble W, 2013, INT J AUDIOL, V52, P409, DOI 10.3109/14992027.2013.781278; Nolle C, 2004, J NEUROTRAUM, V21, P251, DOI 10.1089/089771504322972040; O'Jile JR, 2006, ARCH CLIN NEUROPSYCH, V21, P293, DOI 10.1016/j.acn.2006.03.003; Oleksiak M, 2012, J REHABIL RES DEV, V49, P995, DOI 10.1682/JRRD.2011.01.0001; Oxenham AJ, 2009, J ACOUST SOC AM, V125, P2189, DOI 10.1121/1.3089220; Puckette M., 1996, P 2 INT COMP MUS CON, P37; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roup CM., 1998, AM J AUDIOL, V7, P55; Salthouse TA, 2000, BIOL PSYCHOL, V54, P35, DOI 10.1016/S0301-0511(00)00052-1; Saunders GH, 2015, J REHABIL RES DEV, V52, P343, DOI 10.1682/JRRD.2014.11.0275; Shah P, 1996, J EXP PSYCHOL GEN, V125, P4, DOI 10.1037/0096-3445.125.1.4; Souza PE, 2014, CHARACTERIZING SEVER; Strelcyk O, 2009, J ACOUST SOC AM, V125, P3328, DOI 10.1121/1.3097469; Tellier A, 2009, BRAIN INJURY, V23, P879, DOI 10.1080/02699050903200555; Turgeon C, 2011, EAR HEARING, V32, P667, DOI 10.1097/AUD.0b013e31821209d6; Vanderploeg RD, 2005, J INT NEUROPSYCH SOC, V11, P228, DOI 10.1017/S1355617705050289; Wang XQ, 2007, HEARING RES, V229, P81, DOI 10.1016/j.heares.2007.01.019; Wechsler D, 1945, J PSYCHOL, V19, P87, DOI 10.1080/00223980.1945.9917223; Whitmer WM, 2012, J ACOUST SOC AM, V132, P369, DOI 10.1121/1.4728200; Wilson RH, 2005, J REHABIL RES DEV, V42, P839, DOI 10.1682/JRRD.2005.01.0009; Wilson Richard H, 2003, J Am Acad Audiol, V14, P453; Won JH, 2007, JARO-J ASSOC RES OTO, V8, P384, DOI 10.1007/s10162-007-0085-8	56	22	22	2	18	AMER ACAD AUDIOLOGY	RESTON	11730 PLAZA DR, STE 300, RESTON, VA 20190 USA	1050-0545	2157-3107		J AM ACAD AUDIOL	J. Am. Acad. Audiol.	APR	2017	28	4					325	339		10.3766/jaaa.16051			15	Audiology & Speech-Language Pathology; Otorhinolaryngology	Audiology & Speech-Language Pathology; Otorhinolaryngology	ER7IA	WOS:000398983800006	28418327	Green Accepted			2021-06-18	
J	Wennberg, AMV; Savica, R; Hagen, CE; Roberts, RO; Knopman, DS; Hollman, JH; Vemuri, P; Jack, CR; Petersen, RC; Mielke, MM				Wennberg, Alexandra M. V.; Savica, Rodolfo; Hagen, Clinton E.; Roberts, Rosebud O.; Knopman, David S.; Hollman, John H.; Vemuri, Prashanthi; Jack, Clifford R., Jr.; Petersen, Ronald C.; Mielke, Michelle M.			Cerebral Amyloid Deposition Is Associated with Gait Parameters in the Mayo Clinic Study of Aging	JOURNAL OF THE AMERICAN GERIATRICS SOCIETY			English	Article						amyloid-beta; gait; neuroimaging; epidemiology; cohort	MEDICAL-RECORDS-LINKAGE; ALZHEIMERS-DISEASE; OLDER-ADULTS; COGNITIVE IMPAIRMENT; SLOW GAIT; BRAIN; EPIDEMIOLOGY; AGE; DISORDERS; PATHOLOGY	ObjectivesTo determine the cross-sectional association between cerebral amyloid-beta (A) deposition and gait. DesignCross-sectional. SettingPopulation-based cohort study in Olmsted County, MN. ParticipantsCognitively normal individuals (n = 611), aged 50 to 69 years, enrolled in the Mayo Clinic Study of Aging with concurrent PiB-PET imaging and gait assessment. Participants with a history of stroke, alcoholism, Parkinson's disease, subdural hematoma, traumatic brain injury, or normal pressure hydrocephalus were excluded. MeasurementsPiB-PET SUVR was measured in prefrontal, orbitofrontal, parietal, temporal, anterior cingulate, posterior cingulate, and motor-specific regions of interest (ROIs). Gait parameters (speed, cadence, stride length, double support time, and intra-individual stance time variability) were measured using GAITRite((R)) instrumentation. Linear regression models were adjusted for age, sex, body mass index, education, APOE epsilon 4 allele, Charlson comorbidity index, and depression. In secondary analyses, we additionally adjusted for neurodegeneration (hippocampal volume, FDG PET SUVR, and cortical thickness) in AD-associated regions. ResultsIn fully adjusted models including neuroimaging measures of neurodegeneration, higher PiB-PET SUVR across all ROIs was associated with slower gait speed (P < .05 except for the parietal ROI), lower cadence and longer double support time (P .05 except for the motor ROI), and greater stance time variability (P < .05). In sex-stratified analyses, the association between higher PiB-PET SUVR across all ROIs and measures of gait was only present among women. ConclusionPiB-PET SUVR across ROIs, independent of general measures of AD-associated neurodegeneration, is associated with poorer performance on multiple gait parameters among cognitively normal women, aged 50 to 69 years. Longitudinal studies are needed to determine whether A predicts gait decline in both women and men.	[Wennberg, Alexandra M. V.; Savica, Rodolfo; Hagen, Clinton E.; Roberts, Rosebud O.; Petersen, Ronald C.; Mielke, Michelle M.] Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA; [Savica, Rodolfo; Roberts, Rosebud O.; Knopman, David S.; Petersen, Ronald C.; Mielke, Michelle M.] Mayo Clin, Dept Neurol, Rochester, MN USA; [Hollman, John H.] Mayo Clin, Dept Phys Med & Rehabil, Rochester, MN USA; [Vemuri, Prashanthi; Jack, Clifford R., Jr.] Mayo Clin, Dept Radiol, Rochester, MN USA	Mielke, MM (corresponding author), Mayo Clin, Dept Hlth Sci Res, 200 First St SW, Rochester, MN 55905 USA.	mielke.michelle@mayo.edu	Hollman, John H./AAG-9301-2019; Jack, Clifford R/F-2508-2010	Jack, Clifford R/0000-0001-7916-622X; Hollman, John/0000-0003-4690-223X; Mielke, Michelle/0000-0001-7177-1185	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; TauRX Pharmaceuticals; Lilly Pharmaceuticals; Alzheimer's Disease Cooperative Study; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic; National Institute on Aging, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA); Michael J. Fox Foundation; National Institutes of Health/National Institute on AgingUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01 AG006786, R01 AG011378, R01 AG041851, R01 AG049704]; Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program; Rochester Epidemiology Project [R01 AG034676]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS097495] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON AGINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Aging (NIA) [U01AG006786, P50AG044170, R01AG041851, R01AG049704, R01AG034676, R01AG011378] Funding Source: NIH RePORTER	Drs. Wennberg, Savica, and Hollman, and Mr. Hagen report no disclosures. Drs. Roberts and Vemuri receive funding from the National Institutes of Health. Dr. Knopman serves on a Data Safety Monitoring Board for Lundbeck Pharmaceuticals and for the DIAN study; is an investigator in clinical trials sponsored by TauRX Pharmaceuticals, Lilly Pharmaceuticals and the Alzheimer's Disease Cooperative Study; and receives research support from the NIH. Dr. Jack has provided consulting services for Eli Lilly. He receives research funding from the National Institutes of Health, and the Alexander Family Alzheimer's Disease Research Professorship of the Mayo Clinic. Dr. Petersen serves on data monitoring committees for Pfizer, Inc., Janssen Alzheimer Immunotherapy, and is a consultant for Roche, Inc., Merck, Inc., and Genentech, Inc.; receives publishing royalties from Mild Cognitive Impairment (Oxford University Press, 2003), and receives research support from the National Institutes of Health. Dr. Mielke served as a consultant to Lysosomal Therapeutics, Inc., and receives research support from the National Institute on Aging, National Institutes of Health, and the Michael J. Fox Foundation.; This study was supported by funding from the National Institutes of Health/National Institute on Aging grants U01 AG006786, R01 AG011378, R01 AG041851, and R01 AG049704; the Robert H. and Clarice Smith and Abigail van Buren Alzheimer's Disease Research Program, and was made possible by the Rochester Epidemiology Project (R01 AG034676).	Aboutorabi A, 2016, AGING CLIN EXP RES, V28, P393, DOI 10.1007/s40520-015-0420-6; American Psychiatric Association, 1994, DIAGN STAT MAN MENT; Annweiler C, 2013, J NEURAL TRANSM, V120, P1083, DOI 10.1007/s00702-012-0926-4; Annweiler C, 2012, PANMINERVA MED, V54, P189; Annweiler C, 2014, EXP GERONTOL, V57, P256, DOI 10.1016/j.exger.2014.06.015; Annweiler C, 2013, BRAIN, V136, P859, DOI 10.1093/brain/aws373; Barnes LL, 2005, ARCH GEN PSYCHIAT, V62, P685, DOI 10.1001/archpsyc.62.6.685; BECK AT, 1988, J CONSULT CLIN PSYCH, V56, P893, DOI 10.1037/0022-006X.56.6.893; Buchman AS, 2013, NEUROLOGY, V80, P2055, DOI 10.1212/WNL.0b013e318294b462; CHARLSON ME, 1987, J CHRON DIS, V40, P373, DOI 10.1016/0021-9681(87)90171-8; Curiati PK, 2011, AM J NEURORADIOL, V32, P560, DOI 10.3174/ajnr.A2321; del Campo N, 2016, NEUROLOGY, V86, P36, DOI 10.1212/WNL.0000000000002235; Dickerson BC, 2009, CEREB CORTEX, V19, P497, DOI 10.1093/cercor/bhn113; Dominguez-del-Toro E, 2004, EUR J NEUROSCI, V20, P1945, DOI 10.1111/j.1460-9568.2004.03643.x; Ewers M, 2006, NEUROBIOL AGING, V27, P1118, DOI 10.1016/j.neurobiolaging.2005.05.019; Fritz S, 2009, J GERIATR PHYS THER, V32, P2, DOI 10.1519/00139143-200932020-00002; Hollman JH, 2011, GAIT POSTURE, V34, P111, DOI 10.1016/j.gaitpost.2011.03.024; Jack CR, 2015, JAMA NEUROL, V72, P511, DOI 10.1001/jamaneurol.2014.4821; Jack CR, 2014, NEUROLOGY, V82, P1605, DOI 10.1212/WNL.0000000000000386; Jack CR, 2012, ANN NEUROL, V71, P765, DOI 10.1002/ana.22628; Kaplan E., 1983, BOSTON NAMING TEST; Klunk WE, 2004, ANN NEUROL, V55, P306, DOI 10.1002/ana.20009; Kurland, 1992, CLIN NEUROPSYCHOL, V6, P1, DOI DOI 10.1080/13854049208401877; Landau SM, 2011, NEUROBIOL AGING, V32, P1207, DOI 10.1016/j.neurobiolaging.2009.07.002; Lowe VJ, 2009, J NUCL MED, V50, P878, DOI 10.2967/jnumed.108.058529; Michaud M, 2013, J AM MED DIR ASSOC, V14, P877, DOI 10.1016/j.jamda.2013.05.009; Mielke MM, 2013, J GERONTOL A-BIOL, V68, P929, DOI 10.1093/gerona/gls256; Mucke L, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006338; Reinders I, 2015, J AM GERIATR SOC, V63, P1615, DOI 10.1111/jgs.13524; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Rey A, 1941, ARCH PSYCHOLOGIE, V28, P286; Roberts RO, 2008, NEUROEPIDEMIOLOGY, V30, P58, DOI 10.1159/000115751; Rocca WA, 2012, MAYO CLIN PROC, V87, P1202, DOI 10.1016/j.mayocp.2012.08.012; Rosano C, 2007, J GERONTOL A-BIOL, V62, P1048, DOI 10.1093/gerona/62.9.1048; Rosso AL, 2013, J GERONTOL A-BIOL, V68, P1379, DOI 10.1093/gerona/glt089; Senjem ML, 2005, NEUROIMAGE, V26, P600, DOI 10.1016/j.neuroimage.2005.02.005; St Sauver JL, 2012, INT J EPIDEMIOL, V41, P1614, DOI 10.1093/ije/dys195; Stark AK, 2007, NEUROSCIENCE, V150, P121, DOI 10.1016/j.neuroscience.2007.06.062; Strauss E., 2006, COMPENDIUM NEUROPSYC, V3rd; Su Y, 2015, NEUROIMAGE, V107, P55, DOI 10.1016/j.neuroimage.2014.11.058; van Kan GA, 2009, J NUTR HEALTH AGING, V13, P881; Verghese J, 2006, J AM GERIATR SOC, V54, P255, DOI 10.1111/j.1532-5415.2005.00580.x; Wang HX, 2012, BEHAV BRAIN RES, V233, P237, DOI 10.1016/j.bbr.2012.05.007; Wechsler D., 1987, WECHSLER MEMORY SCAL; Wechsler D, 2008, WECHSLER ADULT INTEL, V4th; Winkler AM, 2010, NEUROIMAGE, V53, P1135, DOI 10.1016/j.neuroimage.2009.12.028; Zheng JJJ, 2011, STROKE, V42, P2086, DOI 10.1161/STROKEAHA.110.610360	47	22	22	2	5	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0002-8614	1532-5415		J AM GERIATR SOC	J. Am. Geriatr. Soc.	APR	2017	65	4					792	799		10.1111/jgs.14670			8	Geriatrics & Gerontology; Gerontology	Geriatrics & Gerontology	ES7CL	WOS:000399707100021	27869301	Green Accepted			2021-06-18	
J	Elnitsky, CA; Fisher, MP; Blevins, CL				Elnitsky, Christine A.; Fisher, Michael P.; Blevins, Cara L.			Military Service Member and Veteran Reintegration: A Conceptual Analysis, Unified Definition, and Key Domains	FRONTIERS IN PSYCHOLOGY			English	Article						veterans; military; reintegration; coping; adjustment; deployment	POSTTRAUMATIC-STRESS-DISORDER; TRAUMATIC BRAIN-INJURY; COMMUNITY REINTEGRATION; VOCATIONAL-REHABILITATION; VIETNAM VETERANS; COMBAT VETERANS; MEDICAL-CARE; HEALTH; DEPLOYMENT; TRANSITION	Returning military service members and veterans (MSMVs) may experience a variety of stress-related disorders and challenges when reintegrating from the military to the community. Facilitating the reintegration, transition, readjustment and coping, and community integration, of MSMVs is a societal priority. To date, research addressing MSMV reintegration has not identified a comprehensive definition of the term or defined the broader context within which the process of reintegration occurs although both are needed to promote valid and reliable measurement of reintegration and clarify related challenges, processes, and their impact on outcomes. Therefore, this principle-based concept analysis sought to review existing empirical reintegration measurement instruments and identify the problems and needs of MSMV reintegration to provide a unified definition of reintegration to guide future research, clinical practice, and related services. We identified 1,459 articles in the health and social sciences literature, published between 1990 and 2015, by searching multiple electronic databases. Screening of abstracts and full text reviewbased on our inclusion/exclusion criteria, yielded 117 articles for review. Two investigators used constant conceptual comparison to evaluate relevant articles independently. We examined the term reintegration and related terms (i.e., transition, readjustment, community integration) identifying trends in their use over time, analyzed the eight reintegration survey instruments, and synthesized service member and veteran self-reported challenges and needs for reintegration. More reintegration research was published during the last 5 years (n = 373) than in the previous 10 years combined (n = 130). The research suggests coping with life stresses plays an integral role in military service member and veteran post-deployment reintegration. Key domains of reintegration include individual, interpersonal, community organizations, and societal factors that may facilitate or challenge successful reintegration, and results suggest that successful coping with life stressors plays an integral role in post-deployment reintegration. Overall, the literature does not provide a comprehensive representation of reintegration among MSMVs. Although, previous research describes military service member and veteran reintegration challenges, this concept analysis provides a unified definition of the phenomenon and identifies key domains of reintegration that may broaden our understanding and guide reintegration research and practice.	[Elnitsky, Christine A.] Univ N Carolina, Coll Hlth & Human Serv, Charlotte, NC 28223 USA; [Fisher, Michael P.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Blevins, Cara L.] Univ N Carolina, Hlth Psychol Program, Charlotte, NC 28223 USA	Elnitsky, CA (corresponding author), Univ N Carolina, Coll Hlth & Human Serv, Charlotte, NC 28223 USA.	celnitsk@uncc.edu					Ackerman R., 2009, CREATING VETERAN FRI, V126; Adler A.B., 2011, DEPLOYMENT PSYCHOL, V1st ed.), P153; Adler AB, 2011, J TRAUMA STRESS, V24, P381, DOI 10.1002/jts.20665; Adler AB, 2009, J CONSULT CLIN PSYCH, V77, P928, DOI 10.1037/a0016877; Bachynski KE, 2012, INJURY PREV, V18, P405, DOI 10.1136/injuryprev-2011-040112; Baechtold M., 2011, CREATING VETERAN FRI, V126, P35; Bauman M., 2009, CREATING VETERAN FRI, V126, P15; Beder J, 2011, SOC WORK HEALTH CARE, V50, P515, DOI 10.1080/00981389.2011.554279; Blais AR, 2009, MIL PSYCHOL, V21, P365, DOI 10.1080/08995600902914727; Bloeser Katharine, 2014, US Army Med Dep J, P109; Bolton Karl, 2008, US Army Med Dep J, P38; Brown ND, 2008, AAOHN J, V56, P343, DOI 10.3928/08910162-20080801-01; Casarett D, 2008, J PAIN SYMPTOM MANAG, V35, P115, DOI 10.1016/j.jpainsymman.2007.03.008; Chandra A, 2010, PEDIATRICS, V125, P16, DOI 10.1542/peds.2009-1180; Cohan CL, 2005, J SOC PERS RELAT, V22, P777, DOI 10.1177/0265407505058680; Collins E, 2013, NURS OUTLOOK, V61, P375, DOI 10.1016/j.outlook.2013.07.004; Corbin J., 2014, BASICS QUALITATIVE R; Currie SL, 2011, J OCCUP HEALTH PSYCH, V16, P38, DOI 10.1037/a0021724; DiRamio D., 2009, NEW DIRECTIONS STUDE, V126, P81, DOI DOI 10.1002/SS.319; Drebing CE, 2007, J REHABIL RES DEV, V44, P851, DOI 10.1682/JRRD.2006.09.0123; Elnitsky CA, 2017, AM J ORTHOPSYCHIAT, V87, P114, DOI 10.1037/ort0000244; Elnitsky CA, 2013, BMC HEALTH SERV RES, V13, DOI 10.1186/1472-6963-13-498; Galvan J.L., 2014, WRITING LIT REV; Gironda RJ, 2009, REHABIL PSYCHOL, V54, P247, DOI 10.1037/a0016906; Glover-Graf N.M., 2010, REHABILITATION ED, V24, P43, DOI [https://doi.org/10.1891/088970110805029921, DOI 10.1891/088970110805029921]; Grantz K. L., 2007, TRAUMATOLOGY, V13, P46, DOI [10.1177/1534765607309944, DOI 10.1177/1534765607309944]; Greene T, 2010, MIL MED, V175, P958, DOI 10.7205/MILMED-D-10-00146; IOM (Institute of Medicine), 2010, RET HOM IQ AFGH PREL; JOHNSON DR, 1994, J TRAUMA STRESS, V7, P217, DOI 10.1002/jts.2490070205; Kaplow JB, 2013, CLIN CHILD FAM PSYCH, V16, P322, DOI 10.1007/s10567-013-0143-1; Kasprow WJ, 2007, PSYCHIAT SERV, V58, P929, DOI 10.1176/appi.ps.58.7.929; Katz LS, 2010, MIL PSYCHOL, V22, P41, DOI 10.1080/08995600903249222; Katz LS, 2007, PSYCHOL SERV, V4, P239, DOI DOI 10.1037/1541-1559.4.4.239; Kuehn BM, 2009, JAMA-J AM MED ASSOC, V301, P1111, DOI 10.1001/jama.2009.342; Kulka RA., 1990, NATL VIETNAM VETERAN; Larson GE, 2014, J REHABIL RES DEV, V51, P415, DOI 10.1682/JRRD.2013.06.0135; Levin A., 2009, PSYCHIAT NEWS; Malphurs FL, 2001, J GERONTOL A-BIOL, V56, pM666, DOI 10.1093/gerona/56.11.M666; McColl MA, 2001, ARCH PHYS MED REHAB, V82, P429, DOI 10.1053/apmr.2001.22195; Nidiffer F. D., 2010, DEV MENT HLTH LAW, V29, P1; Ortega AN, 2000, AM J PSYCHIAT, V157, P615, DOI 10.1176/appi.ajp.157.4.615; Penk W, 2009, PSYCHIATR REHABIL J, V33, P297, DOI 10.2975/33.4.2010.297.307; Penrod J, 2005, J ADV NURS, V50, P403, DOI 10.1111/j.1365-2648.2005.03405.x; Plach HL, 2013, AM J OCCUP THER, V67, P73, DOI 10.5014/ajot.2013.003871; Reistetter Timothy A, 2005, Occup Ther Int, V12, P196; Resnik L, 2012, J REHABIL RES DEV, V49, P87, DOI 10.1682/JRRD.2010.06.0107; Resnik L, 2009, J REHABIL RES DEV, V46, P469, DOI 10.1682/JRRD.2008.07.0082; Robertson HC, 2013, J EMPLOYMENT COUNS, V50, P26, DOI 10.1002/j.2161-1920.2013.00022.x; Rosenheck R, 2003, ARCH GEN PSYCHIAT, V60, P940, DOI 10.1001/archpsyc.60.9.940; Sayer NA, 2015, ADM POLICY MENT HLTH, V42, P493, DOI 10.1007/s10488-014-0564-2; Sayer NA, 2014, SOC ISS POLICY REV, V8, P33, DOI 10.1111/sipr.12001; Sayer NA, 2011, J TRAUMA STRESS, V24, P660, DOI 10.1002/jts.20706; Sayer NA, 2010, PSYCHIAT SERV, V61, P589, DOI 10.1176/ps.2010.61.6.589; Sayers SL, 2009, J CLIN PSYCHIAT, V70, P163, DOI 10.4088/JCP.07m03863; Scherrer JF, 2014, MIL MED, V179, P1391, DOI 10.7205/MILMED-D-14-00094; Schiavone V, 2014, J CONTIN HIGH EDUC, V62, P29, DOI 10.1080/07377363.2014.872007; Schlossberg N.K., 1995, COUNSELING ADULTS TR, V2nd ed.; Sporner ML, 2009, DISABIL REHABIL, V31, P410, DOI 10.1080/09638280802030923; Tanielian T., 2014, READY SERVE COMMUNIT; Taylor LA, 2003, NEUROPSYCHOL REHABIL, V13, P165, DOI 10.1080/09602010244000336; Theiss JA, 2013, J COMMUN, V63, P1109, DOI 10.1111/jcom.12059; U.S. Department of Veterans Affairs [DVA], 2010, VHA HDB, V1172; U.S. Government Accountability Office [GAO], 2014, MIL VET SUPP VA DOD; Wehman P, 2009, J REHABIL RES DEV, V46, P909, DOI 10.1682/JRRD.2008.08.0105; Wilcox SL, 2015, WORK, V50, P73, DOI 10.3233/WOR-141935; WILLER B, 1994, AM J PHYS MED REHAB, V73, P103; WOLFE J, 1993, J TRAUMA STRESS, V6, P179, DOI 10.1002/jts.2490060203	67	22	22	0	11	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	MAR 14	2017	8								369	10.3389/fpsyg.2017.00369			14	Psychology, Multidisciplinary	Psychology	EN8WS	WOS:000396281200001	28352240	DOAJ Gold, Green Published			2021-06-18	
J	Khan, F; Amatya, B; Galea, MP; Gonzenbach, R; Kesselring, J				Khan, Fary; Amatya, Bhasker; Galea, Mary P.; Gonzenbach, Roman; Kesselring, Jurg			Neurorehabilitation: applied neuroplasticity	JOURNAL OF NEUROLOGY			English	Article						Neurological disorder; Rehabilitation; Neuroplasticity; Disability	MULTIPLE-SCLEROSIS; BRAIN PLASTICITY; REHABILITATION; STROKE; DISABILITY; NEUROLOGY; PROGRAM; INJURY	The prevalence of disability due to neurological conditions is escalating worldwide. Neurological disorders have significant disability-burden with long-term functional and psychosocial issues, requiring specialized rehabilitation services for comprehensive management, especially treatments tapping into brain recovery 'neuroplastic' processes. Neurorehabilitation is interdisciplinary and cross-sectorial, requiring coordinated effort of diverse sectors, professions, patients and community to manage complex condition-related disability. This review provides evidence for a range of neurorehabilitation interventions for four common neurological conditions: multiple sclerosis (MS), stroke, traumatic brain injury and Parkinson's disease using the Grade of Recommendation, Assessment, Development and Evaluation tool for quality of evidence. Although, existing best-evidence for many interventions is still sparse, the overall findings suggest 'strong' evidence for physical therapy and psychological intervention for improved patient outcomes; and. 'moderate' evidence for multidisciplinary rehabilitation for longer term gains at the levels of activity (disability) and participation in MS and stroke population. The effect of other rehabilitation interventions is inconclusive, due to a paucity of methodologically robust studies. More research is needed to improve evidence-base for many promising rehabilitation interventions.	[Khan, Fary; Amatya, Bhasker; Galea, Mary P.] Royal Melbourne Hosp, Dept Rehabil Med, 34-54 Poplar Rd, Parkville, Vic 3052, Australia; [Khan, Fary; Amatya, Bhasker; Galea, Mary P.] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Grattan St, Parkville, Vic, Australia; [Khan, Fary] Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia; [Gonzenbach, Roman; Kesselring, Jurg] Rehabil Ctr, Dept Neurol & Neurorehabil, Valens, Switzerland	Khan, F (corresponding author), Royal Melbourne Hosp, Dept Rehabil Med, 34-54 Poplar Rd, Parkville, Vic 3052, Australia.; Khan, F (corresponding author), Univ Melbourne, Dept Med, Royal Melbourne Hosp, Grattan St, Parkville, Vic, Australia.; Khan, F (corresponding author), Monash Univ, Sch Publ Hlth & Prevent Med, Melbourne, Vic, Australia.	fary.khan@mh.org.au	Kesselring, Jurg/AAN-5783-2020; Amatya, Bhasker/E-1062-2017; Galea, Mary/F-4242-2010	Amatya, Bhasker/0000-0003-4793-1104; Galea, Mary/0000-0003-0045-7978			American Psychological Association, 2016, ROAD RES; Aziz NA, 2008, COCHRANE DB SYST REV, V2; Balshem H, 2011, J CLIN EPIDEMIOL, V64, P401, DOI 10.1016/j.jclinepi.2010.07.015; Barclay-Goddard R. E., 2011, COCHRANE DB SYST REV, V5; Bennett M, 2004, COCHRANE DB SYST REV, V1; Bennett M.H., 2004, COCHRANE DB SYST REV, V4; BOURBONNAIS D, 1989, AM J OCCUP THER, V43, P313, DOI 10.5014/ajot.43.5.313; Bowen A, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003586.pub3; BRADT J, 2010, COCHRANE DB SYST REV, V7, DOI DOI 10.1002/14651858.CD006787.PUB2; Braun K, 2011, DEV MED CHILD NEUROL, V53, P14, DOI 10.1111/j.1469-8749.2011.04056.x; Burke D, 1988, Adv Neurol, V47, P401; Cheng D, 2015, COCHRANE DATABASE SY, V6; Chung CSY, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008391.pub2; Corbetta D, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004433.pub3; Cramer SC, 2011, BRAIN, V134, P1591, DOI 10.1093/brain/awr039; das Nair R, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008754.pub2; De Wit L, 2005, STROKE, V36, P1977, DOI 10.1161/01.STR.0000177871.59003.e3; Demetrios M, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009689.pub2; Den Hertog HM, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001247.pub2; DIETZ V, 1983, EXP NEUROL, V79, P680, DOI 10.1016/0014-4886(83)90032-8; Dixon L, 2007, COCHRANE DB SYST REV, V3; Dobkin BH, 2013, CURR OPIN NEUROL, V26, P602, DOI 10.1097/WCO.0000000000000026; Elbers RG, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010925.pub2; Elsner B., 2013, COCHRANE DB SYST REV, V6; Elsner B, 2015, COCHRANE DB SYST REV, V5; Elsner B, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009645.pub2; English C, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007513.pub2; Farinotti M, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004192.pub3; Fletcher-Smith JC, 2013, COCHRANE DB SYST REV, V6; Frasca Diana, 2013, Front Hum Neurosci, V7, P31, DOI 10.3389/fnhum.2013.00031; Freedman MS, 2011, NEUROLOGY, V76, pS26, DOI 10.1212/WNL.0b013e318205051d; French B, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006073.pub2; Freund P, 2013, LANCET NEUROL, V12, P873, DOI 10.1016/S1474-4422(13)70146-7; Galea M, 2016, J REHABIL MED, V48, P522, DOI 10.2340/16501977-2087; George S, 2014, COCHRANE DB SYST REV, V2; Guo TZ, 2014, J PAIN, V15, P1033, DOI 10.1016/j.jpain.2014.07.004; Hao ZL, 2013, SAO PAULO MED J, V131, P440, DOI [10.1590/1516-3180.20131316T2, 10.1002/14651858.CD008862.pub2]; Hassett LM, 2008, COCHRANE DB SYST REV, V2; Heine M, 2015, COCHRANE DB SYST REV, V9, DOI DOI 10.1002/14651858.CD009956.PUB2; Herd CP, 2012, COCHRANE DB SYST REV, V8; Herd CP, 2012, COCHRANE DB SYST REV, V8; Jagannath VA, 2010, COCHRANE DB SYST REV, V12; Johansson BB, 2000, STROKE, V31, P223, DOI 10.1161/01.STR.31.1.223; Khan F, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006036.pub2; Khan F, 2015, EUR J PHYS REHAB MED, V51, P311; Khan F, 2015, COCHRANE DB SYST REV, V4; Khan F, 2010, COCHRANE DB SYST REV, V10; Khan F, 2015, PHYS MED REHABIL INT, V2, P1070; Khan F, 2009, COCHRANE DB SYST REV, V1; Khan F., 2013, INNOV RES CHEM, V1, P1, DOI DOI 10.1111/IRC.V1I1.17; Khan F, 2016, J REHABIL MED, V48, P417, DOI 10.2340/16501977-2081; Khan F, 2010, J REHABIL MED, V42, P708, DOI 10.2340/16501977-0592; Khedr EM, 2005, NEUROLOGY, V65, P466, DOI 10.1212/01.wnl.0000173067.84247.36; Kolb B, 2012, DEV PSYCHOBIOL, V54, P311, DOI 10.1002/dev.20515; Kou ZF, 2014, NEURAL REGEN RES, V9, P693, DOI 10.4103/1673-5374.131568; Krakauer JW, 2012, NEUROREHAB NEURAL RE, V26, P923, DOI 10.1177/1545968312440745; Krakauer JW, 2005, SEMIN NEUROL, V25, P384, DOI 10.1055/s-2005-923533; Lane-Brown A, 2009, COCHRANE DB SYST REV, V2; Laver KE, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD010255.pub2; Laver KE, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD008349.pub2; Loetscher T, 2013, COCHRANE DB SYST REV, V5; Lombardi F, 2002, COCHRANE DB SYST REV, V2, DOI DOI 10.1002/14651858.CD001427; Mehrholz J, 2007, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006185.pub2; Mehrholz J, 2011, COCHRANE DB SYST REV, V1; Mehrholz J, 2015, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD007830.pub4; Mehrholz J, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002840.pub3; Mehrholz J, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006876.pub3; Melzack R, 1989, CHALLENGE PAIN; MRC (Med. Res. Counc.), 2000, FRAM DEV EV RCTS COM; Nair R. D., 2007, COCHRANE DB SYST REV, V3; Pajaro-Blazquez M, 2013, AM J PHYS MED REH S1, V92, pe1; Pang TYC, 2013, NEUROPHARMACOLOGY, V64, P515, DOI 10.1016/j.neuropharm.2012.06.029; Perel P, 2006, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD001530.pub2; Plautz EJ, 2000, NEUROBIOL LEARN MEM, V74, P27, DOI 10.1006/nlme.1999.3934; Pollock A, 2014, COCHRANE DB SYST REV, V5; Prokopenko M, 2009, HFSP J, V3, P287, DOI 10.1080/19552068.2009.9635816; Qiu TM, 2014, J NEUROL NEUROSUR PS, V85, P99, DOI 10.1136/jnnp-2013-304956; Rietberg MB, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003980.pub2; Rosti-Otajarvi EM, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009131.pub3; Royal College of Physicians National Council for Palliative Care British Society of Rehabilitation Medicine, 2008, CONCISE GUIDANCE GOO, V10; Saunders DH, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD003316.pub5; Saxena M, 2014, COCHRANE DB SYST REV, V8; SCHIERHOUT G, 2000, COCHRANE DB SYST REV, V2; Rabert MS, 2012, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD009097.pub2; Soo C, 2007, COCHRANE DB SYST REV, V3; States RA, 2009, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006075.pub2; Steultjens EM, 2003, COCHRANE DB SYST REV, DOI DOI 10.1002/14651858.CD003608; Stifani N, 2014, FRONT CELL NEUROSCI, V8, P1, DOI 10.3389/fncel.2014.00293; Thieme H, 2012, COCHRANE DB SYST REV, V3, DOI DOI 10.1002/14651858.CD008449.PUB2; Thomson P, 2006, CAMBRIDGE INTRO LIT, P1, DOI [10.2277/ 0521542510, 10.1002/14651858.CD004431.pub2]; Tomlinson CL, 2014, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002815.pub2; Tomlinson CL, 2013, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD002817.pub4; Turner-Stokes L, 2005, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD004170.pub2; Turner-Stokes L, 2008, J REHABIL MED, V40, P691, DOI 10.2340/16501977-0265; Turner-Stokes L, 2008, CLIN MED, V8, P186, DOI 10.7861/clinmedicine.8-2-186; Turner-Stokes L, 2007, CLIN MED, V7, P129, DOI 10.7861/clinmedicine.7-2-129; van der Putten JJMF, 1999, J NEUROL NEUROSUR PS, V66, P480, DOI 10.1136/jnnp.66.4.480; WHO, 2011, WORLD REPORT ON DISABILITY, P1; Winter J, 2011, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006609.pub2; World Health Organization, 2001, INT CLASS FUNCT DIS; World Health Organization, 2006, NEUR DIS PUBL HLTH C; Xiao Y, 2012, COCHRANE DB SYST REV, V5; Yin D, 2015, INT J NEUROREHABILIT, V2, P151	103	22	23	2	29	SPRINGER HEIDELBERG	HEIDELBERG	TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY	0340-5354	1432-1459		J NEUROL	J. Neurol.	MAR	2017	264	3					603	615		10.1007/s00415-016-8307-9			13	Clinical Neurology	Neurosciences & Neurology	EN6RV	WOS:000396132000028	27778158				2021-06-18	
J	Zhang, L; Li, Z; Feng, DX; Shen, HT; Tian, XD; Li, HY; Wang, Z; Chen, G				Zhang, Li; Li, Zhen; Feng, Dongxia; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang			Involvement of Nox2 and Nox4 NADPH oxidases in early brain injury after subarachnoid hemorrhage	FREE RADICAL RESEARCH			English	Article						Subarachnoid hemorrhage; early brain injury; Nox2; Nox4; gp91ds-tat; GKT137831; apoptosis; rat	NAD(P)H OXIDASE; HYPERBARIC-OXYGEN; OXIDATIVE STRESS; ANGIOTENSIN-II; RAT MODEL; INHIBITION; EXPRESSION; BARRIER; STROKE	Oxidative stress is responsible for a poor prognosis of subarachnoid hemorrhage (SAH) patients. Nox2 has been shown to participate in SAH-induced early brain injury (EBI). Nox4 is another major subtype of Nox family widely expressed in central nervous system (CNS). Here, we investigated the role of Nox4 and whether there was a synergistic effect of Nox2 and Nox4 in SAH-induced EBI. Clinical brain biopsies of four patients with traumatic brain injury (TBI) and perihematomal brain tissue from six subjects with SAH were examined. Gp91ds-tat (a specific inhibitor of Nox2), GKT137831 (a specific inhibitor of Nox4), and apocynin (a non-specific Nox inhibitor) were used to test the role of Nox2 and Nox4. The protein levels of Nox2 and Nox4 were elevated in rat neurons and astrocytes at 12h after SAH, and in cultured brain microvascular endothelial cells at 24h after exposure to OxyHb. Similarly, there were higher Nox2 and Nox4 protein levels in perihematomal neurons and astrocytes in SAH patients than that in brain tissue from subjects with TBI. In SAH rat model, gp91ds-tat and GKT137831 could reduce SAH-induced neuronal death and degeneration, whereas apocynin did not induce a more intense neuroprotection. Consistently, in in vitro SAH model, siRNA-mediated silencing of Nox2 and Nox4 suppressed the OxyHb-induced neuronal apoptosis, whereas Nox2 and Nox4 co-knockdown also did not show a remarkable overlay effect. In conclusion, Nox4 should contribute to the pathological processes in SAH-induced EBI, and there was not an overlay effect of Nox2 inhibition and Nox4 inhibition on preventing SAH-induced EBI.	[Zhang, Li; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China; [Zhang, Li; Shen, Haitao; Tian, Xiaodi; Li, Haiying; Wang, Zhong; Chen, Gang] Soochow Univ, Affiliated Hosp 1, Brain & Nerve Res Lab, Suzhou, Jiangsu, Peoples R China; [Li, Zhen] Jingjiang Peoples Hosp, Dept Neurosurg, Jingjiang, Jiangsu, Peoples R China; [Feng, Dongxia] Scott & White Clin Temple, Temple, TX USA	Wang, Z; Chen, G (corresponding author), Soochow Univ, Affiliated Hosp 1, Dept Neurosurg, 188 Shizi St, Suzhou 215006, Jiangsu, Peoples R China.	lhy1015@suda.edu.cn; nju_neurosurgery@163.com			Suzhou Key Medical Center [Szzx201501]; National Natural Science Foundation of ChinaNational Natural Science Foundation of China (NSFC) [81571115, 81422013, 81471196]; Scientific Department of Jiangsu Province [BL2014045]; Suzhou Government [SZS201413, KJXW2015041, LCZX201601, SYS201608]; Zhangjiagang Government [ZKS1511]; Jiangsu Province [16KJB320008]	This work was supported by Suzhou Key Medical Center [Szzx201501], grants from the National Natural Science Foundation of China [No. 81571115, 81422013, and 81471196], Scientific Department of Jiangsu Province [No. BL2014045], Suzhou Government [No. SZS201413, KJXW2015041, LCZX201601, and SYS201608], Zhangjiagang Government [No. ZKS1511] Jiangsu Province [No. 16KJB320008].	Brown DI, 2009, FREE RADICAL BIO MED, V47, P1239, DOI 10.1016/j.freeradbiomed.2009.07.023; Byrne JA, 2003, CIRC RES, V93, P802, DOI 10.1161/01.RES.0000099504.30207.F5; Cahill WJ, 2006, J CEREBR BLOOD F MET, V26, P1341, DOI 10.1038/sj.jcbfm.9600283; Cairns B, 2012, CURR DRUG TARGETS, V13, P199, DOI 10.2174/138945012799201676; Cetas JS, 2015, TRANSL STROKE RES, V6, P140, DOI 10.1007/s12975-014-0378-2; Chen H, 2009, J CEREBR BLOOD F MET, V29, P1262, DOI 10.1038/jcbfm.2009.47; Chen Y, 2017, MOL NEUROBIOL, V54, P392, DOI 10.1007/s12035-015-9629-9; Cheng CJ, 2015, TRANSL STROKE RES, V6, P446, DOI 10.1007/s12975-015-0426-6; Cheng GJ, 2001, GENE, V269, P131, DOI 10.1016/S0378-1119(01)00449-8; Cui YH, 2016, MOL NEUROBIOL, V53, P3646, DOI 10.1007/s12035-015-9304-1; Dang BQ, 2015, CRIT CARE MED, V43, pE369, DOI 10.1097/CCM.0000000000001146; Deliyanti D, 2015, J NEUROINFLAMM, V12, DOI 10.1186/s12974-015-0363-z; DiNapoli VA, 2008, NEUROBIOL AGING, V29, P753, DOI 10.1016/j.neurobiolaging.2006.12.007; Ersahin M, 2011, ACTA NEUROCHIR, V153, P333, DOI 10.1007/s00701-010-0853-9; Etminan N, 2015, TRANSL STROKE RES, V6, P167, DOI 10.1007/s12975-015-0398-6; Guresir E, 2015, TRANSL STROKE RES, V6, P242, DOI 10.1007/s12975-015-0392-z; Hasegawa Y, 2015, TRANSL STROKE RES, V6, P458, DOI 10.1007/s12975-015-0423-9; Higashi M, 2003, CIRC RES, V93, P767, DOI 10.1161/01.RES.0000096650.91688.28; Huang W, 2016, BIOMED RES INT, V2016, DOI 10.1155/2016/8263926; Kusaka I, 2004, AM J PHYSIOL-HEART C, V286, pH2442, DOI 10.1152/ajpheart.01169.2003; Lapchak PA, 2017, TRANSL STROKE RES, V8, P307, DOI 10.1007/s12975-016-0518-y; Li HY, 2014, TRANSL STROKE RES, V5, P618, DOI 10.1007/s12975-014-0354-x; Liu SM, 2007, CAN J NEUROL SCI, V34, P356, DOI 10.1017/S031716710000682X; Lu XH, 2010, AM J PHYSIOL-LUNG C, V299, pL559, DOI 10.1152/ajplung.00090.2010; Ostrowski RP, 2006, ACTA NEUROCHIR SUPPL, V96, P188; Ostrowski RP, 2006, STROKE, V37, P1314, DOI 10.1161/01.STR.0000217310.88450.c3; Pang JW, 2017, TRANSL STROKE RES, V8, P257, DOI 10.1007/s12975-016-0507-1; Ray R, 2011, ARTERIOSCL THROM VAS, V31, P1368, DOI 10.1161/ATVBAHA.110.219238; Raz L, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0027039; Reinehr R, 2007, GLIA, V55, P758, DOI 10.1002/glia.20504; Schmued LC, 2000, BRAIN RES, V874, P123, DOI 10.1016/S0006-8993(00)02513-0; Serrano F, 2003, BRAIN RES, V988, P193, DOI 10.1016/S0006-8993(03)03364-X; Shen HT, 2015, STROKE, V46, P2607, DOI 10.1161/STROKEAHA.115.009729; Shin HK, 2002, J CEREBR BLOOD F MET, V22, P869, DOI 10.1097/00004647-200207000-00012; Song JP, 2015, TRANSL STROKE RES, V6, P290, DOI 10.1007/s12975-015-0396-8; Song SX, 2013, MOL MED REP, V7, P327, DOI 10.3892/mmr.2012.1147; Suzuki H, 2015, TRANSL STROKE RES, V6, P1, DOI 10.1007/s12975-014-0380-8; Tong X, 2009, FREE RADICAL BIO MED, V47, P1578, DOI 10.1016/j.freeradbiomed.2009.08.026; Vallet P, 2005, NEUROSCIENCE, V132, P233, DOI 10.1016/j.neuroscience.2004.12.038; Wang Y, 2015, MOL NEUROBIOL, V52, P64, DOI 10.1007/s12035-014-8846-y; Won SJ, 2011, ANN NEUROL, V70, P583, DOI 10.1002/ana.22538; Yang Y, 2017, CURR DRUG DELIV, V14, P832, DOI 10.2174/1567201813666161025115531; ZHANG L, 2016, OXID MED CELL LONGEV, V2016, DOI DOI 10.1155/2016/5026984; Zhang QG, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0034504	44	22	23	3	14	TAYLOR & FRANCIS LTD	ABINGDON	2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND	1071-5762	1029-2470		FREE RADICAL RES	Free Radic. Res.	MAR	2017	51	3					316	328		10.1080/10715762.2017.1311015			13	Biochemistry & Molecular Biology	Biochemistry & Molecular Biology	ES7NM	WOS:000399736900007	28330417				2021-06-18	
J	Zhang, YL; Zhang, ZG; Chopp, M; Meng, YL; Zhang, L; Mahmood, A; Xiong, Y				Zhang, Yanlu; Zhang, Zheng Gang; Chopp, Michael; Meng, Yuling; Zhang, Li; Mahmood, Asim; Xiong, Ye			Treatment of traumatic brain injury in rats with N-acetyl-seryl-aspartyl-lysyl-proline	JOURNAL OF NEUROSURGERY			English	Article						angiogenesis; N-acetyl-seryl-aspartyl-lysyl-proline; functional outcome; controlled cortical impact; neurogenesis; traumatic brain injury	ANGIOTENSIN-CONVERTING ENZYME; FIBRINOGEN SIGNAL-TRANSDUCTION; CENTRAL-NERVOUS-SYSTEM; ANGIOGENESIS IN-VITRO; MARROW STROMAL CELLS; STEM-CELL; ALZHEIMERS-DISEASE; HYPERTENSIVE-RATS; SPATIAL MEMORY; ADULT BRAIN	OBJECTIVE The authors' previous studies have suggested that thymosin beta 4 (T beta 4), a major actin-sequestering protein, improves functional recovery after neural injury. N-acetyl-seryl-aspartyl-lysyl-proline (AcSDKP) is an active peptide fragment of T beta 4. Its effect as a treatment of traumatic brain injury (TBI) has not been investigated. Thus, this study was designed to determine whether AcSDKP treatment improves functional recovery in rats after TBI. METHODS Young adult male Wistar rats were randomly divided into the following groups: 1) sham group (no injury); 2) TBI + vehicle group (0.01 N acetic acid); and 3) TBI + AcSDKP (0.8 mg/kg/day). TBI was induced by controlled cortical impact over the left parietal cortex. AcSDKP or vehicle was administered subcutaneously starting 1 hour postinjury and continuously for 3 days using an osmotic minipump. Sensorimotor function and spatial learning were assessed using a modified Neurological Severity Score and Morris water maze tests, respectively. Some of the animals were euthanized 1 day after injury, and their brains were processed for measurement of fibrin accumulation and neuroinflammation signaling pathways. The remaining animals were euthanized 35 days after injury, and brain sections were processed for measurement of lesion volume, hippocampal cell loss, angiogenesis, neurogenesis, and dendritic spine remodeling. RESULTS Compared with vehicle treatment, AcSDKP treatment initiated 1 hour postinjury significantly improved sensorimotor functional recovery (Days 7-35, p < 0.05) and spatial learning (Days 33-35, p < 0.05), reduced cortical lesion volume, and hippocampal neuronal cell loss, reduced fibrin accumulation and activation of microglia/macrophages, enhanced angiogenesis and neurogenesis, and increased the number of dendritic spines in the injured brain (p < 0.05). AcSDKP treatment also significantly inhibited the transforming growth factor beta 1/nuclear factor-kappa B signaling pathway. CONCLUSIONS AcSDKP treatment initiated 1 hour postinjury provides neuroprotection and neurorestoration after TBI, indicating that this small tetrapeptide has promising therapeutic potential for treatment of TBI. Further investigation of the optimal dose and therapeutic window of AcSDKP treatment for TBI and the associated underlying mechanisms is therefore warranted.	[Zhang, Yanlu; Meng, Yuling; Mahmood, Asim; Xiong, Ye] Henry Ford Hosp, Dept Neurosurg, Detroit, MI 48202 USA; [Zhang, Zheng Gang; Chopp, Michael; Zhang, Li] Henry Ford Hosp, Dept Neurol, Detroit, MI 48202 USA; [Chopp, Michael] Oakland Univ, Dept Phys, Rochester, MI USA	Xiong, Y (corresponding author), Henry Ford Hlth Syst, Dept Neurosurg, E&R Bldg,Rm 3096,2799 West Grand Blvd, Detroit, MI 48202 USA.	yxiong1@hfhs.org		Xiong, Ye/0000-0001-9770-6031	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01 NS 079612]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS079612] Funding Source: NIH RePORTER	This work was partially supported by National Institutes of Health Grant R01 NS 079612 (to Zheng Gang Zhang).	Acosta SA, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0090953; Adams RA, 2007, CURR MED CHEM, V14, P2925, DOI 10.2174/092986707782360015; Akassoglou K, 2002, NEURON, V33, P861, DOI 10.1016/S0896-6273(02)00617-7; Azizi M, 1997, HYPERTENSION, V30, P1015, DOI 10.1161/01.HYP.30.5.1015; Azizi M, 1999, HYPERTENSION, V33, P879, DOI 10.1161/01.HYP.33.3.879; Azizi M, 1996, J CLIN INVEST, V97, P839, DOI 10.1172/JCI118484; Baldwin AS, 1996, ANNU REV IMMUNOL, V14, P649, DOI 10.1146/annurev.immunol.14.1.649; Baskin YK, 2003, J NEUROSCI METH, V129, P87, DOI 10.1016/S0165-0270(03)00212-7; Beschorner R, 2007, HISTOL HISTOPATHOL, V22, P515, DOI 10.14670/HH-22.515; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Capilla-Gonzalez V, 2015, ADV EXP MED BIOL, V853, P1, DOI 10.1007/978-3-319-16537-0_1; Castoldi G, 2013, AM J NEPHROL, V37, P65, DOI 10.1159/000346116; Castoldi G, 2010, CLIN SCI, V118, P211, DOI 10.1042/CS20090234; Cavasin Maria A, 2006, Am J Cardiovasc Drugs, V6, P305, DOI 10.2165/00129784-200606050-00003; Centers for Disease Control and Prevention, 2014, C TRAUM BRAIN INJ US; Chen JL, 2001, STROKE, V32, P2682, DOI 10.1161/hs1101.098367; Choi SH, 2006, J NEUROSCI METH, V156, P182, DOI 10.1016/j.jneumeth.2006.03.002; Christie KJ, 2013, FRONT CELL NEUROSCI, V6, DOI 10.3389/fncel.2012.00070; Cortes-Canteli M, 2012, J ALZHEIMERS DIS, V32, P599, DOI 10.3233/JAD-2012-120820; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Dobolyi A, 2012, INT J MOL SCI, V13, P8219, DOI 10.3390/ijms13078219; Fawcett JW, 1999, BRAIN RES BULL, V49, P377, DOI 10.1016/S0361-9230(99)00072-6; Frick KM, 2003, NEUROBIOL AGING, V24, P615, DOI 10.1016/S0197-4580(02)00138-0; Gage FH, 2002, J NEUROSCI, V22, P612, DOI 10.1523/JNEUROSCI.22-03-00612.2002; Gaudron S, 1999, STEM CELLS, V17, P100, DOI 10.1002/stem.170100; Ghashghaei HT, 2007, NAT REV NEUROSCI, V8, P141, DOI 10.1038/nrn2074; GRILLON C, 1990, FEBS LETT, V274, P30, DOI 10.1016/0014-5793(90)81322-F; Harari OA, 2010, ANN NY ACAD SCI, V1207, P32, DOI 10.1111/j.1749-6632.2010.05735.x; Harford-Wright E, 2010, NEUROSCI LETT, V481, P26, DOI 10.1016/j.neulet.2010.06.044; HAYES RL, 1992, J NEUROTRAUM, V9, pS173; Hernandez-Ontiveros DG, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00030; HOLNESS CL, 1993, BLOOD, V81, P1607; Jayakumar AR, 2014, J NEUROTRAUM, V31, P1249, DOI 10.1089/neu.2013.3169; Junot C, 1999, J PHARMACOL EXP THER, V289, P1257; Kanasaki K, 2014, FRONT PHARMACOL, V5, DOI 10.3389/fphar.2014.00070; Kim DH, 2015, NEUROSCIENCE, V310, P51, DOI 10.1016/j.neuroscience.2015.09.017; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LENFANT M, 1989, P NATL ACAD SCI USA, V86, P779, DOI 10.1073/pnas.86.3.779; Li L, 2012, J CEREBR BLOOD F MET, V32, P2023, DOI 10.1038/jcbfm.2012.106; Li LA, 2011, J NEUROTRAUM, V28, P535, DOI 10.1089/neu.2010.1619; LINZ W, 1986, J CARDIOVASC PHARM, V8, pS91, DOI 10.1097/00005344-198600101-00017; LIU HM, 1988, FORENSIC SCI INT, V38, P285, DOI 10.1016/0379-0738(88)90174-0; Liu JM, 2003, BLOOD, V101, P3014, DOI 10.1182/blood-2002-07-2315; LOGAN A, 1994, EUR J NEUROSCI, V6, P355, DOI 10.1111/j.1460-9568.1994.tb00278.x; Lu DY, 2007, NEUROSURGERY, V61, P596, DOI 10.1227/01.NEU.0000290908.38438.B2; Mahmood A, 2007, NEUROSURGERY, V60, P546, DOI 10.1227/01.NEU.0000255346.25959.99; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; Menon DK, 2009, CRIT CARE MED, V37, pS129, DOI 10.1097/CCM.0b013e3181921225; MONPEZAT JP, 1989, EXP HEMATOL, V17, P1077; Morgan R, 2007, NEUROL RES, V29, P375, DOI 10.1179/016164107X204693; Namas R, 2009, LIBYAN J MED, V4, P97, DOI 10.4176/090325; Narayan RK, 2002, J NEUROTRAUM, V19, P503, DOI 10.1089/089771502753754037; O'Caoimh R, 2014, J ALZHEIMERS DIS, V40, P595, DOI 10.3233/JAD-131694; Paul J, 2007, J EXP MED, V204, P1999, DOI 10.1084/jem.20070304; Peng HM, 2001, HYPERTENSION, V37, P794, DOI 10.1161/01.HYP.37.2.794; Porritt MJ, 2010, J CEREBR BLOOD F MET, V30, P1520, DOI 10.1038/jcbfm.2010.57; Preston E, 2001, J NEUROTRAUM, V18, P83, DOI 10.1089/089771501750055794; Richardson RM, 2007, NEUROSURG CLIN N AM, V18, P169, DOI 10.1016/j.nec.2006.10.007; Rotheneichner P, 2013, EPILEPSIA, V54, P40, DOI 10.1111/epi.12274; ROUSSEAU A, 1995, J BIOL CHEM, V270, P3656, DOI 10.1074/jbc.270.8.3656; Ryu JK, 2009, J THROMB HAEMOST, V7, P151, DOI 10.1111/j.1538-7836.2009.03438.x; Schachtrup C, 2007, P NATL ACAD SCI USA, V104, P11814, DOI 10.1073/pnas.0704045104; Schachtrup C, 2010, J NEUROSCI, V30, P5843, DOI 10.1523/JNEUROSCI.0137-10.2010; Schnell L, 1999, EUR J NEUROSCI, V11, P3648, DOI 10.1046/j.1460-9568.1999.00792.x; Shibuya K, 2005, DIABETES, V54, P838, DOI 10.2337/diabetes.54.3.838; Skolnick BE, 2014, NEW ENGL J MED, V371, P2467, DOI 10.1056/NEJMoa1411090; Smith DH, 1997, J NEUROTRAUM, V14, P715, DOI 10.1089/neu.1997.14.715; STIER CT, 1989, HYPERTENSION, V13, P115, DOI 10.1161/01.HYP.13.2.115; SWANSON LW, 1980, NEUROENDOCRINOLOGY, V31, P410, DOI 10.1159/000123111; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Szmydynger-Chodobska J, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0079328; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Taupin P, 2006, CURR OPIN MOL THER, V8, P225; Teng H, 2008, J CEREBR BLOOD F MET, V28, P764, DOI 10.1038/sj.jcbfm.9600573; Thal SC, 2014, ARCH MED RES, V45, P698, DOI 10.1016/j.arcmed.2014.11.006; Vink R, 2009, NEUROTHERAPEUTICS, V6, P28, DOI 10.1016/j.nurt.2008.10.036; Wang DH, 2004, AM J PHYSIOL-HEART C, V287, pH2099, DOI 10.1152/ajpheart.00592.2004; WERNER C, 1991, STROKE, V22, P910, DOI 10.1161/01.STR.22.7.910; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Worou ME, 2015, HYPERTENSION, V66, P816, DOI 10.1161/HYPERTENSIONAHA.115.05970; Xiong Y, 2013, NAT REV NEUROSCI, V14, P128, DOI 10.1038/nrn3407; Xiong Y, 2011, TRANSL STROKE RES, V2, P619, DOI 10.1007/s12975-011-0120-2; Xiong Y, 2012, J NEUROSURG, V116, P1081, DOI 10.3171/2012.1.JNS111729; Xiong Y, 2011, J NEUROSURG, V114, P102, DOI 10.3171/2010.4.JNS10118; Xiong Y, 2010, CURR OPIN INVEST DR, V11, P298; Zhang J, 2009, NEUROSCIENCE, V164, P1887, DOI 10.1016/j.neuroscience.2009.09.054; Zhang L, 2014, STROKE, V45, P1108, DOI 10.1161/STROKEAHA.113.004399; Zhang R, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-106; Zhang YL, 2015, J NEUROSURG, V122, P856, DOI 10.3171/2014.11.JNS14770; Zhang YL, 2015, J NEUROSURG, V122, P843, DOI 10.3171/2014.11.JNS14271; Zhang YL, 2013, J NEUROSURG, V118, P1343, DOI 10.3171/2013.3.JNS122061; Zhao CM, 2008, CELL, V132, P645, DOI 10.1016/j.cell.2008.01.033; Zheng WM, 2013, J NEUROTRAUM, V30, P1872, DOI 10.1089/neu.2010.1579	94	22	24	4	10	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	MAR	2017	126	3					782	795		10.3171/2016.3.JNS152699			14	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EL9FT	WOS:000394926200012	28245754	Green Accepted			2021-06-18	
J	de Jongh, MAC; Kruithof, N; Gosens, T; van de Ree, CLP; de Munter, L; Brouwers, L; Polinder, S; Lansink, KWW				de Jongh, M. A. C.; Kruithof, N.; Gosens, T.; van de Ree, C. L. P.; de Munter, L.; Brouwers, L.; Polinder, S.; Lansink, K. W. W.		BIOS-Grp	Prevalence, recovery patterns and predictors of quality of life and costs after non-fatal injury: the Brabant Injury Outcome Surveillance (BIOS) study	INJURY PREVENTION			English	Article							TRAUMATIC BRAIN-INJURY; POSTTRAUMATIC-STRESS-DISORDER; MAJOR TRAUMA; SEVERITY SCORE; HEALTH-STATUS; HEAD-INJURY; UK BURDEN; SCALE; VALIDATION; FRAILTY	Introduction Trauma is a major public health problem worldwide that leads to high medical and societal costs. Overall, improved understanding of the full spectrum of the societal impact and burden of injury is needed. The main purpose of the Brabant Injury Outcome Surveillance (BIOS) study is to provide insight into prevalence, predictors and recovery patterns of short-term and long-term health-related quality of life (HRQoL) and costs after injury. Materials and methods This is a prospective, observational, follow-up cohort study in which HRQoL, psychological, social and functional outcome, and costs after trauma will be assessed during 24 months follow-up within injured patients admitted in 1 of 10 hospitals in the county Noord-Brabant, the Netherlands. Data will be collected by self-reported questionnaires at 1 week (including preinjury assessment), and 1, 3, 6, 12 and 24 months after injury. If patients are not capable of filling out the questionnaires, proxies will be asked to participate. Also, information about mechanism and severity of injury, comorbidity and indirect and direct costs will be collected. Mixed models will be used to examine the course of HRQoL, functional and psychological outcome, costs over time and between different groups, and to identify predictors for poor or good outcome. Relevance This study should make a substantial contribution to the international collaborative effort to assess the societal impact and burden of injuries more accurately. The BIOS results will also be used to develop an outcome prediction model for outcome evaluation including, besides the classic fatal, non-fatal outcome.	[de Jongh, M. A. C.; Kruithof, N.; Gosens, T.; van de Ree, C. L. P.; de Munter, L.; Lansink, K. W. W.] Elisabeth TweeSteden Hosp, Dept Trauma TopCare, Postbus 90151, NL-5000 LC Tilburg, Netherlands; [de Jongh, M. A. C.; Brouwers, L.; Lansink, K. W. W.] Brabant Trauma Registry, Network Emergency Care Brabant, Tilburg, Netherlands; [Gosens, T.] Elisabeth TweeSteden Hosp, Dept Orthopaed, Tilburg, Netherlands; [Polinder, S.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands; [Lansink, K. W. W.] Elisabeth TweeSteden Hosp, Dept Surg, Tilburg, Netherlands	de Jongh, MAC (corresponding author), Elisabeth TweeSteden Hosp, Dept Trauma TopCare, Postbus 90151, NL-5000 LC Tilburg, Netherlands.	m.dejongh@etz.nl		de Munter, Leonie/0000-0001-6573-2032	ZonMwNetherlands Organization for Health Research and Development [80-84200-98-14255]	ZonMw (80-84200-98-14255).	Alway Y, 2016, DEPRESS ANXIETY, V33, P19, DOI 10.1002/da.22396; Anke A, 2015, J HEAD TRAUMA REHAB, V30, pE38, DOI 10.1097/HTR.0000000000000080; [Anonymous], 1984, J TRAUMA INJURY INFE, P21201; Ardolino A, 2012, INJURY, V43, P1662, DOI 10.1016/j.injury.2012.05.008; BAKER SP, 1976, J TRAUMA, V16, P882, DOI 10.1097/00005373-197611000-00006; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bakker FC, 2015, INTERD T GERONT GERI, V41, P95, DOI 10.1159/000381171; Baranyi A, 2010, PSYCHOSOMATICS, V51, P237, DOI 10.1176/appi.psy.51.3.237; Bergeron E, 2004, J TRAUMA, V56, P760, DOI 10.1097/01.TA.0000119199.52226.C0; Bhalla K, 2009, PLOS MED, V6, P22, DOI 10.1371/journal.pmed.1000001; Bocci MG, 2016, MINERVA ANESTESIOL, V82, P22; Bouwmans C, 2013, HANDLEIDING IMTA MED; Bouwmans C, 2013, HANDLEIDING IMTA PRO; Bouwmans C, 2013, MED CONSUMPTION QUES; BOYD CR, 1987, J TRAUMA, V27, P370, DOI 10.1097/00005373-198704000-00005; Brouwer WBF, 1999, HEALTH POLICY, V48, P13, DOI 10.1016/S0168-8510(99)00028-7; CHAMPION HR, 1981, CRIT CARE MED, V9, P672, DOI 10.1097/00003246-198109000-00015; Dagum C, 2004, HUMAN CAPITAL; DAUBIGNE RM, 1954, J BONE JOINT SURG AM, V36-A, P451, DOI 10.2106/00004623-195436030-00001; Derrett S, 2009, INJURY PREV, V15, DOI [10.1136/ip.2009.022558a, 10.1136/ip.2009.022558]; Drake AI, 2006, BRAIN INJURY, V20, P469, DOI 10.1080/02699050600676370; Edwards ER, 2006, INJURY, V37, P95, DOI 10.1016/j.injury.2005.02.027; Furlong W, 2000, HLTH UTILITIES INDEX; Furlong WJ, 2001, ANN MED, V33, P375, DOI 10.3109/07853890109002092; Gabbe BJ, 2015, INJURY PREV, V21, P348, DOI 10.1136/injuryprev-2014-041336; Gabbe BJ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0113467; Gabbe BJ, 2013, ANN SURG, V257, P166, DOI 10.1097/SLA.0b013e31825d7422; Gennarelli TA, 2006, INJURY, V37, P1083, DOI 10.1016/j.injury.2006.07.009; Haagsma JA, 2012, BMC PSYCHIATRY, V12, DOI 10.1186/1471-244X-12-1; Hanna CL, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-14; Hasselberg Marie, 2003, Traffic Inj Prev, V4, P249, DOI 10.1080/15389580309882; Holtslag HR, 2007, INJURY, V38, P280, DOI 10.1016/j.injury.2006.10.026; Holtslag HR, 2008, B WORLD HEALTH ORGAN, V86, P111, DOI 10.2471/BLT.06.033803; Holtslag HR, 2007, CLIN REHABIL, V21, P373, DOI 10.1177/0269215507072084; Hukkelhoven CWPM, 2005, J NEUROTRAUM, V22, P1025, DOI 10.1089/neu.2005.22.1025; Jones JM, 2014, ACTA ANAESTH SCAND, V58, P303, DOI 10.1111/aas.12256; Kendrick D, 2013, INJURY PREV, V19, P370, DOI 10.1136/injuryprev-2012-040658; Kennedy RL, 2001, J TRAUMA, V51, P717, DOI 10.1097/00005373-200110000-00016; Kim SW, 2014, JAMA SURG, V149, P633, DOI 10.1001/jamasurg.2014.241; Koopmanschap Marc A, 2005, Expert Rev Pharmacoecon Outcomes Res, V5, P23, DOI 10.1586/14737167.5.1.23; Langley J, 2011, HEALTH QUAL LIFE OUT, V9, DOI 10.1186/1477-7525-9-68; Lefering R, 2014, CRIT CARE, V18, DOI 10.1186/s13054-014-0476-2; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; LINN BS, 1968, J AM GERIATR SOC, V16, P622, DOI 10.1111/j.1532-5415.1968.tb02103.x; Lyons RA, 2007, BMC PUBLIC HEALTH, V7, DOI 10.1186/1471-2458-7-317; MacKenzie EJ, 2006, NEW ENGL J MED, V354, P366, DOI 10.1056/NEJMsa052049; MacKenzie EJ, 2007, J TRAUMA, V63, pS54, DOI 10.1097/TA.0b013e31815acb09; MAJEED SA, 1989, J BONE JOINT SURG BR, V71, P304; Makary MA, 2010, J AM COLL SURGEONS, V210, P901, DOI 10.1016/j.jamcollsurg.2010.01.028; Moore L, 2011, J AM COLL SURGEONS, V213, P402, DOI 10.1016/j.jamcollsurg.2011.05.007; Nichol AD, 2011, INJURY, V42, P281, DOI 10.1016/j.injury.2010.11.047; O'Donnell ML, 2013, J CLIN PSYCHIAT, V74, pE137, DOI 10.4088/JCP.12m08011; PERRY S, 1992, AM J PSYCHIAT, V149, P931; Peters LL, 2012, J AM MED DIR ASSOC, V13, P546, DOI 10.1016/j.jamda.2012.04.007; Polinder S, 2005, J TRAUMA, V59, P1283, DOI 10.1097/01.ta.0000195998.11304.5b; Polinder S, 2007, J TRAUMA, V62, P133, DOI 10.1097/TA.0b013e31802b71c9; Polinder S, 2007, B WORLD HEALTH ORGAN, V85, P27, DOI 10.2471/BLT.06.030973; Polinder S, 2012, EPIDEMIOL REV, V34, P17, DOI 10.1093/epirev/mxr022; Polinder S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-783; Polinder S, 2010, INJURY PREV, V16, P147, DOI 10.1136/ip.2009.022418; Ringburg AN, 2011, J TRAUMA, V70, P916, DOI 10.1097/TA.0b013e3181f6bce8; Salvi F, 2008, J AM GERIATR SOC, V56, P1926, DOI 10.1111/j.1532-5415.2008.01935.x; Sandhaug M, 2015, BRAIN INJURY, V29, P1431, DOI 10.3109/02699052.2015.1063692; Scheenen ME, 2016, J NEUROTRAUM, V33, P339, DOI 10.1089/neu.2015.3926; Schuurmans H, 2004, J GERONTOL A-BIOL, V59, P962; Shi QY, 2014, J HAND THER, V27, P55, DOI 10.1016/j.jht.2013.10.001; Steverink N, 2001, GERONTOLOGIST, V41, P236; Steyerberg EW, 2008, PLOS MED, V5, P1251, DOI 10.1371/journal.pmed.0050165; Sundin EC, 2002, BRIT J PSYCHIAT, V180, P205, DOI 10.1192/bjp.180.3.205; Sutherland AG, 2006, J TRAUMA, V61, P1408, DOI 10.1097/01.ta.0000197562.34651.df; Tan SS., 2012, TIJDSCHRIFT GEZONDHE, V90, P367, DOI [10.1007/s12508-12012-10128-12503, DOI 10.1007/S12508-012-0128-3]; Utomo WK, 2009, INJURY, V40, P973, DOI 10.1016/j.injury.2009.05.034; Van Beeck EF, 2007, J TRAUMA, V62, P534, DOI 10.1097/TA.0b013e31802e70c7; van Delft-Schreurs CCHM, 2014, QUAL LIFE RES, V23, P1353, DOI 10.1007/s11136-013-0546-y; van Delft-Schreurs CCHM, 2014, INJURY, V45, P320, DOI 10.1016/j.injury.2013.02.025; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; van Erp S, 2014, INJURY, V45, P629, DOI 10.1016/j.injury.2013.10.019; vanRoijen L, 1996, INT J TECHNOL ASSESS, V12, P405, DOI 10.1017/S0266462300009764; Vles WJ, 2005, J TRAUMA, V58, P126, DOI 10.1097/01.TA.0000112342.40296.1F; von Steinbuechel N., 2014, EUR HLTH PSYCHOL S, V16, P642; von Steinbuechel N, 2012, J NEUROL NEUROSUR PS, V83, P1041, DOI 10.1136/jnnp-2012-302361; von Steinbuchel N, 2010, J NEUROTRAUM, V27, P1157, DOI 10.1089/neu.2009.1077; Whelan-Goodinson R, 2009, J AFFECT DISORDERS, V114, P94, DOI 10.1016/j.jad.2008.06.007; Whittaker R, 2007, J NEUROL NEUROSUR PS, V78, P644, DOI 10.1136/jnnp.2006.101105; WILLIAMS A, 1990, HEALTH POLICY, V16, P199; Williamson OD, 2011, J TRAUMA, V71, P63, DOI 10.1097/TA.0b013e31820e898d; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; Xue QL, 2011, CLIN GERIATR MED, V27, P1, DOI 10.1016/j.cger.2010.08.009; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	90	22	22	0	4	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	1353-8047	1475-5785		INJURY PREV	Inj. Prev.	FEB	2017	23	1					59	U108		10.1136/injuryprev-2016-042032			9	Public, Environmental & Occupational Health	Public, Environmental & Occupational Health	EJ6IT	WOS:000393323400011	27154507				2021-06-18	
J	Gudi, V; Gai, LJ; Herder, V; Tejedor, LS; Kipp, M; Amor, S; Suhs, KW; Hansmann, F; Beineke, A; Baumgartner, W; Stangel, M; Skripuletz, T				Gudi, Viktoria; Gai, Lijie; Herder, Vanessa; Tejedor, Laura Salinas; Kipp, Markus; Amor, Sandra; Suehs, Kurt-Wolfram; Hansmann, Florian; Beineke, Andreas; Baumgaertner, Wolfgang; Stangel, Martin; Skripuletz, Thomas			Synaptophysin Is a Reliable Marker for Axonal Damage	JOURNAL OF NEUROPATHOLOGY AND EXPERIMENTAL NEUROLOGY			English	Article						Axonal damage; Demyelination; Inflammation; Synaptophysin.	AMYLOID PRECURSOR PROTEIN; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; MULTIPLE-SCLEROSIS LESIONS; CENTRAL-NERVOUS-SYSTEM; CUPRIZONE-INDUCED DEMYELINATION; CULTURED HIPPOCAMPAL-NEURONS; VIRUS-INDUCED DEMYELINATION; SYNAPTIC VESICLE PROTEIN; TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE	Synaptophysin is an abundant membrane protein of synaptic vesicles. The objective of this study was to determine the utility of identifying synaptophysin accumulations (spheroids/ovoids/bulbs) in CNS white matter as an immunohistochemical marker of axonal damage in demyelinating and neuroinflammatory conditions. We studied the cuprizone toxicity and Theiler's murine encephalomyelitis virus (TMEV) infection models of demyelination and analyzed CNS tissue from patients with multiple sclerosis (MS). Synaptophysin colocalized with the amyloid precursor protein (APP), a wellknown marker of axonal damage. In the cuprizone model, numerous pathological synaptophysin/APP-positive spheroids/ovoids were identified in the corpus callosum at the onset of demyelination; the extent of synaptophysin/APP-positive vesicle aggregates correlated with identified reactive microglia; during late and chronic demyelination, the majority of synaptophysin/APP-positive spheroids/ovoids resolved but a few remained, indicating persistent axonal damage; in the remyelination phase, scattered large synaptophysin/APPpositive bulbs persisted. In the TMEV model, only a few large-to medium-sized synaptophysin/APP-positive bulbs were found in demyelinated areas. In MS patient tissue samples, the bulbs appeared exclusively at the inflammatory edges of lesions. In conclusion, our data suggest that synaptophysin as a reliable marker of axonal damage in the CNS in inflammatory/demyelinating conditions.	[Gudi, Viktoria; Gai, Lijie; Tejedor, Laura Salinas; Suehs, Kurt-Wolfram; Stangel, Martin; Skripuletz, Thomas] Hannover Med Sch, Dept Neurol, Clin Neuroimmunol & Neurochem, Hannover, Germany; [Herder, Vanessa; Hansmann, Florian; Beineke, Andreas; Baumgaertner, Wolfgang] Univ Vet Med Hannover, Dept Pathol, Hannover, Germany; [Herder, Vanessa; Tejedor, Laura Salinas; Hansmann, Florian; Beineke, Andreas; Stangel, Martin] Ctr Syst Neurosci, Hannover, Germany; [Kipp, Markus] Ludwig Maximilians Univ Munchen, Dept Anat 2, Munich, Germany; [Amor, Sandra] Vrije Univ Amsterdam Med Ctr, Dept Pathol, Amsterdam, Netherlands; [Skripuletz, Thomas] Hannover Med Sch, Dept Neurol, Carl-Neuberg-Str-1, D-30625 Hannover, Germany	Skripuletz, T (corresponding author), Hannover Med Sch, Dept Neurol, Carl-Neuberg-Str-1, D-30625 Hannover, Germany.	Skripuletz.Thomas@MH-Hannover.de	Stangel, Martin/AAH-5345-2020; Herder, Vanessa/AAG-6647-2020	Hansmann, Florian/0000-0001-6064-7728; Herder, Vanessa/0000-0003-4814-1382			BANATI RB, 1995, J CEREBR BLOOD F MET, V15, P647, DOI 10.1038/jcbfm.1995.80; Benardais K, 2014, GLIA, V62, P1659, DOI 10.1002/glia.22706; Bitsch A, 2000, BRAIN, V123, P1174, DOI 10.1093/brain/123.6.1174; Brady ST, 1999, J NEUROSCI, V19, P7278, DOI 10.1523/JNEUROSCI.19-17-07278.1999; Brown A, 2003, J CELL BIOL, V160, P817, DOI 10.1083/jcb.200212017; CALAKOS N, 1994, J BIOL CHEM, V269, P24534; Centonze D, 2010, CELL DEATH DIFFER, V17, P1083, DOI 10.1038/cdd.2009.179; Clarner T, 2011, J MOL NEUROSCI, V43, P268, DOI 10.1007/s12031-010-9419-9; COCHRAN E, 1991, AM J PATHOL, V139, P485; Creed JA, 2011, J NEUROTRAUM, V28, P547, DOI 10.1089/neu.2010.1729; DAHL D, 1989, ACTA NEUROPATHOL, V79, P154, DOI 10.1007/BF00294373; Dale Jeffrey M, 2012, J Amino Acids, V2012, P382107, DOI 10.1155/2012/382107; Daly C, 2002, J BIOL CHEM, V277, P9010, DOI 10.1074/jbc.M110815200; Daly C, 2000, P NATL ACAD SCI USA, V97, P6120, DOI 10.1073/pnas.97.11.6120; Dashiell SM, 2002, J NEUROCHEM, V81, P1263, DOI 10.1046/j.1471-4159.2002.00927.x; Dawkins E, 2014, J NEUROCHEM, V129, P756, DOI 10.1111/jnc.12675; De Vos KJ, 2008, ANNU REV NEUROSCI, V31, P151, DOI 10.1146/annurev.neuro.31.061307.090711; deSilva HAR, 1997, MOL BRAIN RES, V47, P147; DEWAEGH SM, 1992, CELL, V68, P451, DOI 10.1016/0092-8674(92)90183-D; DiLeonardi AM, 2009, BRAIN RES, V1263, P174, DOI 10.1016/j.brainres.2009.01.021; Ferguson B, 1997, BRAIN, V120, P393, DOI 10.1093/brain/120.3.393; Frischer JM, 2009, BRAIN, V132, P1175, DOI 10.1093/brain/awp070; Galli T, 1996, J BIOL CHEM, V271, P2193, DOI 10.1074/jbc.271.4.2193; GEHRMANN J, 1995, GLIA, V15, P141, DOI 10.1002/glia.440150206; Goldstein AYN, 2008, CURR OPIN NEUROBIOL, V18, P495, DOI 10.1016/j.conb.2008.10.003; Gonzalez-Jamett AM, 2010, J NEUROSCI, V30, P10683, DOI 10.1523/JNEUROSCI.5210-09.2010; Grosse-Veldmann R, 2016, MOL NEUROBIOL, V53, P4905, DOI 10.1007/s12035-015-9420-y; Gudi V, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00073; Gudi V, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022623; Gudi V, 2009, BRAIN RES, V1283, P127, DOI 10.1016/j.brainres.2009.06.005; Haass C, 2012, CSH PERSPECT MED, V2, DOI 10.1101/cshperspect.a006270; Hares K, 2014, MULT SCLER J, V20, P812, DOI 10.1177/1352458513508836; Herder V, 2012, J NEUROIMMUNOL, V244, P84, DOI 10.1016/j.jneuroim.2012.01.010; Herrero-Herranz E, 2008, NEUROBIOL DIS, V30, P162, DOI 10.1016/j.nbd.2008.01.001; Hirokawa N, 2008, PHYSIOL REV, V88, P1089, DOI 10.1152/physrev.00023.2007; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P877, DOI 10.1038/nrm2807; Hirokawa N, 2009, NAT REV MOL CELL BIO, V10, P682, DOI 10.1038/nrm2774; Horikawa HPM, 2002, MOL CELL NEUROSCI, V21, P454, DOI 10.1006/mcne.2002.1191; Hoshino S, 2003, NEUROL MED-CHIR, V43, P165, DOI 10.2176/nmc.43.165; Johnson VE, 2016, ACTA NEUROPATHOL, V131, P115, DOI 10.1007/s00401-015-1506-0; Kaether C, 2000, MOL BIOL CELL, V11, P1213, DOI 10.1091/mbc.11.4.1213; Kamal A, 2000, NEURON, V28, P449, DOI 10.1016/S0896-6273(00)00124-0; KANG J, 1987, NATURE, V325, P733, DOI 10.1038/325733a0; Katsuse O, 2003, J NEUROL SCI, V211, P29, DOI 10.1016/S0022-510X(03)00037-6; KOO EH, 1990, P NATL ACAD SCI USA, V87, P1561, DOI 10.1073/pnas.87.4.1561; Kornek B, 2001, BRAIN, V124, P1114, DOI 10.1093/brain/124.6.1114; Kornek B, 2000, AM J PATHOL, V157, P267, DOI 10.1016/S0002-9440(10)64537-3; Korzhevskii D E, 2007, Morfologiia, V131, P75; Kreutzer M, 2012, BRAIN PATHOL, V22, P454, DOI 10.1111/j.1750-3639.2011.00541.x; Kuhlmann T, 2002, BRAIN, V125, P2202, DOI 10.1093/brain/awf235; LI GL, 1995, J NEUROTRAUM, V12, P269, DOI 10.1089/neu.1995.12.269; Lindner M, 2009, NEUROSCI LETT, V453, P120, DOI 10.1016/j.neulet.2009.02.004; Mallozzi C, 2013, BBA-MOL CELL RES, V1833, P110, DOI 10.1016/j.bbamcr.2012.10.022; Mancardi G, 2001, J NEUROL SCI, V184, P41, DOI 10.1016/S0022-510X(00)00490-1; McMahon HT, 1996, P NATL ACAD SCI USA, V93, P4760, DOI 10.1073/pnas.93.10.4760; Millecamps S, 2013, NAT REV NEUROSCI, V14, P161, DOI 10.1038/nrn3380; Muresan Z, 2004, HUM MOL GENET, V13, P475, DOI 10.1093/hmg/ddh054; Nakata T, 1998, J CELL BIOL, V140, P659, DOI 10.1083/jcb.140.3.659; Neumann H, 2003, CURR OPIN NEUROL, V16, P267, DOI 10.1097/00019052-200306000-00004; Nicklas W, 2002, LAB ANIM-UK, V36, P20, DOI 10.1258/0023677021911740; Nikic I, 2011, NAT MED, V17, P495, DOI 10.1038/nm.2324; Ohyama A, 2001, BIOCHEM BIOPH RES CO, V280, P988, DOI 10.1006/bbrc.2001.4236; PASCHAL BM, 1987, NATURE, V330, P181, DOI 10.1038/330181a0; Paus T, 2014, NEUROSCIENCE, V276, P117, DOI 10.1016/j.neuroscience.2014.01.055; Perrot R, 2008, MOL NEUROBIOL, V38, P27, DOI 10.1007/s12035-008-8033-0; Petzold A, 2008, EXP NEUROL, V213, P326, DOI 10.1016/j.expneurol.2008.06.008; Prekeris R, 1997, J CELL BIOL, V137, P1589, DOI 10.1083/jcb.137.7.1589; REHM H, 1986, EMBO J, V5, P535, DOI 10.1002/j.1460-2075.1986.tb04243.x; Roy S, 2005, ACTA NEUROPATHOL, V109, P5, DOI 10.1007/s00401-004-0952-x; Roy S, 2000, J NEUROSCI, V20, P6849, DOI 10.1523/JNEUROSCI.20-18-06849.2000; Roy S, 2007, J NEUROSCI, V27, P3131, DOI 10.1523/JNEUROSCI.4999-06.2007; Sato Fumitaka, 2011, Pathophysiology, V18, P31, DOI 10.1016/j.pathophys.2010.04.011; Schirmer L, 2013, BRAIN PATHOL, V23, P2, DOI 10.1111/j.1750-3639.2012.00608.x; Schirmer L, 2011, BRAIN PATHOL, V21, P428, DOI 10.1111/j.1750-3639.2010.00466.x; Shea TB, 2008, EUR J NEUROSCI, V27, P1893, DOI 10.1111/j.1460-9568.2008.06165.x; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V87, P55; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Siedler DG, 2014, FRONT CELL NEUROSCI, V8, DOI 10.3389/fncel.2014.00429; Siffrin V, 2010, TRENDS NEUROSCI, V33, P202, DOI 10.1016/j.tins.2010.01.002; SISODIA SS, 1993, J NEUROSCI, V13, P3136; Skripuletz T, 2008, AM J PATHOL, V172, P1053, DOI 10.2353/ajpath.2008.070850; Skripuletz T, 2015, SCI REP-UK, V5, DOI 10.1038/srep14935; Skripuletz T, 2015, BRAIN, V138, P398, DOI 10.1093/brain/awu358; Skripuletz T, 2013, BRAIN, V136, P147, DOI 10.1093/brain/aws262; Skripuletz T, 2010, BRAIN PATHOL, V20, P301, DOI 10.1111/j.1750-3639.2009.00271.x; SOLA C, 1993, NEUROSCIENCE, V53, P267, DOI 10.1016/0306-4522(93)90304-X; Stagi M, 2005, J NEUROSCI, V25, P352, DOI 10.1523/JNEUROSCI.3887-04.2005; STERNBERGER LA, 1983, P NATL ACAD SCI-BIOL, V80, P6126, DOI 10.1073/pnas.80.19.6126; Stone JR, 2000, BRAIN RES, V871, P288, DOI 10.1016/S0006-8993(00)02485-9; SUDHOF TC, 1987, SCIENCE, V238, P1142, DOI 10.1126/science.3120313; Szodorai A, 2009, J NEUROSCI, V29, P14534, DOI 10.1523/JNEUROSCI.1546-09.2009; Tarsa L, 2002, P NATL ACAD SCI USA, V99, P1012, DOI 10.1073/pnas.022575999; TATEOSTROFF B, 1989, P NATL ACAD SCI USA, V86, P745, DOI 10.1073/pnas.86.2.745; Thiele C, 2000, NAT CELL BIOL, V2, P42, DOI 10.1038/71366; Trapp BD, 1998, NEW ENGL J MED, V338, P278, DOI 10.1056/NEJM199801293380502; Tsunoda I, 2003, AM J PATHOL, V162, P1259, DOI 10.1016/S0002-9440(10)63922-3; Tsunoda I, 2002, SPRINGER SEMIN IMMUN, V24, P105, DOI 10.1007/s00281-002-0105-z; Ulrich R, 2006, J NEUROPATH EXP NEUR, V65, P783, DOI 10.1097/01.jnen.0000229990.32795.0d; Vallee RB, 2004, J NEUROBIOL, V58, P189, DOI 10.1002/neu.10314; Valtorta F, 2004, BIOESSAYS, V26, P445, DOI 10.1002/bies.20012; Wang L, 2000, NAT CELL BIOL, V2, P137; WIEDENMANN B, 1985, CELL, V41, P1017, DOI 10.1016/S0092-8674(85)80082-9; Zhao J, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-150; Zheng H, 2011, MOL NEURODEGENER, V6, DOI 10.1186/1750-1326-6-27; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	105	22	22	1	13	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA	0022-3069	1554-6578		J NEUROPATH EXP NEUR	J. Neuropathol. Exp. Neurol.	FEB	2017	76	2					109	125		10.1093/jnen/nlw114			17	Clinical Neurology; Neurosciences; Pathology	Neurosciences & Neurology; Pathology	EP1NA	WOS:000397150400004	28177496	Bronze			2021-06-18	
J	Hespanhol, LC; van Mechelen, W; Verhagen, E				Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert			Health and Economic Burden of Running-Related Injuries in Dutch Trailrunners: A Prospective Cohort Study	SPORTS MEDICINE			English	Article							COST-EFFECTIVENESS; SPORTS INJURIES; ANKLE SPRAINS; PROGRAM; PREVENTION; RUNNERS; ADULTS; INTERVENTIONS; MORTALITY	Background Trailrunning is becoming very popular. However, the risk and burden of running-related injuries (RRI) in trailrunning is not well established. Objective To investigate the prevalence, injury rate, severity, nature, and economic burden of RRIs in Dutch trailrunners. Methods This prospective cohort study included 228 trailrunners aged 18 years or over (range 23-67), and was conducted between October 2013 and December 2014. After completing the baseline questionnaire, the Oslo Sports Trauma Research Center Questionnaire on Health Problems was administered every 2 weeks to collect data on RRIs. Participants who reported RRIs were asked about healthcare utilization (direct costs) and absenteeism from paid work (indirect costs). RRI was defined as disorders of the musculoskeletal system or concussions experienced or sustained during participation in running. Results The mean prevalence of RRIs measured over time was 22.4 % [95 % confidence interval (CI) 20.9-24.0], and the injury rate was 10.7 RRIs per 1000 h of running (95 % CI 9.4-12.1). The prevalence was higher for overuse (17.7 %; 95 % CI 15.9-19.5) than for acute (4.1 %; 95 % CI 3.3-5.0) RRIs. Also, the injury rate was higher for overuse (8.1; 95 % CI 6.9-9.3) than for acute (2.7; 95 % CI 2.0-3.4) RRIs. The median of the severity score was 35.0 [25-75 %, interquartile range (IQR) 22.0-55.7], and the median of the duration of RRIs was 2.0 weeks (IQR 2.0-6.0) during the study. The total economic burden of RRIs was estimated at (sic)172.22 (95 % CI 117.10-271.74) per RRI, and (sic)1849.49 (95 % CI 1180.62-3058.91) per 1000 h of running. An RRI was estimated to have a direct cost of (sic)60.92 (95 % CI 45.11-94.90) and an indirect cost of (sic)111.30 (95 % CI 61.02-192.75). Conclusions The health and economic burden of RRIs presented in this study are significant for trailrunners and for society. Therefore, efforts should be made in order to prevent RRIs in trailrunners.	[Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert] Vrije Univ Amsterdam, Med Ctr, Amsterdam Collaborat Hlth & Safety Sports, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [Hespanhol Junior, Luiz Carlos; van Mechelen, Willem; Verhagen, Evert] Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands; [van Mechelen, Willem] Univ Queensland, Fac Hlth & Behav Sci, Sch Human Movement & Nutr Sci, Brisbane, Qld, Australia; [van Mechelen, Willem; Verhagen, Evert] Univ Cape Town, Fac Hlth Sci, Dept Human Biol, UCT MRC Res Unit Exercise Sci & Sports Med ESSM, Cape Town, South Africa; [van Mechelen, Willem] Univ Coll Dublin, Sch Publ Hlth Physiotherapy & Populat Sci, Dublin, Ireland; [Verhagen, Evert] Federat Univ Australia, Australian Ctr Res Injury Sport & Its Prevent, Ballarat, Vic, Australia	Hespanhol, LC (corresponding author), Vrije Univ Amsterdam, Med Ctr, Amsterdam Collaborat Hlth & Safety Sports, Dept Publ & Occupat Hlth, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.; Hespanhol, LC (corresponding author), Vrije Univ Amsterdam, Med Ctr, EMGO Inst Hlth & Care Res, Boechorststr 7, NL-1081 BT Amsterdam, Netherlands.	l.hespanhol@outlook.com	Hespanhol, Luiz/H-8636-2013; Verhagen, Evert/A-1502-2013	Hespanhol, Luiz/0000-0003-1774-4746; Verhagen, Evert/0000-0001-9227-8234	CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior)Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior (CAPES) [0763/12-8]; Ministry of Education of Brazil	Luiz Carlos Hespanhol Junior is a PhD candidate supported by CAPES (Coordenacao de Aperfeicoamento de Pessoal de Nivel Superior), process number 0763/12-8, Ministry of Education of Brazil. The authors wish to thank MudSweatTrails and Marc Weening for their assistance during the recruitment, and all trailrunners who participated in this study.	Bahr R, 2009, BRIT J SPORT MED, V43, P966, DOI 10.1136/bjsm.2009.066936; Chakravarty EF, 2008, ARCH INTERN MED, V168, P1638, DOI 10.1001/archinte.168.15.1638; Chaudhary MA, 1996, STAT MED, V15, P1447; Clarsen B, 2014, BRIT J SPORT MED, V48, P754, DOI 10.1136/bjsports-2012-092087; Clarsen B, 2013, BRIT J SPORT MED, V47, P495, DOI 10.1136/bjsports-2012-091524; Codogno JS, 2015, INT J PUBLIC HEALTH, V63, P309, DOI 10.1007/s00038-015-0657-z; Coon JT, 2011, ENVIRON SCI TECHNOL, V45, P1761, DOI 10.1021/es102947t; Cumps E, 2008, BRIT J SPORT MED, V42, P767, DOI 10.1136/bjsm.2007.037937; EFRON B, 1987, J AM STAT ASSOC, V82, P171, DOI 10.2307/2289144; Efron B., 1986, STAT SCI, V1, P54, DOI [10.1214/ss/1177013815, DOI 10.1214/SS/1177013815]; Frew EJ, 2014, BRIT J SPORT MED, V48, P207, DOI 10.1136/bjsports-2012-091202; Fuller CW, 2007, CLIN J SPORT MED, V17, P197, DOI 10.1097/JSM.0b013e3180471b89; Gabbett TJ, 2016, BRIT J SPORT MED, V50, P273, DOI 10.1136/bjsports-2015-095788; Hagberg LA, 2006, SCAND J PUBLIC HEALT, V34, P641, DOI 10.1080/14034940600627853; HATZIANDREU EI, 1988, AM J PUBLIC HEALTH, V78, P1417, DOI 10.2105/AJPH.78.11.1417; Hespanhol LC, 2016, SCAND J MED SCI SPOR, V26, P1091, DOI 10.1111/sms.12541; Hespanhol LC, 2016, J SCI MED SPORT, V19, P800, DOI 10.1016/j.jsams.2015.12.004; Hespanhol LC, 2015, BRAZ J PHYS THER, V19, P369, DOI 10.1590/bjpt-rbf.2014.0110; Hespanhol LC, 2015, SPORTS MED, V45, P1455, DOI 10.1007/s40279-015-0359-y; Hoffman MD, 2011, INT J SPORT PHYSIOL, V6, P25, DOI 10.1123/ijspp.6.1.25; Hupperets MDW, 2010, AM J SPORT MED, V38, P2194, DOI 10.1177/0363546510373470; Janssen KW, 2014, AM J SPORT MED, V42, P1534, DOI 10.1177/0363546514529642; King DA, 2009, BRIT J SPORT MED, V43, P595, DOI 10.1136/bjsm.2009.061481; Kluitenberg B, 2016, J SCI MED SPORT, V19, P470, DOI 10.1016/j.jsams.2015.07.003; Kluitenberg B, 2013, BMC PUBLIC HEALTH, V13, DOI 10.1186/1471-2458-13-685; Knowles SB, 2006, J ATHL TRAINING, V41, P207; Lee DC, 2014, J AM COLL CARDIOL, V64, P472, DOI 10.1016/j.jacc.2014.04.058; Lim SS, 2012, LANCET, V380, P2224, DOI 10.1016/S0140-6736(12)61766-8; Lopes AD, 2012, SPORTS MED, V42, P891, DOI [10.2165/11631170-000000000-00000, 10.1007/BF03262301]; Nielsen RO, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0099877; Ottesen L, 2010, SCAND J MED SCI SPOR, V20, P118, DOI 10.1111/j.1600-0838.2010.01123.x; Pluim BM, 2016, SCAND J MED SCI SPOR, V26, P564, DOI 10.1111/sms.12471; Rae K, 2007, CLIN J SPORT MED, V17, P201, DOI 10.1097/JSM.0b013e318059b536; Schmikli SL, 2009, CLIN J SPORT MED, V19, P101, DOI 10.1097/JSM.0b013e31819b9ca3; Stamatakis E, 2008, BRIT J SPORT MED, V42, P901, DOI 10.1136/bjsm.2008.048082; Twisk JWR, 2013, APPLIED LONGITUDINAL DATA ANALYSIS FOR EPIDEMIOLOGY: A PRACTICAL GUIDE, 2ND EDITION, P237; van Dongen JM, 2014, J OCCUP ENVIRON MED, V56, P563, DOI 10.1097/JOM.0000000000000165; van Roijen LH, 2010, COLL ZORGVERZEKERING; vanMechelen W, 1997, SPORTS MED, V24, P176, DOI 10.2165/00007256-199724030-00006; Verhagen EALM, 2005, BRIT J SPORT MED, V39, P111, DOI 10.1136/bjsm.2003.011031; Videbaek S, 2015, SPORTS MED, V45, P1017, DOI 10.1007/s40279-015-0333-8; Scheer BV, 2011, CLIN J SPORT MED, V21, P444, DOI 10.1097/JSM.0b013e318225b0df; WHO, 2009, GLOB HLTH RISKS MORT; Yamato TP, 2015, J ORTHOP SPORT PHYS, V45, P366, DOI 10.2519/jospt.2015.5750	44	22	23	0	14	ADIS INT LTD	NORTHCOTE	5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND	0112-1642	1179-2035		SPORTS MED	Sports Med.	FEB	2017	47	2					367	377		10.1007/s40279-016-0551-8			11	Sport Sciences	Sport Sciences	EJ6LY	WOS:000393332100012	27222128	Green Published, Other Gold			2021-06-18	
J	MacPhersona, SE; Healy, C; Allerhanda, M; Spano, B; Tudor-Sfetea, C; White, M; Smirnif, D; Shalliceg, T; Chan, E; Bozzali, M; Cipolotti, L				MacPhersona, Sarah E.; Healy, Colm; Allerhanda, Michael; Spano, Barbara; Tudor-Sfetea, Carina; White, Mark; Smirni, Daniela; Shalliceg, Tim; Chan, Edgar; Bozzali, Marco; Cipolotti, Lisa			Cognitive reserve and cognitive performance of patients with focal frontal lesions	NEUROPSYCHOLOGIA			English	Article						Cognitive reserve; Frontal lesions; Education; Literacy attainment; Cognitive performance; Age	TRAUMATIC BRAIN-INJURY; ALZHEIMERS-DISEASE; SOCIOECONOMIC-STATUS; EDUCATION; DECLINE; DEMENTIA; AGE; MEMORY; IMPACT; PATHOLOGY	The Cognitive reserve (CR) hypothesis was put forward to account for the variability in cognitive performance of patients with similar degrees of brain pathology. Compensatory neural activity within the frontal lobes has often been associated with CR. For the first time we investigated the independent effects of two CR proxies, education and NART IQ, on measures of executive function, fluid intelligence, speed of information processing, verbal short term memory (vSTM), naming, and perception in a sample of 86 patients with focal, unilateral frontal lesions and 142 healthy controls. We fitted multiple linear regression models for each of the cognitive measures and found that only NART IQ predicted executive and naming performance. Neither education nor NART IQ predicted performance on fluid intelligence, processing speed, vSTM or perceptual abilities. Education and NART IQ did not modify the effect of lesion severity on cognitive impairment. We also found that age significantly predicted performance on executive tests and the majority of our other cognitive measures, except vSTM and GNT. Age was the only predictor for fluid intelligence. This latter finding suggests that age plays a role in executive performance over and above the contribution of CR proxies in patients with focal frontal lesions. Overall, our results suggest that the CR proxies do not appear to modify the relationship between cognitive impairment and frontal lesions.	[MacPhersona, Sarah E.; Allerhanda, Michael] Univ Edinburgh, Ctr Cognit Ageing & Cognit Epidemiol, Edinburgh, Midlothian, Scotland; [MacPhersona, Sarah E.; Allerhanda, Michael] Univ Edinburgh, Dept Psychol, Edinburgh, Midlothian, Scotland; [Healy, Colm; Tudor-Sfetea, Carina; Chan, Edgar; Cipolotti, Lisa] Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, London, England; [Spano, Barbara; Bozzali, Marco] Santa Lucia Fdn, Neuroimaging Lab, Rome, Italy; [White, Mark] Natl Hosp Neurol & Neurosurg, Dept Neuroradiol, London, England; [Smirni, Daniela; Cipolotti, Lisa] Univ Palermo, Dipartimento Sci Psicol Pedagog & Formaz, Palermo, Italy; [Shalliceg, Tim] UCL, Inst Cognit Neurosci, London WC1E 6BT, England; [Shalliceg, Tim] Int Sch Adv Studies SISSA ISAS, Trieste, Italy	Cipolotti, L (corresponding author), Natl Hosp Neurol & Neurosurg, Dept Neuropsychol, London, England.; Cipolotti, L (corresponding author), Univ Palermo, Dipartimento Sci Psicol Pedagog & Formaz, Palermo, Italy.	l.cipolotti@ucl.ac.uk	Smirni, Daniela/R-3445-2019	Smirni, Daniela/0000-0002-4410-2047; MacPherson, Sarah E./0000-0001-8676-6514; Healy, Colm/0000-0001-7974-1861; Bozzali, Marco/0000-0002-0568-2026; cipolotti, lisa/0000-0001-5838-3647	Wellcome TrustWellcome TrustEuropean Commission [089231/A/09/Z]; Department of Health's National Institute for Health Research Biomedical Research Centre's funding schemeNational Institute for Health Research (NIHR); Medical Research CouncilUK Research & Innovation (UKRI)Medical Research Council UK (MRC)European Commission [MR/K026992/1] Funding Source: researchfish	This work was supported by the Wellcome Trust Grant (089231/A/09/Z). This work was undertaken at UCLH/UCL, which received a proportion of funding from the Department of Health's National Institute for Health Research Biomedical Research Centre's funding scheme.	Alexander GE, 1997, AM J PSYCHIAT, V154, P165; Allerhand M, 2014, PSYCHOL AGING, V29, P306, DOI 10.1037/a0036551; Arenaza-Urquijo EM, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00134; Barulli D, 2013, TRENDS COGN SCI, V17, P502, DOI 10.1016/j.tics.2013.08.012; Benedict RHB, 2010, J INT NEUROPSYCH SOC, V16, P829, DOI 10.1017/S1355617710000688; Bennett DA, 2003, NEUROLOGY, V60, P1909, DOI 10.1212/01.WNL.0000069923.64550.9F; Bozzali M, 2015, J ALZHEIMERS DIS, V44, P243, DOI 10.3233/JAD-141824; Brickman AM, 2011, NEUROBIOL AGING, V32, P1588, DOI 10.1016/j.neurobiolaging.2009.10.013; Cipolotti L, 2016, NEUROPSYCHOLOGIA, V93, P1, DOI 10.1016/j.neuropsychologia.2016.09.018; Cipolotti L, 2015, NEUROPSYCHOLOGIA, V75, P233, DOI 10.1016/j.neuropsychologia.2015.06.011; Cipolotti L, 2015, NEUROPSYCHOLOGIA, V68, P21, DOI 10.1016/j.neuropsychologia.2014.12.025; Court JH, 1998, MANUAL RAVENS PROGR; Deary IJ, 2015, INTELLIGENCE, V50, P1, DOI 10.1016/j.intell.2015.02.002; DUVERNOY HM, 1991, HUMAN BRAIN STRUCTUR; Elderkin-Thompson V, 2008, NEUROPSYCHOLOGY, V22, P626, DOI 10.1037/0894-4105.22.5.626; Elkins JS, 2006, NEUROLOGY, V67, P435, DOI 10.1212/01.wnl.0000228246.89109.98; Farfel JM, 2013, NEUROLOGY, V81, P650, DOI 10.1212/WNL.0b013e3182a08f1b; Gonzalez-Fernandez M, 2011, ARCH PHYS MED REHAB, V92, P1809, DOI 10.1016/j.apmr.2011.05.026; GRAFMAN J, 1986, J NEUROSCI, V6, P301; Green RE, 2008, ARCH PHYS MED REHAB, V89, pS16, DOI 10.1016/j.apmr.2008.09.551; Ikanga J, 2017, J CLIN EXP NEUROPSYC, V39, P72, DOI 10.1080/13803395.2016.1201462; Jefferson AL, 2011, J AM GERIATR SOC, V59, P1403, DOI 10.1111/j.1532-5415.2011.03499.x; Jones RN, 2011, J INT NEUROPSYCH SOC, V17, P593, DOI 10.1017/S1355617710001748; Kaleita TA, 2004, J NEURO-ONCOL, V67, P245, DOI 10.1023/B:NEON.0000021900.29176.58; Levi Y, 2013, J INT NEUROPSYCH SOC, V19, P664, DOI 10.1017/S1355617713000192; Lindenberger U., 2013, PRINCIPLES FRONTAL L, V2nd, P609; Liu YY, 2013, J CLIN NEUROSCI, V20, P548, DOI 10.1016/j.jocn.2012.04.020; Lo RY, 2013, ALZ DIS ASSOC DIS, V27, P343, DOI 10.1097/WAD.0b013e3182900b2b; MacPherson SE, 2016, NEUROPSYCHOLOGY, V30, P332, DOI 10.1037/neu0000240; MacPherson SE, 2010, NEUROPSYCHOLOGIA, V48, P3679, DOI 10.1016/j.neuropsychologia.2010.07.033; Manly JJ, 2003, J CLIN EXP NEUROPSYC, V25, P680, DOI 10.1076/jcen.25.5.680.14579; McKenna P.W.E., 1983, GRADED NAMING TEST; Meguro K, 2001, PSYCHIAT CLIN NEUROS, V55, P565, DOI 10.1046/j.1440-1819.2001.00907.x; Meng XF, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0038268; Mirowsky J, 2005, AGEING INT, V30, P27, DOI 10.1007/BF02681006; Morris JC, 2005, ALZ DIS ASSOC DIS, V19, P163; Murphy P, 2013, NEUROPSYCHOLOGIA, V51, P2075, DOI 10.1016/j.neuropsychologia.2013.06.029; Murray AD, 2011, BRAIN, V134, P3684, DOI 10.1093/brain/awr259; Nelson HE, 1982, NATL ADULT READING T; Ngandu T, 2007, NEUROLOGY, V69, P1442, DOI 10.1212/01.wnl.0000277456.29440.16; Nunnari D, 2014, NEUROL SCI, V35, P1513, DOI 10.1007/s10072-014-1897-z; Ojala-Oksala J, 2012, STROKE, V43, P2931, DOI 10.1161/STROKEAHA.112.667618; Okonkwo OC, 2014, NEUROLOGY, V83, P1753, DOI 10.1212/WNL.0000000000000964; Opdebeeck C, 2016, AGING NEUROPSYCHOL C, V23, P40, DOI 10.1080/13825585.2015.1041450; Park DC, 2009, ANNU REV PSYCHOL, V60, P173, DOI 10.1146/annurev.psych.59.103006.093656; Perneczky R, 2006, J NEUROL NEUROSUR PS, V77, P1060, DOI 10.1136/jnnp.2006.094714; Persson N, 2016, NEUROIMAGE, V126, P15, DOI 10.1016/j.neuroimage.2015.11.028; Raven J.C., 1976, MANUAL ADV PROGR MAT; Raymont V, 2008, BRAIN, V131, P543, DOI 10.1093/brain/awm300; Raz N, 2007, NEUROPSYCHOLOGY, V21, P149, DOI 10.1037/0894-4105.21.2.149; Reitan R. M., 1992, TRAIL MAKING TEST MA; Reuter-Lorenz PA, 2014, NEUROPSYCHOL REV, V24, P355, DOI 10.1007/s11065-014-9270-9; Richards M, 2003, J CLIN EXP NEUROPSYC, V25, P614, DOI 10.1076/jcen.25.5.614.14581; Ritchie SJ, 2013, PSYCHOL AGING, V28, P515, DOI 10.1037/a0030820; Robertson IH, 2014, NEUROBIOL AGING, V35, P1375, DOI 10.1016/j.neurobiolaging.2013.11.028; Robinson G, 2012, BRAIN, V135, P2202, DOI 10.1093/brain/aws142; Robinson GA, 2015, BRAIN, V138, P1084, DOI 10.1093/brain/awv003; Roe CM, 2007, NEUROLOGY, V68, P223, DOI 10.1212/01.wnl.0000251303.50459.8a; Ryan NS, 2011, ALZHEIMERS RES THER, V3, DOI 10.1186/alzrt91; Sachdev PS, 2004, NEUROLOGY, V63, P1618, DOI 10.1212/01.WNL.0000142964.83484.DE; Scarmeas N, 2006, J NEUROL NEUROSUR PS, V77, P308, DOI 10.1136/jnnp.2005.072306; Schmand B, 1997, PSYCHOL MED, V27, P1337, DOI 10.1017/S0033291797005461; Serra L., 2014, NEUROBIOL AGING, P1; Siedlecki KL, 2009, J INT NEUROPSYCH SOC, V15, P558, DOI 10.1017/S1355617709090857; Singh-Manoux A, 2011, ANN NEUROL, V70, P296, DOI 10.1002/ana.22391; Stern Y, 2002, J INT NEUROPSYCH SOC, V8, P448, DOI 10.1017/S1355617702813248; Stern Y, 2008, CEREB CORTEX, V18, P959, DOI 10.1093/cercor/bhm134; Stern Y, 2006, ALZ DIS ASSOC DIS, V20, P112, DOI 10.1097/01.wad.0000213815.20177.19; Stern Y, 2012, LANCET NEUROL, V11, P1006, DOI 10.1016/S1474-4422(12)70191-6; Stern Y, 2009, NEUROPSYCHOLOGIA, V47, P2015, DOI 10.1016/j.neuropsychologia.2009.03.004; Suchy Y, 2011, J CLIN EXP NEUROPSYC, V33, P92, DOI 10.1080/13803395.2010.493148; Sumowski JF, 2014, NEUROLOGY, V82, P1776, DOI 10.1212/WNL.0000000000000433; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; Tombaugh TN, 1999, ARCH CLIN NEUROPSYCH, V14, P167, DOI 10.1016/S0887-6177(97)00095-4; Trenerry M.R., 1989, SHOOP NEUROPSYCHOLOG; Tucker AM, 2011, CURR ALZHEIMER RES, V8, P354; Tucker-Drob EA, 2009, DEV PSYCHOL, V45, P431, DOI 10.1037/a0014012; Valenzuela MJ, 2006, PSYCHOL MED, V36, P1065, DOI 10.1017/S0033291706007744; Valenzuela MJ, 2006, PSYCHOL MED, V36, P441, DOI 10.1017/S0033291705006264; Vemuri P, 2011, BRAIN, V134, P1479, DOI 10.1093/brain/awr049; von Hippel PT, 2007, SOCIOL METHODOL, V37, P83, DOI 10.1111/j.1467-9531.2007.00180.x; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WAIS 3 ADM SCORING M; Wechsler D., 1981, WAIS R MANUAL WECHSL; WIENS AN, 1993, CLIN NEUROPSYCHOL, V7, P70, DOI 10.1080/13854049308401889; Wilson, 1991, NATL ADULT READING T; Xu W, 2015, MOL NEUROBIOL, V51, P187, DOI 10.1007/s12035-014-8720-y; Zahodne LB, 2011, J INT NEUROPSYCH SOC, V17, P1039, DOI 10.1017/S1355617711001044; Zieren N, 2013, NEUROBIOL AGING, V34, P400, DOI 10.1016/j.neurobiolaging.2012.04.019	89	22	22	0	4	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	FEB	2017	96						19	28		10.1016/j.neuropsychologia.2016.12.028			10	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	EM3LQ	WOS:000395216900003	28041947	Other Gold, Green Accepted, Green Published			2021-06-18	
J	Mollayeva, T; Cassidy, JD; Shapiro, CM; Mollayeva, S; Colantonio, A				Mollayeva, Tatyana; Cassidy, J. David; Shapiro, Colin M.; Mollayeva, Shirin; Colantonio, Angela			Concussion/mild traumatic brain injury-related chronic pain in males and females: A diagnostic modelling study	MEDICINE			English	Article						chronic pain; cultural/social model; environmental/behavioral model; perceived states; physical/medical model; physiological and brain injury-related model; psychological model; sex differences	POSTTRAUMATIC-STRESS-DISORDER; POSTCONCUSSION SYNDROME; LINEAR-REGRESSION; UNITED-STATES; MENTAL-HEALTH; SLEEP; POPULATION; PREVALENCE; SYMPTOMS; HEADACHE	Pain is an unpleasant, complex, and perceived experience that places a significant burden on patients and clinicians. Its severity may be mediated by emotion, attitude, and environmental influences, and pain may be expressed differently in males and females. Traumatic brain injury (TBI) is frequently associated with chronic pain. This diagnostic modeling study examined sex differences in the construct of chronic pain in patients with delayed recovery from concussion/mild traumatic brain injury (mTBI). Data were collected from standardized questionnaires, neuroimaging records, and comprehensive clinical assessments. Bivariate associations were calculated using the Spearman correlation coefficient or analysis of variance. We established sex-specific stepwise multivariate linear regression models of factors associated with pain. Of the 94 participants diagnosed with mTBI (the mean age was 45.20 +/- 9.94 years; 61.2% were males; the median time since injury was 197 days [interquartile range 139-416]), head/neck, and bodily pain were reported by 93% and 64%, respectively. No sex differences were identified in pain frequencies or severity. Pain was significantly associated with certain socio-demographic, injuryrelated, behavioral, and clinical variables. In the multivariable regression analysis, several determinants explained 60% of the pain variance in males and 46% in females. Pain is common in patients with delayed recovery from mTBI and is significantly associated with potentially modifiable clinical and nonclinical variables. Examining the multidimensional construct of pain in concussion/mTBI through a sex lens garners new directions for future longitudinal research on the pain mechanisms involved in postconcussion syndrome.	[Mollayeva, Tatyana; Colantonio, Angela] Univ Toronto, Fac Med, Rehabil Sci Inst, Mississauga, ON, Canada; [Mollayeva, Tatyana; Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, Mississauga, ON, Canada; [Mollayeva, Tatyana; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Mississauga, ON, Canada; [Cassidy, J. David] Univ Hlth Network, Div Hlth Care & Outcomes Res, Mississauga, ON, Canada; [Cassidy, J. David] Univ Toronto, Dalla Lana Sch Publ Hlth, Div Epidemiol, Mississauga, ON, Canada; [Shapiro, Colin M.] Univ Hlth Network, Toronto Western Hosp, Mississauga, ON, Canada; [Shapiro, Colin M.] Univ Toronto, Youthdale Child & Adolescent Sleep Clin, Mississauga, ON, Canada; [Mollayeva, Shirin] Univ Toronto, Dept Biol, Mississauga, ON, Canada	Mollayeva, T (corresponding author), Univ Toronto, Fac Med, Rehabil Sci Inst, 550 Univ Ave,Rm 11207, Toronto, ON M5G 2A2, Canada.	tatyana.mollayeva@utoronto.ca	, Mollayeva/A-4522-2018	Colantonio, Angela/0000-0003-2094-4765	Frederick Banting and Charles Best Doctoral Research Award from the Canadian Institutes of Health ResearchCanadian Institutes of Health Research (CIHR); postdoctoral fellowship from the Acquired Brain Injury Laboratory of the Rehabilitation Sciences Institute at the University of Toronto; Toronto Rehabilitation Institute-University Health Network research fellowship; Canadian Institutes for Health Research Grant-Institute for Gender and HealthCanadian Institutes of Health Research (CIHR) [CGW-126580]	TM was supported by the 2013/2015 Frederick Banting and Charles Best Doctoral Research Award from the Canadian Institutes of Health Research and the 2015/2016 postdoctoral fellowship from the Acquired Brain Injury Laboratory of the Rehabilitation Sciences Institute at the University of Toronto and the Toronto Rehabilitation Institute-University Health Network research fellowship. AC was supported by the Canadian Institutes for Health Research Grant-Institute for Gender and Health (#CGW-126580).	Al-Harthy M, 2016, J ORAL REHABIL, V43, P81, DOI 10.1111/joor.12346; Alhalabi Mohammad Salem, 2015, Avicenna J Med, V5, P110, DOI 10.4103/2231-0770.165123; American Psychiatric Association, 2000, AM PSYCH ASS DIAGN S, VFourth; Andrews NE, 2015, PAIN, V156, P1991, DOI 10.1097/j.pain.0000000000000259; Austin PC, 2015, J CLIN EPIDEMIOL, V68, P627, DOI 10.1016/j.jclinepi.2014.12.014; Bastuji H, 2012, HUM BRAIN MAPP, V33, P2638, DOI 10.1002/hbm.21390; Behan M, 2008, RESP PHYSIOL NEUROBI, V164, P213, DOI 10.1016/j.resp.2008.06.006; Bigler ED, 2008, J INT NEUROPSYCH SOC, V14, P1, DOI 10.1017/S135561770808017X; Bjorck-van Dijken C, 2008, J REHABIL MED, V40, P864, DOI 10.2340/16501977-0273; Borsook D, 2014, NEUROBIOL DIS, V68, P200, DOI 10.1016/j.nbd.2014.03.008; Brown DA, 2015, SPORTS MED, V45, P1027, DOI 10.1007/s40279-015-0335-6; Campos-Fumero A, 2016, OCCUP ENVIRON MED, V73, P394, DOI 10.1136/oemed-2015-103327; Cassidy J David, 2014, Arch Phys Med Rehabil, V95, pS132, DOI 10.1016/j.apmr.2013.08.299; Casson RJ, 2014, CLIN EXP OPHTHALMOL, V42, P590, DOI 10.1111/ceo.12358; Choe MC, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0573-9; Collins GS, 2015, J CLIN EPIDEMIOL, V68, P112, DOI [10.1016/j.jclinepi.2014.11.010, 10.1186/s12916-014-0241-z]; Dallenbach KM, 1939, AM J PSYCHOL, V52, P331, DOI 10.2307/1416740; Daoust R, 2008, PAIN, V138, P565, DOI 10.1016/j.pain.2008.02.007; Davis A E, 2000, Crit Care Nurs Q, V23, P1; Duan-Porter W, 2015, VA EVIDENCE BASED SY; Edwards RR, 2008, PAIN, V137, P202, DOI 10.1016/j.pain.2008.01.025; ELKIND AH, 1989, OTOLARYNG CLIN N AM, V22, P1251; EPSTEIN LH, 1992, J CONSULT CLIN PSYCH, V60, P493, DOI 10.1037/0022-006X.60.4.493; Ertas M, 2012, J HEADACHE PAIN, V13, P147, DOI 10.1007/s10194-011-0414-5; Fann JR, 2005, J HEAD TRAUMA REHAB, V20, P501, DOI 10.1097/00001199-200511000-00003; Ferrari MD, 2015, LANCET NEUROL, V14, P65, DOI 10.1016/S1474-4422(14)70220-0; Foo H, 2003, SLEEP MED REV, V7, P145, DOI 10.1053/smrv.2002.0224; Giordano Chiara, 2014, Stapp Car Crash J, V58, P29; Gorczyca R, 2013, ANN AGR ENV MED, P23; Gottlieb DJ, 1999, AM J RESP CRIT CARE, V159, P502, DOI 10.1164/ajrccm.159.2.9804051; Guindon J., 2009, HDB NEUROSCIENCE BEH, P635; Hassed C, 2013, AUST FAM PHYSICIAN, V42, P112; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Holtkamp MD, 2016, CURR PAIN HEADACHE R, V20, DOI 10.1007/s11916-016-0572-x; Huskinson EC, 1983, PAIN MEASUREMENT ASS, P33; Jensen MP, 1992, HDB PAIN ASSESSMENT; JOHNS MW, 1992, SLEEP, V15, P376, DOI 10.1093/sleep/15.4.376; Kilpatrick LA, 2015, BIOL PSYCHOL, V112, P107, DOI 10.1016/j.biopsycho.2015.09.010; Lagarde E, 2014, JAMA PSYCHIAT, V71, P1032, DOI 10.1001/jamapsychiatry.2014.666; Lavie P, 2001, J Clin Hypertens (Greenwich), V3, P296, DOI 10.1111/j.1524-6175.2001.00491.x; Lew HL, 2009, J REHABIL RES DEV, V46, P697, DOI 10.1682/JRRD.2009.01.0006; Lindell Odd, 2010, Clin Epidemiol, V2, P261, DOI 10.2147/CLEP.S14761; Logan BW, 2013, BEHAV SCI LAW, V31, P803, DOI 10.1002/bsl.2092; Maguen S, 2012, J REHABIL RES DEV, V49, P1115, DOI 10.1682/JRRD.2011.02.0015; Mandel H, 2014, DEMOGRAPHY, V51, P1597, DOI 10.1007/s13524-014-0320-y; MANSFIELD ER, 1982, AM STAT, V36, P158, DOI 10.2307/2683167; Marshall O, 2015, HUM BRAIN MAPP, V36, P3912, DOI 10.1002/hbm.22886; Martelli MF, 2004, J HEAD TRAUMA REHAB, V19, P10, DOI 10.1097/00001199-200401000-00003; Martelli MF, 2002, PAIN MANAGEMENT PRAC, P465; Mazumdar M, 2003, STAT MED, V22, P559, DOI 10.1002/sim.1333; McCracken LM, 2001, J PAIN SYMPTOM MANAG, V21, P392, DOI 10.1016/S0885-3924(01)00267-6; Meares S, 2011, NEUROPSYCHOLOGY, V25, P454, DOI 10.1037/a0022580; Melzack R., 1991, CHALLENGE PAIN; Mihai Verona, 2010, Pneumologia, V59, P64; Mollayeva T, 2016, SLEEP MED, V19, P153, DOI 10.1016/j.sleep.2015.05.014; Mollayeva T, 2016, CURR NEUROL NEUROSCI, V16, DOI 10.1007/s11910-016-0657-2; Mollayeya T, 2013, SLEEP MED REV, V17, P411, DOI 10.1016/j.smrv.2013.02.001; Moshourab R.A., 2015, BRAIN NEUROTRAUMA MO; MUSE M, 1985, PAIN, V23, P295, DOI 10.1016/0304-3959(85)90108-3; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; Nardone R, 2011, J NEUROTRAUM, V28, P1165, DOI 10.1089/neu.2010.1748; Nicholl BI, 2015, BMC FAM PRACT, V16, DOI 10.1186/s12875-015-0343-5; Palmer KT, 2008, PAIN, V136, P30, DOI 10.1016/j.pain.2007.06.011; PRICE DD, 1986, PAIN, V24, P197, DOI 10.1016/0304-3959(86)90042-4; Roder CH, 2007, PSYCHOTHER PSYCHOSOM, V76, P115, DOI 10.1159/000097970; Sarver J, 2000, J GEN INTERN MED, V15, P256, DOI 10.1111/j.1525-1497.2000.06469.x; Stedman TL, 2000, STEDMANS MED DICT; STEWART WF, 1992, JAMA-J AM MED ASSOC, V267, P64, DOI 10.1001/jama.267.1.64; Valipour A, 2007, SLEEP, V30, P312, DOI 10.1093/sleep/30.3.312; Wahner-Roedler DL, 2007, GENDER MED, V4, P329, DOI 10.1016/S1550-8579(07)80062-3; Wasner G, 2010, CURR PAIN HEADACHE R, V14, P489, DOI 10.1007/s11916-010-0140-8; Xiong C, 2016, DISABIL HEALTH J, V9, P439, DOI 10.1016/j.dhjo.2015.12.002	72	22	22	0	8	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0025-7974	1536-5964		MEDICINE	Medicine (Baltimore)	FEB	2017	96	7							e5917	10.1097/MD.0000000000005917			14	Medicine, General & Internal	General & Internal Medicine	EL2EL	WOS:000394432800012	28207508	DOAJ Gold, Green Published			2021-06-18	
J	Yuan, WH; Treble-Barna, A; Sohlberg, MM; Harn, B; Wade, SL				Yuan, Weihong; Treble-Barna, Amery; Sohlberg, McKay M.; Harn, Beth; Wade, Shari L.			Changes in Structural Connectivity Following a Cognitive Intervention in Children With Traumatic Brain Injury: A Pilot Study	NEUROREHABILITATION AND NEURAL REPAIR			English	Article						traumatic brain injury; structural connectivity; graph theoretical analysis; diffusion tensor imaging; behavioral assessment; cognitive intervention; neuroplasticity	GRAPH-THEORETICAL ANALYSIS; DIFFUSE AXONAL INJURY; WHITE-MATTER; EXECUTIVE FUNCTIONS; WORKING-MEMORY; TENSOR; ATTENTION; ADHD; METAANALYSIS; ACTIVATION	Objective. Structural connectivity analysis based on graph theory and diffusion tensor imaging tractography is a novel method that quantifies the topological characteristics in the brain network. This study aimed to examine structural connectivity changes following the Attention Intervention and Management (AIM) program designed to improve attention and executive function (EF) in children with traumatic brain injury (TBI). Methods. Seventeen children with complicated mild to severe TBI (13.66 +/- 2.68 years; >12 months postinjury) completed magnetic resonance imaging (MRI) and neurobehavioral measures at time 1, 10 of whom completed AIM and assessment at time 2. Eleven matched healthy comparison (HC) children (13.37 +/- 2.08 years) completed MRI and neurobehavioral assessment at both time points, but did not complete AIM. Network characteristics were analyzed to quantify the structural connectivity before and after the intervention. Results. Mixed model analyses showed that small-worldness was significantly higher in the TBI group than the HC group at time 1, and both small-worldness and normalized clustering coefficient decreased significantly at time 2 in the TBI group whereas the HC group remained relatively unchanged. Reductions in mean local efficiency were significantly correlated with improvements in verbal inhibition and both parent- and child-reported EF. Increased normalized characteristic path length was significantly correlated with improved sustained attention. Conclusion. The results provide preliminary evidence suggesting that graph theoretical analysis may be a sensitive tool in pediatric TBI for detecting (a) abnormalities of structural connectivity in brain network and (b) structural neuroplasticity associated with neurobehavioral improvement following a short-term intervention for attention and EF.	[Yuan, Weihong; Treble-Barna, Amery; Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Yuan, Weihong; Wade, Shari L.] Univ Cincinnati, Coll Med, Cincinnati, OH USA; [Sohlberg, McKay M.; Harn, Beth] Univ Oregon, Eugene, OR 97403 USA	Yuan, WH (corresponding author), Cincinnati Childrens Hosp Med Ctr, Pediat Neuroimaging Res Consortium, 3333 Burnet Ave,MLC 5033, Cincinnati, OH 45229 USA.	weihong.yuan@cchmc.org			Department of Education's National Institute on Disability and Rehabilitation Research (Center on Intervention for Children and Youth with Traumatic Brain Injury) [H133B090010-10]; National Institute on Disability, Independent Living, and Rehabilitation ResearchUnited States Department of Health & Human Services [90RT5004]; Emergency Medical Services Grant from the Ohio Department of Public Safety Emergency Medical Services; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	The authors disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported in part by the Department of Education's National Institute on Disability and Rehabilitation Research (Center on Intervention for Children and Youth with Traumatic Brain Injury; Grant No. H133B090010-10, PI Wade), the National Institute on Disability, Independent Living, and Rehabilitation Research (Grant No. 90RT5004, PI Wade), and an Emergency Medical Services Grant from the Ohio Department of Public Safety Emergency Medical Services (Title: The Effects of Cognitive Training on Attention and Neural Processing Following Pediatric TBI, PIs Wade/Yuan).	ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Bassett DS, 2011, NEUROIMAGE, V54, P1262, DOI 10.1016/j.neuroimage.2010.09.006; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Beaulieu C, 2002, NMR BIOMED, V15, P435, DOI 10.1002/nbm.782; BENJAMINI Y, 1995, J R STAT SOC B, V57, P289, DOI 10.1111/j.2517-6161.1995.tb02031.x; Bonelli Raphael M, 2007, Dialogues Clin Neurosci, V9, P141; Bryden DW, 2015, J NEUROSCI, V35, P3903, DOI 10.1523/JNEUROSCI.3587-14.2015; Bullmore ET, 2009, NAT REV NEUROSCI, V10, P186, DOI 10.1038/nrn2575; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Caeyenberghs K, 2014, BRAIN STRUCT FUNCT, V219, P193, DOI 10.1007/s00429-012-0494-2; Caeyenberghs K, 2012, NEUROIMAGE-CLIN, V1, P106, DOI 10.1016/j.nicl.2012.09.011; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chen XH, 2009, BRAIN PATHOL, V19, P214, DOI 10.1111/j.1750-3639.2008.00176.x; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Curtis CE, 2006, HDB FUNCTIONAL NEURO, P269; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Ducreux D, 2005, NEURORADIOLOGY, V47, P604, DOI 10.1007/s00234-005-1389-1; Engvig A, 2012, HUM BRAIN MAPP, V33, P2390, DOI 10.1002/hbm.21370; Fan J, 2005, NEUROIMAGE, V26, P471, DOI 10.1016/j.neuroimage.2005.02.004; Gary KW, 2009, BRAIN INJURY, V23, P775, DOI 10.1080/02699050903200563; Gebauer D, 2012, BRAIN STRUCT FUNCT, V217, P747, DOI 10.1007/s00429-011-0371-4; Gioia G.A., 2000, BEHAV RATING INVENTO; Guye M, 2010, MAGN RESON MATER PHY, V23, P409, DOI 10.1007/s10334-010-0205-z; JAFFE KM, 1995, ARCH PHYS MED REHAB, V76, P17, DOI 10.1016/S0003-9993(95)80037-9; Karch S, 2009, HUM BRAIN MAPP, V30, P2971, DOI 10.1002/hbm.20722; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Kim J, 2014, J INT NEUROPSYCH SOC, V20, P887, DOI 10.1017/S1355617714000812; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kraus MF, 2007, BRAIN, V130, P2508, DOI 10.1093/brain/awm216; Lazaridou A, 2013, INT J MOL MED, V32, P995, DOI 10.3892/ijmm.2013.1476; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Levin HS, 2008, J HEAD TRAUMA REHAB, V23, P197, DOI 10.1097/01.HTR.0000327252.54128.7c; Lovden M, 2010, NEUROPSYCHOLOGIA, V48, P3878, DOI 10.1016/j.neuropsychologia.2010.08.026; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Neufang S, 2008, NEUROIMAGE, V43, P399, DOI 10.1016/j.neuroimage.2008.07.039; Povlishock JT, 2005, J HEAD TRAUMA REHAB, V20, P76, DOI 10.1097/00001199-200501000-00008; Prosperini L, 2013, NEUROREHAB NEURAL RE, V27, P516, DOI 10.1177/1545968313478484; Rubinov M, 2010, NEUROIMAGE, V52, P1059, DOI 10.1016/j.neuroimage.2009.10.003; Schlaug G, 2009, ANN NY ACAD SCI, V1169, P385, DOI 10.1111/j.1749-6632.2009.04587.x; Sisti HM, 2012, LEARN MEMORY, V19, P351, DOI 10.1101/lm.026534.112; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; SOHLBERG MM, 2014, CLIN PRACTICE PEDIAT, V2, P263, DOI DOI 10.1037/CPP0000072; Spain A, 2010, J NEUROTRAUM, V27, P1429, DOI 10.1089/neu.2010.1288; Stemper BD, 2015, ANN BIOMED ENG, V43, P1071, DOI 10.1007/s10439-014-1171-9; Strangman GE, 2012, NEUROREHABILITATION, V31, P295, DOI 10.3233/NRE-2012-0797; Susanto TAK, 2015, J ALZHEIMERS DIS, V45, P253, DOI 10.3233/JAD-142451; Takeuchi H, 2013, BRAIN STRUCT FUNCT, V218, P1017, DOI 10.1007/s00429-012-0444-z; Treble A, 2013, J NEUROTRAUM, V30, P1609, DOI 10.1089/neu.2013.2934; Treble-Barna A, 2016, J HEAD TRAUMA REHAB, V31, P407, DOI 10.1097/HTR.0000000000000200; Wager TD, 2003, COGN AFFECT BEHAV NE, V3, P255, DOI 10.3758/CABN.3.4.255; Wang R, 2007, P INT SOC MAG RESON, V15, P3720; Wang SH, 2013, CLIN NEUROPHYSIOL, V124, P2181, DOI 10.1016/j.clinph.2013.05.008; Wolraich ML, 2003, J PEDIATR PSYCHOL, V28, P559, DOI 10.1093/jpepsy/jsg046; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Yuan WH, 2015, HUM BRAIN MAPP, V36, P779, DOI 10.1002/hbm.22664	57	22	22	1	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	1545-9683	1552-6844		NEUROREHAB NEURAL RE	Neurorehabil. Neural Repair	FEB	2017	31	2					190	201		10.1177/1545968316675430			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EO8DU	WOS:000396920000008	27798379	Bronze			2021-06-18	
J	Bell, KR; Fann, JR; Brockway, JA; Cole, WR; Bush, NE; Dikmen, S; Hart, T; Lang, AJ; Grant, G; Gahm, G; Reger, MA; St De Lore, J; Machamer, J; Ernstrom, K; Raman, R; Jain, S; Stein, MB; Temkin, N				Bell, Kathleen R.; Fann, Jesse R.; Brockway, Jo Ann; Cole, Wesley R.; Bush, Nigel E.; Dikmen, Sureyya; Hart, Tessa; Lang, Ariel J.; Grant, Gerald; Gahm, Gregory; Reger, Mark A.; St De Lore, Jef; Machamer, Joan; Ernstrom, Karin; Raman, Rema; Jain, Sonia; Stein, Murray B.; Temkin, Nancy		INTRuST Investigators	Telephone Problem Solving for Service Members with Mild Traumatic Brain Injury: A Randomized, Clinical Trial	JOURNAL OF NEUROTRAUMA			English	Article						mild traumatic brain injury; problem-solving treatment (or training or therapy); service members (or military); telehealth	POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH-CARE; 1ST YEAR; DEPRESSION; SYMPTOMS; INTERVENTION; THERAPY; VETERANS; PTSD; RELIABILITY	Mild traumatic brain injury (mTBI) is a common injury for service members in recent military conflicts. There is insufficient evidence of how best to treat the consequences of mTBI. In a randomized, clinical trial, we evaluated the efficacy of telephone-delivered problem-solving treatment (PST) on psychological and physical symptoms in 356 post-deployment active duty service members from Joint Base Lewis McChord, Washington, and Fort Bragg, North Carolina. Members with medically confirmed mTBI sustained during deployment to Iraq and Afghanistan within the previous 24 months received PST or education-only (EO) interventions. The PST group received up to 12 biweekly telephone calls from a counselor for subject-selected problems. Both groups received 12 educational brochures describing common mTBI and post-deployment problems, with follow-up for all at 6 months (end of PST), and at 12 months. At 6 months, the PST group significantly improved on a measure of psychological distress (Brief Symptom Inventory; BSI-18) compared to the EO group (p = 0.005), but not on post-concussion symptoms (Rivermead Post-Concussion Symptoms Questionnaire [RPQ]; p = 0.19), the two primary endpoints. However, these effects did not persist at 12-month follow-up (BSI, p = 0.54; RPQ, p = 0.45). The PST group also had significant short-term improvement on secondary endpoints, including sleep (p = 0.01), depression (p = 0.03), post-traumatic stress disorder (p = 0.04), and physical functioning (p = 0.03). Participants preferred PST overEO(p < 0.001). Telephone-delivered PST appears to be a well-accepted treatment that offers promise for reducing psychological distress after combat-related mTBI and could be a useful adjunct treatment post-mTBI. Further studies are required to determine how to sustain its effects. (Trial registration: ClinicalTrials.gov Identifier: NCT01387490 https://clinicaltrials. gov)	[Bell, Kathleen R.; Fann, Jesse R.; Brockway, Jo Ann; Dikmen, Sureyya; Machamer, Joan; Temkin, Nancy] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Fann, Jesse R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA; [Cole, Wesley R.] Womack Army Med Ctr, Def & Vet Brain Injury Ctr, Intrepid Spirit, Ft Bragg, NC USA; [Bush, Nigel E.; Gahm, Gregory; Reger, Mark A.] Natl Ctr Telehealth & Technol, Joint Base Lewis McChord, Tacoma, WA USA; [Dikmen, Sureyya; St De Lore, Jef; Temkin, Nancy] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Hart, Tessa] Moss Rehabil Res Inst, Elkins Pk, PA USA; [Lang, Ariel J.; Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, La Jolla, CA 92093 USA; [Lang, Ariel J.; Stein, Murray B.] VA San Diego Healthcare Syst Ctr Excellence Stres, La Jolla, CA 92093 USA; [Grant, Gerald] Duke Univ, Dept Surg, Durham, NC USA; [Ernstrom, Karin; Raman, Rema; Jain, Sonia; Stein, Murray B.] Univ Calif San Diego, Dept Family Med & Publ Hlth, La Jolla, CA 92093 USA; [Temkin, Nancy] Univ Washington, Dept Biostat, Seattle, WA 98195 USA; [Bell, Kathleen R.] Univ Texas Southwestern, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA; [Grant, Gerald] Stanford Univ, Dept Neurosurg, Palo Alto, CA 94304 USA; [Ernstrom, Karin; Raman, Rema] Univ Southern Calif, Alzheimers Therapeut Res Inst, San Diego, CA USA	Bell, KR (corresponding author), Univ Texas Southwestern, Dept Phys Med & Rehabil, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.	Kathleen.Bell@UTSouthwestern.edu		Bush, Nigel/0000-0002-8137-7998; Bell, Kathleen/0000-0002-0928-2046	U.S. Army Medical Research and Materiel Command (USAMRMC)U.S. Army Medical Research & Materiel Command (USAMRMC) [W81XWH-08-2-0159]; National Institute on Disability and Rehabilitation Research [H133G070143]	This study was supported by the U.S. Army Medical Research and Materiel Command (USAMRMC; contract no.: W81XWH-08-2-0159). Supplementary support was provided by the National Institute on Disability and Rehabilitation Research (grant no.: H133G070143).	Al Sayegh A, 2010, J NEUROL NEUROSUR PS, V81, P1128, DOI 10.1136/jnnp.2008.170092; Arean P, 2008, GERONTOLOGIST, V48, P311, DOI 10.1093/geront/48.3.311; Attkisson C C, 1982, Eval Program Plann, V5, P233, DOI 10.1016/0149-7189(82)90074-X; Bell AC, 2009, CLIN PSYCHOL REV, V29, P348, DOI 10.1016/j.cpr.2009.02.003; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bell KR, 2015, CONTEMP CLIN TRIALS, V40, P54, DOI 10.1016/j.cct.2014.11.001; Bell KR, 2011, ARCH PHYS MED REHAB, V92, P1552, DOI 10.1016/j.apmr.2011.05.018; Bell KR, 2005, ARCH PHYS MED REHAB, V86, P851, DOI 10.1016/j.apmr.2004.09.015; Bombardier CH, 2009, J HEAD TRAUMA REHAB, V24, P230, DOI 10.1097/HTR.0b013e3181ad65f0; Brooks R, 1996, HEALTH POLICY, V37, P53, DOI 10.1016/0168-8510(96)00822-6; Bush NE, 2013, MIL MED, V178, P1157, DOI 10.7205/MILMED-D-13-00234; BUYSSE DJ, 1989, PSYCHIAT RES, V28, P193, DOI 10.1016/0165-1781(89)90047-4; Choi NG, 2014, DEPRESS ANXIETY, V31, P653, DOI 10.1002/da.22242; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Daggett VS, 2013, J REHABIL RES DEV, V50, P327, DOI 10.1682/JRRD.2011.09.0168; Derogatis L, 1993, BRIEF SYMPTOM INVENT; Fann JR, 2015, J NEUROTRAUM, V32, P45, DOI 10.1089/neu.2014.3423; Galarneau MR, 2008, J NEUROSURG, V108, P950, DOI 10.3171/JNS/2008/108/5/0950; Gilbert KS, 2015, CLIN PSYCHOL REV, V40, P195, DOI 10.1016/j.cpr.2015.05.008; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hoge CW, 2014, PSYCHIAT SERV, V65, P997, DOI 10.1176/appi.ps.201300307; Hopko DR, 2011, J CONSULT CLIN PSYCH, V79, P834, DOI 10.1037/a0025450; JACOBSON NS, 1991, J CONSULT CLIN PSYCH, V59, P12, DOI 10.1037/0022-006X.59.1.12; Johnson DR, 1997, J TRAUMA STRESS, V10, P391, DOI 10.1023/A:1024885103409; Kasckow J, 2012, INT J GERIATR PSYCH, V27, P1106, DOI 10.1002/gps.2826; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Kroenke K, 2001, J GEN INTERN MED, V16, P606, DOI 10.1046/j.1525-1497.2001.016009606.x; Ladouceur R, 2000, J CONSULT CLIN PSYCH, V68, P957, DOI 10.1037/0022-006X.68.6.957; Marx B. P., 2009, 25 ANN M INT SOC TRA; Meachen SJ, 2008, ARCH PHYS MED REHAB, V89, P958, DOI 10.1016/j.apmr.2007.12.028; SAUNDERS JB, 1993, ADDICTION, V88, P791, DOI 10.1111/j.1360-0443.1993.tb02093.x; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Schnurr PP, 2003, ARCH GEN PSYCHIAT, V60, P481, DOI 10.1001/archpsyc.60.5.481; Schottenbauer MA, 2008, PSYCHIATRY, V71, P134, DOI 10.1521/psyc.2008.71.2.134; Seal KH, 2010, J TRAUMA STRESS, V23, P5, DOI 10.1002/jts.20493; Sheehan DV, 1996, INT CLIN PSYCHOPHARM, V11, P89, DOI 10.1097/00004850-199606003-00015; Steenkamp MM, 2015, JAMA-J AM MED ASSOC, V314, P489, DOI 10.1001/jama.2015.8370; Ware JE, 1996, MED CARE, V34, P220, DOI 10.1097/00005650-199603000-00003; Weathers F., 1991, PTSD CHECKLIST MILIT; Wilk JE, 2012, PSYCHOSOM MED, V74, P249, DOI 10.1097/PSY.0b013e318244c604; Wilson JAB, 2008, CYBERPSYCHOL BEHAV, V11, P767, DOI 10.1089/cpb.2008.0071	41	22	22	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					313	321		10.1089/neu.2016.4444			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800006	27579992	Green Published			2021-06-18	
J	Liu, M; Bachstetter, AD; Cass, WA; Lifshitz, J; Bing, GY				Liu, Mei; Bachstetter, Adam D.; Cass, Wayne A.; Lifshitz, Jonathan; Bing, Guoying			Pioglitazone Attenuates Neuroinflammation and Promotes Dopaminergic Neuronal Survival in the Nigrostriatal System of Rats after Diffuse Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						brain injury; Parkinson's disease; pioglitazone; substantia nigra	ACTIVATED-RECEPTOR-GAMMA; MITOCHONDRIAL DYSFUNCTION; MOUSE MODEL; PPAR-GAMMA; AGONIST PIOGLITAZONE; PARKINSONS-DISEASE; SUBSTANTIA-NIGRA; HEAD TRAUMA; INFLAMMATION; MICROGLIA	Increasing evidence suggests that traumatic brain injury (TBI) may raise the risk of developing late-onset Parkinson's disease (PD). Recently, the peroxisome proliferation-activated receptor gamma (PPAR gamma) agonist pioglitazone has been demonstrated to be neuroprotective in animal models of neurodegeneration. The present study investigates the vulnerability of the nigrostriatal system after TBI, and intervention with pioglitazone treatment. Adult male Sprague-Dawley rats were subjected to sham or moderate midline fluid percussion brain injury (mFPI), followed by an intraperitoneal injection of 10 mg/kg pioglitazone or vehicle beginning 30 min after the injury and subsequently every 24 h for 5 days. Following injury, pro-inflammatory cytokines and chemokine were acutely increased in the striatum and substantia nigra within 6 h. Dopaminergic axonal damage and microglial activation were revealed using immunohistochemistry in the medial fore-brain bundle at 1 day post-injury. Microglial activation identified by Iba1 and OX-6 immunostaining was persistently increased in the substantia nigra pars compacta 7 to 28 days post-injury. Further, brain injury induced significant dopaminergic neuronal loss, which was quantified by tyrosine hydroxylase immunostaining and retrograde fluorescent tracer fluorogold labeling in the nigra at 28 days. Loss of neurons was accompanied by increased extracellular dopamine (DA) turnover in the striatum, indicating enhanced dopaminergic activity in functional compensation after nigrostriatal damage. Strikingly, pioglitazone treatment greatly attenuated microglial activation and improved dopaminergic neuronal survival in the nigrostriatal system, which may promote locomotor recovery. These results suggest that interventions that attenuate secondary inflammation could be a feasible therapeutic treatment to improve outcome after TBI.	[Liu, Mei; Cass, Wayne A.; Bing, Guoying] Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA; [Bachstetter, Adam D.] Univ Kentucky, Coll Med, Sanders Brown Ctr Aging, Lexington, KY 40536 USA; [Lifshitz, Jonathan] Phoenix Childrens Hosp, BARROW Neurol Inst, Phoenix, AZ USA; [Lifshitz, Jonathan] Univ Arizona, Coll Med, Dept Child Hlth, Phoenix, AZ USA; [Lifshitz, Jonathan] Phoenix Vet Affairs Healthcare Syst, Phoenix, AZ USA; [Lifshitz, Jonathan] Arizona State Univ, Interdisciplinary Grad Program Neurosci, Tempe, AZ USA	Bing, GY (corresponding author), Univ Kentucky, Coll Med, Dept Anat & Neurobiol, 800 Rose St, Lexington, KY 40536 USA.	gbing@uky.edu		Bachstetter, Adam/0000-0003-4646-6757; Bing, Guoying/0000-0003-0609-8152	Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) [11-2A]	The authors greatly thank Amanda Lisembee and Andrea Sebastian for technical assistance with mFPI surgery, and Dr. Michael T. Bardo and Emily D. Denehy for providing the locomotor apparatus. Grant sponsor: Kentucky Spinal Cord and Head Injury Research Trust (KSCHIRT) 11-2A.	Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Bachstetter AD, 2013, J NEUROSCI, V33, P6143, DOI 10.1523/JNEUROSCI.5399-12.2013; Bernardo A, 2000, EUR J NEUROSCI, V12, P2215, DOI 10.1046/j.1460-9568.2000.00110.x; BERNHEIMER H, 1973, J NEUROL SCI, V20, P415, DOI 10.1016/0022-510X(73)90175-5; Breidert T, 2002, J NEUROCHEM, V82, P615, DOI 10.1046/j.1471-4159.2002.00990.x; Cao T, 2012, NEUROSCIENCE, V225, P65, DOI 10.1016/j.neuroscience.2012.08.058; Carta AR, 2011, NEUROSCIENCE, V194, P250, DOI 10.1016/j.neuroscience.2011.07.046; Cass WA, 2003, BRAIN RES, V984, P133, DOI 10.1016/S0006-8993(03)03122-6; Chawla A, 2010, CIRC RES, V106, P1559, DOI 10.1161/CIRCRESAHA.110.216523; Cheng HC, 2010, ANN NEUROL, V67, P715, DOI 10.1002/ana.21995; Cheng HC, 2010, J NEUROCHEM, V113, P683, DOI 10.1111/j.1471-4159.2010.06632.x; Chinetti-Gbaguidi G, 2011, CIRC RES, V108, P985, DOI 10.1161/CIRCRESAHA.110.233775; Clark RB, 2002, J LEUKOCYTE BIOL, V71, P388; Delerive P, 2001, J ENDOCRINOL, V169, P453, DOI 10.1677/joe.0.1690453; Dinarello CA, 2000, CHEST, V118, P503, DOI 10.1378/chest.118.2.503; FACTOR SA, 1991, MOVEMENT DISORD, V6, P225, DOI 10.1002/mds.870060306; Gaetz M, 2004, CLIN NEUROPHYSIOL, V115, P4, DOI 10.1016/S1388-2457(03)00258-X; Gash DM, 2008, ANN NEUROL, V63, P184, DOI 10.1002/ana.21288; GENTLEMAN SM, 1993, NEUROSCI LETT, V160, P139, DOI 10.1016/0304-3940(93)90398-5; Hall ED, 2004, J NEUROTRAUM, V21, P9, DOI 10.1089/089771504772695904; Heneka MT, 2001, ANN NEUROL, V49, P276, DOI 10.1002/1531-8249(20010201)49:2<276::AID-ANA53>3.0.CO;2-5; Herrera AJ, 2008, J NEUROCHEM, V105, P750, DOI 10.1111/j.1471-4159.2007.05170.x; Hetzel M, 2003, THORAX, V58, P778, DOI 10.1136/thorax.58.9.778; Hornykiewicz O, 1998, NEUROLOGY, V51, pS2, DOI 10.1212/WNL.51.2_Suppl_2.S2; Hosseini AH, 2009, MED SCI SPORT EXER, V41, P1687, DOI 10.1249/MSS.0b013e31819fcd1b; Hunter RL, 2007, J NEUROCHEM, V100, P1375, DOI 10.1111/j.1471-4159.2006.04327.x; Hutson CB, 2011, J NEUROTRAUM, V28, P1783, DOI 10.1089/neu.2010.1723; Ito K, 2004, EUR J CARDIO-THORAC, V25, P530, DOI 10.1016/j.ejcts.2003.12.017; Kelly JP, 1999, JAMA-J AM MED ASSOC, V282, P989, DOI 10.1001/jama.282.10.989; Kobayashi K, 2013, CELL DEATH DIS, V4, DOI 10.1038/cddis.2013.54; Kochanek PM, 2013, J NEUROTRAUM, V30, P920, DOI 10.1089/neu.2013.2862; Liu M, 2008, J NEUROSCI RES, V86, P2792, DOI 10.1002/jnr.21725; Liu M, 2010, J NEUROCHEM, V112, P773, DOI 10.1111/j.1471-4159.2009.06497.x; Lloyd E, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-28; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Mandrekar-Colucci S, 2012, J NEUROSCI, V32, P10117, DOI 10.1523/JNEUROSCI.5268-11.2012; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Patro N, 2010, INDIAN J EXP BIOL, V48, P110; Paxinos G, 1998, RAT BRAIN IN STEREOTAXIC COORDINATES, FOURTH ED., pix; Perez XA, 2008, J NEUROCHEM, V105, P1861, DOI 10.1111/j.1471-4159.2008.05268.x; Pilipovic K, 2015, PROG NEURO-PSYCHOPH, V59, P8, DOI 10.1016/j.pnpbp.2015.01.003; Pringsheim T, 2014, MOVEMENT DISORD, V29, P1583, DOI 10.1002/mds.25945; Ricote M, 1998, NATURE, V391, P79, DOI 10.1038/34178; ROFFLERTARLOV S, 1971, BRIT J PHARMACOL, V42, P343, DOI 10.1111/j.1476-5381.1971.tb07118.x; Rose ME, 2002, BRAIN RES, V943, P15, DOI 10.1016/S0006-8993(02)02471-X; Sadeghian M, 2012, J NEUROIMMUNOL, V246, P69, DOI 10.1016/j.jneuroim.2012.03.010; Sauerbeck A, 2011, EXP NEUROL, V227, P128, DOI 10.1016/j.expneurol.2010.10.003; Schutz B, 2005, J NEUROSCI, V25, P7805, DOI 10.1523/JNEUROSCI.2038-05.2005; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; STERN MB, 1991, MOVEMENT DISORD, V6, P95, DOI 10.1002/mds.870060202; Sullivan PG, 1999, EXP NEUROL, V160, P226, DOI 10.1006/exnr.1999.7197; Sun X, 2012, NEUROBIOL DIS, V45, P601, DOI 10.1016/j.nbd.2011.09.018; Tavazzi B, 2005, NEUROSURGERY, V56, P582, DOI 10.1227/01.NEU.0000156715.04900.E6; van Bregt DR, 2012, EXP NEUROL, V234, P8, DOI 10.1016/j.expneurol.2011.12.003; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Xiong Y, 1997, J NEUROTRAUM, V14, P23, DOI 10.1089/neu.1997.14.23; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; YEOMANS JS, 1989, NEUROSCI BIOBEHAV R, V13, P91, DOI 10.1016/S0149-7634(89)80016-8	59	22	22	0	10	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					414	422		10.1089/neu.2015.4361			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800017	27142118				2021-06-18	
J	Ravindra, VM; Bollo, RJ; Sivakumar, W; Akbari, H; Naftel, RP; Limbrick, DD; Jea, A; Gannon, S; Shannon, C; Birkas, Y; Yang, GL; Prather, CT; Kestle, JR; Riva-Cambrin, J				Ravindra, Vijay M.; Bollo, Robert J.; Sivakumar, Walavan; Akbari, Hassan; Naftel, Robert P.; Limbrick, David D., Jr.; Jea, Andrew; Gannon, Stephen; Shannon, Chevis; Birkas, Yekaterina; Yang, George L.; Prather, Colin T.; Kestle, John R.; Riva-Cambrin, Jay			Predicting Blunt Cerebrovascular Injury in Pediatric Trauma: Validation of the "Utah Score''	JOURNAL OF NEUROTRAUMA			English	Article						blunt cerebrovascular injury; computed tomography angiography; pediatrics; traumatic brain injury; Utah Score	COMPUTED TOMOGRAPHIC ANGIOGRAPHY; VERTEBRAL ARTERY INJURIES; RADIATION-EXPOSURE; BRAIN-INJURY; RETROSPECTIVE COHORT; CERVICAL-SPINE; SCREENING-TEST; RISK-FACTORS; CHILDREN; DIAGNOSIS	Risk factors for blunt cerebrovascular injury (BCVI) may differ between children and adults, suggesting that children at low risk for BCVI after trauma receive unnecessary computed tomography angiography (CTA) and high-dose radiation. We previously developed a score for predicting pediatric BCVI based on retrospective cohort analysis. Our objective is to externally validate this prediction score with a retrospective multi-institutional cohort. We included patients who underwent CTA for traumatic cranial injury at four pediatric Level I trauma centers. Each patient in the validation cohort was scored using the "Utah Score'' and classified as high or low risk. Before analysis, we defined a misclassification rate <25% as validating the Utah Score. Six hundred forty-five patients (mean age 8.6 -5.4 years; 63.4% males) underwent screening for BCVI via CTA. The validation cohort was 411 patients from three sites compared with the training cohort of 234 patients. Twenty-two BCVIs (5.4%) were identified in the validation cohort. The Utah Score was significantly associated with BCVIs in the validation cohort (odds ratio 8.1 [3.3, 19.8], p < 0.001) and discriminated well in the validation cohort (area under the curve 72%). When the Utah Score was applied to the validation cohort, the sensitivity was 59%, specificity was 85%, positive predictive value was 18%, and negative predictive value was 97%. The Utah Score misclassified 16.6% of patients in the validation cohort. The Utah Score for predicting BCVI in pediatric trauma patients was validated with a low misclassification rate using a large, independent, multicenter cohort. Its implementation in the clinical setting may reduce the use of CTA in low-risk patients.	[Ravindra, Vijay M.; Bollo, Robert J.; Sivakumar, Walavan; Birkas, Yekaterina; Kestle, John R.; Riva-Cambrin, Jay] Univ Utah, Sch Med, Dept Neurosurg, Salt Lake City, UT USA; [Ravindra, Vijay M.; Bollo, Robert J.; Sivakumar, Walavan; Birkas, Yekaterina; Kestle, John R.; Riva-Cambrin, Jay] Primary Childrens Med Ctr, Div Pediat Neurosurg, Salt Lake City, UT USA; [Akbari, Hassan; Limbrick, David D., Jr.] Washington Univ, Dept Neurosurg, St Louis, MO USA; [Akbari, Hassan; Limbrick, David D., Jr.] St Louis Childrens Hosp, Div Pediat Neurosurg, St Louis, MO 63178 USA; [Naftel, Robert P.; Gannon, Stephen; Shannon, Chevis; Yang, George L.; Prather, Colin T.] Vanderbilt Univ, Dept Neurosurg, 221 Kirkland Hall, Nashville, TN 37235 USA; [Naftel, Robert P.; Gannon, Stephen; Shannon, Chevis; Yang, George L.; Prather, Colin T.] Monroe Carell Jr Childrens Hosp, Div Pediat Neurosurg, Nashville, TN USA; [Jea, Andrew] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA; [Jea, Andrew] Texas Childrens Hosp, Div Pediat Neurosurg, Houston, TX 77030 USA	Riva-Cambrin, J (corresponding author), Alberta Childrens Prov Gen Hosp, Div Pediat Neurosurg, 2888 Shaganappi Trail NW, Calgary, AB T3B 6A8, Canada.	neuropub@hsc.utah.edu			Primary Children's Hospital Foundation Grant; Center for Clinical and Translational Sciences (NCATS/NIH) [8UL1TR000105]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000105] Funding Source: NIH RePORTER; NATIONAL CENTER FOR RESEARCH RESOURCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Research Resources (NCRR) [UL1RR025764] Funding Source: NIH RePORTER	Funding for this project was received through the Primary Children's Hospital Foundation Grant awarded to Vijay M. Ravindra in the amount of $14,750. REDcap use and management was funded by Center for Clinical and Translational Sciences grant support (8UL1TR000105 (formerly UL1RR025764) NCATS/NIH).	Azarakhsh N, 2013, J TRAUMA ACUTE CARE, V75, P1006, DOI 10.1097/TA.0b013e31829d3526; Berne JD, 2004, J TRAUMA, V57, P11, DOI 10.1097/01.TA.0000135499.70048.C7; Berne JD, 2009, J TRAUMA, V67, P1333, DOI 10.1097/TA.0b013e31818888c7; Biffl WL, 2009, J TRAUMA, V67, P1150, DOI 10.1097/TA.0b013e3181c1c1d6; Biffl WL, 2006, J TRAUMA, V60, P745, DOI 10.1097/01.ta.0000204034.94034.c4; Biffl WL, 1999, J TRAUMA, V47, P438, DOI 10.1097/00005373-199908000-00051; Biffl WL, 1999, J TRAUMA, V47, P845, DOI 10.1097/00005373-199911000-00004; Biffl WL, 1999, AM J SURG, V178, P517, DOI 10.1016/S0002-9610(99)00245-7; Bok APL, 1996, J TRAUMA, V40, P968, DOI 10.1097/00005373-199606000-00017; Brenner DJ, 2007, NEW ENGL J MED, V357, P2277, DOI 10.1056/NEJMra072149; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brunetti MA, 2011, J TRAUMA, V70, pE24, DOI 10.1097/TA.0b013e3181e80d8d; Burke D C, 1974, Paraplegia, V11, P268; Burlew CC, 2012, J TRAUMA ACUTE CARE, V72, P330, DOI 10.1097/TA.0b013e31823de8a0; Burroughs AK, 2006, LANCET, V367, P225, DOI 10.1016/S0140-6736(06)68033-1; Carrillo EH, 1999, J TRAUMA, V46, P1120, DOI 10.1097/00005373-199906000-00030; Cothren C. Clay, 2005, Clinics, V60, P489, DOI 10.1590/S1807-59322005000600011; DULA DJ, 1979, JACEP-J AM COLL EMER, V8, P504, DOI 10.1016/S0361-1124(79)80295-6; Eastman AL, 2006, J TRAUMA, V60, P925, DOI 10.1097/01.ta.0000197479.28714.62; Fassett DR, 2008, J SPINAL DISORD TECH, V21, P252, DOI 10.1097/BSD.0b013e3180cab162; Harris PA, 2009, J BIOMED INFORM, V42, P377, DOI 10.1016/j.jbi.2008.08.010; HUBBARD DD, 1974, CLIN ORTHOP RELAT R, P56; Jones TS, 2012, AM J SURG, V204, P7, DOI 10.1016/j.amjsurg.2011.07.015; KALFAS I, 1988, NEUROSURGERY, V23, P295, DOI 10.1227/00006123-198809000-00002; Kaye D, 2011, J TRAUMA, V70, P1051, DOI 10.1097/TA.0b013e318211857d; Kopelman TR, 2011, J TRAUMA, V71, P559, DOI 10.1097/TA.0b013e318226eadd; Kulkarni AV, 2009, J PEDIATR-US, V155, P254, DOI 10.1016/j.jpeds.2009.02.048; Lew SM, 1999, PEDIATR NEUROSURG, V30, P239, DOI 10.1159/000028804; Liesemer K, 2014, PEDIATR CRIT CARE ME, V15, P554, DOI 10.1097/PCC.0000000000000150; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MELZAK J, 1969, LANCET, V2, P45; Miglioretti DL, 2013, JAMA PEDIATR, V167, P700, DOI 10.1001/jamapediatrics.2013.311; Miller PR, 2002, ANN SURG, V236, P386, DOI 10.1097/00000658-200209000-00015; Pearce MS, 2012, LANCET, V380, P499, DOI 10.1016/S0140-6736(12)60815-0; Rang M, 1974, CHILDRENS FRACTURES; Ravindra VM, 2015, J NEUROSURG-PEDIATR, V15, P599, DOI 10.3171/2014.11.PEDS14397; Riva-Cambrin J, 2009, J NEUROSURG-PEDIATR, V3, P378, DOI 10.3171/2009.1.PEDS08298; Roberts DJ, 2013, ANN SURG, V257, P621, DOI 10.1097/SLA.0b013e318288c514; Sarkar K, 2014, J NEUROSURG-PEDIATR, V13, P307, DOI 10.3171/2013.12.PEDS13223; Takei Y, 2016, PEDIATR RADIOL, V46, P280, DOI 10.1007/s00247-015-3474-x; Wang AC, 2012, J TRAUMA ACUTE CARE, V72, P1599, DOI 10.1097/TA.0b013e318246ead4	41	22	22	0	3	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 15	2017	34	2					391	399		10.1089/neu.2016.4415			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EH4QD	WOS:000391754800015	27297774	Green Published			2021-06-18	
J	Abdul-Muneer, PM; Conte, AA; Haldar, D; Long, M; Patel, RK; Santhakumar, V; Overall, CM; Pfister, BJ				Abdul-Muneer, P. M.; Conte, Adriano Andrea; Haldar, Debanjan; Long, Mathew; Patel, Rachel K.; Santhakumar, Vijayalakshmi; Overall, Christopher M.; Pfister, Bryan J.			Traumatic brain injury induced matrix metalloproteinase2 cleaves CXCL12 alpha (stromal cell derived factor 1 alpha) and causes neurodegeneration	BRAIN BEHAVIOR AND IMMUNITY			English	Article						Traumatic brain injury; Stromal cell derived factor; CXCL12; MMP2; Oxidative stress; Apoptosis; Neurodegeneration	HIV-ASSOCIATED NEURODEGENERATION; FLUID PERCUSSION INJURY; INDUCED AXONAL INJURY; FACTOR-I; BARRIER DISRUPTION; OXIDATIVE STRESS; HEAD-INJURY; MATRIX-METALLOPROTEINASE-9; ACTIVATION; PERMEABILITY	Traumatic brain injury (TBI), even at mild levels, can activate matrix metalloproteinases (MMPs) and the induction of neuroinflammation that can result in blood brain barrier breakdown and neurodegeneration. MMP2 has a significant role in neuroinflammation and neurodegeneration by modulating the chemokine CXCL12 alpha (stromal cell derived factor SDF-1 alpha) signaling pathway and the induction of apoptosis. SDF-1 alpha is responsible for cell proliferation and differentiation throughout the nervous system and is also implicated in various neurodegenerative illnesses. We hypothesized that TBI leads to MMP2 activation and cleavage of the N-terminal 4 amino acid residues of CXCL12 alpha with generation of the highly neurotoxic fragment SDF-1(5-67). Using an in vitro stretch-injury model of rat neuronal cultures and the in vivo fluid percussion injury (FPI) model in rats, we found that oxidative stress has a significant role in the activation of MMP2. This is initiated by the induction of free radical generating enzyme NADPH oxidase 1 (NOX1). Induction of NOXI correlated well with the signatures of oxidative stress marker, 4HNE in the injured neuronal cultures and cerebral cortex of rats. Further, using MMP2 siRNA and pharmacological MMP2 inhibitor, ARP100, we established the neurodegenerative role of MMP2 in cleaving SDF-1 alpha to a neurotoxic fragment SDF-1(5-67). By immunofluorescence, western blotting and TUNEL experiments, we show the cleaved form of SDF leads to apoptotic cell death in neurons. This work identifies a new potential therapeutic target to reduce the complications of brain damage in TBI. (C) 2016 Elsevier Inc. All rights reserved.	[Abdul-Muneer, P. M.; Haldar, Debanjan; Patel, Rachel K.] JFK Med Ctr, Lab CNS Injury & Repair, Neurosci Inst, 65 James St, Edison, NJ 08820 USA; [Abdul-Muneer, P. M.; Conte, Adriano Andrea; Haldar, Debanjan; Long, Mathew; Patel, Rachel K.; Pfister, Bryan J.] New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA; [Santhakumar, Vijayalakshmi] Rutgers New Jersey Med Sch, Dept Pharmacol Physiol & Neurosci, Newark, NJ 07103 USA; [Overall, Christopher M.] Univ British Columbia, Dept Biochem & Mol Biol, 2199 Westbrook Mall, Vancouver, BC V6T 1Z3, Canada; [Overall, Christopher M.] Univ British Columbia, Dept Oral Biol & Med Sci, 2199 Westbrook Mall, Vancouver, BC V6T 1Z3, Canada	Abdul-Muneer, PM (corresponding author), JFK Med Ctr, Lab CNS Injury & Repair, Neurosci Inst, 65 James St, Edison, NJ 08820 USA.; Pfister, BJ (corresponding author), New Jersey Inst Technol, Dept Biomed Engn, Newark, NJ 07102 USA.	pmamuneer@gmail.com; pfister@njit.edu	Santhakumar, Viji/K-4856-2019	Santhakumar, Viji/0000-0001-6278-4187; Abdul-Muneer, P. M/0000-0001-8231-4385; Haldar, Debanjan/0000-0002-5061-0953	New Jersey Commission on Brain Injury Research [CBIR11PJT003]; Neuroscience Institute at JFK Medical Center	This work was funded by New Jersey Commission on Brain Injury Research #CBIR11PJT003 to Bryan J. Pfister and in part by the Neuroscience Institute at JFK Medical Center, Edison NJ to P. M. Abdul-Muneer.	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Abdul-Muneer PM, 2013, FREE RADICAL BIO MED, V60, P282, DOI 10.1016/j.freeradbiomed.2013.02.029; Abdul-Muneer P.M., 2016, MOL NEUROBIOL; [Anonymous], 2015, MOL NEUROBIOL; Barlaka E, 2015, PHARMACOL RES, V95-96, P102, DOI 10.1016/j.phrs.2015.03.008; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Blixt J, 2015, BRAIN RES, V1611, P18, DOI 10.1016/j.brainres.2015.03.004; Buki A, 2000, J NEUROSCI, V20, P2825; Buki A, 1999, J NEUROPATH EXP NEUR, V58, P365; Butler GS, 2009, BIOCHEMISTRY-US, V48, P10830, DOI 10.1021/bi901656f; Chen XH, 2004, AM J PATHOL, V165, P357, DOI 10.1016/S0002-9440(10)63303-2; Clark RSB, 1999, FASEB J, V13, P813; Cohen AS, 2007, PROG BRAIN RES, V161, P143, DOI 10.1016/S0079-6123(06)61010-8; Egashira Y, 2015, STROKE, V46, P2909, DOI 10.1161/STROKEAHA.115.010351; Gennarelli Thomas A., 1993, Journal of Emergency Medicine, V11, P5; Hodohara K, 2000, BLOOD, V95, P769, DOI 10.1182/blood.V95.3.769.003a49_769_775; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Ito TK, 2009, BLOOD, V113, P2363, DOI 10.1182/blood-2008-08-172742; Jia F, 2010, J NEUROTRAUM, V27, P1059, DOI 10.1089/neu.2009.1067; Johnston JB, 2002, J VIROL, V76, P2622, DOI 10.1128/JVI.76.6.2622-2633.2002; Ketsawatsomkron P, 2016, HYPERTENSION, V67, P214, DOI 10.1161/HYPERTENSIONAHA.115.06391; Knoblach SM, 2002, J NEUROTRAUM, V19, P1155, DOI 10.1089/08977150260337967; Lorente L, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121739; Lucke-Wold BP, 2015, MOL NEUROBIOL, V52, P1119, DOI 10.1007/s12035-014-8902-7; Magou GC, 2011, J NEUROTRAUM, V28, P2203, DOI 10.1089/neu.2010.1596; Mannello F, 2005, APOPTOSIS, V10, P19, DOI 10.1007/s10495-005-6058-7; McCawley LJ, 2001, CURR OPIN CELL BIOL, V13, P534, DOI 10.1016/S0955-0674(00)00248-9; McQuibban GA, 2001, J BIOL CHEM, V276, P43503, DOI 10.1074/jbc.M107736200; Muneer PMA, 2012, ARTERIOSCL THROM VAS, V32, P1167, DOI 10.1161/ATVBAHA.112.247668; Muradashvili N, 2015, METAB BRAIN DIS, V30, P411, DOI 10.1007/s11011-014-9550-3; Nagase H, 1999, J BIOL CHEM, V274, P21491, DOI 10.1074/jbc.274.31.21491; Neuberger EJ, 2014, J NEUROSCI RES, V92, P1350, DOI 10.1002/jnr.23401; Pierce JES, 1998, NEUROSCIENCE, V87, P359, DOI 10.1016/S0306-4522(98)00142-0; POVLISHOCK JT, 1992, J NEUROTRAUM, V9, pS189; POVLISHOCK JT, 1993, ANN EMERG MED, V22, P980, DOI 10.1016/S0196-0644(05)82738-6; Povlishock JT, 1996, ACT NEUR S, V66, P81; POVLISHOCK JT, 1983, J NEUROPATH EXP NEUR, V42, P225, DOI 10.1097/00005072-198305000-00002; Qiu JH, 2002, J NEUROSCI, V22, P3504; Ransohoff RM, 2003, NAT NEUROSCI, V6, P1009, DOI 10.1038/nn1003-1009; Rodriguez D, 2010, BBA-MOL CELL RES, V1803, P39, DOI 10.1016/j.bbamcr.2009.09.015; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SHERRIFF FE, 1994, ACTA NEUROPATHOL, V88, P433; Sifringer M, 2007, NEUROBIOL DIS, V25, P526, DOI 10.1016/j.nbd.2006.10.019; Smith DH, 2000, J NEUROSURG, V93, P315, DOI 10.3171/jns.2000.93.2.0315; Smith DH, 2003, J HEAD TRAUMA REHAB, V18, P307, DOI 10.1097/00001199-200307000-00003; THOMPSON CB, 1995, SCIENCE, V267, P1456, DOI 10.1126/science.7878464; Trentini A, 2015, MULT SCLER J, V21, P1121, DOI 10.1177/1352458514560925; Vergote D, 2006, P NATL ACAD SCI USA, V103, P19182, DOI 10.1073/pnas.0604678103; Visse R, 2003, CIRC RES, V92, P827, DOI 10.1161/01.RES.0000070112.80711.3D; Wahab RA, 2015, J NEUROSCI METH, V248, P16, DOI 10.1016/j.jneumeth.2015.03.010; Wang XY, 2002, J NEUROTRAUM, V19, P615, DOI 10.1089/089771502753754082; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Yakovlev AG, 2001, MOL NEUROBIOL, V24, P131; Yong VW, 2001, NAT REV NEUROSCI, V2, P502, DOI 10.1038/35081571; Yuan F, 2016, J NEUROCHEM, V136, P581, DOI 10.1111/jnc.13423; Zhang KY, 2003, NAT NEUROSCI, V6, P1064, DOI 10.1038/nn1127; Zhang S., 2016, NEUROCHEM INT; Zhang XP, 2006, J NEUROTRAUM, V23, P1583, DOI 10.1089/neu.2006.23.1583	58	22	23	1	10	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	0889-1591	1090-2139		BRAIN BEHAV IMMUN	Brain Behav. Immun.	JAN	2017	59						190	199		10.1016/j.bbi.2016.09.002			10	Immunology; Neurosciences; Psychiatry	Immunology; Neurosciences & Neurology; Psychiatry	EF8YU	WOS:000390618700018	27614125				2021-06-18	
J	Koning, ME; Scheenen, ME; van der Horn, HJ; Hageman, G; Roks, G; Spikman, JM; van der Naalt, J				de Koning, Myrthe E.; Scheenen, Myrthe E.; van der Horn, Harm J.; Hageman, Gerard; Roks, Gerwin; Spikman, Jacoba M.; van der Naalt, Joukje			Non-Hospitalized Patients with Mild Traumatic Brain Injury: The Forgotten Minority	JOURNAL OF NEUROTRAUMA			English	Article						aftercare; follow-up; mTBI; outcome	GLASGOW OUTCOME SCALE; HEAD-INJURY; EVENT SCALE; TRACK-TBI; IMPACT; VALIDATION; GUIDELINES; COMPLAINTS; SYMPTOMS; DISORDER	Non-hospitalized mild traumatic brain injury (mTBI) patients comprise a substantial part of the trauma population. For these patients, guidelines recommend specialized follow-up only in the case of persistent complaints or problems in returning to previous activities. This study describes injury and outcome characteristics of non-hospitalized mTBI patients, and the possibility of predicting which of the non-hospitalized patients will return to the outpatient neurology clinic. Data from all non-hospitalized mTBI patients (Glasgow Coma Scale [GCS] score 13-15, n = 462) from a prospective follow-up study on mTBI (UPFRONT-study) conducted in three level 1 trauma centers were analyzed. At 2 weeks, and 3 and 6 months after injury, patients completed questionnaires on post-traumatic complaints, depression, anxiety, outpatient follow-up, and resumption of activities. Most patients were male (57%), with a mean age of 40 years (range 16-91 years). Injuries were most often caused by traffic accidents (32%) or falls (39%). Six months after injury, 36% showed incomplete recovery as defined by the Glasgow Outcome Scale - Extended (GOS-E). Twenty-five percent of the non-hospitalized patients returned to the outpatient neurology clinic within 6 months after injury, of which one third had not completely resumed pre-injury activities. Regression analyses showed an increased risk for outpatient follow-up for patients scoring above the cutoff value for anxiety (odds ratio [OR] = 3.0), depression (OR = 3.5), or both (OR = 3.7) 2 weeks after injury. Our findings underline that clinicians and researchers should be aware of recovery for all mTBI patients, preventing their transition into a forgotten minority.	[de Koning, Myrthe E.; van der Horn, Harm J.; van der Naalt, Joukje] Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands; [Scheenen, Myrthe E.; Spikman, Jacoba M.] Univ Groningen, Univ Med Ctr Groningen, Dept Neuropsychol, Groningen, Netherlands; [Hageman, Gerard] Med Spectrum Twente, Dept Neurol, Enschede, Netherlands; [Roks, Gerwin] St Elizabeth Hosp, Dept Neurol, Tilburg, Netherlands	van der Naalt, J (corresponding author), Univ Groningen, Univ Med Ctr Groningen, Dept Neurol, Hanzepl 1, NL-9700 RB Groningen, Netherlands.	j.van.der.naalt@umcg.nl		Spikman, Jacoba/0000-0002-6477-0763	Dutch Brain Foundation [PS2012-06]	This study was funded by the Dutch Brain Foundation (Grant no. PS2012-06).	Andriessen TMJC, 2009, BRAIN INJURY, V23, P345, DOI 10.1080/02699050902791414; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bell KR, 2008, J NEUROL NEUROSUR PS, V79, P1275, DOI 10.1136/jnnp.2007.141762; Bombardier CH, 2010, JAMA-J AM MED ASSOC, V303, P1938, DOI 10.1001/jama.2010.599; Corrigan JD, 2003, ARCH PHYS MED REHAB, V84, P153, DOI 10.1053/apmr.2003.50093; HOROWITZ M, 1979, PSYCHOSOM MED, V41, P209, DOI 10.1097/00006842-197905000-00004; Lingsma HF, 2015, J NEUROTRAUM, V32, P83, DOI 10.1089/neu.2014.3384; Losoi H, 2016, J NEUROTRAUM, V33, P766, DOI 10.1089/neu.2015.4070; MARSHALL LF, 1992, J NEUROTRAUM, V9, pS287; Marshall S, 2015, BRAIN INJURY, V29, P688, DOI 10.3109/02699052.2015.1004755; McCullagh S, 2003, J NEUROL NEUROSUR PS, V74, P39, DOI 10.1136/jnnp.74.1.39; McMahon P, 2014, J NEUROTRAUM, V31, P26, DOI 10.1089/neu.2013.2984; Olesen J, 2012, EUR J NEUROL, V19, P155, DOI 10.1111/j.1468-1331.2011.03590.x; Patel MB, 2015, J NEUROTRAUM, V32, P984, DOI 10.1089/neu.2014.3652; Ponsford J, 2002, J NEUROL NEUROSUR PS, V73, P330, DOI 10.1136/jnnp.73.3.330; Ponsford J, 2011, J NEUROTRAUM, V28, P937, DOI 10.1089/neu.2010.1516; Ratcliff JJ, 2014, AM J EMERG MED, V32, P844, DOI 10.1016/j.ajem.2014.04.003; Ruff R, 2005, J HEAD TRAUMA REHAB, V20, P5, DOI 10.1097/00001199-200501000-00003; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; van der Horn HJ, 2013, ARCH PHYS MED REHAB, V94, P867, DOI 10.1016/j.apmr.2012.11.039; van der Naalt J, 1999, J NEUROL NEUROSUR PS, V66, P207, DOI 10.1136/jnnp.66.2.207; van der Ploeg E, 2004, PSYCHOL ASSESSMENT, V16, P16, DOI 10.1037/1040-3590.16.1.16; Vos PE, 2012, EUR J NEUROL, V19, P191, DOI 10.1111/j.1468-1331.2011.03581.x; Vos PE, 2002, EUR J NEUROL, V9, P207, DOI 10.1046/j.1468-1331.2002.00407.x; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Wilson JTL, 2002, J NEUROTRAUM, V19, P999, DOI 10.1089/089771502760341910; Wohlfarth TD, 2003, PSYCHOL ASSESSMENT, V15, P101, DOI 10.1037/1040-3590.15.1.101; ZIGMOND AS, 1983, ACTA PSYCHIAT SCAND, V67, P361, DOI 10.1111/j.1600-0447.1983.tb09716.x	28	22	22	0	6	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					257	261		10.1089/neu.2015.4377			5	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100027	27029852				2021-06-18	
J	Dubose, DF; Herman, DC; Jones, DL; Tillman, SM; Clugston, JR; Pass, A; Hernandez, JA; Vasilopoulos, T; Horodyski, M; Chmielewski, TL				Dubose, Dominique F.; Herman, Daniel C.; Jones, Deborah L.; Tillman, Susan M.; Clugston, James R.; Pass, Anthony; Hernandez, Jorge A.; Vasilopoulos, Terrie; Horodyski, Marybeth; Chmielewski, Terese L.			Lower Extremity Stiffness Changes after Concussion in Collegiate Football Players	MEDICINE AND SCIENCE IN SPORTS AND EXERCISE			English	Article						NEUROMUSCULAR FUNCTION; JUMP LANDING; BIOMECHANICS; SPORTS-RELATED CONCUSSION	SPORTS-RELATED CONCUSSION; CRUCIATE LIGAMENT INJURY; TRAUMATIC BRAIN-INJURY; LEG STIFFNESS; HOPPING TASKS; MUSCULOSKELETAL INJURY; GENDER-DIFFERENCES; MOTOR; ABNORMALITIES; RISK	Purpose: Recent research indicates that a concussion increases the risk of musculoskeletal injury. Neuromuscular changes after concussion might contribute to the increased risk of injury. Many studies have examined gait postconcussion, but few studies have examined more demanding tasks. This study compared changes in stiffness across the lower extremity, a measure of neuromuscular function, during a jump-landing task in athletes with a concussion (CONC) to uninjured athletes (UNINJ). Methods: Division I football players (13 CONC and 26 UNINJ) were tested pre- and postseason. A motion capture system recorded subjects jumping on one limb from a 25.4-cm step onto a force plate. Hip, knee, and ankle joint stiffness were calculated from initial contact to peak joint flexion using the regression line slopes of the joint moment versus the joint angle plots. Leg stiffness was (peak vertical ground reaction force [PVGRF]/lower extremity vertical displacement) from initial contact to peak vertical ground reaction force. All stiffness values were normalized to body weight. Values from both limbs were averaged. General linear models compared group (CONC, UNINJ) differences in the changes of pre-and postseason stiffness values. Results: Average time from concussion to postseason testing was 49.9 d. The CONC group showed an increase in hip stiffness (P = 0.03), a decrease in knee (P = 0.03) and leg stiffness (P = 0.03), but no change in ankle stiffness (P = 0.65) from pre- to postseason. Conclusion: Lower extremity stiffness is altered after concussion, which could contribute to an increased risk of lower extremity injury. These data provide further evidence of altered neuromuscular function after concussion.	[Dubose, Dominique F.; Jones, Deborah L.; Tillman, Susan M.; Chmielewski, Terese L.] Univ Florida, Dept Phys Therapy, Coll Publ Hlth & Hlth Profess, Gainesville, FL USA; [Herman, Daniel C.; Horodyski, Marybeth] Univ Florida, Coll Med, Dept Orthopaed & Rehabil, Gainesville, FL USA; [Clugston, James R.] Univ Florida, Dept Community Hlth & Family Med, Coll Med, Gainesville, FL USA; [Pass, Anthony] Univ Texas Austin, Dept Athlet, Austin, TX 78712 USA; [Hernandez, Jorge A.] Univ Florida, Dept Large Anim & Clin Sci, Coll Vet Med, Gainesville, FL USA; [Vasilopoulos, Terrie] Univ Florida, Dept Anesthesiol, Coll Med, Gainesville, FL USA; [Chmielewski, Terese L.] TRIA Orthopaed Ctr, Bloomington, MN USA	Dubose, DF (corresponding author), Univ Florida, Dept Phys Therapy, UFHSC, Box 100154, Gainesville, FL 32610 USA.	dlf967@ufl.edu	Vasilopoulos, Terrie/AAF-9157-2019	Clugston, James/0000-0002-2103-1039	NIH-NICHDUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01-HD052713]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD001097] Funding Source: NIH RePORTER; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH &HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K01HD052713] Funding Source: NIH RePORTER	Dr. Chmielewski's effort on the study was supported by the NIH-NICHD (grant no. K01-HD052713).	Benjaminse A, 2008, KNEE SURG SPORT TR A, V16, P400, DOI 10.1007/s00167-007-0432-7; Boden BP, 2009, AM J SPORT MED, V37, P252, DOI 10.1177/0363546508328107; Brauner T, 2014, HUM MOVEMENT SCI, V33, P263, DOI 10.1016/j.humov.2013.08.009; Brooks MA, 2016, AM J SPORTS MED, V19; Butler RJ, 2003, CLIN BIOMECH, V18, P511, DOI 10.1016/S0268-0033(03)00071-8; Chamard E, 2013, BRAIN INJURY, V27, P1038, DOI 10.3109/02699052.2013.794968; Chappell JD, 2007, AM J SPORT MED, V35, P235, DOI 10.1177/0363546506294077; Chmielewski TL, 2004, J ORTHOP RES, V22, P925, DOI 10.1016/j.orthres.2004.01.007; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-109; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; DuBose DF, 2013, J ATHL TRAIN S, V48, pS; DuBose DF, 2014, MED SCI SPORT EXER, V46, P18, DOI 10.1249/01.mss.0000493218.72680.98; Ford KR, 2010, AM J SPORT MED, V38, P1829, DOI 10.1177/0363546510367425; Granata KP, 2002, J ELECTROMYOGR KINES, V12, P127, DOI 10.1016/S1050-6411(02)00003-2; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Herman DC, 2015, CURR SPORT MED REP, V14, P194, DOI 10.1249/JSR.0000000000000157; Hewett TE, 2005, AM J SPORT MED, V33, P492, DOI 10.1177/0363546504269591; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Lynall RC, 2015, MED SCI SPORT EXER, V47, P2487, DOI 10.1249/MSS.0000000000000716; Maquirriain J, 2012, INT J SPORTS MED, V33, P567, DOI 10.1055/s-0032-1304644; Martini DN, 2011, ARCH PHYS MED REHAB, V92, P585, DOI 10.1016/j.apmr.2010.11.029; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; NILSSON J, 1989, ACTA PHYSIOL SCAND, V136, P217, DOI 10.1111/j.1748-1716.1989.tb08655.x; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Padua DA, 2005, J MOTOR BEHAV, V37, P111, DOI 10.3200/JMBR.37.2.111-126; Pearce AJ, 2015, J SCI MED SPORT, V18, P500, DOI 10.1016/j.jsams.2014.07.010; Pietrosimone B, 2015, MED SCI SPORT EXER, V47, P2366, DOI 10.1249/MSS.0000000000000684; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Rapoport S, 2003, J BIOMECH ENG-T ASME, V125, P507, DOI 10.1115/1.1590358; Reed N, 2013, BRIT J SPORT MED, V47, pe1; Serpell BG, 2012, J SPORT SCI, V30, P1347, DOI 10.1080/02640414.2012.710755; Tremblay S, 2011, J NEUROTRAUM, V28, P493, DOI 10.1089/neu.2010.1615; Watsford ML, 2010, AM J SPORT MED, V38, P2058, DOI 10.1177/0363546510370197; Wilk KE, 1996, AM J SPORT MED, V24, P518, DOI 10.1177/036354659602400418; Williams G, 2013, BRAIN INJURY, V27, P434, DOI 10.3109/02699052.2012.750754	38	22	22	0	39	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0195-9131	1530-0315		MED SCI SPORT EXER	Med. Sci. Sports Exerc.	JAN	2017	49	1					167	172		10.1249/MSS.0000000000001067			6	Sport Sciences	Sport Sciences	EF0PH	WOS:000390027700020	27501359	Green Accepted			2021-06-18	
J	Haarbauer-Krupa, J; Taylor, CA; Yue, JK; Winkler, EA; Pirracchio, R; Cooper, SR; Burke, JF; Stein, MB; Manley, GT				Haarbauer-Krupa, Juliet; Taylor, Christopher A.; Yue, John K.; Winkler, Ethan A.; Pirracchio, Romain; Cooper, Shelly R.; Burke, John F.; Stein, Murray B.; Manley, Geoffrey T.		TRACK-TBI Investigators	Screening for Post-Traumatic Stress Disorder in a Civilian Emergency Department Population with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						emergency department screening; post-traumatic stress disorder; traumatic brain injury	COMMON DATA ELEMENTS; GLASGOW OUTCOME SCALE; RISK-FACTORS; HEAD-INJURY; SYMPTOMS; RECOMMENDATIONS; SATISFACTION; VIOLENCE; HEALTH; IMPACT	Post-traumatic stress disorder (PTSD) is a condition associated with traumatic brain injury (TBI). While the importance of PTSD and TBI among military personnel is widely recognized, there is less awareness of PTSD associated with civilian TBI. We examined the incidence and factors associated with PTSD 6 months post-injury in a civilian emergency department population using measures from the National Institute of Neurological Disorders and Stroke TBI Common Data Elements Outcome Battery. Participants with mild TBI (mTBI) from the Transforming Research and Clinical Knowledge in Traumatic Brain Injury Pilot study with complete 6-month outcome batteries (n = 280) were analyzed. Screening for PTSD symptoms was conducted using the PTSD Checklist-Civilian Version. Descriptive measures are summarized and predictors for PTSD were examined using logistic regression. Incidence of screening positive for PTSD was 26.8% at 6 months following mTBI. Screening positive for PTSD was significantly associated with concurrent functional disability, post-concussive and psychiatric symptomatology, decreased satisfaction with life, and decreased performance in visual processing and mental flexibility. Multi-variable regression showed injury mechanism of assault (odds ratio [OR] 3.59; 95% confidence interval [CI] 1.69-7.63; p = 0.001) and prior psychiatric history (OR 2.56; 95% CI 1.42-4.61; p = 0.002) remained significant predictors of screening positive for PTSD, while education (per year OR 0.88; 95% CI 0.79-0.98; p = 0.021) was associated with decreased odds of PTSD. Standardized data collection and review of pre-injury education, psychiatric history, and injury mechanism during initial hospital presentation can aid in identifying patients with mTBI at risk for developing PTSD symptoms who may benefit from closer follow-up after initial injury care.	[Haarbauer-Krupa, Juliet; Taylor, Christopher A.] Ctr Dis Control & Prevent, Natl Ctr Injury Prevent & Control, Div Unintent Injury, Atlanta, GA USA; [Yue, John K.; Winkler, Ethan A.; Cooper, Shelly R.; Burke, John F.; Manley, Geoffrey T.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA; [Pirracchio, Romain] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA; [Yue, John K.; Winkler, Ethan A.; Cooper, Shelly R.; Burke, John F.; Manley, Geoffrey T.] San Francisco Gen Hosp, Brain & Spinal Injury Ctr, San Francisco, CA 94110 USA; [Cooper, Shelly R.] Washington Univ, Dept Psychol, St Louis, MO 63130 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Psychiat, San Diego, CA 92103 USA; [Stein, Murray B.] Univ Calif San Diego, Dept Family & Prevent Med, San Diego, CA 92103 USA	Manley, GT (corresponding author), Univ Calif San Francisco, Dept Neurol Surg, Brain & Spinal Injury Ctr BASIC, 1001 Potrero Ave,Bldg 1,Room 101, San Francisco, CA 94110 USA.	manleyg@neurosurg.ucsf.edu	Taylor, Christopher A/D-2067-2013; Yue, John K/P-1348-2015	Taylor, Christopher A/0000-0002-0937-5461; Yue, John K/0000-0001-9694-7722; Cooper, Shelly/0000-0003-0026-6688; Burke, John/0000-0002-6190-5116	One Mind for Research; National Science FoundationNational Science Foundation (NSF) [DGE-1143954];  [NIH RC2 NS069409];  [NIH RC2 NS064909-02S1];  [NIH U01 NS086090-01];  [DOD W81XWH-13-1-0441];  [DOD W81XWH-14-2-0176]	This study was supported by the following grants: NIH RC2 NS069409, NIH RC2 NS064909-02S1, NIH U01 NS086090-01, DOD W81XWH-13-1-0441, DOD W81XWH-14-2-0176 (Manley), and One Mind for Research.; This material is based upon work supported by the National Science Foundation Graduate Research Fellowship under Grant No. DGE-1143954.	American Psychiatric Association, 2013, DIAGN STAT MAN MENT, V5, DOI [10.1176/appi.books.9780890425596., DOI 10.1176/APPI.BOOKS.9780890425596, 10.1176/appi.books.9780890425596]; American Psychiatric Association, 2002, DIAGN STAT MAN MENT, V4th; Bahraini NH, 2014, PSYCHIAT CLIN N AM, V37, P55, DOI 10.1016/j.psc.2013.11.002; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; Bombardier CH, 2006, J NEUROPSYCH CLIN N, V18, P501, DOI 10.1176/appi.neuropsych.18.4.501; Brewin CR, 2000, J CONSULT CLIN PSYCH, V68, P748, DOI 10.1037/0022-006X.68.5.748; Browne AL, 2013, DISABIL REHABIL, V35, P1149, DOI 10.3109/09638288.2012.721047; Bryant RA, 1999, BRAIN INJURY, V13, P15, DOI 10.1080/026990599121836; Bryant Richard, 2011, Dialogues Clin Neurosci, V13, P251; Carlson KF, 2011, J HEAD TRAUMA REHAB, V26, P103, DOI 10.1097/HTR.0b013e3181e50ef1; Carroll Linda J, 2014, Arch Phys Med Rehabil, V95, pS152, DOI 10.1016/j.apmr.2013.08.300; Cassidy JD, 2004, J REHABIL MED, V36, P28, DOI 10.1080/16501960410023732; Colantonio A, 2010, CAN J NEUROL SCI, V37, P783, DOI 10.1017/S0317167100051441; Combs HL, 2015, J NEUROTRAUM, V32, P956, DOI 10.1089/neu.2014.3585; Delis DC, 2000, CALIFORNIA VERBAL LE; Derogatis L., 2000, BRIEF SYMPTOM INVENT; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Eskridge SL, 2013, J NEUROTRAUM, V30, P1391, DOI 10.1089/neu.2012.2537; Gerhart KA, 2003, J TRAUMA, V55, P1045, DOI 10.1097/01.TA.0000044353.69681.96; Greenspan AI, 2006, BRAIN INJURY, V20, P733, DOI 10.1080/02699050600773276; Gros DF, 2012, PSYCHIAT RES, V196, P267, DOI 10.1016/j.psychres.2011.10.022; Haagsma JA, 2015, J NEUROTRAUM, V32, P853, DOI 10.1089/neu.2013.3283; Han X., 2014, J SLEEP DISORDERS TH, V3, P164; Hanks RA, 2003, ARCH PHYS MED REHAB, V84, P249, DOI 10.1053/apmr.2003.50096; Harrison-Felix C, 1998, ARCH PHYS MED REHAB, V79, P730, DOI 10.1016/S0003-9993(98)90348-3; Ingebrigtsen T, 1998, J NEUROL, V245, P609, DOI 10.1007/s004150050254; Jacobs B, 2010, J NEUROTRAUM, V27, P655, DOI 10.1089/neu.2009.1059; Jagoda AS, 2008, ANN EMERG MED, V52, P714, DOI 10.1016/j.annemergmed.2008.08.021; Kaloupek DG, 2010, ARCH PHYS MED REHAB, V91, P1684, DOI 10.1016/j.apmr.2010.06.032; Kennedy JE, 2007, J REHABIL RES DEV, V44, P895, DOI 10.1682/JRRD.2006.12.0166; Kim H, 2013, DISABIL REHABIL, V35, P2213, DOI 10.3109/09638288.2013.774063; KING NS, 1995, J NEUROL, V242, P587, DOI 10.1007/BF00868811; Levin HS, 2001, J CLIN EXP NEUROPSYC, V23, P754, DOI 10.1076/jcen.23.6.754.1021; Levin HS, 2001, J NEUROTRAUM, V18, P575, DOI 10.1089/089771501750291819; Luethcke CA, 2011, J INT NEUROPSYCH SOC, V17, P36, DOI 10.1017/S1355617710001207; Maas AI, 2010, ARCH PHYS MED REHAB, V91, P1641, DOI 10.1016/j.apmr.2010.07.232; MacDonald Christine L, 2014, J Neurotrauma, V31, P889, DOI 10.1089/neu.2013.3173; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; Michaels AJ, 2000, J TRAUMA, V48, P841, DOI 10.1097/00005373-200005000-00007; Reitan RM, 1955, J CONSULT PSYCHOL, V19, P393, DOI 10.1037/h0044509; Stulemeijer M, 2006, J NEUROTRAUM, V23, P1561, DOI 10.1089/neu.2006.23.1561; Sumowski JF, 2013, ARCH PHYS MED REHAB, V94, P2562, DOI 10.1016/j.apmr.2013.07.023; TEASDALE G, 1974, LANCET, V2, P81; Weathers F, 1993, 9 ANN CONV INT SOC T; Weathers F. W., 2013, PTSD CHECKLIST DSM 5; Wechsler D., 2008, WECHSLER ADULT INTEL, V4th ed; Wilde EA, 2010, ARCH PHYS MED REHAB, V91, P1650, DOI 10.1016/j.apmr.2010.06.033; Wilson JTL, 1998, J NEUROTRAUM, V15, P573, DOI 10.1089/neu.1998.15.573; Yue JK, 2013, J NEUROTRAUM, V30, P1831, DOI 10.1089/neu.2013.2970; Yurgil KA, 2014, JAMA PSYCHIAT, V71, P149, DOI 10.1001/jamapsychiatry.2013.3080; Zatzick DF, 2006, J AM ACAD CHILD PSY, V45, P1188, DOI 10.1097/01.chi.0000231975.21096.45; Zatzick DF, 2010, ARCH GEN PSYCHIAT, V67, P1291, DOI 10.1001/archgenpsychiatry.2010.158	52	22	23	1	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					50	58		10.1089/neu.2015.4158			9	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100007	26936513	Green Published			2021-06-18	
J	Hu, JQ; Han, H; Cao, P; Yu, WC; Yang, C; Gao, Y; Yuan, W				Hu, Jinquan; Han, Hui; Cao, Peng; Yu, Wenchao; Yang, Chen; Gao, Yang; Yuan, Wen			Resveratrol improves neuron protection and functional recovery through enhancement of autophagy after spinal cord injury in mice	AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH			English	Article						Spinal cord injury; resveratrol; apoptosis; autophagy; chloroquine	TRAUMATIC BRAIN-INJURY; CEREBRAL-ISCHEMIA; DORSAL COLUMN; CELL-DEATH; RAT MODEL; DAMAGE; DEGENERATION; APOPTOSIS; RAPAMYCIN; STRESS	Resveratrol (Res), a natural phenolic compound, has been proven to have a wide variety of beneficial health effects. For example, resveratrol has neuroprotective effects in different central nervous system diseases. However, the mechanisms underlying resveratrol neuroprotection in spinal cord injury (SCI) remain unclear. In this study, we showed that resveratrol treatment improved the restoration of locomotor function, and decreased the degeneration of neurons in SCI mice, which was paralleled by a reduction of apoptosis. We further examined autophagy markers via western blot and immunofluorescence. Results showed that the beneficial effects of resveratrol were related to the promotion LC3II and beclin-1 expression. In addition, autophagy suppression with chloroquine (CQ) partially abolished apoptosis inhibition and locomotor functional improvement of Res on SCI, which indicated that the beneficial effect of resveratrol on SCI was through autophagy enhancement. In conclusion, these results illustrated that the neuroprotective effects of resveratrol in SCI are partially through autophagy stimulation, and implied that Res is a promising drug for SCI therapy.	[Hu, Jinquan; Cao, Peng; Yu, Wenchao; Yang, Chen; Gao, Yang; Yuan, Wen] Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China; [Han, Hui] Shanghai Jiao Tong Univ, Sch Med, Rui Jin Hosp, Dept Cardiol, Shanghai 200025, Peoples R China	Gao, Y; Yuan, W (corresponding author), Second Mil Med Univ, Changzheng Hosp, Dept Orthopaed, 415 Fengyang Rd, Shanghai 200003, Peoples R China.	3011547085@qq.com; wen-yuan2014@126.com			international cooperation program of shanghai science and technology committee [13430721000]	The study was supported by the international cooperation program of shanghai science and technology committee (13430721000).	Bethea JR, 2002, CURR OPIN NEUROL, V15, P355, DOI 10.1097/00019052-200206000-00021; Bin Hong Y, 2009, EXP MOL MED, V41, P151, DOI 10.3858/emm.2009.41.3.018; Chen HC, 2012, SPINE, V37, P470, DOI 10.1097/BRS.0b013e318221e859; Engelhard K, 2004, ANESTHESIOLOGY, V101, P912, DOI 10.1097/00000542-200410000-00016; Erlich S, 2007, NEUROBIOL DIS, V26, P86, DOI 10.1016/j.nbd.2006.12.003; Feng Y, 2016, INT J MOL MED, V37, P921, DOI 10.3892/ijmm.2016.2495; Guo DJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0064078; HALL ED, 1992, J NEUROTRAUM, V9, pS425; Hou HP, 2014, J NEUROSURG-SPINE, V20, P568, DOI 10.3171/2014.1.SPINE13237; Impellizzeri D, 2012, BIOCHEM PHARMACOL, V83, P1413, DOI 10.1016/j.bcp.2012.02.001; Kanno H, 2011, SPINE, V36, pE1427, DOI 10.1097/BRS.0b013e3182028c3a; Kanno H, 2009, NEUROBIOL DIS, V33, P143, DOI 10.1016/j.nbd.2008.09.009; Kesherwani V, 2013, NEUROSCIENCE, V241, P80, DOI 10.1016/j.neuroscience.2013.03.015; Lai YC, 2008, J CEREBR BLOOD F MET, V28, P540, DOI 10.1038/sj.jcbfm.9600551; Lee DH, 2014, J NEUROSCI, V34, P15347, DOI 10.1523/JNEUROSCI.1935-14.2014; Lin CM, 2015, DRUG DES DEV THER, V9, P4709, DOI 10.2147/DDDT.S86616; Liu CJ, 2011, BRAIN RES, V1374, P100, DOI 10.1016/j.brainres.2010.11.061; Lopez MS, 2015, NEUROCHEM INT, V89, P75, DOI 10.1016/j.neuint.2015.08.009; Sirin BH, 2002, ACTA CARDIOL, V57, P279, DOI 10.2143/AC.57.4.2005427; Tang PF, 2014, MOL NEUROBIOL, V49, P276, DOI 10.1007/s12035-013-8518-3; Terayama R, 2007, NEUROSCIENCE, V148, P175, DOI 10.1016/j.neuroscience.2007.05.037; Viscomi MT, 2012, AUTOPHAGY, V8, P222, DOI 10.4161/auto.8.2.18599; Wang R, 2014, CELL PHYSIOL BIOCHEM, V34, P854, DOI 10.1159/000366304; Warden P, 2001, EXP NEUROL, V168, P213, DOI 10.1006/exnr.2000.7622; Zhang D, 2017, MOL NEUROBIOL, V54, P3327, DOI 10.1007/s12035-016-9895-1; Zhu SP, 2016, MOL NEUROBIOL, V53, P4375, DOI 10.1007/s12035-015-9372-2	26	22	23	0	0	E-CENTURY PUBLISHING CORP	MADISON	40 WHITE OAKS LN, MADISON, WI 53711 USA	1943-8141			AM J TRANSL RES	Am. J. Transl. Res.		2017	9	10					4607	4616					10	Oncology; Medicine, Research & Experimental	Oncology; Research & Experimental Medicine	FL5MU	WOS:000414290700023	29118921				2021-06-18	
J	Kaneko, Y; Pappas, C; Malapira, T; Vale, FL; Tajiri, N; Borlongan, CV				Kaneko, Yuji; Pappas, Colleen; Malapira, Teresita; Vale, Fernando L.; Tajiri, Naoki; Borlongan, Cesar V.			Extracellular HMGB1 Modulates Glutamate Metabolism Associated with Kainic Acid Induced Epilepsy-Like Hyperactivity in Primary Rat Neural Cells	CELLULAR PHYSIOLOGY AND BIOCHEMISTRY			English	Article						Epilepsy; HMGB1; Kainic acid; Primary rat neural cells; Glutamate; GABA	MOBILITY GROUP BOX-1; TRAUMATIC BRAIN-INJURY; RECEPTOR 4; IN-VITRO; PARKINSONS-DISEASE; ALPHA-SYNUCLEIN; P-GLYCOPROTEIN; PROTEIN HMGB1; UP-REGULATION; MOUSE MODEL	Background/Aims: Neuroinflammatory processes have been implicated in the pathophysiology of seizure/epilepsy. High mobility group box 1 (HMGB1), a non-histone DNA binding protein, behaves like an inflammatory cytokine in response to epileptogenic insults. Kainic acid (KA) is an excitotoxic reagent commonly used to induce epilepsy in rodents. However, the molecular mechanism by which KA-induced HMGB1 affords the initiation of epilepsy, especially the role of extracellular HMGB1 in neurotransmitter expression, remains to be elucidated. Methods: Experimental early stage of epilepsy-related hyperexcitability was induced in primary rat neural cells (PRNCs) by KA administration. We measured the localization of HMGB1, cell viability, mitochondrial activity, and expression level of glutamate metabolism-associated enzymes. Results: KA induced the translocation of HMGB1 from nucleus to cytosol, and its release from the neural cells. The translocation is associated with post-translational modifications. An increase in extracellular HMGB1 decreased PRNC cell viability and mitochondrial activity, downregulated expression of glutamate decarboxylase67 (GAD67) and glutamate dehydrogenase (GLUD1/2), and increased intracellular glutamate concentration and major histocompatibility complex II (MHC II) level. Conclusions: That a surge in extracellular HMGB1 approximated seizure initiation suggests a key pathophysiological contribution of HMGB1 to the onset of epilepsy-related hyperexcitability. (C) 2017 The Author(s)	[Kaneko, Yuji; Malapira, Teresita; Vale, Fernando L.; Tajiri, Naoki; Borlongan, Cesar V.] Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA; [Pappas, Colleen] Univ S Florida, Sch Aging Studies, Tampa, FL USA	Kaneko, Y; Borlongan, CV (corresponding author), Univ S Florida, Coll Med, Dept Neurosurg & Brain Repair, Ctr Excellence Aging & Brain, 12901 Bruce B Downs Blvd, Tampa, FL 33612 USA.	ykaneko@health.usf.edu; cborlong@health.usf.edu		Pappas, Colleen/0000-0001-9140-3558	USF ORI [HSC-18330, COM HSC-18300]; NIH NINDSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [RO1 1R01NS071956-01]; USF Department of Neurosurgery and Brain Repair Funds	This work was supported by USF OR&I HSC-18330 & COM HSC-18300 (YK), NIH NINDS RO1 1R01NS071956-01 (CVB), and USF Department of Neurosurgery and Brain Repair Funds (CVB). YK and CVB contributed to study design. YK, CP, NT, and CVB contributed to data acquisition. YK, CP, TM, FV, NT, and CVB wrote the manuscript.	Acosta SA, 2015, J CELL PHYSIOL, V230, P1024, DOI 10.1002/jcp.24830; Alexopoulou Z, 2016, P NATL ACAD SCI USA, V113, pE4688, DOI 10.1073/pnas.1523597113; Bauer B, 2008, MOL PHARMACOL, V73, P1444, DOI 10.1124/mol.107.041210; BAXEVANIS AD, 1995, NUCLEIC ACIDS RES, V23, P1604, DOI 10.1093/nar/23.9.1604; Bell E, 2003, DIABETES, V52, P2731, DOI 10.2337/diabetes.52.11.2731; Bialer M, 2010, NAT REV DRUG DISCOV, V9, P68, DOI 10.1038/nrd2997; Bonaldi T, 2003, EMBO J, V22, P5551, DOI 10.1093/emboj/cdg516; Cendes F, 2012, NAT REV NEUROL, V8, P70, DOI 10.1038/nrneurol.2011.223; Chen Y, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0140918; Chen ZA, 2015, CELL PHYSIOL BIOCHEM, V37, P1379, DOI 10.1159/000430403; Cheng YJ, 2015, CELL PHYSIOL BIOCHEM, V36, P1577, DOI 10.1159/000430320; Choi JS, 2003, MOL BRAIN RES, V119, P10, DOI 10.1016/j.molbrainres.2003.08.010; DIMOV SI, 1990, BIOCHEM BIOPH RES CO, V166, P819, DOI 10.1016/0006-291X(90)90883-O; Evankovich J, 2010, J BIOL CHEM, V285, P39888, DOI 10.1074/jbc.M110.128348; Fang P, 2012, MOL NEUROBIOL, V45, P499, DOI 10.1007/s12035-012-8264-y; Fenalti G, 2007, NAT STRUCT MOL BIOL, V14, P280, DOI 10.1038/nsmb1228; Gardella S, 2002, EMBO REP, V3, P995, DOI 10.1093/embo-reports/kvf198; Grahenstatter HL, 2008, EPILEPSIA, V49, P1787; Harris HE, 2012, NAT REV RHEUMATOL, V8, P195, DOI 10.1038/nrrheum.2011.222; Hwang JS, 2015, SCI REP-UK, V5, DOI 10.1038/srep15971; Kaneko Y, 2016, SCI REP-UK, V6, DOI 10.1038/srep35659; Kaneko Y, 2016, MOL NEUROBIOL, V53, P1874, DOI 10.1007/s12035-015-9126-1; Kaneko Y, 2014, CNS NEUROSCI THER, V20, P275, DOI 10.1111/cns.12208; Kash SF, 1999, P NATL ACAD SCI USA, V96, P1698, DOI 10.1073/pnas.96.4.1698; Kass I, 2014, P NATL ACAD SCI USA, V111, pE2524, DOI 10.1073/pnas.1403182111; Kim JB, 2006, J NEUROSCI, V26, P6413, DOI 10.1523/JNEUROSCI.3815-05.2006; KIMURA K, 1985, BIOCHEM J, V227, P271, DOI 10.1042/bj2270271; Kleen JK, 2010, NAT MED, V16, P369, DOI 10.1038/nm0410-369; Kuo MF, 2002, PEDIATR NEUROL, V26, P146, DOI 10.1016/S0887-8994(01)00357-5; LAEMMLI UK, 1970, NATURE, V227, P680, DOI 10.1038/227680a0; Li XF, 2016, CELL PHYSIOL BIOCHEM, V39, P1850, DOI 10.1159/000447884; Liu JB, 2016, CELL PHYSIOL BIOCHEM, V40, P847, DOI 10.1159/000453144; Liu Y, 2015, J NEUROSCI, V35, P11514, DOI 10.1523/JNEUROSCI.5288-14.2015; Lotze MT, 2005, NAT REV IMMUNOL, V5, P331, DOI 10.1038/nri1594; Lu B, 2014, P NATL ACAD SCI USA, V111, P3068, DOI 10.1073/pnas.1316925111; Luo L, 2014, CELL MOL NEUROBIOL, V34, P987, DOI 10.1007/s10571-014-0075-4; Maroso M, 2010, NAT MED, V16, P413, DOI 10.1038/nm.2127; Mazarati A, 2011, EXP NEUROL, V232, P143, DOI 10.1016/j.expneurol.2011.08.012; Min SW, 2015, NAT MED, V21, P1154, DOI 10.1038/nm.3951; Okuma Y, 2012, ANN NEUROL, V72, P373, DOI 10.1002/ana.23602; Papageorgiou IE, 2011, GLIA, V59, P1706, DOI 10.1002/glia.21217; Sada N, 2015, SCIENCE, V347, P1362, DOI 10.1126/science.aaa1299; Sasaki T, 2016, EXP NEUROL, V275, P220, DOI 10.1016/j.expneurol.2015.11.003; Segref A, 2009, EMBO REP, V10, P44, DOI 10.1038/embor.2008.229; Tang DL, 2007, J IMMUNOL, V179, P1236, DOI 10.4049/jimmunol.179.2.1236; van Vliet EA, 2006, EPILEPSIA, V47, P672, DOI 10.1111/j.1528-1167.2006.00496.x; VanGuilder HD, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-138; Wang HC, 1999, SCIENCE, V285, P248, DOI 10.1126/science.285.5425.248; Wang JC, 2015, CELL PHYSIOL BIOCHEM, V35, P767, DOI 10.1159/000369736; Yang WS, 2016, CELL PHYSIOL BIOCHEM, V38, P2139, DOI 10.1159/000445570; Yang WS, 2015, CELL PHYSIOL BIOCHEM, V35, P2309, DOI 10.1159/000374034; Yasuhara T, 2013, INT J MOL SCI, V14, P23390, DOI 10.3390/ijms141223390; Youn JH, 2006, J IMMUNOL, V177, P7889, DOI 10.4049/jimmunol.177.11.7889; Yu Y, 2015, FRONT PHYSIOL, V6, DOI 10.3389/fphys.2015.00093; Zsurka G, 2015, LANCET NEUROL, V14, P956, DOI 10.1016/S1474-4422(15)00148-9	55	22	22	0	1	KARGER	BASEL	ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND	1015-8987	1421-9778		CELL PHYSIOL BIOCHEM	Cell. Physiol. Biochem.		2017	41	3					947	959		10.1159/000460513			13	Cell Biology; Physiology	Cell Biology; Physiology	EU3GB	WOS:000400915500008	28222432	DOAJ Gold			2021-06-18	
J	Merkel, SF; Razmpour, R; Lutton, EM; Tallarida, CS; Heldt, NA; Cannella, LA; Persidsky, Y; Rawls, SM; Ramirez, SH				Merkel, Steven F.; Razmpour, Roshanak; Lutton, Evan M.; Tallarida, Christopher S.; Heldt, Nathan A.; Cannella, Lee Anne; Persidsky, Yuri; Rawls, Scott M.; Ramirez, Servio H.			Adolescent Traumatic Brain Injury Induces Chronic Mesolimbic Neuroinflammation with Concurrent Enhancement in the Rewarding Effects of Cocaine in Mice during Adulthood	JOURNAL OF NEUROTRAUMA			English	Article						addiction; adolescent; neuroinflammation; psychostimulants; TBI	CONTROLLED CORTICAL IMPACT; SUBSTANCE-ABUSE; TYROSINE-HYDROXYLASE; RAT STRIATUM; EXPRESSION; ADDICTION; INFLAMMATION; GLUTAMATE; SYSTEM; MODEL	Clinical psychiatric disorders of depression, anxiety, and substance abuse are most prevalent after traumatic brain injury (TBI). Pre-clinical research has focused on depression and anxiety post-injury; however, virtually no data exist examining whether the preference for illicit drugs is affected by traumatic injury in the developing adolescent brain. Using the controlled cortical impact (CCI) model of TBI and the conditioned place preference (CPP) assay, we tested the underlying hypothesis that brain injury during adolescence exacerbates the rewarding properties of cocaine in adulthood possibly through an active inflammatory status in the mesolimbic pathway. Six-week old, C57BL/6 mice sustained a single CCI-TBI to the right somatosensory cortex. CPP experiments with cocaine began 2 weeks post-TBI. Animals receiving cocaine displayed significant place preference shifts compared to saline controls. Further, within the cocaine-experienced cohort, moderate CCI-TBI during adolescence significantly increased the preference shift in adulthood when compared to naive controls. Additionally, persistent neuroinflammatory responses were observed in the cortex, nucleus accumbens (NAc), and ventral tegmental area post-CCI-TBI. Significant increases in both astrocytic, glial fibrillary acidic protein, and microglial, ionization basic acid 1, markers were observed in the NAc at the end of CPP testing. Moreover, analysis using focused array gene expression panels identified the upregulation of numerous inflammatory genes in moderate CCI-TBI animals, compared to naive controls, both in the cortex and NAc at 2 weeks post-TBI, before onset of cocaine administration. These results suggest that sustaining moderate TBI during adolescence may augment the rewarding effects of psychostimulants in adulthood, possibly by induction of chronic mesolimbic neuroinflammation.	[Merkel, Steven F.; Razmpour, Roshanak; Lutton, Evan M.; Heldt, Nathan A.; Cannella, Lee Anne; Persidsky, Yuri; Ramirez, Servio H.] Temple Univ, Sch Med, Dept Pathol & Lab Med, 3500 North Broad St, Philadelphia, PA 19140 USA; [Merkel, Steven F.; Tallarida, Christopher S.; Persidsky, Yuri; Rawls, Scott M.] Temple Univ, Sch Med, Ctr Subst Abuse Res, Philadelphia, PA 19122 USA; [Ramirez, Servio H.] Temple Univ, Sch Med, Shriners Hosp Pediat Res Ctr, Philadelphia, PA 19122 USA; [Tallarida, Christopher S.; Rawls, Scott M.] Temple Univ, Sch Med, Dept Pharmacol, Philadelphia, PA 19122 USA	Ramirez, SH (corresponding author), Temple Univ, Sch Med, Dept Pathol & Lab Med, 3500 North Broad St, Philadelphia, PA 19140 USA.	servio@temple.edu		ramirez, servio/0000-0002-4609-5653; Heldt, Nathan/0000-0002-8631-5438	National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA) [T32 DA007237, P30 DA013429-16]; NIH/National Institute of Neurological Disorders and Stroke (NINDS)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01 NS086570-01]; Shriners Hospitals for Children [85110-PHI-14]; NIH/National Institute of Mental Health (NIMH) [R01 MH65151]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS086570, P01NS043985] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [U01AA023552, R37AA015913] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DRUG ABUSEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Drug Abuse (NIDA)European Commission [T32DA007237, R01DA040619, P30DA013429] Funding Source: NIH RePORTER	This work was supported by National Institutes of Health/National Institute on Drug Abuse (NIH/NIDA) T32 DA007237 (to S.F.M.) and P30 DA013429-16 (to S.M.R. and S.H.R.), NIH/National Institute of Neurological Disorders and Stroke (NINDS) R01 NS086570-01 (to S.H.R.), The Shriners Hospitals for Children 85110-PHI-14 (to S.H.R.), and NIH/National Institute of Mental Health (NIMH) R01 MH65151 (to Y.P.).	Abdul-Muneer PM, 2015, MOL NEUROBIOL, V51, P966, DOI 10.1007/s12035-014-8752-3; Adler MW, 2005, J LEUKOCYTE BIOL, V78, P1204, DOI 10.1189/jlb.0405222; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Alhilali LM, 2015, RADIOLOGY, V277, P793, DOI 10.1148/radiol.2015142974; Ardelt AA, 2013, EXP NEUROL, V248, P246, DOI 10.1016/j.expneurol.2013.06.017; Blednov YA, 2011, BRAIN BEHAV IMMUN, V25, pS92, DOI 10.1016/j.bbi.2011.01.008; Chen SZ, 2008, P NATL ACAD SCI USA, V105, P19962, DOI 10.1073/pnas.0807758105; Corrigan JD, 2013, ARCH PHYS MED REHAB, V94, P1940, DOI 10.1016/j.apmr.2013.05.018; Crews FT, 2011, BRAIN BEHAV IMMUN, V25, pS4, DOI 10.1016/j.bbi.2011.03.003; Cunningham CL, 1999, PSYCHOPHARMACOLOGY, V146, P73, DOI 10.1007/s002130051090; DICHIARA G, 1988, P NATL ACAD SCI USA, V85, P5274; Donnemiller E, 2000, EUR J NUCL MED, V27, P1410, DOI 10.1007/s002590000308; Edut S, 2014, J MOL NEUROSCI, V54, P684, DOI 10.1007/s12031-014-0399-z; Edut S, 2011, PSYCHOPHARMACOLOGY, V214, P877, DOI 10.1007/s00213-010-2098-y; Eierud C, 2014, NEUROIMAGE-CLIN, V4, P283, DOI 10.1016/j.nicl.2013.12.009; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goodrich GS, 2013, J NEUROTRAUM, V30, P1434, DOI 10.1089/neu.2012.2712; Hinzman JM, 2012, J NEUROTRAUM, V29, P1197, DOI 10.1089/neu.2011.2261; Hussain ZM, 2012, J NEUROTRAUM, V29, P1785, DOI 10.1089/neu.2011.2286; Hutchinson MR, 2012, J NEUROSCI, V32, P11187, DOI 10.1523/JNEUROSCI.0684-12.2012; Hyman SE, 2006, ANNU REV NEUROSCI, V29, P565, DOI 10.1146/annurev.neuro.29.051605.113009; Johnson VE, 2013, BRAIN, V136, P28, DOI 10.1093/brain/aws322; Kalivas PW, 2009, NAT REV NEUROSCI, V10, P561, DOI 10.1038/nrn2515; Kerner Berit, 2009, Open Psychiatr J, V3, P1; Khan M, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-32; Koob GF, 1997, SCIENCE, V278, P52, DOI 10.1126/science.278.5335.52; LEVIN HS, 1992, J NEUROL NEUROSUR PS, V55, P255, DOI 10.1136/jnnp.55.4.255; Lim YW, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0125130; Lowing JL, 2014, J NEUROTRAUM, V31, P1700, DOI 10.1089/neu.2013.3286; Lynch WJ, 2010, COMPARATIVE MED, V60, P177; Martin BJ, 2011, SYNAPSE, V65, P490, DOI 10.1002/syn.20865; Mayeux JP, 2015, BEHAV BRAIN RES, V279, P22, DOI 10.1016/j.bbr.2014.10.053; Mithal DS, 2013, GLIA, V61, P1288, DOI 10.1002/glia.22515; Motzkin JC, 2014, HUM BRAIN MAPP, V35, P4282, DOI 10.1002/hbm.22474; Nestler EJ, 2005, NAT NEUROSCI, V8, P1445, DOI 10.1038/nn1578; Olson-Madden JH, 2010, J HEAD TRAUMA REHAB, V25, P470, DOI 10.1097/HTR.0b013e3181d717a7; Ramesh D, 2015, AM J ADDICTION, V24, P341, DOI 10.1111/ajad.12192; Rau TF, 2012, J TRAUMA ACUTE CARE, V73, pS165, DOI 10.1097/TA.0b013e318260896a; Redell JB, 2003, EXP BIOL MED, V228, P261; Sajja VSSS, 2013, J NEUROSCI RES, V91, P593, DOI 10.1002/jnr.23179; Shah S, 2012, BRAIN INJURY, V26, P201, DOI 10.3109/02699052.2012.654591; Shimada R, 2014, NEUROL RES, V36, P239, DOI 10.1179/1743132813Y.0000000289; Shin SS, 2013, J NEUROTRAUM, V30, P259, DOI 10.1089/neu.2012.2462; Tallarida CS, 2015, DRUG ALCOHOL DEPEN, V149, P145, DOI 10.1016/j.drugalcdep.2015.01.035; Torres LH, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0136399; Wagner AK, 2005, J NEUROCHEM, V95, P457, DOI 10.1111/j.1471-4159.2005.03382.x; Wang XH, 2012, P NATL ACAD SCI USA, V109, P6325, DOI 10.1073/pnas.1200130109; Wee S, 2010, PSYCHOPHARMACOLOGY, V210, P121, DOI 10.1007/s00213-010-1825-8; Weil ZM, 2016, J NEUROTRAUM, V33, P895, DOI 10.1089/neu.2015.3953; Whelan-Goodinson R, 2009, J HEAD TRAUMA REHAB, V24, P324, DOI 10.1097/HTR.0b013e3181a712aa; Yan HQ, 2007, BRAIN RES, V1134, P171, DOI 10.1016/j.brainres.2006.11.087; Yan HQ, 2001, NEUROREPORT, V12, P2323, DOI 10.1097/00001756-200108080-00009	53	22	22	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2017	34	1					165	181		10.1089/neu.2015.4275			17	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	EF6DE	WOS:000390420100019	27026056	Green Published			2021-06-18	
J	Mishra, SK; Kumar, BSH; Khushu, S; Singh, AK; Gangenahalli, G				Mishra, Sushanta Kumar; Kumar, B. S. Hemanth; Khushu, Subash; Singh, Ajay K.; Gangenahalli, Gurudutta			Early monitoring and quantitative evaluation of macrophage infiltration after experimental traumatic brain injury: A magnetic resonance imaging and flow cytometric analysis	MOLECULAR AND CELLULAR NEUROSCIENCE			English	Article						Flow cytometry; Macrophages; Magnetic resonance imaging; Microglia; Neuroinflammation; Traumatic brain injury; USPIO	SUPERPARAMAGNETIC IRON-OXIDE; INFLAMMATORY MECHANISMS; MONOCYTE INFILTRATION; BARRIER PERMEABILITY; CONTRAST AGENT; MOUSE-BRAIN; MRI; ISCHEMIA; CELL; NEUROINFLAMMATION	The inflammatory response following traumatic brain injury (TBI) is regulated by phagocytic cells. These cells comprising resident microglia and infiltrating macrophages play a pivotal role in the interface between early detrimental and delayed beneficial effects of inflammation. The aim of the present study was to monitor the early effect of monocyte/phagocytic accumulation and further to explore its kinetics in TBI mice. Localized macrophage population was monitored using ultrasmall superparamagnetic iron oxide (USPIO) nanoparticle enhanced in vivo serial magnetic resonance imaging (MRI). Flow cytometry based gating study was performed to discriminate between resident microglia (Ly6G(-) CD11b+ CD45(low)) and infiltrating macrophages (Ly6G(-) CD11b+ CD45(high)) at the injury site. The T-2* relaxation analysis revealed that maximum macrophage infiltration occurs between 66 and 72 h post injury (42-48 h post administration of USPIO) at the site of inflammation. This imaging data was well supported by iron oxide specific Prussian blue staining and macrophage specific F4/80 immunohistochemistry (IHC) analysis. Quantitative real-time PCR analysis found significant expression of monocyte chemoattractant protein-1 (MCP-1) at 72 h post injury. Also, we found that flow cytometric analysis demonstrated a 7-fold increase in infiltrating macrophages around 72 h post injuries as compared to control. The MR imaging in combination with flow cytometric analysis enabled the dynamic measurement of macrophage infiltration at the injury site. This study may help in setting an optimal time window to intervene and prevent damage due to inflammation and to increase the therapeutic efficacy. (C) 2016 Elsevier Inc All rights reserved.	[Mishra, Sushanta Kumar; Kumar, B. S. Hemanth; Khushu, Subash] DRDO, INMAS, NMR Res Ctr, Delhi 54, India; [Singh, Ajay K.] DRDO, INMAS, Div Radiat Biosci, Delhi 54, India; [Mishra, Sushanta Kumar; Gangenahalli, Gurudutta] DRDO, INMAS, Div Stem Cell & Gene Therapy Res, Delhi 54, India	Khushu, S (corresponding author), DRDO, INMAS, NMR Res Ctr, Delhi 54, India.; Gangenahalli, G (corresponding author), DRDO, INMAS, Div Stem Cell & Gene Therapy Res, Delhi 54, India.	skhushu@yahoo.com; gugdutta@rediffmail.com	Singh, Ajay/AAF-4414-2020; Mishra, Sushanta Kumar/N-5958-2019	Mishra, Sushanta/0000-0002-3403-6891	Defence Research and Development Organization (DRDO), Ministry of Defence, Govt. of IndiaDefence Research & Development Organisation (DRDO) [INM-311, 4.1]; Indian Council of Medical Research (ICMR)Indian Council of Medical Research (ICMR)	The project (INM-311, 4.1) was supported by the Defence Research and Development Organization (DRDO), Ministry of Defence, Govt. of India. The authors also thank Sunil Koundal (SRF, INMAS) for help in MRI data analysis. We also acknowledge Dr. Anurag Agrawal and Mr. Bijaya Ranjan Pattanaik (SRF, IGIB) for providing flow cytometry facility and data interpretation. The fellowship support from the Indian Council of Medical Research (ICMR) is gratefully acknowledged by Mr. Sushanta Kumar Mishra.	Albert-Weissenberger Christiane, 2010, Exp Transl Stroke Med, V2, P16, DOI 10.1186/2040-7378-2-16; Alexander AL, 2007, NEUROTHERAPEUTICS, V4, P316, DOI 10.1016/j.nurt.2007.05.011; Bedi SS, 2013, J NEUROSCI METH, V219, P176, DOI 10.1016/j.jneumeth.2013.07.017; Chen S, 2003, EXP NEUROL, V182, P87, DOI 10.1016/S0014-4886(03)00002-5; CHOMCZYNSKI P, 1993, BIOTECHNIQUES, V15, P532; Danton GH, 2003, J NEUROPATH EXP NEUR, V62, P127, DOI 10.1093/jnen/62.2.127; Dousset V, 2006, AM J NEURORADIOL, V27, P1000; Easo SL, 2013, CARBOHYD POLYM, V92, P726, DOI 10.1016/j.carbpol.2012.09.098; Engberink RDO, 2008, J CEREBR BLOOD F MET, V28, P841, DOI 10.1038/sj.jcbfm.9600580; Farr TD, 2011, NMR BIOMED, V24, P35, DOI 10.1002/nbm.1553; Floris S, 2004, BRAIN, V127, P616, DOI 10.1093/brain/awh068; Foley LM, 2009, J NEUROTRAUM, V26, P1509, DOI 10.1089/neu.2008.0747; Gensel J.C., 2015, BRAIN RES, V14; Gordon R, 2011, J NEUROSCI METH, V194, P287, DOI 10.1016/j.jneumeth.2010.11.001; Habgood MD, 2007, EUR J NEUROSCI, V25, P231, DOI 10.1111/j.1460-9568.2006.05275.x; HOLMIN S, 1995, ACTA NEUROCHIR, V132, P110, DOI 10.1007/BF01404857; Jin R, 2010, J LEUKOCYTE BIOL, V87, P779, DOI 10.1189/jlb.1109766; Lobel U, 2009, NEURORADIOLOGY, V51, P253, DOI 10.1007/s00234-008-0488-1; Longbrake EE, 2007, J NEUROCHEM, V102, P1083, DOI 10.1111/j.1471-4159.2007.04617.x; Marmarou A, 2003, ACT NEUR S, V86, P7; MARMAROU A, 1994, J NEUROSURG, V80, P291, DOI 10.3171/jns.1994.80.2.0291; McIntosh TK, 1996, LAB INVEST, V74, P315; Mishra S.K., 2016, STEM CELL TRANSL MED, V5, P1; Mishra SK, 2016, CONTRAST MEDIA MOL I, V11, P350, DOI 10.1002/cmmi.1698; Mishra SK, 2015, EXP CELL RES, V339, P427, DOI 10.1016/j.yexcr.2015.11.010; Morganti-Kossmann Maria Cristina, 2002, Curr Opin Crit Care, V8, P101; Price CJS, 2003, J NEUROL NEUROSUR PS, V74, P1476, DOI 10.1136/jnnp.74.11.1476; Rausch M, 2002, NMR BIOMED, V15, P278, DOI 10.1002/nbm.770; Saleh A, 2004, BRAIN, V127, P1670, DOI 10.1093/brain/awh191; Saleh A, 2007, STROKE, V38, P2733, DOI 10.1161/STROKEAHA.107.481788; Schilling M, 2003, EXP NEUROL, V183, P25, DOI 10.1016/S0014-4886(03)00082-7; Schmittgen TD, 2008, NAT PROTOC, V3, P1101, DOI 10.1038/nprot.2008.73; Schoettle R J, 1990, J Neurotrauma, V7, P207, DOI 10.1089/neu.1990.7.207; Semple BD, 2010, J CEREBR BLOOD F MET, V30, P769, DOI 10.1038/jcbfm.2009.262; Shanmuganathan K, 2004, AM J NEURORADIOL, V25, P539; Soares HD, 1995, J NEUROSCI, V15, P8223; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Tanaka R, 2003, NEUROSCIENCE, V117, P531, DOI 10.1016/S0306-4522(02)00954-5; Thomale UW, 2007, IMMUNOBIOLOGY, V212, P567, DOI 10.1016/j.imbio.2007.01.007; Trahanas DM, 2015, SHOCK, V43, P255, DOI 10.1097/SHK.0000000000000291; Turtzo LC, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-82; Van Boven RW, 2009, J REHABIL RES DEV, V46, P717, DOI 10.1682/JRRD.2008.12.0161; Wang YXJ, 2001, EUR RADIOL, V11, P2319, DOI 10.1007/s003300100908; WEISSLEDER R, 1989, AM J ROENTGENOL, V152, P167, DOI 10.2214/ajr.152.1.167; Wiart M, 2007, STROKE, V38, P131, DOI 10.1161/01.STR.0000252159.05702.00; Xu FH, 2009, NANOTECHNOLOGY, V20, DOI 10.1088/0957-4484/20/40/405102; Zhang Z, 2006, NEUROSCIENCE, V141, P637, DOI 10.1016/j.neuroscience.2006.04.027	47	22	22	2	13	ACADEMIC PRESS INC ELSEVIER SCIENCE	SAN DIEGO	525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA	1044-7431	1095-9327		MOL CELL NEUROSCI	Mol. Cell. Neurosci.	JAN	2017	78						25	34		10.1016/j.mcn.2016.11.008			10	Neurosciences	Neurosciences & Neurology	EI0LW	WOS:000392167000003	27864037				2021-06-18	
J	Swanson, MW; Weise, KK; Dreer, LE; Johnston, J; Davis, RD; Ferguson, D; Hale, MH; Gould, SJ; Christy, JB; Busettini, C; Lee, SD; Swanson, E				Swanson, Mark W.; Weise, Katherine K.; Dreer, Laura E.; Johnston, James; Davis, Richard D.; Ferguson, Drew; Hale, Matthew Heath; Gould, Sara J.; Christy, Jennifer B.; Busettini, Claudio; Lee, Sarah D.; Swanson, Erin			Academic Difficulty and Vision Symptoms in Children with Concussion	OPTOMETRY AND VISION SCIENCE			English	Article						concussion; school; education; vision; mild traumatic brain injury	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; POSTCONCUSSION SYNDROME; VISUAL FUNCTION; ADOLESCENTS; MANAGEMENT; IMPAIRMENT; STATEMENT; DIAGNOSIS; ATTENTION	Purpose. Academic difficulty is reported in children with prolonged post-concussive symptoms. Despite growing evidence that vestibular-ocular and vision-specific dysfunction are common in children after concussion, vision is rarely mentioned in return-to-learn protocols. The purpose of this project was to evaluate a cohort of children with prolonged post-concussive symptoms to determine if vision symptoms are associated with those reporting academic difficulty. Methods. Data were obtained from the Children's of Alabama Concussion Clinic REDCap dataset from the period January 2007 to October 2013. From this dataset of 1033 concussion events, a cohort of 276 children aged 5 to 18 years with three or more concussion-related symptoms present for 10 days or more was identified. A cross-sectional cohort study was undertaken to evaluate the association of concussion symptoms, SCAT2 scores, and demographic and concussion severity markers to reported educational difficulty among children with prolonged post-concussive symptoms. Univariate and multivariate logistic regression techniques were used to model the association of reported educational difficulty to self-reported vision abnormalities. Results. Mean age was 13.8 years. Median time since the concussive event was 21 days, with 33% (95/276) reporting their concussion more than 30 days before data collection. Academic difficulty was reported by 29% (79/270) and vision abnormalities in 46% (128/274). After model reduction, vision symptoms (OR 2.17, 95% CI 1.02, 4.62), hearing disturbance (OR 2.39, 95% CI 1.06, 5.36), and concentration difficulty (OR 21.62, 95% CI 9.50, 44.47) remained associated with academic difficulty. For those with symptoms 30 days or more after concussion, only vision (OR 3.15, 95% CI 1.06, 9.38) and concentration difficulty (OR 15.33, 95% CI 4.99, 47.05) remained statistically significant. Conclusions. Vision problems were commonly reported in children with concussions and were independently associated with those reporting academic difficulty. Comprehensive vision assessment should be considered in children reporting academic difficulty and in the development of return-to-learn protocols.	[Swanson, Mark W.; Weise, Katherine K.; Busettini, Claudio; Lee, Sarah D.] Univ Alabama Birmingham, Dept Optometry & Vis Sci, Birmingham, AL USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL USA; [Johnston, James] Univ Alabama Birmingham, Sch Med Pediat Neurosurg, Birmingham, AL USA; [Davis, Richard D.; Swanson, Erin] Univ Alabama Birmingham, Dept Pediat, Div Pediat Rehabil Med, Birmingham, AL USA; [Ferguson, Drew; Hale, Matthew Heath; Gould, Sara J.] Univ Alabama Birmingham, UAB Sports Med, Childrens Alabama, Birmingham, AL USA; [Christy, Jennifer B.] Univ Alabama Birmingham, Dept Phys Therapy, Birmingham, AL USA	Swanson, MW (corresponding author), Sch Optometry, 1716 Univ Blvd, Birmingham, AL 35294 USA.			Gould, Sara/0000-0002-0713-1156; Johnston, James/0000-0001-8564-1808	UAB Department of Optometry; UAB Department of Vision Sciences; UAB Vision Science Research Center's National Institutes of Health [P30 EY003039]; NATIONAL EYE INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Eye Institute (NEI) [P30EY003039] Funding Source: NIH RePORTER	This study was supported by the UAB Department of Optometry, the UAB Department of Vision Sciences, and the UAB Vision Science Research Center's National Institutes of Health P30 EY003039 core grant.	Alsalaheen BA, 2016, CLIN J SPORT MED, V26, P46, DOI 10.1097/JSM.0000000000000185; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Baker JG, 2015, CLIN PEDIATR, V54, P961, DOI 10.1177/0009922815588820; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Biederman J, 2015, J NERV MENT DIS, V203, P813, DOI 10.1097/NMD.0000000000000375; Brahm KD, 2009, OPTOMETRY VISION SCI, V86, P817, DOI 10.1097/OPX.0b013e3181adff2d; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Burnham K. P., 2002, MODEL SELECTION INFE; Centers for Disease Control and Prevention, 2001, RAT TBI REL EM DEP V; Chrisman SP, 2013, BRAIN INJURY, V27, P1, DOI 10.3109/02699052.2012.722251; Ciuffreda KJ, 2014, MIL MED, V179, P1212, DOI 10.7205/MILMED-D-14-00059; Corwin DJ, 2015, J PEDIATR-US, V166, P1221, DOI 10.1016/j.jpeds.2015.01.039; Corwin DJ, 2014, J PEDIATR-US, V165, P1207, DOI 10.1016/j.jpeds.2014.08.034; DeMatteo C, 2015, CLIN PEDIATR, V54, P783, DOI 10.1177/0009922814567305; Eisenberg MA, 2013, PEDIATRICS, V132, P8, DOI 10.1542/peds.2013-0432; Ellis MJ, 2015, J NEUROSURG-PEDIATR, V16, P248, DOI 10.3171/2015.1.PEDS14524; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Goodrich GL, 2007, J REHABIL RES DEV, V44, P929, DOI 10.1682/JRRD.2007.01.0003; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Kashluba S, 2006, J INT NEUROPSYCH SOC, V12, P111, DOI 10.1017/S1355617706060036; Kerr ZY, 2015, J ATHL TRAINING, V50, P1174, DOI 10.4085/1062-6050-50.11.11; Master CL, 2016, CLIN PEDIATR, V55, P260, DOI 10.1177/0009922815594367; McCrory Paul, 2013, Phys Ther Sport, V14, pe1, DOI 10.1016/j.ptsp.2013.03.002; McCrory P, 2009, PHYSICIAN SPORTSMED, V37, P141, DOI 10.3810/psm.2009.06.1721; Mittenberg W, 2000, J HEAD TRAUMA REHAB, V15, P783, DOI 10.1097/00001199-200004000-00003; Mucha A, 2014, AM J SPORT MED, V42, P2479, DOI 10.1177/0363546514543775; Olympia RP, 2016, CLIN J SPORT MED, V26, P115, DOI 10.1097/JSM.0000000000000208; Pearce KL, 2015, AM J SPORT MED, V43, P3055, DOI 10.1177/0363546515606430; Purcell L, 2016, CLIN PEDIATR, V55, P452, DOI 10.1177/0009922815589915; Purcell LK, 2014, PAED CHILD HEALT-CAN, V19, P153, DOI 10.1093/pch/19.3.153; Rose SC, 2015, PEDIATR NEUROL, V53, P108, DOI 10.1016/j.pediatrneurol.2015.04.003; Stelmack JA, 2009, OPTOMETRY, V80, P419, DOI 10.1016/j.optm.2009.02.011; Suchoff I B, 1999, J Am Optom Assoc, V70, P301; Vargo MM, 2016, PM&R, V8, P241, DOI 10.1016/j.pmrj.2015.07.006; Zhou GW, 2015, OTOLARYNG HEAD NECK, V152, P1133, DOI 10.1177/0194599815576720	37	22	23	0	9	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1040-5488	1538-9235		OPTOMETRY VISION SCI	Optom. Vis. Sci.	JAN	2017	94	1					60	67		10.1097/OPX.0000000000000977			8	Ophthalmology	Ophthalmology	EM5ZZ	WOS:000395393900009	27668641	Green Accepted			2021-06-18	
J	Wilkerson, GB; Simpson, KA; Clark, RA				Wilkerson, Gary B.; Simpson, Kevin A.; Clark, Ryan A.			Assessment and Training of Visuomotor Reaction Time for Football Injury Prevention	JOURNAL OF SPORT REHABILITATION			English	Article						risk screening; neurocognitive testing; dynamic visual acuity; feed-forward neuromuscular control; decision support techniques	LOWER-EXTREMITY SPRAINS; CONCUSSION; PLAYERS; TASKS; RELIABILITY; EXERCISE; STRAINS; ABILITY; VISION	Context: Neurocognitive reaction time has been associated with musculoskeletal injury risk, but visuomotor reaction time (VMRT) derived from tests that present greater challenges to visual stimulus detection and motor response execution may have a stronger association. Objective: To assess VMRT as a predictor of injury and the extent to which improvement may result from VMRT training. Design: Cohort study. Setting: University athletic performance center. Participants: 76 National Collegiate Athletic Association Division-I FCS football players (19.5 +/- 1.4 y, 1.85 +/- 0.06 m, 102.98 +/- 19.06 kg). Interventions: Preparticipation and postseason assessments. A subset of players who exhibited slowest VMRT in relation to the cohort's postseason median value participated in a 6-wk training program. Main Outcome Measures: Injury occurrence was related to preparticipation VMRT, which was represented by both number of target hits in 60 s and average elapsed time between hits (ms). Receiver operating characteristic analysis identified the optimum cut point for a binary injury risk classification. A nonparametric repeated-measures analysis of ranks procedure was used to compare posttraining VMRT values for slow players who completed at least half of the training sessions (n = 15) with those for untrained fast players (n = 27). Results: A preparticipation cut point of 85 hits (>= 705 ms) discriminated injured from noninjured players with odds ratio = 2.30 (90% confidence interval, 1.05-5.06). Slow players who completed the training exhibited significant improvement in visuomotor performance compared with baseline (standardized response mean = 2.53), whereas untrained players exhibited a small performance decrement (group x trial interaction effect, L-2 = 28.74; P <.001). Conclusions: Slow VMRT appears to be an important and modifiable injury risk factor for college football players. More research is needed to refine visuomotor reaction-time screening and training methods and to determine the extent to which improved performance values can reduce injury incidence.	[Wilkerson, Gary B.] Univ Tennessee, Dept Hlth Human Performance, Chattanooga, TN 37996 USA; [Simpson, Kevin A.] InSite Hlth, Palmdale, CA USA; [Clark, Ryan A.] STAR Phys Therapy, Sports Med Outreach, Nashville, TN USA	Wilkerson, GB (corresponding author), Univ Tennessee, Dept Hlth Human Performance, Chattanooga, TN 37996 USA.	Gary-Wilkerson@utc.edu	Wilkerson, Gary B./AAG-4103-2021	Wilkerson, Gary B./0000-0001-8433-7329			Andersen MB, 1999, J SPORT SCI, V17, P735, DOI 10.1080/026404199365597; Ando S, 2013, EXERC SPORT SCI REV, V41, P87, DOI 10.1097/JES.0b013e318259ad37; Bigsby K, 2014, INT J SPORTS PHYS TH, V9, P436; Breedlove EL, 2012, J BIOMECH, V45, P1265, DOI 10.1016/j.jbiomech.2012.01.034; Clark JF, 2015, OPTOM VIS PERFORM, V3, P7; Durmer JS, 2005, SEMIN NEUROL, V25, P117, DOI 10.1055/s-2005-867080; Eckner JT, 2011, MED SCI SPORT EXER, V43, P382, DOI 10.1249/MSS.0b013e3181f1cc51; Eckner JT, 2010, J ATHL TRAINING, V45, P327, DOI 10.4085/1062-6050-45.4.327; Feldman J, 2007, EFFECTS BLOOD GLUCOS; Harpham JA, 2014, ANN BIOMED ENG, V42, P1, DOI 10.1007/s10439-013-0881-8; Herman D., 2013, CLIN J SPORT MED, V23, P124; Hodges PW, 1997, PHYS THER, V77, P132, DOI 10.1093/ptj/77.2.132; Hutchison M, 2011, AM J SPORT MED, V39, P2331, DOI 10.1177/0363546511413375; KLAVORA P, 1995, PERCEPT MOTOR SKILL, V80, P607, DOI 10.2466/pms.1995.80.2.607; KLAVORA P, 1995, AM J OCCUP THER, V49, P534, DOI 10.5014/ajot.49.6.534; Kontos AP, 2012, AM J SPORT MED, V40, P2375, DOI 10.1177/0363546512455400; Miller JO, 2001, J EXP PSYCHOL HUMAN, V27, P266, DOI 10.1037//0096-1523.27.2.266; Moore RD, 2014, J ATHL TRAINING, V49, P24, DOI 10.4085/1062-6050-49.1.01; Nordstrom A, 2014, BRIT J SPORT MED, V48, P1447, DOI 10.1136/bjsports-2013-093406; Padula WV, 2012, NEUROVISUAL PROCESSI; Schwab S, 2012, J SPORT SCI MED, V11, P624; Singh R, 2014, JAMA-J AM MED ASSOC, V311, P1883, DOI 10.1001/jama.2014.3313; Swanik CB, 2007, AM J SPORT MED, V35, P943, DOI 10.1177/0363546507299532; TAIMELA S, 1990, J SPORT MED PHYS FIT, V30, P194; Talavage TM, 2014, J NEUROTRAUM, V31, P327, DOI 10.1089/neu.2010.1512; Thomas JR, 1999, RES Q EXERCISE SPORT, V70, P11, DOI 10.1080/02701367.1999.10607726; Wells AJ, 2014, J SPORT SCI MED, V13, P145; Wilkerson GB, 2015, J ATHL TRAINING, V50, P643, DOI 10.4085/1062-6050-50.2.04; Wilkerson GB, 2012, INT J ATHL THER TRAI, V17, P4, DOI 10.1123/ijatt.17.6.4; Williams JM, 1997, BEHAV MED, V22, P160, DOI 10.1080/08964289.1997.10543549	30	22	22	2	21	HUMAN KINETICS PUBL INC	CHAMPAIGN	1607 N MARKET ST, PO BOX 5076, CHAMPAIGN, IL 61820-2200 USA	1056-6716	1543-3072		J SPORT REHABIL	J. Sport Rehabil.	JAN	2017	26	1					26	34		10.1123/jsr.2015-0068			9	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	EN4EH	WOS:000395960300004	27632871				2021-06-18	
J	Yang, YQ; Wang, HD; Li, LW; Li, X; Wang, Q; Ding, H; Wang, XL; Ye, ZN; Wu, LY; Zhang, XS; Zhou, ML; Pan, H				Yang, Youqing; Wang, Handong; Li, Liwen; Li, Xiang; Wang, Qiang; Ding, Hui; Wang, Xiaoliang; Ye, Zhennan; Wu, Lingyun; Zhang, Xiangsheng; Zhou, Mengliang; Pan, Hao			Sinomenine Provides Neuroprotection in Model of Traumatic Brain Injury via the Nrf2-ARE Pathway	FRONTIERS IN NEUROSCIENCE			English	Article						traumatic brain injury; nuclear factor erythroid 2-related factor 2; sinomenine; neuroprotection; reactive oxygen species	MESANGIAL PROLIFERATIVE NEPHRITIS; OXIDATIVE STRESS; INTRACEREBRAL HEMORRHAGE; NF-E2-RELATED FACTOR-2; GENE-EXPRESSION; ACTIVATION; INHIBITION; PROTECTION; APOPTOSIS; PROTEINS	The neuroprotective effect of sinomenine (SIN) has been demonstrated in several brain injury models. However, its role and molecular mechanism in traumatic brain injury (TBI) remain unknown. In this study, we investigated the neuroprotective effects of SIN in the weight-drop model of TBI in male ICR mice. Mice were randomly divided into the sham and TBI groups, SIN (10 mg/kg, 30 mg/kg and 50 mg/kg, administered intraperitoneally) or equal volume of vehicle was given at 30 min after TBI. Treatment with 30 mg/kg SIN significantly improved motor performance and alleviated cerebral edema. However, treatment with 10 mg/kg or 50 mg/kg SIN did not exhibit a better outcome. Therefore, we chose 30 mg/kg SIN for our subsequent experiments. SIN significantly increased the expression of Bcl-2 and decreased that of cleaved caspase-3, indicating that SIN is anti-apoptotic. This was confirmed by the observation that SIN-treated animals had fewer apoptotic neurons. Cortical malondialdehyde content, glutathione peroxidase (GPx) activity and superoxide dismutase (SOD) activity were restored in the group that received SIN. Furthermore, Western blot and immunofluorescence experiments showed that SIN enhanced the translocation of nuclear factor erythroid 2-related factor 2 (Nrf2) to the nucleus. SIN administration also significantly upregulated the expression of the downstream factors heme oxygenase 1 and NAD(P)H:quinone oxidoreductase 1 at pre- and post-transcriptional levels. Together, these data demonstrate that SIN exerts a neuroprotective effect in a model of TBI, possibly by activating the Nrf2 antioxidant response element (ARE) pathway.	[Yang, Youqing; Wang, Handong; Ding, Hui; Ye, Zhennan] Southern Med Univ Guangzhou, Clin Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China; [Li, Liwen; Li, Xiang; Wang, Qiang; Wang, Xiaoliang; Wu, Lingyun; Zhang, Xiangsheng; Zhou, Mengliang; Pan, Hao] Nanjing Univ, Sch Med, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China	Wang, HD (corresponding author), Southern Med Univ Guangzhou, Clin Med Coll, Jinling Hosp, Dept Neurosurg, Nanjing, Jiangsu, Peoples R China.	njhdwang@hotmail.com		Zhou, Meng-liang/0000-0002-1165-5489	National Natural Science Fund of ChinaNational Natural Science Foundation of China (NSFC) [81371357, 81401026]	This study was grant-supported by the National Natural Science Fund of China (grant Nos. 81371357 and 81401026).	Adibhatla RM, 2010, ANTIOXID REDOX SIGN, V12, P125, DOI [10.1089/ars.2009.2668, 10.1089/ARS.2009.2668]; Ansari MA, 2008, J NEUROTRAUM, V25, P513, DOI 10.1089/neu.2007.0451; Ansari MA, 2006, FREE RADICAL BIO MED, V41, P1694, DOI 10.1016/j.freeradbiomed.2006.09.002; Bains M, 2012, BBA-MOL BASIS DIS, V1822, P675, DOI 10.1016/j.bbadis.2011.10.017; Bell JD, 2009, CELL DEATH DIFFER, V16, P1665, DOI 10.1038/cdd.2009.106; Bermpohl D, 2006, J CEREBR BLOOD F MET, V26, P625, DOI 10.1038/sj.jcbfm.9600258; Chen G, 2011, J NEUROSCI RES, V89, P515, DOI 10.1002/jnr.22577; Cheng Y, 2013, MOL MED REP, V7, P1223, DOI 10.3892/mmr.2013.1302; Cheng Y, 2009, INT IMMUNOPHARMACOL, V9, P894, DOI 10.1016/j.intimp.2009.03.014; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; de Vries HE, 2008, FREE RADICAL BIO MED, V45, P1375, DOI 10.1016/j.freeradbiomed.2008.09.001; Engel T, 2011, J CEREBR BLOOD F MET, V31, P1196, DOI 10.1038/jcbfm.2011.26; Flierl MA, 2009, NAT PROTOC, V4, P1328, DOI 10.1038/nprot.2009.148; Hou ZG, 2012, BRAIN RES BULL, V88, P560, DOI 10.1016/j.brainresbull.2012.06.006; Huang HC, 2000, P NATL ACAD SCI USA, V97, P12475, DOI 10.1073/pnas.220418997; Lewen A, 2000, J NEUROTRAUM, V17, P871, DOI 10.1089/neu.2000.17.871; Ma Q, 2013, ANNU REV PHARMACOL, V53, P401, DOI 10.1146/annurev-pharmtox-011112-140320; Miller TW, 2009, CHEM REV, V109, P3099, DOI 10.1021/cr8005125; Qian L, 2007, J NEUROINFLAMM, V4, DOI 10.1186/1742-2094-4-23; Qin T, 2016, TOXICOL APPL PHARM, V304, P1, DOI 10.1016/j.taap.2016.05.009; Radak Z, 2013, ANTIOXID REDOX SIGN, V18, P1208, DOI 10.1089/ars.2011.4498; Radjendirane V, 1998, J BIOL CHEM, V273, P7382, DOI 10.1074/jbc.273.13.7382; Reed JC, 1998, ONCOGENE, V17, P3225, DOI 10.1038/sj.onc.1202591; Shao CX, 2006, FREE RADICAL BIO MED, V41, P77, DOI 10.1016/j.freeradbiomed.2006.03.007; Strauss KI, 2004, NEUROTOX RES, V6, P333, DOI 10.1007/BF03033444; Sun M, 2015, J NEUROTRAUM, V32, P66, DOI 10.1089/neu.2012.2432; Tsai CY, 2013, INT J CARDIOL, V168, P1286, DOI 10.1016/j.ijcard.2012.12.004; Wang B, 2012, FREE RADICAL BIO MED, V52, P928, DOI 10.1016/j.freeradbiomed.2011.12.006; Wang JA, 2007, FREE RADICAL BIO MED, V43, P408, DOI 10.1016/j.freeradbiomed.2007.04.020; Wang QX, 2011, INT IMMUNOPHARMACOL, V11, P373, DOI 10.1016/j.intimp.2010.11.018; Werner C, 2007, BRIT J ANAESTH, V99, P4, DOI 10.1093/bja/aem131; Wu WN, 2011, BRIT J PHARMACOL, V164, P1445, DOI 10.1111/j.1476-5381.2011.01487.x; Xu JG, 2014, FREE RADICAL BIO MED, V71, P186, DOI 10.1016/j.freeradbiomed.2014.03.009; Xu JG, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/187873; Xu M, 2008, PLANTA MED, V74, P1423, DOI 10.1055/s-2008-1081346; Yan W, 2008, NEUROSCI LETT, V431, P150, DOI 10.1016/j.neulet.2007.11.060; Yan W, 2009, J TRAUMA, V66, P1431, DOI 10.1097/TA.0b013e318180f5c7; Yang Z, 2014, MOL IMMUNOL, V60, P109, DOI 10.1016/j.molimm.2014.03.005; Yuan JY, 2000, NATURE, V407, P802, DOI 10.1038/35037739; Zhang L, 2016, CELL MOL NEUROBIOL, V36, P131, DOI 10.1007/s10571-015-0227-1; Zipper LM, 2003, TOXICOL SCI, V73, P124, DOI 10.1093/toxsci/kfg083	41	22	24	0	9	FRONTIERS MEDIA SA	LAUSANNE	PO BOX 110, EPFL INNOVATION PARK, BUILDING I, LAUSANNE, 1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	DEC 23	2016	10								580	10.3389/fnins.2016.00580			10	Neurosciences	Neurosciences & Neurology	EF5MK	WOS:000390374100001	28066165	DOAJ Gold, Green Published			2021-06-18	
J	Anderson, BJ; Reilly, JP; Shashaty, MGS; Palakshappa, JA; Wysoczanski, A; Dunn, TG; Kazi, A; Tommasini, A; Mikkelsen, ME; Schweickert, WD; Kolson, DL; Christie, JD; Meyer, NJ				Anderson, Brian J.; Reilly, John P.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Wysoczanski, Alex; Dunn, Thomas G.; Kazi, Altaf; Tommasini, Anna; Mikkelsen, Mark E.; Schweickert, William D.; Kolson, Dennis L.; Christie, Jason D.; Meyer, Nuala J.			Admission plasma levels of the neuronal injury marker neuron-specific enolase are associated with mortality and delirium in sepsis	JOURNAL OF CRITICAL CARE			English	Article						Sepsis; Critical care; Brain injury; Delirium; Neuron-specific enolase	INTENSIVE-CARE-UNIT; MECHANICALLY VENTILATED PATIENTS; CONFUSION ASSESSMENT METHOD; TERM COGNITIVE IMPAIRMENT; CRITICALLY-ILL PATIENTS; BRAIN; SERUM; DYSFUNCTION; PREDICTOR; BLOOD	Purpose: Neuron-specific enolase (NSE) concentrations are prognostic following traumatic and anoxic brain injury and may provide a method to quantify neuronal injury in other populations. We determined the association of admission plasma NSE concentrations with mortality and delirium in critically ill septic patients. Methods: We performed a retrospective analysis of 124 patients from a larger sepsis cohort. Plasma NSE was measured in the earliest blood draw at intensive care unit admission. Primary outcomes were 30-day mortality and intensive care unit delirium determined by chart review. Results: Sixty-one patients (49.2%) died within 30 days, and delirium developed in 34 (31.5%) of the 108 patients who survived at least 24 hours and were not persistently comatose. Each doubling of the NSE concentration was associated with a 7.3% (95% confidence interval [CI] 2.5-12.0, P=.003) increased risk of 30-day mortality and a 5.2% (95% CI 3.2-7.2, P<.001) increased risk of delirium. An NSE concentration N12.5 mu g/L was independently associated with a 23.3% (95% CI 6.7-39.9, P=. 006) increased risk of 30-day mortality and a 29.3% (95% CI 8.8-49.8, P=.005) increased risk of delirium. Conclusions: Higher plasma NSE concentrations were associated with mortality and delirium in critically ill septic patients, suggesting that NSE may have utility as a marker of neuronal injury in sepsis. (C) 2016 Elsevier Inc. All rights reserved.	[Anderson, Brian J.; Reilly, John P.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Wysoczanski, Alex; Dunn, Thomas G.; Kazi, Altaf; Tommasini, Anna; Mikkelsen, Mark E.; Schweickert, William D.; Christie, Jason D.; Meyer, Nuala J.] Univ Penn, Perelman Sch Med, Div Pulm Allergy & Crit Care Med, Philadelphia, PA 19104 USA; [Anderson, Brian J.; Shashaty, Michael G. S.; Palakshappa, Jessica A.; Mikkelsen, Mark E.; Christie, Jason D.] Univ Penn, Ctr Clin Epidemiol & Biostat, Perelman Sch Med, Philadelphia, PA 19104 USA; [Kolson, Dennis L.] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA	Anderson, BJ (corresponding author), Univ Penn, Pulm Allergy & Crit Care Div, 3600 Spruce St,5048 Gates Bldg, Philadelphia, PA 19104 USA.	brian.anderson@uphs.upenn.edu	Shashaty, Michael/X-3690-2019	Shashaty, Michael/0000-0002-8766-3418; Reilly, John/0000-0003-3937-5320; Anderson, Brian/0000-0002-2426-9683; Christie, Jason/0000-0003-0519-218X; Palakshappa, Jessica/0000-0002-6333-365X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32NS061779, F32GM116637, K23HL125723, K23DK097307, K23HL102254, K24HL115354]; American Thoracic Society Foundation Award; NATIONAL HEART, LUNG, AND BLOOD INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Heart Lung & Blood Institute (NHLBI) [K23HL125723, K24HL115354, K23HL102254] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [K23DK097307] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [F32GM116637] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [T32NS061779] Funding Source: NIH RePORTER	This study was supported in part by National Institutes of Health grants T32NS061779 (BJA), F32GM116637 (BJA), K23HL125723 (JPR), K23DK097307 (MGSS), K23HL102254 (NJM), and K24HL115354 (JDC) and an American Thoracic Society Foundation Award (NJM).	Al-Qadheeb NS, 2014, CRIT CARE MED, V42, P1442, DOI 10.1097/CCM.0000000000000224; Barakat MT, 2004, ENDOCR-RELAT CANCER, V11, P1, DOI 10.1677/erc.0.0110001; Barr J, 2013, CRIT CARE MED, V41, P263, DOI 10.1097/CCM.0b013e3182783b72; Bozza FA, 2013, SHOCK, V39, P10, DOI 10.1097/SHK.0b013e31828fade1; Calfee CS, 2014, LANCET RESP MED, V2, P611, DOI 10.1016/S2213-2600(14)70097-9; CLEVELAND WS, 1979, J AM STAT ASSOC, V74, P829, DOI 10.2307/2286407; Ely EW, 2003, JAMA-J AM MED ASSOC, V289, P2983, DOI 10.1001/jama.289.22.2983; Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703; Ely EW, 2004, JAMA-J AM MED ASSOC, V291, P1753, DOI 10.1001/jama.291.14.1753; Fizazi K, 1998, CANCER, V82, P1049, DOI 10.1002/(SICI)1097-0142(19980315)82:6<1049::AID-CNCR6>3.0.CO;2-9; Girard TD, 2010, CRIT CARE MED, V38, P1513, DOI 10.1097/CCM.0b013e3181e47be1; Grandi C, 2011, J CRIT CARE, V26, P133, DOI 10.1016/j.jcrc.2010.10.006; Gunther ML, 2012, CRIT CARE MED, V40, P2022, DOI 10.1097/CCM.0b013e318250acc0; Herrmann M, 2000, STROKE, V31, P645, DOI 10.1161/01.STR.31.3.645; KATO K, 1983, CLIN CHIM ACTA, V127, P353, DOI 10.1016/0009-8981(83)90162-6; Kleinman LC, 2009, HEALTH SERV RES, V44, P288, DOI 10.1111/j.1475-6773.2008.00900.x; Kramer L, 2007, CRIT CARE MED, V35, P1099, DOI 10.1097/01.CCM.0000259462.97164.A0; Levy MM, 2003, CRIT CARE MED, V31, P1250, DOI 10.1097/01.CCM.0000050454.01978.3B; Magder LS, 1997, AM J EPIDEMIOL, V146, P195; MALDONADO G, 1993, AM J EPIDEMIOL, V138, P923, DOI 10.1093/oxfordjournals.aje.a116813; Martens P, 1998, STROKE, V29, P2363, DOI 10.1161/01.STR.29.11.2363; Matthay MA, 2016, JAMA-J AM MED ASSOC, V315, P747, DOI 10.1001/jama.2016.0661; McNicoll L, 2003, J AM GERIATR SOC, V51, P591, DOI 10.1034/j.1600-0579.2003.00201.x; Mehta NJ, 2004, INT J CARDIOL, V95, P13, DOI 10.1016/j.ijcard.2003.02.005; Mehta RL, 2007, CRIT CARE, V11, DOI 10.1186/cc5713; Meric E, 2010, J EMERG MED, V38, P297, DOI 10.1016/j.jemermed.2007.11.032; Meynaar IA, 2003, INTENS CARE MED, V29, P189, DOI 10.1007/s00134-002-1573-2; Nguyen DN, 2006, CRIT CARE MED, V34, P1967, DOI 10.1097/01.CCM.0000217218.51381.49; Norton EC, 2013, STATA J, V13, P492, DOI 10.1177/1536867X1301300304; Ouimet S, 2007, INTENS CARE MED, V33, P66, DOI 10.1007/s00134-006-0399-8; Palakshappa JA, 2016, CRIT CARE, V20, DOI 10.1186/s13054-016-1244-2; Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372; Patel SB, 2014, AM J RESP CRIT CARE, V189, P658, DOI 10.1164/rccm.201310-1815OC; Pfuntner A., 2013, MOST FREQUENT CONDIT; Plog BA, 2015, J NEUROSCI, V35, P518, DOI 10.1523/JNEUROSCI.3742-14.2015; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rasmussen LS, 2000, BRIT J ANAESTH, V84, P242; Reade MC, 2011, CRIT CARE RESUSC, V13, P217; Reilly JP, 2015, CLIN J AM SOC NEPHRO, V10, P1911, DOI 10.2215/CJN.12201214; Salluh JIF, 2016, LANCET RESP MED, V4, pE17, DOI 10.1016/S2213-2600(16)30020-0; Schwebel C, 2013, CRIT CARE MED, V41, P1919, DOI 10.1097/CCM.0b013e31828a3bbd; Semmler A, 2013, J NEUROL NEUROSUR PS, V84, P62, DOI 10.1136/jnnp-2012-302883; Shehabi Y, 2012, AM J RESP CRIT CARE, V186, P724, DOI 10.1164/rccm.201203-0522OC; Sonneville R, 2013, ANN INTENSIVE CARE, V3, DOI 10.1186/2110-5820-3-15; Stammet P, 2015, J AM COLL CARDIOL, V65, P2104, DOI 10.1016/j.jacc.2015.03.538; TAYLOR CB, 1983, ISOZYMES-CURR T BIOL, V11, P95; van Munster BC, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-21; Vasilevskis EE, 2011, J AM GERIATR SOC, V59, pS249, DOI 10.1111/j.1532-5415.2011.03673.x; Vos PE, 2004, NEUROLOGY, V62, P1303, DOI 10.1212/01.WNL.0000120550.00643.DC; Xu J, 2016, NATL VITAL STAT REPO	50	22	24	0	3	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0883-9441	1557-8615		J CRIT CARE	J. Crit. Care	DEC	2016	36						18	23		10.1016/j.jcrc.2016.06.012			6	Critical Care Medicine	General & Internal Medicine	EJ2YS	WOS:000393078100005	27546742	Green Accepted			2021-06-18	
J	Raikes, AC; Schaefer, SY				Raikes, Adam C.; Schaefer, Sydney Y.			Sleep Quantity and Quality during Acute Concussion: A Pilot Study	SLEEP			English	Article						actigraph; concussion; sleep duration; sleep quality	TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; COGNITIVE PERFORMANCE; DEPRESSIVE SYMPTOMS; POSTURAL STABILITY; ACUTE-PHASE; ADOLESCENTS; DISTURBANCES; VARIABILITY; INSOMNIA	Study Objectives: A number of subjective and objective studies provide compelling evidence of chronic post-concussion changes in sleep, yet very little is known about the acute effects of concussion on sleep quality and quantity. Therefore, the purpose of this prospective pilot study was to use actigraphy to examine the changes in sleep quality and quantity acutely following concussion at home rather than in a hospital or sleep laboratory. Methods: Seventeen young adults (7 with acute concussion, 10 controls) were recruited for this study. All participants completed two 5-day testing sessions separated by 30 days from intake (controls) or day of injury (concussion). Participants wore actigraphs and kept a sleep journal. Sleep parameter outcomes included nighttime total sleep time (nTST), 24-h total sleep time (TST), wake after sleep onset (WASO), and sleep efficiency (SE). The coefficient of variation (CV) for each sleep parameter was computed for each session. Results: nTST and TST CV was significantly greater in the concussion group. There is the additional indication that individuals with a concussion may require and obtain more sleep shortly after injury and subsequently have a shorter duration of sleep at 1 mo post-injury. This pattern was not seen in the measures of sleep quality (WASO, SE). Conclusions: Individuals with a concussion demonstrated increased nighttime sleep duration variability. This increase persisted at 1 mo post-injury and may be associated with previously documented self-reports of poor sleep quality lasting months and years after a concussion. Additionally, this increase may predispose individuals to numerous negative health outcomes if left untreated.	[Raikes, Adam C.] Utah State Univ, Coll Educ & Human Serv, Motor Rehabil & Learning Lab, Logan, UT 84322 USA; [Schaefer, Sydney Y.] Arizona State Univ, Sch Biol & Hlth Syst Engn, Tempe, AZ USA	Raikes, AC (corresponding author), Utah State Univ, 7000 Old Main Hill, Logan, UT 84322 USA.	adam.raikes@usu.edu	Raikes, Adam/M-2600-2019	Raikes, Adam/0000-0002-1609-6727	National Athletic Trainers' Association Research and Education Foundation	This was not an industry supported study. This study was partially funded by the National Athletic Trainers' Association Research and Education Foundation. The authors have indicated no financial conflicts of interest. All research was conducted at Utah State University. This was not a clinical trial.	Ancoli-Israel S, 2003, SLEEP, V26, P342, DOI 10.1093/sleep/26.3.342; Anderson B, 2009, PEDIATRICS, V123, pE701, DOI 10.1542/peds.2008-1182; Baron KG, 2016, BEHAV SLEEP MED, P1; Baumann CR, 2007, BRAIN, V130, P1873, DOI 10.1093/brain/awm109; Baumann CR, 2009, ANN NEUROL, V66, P555, DOI 10.1002/ana.21836; Baumann CR, 2005, NEUROLOGY, V65, P147, DOI 10.1212/01.wnl.0000167605.02541.f2; Billiard M, 2013, SLEEP MED, V14, P462, DOI 10.1016/j.sleep.2013.01.009; Castriotta RJ, 2007, J CLIN SLEEP MED, V3, P349; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; Chaput G, 2009, SLEEP MED, V10, P713, DOI 10.1016/j.sleep.2008.07.015; Chiu HY, 2014, INT J NURS STUD, V51, P892, DOI 10.1016/j.ijnurstu.2013.10.020; Chiu HY, 2013, J FORMOS MED ASSOC, V112, P545, DOI 10.1016/j.jfma.2013.06.007; Clinchot DM, 1998, AM J PHYS MED REHAB, V77, P291, DOI 10.1097/00002060-199807000-00006; COLE RJ, 1992, SLEEP, V15, P461, DOI 10.1093/sleep/15.5.461; de Souza L, 2003, SLEEP, V26, P81, DOI 10.1093/sleep/26.1.81; Dean PJA, 2015, BRAIN INJURY, V29, P1211, DOI 10.3109/02699052.2015.1035334; DIJK DJ, 1992, J SLEEP RES, V1, P112, DOI 10.1111/j.1365-2869.1992.tb00021.x; Dillon HR, 2014, J GERONTOL B-PSYCHOL; Duncan MJ, 2015, J PUBLIC HLTH, P1; Faux S, 2008, PAIN MED, V9, P1001, DOI 10.1111/j.1526-4637.2007.00404.x; Fichtenberg NL, 2002, BRAIN INJURY, V16, P197, DOI 10.1080/02699050110103940; Finch CF, 2013, BRIT J SPORT MED, V47, P12, DOI 10.1136/bjsports-2012-091796; Fuligni AJ, 2006, J RES ADOLESCENCE, V16, P353, DOI 10.1111/j.1532-7795.2006.00498.x; Giza CC, 2013, NEUROLOGY, V80, P2250, DOI 10.1212/WNL.0b013e31828d57dd; Gosselin N, 2009, SLEEP MED, V10, P35, DOI 10.1016/j.sleep.2007.11.023; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; He F, 2015, SLEEP MED, V16, P1489, DOI 10.1016/j.sleep.2015.07.028; He F, 2015, SLEEP MED, V16, P856, DOI 10.1016/j.sleep.2015.03.004; Imbach LL, 2016, NEUROLOGY; Imbach LL, 2015, BRAIN, V138, P726, DOI 10.1093/brain/awu391; Kaufman Y, 2001, PEDIATR NEUROL, V24, P129, DOI 10.1016/S0887-8994(00)00254-X; Kempf J, 2010, J NEUROL NEUROSUR PS, V81, P1402, DOI 10.1136/jnnp.2009.201913; Kirkwood M, 2000, CHILD NEUROPSYCHOL, V6, P195, DOI 10.1076/chin.6.3.195.3157; Kostyun RO, 2015, AM J SPORT MED, V43, P633, DOI 10.1177/0363546514560727; Lemola S, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071292; Littner M, 2003, SLEEP, V26, P337, DOI 10.1093/sleep/26.3.337; Matos MG, 2016, INT J PSYCHOL, V51, P323, DOI 10.1002/ijop.12167; Max JE, 2005, J AM ACAD CHILD PSY, V44, P1032, DOI 10.1097/01.chi.0000173293.05817.b1; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2003, JAMA-J AM MED ASSOC, V290, P2556, DOI 10.1001/jama.290.19.2556; McCrea M, 2002, NEUROSURGERY, V50, P1032, DOI 10.1097/00006123-200205000-00017; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; Mezick EJ, 2009, PSYCHONEUROENDOCRINO, V34, P1346, DOI 10.1016/j.psyneuen.2009.04.005; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Milroy G, 2008, J PEDIATR PSYCHOL, V33, P242, DOI 10.1093/jpepsy/jsm099; Monk TH, 2003, CHRONOBIOL INT, V20, P97, DOI 10.1081/CBI-120017812; Mysliwiec V, 2013, SLEEP, V36, P167, DOI 10.5665/sleep.2364; Okun ML, 2011, PSYCHOSOM MED, V73, P142, DOI 10.1097/PSY.0b013e3182020d08; Ouellet MC, 2006, SLEEP MED, V7, P486, DOI 10.1016/j.sleep.2006.03.017; Ouellet MC, 2006, J HEAD TRAUMA REHAB, V21, P199, DOI 10.1097/00001199-200605000-00001; Patel SR, 2014, INT J OBESITY, V38, P1159, DOI 10.1038/ijo.2014.13; Pilcher JJ, 1997, J AM COLL HEALTH, V46, P121, DOI 10.1080/07448489709595597; Rao V, 2008, BRAIN INJURY, V22, P381, DOI 10.1080/02699050801935260; Rao V, 2011, J NEUROPSYCH CLIN N, V23, P201, DOI 10.1176/appi.neuropsych.23.2.201; Reilly T, 2007, PHYSIOL BEHAV, V90, P274, DOI 10.1016/j.physbeh.2006.09.017; Roane BM, 2015, BEHAV SLEEP MED, V13, P491, DOI 10.1080/15402002.2014.940109; Rodriguez-Colon SM, 2015, SLEEP MED, V16, P67, DOI 10.1016/j.sleep.2014.10.007; Sadeh A, 2011, SLEEP MED REV, V15, P259, DOI 10.1016/j.smrv.2010.10.001; Sinclair KL, 2014, BEHAV SLEEP MED, V12, P13, DOI 10.1080/15402002.2012.726203; Sommerauer M, 2013, J SLEEP RES, V22, P634, DOI 10.1111/jsr.12068; Sumpter RE, 2013, J INT NEUROPSYCH SOC, V19, P829, DOI 10.1017/S1355617713000465; Telzer EH, 2015, DEV COGN NEUROS-NETH, V14, P16, DOI 10.1016/j.dcn.2015.05.007; Thomas M, 2000, J SLEEP RES, V9, P335, DOI 10.1046/j.1365-2869.2000.00225.x; Trenchard SO, 2013, BRAIN INJURY, V27, P1217, DOI 10.3109/02699052.2013.812240; Valko PO, 2015, ANN NEUROL, V77, P177, DOI 10.1002/ana.24298; Vanderlind WM, 2014, SLEEP MED, V15, P144, DOI 10.1016/j.sleep.2013.10.006; Verma A, 2007, J CLIN SLEEP MED, V3, P357; Villemure R, 2011, BRAIN INJURY, V25, P53, DOI 10.3109/02699052.2010.531881; Wallace DM, 2011, SLEEP MED, V12, P850, DOI 10.1016/j.sleep.2011.06.004; Watson NF, 2007, J CLIN SLEEP MED, V3, P363; Wickham H, 2009, USE R, P1, DOI 10.1007/978-0-387-98141-3_1; Wickwire EM, 2016, NEUROTHERAPEUTICS, V13, P403, DOI 10.1007/s13311-016-0429-3; Williams BR, 2008, CLIN NEUROPHYSIOL, V119, P429, DOI 10.1016/j.clinph.2007.11.003	74	22	22	0	10	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	DEC 1	2016	39	12					2141	2147	PII sp-00300-16	10.5665/sleep.6314			7	Clinical Neurology; Neurosciences	Neurosciences & Neurology	ED5ZK	WOS:000388932700008	27748242	Green Published, Bronze			2021-06-18	
J	Tapia-Perez, JH; Karagianis, D; Zilke, R; Koufuglou, V; Bondar, I; Schneider, T				Tapia-Perez, J. H.; Karagianis, D.; Zilke, R.; Koufuglou, V.; Bondar, I.; Schneider, T.			Assessment of systemic cellular inflammatory response after spontaneous intracerebral hemorrhage	CLINICAL NEUROLOGY AND NEUROSURGERY			English	Article						Intracerebral hemorrhage; Inflammation; Interleukin 6; Neutrophils	BRAIN-INJURY; INTERLEUKIN-6; NEUROTOXICITY; MECHANISMS; CORRELATE; SEVERITY; PROTECTS	Objective: After spontaneous intracerebral hemorrhage (ICH) a local and systemic inflammatory response is activated. Interleukin-6 (IL) is one of most relevant orchestrators of inflammatory responses in the brain and is released from multiple immune cells, including neutrophils. Herby we assessed the relevance of systemic inflammation in patients suffering ICH. Methods: From October 2010 to October 2011 we included in our routine of laboratory investigations besides to C-reactive protein (CRP), the addition of IL-6 and an analysis of the subpopulation of circulating blood cells. Values at admission, at 3rd and 7th day after admission were evaluated. We analyzed 43 patients with non-traumatic ICH; stroke-related ICH or tumor associated hemorrhage were excluded. Outcome variables were 30 and 90-day mortality and NIHSS at discharge. A natural logarithmic transformation of IL-6, lymphocytes, and monocytes was used. Results: 8.6% died within 30-days and mortality increased to 39.5% at 90th day. Total leukocytes and neutrophils as well as IL-6 at admission were statistically significant increased among patients who died within 30 days after ICH onset (p = 0.002). IL-6 and CRP in follow-up (3rd and 7th day) were higher among patients with poor outcome (NIHSS >15). The number of circulating lymphocytes and monocytes was not different in measurement. Leukocytes and neutrophils at 3rd day after admission were augmented in patients with respiratory infection and CRP in follow-up increased if some kind of infection was clinically or microbiologically detected. IL-6 at admission and in follow-up and monocytes at 7th day were related to ICH volume. CRP-values at 3rd or 7th day but not at admission were associated to bigger ICH-volume. The values of IL-6 were highly correlated to 30-day mortality and volume of ICH as CRP only with ICH volume. Conclusion: After ICH onset a systemic activation of immune system seems to be induced and may be influencing outcome. Peripheral recruitment of leukocytes, especially neutrophils could be a target for future therapeutic interventions. Because of the tighter correlation of IL-6 at admission, it might be more accurate for prognostic issues than CRP. (C) 2016 Elsevier B.V. All rights reserved.	[Tapia-Perez, J. H.; Karagianis, D.; Zilke, R.; Koufuglou, V.; Bondar, I.; Schneider, T.] Otto Von Guericke Univ, Dept Neurosurg, Magdeburg, Germany; [Tapia-Perez, J. H.] Univ Marburg, Dept Neurosurg, Marburg, Germany; [Tapia-Perez, J. H.] Univ Wurzburg, Dept Neurol, Wurzburg, Germany	Tapia-Perez, JH (corresponding author), Josef Schneider Str 11, D-97080 Wurzburg, Germany.	jhtapiap@gmail.com					Adeoye O, 2014, J STROKE CEREBROVASC, V23, pE107, DOI 10.1016/j.jstrokecerebrovasdis.2013.09.006; Amulic B, 2012, ANNU REV IMMUNOL, V30, P459, DOI 10.1146/annurev-immunol-020711-074942; Brunswick AS, 2012, J NEUROL SCI, V321, P1, DOI 10.1016/j.jns.2012.06.008; Conroy SM, 2004, J NEUROIMMUNOL, V155, P43, DOI 10.1016/j.jneuroim.2004.06.014; Diedler J, 2009, CEREBROVASC DIS, V27, P272, DOI 10.1159/000199465; Fang H, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-27; Figueiredo RT, 2007, J BIOL CHEM, V282, P20221, DOI 10.1074/jbc.M610737200; Illanes S, 2011, NEUROSCI LETT, V490, P170, DOI 10.1016/j.neulet.2010.11.065; Islam O, 2009, MOL BIOL CELL, V20, P188, DOI 10.1091/mbc.E08-05-0463; Loftspring MC, 2009, J CEREBR BLOOD F MET, V29, P137, DOI 10.1038/jcbfm.2008.114; Mantovani A, 2011, NAT REV IMMUNOL, V11, P519, DOI 10.1038/nri3024; Mendelow AD, 2013, LANCET, V382, P397, DOI 10.1016/S0140-6736(13)60986-1; Morgenstern LB, 2010, STROKE, V41, P2108, DOI 10.1161/STR.0b013e3181ec611b; Nguyen HX, 2007, J NEUROCHEM, V102, P900, DOI 10.1111/j.1471-4159.2007.04643.x; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Penkowa M, 2003, EXP NEUROL, V181, P130, DOI 10.1016/S0014-4886(02)00051-1; Sarrafzadeh A, 2010, NEUROCRIT CARE, V13, P339, DOI 10.1007/s12028-010-9432-4; Smiley ST, 2001, J IMMUNOL, V167, P2887, DOI 10.4049/jimmunol.167.5.2887; Smith CJ, 2004, BMC NEUROL, V4, DOI 10.1186/1471-2377-4-2; Spooren A, 2011, BRAIN RES REV, V67, P157, DOI 10.1016/j.brainresrev.2011.01.002; Swartz KR, 2001, BRAIN RES, V896, P86, DOI 10.1016/S0006-8993(01)02013-3; Tapia-Perez JH, 2013, NEUROSURG REV, V36, P279, DOI 10.1007/s10143-012-0431-0; Teng WY, 2009, MEDIAT INFLAMM, V2009, DOI 10.1155/2009/473276; Wang JA, 2010, PROG NEUROBIOL, V92, P463, DOI 10.1016/j.pneurobio.2010.08.001; Woiciechowsky C, 2002, J TRAUMA, V52, P339, DOI 10.1097/00005373-200202000-00021; Woo D, 2002, NEUROSURG CLIN N AM, V13, P265, DOI 10.1016/S1042-3680(02)00011-6; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Zhou Y, 2013, OXID MED CELL LONGEV, V2013, P2013, DOI DOI 10.1371/J0URNAL.P0NE.0057558	28	22	23	0	4	ELSEVIER SCIENCE BV	AMSTERDAM	PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS	0303-8467	1872-6968		CLIN NEUROL NEUROSUR	Clin. Neurol. Neurosurg.	NOV	2016	150						72	79		10.1016/j.clineuro.2016.07.010			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	EA5EN	WOS:000386642300013	27611984				2021-06-18	
J	Treble-Barna, A; Sohlberg, MM; Harn, BE; Wade, SL				Treble-Barna, Amery; Sohlberg, McKay Moore; Harn, Beth E.; Wade, Shari L.			Cognitive Intervention for Attention and Executive Function Impairments in Children With Traumatic Brain Injury: A Pilot Study	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						child; cognitive remediation; cognitive rehabilitation; executive function; pilot projects; traumatic brain injury	REMEDIATION PROGRAM; WORKING-MEMORY; REHABILITATION; CHILDHOOD; DEFICITS; ADHD; SELF; RECOMMENDATIONS; METAANALYSIS; SURVIVORS	Objective: To test the effectiveness of the Attention Improvement and Management (AIM) program, a cognitive intervention for improving impairments in attention and executive functions (EFs) after pediatric traumatic brain injury (TBI). Setting: Tertiary care children's hospital. Participants: A total of 13 children with complicated mild-to-severe TBI (average of 5 years postinjury) and 11 healthy comparison children aged 9 to 15 years completed the study. Design: Open-label pilot study with a nontreated control group. Main Measures: Subtests from the Test of Everyday Attention-for Children (TEA-Ch) and the Delis-Kaplan Executive Function System (D-KEFS), the self-and parent-report from the Behavior Rating Inventory of Executive Function (BRIEF), and the Goal Attainment Scale (GAS). Results: Relative to the healthy comparison group, children with TBI demonstrated significant improvement postintervention on a neuropsychological measure of sustained attention, as well as on parent-reported EFs. The majority of families also reported expected or more-than-expected personalized goal attainment. Conclusions: The study provides preliminary evidence for the effectiveness of AIM in improving parent-reported EFs and personalized real-world goal attainment in children with TBI.	[Treble-Barna, Amery] Cincinnati Childrens Hosp Med Ctr, Dept Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA; [Sohlberg, McKay Moore] Univ Oregon, Commun Disorders & Sci, Eugene, OR 97403 USA; [Harn, Beth E.] Univ Oregon, Dept Special Educ & Clin Sci, Eugene, OR 97403 USA; [Wade, Shari L.] Cincinnati Childrens Hosp Med Ctr, Dept Pediat, 3333 Burnet Ave, Cincinnati, OH 45229 USA	Treble-Barna, A (corresponding author), Cincinnati Childrens Hosp Med Ctr, Phys Med & Rehabil, 3333 Burnet Ave, Cincinnati, OH 45229 USA.	amery.treble-barna@cchmc.org			Department of Education's National Institute on Disability and Rehabilitation Research (Center on Interventions for Children and Youth with Traumatic Brain Injury) [H133B090010-10]; Ohio Department of Public Safety Emergency Medical Services Program	This project was supported in part by grants from the Department of Education's National Institute on Disability and Rehabilitation Research (Center on Interventions for Children and Youth with Traumatic Brain Injury; Grant number H133B090010-10) and the Ohio Department of Public Safety Emergency Medical Services Program. This material does not necessarily represent the policy of these agencies, nor is the material necessarily endorsed by the Federal Government.	Anderson V, 2006, AM J PHYS MED REHAB, V85, P767, DOI 10.1097/01.phm.0000233176.08480.22; Beardmore S, 1999, NEUROPSYCHOL REHABIL, V9, P45, DOI 10.1080/713755588; Beauchamp M, 2011, DEV NEUROPSYCHOL, V36, P578, DOI 10.1080/87565641.2011.555572; Bouwens SFM, 2009, CLIN REHABIL, V23, P310, DOI 10.1177/0269215508101744; Butler RW, 2008, J CONSULT CLIN PSYCH, V76, P367, DOI 10.1037/0022-006X.76.3.367; Byerley AK, 2013, REHABIL PSYCHOL, V58, P412, DOI 10.1037/a0034228; Catroppa C, 2007, J PEDIATR PSYCHOL, V32, P354, DOI 10.1093/jpepsy/jsl019; Chapman SB, 2015, CEREB CORTEX, V25, P396, DOI 10.1093/cercor/bht234; Cicerone KD, 1999, J HEAD TRAUMA REHAB, V14, P316, DOI 10.1097/00001199-199906000-00011; Cicerone KD, 2000, ARCH PHYS MED REHAB, V81, P1596, DOI 10.1053/apmr.2000.19240; Cicerone KD, 2011, ARCH PHYS MED REHAB, V92, P519, DOI 10.1016/j.apmr.2010.11.015; Collins A, 2012, PLOS BIOL, V10, DOI 10.1371/journal.pbio.1001293; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Diamond A, 2013, ANNU REV PSYCHOL, V64, P135, DOI 10.1146/annurev-psych-113011-143750; Evans JJ, 2012, CURR OPIN NEUROL, V25, P651, DOI 10.1097/WCO.0b013e3283598f75; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Feingold A, 2013, REV GEN PSYCHOL, V17, P111, DOI 10.1037/a0030048; Galbiati S, 2009, NEUROPSYCHOLOGY, V23, P40, DOI 10.1037/a0013409; Gioia G.A., 2000, BEHAV RATING INVENTO; Gioia GA, 2004, DEV NEUROPSYCHOL, V25, P135, DOI 10.1207/s15326942dn2501&2_8; Kennedy MRT, 2008, NEUROPSYCHOL REHABIL, V18, P257, DOI 10.1080/09602010701748644; Klingberg T, 2010, TRENDS COGN SCI, V14, P317, DOI 10.1016/j.tics.2010.05.002; Krasny-Pacini A, 2015, DEV NEUROREHABIL, P1; Krasny-Pacini A, 2014, J HEAD TRAUMA REHAB, V29, pE49, DOI 10.1097/HTR.0000000000000015; Laatsch L, 2007, J HEAD TRAUMA REHAB, V22, P248, DOI 10.1097/01.HTR.0000281841.92720.0a; Langer N, 2013, CORTEX, V49, P2424, DOI 10.1016/j.cortex.2013.01.008; Levin H, 2007, J DEV BEHAV PEDIATR, V28, P108, DOI 10.1097/01.DBP.0000267559.26576.cd; Luton LM, 2011, BRAIN INJURY, V25, P409, DOI 10.3109/02699052.2011.558044; Malec JF, 1999, NEUROPSYCHOL REHABIL, V9, P253, DOI 10.1080/096020199389365; Manly T, 2001, J CHILD PSYCHOL PSYC, V42, P1065, DOI 10.1111/1469-7610.00806; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Morrison AB, 2012, J APPL RES MEM COGN, V1, P208, DOI 10.1016/j.jarmac.2012.07.005; Muscara F, 2008, DEV NEUROPSYCHOL, V33, P623, DOI 10.1080/87565640802171162; OTTENBACHER KJ, 1990, AM J OCCUP THER, V44, P519, DOI 10.5014/ajot.44.6.519; Posner MI, 2007, ANNU REV PSYCHOL, V58, P1, DOI 10.1146/annurev.psych.58.110405.085516; Robinson KE, 2014, J PEDIATR PSYCHOL, V39, P846, DOI 10.1093/jpepsy/jsu031; Silver CH, 2000, J HEAD TRAUMA REHAB, V15, P973, DOI 10.1097/00001199-200008000-00002; Sjo NM, 2010, ACTA PAEDIATR, V99, P230, DOI 10.1111/j.1651-2227.2009.01587.x; Slomine B, 2009, DEV DISABIL RES REV, V15, P133, DOI 10.1002/ddrr.56; Sohlberg MM, 2003, BRAIN INJURY, V17, P609, DOI 10.1080/0269905031000070189; Sohlberg MM, 2001, ANN NY ACAD SCI, V931, P359; SOHLBERG MM, 2014, CLIN PRACTICE PEDIAT, V2, P263, DOI DOI 10.1037/CPP0000072; Takeuchi H, 2015, BRAIN STRUCT FUNCT, V220, P3101, DOI 10.1007/s00429-014-0845-2; Tamm L, 2015, ADHD-ATTEND DEFICIT, V7, P183, DOI 10.1007/s12402-014-0162-x; Tamm L, 2014, J ATTEN DISORD, V18, P551, DOI 10.1177/1087054712445782; TEASDALE G, 1974, LANCET, V2, P81; Ten Have TR, 2008, PSYCHIAT ANN, V38, P772, DOI 10.3928/00485713-20081201-10; Trombly CA, 2002, AM J OCCUP THER, V56, P489, DOI 10.5014/ajot.56.5.489; Van't Hooft I, 2005, BRAIN INJURY, V19, P511, DOI 10.1080/02699050400025224; van 't Hooft I, 2007, NEUROREHABILITATION, V22, P109; van't Hooft I, 2010, NEUROREHABILITATION, V26, P105, DOI 10.3233/NRE-2010-0541; Wilson KR, 2011, REHABIL PSYCHOL, V56, P100, DOI 10.1037/a0023446; Wolraich ML, 2003, J PEDIATR PSYCHOL, V28, P559, DOI 10.1093/jpepsy/jsg046; Yeates KO, 2005, J AM ACAD CHILD PSY, V44, P574, DOI 10.1097/01.chi.0000159947.50523.64; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Zou P, 2012, ARCH CLIN NEUROPSYCH, V27, P915, DOI 10.1093/arclin/acs095	56	22	22	0	27	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	NOV-DEC	2016	31	6					407	418		10.1097/HTR.0000000000000200			12	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	EC0IW	WOS:000387784800012	26580695				2021-06-18	
J	Vedantam, A; Yamal, JM; Rubin, ML; Robertson, CS; Gopinath, SP				Vedantam, Aditya; Yamal, Jose-Miguel; Rubin, Maria Laura; Robertson, Claudia S.; Gopinath, Shankar P.			Progressive hemorrhagic injury after severe traumatic brain injury: effect of hemoglobin transfusion thresholds	JOURNAL OF NEUROSURGERY			English	Article						severe traumatic brain injury; progressive hemorrhagic injury; hemoglobin transfusion threshold; secondary brain injury	ACUTE SUBDURAL-HEMATOMA; HEAD TRAUMA; DECOMPRESSIVE CRANIECTOMY; OXYGEN DELIVERY; BLOOD; CRANIOTOMY; AGE	OBJECTIVE There is limited literature available to guide transfusion practices for patients with severe traumatic brain injury (TBI). Recent studies have shown that maintaining a higher hemoglobin threshold after severe TBI offers no clinical benefit. The present study aimed to determine if a higher transfusion threshold was independently associated with an increased risk of progressive hemorrhagic injury (PHI), thereby contributing to higher rates of morbidity and mortality. METHODS The authors performed a secondary analysis of data obtained from a recently performed randomized clinical trial studying the effects of erythropoietin and blood transfusions on neurological recovery after severe TBI. Assigned hemoglobin thresholds (10 g/dl vs 7 g/dl) were maintained with packed red blood cell transfusions during the acute phase after injury. PHI was defined as the presence of new or enlarging intracranial hematomas on CT as long as 10 days after injury. A severe PHI was defined as an event that required an escalation of medical management or surgical intervention. Clinical and imaging parameters and transfusion thresholds were used in a multivariate Cox regression analysis to identify independent risk factors for PHI. RESULTS Among 200 patients enrolled in the trial, PHI was detected in 61 patients (30.5%). The majority of patients with PHI had a new, delayed contusion (n = 29) or an increase in contusion size (n = 15). The mean time interval between injury and identification of PHI was 17.2 +/- 15.8 hours. The adjusted risk of severe PHI was 2.3 times higher for patients with a transfusion threshold of 10 g/dl (95% confidence interval 1.1-4.7; p = 0.02). Diffuse brain injury was associated with a lower risk of PHI events, whereas higher initial intracranial pressure increased the risk of PHI (p < 0.001). PHI was associated with a longer median length of stay in the intensive care unit (18.3 vs 14.4 days, respectively; p = 0.04) and poorer Glasgow Outcome Scale scores (42.9% vs 25.5%, respectively; p = 0.02) at 6 months. CONCLUSIONS A higher transfusion threshold of 10 g/dl after severe TBI increased the risk of severe PHI events. These results indicate the potential adverse effect of using a higher hemoglobin transfusion threshold after severe TBI.	[Vedantam, Aditya; Robertson, Claudia S.; Gopinath, Shankar P.] Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA; [Yamal, Jose-Miguel; Rubin, Maria Laura] Univ Texas Houston, Sch Publ Hlth, Dept Biostat, Houston, TX USA	Gopinath, SP (corresponding author), Baylor Coll Med, Dept Neurosurg, 7200 Cambridge,Ste 9A,MS BCM650, Houston, TX 77030 USA.	shankarg@bcm.tmc.edu			National Institute of Neurological Disorders and Stroke, NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01-NS38660]; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [T32GM074902] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study was supported by grant no. P01-NS38660 (National Institute of Neurological Disorders and Stroke, NIH).	Alahmadi H, 2010, J NEUROSURG, V112, P1139, DOI 10.3171/2009.5.JNS081369; Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Boutin A, 2014, SYST REV-LONDON, V3, DOI 10.1186/2046-4053-3-66; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c; GOPINATH SP, 1995, J NEUROSURG, V83, P438, DOI 10.3171/jns.1995.83.3.0438; Hlatky R, 2004, NEUROCRIT CARE, V1, P69, DOI 10.1385/NCC:1:1:69; Hosmer J., 2013, APPL LOGISTIC REGRES, V3; Kurland D, 2012, J NEUROTRAUM, V29, P19, DOI 10.1089/neu.2011.2122; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; MARIK PE, 1993, JAMA-J AM MED ASSOC, V269, P3024, DOI 10.1001/jama.269.23.3024; Morisaki H, 2004, CRIT CARE CLIN, V20, P213, DOI 10.1016/j.ccc.2003.12.003; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Leal-Noval SR, 2008, CRIT CARE MED, V36, P1290, DOI 10.1097/CCM.0b013e3181692dfc; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robertson CS, 2001, ANESTHESIOLOGY, V95, P1513, DOI 10.1097/00000542-200112000-00034; SCHRODER ML, 1995, J NEUROSURG, V82, P966, DOI 10.3171/jns.1995.82.6.0966; Servadei F, 2000, NEUROSURGERY, V46, P70; STEIN SC, 1993, NEUROSURGERY, V32, P25, DOI 10.1227/00006123-199301000-00004; Utter GH, 2011, J NEUROTRAUM, V28, P155, DOI 10.1089/neu.2010.1451; Wang MC, 2006, J TRAUMA, V61, P226, DOI 10.1097/01.ta.0000197385.18452.89; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019; Yamal JM, 2015, J NEUROTRAUM, V32, P1239, DOI 10.1089/neu.2014.3752; Zallen G, 1999, AM J SURG, V178, P570, DOI 10.1016/S0002-9610(99)00239-1	25	22	26	0	3	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	0022-3085	1933-0693		J NEUROSURG	J. Neurosurg.	NOV	2016	125	5					1229	1234		10.3171/2015.11.JNS151515			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DZ8FK	WOS:000386106100023	26943843	Green Accepted			2021-06-18	
J	Zhao, WD; Stutzman, S; Olson, D; Saju, C; Wilson, M; Aiyagari, V				Zhao, Weidan; Stutzman, Sonja; Olson, DaiWai; Saju, Ciji; Wilson, Margaret; Aiyagari, Venkatesh			Inter-device reliability of the NPi-100 pupillometer	JOURNAL OF CLINICAL NEUROSCIENCE			English	Article						Interrater reliability; Neurological illness; Pupil assessment; Pupillometery; Traumatic brain injury	INFRARED PUPILLOMETRY; AGREEMENT	The purpose of this study was to explore the inter-device reliability of NPi-100 pupillometers (NeuroOptics, Inc.). The pupillary examination is a fundamental element of the neurological exam. Current evidence suggests that the traditional examination of the pupil with a hand held flashlight has limited inter-rater reliability. Automated pupillometers were developed to provide an objective scoring of pupil size and reactivity. However, there are no data examining inter-device reliability of automated pupil assessments. This study included 210 paired pupillometer measurements were obtained by 33 practitioners from 20 patients at risk for cerebral edema. There was no statistically significant difference between the mean maximum pupil size at rest, the minimum pupil size during light stimulation, and the mean pupil reactivity, for both the right and left eye, when assessed by two investigators, each with a different pupillometer. In addition, Cohen's Kappa assessments of pupil size and reactivity revealed an almost perfect agreement between the two pupillometers for the maximum pupil size, the minimum pupil size, and for pupil reactivity for both eyes. There is a high inter-device reliability of automated pupillary assessments by two practitioners examining the same patient using different NPi-100 pupillometers. (C) 2016 Elsevier Ltd. All rights reserved.	[Zhao, Weidan; Aiyagari, Venkatesh] UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX 75390 USA; [Stutzman, Sonja; Olson, DaiWai; Saju, Ciji; Wilson, Margaret; Aiyagari, Venkatesh] UT Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75093 USA	Aiyagari, V (corresponding author), UT Southwestern Med Ctr, Dept Neurol Surg, Dallas, TX 75390 USA.; Aiyagari, V (corresponding author), UT Southwestern Med Ctr, Dept Neurol & Neurotherapeut, 5323 Harry Hines Blvd, Dallas, TX 75093 USA.	venkatesh.aiyagari@utsouthwestern.edu	Olson, DaiWai/I-5932-2019	Olson, DaiWai/0000-0002-9280-078X; Aiyagari, Venkatesh/0000-0001-8139-3819			Behrends M, 2012, RESUSCITATION, V83, P1223, DOI 10.1016/j.resuscitation.2012.05.013; Campbell W. W., 2005, DEJONGS NEUROLOGICAL; Chen Jeff W, 2011, Surg Neurol Int, V2, P82, DOI 10.4103/2152-7806.82248; Clark A, 2006, EMERG MED J, V23, P440, DOI 10.1136/emj.2005.030247; Du R, 2005, NEUROSURGERY, V57, P198, DOI 10.1227/01.NEU.0000163425.79170.CB; GOEBERT HW, 1970, SURG CLIN N AM, V50, P427; Hurts KN, 2006, J NEUROSCI NURS, V38, P447; LANDIS JR, 1977, BIOMETRICS, V33, P159, DOI 10.2307/2529310; Litvan I, 2000, NEUROLOGY, V54, P530, DOI 10.1212/WNL.54.2.530; Loewenfeld I.E., 1993, PUPIL ANATOMY PHYSL; Manley GT, 2002, J NEUROSURG ANESTH, V14, P223, DOI 10.1097/00008506-200207000-00009; Meeker R, 2005, J NEUROSCI NURS, V37, P34; Sahar F, 2014, J CRIT CARE, V29, P599; Taylor WR, 2003, J NEUROSURG, V98, P205, DOI 10.3171/jns.2003.98.1.0205; Viera AJ, 2005, FAM MED, V37, P360; Wilson S F, 1988, J Neurosci Nurs, V20, P189; Worthley LI, 2000, CRIT CARE RESUSC, V2, P34	17	22	23	0	2	ELSEVIER SCI LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND	0967-5868	1532-2653		J CLIN NEUROSCI	J. Clin. Neurosci.	NOV	2016	33						79	82		10.1016/j.jocn.2016.01.039			4	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DZ9JW	WOS:000386192200012	27422586				2021-06-18	
J	Dunning, DL; Westgate, B; Adlam, ALR				Dunning, Darren L.; Westgate, Briony; Adlam, Anna-Lynne R.			A Meta-Analysis of Working Memory Impairments in Survivors of Moderate-to-Severe Traumatic Brain Injury	NEUROPSYCHOLOGY			English	Article						TBI; traumatic brain injury; working memory; cognition	HEAD-INJURY; EXECUTIVE FUNCTION; SUSTAINED-ATTENTION; DIVIDED ATTENTION; TASK-PERFORMANCE; SEVERE TBI; SHORT-TERM; CHILDREN; DEFICITS; OUTCOMES	Objectives: To establish the magnitude of deficits in working memory (WM) and short-term memory (STM) in those with moderate-to-severe traumatic brain injury (TBI) relative to age-matched, healthy controls and to explore the moderating effects of time since injury and age at injury on these impairments. Method: Twenty-one studies that compared the WM and/or STM abilities of individuals with at least a moderate TBI relative to healthy controls were included in a random effects meta-analysis. Measures used to examine memory performance were categorized by modality (visuospatial, verbal) and memory system (WM, STM). Results: Individuals with TBI had significant deficits in verbal STM (Cohen's d =.41), visuospatial WM (Cohen's d =.69), and verbal WM (Cohen's d =.37) relative to controls. Greater decrements in verbal STM and verbal WM skills were associated with longer time postinjury. Larger deficits were observed in verbal WM abilities in individuals with older age at injury. Conclusion: Evidence for WM impairments following TBI is consistent with previous research. Larger verbal STM and verbal WM deficits were related to a longer time postinjury, suggesting that these aspects of memory do not "recover" over time and instead, individuals might show increased rates of cognitive decline. Age at injury was associated with the severity of verbal WM impairments, with larger deficits evident for injuries that occurred later in life. Further research needs to chart the long-term effects of TBI on WM and to compare the effects of injury on verbal relative to visuospatial memory.	[Dunning, Darren L.; Westgate, Briony; Adlam, Anna-Lynne R.] Univ East Anglia, Sch Med, Norwich, Norfolk, England; [Adlam, Anna-Lynne R.] Univ Exeter, Ctr Clin Neuropsychol Res, Exeter EX4 4QJ, Devon, England	Dunning, DL (corresponding author), Cognit & Brain Sci Unit, Chaucer Rd, Cambridge CB2 7EF, England.	darren.dunning@mrc-cbu.cam.ac.uk		Adlam, Anna/0000-0001-7212-4051	Henry Smith Charity; Action Medical Research; Action Medical Research [1833] Funding Source: researchfish	This project was supported by generous grants from the Henry Smith Charity and Action Medical Research.	Alloway TP, 2006, CHILD DEV, V77, P1698, DOI 10.1111/j.1467-8624.2006.00968.x; Anderson V, 2005, BRAIN INJURY, V19, P459, DOI 10.1080/02699050400004823; Anderson V, 1995, CHILD NEUROPSYCHOL, V1, P187, DOI 10.1080/09297049508400224; Anderson VA, 2000, BRAIN INJURY, V14, P679; Anderson V, 2007, BRAIN INJURY, V21, P1399, DOI 10.1080/02699050701785070; Anderson V, 2011, NEUROPSYCHOLOGY, V25, P176, DOI 10.1037/a0021217; Anderson V, 2009, BRAIN, V132, P45, DOI 10.1093/brain/awn293; Asloun S, 2008, J CLIN EXP NEUROPSYC, V30, P481, DOI 10.1080/13803390701550144; Azouvi P, 2004, NEUROPSYCHOLOGIA, V42, P1260, DOI 10.1016/j.neuropsychologia.2004.01.001; Baddeley A, 2000, TRENDS COGN SCI, V4, P417, DOI 10.1016/S1364-6613(00)01538-2; Baddeley A., 1974, PSYCHOL LEARN MOTIV, P47, DOI [10.1016/s0079-7421(08)60452-1, DOI 10.1016/S0079-7421(08)60452-1]; Baddeley AD, 2011, NEUROPSYCHOLOGIA, V49, P1393, DOI 10.1016/j.neuropsychologia.2010.12.042; Borenstein M., 2005, COMPREHENSIVE METAAN; Brookshire BL, 2000, J INT NEUROPSYCH SOC, V6, P741, DOI 10.1017/S1355617700677019; BROWN J, 1958, Q J EXP PSYCHOL, V10, P12, DOI 10.1080/17470215808416249; Burgess GC, 2011, J EXP PSYCHOL GEN, V140, P674, DOI 10.1037/a0024695; Carlozzi NE, 2013, J CLIN EXP NEUROPSYC, V35, P906, DOI 10.1080/13803395.2013.833178; Carroll LJ, 2004, J REHABIL MED, V36, P84, DOI 10.1080/16501960410023859; Chapman S.B., 2006, BRAIN INJ PROF, V3, P10; Chapman SB, 2006, BRAIN LANG, V97, P178, DOI 10.1016/j.bandl.2005.10.002; Christodoulou C, 2001, J NEUROL NEUROSUR PS, V71, P161, DOI 10.1136/jnnp.71.2.161; Cohen J., 1988, STAT POWER ANAL BEHA, V2nd; Conklin HM, 2008, BRAIN INJURY, V22, P847, DOI 10.1080/02699050802403565; Curtis CE, 2003, TRENDS COGN SCI, V7, P415, DOI 10.1016/S1364-6613(03)00197-9; Curtis CE, 2006, HDB FUNCTIONAL NEURO, P269; DESPOSITO M, 1995, NATURE, V378, P279, DOI 10.1038/378279a0; Duncan J, 2000, TRENDS NEUROSCI, V23, P475, DOI 10.1016/S0166-2236(00)01633-7; Farmer JE, 1999, DEV NEUROPSYCHOL, V15, P269, DOI 10.1080/87565649909540749; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fontaine A, 1999, NEUROLOGY, V53, P1963, DOI 10.1212/WNL.53.9.1963; Gale SD, 2005, J NEUROL NEUROSUR PS, V76, P984, DOI 10.1136/jnnp.2004.036210; Gamino JF, 2009, TOP LANG DISORD, V29, P224, DOI 10.1097/TLD.0b013e3181b531da; Gathercole S. E., 2014, PERSPECTIVES LANGUAG, V40, P36; Godbolt Alison K, 2014, Arch Phys Med Rehabil, V95, pS245, DOI 10.1016/j.apmr.2013.06.036; GoldmanRakic PS, 1996, PHILOS T ROY SOC B, V351, P1445, DOI 10.1098/rstb.1996.0129; Gorman S, 2012, J INT NEUROPSYCH SOC, V18, P29, DOI 10.1017/S1355617711001251; Hanten G, 2003, BRAIN INJURY, V17, P871, DOI 10.1080/02699050210147220; Health and Social Care Information Centre, 2010, HES TRAUM BRAIN INJ; Hellgren L., 2015, OPEN J THERAPY REHAB, V3, P46, DOI DOI 10.4236/OJTR.2015.32007; Hibbard MR, 1998, J HEAD TRAUMA REHAB, V13, P24, DOI 10.1097/00001199-199808000-00003; Huttenlocher PR, 1997, J COMP NEUROL, V387, P167, DOI 10.1002/(SICI)1096-9861(19971020)387:2<167::AID-CNE1>3.0.CO;2-Z; Jellinger KA, 2004, CURR OPIN NEUROL, V17, P719, DOI 10.1097/00019052-200412000-00012; Jorge RE, 2004, ARCH GEN PSYCHIAT, V61, P42, DOI 10.1001/archpsyc.61.1.42; Kim J, 2012, NEUROREHAB NEURAL RE, V26, P870, DOI 10.1177/1545968311434553; Kolb B., 2013, BRAIN PLASTICITY BEH; Kraus J. F., 2005, TXB TRAUMATIC BRAIN, P3; Kurowski BG, 2013, ARCH PHYS MED REHAB, V94, P543, DOI 10.1016/j.apmr.2012.10.029; Leclercq M, 2000, J CLIN EXP NEUROPSYC, V22, P339, DOI 10.1076/1380-3395(200006)22:3;1-V;FT339; Lehto JH, 1996, Q J EXP PSYCHOL-A, V49, P29, DOI 10.1080/027249896392793; Levin HS, 2005, PEDIATR NEUROL, V33, P79, DOI 10.1016/j.pediatrneurol.2005.02.002; Levin HS, 2004, NEUROPSYCHOLOGY, V18, P240, DOI 10.1037/0894-4105.18.2.240; Levin HS, 2002, ANN NEUROL, V52, P82, DOI 10.1002/ana.10252; Lezak M, 1995, NEUROPSYCHOLOGICAL T; Lundqvist A, 2010, BRAIN INJURY, V24, P1173, DOI 10.3109/02699052.2010.498007; Mandalis A, 2007, DEV NEUROPSYCHOL, V32, P683, DOI 10.1080/87565640701376045; Mazzola CA, 2002, CRIT CARE MED, V30, pS393, DOI 10.1097/00003246-200211001-00003; McCauley SR, 2012, J NEUROTRAUM, V29, P678, DOI 10.1089/neu.2011.1838; McDonald S., 2015, APHASIOLOGY, V29, P1; McDowell S, 1997, NEUROPSYCHOLOGIA, V35, P1341, DOI 10.1016/S0028-3932(97)00082-1; McHugh SB, 2008, BEHAV BRAIN RES, V186, P41, DOI 10.1016/j.bbr.2007.07.021; McVay JC, 2012, J EXP PSYCHOL GEN, V141, P302, DOI 10.1037/a0025250; Merzagora ACR, 2014, BRAIN IMAGING BEHAV, V8, P446, DOI 10.1007/s11682-013-9258-8; Moran C, 2004, BRAIN INJURY, V18, P273, DOI 10.1080/02699050310001617415; Nadebaum C, 2007, DEV NEUROPSYCHOL, V32, P703, DOI 10.1080/87565640701376086; Newsome MR, 2007, CORTEX, V43, P95, DOI 10.1016/S0010-9452(08)70448-9; Nobre Alexandre de Pontes, 2013, Psychol. Neurosci., V6, P331, DOI 10.3922/j.psns.2013.3.10; Oni MB, 2010, J CHILD NEUROL, V25, P976, DOI 10.1177/0883073809356034; Perbal S, 2003, NEUROPSYCHOLOGIA, V41, P1599, DOI 10.1016/S0028-3932(03)00110-6; Perlstein WM, 2006, NEUROPSYCHOLOGIA, V44, P260, DOI 10.1016/j.neuropsychologia.2005.05.009; Perlstein WM, 2004, J INT NEUROPSYCH SOC, V10, P724, DOI 10.1017/S1355617704105110; Phillips N. L., 2015, CHILD NEUROPSYCHOLOG; Raghubar KP, 2013, J INT NEUROPSYCH SOC, V19, P254, DOI 10.1017/S1355617712001312; Roncadin C, 2004, DEV NEUROPSYCHOL, V25, P21; Rosenberg MS, 2005, EVOLUTION, V59, P464, DOI 10.1554/04-602; ROSENTHAL R, 1995, PSYCHOL BULL, V118, P183, DOI 10.1037/0033-2909.118.2.183; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan NP, 2014, J NEUROTRAUM, V31, P649, DOI 10.1089/neu.2013.3153; Salmond CH, 2005, BRAIN, V128, P189, DOI 10.1093/brain/awh352; SALTHOUSE TA, 1991, DEV PSYCHOL, V27, P763, DOI 10.1037/0012-1649.27.5.763; Sanchez-Carrion R, 2008, NEUROIMAGE, V43, P421, DOI 10.1016/j.neuroimage.2008.08.003; Savage RC, 2005, PREV SCH FAIL, V49, P43, DOI 10.3200/PSFL.49.4.43-52; Schwartz L, 2003, J PEDIATR PSYCHOL, V28, P251, DOI 10.1093/jpepsy/jsg013; Slovarp L, 2012, BRAIN INJURY, V26, P48, DOI 10.3109/02699052.2011.635355; Sowell ER, 1999, NAT NEUROSCI, V2, P859, DOI 10.1038/13154; Taylor H G, 1997, J Int Neuropsychol Soc, V3, P555; Taylor HG, 2002, NEUROPSYCHOLOGY, V16, P15, DOI 10.1037//0894-4105.16.1.15; Teichner G, 2000, AGGRESS VIOLENT BEH, V5, P509, DOI 10.1016/S1359-1789(98)00035-4; Valentine JC, 2010, J EDUC BEHAV STAT, V35, P215, DOI 10.3102/1076998609346961; Vallat-Azouvi C, 2007, J INT NEUROPSYCH SOC, V13, P770, DOI 10.1017/S1355617707070993; Vallat-Azouvi C, 2012, NEUROPSYCHOL REHABIL, V22, P634, DOI 10.1080/09602011.2012.681110; Van Den Heuvel C, 2007, PROG BRAIN RES, V161, P303, DOI 10.1016/S0079-6123(06)61021-2; Wallesch CW, 2001, BRAIN INJURY, V15, P401, DOI 10.1080/02699050010005959; WHO, 2008, WORLD HLTH STAT 2008; Wilhelm O, 2013, FRONT PSYCHOL, V4, DOI 10.3389/fpsyg.2013.00433; Willmott C, 2009, NEUROPSYCHOLOGY, V23, P424, DOI 10.1037/a0015058	95	22	22	1	13	AMER PSYCHOLOGICAL ASSOC	WASHINGTON	750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA	0894-4105	1931-1559		NEUROPSYCHOLOGY	Neuropsychology	OCT	2016	30	7					811	819		10.1037/neu0000285			9	Psychology, Clinical; Neurosciences; Psychology	Psychology; Neurosciences & Neurology	DY9FX	WOS:000385440400004	27182710	Green Accepted			2021-06-18	
J	Mutch, CA; Talbott, JF; Gean, A				Mutch, Christopher A.; Talbott, Jason F.; Gean, Alisa			Imaging Evaluation of Acute Traumatic Brain Injury	NEUROSURGERY CLINICS OF NORTH AMERICA			English	Article						Traumatic brain injury; TBI; Imaging; MRI; CT	DIFFUSE AXONAL INJURY; CEREBRAL FAT-EMBOLISM; CRANIAL COMPUTED-TOMOGRAPHY; COMMON DATA ELEMENTS; CLOSED-HEAD INJURY; MAGNETIC-RESONANCE; SUBARACHNOID HEMORRHAGE; CORPUS-CALLOSUM; PROGNOSTIC VALUE; BASAL GANGLIA	Traumatic brain injury (TBI) is a major cause of morbidity and mortality worldwide. Imaging plays an important role in the evaluation, diagnosis, and triage of patients with TBI. Recent studies suggest that it also helps predict patient outcomes. TBI consists of multiple pathoanatomic entities. This article reviews the current state of TBI imaging including its indications, benefits and limitations of the modalities, imaging protocols, and imaging findings for each of these pathoanatomic entities. Also briefly surveyed are advanced imaging techniques, which include several promising areas of TBI research.	[Mutch, Christopher A.] Univ Calif San Francisco, Dept Radiol, 505 Parnassus Ave,M391, San Francisco, CA 94143 USA; [Talbott, Jason F.; Gean, Alisa] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave, San Francisco, CA 94110 USA	Talbott, JF (corresponding author), Univ Calif San Francisco, San Francisco Gen Hosp, Dept Radiol, 1001 Potrero Ave, San Francisco, CA 94110 USA.	jason.talbott@ucsf.edu			NCI NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01 CA094143] Funding Source: Medline; NINDS NIH HHSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30 NS051864] Funding Source: Medline; NATIONAL CANCER INSTITUTEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Cancer Institute (NCI) [R01CA094143] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [F30NS051864] Funding Source: NIH RePORTER		Abu-Judeh HH, 1998, J NUCL MED, V39, P1357; ADAMS JH, 1977, BRAIN, V100, P489, DOI 10.1093/brain/100.3.489; ADAMS JH, 1982, ANN NEUROL, V12, P557, DOI 10.1002/ana.410120610; ADAMS JH, 1980, J CLIN PATHOL, V33, P1132, DOI 10.1136/jcp.33.12.1132; Al-Nakshabandi NA, 2001, RADIOLOGY, V218, P433, DOI 10.1148/radiology.218.2.r01fe09433; Arbelaez A, 1999, AM J NEURORADIOL, V20, P999; Arfanakis K, 2002, AM J NEURORADIOL, V23, P794; Ashwal S, 2004, PEDIATR RES, V56, P630, DOI 10.1203/01.PDR.0000139928.60530.7D; Babikian T, 2006, J MAGN RESON IMAGING, V24, P801, DOI 10.1002/jmri.20696; BALL WS, 1989, RADIOLOGY, V173, P609, DOI 10.1148/radiology.173.3.2813759; BARR HWK, 1971, BRAIN, V94, P607, DOI 10.1093/brain/94.4.607; BAYKANER K, 1988, SURG NEUROL, V30, P339, DOI 10.1016/0090-3019(88)90195-4; Bigler ED, 2012, BRAIN IMAGING BEHAV, V6, P108, DOI 10.1007/s11682-011-9145-0; Bodanapally UK, 2013, NEURORADIOLOGY, V55, P771, DOI 10.1007/s00234-013-1166-5; BRADLEY WG, 1985, RADIOLOGY, V156, P99, DOI 10.1148/radiology.156.1.4001427; Brandstack N, 2013, RADIOLOGY, V267, P231, DOI 10.1148/radiol.12112570; Brenner T, 2003, PEDIATR NEUROL, V28, P104, DOI 10.1016/S0887-8994(02)00491-5; BRICOLO AP, 1984, NEUROSURGERY, V14, P8, DOI 10.1227/00006123-198401000-00003; BRITT RH, 1980, NEUROSURGERY, V6, P623, DOI 10.1227/00006123-198006000-00002; Bromberg WJ, 2010, J TRAUMA, V68, P471, DOI 10.1097/TA.0b013e3181cb43da; Brooks WM, 2000, J NEUROTRAUM, V17, P629, DOI 10.1089/089771500415382; BRUCE DA, 1989, PEDIATR ANN, V18, P482, DOI 10.3928/0090-4481-19890801-07; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; CAPLAN LR, 1977, ANN NEUROL, V1, P587, DOI 10.1002/ana.410010613; Cecil KM, 1998, J NEUROSURG, V88, P795, DOI 10.3171/jns.1998.88.5.0795; CHAKERES DW, 1986, AM J NEURORADIOL, V7, P223; Chen PC, 2013, AM J EMERG MED, V31, DOI 10.1016/j.ajem.2013.05.003; CITERIO G, 1995, INTENS CARE MED, V21, P679, DOI 10.1007/BF01711549; Cohen AR, 2015, AM J EMERG MED, V33, P887, DOI 10.1016/j.ajem.2015.03.052; COHEN RA, 1986, AM J ROENTGENOL, V146, P97, DOI 10.2214/ajr.146.1.97; COLQUHOUN IR, 1989, CLIN RADIOL, V40, P619, DOI 10.1016/S0009-9260(89)80324-1; COOPER PR, 1979, NEUROSURGERY, V4, P115, DOI 10.1227/00006123-197902000-00002; Cooper PR, 1987, HEAD INJURY; Cornelius C, 2013, ANTIOXID REDOX SIGN, V19, P836, DOI 10.1089/ars.2012.4981; Coskun O, 2000, AM J NEURORADIOL, V21, P712; Davalos Deana B, 2002, Appl Neuropsychol, V9, P92, DOI 10.1207/S15324826AN0902_4; DAVIS JM, 1983, NEURORADIOLOGY, V25, P55, DOI 10.1007/BF00333294; Dunning J, 2006, ARCH DIS CHILD, V91, P885, DOI 10.1136/adc.2005.083980; Edwards J D, 1993, Ann Vasc Surg, V7, P368, DOI 10.1007/BF02002892; Faul M.D., 2010, TRAUMATIC BRAIN INJU; FELDMAN RA, 1980, NEUROSURGERY, V6, P670, DOI 10.1227/00006123-198006000-00013; FRIEDE RL, 1966, NEUROLOGY, V16, P1210, DOI 10.1212/WNL.16.12.1210; Garnett MR, 2001, J NEUROTRAUM, V18, P585, DOI 10.1089/089771501750291828; Garnett MR, 2001, J NEUROTRAUM, V18, P231, DOI 10.1089/08977150151070838; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Gean AD, 2010, RADIOLOGY, V257, P212, DOI 10.1148/radiol.10092075; GENNARELLI TA, 1982, J NEUROSURG, V56, P26, DOI 10.3171/jns.1982.56.1.0026; GENNARELLI TA, 1982, ANN NEUROL, V12, P564, DOI 10.1002/ana.410120611; GENTRY LR, 1989, RADIOLOGY, V171, P177, DOI 10.1148/radiology.171.1.2928523; GENTRY LR, 1988, AM J ROENTGENOL, V150, P673, DOI 10.2214/ajr.150.3.673; GENTRY LR, 1988, AM J NEURORADIOL, V9, P1129; GENTRY LR, 1989, RADIOL CLIN N AM, V27, P435; GENTRY LR, 1988, AM J ROENTGENOL, V150, P663, DOI 10.2214/ajr.150.3.663; GENTRY LR, 1994, RADIOLOGY, V191, P1; George EO, 2014, J NEUROTRAUM, V31, P1018, DOI 10.1089/neu.2013.3224; Given CA, 2003, AM J NEURORADIOL, V24, P254; GLAUBITT D, 1983, AM J NEURORADIOL, V4, P560; GOLDBERG HI, 1986, RADIOLOGY, V158, P157, DOI 10.1148/radiology.158.1.3940374; GOMORI JM, 1985, RADIOLOGY, V157, P87, DOI 10.1148/radiology.157.1.4034983; Grossman EJ, 2013, AM J NEURORADIOL, V34, P951, DOI 10.3174/ajnr.A3358; Haacke EM, 2009, AM J NEURORADIOL, V30, P19, DOI 10.3174/ajnr.A1400; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P516, DOI 10.1002/jmri.22259; HAN BK, 1990, AM J ROENTGENOL, V154, P361, DOI 10.2214/ajr.154.2.2105031; Hawryluk Gregory W J, 2015, Handb Clin Neurol, V127, P15, DOI 10.1016/B978-0-444-52892-6.00002-7; Haydel MJ, 2000, NEW ENGL J MED, V343, P100, DOI 10.1056/NEJM200007133430204; Henry LC, 2011, BMC NEUROL, V11, DOI 10.1186/1471-2377-11-105; Henry LC, 2011, J NEUROTRAUM, V28, P2049, DOI 10.1089/neu.2011.1836; Hicks R, 2013, J NEUROTRAUM, V30, P1852, DOI 10.1089/neu.2013.2938; Hilario A, 2012, AM J NEURORADIOL, V33, P1925, DOI 10.3174/ajnr.A3092; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Holbourn AHS, 1943, LANCET, V2, P438; HOLBOURN AHS, 1945, BRIT MED BULL, V3, P147, DOI 10.1093/oxfordjournals.bmb.a071895; Hong YT, 2014, JAMA NEUROL, V71, P23, DOI 10.1001/jamaneurol.2013.4847; Huisman TAGM, 2003, EUR RADIOL, V13, P2283, DOI 10.1007/s00330-003-1843-6; Hulkower MB, 2013, AM J NEURORADIOL, V34, P2064, DOI 10.3174/ajnr.A3395; JACOBS A, 1994, J NUCL MED, V35, P942; JACOBSON DM, 1986, NEUROLOGY, V36, P847, DOI 10.1212/WNL.36.6.847; JAYAKUMAR PN, 1989, ACTA NEUROCHIR, V97, P114, DOI 10.1007/BF01772820; JELLINGER K, 1970, J NEUROL SCI, V10, P51, DOI 10.1016/0022-510X(70)90091-2; JENNETT B, 1976, LANCET, V1, P1031; Johnson PL, 2002, NEUROIMAG CLIN N AM, V12, P217, DOI 10.1016/S1052-5149(02)00008-4; Kaen A, 2010, J TRAUMA, V68, P895, DOI 10.1097/TA.0b013e3181b28a76; KATZ DI, 1989, NEUROLOGY, V39, P897, DOI 10.1212/WNL.39.7.897; Kim JJ, 2011, NEUROTHERAPEUTICS, V8, P39, DOI 10.1007/s13311-010-0003-3; Kinoshita T, 2005, EUR J RADIOL, V56, P5, DOI 10.1016/j.ejrad.2005.04.001; KNUCKEY NW, 1989, J NEUROSURG, V70, P392, DOI 10.3171/jns.1989.70.3.0392; Komiyama M, 1989, Neurol Med Chir (Tokyo), V29, P573, DOI 10.2176/nmc.29.573; Kumar R, 2009, BRAIN INJURY, V23, P675, DOI 10.1080/02699050903014915; LANG DA, 1991, ACTA NEUROCHIR, V109, P5, DOI 10.1007/BF01405689; Le TT, 2012, AM J NEURORADIOL, V33, P61, DOI 10.3174/ajnr.A2761; Le TH, 2009, MT SINAI J MED, V76, P145, DOI 10.1002/msj.20102; Lin AP, 2012, BRAIN IMAGING BEHAV, V6, P208, DOI 10.1007/s11682-012-9181-4; Lipton ML, 2009, RADIOLOGY, V252, P816, DOI 10.1148/radiol.2523081584; Liu AY, 1999, AM J NEURORADIOL, V20, P1636; Lloyd KM, 2008, RADIOLOGY, V248, P725, DOI 10.1148/radiol.2483070362; LOBATO RD, 1983, J NEUROSURG, V59, P762, DOI 10.3171/jns.1983.59.5.0762; LOBATO RD, 1988, J NEUROSURG, V68, P48, DOI 10.3171/jns.1988.68.1.0048; Maeda M, 2003, EUR RADIOL, V13, pL192, DOI 10.1007/s00330-003-1877-9; Mata-Mbemba D, 2015, J NEUROTRAUM, V32, P359, DOI 10.1089/neu.2014.3453; Maura E, ACR APPROPRIATENESS; Menditto VG, 2012, ANN EMERG MED, V59, P451, DOI 10.1016/j.annemergmed.2011.12.003; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Meythaler JM, 2001, ARCH PHYS MED REHAB, V82, P1461, DOI 10.1053/apmr.2001.25137; Miles L, 2008, BRAIN INJURY, V22, P115, DOI 10.1080/02699050801888816; MILO R, 1987, ACTA NEUROCHIR, V84, P13, DOI 10.1007/BF01456345; Mitchell P, 2001, J NEUROL NEUROSUR PS, V70, P205, DOI 10.1136/jnnp.70.2.205; MITTL RL, 1994, AM J NEURORADIOL, V15, P1583; Moen KG, 2014, J NEUROTRAUM, V31, P1486, DOI 10.1089/neu.2013.3258; MOKRI B, 1982, MAYO CLIN PROC, V57, P310; MOSELEY ME, 1990, RADIOLOGY, V176, P439, DOI 10.1148/radiology.176.2.2367658; Mower WR, 2005, J TRAUMA, V59, P954, DOI 10.1097/01.ta.0000187813.79047.42; Murray GD, 1999, ACTA NEUROCHIR, V141, P223, DOI 10.1007/s007010050292; Newcombe VFJ, 2007, BRIT J NEUROSURG, V21, P340, DOI 10.1080/02688690701400882; Niogi SN, 2010, J HEAD TRAUMA REHAB, V25, P241, DOI 10.1097/HTR.0b013e3181e52c2a; ORRISON WW, 1994, AM J NEURORADIOL, V15, P351; Park SY, 2010, J KOREAN NEUROSURG S, V48, P399, DOI 10.3340/jkns.2010.48.5.399; Perez AM, 2014, J NEUROTRAUM, V31, P1478, DOI 10.1089/neu.2013.3216; Pilz P, 1983, Acta Neurochir Suppl (Wien), V32, P75; POZZATI E, 1989, SURG NEUROL, V32, P300, DOI 10.1016/0090-3019(89)90234-6; Prabhu SP, 2013, PEDIATR RADIOL, V43, P575, DOI 10.1007/s00247-012-2546-4; Readnower RD, 2010, J NEUROSCI RES, V88, P3530, DOI 10.1002/jnr.22510; Reljic T, 2014, J NEUROTRAUM, V31, P78, DOI 10.1089/neu.2013.2873; Ro YS, 2011, ACAD EMERG MED, V18, P597, DOI 10.1111/j.1553-2712.2011.01094.x; Rodallec MH, 2008, RADIOGRAPHICS, V28, P1711, DOI 10.1148/rg.286085512; ROSENBLUM WI, 1981, NEUROSURGERY, V9, P613, DOI 10.1227/00006123-198112000-00001; Ross BD, 1998, NEUROIMAG CLIN N AM, V8, P809; Rostami E, 2014, FRONT NEUROL, V5, DOI 10.3389/fneur.2014.00114; ROTHFUS WE, 1987, AM J NEURORADIOL, V8, P1073; SAEKI N, 1985, Neurologia Medico-Chirurgica, V25, P939, DOI 10.2176/nmc.25.939; SATO Y, 1989, RADIOLOGY, V173, P653, DOI 10.1148/radiology.173.3.2813768; Schafer PW, 2004, RADIOLOGY, V233, P58, DOI 10.1148/radiol.2323031173; SEELIG JM, 1981, NEW ENGL J MED, V304, P1511, DOI 10.1056/NEJM198106183042503; SERVADEI F, 1989, ACTA NEUROCHIR, V96, P39, DOI 10.1007/BF01403493; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Shenton ME, 2012, BRAIN IMAGING BEHAV, V6, P137, DOI 10.1007/s11682-012-9156-5; Shutter L, 2004, J NEUROTRAUM, V21, P1693, DOI 10.1089/neu.2004.21.1693; Signoretti S, 2002, ACT NEUR S, V81, P373; SKLAR EML, 1992, RADIOL CLIN N AM, V30, P353; Small GW, 2013, AM J GERIAT PSYCHIAT, V21, P138, DOI 10.1016/j.jagp.2012.11.019; Stiell IG, 2001, LANCET, V357, P1391, DOI 10.1016/S0140-6736(00)04561-X; Stoeger A, 1998, EUR RADIOL, V8, P1590, DOI 10.1007/s003300050592; Stone JA, 1999, AM J NEURORADIOL, V20, P706; Stuckey SL, 2007, AM J ROENTGENOL, V189, P913, DOI 10.2214/AJR.07.2424; Takahashi M, 1999, J TRAUMA, V46, P324, DOI 10.1097/00005373-199902000-00021; Tha KK, 2009, BRIT J RADIOL, V82, P610, DOI 10.1259/bjr/29238647; Thurmond VA, 2010, ARCH PHYS MED REHAB, V91, P1633, DOI 10.1016/j.apmr.2010.06.034; Tomlinson B E, 1970, J Clin Pathol Suppl (R Coll Pathol), V4, P154; Toth A, 2013, J NEUROTRAUM, V30, P2, DOI 10.1089/neu.2012.2486; Trenchs V, 2009, EUR J EMERG MED, V16, P150, DOI 10.1097/MEJ.0b013e328321b7b5; TSAI FY, 1980, AM J ROENTGENOL, V134, P717, DOI 10.2214/ajr.134.4.717; Turazzi S, 1975, J Neurosurg Sci, V19, P215; Vagnozzi R, 2010, BRAIN, V133, P3232, DOI 10.1093/brain/awq200; van Gijn J, 2007, LANCET, V369, P306, DOI 10.1016/S0140-6736(07)60153-6; Vassilyadi M, 2009, CAN J NEUROL SCI, V36, P751, DOI 10.1017/S0317167100008386; Venkatasubramanian C, 2013, J AM HEART ASSOC, V2, DOI 10.1161/JAHA.113.000090; Verma RK, 2013, EUR J RADIOL, V82, P1539, DOI 10.1016/j.ejrad.2013.03.021; Vilaas S, ACR APPROPRIATENESS; Wada R, 2007, STROKE, V38, P1257, DOI 10.1161/01.STR.0000259633.59404.f3; Wang X, 2015, J NEUROTRAUM, V32, P455, DOI 10.1089/neu.2014.3492; Washington CW, 2012, J NEUROSURG, V116, P549, DOI 10.3171/2011.11.JNS111092; Wei SC, 2010, AM J NEURORADIOL, V31, P334, DOI 10.3174/ajnr.A1824; WERNICK S, 1989, J COMPUT ASSIST TOMO, V13, P323, DOI 10.1097/00004728-198903000-00027; Wilde EA, 2008, NEUROLOGY, V70, P948, DOI 10.1212/01.wnl.0000305961.68029.54; Wilde EA, 2010, DEV NEUROPSYCHOL, V35, P333, DOI 10.1080/87565641003696940; Wintermark M, 2015, AJNR Am J Neuroradiol, V36, pE1, DOI 10.3174/ajnr.A4181; Wintermark M, 2004, RADIOLOGY, V232, P211, DOI 10.1148/radiol.2321030824; Wintermark Max, 2015, J Am Coll Radiol, V12, pe1, DOI 10.1016/j.jacr.2014.10.014; Wozniak JR, 2007, ARCH CLIN NEUROPSYCH, V22, P555, DOI 10.1016/j.acn.2007.03.004; Yamaki T, 1996, J NUCL MED, V37, P1166; Yuh Esther L, 2014, Neurosurgery, V75 Suppl 4, pS50, DOI 10.1227/NEU.0000000000000491; Yuh EL, 2014, J NEUROTRAUM, V31, P1457, DOI 10.1089/neu.2013.3171; Yuh EL, 2013, ANN NEUROL, V73, P224, DOI 10.1002/ana.23783; Yuh EL, 2010, NEUROIMAG CLIN N AM, V20, P597, DOI 10.1016/j.nic.2010.07.012; Zacharia TT, 2010, EMERG RADIOL, V17, P97, DOI 10.1007/s10140-009-0842-6; ZIMMERMAN RA, 1979, RADIOLOGY, V130, P687, DOI 10.1148/130.3.687; ZIMMERMAN RA, 1982, RADIOLOGY, V144, P809, DOI 10.1148/radiology.144.4.7111729; ZIMMERMAN RA, 1985, NEURORADIOLOGY, V27, P16, DOI 10.1007/BF00342511	177	22	26	0	8	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1042-3680	1558-1349		NEUROSURG CLIN N AM	Neurosurg. Clin. N. Am.	OCT	2016	27	4					409	+		10.1016/j.nec.2016.05.011			32	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DY9SQ	WOS:000385475800005	27637393	Green Accepted			2021-06-18	
J	Desai, A; Park, T; Barnes, J; Kevala, K; Chen, HZ; Kim, HY				Desai, Abhishek; Park, Taeyeop; Barnes, Jaquel; Kevala, Karl; Chen, Huazhen; Kim, Hee-Yong			Reduced acute neuroinflammation and improved functional recovery after traumatic brain injury by alpha-linolenic acid supplementation in mice	JOURNAL OF NEUROINFLAMMATION			English	Article						Polyunsaturated fatty acids (PUFA); Docosahexaenoic acid (DHA); Alpha-linolenic acid (ALA); Traumatic brain injury (TBI); Inflammation; Diet; Nutrition	SPINAL-CORD-INJURY; FATTY-ACIDS; HEAD-INJURY; RAT-BRAIN; ER STRESS; DHA; ACTIVATION; ASTROCYTES; NEUROPROTECTION; INFLAMMATION	Background: Adequate consumption of polyunsaturated fatty acids (PUFA) is vital for normal development and functioning of the central nervous system. The long-chain n-3 PUFAs docosahexaenoic acid (DHA) and eicosapentaenoic acid are anti-inflammatory and neuroprotective in the models of central nervous system injury including traumatic brain injury (TBI). In the present study, we tested whether a higher brain DHA status in a mouse model on an adequate dietary alpha-linolenic acid (ALA) leads to reduced neuroinflammation and improved spontaneous recovery after TBI in comparison to a moderately lowered brain DHA status that can occur in humans. Methods: Mice reared on diets with differing ALA content were injured by a single cortical contusion impact. Change in the expression of inflammatory cytokines was measured, and cellular changes occurring after injury were analyzed by immunostaining for macrophage/microglia and astrocytes. Behavioral studies included rotarod and beam walk tests and contextual fear conditioning. Results: Marginal supply (0.04 %) of ALA as the sole dietary source of n-3 PUFA from early gestation produced reduction of brain DHA by 35 % in adult offspring mice in comparison to the mice on adequate ALA diet (3.1 %). The DHA-depleted group showed significantly increased TBI-induced expression of pro-inflammatory cytokines TNF-alpha, IL-1 beta, and IL-6 in the brain as well as slower functional recovery from motor deficits compared to the adequate ALA group. Despite the reduction of pro-inflammatory cytokine expression, adequate ALA diet did not significantly alter either microglia/macrophage density around the contusion site or the relative M1/M2 phenotype. However, the glial fibrillary acidic protein immunoreactivity was reduced in the injured cerebral cortex of the mice on adequate ALA diet, indicating that astrocyte activation may have contributed to the observed differences in cellular and behavioral responses to TBI. Conclusions: Increasing the brain DHA level even from a moderately DHA-depleted state can reduce neuroinflammation and improve functional recovery after TBI, suggesting possible improvement of functional outcome by increasing dietary n-3 PUFA in human TBI.	[Desai, Abhishek; Park, Taeyeop; Barnes, Jaquel; Kevala, Karl; Chen, Huazhen; Kim, Hee-Yong] NIAAA, Lab Mol Signaling, NIH, 5625 Fishers Lane,Rm 3N-07, Bethesda, MD 20892 USA	Kim, HY (corresponding author), NIAAA, Lab Mol Signaling, NIH, 5625 Fishers Lane,Rm 3N-07, Bethesda, MD 20892 USA.	hykim@nih.gov			Henry M. Jackson Foundation; Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health; NATIONAL INSTITUTE ON ALCOHOL ABUSE AND ALCOHOLISMUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Alcohol Abuse & Alcoholism (NIAAA) [ZIAAA000501] Funding Source: NIH RePORTER	This study was funded by the Henry M. Jackson Foundation and the Intramural Research Program of the National Institute of Alcohol Abuse and Alcoholism, National Institutes of Health. The funding agencies did not participate in planning the experiments, data analysis, or preparing the manuscript.	Acarin L, 2000, EUR J NEUROSCI, V12, P3505, DOI 10.1046/j.1460-9568.2000.00226.x; Ahmad A, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0057208; Bailes JE, 2010, J NEUROTRAUM, V27, P1617, DOI 10.1089/neu.2009.1239; Begum G, 2014, J NEUROSCI, V34, P3743, DOI 10.1523/JNEUROSCI.2872-13.2014; Begum G, 2012, J NEUROCHEM, V120, P622, DOI 10.1111/j.1471-4159.2011.07606.x; Belayev L, 2009, STROKE, V40, P3121, DOI 10.1161/STROKEAHA.109.555979; Berman JW, 1996, J IMMUNOL, V156, P3017; BLIGH EG, 1959, CAN J BIOCHEM PHYS, V37, P911; Cherry JD, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-98; Desai A, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0086472; Dhillon HS, 1997, EXP NEUROL, V146, P240, DOI 10.1006/exnr.1997.6524; Fernandes A, 2014, CELL MOL LIFE SCI, V71, P3969, DOI 10.1007/s00018-014-1670-8; Glabinski AR, 1996, J IMMUNOL, V156, P4363; Gorina R, 2011, GLIA, V59, P242, DOI 10.1002/glia.21094; Hamazaki K, 2010, J PSYCHIATR RES, V44, P688, DOI 10.1016/j.jpsychires.2009.11.017; Huang WL, 2007, BRAIN, V130, P3004, DOI 10.1093/brain/awm223; Jamieson EC, 1999, LIPIDS, V34, P1065, DOI 10.1007/s11745-999-0458-5; King VR, 2006, J NEUROSCI, V26, P4672, DOI 10.1523/JNEUROSCI.5539-05.2006; Liu HQ, 2013, NUTR RES, V33, P849, DOI 10.1016/j.nutres.2013.07.004; MAKRIDES M, 1994, AM J CLIN NUTR, V60, P189; Mishra A, 2004, ARTERIOSCL THROM VAS, V24, P1621, DOI 10.1161/01.ATV.0000137191.02577.86; Moriguchi T, 2001, J LIPID RES, V42, P419; Mullen A, 2010, J NUTR BIOCHEM, V21, P444, DOI 10.1016/j.jnutbio.2009.02.008; Myer DJ, 2006, BRAIN, V129, P2761, DOI 10.1093/brain/awl165; Persidsky Y, 2006, J NEUROIMMUNE PHARM, V1, P223, DOI 10.1007/s11481-006-9025-3; Pu HJ, 2013, J CEREBR BLOOD F MET, V33, P1474, DOI 10.1038/jcbfm.2013.108; Rossi D, 2000, ANNU REV IMMUNOL, V18, P217, DOI 10.1146/annurev.immunol.18.1.217; SHOHAMI E, 1989, J NEUROCHEM, V53, P1541, DOI 10.1111/j.1471-4159.1989.tb08550.x; Sidhu VK, 2016, NEUROBIOL AGING, V41, P73, DOI 10.1016/j.neurobiolaging.2016.02.007; Simopoulos AP, 2006, BIOMED PHARMACOTHER, V60, P502, DOI 10.1016/j.biopha.2006.07.080; Swanson D, 2012, ADV NUTR, V3, P1, DOI 10.3945/an.111.000893; Wen ZM, 2004, J NEUROCHEM, V89, P1368, DOI 10.1111/j.1471-4159.2004.02433.x; Wu A, 2004, J NEUROTRAUM, V21, P1457, DOI 10.1089/neu.2004.21.1457; Zhang WT, 2010, STROKE, V41, P2341, DOI 10.1161/STROKEAHA.110.586081; Zhao GX, 2007, AM J CLIN NUTR, V85, P385; Ziebell JM, 2010, NEUROTHERAPEUTICS, V7, P22, DOI 10.1016/j.nurt.2009.10.016	36	22	22	0	17	BIOMED CENTRAL LTD	LONDON	236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND	1742-2094			J NEUROINFLAMM	J. Neuroinflamm.	SEP 23	2016	13								253	10.1186/s12974-016-0714-4			10	Immunology; Neurosciences	Immunology; Neurosciences & Neurology	DX8ED	WOS:000384620000003		DOAJ Gold, Green Published			2021-06-18	
J	Wagner, N; Akbarpour, A; Mors, K; Voth, M; Stormann, P; Auner, B; Lehnert, M; Marzi, I; Relja, B				Wagner, Nils; Akbarpour, Annahita; Moers, Katharina; Voth, Maika; Stoermann, Philipp; Auner, Birgit; Lehnert, Mark; Marzi, Ingo; Relja, Borna			ALCOHOL INTOXICATION REDUCES SYSTEMIC INTERLEUKIN-6 LEVELS AND LEUKOCYTE COUNTS AFTER SEVERE TBI COMPARED WITH NOT INTOXICATED TBI PATIENTS	SHOCK			English	Article						Alcohol; inhospital complications; outcome; systemic inflammatory markers; traumatic brain injury	TRAUMATIC BRAIN-INJURY; CONSENSUS CONFERENCE; IMMUNE-SYSTEM; MORTALITY; SCORE; HYPOTHERMIA; CYTOKINES; MODERATE; SCALE; CARE	Background: The effect of alcohol consumption on inflammatory state and outcome in brain-injured patients remains controversial. We analyzed the influence of positive blood alcohol concentration (BAC) on inflammatory changes, inhospital complications, and mortality in traumatic brain injury (TBI) patients. Patients and Methods: Patients with an Injury Severity Score (ISS) at least 16 and Abbreviated Injury Scale of head (AIS-head) at least 3 were included upon arrival in the emergency room and grouped according to positive BAC (>0.5 parts per thousand, BAC) vs. less than 0.5 parts per thousand alcohol (no BAC). Injury severity, vital signs, complications, mortality, and systemic interleukin (IL)-6 levels were prospectively determined, and BAC was quantified. According to ISS, AIS-head, age, and sex, we performed matched-pair analysis. Results: A total of 101 TBI patients were included. Of them 74 patients were dedicated to no BAC group and 27 to BAC group. ISS was significantly higher in the no BAC group. Positive BAC group required significantly less packed red blood cells and fresh frozen plasma (P<0.05). Shorter ICU stays were found in BAC-positive patients. Inhospital complications, including single/multiple organ failure, systemic inflammatory response syndrome, sepsis, pneumonia, and acute respiratory distress syndrome, showed no significant differences. Systemic IL-6 levels and leukocyte counts (IL-6: 65.0 +/- 8.0 vs. 151.8 +/- 22.3; leukocytes: 10.2 +/- 0.9 vs. 13.2 +/- 0.8, both P<0.05) were significantly lower in BAC-positive patients. Matched-pair analysis was performed with 27 pairs. No significant differences in transfusions were monitored after matching. However, lowered systemic IL-6 levels and leukocyte counts in the BAC group were also detected after matching, indicating that this effect is ISS-independent. Conclusions: This study shows that positive BAC in TBI patients is associated with lower systemic IL-6 levels and leukocyte numbers, indicating that positive BAC may have immunosuppressive effects in this cohort of patients compared with TBI patients who were not alcohol intoxicated.	[Wagner, Nils; Akbarpour, Annahita; Moers, Katharina; Voth, Maika; Stoermann, Philipp; Auner, Birgit; Lehnert, Mark; Marzi, Ingo; Relja, Borna] Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, D-60590 Frankfurt, Germany	Wagner, N (corresponding author), Goethe Univ Frankfurt, Univ Hosp Frankfurt, Dept Trauma Hand & Reconstruct Surg, D-60590 Frankfurt, Germany.	nils.wagner@kgu.de	Relja, Borna/B-6642-2016	Relja, Borna/0000-0002-5625-8823			Aibiki M, 1999, J NEUROTRAUM, V16, P225, DOI 10.1089/neu.1999.16.225; Aibiki M, 1999, RESUSCITATION, V41, P263, DOI 10.1016/S0300-9572(99)00052-0; Andresen M, 2015, SCAND J TRAUMA RESUS, V23, DOI 10.1186/s13049-015-0121-3; Arvin B, 1996, NEUROSCI BIOBEHAV R, V20, P445, DOI 10.1016/0149-7634(95)00026-7; BAKER SP, 1974, J TRAUMA, V14, P187, DOI 10.1097/00005373-197403000-00001; BERNARD GR, 1994, INTENS CARE MED, V20, P225, DOI 10.1007/BF01704707; Berry C, 2011, AM SURGEON, V77, P1416; Calandra T, 2005, CRIT CARE MED, V33, P1538, DOI 10.1097/01.CCM.0000168253.91200.83; Choi Y, 2009, AM J EMERG MED, V27, P956, DOI 10.1016/j.ajem.2008.07.035; Dutton RP, 2010, J TRAUMA, V69, P620, DOI 10.1097/TA.0b013e3181bbfe2a; Erskine S, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-99; Feuerstein GZ, 1998, NEUROIMMUNOMODULAT, V5, P143, DOI 10.1159/000026331; Goodman MD, 2013, J SURG RES, V184, P1053, DOI 10.1016/j.jss.2013.04.058; Gottesfeld Z, 2002, J NEUROTRAUM, V19, P317, DOI 10.1089/089771502753594882; GREENSPAN L, 1985, J TRAUMA, V25, P60, DOI 10.1097/00005373-198501000-00010; Gunnarsdottir AS, 2014, BMJ OPEN, V4, DOI 10.1136/bmjopen-2014-006327; Hadjibashi AA, 2012, J SURG RES, V173, P212, DOI 10.1016/j.jss.2011.05.029; Hayakata T, 2004, SHOCK, V22, P102, DOI 10.1097/01.shk.0000131193.80038.f1; JENNETT B, 1975, LANCET, V1, P480; Katada R, 2009, J NEUROTRAUM, V26, P2015, DOI 10.1089/neu.2008.0552; Kelly DF, 1997, J NEUROSURG, V86, P876, DOI 10.3171/jns.1997.86.5.0876; KOSSMANN T, 1995, SHOCK, V4, P311, DOI 10.1097/00024382-199511000-00001; Lin HL, 2014, BIOMED RES INT, V2014, DOI 10.1155/2014/619231; Lustenberger T, 2011, J NEUROTRAUM, V28, P1699, DOI 10.1089/neu.2011.1866; Maier B, 2001, SHOCK, V15, P421, DOI 10.1097/00024382-200115060-00002; Marzi I, PRAXISBUCH POLYTRAUM; Molina PE, 2010, ALCOHOL RES HEALTH, V33, P97; Neugebauer EAM, 2012, DTSCH ARZTEBL INT, V109, P102, DOI 10.3238/arztebl.2012.0102; Pandit V, 2014, J SURG RES, V190, P634, DOI 10.1016/j.jss.2014.04.039; Plurad D, 2010, J EMERG MED, V38, P12, DOI 10.1016/j.jemermed.2007.09.048; Raj R, 2015, J NEUROTRAUM, V32, P95, DOI 10.1089/neu.2014.3488; Relja B, 2012, OXID MED CELL LONGEV, V2012, DOI 10.1155/2012/983427; Relja B, 2012, BRIT J PHARMACOL, V165, P1188, DOI 10.1111/j.1476-5381.2011.01595.x; Roerecke M, 2013, ADDICTION, V108, P1562, DOI 10.1111/add.12231; Romeo J, 2007, BRIT J NUTR, V98, pS111, DOI 10.1017/S0007114507838049; Rundhaug NP, 2015, J NEUROSURG, V122, P211, DOI 10.3171/2014.9.JNS14322; Samraj RS, 2013, SHOCK, V40, P358, DOI 10.1097/SHK.0b013e3182a66bd6; Scheyerer MJ, 2014, EMERG MED J, V31, P813, DOI 10.1136/emermed-2013-202804; Statistisches Bundesamt, 2013, STAT BUNDESAMT TODES; TEASDALE G, 1974, LANCET, V2, P81; Teng SX, 2014, J NEUROTRAUM, V31, P378, DOI 10.1089/neu.2013.3093; Tien HCN, 2006, ARCH SURG-CHICAGO, V141, P1185, DOI 10.1001/archsurg.141.12.1185; Turk EE, 2010, FORENSIC SCI MED PAT, V6, P106, DOI 10.1007/s12024-010-9142-4; Vaaramo K, 2014, EUR J NEUROL, V21, P293, DOI 10.1111/ene.12302; Vincent JL, 1996, INTENS CARE MED, V22, P707, DOI 10.1007/BF01709751; von Elm E, 2007, B WORLD HEALTH ORGAN, V85, P867, DOI 10.2471/BLT.07.045120; Wang T, 2013, J NEUROSURG, V118, P390, DOI 10.3171/2012.8.JNS12736; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Yang SH, 2013, SHOCK, V40, P471, DOI 10.1097/SHK.0000000000000037; Zhao Yongzhen, 2014, Zhonghua Wei Zhong Bing Ji Jiu Yi Xue, V26, P153, DOI 10.3760/cma.j.issn.2095-4352.2014.03.006	50	22	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1073-2322	1540-0514		SHOCK	Shock	SEP	2016	46	3					261	269		10.1097/SHK.0000000000000620			9	Critical Care Medicine; Hematology; Surgery; Peripheral Vascular Disease	General & Internal Medicine; Hematology; Surgery; Cardiovascular System & Cardiology	DU6KI	WOS:000382323100006	27058046				2021-06-18	
J	Selwyn, RG; Cooney, SJ; Khayrullina, G; Hockenbury, N; Wilson, CM; Jaiswal, S; Bermudez, S; Armstrong, RC; Byrnes, KR				Selwyn, Reed G.; Cooney, Sean J.; Khayrullina, Guzal; Hockenbury, Nicole; Wilson, Colin M.; Jaiswal, Shalini; Bermudez, Sara; Armstrong, Regina C.; Byrnes, Kimberly R.			Outcome after Repetitive Mild Traumatic Brain Injury Is Temporally Related to Glucose Uptake Profile at Time of Second Injury	JOURNAL OF NEUROTRAUMA			English	Article						FDG-PET; fluorodeoxyglucose; histopathology; locomotor function; repeated mild traumatic brain injury	CORTICAL IMPACT INJURY; CEREBRAL-BLOOD-FLOW; AXONAL INJURY; PROFESSIONAL FOOTBALL; MACAQUE MONKEYS; MOUSE MODEL; ISOFLURANE; RAT; VULNERABILITY; NEUROTRAUMA	Repeated mild traumatic brain injury (rmTBI) results in worsened outcomes, compared with a single injury, but the mechanism of this phenomenon is unclear. We have previously shown that mild TBI in a rat lateral fluid percussion model results in globally depressed glucose uptake, with a peak depression at 24 h that resolves by 16 days post-injury. The current study investigated the outcomes of a repeat injury conducted at various times during this period of depressed glucose uptake. Adult male rats were therefore subjected to rmTBI with a latency of 24 h, 5 days, or 15 days between injuries, followed by assessment of motor function, histopathology, and glucose uptake using positron emission tomography (PET). Rats that received a 24 h rmTBI showed significant deficits in motor function tasks, as well as significant increases in lesion volume and neuronal damage. The level of microglial and astrocytic activation also was associated with the timing of the second impact. Finally, rmTBI with latencies of 24 h and 5 days showed significant alterations in [F-18]fluorodeoxyglucose uptake, compared with baseline scans. Therefore, we conclude that the state of the metabolic environment, as indicated by FDG-PET at the time of the repeat injury, significantly influences neurological outcomes.	[Selwyn, Reed G.; Cooney, Sean J.; Wilson, Colin M.; Jaiswal, Shalini; Armstrong, Regina C.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Ctr Neurosci & Regenerat Med, Bethesda, MD 20814 USA; [Selwyn, Reed G.] Uniformed Serv Univ Hlth Sci, Dept Radiol, Bethesda, MD 20814 USA; [Cooney, Sean J.; Khayrullina, Guzal; Hockenbury, Nicole; Bermudez, Sara; Armstrong, Regina C.; Byrnes, Kimberly R.] Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd,Room B2048, Bethesda, MD 20814 USA; [Selwyn, Reed G.] Univ New Mexico, Dept Radiol, Albuquerque, NM 87131 USA	Byrnes, KR (corresponding author), Uniformed Serv Univ Hlth Sci, Dept Anat Physiol & Genet, 4301 Jones Bridge Rd,Room B2048, Bethesda, MD 20814 USA.	kimberly.byrnes@usuhs.edu					Abrous DN, 1999, BRAIN RES, V826, P181, DOI 10.1016/S0006-8993(99)01259-7; Allen GV, 2000, NEUROSCIENCE, V99, P93, DOI 10.1016/S0306-4522(00)00185-8; Bailes JE, 2001, NEUROSURGERY, V48, P26, DOI 10.1097/00006123-200101000-00005; Belanger HG, 2007, J NEUROPSYCH CLIN N, V19, P5, DOI 10.1176/appi.neuropsych.19.1.5; Bennett RE, 2012, NEUROSCI LETT, V513, P160, DOI 10.1016/j.neulet.2012.02.024; Bergsneider M, 2000, J NEUROTRAUM, V17, P389, DOI 10.1089/neu.2000.17.389; Blennow K, 2012, NEURON, V76, P886, DOI 10.1016/j.neuron.2012.11.021; Byrnes Kimberly R, 2014, Front Neuroenergetics, V5, P13, DOI 10.3389/fnene.2013.00013; DeRoss AL, 2002, J TRAUMA, V52, P708, DOI 10.1097/00005373-200204000-00017; Donnelly DJ, 2009, J NEUROSCI METH, V181, P36, DOI 10.1016/j.jneumeth.2009.04.010; Farhad K, 2013, J NEUROTRAUM, V30, P84, DOI 10.1089/neu.2011.2283; Fujita M, 2012, J NEUROTRAUM, V29, P2172, DOI 10.1089/neu.2012.2357; GRAHAMJONES S, 1983, NEUROSCIENCE, V9, P679, DOI 10.1016/0306-4522(83)90184-7; Holschneider DP, 2013, J NEUROTRAUM, V30, P907, DOI 10.1089/neu.2012.2657; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Li CX, 2014, MAGN RESON IMAGING, V32, P956, DOI 10.1016/j.mri.2014.04.019; Li CX, 2013, NEUROSCI LETT, V541, P58, DOI 10.1016/j.neulet.2013.02.007; Li J, 2012, J NEUROTRAUM, V29, P2635, DOI 10.1089/neu.2012.2411; Liu YR, 2010, J NUCL MED, V51, P1788, DOI 10.2967/jnumed.110.078626; Loane DJ, 2010, NEUROTHERAPEUTICS, V7, P366, DOI 10.1016/j.nurt.2010.07.002; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Makaryus R, 2011, J CEREBR BLOOD F MET, V31, P1432, DOI 10.1038/jcbfm.2011.1; Manville J, 2007, J MOL NEUROSCI, V31, P95, DOI 10.1385/JMN/31:02:95; Miyauchi T, 2013, J NEUROTRAUM, V30, P1664, DOI 10.1089/neu.2013.2995; Mouzon B, 2012, J NEUROTRAUM, V29, P2761, DOI 10.1089/neu.2012.2498; Nijland PG, 2014, GLIA, V62, P1125, DOI 10.1002/glia.22667; Pellman EJ, 2003, NEUROSURGERY, V53, P1328, DOI 10.1227/01.NEU.0000093499.20604.21; Pellman EJ, 2003, NEUROSURGERY, V53, P799, DOI 10.1093/neurosurgery/53.3.799; Peskind ER, 2011, NEUROIMAGE, V54, pS76, DOI 10.1016/j.neuroimage.2010.04.008; Prins ML, 2013, J NEUROTRAUM, V30, P30, DOI 10.1089/neu.2012.2399; Selwyn R, 2013, J NEUROTRAUM, V30, P1943, DOI 10.1089/neu.2013.2928; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Shultz SR, 2012, J NEUROTRAUM, V29, P281, DOI 10.1089/neu.2011.2123; Yuen TJ, 2009, J NEUROSCI RES, V87, P3620, DOI 10.1002/jnr.22161	34	22	22	0	9	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	AUG 15	2016	33	16					1479	1491		10.1089/neu.2015.4129			13	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	DU6ED	WOS:000382305900002	26650903				2021-06-18	
J	Kipp, M; Hochstrasser, T; Schmitz, C; Beyer, C				Kipp, Markus; Hochstrasser, Tanja; Schmitz, Christoph; Beyer, Cordian			Female sex steroids and glia cells: Impact on multiple sclerosis lesion formation and fine tuning of the local neurodegenerative cellular network	NEUROSCIENCE AND BIOBEHAVIORAL REVIEWS			English	Article; Proceedings Paper	8th International Meeting on Steroids and Nervous System	2015	Torino, ITALY			Multiple sclerosis; Astroglia; Microglia; Inflammation; Invasion; Immune cells; Estrogen; Progesterone; Neuroinflammation; Neuroprotection	EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; CENTRAL-NERVOUS-SYSTEM; CUPRIZONE-INDUCED DEMYELINATION; TRAUMATIC BRAIN-INJURY; ESTROGEN-RECEPTOR-BETA; EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS; ANTIGEN-PRESENTING CELLS; MYELIN BASIC-PROTEIN; TOLL-LIKE RECEPTORS; IN-VITRO	Multiple sclerosis (MS) is a chronic inflammatory and demyelinating disease that shows a female-to male gender prevalence and alleviation of disease activity during late stage pregnancy. In MS-related animal models, sex steroids ameliorate symptoms and protect from demyelination and neuronal damage. Underlying mechanisms of these protective avenues are continuously discovered, in part by using novel transgenic animal models. In this review article, we highlight the regulation of glia cell function by female sex steroids. We specifically focus on the relevance of glia cells for immune cell recruitment into the central nervous system and show how estrogen and progesterone can modulate these cell-cell communication pathways. Since MS is considered to have a strong neurodegenerative component, principal neuroprotective mechanisms, exerted by sex-steroids will be discussed as well. Activation of steroid receptors might not just act as immunosuppressant but at the same time harmonize brain-intrinsic networks to dampen neurodegeneration and, thus, disease progression in MS. (C) 2015 Elsevier Ltd. All rights reserved.	[Kipp, Markus; Hochstrasser, Tanja; Schmitz, Christoph] Univ Munich, Dept Neuroanat, Munich, Germany; [Beyer, Cordian] Rhein Westfal TH Aachen, Fac Med, Inst Neuroanat, D-52074 Aachen, Germany	Kipp, M (corresponding author), Univ Munich, Dept Neuroanat, Munich, Germany.	markus.kipp@med.uni-muenchen.de					Acaz-Fonseca E., 2015, GLIA; Acs P, 2009, GLIA, V57, P807, DOI 10.1002/glia.20806; Agrawal S, 2006, J EXP MED, V203, P1007, DOI 10.1084/jem.20051342; Amantea D, 2005, PHARMACOL RES, V52, P119, DOI 10.1016/j.phrs.2005.03.002; Amantea D, 2009, FEBS J, V276, P13, DOI 10.1111/j.1742-4658.2008.06766.x; Ambrosini E, 2004, NEUROCHEM RES, V29, P1017, DOI 10.1023/B:NERE.0000021246.96864.89; Amor S, 2014, IMMUNOLOGY, V141, P287, DOI 10.1111/imm.12134; Annunziato L, 2013, J CEREBR BLOOD F MET, V33, P969, DOI 10.1038/jcbfm.2013.44; Arevalo MA, 2010, BBA-GEN SUBJECTS, V1800, P1106, DOI 10.1016/j.bbagen.2009.10.002; Babcock AA, 2003, J NEUROSCI, V23, P7922; Bajramovic JJ, 2011, CNS NEUROL DISORD-DR, V10, P4; Baker AE, 2004, ENDOCRINOLOGY, V145, P5021, DOI 10.1210/en.2004-0619; Balabanov R, 2007, J NEUROSCI, V27, P2013, DOI 10.1523/JNEUROSCI.4689-06.2007; Bali N, 2013, ENDOCRINOLOGY, V154, P2468, DOI 10.1210/en.2012-2109; Barnett MH, 2004, ANN NEUROL, V55, P458, DOI 10.1002/ana.20016; Barres BA, 2008, NEURON, V60, P430, DOI 10.1016/j.neuron.2008.10.013; Barreto George, 2011, Central Nervous System Agents in Medicinal Chemistry, V11, P164; Becher B, 2000, GLIA, V29, P293; Becher B, 2001, J EXP MED, V193, P967, DOI 10.1084/jem.193.8.967; Bechmann I, 1999, GLIA, V27, P62, DOI 10.1002/(SICI)1098-1136(199907)27:1<62::AID-GLIA7>3.0.CO;2-S; Bechmann I, 2007, TRENDS IMMUNOL, V28, P5, DOI 10.1016/j.it.2006.11.007; Bedoya SK, 2013, CLIN DEV IMMUNOL, DOI 10.1155/2013/986789; Belarbi K, 2013, FRONT CELL NEUROSCI, V7, DOI 10.3389/fncel.2013.00145; Benedict RHB, 2011, NAT REV NEUROL, V7, P332, DOI 10.1038/nrneurol.2011.61; Blakemore WF, 2008, CURR TOP MICROBIOL, V318, P193; BLAKEMORE WF, 1972, J NEUROCYTOL, V1, P413, DOI 10.1007/BF01102943; Blasko E, 2009, J NEUROIMMUNOL, V214, P67, DOI 10.1016/j.jneuroim.2009.06.023; Bo L, 2006, ACTA NEUROL SCAND, V113, P48, DOI 10.1111/j.1600-0404.2006.00615.x; Bondesson M, 2015, BBA-GENE REGUL MECH, V1849, P142, DOI 10.1016/j.bbagrm.2014.06.005; Brinton RD, 2008, FRONT NEUROENDOCRIN, V29, P313, DOI 10.1016/j.yfrne.2008.02.001; Bruce-Keller AJ, 2000, ENDOCRINOLOGY, V141, P3646, DOI 10.1210/en.141.10.3646; Bsibsi M, 2014, ACTA NEUROPATHOL, V128, P215, DOI 10.1007/s00401-014-1317-8; Buschmann JP, 2012, J MOL NEUROSCI, V48, P66, DOI 10.1007/s12031-012-9773-x; CARLTON WW, 1966, TOXICOL APPL PHARM, V8, P512, DOI 10.1016/0041-008X(66)90062-7; Carson MJ, 2002, GLIA, V40, P218, DOI 10.1002/glia.10145; Cekanaviciute E, 2014, GLIA, V62, P1227, DOI 10.1002/glia.22675; Chen JJ, 2014, REV NEUROSCIENCE, V25, P269, DOI 10.1515/revneuro-2013-0046; Chen Z., 2015, J NEUROCHEM; Chesik D, 2010, NEUROSCI LETT, V468, P178, DOI 10.1016/j.neulet.2009.10.051; Clarner T, 2015, J IMMUNOL, V194, P3400, DOI 10.4049/jimmunol.1401459; Coles AJ, 1999, ANN NEUROL, V46, P296, DOI 10.1002/1531-8249(199909)46:3<296::AID-ANA4>3.0.CO;2-#; Confavreux C, 1998, NEW ENGL J MED, V339, P285, DOI 10.1056/NEJM199807303390501; Cook-Mills JM, 2011, ANTIOXID REDOX SIGN, V15, P1607, DOI 10.1089/ars.2010.3522; Corps KN, 2015, JAMA NEUROL, V72, P355, DOI 10.1001/jamaneurol.2014.3558; Crawford DK, 2010, BRAIN, V133, P2999, DOI 10.1093/brain/awq237; Cross AK, 1999, GLIA, V28, P183, DOI 10.1002/(SICI)1098-1136(199912)28:3<183::AID-GLIA2>3.3.CO;2-V; D'Agostino PM, 2012, ACTA NEUROPATHOL, V124, P599, DOI 10.1007/s00401-012-1018-0; Danchenko N, 2006, LUPUS, V15, P308, DOI 10.1191/0961203306lu2305xx; Dang J, 2011, BRAIN BEHAV IMMUN, V25, P715, DOI 10.1016/j.bbi.2011.01.013; Das M, 2012, J NEUROINFLAMM, V9, DOI 10.1186/1742-2094-9-236; Davalos D, 2005, NAT NEUROSCI, V8, P752, DOI 10.1038/nn1472; De Groot CJA, 2001, BRAIN, V124, P1635, DOI 10.1093/brain/124.8.1635; De Nicola AF, 2013, J NEUROENDOCRINOL, V25, P1095, DOI 10.1111/jne.12043; Dhandapani KM, 2005, ENDOCRINOLOGY, V146, P2749, DOI 10.1210/en.2005-0014; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Drew PD, 2000, J NEUROIMMUNOL, V111, P77, DOI 10.1016/S0165-5728(00)00386-6; El-Etr M, 2015, GLIA, V63, P104, DOI 10.1002/glia.22736; El-Etr M, 2011, MATURITAS, V68, P47, DOI 10.1016/j.maturitas.2010.09.014; Ellwardt E, 2014, EXP NEUROL, V262, P8, DOI 10.1016/j.expneurol.2014.02.006; Eng LF, 1996, NEUROCHEM RES, V21, P511, DOI 10.1007/BF02527717; Fernandez-Fernandez S, 2012, BIOCHEM J, V443, P3, DOI 10.1042/BJ20111943; Ferrini F, 2013, NEURAL PLAST, V2013, DOI 10.1155/2013/429815; Finkelsztejn A, 2011, BJOG-INT J OBSTET GY, V118, P790, DOI 10.1111/j.1471-0528.2011.02931.x; Frankenberger M, 2005, INT IMMUNOPHARMACOL, V5, P289, DOI 10.1016/j.intimp.2004.09.033; Freitas-Andrade M., 2015, NEUROSCIENCE; Fulmer CG, 2014, J NEUROSCI, V34, P8186, DOI 10.1523/JNEUROSCI.4267-13.2014; Fumagalli S, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00081; Gago N, 2001, GLIA, V36, P295, DOI 10.1002/glia.1117; Galbiati M, 2003, ANN NY ACAD SCI, V1007, P162, DOI 10.1196/annals.1286.016; Galea E, 2003, CELL MOL NEUROBIOL, V23, P625, DOI 10.1023/A:1025084415833; Garcia JA, 2013, J IMMUNOL, V191, P1063, DOI 10.4049/jimmunol.1300040; Garcia-Segura LM, 1999, NEUROSCIENCE, V89, P567, DOI 10.1016/S0306-4522(98)00340-6; Giatti S, 2010, NEUROCHEM INT, V56, P118, DOI 10.1016/j.neuint.2009.09.009; Giraud SN, 2010, P NATL ACAD SCI USA, V107, P8416, DOI 10.1073/pnas.0910627107; Gold R, 2006, BRAIN, V129, P1953, DOI 10.1093/brain/awl075; Gold SM, 2009, PROG BRAIN RES, V175, P239, DOI 10.1016/S0079-6123(09)17516-7; Goldmann T, 2015, EMBO J, V34, P1612, DOI 10.15252/embj.201490791; Gravel M, 2009, J NEUROSCI RES, V87, P1069, DOI 10.1002/jnr.21939; Habib P, 2015, J STEROID BIOCHEM, V146, P3, DOI 10.1016/j.jsbmb.2014.02.018; Habib P, 2014, NEUROENDOCRINOLOGY, V99, P156, DOI 10.1159/000362279; Habib P, 2014, J MOL NEUROSCI, V52, P277, DOI 10.1007/s12031-013-0137-y; Habib P, 2013, J STEROID BIOCHEM, V138, P195, DOI 10.1016/j.jsbmb.2013.06.003; Haider L, 2011, BRAIN, V134, P1914, DOI 10.1093/brain/awr128; Heiman A, 2014, BRAIN BEHAV IMMUN, V42, P232, DOI 10.1016/j.bbi.2014.06.203; Henderson APD, 2009, ANN NEUROL, V66, P739, DOI 10.1002/ana.21800; Heppner FL, 2005, NAT MED, V11, P146, DOI 10.1038/nm1177; Herder V, 2011, NEUROPATH APPL NEURO, V37, P676, DOI 10.1111/j.1365-2990.2011.01168.x; Hewett JA, 2009, J NEUROCHEM, V110, P1717, DOI 10.1111/j.1471-4159.2009.06288.x; Hirahara Y, 2013, GLIA, V61, P420, DOI 10.1002/glia.22445; Horvat S, 2006, J NEUROCHEM, V99, P937, DOI 10.1111/j.1471-4159.2006.04134.x; Hussain R, 2011, ENDOCRINOLOGY, V152, P3820, DOI 10.1210/en.2011-1219; Janssen K, 2015, MOL NEUROBIOL; Jarvela JT, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-29; Jebelli J., 2015, ANN N Y ACAD SCI; Johann S, 2013, J STEROID BIOCHEM, V137, P71, DOI 10.1016/j.jsbmb.2012.11.006; Karki P, 2014, MOL CELL ENDOCRINOL, V389, P58, DOI 10.1016/j.mce.2014.01.010; Karve LP., 2015, BR J PHARM; Kerschensteiner M, 2003, ANN NEUROL, V53, P292, DOI 10.1002/ana.10446; Khalaj AJ, 2013, P NATL ACAD SCI USA, V110, P19125, DOI [10.1073/pnas.311763110, 10.1073/pnas.1311763110]; Kigerl KA, 2014, EXP NEUROL, V258, P5, DOI 10.1016/j.expneurol.2014.01.001; Kim H, 2008, BIOCHEM BIOPH RES CO, V372, P243, DOI 10.1016/j.bbrc.2008.05.025; Kim RY, 2014, J NEUROIMMUNOL, V274, P53, DOI 10.1016/j.jneuroim.2014.06.009; Kipp M, 2012, J NEUROENDOCRINOL, V24, P62, DOI 10.1111/j.1365-2826.2011.02163.x; Kipp M, 2008, J MOL NEUROSCI, V35, P235, DOI 10.1007/s12031-008-9057-7; Kipp M, 2006, FRONT NEUROENDOCRIN, V27, P376, DOI 10.1016/j.yfrne.2006.07.001; Kipp M, 2012, MULT SCLER RELAT DIS, V1, P15, DOI 10.1016/j.msard.2011.09.002; Kipp M, 2012, CNS NEUROL DISORD-DR, V11, P506, DOI 10.2174/187152712801661248; Kipp M, 2012, FRONT NEUROENDOCRIN, V33, P1, DOI 10.1016/j.yfrne.2012.01.001; Kipp M, 2009, ACTA NEUROPATHOL, V118, P723, DOI 10.1007/s00401-009-0591-3; Kleinewietfeld M, 2013, NATURE, V496, P518, DOI 10.1038/nature11868; Kohno H, 2014, J IMMUNOL, V192, P3816, DOI 10.4049/jimmunol.1301738; Krauspe BM, 2015, J MOL NEUROSCI, V55, P733, DOI 10.1007/s12031-014-0412-6; Kroenke MA, 2007, J NEUROSCI RES, V85, P1685, DOI 10.1002/jnr.21291; Kumar S, 2013, NEUROBIOL DIS, V56, P131, DOI 10.1016/j.nbd.2013.04.005; Kuo J, 2010, J NEUROSCI, V30, P12950, DOI 10.1523/JNEUROSCI.1158-10.2010; Labombarda F, 2011, EXP NEUROL, V231, P135, DOI 10.1016/j.expneurol.2011.06.001; Lacroix-Fralish ML, 2006, NEURON GLIA BIOL, V2, P227, DOI 10.1017/S1740925X07000385; Lang BT, 2014, EXP NEUROL, V258, P17, DOI 10.1016/j.expneurol.2014.04.031; Lassmann H, 2014, EXP NEUROL, V262, P2, DOI 10.1016/j.expneurol.2013.12.003; Lecca D, 2012, PURINERG SIGNAL, V8, P539, DOI 10.1007/s11302-012-9310-y; Lee YJ, 2012, NATURE, V487, P443, DOI 10.1038/nature11314; Lei BL, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103969; Leussink VI, 2001, ARCH NEUROL-CHICAGO, V58, P91, DOI 10.1001/archneur.58.1.91; Levin ER, 2015, ANNU REV MED, V66, P271, DOI 10.1146/annurev-med-050913-021703; Levine JB, 1999, GLIA, V28, P215; LIBERSKI PP, 1995, FOLIA NEUROPATHOL, V33, P85; Lim DG, 2007, TRANSPL IMMUNOL, V18, P94, DOI 10.1016/j.trim.2007.05.005; Liu W, 2011, LIFE SCI, V89, P141, DOI 10.1016/j.lfs.2011.05.011; Liu X, 2005, J NEUROSCI RES, V81, P653, DOI 10.1002/jnr.20583; Lublin FD, 1996, NEUROLOGY, V46, P907, DOI 10.1212/WNL.46.4.907; Lucchinetti C, 2000, ANN NEUROL, V47, P707, DOI 10.1002/1531-8249(200006)47:6<707::AID-ANA3>3.0.CO;2-Q; Lucchinetti CF, 2004, ANN NEUROL, V56, P308, DOI 10.1002/ana.20182; Luessi F, 2012, EXPERT REV NEUROTHER, V12, P1061, DOI [10.1586/ERN.12.59, 10.1586/ern.12.59]; Maggi P, 2014, ANN NEUROL, V76, P594, DOI 10.1002/ana.24242; Mahad DH, 2015, LANCET NEUROL, V14, P183, DOI 10.1016/S1474-4422(14)70256-X; Matyszak MK, 1999, EUR J IMMUNOL, V29, P3063, DOI 10.1002/(SICI)1521-4141(199910)29:10<3063::AID-IMMU3063>3.0.CO;2-G; McDonald WI, 2001, ANN NEUROL, V50, P121, DOI 10.1002/ana.1032; Meffre D, 2005, J NEUROCHEM, V93, P1314, DOI 10.1111/j.1471-4159.2005.03127.x; Meffre D, 2013, NEUROSCIENCE, V231, P111, DOI 10.1016/j.neuroscience.2012.11.039; Mena MA, 2008, NEUROSCIENTIST, V14, P544, DOI 10.1177/1073858408322839; MENDEL I, 1995, EUR J IMMUNOL, V25, P1951, DOI 10.1002/eji.1830250723; Micevych P, 2008, MOL CELL ENDOCRINOL, V290, P44, DOI 10.1016/j.mce.2008.04.016; Michailidou I, 2015, ANN NEUROL, V77, P1007, DOI 10.1002/ana.24398; Mifsud G, 2014, CNS NEUROSCI THER, V20, P603, DOI 10.1111/cns.12263; Mills SY, 2007, COMPLEMENT THER MED, V15, P1, DOI [10.1016/j.ctim.2007.01.003, 10.1002/0471142735.im1501s77]; Miyamoto N, 2014, CELL MOL LIFE SCI, V71, P1055, DOI 10.1007/s00018-013-1488-9; Moehle MS, 2014, NEUROSCIENCE; Moll NM, 2011, ANN NEUROL, V70, P764, DOI 10.1002/ana.22521; Nalbandian G, 2005, IMMUNOL RES, V31, P91, DOI 10.1385/IR:31:2:091; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Niranjan R, 2013, MOL NEUROBIOL, V48, P412, DOI 10.1007/s12035-013-8428-4; Nurulain SM, 2014, CNS NEUROL DISORD-DR, V13, P1397, DOI 10.2174/1871527313666141023142539; Olah M, 2011, CNS NEUROL DISORD-DR, V10, P108, DOI 10.2174/187152711794488575; Olah M, 2012, GLIA, V60, P306, DOI 10.1002/glia.21266; Orihuela R, 2015, BR J PHARM, DOI 10.1111/bph.13139; Park J, 2008, J NEUROSCI, V28, P12815, DOI 10.1523/JNEUROSCI.2665-08.2008; Parpura V., 2015, NEUROBIOL DIS; Pawlak J, 2005, MOL BRAIN RES, V138, P1, DOI 10.1016/j.molbrainres.2004.10.043; Pawlak J, 2005, GLIA, V50, P270, DOI 10.1002/glia.20162; Pekny M, 2014, NEUROSCI LETT, V565, P30, DOI 10.1016/j.neulet.2013.12.071; PENDER MP, 1991, J NEUROL SCI, V104, P81, DOI 10.1016/0022-510X(91)90219-W; PETTINELLI CB, 1981, J IMMUNOL, V127, P1420; Petzold A, 2002, BRAIN, V125, P1462, DOI 10.1093/brain/awf165; Platania P, 2005, NEUROBIOL DIS, V20, P461, DOI 10.1016/j.nbd.2005.03.025; Ramesh G, 2013, MEDIAT INFLAMM, V2013, DOI 10.1155/2013/480739; Ransohoff RM, 2012, NAT NEUROSCI, V15, P1074, DOI 10.1038/nn.3168; Rao KVR, 2005, NEUROCHEM RES, V30, P1311, DOI 10.1007/s11064-005-8803-2; Rasband MN, 2005, GLIA, V50, P86, DOI 10.1002/glia.20165; Rasmussen S, 2007, BRAIN, V130, P2816, DOI 10.1093/brain/awm219; Reed JL, 2004, NEUROSCI LETT, V367, P60, DOI 10.1016/j.neulet.2004.05.077; Rice GPA, 2000, NEUROLOGY, V54, P1145, DOI 10.1212/WNL.54.5.1145; Rinholm JE, 2011, J NEUROSCI, V31, P538, DOI 10.1523/JNEUROSCI.3516-10.2011; Rossi D., 2015, PROG NEUROBIOL; Rozkova D, 2006, CLIN IMMUNOL, V120, P260, DOI 10.1016/j.clim.2006.04.567; Saijo K, 2011, CELL, V145, P584, DOI 10.1016/j.cell.2011.03.050; Saldanha CJ, 2009, FRONT NEUROENDOCRIN, V30, P106, DOI 10.1016/j.yfrne.2009.04.016; Salmina AB, 2009, J ALZHEIMERS DIS, V16, P485, DOI 10.3233/JAD-2009-0988; Sarvari M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0088540; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; SHIVERS RR, 1988, J SUBMICR CYTOL PATH, V20, P1; Sierra A, 2008, GLIA, V56, P659, DOI 10.1002/glia.20644; Silver J, 2004, NAT REV NEUROSCI, V5, P146, DOI 10.1038/nrn1326; Singhal G, 2014, FRONT NEUROSCI-SWITZ, V8, DOI 10.3389/fnins.2014.00315; Skalnikova H, 2011, PROTEOMICS, V11, P691, DOI 10.1002/pmic.201000402; Skaper SD, 2007, ANN NY ACAD SCI, V1122, P23, DOI 10.1196/annals.1403.002; Skripuletz T, 2011, HISTOL HISTOPATHOL, V26, P1585, DOI 10.14670/HH-26.1585; Skuljec J, 2011, CELL IMMUNOL, V270, P164, DOI 10.1016/j.cellimm.2011.05.001; Slowik A., 2015, J STEROID BIOCH MOL; Sofroniew MV, 2015, NAT REV NEUROSCI, V16, P249, DOI 10.1038/nrn3898; Sohrabji F, 2015, FRONT NEUROENDOCRIN, V36, P1, DOI 10.1016/j.yfrne.2014.05.003; Soos JM, 1999, INT IMMUNOL, V11, P1169, DOI 10.1093/intimm/11.7.1169; Sosa RA, 2013, J IMMUNOL, V191, P5848, DOI 10.4049/jimmunol.1300771; Spence RD, 2013, J NEUROSCI, V33, P10924, DOI 10.1523/JNEUROSCI.0886-13.2013; Spence RD, 2012, FRONT NEUROENDOCRIN, V33, P105, DOI 10.1016/j.yfrne.2011.12.001; Starossom SC, 2012, IMMUNITY, V37, P249, DOI 10.1016/j.immuni.2012.05.023; STEIN M, 1992, J EXP MED, V176, P287, DOI 10.1084/jem.176.1.287; Stidworthy MF, 2003, BRAIN PATHOL, V13, P329; Stoll G, 1998, PROG NEUROBIOL, V56, P149, DOI 10.1016/S0301-0082(98)00034-3; Stys PK, 2012, NAT REV NEUROSCI, V13, P507, DOI 10.1038/nrn3275; Sun PL, 2014, J MOL NEUROSCI, V52, P225, DOI 10.1007/s12031-013-0126-1; Takano T, 2009, STROKE, V40, pS8, DOI 10.1161/STROKEAHA.108.533166; Tan IJ, 2015, AUTOIMMUN REV, V14, P536, DOI 10.1016/j.autrev.2015.02.004; TAOCHENG JH, 1987, J NEUROSCI, V7, P3293; Theien BE, 2003, BLOOD, V102, P4464, DOI 10.1182/blood-2003-03-0974; Trager U, 2013, J MOL MED, V91, P673, DOI 10.1007/s00109-013-1026-0; ULVESTAD E, 1994, J LEUKOCYTE BIOL, V56, P732; van der Star BJ, 2012, CNS NEUROL DISORD-DR, V11, P570, DOI 10.2174/187152712801661284; Vegeto E, 2003, P NATL ACAD SCI USA, V100, P9614, DOI 10.1073/pnas.1531957100; Vegeto E, 2006, ENDOCRINOLOGY, V147, P2263, DOI 10.1210/en.2005-1330; Velasco I, 2011, CURR TOP MED CHEM, V11, P1684, DOI 10.2174/156802611796117586; Vella J, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00108; Voskuhl RR, 2009, J NEUROSCI, V29, P11511, DOI 10.1523/JNEUROSCI.1514-09.2009; Whitacre CC, 2001, NAT IMMUNOL, V2, P777, DOI 10.1038/ni0901-777; Woodcock T, 2013, FRONT NEUROL, V4, DOI 10.3389/fneur.2013.00018; Wu WF, 2013, P NATL ACAD SCI USA, V110, P3543, DOI 10.1073/pnas.1300313110; Xiao L, 2012, GLIA, V60, P1037, DOI 10.1002/glia.22333; Ye JN, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0054590; YEDNOCK TA, 1992, NATURE, V356, P63, DOI 10.1038/356063a0; Yu ZW, 2015, J NEUROSCI, V35, P6350, DOI 10.1523/JNEUROSCI.2468-14.2015; Zendedel A, 2015, J NEUROIMMUNOL, V278, P200, DOI 10.1016/j.jneuroim.2014.11.007; Zendedel A, 2013, J MOL NEUROSCI, V51, P567, DOI 10.1007/s12031-013-0026-4; Zhao YX, 2010, NEUROTHERAPEUTICS, V7, P439, DOI 10.1016/j.nurt.2010.07.004; Zindler E, 2010, BEST PRACT RES-CLIN, V24, P551, DOI 10.1016/j.bpa.2010.11.001	223	22	23	0	11	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0149-7634	1873-7528		NEUROSCI BIOBEHAV R	Neurosci. Biobehav. Rev.	AUG	2016	67						125	136		10.1016/j.neubiorev.2015.11.016			12	Behavioral Sciences; Neurosciences	Behavioral Sciences; Neurosciences & Neurology	DS2QD	WOS:000380627700011	26698019				2021-06-18	
J	Marfia, G; Navone, SE; Hadi, LA; Paroni, M; Berno, V; Beretta, M; Gualtierotti, R; Ingegnoli, F; Levi, V; Miozzo, M; Geginat, J; Fassina, L; Rampini, P; Tremolada, C; Riboni, L; Campanella, R				Marfia, Giovanni; Navone, Stefania Elena; Hadi, Loubna Abdel; Paroni, Moira; Berno, Valeria; Beretta, Matteo; Gualtierotti, Roberta; Ingegnoli, Francesca; Levi, Vincenzo; Miozzo, Monica; Geginat, Jens; Fassina, Lorenzo; Rampini, Paolo; Tremolada, Carlo; Riboni, Laura; Campanella, Rolando			The Adipose Mesenchymal Stem Cell Secretome Inhibits Inflammatory Responses of Microglia: Evidence for an Involvement of Sphingosine-1-Phosphate Signalling	STEM CELLS AND DEVELOPMENT			English	Article							TRAUMATIC BRAIN-INJURY; SPHINGOSINE KINASE 1; SPINAL-CORD-INJURY; MULTIPLE-SCLEROSIS; REGENERATIVE MEDICINE; NONENZYMATIC METHOD; FINGOLIMOD FTY720; STROMAL CELLS; NITRIC-OXIDE; TISSUE	Central nervous system (CNS) inflammation is primarily driven by microglial cells which secrete proinflammatory cytokines and undergo proliferation upon activation, as it occurs in neurodegenerative diseases. Uncontrolled or prolonged CNS inflammation is potentially harmful and can result in cellular damage. Recently, many studies have focused on human adipose tissue as an attractive source of cytokines with immunosuppressive properties that potentially modulate inflammation. Our study aimed to evaluate if different methods of human tissue collection could affect adipose mesenchymal stem cell (ADSC)-derived cytokine secretion and investigate the effects of ADSC secretome in modulating microglia activation and the possible implication of sphingosine-1-phosphate (S1P) in these effects. Our results demonstrate that the conditioned medium (CM) of ADSCs isolated by two different processing methods (lipoaspirate and Lipogems) significantly inhibited the lipopolysaccharide (LPS)-induced effects on microglia activation, including microglial expression of CD68, cytokine secretion, proliferation, and migration. Pulse studies with radiolabeled sphingosine demonstrated that LPS treatment of resting microglia induced a significant increase of both cellular and extracellular S1P. Moreover, and of relevance, FTY720, a functional antagonist of S1P receptor, inhibited the multiple LPS-induced proinflammatory effects on microglia, and S1P suppressed the anti-inflammatory effect of ADSC-CM. This suggests that LPS-mediated microglial activation is countered by ADSC-CM through the modulation of sphingosine kinase/S1P signalling.	[Marfia, Giovanni; Navone, Stefania Elena; Beretta, Matteo; Levi, Vincenzo; Rampini, Paolo; Campanella, Rolando] Univ Milan, Lab Expt Neurosurg & Cell Therapy, Neurosurg Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Francesco Sforza 35, I-20122 Milan, Italy; [Hadi, Loubna Abdel; Riboni, Laura] Univ Milan, LITA Segrate, Dept Med Biotechnol & Translat Med, Milan, Italy; [Paroni, Moira; Berno, Valeria; Geginat, Jens] Ist Nazl Genet Mol Romeo & Enrica Invernizzi, Milan, Italy; [Gualtierotti, Roberta; Ingegnoli, Francesca] Ist Gaetano Pini, Div Rheumatol, Milan, Italy; [Miozzo, Monica] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Div Pathol, Milan, Italy; [Fassina, Lorenzo] Univ Pavia, Dept Hlth Sci & Ind & Informat Engn, Pavia, Italy; [Tremolada, Carlo] Ist Image, Milan, Italy	Marfia, G (corresponding author), Univ Milan, Lab Expt Neurosurg & Cell Therapy, Neurosurg Unit, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Via Francesco Sforza 35, I-20122 Milan, Italy.	giovanni.marfia@unimi.it	Marfia, Giovanni/AAB-8702-2020; Campanella, Rolando/AAB-8998-2019; Marfia, Giovanni/N-4650-2014; navone, stefania/Y-4779-2019; Ingegnoli, Francesca/B-6226-2017; Gualtierotti, Roberta/V-5991-2019; tremolada, Carlo f m/AAN-8027-2020; Berno, Valeria/AAN-3997-2020; navone, stefania e/K-7264-2016; Riboni, Laura/R-4281-2017; Levi, Vincenzo/AAB-9294-2019; Campanella, Rolando/T-9814-2017; Gualtierotti, Roberta/Q-8425-2016; Geginat, Jens/AAA-5818-2019; Paroni, Moira/K-6470-2016; Fassina, Lorenzo/K-9283-2015	Marfia, Giovanni/0000-0002-5849-7000; Marfia, Giovanni/0000-0002-5849-7000; navone, stefania/0000-0002-0097-9146; Ingegnoli, Francesca/0000-0002-6727-1273; Gualtierotti, Roberta/0000-0001-6465-7624; Berno, Valeria/0000-0001-5848-494X; navone, stefania e/0000-0002-0097-9146; Riboni, Laura/0000-0002-4149-8226; Levi, Vincenzo/0000-0003-2713-6357; Campanella, Rolando/0000-0001-8382-1776; Gualtierotti, Roberta/0000-0001-6465-7624; Geginat, Jens/0000-0003-4813-0384; Paroni, Moira/0000-0001-8199-3128; Miozzo, Monica/0000-0002-6523-4575; Abdel Hadi, loubna/0000-0002-5271-0798; Fassina, Lorenzo/0000-0002-5587-4632	IRCCS Foundation Ca' Granda Ospedale Policlinico Milan and Universita degli Studi di Milano, Italy	This work was supported by IRCCS Foundation Ca' Granda Ospedale Policlinico Milan and Universita degli Studi di Milano, Italy. The authors thank Dr. Clara Di Vito for performing ELISAs, Dr. Letizia Venturini for assessing immunofluorescent analyses, and Prof. Giovanni Ricevuti for critical reviewing of the article.	Anelli V, 2005, J NEUROCHEM, V92, P1204, DOI 10.1111/j.1471-4159.2004.02955.x; Anthony DC, 2010, MULT SCLER S10, V16, pS283; AOKI M, 2016, MEDIAT INFLAMM, V2016; Bianchi F, 2013, CELL TRANSPLANT, V22, P2063, DOI 10.3727/096368912X657855; Brinkmann V, 2010, NAT REV DRUG DISCOV, V9, P883, DOI 10.1038/nrd3248; Buehrer Benjamin M, 2013, Methods Mol Biol, V1001, P1, DOI 10.1007/978-1-62703-363-3_1; Carelli S, 2015, CELL TRANSPLANT, V24, P1233, DOI 10.3727/096368914X681603; Chan TM, 2014, CELL TRANSPLANT, V23, P541, DOI 10.3727/096368914X678409; Choi JW, 2011, P NATL ACAD SCI USA, V108, P751, DOI 10.1073/pnas.1014154108; Czech B, 2009, BIOCHEM BIOPH RES CO, V389, P251, DOI 10.1016/j.bbrc.2009.08.142; Dossena M, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0112746; Elahi KC, 2016, STEM CELLS INT, V2016, DOI 10.1155/2016/5646384; Fain JN, 2006, VITAM HORM, V74, P443, DOI 10.1016/S0083-6729(06)74018-3; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Franquesa M, 2015, STEM CELLS, V33, P880, DOI 10.1002/stem.1881; GIORI A, 2015, CELLR4, V3, pE1544; Giri RK, 2003, J IMMUNOL, V170, P5281, DOI 10.4049/jimmunol.170.10.5281; Giunti D, 2012, STEM CELLS, V30, P2044, DOI 10.1002/stem.1174; Gonzalez-Scarano F, 1999, ANNU REV NEUROSCI, V22, P219, DOI 10.1146/annurev.neuro.22.1.219; Gutierrez-Fernandez M, 2015, EXPERT OPIN BIOL TH, V15, P873, DOI 10.1517/14712598.2015.1040386; Hanisch UK, 2002, GLIA, V40, P140, DOI 10.1002/glia.10161; Hla T, 2004, SEMIN CELL DEV BIOL, V15, P513, DOI 10.1016/j.semcdb.2004.05.002; Jackson SJ, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-76; Jiang LX, 2010, STEM CELLS DEV, V19, P221, DOI 10.1089/scd.2009.0170; Jose S, 2014, J NEUROINFLAMM, V11, DOI 10.1186/s12974-014-0149-8; Kapur SK, 2013, BIOCHIMIE, V95, P2222, DOI 10.1016/j.biochi.2013.06.001; Kimura A, 2007, STEM CELLS, V25, P115, DOI 10.1634/stemcells.2006-0223; Kitatani K, 2016, MEDIAT INFLAMM, V2016, DOI 10.1155/2016/7602526; Kolar MK, 2014, STEM CELLS DEV, V23, P1659, DOI 10.1089/scd.2013.0416; Konsman JP, 2007, CLIN SCI, V112, P1, DOI 10.1042/CS20060043; Lin HY, 2011, J NEUROINFLAMM, V8, DOI 10.1186/1742-2094-8-13; Liu Y, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-135; Marfia G, 2014, ARTHRITIS RES THER, V16, DOI 10.1186/s13075-014-0457-5; Marfia G, 2015, STEM CELLS DEV, V24, P320, DOI 10.1089/scd.2014.0282; Marfia G, 2014, GLIA, V62, P1968, DOI 10.1002/glia.22718; Masgutov RF, 2015, CLIN EXP MED, V6, P1; McGeer EG, 2007, CNS DRUGS, V21, P789, DOI 10.2165/00023210-200721100-00001; McIntosh KR, 2013, EXPERT REV CLIN IMMU, V9, P175, DOI [10.1586/ECI.12.96, 10.1586/eci.12.96]; Mehling M, 2011, NEUROLOGY, V76, pS20, DOI 10.1212/WNL.0b013e31820db341; Montelatici E, 2015, BIOCHEM CELL BIOL, V93, P74, DOI 10.1139/bcb-2014-0094; Morganti-Kossmann MC, 2002, CURR OPIN CRIT CARE, V2, P101; Navone SE, 2014, STEM CELL RES THER, V5, DOI 10.1186/scrt396; Nayak D, 2010, NEUROSCIENCE, V166, P132, DOI 10.1016/j.neuroscience.2009.12.020; Neubrand VE, 2014, GLIA, V62, P1932, DOI 10.1002/glia.22714; Nimmerjahn A, 2005, SCIENCE, V308, P1314, DOI 10.1126/science.1110647; Ooi YY, 2015, NEUROIMMUNOMODULAT, V22, P233, DOI 10.1159/000365483; Qin JB, 2012, INT J NANOMED, V7, P5191, DOI 10.2147/IJN.S35647; Ransohoff RM, 2009, ANNU REV IMMUNOL, V27, P119, DOI 10.1146/annurev.immunol.021908.132528; Riazi Ali M., 2009, V482, P55, DOI 10.1007/978-1-59745-060-7_5; Riboni L, 2000, METHOD ENZYMOL, V311, P656; Riboni L, 2001, J BIOL CHEM, V276, P12797, DOI 10.1074/jbc.M011570200; Safford KA, 2005, CURR DRUG TARGETS, V6, P57, DOI 10.2174/1389450053345028; SAWADA M, 1990, BRAIN RES, V509, P119, DOI 10.1016/0006-8993(90)90317-5; Schilling T, 2002, NEUROSCIENCE, V109, P827, DOI 10.1016/S0306-4522(01)00534-6; Shah FS, 2013, CYTOTHERAPY, V15, P979, DOI 10.1016/j.jcyt.2013.04.001; Soliven B, 2011, NEUROLOGY, V76, pS9, DOI 10.1212/WNL.0b013e31820d9507; Streit WJ, 2000, J NEUROSCI RES, V61, P10, DOI 10.1002/1097-4547(20000701)61:1<10::AID-JNR2>3.0.CO;2-E; Tajiri N, 2014, J NEUROSCI, V34, P313, DOI 10.1523/JNEUROSCI.2425-13.2014; Tham CS, 2003, INT J DEV NEUROSCI, V21, P431, DOI 10.1016/j.ijdevneu.2003.09.003; Tremolada C, 2015, EUR J MUSC DIS, V3, P2; Wei X, 2009, STEM CELLS, V27, P478, DOI 10.1634/stemcells.2008-0333; Wei Y, 2011, ANN NEUROL, V69, P119, DOI 10.1002/ana.22186; Yan K, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0084116; Yeh DC, 2015, CELL TRANSPLANT, V24, P487, DOI 10.3727/096368915X686940; Yoshimura K, 2006, J CELL PHYSIOL, V208, P64, DOI 10.1002/jcp.20636; Zhang ZY, 2007, J CELL MOL MED, V11, P307, DOI 10.1111/j.1582-4934.2007.00019.x; Zhi L, 2006, J CELL PHYSL, V208, P109; Zuk PA, 2002, MOL BIOL CELL, V13, P4279, DOI 10.1091/mbc.E02-02-0105	68	22	23	1	7	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	1547-3287	1557-8534		STEM CELLS DEV	Stem Cells Dev.	JUL 15	2016	25	14					1095	1107		10.1089/scd.2015.0268			13	Cell & Tissue Engineering; Hematology; Medicine, Research & Experimental; Transplantation	Cell Biology; Hematology; Research & Experimental Medicine; Transplantation	DR0QD	WOS:000379611100006	27217090				2021-06-18	
J	Howell, DR; Osternig, LR; Christie, AD; Chou, LS				Howell, David R.; Osternig, Louis R.; Christie, Anita D.; Chou, Li-Shan			Return to Physical Activity Timing and Dual-Task Gait Stability Are Associated 2 Months Following Concussion	JOURNAL OF HEAD TRAUMA REHABILITATION			English	Article						cerebral concussion; locomotion; mild traumatic brain injury; physical activity; postural balance; recovery; rehabilitation	SPORTS-RELATED CONCUSSION; BALANCE CONTROL; HIGH-SCHOOL; ADOLESCENTS; STATEMENT; PLAY; PERFORMANCE; MANAGEMENT; ATTENTION; PARADIGM	Objective: The effect of physical activity resumption on functional recovery following concussion is poorly understood. We sought to examine the relationship between physical activity resumption timing and gait stability 2 months following concussion. Setting: Motion analysis laboratory. Participants: Twenty-nine individuals who sustained a concussion and were subsequently allowed to return to preinjury levels of physical activity within 2 months postinjury. Design: Prospective cohort study. Main Measures: The return-to-activity day (RTA-day) was identified as the first day postinjury that each participant was medically cleared to resume regular physical activity. Whole-body center-of-mass (COM) motion during single-task and dual-task walking was assessed 2 months postinjury. Correlation coefficients were calculated between the RTA-day and single/dual-task gait stability as well as symptom severity measurements 2 months postinjury. Results: Dual-task medial-lateral COM displacement (r = -0.52, P = .004) and peak medial-lateral COM velocity (r = -0.37, P = .048) were significantly correlated with RTA-day. Dual-task peak forward velocity and single-task gait stability measures were not significantly correlated with RTA-day. Conclusions: The time of RTA-day clearance, within a 2 months postinjury period, is significantly correlated with dual-task medial-lateral gait stability measured at the end of that period, suggesting that frontal plane gait stability recovery is sensitive to the timing of RTA-day.	[Howell, David R.] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Howell, David R.] Childrens Hosp Boston, Dept Orthoped, Div Sports Med, Boston, MA USA; [Osternig, Louis R.; Christie, Anita D.; Chou, Li-Shan] Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA	Chou, LS (corresponding author), Univ Oregon, Dept Human Physiol, 122 Esslinger Hall,1240 Univ Oregon, Eugene, OR 97403 USA.	chou@uoregon.edu		Howell, David/0000-0002-2955-0191	Translational Research Award from the University of Oregon; Peace Health Oregon Region, the Department of Defense-TATRC Award [W81XWH-11-1-0717]; Eugene; Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology	This work was supported in part by the Translational Research Award from the University of Oregon and Peace Health Oregon Region, the Department of Defense-TATRC Award (W81XWH-11-1-0717), and the Eugene and Clarissa Evonuk Memorial Graduate Fellowship in Environmental, Cardiovascular, or Stress Physiology.	Baker CS, 2014, PHYSIOL REP, V2, DOI 10.14814/phy2.12252; Barr WB, 2012, BRAIN INJURY, V26, P58, DOI 10.3109/02699052.2011.608216; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Broglio SP, 2014, J ATHL TRAINING, V49, P245, DOI 10.4085/1062-6050-49.1.07; Buckley TA, 2013, GAIT POSTURE, V38, P549, DOI 10.1016/j.gaitpost.2013.02.008; Carson JD, 2014, CAN FAM PHYSICIAN, V60, pE310; Catena RD, 2007, EXP BRAIN RES, V176, P23, DOI 10.1007/s00221-006-0596-2; Dettwiler A, 2014, J NEUROTRAUM, V31, P180, DOI 10.1089/neu.2013.2983; Doolan AW, 2012, ANN BIOMED ENG, V40, P106, DOI 10.1007/s10439-011-0413-3; Fait P, 2013, J HEAD TRAUMA REHAB, V28, P293, DOI 10.1097/HTR.0b013e3182407ace; Feddermann-Demont N, 2014, J SPORT SCI, V32, P1217, DOI 10.1080/02640414.2014.918273; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Guskiewicz KM, 2013, BRIT J SPORT MED, V47, P289, DOI 10.1136/bjsports-2013-092225; Hahn ME, 2004, J BIOMECH, V37, P837, DOI 10.1016/j.jbiomech.2003.11.010; Hahn ME, 2003, CLIN BIOMECH, V18, P737, DOI 10.1016/S0268-0033(03)00139-6; Harmon KG, 2013, BRIT J SPORT MED, V47, P15, DOI 10.1136/bjsports-2012-091941; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Howell DR, 2015, MED SCI SPORT EXER, V47, P673, DOI 10.1249/MSS.0000000000000462; Howell DR, 2015, AM J SPORT MED, V43, P625, DOI 10.1177/0363546514560994; Howell DR, 2014, EXP BRAIN RES, V232, P1773, DOI 10.1007/s00221-014-3869-1; Howell DR, 2013, ARCH PHYS MED REHAB, V94, P1513, DOI 10.1016/j.apmr.2013.04.015; Lee H, 2013, J SCI MED SPORT, V16, P2, DOI 10.1016/j.jsams.2012.03.013; Mayers L, 2012, CURR SPORT MED REP, V11, P277, DOI 10.1249/JSR.0b013e318272bbba; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Miller NR, 2014, BRAIN INJURY, V28, P1270, DOI 10.3109/02699052.2014.915987; Parker TM, 2006, MED SCI SPORT EXER, V38, P1032, DOI 10.1249/01.mss.0000222828.56982.a4; Powers KC, 2014, BRAIN INJURY, V28, P465, DOI 10.3109/02699052.2014.888759; Powers KC, 2014, GAIT POSTURE, V39, P611, DOI 10.1016/j.gaitpost.2013.05.026; Prichep LS, 2013, J HEAD TRAUMA REHAB, V28, P266, DOI 10.1097/HTR.0b013e318247b54e; Register-Mihalik JK, 2013, NEUROPSYCHOL REV, V23, P300, DOI 10.1007/s11065-013-9238-1; Register-Mihalik JK, 2013, J HEAD TRAUMA REHAB, V28, P274, DOI 10.1097/HTR.0b013e3182585d37; Rosenthal JA, 2014, AM J SPORT MED, V42, P1710, DOI 10.1177/0363546514530091; Ross LM, 2011, J SPORT REHABIL, V20, P296, DOI 10.1123/jsr.20.3.296; Teel EF, 2014, CLIN NEUROPHYSIOL, V125, P703, DOI 10.1016/j.clinph.2013.08.027; Weinberg S. L., 2002, DATA ANAL BEHAV SCI, P136; Winter D. A., 2009, BIOMECHANICS MOTOR C, P86, DOI 10.1002/9780470549148	36	22	22	0	20	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0885-9701	1550-509X		J HEAD TRAUMA REHAB	J. Head Trauma Rehabil.	JUL-AUG	2016	31	4					262	268		10.1097/HTR.0000000000000176			7	Clinical Neurology; Rehabilitation	Neurosciences & Neurology; Rehabilitation	DR3FW	WOS:000379789000011	26291630				2021-06-18	
J	Lee, JH; Wei, L; Gu, XH; Won, SM; Wei, ZZ; Dix, TA; Yu, SP				Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Won, Soonmi; Wei, Zheng Zachory; Dix, Thomas A.; Yu, Shan Ping			Improved Therapeutic Benefits by Combining Physical Cooling With Pharmacological Hypothermia After Severe Stroke in Rats	STROKE			English	Article						cell death; hypothermia; middle cerebral artery; neurotensin receptor 1; shivering; stroke	TRAUMATIC BRAIN-INJURY; ACUTE ISCHEMIC-STROKE; EMERGING ROLE; TEMPERATURE; INDUCTION; HEMORRHAGE; MANAGEMENT; REVERSAL; ANALOGS; SAFETY	Background and Purpose-Therapeutic hypothermia is a promising strategy for treatment of acute stroke. Clinical translation of therapeutic hypothermia, however, has been hindered because of the lack of efficiency and adverse effects. We sought to enhance the clinical potential of therapeutic hypothermia by combining physical cooling (PC) with pharmacologically induced hypothermia after ischemic stroke. Methods-Wistar rats were subjected to 90-minute middle cerebral artery occlusion by insertion of an intraluminal filament. Mild-to-moderate hypothermia was induced 120 minutes after the onset of stroke by PC alone, a neurotensin receptor 1 (NTR1) agonist HPI-201 (formally ABS-201) alone or the combination of both. The outcomes of stroke were evaluated at 3 and 21 days after stroke. Results-PC or HPI-201 each showed hypothermic effect and neuroprotection in stroke rats. The combination of PC and HPI-201 exhibited synergistic effects in cooling process, reduced infarct formation, cell death, and blood-brain barrier damages and improved functional recovery after stroke. Importantly, coapplied HPI-201 completely inhibited PC-associated shivering and tachycardia. Conclusions-The centrally acting hypothermic drug HPI-201 greatly enhanced the efficiency and efficacy of conventional PC; this combined cooling therapy may facilitate clinical translation of hypothermic treatment for stroke.	[Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Won, Soonmi; Wei, Zheng Zachory; Yu, Shan Ping] Emory Univ, Sch Med, Dept Anesthesiol, Atlanta, GA 30322 USA; [Wei, Ling] Emory Univ, Sch Med, Dept Neurol, Atlanta, GA 30322 USA; [Lee, Jin Hwan; Wei, Ling; Gu, Xiaohuan; Wei, Zheng Zachory; Yu, Shan Ping] Atlanta VA Med Ctr, Ctr Visual & Neurocognit Rehabil, Decatur, GA USA; [Dix, Thomas A.] JT Pharmaceut, Mt Pleasant, SC USA; [Dix, Thomas A.] Med Univ South Carolina, Dept Drug Discovery & Biomed Sci, Charleston, SC 29425 USA	Yu, SP (corresponding author), Emory Univ, Sch Med, 101 Woodruff Circle,Woodruff Mem Res Bldg, Atlanta, GA 30322 USA.	spyu@emory.edu	Wei, Zheng Zachory/I-2109-2019	Wei, Zheng Zachory/0000-0001-7682-9286	American Heart Association (AHA)American Heart Association [12GRNT12060222, 14POST20130024, 15POST25680013, 15POST25710112]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [NS090529, NS062097, NS075338, NS085568]; Veteran Affair (VA) National Merit Grant [RX000666]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [R01NS085568, R01NS057255] Funding Source: NIH RePORTER; Veterans AffairsUS Department of Veterans Affairs [I01RX000666] Funding Source: NIH RePORTER	This investigation was supported by American Heart Association (AHA) Grants 12GRNT12060222 (Dr Yu), 14POST20130024 (Dr Won), 15POST25680013 (Dr Lee), 15POST25710112 (Dr Wei), National Institutes of Health (NIH) grants NS090529 (Dr Dix/Dr Yu), NS062097 (Dr Wei), NS075338 (Dr Wei), NS085568 (Dr Wei/ Dr Yu), and a Veteran Affair (VA) National Merit Grant RX000666 (Dr Yu).	Choi KE, 2012, FASEB J, V26, P2799, DOI 10.1096/fj.11-201822; Dae MW, 2003, STROKE, V34, P734, DOI 10.1161/01.STR.0000057461.56040.FE; Daniele Ornella, 2002, J Stroke Cerebrovasc Dis, V11, P28, DOI 10.1053/jscd.2002.123972; Feigin V, 2003, LANCET NEUROL, V2, P529, DOI 10.1016/S1474-4422(03)00500-3; Feigin VL, 2002, J CLIN NEUROSCI, V9, P502, DOI 10.1054/jocn.2001.1072; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Hadden MK, 2005, NEUROPHARMACOLOGY, V49, P1149, DOI 10.1016/j.neuropharm.2005.06.010; Hajat C, 2000, STROKE, V31, P410, DOI 10.1161/01.STR.31.2.410; Hemmen TM, 2007, STROKE, V38, P794, DOI 10.1161/01.STR.0000247920.15708.fa; Inderbitzen B, 2002, NEUROSURGERY, V50, P364, DOI 10.1097/00006123-200202000-00023; Katz LM, 2004, BRAIN RES, V1017, P85, DOI 10.1016/j.brainres.2004.05.020; Kim JY, 2011, TRANSL STROKE RES, V2, P195, DOI 10.1007/s12975-011-0082-4; Lee JH, 2015, AM J PHYSIOL-CELL PH, V308, pC570, DOI 10.1152/ajpcell.00353.2014; Lee JH, 2014, J NEUROTRAUM, V31, P1417, DOI 10.1089/neu.2013.3251; Leker RR, 2003, STROKE, V34, P2000, DOI 10.1161/01.STR.0000079817.68944.1E; Lenhardt R, 2009, ANESTHESIOLOGY, V111, P110, DOI 10.1097/ALN.0b013e3181a979a3; MARTIN GE, 1980, PEPTIDES, V1, P333, DOI 10.1016/0196-9781(80)90011-X; Morrison SF, 2011, FRONT BIOSCI-LANDMRK, V16, P74, DOI 10.2741/3677; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; Mrozek S, 2012, ANESTHESIOL RES PRAC, V2012, DOI 10.1155/2012/989487; Nichols C, 2010, J NEUROINTERV SURG, V2, P67, DOI 10.1136/jnis.2009.001768; Orwig KS, 2009, J MED CHEM, V52, P1803, DOI 10.1021/jm801072v; Polderman KH, 2004, INTENS CARE MED, V30, P757, DOI 10.1007/s00134-003-2151-y; Presciutti M, 2012, CRIT CARE NURSE, V32, P33, DOI 10.4037/ccn2012189; Schwab S, 1998, ACT NEUR S, V71, P131; Sessler DI, 2009, CRIT CARE MED, V37, pS203, DOI 10.1097/CCM.0b013e3181aa5568; SWANSON RA, 1990, J CEREBR BLOOD F MET, V10, P290, DOI 10.1038/jcbfm.1990.47; Torok E, 2009, NEUROSURGERY, V65, P352, DOI 10.1227/01.NEU.0000345632.09882.FF; van der Worp HB, 2007, BRAIN, V130, P3063, DOI 10.1093/brain/awm083; van der Worp HB, 2010, J CEREBR BLOOD F MET, V30, P1079, DOI 10.1038/jcbfm.2010.44; Wang Y, 2000, STROKE, V31, P404, DOI 10.1161/01.STR.31.2.404; Wei L, 2005, NEUROBIOL DIS, V19, P183, DOI 10.1016/j.nbd.2004.12.016; Wei S, 2013, NEUROSCIENCE, V252, P489, DOI 10.1016/j.neuroscience.2013.07.052; Yenari MA, 2012, NAT REV NEUROSCI, V13, P267, DOI 10.1038/nrn3174; Zhang HF, 2008, BRAIN RES, V1198, P182, DOI 10.1016/j.brainres.2008.01.007; Zhang MJ, 2013, J CEREBR BLOOD F MET, V33, P157, DOI 10.1038/jcbfm.2012.146	36	22	23	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0039-2499	1524-4628		STROKE	Stroke	JUL	2016	47	7					1907	1913		10.1161/STROKEAHA.116.013061			7	Clinical Neurology; Peripheral Vascular Disease	Neurosciences & Neurology; Cardiovascular System & Cardiology	DR4AX	WOS:000379844900048	27301934	Green Accepted, Other Gold, Green Published			2021-06-18	
J	Root, JM; Zuckerbraun, NS; Wang, L; Winger, DG; Brent, D; Kontos, A; Hickey, RW				Root, Jeremy M.; Zuckerbraun, Noel S.; Wang, Li; Winger, Daniel G.; Brent, David; Kontos, Anthony; Hickey, Robert W.			History of Somatization Is Associated with Prolonged Recovery from Concussion	JOURNAL OF PEDIATRICS			English	Article							TRAUMATIC BRAIN-INJURY; SPORT-RELATED CONCUSSION; FUNCTIONAL SOMATIC SYMPTOMS; ABDOMINAL-PAIN; HIGH-SCHOOL; CHILDREN; MILD; PREDICTORS; ADOLESCENTS; SLEEP	Objective To determine the association between a history of somatization and prolonged concussion symptoms, including sex differences in recovery. Study design A prospective cohort study of 10- to 18-year-olds with an acute concussion was conducted from July 2014 to April 2015 at a tertiary care pediatric emergency department. One hundred twenty subjects completed the validated Children's Somatization Inventory (CSI) for pre-injury somatization assessment and Postconcussion Symptoms Scale (PCSS) at diagnosis. PCSS was re-assessed by phone at 2 and 4 weeks. CSI was assessed in quartiles with a generalized estimating equation model to determine relationship of CSI to PCSS over time. Results The median age of our study participants was 13.8 years (IQR 11.5, 15.8), 60% male, with separate analyses for each sex. Our model showed a positive interaction between total CSI score, PCSS and time from concussion for females P < .01, and a statistical trend for males, P = .058. Females in the highest quartile of somatization had higher PCSS than the other 3 CSI quartiles at each time point (B - 26.7 to - 41.1, P values < . 015). Conclusions Patients with higher pre-injury somatization had higher concussion symptom scores over time. Females in the highest somatization quartile had prolonged concussion recovery with persistently high symptom scores at 4 weeks. Somatization may contribute to sex differences in recovery, and assessment at the time of concussion may help guide management and target therapy.	[Root, Jeremy M.] Childrens Natl Med Ctr, Emergency Med & Trauma Serv, 111 Michigan Ave NW, Washington, DC 20010 USA; [Zuckerbraun, Noel S.; Hickey, Robert W.] Childrens Hosp Pittsburgh, Dept Pediat, Div Pediat Emergency Med, Pittsburgh, PA 15213 USA; [Wang, Li; Winger, Daniel G.] Univ Pittsburgh, Off Clin Res, Hlth Sci, Pittsburgh, PA USA; [Brent, David] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA; [Kontos, Anthony] Univ Pittsburgh, Dept Orthopaed Surg, Pittsburgh, PA USA	Root, JM (corresponding author), Childrens Natl Med Ctr, Emergency Med & Trauma Serv, 111 Michigan Ave NW, Washington, DC 20010 USA.	jroot@childrensnational.org		Root, Jeremy/0000-0003-2650-6889; Kontos, Anthony/0000-0002-3749-4310	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [UL1TR000005]; University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders [1K01DC012332-01A1]; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000005] Funding Source: NIH RePORTER; NATIONAL INSTITUTE ON DEAFNESS AND OTHER COMMUNICATION DISORDERSUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute on Deafness & Other Communication Disorders (NIDCD) [K01DC012332] Funding Source: NIH RePORTER	Supported by the National Institutes of Health (UL1TR000005 [to L.W. and D.W.]). A.K. is supported by the University of Pittsburgh from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1). The authors declare no conflicts of interest.	Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2013, J INT NEUROPSYCH SOC, V19, P145, DOI 10.1017/S135561771200104X; Barsky AJ, 2001, J GEN INTERN MED, V16, P266, DOI 10.1046/j.1525-1497.2001.016004266.x; Bastien CH, 2001, SLEEP MED, V2, P297, DOI 10.1016/S1389-9457(00)00065-4; BOHNEN NJ, 1995, J NEUROL REHABIL, V9, P33; Campo JV, 2012, J CHILD PSYCHOL PSYC, V53, P575, DOI 10.1111/j.1469-7610.2012.02535.x; CAMPO JV, 1994, J AM ACAD CHILD PSY, V33, P1223, DOI 10.1097/00004583-199411000-00003; Covassin T, 2013, AM J SPORT MED, V41, P2890, DOI 10.1177/0363546513509962; Covassin T, 2012, AM J SPORT MED, V40, P1303, DOI 10.1177/0363546512444554; ERNST AR, 1984, J PEDIATR PSYCHOL, V9, P77, DOI 10.1093/jpepsy/9.1.77; Essau C. A., 2013, FRONT PUBLIC HEALTH, V1, P1, DOI DOI 10.3389/FPUBH.2013.00072; Fearon I, 1996, PAIN, V68, P55, DOI 10.1016/S0304-3959(96)03200-9; Garber J., 1991, PSYCHOL ASSESS, V3, P588, DOI DOI 10.1037/1040-3590.3.4.588; Guskiewicz KM, 2003, JAMA-J AM MED ASSOC, V290, P2549, DOI 10.1001/jama.290.19.2549; Henry LC, 2016, NEUROSURGERY, V78, P232, DOI 10.1227/NEU.0000000000001041; Janssens KAM, 2014, J PEDIATR-US, V164, P900, DOI 10.1016/j.jpeds.2013.12.003; Kirkwood MW, 2014, PEDIATRICS, V133, P643, DOI 10.1542/peds.2013-3195; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; LISHMAN WA, 1988, BRIT J PSYCHIAT, V153, P460, DOI 10.1192/bjp.153.4.460; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Lovell MR, 2003, IMMEDIATE POSTCONCUS; McClure DJ, 2014, AM J SPORT MED, V42, P472, DOI 10.1177/0363546513510389; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2013, J ATHL TRAINING, V48, P554, DOI 10.4085/1062-6050-48.4.05; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Meehan WP, 2013, J PEDIATR-US, V163, P721, DOI 10.1016/j.jpeds.2013.03.012; Meehan WP, 2010, AM J SPORT MED, V38, P2405, DOI 10.1177/0363546510376737; Mihalik JP, 2013, CLIN J SPORT MED, V23, P343, DOI 10.1097/JSM.0b013e318295a834; Mollayeva T, 2015, SLEEP MED; Postilnik I, 2006, J CAN ACAD CHILD ADO, V15, P64; Sim A, 2008, J NEUROSURG, V108, P511, DOI 10.3171/JNS/2008/108/3/0511; Sufrinko A, 2015, AM J SPORT MED, V43, P830, DOI 10.1177/0363546514566193; Taddio A, 2002, JAMA-J AM MED ASSOC, V288, P857, DOI 10.1001/jama.288.7.857; Taddio A, 2009, PEDIATRICS, V123, pe425, DOI 10.1542/peds.2008-3028; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; WALKER L, 2003, MANUAL CHILDRENS SOM; WALKER LS, 1991, J ABNORM CHILD PSYCH, V19, P379, DOI 10.1007/BF00919084; Walker LS, 2009, J PEDIATR PSYCHOL, V34, P430, DOI 10.1093/jpepsy/jsn093; Yeates Keith Owen, 2005, Pediatr Rehabil, V8, P5; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008	41	22	22	0	7	MOSBY-ELSEVIER	NEW YORK	360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA	0022-3476	1097-6833		J PEDIATR-US	J. Pediatr.	JUL	2016	174						39	+		10.1016/j.jpeds.2016.03.020			7	Pediatrics	Pediatrics	DP6PX	WOS:000378620800010	27059916	Green Accepted			2021-06-18	
J	Chelly, J; Deye, N; Guichard, JP; Vodovar, D; Vong, L; Jochmans, S; Thieulot-Rolin, N; Sy, O; Serbource-Goguel, J; Vinsonneau, C; Megarbane, B; Vivien, B; Tazarourte, K; Monchi, M				Chelly, Jonathan; Deye, Nicolas; Guichard, Jean-Pierre; Vodovar, Dominique; Ly Vong; Jochmans, Sebastien; Thieulot-Rolin, Nathalie; Sy, Oumar; Serbource-Goguel, Jean; Vinsonneau, Christophe; Megarbane, Bruno; Vivien, Benoit; Tazarourte, Karim; Monchi, Merhan			The optic nerve sheath diameter as a useful tool for early prediction of outcome after cardiac arrest: A prospective pilot study	RESUSCITATION			English	Article						Cardiac arrest; Neuroprognostication; Optic nerve sheath diameter; Outcome; Ultrasonography	CEREBRAL-BLOOD-FLOW; EUROPEAN RESUSCITATION COUNCIL; TRAUMATIC BRAIN-INJURY; THERAPEUTIC HYPOTHERMIA; CARDIOPULMONARY-RESUSCITATION; INTRACRANIAL-PRESSURE; COMPUTED-TOMOGRAPHY; HOSPITAL ADMISSION; COMATOSE SURVIVORS; OHCA SCORE	Introduction: Optic nerve sheath diameter (ONSD) measurement could detect increased intracranial pressure, and might predict outcome in post-cardiac arrest (CA) patients. We assessed the ability of bedside ONSD ultrasonographic measurement performed within day 1 after CA occurrence to predict in-hospital survival in patients treated with therapeutic hypothermia (TH). Methods: In two French ICUs, a prospective study included all consecutive patients with CA without traumatic or neurological etiology, successfully resuscitated and TH-treated. ONSD measurements were performed on day 1, 2, and 3 (ONSD1, 2, 3 respectively) after return of spontaneous circulation. All records were registered according to Utstein style. Results: ONSD1, 2, 3 were assessed in 36, 21, and 14 patients respectively. 19/36 patients (53%) were discharged alive from hospital, including 14/36 (39%) with favorable neurological outcome (Cerebral Performance Category [CPC] score 1-2). Survivors and non-survivors were similar regarding age, sex, cardiovascular risk factors, location and etiology of CA, simplified acute physiology score II, occurrence of post-CA shock, and clinical parameters collected during ONSD measurements. Median ONSD1 was significantly larger in non-survivors versus survivors (7.2 mm [interquartile: 6.8-7.4] versus 6.5 mm [interquartile: 6.0-6.8]; p = 0.008). After adjustment on predictive factors, ONSD1 was significantly associated with in-hospital mortality (OR 6.3; 95% CI [1.05-40] per mm of ONSD1 above 5.5 mm; p = 0.03), and CPC score (OR for 1 point increase in CPC score: 3.2; 95% CI [1.2-9.4] per mm of ONSD1 above 5.5 mm; p = 0.03). ONSD1 was significantly correlated with brain edema assessed by the cerebrum gray matter attenuation to white matter attenuation ratio, measured by the brain computed tomography scan performed on admission in 20 patients (Spearman rho = -0.5, p = 0.04). Conclusions: ONSD seems a promising tool to early assess outcome in post-CA patients treated with TH. (C) 2016 Elsevier Ireland Ltd. All rights reserved.	[Chelly, Jonathan; Ly Vong; Jochmans, Sebastien; Thieulot-Rolin, Nathalie; Sy, Oumar; Serbource-Goguel, Jean; Vinsonneau, Christophe; Monchi, Merhan] Hop Marc Jacquet, Intens Care Unit, 1 Rue Freteau de Peny, F-77000 Melun, France; [Deye, Nicolas; Vodovar, Dominique; Megarbane, Bruno] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, Med & Toxicol Intens Care Unit, 2 Rue Ambroise Pare, F-75545 Paris, France; [Deye, Nicolas] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, INSERM U942, 2 Rue Ambroise Pare, F-75545 Paris, France; [Guichard, Jean-Pierre] Grp Hosp Lariboisiere St Louis Fernand Widal, AP HP, Dept Radiol, 2 Rue Ambroise Pare, F-75545 Paris, France; [Vivien, Benoit] Hop Necker Enfants Malad, AP HP, SAMU 75, 149 Rue Sevres, F-75015 Paris, France; [Tazarourte, Karim] Hop Marc Jacquet, SAMU 77, 1 Rue Freteau de Peny, F-77000 Melun, France	Chelly, J (corresponding author), Hop Marc Jacquet, Intens Care Unit, 1 Rue Freteau de Peny, F-77000 Melun, France.	jonathan.chelly@ch-melun.fr	jochmans, sebastien/Y-3897-2019	jochmans, sebastien/0000-0002-7111-4107; Megarbane, Bruno/0000-0002-2522-2764; Chelly, Jonathan/0000-0002-8198-1239; Vodovar, Dominique/0000-0002-8196-5511; tazarourte, karim/0000-0002-3376-1258			Adrie C, 2006, EUR HEART J, V27, P2840, DOI 10.1093/eurheartj/ehl335; Alvarez-Fernandez JA, 2009, RESUSCITATION, V80, P1321, DOI 10.1016/j.resuscitation.2009.07.011; Bauerle J, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-187; Bauerle J, 2012, J NEUROIMAGING, V22, P42, DOI 10.1111/j.1552-6569.2010.00546.x; Bisschops LLA, 2012, CRIT CARE MED, V40, P2362, DOI 10.1097/CCM.0b013e318255d983; Chelly J, 2012, RESUSCITATION, V83, P1444, DOI 10.1016/j.resuscitation.2012.08.321; Crepeau AZ, 2014, RESUSCITATION, V85, P785, DOI 10.1016/j.resuscitation.2014.01.019; Deakin CD, 2010, RESUSCITATION, V81, pE93, DOI 10.1016/j.resuscitation.2010.08.027; Dubourg J, 2011, INTENS CARE MED, V37, P1059, DOI 10.1007/s00134-011-2224-2; Geeraerts T, 2008, INTENS CARE MED, V34, P2062, DOI 10.1007/s00134-008-1149-x; Geeraerts T, 2007, INTENS CARE MED, V33, P1704, DOI 10.1007/s00134-007-0797-6; GUEUGNIAUD PY, 1991, INTENS CARE MED, V17, P392, DOI 10.1007/BF01720676; Hansen HC, 1997, J NEUROSURG, V87, P34, DOI 10.3171/jns.1997.87.1.0034; Hassen GW, 2014, J EMERGENCY MED, P450; Hunziker S, 2011, CRIT CARE MED, V39, P1670, DOI 10.1097/CCM.0b013e318218a05b; Iida K, 1997, CRIT CARE MED, V25, P971, DOI 10.1097/00003246-199706000-00013; Jacobs I, 2004, RESUSCITATION, V63, P233, DOI 10.1016/j.resuscitation.2004.09.008; JENNETT B, 1975, LANCET, V1, P480; Kamps MJA, 2013, INTENS CARE MED, V39, P1671, DOI 10.1007/s00134-013-3004-y; Kim YH, 2014, ACAD EMERG MED, V21, P1121, DOI 10.1111/acem.12477; LEGALL JR, 1993, JAMA-J AM MED ASSOC, V270, P2957, DOI 10.1001/jama.270.24.2957; Legrand M, 2013, CRIT CARE, V17, DOI 10.1186/cc13133; Lemiale V, 2008, RESUSCITATION, V76, P17, DOI 10.1016/j.resuscitation.2007.06.028; Lovrencic-Huzjana A., 2012, PERSPECT MED, V1, P414; Metter RB, 2011, RESUSCITATION, V82, P1180, DOI 10.1016/j.resuscitation.2011.04.001; Nordmark J, 2009, ACTA ANAESTH SCAND, V53, P289, DOI 10.1111/j.1399-6576.2008.01885.x; Oddo M, 2014, CRIT CARE MED, V42, P1340, DOI 10.1097/CCM.0000000000000211; Sandroni C, 2014, RESUSCITATION, V85, P1779, DOI 10.1016/j.resuscitation.2014.08.011; Sandroni C, 2013, RESUSCITATION, V84, P1324, DOI 10.1016/j.resuscitation.2013.06.020; Sekhon MS, 2014, NEUROCRIT CARE, V21, P245, DOI 10.1007/s12028-014-0003-y; Sekhon MS, 2014, INTENS CARE MED, V40, P1267, DOI 10.1007/s00134-014-3392-7; Sunde K, 2007, EUR HEART J, V28, P773, DOI 10.1093/eurheartj/ehl536; Sundgreen C, 2001, STROKE, V32, P128, DOI 10.1161/01.STR.32.1.128; Topcuoglu MA, 2015, J NEUROIMAGING, V25, P906, DOI 10.1111/jon.12233; Ueda T, 2015, J NEUROIMAGING; Voicu S, 2014, CRIT CARE MED, V42, P1849, DOI 10.1097/CCM.0000000000000339; Wessels T, 2006, ULTRASOUND MED BIOL, V32, P1845, DOI 10.1016/j.ultrasmedbio.2006.06.023; Zellner T, 2013, RESUSCITATION, V84, P1382, DOI 10.1016/j.resuscitation.2013.03.021	38	22	26	1	5	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-9572			RESUSCITATION	Resuscitation	JUN	2016	103						7	13		10.1016/j.resuscitation.2016.03.006			7	Critical Care Medicine; Emergency Medicine	General & Internal Medicine; Emergency Medicine	DL8NL	WOS:000375898600014	26995663				2021-06-18	
J	Moriarty, H; Winter, L; Robinson, K; Piersol, CV; Vause-Earland, T; Iacovone, DB; Newhart, B; True, G; Fishman, D; Hodgson, N; Gitlin, LN				Moriarty, Helene; Winter, Laraine; Robinson, Keith; Piersol, Catherine Verrier; Vause-Earland, Tracey; Iacovone, Delores Blazer; Newhart, Brian; True, Gala; Fishman, Deborah; Hodgson, Nancy; Gitlin, Laura N.			A Randomized Controlled Trial to Evaluate the Veterans' In-home Program for Military Veterans With Traumatic Brain Injury and Their Families: Report on Impact for Family Members	PM&R			English	Article							CAREGIVER BURDEN; NEUROPSYCHIATRIC SEQUELAE; SOCIAL SUPPORT; INTERVENTION; REHABILITATION; DEPRESSION; INDIVIDUALS; HEALTH; CARE; DEMENTIA	Background: Traumatic brain injury (TBI) creates many challenges for families as well as for patients. Few intervention studies have considered both the needs of the person with TBI and his or her family and included both in the intervention process. To address this gap, we designed an innovative intervention for veterans with TBI and families-the Veterans' In-home Program (VIP)-targeting veterans' environment, delivered in veterans' homes, and involving their families. Objectives: To determine whether the VIP is more effective than standard outpatient clinic care in improving family members' well-being in 3 domains (depressive symptoms, burden, and satisfaction) and to assess its acceptability to family members. Design: In this randomized controlled trial, 81 dyads (veteran/family member) were randomly assigned to VIP or an enhanced usual care control condition. Randomization occurred after the baseline interview. Follow-up interviews occurred 3-4 months after baseline, and the interviewer was blinded to group assignment. Setting: Interviews and intervention sessions were conducted in veterans' homes or by telephone. Participants: A total of 81 veterans with TBI recruited from a Veterans Affairs (VA) polytrauma program and a key family member for each participated. Of the 81 family members, 63 completed the follow-up interview. Intervention: The VIP, guided by the person-environment fit model, consisted of 6 home visits and 2 telephone calls delivered by occupational therapists over a 3- to 4-month period. Family members were invited to participate in the 6 home sessions. Main Outcome Measures: Family member well-being was operationally defined as depressive symptomatology, caregiver burden, and caregiver satisfaction 3- 4 months after baseline. Acceptability was operationally defined through 3 indicators. Results: Family members in the VIP showed significantly lower depressive symptom scores and lower burden scores when compared to controls at follow-up. Satisfaction with caregiving did not differ between groups. Family members' acceptance of the intervention was high. Conclusions: VIP represents the first evidence-based intervention that considers both the veteran with TBI and the family. VIP had a significant impact on family member well-being and thus addresses a large gap in previous research and services for families of veterans with TBI.	[Moriarty, Helene] Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA; [Moriarty, Helene; Winter, Laraine; Fishman, Deborah] Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA; [Winter, Laraine] Corporal Michael J Crescenz Vet Affairs Med Ctr, Philadelphia Res & Educ Fdn, Philadelphia, PA USA; [Robinson, Keith; Iacovone, Delores Blazer; Newhart, Brian] Corporal Michael J Crescenz Vet Affairs Med Ctr, Rehabil Med Serv, Polytrauma Network Site Vet Integrated Serv Netwo, Philadelphia, PA USA; [Robinson, Keith; True, Gala] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA; [Piersol, Catherine Verrier; Vause-Earland, Tracey] Thomas Jefferson Univ, Jefferson Coll Hlth Profess, Philadelphia, PA 19107 USA; [True, Gala] Corporal Michael J Crescenz Vet Affairs Med Ctr, Ctr Hlth Equity Res & Promot, Philadelphia, PA USA; [Hodgson, Nancy; Gitlin, Laura N.] Johns Hopkins Univ, Ctr Innovat Care Aging, Sch Nursing, Baltimore, MD USA	Moriarty, H (corresponding author), Villanova Univ, Coll Nursing, 800 Lancaster Ave,Driscoll Hall, Villanova, PA 19085 USA.; Moriarty, H (corresponding author), Corporal Michael J Crescenz Vet Affairs Med Ctr, Nursing Serv, Philadelphia, PA USA.	helene.moriarty@villanova.edu		Piersol, Catherine/0000-0003-4992-8988	Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [R21 HD068857-01]	The project described was supported by Award Number R21 HD068857-01 from the Eunice Kennedy Shriver National Institute of Child Health & Human Development, National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the Eunice Kennedy Shriver National Institute of Child Health & Human Development or the National Institutes of Health.	ANDRESEN EM, 1994, AM J PREV MED, V10, P77; Arciniegas David B., 2002, Curr Treat Options Neurol, V4, P43, DOI 10.1007/s11940-002-0004-6; Asher I. E., 2007, OCCUPATIONAL THERAPY; Backhaus SL, 2010, ARCH PHYS MED REHAB, V91, P840, DOI 10.1016/j.apmr.2010.03.015; Bay EH, 2012, J MARITAL FAM THER, V38, P556, DOI 10.1111/j.1752-0606.2011.00231.x; Boschen K, 2007, NEUROREHABILITATION, V22, P19; Brain Trauma Foundation, TRAUM BRAIN INJ STAT; Carnevale GJ, 2006, ARCH PHYS MED REHAB, V87, P1289, DOI 10.1016/j.apmr.2006.06.010; Centers for Disease Control and Prevention, TRAUMATIC BRAIN INJU; Chokshi DA, 2014, NEW ENGL J MED, V371, P297, DOI 10.1056/NEJMp1406868; Dausch BM, 2009, REHABIL PSYCHOL, V54, P279, DOI 10.1037/a0016809; Defense and Veterans Brain Injury Center, DOD WORLDW NUMB TBI; Elder GA, 2010, PSYCHIAT CLIN N AM, V33, P757, DOI 10.1016/j.psc.2010.08.001; Ergh TC, 2002, J HEAD TRAUMA REHAB, V17, P155, DOI 10.1097/00001199-200204000-00006; Ford JH, 2014, J REHABIL RES DEV, V51, P1311, DOI 10.1682/JRRD.2014.03.0066; Foster AM, 2012, DISABIL REHABIL, V34, P1855, DOI 10.3109/09638288.2012.670028; Friedemann-Sanchez G, 2008, REHABIL NURS, V33, P206, DOI 10.1002/j.2048-7940.2008.tb00229.x; Gan C, 2010, NEUROREHABILITATION, V27, P5, DOI 10.3233/NRE-2010-0577; Gitlin LN, 2008, AM J GERIAT PSYCHIAT, V16, P229, DOI 10.1097/JGP.0b013e318160da72; Gitlin LN, 2006, J AM GERIATR SOC, V54, P809, DOI 10.1111/j.1532-5415.2006.00703.x; Gitlin LN, 2010, JAMA-J AM MED ASSOC, V304, P983, DOI 10.1001/jama.2010.1253; Gitlin LN, 2010, J AM GERIATR SOC, V58, P1465, DOI 10.1111/j.1532-5415.2010.02971.x; Gitlin LN, 2003, GERONTOLOGIST, V43, P532, DOI 10.1093/geront/43.4.532; Glynn SM, 2013, CLIN CHILD FAM PSYCH, V16, P410, DOI 10.1007/s10567-013-0153-z; Grant JS, 2002, STROKE, V33, P2060, DOI 10.1161/01.STR.0000020711.38824.E3; Groom KN, 1998, ARCH CLIN NEUROPSYCH, V13, P695, DOI 10.1016/S0887-6177(98)00005-5; Hanks RA, 2007, NEUROREHABILITATION, V22, P43; Hanks RA, 2012, ARCH PHYS MED REHAB, V93, P1297, DOI 10.1016/j.apmr.2012.04.027; Herzberg PA, 1983, PRINCIPLES STAT; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Hsiao CY, 2014, NURS RES, V63, P260, DOI 10.1097/NNR.0000000000000047; Josman N, 1999, Can J Occup Ther, V66, P33; Kim E, 2007, J NEUROPSYCH CLIN N, V19, P106, DOI 10.1176/appi.neuropsych.19.2.106; KINNEY JM, 1995, J APPL GERONTOL, V14, P3, DOI 10.1177/073346489501400101; KINNEY JM, 1989, PSYCHOL AGING, V4, P402, DOI 10.1037/0882-7974.4.4.402; Kizer KW, 2014, NEW ENGL J MED, V371, P295, DOI 10.1056/NEJMp1406852; Knight RG, 1998, BRAIN INJURY, V12, P467, DOI 10.1080/026990598122430; Kreutzer JS, 2009, BRAIN INJURY, V23, P535, DOI 10.1080/02699050902926291; KREUTZER JS, 1994, BRAIN INJURY, V8, P197, DOI 10.3109/02699059409150973; KREUTZER JS, 1994, J HEAD TRAUMA REHAB, V9, P104, DOI 10.1097/00001199-199409000-00009; Landau J., 2008, FAMILIES SYSTEMS HLT, V26, P69, DOI DOI 10.1037/1091-7527.26.1.69; LAWTON MP, 1983, GERONTOLOGIST, V23, P349, DOI 10.1093/geront/23.4.349; LAWTON MP, 1991, J GERONTOL, V46, pP181, DOI 10.1093/geronj/46.4.P181; LAWTON MP, 1989, J GERONTOL, V44, pP61, DOI 10.1093/geronj/44.3.P61; Lazarus R.S., 1984, STRESS APPRAISAL COP; Lerner D, 2008, J OCCUP ENVIRON MED, V50, P401, DOI 10.1097/JOM.0b013e31816bae50; Lewin K., 1935, DYNAMIC THEORY PERSO; Lopez J, 2005, ARCH GERONTOL GERIAT, V41, P81, DOI 10.1016/j.archger.2004.12.001; Loss Boss P., 2005, LOSS TRAUMA RESILIEN; Lui MHL, 2005, STROKE, V36, P2514, DOI 10.1161/01.STR.0000185743.41231.85; Marsh NV, 1998, BRAIN INJURY, V12, P225, DOI 10.1080/026990598122700; Marsh NV, 2002, J CLIN EXP NEUROPSYC, V24, P434, DOI 10.1076/jcen.24.4.434.1030; Marsh NV, 1998, BRAIN INJURY, V12, P1045, DOI 10.1080/026990598121954; McPherson KM, 2000, DISABIL REHABIL, V22, P683, DOI 10.1080/096382800445489; Minuchin S., 1974, FAMILIES FAMILY THER; MORTON MV, 1995, BRAIN INJURY, V9, P81, DOI 10.3109/02699059509004574; Nabors N, 2002, BRAIN INJURY, V16, P1039, DOI 10.1080/02699050210155285; Oddy M, 2003, NEUROPSYCHOL REHABIL, V13, P259, DOI 10.1080/09602010244000345; Okie S, 2005, NEW ENGL J MED, V352, P2043, DOI 10.1056/NEJMp058102; Pagulayan KF, 2008, ARCH PHYS MED REHAB, V89, P1887, DOI 10.1016/j.apmr.2008.03.019; PETERS L C, 1990, Brain Injury, V4, P39, DOI 10.3109/02699059009026147; Pollard D, 2005, ALLENS COGNITIVE LEV; Ponsford J, 2003, BRAIN INJURY, V17, P453, DOI 10.1080/0269905031000070143; Rao V, 2000, PSYCHOSOMATICS, V41, P95, DOI 10.1176/appi.psy.41.2.95; Rath JF, 2003, REHABIL PSYCHOL, V48, P137, DOI 10.1037/0090-5550.48.3.137; Rietdijk R, 2012, J REHABIL MED, V44, P913, DOI 10.2340/16501977-1058; Riley GA, 2007, CLIN REHABIL, V21, P82, DOI 10.1177/0269215506071279; Rivera P, 2003, TOP SPINAL CORD INJ, V9, P53, DOI [DOI 10.1310/G82F-BR2R-T69L-3QX8, 10.1310/G82F-BR2R-T69L-3QX8]; Rivera PA, 2008, ARCH PHYS MED REHAB, V89, P931, DOI 10.1016/j.apmr.2007.12.032; Rodgers ML, 2007, AM J PHYS MED REHAB, V86, P482, DOI 10.1097/PHM.0b013e31805c00a1; Roitman DM, 1997, PHYS OCCUP THER GERI, V14, P43; ROMANO MD, 1974, SCAND J REHABIL MED, V6, P1; Roth DL, 2015, J GERONTOL B-PSYCHOL, V70, P813, DOI 10.1093/geronb/gbv034; Sander AM, 2009, J HEAD TRAUMA REHAB, V24, P248, DOI 10.1097/HTR.0b013e3181ad593a; Sayer NA, 2008, ARCH PHYS MED REHAB, V89, P163, DOI 10.1016/j.apmr.2007.05.025; Sayer NA, 2012, ANNU REV MED, V63, P405, DOI 10.1146/annurev-med-061610-154046; Schneiderman AI, 2008, AM J EPIDEMIOL, V167, P1446, DOI 10.1093/aje/kwn068; Steger MF, 2009, J COUNS PSYCHOL, V56, P289, DOI 10.1037/a0015416; Stejskal TM, 2012, NEUROREHABILITATION, V31, P75, DOI 10.3233/NRE-2012-0776; Stevens LF, 2012, NEUROREHABILITATION, V31, P443, DOI 10.3233/NRE-2012-00815; Struchen MA, 2002, J HEAD TRAUMA REHAB, V17, P132, DOI 10.1097/00001199-200204000-00005; Sveen U, 2008, CLIN REHABIL, V22, P45, DOI 10.1177/0269215507080768; Terrio H, 2009, J HEAD TRAUMA REHAB, V24, P14, DOI 10.1097/HTR.0b013e31819581d8; Tyerman A, 2001, NEUROREHABILITATION, V16, P59; U.S. Department of Veterans Affairs Public Health, VA HLTH CAR UT REC V; Verhaeghe S, 2005, J CLIN NURS, V14, P1004, DOI 10.1111/j.1365-2702.2005.01126.x; Williamson GM, 1998, HEALTH PSYCHOL, V17, P152, DOI 10.1037/0278-6133.17.2.152; Winter L, 2015, 2015 NAT CAP AR TBI; Wisniewski SR, 2003, PSYCHOL AGING, V18, P375, DOI 10.1037/0882-7974.18.3.375; Witol AD, 1996, NEUROREHABILITATION, V7, P175, DOI 10.3233/NRE-1996-7303	90	22	22	0	15	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	1934-1482	1934-1563		PM&R	PM&R	JUN	2016	8	6					495	509		10.1016/j.pmrj.2015.10.008			15	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DO6OX	WOS:000377904100001	26514790				2021-06-18	
J	Robinson, S; Winer, JL; Berkner, J; Chan, LAS; Denson, JL; Maxwell, JR; Yang, YR; Sillerud, LO; Tasker, RC; Meehan, WP; Mannix, R; Jantzie, LL				Robinson, Shenandoah; Winer, Jesse L.; Berkner, Justin; Chan, Lindsay A. S.; Denson, Jesse L.; Maxwell, Jessie R.; Yang, Yirong; Sillerud, Laurel O.; Tasker, Robert C.; Meehan, William P., III; Mannix, Rebekah; Jantzie, Lauren L.			Imaging and serum biomarkers reflecting the functional efficacy of extended erythropoietin treatment in rats following infantile traumatic brain injury	JOURNAL OF NEUROSURGERY-PEDIATRICS			English	Article						controlled cortical impact; diffusion tensor imaging; diffusivity; erythropoietin; infant; serum biomarker; traumatic brain injury; trauma	CONTROLLED CORTICAL IMPACT; DOSE RECOMBINANT ERYTHROPOIETIN; OLIGODENDROCYTE PRECURSOR PROLIFERATION; CHLORIDE CO-TRANSPORTERS; DEVELOPING SPINAL-CORD; BIRTH-WEIGHT INFANTS; CLOSED-HEAD INJURY; PRETERM INFANTS; IMMATURE RAT; NEONATAL-RATS	OBJECTIVE Traumatic brain injury (TBI) is a leading cause of death and severe morbidity for otherwise healthy full term infants around the world. Currently, the primary treatment for infant TBI is supportive, as no targeted therapies exist to actively promote recovery. The developing infant brain, in particular, has a unique response to injury and the potential for repair, both of which vary with maturation. Targeted interventions and objective measures of therapeutic efficacy are needed in this special population. The authors hypothesized that MRI and serum biomarkers can be used to quantify outcomes following infantile TBI in a preclinical rat model and that the potential efficacy of the neuro-reparative agent erythropoietin (EPO) in promoting recovery can be tested using these biomarkers as surrogates for functional outcomes. METHODS With institutional approval, a controlled cortical impact (CCI) was delivered to postnatal Day (P)12 rats of both sexes (76 rats). On postinjury Day (PID)1, the 49 CCI rats designated for chronic studies were randomized to EPO (3000 U/kg/dose, CCI-EPO, 24 rats) or vehicle (CCI-veh, 25 rats) administered intraperitoneally on PID1-4, 6, and 8. Acute injury (PID3) was evaluated with an immunoassay of injured cortex and serum, and chronic injury (PID13-28) was evaluated with digitized gait analyses, MRI, and serum immunoassay. The CCI-veh and CCI-EPO rats were compared with shams (49 rats) primarily using 2-way ANOVA with Bonferroni post hoc correction. RESULTS Following CCI, there was 4.8% mortality and 55% of injured rats exhibited convulsions. Of the injured rats designated for chronic analyses, 8.1% developed leptomeningeal cyst like lesions verified with MRI and were excluded from further study. On PID3, Western blot showed that EPO receptor expression was increased in the injured cortex (p = 0.008). These Western blots also showed elevated ipsilateral cortex calpain degradation products for all-spectrin (alpha II-SDPs; p < 0.001), potassium chloride cotransporter 2 (KCC2-DPs; p = 0.037), and glial fibrillary acidic protein (GFAP-DPs; p = 0.002), as well as serum GFAP (serum GFAP-DPs; p = 0.001). In injured rats multiplex electrochemiluminescence analyses on PID3 revealed elevated serum tumor necrosis factor alpha (TNF alpha; p = 0.01) and chemokine (CXC) ligand 1 (CXCL1). Chronically, that is, in PID13-16 CCI-veh rats, as compared with sham rats, gait deficits were demonstrated (p = 0.033) but then were reversed (p = 0.022) with EPO treatment. Diffusion tensor MRI of the ipsilateral and contralateral cortex and white matter in PID16-23 CCI-veh rats showed widespread injury and significant abnormalities of functional anisotropy (FA), mean diffusivity (MD), axial diffusivity (AD), and radial diffusivity (RD); MD, AD, and RD improved after EPO treatment. Chronically, P13-P28 CCI-veh rats also had elevated serum CXCL1 levels, which normalized in CCI-EPO rats. CONCLUSIONS Efficient translation of emerging neuro-reparative interventions dictates the use of age-appropriate preclinical models with human clinical trial compatible biomarkers. In the present study, the authors showed that CCI produced chronic gait deficits in P12 rats that resolved with EPO treatment and that chronic imaging and serum biomarkers correlated with this improvement.	[Robinson, Shenandoah; Winer, Jesse L.; Berkner, Justin; Chan, Lindsay A. S.; Tasker, Robert C.; Meehan, William P., III; Mannix, Rebekah] Harvard Univ, Sch Med, Brain Injury Ctr, Boston, MA USA; [Robinson, Shenandoah; Winer, Jesse L.; Chan, Lindsay A. S.] Harvard Univ, Sch Med, Dept Neurosurg, Boston, MA USA; [Robinson, Shenandoah; Tasker, Robert C.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA; [Berkner, Justin; Mannix, Rebekah] Harvard Univ, Sch Med, Dept Emergency Med, Boston, MA USA; [Meehan, William P., III] Harvard Univ, Sch Med, Dept Sports Med, Boston, MA USA; [Tasker, Robert C.] Harvard Univ, Sch Med, Dept Anesthesiol, Boston, MA USA; [Robinson, Shenandoah] Harvard Univ, Sch Med, FM Kirby Ctr Neurobiol, Boston Childrens Hosp, Boston, MA USA; [Denson, Jesse L.; Maxwell, Jessie R.; Jantzie, Lauren L.] Univ New Mexico, Sch Med, Dept Pediat, Albuquerque, NM 87131 USA; [Jantzie, Lauren L.] Univ New Mexico, Sch Med, Dept Neurosci, Albuquerque, NM 87131 USA; [Yang, Yirong; Sillerud, Laurel O.] Univ New Mexico, Sch Med, Dept Neurol, Albuquerque, NM 87131 USA	Robinson, S (corresponding author), Boston Childrens Hosp, Dept Neurosurg, 300 Longwood Ave, Boston, MA 02115 USA.	shenandoah.robinson@childrens.harvard.edu	Tasker, Robert C/R-5837-2019; Mannix, Rebekah/AAD-8702-2020; Maxwell, Jessie R./N-1890-2019	Maxwell, Jessie R./0000-0001-8990-7239; Tasker, Robert/0000-0003-3647-8113	Dedicated Health Research funds from the University of New Mexico School of Medicine; Centers for Biomedical Research Excellence Pilot Award [CoBRE P30GM103400/PI:Liu]; Boston Children's Hospital; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040128] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF GENERAL MEDICAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of General Medical Sciences (NIGMS) [P30GM103400] Funding Source: NIH RePORTER	We thank Eun-Hyoung Park, PhD, for her excellent assistance with the MATLAB illustrations. This project was supported in part by the Dedicated Health Research funds from the University of New Mexico School of Medicine and the Centers for Biomedical Research Excellence Pilot Award to Lauren L. Jantzie, PhD (CoBRE P30GM103400/PI:Liu), and Boston Children's Hospital.	Adelson PD, 2013, CHILD NERV SYST, V29, P43, DOI 10.1007/s00381-012-1932-4; Adelson PD, 1997, J NEUROTRAUM, V14, P99, DOI 10.1089/neu.1997.14.99; Adelson PD, 1996, J NEUROSURG, V85, P877, DOI 10.3171/jns.1996.85.5.0877; Aloizos S, 2015, TURK NEUROSURG, V25, P552, DOI 10.5137/1019-5149.JTN.9685-14.4; Anblagan D, 2015, NEUROIMAGE-CLIN, V8, P51, DOI 10.1016/j.nicl.2015.03.021; Arango JI, 2012, CHILD NERV SYST, V28, P1925, DOI 10.1007/s00381-012-1863-0; Aung Wint Yan, 2013, Imaging Med, V5, P427; Berger RP, 2012, J NEUROTRAUM, V29, P162, DOI 10.1089/neu.2011.1989; Blaesse P, 2015, PFLUG ARCH EUR J PHY, V467, P615, DOI 10.1007/s00424-014-1547-6; Bondi CO, 2014, NEUROSCI BIOBEHAV RE; Bonislawski DP, 2007, NEUROBIOL DIS, V25, P163, DOI 10.1016/j.nbd.2006.09.002; Boulenguez P, 2010, NAT MED, V16, P302, DOI 10.1038/nm.2107; Boutte A.M., 2015, J NEUROTRAUMA; Brines M, 2005, NAT REV NEUROSCI, V6, P484, DOI 10.1038/nrn1687; Campbell SL, 2015, GLIA, V63, P23, DOI 10.1002/glia.22730; Cao DL, 2014, EXP NEUROL, V261, P328, DOI 10.1016/j.expneurol.2014.05.014; Chen CY, 2013, DEV NEUROSCI-BASEL, V35, P474, DOI 10.1159/000355874; Dennis EL, 2015, NEUROIMAGE-CLIN, V7, P493, DOI 10.1016/j.nicl.2015.02.002; Dent KA, 2015, PLOS ONE, V10, DOI 10.1371/journal.pone.0121541; Di Battista AP, 2015, FRONT NEUROL, V6, DOI 10.3389/fneur.2015.00110; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P19, DOI 10.1089/neu.2013.3040; Donelan JM, 2004, J BIOMECH, V37, P827, DOI 10.1016/j.jbiomech.2003.06.002; Edman LC, 2008, STEM CELLS, V26, P1891, DOI 10.1634/stemcells.2007-0753; Fauchere JC, 2008, PEDIATRICS, V122, P375, DOI 10.1542/peds.2007-2591; Fauchere JC, 2015, J PEDIATR-US, V167, P52, DOI 10.1016/j.jpeds.2015.02.052; Fraser DD, 2011, PEDIATR CRIT CARE ME, V12, P319, DOI 10.1097/PCC.0b013e3181e8b32d; Gobbel GT, 2007, CHILD NERV SYST, V23, P1171, DOI 10.1007/s00381-007-0345-2; Gu XH, 2015, EXP NEUROL, V267, P135, DOI 10.1016/j.expneurol.2015.02.029; Hellewell SC, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-156; Huang XJ, 2015, J NEUROTRAUM, V32, P1179, DOI 10.1089/neu.2015.3873; Huberfeld G, 2007, J NEUROSCI, V27, P9866, DOI 10.1523/JNEUROSCI.2761-07.2007; Hubner CA, 2001, NEURON, V30, P515, DOI 10.1016/S0896-6273(01)00297-5; Huppi PS, 2006, SEMIN FETAL NEONAT M, V11, P489, DOI 10.1016/j.siny.2006.07.006; Jantzie LL, 2014, MOL CELL NEUROSCI, V61, P152, DOI 10.1016/j.mcn.2014.06.009; Jantzie LL, 2015, FRONT CELL NEUROSCI, V9, DOI 10.3389/fncel.2015.00347; Jantzie LL, 2015, CEREB CORTEX, V25, P2683, DOI 10.1093/cercor/bhu066; Jantzie LL, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-131; Jantzie LL, 2013, PEDIATR RES, V74, P658, DOI 10.1038/pr.2013.155; Jantzie LL, 2015, DEV NEUROSCI; Juul SE, 2008, PEDIATRICS, V122, P383, DOI 10.1542/peds.2007-2711; Keller M, 2006, NEUROBIOL DIS, V24, P357, DOI 10.1016/j.nbd.2006.07.007; Kellert BA, 2007, PEDIATR RES, V61, P451, DOI 10.1203/pdr.0b013e3180332cec; Knabe W, 2005, ANAT EMBRYOL, V210, P209, DOI 10.1007/s00429-005-0019-3; Knabe W, 2004, ANAT EMBRYOL, V207, P503, DOI 10.1007/s00429-003-0365-y; Kocaman C, 2012, BRAIN DEV-JPN, V34, P133, DOI 10.1016/j.braindev.2011.04.003; Leuchter RHV, 2014, JAMA-J AM MED ASSOC, V312, P817, DOI 10.1001/jama.2014.9645; Leventhal JM, 2010, PEDIATRICS, V126, pE104, DOI 10.1542/peds.2009-1076; Mac Donald CL, 2007, J NEUROSCI, V27, P11869, DOI 10.1523/JNEUROSCI.3647-07.2007; Mannix R, 2014, J NEUROSURG, V121, P1337, DOI 10.3171/2014.8.JNS14715; Mannix RC, 2013, BRAIN INJURY, V27, P743, DOI 10.3109/02699052.2013.771797; Mannix RC, 2011, J NEUROTRAUM, V28, P1855, DOI 10.1089/neu.2011.1759; Mannix RC, 2011, J CEREBR BLOOD F MET, V31, P351, DOI 10.1038/jcbfm.2010.99; Mazur M, 2010, J NEUROSURG-PEDIATR, V6, P206, DOI 10.3171/2010.5.PEDS1032; McAdams RM, 2013, J PERINATOL, V33, P226, DOI 10.1038/jp.2012.78; McKinlay A, 2008, BRAIN INJURY, V22, P175, DOI 10.1080/02699050801888824; McMahon PJ, 2015, J NEUROTRAUM, V32, P527, DOI 10.1089/neu.2014.3635; Meng YL, 2011, J NEUROSURG, V115, P550, DOI 10.3171/2011.3.JNS101721; Ment LR, 2009, LANCET NEUROL, V8, P1042, DOI 10.1016/S1474-4422(09)70257-1; Miller TR, 2014, PEDIATRICS, V134, pE1545, DOI 10.1542/peds.2014-1385; Miskowiak KW, 2014, J CLIN PSYCHIAT, V75, P1347, DOI 10.4088/JCP.13m08839; Miskowiak KW, 2014, NEUROPSYCHOPHARMACOL, V39, P1399, DOI 10.1038/npp.2013.335; Murray KJ, 2009, INJURY PREV, V15, P240, DOI 10.1136/ip.2009.021550; O'Neill BR, 2015, J NEUROSURG-PEDIATR, V16, P167, DOI 10.3171/2014.12.PEDS14263; Ohls RK, 2014, PEDIATRICS, V133, P1023, DOI 10.1542/peds.2013-4307; Pallud J, 2014, SCI TRANSL MED, V6, DOI 10.1126/scitranslmed.3008065; Papa L, 2015, J NEUROTRAUM, V32, P661, DOI 10.1089/neu.2014.3655; Payne JA, 2003, TRENDS NEUROSCI, V26, P199, DOI 10.1016/S0166-2236(03)00068-7; Pellegrino C, 2011, J PHYSIOL-LONDON, V589, P2475, DOI 10.1113/jphysiol.2010.203703; Peng WJ, 2014, J NEUROSURG, V121, P653, DOI 10.3171/2014.6.JNS132577; Pike BR, 1998, NEUROREPORT, V9, P2437, DOI 10.1097/00001756-199808030-00002; Ponce Lucido L, 2013, Pathophysiology, V20, P31, DOI 10.1016/j.pathophys.2012.02.005; Puskarjov M, 2012, J NEUROSCI, V32, P11356, DOI 10.1523/JNEUROSCI.6265-11.2012; Quayle KS, 2014, NEW ENGL J MED, V371, P1945, DOI 10.1056/NEJMc1407902; Raghupathi R, 2007, J NEUROTRAUM, V24, P1596, DOI 10.1089/neu.2007.3790; Rivara FP, 2012, J NEUROTRAUM, V29, P2499, DOI 10.1089/neu.2012.2434; Rivera C, 1999, NATURE, V397, P251; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Robinson S, 1998, J NEUROSCI, V18, P10457; Robinson S, 2001, DEV NEUROSCI-BASEL, V23, P338, DOI 10.1159/000048717; Robinson S, 2010, J NEUROPATH EXP NEUR, V69, P565, DOI 10.1097/NEN.0b013e3181dd25bc; Rutkoski JD, 2011, J SURG RES, V166, P199, DOI 10.1016/j.jss.2010.05.051; Sanford RA, 2010, J NEUROSURG-PEDIATR, V5, P213, DOI 10.3171/2009.9.PEDS09180; Sashindranath M, 2015, BEHAV BRAIN RES, V286, P33, DOI 10.1016/j.bbr.2015.02.038; Schober ME, 2015, NEUROTRAUMA; Schober ME, 2014, BRAIN RES, V1574, P105, DOI 10.1016/j.brainres.2014.05.046; Schober ME, 2014, J NEUROTRAUM, V31, P358, DOI 10.1089/neu.2013.2922; Semple BD, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0103386; Semple BD, 2013, PROG NEUROBIOL, V106, P1, DOI 10.1016/j.pneurobio.2013.04.001; Semple BD, 2010, NEUROBIOL DIS, V40, P394, DOI 10.1016/j.nbd.2010.06.015; Shang Y, 2007, APOPTOSIS, V12, P2187, DOI 10.1007/s10495-007-0141-1; Sierra A, 2015, BRAIN STRUCT FUNCT, V220, P781, DOI 10.1007/s00429-013-0683-7; Sivakumaran S, 2015, J NEUROSCI, V35, P8291, DOI 10.1523/JNEUROSCI.5205-14.2015; Soblosky JS, 1996, BEHAV BRAIN RES, V79, P79, DOI 10.1016/0166-4328(95)00264-2; Statler PA, 2007, PEDIATR RES, V61, P671, DOI 10.1203/pdr.0b013e31805341dc; Tasker RC, 2010, DEV NEUROSCI-BASEL, V32, P374, DOI 10.1159/000316806; Tsai HH, 2002, CELL, V110, P373, DOI 10.1016/S0092-8674(02)00838-3; Tsai PT, 2006, J NEUROSCI, V26, P1269, DOI 10.1523/JNEUROSCI.4480-05.2006; Webster SJ, 2015, J NEUROSCI, V35, P6554, DOI 10.1523/JNEUROSCI.0291-15.2015; Winkelmann A, 2015, CELL DEATH DIS, V6, DOI 10.1038/cddis.2015.127; Wu Q, 2000, J NEUROSCI, V20, P2609; Wu YW, 2012, PEDIATRICS, V130, P683, DOI 10.1542/peds.2012-0498; Xiong Y, 2011, J NEUROSURG, V114, P549, DOI 10.3171/2010.10.JNS10925; Xiong Y, 2010, J NEUROSURG, V113, P598, DOI 10.3171/2009.9.JNS09844; Xu J, 2014, J NEUROINFLAMM, V11, DOI 10.1186/1742-2094-11-38; Yokobori S, 2013, CNS NEUROSCI THER, V19, P556, DOI 10.1111/cns.12127; Zhang Z, 2015, J NEUROTRAUM, V32, P1369, DOI 10.1089/neu.2014.3701; Zhang ZQ, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0092698; Zhou HY, 2012, J BIOL CHEM, V287, P33853, DOI 10.1074/jbc.M112.395830	108	22	22	1	7	AMER ASSOC NEUROLOGICAL SURGEONS	ROLLING MEADOWS	5550 MEADOWBROOK DRIVE, ROLLING MEADOWS, IL 60008 USA	1933-0707	1933-0715		J NEUROSURG-PEDIATR	J. Neurosurg.-Pediatr.	JUN	2016	17	6					739	755		10.3171/2015.10.PEDS15554			17	Clinical Neurology; Pediatrics; Surgery	Neurosciences & Neurology; Pediatrics; Surgery	DM6PX	WOS:000376476000018	26894518	Green Accepted, Bronze			2021-06-18	
J	Hajra, SG; Liu, CC; Song, XW; Fickling, S; Liu, LE; Pawlowski, G; Jorgensen, JK; Smith, AM; Schnaider-Beeri, M; Van Den Broek, R; Rizzotti, R; Fisher, K; D'Arcy, RCN				Hajra, Shjoy Ghosh; Liu, Careesa C.; Song, Xiaowei; Fickling, Shaun; Liu, Luke E.; Pawlowski, Gabriela; Jorgensen, Janelle K.; Smith, Anysley M.; Schnaider-Beeri, Michal; Van Den Broek, Rudi; Rizzotti, Rowena; Fisher, Kirk; D'Arcy, Ryan C. N.			Developing Brain Vital Signs: Initial Framework for Monitoring Brain Function Changes Over Time	FRONTIERS IN NEUROSCIENCE			English	Article						clinical neuroscience; ERPs; evoked potentials; vital signs; neurology	EVENT-RELATED POTENTIALS; MISMATCH NEGATIVITY; RETEST RELIABILITY; VEGETATIVE STATE; CONSCIOUSNESS; COMA; IMPAIRMENT; DISORDERS; SCALE	Clinical assessment of brain function relies heavily on indirect behavior-based tests. Unfortunately, behavior-based assessments are subjective and therefore susceptible to several confounding factors. Event-related brain potentials (ERPs), derived from electroencephalography (EEG), are often used to provide objective, physiological measures of brain function. Historically, ERPs have been characterized extensively within research settings, with limited but growing clinical applications. Over the past 20 years, we have developed clinical ERP applications for the evaluation of functional status following serious injury and/or disease. This work has identified an important gap: the need for a clinically accessible framework to evaluate ERP measures. Crucially, this enables baseline measures before brain dysfunction occurs, and might enable the routine collection of brain function metrics in the future much like blood pressure measures today. Here, we propose such a framework for extracting specific ERPs as potential "brain vital signs." This framework enabled the translation/transformation of complex ERP data into accessible metrics of brain function for wider clinical utilization. To formalize the framework, three essential ERPs were selected as initial indicators: (1) the auditory N100 (Auditory sensation): (2) the auditory oddball P300 (Basic attention): and (3) the auditory speech processing N400 (Cognitive processing). First step validation was conducted on healthy younger and older adults (age range: 22-82 years). Results confirmed specific ERPs at the individual level (86.81-98.96%), verified predictable age-related differences (P300 latency delays in older adults, p < 0.05), and demonstrated successful linear transformation into the proposed brain vital sign (BVS) framework (basic attention latency sub-component of BVS framework reflects delays in older adults, p < 0.05). The findings represent an initial critical step in developing, extracting, and characterizing ERPs as vital signs, critical for subsequent evaluation of dysfunction in conditions like concussion and/or dementia.	[Hajra, Shjoy Ghosh; Liu, Careesa C.; Song, Xiaowei; Fickling, Shaun; D'Arcy, Ryan C. N.] Simon Fraser Univ, Sch Engn Sci, Fac Sci Appl, Burnaby, BC V5A 1S6, Canada; [Hajra, Shjoy Ghosh; Liu, Careesa C.; Song, Xiaowei; Fickling, Shaun; Liu, Luke E.; Pawlowski, Gabriela; D'Arcy, Ryan C. N.] Simon Fraser Univ, NeuroTech Lab, Surrey, BC, Canada; [Hajra, Shjoy Ghosh; Liu, Careesa C.; Song, Xiaowei; Fickling, Shaun; Liu, Luke E.; Pawlowski, Gabriela; D'Arcy, Ryan C. N.] Fraser Heath Author, Surrey, BC, Canada; [Song, Xiaowei; D'Arcy, Ryan C. N.] Fraser Hlth Author, Surrey Mem Hosp, Hth Sci & Innovat, Surrey, BC, Canada; [Pawlowski, Gabriela; D'Arcy, Ryan C. N.] Simon Fraser Univ, Fac Sci, Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada; [Jorgensen, Janelle K.; Smith, Anysley M.] Mayo Clin, Sports Med Ctr, Rochester, MN USA; [Schnaider-Beeri, Michal] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA; [Schnaider-Beeri, Michal] Sheeba Med Ctr, Joseph Sago Neurosci Ctr, Ramat Gan, Israel; [Van Den Broek, Rudi; Rizzotti, Rowena; Fisher, Kirk; D'Arcy, Ryan C. N.] Hlth Tech Connex Inc, Surrey, BC, Canada	D'Arcy, RCN (corresponding author), Simon Fraser Univ, Sch Engn Sci, Fac Sci Appl, Burnaby, BC V5A 1S6, Canada.; D'Arcy, RCN (corresponding author), Simon Fraser Univ, NeuroTech Lab, Surrey, BC, Canada.; D'Arcy, RCN (corresponding author), Fraser Heath Author, Surrey, BC, Canada.; D'Arcy, RCN (corresponding author), Fraser Hlth Author, Surrey Mem Hosp, Hth Sci & Innovat, Surrey, BC, Canada.; D'Arcy, RCN (corresponding author), Simon Fraser Univ, Fac Sci, Biomed Physiol & Kinesiol, Burnaby, BC V5A 1S6, Canada.; D'Arcy, RCN (corresponding author), Hlth Tech Connex Inc, Surrey, BC, Canada.	rdarcy@sfu.ca		Ghosh Hajra, Sujoy/0000-0002-8347-6578	Mathematics of Information Technology and Complex Systems (MITACS) [IT03210]; National Sciences and Engineering Council Canada (NSERC) [298457-2009]; Canadian Institutes for Health Research (CIHR)Canadian Institutes of Health Research (CIHR) [CCI-109608]	This work was supported in part by Mathematics of Information Technology and Complex Systems (MITACS, Grant #IT03210), National Sciences and Engineering Council Canada (NSERC, Grant #298457-2009), and Canadian Institutes for Health Research (CIHR, Grant #CCI-109608).	Braverman ER, 2003, CLIN ELECTROENCEPHAL, V34, P124, DOI 10.1177/155005940303400306; Cassidy SM, 2012, PSYCHOPHYSIOLOGY, V49, P659, DOI 10.1111/j.1469-8986.2011.01349.x; Connolly JF, 2000, INT J PSYCHOPHYSIOL, V37, P31, DOI 10.1016/S0167-8760(00)00093-3; CONNOLLY JF, 1995, J CLIN EXP NEUROPSYC, V17, P548, DOI 10.1080/01688639508405145; D'Arcy RCN, 2003, CLIN NEUROPHYSIOL, V114, P662, DOI 10.1016/S1388-2457(03)00007-5; D'Arcy RCN, 2011, IEEE T BIO-MED ENG, V58, P750, DOI 10.1109/TBME.2010.2090880; Daltrozzo J, 2009, COGN BEHAV NEUROL, V22, P53, DOI 10.1097/WNN.0b013e318192ccc8; Davis PA, 1939, J NEUROPHYSIOL, V2, P494; Duncan CC, 2009, CLIN NEUROPHYSIOL, V120, P1883, DOI 10.1016/j.clinph.2009.07.045; Fleck-Prediger C., 2014, CLIN APPL HALIFAX CO; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Gawryluk J. R., 2010, HDB PHYS MED BIOL, V24-1-24-14; Gawryluk JR, 2010, BMC NEUROL, V10, DOI 10.1186/1471-2377-10-11; Giacino JT, 2014, NAT REV NEUROL, V10, P99, DOI 10.1038/nrneurol.2013.279; Golland P., 2003, PERMUTATION TESTS CL, DOI [10.1007/978-3-540-45087-0_28, DOI 10.1007/978-3-540-45087-0_28]; Kotchoubey B, 2005, CLIN NEUROPHYSIOL, V116, P2441, DOI 10.1016/j.clinph.2005.03.028; KUTAS M, 1980, SCIENCE, V207, P203, DOI 10.1126/science.7350657; Lezak M.D., 2004, NEUROPSYCHOLOGICAL A, Vfourth; Luck SJ, 2014, INTRODUCTION TO THE EVENT-RELATED POTENTIAL TECHNIQUE, 2ND EDITION, P1; Marchand Y, 2002, CLIN NEUROPHYSIOL, V113, P1715, DOI 10.1016/S1388-2457(02)00224-9; Morlet D, 2000, AUDIOL NEURO-OTOL, V5, P198, DOI 10.1159/000013881; Nasreddine ZS, 2005, J AM GERIATR SOC, V53, P695, DOI 10.1111/j.1532-5415.2005.53221.x; Neminsky V. V., 1913, ZENTRALBLATT PHYSIOL, V27, P951; Parvar Hossein, 2015, Brain Inform, V2, P1; Reith FCM, 2016, J NEUROTRAUM, V33, P89, DOI 10.1089/neu.2014.3843; Ries AJ, 2014, J NEUROSCI NEUROENG, V3, P10, DOI DOI 10.1166/JNSNE.2014.1092; Schnakers C, 2009, BMC NEUROL, V9, DOI 10.1186/1471-2377-9-35; Sculthorpe-Petley L, 2015, J NEUROSCI METH, V245, P64, DOI 10.1016/j.jneumeth.2015.02.008; SUTTON S, 1967, SCIENCE, V155, P1436, DOI 10.1126/science.155.3768.1436; TEASDALE G, 1974, LANCET, V2, P81; Vanhaudenhuyse A, 2008, NEUROCRIT CARE, V8, P262, DOI 10.1007/s12028-007-9016-0; Wijnen VJM, 2007, CLIN NEUROPHYSIOL, V118, P597, DOI 10.1016/j.clinph.2006.11.020; Williams LM, 2005, INT J NEUROSCI, V115, P1605, DOI 10.1080/00207450590958475; Yeo MVM, 2009, SAFETY SCI, V47, P115, DOI 10.1016/j.ssci.2008.01.007	34	22	23	0	11	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1662-453X			FRONT NEUROSCI-SWITZ	Front. Neurosci.	MAY 12	2016	10								211	10.3389/fnins.2016.00211			10	Neurosciences	Neurosciences & Neurology	DL7OA	WOS:000375828800001	27242415	DOAJ Gold, Green Published			2021-06-18	
J	Anderson, BL; Gittelman, MA; Mann, JK; Cyriac, RL; Pomerantz, WJ				Anderson, Brit L.; Gittelman, Michael A.; Mann, Jessica K.; Cyriac, RoseAnn L.; Pomerantz, Wendy J.			High School Football Players' Knowledge and Attitudes About Concussions	CLINICAL JOURNAL OF SPORT MEDICINE			English	Article						concussion; athletes; knowledge; attitudes	INTERNATIONAL-CONFERENCE; CONSENSUS STATEMENT; SPORT HELD; ZURICH	Objectives: To assess high school (HS) football players' knowledge of concussions and to determine whether increased knowledge is correlated with better attitudes toward reporting concussion symptoms and abstaining from play. Design: Two survey tools were used to assess athletes' knowledge and attitudes about concussions. Surveys collected information about demographics, knowledge about concussions, and attitudes about playing sports after a concussion. All athletes present completed one of the 2 surveys. A knowledge and attitude score for each survey was calculated. Frequencies and mean values were used to characterize the population; regression analysis, analysis of variance, and t tests were used to look for associations. Setting: A football camp for HS athletes in the Cincinnati area. Participants: Male HS football players from competitive football programs in the Cincinnati area. Intervention: None. Main Outcome Measure: Scores on knowledge and attitude sections; responses to individual questions. Results: One hundred twenty (100%) athletes were enrolled although not every athlete responded to every question. Thirty (25%) reported history of a concussion; 82 (70%) reported receiving prior concussion education. More than 75% correctly recognized all concussion symptoms that were asked, except "feeling in a fog" [n = 63 (53%)]. One hundred nine (92%) recognized a risk of serious injury if they return to play too quickly. Sixty-four (54%) athletes would report symptoms of a concussion to their coach; 62 (53%) would continue to play with a headache from an injury. There was no association between knowledge score and attitude score (P = 0.08). Conclusions: Despite having knowledge about the symptoms and danger of concussions, many HS football athletes in our sample did not have a positive attitude toward reporting symptoms or abstaining from play after a concussion. Clinical Relevance: Physicians should be aware that young athletes may not report concussion symptoms.	[Anderson, Brit L.; Gittelman, Michael A.; Cyriac, RoseAnn L.; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Div Emergency Med, Cincinnati, OH 45229 USA; [Gittelman, Michael A.; Mann, Jessica K.; Pomerantz, Wendy J.] Cincinnati Childrens Hosp Med Ctr, Comprehens Childrens Injury Ctr, Cincinnati, OH 45229 USA; [Mann, Jessica K.] Univ Cincinnati, Phys Orthopaed & Sports Med, Cincinnati, OH USA	Anderson, BL (corresponding author), Kosair Childrens Hosp, Div Emergency Med, 231 E Chestnut St, Louisville, KY 40202 USA.	brit.anderson@louisville.edu			Ohio Department of Public Safety Division of EMS; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000077] Funding Source: NIH RePORTER	Supported by a grant from the Ohio Department of Public Safety Division of EMS.	Aubry M, 2002, CLIN J SPORT MED, V12, P6, DOI 10.1097/00042752-200201000-00005; Bagley AF, 2012, CLIN J SPORT MED, V22, P385, DOI 10.1097/JSM.0b013e3182639bb4; Centers for Disease Control National Center for Injury Prevention and Control, 2013, HEADS CONC HIGH SCH; Chrisman SP, 2013, J ADOLESCENT HEALTH, V52, P330, DOI 10.1016/j.jadohealth.2012.10.271; Covassin T, 2012, J SCHOOL HEALTH, V82, P233, DOI 10.1111/j.1746-1561.2012.00692.x; Gessel LM, 2007, J ATHL TRAINING, V42, P495; Gilchrist Julie, 2011, Morbidity and Mortality Weekly Report, V60, P1337; Kaut KP, 2003, CLIN J SPORT MED, V13, P213, DOI 10.1097/00042752-200307000-00004; McCrea HJ, 2013, SPORTS HEALTH, V5, P160, DOI 10.1177/1941738112462203; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory Paul, 2005, Clin J Sport Med, V15, P48; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McCrory P, 2009, CLIN J SPORT MED, V19, P185, DOI 10.1097/JSM.0b013e3181a501db; Rosenbaum AM, 2010, J CLIN EXP NEUROPSYC, V32, P44, DOI 10.1080/13803390902806535; Shenouda C, 2012, PM&R, V4, P427, DOI 10.1016/j.pmrj.2012.02.016; Sye G, 2006, BRIT J SPORT MED, V40, P1003, DOI 10.1136/bjsm.2005.020511; Williamson IJS, 2006, BRIT J SPORT MED, V40, P128, DOI 10.1136/bjsm.2005.021832	17	22	22	0	17	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1050-642X	1536-3724		CLIN J SPORT MED	Clin. J. Sport Med.	MAY	2016	26	3					206	209		10.1097/JSM.0000000000000214			4	Orthopedics; Physiology; Sport Sciences	Orthopedics; Physiology; Sport Sciences	DL4KX	WOS:000375605800008	26035681				2021-06-18	
J	Ferguson, NM; Shein, SL; Kochanek, PM; Luther, J; Wisniewski, SR; Clark, RSB; Tyler-Kabara, EC; Adelson, PD; Bell, MJ				Ferguson, Nikki Miller; Shein, Steven L.; Kochanek, Patrick M.; Luther, Jim; Wisniewski, Stephen R.; Clark, Robert S. B.; Tyler-Kabara, Elizabeth C.; Adelson, P. David; Bell, Michael J.			Intracranial Hypertension and Cerebral Hypoperfusion in Children With Severe Traumatic Brain Injury: Thresholds and Burden in Accidental and Abusive Insults	PEDIATRIC CRITICAL CARE MEDICINE			English	Article						children; cerebral perfusion pressure; intracranial hypertension; intracranial pressure; pediatric neurocritical care; traumatic brain injury	PERFUSION-PRESSURE; UNITED-STATES; AUTOREGULATION; SURVIVAL; TRIAL	Objectives: The evidence to guide therapy in pediatric traumatic brain injury is lacking, including insight into the intracranial pressure/cerebral perfusion pressure thresholds in abusive head trauma. We examined intracranial pressure/cerebral perfusion pressure thresholds and indices of intracranial pressure and cerebral perfusion pressure burden in relationship with outcome in severe traumatic brain injury and in accidental and abusive head trauma cohorts. Design: A prospective observational study. Setting: PICU in a tertiary children's hospital. Patients: Children less than 18 years old admitted to a PICU with severe traumatic brain injury and who had intracranial pressure monitoring. Interventions: None. Measurements and Main Results: A pediatric traumatic brain injury database was interrogated with 85 patients (18 abusive head trauma) enrolled. Hourly intracranial pressure and cerebral perfusion pressure (in mm Hg) were collated and compared with various thresholds. C-statistics for intracranial pressure and cerebral perfusion pressure data in the entire population were determined. Intracranial hypertension and cerebral hypoperfusion indices were formulated based on the number of hours with intracranial pressure more than 20 mm Hg and cerebral perfusion pressure less than 50 mm Hg, respectively. A secondary analysis was performed on accidental and abusive head trauma cohorts. All of these were compared with dichotomized 6-month Glasgow Outcome Scale scores. The models with the number of hours with intracranial pressure more than 20 mm Hg (C = 0.641; 95% CI, 0.523-0.762) and cerebral perfusion pressure less than 45 mm Hg (C = 0.702; 95% CI, 0.586-0.805) had the best fits to discriminate outcome. Two factors were independently associated with a poor outcome, the number of hours with intracranial pressure more than 20 mm Hg and abusive head trauma (odds ratio = 5.101; 95% CI, 1.571-16.563). As the number of hours with intracranial pressure more than 20 mm Hg increases by 1, the odds of a poor outcome increased by 4.6% (odds ratio = 1.046; 95% CI, 1.012-1.082). Thresholds did not differ between accidental versus abusive head trauma. The intracranial hypertension and cerebral hypoperfusion indices were both associated with outcomes. Conclusions: The duration of hours of intracranial pressure more than 20 mm Hg and cerebral perfusion pressure less than 45 mm Hg best discriminated poor outcome. As the number of hours with intracranial pressure more than 20 mm Hg increases by 1, the odds of a poor outcome increased by 4.6%. Although abusive head trauma was strongly associated with unfavorable outcome, intracranial pressure/cerebral perfusion pressure thresholds did not differ between accidental and abusive head trauma.	[Ferguson, Nikki Miller; Shein, Steven L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA; [Ferguson, Nikki Miller; Shein, Steven L.; Kochanek, Patrick M.; Clark, Robert S. B.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA; [Luther, Jim; Wisniewski, Stephen R.] Univ Pittsburgh, Sch Med, Dept Epidemiol & Biostat, Pittsburgh, PA USA; [Tyler-Kabara, Elizabeth C.; Bell, Michael J.] Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA; [Adelson, P. David] Phoenix Childrens Hosp, Barrow Neurol Inst, Dept Neurol Surg, Phoenix, AZ USA	Bell, MJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Crit Care Med, Pittsburgh, PA 15260 USA.; Bell, MJ (corresponding author), Univ Pittsburgh, Sch Med, Safar Ctr Resuscitat Res, Pittsburgh, PA 15260 USA.; Bell, MJ (corresponding author), Univ Pittsburgh, Sch Med, Dept Neurol Surg, Pittsburgh, PA 15260 USA.	bellmj4@upmc.edu	Shein, Steven/I-7763-2019; Ferguson, Nikki Miller/AAA-4548-2020; Adelson, David/W-2083-2019; Tyler-Kabara, Elizabeth/H-4930-2013	Shein, Steven/0000-0003-3382-5159; Tyler-Kabara, Elizabeth/0000-0003-3286-1094; Wisniewski, Stephen/0000-0002-3877-9860	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32 HD040686, NS052478, NS069247, NS081041, HD0499893, NS072308]; National Institutes of Health (NIH)United States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [T32]; Society of Critical Care Medicine; Elsevier book royalties; Consulting through TKGroup, LLC; University of TorontoUniversity of Toronto; DARPA NIH; Codman Neuro;  [NIH/NICHD-5T32HD040686]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [T32HD040686] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [U01NS052478, R01NS072308, U01NS081041, R01NS069247] Funding Source: NIH RePORTER	The authors of this work received National Institutes of Health grants (Drs. Ferguson and Shein: T32 HD040686; Dr. Wisniewski: NS052478 and NS069247; Dr. Clark: NS069247; Dr. Adelson: NS081041 and NS052478, Dr. Bell: NS081041, HD0499893, NS072308, and NS052478).; Dr. Bell received support for article research from the National Institutes of Health (NIH). Dr. Ferguson received support for article research from the NIH. Her institution received funding from the NIH/NICHD-5T32HD040686. Dr. Shein received support for article research from the NIH. His institution received funding from NIH (T32). Dr. Kochanek is also the editor and/or contributor to multiple textbooks in the field. He received support for article research from the NIH, received funding from the Society of Critical Care Medicine, he serves as a guest professor and lectures frequently at Medical Centers and other Institutions of Higher Education, and he has served as an expert witness in legal cases. His institution received funding from the NIH. Dr. Wisniewski received support for article research from the NIH. His institution received funding from the NIH. Dr. Clark received funding from Elsevier book royalties. His institution received funding from NIH grants unrelated to present work. Dr. Tyler-Kabara received funding from Consulting through TKGroup, LLC (No monies personally received) and from University of Toronto. Her institution received funding from DARPA NIH. Dr. Adelson consulted for Adelson Medical Consulting, LLC; is employed by Phoenix Children's Hospital; provided expert testimony for various medical legal case; and received royalties from Thieme Publishing. His institution received grant support from Codman Neuro and the NIH. Dr. Luther disclosed that he does not have any potential conflicts of interest.	Adelson PD, 2005, NEUROSURGERY, V56, P740, DOI 10.1227/01.NEU.0000156471.50726.26; Allen BB, 2014, PEDIATR CRIT CARE ME, V15, P62, DOI 10.1097/PCC.0b013e3182a556ea; Au AK, 2011, PEDIATR CRIT CARE ME, V12, P566, DOI 10.1097/PCC.0b013e3181fe3420; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Brain Trauma Foundation, 2007, J Neurotrauma, V24 Suppl 1, pS59, DOI 10.1089/neu.2007.9990; Catala-Temprano A, 2007, J NEUROSURG, V106, P463, DOI 10.3171/ped.2007.106.6.463; Chambers IR, 2005, CHILD NERV SYST, V21, P195, DOI 10.1007/s00381-004-1060-x; Chesnut RM, 2012, NEW ENGL J MED, V367, P2471, DOI 10.1056/NEJMoa1207363; Cho DY, 1995, PEDIATR NEUROSURG, V23, P192, DOI 10.1159/000120958; Cooper DJ, 2011, NEW ENGL J MED, V364, P1493, DOI 10.1056/NEJMoa1102077; Coronado Victor G., 2011, Morbidity and Mortality Weekly Report, V60, P1; Downard C, 2000, J TRAUMA, V49, P654, DOI 10.1097/00005373-200010000-00012; Exo J, 2011, PEDIATR CRIT CARE ME, V12, P560, DOI 10.1097/PCC.0b013e3181e8b3ee; Grinkeviciute DE, 2008, MEDICINA-LITHUANIA, V44, P119, DOI 10.3390/medicina44020015; Jagannathan J, 2008, J NEUROSURG-PEDIATR, V2, P240, DOI 10.3171/PED.2008.2.10.240; Kochanek PM, 2012, PEDIATR CRIT CARE ME, V13, pS1, DOI 10.1097/PCC.0b013e31823f435c; Mathews TJ, 2011, PEDIATRICS, V127, P146, DOI 10.1542/peds.2010-3175; Mehta A, 2010, DEV NEUROSCI-BASEL, V32, P413, DOI 10.1159/000316804; Schneier AJ, 2006, PEDIATRICS, V118, P483, DOI 10.1542/peds.2005-2588; Vavilala MS, 2007, J NEUROTRAUM, V24, P87, DOI 10.1089/neu.2006.0058; Vavilala MS, 2003, J NEUROSURG ANESTH, V15, P307, DOI 10.1097/00008506-200310000-00003; Venkatesh B, 2004, INTENS CARE MED, V30, P510, DOI 10.1007/s00134-003-2102-7; Vik A, 2008, J NEUROSURG, V109, P678, DOI 10.3171/JNS/2008/109/10/0678; Weersink CSA, 2015, CRIT CARE MED, V43, P1952, DOI 10.1097/CCM.0000000000001165	24	22	23	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1529-7535	1947-3893		PEDIATR CRIT CARE ME	Pediatr. Crit. Care Med.	MAY	2016	17	5					444	450		10.1097/PCC.0000000000000709			7	Critical Care Medicine; Pediatrics	General & Internal Medicine; Pediatrics	DR0KH	WOS:000379595900016	27028792	Green Accepted			2021-06-18	
J	Iverson, GL; Gioia, GA				Iverson, Grant L.; Gioia, Gerard A.			Returning to School Following Sport-Related Concussion	PHYSICAL MEDICINE AND REHABILITATION CLINICS OF NORTH AMERICA			English	Article						Sports; Concussion; Mild traumatic brain injury; TBI; Youth; Pediatric		Following sport-related concussion, the priorities for student athletes are return to school and extracurricular activities. Consensus-based practice recommendations emphasize rest and gradual resumption of activities. Specific evidence-based recommendations are not available. This article provides recommendations, strategies, and a general approach to the recovery process. Most youth recover clinically and return to their normal activities within the first month following injury. It is best to avoid prolonged time off from school and restrictions on social and recreational activities because these might result in adverse consequences, such as life stress, depression, and falling behind in school.	[Iverson, Grant L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Iverson, Grant L.] Spaulding Rehabil Hosp, Boston, MA USA; [Iverson, Grant L.] MassGen Hosp Children, Sport Concuss Program, Boston, MA USA; [Iverson, Grant L.] Massachusetts Gen Hosp, Red Sox Fdn, Home Base Program, Boston, MA 02114 USA; [Iverson, Grant L.] Harvard Univ, Sch Med, Ctr Hlth & Rehabil, Dept Phys Med & Rehabil, 79-96 Thirteenth St, Charlestown, MA 02129 USA; [Gioia, Gerard A.] George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Div Pediat Neuropsychol,Childrens Natl Hlth Syst, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA	Gioia, GA (corresponding author), George Washington Univ, Sch Med, Dept Pediat & Psychiat & Behav Sci, Div Pediat Neuropsychol,Childrens Natl Hlth Syst, 15245 Shady Grove Rd,Suite 350, Rockville, MD 20850 USA.	ggioia@childrensnational.org		Iverson, Grant/0000-0001-7348-9570	CDCCentre National de la Recherche Scientifique (CNRS)United States Department of Health & Human ServicesCenters for Disease Control & Prevention - USA [U17/CCU323352, U49CE001385]; NIH from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH) [M01RR020359]; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P30/HD040677-07]	G. Gioia notes that this article was supported in part by CDC Awards U17/CCU323352 and U49CE001385, and NIH Grants #M01RR020359 from the National Center for Research Resources (NCRR), a component of the National Institutes of Health (NIH), and NIH #P30/HD040677-07.	[Anonymous], 2011, BRAIN 101 CONCUSSION; Belanger HG, 2005, J INT NEUROPSYCH SOC, V11, P345, DOI 10.1017/S1355617705050411; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Centers for Disease Control and Prevention, 2015, HEADS SCH KNOW YOUR; Collins M, 2006, NEUROSURGERY, V58, P275, DOI 10.1227/01.NEU.0000200441.92742.46; Collins MW, 2013, BRAIN INJURY MEDICINE: PRINCIPLES AND PRACTICE, SECOND EDITION, P498; Gioia GA, 2015, J HEAD TRAUMA REHABI; Gioia GA, 2016, J CHILD NEUROL, V31, P93, DOI 10.1177/0883073814555604; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; Pennsylvania Department of Education Brain Injury Association of Pennsylvania Pennsylvania Department of Health, BRAINSTEPS STRAT TEA; Rocky Mountain Hospital for Children, CONC MAN REAP 2015; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008	12	22	22	0	10	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	1047-9651	1558-1381		PHYS MED REH CLIN N	Phys. Med. Rehabil. Clin. N. Am.	MAY	2016	27	2					429	+		10.1016/j.pmr.2015.12.002			10	Rehabilitation	Rehabilitation	DN4RU	WOS:000377055700006	27154854				2021-06-18	
J	Kreutzer, JS; Marwitz, JH; Sima, AP; Bergquist, TF; Johnson-Greene, D; Felix, ER; Whiteneck, GG; Dreer, LE				Kreutzer, Jeffrey S.; Marwitz, Jennifer H.; Sima, Adam P.; Bergquist, Thomas F.; Johnson-Greene, Douglas; Felix, Elizabeth R.; Whiteneck, Gale G.; Dreer, Laura E.			Resilience Following Traumatic Brain Injury: A Traumatic Brain Injury Model Systems Study	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Rehabilitation; Resilience; psychological	CONNOR-DAVIDSON RESILIENCE; PSYCHOLOGICAL RESILIENCE; POSITIVE EMOTIONS; REHABILITATION; PREDICTORS; SCALE; SATISFACTION; INTERVIEW; PEOPLE	Objective: To examine resilience at 3 months after traumatic brain injury (TBI). Design: Cross-sectional analysis of an ongoing observational cohort. Setting: Five inpatient rehabilitation centers, with 3-month follow-up conducted primarily by telephone. Participants: Persons with TBI (N=160) enrolled in the resilience module of the TBI Model System study with 3-month follow-up completed. Interventions: Not applicable. Main Outcome Measure: Connor-Davidson Resilience Scale. Results: Resilience scores were lower than those of the general population. A multivariable regression model, adjusting for other predictors, showed that higher education, absence of preinjury substance abuse, and less anxiety at follow-up were significantly related to greater resilience. Conclusions: Analysis suggests that lack of resilience may be an issue for some individuals after moderate to severe TBI. Identifying persons most likely at risk for low resilience may be useful in planning clinical interventions. (C) 2016 by the American Congress of Rehabilitation Medicine	[Kreutzer, Jeffrey S.; Marwitz, Jennifer H.] Virginia Commonwealth Univ, Dept Phys Med & Rehabil, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Neurol Surg, Richmond, VA USA; [Kreutzer, Jeffrey S.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA; [Sima, Adam P.] Virginia Commonwealth Univ, Dept Biostat, Richmond, VA USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Psychiat & Psychol, Rochester, MN USA; [Bergquist, Thomas F.] Mayo Clin, Coll Med, Dept Phys Med & Rehabil, Rochester, MN USA; [Johnson-Greene, Douglas; Felix, Elizabeth R.] Univ Miami, Miller Sch Med, Dept Phys Med & Rehabil, Miami, FL 33136 USA; [Whiteneck, Gale G.] Craig Hosp, Res Dept, Englewood, CO USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Ophthalmol, Birmingham, AL 35294 USA; [Dreer, Laura E.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA	Marwitz, JH (corresponding author), Virginia Commonwealth Univ, Box 980542, Richmond, VA 23298 USA.	jhmarwit@vcu.edu	Felix, Elizabeth/AAD-6356-2021	Sima, Adam/0000-0001-8426-9987; Felix, Elizabeth/0000-0002-6239-715X	National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR)United States Department of Health & Human Services [90DP0030, 90DP0033, 90DP0034, H133A120096, H133A120099]	Supported by the National Institute on Disability, Independent Living, and Rehabilitation Research (NIDILRR; grant nos. 90DP0030, 90DP0033, 90DP0034, H133A120096, H133A120099). NIDILRR is a Center within the Administration for Community Living (ACL), Department of Health and Human Services (HHS). The contents of this manuscript do not necessarily represent the policy of NIDILRR, ACL, HHS, and you should not assume endorsement by the Federal Government.	Bertisch H, 2014, NEUROREHABILITATION, V34, P573, DOI 10.3233/NRE-141059; Brown SA, 2001, AM J PHYS MED REHAB, V80, P196, DOI 10.1097/00002060-200103000-00009; Campbell-Sills L, 2006, BEHAV RES THER, V44, P585, DOI 10.1016/j.brat.2005.05.001; Campbell-Sills L, 2007, J TRAUMA STRESS, V20, P1019, DOI 10.1002/jts.20271; Campbell-Sills L, 2009, J PSYCHIATR RES, V43, P1007, DOI 10.1016/j.jpsychires.2009.01.013; Cazalis F, 2006, BRAIN INJURY, V20, P1019, DOI 10.1080/02699050600664384; Connor KM, 2006, J CLIN PSYCHIAT, V67, P46; Connor KM, 2003, DEPRESS ANXIETY, V18, P76, DOI 10.1002/da.10113; Curtis WJ, 2003, DEV PSYCHOPATHOL, V15, P773, DOI 10.1017/S0954579403000373; Davis LC, 2012, ARCH PHYS MED REHAB, V93, P1324, DOI 10.1016/j.apmr.2012.02.036; DIENER E, 1985, J PERS ASSESS, V49, P71, DOI 10.1207/s15327752jpa4901_13; Dowrick C, 2008, HEALTH-LONDON, V12, P439, DOI 10.1177/1363459308094419; Edward K.-L., 2005, J AM PSYCHIAT NURSES, V11, P101, DOI [10.1177/1078390305277526, DOI 10.1177/1078390305277526]; Fleminger S, 2008, EUR J ANAESTH, V25, P123, DOI 10.1017/S0265021507003250; Graham DP, 2013, J PSYCHIATR RES, V47, P835, DOI 10.1016/j.jpsychires.2013.02.006; HarrisonFelix C, 1996, J HEAD TRAUMA REHAB, V11, P1, DOI 10.1097/00001199-199610000-00002; Hesdorffer DC, 2009, J HEAD TRAUMA REHAB, V24, P452, DOI 10.1097/HTR.0b013e3181c133fd; Karoly P, 2006, PAIN, V123, P90, DOI 10.1016/j.pain.2006.02.014; Lefebvre H., 2006, ILLNESS CRISIS LOSS, V14, P337, DOI DOI 10.1177/105413730601400403; Losoi H, 2015, J HEAD TRAUMA REHAB, V30, pE24, DOI 10.1097/HTR.0000000000000055; Lukow HR, 2015, J HEAD TRAUMA REHAB, V30, P241, DOI 10.1097/HTR.0000000000000137; Malec JF, 2012, ARCH PHYS MED REHAB, V93, P1603, DOI 10.1016/j.apmr.2012.04.003; McCauley SR, 2013, J NEUROTRAUM, V30, P642, DOI 10.1089/neu.2012.2393; McDonald S, 2008, ARCH PHYS MED REHAB, V89, P1648, DOI 10.1016/j.apmr.2008.02.029; Newman R, 2005, PROF PSYCHOL-RES PR, V36, P227, DOI 10.1037/0735-7028.36.3.227; Norris FH, 2009, SOC SCI MED, V68, P2190, DOI 10.1016/j.socscimed.2009.03.043; Ong AD, 2006, J PERS SOC PSYCHOL, V91, P730, DOI 10.1037/0022-3514.91.4.730; Pavot W, 2009, SOC INDIC RES SER, V39, P101, DOI 10.1007/978-90-481-2354-4_5; Pooley JA, 2010, AUST COMMUNITY PSYCH, V22, P30; Prigatano GP, 2005, J HEAD TRAUMA REHAB, V20, P19, DOI 10.1097/00001199-200501000-00004; RAPPAPORT M, 1982, ARCH PHYS MED REHAB, V63, P118; Rohling ML, 2009, NEUROPSYCHOLOGY, V23, P20, DOI 10.1037/a0013659; Struchen MA, 2008, BRAIN INJURY, V22, P940, DOI 10.1080/02699050802425410; Sullivan KA, 2015, REHABIL PSYCHOL, V60, P147, DOI 10.1037/rep0000037; Tonks J, 2011, BRAIN INJURY, V25, P870, DOI 10.3109/02699052.2011.581641; Tugade MM, 2004, J PERS SOC PSYCHOL, V86, P320, DOI 10.1037/0022-3514.86.2.320; Tulsky DS, 2016, J HEAD TRAUMA REHAB, V31, P40, DOI 10.1097/HTR.0000000000000131; Whelan-Goodinson R, 2008, J REHABIL MED, V40, P850, DOI 10.2340/16501977-0271; White B, 2008, REHABIL PSYCHOL, V53, P9, DOI 10.1037/0090-5550.53.1.9; White B, 2010, REHABIL PSYCHOL, V55, P23, DOI 10.1037/a0018451; Whiteneck GG, 2011, ARCH PHYS MED REHAB, V92, P540, DOI 10.1016/j.apmr.2010.12.002	41	22	22	0	16	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	MAY	2016	97	5					708	713		10.1016/j.apmr.2015.12.003			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DL4UM	WOS:000375633300007	26707459				2021-06-18	
J	Tom, SE; Wickwire, EM; Park, YJ; Albrecht, JS				Tom, Sarah E.; Wickwire, Emerson M.; Park, Yujin; Albrecht, Jennifer S.			Nonbenzodiazepine Sedative Hypnotics and Risk of Fall-Related Injury	SLEEP			English	Article						hip fracture; nonbenzodiazepine sedative hypnotics (NBSH); traumatic brain injury	RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; CASE-CROSSOVER DESIGN; HIP-FRACTURES; OLDER-ADULTS; SLEEP DISTURBANCES; PRIMARY INSOMNIA; ZOLPIDEM; PHARMACOTHERAPY; MEDICATION	Study Objectives: The objective of this study was to test the hypothesis that use of zolpidem, eszopiclone, and zaleplon would be associated with increased risk of traumatic brain injury (TBI) and hip fracture. Methods: We conducted a case-crossover study on a 5% random sample of Medicare beneficiaries age 65 y or older hospitalized with either TBI (n = 15,031) or hip fracture (n = 37,833) during 2007-2009. Use of zolpidem, eszopiclone, or zaleplon during the 30-day period prior to injury hospitalization was compared to use during four control periods at 3, 6, 9, and 12 mo prior to injury. The primary outcome was hospitalization for TBI or hip fracture. Results: Zolpidem use during the month prior to injury was associated with increased risk of TBI (odds ratio [OR] 1.87; 95% confidence interval [CI] 1.56, 2.25); however, eszopiclone use during the same period was not associated with increased risk (OR 0.67; 95% CI 0.40, 1.13). Zolpidem use during the month prior to injury was associated with increased risk of hip fracture (OR 1.59; 95% CI 1.41, 1.79); however, eszopiclone use during the same period was not associated with increased risk (OR 1.12; 95% CI 0.83, 1.50). Analysis of zaleplon use in the month prior to injury was limited by low drug utilization but was not associated with increased risk of TBI (OR 0.85; 95% CI 0.21, 3.34) or hip fracture (OR 0.92; 95% CI 0.40, 2.13) in this study. Conclusions: For the treatment of insomnia in older adults, eszopiclone may present a safer alternative to zolpidem, in terms of fall-related injuries.	[Tom, Sarah E.; Park, Yujin] Univ Maryland, Sch Pharm, Pharmaceut Hlth Serv Res Dept, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Psychiat, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Wickwire, Emerson M.] Univ Maryland, Sch Med, Dept Med, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA; [Albrecht, Jennifer S.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA	Albrecht, JS (corresponding author), Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, 10 S Pine St,MSTF 334C, Baltimore, MD 21201 USA.	jalbrecht@epi.umaryland.edu			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [K12HD43489-14]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K12HD043489] Funding Source: NIH RePORTER	This was not an industry supported study. Dr. Albrecht was supported by NIH grant K12HD43489-14 (Tracey, PI). Dr. Wickwire has moderated non-commercial scientific discussion for Merck and is an equity shareholder in WellTap. The other authors have indicated no financial conflicts of interest.	Ancoli-Israel S, 2009, SLEEP MED, V10, pS7, DOI 10.1016/j.sleep.2009.07.004; Avidan AY, 2005, J AM GERIATR SOC, V53, P955, DOI 10.1111/j.1532-5415.2005.53304.x; Berry SD, 2013, JAMA INTERN MED, V173, P754, DOI 10.1001/jamainternmed.2013.3795; Blackwell T, 2006, J GERONTOL A-BIOL, V61, P405, DOI 10.1093/gerona/61.4.405; Blackwell T, 2014, SLEEP, V37, P655, DOI 10.5665/sleep.3562; Botteman MF, 2007, CNS DRUGS, V21, P319, DOI 10.2165/00023210-200721040-00005; Carroll CP, 2012, NEUROSURGERY, V71, P1064, DOI 10.1227/NEU.0b013e31826f7c16; Center for Medicare and Medicaid Services, CHRON COND DAT WAR; Chung SD, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0067459; Daley M, 2009, SLEEP MED, V10, P427, DOI 10.1016/j.sleep.2008.04.005; Darcourt G, 1999, J PSYCHOPHARMACOL, V13, P81, DOI 10.1177/026988119901300109; Diem Susan J, 2014, J Gerontol Geriatr Res, V3, P158; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fick D, 2012, J AM GERIATR SOC, V60, P616, DOI 10.1111/j.1532-5415.2012.03923.x; Finkle WD, 2011, J AM GERIATR SOC, V59, P1883, DOI 10.1111/j.1532-5415.2011.03591.x; FORD DE, 1989, JAMA-J AM MED ASSOC, V262, P1479, DOI 10.1001/jama.262.11.1479; Ford ES, 2014, SLEEP, V37, P1283, DOI 10.5665/sleep.3914; Fortier-Brochu E, 2012, SLEEP MED REV, V16, P83, DOI 10.1016/j.smrv.2011.03.008; Frey DJ, 2011, J AM GERIATR SOC, V59, P73, DOI 10.1111/j.1532-5415.2010.03229.x; Ganguli M, 1996, J AM GERIATR SOC, V44, P778, DOI 10.1111/j.1532-5415.1996.tb03733.x; Jacobs GD, 2004, ARCH INTERN MED, V164, P1888, DOI 10.1001/archinte.164.17.1888; Kang Dong-Yoon, 2012, J Prev Med Public Health, V45, P219, DOI 10.3961/jpmph.2012.45.4.219; Lai MM, 2014, MAYO CLIN PROC, V89, P589, DOI 10.1016/j.mayocp.2014.01.021; Leger D, 2014, J SLEEP RES, V23, P143, DOI 10.1111/jsr.12104; Lin FY, 2014, SLEEP, V37, P673, DOI 10.5665/sleep.3566; Maclure M, 2000, ANNU REV PUBL HEALTH, V21, P193, DOI 10.1146/annurev.publhealth.21.1.193; MACLURE M, 1991, AM J EPIDEMIOL, V133, P144, DOI 10.1093/oxfordjournals.aje.a115853; Marr AL., 2004, CENTRAL NERVOUS SYST; Morin CM, 2009, JAMA-J AM MED ASSOC, V301, P2005, DOI 10.1001/jama.2009.682; Morin CM, 1999, JAMA-J AM MED ASSOC, V281, P991, DOI 10.1001/jama.281.11.991; Mullington JM, 2009, PROG CARDIOVASC DIS, V51, P294, DOI 10.1016/j.pcad.2008.10.003; SALVA P, 1995, CLIN PHARMACOKINET, V29, P142, DOI 10.2165/00003088-199529030-00002; Sauvanet JP, 1988, IMIDAZOPYRIDINES SLE; Schutte-Rodin S, 2008, J CLIN SLEEP MED, V4, P487; Sivertsen B, 2006, JAMA-J AM MED ASSOC, V295, P2851, DOI 10.1001/jama.295.24.2851; Stone KL, 2008, ARCH INTERN MED, V168, P1768, DOI 10.1001/archinte.168.16.1768; Stone KL, 2014, J AM GERIATR SOC, V62, P299, DOI 10.1111/jgs.12649; Tariq SH, 2008, CLIN GERIATR MED, V24, P93, DOI 10.1016/j.cger.2007.08.009; Thurman DJ., 1995, GUIDELINES SURVEILLA; Wang PS, 2001, J AM GERIATR SOC, V49, P1685, DOI 10.1111/j.1532-5415.2001.49280.x; Zint K, 2010, PHARMACOEPIDEM DR S, V19, P1248, DOI 10.1002/pds.2031	41	22	24	0	9	OXFORD UNIV PRESS INC	CARY	JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA		1550-9109		SLEEP	Sleep	MAY 1	2016	39	5					1009	1014	PII sp-00414-15	10.5665/sleep.5742			6	Clinical Neurology; Neurosciences	Neurosciences & Neurology	DK8PE	WOS:000375188400007	26943470	Green Published, Bronze			2021-06-18	
J	Xu, J; Sisniega, A; Zbijewski, W; Dang, H; Stayman, JW; Wang, X; Foos, DH; Aygun, N; Koliatsos, VE; Siewerdsen, JH				Xu, J.; Sisniega, A.; Zbijewski, W.; Dang, H.; Stayman, J. W.; Wang, X.; Foos, D. H.; Aygun, N.; Koliatsos, V. E.; Siewerdsen, J. H.			Modeling and design of a cone-beam CT head scanner using task-based imaging performance optimization	PHYSICS IN MEDICINE AND BIOLOGY			English	Article						cone-beam computed tomography; cascaded systems analysis; image quality; imaging task; detectability index; traumatic brain injury; intracranial hemorrhage	CASCADED SYSTEMS-ANALYSIS; NOISE-POWER SPECTRUM; FLAT-PANEL DETECTOR; DEDICATED BREAST CT; X-RAY-DETECTOR; COMPUTED-TOMOGRAPHY; ARTIFACT-CORRECTION; QUALITY; MOBILE; RECONSTRUCTION	Detection of acute intracranial hemorrhage (ICH) is important for diagnosis and treatment of traumatic brain injury, stroke, postoperative bleeding, and other head and neck injuries. This paper details the design and development of a cone-beam CT (CBCT) system developed specifically for the detection of low-contrast ICH in a form suitable for application at the point of care. Recognizing such a low-contrast imaging task to be a major challenge in CBCT, the system design began with a rigorous analysis of task-based detectability including critical aspects of system geometry, hardware configuration, and artifact correction. The imaging performance model described the three-dimensional (3D) noiseequivalent quanta using a cascaded systems model that included the effects of scatter, scatter correction, hardware considerations of complementary metaloxide semiconductor (CMOS) and flat-panel detectors (FPDs), and digitization bit depth. The performance was analyzed with respect to a low-contrast (40-80 HU), medium-frequency task representing acute ICH detection. The task-based detectability index was computed using a non-prewhitening observer model. The optimization was performed with respect to four major design considerations: (1) system geometry (including source-to-detector distance (SDD) and sourceto-axis distance (SAD)); (2) factors related to the x-ray source (including focal spot size, kVp, dose, and tube power); (3) scatter correction and selection of an antiscatter grid; and (4) x-ray detector configuration (including pixel size, additive electronics noise, field of view (FOV), and frame rate, including both CMOS and a-Si: H FPDs). Optimal design choices were also considered with respect to practical constraints and available hardware components. The model was verified in comparison to measurements on a CBCT imaging bench as a function of the numerous design parameters mentioned above. An extended geometry (SAD = 750 mm, SDD = 1100 mm) was found to be advantageous in terms of patient dose (20 mGy) and scatter reduction, while a more isocentric configuration (SAD = 550 mm, SDD = 1000 mm) was found to give a more compact and mechanically favorable configuration with minor tradeoff in detectability. An x-ray source with a 0.6 mm focal spot size provided the best compromise between spatial resolution requirements and x-ray tube power. Use of a modest anti-scatter grid (8: 1 GR) at a 20 mGy dose provided slight improvement (similar to 5-10%) in the detectability index, but the benefit was lost at reduced dose. The potential advantages of CMOS detectors over FPDs were quantified, showing that both detectors provided sufficient spatial resolution for ICH detection, while the former provided a potentially superior low-dose performance, and the latter provided the requisite FOV for volumetric imaging in a centered-detector geometry. Task-based imaging performance modeling provides an important starting point for CBCT system design, especially for the challenging task of ICH detection, which is somewhat beyond the capabilities of existing CBCT platforms. The model identifies important tradeoffs in system geometry and hardware configuration, and it supports the development of a dedicated CBCT system for point-of-care application. A prototype suitable for clinical studies is in development based on this analysis.	[Xu, J.; Sisniega, A.; Zbijewski, W.; Dang, H.; Stayman, J. W.; Siewerdsen, J. H.] Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA; [Wang, X.; Foos, D. H.] Carestream Hlth, Rochester, NY 14608 USA; [Aygun, N.; Siewerdsen, J. H.] Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA; [Koliatsos, V. E.] Johns Hopkins Univ, Dept Neurol, Baltimore, MD 21205 USA	Siewerdsen, JH (corresponding author), Johns Hopkins Univ, Dept Biomed Engn, Baltimore, MD 21205 USA.; Siewerdsen, JH (corresponding author), Johns Hopkins Univ, Russell H Morgan Dept Radiol, Baltimore, MD 21205 USA.	jeff.siewerdsen@jhu.edu	Dang, Hao/U-4865-2018	Dang, Hao/0000-0001-5861-6535; Sisniega, Alejandro/0000-0003-2030-2711; Stayman, Joseph/0000-0003-4358-378X	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-CA-112163]; Carestream Health (Rochester NY)	This work was supported by the National Institutes of Health (R01-CA-112163) and academic-industry partnership with Carestream Health (Rochester NY).	ADAMS JH, 1989, HISTOPATHOLOGY, V15, P49, DOI 10.1111/j.1365-2559.1989.tb03040.x; Albert M, 2000, MED PHYS, V27, P2417, DOI 10.1118/1.1286592; ANTONUK LE, 1995, P SOC PHOTO-OPT INS, V2432, P216, DOI 10.1117/12.208340; Badal A, 2009, IEEE T MED IMAGING, V28, P1894, DOI 10.1109/TMI.2009.2021615; Badano A, 2011, MED PHYS, V38, P2095, DOI 10.1118/1.3567497; BARRETT HH, 1993, P NATL ACAD SCI USA, V90, P9758, DOI 10.1073/pnas.90.21.9758; Berger M.J, 1998, NIST STAND REF DATAB, V8, P87; Boone JM, 2001, RADIOLOGY, V221, P657, DOI 10.1148/radiol.2213010334; Boone JM, 1997, MED PHYS, V24, P1661, DOI 10.1118/1.597953; Carlson AP, 2012, J NEUROIMAGING, V22, P408, DOI 10.1111/j.1552-6569.2011.00621.x; Carrino JA, 2014, RADIOLOGY, V270, P816, DOI 10.1148/radiol.13130225; CHO PS, 1995, PHYS MED BIOL, V40, P1863, DOI 10.1088/0031-9155/40/11/007; Cho YB, 2005, MED PHYS, V32, P968, DOI 10.1118/1.1869652; Cunningham IA, 1998, P SOC PHOTO-OPT INS, V3336, P220, DOI 10.1117/12.317021; Dang H, 2015, PHYS MED BIOL, V60, P6153, DOI 10.1088/0031-9155/60/16/6153; DAY GJ, 1983, PHYS MED BIOL, V28, P1429, DOI 10.1088/0031-9155/28/12/008; DUBLIN AB, 1977, RADIOLOGY, V122, P365, DOI 10.1148/122.2.365; Fredenberg E, 2012, MED PHYS, V39, P5317, DOI 10.1118/1.4739195; Frey EC, 2002, IEEE T MED IMAGING, V21, P1040, DOI 10.1109/TMI.2002.804437; Gang GJ, 2014, MED PHYS, V41, P260, DOI 10.1118/1.4883816; Gang GJ, 2011, MED PHYS, V38, P1754, DOI 10.1118/1.3560428; Gean AD, 2010, NEUROIMAG CLIN N AM, V20, P527, DOI 10.1016/j.nic.2010.08.001; Gerlach R, 2008, NEUROSURGERY, V63, P272, DOI 10.1227/01.NEU.0000312362.63693.78; Granfors PR, 2003, MED PHYS, V30, P2715, DOI 10.1118/1.1609151; Hajdok G, 2006, MED PHYS, V33, P3601, DOI 10.1118/1.2336507; Huda W, 2001, MED PHYS, V28, P393, DOI 10.1118/1.1350435; Islam MK, 2006, MED PHYS, V33, P1573, DOI 10.1118/1.2198169; Kidwell CS, 2008, LANCET NEUROL, V7, P256, DOI 10.1016/S1474-4422(08)70041-3; Konstantinidis AC, 2012, NUCL INSTRUM METH A, V689, P12, DOI 10.1016/j.nima.2012.06.024; Laker SR, 2011, PM&R, V3, pS354, DOI 10.1016/j.pmrj.2011.07.017; Leung R, 2011, AM J RHINOL ALLERGY, V25, P299, DOI 10.2500/ajra.2011.25.3641; Levivier M, 2003, NEUROSURGERY, V53, P1001, DOI 10.1227/01.NEU.0000084167.18475.BA; Li K, 2013, MED PHYS, V40, DOI 10.1118/1.4788647; Linfante I, 1999, STROKE, V30, P2263, DOI 10.1161/01.STR.30.11.2263; Manolakis D. G., 1988, INTRO DIGITAL SIGNAL; Mieville FA, 2013, PHYS MEDICA, V29, P99, DOI 10.1016/j.ejmp.2011.12.004; Mozaffarian D, 2015, CIRCULATION, V131, pE29, DOI [10.1161/01.cir.0000441139.02102.80, 10.1161/CIR.0000000000000152, 10.1161/CIR.0b013e31828124ad]; NEITZEL U, 1992, MED PHYS, V19, P475, DOI 10.1118/1.596836; Nilsson HE, 2004, IEEE T NUCL SCI, V51, P1636, DOI 10.1109/TNS.2004.832577; Pineda AR, 2012, MED PHYS, V39, P3240, DOI 10.1118/1.4705354; Powers WJ, 1998, NEUROLOGY, V50, P842, DOI 10.1212/WNL.50.4.842; Prakash P, 2011, MED PHYS, V38, P5612, DOI 10.1118/1.3633937; Prell D, 2009, PHYS MED BIOL, V54, P6575, DOI 10.1088/0031-9155/54/21/009; Reiser I, 2010, MED PHYS, V37, P1591, DOI 10.1118/1.3357288; Richard S, 2008, MED PHYS, V35, P586, DOI 10.1118/1.2826556; Samei E, 1998, MED PHYS, V25, P102, DOI 10.1118/1.598165; Scarfe William C, 2008, Dent Clin North Am, V52, P707, DOI 10.1016/j.cden.2008.05.005; Schafer S, 2011, MED PHYS, V38, P4563, DOI 10.1118/1.3597566; Schellinger PD, 2000, AM J NEURORADIOL, V21, P1184; Sechopoulos I, 2009, MED PHYS, V36, P1199, DOI 10.1118/1.3090889; Siewerdsen J H, 2014, HDB MED IMAGE PERCEP, P335; Siewerdsen JH, 2011, NUCL INSTRUM METH A, V648, pS241, DOI 10.1016/j.nima.2010.11.088; Siewerdsen JH, 1998, MED PHYS, V25, P614, DOI 10.1118/1.598243; Siewerdsen JH, 2005, MED PHYS, V32, P241, DOI 10.1118/1.1836331; Siewerdsen JH, 2004, MED PHYS, V31, P3057, DOI 10.1118/1.1758350; Siewerdsen JH, 2002, MED PHYS, V29, P2655, DOI 10.1118/1.1513158; Siewerdsen JH, 1997, MED PHYS, V24, P71, DOI 10.1118/1.597919; Siewerdsen JH, 1996, P SOC PHOTO-OPT INS, V2708, P484, DOI 10.1117/12.237810; Siewerdsen JH, 2000, MED PHYS, V27, P1903, DOI 10.1118/1.1286590; Sisniega A, 2015, PHYS MED BIOL, V60, P1415, DOI 10.1088/0031-9155/60/4/1415; Sisniega A, 2013, MED PHYS, V40, DOI 10.1118/1.4801895; Suryanarayanan S, 2006, PHYS MED BIOL, V51, P3041, DOI 10.1088/0031-9155/51/12/003; Tanguay J, 2013, MED PHYS, V40, DOI 10.1118/1.4794499; Tward DJ, 2009, MED PHYS, V36, P3830, DOI 10.1118/1.3166933; Tward DJ, 2008, MED PHYS, V35, P5510, DOI 10.1118/1.3002414; Vedantham S, 2013, PHYS MED BIOL, V58, P4099, DOI 10.1088/0031-9155/58/12/4099; Vedula AA, 2003, P SOC PHOTO-OPT INS, V5030, P349, DOI 10.1117/12.480015; Walden RH, 1999, IEEE J SEL AREA COMM, V17, P539, DOI 10.1109/49.761034; Wang AS, 2011, MED PHYS, V38, P4265, DOI 10.1118/1.3592932; Wunderlich A, 2009, IEEE T MED IMAGING, V28, P1198, DOI 10.1109/TMI.2009.2012705; Xi GH, 2006, LANCET NEUROL, V5, P53, DOI 10.1016/S1474-4422(05)70283-0; Xu J, 2014, MED PHYS, V41, DOI 10.1118/1.4894733; Xu J, 2012, MED PHYS, V39, P4932, DOI 10.1118/1.4736805; Yan H, 2014, MED PHYS, V41, DOI 10.1118/1.4898324; Yu LF, 2013, MED PHYS, V40, DOI 10.1118/1.4794498; Yu LF, 2010, AM J ROENTGENOL, V194, pW193, DOI 10.2214/AJR.09.2951; Zbijewski W, 2007, IEEE NUCL SCI CONF R, P2985, DOI 10.1109/NSSMIC.2007.4436761; Zhao B, 2008, MED PHYS, V35, P5219, DOI 10.1118/1.2996014; Zhao W, 2003, MED PHYS, V30, P254, DOI 10.1118/1.1538233; Zhao Z, 2014, MED PHYS, V41, DOI 10.1118/1.4875688	80	22	22	2	15	IOP PUBLISHING LTD	BRISTOL	TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND	0031-9155	1361-6560		PHYS MED BIOL	Phys. Med. Biol.	APR 21	2016	61	8					3180	3207		10.1088/0031-9155/61/8/3180			28	Engineering, Biomedical; Radiology, Nuclear Medicine & Medical Imaging	Engineering; Radiology, Nuclear Medicine & Medical Imaging	DJ2EU	WOS:000374017300014	27025783				2021-06-18	
J	Donker-Cools, BHPM; Wind, H; Frings-Dresen, MHW				Donker-Cools, Birgit H. P. M.; Wind, Haije; Frings-Dresen, Monique H. W.			Prognostic factors of return to work after traumatic or non-traumatic acquired brain injury	DISABILITY AND REHABILITATION			English	Article						Acquired brain injury; return to work; stroke; traumatic brain injury; vocational rehabilitation	TERM-FOLLOW-UP; ISCHEMIC-STROKE; POSTTRAUMATIC AMNESIA; MULTICENTER ANALYSIS; EMPLOYMENT OUTCOMES; RACIAL-DIFFERENCES; ACUTE PREDICTORS; DISABILITY; POPULATION; REHABILITATION	Purpose: To investigate and to determine evidence of prognostic factors for return to work (RTW) after acquired brain injury (ABI). Method: A systematic literature search was conducted in PubMed (2008-2014), applying terms for ABI and RTW. In addition, studies published after 2003 of a previous review on the same topic were added. The methodological quality of the included studies was assessed and evidence was classified. Results: Twenty-seven studies were included. There is strong evidence that a high education level is positively associated with RTW after traumatic ABI; a low education level, unemployment and length of stay in rehabilitation are negatively associated, and a clear tendency has been deduced from the studies that conscious state in the Emergency Department is not associated with RTW. After non-traumatic ABI, there is strong evidence that independence in activities of daily living is positively associated with RTW and aetiology of stroke is not. Conclusions: This study confirms earlier findings that after both traumatic and non-traumatic ABI injury related factors in the Emergency Department are not associated with RTW. In addition, it provides further evidence that personal factors after traumatic ABI and activity-related factors after non-traumatic ABI are strongly associated with RTW.Implications for RehabilitationWe found strong evidence for a significant association between RTW and personal factors (education level, unemployment) after traumatic ABI, and activities of daily living (ADL) after non-traumatic ABI.We advise to focus on work-related activities during the RTW process besides ADL-training and pay attention to and support patients at risk for not returning to work.	[Donker-Cools, Birgit H. P. M.; Wind, Haije; Frings-Dresen, Monique H. W.] Univ Amsterdam, Coronel Inst Occupat Hlth, Acad Med Ctr, NL-1100 DE Amsterdam, Netherlands; [Donker-Cools, Birgit H. P. M.; Wind, Haije; Frings-Dresen, Monique H. W.] Res Ctr Insurance Med, Amsterdam, Netherlands	Donker-Cools, BHPM (corresponding author), Univ Amsterdam, Coronel Inst Occupat Hlth, Acad Med Ctr, POB 22700, NL-1100 DE Amsterdam, Netherlands.	b.h.cools@amc.uva.nl					Alaszewski A, 2007, DISABIL REHABIL, V29, P1858, DOI 10.1080/09638280601143356; Andelic N, 2012, BRAIN INJURY, V26, P261, DOI 10.3109/02699052.2012.654589; Arango-Lasprilla JC, 2008, ARCH PHYS MED REHAB, V89, P988, DOI 10.1016/j.apmr.2008.02.012; Avesani R, 2005, BRAIN INJURY, V19, P933, DOI 10.1080/02699050400002371; Borghouts JAJ, 1998, PAIN, V77, P1, DOI 10.1016/S0304-3959(98)00058-X; Brown AW, 2010, BRAIN INJURY, V24, P472, DOI 10.3109/02699051003610466; Busch MA, 2009, J NEUROL NEUROSUR PS, V80, P888, DOI 10.1136/jnnp.2008.163295; Cifu DX, 1997, ARCH PHYS MED REHAB, V78, P125, DOI 10.1016/S0003-9993(97)90252-5; Clay FJ, 2010, INJURY, V41, P787, DOI 10.1016/j.injury.2010.04.005; de Croon EM, 2004, ANN RHEUM DIS, V63, P1362, DOI 10.1136/ard.2003.020115; Dekkers-Sanchez PM, 2008, OCCUP ENVIRON MED, V65, P153, DOI 10.1136/oem.2007.034983; Detaille SI, 2009, SCAND J WORK ENV HEA, V35, P261, DOI 10.5271/sjweh.1337; Doucet T., 2012, Annals of Physical and Rehabilitation Medicine, V55, P112, DOI 10.1016/j.rehab.2012.01.007; Esbjornsson E, 2013, BRAIN INJURY, V27, P521, DOI 10.3109/02699052.2012.743179; Fadyl JK, 2009, J HEAD TRAUMA REHAB, V24, P195, DOI 10.1097/HTR.0b013e3181a0d458; Franulic A, 2004, BRAIN INJURY, V18, P119, DOI 10.1080/0269905031000149515; Fraser R, 2006, J VOCAT REHABIL, V25, P141; Gary KW, 2009, ARCH PHYS MED REHAB, V90, P1699, DOI 10.1016/j.apmr.2009.04.014; Glozier N, 2008, STROKE, V39, P1526, DOI 10.1161/STROKEAHA.107.503219; Grauwmeijer E, 2012, ARCH PHYS MED REHAB, V93, P993, DOI 10.1016/j.apmr.2012.01.018; Guerin F, 2006, NEUROREHABILITATION, V21, P295; Hackett ML, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0041795; Hannerz H, 2012, J OCCUP REHABIL, V22, P456, DOI 10.1007/s10926-012-9367-z; Hyder AA, 2007, NEUROREHABILITATION, V22, P341; Jang Y, 2005, ARCH PHYS MED REHAB, V86, P681, DOI 10.1016/j.apmr.2004.10.025; Kauranen T, 2013, J NEUROL NEUROSUR PS, V84, P316, DOI 10.1136/jnnp-2012-302629; Kersten P, 2002, DISABIL REHABIL, V24, P860, DOI 10.1080/09638280210142167; Ketchum JM, 2012, NEUROREHABILITATION, V30, P13, DOI 10.3233/NRE-2011-0723; Keyser-Marcus LA, 2002, ARCH PHYS MED REHAB, V83, P635, DOI 10.1053/apmr.2002.31605; Kuluski K, 2014, INT J QUAL STUD HEAL, V9, DOI 10.3402/qhw.v9.22252; Mailles A, 2012, CLIN INFECT DIS, V54, P1455, DOI 10.1093/cid/cis226; Medin J, 2006, DISABIL REHABIL, V28, P1051, DOI 10.1080/09638280500494819; Naess H, 2009, J STROKE CEREBROVASC, V18, P247, DOI 10.1016/j.jstrokecerebrovasdis.2008.10.005; Nakase-Richardson R, 2007, J NEUROL NEUROSUR PS, V78, P872, DOI 10.1136/jnnp.2006.104190; Palmcrantz S, 2012, DISABIL REHABIL, V34, P817, DOI 10.3109/09638288.2011.621507; Saeki S, 2010, J REHABIL MED, V42, P254, DOI 10.2340/16501977-0503; Saeki Satoru, 2004, J Stroke Cerebrovasc Dis, V13, P160, DOI 10.1016/j.jstrokecerebrovasdis.2004.06.006; Shames J, 2007, DISABIL REHABIL, V29, P1387, DOI 10.1080/09638280701315011; Stulemeijer M, 2008, J NEUROL NEUROSUR PS, V79, P936, DOI 10.1136/jnnp.2007.131250; Tanaka H, 2011, ARCH PHYS MED REHAB, V92, P743, DOI 10.1016/j.apmr.2010.12.009; Trygged S, 2011, BMC PUBLIC HEALTH, V11, DOI 10.1186/1471-2458-11-742; U.S. Centers for Disease Control and Prevention, 2012 STROK STAT; van der Giezen AM, 2000, PAIN, V87, P285, DOI 10.1016/S0304-3959(00)00292-X; van Velzen JM, 2009, BRAIN INJURY, V23, P473, DOI 10.1080/02699050902970737; van Velzen JM, 2009, BRAIN INJURY, V23, P385, DOI 10.1080/02699050902838165; Waje-Andreassen U, 2013, EUR J NEUROL, V20, P818, DOI 10.1111/ene.12073; Walker WC, 2006, ARCH PHYS MED REHAB, V87, P1576, DOI 10.1016/j.apmr.2006.08.335; Wilz R, 2009, DISABIL REHABIL, V31, P1487; Wolfenden B, 2009, INT J REHABIL RES, V32, P93, DOI 10.1097/MRR.0b013e328325a358; World Health Organization, 2001, INT CLASS FUNCT DIS; Wozniak MA, 1999, STROKE, V30, P2568, DOI 10.1161/01.STR.30.12.2568	51	22	22	2	42	TAYLOR & FRANCIS LTD	ABINGDON	4 PARK SQUARE, MILTON PARK, ABINGDON OX14 4RN, OXON, ENGLAND	0963-8288	1464-5165		DISABIL REHABIL	Disabil. Rehabil.	APR 9	2016	38	8					733	741		10.3109/09638288.2015.1061608			9	Rehabilitation	Rehabilitation	DA6BF	WOS:000367886000003	26138021				2021-06-18	
J	Chakrabarti, M; Das, A; Samantaray, S; Smith, JA; Banik, NL; Haque, A; Ray, SK				Chakrabarti, Mrinmay; Das, Arabinda; Samantaray, Supriti; Smith, Joshua A.; Banik, Naren L.; Haque, Azizul; Ray, Swapan K.			Molecular mechanisms of estrogen for neuroprotection in spinal cord injury and traumatic brain injury	REVIEWS IN THE NEUROSCIENCES			English	Article						estrogen; inflammation; neuroprotection; spinal cord injury; traumatic brain injury	ACTIVATED PROTEIN-KINASE; PRIMARY CORTICAL-NEURONS; VEIN ENDOTHELIAL-CELLS; RECEPTOR-BETA; MALE RATS; REPLACEMENT THERAPY; VSC4.1 MOTONEURONS; GROWTH-FACTOR; IN-VITRO; NEURODEGENERATIVE DISEASES	Estrogen (EST) is a steroid hormone that exhibits several important physiological roles in the human body. During the last few decades, EST has been well recognized as an important neuroprotective agent in a variety of neurological disorders in the central nervous system (CNS), such as spinal cord injury (SCI), traumatic brain injury (TBI), Alzheimer's disease, and multiple sclerosis. The exact molecular mechanisms of EST-mediated neuro-protection in the CNS remain unclear due to heterogeneity of cell populations that express EST receptors (ERs) in the CNS as well as in the innate and adaptive immune system. Recent investigations suggest that EST protects the CNS from injury by suppressing pro-inflammatory pathways, oxidative stress, and cell death, while promoting neurogenesis, angiogenesis, and neurotrophic support. In this review, we have described the currently known molecular mechanisms of EST-mediated neuroprotection and neuroregeneration in SCI and TBI. At the same time, we have emphasized on the recent in vitro and in vivo findings from our and other laboratories, implying potential clinical benefits of EST in the treatment of SCI and TBI.	[Chakrabarti, Mrinmay; Ray, Swapan K.] Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, 6439 Garners Ferry Rd, Columbia, SC 29209 USA; [Das, Arabinda; Samantaray, Supriti; Smith, Joshua A.; Banik, Naren L.] Med Univ S Carolina, Dept Neurol & Neurosurg, Charleston, SC 29425 USA; [Haque, Azizul] Med Univ S Carolina, Hollings Canc Ctr, Dept Microbiol & Immunol, Charleston, SC 29425 USA	Ray, SK (corresponding author), Univ S Carolina, Sch Med, Dept Pathol Microbiol & Immunol, 6439 Garners Ferry Rd, Columbia, SC 29209 USA.	swapan.ray@uscmed.sc.edu	CHAKRABARTI, MRINMAY/M-5652-2019	Smith, Joshua/0000-0003-2172-9207	South Carolina Spinal Cord Injury Research Fund (SC SCIRF, Columbia, SC, USA); University of South Carolina School of Medicine Research Development Fund (USC SOM RDF, Columbia, SC, USA)	This work was supported in part by grants from South Carolina Spinal Cord Injury Research Fund (SC SCIRF, Columbia, SC, USA) and University of South Carolina School of Medicine Research Development Fund (USC SOM RDF, Columbia, SC, USA).	Asl SZ, 2013, J NEUROSURG, V119, P353, DOI 10.3171/2013.4.JNS121636; Azevedo RB, 2001, BRAZ J MED BIOL RES, V34, P683, DOI 10.1590/S0100-879X2001000500018; Baker KA, 2005, J NEUROTRAUM, V22, P415, DOI 10.1089/neu.2005.22.415; Ball LJ, 2009, MOL CELL ENDOCRINOL, V299, P204, DOI 10.1016/j.mce.2008.10.050; Bayir H, 2004, J NEUROTRAUM, V21, P1, DOI 10.1089/089771504772695896; Beal MF, 1998, BBA-BIOENERGETICS, V1366, P211, DOI 10.1016/S0005-2728(98)00114-5; Behl C, 1997, MOL PHARMACOL, V51, P535; Behl C, 2000, Novartis Found Symp, V230, P221, DOI 10.1002/0470870818.ch16; BEHL C, 1995, BIOCHEM BIOPH RES CO, V216, P473, DOI 10.1006/bbrc.1995.2647; Borras C, 2003, FREE RADICAL BIO MED, V34, P546, DOI 10.1016/S0891-5849(02)01356-4; Bramlett HM, 2001, J NEUROTRAUM, V18, P891, DOI 10.1089/089771501750451811; Brinton LA, 2008, CANCER EPIDEM BIOMAR, V17, P3150, DOI 10.1158/1055-9965.EPI-08-0435; Caliceti C, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0071440; Chakrabarti M, 2014, NEUROSCIENCE, V256, P322, DOI 10.1016/j.neuroscience.2013.10.027; Chakrabarti M, 2014, BRAIN RES BULL, V109, P22, DOI 10.1016/j.brainresbull.2014.09.004; Chakrabarti S, 2008, IUBMB LIFE, V60, P376, DOI 10.1002/iub.48; Chaovipoch P, 2006, J NEUROTRAUM, V23, P830, DOI 10.1089/neu.2006.23.830; Chen G, 2009, EXP NEUROL, V216, P398, DOI 10.1016/j.expneurol.2008.12.019; Chen SH, 2009, CRIT CARE MED, V37, P3097, DOI 10.1097/CCM.0b013e3181bc7986; Chen SH, 2006, ENDOCRINOLOGY, V147, P5303, DOI 10.1210/en.2006-0495; Conti Alfredo, 2010, Cancers (Basel), V2, P693, DOI 10.3390/cancers2020693; Cuzzocrea S, 2008, SHOCK, V29, P362, DOI 10.1097/shk.0b013e31814545dc; Das A, 2005, J NEUROSCI RES, V81, P551, DOI 10.1002/jnr.20581; Das A, 2011, J ENDOCRINOL, V208, P171, DOI 10.1677/JOE-10-0338; Deroo BJ, 2010, MOL ENDOCRINOL, V24, P1703, DOI 10.1210/me.2009-0288; Dimayuga FO, 2005, J NEUROIMMUNOL, V161, P123, DOI 10.1016/j.jneuroim.2004.12.016; Doperalski NJ, 2008, RESP PHYSIOL NEUROBI, V162, P160, DOI 10.1016/j.resp.2008.06.005; Doshi Sejal B, 2013, J Midlife Health, V4, P140, DOI 10.4103/0976-7800.118990; Dubal DB, 1999, J NEUROSCI, V19, P6385; Dubal DB, 1998, J CEREBR BLOOD F MET, V18, P1253, DOI 10.1097/00004647-199811000-00012; Dubal DB, 2001, P NATL ACAD SCI USA, V98, P1952, DOI 10.1073/pnas.041483198; Endoh H, 1997, BIOCHEM BIOPH RES CO, V235, P99, DOI 10.1006/bbrc.1997.6746; Enmark E, 1997, J CLIN ENDOCR METAB, V82, P4258, DOI 10.1210/jc.82.12.4258; Farooque M, 2006, SPINAL CORD, V44, P182, DOI 10.1038/sj.sc.3101816; Filardo EJ, 2000, MOL ENDOCRINOL, V14, P1649, DOI 10.1210/me.14.10.1649; Gatson JW, 2011, ENDOCRINOLOGY, V152, P207, DOI 10.1210/en.2010-0724; Gatson JW, 2012, J NEUROTRAUM, V29, P2209, DOI 10.1089/neu.2011.2274; Gatson JW, 2009, J NEUROINFLAMM, V6, DOI 10.1186/1742-2094-6-30; Gottipati S, 2008, MOL VIS, V14, P898; Greb RR, 1997, HUM REPROD, V12, P1280; Green PS, 1997, J STEROID BIOCHEM, V63, P229, DOI 10.1016/S0960-0760(97)00124-6; Green PS, 2000, INT J DEV NEUROSCI, V18, P347, DOI 10.1016/S0736-5748(00)00017-4; Harris HA, 2007, MOL ENDOCRINOL, V21, P1, DOI 10.1210/me.2005-0459; Hawk T, 1998, BRAIN RES, V796, P296, DOI 10.1016/S0006-8993(98)00327-8; Henderson VW, 1997, NEUROLOGY, V48, pS27, DOI 10.1212/WNL.48.5_Suppl_7.27S; Improta-Brears T, 1999, P NATL ACAD SCI USA, V96, P4686, DOI 10.1073/pnas.96.8.4686; Kabadi SV, 2012, J CEREBR BLOOD F MET, V32, P137, DOI 10.1038/jcbfm.2011.117; Kachadroka S, 2010, J NEUROTRAUM, V27, P611, DOI 10.1089/neu.2009.1069; Keller JN, 1997, J NEUROSCI RES, V50, P522, DOI 10.1002/(SICI)1097-4547(19971115)50:4<522::AID-JNR3>3.0.CO;2-G; Khalil R. A., 2010, Cardiovascular & Hematological Agents in Medicinal Chemistry, V8, P29; KimSchulze S, 1996, CIRCULATION, V94, P1402, DOI 10.1161/01.CIR.94.6.1402; Kuiper GGJM, 1996, P NATL ACAD SCI USA, V93, P5925, DOI 10.1073/pnas.93.12.5925; Lahm T, 2008, CRIT CARE MED, V36, P2174, DOI 10.1097/CCM.0b013e31817d1a92; Lapanantasin S, 2006, SYNAPSE, V60, P406, DOI 10.1002/syn.20308; Le Romancer M, 2008, MOL CELL, V31, P212, DOI 10.1016/j.molcel.2008.05.025; Levin ER, 2009, TRENDS ENDOCRIN MET, V20, P477, DOI 10.1016/j.tem.2009.06.009; Liu W, 1998, NUCLEIC ACIDS RES, V26, P3616, DOI 10.1093/nar/26.15.3616; Rodriguez ABL, 2011, CEREB CORTEX, V21, P2046, DOI 10.1093/cercor/bhq277; Marino M, 2006, CURR GENOMICS, V7, P497, DOI 10.2174/138920206779315737; Martinkovich S, 2014, CLIN INTERV AGING, V9, P1437, DOI 10.2147/CIA.S66690; Mazzeo AT, 2009, EXP NEUROL, V218, P363, DOI 10.1016/j.expneurol.2009.05.026; Mbye LH, 2008, EXP NEUROL, V209, P243, DOI 10.1016/j.expneurol.2007.09.025; McEwen ML, 2007, J NEUROTRAUM, V24, P613, DOI 10.1089/neu.2006.9969; McIntosh TK, 1996, J NEUROTRAUM, V13, P767, DOI 10.1089/neu.1996.13.767; Mittal M, 2014, ANTIOXID REDOX SIGN, V20, P1126, DOI 10.1089/ars.2012.5149; Moosmann B, 1999, P NATL ACAD SCI USA, V96, P8867, DOI 10.1073/pnas.96.16.8867; MORALES DE, 1995, CIRCULATION, V91, P755, DOI 10.1161/01.CIR.91.3.755; Mosselman S, 1996, FEBS LETT, V392, P49, DOI 10.1016/0014-5793(96)00782-X; Murakoshi Masanori, 1999, Journal of Toxicological Sciences, V24, P415; Naderi V, 2015, IRAN J BASIC MED SCI, V18, P138; Nilsen J, 2002, BRAIN RES, V930, P216, DOI 10.1016/S0006-8993(02)02254-0; Paruthiyil S, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006271; Ray SK, 2006, NEUROSCIENCE, V139, P577, DOI 10.1016/j.neuroscience.2005.12.057; Ritz MF, 2008, BRAIN RES, V1203, P177, DOI 10.1016/j.brainres.2008.01.091; Rong W, 2012, INT J NEUROSCI, V122, P381, DOI 10.3109/00207454.2012.668726; Saatman K.E., 2010, J NEUROTRAUM, V25, P719; Sahuquillo J, 2007, CURR PHARM DESIGN, V13, P2310; Samantaray S, 2011, NEUROCHEM RES, V36, P1809, DOI 10.1007/s11064-011-0498-y; Samantaray S, 2010, ANN NY ACAD SCI, V1199, P90, DOI 10.1111/j.1749-6632.2009.05357.x; Schmidt R, 1996, J AM GERIATR SOC, V44, P1307, DOI 10.1111/j.1532-5415.1996.tb01400.x; Selvamani A, 2012, PLOS ONE, V7, DOI 10.1371/journal.pone.0032662; Seo KH, 2004, EUR J IMMUNOL, V34, P2129, DOI 10.1002/eji.200424957; Singer CA, 1999, J NEUROSCI, V19, P2455; Singh M, 1999, J NEUROSCI, V19, P1179; Smiley DA, 2009, CURR MED CHEM, V16, P1863, DOI 10.2174/092986709788186093; Sribnick EA, 2005, J NEUROSCI RES, V82, P283, DOI 10.1002/jnr.20622; Sribnick EA, 2004, NEUROCHEM RES, V29, P2007, DOI 10.1007/s11064-004-6874-0; Sribnick EA, 2003, ANN NY ACAD SCI, V993, P125, DOI 10.1111/j.1749-6632.2003.tb07521.x; Sribnick EA, 2007, NEUROCHEM RES, V32, P2210, DOI 10.1007/s11064-007-9433-7; Sribnick EA, 2010, J NEUROSCI RES, V88, P1738, DOI 10.1002/jnr.22337; Sribnick EA, 2009, BRAIN RES, V1276, P159, DOI 10.1016/j.brainres.2009.04.022; Sribnick EA, 2006, J NEUROSCI RES, V84, P1064, DOI 10.1002/jnr.21016; Srivastava S, 2001, J BIOL CHEM, V276, P8836, DOI 10.1074/jbc.M010764200; Swartz KR, 2007, J NEUROTRAUM, V24, P473, DOI 10.1089/neu.2006.0167; Tang MX, 1996, LANCET, V348, P429, DOI 10.1016/S0140-6736(96)03356-9; Tremblay GB, 1997, MOL ENDOCRINOL, V11, P353, DOI 10.1210/me.11.3.353; Tucker L. B., 2015, J NEUROTRAU IN PRESS; Unnikrishnan AG, 2000, NATL MED J INDIA, V13, P145; Varea O, 2010, STEROIDS, V75, P565, DOI 10.1016/j.steroids.2009.09.006; Varma AK, 2013, NEUROCHEM RES, V38, P895, DOI 10.1007/s11064-013-0991-6; Vegeto E, 2008, FRONT NEUROENDOCRIN, V29, P507, DOI 10.1016/j.yfrne.2008.04.001; Venkov CD, 1996, CIRCULATION, V94, P727, DOI 10.1161/01.CIR.94.4.727; Wade CB, 2001, ENDOCRINOLOGY, V142, P2336, DOI 10.1210/en.142.6.2336; Wang TD, 2007, J FORMOS MED ASSOC, V106, P919, DOI 10.1016/S0929-6646(08)60062-5; Weitzmann MN, 2006, J CLIN INVEST, V116, P1186, DOI 10.1172/JCI28550; Yaffe K, 1998, JAMA-J AM MED ASSOC, V279, P688, DOI 10.1001/jama.279.9.688; Yan J, 2012, J CELL MOL MED, V16, P2968, DOI 10.1111/j.1582-4934.2012.01624.x; Yanhong Li, 2007, Neural Regeneration Research, V2, P471; Yune TY, 2008, J NEUROTRAUM, V25, P1121, DOI 10.1089/neu.2008.0544; Yune TY, 2004, J NEUROTRAUM, V21, P293, DOI 10.1089/089771504322972086; Zandi PP, 2002, JAMA-J AM MED ASSOC, V288, P2123, DOI 10.1001/jama.288.17.2123; Zlotnik A, 2012, INTENS CARE MED, V38, P137, DOI 10.1007/s00134-011-2401-3	112	22	25	0	18	WALTER DE GRUYTER GMBH	BERLIN	GENTHINER STRASSE 13, D-10785 BERLIN, GERMANY	0334-1763	1607-8470		REV NEUROSCIENCE	Rev. Neurosci.	APR	2016	27	3					271	281		10.1515/revneuro-2015-0032			11	Neurosciences	Neurosciences & Neurology	DK6QY	WOS:000375051300003	26461840				2021-06-18	
J	Gardner, AJ; Iverson, GL; Stanwell, P; Moore, T; Ellis, J; Levi, CR				Gardner, A. J.; Iverson, G. L.; Stanwell, P.; Moore, T.; Ellis, J.; Levi, C. R.			A Video Analysis of Use of the New "Concussion Interchange Rule' in the National Rugby League	INTERNATIONAL JOURNAL OF SPORTS MEDICINE			English	Article						concussion; video analysis; injury management; return to play	INCIDENT ANALYSIS; PROFESSIONAL FOOTBALL; INJURY; SITUATIONS; MATCH; SPORT	The National Rugby League (NRL) in Australia introduced a new concussion interchange rule' (CIR) in 2014, whereby a player suspected of having sustained a concussion can be removed from play, and assessed, without an interchange being tallied against the player's team. We conducted a video analysis, describing player and injury characteristics, situational factors, concussion signs, and return to play for each CIR event for the 2014 season. There were 167 reported uses of the CIR. Apparent loss of consciousness/unresponsiveness was observed in 32% of cases, loss of muscle tone in 54%, clutching the head in 70%, unsteadiness of gait in 66%, and a vacant stare in 66%. More than half of the players who were removed under the CIR returned to play later in the same match (57%). Most incidences occurred from a hit up (62%) and occurred during a tackle where the initial contact was with the upper body (80%). The new concussion interchange rule has been used frequently during the first season of its implementation. In many cases, there appeared to be video evidence of injury but the athlete was cleared to return to play. More research is needed on the usefulness of video review for identifying signs of concussive injury.	[Gardner, A. J.] Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia; [Iverson, G. L.] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA; [Stanwell, P.] Univ Newcastle, Sch Hlth Sci, Callaghan, NSW 2308, Australia; [Moore, T.] Hunter New England Local Hlth Dist, Neuropsychiat Serv, Newcastle, NSW, Australia; [Ellis, J.] Gold Coast Univ Hosp, Dept Med Imaging, Gold Coast, Australia; [Levi, C. R.] Hunter New England Local Hlth Dist, Sports Concuss Program, New Lambton Hts, Australia	Gardner, AJ (corresponding author), Univ Newcastle, Sch Med & Publ Hlth, Ctr Translat Neurosci & Mental Hlth, Level 5, Waratah 2298, Australia.	andrew.gardner@neurogard.com.au	Stanwell, Peter/F-9136-2012	Stanwell, Peter/0000-0002-4780-0393; Levi, Christopher/0000-0002-9474-796X; Iverson, Grant/0000-0001-7348-9570	NSW Sporting Injuries Committee; Brain Foundation, Australia; Hunter Medical Research Institute Life Govenor; Mooney-Reed Charitable Foundation; Australian Football League (AFL); ImPACT(R) Applications Systems	This study was conducted as partial fulfillment for the requirements of a PhD thesis for the first author. A portion of these data was presented at the International Neuropsychological Society Mid-Year Conference, Sydney, Australia. Funding Sources: AJG, PS and CL have received funding support from the NSW Sporting Injuries Committee, and the Brain Foundation, Australia to conduct research in rugby league. AJG also acknowledges support from Jennie Thomas, Hunter Medical Research Institute Life Govenor. GLI acknowledges support from the Mooney-Reed Charitable Foundation. Financial Disclosure: None General Disclosure: AJG has a clinical practice in neuropsychology involving the assessment and management of individuals who have sustained sport-related concussion (including current and former athletes). He has received travel funding from the Australian Football League (AFL) to present at the Concussion in Football Conference in 2013. He also serves in a non-remunerated capacity as a member of the Concussion Advisory Group for the Australian Rugby Union (ARU). GLI has been reimbursed by the government, professional scientific bodies, and commercial organizations for discussing or presenting research relating to MTBI and sport-related concussion at meetings, scientific conferences, and symposiums. He has a clinical practice in forensic neuropsychology involving individuals who have sustained mild TBIs (including athletes). He has received honorariums for serving on research panels that provide scientific peer review of programs. He is a co-investigator, collaborator, or consultant on grants relating to mild TBI funded by several organizations. He has received research support from test publishing companies in the past, including ImPACT (R) Applications Systems (not in the past 5 years).	Andersen TE, 2003, BRIT J SPORT MED, V37, P226, DOI 10.1136/bjsm.37.3.226; Arnason A, 2004, AM J SPORT MED, V32, P1459, DOI 10.1177/0363546504262973; Bjorneboe J, 2014, BRIT J SPORT MED, V48, P774, DOI 10.1136/bjsports-2012-091856; Gardner A, 2015, BRIT J SPORT MED, V49, P495, DOI 10.1136/bjsports-2013-093102; Gardner AJ, 2015, BRAIN INJURY, V29, P1182, DOI 10.3109/02699052.2015.1034179; Hallgren Kevin A, 2012, Tutor Quant Methods Psychol, V8, P23; Harriss DJ, 2015, INT J SPORTS MED, V36, P1121, DOI 10.1055/s-0035-1565186; Hoskins W, 2006, J SCI MED SPORT, V9, P46, DOI 10.1016/j.jsams.2006.03.013; Hutchison MG, 2013, BRIT J SPORT MED, P1; Hutchison MG, 2014, BRIT J SPORT MED, V48, P125, DOI 10.1136/bjsports-2012-092059; IBM Corp, IBM SPSS STAT MAC VE; King DA, 2010, SPORTS MED, V40, P163, DOI 10.2165/11319740-000000000-00000; Koh JO, 2004, BRAIN INJURY, V18, P1287, DOI 10.1080/02699050410001719907; Lincoln AE, 2013, AM J SPORT MED, V41, P756, DOI 10.1177/0363546513476265; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McHugh ML, 2012, BIOCHEM MEDICA, V22, P276, DOI 10.11613/bm.2012.031; Miele VJ, 2007, NEUROSURGERY, V60, P307, DOI 10.1227/01.NEU.0000249247.48299.5B; Putukian M, 2013, BRIT J SPORT MED, V47, P285, DOI 10.1136/bjsports-2013-092158; Savage J, 2013, J SPORTS MED	19	22	23	0	9	GEORG THIEME VERLAG KG	STUTTGART	RUDIGERSTR 14, D-70469 STUTTGART, GERMANY	0172-4622	1439-3964		INT J SPORTS MED	Int. J. Sports Med.	APR	2016	37	4					267	273		10.1055/s-0035-1565203			7	Sport Sciences	Sport Sciences	DJ1YZ	WOS:000374002200002	26837928				2021-06-18	
J	Ko, A; Harada, MY; Barmparas, G; Thomsen, GM; Alban, RF; Bloom, MB; Chung, R; Melo, N; Margulies, DR; Ley, EJ				Ko, Ara; Harada, Megan Y.; Barmparas, Galinos; Thomsen, Gretchen M.; Alban, Rodrigo F.; Bloom, Matthew B.; Chung, Rex; Melo, Nicolas; Margulies, Daniel R.; Ley, Eric J.			Early propranolol after traumatic brain injury is associated with lower mortality	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; propranolol; -blockers; mortality	CEREBRAL PERFUSION; BETA-BLOCKADE; BLOCKERS; SURVIVAL	BACKGROUND -Adrenergic receptor blockers (BBs) administered after trauma blunt the cascade of immune and inflammatory changes associated with injury. BBs are associated with improved outcomes after traumatic brain injury (TBI). Propranolol may be an ideal BB because of its nonselective inhibition and ability to cross the blood-brain barrier. We determined if early administration of propranolol after TBI is associated with lower mortality. METHODS All adults (age 18 years) with moderate-to-severe TBI (head Abbreviated Injury Scale [AIS] score, 3-5) requiring intensive care unit (ICU) admission at a Level I trauma center from January 1, 2013, to May 31, 2015, were prospectively entered into a database. Administration of early propranolol was dosed within 24 hours of admission at 1 mg intravenous every 6 hours. Patients who received early propranolol after TBI (EPAT) were compared with those who did not (non-EPAT). Data including demographics, hospital length of stay (LOS), ICU LOS, and mortality were collected. RESULTS Over 29 months, 440 patients with moderate-to-severe TBI met inclusion criteria. Early propranolol was administered to 25% (109 of 440) of the patients. The EPAT cohort was younger (49.6 years vs. 60.4 years, p < 0.001), had lower Glasgow Coma Scale (GCS) score (11.7 vs. 12.4, p = 0.003), had lower head AIS score (3.6 vs. 3.9, p = 0.001), had higher admission heart rate (95.8 beats/min vs. 88.4 beats/min, p = 0.002), and required more days on the ventilator (5.9 days vs. 2.6 days, p < 0.001). Similarities were noted in sex, Injury Severity Score (ISS), admission systolic blood pressure, hospital LOS, ICU LOS, and mortality rate. Multivariate regression showed that EPAT was independently associated with lower mortality (adjusted odds ratio, 0.25; p = 0.012). CONCLUSION After adjusting for predictors of mortality, early administration of propranolol after TBI was associated with improved survival. Future studies are needed to identify additional benefits and optimal dosing regimens. LEVEL OF EVIDENCE Therapeutic study, level IV.	[Ko, Ara; Harada, Megan Y.; Barmparas, Galinos; Thomsen, Gretchen M.; Alban, Rodrigo F.; Bloom, Matthew B.; Chung, Rex; Melo, Nicolas; Margulies, Daniel R.; Ley, Eric J.] Cedars Sinai Med Ctr, Dept Surg, Div Trauma & Crit Care, Los Angeles, CA 90048 USA	Ley, EJ (corresponding author), Cedars Sinai Med Ctr, Dept Surg, 8700 Beverly Blvd,Suite 8215 N, Los Angeles, CA 90048 USA.	Eric.Ley@cshs.org	Barmparas, Galinos/L-6530-2019; Bloom, Matthew/E-5660-2013	Bloom, Matthew/0000-0001-8102-4394			Acosta JA, 1998, J AM COLL SURGEONS, V186, P528, DOI 10.1016/S1072-7515(98)00082-9; Arbabi S, 2007, J TRAUMA, V62, P56, DOI 10.1097/TA.0b013e31802d972b; Bible LE, 2014, J TRAUMA ACUTE CARE, V77, P54, DOI 10.1097/TA.0000000000000264; Bukur M, 2012, J TRAUMA ACUTE CARE, V72, P1013, DOI 10.1097/TA.0b013e318241bc5b; Bullock MR, 2007, J NEUROTRAUM, V24, pVII, DOI 10.1089/neu.2007.9998; CLIFTON GL, 1981, NEUROSURGERY, V8, P10, DOI 10.1227/00006123-198101000-00003; COLGAN FJ, 1983, CRIT CARE MED, V11, P368, DOI 10.1097/00003246-198305000-00010; Cotton BA, 2007, J TRAUMA, V62, P26, DOI 10.1097/TA.0b013e31802d02d0; CRUICKSHANK JM, 1987, LANCET, V2, P585, DOI 10.1016/s0140-6736(87)92984-9; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Heffernan DS, 2010, J TRAUMA, V69, P1602, DOI 10.1097/TA.0b013e3181f2d3e8; HORTNAGL H, 1980, INTENS CARE MED, V6, P169, DOI 10.1007/BF01757299; Inaba K, 2008, J AM COLL SURGEONS, V206, P432, DOI 10.1016/j.jamcollsurg.2007.10.005; Ley EJ, 2012, J TRAUMA ACUTE CARE, V73, P33, DOI 10.1097/TA.0b013e31825a769b; Ley EJ, 2010, J TRAUMA, V68, P353, DOI 10.1097/TA.0b013e3181c8269a; Ley EJ, 2009, J TRAUMA, V66, P154, DOI 10.1097/TA.0b013e31819388be; LIU MY, 1995, J FORMOS MED ASSOC, V94, P386; Ma VY, 2014, ARCH PHYS MED REHAB, V95, P986, DOI 10.1016/j.apmr.2013.10.032; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Murry JS, 2016, J SURG RES, V200, P221, DOI 10.1016/j.jss.2015.06.045; NEILDWYER G, 1981, BRIT J CLIN PHARMACO, V11, P549, DOI 10.1111/j.1365-2125.1981.tb01169.x; ROSENBERG PA, 1988, J NEUROSCI, V8, P2887, DOI 10.1523/jneurosci.08-08-02887.1988; Salim A, 2008, J TRAUMA, V64, P46, DOI 10.1097/TA.0b013e31815eb15a; Schroeppel TJ, 2014, J TRAUMA ACUTE CARE, V76, P504, DOI 10.1097/TA.0000000000000104; WALTER P, 1982, BRIT MED J, V284, P1661, DOI 10.1136/bmj.284.6330.1661; Zangbar B, 2016, J SURG RES, V200, P586, DOI 10.1016/j.jss.2015.08.020	26	22	22	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	APR	2016	80	4					637	642		10.1097/TA.0000000000000959			6	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DI1ED	WOS:000373237900016	26808028				2021-06-18	
J	Rush, B; Rousseau, J; Sekhon, MS; Griesdale, DE				Rush, Barret; Rousseau, Justin; Sekhon, Mypinder S.; Griesdale, Donald E.			Craniotomy Versus Craniectomy for Acute Traumatic Subdural Hematoma in the United States: A National Retrospective Cohort Analysis	WORLD NEUROSURGERY			English	Article						Acute traumatic subdural; Craniectomy; Craniotomy	AXONAL STRETCH INJURY; DECOMPRESSIVE CRANIECTOMY; BRAIN-INJURY; SURGICAL-MANAGEMENT; PROPENSITY SCORE; MORTALITY; OUTCOMES; AXOTOMY; EXAMPLE; ADULTS	OBJECTIVE: The optimal surgical management of acute traumatic subdural hematoma (ASDH) is controversial; both craniectomy and craniotomy are performed. The purpose of this study was to determine the current management of ASDH in the United States. METHODS: This retrospective cohort study used the Nationwide Inpatient Sample from the years 2006-2011 to examine patients with a primary diagnosis of ASDH. All patients >= 18 years old with a primary diagnosis of ASDH were included in the analysis. Patients with procedure codes for craniectomy and craniotomy were isolated from the database. Propensity score matching based on logistic regression was used to match craniotomy to craniectomy in a 1: 1 fashion. RESULTS: There were 47,911,414 hospitalizations analyzed. Of 60,435 patients with ASDH identified, 1763 underwent craniotomy and 177 underwent craniectomy. The average age of patients who underwent craniectomy was 49.5 years (SD 20.8) compared with an average age of 68.9 years (SD 17.1) of patients who underwent craniotomy (P < 0.0001). Hospital mortality was significantly higher in patients who underwent craniectomy (35.0% vs. 10.9%, P < 0.0001). Patients who underwent craniectomy had longer hospital stays compared with patients who underwent craniotomy (median duration 14.3 days [interquartile range 25] for craniectomy vs. 10.9 days [interquartile range 9] for craniotomy, P < 0.0001). Patients who underwent craniectomy were also more likely to be discharged to a skilled nursing or rehabilitation facility (79.1% vs. 63.9%, P = 0.0011). CONCLUSIONS: Craniotomy is the preferred surgical technique for management of ASDH in the United States, being performed 10 times more frequently than craniectomy. Craniectomy was associated with significantly higher in hospital mortality after propensity score matched analysis.	[Rush, Barret; Sekhon, Mypinder S.; Griesdale, Donald E.] Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Vancouver, BC V5Z 1M9, Canada; [Rush, Barret] Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA; [Rousseau, Justin] Harvard Univ, Sch Med, Dept Biomed Informat, Boston, MA USA; [Rousseau, Justin] Brigham & Womens Hosp, Ctr Evidence Based Imaging, 75 Francis St, Boston, MA 02115 USA; [Griesdale, Donald E.] Univ British Columbia, Dept Anesthesia Pharmacol & Therapeut, Vancouver, BC V5Z 1M9, Canada; [Griesdale, Donald E.] Vancouver Coastal Hlth Res Inst, Ctr Clin Epidemiol & Evaluat, Vancouver, BC, Canada	Rush, B (corresponding author), Univ British Columbia, Vancouver Gen Hosp, Dept Med, Div Crit Care Med, Vancouver, BC V5Z 1M9, Canada.; Rush, B (corresponding author), Harvard Univ, Harvard TH Chan Sch Publ Hlth, Boston, MA 02115 USA.	bar890@mail.harvard.edu		Rush, Barret/0000-0001-9201-8352; Griesdale, Donald/0000-0001-5985-8624; Rousseau, Justin/0000-0002-2817-9124	National Library of MedicineUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007092]; VGH & UBC Hospital Foundation Best of Health Fund; NATIONAL LIBRARY OF MEDICINEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Library of Medicine (NLM) [T15LM007092] Funding Source: NIH RePORTER	This study was funded in part by the National Library of Medicine Grant No. T15LM007092. D.G. is funded by the VGH & UBC Hospital Foundation Best of Health Fund. The remaining authors have no conflicts to report.	Averill Richard F, 2002, J AHIMA, V73, P46; Bor-Seng-Shu E, 2012, J NEUROSURG, V117, P589, DOI 10.3171/2012.6.JNS101400; Cepeda MS, 2003, AM J EPIDEMIOL, V158, P280, DOI 10.1093/aje/kwg115; CHARLSON M, 1994, J CLIN EPIDEMIOL, V47, P1245, DOI 10.1016/0895-4356(94)90129-5; Chen SH, 2011, J TRAUMA, V71, P1632, DOI 10.1097/TA.0b013e3182367b3c; Chung RS, 2005, J NEUROTRAUM, V22, P1081, DOI 10.1089/neu.2005.22.1081; COOPER PR, 1979, NEUROSURGERY, V4, P296, DOI 10.1227/00006123-197904000-00004; Elixhauser A, 1998, MED CARE, V36, P8, DOI 10.1097/00005650-199801000-00004; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Karibe H, 2014, NEUROL MED-CHIR, V54, P887, DOI 10.2176/nmc.cr.2014-0204; Kim KH, 2009, J KOREAN NEUROSURG S, V45, P143, DOI 10.3340/jkns.2009.45.3.143; Kolias AG, 2013, BRIT J NEUROSURG, V27, P330, DOI 10.3109/02688697.2013.779365; Kolias AG, 2013, ACTA NEUROCHIR, V155, P187, DOI 10.1007/s00701-012-1531-x; Kolias AG, 2012, ACTA NEUROCHIR, V154, P1563, DOI 10.1007/s00701-012-1349-6; KOTWICA Z, 1993, ACTA NEUROCHIR, V121, P95, DOI 10.1007/BF01809257; Leitgeb J, 2012, J NEUROSURG, V117, P324, DOI 10.3171/2012.4.JNS111448; Li LM, 2012, ACTA NEUROCHIR, V154, P1555, DOI 10.1007/s00701-012-1428-8; Marion DW, 2006, NEUROSURGERY, V58, P655; Massaro F, 1996, ACTA NEUROCHIR, V138, P185, DOI 10.1007/BF01411359; PATERNITI S, 1994, ACTA NEUROCHIR, V131, P207, DOI 10.1007/BF01808614; Rutland-Brown W, 2006, J HEAD TRAUMA REHAB, V21, P544, DOI 10.1097/00001199-200611000-00009; Ryan CG, 2012, J TRAUMA ACUTE CARE, V73, P1348, DOI 10.1097/TA.0b013e31826fcb30; Salas M, 1999, AM J EPIDEMIOL, V149, P981; Seeger JD, 2007, MED CARE, V45, pS143, DOI 10.1097/MLR.0b013e318074ce79; Staal JA, 2010, J NEUROCHEM, V112, P1147, DOI 10.1111/j.1471-4159.2009.06531.x; Stiver SI, 2009, NEUROSURG FOCUS, V26, DOI 10.3171/2009.4.FOCUS0965; Tang-Schomer MD, 2010, FASEB J, V24, P1401, DOI 10.1096/fj.09-142844; Vandenbroucke JP, 2007, EPIDEMIOLOGY, V18, P805, DOI 10.1097/EDE.0b013e3181577511; Walcott BP, 2014, J CLIN NEUROSCI, V21, P2107, DOI 10.1016/j.jocn.2014.05.016; WILBERGER JE, 1991, J NEUROSURG, V74, P212, DOI 10.3171/jns.1991.74.2.0212; Woertgen C, 2006, J CLIN NEUROSCI, V13, P718, DOI 10.1016/j.jocn.2005.08.019	31	22	22	0	5	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	APR	2016	88						25	31		10.1016/j.wneu.2015.12.034			7	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DK1CI	WOS:000374649700006	26748175	Green Accepted			2021-06-18	
J	Wood, JN; French, B; Fromkin, J; Fakeye, O; Scribano, PV; Letson, MM; Makoroff, KL; Feldman, KW; Fabio, A; Berger, R				Wood, Joanne N.; French, Benjamin; Fromkin, Janet; Fakeye, Oludolapo; Scribano, Philip V.; Letson, Megan M.; Makoroff, Kathi L.; Feldman, Kenneth W.; Fabio, Anthony; Berger, Rachel			Association of Pediatric Abusive Head Trauma Rates With Macroeconomic Indicators	ACADEMIC PEDIATRICS			English	Article						child abuse; economic recession; traumatic brain injury	CHILD MALTREATMENT; BRAIN-INJURY; RECESSION; INFANTS; IMPACT	OBJECTIVE: We aimed to examine abusive head trauma (AHT) incidence before, during and after the recession of 2007-2009 in 3 US regions and assess the association of economic measures with AHT incidence. METHODS: Data for children <5 years old diagnosed with AHT between January 1, 2004, and December 31, 2012, in 3 regions were linked to county-level economic data using an ecologic time series analysis. Associations between county level AHT rates and recession period as well as employment growth, mortgage delinquency, and foreclosure rates were examined using zero-inflated Poisson regression models. RESULTS: During the 9-year period, 712 children were diagnosed with AHT. The mean rate of AHT per 100,000 child years increased from 9.8 before the recession to 15.6 during the recession before decreasing to 12.8 after the recession. The AHT rates after the recession were higher than the rates before the recession (incidence rate ratio 1.31, P =.004) but lower than rates during the recession (incidence rate ratio 0.78, P =.005). There was no association between the AHT rate and employment growth, mortgage delinquency rates, or foreclosure rates. CONCLUSIONS: In the period after the recession, AHT rate was lower than during the recession period yet higher than the level before the recession, suggesting a lingering effect of the economic stress of the recession on maltreatment risk.	[Wood, Joanne N.; Scribano, Philip V.] Childrens Hosp Philadelphia, Div Gen Pediat, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Fakeye, Oludolapo] Childrens Hosp Philadelphia, PolicyLab, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA; [Wood, Joanne N.; Scribano, Philip V.] Univ Penn, Dept Pediat, Perelman Sch Med, Philadelphia, PA 19104 USA; [French, Benjamin] Univ Penn, Perelman Sch Med, Dept Biostat & Epidemiol, Philadelphia, PA 19104 USA; [Fromkin, Janet; Berger, Rachel] UPMC, Childrens Hosp Pittsburgh, Dept Pediat, Pittsburgh, PA USA; [Letson, Megan M.] Nationwide Childrens Hosp, Columbus, OH USA; [Letson, Megan M.] Ohio State Univ, Coll Med, Columbus, OH 43210 USA; [Makoroff, Kathi L.] Mayerson Ctr Safe & Healthy Children, Cincinnati, OH USA; [Makoroff, Kathi L.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA; [Feldman, Kenneth W.] Seattle Childrens Hosp, Div Gen Pediat, Seattle, WA USA; [Feldman, Kenneth W.] Seattle Childrens Hosp, Childrens Protect Program, Seattle, WA USA; [Feldman, Kenneth W.] Univ Washington, Sch Med, Seattle, WA USA; [Fabio, Anthony] Epidemiol Data Coordinating Ctr, Dept Epidemiol, Baltimore, MD USA; [Fabio, Anthony] Epidemiol Data Coordinating Ctr, Grad Sch Publ Hlth, Baltimore, MD USA; [Berger, Rachel] Univ Pittsburgh, Safar Ctr Resuscitat Res, Pittsburgh, PA USA	Wood, JN (corresponding author), Childrens Hosp Philadelphia, 3535 Market St,Room 1517, Philadelphia, PA 19104 USA.	woodjo@email.chop.edu		Feldman, Kenneth/0000-0002-9020-5223; Fabio, Anthony/0000-0002-6808-4939	Casey Family Programs; Matty Eapen Foundation; CoreLogic Solutions LLC.	This study was funded in part by a grant from Casey Family Programs, and the related parent study was funded by a grant from the Matty Eapen Foundation. Access to mortgage delinquency and foreclosure data for the study was provided through a grant from CoreLogic Solutions LLC. Sponsors had no role in study design, collection, analysis, and interpretation of data, the writing of the report, and the decision to submit for publication. We thank Lori Vavul-Roediger, MD (Dayton Children's Hospital), and Yolanda Duralde (Mary Bridge Hospital) for obtaining data about children with AHT evaluated at hospitals other than the study hospitals.	Aboa-Eboule C, 2013, J NEUROL, V260, P605, DOI 10.1007/s00415-012-6686-0; [Anonymous], 2011, STAT NAT HOUS; Barlow KM, 2000, LANCET, V356, P1571, DOI 10.1016/S0140-6736(00)03130-5; Berger LM, 2005, SOC SERV REV, V79, P237, DOI 10.1086/428957; Berger RP, 2015, INJURY PREV, V21, pE133, DOI 10.1136/injuryprev-2013-040924; Berger RP, 2011, PEDIATRICS, V128, P637, DOI 10.1542/peds.2010-2185; Brooks-Gunn J, 2013, CHILD ABUSE NEGLECT, V37, P721, DOI 10.1016/j.chiabu.2013.08.004; Cancian Maria., 2010, EFFECT FAMILY INCOME; Child Welfare Information Gateway, 2014, DIFF RESP REP CHILD; COULTON CJ, 1995, CHILD DEV, V66, P1262, DOI 10.2307/1131646; Curtis T, 2000, CHILD ABUSE NEGLECT, V24, P1151, DOI 10.1016/S0145-2134(00)00176-9; Drake B, 1996, CHILD ABUSE NEGLECT, V20, P1003, DOI 10.1016/0145-2134(96)00091-9; Duhaime AC, 1998, NEW ENGL J MED, V338, P1822, DOI 10.1056/NEJM199806183382507; Eckenrode J, 2014, PEDIATRICS, V133, P454, DOI 10.1542/peds.2013-1707; Federal Interagency Forum on Child and Family Statistics, 2011, AM CHILDR KEY NAT IN; Finkelhor D, 2009, UPDATED TRENDS CHILD; Finkelhor D., 2012, HAVE SEXUAL ABUSE PH; Freisthler B, 2006, CHILD MALTREATMENT, V11, P263, DOI 10.1177/1077559506289524; Frioux S, 2014, MATERN CHILD HLTH J, V18, P2202, DOI 10.1007/s10995-014-1469-0; Hooft A, 2013, J PEDIATR-US, V162, P80, DOI 10.1016/j.jpeds.2012.06.037; Huang MI, 2011, J NEUROSURG-PEDIATR, V8, P171, DOI 10.3171/2011.5.PEDS1139; Kan J, 2008, SOURCES FORECLOSURE; Keenan HT, 2004, AM J PREV MED, V26, P189, DOI 10.1016/j.amepre.2003.10.023; Keenan HT, 2003, JAMA-J AM MED ASSOC, V290, P621, DOI 10.1001/jama.290.5.621; KOTCH JB, 1995, CHILD ABUSE NEGLECT, V19, P1115, DOI 10.1016/0145-2134(95)00072-G; LAMBERT D, 1992, TECHNOMETRICS, V34, P1, DOI 10.2307/1269547; Lovell P., 2008, IMPACT MORTGAGE CRIS; Millett L, 2011, CHILD YOUTH SERV REV, V33, P1280, DOI 10.1016/j.childyouth.2011.03.001; National Bureau of Economic Research, 2014, US BUS CYCL EXP CONT; Rajmil L, 2014, INT J ENV RES PUB HE, V11, P6528, DOI 10.3390/ijerph110606528; Sermons MW, 2011, STATE HOMELESSNESS A; Shanahan ME, 2013, PEDIATRICS, V132, pE1546, DOI 10.1542/peds.2013-2049; U. S. Census Bureau Population Division, INT EST RES POP 5 YE; United States Census Bureau, 2010, AN EST RES POP COUNT; United States Census Bureau, 2011, 2009 2011 AM COMM SU; United States Census Bureau, 2010 CENS DAT; Wood JN, 2012, PEDIATRICS, V130, pE358, DOI 10.1542/peds.2011-3755; Xiang J, 2013, BRAIN INJURY, V27, P1555, DOI 10.3109/02699052.2013.831126	38	22	22	0	7	ELSEVIER SCIENCE INC	NEW YORK	STE 800, 230 PARK AVE, NEW YORK, NY 10169 USA	1876-2859	1876-2867		ACAD PEDIATR	Acad. Pediatr.	APR	2016	16	3					224	232		10.1016/j.acap.2015.05.008			9	Pediatrics	Pediatrics	DI3RZ	WOS:000373417500003	26183000				2021-06-18	
J	Baimukanova, G; Miyazawa, B; Potter, DR; Muench, MO; Bruhn, R; Gibb, SL; Spinella, PC; Cap, AP; Cohen, MJ; Pati, S				Baimukanova, Gyulnar; Miyazawa, Byron; Potter, Daniel R.; Muench, Marcus O.; Bruhn, Roberta; Gibb, Stuart L.; Spinella, Philip C.; Cap, Andrew P.; Cohen, Mitchell J.; Pati, Shibani			Platelets regulate vascular endothelial stability: assessing the storage lesion and donor variability of apheresis platelets	TRANSFUSION			English	Article							TRAUMATIC BRAIN-INJURY; FRESH-FROZEN PLASMA; LARGE ANIMAL-MODEL; HEMORRHAGIC-SHOCK; MOLECULAR-BASIS; RESUSCITATION; MAINTENANCE; SURVIVAL; PERMEABILITY; CONTAINERS	BACKGROUNDIn current blood banking practices, platelets (PLTs) are stored in plasma at 22 degrees C, with gentle agitation for up to 5 days. To date, the effects of storage and donor variability on PLT regulation of vascular integrity are not known. STUDY DESIGN AND METHODSIn this study, we examined the donor variability of leukoreduced fresh (Day 1) or stored (Day 5) PLTs on vascular endothelial barrier function in vitro and in vivo. In vitro, PLT effects on endothelial cell (EC) monolayer permeability were assessed by analyzing transendothelial electrical resistances (TEER). PLT aggregation, a measure of hemostatic potential, was analyzed by impedance aggregometry. In vivo, PLTs were investigated in a vascular endothelial growth factor A (VEGF-A)-induced vascular permeability model in NSG mice, and PLT circulation was measured by flow cytometry. RESULTSTreatment of endothelial monolayers with fresh Day 1 PLTs resulted in an increase in EC barrier resistance and decreased permeability in a dose-dependent manner. Subsequent treatment of EC monolayers with Day 5 PLTs demonstrated diminished vasculoprotective effects. Donor variability was noted in all measures of PLT function. Day 1 PLT donors were more variable in their effects on TEER than Day 5 PLTs. In mice, while all PLTs regardless of storage time demonstrated significant protection against VEGF-A-induced vascular leakage, Day 5 PLTs exhibited reduced protection when compared to Day 1 PLTs. Day 1 PLTs demonstrated significant donor variability against VEGF-A-challenged vascular leakage in vivo. Systemic circulating levels of Day 1 PLTs were higher than those of Day 5 PLTs CONCLUSIONSIn vitro and in vivo, Day 1 PLTs are protective in measures of vascular endothelial permeability. Donor variability is most prominent in Day 1 PLTs. A decrease in the protective effects is found with storage of the PLT units between Day 1 and Day 5 at 22 degrees C, thereby suggesting that Day 5 PLTs are diminished in their ability to attenuate vascular endothelial permeability.	[Baimukanova, Gyulnar; Potter, Daniel R.; Muench, Marcus O.; Bruhn, Roberta; Gibb, Stuart L.; Pati, Shibani] Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA; [Miyazawa, Byron; Cohen, Mitchell J.] Univ Calif San Francisco, Dept Surg, San Francisco, CA USA; [Pati, Shibani] Univ Calif San Francisco, Dept Lab Med, San Francisco, CA 94143 USA; [Spinella, Philip C.] Washington Univ, Sch Med, Dept Pediat, Div Crit Care Med, St Louis, MO 63110 USA; [Cap, Andrew P.] US Army, Inst Surg Res USAISR, Jbsa Ft Sam Houston, TX USA	Pati, S (corresponding author), Blood Syst Res Inst, 270 Mason Ave, San Francisco, CA 94118 USA.	spati@bloodsystems.org	Muench, Marcus O./C-5025-2009	Muench, Marcus O./0000-0001-8946-6605; Bruhn, Roberta/0000-0002-5898-8168	National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01 DK088760]; Blood Systems Research Institute; NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Diabetes & Digestive & Kidney Diseases (NIDDK) [P01DK088760] Funding Source: NIH RePORTER	This work was supported by grants from the National Institutes of Health, P01 DK088760 (to MM), and funding from Blood Systems Research Institute.	Bates DO, 2010, CARDIOVASC RES, V87, P262, DOI 10.1093/cvr/cvq105; Benest AV, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0070459; Borgman MA, 2007, J TRAUMA, V63, P805, DOI 10.1097/TA.0b013e3181271ba3; Brkovic A, 2007, J CELL BIOCHEM, V100, P727, DOI 10.1002/jcb.21124; CHERNOFF A, 1992, TRANSFUSION, V32, P386, DOI 10.1046/j.1537-2995.1992.32492263456.x; Devine DV, 2010, CLIN LAB MED, V30, P475, DOI 10.1016/j.cll.2010.02.002; GIAEVER I, 1986, IEEE T BIO-MED ENG, V33, P242, DOI 10.1109/TBME.1986.325896; Glenister KM, 2008, TRANSFUSION, V48, P99, DOI 10.1111/j.1537-2995.2007.01487.x; Grozovsky R, 2010, CURR OPIN HEMATOL, V17, P585, DOI 10.1097/MOH.0b013e32833e7561; Ho-Tin-Noe B, 2011, J THROMB HAEMOST, V9, P56, DOI 10.1111/j.1538-7836.2011.04317.x; Holcomb JB, 2008, ANN SURG, V248, P447, DOI 10.1097/SLA.0b013e318185a9ad; Holcomb JB, 2013, HEMATOL-AM SOC HEMAT, P656, DOI 10.1182/asheducation-2013.1.656; Holcomb JB, 2013, JAMA SURG, V148, P127, DOI 10.1001/2013.jamasurg.387; Holcomb JB, 2011, J TRAUMA, V71, pS318, DOI 10.1097/TA.0b013e318227edbb; HOLME S, 1987, VOX SANG, V53, P214, DOI 10.1111/j.1423-0410.1987.tb05069.x; HOLME S, 1992, J LAB CLIN MED, V119, P144; Imam AM, 2013, J TRAUMA ACUTE CARE, V75, P976, DOI 10.1097/TA.0b013e31829e2186; Inaba K, 2011, J TRAUMA, V71, P1766, DOI 10.1097/TA.0b013e31823bdbf9; Jenkins DH, 2014, SHOCK, V41, P3, DOI 10.1097/SHK.0000000000000140; Jin G, 2012, SHOCK, V38, P49, DOI 10.1097/SHK.0b013e3182574778; Keese CR, 2002, BIOTECHNIQUES, V33, P842, DOI 10.2144/02334rr01; Kozar RA, 2011, ANESTH ANALG, V112, P1289, DOI 10.1213/ANE.0b013e318210385c; Krailadsiri P, 2001, TRANSFUSION, V41, P243, DOI 10.1046/j.1537-2995.2001.41020243.x; MURPHY S, 1975, BLOOD, V46, P209; MURPHY S, 1971, J CLIN INVEST, V50, P370, DOI 10.1172/JCI106504; MURPHY S, 1970, BLOOD-J HEMATOL, V35, P549, DOI 10.1182/blood.V35.4.549.549; MURPHY S, 1971, VOX SANG, V20, P427, DOI 10.1111/j.1423-0410.1971.tb01814.x; MURPHY S, 1976, TRANSFUSION, V16, P2; MUSTARD JF, 1972, BRIT J HAEMATOL, V22, P193, DOI 10.1111/j.1365-2141.1972.tb08800.x; Nachman RL, 2008, NEW ENGL J MED, V359, P1261, DOI 10.1056/NEJMra0800887; Newman PJ, 2007, J THROMB HAEMOST, V5, P305, DOI 10.1111/j.1538-7836.2007.02466.x; Pati S, 2010, J TRAUMA, V69, pS55, DOI 10.1097/TA.0b013e3181e453d4; Peng ZL, 2013, SHOCK, V40, P195, DOI 10.1097/SHK.0b013e31829f91fc; Rinder HM, 2003, TRANSFUSION, V43, P2, DOI 10.1046/j.1537-2995.2003.00261.x; Schaphorst KL, 2003, AM J PHYSIOL-LUNG C, V285, pL258, DOI 10.1152/ajplung.00311.2002; Stroncek DF, 2007, LANCET, V370, P427, DOI 10.1016/S0140-6736(07)61198-2	36	22	24	0	2	WILEY	HOBOKEN	111 RIVER ST, HOBOKEN 07030-5774, NJ USA	0041-1132	1537-2995		TRANSFUSION	Transfusion	MAR	2016	56			1	SI		S65	S75		10.1111/trf.13532			11	Hematology	Hematology	DI2YJ	WOS:000373364800009	27001364	Green Accepted			2021-06-18	
J	Crowe, L; Collie, A; Hearps, S; Dooley, J; Clausen, H; Maddocks, D; McCrory, P; Davis, G; Anderson, V				Crowe, Louise; Collie, Alex; Hearps, Stephen; Dooley, Julian; Clausen, Helen; Maddocks, David; McCrory, Paul; Davis, Gavin; Anderson, Vicki			Cognitive and physical symptoms of concussive injury in children: a detailed longitudinal recovery study	BRITISH JOURNAL OF SPORTS MEDICINE			English	Article							SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; POSTCONCUSSION SYNDROME; HIGH-SCHOOL; EPIDEMIOLOGY; PREDICTORS; APPROPRIATE; GUIDELINES; OUTCOMES; PLAY	Background Recovery from concussion sustained in childhood and adolescence is poorly understood. We explored patterns of recovery for neurocognition and postconcussive symptoms following concussion in children and adolescents. Methods Using a prospective, longitudinal design, we collected baseline data on 728 children and adolescents aged 10-17 years. 10 participants sustained a concussive injury (n=10) in the 12 months following baseline testing and they were reviewed at day 5, 10 and 30 postconcussion. Assessments included the CogSport for Kids computerised test battery to evaluate neurocognitive function and self-report, and parent measures of postconcussive symptoms. At day 30, parents also completed measures rating their child's quality of life and executive functions. Results Children and adolescents displayed a gradual reduction in postconcussive symptoms over the 30 days following injury. At day 5, 87% of participants were reporting physical and cognitive symptoms, with a generalised reduction in all symptoms by day 10 (40% of participants). On the computerised measure, reaction time was slower after concussion, but returned to baseline levels by day 30. At day 30, 10% of participants demonstrated ongoing postconcussive symptoms. Number of previous concussions was related to speed of symptom resolution. Conclusions At 5 days postconcussion, the majority of children and adolescents experienced debilitating postconcussive symptoms. However, by 30 days postinjury, 90% demonstrated recovery to normal for both neurocognition and postconcussive symptoms.	[Crowe, Louise; Dooley, Julian; Anderson, Vicki] Murdoch Childrens Res Inst, Child Neuropsychol, Melbourne, Vic, Australia; [Collie, Alex] Monash Univ, Inst Safety Compensat & Recovery Res, Melbourne, Vic 3004, Australia; [Hearps, Stephen] Murdoch Childrens Res Inst, Ctr Adolescent Hlth, Melbourne, Vic, Australia; [Clausen, Helen] Melbourne Neuropsychol Serv, Melbourne, Vic, Australia; [Maddocks, David] Perry Maddocks Trellope, Melbourne, Vic, Australia; [McCrory, Paul] Florey Inst Neurosci & Mental Hlth, Melbourne, Vic, Australia; [Davis, Gavin] Cabrini Hosp, Dept Neurosurg, Melbourne, Vic, Australia	Anderson, V (corresponding author), Murdoch Childrens Res Inst, Child Neuropsychol, 4 West,50 Flemington Rd, Parkville, Vic 3052, Australia.	vicki.anderson@rch.org.au	Hearps, Stephen/L-6853-2016; McCrory, Paul/Q-8688-2019; Meijer, Anna/K-5118-2016	Collie, Alex/0000-0003-2617-9339; Crowe, Louise/0000-0003-4619-9708; McCrory, Paul/0000-0003-4850-0568	Australian National Health and Medical Research CouncilNational Health and Medical Research Council of Australia [334337]; Victorian Government Operational Infrastructure grant; NHMRCNational Health and Medical Research Council of Australia	This study was funded by the Australian National Health and Medical Research Council (#334337) and was supported by a Victorian Government Operational Infrastructure grant to the Murdoch Childrens Research Institute. VA is funded by an NHMRC Senior Practitioner. Fellowship of LC is funded by a NHMRC Early Career Fellowship.	Anastasi A, 1997, PSYCHOL TESTING, V7th; Babcock L, 2013, JAMA PEDIATR, V167, P156, DOI 10.1001/jamapediatrics.2013.434; Babikian T, 2011, J INT NEUROPSYCH SOC, V17, P886, DOI 10.1017/S1355617711000907; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Blume H, 2012, CURR OPIN PEDIATR, V24, P724, DOI 10.1097/MOP.0b013e328359e4cc; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broshek DK, 2014, J CHILD NEUROL; Carney N, 2014, NEUROSURGERY, V75, pS3, DOI 10.1227/NEU.0000000000000433; Castile L, 2012, BRIT J SPORT MED, V46, P603, DOI 10.1136/bjsports-2011-090115; Collie A, 2003, CLIN J SPORT MED, V13, P28, DOI 10.1097/00042752-200301000-00006; Crowe L, 2009, J PAEDIATR CHILD H, V45, P346, DOI 10.1111/j.1440-1754.2009.01499.x; Davis GA, 2014, BRIT J SPORT MED, V48, P98, DOI 10.1136/bjsports-2012-092132; Falleti MG, 2006, J CLIN EXP NEUROPSYC, V28, P1095, DOI 10.1080/13803390500205718; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Gioia GA, 2009, BRIT J SPORT MED, V43, pI13, DOI 10.1136/bjsm.2009.058255; Gioia G.A., 2000, BEHAV RATING INVENTO; Guskiewicz KM, 2001, J ATHL TRAINING, V36, P263; Iverson GL, 2006, BRAIN INJURY, V20, P245, DOI 10.1080/02699050500487910; Landgraf JM, 1996, CHILD HLTH QUESTIONN, V1st; Langlois JA, 2006, TBI US EMERGENCY DEP; Lovell MR, 2013, J PEDIATR-US, V163, P1192, DOI 10.1016/j.jpeds.2013.05.061; Mayer AR, 2012, J NEUROSCI, V32, P17961, DOI 10.1523/JNEUROSCI.3379-12.2012; McCrea M, 2013, J INT NEUROPSYCH SOC, V19, P22, DOI 10.1017/S1355617712000872; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McKinlay A, 2010, CHILD CARE HLTH DEV, V36, P22, DOI 10.1111/j.1365-2214.2009.00947.x; McNally KA, 2013, NEUROPSYCHOLOGY, V27, P1, DOI 10.1037/a0031370; Ponsford J, 1999, J HEAD TRAUMA REHAB, V14, P360, DOI 10.1097/00001199-199908000-00005; Purcell L, 2009, BRIT J SPORT MED, V43, pI51, DOI 10.1136/bjsm.2009.058214; Taylor HG, 2010, NEUROPSYCHOLOGY, V24, P148, DOI 10.1037/a0018112; WATERS E, 1999, AUSTR AUTHORISED ADA; Williams J, 2014, APP NEUROPSYCHOL CHI, P1; Yeates KO, 2012, INT J DEV NEUROSCI, V30, P231, DOI 10.1016/j.ijdevneu.2011.05.008; Yeates KO, 2009, PEDIATRICS, V123, P735, DOI 10.1542/peds.2008-1056; Zemek RL, 2013, JAMA PEDIATR, V167, P259, DOI 10.1001/2013.jamapediatrics.216	35	22	22	0	22	BMJ PUBLISHING GROUP	LONDON	BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND	0306-3674	1473-0480		BRIT J SPORT MED	Br. J. Sports Med.	MAR	2016	50	5					311	U69		10.1136/bjsports-2015-094663			7	Sport Sciences	Sport Sciences	DF4KT	WOS:000371317800015	26429808				2021-06-18	
J	Moore, M; Jimenez, N; Rowhani-Rahbar, A; Willis, M; Baron, K; Giordano, J; Crawley, D; Rivara, FP; Jaffe, KM; Ebel, BE				Moore, Megan; Jimenez, Nathalia; Rowhani-Rahbar, Ali; Willis, Margaret; Baron, Kate; Giordano, Jessica; Crawley, Deborah; Rivara, Frederick P.; Jaffe, Kenneth M.; Ebel, Beth E.			Availability of Outpatient Rehabilitation Services for Children After Traumatic Brain Injury Differences by Language and Insurance Status	AMERICAN JOURNAL OF PHYSICAL MEDICINE & REHABILITATION			English	Article						Disability; Health Care Accessibility; Rehabilitation; Health Care Disparities; Hispanic Children; Brain Injuries	HEALTH-CARE; ETHNIC DISPARITIES; PROFICIENCY; IMPACT; BARRIERS; OUTCOMES; SPANISH; TBI	Objective The objective of this study was to explore associations between English proficiency, insurance status, outpatient rehabilitation service availability, and travel time for children with traumatic brain injury. Design The authors used an ecologic cross-sectional design. Data were analyzed from a cohort of 82 children with moderate to severe traumatic brain injury and rehabilitation providers in Washington State. Main measures included availability and travel time to services. Results Less than 20% of providers accepted children with Medicaid and provided language interpretation. Mental health services were most limited. Adjusted for median household income, multilingual service availability was lowest in counties with greater language diversity; for every 10% increase in persons older than 5 yrs speaking a language other than English at home, there was a 34% decrease in availability of multilingual services (prevalence ratio, 0.66; 95% confidence interval, 0.48-0.90). Adjusted for education and Medicaid status, children from Spanish-speaking families had significantly longer travel times to services (mean, 16 additional minutes to mental health; 9 to other therapies). Conclusions Children in households with limited English proficiency and Medicaid faced significant barriers in availability and proximity of outpatient rehabilitation services. Innovative service strategies are needed to equitably improve availability of rehabilitation for children with traumatic brain injury. Similar studies in other regions will inform one's understanding of the scope of these disparities.	[Moore, Megan; Jimenez, Nathalia; Rowhani-Rahbar, Ali; Baron, Kate; Rivara, Frederick P.; Jaffe, Kenneth M.; Ebel, Beth E.] Univ Washington, Harborview Injury Prevent & Res Ctr, Seattle, WA 98195 USA; [Moore, Megan] Univ Washington, Sch Social Work, 4101 15th Ave NE,Box 354900, Seattle, WA 98195 USA; [Jimenez, Nathalia] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA; [Rivara, Frederick P.; Jaffe, Kenneth M.; Ebel, Beth E.] Univ Washington, Dept Pediat, Seattle, WA 98195 USA; [Rowhani-Rahbar, Ali; Ebel, Beth E.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA; [Jaffe, Kenneth M.] Univ Washington, Dept Neurol Surg, Seattle, WA 98195 USA; [Willis, Margaret] Boston Coll, Dept Sociol, Chestnut Hill, MA 02167 USA; [Giordano, Jessica; Crawley, Deborah] Brain Injury Alliance Washington, Seattle, WA USA	Moore, M (corresponding author), Univ Washington, Sch Social Work, 4101 15th Ave NE,Box 354900, Seattle, WA 98195 USA.			Jimenez, Nathalia/0000-0002-6785-8330	National Center for Advancing Translational Sciences of the National Institutes of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421]; National Institute of Child Health and Human DevelopmentUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [1K23HD078453-01]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD078453] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [KL2TR000421, KL2TR002317] Funding Source: NIH RePORTER	Supported by the National Center for Advancing Translational Sciences of the National Institutes of Health (KL2TR000421 [MM]) and the National Institute of Child Health and Human Development (1K23HD078453-01 [NJ]). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.	[Anonymous], 1999, JAMA, V282, P974; Antonini TN, 2014, BEHAV THER, V45, P455, DOI 10.1016/j.beth.2014.02.003; Asemota AO, 2013, J NEUROTRAUM, V30, P2057, DOI 10.1089/neu.2013.3091; Bauer GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/j.socscimed.2014.03.022; Blume HK, 2012, PEDIATRICS, V129, pE31, DOI 10.1542/peds.2011-1742; Burnett DM, 2003, ARCH PHYS MED REHAB, V84, P263, DOI 10.1053/apmr.2003.50091; Carroll LJ, 2004, J REHABIL MED, V36, P113, DOI 10.1080/16501960410023877; Davidson GH, 2011, JAMA-J AM MED ASSOC, V305, P1001, DOI 10.1001/jama.2011.259; DeCamp LR, 2013, PEDIATRICS, V132, pE396, DOI 10.1542/peds.2012-2909; Decker SL, 2012, HEALTH AFFAIR, V31, P1673, DOI 10.1377/hlthaff.2012.0294; Dettmer J, 2014, J HEAD TRAUMA REHAB, V29, P224, DOI 10.1097/HTR.0b013e3182a1cd68; [DHHS U.S. Department of Health and Human Services], 2001, NAT STAND CULT LING; Diamond LC, 2010, MED CARE, V48, P1080, DOI 10.1097/MLR.0b013e3181f380bc; Englum BR, 2011, J AM COLL SURGEONS, V213, P699, DOI 10.1016/j.jamcollsurg.2011.08.017; Flores GF, 2005, PUBLIC HEALTH REP, V120, P418, DOI 10.1177/003335490512000409; Gregory PC, 2006, AM J PHYS MED REHAB, V85, P705, DOI 10.1097/01.phm.0000233181.34999.3d; Jimenez Nathalia, 2014, Hosp Pediatr, V4, P23, DOI 10.1542/hpeds.2013-0031; Jimenez N, 2013, PEDIATRICS, V131, pE1850, DOI 10.1542/peds.2012-3354; Koepsell TD, 2011, PEDIATRICS, V128, P946, DOI 10.1542/peds.2010-2259; Krieger N, 2012, AM J PUBLIC HEALTH, V102, P936, DOI 10.2105/AJPH.2011.300544; Kurowski BG, 2014, JAMA PEDIATR, V168, P523, DOI 10.1001/jamapediatrics.2013.5070; Lion KC, 2013, ACAD MED, V88, P1478, DOI 10.1097/ACM.0b013e3182a2e30d; Lion KC, 2012, PEDIATRICS, V130, pE80, DOI 10.1542/peds.2011-2794; de la Plata CM, 2007, J HEAD TRAUMA REHAB, V22, P113, DOI 10.1097/01.HTR.0000265099.29436.56; Marr AL., 2004, CENTRAL NERVOUS SYST; National Center for Injury Prevention and Control, 2003, C MILD TRAUM BRAIN I; Rivara FP, 2011, PEDIATRICS, V128, pE1129, DOI 10.1542/peds.2011-0840; Schwei RJ, 2015, INT J NURS STUD; Seedall RB, 2014, J MARITAL FAM THER, V40, P139, DOI 10.1111/jmft.12015; Shafi S, 2007, J TRAUMA, V63, P1138, DOI 10.1097/TA.0b013e3181568cd4; Slomine BS, 2006, PEDIATRICS, V117, pE663, DOI 10.1542/peds.2005-1892; Staudenmayer KL, 2007, J TRAUMA, V63, P1364, DOI 10.1097/TA.0b013e31815b897b; Tham SW, 2012, J NEUROTRAUM, V29, P154, DOI 10.1089/neu.2011.2126; Timmins CL, 2002, J MIDWIFERY WOM HEAL, V47, P80, DOI 10.1016/S1526-9523(02)00218-0; Wade SL, 2014, J HEAD TRAUMA REHAB, V29, P198, DOI 10.1097/HTR.0b013e31828f9fe8; Ylvisaker M, 2005, J HEAD TRAUMA REHAB, V20, P95, DOI 10.1097/00001199-200501000-00009; Zuckerman S, 2011, HLTH AFF MILLWOOD, V30, P1997, DOI DOI 10.1377/hlthaff.2011.0604	37	22	23	0	5	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0894-9115	1537-7385		AM J PHYS MED REHAB	Am. J. Phys. Med. Rehabil.	MAR	2016	95	3					204	213		10.1097/PHM.0000000000000362			10	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DE9LI	WOS:000370958600005	26259055	Green Accepted			2021-06-18	
J	de Almeida, CER; de Sousa, JL; Dourado, JC; Gontijo, PAM; Dellaretti, MA; Costa, BS				Romeu de Almeida, Carlos Eduardo; de Sousa Filho, Jose Lopes; Dourado, Jules Carlos; Magalhaes Gontijo, Pollyana Anicio; Dellaretti, Marcos Antonio; Costa, Bruno Silva			Traumatic Brain Injury Epidemiology in Brazil	WORLD NEUROSURGERY			English	Article						Economics; Epidemiology; Head trauma; Prevention and control	HEAD-INJURY; MORTALITY; MORBIDITY; CITY	BACKGROUND: Traumatic brain injury (TBI) stands out as a grave social and economic problem. Emerging countries possess few epidemiologic studies on the range and impact of TBI. OBJECTIVE: Our study aimed to characterize the demographic, social, and economic profile of people suffering from TBI in Brazil. METHODS: Data on TBI cases in Brazil between 2008 and 2012 were collected through the website of the Information Technology Department of the Unified Health System (DATASUS) maintained by the Brazilian Ministry of Health. This database is fed by public hospital admission authorization forms provided nationwide. RESULTS: There were around 125,000 hospital admissions due to TBI a year, an incidence of 65.7 admissions per 100,000 inhabitants per year. Hospital mortality was 5.1/100,000/year, and the case fatality rate was 7.7%. The average annual cost of hospital expenses was US$70,960,000, with an average cost per admission of US$568. The age group 20-29, frequently admitted to the hospital due to TBI, presented the largest number of hospital deaths; however, the population >80 years of age showed the highest admission rate per age group, around 138/100,000/year, followed by the age group 70-79. CONCLUSIONS: TBI should be recognized as an important public health problem in Brazil because it is responsible for considerable social and economic costs. Besides the young adult age group (20-29 years old), the geriatric age group is especially vulnerable to the frequent and devastating consequences of TBI. The implementation of a system of effective epidemiologic vigilance for neurotrauma is urgent in Brazil and other countries worldwide.	[Romeu de Almeida, Carlos Eduardo; de Sousa Filho, Jose Lopes; Dourado, Jules Carlos; Magalhaes Gontijo, Pollyana Anicio; Dellaretti, Marcos Antonio; Costa, Bruno Silva] Santa Casa Belo Horizonte, Dept Neurosurg, Belo Horizonte, MG, Brazil	de Almeida, CER (corresponding author), Santa Casa Belo Horizonte, Dept Neurosurg, Belo Horizonte, MG, Brazil.	cadu_romeu@yahoo.com.br	Costa, Bruno/G-6500-2012; Dellaretti, Marcos/G-4664-2012	Costa, Bruno/0000-0003-0780-4709; 			Agrawal Amit, 2012, Int J Crit Illn Inj Sci, V2, P167, DOI 10.4103/2229-5151.100915; Bener A, 2010, BRAIN INJURY, V24, P74, DOI 10.3109/02699050903508192; Brasure M., 2012, MULTIDISCIPLINARY PO; Coronado VG, 2012, J SAFETY RES, V43, P299, DOI 10.1016/j.jsr.2012.08.011; de Moura JC, 2011, BRAZ NEUROSURG, V30, P99; Feigin VL, 2013, LANCET NEUROL, V12, P53, DOI 10.1016/S1474-4422(12)70262-4; Hu JH, 2013, J NEUROTRAUM, V30, P1755, DOI 10.1089/neu.2013.2857; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Martins ET, 2009, J TRAUMA, V67, P85, DOI 10.1097/TA.0b013e318187acee; Maset A, 1993, ARQ BRAS NEUROCIRURG, V12, P293; Masini M, 1991, J BRAS NEUROCIR, V5, P61; Melo JRT, 2005, ARQ NEURO-PSIQUIAT, V63, P1054, DOI 10.1590/S0004-282X2005000600026; Melo JRT, 2004, ARQ NEURO-PSIQUIAT, V62, P711, DOI 10.1590/S0004-282X2004000400027; Menon DK, 2010, ARCH PHYS MED REHAB, V91, P1637, DOI 10.1016/j.apmr.2010.05.017; Ministry of Health of Brazil, 2008, EX SECR MOR HLTH RIG; NELL V, 1991, SOC SCI MED, V33, P289, DOI 10.1016/0277-9536(91)90363-H; Ponsford JL, 2013, J NEUROTRAUM, V30, P1498, DOI 10.1089/neu.2012.2843; Fernandes RNR, 2013, BRAZ NEUROSURG, V32, P136; Roozenbeek B, 2013, NAT REV NEUROL, V9, P231, DOI 10.1038/nrneurol.2013.22; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thompson HJ, 2006, J AM GERIATR SOC, V54, P1590, DOI 10.1111/j.1532-5415.2006.00894.x; Thruman DJ, 1995, STANDARDS SURVEILLAN, P9; Wright RM, 2013, J NEUROTRAUM, V30, P102, DOI 10.1089/neu.2012.2418	23	22	25	0	7	ELSEVIER SCIENCE INC	NEW YORK	360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA	1878-8750	1878-8769		WORLD NEUROSURG	World Neurosurg.	MAR	2016	87						540	547		10.1016/j.wneu.2015.10.020			8	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	DI3HR	WOS:000373390200076	26485419				2021-06-18	
J	Wing, R; Amanullah, S; Jacobs, E; Clark, MA; Merritt, C				Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Clark, Melissa A.; Merritt, Chris			Heads Up: Communication Is Key in School Nurses' Preparedness for Facilitating "Return to Learn" Following Concussion	CLINICAL PEDIATRICS			English	Article						concussion; head injury; mild traumatic brain injury; school nurses; return to learn; return to school; pediatrics	COGNITIVE REST; SPORT; RECOMMENDATIONS; STATEMENT; RECOVERY	Background. Recent literature advocates for a school academic team, including school nurses, to support concussed students' return to the classroom. This study aimed to assess the current understanding and practices of a sample of school nurses regarding the concept of return to learn in concussed students. Methods. Cross-sectional survey of New England school nurses. Results. The greatest barrier to the school nurses' functioning within the academic rehabilitation team for students with concussion was inadequate communication with the provider that diagnosed the concussion (73%). Of the 151 school nurses surveyed, 19% felt that they did not have the training necessary for this role. Other barriers included inadequate concussion training (38%) and inadequate time necessary to care for a student with concussion (30%). Conclusions. By identifying specific gaps in knowledge and challenges at the school level, these results inform interdisciplinary medical teams about the importance of educating and facilitating effective return to learn academic plans.	[Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Clark, Melissa A.; Merritt, Chris] Brown Univ, Providence, RI 02912 USA; [Wing, Robyn; Amanullah, Siraj; Jacobs, Elizabeth; Merritt, Chris] Rhode Isl Hosp, Hasbro Childrens Hosp, Providence, RI 02903 USA	Wing, R (corresponding author), Hasbro Childrens Hosp, 593 Eddy St,Claverick 2, Providence, RI 02903 USA.	robyn_wing@brown.edu	Meijer, Anna/K-5118-2016		University Emergency Medicine Foundation of Providence, RI	The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: Funding was provided through a seed grant from the University Emergency Medicine Foundation of Providence, RI.	Arbogast KB, 2013, CLIN PEDIATR, V52, P397, DOI 10.1177/0009922813478160; Bakhos LL, 2010, PEDIATRICS, V126, pE550, DOI 10.1542/peds.2009-3101; Bergren Martha Dewey, 2012, NASN Sch Nurse, V27, P36; Brown NJ, 2014, PEDIATRICS, V133, pE299, DOI 10.1542/peds.2013-2125; de Kruijk JR, 2002, J NEUROL NEUROSUR PS, V73, P167, DOI 10.1136/jnnp.73.2.167; Gibson S, 2013, BRAIN INJURY, V27, P839, DOI 10.3109/02699052.2013.775494; Gioia GA, 2010, J INT NEUROPSYCH SOC, V16, P178; Giza CC, 2001, J ATHL TRAINING, V36, P228; Grady MF, 2012, PEDIATR ANN, V41, P377, DOI 10.3928/00904481-20120827-12; Halstead ME, 2013, PEDIATRICS, V132, P948, DOI 10.1542/peds.2013-2867; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harmon KG, 2013, CLIN J SPORT MED, V23, P1, DOI 10.1097/JSM.0b013e31827f5f93; Howell D, 2013, MED SCI SPORT EXER, V45, P1030, DOI 10.1249/MSS.0b013e3182814595; Lovell MR, 2007, NEUROSURGERY, V61, P352, DOI 10.1227/01.NEU.0000279985.94168.7F; Majerske CW, 2008, J ATHL TRAINING, V43, P265, DOI 10.4085/1062-6050-43.3.265; Master CL, 2012, PEDIATR ANN, V41, pE180, DOI 10.3928/00904481-20120827-09; McAvoy K., REAP BENEFITS GOOD C; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McCrory Paul, 2009, J Athl Train, V44, P434, DOI 10.4085/1062-6050-44.4.434; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Meehan WP, 2010, J PEDIATR-US, V157, P889, DOI 10.1016/j.jpeds.2010.06.040; Moser RS, 2012, J PEDIATR-US, V161, P922, DOI 10.1016/j.jpeds.2012.04.012; Ohio Department of Health, 2008, 2008 SCH NURS SURV F; Piebes SK, 2009, J SCH NURS, V25, P270, DOI 10.1177/1059840509339782; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Thomas DG, 2015, PEDIATRICS, V135, P213, DOI 10.1542/peds.2014-0966; Wang LY, 2014, JAMA PEDIATR, V168, P642, DOI 10.1001/jamapediatrics.2013.5441	27	22	22	0	13	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0009-9228	1938-2707		CLIN PEDIATR	Clin. Pediatr.	MAR	2016	55	3					228	235		10.1177/0009922815592879			8	Pediatrics	Pediatrics	DE1VN	WOS:000370414700004	26130394				2021-06-18	
J	Bosco, FM; Gabbatore, I; Gastaldo, L; Sacco, K				Bosco, Francesca M.; Gabbatore, Ilaria; Gastaldo, Luigi; Sacco, Katiuscia			Communicative-Pragmatic Treatment in Schizophrenia: A Pilot Study	FRONTIERS IN PSYCHOLOGY			English	Article						rehabilitation; schizophrenia; pragmatic; communication; training	TRAUMATIC BRAIN-INJURY; FACIAL AFFECT RECOGNITION; TRAINING-PROGRAM; MIND; IMPAIRMENTS; LANGUAGE; DEFICITS; REHABILITATION; REMEDIATION; PERSPECTIVE	This paper aims to verify the efficacy of Cognitive Pragmatic Treatment (CPT), a new remediation training for the improvement of the communicative-pragmatic abilities, in patients with schizophrenia. The CPT program is made up of 20 group sessions, focused on a number of communication modalities, i.e., linguistic, extralinguistic and paralinguistic, theory of mind (ToM) and other cognitive functions able to play a role on the communicative performance, such as awareness and planning. A group of 17 patients with schizophrenia took part in the training program. They were evaluated before and after training, through the equivalent forms of the Assessment Battery for Communication (ABaCo), a tool for testing, both in comprehension and in production, a wide range of pragmatic phenomena such as direct and indirect speech acts, irony and deceit, and a series of neuropsychological and ToM tests. The results showed a significant improvement in patients' performance on both production and comprehension tasks following the program, and in all the communication modalities evaluated through the ABaCo, i.e., linguistic, extralinguistic, paralinguistic, and social appropriateness. This improvement persisted after 3 months from the end of the training program, as shown by the follow-up tests. These preliminary findings provide evidence of the efficacy of the CPT program in improving communicative-pragmatic abilities in schizophrenic individuals.	[Bosco, Francesca M.; Sacco, Katiuscia] Univ Turin, Dept Psychol, Ctr Cognit Sci, Turin, Italy; [Bosco, Francesca M.] Neurosci Inst Turin, Turin, Italy; [Gabbatore, Ilaria] Oulu Univ, Child Language Res Ctr, Res Unit Logoped, Fac Humanities, Oulu, Finland; [Gastaldo, Luigi] AslTo2 Dept Mental Hlth, Turin, Italy; [Sacco, Katiuscia] Brain Imaging Grp, Turin, Italy	Gabbatore, I (corresponding author), Oulu Univ, Child Language Res Ctr, Res Unit Logoped, Fac Humanities, Oulu, Finland.	ilaria.gabbatore@oulu.fi	bosco, francesca marina/B-6746-2013; Gabbatore, Ilaria/AAC-1925-2019	bosco, francesca marina/0000-0001-6101-8587; Gabbatore, Ilaria/0000-0002-9724-8066	University of Turin	The project was founded by the University of Turin ex-60% project, "La riabilitazione delle abilita comunicativo pragmatiche in soggetti con trauma cranico".	Abu-Akel A, 2000, PSYCHOL MED, V30, P735, DOI 10.1017/S0033291799002123; Adolphs R, 2003, NEUROPSYCHOLOGIA, V41, P119, DOI 10.1016/S0028-3932(02)00142-2; AIRENTI G, 1993, COGNITIVE SCI, V17, P197, DOI 10.1016/0364-0213(93)90011-V; American Psychiatric Association (APA), 2013, DIAGN STAT MAN MENT, V5th; Angeleri R, 2008, BRAIN LANG, V107, P229, DOI 10.1016/j.bandl.2008.01.002; Angeleri R, 2012, BEHAV RES METHODS, V44, P845, DOI 10.3758/s13428-011-0174-9; APA, 2000, DIAGN STAT MAN MENT; Austin J. L., 1962, PHILOS ANAL; Bara BG., 2010, COGNITIVE PRAGMATICS; BARONCOHEN S, 1985, COGNITION, V21, P37, DOI 10.1016/0010-0277(85)90022-8; BaronCohen S, 1997, J CHILD PSYCHOL PSYC, V38, P813, DOI 10.1111/j.1469-7610.1997.tb01599.x; Bazin N, 2005, SCHIZOPHR RES, V77, P75, DOI 10.1016/j.schres.2005.01.020; Bibby H, 2005, NEUROPSYCHOLOGIA, V43, P99, DOI 10.1016/j.neuropsychologia.2004.04.027; Bosco FM, 2004, J PRAGMATICS, V36, P467, DOI 10.1016/S0378-2166(03)00055-9; Bosco FM, 2008, J PRAGMATICS, V40, P583, DOI 10.1016/j.pragma.2007.05.004; Bosco FM, 2006, J PRAGMATICS, V38, P1398, DOI 10.1016/j.pragma.2005.06.011; Bosco FM, 2015, INT J LANG COMM DIS, V50, P63, DOI 10.1111/1460-6984.12114; Bosco FM, 2013, J CHILD LANG, V40, P741, DOI 10.1017/S0305000913000081; Bosco FM, 2012, J COMMUN DISORD, V45, P290, DOI 10.1016/j.jcomdis.2012.03.002; Bosco FM, 2012, J COMMUN DISORD, V45, P181, DOI 10.1016/j.jcomdis.2012.01.005; Bosco FM, 2009, CONSCIOUS COGN, V18, P306, DOI 10.1016/j.concog.2008.06.006; Brookshire R.H., 1997, DISCOURSE COMPREHENS; Brune M, 2011, CURR PSYCHIATRY REV, V7, P239, DOI 10.2174/157340011797183210; Clark H., 1992, ARENAS LANGUAGE USE; Colle L, 2013, J COMMUN DISORD, V46, P294, DOI 10.1016/j.jcomdis.2013.01.003; Corcoran Rhiannon, 2003, Cogn Neuropsychiatry, V8, P223, DOI 10.1080/13546800244000319; Cummings L., 2014, PRAGMATIC DISORDERS; Edwards J, 2002, CLIN PSYCHOL REV, V22, P789, DOI 10.1016/S0272-7358(02)00130-7; Ekman P., 1976, PICTURES FACIAL AFFE; FLAVELL JH, 1979, AM PSYCHOL, V34, P906, DOI 10.1037/0003-066X.34.10.906; FOLSTEIN MF, 1975, J PSYCHIAT RES, V12, P189, DOI 10.1016/0022-3956(75)90026-6; Frith CD, 2004, PSYCHOL MED, V34, P385, DOI 10.1017/S0033291703001326; Frith CD, 1996, PSYCHOL MED, V26, P521, DOI 10.1017/S0033291700035601; Frith CD., 1992, COGN NEUROPSYCHOL; Frommann N, 2003, PSYCHIAT RES, V117, P281, DOI 10.1016/S0165-1781(03)00039-8; Gabbatore I, 2015, J HEAD TRAUMA REHAB, V30, pE14, DOI 10.1097/HTR.0000000000000087; Grice H.P, 1989, STUDIES WAY WORDS; Happe F, 2002, MIND LANG, V17, P24, DOI 10.1111/1468-0017.00187; HAPPE FGE, 1994, J AUTISM DEV DISORD, V24, P129, DOI 10.1007/BF02172093; Huber W., 1983, AACHENER APHASIE TES; Kanade T., 2000, Proceedings Fourth IEEE International Conference on Automatic Face and Gesture Recognition (Cat. No. PR00580), P46, DOI 10.1109/AFGR.2000.840611; KAY SR, 1987, SCHIZOPHRENIA BULL, V13, P261, DOI 10.1093/schbul/13.2.261; Kayser N, 2006, NEUROPSYCHOL REHABIL, V16, P83, DOI 10.1080/09602010443000236; Kertesz A., 1982, W APHASIA BATTERY; Kurtz MM, 2008, J CONSULT CLIN PSYCH, V76, P491, DOI 10.1037/0022-006X.76.3.491; Kurtz MM, 2012, SCHIZOPHRENIA BULL, V38, P1092, DOI 10.1093/schbul/sbr036; Langdon R, 2002, MIND LANG, V17, P68, DOI 10.1111/1468-0017.00189; Linscott RJ, 2005, SCHIZOPHR RES, V75, P225, DOI 10.1016/j.schres.2004.10.007; Marder SR, 2006, J CLIN PSYCHIAT, V67, P31; Marini A, 2008, SCHIZOPHR RES, V105, P144, DOI 10.1016/j.schres.2008.07.011; Matsumoto D, 2000, J NONVERBAL BEHAV, V24, P179, DOI 10.1023/A:1006668120583; Matsumoto D., 1988, JAPANESE CAUCASIAN F; Mazza M, 2008, PSYCHOPATHOLOGY, V41, P254, DOI 10.1159/000128324; MORITZ S, 2005, METACOGNITIVE SKILL; Moritz S, 2010, CURR OPIN PSYCHIATR, V23, P561, DOI 10.1097/YCO.0b013e32833d16a8; NELSON HE, 1976, CORTEX, V12, P313, DOI 10.1016/S0010-9452(76)80035-4; Penn DL, 2007, PSYCHIAT SERV, V58, P449; PREMACK D, 1978, BEHAV BRAIN SCI, V1, P515, DOI 10.1017/S0140525X00076512; Raven J. C., 1938, PROGR MATRICES PERCE; Reichenberg A, 2007, PSYCHOL BULL, V133, P833, DOI 10.1037/0033-2909.133.5.833; REITAN R. M., 1958, PERCEPT MOT SKILLS, V8, P271; Roncone R, 2004, NEUROPSYCHOL REHABIL, V14, P421, DOI 10.1080/09602010343000291; Sacco K, 2008, J COGN SCI, V9, P111; Salvatore G, 2008, B MENNINGER CLIN, V72, P191, DOI 10.1521/bumc.2008.72.3.191; Searle, 1979, EXPRESSION MEANING S; SHALLICE T, 1982, PHILOS T ROY SOC B, V298, P199, DOI 10.1098/rstb.1982.0082; Sperber D, 2002, MIND LANG, V17, P3, DOI 10.1111/1468-0017.00186; Spinnler H., 1987, ITALIAN J NEUROLOGIC, V6, P20; Sponheim SR, 2003, SCHIZOPHR RES, V65, P117, DOI 10.1016/S0920-9964(02)00525-X; Tavano A, 2008, SCHIZOPHR RES, V102, P53, DOI 10.1016/j.schres.2008.02.008; Tenyi T, 2002, PSYCHOPATHOLOGY, V35, P25, DOI 10.1159/000056212; Tirassa M, 2006, CONSCIOUS COGN, V15, P197, DOI 10.1016/j.concog.2005.06.005; Tirassa M, 2006, COGN SYST RES, V7, P128, DOI 10.1016/j.cogsys.2006.01.002; Tirassa M, 2008, EMERG COMMUN-STUD NE, V10, P81; Wolwer W, 2005, SCHIZOPHR RES, V80, P295, DOI 10.1016/j.schres.2005.07.018	75	22	23	0	14	FRONTIERS MEDIA SA	LAUSANNE	AVENUE DU TRIBUNAL FEDERAL 34, LAUSANNE, CH-1015, SWITZERLAND	1664-1078			FRONT PSYCHOL	Front. Psychol.	FEB 23	2016	7								166	10.3389/fpsyg.2016.00166			12	Psychology, Multidisciplinary	Psychology	DE4JZ	WOS:000370596300001	26941667	DOAJ Gold, Green Published			2021-06-18	
J	Aisiku, IP; Yamal, JM; Doshi, P; Rubin, ML; Benoit, JS; Hannay, J; Tilley, BC; Gopinath, S; Robertson, CS				Aisiku, Imoigele P.; Yamal, Jose-Miguel; Doshi, Pratik; Rubin, Maria Laura; Benoit, Julia S.; Hannay, Julia; Tilley, Barbara C.; Gopinath, Shankar; Robertson, Claudia S.			The incidence of ARDS and associated mortality in severe TBI using the Berlin definition	JOURNAL OF TRAUMA AND ACUTE CARE SURGERY			English	Article						Traumatic brain injury; adult respiratory distress syndrome; acute lung injury	RESPIRATORY-DISTRESS-SYNDROME; ACUTE LUNG INJURY; TRAUMATIC BRAIN-INJURY; CLINICAL-TRIAL; UNITED-STATES; BLUNT TRAUMA; HEAD-INJURY; OUTCOMES; CARE	BACKGROUND: The incidence of adult respiratory distress syndrome (ARDS) in severe traumatic brain injury (TBI) is poorly reported. Recently, a new definition for ARDS was proposed, the Berlin definition. The percentage of patients represented by TBI in the Berlin criteria study is limited. This study describes the incidence and associated mortality of ARDS in TBI patients. METHODS: The study was an analysis of the safety of erythropoietin administration and transfusion threshold on the incidence of ARDS in severe TBI patients. Three reviewers independently assessed all patients enrolled in the study for acute lung injury/ARDS using the Berlin and the American-European Consensus Conference (AECC) definitions. A Cox proportional hazards model was used to assess the relationship between ARDS and mortality and 6-month Glasgow Outcome Scale (GOS) score. RESULTS: Two hundred patients were enrolled in the study. Of the patients, 21% (41 of 200) and 26% (52 of 200) developed ARDS using the AECC and Berlin definitions, respectively, with a median time of 3 days (interquartile range, 3) after injury. ARDS by either definition was associated with increased mortality (p = 0.04) but not with differences in functional outcome as measured by the GOS score at 6 months. Adjusted analysis using the Berlin criteria showed an increased mortality associated with ADS (p = 0.01). CONCLUSION: Severe TBI is associated with an incidence of ARDS ranging from 20% to 25%. The incidence is comparable between the Berlin and AECC definitions. ARDS is associated with increased mortality in severe TBI patients, but further studies are needed to validate these findings. (Copyright (C) 2016 Wolters Kluwer Health, Inc. All rights reserved.)	[Aisiku, Imoigele P.] Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA; [Yamal, Jose-Miguel; Rubin, Maria Laura; Tilley, Barbara C.] Univ Texas Houston, Sch Publ Hlth, Div Biostat, Houston, TX USA; [Doshi, Pratik] Univ Texas Hlth Sci Ctr Houston, Dept Emergency Med & Internal Med, Houston, TX 77030 USA; [Benoit, Julia S.] Univ Houston, Dept Basic Vis Sci, Houston, TX USA; [Hannay, Julia] Univ Houston, Coll Optometry, Texas Inst Measurement Evaluat & Stat, Houston, TX USA; [Hannay, Julia] Univ Houston, Dept Psychol, Houston, TX USA; [Gopinath, Shankar; Robertson, Claudia S.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA	Aisiku, IP (corresponding author), Brigham & Womens Hosp, Dept Emergency Med, 75 Francis St, Boston, MA 02115 USA.	iaisiku@partners.org			NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [P01-NS38660]; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS038660] Funding Source: NIH RePORTER	This study was supported by the NIH grant P01-NS38660.	Acker JE, 2007, STROKE, V38, P3097, DOI 10.1161/STROKEAHA.107.186094; ASHBAUGH DG, 1967, LANCET, V2, P319; BERNARD GR, 1994, AM J RESP CRIT CARE, V149, P818, DOI 10.1164/ajrccm.149.3.7509706; Bersten AD, 2002, AM J RESP CRIT CARE, V165, P443, DOI 10.1164/ajrccm.165.4.2101124; Bordes J, 2014, BURNS, V40, P562, DOI 10.1016/j.burns.2014.03.004; Bratton SL, 1997, NEUROSURGERY, V40, P707, DOI 10.1097/00006123-199704000-00009; Britos M, 2011, CRIT CARE MED, V39, P2025, DOI 10.1097/CCM.0b013e31821cb774; Brower RG, 2000, NEW ENGL J MED, V342, P1301, DOI 10.1056/nejm200005043421801; Contant CF, 2001, J NEUROSURG, V95, P560, DOI 10.3171/jns.2001.95.4.0560; Holland MC, 2003, J TRAUMA, V55, P106, DOI 10.1097/01.TA.0000071620.27375.BE; Mascia L, 2008, INTENS CARE MED, V34, P720, DOI 10.1007/s00134-007-0974-7; Miller PR, 2002, AM SURGEON, V68, P845; Needham DM, 2006, CRIT CARE, V10, DOI 10.1186/cc3948; Ranieri VM, 2012, JAMA-J AM MED ASSOC, V307, P2526, DOI 10.1001/jama.2012.5669; Rincon F, 2012, NEUROSURGERY, V71, P795, DOI 10.1227/NEU.0b013e3182672ae5; Robertson CS, 2014, JAMA-J AM MED ASSOC, V312, P36, DOI 10.1001/jama.2014.6490; Rubenfeld GD, 2005, NEW ENGL J MED, V353, P1685, DOI 10.1056/NEJMoa050333; Salim A, 2008, INJURY, V39, P30, DOI 10.1016/j.injury.2007.06.015; SOSIN DM, 1989, JAMA-J AM MED ASSOC, V262, P2251, DOI 10.1001/jama.262.16.2251; Tibshirani R, 1997, STAT MED, V16, P385, DOI 10.1002/(SICI)1097-0258(19970228)16:4<385::AID-SIM380>3.0.CO;2-3	20	22	25	0	2	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	2163-0755	2163-0763		J TRAUMA ACUTE CARE	J. Trauma Acute Care Surg.	FEB	2016	80	2					308	312		10.1097/TA.0000000000000903			5	Critical Care Medicine; Surgery	General & Internal Medicine; Surgery	DK9EY	WOS:000375234800026	26491799	Green Accepted			2021-06-18	
J	Leung, A; Fallah, A; Shukla, S; Lin, L; Tsia, A; Song, D; Polston, G; Lee, R				Leung, Albert; Fallah, Amir; Shukla, Shivshil; Lin, Lisa; Tsia, Alice; Song, David; Polston, Gregory; Lee, Roland			rTMS in Alleviating Mild TBI Related Headaches - A Case Series	PAIN PHYSICIAN			English	Article						Transcranial magnetic stimulation; MTBI; mild traumatic rrain injury; headaches; pain neuromodulation	TRANSCRANIAL MAGNETIC STIMULATION; TRAUMATIC BRAIN-INJURY; MOTOR CORTEX; PAIN-CONTROL; DOUBLE-BLIND; PREVALENCE; MIGRAINE; PLACEBO	Background: Headache is one of the most common debilitating chronic pain conditions in patients with mild traumatic brain injury. Conventional pharmacological treatments have not been shown to be effective in alleviating debilitating mild traumatic brain injury related headaches (MTBI-HA). Therefore, the development of an innovative non-invasive therapy in managing MTBI-HA is needed in the field of pain management. Repetitive transcranial magnetic stimulation (rTMS) utilizes a basic electromagnetic coupling principle in which a rapid discharge of electrical current is converted into dynamic magnetic flux, allowing the induction of a localized current in the brain for neuromodulation. The treatment is currently FDA approved for treating depression in the United States. Recent meta-analysis studies have implicated its usage in chronic pain management. Objective: The objective of the prospective case series is to assess the potential application of rTMS in alleviating MTBI-HA. Study Design: A prospective evaluation was conducted in patients with established diagnoses of MTBI-HA and treated with neuronavigational guided rTMS. Setting: The study was conducted at the Veteran Administration San Diego Healthcare System where over 400 patients with MTBI were being evaluated annually by the Rehabilitation Medicine Service. A fraction of this patient population was referred and evaluated in the Anesthesia Pain Clinic for the consideration of rTMS for their headaches. Methods: A prospective case series was conducted with human subject protection committee approval. Patients with established diagnoses of MTBI and constant headaches rated at >= 4 on a 0 - 10 Numerical Rating Pain Scale (NRPS), and on stable headache medication regimens were selected to receive the treatment. Four sessions of rTMS were delivered to specific areas of cortices over a 2-month period. Patients' average intensities of lingering constant headaches (defined as duration of headache lasting more than 48 hours), and the average frequency (number of severe headache episodes per day), intensity (NRPS), and duration (hours) of headache exacerbations were assessed before and after the rTMS treatment protocol. Results: Six men (average age of 50) with MTBI-HA received the rTMS treatment protocol. Average pre and post-rTMS constant headache scores (+/- SD) on the NRPS were 5.50 (+/- 1.38) and 2.67 (+/- 1.75), respectively, with an average post-rTMS headache intensity reduction of 53.05% (+/- 19.90). The average headache exacerbation frequency (episodes per week) was reduced by 78.97% (+/- 19.88) with 2 patients reporting complete cessation of severe headache episodes. For those (N = 4) with persistent headache exacerbations, the average duration and intensity of these exacerbations were reduced by 50.0% and 31.7%, respectively. Limitations: This prospective evaluation provides the initial insight that rTMS may be beneficial in alleviating a debilitating chronic pain condition in patients with MTBI-HA. More controlled randomized studies should be conducted to validate its efficacy. Other co-existing cognitive and mood dysfunction should be assessed as well. Conclusions: rTMS offers a non-invasive treatment option for MTBI-HA. The tested treatment protocol was well tolerated by the patients and can be adopted for future randomized controlled studies in further validating the treatment efficacy.	[Leung, Albert; Fallah, Amir; Shukla, Shivshil; Lin, Lisa; Tsia, Alice; Song, David; Polston, Gregory; Lee, Roland] Univ Calif San Diego, Dept Anesthesiol, Sch Med, Vet Adm San Diego Healthcare Syst, 9300 Campus Point Dr 7651, La Jolla, CA 92073 USA	Leung, A (corresponding author), Univ Calif San Diego, Dept Anesthesiol, Sch Med, Vet Adm San Diego Healthcare Syst, 9300 Campus Point Dr 7651, La Jolla, CA 92073 USA.	ayleung@ucsd.edu					Andre-Obadia N, 2006, CLIN NEUROPHYSIOL, V117, P1536, DOI 10.1016/j.clinph.2006.03.025; DiTommaso C, 2014, HEADACHE, V54, P511, DOI 10.1111/head.12254; Garcia-Larrea L, 1999, PAIN, V83, P259, DOI 10.1016/S0304-3959(99)00114-1; George MS, 2013, CURR OPIN PSYCHIATR, V26, P13, DOI 10.1097/YCO.0b013e32835ab46d; Hirayama A, 2006, PAIN, V122, P22, DOI 10.1016/j.pain.2005.12.001; Hoge CW, 2008, NEW ENGL J MED, V358, P453, DOI 10.1056/NEJMoa072972; Khedr EM, 2005, J NEUROL NEUROSUR PS, V76, P833, DOI 10.1136/jnnp.2004.055806; Koski L, 2015, J NEUROTRAUM, V32, P38, DOI 10.1089/neu.2014.3449; Lefaucheur JP, 2014, CLIN NEUROPHYSIOL, V125, P2150, DOI 10.1016/j.clinph.2014.05.021; Leung A, 2009, J PAIN, V10, P1205, DOI 10.1016/j.jpain.2009.03.010; Lewine JD, 2007, J HEAD TRAUMA REHAB, V22, P141, DOI 10.1097/01.HTR.0000271115.29954.27; Lipton RB, 2010, LANCET NEUROL, V9, P373, DOI 10.1016/S1474-4422(10)70054-5; Lorenz J, 2003, BRAIN, V126, P1079, DOI 10.1093/brain/awg102; Lorenz J, 2002, NEURON, V35, P383, DOI 10.1016/S0896-6273(02)00767-5; Misra UK, 2013, J NEUROL, V260, P2793, DOI 10.1007/s00415-013-7072-2; Nampiaparampil DE, 2008, JAMA-J AM MED ASSOC, V300, P711, DOI 10.1001/jama.300.6.711; PascualLeone A, 1995, AUST NZ J PSYCHIAT, V29, P698; Patil VK, 2011, HEADACHE, V51, P1112, DOI 10.1111/j.1526-4610.2011.01946.x; Paus T, 2001, EUR J NEUROSCI, V14, P1405, DOI 10.1046/j.0953-816x.2001.01757.x; Pleger B, 2004, NEUROSCI LETT, V356, P87, DOI 10.1016/j.neulet.2003.11.037; Wassermann EM, 1998, EVOKED POTENTIAL, V108, P1, DOI 10.1016/S0168-5597(97)00096-8	21	22	22	1	11	AM SOC INTERVENTIONAL PAIN PHYSICIANS	PADUCAH	81 LAKEVIEW DR, PADUCAH, KY 42001 USA	1533-3159			PAIN PHYSICIAN	Pain Physician	FEB	2016	19	2					E347	E353					7	Anesthesiology; Clinical Neurology	Anesthesiology; Neurosciences & Neurology	DC1QI	WOS:000368991000010	26815263				2021-06-18	
J	Stergiou-Kita, M; Mansfield, E; Sokoloff, S; Colantonio, A				Stergiou-Kita, Mary; Mansfield, Elizabeth; Sokoloff, Sandra; Colantonio, Angela			Gender Influences on Return to Work After Mild Traumatic Brain Injury	ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION			English	Article						Brain injuries; Employment; Rehabilitation; Return to work	HEALTH RESEARCH; UNITED-STATES; HELP-SEEKING; MENS HEALTH; WAGE GAP; MASCULINITY; SEX; WORKPLACE; PERSPECTIVE; DISABILITY	Objective: To examine the influence of gender on the return to work experience of workers who sustained a work-related mild traumatic brain injury (TBI). Design: Qualitative study using in-depth telephone interviews. Setting: Community. Participants: Purposive sampling was used to recruit participants. Participants were adults (N=12; males, n=6, females, n=6) with a diagnosis of mild TBI sustained through a workplace injury. Interventions: Not applicable. Main Outcome Measures: Not applicable. Results: Our findings suggest that gender impacts return to work experiences in multiple ways. Occupational and breadwinner roles were significant for both men and women after work -related mild TBI. Women in this study were more proactive than men in seeking and requesting medical and rehabilitation services; however, the workplace culture may contribute to whether and how health issues are discussed. Among our participants, those who worked in supportive, nurturing (eg, feminine) workplaces reported more positive return to work (RTW) experiences than participants employed in traditionally masculine work environments. For all participants, employer and coworker relations were critical elements in RTW outcomes. Conclusions: The application of a gender analysis in this preliminary exploratory study revealed that gender is implicated in the RTW process on many levels for men and women alike. Further examination of the work reintegration processes that takes gender into account is necessary for the development of successful policy and practice for RTW after work -related MTBI. (C) 2016 by the American Congress of Rehabilitation Medicine	[Stergiou-Kita, Mary; Sokoloff, Sandra; Colantonio, Angela] Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada; [Stergiou-Kita, Mary; Mansfield, Elizabeth; Colantonio, Angela] Univ Hlth Network, Toronto Rehabil Inst, Toronto, ON, Canada; [Stergiou-Kita, Mary] Inst Work & Hlth, Toronto, ON, Canada	Colantonio, A (corresponding author), Univ Toronto, Dept Occupat Sci & Occupat Therapy, 160-500 Univ Ave, Toronto, ON M5G 1V7, Canada.	angela.colantonio@utoronto.ca	Mansfield, Elizabeth/S-3426-2016	Mansfield, Elizabeth/0000-0003-1776-8641; Colantonio, Angela/0000-0003-2094-4765	Canadian Institutes of Health Research-Institute for Gender and HealthCanadian Institutes of Health Research (CIHR) [OGW-123786]; Toronto Rehabilitation Institute Foundation; Ontario Ministry of Health and Long Term Care, Provincial Rehabilitation Research Program to the Toronto Rehabilitation Institute, University Health Network; Canadian Institutes of Health Research Research Chair in Gender, Work and Health from the Institute of Gender and Health [CGW-126580]; Saunderson Family Chair in Acquired Brain Injury Research at the Toronto Rehabilitation Institute	Supported by the Canadian Institutes of Health Research-Institute for Gender and Health (grant no. OGW-123786); the Toronto Rehabilitation Institute Foundation and the Ontario Ministry of Health and Long Term Care, which provided funding under the Provincial Rehabilitation Research Program to the Toronto Rehabilitation Institute, University Health Network; the Canadian Institutes of Health Research Research Chair in Gender, Work and Health (grant no. CGW-126580) from the Institute of Gender and Health; and the Saunderson Family Chair in Acquired Brain Injury Research at the Toronto Rehabilitation Institute.	Armstrong P, 2014, POLICY PRACT HEALTH, V12, P3, DOI 10.1080/14774003.2014.11667794; Bauer GR, 2014, SOC SCI MED, V110, P10, DOI 10.1016/j.socscimed.2014.03.022; Bilsker D, 2010, ROADMAP MENS HLTH CU; Boudarbat B, 2013, CAN J ECON, V46, P1037, DOI 10.1111/caje.12036; Braun V., 2006, QUALITATIVE RES PSYC, V3, P77, DOI [10.1191/1478088706qp063oa, DOI 10.1191/1478088706qp063oa]; Breslin FC, 2007, SOC SCI MED, V64, P782, DOI 10.1016/j.socscimed.2006.10.024; Charles N, 2008, HEALTH RISK SOC, V10, P117, DOI 10.1080/13698570802160954; Colantonio A, 2012, WORK, V43, P195, DOI 10.3233/WOR-2012-1377; Cote D, 2010, DISABIL REHABIL, V32, P87, DOI 10.3109/09638280903026572; Desmond M., 2006, ETHNOGRAPHY VOL, V7, P387, DOI DOI 10.1177/1466138106073142; Dolan A, 2011, SOCIOL HEALTH ILL, V33, P586, DOI 10.1111/j.1467-9566.2010.01300.x; Doyal L, 2001, BRIT MED J, V323, P1061, DOI 10.1136/bmj.323.7320.1061; Farrimond H, 2012, HEALTH-LONDON, V16, P208, DOI 10.1177/1363459311403943; Finnegan Alan, 2010, Br J Nurs, V19, P1355; Francis JJ, 2010, PSYCHOL HEALTH, V25, P1229, DOI 10.1080/08870440903194015; Galdas PM, 2005, J ADV NURS, V49, P616, DOI 10.1111/j.1365-2648.2004.03331.x; Gillespie BM, 2010, INT J NURS STUD, V47, P732, DOI 10.1016/j.ijnurstu.2009.11.001; Green J., 2004, QUALITATIVE METHODS; Harkins C, 2010, BMC PUBLIC HEALTH, V10, DOI 10.1186/1471-2458-10-391; Hennessy M, 2014, INT J MED HLTH SCI R, V1, P13; Hilgert JA, 2012, AM J IND MED, V55, P506, DOI 10.1002/ajim.22023; Hooson JM, 2013, NEUROPSYCHOL REHABIL, V23, P19, DOI 10.1080/09602011.2012.713314; Hultin M, 2003, WORK OCCUPATION, V30, P30, DOI 10.1177/0730888402239326; Jensen SQ, 2014, SAFETY SCI, V64, P190, DOI 10.1016/j.ssci.2013.12.004; Johnson JL, 2009, INT J EQUITY HEALTH, V8, DOI 10.1186/1475-9276-8-14; Johnson Joy L., 2007, BETTER SCI SEX GENDE; Knaak S, 2004, SOCIOL INQ, V74, P302, DOI 10.1111/j.1475-682X.2004.00093.x; Levack W, 2004, DISABIL REHABIL, V26, P290, DOI 10.1080/09638280310001647615; Lips HM, 2013, SEX ROLES, V68, P169, DOI [10.1007/s11199-012-0165-z, 10.1007/s11199-012-0245-0]; Mackenzie CR, 2014, SOC SCI MED, V117, P96, DOI 10.1016/j.socscimed.2014.07.043; Marchant T, 2013, CONSTR MANAG ECON, V31, P845, DOI 10.1080/01446193.2013.808353; Menendez M, 2007, SOC SCI MED, V64, P776, DOI 10.1016/j.socscimed.2006.10.035; Messing K, 2003, AM J IND MED, V43, P618, DOI 10.1002/ajim.10225; Mikkonen J., 2010, SOCIAL DETERMINANTS; Miles M. B., 2013, QUALITATIVE DATA ANA; Misra J, 2014, SOCIOL COMPASS, V8, P1281, DOI 10.1111/soc4.12213; Morse JM, 2000, QUAL HEALTH RES, V10, P3, DOI 10.1177/104973200129118183; O'Brien R, 2005, SOC SCI MED, V61, P503, DOI 10.1016/j.socscimed.2004.12.008; O'Brien R, 2005, SIGNS, V30, P1529, DOI 10.1086/423350; Peerson A., 2009, Critical Public Health, V19, P441, DOI 10.1080/09581590902906229; Schofield T, 2000, J AM COLL HEALTH, V48, P247, DOI 10.1080/07448480009596266; Sharman Z, 2012, SOC SCI MED, V74, P1812, DOI 10.1016/j.socscimed.2011.08.039; Silva S., 2012, EPIDEMIOLOGY CURRENT, P63; Soeker MS, 2011, J OCCUP SCI, V18, P81, DOI 10.1080/14427591.2011.554155; Stergiou-Kita M, 2011, J OCCUP REHABIL, V21, P374, DOI 10.1007/s10926-010-9282-0; Stewart BJ, 2012, INT J NURS STUD, V49, P560, DOI 10.1016/j.ijnurstu.2011.11.004; WHO, 2008, CLOS GAP GEN HLTH EQ; Workplace Safety and Insurance Board (WSIB), 2013, NUMB 2012 WSIB STAT	48	22	22	0	13	W B SAUNDERS CO-ELSEVIER INC	PHILADELPHIA	1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA	0003-9993	1532-821X		ARCH PHYS MED REHAB	Arch. Phys. Med. Rehabil.	FEB	2016	97	2		1			S40	S45		10.1016/j.apmr.2015.04.008			6	Rehabilitation; Sport Sciences	Rehabilitation; Sport Sciences	DC4RI	WOS:000369207600006	25921979	Green Accepted			2021-06-18	
J	Cristofori, I; Bulbulia, J; Shaver, JH; Wilson, M; Krueger, F; Grafman, J				Cristofori, Irene; Bulbulia, Joseph; Shaver, John H.; Wilson, Marc; Krueger, Frank; Grafman, Jordan			Neural correlates of mystical experience	NEUROPSYCHOLOGIA			English	Article						Mystical experience; Religious belief; Voxel-based lesion-symptom mapping; Penetrating traumatic brain injuries	COGNITIVE CONTROL; CORTICAL-LESIONS; HEAD-INJURY; RELIGION; EMOTION; CONSCIOUSNESS; INHIBITION; REGISTRATION; SYSTEMS; STATES	Mystical experiences, or subjectively believed encounters with a supernatural world, are widely reported across cultures and throughout human history. Previous theories speculate that executive brain functions underpin mystical experiences. To evaluate causal hypotheses, structural studies of brain lesion are required. Previous studies suffer from small samples or do not have valid measures of cognitive functioning prior to injury. We investigated mystical experience among participants from the Vietnam Head Injury Study and compared those who suffered penetrating traumatic brain injury (pTBI; n=116) with matched healthy controls (HC; n =32). Voxel-based lesion-symptom mapping analysis showed that lesions to frontal and temporal brain regions were linked with greater mystical experiences. Such regions included the dorsolateral prefrontal cortex (dIPFC) and middle/superior temporal cortex (TC). In a confirmatory analysis, we grouped pTBI patients by lesion location and compared mysticism experiences with the HC group. The dIPFC group presented markedly increased mysticism. Notably, longitudinal analysis of pre-injury data (correlating with general intelligence and executive performance) excludes explanations from individual differences. Our findings support previous speculation linking executive brain functions to mystical experiences, and reveal that executive functioning (d1PFC) causally contributes to the down regulation of mystical experiences. (C) 2015 Elsevier Ltd. All rights reserved.	[Cristofori, Irene; Grafman, Jordan] Rehabil Inst Chicago, Cognit Neurosci Lab, Brain Injury Res, Chicago, IL 60611 USA; [Cristofori, Irene; Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Phys Med & Rehabil, Chicago, IL 60611 USA; [Bulbulia, Joseph; Shaver, John H.] Victoria Univ New Zealand, Sch Art Hist Class & Religious Studies, Wellington 6140, New Zealand; [Wilson, Marc] Victoria Univ New Zealand, Dept Psychol, Wellington 6012, New Zealand; [Krueger, Frank] George Mason Univ, Mol Neurosci Dept, Fairfax, VA 22030 USA; [Krueger, Frank] George Mason Univ, Dept Psychol, Fairfax, VA 22030 USA; [Grafman, Jordan] Northwestern Univ, Feinberg Sch Med, Dept Neurol, Chicago, IL 60611 USA	Grafman, J (corresponding author), Rehabil Inst Chicago, Cognit Neurosci Lab, Brain Injury Res Program, 345 E Super St, Chicago, IL 60611 USA.	irene.cristofori@northwestern.edu; jgrafman@northwestern.edu		Cristofori, Irene/0000-0003-2339-1457; Shaver, John/0000-0002-9522-4765; Wilson, Marc/0000-0002-3009-5229; Bulbulia, Joseph/0000-0002-5861-2056	National Naval Medical Center; National Institute of Neurological Disorders and StrokeUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS); US Department of EducationUS Department of Education [H133F130009]; Templeton World Charity Foundation [0077]; Royal Society of New Zealand Marsden GrantRoyal Society of New ZealandMarsden Fund (NZ) [VUW1321]	We thank our dedicated Vietnam veterans for their invaluable participation in the study. We also thank G. J. Solomon for his assistance with ABLe, as well as V. Raymont, S. Bonifant, B. Cheon, C. Ngo, A. Greathouse, K. Reding, and G. Tasick for testing and evaluating participants. Lastly, we thank the National Naval Medical Center and the National Institute of Neurological Disorders and Stroke for their support and provision of their facilities. The US Department of Education (M. Switzer Research Fellowship: ID: H133F130009) supported IC. A Templeton World Charity Foundation Grant (ID: 0077) and a Royal Society of New Zealand Marsden Grant (ID: VUW1321) supported JB and JS. The views expressed in this article are those of the authors and do not necessarily reflect the official policy or position of the Department of the Navy, the Department of Defense, or the U.S. Government.	Alcorta CS, 2005, HUM NATURE-INT BIOS, V16, P323, DOI 10.1007/s12110-005-1014-3; Amting JM, 2010, J NEUROSCI, V30, P10039, DOI 10.1523/JNEUROSCI.6434-09.2010; Andersen M, 2014, METH THEORY STUD REL, V26, P217, DOI 10.1163/15700682-12341323; [Anonymous], 1960, AFQT7A DEP DEF; Aron AR, 2004, TRENDS COGN SCI, V8, P170, DOI 10.1016/j.tics.2004.02.010; Banks SJ, 2007, SOC COGN AFFECT NEUR, V2, P303, DOI 10.1093/scan/nsm029; Barrett JL, 1996, COGNITIVE PSYCHOL, V31, P219, DOI 10.1006/cogp.1996.0017; Beauregard M, 2006, NEUROSCI LETT, V405, P186, DOI 10.1016/j.neulet.2006.06.060; Beck A. T., 1996, BECK DEPRESSION INVE, VII; BEEMAN M, 1994, J COGNITIVE NEUROSCI, V6, P26, DOI 10.1162/jocn.1994.6.1.26; BENSON DF, 1990, SCHIZOPHRENIA BULL, V16, P403, DOI 10.1093/schbul/16.3.403; Botero CA, 2014, P NATL ACAD SCI USA, V111, P16784, DOI 10.1073/pnas.1408701111; Brugger P, 2008, CORTEX, V44, P1291, DOI 10.1016/j.cortex.2008.05.008; Bulbulia J., 2009, RELIGIOSITY MENTAL T; Bulbulia J, 2011, RELIG BRAIN BEHAV, V1, P220, DOI 10.1080/2153599X.2011.647851; Bulbulia J, 2013, CONT TOP COGN NEUROS, P169; Cassotti M, 2010, BRAIN COGNITION, V72, P378, DOI 10.1016/j.bandc.2009.11.004; COLLINS DL, 1994, J COMPUT ASSIST TOMO, V18, P192, DOI 10.1097/00004728-199403000-00005; Corbetta M, 2002, NAT REV NEUROSCI, V3, P201, DOI 10.1038/nrn755; Coruh BA, 2005, EXPLORE-NY, V1, P186, DOI 10.1016/j.explore.2005.02.001; Cristofori I, 2015, SOC COGN AFFECT NEUR, V10, P1038, DOI 10.1093/scan/nsu155; CUTTING J, 1987, BRIT J PSYCHIAT, V151, P324, DOI 10.1192/bjp.151.3.324; Dal Monte O, 2014, CORTEX, V58, P9, DOI 10.1016/j.cortex.2014.05.002; DAQUILI EG, 1993, ZYGON, V28, P177, DOI 10.1111/j.1467-9744.1993.tb01026.x; Davidson RJ, 2000, SCIENCE, V289, P591, DOI 10.1126/science.289.5479.591; DEELEY PQ, 2003, PHILOS PSYCHIAT PSYC, V10, P161, DOI DOI 10.1353/PPP.2003.0095; Deeley Q, 2014, CORTEX, V53, P107, DOI 10.1016/j.cortex.2014.01.004; Delis D.C., 2001, DELIS KAPLAN EXECUTI; Devinsky O, 2003, EPILEPSY BEHAV, V4, pS2, DOI 10.1016/j.yebeh.2003.10.002; Devinsky O, 2008, EPILEPSY BEHAV, V12, P636, DOI 10.1016/j.yebeh.2007.11.011; DEWHURST K, 1970, BRIT J PSYCHIAT, V117, P497, DOI 10.1192/bjp.117.540.497; Dietrich A, 2003, CONSCIOUS COGN, V12, P231, DOI 10.1016/S1053-8100(02)00046-6; Friedman NP, 2004, J EXP PSYCHOL GEN, V133, P101, DOI 10.1037/0096-3445.133.1.101; Genovese CR, 2002, NEUROIMAGE, V15, P870, DOI 10.1006/nimg.2001.1037; GESCHWIND N, 1983, EPILEPSIA, V24, pS23, DOI 10.1111/j.1528-1157.1983.tb04640.x; Ghorbani N, 2007, PSYCHOL REP, V100, P451, DOI 10.2466/PR0.100.2.451-454; Glascher J, 2009, NEURON, V61, P681, DOI 10.1016/j.neuron.2009.01.026; Goldman-Rakic P. S., 1987, CIRCUITRY PRIMATE PR, V5; Gozzi M, 2009, NEUROPSYCHOLOGIA, V47, P2125, DOI 10.1016/j.neuropsychologia.2009.04.002; GRAFMAN J, 1988, BRAIN, V111, P169, DOI 10.1093/brain/111.1.169; Han SD, 2007, J NEUROL NEUROSUR PS, V78, P1103, DOI 10.1136/jnnp.2006.108183; HOOD RW, 1975, J SCI STUD RELIG, V14, P29, DOI 10.2307/1384454; HOOD RW, 1981, J SCI STUD RELIG, V20, P261, DOI 10.2307/1385548; Inzlicht M, 2009, PSYCHOL SCI, V20, P385, DOI 10.1111/j.1467-9280.2009.02305.x; Kapogiannis D, 2009, P NATL ACAD SCI USA, V106, P4876, DOI 10.1073/pnas.0811717106; Karlsgodt KH, 2009, SCHIZOPHR RES, V108, P143, DOI 10.1016/j.schres.2008.12.025; KEANE TM, 1988, J CONSULT CLIN PSYCH, V56, P85, DOI 10.1037/0022-006X.56.1.85; Kim SH, 2007, J COGNITIVE NEUROSCI, V19, P776, DOI 10.1162/jocn.2007.19.5.776; Koechlin E, 2003, SCIENCE, V302, P1181, DOI 10.1126/science.1088545; Kounios J, 2014, ANNU REV PSYCHOL, V65, P71, DOI 10.1146/annurev-psych-010213-115154; LEVIN HS, 1987, J NEUROL NEUROSUR PS, V50, P183, DOI 10.1136/jnnp.50.2.183; Lindeman M, 2013, SOC COGN AFFECT NEUR, V8, P943, DOI 10.1093/scan/nss096; LUDLOW CL, 1986, BRAIN, V109, P55, DOI 10.1093/brain/109.1.55; Luhrmann, 2005, SPIRITUS, V5, P133, DOI [DOI 10.1353/SCS.2006.0014, DOI 10.1353/scs.2006.0014]; Luhrmann Tanya, 2012, GOD TALKS BACK UNDER; Makale M, 2002, BEHAV RES METH INS C, V34, P6, DOI 10.3758/BF03195419; McCullough ME, 2009, PSYCHOL BULL, V135, P69, DOI 10.1037/a0014213; McNeil M. M., 1994, REVISED TOKEN TEST; Miller EK, 2001, ANNU REV NEUROSCI, V24, P167, DOI 10.1146/annurev.neuro.24.1.167; Mizumori SJY, 2013, HIPPOCAMPUS, V23, P1103, DOI 10.1002/hipo.22176; Mori S, 2008, NEUROIMAGE, V40, P570, DOI 10.1016/j.neuroimage.2007.12.035; Newberg AB, 2006, PSYCHIAT RES-NEUROIM, V148, P67, DOI 10.1016/j.pscychresns.2006.07.001; Ng F, 2007, AUSTRALAS PSYCHIATRY, V15, P62, DOI 10.1080/10398560601083118; Nigg JT, 2000, PSYCHOL BULL, V126, P220, DOI 10.1037/0033-2909.126.2.220; Ochsner KN, 2005, TRENDS COGN SCI, V9, P242, DOI 10.1016/j.tics.2005.03.010; Ochsner KN, 2004, NEUROIMAGE, V23, P483, DOI 10.1016/j.neuroimage.2004.06.030; Pena-Gomez C, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0022812; Persinger MA, 2001, J NEUROPSYCH CLIN N, V13, P515, DOI 10.1176/appi.neuropsych.13.4.515; Previc FH, 2006, CONSCIOUS COGN, V15, P500, DOI 10.1016/j.concog.2005.09.009; Raymont Vanessa, 2011, Front Neurol, V2, P15, DOI 10.3389/fneur.2011.00015; Saver JL, 1997, J NEUROPSYCH CLIN N, V9, P498; Schjoedt U, 2013, RELIG BRAIN BEHAV, V3, P39, DOI 10.1080/2153599X.2012.736714; Schjoedt U, 2011, SOC COGN AFFECT NEUR, V6, P119, DOI 10.1093/scan/nsq023; Schjoedt U, 2009, SOC COGN AFFECT NEUR, V4, P199, DOI 10.1093/scan/nsn050; Simons JS, 2003, NAT REV NEUROSCI, V4, P637, DOI 10.1038/nrn1178; Solomon J, 2007, COMPUT METH PROG BIO, V86, P245, DOI 10.1016/j.cmpb.2007.02.006; Spilka B., 2009, PSYCHOL RELIG EMPIRI; Stace Walter T., 1960, MYSTICISM PHILOS; TEASDALE G, 1974, LANCET, V2, P81; Tzourio-Mazoyer N, 2002, NEUROIMAGE, V15, P273, DOI 10.1006/nimg.2001.0978; Urgesi C, 2010, NEURON, V65, P309, DOI 10.1016/j.neuron.2010.01.026; Vivas AB, 2003, NEUROPSYCHOLOGIA, V41, P1531, DOI 10.1016/S0028-3932(03)00063-0; Warrington E., 1991, VISUAL OBJECT SPACE; Wechsler D., 1997, WMS 3 WECHSLER MEMOR; Wildman W.L., 2011, RELIG SPIRITUAL EXPE; Woods RP, 1998, J COMPUT ASSIST TOMO, V22, P139, DOI 10.1097/00004728-199801000-00027	86	22	22	0	24	PERGAMON-ELSEVIER SCIENCE LTD	OXFORD	THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND	0028-3932	1873-3514		NEUROPSYCHOLOGIA	Neuropsychologia	JAN 8	2016	80						212	220		10.1016/j.neuropsychologia.2015.11.021			9	Behavioral Sciences; Neurosciences; Psychology, Experimental	Behavioral Sciences; Neurosciences & Neurology; Psychology	DC1CB	WOS:000368953300022	26631541	Bronze			2021-06-18	
J	Cacabelos, R; Torrellas, C; Fernandez-Novoa, L; Aliev, G				Cacabelos, Ramon; Torrellas, Clara; Fernandez-Novoa, Lucia; Aliev, Gjumrakch			Neuroimmune Crosstalk in CNS Disorders: The Histamine Connection	CURRENT PHARMACEUTICAL DESIGN			English	Article						Neuroimmune system; CNS disorders; Alzheimer's disease; genomics; histamine; immune markers	CENTRAL-NERVOUS-SYSTEM; INTERLEUKIN-10 GENE PROMOTER; TNF-ALPHA GENE; ALZHEIMERS-DISEASE; MICROGLIAL ACTIVATION; IMMUNE-SYSTEM; T-CELLS; THERAPEUTIC STRATEGIES; INFLAMMATORY RESPONSES; INCREASED EXPRESSION	The neuroimmune system represents a dense network of biochemical signals associated with neurotransmitters, neuropeptides, neurohormones, cytokines, chemokines, and growth factors synthesized in neurons, glial cells and immune cells, to maintain systemic homeostasis. Endogenous and/or exogenous, noxious stimuli in any tissue are captured by sensor cells to inform the brain; likewise, signals originating at the central nervous system (CNS) level are transmitted to peripheral immune effectors which react to central stimuli. This multidirectional information system makes it possible for the CNS to respond to peripheral damage and for alterations in brain function to be reflected in peripheral immune changes. Different CNS disorders, such as anxiety, depression, psychosis, stroke, Alzheimer's disease, Parkinson's disease, attention-deficit hyperactivity disorder, migraine, epilepsy, vascular dementia, mental retardation, cerebrovascular encephalopathy, multiple sclerosis, brain tumors, cranial nerve neuropathies, mental retardation and post-traumatic brain injury exhibit changes in CD3, CD4, CD7, HLA-DR, CD25, CD28, and CD56 immune markers. Histamine is an important pleiotropic factor in neuroimmune regulation. This biogenic amine shows age-and sex-dependent changes in the CNS, and is significantly altered, together with interleukin-1 beta and TNF-alpha, in Alzheimer's disease and other neurodegenerative disorders in which neuroinflammation appears to be an aggravating phenotype. Therapeutic intervention to halt progression of deleterious neuroinflammatory reactions in CNS disorders is a major challenge for molecular pharmacology in the future.	[Cacabelos, Ramon; Torrellas, Clara] Camilo Jose Cela Univ, Madrid, Spain; [Cacabelos, Ramon; Torrellas, Clara] Inst Med Sci & Genom Med, EuroEspes Biomed Res Ctr, Bergondo 15165, Coruna, Spain; [Cacabelos, Ramon; Fernandez-Novoa, Lucia] EuroEspes Biotechnol, Corunna, Spain; [Aliev, Gjumrakch] Univ Atlanta, Sch Hlth Sci & Healthcare Adm, Atlanta, GA USA; [Aliev, Gjumrakch] Russian Acad Sci, Inst Physiol Act Cpds, Chernogolovka 142432, Russia; [Aliev, Gjumrakch] GALLY Int Biomed Res Consulting LLC, San Antonio, TX 78229 USA	Cacabelos, R (corresponding author), Inst Med Sci & Genom Med, EuroEspes Biomed Res Ctr, Bergondo 15165, Coruna, Spain.	rcacabelos@euroespes.com	Aliev, Gjumrakch/K-7302-2017; Aliev, Gjumrakch/AAE-7734-2020	Aliev, Gjumrakch/0000-0001-7373-3182			Achour SB, 2010, NEUROCHEM INT, V57, P440, DOI 10.1016/j.neuint.2010.02.013; Ader R., 1991, PSYCHONEUROIMMUNOLOG; Ager RR, 2010, J NEUROCHEM, V113, P389, DOI 10.1111/j.1471-4159.2010.06595.x; Alvarez XA, 1996, MOL CHEM NEUROPATHOL, V29, P237, DOI 10.1007/BF02815005; Alvarez XA, 1997, CNS DRUG REV, V3, P181; Alvarez XA, 1992, ANN PSYCHIAT, V3, P329; Anders S, 2015, BRAIN RES, V1617, P93, DOI 10.1016/j.brainres.2015.02.043; Anderson CNG, 2006, J PHYSIOL-LONDON, V575, P367, DOI 10.1113/jphysiol.2006.113795; Arion D, 2007, BIOL PSYCHIAT, V62, P711, DOI 10.1016/j.biopsych.2006.12.021; Bajetto A, 2001, FRONT NEUROENDOCRIN, V22, P147, DOI 10.1006/frne.2001.0214; Banks WA, 2010, NEUROBIOL DIS, V37, P26, DOI 10.1016/j.nbd.2009.07.031; Banks WA, 2009, IMMUNOL ALLERGY CLIN, V29, P223, DOI 10.1016/j.iac.2009.02.001; Baronio D, 2014, ANN GEN PSYCHIATR, V13, DOI 10.1186/s12991-014-0034-y; Bechmann I, 2005, NEUROMOL MED, V7, P217, DOI 10.1385/NMM:7:3:217; Behrens MM, 2008, J NEUROSCI, V28, P13957, DOI 10.1523/JNEUROSCI.4457-08.2008; Bennett M, 2009, AUST NZ J PSYCHIAT, V43, P711, DOI 10.1080/00048670903001943; Bernstein HG, 2009, EXPERT REV NEUROTHER, V9, P1059, DOI 10.1586/ERN.09.59; Bilbo SD, 2009, FRONT BEHAV NEUROSCI, V3, DOI 10.3389/neuro.08.014.2009; Bitanihirwe BKY, 2010, INT J NEUROPSYCHOPH, V13, P981, DOI 10.1017/S1461145710000192; Boksa P, 2010, BRAIN BEHAV IMMUN, V24, P881, DOI 10.1016/j.bbi.2010.03.005; Bonifati DM, 2007, MOL IMMUNOL, V44, P999, DOI 10.1016/j.molimm.2006.03.007; Bradshaw NJ, 2008, BIOCHEM BIOPH RES CO, V377, P1091, DOI 10.1016/j.bbrc.2008.10.120; Bresee C, 2009, INT J NEUROPSYCHOPH, V12, P861, DOI 10.1017/S1461145709000315; Brietzke E, 2009, J AFFECT DISORDERS, V116, P214, DOI 10.1016/j.jad.2008.12.001; Brown AS, 2010, AM J PSYCHIAT, V167, P261, DOI 10.1176/appi.ajp.2009.09030361; Brynskikh A, 2008, BRAIN BEHAV IMMUN, V22, P861, DOI 10.1016/j.bbi.2007.12.008; CACABELOS R, 1989, METHOD FIND EXP CLIN, V11, P353; CACABELOS R, 1987, TOHOKU J EXP MED, V151, P429, DOI 10.1620/tjem.151.429; CACABELOS R, 1987, NEUROENDOCRINOLOGY, V45, P368, DOI 10.1159/000124761; CACABELOS R, 1985, BIOGENIC AMINES, V3, P9; Cacabelos R, 2005, EXPERT OPIN PHARMACO, V6, P1967, DOI 10.1517/14656566.6.12.1967; Cacabelos R, 2003, NEUROL RES, V25, P567, DOI 10.1179/016164103101202002; Cacabelos R, 2003, PHARMACOGENOMICS, V4, P597, DOI 10.1517/phgs.4.5.597.23795; CACABELOS R, 1993, AGENTS ACTIONS, V38, pC260, DOI 10.1007/BF01996479; CACABELOS R, 1993, ANN NY ACAD SCI, V695, P321, DOI 10.1111/j.1749-6632.1993.tb23076.x; CACABELOS R, 1994, METHOD FIND EXP CLIN, V16, P141; CACABELOS R, 1991, METHOD FIND EXP CLIN, V13, P703; CACABELOS R, 1990, METHOD FIND EXP CLIN, V12, P341; Cacabelos R, 2013, DRUG DES, V2, P2; Cacabelos R, 1986, B JPN NEUROCHEM SOC, V25, P271; Cacabelos R, 2011, GEN T EUROESPES J IN, V3, P6; Cacabelos R, 1992, ANN PSYCHIAT, V3, P147; CACABELOS R, 2006, DRUGS FUTURE SB, V31, P5, DOI DOI 10.2217/1745509X.1.2.303; CACABELOS R, 1992, ANN PSYCHIAT, V3, P233; Cacabelos R., 2013, OPEN J PSYCHIAT, V3, P46, DOI [10.4236/ojpsych.2013.31008., DOI 10.4236/OJPSYCH.2013.31008]; Cacabelos R., 1990, HISTAMINERGIC NEURON, P241; Cacabelos R, 2005, AGING HLTH, V1, P303; Cacabelos R, 2014, J EXP CLIN MED, V6, p75e82, DOI [10.1016/j.jecm.2014.03.010, DOI 10.1016/J.JECM.2014.03.010]; Cacabelos R, 2009, HDB NEUROPSYCHIATRIC, V4, P3; Cacabelos Ramon, 2005, Methods Find Exp Clin Pharmacol, V27 Suppl A, P1; Cacabelos R, 2014, METHODS MOL BIOL, V1175, P323, DOI 10.1007/978-1-4939-0956-8_13; Cacabelos R, 2014, EXPERT OPIN DRUG DIS, V9, P1059, DOI 10.1517/17460441.2014.930124; Cacabelos R, 2011, CNS NEUROSCI THER, V17, P541, DOI 10.1111/j.1755-5949.2010.00187.x; Cacabelos R, 2009, EXPERT REV MOL DIAGN, V9, P567, DOI [10.1586/erm.09.42, 10.1586/ERM.09.42]; Calingasan NY, 2002, NEUROBIOL AGING, V23, P31, DOI 10.1016/S0197-4580(01)00246-9; Carrera I, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/709145; Carter CJ, 2009, SCHIZOPHRENIA BULL, V35, P1163, DOI 10.1093/schbul/sbn054; Catania A, 2009, BRAIN BEHAV IMMUN, V23, P877, DOI 10.1016/j.bbi.2009.04.006; Cerri AP, 2009, ARCH GERONTOL GERIAT, V49, P29, DOI 10.1016/j.archger.2009.09.009; Chakrabarty P, 2010, FASEB J, V24, P548, DOI 10.1096/fj.09-141754; Chakraborty S, 2010, J NEUROSCI RES, V88, P1615, DOI 10.1002/jnr.22343; Chandley MJ, 2009, SCHIZOPHR RES, V109, P98, DOI 10.1016/j.schres.2009.01.023; Chang RCC, 2009, CELL MOL IMMUNOL, V6, P317, DOI 10.1038/cmi.2009.42; Chen YX, 2016, CURR TOP MED CHEM, V16, P485, DOI 10.2174/1568026615666150813142423; Chittiprol S, 2009, INT IMMUNOPHARMACOL, V9, P1215, DOI 10.1016/j.intimp.2009.07.002; Christian LM, 2009, BRAIN BEHAV IMMUN, V23, P750, DOI 10.1016/j.bbi.2009.02.012; Chrousos GP, 2009, ANN NY ACAD SCI, V1179, P153, DOI 10.1111/j.1749-6632.2009.04988.x; Chu TT, 2009, J HUM GENET, V54, P665, DOI 10.1038/jhg.2009.93; Chubb JE, 2008, MOL PSYCHIATR, V13, P36, DOI 10.1038/sj.mp.4002106; Cimino PJ, 2009, AM J PATHOL, V175, P1622, DOI 10.2353/ajpath.2009.090443; Clerici M, 2009, CNS SPECTRUMS, V14, P419, DOI 10.1017/S1092852900020393; Coogan AN, 2008, BRAIN RES, V1232, P104, DOI 10.1016/j.brainres.2008.07.087; Cotman CW, 1987, NEUROIMMUNE ENDOCRIN; Cox D, 2015, J NERV MENT DIS, V203, P393, DOI 10.1097/NMD.0000000000000289; Crepel A, 2010, CLIN GENET, V77, P389, DOI 10.1111/j.1399-0004.2009.01318.x; Cui K, 2009, SCHIZOPHR RES, V113, P288, DOI 10.1016/j.schres.2009.05.003; Czerski PM, 2008, NEUROPSYCHOBIOLOGY, V57, P88, DOI 10.1159/000135642; Da Mesquita S, 2015, BRAIN BEHAV IMMUN, V49, P280, DOI 10.1016/j.bbi.2015.06.008; Davenport CM, 2010, J NEUROCHEM, V112, P552, DOI 10.1111/j.1471-4159.2009.06485.x; Dean B, 2009, AUST NZ J PSYCHIAT, V43, P13, DOI 10.1080/00048670802534416; Debnath M, 2015, J NEUROIMMUNE PHARM, V10, P610, DOI 10.1007/s11481-015-9626-9; Deneka A, 2015, GENE, V570, P25, DOI 10.1016/j.gene.2015.06.062; Dhabhar FS, 2009, J PSYCHIATR RES, V43, P962, DOI 10.1016/j.jpsychires.2009.05.010; Dheen ST, 2007, CURR MED CHEM, V14, P1189, DOI 10.2174/092986707780597961; Ding Ying, 2015, Mol Neuropsychiatry, V1, P1; Dorban G, 2010, HISTOCHEM CELL BIOL, V133, P493, DOI 10.1007/s00418-010-0687-9; Drerup CM, 2009, DEVELOPMENT, V136, P2623, DOI 10.1242/dev.030577; Eikelenboom P, 2006, J NEURAL TRANSM, V113, P1685, DOI 10.1007/s00702-006-0575-6; Enomoto A, 2009, NEURON, V63, P774, DOI 10.1016/j.neuron.2009.08.015; Fang F, 2010, FASEB J, V24, P1043, DOI 10.1096/fj.09-139634; Fatemi SH, 2009, SCHIZOPHRENIA BULL, V35, P528, DOI 10.1093/schbul/sbn187; Feleder C, 2010, BIOL PSYCHIAT, V67, P386, DOI 10.1016/j.biopsych.2009.09.028; Fernandes BS, 2016, MOL PSYCHIATR, V21, P554, DOI 10.1038/mp.2015.87; Fernandez-Novoa L, 2001, BEHAV BRAIN RES, V124, P213, DOI 10.1016/S0166-4328(01)00215-7; FERNANDEZNOVOA L, 1995, INFLAMM RES, V44, P55, DOI 10.1007/BF01630488; FERNANDEZNOVOA L, 1994, METHOD FIND EXP CLIN, V16, P279; FERNANDEZNOVOA L, 1993, METHOD FIND EXP CLIN, V15, P735; Ferreira AC, 2015, PROG NEUROBIOL, V131, P120, DOI 10.1016/j.pneurobio.2015.06.005; Frank-Cannon TC, 2009, MOL NEURODEGENER, V4, DOI 10.1186/1750-1326-4-47; Frezza D, 2009, INT J IMMUNOPATH PH, V22, P115, DOI 10.1177/039463200902200113; Gabbay V, 2009, J CHILD ADOL PSYCHOP, V19, P423, DOI 10.1089/cap.2008.0140; Glanzer JG, 2007, J NEUROCHEM, V102, P627, DOI 10.1111/j.1471-4159.2007.04568.x; Gos T, 2014, BRAIN BEHAV IMMUN, V41, P59, DOI 10.1016/j.bbi.2014.05.012; Griffiths M, 2007, INT REV NEUROBIOL, V82, P29, DOI 10.1016/S0074-7742(07)82002-2; Grippo AJ, 2009, STRESS, V12, P1, DOI 10.1080/10253890802046281; Grove RA, 2014, CURR ALZHEIMER RES, V11, P47, DOI 10.2174/1567205010666131212110148; Guilloux JP, 2015, NEUROPSYCHOPHARMACOL, V40, P701, DOI 10.1038/npp.2014.226; Haig GM, 2014, J ALZHEIMERS DIS, V42, P959, DOI 10.3233/JAD-140291; Halacheva K, 2009, PSYCHIAT RES, V169, P51, DOI 10.1016/j.psychres.2008.05.011; Hanson DR, 2005, BMC MED GENET, V6, DOI 10.1186/1471-2350-6-7; Hein AM, 2010, BRAIN BEHAV IMMUN, V24, P243, DOI 10.1016/j.bbi.2009.10.002; Heinisch S, 2009, NEUROSCIENCE, V164, P1210, DOI 10.1016/j.neuroscience.2009.08.075; Heneka MT, 2015, LANCET NEUROL, V14, P388, DOI 10.1016/S1474-4422(15)70016-5; Herberth M, 2010, MOL PSYCHIATR, V15, P364, DOI 10.1038/mp.2008.120; Hope S, 2009, BIPOLAR DISORD, V11, P726, DOI 10.1111/j.1399-5618.2009.00757.x; Hoppe JB, 2010, J PINEAL RES, V48, P230, DOI 10.1111/j.1600-079X.2010.00747.x; Hosoi Toru, 2002, Current Drug Targets - Inflammation and Allergy, V1, P257, DOI 10.2174/1568010023344599; Howes OD, 2009, SCHIZOPHRENIA BULL, V35, P549, DOI 10.1093/schbul/sbp006; Hu F, 2009, BRAIN BEHAV IMMUN, V23, P455, DOI 10.1016/j.bbi.2009.01.001; Hu RD, 2015, ACS CHEM NEUROSCI, V6, P1759, DOI 10.1021/acschemneuro.5b00192; Husband AJ, 1992, BEHAV IMMUNITY; Ibi D, 2010, BEHAV BRAIN RES, V206, P32, DOI 10.1016/j.bbr.2009.08.027; Ito HT, 2010, BRAIN BEHAV IMMUN, V24, P930, DOI 10.1016/j.bbi.2010.03.004; Kanerva K, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006858; Kim JY, 2009, NEURON, V63, P761, DOI 10.1016/j.neuron.2009.08.008; Kim YK, 2016, PROG NEURO-PSYCHOPH, V64, P277, DOI 10.1016/j.pnpbp.2015.06.008; Kinney DK, 2010, MED HYPOTHESES, V74, P555, DOI 10.1016/j.mehy.2009.09.040; Kiyota T, 2009, PLOS ONE, V4, DOI 10.1371/journal.pone.0006197; Koido K, 2010, J PSYCHIATR RES, V44, P275, DOI 10.1016/j.jpsychires.2009.09.001; Kornhuber J, 2009, EUR ARCH PSY CLIN N, V259, P199, DOI 10.1007/s00406-009-0061-x; Kraft R, 2015, CHANNELS, V9, P244, DOI 10.1080/19336950.2015.1071747; Kudrna JJ, 2015, HUM VACC IMMUNOTHER, V11, P1921, DOI 10.1080/21645515.2015.1065364; Lang UE, 2007, CELL PHYSIOL BIOCHEM, V20, P687, DOI 10.1159/000110430; Laske C, 2008, PSYCHIAT RES, V158, P83, DOI 10.1016/j.psychres.2006.04.023; Levite M, 2016, ACTA PHYSIOL, V216, P42, DOI 10.1111/apha.12476; Leza JC, 2015, NEUROSCI BIOBEHAV R, V55, P612, DOI 10.1016/j.neubiorev.2015.05.014; Liao P, 2010, PFLUG ARCH EUR J PHY, V460, P353, DOI 10.1007/s00424-009-0753-0; Licinio J, 2007, EXP PHYSIOL, V92, P807, DOI 10.1113/expphysiol.2007.038471; Lindqvist D, 2009, BIOL PSYCHIAT, V66, P287, DOI 10.1016/j.biopsych.2009.01.030; Loftis JM, 2010, NEUROBIOL DIS, V37, P519, DOI 10.1016/j.nbd.2009.11.015; Lombardi VRM, 1998, J NEUROSCI RES, V54, P539, DOI 10.1002/(SICI)1097-4547(19981115)54:4<539::AID-JNR11>3.3.CO;2-H; Lombardi VRM, 2004, METHOD FIND EXP CLIN, V26, P523, DOI 10.1358/mf.2004.26.7.863735; Lombardi VRM, 1998, METHOD FIND EXP CLIN, V20, P377, DOI 10.1358/mf.1998.20.5.485697; MacLean AG, 2012, WORLD J VIROL, V4, P42; Maletic V, 2014, FRONT PSYCHIATRY, V5, DOI 10.3389/fpsyt.2014.00098; Maneiro E, 1997, METHOD FIND EXP CLIN, V19, P5; Manenschijn L, 2009, ANN NY ACAD SCI, V1179, P179, DOI 10.1111/j.1749-6632.2009.05013.x; Matsumoto A, 2015, ANESTH ANALG, V120, P895, DOI 10.1213/ANE.0000000000000606; Matsunaga M, 2009, BRAIN BEHAV IMMUN, V23, P931, DOI 10.1016/j.bbi.2009.03.007; Matsuzaki S, 2007, NEUROCHEM INT, V51, P165, DOI 10.1016/j.neuint.2007.06.018; Mayilyan KR, 2008, DRUG NEWS PERSPECT, V21, P200, DOI 10.1358/dnp.2008.21.4.1213349; Mccoy MK, 2008, J NEUROINFLAMM, V5, DOI 10.1186/1742-2094-5-45; McGeer PL, 2002, J NEUROVIROL, V8, P529, DOI 10.1080/13550280290100969; McGeer PL, 2001, NEUROBIOL AGING, V22, P799, DOI 10.1016/S0197-4580(01)00289-5; Mehlhorn G, 2000, INT J DEV NEUROSCI, V18, P423, DOI 10.1016/S0736-5748(00)00012-5; Meyer U, 2009, PSYCHOPHARMACOLOGY, V206, P587, DOI 10.1007/s00213-009-1504-9; Milior G, 2015, BRAIN BEHAV IMMUN; Millar JK, 2007, J PHYSIOL-LONDON, V584, P401, DOI 10.1113/jphysiol.2007.140210; Miller AH, 2010, BRAIN BEHAV IMMUN, V24, P1, DOI 10.1016/j.bbi.2009.09.009; Miller AH, 2009, BRAIN BEHAV IMMUN, V23, P149, DOI 10.1016/j.bbi.2008.08.006; Muller N, 2010, CURR OPIN INVEST DR, V11, P31; Mundo E, 2005, AM J MED GENET B, V132B, P1, DOI 10.1002/ajmg.b.30100; Na KS, 2007, NEUROPSYCHOBIOLOGY, V56, P55, DOI 10.1159/000111535; Naegelen I, 2015, J LEUKOCYTE BIOL, V97, P557, DOI 10.1189/jlb.3A0514-254RR; Nakata K, 2009, P NATL ACAD SCI USA, V106, P15873, DOI 10.1073/pnas.0903413106; Nautiyal KM, 2008, P NATL ACAD SCI USA, V105, P18053, DOI 10.1073/pnas.0809479105; O'Connor JC, 2009, J NEUROSCI, V29, P4200, DOI 10.1523/JNEUROSCI.5032-08.2009; Ohi K, 2015, SCHIZOPHRENIA BULL, V41, P909, DOI 10.1093/schbul/sbu171; Ovaskainen Y, 2009, PSYCHIAT RES, V167, P73, DOI 10.1016/j.psychres.2007.12.004; Ozbey U, 2008, PSYCHIAT CLIN NEUROS, V62, P307, DOI 10.1111/j.1440-1819.2008.01798.x; Ozbey U, 2009, WORLD J BIOL PSYCHIA, V10, P461, DOI 10.1080/15622970802626580; Pace TWW, 2009, ANN NY ACAD SCI, V1179, P86, DOI 10.1111/j.1749-6632.2009.04984.x; Park KM, 2010, CELL SIGNAL, V22, P519, DOI 10.1016/j.cellsig.2009.11.006; Passos GF, 2009, AM J PATHOL, V175, P1586, DOI 10.2353/ajpath.2009.081113; Peng YP, 2005, NEUROSCI LETT, V374, P192, DOI 10.1016/j.neulet.2004.10.069; Piehl F, 2009, NEUROSCIENCE, V158, P1143, DOI 10.1016/j.neuroscience.2008.08.031; Postal M, 2015, AUTOIMMUN REV, V14, P30, DOI 10.1016/j.autrev.2014.09.001; Potvin S, 2008, BIOL PSYCHIAT, V63, P801, DOI 10.1016/j.biopsych.2007.09.024; Qiu LQ, 2015, J LEUKOCYTE BIOL, V97, P723, DOI 10.1189/jlb.3A0214-106R; Rapaport MH, 2010, NEUROPSYCHOPHARMACOL, V35, P428, DOI 10.1038/npp.2009.145; Rasmussen HB, 2006, AM J PSYCHIAT, V163, P507, DOI 10.1176/appi.ajp.163.3.507; Rettori V, 2009, ANN NY ACAD SCI, V1153, P35, DOI 10.1111/j.1749-6632.2008.03968.x; Ribeiro-Santos R, 2014, CURR NEUROPHARMACOL, V12, P273, DOI 10.2174/1570159X1203140511160832; Ross R, 1991, CYTOKINE INTERACTION; Rossi D, 2009, BRAIN RES BULL, V80, P224, DOI 10.1016/j.brainresbull.2009.07.012; Saetre P, 2007, BMC PSYCHIATRY, V7, DOI 10.1186/1471-244X-7-46; Savage JC, 2015, J NEUROSCI, V35, P6532, DOI 10.1523/JNEUROSCI.4586-14.2015; Schafer DP, 2010, BIOCHEM SOC T, V38, P476, DOI 10.1042/BST0380476; Schmitt Andrea, 2005, Neuropsychiatr Dis Treat, V1, P171, DOI 10.2147/nedt.1.2.171.61048; Schosser A, 2007, AM J MED GENET B, V144B, P347, DOI 10.1002/ajmg.b.30416; Schumacher J, 2009, HUM MOL GENET, V18, P2719, DOI 10.1093/hmg/ddp204; Schwarz MJ, 2006, EUR ARCH PSY CLIN N, V256, P72, DOI 10.1007/s00406-005-0603-9; Severance EG, 2015, BRAIN BEHAV IMMUN, V44, P148, DOI 10.1016/j.bbi.2014.09.009; Shan L, 2015, TRENDS NEUROSCI, V38, P167, DOI 10.1016/j.tins.2014.12.008; Shembade N, 2010, SCIENCE, V327, P1135, DOI 10.1126/science.1182364; Singh B, 2009, CYTOKINE, V47, P1, DOI 10.1016/j.cyto.2009.05.005; Skaper SD, 2010, FASEB J, V24, P337, DOI 10.1096/fj.09-138883; Song J, 2015, FRONT AGING NEUROSCI, V7, DOI 10.3389/fnagi.2015.00061; Spector NH, 1989, NEUROIMMUNE NETWORKS; Sperner-Unterweger B, 2015, CURR OPIN PSYCHIATR, V28, P201, DOI 10.1097/YCO.0000000000000153; Sriskantharajah S, 2010, SCIENCE, V327, P1093, DOI 10.1126/science.1187271; Stefansson H, 2009, NATURE, V460, P744, DOI 10.1038/nature08186; Stone JL, 2008, NATURE, V455, P237, DOI 10.1038/nature07239; Streit WJ, 2009, J NEUROIMMUNE PHARM, V4, P371, DOI 10.1007/s11481-009-9163-5; Stringer S, 2014, SCHIZOPHR RES, V159, P347, DOI 10.1016/j.schres.2014.09.004; Su SY, 2009, CIRC-CARDIOVASC GENE, V2, P614, DOI 10.1161/CIRCGENETICS.109.870386; Sugino H, 2009, PROG NEURO-PSYCHOPH, V33, P303, DOI 10.1016/j.pnpbp.2008.12.006; Sun SL, 2009, BRAIN RES, V1268, P13, DOI 10.1016/j.brainres.2009.02.071; Takahashi T, 2009, PSYCHIAT RES-NEUROIM, V172, P128, DOI 10.1016/j.pscychresns.2009.01.005; Takata K, 2007, EUR J NEUROSCI, V26, P2458, DOI 10.1111/j.1460-9568.2007.05852.x; Takenouchi T, 2010, ARCH IMMUNOL THER EX, V58, P91, DOI 10.1007/s00005-010-0069-y; Tan MG, 2010, J NEUROSCI RES, V88, P1157, DOI 10.1002/jnr.22290; Teixeira AL, 2008, PROG NEURO-PSYCHOPH, V32, P710, DOI 10.1016/j.pnpbp.2007.11.019; THEZE J, 1999, CYTOKINE NETWORK IMM; Tiligada E, 2009, EXPERT OPIN INV DRUG, V18, P1519, DOI 10.1517/14728220903188438; Toben C, 2015, J NEUROIMMUNE PHARM, V10, P595, DOI 10.1007/s11481-015-9620-2; Tomasik J., 2014, SCHIZOPHR RES; Tomppo L, 2009, BIOL PSYCHIAT, V65, P1055, DOI 10.1016/j.biopsych.2009.01.014; Torres KCL, 2009, PROG NEURO-PSYCHOPH, V33, P229, DOI 10.1016/j.pnpbp.2008.11.011; Torres KCL, 2009, PROG NEURO-PSYCHOPH, V33, P214, DOI 10.1016/j.pnpbp.2008.10.020; Tweedie D, 2007, CURR ALZHEIMER RES, V4, P378, DOI 10.2174/156720507781788873; Verma S, 2006, BRAIN BEHAV IMMUN, V20, P449, DOI 10.1016/j.bbi.2005.10.005; Vojdani A, 2011, EVID-BASED COMPL ALT, V2011, DOI 10.1093/ecam/nep064; Walker DG, 2009, EXP NEUROL, V215, P5, DOI 10.1016/j.expneurol.2008.09.003; Watanabe T., 1991, HISTAMINERGIC NEUROS; Wei JY, 2015, PSYCHIAT RES, V228, P695, DOI 10.1016/j.psychres.2015.06.002; Xie LK, 2015, BRAIN RES, V1623, P63, DOI 10.1016/j.brainres.2015.03.026; Xu J, 2015, J CLIN INVEST, V125, P1579, DOI 10.1172/JCI76468; Xu X, 2007, GENOME BIOL, V8, DOI 10.1186/gb-2007-8-11-r234; Yang JH, 2015, FREE RADICAL BIO MED, V78, P156, DOI 10.1016/j.freeradbiomed.2014.11.002; Yin Y, 2015, ARTERIOSCL THROM VAS, V35, P804, DOI 10.1161/ATVBAHA.115.305282; Yu L, 2004, SCHIZOPHR RES, V71, P179, DOI 10.1016/j.schres.2004.01.001; Zai G, 2006, PSYCHOPHARMACOLOGY, V188, P171, DOI 10.1007/s00213-006-0482-4; Zhan Y, 2014, EUR PSYCHIAT, V29, P307, DOI 10.1016/j.eurpsy.2014.03.004; Zhang Q, 2010, NATURE, V464, P104, DOI 10.1038/nature08780; Zhang XY, 2009, PSYCHOPHARMACOLOGY, V204, P177, DOI 10.1007/s00213-008-1447-6; Zhu J, 2009, EXP CLIN PSYCHOPHARM, V17, P198, DOI 10.1037/a0016033	237	22	24	0	22	BENTHAM SCIENCE PUBL LTD	SHARJAH	EXECUTIVE STE Y-2, PO BOX 7917, SAIF ZONE, 1200 BR SHARJAH, U ARAB EMIRATES	1381-6128	1873-4286		CURR PHARM DESIGN	Curr. Pharm. Design		2016	22	7					819	848		10.2174/1381612822666151209150954			30	Pharmacology & Pharmacy	Pharmacology & Pharmacy	DG4VQ	WOS:000372071600007	26648474				2021-06-18	
J	Liu, J; Xia, S; Hanks, R; Wiseman, N; Peng, CY; Zhou, SK; Haacke, EM; Kou, ZF				Liu, Jun; Xia, Shuang; Hanks, Robin; Wiseman, Natalie; Peng, Changya; Zhou, Shunke; Haacke, E. Mark; Kou, Zhifeng			Susceptibility Weighted Imaging and Mapping of Micro-Hemorrhages and Major Deep Veins after Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						cerebral microbleeds (CMBs); quantitative susceptibility mapping (QSM); susceptibility weighted imaging; susceptibility weighted imaging and mapping (SWIM); traumatic brain injury	SMALL-VESSEL DISEASE; CEREBRAL AMYLOID ANGIOPATHY; DIFFUSE AXONAL INJURY; VASCULAR COGNITIVE IMPAIRMENT; WHITE-MATTER HYPERINTENSITIES; ALZHEIMER-DISEASE; PERIVASCULAR SPACES; ACUTE STROKE; RISK-FACTORS; MICROBLEEDS	Micro-hemorrhages are a common result of traumatic brain injury (TBI), which can be quantified with susceptibility weighted imaging and mapping (SWIM), a quantitative susceptibility mapping approach. A total of 23 TBI patients (five women, 18 men; median age, 41.25 years old; range, 21.69-67.75 years) with an average Glasgow Coma Scale score of 7 (range, 3-15) at admission were recruited at mean 149d (range, 57-366) after injury. Susceptibility-weighted imaging data were collected and post-processed to create SWIM images. The susceptibility value of small hemorrhages (diameter 10mm) and major deep veins (right septal, left septal, central septal, right thalamostriate, left thalamostriate, internal cerebral, right basal vein of Rosenthal, left basal vein of Rosenthal, and pial veins) were evaluated. Different susceptibility thresholds were tested to determine SWIM's sensitivity and specificity for differentiating hemorrhages from the veins. A total of 253 deep veins and 173 small hemorrhages were identified and evaluated. The mean susceptibility of hemorrhages was 435 +/- 206 parts per billion (ppb) and the mean susceptibility of deep veins was 108 +/- 56ppb. Hemorrhages showed a significantly higher susceptibility than all deep veins (p<0.001). With different thresholds (250, 227 and 200ppb), the specificity was 97%, 95%, and 92%, and the sensitivity was 84%, 90%, and 92%, respectively. These results show that SWIM could be used to differentiate hemorrhages from veins in TBI patients in a semi-automated manner with reasonable sensitivity and specificity. A larger cohort will be needed to validate these findings.	[Liu, Jun; Zhou, Shunke] Cent S Univ, Xiangya Hosp 2, Dept Radiol, Changsha, Hunan, Peoples R China; [Liu, Jun; Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Biomed Engn, Detroit, MI 48201 USA; [Hanks, Robin] Wayne State Univ, Sch Med, Dept Phys Med & Rehabil, Detroit, MI 48201 USA; [Wiseman, Natalie] Wayne State Univ, Sch Med, Dept Psychiat & Behav Neurosci, Detroit, MI 48201 USA; [Peng, Changya] Wayne State Univ, Sch Med, Dept Neurol Surg, Detroit, MI 48201 USA; [Haacke, E. Mark; Kou, Zhifeng] Wayne State Univ, Sch Med, Dept Radiol, Detroit, MI 48201 USA; [Xia, Shuang] Tianjin First Cent Hosp, Dept Radiol, Tianjin, Peoples R China	Kou, ZF (corresponding author), Wayne State Univ, Sch Med, Dept Biomed Engn, 818 W Hancock St, Detroit, MI 48201 USA.	Zhifeng_kou@wayne.edu	liu, jun/AAW-9645-2020	liu, jun/0000-0002-0344-4745; Wiseman, Natalie/0000-0003-0884-6425	International Society for Magnetic Resonance in Medicine (ISMRM); Department of DefenseUnited States Department of Defense [W81XWH-11-1-0493]; NIDRR [H133A020515]; China Scholarship CouncilChina Scholarship Council; Second Xiang Ya Hospital of Central South University of China	This study was supported by the International Society for Magnetic Resonance in Medicine (ISMRM) seed grant (PI: Zhifeng Kou), the Department of Defense W81XWH-11-1-0493 grant (PI: E Mark Haacke), and NIDRR H133A020515 grant (PI: Robin Hanks), State Scholarship Fund from China Scholarship Council (Awardee: Jun Liu), and the Second Xiang Ya Hospital of Central South University of China.	Atlas S.W., 2009, MRI BRAIN SPINE; Ayaz M, 2010, J MAGN RESON IMAGING, V31, P142, DOI 10.1002/jmri.22001; Bai QK, 2013, NEUROL RES, V35, P586, DOI 10.1179/1743132813Y.0000000179; Baik SK, 2012, CEREBROVASC DIS, V34, P206, DOI 10.1159/000342148; Barnes SRS, 2011, MAGN RESON IMAGING, V29, P844, DOI 10.1016/j.mri.2011.02.028; Barnes SRS, 2009, MAGN RESON IMAGING C, V17, P47, DOI 10.1016/j.mric.2008.12.002; Benedictus MR, 2013, NEUROBIOL AGING, V34, P2488, DOI 10.1016/j.neurobiolaging.2013.04.023; Bian W, 2014, NEURORADIOLOGY, V56, P91, DOI 10.1007/s00234-013-1297-8; Binder LM, 1997, J CLIN EXP NEUROPSYC, V19, P421, DOI 10.1080/01688639708403870; Blumbergs P. C., 1997, HEAD INJURY PATHOPHY, P39; Bouvy WH, 2014, INVEST RADIOL, V49, P307, DOI 10.1097/RLI.0000000000000027; Brundel M, 2012, J ALZHEIMERS DIS, V31, P259, DOI 10.3233/JAD-2012-120364; Buch S., 2014, MAGN RESON MED, V32, P663; Cavalieri M, 2012, NEURODEGENER DIS, V10, P253, DOI 10.1159/000333120; Cavalieri M, 2010, J NEUROL SCI, V299, P11, DOI 10.1016/j.jns.2010.08.031; Chabriat H, 2014, GERIATR PSYCHOL NEUR, V12, P183, DOI 10.1684/pnv.2014.0467; Cheng AL, 2013, STROKE, V44, P2782, DOI 10.1161/STROKEAHA.113.002267; Choi P, 2012, STROKE, V43, P1505, DOI 10.1161/STROKEAHA.111.647271; Cordonnier C, 2006, NEUROLOGY, V66, P1356, DOI 10.1212/01.wnl.0000210535.20297.ae; Cordonnier C, 2011, BRAIN, V134, P335, DOI 10.1093/brain/awq321; Danve A, 2014, SEMIN ARTHRITIS RHEU, V44, P86, DOI 10.1016/j.semarthrit.2014.02.001; De Reuck J, 2012, EUR J NEUROL, V19, P1355, DOI 10.1111/j.1468-1331.2012.03776.x; de Rochefort L, 2008, MAGN RESON MED, V60, P1003, DOI 10.1002/mrm.21710; Dichgans M, 2002, STROKE, V33, P67, DOI 10.1161/hs0102.100885; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Fernandez-Seara MA, 2006, MAGN RESON MED, V55, P967, DOI 10.1002/mrm.20892; Fukui T, 2013, DEMENT GER COGN D EX, V3, P148, DOI 10.1159/000351423; Gasparotti R, 2011, INSIGHTS IMAGING, V2, P335, DOI 10.1007/s13244-011-0086-3; Ghelmez D, 2013, J Med Life, V6, P437; Glushakova OY, 2014, J NEUROTRAUM, V31, P1180, DOI 10.1089/neu.2013.3080; Goos JDC, 2012, NEUROBIOL AGING, V33, DOI 10.1016/j.neurobiolaging.2011.10.026; Greenberg SM, 2009, LANCET NEUROL, V8, P165, DOI 10.1016/S1474-4422(09)70013-4; Grossman RI, 2003, NEURORADIOLOGY; Haacke EM, 2007, AM J NEURORADIOL, V28, P316; Haacke EM, 2010, J MAGN RESON IMAGING, V32, P663, DOI 10.1002/jmri.22276; Haacke EM, 2015, MAGN RESON IMAGING, V33, P1, DOI 10.1016/j.mri.2014.09.004; Haacke EM, 2004, MAGN RESON MED, V52, P612, DOI 10.1002/mrm.20198; Ham JH, 2014, J NEUROL, V261, P1628, DOI 10.1007/s00415-014-7403-y; Hanyu H, 2003, J NEUROL, V250, P1496, DOI 10.1007/s00415-003-0245-7; Hanyu H, 2003, NEUROSCI LETT, V340, P213, DOI 10.1016/S0304-3940(03)00121-6; Hartz AMS, 2012, STROKE, V43, P514, DOI 10.1161/STROKEAHA.111.627562; Hellyer PJ, 2013, ANN NEUROL, V73, P489, DOI 10.1002/ana.23824; Helmer KG, 2014, J NEUROSURG, V120, P864, DOI [10.3171/2013.12.JNS132093, 10.3171/2013.12.JNS132090]; Heringa SM, 2014, J ALZHEIMERS DIS, V38, P211, DOI 10.3233/JAD-130542; Hermier M, 2004, STROKE, V35, P1989, DOI 10.1161/01.STR.0000133341.74387.96; Hilal S, 2014, NEUROSCI LETT, V577, P95, DOI 10.1016/j.neulet.2014.06.024; Hilal S, 2014, ALZ DIS ASSOC DIS, V28, P106, DOI 10.1097/WAD.0000000000000015; Hommet C, 2011, DEMENT GERIATR COGN, V32, P367, DOI 10.1159/000335568; Hu J, 2008, J MAGN RESON IMAGING, V28, P300, DOI 10.1002/jmri.21435; Huang PY, 2012, J NEUROL, V259, P1426, DOI 10.1007/s00415-011-6369-2; Ihara Masafumi, 2013, Brain Nerve, V65, P801; Imaizumi T, 2011, J NEUROIMAGING, V21, P359, DOI 10.1111/j.1552-6569.2011.00593.x; Kanmanthareddy A, 2014, CURR CARDIOL REP, V16, DOI 10.1007/s11886-014-0519-y; Katchanov J, 2005, NERVENARZT, V76, P1250, DOI 10.1007/s00115-005-1884-y; Kester MI, 2014, JAMA NEUROL, V71, P855, DOI 10.1001/jamaneurol.2014.754; Kinnunen KM, 2011, BRAIN, V134, P449, DOI 10.1093/brain/awq347; Kirsch W, 2009, J ALZHEIMERS DIS, V17, P599, DOI 10.3233/JAD-2009-1073; Kou Z, 2010, CLIN MR NEUROIMAGING; Kou Z., 2011, SUSCEPTIBILITY WEIGH; Kou ZF, 2010, J HEAD TRAUMA REHAB, V25, P267, DOI 10.1097/HTR.0b013e3181e54793; Kuijf HJ, 2012, NEUROIMAGE, V59, P2266, DOI 10.1016/j.neuroimage.2011.09.061; Lanfranconi S, 2010, STROKE, V41, pE513, DOI 10.1161/STROKEAHA.110.581918; Lawrence AJ, 2013, PLOS ONE, V8, DOI 10.1371/journal.pone.0061014; Lian LF, 2013, J HEADACHE PAIN, V14, DOI 10.1186/1129-2377-14-98; Liem MK, 2007, STROKE, V38, P923, DOI 10.1161/01.STR.0000257968.24015.bf; Liu S., 2014, BIOMEDICAL ENG; Liu SF, 2013, MAGN RESON MED, V69, P716, DOI 10.1002/mrm.24305; Liu T, 2013, MAGN RESON MED, V69, P467, DOI 10.1002/mrm.24272; Liu T, 2012, RADIOLOGY, V262, P269, DOI 10.1148/radiol.11110251; Lupo JM, 2012, INT J RADIAT ONCOL, V82, pE493, DOI 10.1016/j.ijrobp.2011.05.046; Maia LF, 2006, CEREBROVASC DIS, V22, P155, DOI 10.1159/000093245; Martinez-Ramirez S, 2013, NEUROLOGY, V80, P1266, DOI 10.1212/WNL.0b013e31828b8c16; Miyata K, 2003, NEUROL SURG TOKYO, V31, P1223; Monson KL, 2005, J BIOMECH, V38, P737, DOI 10.1016/j.jbiomech.2004.05.004; Monson KL, 2003, J BIOMECH ENG-T ASME, V125, P288, DOI 10.1115/1.1554412; Mori N, 2008, INVEST RADIOL, V43, P574, DOI 10.1097/RLI.0b013e31817fb432; Muller M, 2014, NEUROLOGY, V82, P2187, DOI 10.1212/WNL.0000000000000517; Nagata K, 2012, J NEUROL SCI, V322, P87, DOI 10.1016/j.jns.2012.07.001; Nakata-Kudo Y, 2006, DEMENT GERIATR COGN, V22, P8, DOI 10.1159/000092958; Nardone R, 2011, J NEURAL TRANSM, V118, P1349, DOI 10.1007/s00702-011-0650-5; Niwa T, 2010, PEDIATR RADIOL, V40, P1657, DOI 10.1007/s00247-010-1665-z; O'Rourke MF, 2008, HYPERTENSION, V51, pE20, DOI 10.1161/HYPERTENSIONAHA.107.109199; Oberstein SAJL, 2001, NEUROLOGY, V57, P1066, DOI 10.1212/WNL.57.6.1066; Olazaran J, 2014, AM J ALZHEIMERS DIS, V29, P263, DOI 10.1177/1533317513517043; Park JH, 2013, ANN NEUROL, V73, P584, DOI 10.1002/ana.23845; Park JH, 2009, J KOREAN NEUROSURG S, V46, P365, DOI 10.3340/jkns.2009.46.4.365; Patel B, 2013, STROKE, V44, P356, DOI 10.1161/STROKEAHA.112.670216; Pettersen JA, 2008, ARCH NEUROL-CHICAGO, V65, P790, DOI 10.1001/archneur.65.6.790; Poels MMF, 2012, NEUROLOGY, V78, P326, DOI 10.1212/WNL.0b013e3182452928; Qin Y, 2015, ACTA RADIOL, V56, P329, DOI 10.1177/0284185114524198; Reichenbach JR, 1997, RADIOLOGY, V204, P272, DOI 10.1148/radiology.204.1.9205259; Riba-Llena I, 2013, BMC NEUROL, V13, DOI 10.1186/1471-2377-13-130; Romero JR, 2012, STROKE, V43, P3091, DOI 10.1161/STROKEAHA.112.656744; Ryan NS, 2012, BRAIN, V135, DOI 10.1093/brain/awr126; Santhosh K, 2009, CLIN RADIOL, V64, P74, DOI 10.1016/j.crad.2008.04.022; Scheid R, 2006, ARCH NEUROL-CHICAGO, V63, P418, DOI 10.1001/archneur.63.3.418; Scheid R, 2003, AM J NEURORADIOL, V24, P1049; Scheid R, 2007, J NEUROTRAUM, V24, P1811, DOI 10.1089/neu.2007.0382; Scheltens P, 2012, NAT REV NEUROL, V8, P68, DOI 10.1038/nrneurol.2011.222; Schneider JA, 2007, STROKE, V38, P1730, DOI 10.1161/STROKEAHA.107.487173; Schrag M, 2010, ACTA NEUROPATHOL, V119, P291, DOI 10.1007/s00401-009-0615-z; Schweser F, 2010, MED PHYS, V37, P5165, DOI 10.1118/1.3481505; Sehgal V, 2005, J MAGN RESON IMAGING, V22, P439, DOI 10.1002/jmri.20404; Sehgal V, 2006, J MAGN RESON IMAGING, V24, P41, DOI 10.1002/jmri.20598; Seo SW, 2007, STROKE, V38, P1949, DOI 10.1161/STROKEAHA.106.477315; Seo SW, 2012, J NEUROL SCI, V322, P200, DOI 10.1016/j.jns.2012.05.032; Sharp DJ, 2011, CURR OPIN NEUROL, V24, P558, DOI 10.1097/WCO.0b013e32834cd523; Tang J, 2013, MAGN RESON MED, V69, P1396, DOI 10.1002/mrm.24384; Tang WK, 2011, J AFFECT DISORDERS, V129, P354, DOI 10.1016/j.jad.2010.08.007; Tang WK, 2011, INT J STROKE, V6, P498, DOI 10.1111/j.1747-4949.2011.00682.x; Theysohn JM, 2011, J MAGN RESON IMAGING, V33, P782, DOI 10.1002/jmri.22513; Tomimoto Hidekazu, 2013, Rinsho Shinkeigaku, V53, P915; Tomimoto Hidekazu, 2012, Brain and Nerve (Tokyo), V64, P1377; Tong KA, 2004, ANN NEUROL, V56, P36, DOI 10.1002/ana.20123; Tong KA, 2003, RADIOLOGY, V227, P332, DOI 10.1148/radiol.2272020176; Uetani H, 2013, AM J NEURORADIOL, V34, P984, DOI 10.3174/ajnr.A3332; van der Flier WM, 2012, J NEUROL SCI, V322, P56, DOI 10.1016/j.jns.2012.07.009; Van der Flier WM, 2012, EXP GERONTOL, V47, P853, DOI 10.1016/j.exger.2012.07.007; van der Vlies AE, 2012, NEUROLOGY, V79, P763, DOI 10.1212/WNL.0b013e3182661f91; van Norden AGW, 2013, NEUROBIOL AGING, V34, P2225, DOI 10.1016/j.neurobiolaging.2013.03.021; van Norden AGW, 2012, J ALZHEIMERS DIS, V32, P667, DOI 10.3233/JAD-2012-120784; van Rooden S, 2014, RADIOLOGY, V270, P205, DOI 10.1148/radiol.13130743; Viswanathan A, 2011, ANN NEUROL, V70, P871, DOI 10.1002/ana.22516; Wang X, 2014, NEUROL SCI, V35, P1533, DOI 10.1007/s10072-014-1788-3; Werring DJ, 2010, J NEUROL SCI, V299, P131, DOI 10.1016/j.jns.2010.08.034; Wycliffe ND, 2004, J MAGN RESON IMAGING, V20, P372, DOI 10.1002/jmri.20130; Xia S, 2014, MAGN RESON IMAGING, V32, P1272, DOI 10.1016/j.mri.2014.08.012; Xu B, 2014, MAGN RESON MED, V72, P438, DOI 10.1002/mrm.24937; Xu Jiewen, 2012, Nan Fang Yi Ke Da Xue Xue Bao, V32, P1362; Yakushiji Y, 2008, STROKE, V39, P3323, DOI 10.1161/STROKEAHA.108.516112; Yamada S, 2012, J NEUROL, V259, P2707, DOI 10.1007/s00415-012-6574-7; Yamaguchi T, 2013, NEUROL MED-CHIR, V53, P318, DOI 10.2176/nmc.53.318; Yan L, 2014, RADIOL MED, V119, P175, DOI 10.1007/s11547-013-0328-1; Yates PA, 2014, NEUROLOGY, V82, P1266, DOI 10.1212/WNL.0000000000000285; Yin J, 2013, TOHOKU J EXP MED, V230, P133, DOI 10.1620/tjem.230.133; Zheng WL, 2013, NEUROIMAGE, V78, P68, DOI 10.1016/j.neuroimage.2013.04.022; Zonneveld HI, 2014, NEUROLOGY, V82, P698, DOI 10.1212/WNL.0000000000000150	137	22	25	2	14	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	JAN 1	2016	33	1					10	21		10.1089/neu.2014.3856			12	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CZ4EW	WOS:000367057200002	25789581				2021-06-18	
S	Marklund, N		Kobeissy, F; Dixon, CE; Hayes, RL; Mondello, S		Marklund, Niklas			Rodent Models of Traumatic Brain Injury: Methods and Challenges	INJURY MODELS OF THE CENTRAL NERVOUS SYSTEM: METHODS AND PROTOCOLS	Methods in Molecular Biology		English	Article; Book Chapter						Traumatic brain injury; Controlled cortical impact (CCI); Fluid percussion injury (FPI); Rats; Mice; Neurodegeneration; Outcome	CONTROLLED CORTICAL IMPACT; FLUID PERCUSSION INJURY; POSTTRAUMATIC EPILEPSY; AXONAL INJURY; PRESSURE; MODERATE; MOUSE; EPIDEMIOLOGY; CRANIOTOMY; POSITION	Traumatic brain injury (TBI) has been named the most complex disease in the most complex organ of the body. It is the most common cause of death and disability in the Western world in people <40 years old and survivors commonly suffer from persisting cognitive deficits, impaired motor function, depression and personality changes. TBI may vary in severity from uniformly fatal to mild injuries with rapidly resolving symptoms and without doubt, it is a markedly heterogeneous disease. Its different subtypes differs in their pathophysiology, treatment options and long-term consequences and to date, there are no pharmacological treatments with proven clinical benefit available to TBI patients. To enable development of novel treatment options for TBI, clinically relevant animal models are needed. Due to their availability and low costs, numerous rodent models have been developed which have substantially contributed to our current understanding of the pathophysiology of TBI. The most common animal models used in laboratories worldwide are likely the controlled cortical impact (CCI) model, the central and lateral fluid percussion injury (FPI) models, and weight drop/impact acceleration (I/A) models. Each of these models has inherent advantages and disadvantages; these need to be thoroughly considered when selecting the rodent TBI model according to the hypothesis and design of the study. Since TBI is not one disease, refined animal models must take into account the clinical features and complexity of human TBI. To enhance the possibility of establishing preclinical efficacy of a novel treatment, the preclinical use of several different experimental models is encouraged as well as varying the species, gender, and age of the animal. In this chapter, the methods, limitations, and challenges of the CCI and FPI models of TBI used in rodents are described.	[Marklund, Niklas] Uppsala Univ, Dept Neurosci, Div Neurosci, Uppsala, Sweden	Marklund, N (corresponding author), Uppsala Univ, Dept Neurosci, Div Neurosci, Uppsala, Sweden.			Marklund, Niklas/0000-0002-9797-5626			Alder J, 2011, JOVE-J VIS EXP, DOI 10.3791/3063; Armstead WM, 1997, P SOC EXP BIOL MED, V214, P210; Axelson HW, 2013, RESTOR NEUROL NEUROS, V31, P73, DOI 10.3233/RNN-2012-120242; Bolkvadze T, 2012, J NEUROTRAUM, V29, P789, DOI 10.1089/neu.2011.1954; Bondi CO, 2015, NEUROSCI BIOBEHAV R, V58, P123, DOI 10.1016/j.neubiorev.2014.12.004; Brody DL, 2007, J NEUROTRAUM, V24, P657, DOI 10.1089/neu.2006.0011; Brody DL, 2015, MOL CELL NEUROSCI, V66, P91, DOI 10.1016/j.mcn.2015.02.005; Carbonell WS, 1998, J NEUROTRAUM, V15, P217, DOI 10.1089/neu.1998.15.217; Clausen F, 2005, ACTA NEUROCHIR, V147, P775, DOI 10.1007/s00701-005-0550-2; Clausen F, 2014, BRAIN RES, V1588, P37, DOI 10.1016/j.brainres.2014.08.043; Clausen F, 2011, EUR J NEUROSCI, V34, P110, DOI 10.1111/j.1460-9568.2011.07723.x; Cole JT, 2011, J NEUROTRAUM, V28, P359, DOI 10.1089/neu.2010.1427; Corrigan JD, 2010, J HEAD TRAUMA REHAB, V25, P72, DOI 10.1097/HTR.0b013e3181ccc8b4; D'Ambrosio R, 2004, BRAIN, V127, P304, DOI 10.1093/brain/awh038; Diaz-Arrastia R, 2014, J NEUROTRAUM, V31, P135, DOI 10.1089/neu.2013.3019; DIXON CE, 1987, J NEUROSURG, V67, P110, DOI 10.3171/jns.1987.67.1.0110; DIXON CE, 1991, J NEUROSCI METH, V39, P253; Ekmark-Lewen S, 2013, J NEUROINFLAMM, V10, DOI 10.1186/1742-2094-10-44; FEENEY DM, 1981, BRAIN RES, V211, P67, DOI 10.1016/0006-8993(81)90067-6; Feng JF, 2012, J NEUROTRAUM, V29, P1167, DOI 10.1089/neu.2011.1867; Floyd CL, 2002, J NEUROTRAUM, V19, P303, DOI 10.1089/089771502753594873; Flygt J, 2013, EUR J NEUROSCI, V38, P2153, DOI 10.1111/ejn.12179; GENTILE NT, 1993, ANN EMERG MED, V22, P1028, DOI 10.1016/S0196-0644(05)82746-5; Greer JE, 2011, J NEUROSCI, V31, P5089, DOI 10.1523/JNEUROSCI.5103-10.2011; Hall ED, 2008, J NEUROTRAUM, V25, P235, DOI 10.1089/neu.2007.0383; Hanell A, 2014, FRONT BEHAV NEUROSCI, V8, DOI 10.3389/fnbeh.2014.00252; Hanell A, 2012, J NEUROTRAUM, V29, P2660, DOI 10.1089/neu.2012.2376; Kabadi SV, 2010, NAT PROTOC, V5, P1552, DOI 10.1038/nprot.2010.112; Kilkenny C, 2010, J PHARMACOL PHARMACO, V1, P94, DOI 10.4103/0976-500X.72351; Lighthall JW, 1988, J NEUROTRAUM, V5, P1, DOI 10.1089/neu.1988.5.1; LINDGREN S, 1966, BIOPHYSIK, V3, P174, DOI 10.1007/BF01191611; Maas AIR, 2008, LANCET NEUROL, V7, P728, DOI 10.1016/S1474-4422(08)70164-9; Marklund N, 2001, J CEREBR BLOOD F MET, V21, P1259, DOI 10.1097/00004647-200111000-00002; Marklund N, 2011, BRIT J PHARMACOL, V164, P1207, DOI 10.1111/j.1476-5381.2010.01163.x; MCINTOSH TK, 1989, NEUROSCIENCE, V28, P233, DOI 10.1016/0306-4522(89)90247-9; NILSSON P, 1994, BRAIN RES, V637, P227, DOI 10.1016/0006-8993(94)91237-8; Plantman S, 2012, J NEUROTRAUM, V29, P1219, DOI 10.1089/neu.2011.2182; Risling Marten, 2012, Front Neurol, V3, P30, DOI 10.3389/fneur.2012.00030; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Sato M, 2001, BRAIN RES, V917, P45, DOI 10.1016/S0006-8993(01)02905-5; Schutz C, 2006, CRIT CARE MED, V34, P492, DOI 10.1097/01.CCM.0000198326.32049.7F; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; Statler KD, 2006, J NEUROTRAUM, V23, P97, DOI 10.1089/neu.2006.23.97; Tagliaferri F, 2006, ACTA NEUROCHIR, V148, P255, DOI 10.1007/s00701-005-0651-y; Thal SC, 2007, J NEUROSCI METH, V159, P261, DOI 10.1016/j.jneumeth.2006.07.016; Thompson HJ, 2005, J NEUROTRAUM, V22, P42, DOI 10.1089/neu.2005.22.42; Todd MM, 1996, J NEUROSURG ANESTH, V8, P296, DOI 10.1097/00008506-199610000-00007; Vink R, 2001, J NEUROTRAUM, V18, P839, DOI 10.1089/089771501316919201; Washington PM, 2012, J NEUROTRAUM, V29, P2283, DOI 10.1089/neu.2012.2456; Xu LY, 2016, EXP NEUROL, V275, P436, DOI 10.1016/j.expneurol.2014.11.004; Zweckberger K, 2003, J NEUROTRAUM, V20, P1307, DOI 10.1089/089771503322686102	51	22	23	0	1	HUMANA PRESS INC	TOTOWA	999 RIVERVIEW DR, STE 208, TOTOWA, NJ 07512-1165 USA	1064-3745	1940-6029	978-1-4939-3816-2; 978-1-4939-3814-8	METHODS MOL BIOL	Methods Mol. Biol.		2016	1462						29	46		10.1007/978-1-4939-3816-2_3	10.1007/978-1-4939-3816-2		18	Biochemical Research Methods; Biochemistry & Molecular Biology; Neurosciences	Biochemistry & Molecular Biology; Neurosciences & Neurology	BH1UG	WOS:000398551500005	27604711				2021-06-18	
J	Wackym, PA; Balaban, CD; Mackay, HT; Wood, SJ; Lundell, CJ; Carter, DM; Siker, DA				Wackym, P. Ashley; Balaban, Carey D.; Mackay, Heather T.; Wood, Scott J.; Lundell, Christopher J.; Carter, Dale M.; Siker, David A.			Longitudinal Cognitive and Neurobehavioral Functional Outcomes Before and After Repairing Otic Capsule Dehiscence	OTOLOGY & NEUROTOLOGY			English	Article						Cognitive dysfunction; Depression; Memory; Migraine; Otic capsule dehiscence syndrome; Perilymph fistula; Superior canal dehiscence syndrome; Traumatic brain injury	SEMICIRCULAR CANAL DEHISCENCE; DUAL-TASK INTERFERENCE; VESTIBULAR STIMULATION; PARABRACHIAL NUCLEUS; SURGICAL-MANAGEMENT; MOTION SICKNESS; SPATIAL MEMORY; DEPRESSION; ANXIETY; SYSTEM	Objective:Patients with peripheral vestibular dysfunction because of gravitational receptor asymmetries display signs of cognitive dysfunction and are assumed to have neurobehavioral sequelae. This was tested with pre- and postoperatively quantitative measurements in three cohort groups with superior semicircular canal dehiscence syndrome (SSCDS) symptoms with: 1) superior canal dehiscence (SCD) repaired via a middle cranial fossa craniotomy and canal plugging only; 2) otic capsule defects not visualized with imaging (no-iOCD) repaired with round window reinforcement (RWR) only; or 3) both SCD plugging and subsequent development of no-iOCD followed by RWR.Study Design:Prospective patient series.Setting:Tertiary referral center.Patients:There were 13 adult and 4 pediatric patients with SSCDS who had completion of neuropsychology test batteries pre- and every 3 months postoperatively. Eight patients had no-iOCD and RWR exclusively, 5 had SCD and plugging exclusively, and 4 had both SCD plugging and then development of no-iOCD with RWR. These cohorts included SSCDS with 2 different dehiscence locations.Interventions:Completion of a neuropsychology test battery preoperatively and at 3, 6, 9, and 12 months postoperatively that included: Beck Depression Inventory-II (BDI); Wide Range Intelligence Test (WRIT FSIQ) including average verbal (crystallized intelligence) and visual (fluid intelligence); Wide Range Assessment of Memory and Learning (WRAML), including the four domains of verbal memory, visual memory, attention/concentration, and working memory; and Delis-Kaplan Executive Function System (D-KEFS). The Dizziness Handicap Inventory (DHI) and the Headache Impact Test (HIT-6) were also completed to assess the impact of their disease on activities pre- and postoperatively.Main Outcome Measures:Quantitative and statistical analysis of their cognitive and neurobehavioral function.Results:The pattern of differences between the SCD group and the no-iOCD group from WRAML verbal, visual, and attention test performance indicate different postoperative clinical trajectories. For the WRAML, there was a statistically significant improvement for visual memory and verbal memory for the no-iOCD only and both (SCD and subsequent no-iOCD) groups, but no mean improvement for the SCD only group. By contrast, the no-iOCD group had significantly lower scores on the WRAML attention test preoperatively, but they recovered postoperatively to match the other groups. The preoperative findings and postoperative outcomes did not differ significantly among patient groups on the WRAML working memory test, D-KEFS motor scores, D-KEFS number and letter scores, or Wide Range Intelligence Test scores. There was a significant decrease in the BDI for all groups. The IQ scores were unchanged. There was a statistically significant improvement in the DHI and HIT-6 scores postoperatively in all groups.Conclusions:There was a marked overall improvement in cognitive and neurobehavioral function postoperatively. Variability may result from duration of underlying disease before intervention. The initial decrement or delay in performance improvement measured in several patients may represent brain reorganization. Greater longitudinal data and greater subject numbers are necessary to better understand and optimize cognitive recovery.	[Wackym, P. Ashley; Mackay, Heather T.; Lundell, Christopher J.] Ear & Skull Base Ctr, Portland, OR 97232 USA; [Wackym, P. Ashley; Mackay, Heather T.; Lundell, Christopher J.] Legacy Res Inst, Portland, OR USA; [Balaban, Carey D.] Univ Pittsburgh, Dept Otolaryngol, Pittsburgh, PA 15260 USA; [Wood, Scott J.] Azusa Pacific Univ, Dept Psychol, Azusa, CA USA; [Carter, Dale M.] NW Headache & Wellness Ctr, Portland, OR USA; [Siker, David A.] Siker Med Imaging, Portland, OR USA	Wackym, PA (corresponding author), Ear & Skull Base Ctr, 1225 NE 2nd Ave,Suite 305, Portland, OR 97232 USA.	wackym@neurotology.org	Balaban, Carey/O-6586-2019; Balaban, Carey/I-3467-2017	Balaban, Carey/0000-0002-3570-3844; Balaban, Carey/0000-0002-3570-3844	Legacy Good Samaritan Foundation; Ear and Skull Base Center	The Legacy Good Samaritan Foundation and the Ear and Skull Base Center provided funding to help support this work.	Al-Yahya E, 2011, NEUROSCI BIOBEHAV R, V35, P715, DOI 10.1016/j.neubiorev.2010.08.008; American Psychiatric Association, 2000, DIAGN STAT MAN MENT; Andersson G, 1998, AM J OTOL, V19, P632; Baek JH, 2010, NEUROBIOL LEARN MEM, V94, P402, DOI 10.1016/j.nlm.2010.08.007; Balaban CD, 2012, BRAIN RES, V1482, P101, DOI 10.1016/j.brainres.2012.08.040; Balaban CD, 2004, BRAIN RES, V996, P126, DOI 10.1016/j.brainres.2003.10.026; Balaban CD, 2002, J NEUROPHYSIOL, V88, P3175, DOI 10.1152/jn.00499.2002; Balaban CD, 2001, J ANXIETY DISORD, V15, P53, DOI 10.1016/S0887-6185(00)00042-6; Balabann CD, 2011, EXPERT REV NEUROTHER, V11, P379, DOI 10.1586/ERN.11.19; Bayliss M., 2002, HIT 6TM USERS GUIDE; Bear ZW, 2015, ACTA OTO-LARYNGOL, V135, P974, DOI 10.3109/00016489.2015.1060630; Bechterew W., 1883, PFLUGERS ARCH, V30, P312; BECK AT, 1974, PSYCHOL REP, V34, P1184; BECK AT, 1984, J CLIN PSYCHOL, V40, P1365, DOI 10.1002/1097-4679(198411)40:6<1365::AID-JCLP2270400615>3.0.CO;2-D; BECK AT, 1961, ARCH GEN PSYCHIAT, V4, P561, DOI 10.1001/archpsyc.1961.01710120031004; Bergquist F, 2008, J PHYSIOL-LONDON, V586, P4441, DOI 10.1113/jphysiol.2008.155291; Besnard S, 2012, HIPPOCAMPUS, V22, P814, DOI 10.1002/hipo.20942; Bilgrei R, PSYCHOL VESTIBULAR 1; BLACK FO, 1987, OTOLARYNG HEAD NECK, V96, P125, DOI 10.1177/019459988709600203; BLACK FO, 1992, AM J OTOL, V13, P254; Brandt T, 2005, BRAIN, V128, P2732, DOI 10.1093/brain/awh617; Calamia M, 2012, CLIN NEUROPSYCHOL, V26, P543, DOI 10.1080/13854046.2012.680913; Coalson D, 2008, WAIS 4 TECHNICAL INT; Delis D.C., 2001, EXAMINERS MANUAL; Delis DC, 2004, J INT NEUROPSYCH SOC, V10, P301, DOI 10.1017/S1355617704102191; Deroualle D, 2014, FRONT INTEGR NEUROSC, V8, DOI 10.3389/fnint.2014.00016; Dodson MJ, 2004, J NEUROL NEUROSUR PS, V75, P168; Elmali M, 2013, EUR J RADIOL, V82, pE606, DOI 10.1016/j.ejrad.2013.06.022; Furman JM, 2013, LANCET NEUROL, V12, P706, DOI 10.1016/S1474-4422(13)70107-8; Gizzi M, 2003, J HEAD TRAUMA REHAB, V18, P398, DOI 10.1097/00001199-200309000-00002; Glutting J, 2000, WIDE RANGE INTELLIGE; GRIMM RJ, 1989, ACTA OTO-LARYNGOL, P1, DOI 10.3109/00016488909138632; Guedry Jr FE, 1974, HDB SENSORY PHYSL, VVI, P3; Gurvich C, 2013, BRAIN RES, V1537, P244, DOI 10.1016/j.brainres.2013.08.058; Heilbronner RL, 2010, CLIN NEUROPSYCHOL, V24, P1267, DOI 10.1080/13854046.2010.526785; Ho TW, 2010, NAT REV NEUROL, V6, P573, DOI 10.1038/nrneurol.2010.127; Hufner K, 2007, HIPPOCAMPUS, V17, P471, DOI 10.1002/hipo.20283; JACOBSON GP, 1990, ARCH OTOLARYNGOL, V116, P424; Jessup AB, 2014, J DIABETES METAB, V5, P383; Kennedy RS, 1997, AVIAT SPACE ENVIR MD, V68, P13; KENNEDY RS, 1988, HUM FACTORS, V30, P153; KOHL RL, 1983, AVIAT SPACE ENVIR MD, V54, P464; Levine J, 2012, BRAIN STIMUL, V5, P267, DOI 10.1016/j.brs.2011.03.004; MARGOLIS RH, 1995, ARCH OTOLARYNGOL, V121, P44; Meiklejohn DA, 2015, OTOL NEUROTOL, V36, P1383, DOI 10.1097/MAO.0000000000000811; OMAN CM, 1990, CAN J PHYSIOL PHARM, V68, P294, DOI 10.1139/y90-044; Park JJH, 2015, AM J OTOLARYNG, V36, P347, DOI 10.1016/j.amjoto.2014.12.006; PASHLER H, 1994, PSYCHOL BULL, V116, P220, DOI 10.1037/0033-2909.116.2.220; Reason J.T., 1975, MOTION SICKNESS; REDFERN MS, 1994, J VESTIBUL RES-EQUIL, V4, P221; Schmidt M., 2003, J INT NEUROPSYCH SOC, V9, P962, DOI DOI 10.1017/S1355617703230162; Sharp LK, 2002, AM FAM PHYSICIAN, V66, P1001; SHARP PE, 1995, J NEUROSCI, V15, P173; Sheslow D, 2004, WIDE RANGE ASSESSMEN; Smith PF, 2013, FRONT HUM NEUROSCI, V7, DOI 10.3389/fnhum.2013.00678; Smith Paul F, 2010, Front Neurol, V1, P141, DOI 10.3389/fneur.2010.00141; Smith PF, 2010, HIPPOCAMPUS, V20, P36, DOI 10.1002/hipo.20588; Smith PF, 2005, PROG NEUROBIOL, V75, P391, DOI 10.1016/j.pneurobio.2005.04.004; SMITH PF, 1989, BRAIN RES REV, V14, P155, DOI 10.1016/0165-0173(89)90013-1; Staab JP, 2013, SEMIN NEUROL, V33, P297, DOI 10.1055/s-0033-1356462; Talkowski ME, 2005, J COGNITIVE NEUROSCI, V17, P1432, DOI 10.1162/0898929054985419; Vlastarakos PV, 2009, EUR ARCH OTO-RHINO-L, V266, P177, DOI 10.1007/s00405-008-0840-4; Wackym P Ashley, 2015, Ear Nose Throat J, V94, pE8; Wackym PA, 2012, OTOL NEUROTOL, V33, P1392, DOI 10.1097/MAO.0b013e318268d234; WACKYM PA, 1993, AM J OTOL, V14, P41; Wackym PA, 1998, OTOLARYNG HEAD NECK, V118, pS16, DOI 10.1016/S0194-5998(98)70003-8; Wackym PA, 2015, COGNITIVE DYSFUNCTIO; Wackym PA, 2015, TUNING FORK TESTING; Wackym PA, 2012, VESTIBULAR MIGRAINE; Wackym PA, 2015, TRAUMATIC OTIC CAPSU; Wackym PA, 2015, LEFT OTIC CAPSULE DE; Wackym PA, 2014, RIGHT PERILYMPH FIST; Wackym PA, 2015, OTIC CAPSULE DEHISCE; Ward BK, 2012, OTOL NEUROTOL, V33, P1386, DOI 10.1097/MAO.0b013e318268d20d; Watanabe K, 2014, NAT NEUROSCI, V17, P601, DOI 10.1038/nn.3667; Winter D.A., 2004, BIOMECHANICS MOTOR C; Winter L, 2012, FRONT PSYCHOL, V3, DOI 10.3389/fpsyg.2012.00499; Wood SJ, 2012, GAIT POSTURE, V36, P487, DOI 10.1016/j.gaitpost.2012.04.014; Yang M, 2011, CEPHALALGIA, V31, P357, DOI 10.1177/0333102410379890; Yardley L, 2001, J NEUROL NEUROSUR PS, V71, P48, DOI 10.1136/jnnp.71.1.48; Young L, 2010, OTOL NEUROTOL, V31, P697, DOI 10.1097/MAO.0b013e31819bd803; Zheng YW, 2014, HIPPOCAMPUS, V24, P541, DOI 10.1002/hipo.22247	82	22	22	0	4	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	1531-7129	1537-4505		OTOL NEUROTOL	Otol. Neurotol.	JAN	2016	37	1					70	82		10.1097/MAO.0000000000000928			13	Clinical Neurology; Otorhinolaryngology	Neurosciences & Neurology; Otorhinolaryngology	DA7XM	WOS:000368018900013	26649608	Green Published			2021-06-18	
J	Tian, J; Dai, HM; Deng, YY; Zhang, J; Li, Y; Zhou, J; Zhao, MY; Zhao, MW; Zhang, C; Zhang, YX; Wang, PP; Bing, GY; Zhao, LL				Tian, Jing; Dai, Hongmei; Deng, Yuanying; Zhang, Jie; Li, Ying; Zhou, Jun; Zhao, Mingyi; Zhao, Mengwen; Zhang, Chen; Zhang, Yuxi; Wang, Peipei; Bing, Guoying; Zhao, Lingling			The effect of HMGB1 on sub-toxic chlorpyrifos exposure-induced neuroinflammation in amygdala of neonatal rats	TOXICOLOGY			English	Article						Chlorpyrifos; Inflammatory; High-mobility group box 1; Nuclear factor kappa B; Interleukin-6; Tumor necrosis factor-alpha	TRAUMATIC BRAIN-INJURY; PRENATAL EXPOSURE; PESTICIDE; INFLAMMATION; PATHWAY; TARGET	Chlorpyrifos (CPF), one of organophosphorus pesticides (OPs), is associated with developmental neurotoxicity. Inflammatory response is closely related with CPF-induced neurotoxicity. The present study aimed at exploring whether sub-toxic CPF exposure on neonatal rats results in neuroinflammation that mediated by HMGB1/TLR4/NF-kappa B signaling pathway in the amygdala. The neonatal rats were subcutaneously injected with 5 mg/kg CPF for 4 consecutive days (postnatal day 11-14) with or without HMGB1 inhibitor, glycyrrhizin. We assessed the levels of pro-inflammatory cytokines at 12, 24, and 72 h after CPF exposure. The role of HMGB1 on neuroinflammation in sub-toxic exposure during brain development was studied. CPF-treated neonatal rats exhibited a significant increase in the expression of pro-inflammatory cytokines, such as IL-6, TNF-alpha and HMGB1, and a significant increase in the activation of NF-kappa B in the amygdala after CPF exposure. Inhibited HMGB1 reduced the release of IL-6 and TNF-alpha, and inhibited activation of NF-kappa B. Our findings indicate that CPF exposure on developmental brain might induce the activation of neuroinflammation mediated by HMGB1/TLR4/NF-kappa B pathway in the amygdala. (C) 2015 The Authors. Published by Elsevier Ireland Ltd.	[Tian, Jing; Dai, Hongmei; Deng, Yuanying; Li, Ying; Zhou, Jun; Zhao, Mingyi; Zhao, Mengwen; Zhang, Chen; Wang, Peipei; Zhao, Lingling] Cent S Univ, Xiangya Hosp 3, Dept Pediat, Changsha 410013, Hunan, Peoples R China; [Zhang, Jie] Cent S Univ, Xiangya Hosp 2, Dept Neurol, Changsha 410013, Hunan, Peoples R China; [Zhang, Yuxi] Nanjing Med Univ, Nanjing Childrens Hosp, Dept Cardiol Surg, Nanjing, Jiangsu, Peoples R China; [Bing, Guoying] Univ Kentucky, Sch Med, Dept Anat & Neurobiol, Lexington, KY 40536 USA	Zhao, LL (corresponding author), Cent S Univ, Xiangya Hosp 3, Dept Pediat, 138 Tongzipo Rd, Changsha 410013, Hunan, Peoples R China.	llzhao2011@qq.com		Bing, Guoying/0000-0003-0609-8152	Key Subjects of Hunan Province [2012]	This research received specific grant from Key Subjects of Hunan Province (2012).	Ahmed A, 2013, ONCOIMMUNOLOGY, V2, DOI 10.4161/onci.22945; Andersson U, 2011, ANNU REV IMMUNOL, V29, P139, DOI 10.1146/annurev-immunol-030409-101323; Bouchard MF, 2011, ENVIRON HEALTH PERSP, V119, P1189, DOI 10.1289/ehp.1003185; Chang ZL, 2010, INFLAMM RES, V59, P791, DOI 10.1007/s00011-010-0208-2; Crews FT, 2013, BIOL PSYCHIAT, V73, P602, DOI 10.1016/j.biopsych.2012.09.030; Dai HM, 2015, TOXICOLOGY, V334, P72, DOI 10.1016/j.tox.2015.06.003; Day HEW, 2005, EUR J NEUROSCI, V21, P441, DOI 10.1111/j.1460-9568.2005.03865.x; Gong G, 2014, PLOS ONE, V9, DOI 10.1371/journal.pone.0089450; Holloway-Erickson CM, 2012, FRONT BEHAV NEUROSCI, V6, DOI 10.3389/fnbeh.2012.00017; Jung HS, 2014, KOREAN J ANESTHESIOL, V66, P136, DOI 10.4097/kjae.2014.66.2.136; Juranek J, 2012, BRAIN IMAGING BEHAV, V6, P36, DOI 10.1007/s11682-011-9140-5; Kang S, 2007, FASEB J, V21, pA484; Koob GF, 2010, NEUROPSYCHOPHARMACOL, V35, P217, DOI 10.1038/npp.2009.110; Marks AR, 2010, ENVIRON HEALTH PERSP, V118, P1768, DOI 10.1289/ehp.1002056; Meyer U, 2011, PHARMACOL THERAPEUT, V132, P96, DOI 10.1016/j.pharmthera.2011.06.003; Montgomery SL, 2012, J NEUROIMMUNE PHARM, V7, P42, DOI 10.1007/s11481-011-9287-2; Mullins RJ, 2015, NEUROTOXICOLOGY, V48, P9, DOI 10.1016/j.neuro.2015.02.002; Paxinos C.Wa.G., 2007, RAT BRAIN STEREOTAXI; Rauh V, 2011, ENVIRON HEALTH PERSP, V119, P1196, DOI 10.1289/ehp.1003160; Roya TS, 2004, DEV BRAIN RES, V148, P197, DOI 10.1016/j.devbrainres.2003.12.004; Shelton JF, 2014, ENVIRON HEALTH PERSP, V122, P1103, DOI 10.1289/ehp.1307044; Sims GP, 2010, ANNU REV IMMUNOL, V28, P367, DOI 10.1146/annurev.immunol.021908.132603; Su XF, 2011, MEDIAT INFLAMM, V2011, DOI 10.1155/2011/807142; Teng SX, 2015, BRAIN BEHAV IMMUN, V45, P145, DOI 10.1016/j.bbi.2014.11.006; Trendelenburg G, 2008, J CEREBR BLOOD F MET, V28, P867, DOI 10.1038/sj.jcbfm.9600609; Venerosi A, 2010, PSYCHOPHARMACOLOGY, V208, P99, DOI 10.1007/s00213-009-1713-2; Zhang JC, 2014, BRAIN RES, V1582, P176, DOI 10.1016/j.brainres.2014.07.002; Zhang J, 2015, TOXICOLOGY, V336, P17, DOI 10.1016/j.tox.2015.07.014; Zhang Jie, 2011, Zhongguo Dang Dai Er Ke Za Zhi, V13, P989	29	22	22	1	9	ELSEVIER IRELAND LTD	CLARE	ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND	0300-483X			TOXICOLOGY	Toxicology	DEC 2	2015	338						95	103		10.1016/j.tox.2015.10.010			9	Pharmacology & Pharmacy; Toxicology	Pharmacology & Pharmacy; Toxicology	CZ2VF	WOS:000366962000011	26524701	Other Gold			2021-06-18	
J	Buckley, EM; Miller, BF; Golinski, JM; Sadeghian, H; McAllister, LM; Vangel, M; Ayata, C; Meehan, WP; Franceschini, MA; Whalen, MJ				Buckley, Erin M.; Miller, Benjamin F.; Golinski, Julianne M.; Sadeghian, Homa; McAllister, Lauren M.; Vangel, Mark; Ayata, Cenk; Meehan, William P., III; Franceschini, Maria Angela; Whalen, Michael J.			Decreased microvascular cerebral blood flow assessed by diffuse correlation spectroscopy after repetitive concussions in mice	JOURNAL OF CEREBRAL BLOOD FLOW AND METABOLISM			English	Article						animal models; brain trauma; optical imaging	TRAUMATIC BRAIN-INJURY; SPORTS-RELATED CONCUSSION; COGNITIVE IMPAIRMENT; MILD; PERFUSION; SINGLE; RECOVERY; DEFICITS; DISEASE; MODELS	Repetitive concussions are associated with long-term cognitive dysfunction that can be attenuated by increasing the time intervals between concussions; however, biomarkers of the safest rest interval between injuries remain undefined. We hypothesize that deranged cerebral blood flow (CBF) is a candidate biomarker for vulnerability to repetitive concussions. Using a mouse model of human concussion, we examined the effect of single and repetitive concussions on cognition and on an index of CBF (CBFi) measured with diffuse correlation spectroscopy. After a single mild concussion, CBFi was reduced by 35 +/- 4% at 4 hours (P < 0.01 versus baseline) and returned to preinjury levels by 24 hours. After five concussions spaced 1 day apart, CBFi was also reduced from preinjury levels 4 hours after each concussion but had returned to preinjury levels by 72 hours after the final concussion. Interestingly, in this repetitive concussion model, lower CBFi values measured both preinjury and 4 hours after the third concussion were associated with worse performance on the Morris water maze assessed 72 hours after the final concussion. We conclude that low CBFi measured either before or early on in the evolution of injury caused by repetitive concussions could be a useful predictor of cognitive outcome.	[Buckley, Erin M.; Miller, Benjamin F.; Vangel, Mark; Franceschini, Maria Angela] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Dept Radiol, Charlestown, MA 02129 USA; [Golinski, Julianne M.; McAllister, Lauren M.; Whalen, Michael J.] Massachusetts Gen Hosp, Dept Pediat, Div Crit Care Med, Charlestown, MA 02129 USA; [Sadeghian, Homa; Ayata, Cenk] Massachusetts Gen Hosp, Dept Radiol, Neurovasc Res Lab, Charlestown, MA 02129 USA; [Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA; [Meehan, William P., III] Boston Childrens Hosp, Div Sports Med, Div Emergency Med, Boston, MA USA	Whalen, MJ (corresponding author), Massachusetts Gen Hosp, Dept Pediat Crit Care Med, Charlestown, MA 02129 USA.	mwhalen@mgh.harvard.edu			National Football League Players Association [PO1NS 55104 06]; National Institute of HealthUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [R01-EB001954]; Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health) [UL1 TR001102]; Harvard University; MGH ECOR Fund for Medical Discovery; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001102] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF BIOMEDICAL IMAGING AND BIOENGINEERINGUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Biomedical Imaging & Bioengineering (NIBIB) [R01EB001954] Funding Source: NIH RePORTER; NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKEUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Institute of Neurological Disorders & Stroke (NINDS) [P01NS055104] Funding Source: NIH RePORTER	This study was supported by National Football League Players Association Grant to Harvard College and PO1NS 55104 06 (MJW); National Institute of Health award R01-EB001954 (MAF); the Harvard Clinical and Translational Science Center (National Center for Research Resources and the National Center for Advancing Translational Sciences, National Institutes of Health award UL1 TR001102) and financial contributions from Harvard University and its affiliated academic healthcare centers; and MGH ECOR Fund for Medical Discovery (EMB).	Agrawal D, 2005, J NEUROSURG, V102, P167, DOI 10.3171/jns.2005.102.2.0167; Angoa-Perez M, 2014, J NEUROCHEM, V129, P916, DOI 10.1111/jnc.12690; Barkhoudarian G, 2011, CLIN SPORT MED, V30, P33, DOI 10.1016/j.csm.2010.09.001; Boas DA, 1997, J OPT SOC AM A, V14, P192, DOI 10.1364/JOSAA.14.000192; Bonne O, 2003, PSYCHIAT RES-NEUROIM, V124, P141, DOI 10.1016/S0925-4927(03)00109-4; Buckley EM, 2014, NEUROPHOTONICS, V1, DOI 10.1117/1.NPh.1.1.011009; DeFord SM, 2002, J NEUROTRAUM, V19, P427, DOI 10.1089/08977150252932389; Dimou S, 2014, J NEUROTRAUM, V31, P413, DOI 10.1089/neu.2013.3050; Diop M, 2011, BIOMED OPT EXPRESS, V2, P2068, DOI 10.1364/BOE.2.002068; Durduran T, 2010, REP PROG PHYS, V73, DOI 10.1088/0034-4885/73/7/076701; Durduran T, 2014, NEUROIMAGE, V85, P51, DOI 10.1016/j.neuroimage.2013.06.017; Garry PS, 2015, EXP NEUROL, V263, P235, DOI 10.1016/j.expneurol.2014.10.017; Ge YL, 2009, BRAIN INJURY, V23, P666, DOI 10.1080/02699050903014899; Henninger N, 2007, CRIT CARE MED, V35, P2607, DOI 10.1097/01.CCM.0000286395.79654.8D; Hofman PAM, 2001, AM J NEURORADIOL, V22, P441; Jain V, 2014, J CEREBR BLOOD F MET, V34, P380, DOI 10.1038/jcbfm.2013.214; Jeter CB, 2013, J NEUROTRAUM, V30, P657, DOI 10.1089/neu.2012.2439; Johnson B, 2012, NEUROIMAGE, V59, P511, DOI 10.1016/j.neuroimage.2011.07.081; Khuman J, 2011, J CEREBR BLOOD F MET, V31, P778, DOI 10.1038/jcbfm.2010.172; Lehman EJ, 2012, NEUROLOGY, V79, P1970, DOI 10.1212/WNL.0b013e31826daf50; Liu W, 2013, NMR BIOMED, V26, P651, DOI 10.1002/nbm.2910; Longhi L, 2005, NEUROSURGERY, V56, P364, DOI 10.1227/01.NEU.0000149008.73513.44; Lovell MR, 2006, APPL NEUROPSYCHOL, V13, P166, DOI 10.1207/s15324826an1303_4; Mannix R, 2013, ANN NEUROL, V74, P65, DOI 10.1002/ana.23858; Maugans TA, 2012, PEDIATRICS, V129, P28, DOI 10.1542/peds.2011-2083; Mayer AR, 2015, NEUROSCI BIOBEHAV R, V49, P8, DOI 10.1016/j.neubiorev.2014.11.016; McCrea M, 2004, CLIN J SPORT MED, V14, P13, DOI 10.1097/00042752-200401000-00003; McCrory P, 2013, CLIN J SPORT MED, V23, P89, DOI 10.1097/JSM.0b013e31828b67cf; McKee AC, 2013, BRAIN, V136, P43, DOI 10.1093/brain/aws307; Meehan WP, 2012, NEUROSURGERY, V71, P885, DOI 10.1227/NEU.0b013e318265a439; Metting Z, 2009, ANN NEUROL, V66, P809, DOI 10.1002/ana.21785; PATTERSON MS, 1995, APPL OPTICS, V34, P22, DOI 10.1364/AO.34.000022; R Development Core Team, 2011, R LANG ENV STAT COMP; Shitaka Y, 2011, J NEUROPATH EXP NEUR, V70, P551, DOI 10.1097/NEN.0b013e31821f891f; Slobounov S, 2012, BRAIN IMAGING BEHAV, V6, P224, DOI 10.1007/s11682-012-9167-2; Smith DH, 2013, NAT REV NEUROL, V9, P211, DOI 10.1038/nrneurol.2013.29; Tan CO, 2014, NEUROLOGY, V83, P1665, DOI 10.1212/WNL.0000000000000944; Uryu K, 2002, J NEUROSCI, V22, P446, DOI 10.1523/JNEUROSCI.22-02-00446.2002; Weber JT, 2007, PROG BRAIN RES, V161, P253, DOI 10.1016/S0079-6123(06)61018-2; Yemisci M, 2009, NAT MED, V15, P1031, DOI 10.1038/nm.2022	40	22	22	0	11	SAGE PUBLICATIONS INC	THOUSAND OAKS	2455 TELLER RD, THOUSAND OAKS, CA 91320 USA	0271-678X	1559-7016		J CEREBR BLOOD F MET	J. Cereb. Blood Flow Metab.	DEC	2015	35	12					1995	2000		10.1038/jcbfm.2015.161			6	Endocrinology & Metabolism; Hematology; Neurosciences	Endocrinology & Metabolism; Hematology; Neurosciences & Neurology	CX7OI	WOS:000365891300011	26154866	Green Published, Bronze			2021-06-18	
J	Locher, RJ; Lunnemann, T; Garbe, A; Schaser, KD; Schmidt-Bleek, K; Duda, G; Tsitsilonis, S				Locher, R. J.; Luennemann, T.; Garbe, A.; Schaser, K-D.; Schmidt-Bleek, K.; Duda, G.; Tsitsilonis, S.			Traumatic brain injury and bone healing: radiographic and biomechanical analyses of bone formation and stability in a combined murine trauma model	JOURNAL OF MUSCULOSKELETAL & NEURONAL INTERACTIONS			English	Article						Traumatic Brain Injury; Fracture Healing; Polytrauma; microCT	CONTROLLED CORTICAL IMPACT; HEAD-INJURY; FEMORAL FRACTURES; ENERGY-METABOLISM; CALLUS FORMATION; RAT MODEL; UNION; MASS	Introduction: The combination of traumatic brain injury (TBI) and long-bone fractures has previously been reported to lead to exuberant callus formation. The aim of this experimental study was to radiographically and biomechanically study the effect of TBI on bone healing in a mouse model. Materials and methods: 138 female C57/Black6N mice were assigned to four groups (fracture (Fx) / TBI / combined trauma (Fx/TBI) / controls). Femoral osteotomy and TBI served as variables: osteotomies were stabilized with external fixators, TBI was induced with controlled cortical impact injury. During an observation period of four weeks, in vivo micro-CT scans of femora were performed on a weekly basis. Biomechanical testing of femora was performed ex vivo. Results: The combined-trauma group showed increased bone volume, higher mineral density, and a higher rate of gap bridging compared to the fracture group. The combined-trauma group showed increased torsional strength at four weeks. Discussion: TBI results in an increased formation of callus and mineral density compared to normal bone healing in mice. This fact combined with a tendency towards accelerated gap bridging leads to increased torsional strength. The present study underscores the empirical clinical evidence that TBI stimulates bone healing. Identification of underlying pathways could lead to new strategies for bone-stimulating approaches in fracture care.	[Locher, R. J.; Luennemann, T.; Garbe, A.; Schaser, K-D.; Tsitsilonis, S.] Charite, Ctr Musculoskeletal Surg, D-13353 Berlin, Germany; [Schmidt-Bleek, K.; Duda, G.] Charite, Julius Wolff Inst, D-13353 Berlin, Germany; [Schmidt-Bleek, K.; Duda, G.; Tsitsilonis, S.] Charite, Berlin Brandenburg Ctr Regenerat Therapies, D-13353 Berlin, Germany	Locher, RJ (corresponding author), Charite, Ctr Musculoskeletal Surg, Augustenburger Pl 1, D-13353 Berlin, Germany.	ricarda.locher@charite.de	Schmidt-Bleek, Katharina/O-9816-2015; Duda, Georg N/H-2085-2016	Duda, Georg N/0000-0001-7605-3908; Seemann, Ricarda/0000-0001-5752-070X	German Research Society (DFG)German Research Foundation (DFG) [TS 303/1-1]	The authors have no conflict of interest. This study was funded by the German Research Society (DFG, project TS 303/1-1).	Boes M, 2006, J BONE JOINT SURG AM, V88A, P738, DOI 10.2106/JBJS.D.02648; CALANDRIELLO B, 1964, Bull Hosp Joint Dis, V25, P170; Cheung KMC, 2003, J ORTHOP RES, V21, P685, DOI 10.1016/S0736-0266(03)00026-3; Council N. R, 2011, GUID CAR US LAB AN; Ducy P, 2000, CELL, V100, P197, DOI 10.1016/S0092-8674(00)81558-5; Einhorn TA, 2005, J ORTHOP TRAUMA, V19, pS4, DOI 10.1097/00005131-200511101-00002; Ferron M, 2010, CELL, V142, P296, DOI 10.1016/j.cell.2010.06.003; Fulzele K, 2010, CELL, V142, P309, DOI 10.1016/j.cell.2010.06.002; GARLAND DE, 1982, CLIN ORTHOP RELAT R, P219; Giannoudis PV, 2006, INJURY, V37, pS18, DOI 10.1016/j.injury.2006.08.020; Histing T, 2011, BONE, V49, P591, DOI 10.1016/j.bone.2011.07.007; Karsenty G, 2012, ANNU REV PHYSIOL, V74, P87, DOI 10.1146/annurev-physiol-020911-153233; Katsnelson A, 2010, NATURE, V466, P914, DOI 10.1038/466914a; Kooistra BW, 2010, J ORTHOP TRAUMA, V24, pS81, DOI 10.1097/BOT.0b013e3181ca3fd1; Lee NK, 2007, CELL, V130, P456, DOI 10.1016/j.cell.2007.05.047; Maegele M, 2005, SHOCK, V23, P476, DOI 10.1097/01.shk.0000159929.87737.5c; Mehta M, 2010, BONE, V47, P219, DOI 10.1016/j.bone.2010.05.029; Morley J, 2005, INJURY, V36, P363, DOI 10.1016/j.injury.2004.08.028; NEWMAN RJ, 1987, INJURY, V18, P241, DOI 10.1016/0020-1383(87)90006-4; PERKINS R, 1987, J BONE JOINT SURG BR, V69, P521; SMITH DH, 1995, J NEUROTRAUM, V12, P169, DOI 10.1089/neu.1995.12.169; SPENCER RF, 1987, J BONE JOINT SURG BR, V69, P525; Takeda S, 2002, CELL, V111, P305, DOI 10.1016/S0092-8674(02)01049-8; Thomale UW, 2002, J NEUROTRAUM, V19, P403, DOI 10.1089/08977150252932361; Tsitsilonis S, 2015, INJURY, V46, P661, DOI 10.1016/j.injury.2015.01.044; Wang L, 2011, CHIN J TRAUMATOL, V14, P7, DOI 10.3760/cma.j.issn.1008-1275.2011.01.002; Wei YZ, 2008, J PHARM PHARMACOL, V60, P1667, DOI 10.1211/jpp/60.12.0013; Yadav VK, 2009, CELL, V138, P976, DOI 10.1016/j.cell.2009.06.051	28	22	24	0	8	JMNI	NAFPLION	7 SPILIADOU SQ, NAFPLION, 21 100, GREECE	1108-7161			J MUSCULOSKEL NEURON	J. Musculoskelet. Neuronal Interact.	DEC	2015	15	4					309	315					7	Neurosciences; Physiology	Neurosciences & Neurology; Physiology	DB1CF	WOS:000368244900002	26636276				2021-06-18	
J	Quatman-Yates, CC; Bonnette, S; Hugentobler, JA; Mede, B; Kiefer, AW; Kurowski, BG; Riley, MA				Quatman-Yates, Catherine C.; Bonnette, Scott; Hugentobler, Jason A.; Mede, Butovens; Kiefer, Adam W.; Kurowski, Brad G.; Riley, Michael A.			Postconcussion Postural Sway Variability Changes in Youth: The Benefit of Structural Variability Analyses	PEDIATRIC PHYSICAL THERAPY			English	Article						adolescent; analysis of variance; brain concussion/diagnosis; brain concussion/physiopathology; child; female humans; male; mild traumatic brain injury; postural balance	SPORT-RELATED CONCUSSION; TRAUMATIC BRAIN-INJURY; HEART-RATE-VARIABILITY; CEREBRAL CONCUSSION; NEUROCOGNITIVE FUNCTION; EARLY ADULTHOOD; MANAGEMENT; SYMPTOMS; DYNAMICS; ENTROPY	Purpose: The purpose of this study was to evaluate the utility of postural sway variability as a potential assessment to detect altered postural sway in youth with symptoms related to a concussion. Methods: Forty participants (20 who were healthy and 20 who were injured) aged 10 to 16 years were assessed using the Balance Error Scoring System (BESS) and postural sway variability analyses applied to center-of-pressure data captured using a force plate. Results: Significant differences were observed between the 2 groups for postural sway variability metrics but not for the BESS. Specifically, path length was shorter and Sample and Renyi Entropies were more regular for the participants who were injured compared with the participants who were healthy (P < .05). Conclusion: The results of this study indicate that postural sway variability may be a more valid measure than the BESS to detect postconcussion alterations in postural control in young athletes.	[Quatman-Yates, Catherine C.; Hugentobler, Jason A.] Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine C.; Hugentobler, Jason A.; Kiefer, Adam W.] Cincinnati Childrens Hosp Med Ctr, Div Sports Med, Cincinnati, OH 45229 USA; [Kurowski, Brad G.] Cincinnati Childrens Hosp Med Ctr, Div Phys Med & Rehabil, Cincinnati, OH 45229 USA; [Quatman-Yates, Catherine C.; Kiefer, Adam W.] Univ Cincinnati, Coll Med, Div Pediat, Cincinnati, OH USA; [Quatman-Yates, Catherine C.; Bonnette, Scott; Kiefer, Adam W.; Riley, Michael A.] Univ Cincinnati, Dept Psychol, Ctr Cognit Act & Percept, Cincinnati, OH 45221 USA; [Mede, Butovens] CUNY City Coll, New York, NY 10031 USA	Quatman-Yates, CC (corresponding author), Cincinnati Childrens Hosp Med Ctr, Div Occupat & Phys Therapy, 3333 Burnet Ave,MLC 10001, Cincinnati, OH 45229 USA.	Catherine.quatman@cchmc.org	Quatman-Yates, Catherine/AAK-4507-2021; Quatman-Yates, Catherine/U-9580-2019; Kiefer, Adam/F-1756-2018		Cincinnati Children's Hospital Research In-Patient Services PS2 Mentored Career Grant; University of Cincinnati Research Council; NIHUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USA [1K23HD074683-01A1]; EUNICE KENNEDY SHRIVER NATIONAL INSTITUTE OF CHILD HEALTH & HUMAN DEVELOPMENTUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH Eunice Kennedy Shriver National Institute of Child Health & Human Development (NICHD) [K23HD074683] Funding Source: NIH RePORTER; NATIONAL CENTER FOR ADVANCING TRANSLATIONAL SCIENCESUnited States Department of Health & Human ServicesNational Institutes of Health (NIH) - USANIH National Center for Advancing Translational Sciences (NCATS) [UL1TR001425] Funding Source: NIH RePORTER	The Cincinnati Children's Hospital Research In-Patient Services PS2 Mentored Career Grant, University of Cincinnati Research Council Post-Doctoral Fellow Grant, and NIH grant 1K23HD074683-01A1.	Baugh CM, 2012, BRAIN IMAGING BEHAV, V6, P244, DOI 10.1007/s11682-012-9164-5; Bell DR, 2011, SPORTS HEALTH, V3, P287, DOI 10.1177/1941738111403122; Broglio SP, 2008, SPORTS MED, V38, P53, DOI 10.2165/00007256-200838010-00005; Broglio SP, 2009, CLIN J SPORT MED, V19, P377, DOI 10.1097/JSM.0b013e3181b625fe; Carpenter MG, 2010, NEUROSCIENCE, V171, P196, DOI 10.1016/j.neuroscience.2010.08.030; Cavanaugh JT, 2006, J ATHL TRAINING, V41, P305; Cavanaugh JT, 2005, SPORTS MED, V35, P935, DOI 10.2165/00007256-200535110-00002; Cavanaugh JT, 2005, BRIT J SPORT MED, V39, P805, DOI 10.1136/bjsm.2004.015909; De Beaumont L, 2007, NEUROSURGERY, V61, P329, DOI 10.1227/01.NEU.0000280000.03578.B6; De Beaumont L, 2011, J ATHL TRAINING, V46, P234; De Beaumont L, 2009, BRAIN, V132, P695, DOI 10.1093/brain/awn347; Deffeyes JE, 2009, J NEUROENG REHABIL, V6, DOI 10.1186/1743-0003-6-34; Deffeyes JE, 2009, CLIN BIOMECH, V24, P564, DOI 10.1016/j.clinbiomech.2009.05.004; Dusing SC, 2010, PHYS THER, V90, P1838, DOI 10.2522/ptj.2010033; Field M, 2003, J PEDIATR-US, V142, P546, DOI 10.1067/mpd.2003.190; Ford KR, 2010, MED SCI SPORT EXER, V42, P1923, DOI 10.1249/MSS.0b013e3181dc99b1; Ford KR, 2010, AM J SPORT MED, V38, P1829, DOI 10.1177/0363546510367425; Gao JH, 2011, PLOS ONE, V6, DOI 10.1371/journal.pone.0024446; Gogtay N, 2004, P NATL ACAD SCI USA, V101, P8174, DOI 10.1073/pnas.0402680101; Goldberger AL, 2002, P NATL ACAD SCI USA, V99, P2466, DOI 10.1073/pnas.012579499; Goldberger AL, 2000, CIRCULATION, V101, pE215, DOI 10.1161/01.CIR.101.23.e215; Goldberger AL, 2001, AM J RESP CRIT CARE, V163, P1289, DOI 10.1164/ajrccm.163.6.ed1801a; Goldberger AL, 1997, PERSPECT BIOL MED, V40, P543; Goldfield E. C., 1995, EMERGENT FORMS ORIGI; Grady MF, 2010, CURR PROB PEDIATR AD, V40, P154, DOI 10.1016/j.cppeds.2010.06.002; Gribble PA, 2004, J ELECTROMYOGR KINES, V14, P641, DOI 10.1016/j.jelekin.2004.05.001; Guskiewicz KM, 2007, MED SCI SPORT EXER, V39, P903, DOI 10.1249/mss.0b013e3180383da5; Guskiewicz Kevin M, 2003, Curr Sports Med Rep, V2, P24; Guskiewicz KM, 2011, PM&R, V3, P353, DOI 10.1016/j.pmrj.2010.12.006; Guskiewicz KM, 2011, CLIN SPORT MED, V30, P89, DOI 10.1016/j.csm.2010.09.004; Haddad JM, 2008, EXP BRAIN RES, V190, P431, DOI 10.1007/s00221-008-1483-9; Halstead ME, 2010, PEDIATRICS, V126, P597, DOI 10.1542/peds.2010-2005; Harbourne RT, 2009, PHYS THER, V89, P284, DOI 10.2522/ptj.20080130.ar; Harbourne RT, 2009, NONLIN DYNAM PSYCHOL, V13, P123; Harbourne RT, 2003, DEV PSYCHOBIOL, V42, P368, DOI 10.1002/dev.10110; Hewett TE, 2004, J BONE JOINT SURG AM, V86A, P1601, DOI 10.2106/00004623-200408000-00001; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Korn A, 2005, J CLIN NEUROPHYSIOL, V22, P1, DOI 10.1097/01.WNP.0000150973.24324.A7; Kuznetsov N, 2014, COMPLEX SYSTEMS SPOR, P85; Lake DE, 2002, AM J PHYSIOL-REG I, V283, pR789, DOI 10.1152/ajpregu.00069.2002; Leddy JJ, 2012, SPORTS HEALTH, V4, P147, DOI 10.1177/1941738111433673; Lee SP, 2014, GAIT POSTURE, V39, P933, DOI 10.1016/j.gaitpost.2013.12.004; Makdissi M, 2013, BRIT J SPORT MED, V47, P308, DOI 10.1136/bjsports-2013-092255; Makdissi M, 2013, BRIT J SPORT MED, V47, P314, DOI 10.1136/bjsports-2013-092256; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, BRIT J SPORT MED, V47, P250, DOI 10.1136/bjsports-2013-092313; McLeod TCV, 2006, J ATHL TRAINING, V41, P399; McLeod TCV, 2004, CLIN J SPORT MED, V14, P287, DOI 10.1097/00042752-200409000-00007; Murnaghan CD, 2011, NEUROSCIENCE, V195, P54, DOI 10.1016/j.neuroscience.2011.08.020; Murnaghan CD, 2013, GAIT POSTURE, V38, P734, DOI 10.1016/j.gaitpost.2013.03.012; Ptito A, 2007, NEUROREHABILITATION, V22, P217; Quatman-Yates CC, 2013, INT J SPORTS PHYS TH, V8, P741; Quatman-Yates CC, 2013, PEDIATR PHYS THER, V25, P271, DOI 10.1097/PEP.0b013e31828e1e9d; Quatman-Yates CC, 2012, BRIT J SPORT MED, V46, P649, DOI 10.1136/bjsm.2010.079616; Ramdani S, 2009, MED ENG PHYS, V31, P1023, DOI 10.1016/j.medengphy.2009.06.004; Renyi A., 1961, 4 BERK S MATH STAT P; Riccio G, 1993, VARIABILITY MOTOR CO, P933; Riley M.A., 2011, SCI MOTRICITE, V74, P5, DOI [10.1051/sm/2011117, DOI 10.1051/SM/2011117]; Riley MA, 2002, J MOTOR BEHAV, V34, P99, DOI 10.1080/00222890209601934; Schmit JM, 2006, EXP BRAIN RES, V168, P357, DOI 10.1007/s00221-005-0094-y; Sheehan DP, 2011, MEAS PHYS EDUC EXERC, V15, P234, DOI 10.1080/1091367X.2011.568368; Sigurdardottir S, 2009, BRAIN INJURY, V23, P489, DOI 10.1080/02699050902926309; Sosnoff JJ, 2011, J ATHL TRAINING, V46, P85, DOI 10.4085/1062-6050-46.1.85; Stergiou Nicholas, 2006, J Neurol Phys Ther, V30, P120; Stergiou N, 2011, HUM MOVEMENT SCI, V30, P869, DOI 10.1016/j.humov.2011.06.002; Takacs J, 2012, J BIOMECH, V45, P2791, DOI 10.1016/j.jbiomech.2012.08.041; Thayer JF, 2012, NEUROSCI BIOBEHAV R, V36, P747, DOI 10.1016/j.neubiorev.2011.11.009; THEILER J, 1992, PHYSICA D, V58, P77, DOI 10.1016/0167-2789(92)90102-S; Tomei KL, 2012, NEUROSURG FOCUS, V33, DOI 10.3171/2012.9.FOCUS12280; Webber Jr CL, 2005, TUTORIALS CONT NONLI; Winter DA., 2005, BIOMECHANICS MOTOR C, V3rd ed	71	22	22	0	10	LIPPINCOTT WILLIAMS & WILKINS	PHILADELPHIA	TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA	0898-5669	1538-005X		PEDIATR PHYS THER	Pediatr. Phys. Ther.	WIN	2015	27	4					316	327		10.1097/PEP.0000000000000193			12	Pediatrics; Rehabilitation	Pediatrics; Rehabilitation	DD1YP	WOS:000369719600003	26397071	Green Accepted			2021-06-18	
J	Kim, DY; O'Leary, M; Nguyen, A; Kaji, A; Bricker, S; Neville, A; Bongard, F; Putnam, B; Plurad, D				Kim, Dennis Yong; O'Leary, Michael; Nguyen, Andrew; Kaji, Amy; Bricker, Scott; Neville, Angela; Bongard, Fred; Putnam, Brant; Plurad, David			The Effect of Platelet and Desmopressin Administration on Early Radiographic Progression of Traumatic Intracranial Hemorrhage	JOURNAL OF NEUROTRAUMA			English	Article						desmopressin; intracranial hemorrhage; platelets; radiographic progression; traumatic brain injury	BRAIN-INJURY; INTRACEREBRAL HEMORRHAGE; HEAD TRAUMA; CLOPIDOGREL; TRANSFUSION; PREDICTORS; MORTALITY; ASPIRIN; RISK	Limited data exist regarding the use of hemostatic adjuncts on the progression of traumatic intracranial hemorrhage (tICH). The objective of this study was to examine the impact of platelet transfusion and desmopressin (DDAVP) administration on hemorrhage progression following tICH. We hypothesized that platelet and DDAVP administration would not result in decreased early hemorrhagic progression. We performed a three-year retrospective analysis of a Level 1 trauma center database to identify all adult patents with blunt tICH. The primary outcome was early (4 hours) radiographic hemorrhagic progression. Secondary outcomes included mortality, frequency of operative interventions, and complications. Multiple logistic regression analysis was performed to identify predictors for hemorrhage progression and mortality. A propensity score analysis also was performed to minimize differences and improve comparability between patients who received platelets and DDAVP and those who did not. Of 408 patients with tICH meeting the inclusion criteria, 126 received platelets and DDAVP (P/D [+]) and 282 did not (P/D [-]). Overall, 37% of patients demonstrated early radiographic hemorrhage progression. On univariate analysis, there was no difference in the incidence of hemorrhage progression between groups (43.7% [P/D (+)] vs. 34.2% [P/D (-)]; p = 0.07). On multivariate analyses, platelet and DDAVP administration was not associated with either a decreased risk of hemorrhage progression (odds ratio [OR] = 1.40, confidence interval [CI] = 0.80-2.40; p = 0.2) or mortality (OR = 1.50, CI = 0.60-4.30; p = 0.4). The administration of platelets and DDAVP is not associated with a decreased risk for early radiographic hemorrhage progression in patients with tICH. Further prospective study of these potentially hemostatic adjuncts in patients with tICH is potentially warranted.	[Kim, Dennis Yong; Bricker, Scott; Neville, Angela; Bongard, Fred; Putnam, Brant; Plurad, David] Harbor UCLA Med Ctr, Div Trauma Acute Care Surg Surg Crit Care, Torrance, CA 90509 USA; [O'Leary, Michael; Nguyen, Andrew] Harbor UCLA Med Ctr, Dept Surg, Torrance, CA 90509 USA; [Kaji, Amy] Harbor UCLA Med Ctr, Dept Emergency Med, Torrance, CA 90509 USA	Kim, DY (corresponding author), 1000 W Carson St,Box 42, Torrance, CA 90502 USA.	dekim@dhs.lacounty.gov					Allard CB, 2009, J TRAUMA, V67, P959, DOI 10.1097/TA.0b013e3181ad5d37; Anderson CS, 2010, STROKE, V41, P307, DOI 10.1161/STROKEAHA.109.561795; [Anonymous], 2011, BMJ-BRIT MED J, V343, DOI 10.1136/bmj.d3795; Batchelor JS, 2012, BMJ OPEN, V2, DOI 10.1136/bmjopen-2011-000588; Beshay JE, 2010, J NEUROSURG, V112, P307, DOI 10.3171/2009.7.JNS0982; Beynon C, 2012, CRIT CARE, V16, DOI 10.1186/cc11292; Chang EF, 2006, NEUROSURGERY, V58, P647, DOI 10.1227/01.NEU.0000197101.68538.E6; CHESNUT RM, 1993, J TRAUMA, V34, P216, DOI 10.1097/00005373-199302000-00006; Chieregato A, 2005, NEUROSURGERY, V56, P671, DOI 10.1227/01.NEU.0000156200.76331.7A; Corso P, 2006, INJURY PREV, V12, P212, DOI 10.1136/ip.2005.010983; Downey DM, 2009, AM SURGEON, V75, P1100; Engstrom M, 2005, J NEUROTRAUM, V22, P291, DOI 10.1089/neu.2005.22.291; Faul M.D., 2010, TRAUMATIC BRAIN INJU; Ivascu FA, 2008, J TRAUMA, V65, P785, DOI 10.1097/TA.0b013e3181848caa; Jones K, 2006, AM J SURG, V192, P743, DOI 10.1016/j.amjsurg.2006.08.037; Kothari U, 1996, STROKE, V27, P1304, DOI 10.1161/01.STR.27.8.1304; Naidech AM, 2012, NEUROCRIT CARE, V16, P82, DOI 10.1007/s12028-011-9619-3; Naidech AM, 2011, NEUROCRIT CARE, V15, P442, DOI 10.1007/s12028-011-9557-0; Narayan RK, 2008, J NEUROTRAUM, V25, P629, DOI 10.1089/neu.2007.0385; Nekludov M, 2007, J NEUROTRAUM, V24, P1699, DOI 10.1089/neu.2007.0322; Nishijima DK, 2012, J TRAUMA ACUTE CARE, V72, P1658, DOI 10.1097/TA.0b013e318256dfc5; Nishijima DK, 2012, ANN EMERG MED, V59, P460, DOI 10.1016/j.annemergmed.2012.04.007; Oertel M, 2002, J NEUROSURG, V96, P109, DOI 10.3171/jns.2002.96.1.0109; Ohm C, 2005, J TRAUMA, V58, P518, DOI 10.1097/01.TA.0000151671.35280.8B; Patel NY, 2000, J TRAUMA, V48, P367, DOI 10.1097/00005373-200003000-00001; Schnuriger B, 2010, J TRAUMA, V68, P881, DOI 10.1097/TA.0b013e3181d3cc58; Vilahur G, 2007, J THROMB HAEMOST, V5, P82, DOI 10.1111/j.1538-7836.2006.02245.x; Washington CW, 2011, J TRAUMA, V71, P358, DOI 10.1097/TA.0b013e318220ad7e; Wong DK, 2008, J TRAUMA, V65, P1303, DOI 10.1097/TA.0b013e318185e234	29	22	22	0	4	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1815	1821		10.1089/neu.2014.3728			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500012	25604812				2021-06-18	
J	Silva, PPB; Bhatnagar, S; Herman, SD; Zafonte, R; Klibanski, A; Miller, KK; Tritos, NA				Silva, Paula P. B.; Bhatnagar, Saurabha; Herman, Seth D.; Zafonte, Ross; Klibanski, Anne; Miller, Karen K.; Tritos, Nicholas A.			Predictors of Hypopituitarism in Patients with Traumatic Brain Injury	JOURNAL OF NEUROTRAUMA			English	Article						adrenal insufficiency; diabetes insipidus; growth hormone deficiency; hypogonadism; hypopituitarism; hypothyroidism; traumatic brain injury	ANEURYSMAL SUBARACHNOID HEMORRHAGE; ANTERIOR-PITUITARY FUNCTION; INSULIN TOLERANCE-TEST; BODY-MASS INDEX; GROWTH-HORMONE; NEUROENDOCRINE DYSFUNCTION; ACUTE-PHASE; PREVALENCE; SECRETION	Hypopituitarism may often occur in association with traumatic brain injury (TBI). Identification of reliable predictors of pituitary dysfunction is of importance in order to establish a rational testing approach. We searched the records of patients with TBI, who underwent neuroendocrine evaluation in our institution between 2007 and 2013. One hundred sixty-six adults (70% men) with TBI (median age: 41.6 years; range: 18-76) were evaluated at a median interval of 40.4 months (0.2-430.4).Of these, 31% had 1 pituitary deficiency, including 29% of patients with mild TBI and 35% with moderate/severe TBI. Growth hormone deficiency was the most common deficiency (21%); when body mass index (BMI)-dependent cutpoints were used, this was reduced to 15%. Central hypoadrenalism occurred in10%, who were more likely to have suffered a motor vehicle accident (MVA, p=0.04), experienced post-traumatic seizures (p=0.04), demonstrated any intracranial hemorrhage (p=0.05), petechial brain hemorrhages (p=0.017), or focal cortical parenchymal contusions (p=0.02). Central hypothyroidism occurred in 8% and central hypogonadism in 12%; the latter subgroup had higher BMI (p=0.03), were less likely to be working after TBI (p=0.002), and had lower Global Assessment of Functioning (GAF) scores (p=0.03). Central diabetes insipidus (DI) occurred in 6%, who were more likely to have experienced MVA (p<0.001) or sustained moderate/severe TBI (p<0.001). Patients with MVA and those with post-traumatic seizures, intracranial hemorrhage, petechial brain hemorrhages, and/or focal cortical contusions are at particular risk for serious pituitary dysfunction, including adrenal insufficiency and DI, and should be referred for neuroendocrine testing. However, a substantial proportion of patients without these risk factors also developed hypopituitarism.	[Silva, Paula P. B.; Klibanski, Anne; Miller, Karen K.; Tritos, Nicholas A.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA; [Bhatnagar, Saurabha; Herman, Seth D.; Zafonte, Ross] Massachusetts Gen Hosp, Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Boston, MA 02114 USA; [Bhatnagar, Saurabha; Herman, Seth D.; Zafonte, Ross] Harvard Univ, Sch Med, Boston, MA USA	Tritos, NA (corresponding author), Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl 112, Boston, MA 02114 USA.	ntritos@mgh.harvard.edu	Tritos, Nicholas/W-1594-2019; Miller, Karen/AAI-6901-2021	Tritos, Nicholas/0000-0001-8867-607X; 	NIDILRR TBIMS grants [90DP0039-01-02, W81XWH-08-2-0159]	No conflicting financial interests exist. The work was supported in part by NIDILRR TBIMS grants nos. 90DP0039-01-02 and W81XWH-08-2-0159.	Agha A, 2004, J CLIN ENDOCR METAB, V89, P5987, DOI 10.1210/jc.2004-1058; Agha A, 2004, CLIN ENDOCRINOL, V60, P584, DOI 10.1111/j.1365-2265.2004.02023.x; Agha A, 2004, J CLIN ENDOCR METAB, V89, P4929, DOI 10.1210/jc.2004-0511; Aimaretti G, 2005, J CLIN ENDOCR METAB, V90, P6085, DOI 10.1210/jc.2005-0504; Aimaretti G, 2007, NAT CLIN PRACT ENDOC, V3, P318, DOI 10.1038/ncpendmet0460; Baxter D, 2013, ANN NEUROL, V74, P527, DOI 10.1002/ana.23958; Benvenga S, 2000, J CLIN ENDOCR METAB, V85, P1353, DOI 10.1210/jc.85.4.1353; Berg C, 2010, EUR J ENDOCRINOL, V162, P477, DOI 10.1530/EJE-09-0824; Bonert VS, 2004, J CLIN ENDOCR METAB, V89, P3397, DOI 10.1210/jc.2003-032213; Boughey JC, 2004, AM SURGEON, V70, P500; Bredella MA, 2009, J CLIN ENDOCR METAB, V94, P3995, DOI 10.1210/jc.2009-0438; Coronado VG, 2011, MMWR SURVEILL SUMM, V60, P1; Dichtel LE, 2014, J CLIN ENDOCR METAB, V99, P4712, DOI 10.1210/jc.2014-2830; Frieden TR, 2013, MMWR-MORBID MORTAL W, V62, P1; Glynn N, 2013, CLIN ENDOCRINOL, V78, P17, DOI 10.1111/cen.12010; HALL RCW, 1995, PSYCHOSOMATICS, V36, P267, DOI 10.1016/S0033-3182(95)71666-8; Kelly DF, 2000, J NEUROSURG, V93, P743, DOI 10.3171/jns.2000.93.5.0743; Klose M, 2007, CLIN ENDOCRINOL, V67, P193, DOI 10.1111/j.1365-2265.2007.02860.x; Kokshoorn NE, 2011, EUR J ENDOCRINOL, V165, P225, DOI 10.1530/EJE-11-0365; Kopczak A, 2011, EUR J ENDOCRINOL, V164, P31, DOI 10.1530/EJE-10-0821; Kopczak A, 2014, J NEUROTRAUM, V31, P99, DOI 10.1089/neu.2013.3002; Leong KS, 2001, CLIN ENDOCRINOL, V54, P463, DOI 10.1046/j.1365-2265.2001.01169.x; Lieberman SA, 2001, J CLIN ENDOCR METAB, V86, P2752, DOI 10.1210/jc.86.6.2752; Molitch ME, 2011, J CLIN ENDOCR METAB, V96, P1587, DOI 10.1210/jc.2011-0179; Qu XD, 2005, J CLIN ENDOCR METAB, V90, P1563, DOI 10.1210/jc.2004-1450; Schneider HJ, 2007, JAMA-J AM MED ASSOC, V298, P1429, DOI 10.1001/jama.298.12.1429; Schneider HJ, 2007, LANCET, V369, P1461, DOI 10.1016/S0140-6736(07)60673-4; Schneider HJ, 2006, EUR J ENDOCRINOL, V154, P259, DOI 10.1530/eje.1.02071; Tanriverdi F, 2011, J ENDOCRINOL INVEST, V34, P541, DOI 10.3275/7805; Tanriverdi F, 2006, J CLIN ENDOCR METAB, V91, P2105, DOI 10.1210/jc.2005-2476; Tanriverdi F, 2013, J NEUROTRAUM, V30, P1426, DOI 10.1089/neu.2012.2752; Traumatic Brain Injury Model Systems National Database Syllabus, 2009, TRAUM BRAIN INJ MOD; Vahl N, 1997, AM J PHYSIOL-ENDOC M, V272, pE1108; Wilkinson Charles W, 2012, Front Neurol, V3, P11, DOI 10.3389/fneur.2012.00011; Yuen KCJ, 2009, J CLIN ENDOCR METAB, V94, P2702, DOI 10.1210/jc.2009-0299	35	22	22	0	11	MARY ANN LIEBERT, INC	NEW ROCHELLE	140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA	0897-7151	1557-9042		J NEUROTRAUM	J. Neurotrauma	NOV 15	2015	32	22					1789	1795		10.1089/neu.2015.3998			7	Critical Care Medicine; Clinical Neurology; Neurosciences	General & Internal Medicine; Neurosciences & Neurology	CV6ST	WOS:000364401500009	26413767				2021-06-18	
J	Deepika, A; Prabhuraj, AR; Saikia, A; Shukla, D				Deepika, Akhil; Prabhuraj, A. R.; Saikia, Amrit; Shukla, Dhaval			Comparison of predictability of Marshall and Rotterdam CT scan scoring system in determining early mortality after traumatic brain injury	ACTA NEUROCHIRURGICA			English	Article						Marshall CT scan classification; Rotterdam CT scan score; Traumatic brain injury	CLASSIFICATION	Marshall computed tomographic (CT) classification is widely used as a predictor of outcome. However, this grading system lacks the following variables, which are found to be useful predictors: subarachnoid/intraventricular hemorrhage, extradural hematoma, and extent of basal cistern compression. A new classification called the Rotterdam grading system, incorporating the above variables, was proposed later. In the original paper, this system was found to have superior discrimination as compared to Marshall grading, however, Rotterdam grading has not been validated widely. We aimed to compare the discriminatory power of both grading systems. This is a prospective study of patients with moderate and severe TBI (Glasgow coma scale (GCS) 3-12) who presented to our casualty. All the patients were followed up for 2 weeks to determine early mortality. The discriminatory power of each grading system was determined using area under the receiver operating characteristic curve (AUC). A total of 134 patients, mean age 38.3 (+/- 15.7) years, were recruited for study. The overall mortality was 11.2 %. The mean GCS of these patients was 9.6 (+/- 2.3). There was good correlation between Marshall and Rotterdam grading, r = 0.68 (significant at 0.01 level). The Marshall CT classification had reasonable discrimination (AUC - 0.707), and Rotterdam grading had good discrimination (AUC - 0.681). Both Marshal and Rotterdam grading systems are good in predicting early mortality after moderate and severe TBI. As the Rotterdam system also includes additional variables like subarachnoid hemorrhage, it may be preferable, particularly in patients with diffuse injury.	[Deepika, Akhil; Prabhuraj, A. R.; Saikia, Amrit; Shukla, Dhaval] Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore 560029, Karnataka, India	Shukla, D (corresponding author), Natl Inst Mental Hlth & Neurosci NIMHANS, Dept Neurosurg, Bangalore 560029, Karnataka, India.	neurodhaval@rediffmail.com					Bobinski L, 2012, ACTA NEUROCHIR, V154, P1069, DOI 10.1007/s00701-012-1345-x; Bullock AR, 2006, NEUROSURGERY, V58, pVI; Chesnut RM, 2000, J NEUROTRAUM, V17, P555; Maas AIR, 2005, NEUROSURGERY, V57, P1173, DOI 10.1227/neu.0000186013.6304668; MARSHALL LF, 1991, J NEUROSURG, V75, pS14, DOI 10.3171/sup.1991.75.1s.0s14; Mata-Mbemba D, 2014, ACAD RADIOL, V21, P605, DOI 10.1016/j.acra.2014.01.017; Morris GF, 1997, ACTA NEUROCHIR S, V71, P382; Nelson DW, 2010, J NEUROTRAUM, V27, P51, DOI 10.1089/neu.2009.0986; Perel P, 2008, BMJ-BRIT MED J, V336, P425, DOI 10.1136/bmj.39461.643438.25; Raj R, 2014, NEUROSURGERY, V75, P632, DOI 10.1227/NEU.0000000000000533; Saatman KE, 2008, J NEUROTRAUM, V25, P719, DOI 10.1089/neu.2008.0586; Servadei F, 2002, NEUROSURGERY, V50, P261, DOI 10.1097/00006123-200202000-00006; Shukla D, 2007, CLIN NEUROPATHOL, V26, P197; Shukla D, 2010, J NEUROSCI RURAL PRA, V1, P82, DOI 10.4103/0976-3147.71723; Shukla D, 2011, CLIN NEUROL NEUROSUR, V113, P435, DOI 10.1016/j.clineuro.2011.02.013	15	22	23	0	4	SPRINGER WIEN	WIEN	SACHSENPLATZ 4-6, PO BOX 89, A-1201 WIEN, AUSTRIA	0001-6268	0942-0940		ACTA NEUROCHIR	Acta Neurochir.	NOV	2015	157	11					2033	2038		10.1007/s00701-015-2575-5			6	Clinical Neurology; Surgery	Neurosciences & Neurology; Surgery	CT7CL	WOS:000362970800034	26374440				2021-06-18	
J	Iadevaia, C; Roiger, T; Zwart, MB				Iadevaia, Cheree; Roiger, Trevor; Zwart, Mary Beth			Qualitative Examination of Adolescent Health-Related Quality of Life at 1 Year Postconcussion	JOURNAL OF ATHLETIC TRAINING			English	Article						concussions; postconcussion recovery; secondary schools	TRAUMATIC BRAIN-INJURY; PARENT-CHILD AGREEMENT; FAMILY BURDEN; CONCUSSION; SPORT; RECOMMENDATIONS; EPIDEMIOLOGY; PERFORMANCE; PEDSQL(TM); INVENTORY	Context: Moderate to severe traumatic brain injuries can negatively influence health-related quality of life (HRQOL) in adolescent patients. The effect of sport-related concussion on adolescent HRQOL remains unclear. Objective: To investigate the perceptions of adolescent student-athletes and their parents regarding the adolescents' HRQOL 1 year after sport-related concussion. Design: Qualitative study. Setting: Secondary school. Patients or Other Participants: Seven adolescent student-athletes (age range, 12-16 years) who sustained a sport-related concussion at least 1 year (15.3 +/- 2.8 months) before the study participated along with their primary care-giving parents (n = 7). Data Collection and Analysis: Fourteen semistructured face-to-face interviews (7 adolescents, 7 parents) were completed. Interviews were transcribed and inductively analyzed by a team of 3 athletic trainers with 32 combined years of professional experience. Themes were negotiated through a consensual review process. Participant checks were completed to ensure trustworthiness of the results. Results: Four major themes emerged from the interviews: (1) significant effect of symptoms, (2) feelings of frustration, (3) influence on school attendance and activities, and (4) nature of interpersonal and team relationships. Participants indicated that the physical symptoms of the concussion substantially affected their emotional and academic function. The influence of the concussion on social interactions seemed to depend on the nature of interpersonal relationships. Conclusions: Sport-related concussion can negatively influence physical and emotional function, academics, and interpersonal interactions as perceived by adolescent student-athletes and their parents. Education of parents and their children, school professionals, coaches, and teammates remains critical to effectively recognize and manage sport-related concussion. Secondary school districts also play a critical role in the concussion-management process by establishing and implementing accommodation policies that alleviate student concerns about falling behind while ensuring a healthy return to normal school routines. Furthermore, adolescent support systems must be considered throughout the recovery process.	[Iadevaia, Cheree; Roiger, Trevor; Zwart, Mary Beth] S Dakota State Univ, Dept Hlth & Nutr Sci, Box 2203 SIM 116, Brookings, SD 57007 USA	Roiger, T (corresponding author), S Dakota State Univ, Dept Hlth & Nutr Sci, Box 2203 SIM 116, Brookings, SD 57007 USA.	trevor.roiger@sdstate.edu			Office of Academic Affairs at South Dakota State University, Brookings, South Dakota	We thank the Office of Academic Affairs at South Dakota State University, Brookings, South Dakota, for financial support of this project.	[Anonymous], LIV BRAIN INJ FAM CA; Barlow KM, 2010, PEDIATRICS, V126, pE374, DOI 10.1542/peds.2009-0925; Broglio SP, 2007, J ATHL TRAINING, V42, P504; Cremeens J, 2006, HEALTH QUAL LIFE OUT, V4, DOI 10.1186/1477-7525-4-58; Davis A, 2012, J APPL REHABIL COUNS, V43, P3; DeSalvo KB, 2006, J GEN INTERN MED, V21, P267, DOI 10.1111/j.1525-1497.2005.00291.x; EDELBROCK C, 1986, J CHILD PSYCHOL PSYC, V27, P181, DOI 10.1111/j.1469-7610.1986.tb02329.x; Eiser C, 2001, Health Technol Assess, V5, P1; Ellis MJ, 2015, BRAIN INJURY, V29, P238, DOI 10.3109/02699052.2014.965207; Ganesalingam K, 2008, J PEDIATR PSYCHOL, V33, P621, DOI 10.1093/jpepsy/jsm133; Gauvin-Lepage J, 2010, BRAIN INJURY, V24, P1087, DOI 10.3109/02699052.2010.494593; Goldstein SL, 2008, AM J KIDNEY DIS, V51, P285, DOI 10.1053/j.ajkd.2007.09.021; Hajek CA, 2011, CHILD NEUROPSYCHOL, V17, P17, DOI 10.1080/09297049.2010.495058; Hardy CJ, 1999, PSYCHOL BASES SPORT, V2, P175; Hessen E, 2008, BRAIN INJURY, V22, P39, DOI 10.1080/02699050701846179; HODGES K, 1990, J CHILD PSYCHOL PSYC, V31, P427, DOI 10.1111/j.1469-7610.1990.tb01579.x; Kalpinski RJ, 2013, BIOMED RES INT, V2013, DOI 10.1155/2013/102570; Karlin AM, 2011, PM&R, V3, pS369, DOI 10.1016/j.pmrj.2011.07.015; Langlois JA, 2006, J HEAD TRAUMA REHAB, V21, P375, DOI 10.1097/00001199-200609000-00001; Levin HS, 2009, DEV NEUROREHABIL, V12, P320, DOI 10.3109/17518420903087673; Limond J, 2009, BRAIN INJURY, V23, P617, DOI 10.1080/02699050902997870; McCarthy ML, 2005, ARCH PHYS MED REHAB, V86, P1901, DOI 10.1016/j.apmr.2005.03.026; McCrory P, 2004, BRIT J SPORT MED, V38, P516, DOI 10.1136/bjsm.2004.014811; McCrory P, 2013, J AM COLL SURGEONS, V216, pE55, DOI 10.1016/j.jamcollsurg.2013.02.020; McGrath N, 2010, J ATHL TRAINING, V45, P492, DOI 10.4085/1062-6050-45.5.492; Moran LM, 2012, J PEDIATR PSYCHOL, V37, P736, DOI 10.1093/jpepsy/jsr087; Petitpas A., 1995, Sport psychology interventions., P255; Pope C, 2002, QUAL SAF HEALTH CARE, V11, P148, DOI 10.1136/qhc.11.2.148; Powers SW, 2004, CEPHALALGIA, V24, P120, DOI 10.1111/j.1468-2982.2004.00652.x; Ravens-Sieberer U, 2002, RESTOR NEUROL NEUROS, V20, P151; Reddy CC, 2008, PHYS MED REH CLIN N, V19, P247, DOI 10.1016/j.pmr.2007.12.002; Ritchie J, 2003, QUALITATIVE RES PRAC, P251; RIVARA JB, 1992, ARCH PHYS MED REHAB, V73, P899; Robson C., 2002, REAL WORLD RES RESOU, P289; Roscigno CI, 2011, BRAIN INJURY, V25, P882, DOI 10.3109/02699052.2011.581638; Sady MD, 2011, PHYS MED REH CLIN N, V22, P701, DOI 10.1016/j.pmr.2011.08.008; Siponkoski ST, 2013, J REHABIL MED, V45, P835, DOI 10.2340/16501977-1189; TRELEAVEN J, 1994, CEPHALALGIA, V14, P273, DOI 10.1046/j.1468-2982.1994.1404273.x; Varni JW, 1999, MED CARE, V37, P126, DOI 10.1097/00005650-199902000-00003; Wade SL, 1998, PEDIATRICS, V102, P110, DOI 10.1542/peds.102.1.110	40	22	22	1	17	NATL ATHLETIC TRAINERS ASSOC INC	DALLAS	2952 STEMMONS FREEWAY, DALLAS, TX 75247 USA	1062-6050	1938-162X		J ATHL TRAINING	J. Athl. Train.	NOV	2015	50	11					1182	1189		10.4085/1062-6050-50.11.02			8	Sport Sciences	Sport Sciences	DK2OO	WOS:000374754500009	26509684	Green Published, Bronze			2021-06-18	
J	Teixeira, SN; Osaku, EF; Costa, CRLD; Toccolini, BF; Costa, NL; Candia, MF; Leite, MA; Jorge, AC; Duarte, PAD				Teixeira, Sandy Nogueira; Osaku, Erica Fernanda; Lima de Macedo Costa, Claudia Rejane; Toccolini, Beatriz Fernandes; Costa, Nicolle Lamberti; Candia, Maria Fernanda; Leite, Marcela Aparecida; Jorge, Amaury Cezar; Delfino Duarte, Pericles Almeida			Comparison of Proportional Assist Ventilation Plus, T-Tube Ventilation, and Pressure Support Ventilation as Spontaneous Breathing Trials for Extubation: A Randomized Study	RESPIRATORY CARE			English	Article						intensive care units; ventilator weaning; airway extubation; respiration; artificial; respiratory insufficiency; protocols; mortality	MECHANICAL VENTILATION; PREDICTORS; OUTCOMES	BACKGROUND: Failure to wean can prolong ICU stay, increase complications associated with mechanical ventilation, and increase morbidity and mortality. The spontaneous breathing trial (SBT) is one method used to assess weaning. The aim of this study was to assess proportional assist ventilation plus (PAV+) as an SBT by comparing its applicability, safety, and efficacy with T-tube and pressure support ventilation (PSV). METHODS: A randomized study was performed involving 160 adult subjects who remained on mechanical ventilation for > 24 h. Subjects were randomly assigned to the PAV+, PSV, or T-tube group. When subjects were ready to perform the SBT, subjects in the PAV+ group were ventilated in PAV+ mode (receiving support of up to 40%), the pressure support was reduced to 7 cm H2O in the PSV group, and subjects in the T-tube group were connected to one T-piece with supplemental oxygen. Subjects were observed for signs of intolerance, whereupon the trial was interrupted. When the trial succeeded, the subjects were extubated and assessed until discharge. RESULTS: The subjects were predominantly male (66.5%), and the leading cause of admission was traumatic brain injury. The groups were similar with respect to baseline characteristics, and no significant difference was observed among the groups regarding extubation success or failure. Analysis of the specificity and sensitivity revealed good sensitivity for all groups; however, the PAV+ group had higher specificity (66.6%) and higher sensitivity (97.6%), with prediction of similar to 92.1% of the success and failure events. CONCLUSIONS: No significant differences in the groups was observed regarding the rate of extubation failure, duration of mechanical ventilation, and ICU and hospital stay, indicating that PAV+ is an alternative for use as an SBT.	[Teixeira, Sandy Nogueira; Osaku, Erica Fernanda; Lima de Macedo Costa, Claudia Rejane; Toccolini, Beatriz Fernandes; Costa, Nicolle Lamberti; Candia, Maria Fernanda; Leite, Marcela Aparecida; Jorge, Amaury Cezar; Delfino Duarte, Pericles Almeida] Western Parana State Univ Hosp, Intens Care Unit, BR-85806470 Cascavel, Parana, Brazil; [Jorge, Amaury Cezar] Western Parana State Univ Hosp, Dept Med, BR-85806470 Cascavel, Parana, Brazil	Teixeira, SN (corresponding author), Western Parana State Univ Hosp, Ave Tancredo Neves 3224, BR-85806470 Cascavel, Parana, Brazil.	sandy.fisio@hotmail.com		Osaku, Erica/0000-0001-7642-8394			Aguirre-Bermeo H, 2014, MED INTENSIVA, V38, P363, DOI 10.1016/j.medin.2013.08.003; Ambrosino N, 2012, EUR RESPIR J, V39, P487, DOI 10.1183/09031936.00094411; Artime CA, 2014, RESP CARE, V59, P991, DOI 10.4187/respcare.02926; Blackwood B, 2010, COCHRANE DB SYST REV, DOI 10.1002/14651858.CD006904.pub2; Boles JM, 2007, EUR RESPIR J, V29, P1033, DOI 10.1183/09031936.00010206; Bosma K, 2007, CRIT CARE MED, V35, P1048, DOI 10.1097/01.CCM.0000260055.64235.7C; Bosma K, 2013, CHEST, V144, DOI 10.1378/chest.1704978; Caruso P, 1999, CHEST, V115, P1096, DOI 10.1378/chest.115.4.1096; Cordioli RL, 2013, CURR OPIN CRIT CARE, V19, P31, DOI 10.1097/MCC.0b013e32835c517d; Costa R, 2011, INTENS CARE MED, V37, P1494, DOI 10.1007/s00134-011-2297-y; Deab SAE, 2014, RESP CARE, V59, P301, DOI 10.4187/respcare.03037; Dries DJ, 2004, J TRAUMA, V56, P943, DOI 10.1097/01.TA.0000124462.61495.45; Ely EW, 2000, CHEST, V15, P522; Epstein SK, 1997, CHEST, V112, P186, DOI 10.1378/chest.112.1.186; Eskandar N, 2007, CRIT CARE CLIN, V23, P263, DOI 10.1016/j.ccc.2006.12.002; Esteban A, 1997, AM J RESP CRIT CARE, V156, P459, DOI 10.1164/ajrccm.156.2.9610109; Esteban A, 2000, AM J RESP CRIT CARE, V161, P1450, DOI 10.1164/ajrccm.161.5.9902018; Gil B, 2003, CLIN PULM MED, V10, P226; Hannan LM, 2013, RESPIROLOGY, V18, P154, DOI 10.1111/j.1440-1843.2012.02266.x; Kacmarek RM, 2011, RESP CARE, V56, P140, DOI 10.4187/respcare.01021; Khamiees M, 2001, CHEST, V120, P1262, DOI 10.1378/chest.120.4.1262; Krishnan JA, 2004, AM J RESP CRIT CARE, V169, P673, DOI 10.1164/rccm.200306-761OC; Lellouche F, 2006, AM J RESP CRIT CARE, V174, P894, DOI 10.1164/rccm.200511-1780OC; Lone NI, 2011, CRIT CARE, V15, DOI 10.1186/cc10117; MacIntyre NR, 2001, CHEST, V120, p375S, DOI 10.1378/chest.120.6_suppl.375S; Macnaughton PD, 2007, ANAEST INTENS CARE M, V8, P489, DOI 10.1016/j.mpaic.2007.08.021; Moore FA, 2004, J TRAUMA, V56, P951; Namen AM, 2001, AM J RESP CRIT CARE, V163, P658, DOI 10.1164/ajrccm.163.3.2003060; Nemer SN, 2011, J BRAS PNEUMOL, V37, P669, DOI 10.1590/S1806-37132011000500016; Thille AW, 2013, CURR OPIN CRIT CARE, V19, P57, DOI 10.1097/MCC.0b013e32835c5095; Tobin MJ, 2004, AM J RESP CRIT CARE, V169, P661, DOI 10.1164/rccm.2401006; Vitacca M, 2003, Monaldi Arch Chest Dis, V59, P342; Xirouchaki N, 2008, INTENS CARE MED, V34, P2026, DOI 10.1007/s00134-008-1209-2	33	22	22	1	5	DAEDALUS ENTERPRISES INC	IRVING	9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA	0020-1324	1943-3654		RESP CARE	Respir. Care	NOV	2015	60	11					1527	1535		10.4187/respcare.03915			9	Critical Care Medicine; Respiratory System	General & Internal Medicine; Respiratory System	CV6FH	WOS:000364365600002	26152472	Bronze			2021-06-18	
